Cancer Incidence in Five Continents

Volume IX

International Agency for Research on Cancer

The International Agency for Research on Cancer (IARC) was established in 1965 by the World Health Assembly, as an independently financed organization within the framework of the World Health Organization. The headquarters of the Agency are at Lyon, France. The Agency conducts a programme of research concentrating particularly on the epidemiology of cancer and the study of potential carcinogens in the human environment. Its epidemiological studies are supplemented by studies of the mechanisms of carcinogenesis carried out in the Agencys laboratories in Lyon. The promotion of collaborative research among scientists worldwide is a strong feature of the Agencys activities. The Agency also conducts a programme for the education and training of personnel for cancer research. The publications of the Agency are intended to contribute to the dissemination of authoritative information on different aspects of cancer research. A complete list is printed at the back of the book. Information about IARC publications and how to order them is also available via the Internet at: http://www.iarc.fr/

INTERNATIONAL ASSOCIATION OF CANCER REGISTRIES

The International Association of Cancer Registries (IACR) was created following a decision taken during the Ninth International Cancer Congress held in Tokyo, Japan, in 1966. The Association is a voluntary nongovernmental organization in official relations with WHO, representing the scientific and professional interests of cancer registries, with members interested in the development and application of cancer registration and morbidity survey techniques to studies of well-defined populations. The constitution provides for a Governing Body composed of a President, General Secretary, Deputy Secretary and nine regional representatives. From 1973 the IARC has provided a secretariat for the Association with the primary functions of organizing meetings and coordinating scientific studies. Information about the Association, including membership, activities and publications, can be found on the Internet at: http://www.iacr.com.fr/

International Agency for Research on Cancer (WHO)

International Association of Cancer Registries

Cancer Incidence in Five Continents

Volume IX

Edited by M.P. Curado, B. Edwards, H.R. Shin, H. Storm, J. Ferlay, M. Heanue and P. Boyle

IARC Scientific Publications No. 160

International Agency for Research on Cancer Lyon, France 2007

Published by the International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France International Agency for Research on Cancer, 2007, printed in 2009. Distributed by WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 3264; fax: +41 22 791 4857; email: bookorders@who.int). Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the World Health Organization concerning the legal status of any country, territory, city, or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The mention of specific companies or of certain manufacturers products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The authors alone are responsible for the views expressed in this publication. The International Agency for Research on Cancer welcomes requests for permission to reproduce or translate its publications, in part or in full. Requests for permission to reproduce or translate IARC publications whether for sale or for noncommercial distribution should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

IARC Library Cataloguing in Publication Data Cancer Incidence in Five Continents, Volume IX / edited by M.P. Curado [et al.] (IARC Scientific Publications ; 160) 1. Neoplasms epidemiology 2. Neoplasms prevention & control I.Curado, M.P. II.Title III.Series ISBN 978 92832 2160 9 ISSN 0300-5085 (NLM Classification: W1)

Contents
Foreword ix Contributors to Introductory Chapters xi Contributors xiii Chapter 1. Introduction 1 M.P. Curado, H. R. Shin, J. Ferlay Chapter 2. Techniques of registration14 M.P. Curado Chapter 3. Classification and coding 40 H. R. Shin Chapter 4. Histological groups61 L. Egevad, M. Heanue, D. Berney, K. Fleming, J. Ferlay Chapter 5. Comparability and quality of data67 H. R. Shin, M.P. Curado, J. Ferlay, M. Heanue, B. Edwards, H. Storm Chapter 6. Processing of data95 J. Ferlay Chapter 7. Age-standardisation and denominators99 M. Boniol, M. Heanue THE NARRATIVES AND THE MAPS103 Africa Map of Africa  104 Algeria  105 Egypt 106 Tunisia  107 Uganda 108 Zimbabwe 110 Central and South America Map of Central and South America 111 Argentina  112 Brazil  113 Chile  117 Colombia  118 Costa Rica  119 Ecuador 120 France, Martinique  121 Peru 122 North America Maps of Canada and United States of America123 Canada 124 United States of America 136 Asia Maps of Asia 209 Bahrain  214 China 216

Contents
Cyprus 223 India 224 Israel 232 Japan 234 Korea  242 Kuwait  253 Malaysia  255 Oman  257 Pakistan 258 Philippines260 Singapore 262 Thailand264 Turkey 267 Europe Maps of Europe  269 Austria 276 Belarus280 Belgium 281 Bulgaria  283 Croatia  285 Czech Republic 286 Denmark 288 Estonia 290 Finland 292 France293 Germany303 Iceland  312 Ireland313 Italy314 Latvia 340 Lithuania 341 Malta342 Norway 343 Poland 344 Portugal348 Russia 350 Serbia 351 Slovak Republic 352 Slovenia353 Spain354 Sweden  368 Switzerland 369 The Netherlands 378 United Kingdom 382 Oceania Map of Oceania  398 Australia 399 French Polynesia  411 New Zealand 413 USA, Hawaii 414

vi

Contents
THE TABLES Age-standardized and cumulative incidence rates (three-digit rubrics) 417 Age-standardized incidence rates by histological type 679 Indices of data quality 801 Cancer Incidence in Five Continents Volume VIII: Errata895

vii

Foreword
It is difficult to estimate the number of people around the world who work diligently to collect the data that are presented in Cancer Incidence in Five Continents. One thing is clear: it is a large number. Surgeons, oncologists, pathologists, radiologists, radiotherapists, epidemiologists, statisticians, coding clerks and many other staff from different specialist backgrounds engaged in medical practice and medical records contribute to the accurate diagnosis and coding of cancer. Their combined work is summarised in the pages of this volume. Cancer Incidence in Five Continents (CI5) has become the recognised reference source on the incidence of cancer in populations around the world. The ninth volume has a wider coverage than before presenting data from around the year 2000 (ideally the period 19982002) not only for entire populations but also for sub-populations living in the same geographic area. This volume presents incidence data from populations all over the world for which good quality data are available. Scanning through the information gives a clear presentation of the changing cancer patterns worldwide. The nine volumes of Cancer Incidence in Five Continents now cover a period of approximately forty years. These new data are meant to be used and be useful. Looking ahead, with the rapidly rising cancer burden in low-income and medium-income countries, more high-quality incidence data are needed from regions and countries in such settings. Reliable data are needed to establish the cancer burden and to monitor its evolution in all parts of the world, particularly in response to cancer control activities. Nurturing the development of cancer registration in such countries is of major importance and one issue that the International Agency for Research on Cancer is addressing. On behalf of the International Agency for Research on Cancer, and the Editors, I would like to acknowledge the fruitful collaboration with the International Association of Cancer Registries, and IARC looks forward to the continual development of this collaboration. It is also a pleasure to acknowledge the directors and staff of all the registries who submitted their data, and responded to their series of questions and clarifications. Without their great efforts and dedication, information on the incidence of cancer, as made available in this volume, would not be available to all those concerned in the fight against cancer.
Peter Boyle, PhD Director, IARC

ix

Contributors to Introductory Chapters

Dan Berney Department of Cellular Pathology 80 Newark St, Whitechapel London E1 2ES United Kingdom Mathieu Boniol International Agency for Research on Cancer Biostatistics and Epidemiology Cluster Epidemiology Methods and Support Group 150 cours Albert Thomas 69372 Lyon cedex 08 France Maria-Paula Curado Registro de Cncer de Base Populacional de Goinia (Cancer Registry of Goiania) Associacao de Combate ao Cncer em Gois Rua 239 No. 209 Sector Oeste Universitrio 74605-070 Goinia - GO Brazil Brenda Edwards National Cancer Institute Suite 504, MSC 8315 6116 Executive Boulevard Bethesda, MD 20892-8315 USA Lars Egevad International Agency for Research on Cancer Pathogenesis and Prevention Cluster Pathology Group 150 cours Albert Thomas 69372 Lyon cedex 08 France Jacques Ferlay International Agency for Research on Cancer Biostatistics and Epidemiology Cluster Data Analysis and Interpretation Group 150, cours Albert Thomas 69372 Lyon Cedex 08 France Kenneth Fleming Head of Medical Sciences Division University of Oxford Medical School Office Level 3 John Radcliff Hospital Headington Oxford OX3 9du United Kingdom Mary Heanue International Agency for Research on Cancer Biostatistics and Epidemiology Cluster Descriptive Epidemiology Production Group 150, cours Albert Thomas 69372 Lyon Cedex 08 France Hai Rim Shin Korea Central Cancer Registry National Cancer Center 809 Madu-Dong, Ilsan-Gu Goyang Gyonggi 411-769 Korea Hans Storm Danish Cancer Registry Dept. of Cancer Prevention & Documentation Danish Cancer Society Strandboulevarden 49, Box 839 2100 Copenhagen Denmark

IARC Secretariat John Daniel; Office of the Director, Communications Group Morten J. Ervik; Biostatistics and Epidemiology Cluster, Descriptive Epidemiology Production Group Eric Masuyer; Biostatistics and Epidemiology Cluster, Data Analysis and Interpretation Group Mathieu Mazuir; Biostatistics and Epidemiology Cluster, Descriptive Epidemiology Production Group
xi

Contributors Contributors
Note: The contributors to this volume are listed below. Their names are given as communicated to the editors, hence the lack of consistency in presentation. Without the patient cooperation of the contributing registries, the editors of this monograph would have had no material to edit. The editors hope that scientists will give due recognition to this fact and use the following style of reference when quoting the data from a given registry: NORTH, A.B., SOUTH, C.D. Cancer Incidence in Antarctica, 1998-2002. In: Curado. M. P., Edwards, B., Shin. H.R., Storm. H., Ferlay. J., Heanue. M. and Boyle. P., eds (2007), Cancer Incidence in Five Continents, Vol. IX, IARC Scientific Publications No. 160, Lyon, IARC.

Africa
Algeria, Stif Stif Cancer Registry Hpital Mre Enfant 19000 CHU de Stif Algeria Tel: +(213) 36 91 13 85 Fax: +(213) 36 91 13 85 Email: hamdicherif@wissal.dz mokhtar@globalink.org Egypt, Gharbiah Gharbiah Population-based Cancer Registry P.O. Box 295 Tanta Egypt Tel.: +(20) 10-603-0480 Fax: +(20) 2-364-4720 E-mail: amalsamyibrahim@yahoo.com ghb_1@hotmail.com Tunisia, Central Region Cancer Registry of Sousse Laboratoire d'Anatomie pathologique C.H.U. F. Hached Rue Dr Moro 4002 Sousse Tunisia Tel.: +(216) 32-10355 Fax: +(216) 32-10355 E-mail: hmissa_s@yahoo.fr Uganda, Kyadondo County Kampala Cancer Registry Department of Pathology Makerere University Medical School PO Box 7072 Kampala Uganda Tel.: +(256) 41-531730 / 558731 / 17 Fax: +(256) 41-530412 / 543895 E-mail: cancer-reg@infocom.co.ug Hamdi Cherif Mokhtar Guerra Djahid Abdellouche Djamel Kadri Loubna Zaidi Zoubida Bourenane Cherif Sara Mahnane abbes Menaa Nadia Laouamri slimane Hamdi Meriem Amal S. Ibrahim Hany Hussein Kadry Ismail Ahmed Hablas Ibrahim Abdel Bar Mohammad Ramadan Hisham Elhamza

Korbi Sadok Hmissa Sihem Jaidane Lilia Chatti Danielle Mokni Moncef

Henry Wabinga Sarah Nambooze Juma Amero Max Parkin

xiii

xiii

Contributors

Zimbabwe, Harare Zimbabwe National Cancer Registry Parirenyatwa Hospital P.O. Box A 449, Avondale Harare Zimbabwe Tel.: +(263) 4-791631, ext. 152 Fax: +(263) 4-794445 E-mail: cancer.registry@healthnet.zw

E. Chokunonga M.Z. Borok B.G. Mauchaza Z.M. Chirenje A.M. Nyakabau

xiv

xiv

Contributors

Central & South America

Argentina, Bahia Blanca Registro Regional de Tumores del Sur de la Provincia de Buenos Aires Lainez 2403 B8001DDU Baha Blanca Argentina Tel: +(54) 291-459-3669 Fax: +(54) 291-459-3669 E-mail: aapec1@criba.edu.ar Brazil, Brasilia Registro de Cncer de Base Populacional do Distrito Federal (Cancer Registry of Brasilia) SIA Trecho 1 Lote 1730 Bloco E Sala 309 Brasilia, DF, Brazil Zip Code 71200-010 Brazil Tel.: +(55) 61 340 32 601 Fax: +(55) 61 340 32 393 E-mail: cristinascandiuzzi@gmail.com Brazil, Cuiaba Registro de Cncer de Base Populacional de Cuiab Brazil Tel:+(55) 65-3613-5359. Fax:+(55) 65 3613-5477 E-mail: copcca@ses.mt.gov.br m_cris10@hotmail.com Eduardo A. Laura Mariana S. Gonzalez Vanina S. Mendiondo Claudia Grimi Elena Elverdin Mario Aggio Gustavo Salum Miguel Aimale Jorge Blasco Diego Bereilh Elza Pastor Martinez Maria Cristina Scandiuzzi Maria Jos Amparo Juliana Bernardo da Silva Katia Silene da Silva Brando Aline Soares Dantas Helena de Melo Franco

Mrcia Regina Gomes Pereira Mrcia Cristina Claudiano Maria Ilma Castilho Maria Jos Lemes de Oliveira Lucelleuzy C. Campos Lima Paulo Csar Fernandes de Souza Wilson G. Pereira Rubens Carlos de O Junior Ney Pereira da Silva Helen Rosane Meinke Curvo Maria Paula Curado Carleane Maciel Bandeira e Silva Edesio Martins Elcivone Cirineu de Sousa Matinair Siqueira Mineiro Jose Carlos de Oliveira

Brazil, Goinia Registro de Cncer de Base Populacional de Goinia (Cancer Registry of Goiania) Associaao de Combate ao Cncer em Gois Rua 239 No. 209 Sector Oeste Universitrio 74605-070 Goinia - GO Brazil Tel.: +(55) 62-3243-7000 Fax: +(55) 62-3243-7076 E-mail: rcbpgo@gmail.com Website: www.rcbp-goiania.com

xv

xv

Contributors

Brazil, Sao Paulo Registro de Cncer de So Paulo (Cancer Registry of Sao Paulo) Faculdade de Saude Publica Universidade de Sao Paulo Av. Dr. Arnaldo, 715 - 1 andar, sala 112 Sao Paulo - SP CEP 01246-904 Brazil Tel.: +(55) 11-3061-7799 Fax: +(55) 11-3061-7799 E-mail: apmirra@usp.br Chile, Valdivia Registro Poblacional del Cncer Provincia de Valdivia Chile (Cancer Registry of Validivia) Servicio de Salud Valdivia Chacabuco No. 700 Valdivia Chile Tel.: +(56) 63-297875 / 297889 Fax: +(56) 63-297912 / 297895 E-mail: mbertran@ssvaldivia.cl Colombia, Cali Cali Cancer Registry Department of Pathology Faculty of Health Sciences Universidad del Valle P.O. Box 25360 Cali, Colombia Tel.: +(57) 2-554-2489 Fax: +(57) 2-558-6304 E-mail: regcal@univalle.edu.co Costa Rica, Costa Rica National Tumor Registry Registro Nacional de Tumores Direccin de Vigilancia de la Salud Ministerio de Salud P.O. Box 10123-1000 San Jos Costa Rica Tel.: +(506) 221-1662 Fax: +(506) 221-1167 E-mail: aortiz@netsalud.sa.cr Ecuador, Quito Registro Nacional de Tumores (National Cancer Registry) Sociedad de Lucha Contra el Cancer SOLCA, Ncleo de Quito Av. Eloy Alfaro 53-94 y Los Pinos Casilla 1711 4965 CCI Quito Ecuador Tel.: +(593) 2-419763 Fax: +(593) 2-403123 E-mail: fbernardcorral@hotmail.com

Antonio Pedro Mirra Maria do Rosrio Dias de Oliveira Latorre Jos Maria Pacheco de Souza Sabina La Davidson Gotlieb Maria Lucia Lebro Joo Paulo Ach de Freitas Carlos Marigo

Mara Enriqueta Bertrn Vives Katy Elena Heise Mora Ana Mara Jofr Salazar

Luis Eduardo Bravo Edwin Carrascal Tito Collazos Luz Stella Garcia Mariela Palacios Julio Cesar Guarnizo Juan Carlos Hernandez

Adolfo Ortz Barboza Georgina Muoz Guillermo Torres Mara Guevara Rosa Mara Vargas Ricardo Rojas Daniel Antich Rolando Herrero

Fabin Corral Cordero Patricia Cueva Ayala Jos Ypez Maldonado Mara Beln Morejn Mnica Galarza Doris Chauca Paulina Bedn

xvi

xvi

Contributors

France, Martinique Registre des Cancers de la Martinique (Cancer Registry of Martinique) A.M.R.E.C. Centre d'Affaires de Californie, Entre Elodie 97232 Lamentin France Tel.: +(596)596603248 Fax: +(596)596704239 E-mail: amrec@wanadoo.fr Peru, Trujillo Registro de Cncer de Base Poblacional de Trujillo (Population-Based Cancer Registry of Trujillo) Calle Guillermo Charn 279 Urb. San Andrs Trujillo Peru Tel.: +(51) 44-244377 Fax: +(51) 44-244261 E-mail: albujarb@ec-red.com

Moustapha Dieye Jacqueline Vronique-Baudin Carole Gentil Marie Jos Dorival Pierre Armel Ngasseu Cyprian Draganescu Juliette Smith Ravin Roger Salamon Herv Azaloux Pedro F. Albjar

xvii

xvii

Contributors

North America
Canada Canadian Cancer Registry Health Statistics Division Statistics Canada Main Building, Room 2200 Ottawa, Ontario, K1A 0T6 Canada Tel: +(1) 613-951-1775 Fax:+(1) 613-951-0792 E-mail: michel.cormier@statcan.ca frieing@statcan.ca Canada, Alberta Alberta Cancer Registry Alberta Cancer Board Holy Cross, 5th Floor Box ACB 2210 2 Street SW Calgary, AB T2S 3C3 Canada Tel.: +(1) 403-698-8191 Fax: +(1) 403-698-8159 E-mail: heatherb@cancerboard.ab.ca Canada, British Columbia British Columbia Cancer Registry British Columbia Cancer Research Centre Cancer Control Research Program 2nd floor, Room 115 - 675 West 10th Avenue Vancouver, BC V5Z 1L3 Canada Tel.: +(1) 604-675-8059 Fax: +(1) 604-675-8180 E-mail: mmcbride@bccancer.bc.ca Canada, Manitoba Epidemiology & Cancer Registry - CancerCare Manitoba Room 2114, 675 McDermot Ave. Winnipeg, MB R3E OV9 Canada Tel.: +(1) 204-787-2174 Fax: +(1) 204-786-0628 E-mail: Grace.Musto@cancercare.mb.ca Canada, New Brunswick New Brunswick Provincial Cancer Registry P.O. Box 5100 Fredericton New Brunswick, E3B 5G8 Canada Tel.: +(1) 506-453-3092 Fax: +(1) 506-453-2780 E-mail: christofer.balram@gnb.ca Christofer Balram Wilfred Pilgrim Suzanne Leonfellner Michel Cormier Ginette Dussault Sandra Ladouceur

Heather Bryant Carol Russell Maxine Raphael Lorette Bowers Victoria McQuaid

Mary McBride Cathy MacKay

xviii

xviii

Contributors

Canada, Newfoundland Newfoundland Cancer Registry Provincial Cancer Care Program, Eastern Health Dr H. Bliss Murphy Cancer Centre 300 Prince Philip Drive St. John's, NL A1B 3V6 Canada Tel.: +(1) 709-777-7602 Fax: +(1) 709-753-0927 E-mail: susan.ryan@easternhealth.ca Canada, Northwest Territories Northwest Territories Cancer Registry Dept. of Health and Social Services 6th floor, Centre Square Tower P.O. Box 1320 Yellowknife, NT XIA 2L9 Canada Tel.: +(1) 867-873-3231 Fax: +(1) 867-873-0442 E-mail: andre_corriveau@gov.nt.ca Canada, Nova Scotia Nova Scotia Cancer Registry Surveillance & Epidemiology Unit 1278 Tower Road, Room 569 Bethune Building Halifax, Nova Scotia, Canada B3H 2Y9 Canada Tel.: +(1) 902-473-5172 Fax: +(1) 902-473-4425 E-mail: epi.unit@ccns.nshealth.ca Canada, Ontario Cancer Care Ontario 620 University Avenue, 12th Floor Toronto, Ontario, M5G 2L7 Canada Tel.: +(1) 416-971-9800, Fax: +(1) 416-971-6888 E-mail: maryjane.king@cancercare.on.ca Canada, Prince Edward Island Prince Edward Island Cancer Registry Queen Elizabeth Hospital P.O. Box 6000 Charlottetown, PE C1A 8T5 Canada Tel.: +(1) 902-894-2167 Fax: +(1) 902-894-2187 E-mail: ddryer@isn.net

Susan Ryan Sharon Smith

Maureen MacIntyre Ron Dewar

Kamini Milnes Mary Jane King Phil Parsons Karen Hofmann Jeff Bowler Susan Sargant Joshua Mazuryk Dagny Dryer

xix

xix

Contributors

Canada, Saskatchewan Saskatchewan Cancer Registry Saskatchewan Cancer Agency 4101 Dewdney Avenue Regina, Saskatchewan, S4T 7T1 Canada Tel.: +(1) 306-766-2695 Fax: +(1) 306-766-2179 E-mail: heather.stuart@scf.sk.ca USA, Alabama Alabama Statewide Cancer Registry 201 Monroe St. Suite 1480 Montgomery AL 36130 USA Tel.: +00-251-438-2809 Fax: +00-251-432-3238 E-mail: vnelson@adph.state.al.us

H. Stuart K. Robb T. Goh D. Popkin

Janice Cook Vicki Nelson Shirley Bowman XJ Shen Justin George Diane Hadley Regina Dillard Mark Jackson Shri Walker Shirley Williams Bobbie Bailey Tracey Taylor Ann Marie Bailey David K. O'Brien Elizabeth J. Blair Jim G. Whitecavage Chris J. Geri

USA, Alaska Alaska Cancer Registry 3601 C Street Suite 722 P.O Box 240249 Anchorage AK 99524-0249 USA Tel.: +00-907-269-8037 Fax: +00-907-561-1896 E-mail: annmarie_bailey@health.state.ak.us USA, Arizona Arizona Cancer Registry Arizona Department of Health Services 150 N. 18th Avenue Suite 550 Phoenix Arizona 85007-3248 USA Tel.: +00-602-542-7320 Fax: +00-602-542-7362 E-mail: yeega@azdhs.gov USA, California Cancer Surveillance & Research Branch California Department of Public Health California Cancer Registry 1700 Tribute Road, Suite 100 Sacramento, CA 95815-4402 USA Tel.: +(1) 916-779-0303 Fax: +(1) 916-779-0264 E-mail: ksnipes@ccr.ca.gov

Georgia Armenta Yee Richard S. Porter Timothy J. Flood

Kurt Snipes Margaret McCusker Rosemary Cress Janet Bates Dennis Deapen Dee West

xx

xx

Contributors

USA, California, Los Angeles County Los Angeles County Cancer Surveillance Program Keck School of Medicine University of Southern California, 1540 Alcazar Street, CHP 204 Los Angeles, CA 90033-1042 USA Tel.: +(1) 323-442-1574 Fax: +(1) 323-442-2301 E-mail: ddeapen@usc.edu USA, California, San Francisco Bay Area Greater Bay Area Cancer Registry Northern California Cancer Center 2201 Walnut Avenue, Suite 300 Fremont, CA 94538 USA Tel.: +(1) 510-608-5000 Fax: +(1) 510-608-5085 E-mail: tina@nccc.org USA, Colorado Colorado Central Cancer Registry State Department of Health 4300 Cherry Creek Drive South Denver, CO 80246-1530 USA Tel.: +(1) 303-692-2540 Fax: +(1) 303-691-7721 E-mail: rrycroft@smtpgate.dphe.state.co.us USA, Connecticut Connecticut Tumor Registry State of Connecticut, Dept. of Public Health 410 Capitol Avenue, MS# 13TMR P.O. Box 340308 Hartford, CT 06134-0308 USA Tel.: +(1) 860-509-7163 Fax: +(1) 860-509-7161 E-mail: cathryn.phillips@po.state.ct.us USA, District of Columbia District of Columbia Cancer Registry 825 North Capital Street, NE. Room 3145 Washingon DC 20002 USA Tel.: +00-202-442-5910 Fax: +00-202-442-9432 E-mail: aaron.adade@dc.gov

Dennis Deapen Leslie Bernstein Lihua Liu Dianne Kerford Peg Balcius Donna Morrell

Sally L. Glaser Dee W. West Kathleen Davidson-Allen Christina A. Clarke Scarlett Lin Gomez

Jack Finch Randi Rycroft Kieu Vu

Aaron Adade Genevieve Matanoski Xuguang (Grant) Tao Emmanuel Nwokolo

xxi

xxi

Contributors

USA, Florida Florida Cancer Data System Sylvester Comprehensive Cancer Center University of Miami School of Medicine P.O. Box 016960 (D4-11) Miami, Fl 33101 USA Tel.: +(1) 305-243-4600 Fax: +(1) 305-243-4871 E-mail: lfleming@med.miami.edu USA, Georgia Georgia Comprehensive Cancer Registry 2 Peachtree Street NW 14th Floor Atlanta, Georgia 30303 USA Tel.: +(1) 404 657 1943 Fax: +(1) 404 463 0780 E-mail: arbayakly@dhr.state.ga.us

Youjie Huang Lora E. Fleming Jill A. MacKinnon

A. Rana Bayakly Carol Crosby Margaret Padgett Betty Gentry Sheree Holloway Judy Andrews John Young Kevin Ward May Ting Liu Phyllis Wilson John Horan John L. Young, Jr. Jonathan Liff Kevin C. Ward Phyllis Wilson

USA, Georgia, Atlanta Metropolitan Atlanta, Georgia SEER Registry GA Center for Cancer Statistics Rollins School of Public Health, Emory University 1518 Clifton Road NE Atlanta, GA 30322 USA Tel.: +(1) 404-727-8487 Fax: +(1) 404-727-7261 E-mail: jlyoung@sph.emory.edu USA, Idaho Cancer Data Registry of Idaho 615 N.7th Street Boise ID 83702 USA Tel.: +00-208-338-5100 Fax: +00-208-338-7800 E-mail: scarson@teamiha.org USA, Illinois Illinois State Cancer Registry Division of Epidemiologic Studies Illinois Department of Public Health 605 W. Jefferson St Springfield, IL 62761 USA Tel.: +(1) 217-785-7132 Fax: +(1) 217-524-1770 E-mail: tiefu.shen@illinois.gov

Stacey L. Carson Christopher J. Johnson Denise Jozwik

Tiefu Shen Melinda Lehnherr Jan Snodgrass

xxii

xxii

Contributors

USA, Indiana Indiana State Cancer Registry Indiana State Department of Health 2 N. Meridian St., Sec. 5-L Indianapolis IN 46204 USA Tel.: +00-317-233-7424 Fax: +00-317-233-7722 E-mail: mgraves@isdh.in.gov USA, Iowa State Health Registry of Iowa Department of Epidemiology 2600 University Capitol Centre University of Iowa Iowa City, IA 52242 USA Tel.: +(1) 319-335-8609 Fax: +(1) 319-335-8610 E-mail: charles-lynch@uiowa.edu USA, Kentucky Kentucky Cancer Registry 2365 Harrodsburg Road, Suite A230 Lexington, KY 40504-3381 USA Tel.: +(1) 859-219-0773 Fax: +(1) 859-219-0557 E-mail: tct@kcr.uky.edu USA, Louisiana Louisiana Tumor Registry School of Public Health Louisiana State University Health Sciences Center 2021 Lakeshore Drive, Ste. 201 New Orleans, LA 70122 USA Tel.: +(1) 504-280-1564 Fax: +(1) 504-280-1590 E-mail: vchen@lsuhsc.edu USA, Louisiana New Orleans Louisiana Tumor Registry School of Public Health Louisiana State University Health Sciences Center 2021 Lakeshore Drive, Ste. 201 New Orleans, LA 70122 USA Tel.: +(1) 504-280-1564 Fax: +(1) 504-280-1590 E-mail: vchen@lsuhsc.edu

Martha Graves

Charles F. Lynch Charles E. Platz Kathleen M. McKeen

Thomas C Tucker Frances Ross Eric Durbin

Vivien W. Chen Xiaocheng Wu Meichin Hsieh Patricia A. Andrews Catherine N. Correa

Vivien W. Chen Xiaocheng Wu Meichin Hsieh Patricia A. Andrews Catherine N. Correa

xxiii

xxiii

Contributors

USA, Maine Maine Cancer Registry Maine Bureau of Health State House Station 11 Key Bank Plaza, 4th floor Augusta, ME 04333 USA Tel.: +(1) 207-287-5296 Fax: +(1) 207-287-4631 E-mail: molly.schwenn@maine.gov USA, Massachusetts Massachusetts Cancer Registry Department of Public Health 250 Washington Street 6th floor Boston, MA 02108-4619 USA Tel.: +(1) 617-624-5646 Fax: +(1) 617-624-5695 E-mail: susan.gershman@state.ma.us USA, Michigan Michigan Cancer Surveillance Program 201 Townsend P.O. Box 30691 Lansing, MI 48909 USA Tel.: +(1) 517-335-8677 Fax: +(1) 517-335-9513 E-mail: copelandg@michigan.gov USA, Michigan Detroit Metropolitan Detroit Cancer Surveillance System Wayne State University Karmanos Cancer Institute 110 East Warren Ave. Detroit, MI 48201 USA Tel.: +(1) 313-578-4201 Fax: +(1) 313-578-4306 E-mail: schwarta@karmanos.org USA, Missouri Missouri Cancer Registry 324 Clark Hall Columbia Missouri 65211 USA Tel.: +00-573-882-7775 Fax: +00-573-884-9655 E-mail: jacksonthompsonj@health.missouri.edu

Castine Verrill Molly Schwenn

Susan T. Gershman Mary Jane King

Glenn Copeland Won Silva Georgia Spivak Michelle Hulbert Georgetta Alverson

Ann G. Schwartz

Jeannette Jackson-Thompson Sue Vest Nancy Cole Gentry White

xxiv

xxiv

Contributors

USA, Montana Montana Central Tumor Registry 1400 Broadway Room C317 PO Box 202952 Helena MT 59620 USA Tel.: +00-406-444-6786 Fax: +00-406-444-6557 E-mail: dlemons@mt.gov USA, New Jersey New Jersey State Cancer Registry P.O. Box 369 Trenton, NJ 08525-0369 USA Tel.: +(1) 609-588-3500 Fax: +(1) 609-588-3638 E-mail: betsy.kohler@doh.state.nj.us USA, New Mexico New Mexico Tumor Registry MSC11 6020 1 University of New Mexico Albuquerque, NM 87131-0001 USA Tel.: +(1) 505-272-3127 Fax: +(1) 505-272-8572 E-mail: ckey@nmtr.unm.edu USA, New York State New York State Cancer Registry N.Y. State Dept of Health Corning Tower - Room 536 Empire State Plaza Albany, NY 12237-0679 USA Tel.: + Fax: + E-mail: mjs08@health.state.ny.us USA, NPCR Cancer Surveillance Branch Division of Cancer Prevention and Control Centers for Disease Control and Prevention 4770 Buford Highway NE, Mail Stop K53 Atlanta, GA 30341-3717 Tel.: +(1) 770-488-3005 Fax: +(1) 770-488-4759 E-mail: hbw4@CDC.GOV USA, Ohio Ohio Cancer Incidence Surveillance System 246 N. High Street, PO Box 118 Columbus, OH 43216-0118 USA Tel.: +00-614-644-7058 Fax: +00-614-644-1909 E-mail: bette.smith@odh.ohio.gov

Debbi Lemons

Betsy A. Kohler Susan Van Loon Xiaoling Niu Toshi Abe

Charles L. Wiggins Virginia Williams Charles R. Key.

Maria J. Schymura Amy Kahn Colleen G. Sherman Colleen C. McLaughlin

Hannah Weir Cheryll Cardinez

Robert Campbell Bette Smith Holly Engelhardt William Ruisinger

xxv

xxv

Contributors

USA, Oklahoma Oklahoma Central Cancer Registry 1000 NE 10th Street Room 1205 P.O Box 53551 Oklahoma City OK 74117-1299 USA Tel.: +00-405-271-4072/57119 Fax: +00-405-271-6315 E-mail: charlotr@health.ok.gov USA, Oregon Oregon State Cancer Registry 800 NE Oregon Street Ste 730 Portland OR 97232 USA Tel.: +00-971-673-0986 Fax: +00-971-673-0996 E-mail: donald.k.shipley@state.or.us USA, Pennsylvania Pennsylvania Cancer Registry Health Statistics and Research PA Department of Health 555 Walnut Street, 6th Floor Harrisburg, PA 17101-1914 USA Tel.: +00-717-783-2548 Fax: +00-717-773-3258 E-mail: ROOTTO@state.pa.us USA, Rhode Island Rhode Island Cancer Registry Rhode Island Department of Health 3 Capitol Hill, Room 403 Providence, RI 02908-5097 USA Tel.: +(1) 401-277-1172 Fax: +(1) 401-277-3551 E-mail: john.fulton@health.ri.gov USA, SEER Surveillance Research Program National Cancer Institute Suite 504, MSC 8315 6116 Executive Blvd Bethesda, MD 20892-8315 USA Tel.: +(1) 301-496-8506 Fax: +(1) 301-480-4077 E-mail: edwardsb@mail.nih.gov

Adeline Yerkes Janis Campbell Charlotte Russell

Donald Shipley Claudia Feight

Raymond K. Powell Jerry Orris

John P. Fulton Leanne C. Chiaverini David Rousseau

xxvi

xxvi

Contributors

USA, South Carolina South Carolina Central Cancer Registry SC DHEC 2600 Bull St. Columbia SC 29201 USA Tel.: +00-803-731-1419 Fax: +00-803-898-3599 E-mail: bolicks@dhec.sc.gov USA, Texas Texas Cancer Registry 1100 West 49th Street Austin TX 78756 USA Tel.: +00-512-458-7523 Fax: +00-512-458-7681 E-mail: Melanie.Williams@dshs.state.tx.us USA, Utah Utah Cancer Registry 650 Komas Drive, Suite 106B Salt Lake City, UT 84108 USA Tel.: +(1) 801-581-8407 Fax: +(1) 801-581-4560 E-mail: nan.stroup@hsc.utah.edu USA, Vermont Vermont Cancer Registry 108 Cherry Street Burlington, VT 05401 USA Tel.: +00-802-863-7644 Fax: +00-802-652-4157 E-mail: ajohnso@vdh.state.vt.us USA, Washington Washington State Cancer Registry PO Box 47855 Olympia, WA, 98597-4855 USA Tel.: +(1) 360-236-3624 Fax: +(1) 360-586-2714 E-mail: kathryn.golub@doh.wa.gov USA, Washington, Seattle SEER-Puget Sound/Seattle Fred Hutchinson Cancer Research Center 1100 Fairview Ave. North, MD-B706 P.O. Box 19024 Seattle, WA 98109-1024 USA Tel.: +(1) 206-667-4716 Fax: +(1) 206-667-4870 E-mail: sschwart@fhcrc.org

Susan Bolick-Aldrich Virginia Andrews Catishia Mosley Deborah Hurley

Melanie Williams

Antoinette M. Stroup Wallace Akerley Rosemary Dibble

Ali Johnson

Kathryn Golub Mahesh Keitheri Cheteri

Thomas L. Vaughan Stephen M. Schwartz Mary S. Potts

xxvii

xxvii

Contributors

USA, West Virginia West Virginia Cancer Registry 350 Capitol Street, Room 125 Charleston,WV 25301USA USA Tel.: +(1) 304 558 6421 Fax: +(1) 304 558 4463 E-mail: patcolsher@wvdhhr.org USA, Wisconsin Wisconsin Cancer Reporting System Dept. of Health and Family Services Wisconsin Division of Public Health P.O. Box 2659 Madison, WI 53701 USA Tel.: +(1) 608-266-8926 Fax: +(1) 608-264-9881 E-mail: stephla@dhfs.state.wi.us

Patricia Colsher

Laura Stephenson Mary Foote Robert Borchers Kim Ortman LuAnn Hahn Diane Austin

xxviii

xxviii

Contributors

Asia
Bahrain Bahrain Cancer Registry Medical Review Office P.O. Box 12 Manama Bahrain Tel.: +(973) 1727-9843 Fax: +(973) 1727-3540 E-mail: jsayyad@health.gov.bh China, Guangzhou Guangzhou Cancer Registry Cancer Center Sun Yat-sen Unviversity 651 Dongfeng Road East Guangzhou 510060 China Tel: +(86) 20-873-43283 Fax: +(86) 20-873-43293 Email: caokajia@mail.sysu.edu.cn China, Hong Kong Hong Kong Cancer Registry C/o Department of Clinical Oncology Queen Elizabeth Hospital 30 Gascoigne Road Kowloon, Hong Kong China Tel.: +(852) 2958-6021 Fax: +(852) 2958-5559 E-mail: cancereg@ha.org.hk China, Jiashan Jiashan County Cancer Registry 142 Garden Road Weitang Town Jiashan County 314100 Zheijiang Province China Tel.: +(86) 573-402-4016 Fax: +(86) 571-814-7297 E-mail: zgzl@mail.hz.zj.cn China, NanGang District, Harbin City Epidemic Prevention Station of Nan Gang District Wen Chang Street 227 Nan Gang District Harbin 150040 China Tel.: +(86) 451-8621-2954 Fax: +(86) 451-8622-1502 E-mail: ngqfyz@hotmail.com Jamal Alsayyad Adulkareem Ateya Abdulla Darwish

Kajia Cao Guosheng Ma Qiaoyang Fan Chuanzhong Yin Yilong Liu Ziqun Liu Fang Deng

Stephen Chun Key Law Oscar W.K. Mang

Xinyuan Ma Kaiyan Yao Wanli Ma Qilong Li Lingling Yu Ning Zhao Xiaogang Huang

Shu Ling Wu Hui He Li Qiu Yang Hui Li Han Xiao Li Shan Bo Y u

xxix

xxix

Contributors

China, Shanghai Shanghai Municipal Center for Disease Control and Prevention Shanghai Municipal Center for Disease Control & Prevention 1380 Zhong Shan Road (West) Shanghai 200336 China Tel.: +(86) 21-6275-8710 / 1314 Fax: +(86) 21-6208-4193 E-mail: ytgao@vip.sina.com China, Zhongshan Zhongshan Cancer Research Institute East-Sun-Wen Road Guangdong 528403 Zhongshan City China Tel.: + Fax: + E-mail: zszlzl@yahoo.com.cn Cyprus Cyprus Cancer Registry c/o Ministry of Health 10 Markou Drakou Str. 1448 Lefkosia Cyprus Tel.: +(357) 22603001 Fax: +(357) 22603154 E-mail: cancer.registry@moh.gov.cy India, Chennai (Madras) Madras Metropolitan Tumour Registry Cancer Institute (W.I.A.) 38, Sardar Patel Road Chennai - 600 036 India Tel.: +(91) 44-2491-0754 / 1526 Fax: +(91) 44-2491-2085 E-mail: rajaraman.swaminathan@yahoo.co.uk India, Karunagappally Rural Cancer Registry, Karunagappally Natural Background Radiation Cancer Registry (NBRR) Puthenthura P.O. Neendakara, Kollam District Kerala 691588 India Tel.: +(91) 476-620609 Fax: + E-mail: qln_nbrrkply@sancharnet.in

Yu-Tang Gao Fan Jin Yongbing Xiang Wei Zhang Wei Lu Ying Zheng Kai Gu Pingping Bao Guixiang Song Ming Han Wang De Kun Yu Yuan Long Wei Kuang-rong Liang ZHi-heng Ren Xiao-qing

Charitini Komodiki

V. Shanta R. Swaminathan S. Nalini M. Kavitha R. Rama

P. Jayalekshmi B. Rajan

xxx

xxx

Contributors

India, Mumbai Mumbai Cancer Registry c/o Mumbai Cancer Registry 74 Jerbai Wadia Rd Parel, Mumbai - 400012 India Tel.: +(91) 22-2412-2351 Fax: +(91) 22-2412-2351 E-mail: bcrics@vsnl.com India, Nagpur Nagpur Cancer Registry c/o Mumbai Cancer Registry 74 Jerbai Wadia Rd Parel, Mumbai - 400012 India Tel.: +(91) 22-2412-2351 Fax: +(91) 22-2412-2351 E-mail: bcrics@vsnl.com India, New Delhi Delhi Population Based Cancer Registry Dr B.R. Ambedkar Institute Rotary Cancer Cancer Hospital All India Institute of Medical Sciences New Delhi, 110 029 India Tel: (91) 11 25 688 700, (91) 11 26 588 900 ext 4823 Fax: (91) 11 26 588 408 E-mail: btyagi51@yahoo.co.in India, Poona Poona Cancer Registry c/o Mumbai Cancer Registry 74 Jerbai Wadia Rd Parel, Mumbai - 400012 India Tel.: +(91) 22-2412-2351 Fax: +(91) 22-2412-2351 E-mail: bcrics@vsnl.com India, Trivandrum Trivandrum Cancer Registry Regional Cancer Center P.O. Box 2417 Trivandrum 695 011, Kerala India Tel.: +(91) 471-2443128 Fax: +(91) 471-244 7454 E-mail: amathew@rcctvm.org

Balkrishna B.Yeole Arun P. Kurku

Balkrishna B.Yeole Arun P. Kurkure Varsha Sagdeo

B.B. Tyagi N. Manoharan Vinod Raina

Balkrishna B.Yeole Arun P. Kurkure S.S.Javadekar

Aleyamma Mathew B. Vijayaprasad P. Jayakumar B. Rajan

xxxi

xxxi

Contributors

Israel Israel National Cancer Registry 4 Shalom Yehuda St. P.O. Box 1176 Jerusalem 91010 Israel Tel.: +(972) 2-670-6818 Fax: +(972) 2-670-6884 E-mail: micha.barchana@moh.health.gov.il Japan, Aichi Prefecture Aichi Cancer Registry c/o Division of Epidemiology & Prevention Aichi Cancer Center Research Institute I-I Kanokoden, Cikusa-ku Nagoya 464-8681 Japan Tel.: +(81) 52-762-6111 Fax: +(81) 52-763-5233 E-mail: kmatsuo@aichi-cc.jp Japan, Fukui Prefecture Fukui Prefectural Cancer Registry Fukui Social Insurance Hospital 2-6-21 Nagayama-cho Katuyama-shi 911-8558 Japan Tel.: + Fax: + E-mail: fsih-08@crocus.ocn.ne.jp Japan, Hiroshima Hiroshima City Cancer Registry Department of Epidemiology Radiation Effects Research Foundation 5-2 Hijiyama Park, Minami-ku Hiroshima 732-0815 Japan Tel.: +(81) 82-261-3131 Fax: +(81) 82-262-9768 E-mail: nnishi@rerf.or.jp Japan, Miyagi Prefecture Miyagi Prefectural Cancer Registry Miyagi Cancer Society 5-7-30, Kamisugi, Aoba Sendai 980-0011 Japan Tel.: +(81) 22-233-0241 Fax: +(81) 22-262-3775 E-mail: registry@miyagi-taigan.or.jp

Micha Barchana Irena Liphshitz Rachel Alon

Kazuo Tajima Hidemi Ito Keitaro Matsuo Manami Inoue Tsuneo Masui Sachiko Hiraiwa Mariko Nakano

Manabu Fujita Masakazu Hattori

Nobuo Nishi Hiromi Sugiyama Hiroaki Katayama Kazunori Kodama Hirofumi Okuno Masao Kuwabara Keiichi Hiramatsu Kenichi Arita Wataru Yasui Shizuteru Usui Yoshikazu Nishino Ichiro Tsuji Kenya Moro

xxxii

xxxii

Contributors

Japan, Nagasaki Prefecture Nagasaki Prefectural Cancer Registry Department of Epidemiology Radiation Effects Research Foundation (RERF) 1-8-6 Nakagawa Nagasaki 850-0013 Japan Tel.: +(81) 95-823-1125 Fax: +(81) 95-825-7202 E-mail: soda@rerf.or.jp Japan, Osaka Prefecture Osaka Cancer Registry Department of Cancer Control and Statistics Osaka Medical Center for Cancer and Cardiovascular Disease Nakamichi 1-3-3, Higashinari-ku Osaka 537-8511 Japan Tel.: +(81) 6-6972-1181, ext. 2301 Fax: +(81) 6-6978-2821 E-mail: ioka-ak@mc.pref.osaka.jp Japan, Yamagata Prefecture Yamagata Prefectural Cancer Registry Yamagata Prefectural Medical Center for Cancer and Life-style Related Disease 1800 Aoyagi Yamagata 990-2292 Japan Tel.: +(81) 23-685-2752 Fax: +(81) 23-685-2605 E-mail: ashibata@ypch.gr.jp Korea Korea Central Cancer Registry National Cancer Center 809 Madu-Dong, Ilsan-Gu Goyang Gyonggi 411-769 Korea Tel.: +(82) 31-920-1504 Fax: +(82) 31-920-1520 E-mail: hrshin@ncc.re.kr

Midori Soda Ichiro Sekine Hisao Morooka Takeshi Matsuo Shinichiro Yamazaki Akihiko Suyama Takayoshi Ikeda

Akiko Ioka Hideaki Tsukuma Kunio Sakai Yasunori Sasai

Toru Matsuda Akiko Shibata

Hai-Rim Shin Young-Joo Won Kyu-Won Jung Jae-Gahb Park Eun-Kyung Hong Chang-In Suh Sang-Yi Lee Ki-Young Kim Sun-Won Seo Jong-Koo Lee

Korea, Busan Busan Cancer Registry Division of Cancer Control & Epidemiology Research Institute for National Cancer Control & Evaluation 809 Madu-Dong, Ilsan-Gu Goyang Gyonggi 411-764 Korea Tel.: + (82) 31-920-2003 Fax: +(82) 31-920-1520 E-mail: hrshin@ncc.re.kr

Hai-Rim Shin Soon-Yong Lee In-Kyoung Hwang Seo-Hee Rah Jong-Tae Lee Duk-Hee Lee Hee-Kyoung Jang Hee-Weon Lee Hyun-Joo Kong Ho-Guk Park

xxxiii

xxxiii

Contributors

Korea, Daegu Daegu Cancer Registry Department of Preventive Medicine College of Medicine Keimyung University 194 Dongsan-dong, Jung-gu Daegu 700-712 Korea Tel.: +(82) 53-250-7492 Fax: +(82) 53-250-7494 / 252-6567 E-mail: nukelee@dsmc.or.kr Korea, Daejeon Daejeon Cancer Registry Department of Preventive Medicine & Public Health College of Medicine Chungnam National University 6 Munhwa-Dong, Jung-Ku Daejeon 301-747 Korea Tel.: +(82) 42 580 8263 Fax: +(82) 42 586 8875 E-mail: ttylee@cnu.ac.kr Korea, Gwangju Gwangju Cancer Registry Department of Preventive Medicine Chonnam University Medical School #5 Hak-1-dong Dong-gu Gwangju 501-746 Korea Tel.: +(82)-62-220-4162 Fax: +(82) 62-233-0305 E-mail: jschoix@jnu.ac.kr Korea, Incheon Incheon Cancer Registry Dept. of Medical Information & Record Services INHA University of Medical Colleges 7-206, 3-Ga, Shinheung-dong, Jung-gu Incheon 400-103 Korea Tel: +(82) 32-890-3434 Fax: +(82) 32-890-2012 E-mail: woopark@inha.ac.kr Korea, Jejudo Jejudo Cancer Registry Department of Preventive Medicine Cheju National University College of Medicine #1-Ara-1-dong, Jeju, 690-756, Jejudo Korea Tel.: +(82) 64-755-5567 Fax: +(82) 64-725-2593 E-mail: jrcr@cheju.ac.kr jmbae@cheju.ac.kr aquopura@gmail.com

Choong Won Lee Sang Pyo Kim Jong Won Park In Sung Jung Hye Young Shim Eun Hee Kim

Tae Yong Lee In Sun Kwon Dae-Young Kang Seung-Moo Noh Samyong Kim Byung-Yeon Yu Suk Young Park Joo Seung Park Gye-Sung Lee In-Gyu Hong Jin-su Choi Tai-ju Hwang Young-Jin Kim Sun-Seog Kweon Min-Ho Shin

Ze-Hong Woo Woo-Chul Kim Jae-Hwan Oh Moon-Hee Lee Jeong-Soo Im Jong-Han Leem Sun-Ok Lee

Jong-Myon Bae Yeong-Ja Yang

xxxiv

xxxiv

Contributors

Korea, Seoul Seoul Cancer Registry Department of Preventive Medicine Sungkyunkwan University & Seoul National University 28 Yongon-dong, Chongno-gu Seoul 110-779 Korea (Republic of) Tel.: +(82) 2-740-8322 Fax: +(82) 2-747-4830 E-mail: mhshin@skku.edu yoahn@plaza.snu.ac.kr Korea, Ulsan Ulsan Cancer Registry Dept. of Occupational & Environmental Medicine Ulsan University Hospital #290-3 Jeonha-Dong, Dong-Gu Ulsan City 682-714 Korea Tel.: +(82) 52-250-7283 / 8819 Fax: +(82) 52-250-7289 E-mail: ciyoo62@hanmail.net Kuwait Kuwait Cancer Registry Kuwait Cancer Control Center Ministry of Health Al Shwaikh P O Box 42262 70653 Kuwait Tel.: +(965) 4812931 Fax: +(965) 4810007 E-mail: ohattab@hotmail.com Malaysia, Penang Penang Cancer Registry Penang State Health Department Level 35 & 37 Komtar 10590 Penang Malaysia Tel.: +(60) 4-262-5533 Fax: +(60) 4-261-3508 E-mail: binarai@ppg.moh.gov.my Malaysia, Sarawak Sarawak Cancer Registry Sarawak Health Department Tun Abang Haji Openg Road 93590 Kuching, Sarawak Malaysia Tel.: +(60)-82-237466 Fax: +(60)-82-254490 E-mail: ooichoohuck@yahoo.com

Myung-Hee Shin Yoon-Ok Ahn

Cheol-In Yoo Yangho Kim KyoungSook Jeong Ji Ho Lee Choong Ryeol Lee

Omar H. El Hattab Amany A.El Basmy Adel Al Asfour

Saraswathi Bina Rai T. Devaraj Aishah Knight Asikin Abdul Kadir Yasmin Sulaiman

Ooi Choo Huck Andrew Kiyu Yao Sik King Mastulu Wahab Japar Assan

xxxv

xxxv

Contributors

Oman Oman National Cancer Registry Non-Communicable Diseases Surveillance & Control Dept. DGHA (HQ) Ministry of Health P.O. Box 393 AC 113, Muscat Oman Tel: +(968) 2469-6187 Fax: +(968) 2469-5480 Email: ncd-oman@moh.gov.om dir-ncd@moh.gov.om Pakistan, South Karachi Karachi Cancer Registry Department of Pathology Sindh Medical College (adjacent JPMC) Rafiqui Shaheed Road, Cantt Karachi, 75510 Pakistan Tel.: +(92) 21-586-8421 / 0913 Fax: +(92) 21-586-0913 E-mail: yasmin.bhurgri@gmail.com

Jawad A. Al-Lawati, MD Ali J. Mohammed, MD Shalini C. Nooyi, MD Nabil H. Al-Siyabi

Yasmin Bhurgri Mishaal Bhurgri Shahid Pervez Ahmed Usman Asif Bhurgri Naveen Faridi SMH Zaidi Imtiaz Bashir Kauser Nazir Hadi Bhurgri GN Kakepoto Naila Kayani Sheema H. Hasan Mohammed Khurshid Adriano V. Laudico Ma. Rica Lumague Divina B. Esteban Lilia M. Reyes Cynthia A. Mapua Ma. Theresa Redaniel

Philippines, Manila Philippine Cancer Society - Manila Cancer Registry P.O. Box 3066 310 San Rafael St., San Miguel 1005 Manila Philippines Tel.: +(63) 2-734-2114/ (63) 2-734-2127 Fax: +(63) 2-735-2707 E-mail: mcr@philcancer.com Singapore Singapore Cancer Registry Health Promotion Board/NDRO Level 5, 3 Second Hospital Avenue Singapore 168937 Singapore Tel.: +(65) 6435-3068 Fax: +(65) 6536-5307 E-mail: hpb_cancer_registry@hpb.gov.sg Thailand, Chiang Mai Chiang Mai Cancer Registry Department of Otolaryngology Faculty of Medicine Chiang Mai University Chiang Mai 50200 Thailand Tel.: +(66) 53-945562 Fax: +(66) 53-945564 E-mail: cancer_unit@yahoo.com

Adeline L.H. Seow W.P. Koh K.S. Chia K.Y. Chow H.P. Lee K. Shanmugaratnam

Yupa Sumitsawan Songphol Srisukho Ampai Sastraruji Udomluck Chaisaengkhum Puttachart Maneesai Narate Waisri Luckkana Thetpiam Ubol Chompuphan Varunee Khamsan

xxxvi

xxxvi

Contributors

Thailand, Lampang Lampang Cancer Center 199 Moo 12 Lampang-Chiang Rai Road Pichai, Muang District Lampang 52000 Thailand Tel.: +(66) 5433-5262 Fax: +(66) 5433-5273 E-mail: lampangregistry@yahoo.com Thailand, Songkhla Songkhla Cancer Registry Faculty of Medicine Prince of Songkla University Hat Yai Songkhla 90110 Thailand Tel.: +(66) 74-451595 Fax: +(66) 74-212900 E-mail: hutcha.s@psu.ac.th Turkey, Antalya Antalya Cancer Registry Provincial Health Directorate of Antalya Toros M. Atatrk Bul. N74 07070 Antalya Turkey Tel.: + Fax: + E-mail: hulyakarakilinc@yahoo.com Turkey, Izmir Izmir Cancer Registry KIDEM, Il Saglik Mudurlugu 35210 Alsancak Izmir Turkey Tel.: +(90) 232-441-0571 Fax: +(90) 232-483-3639 E-mail: eseres@ttnet.net.tr

Surathat Pongnikorn Nimit Martin Wullop Pornruangwong Nilubol Raunroadroong Karnchana Daoprasert Nichapa Yapunya Panicha Pongnikorn Arada Pawong Hutcha Sriplung Paramee Thongsuksai Temsak Phungrassami Paradee Prechavittayakul

Hulya Karakilinc Yeliz Tepe zlem Gunduz Nuket Ozdemir Huriye Tekin Gulcan Yenigelen Gulsen Buyukgebiz Hamide Tufekci Sultan Eser Saniye Ozalan Cankut Yakut Tunay Nazli

xxxvii

xxxvii

Contributors

Europe
Austria Austrian National Cancer Registry Bundesanstalt Statistik sterreich Demographie und Arbeitsmarkt Guglgasse 13 1110 Wien Austria Tel.: +(43) 1-71128-7228 Fax: +(43) 1-71128-7445 E-mail: Monika.Hackl@statistik.gv.at Austria, Tyrol Cancer Registry of Tyrol University Hospital Innsbruck Anichstrae 35 6020 Innsbruck Austria Tel.: +(43) 512-504-22313 Fax: +(43) 512-504-22315 E-mail: willi.oberaigner@tilak.at Austria, Vorarlberg Krebsregister Vorarlberg (Cancer Registry of Vorarlberg) AKS GmbH Rheinstrasse 61 6900 Bregenz Austria Tel.: + Fax: + E-mail: elmar.stimpfl@aks.or.at Belarus Belarussian Cancer Registry Belarussian Centre for Medical Technologies Information Computer Systems, Health Adm. & Management 7a P. Brovki Street 220600 Minsk Belarus Tel.: +375 (17) 231-31-29, 292-30-80 Fax: +375 (17) 231-34-84 E-mail: spolyakov@belcmt.by belcmt2@mail.belpak.by Belgium, Antwerp Antwerp Cancer Registry University of Antwerp, Campus Drie Eiken Dept. of Epidemiology and Community Health Building R, 2nd floor Universiteitsplein 1 2610 Antwerp Belgium Tel.: +(32) 3-820-2539 Fax: +(32) 3-820-2640 E-mail: jos.droste@ua.ac.be Monika Hackl Jeannette Klimont Thomas Pascher Regina He Ernst Leser

Willi Oberaigner Helmut Mhlbck Christine Wartha Alois Harrasser Hermann Leitner

H. Concin G. Diem G. Mathis K. Parschalk E. Stimpfl W. Oberaigner

Semyon Polyakov Leonid Levin Nina Shebeko Alexander Grakovich

Eric Van Marck Joost Weyler Jos Droste

xxxviii

xxxviii

Contributors

Belgium, Flanders Belgian Cancer Registry Rue Royale 215 B-1210 Brussels Belgium Tel.: +(32) 2-250-1013 Fax: +(32) 2-250-1011 E-mail: elizabeth.vaneycken@kankerregister.org Bulgaria Bulgarian National Cancer Registry National Oncological Hospital 6 Plovdivsko Pole Street 1756 Sofia Bulgaria Tel.: +(359) 2-870-6258 Fax: +(359) 2-872-0651 E-mail: BNCR_Zdravka@netbg.com Croatia Croatian National Cancer Registry Croatian National Institute of Public Health Rockefellerova 7, 10000 Zagreb Croatia Tel: (385) 1 4863280 Fax: (385) 1 4863271 E-mail: marija.strnad@hzjz.hr ariana.znaor@hzjz.hr Czech Republic National Cancer Registry of the Czech Republic Institute of Health Information & Statistics of the Czech Republic Palackho nm. 4 P.O. Box 60 128 01 Prague 2 Czech Republic Tel.: +(420) 22-497-2660 Fax: + E-mail: uzis@uzis.cz Denmark Danish Cancer Registry Danish National Board of Health Islands Brygge 67 Postboks 1881 2300 Copenhagen S Denmark Tel.: +(45) 7222-7400 Fax: +(45) 7222-7404 E-mail: obl@sst.dk

Elisabeth Van Eycken Kris Henau Nathalie De Wever Michiel Callens Hedwig Verhaegen Karin Haustermans

Shemuel Danon Zdravka Valerianova Tsvetelina Ivanova

Marija Strnad Ariana Znaor Ljubica Bubanovic Petar Novak Djurdja Selendic Nedjeljka Vujanic

Vlasta Mazankova Jiri Holub Lenka Jurickova Eliska Vankova Blanka Skorpilova

Hans H. Storm Morten A. Hjulsager

xxxix

xxxix

Contributors

Estonia Estonian Cancer Registry North Estonian Regional Hospital Foundation's Cancer Centre Hiiu 44 11619 Tallinn Estonia Tel.: +(372) 6-172337 Fax: +(372) 6-172303 E-mail: margit.magi@regionaalhaigla.ee Finland Finnish Cancer Registry Institute for Statistical and Epidemiological Cancer Research Liisankatu 21 B 00170 Helsinki Finland Tel.: +(358) 9-135-331 Fax: +(358) 9-135-5378 E-mail: timo.hakulinen@cancer.fi France, Bas-Rhin Registre des cancers du Bas-Rhin Laboratoire dpidmiologie et de Sant Publique Facult de mdecine 11 rue Humann F-67085 Strasbourg Cedex France Tel: +(33) 3 90 24 31 95 Fax: +(33) 3 90 24 31 89 E-mail: cancer@medecine.u-strasbg.fr michel.velten@medecine.u-strasbg.fr France, Calvados Registre Gnral des Tumeurs du Calvados Centre Franois Baclesse Av du Gnral Harris B.P. 5026 14076 CAEN Cedex 05 France Tel: +(33) 2 31 45 52 45 Fax: +(33) 2 31 45 51 72 E-mail: av.guizard@baclesse.fr

Tiiu Aareleid Pille Hrmaorg Margit Mgi Kaja Rahu Mati Rahu

T. Hakulinen I. Ovaska E. Pukkala R. Sankila

Michel Velten Guy Hdelin Florence Binder-Foucaud

Anne-Valrie Guizard Vronique Bastard Jaouen Ccile Chauveau Michel Henry-Amar Jean-Franois Heron

Registre des Tumeurs Digestives du Calvados Facult de Mdecine CHU Cte de Nacre 14032 Caen Cedex France Tel: +(33) 2 31 06 51 20 Fax: +(33) 2 31 53 08 52 E-mail :guy.launoy@unicaen.fr

Vronique Bouvier Sbastien Boutreux Sverine Gonfroy-Marlire Marie Ingouf Isabelle Salomez Brice Dubois Guy Launoy

xl

xl

Contributors

France, Doubs Registre des tumeurs du Doubs Centre Hospitalier Universitaire Saint-Jacques 25030 Besanon Cedex France Tel: +(33) 3 81 21 83 12 Fax: +(33) 3 81 21 83 11 E-mail: registre-cancers@chu-besancon.fr France, Haut-Rhin Registre des cancers du Haut-Rhin 87 avenue dAltkirch BP 1070 F 68051 MULHOUSE Cedex France Tel: +(33) 3 89 64 62 51 Fax: +(33) 3 89 64 62 52 E-mail: buemia@ch-mulhouse.fr France, Hrault Registre des tumeurs de lHrault Batiment Recherche 208 rue des Apothicaires 34298 Montpellier Cedex 5 France Tel: +(33) 4 67 41 34 17 Fax: +(33) 4 67 63 42 26 E-mail: registre-tumeur@wanadoo.fr France, Isre Isre Cancer Registry 23 Chemin des Sources 38240 Meylan France Tel: +(33) 4 76 90 76 10 Fax: +(33) 4 76 41 87 00 E-mail: registre.cancer.isere@wanadoo.fr France, Loire Atlantique Registre des cancers de Loire-Atlantique et Vende CHU de Nantes Plateau des coles 50 Route de St Sbastien 44 093 NANTES CEDEX 1 France Tel: +(33) 2 40 84 69 81 Fax: +(33) 2 40 84 69 82 E-mail: fmolinie@chu-nantes.fr France, Manche Registre Gnral des Cancers de la Manche Centre Hospitalier Public du Cotentin 46 rue du Val de Saire BP 208 50102 CHERBOURG cedex France Tel: +(33) 2 33 20 70 48 Fax: +(33) 2 33 20 76 22 E-mail: s.bara@ch-cherbourg.fr

A. Danzon M. Mercier Y. Kieffer C. Langlois V. Queuche C. Gil S. Munier Antoine Buemi Jean-Michel Halna Erik-Andr Sauleau Mireille Grandadam

Brigitte Trtarre Jean-Pierre Daurs Claudine Gras-Aygon Hlne Mathieu-Daud

Marc COLONNA Patricia DELAFOSSE

Marie-Jose Leroux Marie-Franoise Le Bodic Pierre Lombrail Florence Molini Solenne Billon-Delacour Nathalie Auffret Ana-Maria Chouillet Christine Cerbelaud Anne-Delphine Tagri Magali Mtais Aurlie Bouron

xli

xli

Contributors

France, Somme Registre du Cancer de la Somme CHU Nord Ple Sant Publique 80054 AMIENS Cedex 1 France Tel: +(33) 3 22 66 82 26 Fax: +(33) 3 22 66 82 25 E-mail: registre.80@chu-amiens.fr France, Tarn Registre des cancers du Tarn B.P. 37 81001 Albi Cedex France Tel: +(33) 5 63 47 59 51 Fax: +(33) 5 63 38 20 12 E-mail: registre-cancer-du-tarn@wanadoo.fr France, Vende Registre des cancers de Loire-Atlantique et Vende CHU de Nantes Plateau des coles 50 Route de St Sbastien 44 093 NANTES CEDEX 1 France Tel: +(33) 2 40 84 69 81 Fax: +(33) 2 40 84 69 82 E-mail: fmolinie@chu-nantes.fr Germany, Brandenburg Gemeinsames Krebsregister der Lnder Berlin, Brandenburg, Mecklenburg-Vorpommern, SachsenAnhalt und der Freistaaten Sachsen und Thringen (GKR) (Common Cancer Registry) Brodauer Str. 16-22 12621 Berlin Germany Tel.: +(30) 565 81 401 Fax: +(30) 565 81 444 E-mail: Roland.Stabenow@gkr.verwalt-berlin.de Germany, Hamburg Hamburgisches Krebsregister (Hamburg Cancer Registry) Billstrasse 80 D - 20539 Hamburg Germany Tel.: +(49) 40-428-37-2211 Fax: +(49) 40-428-37-2655 E-mail: HamburgischesKrebsregister@bsg.hamburg.de

Olivier Ganry Alain Dubreuil Nicole Bourdon-Raverdy Elvira Martin Agns Thulliez Christine Cott

Pascale Grosclaude Martine Sauvage Laetitia Daubisse-Marliac Yves Duchne Corine Ferre-Grevaz Rgine Litre-Tournier Chantal Miquel-Herail Hlne Siguier Anne-Marie Kadi-Hanifi Paolo Bercelli Florence Molini Solenne Billon-Delacour Marie Proux Assia Hami Katia Mnanteau Thrse Rabaud Blandine Chauvet Marie-Louise Rouvier Roland Stabenow Bettina Eisinger Brigitte Streller Mandy Schulz

Stefan Hentschel Ulf Haartje Norbert Burkhardt Annie Funk Alice Nennecke

xlii

xlii

Contributors

Germany, Mecklenburg-Western Pomerania Gemeinsames Krebsregister der Lnder Berlin, Brandenburg, Mecklenburg-Vorpommern, SachsenAnhalt und der Freistaaten Sachsen und Thringen (GKR) (Common Cancer Registry) Brodauer Str. 16-22 12621 Berlin Germany Tel.: +(30) 565 81 401 Fax: +(30) 565 81 444 E-mail: Roland.Stabenow@gkr.verwalt-berlin.de Germany, Munich Tumorregister Mnchen (Munich Cancer Registry) IBE / Klinikum Grosshadern Marchioninistr. 15 81377 Mnchen Germany Tel.: +(49) 89-7095- 4752 Fax: +(49) 89-7095-4753 E-mail: tumor@ibe.med.uni-muenchen.de Germany, North Rhine-Westphalia: Mnster Epidemiologisches Krebsregister NRW (Cancer Registry of Northrhine-Westphalia) Krebsregister Mnster Domagkstrasse 3 D-48149 Mnster Germany Tel.: +(49) 251 8358571 Fax: +(49) 251 8358577 E-mail: volker.krieg@krebsregister.nrw.de volkmar.mattauch@krebsregister.nrw.de Germany, Saarland Saarland Cancer Registry Ministry of Public Health Virchowstr. 7 66119 Saarbrcken Germany Tel.: +(49) 681-501-5969 Fax: +(49) 681-501-5998 E-mail: h.ziegler@gbe-ekr.saarland.de Germany, Free State of Saxony Gemeinsames Krebsregister der Lnder Berlin, Brandenburg, Mecklenburg-Vorpommern, SachsenAnhalt und der Freistaaten Sachsen und Thringen (GKR) (Common Cancer Registry) Brodauer Str. 16-22 12621 Berlin Germany Tel.: +(30) 565 81 401 Fax: +(30) 565 81 444 E-mail: Roland.Stabenow@gkr.verwalt-berlin.de

Roland Stabenow Bettina Eisinger Brigitte Streller Mandy Schulz

D. Hlzel G. Schubert-Fritschle J. Engel M. Schmidt W. Tretter U. Mansmann

Volker Krieg Martin Lehnert Volkmar Mattauch Hans-Werner Hense Birgit Weihrauch

Hartwig Ziegler Christa Stegmaier Rainer Mller

Roland Stabenow Bettina Eisinger Brigitte Streller Mandy Schulz

xliii

xliii

Contributors

Iceland The Icelandic Cancer Registry Skgarhld 8 P.O. Box 5420 125 Reykjavik Iceland Tel.: +(354) 540-1900 Fax: +(354) 540-1910 E-mail: jongj@krabb.is Ireland National Cancer Registry Ireland University College Elm Court Boreenmanna Road Cork Ireland Tel.: +(353) 21-431-8014 Fax: +(353) 21-431-8016 E-mail: h.comber@ncri.ie Italy, Biella Province Piedmont Cancer Registry, Province of Biella Epidemiology Unit Prevention Department ASL 12 Biella Via Don Sturzo 20 13900 Biella (BI) Italy Tel.: +(39) 015-350-3665 / 3655 Fax: +(39) 015-8495222 E-mail: adriano.giacomin@asl12.piemonte.it Italy, Brescia Province Brescia Health Unit Cancer Registry Registro Tumori dellASL di Brescia Via Cantore, 20 25128 Brescia Italy Tel.: +(39) 030 3838713/714 Fax: +(39) 030 3701404 E-mail: regtumbs@med.unibs.it

Jn Gunnlaugur Jnasson Laufey Tryggvadttir Anna Jnsdttir Kristn Bjarnadttir Sigrn Stefnsdttir Elnborg J. lafsdttir Gudrdur H. lafsdttir Thorgils Vlundarson Mary Chambers Harry Comber Fiona Dwane Tracy Kelleher Paul Walsh

Adriano Giacomin Simona Andreone Lucia Preto Piercarlo Vercellino Roberto Zanetti

Francesco Donato Rosa Maria Limina Mario Lazzari Assunta Omassi Milena Guarinoni Giuseppe Zani Francesco Piovani Mauro Damiolini Annamaria Indelicato Carmelo Scarcella Giovanna Tagliabue Paolo Contiero Paolo Crosignani Stefano Ferretti Laura Marzola Elena Migliari Nada Carletti Italo Nenci

Italy, Ferrara Province Registro Tumori della Provincia di Ferrara (Ferrara Cancer Registry) Sez. Anatomia Patologica Dip. Med. Sperimentale & Diagnostica Universit di Ferrara Via Fossato di Mortara, 64 44100 Ferrara Italy Tel.: +(39) 0532-291513 / 501 Fax: +(39) 0532-248021 E-mail: frs@unife.it

xliv

xliv

Contributors

Italy, Florence & Prato Registro Tumori Toscano (R.T.T) (Tuscany Cancer Registry) Unit of Epidemiology Research Institute of the Tuscany Region Via di San Salvi 12 50135 Florence Italy Tel.: +(39) 055-626-8321 Fax: +(39) 055-679954 E-mail: e.paci@cspo.it Italy, Genoa Province Liguria Region Cancer Registry Epidemiologia Descrittiva Istituto Nazionale per la Ricerca sul Cancro Largo Rosanna Benzi, n. 10 16132 Genova Italy Tel.: +(39) 010-5600-0961 Fax: +(39) 010-5600-0956 E-mail: marina.vercelli@istge.it

Eugenio Paci Emanuele Crocetti Alessandra Benvenuti Carlotta Buzzoni Adele Caldarella Lucia Giovannetti Francesco Giusti Teresa Intrieri Gianfranco Manneschi Guido Miccinesi Claudio Sacchettini Marina Vercelli Marani Enza Claudia Casella Puppo Antonella Celesia Maria Vittoria Cogno Roberta Grondona Anna Maria Elsa Garrone Giovanna Giachero Simone Manenti Alberto Quaglia Maria Antonietta Orengo Susanna Vitarelli Silvia Antonini

Italy, Macerata Province Macerata Province Cancer Registry Dip. Medicina Sperimentale e Sanit Pubblica Universit, Via E. Betti 3 62032 Camerino (MC) Italy Tel: +(39) 0737-402403 Fax: +(39) 0737-402403 E-mail: susanna.vitarelli@unicam.it Italy, Milan Cancer Registry of Milan Epidemiology Unit Local Health Autority of Milan Corso Italia, 19 20122 Milano Italy Tel.: +(39) 02 85782124 Fax: +(39) 02 85782128 E-mail: arusso@asl.milano.it Italy, Modena Province Registro Tumori della Provincia di Modena (Modena Cancer Registry) Policlinico Via del Pozzo, 71 41100 Modena Italy Tel.: +(39) 059-422-4337 / 2577 Fax: +(39) 059-422-4152 / 4549 E-mail: rtm@unimore.it

Antonio Russo Mariangela Autelitano Simona Ghilardi Annamaria Bonini Luisa Filipazzi Cinzia Giubelli Luigi Bisanti

Massimo Federico Maria Elisa Artioli Claudia Cirilli Ivan Rashid Katia Valla

xlv

xlv

Contributors

Italy, Naples Registro Tumori di Popolazione Regione Campania (Campania Cancer Registry) Azienda Sanitaria Locale Napoli 4 Piazza San Giovanni 80031 Brusciano (NA) Italy Tel.: +(39) 081-519-0505 Fax: +(39) 081-519-0505 E-mail: mariofusco2@virgilio.it Italy, North East North East of Italy Cancer Surveillance Network (NEICSN) Agenzia Regionale della Sanit Regione Autonoma Friuli Venezia Giulia Via Pozzuolo, 330 33100 UDINE Italy Tel.: +(39) 434-659-354 Fax: +(39) 434-659-222 E-mail: registro.tumori@sanita.fvg.it Italy, Parma Province Registro Tumori di Parma (Parma Province Cancer Registry) Divisione di Oncologia Medica Azienda Ospedaliera di Parma Via dell'Abbeveratoia 4 43100 Parma Italy Tel.: +(39) 0521-991660 Fax: +(39) 0521-995448 E-mail: vdelisi@ao.pr.it Italy, Ragusa Province Ragusa Cancer Registry Department of Oncology Azienda Ospedaliera Civile M.P.Arezzo. Via Dante, 109 97100 Ragusa Italy Tel.: +(39) 0932-600050/600055 Fax: +(39) 0932-682169 E-mail: rtumino@tin.it

Mario Fusco Raffaele Palombino Biagio Vassante Caterina Bellatalla Maria Fusco Margherita Panico Carmela Perrotta

Diego Serraino Margherita de Dottori Laura Battisti Francesco Bell Eduard Egarter-Vigl Silva Franchini Silvano Piffer Fabio Vittadello Loris Zanier

Vincenzo De Lisi Paolo Sgargi Lidia Serventi Francesco Bozzani Francesco Leonardi

Rosario Tumino Giuseppina Pavone Maria Guglielmina La Rosa Giuseppe Cascone Graziella Frasca Maria Concetta Giurdanella Carmela Nicita Patrizia Concetta Rollo Aurora Sigona Eugenia Spata Giuseppe Cianciolo Caterina Martorana Gabriele Morana Maria Grazia Ruggeri Stefania Vacirca Lucia Mangone Silvia Candela

Italy, Reggio Emilia Province Reggio Emilia Cancer Registry Registro Tumori Reggiano c/o Dip. Sanita Pubblica AUSL RE via Amendola 2 42100 Reggio Emilia Italy Tel.: + E-mail: Lucia.Mangone@ausl.re.it

xlvi

xlvi

Contributors

Italy, Romagna Region Registro Tumori della Romagna (Romagna Cancer Registry) c/o Romagna Cancer Institute (I.R.S.T.) Department of Medical Oncology Istituto Oncologico Romagnolo Hospital Morgagni-Pierantoni Via Carlo Forlanini, 34 47100 Forl Italy Tel.: +(39) 0543-731583 Fax: +(39) 0543-731583 E-mail: rtromagna@ausl.fo.it Italy, Salerno Province Salerno Cancer Registry via Loria, 24 84129 Salerno Italy Tel.: +(39) 089 522024 Fax: +(39) 089 338514 E-mail: regtum@tiscali.it Italy, Sassari Province Registro Tumori della Provincia di Sassari (Cancer Registry of Sassari) Via Tempio 5 07100 Sassari Italy Tel.: +(39) 079-206-2442 Fax: +(39) 079-206-2445 E-mail: mariobudroni@tiscali.it Italy, Syracuse Province Territorial Registry of Pathology (RTP) Siracusa Local Health Authority of Syracuse Corso Gelone 17-96100 Syracuse Italy Tel.: +(39) 0931-48 4341 Fax: +(39) 0931-484383 E-mail: distretto1.asl8sr@interbusiness.it Italy, Sondrio Registro Tumori Della Provincia Di Sondrio (Sondrio Cancer Registry) Azienda Sanitaria Locale Sondrio Via Nazario Sauro, 38 23100 Sondrio Italy Tel.: +(39) 342 555845 Fax: +(39) 342 555812 E-mail: r.tessandori@asl.sondrio.it

Dino Amadori Fabio Falcini Chiara Balducci Lauro Bucchi Carlo Cordaro Carla Fabbri Flavia Foca Stefania Giorgetti Alessandra Ravaioli Mila Ravegnani Rosa Vattiato Benedetta Vitali Andrea Donato Anna Maria Apicella Andrea Ferrentino Arturo Iannelli Gennaro Senatore Arrigo Zevola

Mario Budroni Rosaria Cesaraccio Daniela Pirino Ornelia Sechi Massimiliano Oggiano Daniela Piras Amelia Sechi Antonio Cossu Giuseppe Palmieri Francesco Tanda Salvatore Sciacca Anselmo Madeddu Maria Lia Contrino Francesco Tisano

R. Tessandori M. Tognela R. Giardini A. Buscemi G. Tagliabue P. Contiero M.C. Manca A. Tittarelli S. Fabiano A. Bertolini

xlvii

xlvii

Contributors

Italy, Torino Piedmont Cancer Registry, City of Torino Centro di Prevenzione Oncologica Via San Francesco da Paola, 31 10123 Torino Italy Tel.: +(39) 011-633-3870 Fax: +(39) 011-633-3861 E-mail: roberto.zanetti@cpo.it Italy, Umbria Region Registro Tumori Umbro di Popolazione (Umbria Cancer Registry) Dipartimento di Specialit Medico-Chirurgiche e Sanit Pubblica Universit degli Studi Via del Giochetto 06100 Perugia Italy Tel.: +(39) 075-585-7329 Fax: +(39) 075-585-7317 E-mail: larosaf@unipg.it Italy, Varese Province Lombardy Cancer Registry, Varese Province National Cancer Institute Via Venezian 1, 20133 Milan Italy Tel: (39) 02.23902501 Fax: (39) 0223902762 E-mail: canreg@istitutotumori.mi.it occam@istitutotumori.mi.it Paolo.Contiero@istitutotumori.mi.it

Roberto Zanetti Stefano Rosso Silvia Patriarca Piera Vicari Rossana Prandi Irene Sobrato Franca Gilardi Maria Giusy Miglietta Cristina Lefevre La Rosa Francesco Stracci Fabrizio Cassetti Tiziana Petrinelli Annamaria Costarelli Daniela Canosa Antonio Scheibel Massimo Mastrandrea Vito

Crosignani Paolo Tagliabue Giovanna Contiero Paolo Fabiano Sabrina Maghini Anna Tittarelli Andrea Codazzi Tiziana Frassoldi Emanuela Costa Enrica Gada Daniela Vigano Clotilde Berrino Franco Paola Zambon Alessandro Andolfo Maddalena Baracco Francesca Barizza Emanuela Bovo Antonella Dal Cin Anna Rita Fiore Alessandra Greco Stefano Guzzinati Daniele Monetti Alberto Rosano Carmen Fiorella Stocco Sandro Tognazzo A.Stengrevics A.Eglite I.Gajevska U.Kojalo K.Rudzitis

Italy, Veneto Region Veneto Tumour Registry Regione del Veneto - Assessorato alle Politiche Sanitarie Istituto Oncologico Veneto - IRCCS Via Gattamelata, 64 35128 Padova Italy Tel.: +(39) 049-821-5605 Fax: +(39) 049-821-5983 E-mail: paola.zambon@unipd.it

Latvia Latvian Cancer Registry Latvian Oncological Center Hipokrata str. 4 1079 Riga Latvia Tel.: +(371) 704-2055 Fax: +(371) 753-9160 E-mail: aivars@onkoc.mt.lv

xlviii

xlviii

Contributors

Lithuania Lithuanian Cancer Registry Lithuanian Oncology Center Polocko 2 Vilnius 2007 Lithuania Tel.: +(370) 2-614130 Fax: +(370) 2-614130 E-mail: kancerreg@is.lt Malta Malta National Cancer Registry (MNCR) Dept. of Health Information Guardamangia Hill Guardamangia PTA 1313 Malta Tel.: +(356) 25599000 Fax: +(356) 25599385 E-mail: miriam.dalmas@gov.mt The Netherlands Netherlands Cancer Registry Association of Comprehensive Cancer Centres Catharijnesingel 53 P.O. Box 19001 3501 DA Utrecht The Netherlands Tel.: +(31) 30-234-3780 Fax: +(31) 30-234-3632 E-mail: j.vandijck@iko.nl s.siesling@ikst.nl Netherlands, Eindhoven Eindhoven Cancer Registry Comprehensive Cancer Centre South (IKZ) P.O. Box 231 5600 AE Eindhoven Netherlands Tel: +(31) 40 -297-1616 Fax: +(31) 40-297-1610 Email: jw.coebergh@ikz.nl coebergh@planet.nl The Netherlands, Maastricht Maastricht Cancer Registry Comprehensive Cancer Centre Limburg (IKL) Parkweg 20 P.O. Box 2208 6201 HA Maastricht The Netherlands Tel.: +(31) 43-325-4059 Fax: +(31) 43-325-2474 E-mail: m.dirx@ikl.nl

Juozas Kurtinaitis Giedre Smailyte Birute Aleknaviciene Kristina Rotkevic Michailas Aizenas Arvydas Laurinavicius

Miriam Dalmas

J. van Dijck S. Siesling M. Dirx O. Visser M. Janssen-Heijnen M. van der Heiden M. Schaapveld A. Reedijk M. Jansen-Landheer R. Otter A. Wit JWW Coebergh M. Louwman LH van der Heijden

Miranda Dirx Hans Huveneers Anita Botterweck Johan Bruijnen

xlix

xlix

Contributors

Norway Cancer Registry of Norway Institute for Epidemiological Research Montebello 0310 Oslo Norway Tel.: +(47) 22-451300 Fax: +(47) 22-451370 E-mail: Kreftregisteret@kreftregisteret.no Poland, Cracow Cracow Cancer Registry Unit of Epidemiology Centre of Oncology Maria Sklodowska-Curie Memorial Institute Garncarska 11 31-115 Krakw Poland Tel.: +(48) 12-422-9900 Fax: +(48) 12-426-1370 E-mail: z5rachta@cyf-kr.edu.pl Poland, Kielce Holycross Cancer Registry Holycross Cancer Centre Artwinskiego 3 25-734 Kielce Poland Tel.: +(48) 41-367-4901 Fax: +(48) 41-345-4471 E-mail: ryszard.mezyk@onkol.kielce.pl Poland, Warsaw City Warsaw Cancer Registry The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology ul. W.K. Roentgen 5 P.O. Box 106 02-781 Warsaw Poland Tel.: +(48) 22-546-28-85 Fax: +(48) 22-546-28-79 E-mail: mzwierko@coi.waw.pl Portugal, Porto Registo Oncologico Regional do Norte - RORENO Servico de Epidemiologia Inst. Portugus de Oncologia do Porto Rua Antnio Bernardino da Almeida 4250-072 Porto Portugal Tel: +(351) 22-550-2011 Fax: +(351) 22-502-6489 Email: diripo@ipoporto.min-saude.pt

Frydis Langmark Bjrn Mller Freddie I. Bray Tom B. Johannesen Aage Johansen Svein Erling Tysvr Siri Larnningen Olaug Talleraas Jadwiga Rachtan Lucja Molong Justyna Bajorek Malgorzata Geleta Renata Zmurko 6.Anna Widawska

Stanislaw Gd Urszula Siudowska Ryszard Myk Teresa Karpacz Sebastian Czarnecki Anna Giemza Dorota Stpie Edyta Pokrzepa Zbigniew Popioek Zwierko Maria Wronkowski Zbigniew Turowicz Agnieszka Karwowski Andrzej Charazinska Ewa Chorchos Ewa Czerwinska Urszula Przybysz Elzbieta Przybysz Zofia Wasowska Jadwiga Maria Jos Bento Sofia Silvestre Beatriz Serro Teresina Amaro Rui Henrique Rosa Morais Laranja Pontes

Contributors

Portugal, South Regional Registo Oncolgico Regional Sul (South Regional Cancer Registry) Instituto Portugus de Oncologia de Francisco Gentil Centro Regional de Lisboa Rua Professor Lima Basto 1093 Lisbon codex Portugal Tel.: +(351) 21-722-9852 Fax: +(351) 21-722-9806 E-mail: ana.miranda@ipolisboa.min-saude.pt Russia, St Petersburg Population-Based Cancer Registry of St Petersburg N.N. Petrov Research Institute of Oncology Leningradskaya St. 68, Pesochny 2 197758 St Petersburg Russia Tel.: +(7) 812-252--5110 Fax: +(7) 812-252-7944 E-mail: cr@miac.zdrav.spb.ru Serbia Cancer Registry of Central Serbia Institute of Public Health of Serbia 5, Dr Subotica St. 11000 Belgrade Serbia Tel.: +(381) 11-684566 Fax: +(381) 11-685735 E-mail: nezaraznibatut@yahoo.com Slovak Republic National Cancer Registry of the Slovak Republic National Health Information Center Lazaretsk 26 811 09 Bratislava Slovak Republic Tel.: +(421) 2-4464-7094 Fax: +(421) 2-4464-7095 E-mail: martina.ondrusova@nczisk.sk diba@nczisk.sk Slovenia Cancer Registry of Slovenia Epidemiology and Cancer Registries Institute of Oncology Zaloka 2 1000 Ljubljana Slovenia Tel.: +(386) 1-432-2316 Fax: +(386) 1-431-0271 E-mail: mzakelj@onko-i.si

Ana Da Costa Miranda Rute Martins Fonseca Alexandra Mayer Pereira Paulo Pinheiro Luisa Gloria Pedro Oliveira Manuel Castro Ribeiro Edward Limbert

V.M.Merabishvili T.L.Tsvetkova O.F.Chepik O.T.Dyatchenko I.V.Apalkova I.V.Kiselnikova

Andjelka Vukicevic Dragan Miljus Snezana Zivkovic Natasa Mickovski Ivana Rakocevic Snezana Plavsic Sanja Savkovic

Martina Ondruov Adriana Obsitnikov Ivan Pleko Chakameh Safaei Diba Daniela tefakov Ivan Kuzma Juraj Adamk Boena Hlavat

Maja Primic akelj Vera Pompe Kirn Vesna Zadnik Tina agar Franika krlec

li

li

Contributors

Spain, Albacete Registro de Cncer de Albacete (Albacete Cancer Registry) Junta de Comunidades de Castilla - La Mancha Seccion de Epidemiologia - Delegacion de Sanidad Avda. Guardia Civil 5 02005 Albacete Spain Tel.: +(34) 967-557956 Fax: +(34) 967- 557964 E-mail: ealmar@jccm.es Spain, Asturias Registro de Tumores del Principado de Asturias (Asturias Cancer Registry) Seccin de Informacin Sanitaria Consejera de Salud y Servicios Sociales C/ General Elorza 32,33001 Oviedo Asturias Spain Tel.: +(34) 985-10-63-79 Fax: +(34) 985-10-65-20 E-mail: ramonqg@princast.es Spain, Basque Country Basque Country Cancer Registry Departamento de Sanidad Gobierno Vasco c/ Duque de Wellington, 2 01010 Vitoria-Gasteiz Spain Tel.: +(34) 945-019235 Fax: +(34) 945-019280 E-mail: info5-san@ej-gv.es Spain, Canary Islands Registro Poblacional de Cncer de la Comunidad Autnoma de Canarias (Canary Cancer Registry) Direccin General de Salud Pblica Rambla General Franco, 53 38006 Santa Cruz de Tenerife Tenerife Spain Tel.: +(34) 928-452626 or (34) 922-474238 / 247 Fax: +(34) 928-452226 or (34) 922-474236 E-mail: mrojmar@gobiernodecanarias.org Spain, Cuenca Registro de Cncer de Cuenca (Cuenca Cancer Registry) Delegacin Provincial de Sanidad C/ Las Torres, 61 16071 Cuenca Spain Tel.: +(34) 969-176544 Fax: +(34) 969-176544 E-mail: epicuenca@jccm.es

Enrique Almar Marqus Antonio Mateos Ramos Cristina Ramrez Crcoles Jos Anglica Gmez Martnez Isidro de la Cruz de Julian Carlos Navarro Honrubia Adelaida Gonzalez Gmez Manuel Atienzar Tobarra Pablo Lemberg Lapaco

Marcial Argelles Adamina Losada J. Ramn Quirs

M Isabel Izarzugaza Mikel Errasti Joseba Bidaurrazaga Nerea Larraaga M Cres Tobalina M Jess Michelena Enrique Peir Cristina Sarasqueta Maite Barriola Isabel Portillo Martin Rodriguez Aleman Herrera Rojas Martin Fernandez Nakoura

Jos Maria Diaz Garcia Rosario Jimnez Chillaron Amparo Chumillas Martinez Ricardo Luengo Higueras Maria Angeles Higueras Medina Jesus Razquin Murillo Jos Luis Guerra Moyano Maria Otero Lorenzo Antonio De Lucas Veguillas

lii

lii

Contributors

Spain, Girona Girona Cancer Registry Passatge Farinera Teixidor, 1, 1r-2a 17005 Girona Spain Tel.: +(34) 972-207406 Fax: +(34) 972-206180 E-mail: aizquierdo@ico.scs.es

Angel Izquierdo Rafael Marcos-Gragera Loreto Vilardell Pau Viladiu Josep Maria Borrs Josepa Ribes Joan Borrs Jaume Galceran Francesc-Xavier Bosch Vctor Moreno Carmen Martnez Garca Maria-Jos Snchez Prez Victoria Barragn Snchez Carmen Ruiz Baena Carmen Estvez Estvez Yoe Ling Chang Chan Adriano Calzas Urrutia

Spain, Granada Granada Cancer Registry Escuela Andaluza de Salud Pblica Campus Universitario de Cartuja, s/n Ap. Correos 2070 18080 Granada Spain Tel.: +(34) 958-027477 Fax: +(34) 958-027503 E-mail: carmen.martinez.easp@juntadeandalucia.es Spain, Murcia Murcia Cancer Registry Servicio de Epidemiologa Consejera de Sanidad Ronsa de Levante, 11 30008 Murcia Spain Tel: +(34) 968 362039 Fax: +(34) 968 366656 E-mail: carmen.navarro@carm.es mdolores.chirlaque@carm.es Spain, Navarra Navarra Cancer Registry Instituto de Salud Pblica Servicio de Epidemiologa C/. Leyre, 15 31003 Pamplona Spain Tel.: +(34) 848-423464 Fax: +(34) 848-423474 E-mail: me.ardanaz.aicua@cfnavarra.es Spain, Tarragona Tarragona Cancer Registry Fundacio Lliga per a la Investigaci i Prevenci del Cancer (FUNCA) C/Sant Joan, s/n 43201 Reus Catalonia Spain Tel.: +(34) 977-326530 Fax: +(34) 977-312353 E-mail: jgalceran@grupsagessa.com

Carmen Navarro Mara-Dolores Chirlaque Isabel Valera Jacinta Tortosa Encarna Prraga Concepcin Lpez-Rojo Sandra Garrido Mirari Mrquez Mara-Jos Snchez Diego Salmern Eva Ardanaz Aurelio Barricarte M. Eugenia Prez de Rada Carmen Ezponda Nieves Navaridas

Joan Borrs Jaume Galceran Llus Piol Xavier Card Alberto Ameijide ngel Izquierdo Rafael Marcos Vctor Moreno Pau Viladiu F. Xavier Bosch

liii

liii

Contributors

Spain, Zaragoza Registro de Cncer de Zaragoza (Cancer Registry of Zaragoza) Departamento de Salud y Consumo Direccin General de Salud Publica Ramn y Cajal 68 50004 Zaragoza Spain Tel.: +(34) 976-715915 Fax: +(34) 976-447148 E-mail: cmartos@aragon.es Sweden Swedish Cancer Registry Centre for Epidemiology National Board of Health and Welfare SE-106 30 Stockholm Sweden Tel.: +(46) 75-247-3000 Fax: +(46) 75-247-3327 E-mail: cancerregistret@socialstyrelsen.se Switzerland, Geneva Registre Genevois des Tumeurs (Geneva Cancer Registry) 55 boulevard de la Cluse 1205 Genve Switzerland Tel.: +(41) 22-379-4950 Fax: +(41) 22-379-4971 E-mail: christine.bouchardymagnin@imsp.unige.ch Switzerland, Graubnden & Glarus Kantonales Krebsregister Graubnden und Glarus (Cancer Registry of Graubnden und Glarus) Institut fr Pathologie Rt. Kantonsspital Chur Loestrae 170 7000 Chur Switzerland Tel.: +(41) 81-256-6543 Fax: +(41) 81-256-6544 E-mail: Harald.Frick@ksgr.ch Switzerland, Neuchtel Registre Neuchtelois des Tumeurs (Neuchtel Cancer Registry) 7, Avenue des Cadolles 2000 Neuchtel Switzerland Tel.: +(41) 32-722-9644 Fax: +(41) 32-722-9643 E-mail: fabio.levi@chuv.ch

M.Carmen Martos Gloria Garcia-Carpintero M.Pilar Marco Salvador Pastor Jose Luis Arribas Javier Mateos Milagros Bernal Desiderio Buil Cristina Feja Mariano Esteba Lotti Barlow Mats Talbck sa Klint

Harald Frick

F. Levi G. Erler* M. Maspoli R. Choffat L. Randimbison * Deceased

liv

liv

Contributors

Switzerland, St Gall-Appenzell Krebsregister St. Gallen Appenzell (Cancer Registry of St. Gall-Appenzell) 7 Flurhofstr. 9000 St Gallen Switzerland Tel.: +(41) 71-494-2107 Fax: +(41) 71-494-6176 E-mail: silvia.ess@kssg.ch Switzerland, Ticino Registro dei Tumori del Cantone Ticino (Ticino Cancer Registry) Istituto Cantonale di Patologia Via in Selva 24 6601 Locarno 1 Switzerland Tel.: +(41) 91-816-0823 Fax: +(41) 91-816-0829 E-mail: andrea.bordoni@ti.ch Switzerland, Valais Registre Valaisan des Tumeurs Institut Central des Hpitaux Valaisans Avenue Grand-Champsec 86 Case Postale 736 1951 Sion Switzerland Tel: +(41) 27-603-4855 Fax: +(41) 27-603-4974 Email: isabelle.konzelmann@ichv.ch observatoire@ichv.ch Switzerland, Vaud Registre Vaudois des Tumeurs (Vaud Cancer Registry) Institut de mdecine sociale et prventive (IUMSP) Centre Hospitalier Universitaire Vaudois et Universit de Lausanne CHUV- Falaises 1 CH-1011 Lausanne Switzerland Tel.: +(41) 21-314-7311 Fax: +(41) 21-323-0303 E-mail: fabio.levi@chuv.ch UK, England, East of England Region Eastern Cancer Registration and Information Centre (ECRIC) Unit C, Magog Court Shelford Bottom Hinton Way Cambridge CB22 3AD UK Tel.: +(44) 1223-216591 Fax: +(44) 1223-213571 E-mail: david.greenberg@nhs.net

Silvia Ess Dyntar Daniela Egger Hansruedi

A.Bordoni P. Mazzola

Isabelle Konzelmann Daniel de Weck Frdric Favre Jean-Christophe Lthi

F. Levi V.C. Te L. Randimbison R. Choffat

David Greenberg Karen Wright Clem Brown Jem Rashbass

lv

lv

Contributors

UK, England, Merseyside and Cheshire Merseyside & Cheshire Cancer Registry 2nd Floor, Muspratt Building University of Liverpool Liverpool L69 3GB UK Tel.: +(44) 151-794-5691 Fax: +(44) 151-794-5700 E-mail: tony.moran@nwcr.nhs.uk UK, England, North Western North Western Cancer Registry Christie Hospital NHS Trust Kinnaird Road Withington Manchester M20 4QL UK Tel.: +(44) 161-446-8080 Fax: +(44) 161-446-3590 E-mail: tony.moran@nwcr.nhs.uk UK, England, Northern and Yorkshire Northern & Yorkshire Cancer Registry & Information Service Arthington House Hospital Lane Leeds LS16 6QB UK Tel.: +(44) 113-392-4309 Fax: +(44) 113-392-4178 E-mail: d.forman@leeds.ac.uk UK, England, Oxford Region Oxford Cancer Intelligence Unit 4150 Chancellor court Oxford Business Park South OX4 2GX UK Tel.: +(44)1 865 33 4792 Fax: +(44)1 865 33 4794 E-mail: neil.kennedy@ociu.nhs.uk UK, England, South and Western Regions South West Cancer Intelligence Service South West Public Health Observatory 149 Whiteladies Road Bristol, BS8 2RA UK Tel.: +(44) 1179-706474 Fax: +(44) 1179-706481 E-mail: andy.pring@swpho.nhs.uk

A. Moran L. Shack J. Kelly

A. Moran L. Shack

David Forman Caroline Brook Machael Walkley Roman Taterek-Gintowt Gareth Adams

Monica Roche Neil Kennedy Pat Hall Sandra Edwards Ann Watters

Andy Pring Tina Ball Diane Prior Julia Verne

lvi

lvi

Contributors

UK, England, Thames Thames Cancer Registry King's College London 1st Floor, Capital House 42 Weston Street London SE1 3QD UK Tel.: +(44) 20-7378-7688 Fax: +(44) 20-7378-9510 E-mail: henrik.moller@kcl.ac.uk UK, England, Trent Trent Cancer Registry 5 Old Fulwood Road Sheffield S10 3TG South Yorkshire UK Tel.: +(44) 114-226-3560 Fax: +(44) 114-226-3561 E-mail: andy.smith@trentcancer.nhs.uk UK, England, West Midlands West Midlands Cancer Intelligence Unit Public Health Building The University of Birmingham Birmingham B15 2TT UK Tel.: +(44) 121-414-7711 Fax: +(44) 121-414-7712 E-mail: gill.lawrence@wmciu.nhs.uk UK, Northern Ireland Northern Ireland Cancer Registry Centre for Clinical and Population Sciences Mulhouse Building Grosvenor Road Belfast BT 12 6BJ UK Tel.: +(44) 28-9063-2573 Fax: +(44) 28-9024-8017 E-mail: a.gavin@qub.ac.uk w.hamill@qub.ac.uk UK, Scotland Scottish Cancer Registry Information Services Division (NHS National Services Scotland) Area 159A Gyle Square 1 South Gyle Crescent Edinburgh EH12 9EB UK Tel.: +(44) 131-275-6092 Fax: +(44) 131-275-7511 E-mail: David.Brewster@isd.csa.scot.nhs.uk

Henrik Mller Neil Hanchett Heather Bourne Pat McDade

Sarah Cuthbertson Louise Hollingworth Gillian Percival Jason Poole Paul B. Silcocks Andrew Smith Alexandra E.A. Thackeray Sue Wild G. M. Lawrence C. Livings M. Porter C. Jones D. Thomas C.Thomson

Anna T Gavin Richard J Middleton Wendy Hamill Colin R. Fox

David Brewster Lesley Bhatti Alison McDonald Judith Stark Roger Black

lvii

lvii

Contributors

Oceania
Australia, Australian Capital Territory ACT Cancer Registry Population Health Research Centre ACT Health Level 1, Building 5 The Canberra Hospital P.O. Box 11 Woden, ACT 2606 Australia Tel.: +(61) 2-6207-4032 Fax: +(61) 2-6244-4138 E-mail: cancerregistry@act.gov.au Australia, New South Wales New South Wales Central Cancer Registry Cancer Institute (NSW) Level 1 Biomedical Building Australian Technology Park Everleigh, NSW 2015 Locked mail bag 1 Kings Cross, NSW 1340 Australia Tel.: +(61) 2-8374-5747 Fax: +(61) 2-8374-5744 E-mail: elizabeth.tracey@cancerinstitute.org.au Australia, Northern Territory Northern Territory Cancer Registry Health Gains Planning Branch NT Department of Health & Community Services P.O. Box 40596 Casuarina, NT 0811 Australia Tel.: +(61) 8-8922-7324 Fax: +(61) 8-8922-7144 E-mail: lindy.garling@nt.gov.au Australia, Queensland Queensland Cancer Registry 553 Gregory Terrace Fortitude Valley Q 4006 Australia Tel.: +(61) 7-3258-2333 Fax: +(61) 7-3258-2345 E-mail: Kerrie_Dennison@health.qld.gov.au South Australia South Australian Cancer Registry Epidemiology Branch Dept of Health P.O. Box 6 Rundle Mall, SA 5000 South Australia Tel.: +(61) 8-8226-6360 Fax: +(61) 8-8226-6291 E-mail: colin.luke@health.sa.gov.au Linda Halliday Rosalind Sexton Janet Li Elizabeth Tracey

Elizabeth Tracey Maria Arcorace Noreen Panos Shuling Chen Bruce Armstrong Freddy Sitas Paul Jelfs

John R Condon Lindy Garling Xiaohua Zhang

Kerrie Dennison Julie Moore

Colin Luke Heather Tredrea Maria Cirillo Cathy Weisner Mary Merdo Teresa Molik Chris Groeschel Maxene Rosenberg Kevin Priest

lviii

lviii

Contributors

Australia, Tasmania Tasmanian Cancer Registry Menzies Research Institute Private Bag 23 Hobart, TAS 7001 Australia Tel.: +(61) 3-6226-7706 / 57 Fax: +(61) 3-6226-7755 E-mail: alison.venn@utas.edu.au Australia, Victoria Victorian Cancer Registry The Cancer Council Victoria Cancer Epidemiology Centre 1 Rathdowne Street Carlton, South, Vic. 3053 Australia Tel.: +(61) 3-9635-5154 Fax: +(61) 3-9635-5330 E-mail: Graham.Giles@cancervic.org.au Western Australia Western Australian Cancer Registry Dept of Health (WA) 1st floor C Block 189 Royal St East Perth WA 6004 Western Australia Tel.: +(61) 8-9222-4022 / 4249 Fax: +(61) 8-9222-4236 E-mail: tim.threlfall@health.wa.gov.au French Polynesia Registre des Cancers de Polynsie franaise (French Polynesia Cancer Registry) Direction de la Sant Bureau de la Veille Sanitaire BP 611 98713 Papeete Tahiti French Polynesia Tel.: +(689) 46.00.52 / 50 Fax: +(689) 46.00.59 E-mail: nicole.cerf@sante.gov.pf New Zealand New Zealand Cancer Registry NZ Health Information Service P.O. Box 5013 Wellington New Zealand Tel.: +(64) 4-460-4034 Fax: +(64) 4-922-1897 E-mail: susan_hanna@nzhis.govt.nz

A. Venn L. Newman M. Dalton

Graham Giles Helen Farrugia Vicky Thursfield Debbie Billiet

Timothy J. Threlfall Judith R. Thompson

Mareva Tourneux Nicole Cerf Laure Yen Kai Sun

Susan Hanna Chris Lewis

lix

lix

Contributors

USA, Hawaii Hawai'i Tumor Registry Cancer Research Center of Hawai'i University of Hawai'i 1236 Lauhala St Honolulu, HI 96813-2424 USA Tel.: +808-586-9750 Fax: +808-587-0024 E-mail: StevensJ@imsweb.com

Marc T. Goodman Brenda Y. Hernandez Laurence N. Kolonel

lx

lx

M.P. Curado, H.R. Shin and J. Ferlay

Cancer Incidence in Five Continents (CI5) Volume IX presents incidence data from populations all over the world for which good quality data are available. Background A detailed questionnaire was requested to be completed by all cancer registries that were able to contribute to Volume IX and also by national registry associations and networks. The registries could delegate data submission to their associations but had to submit their own questionnaires. All instructions for preparing the data were explained in the questionnaire and an email address, CI5-IX@iarc.fr, was expressly created to handle all correspondence relative to the preparation of this volume. The reference time period for Volume IX was defined to be 19982002; in order to allow the Editors to verify some aspects of quality, comparability and completeness for each submission, the contributors were asked to also send data for the years prior to the reference period. The publication The data presented in Volume IX are expanded on by seven introductory chapters, reduced from nine in the previous volume: this Introduction, Techniques of registration; Classification and coding; Histological groups; Comparability and quality of data; Processing of data; and Age standardization and denominators. The evaluation criteria used to analyse the data submitted by the cancer registries were based on Cancer Registration, Principles and Methods (IARC, 1991). We received data from 406 cancer registry populations (Table 1.1). Data submitted on 106 populations from cancer registries were excluded. Volume IX thus presents cancer incidence data from 300 populations, 225 cancer registries and 60 countries, an increase of 28.6% over Volume VIII. Table 1.1 Cancer population data submitted to CI5 Volume IX for the period 19982002 Submitted Countries Registries Populations 80 313 406 Accepted 60 225 300 Geographical coverage in CI5 Volume IX The geographical coverage of CI5 Volume IX by continent is shown in Table 1.2 below: Africa has included data from 5 of the 14 countries that submitted data, South and Central America 8 of 11, North America 2 of 2 countries, Asia 15 of 18, Europe 29 of 30 countries and Oceania 4 of 6 countries. The proportion of cancer registries represented by continent is as follows: Africa 31% (5/16), South and Central America 38% (11/29), North America 93% (54/58), Asia 57% (44/77), Europe 83% (100/120) and Oceania 85% (11/13). The share of the world population covered in this volume is 11%, distributed as follows: Africa: 8.8 million (1%), South and Central America: 23 million (4%), North America: 258.5 million (80%), Asia: 152.3 million (4%), Europe: 238.8 million (33%) and Oceania: 23 million (73%). Table 1.2 Geographical coverage by country, registry and population group Countries Submitted Accepted Registries Submitted Accepted Populations Submitted 16 29 136 84 123 18 406 Accepted 5 11 118 50 100 16 300

Chapter 1: Introduction

Africa South and Central America North America Asia Europe Oceania Total

14 11 2 18 30 6 80

5 8 2 15 29 4 60

16 29 58 77 120 13 313

5 11 54 44 100 11 225

Note: The sum of the individual countries is greater than the total, reflecting the fact that some countries are present in more than one continent Geographical coverage in the nine successive volumes of Cancer Incidence in Five Continents Tables 1.3 and 1.4 and Figure 1.1 outline the overall geographical coverage in terms of the number of registries, populations and countries included in each volume of CI5.

Table 1.3 Coverage in nine volumes of Cancer Incidence in Five Continents Volume I II III IV V VI VII VIII IX Year of publication 1966 1970 1976 1982 1987 1992 1997 2002 2007 Registries 32 47 61 79 105 138 150 186 225 Populations 35 58 79 103 137 166 183 214 300 Countries 29 24 29 32 36 49 50 57 60 Period (approx.) 19601962 19631967 19681972 19731977 19781982 19831987 19881992 1993-1997 1998-2002

Introduction

300 250 200

Countries Populations Registries

traditional tables of incidence rates and registry descriptions as in previous editions. The website http://www-dep.iarc. fr/ provides multiple options for analysis of cancer incidence Countries across the world, in order to be beneficial to epidemiologists, Populations oncologists, researchers and cancer policy makers.
Registries Acknowledgments:

150 100 50 0
I II III IV V VI VII VIII IX

Figure 1.1 Coverage in nine volumes of Cancer Incidence in Five Continents This publication was developed via an interactive relationship among the contributors and the editors mainly through the power of the electronic presentation of data, while retaining the

The Editors would like to thank Vincent Benoist and Marilyne Goutagny, who abstracted and tabulated the information from the questionnaires completed by each contributor, and Krittika Guinot, who created the maps. The Editors would also like to thank the directors and registrars from all the cancer registries who submitted their data to this volume for their efforts to produce cancer incidence data and make it available to the world. Their work is the cornerstone of cancer descriptive epidemiology and provides a basis for future cancer research and health policies. Reference Jensen, O.M., Parkin, D.M., Maclennan, R., Muir, C.S., Skeet, R.G. (1991). Cancer Registration: Principles and Methods. IARC Scientific Publication No. 95. Lyon: IARCPress.

Introduction

Table 1.4 Geographical coverage in the nine successive volumes of Cancer Incidence in Five Continents
Africa Vol. I 1956-60 1960-62 1953-55 1954-60 Vol. II 1960-65 1963-67 Vol. III 1960-69 1968-72 1968-72 Vol. IV 1969-74 Vol. V Vol. VI Algeria, Algiers Algeria, Stif Egypt, Gharbiah The Gambia -

Vol. VII

Vol. VIII 1993-97 -

Vol. IX -

1986-89

1990-93 1988-92 1988-92

1998-2002 1999-2002 1998-2002 1998-2002 -

France, La Runion Mali, Bamako

1987-89 1987-89 -

1993-94 1997-98 1994-96 1993-97 -

Mozambique, Loureno Marques Nigeria, Ibadan Senegal, Dakar White Bantu Bantu Rhodesia, Bulawayo: African South Africa, Cape Province: Coloured

1956-59 1956-59 1956-59 -

South Africa, Johannesburg: Natal : African Tunisia, Central Region Zimbabwe: Indian

1964-66 1964-66 1963-67 -

Uganda, Kyadondo County Bulawayo: African Harare: African European

1991-93 -

1990-92 1990-92

1993-97

1998-2002

Central and South America Argentina, Baha Blanca Argentina, Concordia Bermuda: Black Brazil, Belm

1959-61 1962-64 -

1962-66 -

1968-71 1969 -

1973 -

1978-82 1979-82 1980 1978 -

1983-87 1983-87 1988-89 1987 1982-86 1984-87 -

1990-94 1990-93 1990-92 1987-91 1988-92 -

1993-97 1993-97 1991-95 1992-96 1993-97 -

1998-2002 1998-2001 2000-2002 1999-2002 -

White and Other

Brazil, Brasilia Brazil, Cuiaba

1989-91

Brazil, Campinas Brazil, Fortaleza Brazil, Goinia Brazil, Recife Chile Brazil, Porto Alegre Brazil, So Paulo Chile, Valdivia Costa Rica

1995-98

1998-2002 1998-2002 1998-2002 1998-2002

Colombia, Cali

1967-71

1972-76

1977-81 1980-82

Introduction

Table 1.4 Geographical coverage in the nine successive volumes of Cancer Incidence in Five Continents
Cuba Vol. I 1958-63 1962-63 Vol. II 1964-66 1964-66 Cuba, Villa Clara Ecuador, Quito France, Martinique 1968-72 1967-72 1968-72 Vol. III 1973-77 1973-77 1973-78 1973-77 Vol. IV Vol. V 1981-82 1978-82 1978-82 Vol. VI 1986 -

Vol. VII

Vol. VIII 1995-97 1993-97 1993-95 1993-95 1992-93 -

Vol. IX -

1985-87 1983-87 1988-89 1984-87 1983-87 -

1988-92

1998-2002 1998-2002 1998-2002 -

Jamaica, Kingston and St Andrews Paraguay, Asuncin Peru, Lima Peru, Trujillo

Netherlands Antilles (less Aruba)

1990-91 1988-90 1990-92 1988-91

Uruguay, Montevideo USA, Puerto Rico North America Canada Canada, Alberta

Canada, British Columbia Canada, Manitoba Canada, Maritime Provinces (New Brunswick, Nova Scotia, Prince Edward Island) Canada, New Brunswick Canada, Newfoundland and Labrador

1960-62 1960-62 1962-64 1960-62 1960-62 -

1963-66 1963-66 1965-66 1963-66 1963-66 1963-66 -

1969-72 1969-72 1969-72 1969-72 1969-72 1969-72 1969-72 -

1973-77 1973-77 1973-77 1973-77 1973-77 1973-77 1969-71 1973-77 1973-77 -

1978-82 1978-82 1978-82 1978-82 1978-82 1978-82 1978-82 1978-82 1978-82 1978-82 1978-82 1978-81 1978-82 -

1983-87 1983-87 1983-87 1983-87 1983-87 1983-86 1983-87 1983-87 1983-87 1983-87 1983-87 1983-87 1983-87 -

1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1983-92 1988-92 1988-92 1988-92 1988-92 1988-92 1983-92 -

1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1983-97 1993-97 1993-97 1993-97 1993-97 1993-97 1983-97 -

1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 -

Canada, Northwest Territories and Yukon Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Quebec Canada, Yukon Black

Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama: White

USA, Alaska

USA, Arizona

USA, California: Black

Asian and Pacific Islander Hispanic White

USA, California, Alameda County: White Black

Non-Hispanic White

1960-64 1960-64

1969-73 1969-73

1973-77 1973-77

1978-82 1978-82

1983-87 1983-87

Introduction

Table 1.4 Geographical coverage in the nine successive volumes of Cancer Incidence in Five Continents
USA, California, Central Valley: Hispanic Non-Hispanic White Vol. I 1960-62 Vol. II 1963-65 Vol. III 1969-73 1969-73 1969-73 1968-72 1969-71 Vol. IV 1973-77 1973-77 1973-77 1973-77 1972-77 1972-77 1972-77 1972-77 1972-77 1973-77 1975-77 1975-77 1973-77 Vol. V 1978-82 1978-82 1978-82 Vol. VI 1983-87 1983-87 1983-87 1983-87 1983-87 -

Vol. VII

Vol. VIII 1993-97 -

Vol. IX 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 -

1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 -

USA, California, Greater San Francisco Bay Area Black Chinese Filipino Hispanic White Japanese

Non-Hispanic White White

1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 -

1978-82 1978-82 1978-82 1978-82 1978-82 -

USA, California, Los Angeles County: Black Chinese Filipino Hispanic White Japanese Korean

Non-Hispanic White

1978-82 1978-82 1978-82 1978-82 -

1983-87 1983-87 1983-87 1983-87 -

Spanish-surnamed White USA, Colorado Black Other White

USA, Connecticut: White Black

1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002

1978-82 1978-82 1978-82 1978-82 1978-82 -

1983-87 1983-87 1983-87 1983-87 1983-87 -

USA, District of Columbia: White Black

USA, Florida: White Black

USA, Georgia: White Black

USA, Georgia, Atlanta: White

USA, Idaho Black

USA, Illinois: White

USA, Indiana USA, Iowa

Introduction

Table 1.4 Geographical coverage in the nine successive volumes of Cancer Incidence in Five Continents
USA, Kentucky Black Vol. I 1959-61 Vol. II 1959-66 Vol. III 1969-71 1969-71 1969-72 1969-72 1969-71 Vol. IV 1974-77 1974-77 1973-77 1973-77 1973-77 1973-77 1973-77 Vol. V 1978-82 1978-82 1978-82 1978-82 1978-82 1978-82 Vol. VI 1983-87 1983-87 1983-87 1983-87 1983-87 1983-87 1983-87 USA, Louisiana: White Black -

Vol. VII

Vol. VIII 1993-93 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 -

1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 -

Vol. IX

USA, Louisiana, Central Region: White Black

1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 -

USA, Louisiana, New Orleans: White

USA, Maine

USA, Massachusetts USA, Michigan: White Black Black

USA, Michigan, Detroit: White Black

USA, Missouri: White

USA, Montana USA, Nevada Black USA, New Jersey: White

USA, New Mexico: Hispanic

American Indian Hispanic White

Non-Hispanic White USA, New York City Black

Other White (Anglo)

1969-72

1973-77

1978-82 1978-82 1978-82 -

USA, New York State: White

1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 -

USA, New York State (less New York City): White Black Black

USA, NPCR: White

Introduction

Table 1.4 Geographical coverage in the nine successive volumes of Cancer Incidence in Five Continents
USA, Ohio: White Black Vol. I Vol. II 1960-66 1960-66 Vol. III 1968-70 1968-70 1966-70 Vol. IV 1973-77 Vol. V 1978-82 Vol. VI 1983-87 1983-87 1983-87 -

Vol. VII

Vol. VIII 1993-97 1993-97 1993-97 -

1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 -

Vol. IX

USA, Oklahoma USA, Oregon Black USA, Pennsylvania: White

USA, Rhode Island Black

USA, SEER (9 Registries): White

1988-92 1988-92 1988-92 -

USA, SEER (14 Registries): Black

Asian and Pacific Islander Hispanic White

USA, South Carolina: White Black Black

Non-Hispanic White

USA, Texas: White Latin

USA, Texas, El Paso: Other than Latin

USA, Utah

USA, Vermont

USA, Washington

USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia

1974-77

1978-82

1983-87

1988-92

1993-97

Bahrain: Bahraini China, Beijing China, Cixian China, Changle China, Guangzhou City China, Hong Kong China, Jiashan

1974-77 -

1978-82 -

1983-87 1983-87 -

1988-92 1988-92 -

1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 -

1998-2002 2000-2002 1998-2002 1998-2002 1998-2002 -

China, Nangang District, Harbin City China, Qidong County

Introduction

Table 1.4 Geographical coverage in the nine successive volumes of Cancer Incidence in Five Continents
China, Shanghai China, Taiwan China, Tianjin China, Wuhan Cyprus Vol. I 1960-63 1959-60 Vol. II 1964-66 1960-66 1960-66 1960-66 1960-66 1960-66 1962-64 1966 Vol. III 1968-72 1967-71 1967-71 1967-71 1967-71 1967-71 1968-71 1969 Vol. IV 1975 1973-75 1978-82 1981-82 1982 1982 1978-82 1980-82 1978-82 Vol. V 1983-87 1983-87 1983-87 1983-87 1983-87 1983-87 1982-86 1982-86 1982-86 1982-86 1982-86 1981-85 1983-87 1983-87 1983-87 1984-86 1983-86 Vol. VI -

1988-92 1988-92

Vol. VII

Vol. VIII 1993-97 1993-97 1993-97 1997

1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1996-2000 1998-2002 1998-2002 1998-2002 1998-2002 1999-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 2000-2002 1998-2002 1999-2002 -

Vol. IX

China, Zhongshan India, Ahmedabad India, Bangalore India, Barshi, Paranda and Bhum India, Chennai (Madras) India, Karunagappally India, Nagpur

1988-92 1988-92 1988-92 1991-92 1988-92 1991-92 1988-92 1988-92 1988-92 1988-92 1988-92 1986-90 1988-92 1988-92 1988-92 1988-92 1988-92 1986-92 -

1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-96 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1991-95 1993-97 1993-97 1993-97 1993-97 1993-97 1996-97 1997-98 1993-97 1993-97 -

India, Mumbai (Bombay) India, New Delhi

India, Poona (Pune) India, Trivandrum Israel: All Jews

1973-77

Jews born in Israel

1972-76 1972-76 1972-76 1972-76 1972-76 -

1977-81 1977-81 1977-81 1977-81 1977-81 1978-80 1978-81 1978-82 1979-82 -

Jews born in Europe or America Japan, Aichi Prefecture Japan, Fukuoka Non-Jews

Jews born in Africa or Asia

Japan, Fukui Prefecture Japan, Hiroshima

1974-75 1973-77 1973-77 1973-77 -

Japan, Miyagi Prefecture Japan, Okayama Japan, Saga Korea

Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea, Busan

1970-71

Korea, Daegu

Korea, Daejeon Korea, Incheon Korea, Jejudo Korea, Seoul

Korea, Gwangju

Korea, Kangwha County Korea, Ulsan

Introduction

Table 1.4 Geographical coverage in the nine successive volumes of Cancer Incidence in Five Continents
Vol. I 1950-61 Vol. II Vol. III 1968-72 1968-72 1968-72 Vol. IV 1973-77 1973-77 1973-77 Vol. V Vol. VI Kuwait: Kuwaitis Non-Kuwaitis Kyrgyzstan Malaysia, Penang Oman: Omani 1979-82 1979-82 1978-82 1978-82 1978-82 1978-82 1983-87 1983-87 1986-87 1983-87 1983-87 1983-87 1983-87 1983-87 1983-87 1988-89 -

1988-89 1992-93 1988-89 1992-93 1988-92 -

Vol. VII

Vol. VIII 1994-98 1994-98 1993-97 1995-97 1993-97 1993-97 1993-97 1993-97 1993-97 1995-97 1993-97 1993-97 1993-97 1993-96 -

Vol. IX 1998-2002 1998-2002 1998-2002 1998-2002 1998-2001 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 -

Malaysia, Sarawak Pakistan, South Karachi Philippines, Manila Philippines, Rizal Singapore: Indian Malay Chinese

1988-92 1988-92 1988-92 1988-92 1990-93 1991-93 -

Thailand, Bangkok

Thailand, Chiang Mai Thailand, Khon Kaen Thailand, Lampang Turkey, Antalya Turkey, Izmir Thailand, Songkhla

Viet Nam, Hanoi

Viet Nam, Ho Chi Minh City Europe Austria Austria, Tyrol Belarus

1993-97 1995-98

1953-57 1959-61 -

1958-62 1962-65 -

1963-67 1966-70 -

1968-72 1973-76 1971-76 1975-77 -

1978-82 1977-81 1978-81 1978-82 -

1983-87 1983-87 1983-87 1983-87 1982-86 1983-87 1983-87 -

Austria, Vorarlberg Belgium, Antwerp Belgium, Flanders Belgium, Flanders (less Limburg) Belgium, Limburg Bulgaria Croatia

1988-92 1988-92 1988-91 1988-92 1988-92 1988-92 1987-92 1988-92 1988-92 -

1993-97 1993-97 1993-97 1997-98 1997-98 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 -

1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2001 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 -

Czech Republic Denmark Estonia Finland

France, Bas-Rhin France, Calvados France, Cte dOr

Introduction

Table 1.4 Geographical coverage in the nine successive volumes of Cancer Incidence in Five Continents
France, Doubs Vol. I Vol. II Vol. III Vol. IV 1977 France, Haut-Rhin France, Hrault France, Isre 1978-82 Vol. V 1983-87 Vol. VI

1988-92 1988-92 1988-92 1988-92 -

Vol. VII

Vol. VIII 1993-97 1993-97 1993-97 1993-97 1994-97 1993-97 1993-97 -

1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002

Vol. IX

France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vende

1979-82

1983-87

1983-84 1983-87 -

1988-92 1988-92 -

Germany, Federal States of Berlin etc. : Germany, Brandenburg Germany, Free State of Saxony

1960-62 1955-63 -

1964-66 1963-66 1962-66 1962-66 1962-66 -

1968-72 1969-72 1968-72 1969-71 1968-72 1964-72 -

1973-77 1973-77 1973-77 1973-77 1973-77 -

1978-82 1978-79 1978-82 1978-82 1978-82 1973-82 1980-82 1978-82 -

1983-87 1983-87 1983-87 1983-87 1983-87 1983-86 1985-87 1986-87 1983-85 1983-87 1986-87 1985-87 -

1988-89 1988-92 1988-92 1988-92 -

1993-97 1993-97 1994-97 1995-97 1993-97 1993-97 -

1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1999-2001 1998-2002 1998-2002 1998-2000 1998-2000 1999-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 -

Germany, Mecklenburg-Western Pomerania Germany, Eastern States (ex-GDR) Germany, Hamburg Germany, Munich

Germany, North RhineWestphalia: Mnster Germany, Saarland Hungary, County SzabolcsSzatmar Hungary, County Vas Hungary, Miskolc Iceland Ireland

Italy, Biella Province

Italy, Brescia Province Italy, Ferrara Province Italy, Genoa Italy, Latina Italy, Florence and Prato

1991-92 1988-91 1988-92 1988-91 -

Italy, Liguria

Italy, Liguria, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East

1996-97 1993-96 1993-97 1993-97 1995-97 1993-97 1993-97 1993-97 -

1991-92 1988-92

Italy, Parma Province

Italy, Ragusa Province

1988-92 1988-92 1989-92 -

Italy, Reggio Emilia Province Italy, Romagna Region

10

Introduction

Table 1.4 Geographical coverage in the nine successive volumes of Cancer Incidence in Five Continents
Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Torino Vol. I 1960-62 1956-60 Vol. II 1964-66 1965-66 1965-66 1965-66 1965-66 1967 1961-65 Vol. III 1969-72 1968-72 1968-72 1968-72 1970-72 Vol. IV 1976-77 1973-77 1973-77 1973-77 1973-74 Vol. V 1978-81 1978-82 1978-82 1978-81 1978-81 1980-82 1979-82 1978-82 1978-81 Vol. VI 1984-85 1983-87 1983-87 1983-87 1983-87 1986-88 1983-87 1983-86 -

Vol. VII

Vol. VIII 1993-97 -

1998-2001 1998-2002 1998-2002 1999-2002 1998-2002 1998-2002 1998-2000 1998-2001 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1999-2001 1998-2002 1999-2002 1998-2002 1998-2002 1998-2001 1996-2000 1998-2001 1997-2001 1998-2002 1998-2002 -

Vol. IX

Italy, Syracuse Province Italy, Trieste

1988-91 1989-92 1988-92 1988-92 1988-92 1992-93 1989-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1991-92 1988-91 1988-91 -

1993-97 1994-96 1993-97 1993-96 1993-97 1988-92 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-96 1993-97 1993-97 1994-97 1993-97 1993-97 1993-97 1992-95 1993-95 1993-97 1994-97 -

Italy, Umbria Region Italy, Veneto Region Latvia Lithuania Malta The Netherlands

Italy, Varese Province

The Netherlands, Three Provinces The Netherlands, Eindhoven The Netherlands, Maastricht Norway Poland, Cieszyn Area Poland, Cracow Poland, Kielce Poland, Katowice District Poland, Lower Silesia Poland, Nowy Sacz Poland, Opole

1959-61

1968-72 1968-72 1968-72 1970-72 1968-72 -

1973-77 1973-77 1973-77 1974-78 1973-77 1973-76 -

1984-87 1983-86 1985-87 1983-87 1983-87 -

Poland, Warsaw City Portugal, Porto

Poland, Warsaw Rural Areas Portugal, South Regional Romania, Banat Region Romania, County Cluj Russia, St Petersburg Serbia Slovak Republic Slovenia

1989-92

1993-97

Portugal, Vila Nova de Gaia

1983-87 1983-87 1983-87 1983-87 1982-87

Romania, County Timis

Slovakia, Western Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona

1986-87

11

Introduction

Table 1.4 Geographical coverage in the nine successive volumes of Cancer Incidence in Five Continents
Spain, Granada Spain, Murcia Vol. I 1959-61 1959-63 1960-62 Vol. II 1962-65 1963-66 1963-66 Vol. III 1968-72 1966-70 1970-72 1968-72 1968-72 1963-66 1967-71 1966-70 1967-70 1968-72 1970-72 Vol. IV 1973-77 1973-77 1971-75 1973-77 1974-76 1975-77 1975-77 1973-77 1974-77 1973-77 1974-76 1973-76 1973-77 1973-77 1973-77 1973-77 1975-77 Vol. V 1978-82 1980-83 1978-82 1978-82 1981-82 1979-82 1978-82 1978-82 1980-82 1979-82 1978-82 1979-82 1979-82 1978-82 1979-82 1979-82 1979-82 Spain, Mallorca Spain, Navarra 1985-87 1984-87 1983-86 1984-87 1983-85 1983-87 1983-87 1983-87 1983-87 1983-87 Vol. VI

1988-92 1988-92 1988-92 1987-91 1988-92 1986-90 1988-92 1988-92 1988-92 1989-92 1988-92 1988-92 1989-92 1988-92 1988-92 1988-90 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 -

Vol. VII

Vol. VIII 1993-97 1993-96 1993-96 1993-97 1993-97 1991-95 1993-97 1993-97 1993-97 1993-97 1993-96 1993-97 1996-97 1993-97 1993-96 1993-96 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 -

1998-2002 1997-2001 1998-2002 1998-2001 1996-2000 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 -

Vol. IX

Spain, Tarragona Spain, Zaragoza Sweden

Switzerland, Basel

Switzerland, Geneva

Switzerland, Graubnden

Switzerland, Graubnden and Glarus Switzerland, Neuchtel Switzerland, Ticino Switzerland, Valais Switzerland, Vaud UK, England Switzerland, St Gall-Appenzell

Switzerland, Zrich UK, England and Wales

1983-87 1983-87 1983-86 1983-87 1983-87 1983-87 1983-87 1983-87 1983-87 1983-86 1983-87 1983-87 1983-87 1983-87 1983-87 1983-87 1983-87 -

UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire

UK, England, Oxford Region UK, England, South Thames (South Metropolitan)

UK, England, South and Western 1960-62 Regions UK, England, Thames UK, England, Trent UK, England, Wessex 1960-62 -

1962-65 1963-66 1963-66 -

UK, England, West Midlands UK, England, Yorkshire UK, Northern Ireland UK, Scotland

UK, Scotland, Ayrshire UK, Scotland, East UK, Scotland, North

1963-66

1978-82 1978-82 1978-82 1978-82 1978-82 1978-82 -

UK, Scotland, North-East UK, Scotland, West

UK, Scotland, South-East Yugoslavia, Vojvodina

12

Introduction

Table 1.4 Geographical coverage in the nine successive volumes of Cancer Incidence in Five Continents
Vol. I Vol. II Vol. III Vol. IV Vol. V Vol. VI Oceania

Vol. VII

Vol. VIII

Vol. IX

Australian Capital Territory

Australia, New South Wales Australia, Queensland South Australia Australia, Tasmania Australia, Victoria Western Australia French Polynesia New Zealand: Maori

1960-62 1960-63 -

1962-66 1962-66 -

1968-71 1968-71 -

Australia, Northern Territory

1973-77 1972-76 1972-76 -

1978-82 1978-82 1982 -

1983-87 1983-87 -

1988-92 1988-92 -

1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 1993-97 -

1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 1998-2002 -

1977

1978-82 1978-82 1982 1982 -

1983-87 1983-87 1983-87 1983-87 -

1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 1988-92 -

USA, Hawaii: Chinese Filipino

Pacific Polynesian Islanders

Non-Maori

1978-82 1978-82 1978-82 1978-82 1978-82 1978-82 1978-82 1978-82 -

1983-87 1983-87 -

1960-64 1960-64 1960-64 1960-64 1960-64

1968-72 1968-72 1968-72 1968-72 1968-72

1973-77 1973-77 1973-77 1973-77 1973-77

1983-87 1983-87 1983-87 1983-87 1983-87

Hawaiian Japanese White

1960-63 1960-63 1960-63

13

Chapter 2: Techniques of registration

M.P. Curado

The quality of the cancer database in a cancer registry rests not only upon the quality of its sources of information but also upon the registration techniques adopted by the cancer registration team. If these techniques follow the international rules of cancer registration, populations may be compared with confidence. This chapter describes the variation between registries in the methods used to collect data on new cancer cases and on the population at risk in the geographical area covered by the cancer registry. Registry background The background of each cancer registry is relevant to the information it delivers. These definitions could affect the data, potentially resulting in an under- or over-reporting of cases. Each point of this issue is discussed briefly below. Table 2.1 presents a definition of the area covered by the cancer registry. This includes its population, surface area, latitude, the year the registry started, the year population-based data became available, and whether cancer is reportable by L (Legislation), A (Administrative), N (Not reportable) or M (Mixed, a combination of the above). Other variables presented include the percentage of cases treated outside the registration area and the percentage of non-residents treated in the registration area. These topics are discussed in greater detail below. Populations. The denominator used to calculate rates generally comes from official census data. Rates based on interpolations between censuses tend to be better than projections since the last census. The absolute size of the populations on which the rates are based affects the accuracy of the estimated rates. Rates based on small numbers are more subject to random variation than are rates based on large populations. Surface area. The population density is calculated by each registry based on the population estimates from the surface area. Latitude. This localises the position of the cancer registry and enables comparison within the same region. Year registry started and Year population based data available. To get good-quality data in cancer incidence takes time. For instance, data from new cancer registries should be viewed with some caution, because in the first years of data collection the rates can be underestimated (due to over selectivity causing under collection) or overestimated (due to conflation with already-existing cases). Cancer reportable. This is a tool used to get a better picture of completeness in cancer registration. The presence of laws and rules that make cancer diagnosis a reportable disease can ensure completeness of the registry data collection, especially in countries where the cancer registry is part of an integrated cancer control programme. Percentage of cases treated outside the area. If the area covered by the population cancer registry has limited facilities for cancer diagnosis and care, such as surgery, radiotherapy, chemotherapy and pathology laboratories, it will be quite difficult for the cancer registry to get completeness in the area, as the residents with a

suspicion of cancer will seek treatment outside the catchment area. Patients may also die outside the catchment area, or even return to die at home after having being diagnosed elsewhere, thus causing underestimation of the local incidence rates. Percentage of non-residents treated inside the area. If the catchment area has a cancer care centre with a good reputation and treatment and diagnosis facilities available to the population, there may be an increased number of non-residents being treated in the same area as the resident cases. If these non-resident cancer cases are included in the cancer registry database, the local rates may be overestimated. Case finding If the geographical area covered by the cancer registry includes cancer centres and radiotherapy services, or any type of oncology or onco- haematological treatment and diagnosis centres such as pathology laboratories where cases can be microscopically verified, this can improve data quality in cancer diagnosis, and is also an important source of quality data on local health services. The main sources of cases are described in Table 2.2. Data Sources. These sources include hospital in-patient records, radiotherapy departments, public and private hospitals and their in- and out-patient facilities, pathology laboratories, autopsies, haematology laboratories, death certificates and screening programmes. Abstraction and coding. This details the proportion of manual abstraction and coding of cancer information done by trained cancer registry personnel. Nowadays some cancer registries have automatic registration for which cancer registry personnel must verify the data quality and comparability. Information recorded Table 2.3 presents the information recorded by the populationbased cancer registry. This is the most relevant information that should be collected by the cancer registries: Basic information includes name, sex, date of birth or age, and usual resident address (permanent) of each patient, which enables personal identification. Further information collected includes ID number; ethnic group/race/colour; incidence date, stage of disease; nature of the first treatment; brain and nervous system; followup for vital status (all/selected/none); death certificates used to update vital status; and active follow-up of the alive cases. Basic information includes name, sex, date of birth or age, and permanent address of the patient. These items are essential for establishing the patients background in the cancer registry database, precluding double entry of the same case in the registry. Incidence date includes the date of diagnosis or hospitalisation for first treatment, as well as if possible the primary site and histological type of the cancer diagnosed. It must be coded according to ICD-O-3 (see Chapter 3). Date of birth is important to assist identification, particularly where there is limited variation in names, or when other specific identifying information is lacking. For comparability, it is necessary to convert any local dating system to a standard system used internationally.

14

Techniques of registration

ID number. Some countries have a number unique to the individual, and others have more than one. The use of these identification numbers varies, but whenever such a number exists, the cancer registry should promote its inclusion in the notification form of the cancer registry, as it can be used to eliminate double notification stemming from using multiple sources of information. Ethnic group/race/colour. For some cancer registries this is an essential item, because social and cultural differences between groups may be related to the utilisation of medical facilities. It can be an indicator of differences in culture and habits that may determine exposure to carcinogenic factors. The definitions of the ethnic groups used by the cancer registries should be compatible with official definitions used for census reports. Stage of disease can be identified when the diagnosis is made by the physician, and is a standard data point used to analyse References Jensen, O.M., Parkin, D.M., Maclennan, R., Muir, C.S., Skeet, R.G. (1991). Cancer Registration: Principles and Methods. IARC Scientific Publication No. 95. Lyon: IARCPress.

post-diagnosis survival and disease stage. The final evaluation of survival depends upon the topography of the tumour at time of the diagnosis. Nature of the first treatment. The type of treatment modality reflects the general access to basic treatment modalities (but it cannot be used to assess the efficacy of specific treatment). Brain and nervous system identifies whether cancer registries include benign cancers of the brain and nervous system or not. Follow-up for vital status, Death certificates used to update vital status, and Active follow-up of the living cases. The follow-up for vital status is important to evaluate survival after treatment and diagnosis, and it can be done actively through a phone call or visit, or passively by matching death certificates with incidence cases.

International Agency for Research on Cancer (2002). Cancer Incidence in Five Continents Volume VIII. eds: Parkin, D.M., Whelan, S.L., Ferlay, J., Teppo, L., and Thomas, D.B. Lyon: IARCPress. Pgs. 1143.

15

16
Table 2.1 Registry background Surface area (km2) Latitude Year registry started 1986 1989 N N NS NS 1999 A ~5 A 8 1986 A 60 20 10 8 Year population-based data available Cancer reportable by: L/A/N/M* % cases treated outside registration area % non-residents treated inside registration area

Population

Africa 1 943 0 N 18 1986 1990 NS 1951 1960 1987 6 504 31 N 1998 35 N

Techniques of registration

Zimbabwe, Harare

Uganda, Kyadondo County 872

Tunisia, Central Region 1 914

Egypt, Gharbiah 2 669

Algeria, Setif

3 665 524

1 365 488

1 736 809

1 526 966

494 800

70

70

South and Central America 5 789 16 S 39 S NS 14 N 8 S 1990 0 1983 1984 1981 1985 NS 1977 1980 1962 1962 23 S 1992 1993 1969 1969 NS 1986 1988 N N 1999 2000 N 2 300 15 - 16 S 1997 1996 N 38 - 42 S 1989 1989 M

Peru, Trujillo

France, Martinique 112

Ecuador, Quito 1 080

Costa Rica 360

Colombia, Cali 51 100

Chile, Valdivia 121

Brazil, So Paulo 18 472

Brazil, Goinia 1 509

Brazil, Cuiaba 739

Brazil, Brasilia 4 476

Argentina, Bahia Blanca

2 009 106

284 776

10 408 477

1 097 218

713 391

1 420 578

3 921 558

1 839 932

362 394

M N L

592 568

381 639

1984

NS

NS

NS

NS

NS

NS

NS 30 50

30

35.1 1

3.04 6.2 2

52 12,1

39.1

North America 9 970 610 892 677 73 437 NS NS NS 45 - 48 N NS 661 848 50 N 52 N 42 - 83 N 1942 1992 1966

Canada, Saskatchewan

Canada, Prince Edward Island 651 903

Canada, Ontario 5 660

Canada, Nova Scotia 1 070 000

Canada, Northwest Territories 55 491

Canada, Newfoundland and Labrador 1 346 106

Canada, New Brunswick 371 364

Canada, Manitoba

Canada, British Columbia

Canada, Alberta

Canada

23 363 550

3 009 814

1 152 523

4 060 110

535 263

753 833

11 717 355

938 857

41 123

1 016 987

137 693

46 - 48 N 51 N

44 N

NS

1964

1964

1986

1955

1955

1937

1932

1969

1964

1964

1950

1955

1989

1956

1969

1951

1969

NS

NS 1

A L 1969 1944 L

NS

NS 2

NS N L L <1 NS NS 3

NS

NS

NS

~2 NS 1.7

Table 2.1 Registry background Surface area (km2) 133 550 33 N 1988 1973 1968 1996 M L L 1935 L L 1970 1988 L 1972 L NS NS NS 1973 L NS 1988 L NS 61 N 1980 1995 L 1,6 1996 1996 L 18,9 5 30 - 35 N 1996 1996 L 4,5 5 Latitude Year registry started 12.8 0.03 15.8 14.6 NS 15 5 NS Year population-based data available Cancer reportable by: L/A/N/M* % cases treated outside registration area % non-residents treated inside registration area

Population

USA, California 6 427 269 620 12 973 27 1975 1986 1971 1995 1975 1999 39 1981 1981 1985 170 30 - 35 N 44 N 1987 1995 1973 1985 1987 33 N 1969 41 - 42 N 1941 404 000 40 N 34 N 38 - 39 N

USA, Arizona 404 000 34 N

USA, Alaska 295 274

USA, Alabama 1 481 350

4 446 355

34 001 960

5 162 349

629 290

USA, Florida 150 000 4 500 37 - 42 N 44 N 1974 1991 40 N 1973 NS

USA, District of Columbia NS

USA, Connecticut

USA, Colorado

USA, California, Los Angeles County

USA, California, Greater San Francisco Bay Area

4 136 868

4 319 872

9 543 402

3 411 252

USA, Georgia

16 068 139

569 765

Techniques of registration

USA, NPCR 177 850 116 105

USA, New York State

USA, New Mexico 123 234

USA, New Jersey 314 926

USA, Montana 20 300 35 N 40 N

USA, Missouri 381 160 44 - 49 N

USA, Michigan, Detroit 180 550 38

USA, Michigan 5 094 42 - 43 N

USA, Massachusetts 264 180 41 - 47 N

USA, Maine 27 340 42 N 1981 1980

USA, Louisiana, New Orleans 91 660 44 N 1981

USA, Louisiana 7 217 30 N 1974

USA, Kentucky 134 382 30 N

USA, Iowa 102 900 38 N

USA, Indiana 145 800

USA, Illinois 94 330

USA, Idaho 146 080

USA, Georgia, Atlanta

8 215 680

12 434 662

1 298 409

2 915 231

3-5 L NS L 5 L

2-3 NS 4 A 2 NS L 3,1 1

12

30

4 462 873

4 042 038

2 923 062

6 083 754

NS 4.8 4

3.7

5 599 094

4 048 728

9 949 858

6 354 587

1 276 563

971 090

USA, Oklahoma

USA, Ohio

223 467 872

18 974 870

1 822 108

8 432 830

901 930

43 N

1940 38 - 42 N 35 N

1967

1979

1979

1972

1949

1976 1992 1995

1969

1979

1979

1985

1973

1985

1982

1981

1974

1988

M L 1996 1997

1,42 NS NS 5 2

NS

0,2

1,9

7.1

4.7 3

13.53 NS NS NS 1,7 L L 6 10 7 3

<5 9

11 360 971

3 450 643

NS

NS

17

18
Table 2.1 Registry background Surface area (km2) 251 180 117 330 41 - 42 N NS 1966 1992 L L 1996 L L 1979 1966 M 1995 L NS NS 25 1,1 NS 1993 1996 L 5,7 1973 1973 L NS 1986 1986 L NS 3 145 40 N 1982 1985 L 2 45 N 1996 1996 L 3,2 7.9 Latitude Year registry started 7.7 Year population-based data available Cancer reportable by: L/A/N/M* % cases treated outside registration area % non-residents treated inside registration area

Population

Techniques of registration

USA, Washington 62 360 44 N 1976 1978 45830 39 N 1993 1993 M 47 N 1974 1974

USA, Vermont 184 675 45 - 49 N 1991

USA, Utah 23 960 44 N 1994

USA, Texas 219 888 41 N

USA, South Carolina 678 055 31 N

USA, SEER 80 650

USA, Rhode Island NS

USA, Pennsylvania

USA, Oregon

12 284 430

3 434 016

74 331 088

1 049 908

20 948 520

4 016 127

NS NS 10 15 3.5

10

2 242 702

USA, Wisconsin

USA, West Virginia 145 440

USA, Washington, Seattle

5 916 597

608 882

5 369 826

1 808 253

4 060 760

<5 12 2

~5 13.6 2 10

Asia 1 335 30 50 N 1963 1997 22 N 1987 1963 118 22 N 1999 1965 1999 NS 1994 1998

Bahrain 1 098 188 31 N 1998 1970 NS 507 44 - 44 N

China, Hong Kong

China, Guangzhou

China, Nangang District, Harbin City 1 683 170 18 - 19 N 28 N 21 N 9 N NS 13 N NS 289

China, Jiashan

6 665 420

3 608 260

398 455

Japan, Fukui Prefecture

Japan, Aichi Prefecture 4 189

Israel 646

India, Trivandrum 22 145

India, Poona 336

India, New Delhi 344

India, Nagpur 891

India, Mumbai (Bombay) 438

India, Karunagappally 438

India, Chennai (Madras) 192

Cyprus

China, Zhongshan

China, Shanghai

1 325 722

6 284 314

843 937

381 289

1987 1963 1980 1970

< 0,5 A A 1998 A M 1982 N N NS 45

NS

> 50 NI NS 3 < 0,1 NS 30

NS

60 20 <2 40-45 4 0

4 308 843

698 320

11 815 502

413 094

12 527 357

2 020 995

1 060 078

6 128 406

1 157 702

3 550 945

17 - 19 N 8 N NS

829 265

36 N

35 N

1984

1962

1960

1994

1972

1986

1980

1963

1990

1981

1984

1962

1960

1991

1972

1986

1980

1964

1990

100 0,5 5

NS 3 N N L 5

NS

NS

NS

NS

NS

NI

90

50

40

50

60

Table 2.1 Registry background Surface area (km2) 742 33 N 1974 1996 N A L N 1999 M 10,6 < 30 30 30 8,7 M NS 1962 1974 N NS 1963 N NS 38 N 1958 1958 N 1,6 1951 1959 N NS NS NS NS 1957 1957 A NS NS Latitude Year registry started Year population-based data available Cancer reportable by: L/A/N/M* % cases treated outside registration area % non-residents treated inside registration area

Population

Korea 886 36 N 2000 2001 1991 1996 2000 M N N 1997 NS 1997 1996 1998 1998 764 35 N 1997 1997 35 N 1995

Japan, Yamagata Prefecture 99 500 36 - 37 N 1980

Japan, Osaka Prefecture 9 323 39 N

Japan, Nagasaki Prefecture 1 893 34 N

Japan, Miyagi Prefecture 4 092

Japan, Hiroshima 7 291

Malaysia, Penang 309 500 274 18 N 1 N 1993 1978 1950 100 14 N 1959 24 N 1995 124 450 23 N 1985 3 N 1996 1996 1996

Kuwait 1 031 5 N 1994 1994

Korea, Ulsan 17 818 NS 1974 1974

Korea, Seoul 1 057 35 N 2001

Korea, Jejudo 605 37 N 1991

Korea, Incheon 1 848 33 - 34 N

Korea, Gwangju 986 37 N

Korea, Daejeon 501

Korea, Daegu 540

Korea, Busan

47 675 096

1 244 260

8 789 355

1 517 713

2 364 498

1 117 564

NS

NS

2 536 528

1 369 836

1 372 533

2 524 362

3 800 836

NS NS 36

< 40 NS < 0,1 29,3 50

Turkey, Izmir

Turkey, Antalya 11 973 38 N

Thailand, Songkhla 20 723 36 N

Thailand, Lampang 7 394 7 N

Thailand, Chiang Mai 12 543 17 - 18 N

Singapore 20 107

Philippines, Manila 683

Pakistan, South Karachi

Oman

Malaysia, Sarawak

1 500 127

3 263 209

5 287 426

1 723 615

1 777 685

2 071 506

1 007 173

2 172 958

1 040 089

9 853 972

546 696

<1 55 M N A L 20.7 0,05 NS 1 20-30 25 0 1 0 76

3 353 446

1 392 172

1 255 662

782 152

1992

1995

1988

1993

1995

1989

1995

1983

1968

1980

1995

L;M N N

14,78 NS N A L NS

~ 85

~ 85 80.6 NI 15

40 10 L

< 10 <1

NS 55 15

20

Europe 12 648 207 600 2 601 83 871

Techniques of registration

Belarus

Austria, Vorarlberg

Austria, Tyrol

Austria

8 021 504

10 038 230

349 737

670 595

54 N

47 N

46 N

NS

1972

1978

1987

1958

1972

1981

1988

1970

NS <1 NS 5

NS

NI

19

20
Table 2.1 Registry background Surface area (km2) 2 867 41 - 44 N 50 N 1978 1974 1977 1978 N N N 1952 1975 N 1953 L 1942 1968 A 1943 A NS NS <5 N NS N 2 N 2,4 0,1 0 45 1976 1976 L 0 1959 1962 L NS 51 N 1952 1952 A NS 1983 1996 N NS 51 N 1990 1990 N NS NI Latitude Year registry started NS Year population-based data available Cancer reportable by: L/A/N/M* % cases treated outside registration area % non-residents treated inside registration area 110 912 78 866 58 N 48 N 1976 1986 1988 1978 62 N 55 N 56 542 13 522 NS 0 1

Population

Bulgaria

Belgium, Flanders

Belgium, Antwerp

Techniques of registration

Finland 5 548 48 N 1978 1994 1998 1983 1979 47 N 1989 NS 49 N

Estonia 304 112

Denmark 45 227

Czech Republic 43 080

Croatia

8 080 354

5 940 556

1 644 169

10 255 038

4 418 155

Germany, Hamburg 23 180 310 6 906 103 000 70 280 914 2 567 51 N 64 N 49 N 53 N 49 N 54 N

Germany, Free State of Saxony 755 53 N

Germany, Brandenburg 18 416 51 N 1926 1953

France, Vende 29 479 52 N 1953

France, Tarn 6 720 47 N 1997

France, Somme 5 758 44 N 1981

France, Manche 6 170 49 N 1982

France, Loire-Atlantique 5 938 49 N 1994 1982

France, Isre 6 815 47 N 1997

France, Hrault 7 431 45 N

France, Haut-Rhin 6 101 43 N

France, Doubs 3 522

France, Calvados 5 234

France, Bas-Rhin

5 182 506

1 370 505

5 337 420

<1 NS NI

1 036 738

1 151 896

1 109 587

915 645

714 738

502 897

652 274

NS 20 N

NS

NS

15

1 703 189

4 439 006

2 591 809

550 743

348 036

556 929

483 644

NS N <5 10

1900 1953 1978 1986 1954 1967 1994

1953

1953

1998

1982

L 1953 1998 1986 1955 1967 1994

<5 L L N N L NS <2 NS ~ 10 N 0-1 NS

NS

NS

NS

35

NS

NS

NS

10

30

NS 0 0

15-25 0 > 40 NS 10-15 NS 0

Germany, Munich

Germany, MecklenburgWestern Pomerania

1 780 055

2 340 075

Italy, Brescia Province

Italy, Biella Province 3 460

Ireland

Iceland

Germany, Saarland

Germany, North Rhine-Westphalia: Mnster

2 613 486

1 070 388

3 799 840

280 949

1 001 930

188 791

45 N

45 N

1994

1997

1993

1995

NS A

40,4 9,8

NS

Table 2.1 Registry background Surface area (km2) 2 632 44 N 43 N 1988 1995 N A 1997 A A 80 6 7 2002 1988 M 4 1999 N 2,57 44 N 1989 1991 A 65 1984 1986 N 5 1984 1985 A ~2 ~ 19 20 5 45 N 1987 1991 M 14,6 NS Latitude Year registry started Year population-based data available Cancer reportable by: L/A/N/M* % cases treated outside registration area % non-residents treated inside registration area

Population

Italy, Florence and Prato 2 774 2 690 21 451 3 449 44 N 1997 1998 1992 1985 1996 1986 M M 37 N 2001 1996 M 1979 1981 1 614 44 N 1991 1999 45 N 1976 1978 499 46 N 1998 40 N 1996 182 44 N 45 N 1 834

Italy, Ferrara Province 3 879

Italy, Parma Province 2 293 40 N 2001 1985

Italy, North East

Italy, Naples

Italy, Modena Province

Italy, Milan

Italy, Macerata Province

Italy, Genoa Province

1 162 009

348 068

1 302 388

300 362

905 261

2 108 544

536 106

632 493

5-10 10 4

50

Latvia 64 000 316 52 N 53 N NS 51 N 36 N NS 1985 1975

Italy, Veneto Region 64 589 55 - 58 N 1993

Italy, Varese Province 9 081 45 N 1990

Italy, Umbria Region 1 199 45 N 1974

Italy, Torino 8 456 43 N 1991

Italy, Syracuse Province 130 45 N 1985 1994

Italy, Sondrio 2 109 37 N 1997

Italy, Sassari Province 3 212 46 N

Italy, Salerno Province 7 520 41 N

Italy, Romagna Region 4 922

Italy, Reggio Emilia Province 5 303

Italy, Ragusa Province

1 087 279

984 424

456 026

295 754

400 056

20 3-5 5

5-10 NS 25 10

10-15 N NS N A N A 47 15 NS NS

Techniques of registration

Portugal, South Regional

Portugal, Porto 39 700

Poland, Warsaw City 21 278

Poland, Kielce 495

Poland, Cracow 11 691

Norway 327

The Netherlands, Maastricht 324 000 57 - 71 N 51 N 51 N

The Netherlands, Eindhoven 1 355

The Netherlands 2 500

Malta

Lithuania

2 381 395

2 003 027

806 107

824 525

903 568

396 175

176 878

470 153

10 12

1987

1976

3 514 664

15 927 902

388 414

4 500 716

867 248

987 198

4 450 012

3 165 766

1 648 296

1 290 791

743 722

41,5 N 38 N

NS

1989

1988

1963

1962

1965

1952

1984

1955

1955

1994

1988

1963

1988

1978

1952

1986

1958

1989

1991

1978

1965

A N N N L

~ 0,1 NS NS

NS

13

10

~ 0.05 NS <1 0,9 L L 3 L L 0 2 NS

NS

16

20

46

NI

3.5 5 NS L L NS 1 0

NS 7 5 1

10

21

22
Table 2.1 Registry background Surface area (km2) 570 47 - 49 N 39 N 1986 1993 N A 1993 A N 1978 1986 M 1982 N NS NS 4,2 <5 N N 9,6 L 1989 1970 L 0 N 1980 1974 N N 1996 2 1 5 M 10 1,7 46 N 1990 1991 L 8 1950 1950 L NS NS 1976 1968 M NS 1996 1999 L ~5 60 N 1953 1980 L 0,5 5 Latitude Year registry started ~ 30 Year population-based data available Cancer reportable by: L/A/N/M* % cases treated outside registration area % non-residents treated inside registration area 49 035 14 862 43 N 1993 1985 1994 1992 43 N 20 273 55 968 < 0.5 7 1

Population

Slovak Republic

Serbia

Russia, St Petersburg

Techniques of registration

Spain, Girona 12 531 10 491 17 252 46 N 1972 1989 58 N 1970 1958 1958 6 283 41 N 1960 1960 41 N 1979 1980 11 317 42 - 43 N 1970 1973 37 N 1981 1982 37 N 1985

Spain, Cuenca 5 569 41 - 42 N 1995

Spain, Canary Islands 17 061 40 N

Spain, Basque Country 7 500 28 N

Spain, Asturias 7 261

Spain, Albacete 10 565

Slovenia

5 400 679

5 482 807

4 669 043

1 987 309

1 447 771

2 087 227

1 081 836

362 543

NS 3.5 10

Spain, Murcia

Spain, Granada

547 305

201 008

UK, England, Oxford Region 28 500 14 763 16 000

UK, England, Northern and Yorkshire 8 200

UK, England, North Western 30 000 52 N 54 N 50 N

UK, England, Merseyside and Cheshire NS NS

UK, England, East of England Region NS NS

Switzerland, Vaud 13 800 52 N

Switzerland, Valais 3 211 47 N

Switzerland, Ticino 5 225 NS

Switzerland, St Gall-Appenzell 2 812 NS 1988 1995

Switzerland, Neuchtel 2 430 47 N 1960

Switzerland, Graubnden and Glarus 796 47 N

Switzerland, Geneva 7 790 46 N

Sweden 282

Spain, Zaragoza 449 964

Spain, Tarragona

Spain, Navarra

1 149 595

810 967

8 880 323

844 261

593 176

555 735

NS

NS 1

20

NI NS 17 <5 N < 10 NS L NS 1 10 20 5 0

4 130 253

2 357 153

2 732 948

614 829

275 600

309 578

517 318

166 459

224 541

411 794

2 716 680

6 560 118

1952

1965

1962

1944

1960

1972

1976 1945

1962

1944

1960

1974

1989

N NS

NS

NS

NS

NS 4 A A 1971 N

NS 40 <1 2,4 7

1.2 1,6

9.1 8

UK, England, Trent

UK, England, Thames

UK, England, South and Western Regions

6 684 815

0.2 51 - 52 N 53 N 1955 1958 1971 1960 N N 10-15 5 10-15 7

13 883 842

4 785 950

Table 2.1 Registry background Surface area (km2) 13 014 56 N 54 N 1936 1958 N < 0,5 1994 1993 N <5 1-4 <5 52 N 1936 1957 N 3 4.9 Latitude Year registry started Year population-based data available Cancer reportable by: L/A/N/M* % cases treated outside registration area % non-residents treated inside registration area

Population

UK, Scotland

UK, Northern Ireland 77 925

UK, England, West Midlands 14 139

5 066 191

1 685 136

5 279 560

Oceania 801 400 26 S 1978 1982 1982 L L 1977 1978 L 1977 L 13 S 1982 1982 L 1981 1991 L 2 400 28 - 38 S 1971 1972 L NS 0 35 S 1971 1972 L NS

USA, Hawaii

New Zealand 16 635 21 N 1960 1960

French Polynesia 270 534 39 S 1948 1972

Western Australia 4 000 7 - 29 S 1981 1985

Australia, Victoria NS NS 1981

Australia, Tasmania 227 420 37 S 1940

South Australia 68 114 42 S

Australia, Queensland 984 375 26 - 38 S

Australia, Northern Territory 1 600 000

Australia, New South Wales 1 346 200

Australian Capital Territory

6 489 196

315 652

1 504 567

3 575 470

194 922

NS NS NS 0,8

NS 5

1 877 923

4 763 103

472 195

<1 L NS L L NS

0.4 NS 0 <1 NS 0 NI

1 218 833

3 853 350

232 782

8-12

* L = legislation (a law exists) A = administrative order (without a specic law) N = not reportable M = mixed (a combination of above) NS, not stated NI, not included

Techniques of registration

23

24
Table 2.2 Case nding, abstracting and coding Radiotherapy depts. Pathology labs Autopsy Haematology labs Death certicates Screening programmes Public hospital in-patient facilities % cases abstracted by registry personnel 100 100 NS Y Y N Y Y N Y Y Y Y Y N Y Y N N N Y Y Y Y Y N Y N Y Y Y Y N Y Y N Y Y Y Y Y Y Y Y Private hospital/ clinic in-patient facilities Private Public hospital/ hospital clinic out-patient out-patient facilities facilities % cases coded by registry personnel 100 100 100 99 100 100 100

Hospital in-patient records

Africa Y Y Y Y Y Y

Techniques of registration

Tunisia, Central Region Y Y

Egypt, Gharbiah Y

Algeria, Setif

Zimbabwe, Harare

Uganda, Kyadondo County

South and Central America Y Y Y N Y N N Y N Y Y Y N Y Y Y Y Y Y Y Y N Y N N Y Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N N Y N Y

Argentina, Bahia Blanca

Ecuador, Quito Y N Y Y Y Y

Costa Rica N Y Y

Colombia, Cali Y Y

Chile, Valdivia Y Y

Brazil, So Paulo Y N

Brazil, Goinia Y

Brazil, Cuiaba Y

Brazil, Brasilia

France, Martinique

Peru, Trujillo

Y Y

Y Y

100

10

100 100 100 NS 90

90

75

100

100

100 Y

100

25

100

100 95

100

100

North America N Y N N Y N N Y Y N Y N N N N N N N N Y Y Y Y Y N Y N N N

Canada, Alberta

Canada

Canada, British Columbia

Canada, Newfoundland and Labrador Y Y Y Y Y Y

Canada, New Brunswick Y

Canada, Manitoba

Canada, Northwest Territories

Canada, Nova Scotia

Canada, Ontario

Y Y Y Y

Y Y Y N N Y Y

Y Y N Y Y N Y Y Y

Y Y Y Y Y Y Y Y

Y Y Y Y Y Y Y Y Y

Y Y N Y Y Y Y Y Y

100

0 50 100 Y Y N Y N NS

100 100 100 100 50 100 0 100 NS

100 100 50

Canada, Prince Edward Island

100

Table 2.2 Case nding, abstracting and coding Radiotherapy depts. Pathology labs Autopsy Y N N NS Y NS N Y Y Y Y N Y Y Y Y Y 50 100 2 6 Y Y Y 97 Y N Y NS Y Y Y Y Y Y Haematology labs Death certicates Screening programmes Y N Y NS Y Y Y Y N N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y NS NS NS NS Y Y Y Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y N N N Public hospital in-patient facilities % cases abstracted by registry personnel 100 50 100 NS 7 6 % cases coded by registry personnel Private hospital/ clinic in-patient facilities Private Public hospital/ hospital clinic out-patient out-patient facilities facilities

Hospital in-patient records

USA, Alaska Y NS Y Y Y Y Y Y Y Y Y Y

USA, Alabama Y

Canada, Saskatchewan Y

USA, Maine NS Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y

USA, Louisiana, New Orleans Y Y Y Y NS Y Y

USA, Louisiana Y Y Y Y Y

USA, Kentucky Y Y Y Y Y

USA, Iowa Y Y Y Y Y Y

USA, Indiana Y Y Y Y Y Y

USA, Illinois Y Y Y Y Y Y

USA, Idaho Y Y Y Y Y

USA, Georgia, Atlanta Y Y Y Y Y

USA, Georgia Y Y Y Y

USA, Florida Y Y Y Y

USA, District of Columbia Y Y Y

USA, Connecticut Y Y Y

USA, Colorado Y Y

USA, California, Los Angeles County Y Y

USA, California, Greater San Francisco Bay Area NS Y

USA, California

USA, Arizona

NS

NS 100 Y Y Y NS 15

USA, Montana Y Y Y Y

USA, Missouri Y

USA, Michigan, Detroit Y

USA, Michigan

USA, Massachusetts

NS

100 100 NS 0

Techniques of registration

USA, NPCR

USA, New York State

USA, New Mexico Y

USA, New Jersey

Y Y Y Y Y

NS Y Y

NS Y NS Y Y Y Y Y Y Y Y Y

100

95

99

10

1-2

80

100 NS Y N Y Y Y Y Y N

100

1-2 100

N Y Y Y

95-98 2 Y 1

100

100

85

100

NS

95-98 15 6.3 Y Y Y Y 65 1

100

100

15

100 0 100 N 90

0.5

<3

100

100

15

<3

25

26
Table 2.2 Case nding, abstracting and coding Radiotherapy depts. Pathology labs Autopsy Y Y Y Y Y Y Y Y Y Y Y Y N Y Y 8 6 4 Y Y Y Y Y Y Y Haematology labs Death certicates Screening programmes Y Y NS Y Y Y Y N Y Y Y N Y N Y Y Y Y Y Y Y Y N Y Y Y N N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N NS NS Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Public hospital in-patient facilities % cases abstracted by registry personnel Private hospital/ clinic in-patient facilities Private Public hospital/ hospital clinic out-patient out-patient facilities facilities % cases coded by registry personnel 4 0 5 4 ~100 Y

Hospital in-patient records

Techniques of registration

USA, Wisconsin

USA, West Virginia Y Y Y Y Y N

USA, Washington, Seattle Y Y Y Y Y Y

USA, Washington Y Y Y Y Y

USA, Vermont Y Y Y Y Y

USA, Utah Y Y Y Y

USA, Texas Y Y Y Y

USA, South Carolina Y Y Y

USA, SEER Y Y Y

USA, Rhode Island Y Y

USA, Pennsylvania Y Y

USA, Oregon Y NS

USA, Oklahoma Y

USA, Ohio Y

NS N

~100 85 N

20

NS 100

23.4

NS Y N

90

100

100

15

20

95

100 0

NS

10

10

20

Asia N Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y N Y Y N Y N N Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y N N Y

Bahrain

China, Nangang District, Harbin City N N Y Y Y Y Y Y Y Y Y Y

China, Jiashan Y

China, Hong Kong Y

China, Guangzhou

China, Shanghai

Cyprus

China, Zhongshan

Y Y Y Y N Y

Y Y Y Y

Y Y N Y Y Y Y

Y Y Y Y N Y Y Y Y

N Y

100 15 N Y Y N Y N 2

100 0

100 85 0 Y Y Y Y Y

India, Nagpur Y Y Y

India, Mumbai (Bombay) Y

India, Karunagappally Y

India, Chennai (Madras)

Y Y N N N Y Y N Y Y Y Y N Y Y Y Y Y Y Y N N N N

90-92

100 100

90

100

NS

100

100 100 100 100 100 100 100 100

India, Trivandrum

India, Poona Y

India, New Delhi

100

100

100

100

100

100

Table 2.2 Case nding, abstracting and coding Radiotherapy depts. Pathology labs Autopsy Y N N N N N Y Y Y Y Y Y Y N Y Y Y Y Y N Y Y Y N 0 0 75.7 70 Y Y NS 100 Y N N N Y Y Y Haematology labs Death certicates Screening programmes N Y Y N N Y Y N Y Y Y Y Y Y Y Y Y Y Y N N Y Y Y Y Y N Y Y Y Y Y Y N Y Y N Y Y Y N N N N Y Y Y Y Y Y N N Y N N Public hospital in-patient facilities % cases abstracted by registry personnel 100 100 100 NS Y Y Y Y Y Y 50 100 18 % cases coded by registry personnel Private hospital/ clinic in-patient facilities Private Public hospital/ hospital clinic out-patient out-patient facilities facilities

Hospital in-patient records

Israel N N Y N Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y Y

Japan, Fukui Prefecture

Japan, Aichi Prefecture

Japan, Yamagata Prefecture Y Y Y N Y Y Y Y NS Y Y N Y Y Y Y Y Y

Japan, Osaka Prefecture N

Japan, Nagasaki Prefecture N

Japan, Miyagi Prefecture Y

Japan, Hiroshima

100 25 100 Y Y 100

Oman Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y Y N

Malaysia, Sarawak Y Y N Y N

Malaysia, Penang Y Y Y Y

Kuwait Y Y Y Y

Korea, Ulsan Y Y Y

Korea, Seoul Y Y Y

Korea, Jejudo Y Y Y

Korea, Incheon Y Y Y

Korea, Gwangju Y Y

Korea, Daejeon Y Y

Korea, Daegu Y

Korea, Busan Y

Korea

Thailand, Lampang Y Y Y Y Y

Thailand, Chiang Mai Y

Singapore Y

Philippines, Manila Y

Pakistan, South Karachi

N Y Y Y

Techniques of registration

Turkey, Antalya

Thailand, Songkhla

Turkey, Izmir

100 Y Y Y

6.2

100

100

100

NS

56.1

35

100

8.3

100 Y

43.9 7 NS Y Y Y Y N Y Y Y

35

100 100

100 N

100

50 N

N Y Y N Y Y

~30

80 100 Y

100

100

100

100

100 Y N Y Y

100 Y

60 95 100

100

100

100

100

100

100 80

95

100

27

28
Table 2.2 Case nding, abstracting and coding Radiotherapy depts. Pathology labs Autopsy Haematology labs Death certicates Screening programmes Public hospital in-patient facilities % cases abstracted by registry personnel 5 100 40 Y Y N Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N N Y Y Y Y Y Y Y Y Y Y Y Y Y N Y N Y N N N N Y Y NS Y NS N Y N N Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y N Private hospital/ clinic in-patient facilities Private Public hospital/ hospital clinic out-patient out-patient facilities facilities % cases coded by registry personnel 92 100 100 0 36 100

Hospital in-patient records

Europe Y N Y N Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y N Y N Y Y

Techniques of registration

Belarus Y N Y Y N Y Y Y Y Y Y Y Y Y

Austria, Vorarlberg N

Austria, Tyrol Y

Austria

Croatia Y Y Y Y Y Y

Bulgaria N

Belgium, Flanders Y

Belgium, Antwerp

France, Isre Y Y Y Y Y N Y Y Y Y Y Y Y Y N Y Y Y Y N Y Y Y Y Y Y Y Y N N Y N Y Y Y N N

France, Hrault Y Y Y Y

France, Haut-Rhin Y Y Y Y

France, Doubs Y N N

France, Calvados Y Y Y

France, Bas-Rhin Y Y

Finland Y Y

Estonia Y

Denmark Y

Czech Republic

100 NS Y

0 64 0 N 100 0

100

France, Loire-Atlantique

France, Vende Y Y Y Y Y

France, Tarn Y

France, Somme Y

France, Manche

Germany, Hamburg

Germany, Free State of Saxony

Germany, Brandenburg

N Y Y Y

Y Y N Y Y

N N N Y Y N Y N N

Y Y N Y Y N Y Y Y N Y N N Y

100 100 80

NS

100 100 100 32 NS

NS

100

100

100

100

100

100

100

90

80

100

NS

Germany, Munich

Germany, MecklenburgWestern Pomerania

Y Y Y N

Y Y Y N

Y Y Y Y

Y Y N Y

Y Y Y

NS 0 N Y N 0

100

100

100

100

NS 0 Y

100

100

100

100 <5

NS

100

Table 2.2 Case nding, abstracting and coding Radiotherapy depts. Pathology labs Autopsy N Y Y Y Y Y Y Y Y Y Y Y Y Y NS Y Y Y Y N 0 100 100 N Y N 75 Y Y Y Y Y Y Y Y Haematology labs Death certicates Screening programmes Y Y Y N NS Y N N Y N Y Y N Y Y Y Y N Y Y Y N Y Y N Y Y Y Y N N N Y Y Y Y N Y Y Y Y Y Y Y NS Y Y Y Y Y Y Y NS NS Y Y Y Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Public hospital in-patient facilities % cases abstracted by registry personnel 100 100 100 100 0 100 Y Y 10 N Y Y 100 % cases coded by registry personnel Private hospital/ clinic in-patient facilities Private Public hospital/ hospital clinic out-patient out-patient facilities facilities

Hospital in-patient records

Italy, Brescia Province NS Y N Y Y N Y Y Y Y N Y Y Y N NS Y

Italy, Biella Province Y N

Ireland Y Y

Iceland Y

Germany, Saarland Y

Germany, North Rhine-Westphalia: Mnster

Italy, Ragusa Province Y Y Y N Y Y N Y Y Y Y Y Y Y Y Y Y Y Y N N Y N Y Y Y Y Y Y Y Y Y N Y Y

Italy, Parma Province Y Y Y

Italy, North East Y Y

Italy, Naples Y Y

Italy, Modena Province Y

Italy, Milan Y

Italy, Macerata Province N

Italy, Genoa Province

Italy, Florence and Prato

Italy, Ferrara Province

NS

79.7 100 100 Y Y 85 100

100

Italy, Syracuse Province Y Y Y Y Y Y Y Y N

Italy, Sondrio N Y

Italy, Sassari Province Y Y

Italy, Salerno Province Y

Italy, Romagna Region Y

Italy, Reggio Emilia Province

Y Y Y Y

Italy, Varese Province Y Y

Italy, Umbria Region N

Italy, Torino

Y N

Italy, Veneto Region N Y Y Y

Y Y Y Y N Y Y Y Y

N Y N N N Y Y Y Y Y Y

Latvia

Techniques of registration

Lithuania

The Netherlands

Malta

Y Y Y Y

NS

NS

51

100

100

Y Y Y Y Y Y

100

0 100 10-30 NS

100

NS

51

100

30

100 100 100 90 Y Y Y Y Y Y N Y Y NS

100 63

98.8 Y N Y N Y

100

98.8 0 NS 80 100 NS

100

100

37

30

100

30 95 100 NS

29

30
Table 2.2 Case nding, abstracting and coding Radiotherapy depts. Pathology labs Autopsy Y Y Y N N Y Y Y Y Y N Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N N NS N N Y Y Y Y N Y N Y Y N N N Y Y Y Y Y N Y Y Y Y Y N Y Y Y Y 0 Y Y Y N N Y Y Y Haematology labs Death certicates Screening programmes Y Y Y N Y Y Y Y N N N Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y N N Y N Y Y N N Y Y Y Y Y Y Y Y Y Y Y Y Y Y N Y N Y N Y N Public hospital in-patient facilities % cases abstracted by registry personnel 100 NS 10 Private hospital/ clinic in-patient facilities Private Public hospital/ hospital clinic out-patient out-patient facilities facilities % cases coded by registry personnel 100 100 NS 30 100 NS

Hospital in-patient records

The Netherlands, Eindhoven

The Netherlands, Maastricht Y Y

Techniques of registration

Poland, Warsaw City Y Y Y Y N N Y N Y Y Y N Y Y Y Y Y Y Y Y Y

Poland, Kielce N

Poland, Cracow Y

Norway

Portugal, Porto Y Y

Spain, Asturias Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y N Y N Y

Spain, Albacete N Y

Slovenia N Y

Slovak Republic Y Y

Serbia Y

Russia, St Petersburg Y

Portugal, South Regional

Spain, Basque Country N Y Y Y N N Y Y Y Y Y

40 N Y

44 1 N

100

70

~ 75 Y Y Y Y Y Y Y Y N Y

NA 100 Y N Y N Y Y Y Y Y 0

~ 25

100

100

61

Spain, Cuenca

Spain, Canary Islands

Switzerland, Geneva Y Y Y Y Y Y

Sweden Y Y

Spain, Zaragoza N Y

Spain, Tarragona Y Y

Spain, Navarra Y Y

Spain, Murcia Y

Spain, Granada Y

Spain, Girona

100

40 78

100

100

100

100 100 5-10 Y Y Y Y Y Y N Y Y 100 35 100 100 100 20 65 99 Y

Switzerland, Graubnden and Glarus Y Y

Switzerland, Vaud

Switzerland, Valais Y

Switzerland, Ticino Y

Switzerland, St Gall-Appenzell Y

Switzerland, Neuchtel

Y Y Y N Y N Y Y Y Y Y Y Y

N Y Y Y Y Y Y

N Y Y Y Y Y Y

100

50

50

85

100

100

80

100 100 100 Y Y 100

50

100

100

100

100

100

100

100

100

100

100

Table 2.2 Case nding, abstracting and coding Radiotherapy depts. Pathology labs Autopsy Y Y Y Y Y Y Y Y Y Y Y Y Y 95 100 0 Y Y Y 100 Y Y Y Y N Y Y Y N Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y N Y Y N Haematology labs Death certicates Screening programmes Y Y Y Y Y N Y Y Y Y Y N Y N Y Y Y Y Y Y N Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y N Y N Y N Y N Y N Public hospital in-patient facilities % cases abstracted by registry personnel 100 100 100 1-2 50 Y 100 % cases coded by registry personnel Private hospital/ clinic in-patient facilities Private Public hospital/ hospital clinic out-patient out-patient facilities facilities

Hospital in-patient records

UK, England, East of England Region

UK, England, Merseyside and Cheshire

UK, Northern Ireland Y Y Y

UK, England, West Midlands Y Y N

UK, England, Trent Y Y Y

UK, England, Thames Y Y

UK, England, South and Western Regions Y Y

UK, England, Oxford Region Y

UK, England, Northern and Yorkshire Y

UK, England, North Western

UK, Scotland

100 91 Y

~ 90

>1

100

20

~ 90

90

91

50

100

Oceania N N Y Y N Y N Y Y Y N Y Y N N Y Y N N Y Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y N N Y Y Y Y Y Y N N N N Y N Y Y Y Y Y Y

Australia, Northern Territory

Australia, New South Wales

Australia, Queensland

Y Y Y Y Y

Y Y Y Y Y Y Y

French Polynesia N Y Y Y Y

Western Australia N Y

South Australia Y N

Australian Capital Territory Y

Australia, Victoria Y

Australia, Tasmania

N N Y Y Y Y N Y Y N Y Y

20

0 35 20 0 Y Y Y Y

100 100 0 65 80 100

75

New Zealand

USA, Hawaii

100

100

60

99.5

100

75

100 100 100

Techniques of registration

NS, not stated

31

32
Table 2.3 Information recorded Date of birth ID number Ethnic group/ race/ colour Incidence date Stage of the disease Nature of 1st treatment Brain and nervous system N Y N Y Y N Sel N N Sel Y Y Y Y Sel Y N N Sel N Y Y N N N Sel Y Y N N Y Y Follow-up for vital status: all/ selected/ none Death certicates used to update vital status Active follow-up of alive cases

Basic information

Africa Y N Y Y Y N Y Y N Y Y N Y

Techniques of registration

Zimbabwe, Harare

Uganda, Kyadondo County Y

Tunisia, Central Region N

Egypt, Gharbiah Y

Algeria, Setif

South America Y Y N Y Y Y N Y N N Y Y N N N Y N N Y N Y Y N Y Y N N Y N Y Y N N Y Y Y N Y N N Y

Peru, Trujillo

France, Martinique Y N N Y

Ecuador, Quito Y Y N Y

Costa Rica Y Y N Y

Colombia, Cali Y Y N

Chile, Valdivia Y Y N

Brazil, So Paulo Y Y

Brazil, Goinia Y N

Brazil, Cuiaba Y

Brazil, Brasilia Y

Argentina, Bahia Blanca

None

None Sel

All

None None Y N Y All All All

Sel

All

Y Y N N

North America Y Y N N Y N N Y Y N Y N Y Y Y

Canada, Ontario Y

Canada, Nova Scotia Y

Canada, Northwest Territories Y Y Y

Canada, Newfoundland and Labrador Y Y

Canada, New Brunswick Y Y

Canada, Manitoba Y Y

Canada, British Columbia Y

Canada, Alberta Y

Canada

Canada, Prince Edward Island

Y Y Y Y

N N

Y Y N N Y

None All Y All

All

All

All

All

All

All

All

Y Y

Table 2.3 Information recorded Date of birth Y Y Y NS Y Y Y Y Y Y N N Y Y Y Y Y Y Y Y All All All NS NS NS NS Y Y Y Y Y All Y Y Y Y All Y Y Y Y Y Y Y Y All Y Y Y Y Y Y Sel Y Y N Y Y Y Y All Y Y N N ID number Ethnic group/ race/ colour Incidence date Stage of the disease Nature of 1st treatment Brain and nervous system Active follow-up of alive cases Follow-up for vital status: all/ selected/ none Death certicates used to update vital status

Basic information

Techniques of registration

USA, NPCR

USA, New York State

USA, New Mexico Y Y

USA, New Jersey Y Y

USA, Montana Y Y

USA, Missouri Y Y Y Y

USA, Michigan, Detroit Y Y Y

USA, Michigan Y Y Y

USA, Massachusetts Y Y Y

USA, Maine Y Y Y Y Y

USA, Louisiana, New Orleans Y Y Y Y

USA, Louisiana Y Y Y Y

USA, Kentucky Y Y Y Y

USA, Iowa Y Y Y Y Y Y

USA, Indiana Y Y Y Y Y

USA, Illinois Y Y Y Y Y

USA, Idaho Y Y Y Y Y

USA, Georgia, Atlanta Y Y Y Y Y Y Y

USA, Georgia Y Y Y Y Y Y

USA, Florida Y Y Y Y Y Y

USA, District of Columbia Y Y Y Y Y

USA, Connecticut Y Y Y Y Y

USA, Colorado Y Y Y Y

USA, California, Los Angeles County Y Y Y Y

USA, California, Greater San Francisco Bay Area Y Y Y

USA, California NS Y NS

USA, Arizona Y Y

USA, Alaska Y Y

USA, Alabama Y

Canada, Saskatchewan Y

N NS Y Y Y

NS Y N Y

None Y Y Y All All

All

All

All

All

All

All

All

All

All

Sel

All

Sel

Sel

All

All

All

All

33

34
Table 2.3 Information recorded Date of birth Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y All All Y Y Y Y Y All Y Y Y Y All Y Y Y Y Y Y All Y Y Y Y Y Y N None Y Y Y Y Y Y Y All Y ID number Ethnic group/ race/ colour Incidence date N N Y N Stage of the disease Nature of 1st treatment Brain and nervous system Follow-up for vital status: all/ selected/ none Death certicates used to update vital status Active follow-up of alive cases

Basic information

Techniques of registration

USA, Wisconsin

USA, West Virginia Y Y Y Y Y Y

USA, Washington, Seattle Y Y Y Y Y Y

USA, Washington Y Y Y Y Y Y

USA, Vermont Y Y Y Y Y

USA, Utah Y Y Y Y Y

USA, Texas Y Y Y Y

USA, South Carolina Y Y Y Y

USA, SEER Y Y Y

USA, Rhode Island Y Y Y

USA, Pennsylvania Y Y

USA, Oregon Y Y

USA, Oklahoma Y

USA, Ohio Y

All

All

All

Sel

All

All

Sel

Y Y N Y

Asia Y Y Y Y Y Y Y Y N Y N Y Y Y N Y N Y N N Y N Y Y

India, Nagpur N N N N Y N

India, Mumbai (Bombay) N Y

India, Karunagappally N Y

India, Chennai (Madras) N Y Y Y

Cyprus N N Y

China, Zhongshan Y Y Y

China, Shanghai Y Y Y

China, Nangang District, Harbin City Y N

China, Jiashan Y N

China, Hong Kong Y

China, Guangzhou Y

Bahrain

India, Poona

India, New Delhi

India, Trivandrum

Y Y N

Y Y Y Y

Y Y

Y Y

None Y N Y Y N All Sel

All

All

All

All

All

Sel

Sel

N Y N Y

None N N None Sel All

Sel

NS Y Y N N

Table 2.3 Information recorded Date of birth Y N N Y Y N Y Y Y Y Y Y Y Y Y Y N Y Y Y Y All All Y Y Y All N Y Y Y Y All Y Y Y Y None N Y Y All Y N N Y Y Y N All Y N Y Y Y N None Y Y Y Y Y Y Y All Y Y N Y N N ID number Ethnic group/ race/ colour Incidence date Stage of the disease Nature of 1st treatment Brain and nervous system Active follow-up of alive cases Follow-up for vital status: all/ selected/ none Death certicates used to update vital status

Basic information

Korea, Ulsan Y N N Y N N Y N Y Y Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y N Y Y

Korea, Seoul Y Y N Y N

Korea, Jejudo Y Y Y Y N

Korea, Incheon Y Y N Y Y Y Y

Korea, Gwangju Y Y N Y Y Y

Korea, Daejeon Y Y Y Y N

Korea, Daegu Y Y Y Y N

Korea, Busan Y Y N Y N

Korea Y Y N Y Y

Japan, Yamagata Prefecture Y Y N Y

Japan, Osaka Prefecture Y N N Y

Japan, Nagasaki Prefecture Y N Y

Japan, Miyagi Prefecture Y N N

Japan, Hiroshima Y N

Japan, Fukui Prefecture Y N

Japan, Aichi Prefecture Y

Israel Y

Techniques of registration

Turkey, Izmir

Turkey, Antalya Y Y

Thailand, Songkhla Y Y

Thailand, Lampang Y Y

Thailand, Chiang Mai Y Y

Singapore Y

Philippines, Manila Y

Pakistan, South Karachi Y

Oman Y

Malaysia, Sarawak Y

Malaysia, Penang Y

Kuwait

N Y

All

All

All

All

All

All

All

Y Y Y Y Y Y Y

None Sel N Y Sel

Sel

Sel

All

All

Y Y Y All Y N Y N Y Y All All Y N Y N Y All Y All Y Y

All

35

36
Table 2.3 Information recorded Date of birth ID number Ethnic group/ race/ colour Incidence date Stage of the disease Nature of 1st treatment Brain and nervous system N Y Y Y N Y Y Y Y Y Y Y All All Y Y All Y Y N Y None Y Y N All Y Y Y Y Y NS All Y N N Y Y N All N N None All Y Y All Y Y Y All N N N Y Y Follow-up for vital status: all/ selected/ none Death certicates used to update vital status Active follow-up of alive cases

Basic information

Europe Y N Y N Y Y N Y Y Y Y Y Y Y Y N Y Y Y Y Y Y N Y Y N Y Y N Y N Y N N Y

Techniques of registration

Germany, Munich

Germany, MecklenburgWestern Pomerania Y N

Germany, Hamburg Y N

Germany, Free State of Saxony Y N

Germany, Brandenburg Y N N N

France, Vende Y N N

France, Tarn Y N N

France, Somme Y N N

France, Manche Y N N Y Y

France, Loire-Atlantique Y N N Y

France, Isre Y N N Y

France, Hrault Y N N Y

France, Haut-Rhin Y Y N Y Y Y

France, Doubs Y N N Y Y

France, Calvados Y N N Y N

France, Bas-Rhin Y N N Y N

Finland Y N N Y Y

Estonia Y Y N Y

Denmark Y Y Y Y

Czech Republic Y Y N

Croatia Y Y N

Bulgaria Y Y

Belgium, Flanders Y Y

Belgium, Antwerp Y

Belarus Y

Austria, Vorarlberg Y

Austria, Tyrol Y

Austria

N Y All

N N

Y Y Y Y Y N

Sel

All

All

N Y

N Y Y N Y Y Y Y Y

N Y N N

Y Y Y N Y N Y Y Y

All

Sel

All

Y N

Y Y

Y Y Y

All Y

All

All

All

All

Sel

Sel

Y Y N Y

Y All

N Y

Table 2.3 Information recorded Date of birth Y Y N Y N Y Y N N Y N N N Y Y Y N Y N Y Y Y Y N Y Y N Y Y Y N Y N Y N Y Y Y Y Y Y Y N Sel All Y N Y N N Y All N Y Y Y Y All Y N Y Y Y Y All N Y N N Y Sel Y Y N N Y Y Y Y None Y N N Y Y Y Y All Y N N ID number Ethnic group/ race/ colour Incidence date Stage of the disease Nature of 1st treatment Brain and nervous system Active follow-up of alive cases Follow-up for vital status: all/ selected/ none Death certicates used to update vital status

Basic information

Techniques of registration

The Netherlands

Malta Y N

Lithuania Y Y

Latvia Y Y

Italy, Veneto Region Y Y

Italy, Varese Province Y Y N N

Italy, Umbria Region Y Y N

Italy, Torino Y Y N

Italy, Syracuse Province Y Y N

Italy, Sondrio Y Y N

Italy, Sassari Province Y Y N Y

Italy, Salerno Province Y N N Y

Italy, Romagna Region Y N N Y

Italy, Reggio Emilia Province Y Y N Y Y

Italy, Ragusa Province Y Y N Y Y

Italy, Parma Province Y N N Y Y

Italy, North East Y Y N Y Y

Italy, Naples Y Y N Y N

Italy, Modena Province Y Y N Y Y

Italy, Milan Y Y N Y

Italy, Macerata Province Y Y N Y

Italy, Genoa Province Y Y N

Italy, Florence and Prato Y Y N

Italy, Ferrara Province Y Y

Italy, Brescia Province Y Y

Italy, Biella Province Y

Ireland Y

Iceland Y

Germany, Saarland Y

Germany, Northrhine-Westphalia: Mnster

N Y

NS N Y Y

All

All

All

All

All

All

All

All

All

All

All

All

All

All

All

All

All

All

All

All

All

All

NS Y Y

Y Y Y Y

37

38
Table 2.3 Information recorded Date of birth Y N Y N Y Y Y Y Y N N Y Y Y Y N Y Y Y Y Y Y Y N Y Y N Y Sel All Y Y Y Y Sel Y N Y Y Y Y All N Y Y Y Y All Y Y N Y Y Y Y All Y N N Y Y Y Y All N ID number Ethnic group/ race/ colour Incidence date Y N Y Y Stage of the disease Nature of 1st treatment Brain and nervous system Follow-up for vital status: all/ selected/ none Death certicates used to update vital status Active follow-up of alive cases

Basic information

Techniques of registration

Switzerland, Vaud

Switzerland, Valais Y

Switzerland, Ticino Y

Switzerland, St Gall-Appenzell Y N Y N

Switzerland, Neuchtel Y N

Switzerland, Graubnden and Glarus Y N

Switzerland, Geneva Y N N N

Sweden Y N N

Spain, Zaragoza Y Y N

Spain, Tarragona Y Y N

Spain, Navarra Y Y N Y Y

Spain, Murcia Y Y N Y

Spain, Granada Y Y N Y

Spain, Girona Y Y N Y

Spain, Cuenca Y Y N Y N Y

Spain, Canary Islands Y Y N Y Y

Spain, Basque Country Y Y N Y N

Spain, Asturias Y Y N Y N

Spain, Albacete Y Y N Y N N Y N N

Slovenia Y Y N Y N N

Slovak Republic Y Y N Y Y

Serbia Y Y N Y Y

Russia, St Petersburg Y Y N Y

Portugal, South Regional Y Y N Y

Portugal, Porto Y N N

Poland, Warsaw City Y N N

Poland, Kielce Y Y

Poland, Cracow Y Y

Norway Y

The Netherlands, Maastricht Y

The Netherlands, Eindhoven Y

N Y N Y Y Y N

None All Y Y N Y Sel

All

All

Sel

All

All

Sel

All

All

N Y Y Y

All

All

All

All

All

All

All

All

All

All

All

All

All

Table 2.3 Information recorded Date of birth Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y None All All All Y Y Y Y All N Y Y Y Y All Y Y Y Y None Y Y Y N Y Y Y Y All Y N Y Y N Y All Y Y Y Y Y Y Y All Y Y N N ID number Ethnic group/ race/ colour Incidence date Stage of the disease Nature of 1st treatment Brain and nervous system Active follow-up of alive cases Follow-up for vital status: all/ selected/ none Death certicates used to update vital status

Basic information

UK, Scotland

UK, Northern Ireland Y Y Y Y

UK, England, West Midlands Y N Y Y

UK, England, Trent Y Y Y

UK, England, Thames Y Y Y

UK, England, South and Western Regions Y Y

UK, England, Oxford Region Y Y

UK, England, Northern and Yorkshire Y Y

UK, England, North Western Y Y

UK, England, Merseyside and Cheshire Y

UK, England, East of England Region Y

N Y

All

Oceania Y Y Y Y Y Y Y N Y N Y Y Y Y Y Y N Y Y Y N Y Y N Y N Y Y Y N N N Y Y Y N

Techniques of registration

USA, Hawaii

New Zealand Y Y Y

French Polynesia Y Y Y

Western Australia Y Y N Y

Australia, Victoria Y N Y

Australia, Tasmania Y N N

South Australia Y Y

Australia, Queensland Y N

Australia, Northern Territory Y

Australia, New South Wales Y

Australian Capital Territory

Y Y Y N Y Y Y

None N All N Y All

All

All

All

All

All

All

All

Sel

Y Y

39

Chapter 3: Classification and coding

H.R. Shin
The Cancer Incidence in Five Continents series has followed the evolution of the International Classification of Diseases through four revisions and the creation of a coding scheme for oncology, the International Classification of Diseases for Oncology (ICDO), now in its third edition (ICDO3). Volumes I and II (Doll et al., 1966; 1970) presented the data on cancer incidence coded to the 7th Revision (ICD7; WHO, 1957). Volume III (Waterhouse et al., 1976) published data using both the 7th and the 8th (ICD8; WHO, 1967) revisions. ICD8, which came into effect in 1968, was used in Volume IV (Waterhouse et al., 1982), presenting data for the years 197377. The 9th Revision of the ICD (ICD9; WHO, 1977) was used for Volumes V (Muir et al., 1987), VI (Parkin et al., 1992), VII (Parkin et al., 1997), The 10th revision of the ICD (ICD10, WHO, 1992) was used for Volume VIII (Parkin et al., 2002) and the present volume. The data are published at the level of the 3-character ICD 10 codes in the individual registry tables and, as in previous volumes, some grouping of ICD codes has been used. Malignant neoplasm of gum, floor of mouth and other and unspecified parts of mouth have been put together (ICD10 C03-C06). Follicular (nodular) non-Hodgkin lymphoma, diffuse non-Hodgkin lymphoma, peripheral and cutaneous T-cell lymphomas and other and unspecified types of non-Hodgkin lymphoma have been combined as Non-Hodgkin lymphoma. Other categories have been combined to correspond to a single three-digit rubric in ICD10; for example base of tongue + other and unspecified parts of tongue (ICD10 C01C02), and rectosigmoid junction and rectum (C19C20). Myeloproliferative disorders (MPD) including morphology behavior M9950/3, 996_/3, 9975/3 and Myelodysplastic syndromes (MDS) including M998_/3 were separately presented according to the ICDO3. Table 3.1 presents the ICD10 individual site codes, the full ICD10 titles, the Volume IX groupings and short titles used in the tables of incidence.

Site C00 C01 C02 C03 C04 C05 C06 C07 C08 C09 C10 C11 C12 C13 C14 C15 C16 C17 C18 C19 C20 C21 C22 C23 C24 C25 C26

Full title Malignant neoplasm of lip

Table 3.1 Classification used in incidence tables

Malignant neoplasm of base of tongue Malignant neoplasm of gum

Groupings used in tables C01-C02 are grouped C03-C06 are grouped

Short title used in tables Lip Tongue Mouth

Malignant neoplasm of other and unspecified parts of tongue Malignant neoplasm of floor of mouth Malignant neoplasm of palate Malignant neoplasm of other and unspecified parts of mouth Malignant neoplasm of parotid gland Malignant neoplasm of other and unspecified major salivary glands Malignant neoplasm of tonsil Malignant neoplasm of oropharynx

C07-C08 are grouped

Salivary gland Tonsil

C12-C13 are grouped C19-C20 are grouped C23-C24 are grouped -

Malignant neoplasm of nasopharynx

Other oropharynx Nasopharynx Hypopharynx Pharynx unspecified Oesophagus Stomach Colon Small intestine Rectum Anus

Malignant neoplasm of pyriform sinus Malignant neoplasm of hypopharynx Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx Malignant neoplasm of oesphagus Malignant neoplasm of stomach Malignant neoplasm of colon

Malignant neoplasm of small intestine Malignant neoplasm of rectosigmoid junction Malignant neoplasm of rectum Malignant neoplasm of anus and anal canal Malignant neoplasm of gallbladder

Malignant neoplasm of liver and intrahepatic bile ducts Malignant neoplasm of other and unspecified parts of biliary tract Malignant neoplasm of pancreas Malignant neoplasm of other and ill defined digestive organs

Liver

Gallbladder etc.

C26 is included in other and unspecified

Pancreas

40

Classification and coding

Site

C30 C31 C32 C33 C34 C37 C38 C39 C40 C41 C43 C44 C45 C46 C47 C48 C49 C50 C51 C52 C53 C54 C55 C56 C57 C58 C60 C61 C62 C63 C64 C65 C66 C67 C68 C69 C70 C71 C72 C73 C74

Full title

Table 3.1 Classification used in incidence tables

Malignant neoplasm of nasal cavity and middle ear Malignant neoplasm of accessory sinuses Malignant neoplasm of larynx Malignant neoplasm of trachea Malignant neoplasm of bronchus and lung Malignant neoplasm of thymus Malignant neoplasm of heart, mediastinum and pleura

Groupings used in tables C30-C31 are grouped C33-C34 are grouped C37-C38 are grouped C39 is included in other and unspecified C40-C41 are grouped

Nose, sinuses, etc. Larynx

Short title used in tables

Trachea, bronchus and lung Other thoracic organs

Malignant neoplasm of other and ill-defined sites in the respiratory system and introthoracic organs

Malignant neoplasm of bone and articular cartilage of limbs

Malignant neoplasm of bone and articular cartilage of other and unspecified sites Malignant melanoma of skin Mesothelioma Other malignant neoplasms of skin Kaposi sarcoma

Bone

C47+C49 are grouped C48 is included in other and unspecified C70-72 are grouped together -

Melanoma of skin Other skin Mesothelioma

Malignant neoplasm of peripheral nerves and autonomic nervous system Malignant neoplasm of retroperitoneum and peritoneum Malignant neoplasm of other connective and soft tissue Malignant neoplasm of breast Malignant neoplasm of vulva

Kaposi sarcoma

Connective and soft tissue

C49 is grouped with C47

Breast Vulva Vagina

Malignant neoplasm of vagina

Malignant neoplasm of cervix uteri

Malignant neoplasm of corpus uteri Malignant neoplasm of ovary

Cervix uteri

Malignant neoplasm of uterus, part unspecified Malignant neoplasm of other and unspecified female genital organs Malignant neoplasm of placenta Malignant neoplasm of penis Malignant neoplasm of testis Malignant neoplasm of prostate Malignant neoplasm of other and unspecified male genital organs Malignant neoplasm of kidney, except renal pelvis Malignant neoplasm of renal pelvis Malignant neoplasm of ureter Malignant neoplasm of bladder

Corpus uteri Ovary

Uterus unspecified Other female genital organs Placenta Penis Prostate Testis Other male genital organs Kidney Ureter Renal pelvis Bladder Eye

Malignant neoplasm of other and unspecified urinary organs Malignant neoplasm of eye and adnexa Malignant neoplasm of meninges Malignant neoplasm of brain Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system Malignant neoplasm of thyroid gland Malignant neoplasm of adrenal gland

Other urinary organs Brain, nervous system

Thyroid

Adrenal gland

41

Classification and coding

Site C75 C76 C80 C81 C82 C83 C84 C85 C88 C90 C91 C92 C93 C94 C95 C96 O&U MPD MDS ALL ALLb

Full title

Table 3.1 Classification used in incidence tables

Malignant neoplasm of other endocrine glands and related structures Malignant neoplasm of other and ill-defined sites Malignant neoplasm without specification of site Hodgkin disease Follicular (nodular) non-Hodgkin lymphoma Diffuse non-Hodgkin lymphoma Peripheral and cutaneous T-cell lymphomas Malignant immunoproliferative diseases Multiple myeloma and malignant plasma cell neoplasms Lymphoid leukaemia Myeloid leukaemia Monocytic leukaemia Other leukaemias of specified cell type Leukaemia of unspecified cell type Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue

Groupings used in tables C76 is included in other and unspecified C80 is included in other and unspecified C82-C85, C96 are grouped

Short title used in tables Other endocrine

Hodgkin disease Non-Hodgkin lymphoma

Other and unspecified types of non-Hodgkin lymphoma C92-C94 are grouped (following ICD-O-3) -

Immunoproliferative diseases Multiple myeloma Lymphoid leukaemia Myeloid leukaemia

C96 is grouped with C82-C85

Leukaemia unspecified

Includes C26, C39, C48, C76 and C80 Includes ICD-O-3 M 9950/3, 996_/3, 9975/3 Includes ICD-O-3 M 998_/3

Other and unspecified Myeloproliferative disorders Myelodysplastic syndromes All sites

Myeloproliferative disorders Myelodysplastic syndromes

All sites but C44

Classifications used in the cancer registry Since the publication in 1976 of the first edition of the ICDO (WHO, 1976) with clearly defined axes of anatomical location, histology and behaviour, international conformity to standard classification systems and coding rules has increased steadily. For data published in Volume IV (197377), 90% of registries recorded histological diagnosis; for coding just over one third of the registries used MOTNAC (ACS, 1951; 1968), one third had started to use ICDO and 12% used SNOP (CAP, 1965). About 75% of contributors to Volume V used ICDO to code histology, and this figure rose to over 90% for Volumes VI and VII. Four of the 186 contributors to the Volume VIII and only one of the 225 contributors to the present volume did not code their histological data to ICDO. Data submitted for the first four volumes of Cancer Incidence in Five Continents were sent in tabular format, by sex, site and five-year age group, on tape, diskette or, most frequently, the forms designed for the purpose. The only verification possible was to tally the columns and rows. For the fifth volume, registries were given the opportunity of sending data in the form of a case-listing coded

to ICD9 topography only, or to ICD9 or ICDO topography plus ICDO morphology. A very small minority of registries sent data coded to ICDO. Contributors to Volume VI were encouraged to send data as a listing of cases, but 24% sent tabulated data. For Volumes VII, VIII and IX, data had to be sent as a case listing. In practice, it was still necessary to ask registries some questions, notably in relation to non-melanoma skin, breast, ovary and bladder cancer. While the majority of the data submitted for this volume had been coded or converted to ICDO, registries were asked what classification systems were used for coding data in the registry during the period. Of the 225 registries contributing data to this volume, 202 (89.8%) coded to ICDO3 or ICDO2 topography and morphology, 29 (12.9%) to ICD9 or ICD10 topography and ICDO morphology, and 4 (1.8%) did not register histology and coded topography to ICD9 or ICD10. Seven registries used ICDO1 topography and morphology, and one registry coded morphology to MOTNAC with ICDO7 topography (Table 3.2).

42

Classification and coding

ICD-9 + ICD-9 + ICD-10 + ICD-10 + Continents ICD-O-3 ICD-O-2 ICD-O-1 ICD-O-1 ICD-O-2 ICD-O-2 ICD-O-3 (No. of Registries) (T+M) (T+M) (T+M) (M) (M) (M) (M) Africa (5) 4 1 0 0 0 0 0 South and Central 7 4 0 0 0 0 0 America (11) North America (54) 53 1 0 0 0 0 0 Asia (44) 31 5 2 1 1 6 0 Europe (100) 75 12 5 3 1 12 3 Oceania (11) 8 1 0 1 0 1 0

Table 3.2 Coding practices

ICD-9 0 0 0 0 2 0 2

ICD-7+ Total ICD-10 MOTNAC 0 0 0 0 2 0 2 0 0 0 0 1 0 1 5 11 54 56* 116** 11 253

*Total greater than 44 (registries using two systems).

Total (225)

178

24

**Total greater than 100 (registries using two or three systems). behavior /3 according to the ICDO3. However, some registries are still coding it as /3. For the comparison of cancer incidence from these selected sites, the coding practices of each registry should be reviewed. Table 3.4a and Table 3.4b present the coding practices recorded in the questionnaires by registry

19

Table 3.3 presents the summary table of coding practices for the selected sites, carcinoma of bladder, benign tumors of brain and nervous system, borderline tumours of brain, endometrium of uterus, ovary and carcinoma of breast with ductal carcinoma in situ, intraductal and lobular carcinoma in situ. Borderline ovary cancer is no longer
Continents (No. of Registries) Africa (5) South and Central America (11) Carcinoma of Bladder In situ 3 (0) 8 (1) NOS 4 (4) 11 (9) Benign Tumours of Brain and Nervous system 1 (0) 5 (3) 43 (1) 19 (3) 70 (3) 4 (0) 142 (10) 63.1 (4.4)

Table 3.3 Summary table of coding practices for the selected sites
Borderline Tumours Brain 2 (0) 4 (2) 38 (0) 23 (5) 79 (4) 4 (0) 150 (11) 66.7 (4.9) Endometrium 2 (0) 2 (0) 10 (0) 21 (6) 58 (3) 5 (0) 98 (9) 43.6 (4) Ovary 2 (0) 5 (1) Ductal, Intraductal Lobular, in situ NOS in situ 3 (0) 4 (1) 3 (0) 11 (1) 11 (4) 50 (4) 30 (9) 82 (10) 10 (0) 187 (28) 83.1 (12.4) 11(2) 50 (0) 28 (2) 82 (2) 9 (0) 183 (6) 81.3 (2.7) Carcinoma of Breast

North America (54) Asia (44) Europe (100) Oceania (11) Total (225) % of coded (% of behavior/3)

( ) Recoded to behaviour /3 References

51 (6) 49 (31) 25 (2) 36 (33) 86 (8) 89 (55) 8 (0) 8 (7) 181 (17) 197 (139) 80.4 87.6 (7.6) (61.8)

28 (3) 50 (0) 23 (7) 27 (1) 77 (14) 83 (3) 6 (1) 10 (0) 141 (26) 184 (5) 62.7 81.8 (11.6) (2.2)

ACS (1951). Manual of Tumor Nomenclature and Coding. New York, NY, American Cancer Society. ACS (1968). Manual of Tumor Nomenclature and Coding, 1968 Edition. New York, American Cancer Society. CAP (1965). Systematized nomenclature of pathology. Chicago, IL, College of American Pathologists. Doll, R., Payne, P. & Waterhouse, J. (eds) (1966). Cancer Incidence in Five Continents: A Technical Report. Berlin, Springer-Verlag (for UICC). Doll, R., Muir, C. & Waterhouse, J. (eds) (1970). Cancer Incidence in Five Continents, Volume II. Berlin, SpringerVerlag (for UICC). Fritz, A., Percy, C., Jack, A., Shanmugaratnam, K., Sobin, L., Parkin, D.M. & Whelan, S.L. (eds) (2000). International Classification of Diseases for Oncology, 3rd edition. World Health Organization, Geneva.

Muir, C., Waterhouse, J., Mack, T., Powell, J. & Whelan, S. (eds) (1987). Cancer Incidence in Five Continents, Volume V (IARC Scientific Publications No. 88), Lyon, IARC. Parkin, D.M., Muir, C.S., Whelan, S.L., Gao, Y.-T., Ferlay, J. & Powell, J. (1992). Cancer Incidence in Five Continents, Volume VI. (IARC Scientific Publications No. 120), Lyon, IARC. Parkin, D.M.,Whelan, S.L., Ferlay, J., Raymond, L. & Young, J. (1997). Cancer Incidence in Five Continents, Volume VII. (IARC Scientific Publications No. 143), Lyon, IARC. Parkin, D.M., Whelan, S.L., Ferlay J., Teppo L., Thomas D.B. (2002). Cancer Incidence in Five Continents , Volume VII1. (IARC Scientific Publications No. 155), Lyon, IARC. Waterhouse, J., Muir, C., Correa, P. & Powell, J. (eds) (1976). Cancer Incidence in Five Continents, Volume III (IARC Scientific Publications No. 15), Lyon, IARC.

43

Classification and coding

Waterhouse, J., Muir, C., Shanmugaratnam, K. & Powell, J. (eds) (1982). Cancer Incidence in Five Continents, Volume IV (IARC Scientific Publications No. 42), Lyon, IARC. WHO (1957). International Classification of Diseases, 1955 Revision, Geneva, World Health Organization. WHO (1967). International Classification of Diseases, 1965 Revision, Geneva, World Health Organization. WHO (1977). International Classification of Diseases, 1975 Revision, Geneva, World Health Organization.

WHO (1992). International Statistical Classification of Diseases and Related Health Problems, tenth revision, Geneva, World Health Organization. WHO (1976). International Classification of Diseases for Oncology, first edition, Geneva, World Health Organization. WHO (1990). International Classification of Diseases for Oncology, second edition, Geneva, World Health Organization.

44

Table 3.4a Coding practices: Recorded Carcinoma of bladder NOS Benign tumours of brain and nervous system Ductal carcinoma in situ of breast N Y Y Y Y Y Y N N Intraduct carcinoma NOS of breast N N N N N N Y Y N N N Y Y Y Y Y Y N N N Borderline Borderline Borderline tumour, uns. and tumour, uns. and tumour, uns. and unk. behaviour unk. behaviour unk. behaviour of ovary of endometrium of brain Lobular carcinoma in situ of breast

Carcinoma of bladder, in situ N Y N N Y

Africa

Algeria, Setif

Egypt, Gharbiah Y Y

Tunisia, Central Region

Uganda, Kyadondo County

Zimbabwe, Harare

Y N Y Y

South and Central America Y Y Y Y Y Y Y N N Y Y N Y Y Y N Y Y Y N N N Y N N Y Y N N N Y N N Y N N N N N Y Y N Y N N N N N N N N Y Y Y Y Y Y Y Y Y Y Y

Argentina, Bahia Blanca

Brazil, Brasilia

Brazil, Cuiaba

Y Y Y Y Y Y Y Y Y Y Y

Y Y Y Y Y Y Y Y Y Y Y

Brazil, Goinia

Brazil, So Paulo

Chile, Valdivia

Colombia, Cali

Costa Rica

Ecuador, Quito

France, Martinique

Y Y Y Y

Peru, Trujillo

North America N Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y NS Y Y N Y Y Y Y NS Y Y

Canada

Canada, Alberta

Canada, British Columbia

Canada, Manitoba

NS Y Y NS Y Y N N Y

Y Y Y Y Y Y Y N Y Y

Y Y Y Y Y Y Y N Y Y

Y Y Y Y Y Y Y N Y Y

Y Y Y Y Y Y Y N Y Y

Canada, New Brunswick

Canada, Newfoundland and Labrador

Canada, Northwest Territories

Classification and coding

Canada, Nova Scotia

Canada, Ontario

Canada, Prince Edward Island

45

46
Table 3.4a Coding practices: Recorded Carcinoma of bladder NOS Y Y Y Y NS Y Y Y Y Y N Y N N N Y N N Y Y Y Y N Y Y Y Y Y Y Y N N Y N N N N N Y N Y Y Y Y N N N N N N N N N Y N Y N N N N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y NS Y N Y N N Y Y Y Y Y Y N N Y Y Y Y N Y N N Y Y Y Y Y Y N Y N Y Y Y Y Y Y Y N Y N Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y N N Y Y Y Y N Y Y Y NS NS NS NS NS Y Y N Y Y Y Y Y N Y Y Y NS Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N N N Y Y Y N N Y Y Y Y Y Y Y Y Y Y Y Y Y NS Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Benign tumours of brain and nervous system Ductal carcinoma in situ of breast Intraduct carcinoma NOS of breast Borderline Borderline Borderline tumour, uns. and tumour, uns. and tumour, uns. and unk. behaviour unk. behaviour unk. behaviour of ovary of endometrium of brain Lobular carcinoma in situ of breast

Carcinoma of bladder, in situ

Canada, Saskatchewan

USA, Alabama

Classification and coding

USA, Alaska

USA, Arizona

USA, California

USA, California, Greater San Francisco Bay Area

NS

USA, California, Los Angeles County

USA, Colorado

USA, Connecticut

USA, District of Columbia

USA, Florida

USA, Georgia

USA, Georgia, Atlanta

USA, Idaho

USA, Illinois

USA, Indiana

USA, Iowa

USA, Kentucky

USA, Louisiana

USA, Louisiana, New Orleans

USA, Maine

USA, Massachusetts

USA, Michigan

USA, Michigan, Detroit

USA, Missouri

USA, Montana

USA, New Jersey

USA, New Mexico

USA, New York State

USA, NPCR

USA, Ohio

Table 3.4a Coding practices: Recorded Carcinoma of bladder NOS N Y Y N Y N N N N N N N N Y Y Y Y Y Y Y Y Y N Y Y Y Y N Y Y N N N N Y Y Y N Y Y Y Y Y Y Y Y Y Y Y N Y Y Y Y N Y Y Y Y Y Y Y Y N N Y Y Y Y Y Y Y Y Y Y Y Y Y Y N N N N Y Y N N N N NS NS NS Y Y Y Y Y Y Y Y Y Y Y Y Benign tumours of brain and nervous system Ductal carcinoma in situ of breast Intraduct carcinoma NOS of breast Lobular carcinoma in situ of breast Borderline Borderline Borderline tumour, uns. and tumour, uns. and tumour, uns. and unk. behaviour unk. behaviour unk. behaviour of ovary of endometrium of brain

Carcinoma of bladder, in situ

USA, Oklahoma

USA, Oregon

USA, Pennsylvania

USA, Rhode Island

USA, SEER

USA, South Carolina

USA, Texas

USA, Utah

USA, Vermont

USA, Washington

USA, Washington, Seattle

USA, West Virginia

USA, Wisconsin

Asia Y Y Y Y N N Y N N Y N NS N N N Y N Y N Y Y N Y N N N N Y Y Y Y N N Y Y Y

Bahrain

China, Guangzhou

China, Hong Kong

China, Jiashan N Y N N N N N Y

China, Nangang District, Harbin City

China, Shanghai

China, Zhongshan Y Y Y Y Y Y NS Y

Cyprus

Y Y N N

Y Y

N Y N N N N Y N N N

Y N

India, Chennai (Madras)

India, Karunagappally

Y N N N N Y N N Y N N N N N N

Y N Y N N N Y N N

Y N Y N N N N N N

India, Mumbai (Bombay)

India, Nagpur

India, New Delhi

India, Poona

Classification and coding

India, Trivandrum

Israel

NS

NS

NS

NS

NS

NS

NS

47

48
Table 3.4a Coding practices: Recorded Carcinoma of bladder NOS Y Y Y Y Y Y N N N N Y N N N Y Y Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y N N N N Y Y Y Y N Y N Y N N N N N Y N N Y N N N N Y Y Y Y N N N N Y Y N Y N Y N N N N Y N N N N Y Y N N Y Y Y Y Y Y Y Y Y Y Y Y Y N Y N Y N Y Y Y Y Y Y Y Y Y Y Y Y N Y Y N Y Y Y Y Y Y N Y N Y Y Y Y Y Y Y Y Y NS Y Y N N N N Y Y N Y Y N Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y Y N Y Y N Y Y Y Y Y Y N Y N Benign tumours of brain and nervous system Ductal carcinoma in situ of breast Intraduct carcinoma NOS of breast Borderline Borderline Borderline tumour, uns. and tumour, uns. and tumour, uns. and unk. behaviour unk. behaviour unk. behaviour of ovary of endometrium of brain Lobular carcinoma in situ of breast

Carcinoma of bladder, in situ

Japan, Aichi Prefecture

Japan, Fukui Prefecture

Classification and coding

Japan, Hiroshima

Japan, Miyagi Prefecture

Japan, Nagasaki Prefecture

Japan, Osaka Prefecture

Japan, Yamagata Prefecture

Korea

Korea, Busan

Korea, Daegu

Korea, Daejeon

Korea, Gwangju

Korea, Incheon

Korea, Jejudo Y Y N N N N N Y Y Y Y Y

Korea, Seoul

Korea, Ulsan

Kuwait N N Y Y Y Y Y Y Y Y

Y N Y Y N Y Y N Y Y Y Y Y Y N

Malaysia, Penang

Malaysia, Sarawak

Oman

Pakistan, South Karachi

Philippines, Manila

Singapore

Thailand, Chiang Mai

Thailand, Lampang

Thailand, Songkhla

Turkey, Antalya

Turkey, Izmir

Europe Y

Austria

Table 3.4a Coding practices: Recorded Carcinoma of bladder NOS Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y N Y Y Y Y Y Y N Y Y N Y Y Y Y Y N Y Y N Y Y Y Y Y N Y N Y N Y Y Y N Y Y N Y N Y N Y Y Y Y Y Y Y Y N N Y Y Y Y Y Y N Y Y Y Y Y Y Y Y N Y Y Y N Y Y Y Y Y Y N Y Y N Y Y Y N Y Y N N N N N N N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N N Y Y Y Y N Y Y Y Y Y Y N N Y NS N N N N Y Y Y Y Y Y Y NS Y Y Y Y Y Y Y Y Y N Y Y Y N Y Y Y Y Y Y N Y Y N Y Y N N Y Y Y N N N N Y Y Y Y Y Y Y Y N Y Y NS Y Y Y Y Y Y Y NS Y Y Y Y Y Y Y Y Y N Y Y Y N Y Y Y Y Y Y N Y Y N Y Benign tumours of brain and nervous system Ductal carcinoma in situ of breast Intraduct carcinoma NOS of breast Lobular carcinoma in situ of breast Borderline Borderline Borderline tumour, uns. and tumour, uns. and tumour, uns. and unk. behaviour unk. behaviour unk. behaviour of ovary of endometrium of brain

Carcinoma of bladder, in situ

Austria, Tyrol

Austria, Vorarlberg

Belarus

Belgium, Antwerp

Belgium, Flanders

Bulgaria

Croatia

Czech Republic

Denmark

Estonia

Finland

France, Bas-Rhin

France, Calvados

France, Doubs

France, Haut-Rhin

France, Hrault

France, Isre

France, Loire-Atlantique

France, Manche

France, Somme

France, Tarn

France, Vende

Germany, Brandenburg

Germany, Free State of Saxony

Germany, Hamburg

Germany, Mecklenburg-Western Pomerania

Germany, Munich

Germany, North Rhine-Westphalia: Mnster

Germany, Saarland

Classification and coding

Iceland

Ireland

49

50
Table 3.4a Coding practices: Recorded Carcinoma of bladder NOS N N Y N N N Y Y N N NS N N N Y Y Y Y Y Y Y Y N Y N Y Y Y NS Y Y NS Y Y Y Y NS Y N Y N Y NS Y N NS N Y Y Y N Y Y Y N Y Y Y N N Y Y N N Y Y Y Y N Y Y Y Y Y Y N Y Y Y Y N Y Y Y NS Y Y NS Y Y Y Y N N Y Y N N N Y Y Y Y Y N N N N Y Y Y Y N Y Y N Y N Y Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y N Y Y N Y Y Y Y Y Y Y Y N N N N N N Y Y N Y N N N Y Y Y N N N Benign tumours of brain and nervous system Ductal carcinoma in situ of breast N N Y N Y Y N Y N Y Y Y Y Y Y N Y Y Y Y Y Y Y NS Y Y N Y Y N Intraduct carcinoma NOS of breast Borderline Borderline Borderline tumour, uns. and tumour, uns. and tumour, uns. and unk. behaviour unk. behaviour unk. behaviour of ovary of endometrium of brain Lobular carcinoma in situ of breast

Carcinoma of bladder, in situ

Italy, Biella Province

Italy, Brescia Province

Classification and coding

Italy, Ferrara Province

Italy, Florence and Prato Y N N Y Y Y Y

Italy, Genoa Province

Italy, Macerata Province

Italy, Milan

Italy, Modena Province

Italy, Naples

Italy, North East

Italy, Parma Province NS Y Y N N Y Y Y Y Y Y

Italy, Ragusa Province

Italy, Reggio Emilia Province

Italy, Romagna Region

Italy, Salerno Province

Italy, Sassari Province N Y Y N Y Y Y Y Y Y Y Y Y Y Y N Y Y Y

Italy, Sondrio

Italy, Syracuse Province

Italy, Torino

Italy, Umbria Region

Italy, Varese Province

Y Y Y Y Y Y Y NS Y Y N Y Y

Italy, Veneto Region

Latvia

Lithuania

Malta

The Netherlands

The Netherlands, Eindhoven

The Netherlands, Maastricht N Y

Norway

Poland, Cracow

Poland, Kielce

Table 3.4a Coding practices: Recorded Carcinoma of bladder NOS Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y NS N Y Y Y Y Y Y Y Y Y N N NS N N Y N N N N N N Y Y Y Y Y Y Y NS Y Y Y Y Y Y Y Y N Y N Y Y Y Y Y Y Y Y Y Y Y N Y Y Y N Y Y Y Y N Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y N N Y Y Y Y N Y Y Y Y N Y Y Y Y Y Y Y N N N N Y Y Y Y Y Y Y Y Y N Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y NS NS Y NS NS Y Y Y Y Y Y Y Y Y Y Y Y Y NS Y Y Y Y Y Y Y Y Y N Y Y Y N Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Benign tumours of brain and nervous system Ductal carcinoma in situ of breast Intraduct carcinoma NOS of breast Lobular carcinoma in situ of breast Borderline Borderline Borderline tumour, uns. and tumour, uns. and tumour, uns. and unk. behaviour unk. behaviour unk. behaviour of ovary of endometrium of brain

Carcinoma of bladder, in situ

Poland, Warsaw City

Portugal, Porto

Portugal, South Regional

Russia, St Petersburg

Serbia

Slovak Republic

Slovenia

Spain, Albacete

Spain, Asturias

Spain, Basque Country

Spain, Canary Islands

Spain, Cuenca

Spain, Girona

Spain, Granada

Spain, Murcia

Spain, Navarra

Spain, Tarragona

Spain, Zaragoza

Sweden

Switzerland, Geneva

Switzerland, Graubnden and Glarus

Switzerland, Neuchtel

Switzerland, St Gall-Appenzell

Switzerland, Ticino

Switzerland, Valais

Switzerland, Vaud

UK, England, East of England Region

UK, England, Merseyside and Cheshire

UK, England, North Western

Classification and coding

UK, England, Northern and Yorkshire

UK, England, Oxford Region

51

52
Table 3.4a Coding practices: Recorded Carcinoma of bladder NOS Y Y Y Y Y Y Y Y Y Y Y Y NS Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Benign tumours of brain and nervous system Ductal carcinoma in situ of breast Intraduct carcinoma NOS of breast Borderline Borderline Borderline tumour, uns. and tumour, uns. and tumour, uns. and unk. behaviour unk. behaviour unk. behaviour of ovary of endometrium of brain Lobular carcinoma in situ of breast

Carcinoma of bladder, in situ

UK, England, South and Western Regions

UK, England, Thames

Classification and coding

UK, England, Trent

UK, England, West Midlands

UK, Northern Ireland

UK, Scotland

Oceania N N Y N Y Y N Y Y N Y Y N Y Y Y N N N Y Y Y Y Y N Y N N Y N N N Y Y Y Y Y Y Y N Y Y Y N N N N N N N N N N N N Y Y Y Y Y Y Y N Y Y Y

Australian Capital Territory

Australia, New South Wales

Australia, Northern Territory

Y Y Y Y Y Y Y N Y Y Y

Y Y Y Y Y Y Y N Y N

Australia, Queensland

South Australia

Australia, Tasmania

Australia, Victoria

Western Australia

French Polynesia

New Zealand

USA, Hawaii

NS, not stated

Table 3.4b Coding practices: Recoded to behaviour /3 Carcinoma of bladder NOS Benign tumours of brain and nervous system Ductal carcinoma in situ of breast Intraduct carcinoma NOS of breast Lobular carcinoma in situ of breast Borderline Borderline Borderline tumour, uns. and tumour, uns. and tumour, uns. and unk. behaviour unk. behaviour unk. behaviour of ovary of endometrium of brain

Carcinoma of bladder, in situ

Africa N Y Y Y NA NA NA NA N NA NA NA NA NA Y N N N N N N Y N NA N N N N N N N N N N N

Algeria, Setif

Egypt, Gharbiah

Zimbabwe, Harare

Uganda, Kyadondo County

Tunisia, Central Region

NA

NA N

South America Y Y N N NA N N NA N NA NA Y N N N N N Y Y NA NA NA Y NA Y Y N N N N NA NA NA NA Y N N N N N N Y N N NA NA NA N N N N

Argentina, Bahia Blanca

Brazil, Cuiaba N Y NA NS NS N NA Y Y

Brazil, Brasilia

Chile, Valdivia N Y Y

Brazil, So Paulo

Brazil, Goinia

Y Y Y N

Colombia, Cali

NA

N N

Y Y N N N N N N N N N N Y N N N N

France, Martinique Y

Ecuador, Quito

Costa Rica

Peru, Trujillo

North America NA Y NS N N N Y N N NS NS NS N N NS NS

Canada

Canada, Alberta

NS

Canada, British Columbia NS N N Y Y

NS NS N N

NS NS N N

NS NS N N

NS NS N Y

NS NS N N

Canada, New Brunswick

Canada, Manitoba

Classification and coding

Canada, Nova Scotia

Canada, Northwest Territories

Canada, Newfoundland and Labrador

NS

NS NS N N

NS NS N N

NS N N

NS N N N

NS N N N

NS N N N

Canada, Ontario

NA

NA

NA

NA

NA

53

54
Table 3.4b Coding practices: Recoded to behaviour /3 Carcinoma of bladder NOS N Y Y Y NS N NA N N NA NA NA NA NA N NA NA N NS NS N NA N NA NS NA N N N NA NA NA N N N N N NA NA N NS N N N N N N N NA NA NS NA N N N N N NA N N NS NS NS NS Y N N NA N NS N NS NS N N NS NS N N N N N N N N N N N N N Y N NA NA N N N N N N N N N N NS NS N N N N N N Benign tumours of brain and nervous system Ductal carcinoma in situ of breast Intraduct carcinoma NOS of breast Borderline Borderline Borderline tumour, uns. and tumour, uns. and tumour, uns. and unk. behaviour unk. behaviour unk. behaviour of ovary of endometrium of brain Lobular carcinoma in situ of breast

Carcinoma of bladder, in situ

Canada, Prince Edward Island

Canada, Saskatchewan

Classification and coding

USA, Arizona NS Y N N

USA, Alaska

USA, Alabama

USA, California

USA, California, Greater San Francisco Bay Area Y N

NS

NS NS N N N N N N N N N N

USA, California, Los Angeles County Y N

USA, Colorado N N NA N NS N N NA N N N

USA, Florida NA NS Y NA N NA Y N NA Y Y N N N Y NA N

USA, District of Columbia

USA, Connecticut

USA, Idaho

USA, Georgia, Atlanta

USA, Georgia

USA, Illinois

USA, Kentucky N Y N N Y NA N N

USA, Iowa

USA, Indiana

N N N N

N N N N N N NA NA N NS N N N N

N N N N N N N N N N N N N N N

USA, Louisiana

USA, Massachusetts Y Y

USA, Maine

USA, Louisiana, New Orleans

N N N N N N NA NA N N N N

USA, Missouri Y Y

USA, Michigan, Detroit NS

USA, Michigan

USA, Montana N N

USA, New York State

USA, New Mexico

USA, New Jersey

N N N N N NA N N N N N

N N N

USA, NPCR

Table 3.4b Coding practices: Recoded to behaviour /3 Carcinoma of bladder NOS Y NA N NS NS NA N N N N N N N N NA NS N NA N N N N N N Y NS N N N NA N NA NA Y NA NA N NA N NA N NA NA NA N NA NA N N NS NA NA NS N Y N NA NA NA N N N N N N N N NA NA NS N N N N N N N N NS N N N N N N NS Y N N Benign tumours of brain and nervous system Ductal carcinoma in situ of breast Intraduct carcinoma NOS of breast Lobular carcinoma in situ of breast Borderline Borderline Borderline tumour, uns. and tumour, uns. and tumour, uns. and unk. behaviour unk. behaviour unk. behaviour of ovary of endometrium of brain

Carcinoma of bladder, in situ N

USA, Ohio NS Y Y Y Y Y N N Y

USA, Pennsylvania

USA, Oregon

USA, Oklahoma

USA, Rhode Island

USA, SEER

USA, South Carolina

USA, Texas Y Y NS N Y Y N N

NS

USA, Utah

USA, Washington, Seattle

USA, Washington

USA, Vermont

N N N N

USA, West Virginia

USA, Wisconsin

Asia Y Y N Y N N N Y N N NA Y N Y NA N N Y Y NA NA N N N

China, Guangzhou Y N Y N N Y N N Y

Bahrain

China, Hong Kong

NA

China, Shanghai

China, Nangang District, Harbin City

China, Jiashan

Cyprus Y Y N Y NA N N N Y

China, Zhongshan

N N N Y Y N N

N N N Y N N Y

N N N N

India, Mumbai (Bombay) Y

India, Karunagappally

India, Chennai (Madras)

N N

N N N N N Y N

NA N N N Y NA NA N N

N N N N N

N N Y NA N NA N N N

Y N N N N N Y N N N

India, Nagpur Y

Classification and coding

India, Poona Y

India, New Delhi

NA

India, Trivandrum

NA N N

55

56
Table 3.4b Coding practices: Recoded to behaviour /3 Carcinoma of bladder NOS NS Y NA NS N NA N N NA N N N N N N N N N N N N N N NA NA N N N Y N N N Y N N N N N N N NA N Y NS N Y NA NA NA N N Y NA Y Y NA N N NS NS NS NS NS NS NS N N N N N N N NA N N N N N Benign tumours of brain and nervous system Ductal carcinoma in situ of breast Intraduct carcinoma NOS of breast Borderline Borderline Borderline tumour, uns. and tumour, uns. and tumour, uns. and unk. behaviour unk. behaviour unk. behaviour of ovary of endometrium of brain Lobular carcinoma in situ of breast

Carcinoma of bladder, in situ

Israel

Classification and coding

Japan, Fukui Prefecture Y Y NA N N N N N Y N NA N N N N NA Y N N Y

Japan, Aichi Prefecture

NS

Japan, Nagasaki Prefecture Y

Japan, Miyagi Prefecture

Japan, Hiroshima

Japan, Osaka Prefecture N N N N N NS NA N Y N N N NS NA N N N N Y N N N N N N N N N N N Y N NA Y N N

Korea, Busan

Korea

Japan, Yamagata Prefecture

N N N N NA N N

Korea, Incheon N Y NA NA N N N N N Y Y Y

Korea, Gwangju

Korea, Daejeon

Korea, Daegu

NA

Korea, Jejudo

NA N N N N Y N

Oman N Y NA N N N Y Y Y N Y N

Malaysia, Sarawak Y

Malaysia, Penang NA

Kuwait

Korea, Ulsan

Korea, Seoul

N NS NA N N N N N Y NA N N N N N Y N Y Y NA N N NA N N N N N

NA

Pakistan, South Karachi

Thailand, Chiang Mai

Singapore

Philippines, Manila

N Y N N N N Y N N N N N N N N N Y N Y N N N N N N N

Thailand, Lampang

Thailand, Songkhla N

Turkey, Antalya

Turkey, Izmir

Table 3.4b Coding practices: Recoded to behaviour /3 Carcinoma of bladder NOS Benign tumours of brain and nervous system Ductal carcinoma in situ of breast N N N Y N N N N N Y N N N N N N Y N N NS N N N NA N N N N Y Intraduct carcinoma NOS of breast Lobular carcinoma in situ of breast NA N NA N N NS N N N N NS N N N Y N N NA N N NA N Y N N Y NS Y NA NA Borderline Borderline Borderline tumour, uns. and tumour, uns. and tumour, uns. and unk. behaviour unk. behaviour unk. behaviour of ovary of endometrium of brain

Carcinoma of bladder, in situ Y NA NA N N NA NS N N N NA NS NA N N N NA N NA

Europe Y Y N Y N N N NA NA NA N N NA N N N N N N N N N N N N N Y Y Y N N Y Y

Austria

Austria, Tyrol

Belgium, Antwerp

Belarus

Austria, Vorarlberg

Belgium, Flanders

Bulgaria N Y N N Y N NS N N

Czech Republic

Croatia

NA

Estonia N N N N NA NA NA N NA Y N N N N NA N Y N N N N Y

Denmark

Finland

NS N N NS N N N N N

France, Calvados

France, Bas-Rhin

France, Doubs

N N

N NS N NA NA NA N N N N N NA N N N N NS N NA N NA N N N N N N N

France, Haut-Rhin N N N Y NA NA Y NA Y N

France, Manche

France, Loire-Atlantique

France, Isre

France, Hrault

NA

Germany, Brandenburg Y Y Y NA Y

France, Vende

France, Tarn

France, Somme

NA N NA N NA N NA N N N N N N

NA

Germany, Free State of Saxony

NA N N N N N N N N N N N N N

Germany, Mecklenburg-Western Pomerania N

Germany, Hamburg

N N N Y N

Classification and coding

Germany, Munich

Germany, North Rhine-Westphalia: Mnster

57

58
Table 3.4b Coding practices: Recoded to behaviour /3 Carcinoma of bladder NOS N N N NA N NA NA N N N N Y N N NA Y NA NA N N N N NS NA NA N N NA NA N Y Y N NS N N NS NS N NS N N Y N N N N N N N N NS N N N NA NA N N Y N N N N N N N N N N N Y N N N N N N N N NA N N N NA N N N N N N N N Benign tumours of brain and nervous system Ductal carcinoma in situ of breast Intraduct carcinoma NOS of breast Borderline Borderline Borderline tumour, uns. and tumour, uns. and tumour, uns. and unk. behaviour unk. behaviour unk. behaviour of ovary of endometrium of brain Lobular carcinoma in situ of breast

Carcinoma of bladder, in situ

Germany, Saarland

Iceland N N N NA N N N Y NA

Classification and coding

Italy, Brescia Province N Y NA NA N N N NA N N NA N N N NA NA N N N N Y

Italy, Biella Province

Ireland

Italy, Ferrara Province

Italy, Genoa Province Y

Italy, Florence and Prato

Italy, Milan N N N N NA N Y N Y N

Italy, Macerata Province

NA

N NS

Italy, Modena Province

NA N N N N N N N N N N N N N N

NA N N

NS

Italy, Naples

Italy, North East

Italy, Reggio Emilia Province Y N NA N N N Y NA

Italy, Ragusa Province NS

Italy, Parma Province

N N N N N N

Italy, Romagna Region N NA N N N Y N NA N NA

Italy, Sondrio

Italy, Sassari Province

Italy, Salerno Province

N N NA N N NA N N N NA NS NS NS N N NS N N N N NA N N N N N N NS N N NS N N N N N NA N N N NS N NS N N N

Italy, Varese Province Y NS Y NA

Italy, Umbria Region Y

Italy, Torino

Italy, Syracuse Province

NA

Lithuania N N

Latvia NS

Italy, Veneto Region

The Netherlands NA N

Malta

NS

The Netherlands, Eindhoven

NS N NS N N

The Netherlands, Maastricht

NS N

Table 3.4b Coding practices: Recoded to behaviour /3 Carcinoma of bladder NOS N N NS N N N N NA N N N N N N N N N N N N NA N N N N N N N N N NA N NA N N NA N N Y Y N N N Y Y N Y NS NS NS Y N NS NS NS NS NS Y Y N N N N N N NS NS NS NS NS N N N N N N N N N N N N NS NS N N Y N N N N N N NA N N N N N N N N NS N NA N N N NS N N N N N N Y N N Benign tumours of brain and nervous system Ductal carcinoma in situ of breast Intraduct carcinoma NOS of breast Lobular carcinoma in situ of breast Borderline Borderline Borderline tumour, uns. and tumour, uns. and tumour, uns. and unk. behaviour unk. behaviour unk. behaviour of ovary of endometrium of brain

Carcinoma of bladder, in situ N

Norway N NS Y N N N N N NA N Y N Y Y Y

Poland, Kielce

Poland, Cracow

Portugal, Porto

Poland, Warsaw City

Russia, St Petersburg N Y N Y N N NA NA N N Y N NA N Y Y

Portugal, South Regional

NS

Serbia

Slovenia

Slovak Republic

Spain, Asturias

Spain, Albacete

NS N N

Spain, Basque Country Y Y Y N NA N N N NA NA Y NA NA

Spain, Canary Islands

Spain, Murcia Y NA N NS NS N N N N Y N Y N

Spain, Granada

Spain, Girona

Spain, Cuenca

NS N N NA N NA N N N N NA N N N NA N N NA N N N N

Sweden Y

Spain, Zaragoza

Spain, Tarragona

Spain, Navarra

NA

Switzerland, Graubnden and Glarus N Y Y

Switzerland, Geneva

Switzerland, St Gall-Appenzell N N N Y

Switzerland, Neuchtel

Switzerland, Ticino

Switzerland, Valais

Classification and coding

UK, England, East of England Region

Switzerland, Vaud

UK, England, Merseyside and Cheshire

NA NS N N

NS

NS NS NS N N

N N N NS N N N

Y Y NS N N N N

N N N N

NS N N N

59

60
Table 3.4b Coding practices: Recoded to behaviour /3 Carcinoma of bladder NOS Y N NS Y N N N N N N Y N N N N N N NS NS NS N N N N N N N N N N N N N Y Y N N N N N N N N N N N N N Benign tumours of brain and nervous system Ductal carcinoma in situ of breast Intraduct carcinoma NOS of breast Borderline Borderline Borderline tumour, uns. and tumour, uns. and tumour, uns. and unk. behaviour unk. behaviour unk. behaviour of ovary of endometrium of brain Lobular carcinoma in situ of breast

Carcinoma of bladder, in situ Y N

UK, England, North Western N N

UK, England, Northern and Yorkshire N Y N Y N NS Y N

Classification and coding

UK, England, Thames Y NS Y NS

UK, England, South and Western Regions

UK, England, Oxford Region

UK, England, Trent

UK, Scotland

UK, Northern Ireland

UK, England, West Midlands

NS

N N N

N N N

Oceania NA NA Y NA N NA NS Y N NA NA NS N N N N N N NA NA Y N N N NA NA NA NA NA N N NA NA NA N N NA NA NA NA NA NA NA NA

Australian Capital Territory

Australia, New South Wales

NA

Australia, Northern Territory N

NA

NS NS N N

NS NS N N N N N NA N N N

NS NS N N N N N N

Australia, Tasmania Y Y NA Y NA NA Y N

South Australia NS

Australia, Queensland

Australia, Victoria

N N NA N N N N

USA, Hawaii

New Zealand Y

French Polynesia

Western Australia

NA

NS, not stated

NA

NA N

NA, not applicable (not recorded)

L. Egevad, M. Heanue, D. Berney, K. Fleming, J. Ferlay

Background The data presented in this edition of Cancer Incidence in Five Continents (CI5) are mainly organised according to anatomical site. However, for some sites, the histological type of cancer is particularly relevant clinically and epidemiologically. For practical reasons, detailed data on every available morphological entity cannot be presented or used for longitudinal and geographic comparisons. In the latest editions of CI5, edition VII (Parkin et al., 1997) and VIII (Parkin et al., 2002), these data were grouped according to histological types as defined in Histological Groups for Comparative Studies (Parkin et al., 1998), based on the second edition of International Classification of Diseases for Oncology (ICD-O-2) (Percy et al., 1990). Since then, the second edition has been followed by the third edition (ICD-O-3) (Fritz et al., 2000). Furthermore, some cancer classifications have been revised, e.g. through the third edition of the WHO Classification of Tumours. Consequently, there was a need to update the Histological Groups for Comparative Studies, and the revised version is presented in this chapter. Types of neoplasms that are included The CI5 data include all invasive malignant neoplasms and some non-invasive malignant neoplasms. For most morphology codes, a fifth digit /1 or /2 automatically excludes the data entry. Carcinoma in situ is reported to many cancer registries, but is generally not dealt with in this volume, with the exception of urothelial carcinoma in situ. A few lesions of borderline malignancy are included, such as low-grade non-invasive papillary transitional cell tumours, which are now designated as Papillary urothelial neoplasia of low malignant potential, PUNLMP (8130/1). Flat carcinoma in situ of urothelium (8120/2) and PUNLMP (8130/1, 8130/2) have been grouped with Transitional cell carcinoma in this edition. As the skin has been added to the sites, Basal cell carcinoma is reported as a separate group although many cancer registries do not have statistics on them. Within the 15 tumour sites presented, there are no cases of mesothelioma (ICD-O M905_), Kaposi sarcoma (9140), lymphoma or leukaemia (9590-9989), as these cancers have their own specific ICD-10 codes and are presented separately in the volume.

Chapter 4: Histological groups

General structure The main structure of the histological grouping is that Morphology codes specific types of malignant neoplasms are listed as well as Grouping of morphological codes presents several difficulties. Unspecified malignant neoplasms (Unspecified cancer in the The ICD-O system is based on separate site (topography) and previous edition), i.e. malignant tumours that are so poorly morphology (histology) codes that can be combined. Inevitably, differentiated that we are unable to classify them in major in registry data morphology codes may mistakenly have been groups such as carcinoma or sarcoma. Neoplasms that have combined with codes for sites where these entities do not a specific morphology but are too unusual to be listed among occur or have not been reported yet. Some morphology codes the specific types of malignant neoplasms are lumped under are redundant, i.e. multiple codes can be applied for the same Other specified malignant neoplasm (Other specified cancer tumour. Other codes are obsolete, i.e. the entities have been in the previous edition). Similarly, under Carcinoma, specific renamed or deleted in later revisions of tumour classifications. cancer subtypes such as Squamous cell carcinoma and A major difficulty is the variation in coding precision (specific Adenocarcinoma are listed as well as Unspecified carcinoma, codes for tumour subtypes vs. comprehensive codes for broad i.e. carcinomas that are so poorly differentiated that we are categories such as adenocarcinoma), which limits the utility of unable to classify them according to histogenetic subtype, detailed codes. An example of this is the kidney tumours where while it is still possible to distinguish them from non-epithelial renal cell carcinomas are often coded as renal cell carcinoma, malignant neoplasms such as sarcoma. Morphological codes NOS (8312) or adenocarcinoma, NOS (8140), while others are are listed under the specific types of neoplasms (or carcinoma) subtyped. Therefore, all of these carcinomas of the kidney are and under Unspecified malignant neoplasms (or carcinoma). grouped together in this chapter. The remaining codes of neoplasia (or carcinoma) will then automatically be assigned to the Other specified malignant Some specified cancer types occur in several organs, but may have neoplasm (or carcinoma) group. different clinical behaviour depending on site of origin. For most sites adenosquamous carcinoma (8560) and mucoepidermoid Sites carcinoma (8430) are included in Other specified carcinoma. For inclusion as a histological group, a cancer type has An exception is corpus uteri (C54) where these are included to be sufficiently common at the site and clinically and in Adenocarcinoma because they are supposed to have epidemiologically relevant. The following 15 sites are similar biology (Zaino et al., 1988). Furthermore, squamous included: oesophagus, anus, liver, lung, bone, skin, cervix, differentiation is very common in Endometrioid carcinoma, corpus uteri, ovary, testis, kidney/renal pelvis, urinary bladder, which makes it difficult to separate between these tumours. eye, central nervous system and thyroid, together with the Another example is metaplastic carcinoma (8575), which is haematological system. Some major cancer sites such as breast generally included under Other specified carcinoma. However, and prostate were not included because the vast majority of for the corpus uteri, it is grouped with Other specified neoplasm malignant neoplasms at these sites are adenocarcinomas, and because metaplastic carcinoma is considered equivalent with the coding of subtypes of these is not consistent. Compared to carcinosarcoma on this site (Silverberg et al., 1990). the previous edition of Histological Groups for Comparative Studies, the anus and skin have been added. The kidney was Unspecified carcinoma includes tumours that are coded as combined with the renal pelvis because some urothelial Carcinoma NOS, but also some descriptive diagnoses of poorly carcinomas originating from the renal pelvis are site coded as differentiated cancers. These tumours can be recognised as kidney cancers while others are coded as renal pelvis cancers. carcinomas but are too undifferentiated to be further classified Hodgkin disease and leukaemias were lumped together in the according to their histogenetic origin. This group generally includes haematological system. the morphology codes 8010-8035. An exception is lung tumours,

61

Histological groups

where Large cell carcinoma is a separate entity in the WHO classification and includes 8010-8012, 8014-8031 and 8035 (Travis et al., 2004). The thyroid is another exception where Anaplastic carcinoma also is a specific entity in the WHO classification and includes the morphology codes 8020-8035 (Delellis et al., 2004).

1.4 2 3

Unspecified carcinoma Melanoma Other specified malignant neoplasm

Unspecified malignant Some tumours are evidently miscoded in cancer registry data, 4 neoplasm because their incidence is far higher than expected. Papillary carcinomas NOS (8050) are listed under Squamous cell neoplasm in ICD-O-3. When used for bladder tumours, most of Liver (C22) them are probably miscoded urothelial carcinomas rather than Hepatocellular carcinoma includes hepatoid carcinoma (8576), papillary squamous cell carcinomas, and therefore included in assuming that these are miscoded Hepatocellular carcinomas. the Transitional cell carcinoma group. In the thyroid, it can be The category Cholangiocarcinoma applies to all primary assumed that carcinomas that have been assigned the morphology carcinomas of the liver of biliary epithelial type, i.e. excluding code 8050 are actually papillary carcinomas of the thyroid, and hepatocellular carcinoma and combined hepatocellular and they are therefore included in that category. In the kidney it can cholangiocarcinoma. Klatskin tumours (8162) are excluded be assumed that a majority of tumours with the morphology code because they are by definition extrahepatic. Combined 8050 are miscoded papillary renal cell carcinomas, and they are hepatocellular and cholangiocarcinomas (8180), with less than 1% of cancers of known histology in the Cancer Incidence in consequently grouped with the Renal cell carcinoma group. Five Continents Vol. IX database, appear in the Other specified carcinoma category. Carcinoid is included in the same group. Oesophagus (C15) Adenocarcinoma excludes Linitis plastica (8142), which occurs in 1 Carcinoma 8010-8576 gastric epithelium. Squamous cell carcinomas includes basaloid 1.1 Hepatocellular carcinoma 8170-8176 squamous cell carcinoma (8083). The principal cancers in the Other Cholangiocarcinoma 8050, 8140-8141, 8160specified carcinoma group are Small cell carcinomas (8041-8045). 1.2 (all intrahepatic biliary 8161, 8260, 8440, 8480Melanoma and Carcinosarcoma are included among Other specified carcinomas, i.e. all primary 8500, 8570-8572 malignant neoplasms. adenocarcinomas) 1.3 Other specified carcinoma 1.4 Unspecified carcinoma 8010-8035 1 Carcinoma 8010-8576 2 Hepatoblastoma 8970 1.1 Squamous cell carcinoma 8050-8078, 8083-8084 Sarcoma 1.2 Adenocarcinoma 8140-8141, 8143-8145, 3 9120-9133, 9161 8190-8231, 8260-8263, 3.1 Haemangiosarcoma 8800-8811, 8830, 88408310, 8401, 8480-8490, 3.2 Other sarcomas 8921, 8990-8991, 90408550-8551, 8570-8574, 9044, 9150, 9170, 95408576 9581 1.3 Other specified carcinoma 4 Other specified malignant 1.4 Unspecified carcinoma 8010-8035 neoplasm 2 Sarcoma 8800-8811, 8830, 8800Unspecified malignant 8000-8005 8811, 8830, 8840-8921, 5 neoplasm 8990-8991, 9040-9044, 9120-9133, 9150, 9540Lung (C34) 9581 Squamous cell carcinoma includes papillary carcinoma NOS (8050) 3 Other specified malignant because these are listed under Squamous cell neoplasms in ICD-O-3. neoplasm Adenocarcinoma includes bronchiolo-alveolar adenocarcinoma 4 Unspecified malignant 8000-8005 (8250-8254) but excludes adenoid cystic (8200), mucoepidermoid neoplasm (8430) and adenosquamous carcinoma (8560), which appear in Other specified carcinoma. Small cell carcinoma includes Anus (C21) The category Squamous cell carcinoma includes basaloid and neuroendocrine carcinoma NOS (8246). These may include some cloacogenic carcinomas (8123-8124) and basaloid squamous cell large cell neuroendocrine carcinomas, but it is assumed that the vast carcinomas (8083). Cloacogenic carcinoma is a controversial entity, majority of cancers that are coded 8246 are small cell carcinomas. sometimes defined as carcinoma arising from the anal transition zone, Large cell carcinoma includes cancers so described (8012), as well as sometimes as a morphological variant of squamous cell carcinoma. other morphological variants of undifferentiated carcinomas (except The term basaloid carcinoma has also been used to designate this those with neuroendocrine or spindle cell differentiation) and clear group of tumours. Their reported incidence is highly variable, possibly cell adenocarcinoma (8310). Other specified carcinoma includes because of the confusing nomenclature. Hence, these tumour types non-small cell carcinoma (8046), carcinoid tumours (8240-8245), adenoid cystic (8200), mucoepidermoid (8430), adenosquamous are lumped together with Squamous cell carcinoma. (8560) and large cell neuroendocrine carcinomas (8013). 1 Carcinoma 8010-8576 1 Carcinoma 8010-8576 1.1 Squamous cell carcinoma 8050-8076, 8083-8084, 1.1 Squamous cell carcinoma 8050-8078, 8083-8084 8123-8124 1.2 Adenocarcinoma 8140, 8211, 8230-8231, 1.2 Adenocarcinoma 8140-8145, 8190-8231, 8250-8260, 8323, 84808260-8263, 8310, 8401, 8490, 8550-8551, 85708480-8490, 8550-8551, 8574, 8576 8570-8574, 8576 1.3 Small cell carcinoma 8041-8045, 8246 1.3 Other specified carcinoma

8010-8011 8720-8790 8800-8811, 8830, 88408920, 8990-8991, 90409044, 9120-9133, 9150, 9540-9581 8000-8005

62

Histological groups

1.4

1.5 2

3 4

4 8000-8005 Bone (C40-41) The main categories are Osteosarcoma, Chondrosarcoma and Ewing sarcoma. These three groups contain the same Corpus uteri (C54) ICD-O entities as groups VIII A-C in the International Squamous cell carcinomas are grouped with Other specified Classification of Childhood Cancer, Third Edition carcinoma because of their rarity at this site. Contrary to (Steliarova-Foucher et al., 2005). The Other specified other sites, mucoepidermoid (8430) and adenosquamous sarcomas category includes epithelioid sarcoma (8804), carcinoma (8560) are included in Adenocarcinoma because fibrosarcoma (8810-8812), malignant fibrous histiocytoma squamous differentiation is very common in adenocarcinoma (8830), liposarcomas (8850-8858), angiosarcomas (9120- of the corpus uteri, and it is assumed that partial squamous 9133) and malignant giant cell tumours (9250). The Other differentiation does not change the behaviour of these specified malignant neoplasm category includes desmoplastic neoplasms. As opposed to other sites, metaplastic carcinoma small round cell tumour (8806), mesenchymoma (8990), (8575) is grouped with Other specified malignant neoplasm chordoma (9370-9372), adamantinomas (9261, 9310) and in the corpus uteri because metaplastic carcinoma of the PNET (9473). endometrium has been equated with carcinosarcoma. Endometrioid adenofibroma, malignant (8381) is classified as 1 Sarcoma 8800-8921, 9040-9044, Other specified malignant neoplasm. 9120-9133, 9150, 91809250, 9260, 9540-9581 1.1 Osteosarcoma 9180-9200 1 Carcinoma 8010-8574, 8576 1.2 Chondrosarcoma 9210-9243 1.1 Adenocarcinoma (include 8140-8141, 8190-8211, 1.3 Ewing sarcoma 9260 mucoepidermoid and 8230-8231, 8260-8263, 1.4 Other specified sarcomas adenosquamous carcinoma) 8310, 8380, 8382-8384, 1.5 Unspecified sarcoma 8800-8803, 8805 8430, 8440-8490, 8510, 2 Other specified malignant 8560, 8570-8574, 8576 neoplasm 1.2 Other specified carcinoma 3 Unspecified malignant 8000-8005 1.3 Unspecified carcinoma 8010-8035 neoplasm 2 Sarcoma 8800-8811, 8830, 88408921, 8990-8991, 9040Skin (C43-44) 9044, 9120-9133, 9150, The skin has been added since the last edition of Histological Groups 9540-9581 for Comparative Studies. Basal cell carcinoma is registered and 3 Other specified malignant reported by several cancer registries and has thus been included. neoplasm 4 Unspecified malignant 8000-8005 1 Carcinoma 8010-8576 neoplasm 1.1 Squamous cell carcinoma 8050-8078, 8083-8084 1.2 Basal cell carcinoma 8090-8098 Ovary (C56) 1.3 Other specified carcinoma The first four carcinomas correspond to malignant serous, 1.4 Unspecified carcinoma 8010-8035 mucinous, endometrioid and clear cell tumours. Among the 2 Melanoma 8720-8790 carcinomas not encompassed within these four groups, there 3 Other specified malignant are various adenocarcinomas that cannot with certainty be neoplasm allocated to any of the above groups, and are hence included in 4 Unspecified malignant 8000-8005 Adenocarcinoma, NOS. In this category are grouped papillary neoplasm adenocarcinoma (8260), cystadenocarcinoma (8440) and other variants of adenocarcinoma. Within adenocarcinoma, Cervix uteri (C53) NOS, there are most likely a substantial number of tumours Mucoepidermoid carcinoma (8430) and adenosquamous that actually belong to categories 1.1-1.4. Truly unclassified carcinomas (8560) are included with Other specified carcinoma. adenocarcinomas of the ovary are uncommon. Sex cord/ The Other specified malignant neoplasm category includes stromal tumours have their own group. Germ cell tumours mullerian mixed tumour (8950), carcinosarcoma (8980) and include dysgerminomas, embryonal carcinomas and teratomas, melanoma (8720-8790). as well as the rare carcinoid tumours of the ovary, and the very rare gonadoblastomas. Lipid cell tumours, malignant Brenner 1 Carcinoma 8010-8380, 8382-8576 tumours and sarcomas are very rare and are consigned to Other 1.1 Squamous cell carcinoma 8050-8078, 8083-8084 specified malignant neoplasm.

Large cell carcinoma (include 8010-8012, 8014-8031, giant cell, clear cell and 8035, 8310 large cell undifferentiated carcinoma) Other specified carcinoma Sarcoma 8800-8811, 8830, 88408921, 8990-8991, 90409044, 9120-9133, 9150, 9540-9581 Other specified malignant neoplasm Unspecified malignant 8000-8005 neoplasm

1.2

Adenocarcinoma

1.3 1.4 2

Other specified carcinoma Unspecified carcinoma Sarcoma

8140-8141, 8190-8211, 8230-8231, 8260-8263, 8310, 8380, 8382-8384, 8440-8490, 8570-8574, 8576 8010-8035 8800-8811,8830, 88408921, 8990-8991, 90409044, 9120-9133, 9150, 9540-9581

Other specified malignant neoplasm Unspecified malignant neoplasm

63

Histological groups

1 1.1 1.2 1.3 1.4 1.5 1.6 1.7 2 3 4

Carcinoma Serous carcinoma Mucinous carcinoma Endometrioid carcinoma Clear cell carcinoma Adenocarcinoma NOS Other specified carcinoma Unspecified carcinoma Sex cord-stromal tumours Germ cell tumours Other specified malignant neoplasm (include Mullerian mixed tumour, carcinosarcoma) Unspecified malignant neoplasm

8010-8231, 8246-8576, 9014-9015, 9110 8441, 8460-8463, 9014 8470-8490, 9015 8380-8383, 8560, 8570 8310-8313, 9110 8140-8147, 8170-8190, 8211-8231, 8260, 8384, 8440, 8576 8010-8035 8590-8671 8240-8245, 9060-9102

1.3 1.4 2 3

Other specified carcinoma Unspecified carcinoma Other specified malignant neoplasm Unspecified malignant neoplasm

8010-8035 8000-8005

Urinary bladder (C67) The classification of urinary bladder tumours has undergone several revisions in recent years. Some low-grade papillary transitional cell tumours are now designated as papillary urothelial neoplasia of low malignant potential, PUNLMP (8130/1). In order to enable longitudinal comparisons, flat carcinoma in situ (8120/2) and PUNLMP (8130/1, 8130/2) have been grouped with Transitional cell carcinoma. Papillary carcinomas (NOS 8050) are listed under squamous cell neoplasm in ICD-O-3. When used for bladder tumours, most of these are probably miscoded transitional cell carcinomas, and are therefore included in the Transitional cell carcinoma group. Pheochromocytoma, malignant paraganglioma, melanoma and carcinosarcoma are included in Other specified malignant neoplasm. 1 1.1 1.2 Carcinoma Squamous cell carcinoma Transitional cell carcinoma (include transitional cell carcinoma with squamous and/ or glandular differentiation) Adenocarcinoma 8010-8576 8051-8078, 8083-8084 8050, 8120-8122, 81308131 8140-8145, 8190-8231, 8260-8263, 8310, 8401, 8480-8490, 8550-8551, 8570-8574, 8576 8010-8035 8800-8811, 8830, 88408921, 8990-8991, 90409044, 9120-9133, 9150, 9540-9581

8000-8005

Testis (C62) The grouping of the testicular tumours has been completely revised. Spermatocytic seminoma has a more favourable prognosis than seminoma, and these tumours should not be grouped. Embryonal carcinoma, malignant teratoma, Yolk sac tumour, choriocarcinoma and mixed germ cell tumours are included in non-seminomatous germ cell tumours. Sex cordstromal tumours are included in Other specified malignant neoplasm. 1 1.1 1.2 1.3 2 3 Germ cell tumours Seminoma Spermatocytic seminoma Non-seminomatous germ cell tumours Other specified malignant neoplasm Unspecified malignant neoplasm 9060-9102 9060-9062, 9064 9063 9065-9102

1.3

8000-8005

1.4 1.5 2

Other specified carcinoma Unspecified carcinoma Sarcoma

3 Other specified malignant neoplasm Kidney (C64) and Renal Pelvis (C65) There are several major difficulties with the histological grouping 4 Unspecified malignant 8000-8005 neoplasm of kidney tumours. Transitional cell and squamous carcinomas in the kidney usually originate from the renal pelvis, although it may be difficult to trace the origin of the tumour. It can be assumed Eye (C69) that some of these are site coded kidney (C64) and others renal The principal eye cancersretinoblastoma and malignant pelvis (C65). Hence, these two sites are now grouped. melanomaform two groups. The carcinomas (11.4% of eye Renal cell carcinomas have recently undergone a reclassification cancers in the IARC database) are divided into three subgroups: based on molecular, cytogenetic, morphological and clinical Squamous cell carcinomas (70% of the carcinomas, principally data. However, a substantial portion of these tumours are tumours of the conjunctiva and cornea), Other specified coded as renal cell carcinoma, NOS (8312) or adenocarcinoma, carcinomas (comprising almost entirely adenocarcinomas, NOS (8140), while others are subtyped. Therefore, the renal 14.6%, and mainly originating in the lacrimal gland and cell carcinomas are grouped together with adenocarcinoma, duct), and Unspecified carcinoma. Squamous cell carcinomas NOS (8140), specific subtypes of renal cell carcinoma and that are site coded for the eye (C69) probably include some also obsolete entities such as granular cell carcinoma (8320). cancers that originate in the skin (C44) of the eyelids. Papillary carcinoma, NOS (8050) is listed under squamous cell 1 Retinoblastoma 9510-9513 neoplasm in ICD-O-3. When used for renal tumours most of 2 Malignant melanoma 8720-8790 these are probably miscoded papillary renal carcinomas, and 3 Carcinoma 8010-8576 are therefore included in 1.2. 3.1 Squamous cell carcinoma 8050-8078, 8083-8084 3.2 Other specified carcinoma 1 Carcinoma 8010-8576 3.3 Unspecified carcinoma 8010-8035 1.1 Squamous, transitional cell 8051-8084, 8120-8122, 4 Sarcoma 8800-8811, 8830, 8840carcinoma 8130-8131 8921, 8990-8991, 90401.2 Renal cell carcinoma 8050, 8140, 8260, 8270, 9044, 9120-9133, 9150, 8280-8312,8316-8320, 9540-9581 8340-8344

64

Histological groups

5 6

Other specified malignant neoplasm Unspecified malignant neoplasm

1 8000-8005 1.1 1.2 1.3 1.4 1.5 1.6 2

Carcinoma Follicular carcinoma Papillary carcinoma Medullary carcinoma Anaplastic carcinoma Other specified carcinoma Unspecified carcinoma Sarcoma

8010-8576 8290, 8330-8335 8050, 8260, 8340-8344, 8350, 8450-8460 8345, 8510-8513 8020-8035

Brain and central nervous system (C71-C72) The categories are based upon those of the WHO Pathology & Genetics classification (Kleihues & Webster, 1997). Atypical teratoid/rhabdoid tumour (9508) is included in Embryonal tumours. Olfactory, pineal and some pituitary tumours are lumped together under Other neuroepihelial tumours. These are craniopharyngioma (9350-9352), pinealoma, pineocytoma, pineoblastoma (9360-9362) and olfactory neuroepitheliomatous neoplasms (9520-9523). Pinealoma (9360) encompasses pineocytoma (9361) and pineoblastoma (9362). The lymphomas and haemopoietic neoplasms are not included. 1 1.1 1.1.1 1.1.2 1.1.3 1.1.4 1.2 1.2.1 1.2.2 1.3 2 3 Tumours of neuroepithelial tissue Gliomas Astrocytic tumours 8680, 9350-9362, 93809508, 9520-9523 9380-9384, 9391-9460 9384, 9400-9421, 9424, 9440-9442 Oligodendroglial tumours and 9382, 9450-9451 mixed gliomas Ependymal tumours 9383, 9391-9394 Gliomas, others 9380-9381, 9423, 9430, 9444, 9460 Embryonal tumours 9470-9474, 9490, 95009504, 9508 Medulloblastoma 9470-9472, 9474 Other 9473, 9490, 9500-9504, 9508 Other neuroepithelial tumours Other specified malignant neoplasm Unspecified malignant 8000-8005 neoplasm

8010-8015 8800-8811, 8830, 88408921, 8990-8991, 90409044, 9120-9133, 9150, 9540-9581

3 4

Other specified malignant neoplasm Unspecified malignant neoplasm 8000-8005

Haematopoietic and lymphoid tissues (9590-9989) In the previous edition of Histological Groups for Comparative Studies, haematologic tumours were listed separately as Hodgkin disease and Leukaemias, but are now included in the same grouping based on cellular origin. Hodgkin lymphoma has been reclassified and lymphocytic predominance (9657-9659, 9660) is replaced by the new categories nodular lymphocytic predominance (9659) and classical lymphocyte-rich (9651). The category Non-Hodgkin lymphoma NOS is used because some cancer registries lack sufficiently specific data for lineagebased classification. 1 1.1 1.2 1.3 1.4 1.5 1.6 2 3 4 5 6 7 Hodgkin lymphoma Nodular lymphocytic predominance Classical lymphocyte-rich Nodular sclerosis Mixed cellularity Lymphocytic depletion Unspecified B-cell neoplasms 9650-9667 9659 9651 9663-9667 9652 9653-9655

Thyroid (C73) Follicular and Papillary carcinomas make up the majority of thyroid cancers; the latter includes follicular carcinomas with a papillary component (8340). It is assumed that the vast majority of cases of Papillary squamous carcinoma (8050) are actually papillary carcinomas, and they are therefore included in this category. Minimally invasive follicular carcinoma (8335) is a new code in ICD-O-3 and is included among Follicular carcinomas. Squamous carcinomas are no longer recognised as a major histological type in the WHO Classification of Tumours and are included in Other specified carcinomas. Anaplastic carcinomas (undifferentiated, giant cell, spindle cell carcinomas) are separated from Unspecified carcinomas. The entity Poorly differentiated carcinoma is controversial and has been lumped with Anaplastic carcinoma. Small cell carcinoma (8040-8045) is specifically excluded, since the great majority of tumours previously so diagnosed are in fact lymphomas. Insular thyroid carcinoma (8337) is a distinctive clinicopathologic entity that has been included in Other specified carcinoma. Mixed medullary-follicular carcinoma (8346) and mixed medullary-papillary carcinoma (8347) are also included in Other specified carcinoma.

9670-9699, 9728, 97319734, 9761-9764, 98239826, 9833, 9836, 9940 T-cell and NK-cell neoplasms 9700-9719, 9729, 98279831, 9834, 9837, 9948 Myeloid neoplasms 9840, 9860-9931, 99459946, 9950, 9960-9964, 9975, 9980-9989 Non-Hodgkin lymphoma 9591 NOS Other specified malignant neoplasms Unspecified malignant 9590, 9596, 9727, 9760, neoplasms 9800-9801, 9805, 9820, 9832, 9835

65

Histological groups

References Delellis, R. A., Lloyd, R. V., et al. (2004). Pathology and Genetics of Tumours of Endocrine Organs, Volume 8 (World Health Organization Classification of Tumours). Lyon: IARC Press. Fritz, A., Percy, C., et al. (2000). International Classification of Diseases for Oncology (ICD-O). Geneva: World Health Organization. Parkin, D. M., Shanmugaratnam, K. et al. (1998). Histological Groups for Comparative Studies (IARC Technical Report No. 31). Lyon: IARC Press. p. 184-187. Parkin, D. M., Whelan, S. L., et al. (1997). Cancer Incidence in Five Continents Vol. VII (IARC Scientific Publications No.143). Lyon: IARC Press. p. 34. Parkin, D. M., Whelan, S. L. et al. (2002). Cancer Incidence in Five Continents Vol. VIII (IARC Scientific Publications No.155). Lyon: IARC Press. p. 45-55.

Percy, C., Van Holten, V., et al. (1990). International Classification of Diseases for Oncology (ICD-O). Geneva: World Health Organization. Silverberg, S. G., Major, F. J. et al. (1990). Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol, 9, n.1, p.1-19. Steliarova-Foucher, E., Stiller, C. A., et al. (2005). International Classification of Childhood Cancer. Cancer, 103, n.7, p.1457-1467. Travis, W. D., Brambilla, E., et al. (2004). Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart, Volume 10 (World Health Organization Classification of Tumours). Lyon: IARC Press. p. 179-184. Zaino, R. J., Kurman R. J. (1988). Squamous differentiation in carcinoma of the endometrium: a critical appraisal of adenoacanthoma and adenosquamous carcinoma. Semin Diagn Pathol, 5, n.2, May, p.154-71.

66

H.R. Shin, M.P. Curado, J. Ferlay, M. Heanue, B. Edwards and H. Storm

The purpose of Cancer Incidence in Five Continents is to present comparable incidence rates of cancer from different populations world-wide. The process of selecting the data to be included and the review and evaluation of the datasets by the Editors therefore require careful attention to several aspects related to comparability. As far as the cases registered (numerators of the rates) are concerned, these include: (a) The definition of an incident case of cancer, (b) The completeness of enumeration of cases in the population covered, and (c) The accuracy of abstraction and coding of information. In addition to these, the denominatorperson-years at risk for the period under considerationshould be estimated as accurately as possible. In this chapter we explain the evaluation of data comparability and quality undertaken by the Editors for this volume, and introduce the traditional tables of Indices of Data Quality with which the users themselves can make judgements on the completeness and validity of the different datasets. Details of the standard definitions used by cancer registries to define an incident cancer, and the indices of comparability or validity that are found in the publication Comparability and Quality Control in Cancer Registration (Parkin 1994) and Chapter 5, Comparability and quality of data in the previous volumes (Parkin and Plummer 2002, in Volume VIII), were adopted to evaluate submissions for this volume. In contrast to Volume VIII of Cancer Incidence in Five Continents, a comparison with standard values for several quantitative indices in the same region (see Chapter 5 in Volume VIII, pp. 6667) was not executed for this volume. However, the editors tried to achieve standardization for this volume with more thorough efforts. For Volume IX, the Editors considered these items: (a) The number of cases in each year within the reference years 19982002, for the abrupt changes of number of cases by year in terms of completeness; (b) The rates for each year, to check the tendency and stability of cancer incidence rates within the reference year; (c) Other indices of data quality traditionally used by cancer registries, which are described later in detail; (d) The existence and usage of official mortality data; and (e) The coverage of the defined population. The following Chapter 6, on Processing of Data, makes it clear that an extensive process of verifying coding, identifying possible duplicate registrations, querying unlikely or impossible combinations of codes, and converting data to a standard format has been carried out before any tabulations are prepared for editorial evaluation. These steps in validation of the data are part of the routine to which all datasets are subjected, and the successful completion of these steps forms part of the editorial evaluation. A systematic and standard analysis according to the internal protocol at IARC produced the editorial tables and figures (listed below) that were provided to each contributor to allow an opportunity for feedback. These editorial sheets, along with the responses to the questionnaire filled by the registry and data process summary sheet were transferred to the secure FTP site. The site was subdivided into directories for each continent, country and registry. The external Editors, each assigned a continent, downloaded them for an initial review of the editorial sheets, and filled in a review summary form that was uploaded to the FTP site before the editorial meetings. The systematic analysis produced the following: (a) A set of editorial tables and figures including Editorial Sheets 1a (number of cancer cases) and 1b (agestandardized rates in major diagnosis groups in single calendar years of observation by sex)(Tables 5.1, 5.2), and Editorial Sheets 2a and 2b, age-specific graphs for major diagnosis groups, linear and logarithmic (Figures 5.1 and 5.2 respectively); (b) The tables of age- and site-specific rates and summary rates (crude, age-standardized, percentage of Microscopically Verified cases (MV), and the change from the rates reported in Volume VIII (CH V8) (when available: see subsection Comparison of rates with those in Volume VIII in the section Stability of incidence over time) (Table 5.3); (c) Other indices of data quality traditionally used for cancer registration, which are described later in detail (Table 5.4); (d) The estimated population at risk, with the source of information as a form of population pyramid by sex and age, and the method of estimation used (population pyramids: Figure 5.3); (e) The questionnaire responses provided by the registry; and (f) Summary sheet to check the coding system, with applied rules for multiple primaries in the questionnaire (Figure 5.4). At their formal meetings, the editors had access to all of the above, and each external editor reported the review result. All Editors agreed upon the final decision, and the responsible Editor filled in an evaluation form with the final decision and some queries, if necessary. Comparability Definition of incidence In defining incidence rates, particular attention is required in three broad areas: (a) The distinction between recurrence or extension of an existing cancer and the development of a new primary; (b) The detection of cancers incidentally, in asymptomatic individuals; and (c) The detection of cancers at autopsy. Multiple primaries Contributing registries were invited to submit all malignant and non-malignant diagnoses collected so that a common set of multiple primaries rules could be applied to each dataset. In this volume, the data were recoded (when necessary) into ICDO3 (Fritz et al., 2000), and the international rules used to distinguish new primary cancers from existing extensions/recurrences were those set out in the IARC/IACR definitions (IARC, 2004). This also requires that all cancers in the same individual could be identified. Of the registries included in this volume, 46 did not provide a patient identification number, making it impossible for the Editors to distinguish multiple primary tumours from duplicate registrations. For those registries, the rules used prior to submission are indicated below the population pyramid of the corresponding registry.

Chapter 5: Comparability and quality of data

67

Comparability and quality of data

As a result of recoding the datasets to the international standard, for those contributors who sent data already recoded according to a different set of rules, the results published in the volume do not exactly correspond to those published by the registries themselves. Table 5.5 shows the registration practices for the multiple primary rules by continent. The second multiple primary check procedure performed at IARC may have removed some cases considered as duplicate registrations and, conversely, some records that are considered multiple primaries following the IARC/IACR rules (2004) may have been considered duplicates following the registry rules and excluded from the submission. For example, the Korea Central Cancer Registry submitted data for the period 19992002 according to the IARC/IACR rules (IARC, 2000). According to these rules, at least 261 cancer cases (of a total of approximately 430 000) that should have been considered multiple primaries following the IARC/IACR rules (2004) were considered duplicates by the registry and were not sent to IARC. In addition, 433 records that were considered multiple primaries by the registry were considered duplicates following the IARC/ IACR (2004) rules and excluded from the final tables. The number of cases to be removed due to duplicate cases on the basis of the 2004 rule is in fact very small, mostly affecting the number of cases from groups of tumours of the bladder, kidney and renal pelvis. Groups of haematopoietic and lymphoid tissues were changed to a more detailed classification. To compare the effect on incidence rates and time trends of certain sites, therefore, we should pay special attention to the changes in application of the multiple primary rules. Incidental diagnosis Almost all registries include malignant tumours diagnosed during screening programmes, or histological specimens taken from individuals in whom there were no symptoms, or no clinical suspicion of cancer. These cases will increase incidence rates if the malignant cells so identified would never have resulted in a clinical cancer had they remained undetected. The incidence of breast cancer appears to have been increased by the introduction of systematic mammographic screening for cancer. More striking, however, are the effects of such incidental diagnoses on the reported incidence of prostate cancer following the introduction of screening with prostate-specific antigen. Similarly, the increase in diagnostic activity may have influenced the incidence of thyroid cancer. Table 5.6 and 5.7 show the registration practices for using a screening program as a data source by continents. Autopsy diagnosis Most registries include cancers identified in necropsy examinations of subjects in whom cancer was not diagnosed (or perhaps even suspected) during life. The possible influence on incidence rates will depend upon the extent of necropsy examinations in different populations; in general this has been declining in most countries in recent decades. The registries own appraisal of the percentage of cancer deaths autopsied is reproduced in Table 5.7. Coding practice For five cancer sitesskin, non-melanoma (ICD10 C44), ovary (ICD10 C56), urinary bladder (ICD10 C67), brain and central nervous system (ICD10 C7072), and myeloproliferative disorders and myelodysplastic syndromes (MPD/MDS) comparability is particularly affected by differences in classification and coding practices. These sites are printed in italics in the cancer registry tables, and care should be taken when comparing data from different registries for these sites. Non-melanoma skin cancer. The incidence of non-melanoma skin cancer (NMSC) is difficult to assess. These cancers are very

common but rarely fatal, and completeness of registration varies widely depending on access to outpatient records and general practitioners. Most NMSCs are basal cell (BCC) or squamous cell (SCC) carcinomas; other skin cancers are rare. While some registries record the first occurrence of all NMSC, others register BCC only, several registries collect information for lip and/or genital sites only, and many do not collect data on either SCC or BCC. Ovarian cancer. Registries contributing to this volume were asked how they coded ovarian cystadenoma of borderline malignancy and borderline tumour of the ovary (see Chapter 3). Clearly, for these diagnoses, registration practice varies considerably. The borderline ovarian diagnoses were considered as non-malignant tumours in ICDO1/ICD9. They were considered malignant in ICDO2/ICD10, and have been changed back to the /1 borderline category in ICDO3; as a result, they have been excluded from the final tables in the present volume. Studies of trends in incidence should take into account the practice in previous volumes. Bladder cancer. The problem of the coding of non-invasive tumours, taking into account recorded level of invasion and grade, and which to include in the tables as cancer of the bladder has long been the subject of debate. In principle, the availability of data on histological type and behaviour has made it possible to publish only data on malignant cancer by excluding diagnoses with any behaviour code other than /3. However, many registries assign the behaviour code /3 to both non-invasive and unspecified diagnoses, making it impossible to distinguish such cases. The Editors decided to follow the policy adopted in the last two volumes and to accept that noninvasive diagnoses of bladder cancer (/1 and /2) are considered malignant, and the bladder cancer category includes the in situ and unspecified categories. A few registries preferred not to include such cases in their dataset, even when available in the registry, for the sake of continuity over time. Brain and central nervous system. Benign and unspecified tumours of the brain and central nervous system are excluded from the tabulation. Some registries choose to include benign and unspecified tumours of the brain and central nervous system in their data because of the potentially serious clinical consequences of these tumours, and assign the behaviour code /3 to both benign and unspecified diagnoses, so making it impossible to distinguish such cases. Myeloproliferative disorders and myelodysplastic syndromes. Unlike ovarian borderline tumours, these diagnoses that were considered as non-malignant disease (/1) in ICDO2 and in ICD10 (D45D47) have changed behaviour code to malignant (/3) in ICDO3. Only registries that collect information according to ICDO3, or those registries which have collected and submitted such cases although they were considered as nonmalignant, can present data. Because no ICD10 codes in the C (malignant) category have been allocated to them, they are presented under the category MPD/MDS. Completeness Completeness of registration is the proportion of all incident cases in the registry population that have been included in the registry database. Completeness should be as close to 100% as possible, so that comparison of incidence rates between registries reflects true differences in cancer risk. The Editors main concern is with the possibility of incompleteness in the data submitted. Duplicate registration of the same case should be avoided by careful attention to record linkage during the registration process. Because the case lists submitted do not contain personal identifying information, it is impossible for the Editors to check for possible duplicates. However, sometimes the existence of duplicate registration was suspected, e.g. by indices of completeness (see below) being

68

Comparability and quality of data

higher than expected, and listings of possible duplicates (based on birthdate, sex, diagnosis and date of incidence) were returned to the registry for checking. The following indices of completeness are routinely used during the editorial process: (1) Historic data methods: (a) Stability of incidence rates over time (b) Age-specific incidence curves (c) Childhood cancer (2) Proportion of cases microscopically verified (3) Proportion of unknown basis of diagnosis (4) Mortality:incidence (M:I) ratio (5) Death certificate methods Stability of incidence over time Constancy of registrations during the period under review Editorial Tables 1a and 1b (Tables 5.1 and 5.2) simply present the distribution of cases registered and age-standardized rates, by site and year. Those permit a rapid visual check on the stability of numbers of cases being recorded each year and signal potential problems in the registration process and/or in the population during the period under review. Comparison of rates with those in Volume VIII The change in incidence rates (as average percentage annual change) since Volume VIII is presented in the column headed CH V8 in Editorial Table 3 (Table 5.3). Those changes that are statistically significant, based on a comparison of the agestandardized rate in Volume VIII, are marked in bold. Changes in incidence rates over time that are greater than expected, and which cannot be ascribed to discrepancies in the estimation of person-years at risk, suggest the possibility of changes in the completeness of case ascertainment. When there was no corresponding rate published for that site in Volume VIII, the current rate was compared with an average value from other regions in the same country, or from neighbouring countries. Age-specific incidence curves Age-specific incidence curves for 12 sites in each sex comprised Editorial Sheet 2a, 2b (Figures 5.1 linear, 5.2 logarithmic). The curves were examined during the editorial process in order to detect abnormal fluctuations in the anticipated patterns, including any fall-off in the rate of increase in incidence in older subjects (suggestive of under-ascertainment in the oldest age groups). The curves also reveal problems with estimates of population at risk for specific age groups. Childhood cancer The possibility of under-enumeration (or duplicate registrations) in this age range was investigated by comparing the observed age-specific rates in the childhood age range (groups: 04, 59, 1014 for all cancer sites) with the corresponding rates in Volume VIII, when available. Proportion of cases microscopically verified Editorial Sheet 4 (Table 5.4) tabulates, for each site by sex (19 for men, 21 for women), the percentage of cases for which the diagnosis was based upon microscopic verification of a tissue specimen (MV%). This includes, in addition to histological confirmation of diagnosis, those based upon exfoliative cytology specimens, and diagnoses of leukaemia based on haematological examination (without examination of bone marrow). The MV% figures are also presented in the tables of Indices of Data Quality on the website. The main value of the MV% is as an indicator of the validity of the diagnostic information (Parkin et al., 1994). However, a very high proportion of cases diagnosed by histology or

cytology/haematologyhigher than might reasonably be expectedsuggests over-reliance on the pathology laboratory as a source of information, and failure to find cases diagnosed by other means. In Editorial Sheet 4 (Table 5.4), the column MV% values in bold, accompanied by a flag (</>) signifies that the number of cases so diagnosed is significantly greater than (>) or less than (<) the value observed by sex and site in Volume VIII when available. When there was no MV% published for that site in Volume VIII, the current MV% was compared with an average MV% value from the other regions in the same country, or from neighbouring countries. Proportion of cases of unknown basis of diagnosis When each new cancer case is registered, the diagnostic modality is described as being by histology, cytology/haematology, clinical investigation with X-ray, ultrasound, MRI, autopsy or clinical diagnosis only. Cases not distinguished by the above modalities are listed as unknown basis of diagnosis. If the proportion of cases denoted as unknown basis of diagnosis is higher than 20%, completeness of the registry is not sufficient to be included in this volume. Mortality:Incidence ratio This ratio is an important indicator of completeness, an example of the independent case ascertainment method (Parkin et al., 1994). Registries are asked to provide the mortality data on cancer by sex, age group and site, for the same period as the registered cases, from the local vital statistics office (municipal, provincial, national, etc.). Registry-generated mortality statistics (based on cases in the registry database who die during the period, or incorporating corrections to the certified cause of death) are not acceptable, since they do not constitute an independent data source. When the quality of the mortality data is good, the M:I ratio is related to case fatality (1-survival). However, when mortality statistics are of poorer quality (incomplete certification, inaccurate cause of death statements) the relationship will be less close. Evaluation of the M:I ratio should take this into account. Since both survival and quality of mortality statistics are somewhat related to geographical region the regional location of the registry is important in evaluation of the statistic. As it is typical to use M:I ratio as a criteria for inclusion or exclusion, in the process of evaluation the editors compared the M/I ratio by site with a reasonable threshold level. In Editorial Sheet 4 (Table 5.4), the M:I ratios for a given site are marked as being significantly greater (>) or less (<) than observed on the Cancer Incidence in Five Continents, Volume VIII, when available. When there was no corresponding ratio published for that site in Volume VIII, the current ratio was compared with an average value from the other regions in the same country, or from neighbouring countries. The tables of Indices of Data Quality show the values of the M:I ratio for registries where official mortality statistics are available. Death certificate methods Death certificates provide an important supplementary source of information for cancer registries. As far as incidence statistics are concerned, they function as a means of capturing information on cases that escaped the registration process during life. Completeness of registration may be evaluated on the basis of the proportion of incident cancers that first come to the registrys attention via a death certificate notification of cancer (DCN cases). This proportion was provided by the registry to the editors of Cancer Incidence in Five Continents, whose data include only the numbers of death certificate only (DCO cases)that is, the residuum of cases remaining after various follow-back procedures have been carried out on DCN cases. By itself, therefore, the DCO% is not an indicator

69

Comparability and quality of data

of completeness of registration; a low DCO% may indicate efficient case-finding, but it could equally well result from the efficient traceback of DCN cases (for example, there are actually no DCO cases with complete traceback in the Australia South and Canada Northwest Territories datasets). Nevertheless, the DCN% will always be equal to or greater than the DCO%, so an elevated DCO% is suggestive of incompleteness. Even this must be interpreted in the light of local circumstances; in some developing countries, the quality of death certificates may be very poor, with a fair number of erroneous cancer deaths, which the registry may have difficulty tracing back to a hospital capable of confirming (or not) the death certificate statement. Table 5.8 shows the registration practice used to distinguish the DCN cases and DCN (%) by each registry. Failure to use death certificates, when these are available and can be linked to the registry database, is generally taken to mean that some lack of completeness is likely to be present. Validity Validity is defined as the proportion of cases in a data-set with a given characteristic (e.g., site, age) that truly have the attribute. Cancer Incidence in Five Continents uses five of the common indices of validity (Parkin et al., 1994): (a) Internal consistency (b) Histological verification (c) Death certificate only (d) Other and unspecified cases (ill-defined cases) (e) Age unknown The use of the IARC-CHECK program to perform consistency checks on the submitted data-sets is described in the chapter on data processing (Chapter 6). In practice, all datasets were submitted to this process, and the cases queried checked by the registry before incorporation into the database. Microscopical verification For most cases, the accuracy of the stated diagnosis is likely to be higher if it is based on histological examination by a pathologist. Previous surveys have shown that many cancer registries code diagnoses based on exfoliative cytology or on haematological examination of peripheral blood in the same category as histological examinations, so that it is impossible to distinguish between them. Partly for this reason, the index of validity used in the Editorial Sheet (Table 5.4) and the tables of Indices of Data Quality in this volume concern the percentage of cases microscopically verified. For example, the MV% of liver cancer gradually decreased in the data from some Asian registries. In the practice guidelines, the diagnostic criteria of hepatocellular carcinoma included the non-invasive methods defined by the European Association for the Study of the Liver (Bruix et al., 2001) and by the American Association for the Study of Liver Disease (Bruix & Sherman 2005). In the regions with a high proportion of liver cancer among the total number of incidence cases, the overall MV% will be highly affected by the MV% of liver cancer. The practice guidelines should be considered in the evaluation of cancer cases from registries. Therefore, MV% without liver cancer was considered as one of the criteria for acceptance. Also, MV% without leukaemia was considered when the MV% of each registry was less than the threshold of inclusion criteria. Death certificate only In this volume, considerable effort has been made to ensure that what is reported as DCO cases in the Editorial Tables and Indices of Data Quality Tables does, indeed, refer to such cases. That is, they represent the residuum of casesafter all trace-back manoeuvres have been completedfor which no other information than a death certificate mentioning cancer could be obtained. Inasmuch as the

diagnostic information on death certificates is well known to suffer from lack of accuracy, or lack of precision, a high proportion of DCO cases implies a lack of validity of the data. It would usually imply a lack of completeness also, as noted earlier (see section on Death certificate methods). There are many considerations involved in interpretation, and the sensitivity of the DCO% to local circumstances (availability of death certificates, quality of cause-of-death statements, facility to trace back cases). In this volume, the datasets with less than 20% of DCO cases were considered for the evaluation. Other and unspecified (ill-defined) cases The content of this category is defined in Chapter 3 (see Table 3.1). A high proportion of cases assigned to these rubrics generally implies poor diagnostic precision (as evidenced by the low MV% observed for this rubric), or failure to specify the site of the primary cancer in cases diagnosed on the basis of tissue obtained from a metastasis. The percentage of ill-defined cases is given in Editorial Sheet 4 (Table 5.4). In this volume, only data with less than 20% of ill-defined cases were considered for the evaluation. Age unknown The proportion of cases for which age was unknown is reported in Table 5.3. In this volume, only data with less than 20% of age-unknown cases were taken into account for the evaluation. Population It is obvious that a 10% error in the estimation of population at risk produces just as much inaccuracy in the calculated incidence rate as a 10% error in enumeration of cases. However, cancer registries are generally not responsible for population estimates, and must rely upon various departments of central and local government to supply the required information. Registries should, however, inform themselves about the source of the population-at-risk figures that they use, and the methods used to produce estimates and projections. The Editors of this volume asked all contributing registries to provide this information, and it is summarised, along with the average annual population at risk for the period covered by the registrations, for each entry. The population data provided by a registry could rarely be subjected to verification by the Editors. The shape of the population pyramids and irregularities in the age-specific incidence curves sometimes suggested errors in the estimates, and occasionally the appropriateness of the source of the information provided was queried. For Volume IX, which mainly concerns periods of time around 2000, census data were usually available, so that part of population at risk was based on post-censal and the other on intercensal estimates. Grouping of datasets according to the inclusion criteria Inclusion criteria The Editors applied standard definitions for the inclusion criteria using the indices described above. Up until Volume VIII, there were no rigidly defined criteria with ranges of acceptability for some quality indices; however, the Editors considered the guidelines for scrutinising the data when comparing them to previous volumes. The comparability groups A, B and C were created to facilitate high throughput of evaluation, did not require strict criteria for inclusion, and aided the Editors in the evaluation process. Table 5.7 shows the summarised inclusion criteria used for the review and evaluation of submissions and resubmissions. For some datasets, the intrinsic interest in providing information on little-known geographical and ethnic patterns, or continuity with earlier data from the same registry, were taken into consideration. The specialised cancer registriese.g. sitespecific cancer registries and childhood cancer registrieswere not considered for inclusion.

70

Comparability and quality of data

Categorisation (Grouping) Submissions with more than three-year data were taken into account for evaluation. Data with less than 20% of DCO cases, ill-defined cases, age-unknown cases were considered, except for some registries of special interest due to their geographical location. An overall MV% of more than 75% was considered acceptable (data with higher than 99% of MV% were not considered for evaluation; see section on Proportion of cases microscopically verified). However, some registries reported a MV% without liver cancer or ill-defined cases that was higher than 75% (higher than 70% for some special-interest registries, for example China Jiashan) and were included as described in subsection Microscopical verification in the Validity section. Even though there was no strictly applied threshold of Mortality:Incidence ratio, a practically reasonable value by site was considered. Those with implausibly low or high incidence rates were not included in this volume. The Editors received 313 submissions from cancer registries. For the editorial process, the submissions were categorized into three groups (group A, B, and C) according to the quality indicators. Of these, 225 (71.8% of submissions) were included. Group A The registries that included death reporting in the registry region that was in compliance with WHO recommendations were grouped as Group A. Data in this group also had more than 80% MV% and less than 10% ill-defined site, DCO% and unknown basis of diagnosis. Ideally, the registries with almost 100% completeness were considered for this group. The registries should have well-defined denominators and not show abrupt changes in trends. (For an example of Group A, see Editorial Sheet 4; Table 5.4a).

Group B If a cancer registry had no access to death certificate data, even the existence of official mortality with causes of death, it was classified as comparability Group B. The registries were those with MV% between 75% and 80%. As described above, registries with a MV% due to a high proportion of liver cancer were calculated without liver cancer. MV% without leukaemia was also considered for this group. (For an example of Group B, see Editorial Sheet 4; Table 5.4b). Group C Regions or countries without official mortality were grouped as C for comparability. In terms of completeness, the registries in which ad hoc study is not available and death clearance is not a source of case finding were grouped into Group C. (For examples 1 and 2 of Group C, see Editorial Sheet 4; Table 5.4c). The asterisk (*) for Group C and datasets of special interest The presence of an asterisk on a registry table denotes that care should be taken in interpreting the rates for some or all of the cancer sites listed. The principal reason for use of an asterisk is to indicate those datasets, a total of 26, that the Editors considered to have some limitations in determining the number of cases or the population at risk that could affect the ability to make direct comparisons with other registry datasets. The criteria used to assign an asterisk were not strictly defined, being based instead on a number of quantitative indices discussed in this chapter as well as knowledge of the circumstances under which the registry operates. Certain registries were considered to be of special interest due to their providing important data on geographic or population groups little represented in the literature, and this was taken into consideration as well. The submitting registries were notified of the assigned comparability group, but this information does not appear in the published volume.

References Bruix J., Sherman M., Llovet J.M., et al. (2001). Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35(3):421-30. Bruix J., Sherman M. (2005). Management of hepatocellular carcinoma. Hepatology 42(5):1208-36. Chirpaz E., Colonna M., Mngoz F., Grosclaude P., Schaffer P., Arveux P., Mace-Lesech J., Exbrayat C., Schaerer R. (2002). Incidence and mortality trends for prostate cancer in 5 French areas from 1982 to 1996. Int J Cancer, 97:372-6. Fritz A., Percy C., Jack A., Shanmugaratnam K., Sobin L., Parkin D.M., Whelan S. (eds) (2000). International Classification of Diseases for Oncology, 3rd edition. Geneva: World Health Organization, Geneva. IARC (2000). Multiple Primaries. Internal Report No. 94/003, distributed in 1995 and revised in 2000. Lyon: IARC. IARC (2004). International Rules for Multiple Primary Cancers ICD-O Third Edition. Internal Report No. 2004/02. Lyon: IARC. Parkin D.M., Chen V.W., Ferlay J., Galceran J., Storm H.H., Whelan S.L. (1994). Comparability and Quality Control in Cancer Registration (IARC Technical Reports No. 19). Lyon: IARC. Parkin DM, Plummer M (2002). Comparability and quality of data. In: Parkin D.M., Whelan S.L., Ferlay J., Teppo L., Thomas D.B. Cancer Incidence in Five Continents, Volume VIII. (IARC Scientific Publications No. 155). Lyon: IARC.

71

Comparability and quality of data

Table 5.1 Number of cases major diagnosis groups in single calendar years of observation Tablein 5.1 CI5 Volume IX (Editorial Table 1a)

ELSEWHERE (1998-2002)
Number of cases in major diagnosis groups in single calendar years of observation
SITE Oral cavity & pharynx Digestive organs Respirathory organs Bone & cartilage Breast Male genital Urinary organs Eye, brain & NS Thyroid & endocrine Ill-defined & unknown Haematopoietic All sites but skin 1998 88 (23) 2375 (614) 694 (179) 26 (07) 1 (00) 69 (18) 237 (61) 57 (15) 45 (12) 84 (22) 157 (41) 3867 (1000) 1999 79 (18) 2641 (616) 745 (174) 12 (03) 2 (00) 110 (26) 230 (54) 56 (13) 50 (12) 96 (22) 215 (50) 4285 (1000) MALE 2000 99 (23) 2655 (613) 807 (186) 13 (03) 4 (01) 97 (22) 236 (54) 72 (17) 51 (12) 65 (15) 198 (46) 4334 (1000) FEMALE 2000 50 (15) 1425 (413) 277 (80) 19 (06) 496 (144) 540 (157) 92 (27) 55 (16) 202 (59) 90 (26) 158 (46) 3448 (1000) BOTH SEXES 2000 149 (19) 4080 (524) 1084 (139) 32 (04) 500 (64) 540 (69) 97 (12) 328 (42) 127 (16) 253 (33) 155 (20) 356 (46) 7782 (1000) 2001 110 (24) 2919 (624) 812 (174) 23 (05) 5 (01) 117 (25) 287 (61) 47 (10) 54 (12) 81 (17) 180 (38) 4679 (1000) 2002 114 (24) 2968 (614) 850 (176) 18 (04) 3 (01) 139 (29) 314 (65) 45 (09) 56 (12) 73 (15) 204 (42) 4834 (1000) Total 490 (22) 13558 (616) 3908 (178) 92 (04) 15 (01) 532 (24) 1304 (59) 277 (13) 256 (12) 399 (18) 954 (43) 21999 (1000)

SITE Oral cavity & pharynx Digestive organs Respirathory organs Bone & cartilage Breast Female genital Urinary organs Eye, brain & NS Thyroid & endocrine Ill-defined & unknown Haematopoietic All sites but skin

1998 29 (10) 1266 (431) 217 (74) 12 (04) 408 (139) 520 (177) 67 (23) 40 (14) 144 (49) 73 (25) 114 (39) 2934 (1000)

1999 40 (12) 1427 (424) 309 (92) 12 (04) 465 (138) 562 (167) 74 (22) 44 (13) 184 (55) 81 (24) 118 (35) 3362 (1000)

2001 38 (10) 1465 (402) 329 (90) 22 (06) 550 (151) 567 (156) 106 (29) 53 (15) 250 (69) 71 (19) 154 (42) 3646 (1000)

2002 40 (10) 1624 (421) 308 (80) 16 (04) 621 (161) 608 (158) 101 (26) 39 (10) 230 (60) 60 (16) 170 (44) 3858 (1000)

Total 197 (11) 7207 (418) 1440 (83) 81 (05) 2540 (147) 2797 (162) 440 (26) 231 (13) 1010 (59) 375 (22) 714 (41) 17248 (1000)

SITE Oral cavity & pharynx Digestive organs Respirathory organs Bone & cartilage Breast Female genital Male genital Urinary organs Eye, brain & NS Thyroid & endocrine Ill-defined & unknown Haematopoietic All sites but skin

1998 117 (17) 3641 (535) 911 (134) 38 (06) 409 (60) 520 (76) 69 (10) 304 (45) 97 (14) 189 (28) 157 (23) 271 (40) 6801 (1000) 1998

1999 119 (16) 4068 (532) 1054 (138) 24 (03) 467 (61) 562 (73) 110 (14) 304 (40) 100 (13) 234 (31) 177 (23) 333 (44) 7647 (1000)

2001 148 (18) 4384 (527) 1141 (137) 45 (05) 555 (67) 567 (68) 117 (14) 393 (47) 100 (12) 304 (37) 152 (18) 334 (40) 8325 (1000)

2002 154 (18) 4592 (528) 1158 (133) 34 (04) 624 (72) 608 (70) 139 (16) 415 (48) 84 (10) 286 (33) 133 (15) 374 (43) 8692 (1000) 2002

Total 687 (18) 20765 (529) 5348 (136) 173 (04) 2555 (65) 2797 (71) 532 (14) 1744 (44) 508 (13) 1266 (32) 774 (20) 1668 (43) 39247 (1000)

ALL SITES NUMBER OF CASES BOTH SEXES 1999 2000 2001

782%

880%

895%

958%

1000%

72

Population data provided for 5 year(s) Mon Nov 26 2007

Comparability and quality of data

Table 5.2 ASR in major diagnosis groups single calendar years of observation Table 5.2 CI5 Volume IXin (Editorial Table 1b)

ELSEWHERE (1998-2002)
ASR in major diagnosis groups in single calendar years of observation
SITE Oral cavity & pharynx Digestive organs Respirathory organs Bone & cartilage Breast Male genital Urinary organs Eye, brain & NS Thyroid & endocrine Ill-defined & unknown Haematopoietic All sites but skin 1998 57 (22) 1565 (602) 511 (197) 15 (06) 00 (00) 63 (24) 154 (59) 35 (14) 24 (09) 59 (23) 95 (36) 2598 (1000) 1999 48 (17) 1660 (598) 538 (194) 06 (02) 01 (00) 92 (33) 151 (54) 34 (12) 28 (10) 67 (24) 125 (45) 2776 (1000) MALE 2000 60 (23) 1567 (594) 533 (202) 07 (03) 05 (02) 74 (28) 150 (57) 41 (16) 25 (10) 43 (16) 111 (42) 2637 (1000) FEMALE 2000 23 (15) 658 (421) 129 (83) 09 (05) 208 (133) 231 (148) 46 (30) 28 (18) 87 (56) 42 (27) 82 (52) 1563 (1000) BOTH SEXES 2000 39 (19) 1052 (527) 296 (148) 08 (04) 109 (55) 123 (61) 28 (14) 90 (45) 34 (17) 57 (29) 42 (21) 96 (48) 1995 (1000) 2001 62 (22) 1679 (603) 537 (193) 14 (05) 03 (01) 87 (31) 172 (62) 25 (09) 28 (10) 53 (19) 99 (35) 2784 (1000) 2002 61 (22) 1635 (594) 521 (189) 12 (04) 02 (01) 95 (34) 183 (67) 24 (09) 31 (11) 47 (17) 113 (41) 2752 (1000) Total 58 (21) 1622 (598) 529 (195) 11 (04) 02 (01) 83 (31) 163 (60) 32 (12) 27 (10) 53 (20) 109 (40) 2713 (1000)

SITE Oral cavity & pharynx Digestive organs Respirathory organs Bone & cartilage Breast Female genital Urinary organs Eye, brain & NS Thyroid & endocrine Ill-defined & unknown Haematopoietic All sites but skin

1998 14 (10) 629 (448) 108 (77) 06 (04) 176 (126) 234 (167) 35 (25) 22 (16) 64 (46) 35 (25) 56 (40) 1404 (1000)

1999 19 (12) 685 (437) 148 (94) 06 (04) 200 (128) 247 (157) 37 (24) 21 (13) 83 (53) 40 (26) 61 (39) 1569 (1000)

2001 17 (11) 658 (409) 151 (94) 13 (08) 224 (139) 238 (148) 49 (30) 27 (17) 108 (67) 32 (20) 76 (47) 1611 (1000)

2002 17 (10) 710 (428) 134 (81) 09 (05) 250 (150) 254 (153) 45 (27) 18 (11) 96 (58) 26 (15) 84 (50) 1660 (1000)

Total 18 (11) 669 (428) 134 (86) 08 (05) 212 (136) 241 (154) 43 (27) 23 (15) 88 (56) 35 (22) 72 (46) 1564 (1000)

SITE Oral cavity & pharynx Digestive organs Respirathory organs Bone & cartilage Breast Female genital Male genital Urinary organs Eye, brain & NS Thyroid & endocrine Ill-defined & unknown Haematopoietic All sites but skin

1998 32 (17) 1017 (545) 270 (145) 11 (06) 92 (49) 124 (66) 23 (12) 85 (46) 28 (15) 45 (24) 45 (24) 73 (39) 1868 (1000) 1998

1999 31 (15) 1099 (539) 302 (148) 06 (03) 104 (51) 131 (64) 34 (16) 83 (41) 27 (13) 56 (27) 50 (25) 90 (44) 2038 (1000) 1999

2001 36 (18) 1100 (531) 307 (148) 13 (06) 116 (56) 125 (60) 33 (16) 100 (48) 25 (12) 68 (33) 40 (19) 87 (42) 2071 (1000) 2001

2002 37 (18) 1110 (531) 294 (141) 10 (05) 129 (62) 133 (64) 36 (17) 104 (50) 21 (10) 63 (30) 34 (16) 95 (46) 2090 (1000) 2002

Total 35 (17) 1077 (534) 294 (146) 09 (05) 110 (55) 127 (63) 31 (15) 93 (46) 27 (13) 58 (29) 42 (21) 89 (44) 2016 (1000)

ALL SITES ASR BOTH SEXES 2000

894%

975%

955%

991%

1000%

Population data provided for 5 year(s) Mon Nov 26 2007

73

Comparability and quality of data

Figure 5.1 Age-specific rates for major diagnosis - linear Figure 5.1 CI5 Volume IX (Editorial Table groups 2a)

ELSEWHERE (1998-2002)
Stomach

Age-specific rates for major diagnosis groups - linear

Oesophagus 1000 800 600 400 200 00 4000 6000 5000 4000 3000 2000 1000 515- 25- 35- 45- 55- 65- 75- 85+ Liver 00 1000 800 600 2000 400 1000 200 00 500 400 300 400 200 200 100 00 400 500 1000 2000 4000 515- 25- 35- 45- 55- 65- 75- 85+ Pancreas Colon, rectum and anal canal 3000 2500 2000 1500 1000 500 00 8000 515- 25- 35- 45- 55- 65- 75- 85+ Lung

3000 -

6000 -

00 800 -

5-

15- 25- 35- 45- 55- 65- 75- 85+ Breast

5-

15- 25- 35- 45- 55- 65- 75- 85+ Cervix uteri

00 2000 -

5-

15- 25- 35- 45- 55- 65- 75- 85+ Prostate

600 -

1500 -

00 20 -

5-

15- 25- 35- 45- 55- 65- 75- 85+ Hodgkins disease

5- 15- 25- 35- 45- 55- 65- 75- 85+ Non-Hodgkin lymphoma

00 250 200 150 -

5-

15- 25- 35- 45- 55- 65- 75- 85+ Leukaemia

15 -

300 -

10 -

200 100 -

05 -

100 -

50 00

00

5-

15- 25- 35- 45- 55- 65- 75- 85+

00

5-

15- 25- 35- 45- 55- 65- 75- 85+ Mon Nov 26 2007

5-

15- 25- 35- 45- 55- 65- 75- 85+

74

Comparability and quality of data

Figure 5.2 Age-specific for major - logarithmic scale Figure 5.2rates CI5 Volume IXdiagnosis (Editorial groups Table 2b)

ELSEWHERE (1998-2002)
5200 Stomach

Age-specific rates for major diagnosis groups - logarithmic scale

860 Oesophagus Colon, rectum and anal canal 2800

01 3300

5-

15- 25- 35- 45- 55- 65- 75- 85+ Liver

01 970

5-

15- 25- 35- 45- 55- 65- 75- 85+ Pancreas

01 6200

5-

15- 25- 35- 45- 55- 65- 75- 85+ Lung

01 690

5-

15- 25- 35- 45- 55- 65- 75- 85+ Breast

01 490

5-

15- 25- 35- 45- 55- 65- 75- 85+ Cervix uteri

02 1700

5-

15- 25- 35- 45- 55- 65- 75- 85+ Prostate

01 20

5-

15- 25- 35- 45- 55- 65- 75- 85+ Hodgkins disease

5- 15- 25- 35- 45- 55- 65- 75- 85+ 340 Non-Hodgkin lymphoma

02

01 210

5-

15- 25- 35- 45- 55- 65- 75- 85+ Leukaemia

01

5-

15- 25- 35- 45- 55- 65- 75- 85+

01

5-

15- 25- 35- 45- 55- 65- 75- 85+ Mon Nov 26 2007

10

5-

15- 25- 35- 45- 55- 65- 75- 85+

75

76

Table CI5 Volume (editorial table 3a) Table 5.35.3 CI5 Volume IX IX (Editorial Table 3a) ELSEWHERE (1998-2002) ANNUAL INCIDENCE PER 100 000 BY AGE GROUP (YEARS) - MALE
1002 02 02 02 02 24 08 02 02 20 02 03 09 27 15 02 119 118 01 02 01 05 01 07 01 02 07 15 02 05 01 08 07 05 02 15 12 16 03 01 120 120 02 01 03 13 03 07 07 01 02 02 04 07 04 01 02 01 09 01 03 02 17 10 03 01 10 10 13 04 147 144 01 05 01 03 01 29 01 13 11 16 02 02 01 09 08 06 05 01 06 01 08 03 05 21 10 01 11 01 08 11 02 07 211 206 05 01 02 105 21 16 63 04 09 22 04 05 07 01 02 10 02 05 10 11 15 15 04 27 05 05 21 07 406 396 04 07 07 05 02 01 08 08 09 02 02 10 214 372 01 03 43 74 42 75 163 432 05 30 08 30 03 05 06 10 29 84 04 08 05 08 10 12 01 01 01 05 08 07 02 01 03 02 02 01 02 14 47 26 63 22 20 18 36 02 02 01 06 30 43 05 04 05 24 28 01 05 03 11 18 721 1492 713 1485 09 06 13 13 11 09 01 47 697 13 120 158 783 74 51 06 10 33 211 17 06 16 01 03 21 01 06 01 04 61 87 36 44 04 07 60 16 06 14 07 43 2723 2702 02 20 04 15 18 20 22 143 1091 15 197 234 1294 119 115 05 16 79 516 09 05 20 04 09 33 02 16 02 02 135 106 02 44 40 05 07 86 22 07 31 05 73 4592 4559 05 09 44 60 35 27 50 18 18 10 45 33 22 60 110 90 100 42 36 80 54 17 29 27 50 18 17 24 57 65 81 50 09 10 18 17 216 420 623 587 853 1782 2601 3509 4338 4365 22 48 70 90 100 299 530 723 831 1405 370 554 798 922 1154 1696 2101 2383 3163 3261 218 337 578 904 1037 198 337 518 560 970 09 03 05 18 17 33 12 40 72 17 150 241 374 380 435 1060 1907 3295 4672 5468 29 24 40 72 84 11 27 25 18 33 26 51 40 36 84 11 03 05 27 15 24 25 27 17 55 89 140 181 234 04 10 09 17 95 212 449 840 1421 02 06 05 09 11 06 10 18 17 09 15 33 242 355 643 994 1154 172 313 304 425 318 03 10 27 57 66 70 172 100 64 66 65 54 84 04 03 15 27 17 11 06 10 17 119 185 160 262 334 29 69 65 99 84 07 12 25 09 68 60 75 99 100 03 05 09 17 03 11 15 35 72 84 117 203 354 587 552 7397 11157 15876 20958 24164 7342 11067 15736 20777 23930 41 201 41 165 201 41 247 535 603 5146 4118 288 1688 1306 1112 603 2841 2210 1029 1406 618 904 247 301 6134 3515 41 100 82 100 41 41 100 165 402 124 100 1647 1306 82 1482 904 247 201 165 402 165 82 41 100 82 100 741 904 25400 20088 25236 19687 00 04 02 04 04 04 04 01 28 228 04 46 49 202 31 27 01 03 17 153 04 04 05 01 00 02 09 01 21 02 01 00 35 24 01 12 10 02 01 19 04 06 11 00 00 03 20 1009 1000 152025303540455055606570758085+ CRUDE RATE 00 09 05 10 09 08 09 01 65 527 09 107 114 467 72 62 02 06 40 355 10 10 13 02 00 04 20 02 48 05 02 01 81 57 01 28 23 04 03 44 10 13 25 01 00 06 46 2336 2317 (%) *CH V8 -47.5 -72 13.6 -26 50 20 6.5 -10.0 -59 -53 16.5 31 65 -49 -13 -06 -16.0 -10.9 -50 -30 03 -55 -14 -14.9 -50.5 7.1 -77 -3.1 10 1.3 -9.4 -9.0 02 -33 -13.3 -20 100 12.4 1.5 27 52 111 46 15.4 -31.1 92 -12.0 -2.9 -2.9 MV ASR (%) (W) 1000 0.0 928 1.0 922 0.5 898 1.3 890 0.9 962 0.8 877 1.0 583 0.1 824 8.1 888 59.9 871 1.1 844 12.7 913 13.0 199 49.8 462 9.3 341 7.7 739 0.3 915 0.7 838 4.9 706 46.2 792 1.1 772 1.1 899 1.3 1000 0.2 1000 0.0 976 0.5 947 2.4 800 0.2 796 7.3 936 0.6 1000 0.2 1000 0.1 883 10.2 812 6.1 769 0.2 598 3.0 930 2.2 439 0.5 1000 0.3 930 4.5 938 1.1 984 1.7 979 2.5 1000 0.1 1000 0.0 564 0.7 00 5.9 677 273.7 675 271.3 ICD (10th) C00 C01-02 C07-08 C03-06 C09-10 C11 C12-13 C14 C15 C16 C17 C18 C19-21 C22 C23-24 C25 C48 C30-31 C32 C33-34 C37-38 C40-41 C47,49 C45 C46 C43 C44 C50 C61 C62 C60 C63 C67 C64-66,68 C69 C70-72 C73 C74-75 C81 C82-85,96 C88,90 C91 C92 C93 C94 C95 O&U ALL ALLb

ALL AGE AGES UNK 0 3 Lip 0 83 Tongue 0 51 Salivary gland 0 98 Mouth 0 82 Oropharynx 0 80 Nasopharynx 0 81 Hypopharynx 0 12 Pharynx unspecified 0 620 Oesophagus 0 5009 Stomach 0 85 Small intestine 0 1014 Colon 0 1087 Rectum 0 4438 Liver 0 682 Gallbladder etc 0 592 Pancreas 0 23 Peritoneum 0 59 Nose, sinuses etc 0 382 Larynx 0 3368 Bronchus, lung 0 96 Other thoracic organs 0 92 Bone 0 119 Connective tissue 0 15 Mesothelioma 0 2 Kaposis sarcoma 0 42 Melanoma of skin 0 187 Other skin 0 15 Breast 0 455 Prostate 0 47 Testis 0 21 Penis 0 9 Other male genital 0 766 Bladder 0 538 Kidney etc 0 13 Eye 0 264 Brain, nervous system 0 215 Thyroid 0 41 Other endocrine 0 31 Hodgkins disease 0 Non-Hodgkin lymphoma 417 0 97 Multiple myeloma 0 128 Lymphoid leukaemia 233 Myeloid leukaemia 0 5 Monocytic leukaemia 0 1 Other leukaemia 0 55 Leukaemia unspecified 0 433 Other and unspecified 0 22186 All sites 0 21999 All sites but skin 0

SITE

0-

5-

02 02 02 02 07 14 23 14 07 18 11 07 40 16 04 05 172 172

01 03 06 04 01 01 21 01 06 01 40 07 96 96

* Average percentage annual change since volume VIII (1993-1997) Significant changes (95% confidence level, Miettinen method, page 869 of Volume VI) are marked in bold Rate 5- is significally different (96 vs 102) Rate 10- is significally different (118 vs 136)

Mon Nov 26 2007

Comparability and quality of data

Table 5.4 Volume CI5 Volume IX (editorial table Table 5.4 CI5 IX (Editorial Table 4) 4)
ELSEWHERE (1998-2002)
Quality indicators MALE
SITE Cases ASR (l-u) ASR v8 MV(%) MV v8(%) DCO(%) M/I(%) UB(%) ICD-10 90.4 > 82.4 > 88.8 > 88.0 > 19.9 < 341 83.8 > 70.6 > 792 97.6 < 796 936 812 883 598 93.0 > 936 927 471 67.5 > 829 763 835 816 279 410 696 653 719 1000 831 955 776 869 559 784 976 920 531 649 24 48 33 27 55 91 47 61 73 24 24 13 30 129 05 35 64 80 46 41.2 < 824 535 374 788 1019 675 874 39.6 < 59.5 < 424 213 355 316 88.3 > 167 54.5 > 70.9 < 514 648 -

Mouth & pharynx Oesophagus Stomach Colon, rectum, anus Liver Pancreas Larynx Lung, trachea, bronchus Pleura & other thoracic Melanoma of skin Prostate Testis Kidney & urinaryNOS Bladder Brain & nervous sytem Thyroid Lymphoma Leukaemia Ill-defined (18%) All sites but skin

490 620 5009 2101 4438 592 382 3368 96 42 455 47 538 766 264 215 545 422 399 21999

58 (48 - 69) 8.1 (6.9 - 9.5) < 599 (463 - 775) 258 (186 - 356) 498 (364 - 682) 77 (68 - 88) 4.9 (4.1 - 5.8) < 462 (385 - 553) 11 (09 - 15) 05 (04 - 07) 73 (58 - 92) 06 (05 - 08) 61 (48 - 78) 102 (88 - 117) 30 (25 - 34) 2.2 (1.8 - 2.8) > 59 (46 - 77) 5.1 (4.6 - 5.6) > 5.3 (3.8 - 7.4) < 271.3 (258.7 - 284.6) <

60 100 725 219 594 79 58 513 11 04 71 06 69 101 32 16 53 40 86 3008

C00-14 C15 C16 C18-21 C22 C25 C32 C33-34 C37-38 C43 C61 C62 C64-66,68 C67 C70-72 C73 C81-85,90,88,96 C91-95 C76-80 ALLb

FEMALE
SITE Cases ASR (l-u) ASR v8 MV(%) MV v8(%) DCO(%) M/I(%) UB(%) ICD-10 848 640 85.5 > 84.4 > 19.7 < 294 72.4 > 59.2 > 820 100.0 < 95.6 > 93.4 > 85.4 > 876 754 744 523 95.0 > 943 949 477 75.7 > 827 644 796 800 237 300 333 497 692 1000 892 890 538 826 731 763 509 852 973 945 517 704 66 160 55 39 76 78 172 90 20 13 13 116 16 27 62 151 08 33 38 107 47 365 813 587 431 742 981 862 881 38.0 < 42.1 < 210 225 657 460 394 449 83.0 > 74 46.5 > 64.6 < 515 499 -

Mouth & pharynx Oesophagus Stomach Colon, rectum, anus Liver Pancreas Larynx Lung, trachea, bronchus Pleura & other thoracic Melanoma of skin Breast Cervix Corpus & uterus NOS Ovary Kidney & urinaryNOS Bladder Brain & nervous sytem Thyroid Lymphoma Leukaemia Ill-defined (22%) All sites but skin

197 75 2617 1665 1582 411 58 1303 50 38 2540 1812 335 565 264 176 218 989 424 316 375 17248

18 (14 - 23) 0.7 (0.6 - 0.9) < 23.9 (19.8 - 28.8) < 154 (134 - 177) 149 (120 - 186) 38 (30 - 49) 06 (04 - 07) 122 (105 - 141) 0.5 (0.3 - 0.6) > 03 (03 - 04) 21.2 (20.1 - 22.4) > 15.3 (13.0 - 17.9) < 30 (26 - 33) 51 (44 - 59) 26 (20 - 34) 17 (14 - 21) 2.1 (1.8 - 2.6) < 8.5 (7.0 - 10.4) > 41 (34 - 50) 3.3 (2.9 - 3.8) > 35 (24 - 51) 156.4 (148.1 - 165.2) <

19 12 304 144 171 45 07 124 03 03 186 211 30 48 21 20 30 61 39 23 45 1668

C00-14 C15 C16 C18-21 C22 C25 C32 C33-34 C37-38 C43 C50 C53 C54-55 C56 C64-66,68 C67 C70-72 C73 C81-85,90,88,96 C91-95 C76-80 ALLb

Data compared to: ELSEWHERE (1993-1997) (Published in CI5 Volume VIII)

77
Mon Nov 26 2007

Comparability and quality of data

Table 5.4a CI5 Volume IX (editorial table 4)

Group A (1998-2002)
CI5 volume 9 (Editorial sheet 4) Quality indicators MALE
SITE Cases ASR (l-u) ASR v8 MV(%) MV v8(%) DCO(%) M/I(%) UB(%) ICD-10 991 963 965 961 83.5 < 609 99.4 > 87.4 < 763 99.7 < 92.1 < 996 86.1 < 979 85.0 > 984 97.5 > 93.3 > 60.7 < 91.7 > 989 940 963 964 890 642 975 903 758 1000 952 995 890 984 752 987 841 601 661 913 07 03 04 21 17 10 32 00 10 10 02 04 04 05 49 35 09 407 887 814 50.1 < 781 963 324 886 92.5 > 281 36.8 < 43 513 320 77.7 > 263 54.9 < 43.0 < 1002 52.3 < 00 01 00 00 00 01 01 00

Mouth & pharynx Oesophagus Stomach Colon, rectum, anus Liver Pancreas Larynx Lung, trachea, bronchus Pleura & other thoracic Melanoma of skin Prostate Testis Kidney & urinaryNOS Bladder Brain & nervous sytem Thyroid Lymphoma Leukaemia Ill-defined (26%) All sites but skin

1252 600 1825 7808 388 1403 534 6516 93 2305 14669 1171 1652 3889 955 247 2964 1817 1412 53499

76 (58 - 99) 33 (30 - 36) 9.1 (8.0 - 10.4) < 407 (379 - 438) 21 (16 - 26) 73 (60 - 90) 30 (25 - 36) 355 (252 - 499) 06 (04 - 08) 142 (111 - 181) 76.0 (61.2 - 94.3) > 9.6 (8.5 - 10.8) > 95 (74 - 121) 196 (159 - 241) 6.7 (5.9 - 7.5) < 16 (13 - 20) 178 (157 - 202) 11.0 (10.0 - 12.1) > 6.8 (5.3 - 8.6) < 2938 (2821 - 3059)

82 33 116 396 17 75 33 364 05 143 609 82 103 213 78 15 163 81 91 2825

C00-14 C15 C16 C18-21 C22 C25 C32 C33-34 C37-38 C43 C61 C62 C64-66,68 C67 C70-72 C73 C81-85,90,88,96 C91-95 C76-80 ALLb

FEMALE
SITE Cases ASR (l-u) ASR v8 MV(%) MV v8(%) DCO(%) M/I(%) UB(%) ICD-10 989 956 941 945 772 50.0 < 958 87.1 < 610 99.8 < 984 996 985 940 79.0 < 956 77.3 > 985 96.1 > 95.5 > 57.1 < 92.0 > 987 930 937 942 750 589 990 896 759 1000 985 993 980 950 861 960 691 980 831 543 646 910 04 07 05 24 27 09 73 03 02 07 12 06 10 02 07 25 65 08 411 841 852 49.7 < 892 976 417 830 976 163 29.4 < 356 23.1 < 678 564 417 76.1 > 193 54.7 < 52.0 < 1007 49.1 < 00 02 01 02 00

Mouth & pharynx Oesophagus Stomach Colon, rectum, anus Liver Pancreas Larynx Lung, trachea, bronchus Pleura & other thoracic Melanoma of skin Breast Cervix Corpus & Uterus NOS Ovary Kidney & urinaryNOS Bladder Brain & nervous sytem Thyroid Lymphoma Leukaemia Ill-defined (36%) All sites but skin

655 252 1192 8066 250 1633 96 3761 41 2472 12521 1524 2813 2343 1078 1341 736 649 2670 1278 1757 49387

32 (26 - 40) 1.0 (0.9 - 1.2) > 4.4 (3.7 - 5.3) < 327 (267 - 401) 11 (08 - 15) 58 (48 - 71) 0.5 (0.4 - 0.6) < 192 (151 - 244) 02 (01 - 02) 146 (111 - 191) 71.0 (65.2 - 77.3) > 10.0 (8.3 - 12.1) < 144 (130 - 159) 128 (101 - 162) 48 (37 - 63) 54 (39 - 75) 4.8 (4.2 - 5.4) < 42 (39 - 46) 129 (110 - 153) 6.7 (5.9 - 7.5) > 58 (40 - 84) 2464 (2356 - 2576)

32 08 55 327 09 58 06 166 02 161 632 122 138 132 55 55 65 43 110 54 77 2413

C00-14 C15 C16 C18-21 C22 C25 C32 C33-34 C37-38 C43 C50 C53 C54-55 C56 C64-66,68 C67 C70-72 C73 C81-85,90,88,96 C91-95 C76-80 ALLb

Data compared to: Group A (1993-1997) (Published in CI5 Vol8)

78

Comparability and quality of data

Table 5.4b CI5 Volume IX (editorial table 4)

Group B (1998-2002)
CI5 volume 9 (Editorial sheet 4) Quality indicators MALE
SITE Cases ASR (l-u) ASR v8 MV(%) MV v8(%) DCO(%) M/I(%) UB(%) ICD-10 85.5 > 78.1 > 79.5 > 81.8 > 94.7 < 360 81.5 > 66.9 > 547 996 83.8 > 76.5 < 74.1 > 858 584 85.9 < 994 991 442 79.0 > 811 685 711 768 1000 352 730 597 400 998 776 852 654 840 612 911 998 997 436 735 49 93 84 62 12 270 68 138 216 53 20 91 47 149 12 222 76 35.3 > 65.1 > 55.1 > 37.9 > 209.9 < 927 473 72.8 > 743 200 20.4 < 134 337 26.6 > 61.5 > 78 358 51.0 > 401 416 -

Mouth & pharynx Oesophagus Stomach Colon, rectum, anus Liver Pancreas Larynx Lung, trachea, bronchus Pleura & other thoracic Melanoma of skin Prostate Testis Kidney & urinaryNOS Bladder Brain & nervous sytem Thyroid Lymphoma Leukaemia Ill-defined (50%) All sites but skin

5006 2406 5895 6570 585 1315 2542 6525 148 1392 16155 740 1469 3309 1796 861 3887 2029 3541 70229

23.9 (21.0 - 27.2) < 12.0 (10.4 - 13.8) < 29.4 (26.7 - 32.4) < 328 (273 - 393) 2.9 (2.2 - 3.8) > 66 (57 - 75) 12.8 (11.4 - 14.4) < 33.5 (31.0 - 36.2) < 07 (05 - 09) 6.5 (5.8 - 7.3) > 84.8 (71.4 - 100.7) > 2.7 (2.3 - 3.0) > 72 (62 - 83) 168 (130 - 218) 80 (76 - 85) 3.6 (3.4 - 3.9) > 178 (169 - 188) 9.1 (8.7 - 9.6) < 17.3 (15.3 - 19.5) < 346.6 (339.6 - 353.8) <

283 150 398 342 19 68 176 440 05 53 666 23 66 206 80 31 181 102 225 3733

C00-14 C15 C16 C18-21 C22 C25 C32 C33-34 C37-38 C43 C61 C62 C64-66,68 C67 C70-72 C73 C81-85,90,88,96 C91-95 C76-80 ALLb

FEMALE
SITE Cases ASR (l-u) ASR v8 MV(%) MV v8(%) DCO(%) M/I(%) UB(%) ICD-10 795 75.0 > 77.9 > 81.0 > 91.3 < 382 745 66.6 > 63.0 > 100.0 < 82.2 > 856 762 74.4 > 74.3 > 791 53.6 < 86.3 < 996 99.4 < 448 78.5 > 793 684 691 739 1000 335 717 598 387 1000 788 842 765 690 662 747 612 919 996 1000 457 752 55 106 96 70 40 289 49 142 136 46 41 83 91 86 62 161 07 214 71 221 548 502 368 2800 927 286 65.5 > 591 172 228 24.9 > 40.1 > 383 330 273 59.3 > 33 366 529 404 345 -

Mouth & pharynx Oesophagus Stomach Colon, rectum, anus Liver Pancreas Larynx Lung, trachea, bronchus Pleura & other thoracic Melanoma of skin Breast Cervix Corpus & Uterus NOS Ovary Kidney & urinaryNOS Bladder Brain & nervous sytem Thyroid Lymphoma Leukaemia Ill-defined (47%) All sites but skin

1682 621 3600 7518 300 1449 486 3247 154 1687 22598 6028 2940 3197 925 1299 1716 4399 3656 1739 3662 77358

5.9 (4.8 - 7.3) < 2.2 (1.9 - 2.6) < 12.4 (11.0 - 13.9) < 263 (219 - 315) 11 (08 - 16) 50 (44 - 57) 18 (14 - 23) 11.7 (10.8 - 12.6) < 0.6 (0.4 - 0.8) > 57 (44 - 75) 808 (741 - 881) 21.1 (20.2 - 22.0) < 10.7 (8.6 - 13.3) < 116 (99 - 135) 34 (30 - 40) 45 (31 - 64) 63 (59 - 67) 14.9 (12.4 - 17.8) > 130 (121 - 139) 6.4 (6.0 - 6.8) < 12.7 (11.2 - 14.4) < 273.8 (267.9 - 279.8) <

74 30 156 270 09 55 20 131 03 46 876 263 154 120 34 46 67 107 130 74 166 3022

C00-14 C15 C16 C18-21 C22 C25 C32 C33-34 C37-38 C43 C50 C53 C54-55 C56 C64-66,68 C67 C70-72 C73 C81-85,90,88,96 C91-95 C76-80 ALLb

Data compared to: Group B (1993,1997) (Submitted for CI5 Vol8 - Not published)

79
Mon Nov 26 16:51:38 CET 2007

Comparability and quality of data

Table 5.4c CI5 Volume IX (editorial table 4)

Group C, Example 1 (1998-2002)
CI5 volume 9 (Editorial sheet 4) Quality indicators MALE
SITE Cases 93 125 59 75 100 12 14 46 1 9 262 7 23 29 10 11 198 33 90 2173 ASR (l-u) ASR v8 MV(%) MV v8(%) DCO(%) M/I(%) UB(%) ICD-10 65.6 < 56.0 > 424 587 400 167 571 652 100.0 < 100.0 > 57.6 < 714 783 517 500 54.5 < 818 100.0 > 556 67.1 < 805 396 509 588 365 250 900 606 1000 909 772 500 727 529 636 1000 814 783 688 742 -

Mouth & pharynx Oesophagus Stomach Colon, rectum, anus Liver Pancreas Larynx Lung, trachea, bronchus Pleura & other thoracic Melanoma of skin Prostate Testis Kidney & urinaryNOS Bladder Brain & nervous sytem Thyroid Lymphoma Leukaemia Ill-defined (41%) All sites but skin

64 (49 - 83) 141 (116 - 171) 62 (41 - 94) 75 (59 - 96) 87 (57 - 133) 12 (09 - 16) 14 (11 - 18) 48 (39 - 61) 0.0 (0.0 - 0.0) < 0.9 (0.7 - 1.1) < 376 (302 - 468) 06 (05 - 08) 08 (06 - 12) 30 (22 - 41) 06 (04 - 10) 05 (04 - 07) 8.4 (7.1 - 9.9) > 1.3 (0.9 - 1.9) > 69 (50 - 96) 1536 (1453 - 1624)

60 132 70 77 65 10 13 39 03 13 371 05 12 29 08 06 71 09 91 1581

C00-14 C15 C16 C18-21 C22 C25 C32 C33-34 C37-38 C43 C61 C62 C64-66,68 C67 C70-72 C73 C81-85,90,88,96 C91-95 C76-80 ALLb

FEMALE
SITE Cases 61 78 64 89 73 6 6 40 3 16 332 649 57 114 17 17 14 26 156 29 92 2777 ASR (l-u) ASR v8 MV(%) MV v8(%) DCO(%) M/I(%) UB(%) ICD-10 689 474 453 640 288 167 667 700 667 938 684 592 719 491 706 647 35.7 < 923 788 100.0 > 50.0 < 65.9 < 721 418 447 672 390 222 875 652 600 615 634 639 833 547 727 250 1000 809 799 625 675 690 03 00

Mouth & pharynx Oesophagus Stomach Colon, rectum, anus Liver Pancreas Larynx Lung, trachea, bronchus Pleura & other thoracic Melanoma of skin Breast Cervix Corpus & Uterus NOS Ovary Kidney & urinaryNOS Bladder Brain & nervous sytem Thyroid Lymphoma Leukaemia Ill-defined (33%) All sites but skin

33 (22 - 49) 8.4 (6.4 - 11.1) < 69 (51 - 93) 81 (63 - 105) 58 (47 - 72) 0.4 (0.3 - 0.5) < 0.3 (0.2 - 0.5) < 3.8 (2.9 - 5.0) > 0.2 (0.2 - 0.3) < 1.4 (1.1 - 1.8) < 23.4 (20.8 - 26.4) > 45.8 (42.8 - 49.1) > 54 (45 - 66) 81 (58 - 114) 0.4 (0.3 - 0.5) < 1.8 (1.4 - 2.3) > 0.7 (0.5 - 1.0) > 1.5 (1.2 - 1.9) < 64 (53 - 78) 14 (09 - 21) 79 (54 - 115) 1714 (1618 - 1815)

47 122 55 73 60 11 11 23 05 20 207 417 54 63 15 12 04 46 61 16 68 1699

C00-14 C15 C16 C18-21 C22 C25 C32 C33-34 C37-38 C43 C50 C53 C54-55 C56 C64-66,68 C67 C70-72 C73 C81-85,90,88,96 C91-95 C76-80 ALLb

Data compared to: Group C, Example 1 (1993-1997) (Published in CI5 Vol8) No mortality data to compare to

80
Mon May 14 11:04:27 CEST 2007

Comparability and quality of data

Table 5.4c (contd). CI5 Volume IX (editorial table 4)

Group C, Example 2 (1998-2002)
CI5 volume 9 (Editorial sheet 4) Quality indicators MALE
SITE Cases 83 254 431 272 440 91 14 600 7 2 16 8 24 73 46 11 48 52 17 2586 ASR (l-u) ASR v8 MV(%) MV v8(%) DCO(%) M/I(%) UB(%) ICD-10 964 77.2 < 90.7 < 967 20.0 > 308 100.0 < 32.5 > 286 100.0 < 562 100.0 < 625 973 543 72.7 < 100.0 < 100.0 < 88.2 > 613 984 898 970 988 103 190 1000 256 250 1000 688 1000 700 923 458 1000 1000 1000 613 12 05 04 05 05 118 05 -

Mouth & pharynx Oesophagus Stomach Colon, rectum, anus Liver Pancreas Larynx Lung, trachea, bronchus Pleura & other thoracic Melanoma of skin Prostate Testis Kidney & urinaryNOS Bladder Brain & nervous sytem Thyroid Lymphoma Leukaemia Ill-defined (07%) All sites but skin

64 (56 - 73) 202 (169 - 242) 32.1 (29.2 - 35.2) < 209 (169 - 257) 338 (261 - 437) 71 (56 - 90) 11 (09 - 13) 467 (422 - 517) 0.6 (0.5 - 0.7) < 0.1 (0.1 - 0.2) < 1.4 (1.3 - 1.5) < 0.7 (0.6 - 0.8) > 1.8 (1.5 - 2.2) > 59 (48 - 72) 40 (29 - 56) 1.0 (0.7 - 1.4) > 43 (29 - 64) 58 (39 - 86) 1.3 (1.1 - 1.6) > 2027 (1567 - 2621)

56 207 389 218 367 60 10 441 07 04 19 04 10 61 47 06 43 54 03 2097

C00-14 C15 C16 C18-21 C22 C25 C32 C33-34 C37-38 C43 C61 C62 C64-66,68 C67 C70-72 C73 C81-85,90,88,96 C91-95 C76-80 ALLb

FEMALE
SITE Cases 33 70 156 242 174 82 2 182 5 4 199 33 17 47 11 15 45 20 23 41 11 1507 ASR (l-u) ASR v8 MV(%) MV v8(%) DCO(%) M/I(%) UB(%) ICD-10 93.9 < 843 81.4 < 971 16.7 > 256 100.0 < 32.4 > 60.0 > 100.0 < 995 100.0 < 882 100.0 > 727 867 511 95.0 < 100.0 < 100.0 < 81.8 > 711 1000 909 947 990 48 220 1000 212 1000 981 1000 812 889 500 875 615 1000 1000 1000 704 29 06 06 05 22 91 05 -

Mouth & pharynx Oesophagus Stomach Colon, rectum, anus Liver Pancreas Larynx Lung, trachea, bronchus Pleura & other thoracic Melanoma of skin Breast Cervix Corpus & Uterus NOS Ovary Kidney & urinaryNOS Bladder Brain & nervous sytem Thyroid Lymphoma Leukaemia Ill-defined (07%) All sites but skin

23 48 10.6 178 126 5.4 0.2 13.0 0.4 0.3 14.7 2.4 1.2 3.7 0.8 1.0 3.6 15 25 4.5 0.8 1109

(18 - 29) (37 - 62) (9.0 - 12.5) < (138 - 230) (103 - 155) (4.5 - 6.5) > (0.1 - 0.2) > (11.7 - 14.4) > (0.3 - 0.4) > (0.2 - 0.3) < (13.3 - 16.3) > (2.0 - 2.9) > (1.1 - 1.4) < (2.9 - 4.8) > (0.7 - 1.0) > (0.8 - 1.3) > (2.6 - 5.1) > (11 - 19) (18 - 33) (3.2 - 6.4) > (0.7 - 0.9) > (907 - 1356)

22 53 157 179 145 34 01 110 01 03 91 12 29 23 06 07 24 12 19 30 01 1037

C00-14 C15 C16 C18-21 C22 C25 C32 C33-34 C37-38 C43 C50 C53 C54-55 C56 C64-66,68 C67 C70-72 C73 C81-85,90,88,96 C91-95 C76-80 ALLb

Data compared to: Group C, Example 2 (1993-1997) (Published in CI5 Vol8)

81
Wed Oct 17 14:27:31 CEST 2007

Comparability and quality of data

Figure 5.3 Population pyramids Figure 5.3 CI5 Volume IX (Editorial Table 5)

ELSEWHERE (1998-2002)
Population Pyramids

1991 4858 11960 22130 40124 67116 90928 109406 140564 173728 166700 161440 174945 180112 173127 132279 134001 113899 1899314 Vol 8: 1928923 (V9/V8: 98%)

50%

85+ 80757065605550454035302520151050MALE FEMALE Population data provided for 5 year(s)

50%

8331 13150 25783 40346 54648 74145 91724 108644 140952 179626 170615 160355 168065 170870 161110 118404 114291 100458 1901520 Vol 8: 1930295 (V9/V8: 98%)

82
Mon Nov 26 2007

Comparability and quality of data

Figure 5.4 CI5 Volume IX ProcessSummary Figure 5.4 CI5 Volume IX Data Data Process-Summary Registry number: 441099 Registry name: Elsewhere Cancer Registry Date: 20/03/2007 Files submitted: Case listing Population Mortality No

Data originally re-coded/coded according to ICDO-3. yes Data originally coded according to: Topography:.ICD9 ICD10 T-ICDO-2 M-ICDO-2 IARC by registry & confirmed by IARC Data-check list

Other Other

Morphology: M-ICDO-1 Re-code performed by:registry or

Validity of single records checked (IARCcrgTools)

Date:

Multiple Primaries ICDO-3 (2004) by IARC-DEP (IARCcrgTools) on historical data .. ICDO-3 (2004) by IARC-DEP (IARCcrgTools) only on the CI5 IX period .. Years .. Remarks 1998-2002

DATA VALIDATED

yes

No

83

Comparability and quality of data

Table 5.5 Multiple primary rules for the years 19982002 Continents (No. of registries) Africa (5) South and Central America (11) North America (54) Asia (44) Europe (100) Oceania (11) Total (225) ICD-O-1 1 0 0 1 4 0 6 (2.7%) ICD-O-2 1 5 14 28 6 55 (24.4%) 1 ICD-O-3 2000 2 2 2 12 2 26 (11.6%) 6 ICD-O-2 + ICD-O-3 2000 0 1 29 7 8 1 46 (20.4%) ICD-O-3 2004 0 3 4 25 0 39 (17.3%) 7 Others 1 0 13 22 2 42 (18.7%) 4 N/A 0 0 5 5 1 0 11 (4.9%)

Table 5.6 Screening program as data source Continents (No. of registries) Cervix Africa (5) South and Central America (11) North America (54) Asia (44) Europe (100) Oceania (11) Total (225) 3 10 35 18 45 7 Breast Prostate 1 5 36 16 59 7 0 2 4 1 5 1 Cases with Distinguish Necropsy DCN Colorectal 0 1 4 13 14 1 Melanoma 0 1 1 0 7 1 Lung 0 0 0 5 2 1 8 (3.6%) Mouth 0 0 1 3 1 1 6 (2.7%) Others 0 0 0 12 1 1 14 (6.2%) Yes 3 5 51 21 86 9 175 (77.8%) Yes 2 6 20 31 53 4 116 (51.6%)

118 124 13 33 10 (52.4%) (55.1%) (5.8%) (14.7%) (4.4%)

Table 5.8 Summary of applied inclusion criteria for comparability and quality of data in Volume IX Group A Complete coverage Death reporting meets WHO recommendations %Unk <10% DCO <10% Ill-defined site <10% MV% >80% DCO 0.0% (no DCOs)* No abrupt trends, cases; Denominators OK Group B No access to death certificates Official mortality data not available by cause, or poor quality by cause 10% < %Unk <20% 10% < DCO <20% 10% < ill defined <20% 10% < age unk <20% 75% < MV% <80% MV% but C22** MV% but C91-95*** Group C No ad hoc study of completeness No death clearance as source of case finding Excluded Data with <2 years DCO >20% %Unk >20% ill-defined site >20%; overall MV% <75% MV% too high (99100%) MV% low for selected sites; M/I threshold by site Implausible incidence rates; Specialized registries, e.g. childhood, mesothelioma

No official mortality data

*No DCO cases due to complete trace back for the DCN cases; **C22: liver cancer; ***C91-95: leukaemia.

84

MP rules Cervix Yes Yes Yes No Yes No No No No No NA Yes No No No No No No No Yes NK NK No No No No No No No No Yes <1 No No No No No No No No No No No No No No No No No No Breast Prostate Colorectal Mouth Others Necropsy DCN Yes No Melanoma Lung Necropsy (%) DCN%

Table 5.7 Registration practices Screening programme as data source Cases with Distinguish

Registry

1998-2002

Africa

Algeria, Setif

Egypt, Gharbiah

ICDO-1

Tunisia, Central Region

Uganda, Kyadondo County

Zimbabwe, Harare

ICDO-3 (2000)

ICDO-2

Other

5.5 Yes -

ICDO-3 (2000)

10

South and Central America Yes Yes No No No No Yes No No No No No No No No Yes No No No No No No No No No No No No No No No No No No No No No No No No No No No Yes Yes Yes Yes No No No No No No No Yes No Yes No No No No No No No Yes Yes No No No No No

Argentina, Bahia Blanca

Brazil, Brasilia Yes Yes Yes Yes

ICDO-3 (2004)

Brazil, Cuiaba

ICDO-2

Yes

ICDO-2

Yes No No Yes Yes

12 NK 0.6

Yes No Yes Yes No

No

60 4.23 9.6 -

Brazil, Goinia

Brazil, So Paulo

ICDO-2 and ICDO-3 (2000)

Chile, Valdivia Yes

Colombia, Cali No

ICDO-3 (2004)

ICDO-2

Costa Rica Yes Yes

ICDO-3 (2004)

Ecuador, Quito

ICDO-3 (2000)

No No

France, Martinique

ICDO-2

No No No No No No

Yes No No No

No

0.42 No 2

NK

Yes Yes NA Yes

No

1.75 NA 8.2

Peru, Trujillo

ICDO-3 (2000)

ICDO-2

86.3

North America No No Yes Yes No Yes Yes Yes No Yes Yes Yes No No No Yes No Yes No No No No No No No No No No

Canada

ICDO-3 (2004)

No No No No No No No

No No No No No No No

No No No No No No No

No No No No No No No

Yes Yes No Yes Yes No Yes

NK 0.3 0.69 NK

No Yes No NA No No Yes

0.3 NA NK

Canada, Alberta

Canada, British Columbia

ICDO-2 and ICDO-3 (2000)

Other

Canada, Manitoba

Canada, New Brunswick

ICDO-2 and ICDO-3 (2000)

SEER rules

Comparability and quality of data

Canada, Newfoundland and Labrador

ICDO-2 and ICDO-3 (2000)

Canada, Northwest Territories

ICDO-2 and ICDO-3 (2004)

85

86
Table 5.7 Registration practices Screening programme as data source Lung No No NA No No No No NA No No No No No No No No No No No No No No No No No No No No No Yes No No No No No No No No No No No No No NA No No No No No No No No No NA NA No No No No No No No No No No No No No No No No No No No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No No Yes No NA NA Yes 2.4 NK 2.6 0.1 0.21 NK NK <1 NK <0.5 NK NK NK NK NK NK 0.1 0.2 <3 No No Yes NK No No Yes <5 No No No No Yes <1 No Mouth Others Necropsy Necropsy (%) DCN Cases with Distinguish DCN% Yes No Yes NA No NA No No Yes Yes No No Yes No No Yes No No No Cervix Yes No Yes Yes Yes No Yes NA No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No No No No No No No Yes No No No Yes Yes Yes Yes Yes Yes No No Yes Yes No No Yes No No No Yes No No No No No No No NA NA NA NA Yes No No No No No No No Yes No No No Yes No No No No Yes NA NA NA No No No No No No No No Yes Yes No No Breast Prostate Colorectal Melanoma 2.78

MP rules

Registry

1998-2002

Canada, Nova Scotia

Canada, Ontario

ICDO-2 and ICDO-3 (2000)

Canada, Prince Edward Island

ICDO-3 (2004)

Canada, Saskatchewan

ICDO-3 (2004)

Other

Comparability and quality of data

USA, Alabama

ICDO-2 and ICDO-3 (2000)

2.06 (2002) 1 NA NA 1 <1 2.7 5.22 1.2 -

USA, Alaska

USA, Arizona

ICDO-2 and ICDO-3 (2000)

SEER rules

USA, California

ICDO-2 and ICDO-3 (2000)

USA, California, Greater San Francisco Bay Area

NA

USA, California, Los Angeles County

ICDO-2, ICDO-3 (2000) and SEER rules

USA, Colorado

ICDO-2 and ICDO3(2000)

USA, Connecticut

USA, District of Columbia

ICDO-2, ICDO-3 (2000) and SEER rules

USA, Florida

ICDO-3 (2000)

NA

USA, Georgia

USA, Georgia, Atlanta

ICDO-2 and ICDO-3 (2000)

ICDO-3 (2004)

USA, Idaho

USA, Illinois

ICDO-2 and ICDO-3 (2000)

SEER rules

USA, Indiana

USA, Iowa

ICDO-2 and ICDO-3 (2000)

USA, Kentucky

SEER rules

SEER rules

USA, Louisiana

ICDO-2 and ICDO-3 (2000)

MP rules Cervix No No Yes Yes No Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes No No Yes No No NA No No Yes No No No NA No No No No No No No No No No NA No No No No Yes No No No No No No No No No NA No Yes No No No No No No No No No Yes No No No No No No No NA Yes No No No No No Yes No No No No No No No No No No No No No No No No No NA Yes No No No No No No Yes No No No No No No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No No No No No No No Yes Yes No No No No No No Yes <5 NK <1 0.1 34 2 3 0.001 1.3 0.1 NK 0.1 NK NK NK NK 0.2 Yes Yes No No No No No Yes 0.15 No No No No No No No Yes 0.04 No Yes Yes Yes Yes Yes Yes No No No Yes No No Yes No No No No Yes No No No No No No No Yes 0.2 No 3 7 NA NK 5 1.3 1.7 1-2 1 Breast Prostate Colorectal Mouth Others Necropsy DCN Melanoma Lung Necropsy (%) DCN%

Table 5.7 Registration practices Screening programme as data source Cases with Distinguish

Registry

1998-2002

USA, Louisiana, New Orleans

ICDO-2 and ICDO-3 (2000)

USA, Maine

USA, Massachusetts

ICDO-2 and ICDO-3 (2000)

USA, Michigan

SEER rules

SEER rules

USA, Michigan, Detroit

ICDO-2 and ICDO-3 (2000)

USA, Missouri

ICDO-2 and ICDO-3 (2000)

USA, Montana

ICDO-2 and ICDO-3 (2000)

USA, New Jersey

USA, New Mexico

ICDO-2 and ICDO-3 (2000)

USA, New York State Yes Yes Yes Yes Yes Yes Yes No No Yes

USA, NPCR

SEER rules

NA

USA, Ohio

NA

USA, Oklahoma

ICDO-2 and ICDO-3 (2000)

USA, Oregon

USA, Pennsylvania

ICDO-2 and ICDO-3 (2000)

SEER rules

USA, Rhode Island

ICDO-2 and ICDO-3 (2000)

USA, SEER

ICDO-2, ICDO-3 (2000) and SEER rules

USA, South Carolina

ICDO-2, ICDO-3 (2000) and SEER rules

USA, Texas

USA, Utah

ICDO-2, ICDO-3 (2000) and SEER rules

SEER rules

Comparability and quality of data

USA, Vermont

ICDO-2 and ICDO-3 (2000)

87

88
Table 5.7 Registration practices Screening programme as data source Lung No No NA No No No Yes 3 NA NA Yes NK No No Yes NK Yes Yes No No No Yes <0.5 Yes Mouth Others Necropsy Necropsy (%) DCN Cases with Distinguish DCN% 1-2 <1 7 Cervix Yes No Yes No No No No No Yes NA NA NA No No No No Yes No Yes No Breast Prostate Colorectal Melanoma

MP rules

Registry

1998-2002

USA, Washington

ICDO-2 and ICDO-3 (2000)

USA, Washington, Seattle

USA, West Virginia

ICDO-2 and ICDO-3 (2000)

USA, Wisconsin

ICDO-3 (2000)

ICDO-2

Comparability and quality of data

Asia Yes No No No No No Yes No Yes No No No No NA NA No No NA NA No No No No No No No No No NA NA Yes No No No No No NA NA NA No No No No NA NA No No No No No No NA No No No No NA NA No No No No No No No No No No No No No No Yes No No No No Yes NA No No No No No No No No No No No No No No No No Yes No Yes No No No No NA NA No No No Yes No No No No No No Nasopharynx No No Other No No No No NA Stomach No No No No No No No No No No No No No No No No No No No Yes No No No No No No No No

Bahrain

China, Guangzhou

ICDO-3 (2004)

China, Hong Kong

ICDO-2

China, Jiashan

China, Nangang District, Harbin City

ICDO-3 (2000)

NA

Yes

NK Yes No No Yes No No No No No No No Yes Yes No No <0.01 NK <0.01 <1 Yes NK

Yes

Yes Yes Yes Yes Yes NA Yes Yes Yes Yes Yes Yes Yes Yes No

15-25 9.3 -

China, Shanghai

ICDO-2

Other

1.94 10 0.08 NA 5.1 NA 52 30 NA 42 2.9 Yes NK NA No 3

0.5

China, Zhongshan

ICDO-2

Cyprus

ICDO-2 and ICDO-3 (2000)

India, Chennai (Madras)

India, Karunagappally

ICMR National Cancer Registry

NA

India, Mumbai (Bombay)

ICDO-2 and ICDO-3 (2000)

India, Nagpur

India, New Delhi

ICDO-2 and ICDO-3 (2000)

ICDO-1

India, Poona

India, Trivandrum

ICDO-2 and ICDO-3 (2000)

Israel No

Japan, Aichi Prefecture No

ICDO-3 (2000)

ICDO-2

Japan, Fukui Prefecture

ICDO-2

Japan, Hiroshima

Other

NA

NA 1.7 -

MP rules Cervix Yes Yes No No Yes Yes Yes No No No No No No Yes No No No No No No No No No No No No No No No Yes No No No No No NA Yes No NA NA NA No No Yes No No Yes No Yes No No Yes No No No No No No No No No NA No Yes No No No No No Yes No No Stomach, liver No Stomach, liver NA No No No No No No No No No No No No No No No Yes No Yes No Stomach, liver No Yes No No No No Yes No No No No No Yes Yes No Yes No No No No No No No No No Yes No No Yes Yes Yes Yes Yes No No No No No NA No Yes No No No No Yes No Yes No No No No Yes NK NK NK NK 0.028 Yes No No <1 0 No Yes No No No Stomach Yes <1 No No No No No No Yes 5.5 in 2000 Yes Yes Yes Yes Yes No Yes Yes No Yes Yes Yes Yes No No No No No 10 Yes Yes No Yes No No No Yes No Yes No Yes No Stomach Yes NK No No No Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes No No No No No No NA Yes No Yes No Yes No Stomach Yes NK Yes Breast Prostate Colorectal Mouth Others Necropsy DCN 14 35.1 in 2000 22 7.9 12.9 33.1 4.6 5.1 6.4 10.4 Yes Yes 0.01 NK 0 Yes No Yes No Yes NA No No NA 0.1 0.9 5 NA NA 10 Melanoma Lung Necropsy (%) DCN%

Table 5.7 Registration practices Screening programme as data source Cases with Distinguish

Registry

1998-2002

Japan, Miyagi Prefecture

Japan, Nagasaki Prefecture

ICDO-3 (2004)

ICDO-2

Japan, Osaka Prefecture

ICDO-2

Japan, Yamagata Prefecture

Korea

Other and ICDO-3 (2004)

Korea, Busan

ICDO-3 (2000)

Korea, Daegu

ICDO-3 (2000)

ICDO-2

Korea, Daejeon

ICDO-3 (2000)

Korea, Gwangju

ICDO-3 (2004)

Korea, Incheon

ICDO-2 and ICDO-3 (2000)

Korea, Jejudo

ICDO-3 (2004)

Korea, Seoul

ICDO-3 (2004)

Korea, Ulsan

ICDO-3 (2000)

Kuwait

Malaysia, Penang

Malaysia, Sarawak No No Yes Yes Yes No No No No Yes No

Oman, Omani

ICDO-3 (2004)

ICDO-2

NA

Pakistan, South Karachi

Philippines, Manila

ICDO-3 (2004)

ICDO-2

Singapore

Thailand, Chiang Mai

ICDO-2

NA

ICDO-2

Thailand, Lampang

ICDO-2 and ICDO-3 (2000)

Thailand, Songkhla

Comparability and quality of data

Turkey, Antalya

ICDO-2 and ICDO-3 (2000)

Turkey, Izmir

ICDO-2

ICDO-2

89

90
Table 5.7 Registration practices Screening programme as data source Lung Mouth Others Necropsy Necropsy (%) DCN Cases with Distinguish DCN% Cervix Breast Prostate Colorectal Melanoma No Yes Yes NA No Yes No No Yes No Yes Yes No No No Yes No No No No No No No Yes Yes No NA NA NA No No Yes No No No No No No No No No No No Yes No No No No No NA No No No No No No No No No No No No No No No No No No No Yes No No Regional practices No No No No No No No Yes Yes No No No No No NA No No No No No No Yes Yes Yes No Yes NA No No No No No No NA NA NA NA NA NA NA Yes No Yes No No Yes No Yes Yes No No No Yes Yes Yes No Yes Yes Yes No No No No Yes <1 Yes Yes Yes Yes No No No Yes 15 0.2-0.5 0.05 <1 5 21 in 2002 < 12 Yes NK Yes Yes Yes No No No No No No No No No No No Yes NK No Yes Yes No No NA Yes NA No No NA <1 No 4 4 NA 13 NA 6-8 No NA NK NA Yes No Yes No No No NA <1 -

MP rules

Registry

1998-2002

Europe

Austria

ICDO-2

Austria, Tyrol

Comparability and quality of data

Austria, Vorarlberg

ICDO-1 and ICDO-3 (2000)

Belarus

ICDO-2

Other

Belgium, Antwerp

ICDO-2 and ICDO-3 (2000)

Belgium, Flanders

ICDO-2

Bulgaria

ICDO-2

Croatia

ICDO-2, ICDO-3 (2000) and ICDO-3 (2004)

Czech Republic

ICDO-3 (2000)

Denmark

Estonia

ICDO-3 (2004)

Finland

ICDO-2

France, Bas-Rhin No Yes No No Yes No

ICDO-3 (2000)

Other

NA No No No No

France, Calvados

France, Doubs

ICDO-2, ICDO-3 (2000) and ICDO-3 (2004)

France, Haut-Rhin

ICDO-2

ICDO-2

France, Herault

ICDO-2 and ICDO-3 (2000)

France, Isere

ICDO-2, ICDO-3 (2000) and ICDO-3 (2004)

France, Loire-Atlantique

ICDO-2 and ICDO-3 (2000)

MP rules Cervix No No No No No No No No No No No No No No Yes Yes Yes No No Yes No No No NA Yes No No NA No No NA No No NA No No No No No No No No Yes No No No No No No No No No No No No No No No No No No No Yes No No NA No No NA No No No No No No No No No No No No No No No No No No No No No NA No No NA No No No No No No No No No No No No No Yes Yes No Yes Yes Yes Yes Yes No Yes No No No NA No No NA No No No No No Yes Yes Yes Yes No No NA No Yes No No No No No No No No No No Yes No No No No No No No Yes Yes No No No No No No No 2 2 No No No No No No No Yes NK Yes No No No No No No Yes 0.02 Yes No No Yes <1 2 2 <1 NK NK 9 Yes No Yes Yes Yes Yes Yes 0.06 Yes 0.02 Yes Yes Yes Yes Yes No Yes Yes No 0.06 <1 0.1 0.07 0.1 <1 Yes No No No No No No No No Yes NK Yes Breast Prostate Colorectal Mouth Others Necropsy DCN NK 29 NA NA NA 10 18 10 2.38 No Yes Yes No No Yes Yes 0.25 NK 2 Melanoma Lung Necropsy (%) DCN%

Table 5.7 Registration practices Screening programme as data source Cases with Distinguish

Registry

1998-2002

France, Manche

France, Somme

ICDO-2, ICDO-3 (2000) and ICDO-3 (2004)

France, Tarn

ICDO-3 (2004)

ICDO-3 (2004)

France, Vendee

Germany, Brandenburg

ICDO-2 and ICDO-3 (2000)

Germany, Free State of Saxony No Yes No Yes Yes Yes Yes Yes since 2000 No Yes Yes Yes Yes No No Yes Yes Yes Yes Yes Yes No No No No No

ICDO-3 (2004)

Germany, Hamburg

ICDO-3 (2004)

ICDO-3 (2004)

Germany, Mecklenburg-Western Pomerania

ICDO-3 (2004)

Germany, Munich

ICDO-3 (2004)

Germany, North Rhine-Westphalia: Mnster

ICDO-3 (2004)

Iceland

Germany, Saarland

ICDO-2

Italy, Biella Province

Ireland

Italy, Brescia Province

ICDO-3 (2004)

ICDO-2

Other

Italy, Ferrara Province

Italy, Florence and Prato

ICDO-3 (2004)

ICDO-2

ICDO-3 (2004)

0.1

1.3 2.2 Yes No Yes Yes 1.3 1.2 1.6 2

Italy, Genoa Province

ICDO-3 (2004)

Italy, Macerata Province

Italy, Milan

ICDO-2 and ICDO-3 (2004)

Italy, Modena Province

ICDO-3 (2004)

Italy, Naples

ICDO-3 (2000)

ICDO-3 (2000)

Italy, North East

Comparability and quality of data

Italy, Parma Province

ICDO-1 and ICDO-2 and ICDO-3 (2004)

Italy, Ragusa Province

ICDO-3 (2004)

ICDO-3 (2004)

91

92
Table 5.7 Registration practices Screening programme as data source Lung NA NA No No Yes No No No Yes NA No No No No Yes 1 <1 0.01 1.5 Yes No No No No No NA NA No No No No No Yes No No No No No No No Yes No No No No No No No No No NA NA Yes No No No No No No No No Yes No 12 Yes No No No NA NA Yes No No No No No No No No Yes 8 <1 Yes 0.3 No No No No No No No Yes NK No No No No No NA No No No NA NA Yes 1.7 Yes Yes Yes Yes No Yes No No No NA NA Yes NK Yes Mouth Others Necropsy Necropsy (%) DCN Cases with Distinguish DCN% 2 3 Cervix Yes Yes Yes No No Yes No No No No No No No No No No No No Yes NA No No No No No No No No No Yes No No No No No No No No NA No No No No No No No No No No No Yes No No No Yes Yes since 2000 Yes Yes Yes NA Yes NA Yes NA Yes Yes Breast Prostate Colorectal Melanoma Yes 0.3 0.6 1.5 1.5 NA 0.2 NA Yes Yes NA NA No No No No No No No No Yes Yes 0.4 No NA NK 0.45 Yes Yes Yes No 0.2 1 5 No Yes Yes Yes Yes Yes Yes Yes No No NA NA Yes No No No NA No No Yes No No No No No Yes Yes Yes Yes Yes Yes No No No No No No No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No No Yes No No No No No No No No No No No

MP rules

Registry

1998-2002

Italy, Reggio Emilia Province

Italy, Romagna Region

Italy, Salerno Province

ICDO-3 (2004)

ICDO-2

Italy, Sassari Province

ICDO-3 (2004)

ICDO-2

Italy, Sondrio

ICDO-3 (2004)

Comparability and quality of data

Italy, Syracuse Province

Italy, Torino

ICDO-3 (2004)

ICDO-1

Italy, Umbria Region

Italy, Varese Province

ICDO-1 and ICDO-3 (2004)

Italy, Veneto Region

Latvia

ICDO-3 (2004)

ICDO-2

Lithuania

ICDO-2

Malta

ICDO-2

The Netherlands

The Netherlands, Eindhoven

ICDO-3 (2004)

ICDO-2

5 - 10 No No No Yes 0.1 No -

NA

NA

7.2 Yes NK Yes No Yes Yes Yes Yes 4-6 4 NK <0.1 0.8 <1 No No 3 Yes -

The Netherlands, Maastricht

Norway

ICDO-2 and ICDO-3 (2000)

Poland, Cracow

Poland, Kielce

ICDO-3 (2000)

ICDO-2

Poland, Warsaw City

Portugal, Porto

ICDO-3 (2004)

Other

Portugal, South Regional

ICDO-3 (2000)

Russia, St Petersburg

ICDO-3 (2000)

ICDO-2

Yes NA No No Yes No

12.4

4-6 NA 8 -

Serbia

Slovak Republic

ICDO-2 and ICDO-3 (2000)

ICDO-1

Slovenia

Spain, Asturias

Spain, Albacete

ICDO-2 and ICDO-3 (2000)

ICDO-3 (2004)

ICDO-2

MP rules Cervix No No Yes No Yes Yes Yes No No No No No No No No No No No No No No No No No No No NA No No Yes No No NA No No No No No NA No No No No No No No NA No No No No No No No No No No No No No No No No No No No No No No No No No No No No No No No No No No No No NA NA NA NA NA NA Yes No No No No No No Yes No No No No No No No Yes No No No No No No Yes No No No No No No No No Yes 0.1 <1 No Yes No No No No No No Yes NK Yes No No No No No No Yes 0.1 No No No No No No No Yes NK Yes Yes Yes 1.15 Yes 10 Yes Yes No No No No No No No No No No No No NA No Yes No Yes NK Yes Yes No 10 2.5 Yes Yes Yes No Yes No No No No No No No NA No No 10 3 8 No No No Yes No No No No No No Yes NK Yes Breast Prostate Colorectal Mouth Others Necropsy DCN 4.8 12.5 5.7 Melanoma Lung Necropsy (%) DCN%

Table 5.7 Registration practices Screening programme as data source Cases with Distinguish

Registry

1998-2002

Spain, Basque Country

Spain, Canary Islands

ICDO-2 and ICDO-3 (2000)

Spain, Cuenca

ICDO-3 (2000)

Spain, Girona

ICDO-3 (2000)

Spain, Granada Yes

ICDO-3 (2000)

Spain, Murcia Yes NA No No No No No No No No No No No No No

ICDO-3 (2000)

Spain, Tarragona

Spain, Navarra

ICDO-2

Spain, Zaragoza No

Sweden No No No No Yes Yes No Yes No No No No No

Switzerland, Geneva

ICDO-3 (2000)

ICDO-2

Other

Other

3.4

4.1 9.2 Yes Yes Yes -

Switzerland, Graubnden and Glarus

ICDO-2

Switzerland, Neuchtel No No No Yes No Yes Yes Yes Yes Yes No Yes

ICDO-2

Switzerland, St Gall-Appenzell

ICDO-1

NK Yes 1-2 Yes 1.4 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 6 Yes Yes Yes NK NK 1.6 2-3 NK NK NK 0.8 Yes Yes Yes Yes No Yes Yes NK <1 Yes Yes No No

0.7

Switzerland, Ticino

ICDO-2

NA 2 2

Switzerland, Valais

ICDO-2

Switzerland, Vaud Yes Yes Yes Yes Yes Yes Yes No No

ICDO-2

UK, England, East of England Region

ICDO-1

NA

UK, England, Merseyside and Cheshire

UK, England, North Western

ICDO-2

Other

NK

NA 19

UK, England, Northern and Yorkshire

ICDO-2

Other

NK 17 13 in 2002 NK 30 2.4 -

UK, England, Oxford Region

Other

UK, England, South and Western Regions

Other

UK, England, Trent

UK, England, Thames

UK, England, West Midlands Yes

Other

Other

Comparability and quality of data

UK, Scotland

UK, Northern Ireland

Other

Other

Other

NA 3.2

93

94
Table 5.7 Registration practices Screening programme as data source Lung Mouth Others Necropsy Necropsy (%) DCN DCN% Cases with Distinguish Cervix Breast Prostate Colorectal Melanoma No No No No No No No No No Yes Yes No No Yes No No No No No No No No Yes No No Yes No No No No No No No No No No No Yes Yes No Yes Yes No No No No No No Yes 0.08 NK NK NK 0 No No No No No No Yes NK No No Yes Yes No No Yes Yes No No No No No No No Yes NK No No No No No No No Yes NK No No No Yes Yes 1.31 (based on 2003 dx patients) Yes No Yes NA No 15 NA NA 4

MP rules

Registry

1998-2002

Oceania

Australian Capital Territory

Australia, New South Wales

ICDO-2

Australia, Northern Territory No Yes Yes Yes Yes Yes Yes

ICDO-2

ICDO-2

Comparability and quality of data

Australia, Queensland

ICDO-3 (2000)

Western Australia

Australia, Tasmania Yes Yes Yes

Australia, Victoria

ICDO-3 (2000)

ICDO-2

ICDO-2

French Polynesia

New Zealand

ICDO-3 (2000) and ICDO-3 (2004)

ICDO-2

USA, Hawaii

ICDO-2 and ICDO-3 (2000)

NA = not applicable

NK = not known

Chapter 6: Processing of data

J. Ferlay

There were 313 cancer registries that replied to the invitation to participate by submitting data for Volume IX of Cancer Incidence in Five Continents (CI5) Each cancer registry sent its own data, except the registry members of the Surveillance Epidemiology and End Results (SEER) and of the National Program of Cancer Registries (NPCR) of the United States, and six Canadian registries that provided their data in a single data submission The data were generally sent to the IARC secretariat through electronic mail or on CD-ROM for large files, and as usual, were accepted in any electronic format (text files, Excel spreadsheet, database files, etc.) and with any file layout Contributing registries were also invited to send all their data containing all malignant and non-malignant diagnoses collected. In addition, official cancer mortality data for the reference period, and population data, ideally for each calendar year of the reference period, should also be provided and checked by the IARC secretariat This resulted in the manipulation of more than thirty million individual records, and in the production of 389 preliminary datasets (including different ethnic groups) to be examined carefully by the editors A procedure for data validation and storage, summarised in Figure 61, was established to handle the large amount of data submitted for the project Incidence data The incidence data were submitted as listings of individual anonymous cases with at least the following variables: 1 2 3 4 5 6 7 8 9 A registration number that identifies the patient or the case Sex Ethnic group or race (optional) Age and/or birth date Date of incidence Site of the tumour (topography) Morphology of the tumour Behaviour of the tumour Most valid basis of diagnosis

and ICD-10 codes (for coding of the DCO cases) depending on the year of incidence of the case, so that they had to be split into two or more files, each piece of the puzzle being converted using the appropriate program (Figure 62) These preliminary conversions proved to be particularly valuable in detecting incompatibilities between ICD-9 or ICD-10 codes and ICD-O morphology and behaviour (Table 61), which were transmitted back to the cancer registry for review and correction Figure 6.1. Processing of cancer registry data to generate Cancer Incidence in Five Continents Volume IX

A description of all the codes used for the variables had to be provided with the data However, it was not unusual for the code values to not match the description provided or for the coding information to be missing In that case, the registry was asked for clarification and to provide the correct codes if necessary This is particularly important when computing the percentage of microscopically verified (MV) or death certificate only (DCO) cases used for the editorial process: a misinterpretation of the basis of diagnosis code could lead to a false picture of the data quality Conversion into ICD-O-3 The first stage of the editorial process is to examine the incidence data using the standard IARC-CHECK program This requires the data to be coded into a full (Topography and Morphology) ICD-O-3 coding schema A large majority (230) of the registries submitted data according to this classification, but the others (72) had to be converted before they could be handled by the program Several datasets included both ICD-O-1 and ICD-O-2, not to mention ICD-9

95

Processing of data

ICD-10 C22.0 C45.0 C46.0 C91.0 C81.9 C43.9 C34.9 C53.9

Table 6.1 Examples of unlikely ICD-10 site/ICD-O-2 morphology combinations ICD-O second edition (correct code if incorrect) Hepatocellular carcinoma 8010/3 Carcinoma, NOS (8170/3) Mesothelioma of pleura 8050/3 Papillary carcinoma, NOS (9050/3) Kaposi sarcoma of skin 8140/3 Adenocarcinoma, NOS (9140/3) Acute Lymphoid Leukaemia 9823/3 Chronic Lymphocytic Leukaemia (9821/3) Hodgkin disease, NOS 9670/3 Malignant lymphoma, small lymphocytic (9650/3) Melanoma of skin, NOS 8090/3 Basal cell carcinoma (8720/3) Lung (primary cancer) 8140/6 Adenocarcinoma, metastatic (8140/3) Uterine cervix, malignant 8070/2 Squamous cell carcinoma in situ (8070/3) For Finland, the site was coded to ICD-7 (1955) and the morphology using a modified version of the Manual of Tumor Nomenclature and Coding by the American Cancer Society (1951). A specific conversion program had been developed within the framework of the NORDCAN project, a collaboration between the IARC and the Nordic Association of Cancer Registries. Although the ICD-O-3 gives clear instructions that behaviour codes /6 and /9 should not be used by cancer registries (page 27 of ICD-O-3), these codes appeared in few datasets, giving rise to problems with respect to the corresponding topography code. Usually, this was assumed to represent the site of the primary tumour. Where this was evidently not the case (carcinomas in lymph nodes, in bone, etc.), a listing of such cases was sent back to the registries with a request for clarification. As a last resort, they were recoded to topography C80.9 (primary site unknown). Checking Once a dataset had been converted into ICD-O-3, or if it had been originally coded using ICD-O-3 codes, it was submitted to the IARC-CHECK program, which performed the following edits: 1. Code verification Sex Incidence date and, if provided, birth date ICD-O-3 topography and morphology 2. Consistency between items Age versus birth/incidence dates Sex versus site Sex versus histology Age versus site Age versus histology Site versus histology Basis of diagnosis versus histology

Figure 6.2 Preliminary conversions of cancer registry data (1) ICD-9 (1975), chapter II neoplasms, to the second edition of ICD-O (1990) conversion program. (2) ICD-10 (1990), chapter II neoplasms, to the second edition of ICD-O (1990) conversion program. (3) ICD-9 (1975), chapter II neoplasms for topography and the first edition of ICD-O (1976) for morphology to the second edition of ICD-O (1990) conversion program. (4) ICD-10 (1992), chapter II neoplasms for topography and the second edition of ICD-O (1990) for morphology to the second edition of ICD-O (1990) conversion program. (5) First edition of ICD-O (1976) to the second edition of ICD-O (1990) conversion program. (6) Second edition of ICD-O (1990) to the third edition of ICD-O (2000) conversion program.

Registries submitting data for Vol. IX were invited to run their own data through the IARC-CHECK program prior to submission, and a number of contributors did so (143), particularly the users of the CanReg-4 software (30), which includes the same edits. However, these datasets were automatically re-checked by the IARC secretariat. All errors or unlikely or rare combinations of items were sent back to the cancer registry for verification. The corrections or new submissions were then incorporated, converted again (if necessary) and always re-checked to ensure no more errors were found.

96

Processing of data

Multiple primaries For the datasets that included a unique patient identification number, it was possible to check for multiple primary tumours following the IARC/IACR rules (IARC, 2004) especially defined for ICD-O-3 (see Chapter 5). The multiple primary check program can detect all the duplicate records that appeared during the reference period if the cancer registry submitted a complete dataset of the malignant cancer cases collected since the starting of registration; otherwise, some of the multiple tumours (generally those occurring at the beginning to the reference period) may not have been detected because of a lack of information on the earlier diagnoses. Conversion into ICD-10 When no more errors remained, the incidence data were converted from ICD-O-3 to ICD-10. This ensured that the final ICD-10 codes used in the publication followed a standard ICD-O-3 to ICD-10 conversion program. When a dataset included an ICD-10 code, this was ignored in the tabulations. The ICD-O-3 to ICD-10 conversion program was written at IARC using the rules of the ICD-O-2 to ICD-10 conversion program, which was used for processing data for Volume VIII of CI5. The ICD-O-2 to ICD-10 conversion program was also developed at IARC, based on the Conversion of neoplasms by topography and morphology from ICD-O-2 to ICD-9. The terms deleted from ICD-O-3 (as indicated in Appendix 5) were first removed from the list of ICD-O-2. The conversion rules for the new ICD-O (M) codes (listed in Appendix 1) were defined by looking first at the most appropriate ICD-O-2 (M) code using the ICD-O-3 to ICD-O-2 conversion program, and then by applying the corresponding conversion rule to the ICD-O-3 (M) code. For example, the ICD-O-3 code M8174/3 Hepatocellular carcinoma, clear cell type is converted into ICD-10 following the rule that applies to the ICD-O-2 code M8170/3 Hepatocellular carcinoma, NOS. The ICD-O-3 codes M995_, M996_ (myeloproliferative disorders) and M998_ (myelodysplastic syndromes) that changed behaviour code from borderline (/1) to malignant (/3), and for which no ICD-10 code in the malignant C category can be found, have been converted to the ICD-10 codes D45, D46_ and D47_ (i.e. non-malignant tumours). They are included and presented in the tables under the categories MPD and MDS respectively. When a dataset was submitted with cases coded to ICD-9 or ICD10 for topography and ICD-O-1 or ICD-O-2 for morphology, the series of conversion processes (Figure 6.2) and the final conversion from ICD-O-3 to ICD-10 produced some unexpected results and, for example, created new ICD-10 codes which were not originally recorded in the input file. For example, suppose the following combination of ICD-10 (T) and ICD-O-2 (M) was present: ICD-10 ICD-O-2 (M) C80 8640/3 Unknown primary

Finally, the ICD-O-3 to ICD-10 conversion program used for the data processing will create the following ICD-10 code: C62.9 Testis, NOS Thus the final ICD-10 site becomes sex-specific and does not correspond to that provided in the original record. Generally, such change in ICD-10 codes will occur when the registry has not followed the rules in the ICD-O manuals; in the example above, a Sertoli cell carcinoma (M8640/3) should have been coded to testis (C62.9) if the site of the tumour was not specified (rule 8 of ICD-O-2 or rule H of ICD-O-3). It would also have occurred with other specific morphological diagnoses such as malignant melanoma, regressing (M8723/3) or osteosarcoma (M9180/3), which are automatically converted to an ICD-10 code for skin (C43._) or bone (C40._) cancer. This example illustrates the importance of the primary conversion into ICD-O-3 and explains why the ICD-10 code provided by the cancer registry (if any) has not been used in the final tabulations. For certain morphological codes, the conversion is independent of topography. Hepatocellular carcinoma (M8170/3), for instance, is automatically converted to ICD-10 C22.0 irrespective of the ICD-O topography code (whether specific or unknown). The combination C34.9 (lung) plus M8170/3 will be converted to C22.0. This combination of topography and morphology is certainly incorrect. These types of potential errors are at the origin of the creation of the first version of the IARCCHECK program. The validation of ICD-O-3 topography and histology combinations is an essential part of the data processing. Miscellaneous conversions In addition to the topography and the morphology codes, certain variablessex, basis of diagnosis, ethnic group or race and datesmust be re-coded into a common schema following the instructions supplied by the cancer registry. When necessary, the basis of diagnosis variable was recoded following the IARC proposal (ICD-O-3, pg. 38). After the conversions into a common dictionary, the data corresponding to a registry are stored in the CI5 Vol. IX database, irrespective of whether they will be published in Cancer Incidence in Five Continents Vol. IX. All malignant neoplasms and non-malignant (except benign) neoplasms of the bladder are recorded in the database. These are stored as individual records containing the nine compulsory variables having topography and morphology coded to ICD-O-3 together with the corresponding ICD-10 code used for tabulation. Mortality data The mortality data are used for editorial purposes as an indicator of the completeness of registration, and are generally provided as a tabulation of ICD-9 or ICD-10 threedigit categories by sex and five-year age group, so that no validity check (except the basic combination of sex and site) can be performed. For some data sources, the original data were grouped by cancer sites or by wider age groups than the traditional five-year age groups, and had to be formatted before being handled by the series of editorial programs and stored in the CI5 Vol. IX database. Population data Cancer registries generally submitted population denominators for each individual year of the reference period, or for one year corresponding to the mid-year of the reference period. These are based on a census, which was carried out around the year

The first conversion into ICD-O-2 (T+M) will produce the following output: ICD-O-2 (T+M) C80.9 Unknown primary 8640/3

The second conversion into ICD-O-3 (T+M) will produce the following output: ICD-O-3 (T+M) C80.9 8640/3

97

Processing of data

2000 in most of the countries. File editing and misinterpretation of the codes were the only source of errors discovered in the last three volumes. Whenever possible, the population data have been checked by comparing the age distribution with that from the previous volume. Unexpected change in the age structure or in the total population by year and sex were identified and sent to the registry for clarification. After this careful examination, the population files were formatted and stored in the CI5 Vol. IX database. Conclusion This protracted process for both cancer registry staff and the IARC secretariat took several months. However, it ensured a maximum level of data comparability and validity, but it is not in itself sufficient to ensure inclusion in the present volume. This depended upon other considerations of comparability and quality, as described in Chapter 5. The seven conversion programs, together with the latest version of the IARCCHECK and the multiple primary check programs used in References Cooke, A.P., Parkin, D.M., Ferlay, J. CanReg4: Computer Software for Cancer Registries. Available at http://www.iacr.com.fr. Ferlay, J., Burkhard, C., Whelan, S., Parkin, D.M. (2005). Check and Conversion Programs for Cancer Registries (IARC/IACR Tools for Cancer Registries). IARC Technical Report No. 42. Lyon, IARCPress. Fritz, A., Ries, L. Conversion of Neoplasms by Topography and Morphology from the International Classification of Diseases for Oncology, Third Edition (ICD-O-3), to International Classification of Diseases for Oncology, Second Edition (ICD-O-2). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Fritz, A., Percy, C.L., Jack, A., Shanmugaratnam, K., Sobin, L., Parkin, D.M., Whelan, S. eds (2000). International Classification of Diseases for Oncology, third edition, Geneva, World Health Organization. Parkin, D.M., Whelan, S.L., Ferlay, J., Teppo, L., and Thomas, D.B., eds (2002). Cancer Incidence in Five Continents, Vol. VIII. IARC Scientific Publications No. 155, Lyon, IARCPress. Parkin, D.M., Chen, V.W., Ferlay, J., Galceran, J., Storm, H.H and Whelan, S.L. (1994). Comparability and Quality Control in Cancer Registration. (IARC Technical Report No. 19), Lyon, IARCPress.

the incidence data process, have been published as a PC Windows-based package, IARCcrgTools. This is available for free at the International Association of Cancer Registries (IACR) web site http://www.iacr.com.fr/. IARCcrgTools also includes the detailed definition of the edits and controls performed on each variable or within variables. All of the necessary programs to convert and check the data, then to create the tables were written in C++ and Java. The thousands of tables produced were generated in PostScript format and later converted into PDF files for publication. The Editors would like to particularly thank Mr Mathieu Mazuir who performed most of the data entry and the data cleaning, Mr Eric Masuyer for his help in the data cleaning, and Mr Morten Ervik for his help in the data processing and his work in creating and managing the necessary tables. Finally, the Editors would like to acknowledge the contributors who converted and checked their data prior to submission. This was very helpful and much appreciated. Percy, C.L. ed. (1992). Conversion of Neoplasms by Topography and Morphology from the ICD-0-2 to ICD9 and the ICD-9-CM. Washington, National Cancer Institute. Percy, C.L, Van Holten, V. & Muir, C.S., eds (1990). International Classification of Diseases for Oncology, 2nd edition (ICD-O-2). Geneva, World Health Organization. WHO (World Health Organization) (1957). Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death (Based on the Recommendations of Seventh Revision Conference, 1955), Geneva, World Health Organization. WHO (World Health Organization) (1976). International Classification of Diseases for Oncology (ICD-O), Geneva, World Health Organization. WHO (World Health Organization) (1977). Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death (Based on the Recommendations of Ninth Revision Conference, 1975), Geneva, World Health Organization. WHO (World Health Organization) (1992). Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death (Based on the Recommendations of Seventh Revision Conference, 1990), Geneva, World Health Organization.

98

Objective The key determinant of cancer incidence is age, as the risk of cancer increases exponentially with increasing age. The crude rate of incidence is therefore influenced by the population structure, and cannot be used alone to evaluate whether the burden of cancer differs between populations. To compare the incidence of cancer, the summary rates should be independent of age. A common way to take into account the age structure of a population is to standardise incidence rates for age using an external (standard) population. Crude incidence rate The crude incidence is the rate at which new cases occur in a population during a specific period. This rate is classically expressed as the average number of cases occurring per 100 000 persons each year or 100 000 person-years. In Cancer Incidence in Five Continents (CI-5), Volume IX, numbers of cancer cases are reported for the period 19982002. Hence the crude incidence rate is computed with the following formula:

Chapter 7: Age-standardisation and denominators

Crude incidence rate =

M. Boniol and M. Heanue Number of new cancer cases observed in the period 1998 - 2002
Total population in the period 1998 - 2002

i i crude rate of incidence is therefore influenced by the population structure, and cannot be used alone to evaluate whether Age - standardised rate = the burden of cancer differs between populations. yi Crude incidence rate i To compare the incidence of cancer, the summary rates should be independent of age. A common way to take into The crude incidence is the rate at rates which new cases occur in population. Such that i represents each age group, account the age structure of a population is to standardise incidence for age using an external (standard) Such that i represents each age group, a population during a specific period. This rate is classically di theinnumber of cases in the ith age group, the ith age group, di the number of cases expressed as the average number of cases occurring per 100 y the population size in the ith age group, population size in the ith age group yi the 000 i Crude incidence rate applied for the ith age group, with for the ith age group, with and wi the weight persons 100 person-years. In Cancer Incidence wi the weight applied The crude incidence is theeach rate atyear which or new cases000 occur in a population during a specific period . This rate isand classically di/yi being the age-specific rates for each ith category expressed as the number of cases occurring per 100 IX 000, persons each of year or 100 000 person-years. In/y Cancer inaverage Five Continents (CI5), Volume numbers cancer cases are d being the age-specific rates for eachrate ith category being equal to 100 000 to express the age-standardised per 100 000 person-years. With the sum of w i i i the Incidence in Five Continents (CI-5), Volume IX, numbers of cancer cases are reported for the period 19982002. Hence reported for with the the period 19982002. Hence the crude incidence and the sum of wi being equal to 100 000 to express the agecrude incidence rate is computed following formula: It should be stressed that the objective of age standardisation is essentially to establish rates for comparison purposes. Any rate is computed with the following formula: standardised rate per 100 000 person-years. population standard would enable comparison, even considering equal weights for each age group. The most commonly used standard worldwide is the Segi standard population (Segi 1960). Modified by Doll et al. Number of new cancer cases observed in the period 1998 - 2002 (1966), it was It based on the be age structure of the pooling of populationsof from 46 countries. The use of this standard Crude incidence rate = should stressed that the objective age standardisation Total population in the period 1998 - 2002 population allows international comparison and evaluation of changes in incidence by comparing them to rates published is essentially to establish rates for comparison purposes. Any in previous volumes of CI-5.

Objective Age-standardised incidence The total population in the period 19982002 corresponds rate to the sum of population size for each year between 1998 and The key determinant of cancer incidence is age, as the2002. riskThis of rateThe age-standardised rateto iseach a summary the individual age-specific is called crude because it relates population of as a whole and is influenced by the age structure of each population. It cannot be used comparison purposes. called a standard population. This cancer increases exponentially with increasing age. The crude rates using an for external population rate of incidence is therefore influenced by the population is the incidence that would be observed if the population had the age Age-standardised incidence rate structure, and cannot be used alone to evaluate whether the structure of the standard population, and corresponds to the crude The age-standardised rate is a summary of the individual age-specific rates using an external population called a standard burden of cancer differs between populations. incidence rate thebe standard population. The age-standardised population. This is the incidence thatin would observed if the population had the age structure of the standard population, and corresponds to the crude incidence rate in the standard population. The age-standardised incidence is expressed, as To compare the incidence of cancer, the summary rates should incidence rate is expressed, as is the crude incidence rate, asrate the Chapter 7 Age-standardisation and Denominators is the crude incidence rate, as the number of new cases per 100 000 person-years. beHeanue independent of age. A common way to take into account the number of new cases per 100000 person-years. M. Boniol, M. age structure of a population is to standardise incidence rates for The calculation is a weighted The calculation is a weighted average of age-specific rates. average of age-specific rates. Objective age using an external (standard) population. The key determinant of cancer incidence is age, as the risk of cancer increases exponentially with increasing age. The

dw

Anyear example of this ageand standardisation appears in table 1. The total population in the period 19982002 corresponds to the sum of population size for each between 1998 sum of population size for each year between 1998 and 2002. equal weights for each age group. 2002. This rate is called crude because it relates to each population as a whole and is influenced by the age structure of This rate is called crude because The most commonly used standard each population. It cannot be used for comparison purposes. it relates to each population as a

The total population in the period 19982002 corresponds to the

population standard would enable comparison, even considering

whole and is influenced by the age structure of each population. It cannot be used for comparison purposes. Age-standardised incidence rate

The age-standardised rate is a summary of the individual age-specific rates using an external population called a standard population. This is the incidence that would be observed if the population had the age structure of the standard population, and corresponds to the crude incidence rate in the standard population. The age-standardised incidence rate is expressed, as is the crude incidence rate, as the number of new cases per 100 000 person-years. The calculation is a weighted average of age-specific rates.

worldwide is the Segi standard population (Segi, 1960). Modified by Doll et al. (1966), it was based on the age structure of the pooling of populations
111

Table 7.1 Computation of age-standardised incidence rates (Melanoma cancer, Denmark, males, 19982002)
Age-specific incidence (per 105 years) 105(di /yi) 0.00 0.00 0.00 Standard world population wi 12000 10 000 9 000 9 000 8 000 8 000 6 000 6 000 6 000 6 000 5 000 4 000 3 000 2 000 500 500 1 000 4 000 Expected cases in standard population di wi /yi 0.00 0.00 0.00 0.09 0.22 0.49 0.48 0.67 0.96 1.21 1.32 1.39 1.28 1.68

d i wi Age group Age - standardis No. of at risk edcases rate = Person-years yi i

i group, di yi Such that i represents each age di the number of cases in the ith age group, 0 869 668 ith age group yi the population size in the 04 and wi the weight applied for the ith age group, with 59for each ith category 0 878 535 di/yi being the age-specific rates With the sum of wi being equal to 100 000 to express the age-standardised rate per 100 000 person-years. 1014 0 779 915

It should be stressed that the objective of age standardisation is essentially to establish rates for comparison purposes. Any 7 equal weights for each age 723 313 0.97 population standard would1519 enable comparison, even considering group. The most commonly used standard worldwide is the Segi standard population (Segi 1960). Modified by Doll et al. 2024 840 592 (1966), it was based on the age structure of the pooling 23 of populations from 46 countries. The use of this standard2.74 population allows international comparison and evaluation of changes in incidence by comparing them to rates published 2529 59 961 907 6.13 in previous volumes of CI-5. An example of this age standardisation appears in table 1.

3034 3539 4044 4549 5054 5559 6064

153 188 262 303 223 217 119 115 162 272

117

83

1 042 749 1 041 800 953 731 930 210 990 187 871 969 523 486 439 676 342 435 210 084 649 423

16.04 20.21 26.46 34.75 111 42.60 49.35 47.31 56.64 82.10 17.46 41.88

11.23

7.96

6569 7074 7579 8084 Total 85+

0.99 0.47 0.28

2 303

13 189 753

140 073

100 000

11.94

0.41

99

Age-standardisation and denominators

from 46 countries. The use of this standard population allows The sum of the age specific rates between ages 074 is: (0.97 international comparison and evaluation of changes in incidence +2.74+6.13+7.96+11.23+16.04+20.21+26.46+34.75+41.88+4 by comparing them to rates published in previous volumes of CI5. 2.60+49.35)/100 000 = 260.33/100 000. Hence the cumulative e 1. Computation of age-standardised incidence rates (Melanoma cancer, Denmark, males, 19982002) An example of this age standardisation appears in Table 7.1. rate is (260.33/100 000) 5, or 1.3%. In this example, the crude rate is 2303 / 13 189 753 = 17.46 Standard world Expected cases in Age group No. of Person-years at Age-specific cases per 100 and the age-standardised age-specific incidence rates calculated in a registry are population rate is The standard cases risk000 person-years, incidence The cumulative incidence rate ranges between 0 and 75, and cohorts; by its construction overestimates 5 11.94 per 100 000 person-years. derived from different birth i.e. populations born at the probability population (per 10 years) a cancer during life when incidence rates are high. However when incidence rates are sufficiently small, apar yi 105(dis /y ) w d w / y I di The age-standardised rate lower than the crude rate different periods who experienced different levels of exposure i i i incidence rate ranges i i i between 0 and 75, and by its construction overestimates the probability of d The cumulative 4 0 869standard 668 0.00 12 000 0.00 cancer sites combined, the cumulative rate is not significantly affected by this bias. because the population is on average younger than the to carcinogens. The cohort effect is an important determinant a cancer during life when incidence rates are high. However when incidence rates are sufficiently small, apart fro 9 0 878 535 0.00 10be 000 0.00 observed Danish population. However, the rate of 11.94 can compared of the incidence for most sites. For can example, In the previous example for melanoma inis men in Denmark, the cancer cumulative rate be estimated from the cancer sites combined, the cumulative rate not significantly affected by this bias. 014 0 779 915 0.00 9 000 0.00 with other rates standardised on the world population. mesothelioma incidence is driventhe by asbestos exposure that took rates: In the previous example for melanoma in men in Denmark, cumulative rate can be estimated from the age 519 7 723 313 0.97 9 000 0.09 place in the past (until the 1990s in most developed countries), The sum of the age specific rates between ages 074 is: rates: 024 23 840 592 2.74 8 000 0.22 Reference population and the cumulative rates calculated in CI5 Volume IX would not The sum of 8 the age specific rates between ages 074 is: 529 59 961 907 6.13 000 0.49 (0.97+2.74+6.13+7.96+11.23+16.04+20.21+26.46+34.75+41.88+42.60+49.35)/100 000 = 260.33/100 000. H A new standard population was proposed by WHO in 2000 reflect the lifetime risk of mesothelioma of a population born 034 83 1 042 749 7.96 6 000 0.48 (0.97+2.74+6.13+7.96+11.23+16.04+20.21+26.46+34.75+41.88+42.60+49.35)/100 000 = 260.33/100 000. Henc cumulative rate is 260.33/100 000*5, or 1.3%. The cumulative incidence in rate ranges between 0 and 75, and by its construction overestimates the probability of devel (Ahmad al ., 2000). This new standard allows the estimation 2000. 539 117 1 et 041 800 11.23 6 000 0.67 cumulative rate is 260.33/100 000*5, or 1.3%. a cancer life when incidence rates are high. However when rates are sufficiently 044 153 953 731 16.04world population. 6 during 000 0.96 of incidence for the theoretical This new Nevertheless, the cumulative rateincidence reflects the burden of cancersmall, apart from all cancer sites combined, thein cumulative rate is a not significantly affectedover by this bias. Theutility age-specific rates calculated in registry are derived from different birth cohorts; i.e. popu 549 188 930 210 6 incidence 000 1.21 population is, however, not of20.21 great for cancer incidence a place, and has the added advantage the age-standardised The age-specific incidence rates calculated inmen a registry are derived from different birth cohorts; i.e.the populatio In the previous example for melanoma in in Denmark, the cumulative rate can be estimated from age-spec 054 262 990 187 26.46 5 000 1.32 different periods who experienced different levels of exposure to carcinogens. The cohort effect is standardisation for two main reasons: different periods who experienced rate of not imposing an external population structure. The different levels of exposure to carcinogens. cohort effect is an rates: 559 303 871 969 34.75 4 000 1.39 of the observed incidence for most cancer sites. For example, mesothelioma incidence is driv This new standard populationdeterminant is supposed to better represent determinant observed incidence for most cancer The sum of the the age specific rates between ages 074 is: sites. For example, mesothelioma incidence is driven by 064 272 649 423 41.88 4 of 000 1.68 exposure that took place in the past (until the 1990s developedcountries), countries), and cumulative the theoretical world population42.60 compared to Segis population, but Statistical tests exposure that took place in the past (until the 1990sin in most most developed and thethe cumulative ratesrate cal (0.97+2.74+6.13+7.96+11.23+16.04+20.21+26.46+34.75+41.88+42.60+49.35)/100 000 = 260.33/100 000. Hence the 569 223 523 486 3 000 1.28 still does 439 so insufficiently, as population data is lacking for many tests, the results of which are not born published here, volume IX would not reflect theStatistical lifetime risk ofof mesothelioma of a a population population born 2000. cumulative rate is 260.33/100 000*5, or 1.3%. volume IX would not reflect the lifetime risk mesothelioma of in in 2000. 074 217 676 49.35 2 000 0.99 regions in the world. Secondly, there is noNevertheless, additional statistical were used to flag certain registries as unusual or possibly 579 162 342 435 47.31 1 000 0.47 Nevertheless, the cumulative rate reflects the inaa place, and has added advantage the cumulative rate reflects theburden burden of of cancer cancer in place, and has thethe added advantage ove property from this standard to the Segi population forof comparison inconsistent with published data. 084 119 210 084 56.64 500 0.28 Therate age-specific incidence rates calculated inprevious a registry are derived from different birth cohorts; i.e. populations bo standardised rate of imposing not imposing an external population structure. standardised not an external population structure. 5+ 115 073 2002). For data 82.10 500 0.41 purposes 140 (Bray, in the present volume, forwho all experienced different periods different levels of exposure to carcinogens. The cohort effect is an impo The cumulative incidence rate ranges between 0 and 75, and by its construction overestimates the probability of developing otal 2 303 189 753 100 000 11.94 determinant of the observed incidence for most cancer For example, mesothelioma incidence is driven by asb cancer13 incidences excluding 17.46 non-melanoma skin cancer, we Calculation of variance of sites. ASRs Statistical tests a cancer during life when incidence rates are high. However when incidence rates are sufficiently small, apart from all Statisticalexposure tests that took place in the past (until the 1990s in here, most developed countries), and the cumulative calcula estimated the Spearman correlation (r)Statistical between the rates using Variances ofnot age-standardised rates (ASR) are used to assess the as rates cancer sites combined, the cumulative rate is not significantly affected by this bias. tests, the results of which are published were used to flag certain registries unusual o Statistical tests, the results of which are not published here, were used to flag certain registries as unusu is example, the crude rate is 2303 / 13 189 753 = 17.46 cases per 100 000 person-years, the age-standardised rate volume IX would not reflect the lifetime risk ofin mesothelioma of a cumulative population born in 2000. In and the previous example forsignificance melanoma men inthe Denmark, the rate can be estimated from the age-specific Segis standard compared to the new standard. The percentage of statistical of difference between rates in Volume inconsistent with previous published data. .94 per 100 000 person-years. rates: inconsistent with previous published data. Nevertheless, the cumulative rate Volume reflects the of compute cancer in a place, and has the added not explained by the new standard compared to is the old VIII and IXburden andis:to confidence intervals of advantage over the The sum the age specific rates between ages 074 The age-standardised variation rate is lower than the crude rate because the standard population on average younger than the population standardised rate of of not imposing an external structure. 2 standard (1-r ) was 0.14% for men and 0.11% for women. When rates in Volume IX. We based the estimation of variance of (0.97+2.74+6.13+7.96+11.23+16.04+20.21+26.46+34.75+41.88+42.60+49.35)/100 000 = 260.33/100 000. Hence the Calculation of variance ofworld ASRspopulation. sh population. However, the rate of 11.94 can be compared with other rates standardised on the cumulative rate isASR 260.33/100 000*5, or 1.3%. Calculation of variance ASRs looking at ranking of registries by level of incidence, theof new on Breslow and Days method modified significance to use a binomial Variances of age-standardized rates (ASR) are used to assess the statistical of the difference betwee Statistical tests Variances oflevels age-standardized rates (ASR) are to assess the statistical significance of We the difference b rence population standard produces an average change of 2.9 rank men and assumption (Keyfitz, 1966) for variance of the crude ageVolume VIII for and IX and to compute confidence intervals of to rates in Volume IX. based the The Volume age-specific incidence rates calculated in a registry are derived from different birth cohorts; i.e. populations born at esti Statistical tests, the results of which are not used published here, were used flag certain registries as unusual or pos w standard population was WHO in 2000 (Ahmad etvariance al, VIII 2000). This new standard allows the estimation 1.9 forproposed women by in data including all registries; this corresponds to specific rates. Volume and Volume IX and to compute confidence intervals of rates in Volume IX. We based the different periods who experienced different levels of exposure to carcinogens. The cohort effect is an important of ASR on Breslow and Days method modified to use a binomial assumption (Keyfitz 1966) for the v inconsistent with previous published data. cidence for the theoretical world population. This new is, however, notfor of great utility forobserved cancer incidence determinant of the formodified most cancer to sites. For a example, mesothelioma incidence is driven by asbestosfor an average of 0.7% change forpopulation men and the 0.5% change women. variance of ASR on Breslow and Days incidence method use binomial assumption (Keyfitz 1966) crude age-specific rates. exposure that took place in the past (until the 1990s in most developed countries), and the cumulative rates calculated in dardisation for two main reasons: The lack of clear difference between incidence rates computed Calculation of population variance of ASRs the crude age-specific rates. 18 volume IX would not reflect the of a population born in 2 This new standard population is supposed to better represent the theoretical world compared to lifetime Segis risk of mesothelioma - d i )significance * (statistical * d the yin wi 2000. with Segis population compared to the new world standard does i of age-standardized rates (ASR) are used assess of the difference between Nevertheless, cumulative rate is reflects the to burden a place, and has the advantage over the age- ra of icancer 2 added lation, but still does so insufficiently, as population data is lacking for Variances many regions in the world.the Secondly, there 18 3 IX. We based the estimati standardised rate ofIX not and imposing an external population structure. Volume VIII and Volume to compute confidence intervals of rates in Volume * ( ) * d y d w not justify the use of the new population. i i i i dditional statistical property from this standard to the Segi population for comparison purposes (Bray, 2002). For data y i =1 i (Keyfitz 1966) for the varian variance of ASRwe on Breslow and method to use a binomial Forcancer these incidences reasons, and to allow international he present volume, for all excluding non-melanoma skin comparisons cancer, theDays Spearman 3 assumption ( ASRmodified )= Var Statistical estimated tests 2 y the crude age-specific rates. 18 i = 1 with continuity from the previous use here elation (r) between the rates using Segis standard compared volumes, to the newwe standard. The only percentage of variation not i flag certain registries as unusual or possibly Statistical tests, the results of which are not published here, were used to 2 ( ) Var ASR = 2 18 inconsistent with previous published data. and 0.11% for women. When ained by the new standard to the old standard (1-r ) was 0.14% for men wi ) * ( y Segis compared world standard. 2w d * 18 d

yi i =1on an assumption mulative rate the age-specific rates independently of the We ageestimated structure of the 95% confidence intervals (CI) of rates based of the normal distribution of the rates. Var ( ASR) = 2 cumulative rate is an approximation of the probability to develop a individual cancer during a certain periodfor example, a 18 population, and gives the probability of an developing me. We present the cumulative for the life spans oftheoretical 064 and 074 years. This has the advantage of summarising wi a cancer. rates This calculation is and assumes that no CI = 1.96 * Var ( ASR ) i =1VIII age-specific rates independently of in the the age period, structureand of the population, and gives the probability of an Comparison of ASRs from Volume IXindividual with the values from from Volume death occurs that the age-specific incidence Comparison of ASRs Volume IX with the values from loping a cancer. This calculation is theoretical and assumes that no death occurs in the period, and that the age-specific changes in VIII incidence between Volume VIII and Volume IX we of estimated the Co rates will be stable for an individual. To identify significant Volume We estimated 95% confidence intervals (CI) of rates based on an assumption of the normal distribution the rates. ence rates will be stable for an individual.
3

i i i ing at ranking of registries by level of incidence, the new standard produces an average change of 2.9 rank levels for i =1 i 3 Calculation of variance of ASRs w and 1.9 for women in data including all registries; this corresponds to an average of 0.7% change for men and 0.5% y i =1 i i of the difference between rates in Cumulative rate Variances of age-standardized rates (ASR) are)used to assess the statistical significance ( Var ASR = ge for women. The lack of clear difference between incidence rates computed with Segis population compared to the i = 1 2 in of Volume VIII and Volume IX and to of compute confidence intervals of rates Volume IX. We based the estimation of rate The cumulative rate is an approximation of the 95% probability 18 We estimated confidence intervals (CI) rates based on an assumption the normal distribution of the world standard does not justify the use of the new population. a binomial assumption (Keyfitz variance of a ASR We on Breslow and Days method modified to use 1966) for the variance of to develop a cancer during a certain periodfor example, estimated 95% confidence intervals (CI) of rates based on an w or these reasons, and to allow international comparisons with continuity from the previous we use here only i the crudevolumes, age-specific rates. rates for the life spans of intervals assumption ofof the normal distribution the rates. =1 of i assumption We estimated 95% confidence (CI) rates s world standard. lifetime. We present the cumulative 18on CI = based 1.96 * an Var ( ASR )2 of the normal distribution of th

064 and 074 years. This has the advantage of summarising

CI = 1.96 * Var ( ASR )

d i * ( yi d i ) * wi

di=number ofgroup. cases in the ith age group, and umber of person-years in the ith age

d i in Comparison of ASRs15 from Volume IX with the values from Volume VIII age-standardised rate Volume VIII. Volume IXthe we estimated the CI = 1.96 * Comparative Var ( ASR ) Incidence Figure Cumulative rate between 0 -To 74 identify years old = 5 of Comparison ASRs from and Volume IX with values from Volume VIII significant changes in incidence between Volume VIII and Volume IX we estimated the (CIF), in which corresponds the ratio the age standardised To identify i significant changes incidence between to Volume VIIIof and Volume IX we estimated the Compa =1 yi ASR from Volume rate Incidence Figure (CIF), which corresponds to the ratio of the age standardised incidence in Volume IXb incidence rate in Volume IX divided by the age-standardised Incidence Figure (CIF), Comparativ which corresponds the ratio of the age standardised Volume IX divided eto Incidence Figure = incidence rate inIX that i = 5-year age groups, rate in Volume VIII. that i = and 5-year age groups, age-standardised rate in Volume VIII. age-standardised rate in Volume VIII. umber of cases in theSuch ith age group, ASR Comparison of ASRs from Volume IX with the values from Volume VIII

Incidence Figure (CIF), which to the ratio of the standardised incidence rate in Volume IX divid Tocorresponds identify significant changes inage incidence between Volume VIII

yi=number of person-years in the ith age group. The upper

ASRfrom Volume from Volume VIII The cumulative incidence rate ranges between ages 0 and IX Comparative Incidence Figure = 75, and by its construction overestimates the probability of The upper (CI ) and lower (CI ) 95% confidence interval limits ( ) ( ) Var ASR Var ASR ASR interval limits CIF were IX computed following formula: The upper (CIu) and lower (CIl) 95% confidence u l of fromVolume fromVolume VIII from Volume VIII the (CIF computed ) 1.96 * using + using Ln developing a cancer during life when incidence high. CIF were the following formula: 2 computed using the following 2 ) andare lower (CIl) of 95% confidence interval limits of CIF were fo The upper (CIurates ASR ASR fromVolume IX VIII limits of CIF were computed using the fromVolume following formula: The upper However when incidence rates are sufficiently small, apart u / (CI l u) and lower (CIl) 95% confidence interval Var ( ASRfromVolume IX ) Var ( ASRfromVolume VIII ) from all cancer sites combined, the cumulative rate is not + Ln (CIF )1.96* 2 Var ( ASR ( ASR ) 2 Var ( ) Volume ( ASR Var ASR Var significantly affected by this bias. fromVolume IX ) IX fromVolume VIII VIII ASR ASR fromVolume VIII ) if fromVolume IX fromVolume ( ) 1 . 96 * + Ln CIF We considered the difference between rates Volume XI compared to2rates in + VIII2fromVolume to be significant u / l Ln (CIF )1.in 96 * In the previous example for melanoma in men in Denmark CI ASR ASR = 2 fromVolume IX fromVolume VIII /l u confidence 1.0 was not included in the 95% interval of the CIF. ASR ASRfromVolume VIII 2 (Table 7.1), the cumulative rate can be estimated from u the fromVolume IX /the lageWe considered difference between rates in Volume XI compared to rates in Volume VIII to be significant if the specific rates: We considered the difference between rates in Volume XI compared to rates in Volume VIII to be significant if the value

To identify significant changes in incidence between Volume VIII and Volume IX we estimated the Comparative fromfrom Volume IX Incidence Figure (CIF), which corresponds to the ratio of the age standardised incidence rate in Volume IX Volume IXdivided by the and lower (CI confidence interval limits of CIF were computed using the following formul (CIu)age-standardised rate in Volume VIII. l) 95% from Volume VIII

ASR ASR Comparativ e Incidence Figure Figure == Comparativ e Incidence ASR ASR

from Volume VIII

CI

CI

CI

=e

We considered the difference between rates in Volume XI compared to rates in Volume VIII to be significa 1.0 was not included in the 95% confidence interval of the CIF.
100
113

1.0 was not 1.0 included in the 95% confidence interval of the CIF. was not included in the 95% confidence interval of the CIF.

=e

=e

Age-standardisation and denominators

We considered the difference between rates in Volume XI compared to rates in Volume VIII to be significant if the value 1.0 was not included within the 95% confidence interval of the CIF.

population estimate. Moreover, population estimates are often revised once a new census is available but not all cancer registries collect these updated figures. Hence the drift and even a significant change in incidence rate between the year of the census and the Comparison of percentage of microscopically verified cases preceding year could occur simply because of the imprecision of Comparison of IX percentage ofvalues microscopical verification (MV%) from the volume IX with the values from volume VIII (MV%) from volume with the from volume VIII population estimate. This is especially true when population We estimated the Z statistic We estimated the Z statistic as: as: sizes are small and susceptible to more variability, for example, when there is migration within a country. Despite these considerations, for most countries contributing VVIII V - Ln IX to CI5 a census occurred during the period 19982002. Hence, Ln nV nV we can expect that the biases described earlier could be largely IX VIII alleviated. However, in some registries the population figures Z= 1 1 1 1 were estimated from a census performed more than 10 years + + + before the period used in Cancer Incidence in Five Continents, VVIII nVVIII VIX nVIX Volume IX. With VVIII and VIX being the number of cases microscopically Another limitation in the population figure is the choice of VIX being number of cases microscopically verified in volumes IX, respectively, andestimate. nVVIII and The best estimate VVIII and VIII verified With in Volumes andthe IX, respectively, and nVVIII and the date in VIII the and year for population nVIX being the number of cases not microscopically verified in Volumes VIII and IX, respectively. nVIX being the number of cases not microscopically verified in of the population at risk for a specific year in which cancer We considered the difference in the proportion of cases microscopically verified to be significant if Z was greater Volumesthan VIII and IX, respectively. incidence was observed is considered to be at mid-year, and 1.96. We considered the difference in the proportion of some registries provided yearly population estimates for the 1st microscopically verified Population at risk cases to be significant if Z was greater of July. However, this is not a systematic practice and many Population at risk figures are used as denominators in the formulas for the calculation of incidence rates, crude statistics or adjusted. estimated at the than 1.96. registries provided populations These denominators are often disregarded, and readers tend to only focus on the incidence rates and the In a population beginning of final the year, using the 1st discuss of January. variability in incidence data gathering (completeness, classification). This notion isthe driven the st age standardisation Population at risk that increases, use by of 1 of January for population size could process, which tends to eliminate the effect of population age structure and gives the reassuring but false impression that Population at risk figures are used as denominators theIt must induce a systematic overestimation of incidence rates. It is population structure is no longer influencing the incidencein rates. be stressed that denominators are an essential part formulasof for the calculation of incidence rates, crude or adjusted. expected to have only be a minor in Cancer Incidence in the calculation of incidence rates, and have their own biases and limitations that must kept ininfluence mind. The age These denominators often disregarded, and imprecise readers tend to size Five Continents, which uses a period of 5 years combined. standardisationare process is not intended to solve population estimation. Numbers of incidence population at riskand are discuss routinelythe collected by registries from official statistical offices for example and only focus on the final rates variability registries provided these figures to Cancer classification). Incidence in Five This Continents along with their incidence figures. in incidence data gathering (completeness, Migration notion is driven by the age standardisation process, which tends Population size could also be overestimated or underestimated Comparability to eliminate the effect of population age structure and gives the if migration flux patterns are not considered. Some registries Population size estimates are frequently calculated by the official statistical office using the results from a census and a reassuring but false impression that population structure is no population data for projection for the years following the most recent census. The closer collected the year a population estimate is tocorrected a census date, the immigration and longer influencing the rates. It mustwhen be stressed emigration. Between-country is often better handled more accurate theincidence estimate will be. Therefore countries that do not have the same census year, there willmigration be differences in denominators are anof essential part of estimate. the calculation ofpopulation incidence than are within country migration, which is of major concern to the precision their population Moreover, estimates often revised once a new census is available buthave not all cancer registries collect updated that figures. Hence drift and even a significant change in incidence rate rates, and their own biases and these limitations must be theregional registries tasked with maintaining optimal coverage of between the year of the census and the preceding could occur simply because of the imprecision of the population kept in mind. The age standardisation process is notyear intended to their population. Indeed, populations of a highly nomadic nature estimate. population This is especially true when population sizes are small and susceptible to more variability, example, when estimates a real solve imprecise size estimation. make the production of inter for censal population there is migration within a country. Numbers of population at risk are routinely collected challenge. Hence incidence figures for these populations must be Despite these considerations, for most countries contributing to CI5 a census occurred during the period 1998-2002. by registries from official offices for example and be evaluated with care, and their comparability is to be questioned. Hence, we can expectstatistical that the biases described earlier could largely alleviated. However, in some registries the registries provided these figures to Cancer Incidence in more Five than 10 years before the period used in Cancer Incidence population figures were estimated from a census performed Continents along with their incidence figures. A few words of caution in Five Continents, Volume IX. Another limitation in the population figure is the choice of the date in is the year for that population estimate. best ages, and standard Cancer a disease mainly occurs The at older estimate of the population at risk for a specific year in which cancer incidence was observed is considered to be at midComparability populations such as Segi have the tendency to give more weight of July. However, this age is not a systematic practice year, and some registries provided yearly population estimates for theto 1stincidence Population size estimates are frequently calculated by the official in young groups and hide differences observed st and many registries provided populations statistics estimated at the beginning of the year, using the 1 of January. In a statistical office using the results from a census and a projection in older populations. Therefore it cannot be stressed enough population that increases, the use of 1st of January for population size could induce a systematic overestimation of for the years following the most recent census. The closer the that neitherin the age-standardised ratea nor the cumulative rate incidence rates. It is expected to have only a minor influence in Cancer Incidence Five Continents, which uses period year a population estimate is to a census date, the more accurate are alternatives to the age-specific incidence rates, which should of 5 years combined. the estimate will be. Therefore when countries do not have the always be the starting point and foundation of any thorough Migration same census year, there will be differences in the precision of their analysis of the incidence data.
Population size could also be overestimated or underestimated if migration flux patterns are not considered. Some registries collected population data corrected for immigration and emigration. Between-country migration is often better handled than within country migration, which is of major concern to regional registries tasked with maintaining optimal References coverage of their population. Indeed, populations of a highly nomadic nature, make the production of inter censal population estimates a real challenge. Hence incidence figures for these populations have to be evaluated with care, and Ahmad their O., comparability Boschi-Pinto C., A., Murray C., Lozano Doll R., Payne P., Waterhouse J. (1966). Cancer is to be Lopez questioned.

Incidence R., Inoue M. (2000). Age standardization of rates: a new in Five Continents: A Technical Report. Berlin: SpringerWHO standard. In GPE Discussion Paper Series: no31. Verlag (for UICC). A few words of caution Cancer is a disease that mainly occurs at older ages, and standard populations such as Segi have the tendency to give more Geneva:World Health Organization.
weight to incidence in young age groups and hide differences observed in older populations. Therefore it cannot be

Bray F., Guilloux A., Sankila R., Parkin D.M. (2002). Practical implications of imposing a new world standard population. Cancer Causes Control 13:175-182.

Keyfitz N. (1966). Sampling variance of age standardised mortality rates. Human Biology 38; 309-317. Segi M. (1960). Cancer Mortality for Selected Sites in 24 Countries (1950-57). Sendai, Tohoku University School of Public Health.

114 Breslow N.E., Day N.E. (1987). Statistical Methods in Cancer Research, Volume II: The Design and Analysis of Cohort Studies. Lyon: IARCPress:59.

101

The Narratives and The Maps

117

Africa

Africa

Algeria, Stif
Registration area The Stif Cancer registry covers the population of 10 dairates, which include a total of 60 communes. The population at the last census (1998) was 1 299 117, representing 4.33% of the overall Algerian population making it the second-largest population centre after Algiers. The population growth rate for this area in 2001 was 1.8%. About 48% of the population live in rural areas, and 99% are Sunni Muslims. The Wilaya (province) of Stif covers an area of 6504 km2, corresponding to 0.27% of the country. The Wilaya of Stif is the capital of the highlands, having an altitude of 1300m and a semi-arid continental climate. It represents 4.7% of the national population at a density of 213 inhabitants per km2. hospitals and ofces, insurance ofces, other cancer registries in Algeria and death registration ofces. The death registration system is incomplete; the certicates of death are examined and a record completed for each certicate mentioning cancer or malignant tumour. Collection is primarily active. For each patient we collect data from four or ve different sources, which permits the information to be completed and checked before coding. For each cancer case a limited number of variables (18) have been put into a sample record. The variables include the sources of information. For the tumour, only four variables are collected, including the date of diagnosis, the site, and the morphology. The data are coded according to ICD-O. Impossible or improbable combinations (site, sex, age and morphology) are identied by computer. Duplicate registrations have been reduced to a minimum ALGERIA, SETIF (1998-2002) thanks to a careful control of ALGERIA, SETIF (1998-2002) name, sex, date of birth and diagnosis. The registry staff visit these sources once a month.

Cancer care facilities General health care in the region is provided predominantly by the CHU (University Hospital Centre) and 6 other hospitals, 16 health centres and 55 primary care centres. These Interpreting the results are supplemented by private Arrangements have been made practitioners and hospitals for 


 









with the hospitals outside the a total of 2115 beds, or 1 bed 







registration area to notify the per 690 inhabitants. The total 














registry of any area-resident number of health workers is 







cancer cases that they may 5772: 215 public specialists, 














diagnose and treat. These 198 private specialists, 387 







outside hospitals are visited public generalists, 278 private 














regularly to collect records, but generalists, 2944 public nurses 







some small underestimation due and 50 private nurses. 





 


 





to cancer cases treated outside The CHU, located in 







the area is possible. Stif, provides cancer surgery and chemotherapy services.       
(#% 

(#% Uses of the data Radiotherapy is provided by the 


')$('"'(((  The registry has prepared a cancer centres of Constantine report of cancer incidence from (120 km distant) and Algiers  
 1986 to 2005, with 20 years of (300 km distant), and as a result 
(  (( ***,!,! ,!!(
(

((
((( **)((
(  
   
( 
(#!%( many patients are treated in Algiers and Constantine. All breast registration highlighting trends and changes. A study of survival    cancers are treated at the breast health centre in Algiers. A large of registered cancer cases of breast, colon, rectum, large bowel, 
( (

((
(
(
(
((
(

((

(+(

( 
(&(#
 %( new Cancer Centre is now being implemented in Stif, and is and prostate during 19901994 has been carried out within the expected to provide care for all cancer patients from the area of CONCORD Survival study. about 5 million inhabitants in 2008. Registry structure and methods The registry, founded in 1989, is located in the epidemiology and preventive Medicine service of the Hospital Mere Enfant of the CHU in Stif under the auspices of the Ministry of Health and Ministry of Research and Education. The registry is staffed by two epidemiology assistants, one pathology assistant, one technician in epidemiology, and 3 postgraduate students in epidemiology. The Stif Cancer Registry uses active case nding from 16 sources of data consisting of University Hospital Centres, cancer hospitals, public health hospitals, pathology laboratories, private

Source of population The populations of 1999 2000 2001 2002 are estimated on the basis of the1998 National Census. Multiple primary rules used IACR rules (2000) Notes on the data The Editors recommend that some care be taken in the interpretation of these data; see Chapter 5 (Categorisation).

105

Africa

Egypt, Gharbiah
Registration area The Gharbiah Population-based Cancer Registry (GPCR) covers the population of eight districts (Tanta, Elmahalla Elkobra, Kafr Elzayat, Zefta, Kotour, Elsanta, Basyoun & Samannoud) within the state of Gharbiah, in the west and central Delta region in lower Egypt. The population at the most recent census (1996) was 3.406 million (5.7% of the total population of Egypt). About 40% of the population lives in urban areas. The majority are Moslems and the remainder are Christians. The death registration system is adequate; the cause of death from cancer is often mentioned. The registry staff visit these sources, where they scrutinise the records kept in medical records departments and the registers of individual departments concerned with diagnosis and treatment of cancers in order to identify and abstract information on cases of cancer, diagnosed by all methods, among residents of the registry region. Although cancer is a notiable disease by administrative order (without a specic law), few registration forms are received from private practitioners. Arrangements have been made with the hospitals outside the registration area to be visited every 13 months according to workload in order to abstract resident cancer cases which are diagnosed and treated in them.

Cancer care facilities General health care in the region is provided predominantly by the Gharbiah Health Services Department (Ministry of Health and Population), through the Interpreting the results district hospitals and a network of primary health centres. It is not possible to estimate EGYPT, GHARBIAH (1999-2002) These are supplemented by how many cancer cases remain EGYPT, GHARBIAH (1999-2002) Tanta University Hospitals, undiagnosed, but underdiagnosis insurance hospitals and clinics, probably occurs for elderly private practitioners and private subjects in rural areas. TCC has a hospitals. The Tanta Cancer full range of diagnostic facilities, Center (TCC) is located in Tanta, so that it is unlikely that cases the principal town and capital of referred will be missed. 


 









Gharbiah, and provides cancer There is a breast cancer 







surgery and chemotherapy early detection program in Tanta 














services. Gharbiah Cancer Cancer Centre. PSA testing is 







Society (GCS), NGO, and the not common in this population. 













radiotherapy department at Bladder cancer, which is the 

 





Tanta University Hospital in the most common cancer in Egypt, is 





 

 




 

vicinity of Tanta Cancer Centre related to Schistosomiasis, which 







provide radiotherapy services. is currently being eradicated. 




 



 


 


In the registry area, patients Smoking is becoming the most 







at the primary and secondary important risk factor for bladder care facilities suspected to have cancer. Liver cancer incidence       
'"$ 

'"$ cancer are generally referred is high compared to almost all 



')%('& )'''  to TCC or to one of the two countries in the world except some hospitals with comprehensive 
   in Asia and Africa; this could be **&'
' '
''''
''''' 
''

' cancer services within a 60-km 
'

''
'  ,,''
''
' attributed to high prevalence of  '''''
'
'
+' radius (Mansoura Urology Center 



 & Mansoura Gastroenterology the hepatitis virus, mainly HCV. Aatoxin contamination might be 
'
'"!#$''%''
' Center) or to the National Liver Institute, Menoufeya University another risk factor. High incidence of NHL is another characteristic (40 km distant), or occasionally to National Cancer Institute, feature in Egypt, but no specic culprit risk factor for this has been Cairo University (100 km distant). identied. Registry structure and methods The registry is located within TCC, and is sponsored by MECC, the US National Cancer Institute in Bethesda, USA, and the Ministry of Health and Population, Cairo, Egypt. A principal investigator, executive director, two co-investigators and eld supervisors, two data managers, four part-time registrars and four full-time secretaries staff the registry. The Gharbiah Population-based Cancer Registry (GPCR) uses active case nding from 57 sources of data consisting of cancer hospitals, general hospitals, university hospitals, insurance hospitals, private hospitals and clinics, specialized hospitals and centres, pathology and haematology labs and the district death registration ofces. Use of the data The registry prepares an annual report of cancer incidence, highlighting trends and changes. Some specic studies of survival of registered cancer cases (breast and liver cancer) have been carried out. Source of population The estimate of the populationatrisk is based on the 1996 census, making allowance for births and deaths, but it was not possible to estimate migration into and out of the registration area. Multiple primary rules used IACR rules (2004) on CI5 IX period.

106

Africa

Tunisia, Central Region

Registration area Tunisia, an Arab-Islamic North African country, is usually divided into three regions: the northern, the central and the southern region. The Central Region registry includes six provinces: Sousse, Monastir, Mahdia, Kairouan, Kasserine and Sidi Bouzid. Sousse province, with an area of 2669 km2 and the capital of the central region, had a 2000 population of 495 000, 18.3% of the overall population of the central region (2 697 200). The population is relatively young, with 48.1% being under 20 years of age, and 8% being over 60 years. The main economic sectors of the region are agriculture, industry (textile) and tourism. suggest therefore studying the epidemiological particularities of that province and not of the whole region. Moreover, we have encountered other practical difculties related to the systematic declaration of cancerous diseases, changes in patient names, and the lack of information on the evolution of patients (treated outside the hospitals of Sousse or lost). These difculties are also due to the lack of precision in issued death certicates, which can be a source of information on the evolution of the diseases. We have two national screening programs concerning cervix and breast cancer. PSA testing is done only in university institutions; to date there is no large screening program for prostate cancer.

Registry structure and Use of the data methods The registry develops an annual The registry of the central TUNISIA, TUNISIA, CENTRAL REGION (1998-2002) report on the incidence of region, staffed by four full-time CENTRAL REGION (1998-2002) cancer in order to define the physicians, is located in the epidemiological profile of the Department of Pathology of the region and compare it with those University Hospital of Sousse. of the north and south regions The search for new cases of Tunisia and those of other is proactive, which means that countries. Certain special studies the registry does not wait to be 












of five-year survival of cervical informed, but actively looks for 







cancer, breast cancer and lung information from certain specic 














cancer have been performed. sources. Primary sources include 







Our registry is involved in the Departments of Pathology of 














some epidemiological research, the public and private medical 







especially in cancer genetics. centres (ve, three of which are 














Our registry is used as a base for in Sousse). The other primary 







planning and providing some sources are the Departments 














health services, for example of Radiotherapy (in Sousse), 







providing instruments for new Oncology (in Sousse) and cancer diagnosis and treatment Haematology, in addition to       
'# % 

'# % (radiation, new-generation CT the other 24 departments of the 


"&'&'''  scans, and mammographs). University Hospital of Sousse. In addition to the  
 Source of population histologically conrmed cases, !))(+""'

'#'''
'
%'
''!))$'
'  
   
'
'#"$%''&''
' more and more cases have been discovered in recent years 19982002 estimates (Institut National de Statistique) based on    without microscopic conrmation and are related to the gall the 1994 census. 
' '

''
'
'
'
''
'
 
''

'*'

' 
'&'#
%' bladder, the pancreas, the prostate, the lungs and the ovaries. Multiple primary rules used IACR rules (2004) on CI5 IX period. Interpreting the results The registry counts all of the new declared cases of cancer in the entire central region of Tunisia. Nevertheless, apart from Notes on the data the province of Sousse where the completeness reaches 97%, a The Editors recommend that some care be taken in the lack of completeness is observed in the other 5 provinces. We interpretation of these data; see Chapter 5 (Categorisation).

107

Africa

Uganda, Kyadondo County

The registry is computerised, and data management is Registration area The Kampala Cancer Registry collects data on the population carried out using the IARC/IACR CanReg software, which of Kyadondo County, which includes the city of Kampala (the includes checks for consistency and validity and permits a capital of Uganda), with its peri-urban areas and an area extending search for potential duplicate registrations. Patient condentiality is ensured by using only registration 30km to the north. This population, which is mainly urban (80%), is composed of the Ganda ethnic group (50%) and other ethnic numbers during analysis of data. The registry is off-limits for groups (30%). There are also immigrants from neighbouring unauthorised persons. Completeness of registration was evaluated at 90% for the countries, particularly from Kenya and Rwanda. Europeans, Asians period 19941996 (Wabinga et al, Cancer Causes & Control and other nationalities make up 1% of the population. The major activities of the residents of the capital include 2001; 12:147-52) administration, trade, professional and para-professional activities, personal services, and plant and machine operation. There are no Interpreting the results major industries in the county; subsistence farming is carried out Since its inception in 1951, the county covered by the registry has not changed its boundaries. on the outskirts of the capital. However the population Fifty percent of the population is becoming increasingly are Catholic, 30% Anglican, 15% UGANDA, KYADONDO COUNTY (1998-2002) urbanised as the city expands. Muslim and 5% other. UGANDA, KYADONDO COUNTY (1998-2002) Immigration is also increasing Staple foods consumed by the as part of the worldwide trend population of Kyadondo County of rural to urban migration. include matoke (steamed green Another factor that may banana), posho (maize bread), inuence incidence rates is the beans and groundnuts. About improvement in availability of 50% of the city dwellers receive ,.&1'... /#1.1''... &.00&... ,+! '.&1#... diagnostic services, particularly chlorine-treated piped water from +.#',... ,#! ,.&/0... in the national referral hospital the freshwater Lake Victoria. +./1%... ++! +.))&... %#.1/0... +#! %#.+,'... Screening programmes %+.'+'... )+! %'.&+&... for cancer are not organised, Cancer care facilities &+.)''... )#! &&.#0%... '/.10&... '+! '&.,&#... but with the health-oriented Kyadondo County is served ,&.%''... '#! +%.##)... population of the county, many by a 900-bed national referral 0+./,'... &+! 0+.###... 1,.,)/... &#! %%+.%%#... patients seek screening services. hospital, Mulago Hospital, 0,.##0... %+! %%0.)'%... PSA testing, mammography which is well equipped with 0+.0/#... %#! %#).''1... 1'.,1,... +! 11.1++... and Pap smears are done on an modern diagnostic facilities. %%).%+%... #! %%+.,+%... individual basis. Mulago, which is also a teaching Uganda was one of the rst hospital for Makerere University %# + # # + %# countries to be severely affected Faculty of Medicine, is well .($* .($* by the HIV/AIDS epidemic, and supplied with consultants and /1&.1+%... /').#%+...  this has profoundly inuenced the teaching staff in all disciplines  
 ........... pattern of cancer in Kyadondo of medicine. An oncology unit .

..........%11&..&##&.. .+...
". involved in chemotherapy for various types of cancer and a County (Wabinga et al, Int J Cancer. 1993; 54:26-36). However,  
   
..(&##)*.. +..
. radiotherapy unit are attached.   The county has three other as a result of vigorous national campaigns, prevalence of HIV . .........
...2.. 
.+.( *". ..........
". missionary hospitals with 100 beds each. The Uganda Hospice infection is now fallingaccording to UNAIDS, prevalence in provides services for the care of terminal cases of cancer in pregnant women in Kampala fell from 18.5% in 1995 to 13.8% in addition to other terminal diseases. Two private histopathology 1998 and 8.3% in 2002. This, together with the slowly increasing laboratories provide additional histological data to the registry. availability of anti-retroviral therapy, will result in changes in the incidence of AIDS-related cancers. Registry structure and methods The Kampala Cancer Registry is situated in the Department of Use of the data Pathology, Faculty of Medicine, Makerere University. Personnel The registry provides the longest continuous time series of include a pathologist director, a cancer registrar and an assistant cancer incidence in Africa. This makes the data of special value in cancer surveillance and research, particularly to monitor the cancer registrar. All are employees of Makerere University. However, in various hospitals and units the registry has effects of the HIV/AIDS epidemic and to serve as the baseline recruited personnel to assist in coordinating collection of data. for analytical studies and intervention studies. The registry has Submission of data to the registry is voluntary, as cancer is not also published the rst population-based estimates of cancer a notiable disease, and registration is almost entirely active. survival in sub-Saharan Africa. Doctors report a few cases to the registry directly. For hospitals, hospices and histopathology laboratories, the registrars visit Source of population at least once a month and consult the hospital records, which The population at risk is based on the results of the 1992 and include admissions and discharge registers, clinical notes and 2002 census data, with intercensal years estimated from the pathology reports. For each case both demographic and cancer observed rate of growth within 5 year age groups. diagnostic data are sought. Certication of death is only carried out for legal reasons, and is very incomplete, so death certicates Multiple primary rules used IACR rules (2004) on CI5 IX period. are not used as a source of information.

108

Africa

Notes on the data The Editors recommend that some care be taken in the interpretation of these data; see Chapter 5 (Categorisation).

This registry has the lowest histological verication rate in the monograph.

109

Africa

Zimbabwe, Harare
Registration area Harare is located in north-eastern Zimbabwe and is the capital city. The population of the city according to the 2002 national census was 1.9 million. The national population was 11.6 million. Histology reports from the public and private sectors, medical records of the radiotherapy department, death certicates of patients dying of cancer in greater Harare, and records of specic clinical research studies. Hospital inpatients are interviewed to verify the accuracy of reported age, residential status and other demographic data. Cancer care facilities The current difcult economic situation currently in Zimbabwe Information recorded on each case includes sex, date of birth or is negatively affecting healthcare delivery, particularly in the age, residence, racial group, basis of diagnosis, tumour site and public sector. In spite of this, the system in Harare, based on histology. Residence status is dened as the patients place of a network of primary health care facilities provided by the residence during the previous six months. All notications coming into the registry are thoroughly municipality, government-funded referral facilities and a private sector that caters mainly to middle- and higher-income groups, vetted to ensure that only incident cases are recorded. Incident cases are veried by the treating doctors to conrm continues to perform reasonably. the diagnosis, and completed forms are coded. The data are Registry structure and stored electronically using the methods ZIMBABWE, HARARE: AFRICAN (1998-2002) IARC/IACR CanReg system. The Zimbabwe National Cancer ZIMBABWE, HARARE: AFRICAN (1998-2002) Patient name lists are generated Registry (NCR) was established periodically to physically in 1985 in Harare as a result of eliminate duplicates. an agreement between IARC When several lesions of the and the Zimbabwean Ministry same histological type occur in of Health. The target population a patient, only the rst lesion is of the registry is that of Harare 


 









recorded. Subsequent lesions city, and adequate population 







are ignored. For example, the coverage was achieved in 1990. 














incidence of non-melanoma Although the registry records all 







skin cancer is very high in the cancer patients identied from 

 












white community of Zimbabwe, its diverse sources irrespective 







and many patients develop of residence, the present data 














several lesions of the same for 19982002 are conned to 







histological type during their the Harare city population. 

 












lifetime. However, if basal cell The activities of the registry 







carcinoma and squamous cell are overseen by a constituted carcinoma of the skin occur in advisory committee, and the       the same patient affecting the day-to-day administration is the +&#( +&#( 


-*,+-%,+++  same or different sites, they are responsibility of the registrar recorded separately. under the guidance of the  
 medical director. The registry ++%""% ++++$..-0%""%+
+++
+  
   has four full-time staff comprising the registrar, secretary Use of the data 
++&%""'(++ )++
+ and two data collection clerks.   It is strategically located at Data from the registry are extensively utilised by both indigenous + +++++++++
+++/++ 
+)+& (!+ ++++++++++
!+ Parirenyatwa Hospital, a large government referral centre and and foreign researchers, lecturers, students, conference participants, also the location of the University of Zimbabwe College of health educators, and the Ministry of Health and Child Welfare for Health Sciences. The registry is supported by the Ministry of management planning and cancer control programmes. Health and Child Welfare, the IARC and other organisations. Case-nding is mainly active, with the registry staff visiting Source of population institutions within the healthcare delivery system which are Claimed to derive from the 2002 census, but the data do not correspond to the period 1998-2002. involved in the management of cancer patients. The registry information sources include: Routine weekly visits to the inpatient wards of the two government central referral hospitals (Harare and Parirenyatwa); Medical records of discharged and deceased cancer patients from the two central hospitals and visits to oncology outpatient clinics; Multiple primary rules used IACR rules (2004) on CI5 IX period. Notes on the data The Editors recommend that some care be taken in the interpretation of these data; see Chapter 5 (Categorisation). This registry has the lowest histological verication rate in the monograph.

110

Central and South America

Central and South America

Argentina, Bahia Blanca

has been received from IARC. The foundation Alberto J. Registration area The Regional Tumor Registry of the South of the Province Roemmers provided funds for epidemiological research in of Buenos Aires covers an area corresponding to 15 political 20002001, and the National Ministry of Health in 2004. Data collection is mainly active. The sources of cancer cases areas, with a population of 627 505 inhabitants in 2001. The data presented are for the political area of Bahia Blanca are public, private and military hospitals, as well as pathology laboratories and a flux cytometry laboratory. We also visit (population 284 776) only. Bahia Blanca is mainly an urban area, with a large Radiotherapy Institutes and haematology doctors ofces. Data management is carried out using the IARC/IACR petrochemical industry. The remainder of the population CanReg software. lives in small rural villages. Practically 100% of the population is white, most of them descended from European immigrants who arrived Interpreting the results during the late 19th and early 20th centuries. In some political There have been few changes in the population since the areas, such as Coronel Suarez, there are settlements of establishment of the Registry. The Registry has more information sources for this German descendants. In the period compared to in 1989 south of the province, there 92 and 19931997, so the data is a varying population of ARGENTINA, BAHIA BLANCA (1998-2002) are now more complete. workers who come from Chile ARGENTINA, BAHIA BLANCA (1998-2002) There are no organised for the onion harvest, but the screening programmes within permanent Chilean population the region. PSA is used more amounts to less than 5%. frequently, but it is not possible The predominant religion is 

 









to determine the proportion Catholic, but there are also 







of the male adult population other Christian minorities. 














screened. 






Cancer care facilities 

 









Use of the data The two public hospitals of the 







Reporting of incidence is area have oncology services. 











considered the most important Surgery is performed in the 







activity of the registry, as general surgical services. 





 








population-based cancer There are two private 







registration is so limited in the radiotherapy institutes, which 














country. also treat patients from public 







In combination with the hospitals; one has a linear registry, the Epidemiological accelerator. Computerised       Investigation Unit on Cancer tomography is available in  % "   % " performs some tobacco almost all of the larger public 


$%&''%%%  control activities. and private institutions, and 

   During the last three one of them has a nuclear  %  %
% %(%) % % %% %%   %%  



 years we have been consulted at the national and provincial magnetic resonance imaging facility. 
% % !"%%#%% % levels to develop new cancer registries, and we have trained professionals and technicians in the provinces of La Pampa Registry structure and methods Although the registry was recognised by Provincial law and and Jujuy, where new cancer registries have recently been a municipal resolution in 1993, it still does not have a specic established. The registry is currently involved in epidemiological budget. It is based in the Dr. Jose Penna General Hospital and its Director has been appointed Chief of the Biomedical research, and policymakers use our data for planning and Investigation Unit, but no specic personnel or funds have evaluation of health services. been assigned. The Argentinean Association for Education and Prevention of Cancer, a non-prot organization founded Source of population in 1986 to improve cancer control, maintains the registry The estimate of the populationatrisk is based on the 2001 and other high-priority activities of the Association, such Census. as the Tobacco Control Programme. Although its resources are limited, it is able to pay for a registrar, and has provided Multiple primary rules used small fellowships for training young students. Some support IACR rules (2004) on CI5 IX period.

112

Central and South America

Brazil, Brasilia
Cancer care facilities Registration area The PBCR Federal District (DF) covers the capital city, in the In 2002 the DF had 60 hospitals: 14 state-provided, 5 federal Mid-West region of Brazil. It is located between 1530 and and 41 private. Early Detection programs are available in basic 1603 South latitude and 4725 and 4812 West longitude, care units (68 Health Centres and Units with Family Health covers an area of 5 789.16 km, with 255.25 km being urban Program - PSF), and in the regional referral units (10 Regional and 5533.91 km being rural. The climate includes tropical Hospitals). The Federal District has High Complexity Centres savannas and temperate rainy areas with dry winters; of Cancer Treatment (CACON) at 3 hospitals. annual average temperature is 20.5C (69F) with average air humidity varying between 39 to 83%, being lowest in August Registry structure and methods and September and highest in December. The altitude is The Epidemiology and Regulation Management coordinates the Population-Based Cancer Registry in the DF and between 1000 and 1152 meters above sea level. The last demographic census carried out in 2000 by supervises, assesses and monitors the hospital-based cancer the Brazilian Institute of Geography and Statistics (IBGE) registries in this district. In the DF there is a Skin Cancer Registry that assesses skin disclosed that in the DF, cancer cases diagnosed in the the resident population was public health system. 2 139 580 inhabitants (1 BRAZIL, BRASILIA (1998-2001) The PBCR of the Federal 069 790 women and 981 BRAZIL, BRASILIA (1998-2001) District registers all the cases 356 men), distributed in 28 of cancer (invasive and in situ) Administrative Regions, with and benign CNS tumours 4.2% (89 647) in the rural (in children and adolescents area. The vast majority of the 


 









under 19 years old) diagnosed population is Catholic. 







in the DF resident population. 














Cancer is not a notiable Interpreting the data 







disease. The main sources The life expectancy for those 












 

of data collection are located born in 2000 was of 69.24 







in pathology labs, health years. Currently, the Federal 














information systems, hospitals District as well as the whole 







and private oncology clinics. country is experiencing rapid 














and expansive demographic The PBCR initiated its 





 

change, with an aging activities on 27 November 














population and consequent 1997 and follows the rules 







increase in the chronic of the National Institute of degenerative illnesses reected Cancer/Brazil (INCA). It uses       in mortality statistics. In 2002, SISBASEPOP/INCA software  0+'! 0+'/),000 $ 1*2000 cardiovascular illness was the and it has published data referring 



3/*0&12000   most frequent cause of death to the years 19962001. 
   in the DF, representing 27.7%
0)&&&$0(332#0(333#0)&&(#0)&&)0!  0"0  000 0  0 040%

0  



 of all deaths, followed by cancer (16.6%). In 1979 cancer Use of the data 

00+)&&,-00
.00 0 was responsible for 9.4% of the deaths in the DF; therefore, The Cancer Registry works in cooperation with Cancer Care from 1979 to 2002 cancer mortality increased by 76%. The Coordination, which is responsible for planning, evaluating and Ministry of Health (MS) has been publishing data on causes executing the Oncological Plan for the DF. The structure of the of mortality in Brazilian capitals since 1944. In 1975, the coordination includes Care Delivery Management, Primary MS implemented the Subsystem of Information of Mortality Prevention Management, Early Detection Management, (SIM), dening the national model of death certication Epidemiology and Regulation Management, Financial and and centralising the processing and annual publication of Human Resources Management, Palliative Care Management, these data. The quality of information in the DF is partially and Evaluation, Teaching and Research Management. It is attributed to low levels of unclear causes of mortality (0.8 responsible for planning and coordinating health promotion, 5%) in the last ve years, the lowest rate among states of prevention and care activities in the district. the federation. A study carried out in 130 480 deaths in the DF from 19791988 disclosed that 16 098 deaths had cancer Source of population as the primary cause; 41.3% of the deaths had been veried Census 2000. 1998, 1999, 2001, 2002 estimated by Brasilian through autopsies. However, in the deaths caused by cancer, Institute of Geography and Statistics (IBGE/DATASUS). only 12.2% were submitted to necropsy; the younger the patient the higher the number of autopsies. Thus, the fewest Multiple primary rules used autopsies were performed in patients over 74 years old. IACR rules (2004) on CI5 IX period.

113

Central and South America

Brazil, Cuiaba
Registration area The PBCR of Cuiab covers the cities of Cuiab and Vrzea Grande, in the Midwest region of Brazil. Cuiab and Vrzea Grande have a total area of 4482 Km2. About 98.44% of the population (some 686,481 inhabitants) lives in urban areas, and the annual growth rate is 2.72% for Cuiab and 2.66% for Vrzea Grande. The city of Cuiab is 177 meters above sea level, and Vrzea Grande, 191 meters. The climate is continental tropical, with a mean annual temperature of 33C. Registry structure and methods The PBCR was established in 1999, and data collection started in the year 2000. It is located in the Health Care Department of the State Health Secretariat of Mato Grosso, and has xed funding. The registry staff includes a coordinator, a supervisor and 3 registrars. The advisory committee includes an epidemiologist, a pathologist and an oncologist. Data are actively collected from 25 sources: one specialised hospital, two university hospitals, one general hospital, 10 pathology labs, one hematology clinic, two oncology clinics, two radiation therapy clinics, and 6 chemotherapy clinics. Information on deaths is retrieved from the Mortality Information System (SIM). Use of the data In addition to determining cancer incidence and geographic distribution in the city of Cuiab, the information has been used to study temporal trends, to provide access to screening programs, to collect dat a for epidem iologica l studies, to provide resources for teaching and delivery of lectures, and to support cancer prevention and care actions. Source of population 2001 and 2002, estimates. 2000: census. Estimated by Brasilian Institute of Geopgraphy and Statistics (IBGE) Official Bureau (www.ibge.gov.br). Multiple primary rules used IACR rules (1990).

Cancer care facilities The State Cancer Control and Prevention Coordination of the State Health Secretariat of Mato Grosso has been working to meet the needs for those BRAZIL, CUIABA (2000-2002) BRAZIL, CUIABA (2000-2002) who work in the eld of oncology, supporting prevention and delivery of care actions, research and 

 









epidemiological studies. 
 





Health progra ms and 





 


 





services are provided by 







4 public hospitals and 1














private hospital, with 162 







public beds (2.3 per 1000 














i n habit a nt s). T her e a r e 







also healthcare units with 














cancer prevention and early 







detection facilities. Other 





 








cancer diagnostic and 







treatment facilities include: two radiation therapy clinics,       5 chemotherapy clinics, and -)%+  -)%+ 10 pathology labs. There are 


(,$-*.'-- 22 universities, 3 of which 

   '$$&--'$$'"- #-'$$$0-#- -!--- -

---1--1- -have medical schools. )#!##!+ 



 
--)&//$+--

114

Central and South America

Brazil, Goinia
also an Advisory Council comprising seven specialists in Registration area The Cancer Registry of Goinia is a population-based cancer oncology. Data collection is active and no precoded data are received. registry that covers an area of 739 Km2. The city is a part of the central plateau in Brazil. The local altitude is 800 The main sources of information are the Cancer Hospital, meters, at latitude 16 40 and longitude 49 15. The climate outpatient cancer clinics, histopathology laboratories and is tropical and the city is hot and sunny almost all year. the University Hospital. The registry has access to death The average annual temperature is 1030C.The humidity certicates, which include identifying information. Cancer averages 43% during the winter and 74% during the summer. is not a notiable disease. Quality control procedures include verication of date Two rivers, Joo Leite and Meia Ponte, cross the city and provide its water. Goinia, the second planned city in Brasil, of birth versus topography, sex versus topography and morphology, etc. Analyses of incidence and mortality is now 72 years old. The majority of the population comes from rural areas. In the being evaluated include: cervix cancer, breast cancer, and last ten years, the population migrating to the city is decreasing, prostate cancer. We also carry out studies on survival of cervix cancer, breast cancer, because agricultural industries colon cancer, larynx, mouth, are increasing in the rural oesophagus and cutaneous areas. The ethnic composition BRAZIL, GOIANIA (1999-2002) melanoma. is primarily mulattos and BRAZIL, GOIANIA (1999-2002) whites, with a few blacks. The Interpreting the results main religion is Catholic but There are screening the number of evangelicals is programmes for detection increasing. of breast, skin and prostate 


 









cancer. PSA testing is not Cancer care facilities 







common. We have one Cancer Hospital 














founded 50 years ago, which 





 








Use of the data provides 180 beds, chemotherapy, 







Data on incidence are reported 4 radiotherapy machines, surgery, 

 












to the providers of information and chemotherapy, as well as 





 

to the registry, and the registry bone marrow transplantation 














collaborates with postgraduate since 2000. There are 5 private 







students doing theses. clinics also doing chemotherapy. 

 












Research is being carried out The cancer centre also provides 







on cancer of the oral cavity, cancer training courses in larynx and oesophagus in a surgery, radiotherapy and       collaborative study. chemotherapy. "!/+'#"!/+'Source of population Registry structure and 
   #" /$/"!"///"/" /"/2//2/ "!/"/+ %$%%$-/ Estimated by the Brasilian methods The registry is located in the 



 Cancer Hospital. Financial Institute of Geography and Statistics (IBGE) Ofcial Bureau 

/!/+)&&,-//
.// / support comes from the Associao de Combate ao Cancer (www.ibge.gov.br). em Gois (ACCG). The registry is coordinated by an oncologist. Four Multiple primary rules used people collect data and there is one to code. There is IACR rules (2004) on CI5 IX period.
(,0/// .)*/.(&/// % "! (1,/// 


115

Central and South America

Brazil, So Paulo
Registration Area The So Paulo Cancer Registry covers the resident population of the city of So Paulo, capital of the State of So Paulo, located in the Brazilian Southeast Administrative Region. The population data is based in the most recent Census (2000), and it includes more than 10 million people, mostly urban (almost 99%) and formed by migrants of many nationalities (Italians, Portuguese, Spanish, Japanese, Germans, etc.). A high percentage of the population is Catholic. Although cancer is not considered a notiable disease, the methods of data collection are mixed; some hospitals have active notications (spontaneously) of newly diagnosed cases, and others have passive notications. The main data sources (380 units) are hospitals (some are cancer hospitals) and pathology laboratories. A special study of survival of cervix cancer and breast cancer in young women illustrated the very good completeness and accuracy of the information recorded in the registry. cancer screening programmes in the area covered, and PSA testing is also common. Use of the data Annual reports on cancer incidence and mortality are prepared highlighting trends and changes. Some special survival studies (cancer in childhood and cervix cancer) have been carried out. Many graduate students use the registry data bank for their PhD theses or Masters Degree dissertations; the local health authorities use it as well.

Cancer care facilities General health care is provided by the local and state Interpreting the results health services departments through the district health There are breast and cervix centres and hospitals, supplemented by private practitioners and covered BRAZIL, SAO PAULO (1998-2002) by insurance. Regarding BRAZIL, SAO PAULO (1998-2002) cancer, So Paulo has many hospitals, radiotherapy and chemotherapy services and pathology laboratories.

.',!%.,,, -)+ #)%,))),,, Registry structure and -*,#/#,,, -! ##%,--*,,, #!#,!.-,,, *) #%.,'#.,,, methods #%$,*-',,, *! #-!,-*),,, The Registry belongs to the #**,$-),,, )) $!$,.)$,,, $$-,.-/,,, )! $*/,$--,,, Department of Epidemiology $.','#!,,, ') %%#,.*/,,, of the School of Public Health %'$,!/*,,, '! %/!,%!$,,, %.-,/).,,, %) '%#,-#-,,, of the University of So Paulo, '$%,#./,,, %! ')),$'),,, one of the ve preeminent ').,'.#,,, $) './,$)#,,, '..,%!$,,, $! )#-,.)',,, Brazilian universities. '-%,/*',,, #) '/#,'%/,,, The nancial support is ''!,/'$,,, #! '%-,%!.,,, '$),*!%,,, ) '#',%'#,,, Source of population provided at all three government ')#,!%-,,, ! '%*,%.*,,, Census 2000. 1998, 1999, 2001, levels (local, state and federal 2002 estimated by Foundation resources). A coordinator (a #! ) ! ! ) #! Seade (Ofcial Institucion For cancer surgeon physician), ,&"( ,&"( Population Statistics In The 8 data collectors, and three ),''',%)',,, ',/*',#$-,,,  State Of Sao Paulo). informatics processors 
   compose the administrative ,$!!! ,#//.,#///,$!!#,$!!$,,,,,& ,,,
,,,,, ,,( ,  



 framework. There is also a Scientic Commission that provides Multiple primary rules used 
,,&$!!'(,, ),,
, IACR rules (2004) on CI5 IX period. epidemiological, statistical and pathology assistance.

116

Central and South America

Chile, Valdivia
Registration area Valdivias registry area corresponds to Valdivia province, which is divided into 12 districts, located in the 10th region in the south of Chile. The total population of the province, based on the last 2002 census, is 356 396 inhabitants, with a male:female ratio of 1:1; the rural population reaches 38%. Some 70% of the population is in the public health system. According to the 2002 national census, among the population over 15 years old in Valdivia province 62.5% are Catholic, with 24.5% evangelicals, 7.8% atheists and 5.2% other religions. Ethnic groups comprise 11.4%; the indigenous Mapuche represent 99.1% of these. We use the CanReg program to register the basic variables dened for the population cancer registries of Chile. The quality standards used are: Percentage of cases with microscopic conrmation; Percentage of cases with death certicate only; Percentage of cases registered without age; and Ratio mortality/ Incidence. Cases are maintained condentially, preserving the patients individual information.

Interpreting the results It is not possible to estimate the proportion of cases of Valdivia residents who choose to continue study or seek treatment in another province, but it is considered to be low as Valdivia Regional Clinical Hospital is the referral centre for the southern area of the country. Cancer care facilities Data are evaluated by The health care network of checking different data sources Valdivia province is mainly CHILE, VALDIVIA (1998-2002) and their validity, as well as public. It comprises 16 CHILE, VALDIVIA (1998-2002) the coding system and correct primary care centers and computational support and 8 public general hospitals, quality standards. We apply the which refer their patients IARC Check program once a with presumed oncological '/'(*/// 1$. (/$1$/// year in order to nd and correct diseases to Valdivia Regional '/*$0/// 0," (/$02/// any errors. Clinical Hospital. This is (/*$0/// 0$" */&-(/// */-'-/// -," ,/(2&/// There are national the only oncology centre of ,/,$*/// -$" -/&11/// programs of early detection the registry area, and it also -/2$(/// ,," 0/'$$/// 1/'((/// ,$" 1/*('/// for cancer of the cervix (Pap provides teaching and health &$/&-0/// *," 2/00&/// smear) and breast (physical services in coalition with the &'/-&$/// *$" &'/$1-/// &*/1((/// (," &*/&-0/// exam and breast x-ray in Universidad Austral de Chile. &(/2*&/// ($" &(/0*0/// high risk group). There This core hospital has &(/(10/// '," &(/&''/// &(/2-&/// '$" &(/*,-/// is no national program of a pathology laboratory and &-/1*$/// &," &-/$*,/// PSA testing; it is usually provides surgical, radiotherapy &1/-*(/// &$" &0/-&1/// &1/(,2/// ," &0/,0,/// requested in patients with and chemotherapy treatments. &,/1,,/// $" &,/(-(/// benign prostate hyperplasia, The child radiotherapy and sometimes requested in treatment facility is the only &$ , $ $ , &$ preventive medicine. one in our region. /)%+  /)%+ No environmental changes &1$/*1*/// &1&/2&$///  Registry structure and that would affect cancer incidence 
   / /// //////&$/#//////'$$'/#///// / methods have been registered during the // //!/// / The population cancer registry 



 is in the Epidemiology Unit study period, but in 2004 a cellulose factory began operating. 

//)'$$*+//
,/// Ofce of Valdivia Province, which is part of the Regional Health Authority of the 10th region, a dependent unit of the Use of the data Undersecretary of Public Health of the Health Ministry. The registry has prepared incidence reports for publication in It receives technical support from the oncology committee the epidemiology bulletin El Vigia from the Health Ministry, of Valdivia Regional Clinical Hospital and it has one nutrition and which are available on the Ministrys web site. Last year professional with 33-hour week and two physicians part- we completed specic survival studies in gastric and gall time, all with masters degrees in public health. bladder cancer; these were provided to the groups in charge The registry uses six information sources, passively of the protocols for both diseases in the Health Ministry. receiving weekly notifications from the pathology Registry information was also used in planning laboratory of the Valdivia Regional Clinical Hospital and modernisation and enlargement projects for the oncology actively reviewing all of the clinical records of previous service at Valdivia Regional Hospital. weeks patients discharged with cancer diagnosis, both from the Regional Hospital of Valdivia and from Source of population the private centres. Also, all cases that enter through The National Statistics Institute makes a national population particular units and programs are reviewed: Hematology, census every 10 years. the last of which was in 2002. This National Program for Cancer Medication (drugs) and provides a projection of the population for each region, Pain Control Program. The registry also has access to province and commune. review all of the provinces death certicates and the data kept by the Statistical Departments of the Chilean Multiple primary rules used Health Ministry. IACR rules (2004) on CI5 IX period.

117

Central and South America

Colombia, Cali
Registration area clerks and a secretary. Once a year, a group of specially The Registry, in operation since 1962, is limited to the urban area trained medical students is selected to carry out a eld survey of the city of Cali. Cali is the capital of the Department of Valle, of les of all private physicians who diagnose or treat cancer one of Colombias 32 departments. The department is located in patients. The registry staff and part of the operating cost are the south-west of Colombia on the Pacic Ocean. Cali is situated covered by de Universidad del Valle. Most of the operating 1000m above sea level between the Cauca river to the east and the costs are obtained from foundations and specic grants for chain of the Andes to the west, at latitude 327 N and longitude each activity. The CCR registry uses active case nding from 57 sources 731 W. The average temperature is 24C. The urban registration area of the registry is 120.9 km2. The population at the most of data, including cancer hospitals, general hospitals, teaching recent census (2005) was 2 030 000. The great majority of the hospitals and 32 pathology laboratories. The information population are Mestizos (a mixture of Spanish and Indian) with a from death certicates is obtained from the Municipal Ofce minority of blacks and whites. More than half of the population of Vital Statistics to check against cancer registration. The are migrants from other areas of Colombia, and in lesser part death registration system is very adequate and complete, and the cause of death is always from other countries. The noted. The registry staff visit major part of the population is these sources, where they Catholic. The ofcial language COLOMBIA, CALI (1998-2002) scrutinise the records kept in is Spanish. COLOMBIA, CALI (1998-2002) medical records departments, and registers of individual Cancer care facilities departments concerned with The Colombian Social diagnosis and treatment Security System reformed in $+ -,+++ -(* (+&)#+++ &+("&+++ -  )+.(&+++ of cancers, to identify and 1993, creating two healthcare -+&).+++ ,( ""+(,,+++ abstract information on cases systems, one for those who "#+",,+++ ,  ")+&),+++ ")+..$+++ )( #"+,( +++ of cancer, diagnosed by all can afford to pay for health ##+& #+++ )  #,+,)-+++ methods, among residents care and one for those #,+(",+++ (( $$+."-+++ $(+.&,+++ (  &$+"$"+++ of the registry region. The who cannot. Because the &$+-()+++ &( ("+-,(+++ data concerning each case subsidised healthcare system ()+# -+++ &  )&+ ."+++ )$+$)&+++ $( ,&+&--+++ are registered on a special does not have the capacity to ,"+.((+++ $  -"+..(+++ form at the source site. They meet demand, a third system ,-+( "+++ #( . +-&$+++ -#+.-&+++ #  .,+ $.+++ are classied and revised has developed for those who - +-"#+++ "( ."+( +++ at the registry ofce, and are linked to the subsidised -.+()(+++ "  -.+)""+++ -,+ & +++ ( -&+-,#+++ the information is entered health care system but are -"+-.)+++  ,.+$ (+++ into a computer database not part of it. Those who are for checking for duplicates, linked receive a document " ( ( " errors and inconsistencies. attesting to their status, and 
+%!' 

+%!' Difcult cases are discussed they can receive emergency .,#+)&(+++ -),+#--+++  by the staff and resolved care. Health services 
   +# "++# #+++
+

+

+

+ either by the registry director management and delivery 

+

++
+

+  ++
+
++
+
+"..,+"..-+"...+# 
++
 
+
 ++
+
+++"..$++# (+ are decentralised to strengthen 



 the role of departments and or by revisiting the source and sometimes reviewing the 
+
+%# '+ municipalities, the private sector is incorporated within the microscopic slides. No active follow-up is carried out. insurance and health services delivery functions, and basic Use of the data health services are free and compulsory. A basic network of health centres has been planned The population-based cancer registry of Cali has been for the entire urban territory, and programmes of primary studying incidence and mortality trends in the city for the care and prevention have been promoted. About 60% of period 19622001 using the age-period-cohort model. A the cancer patients diagnosed in Cali are treated at Valle long-term analysis of survival of uterine cervix cancer is University Hospital, a public general hospital with a total of underway. A brochure that contains information on CCR activities 630 beds. A hospital-based cancer registry was established in 1986, a team for the management of childhood cancer began and incidence and trends in Cali was issued by CCR and activities in 1989, and a formal oncology department was distributed to physicians and Health Services. The Cali initiated at the end of the 1990s. The hospital also maintains Cancer Registry is pleased to provide cancer statistics radio- and chemotherapy facilities. Other facilities for cancer through this Web page: http://rpcc.univalle.edu.co. diagnosis and treatment include four major non-university hospitals, cytopathology and haematology laboratories, and Source of population Intercensal estimates of the resident population by age and radiotherapy and chemotherapy centres. sex for each year 1997, 1998, 1999, 2000, 2001 and 2002. The intercensal estimates were obtained by exponential Registry structure and methods The registry is located in the Department of Pathology of interpolation from the census counts of 1993 and 2005. the Medical School in the Universidad del Valle. The staff includes a Director, who is the Professor of Pathology, three Multiple primary rules used assessing pathologists, a statistician coordinator, three record IACR rules (2000)

118

Central and South America

Costa Rica
of the healthcare system, after which they are classied as DCN or DCO cases or are discarded. The registry is fully computerised, and each report sheet is checked against the Civil Registry database to determine if the report concerns a Costa Rican. For nationals the personal identication number, name and date of birth or death are veried. Foreigners are included and coded as such in the ID variable; there is a special code for cases of uncertain origin. Reports are then linked to the registry database, using Cancer care facilities The country has a national health care system and good- software specially designed to nd duplicates, to classify the quality vital statistics. The National Social Security system case as incident or not. Each primary tumour case is given a covers more than 90% of the population. The remaining 10% unique identifying registry number, which is included in the are attended by private health services. Social Security is registry database. Several consistency check edits are carried out during data entry, including organized in 3 levels: patients date of birth/incidence date/ with suspected cancer are date of death, sex/site, age/ referred to the 2nd and 3rd COSTA RICA (1998-2002) site, age/histology, and site/ levels (specialised). The Social COSTA RICA (1998-2002) histology. Multiple primaries Security system is made up of are registered according to the 29 hospitals; 5 of them have an IARC rules. Oncology Department. Only Follow-up of cases is 2 hospitals have radiotherapy mostly passive, although every departments, and there are 2 !&()%)((( )%' #!(+*((( four years an update of death private radiotherapy centres. )( %((( ) +(#!((( !#(!#*((( &% !&(*((( dates is conducted with the #!())((( & #%( %+((( Civil Registry. Registry structure and %#()&&((( %% %%(+!*((( )!(& *((( % )!(%!)((( methods (*%((( #% +)(&&+((( Interpreting the results The Costa Rica National !(#++((( #  #(*((( %!(%)((( !% #&( #((( Although no study has Tumour Registry was %+(!%&((( ! %(+& ((( been made to evaluate the founded in December 1976 %)()%((( % %(#!*((( *(#)(((  ) ( )((( registrys completeness of by Executive Decree and !(*%((( % +!(+%)((( coverage, under-registration is started functioning in 1977, +() !(((  )(+ )((( %(&# ((( % !(#&#((( estimated to be low given the but nationwide coverage was !()*(((  +!( !*((( characteristics of the health achieved only in 1980. The system and the vital statistics. aims were to collect data  %   %  Cases with a cytological about cancer incidence and 
("$

("$ (+ )(#((( (++#(%)(((  diagnosis are accepted when prevalence regarding age, sex, localized in specic sites such cancer site and geographical 
   as lung and cervix. distribution within the 
(

((  (

(
((
(

((+*#(( (  



 The country has made important efforts to establish early country. 
(
(" $((%((
( The registry occupies a section of the Statistics cancer detection programmes, especially for cervix, breast, Department of the Ministry of Health, which provides stomach, colon, prostate and skin cancers. all nancial support. One physician, a medical registry technician and two statistical assistants are dedicated full Use of the data time to the registry. Several medical registry technicians The registry information is used in cancer control decision-making of the Statistics Department collaborate with the registry at several levels, and also has been used in various studies regarding obtaining information on incomplete cases at the hospitals occupational exposure cohorts and the risk of cancer during recent and clinics and during the death clearance process. years, as well as in descriptive and survival studies. The sources of information for the registry are the The country will soon reinforce the Cancer National compulsory notication sheets on patients leaving hospital, Health Care Network as part of the recently-dened National biopsy and autopsy reports with a diagnosis of cancer Cancer Plan. As cancer is the second cause of mortality in the from all pathology services (public and private), and death country, it is considered a principal public health problem. certicates mentioning cancer from the National Institute of Statistics and Census. Source of population Except for death certicates, which must be retrieved by The estimated annual populations were based on the censuses the staff, data collection and case follow-up are passive. Death of 1984 and 2000. registration is complete, as it is compulsory to show a death certicate before burial. All death certicates mentioning Multiple primary rules used cancer undergo a clearance process within the hospitals IACR rules (2000) on CI5 IX period Registration area Costa Rica covers an area of 51 100 km2. At the 2000 census the population was 3 810 179 (1 902 614 males and 1 907 565 females), of whom 59% lived in cities and 41% in rural areas. The ofcial religion is Roman Catholic. The main ethnic group is Caucasian-Native, and there are smaller proportions of Blacks, Natives, Chinese and Caucasian-Black.

119

Central and South America

Ecuador, Quito
Registration area The National Cancer Registry covers the population living in the city of Quito, the capital of the Republic of Ecuador, situated at 2810m above sea level, in the Andes Cordillera. The city is surrounded by mountains and the average temperature is 17C. The average annual growth rate of the population is 2%, which includes a large number of immigrants from rural areas and migrants to migrants to other countries. Most of the population are mestizos (mixed race), and the main religion is Catholic. The literacy rate is 97% of the population; 39% have received primary school education and 23% higher studies. Cancer care facilities The healthcare facilities in the city comprise nine general hospitals, relying on the Social Security system and the Ministry of Health, two private hospitals and 30 private clinics. The largest hospital belongs to the Social Security system and has 700 beds used by afliated workers. The private clinics have between 20 and 80 beds. There is a new modern oncological hospital with 160 beds, which belongs to the Fight Against Cancer Association (Lucha contra el Cncer, or SOLCA). A full range of diagnostic facilities and treatment by surgery, chemotherapy and radiotherapy are available. According to registry data 34% of patients are diagnosed in the private sector. and the private sectors, and clinical records of public and private hospitals. Registrars also contact many physicians who treat cancer patients in the private sector. The 53 pathologists in the city collaborate voluntarily and enthusiastically in the work of the registry, allowing the registrars to consult their records and in many cases lling out a part of the notication form themselves. Other sources of information are the death certicates and hospital discharge lists collected by the Institute of Statistics and Census of Ecuador (Instituto de Estadsticas y Censos del Ecuador, or INEC). Follow-up is passive and consists of matching death certicates with the cases registered. The registry has promoted the creation of cancer registries in other cities in the country, and is monitoring their activities; there are ECUADOR, QUITO (1998-2002) now registries in the cities ECUADOR, QUITO (1998-2002) of Guayaquil, Cuenca, Portoviejo, Loja, and Machala, and a gastric cancer registry in the province of Tungurahua.  













 















Interpreting the results The National Cancer Registry 







publishes data in an annual 














report that is distributed 







within the country and abroad. 





 






 

The 19992002 report shows 







a signicant improvement 













in the quality of the data. 







Data on 73 651 cases, 48% of 














whom were residents of Quito, 







were received in the registry between 1985-2003.       -(%*  -(%* In the last three years 


,.,-&$&-- a screening programme for cervical cancer has 

   '$$&-
"-- -2--- - #-- --0--
- 
#---!/-been undertaken with great "-"-1"-----#--$&- -'$,#-#-
-'$$)- 



 enthusiasm. It is supported by WHO, and the registry 

--('$$)*--
+--provides the baseline data to monitor results. Registry structure and methods The National Cancer Registry of Ecuador was created in Use of the data 1984, with the initial collaboration of PAHO/WHO, by a The registry has carried out a number of studies on the ministerial degree in which SOLCA was declared responsible epidemiology of selected cancer sites and on quality control, for the funding and administration of the registry. The and results have been published locally or internationally. registry has a Steering Committee directed by the President The majority of the scientic research on cancer carried out in the city and in much of the country uses the data from the of the Association. The personnel of the registry comprises a Director, registry. two epidemiologists and four full-time registrars including on responsible for the computer system. The Director Source of population is a medical pathologist and establishes the registry 2001 Census, corrected for nonresponse rate and for procedures, coordinates the general activities of the registry migration. Instituto Nacional de Estadstica y Censos INEC. and is responsible for inter-institute relationships. The Proyecciones de Poblacin por provincias, cantons, reas, epidemiologists coordinate personnel activities, control data sexo y grupos de edad. Serie 01 Nro 206. Quito. Agosto quality and set up and facilitate studies, particularly between 2004. physicians in SOLCA. Data collection is active, and the main data sources are Multiple primary rules used pathology and haematology records, from both the public IACR rules (2004) on CI5 IX period.



120

Central and South America

France, Martinique
Registration area Martinique, a French overseas department, is a 1100 km2 island located between the Caribbean sea and the Atlantic ocean. The department is divided into 34 administrative areas called communes (municipalities). In the 1999 census, 381 500 inhabitants were living on the island; 57% of people aged >65 years were women. The ethnic distribution was: African or African/white/Indian mixture 90%, white 5%, and East Indian, Lebanese, and Chinese less than 5% each. Immigrants made up about 1% of Martinique inhabitants. of the national public medical insurance system. Cases are also declared spontaneously by doctors or by active collection. Letters are sent regularly to all private and public cancer treatment structures. Cancer diagnoses are veried using private and public laboratories of pathology. Cancer cases are only kept for people living in Martinique at the time of diagnosis. The registry is staffed by a full-time medical ofcer, a full-time registrar and one full-time health worker.

Interpreting the results In the last decade cancer has become a high public health concern in Martinique. It is the second leading cause of death Cancer care facilities in men and in women. Several tumoursprostate, breast, colon The population is served by and rectum, non-Hodgkins 9 public hospitals, including lymphomaare increasing in the University Hospital of the general population. The way FRANCE, MARTINIQUE (1998-2002) Fort-de-France. The medical of life in Martinique has been FRANCE, MARTINIQUE (1998-2002) infrastructure in Martinique changing considerably over is almost entirely located in the past 20 years. The socioFort de France: the University economic status is now among Hospital, which comprises the highest the Caribbean " """ $! "$""" "$""" $ "$""" the radiotherapy-oncology area, and Martiniques way of "#""" # "##""" service, the nuclear medicine life tends to be westernised "$""" # "%""" "%"""  #" """ service, the haematological because of constant exchange #"$"""  $"""" and pathological laboratories, with metropolitan France. Other #"#%"""  $"#$""" %" """  "$#""" the clinical haematology characteristics include a highly "$%"""  "$""" service and department mixed population, low tobacco """"  "#%""" " """  #"""" of medical information, consumption and, in most areas, "$"""   "%""" two private clinics and replacement of traditional diet "%#%"""  "#""" " """  " $""" one laboratory. Eight other by imported food. Changes "#"""  """" municipal hospitals contribute in a common set of exposures  """"  " #""" "%#"""  "$%""" to diagnosis and treatment of (lifestyle modification, life " """  "%""" cancer. Medical care is free of expectancy) and improved diagnostic procedures, earlier charge, allowing unrestricted       detection (use of the PSA test, access to high-quality medical "
" services for all cancer patients mammography, the Hemoccult " %$""" $"%"""  registered in regional health test and an organised cervical 
  


 insurance les. cancer screening programme 
 " """ "" in Martinique since 1991) have been suggested to explain these Registry structure and methods trends. Cancer registration has been mandatory in Martinique since 1981, with the Association Martiniquaise pour la Recherche Use of the data Epidemiologique en Cancrologie (AMREC) being ofcially The registry provides a ve-year report of cancer incidence, created in 1986. The Registry has been integrated into the highlighting trends and changes. Data are also use for CHU de Fort de France since 2003. In France, the Registry evaluation of cancer screening, medical practices and is integrated into the National Cancer Registry Association environmental risk assessment. Survival studies for prostate (France Cancer Incidence Monitoring, or FRANCIM). and colorectal cancer patients have also been carried out. Cancer cases are identied using common sources of information: medical evacuation les, data from private and Multiple primary rules used public hospitals, laboratory les, regional insurance records IACR rules (2004) on historical data.

121

Central and South America

Peru, Trujillo
Registration area The Trujillo Cancer Registry covers the population of ve districts (Trujillo, La Esperanza, El Porvenir, Florencia de Mora and Vctor Larco). They represent Metropolitan Trujillo, on the north coast of Per. The population at the most recent census (1993) was 513 223. About 96% of the population live in urban areas; 90% are Roman Catholics A formal evaluation of the completeness or accuracy has not been accomplished for the 19982002 period, but quality data are available. Interpreting the results The high incidence of cervical cancer is probably results from the cervical screening programmes implemented by MINSA, EsSALUD and the Trujillo Cancer Prevention League. Breast cancer detection is limited, and PSA screening has Cancer care facilities Diagnostic and treatment facilities are provided by the not been established. Transformative industries (agro-industrial, leather, Ministry of Health (MINSA) and the Social Security (EsSALUD) hospitals, supplemented by private clinics. metalmechanic) are located in the suburban areas of the Radiotherapy is supplied by one telecobalt unit and radium region. Trujillo has a high proportion of motor vehicles, but results of ofcial CO testing devices at Beln Hospital. are within acceptable limits. The relatively high cost of Registry structure and PERU, TRUJILLO (1998-2002) cigarettes probably explains methods PERU, TRUJILLO (1998-2002) the low lung cancer incidence. Financial and technical assistance are received from Use of the data IARC under a Collaborative Every ve years a cancer Agreement with the National %.#+,... 0+%.,/)... %.&,#... 0#! %.01#... incidence and mortality report University of Trujillo. %.110... /+! &.,+'... is published and delivered to the The Central Ofce of the '.##&... /#! './/0... ).#&%... ,+! +.%#1... health authorities, universities Registry is at Belen Hospital. +./%'... ,#! ,./0/... and medical institutions. The The Registry is staffed by /.%#+... ++! 0.#%'... 1.+%1... +#! %#.+/%... Registry has also carried out a pathologist (head of the %%./,,... )+! %'.&&'... cervical cancer survival and Registry), one statistician %'.0%'... )#! %,.)&/... %,.++'... '+! &#.&&'... childhood cancer research. pathologist, one computer &#.&0/... '#! &).','... Registry data have also been analyst and one part-time &'.,1&... &+! &0.&0%... &1.+1'... &#! ''.1/%... used for university theses and statistical technician. ''.&+#... %+! '0.#))... in planning for the Northern Data are collected '&.1#'... %#! ''./)%... '%.,,+... +! '%.+'#... Cancer Hospital. actively from three general '&.1,#... #! '&.%')... hospitals, the radiotherapy Source of population service, and private clinics, %# + # # + %# The population data were pathology laboratories and .($* .($* estimated by linear interpolation oncologists. Mortality data '%&.)%&... &0#.%+,...  on the basis of the 1981 National are obtained from the original  
 ..
... ...%10%.. ...%11'.. "..
. Census and the 1993 National death certicates furnished by .

.... .. ..
...". the Regional Health Authority.  
   The Registry staff scrutinise Census. The projection was made by age group for each sex. 
..(&###*... the death certicates to complete the database records or to    . ..... ....
...2.. 
.+.( *". follow up. The Registry members visit the sources to screen Multiple primary rules used the hospital discharge notes and scrutinise the cancer medical IACR rules (2000). records to abstract the required information onto special forms. Data from patients referred to the National Cancer Notes on the data Hospital (Instituto Nacional de Enfermedades Neoplsicas) The Editors recommend that some care be taken in the interpretation of these data; see Chapter 5 (Categorisation). in Lima are also recorded.

122

North America
Canada

North America

Canada (Excluding Quebec, Yukon and Nunavut)

Canadian incidence and survival information required for cancer control. The Canadian Cancer Registry forms a personal information bank that is listed in the annual publication Info Source: Sources of Federal Government Information. The Canadian Cancer Registry is a collaborative effort between the thirteen Canadian provincial and territorial cancer registries and the Health Statistics Division of Statistics Canada. The Canadian Cancer Registry is a dynamic database of all Canadian residents alive or dead who have been diagnosed with cancer. The function of the Canadian Cancer Registry is to produce standardised and comparable cancer incidence data for each newly diagnosed primary site of cancer. The Canadian Cancer Registry Registration area system records the kind and Canada is the second-largest number (incidence) of primary country in the world, with CANADA (Excluding Quebec, Yukon and Nunavut) cancers diagnosed for each an area of 9 984 670 km2 (1998-2002) CANADA (Excluding Quebec, Yukon and Nunavut) (1998-2002) person over a number of years extending from longitude 53 until death. The advantage of to 141 W and from latitude this system is that longitudinal 42 to 83 N. It is bounded to data are available for each the west by the Pacic Ocean 


 
 








cancer patient. New primary and Alaska, to the north by the 






cancers occurring for previous Arctic Ocean, to the east by 












 

cancer patients are identied. the Atlantic Ocean and to the 






The patient data are linked south by the United States. 














annually to the Canadian In 2001, the population of 







Mortality Database so that the Canada numbered 31 110 565, 
















date, place and cause of death of whom 25.5% were under 20  







of every cancer patient are years of age and 12.6% aged 














eventually known. 65 or over. Most Canadians 







In addition to information live in a corridor about 300 














on cancer incidence, data km wide along the southern 







are available about the border. Almost one third of characteristics of patients as the population is concentrated       well as about the nature and in the metropolitan areas 
)%!' 

)%!' frequency of their tumour(s). of Toronto, Montreal and 



"")(*+)&**)))  Since patients records remain Vancouver.

  
active on the Canadian Cancer Between 1991 and 2001, 
)) ))

))
)))
)
))
)

)%",,+-# $')) Canada attracted 1 830 680 new immigrants (almost 6% of its Registry until conrmation of their death, survival rates for population). Ontario attracted 55.8% of the new arrivals, followed the various forms of cancer can be calculated. The Canadian Cancer Registry also employs specialised by British Columbia (20.2%), Quebec (13.4%) and Alberta (7.1%). internal record linkage software for detecting duplicate Almost one fth of all Canadians are foreign-born. Canada is an ethnocultural society. In 2001, visible records and for clearing death records. These procedures are minorities constituted 13.4% of the population. Of these, done annually. Conicting information and other problems the largest three groups are: Chinese (25.8%), South Asian with the cancer data are resolved through consultation with (23.0%), Black (16.6%), and Filipino (7.7%). English is the the reporting provinces and territories. mother tongue of 58.5% of the population and French is the mother tongue of 22.6% of the population. The major Use of the data religious denominations are: Catholic (42.9%), United Church The annual publication Canadian Cancer Statistics is (9.6%), and Anglican (6.8%). The aboriginal population of produced by the Canadian Cancer Society, the National Canada (accounting for 3.4% of the population) is primarily Cancer Institute of Canada, the Public Health Agency of Canada, Statistics Canada, the Provincial/Territorial Cancer comprised of North American Indians, Mtis, and Inuits. Registries and Health Canada. The estimates are calculated through extrapolation of cancer incidence data from the Registry structure and methods The patient-oriented Canadian Cancer Registry evolved from National Cancer Incidence Reporting System (NCIRS, 1969 the event-oriented National Cancer Incidence Reporting 1991) and the Canadian Cancer Registry. Also, non-nominal System1 established in 1969. The Canadian Cancer Registry data for all Canadian registries are published annually by is an administrative survey. Beginning with cases diagnosed NAACCR in Cancer Incidence in North America. in 1992, cancer incidence gures collected by provincial and territorial cancer registries have been reported to the Canadian Source of population Cancer Registry, which is maintained by Statistics Canada. Estimates of Population by Age and Sex for Canada, the The Canadian Cancer Registry has been developed to provide Provinces and the Territories (19982003). Since 1969, Statistics Canada, Canadas central statistical agency, has collected population-based cancer incidence data. Starting with the 1992 data year, these data have been compiled by the Canadian Cancer Registry (CCR), replacing the event-oriented National Cancer Incidence Reporting System that existed from 1969 to 1991. The CCR provides national incidence and survival information required for cancer control. Reporting of cancer data by the ten Canadian provinces and two territories is coordinated by the Canadian Council of Cancer Registries, which includes representatives from each of the provincial and territorial cancer registries, Statistics Canada, and the Public Health Agency of Canada.

124

North America

Canada, Alberta
Registration area Alberta is one of the Prairie Provinces of Canada. Its area of 661 688 km2 lies between latitudes 49 and 60 W. The Alberta Cancer Registry covers the population of the 9 Regional Health Authorities within the province of Alberta. The population estimated for Alberta in 1999 consisted of 1 466 696 females and 1 497 933 males. Alberta has a multi-ethnic population; half of the population are of British extraction, the remainder including people of other European, Asian and Native American origins. enables the Registry to identify patients who have died from cancer or cancer patients dying from other causes. The Alberta Cancer Registry maintains routine computerised and manual quality assurance data reviews of specic variables on a monthly, quarterly, and yearly basis as required. Mechanisms have also been established to measure the quality of registry-collected variables with respect to completeness, accuracy, and timeliness. The Alberta Cancer Registry received the Gold Standard awarded by the North American Association of Central Cancer Registries (NAACCR) for 1998, 1999, 2000, 2002, 2003, and 2004 incidence data. For 2001 data, silver certication was awarded.

Cancer care facilities Cancer care is provided and administered by the Alberta Cancer Board in two major treatment centres, four associate and eleven community cancer treatment CANADA, ALBERTA (1998-2002) centres throughout the province. CANADA, ALBERTA (1998-2002) The two major tertiary centres, the Cross Cancer Institute, in Edmonton and the Tom Baker Cancer Centre, in Calgary 


 



provide radiotherapy, systemic 




therapy, and limited surgical 








procedures. The associate and 




community cancer centres 

 






provide chemotherapy services.

Use of the data The Alberta Cancer Registry publishes or is involved in the development of several documents on cancer incidence and mortality in Alberta. Publications include the annual report, A Regional Picture of 





Cancer in Alberta (for the 

 

Regional Health Authorities), A 






Snapshot of Cancer in Alberta, 

 

and various monographs. 






The registry is the key source 







of information for service provision 














Registry structure and planning by the Alberta Cancer 







methods Board, its host agency. Information 














The Alberta Cancer Boards on cancer within each regional 





 

Division of Population Health health authority in Alberta is also 

 












and Information operates a released to them for planning 







number of cancer prevention, services. The registry provides screening and surveillance data to the screening programs       
/*&, 
!
/*&, initiatives on behalf of to allow for quality assurance and 
 


'/-'1/+)'///  the organisation. Several follow-up of mammography and organisation-wide services 
   cervical screening. #/
//!/'1102(%%)/
/"

/
!
//
/
/

// 
/
!
/"
//
/ are also coordinated by this 
/  22/"/
The Cancer Registry also has '11./
#// 
/"/
/  /!
/
#/
! /#//$/  



 Division, which maintains the Alberta Cancer Registry under a close relationship with the Alberta Cancer Boards clinical 
/
/*(%%+,//// the directorship of Dr. Heather Bryant. The Alberta Cancer database, which enhances data analysis opportunities. Registry operates out of the two tertiary cancer centres. We also respond to over 100 requests for information from Calgary is responsible for the southern half of the province the Registry each year. Many of these requests involve the use while Edmonton maintains data for the northern half. The of Registry data for population or clinical research questions. Registry staff is involved in coding and abstracting, entering Examples of this include the use of registry data to invite data into the collaborative stage program, research projects, participants into intervention trials, or studies of the use of and quality assurance activities. Completeness of cancer cases complementary therapies for cancer treatment. All research is very high in the Registry; however, passive follow-up to nd projects must be approved by the Research Ethics Board prior additional cases includes record linkage with Alberta Vital to initiation, and the registry, rather than the investigator, is Statistics and an ongoing case ascertainment project with the the usual originator of contact with the individual. Registry Alberta Health Registration le. data has also been included in several multi-centre studies, and Provincial legislation mandates the registration of all the Alberta Cancer Registry has combined registry data with reportable cancers from diagnostic facilities and medical other research data to examine the projected impact of the use practitioners within Alberta. The Alberta Cancer Registry of Hormone Replacement Therapy in the population. primarily uses a passive case-nding approach. Pathology, cytology, and operative cytology reports as well as reports Source of population from scans, x-rays, etc. with the mention of cancer are sent to The populationatrisks by sex and age from 19982003 have the registry. The province is in the process of implementing been estimated using the adjusted intercensal or postcensal a provincial electronic health record, which will improve estimates based on the 1996 Census, as provided by the Population the accuracy of patient demographic information as well as Estimates Section, Demography Division, Statistics Canada. provide timelier access to the reports previously outlined. In addition, Alberta Vital Statistics provides an electronic le Multiple primary rules used each month of all individuals dying in the province, which IACR rules (2004) on historical data

125

North America

Canada, British Columbia

about 61% of cancer cases are treated or seen at some Registration area The registry covers all of British Columbia (BC) (926 492 point. The registry receives listings of all deaths in the km2), the most westerly province of Canada, bordered by province from the BC Vital Statistics Agency. Follow-up is Alberta to the east and by the Pacic Ocean to the west. Most performed to obtain complete registration information and of the population is concentrated in the southwest corner of documentation on all cases. The personnel consists of a director and a scientic the province, where the climate is the mildest. The proportion of immigrants in the population has director, one senior, one supervisor and eight health record increased by 1.3% from 17.7% for the 19911995 period to technicians. 19.0% for 19962001. Currently, most immigrants to BC come from Asia, in particular China, Taiwan, India, Hong Kong, the Interpreting the results Philippines and South Korea. Based on the 2001 census, 56% The Screening Mammography Program of BC (SMPBC) was of British Columbians belong to a single ethnic origin and established in 1988 through the BC Cancer Agency to reduce 44% to more than one. The largest group of visible minorities breast cancer mortality through early detection. From 20002004 within British Columbia is (inclusive), 1 134 806 examinations the Chinese, followed by were performed for 512 372 South Asians. Aboriginal women, and 4627 breast cancers CANADA, BRITISH COLUMBIA (1998-2002) people comprised 4.4% of the were diagnosed (overall cancer CANADA, BRITISH COLUMBIA (1998-2002) population in 2001. detection rate of 4.1 per 1,000). The top three industries The BCCAs Cervical within British Columbia are Cancer Screening Program retail trade, health care and was the rst organised 


 









manufacturing, with the largest programme in the world to 







component of the working screen for cervical cancer. 














population employed in clerical In BC, approximately 71% 







and sales occupations. of women age 20 to 69 were 














screened in a recent 30-month 







Cancer care facilities period. The cervical screening 














programme is credited with an Cancer diagnostic services 







85% reduction in the number are provided through general 

 










 

of BC women getting cancer hospitals and specialty clinics. 







of the cervix and for reducing Cancer therapy is provided 














cervical cancer deaths by 75% through a mix of dedicated 







since the 1950s. cancer facilities and general The Hereditary Cancer hospitals. The BC Cancer        0+'" 0+'Program (HCP) is a result Agency (BCCA), a provincial 



)0&(/0),(000   of the BCCA and the BC government agency responsible Provincial Medical Genetics for cancer care, control and 
   3 30#0!$0 00 "0(2213)&&*0 0#0" 000 0 00
 0" 0# 000 Program working together to research in British Columbia, 0

 (22/0 $0 0
0#00
 0" 0$0"
0$0 0   %0  



 operates four regional cancer centres that have close links provide information and genetic counselling for individuals 
00+)&&,-00 .00
0 with local hospitals. Radiation therapy is provided exclusively and families with a strong history of cancer. PSA screening for prostate cancer became common in the through the four regional cancer centres. The regional cancer centres also provide approximately 50% of cancer chemotherapy early 1990s although it is not a publicly funded service. Rates of services, with the remainder provided through the Communities prostate cancer peaked in 1993 and have declined since then. Oncology Network, a collaborative voluntary partnership with 19 Community Cancer Centres, 6 Community Cancer Services and 12 Use of the data Consultative Clinics across BC, in conjunction with the Regional The registry was originally set up to monitor cancer incidence Cancer Centres and the Systemic and Radiation Programs. The and mortality in the province, but is now extensively used for Network also supports appropriate delivery of cancer patient care health services planning and epidemiological research. Registry data are used as a source of cases for surveys and case-control and support in 33 other Community Hospitals. studies, and as outcome data for cohort studies of occupational groups. Registry statistics and estimates of future incidence Registry structure and methods The registry is part of a combined population-based registry trends have also been used in conjunction with clinic referral and clinical database maintained by the BCCA. The registry data for cancer services, budgeting and facilities planning. has monitored the impact of cancer on the BC population since 1969. For many years it was mandatory to report cancer Source of population cases; however, legislation passed in 1987 authorised the The populationatrisks by sex and age from 19982003 have registry to obtain relevant information without the provision been estimated using the adjusted intercensal or postcensal of mandatory reporting. estimates based on the 1996 Census, as provided by the Population The registry received notication of 95% or more of Estimates Section, Demography Division, Statistics Canada. the cancer cases diagnosed in the province by submission of pathology reports from hospital laboratories or following Multiple primary rules used attendance at one of the four BCCA Cancer Centres, where IACR rules (2004) on CI5 IX period.

126

North America

Canada, Manitoba
eight cancer registrars, a quality assurance technician, a Registration area Manitoba is a province located in central Canada, bordered senior cancer registrar, three clerks and an administrative to the east by Ontario and Hudson Bay, to the west by assistant. Three of the staff are Certied Tumor Registrars. Saskatchewan, to the north by Nunavut and the Northwest Staff from the epidemiology section of the department also Territories and to the south by the American states of North provide support for the registry (four epidemiologists and six Dakota and Minnesota. It lies between latitude 49 and 60 analysts); the epidemiology staff are also extensively involved N and longitude 90 and 102 W. The altitude varies from in research, much of which revolves around the cancer sea level to 823m, and the province covers an area of 649 registry and linkage to other population-based datasets. 950 km2. Reporting of cancer has been mandated by law since 1956. At the time of the 2001 census, 72% of the population Case nding is passive, and multiple sources of ascertainment was urban, with 60% living in the capital city of Winnipeg. are used. These include physician notications, pathology and Manitoba is ethnically diverse. Approximately 13.6% of all cytology reports, and hospitalisation, mortality and autopsy residents were Aboriginal (Native Americans 60.2%; Mtis records. Cancer registrars collect, classify and maintain 37.9%; Inuits 2.3%). A similar comprehensive information on number had immigrated from cancer patients. Quality control other countries. Of the 133 660 is an important part of cancer CANADA, MANITOBA (1998-2002) immigrants, 47.5% where born registration in Manitoba, and the CANADA, MANITOBA (1998-2002) in Europe and 30.3% were registry has been consistently born in Asia. The majority of certied by NAACCR for the Manitobans reported British past eight years. (36.7%), French (12.6%) and/ 


 









or other European (48.0%) Interpreting the results 







heritage. The cancer statistics presented in 














this volume may be inuenced 





 

Cancer care facilities by diagnostic and early detection 














CancerCare Manitoba is a tech nologies. T he most 







provincial cancer agency significant effect is expected 














with a mandate to coordinate to be increased breast cancer 







all aspects of cancer control incidence resulting from the 














in Manitoba. Direct patient establishment of the provincial 







care involves the provision of breast screening programme 








 





treatment services, including in 1995. An organised cervical 







outpatient-based radiation cancer screening programme therapy at one centre in wa s i n it iat e d i n 19 9 9.       the major urban centre Opportunistic screening for  0+'" 0+'


./10/.)000   (Winnipeg), chemotherapy prostate and colorectal cancer and breast screening 
   occurs, but the magnitude of 3 30#0!$0 00 "0(2213)&&*0 0#0" 000 0 00
 0" 0# 000 mammography. The cancer 0

 these practicesand therefore (22/0 $0 0
0#00
 0" 0$0"
0$0 0   %0 agency partners with other community the effect on cancer incidence ratesremains unknown.  



 care facilities to 
00+)&&,-00 .00
0 provide cancer services through the Community Cancer Programs Network, an innovative program for delivering Use of the data cancer careprimarily chemotherapyin local communities The data are used to answer questions relating to the whole throughout the province. Supportive activities include cancer- spectrum of cancer control in Manitoba. They are also used related consultation services for other healthcare providers for surveillance, research, evaluation, planning and teaching and the development of standards for the delivery of cancer purposes and to provide diagnostic conrmation and care in Manitoba, as well as the facilitation of cancer-related treatment-related information to healthcare providers. education, surveillance and research activities. Source of population Registry structure and methods The populationatrisks by sex and age from 19982003 Manitoba has one of the longest standing cancer registries have been estimated using the adjusted intercensal or in the world. It was started in 1937, although it did not postcensal estimates based on the 1996 Census, as provided become fully population-based until 1956. The registry by the Population Estimates Section, Demography Division, is located within the Department of Epidemiology and Statistics Canada. Cancer Registry at CancerCare Manitoba. It is funded via CancerCare Manitoba by Manitoba Health, the provincial Multiple primary rules used health department. The registry staff include the manager, IACR rules (2004) on CI5 IX period.

127

North America

Canada, New Brunswick

Epidemiology Services and the Provincial Epidemiologist Registration area The New Brunswick (NB) registry covers the population of for NB. The NB registry uses passive case-nding predominantly seven regions and eight Regional Health Authorities within the province. The provinces of Quebec, Nova Scotia and from pathology laboratories, radiation and haematology the state of Maine, USA border NB. The population at the centres, death registrations, autopsies and data from other most recent census (2001) was 729 498. About 50.4% of the provincial registries. An electronic linkage is conducted population lives in urban areas (>1000 and no fewer than 400 annually between Vital Statistics and the registry database persons per km2). There are seven cities, none of which has a to reconcile missing death information and to identify cases where there is a mention of cancer on the death certicate population greater than 100 000. In New Brunswick, religious makeup as reported by the but no abstract is found in the registry database. The cancer registry is a patient- and disease-oriented Statistics Canada 2001 census is reported as 54% Catholic, 37% Protestant and 8% with no religious afliation. Men database. Persons may have more than one type of tumour in account for 49.4%, of whom 6% are over 65 years of age, the database, and the rules governing multiple primary tumours are those of the CCR and SEER. compared to women, 50.6% NB also registers basal and and 8% respectively. Ethnicity squamous cell carcinoma of is reported predominantly as CANADA, NEW BRUNSWICK (1998-2002) the skin, one of each, per person Canadian and then French, CANADA, NEW BRUNSWICK (1998-2002) per lifetime since 1989. English and Irish. The AJCC TNM classication method is Cancer care facilities currently used to assign stage Medical treatment of cancer 


 









to breast cancer cases. focuses on four modalities: 







Authorization to submit surgery, medical oncology, 














patient-specic information radiation and supportive 







is derived from Section services. Paediatric oncology 





 








21(1), regulation 92-84 of the cases are generally referred 







Hospital Services Act of NB. to Nova Scotia or Quebec for 














initial consultations with a 







Interpreting the results paediatric oncologist. There 








 





NAACCR has awarded silver are two major radiation-based 







certication to the NB Cancer cancer centres located in the 














Registry for years 1997, 1998, southern part of the province 





 

1999, 2000, 2002, and 2003, in the cities of Moncton and and gold in 2001. Incidence Saint John. In 1993, the second       is grouped according to the radiation facility was added in  0+'" 0+'


Surveillance, Epidemiology and *1*0&))000   Moncton. End Results (SEER) Groups for Chemotherapy is 
   4 40#0!$0 00 "0(3324)&&*0 0#0" 000 0 00
 0" 0# 000 Primary site of ICD-0-3. administered in the major 0

 (33/0 $0 0
0#00
 0" 0$0"
0$0 0   %0 centres and in 12 outreach centres. There is a provincial  



 
00+)&&,-00 .00
0 Breast Cancer Screening Program that was rolled out in 16 Use of the data facilities in NB in 1995 to service asymptomatic women The registry prepares a ve-year report of cancer incidence between the ages of 50 and 69. There is decentralised cervical and mortality, highlighting trends and changes by region and community. Some special studies of survival of registered screening in NB. There is no organized prostate screening. PSA testing is cancer cases (breast), as well as epidemiological research, ordered at the discretion of the urologist or family physicians have been carried out. Policymakers use our data to assess the need for specialized oncology services in the regions in the regions. and to assess costs on insurance reimbursements for various drugs and equipment related to cancer. Registry structure and methods The registry is a population-based central cancer registry located in Saint John, NB. The registry is funded by Source of population the Department of Health and overseen by Provincial The populationatrisks by sex and age from 19982003 Epidemiology Services (PES), which is located in the city have been estimated using the adjusted intercensal or postcensal estimates based on the 1996 Census, as provided of Fredericton. The registry is staffed by 4 permanent employees, one by the Population Estimates Section, Demography Division, PES person who serves as liaison between the coding staff Statistics Canada. and several internal and external parties, such as Statistics Canada, NAACCR, and the Public Health Agency of Canada. Multiple primary rules used The Director of the registry is Director of the Provincial IACR rules (2004) on CI5 IX period.

128

North America

Canada, Newfoundland and Labrador

Registration area The Registry covers the whole of the province of Newfoundland and Labrador, which lies on the east coast of Canada. The island of Newfoundland is surrounded by the Atlantic Ocean. Labrador is bounded by the Atlantic to the east and the province of Quebec to the west and south. The landmass of the province extends between 47 and 61 N and longitudes 52 and 76 W. The altitude varies from sea level to 1600m in the interior of Labrador. The total area is 371 634 km. The population according to the 2000 census was 554 076 and in 1991 the population was 568 475. The decrease in population is the result of the net outow due to migration to other provinces. Happy Valley-Goose Bay. The Registry is staffed by a fulltime director, a manager, a part-time programmer analyst and three full-time health record professionals. The process for cancer registration is through an Electronic Pathology reporting system (E-Path). The Cancer Registry receives pathology reports electronically from six pathology laboratories through a HL7 interface. Each report is ltered using the ICD-0-3 auto-coding engine. The automated ltering logic examines the topography and morphology codes, and then based on registry reporting requirements selects reports for submission to the registry. E-path has improved the timeliness, completeness and consistency of pathology information. Cancer is not a reportable disease in our province; the CANADA, NEWFOUNDLAND AND LABRADOR Cancer Act provides a legal mandate for the Provincial (1998-2002) CANADA, NEWFOUNDLAND AND LABRADOR (1998-2002) Cancer Care Program to establish and maintain a cancer registry.

Registry structure and methods The Provincial Cancer Registry was started by the Department of Radiotherapy of St. Johns General Hospital 


 









Interpreting the results in 1954. In 1974, the registry 







The Cancer Registry is in came under the jurisdiction 













the process of reactivating a of the Newfoundland Cancer 







provincial death clearance Treatment and Research 

 












process. We have purchased Foundation (NCTRF). 

 





a software package (Linkage NCTRF was dissolved in 












 

Wiz) to assist with this 2005 and is know under one 







process. of four Regional Integrated 














Health Authorities. The 







Use of the data Newfoundland Cancer 








 





The data are used to answer Registry is a part of the 







questions relating to the Provincial Cancer Care whole spectrum of cancer Program, Eastern Health,       control in Newfoundland formed on 1 April 2005.  0+'" 0+'and Labrador. The data are Eastern Health is the largest 


)/,03&1000   also used for surveillance, integrated health network in 
   4 40#0!$0 00 "0(3324)&&*0 0#0" 000 0 00
 0" 0# 000 research, evaluation, planning Newfoundland and Labrador, 0

 (33/0 $0 0
0#00
 0" 0$0"
0$0 0   %0 serving a regional population  



 of more than 290 000 and and to provide diagnostic conrmation and treatment-related 
00+)&&,-00 .00
0 offering unique provincial programs and services. The new information to healthcare providers. health region extends west to Port Blandford and includes all communities on the Avalon, Burin and Bonavista Peninsulas. Source of population There are more than 80 hospital, health care centres, long- The populationatrisks by sex and age from 19982003 have been estimated using the adjusted intercensal or term care facilities and community care sites. The Provincial Cancer Registry is located within the postcensal estimates based on the 1996 Census, as provided Dr. H. Bliss Murphy Cancer Centre, in St. Johns. There are by the Population Estimates Section, Demography Division, regional programs in Corner Brook, Grand Falls-Windsor, Statistics Canada. St. Anthony and Gander, and regional clinics at the Burin Peninsula Health Centre, Burin; Captain William Jackman Multiple primary rules used Memorial Hospital, Labrador City; and Melville Hospital, IACR rules (2004) on CI5 IX period.

129

North America

Canada, Northwest Territories

and visited by itinerant physicians. Three hospitals provide Registration area The area covered by the registry is the one of the largest in second-line specialist services. However, most tertiary-level Canada, yet is sparsely populated. The Northwest Territories services are offered outside the jurisdiction. All cancers are registered using a form that must be (NWT) comprises the area north of the 60th parallel, lying between the Yukon Territory and the Beaufort Sea to the completed by the treating physician at the time of diagnosis. west and Nunavut to the east. The Arctic Ocean forms the Also, the contract with out-of-territory laboratories requires that a copy of pathology reports indicative of cancer be northern border, which reaches as far as the 83rd parallel. All forms of malignancy have been reportable in the forwarded to the Registrar. Other sources of information Northwest Territories since late 1980. However, the very result from an active search of vital statistics, discharge extensive circumpolar geographical area, which constitutes summaries and physicians notes. The principal sources this jurisdiction, results in an additional reliance on diagnostic of information on cancer cases are laboratory reports and service and reporting and may also affect completeness. It discharge summaries. Death certicates are retrieved from should be noted that collection of cancer data was initiated the Northwest Territories Vital Statistics ofce in Inuvik. Informal evaluations are in the late 1950s. performed to ensure validity In 2003 the population and completeness. of NWT was about 42 406 CANADA, NORTHWEST TERRITORIES persons living in some 32 (1998-2002) CANADA, NORTHWEST TERRITORIES (1998-2002) Interpreting the data communities, half of which In 1999, Nunavut separated had populations of fewer than from the Northwest Territories. 500 residents. One-quarter of Over time we have gained the population is under 15 years 




services for mammography of age. Health programmes 




and are now able to provide and services were provided 









chemotherapy and hormone by eight health and social 




therapy treatment. Since services authorities and/or 











last year, we now have an boards, reecting ten ofcial 

 





oncologist that comes to the language groups in four ethnic 














territories on a monthly basis. categories (Dene, Inuit, Metis, 







There is an organized and non-Aboriginal). Half of 














screening programme the population are Aboriginal 







for breast cancer in the people. 














Yellowknife region, and PSA 







testing is common in our Cancer care facilities population. In NWT it is possible to        0+'" 0+'perform biopsies, but all 


)(0)1,000   Use of the data diagnostic laboratories are The registry is not currently based in Alberta, Canada. 
   4 40#0!$0 00 "0(3324)&&*0 0#0" 000 0 00
 0" 0# 000 involved in epidemiological It is possible to perform 0

 (33/0 $0 0
0#00
 0" 0$0"
0$0 0   %0 chemotherapy and hormone therapy in the Territories, but research beyond the production of routine statistics, but  



 
00+)&&,-00 .00
0 policymakers use our cancer registry data for planning and there are no radiotherapy departments in the area. evaluation of health services. Registry structure and methods The NWT Cancer Registry is maintained by two registry Source of population staff within the Population Health Division, Department of The populationatrisks by sex and age from 19982003 Health and Social Services, Government of the Northwest have been estimated using the adjusted intercensal or Territories. These consist of one coder and one analyst. postcensal estimates based on the 1996 Census, as provided Two are in the process of training to code and we are in the by the Population Estimates Section, Demography Division, process of having the Alberta Cancer Registry administer Statistics Canada. the database. Most formal health services and programmes are Multiple primary rules used provided through community health centres staffed by nurses IACR rules (2004) on CI5 IX period.

130

North America

Canada, Nova Scotia

The Nova Scotia Cancer Registry (NSCR) is operated Registration area The registry covers the whole of the province of Nova Scotia, as part of the provincial cancer program and funded by one of the three Maritime Provinces of Canada, lying to the government. It is physically located in Halifax, at a site south of the St. Lawrence River, east of the Gulf of Maine within the largest district health authority. A total of 12 and south of the provinces of New Brunswick and Prince FTEs are in place (registrars, analytic, administrative staff). Edward Island. Although joined to New Brunswick by a Two cancer centres that operate as part of DHAs also have central peninsula to the north, it is separated from Prince on-site abstracting staff who submit cases to the registry. Edward Island by the Northumberland Strait; to the south, Cancer has been a reportable disease by law since 1964. west and east lies the Atlantic Ocean. Most of the province The main reporting sources include hospital health record is less than 200m above sea level, the highest point being at departments (since 1964), pathology/cytology laboratories 529m in Cape Breton. The province covers and area of 55 (since 1964), cancer centres since 1981 (includes all radiotherapy delivery), death record linkage (since 1969) and 491km2. At the 2001 census, the total population of Nova Scotia more recently, screening of visits at targeted clinical areas (e.g. haematology clinics). was 932 389, of which 45% report to be of United Kingdom Interpreting the results origin, and 16% French while CANADA, NOVA SCOTIA (1998-2002) The NSCR is active in the just over 3% indicate North CANADA, NOVA SCOTIA (1998-2002) Canadian Council of Cancer American Indian. Some Registries and is a full member 40% of census respondents of t h e No r t h A m e r i c a n indicate multiple ethnic Association of Cent ra l origins. The active labour 


 









Cancer Registries, including force (443 000) was employed 







participation in the annual in the following categories 














certification program. In the of industry: manufacturing, 







ve-year period covered by this 9.3%; construction 6.1%; 








 





data submission, several studies primary industry (agriculture, 







were carried out to review case shing, forestry, mining), 














completeness and demonstrated 4.2%. Almost 80% report 







excellent results. New processes being involved in service














have been put in place to target related industries (e.g. 







out patient haematological trade; nance, healthcare, 














diagnoses. During and at the government, education). In 







end of each calendar year, a 2001, 56% of the population series of edit checks ensure the described itself as urban and       quality of data, which are then 44% as rural dwellers. Over  0+'" 0+'submitted to Statistics Canada 95% of the population who 


,/&0(&&000   to become part of the Canadian report religion on the census 
   3 30#0!$0 00 "0(2213)&&*0 0#0" 000 0 00
 0" 0# 000 Cancer Registry. indicate Christian, while 11% 0

 (22/0 $0 0
0#00
 0" 0$0"
0$0 0   %0 did not respond.  



 
00+)&&,-00 .00
0 Use of the data The registry prepares an annual report of cancer incidence Cancer care facilities All residents of Nova Scotia are covered by a publicly funded and provides this data to users, highlighting trends and comprehensive health insurance scheme. This includes access changes. A major monograph is produced every ve years, to family physician and hospital-based care. Many residents and includes incidence, mortality, survival, projections and have supplemental insurance programs for costs not covered prevalence analyses. Ad-hoc queries are frequently received by the public system (e.g. prescription drugs). Since 1993, and responses provided. Data are also made available for all residents are assigned a unique health card number that research purposes to ethically-approved studies. remains with them for life and aids in the maintenance of an unduplicated patient index. Health care is administratively Source of population managed and delivered by district health authorities (DHAs). The populationatrisks by sex and age from 19982003 have Cancer care is highly centralised, with coordination been estimated using the adjusted intercensal or postcensal occurring under a provincial cancer program. There are estimates based on the 1996 Census, as provided by the Population two main provincial cancer centres that operate satellite Estimates Section, Demography Division, Statistics Canada. facilities across the province for oncology specialist referral and follow-up. Approximately 60% of all patients have some Multiple primary rules used contact with a centre or satellite clinic at diagnosis. IACR rules (2004) on CI5 IX period.

131

North America

Canada, Ontario
Registration area The Ontario Cancer Registry is the largest patient-specic population-based cancer registry in Canada. Operated by Cancer Care Ontario (CCO) since 1964, it covers the entire province of Ontario. The population at most recent census (2001) is approximately 11.4 million people, with over 80% of the population living in urban centres. The major racial/ ethnic groups in Ontario are: European 80.9%, South Asian 4.9%, Chinese 3.7%, Black 3.6%, Aboriginal 1.7%, Filipino 1.3%, Latin-American 0.9% and other 3.0% for compiling statistics or carrying out medical or epidemiological research. Under the 2004 Personal Health Information and Privacy Act, CCO is also mandated to use this information for planning and management of the cancer system in Ontario.

Interpreting the results Because of changes in diagnostic practices or rules of coding and registration, interpretation of temporal trends must be done with caution. For example, with the introduction of ICD0-2 in Ontario in 1993, borderline ovarian tumours were now registered as invasive Cancer care facilities Cancer Care Ontario is the principal adviser on cancer issues neoplasms; this increased incidence by about 30%. But with the introduction of ICD0-3 for the Provincial Government. in 2002, the classication of CCO is responsible for longborderline tumours reverted term planning of the cancer CANADA, ONTARIO (1998-2002) from malignant to uncertain care system and coordination CANADA, ONTARIO (1998-2002) behaviour. Thus, incidence of cancer prevention and seemingly fell by 30%. control activities and Limitations in the range programmes (cancer of registered tumours may surveillance, prevention, 


 









limit comparability. For screening, diagnostic services, 

 





example, the Ontario Cancer treatment, supportive care and 














Registry does not register research) in Ontario. 







non-malignant brain tumours, CCO does much of its 




 









non-melanoma skin cancers, work through 14 Regional 







or in-situ cancers, nor is there Cancer Programs, which are 




 
 








registration of other cancer geographically aligned with 







precursors (e.g. adenomatous Ontarios health planning 







 




 

polyps of the colorectum). regions (called Local Health  







Limitations in the accuracy Integration Networks, or 














and timeliness of registering LHINs). The 12 Integrated 







and reporting actual incident Cancer Programs are located cases may also be critical in major urban centres,       factors. For example, annual and serve as the hub of the  0+'" 0+'incidence data are generally not Regional Cancer Programs. 



.012)0(*1000   considered nal and reported CCO continues to directly 
   4 40#0!$0 00 "0(3324)&&*0 0#0" 000 0 00
 0" 0# 000 publicly until approximately manage the Ontario Breast 0

 (33/0 $0 0
0#00
 0" 0$0"
0$0 0   %0 1824 months following initial diagnosis. This may be a Screening Program and the New Drug Funding Program.  



 
00+)&&,-00 .00
0 limitation for researchers who desire more rapid reporting. Problems in coding consistency and classication constancy Registry structure and methods The registry operates under CCOs Informatics Unit. CCOs may also occur. Further, new methods of screening and diagnosis can operating expenses were approximately $460 million in FY 2005/06, and it currently has approximately 330 employees, also change patterns of incidence. With rapid diffusion of including planners, scientists, analysts, statisticians, new methods (e.g. PSA screening introduced in Ontario in clinical and non-clinical managers, technicians and other 1989) incidence may increase dramatically, often within months, and may distort assessment of the underlying risk professionals. Cancer registration in Ontario is passive, relying of cancer, or present a sudden increase in demand for the almost completely on electronic records collected for other cancer system. purposes. Close to one million source records are submitted to the OCR each year. Since 1979, the OCR has relied on Use of the data four major data sources: hospital discharge (including day The OCR is an invaluable resource for conducting surgery) summaries that include a diagnosis of cancer; epidemiological studies, and is also used to follow up patients pathology reports with any mention of cancer; records of or individuals who may have been exposed to risk factors. The OCR can also be used to help evaluate the patients referred to the Integrated Cancer Programs; and effectiveness of screening programmes. The Ontario Breast death certicates for all underlying causes of death. While cancer is not a legally reportable disease in Screening Program links its database to the OCR in order Ontario, the Cancer Act provides a legal mandate for to conrm diagnoses of cancer in the screened population, Cancer Care Ontario to establish and maintain a cancer identify interval cancers and verify vital status. Over the 1990s, use of the OCR expanded to include registry. Further, under the Cancer Act, any information about a registered case must be kept confidential and health care utilisation studies. The availability of data not be used or disclosed for any purpose other than regarding utilisation of hospitals and cancer clinics by

132

North America

cancer patients as well as details regarding treatment (e.g. surgical procedures) provides researchers with a useful tool in performing these studies. Finally, with the evolution of CCO into Ontarios planning agency for cancer services, there has been a substantial investment in modern statistical methods of forecasting, as applied to predicting future incidence, survival, prevalence and mortality, over the short (35 yrs) and medium (1015 yrs) terms.

Source of population The populationatrisks by sex and age from 19982003 have been estimated using the adjusted intercensal or postcensal estimates based on the 1996 Census, as provided by the Population Estimates Section, Demography Division, Statistics Canada. Multiple primary rules used IACR rules (2004) on CI5 IX period.

133

North America

Canada, Prince Edward Island

to the registry from the provincial pathology laboratory. The Registration area The registry covers all of Prince Edward Island, the smallest registry has 98% completeness using the Canadian I/M ratio. province of Canada, which is situated to the southwest of the Gulf The percentage of microscopically conrmed cases for PEI of St. Lawrence, lying between longitudes 62 and 65 W and was 93% for the 2003 data submission year. Additional data latitudes 46 and 48 N. The island covers an area of 5684 km. necessary for cancer registration are obtained from the outpatient The population according to the 2001 census was 135 294, cancer treatment centre charts and hospital charts. Physicians with 60 675 being urban and 74 619 being rural. A preliminary and nursing homes are also contacted as needed to obtain population count on 1 July 2005 showed a population of 138 information. Electronic sources of data available to the cancer 113 on PEI. The male to female breakdown from the 2005 registry staff include the radiology information system, and the population estimates that 67 198 are men and 70 915 are laboratory case management system. Death lists are sent from women. Of these, 11 993 of the females and 12 459 of the Vital Statistics to the registry monthly. All deaths with mention males were under age 15. A large majority of the population of cancer are researched and followed back to ensure all cases are of PEI is of British Isles origins, followed by French origins. registered. Death certicates as the only source of information A smaller number are of other comprise a very small number of European origins. registrations due to the rigorous The primary employment follow-up procedures; in fact EDWARD ISLAND (1998-2002) for the 2003 data submission by industry are service sector CANADA, PRINCE CANADA, PRINCE EDWARD ISLAND (1998-2002) jobs followed by agriculture year there were no cancer and shing. registrations in which death certicates were the only source Cancer care facilities of the cancer registration data. 

 






 

The PEI Cancer Registry was The registry staff follows up 







formerly part of the Provincial on any cases that require further 





 








Health Services Authority information for registration. The 







and is now a division of the small size of the province and 














Department of Health under the the accessibility of information 





 

Queen Elizabeth Hospital (QEH) enable staff to complete cases 














and the PEI Cancer Treatment with a very high degree of 







Centre (PEICTC). Hospital quality. The implementation 














organisation and practice are of an electronic health record 







based on a comprehensive in the spring of 2007 will 











government-organised health further enhance the ability of 





 

insurance scheme. There are the registry to follow up cases no private hospital facilities. for further information.       
/*&, 
!
/*&, Treatment services are provided The registry started to 


.0/-')///  at the Queen Elizabeth Hospital collect staging information on in the PEI Cancer Treatment 
   all breast and colorectal cancers #/
//!/'2213(%%)/
/"

/
!
//
/
/

// 
/
!
/"
//
/ Centre. Satellite clinics are held 
/  33/"/
starting with cases diagnosed in '22./
#// 
/"/
/  /!
/
#/
! /#//$/ at the Prince County and Kings 



 County Memorial Hospitals, 2003. Staging information on all lung and prostate cancers was 
/
/*(%%+,//// providing medical oncology services. Diagnostic services added for diagnosis year 2005 with the expectation of stage include CAT scan and MRI, both of which are located in the collection on the whole incidence le in future years. The time Diagnostic Imaging Department of the QEH adjacent to the frame for this is nancial/human resource dependant. The PEICTC. Radiation treatment on a Linear Accelerator became registry staff has received formalised training on the staging available on Prince Edward Island in October 2003. Previously of breast, colorectal and lung cancer using the Collaborative all radiation treatments delivered on PEI were via a Cobalt Stage method of data collection, with prostate and head and 60 machine. All radiation treatment necessitating a Linear neck sites completed in September 2006 and 2007 respectively. Accelerator required travel to another province prior to this The manager of the registry has been very involved in the time. There is an organised Breast Screening program in PEI. national implementation of stage collection and is currently There is no formalised colorectal screening program. PSA one of six Canadian staging specialists providing training to testing and colorectal screenings are done at the discretion other cancer registrars. The manager of the cancer registry of the physicians. keeps the statistics for cancer incidence as well as all workload statistics for the PEICTC, which are used by policymakers for Registry structure and methods future planning of required health services. The PEI Cancer Registry commenced with cancer collection in 1969 and has been submitting cancer data nationally to Statistics Source of population Canada since then. The registry personnel consist of the director The populationatrisks by sex and age from 19982003 have (medical oncologist), the manager (1FTE) and a health records been estimated using the adjusted intercensal or postcensal technician (.5 FTE). The PEI Cancer Registry is not currently estimates based on the 1996 Census, as provided by the Population involved in any epidemiological research projects but did participate Estimates Section, Demography Division, Statistics Canada. in the National Enhanced Cancer Surveillance study. The main source of data for the registry is pathology Multiple primary rules used reports with a diagnosis of cancer, copies of which are sent IACR rules (2004) on historical data.

134

North America

Canada, Saskatchewan
each year. All cancer cases in the database are coded according Registration area The registry includes all of Saskatchewan, a province of to ICD-O-3. Causes of death from cancer are coded using ICD651 903 km2 located between Alberta to the west, Manitoba 10, and non-cancer causes of death up to 1999 remain as ICD-9. to the east, the Northwest Territories to the north and the In 2005 the Registry started using Collaborative Staging for USA to the south. Saskatchewan is between latitudes 49 and breast and colon cancers. In 2006 additional cancer sites will 60 N and longitudes 102 and 110 W. Most of the province is have collaborative staging applied to them. The Saskatchewan at or above 300m altitude, and the majority of the population Cancer Registry is a member of the Canadian Council of Cancer Registries and the North American Association of Central live in the southern half of the province. Among provinces, Saskatchewan ranks sixth in population Cancer Registries (NAACCR). Our data are submitted annually with 990 930 people according to the 2006 census estimate. to the Canadian Cancer Registry and the NAACCR. The population of Saskatchewan is of mixed ethnic origin. The quality of the registry data is maintained through internal More than 40% of inhabitants trace their ancestry to the British edit processes at the point of data entry as well as yearly processing Isles. The next largest ethnic groups claim German, French, of edit checks. Edits are also conducted by Statistics Canada/ Ukrainian, American Indian, Canadian Cancer Registry and Metis and Scandinavian NAACCR on the data we submit ancestry. Indigenous peoples, to them for quality, accuracy, CANADA, SASKATCHEWAN (1998-2002) mainly Cree, Assiniboine, and timeliness and completeness. CANADA, SASKATCHEWAN (1998-2002) Chipewyan account for 17.3% Statistics Canada now produces of the population. a report card each year; both Approximately 64% of the the Statistics Canada report and population resides in cities of the NAACCR report outline our 


 






more than 5000 inhabitants, results and subsequent areas for 







including Saskatoon (237 017) improvement. 














and the provincial capital, Patient follow-up has been 







Regina (200 854). active since 1932. Every case 














diagnosed (excluding non







Cancer care facilities melanoma skin cancer) is 














The Saskatchewan Cancer reviewed at least annually either 







Commission Act of 1930 authorised through an examination at one 














of the clinics or through our a commission to establish a cancer 







control program in Saskatchewan. follow-by-mail program, which 














In 1979, the Saskatchewan Cancer sends letters to family/referring 







Foundation Act established a new physicians at regular intervals for organisation to replace the Cancer 10 years minimum. Although this        0+'" 0+'Commission. The Saskatchewan program is still used as a method 


.&.0(22000   of survival/recurrence analysis, it Cancer Agency is now responsible for treatment, prevention and early 
   now also helps ensure continuity 3 30#0!$0 00 "0(2213)&&*0 0#0" 000 0 00
 0" 0# 000 detection programs, research, and 0

 of patient care once the patient (22/0 $0 0
0#00
 0" 0$0"
0$0 0   %0  



 education services. The Agency maintains two clinics, the Allan is discharged from the Clinic. The response rate to these letters 
00+)&&,-00 .00
0 Blair Memorial Clinic in Regina and the Saskatoon Cancer Centre in is approximately 98%. The Registry began performing an active Saskatoon, which provide radiotherapy, chemotherapy and follow-up follow-back process on all registered DCO cases in 2002. services. The Agency also has two Cancer Patient Lodges associated with the clinics, a Health Research Division, a Screening Program Interpreting the results for Breast Cancer, a Prevention Program for Cervical Cancer, as well The vast majority of the population is involved in farming, which as an Education Division. The Screening Program for Breast Cancer may result in higher exposure to pesticides, herbicides, fungicides was established in 1990 and the Prevention Program for Cervical etc. Recent literature also suggests a link between cancer and diabetes; if substantiated this could have a huge impact on our Cancer began in 2003. First Nations population that have a higher rate of diabetes. Registry structure and methods The province is covered by a universal comprehensive health Use of the data insurance plan. The Cancer Foundation Act mandates that all The Cancer Agency will be producing its third annual Cancer cancers be reported to the Agency. This reporting structure Control Report this year. The information in the registry also captures approximately 95% of our case ascertainment. The other supports Agency planning for cancer control services and is also 5% is captured through death certicate notication received used as an information source for various research studies. monthly from the Vital Statistics branch of Saskatchewan Health. The Saskatchewan Cancer Agency is funded by the Source of population Saskatchewan Government. The Registry is staffed by 10 FTE The populationatrisks by sex and age from 19982003 have cancer registrars, 2 supervisors, 1 coordinator and the director. been estimated using the adjusted intercensal or postcensal Complete computerised information is available on all estimates based on the 1996 Census, as provided by the Population cancers diagnosed since 1967. There are currently about 212 200 Estimates Section, Demography Division, Statistics Canada. patients and about 281 000 case records on the database. The registry also records follow-up information on approximately 36 Multiple primary rules used 000 clinic examinations per year and 25 000 physician reports IACR rules (2004) on CI5 IX period.

135

North America

USA, Alabama
Registration area Public Health. The ASCR staff comprises 12 permanent Alabama is located on the southern coast of the United States. employees, including an Administrative Director, a Program The state is divided into 67 counties, and the states largest Manager, an Epidemiologist, an Operations Analyst, and city is Birmingham, located in the central region of the state. four Regional Coordinators (RC), three of which also have Among the 50 states, Alabama ranks 30th in size, covering additional functions within the registry such as Completeness 52 423 square miles. According to the 2000 U.S. Census, it Coordinator, Quality Assurance Coordinator, and Education the 23rd most populous state, with 4 447 100 residents, and Coordinator. In addition, the ASCR has a Death Clearance the states population is projected to increase to 4.8 million and Research Coordinator, two case nding auditors and an by 2010 (Alabama Dept. of Industrial Relations). According Administrative Assistant. to the Census Bureau, Alabama is considered an urban The ASCR is supported through Federal funds under the state with 55 percent of its population living in an urban US Centers for Disease Control and Preventions National setting and 45 percent in rural areas. Nearly every county in Program of Cancer Registries (NPCR). The ASCR does not Alabama has some rural population, even the most densely currently receive any state funds except through support settled counties, but some from ve county health sparsely settled counties have departments, which provide no urban population at all. ofce space for regionallyUSA, ALABAMA (1998-2002) Residents of Alabama are based staff. USA, ALABAMA (1998-2002) predominantly white (71.1%), Electronic reporting is with a signicant Africancurrently being phased in with American population (26.0%). pathology labs and physician Hispanics make up 1.7% of groups. All other reporting 


 









the states population, though sources report via the ASCRs 





 

Birmingham has been ranked secure website. Thirty-eight 














6th among US cities with of these healthcare facilities 







the fastest growing Hispanic are certied by the American 





 






 

population (http://apha. College of Surgeons and 







c on fex.com /apha /133a m / report approximately 80% of 














techprogram/paper_112388. Alabamas incidence. 







htm). Asians make up 0.7% 

 












of the states population, Interpreting the results 







and Native Americans 0.5%. Alabama has captured at least 

 












Alabama has a large number 95% of its expected caseload 







of prime workforce-age over the past several years, residents, with 29% of the and is proud to provide a high       states population between quality, statistically useful /*', !/*', ages 25 and 44. database. 

 

)/(+./0.+///  Screening programs are 

   /(//

/!/"/#/ #/ #//
/ 2/
/!/"//)&&&/// $// Cancer care facilities offered through hospitals,

////" /3 /!/ / !// /!
3 / ///)&&&/// $/ Cancer is a reportable disease 
1%%$ $ $%

$/ under Alabama Act 95-275. physicians and community organisations such as the American  



 
/ /*)&&+,// -//
 / There are 55 healthcare facilities in the state that have fully Cancer Society for sites such as breast, skin, colorectal, and staffed and functioning cancer registries, along with 54 non- prostate. The Alabama Breast and Cervical Cancer Early registry facilities who utilise independent CTR contractors Detection Program (ABCCEDP) offers screenings for to capture and report cancer data. In addition, there are 22 breast and cervical cancers. Prostate Specic Antigen (PSA) free-standing treatment centres, 36 physicians or physician testing is a common practice used by healthcare providers groups and 13 pathology laboratories that currently report in Alabama. to the ASCR. Full-service cancer health care is provided by many Use of the data hospitals in Alabama including two academic teaching The ASCR, in conjunction with the American Cancer facilities. Physicians also deliver limited diagnostic and Societys Alabama Afliate Ofce, prepares an annual treatment services in ofce settings. There are 25 free- report of cancer incidence, highlighting trends and changes, standing cancer centres (including radiation centres) and as well as the efforts of Alabamas Comprehensive Cancer clinics that also provide a full scope of therapeutic options Control Program. In addition, the ASCR collaborates with for their patients. researchers and Principal Investigators across Alabama and around the US on special data linkages and research projects Registry structure and methods addressing issues from cancer prevalence to disparities in The ASCR is housed in the Bureau of Health Promotion care. The ASCR limits participation in such activities to and Chronic Disease of the Alabama Department of twelve open research projects at any given time.

136

North America

USA, ALABAMA: BLACK (1998-2002) USA, ALABAMA: BLACK (1998-2002)

USA, ALABAMA: WHITE (1998-2002) USA, ALABAMA: WHITE (1998-2002)























































 







































































 








 








































 









































































 0+'-

 !0+'-





 0+'-

 !0+'-



.,*0/&1000






(0.1*012/000








   0(00

0!0"0#0 #0 #00
0 30
0!0"00)&&&000 $00

0000" 04 0!0 0 !00 0!
4 0 000)&&&000 $0 
2%%$ $ $%

$0


   0(00

0!0"0#0 #0 #00
0 40
0!0"00)&&&000 $00

0000" 05 0!0 0 !00 0!
5 0 000)&&&000 $0 
3%%$ $ $%

$0

Source of population July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. The population data include the bridged singlerace estimates derived from the original multiplerace

 



 
0 0+)&&,-00 .00
 0

categories in the 2000 United States Census. http://www. seer.cancer.gov/popdata. Multiple primary rules used IACR rules (2004) on CI5 IX period.

 



 
0 0+)&&,-00 .00
 0

137

North America

USA, Alaska
Manual case reports are also generated as a result of Registration area The Alaska Cancer Registry (ACR) covers the population of casending audits of hospitals and death clearance. Casending the State of Alaska, the northernmost state in the United States. audits are conducted by reviewing the medical disease index Alaska represents 16% of the total land area of the country, but from the hospital for a given time period for cancer cases and only 0.2% of the countrys population. The population at the most removing cases that have already been reported by the hospital. recent census (2000) was 626 932. The state is divided into 27 The remaining cases are researched by the registrars, and new county-equivalent areas of municipalities, boroughs, and census cases are added to the registry. Death clearance is performed areas. Most of the state is rural and sparsely populated. About by comparing a list of all Alaska resident cancer deaths for a 42% of the population lives in the Municipality of Anchorage given time period against the registry database and removing (260 283), although Anchorage represents only 0.3% of the land death cases that have already been reported by other sources. area of the state. The top ve county-equivalent areas in the state The remaining cases are researched by the registrars, and new (Municipality of Anchorage, Fairbanks North Star Borough, cases are added to the registry. Quality control is performed on the data on a regular Matanuska-Susitna Borough, Kenai Peninsula Borough, and basis. All new cases need Juneau Borough) make up 77% to pass at minimum the of the states population and NPCR Required, NPCR represent only 9.2% of the land USA, ALASKA (1998-2002) Supplemental, and Site/Typearea. The statewide population USA, ALASKA (1998-2002) -Over-rides - Missue Edit is 73.5% White, 17.2% Native Sets of the current NAACCR Alaskans or American Indians, Edits Metale. In addition, 5.1% Asian or Pacic Islanders, during the annual NAACCR and 4.3% Black.  

 







 

and CDC Calls for Data, the 







data submission le must pass Cancer care facilities 














specic Edits Sets specied General healthcare in the state







by NAACCR and CDC at the is provided by 24 hospitals, 





 








time of data submission. Also numerous health clinics, and many 







during the Calls for Data, ACR private practitioners. Because 












 

runs specic database queries the Anchorage Municipality 







to check for data quality. has the highest population, it 














also has the highest number of 







Interpreting the results healthcare facilities, including 














There are no unusual four hospitals. In rural areas, 







geographical, clinical, or many boroughs/census areas only coding factors that inuence have one hospital, and some have       0+'!0+'incidence rates. However, the no hospitals. Alaska Natives are 


*).0/.*000  Alaska Department of Labor provided healthcare at no cost at a publishes annual population central hospital in Anchorage. 
   0(00

0!0"0#0 #0 #00
0 20
0!0"00)&&&000 $00 estimates for Alaska that are

0000" 03 0!0 0 !00 0!
3 0 000)&&&000 $0 
1%%$ $ $%

$0 different from those published by the federal government Registry structure and methods  



 
0 0+)&&,-00 .00
 0 ACR is located in the city of Anchorage, and is part of the Alaska (CDCs National Center for Health Statistics). The incidence Department of Health and Social Services, Division of Public and mortality rates ACR generates are based on federal Health, Section of Chronic Disease Prevention. It is funded governments population data. mostly by the US Centers for Disease Control and Prevention (CDC) through the National Program of Central Cancer Use of the data Registries (NPCR), and partly by the state health department. ACR prepares an annual report of cancer incidence and ACR is staffed by a full-time manager, three full-time registrars, mortality. Data are submitted annually to NAACCR and and a full-time data analyst. Several full-time administrative CDC for use in multi-registry databases and data reports. In addition, registry data are regularly requested by members clerks provide part-time support for the program. Cancer is a reportable disease by state law; a hospital, of the US Congress, the Alaska state legislature, researchers, physician, surgeon, or other healthcare facility or provider physicians, researchers, and the general public. diagnosing, screening, or providing treatment for a cancer patient is required to report to the registry. The annual caseload for ACR is approximately 2000 consolidated Source of population cases per year. ACR receives about 50% of its case reports July 1 county population estimates by age, sex, race, and (source records) electronically from hospitals in the standard Hispanic origin; postcensal estimates based on 2000 United NAACCR Record Layout. Electronic cases are also received States Census. The population data include the bridged from other state central cancer registries in the United States singlerace estimates derived from the original multiplerace with which ACR has data exchange agreements (currently categories in the 2000 United States Census. ACR has 30 of these agreements). The rest are manually http://www.seer.cancer.gov/popdata. abstracted in-house by the registrars. The manual case reports consist of hardcopy medical records sent to the registry by Multiple primary rules used IACR rules (2004) on CI5 IX period. hospitals, private physicians, and pathology laboratories.

138

North America

USA, Arizona
Registration area The Arizona Cancer Registry covers the population of the State of Arizona in the United States of America. Arizona is located in the west in the Rocky Mountain region. The population at the most recent population census projection (2005) was 5.8 million. About 89% of the population lives in urban areas (>5000 population). Arizona has the second largest state concentration of Native Americans in the United States, comprising 5% of the population. The racial breakdown of the population in Arizona is: White Non-Hispanic 60%, Hispanic 29%, and all other races, Non-Hispanic 11%. Cancer care facilities General health care in the region is provided by private practitioners, clinics, and hospitals. Health insurance is used by 82% of the population to pay for health care. Most health insurance is private, non-governmental insurance (75%) of healthcare coverage. The amount the insurance plan pays varies greatly between health plans. The remainder of health insurance is provided by the government. There are both hospital and freestanding radiotherapy departments in Arizona. completeness and accuracy, visual editing and immediate and batch editing. The staff also collects cases from facilities that do not report directly to the registry, including hospitals with fewer than 50 beds and pathology laboratories. The Data section analyses the incidence, mortality and survival of people diagnosed with cancer in Arizona. It provides this data to cancer support organizations and government agencies as well as to researchers, members of the medical community and the public. The section also audits reporting hospitals, to identify areas for improvement when abstracting and reporting cases. The training section plans and administers a statewide training program for registry staff, reporting facilities including hospital and clinic personnel, and physicians and their staff. In addition, the training section USA, ARIZONA (1998-2002) develops written materials such USA, ARIZONA (1998-2002) as brochures and newsletters. Finally, it is also responsible for keeping cancer registry and reporting facility staff updated  






of coding and regulatory 




changes. 











 




















 




Interpreting the results The rate of cancer in Arizona 







is stable, with rates of increase 







 



 


and decline following United  







States trends. Arizona age 







 






adjusted incidence rates of 







cancer are generally lower than Registry structure and  











 


the overall United States cancer methods 




 


rates. Completeness of data The registry is located in coverage is between 90 and Phoenix, Arizona, the state       95%. Arizona has organised capital. The registry receives /*', !/*', screening programs for breast, 



its funding from state )/-0./1+2///  cervical, and colorectal cancer. legislature appropriations to 
   #/ #//
/ 4/
/!/"//)&&&/// $// Over half of all men over age 40 the Arizona Department of /(//

/!/"/#/

////" /5 /!/ / !// /!
5 / ///)&&&/// $/ Health Services. Enhancement
3%%$ $ $%

$/ funds are provided through yrs are screened for prostate cancer using the PSA test.  



 
/ /*)&&+,// -//
 / the National Program of Cancer Registries (NPCR) from a US Centers for Disease Control and Prevention cooperative Use of the data Agreement. The registry is staffed with 13 FTEs and The registry prepares an annual report of cancer incidence, highlighting trends and changes. The registry also is involved in comprises three sections, Operations, Data, and Training. The ACR is considered a population-based surveillance research studies that have been approved by our Human Subjects system that collects, manages, and analyses information on Review Committee. Data are used for comprehensive cancer the incidence, survival, and mortality of persons having been control planning; to respond to concerns in the community diagnosed with cancer. Arizona Revised Statute 36-133 about cancer; to assist in the identication of geographic regions mandates the reporting of cancer cases in the state of Arizona. of the state that need intervention programs or epidemiologic Reporting rules (Arizona Administrative Code Title 9, Chapter research, detection, and prevention; to perform epidemiologic 4) require hospitals, clinics, and physicians to report cases to studies; and to provide biostatics and epidemiologic information the ACR. The registry also collects information from pathology to the medical community. laboratories. All hospitals are required to perform follow-up on cases. All data reported from hospitals is electronic. The Source of population registry also performs a linkage with vital records on the death July 1 county population estimates by age, sex, race, and certicate le. The registry also performs case ascertainment Hispanic origin; postcensal estimates based on 2000 United reviews and reabstracting studies at hospitals. The registry has States Census. The population data include the bridged 17 data exchange agreements with other US states, including singlerace estimates derived from the original multiplerace categories in the 2000 United States Census. all bordering states. The sections of the registry are as follows: The Operations http://www.seer.cancer.gov/popdata. section processes incoming case information from hospitals, clinics, and physicians. The quality assurance program is a Multiple primary rules used comprehensive program that includes reviewing data to ensure IACR rules (2004) on CI5 IX period.






139

North America

USA, California
approximately 2.5 million records for cases diagnosed 1988 Registration area The California Cancer Registry (CCR) is a collaborative forward, and adds approximately 150 000 new cases to the effort between the California Department of Public Health database each year. The Central Registry in Sacramento houses numerous Cancer Surveillance and Research Branch, the Public Health Institute, and ten Regional Cancer Registries. These research scientists, quality control staff, IT programmers, Registries encompass all of Californias approximately and scal and administrative support staff. Additionally, 156 000 square miles (404 000 km2). All cancers, with the each Regional Registry maintains their own ofce of exception of basal and squamous cell skin cancers and in epidemiologists, research scientists, certied tumour situ cervical cancers, diagnosed among Californias 34 043 registrars and support staff. The CCR combines elements of an active and a passive 198 residents are considered reportable cancers. California is not only the most populous state in the United States, but surveillance system at both the Regional and Central Registry also the most ethnically diverse, with substantial Hispanic, levels. Active follow-up includes letters to physicians and African-American, and Asian-American populations in telephone calls to patients. Passive follow-up involves computer linkages to vital addition to a large nonstatistics, voter registration, Hispanic White population. credit records and medical There are also a wide variety USA, CALIFORNIA (1998-2002) resources. These various of religious afliations, USA, CALIFORNIA (1998-2002) surveillance systems have socioeconomic levels, and allowed CCR to follow up sociocultural characteristics over 95% of patients. within California. Over 90 percent of 


  
 








cancer reports are received Cancer care facilities 





 

electronically from hospitals, Health care in California is 














using hospital-based computer provided by a variety of health 







software supported by the care facilities, including 















CCR. Regional Registry approximately 422 acute care 









staff also routinely review hospitals, 42 radiation therapy 


















the records of outpatient centres, 308 free-standing 









radiation and surgery centres, surgery centres, and numerous 


 















as well as all non-hospital healthcare clinics. This care 









based pathology laboratories is supplemented by more 











 






to identify unreported cases. than 80 000 physicians, both 









Physicians complete cancer general practice and those reports of patients diagnosed specialising in oncology.       or treated in non-hospital 0+'!0+'facilities. All CCR data are Registry structure and 



(/02.)0/*1000  edited for completeness and methods 

   #0 #00
0 40
0!0"00)&&&000 $00 accuracy and then are checked Legislation declaring cancer 0(00

0!0"0#0

0000" 05 0!0 0 !00 0!
5 0 000)&&&000 $0 to be a reportable disease in 
3%%$ $ $%

$0 California became effective by computer for allowable codes and compatibility between  



 
0 0+)&&,-00 .00
 0 in 1985. Statewide collection of cancer cases began in 1988 different data elds. Regular audits are conducted at selected under the Statewide Cancer Reporting Law. Additionally, hospitals to check for completeness and accuracy. state law mandates that hospitals and physicians report all cancer diagnoses to their Regional Registry. While recent Interpreting the results legislation has made all CCR data variables condential, CCR The CCR makes efforts to identify persons who resided in has always considered personally identifying information to California at the time of diagnosis, but were diagnosed or treated in another state. California has case-sharing agreements be condential. The Central Registry of the CCR is located in Sacramento, not only with neighbouring states, but also with many states California; there are eight Regional ofces throughout throughout the nation. While there have been no changes in California, housing the ten Regional Registries. All of the area covered by the CCR, the population in California has California participates in the Surveillance, Epidemiology, steadily increased since its 1988 inception. Efforts to improve and End Results (SEER) Program, although there are screening rates among immigrant and low-income populations three separate SEER Registries within California. The San through community outreach programs have increased over Francisco Bay Area Registry became a SEER Registry the years. Cancer incidence in California is similar to that in in 1973, with four adjacent counties added in 1992. The other parts of the United States; however an aggressive antiregistry in Los Angeles County became a SEER Registry smoking campaign has resulted in the dramatic reduction in in 1992. The remaining areas of California, known as the smoking-related cancers in recent years. Cancer Registry of Greater California, became a SEER Registry in 2000. The CCR also participates in the National Use of the data Program of Cancer Registries (NPCR) at the US Centers The CCR produces an annual report of cancer incidence and for Disease Control and Prevention (CDC) and annually mortality in California for all of the major cancer sites. This submits statewide data for inclusion in the NPCR Cancer report lists rates by year of diagnosis, sex, race/ethnicity, Surveillance System. The CCR database currently contains and age. Additionally, each Regional Registry produces an

140

North America

annual report that lists rates by county. CCR data is used by researchers throughout the United States to investigate causes of cancer, survival, quality of care, tumour characteristics and treatment. Since 1988, researchers in California have used CCR data in 450 funded studies and have published

nearly 1700 articles using CCR data. CCR data also are used by policymakers and currently are being utilised by Californias cancer control planning organisation to measure the burden of cancer in California and evaluate interventions to reduce incidence and mortality.

USA, CALIFORNIA: BLACK (1998-2002)

USA, CALIFORNIA: BLACK (1998-2002)

USA, CALIFORNIA: NON-HISPANIC WHITE USA, CALIFORNIA: NON-HISPANIC WHITE (1998-2002) (1998-2002)














































 



























 


















































 











 







 


 


 





 



 







 






























 













 















 

 










 /+'-

 !/+'-





 /*',

 !/*',



(/)*0/(,(///







0/(&(/.0.///




   /(//

/!/"/#/ #/ #//
/ 2/
/!/"//)&&&/// $//

////" /3 /!/ / !// /!
3 / ///)&&&/// $/ 
1%%$ $ $%

$/  



 
/ /+)&&,-// .//
 /


   /(//

/!/"/#/ #/ #//
/ 2/
/!/"//)&&&/// $//

////" /3 /!/ / !// /!
3 / ///)&&&/// $/ 
1%%$ $ $%

$/  



 
/ /*)&&+,// -//
 /

USA, CALIFORNIA: HISPANIC WHITE (1998-2002)

USA, CALIFORNIA: HISPANIC WHITE (1998-2002)

USA, CALIFORNIA: ASIAN AND PACIFIC ISLANDER (1998-2002) USA, CALIFORNIA: ASIAN AND PACIFIC ISLANDER (1998-2002)











 











 































 



































 








 
 

















 


























































 





















 



















































 0+'-

 !0+'-





 /+'-

 !/+'-



.0*/)0,/1000







)/&(0/*(0///







 



 Source of population 
0 0+)&&,-00 .00
 0 July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. The population data include the bridged singlerace estimates derived from the original multiplerace categories in the 2000 United States Census. http://www.seer.cancer.gov/popdata.


   0(00

0!0"0#0 #0 #00
0 30
0!0"00)&&&000 $00

0000" 04 0!0 0 !00 0!
4 0 000)&&&000 $0 
2%%$ $ $%

$0

 



 Multiple primary rules used 
/ /+)&&,-// .//
 / IACR rules (2004) on CI5 IX period.


   /(//

/!/"/#/ #/ #//
/ 2/
/!/"//)&&&/// $//

////" /3 /!/ / !// /!
3 / ///)&&&/// $/ 
1%%$ $ $%

$/

141

North America

USA, California, Greater San Francisco Bay Area

Registration area The registration area includes nine counties (Alameda, Contra Costa, Marin, Monterey, San Benito, San Francisco, Santa Clara, San Mateo, Santa Cruz) in northern California, USA. The US Census counted 6 516 923 persons living in the region in the year 2000. Compared to other parts of the USA, this area is noteworthy for its racial/ethnic diversity, with substantial Hispanic, Chinese, Filipino, and other Asian populations. The majority of the population lives in the urban San Francisco Bay Area, which includes a major financial centre as well as the Silicon Valley centre for technology innovation and industry. Overall levels of education and income are higher than USA averages and accordingly, cost of living tends to be higher in the Greater San Francisco Bay Area than in other parts of the USA. Cancer care facilities Healthcare services in this region, including cancer screening, diagnosis and treatment, are provided mostly by private hospitals and physicians, but also by publicly funded hospitals, clinics and public health agencies. At least 61 hospitals and over 21 000 physicians treat cancer patients in the region and two major academic cancer centres are located in the region. In addition, there are a number of freestanding radiation centres, surgery centres, and pathology laboratories involved in cancer diagnosis and treatment. A signicant proportion of residents receive managed health care services through health maintenance organizations. Registry structure and methods The Greater Bay Area Cancer Registry, with a staff of about 50, is operated by the Northern California Cancer Center (NCCC), founded in 1974 as an independent consortium centre for cancer research in Northern California. The registry has been part of the Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute since 1973 and has contributed data to the statewide California Cancer Registry since 1988. Cancer registry efforts at NCCC also include a population-based registry covering four counties south of the Bay Area (Santa Clara, Santa Cruz, San Benito, Monterey) that have been included in the SEER program since 1992 and the California Cancer Registry since 1988. Data from these two registries have been combined to create the Greater San Francisco Bay Area region shown in this volume. In total, this registry contains well over 700 000 incident cases and processes about 30 000 incident cases annually. The registry collects data not only on incident cancer diagnoses but on diagnostic procedures, tumour characteristics (including stage, grade and tumour markers), treatment and survival time. Each patient is given a unique identifying number and multiple primaries designated by sequence number. All patients reported to the registry are followed both actively and passively for vital status to monitor survival time. Active follow-up consists of letters to physicians. Passive follow-up involves computer linkages to vital statistics, voter registration, credit records and medical resources. Through these methods, the registry maintains current follow-up information for over 95% of cancer patients. Cancer has been a reportable disease by California state mandate since 1987. This law requires that hospitals report to regional registries such as NCCC all cancer diagnoses occurring in their facilities and that physicians report cancers not diagnosed in a hospital. Well over 90% of cancer registry reports are received electronically from hospitals. The registry supports a hospital-based computerised reporting system allowing each hospital to collect, maintain, and easily transmit registry-reportable information and facilitating editing by cancer registry staff. Quality assurance procedures implement SEER and NAACCR standards for visual and computerized editing, reabstractions and audits. Interpreting the results The registry identies cases residing in the Bay Area but who are diagnosed or treated elsewhere through well-established data sharing programs with neighbouring cancer registries. The registry is also linked semi-annually to California vital statistics records in order to identify persons for whom cancer is mentioned on the death certicate but not already reported to the registry. It is estimated that over 98% of cancer diagnoses in region residents are captured by the registry. Use of the data Registry data are used primarily for investigating trends in cancer incidence, survival, tumour characteristics and treatment, thus providing a critical resource for monitoring the burden of cancer in the region. Data are routinely combined with California Cancer Registry and SEER program data for larger surveillance efforts. A number of investigators apply each year to access cancer registry information needed to carry out analytic epidemiologic studies of many different cancer types and outcomes. The large and diverse population has made this registry a valuable resource for epidemiologic research into the genetic and environmental causes of cancer, as well as for cancer control interventions and healthcare planning efforts.

USA, CALIFORNIA, GREATER SAN FRANCISCO BAY BAY AREA (1998-2002) USA, CALIFORNIA, GREATER SAN FRANCISCO AREA (1998-2002)

%.-.0&--&0-+.(--+%-*0&--..-((&--0"-"$(--$$&-"0+--$*&-/&%--%$$-""&--%($-/*&--%..-0"$--%0/-*%&--%0/-/+0--%+/-%%(--%$(-&/+--%".-+%.--%$.-+(%--%%.-+/&--%%%-((/---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

+%-"/"--+&-"*%--//-+(&--0.-0"$--$"(-%/%--$%%-/+"--$+"-..+--%$.-*/.--%(%-+(*--%++-.%*--%.0-*0+--%.+-"(&--%(0-.++--$0+-%%$--$0&-&++--%"+-%$+--%$+-+(/--%$$-0//---

$"

* -'#)

"

"

* -'#)

$"

&-%*"-+"+---



&-%*+-&0+---

 
   
- -'%""()-- *--

 Source of population    July 1 county population estimates by age and sex; postcensal ---------- - 
-
!estimates based on 2000 United States Census.

 
 -$--

-----1-
----%"""--- !-

Multiple primary rules used IACR rules (2004) on CI5 IX period. Notes on the data This is not the same as the sum of the other groups presented.

142

North America

USA, CALIFORNIA, GREATER SAN FRANCISCO BAY AREA: BLACK (1998-2002)

USA, CALIFORNIA, GREATER SAN FRANCISCO BAY AREA: BLACK (1998-2002)

USA, CALIFORNIA, GREATER SAN FRANCISCO BAY AREA: FILIPINO (1998-2002)

USA, CALIFORNIA, GREATER SAN FRANCISCO BAY AREA: FILIPINO (1998-2002)

#,''-,,, $,$%',,, %,)/.,,, ',*.',,, *,!$.,,, -,/*!,,, #!,#/*,,, #',*#',,, #-,-#',,, $!,./%,,, $#,-'/,,, $!,'-!,,, #-,)#-,,, #*,-#*,,, #/,#*/,,, $#,)!!,,, $$,$#$,,, #/,#!',,,

.)+ .! -) -! *) *! )) )! ') '! %) %! $) $! #) #! ) !

%,)'/,,, ',!%),,, ),--#,,, *,%)*,,, -,%//,,, .,//',,, ##,)#-,,, #),/*/,,, #.,*#!,,, $#,#$/,,, $#,/$!,,, $!,)-*,,, #.,)-#,,, #*,///,,, #.,).#,,, $!,---,,, $#,*)#,,, #.,%/$,,,

#,$/),,, #,%!.,,, $,*$*,,, %,*'*,,, %,.-!,,, ),%/*,,, *,''',,, /,*/*,,, #!,-%!,,, ##,.*),,, #$,$%#,,, #$,%$.,,, #$,-!*,,, #$,%$',,, #$,!$$,,, ##,-'-,,, ##,)/%,,, #!,*'-,,,

.)+ .! -) -! *) *! )) )! ') '! %) %! $) $! #) #! ) !

#,''/,,, #,//%,,, %,-*#,,, ),%'%,,, *,!.$,,, -,$/*,,, .,'*),,, ##,/.#,,, #$,/-!,,, #',%/*,,, #',)*',,, #',#%-,,, #%,$%/,,, #$,$$#,,, ##,%)-,,, #!,/'!,,, #!,-)*,,, /,/#),,,

#!

) ,&"(

) ,&"(

#!

#!

) ,&"(

) ,&"(

#!

$'-,.!),,,



$*!,-/*,,,

#)$,'-',,,



#-!,.*),,,

,#,,

,,, ,,,0,
,,,,$!!!,,,  , Source of population  



 
,,&$!!'(,, ),,
, July 1 county population estimates by age, sex and race; postcensal estimates based on 2000 United States Census. 
  

,#,,

,,, ,,,0,
,,,,$!!!,,,  , Source of population  



 
,,&$!!'(,, ),,
, July 1 county population estimates by age, sex and race; postcensal estimates based on 2000 United States Census. 
  

Multiple primary rules used IACR rules (2004) on CI5 IX period.

Multiple primary rules used IACR rules (2004) on CI5 IX period.

USA, CALIFORNIA, GREATER SAN FRANCISCO BAY AREA: CHINESE (1998-2002)

USA, CALIFORNIA, GREATER SAN FRANCISCO BAY AREA: CHINESE (1998-2002)

USA, CALIFORNIA, GREATER SAN FRANCISCO BAY AREA: HISPANIC WHITE (1998-2002)

USA, CALIFORNIA, GREATER SAN FRANCISCO BAY AREA: HISPANIC WHITE (1998-2002)

#,./%,,, %,!.),,, ),-%$,,, -,#.-,,, .,.%#,,, .,/$%,,, /,!$',,, #),'//,,, #/,!!*,,, $!,-..,,, $$,--),,, #/,*!%,,, #.,-)#,,, #),-##,,, #',.!$,,, #),$%*,,, #),)$',,, #','%',,,

.)+ .! -) -! *) *! )) )! ') '! %) %! $) $! #) #! ) !

%,'%),,, ',#!),,, *,*#),,, /,##-,,, /,.-*,,, #!,'.',,, #!,#.%,,, #-,%!/,,, $#,$*%,,, $$,.'$,,, $',/%!,,, $$,').,,, #/,-*/,,, #),%*-,,, #',!)#,,, #',!-.,,, #),!*%,,, #%,.-',,,

$-/.0--%-*.0--*-"$0--.-(/(--0-+"+--$%-+.0--$+-/((--%(-(**--&&-*.$--(+-$(+--*0-"./--.$-*0*--..-.""--.$-/./--*/-+(*--*+-.%$--++-$%*--+/-($"---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

(-$./--(-**0--.-%*$--$"-"&$--$%-"*$--$(-.%.--$/-%0/--%*-"$$--&%-&$$--($-+&.--*"-%&*--*.-+%+--+"-(%+--*+-"0&--*$-+.*--*(-""%--+&-"0/--+*-*0&---

#!

) ,&"(

) ,&"(

#!

$"

* -'#)

"

"

* -'#)

$"

$%*,.!',,,



$)',.#/,,,

+0"-($&---



+%/-/""---


   ,#,,

,,, ,,,0,
,,,,$!!!,,,  ,


   -$--

--- ----
- 1-
----%"""--- !
--'%""()-- *--
Source of population July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census.  





Source of population July 1 county population estimates by age, sex and race; postcensal estimates based on 2000 United States Census.
 



 
,,&$!!'(,, ),,
,

Multiple primary rules used IACR rules (2004) on CI5 IX period.

Multiple primary rules used IACR rules (2004) on CI5 IX period.

143

North America

USA, CALIFORNIA, GREATER SAN FRANCISCO BAY AREA: JAPANESE (1998-2002)

USA, CALIFORNIA, GREATER SAN FRANCISCO BAY AREA: JAPANESE (1998-2002)

USA, CALIFORNIA, GREATER SAN FRANCISCO BAY AREA: NON-HISPANIC WHITE (1998-2002)
USA, CALIFORNIA, GREATER SAN FRANCISCO BAY AREA: NON-HISPANIC WHITE (1998-2002)

%//,,, .*',,, #,%)%,,, #,'#.,,, #,%-/,,, #,%.!,,, #,/--,,, $,-$.,,, %,'*#,,, ',$!-,,, ',$!.,,, %,-%-,,, %,!!),,, $,$##,,, #,/-!,,, $,$)-,,, $,)!),,, $,%)',,,

.)+ .! -) -! *) *! )) )! ') '! %) %! $) $! #) #! ) !

-%/,,, #,#)#,,, $,!'#,,, $,/$#,,, $,-/%,,, $,!)',,, $,'-.,,, %,$!#,,, %,-#/,,, ','!%,,, ),!#.,,, ',)*',,, %,-##,,, $,*-),,, #,/.),,, $,#'.,,, $,''!,,, $,$/!,,,

%"-"."--%/-%++--(%-"".--(0-%**--**-"$&--+0-*.(--00-&$%--$&"-(0+--$("-*0&--$*$-/0/--$*$-(%*--$&.-/.0--$"+-.*(--.*-(.+--/%-(*%--0"-((+--/0-%*/--/(-++*---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

(.-&**--(*-&""--+"-"".--*0-00+--*0-/&+--.$-.$*--00-++/--$&"-%.0--$&+-&%*--$($-+$(--$&0-$..--$%+-*+"--$"%-"(&--.&-"%*--./-&%%--/*-($+--/(-&$/--/"-*+/---

#!

) ,&"(

) ,&"(

#!

$"

* -'#)

"

"

* -'#)

$"

'#,'#%,,,



)!,%%#,,,

$-+"(-/&0---



$-+%$-*%*---

Source of population July 1 county population estimates by age, sex and race; postcensal estimates based on 2000 United States Census.
 



 
,,&$!!'(,, ),,
,


   ,#,,

,,, ,,,0,
,,,,$!!!,,,  ,

 



 Source of population 
--'%""()-- *--
July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census.


   -$--

--- ----
- 1-
----%"""--- !-

Multiple primary rules used IACR rules (2004) on CI5 IX period.

Multiple primary rules used IACR rules (2004) on CI5 IX period.

144

North America

USA, California, Los Angeles County

Registration area Los Angeles County is an urban area covering more than 10 000 km2 and has the largest population of any county in the United States, with nearly 9.5 million residents in the 2000 census. Among these residents are more than four million selfdeclared Latinos including more than three million Mexicans, 38 000 Puerto Ricans, 38 000 Cubans and sizeable populations representing various Central and South American countries. There are nearly one million blacks in the county and between 100 000 and 400 000 each of Japanese, Chinese, Koreans and Filipinos. Other major south-east Asian groups include Vietnamese, Asian Indians, Cambodians and Thais. There is wide variation in socioeconomic as well as socio-cultural characteristics in the county. Registry structure and methods The Cancer Surveillance Program (CSP) of Los Angeles County was started at the University of Southern California in 1970 as part of an epidemiology and biostatistics program. In June 1987, the CSP became one of the ten regional registries of the population-based California Cancer Registry. This registry, established by California law in 1985, places the obligation for identifying and abstracting cancer cases on those facilities where cancer is diagnosed or treated. The CSP combines elements of an active and a passive surveillance system. Under the active surveillance component, CSP personnel systematically screen pathology reports and other relevant les at all hospitals and free-standing pathology laboratories, as well as some treatment facilities, to obtain pathology reports for each cancer patient diagnosed or treated. For passive surveillance, each hospital or other reporting facility completes a full abstract, including stage and treatment information on every cancer patient diagnosed and/or treated at that facility. For each cancer patient, over 200 data items including disease or medical variables, demographics and administrative descriptors are coded and computerised. The responsibility for completing reporting at some hospitals is contracted back to the CSP; currently about 9% of all hospital reports in Los Angeles County are so reported. All of the completed abstracts are record-linked by the CSP to the pathology reports obtained under active surveillance to assure that an abstract is completed on every histologically veried cancer case. Before 1992, linkage with the State of California death tapes was the only means of passive follow-up. However, beginning with 1992 diagnoses, the CSP instituted complete follow-up as a function of its new afliation with the National Cancer Institutes Surveillance, Epidemiology and End Results (SEER) Program. Follow-up data are collected by record linkages with multiple sources as well as incorporating active follow-up information provided by hospitals. Manual and computerised record linkages are performed separately with a variety of external data sources, using a sophisticated probabilistic methodology. Multiple primaries are noted by a tumour sequence number. Each data item is checked as an allowable code, and selected intereld checks are performed. Interpreting the results Los Angeles County has more than 100 hospitals and clinics, many of them providing screening programs. The availability of cancer screening programs can, in some instances such as PSA for prostate cancer, result in increasing incidence rates. Cancer mortality rates may not be directly related to cancer incidence rates due to several factors including migration. Differences in classifying cancers by primary site between incidence and mortality data sources may also differentially affect incidence and mortality rates. Furthermore, a cancer may be reported as a cause of death when in fact it is a site of metastasis from other cancer(s). Race/ethnicity information for cancer incidence is based primarily on information contained in the patients medical record. Race/ethnicity for cancer deaths, on the other hand, is based on information on the death certicate, which may not always be based on information provided by next-of-kin. The reporting of race/ethnicity in either system may be inuenced by the racial/ethnic distribution of the local population, by local interpretation of data collection guidelines, and other factors. Some differences in race/ethnicity-specic rates likely reect biases of classication rather than true differences in risk. Use of the data The CSP is one of the most productive cancer registries in the world, in terms of scientic contributions toward understanding the demographic patterns and the etiology of specic cancers. More than 850 publications using CSP data have been contributed to scientific journals. The registry supports a large ongoing body of research funded mainly by the National Cancer Institute. The CSP also prepares an annual report of cancer incidence and mortality in Los Angeles County and other monographs monitoring the trends and patterns of cancer among the Countys populations. As a service to the community, the CSP provides community-wide or hospital-specic data on cancer occurrence. The CSP responds to requests from concerned residents, community physicians, or from the County and State health departments seeking assistance in investigating perceived cancer risks from environmental exposures.

USA, CALIFORNIA, LOS ANGELES COUNTY (1998-2002)

USA, CALIFORNIA, LOS ANGELES COUNTY (1998-2002)

%',/%!,,, )!,#!',,, .!,)/!,,, #!#,*$/,,, ##.,'*/,,, #'*,)!',,, #./,*!/,,, $)%,).$,,, %!.,)$$,,, %*',*/$,,, '!#,%$-,,, '#*,)#!,,, %/%,.%%,,, %)%,./!,,, %'/,!**,,, %-$,%$-,,, '!',.*-,,, %-/,)#-,,,

.)+ .! -) -! *) *! )) )! ') '! %) %! $) $! #) #! ) !

-),.'%,,, .!,#/.,,, ##),$'.,,, #%#,**$,,, #'$,*'$,,, #*',*-#,,, $!.,#.#,,, $-','.-,,, %$$,#-#,,, %**,-%),,, %/#,%.),,, %//,$)$,,, %-/,/!/,,, %%*,.$*,,, %$.,.'#,,, %)*,!/),,, %.-,-!$,,, %*#,).$,,,

#!

) ,&"(

) ,&"(

#!

',-#/,/**,,,



',.$%,'%#,,,

 



 Source of population 
,,&$!!'(,, ),,
, July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census.


   ,#,,

,,, ,,,,
, 0,
,,,,$!!!,,, ,

Multiple primary rules used IACR rules (2004) on CI5 IX.

145

North America

USA, CALIFORNIA, LOS ANGELES COUNTY: BLACK (1998-2002)

USA, CALIFORNIA, LOS ANGELES COUNTY: BLACK (1998-2002)

USA, CALIFORNIA, LOS ANGELES COUNTY: FILIPINO (1998-2002)

USA, CALIFORNIA, LOS ANGELES COUNTY: FILIPINO (1998-2002)

%-+*+--&-//.--+-/*"--0-%0"--$&-$.%--$+-*%"--$0-%"/--%(-/%0--&"-%+"--&.-&"%--&0-&(+--&.-&""--&$-%*+--&"-+/"--&/-0"%--(*-0*/--(+-/(&--&0-($*---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

.-$.0--.-*&*--$"-000--$&-$.+--$+-**.--%"-"//--%(-%"$--&$-"*"--&+-&$/--(&-%&"--(+-%((--(&-0+$--&.-."%--&(-.(/--&/-"0/--((-*+"--(*-+*0--&/-%%0---







































 































































$"

* -'#)

"

"

* -'#)

$"



 -)%+

  -)%+



(.&-+.(---



*&0-*&*---

&'.-('*---






-$--

--- ----
- 1-
----%"""--- !Source of population  



 
--'%""()-- *--
July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. 
  

Multiple primary rules used IACR rules (2004) on CI5 IX period.

USA, CALIFORNIA, LOS ANGELES COUNTY: CHINESE (1998-2002) USA, CALIFORNIA, LOS ANGELES COUNTY: CHINESE (1998-2002)

-'$$$#----'$$$-

- - -- --"----- ---- -Source of population --/---  ---- -  -- -------"----  --- -  -- -----------  -- --- !---)+#----  --- --- -- - multiple  - -   selection -- -Census 2000. Because the US 2000 Census allowed  --000 -#of race categories, there are two ways of counting the population for  



 

--)'$$*+--
,-- a given race group: one is the minimum count, which consists of individuals who reported that particular race as their only race, the other is the maximum count that includes individuals who reported that race alone as their only race, as well as individuals who reported that race in combination with other race(s). The population counts included in this le are the simple averages of the minimum and maximum counts for each of the agesexracespecic groups. 
  

Multiple primary rules used IACR rules (2004) on CI5 IX period.


 



































 















 





































































*-%"$--.-$+.--$&-/%(--%"-*0%--%+-++%--&*-/"&--(0-+&.--.%-%+$--  -(%* &,.-/.'--     -(%* 



 00-...--$&&-*$"--$+/-/."--%"$-"/.--%".-$+$--
  
-'$$$#----'$$$-
- - -- --"----- ---- ---0----   ---- -  -- -------"----  --- -  -- -----------  -- --- !---(*#----  --- --- -- --   - -   -- - --111 -#$0%-%+*--$.0-""0--$0%-(.*--%%+-&..--%%"-/%"--/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * " $$-%+%--$%-+$%--%$-%(&--%0-*/.--&*-+0%--(&-0".--*.-/&(--/$-"&"--$"*-/%"--$&&-*./--$*.-+*&--$.0-0*/--$/+-(%0--$.%-."0--$+*-0/*--$/(-*%/--%$.-&&"--%$$-%*.---

USA, CALIFORNIA, LOS ANGELES COUNTY: HISPANIC WHITE (1998-2002)

USA, CALIFORNIA, LOS ANGELES COUNTY: HISPANIC WHITE (1998-2002)

Source of population Census 2000. Because the US 2000 Census allowed multiple selection  



 

--('$$)*--
+-- of race categories, there are two ways of counting the population for a given race group: one is the minimum count, which consists of individuals who reported that particular race as their only race, the other is the maximum count that includes individuals who reported that race alone as their only race, as well as individuals who reported that race in combination with other race(s). The population counts included in this le are the simple averages of the minimum and maximum counts for each of the agesexracespecic groups. Multiple primary rules used IACR rules (2004) on CI5 IX period.

$"

* -'#)

"

"

* -'#)

$"

%-"*%-(0/---



%-""/-($*---

Source of population  




 
--'%""()-- *--
-


   -$--

--- ----
- 1-
----%"""--- !-

July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. Multiple primary rules used IACR rules (2004) on CI5 IX.

146

North America

USA, CALIFORNIA, LOS ANGELES COUNTY: JAPANESE (1998-2002)

USA, CALIFORNIA, LOS ANGELES COUNTY: JAPANESE (1998-2002)

individuals who reported that particular race as their only race, the other is the maximum count that includes individuals who reported that race alone as their only race, as well as individuals who reported that race in combination with other race(s). The population counts included in this le are the simple averages of the minimum and maximum counts for each of the agesexracespecic groups. Multiple primary rules used IACR rules (2004) on CI5 IX period.







 














































 
























 


























 
















USA, CALIFORNIA, LOS ANGELES COUNTY: NON-HISPANIC WHITE (1998-2002)

USA, CALIFORNIA, LOS ANGELES COUNTY: NON-HISPANIC WHITE (1998-2002)

%%-+0.--&%-$%%--  ,(%* +.,'-),,,      ,(%* 



 (/-%"*--*+-%%"--+"-$.+--."-/""--0$-"/+--
  
,&$$$#,,,,&$$$,
, , ,, ,,",,,,, ,,,, ,, ,,/,,,,   ,,,, ,  ,, ,,,,,,,",,,,,   ,,, ,  ,, ,,,,,,,,,,,  ,, ,,,,  !,,,(*#,,,,  ,,, ,,, ,, ,,   , ,   ,, ,,  ,,000 ,#, $$*-$/.--$%0-%"$--$("-$+0--$&/-(*.--$%&-"*+--$""-*"0--.0-%(/--/$-$+$--/*-+.+--/*-".%--..-(//---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

*"-(0*--*"-&(/--+.-%(*--+/-+0*--++-.&(--.&-+("--0%-&0(--$$(-.%$--$%%-*/%--$%/-%//--$%+-0$%--$$*-&*+--0+-(+*--..-0%&--..-(%/--/$-/&0--/"-(/.--.%-.$"---

Source of population  




 Census 2000. Because the US 2000 Census allowed multiple selection 

,,(&$$)*,,
+,, , of race categories, there are two ways of counting the population for a given race group: one is the minimum count, which consists of individuals who reported that particular race as their only race, the other is the maximum count that includes individuals who reported that race alone as their only race, as well as individuals who reported that race in combination with other race(s). The population counts included in this le are the simple averages of the minimum and maximum counts for each of the agesexracespecic groups. Multiple primary rules used IACR rules (2004) on CI5 IX period.

$"

* -'#)

"

"

* -'#)

$"

$-*&+-*&&---



$-*+(-%+"---

 



 Source of population 
--'%""()-- *--
July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census.


   -$--

--- ----
- 1-
----%"""--- !-

USA, CALIFORNIA, LOS ANGELES COUNTY: KOREAN (1998-2002)

USA, CALIFORNIA, LOS ANGELES COUNTY: KOREAN (1998-2002)

Multiple primary rules used IACR rules (2004) on CI5 IX period.
























 











 


 







 




















































 









 +'%)

  +'%)



,$+&(*+++






Source of population Census 2000. Because the US 2000 Census allowed multiple selection  



 

++'&$$()++
*++ + of race categories, there are two ways of counting the population for a given race group: one is the minimum count which consists of


  
+&$$$#++++&$$$+
+ + ++ ++"+++++ ++++ ++ ++-++++   ++++ +  ++ +++++++"+++++   +++ +  ++ +++++++++++  ++ ++++  !+++')#++++  +++ +++ ++ ++   + +   ++ ++  ++... +#+

147

North America

USA, Colorado
Registration area The Colorado Central Cancer Registry (CCCR) covers the population of the entire state of Colorado (United States). The state is composed of 64 counties with a total population of approximately 4.3 million. Cancer care facilities Colorado has 75 inpatient facilities around the state that provide most cancer care; most are privately operated, 2 are public institutions, and 3 are military facilities. Colorado also has many free-standing surgery and radiation therapy facilities, as well as a large network of cancer care specialty clinics that provide radiation and chemotherapy services. Private oncology practitioners also provide care in their ofces. pathology labs and some of the free-standing radiation and surgery centres. Annually, the CCCR links its database with the ofcial death le for Colorado to obtain follow-up information, and to identify potential missed cases. Interpreting the results Colorado has no special characteristics that inuence incidence rates.

Registry structure and methods The registry is located in Denver, the capital of Colorado. The registry is funded mostly 





by federal funds through the 



US Centers for Disease Control 










and Preventions National 







Source of population Program of Cancer Registries 














July 1 county population (NPCR) and receives some 







estimates by age, sex, race, and support from state funding. 












 

Hispanic origin; postcensal The registry is staffed by 







estimates based on 2000 11.5 FTEs: a Director, 2 














United States Census. The statisticians, 1 administrative 







population data include the assistant, 1 data quality and 








 





bridged singlerace estimates training coordinator, and 6.5 







derived from the original registrars. multiplerace categories in the Hospitals in Colorado with       2000 United States Census. 50 beds or more must actively 0+'!0+'http://www.seer.cancer.gov/ report their cancer cases to 



)0(1,0(*/000  popdata. the Colorado Central Cancer 

   #0 #00
0 30
0!0"00)&&&000 $00 Registry. Staff from the Central 0(00

0!0"0#0

0000" 04 0!0 0 !00 0!
4 0 000)&&&000 $0 
2%%$ $ $%

$0 Registry travel to smaller facilities once per year to collect Multiple primary rules used  



 data. The CCCR also receives 
0 0+)&&,-00 .00
 0 data reports from numerous IACR rules (2004) on CI5 IX period.

Use of the data The CCCR produces an annual report of incidence and mortality. In alternate years, the report includes survival statistics and county-level data. The data are published on the internet and can be queried interactively. The CCCR data are also used for many USA, COLORADO (1998-2002) special studies, including USA, COLORADO (1998-2002) epidemiologic studies, clinical studies, environmental risk analyses, cancer control program evaluation, cancer  






care facility market analyses, 




and citizen inquiries. 




148

North America

USA, Connecticut
Registration area The Connecticut Tumor Registry (CTR) covers the entire State of Connecticut, which is bounded by Massachusetts to the north, Rhode Island to the east, Long Island to the south and New York to the west. It lies between latitudes 41 and 42 N and longitudes 71 and 73 W. The total registration area is 12 973 km. At the 2000 census, the population of Connecticut was 3.4 million, composed of 82% white, and 9.1% black. Approximately 9.4% of the Connecticut population is Hispanic, the majority of Puerto Rican origin. In an effort to increase the accuracy, timeliness and completeness of reporting to the CTR, the registry has implemented a quality control plan. This calls for biannual audits and annual re-abstracting audits of hospitals, regular detailed analysis of reporting errors received by the CTR, regular quality and quantity reports of CTR staff productivity, and training workshops for in-house and hospital registrars. All death certicates that mention cancer are reviewed and checked against the CTR for prior registration. Followback is initiated on all death certicates that do not match to a patient in the registry database. From its inception in 1941, the CTR has maintained Cancer care facilities Health care related to cancer is provided predominantly by lifetime follow-up on all tumours. Follow-up information is primarily obtained from hospitals in Connecticut, but the hospitals. Follow-up reciprocal reporting agreements information is also obtained with surrounding states also USA, CONNECTICUT (1998-2002) from periodic linkages with identify some cases. Most USA, CONNECTICUT (1998-2002) the Connecticut mortality patients suspected to have cancer les, State of Connecticut who are rst seen in facilities motor vehicle license les, the outside of a hospital are likely Medicare les of the Centers to be referred to a hospital for $/-///--/*, (.-(&*--%.-"/(--/" (+-...--for Medicare and Medicaid testing and/or treatment. ("-.$&--.* *0-&&"--Services, and the Social There are 32 acute care (0-.%%--." +&-+*0--*&-$&$--+* +&-$(/--Security Administration. hospitals in the state of +&-.+*--+" ."-*"*--Although not legislatively Connecticut. All hospitals /.-"(0--** 0&-"&+--$$"-(0&--*" $$.-0$"--mandated to report cancer have diagnostic radiology $%*-($(--(* $&"-+(&--cases to the CTR, physicians services; in addition there are $(&-"."--(" $(.-0&+--$($-.0(--&* $(.-%0"--have also been contacted as many free-standing radiology $%%-(.$--&" $%+-0+0--part of follow-up activities. facilities located throughout 00-*(0--%* $""-&%*--0.-+.%--%" 0(-(.(--To ascertain completeness, the state, operated by hospitals $$%-((+--$* $"+-(+.--we monitor hospitals or by private companies. $%&-$$.--$" $$.-&"(--$%&-+0*--* $$/-"/$--submissions on a monthly Approximately one third $$%-&.+--" $".-*$%--basis; we also send eld staff of Connecticuts hospitals to the pathology departments have therapeutic radiology $" * " " * $" -'#) -'#) of all hospitals to perform facilities. In addition, there $-.*/-/"%--$-+*%-(*"-- case-nding audits. All case are a number of free-standing submissions received from radiation therapy centres, three 
   each hospital and private of which are privately operated; -$--

--- ----
- 1-
----%"""--- ! 



 
--'%""()-- *--
laboratory are visually edited by the CTRs coding and the remainder are associated with a parent hospital. abstracting staff. Registry structure and methods The CTR is located in the Connecticut Department of Public Interpreting the results Health in Hartford, Connecticut. The CTR is funded by Lack of reporting of cancer diagnoses from physicians the State of Connecticut and the federal government. Since may result in under-ascertainment, mainly for certain 1973, the registry has participated in the Surveillance, cancers treated and diagnosed solely in physicians or Epidemiology and End Results (SEER) Program sponsored dermatopathologists ofces. The possibility of use of by the National Cancer Institute (NCI). The registry is staffed out-of-state pathology laboratories also requires periodic by over 20 full-time employees including an epidemiologist, examination. research analyst, supervisor, coders, quality control staff and Use of the data ofce support personnel. The CTR is primarily a hospital-based reporting system. CTRs database contains statistical information on cancers All hospitals in Connecticut are required by public health diagnosed since 1935, the earliest year among registries in legislation to report incident cases, along with follow- the USA. Data from the registry are included with those from up and treatment information, to the registry. Reports containing pre-coded data are prepared by hospital-based other SEER registries in the NCIs annual publication tumour registrars and submitted, either on paper, diskette or entitled Cancer Statistics Review. This document is used electronically, to the registry. In 1981, this reporting mandate by the NCI as part of the process of setting priorities for was extended to include private pathology laboratories. The research on the prevention and treatment of cancer in the CTR also has reciprocal cancer-reporting agreements with US population. The data the CTR collects are also used to all the adjacent states and several other states. This allows identify priorities and target prevention and control activities for the identication of Connecticut residents whose cancers in Connecticut, educate the public and health professionals about specic cancer risks, trends and treatments, monitor are diagnosed or treated in other states.

149

North America

cancer incidence and trends and aid research studies. Data from the CTR have been used in hundreds of scientic publications by researchers worldwide, including the Pratt and Whitney Brain Cancer Study. http://www.dph.state. ct.us/. Incidence rates in Connecticut are routinely reported in various monographs produced by the CTR.

USA, CONNECTICUT: WHITE (1998-2002)

USA, CONNECTICUT: WHITE (1998-2002)

$/-%&+--%+-"*/--&/-+".---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

(*-*(*--((-/($--*+-"+0--*0-&+%--*.-+$(--+&-%$&--/&-***--$"*-%0&--$$+-""/--$%0-0"%--$%+-*%(--$"+-$*%--/$-(($--.+-&%(--//-*+0--0.-+".--0.-*%%--//-".$---

USA, CONNECTICUT: BLACK (1998-2002)

USA, CONNECTICUT: BLACK (1998-2002)

(+-+(/--(/-//0--*.-/*&--.0-%0%--00-0+*--$$%-+.%--$%+-/+*--$%&-$*.---

*&*--/%/--$-.&*--%-(.&--&-&&0--(-*(.--*-//$--.-/."--0-&.$--$%-""0--$&-&/.--$&-&(+--$%-%+(--$&-(+%--$*-""/--$+-&.&--$.-$&*--$*-.."---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

$-+.0--$-+*/--%-..%--&-*+*--(-**"--*-0&/--.-*"+--0-.+(--$$-"(0--$&-.%*--$*-.&*--$*-%"%--$&-&//--$&-+.&--$(-$0.--$+-"%&--$+-*(%--$(-/0.---

$"&-*..--/%-%"*--.0-.+&--0&-*+/--$"%-0.$--$"%-**.--0%-%(/---

$"

* -'#)

"

"

* -'#)

$"

$-(&*-$&"---



$-*%&-+$(---


   -$--

--- ----
- 1-
----%"""--- !
--'%""()-- *--
Source of population July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census.  





$"

* -'#)

"

"

* -'#)

$"

$+*-&&(---



$/$-/+(---


   -$--

--- ----
- 1-
----%"""--- ! 



 
--'%""()-- *--
-

Multiple primary rules used IACR rules (2004) on CI5 IX period.

150

North America

USA, District of Columbia

Registration area The District of Columbia Cancer Registry (DCCR) operates within the DC Department of Health (DOH) and serves a total population of 572 059 (2000 census) District residents. The District population consists of about 60% AfricanAmericans, 31% Caucasians and the remainder from other racial/ethnic backgrounds. The gender distribution is 47% males and 53% females. In addition, the Districts area hospitals provide cancer diagnosis and treatment to residents from the surrounding jurisdictions (Maryland and Virginia). pathology laboratories. Death registration is performed by the State Center for Health Statistics where the DCCR obtains a death tape to match the registry database. Death certicates received at the registry are manually entered into the registrys database. For verication, registry staff performs a follow-up by contacting the physician signing the certicate or the institution listed on the certicate where the patient might have died. Interpreting the results The number of cases for the District of Columbia has been on a steady decline since the 2000 diagnosis year. Almost all of the decline can be attributed to a decrease in the population. PSA testing is common. Use of the data The DCCR prepares and publishes an annual report of cancer incidence and mortality. The DCCR collaborates with the George Washington University on a number of cancer research studies. Some recent titles include: 1. The Association of SES with Breast Cancer Incidence, Grade & Stage at Diagnosis Among Caucasian & African American Women in Washington, D.C. 2. The Role of Race and Poverty in Determining Breast Cancer Patterns in the District of Columbia. 3. Using Demographic Data to Improve Breast Cancer Screening and Education in Underserved DC

Cancer care facilities The District of Columbia has 3 teaching hospitals, 1 specialty hospital for children, 2 federal hospitals, and 3 other hospitals. All of the hospitals provide USA, DISTRICT OF COLUMBIA (1998-2002) diagnostic and treatment services USA, DISTRICT OF COLUMBIA (1998-2002) for cancer patients. Almost all of the radiotherapy departments are located in a hospital facility. Almost all of the Districts private 


 
 








practitioners are associated with 

 





at least one of the hospitals where 














cancer patients receive diagnostic 







and/or treatment services. 



















 

Registry structure and 














methods 






The District of Columbia Cancer 














Registry (DCCR) is located within 







the DC Department of Health 








 





(DOH) and is funded partly by the 

 





US Centers for Disease Control and Preventions National Program       0+'!0+'of Cancer Registries (NPCR), 


)/20*1/000  which pays the salaries of 3 staff members and a contractor. The 
   #0 #00
0 40
0!0"00)&&&000 $00 DOH pays the salaries of 2 staff 0(00

0!0"0#0

0000" 05 0!0 0 !00 0!
5 0 000)&&&000 $0 
3%%$ $ $%

$0 Communities. members, one of whom is the Program Director.  



 
0 0+)&&,-00 .00
 0 In addition, the DCCR also collaborates with other Data collection is passive notication of pre-coded data from the hospitals through electronic means (e.g. diskette, independent researchers by providing data, or performing data linkage of its data with other databases. The DCCR also CD-ROM, etc.). The principal sources of information on cancer cases are performs statistical reviews for the Comprehensive Cancer the hospitals. The District does not have any freestanding and Breast Cancer Programs.

151

North America

USA, DISTRICT OF COLUMBIA: BLACK (1998-2002)

USA, DISTRICT OF COLUMBIA: BLACK (1998-2002)

USA, DISTRICT OF COLUMBIA: WHITE (1998-2002)

USA, DISTRICT OF COLUMBIA: WHITE (1998-2002)








 













 































 












































 














































 
















 





 

 













































 

















 





 



 .*',

 !.*',





 0+'-

 !0+'-



(-0./+-...



 


110/*/000




   .(..

.!.".#. #. #..
. 2.
.!."..)&&&... $..

...." .3 .!. . !.. .!
3 . ...)&&&... $. 
1%%$ $ $%

$.  



 
. .*)&&+,.. -..
 .


   0(00

0!0"0#0 #0 #00
0 30
0!0"00)&&&000 $00

0000" 04 0!0 0 !00 0!
4 0 000)&&&000 $0 
2%%$ $ $%

$0  



 
0 0+)&&,-00 .00
 0

Source of population July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. The population data include the bridged singlerace estimates derived from the original multiplerace

categories in the 2000 United States Census. http://www. seer.cancer.gov/popdata. Multiple primary rules used IACR rules (2004) on CI5 IX period.

152

North America

USA, Florida
Registration area The Florida Cancer Data System (FCDS) is a legislatively mandated, statewide population-based registry covering a population of approximately 16 million. The State is comprised of 67 counties. Approximately 95% of the population (~15 million) live in 38 counties designated as Urban by the 2003 Beale codes. The remaining 29 counties are classied as Rural. registries that meet or exceed all standards for completeness, timeliness, and quality. Data collected and coded by the FCDS are in accordance with national standards as put forth by the NAACCR. To code primary site (typography and morphology), the FCDS uses the International Classication of Diseases Oncology, 3rd edition (ICD-O-3). During the study time period, the national staging criteria were revised. Tumours diagnosed between 1998 and 2000 were staged using the SEER General Cancer care facilities Summary Stage 1977. Tumours diagnosed between 2001 There are over 230 primary care facilities reporting data and 2002 were staged under the SEER General Summary to FCDS. Additionally, data are collected from over 350 Stage 2000 schema. Both schemas as presented in Table ambulatory care facilities, 800 pathology laboratories, the 2 categorise stage of disease as in-situ, local, regional or State of Florida Vital Statistics, distant, but the site-specic the State of Florida discharge conversion was not necessarily database and inter-state data a one-to-one conversion within USA, FLORIDA (1998-2002) exchange agreements. and between the regional and USA, FLORIDA (1998-2002) distant categories. However Registry structure and because regional and distant methods staged breast cancer were The FCDS is a joint project combined into late stage, the 


 









of the Florida Department revised coding schema had 







of Health and the University no effect on this analysis, and 




 






 
 

of Miami Miller School of the year-specic stages could 




 


Medicine (UMMSM). The be combined into a common  














UMMSM has operated the stage variable. 







FCDS since its inception in 














1981 under contract with the Interpreting the results 







DOH. The FCDS collects in excess 














FCDS is part of the of 95% of cancer cases among 




 


US Centers for Disease Florida residents. 














Control and Preventions  







National Program of Cancer Use of the data Registries (NPCR) and is The FCDS prepares an annual       /*', !/*', nationally certied by the report of cancer incidence, 



0/1++/.1-///  North American Association highlighting trends and of Central Cancer Registries 
   changes, and maintains a #/ #//
/ 3/
/!/"//)&&&/// $// (NAACCR) at its highest level, /(//

/!/"/#/ web site for dissemination of

////" /4 /!/ / !// /!
4 / ///)&&&/// $/ 
2%%$ $ $%

$/ gold certication. Gold certication is conferred on central tabular data. Additionally, data are provided for researchers.  





/ /*)&&+,// -//
 /

153

North America

USA, FLORIDA: BLACK (1998-2002)

USA, FLORIDA: BLACK (1998-2002)

USA, FLORIDA: WHITE (1998-2002)

USA, FLORIDA: WHITE (1998-2002)
































 





 
















 










































 
















 












































 

 





 





 





 



























 













































 /+'-

 !/+'-





 0+'-

 !0+'-



(/)&(/0,*///




 


/0,.20*1.000








   /(//

/!/"/#/ #/ #//
/ 2/
/!/"//)&&&/// $//

////" /3 /!/ / !// /!
3 / ///)&&&/// $/ 
1%%$ $ $%

$/  



 
/ /+)&&,-// .//
 /


   0(00

0!0"0#0 #0 #00
0 40
0!0"00)&&&000 $00

0000" 05 0!0 0 !00 0!
5 0 000)&&&000 $0 
3%%$ $ $%

$0  



 
0 0+)&&,-00 .00
 0

Source of population July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. The population data include the bridged singlerace estimates derived from the original multiplerace

categories in the 2000 United States Census. http://www. seer.cancer.gov/popdata. Multiple primary rules used IACR rules (2004) on CI5 IX period.

154

North America

USA, Georgia
Registration area The Georgia Comprehensive Cancer Registry is a population-based cancer registry covering the population of the entire state of Georgia. The population as of the most recent census projection (2000) is 8 186 453. Based on the 2000 census 65.1% of Georgia population is white, 28.7% black or African American, 2.1% Asian, 0.3% American Indian and Alaska Native, 0.1% Native Hawaiian and Other Pacic Islander, and 2.4% other race. Additionally 5.3% of the Georgia population is of Hispanic or Latino origin. The majority (80%) of Georgians live in urban areas, while 20% live in areas classied as rural. pathology laboratories submit their pathology reports electronically, and small pathology laboratories whether in-state or out-of-state may submit a photocopy of their pathology reports. Since 2001, the GCCR has conducted a yearly electronic match with the Georgia Hospital Discharge database to identify potential missed cases. Cases identied are researched by the GCCR regional cancer coordinators for reportability; identied missed cases are the responsibility of the facility to report. Additionally, the GCCR conducts death linkage with the State of Georgia death le, and follow-up of missed cases is done via hospitals, nursing homes, hospice and next-of-kin. Additionally the GCCR regional cancer coordinators conduct yearly casending audits on a sample of hospitals. During these Cancer care facilities audits cancer registrars check For each cancer case, facilities on missed cases in hospital are required to report USA, GEORGIA (1998-2002) departments of medical information such as sex, race USA, GEORGIA (1998-2002) records, pathology, radiology, and date of birth; cancer outpatient department, and diagnostic information such other hospital sources. as primary site, histology, Since 1995 all healthcare grade, and date of diagnosis; 


 
 






 

providers in the state of diagnostic conrmation and 







Georgia have been required stage information such as 





 








to report specic information SEER summary stage 2000 

 





on all cancers in their patient and Extent of Disease (EOD); 

 


 









population to the Georgia and treatment information 




 


Comprehensive Cancer related to rst course of 














Registry. This includes all treatment such as surgery, 





 

facilities providing diagnostic radiation, chemotherapy, 

 



 








evaluations and/or treatment hormone and other treatment. 







for cancer patients, including Additionally information is 




 









hospitals, outpatient surgical collected on the patients vital 

 


 


facilities, laboratories, status. radiation therapy and medical       oncology facilities, and Registry structure and .*', !.*', physicians ofces. In addition, methods 



+.&+&.+&(...  reporting agreements are The Georgia Comprehensive 

   #. #..
. 0.
.!."..)&&&... $.. maintained with neighbouring Cancer Registry (GCCR) is .(..

.!.".#.

...." .1 .!. . !.. .!
1 . ...)&&&... $. 
/%%$ $ $%

$. located in the Georgia Department of Human Resources, states so that Georgia residents who are diagnosed or treated  



 
. .*)&&+,.. -..
 . Division of Public Health in Atlanta, Georgia. The registry in out-of-state facilities can be identied. is funded by the state of Georgia and the federal government. Since 1995, the GCCR has participated in the National Use of the data Program for Cancer Registries (NPCR) that was established The registry prepares an annual report of cancer incidence by the US Centers for Disease Control and Prevention and mortality, highlighting trends and changes. Special reports on breast, cervical, colorectal, lung, prostate, and (CDC). The GCCR registry covers the entire State of Georgia, childhood cancers are prepared on an annual basis. GCCR which is bounded by Tennessee and North Carolina to the annual reports, cancer incidence and mortality analysis are north, Alabama to the east, Florida to the south, and South available at http://health.state.ga.us/programs/gccr. Cancer Carolina to the west. Reports are prepared by cancer registrars data are analysed regularly to meet the needs of the statelocated in hospitals with more than 100 licensed beds and wide Georgia Comprehensive Cancer Control Program. The submitted to the central registry. The GCCRs ve regional GCCR provides qualied researchers with cancer data to coordinators are responsible for abstracting cancer reports assist in investigating their proposed studies, and responds for facilities with less than 100 licensed beds. Independent to various data requests and cancer cluster for the public.

155

North America

USA, GEORGIA: BLACK (1998-2002)

USA, GEORGIA: BLACK (1998-2002)

USA, GEORGIA: WHITE (1998-2002)

USA, GEORGIA: WHITE (1998-2002)
































 








 













 
















































 






































 


 






















 


 


 


 


 
























 

















 






























 /+'-

 !/+'-





 .*',

 !.*',



(/(*&/,0)///







)./&).(&0...








   /(//

/!/"/#/ #/ #//
/ 2/
/!/"//)&&&/// $//

////" /3 /!/ / !// /!
3 / ///)&&&/// $/ 
1%%$ $ $%

$/ 
/ /+)&&,-// .//
 / Source of population July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. The population data include the bridged singlerace estimates derived from the original multiplerace  






   .(..

.!.".#. #. #..
. 2.
.!."..)&&&... $..

...." .3 .!. . !.. .!
3 . ...)&&&... $. 
1%%$ $ $%

$. 
. .*)&&+,.. -..
 . categories in the 2000 United States Census. http://www. seer.cancer.gov/popdata.  





Multiple primary rules used IACR rules (2004) on CI5 IX period.

156

North America

USA, Georgia, Atlanta

Registration area the area identify and electronically transmit their cases to The Metropolitan Atlanta Registry records cancer diagnosed in the registry on a monthly basis. Registry eld staff actively residents of ve contiguous counties (Clayton, Cobb, DeKalb, identify and collect cases from radiation therapy facilities, Fulton and Gwinnett) surrounding the state capital of Atlanta, large physician practices and other selected facilities without Georgia. Covering an area of 4500 km2, the metropolitan Atlanta the ability to report data electronically. Patient follow-up is primarily conducted through area is situated in the southeastern United States at latitude 33 N and longitude 84 W. The population in 2000 was estimated hospital cancer registries, treating physicians and record to be 2 914 587, of which 54% were white, 36% were black, 4% linkage against a variety of available data sources. Death were Asian and 6% were other races. Approximately 6% of the certicates are obtained electronically on a monthly basis population were Hispanic. The combined population of these and are used to supplement case-nding and update patient 5 metropolitan Atlanta counties comprised 36% of the entire follow-up. Data are processed at the registry using software population of Georgia (159 counties). The area has one of the developed by in-house staff. Extensive automated and visual fastest-growing populations in the USA, with an increase of editing is performed on the data to enhance and ensure quality. Both case-nding and 737 546 (33.8%) between 1990 re-abstraction audits are and 2000. Atlanta lies at an periodically performed at altitude of over 320m and enjoys USA, GEORGIA, ATLANTA (1998-2002) facilities reporting data. a temperate climate with 4 USA, GEORGIA, ATLANTA (1998-2002) distinct seasons. Air pollution is Interpreting the results a growing problem, particularly The Metropolitan Atlanta during summer months. Registry actively shares +-$&*--/*, $.-/(&--0-&"0--/" $/-(&*--data with the Georgia Registry structure and $*-0*0--.* %+-"0*--Comprehensive Cancer methods %%-$"&--." &"-/*(--%0-%"*--+* &*-(.*--Registry to help ensure The Georgia Center for &0-0(0--+" ((-(*.--complete case ascertainment Cancer Statistics (GCCS), a *0-+0*--** +&-*.&--/*-/%*--*" 0&-0/0--and treatment information division of the Department of $"$-0".--(* $"0-0&.--on residents of the 5-county Epidemiology in the Rollins $%$-*$.--(" $%+-&+"--$&*-&%*--&* $&+-&%%--catchment area diagnosed School of Public Health $&0-(*0--&" $&+-$/(--and/or treated elsewhere at Emory University, was $&&-"0&--%* $%0-*0.--$".-&+"--%" $""-"0&--in Georgia. Case sharing founded in 1976 to provide $"$-00$--$* 0(-$*%--agreements with Georgias population-based incidence $"+-%&*--$" $"$-+&&--$"0-0&.--* $"+-"&.--bordering states also exist. For data for a 5-county region in $$%-"0&--" $".-"0+--selected cancers that may be the southeastern USA as part of solely diagnosed and treated in the National Cancer Institutes $" * " " * $" the physicians ofce setting, Surveillance, Epidemiology -'#) -'#) incidence records may be and End Results (SEER) $-(./-$&%--$-(&.-"00-- missing from the registry due Program. Metropolitan 
   to a general lack of reporting Atlanta was a logical choice, -$--

--- ----
- 1-
----%"""--- !since it had been included in  



 the First, Second and Third by physicians throughout the state. 
--'%""()-- *--
National Cancer Surveys. Since its inception the population covered by the registry has increased dramatically, but the Use of the data The Metropolitan Atlanta Registry submits data on an annual geographical boundaries have not changed. The GCCS also operates the Rural Georgia SEER basis to the National Cancer Institutes SEER Program and Registry and carries out the day-to-day operations of the the Center for Disease Control and Preventions National Georgia Comprehensive Cancer Registry. It collaborates Program of Cancer Registries, in collaboration with the with the SEER Program of the National Cancer Institute, Georgia Comprehensive Cancer Registry. A number of the Cancer Control Program of the State of Georgia and population-based descriptive and analytical epidemiological the National Program of Cancer Registries at the Centers investigations have been conducted through the registry. for Disease Control and Prevention on these cancer registry Several of these have focused on factors, which may relate projects. The registry is staffed by over 25 full-time employees to the observed high incidence and low survival rates for including epidemiologists, data abstractors, quality control cancer among blacks. These studies have included cancers of the prostate, breast, pancreas, esophagus, ovary, colon, editors, data analysts and other support staff. Cancer is a reportable disease in the state of Georgia. rectum and multiple myeloma. Registry data extensively The Metropolitan Atlanta Registry combines both active support the research of faculty within the Rollins School of and passive case-nding and reporting systems. Most of Public Health at Emory University as well as many other the hospitals and free-standing pathology laboratories in researchers throughout the state.

157

North America

USA, GEORGIA, ATLANTA: BLACK (1998-2002)

USA, GEORGIA, ATLANTA: BLACK (1998-2002)

USA, GEORGIA, ATLANTA: WHITE (1998-2002)

USA, GEORGIA, ATLANTA: WHITE (1998-2002)

$-%.$--$-.((--%-0.%--(-*"0--+-0.$--0-0((--$(-+./--%&-*"0--&$-*0.--&0-.(0--(+-*&(--(.-+&0--((-*+(--&0-$&%--($-&%(--(+-.0"--(0-"//--(.-(%*---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

(-"+0--(-"/+--*-.*0--.-+0.--0-0&&--$%-/.*--$/-$(%--%0-$*/--&/-//*--(.-*"%--*(-$((--*(-/&/--*$-/$/--(&-+$0--($-&+(--(*-./"--(/-"(*--(*-+0%---

(-.+&--.-&.*--$%-+$+--$+-/+&--%$-"*+--%/-$*0--(%-&*+--*/-*%/--+*-*%&--.*-.&0--/$-+(%--/&-*0/--/"-$./--+%-"0.--**-&"&--*(-*%.--**-*0/--*/-0(.---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

$&-+"%--$(-"+(--$0-.0.--%%-&%"--%(-%&.--%0-./&--(%-//&--+"-/$/--++-"*&--.%-/%(--.*-(""--.&-((*--+0-&$"--*"-.((--(.-0*%--*$-$(0--*&-"%0--**-.%+---

$"

* -'#)

"

"

* -'#)

$"

$"

* -'#)

"

"

* -'#)

$"

(00-(&0---



*+&-("(---

/+(-/+0---



/(&-$&0---


   -$--

--- ----
- 1-
----%"""--- !-


   -$--

--- ----
- 1-
----%"""--- !-

Source of population July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census.

 



 
--'%""()-- *--
-

Multiple primary rules used IACR rules (2004) on CI5 IX period.

 



 
--'%""()-- *--
-

158

North America

USA, Idaho
Both hospital-based registrars and central registry Registration area According to the US Census Bureau (internet release 22 personnel conduct active and passive follow-up of cancer December 2006), Idahos total resident population for 1 July patients. CDRI conducts an annual linkage with vital records 2006 was 1 466 465. Idaho is the 4th fastest growing state to obtain survival data as well as determine cancer cases that since the 2000 Census. Idaho ranks 3rd among the 50 states were not identied through other sources. CDRI has worked since 1999 with the Northwest Portland plus the District of Columbia in terms of the proportion of the population aged 18 and under, and 41st in terms of Area Indian Health Board (NPAIHB) on probabilistic the proportion of the population aged 65 and older (2000 linkages between cancer registry, tribal registry and Indian Census). The majority of Idahoans are non-Hispanic whites; Health Service administrative data to improve the accuracy Hispanics and Native Americans are the two largest minority of cancer statistics among Native Americans in Idaho. groups, comprising 8.9% and 1.6% of Idahos population, Interpreting the results respectively (2004). Idaho ranks near the bottom of states on several CDRI has achieved NPCR and North American Association of Central Cancer Registries demographic measures that (NAACCR) standards for have been shown to be related data completeness, timeliness to lower rates of cancer USA, IDAHO (1998-2002) and quality since 1993; for screening and later stage at USA, IDAHO (1998-2002) the last ten years of submitted diagnosis. Idaho is a large data (19952004) CDRI has geographical state of 82 413 achieved the NAACCR Gold square miles, and over one Standard. Idaho data are third of Idaho counties are 


 






included in USCS and CINA. classied as frontier with less 

 





In 2004, Idaho was than 6.0 persons per square 

 












twelfth-worst in the nation mile. The rural character of 







for men aged 40 and older Idaho combined with severe 














who have not had a prostate winters in much of the state 







specic antigen (PSA) test pose difculties with access 














within the past two years, to cancer care. 







according to the Behavioral 














Risk Factor Surveillance Cancer care facilities 







System (BRFSS). Thirty-seven hospitals 








 





routinely provide cancer 







Use of the data diagnosis and/or treatment. CDRI data are used for There are seven hospitals       /*', !/*', many purposes, including in Idaho that have approved 


.-&/+0+///  surveillance of cancer cancer programs from the incidence rates, program American College of Surgeons 
   #/ #//
/ 2/
/!/"//)&&&/// $// planning and evaluation, Commission on Cancer. Seven /(//

/!/"/#/

////" /3 /!/ / !// /!
3 / ///)&&&/// $/ 
1%%$ $ $%

$/ quality assurance, measurement against clinical guidelines hospitals offer radiotherapy, and there is one free-standing  



 
/ /*)&&+,// -//
 / and benchmarks, central registry systems development, radiation facility in Idaho. responding to requests for information from hospitals, media and the public, and public health practice. Registry structure and methods CDRI data are used in approved projects for use in The Cancer Data Registry of Idaho (CDRI) is a populationbased, statewide cancer registry that collects incidence and epidemiologic and translational studies. In 2006 CDRI was survival data on all cancer patients who reside in the state of funded to participate in the CDC/ORC Macro study Accuracy Idaho or who are diagnosed and/or treated for cancer in the state of Cancer Mortality Measured by Death Certicates. CDRI of Idaho. Idaho has one of the oldest cancer registries in the worked with NPAIHB to link tribal registries to CDRI data United States. Established before the National Cancer Institutes to improve quality of race-specic incidence rates and used Surveillance, Epidemiology, and End Results (SEER) Program, linked data in studies. Published reports of cancer incidence and mortality are the Cancer Data Registry of Idaho (CDRI) has functioned since available on the CDRI web site at: www.idcancer.org. 1969 and has been population-based since 1971. Since 1969, CDRI has been supported with state funding by a dedicated fund from a portion of Idahos tobacco tax. Source of population Since 1994, CDRI has enhanced cancer registry operations July 1 county population estimates by age, sex, race, and and increased utilisation of cancer registry data with National Hispanic origin; postcensal estimates based on 2000 United Program of Cancer Registries (NPCR) funding administered States Census. The population data include the bridged by the US Centers for Disease Control and Prevention (Public singlerace estimates derived from the original multiplerace categories in the 2000 United States Census. Law 102-515). CDRI is staffed by six employees, including a vice http://www.seer.cancer.gov/popdata. president of operations and registry services, a director, an epidemiologist, a database coordinator and two cancer data Multiple primary rules used IACR rules (2004) on CI5 IX period. controllers.

159

North America

USA, Illinois
Registration area The Illinois State Cancer Registry covers the population of the State of Illinois, USA. The population at the most recent census was 12 439 738, with an urban population of 12 378 679 and a rural population of 61 059. Eighty percent of the population is white, 16% African American, and 4% of the Illinois residents reported themselves as some other race; 12% of the population is Hispanic or Latino. All hospitals are visited at least once every ve years for casending. Re-abstracting studies will be performed online within the next year, and online abstracting will also be available. Death clearance is performed as a casending tool, and data exchange is performed with 12 other US states. There are 23 staff supporting the registry and include a PhD, MD Medical Director, along with 11 certied tumour registrars (including registry manager, trainer and QC manager), 3 database support staff, 1 data use coordinator, 2 registry operations staff, 1.75 clerical support staff, 2.5 epidemiologists and 1.75 research support staff. The registry performs all activities required by the National Program of Cancer Registries and has been certied as a gold standard registry by the North American Association of Central Cancer Registries for the past 9 years. Interpreting the results The completeness of reporting for the Illinois State Cancer Registry is at estimated to be 100%. However, melanomatous cancers of the skin and prostate cancer are estimated to be under reported.

Cancer care facilities Throughout Illinois cancer patients are treated at hospitals, ambulatory surgery centres, out-patient non-hospital facilities that house radiation therapy equipment, physicians ofces and chemotherapy centres. The size of the hospitals varies from large teaching USA, ILLINOIS (1998-2002) and university-based hospitals USA, ILLINOIS (1998-2002) to small rural community hospitals. There are two NCIdesignated Comprehensive Cancer Centers in Illinois. 


 



About 6% of the Illinois 




residents visit hospitals in 








other states for diagnosis and 




treatment. 




























 











Registry structure and 




 
 

 



 


Use of the data methods 







The registry provides yearly The Illinois State Cancer 














annual reports at the state and Registry is housed in the Illinois 







county levels; a public dataset Department of Public Health, 














le with data at state, county Division of Epidemiologic 







and postal code levels; an Studies and state law provides interactive query system of all the authority for collection of       public data on the Departments cancer incidence cases. /*', !/*', web site; access to condential The state accounts for 



./&11/.0(///  data by researchers through one third of the Registry /(//

/!/"/#/ #/ #//
/ 3/
/!/"//)&&&/// $// application and IRB review; funding, and the other two 
  

////" /4 /!/ / !// /!
4 / ///)&&&/// $/ 
2%%$ $ $%

$/ thirds is funded by the US Centers for Disease Control and cluster investigations; quality control reports to reporting  



 
/ /*)&&+,// -//
 / Preventions National Program of Cancer Registries (NPCR). facilities; linkage with the Departments Breast and Cervical The registry receives reports from over 400 facilities, cancer program and the States death certicates and various and 97% of the reports are received in electronic format. non-condential data requests from reporting facilities.

160

North America

USA, ILLINOIS: BLACK (1998-2002)

USA, ILLINOIS: BLACK (1998-2002)

USA, ILLINOIS: WHITE (1998-2002)

USA, ILLINOIS: WHITE (1998-2002)














 





 





























 

 





















 











 

















 














 









































 













 


















 











 








 







 

























 /*',

 !/*',





 /+'-

 !/+'-



1&./0&0///







,/0*)/,,)///





 


   /(//

/!/"/#/ #/ #//
/ 3/
/!/"//)&&&/// $//

////" /4 /!/ / !// /!
4 / ///)&&&/// $/ 
2%%$ $ $%

$/  



 
/ /*)&&+,// -//
 /


   /(//

/!/"/#/ #/ #//
/ 2/
/!/"//)&&&/// $//

////" /3 /!/ / !// /!
3 / ///)&&&/// $/ 
1%%$ $ $%

$/  



 
/ /+)&&,-// .//
 /

Source of population July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. The population data include the bridged singlerace estimates derived from the original multiplerace

categories in the 2000 United States Census. http://www. seer.cancer.gov/popdata. Multiple primary rules used IACR rules (2004) on CI5 IX period.

161

North America

USA, Indiana
Interpreting the results Registration area The Indiana State Cancer Registry covers the population in Estimates of completeness of case ascertainment are made the state of Indiana, USA. The population at the most recent using the NAACCR method, which compares the ratio of census (2000) was 6 080 485. The majority of the population incidence rates to mortality rates for over a dozen cancers, (85.8%) is white, non-Hispanic. Non-Hispanic Black or and compares this ratio with the ratio calculated for areas African Americans comprise 8.3% of the population, covered by SEER. The Indiana State Department of Health (ISDH) has a Hispanics of any race 3.5%, and all other non-Hispanics 2.3%. The majority of the population (70.8%) resides in urban areas Breast and Cervical Cancer Program through the Centers with 56.1% of the total population living in areas with more for Disease Control and Prevention (CDC), which provides than 50 000 residents. Although 29.2% of the population lives funding and guidelines for the program. This program in rural areas, only 2.1% of the total population live on farms. provides mammograms and Papanicolau testing for lowSurveys from 1990 suggest that about 87.5% of the population income women ages 4065. The ISDH organizes the annual is Christian (Catholic 16%), about 7.4% is nonreligious, Black & Minority Health Fair, which occurs in conjunction with the Indiana Black Expo about 0.30.4% is Jewish, Summer Celebration. Free about 0.1% is Muslim, and PSA testing is offered as one the others belong to a variety USA, INDIANA (1998-2002) of a number of screening of religions. Approximately USA, INDIANA (1998-2002) tests for chronic diseases. 14% of the population has There is information available no health insurance, 24% about screening for other has government-sponsored cancers, including breast health insurance, and 63% has 


 









cancer, cervical cancer, and private health insurance (59% 







colon cancer, though these through their employers). 












 

screenings are not generally 







offered at the fair. Outside of Cancer care facilities 











 


ISDH, there are many public Approximately 44 of the 







and private organisations approximately 120 acute care 

 












offering free or low-cost hospitals in Indiana have a 







screenings for breast, cervical, cancer program approved by 














prostate, and colon cancers. the Commission on Cancer/ 







Self-reported information American College of Surgeons. 














from the 2004 Indiana Survey Patients also receive cancer 






of the Behavioral Risk Factors care in a variety of outpatient Surveillance System indicates settings, such as ambulatory       that an estimated 48.9% of surgery centres, radiation /+'!/+'Indiana men age 40 or above therapy centres, cancer clinics, 



)/10*/.,)///  have had a PSA test within the home care, private physician 
   /(//

/!/"/#/ #/ #//
/ 3/
/!/"//)&&&/// $// past 2 years. This is lower than ofces, and other locales.

////" /4 /!/ / !// /!
4 / ///)&&&/// $/ 
2%%$ $ $%

$/ the nationwide (USA) average of 51.8%. In Indiana, only an  



 
/ /+)&&,-// .//
 / estimated 55% of men age 40 or over report ever having had Registry structure and methods The registry is located within the Indiana State Department a PSA test. Indiana is second highest in the USA in the percentage of Health, and is funded through state and federal funds from the US Centers for Disease Control and Preventions National of current smokers (27.3% of the population age 18 or older). Program of Cancer Registries (NPCR). The registry is staffed by Both tobacco growing and coal mining are fairly common a director, three full-time cancer registrars, one full-time software occupations in southern Indiana. programmer/analyst, one grant coordinator, and one secretary. The registry collects data from approximately 120 Use of the data hospitals throughout the state plus additional surgery centres, The Cancer Registry supports the Comprehensive Cancer radiation centres, pathology laboratories, and physician Control program with data used both in educational ofces. Cancer registry records are matched electronically publications and to provide an evidence base for the planning with death certicates every year. Unreported cancer cases and implementation of strategies. The registry prepares an identied through this death clearance process are followed annual report of cancer incidence. Cancer registry data are back and added to the registry as either a new case or a Death also matched with data from the Breast and Cervical Cancer Early Detection Program annually. Cancer registry data are Certicate Only (DCO) case. Cancer is a reportable disease by state statute. Most cases provided to the Shared Information Pathology Network project are reported electronically by hospitals using various cancer at Regenstrief Clinic in Indianapolis quarterly. Data are also registry software programs. Case-sharing agreements are in used to respond to numerous unscheduled requests for data place with the four surrounding states (MI, OH, KY, & IL) from other sources. Neither the registry nor any other programs or divisions in the ISDH does epidemiological cancer research and approximately 14 other states. Numerous quality control procedures are performed on beyond producing routine statistics. However, the Indiana all incoming data using electronic and manual edit checking State Cancer Registry makes its data available to bona fide researchers in both public and private organisations. procedures.

162

North America

Source of population July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. The population data include the bridged singlerace estimates derived from the original multiplerace

categories in the 2000 United States Census. http://www.seer. cancer.gov/popdata. Multiple primary rules used IACR rules (2004) on CI5 IX period.

163

North America

USA, Iowa
residents are obtained from 154 hospitals, clinics, and pathology Registration area The state of Iowa is located near the geographical middle of the laboratories located both within the state and bordering the United States and is part of its agricultural heartland. Iowa state. Cancer data are exchanged with other states. Data are collected by Hospital Cancer Registrars and by is bordered on the north by Minnesota, the south by Missouri, the east by Illinois, and the west by Nebraska. The total area 20 eld staff employed by the Registry to cover specied is about 145 800 km2 with elevation ranging between 146 and geographic areas. The eld personnel visit hospitals and other facilities in their areas and abstract data using laptop 505m above sea level. Ninety-two percent of the land area in the state is devoted computers. The Registrys remaining 30 full-time employees to agriculture, ranking the highest in the USA among its 50 work in the central ofce where they edit the data, consolidate states. Agricultural exposures include pesticides, fertilizers, multiple reports for the same cancer, perform follow-up, fuels and oils, animal viruses, organic solvents, engine respond to data requests, and conduct research. Since 1969, there have been changes in case denition exhausts and paints. These may inuence cancer incidence in this population, but likely not as strongly as lifestyle factors and coding. These are documented in revisions to coding manuals and extent of disease like tobacco use, alcohol classications, provided at consumption and overweight/ http://www.seer.cancer.gov/ physical inactivity. USA, IOWA (1998-2002) tools/codingmanuals. Iowa had a 2000 population USA, IOWA (1998-2002) The International of 2 926 324, a 3.6% increase Classication of Disease for over its 1970 population. The Oncology is used to assign codes population aged 65 years for topology, morphology, and and older increased from %0.)%+... 0+)/.0+0... &).00/... 0#! )&.,01... tumour behaviour. The Registry 12.4% in 1970 to 14.9% in '/.11/... /+! +'.'))... is currently using the 3rd edition 2000. The principal ethnic )+.//0... /#! +/.)&/... )1.0&/... ,+! +/./1)... group is Northern European, of ICD-O. +/.+%0... ,#! ,&.%,&... with Germans, Danes and The Registry uses active ,1.+#)... ++! /%.1#)... 1%.',#... +#! 1%.##%... Swedes accounting for a large and passive follow-up activities %#/.+&%... )+! %#,.%&/... segment of the population. to obtain survival data. Passive %%).#,/... )#! %%'.100... %#/.,1'... '+! %#/.&'#... The 2000 population is 93.9% follow-up activities include 1'.1)0... '#! 1#.00'... white with 2.1% blacks, 1.3% computerized linkage of 1%.%'1... &+! 0/.0#0... %#,./0,... &#! %#&.0&&... Asian/Pacic Islander, 0.3% data with death certicate %%).&11... %+! %#0.01#... American Indian/Alaskan information, drivers license %#,.0#'... %#! %#%.&&/... %#%.%0#... +! 1,.%11... Native, and 2.4% other or more les from the Iowa Department 1).0)+... #! 1#.%)'... than one race. Over 80% of of Transportation, the Social Iowa residents are native-born. Security Administration %# + # # + %# The population is primarily Epidemiological Vital Status .($* .($* %.)01.)1+... Christian, the most prevalent %.)''.+,/...  data, and Medicare information religions being Roman Catholic,  
 provided by the Centers for
... ...&###.
 . .......
". Lutheran, and Methodist. Medicare & Medicaid Services.  
   Cancer diagnostic and treatment services are widely Active patient follow-up is conducted annually. 

..(&##)*..
+.. .    available to the entire Iowa population through both in-state Quality control activities, including computer edits,
)). .. .... ..". and out-of-state facilities. These include surgery, radiation statistical comparisons, and visual review of data, occur therapy, chemotherapy, and other treatment modalities such daily. Site-specic re-casending and re-abstracting are also as immunotherapy. Radiation oncology services are provided performed on a regular basis. as in-hospital facilities as well as stand-alone facilities. These types of diagnostic and treatment services have increased Interpreting the results over time and have been accompanied by increasing numbers Although some Iowans who leave the state for care are not of medical, surgical, and radiation oncologists. identied and missed, ascertainment is thought to be about 99%. The Iowa Cancer Registry successfully follows over 98% Registry structure and methods of all patients into the current year. Cancer data collection for the entire state of Iowa began in 1969 with the Third National Cancer Survey sponsored by the Use of the data National Cancer Institute (NCI). With the completion of the The Registry functions as a collaborative program with the survey in 1971, no further funding for cancer registration was Iowa Department of Public Health. Many University of Iowa available and 1972 data are incomplete. In 1973 the State Health researchers have used Registry data. Registry data have also Registry of Iowa, frequently referred to as the Iowa Cancer been used extensively in a number of local, national and Registry, became part of the NCI Surveillance, Epidemiology international epidemiological studies. and End Results (SEER) Program. The area covered by the Policymakers look to the cancer registry to provide Registry has not changed since 1969, and includes all 99 information regarding the burden of cancer and time trends counties in the state of Iowa. in cancer incidence, stage of disease at diagnosis, survival, Cancer became a reportable disease in Iowa in 1982. The and mortality. To this extent, they are currently used to Iowa Department of Public Health has designated responsibility address and assess cancer prevention and control issues. for cancer data collection to the Registry. Cancer data for Iowa Occasionally, the data are also used to determine certicate

164

North America

of need requests for new medical facilities and equipment in selected geographic areas of the state. Source of population Annual census projection based on the 2000 Census, prepared by the US Bureau of the Census.

Multiple primary rules used IACR rules (2004) on CI5 IX period. Notes on the data C44 does not include basal cell or squamous cell carcinoma.

165

North America

USA, Kentucky
Registration area The Kentucky Cancer Registry (KCR) is a population-based central cancer registry for the entire state of Kentucky. According to the 2000 U.S. Census, the population of Kentucky was approximately 4 042 000. Of that, 75.1% are White, 12.3% are Black and the remaining 12.6% are American Indians, Alaska Natives, Asian, Hawaiian Natives, Pacic Islanders or other races. into four regions and assigned to one of four Regional Abstractors employed by KCR. The Regional Abstractors record and report information on all cases of cancer seen in these smaller institutions. The KCR Regional Coordinators and Regional Abstractors are required to be Certied Tumor Registrars (CTRs) or become CTRs within two years of their date of employment.

Interpreting the results Data from KCR have been submitted to the North American Cancer care facilities All health care facilities in Kentucky that diagnose or Association of Central Cancer Registries (NAACCR) for treat cancer patients are required to report cancer cases to an objective evaluation of completeness, accuracy and KCR. Facilities that are also required to report cancer cases timeliness each year since a formal certication program was established in 1997. In include freestanding treatment each year (19992001), KCR centres, non-hospital (private) received the highest level pathology laboratories, and USA, KENTUCKY (1998-2002) of NAACCR certication physician ofces. USA, KENTUCKY (1998-2002) available (Gold). KCR has also submitted its data for inclusion Registry structure and in the Cancer in North methods America (CINA) publication. KCR has been collecting $*-++*--/*, (%-&($--%(-%&+--/" ((-*&"--A registry must have complete data on incident cases of ($-*+0--.* +$-/*.--data for the most current vecancer since 1991, when **-0*"--." .&-"0*--+.-$+/--+* ./-+"(--year period before their data the State General Assembly /"-+&$--+" //-0("--can be evaluated for inclusion approved legislation requiring $""-&$.--** $"+-("0--$%/-//"--*" $&&-0/"--in the CINA combined rates. mandatory reporting of $(*-$("--(* $(0-+(/--KCR data have been included all cases of cancer to the $*.-/."--(" $+%-+%0--$*.-*$%--&* $+"-&00--in the CINA combined rates registry. The legislation $((-&*/--&" $((-*$+--each year since ve years of provided recurring funding $&0-0/%--%* $&.-0"(--$(*-+%%--%" $($-"&$--KCR data became available. for staff, travel and computer $(/-&.*--$* $("-(..--equipment. KCR also receives $((-&((--$" $&+-$$*--$($-/%0--* $&(-%&$--Use of the data funding from the US Centers $&+-$&"--" $%0-.**--KCR data are used to initiate for Disease Control and cancer control programs, Prevention (CDC) through the $" * " " * $" evaluate intervention activities, National Program of Cancer -'#) -'#) or conduct epidemiological Registries (NPCR) and the %-"++-(+$--$-0.*-*/"-- research. KCR data have been National Cancer Institutes -$--

--- ----
- 1-
----%"""--- !used in preparing hundreds Surveillance Epidemiology 
    



 and End Results (SEER) program. KCR employs three of research projects and proposals. Also, data from KCR 
--'%""()-- *--
Regional Coordinators to work with larger institutions and are presented each year to cancer councils in 15 Area four Regional Abstractors that work with smaller hospitals in Development Districts (groups of counties) covering the order to ensure the quality, accuracy, timeliness of the data entire state. These District Cancer Councils use the data from KCR to identify specic types of cancer that occur in reported. The larger hospitals (those diagnosing or treating more their area at substantially different rates compared to state than 100 new primary cancer cases annually) are required to and US rates. have their own tumour registrar(s). These larger hospitals are divided into three geographic regions. The three Regional Source of population Coordinators employed by KCR spend one day each month July 1 county population estimates by age, sex, race, and in each of these larger facilities providing additional Hispanic origin; postcensal estimates based on 2000 United training, re-abstracting cases for quality control and helping States Census. the hospital-based registrars prepare reports from the data. The smaller hospitals (those diagnosing or treating fewer Multiple primary rules used than 100 new primary cancer cases annually) are divided IACR rules (2004) on CI5 IX period.

166

North America

USA, Louisiana
Registration area Louisiana law requires all licensed healthcare providers to Louisiana belongs to what is historically known as the Deep report cancer cases who receive medical services for cancer. South of the US, a warm and at section of the country. The Because the LTR is considered a public health authority, it is 2000 Louisiana population of 4 468 976 is 63.9% white and exempt from the patient consent requirement of the HIPAA 32.5% African-American. Louisiana has less racial diversity legislation. than the nation, with 1.2% Asians, 2.4% Latin Americans, Most incident cases are identied in hospitals. One fourth and 2.6% foreign-born. One population group unique to the of the hospitals in Louisiana operate cancer registries, and state is the Cajuns, descendants of French-Canadians who these report about two thirds of new cases. Registrars from live in central and southwest Louisiana. the LTR regional ofces screen and abstract at the remaining Per-capita income and graduation rates for high school hospitals. The LTR follows the reportability guidelines of the and college well below the national levels reect Louisianas SEER Program and the CDC National Program of Cancer low socioeconomic ranking in the US. The percentage Registries andthe coding guidelines of the SEER Program. living below the poverty level is 50% higher in Louisiana Non-hospital sources of reportable cancer cases include than nationally. Louisiana pathology laboratories, is unusual, however, in its radiation and dermatology dedication to providing clinics, and one-day surgery USA, LOUISIANA (1998-2002) free medical care through a facilities. Pathology reports USA, LOUISIANA (1998-2002) statewide system of ten public from both hospital and hospitals. freestanding laboratories, including out-of-state labs, Cancer care facilities are screened, and all positive $+-%0&--/*, ($-*0/--%(-.&"--/" ((-/0%--During the years 19982002 reports are followed back to (&-"*(--.* +&-/"/--cancer diagnostic care and the diagnosing healthcare *.-+**--." .+-./.--++-/+.--+* /"-/*/--treatment were available at provider to obtain the /"-%/0--+" 0$-$%"--approximately 125 inpatient required information. Death $""-(/"--** $$"-"%/--$&$-+0&--*" $&0-*0/--hospitals in Louisiana. The certicates also identify a $*&-+(+--(* $+%-"%.--cancer programs at 29 hospitals small number of cases, and $+0-*(&--(" $..-*(/--$+(-(/&--&* $.&-...--and one cancer treatment these too are followed back $(0-&(0--&" $**-((*--centre were accredited by to the diagnosing physician or $(*-*&(--%* $*"-/*%--$+(-+.(--%" $+.-(&0--the Commission on Cancer. hospital if possible. $/&-/*(--$* $.0-*(*--Radiotherapy services were $.+-/&.--$" $+0-("&--$+0-/$*--* $+$-+&*--available at most of these Industry in Louisiana $+$-00%--" $**-.%+--facilities, located in the Although the states economy larger cities throughout the traditionally relied on $" * " " * $" -'#) -'#) state. One notable change in agriculture, Louisiana is now %-&"%-"/(--%-$+"-./0-- medical practice has been the the second-largest rener rise of freestanding outpatient 
   of petroleum in the US, surgery facilities. Only a -$--

--- ----
- 1-
----%"""--- !and manufactures a quarter  



 
--'%""()-- *--
handful existed in Louisiana in 19982002, but two dozen of the nations petrochemicals. Over 25 000 people are are open now. employed in chemical manufacturing and another 14 000 in shipbuilding. The presence of 100 large petrochemical Registry structure and methods facilities has given rise to concerns about excess cancer The Louisiana Tumor Registry (LTR) was established in incidence among workers and residents there. The LTR 1974 to monitor cancer incidence in the three-county area of publishes comparisons of cancer incidence rates in the Greater New Orleans. Its catchment area gradually expanded industrial corridor from Baton Rouge to New Orleans with to include the entire state by 1988. The LTR participates in those for the state and the nation in its annual Cancer in both the US Centers for Disease Control and Preventions Louisiana series. Although monitoring environmental National Program of Cancer Registries and the National indicators remains the responsibility of the federal Cancer Institutes Surveillance, Epidemiology, and End Environmental Protection Agency and the state Department Results (SEER) Program. of Environmental Quality, the LTR collaborates with the The LTR comprises a central ofce and eight regional Louisiana Ofce of Public Health in investigating reports ofces. The LSU Health Sciences Center operates the LTR of excess cancer incidence in specic areas. central ofce and three of the regional ofces while local academic and medical organisations with cancer research Use of the data and treatment interests coordinate the activities of the Louisiana incidence and mortality data are published annually remaining ve regions. in Cancer in Louisiana and are available on the registry The registry staff in early 2005 numbered 54, with 18 website: http://publichealth.lsuhsc.edu/tumorregistry. In of those in the central ofce. The LTR staff included 23 addition, they are incorporated into several databases on Certied Tumor Registrars, and the central ofce, housed the Web: the CDC/NCIs State Cancer Proles, the CDCs in the Louisiana State University in New Orleans, had a WONDER, and the North American Association of Central research/technical team that included 4 doctorate degrees Cancer Registries CINA+. The LTR cooperates with and 6 Masters degrees. outside researchers investigating the correlations between

167

North America

cancer incidence and workplace exposures or lifestyle risk factors and with the Louisiana Ofce of Public Health in investigations of potential cancer clusters. LTR staff members also participate in patterns-of-care studies for the CDC and the SEER Program, as well as publishing numerous descriptive epidemiology articles.

USA, LOUISIANA: WHITE (1998-2002)

USA, LOUISIANA: WHITE (1998-2002)

$$-/(/--$0-&("---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

&$-(*%--&(-.*"--(/-00/--*.-."*--*/-0&0--+*-&*+--./-*&&--0+-(%+--$".-$//--$$+-%.&--$$%-(0&--00-"."--0(-%+(--00-.$(--$"(-&+.--0.-$"$--0$-%$/--//-.$+---

USA, LOUISIANA: BLACK (1998-2002)

USA, LOUISIANA: BLACK (1998-2002)

&&-/.0--((-0/$--*"-.(+--+"-$0$--.(-..$--0(-0&/--$".-&.*--$$.-%./--$$%-&.&---

(-&$.--*-$00--/-/&*--$%-"/&--$*-%*&--$/-//"--%(-""$--&(-&*0--(&-&*.--(/-0&.--(/-(&/--(*-".$--(+-$"&--*/-("(--.$-%((--."-.$/--+0-/"$--+*-0+/---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

0-0$0--0-0"%--$(-&+(--$/-&&.--%"-0+"--%(-(.*--%0-."+--("-*+/--*$-+((--*.-.&*--*.-.%&--*%-..0--*%-."/--+&-//*--.$-&*(--+/-/$$--+.-$+(--+&-//0---

$""-."%--0*-(0$--$"%-"%"--$"/-**.--$"%-&$(--0+-*%/--0%-.%0---

$"

* -'#)

"

"

* -'#)

$"

$-(%+-"+$---



$-(/%-*++---

$"

* -'#)

"

"

* -'#)

$"

-$--

--- ----
- 1-
----%"""--- !Source of population  



 
--'%""()-- *--
July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. 
  

+0"-0+/---



..*-0%&---


   -$--

--- ----
- 1-
----%"""--- ! 



 
--'%""()-- *--
-

Multiple primary rules used IACR rules (2004) on CI5 IX period.

168

North America

USA, Louisiana, New Orleans

Registration area The New Orleans region, comprising three counties in southeast Louisiana in the American Deep South, had a population of 1 007 369 in 2000. Of these, 99% were considered urban dwellers. The average per capita income of metropolitan New Orleans was slightly higher than the state average, but the state per capita income is 22% lower than the national level. The areas population is approximately 44% African American and 53% white, with only a small presence of Asians or American Indians. About 5% of the population is of Hispanic origin. Cancer care facilities Cancer registration in the three-county area of Greater New Orleans began in 1974. The New Orleans Regional Registry, which also documents cancer incidence in eight surrounding counties, has a staff of six full-time employees and a supervisor. Of these, ve are Certied Tumor Registrars. Diagnosis and treatment for cancer during the period 1998-2002 was available at 18 hospitals in Greater New Orleans. Eight offered cancer programs approved by the Commission on Cancer, and a few others had extensive cancer services as well. Radiotherapy was available only at these large facilities. Registry structure and methods Although the Louisiana Tumor Registry (LTR) encompassed only the New Orleans area in 1974, its catchment area expanded incrementally, covering the entire state in 1988. The LTR participates in both the U.S. Centers for Disease Control and Preventions National Program of Cancer Registries and the National Cancer Institutes Surveillance, Epidemiology, and End Results (SEER) Program. The LTR comprises a central ofce and eight regional ofces. The LSU Health Sciences Center operates the LTR central ofce and three of the regional ofces, while local academic and medical organizations with cancer research and treatment interests coordinate the activities of the remaining ve regions. Louisiana law requires all licensed healthcare providers to report cases that receive medical services for cancer, whether a resident of the state or not. Because the LTR is considered a public health authority, it is exempt from the patient consent requirement of the HIPAA legislation. Most incident cases are identied in hospitals. One fourth of the hospitals in Louisiana operate cancer registries, and these report about two thirds of the new cases. Registrars from the LTR regional ofces screen and abstract at the remaining hospitals. The LTR follows the reportability guidelines of the SEER Program and the CDC National Program of Cancer Registries, abstracting all data items required by these programs as well as other data items. Non-hospital sources of reportable cancer cases include pathology laboratories, radiation and dermatology clinics, and one-day surgery facilities. Pathology reports from both hospital and freestanding laboratories, including out-of-state labs, are screened, and all positive reports are followed back to the diagnosing healthcare provider to obtain the required information. Death certicates also identify a small number of cases, and these too are followed back to the diagnosing physician or hospital. For cancer cases diagnosed in its area, each regional ofce abstracts, consolidates, and edits data and documents survival through active follow-up. The central ofce consolidates and edits data from the regional registries, monitors completeness of case ascertainment, exchanges case reports with other states, obtains survival information through data linkages, and analyzes and interprets the statistical information derived from the data. Both regional registries and the central ofce evaluate case completeness on an ongoing basis by comparing each facilitys case counts with those for previous years. The LTR conducts case-nding audits throughout the state, as do the major funding agencies (the CDC and the SEER Program). Abstractors from the central and regional ofces participate in national reliability studies at least biennially to evaluate their coding expertise, and samples of cases prepared by hospital registrars are re-abstracted to appraise their accuracy. The LTR follows the coding guidelines of the SEER Program. Over time, some changes have been adopted nationwide to reect changes in the understanding of cancer and in treatment modalities. These include the transition from the First Edition to the Third Edition of the ICD-O manuals and from the SEER 1977 staging manual to the SEER 2000 staging manual, as well as updates to the treatment codes. Use of the data Louisiana incidence and mortality data are published annually in the LTRs Cancer in Louisiana series and are available on the registry website: http://publichealth.lsuhsc. edu/tumorregistry. In addition they are incorporated into several databases on the Web: the CDC/NCIs State Cancer Proles, the CDCs WONDER, and the North American Association of Central Cancer Registries CINA+. The LTR cooperates with outside researchers studying correlations between cancer incidence and workplace exposures or lifestyle risk factors, and with the Louisiana Ofce of Public Health in investigations of areas with possible high rates of cancer incidence. In addition, LTR staff participates actively in patterns-of-care studies for the CDC and the SEER Program, as well as publishing numerous descriptive epidemiology articles.

169

North America

USA, LOUISIANA, NEW ORLEANS: BLACK (1998-2002)

USA, LOUISIANA, NEW ORLEANS: BLACK (1998-2002)

USA, LOUISIANA, NEW ORLEANS: WHITE (1998-2002)

USA, LOUISIANA, NEW ORLEANS: WHITE (1998-2002)

$-"$/--$-($*--%-.$"--&-*%/--(-*%%--*-+++--.-&$&--$"-+$.--$&-"*0--$(-&.*--$&-0((--$%-/*0--$&-+/%--$+-$%"--$0-/+%--%"-.+(--%"-/%0--$0-%."---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

%-*&%--%-.".--(-&$*--*-($%--+-&"/--.-*.&--0-*$&--$&-%/"--$+-&00--$/-"$/--$.-0"/--$+-(*.--$.-(("--$0-%/(--%"-0$.--%"-&$(--%"-".*--$/-*"&---

%-(/*--(-$/%--.-+(0--0-%/*--0-%+*--$$-$(&--$(-.(0--$/-/&*--%"-.%0--%$-/+"--%$-$//--%"-$$$--$0-"""--$.-"%%--$+-%+(--$*-*"*--$(-.%+--$(-(/"---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

.-%%(--.-.%&--$$-(/%--$%-.*/--$$-(++--$%-(+&--$*-++*--$0-*/%--%"-+/.--%$-&*"--%"-(%*--$/-0%.--$/-+&(--$.-%.*--$*-.*&--$(-/%"--$&-0&/--$&-0&$---

$"

* -'#)

"

"

* -'#)

$"

$"

* -'#)

"

"

* -'#)

$"

%"$-**(---



%&+-0**---

%*/-(./---



%.(-$"(---


   -$--

--- ----
- 1-
----%"""--- ! 



 
--'%""()-- *--
-


   -$--

--- ----
- 1-
----%"""--- ! 



 
--'%""()-- *--
-

Source of population July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census.

Multiple primary rules used IACR rules (2004) on CI5 IX period.

170

North America

USA, Maine
Registration area The Maine Cancer Registry covers the entire population of the state of Maine in the United States of America. According to the 2000 US Census, 58% of the population lives in a rural area. About 82% are Christian, while 17 % classify themselves as non-religious. About 97% of the population is Caucasian. Cancer care facilities Health care in Maine is provided by 37 hospitals and many private physician ofces. Of the 37 hospitals, 11 have approved cancer care programs. The availability of care is more prominent in the more populous southern regions of Maine. Citizens in northern Maine may have to drive further to obtain appropriate cancer care. Interpreting the results Maines cancer incidence database meets the highest standards for quality, completeness, and timeliness. The registry database is 100% complete for the data years of interest. Screening for prostate, colon, breast, and cervical cancer have increased but remain largely opportunistic. Environmental concerns in Maine include high levels of arsenic in private well water, and high radon air concentrations in Maine homes, as these chemicals occur naturally in Maines geography. Maine is also home to a shipbuilding company that used asbestos in the past.

Registry structure and methods The registry is located in Augusta, the state capital. The registry is staffed by 6.5 fulltime employees, two of whom are certied tumour registrars. 


Funding for the central registry 



is a 3:1 match between federal 






dollars from the US Centers 



for Disease Control and 






Preventions National Program 



of Cancer Registries (NPCR) 




 

and state dollars. Cancer is a 



reportable disease according 














to state law. The majority 







Source of population of our cases are reported by 














July 1 county population hospitals on a routine basis. 







estimates by age, sex, race, and These data are supplemented Hispanic origin; postcensal by required physician reporting,       0+'!0+'estimates based on 2000 active case-nding at Maines 


/)(0).*000  United States Census. The one independent pathology population data include the laboratory, and review of death 
   #0 #00
0 20
0!0"00)&&&000 $00 bridged singlerace estimates certicates with a mention of 0(00

0!0"0#0

0000" 03 0!0 0 !00 0!
3 0 000)&&&000 $0 
1%%$ $ $%

$0 cancer. Death registry information in Maine is very complete derived from the original multiplerace categories in the  



 
0 0+)&&,-00 .00
 0 and accessible. Maine also has data exchange agreements with 2000 United States Census. all bordering states and other states where Maine residents http://www.seer.cancer.gov/popdata. tend to vacation during the winter. The Maine Cancer Registry has a quality control program, and the resulting data meet the Multiple primary rules used IACR rules (2004) on CI5 IX period. highest standards for data quality.

Use of the data The registry prepares an annual report of cancer incidence and includes mortality from the states vital statistics ofce. Annual reports may USA, MAINE (1998-2002) also include information on USA, MAINE (1998-2002) trends and stage at diagnosis. Maine does not operate a follow-up registry, so survival studies are not produced. Data  






are used for program planning 




and evaluation. Maines 








database has also been used 




in special studies of bladder 


 





cancer, cervical cancer, colon 




cancer treatment, and quality








of-life surveys. 




171

North America

USA, Massachusetts
Registration area The Massachusetts Cancer Registry (MCR) covers the population of the Commonwealth of Massachusetts. The population at the most recent US Census (2000) was 6 349 097. The population is represented as follows: 84% White non-Hispanic; 5% Black non-Hispanic; 7% Hispanic; 4% Asian non-Hispanic; .02% Native American non-Hispanic. ofces when this information is available. Not all hospitals report this type of case, however, and some hospitals report such cases as if the patients had been diagnosed and treated by the hospital directly. Collecting this type of data makes the MCRs overall case ascertainment more complete. The cancer types most often reported to the MCR in this manner are prostate cancer and melanoma. In addition, the MCR identies previously unreported cancer cases through death certicate clearance to further Cancer care facilities The MCR collects reports of newly diagnosed cancer cases improve case completeness. When possible, the MCR obtains from multiple sources. In 2003, 70 Massachusetts acute care additional information on these cases through follow-up hospitals, 3 medical practice associations, 5 laboratories, activities with hospitals, nursing homes and physicians 1 radiation/oncology facility, dermatologists and urologists ofces. Otherwise, a cancer-related cause of death recorded on a Massachusetts death reported to the MCR. certicate is the only source of information for a cancer Registry structure and USA, MASSACHUSETTS (1998-2002) case. As a result, these cancer methods USA, MASSACHUSETTS (1998-2002) cases identied through The MCR is located within the death certicates are poorly Center for Health Information, documented and have not Statistics, Research and been conrmed by review of Evaluation (CHISRE), 


 



 





complete clinical information. Massachusetts Department 





 

These cases, however, of Public Health (DPH). 

 












comprise less than 3% of all The MCR is 75% funded by 







cancer cases in this report. the US Centers for Disease 












 

Control and Preventions There are organised screening 





 

National Program of Cancer programs at the state level for 














Registries (NPCR), and 25% breast, cervical and prostate 







by the Commonwealth of cancer. According to data from 





 


 





Massachusetts. The Registrys the behavioural risk factor 





 

staff include a director, survey (BRFS), a questionnaire 














assistant director of registry administered randomly to the 




 


operations, an administrative state, 57.9% of men over 50 had assistant, 9 operations staff a prostate specic antigen PSA in       (quality assurance and data the past year. Additionally, 65.4% 0+'!0+'acquisition), 3 epidemiology 
 


of men over 50 had a digital rectal *0&/*0(((000  staff, and 3 geographic exam (DRE). 
   #0 #00
0 20
0!0"00)&&&000 $00 information systems/special 0(00

0!0"0#0

0000" 03 0!0 0 !00 0!
3 0 000)&&&000 $0 
1%%$ $ $%

$0 project staff. Use of the data  



 
0 0+)&&,-00 .00
 0 The MCR follows all CDC/NPCR program requirements The MCR produces two annual reports: Cancer Incidence for data collection and reporting. We are certied by the and Mortality in Massachusetts (providing information on North American Association for Central Cancer Registries cancer incidence and mortality for the state as a whole), (NAACCR) and have received their gold standard for and Cancer Incidence in Massachusetts: City and Town completeness, quality and timeliness for the past several Supplement (providing information on cancer incidence years. for Massachusetts 351 cities and towns). We also produce special reports on a periodic basis, such as Data Report on Interpreting the results In Situ Breast Cancer in Massachusetts, Data Report on As noted above, the MCR collects reports of newly diagnosed Colorectal Cancer in Massachusetts, Childhood Cancer cancer cases from multiple sources, including acute care in Massachusetts, 19901999, Cancer in Massachusetts hospitals, medical practice associations, laboratories, Women, 19891998: Data Report, and Selected Cancers in radiation/oncology facilities, dermatologists and urologists Massachusetts Men, 19821996. reported to the MCR. Reports from dermatologists ofces Data are available to the public via MassCHIP, and dermatopathology laboratories, particularly on cases the MDPHs online information service that provides of melanoma, have only been collected by the MCR since community-level data (http://masschip.state.ma.us), and at 2001. Reports from urologists ofces have only been Massachusetts Cancer Information Online, a website that collected by the MCR since 2002. Currently, the MCR allows users to access a variety of local, state and national collects information on in situ and invasive cancers and cancer information in three waysby age, by geography and benign tumors of the brain and associated tissues. The MCR by type of cancer (http://www.mass.gov/dph/cancer). MCR does not collect information on basal and squamous cell reports are also posted on the program website (http://www. carcinomas of the skin. mass.gov/dph/bhsre/mcr). The MCR also collects information from reporting The MCR receives approximately 1015 requests for hospitals on cases diagnosed and treated in staff physician data each month. Data are used by other DPH programs for

172

North America

program planning and evaluation, and by external researchers for epidemiologic studies. MCR staff provide support and consultation to other DPH programs and outside agencies. Source of population July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United

States Census. The population data include the bridged singlerace estimates derived from the original multiplerace categories in the 2000 United States Census. http://www.seer.cancer.gov/popdata. Multiple primary rules used IACR rules (2004) on CI5 IX period.

173

North America

USA, Michigan
Registration area This Registry covers the State of Michigan within the United States of America. The state of Michigan is approximately 82% white, 12% black, 4% Asian and 2% Native American. The state is roughly 3% Hispanic. Cancer care facilities Diagnostic and treatment services for cancer are widely available throughout the state. Radiotherapy services are widespread and generally readily available in population centres, with some access issues in rural areas. pathology laboratories, clinics, physicians and dentists. Resident case exchange agreements are in place with 19 other states. The registry is located within the vital records ofce with ready access to death information. Reporting is required USA, MICHIGAN (1998-2002) by law. Case information is USA, MICHIGAN (1998-2002) condential and protected by law. Improper use or release of the information is a crime. R e g i s t r y q u a l i t y,  
 





completeness, accuracy and 




timeliness a re mon itored 








t h roug h ongoi ng rout i ne 




auditing of reporting facilities, 








with independent assessments 




of quality conducted annually 





 


by NAACCR and by CDC. 





























 





 

Registry structure and 



methods 













Interpreting the results The registry is located within 








 





Breast and cervical cancer the Department of Community 







screening programs for Health for the State of 







the uninsured are in place Michigan. It is staffed using 12       throughout the state. Screening full time equivalent positions. 0+'!0+'prevalence for breast and The registry is funded in part 



,02120/*/000  cervical cancer is reasonably by the US Centers for Disease high by US standards, and Control and Preventions 
   #0 #00
0 40
0!0"00)&&&000 $00 PSA testing is common in the National Program of Cancer 0(00

0!0"0#0

0000" 05 0!0 0 !00 0!
5 0 000)&&&000 $0 
3%%$ $ $%

$0 population. Registries (NPCR).  



 
0 0+)&&,-00 .00
 0 Data collection is passive, with routine auditing of Use of the data reporting by health facilities using CTRs. Eighty-five percent of case reports are submitted Registry data are used for reporting incidence, extent of electronically. Reports are received largely from hospitals disease, and survival. Data are also used in research, and for and regional cancer registries. Reporting is supplemented by planning and evaluation of heath services.

USA, MICHIGAN: BLACK (1998-2002) USA, MICHIGAN: BLACK (1998-2002)

USA, MICHIGAN: WHITE (1998-2002) USA, MICHIGAN: WHITE (1998-2002)























































 

































































































 



 


 











 

 




































 




































 0+'-

 !0+'-





 .*',

 !.*',



/2*02*1000






+.&-(.&&/...







Source of population  




 July 1 county population estimates by age, sex, race, and 
0 0+)&&,-00 .00
 0 Hispanic origin; postcensal estimates based on 2000 United States Census. The population data include the bridged singlerace estimates derived from the original multiplerace

   0(00

0!0"0#0 #0 #00
0 40
0!0"00)&&&000 $00

0000" 05 0!0 0 !00 0!
5 0 000)&&&000 $0 
3%%$ $ $%

$0

categories in the 2000 United States Census. http://www.  




 seer.cancer.gov/popdata. 
. .*)&&+,.. -..
 .

   .(..

.!.".#. #. #..
. 1.
.!."..)&&&... $..

...." .2 .!. . !.. .!
2 . ...)&&&... $. 
0%%$ $ $%

$.

Multiple primary rules used IACR rules (2004) on CI5 IX period.

174

North America

USA, Michigan, Detroit

We have a staff of 35 in abstracting, 14 in editing, 5 in followRegistration area The Metropolitan Detroit Cancer Surveillance System (MDCSS) up and 4 in IT who handle case nding, abstracting, editing, covers three adjacent counties in southeastern Michigan in the follow-up and computer issues. In addition, there are over 40 United States (US) of America. Metropolitan Detroit is between individuals working in research. The MDCSS provides both incidence and survival longitudes 82 and 83 W and latitudes 42 and 43 N. These three counties, Wayne, Oakland and Macomb, comprise 42% of the reporting for the Metropolitan Detroit area. Data are overall population of the state of Michigan. The total population of collected by the MDCSS abstracting staff from area hospitals, the Metropolitan Detroit area, according to the 2000 US Census was private pathology laboratories, radiation therapy facilities 4 043 467. Of this total, 2 784 071 (68.8%) persons were Caucasian and selected clinics and physician ofces. These facilities and 1 011 038 (25.0%) persons were African American. Of the total include those located within Metropolitan Detroit, as well population, 118 641 (2.9%) persons were of Hispanic origin. The as facilities outside the area, which routinely provide care City of Detroit is the major urban centre of this area. In the City for cancer patients who reside in the MDCSS registration of Detroit, 12.3% of the population was Caucasian and 81.6% was area. Both passive and active follow-up are maintained for all cases. Re-admissions to African-American, with 5.0% hospitals are also abstracted of the total being of Hispanic for follow-up data. Death descent. The Metropolitan USA, MICHIGAN, DETROIT (1998-2002) certicates for the State of Detroit area is culturally diverse, USA, MICHIGAN, DETROIT (1998-2002) Michigan, and for other states with representation from Arabic, that are primary retirement Polish, Greek, Italian, German, areas for local residents, are English, Irish and Scottish linked by computer tape each ancestry. The area is heavily $+-"0(--/*, ($-"&"--%*-/0(--/" (+-&/0--quarter to provide up-to-date industrialised, being the centre (&-(0(--.* +*-$&*--information on new deaths of the United States automobile *&-+.0--." .%-$*+--*+-&%+--+* .$-&(*--and causes of death. manufacturing industry. The total +0-&"0--+" ./-(%.--registration area is 5094 km2. The completeness and 0*-(&"--** $"$-0/(--$%+-($&--*" $&(-($"--accuracy of our data are $(.-$"%--(* $*(-.&%--Cancer care facilities evaluated both by the SEER $+&-/%*--(" $.$-"*&--$+%-%(%--&* $+*-/*%--The MDCSS began in 1949 program and internally on a $*&-*0%--&" $*.-$+(--as a pathology registry for 25 routine basis. The Metropolitan $&.-%/$--%* $(%-./"--$$.-*/&--%" $$0-"$(--collaborating hospitals. In 1960, Detroit Cancer Surveillance $&*-+"(--$* $%/-%&*--System routinely scores in the the MDCSS became a central $*(-//&--$" $(/-$/&--$*/-0(.--* $*$-(&0--top 5 of all SEER registries statistical resource for these $((-%"/--" $&.-(0+--25 hospitals, providing reports nationally. comparing the experience of $" * " " * $" -'#) -'#) each hospital with the entire Interpreting the results %-"/+-/%(--$-0+$-0"(-- Besides the metropolitan Detroit group of collaborating hospitals. area being highly industrialised, In 1969 the MDCSS became the 
   the area is also home to a plant designated arm of the Michigan -$--

--- ----
- 1-
----%"""--- ! 



 
--'%""()-- *--
Department of Community Health (MDCH) for collection of that was involved in the processing of vermiculite contaminated cancer information in the Metropolitan Detroit area. In this same with asbestos. year, the MDCSS was organised in its current form to participate in the Third National Cancer Survey for the years 19691971. In Use of the data 1973 the MDCSS became one of the founding participants in the From 1973 through 1978, the MDCSS and the Metropolitan National Cancer Institutes (NCI) Surveillance, Epidemiology Detroit SEER Program were essentially data collection operations, with minimal reporting of descriptive data. and End Results (SEER) Program. Development of a research program in cancer epidemiology began in 1979. Cancer epidemiology evolved into a major Registry structure and methods In 1976, the MCF became a member of the NCI-funded research program with a current focus on racial disparities in Comprehensive Cancer Center in Detroit along with Wayne State risk and survival. The Metropolitan Detroit SEER data are University (WSU) and the Detroit Medical Center. In 1995, all utilised extensively for descriptive and analytic epidemiology. programs of the Comprehensive Cancer Center were consolidated The data are also utilised by local health departments, under the name of the Barbara Ann Karmanos Cancer Institute the Michigan Department of Community Health and area (KCI). The Director of KCI reports to the Dean of the WSU health professionals for planning, evaluation and educational School of Medicine and the Comprehensive Cancer Centers purposes. Community concerns regarding cancer risk are also addressed through use of MDCSS data. Programs are administered by the School of Medicine.

175

North America

USA, MICHIGAN, DETROIT: BLACK (1998-2002)

USA, MICHIGAN, DETROIT: BLACK (1998-2002)

USA, MICHIGAN, DETROIT: WHITE (1998-2002)

USA, MICHIGAN, DETROIT: WHITE (1998-2002)

%-0$$--(-&..--.-0$0--0-/&%--$$-&/0--$&-%+.--$/-.$0--%+-**0--&$-%+%--&(-(0*--&&-("(--&(-+0+--&*-"."--&%-/**--&/-((+--(/-(%*--*%-"*%--(%-0((---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

.-"$+--.-.+$--$%-"&&--$(-(($--$+-".&--$.-*$.--%%-/0&--&%-//%--&0-("$--(%-/%"--($-0"%--(&-"//--(&-&%/--&.-%&/--&/-&+*--(.-$/0--*"-.%$--($-.&$---

$&-"$(--%$-%++--&*-"*.--(&-$$(--(&-/$&--*(-$%"--.(-"0"--0+-&*"--$$$-.*.--$%(-%"&--$%%-($&--$$$-0($--0*-(%.--/"-+/&--0%-.$.--$"$-&$.--$"$-(($--0*-%+(---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

&&-.%$--&/-$0/--*%-&*"--*+-+.$--*&-0+0--*0-"&&--.+-("$--0.-+%%--$$$-""%--$%&-&(/--$$.-0**--$".-""0--0%-&*%--..-&("--/*-+0+--0+-"0&--0*-*+.--0"-$/&---

$"

* -'#)

"

"

* -'#)

$"

$"

* -'#)

"

"

* -'#)

$"

(./-+%$---



**+-&0/---

$-($.-0/*---



$-(+(-*"0---


   -$--

--- ----
- 1-
----%"""--- !-


   -$--

--- ----
- 1-
----%"""--- !
--'%""()-- *--
Multiple primary rules used  





Source of population
 



 
--'%""()-- *--
-

July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census.

IACR rules (2004) on CI5 IX period.

176

North America

USA, Missouri
Registration area The Missouri Cancer Registry (MCR) covers the population of the state of Missouri, located in the middle of the United States and having as its eastern border the Mississippi River. The majority of Missouris 5.5 million people live in two major metropolitan areas (Kansas City and St. Louis) and ve minor metropolitan areas. The remainder of the state consists of small towns and rural areas. melanoma skin cancer by physician ofces. Another source is death certicates. Death information for Missouri residents who died in Missouri is available both in an electronic le and as a paper record through a Memorandum of Understanding with DHSSs vital records unit. Death information for Missouri residents that die elsewhere is available from some but not all states. MCR staff conduct death clearance and follow-back on in-state cancer deaths not matched in the registry database; the number of new cases identied only through death certicates is <3% for data from 19982003. Cancer care facilities Over 85% of annual cancer incidence cases are reported by MCR staff process over 45 000 records annually. After case hospitals, of which there are 126 in Missouri, including four consolidation, this yields approximately 28 000 Missouri Veterans Affairs (VA) hospitals and two military hospitals. incident cases. Quality control is an Most of the remaining cases ongoing process at MCR. All are reported by long-term care records receive an initial review facilities, ambulatory surgery USA, MISSOURI (1998-2002) and an additional in-depth centres, freestanding cancer USA, MISSOURI (1998-2002) review. Before each call for clinics and treatment centres, data, all cases are run against pathology laboratories and GenEdits and Interrecord physician ofces/groups Edits and corrections made that diagnose or treat cancer 


 









prior to submission. Quality or through case-sharing 







control is also part of each agreements with 18 other 














data request. Prior to nalising states. The states of Kansas, 







the data request, the data are Illinois and Texas contribute 




 








reviewed for accuracy. In the largest number of data  

 





addition, reports are produced exchange cases. 














whenever necessary to look at  




 


possible errors that have been Registry structure and 














identied through the review methods 







process. MCR is a joint endeavour of the 











 


University of Missouri and the 







Interpreting the results Missouri Department of Health MCR data meet NPCR and Senior Services (DHSS).       standards and North American It is located on the campus of /+'!/+'



)/0))/10*///  Association of Central Cancer the University of MissouriRegistry (NAACCR) criteria Columbia and is housed 
   #/ #//
/ 3/
/!/"//)&&&/// $// for timeliness completeness in the School of Medicine, /(//

/!/"/#/

////" /4 /!/ / !// /!
4 / ///)&&&/// $/ 
2%%$ $ $%

$/ Department of Health Management and Informatics (HMI). and quality. While MCR data are more than 95% complete  



 
/ /+)&&,-// .//
 / The primary funding source for operating the registry is the (i.e., >95% of expected cases are available within 24 months US Centers for Disease Control and Preventions National of the close of a diagnosis year), some sites are less complete. Program of Cancer Registries (NPCR) through a contract Less than 60% of expected melanoma skin cancer cases were between the University and DHSS. The registrys operations reported annually through 2003. In 2004, MCR initiated director is also a member of the HMI faculty. Registry staff reporting of melanoma skin cancers by physicians; this has include 9.25 Certied Tumor Registrars (CTRs), 3 health resulted in increased reporting of these cases. Prostate cancer program specialists or assistants, 2.25 technical staff (data cases were also underreported. In 2005, Missouri became base manager and IT support), a half-time statistician, 1 one of eight states funded by CDC-NPCR to pilot web-based support staff and 2 part-time graduate research assistants. reporting of prostate cancers by physicians. We hope to see The registry also receives support from four DHSS staff an increase in reporting of these cases in 2006. members who are partly funded by CDC-NPCR. Data collection from hospitals is 8085% automated. Use of the data Approximately 5% of the cases are received as copies of Missouri incidence data are used for program planning medical records, which are then abstracted by MCR staff. and evaluation, epidemiological studies, cancer cluster Another 5% are submitted by non-hospital facilities (surgery investigations, annual reports and a variety of other purposes. centres, radiation centres, physician ofces and nursing Missouri incidence data are available online at http://www. homes); most of these cases are submitted on paper but dhss.mo.gov/cancerMICA/ by site, race, age group and MCR is piloting web-based reporting of prostate cancer and geographic unit.

177

North America

USA, MISSOURI: BLACK (1998-2002)

USA, MISSOURI: BLACK (1998-2002)

USA, MISSOURI: WHITE (1998-2002)

USA, MISSOURI: WHITE (1998-2002)
































 






















 






































 








 





 






































 




 












 













 











































 















 








 



 /+'-

 !/+'-





 0+'-

 !0+'-



*&./.0*///






)0*/10)2)000








   /(//

/!/"/#/ #/ #//
/ 2/
/!/"//)&&&/// $//

////" /3 /!/ / !// /!
3 / ///)&&&/// $/ 
1%%$ $ $%

$/


   0(00

0!0"0#0 #0 #00
0 40
0!0"00)&&&000 $00

0000" 05 0!0 0 !00 0!
5 0 000)&&&000 $0 
3%%$ $ $%

$0

Source of population July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. The population data include the bridged singlerace estimates derived from the original multiplerace

 



 
/ /+)&&,-// .//
 /

categories in the 2000 United States Census. http://www. seer.cancer.gov/popdata. Multiple primary rules used IACR rules (2004) on CI5 IX period.

 



 
0 0+)&&,-00 .00
 0

178

North America

USA, Montana
Registration area The Montana Central Tumor Registry (MCTR) is a population-based registry covering the entire State of Montana. The MCTR was started in 1979 by the Montana Tumor Registry Act. About 60% of the state is actually prairie in the Great Plains. Montana is primarily rural. The state ranks fourth among US states in size but has a relatively low population and consequently a very low population density. The race of Montanans is about 92% Caucasian and 6% American Indian. laboratories. MCTR has access to all death certicates from the Ofce of Vital Statistics on a quarterly basis. Quality control procedures are being developed. Presently, the MCTR undergoes a casending, data quality, and timeliness audit by the CDC once every 5 years. Interpreting the results The population in Montana is growing and grew almost 10% in 2005. Prior to that, the population increased about 3% since the year 2000. Diagnostic and treatment facilities for cancer patients are increasing, and several cancer treatment facilities are seeking ACoS approval. Montana has breast and cervical cancer screening and a health assistance programme, and PSA testing is common in the population. Use of the data The MCTR publishes an annual report that presents topics on incidence rates, mortality rates, incidence by sites, stage at diagnosis, rates by counties, risk and associated factors, age-specic incidence rates, and ten-year trends. Data are used for individual requests for information and are used for cancer cluster investigations. The registry is not currently involved in epidemiological research beyond the production of routine statistics, but the Montana Comprehensive Cancer Program routinely uses our cancer registry data.

Cancer care facilities Montana has 4 American College of Surgeons cancer approved programmes; Benes Healthcare in Great Falls, St. Patrick Hospital in USA, MONTANA (1998-2002) Missoula, St. Peters Hospital USA, MONTANA (1998-2002) in Helena, and Billings Clinic in Billings. Other cancerrelated facilities include: St. Vincents Hospital in 


 



Billings, Bozeman Deaconess 




Hospital in Bozeman, St. 








James Community Hospital in 




Butte, and Kalispell Regional 








Hospital in Kalispell. 



























 



















Registry structure and 







methods 




 








The MCTR is housed in the 







Montana State Department 














of Public Health and Human 







Services, Division of Public Health and Safety, Bureau of       .*', !.*', Chronic Disease Prevention 


++0.)/+...  and Health Promotion, Cancer Control Section. Financial 
   #. #..
. 2.
.!."..)&&&... $.. Source of population support includes about 20% of .(..

.!.".#.

...." .3 .!. . !.. .!
3 . ...)&&&... $. 
1%%$ $ $%

$. the budget covered by State funds and about 80% of the budget July 1 county population estimates by age, sex, race, and  



 
. .*)&&+,.. -..
 . covered by Federal support through the US Centers for Disease Hispanic origin; postcensal estimates based on 2000 United Control and Preventions National Program of Cancer Registries States Census. The (NPCR). MCTR staff include: 1 Cancer Epidemiologist, 1 population data include the bridged singlerace estimates Program Manager, 1 Administrative Support/Follow-up, and derived from the original multiplerace categories in the 2 Quality Assurance Technicians. Data collection is passive, 2000 United States Census. with each facility responsible for abstracting and reporting http://www.seer.cancer.gov/popdata. its own cancer cases. MCTR staff do not abstract for any facility. The principal sources of information on cancer cases Multiple primary rules used are hospitals, radiation centres and independent pathology IACR rules (2004) on CI5 IX period.

179

North America

USA, New Jersey

Registration area New Jersey is located on the east coast of the United States, bordered by the states of New York, Pennsylvania, and Delaware. In 2000, the population of the state of New Jersey comprised over 8.4 million inhabitants. Of these, 13.6% were African American, 13.3% were Hispanic and 5.7% were Asian. The median household income, according to the 2000 census, was US$55 146 (in 1999 dollars). Of the population over 16 years of age, 64.2% are in the labour force. psychiatric facilities and rehabilitation facilities. Physicians and dentists are required to report non-hospitalised cases. Matching of the registry database with the Departments AIDS registry and the Breast and Cervical Cancer Early Detection Program have resulted in the identication of cases. Quarterly record linkages are performed between the registry database and the state death le. A built-in death certicate match system links and updates cancer registry records with death information. Linkages are also performed with individual state tax return les, hospital discharge les, motor vehicle drivers license files, the federal Centers for Medicare and Medicaid Services, Social Security Administration, and National Death Index to obtain follow-up information. Interpreting the results New Jersey has Gold Certication Status from NAACCR. The data quality assurance programme is a continuous multi-faceted programme of checks and balances, performed by highly skilled CTRs with years of quality control experience. Other components include consistent application of computerised edits, systematic review of problem cases, re-abstracting and re-coding studies centred in hospitals, feedback and training programmes for hospital staff, documentation of policies and procedures, and case-nding audits. Denite and possible duplicates are electronically generated and resolved by staff. Computerised programs are used to identify multiple

Cancer care facilities A total of 76 in-state hospitals report to the registry on a monthly basis via e-mail to a secure, encrypted e-mail server. The proximity of New Jersey to prestigious cancer centres in neighbouring states USA, NEW JERSEY (1998-2002) attracts many residents to seek USA, NEW JERSEY (1998-2002) diagnosis and treatment outside the state. Over 10 000 case reports are received annually from out-of-state sources $.+)#.+++ -(* (.+-&,+++ -  through reciprocal reporting .(+$-(+++ ,( agreements with other states. "# +&-)+++ , 
"$#+ &#+++ )(

.-+&-,+++ " (+$&$+++ "&$+$,$+++ "(-+.$,+++ "(.+,,.+++

"(,+-()+++ )  ",)+,-$+++ Registry structure and # (+), +++ (( ##&+"#(+++ #)$+)$#+++ (  #-&+ -(+++ methods $ "+&,#+++ &( $")+)- +++ Cancer Epidemiology $&.+$&-+++ &  $) +"(#+++ $(.+"#(+++ $( $))+, ,+++ Services (CES) is located in $#"+##-+++ $  $#)+($ +++ the Division of Epidemiology, #),+-.)+++ #( #))+ ,-+++ #&(+. +++ #  #$(+#) +++ Environmental and #,)+&-&+++ "( #) + .-+++ Occupational Health Services. $ #+)")+++ "  #-,+.#-+++ $ ,+&. +++ ( #.$+"&$+++ CES is nanced by both state #-,+),$+++  #,(+()"+++ and federal sources, including the US Centers for Disease " ( ( " Control and Preventions +%!' +%!' &+$$.+ &.+++ &+ .$+,,.+++  National Program of Cancer Registries (NPCR). There are 
   42 full-time equivalent staff # + +++++

 ++++ +++ +  



 working in the unit on cancer registry cancer surveillance primary cancers for review. 
+ +%# and &'++ (++
 + activities. Certied Tumor Registrars (CTRs) are employed in all aspects of the registry operations including data collection, Use of the data The Cancer Surveillance Program, staffed by epidemiologists quality assurance, reporting and analysis. The majority of cases are reported by hospitals throughout and a statistician, monitors cancer incidence trends, the state. Abstracting, coding and data entry are conducted at disseminates data, and responds to citizens concerns about the hospital level by CTRs directly from source records and cancer. The staff have published a variety of registry reports, reported electronically to the central ofce. All health care including a report on trends in cancer incidence and mortality, facilities are required by law to report cancer cases electronically cancer survival, cancer prevalence, an in-depth analysis of within three months of discharge or six months of diagnosis prostate cancer, breast cancer, colon and rectum cancer, and or face a penalty. Hospitals are required to report all cases of childhood cancer. The data are employed in a wide range of activities including cancer, regardless of in- or out-patient status. Reporting from non-hospital facilities accounts for a small but growing number applications in cancer control and prevention, aetiological of cases. The majority of non-hospitalised cases are reported by studies, policymaking, and epidemiological research. Registry 16 independent pathology laboratories. Other sources include data were also used to dene baseline measures for the general 117 surgery centres and 9 free-standing radiation treatment and special populations in the state to establish public health centres. Reports are also received from nursing homes, objectives for the next decade.

180

North America

USA, NEW JERSEY: BLACK (1998-2002)

USA, NEW JERSEY: BLACK (1998-2002)

USA, NEW JERSEY: WHITE (1998-2002)

USA, NEW JERSEY: WHITE (1998-2002)

#+&-#+++ $+).&+++ ,+ ("+++ " +($"+++ "&+# .+++ "-+) (+++ #$+ $&+++ #.+("$+++ $(+)& +++ &&+)-"+++ ( +$--+++ &-+#.$+++ &$+&&"+++ &&+&,"+++ ( + ))+++ (&+, $+++ ()+#) +++ ("+)("+++

-(* -  ,( ,  )( )  (( (  &( &  $( $  #( #  "( "  ( 

,+ $$+++ ,+&-$+++ ""+-" +++ "(+#-"+++ ".+&),+++ #&+",-+++ #.+$))+++ $,+(#"+++ &$+##"+++ ("+&(.+++ ()+,,.+++ (&+# &+++ &,+"&$+++ &(+$,$+++ &-+,$(+++ (#+.-&+++ (&+ $.+++ &.+,- +++

$)+&&"+++ (&+..(+++ -)+"$ +++ " )+(#(+++ ""#+$.#+++ "$ +()(+++ ", +.-,+++ #",+-))+++ #&(+.)$+++ #- +& $+++ #-#+ --+++ #&)+)",+++ "..+)-$+++ "-$+$,(+++ # ,+, +++

-(* -  ,( ,  )( )  (( (  &( &  $( $  #( #  "( "  ( 

. +##$+++ .)+ ) +++ "#-+$,)+++ "$-+.$ +++ "$$+.$.+++ "&&+ &&+++ "-#+."&+++ ##.+)$#+++ #(#+)-#+++ #-$+&$-+++ #-#+--#+++ #&$+,$$+++ ".$+#$.+++ ","+-(-+++ ".$+-#"+++ #")+#$-+++ #"-+-#.+++ # &+,$.+++

##,+-,.+++ ##.+.,#+++ #"&+& $+++

"

( +%!'

( +%!' 

"

"

( +%!'

( +%!' 

"

(--+,"$+++

)((+-((+++

$+#$$+.-&+++

$+& (+(,)+++


   # + +++++

 ++++ +++ +  



 
+ +%# &'++ (++
 +


   # + +++++

 ++++ +++ +  



 
+ +%# &'++ (++
 +

Source of population 2000 Census of the United States, prepared by the US Bureau of the Census.

Multiple primary rules used IACR rules (2004) on CI5 IX period.

181

North America

USA, New Mexico

cases are registered from hospital admission and outpatient Registration area With an area of 314 926 km2, New Mexico is the fth largest records. Other methods of casending are used to obtain state in the USA. Located in the southwest of the country information on cancer cases not seen in reporting hospitals. (latitude 30 to 37 N), it has extensive high desert and Radiation therapy records and death certicates are reviewed mountain terrain, the altitude ranging from 859 to 4010m regularly. Medical chart data are entered directly onto diskettes above sea level. Rainfall and humidity are low. Its population is about 1.9 million, of whom approximately using a software package assembled locally, allowing one third live in the Albuquerque metropolitan area; the collection of supplemental data items of special interest remainder live in small cities or in villages. The population to individual hospitals and physicians. It also allows each come from diverse ethnic backgrounds: 42% have Spanish hospital to analyse its own 30+ year complete dataset and and/or Mexican-American heritage (Hispanics); 9.5% are to compare it with a statewide analytical dataset. Data from American Indians (Navajo, Pueblo, Apache); 1.9% are Black; the abstractors diskettes are edited, linked and merged into about 1% are Asian; the remaining 45% are non-Hispanic white the master le. Abstracted cases are of European descent. A sizeable reviewed for thoroughness subgroup of New Mexicos and accuracy. The le is Hispanic population traces its USA, NEW MEXICO (1998-2002) ordered by the computerancestry to Spanish soldiers and USA, NEW MEXICO (1998-2002) generated accession numbers, colonists who settled in New but can be sorted by any item Mexico during the 17th and of data. Numerous routine 18th centuries. Median levels of crosschecks are made to education and per capita income .-.+%--/*, $*-.%/--$$-(0(--/" $+-+*%--eliminate duplicate cases. are in the lowest decile of the $/-.+(--.* %(-%"(--50 states. %*-&"(--." %0-/&%--&"-"*+--+* &%-/+"--Interpreting the results &(-+%(--+" &.-0""--Cancer surveillance in Cancer care facilities (%-+0"--** (*-0"(--*+-($&--*" */-0$(--New Mexico is conducted An overwhelming majority +&-..0--(* +.-&0/--according to prevailing of cancer patients in New +0-*+"--(" .%-$"(--+/-%(%--&* +0-+%$--standards promulgated by Mexico are diagnosed and *0-+00--&" +"-"($--the SEER Program and the treated at one or more of *+-0"/--%* *+-.."--+&-$/%--%" +$-&&*--North American Association seven medical facilities that .*-&%.--$* .$-(*0--of Central Cancer Registries support cancer programmes .(-/.*--$" .$-//+--."-/.+--* +/-*$0--(NAACCR). As such, the data accredited by the American ++-+%0--" +(-.0*--have been subject to the same College of Surgeons. Cancerchanges in denitions and related care is also provided by $" * " " * $" -'#) -'#) coding as other registries that several private oncology and 0%*-0%*--/0+-$/&-- abide by SEER and NAACCR radiation-oncology practices standards. The Registrys afliated with the latter 
   geographic area of coverage medical facilities. Some New -$--

--- ----
- 1-
----%"""--- ! 



 
--'%""()-- *--
Mexico residents receive cancer-related care in neighbouring has remained constant since it initiated statewide coverage states; the registry has longstanding agreements with central in 1969. Because incidence rates vary by cancer primary site cancer registries in all bordering states to routinely receive among the States three largest racial/ethnic groups, New reports on diagnosis or treatment of New Mexico residents. Mexico data must not be considered in aggregate, that is, without stratication by race/ethnicity. Descriptive Registry structure and methods Cancer reporting has been required (but not enforced) epidemiological analyses have shown that Hispanics and by a State Health Agency regulation since 1922. The American Indians have lower rates than the non-Hispanic New Mexico Tumor Registry, located at the University white population for skin, breast, endometrium, lung and of New Mexico Cancer Research and Treatment Center colorectal cancers, and higher rates for stomach, uterine in Albuquerque, began operation in 1966 and became the cervix, kidney and gallbladder cancers. ofcial cancer data repository for the State Health Agency in 1975. Registry funding initially came from the New Mexico Use of the data Regional Medical Program and since 1973 primarily from Periodic reports are sent to participating hospitals and the National Cancer Institutes Surveillance, Epidemiology, individual physicians. The registry also handles over 100 special requests for cancer data annually. The registry has and End Results (SEER) Program. The registry abstracts and follows all cases of known been a casending source for a variety of population-based malignancy. Multiple primaries are counted separately by assigning casecontrol studies relating to cancer etiology. It has also sequence numbers within the records of individual patients. Patients been used to monitor patterns of cancer care and survival in relation to factors such as ethnicity, age and marital status. entered into the registry system are followed for life. The development of new techniques for investigating Some of the larger hospitals employ tumour registrars, and abstractors from the central registry travel to other molecular and cellular changes in preserved tissue specimens hospitals and clinics throughout the state to review and has created requests for the registry to help select cases that have abstract cancer patient records. The majority of the registrys documentation of different clinical courses and outcomes.

182

North America

USA, NEW MEXICO: AMERICAN INDIAN (1998-2002) USA, NEW MEXICO: AMERICAN INDIAN (1998-2002)

USA, NEW MEXICO: NON-HISPANIC WHITE (1998-2002)

USA, NEW MEXICO: NON-HISPANIC WHITE (1998-2002)

(&(--*"(--.0(--$-$0%--$-*.(--%-$"+--%-.*(--&-/%*--(-..&--*-0.&--+-+%&--+-%.+--+-(+0--.-("*--0-&0%--$"-&(&--0-0"*--/-../---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

.*(--.%$--$-"."--$-*&$--%-"."--%-."(--&-%./--(-&+%--*-*+%--+-.&&--.-$.$--+-+"0--+-."+--.-*/$--0-%*0--$"-$0.--0-0%&--/-+."---

*-"**--.-00*--$%-(0&--$+-%+%--$/-*0.--%"-+&(--%*-*$(--&%-(/.--&(-+"$--&(-*++--&"-%+&--%(-*.(--%$-.*%--%%-0(%--%.-/*$--%+-."*--%&-.(.--%$-"%0---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

$"-./0--$$-*%0--$+-%%+--$/-++$--$0-*++--%%-"&"--%.-"&$--&&-+$.--&+-*+(--&*-.&&--&$-"%0--%(-+%0--%$-+%"--%$-00%--%*-0"&--%*-"0/--%%-(".--%"-%/%---

$"

* -'#)

"

"

* -'#)

$"

$"

* -'#)

"

"

* -'#)

$"

/0-$$0---



0(-0"$---

(".-"+/---



(%(-."+---


   -$--

--- ----
- 1-
----%"""--- ! 



 
--'%""()-- *--
-


   -$--

--- ----
- 1-
----%"""--- ! 



 
--'%""()-- *--
-

USA, NEW MEXICO: HISPANIC WHITE (1998-2002)

USA, NEW MEXICO: HISPANIC WHITE (1998-2002)

Source of population July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. Multiple primary rules used IACR rules (2004) on CI5 IX period.

%-$(/--%-/%"--*-$(/--.-&+0--0-$&(--$$-"*&--$&-&""--$/-(/(--%%-%"*--%+-(..--%/-(.*--%+-%$(--%*-0%"--%0-+%&--&(-///--&(-.(+--&(-$+*--&&-+%/---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

&-0%&--(-$&.--+-(+*--/-0%(--$"-&/(--$%-%*.--$(-&+0--$0-$+.--%&-"&$--%.-"+$--%/-+((--%+-%"+--%*-.*%--%/-0+(--&&-(*%--&&-+*(--&&-"0*--&%-.0.---

$"

* -'#)

"

"

* -'#)

$"

&+*-.0/---



&.%-%/%---


   -$--

--- ----
- 1-
----%"""--- ! 



 
--'%""()-- *--
-

183

North America

USA, New York State

complete diagnostic information. To further assure complete Registration area The New York State Cancer Registry (NYSCR) contains reporting, cases diagnosed and/or treated in 16 other states reports on all malignant tumours (except basal cell and are identied through reciprocal reporting agreements. In order to provide detailed geographic information for squamous cell skin cancers), most in situ lesions, and certain benign tumours. The Registry, the second oldest state tumour cancer surveillance and cancer mapping, attempts are made registry in the United States, has had mandated cancer to geo-code the addresses of all cancer cases to the county, reporting since 1940, when the registration area covered the postal code and census block level. In order to evaluate the quality and completeness of entire state except New York City. Beginning in 1973, the reporting mandate was extended to include New York City. cancer reporting, the Registry conducts routine audits at hospitals throughout the state. Staff from the Field Services The Registry has been population-based since 1976. The population of New York State was 18 976 457 in the year Unit also compare the number of cases reported to the number 2000, according to the U.S. census; the estimated population of cancer-related hospital discharges for consistency. Results for 2004 is 19 227 088. In 2000, about 90% of the population are used to target the location and content of statewide educational and training lived in metropolitan areas; 62% programs. were Non-Hispanic Caucasians, 16% were African-Americans, USA, NEW YORK STATE (1998-2002) Interpreting the results 15% were Hispanics (of any USA, NEW YORK STATE (1998-2002) The registration area for the race), 0.4% were American Registry has been constant since Indians and 5.5% were Asians 1973. Although no new class of (including Pacic Islanders). sources of cancer case reports ..,'.),,, .)+ $$),)%/,,, #$*,$/!,,, .! $$',*-!,,, was added during 19982002, Cancer care facilities $!),/%),,, -) %!-,-)-,,, ambulatory surgery centres Residents of New York State $*$,%/!,,, -! %'.,#-!,,, $/*,''!,,, *) %*!,*#$,,, have been added as sources have access to more than 250 %)',!!',,, *! '#!,.#),,, more recently. acute-care hospitals, including ''),$$$,,, )) )!',''%,,, )-.,.'/,,, )! *%',/).,,, Changes in cancer screening 22 Community Hospital *)%,-)$,,, ') */*,!'),,, patterns have had a large impact Comprehensive Cancer Care -'!,!%$,,, '! --!,-**,,, -*-,)*$,,, %) -/#,/*-,,, on the number of cancer cases facilities located throughout -#.,##),,, %! -'!,-#.,,, diagnosed in New York State. the State and three National *'$,-#!,,, $) **',)!/,,, *%$,#*-,,, $! *$%,$$#,,, According to the Behavioral Cancer Institute-designated *)),)%%,,, #) *$!,''$,,, Risk Factor Surveillance System Comprehensive Cancer Centers. *-',/)-,,, #! *'$,*#),,, *-.,/'),,, ) *'/,!/*,,, telephone survey, the percentage In addition, many freestanding *%$,-#*,,, ! *!','##,,, of persons aged 50 years or older healthcare facilities and private who ever had colorectal cancer physicians diagnose and treat #! ) ! ! ) #! screening grew from 56.6% in cancer. There are 54 Ambulatory ,&"( ,&"( 1996 to 67.8% in 2002. By 1997 /,.$!,-)),,, /,#)',#!),,,  Surgery Centers and 12 Veterans (the most recent available data), Administration Hospitals that 
   , ,,,0, ,,, , ,

,,,,
0   

 , 74.6% of New York women aged also provide cancer services.  



 fty or older had had a mammogram and clinical breast exam 
, ,&$!!'(,, ,, within the previous two years; 77% of men aged fty or older Registry structure and methods The Registry is located within the New York State Department had ever had a prostate specic antigen (PSA) test. of Health (NYSDOH), and is funded partly by the NYSDOH and partly by the National Program of Cancer Registries. Use of the data The Registry has a director, eld staff, coding staff, quality The Registry prepares an extensive annual report of cancer assurance staff, research scientists, computer programmer incidence and mortality. The most frequently requested tables analysts, and geo-coding and secretarial support staff; 22 are produced in a printed volume, whereas the entire report is available on our Web site: http://www.health.state.ny.us. staff members are Certied Tumor Registrars. Within the New York State Department of Health, Law mandates cancer reporting with full personal identiers. The NYSCR uses passive notication of reports Registry data are used extensively for cancer surveillance and from more than 300 sources including hospitals, pathology for program planning. The Cancer Surveillance Program has and cytology laboratories, radiation treatment centres, access to the database for use in investigating possible cancer ambulatory surgery centres, and state vital records. Data are clusters and addressing community concerns. The Cancer received electronically in the NAACCR (North American Screening Research and Evaluation unit uses Registry data Association of Central Cancer Registries) format and are for programme evaluation, targeting and prioritisation. The mostly pre-coded. Many quality checks, including single Health Department provides cancer education and awareness eld range and validity edits as well as intereld edits, are programs and funds screening for breast, cervical and routinely applied to the data and much time and effort are colorectal cancer for under- or uninsured individuals. Cancer Registry data are routinely provided to other devoted to elimination of duplicate case reports. New York State law mandates reporting of mortality, organisations within the state for planning and evaluation of and death certicates are electronically matched against health services, grass-roots advocacy, and generating etiologic Registry les. Cancer deaths not previously reported to the hypotheses. In addition, the Registry is utilised by researchers Registry are followed back to hospitals and physicians for nationwide for a variety of epidemiological studies.

184

North America

USA, NEW YORK STATE: BLACK (1998-2002)

USA, NEW YORK STATE: BLACK (1998-2002)

USA, NEW YORK STATE: WHITE (1998-2002)

USA, NEW YORK STATE: WHITE (1998-2002)

*,'-),,, /,%%.,,, #-,-'-,,, $',-'#,,, %%,*##,,, '',%)),,, )',/.),,, -!,-'%,,, .',%%#,,, #!$,.--,,, ##$,)/#,,, #!',.%.,,, /),/*-,,, #!%,-*$,,, ##-,#%!,,, #$*,))/,,, #$/,#-!,,, ##',---,,,

.)+ .! -) -! *) *! )) )! ') '! %) %! $) $! #) #! ) !

#/,-)-,,, $#,!'/,,, %$,.)%,,, '#,!*/,,, '/,*)*,,, *$,/!*,,, -*,/)),,, /%,#'*,,, #!),'$%,,, #$',)%$,,, #%',*!%,,, #$),*%/,,, ##$,/.),,, ###,)*$,,, ##),%)/,,, #$%,$'*,,, #$),!#/,,, ##$,!'/,,,

-/,*)*,,, ##%,'%.,,, #.#,)*#,,, $$-,/%),,, $'.,''),,, $./,)%%,,, %*),'-$,,, '-#,.#),,, )$',.*.,,, ).%,/-),,, )//,/##,,, ))*,*/#,,, '/!,*-%,,, '-/,!)!,,, '/-,#)!,,, )!.,/*#,,, )!/,$%%,,, '--,'#%,,,

.)+ .! -) -! *) *! )) )! ') '! %) %! $) $! #) #! ) !

$!#,)/%,,, #/.,)/-,,, $**,''),,, $/',./),,, $/),!!.,,, %$-,!'%,,, '!#,%'%,,, )!%,/$/,,, )'*,###,,, )/),#!$,,, *!#,$/#,,, ))),-!),,, '/#,'%$,,, '*#,.#*,,, '**,%!*,,, '.$,-%%,,, '.),*)$,,, ')%,#'-,,,

#!

) ,&"(

) ,&"(

#!

#!

) ,&"(

) ,&"(

#!

#,%)%,//-,,,



#,).-,.!.,,,

-,$!),--/,,,



-,*$.,#'-,,,


   , ,,,0, ,,, , ,

,,,,
0   

 ,


   , ,,,0, ,,, , ,

,,,,
0   

 ,

Source of population Modied Census and census estimates: NCI modication of U.S.Census Bureau population estimates. See http://seer.cancer. gov/popdata/
 



 
, ,&$!!'(,, ,,

Multiple primary rules used

 



 
, ,&$!!'(,, ,,

IACR rules (2004) on historical data.

185

North America

USA, National Program of Cancer Registries (NPCR)

Registry structure and methods Registration area The United States Centers for Disease Control and Prevention Participating cancer registries transmit data to CDC using a (CDC) provides nancial and technical support to Public standardised record layout and coding system documented by Health Departments (or their designees) for the operation the North American Association of Central Cancer Registries. and maintenance of population-based cancer registries The data les are updated annually beginning with the diagnosis in 45 states, the District of Columbia and 3 US territories year for which the cancer registry rst received federal support (Palau, Puerto Rico, and Virgin Islands): 27 to collect data (e.g. 1995 or later). Reportable cases include all malignant and for cases diagnosed beginning in 1995; 13 to collect data in situ neoplasm as dened in ICD-0, excepting most nonfor cases diagnosed beginning in 1996; 4 to collect data for melanoma skin cancers and in situ cervical cancer. Neither cases diagnosed beginning in 1997; and the remaining 5 to the patients name nor the name of the reporting facility is collect data for cases diagnosed either beginning in 1999 provided to CDC. Upon arrival at CDC, the data undergo evaluation prior to publication or 2000. The remaining 5 and use. statesConnecticut, Hawaii, Data included in this Iowa, New Mexico, and USA, NPCR (1998-2002) report are from statewide Utahreceive federal support USA, NPCR (1998-2002) or metropolitan area cancer from the National Cancer registries that have high quality Institutes (NCI) Surveillance cancer incidence data for Epidemiology and End Results 19982002 as demonstrated (SEER) Program. In addition, 



 




 







by meeting the following data SEER supports metropolitan 


 






quality criteria for all cancer area cancer registries in the 

 








 







sites combined: states of California, Georgia, 

 







Case ascertainment is Michigan and Washington. 
















 

90% or more complete. The These metropolitan area 









registry data include at least registries report their 


















90% of the expected cases incidence data both to the 


 



 


where the expected cases are National Cancer Institute and 


















estimated by using methods to the statewide NPCR-funded 

 







developed by the North cancer registries and, thus, 


















American Association of these data are included in the 


 






Central Cancer Registries. NPCR statewide database. No more than 5% of The NPCR programme covers       cases are ascertained solely 96% of the US population. In 0+'!0+'on the basis of a death 2000, SEER began to provide (&10/.&0*,,000 



 certicate. support for the operations of 

   #0 #00
0 30
0!0"00)&&&000 $00 No more than 3% of cancer registries in California, 0(00

0!0"0#0

0000" 04 0!0 0 !00 0!
4 0 000)&&&000 $0 cases are missing information on sex. Kentucky, Louisiana and New 
2%%$ $ $%

$0 Jersey. These four registries  



 
0 0+)&&,-00 .00
 0 No more than 3% of cases are missing information on report their incidence data to both CDC and NCI. age. To be eligible for inclusion in this volume of Cancer in Five Continents, NPCR-funded cancer registries had to consent No more than 5% of cases are missing information on race. and had to report data that met stringent criteria for incidence reporting as established by CDC (see below). Incidence data At least 97% of the registrys records passed a set of single-eld and inter-eld computerised edits. from 31 cancer registries reported to CDC as of January 2005 (Alabama, Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kentucky, Use of the data Louisiana, Maine, Massachusetts, Michigan, Missouri, CDC and NCI annually publish the United States Cancer Montana, New Jersey, New York, Ohio, Oklahoma, Oregon, Statistics report, beginning with cases diagnosed in 1999 Pennsylvania, Rhode Island, South Carolina, Texas, Vermont, forward. These federal cancer statistics are also made available Washington, West Virginia, Wisconsin), covering 83% of the to the public and cancer control planners through public use U.S. population, met these criteria and are included. Each and restricted access data sets. In addition, several monographs and reports on special topics have been published. registry is featured separately in this report.

186

North America

USA, NPCR: BLACK (1998-2002)

USA, NPCR: BLACK (1998-2002)

USA, NPCR: WHITE (1998-2002)

USA, NPCR: WHITE (1998-2002)

















 












 
































 






























































 















 






 


 











































 


















 



























 






















 























 
















 0+'-

 !0+'-





 /+'-

 !/+'-



(*0,))0/,&000







1&/,)*/110///







 



 Source of population 
0 0+)&&,-00 .00
 0 July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. The population data include the bridged singlerace estimates derived from the original multiplerace


   0(00

0!0"0#0 #0 #00
0 20
0!0"00)&&&000 $00

0000" 03 0!0 0 !00 0!
3 0 000)&&&000 $0 
1%%$ $ $%

$0

 



 categories in the 2000 United States Census. http://www. 
/ /+)&&,-// .//
 / seer.cancer.gov/popdata.


   /(//

/!/"/#/ #/ #//
/ 3/
/!/"//)&&&/// $//

////" /4 /!/ / !// /!
4 / ///)&&&/// $/ 
2%%$ $ $%

$/

Multiple primary rules used IACR rules (2004) on CI5 IX period.

187

North America

USA, Ohio
Registration area Ohios cancer registry covers a population of over 11 000 000 residents. The state has large metropolitan areas of over 1 000 000 as well as rural areas. Manufacturing, agriculture, and business are all important factors in Ohios economy and play roles in the lifestyles of Ohioans. Cancer care facilities Ohio has two National Cancer Institute designated Comprehensive Cancer Centers: Case Western Reserve University in Cleveland and The Arthur G. James Cancer Hospital in Columbus. The state has over 160 other hospitals, most of which offer cancer treatment services. surgery centres. Physicians ofces and pathology laboratories also report data. The pathology laboratories are seen as increasingly good sources of initial cancer data as electronic means for them to report are developed. Death certicates are available for the death clearance procedures that are performed annually. The Bureau of Vital Statistics, where the death certicates are housed, is a part of the Department of Health, where the Registry is housed. Automated editing processes are part of the database software used by the Registry and of the Web-based reporting system recently put into operation. Quality control procedures are attended to on a daily basis by OCISS registrars. Evaluation of data by two national organisations each year also comprises part of quality control.

Registry structure and methods USA, OHIO (1998-2002) Use of the data The registry, established by USA, OHIO (1998-2002) Reporting of incidence, Ohio law in 1991, is in the extent of disease, survival: Ohio Department of Health The registry produces an and is funded by the US annual report and posts data Centers for Disease Control 


 



 





in the Data Warehouse at the and Preventions National 




 


Ohio Department of Healths Program of Cancer Registries 














website. In addition, several (NPCR) and by the State of 







fact sheets are published Ohio. 

 


 









each year for different Staff include 13 cancer 







types of cancers. These are registrars, four administrative 














available on the registrys staff, and two IT staff  

 


 


website or in paper form. members. 














Data are also submitted to Cancer data are 







the National Program for reportable by law for all 











 


Cancer Registries and to the who diagnose and/or treat 







North American Association cancer patients, including for Central Cancer Registries, pathology laboratories.       both of which publish annual Some data are submitted on 0+'!0+'reports and post data to web paper, but increasingly data 



.0.(/01/*000  sites. are submitted in electronic 

   #0 #00
0 30
0!0"00)&&&000 $00 Research use: Registry formats, either on diskettes or 0(00

0!0"0#0

0000" 04 0!0 0 !00 0!
4 0 000)&&&000 $0 
2%%$ $ $%

$0 via email in encrypted les. The OCISS recently opened a data are accessed by researchers several times each year,  



 
0 0+)&&,-00 .00
 0 Web-based system for reporting and is enrolling the larger often including Institutional Review Board approvals for reporting sources to use it at this time. This is the mode of condential data. Planning and evaluation of heath services: Local health reporting that the registry is promoting, as it automates much departments use registry data to perform surveillance studies of the processing of data as they are submitted. Principal sources of information on cancer cases are the and to support funding efforts to provide screening and other hospitals, free-standing radiation centres, and ambulatory cancer-related services.

188

North America

USA, OHIO: BLACK (1998-2002) USA, OHIO: BLACK (1998-2002)

USA, OHIO: WHITE (1998-2002) USA, OHIO: WHITE (1998-2002)











 








































 















































 


































 











 


















 


 




 
























 

 


 






























 












 0+'-

 !0+'-





 .*',

 !.*',



/,*0,*(000






+./0+.&/+...





 


   0(00

0!0"0#0 #0 #00
0 20
0!0"00)&&&000 $00

0000" 03 0!0 0 !00 0!
3 0 000)&&&000 $0 
1%%$ $ $%

$0


   .(..

.!.".#. #. #..
. 2.
.!."..)&&&... $..

...." .3 .!. . !.. .!
3 . ...)&&&... $. 
1%%$ $ $%

$.

Source of population July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. The population data include the bridged singlerace estimates derived from the original multiplerace categories in the 2000 United States Census. http://www.seer.cancer.gov/popdata.

 



 
0 0+)&&,-00 .00
 0

Multiple primary rules used IACR rules (2004) on CI5 IX period.

 



 
. .*)&&+,.. -..
 .

189

North America

USA, Oklahoma
Registration area The Oklahoma Central Cancer Registry covers the population of 77 counties within the state of Oklahoma, in the central United States. The population at the most recent census (2000) was 3 450 654. About 65% of the population lives in urban areas (>2 250 000 inhabitants). Cancer care facilities General health care in the state is provided predominantly by private practitioners and hospitals. This includes 17 facilities that have been designated as Approved Cancer Programs by the American College of Surgeons Commission on Cancer. Registrars within individual facilities involved in diagnosis and treatment of cancers identify and abstract information on cases of cancer, diagnosed by all methods, among residents of the state. Interpreting the results OCCR is obtaining 96% of the incident cancer cases in Oklahoma each year, of which 2% are Death Certicate Only cases. An additional 4% is believed to be diagnosed and/or treated but not reported to OCCR, or may be attributable to error in the method of estimating completeness.

Registry structure and methods The registry is located within the Oklahoma State Department of Health, and is funded partly by the US Centers for Disease Control and Preventions National Program of Cancer 
 




Registries (NPCR), and partly 



by the state health department. 






The registry is staffed by 

 

a surveillance coordinator, 





nine full-time registrars, an 

 

administrative assistant and a 










part-time epidemiologist. 





 

Source of population The OCCR utilizes 














July 1 county population automated data collection via 







estimates by age, sex, race, and electronic media to receive an 














Hispanic origin; postcensal average of 31 000 cancer reports 







estimates based on 2000 per year from approximately United States Census. The 230 active sources of data such       /*', !/*', as cancer hospitals, general population data include the 



(/.0./+++///  hospitals, teaching hospitals, bridged singlerace estimates pathology laboratories, 
   derived from the original #/ #//
/ 2/
/!/"//)&&&/// $// freestanding oncology centres, /(//

/!/"/#/ multiplerace categories in the

////" /3 /!/ / !// /!
3 / ///)&&&/// $/ 
1%%$ $ $%

$/ mammography centres, ambulatory surgery centres, Indian 2000 United States Census. http://www.seer.cancer.gov/popdata.  



 
/ /*)&&+,// -//
 / Health facilities, some dermatologists and urologists ofces, and the vital statistics ofce of the Oklahoma State Department Multiple primary rules used of Health, along with data sharing with surrounding states. IACR rules (2004) on CI5 IX period.

Use of the data OCCR publishes a quarterly report of Chronic Disease Service Data Analysis, or an article focussing on a specic topic around cancer important USA, OKLAHOMA (1998-2002) for Oklahoma. Data are USA, OKLAHOMA (1998-2002) presented to interested groups, including but not limited to Comprehensive Cancer, Indian Health Services, College  






of Public Health, and the 




Oklahoma State Legislature, 








and OCCR has instituted and 




maintains a queryable cancer 








data website (http://www. 




health.ok.gov/stats/cancer/). 




190

North America

USA, Oregon
Registration area The Oregon State Cancer Registry (OSCaR) is a populationbased registry covering the state of Oregon. Oregon, located in the northwestern United States, is about 360 miles long and 261 miles wide. The population in the 2000 census was 3 421 399 and is estimated to have increased to 3 594 586 by 2004. About 70% of the population lives in urban areas. The racial make-up is approximately 87% White, 3% Asian, 1.6% Black and 1.3% American Indian/Alaska Native (approximately 7% are some other race or two or more races). of Oregons cancer cases are collected by certied tumour registrars (CTR) in established hospital cancer registries and are reported to OSCaR. The statewide populationbased cancer registry collects the remaining 25% from nonregistry hospitals, outpatient clinics, physician ofces, and neighbouring state registries diagnosing or treating Oregon residents. The annual process of death clearance identies missed cases by comparing the Registry database with Oregon death certicates. The majority of cases identied through death clearance are subsequently reported by one of the above-mentioned sources. Remaining cases are recorded as death certicate only cases. Interpreting the results OSCaR consistently exceeds the NPCR standard of ascertaining 95% of expected cases based on the North American Association of Central Cancer Registries case completeness calculation. Use of the data The registry prepares an annual report of cancer incidence and mortality highlighting cancer risks, screening and trends. Other cancer control programmes use registry data for planning and evaluation. The registry also collaborates with local and national researchers on a variety of special studies designed to reduce the burden of cancer in Oregonians.

Cancer care facilities Cancer care in the state is provided predominantly by 56 hospitals. Of these, 18 have American College of Surgeons Commission on USA, OREGON (1998-2002) Cancer-approved cancer USA, OREGON (1998-2002) programs. Additional services are provided at ambulatory surgery centres, freestanding cancer treatment facilities, 


 



physicians ofces and clinics 




around the state. 
































Registry structure and 












 

methods 






The registry is located within 












 

the Health Promotion and 







Chronic Disease Prevention 














section of the Oregon 







Department of Human Services, 














along with the Oregon Breast 







and Cervical Cancer Early Detection Program and the       Oregon Comprehensive Cancer /+'!/+'



(/0&)/1*(///  Control Program. Funding for the registry comes through a 
   #/ #//
/ 3/
/!/"//)&&&/// $// Source of population cooperative agreement with /(//

/!/"/#/

////" /4 /!/ / !// /!
4 / ///)&&&/// $/ 
2%%$ $ $%

$/ the US Centers for Disease Control and Preventions National July 1 county population estimates by age, sex, race, and  



 
/ /+)&&,-// .//
 / Program of Cancer Registries (NPCR). The program manager, Hispanic origin; postcensal estimates based on 2000 United one ofce-support staff, ve certied cancer registrars and States Census. The population data include the bridged singlerace estimates derived from the original multiplerace three research analysts staff the registry. Information processed by OSCaR comes from a variety of categories in the 2000 United States Census. sources including: hospital cancer registries, state cancer http://www.seer.cancer.gov/popdata. registries, ambulatory surgery centres, physician ofces, vital statistics, pathology laboratories, hospital medical record Multiple primary rules used departments and the US Census Bureau. Approximately 75% IACR rules (2004) on CI5 IX period.

191

North America

USA, Pennsylvania
Registration area Principal sources of information on cancer cases include The Pennsylvania Cancer Registry covers the population of the acute care hospitals, freestanding pathology laboratories, entire state and has been collecting statewide cancer data since radiation therapy and cancer centres, physicians ofces, and 1985. In Pennsylvania, racial categories other than White made death certicates. up 13.5% of the total population in 2004, compared to 11.5% in Death certicate les (with personal identiers) are 1990, 9.6% in 1980, and 9.0% in 1970. Of the 1 674 223 residents used annually to conduct death clearance by linking to other than White in 2004, 77.7% identied themselves as Black. update existing cancer cases with death information, and by The number of Asian/Pacic Islanders in the state increased identifying cancer deaths not included in the registry. Cancer is a reportable disease in Pennsylvania as by 9.2% between 2000 and 2004, and by 77% between 1990 and 2004. The number of black residents increased by 6.3% mandated by the Pennsylvania Cancer Control, Prevention, between 2000 and 2004, and by 19.4% between 1990 and and Research Act (Act 224) and Department of Health 2004. The number of Hispanics in Pennsylvania increased by Regulations regarding communicable and non-communicable 81 464 (20.7%) between 2000 and 2004. Between 1990 and diseases. According to Act 224, information collected by the Cancer Registry is condential 2000, the number of Hispanic but can be used for medical residents increased by almost research as approved by the 70%. Pennsylvania Hispanics USA, PENNSYLVANIA (1998-2002) PA Department of Health tend to be much younger than USA, PENNSYLVANIA (1998-2002) Policy. white, black or even Asian/ The PA Cancer Registry Pacic Islander residents. The uses national and local edits 2004 median age for Hispanics metales to edit data to meet was 24.9, compared to 31.7 for 


 









national and local standards; Asian/Pacic Islanders, 31.1 for 







conducts casending and reBlacks, and 39.9 for Whites. 














abstracting audits at reporting 







hospitals; performs special Cancer care facilities 







 






studies to check data and Cancer cases are reported 







identify potential quality by all acute care hospitals  





 








issues used to improve data in Pennsylvania. Interstate 







and train staff; and requests data exchange is conducted 














feedback from data users to regularly with all contiguous 







improve data and increase states as well as Florida and 











 


usability of data. Michigan. Other non-hospital 

 





sources where patients are Interpreting the results diagnosed or treated for       There has been a shift in cancer also report to the PA /+'!/+'



./0*)/)&)///  diagnosis and treatment of Cancer Registry, including certain types of cancer from freestanding pathology 
   #/ #//
/ 2/
/!/"//)&&&/// $// inpatient to outpatient facilities. laboratories, radiation therapy /(//

/!/"/#/

////" /3 /!/ / !// /!
3 / ///)&&&/// $/ The only recent change in case denition and coding is the centres and physicians ofces. 
1%%$ $ $%

$/  



 
/ /+)&&,-// .//
 / addition of benign brain and CNS tumours to reportable diagnoses effective in 2004. Pennsylvania participates in the Registry structure and methods The PA Cancer Registry operates in the Pennsylvania CDC Breast and Cervical cancer screening program. In the 2004 Behavioral Risk Factor Surveillance System Department of Health, and is funded by the state and the US Centers for Disease Control and Preventions National (BRFSS) survey, 78% of Pennsylvania men aged 50 and older said that they had ever had a prostate-specic antigen Program of Cancer Registries (NPCR). Fifteen staff work directly on PA Cancer Registry operations blood test to detect the presence of prostate cancer. (8/15 are CTRs); two additional statistical support staff generate cancer reports and statistics; 1 IT staff provides computer Use of the data Incidence, extent of disease, and survival data are produced support; 1.5 epidemiologists perform analysis of cancer data. The PA Cancer Registry uses the CDC Registry Plus and made available on PA Department of Health website cancer data system; uses active casending from all reporting at www.health.state.pa.us/stats. Cancer data are used for sources and passive follow-up through death clearance. PA medical research studies as approved by the PA Department Cancer Registry has received NAACCR Gold Certication of Health, and we receive numerous requests for hospitalspecic data, which is used to evaluate their services. for approximately six years.

192

North America

USA, PENNSYLVANIA: BLACK (1998-2002)

USA, PENNSYLVANIA: BLACK (1998-2002)

USA, PENNSYLVANIA: WHITE (1998-2002)

USA, PENNSYLVANIA: WHITE (1998-2002)































 






















 








































































 

 


















 

























 



































 
 































 
 



 /*',

 !/*',





 /*',

 !/*',



.&1/&(0///






-/(1)/.+0///







Source of population  




 
/ /*)&&+,// -//
 / July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. The population data include the bridged singlerace estimates derived from the original multiplerace


   /(//

/!/"/#/ #/ #//
/ 3/
/!/"//)&&&/// $//

////" /4 /!/ / !// /!
4 / ///)&&&/// $/ 
2%%$ $ $%

$/

categories in the 2000 United States Census. http://www.  




 
/ /*)&&+,// -//
 / seer.cancer.gov/popdata. Multiple primary rules used IACR rules (2004) on CI5 IX period.


   /(//

/!/"/#/ #/ #//
/ 3/
/!/"//)&&&/// $//

////" /4 /!/ / !// /!
4 / ///)&&&/// $/ 
2%%$ $ $%

$/

193

North America

USA, Rhode Island

Registration area The Rhode Island Cancer Registry, an administrative unit of the Rhode Island Department of Health (RIDOH), covers the population of the State of Rhode Island and Providence Plantations in the Northeastern region of the United States. The population at the most recent census (2000) was 1 048 000. About 85% of the population lives in urban areas; roughly 10% are of recent immigrant status. Registry is a member of the North American Association of Central Cancer Registries (NAACCR), and conforms to NAACCR standards for central registry operations, including data reporting, editing and transmission.

Interpreting the results Data from the Rhode Island Cancer Registry have consistently met NAACCR quality control standards for inclusion in national and international aggregates of cancer incidence. Reporting completeness exceeds 95 %, with less than 3% of Cancer care facilities General health care in the region is provided by 10 privately cases being reported on the basis of death certicates only funded acute care hospitals, one federally funded acute care (DCO). During the 1990s, Rhode Island experienced surges (veterans) hospital, 25 community health centres (for primary in screening for cancers of the breast (clinical breast exam and mammogram), cervix care), and several hundred (pelvic exam and Pap test), private physician ofces (for colon-rectum (faecal occult primary and specialty care). USA, RHODE ISLAND (1998-2002) blood and endoscopy), and All eleven hospitals provide USA, RHODE ISLAND (1998-2002) prostate (PSA), resulting in cancer care; all have Cancer increases in the incidence of Care Committees. Nine of cancers of the breast, cervix the eleven acute care hospitals and prostate, and a decrease have American College of 
 

 






in the incidence of cancer of Surgeons-approved cancer 







the colon-rectum (because of programs. In addition, the state 














the removal of pre-cancerous is served by two freestanding 







lesions). radiotherapy centres. 














Rhode Island is a highly 







urbanised state, best compared Registry structure and 














with highly urbanised areas methods 







such as cities. Historically, The Rhode Island Cancer 














Rhode Island has had an Registry (RICR) is a 







urban cancer prole, with population-based cancer 

 












higher incidence of cancers registry established in 1985. 







related to tobacco and alcohol It began collecting reports use, cancers related to diet, of newly diagnosed cancers       and cancers of the female on 1 October 1986. Under /*', !/*', breast and of the prostate. Rhode Island law, all newly 


-&+/.)0///  diagnosed cases of cancer 

   #/ #//
/ 2/
/!/"//)&&&/// $// Use of the data and of benign tumours of the /(//

/!/"/#/

////" /3 /!/ / !// /!
3 / ///)&&&/// $/ 
1%%$ $ $%

$/ brain and central nervous system are reportable to the Rhode The Registry produces ofcial cancer statistics for Rhode  



 
/ /*)&&+,// -//
 / Island Cancer Registry. The Registry is funded by the State Island, including an annual report posted on the RIDOH and by the US Centers for Disease Control and Preventions website, and also supplies cancer data to researchers (strict National Program of Cancer Registries (NPCR). It is run guidelines are used to protect patient condentiality so collaboratively by the Rhode Island Department of Health that individuals cannot be identied). Special studies are (HEALTH) and the Hospital Association of Rhode Island performed regularly to support the planning and management (HARI). There are 5 persons employed: a Registry Manager, of cancer control efforts in the state, and also to assist with 2 Registrars (CTR), a Data Manager and an epidemiologist. environmental health risk assessments. The prole of the principal sources of information are as follows: 8590% of case reports are received from 11 acute Source of population care hospitals; ~10% of case reports are developed from July 1 county population estimates by age, sex, race, and pathology reports; ~5% of case reports are developed from Hispanic origin; postcensal estimates based on 2000 United States Census. The population data include the bridged death certicates (12% death certicate only cases). In Rhode Island, all cancer registries (including 11 hospital- singlerace estimates derived from the original multiplerace based tumour registries and the central registry) conform to categories in the 2000 United States Census. data collection standards adopted by the American College http://www.seer.cancer.gov/popdata. of Surgeons (FORDS). Data are transmitted electronically from hospital registries and other reporting sources to the Multiple primary rules used central registry and vice versa. The Rhode Island Cancer IACR rules (2004) on CI5 IX period.

194

North America

USA, SEER
reporting system and for their epidemiologically signicant Registration area Participants in the Surveillance, Epidemiology, and End population subgroups. The Program aims to determine the incidence and Results (SEER) Program were selected on the basis of their ability to operate and maintain a population-based cancer survival of cancer in selected geographical areas in relation reporting system and for their population sub-groups, to demographic and social characteristics of the population which were of special epidemiological interest. The SEER and to estimate annual cancer incidence for the US. Trends Program now covers over one fourth of the United States in incidence by site and histology are monitored, as are (US) population. Data are available back to at least 1975 survival and trends in survival. Studies are conducted to from the SEER 9 areas (States of Connecticut, Iowa, New identify etiological factors that can possibly reveal groups Mexico, and Utah and metropolitan areas San Francisco- of the population at high or low cancer risk, which may be Oakland (California), Detroit (Michigan), Seattle-Puget dened by social, occupational, environmental, dietary or Sound (Washington), and Atlanta (Georgia)), which represent other characteristics. Geographical information systems are about 10% of the total US population. The SEER 14 areas developed for use with SEER and other population-based central cancer registries in (States of Connecticut, Iowa, the USA through linkage with New Mexico, Utah, Kentucky, small area demographic census New Jersey, and Louisiana USA, SEER (9 registries) (1998-2002) data and national surveys on and metropolitan areas USA, SEER (9 registries) (1998-2002) health behaviours, risk factors Greater California (San and environmental exposures Francisco-Oakland and San for use in cancer control and Jose-Monterey) (California), surveillance research. Los Angeles (California), $$0-"*$--/*, %./-$(0--$.%-0.&--/" %/(-&"&--Greater California (California Data for publication are %.%-%./--.* &/+-""$--excluding SF/SJM/LA), transmitted by the participants &&.-$0+--." (%.-++%--&/"-%$&--+* ((&-*+%--Detroit (Michigan), Seattleto NCI 22 months after the end of (+(-"$$--+" *"(-0$"--Puget Sound (Washington), each calendar year. All malignant +%*-""(--** +**-%0"--/&0-*%0--*" /.&-.*.--and Atlanta plus Rural and in situ neoplasms as dened 0.$-%$"--(* 000-+/*--Georgia (Georgia)) cover in ICD-O are collected except $-"/*-*&&--(" $-"0/-.&(--$-$"$-%$.--&* $-"0*-...--26.1% of the US population. for basal and squamous skin $-"((-0**--&" $-"%%-(/+--The data are considered cancers since 1973, in situ and 0+/-$*"--%* 0(%-0"$--0$(-*+"--%" /.0-+(0--fairly representative of the CIN III of the cervix uteri since 0*/-+0.--$* 0"+-+&*--US population with respect 1996, and PIN III since 2001. 0/.-*.$--$" 0("-.$%--0/0-".*--* 0(%-$&+--to selected demographic SEER registries must collect 0(.-.%.--" 0"&-/(/--variables. With regard to information about extent of race, rural blacks are underdisease, rst course of therapy, $" * " " * $" represented, whereas other and follow-up. Neither the -'#) -'#) minority populations such as patients name nor the name of $&-*/+-$0.--$&-$./-0(0-- Chinese, Japanese, Hawaiians the hospital is provided to NCI. 
   and American Indians are -$--

--- ----
- 1-
----%"""--- !The SEER Program  



 over-represented. Over 350 000 new cases of in situ and conducts studies to evaluate quality and completeness of 
--'%""()-- *--
invasive cancers are added each year to the SEER database. data, and provides specialist training for personnel. In addition to contributing to SEER, many of the SEER areas report data separately for their own registry in this volume. Use of the data Updated annually and provided as a public service in print Registry structure and methods and electronic formats, SEER data are used by thousands The SEER Program is a continuing project of the Surveillance of researchers, clinicians, public health ofcials, legislators, Research Program of the US National Cancer Institute policymakers, community groups, and the public. Each year (NCI). The Program was initiated in 1973 as an outgrowth since 1985, the NCI has published a SEER Annual Cancer of the End Results Program and the three National Cancer Statistics Review (www.seer.cancer.gov/publications), which Surveys and The National Cancer Act of 1971, which comprises principally SEER cancer incidence and survival mandated the collection, analysis and dissemination of data data, and cancer mortality data from the National Center for useful in the prevention, diagnosis and treatment of cancer. Health Statistics. In addition, data are made available on the The participating regions were selected principally for their SEER home page (www.seer.cancer.gov) and via SEER*Stat ability to operate and maintain a population-based cancer software on a client-server and CD-ROM.

195

North America

USA, SEER (9 registries): BLACK (1998-2002)

USA, SEER (9 registries): BLACK (1998-2002)

USA, SEER (9 registries): WHITE (1998-2002)

USA, SEER (9 registries): WHITE (1998-2002)

+-+$0--0-/&/--$.-(.*--%&-$%(--%0-00%--&/-(**--*&-($%--./-/"(--0/-.*(--$$/-$"$--$%.-*0&--$%0-$"(--$%%-&/$--$$+-00"--$%.-0/(--$(/-$&"--$*.-(&%--$(%-$%*---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

$.-%&"--$/-*+/--%/-"*$--&(-$"*--("-$..--(.-..+--+&-&("--0%-0(%--$$*-"0.--$&(-%%0--$((-$*&--$((-%+&--$&/-"+(--$%&-*""--$%*-".0--$(&-0(/--$*%-0(*--$&+-*..---

$"$-+.0--$(/-*&"--%%0-*+*--%/$-0&0--&$%-*&0--&.0-*(&--*$&-*((--+./-*/0--..*-/""--/*+-&/$--/*&-*$0--.0&-/*/--.%(-*"/--+/+-/.(--.$0-.".--.%+-.$+--.$/-.%/--+0*-0$(---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

%((-%00--%(*-%"%--&%(-.*0--&(0-+*(--&*(-0$.--("&-$&(--*%+-$*(--+//-.%/--..+-$*/--/((-$+&--/%(-&*&--.(0-&+0--+./-.$.--+(+-.*"--+.*-+0/--+/0-""*--+/$-*%"--++%-$$(---

$"

* -'#)

"

"

* -'#)

$"

$"

* -'#)

"

"

* -'#)

$"

$-*(+-&$&---



$-.""-"(&---

$"-$0.-0&(---



$"-&+(-+0%---


   -$--

--- ----
- 1-
----%"""--- ! 



 
--'%""()-- *--
-


   -$--

--- ----
- 1-
----%"""--- ! 



 
--'%""()-- *--
-

USA, SEER (14 registries) (1998-2002)

USA, SEER (14 registries) (1998-2002)

USA, SEER (14 registries): BLACK (1998-2002)

USA, SEER (14 registries): BLACK (1998-2002)

&$"-+0"--(+"-/(+--.&*-(."--0%+-&&.--$-"*+-(*"--$-%.&-("*--$-+.*-%/+--%-%&*-/+0--%-+"/-.(%--%-0+0-%"%--&-"*.-$*&--%-0".-&%"--%-+0+-(+&--%-+$%-".%--%-.&.-*0"--%-/&*-/0%--%-//0-&.+--%-.$.-$0/---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

.$(-(00--.*%-0*&--$-"(+-0+"--$-$..-+%%--$-%&+-$$$--$-&00-"(%--$-...-&"+--%-&&%-0".--%-+/(-"+*--%-00$-.*/--&-"%*-("*--%-/%*-/0.--%-*0$-(*$--%-(*%-&$+--%-*.%-**&--%-.""-$./--%-.*"-00&--%-*0&-.%$---

$/-.0&--%+-(0%--(.-%$.--+(-0+.--/+-/("--$$"-$+*--$(%-%$&--%"$-$"&--%*&-.0%--&"/-"0$--&&"-$.+--&%"-&+&--&"$-"*$--&$&-*%&--&**-*&&--&0$-./+--(".-$$*--&+.-"$$---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

(/-$/$--*"-&%0--.*-&&0--0(-""+--$$&-+$&--$&+-%0*--$."-+//--%&+-$.0--%0$-$+&--&(%-&/%--&+(-"/&--&(0-%/"--&%+-%**--&%$-""&--&((-%+$--&.0-/$&--&0&-$&(--&*(-"."---

$"

* -'#)

"

"

* -'#)

$"

$"

* -'#)

"

"

* -'#)

$"

&+-."*-&+"---



&.-+%*-.&/---

(-"(+-%&$---



(-&0"-".(---


   -$--

--- ----
- 1-
----%"""--- ! 



 
--'%""()-- *--
-

USA, SEER (14 registries): ASIAN AND PACIFIC ISLANDER (1998-2002)


   -$--

--- ----
- 1-
----%"""--- ! 



 
--'%""()-- *--
-

USA, SEER (14 registries): ASIAN AND PACIFIC ISLANDER (1998-2002)

USA, SEER (14 registries): HISPANIC WHITE (1998-2002)

USA, SEER (14 registries): HISPANIC WHITE (1998-2002)

%"-$.*--%0-&%&--*$-"$.--+.-(&&--/$-+//--$"%-/&(--$&"-*$.--$/(-(//--%%$-0/*--%*%-((/--%."-/%&--%.(-&(*--%."-/((--%(&-+&"--%((-*$*--%(%-.&"--%($-$."--%&$-/&"---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

&"-$&"--("-*&%--+.-+"%--0$-(/(--$"*-/+$--$$0-&"*--$(+-0+&--%"/-.(0--%*$-+/(--%./-*&.--%/0-%0"--%0*-$&0--%/+-+$%--%($-(.*--%&$-/$&--%%/-(/0--%%/-(0(--%%"-+%(---

$.-0(&--%*-&/.--(0-&*/--.&-//.--0+-%"&--$%+-"+$--$+0-*"%--%(+-*..--&&.-$+(--(**-%."--*."-0"0--++"-&"+--+0*-+($--+/(-*&(--+$0-*&"--+&&-..(--.%*-&("--.%.-/&*---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

&*-0((--("-0("--+/-*"/--0+-0($--$$/-(/(--$(*-$/$--$/.-$.%--%*/-.&*--&&/-(%&--(&*-"$+--*$/-%00--*.$-00+--*0"-"(/--*+/-++.--**/-$&+--+"*-+++--+0(-"*&--+0.-"++---

$"

* -'#)

"

"

* -'#)

$"

$"

* -'#)

"

"

* -'#)

$"

&-$+$-.0*---



&-&+%-./&---

+-0$*-%$0---



+-*%0-%.(---


   -$--

--- ----
- 1-
----%"""--- !-


   -$--

--- ----
- 1-
----%"""--- ! 



 
--'%""()-- *--
-

196

 



 
--'%""()-- *--
-

North America

USA, SEER (14 registries): NON-HISPANIC WHITE (1998-2002)

USA, SEER (14 registries): NON-HISPANIC WHITE (1998-2002)

Source of population July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. Multiple primary rules used IACR rules (2004) on CI5 IX period.

%*%-$0+--&..-(($--*/&-0&0--.$&-/.(--./&-%00--0%%-(*(--$-%$+-(.%--$-*/"-"0$--$-.+*-///--$-0$.-%&(--$-/(*-.%+--$-+$&-..*--$-&0"-("%--$-&%/-.%&--$-(."-.(.--$-*$.-*"+--$-(++-"(/--$-&(/-&$.---

/*, /" .* ." +* +" ** *" (* (" &* &" %* %" $* $" * "

*0.-$./--+$.-../--/&"-"$(--//.-+%*--///-%&0--0/*-%&&--$-%*(-**.--$-+"(-"0%--$-..$-$".--$-/0/-$**--$-/$(-%"+--$-*.%-(*$--$-&*%-/$&--$-%/%-00+--$-&0&-$$0--$-(&.-$&%--$-&/.-"%(--$-%/$-+&&---

$"

* -'#)

"

"

* -'#)

$"

%%-"0(-$&$---



%%-/**-&*%---


   -$--

--- ----
- 1-
----%"""--- ! 



 
--'%""()-- *--
-

197

North America

USA, South Carolina

Registration area The South Carolina Central Cancer Registry covers the entire state. The state is 60.5% urban and 39.5% rural, comprised racially of 31% African American, 68% Caucasian, and 1% Other Races. Cancer care facilities Health care is provided in SC by 65 acute care hospitals, ~35 freestanding surgical and oncology treatment centres, and private oncology practices. and physician identiers are reported via state statute and protected by this law. Quality control procedures include visual review of patient abstracted data along with computerised interrecord, intra-record edits. USA, SOUTH CAROLINA (1998-2002) Routine casending and USA, SOUTH CAROLINA (1998-2002) quality audits are performed at reporting facilities. Once every ve years, the SCCCR undergoes a national data  


completeness and quality 


 





audit. Results of most 




recent national audit: 97% 








completeness, 98% accuracy. 








The SCCCR has attained 




Gold Certication for 6 years, and 








Silver for 2 from the NAACCR 




certication process since 1997. 











 










Registry structure and 






methods 

The SCCCR is located at the 






SC Department of Health and 



Environmental Control, funded 








 

by the US Centers for Disease 







Use of the data Control and Preventions National 














The data are used to report Program of Cancer Registries 







ofcial annual cancer (NPCR) and state funds. incidence, extent of disease The SCCCR is comprised       and survival for the state. of 17 staff, including the .*', !.*', An annual Cancer Report Director, 10 CTRs who 



(./-&.()-...  Card is produced as well as perform data coordination and .(..

.!.".#. #. #..
. 1.
.!."..)&&&... $.. County Cancer Fact Sheets. quality control, 4 Masters- 
  

...." .2 .!. . !.. .!
2 . ...)&&&... $. 
0%%$ $ $%

$. level research analysts, database manager and statistician, Assessments of community cancer concerns (potential  



 cancer clusters) are carried out with the data. and administrative coordinator.
. .*)&&+,.. -..
 . The data are available through the on-line query system, The majority of data collection (85%) comes from pre-coded data from hospital registries. The remainder is called SC Community Assessment Network (SCAN). actively sought by staff from small hospitals, pathology labs, Researchers and the public can create their own query by accessing the cancer module on SCAN. Maps, trend graphs, freestanding treatment centres and physicians. The hospital medical record is the principal source of bar charts and tables are provided. The data are used for research as prescribed by the information on cancer cases. Secondly, pathology reports from reference labs are a contributing source of information. protocol for data release and approval by the advisory Access to death certicates (with personal identiers) is committee. Data are used by multiple university researchers as well as SC medical schools, by state cancer control provided by the SC Div of Vital Registry. Cancer reporting is mandated in SC by the state statute planners and evaluators, the statewide Cancer Alliance, and SC Code Section 44-35-10-60. Condential patient, hospital the American Cancer Society.

USA, SOUTH CAROLINA: BLACK (1998-2002) USA, SOUTH CAROLINA: BLACK (1998-2002)

USA, SOUTH CAROLINA: WHITE (1998-2002) USA, SOUTH CAROLINA: WHITE (1998-2002)









































 













 





































 















































 



















 













 


















 









































 












 /*',

 !/*',





 0+'-

 !0+'-



-.-/-0&///






(0*./01,*000




 



   /(//

/!/"/#/ #/ #//
/ 2/
/!/"//)&&&/// $//

////" /3 /!/ / !// /!
3 / ///)&&&/// $/ 
1%%$ $ $%

$/


   0(00

0!0"0#0 #0 #00
0 30
0!0"00)&&&000 $00

0000" 04 0!0 0 !00 0!
4 0 000)&&&000 $0 
2%%$ $ $%

$0  



 
0 0+)&&,-00 .00
 0

198

 



 
/ /*)&&+,// -//
 /

North America

Source of population July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. The population data include the bridged singlerace estimates derived from the original multiplerace

categories in the 2000 United States Census. http://www. seer.cancer.gov/popdata. Multiple primary rules used IACR rules (2004) on CI5 IX period.

199

North America

USA, Texas
Registration area The Texas Cancer Registry (TCR) covers the statewide population of Texas, in the south central United States of America. The estimated mid-year 2000 population census was 20 851 820. Although 86% of the population lives in urban counties, these represent only 30.3% of all Texas counties. The 2000 Texas population also shows considerable race/ethnic diversity with 53.1% being non-Hispanic White, 32.0% Hispanic (of any race), 11.6% Black and 3.3% Other Races. agreements with other states to obtain data on Texas residents diagnosed and/or treated out-of-state. Interpreting the results We estimate the completeness of our cancer data by predicting the number of cases to be expected each year, based on standard age-, sex-, and race/ethnic-specic rates from another state registry with a similar population to the Texas population. Based on these estimates, we do not produce a nal dataset for any given year until the estimated completeness of the data is at least 95%. The average completeness of the entire 19982002 dataset is 96.3%. Cancer care facilities Cancer care in Texas may be provided by a wide variety of The population of Texas is unusual in that there is a large facilities, from large medical proportion of the total statewide centres specialising in cancer population made up of Hispanics. treatment to community For most major cancer types, USA, TEXAS (1998-2002) hospitals. The M.D. Anderson incidence rates in Hispanics are USA, TEXAS (1998-2002) Cancer Center in Houston, lower than for many other race/ Texas is a leader with a ethnic groups, leading to generally worldwide reputation in cancer lower (overall) incidence rates in care, as well as research, Texas than in surrounding states. 


 









education and prevention. For this reason, Texas rates are 







Numerous other researchalso reported by race/ethnicity. 




 









based University medical The goal of the DSHS 







centres and American College Breast and Cervical Cancer 





 








of Surgeons Accredited Control Program is to reduce 







Cancer Programs are found in mortality from breast and 














the state, and provide state-ofcervical cancer in Texas. This 







the-art cancer diagnosis and program provides free breast 














treatment. and cervical cancer screening 







and diagnostic services to 

 












Registry structure and low-income women with no 







methods health insurance at over 200 The TCR is part of the Texas sites throughout Texas. Since       /+'!/+'Department of State Health 1991, more than 190 000 



(&/,&(/0*.///  Services (DSHS), and also women in Texas have received receives federal funding from 
   early cancer detection services #/ #//
/ 2/
/!/"//)&&&/// $// the US Centers for Disease /(//

/!/"/#/ through this program.

////" /3 /!/ / !// /!
3 / ///)&&&/// $/ 
1%%$ $ $%

$/ Control and Prevention, National Program of Central Cancer According to the DSHS Texas Behavioral Risk Factor  



 
/ /+)&&,-// .//
 / Registries (NPCR). The TCR is staffed by 46 full-time state Surveillance System, in 2002, 70% of Texas men 50 years staff and 10 contract staff. and older had a PSA test within the past ve years. NonOur cancer data are reported to the TCR primarily by Hispanic white men and men 65 and older had higher PSA hospitals, but also by cancer treatment centres, pathology prevalence rates, while Hispanic males and those with less labs and medical practitioners. than a high school education have lower PSA rates. Cancer case reporting in Texas is required by state law (Chapter 82, Health and Safety Code), and the TCR has Use of the data specic cancer reporting rules. Cancer death reporting The registry produces an annual report of cancer incidence is through the Texas DSHS, Vital Statistics Unit. Cancer and mortality, examining race/ethnic differences, trends, case reporting is done electronically for approximately and other patterns in statewide cancer data, and maintains 98% of cases, and 0% of deaths. All personal identifying tables of average annual rates, published on our website. data are considered condential, and are used internally These data are provided statewide, by sex and race/ethnicity, by TCR staff for registry operations and approved research and by various geographical areas including counties. Also purposes. Condential data may only be released with DSHS provided are childhood cancer incidence and mortality rates, Institutional Review Board approval. as well as estimated cases and deaths for future years at the Texas Cancer Registry staff work with the cancer statewide, regional and county levels. Data are also provided reporters to provide training in case reporting as needed, to external customers upon request, and have resulted and technical assistance to identify and abstract information in numerous specialised studies of cancer incidence and on cancer cases. In addition, the TCR has data exchange mortality, as well as health services studies.

200

North America

USA, TEXAS: BLACK (1998-2002)

USA, TEXAS: BLACK (1998-2002)

USA, TEXAS: WHITE (1998-2002)

USA, TEXAS: WHITE (1998-2002)


































 
















 






















































































 


 


 




 

















 


 





 









































































 .*',

 !.*',





 /*',

 !/*',



(.)&-.&)+...







1/1&./002///





 


   .(..

.!.".#. #. #..
. 0.
.!."..)&&&... $..

...." .1 .!. . !.. .!
1 . ...)&&&... $. 
/%%$ $ $%

$.


   /(//

/!/"/#/ #/ #//
/ 4/
/!/"//)&&&/// $//

////" /5 /!/ / !// /!
5 / ///)&&&/// $/ 
3%%$ $ $%

$/

Source of population July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. The population data include the bridged singlerace estimates derived from the original multiplerace

 



 
. .*)&&+,.. -..
 .

categories in the 2000 United States Census. http://www. seer.cancer.gov/popdata. Multiple primary rules used IACR rules (2004) on CI5 IX period.

 



 
/ /*)&&+,// -//
 /

201

North America

USA, Utah
pathology reporting and plans to receive some 90% of Registration area The State of Utah covers 299 888 km2 and is geographically pathology reports electronically within the next 5 years. Both hospital-based registrars and central registry the 11th largest US state. There were 2 233 169 residents in Utah at the time of the decennial census conducted in 2000. personnel conduct active and passive follow-up of cancer Approximately 89% of Utah residents are white, and 9% patients. For example, registry records are routinely linked are of Hispanic origin (any race). The remaining population with administrative databases, including those maintained comprises American Indians (1.3%), Asians (1.7%), Pacic by the Centers for Medicare/Medicaid Services and the Utah Islanders (0.7%), blacks (0.8%), and individuals of other Department of Public Safetys Driver License Division, and local voter registration les. UCR routinely queries vital racial/ethnic backgrounds (4.2%). Utahs 2000 birth rate of 21.1/1000 was approximately records from the Utah Department of Health for information 47% higher than the national average of 14.4/1000. As a about cancer patients who may have died. In rare instances, result, the median age of Utah residents was 27.1 years, fully death certicates may provide information about cancer cases that were not identied through other sources. 8 years younger than the national gure of 35.3 years. Cancer data are abstracted Approximately 70% of and coded by both hospitalUtah residents are members of based registrars and central the Church of Jesus Christ of USA, UTAH (1998-2002) registry personnel. HospitalLatter-day Saints (LDS), whose USA, UTAH (1998-2002) based registrars submit doctrine places a high value abstracts and pathology on marriage and encourages reports to UCR, allowing large families (hence, high central registry staff to fertility rates). The church also 


 









monitor the quality of data discourages consumption of 







and process difcult-to-code tobacco, alcohol and caffeine, 





 








items such as extent of disease and proscribes premarital sex, 







and site-specic treatment. All profoundly inuencing cancer 

 






 





electronic records are subjected incidence and mortality rates 







to various automated edits in Utah. 














developed by SEER and other 







professional organizations. Cancer care facilities 














UCR also participates in Forty-ve health care facilities 







SEER-sponsored quality in Utah routinely provide











control projects. cancer-related services to 

 





state residents. Seven of Interpreting the results Utahs largest facilities have       With respect to the 1998 ACoS accredited cancer &%71-3 (&%71-3 



2002 data, the UCR has .7./07808777  &% care programmes. Fourteen had consistent coverage, hospitals in Utah support one  
 %%&*7 
( % *7&
7
7%7137 &(71$$$++&+ 375&7&&)&:7 %& 7;7 &%7"++7 geographically and or more cancer registrars on  1.969;/,,037;7
!
7 7 7)7;7 &%7"++*7.969;/,,07 *7& &%7&7*7*7 %%&7&7  &(*7&7&7&*7%&
7#&&7/,,6+7 their staff, including each of the AcoS-accredited facilities. demographically. UCR, along with other registries in the  
   7%71/,,237 7477 
7 Six Utah hospitals have radiation therapy units; there are 2 SEER Program, changed topograhy and morphology coding    227
7 7%
7)&&%7%%7 7&( 7%%7& (&7' 7 7!7 7&+7 rules from ICD-O-1 to ICD-O-2 for cases diagnosed from freestanding radiation therapy units in the state. 19982000 and 20012002, respectively. However, these changes in coding rules will not have an effect on the 1998 Registry structure and methods The Utah Cancer Registry (UCR) has operated since 1966 2002 statistics, as 19982000 cases were retrospectively on a population-based, statewide level. In 1973, UCR coded using ICD-O-2. According to data from the Utah Behavioral Risk Factor became one of the original members of the National Cancer Institutes Surveillance, Epidemiology, and End Results Surveillance System (BRFSS), as many as 64% (95%CI (SEER) Program. UCR has continuously participated in the 6168%) of men aged 40+ surveyed in 2002 reported a PSA test within the last ve years. Therefore, PSA is relatively SEER program since that time. UCR is staffed by 20 employees, including 5 administrative common in the Utah population. personnel, 1 research coordinator, 2 supervisors, 3 coders, 4 eld pathology and hospital abstractors, 1 follow-up coordinator, Use of the data UCR data are combined with those from other SEER Program 3 IT and data support staff, and 1 data entry/le clerk. Cancer cases are identied and followed using participants to monitor cancer trends in the USA. UCR data information from hospitals, pathology laboratories, radiation are also well utilised by independent investigators and the treatment centres, physician ofces, nursing homes, vital Utah Department of Health for studies of cancer etiology, records, other central cancer registries, and by direct patient prevention and control. By combining UCR records with contact. Cancer reporting in Utah is mandated by legislation genealogy les and other sources, researchers have made notable contributions in the eld of cancer genetics. The and regulatory rule. Central registry personnel annually travel to outlying registry maintains a web page (http://ucr.utah.edu), publishes areas to identify and abstract cases in the smaller rural trends in incidence and mortality annually, and responds to hospitals. The UCR is now advancing toward electronic ad hoc requests for cancer-related data.

202

North America

Source of population Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Populations Total U.S. (19692003) Linked To County Attributes Total U.S., 19692003 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released January 2006.

Multiple primary rules used IACR rules (2004) on CI5 IX period . Notes on the data C44 does not include basal cell or squamous cell carcinoma except for skin of anus.

203

North America

USA, Vermont
Registration area The Vermont Cancer Registry (VCR) covers the population of the State of Vermont. The population at the most recent census (2000) was 608 827. About 38% of the population lives in urban areas (areas designated by the U.S. Census Bureau as Urbanized Areas and/or Urban Clusters); 97% are white, the remainder other races. Interpreting the results VCR data are estimated to be at least 95% complete, 24 months after the close of the diagnosis year. Ladies First is a health screening program for Vermont women. Ladies First removes nancial barriers, which prevents many women from being screened for breast and cervical cancer.

Use of the data Cancer care facilities General health care in the region is provided predominantly VCR prepares an annual report of cancer incidence, by 15 hospitals, including a Veterans Affairs Medical Center. highlighting trends and changes. Site-specic reports are This is supplemented by private practitioners and one outpatient also published. Because active follow-up is not conducted, radiation therapy facility. The Vermont Cancer Center (VCC) is survival analyses have not been possible. The registry is currently an NCI-designated facility for involved in the NCI-sponsored Phase I, II and III therapeutic New England Study of clinical trials. VCC and Fletcher USA, VERMONT (1998-2002) Environment and Health, Allen Health Care (FAHC) are USA, VERMONT (1998-2002) which is investigating the located in Burlington, the largest possible causes of elevated city in Vermont, and provide bladder cancer incidence radiotherapy, cancer surgery and and mortality in the states of chemotherapy services. Patients 


 









Maine, New Hampshire and suspected to have cancer in the 







Vermont. primary and secondary care 














VCR data are used for facilities in the registry area 







planning and evaluation of are mostly referred to VCC, 














cancer control objectives e.g. FAHC, Dartmouth Hitchcock 







comprehensive cancer control, Medical Center in neighbouring 














detailed incidence/mortality New Hampshire, one of the 





 

statistics, health event hospitals with comprehensive 














investigations and program cancer services in the state, 







evaluation. or occasionally to one of the 














For Needs Assessment/ hospitals in Boston, MA or 







Program Planning: VCR Albany, NY. completed a project using       .*', !.*', GIS to identify opportunities Registry structure and 


)10.-&/...  for breast cancer screening of methods income-eligible women. The The registry is located within 
   #. #..
. 3.
.!."..)&&&... $.. purpose of the project was the Vermont Department of .(..

.!.".#.

...." .4 .!. . !.. .!
4 . ...)&&&... $. 
2%%$ $ $%

$. Health and is funded by the US Centers for Disease Control to identify areas where the Ladies First breast and cervical  



 
. .*)&&+,.. -..
 . and Preventions National Program of Cancer Registries program services are less utilised and enrolment could be (NPCR) and in-kind support from reporting hospitals. The increased, particularly for women ages 4064 who meet registry is staffed by a full-time director, a cancer data eligibility requirements, by examining the current enrolment specialist, a certied cancer registrar and an epidemiologist. of Ladies First clients, the distribution of providers and The VCR uses active case nding from 13 non-federal facilities providing services, screening patterns and stage hospital cancer registries, one out-of-state reference distribution of breast cancers to determine if there were any pathology laboratory, one radiation therapy centre, 5 parallels with areas of lower membership. The VCR has started routinely evaluating late stage dermatologists, 8 urologists, 1 VA hospital, and a small number of other physicians. The cancer registry is linked diagnosis of certain cancers (colon, breast, cervical) as a with the VT death le annually. Non-matches are followed measure of the effectiveness of cancer screening efforts. back to identify cases potentially unreported to VCR. These cases identied by death certicates are followed back with Source of population hospitals and physicians to either rule out reportability or July 1 county population estimates by age, sex, race, and be reported to VCR. Records that cannot be followed back Hispanic origin; postcensal estimates based on 2000 United to source records are accessioned as death-certicate-only States Census. The population data include the bridged cases. Cancer is required to be reported by Vermont health singlerace estimates derived from the original multiplerace care facilities and healthcare providers. Interstate data categories in the 2000 United States Census. exchange agreements exist with all bordering states and http://www.seer.cancer.gov/popdata. Florida. Electronic editing, visual editing, and hospital auditing Multiple primary rules used IACR rules (2004) on CI5 IX period. are all used as quality assurance strategies.

204

North America

USA, Washington State

Registration area The Washington State Cancer Registry is responsible for cancer case surveillance throughout the State of Washington (USA). The mid-2000 population for Washington State is reported at 5 894 121 of which approximately 49.8% are males, 50.2% females. Registry structure and methods Case information is provided to the State Cancer Registry by healthcare facilities (hospitals, laboratories, physician ofces) throughout the state. The registry is located within the Washington State Department of Health and is funded by the US Centers for Disease Control and Preventions National Program of Cancer Registries (NPCR) and partly by state funds. The registry is staffed by experienced certied tumour registrars (CTRs) and an epidemiologist. Use of the data The registry prepares an annual report of cancer incidence, highlighting trends and changes.

 





 













 






 

























USA, WASHINGTON STATE (1998-2002)

USA, WASHINGTON (1998-2002)

 
























 










 














 


 











 




 /*',

 !/*',



)/0+./&.0///








   /(//

/!/"/#/ #/ #//
/ 2/
/!/"//)&&&/// $//

////" /3 /!/ / !// /!
3 / ///)&&&/// $/ 
1%%$ $ $%

$/  



 
/ /*)&&+,// -//
 /

Source of population July 1 county population estimates by age, sex, race, and Hispanic origin; postcensal estimates based on 2000 United States Census. The population data include the bridged singlerace estimates derived from the original multiplerace categories in the 2000 United States Census. http://www.seer.cancer.gov/popdata. Multiple primary rules used IACR rules (2004) on CI5 IX period.

205

North America

USA, Washington, Seattle

in the central ofce by registry staff. Both active and passive Registration area The Cancer Surveillance System (CSS) operates under follow-up methods are used. Passive follow-up is performed the Surveillance, Epidemiology, and End Results (SEER) via data linkage with both medical and non-medical source program to provide incidence, treatment, and follow-up data records. Active follow-up consists of annual letters sent to on all newly-diagnosed malignancies (except non-melanotic the physicians. Death clearance and unduplication activities skin cancers and in situ cancers of the cervix) occurring in are performed annually. The data are submitted annually to the SEER Program and North American Association of residents of 13 counties of northwest Washington State. While the geographic area has not changed, the population Central Cancer Registries (NAACCR), and monthly to the has grown substantially in size. The CSS reporting area has a State registry. population of over 4.2 million (based on 2000 census), which As a member of SEER, we annually evaluate the is approximately 70% of the state population. Counties in the reporting area include Clallum, Grays Harbor, Island, completeness and accuracy of the information recorded. Jefferson, King, Kitsap, Mason, Pierce, San Juan, Skagit, Interpreting the results Snohomish, Thurston and This registry has no Whatcom. The CSS reporting circumstances that are area includes four Primary USA, WASHINGTON, SEATTLE (1998-2002) particularly different from Metropolitan Statistical Areas USA, WASHINGTON, SEATTLE (1998-2002) any other region with a highly(PMSAs). Approximately medicalised society. 86% of the people in the CSS reporting area reside in these Use of the data PMSAs: Seattle-Bellevue$.-.%/--/*, &0-$""--%+-%&0--/" ("-(+%--CSS provides reports to Everett (57.7%), Tacoma &0-**&--.* **-""&--reporting hospitals on a (17.5%), Bremerton (5.6%) and (/-%(/--." */-+(0--*+-0%&--+* +%-&*&--monthly basis. Identiable Olympia (5.1%). The racial .$-(""--+" .&-(+"--information is reported only distribution of the population 00-/**--** $""-0/%--$&+-%((--*" $&/-/"%--to the reporting physician base is as follows (2000 data): $*/-(.*--(* $+$-$0.--or institution, to FHCRC 80.4% White, 5.3% Hispanic, $.*-$+%--(" $.(-"%(--$.(-0$&--&* $+0-0*&--investigators conducting IRB4.2% Black, 7.2% Asian, 1.4% $+*-&"/--&" $*.-%.*--approved research, and to the Native American, and 1.5% $(+-+&"--%* $&0-$.+--$&/-$*/--%" $%0-("0--state Department of Health Other. $((-&/*--$* $&+-$/$--as required by law. Statistical $(+-..&--$" $&0-*$(--$(&-&*0--* $&*-+$.--reports for publication contain Cancer care facilities $&&-&0+--" $%+-/**--no data identifying patients, Cancer patients have extensive physicians or institutions. Nonaccess to diagnostic and $" * " " * $" identiable data are released treatment facilities throughout -'#) -'#) %-"&/-"$%--%-"%%-.(/-- to scientists working at the the CSS catchment area. local, regional, national and The increasing provision of 
   international level. Aggregate services in outpatient settings -$--

--- ----
- 1-
----%"""--- !has necessitated expansion of  



 activities to make sure that reports of non-identiable data, such as incidence rates by 
--'%""()-- *--
county or 5-year survival rates, are provided to the public cancers and details about them are not missed. upon request. The CSS responds to many requests from the local medical and scientic community, registrars, health Registry structure and methods The registry is located within Fred Hutchinson Cancer care administrators, news media, public, Cancer Information Research Center (FHCRC), and is funded primarily by Service, and students receiving graduate training in public the SEER Program, and partly by the FHCRC and the health sciences. CSS also contributes to collaborative studies involving Washington State Department of Health. The registry is staffed by 28 full-time technical staff members and 9 hourly multiple SEER areas. Data released to SEER are stripped technical/data processing staff, and 3.5 programming staff, of information which would identify the patient, physician, 2 part-time epidemiologists, 1 part-time staff scientist, and 1 or reporting institution and is identied only by a unique number assigned by the CSS. part-time administrator. The CSS registry uses active case nding from over 100 sources of data consisting of cancer hospitals, general hospitals, teaching hospitals, pathology laboratories and the Source of population Washington State Bureau of Vital Statistics. All the case July 1 county population estimates by age, sex, race, and nding is performed at the central registry ofce. Abstraction Hispanic origin; postcensal estimates based on 2000 United of medical records is performed by a mix of hospital staff States Census. and registry staff. The latter perform abstracting either at the healthcare facilities or via remote access at the central Multiple primary rules used ofce. All the coding and case consolidation is performed IACR rules (2004) on CI5 IX period.

206

North America

USA, West Virginia

Registration area The West Virginia Cancer Registry (WVCR) covers the state of West Virginia, which is the only state that is classied as entirely Appalachian. West Virginia is racially and ethnically homogeneous, with 95% of its population identifying as white and 0.7% identifying as Hispanic. West Virginians have an overall lower educational attainment than the US as a whole, with 75.2% of persons 25 and older having a high school education or higher (80.4% for the US), lower per capita income ($16 477 compared to $21 587) and a higher median age (38.9 years compared to 35.3 years). West Virginia is one of the least urban states in the United States, with 46.1% of the states population living in urban areas. Cancer care facilities As of January 2006, 51 of West Virginias 55 counties were classied by the US Department of Health and Human Services as medically underserved or had medically underserved populations. West Virginia has 57 hospitals, 11 of which have cancer programs approved by the Commission on Cancer. In addition, there are 18 freestanding cancer diagnostic and treatment centres and 7 day surgery centres. WVCR performs computerised edits on all data and visual editing on a minimum of 10% of cases from each reporter. Additional data quality studies are performed as indicated by the results of the computerised and visual edits. Hospitals undergo case-nding and re-abstracting audits every ve years but may be audited more frequently if systematic problems are found. To maintain quality control, formal studies/evaluations are carried out. West Virginia Cancer Registry data are submitted to NAACCR for evaluation of completeness and quality, and also undergo regular audit by NPCR.




























Interpreting the results West Virginia is known to have relatively high levels of cancer risk factors including tobacco use and obesity in comparison to the US, screening rates USA, WEST VIRGINIA (1998-2002) for breast and cervical USA, WEST VIRGINIA (1998-2002) cancer similar to those of the US and colonoscopy and sigmoidoscopy rates lower than those of the US. BRFSS  






data indicate that PSA testing 




levels in West Virginia are 








similar to those in the US as 




a whole. 


















 

Use of the data The West Virginia Cancer 







Registry publishes an annual 














report on cancer incidence and 






mortality in West Virginia, Registry structure and 








 





conducts investigations of methods 







possible cancer clusters, The West Virginia Cancer performs analyses as needed Registry is part of the West       for special projects, promotes Virginia Department of Health .*', !.*', the use of WVCR data in and Human Resources, Bureau 


0/1.(0/...  planning and evaluation of for Public Health, Ofce of 
   #. #..
. 3.
.!."..)&&&... $.. cancer control activities and Epidemiology and Health .(..

.!.".#.

...." .4 .!. . !.. .!
4 . ...)&&&... $. 
2%%$ $ $%

$. Promotion, Division of Surveillance and Disease Control and makes de-identied data available to approved researchers.  



 is funded by the State of West 
. .*)&&+,.. -..
 . Virginia and the US Centers for Disease Control and Preventions National Program of Source of population Cancer Registries (NPCR). WVCR has 10 full-time staff July 1 county population estimates by age, sex, race, and including 4 cancer surveillance staff, 3 data quality staff, a Hispanic origin; postcensal estimates based on 2000 United programmer analyst, an epidemiologist/program director and States Census. The an administrative professional. WVCR receives electronic population data include the bridged singlerace estimates reports from hospitals with cancer registries and provides derived from the original multiplerace categories in the abstracting services to other hospitals as well as free-standing 2000 United States Census. diagnostic and treatment facilities, day surgery centres and http://www.seer.cancer.gov/popdata. large urology and dermatology practices. WVCR also receives pathology reports and conducts annual linkages with death Multiple primary rules used IACR rules (2004) on CI5 IX period. certicates. Cancer is reportable by law in West Virginia.

207

North America

USA, Wisconsin
Registration area The Wisconsin Cancer Reporting System (WCRS) covers the statewide population of Wisconsin, USA. The population at the most recent census (2000) was 5 363 675. About 89% of the population is white, 6% African American, 1% American Indian or Native Alaskan, 2% Asian/Pacic Islander and 1% multiple race. Almost 4% are of Hispanic origin. reported and identify cases not previously reported by the above mentioned sources. Follow up is conducted on the death certicate only cases annually. Cancer is a reportable disease in Wisconsin per Chapter 255.04, Wisconsin statutes. Data submitted to WCRS is processed through a combination of NPCR-required and recommended edits and Wisconsin-specic edits. All cases are edited electronically, and the incoming paper reports are also reviewed manually. WCRS participates annually in the NAACCR Certication Process and has received the Silver or Gold standard for its data every year since 1995. Wisconsin incidence rates overall remain stable but can be inuenced by periodic reporting anomalies (e.g. a facility loses cancer reporter and cannot submit for extended period) or inconsistent reporting on residents seen outside of Wisconsin for diagnosis and/or care.

Cancer care facilities Wisconsin has approximately 150 hospitals and over 1700 clinics (including radiation therapy centres, health maintenance organisation outpatient clinics and private physician ofces) serving its population. Residents living near Interpreting the results state borders may cross into other states for their cancer diagnoses and care depending USA, WISCONSIN (1998-2002) on proximity to the out-ofUSA, WISCONSIN (1998-2002) state facilities and restrictions based on insurance coverage.

Registry structure and 



 









methods 






WCRS is located within the 














Bureau of Health Information 







Use of the data and Policy, Wisconsin 














WCRS data are published in Department of Health and 




 


an annual report (incidence Family Services. It is funded 














and mortality rates by site, partly by general purpose 







diagnosis year, race and revenue funds (25%) and by 














county, stage at diagnosis). the US Centers for Disease 




 


Special site-specic reports are Control and Prevention 




 


 






periodically produced. Data through the National Program 







are used by researchers for of Cancer Registries (NPCR) case control studies, linkage (75%). The registry has six       studies, and extensively by full-time staff: a program /*', !/*', comprehensive cancer control director, epidemiologist, CTR 



)/.-(/0&&///  organisations for planning and data editor and state trainer, 
   #/ #//
/ 2/
/!/"//)&&&/// $// prevention strategies. quality control data and GIS /(//

/!/"/#/

////" /3 /!/ / !// /!
3 / ///)&&&/// $/ 
1%%$ $ $%

$/ analyst, data processor, ofce operations assistant and a part  



 
/ /*)&&+,// -//
 / time data entry staff person. WCRS collects data (passive Source of population data collection) from Wisconsin hospitals, clinics, physician July 1 county population estimates by age, sex, race, and ofces and out-of-state hospitals along state borders. These Hispanic origin; postcensal estimates based on 2000 United facilities are required to submit data electronically using States Census. The population data include the bridged the NAACCR standard layout or on paper using the WCRS singlerace estimates derived from the original multiplerace reporting form. Wisconsin also has data exchange agreements categories in the 2000 United States Census. with 19 other state central cancer registries, and receives http://www.seer.cancer.gov/popdata. data on Wisconsin residents from those registries annually. WCRS conducts an annual link with the Wisconsin Resident Multiple primary rules used Death File to update death information on cases previously IACR rules (2004) on CI5 IX period.

208

Asia

China

India

Japan and Republic of Korea

South-East Asia

Asia

Bahrain
a specially designed registration form, and entered and Registration area The Kingdom of Bahrain is located centrally on the southern checked for duplication and consistency using CANREG shores of the Arabian Gulf, and comprises an archipelago IV. Coding anatomical sites and morphology of tumours is with a total area of 717.5 km2. Bahrain Island is the largest according to the ICD-O-3. In addition to passive notication, case nding is enhanced of these islands, accounting for nearly 83% of the total area by several approaches. Clinical records of cancer patients of the kingdom and the capital, Manama. According to the 2001 census, the total population of admitted to SMC, the main source of cases, are sorted out Bahrain was 650 604 persons of whom 405 667 (62.4%) at the Medical Record Department (MRD) upon discharge and checked for their registration status. The registrar visits were Bahraini, and 244 937 non-Bahraini. The growth rate between the 1991 and 2001 censuses was the BDF Hospital periodically to review and identify lists of 2.7% for the total population, 2.5% for the Bahraini and 3.1% newly diagnosed cases. The registry also receives regular cancer death notications for non-Bahraini. The ve-year average estimated mid-year population for 19982002 was 638 033 of whom 398 455 from the Birth and Death Registration Ofce at the Ministry of Health. Death cases are cross(62.5%) were Bahraini and 239 matched with the registered 578 (37.5%) non-Bahraini. The cases to sort out the unmatched majority of the non-Bahraini BAHRAIN: BAHRAINI (1998-2002) cases, which are then followed population (69.2%) are males, BAHRAIN: BAHRAINI (1998-2002) back for any information on who form the major part of the their malignancy and date workforce. This population is of diagnosis. Those with characterised by a very rapid insufcient clinical information turnover during the year, and or information not indicative of their transitional nature could "*#+*** +') "*"!,*** cancer are registered as Death affect the interpretation of "*!((*** + "*!+"*** "*(,'*** (' "*-%(*** Certicate Only (DCO) cases. cancer occurrence. #*+-%*** ( %*!*** Using the check program, %*!+#*** '' %*#"!*** (*##,*** ' '*%!#*** data are examined for Cancer care facilities ,*-%,*** %' ,*'!#*** duplicate registration as well The government provides !!*#+,*** % !"*!,%*** !#*((*** #' !%*+*** as for illogical errors in the high-standard comprehensive !#*+,%*** # !%*'!(*** combinations of variables such health care to residents, !'*",+*** "' !'*"!*** !-*"%#*** " !,*#"+*** as site-sex, site-morphology including public health, ""*!%'*** !' "!*'*** and age-morphology. Data are primary, secondary and "%*,'(*** ! "#*'%"*** "'*%#%*** ' "%*+++*** also examined for illogical tertiary care services. Primary "%*+-"***  "#*(%+*** combinations that cannot be healthcare is delivered captured by CANREG, such through 22 well-equipped ! '   ' ! as morphology versus basis health centres distributed *$ & *$ & of diagnosis (e.g. leukaemia), in all geographic regions. !-+*%"*** "!*'#***  behaviour versus stage codes Secondary care is provided 
   (for in-situ), basis of diagnosis through the main government *
***"!** * ** hospital, Salmaniya Medical  



 Complex (SMC), recently versus status codes (for DCO) and morphology versus 
**$"%&** '**
* expanded to house the new Oncology Services Centre stage. Cases in which diagnosis was based on histology of equipped with the latest diagnostic and treatment technology metastasis (secondary site) are reviewed to ensure that the including chemotherapy, radiotherapy, immunotherapy and depicted site is for the suggested primary tumour. Missing data on date of birth are replaced by the rst bone marrow transplant. The Royal Medical Services Hospital of the Bahrain two digits of the Central Population Register (CPR) number, Defense Force (BDF) is the second general secondary which represents the year of birth. In this case the rst day hospital, primarily serving Ministry of Defense employees of January is designated to complete the full date of birth. and their families. Secondary care is also provided by six Missing data for unknown primary site (PSU) and other other private hospitals. Together, the government and private variables are sought and recorded when found. hospitals have a capacity of around 2000 beds and ratios of Interpreting the results 22 doctors and 50 nurses per 10 000 population. Underreporting is expected especially for patients who might have sought treatment in private hospitals or abroad. Registry structure and methods The Bahrain Cancer Registry (BCR) is a population-based However, Bahrain is a small country, and free cancer registry covering all residents in the country. Per ministerial treatment facilities, especially radiotherapy, are located in decree 5/1994 cancer became notiable to the Cancer one public hospital (SMC) providing good opportunity for Registry Ofce, part of the Medical Review Ofce of the capturing cases not known to the registry. Those seeking Ministry of Health. The registry is operated by a part-time treatment abroad may eventually come to the SMC for epidemiologist and a part-time medical records technician further treatment or follow-up, or will be captured by the national and well established death register. The CANREG working as a tumour registrar. Cases are registered as having a malignant disease in software has limitations in morphology descriptions of nonthe BCR whether microscopically or clinically diagnosed. invasive cancer (e.g. in situ or non-inltrating intraductal Personal, clinical and tumour details are collected using carcinoma); however, these can be identied by behaviour

214

Asia

and stage codes. The problems of duplication and unknown age in Bahrain is minimal because of the unique identication number (the CPR number) that is assigned for each resident. Use of the data The registry produces regular statistical reports that show the distribution of different types of cancer according to age, gender and nationality. These reports are being utilised by health planners and policymakers to address the importance

of cancer problem, allocate resources and to evaluate cancer prevention and control activities. Source of population Medium projections based on the 2001 census. Central Informatics Organization. Multiple primary rules used IACR rules (2004) on CI5 IX period.

215

Asia

China, Guangzhou City

Registration area Guangzhou is the largest city in southern part of China, with a population of about 7.25 million and an area of 7434.4 km2. It is the capital of Guangdong province and is situated at latitude 22N and longitude 112E. The Guangzhou Cancer Registry covers the population of seven districts (central urban area) within Guangzhou city with an area of 1335.3 km2. The population was 3 560 810 in 2000, with people of the Han race making up more than 99%. by the Guangzhou Health Bureau as a part of the medical quality control service in each hospital. The registry staff also periodically goes to review the patient records in all hospitals that are located in registry area in order to control report quality. The registry staff check, code and le the cards according to year, sex, usual residence, ICD code, etc. Then the registry staff determines whether a patient has already been reported to the registry, so as to avoid duplication.

Interpreting the results Guangzhou has a full range of diagnostic facilities, so that it Cancer care facilities The Cancer Centre in Sun Yat-sen University is one of is unlikely that cases referred will be missed. Screening service for cancer the largest cancer centres was not operated in Guangzhou in China. It has more than in the period 20002002. PSA 1000 beds and employs 1300 CHINA, GUANGZHOU (2000-2002) testing is not common in our people. More than 40% of the CHINA, GUANGZHOU (2000-2002) population, being only carried cancer patients in Guangzhou out in urology departments of are diagnosed and treated in some hospitals. the centre. There are national, provincial, municipal $+."-+++ -(* "#+$"$+++ .+ ,+++ -  ",+)((+++ Use of the data and district hospitals in # +-(,+++ ,( $ +$&-+++ Cancer incidence and Guangzhou, which provide $&+.,-+++ ,  &#+,)$+++ ("+,.)+++ )( (,+).(+++ mortality data are provided to radiotherapy, cancer surgery ,"+&##+++ )  , +).)+++ the Guangzhou government and chemotherapy services -$+#-"+++ (( -)+"-#+++ .,+#,)+++ (  .#+,")+++ as a reference for planning for cancer patients. " #+& (+++ &( ..+)#,+++ projects in cancer prevention "$#+,-)+++ &  "#$+- &+++ ",$+(((+++ $( ")"+&,$+++ and control. The registry Registry structure and "-#+&-(+++ $  ", +##.+++ has also carried out some methods ".-+)- +++ #( ",$+,,"+++ ",.+$#-+++ #  "&$+)#$+++ epidemiological studies based The registry is located within ")&+.)"+++ "( "&"+&,,+++ on the data from Guangzhou. the Cancer Center, Sun Yat"".+#&$+++ "  " .+&(#+++ "#,+ #&+++ ( ""(+((,+++ sen University and is funded "" +".)+++  .(+)-"+++ Source of population partly by the cancer centre Projections based on 2000 and partly by the Guangzhou " ( ( " census. Health Bureau. There are 7  +%!'   +%!' "+,&(+ )$+++ "+-)$+".-+++  registrars in the registry. Multiple primary rules used Physicians and medical  
 IACR rules (1990). clerks in the hospitals of the   + ++# + +  
   registry area are responsible for lling 
+  +%".. '+ out a report card for each newly diagnosed cancer    patient. Each hospital has a Notes on the data  + +  ++ + + + ++ +  +
+  +/+ + +(+%  '+ special department to collect, check and send the cards to The Editors recommend that some care be taken in the the registry on time. The quality of this work is checked interpretation of these data; see Chapter 5 (Categorisation).

216

Asia

China, Hong Kong

Registration area Situated in the south-eastern part of China, Hong Kong is one of the most densely populated places in the world with an average population density of 6,140 persons per km2. The population was about 6.78 million in mid-2004. About 93% are Chinese, mostly descendents from people of the Guangdong Province in southern China. Hong Kong Cancer Registry covers the entire population of the area. years. Death certicate only percentage (DCO%) is the other indicator. Our completeness in data collection is illustrated by the very low DCO% of 1.5% in 2003 against 7.6% in 1990. The only organised mass screening programme (by Health authorities) is cervical cancer screening; PSA testing is not common in the population covered.

Expanding the scope of data collection Information Technology in Hospital Authority (HA) has Cancer care facilities The Hospital Authority (HA) is a statutory body to manage contributed signicantly to the Registry in recent years. The all public hospitals in Hong Kong. Clinical Oncology is a Registry was linked up with the Electronic Patient Record discipline of medicine that manages cancer patients by (ePR) System of HA in 2004. Since then, the registry has been able to collect histological data non-surgical means such as and staging information more radiotherapy, chemotherapy, comprehensively and easily. biological therapy and CHINA, HONG KONG (1998-2002) On the other hand, death palliative care. There are CHINA, HONG KONG (1998-2002) data are collected from currently six Clinical the Death Registry of the Oncology centres in the Government. Previously death Hospital Authority. A few records other than cancer private hospitals also provide 


 









were not available to the similar services. 







registry because of legislative 














restrictions. The individual Registry structure and 







case record obtained was methods 














anonymous and without The Registry is an ofcial 







the unique identity number. and professional body 














Therefore survival analysis for population-based 







has not been part of the output data collection in cancer 













of the registry. Since 2000 the epidemiology. It is currently 







death data has been linked run by one statistical 











 


with the Registry data, which analyst and four clerks in 






helps minimise loss of patients the Department of Clinical to follow-up. The Registry can Oncology of Queen Elizabeth       thus target compilation of a Hospital, Hospital Authority.  *&!(   *&!( population-based survival The director is a specialist in 



%*$+ *)' ***  analysis in the near future. Clinical Oncology who, apart  
 *$ $.*0
*  * *
* *  /* *#**
 *$ "** ** *
* from overseeing operations, "--,0$  *  /* *#**
 * Use of the data provides regular input on the validity of clinical data.  
    **  * *
* The Registry obtains data through electronic means The Registry updates annual reports of cancer incidence and    ** 
*
*
0-*%* *  *  * * directly from clinical oncology centres, pathology mortality in electronic format on its website. Basic descriptive laboratories and hospital discharge summaries of all public epidemiological analyses are included. Registry data are hospitals. For the private sector, the Registry has had a good routinely used by ofcials, health professionals, cancer control working relationship with most cancer centres and pathology groups and the public. The data are also extensively used by laboratories over the years. Near-complete coverage can be local researchers for various epidemiological studies. achieved within the territory. Voluntary notication nowadays contributes very little to the data pool. Death certicates are Source of population 19982000, 2002: Midyear estimate produced by the obtained from the Department of Health. Cancer notication is by administrative order without a specic Governments Census & Statistics Department. law in Hong Kong. The privacy of the cancer patient and the use of 2001: Population Census data produced by the Governments the related information are protected by the Governments Personal Census & Statistics Department. Data (Privacy) Ordinance. There is no personal contact with cases Multiple primary rules used or patient follow-up by the registry staff. The Registry evaluates the quality of incoming and output Impossible to detect multiple primaries. data using both automatic and manual review processes. Histological verication percentage (HV%) is one of the two Notes on the data internationally accepted indicators of data quality in cancer For this registry, only ICD9 3 digit categories were registries, and we achieved over 85% conrmation in recent available.

217

Asia

China, Jiashan
Registration area Jiashan County is located in the north of Zhejiang province, near Shanghai City. It is at latitude 30 N and longitude 120 E. The area of Jiashan County is about 506.6 km2; 14.3% of the county is covered by rivers and lakes. The average annual temperature is around 16 C. Jiashan County is covered by atlands with a network of waterways. About 80% of the population lives in rural areas. Population density in the county is 751 persons per km2. Agriculture is a major industry, and the main crops are rice, wheat and broad beans. The county once had a serious schistosomiasis epidemic, but the disease was eradicated in 1985. Cancer accounted for 23.8% of all deaths in 1997. Cancer care facilities There were 24 medical establishments, 1296 medical workers and 1135 hospital beds in the county at the end of 1997. in the rural area hospitals collect cancer cases in each village and lling in report cards. All the cards are sent to the cancer registry. After receiving the report cards, the doctors in the cancer registry check details by phone or by going to the source. Multiple cards on the same patient are merged, and cards for non-resident patients are removed. Physicians working in the cancer registry visit the medical establishments several times a year and inspect the reporting of cancer cases to assess quality and completeness. A meeting is held at the end of every year, with ofcers of the county health bureau, to discuss problems encountered in order to improve quality. In 1991, two computers were purchased. Software for vital statistics and cancer reporting, produced by the Sanitary and Anti-Epidemic Station of Liaoning Province and recommended by the National CHINA, JIASHAN (1998-2002) Cancer Research and Control CHINA, JIASHAN (1998-2002) Ofce, was adopted. Use of the data Data on cancer incidence, prevalence and mortality by sex, age and site are used in cancer prevention and treatment and for research into etiology.












 




 

















Registry structure and 







methods 













A population-based cancer 






registry was established 














Source of population in Jiashan County in 1987, 





 

The sex and age distribution according to documents of the 

 












of the population 19981999 Jiashan County Government







was estimated by interpolation and Health Bureau on 














based the sex and age reporting cancer incidence







distributions of the 1990 and and mortality, and mortality 2000 census populations. The from all causes. It is attached       
($!% 

($!% sex and age distribution of the to the Jiashan Institute of 


"*"('#'(((  population 20012002 was Cancer Research. estimated by extrapolation In accordance with  
 (( based on the sex and age Jiashan County Health Bureau 
(
((
( ((
(  ("**),"***((

((
(
((
(
((
( ((
("** # (
(  (
(
((
( ((
(  (# ",# #((

((
  (
(((
(
((
(  ((# (
(  ( regulations, all medical establishments, whether hospital or distribution of the 2000 census population.  
   clinic, must report new cases of
( 
($# cancer%(((diagnosed, including    
( (

((
(
(
(
((
(

((

(+(

( 
(&($
 %( benign tumours of the central nervous system, and cause of Multiple primary rules used IACR rules (2000). death for all diseases. Physicians in healthcare departments of medical establishments in the county towns are charged with collecting Notes on the data report cards on cancer, which are completed by doctors in each The Editors recommend that some care be taken in the ward and diagnostic service. Doctors of preventive medicine interpretation of these data; see Chapter 5 (Categorisation).

218

Asia

China, Nangang District, Harbin City

Registration area Nangang district, located in the centre of Harbin, is the largest canton in Harbin and borders on the Daoli, Daowai, Xiangfang, Dongli and Pingfang districts. It lies within longitude 12542 and 13010W, and latitude 4404 and 4640N. It has a temperate zone continent/trade wind climate, with an average monthly rainfall of 3868mm and average annual humidity of 65%. The total area of the district is 182.87 km2, including an urban area of 60 km2, which is one third of the total area of Harbin. The population of Nangang is 1 001 377 persons, of which 90% are Han. The rural/urban breakdown is 61 146 and 940 231 persons respectively. area, pinyin and kinds of diseases and after coordination and elimination; they are coded according to the international disease classication ICD-10 and reserved in the tumour cards tank. Computers manage and analyse the data, and all tasks of the registry ofce are now computerised.

Use of the data Data accumulated through the years have been used in epidemiological research, cancer trend prediction and research on cancer control policies and counter-measures. Since the tumour reporting system was established in 1997, we have accumulated malignant tumour occurrence and death data from 1990 to 2001 in Nangang district. These data play a vital role in tumour prevention and Cancer care facilities treatment as well as scientic The following diagnostic CHINA, NANGANG DISTRICT, HARBIN CITY research, and have been used facilities are available in (1998-2002) CHINA, NANGANG DISTRICT, HARBIN CITY (1998-2002) in 10 articles published in the area: clinical, surgical, China Fundamental Medical pathology, radioactive x-ray, Care, Public Hygiene and supravital, CT scan, bone Management of China Public marrow aspiration and autopsy. ##" "  !  # "  ! Hygiene. In the framework of Chemotherapy, radiotherapy,  ! !  !" the Ninety-Five National surgery, Chinese medical # #"" ! # #      Science and Technology science and immunization are ! !    Innovation Programme, we the treatments available to the  #  " !#  "   ## have submitted basic and community.  "   ! statistical data of tumour       #    registration reports to some Registry structure and    ! ! relevant faculties. Malignant methods       #   # tumour occurrence and The Harbin cancer registry  #"   ! death data from 1990 and ofce was established in  "#   " #   ! !! 1992 were published in the 1997, comprising the people  !!   # book The Occurrence and of Nangang district, which Death of Malignant Tumor in includes 18 community ofces       Experimental Cities in China. in 3 counties and 1 town. It is 
 
 Data on tumour occurrence located in the chronic faculty " ""    and death during 1993 and of the Nangang disease 1997 in Nangang district have prevention and control centre, 
  


 

     
with the supervision of the Nangang board of health. The been constantly used by Malignant Tumor Occurrence and ofce is in charge of the registration and reporting of newly Death (93-97 volume) of 11 experimental cities around the acquired malignant tumours and carcinoids of the central country; occurrence and death data during 1998 and 2002 nervous system among permanent residents in the district. have been used in the compiled book of volume. The data The administrative obligatory report system is used in the are an important component of the project The Research of Common Malignant Tumor Occurrence, Death and ofce. The ofce now has 2 full-time and part-time clerks. All personnel providing health care at all levels in Harbin Dangerous Factors Monitoring Method, which is the product are required to complete a report card and submit it to the of many years of hard work; it will be of vital importance supervising epidemic prevention station if they diagnose a in future cancer control projects, hygiene projects, hygiene malignant tumour. Malignant tumour death reports are to be cause planning, and investigations of cancer prevalence. It is believed that with time, these data can play more submitted with data on the cause of death. All healthcare personnel are also required to complete important roles. With support from health policy leaders at the death report card as well as the medical certicate of various levels, and with continued effort from the staff, the death. At present, follow-up visits are limited to tumour death Nangang tumour registry ofce can be expected to achieve cases, and family doctors in the community health service greater coverage and completeness, and will contribute richer centre complete the tumour follow-up table. This measure has and more accurate data for cancer prevention and control in been in place for three years. The Nangang district includes the future. 1 tumour professional hospital, 6 large polyclinics, and 109 medical units in 23 medium-sized polyclinics. The tumour Multiple primary rules used report cards are catalogued according to administrative Impossible to detect multiple primaries.

219

Asia

China, Shanghai
Registration area Shanghai is situated on the east coast of China at 3114 N latitude and 12129 E longitude. The total area of Shanghai Municipality is 6340.5 km2. There are about 13.52 million inhabitants in the municipality. The registration area during 19982002 covered nine urban districts with an area of about 289.4 km2 and 6.19 million inhabitants, 99.1% of whom are Han Chinese. Ninety-ve percent of the population are nonreligious; the other 5% are Buddhists, Taoists, Islamites and Christians. Most of the population is immigrants from all over China, mainly from neighbouring Zhe Jiang and Jiang Su Provinces. Cancer care facilities Shanghai has a 3-level general health care network, including more than 400 hospitals and community health service centres. The rst-level facilities are all the community health service centres providing predominantly primary health care. The secondlevel facilities are the district hospitals, most of which have a Cancer Department. The third-level facilities are all the municipal hospitals and the Shanghai Cancer Hospital. Most of the second- and third-level facilities provide radiotherapy, cancer surgery and chemotherapy services. notication card, which includes demographic information, cancer site, date and basis of cancer diagnosis, is used for reporting cancer cases. The notications are sent to the cancer registry and led according to the name of the patient and administrative district of residence. Home visits are carried out for every case to conrm if the cancer patient is a permanent resident. All patients residing outside the registration area are deleted from the cancer registry. Data on cancer notication cards are computerised using specially-designed computer software that directly reads Chinese characters. Cards with similar contents are examined by registry staff and duplicates are deleted. Death certicates for all cancer patients are obtained monthly from the Vital Statistics Section of the Shanghai Municipal Center CHINA, SHANGHAI (1998-2002) for Disease Control and CHINA, SHANGHAI (1998-2002) Prevention and collated with the le of new cases kept in the registry. If the deceased was not registered prior 0+&1.)1,... 0#! +%.,1/... to death, the registry staff /+! 1'.01%... interviews the relatives of the /#! %'+.+1,... ,+! %,+.,10... case to obtain information on ,#! %&1.,1#... the hospital where the case ++! %&#.'',... +#! %1'.1,,... was diagnosed and treated, )+! '%#.#,1... date and basis of cancer )#! ',+.+1,... '+! &,1.+10... diagnosis. '#! %1,./,#...
&+! &#! %+! %1).0#&... &%1.1)+... &+1.'++... %1%.'1,... %#!

%,.#%'... '+./&+... /&.)0'... %%%.&'%... %'1./&&... %%/./,,... %&).&&#... &%'.'1%... ''+.%0&... '0+.'%,... &1,.'&,... &&/./&1... &&%.&#)... &)).,)1... &,&./)#...

Interpreting the results For a long time the Registry %#,.&,1... +! %#&./%,... collected information on /+.1%+... #! /#.0'%... new cancer cases only in the urban area, and in suburban %# + # # + %# 
.($* 

.($* and rural areas of Shanghai Registry structure and '.%#%.)'1... '.%0&.0/)...  collected information only on methods cancer deaths. The urban area Organisation of the Shanghai  
 .%1112.

..
.
..
. ..
.  ..
.%11,..&###.
.".&###2.
".&##% .&##&2. expanded from 159 km2 to Cancer Registry is now based %110   
..
.
..
. ..
.  ..&###.
". 2  
   upon a 3-level network of disease prevention and control. 289 km over the past 30 years, and the population increased 
. 
.(%11#*. The rst level is the Registry of   Shanghai CDC. The staff of from about 5.7 million to 6.3 million. 
. .

..
.
.
.
..
.

..

.3.

. 
.+.(
 *". .
 ..
.
..
. 
..
.  ". this level consists of 2 senior and 3 junior epidemiologists, In the past 30 years the number of hospitals responsible 2 statisticians and 1 assistant statistician. The second level for cancer cases increased from 117 to 175 in Shanghai. consists of CDCs in 19 districts. In each district CDC, 12 Shanghai is one of the areas with the highest level of cancer epidemiologists and 1 assistant are responsible for cancer diagnosis and treatment in China. Almost all of the cancer registration. The third level consists of 207 community patients in urban area covered by our Registry are diagnosed health service centres. There are 12 workers responsible for and treated in those hospitals. home visit and data checking; most of them are community A mass screening programme on cervical cancer with GPs. Pap smear examination began in urban Shanghai in the late Shanghai Cancer Registry is a population-based cancer 1950s. All employed women have a Pap smear every 2 years, registry that collects, analyses and disseminates information provided by local maternal hospitals and paid for by both the on cancer incidence, mortality and survival in the Shanghai government and the employer. Almost all of the hospitals in urban area. The registry was established and started operating Shanghai can provide PSA testing when necessary, but there in 1963. The registry became essentially population-based is no mass PSA testing programme screening for prostate by 1972, and complete incidence and mortality data for the cancer. urban area in Shanghai Municipality are available from 1973 The anatomic sites of cancer cases were coded using both onward. The registry was operated by the Shanghai Cancer ICD-9 and ICD-10 from 1998 to 2001 and using only ICD-10 Institute before 2002, when it moved to Shanghai Municipal since 2002. The histology and behaviour have been coded Centre for Disease Control and Prevention. using ICD-O-2 since 2002. All second- and third-level medical facilities (about 170 units) in Shanghai are responsible for notifying all newly Use of the data diagnosed cancer cases and cases of benign tumours of The registry provides a Shanghai Cancer Report annually the central nervous system to the registry. A standardised to the government, institutes and hospitals. The report
%1,.11&...

220

Asia

helps to establish cancer prevention plan and policy. The report also provides basic cancer information to support community cancer control and prevention activities, such as community-based cancer patient care services. More than 20 casecontrol and cohort studies have been conducted in the past 30 years using Shanghai Cancer Registry data. Source of population 1998, 1999: Interpolated by the sex and age distribution of the population of the 1996 and 2000 census data. 2000: census.

2001, 2002: Extrapolated by the sex and age distribution of the population in the 2000 census. Multiple primary rules used IACR rules (1990). Notes on the data The Editors recommend that some care be taken in the interpretation of these data; see Chapter 5 (Categorisation). This registry has the lowest histological verication rate in the monograph.

221

Asia

China, Zhongshan
Interpreting the results Theoretically all cancer data should be reported to Zhongshan cancer registry if all cancer patients go to hospitals for diagnosis and treatment. But some patients do not want it known they are ill with cancer, and use a false address or name; these patients are very often missed. Some foreign cancer patients use the local address when asked to provide their place of residence, which results in the cancer patient being mistakenly identied as a native cancer Cancer care facilities The city hygiene bureau, through all kinds of hospitals, clinics patient. As Zhongshan is one of the areas with high incidence and the CDC, provides health care in Zhongshan. Private practitioners are relatively few in the region. Although there are of and mortality from nasopharyngeal cancer in China, in not any independent cancer centres or hospitals in Zhonghsan, 1986 we screened more than 42 000 natives aged 2565 in 16 of 34 towns in Zhongshan several large comprehensive using EBV VCA/IGA and hospit a ls have ca nc er EA/IGA immuno-enzyme departments that provide surgery CHINA, ZHONGSHAN (1998-2002) serological tests; most of and chemotherapy service CHINA, ZHONGSHAN (1998-2002) them were followed up until for cancer patients. Only the 2000. Municipal Peoples Hospital has PSA testing is part of radiotherapy facilities, to which routine hospital checkups, all cancer patients in Zhongshan $,#!/,,, .)+ ),#-',,, ',#.),,, .! -,#.),,, and almost every hospital in are referred when radiotherapy is .,'%#,,, -) #$,$*#,,, Zhongshan provides it. necessary. For differing reasons, #%,/$!,,, -! #),--%,,, #-,*)',,, *) #.,%/.,,, Before 1990, liver some cancer patients will go to $!,!.#,,, *! #/,%$#,,, trematode disease, cirrhosis hospitals of neighbouring cities $!,''*,,, )) $!,%#%,,, %',/-*,,, )! %',).!,,, and bile duct cancer were very such as Guangzhou for diagnosis '-,)#%,,, ') '*,%$!,,, common in Zhongshan due to or treatment. '),-#-,,, '! '%,-).,,, )-,#-),,, %) )*,.)*,,, special sh breeding methods *$,!!!,,, %! *),*)),,, and the local diet that includes Registry structure and )-,..*,,, $) *#,*%.,,, '),#.-,,, $! '),'-),,, uncooked sh meat. Since then methods )$,-$%,,, #) '/,#*.,,, sh breeding methods and the The Zhongshan cancer registry *-,*//,,, #! *$,$$-,,, ).,)$/,,, ) )#,./%,,, habit of eating uncooked sh is afliated with Zhongshan )!,.#.,,, ! '$,*.!,,, meat have changed, and the Peoples Hospital, and is incidence of those diseases funded by the hospital and #! ) ! ! ) #! 
,&"( 

,&"( decreased greatly. In recent the municipal and provincial *).,*-$,,, **-,!)#,,,  years, with the progression of health departments. One fullindustrialisation, urbanisation time medical ofcer and two  
 and heavy transportation, full-time registrars staff the 
,
,1 ,  ,,$!!!,,
,,
 ,
,  ,,,

, ,  
   
,
,&#//!(, registry. Each hospital in Zhongshan has a part-time registrar environmental pollution has worsened, which may inuence cancer incidence and mortality in Zhongshan. to help collect cancer data and    to follow up cancer patients. 
, ,

,,
,
,
,
,,
,
 
,,

,0,

, 
,),&
( , Passive and active registration methods are used in Zhongshan cancer registry. The active case nding method is Use of the data the major means of nding new cancer cases, as more and more The registry prepares an annual report of cancer incidence, highlighting trends and changes. Some special studies of doctors do not notify cancer cases on their own initiative. The registrars identify cancer cases from all possible survival of registered cancer cases (nasopharyngeal and lung sources, such as medical record departments, pathology cancer) have been carried out, and we are now collaborating departments, bone marrow test laboratories, radiotherapy with Queen Mary Hospital of Hong Kong to explore new departments, the death registry, etc. All cancer data are serological screening tests of nasopharyngeal carcinoma. collected and sent to Zhongshan cancer registry, where an Zhongshan policymakers are paying increased attention to experienced registrar rst checks the data to see if it is a health problems, and refer to our cancer registry data when duplicate case, is missing any important items or has any making health policy. logic mistakes. If everything is acceptable, the cancer data are coded and entered on computer for storage and analysis, Source of population and the notifying card is stored in the data room. If not, the The age group proportion of 2000 was obtained through data are traced back to correct or complete the faulty or census. Other population data were estimated accordingly. missed information. Arrangements are also made with the hospitals outside Multiple primary rules used the registration area to notify the registry of any resident IACR rules (1990). cancer cases that they diagnosed or treat; they are visited once a year to review these procedures. Data are evaluated Notes on the data according to the IARC and the Cancer Prevention and The Editors recommend that some care be taken in the interpretation of these data; see Chapter 5 (Categorisation). Treatment Ofce of China rules. Registration area Located at the mid-southern part of Canton in the hinterland of the Pearl River delta, the Zhongshan cancer registry covers 1683 km2 and includes the population of 24 towns and districts. In 2000, the population of Zhongshan was 1 360 302, about 45% of whom lived in urban areas. Most Zhongshan residents practice Buddhism, Daoism, or Christianity.

222

Asia

Cyprus
Registration area The Cyprus Cancer Registry covers the population of ve districts (Nicosia, Limassol, Larnaka, Paphos and Famagusta). The population in the government-controlled areas was 715 100 in 2002. Cancer care facilities General health care in Cyprus is provided by both the Ministry of Health through the district hospitals and the primary health care centres and through the private sector. The Bank of Cyprus Oncology Center, a non-prot organisation funded by the Government provides healthcare services to cancer patients. The services provided at the oncology centre include radiotherapy, chemotherapy and hormonotherapy. death registration system is inadequate and incomplete for the time being. A restructuring of the death registration system is currently underway. The registry staff visits all sources and scrutinises the records kept in the medical records departments and registers of individual departments concerned with diagnosis and treatment of cancers, in order to identify and abstract information on cases of cancer diagnosed by all methods among residents of the registry coverage area. Cancer is not currently a notiable disease in Cyprus.

Registry structure and methods The Registry is co-funded by the Ministry of Health and the Middle East Cancer *)'))) Consortium (MECC). Its main ')+'))) ofces are located within the ,)"$))) )''))) Ministry of Health. It comes $)$$))) under the supervision of the *)$))) !)''))) Chief Health Ofcer and it !!)'!))) $& !")$))) is staffed by three full-time !&)$+))) $ !&),$))) !&)''))) "& !*)$))) Use of the data registrars. !")+'))) " !&),))) The Registry prepares a The Cyprus Cancer !")&))) !& !&)&!))) !&)+$))) ! !')"))) triennial report of cancer Registry (CyCR) uses active !+)*!))) & !*)'))) incidence, highlighting trends case nding from various !+)$)))  !')*$))) !*)'!))) & !') !))) and changes. sources, mainly (a) general !")$$)))  !!)"$))) hospitals in-patient records, Multiple primary rules used and inpatient and outpatient  &   &  IACR rules (2000) facilities in each district, (b)  )#%   )#% "&&)!!))) "$") )))  the bank of Cyprus Oncology Notes on the data Center, (c) the private The Editors recommend that sector hospitals inpatient   
 

 
) )#!%) and outpatient facilities, (d) 
 pathology laboratories, (e) some care be taken in the interpretation of these data; see  ))  )) ) ) ) )) )  )
)  )-) ) )&)# %) haematology laboratories and (f) cytology department. The Chapter 5 (Categorisation).

Interpreting the results Estimation of the completeness and accuracy of data is performed by external quality control group. A breast cancer screening program has CYPRUS (1998-2002) been operating since 2003; CYPRUS (1998-2002) screening is provided by the Ministry of Health free of charge to all women between the ages of 5069. +( )&'))) The data provided in *& +)'!))) Volume IX includes all * )&'))) '& ")&!))) foreigners registered in the ' &)"'))) CyCR, which is not the case && *),$))) & ! ) !))) in our cancer report.

223

Asia

India, Chennai (Madras)

from various departments within a hospital for completeness Registration area The Madras Metropolitan Tumour Registry (MMTR), a of details. Mortality information on all deaths occurring in the population-based cancer registry, was established at the Cancer Institute (WIA) in 1981 in the network of the National city, irrespective of the cause of death stated on the death Cancer Registry Programme (NCRP) of Indian Council of certicate, is collected from the Vital Statistics Division Medical Research, New Delhi, to study patterns and trends (VSD) of the Corporation of Chennai. Management of data has been progressively computerised in cancer incidence and mortality in Chennai City (formerly to minimize the manual work, resulting in the enhancement Madras). Data collection commenced 1st January 1982. The city of Chennai is situated at sea level on the of data quality. Reliability of data and quality of registration Coromandel coast of peninsular India at latitude 13.04 N and are constantly monitored, with emphasis on re-abstraction longitude 80.17oE. The MMTR caters to an area of 170 km2 and coding on a random sample of cases and case nding. and a population (entirely urban) of 4.3 million (957 females Validity checks are done using IARC, NCRP and other into 1000 males) as on 1st March 2001, constituting 0.4% and house developed computer programs. 7.0% of the total population Interpreting the results & of India and the state of use of the data Tamil Nadu respectively. The INDIA, CHENNAI (MADRAS) (1998-2002) The completeness of decadal population growth INDIA, CHENNAI (MADRAS) (1998-2002) registration of cancer cases rate during 19912001 was in MMTR is estimated to be 13.07%, and the population 96%. Cancer information is density was estimated to be 24 disseminated by publishing 964 persons/km2. The literacy periodic reports and rate is 85% (M: 90%; F: 80%) 


 


descriptive epidemiological and the predominantly spoken 














studies on cancer incidence language is Tamil. The 







and mortality highlighting the majority are Hindus (82%) 














trends and patterns. followed by Muslims (9%) and 







MMTR has been the Christians (8%), with the rest 













pioneer in many registrybelonging to other religious  

 





related activities in India: groups (1%). 














systematic trace-back of death 







certicate notications, active Cancer care facilities 




 









follow-up of registered cases, General health care, 







collection of mortality data including cancer diagnostic and survival analysis of top and treatment facilities, is       "!3/*1 %"!3/*1 ten cancers. provided by the government 



-3-).300)333 "! A new registry known health service, the Cancer as the Dindigul Ambilikkai Institute (WIA), which is 
   Cancer Registry, covering a Regional Cancer Centre %"33+6657-)))3,333-))+3,3-))-(3!"3%"3&33"3"33"33$3&33&3 %33$"!3 3"3& 3+66+3,3-))+33!"33
"3(3
33"3+66+(3373
!"!3"&!3 #!(333-.383"%!3 "'3"3#3
373
3(3"33
3 "'3"%!3 "3+664(3
33"3-))+(33"3 "&!33
(3"%!3 "'3
7+03(3"33
3 "'3"%!3 "3-))2(3 in Ministry of Health and Family Welfare, Government a population of 2 million, was started in 2004 to provide  



 of India and supplemented by private practitioners and reliable data on cancer incidence in rural area and to evaluate 

3!3/-))0133
2333 hospitals. The Radiation Oncology division at the Cancer the randomised eld intervention trial on cervix cancer Institute (WIA) is one of the best equipped centres in India. under the auspices of the International Agency for Research Radiation facilities are also available in four Government on Cancer, France. MMTR provides data to the ICMR project on and ve private hospitals. Surgical and Chemotherapeutic services are offered in government and private hospitals and Development of an Atlas of Cancer in India. It is also involved in a population-screening program on cancers of nursing homes. the cervix, breast and oral cavity that is conducted by the Cancer Institute (WIA) in the neighbourhood. Registry structure and methods The MMTR, besides a Principal Investigator, comprises a medical ofcer, two statisticians, a computer programmer, Source of population ten social workers and a data entry operator. Cancer is not a Estimated for 19982000 & projected for 2001 & 2002. notiable disease in India; therefore registration of cases is Population estimates by ve-year age groups according to sex by difference distribution method using exponential growth done actively. The registry continues to enjoy good cooperation from all rate between 1991 & 2001 census populations of Chennai healthcare facilities in and around Chennai, with more than city. Census of India 1991. Socio Cultural Tables Vol. I 225 sources of registration to date: government and private Series 23, Tamil Nadu, Part IV A C Series. Directorate hospitals, nursing homes, clinics, consultants, pathology of Census Operations, Tamil Nadu 1997. Census of India 2001. Report and Tables on Age. Tamil Nadu, C14 Series. laboratories, imaging centres and hospices. The Social Scientists of the registry visit the collaborating Directorate of Census Operations, Tamil Nadu 2005. hospitals regularly and collect data on cancer by interviewing the cases wherever possible and/or medical records. Decient Multiple primary rules used medical records are updated via linkage of data collected IACR rules (2004) on CI5 IX period.

224

Asia

India, Karunagapally
continued with funding from Health Research Foundation, Registration area The Cancer Registry Karunagapally, India is located in the Japan & Local Area Development fund, Government of Kollam District of Kerala, situated around 9 N latitude Kerala. Registry staff includes one Research Ofcer from and 77 E longitude. The area is rural as per census RCC, 6 Field Investigators, 3 Data Processing Assistants and denition; geographically, it is lowlands with backwaters one Statistician. We adopted active cancer case finding method for and coastlines. The Registry area covers 212 km 2 (land area 193 km 2) covering the total taluk of Karunagapally Cancer Registration, as cancer is not a notiable disease with a population density of over 2000/km 2. The coastal here. The eld investigators scrutinise medical records belt of this taluk is known worldwide for its rich deposits of of several hospitals to locate cancer cases. More than rare earth mineral sands containing radioactive materials, 60 sources including Regional Cancer Centre, Medical mainly thorium. About 100 000 people are constantly College Hospital Thiruvananthapuram, District Hospital exposed to this radiation. Population is more or less stable, Kollam and Taluk Hospital and other Government and the majority are agricultural labourers, fishermen, hospitals in Karunagappally are visited regularly. Major pr ivate hospitals in the coir labourers, etc. 99% of registry area and nearby the people live in rural areas Kollam town are also visited and 1% in semi-urban area. INDIA, KARUNAGAPPALLY (1998-2002) regularly for case finding. Births & deaths occurring in INDIA, KARUNAGAPPALLY (1998-2002) Further, records maintained the Panchayats are registered by Pathological laboratories in the respective Panchayat i n Kol la m Dist r ict a nd ofces. Thir uvananthapuram and The three major religions also of the Vital Statistics are Hindus, Christians and 


 


d ivision of t he loca l Muslims. The population at 














pa nchayat s a nd Kol la m the 1991 census was 383 514 





 

Muncipal Cor poration (189 647 males and 193 867 











are scrutinised to locate females). There has been no 

 





cases from the panchayat. change in area or population 














Investigators abstract cancer covered by the registry since 





 

cases d iag nose d by a l l its initiation in 1990. 














methods among residents of 





 

the registry area. Medical Cancer care facilities 














Practitioners give details Health Care Services in 







about t he ca ncer cases Karunagapally taluk is seen in outpatient clinics. provided mainly by State       Systematised eld visits are Health & Family Welfare  +'$)   +'$) 


&#(+-.#+++  done in the registry area to Department through a Taluk locate these cases. Death Headquarters Hospital, 12 
    "+ + + +  + registers are available in Vital Primary Health Centres and +  ++++
"+ +  + +++
+%.-%!+%..%++&##%+  + %..%++&##%+++++,"..$!+++ ++ + + +  +%.-%/%..%+'%#"*-$)"+
+ 
+ ++
+&##%+ ++  +
+ +"+ +%..%/&##%+ + ++ ++ + +
+%..%+  + ++ Division of the panchayats but the information is few sub-centres. There are several Private Hospitals and Statistics + +  + + !+ ++ + ++ ++++&###++  "+  



 not adequate for scientic purposes. We trace back all the Medical Practitioners in the area.   ++  + ++ Regional Cancer Centre in Thiruvananthapuram located deaths in the community through house visits and obtain 100 km away and Alappuzha Medical College Hospital relevant information about cause of death etc. Autopsies 65 km away are the two nearest cancer treatment centres are extremely rare, restricted to medico-legal cases. The collected data are processed and computerised after offering cancer care and treatment facilities. There are no cancer detection facilities or dedicated duplicate elimination and checked for consistency using a cancer treatment facilities in the area except cytology computer programme. Regular evaluatory procedures are detection facilities, pain clinics and supportive clinics done to ensure accuracy of the registry data. The radiation effects study has progressed from 1999 offered by the registry with the technical help of Regional Cancer Center, Thiruvananthapuram. There are no added onwards based on a cohort approach. A radiation cohort diagnostic facilities like PSA testing in this area, and the with high radiation and a control cohort with low radiation only regular screening procedure available was Pap smear exposure were selected, and the study was pursued with individual dose estimation and special surveys like screening programs. migration, occupancy, and mortality for in-depth analysis and estimation. Registry structure and methods Regional Cancer Centre, the comprehensive cancer treatment centre of Kerala, started Cancer Registry, Karunagappally Interpreting the results as a special purpose registry in 1990. The Registrys main The Registry ofce has a well-equipped cytology laboratory, objective is to study cancer occurrence and its relation to the and weekly detection clinics are run by the registry in natural radiation present in the sea coast of Karunagappally Government Taluk Headquarters Hospital. This increased the taluk. The registry ofce is located in Neendakara. The study microscopically veried percentage of cases. Cancer followand the Registry were initiated in 1990 with the support up clinics, pain & palliative care services, eld detection of Department of Atomic Energy, and since 1999 it has clinics and Pap screening programmes were organised by

225

Asia

the Registry in which doctors from RCC participated. Thus cancer cases diagnosed in this area will not be missed due to intensive casending methods including house-to-house visits in the registry area. Use of the data The main objective of the data is research on the effects of chronic exposure to the natural radiation. Cancer control measures and cancer patient services are developed in the registry area using the registry data. Studies are ongoing for population-based survival and mortality data analysis. The registry annually prepares reports on cancer incidence highlighting trends and changes.

Source of population The Governmental census population data of 1981, 1991 and 2001 were available. The growth rate between 1991 and 2001 in rural Kollam was 7.99%, which was lower than the growth rate between 19811991 (10.68%). Age-specic census data of 2001 was not available for Karunagappally Taluk. The 19912001 growth rate was applied to each group of 1991 estimated Karunagappally population and using exponential growth rate, the population by age and sex as on July 2000 was obtained. Multiple primary rules used Impossible to detect multiple primaries.

226

Asia

India, Mumbai (Bombay)

The registry staff consists of a Deputy Director who looks Registration area The Mumbai (Bombay) registry covers the resident population after the day-to-day administration, prepares research articles of Greater Mumbai, a densely-populated metropolis on the and annual reports, attends National & International conferences west coast of India, occupying an area of 437.7 km2 between etc.; social investigators (12 involved in data collection); research latitudes 18190 N and longitudes 70710 E. Greater Mumbai assistants (6 Editing and Coding); two data entry operators; a is in fact an island joined to the mainland by bridges, and has programmer; an ofce superintendent and two attendants. Information is obtained on all cancer patients registered in a warm, humid climate. The population of Greater Mumbai as per 2001 census (1st 160 Government hospitals/institutions and private hospitals/ March) was 11.9 million with a sex ratio of 811 females per 1000 nursing homes in Mumbai who are under the care of a specialist. males. It has a density of 2220 inhabitants per km2, making General Medical Practitioners are not contacted individually it the most populated district in the country. The decennial as according to local practice. Only specialists assume charge growth rates of the population between 1991 and 2001 were in of cancer patients in private hospitals and nursing homes, and even the few patients not admitted for hospital care are at some the order of 20.2. The literacy rate was found to be 87%. stage referred to a specialist. The city is the industrial Staff members of the registry heart of India. As a result visit the wards of all co-operating of continuing immigration INDIA, MUMBAI (BOMBAY) (1998-2002) hospitals at least weekly to it has multi religious and INDIA, MUMBAI (BOMBAY) (1998-2002) personally interview each multilingual population cancer patient as well as those representing every state in the suspected of having cancer. All Union, approximately 67.4% les maintained by the various being Hindus, 18.6% Muslims, 


 


departments of these hospitals are 3.7% Christians, 5.2% Neo







crosschecked individually. Care Buddhists and 3.7% Jains, 














is taken to prevent duplication 0.5% Parsis and 0.6% Sikhs. 







of an entry relating to a patient 














already registered. Cancer care facilities 







With the exception of Tata Municipal Corporation and 








 





Memorial Hospital for cancer, State Government maintain 







hospital outpatient records are the majority of hospitals in 














not included in the registry les, Mumbai and the major source 




 

because of the paucity of clinical of the data is the Tata Memorial 










 


details and the lack of specic Center, which is a postgraduate  

 





information on the residential university teaching centre for status of patients attending cancer research. The City has       these clinics. Supplementary five medical colleges. The 
*%!' 

*%!' +*&,(***  (*(&#*** information is gleaned from the diagnosis and treatment of 
 


)*($(*+")***  death records maintained by the cancer is centralised in certain 
   Municipal Corporation. hospitals. Major cancer surgery 
**

 * 
** *


*
*
**"--".# "*  



 The registry records follow-up information for almost all is undertaken in all the major hospitals and well-equipped private 
* 
*%# &'**(**
* nursing homes. Facilities for cobalt60 are available in 9 hospitals, major sites. Already we have carried out two special studies on the while ulto-voltage deep x-ray therapy is available in 15 hospitals. A total of about 30 000 hospital beds are available in evolution of the completeness and accuracy of the data. the registration area. There have been improvements in diagnostic facilities, as new hospitals have immerged with Interpreting the results histopathology and imaging facilities in registration areas. There are no screening programmes underway in the area covered. Radiotherapy departments have also increased from 2 to 9 Tobacco chewing is very prevalent in both sexes. Smoking, hospitals. Chemotherapy is available in many new hospitals. particularly bidi, is prevalent in males but almost nil in females. Registry structure and methods The Mumbai cancer registry was established in June 1963 as a unit of the Indian Cancer Society with the aim of obtaining reliable incidence and mortality on cancer from a precisely dened urban population. Compilation of data began in 1964. Until then, no continuing activity on registration of cancer cases in a population had been undertaken in India. The registry started in collaboration with and up to 1975 received nancial support from the Biometry branch of the US National Cancer Institute. During 197680 the registry received Financial support from the Department of Science & Technology, of the Government of India and the Indian Cancer Society. Since 198182, the registry has been funded in part by the Indian Council of Medical Research. Use of the data The registry publishes annual reports, and has published numerous journal articles and monographs. The data are also used by public health workers for etiological and cancer control studies. As the oldest registry in the country, the registry is a rich source of data for studying time trends in cancer incidence and mortality. Source of population Estimated using geometric rate of growth between census periods of 19912001. Multiple primary rules used IACR rules (2004) on CI5 IX period.

227

Asia

India, Nagpur
of these hospitals histopathology and imaging methods are Registration area Western Maharashtra, Vidarbha, and Marathwada are three available. In Nagpur there are two radiotherapy centres, and geographical divisions of Maharashtra state. Nagpur city is chemotherapy treatment is available in 5 hospitals. the headquarters of the Vidarbha region. The city of Nagpur is located in the centre of the Indian sub-continent and is Registry structure and methods linked by air with all parts of the world and by rail and road The Nagpur Cancer Registry division of the Indian cancer with all parts of the country. Its conguration presents a Society became operative on 1st January 1980, with the unique combination of plateau, plain, hill and dale along the collaborative effort with Nagpur Medical College, with the Nag Stream following West-East. aim of obtaining reliable incidence and mortality data on Nagpur city has extremely hot summers and moderately cancer from a precisely dened urban population. cold winters. The lowest temperature reaches to 3.90C in Since its inception this registry has been nancially January and the maximum reaches 47.80C in May. The main supported by Indian Cancer Society, Mumbai. The staff of precipitation occurs during the Monsoon, which begins around the registry consists of 4 Social Investigators (registrars are involved in data collection) mid-June and lasts until midand one supervisor (who October. The average annual looks after administration rainfall is about 1130mm. INDIA, NAGPUR (1998-2002) and completeness of data Nagpur city receives its water INDIA, NAGPUR (1998-2002) collection). Editing, coding supply from the Ambazari and and analysis are carried out at Gorewara tanks. the Mumbai Registry Ofce Nagpur lies on latitude where 1 coder and 1 DEO are 21N and longitude 79E. 


 
 

involved. Nagpur city covers 236.93 







Data are maintained on km2 with a population of 2.05 














registry proformas and on million (2001 Census). The 







computer les. Duplication density of population is 8660 

 












of cases is checked via a per km2, and the population 







comprehensive alphabetical is multi-religious, with 71.4% 














index card system and by Hindus, 10.3% Muslims, 1.1% 







computer programmes. Data Christians, and 15.4% Neo 














analysis is carried out at the Buddhists. 







Mumbai Cancer Registry. Nagpur city is of historical 












 

The registry does not record importance. In mythology the 







follow-up information. god Ram traversed this region in route to the hermitage of       Interpreting the results Saint Shrutikrishna. He is  &"$   &"$ There are no screening supposed to have proposed on 


&##&#('&&&  programmes underway in the the Ramtek Hill, which has  
 area covered. Tobacco chewing the name of Ramgiri, where  & &  & &
& &  & & &
& )) +! & a very beautiful Meghdoot  
   was ))$& composed and written is very prevalent in both sexes. Smoking, particularly bidi, is 
& &"    by the famous Sanskrit poet Kalidas. Buddhist ruins and prevalent in males but almost nil in females.  &&  && & & & && &  &
&  &*& & &%&" $& archaeological remains show that this region was underdeveloped until the 18th century. Although it was ruled by Use of the data the dynasties such as the Vakataka Rajputs, Rashtrakuts, The registry publishes reports every ve years. The State the Parmars, and the Shails, the semi-aboriginal nomadic Government also uses the data for district cancer control programs. The data are also used by public health workers Gaolies also occupied it from the 6th to 16th centuries. for etiological and cancer control studies. Cancer care facilities Information is obtained on all cancer patients registered at Source of population the 10 major hospitals and 25 nursing homes in Nagpur, and Estimated using geometric rate of growth between census from the Tata Memorial Hospital and other leading hospitals periods of 19912001. in Mumbai, as patients from Nagpur go there for treatment because of their excellent facilities. General medical Multiple primary rules used practitioners are not contacted individually. Missed cases IACR rules (1990). are checked via the death records maintained by Nagpur Notes on the data Municipal Corporation. The 10 major hospitals in Nagpur City and 6 major The Editors recommend that some care be taken in the hospitals in Mumbai contribute data to this registry. In all interpretation of these data; see Chapter 5 (Categorisation).

228

Asia

India, New Delhi

Registration area Medical social workers visit various collaborating hospitals and Delhi is a densely populated urban metropolis situated between nursing homes and interviews the patients who are either undergoing the Himalayas and the Aravalli range in the heart of Indian sub- cancer treatment or being investigated for cancer at radiotherapy continent. It lies between 28 25 and 28 53 N latitude and 76 department. They also examine the case records maintained 50 and 73 20 E longitude. It is surrounded on the north, west by various departments of these hospitals, viz. Pathology, and south by Haryana and the east by the Uttar Pradesh. Haematology, Radiology etc. Many patients present at advanced The population census is taken every ten years in India, the last stages of disease, and treatment may commence without waiting one being in 2001. According to the 2001 census the population in for the results of investigations. Therefore even cases diagnosed Delhi was 13 850 507 (Males: 7 607 234; Females: 6 243 273). The on the basis of clinical ndings alone are also registered. All the sex ratio in Delhi is 821 females per 1000 males. The density of information collected is cross-checked for completeness of the data. population is 9 294 persons per km2, versus 6352 persons in 1991. Sometimes the same patient may register in more than one hospital The total population of Delhi UT as per 2001 census for treatment, so care has been taken to exclude duplicates. (as on 1 March 2001) was 12 819 761 (Males: 7 030 671; The death registration system is very inadequate and incomplete; Females: 5 782 090). The sex the cause of death often not ratio in Delhi UT Urban was mentioned or given as cardio822 females per 1 000 males. respiratory arrest. The registry INDIA, NEW DELHI (1998-2002) staff visits these sources, where The total area of NCT of INDIA, NEW DELHI (1998-2002) they scrutinise the records kept Delhi is 1483 km2. Per the in medical records departments, 1991 census, its rural and urban and registers of individual composition are 797.66 km2 and departments concerned with 685.34 km2 respectively. During the diagnosis and treatment of Population Census 2001, the area 


 


cancers, to identify and abstract of the NCT of Delhi remained 














the same at 1483 km2. However, information on cancer, diagnosed 

 





its rural-urban composition has by all methods, among residents 














undergone change. According of registry area. These death 







records are then matched with to provisional results released by 




 



 





the morbidity records. Cases not Directorate of Census Operations,  







matching with the records are Delhi, the rural-urban distribution 














registered as Death Certicate of the NCT of Delhi is 591.91 km2  







Only cases (DCOs) in that and 891.09 km2 respectively. 








 





corresponding year. Since the population by 







All the data collected were age is available for Delhi coded using ICD-O-1 and ICDUT urban areas only, it was        )%"&   )%"& 9. Inconsistencies in coding are therefore suggested that Delhi 



()+*()*$$)))  corrected using quality check Registry may be dened for Delhi UT Urban areas only.  
 programmes. Validity checks are  ) )))) )))) )
)#,,+))$!!$)) ) )
)  ) )
)) ) )) also carried out on all variables, #,+##,,#))$!!#) )  )  
   Registry structure and methods and records with missing values and impossible codes were checked .
.#))%#,+!&) The population-based cancer registry at Institute Rotary Cancer against the original les and corrected. Finally, a series of checks     ) )  )) ) ) ) )) )  ))  )-) ) )')% & ) Hospital (IRCH), All India Institute of Medical Sciences such as site versus sex and histology, sex versus histology, age, (AIIMS), New Delhi was established in January 1986 with the etc., were carried out to detect coding or keying errors. aim of obtaining reliable morbidity and mortality cancer data among the Delhi residents. Use of the data The registry collects morbidity and mortality data on The registry regularly prepares annual/biennial reports on cancer patients from 159 major government hospital centres and cancer morbidity and mortality along with the cancer incidence, institutions, more than 250 private hospitals and nursing homes, highlighting trends and changes. Casecontrol studies on gall and the Dept. of Vital Statistics of the Delhi Municipal Corporation, bladder cancer and prostate cancer among the Delhi resident New Delhi Municipal Committee and the Cantonment Board. population have also been carried out. Some special studies Staff working in Population Based Cancer Registry, Delhi, on patterns of care and survival in breast, cervix and head and Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute neck cancers are ongoing. of Medical Sciences, Ansari Nagar, New Delhi-110 029 are 3 scientists in statistics and medicine, 9 medical social workers, Source of population one data entry operator and one lower division clerk. The estimation of population for Delhi UT urban for the Although cancer is not a notiable disease, arrangements years 1998 to 2002 has been done exponential method by have been made with the hospitals outside the registration area taking as a basis a 1981, 1991 and 2001 census gures. to notify the registry of resident cases which are diagnosed and treated in them; they are visited once a month or year to review Multiple primary rules used these procedures. General medical practitioners are not contacted ICDO1 (1980) individually, as at one stage or the other almost all cancer patients are referred to specialists. The smaller nursing homes/clinics are Notes on the data contacted by letters and registration about cancer patients being The Editors recommend that some care be taken in the interpretation of these data; see Chapter 5 (Categorisation). treated by them are recovered on a per forma.

229

Asia

India, Poona (Pune)

and completeness of data collected. Editing, coding, analysis Registration area The Poona (Pune) is a district of Maharashtra lying between is carried out in the Mumbai Registrys ofce by 1 coder and 170 & 190 N and 170 & 750 E. It has a dry and invigorating 1 DEO. Information is obtained on all cancer patients attending climate due to its attitude (487m) above sea level and the prevalence of westerly breezes. Its soil is free from alluvial the 35 hospitals in Poona, and from the Tata Memorial deposits. The lowest temperature is 90C in January and Hospital and other leading hospitals in Mumbai where maximum reaches 400C in May. Precipitation occurs patients from Poona go for treatment because of the excellent primarily during the south-west monsoon, which begins medical facilities there. General medical practitioners are around the middle of June and lasts until mid-October. The not contacted individually, according to local practice only. average rainfall is about 900mm. Poona city receives its Specialists are in charge of cancer patients in private hospitals and nursing homes in Poona City. Even those patients not water supply from Khadakwasala dam nearby. The Poona city agglomeration covers 344.18 km2 with admitted for hospital care are referred to a specialist by the a population of 3.55 million (2001 Census). The population general practitioners at some stage. The death records density in 2001 was 10 330/ maintained by the Poona km2, and the area supports Municipal Corporation a multi-religious group. INDIA, POONA (1998-2002) provide a means for checking According to 2001 Census, INDIA, POONA (1998-2002) on missed cases. 79.7% are Hindus, 8.9% St a f f memb er s of t he Muslims, 2.6% are Christians, registry visit the wards of all co5.8% Neo-Buddhisst, and operating hospitals at least once 2.2% Jains. 


 


a week to personally interview Poona city is of great 







each cancer patient, including historical importance. It was 














those only suspected of having once the capital of the old 







cancer. All les maintained by Maratha Kingdom of Shivaji 














the various departments of these and Peshwas. It has been 







hospitals are also crosschecked renowned for its educational 














individually. Editing, coding facilities since the early part 







a nd a na lysis of d at a a re of the century. Being the  














carried out at Mumbai Cancer district headquarters, medical  







Registry. Data are maintained and educational facilities are 














on computer files. Duplicates available in abundance, and 







are sought using computer many industries have been programs and a comprehensive established in the city and its       alphabetical card index. No surroundings. 
)$ & 

)$ & patient is followed-up directly 



!)+(+)#+*)))  by the registry staff. Cancer care facilities  

 About 10 000 hospital beds 
))

 ) 
)) )


)
)
))!,,!."!)  
   are available in the registry area. The Tata Memorial Center Interpreting the results 
) 
)$"%&))'))
)    in Mumbai is the only specialised cancer institute in the There are no screening programmes underway in the area covered. 
) )

))
)
)
)
))
)

))

)-)

) 
)')$
 &) India, and patients from Poona often seek treatment there. Tobacco chewing is very prevalent in both sexes. Smoking, There are 35 major hospitals offering cancer diagnosis and particularly bidi, is prevalent in males but almost nil in females. treatment facilities in Poona. There are 16 major hospitals in Poona City and 6 major Use of the data hospitals in Mumbai that contribute data to this registry. In A ve-year report on cancer incidence and mortality is Poona and Mumbai hospitals, histopathology and imaging published regularly, and the seventh in this series is ready for method are available. In Poona city there are 2 radiotherapy publication. The data have also been used for special studies centres, and chemotherapy treatment is also available in of cancer epidemiology. We report on extent of disease for 9 hospitals. In 1999, a specialised cancer hospital (Inlak all sites, and survival only for breast and cervix. District and Badharani) was established in Poona City. state cancer control programmes also use this registry data. Registry structure and methods The Poona Cancer Registry, a satellite registry of the Mumbai Cancer Registry of Poona, commenced operations on 1 March 1972 as a collaborative effort with the B.J. Medical College and the Sasson hospital at Poona with the aim of obtaining reliable incidence and mortality data on a cancer in a precisely dened urban population. Since then, the Indian Cancer Society has provided nancial support. Registry staff includes 3 social investigators for data collection, and a supervisor who looks after administration Source of population Estimated using geometric rate of growth between census periods of 19912001. Multiple primary rules used IACR rules (2004) on CI5 IX period. Notes on the data The Editors recommend that some care be taken in the interpretation of these data; see Chapter 5 (Categorisation).

230

Asia

India, Trivandrum
Registration area Trivandrum registry is situated in Kerala, the most South Western state of India. The health status of Kerala is very advanced, higher than the national average, and is comparable with developed countries. The registry covers both urban and rural population. The estimated urban and rural populations are 568 421 and 589 280 respectively as on 1st July 2000 using data from the census of India. The major religion in this part of the population is Hindus (68%), followed by Christians (18%) and Muslims (13%). certication by a medical practitioner is not. Hence it is assumed that cancer deaths are underestimated. Quality control (QC) procedures: Annually a 10% random sample is selected from all cases, and re-abstraction is made by a senior staff member with the help of medical ofcers at RCC. Re-abstraction is done using the same procedure adopted for data abstraction, without reference to the original data. QC data is then checked with the original data; the error percentage is less than 5%.

Interpreting the results Registry structure and methods The population at risk was obtained from the decennial census The physical location of the registry is at the Regional Cancer gures. The census data for the year 1991 and 2001 are available Centre (RCC), Trivandrum. by sex and ve-year age groups. The registry is partially The populations for urban and supported by the Finnish rural areas are estimated by INDIA, TRIVANDRUM (1998-2002) Cancer Society, Finland. Four using an exponential growth INDIA, TRIVANDRUM (1998-2002) eld staff and a data manager rate method based on 1991 and work in the registry. The active 2001 census gures (Census of registration method is used for India report 1991 & 2001, Final casending by periodic visits Population Total, Kerala, India). to major hospitals, pathology Further, an organised oral !!*#,*** +') !'*',*** laboratories, and vital statistic cancer-screening programme -*'((*** + !!*'(*** !%*(%(*** (' !+*'%%*** ofces in the registry area. is conducted during the !,*(+*** ( "*'++*** The major sources of data reporting period in some rural ""*%((*** '' "#*-*** ",*%#+*** ' "+*+!-*** for the registry are the Hospital populations in the registry #,*%'*** %' #+*-(+*** Based Cancer Registry of the area. PSA testing is not #,*(#+*** % #,*+!%*** %'*-("*** #' %-*#""*** RCC, Trivandrum Medical common in the population. %'*-(#*** # %-*(%,*** College hospitals (two), and As the registry data (more %,*'+*** "' '%*%%#*** '*'!*** " '%*+,#*** Sree Chitra Thirunal hospital, than 80%) are obtained from '*,(*** !' %-*(%,*** Trivandrum. All four of the hospital-based registry of '"*#,#*** ! %-*'#-*** %'*,((*** ' %#*("*** these hospitals are located in the RCC, information such as %,*"'-***  %'*%,#*** the same campus. Regional extent of disease, treatment and Cancer Centre has excellent disease status are available for ! '   ' ! diagnostic and treatment most patients. Thus the registry 
*$ & 

*$ & facilities. Patients come from data are largely utilised for ',,*(-+*** '(-*'***  all parts of the state of Kerala cancer control evaluation and from adjoining states.   
 

 programmes in the state of 
* 
*$"%&**'**
* Annually around 10 000 cancer patients are reported in Kerala. The data have also been widely used for a variety of 
 
* *

**
*
*
*
**
*

**

*.*

* 
*'*$
 &* this hospital. In the medical college hospitals, around 2000 analyses resulting in several scientic publications. cancer patients are reported annually. Other data sources include a few government and private hospitals, pathology Multiple primary rules used laboratories and radiological diagnostic centres. IACR rules (2004) on CI5 IX period. Information on cancer death is collected from the vital statistics ofces. For personal identication, name, age Notes on the data and address of the deceased are obtained from the above The Editors recommend that some care be taken in the ofces. Death certication is mandatory, but cause of death interpretation of these data; see Chapter 5 (Categorisation).

231

Asia

Israel
Registration area Israel is home to a widely diverse population. Of its 7 million people, 76.2% are Jews, 19.5% are Arabs (mostly Muslim) and the remaining 4.3% comprise Druze, Circassians and others not classied by religion. In the Jewish population there are marked differences in incidence based on birthplace: (Europe and America, Asia, Africa, of Israel). The Israeli population is growing rapidly, both by internal and external means. In the late 80s approximately one million (a fth of the existing population at that time) immigrated to Israel, mostly from the former Soviet Union. The Israeli population is relatively young; 9.9% are 65 years old and above. a le containing all deaths in the country, which it uses to update vital statuses. Accuracy and completeness of registration at the Israel National Cancer Registry (INCR) is checked regularly, and a systematic review is done every few years. Ongoing monitoring includes monitoring all reporting sources (more than 90) for volume of reporting, continuous colloquium and monitoring changes and by record linkage with specic cancer databases. A 2003 report based on registration in the early 1990s, estimated completeness of solid tumours to be >95% (90% for non-solid tumours). As a result the INCR, together with the Israeli Center for Disease Control and the 4 HMOs operating in Israel, developed a continuous medical education and training Cancer care facilities program. In addition, the There are 33 public general Israeli Cancer Organization hospitals and numerous private nances 10 clerical positions at facilities that diagnose and ISRAEL (1998-2002) ISRAEL (1998-2002) various oncology departments treat cancer patients, including for secretaries devoted to 18 public oncology institutes registration and notication and several private facilities. to the INCR. More than 150 There are 7 radiotherapy clerks, nurses and physicians institutes with more than ,)*))) *&( &*)$$))) have attended these courses 18 linear accelerators and ',)''))) * , )+!))) +)*!))) '& ,,)+$))) to date, and several hundred other facilities for treating ,")*))) ' +)"))) attended the seminars. cancer patients. Radiotherapy  ),$))) && ) ))) &"),'))) & '$)'))) In 2001, the entire database institutes distributed *"),!))) $& +$)&!))) was converted to ICD-O-3. throughout the country are **) ))) $ +')'))) +!)$+))) "& ++)!))) Prior to this change, sites accessible to all patients. There ! ),))) " ,&)+$))) were coded by the ICD-9 and are however only 14 active !$")'))) !& !"*)$+))) !'")++))) ! !&&)!'))) morphology by ICD-O-2. All radiotherapists (physicians). !*")"'))) & !&,)'+))) copies of medical documents !+!)"!!)))  !'+)*))) !,*)*'))) & !+!)+'))) are archived (electronically Registry structure and "!&)')))  "*),$))) since 1997), and in cases methods where simple code conversion The Israel National Cancer  &   &  )#% )#% was not possible, we revised Registry, established in 1960, "),*)++$))) ")")&!!)))  the original documentation is part of the Center for Disease and assigned the new code. Control at the Ministry of 
   The database still contains Health of Israel. Reporting
)))) )))
)) ))  



 

))#!$%))
&)) ) has been mandatory since 1982, and all Israeli hospitals (and backups of the former coding. since the late 1980s, also the private pathology laboratories) report, usually by submitting a copy of the medical Interpreting of the results documentation. Thus data collection is mostly passive, but The Ministry of Health together with the Israeli Cancer when needed, registry staff visit reporting sources to collect Association and the 4 HMOs operates screening programs for breast and colorectal cancers. Active mammography data actively. Reporting sources include pathology, cytology, and screening began in late 1996, and all women aged 5074 haematology laboratories; hospital discharge forms; receive biennially a personal invitation for screening. oncology institutes; death notication from district health Screening for colorectal cancer, which began in 2005, is made ofces; and the le of deaths from the Central Bureau of by Faecal Occult Blood Tests. The recruitment technique is Statistics. Since 2000, through collaboration with the Israeli the same as for mammography and involves active recruiting. Hematology Society, all haematologists have been reporting Compliance for the mammography screening is about 60%. There is no organised cervical cancer screening due to its the haematological malignancies that they see. Beginning in the 1970s, several studies have assessed the low incidence. The INCR collects data on CIN-III that can registrys completeness, with the latest one based on 1994 also serve as an estimation of ad-hoc screening. There is data. These studies actively searched for cancer patients no ofcial recommendation or screening programme for in a dened period in major hospitals, and compared the prostate cancer and PSA testing. Survey data show that resulting data with the registry le. These studies resulted awareness of PSA screening is relatively high and use of this in estimated completeness rates of >94% (usually >95%) for test is widespread. There is an elevated risk of radiation-induced malignant solid tumours. All Israeli citizens are given unique identication number brain tumours and benign meningiomas after childhood (at birth or immigration). This number, used in all contacts exposure to ionizing radiation used in the 1950s to treat with the health system and government departments, tinea capitis, almost exclusively affecting the sub-group prevents duplication of data. The registry annually receives originating from North African countries. Thyroidal cancer

232

Asia

morbidity may be increased in that population as well as in those emigrating from regions in the former Soviet Union affected by the 1986 Chernobyl accident. Use of the data The registry is involved in active cancer research and health planning. Numerous record linkage studies have

been performed locally and internationally. The registry participates in the national council for oncology, the countrys policymaking body in the eld, collaborates with HMOs helping them build capacity and monitoring abilities, participates in new technologies for screening and treatment implementation, as well as conducting cluster investigations and disseminating information.

ISRAEL: JEWS (1998-2002)

ISRAEL: JEWS (1998-2002)

ISRAEL: NON-JEWS (1998-2002)

ISRAEL: NON-JEWS (1998-2002)

"),))) '&)!+))) *$)$))) +")*+))) ++)$+))) "+)+))) &!)$+))) $+)$!))) $$)$!))) &*)"+))) ,)*))) !*) +))) ! ")*!))) ! $) !!))) ! $)!))) !!+)!$)))

*&( * '& ' && & $& $ "& " !& ! &  & 

&)*'))) +') !))) , )+$))) ,*),'))) ,')+!))) $*),+))) '") ))) &+)&+))) & )'))) &,),*))) +')+!))) !)))) !!)*!))) !")"'))) !")&'))) ! ')')))

&)+))) $)"+))) ')'+))) ,),!))) ")$'))) &)++))) ! )$$))) !+)'+))) "+)'))) $$)&!))) &!)"'))) &')*))) &,)'$))) '+)!))) +")*$))) ,')+!)))

*&( * '& ' && & $& $ "& " !& ! &  & 

')'+))) &)*))) +)))) )"$))) ")!+))) ')+))) ! )$!))) !+)!))) "')'))) "&) $)))

&)''))) &&)!'))) &'),'))) '&)"$))) *,)"))) , )++)))

& )#%

& )#%

& )#%

& )#%

!)$!$)!$!)))



!)& *)!&)))

'')!+)))



&+)'"$)))


  
)))) )))
)) ))  



 

))#!$%))
&)) )


  
)))) )))
)) ))  



 

))#!$%))
&)) )

Source of population Annual population estimates are published by the Central Bureau of Statistics.

Multiple primary rules used IACR rules (2004) on CI5 IX period.

233

Asia

Japan, Aichi Prefecture

The registry staff consists of 2 doctors and 3 registrars, Registration area Aichi Prefecture is located in the approximate centre of and a local government ofcer for Registry who is also a Japan, between latitudes 34.5and 35.2N and longitudes doctor. A dramatic overhaul of the registration system has 136.5and 137.5E, and is anked on the south by the Pacic Ocean. The prefecture spans an area of 5,146 km2 and has been undertaken with a view to rationalising Aichi Cancer a population of 7.4 million. The altitude ranges from sea Registry and strengthening its effectiveness. This has been level to 1415m. Nagoya, the capital city of Aichi Prefecture, supported by a grant from the Ministry of Health, Labour is situated about 350 km west of Tokyo. The annual mean and Welfare (awarded 1998). The aims of the Revised Cancer temperature in Nagoya is 15.6 (5.919.9 degrees) and annual Registry System are: 1) to establish a more comprehensive organization, with Aichi Cancer Center as a core institution rainfall is about 1500mm. The quality of the Aichi Cancer Registry remains for cancer research and treatment, and the prefectural modest, mainly due to dependence on voluntary-based public health centres as core facilities for community health operations without legal obligations. During the last 20 years services; 2) to promote the installation of a hospital cancer registration system in every we established a model area, relevant medical institution; 3) located in the central part of to provide cancer information Aichi Prefecture, with goodJAPAN, AICHI PREFECTURE (1998-2002) and expedite cancer control quality registry data, covering JAPAN, AICHI PREFECTURE (1998-2002) measures in the community. a reasonable population, The new system has been in including both urban and rural operation since 1999. areas. The Central Area of The research group Aichi Prefecture consists of 8 


 









supported by a Grant-in-Aid cities and one town. The total 







from the Ministry of Health, registration area is 646 km2, 














Labour and Welfare from and the population as of 2000 







2004 monitors the quality was 1 060 529. Only 2.1% of 












 

in the registry every year. In the economy is engaged in 







2006, a national standardised primary industry; 46.7% is in 












 

database system for regional secondary industry and the 







cancer registry developed remaining 50.5% in tertiary 














by the research group was industry. 







introduced. All of the registered 














subjects are Japanese. 

 





Interpreting the results Buddism is traditionally the As in other areas in Japan, local dominant religion (more than       *&"( *&"( governments support stomach, 90%); however, precise data %'#***  ##!*** 


)')*!)+***  colon, breast, lung and cervix on religion are not available. screening. In practice, PSA is 
   ***$!!! *** *#--,**#---* *** *
* *#--).$!!!***** *$!!#** commonly available; however, Cancer care facilities $!!$* ** * 
 * As in large cities in Japan,  



 every kind of diagnostic/ PSA is not dened as ofcial tool for prostate cancer 
* *&$!!'(** )**
 * treatment service for cancer is easily available. The costs screening. required are covered by public health insurance in general; there is no limitation for access to each service. Radiotherapy Use of the data In addition to providing descriptive data on cancer incidence, departments are available in large institutions in the area. the data have been used for various epidemiological investigations including cohort studies, case-control studies Registry structure and methods Aichi Cancer Registry was established in 1962 as a population- and evaluation of screening programmes for important based cancer registry, the purpose of which was to form an cancer sites. accurate picture of cancer in Aichi Prefecture, in order to control its impact. Initially under the direction of the Aichi Source of population Prefecture Department of Health and Public Welfare, all Census data in 2000. The data for 1998 and 1999 were medical institutions in Aichi Prefecture are requested to report estimated by linear interpolation from 19952000 incident cancer cases on the basis of the cancer registry outline. census data, and those for 2001 and 2002 were by linear The registry has received technical support from the Division of extrapolation. Epidemiology and Prevention, Aichi Cancer Center Research Institute, since 1983, and has been subject to periodic evaluation Multiple primary rules used IACR rules (2004) on CI5 IX period. by the Administration and Guidance Council since 1984.

234

Asia

Japan, Fukui Prefecture

Registration area Fukui Prefecture is located in the centre of Japan, and has a population of about 820 000 people and an area of 4189 km2. About 90% of the population lives in urban areas (>10 000 inhabitants); 99% are Buddhist. Cancer care facilities The six main district hospitals provide radiotherapy, cancer surgery and chemotherapy services. Patients suspected to have cancer in the primary and secondary care facilities in the registry area are mostly referred to these six hospitals. cancer reports and the copies of death certicates mentioning cancer are also stored, living cases being led by date of birth, dead cases grouped by year of death and led by date of birth. Multiple primary cancers in the same patient are counted separately. The research group, supported by a Grant-in-Aid from the Ministry of Health, Labour and Welfare from 2004, monitors quality in the registry. Interpreting the results Organised screening services for stomach, colorectal and cervix are operated. PSA testing is not common.

Registry structure and methods Use of the data In 1984, the Fukui Prefectural The data are used for Government (FPG) decided geographical analysis in the to start cancer registration on JAPAN, FUKUI PREFECTURE(1998-2002) prefecture and comparison of a voluntary basis in order to JAPAN, FUKUI PREFECTURE(1998-2002) cancer morbidity with existing obtain information about the cancer registries in Japan. The nature and extent of the cancer registry prepares an annual problem in Fukui and assist report of cancer incidence, in planning cancer control '*%%*** ,') !#*(++*** +*%%#*** , !%*!(#*** highlighting trends and programs, and entrusted the !"*-!*** +' "*##'*** changes. Some special studies survey to the Fukui Medical "*,",*** + "%*-#"*** "#*##+*** (' "(*++!*** Association (FMA). The of survival of registered cancer "#*'!*** ( "'*'"-*** registry is located within FPG cases (stomach, colorectal "'*+,*** '' "(*%+*** #"*-',*** ' #"*"%%*** and is staffed by a part-time and cervix cancer) have been "-*+#,*** %' "-*!-%*** registrar and a full-time health carried out. Policymakers use "'*-+(*** % "'*,##*** "%*,#(*** #' "'*!!(*** worker. the cancer registry data for "'*("+*** # "'*'-#*** The central registry evaluation of screening for "+*-#+*** "' "+*"!(*** "#*-'*** " "!*-%'*** receives monthly a batch of gastric cancer and colorectal "'*+!%*** !' "%*#%!*** cancer reports transferred cancer. "%*+-*** ! ""*,,#*** "!*-'!*** ' "*'-,*** from the FMA and death "*-#"***  "*",*** certicates from the Source of population Department. Each data card 1998, 1999, 2001, 2002 ! '   ' ! is checked for consistency, Estimates based on the 1995  *$ &  *$ & !'"***  '-*** coded and stored on computer and 2000 census data. 2000 %"(*-"+*** %"*'%,***  les. Questionnaires are sent census (Vital statistics of 
   to physicians who signed !--,*!---"!*""*
 * ***!--'**"*  **"*  **$*   * *&* Japan).  



 death certicates that are unmatched with cancer reports.  ****
* The data in the questionnaire replies are also stored in the Multiple primary rules used computer le after being checked for logicality. The original Impossible to detect multiple primaries.

235

Asia

Japan, Hiroshima
eld personnel visit the medical record rooms of various Registration area Hiroshima City, the capital of Hiroshima Prefecture, is departments and services of most large hospitals in the area, located in the western part of Japan facing an inland sea. It and review all hospital records, including clinical records, covers an area of 742 km2, from 13218 to 13241E and from surgical reports, radiology reports, and cytology, pathology 3417 to 3436 N, and the altitude ranges from sea level and autopsy reports. Causes of death are also ascertained at to 890m. The annual mean temperature of the city is 16.1 that time. The Hiroshima Prefecture Tissue Registry was started in and the annual rainfall is about 1320mm. Hiroshima City is an administratively dened area that does not completely 1973 under the auspices of the Hiroshima Prefectural Medical correspond to the Hiroshima metropolitan area. The latter Association and has been integrated with the Hiroshima Prefecture Cancer Registry since April 2005, serving as includes the city itself and its surrounding areas. As is widely known, Hiroshima City was destroyed by an an additional source of information. The Tissue Registry is atomic bombing in 1945. After the war, it developed into the designed to collect and examine surgically removed tumour administrative centre of the Chugoku and Shikoku regions. tissues; tumours are then classied and tissue slides of malignant tumours are stored. The major industries include Malignant cases residing in shipbuilding, automobile, the city and identied through metalworking, machinery JAPAN, HIROSHIMA (1996-2000) the Tissue Registry are added and other manufacturing/ JAPAN, HIROSHIMA (1996-2000) to the Cancer Registry le. production. Cases identied from The population in 2000 was various hospitals and sources 1.13 million, comprising mostly are collated, and data are Japanese (99%) and very few 


 







 

stored in computerised les. non-Japanese nationals (1%). 







Checking for duplicate entries The population density was 














is performed manually with 1518/km2 in 2000, slightly 







the assistance of a computer. higher than the 1467 calculated 














All cases with possible in 1990. The proportion of 





 

multiple primary tumours are residents 65 years and over was 














reviewed; pathology slides 14.2% in 2000, compared with 







from the Tissue Registry are 9.8% in 1990. The population 





 








also reviewed, if necessary. is primarily urban; 73% of 







RERF are involved in all employees are in the sales trade 





 





of the registries mentioned and service industries, 24% in 







above, and 16 staff including construction and manufacturing one medical doctor are industries and only 1% are       employed in the Tumor and engaged in agriculture and 
&!#

&!# & &&&  $ &&& Tissue Registry Ofce. related work. 


$"$&$ $&&& 

''%('''&
&
&&
&''$&& &
&& &
& Cancer care facilities  



 The number of hospital beds per 100 000 population was 
&
&! "#&&$&&
& 1351 in 2000, and the number of physicians per 100 000 population was 246. Diagnostic and treatment services for cancer are abundant in the area, and cancer patients are treated with radiotherapy in most of the major hospitals. Cancer screenings for stomach, colon, lung, female breast, and cervix uteri are provided in local governments and workplaces as well as private sectors. PSA testing is also widely available. 
  

Interpreting the results Since a majority of cases are ascertained by visits to large hospitals, cases missed by not including all area hospitals present a source of concern. However, a previous survey of three medium-sized hospitals not included in the regular data abstraction schedule showed the number of missed cases from medium-sized hospitals to represent less than 1% of the total cancers. Use of the data The objectives are to maintain a source of information on tumours diagnosed in the community and to provide cancer incidence data for studies on the effects of exposure to radiation from the atomic bombing in 1945. This has resulted in a number of large-scale cancer studies in the area. The incidence data are used for health promotion planning for Hiroshima City. Source of population 19961999 Estimates based on the 1995 and 2000 census data; 2000 census. Multiple primary rules used IACR rules (2004) on CI5 IX period.

Cancer registry and structure The Hiroshima City Medical Associations Tumor Statistics registry was established in 1957 with technical support from the Atomic Bomb Casualty Commission (ABCC), predecessor of the Radiation Effects Research Foundation (RERF). As of April 2005, the registry has been placed under the auspices of the Hiroshima City government and renamed the Hiroshima City Cancer Registry. The case-nding and data-collection procedures combine both active and passive approaches. All physicians and hospitals in the city are requested to report tumour cases to the registry. However, the great majority (about 90%) of cases are accessed by means of hospital visits. RERF

236

Asia

Japan, Miyagi Prefecture

Registration area Miyagi prefecture is situated in the northern part of Japan, between latitudes 37 and 39N and longitudes 140 and 141E, and is anked on the east by the Pacic Ocean. Sendai, the capital city of the prefecture, is situated about 350 km north of Tokyo. The annual mean temperature in Sendai is 12.3C, and the annual rainfall is about 1200mm. The altitude ranges from sea level to 1841m. The total registration area is 7291 km2, and the population as of 2000 was 2 365 320, including 10401 foreigners (4515 male and 5886 female). Of the economically active population, 26% is engaged in personal services, 25% in commerce, 15% in industry and 5% in agriculture. each area. Radiation therapy is available at the university hospital, one cancer centre (Miyagi Cancer Center), and several general hospitals. Cancer cases are registered from clinics and hospitals (inpatients and outpatients), radiology and pathology departments, autopsy records, mass screening records and death certicates. Reporting by clinics and hospitals is voluntary. About 30% of cases are reported from hospitals and clinics, and 70% abstracted by the registrars at the cancer registry. Multiple primary cancers are counted separately in computing incidence. All the death certicates of Miyagi Prefecture are collated with the registered cases. Follow-up is passive, with only perusal of all death certicates. Active follow-up of the cases is not JAPAN, MIYAGI PREFECTURE (1998-2002) currently conducted. Quality JAPAN, MIYAGI PREFECTURE (1998-2002) of the information recorded is evaluated by the research group supported by a Grantin-Aid from the Ministry of 


 









Health, Labor and Welfare.

Registry structure and methods The Miyagi Prefectural Cancer Registry (formerly Miyagi Cancer Registry, initiated in 1951 by the late Professor Mitsuo Segi at the Department of Public Health, 






Tohoku University School 














Use of the data of Medicine) marked its 







In addition to providing 47th year since registration 














descriptive data on cancer was restarted in 1959. The 







incidence, the data have registry has covered the 














been used for various entire prefecture from the 







epidemiological investigations beginning. The ofce has been 














including evaluation of located in the Miyagi Cancer 







screening programs for Society since 1976. Miyagi 














cancers of the stomach, Prefecture provides grants for 







colon, prostate, cervix and cancer registration, and the breast, and population-based Miyagi Cancer Society also       prospective cohort studies of supports it nancially. All 
,(%* 

,(%* &$.,,, # ++,,, cancer and lifestyle factors the work of the registry is the 



&,&+-,&-+,,,  (such as smoking, drinking, responsibility of the Registry 

   
,!
,,
,&..+,,'$$$,
,#,'$$$,
#,,&..+, ,
,, ,#,'/'/$)", and diet). Committee, comprising &..-",&..."'$$&",'$$',  /
#,,'$$$, ,
,, ,#'/'/$)",/
, representatives of the Miyagi Medical Association, Tohoku  



 
,
,('$$)*,,,, University Graduate School of Medicine, Miyagi Prefecture, Source of population and the Miyagi Cancer Society. The registry is staffed by a 1998, 1999, 2001, 2002 estimates based on the 1995 and part-time medical doctor, three full-time registrars and three 2000 census data. 2000 census. 1995 Population census of Japan vol. 2204. personnel. In Sendai, cancer diagnostic and treatment services MiyagiKen. 2000 Population census of Japan vol. 2204, are mainly provided at Tohoku University Hospital and MiyagiKen. several general hospitals. Provincial areas outside Sendai are divided into nine secondary medical care areas; a few Multiple primary rules used general hospitals provide cancer diagnosis and treatment in IACR rules (2004) on historical data.

237

Asia

Japan, Nagasaki Prefecture

sets. With respect to cases recorded as cancer, if there are Registration area The Nagasaki Prefectural Cancer Registry is a community- no matched cases among the registered cases, the cases are based cancer registry covering the entire prefecture. Nagasaki registered as DCO (death certicate only). Medical organisations in Japan are not legally required to prefecture is located on the western end of the Japanese archipelago, comprising 4092 km2 and 1.52 million people le notices of cancer cases. As a result, obtaining notication (based on a 2000 National Census). The proportion of non- of cancer cases remains difcult, particularly in Nagasaki, since data collection has traditionally depended on medical Japanese citizens is only 0.3% of the total population. One third of the prefectures population resides in Nagasaki record abstraction. A Personal Information Protection Law City, where shipbuilding is one of the primary industries. For became effective in April 2005. However, the Ministry of the overall prefecture, the combined proportion of service Health, Labour and Welfare informed medical organisations and retail/restaurant industries is over 60% of the total, that providing cancer registries with incident data would while the manufacturing industry including shipbuilding be exempt from application of this law, thus avoiding any comprises 12%. The combined proportion of agriculture, decrease in registration rate caused by the laws effects. For the pur pose of forestry and shery makes up preventing errors in coding and only 1% of all industries. entry, varied logical checking Nagasaki Prefecture also JAPAN, NAGASAKI PREFECTURE (1998-2002) functions are utilised at the time contains 55 inhabited islands JAPAN, NAGASAKI PREFECTURE(1998-2002) of data entry. Also, comparison whose residents comprise 10% among the registry cases is of the prefectures population. conducted once a year to prevent This is a primary reason for overlapping, with error in such the difculty of providing /,'#!,,, .)+ $',.!%,,, #%,$%',,, .! $*,!'-,,, comparison work detected at a medical care uniformly within $%,/-!,,, -) %/,%!-,,, rate of about 0.2%. the prefecture. %*,')',,, -! '-,//',,,
'$,)-%,,, *! )!,.-%,,, Interpreting the results Cancer care facilities '$,%..,,, )) '/,#%!,,, )-,**.,,, )! )/,)/),,, In 1958 a cancer registry Nagasaki Prefecture does )-,-/-,,, ') ).,.$-,,, covering Nagasaki city was not have a cancer centre but '.,-$!,,, '! )!,/'#,,, '$,--/,,, %) '*,%#',,, started, and in 1985 the does have 13 hospitals where '!,/%#,,, %! '),%/.,,, Nagasaki Prefectural Cancer more than 100 cancer cases '$,-*!,,, $) '*,!-/,,, %-,$/$,,, $! '#,!.),,, Registry was initiated, thus are treated annually. These '/,%#$,,, #) '-,./-,,, covering the entire prefecture. hospitals are concentrated in '*,/)!,,, #! '',*$',,, '!,.!*,,, ) %.,/$/,,, Concerning the effect of the Nagasaki city and in the city %-,!!!,,, ! %),$'),,, changes of coding rules on of Sasebo, and 70% of cancer incidence, it is conceivable patients in the prefecture are #! ) ! ! ) #! that the incidence of MDS and  ,&"(  ,&"( treated at hospitals in these )$%,,,  $)-,,, .!),%#%,,, -#%,#.!,,,  uterine cervical severe dysplasia cities. have contributed to an increase Nagasaki Prefecture 
   in incidence because these two also has cancer screening #//.,#///$!!#,$!!$, , ,, ,#//),,$!!!, , ,$!!!,  ,,&,,
,(, facilities, where examinations  



 are conducted for cancers of diagnoses are coded as malignancy using ICD-O-3. 
, ,&$!!'(,,,, Although screening has been conducted for stomach the stomach, colon, lung, breast and uterus. cancer (12.4% participation), colon cancer (16.5%), lung cancer (27.5%), breast cancer (16.9%) and uterus cancer Registry structure and methods The Department of Epidemiology of the Radiation Effects (18.7%), such screening is not obligatory and the participation Research Foundation houses the central registry ofce of rates are not very high. Recent changes of note are increased the Nagasaki Prefectural Cancer Registry, which consists of use of mammography in breast cancer screening and change one physician, nine full-time employees, and a few part-time in the eligible age for undergoing uterus cancer screening from 30 years and over to 20 and over. Although PSA testing employees. The Nagasaki Prefectural Cancer Registry collects cancer is commonly utilised, it is still being debated whether the test incidence data mainly by abstraction from clinical records, should be used in cancer screening, and as a result testing and three of the full-time staff members are exclusively remains unorganised. Many A-bomb survivors still reside in Nagasaki, on engaged in visiting hospitals for such abstraction work. Every year these staff members visit 2030 hospitals (most which an atomic bomb was dropped in 1945. The effects are hospitals with 200 beds or more) within the prefecture of A-bomb radiation on cancer incidence remain, but there to collect the necessary information. We also make an effort have been no other reports on environmental or occupational to collect data on pathological diagnoses with support from exposure that could affect cancer incidence. pathologists. Cases with histological diagnoses comprise more than 80% of the registered cases. Data on cancer Use of the data cases detected in such screening programs have also been Every year we compile and announce the incidence, mortality, and survival on cancer in Nagasaki prefecture, and we also obtained. The Nagasaki Prefecture government provides data on participate in a project to estimate nationwide cancer incidence all deaths within the prefecture, enabling verication of the in Japan, providing the project with our data. Our data are deaths in the registered cases through matching both data often used for research purposes, thus greatly contributing '$,*#%,,, *) )#,/*-,,,

238

Asia

to the elucidation of association between radiation exposure and cancer incidence. Additionally, the data are frequently utilised in descriptive epidemiology involving ATL/ATLL, which are unique to Nagasaki Prefecture. For governmentrelated purposes, our data is also utilised in the design of medical projects and assessments of cancer screening.

Source of population 1998, 1999, 2001, 2002 estimates based on the 1995 and 2000 census data; 2000 census. (Vital statistics of Japan). Multiple primary rules used IACR rules (2004) on historical data.

239

Asia

Japan, Osaka Prefecture

Registration area Osaka Prefecture is located in the central part of the main island of Japan. The surface area is the second-smallest (1893 km2), but its population density is the second highest (4652/ km2) among all 47 prefectures in Japan. Osaka City is the capital of the Prefecture. The population of Osaka Prefecture was 8.8 million in the 2000 census; 98% were Japanese, 1.5% Koreans, and 0.2% Chinese. Of all workers, 30% are engaged in industry, 68% in commerce, and 0.5% in agriculture. hospital-based cancer registries, and assist in notication of cases to the OCR. In order to assess accuracy and completeness we have incorporated a data check program compatible with the IARC-CHECK, and routinely used several validity indexes such as DCN/I, DCO/I, I/D and HV/I. The Osaka Prefecture Privacy Protection Law has been effective since October 1996, while the Prefecture Privacy Protection Council has approved the schemes of OCR as legitimate under the Law. On April 2005 a Privacy Protection Law came into effect in Japan, but informed consent is waived when personal information is needed to improve public health, including submission of cancer data from medical institutions for populationbased cancer registries.

Registry structure and methods The Osaka Cancer Registry (OCR), covering Osaka Prefecture, has been operating in cooperation with the Osaka Prefectural Department of Health and Welfare (OPDHW), the Osaka Medical Association (OMA) Interpreting the results JAPAN, OSAKA PREFECTURE (1998-2002) and the Osaka Medical Center According to recommendation JAPAN, OSAKA PREFECTURE (1998-2002) for Cancer and Cardiovascular of the Japanese Ministry of Diseases (OMCCD) since 1962. Health, Labor and Welfare, women over age 30 have been The central registry, located in the screened for cervical cancer Department of Cancer Control 


 









since 1982 (proportion of cases and Statistics of the OMCCD, is 







receiving screening was 16.5 % staffed by 9 regular employees (2 

 












medical doctors, 2 public health in 2001, in Osaka), and for breast 




 


nurses, 2 system engineers, 1 cancer since l987 (11.2%). The 














operator and 2 clerks) and 7 partpopulation over age 40 has been 







time workers. screened for stomach cancer since 














The OMA requests that 1982 (15.7% in male and 11.8% 







all medical institutions in in female), lung cancer since 

 












the Prefecture cooperate 1987 (9.2% in male and 6.5% in 





 

with cancer registration, and female) and large bowel cancer 







 


 


prepare cancer reports when since 1992 (11.2% in male and 





 

cancer diagnoses are made. The 9.0% in female). The screenings cancer reports are sent to the are all opportunistic and the       OMA, and they are transferred proportions screened remain "!3.*0 %"!3.*0 +)3,62333 ( 13/-+333 monthly from the OMA to the low in Osaka. PSA testing is not 



/3-)/3)16333 "! central registry. Information on common yet in the population. 
   3%"3&3!"3
!"3 %33+6613"3,)))33""'3"33 3,))+3"3,)),3 death certicates mentioning ,)))3(33""3 3+6653"3+6663 3&3!"3$"
!"(3 73,)))(3"3"'3""%3"3 "3
'3%3 3"
"'3,)))3
!"3 cancer is also obtained through 3 3"
"'3#!(3,8,8,43)""8 (3'3,))+(3+661(3"3"'3""%3"3 "3
'3%3 3 the OPDHW. Use of the data "
"'3+6613
!"3 3 3"
"'3#!(3,8,8,43""8 (3'3+662(3  



 The data are processed in an annual batch via mainframe, The major objectives of the OCR are (1) to estimate incidence 
3!3.+66)03 although the data processing has changed to an online network rates, (2) to compute statistics on medical treatment given with client-server system. Computerised record linkage is to cancer patients and (3) to estimate survival for cancer used to avoid duplicate registration, distinguish multiple patients. Annual reports including these statistics have primaries, and identify registered cases who died of cancer been published. Summary statistics of these can be seen and cancer deaths that had not been registered. Computer- on the OMCCD website (http://www.mc.pref.osaka.jp/ produced possible matches are shown and resolved manually ocr_e/index.html). The OCR takes the initiative to conduct through referring to the original reports. epidemiological research, and policymakers use our cancer In order to evaluate survival of cancer patients, active follow- registry data for planning and evaluation of health services. up to ascertain vital status has been undertaken progressively. High-quality survival data have been available for patients Source of population diagnosed from 1975 except for Osaka City, and all patients 2000 census. The data for 1998 and 1999 were estimated by diagnosed after 1993 in Osaka Prefecture. Proportion of the linear interpolation from the 1995 and 2000 census data, and lost-follow-ups has been 1-2% at ve years after diagnosis. those for 2001 and 2002 were by linear extrapolation. Refs: The OCR has implemented cancer information service 2000. Statistics Bureau, Management and Coordination programs since 1975. The prognoses of reported patients, as Agency, Government of Japan, 2000 Population Census of well as cancer statistics of each hospital, are provided at the Japan, Vol. 2227 0sakaPrefecture. Tokyo, 2001. 1995. request of participating hospitals or hospital doctors. The Statistics Bureau, Management and Coordination Agency, central registry holds an annual conference to report and Government of Japan, 1995 Population Census of Japan, Vol. discuss cancer registration activities, inviting representatives 2227 OsakaPrefecture. Tokyo, 1996. from all large and medium-sized general hospitals and clinical departments of medical university hospitals. Since Multiple primary rules used 1999 software has been developed and distributed to support IACR rules (1990).

240

Asia

Japan, Yamagata Prefecture

Registration area The Yamagata prefectural cancer registry covers the entire Prefecture of Yamagata, which is located in northeastern Japan. It lies between latitudes 37 and 39N and longitudes 139 and 140E. The total registered area is 9323 km2, and over two thirds of the area consists of forests and mountains. The 2000 census determined the total population of the Yamagata prefecture was 1 244 147 and composed of 99.6% Japanese nationals. Of working adults, 54% are engaged in the sales and service industry, 35% work in construction and manufacturing, and 11% work in agriculture. The population of people who are 65 years and over was 23% in 2000 and 16% in 1990. Cancer care facilities In 2000, Yamagata had 2307 physicians (1.9 per 1000 inhabitants) and 11 336 hospital beds (excluding psychiatric hospitals). The prefecture is divided into 4 healthcare districts. Each district has several core general hospitals, where two thirds of the cancer patients in Yamagata prefecture are diagnosed and treated. Eight of the hospitals have a radiotherapy unit. about these cases. The registry staff has access to all death certicates with their personal information. A research group supported by the Grant-in-Aid from the Ministry of Health, Labour and Welfare since 2004 monitors quality standards in the registry every year. In 2005, we performed data cleaning for all registered data in 2005, including converting site and histological codes from ICD-10 and ICD-O-3 to ICD-O-3.

Registry structure and #!*',*** ' "-*-("*** methods ",*'(%***  "+*"(#*** The Yamagata prefectural Use of the data cancer registry was established The registry provides periodic ! '   ' ! in 1974. The prefectural reports on cancer incidence  *$ &  *$ & !,#***  !*** government nances the and ve-year survival (%#*#'(*** (!*!,(***  registry. A full-time medical statistics. The regional health 
   doctor as the medical !--,*!---"!*""*
 * ***!--'**"*  **"*  **$*   * *&* authority for planning and  



 supervisor and researcher staffs the registry, and also a full- evaluating health services uses the data. The data are also  ****
* time and a part-time registered staff member since 2004. used to estimate cancer incidence in Japan. Before 2004, it was staffed by a part-time medical doctor and a part-time registered staff member. Source of population Although cancer is not a notiable disease, the main 1998, 1999, 2001, 2002 estimates based on the 1995 and method of data collection is passive notication. To increase 2000 census data; 2000 census. (Vital statistics of Japan). the number of notications, the registry staff supplements their casending with pathology reports from several major Multiple primary rules used general hospitals and request physicians to be notied Impossible to detect multiple primary.

Interpreting the results The establishment of three major general hospitals in 1976, 1993 and 2000 likely altered the availability of diagnostic and/or treatment services. Since our establishment in 1974, there has been no serious environmental or occupational exposure that may inuence JAPAN, YAMAGATA PREFECTURE (1998-2002) cancer incidence in the JAPAN, YAMAGATA PREFECTURE (1998-2002) population. Organised screening programs are conducted in Japan (for gastric and cervical ,*%"-*** ,') "*%*** !"*(-+*** , ""*,%,*** cancer since 1961 and for colon, ""*(!%*** +' #'*,",*** lung and breast cancer since #%*%+'*** + %%*-#*** #,*!(,*** (' %'*%+%*** 1987). Screening for breast #(*-#*** ( %!*(#(*** cancer by mammography #(*-*** '' #+*+,*** %,*+('*** ' %'*#+'*** was introduced in 2002. %,*!-+*** %' %(*++*** The prostate cancer cases %*,+,*** % %*"-*** #'*-",*** #' #'*-%,*** diagnosed by opportunistic #%*#"#*** # ##*-'(*** PSA testing have been #(*"+!*** "' #%*,+!*** ##*(%*** " #!*!(!*** increasing in several hospitals #+*'''*** !' #'*+,#*** recently. #'*(!"*** ! #%*!'!***

241

Asia

Korea
cancer registrar training, (3) analyses and summary of data Registration area The Republic of Korea (South Korea) occupies the southern from the central and regional cancer registries, (4) carrying portion of the Korean Peninsula. It lies between longitudes out administrative tasks related to the registry. The KCCR established the Korea National Cancer 124 and 131E and latitudes 33 and 38N, and has an area of 99 500 km2 including about 3000 islands. South Korea is Incidence Data Bases (KNCIDB) by merging the KCCR highly mountainous, and lowlands constitute only 30% of mother DB and all 8 population-based Regional Cancer the total area. There are seven cities with provincial status Registry databases, the site-specic cancer registry databases (breast, uterus, ovary, oral cavity, liver cancer), and nine provinces. The population of the Republic of Korea is 48 million the medical record review survey and the cancer mortality (2005 estimates), which the Central Cancer Registry is database from National Statistics Ofce. For the medical supposed to cover. Its population density of 493/km2 is one review survey, a 1999-2003 cancer claims DB from the of the highest in the world. Annual population growth has National Health Insurance Corporation was also used. The dropped steadily from more than 3% in the late 1950s to dataset was rened further by conrming multiple primaries and removing duplicates with 0.38% in 2005. Due to rapid expert help from various urbanisation, 80% of the elds-clinicians, pathologists population is now classied KOREA (1999-2002) and medical recorders. as urban. The population is KOREA (1999-2002) In an effort to improve ageing very quickly: The 2003 the KCCR data quality, population estimate revealed data completeness has been that 8.3% were 65 years old evaluated, with a preliminary or over; 71% were aged 1564 


 








result as high as 90.3%. We years. South Korea is one of the 







are in the process of evaluating most ethnically homogeneous 





 






 

the accuracy of stomach countries in the world. Most 







cancer data through abstractpeople are ethnically Korean. 











 






reabstract method, and plan Buddhism and Christianity are 






 


to perform the evaluation on the largest religions in South 


















a regular basis for additional Korea, but Confucianism, 









types of cancers. rather a philosophy than a 


















religion, is in many ways more 






 


Interpreting the results prominent in Korean culture 


















To cover cases diagnosed than any organised religion. 









outside KCCR-afliated In 2004, the economically hospitals, we perform an active population was 23.3       .)%+  .)%+ additional medical record million. Of this gure, 8% 



'(./(&.,(-...  review survey and supplement were engaged in agriculture, our data with cases from forestry and shing; 27% in 
   0..)....&..+".!...".. . regional registries. Thus industry; and 65% in services. ......... ........ ...  ..#.  



 data completeness in areas with regional registries may be 

..)'$$*+..
,... different from those without. Cancer care facilities In 2000, most teaching hospitals in Korea could not In 2005, there were approximately 1500 hospitals in Korea, 1000 of them, including 29 multidisciplinary cancer provide medical service properly at least for 3 months due treatment units, providing specialised cancer diagnostic to a doctors strike. Delayed diagnosis and reporting of new and therapeutic services. There were 60 radiology units and cases resulted, which could decrease the number of 2000 123 specialists nationwide in 2006. In addition, 2500 out of cases and increase the 2001 cases. The National Cancer Screening Program (NCSP) was 26 000 private clinics provide general cancer care services. implemented in 1999 and has since expanded its target population and cancers. NCSP provides screening for Registry structure and methods The Korea Central Cancer Registry (KCCR) was one stomach, liver (high-risk groups only), cervical, breast and of the ambitious projects of the Ministry of Health and colorectal cancer. Opportunistic screening is also common. Welfare in 1980. Beginning in 1982, 47 general hospitals Annual PSA testing is actively recommended by urologists voluntarily participated in this program. Participating for men aged over 50. Though there are no ofcial data, most hospitals and registered malignancies increase annually, men over 50 have received a PSA test. Even though the 2003 Cancer Act clearly stated that and 154 of 242 teaching hospitals participated in 2005. The KCCR is composed of a chief, an executive secretary (head cancer registration should be performed to know the burden of cancer registration), a medical ofcer, 6 cancer registrars, of cancer, privacy protection laws prohibit access to personal 6 statisticians, and 11 advisors. In a 2004 workshop for information. An amendment to the Cancer Act to allow the new cancer registry manual, approximately 300 cancer access is underway. registrars attended from the hospitals. The KCCR is responsible for (1) collection, analysis Use of the data and management of national cancer statistics, (2) technical The KCCR has released its annual reports since 1983, and and nancial support of regional cancer registries including published Cancer Incidence in Korea 19992001 in August

242

Asia

2005 as the rst cancer incidence report based on the entire population using KNCIDB. Annual data are published in the ofcial journal of Korean Cancer Association (Cancer Research and Treatment). The KCCR provides data without personal information to researchers as well as other government departments for statistical analysis. Registry data are essential to evaluate cancer control programmes in Korea, including the National Cancer Screening Program.

Source of population The population used to calculate cancer incidences is a midyear population (the population at the 1st of July), but in this report, the modied resident registration population data that is released annually from the Korea NSO was used. Multiple primary rules used IACR rules (2004) on CI5 IX period.

243

Asia

Korea, Busan
Registration area In 1995, the Busan Cancer Registry (BSCR) was established in cooperation with the Cancer Centres of four University hospitals, and has administratively been supported by the Department of Public Health and Sanitation of Busan City and the Medical Association of Busan. The Korean National Cancer Control Program is responsible for the nancial support of the registry, with technical support from the Korea Central Cancer Registry. The city of Busan is located on the southeastern tip of the Korean Peninsula, between latitudes 3452 and 3523 N, and longitudes 12852 and 1298 E. The city has an area of 531.17 km2. At the 1995 census, the total population of Busan was 3 806 888, of whom 99.6% were Korean. Statistical Ofce (NSO), and are compared with Registry les. If a deceased person were not registered, the Registry staff would obtain the appropriate medical records from the hospital where the case was diagnosed and treated. We are in the process of evaluating the accuracy of stomach cancer data through abstract-reabstract method, and plan to perform the evaluation regularly for additional types of cancers.

Interpreting the results We collected data according to ICD-O-2, but reported in ICD-O-3 format. In 2000, most teaching hospitals in Korea could not provide medical service properly for at least for 3 months due to a doctors KOREA, BUSAN (1998-2002) strike. As a result, diagnosis Cancer care facilities KOREA, BUSAN (1998-2002) and reporting of new cases In 2005, there were were delayed, which could approximately 110 hospitals decrease the number of 2000 including teaching and cases and increase the cases general hospitals (4 university 


 









reported in 2001. hospitals and 22 general 







Even though the Cancer hospitals) in Busan. Because 














Act launched in 2003 clearly Korea is a one-day life zone 







stated that cancer registration for the whole country, every 














should be performed to know cancer patient can go to other 







the burden of cancer; the regional hospital if he/she 














regulations prohibit accessing wants. 







personal information based on 














the personal privacy protection Registry structure and 







law. The amendment of the methods 












 

Cancer Act to allow access for The nation-wide, hospital-based 







personal information based Korea Central Cancer Registry on the National Statistics Law (KCCR) was established in       is underway. Registration of 1980 and has been managed -)%+  -)%+ 2003 cancer cases is ongoing. by the Ministry of Health and 



&-.//-(&*-- The Korean Government Welfare (MOHW) since then. 

   0--)----&--+"-!---"-- began implementing the All inpatient cancer cases are ---------------- ---  --#voluntarily notied to the KCCR by the Medical Record National Cancer Screening Program (NCSP) in 1999 and  



 

--)'$$*+--
,--has since expanded its target population and target cancers. Department of about 80% of teaching hospitals. In 1995, a pilot study was conducted to expand the into In 2006, NCSP provides cancer screening for 5 major a population-based registry of Busan. We found that 72% cancers including stomach, liver (only for high-risk groups), (67% from hospitals in Busan; 5% from other places) of the cervical, breast and colorectal cancer. Urologists actively total incidental cancer cases could be registered using the recommend annual PSA testing for men aged over 50. There is no available information on the prevalence of the test; KCCR data and the remaining 28% by active registration. In Busan, there are 26 large hospitals including four however, most men over 50 receive a PSA test. university hospitals and additional 80 medium- and smallsized hospitals. Among these, 22 teaching hospitals notify all Use of the data inpatient cases as well as some of outpatient cases to KCCR. The Registry holds an annual conference to report and discuss The KCCR annually gives data to the BSCR on the cancer cancer registration activities in Busan, and invites oncologists patients living in Busan at the time of their initial cancer from the four University hospitals, representatives of the diagnosis. Cases from hospitals in other places are treated Association of Anatomical Pathologists and Diagnostic similarly. Additional cancer cases from outpatient clinics are Radiologists, radiation therapists and medical recorders of identied from the records of the Departments of Anatomical the Busan hospitals. The President of the Medical Association of Busan and the Chief of the Department of Public Health Pathology, Diagnostic Radiology, and Radiation Oncology. Three part-time medical ofcers visit 110 hospitals and Hygiene of Busan City are also invited. The data are published in an annual report that provides that are currently not notifying cancer patients to the KCCR, and collect the medical records of newly diagnosed the basic statistics on cancer incidence that may be helpful for cancer patients. They register the cancer cases, which are evaluating survival of cancer patients. BSCR data, included then scrutinised by Registry faculty members under the in the KCCR data, is provided without personal information supervision of the Registry Director. Death certicates of to researchers as well as other government departments for all cancer patients are obtained annually from the National statistical analysis. The cancer registry data are essential to

244

Asia

evaluate various cancer control programs in Korea, including the National Cancer Screening Program. Source of population The population used to calculate cancer incidences is a midyear population (the population at the 1st of July), but

in this report, the modied resident registration population data that is released annually from the Korea NSO was used. Multiple primary rules used IACR rules (2004) on CI5 IX period.

245

Asia

Korea, Daegu
Registration area Daegu is an extended metropolitan city in southeastern Korea with a well-dened geographical border surrounded by mountains. It covers an area of 885.56 km2. The climate is temperate; it is situated at 128 E and 35 N. The 2000 population was 2 473 990 by 2000 census report. About 6% of the population lives in rural areas. Korea has virtually no ethnic group except Korean, only about 151 000 persons being registered as foreigners nationwide. However, international marriages are increasing rapidly, especially in rural areas. The proportion who had more than junior college education is 18.7%. More than half (52.4%) of Daegu citizens reported practicing a religion in 1995; 33.1% Buddhist, 11.6% Protestant, 6.7% Catholic. Cancer care facilities Medical care for the whole population is covered and provided by the National Health Insurance Plan. Daegu has 16 223 hospital beds in 2002, in 74 hospitals (12 general hospitals, 51 hospitals, 9 dental hospitals, and 2 mental hospitals), of which four are university hospitals and 1274 private clinics. There are 4722 doctors including dentists. records. Mortality les containing data on all cancer deaths are obtained annually from the Korea National Statistical Ofce. Cancer cases on insurance claims not matched to DCR data are followed back to the hospitals to conrm the diagnosis. The data are processed using the IARC/IACR CanReg software. The registry uctuations in reporting of new cancer cases by institution and source of case-nding are analysed monthly and annually. The registry carries out reabstracting and recoding periodically and uses CanReg to ascertain multiple primaries and DEPedits to see unusual combinations of various kinds. Conventional medical records are being replaced by EMRs (electronic medical records) including inpatient records in some university hospitals. We are establishing a new system to more efciently collect computerised incident cases.

Interpreting the results There was no change in area KOREA, DAEGU (1998-2002) or population covered during 19982002. The DCR has been using ICD-O-2 for coding since its inception. However, several 


 


doctors strikes happened during 







2000, substantially lowering 

 












cancer cases diagnosed that 







year. DCO% is 4.4 (males 4.5, 














females 4.4). 






Organised stomach, breast, 








 





Registry structure and cervical, liver and colorectal 





 

methods cancer screening programmes 














Daegu Cancer Registry, for persons aged more than 40 





 

nancially supported by the began in 1999. However, these 














Ministry of Health & Welfare, programmes are not the same 







has been collecting new cancer as those in developed countries. cases in Daegu since 1 January Some of their costs are just       
($ & 

($ & 1997. Located in the Dongsan covered by Gover n ment 



!(")#(%"#(((  Medical Centre, Keimyung subsidies. During 19992002, University, the staff consists 
   the uptake rate of the screening of two doctors, one medical 
(

((
(  **(
(
((
("(
( (
(((
(( ( tests was very low. We do not  



 
(
($"%&(('((
( records administrator and one medical records technician. collect information on whether a cancer case is diagnosed by the Cancer reporting is voluntary in Korea. DCR receives screening or diagnostic tests, so the number of these included in inpatient cases from the medical record technicians responsible for our databases is unknown. PSA testing in Korea is opportunistic; it reporting cases to the Central Hospital Cancer Registry (CHCR), is usually done as part of Comprehensive Health Checkups but and inpatient cases with an address in Daegu treated outside it there are no statistics to cite. direct from the CHCR. CHCR has been collecting cancer cases from major member hospitals in Korea since 1980. The staff of Use of the data the DCR visits every major hospital dealing with diagnosis and DCR is an incidence registry and is not actively collecting survival treatment of cancer to nd and abstract cancer cases from sources data on registered cases. It collects vital status when the information other than inpatients, such as pathology, haematology, CT/MRI, is available, for example from medical records, death certicates nuclear medicine and radiotherapy medical records. The cases or the ofcial cancer mortality data. It does not collect stage of from the other sources in hospitals are followed back to the disease. Currently, the registry is being used in Effects of doctors original medical records to check the addresses, unique Resident walkouts on cancer cases diagnosed in 2000 in Daegu, Estimation Registration Number (RRN) and diagnosis date. The staff also of lifetime and age conditional probabilities of developing cancer, visits private pathology laboratories to review pathology reports Survival of gastric cancer patients in the young, and Changes of and sends query letters to physicians who sent their samples to cancer stages for major cancers in 19972003. We are planning the laboratory to obtain further information. to establish an occupational cancer registry as well as a birth After checking for duplicates, the database is matched defect registry as ramications of the DCR. against two external data sources, the ofcial cancer mortality data and insurance claims. Cases not already in the database Source of population become Death Certicate Notication (DCN) cases because The estimates of the populationatrisk are based on the 2000 death certicates do not contain information that makes follow- census, making allowance for births, deaths and migration. back possible. Instead, the RRN is used to clear the DCNs. The DCNs were matched with the databases of the seven major Multiple primary rules used hospitals using the RRN to find out and abstract medical IACR rules (2004) on CI5 IX period.

KOREA, DAEGU (1998-2002)

246

Asia

Korea, Daejeon
medical record review surveys, site-specic cancer registry Registration area Daejeon is located in the centre of South Korea: 167.3 km databases and cancer mortality data for identifying Death from Seoul, 294 km from Busan, and 169 km from Gwangju. Certicate Only (DCO) from the Korea National Statistical The city is located between 1273321 and 1271454 E Ofce (KNSO). In an effort to improve the quality of the KCCR data, longitude, and 361050 through 362947 N latitude. Daejeon is surrounded by four mountains and located along an evaluation of data completeness has been conducted, in three major rivers; the city originally developed from farms particular cases diagnosed during 19992001 and cases and houses that were on the hillsides and the valleys between deceased until 2003. We used the ow method developed them. The three rivers divide the citys ve boroughs: Dong- by Bullard et. al (Br. J Cancer 2000). The ow method is gu and Daedeok-gu are located east of Daejeoncheon; Jung- based on the concept that registration is a time-dependent gu is between Daejeoncheon and Yudeungcheon; Seo-gu is event observed after diagnosis, following a probabilistic between Yudeungcheon and Gapcheon; and Yuseong-gu is approach. The overall 3-year completeness of all cancer was west of Gapcheon. 90.5%, 90.7% in males and 90.3% in females. There were Daejeon is the fth among no differences in gender and South Koreas largest six among different age groups. cities, including Seoul, Busan, We are in the process KOREA, DAEJEON (1998-2002) Daegu, Incheon, and Gwangju. of evaluating the accuracy KOREA, DAEJEON (1998-2002) Its population is 1 390 510 and of stomach cancer data it covers an area of 539.83 km through abstract-reabstract at the end of 2000. method, and plan to perform The population is mainly the evaluation on a regular " """ $! "$""" """" $ """" of the Asian race (mostly basis for additional types of " """ # $" #""" Korean); religions are cancers. #"%""" # "$$""" """"   "%$""" Buddhism 26.0%, Christianity $"%$"""  " """ Interpreting the results 20.6%, Catholicism 5.4% the "$"""  " """ """"  %" %""" We collected data according others 1.6% and no religion "#%"""  " #""" to ICD-O-2, but reported in 46.5%. """"  "#""" "#%"""  " """ the ICD-O-3 format. "%"""  " #%""" To cover cases diagnosed Cancer care facilities "%"""  " """ %"#$$"""  %"%#""" outside Daejeon hospitals, we Both public and private sectors "%"""   " $""" performed additional medical provide cancer-related services " """  #"$ """ $" """  "%%#""" record review surveys and in this region. General health "$ """  #" """ also supplemented our data care in the region is provided with cases from KCCR. by the 9 general hospitals and       In 2000, most teaching 20 hospitals (2003). Daejeon  "   " hospitals in Korea could cancer registry cooperates $"$#%""" $%" """  not provide medical service with 6 registry hospitals and 
   properly at least for 3 months many non-registry hospitals.  ""  "  



 due to doctors strikes regarding separation of prescribing There were 4 therapeutic radiology units in 2006. 
 "
 """""
" Also, the Korean government provides the National Cancer from drug dispensing. As a result, diagnosis as well as Control Programme, mainly related to cancer prevention, reporting of new cases were delayed, which could increase screening and supportive-palliative care including National the reported cases in 2001 as the incidence date is the rst Cancer Screening Program, Terminal Cancer Patient date of diagnosis on cancer. Urologists actively recommend PSA testing for men Management, Home-based Cancer Patient Management through National Cancer Center of Korea. Private hospitals provide aged over 50 annually. There is no available information on mainly diagnostic and therapeutic services. the prevalence of the test; however, most men aged over 50 receive a PSA test once in their lifetime. Registry structure and methods Cancer is not a notiable disease in Korea; however the Use of the data Cancer Act (2003) clearly states that cancer registration must The registry prepares an annual report of cancer incidence, be performed to know the burden of cancer. The Daejeon highlighting trends and changes. Some special studies of Cancer Registry (DJCR) is a population-based registration survival of registered cancer cases will be carried out. that has been in operation since 1998. The registry is located The cancer registry data is essential to evaluate various in Medical School of Chungnam National University. A cancer control programs in Daejeon, Korea including the medical doctor, a full-time registrar and one part-time National Cancer Screening Program. registar staff the registry. The DJCR is responsible for (1) collection, analysis and Source of population management of Daejeon cancer statistics; and (2) analyses Census and estimate. and summary of data from Daejeon cancer registries. The data sources for the Daejeon cancer incidence database are Multiple primary rules used the DJCR, the KCCR database, the data from additional IACR rules (2004) on CI5 IX period.

247

Asia

Korea, Gwangju
registered. Data obtained from outside sources are reviewed Registration area Gwangju (formerly transliterated into English as Kwangju) with the collaboration of Korean National Cancer Institute has 1.36 million inhabitants and is situated on the and other regional cancer registries. Death certicate data are obtained from the Korea southwestern tip of the Korean Peninsula. The city is the economic, educational and cultural centre of essentially rural National Statistical Ofce. The death certicate data are surrounding provinces. The rapid transition of the Korean then merged and veried with the GCR database, teaching economy from agriculture to manufacturing industries hospital records and cancer claims data. Subsequently, the during the authoritarian governments during the past 30 years death certicates, which have no linked information, would leaves the area to suffer from low income and emigration of be treated as death certicate only (DCO). Our registry has regularly evaluated the completeness and working-age population to the more industrialised parts of accuracy of information recorded through record linkages the country. The 1980 uprising proclaiming the democratic with other registries, routine checks using the IARC tool, governmentthe Gwangju democratization movement and reabstracting of medical records. The Ministry of Health allegedly made the city and Welfare of the Korean politically well known. government provides nancial There are some KOREA, GWANGJU (1998-2002) support. manufacturing industries KOREA, GWANGJU (1998-2002) including an automobile Interpreting the results assembly plant, though the In Korea, there are ve service industries occupy national screening programs the majority of the citys .$$+++ -(* &+#"#+++ #+ &&+++ -  (+)) +++ for stomach, colorectum, workforce. &+&()+++ ,( .+$# +++ breast, uterine cervix, liver ,+," +++ ,  "$+ ,,+++ "#+&$-+++ )( ",+$,-+++ cancer. PSA testing has Cancer care facilities ".+,.&+++ )  ##+--$+++ increased during this period According to 2002 statistics, #(+&$,+++ (( #)+- (+++ $"+$(&+++ (  $#+)".+++ even though it is not involved the city has 10 general $-+.- +++ &( & + #.+++ in routine screening for hospitals, 24 hospitals with ((+# )+++ &  ()+&,&+++ )"+" $+++ $( ) +"))+++ cancer, and its inuence on 7674 hospital beds. Two )&+. #+++ $  )$+&.&+++ the prostate cancer incidence traditional medicine hospitals )(+,&-+++ #( )(+ ($+++ )$+&$(+++ #  )#+.&&+++ is not clear. ICD-O-2 was also provide palliative services )"+#$-+++ "( (,+)& +++ used for years 19982002; to cancer patients. (#+("(+++ "  &-+),.+++ (.+"$-+++ ( ($+&$#+++ for incident cases from 2003, ($+.#.+++  &.+)"$+++ ICD-O-3 has been used. Registry structure and methods " ( ( " 
+%!' 

+%!' Use of the data The Gwangju Cancer Registry )-.+&,,+++ )- +$(.+++  The cancer incidence and was established in 1997 after other statistics contained in the a yearlong feasibility study. 
   annual report are recognised The registry is operated "..-+"...+# +# "+# #/+


+  +
+++


+  +% ++"...+# +# "+# #+# $'+  



 
+
+%# by director, part-time medical staff &'++++ and one or two full- as ofcial public data of Gwangju metropolitan city. Each year the Registry submits the annual report to the time registrars. The registry has a management committee composed of directors and oncologists of major hospitals City Hall. The City Hall then makes a public announcement and the chief of the Gwangju metropolitan city health of the statistics and distributes copies to the relevant department. The committee determines the major direction agencies. Local health departments and public health centres of the registry activities and cooperates in data collection use Registry data for planning or evaluation of their health as well as advocates the registry. There is also a practicum services. We permitted access to our registry database for committee composed of hospital medical record keepers to public health and clinical study, if not conicting with our condentiality guidelines. handle the practical details of cancer registration. The Registry has participated in some epidemiological study The majority of the case information is linked to the Korean Central Cancer Registry (KCCC), which is for regional difference of cancer, such as thyroid cancer. Follow-up for survival of cancer patients and publication provided by teaching hospitals throughout the country. The corresponding hospitals in the city provide the data directly of an English version of the annual report are under to our registry. Data on Gwangju residents registered from consideration. hospitals outside of Gwangju city are obtained from KCCC database. The cancer claims data for medical insurance Source of population are also used, especially for the non-teaching hospitals. 1998, 1999, 2000, 2001, 2002: Registered population; the The pathology reports without signicant hospital records, statistics of registered population (Gwangju city, 1999, 2000, outpatient department (OPD) reports and radiation oncology 2001, 2002, 2003). records are also examined for adjuvant information. The registrar reviews the original information by hospital Multiple primary rules used visit and medical record check. The justied cases are nally IACR rules (2004) on historical data.

248

Asia

Korea, Incheon
Registration area Incheon is the third largest city in South Korea and is located on the western part of the Korean peninsula with the sea to the west and metropolitan Seoul to the east. It is an industrialized city with a well-established medical delivery infrastructure. The population of the city according to socialID registration by Statistics of Incheon city was about 2.63 million in December 2005. Most of the population is Korean (98.6%). ofcials, and has performed mail research to identify cancer patients from the hospitals which had identied the patient as having died of cancer. ICR primarily classies cancer patients by ICD-O-3 and multiple cancer and other specic classications in accordance with the KCCR guidelines based on IARC manual. ICR uses its own registration format, which has more mandatory and optional items than KCCRs, and removes duplications and errors from the data by an ICR computer programme. Follow up information is obtained predominantly by passive methods. These include obtaining cancer mortality Cancer care facilities More than 100 medical institutions are in Incheon, and three information from death certicates in the Vital Statistics university hospitals are available in diagnostic and treatment section. The mortality data are periodically matched with the incident cancer database service for cancer. Patients using the National Identity suspected to have cancer in the number. The vital status of the primary and secondary care KOREA, INCHEON (1998-2002) unmatched incident cases is facilities are mostly referred KOREA, INCHEON (1998-2002) also ascertained by review of to one of the three University medical records. However, all hospitals. Two hospitals have incident cases for which death all cancer treatment facilites, information is not forthcoming 10 have chemotherapy, 3 have #,/'*,,, .)+ ),'#-,,, ',%)',,, .! .,.%.,,, are presumed to be alive on radiotherapy and 46 have .,.%.,,, -) #*,%/.,,, the last day of the year for surgery. #%,)!#,,, -! $',!/!,,, $$,'#',,, *) %$,%*',,, which the mortality data are %',-/),,, *! '!,'*-,,, fully utilised for matching. Registry structure and '',/*#,,, )) '),-'.,,, )-,.%-,,, )! )%,%-%,,, methods .#,//!,,, ') -',#/!,,, Interpreting the results The Incheon Cancer Registry #$*,.-),,, '! ##),!%',,, #%.,*/',,, %) #%!,#/!,,, National cancer screening was organized in 1997 by #$/,.%',,, %! #%!,-//,,, programs have been applied Inha University Hospital in ##%,%'!,,, $) ##$,*.-,,, /-,)%!,,, $! /','%/,,, for cervix and lung cancer. collaboration with the Korean //,-.-,,, #) /',$#%,,, The incidences of prostate Central Cancer Registry /-,#'.,,, #! /!,').,,, ###,)/*,,, ) #!#,$%),,, cancer have been very low as (KCCR) and is incorporated in /',*!!,,, ! .*,)'*,,, compared to other developed the International Association countries, so the national of Cancer Registries. #! ) ! ! ) #! cancer screening program Financial support is ,&"( ,&"( #,$)*,'.*,,, #,$.!,!'$,,,  did not cover PSA test for provided primarily by KCCR detection of prostate cancer. and partly by Inha University 
   ,$!!!, ,
 ,$!!#,$!!$,, Many individual hospitals Hospital. ICR was composed #//.,#///,,
,, ,,,,, ,, 
,, ,,,,, ,,  , of 7 members, 5 from Inha University Hospital and 2 from employ PSA testing on a case-by-case basis.  



 

,,&$!!'(,,
),,, GachunGil hospital. There are four main sources of cancer registry in Use of the data ICR. The primary source of the ICR data is the registry We report the incidence of cancer annually by site, sex and les from the KCCR (Korean Central Cancer Registry) at age excluding extent of disease or survival to the government. National Medical Center, which are transferred from each Policymakers in government use regional cancer registry regional cancer registries including ICR, allowing ICR to data, including Incheon Cancer Registry, for developing collect cancer cases diagnosed in Incheon as well as outside health services or laws. Incheon. The secondary source was cancer cases registered at non-KCCR hospitals in Incheon. Others come from health Source of population insurance documents (medical insurance claims) and death 1998, 1999 estimated, Annual statistics of Incheon city on Registration of Social Identication. 2000 National Census. records from the National Statistic Ofce. Trained medical record administrators (MRA) review 2001, 2002 estimated, Annual statistics of Incheon city on the inpatient and outpatient medical record including Registration of Social Identication. pathologic, radiologic and endoscopic reports. To collect the death certicate cases from death records, ICR has applied Multiple primary rules used the public-health personnel with the support of Incheon city IACR rules (2004) on CI5 IX period.

249

Asia

Korea, Jejudo
epidemiology. The other staff member is a medical recorder Registration area The Jejudo registry covers the population of Jejudo Island, who visits the regional hospitals that are able to diagnose which is situated in the southern part of Korea peninsula, cancer; reviews medical charts, and gathers information between latitudes 33 and 34 N and longitudes 126 and about cancer incidence. 126 E, and is the largest island in South Korea with a total Among the six hospitals in Jejudo, two teaching hospitals area of 1848 Km. The island came into existence 700 to report all inpatient cancer cases as well as some outpatient cases 1200 thousand years ago when lava spewed from a sub-sea to KCCR. The KCCR annually offers information to the JCR on volcano and surfaced above the waters. The annual mean the cancer patients with an address in Jejudo at the time the initial temperature reaches 17C and the annual rainfall is about diagnosis of cancer is made. Another source of registration is an 1676 mm. It is famous as the clean island in Korea because active search by the registrars for cancer patients diagnosed in there are no industrial factories giving rise to air and/or the non-KCCR registered hospitals in Jejudo. The registrar visits environmental pollution. these hospitals to review and abstract medical records of potential The population as of 2001 was 546 696. Of the economically cancer patients who appear in the list of cancer claims submitted active population, 71% is to the NHI. This list also serves engaged in the service industry, as a good source for tracking the 25% in agriculture including identity of cases notified by a KOREA, JEJUDO (2000-2002) shing, and 4% in industry. death certicate alone. KOREA, JEJUDO (2000-2002) The religious distribution Death certificates for all in residents is as follows: cancer patients are obtained Buddhist 36%, Christian 17%, annually from the National Confucian 3%, and atheist Statistical Office, and are """ $! """" "#""" $ "$""" 44%. Almost all of residents compared with the le entries "$$#""" # "#""" are Korean; the proportion of cases in the registry using the "#""" # #"##""" #" """  """" of foreigners is 0.1%. Thus, unique Resident Registration """"  "#""" we exclude events of cancer Number (RRN). The cases not "#$"""  "%""" """"  "#$""" incidence in foreigners. already registered in the databases  " %"""   """" become Death Certificate "#%"""  "%""" "%"""  "#$""" Cancer care facilities Notication (DCN) cases. For  "%"""  "#""" the DCNs, the registrar searches Medical care for the whole """"  "$$""" "$%"""  " $ """ population is covered and and reviews medical records from """"  %" """ the six hospitals using RRN. provided by the National Health $"$ """  #"%""" """"  """" The JCR evaluates the Insurance (NHI) Plan. All "%# """  %"""" validity of the registry data six hospitals (two general and with the IARC CHECK four private) on the island can        "   " program and re-abstracts the diagnose cancer. However, one #"""" #" """   medical records to check for general and one private hospital errors in the data. among them can treat cancer 
   patients because only these two  "  



  " "  "  "


" hospitals have oncologists and cancer treatment facilities including Interpreting the results radiotherapy departments. Hospital beds in these hospitals total There was no change in area or population covered during the period of 20002002. The JCR has been using ICD-O-3 1528, approximately 2.8 beds per 1000 residents. for coding since its inception, and there has been no change in case denition and coding. Registry structure and methods The NHI in Korea supports a biennial cancer screening Jejudo Cancer Registry (JCR) has been collecting new cancer cases occurring in Jejudo since 1 January 1999. It is program for all Korean people aged above 40 years, including located in the Cheju National University College of Medicine Jejudo residents. The sites covered by the programme are (CNUMC). It receives nancial support from the Korean stomach by endoscopy, colon by colonoscopy, breast by National Cancer Control Program, and is administratively mammography, uterine cervix by Pap smear test, and liver by supported by the Department of Public Health and Sanitation ultrasonography. PSA testing is not common but is feasible as it is not expensive. of Jejudo Provincial Government. The Ministry of Health and Welfare (MOHW) established the nationwide, hospital-based Korea Central Cancer Use of the data Registry (KCCR) in 1980. According to the KCCR program, The registry prepares an annual report of cancer incidence, the medical records department of nationwide teaching highlighting trends and changes in Jejudo, Korea. Some hospitals noties all in-patient cancer cases voluntarily. In special studies of the utilisation pattern of medical services 2000, a pilot study was conducted to expand the pre-existing in the registered cancer cases have been carried out. hospital-based registry into a population-based registry for Jejudo. It was found that 78% of the total incidental cancer Source of population cases could be registered using the KCCR data and that the Census. remaining 22% could be collected by active registration. There are two staff in the registry. The chief, taking total Multiple primary rules used responsibility for the operation the registry, has majored in Impossible to detect multiple primaries.

250

Asia

Korea, Seoul
Registration area The Seoul Cancer Registry (SCR) covers the population of Seoul Metropolitan city, the capital of the Republic of Korea. The population at the most recent census (2001) was 10 263 336, about 21% of the total population of the country. The Korean population is very homogeneous, with a very small Chinese minority of around 20 000. Traditional culture is mostly based on Confucianism, while Buddhism (25%) and Christianity (19%) are two of the most vigorous religions. mid-sized hospitals to review and abstract medical records of potential cancer patients who made insurance claims for cancer to the Association of Korean Medical Insurance. The insurance claim data also serves as a good source for tracking the identity of cases notied by a death certicate alone. The third source is the death certicates to nd the vital status of the registered cases and to register the Death Certicate Only cases (DCO). Death certicates from the National Statistics Ofce (NSO) cover all deaths occurring in Korea and include the full National Identity Number issued by the Korean Government to every Korean citizen at birth. The quality of death certicates Cancer care facilities Cancer care in the region is provided predominantly by large in Seoul is good, about 98% being certied by medical doctors. teaching hospitals and midsized hospitals, numbering 63 Using both the health insurance and 117, respectively, in 2003. data and mortality data further KOREA, SEOUL (1998-2002) There are also 5948 enhances the completeness of KOREA, SEOUL (1998-2002) clinics and 25 community the registration. health centres, but cancers The SCR evaluates the are rarely conrmed in these validity of the registry data facilities. Patients suspected with the IARC CHECK "$$$$ &!# $$$$ $"!$$$ & $"$$$ to have cancer in primary program and re-abstracts the $!"$$$ %! "$%!$$$ clinics and community health medical records to correct the !$%!$$$ % &%$$$$ $%&$$$ "! $%$$$ centres are referred to one of errors in the data. %$$$$ " %$&&!$$$ the teaching hospitals, except $'"$$$ !! $!!%$$$ &$&"$$$ ! &'$!$$$ for some elderly patients Interpreting the results &$'&$$$ ! !%$$$$ who decline further medical The size of the population and !$&$$$  "$"%%$$$ &$&&&$$$ ! $%'&$$$ work-ups. This might cause the number of medical facilities %$&"$$$  '$!$$$ incomplete registration among to be covered make it necessary !$&%$$$ ! !%$!!'$$$ &'$$$$  "'$"!$$$ the elderly, unless the elderly to accept the data from KCCR '$%$$$ ! %"$!"$$$ cases are captured through the pre-coded by many medical $'!&$$$  &$$$$ !$&"$$$ ! '%$&'$$$ death certicates. Ninety-nine recorders from each hospital. "$!"%$$$  &$'"%$$$ percent of cancers occurring Although the Association of in Seoul are treated in Seoul, Medical Recorders continuously  !   !  and about 76% of patients instructs its members on  $   $ treated in Seoul are from cancer registry methods, the $'$$$$ $'$!!$$$  outside the city. process still calls for a constant 
   Apart from these  $
$   $($$ evaluation of the validity of the  



 facilities, there are 2545 clinics and$$!$$ $ hospitals practicing registry data. 
$ $ traditional oriental medicine. Although most cancer patients Around 1998, opportunistic screening for breast and resort to western medicine eventually, some patients would thyroid cancer started to become popular among women. only go to these traditional oriental clinics. These patients The rapid increase in thyroid cancer among women could be are not registered to SCR unless they are captured through accounted for by this change in screening rate. the death certicates. Uses of the data Registry structure and methods The registry produces reports on cancer incidence by sub The SCR is located in the Department of Preventive district in Seoul, Korea. A special study of survival for all Medicine, Seoul National University College of Medicine, cancers has been carried out. and in the Department of Social and Preventive Medicine, Sungkyunkwan University School of Medicine. It is funded Source of population by the Ministry of Health and Welfare. There are two part- Seoul Population Census : 2000 time medical ofcers, one data manager, and four full-time registrars. Multiple primary rules used The SCR uses several sources of data nding. About 87% IACR rules (2004) on CI5 IX period of the SCR data are registered through the Korean Central Cancer Registry (KCCR). KCCR is operated by voluntary Acknowledgement registration from teaching hospitals throughout the country. We thank Dr. Jae-Gab Park and Dr. Keun-Young Yoo, the The second source of registration is active case nding former and current President of National Cancer Center in by the registrars. The registrars make visits to about 81 Korea, for their support to SCR.

251

Asia

Korea, Ulsan
Registration area The Ulsan Cancer Registry (UCR) covers the population of Ulsan metropolitan city in Korea. Ulsan is a representative port city located in southeastern region of Korea. It covers an area of 1056.7 km2. The population at the most recent census (2000) was 1 012 110. About 84% of the population (>850,000 inhabitants) lives in urban areas. In general, Korea has virtually no other ethnic group except Korean and only 2318 persons are registered as foreigners in Ulsan. The annual mean temperature in Ulsan is 14.3 C, and annual rainfall is about 1272 mm. Ulsan has become a rapidly industrialised city, accounting for 12.2% of the manufacturing industry in Korea. The main industries are the petrochemical, shipbuilding, and automobile industries. Cancer care facilities Medical care for the whole population is covered and provided by the National Health Insurance Plan. In 2004, Ulsan had 7279 hospital beds and 39 hospitals (2 teaching hospitals, 1 general hospital, 23 hospitals, 2 dental hospitals, 3 psychiatric hospitals, 4 sanatorium hospitals, and 4 traditional medicine hospitals), of which one is a university hospital, and 912 private clinics. The university hospital provides cancer surgery, chemotherapy and radiotherapy services. The third source is the death certicates. The cases not already registered in the UCR database become Death Certicate Notication (DCN) cases. Death certicates from the National Statistics Ofce (NSO) cover all deaths occurring in Korea and include the unique Resident Registration Number (RRN) issued by the Korean Government to every Korean citizen at birth. The RRN also serves as a good indicator for tracking cases notied by death certicate alone. In addition to these three major sources, several secondary data sources, such as log les from pathology laboratories and radiotherapy departments, help to identify unregistered cancer patients. The UCR evaluates the validity of the registry data with the IARC CHECK program and re-abstracts the medical records to check for errors in data. A formal evaluation of the data is done in collaboration with the Korean KOREA, ULSAN (1999-2002) National Cancer Centre. KOREA, ULSAN (1999-2002) Interpreting the results There has been no change in area or population covered by the UCR during the period 19992002. The UCR has been using ICD-O-2 for coding since its inception, and there has been no change in case denition and coding. There are 5 cancer screening programs in Korea, namely cervix, breast, prostate, stomach and liver. If prostate cancer is suspected or if symptomatic of BPH, then PSA testing is regularly performed.



















 


































 


















































 





















 
'# %

 

'# %



Use of the data 



&""'&)('''  Registry structure and The registry produces annual 
   
'

''
'  **''
''
'!'
' '
''''
''''' 
''

' methods reports on cancer incidence  '''''
'
'
' The registry is located in the department of occupational and and mortality in Ulsan. The data have been used for several  



 
'
'#!$%''&''
' environmental medicine, Ulsan university hospital, and is epidemiological studies on primary, secondary and tertiary funded partly by Ministry of Health and Welfare, and partly prevention of cancer. The registry is especially interested in by the citys health department. Two part-time medical monitoring occupational cancer. doctors and one full-time registrar staff the registry. Approximately 79% of the cases are registered from the Source of population data les of the Korean Central Cancer Registry (KCCR). The The estimate of the populationatrisk is based on the KCCR identies incidence from cancer cases in Korea through 2000 census, making allowance for births and deaths, but the nationwide hospital-based discharge system. This hospital- it was not possible to estimate migration into and out of the based database covers all general hospitals in Korea. registration area. The second source of registration is the list of cancer cases from claims made through the National Health Insurance Multiple primary rules used Corporation. IACR rules (2004) on CI5 IX period

252

Asia

Kuwait
Registration area Kuwait is one of the major oil-producing countries in the Middle East, with a surface area of 17 818 km2, and is situated in the northwestern corner of the Arabian Gulf. The mainland is at sandy desert with a scattering of oases. There are a few rocky hills ranging from 180 to 300m above sea level. Kuwait experiences wide variation in temperature, ranging from an average of 45C in July to an average of 8C in January. There is also wide variation in annual rainfall, ranging from as little as 22 mm to 350 mm. This falls almost entirely between November and April. Kuwait has experienced rapid social and economic development over the past four decades. It is a society undergoing demographic and epidemiological transition. For Kuwaiti nationals, these changes have included important declines in infant mortality (11.4/1000 live births) and improvements in life expectancy (75 years). Kuwait also has one of the highest annual population growth rates in the world (4.5%) and has greatly increased the literacy rate to about 85%. The total population in 1995 was about 1.88 million: 37% are Kuwaiti nationals and 63% are nonKuwaitis (expatriates). Expatriates living in Kuwait are a heterogeneous and transitory group representing over 50 countries. However, it is noteworthy that the vast majority (95%) are from Southeast Asian and Arab countries. In 1994, Southeast Asians (from Afghanistan, Bangladesh, India, Iran, Pakistan, Philippines, and Sri Lanka) represented 58% and Arabs (from Egypt, Jordan, Lebanon, and Syria) 37% of the expatriate population. Compared with countries in Europe and North America, Kuwait has a relatively young population structure: about 44% of Kuwaitis and 17% of non-Kuwaitis are aged <15 years. Cancer care facilities For administrative purposes, the country is divided into ve health regions: Capital, Hawali, Al-Farwania, Al-Ahmadi, and Al-Jahra. The medical services in each health region comprise a number of primary/family healthcare clinics, which provide general, maternal, child and dental healthcare services, and a general public hospital. Besides these facilities, there are a number of centralised specialist hospitals including Kuwait Cancer Control Centre. The centre was established in 1982 and is the only specialised cancer treatment hospital in the country. It offers modern facilities for cancer diagnosis, treatment and follow-up. Registry structure and methods The Kuwait Cancer Registry was established in 1971 in the Radiotherapy Department at the Al-Sabah hospital. The initial purpose of the registry was to study the incidence and morphology of cancers in the Kuwaiti population and to use this information as the basis for establishing a comprehensive cancer centre for diagnosis, treatment, follow-up and care of cancer patients. Subsequently, the Kuwait Cancer Control Centre was established in 1982 and the registry became a separate department of the hospital. Notication of cancer is compulsory through a Ministerial Decree. Cancer registrations are fairly comprehensive as almost all cases not initially diagnosed or treated at the Kuwait Cancer Control Centre (including those who receive initial treatment at other hospitals or abroad) are ultimately referred to the centre for further treatment or follow-up. The registry maintains a separate alphabetical and numerical index, which includes information such as case note number, name, age, sex, nationality, year of diagnosis, and site. Pathology reports and death certicates are led numerically by year. All new registrations are checked against these data items to avoid duplication. The sources of information are: case notes from the Cancer Control Centre and other hospitals; reports from the pathology departments of the Cancer Control Centre and of other hospitals; and mortality data from the Vital and Health Statistics Division of the Ministry of Health. All coding (topography, morphology, TNM classication, etc.) and computerisation of data is done by the registry staff. The registry is staffed by a director, a medical ofcer and an administrator, two cancer registrars, and one medical records clerk and two computer technicians. Use of the data The data are used for monitoring trends in incidence and in research. They are also used for planning and evaluation of cancer care facilities. The registry is especially interested in monitoring any change in the incidence of cancer that may have occurred following the Gulf War in 1991.

253

Asia

KUWAIT: KUWAITIS (1998-2002)

KUWAIT: KUWAITIS (1998-2002)

KUWAIT: NON-KUWAITIS (1998-2002)

KUWAIT: NON-KUWAITIS (1998-2002)

 #    ! ! ! ! " " #   ! "#  ! #   # "     !  #  "

! !              

 !     ! #  #  "" ! #  "  !!  "   "   !  "  #  #

   !  "!    "  " !" ""  #! ! # ! #      "#  #  !  "

! !              

 !      #  #  "#  !#    ! !   !  # #   #  !  !



 


 








 


 






 #!



 

"# 



 #


    



    



     
Multiple primary rules used Impossible to detect multiple primaries.  





Source of population 2001 estimates.

 



 

     

254

Asia

Malaysia, Penang
well as pathology record listings from the public and private Registration area The Penang Cancer Registry covers the population of 5 laboratories, to ensure completeness of data. Registry staff districts (Timur Laut, Barat Daya, Seberang Perai Utara, visit the sources of data to extract required information. The Seberang Perai Tengah and Seberang Peri Selatan) within registry also relies on other healthcare workers to complete the state of Penang, in the northwestern part of the Malaysian notication forms and forward them to the registry. This is peninsula. The population at the most recent census (2000) supplemented by case detection from death records supplied was 1 313 449, with 79.6% of the population living in urban by the National Registration Department. All possible areas. Penang has a higher population density than the rest sources of data in the State are identied. Arrangements are also made with other hospitals outside the registration of the country. The ethnic composition and socio-economic prole of area to notify the registry of resident cancer cases that are the Penang population differs from the other states within diagnosed and treated there. The Cancer Registry Committee and the State Technical Malaysia in that Penang has a better economic attainment and higher per-capita income than most other states. It also Committee evaluate the completeness and accuracy of the information. has a higher proportion of Chinese residents than the rest Interpreting the results of the country, with an overall MALAYSIA, PENANG (1998-2002) It is not possible to estimate ethnic composition of 53.4% MALAYSIA, PENANG (1998-2002) how many cancer cases remain Malays, 26.0% Chinese, 7.6% undiagnosed. However, Indians and 12.9% others Penangs health coverage is (Department of Statistics, very extensive even in the 2001). The ofcial religion is remotest areas, and a full range Islam. #%'%%% &"$ (%&&%%% of diagnostic and treatment #% &%%% & '% "%%% '%"'%%% #" %&'#%%% facilities are available here, Cancer care facilities  % %%% # "%"&%%% so it is very unlikely that any Both the private and the #%"&%%% "" #%"%%% "%&%%% "  %## %%% referred cases will be missed. public sector, through a %'"%%% " %"'%%% Screening services for network of regional hospitals, #%"'%%%  #%& %%% '%'"%%% " (%''%%% cervical cancer and a breast provide general health care in %&'%%%  %( %%% self examination programme the regions district hospitals %((#%%% " "% "&%%% '% %%%  " %%%% are routinely carried out by the with and without specialists &%"(%%% " %&(%%% primary healthcare facilities. and a network of primary %&(%%%  %(#%%% #%# &%%% " %&%%% Extensive screening services health centres. In addition #%(''%%%  %' %%% are also provided by the private there are 11 private hospitals sector. PSA testing is offered in the state and 426 General  "   "  by all the private hospitals for practitioners. All modalities %! %! a fee, and in general hospitals of treatment for cancer are "#%&(%%% "%&( %%%  only when indicated. available in Penang. However, 
   radiotherapy services are only (((%)
%
%((%%)%%%)%
%
%%%  



 available at Mount Miriam Hospital and at Pantai Mutiara Use of the data 
 %
%((!% Hospital. Mount Miriam Hospital is the regional cancer The registry has prepared annual statistical reports for the years 1994, 1995, 1996 and 1997 as well as two 5-year reports centre for Northern Peninsula Malaysia. (19941998 and 19992003). The reports highlight trends and changes. The data are used for planning and evaluation Registry structure and methods The registry is located within and funded by the State of cancer control programme in the state, and are also used Health Department. An epidemiologist, nurse, 2 clerical by universities for specic research. staff and part-time clerical staff (when the need arises) staff the registry. In addition, nurses from each of the districts Source of population also assist in active case detection. Strict condentiality is 1999: projection from 1991 census. 2000: census. 2001, 2002: projection from 2000 census. maintained at all times at the registry. The Penang Cancer Registry uses both active and passive nding methods. Active case nding and routine checks are Multiple primary rules used done using public and private hospital discharge records, as IACR rules (1990).

255

Asia

Malaysia, Sarawak
Registration area The Sarawak Cancer Registry is a population-based cancer registry that commenced data collection on 1 January 1996. The registry covers the population of 11 divisions (Kuching, Sri Aman, Sibu, Kapit, Miri, Limbang, Sarikei, Bintulu and Samarahan, Mukah and Betong Divisions) in the state of Sarawak in Malaysia. The population at the most recent census (2000) was 2 071 506. About 48% of the population lives in urban areas; ethnic composition is 30.0% Iban, 26.7% Chinese, 23.0% Malays, 8.3% Bidayuh, 5.9% other Indigenous, 5.6% Melanau and 0.4% other ethnic Groups Cancer care facilities General health care in Sarawak is provided predominantly by the Sarawak Health Department, through the district hospitals and a network of primary health centres. Private practitioners and hospitals supplement this. Radiotherapy service in Sarawak is only available at the Sarawak General Hospital in Kuching. Patients who require radiotherapy treatment are referred to the Sarawak General Hospital for treatment. Furthermore, as this is the only hospital providing radiotherapy services in the State, the likelihood of cancer patients seeking radiotherapy treatment beyond the catchment area of the registry is minimal. In order to ascertain high coverage and accuracy of data, the Sarawak Cancer Registry team performs several quality control checks. These include sourcing out missed cases, identifying multiple notications and inaccurate information and inspecting case notes of discharged cancer patients in all government hospitals in Sarawak. Although cancer is not a notiable disease, a fair number of registration forms are received from private practitioners.

 '*()''' '%''' %' $''' ')"''' ') '''

Interpreting the results It is not possible to estimate how many cancer cases remain undiagnosed, but underestimation could occur for elderly subjects in rural areas. Health services in Sarawak have a full range of diagnostic facilities, so that it is unlikely that cases referred will be MALAYSIA, SARAWAK (1998-2002) missed. Screening service MALAYSIA, SARAWAK (1998-2002) for cervical cancer is ongoing and provided by the primary health centres. While there is increasing interest in PSA testing, it is not routinely done ($& "')* ''' in our population. ( '( '''
%$ % $$ $ )' ''' '% (''' )'()''' *'$'''

Use of the data The registry had published $"'''' "$ ")'%($''' the 19962000 cancer report %$'''' " %'* ''' ($' "''' $ ('$ ''' highlighting incidence of ) '("'''  )'"%*''' cancer in Sarawak by gender, )%'%)%''' $ )%' %''' )('%( '''  )*'"''' age and ethnic group. The data **' %)''' $ *('$ ''' from the cancer registry are *' '''   '%)"''' *'%''' $ '*''' being used for planning and  $'$$"'''   '''' evaluation of health services. The registry is currently  $   $  developing a cancer atlas for 
'!#

'!# Sarawak and analysing cancer ')'" ''' '$ '(%'''  survival in Sarawak. 
   Our registry is currently Registry structure and **)'***'+ 
''**'
'+'
''+' 
'''
'  



 doing research on the geographical distribution of common methods 
'
'!"#''$''
' The registry is located in the Non-Communicable Diseases cancers in our population, such as nasopharyngeal Control Section of the Sarawak Health Department, and carcinoma, colorectal cancer, breast cancer and cervical fully managed and fully funded by the Sarawak Health cancer. Preliminary results of the research on the Department. A full-time medical ofcer, two full-time geographical distribution of nasopharyngeal carcinoma in Sarawak were presented as part of the paper Epidemiology registrars and a part-time registrar staff the registry. Cancer registration is based primarily on voluntary of Nasopharyngeal Cancer in Sarawak, presented at the notications. The registry seeks basic epidemiological Beijing IACR Meeting. Our registry is currently working on and clinical data for all cancers diagnosed in Sarawak a proposal for research into screening for nasopharyngeal since 1 January 1996. The registry receives notications cancer in Sarawak. in a standardised format from all sections of the medical profession in Sarawak. Active case nding and routine checks Source of population are made of government and private hospital discharge 1998, 1999: projection from 1990 census. 2000: census. records as well as pathology record listings from the public 2001, 2002: projection from 2000 census. and private laboratories to ensure completeness of the data. This is supplemented by case detection from death Multiple primary rules used IACR rules (2004) on CI5 IX period. records supplied by the National Registration Department.
"'( *'''

256

Asia

Oman
two full-time cancer registrars. Cancer notication forms Registration Area The Sultanate of Oman is located in the southeastern corner were modied and distributed to all regional hospitals and of the Arabian Peninsula. It has a costal line extending sister institutions for reporting. Sources of cancer information for the Registry include almost 1700 km from the Strait of Hormuz in the north to the borders of the Republic of Yemen in the south and passive reporting by the diagnosing physicians from different overlooks three seas; the Arabian Gulf the Gulf of Oman hospitals including University, Police and Armed Forces and the Arabian Sea. The Sultanate of Oman borders the Hospitals, histopathology and cytology reports from the ve Kingdom of the Saudi Arabia and United Arab Emirates in main laboratories in the country and the outpatient logbooks the west, the Republic of Yemen in the south, the Strait of and radiotherapy and chemotherapy appointment lists of the Hormuz in the north and the Arabian Sea in the east. There Oncology Department at the main tertiary facility, the Royal are a number of scattered Omani islands in the Arabian Sea; Hospital. In addition, discharge diagnosis and monthly hospital mortality lists of patients with diagnosis of cancer the most important are Masirah and Al Halaniyat. The total area of the Sultanate of Oman is approximately are obtained from different hospitals in the country. In December 2004 309 500 km2, making it the radiotherapy services became second largest country in available in Oman in addition the Arabian Peninsula. The OMAN: OMANI (1998-2001) to the other modalities of Sultanate is composed of OMAN: OMANI (1998-2001) treatment, which already varying topographic areas existed. This minimised the consisting of plains, wadis (dry number of patients sent abroad river beds) and mountains. The for treatment and provided the most densely populated and registry with an extra source agriculturally fertile area is 





of cancer notication. Details plain overlooking the Gulf of 














of the patients sent abroad Oman and the Arabian Sea (3% 






for treatment (mainly for of the total area). The mountain 














radiotherapy) were obtained ranges occupy almost 15% of 







from the Department of the total land of Oman and are 














Treatment Abroad and from inhabited by about 5% of the 







Tuwam Hospital (main referral population. The remaining 














hospital for radiotherapy in area is mainly sand, wadis 







the neighbouring United Arab and desert (about 82% of the 













Emirates). total area). The climate differs 







Between 1985 and 1997, from one area to another: it is the registry used Dbase hot and humid in the coastal       software for data entry. In areas in summer, hot and dry 
-)%* 

-)%* 


1998 the whole database /0&-0.,-- in the interior with exception of converted to the IARC/IACR higher mountains and southern  
 
--
-- 
-

"--!
--
- 
-
-- 
--
-&00(CanReg software programme. regions of Dhofar, which enjoy - -&00/2'$$&-
-- 

a moderate climate throughout  
   the year. 
-
-)&00$*Based on the 1993 census the estimated Omani population Interpreting the results    
--

--
-
-
-
--
-
 
- -

-1-

- 
-+-)
*#in 1998 was 1 684 850. Based on a second census conducted Opportunistic screening activities are ongoing for cervical in 2003, the estimated Omani population in 2004 was 1 802 cancer. However there are no organised screening programmes 931. In 2004 about 12% of the population was under 5 years yet. PSA testing is not common in the population. of age and 40% were under 15 years. Only 3.1% of the total Smoking is on the increase in Omanis, and many Omani population was above the age of 60 years. There were industries are promoted now, both of which could result in 102 males for every 100 females. an increase in the incidence of cancer. Patients are classied as nationals and non-nationals. However, no data is collected on ethnic background of Source of population patients. Data for 19982001 are annual projections based on the Cohort Component Technique, using the West UN life table Registry Structure and Methods model and based on the 1993 census. The cancer registry in Oman was established in 1985 in Al Nahdha Hospital as a hospital-based registry. In 1996 it was Multiple primary rules used moved to the Department of Non-Communicable Diseases IACR rules (1990). Control at the Ministry of Health Headquarters. Since then the Oman National Cancer Registry has functioned as a Notes on the data population-based registry covering the entire Sultanate of The Editors recommend that some care be taken in the Oman and is staffed by two part-time epidemiologists and interpretation of these data; see Chapter 5 (Categorisation).

257

Asia

Pakistan, South Karachi

volunteer workers in 2 ofces at the Sindh Medical College Registration area Karachi is the largest city of Pakistan, an Islamic Republic in and Aga Khan University (pathology department). Data collection is a combination of active search, passive south central Asia and the capital of Sindh province. Located on coast of the Arabian Sea, at latitude 24 51 N, longitude 67 02 notication, and automated notication. The principal source S, it is the nations major commercial and industrial centre as of information on cancer cases is the diagnostic centres of well as the largest seaport. The city covers 591 km2 while the the Aga Khan University. The registry has access to death certicates with personal metropolitan area covers 1450 km. The city of Karachi is divided into 5 districts. The Karachi Cancer Registry (KCR) identiers. This source has limited value as the cause of registers incident cases of the southernmost district of the city. death registered is non-specic. Cancer is not a notiable Karachi South has a year-2000 population of 1 723 617; males disease and problems of condentiality are high with major centres, e.g. the Aga Khan University. 928 695 and females 794 922. The population is urban. Karachi is a multi-ethnic city. The dominant ethnic group in Karachi is the Urdu-speaking Muhajirs; the other large groups Quality control include the Sindhis, Balochis, The data are classified using Punjabis, Pashtuns, Kashmiris ICD-O3 and computerised using a customised version of and Seraikis. There is a refugee PAKISTAN, SOUTH KARACHI (1998-2002) population that includes Afghan, CanReg-4, with internal checks PAKISTAN, SOUTH KARACHI (1998-2002) Pakhtuns, Tajiks, Hazaras, on the validity of entered data. Uzbeks, and Turkmens. There Manual and computerised validity checks for the cancer are also Bengali, Arab, Iranian and African immigrants, data were performed as per IARC and a large community of and IACR recommendations. 


 


Zoroastrian-Persian Parsis This involved factors inuencing 














and Goan Catholic Christians. comparability, i.e. classication 







The linguistic distribution of and coding. Demographic 














variables recorded were the population was: Urdu-speaking 







hospital patient-number, date 48.52%; Punjabi 13.94%; Sindhi 














of incidence, name, age, sex, 7.22%; Pushto 11.42%; Balochi 







address, ethnicity, topography, 4.34%; Seraiki 2.11%; others 

 












morphology, grading and 12.4%. Most inhabitants are







Muslim (96.49%), with some staging. 














Christians (2.35%), Hindus 

 



 

(0.83%) and Qadiani (0.17%). Interpreting the results Private sector input has Karachi South is a sample        '"$   '"$ signicantly increased and population of Pakistan, having  


)!('&)%'''  altered the contribution from an equal distribution of the data sources. Whereas the major ethnic groups and all the  
 public health sector contribution minority groups of the country.  ' ))(' )))+!!'  ' ' )#' ' '
' ' ))('  
   
' '"!#$'''' The population distribution of KS and Pakistan are similar as was more in 19951997, the private health sector contribution    regards age, gender and religion. The male preponderance reects far outweighs the former in the present reference period.  ''  '' ' ' ' '' '  '
'  '*' ' '%'" $' There are no screening programs for any region in the in-migration for work from other regions of Pakistan i.e. Sindh, Baluchistan, NWFP and Punjab. These men are residents of the Pakistan; however, there are facilities for PSA testing, PAP district, as they spend an entire life in Karachi, going back to their smears and mammography. It is not possible to precisely estimate how many cancer village only during their annual or bi-annual leave. cases remain undiagnosed, as there are no autopsies and the death registration system is very inadequate and incomplete. Cancer care facilities Karachi South has 2 provincially administered tertiary care The registry however annually conducts a formal evaluation public health hospitals and 1 armed force administered hospital, of the completeness or accuracy by utilizing the wellone with a radiotherapy facility, that provide free to subsidized maintained and documented cancer data at Zainab Punjwani surgery and diagnosis. The Aga Khan University had 6 diagnostic Medical Centre and the Baqai Institute of Oncology. The district has a preponderance of self-inicted centres in the district during the reference period. Other private medical facilities provide surgical and diagnostic facilities but (tobacco, arecanut, paan misuse) malignancies in men and provide less-than-optimal quantitative medical oncology or breast cancer in women. These outweigh any occupational radiotherapy treatment cover, as the tertiary care facilities are exposures if present, there being oil reneries and tanneries also shared by numerous referral cases from across the Province in this district. Karachi South is a belt fringing the Arabian of Sindh. Thus the majority of the cancer patients utilise services Sea. Potential environmental hazards could be oil spillage and un-detoxied chemical products discharged into the sea outside the district, city or even the country. by tanneries and other factories. Registry structure and methods The Karachi Cancer Registry (KCR), the rst population- Use of the data based registry in Pakistan, has been philanthropically funded The incidence data are reported regularly to the Federal for 12 years. It has 6 permanent staff members and many Government and various agencies in Pakistan requiring the same

258

Asia

for health sector planning and monitoring. The data are used for casecontrol studies, for research theses and dissertations of post-graduate students and fellows. The NCCP Pakistan planning, implementation and monitoring is based on this data. Source of population Census 1998. 19992002 estimated using 1.94% growth rate from Census 1998.

Multiple primary rules used IACR rules (2004) on historical data Notes on the data The Editors recommend that some care be taken in the interpretation of these data; see Chapter 5 (Categorisation).

259

Asia

Philippines, Manila
logs, radiology, ultrasound, nuclear medicine, CT/MRI Registration area The registry covers the four major cities (Manila, Quezon, reports and logs, and hospital tumour registries. Death Pasay, Caloocan) of the National Capital Region (NCR), the certicates from the ofce of the Local Civil Registries are major urban centre of the country. It encompasses a land also reviewed. The registry staff also visits selected private area of 274.2 km2 located in the southwest portion of Luzon surgeons, oncologists and hematologists. Data received are checked manually and electronically between latitudes 144823 and 143115 N and longitudes 143953 and 1210520 W. Manila is the capital and main for completeness and consistency as well as for duplication. port of the Philippines, the hub of commerce and trade and Coding consistency and validity is checked with the IARC/ IACR CanReg-4 software. Followup was done previously the seat of cultural and intellectual activities. The population covered by the registry, based on the through death certicate review. In 1997, however, PCS2000 census of Population and Housing, is 5 287 425, a 4.1% MCR conducted its rst population-based survival study increase over 1995. As a whole, the population is young, on the 1987 incident cancer cases, using both active and with 31.87% under 15 years of age and only 2.10% over 65. passive follow-up. Although regular formal evaluation of data completeness or accuracy It comprises 140 different is ideal, limitation in funding ethnic groups, the largest of still restricts this activity. which are Tagalog (69.85%), PHILIPPINES, MANILA (1998-2002) Bicol (4.27%), Ilocano PHILIPPINES, MANILA (1998-2002) Interpreting the results (4.16%), Bisaya (3.87%) and Some challenges faced by the Waray (2.81%). Among the registry include inadequate foreign ethnic groups the manpower for data collection largest are Chinese (0.59%), 


 


and other registry procedures; Other Foreign (0.04%) and







poor record-keeping in some American/English (0.02%). 














hospitals; non-inclusion of Most (88.8%) are Roman 







private pathologists reports in Catholic, 3.2% Iglesia ni 

 












some hospital records; use of Kristo and 0.6 % Muslim. 





 

different names (particularly 





 








among Chinese); and delayed Cancer care facilities 







data collection due to Health services in the 

 












condentiality concerns in National Capital Region and 







some hospitals. the adjacent province of Rizal 












 

The increase in availability include four cancer institutes, 







of diagnostic and treatment 168 secondary and tertiary facilities has not necessarily care hospitals, 43 primary care       increased their utilisation hospitals and 32 Department 
*&$( 

*&$( because of economic and of Health clinics for out-patient 



%*),+*%#%***  educational factors; PSA consultations. Ten hospitals  

 *
*

**
..
***

*** testing is not common, and have radiotherapy facilities. 
*%###"*
**  *****

* 
  
*

**
*
"*
*
**
*

*"*

!** 

*** !**** 
!***
* there are no organised screening programmes for any cancer  
   
*
*&%##'(**** site. There were no unusual environmental or occupational Registry structure and methods    
* *

**
*
*
*
**
*
 
**

*-*

* 
*)*&
("* The Philippine Cancer Society (PCS) began cancer exposures which could have inuenced cancer incidence in registration in 1959 in an attempt to organise a national cancer the population. Those changes in case denition and coding initiated registry. Although this was not successful, it served as a pilot study. In 1968, the Central Tumor Registry of the Philippines by IARC are the only ones used by the registry. High (CTRP) was launched, covering 25 hospitals in Manila and percentages of DCO registrations in 19931997 led to one in Cebu, completely relying on notications from these more thorough trace-back of DCN cases in the hospitals hospitals. In 1983, it was converted to a population-based and patient residences, particularly for liver cases (50% at cancer registry and renamed the Philippine Cancer Society- the time). In spite of these problems, the staff continues its Manila Cancer Registry. Cancer registry clerks were trained efforts at improving completeness as well as data accuracy. to abstract pertinent information from hospital records and death certicates and they actively collected data on cancer Use of the data cases in its catchment area for the period 198082 onwards. The registry prepares reports on cancer incidence as The registry is located in the PCS building, and is fully well as trends. Data generated from the Manila and Rizal funded by the PCS. The registry staff comprises six part-time registries have served as a basis for planning of most of the consultants, one full-time supervisor, and six cancer registry cancer control activities of the Philippine Cancer Control research assistants. In 1984, the registry started a cooperative Program of the Department of Health. They have been effort with the Department of Health-Rizal Cancer Registry used for epidemiological research, as well as for public in covering 134 hospitals within the National Capital Region information activities of the media and NGOs. There is an and Rizal Province. Both registries use the same active data ongoing collaboration with the German Cancer Research Center regarding recent trends, up-to-date estimates and collection methods. Hospital data sources include medical records, determinants of cancer survival on 10 leading sites among radiotherapy records, pathology/haematology records and 19932002 incident cases.

260

Asia

Source of population Census 2000. Gathering of population and housing data was performed by census enumerators through househouse visits and interview of a responsible member of each household. The household was the enumeration unit.

Multiple primary rules used IACR rules (2004) on historical data Notes on the data The Editors recommend that some care be taken in the interpretation of these data; see Chapter 5 (Categorisation).

261

Asia

Singapore
Registration area that notications are as complete as possible by checking The registry covers the whole of the Republic of Singapore, all pathology reports from public and private laboratories, situated in Southeast Asia, and comprises the main island of and death certicates issued in Singapore as well as records Singapore and several offshore islands which jointly cover of all public hospitals. Cancer cases identied from these an area of 682.7 km2. The main island measures 42 km from sources are checked against registered cases, and reminders east to west and 23 km from north to south, and is situated are sent to doctors in charge of cases that have not been on latitude 117N and longitude 10315E, at the southern notied to the Registry. Cancer cases not notied by doctors tip of the Malayan Peninsula. The island is rather at, the (approximately 10%) are registered by the Registry staff on highest point being a central granite hill 166 metres high. the basis of information derived from the sources mentioned The maximum temperature is around 31C and the minimum above. Cancer registration is generally comprehensive since 24C. The mean relative humidity is around 84%. The island all cases diagnosed histologically and all cases with mention generally has rainfall throughout the year (total annual of cancer in hospital discharge forms and death certicates rainfall approximately 2344mm), but is particularly wet are included. There is no personal during the monsoon season contact with cases or patient from November to January. follow-up by the Registry. The resident population (3 SINGAPORE (1998-2002) Information on diagnosis and 263 209 in 2000) comprises SINGAPORE (1998-2002) survival is obtained through several ethnic groups, the hospital, pathology and death largest of which are Chinese records. (76.8%), Malays (13.9%) and The cancer notication Indians (7.9%). Overall, the  %&%%% '$ "%"#%%% forms and a register of cases population density (2000 &%"'%%% &" %''%%% are maintained on a current Census) is 4780 persons per %((%%% & "%#"%%% % %%% #" "%'(%%% chronological basis. All km2. "%'%%% # ""%(#%%% relevant information is coded, #% &%%% "" #%" #%%% %'(%%% " %%%% and the Registry maintains a Cancer care facilities %&"%%% " '%('%%% computerised le of all cases. In 2000, there were "#%%%%  "%((%%% #%&%%% " "'%%%% Duplication of cases is avoided 5395 registered medical  %"'%%%   #%%%% by checking all new cases practitioners (one medical '%(%%% " #%%%% "%""%%%   %''%%% against the master index. practitioner to 745 people), of &%#'%%% " %''%%% Certication of death whom 2779 were in private (%("%%%  %(%%% &%'##%%% " % %%% is virtually complete in practice and 2616 in the '%&#%%%  %("#%%% Singapore. In 2000, 97.6% of public sector. A total of 11 all deaths were certied by 798 hospital beds (2.9 hospital  "   "  qualied medical practitioners beds per 1000 population) %! %! or the Coroner and 2.4% by were available: 9556 in 13 %#%&&%%% %#%" &%%%  Inspecting Ofcers. The latter public hospitals and 2242 in 
   would certify a case as cancer 13 private hospitals. There %%% %((%%%%% were also 16 public outpatient 



 Polyclinics, which together only on the basis of a previous hospital diagnosis. 
%
%((!% Evaluation of completeness or accuracy of information with private clinics offer primary health care. Diagnostic and treatment services including radiotherapy are available recorded will be carried out at the end of a 5-year period before publishing the Singapore Cancer Registry 5-year monograph. in the public and private hospitals. Registry structure and methods Comprehensive population-based cancer registration began in January 1968. The Registry was founded primarily to obtain information on cancer patterns and trends in Singapore. Until March 2001, the Registry was staffed by one pathologist and three epidemiologists (part- time), and three secretaries and one record searcher (full-time). In April 2001, the Registry came under the auspices of the National Disease Registries Ofce and is currently situated at the Health Promotion Board with two additional full-time staff. There is a Steering Committee comprising representatives of the Ministry of Health and various hospitals. Sources of data are: (a) cancer notications from all sections of the medical profession, (b) pathology records, (c) hospital records and (d) death certicates. Cancer notication is voluntary. All doctors in Singapore are provided with notication forms with prepaid postage. The Registry ensures Interpreting the results Although the population covered by the registry has increased (the growth rate for resident population was 1.8% in 2000), it is unlikely that cancer cases will be missed as the public and private hospitals in Singapore have the full range of diagnostic and treatment facilities and the populationto-doctor ratio continued to improve. Opportunistic cancer screening services were offered by hospitals and clinics in the public and private sectors. Use of the data The data have been used mainly to determine incidence levels and relative risks of cancers in Singapore by sex, ethnic groups and migrant status. Such information has formed the basis of epidemiological and clinical studies on specic cancers. The Ministry of Health Singapore and hospitals administrators use the data for planning and evaluation.

262

Asia

SINGAPORE: CHINESE (1998-2002)

SINGAPORE: CHINESE (1998-2002)

SINGAPORE: MALAY (1998-2002)

SINGAPORE: MALAY (1998-2002)

%"(%%% %"((%%% % "%%% %(&'%%% %&%%% "%"'%%% '"%&# %%% &%(%%% %'#%%% % '(%%% '% %%% %"#%%% ' %%%% '%(%%% '#%#(%%% (%# %%% &#%'%%%

'$ &" & #" # "" " "  "  "  "  " 

% %%% '%&(%%% (%#"%%% &% "%%% #%"%%% "% %%% ' %"&%%%  %'&%%% %("&%%% %&%%%  %"%%% (%'&%%% '%"'%%% & %&%%% '%(#%%% '"%('%%% &% '%%%

% &'%%% % "'%%% %('%%% %#&%%% "%#%%% "%""%%% %&%%%  %# %%% (%(# %%% %(( %%% '%' %%% #%#%%%  %(%%% '%('#%%% %'(%%%  %'(%%% %#'%%%

'$ &" & #" # "" " "  "  "  "  " 

%"%%% %%%% %#%%% "%&&%%% "%(((%%% #%(%%% %"%%% "%'%%% (%&%%% %'('%%% (% "%%% #%#'%%% %#& %%% &%(&%%% %'%%% %"%%% (%'"%%%



" %!

" %!





" %!

" %!



% &%'%%%



%#%'(%%%

'%#%%%



"%'&%%%


   %%% %((%%%%%  



 
%
%((!%


   %%% %((%%%%%  



 
%
%((!%

SINGAPORE: INDIAN (1998-2002)

SINGAPORE: INDIAN (1998-2002)

Source of population Estimates based on the 1990 and 2000 census data. Multiple primary rules used IACR rules (1990)

%#%%% %" %%% "%%%% %"#"%%% %((%%% %" %%% &%"'%%% (%(%%% % ( %%% %''&%%% %'%%% (% ''%%% &% (%%% '%# %%% %"%%% %&%%% %(#%%%

'$ &" & #" # "" " "  "  "  "  " 

"#"%%% (" %%% %%%% %((%%% %'"&%%% %(%%% #%((%%% (%(%%% %&%%% %'&"%%% %#(%%% %## %%% &%#&%%% '%%%% (%'#"%%% %(#%%% (%#"#%%%



" %!

" %!



 %''%%%



%""%%%


   %%% %((%%%%%  



 
%
%((!%

263

Asia

Thailand, Chiang Mai

Registration area Chiang Mai Cancer Registry covers the population of Chiang Mai province. The population of the province at the 2000 census was 1 500 127 persons. There were approximately 430 154 families, and the population density averaged 79.1 people per km2. In the municipal area, this gure increased to 4789.9 per km2. Only 26.5% of the total population was living in the municipal area. Eighty-two percent of the population was local by birth, and the remainder was made up of Thai nationals, Chinese, Laos, and hill tribe people. Buddhism was the professed religion of 91.7% of the people in the province. For the remainder, most were either Christians or Muslims. against the registered cases. Every cancer death not traceable to an existing entry is labelled as death certicate only. The registry staff visits all sources and registers of individual departments concerned with diagnosis and treatment of cancers, to identify and abstract information on cases of cancer into the tumour registration forms. Although cancer is not a notiable disease, the hospitals in the registration area cooperate with the registry.

Cancer care facilities The Chiang Mai Provincial Public Health Office, through the provincial hospitals and district hospitals, predominantly provides general health care in Chiang Mai province. Cancer diagnostic services (clinical consultations, radiological and pathological investigations) are available at most public and private hospitals in the province. However, diagnostic and cancerrelated therapeutic facilities are available within the same institution only at the University Hospital (Maharaj Nakorn Chiang Mai Hospital). Cancer surgery services are provided at several locations; the university hospital, five government hospitals, two community hospitals and eight private hospitals. Cancer chemotherapy 
0(%%%"0
0(%%%0  000
"000 
"000
"0
00
0 
0
$0  
   services are provided at the university hospital, two government Use of the data 
0
0*'33%,0    and six private hospitals. Radiotherapy equipment is available at The registry has reported annually on cancer occurrence 
00

00
0
0!
0
00
0
 
00

040

0 
0-0*
,$0 the university hospital. Most patients at primary and secondary since the rst volume in 1978, when it was a hospital-based care facilities suspected of having cancer are referred to Maharaj registry. Population-based registration was started in 1986 to Nakorn Chiang Mai Hospital. report the incidence and mortality of cancer in Chiang Mai province since 1983. Registry structure and methods The registry has also joined with the other registries in The registry is located within The Maharaj Nakorn Chiang Thailand to report on national cancer incidence every 35 years. Mai Hospital, and is fully supported by the Faculty of The registry is involved in epidemiological research of Medicine of Chiang Mai University. The registry is staffed common cancer in Chiang Mai. by 3 part-time physicians, 4 full-time registrar nurses, and Chiang Mai Cancer Registry data are used together with other 3 practical nurses, and is supervised by members of the Cancer Registries to inform the Ministry of Public Health. Hospital Cancer Committee. Data on patients diagnosed with cancer are collected Source of population actively from the university hospital (Maharaj Nakorn Chiang Census 2000, the 2000 Population and Housing Census, Mai Hospital, 1800 beds), 11 government hospitals (2200 beds), Chiang Mai province, National Statistical Ofce, Ofce of 17 community hospitals (620 beds), 13 private hospitals (1500 the Prime Minister. beds) and medical clinics, under the care of 900 physicians, with the total of about 6185 beds in Chiang Mai province. Multiple primary rules used The principal sources of information on cancer cases are IACR rules (1990). hospital and pathology laboratory records. Death certificates were taken from the Unit of Data Notes on the data Processing, 5th Region of Ministry of Interior. All death The Editors recommend that some care be taken in the certicates that mention cancer as the cause of death are matched interpretation of these data; see Chapter 5 (Categorisation).

Interpreting the results It is not possible to estimate how many cancer cases remain undiagnosed, but this probably occurs for subjects in rural areas. Maharaj Nakorn Chiang Mai Hospital is the only university hospital in the area and has a full range of diagnostic facilities, so that it is unlikely that cases THAILAND, CHIANG MAI (1998-2002) referred will be missed. The THAILAND, CHIANG MAI (1998-2002) diagnostic facilities are increased by image studies (CT scan and MRI) and especially by cytology (ne needle aspiration biopsy) and histology. '.0--'000 1-/ '30%(3000 There is only one screening '10'..000 1%# '20)''000 ()03'1000 .-# (-0-'3000 program for cancer of cervix, (+03)%000 .%# (.0++'000 and there are sporadic health (-0-%-000 --# (-0'.2000 )+02+%000 -%# )+0-+)000 education campaigns about -(022'000 +-# -+0%3%000 common cancers in the region. 1%0.+(000 +%# 1+0%1)000 1%0%1%000 )-# 1+02.(000 PSA testing is commonly used -302(3000 )%# ..0'3.000 in the Maharaj Nakorn Chiang --0(.-000 (-# -20'%%000 .(0+''000 (%# .(0-'.000 Mai Hospital. .)02'3000 '-# .)0(%)000 Coding was changed from -201-2000 '%# --0.+1000 -102'+000 -# --0+--000 ICD-0-2 to ICD-0-3 as of the +10)(2000 %# +-0(+2000 cases registered in 2000. Plans are underway to use the IT '% % % '% system of the hospitals in Chiang 
0*&, 

0*&, 1-20+%'000 1+'01(.000  Mai to evaluate the completeness and accuracy of data.  


264

Asia

Thailand, Lampang
New cancer cases from all hospitals are collected from Registration data Lampang is one of the 17 provinces located in the northern out- and inpatient departments, wards, radiotherapy units, part in Thailand, between 17-19N and 98-100E, 269 m surgery units and pathology services. Data collection consists above sea level, 602 km by car from Bangkok (625 km of: registry number, name, residential address, date of birth, age, by train) with a land area of 12 534 km2. It has common sex, date of diagnosis, site of cancer, histology of cancer, staging, boundary with Chiang Mai in the north and the west. This extension of disease, method of diagnosis, treatment, date of last contact and status of cancer patients (alive or dead). registry covers the population of 13 districts. We carried out follow-up of registered cases by matching The total population in 2000 (housing census by National Statistical Ofce, ofce of the Prime Minister) was 782 152, of cases with all death certicates. Death certicates with 390 256 males and 391 896 females at a population density mentioning cancer death without other information about of 62 people per km2. About 30% of the population live in urban the individual traceable from other sources are registered as Death Certicate Only (DCO). areas; 97% are Buddhists, the remainder mainly Christians. We have used histologically veried percentage (%HV), The climate is generally cooler than the rest of the country Mortality Incidence ratio (MI in winter from November Ratio) and percent of DCO to February, and hot and (%DCO) for evaluation of our dry during March to May in THAILAND, LAMPANG (1998-2002) completeness since our rst summer. The average total THAILAND, LAMPANG (1998-2002) report on 2002. rainfall is 974.5 mm per year. Most people are farmers, Interpreting the results working in rice and tobacco. There are many porcelain Cancer cases are collected &/*'2/// 1,. '/(01/// '/,1(/// 1$" (/(00/// production and very large open from all hospitals in Lampang. */12-/// 0," -/$20/// cast-mines (with national coalHowever, there were some 1/-'0/// 0$" &$/(('/// &(/*,2/// -," &*/-,'/// red electricity-generating patients referred to Chiang Mai &,/(-2/// -$" &,/02,/// plants close by). University Hospital and the &-/$'2/// ,," &-/&-$/// &2/12*/// ,$" &2/,'$/// National Cancer Institute in '2/*22/// *," '1/20-/// Cancer care facilities Bangkok. We therefore collected (0/2,,/// *$" (0/-&1/// (1/,2*/// (," (2/(-$/// General health care in the region these cases in our registry as ('/20'/// ($" (,/$2*/// is provided in all 13 districts. In well. We also have back up data '0/,'(/// '," '1/*11/// ',/20'/// '$" '*/,1$/// the urban area (Muang district), since 1983. Due to these reasons, '2/('1/// &," '1/$$$/// there is one cancer centre we believe that cases might not ($/2-$/// &$" '2/*$(/// ($/-$*/// ," '1/0(,/// (Lampang Cancer Center), be missed or repeated. Data are '*/,-(/// $" '(/((&/// two private hospitals and one entered using the IARC/IACR milita r y hospital. Cancer CanReg software. &$ , $ $ , &$ diagnostic services including A cervical cancer screening 
/)%+ 

/)%+ CT scan (clinical consultations programme (Pap smear every (2&/12-/// (2$/',-///  and radiological/pathological 5 years) has been supported by  
 investigations), cancer surgery 
/'$$$!/
 / //
#/ Ministry of Public Health since services and chemotherapy are  
   available in Lampang Cancer 1999. The target population is women aged 3564 years old. Pap /
/)&22$+/    Center and Lampang provincial hospital. Radiation therapy smear is available in all hospitals in Lampang and easily accessible. 
//

//
/
/
/
//
/
 
//

/3/

/ 
/,/)
+#/ equipment (one simulator, two cobalt-60 machines, one linear PSA testing is available only at provincial hospitals, accelerator and two remotes after-loading for brachytherapy) university hospitals, cancer centres and some private hospitals, is provided at Lampang Cancer Center. All hospitals in the and is not routinely included in yearly checkup programmes, province provide palliative care. except in cancer centres. Patients suspected to have cancer in the primary and secondary health care centres in the registry area are mostly referred to Use of the data The registry provides periodic reports on cancer incidence, Lampang Cancer Center and Lampang provincial hospital. mortality and survival in Lampang. The data are also sent to the National Cancer Institute to help compile the report Registry structure and methods The registry is located within Lampang Cancer Center, Cancer in Thailand. The data are also used by the local which also provides equipment, and is funded by cancer health authority for the evaluation of public health measures research foundation for National Cancer Institute. A part- in the prevention, screening and treatment of cancer. time expert consultant, a part-time doctor, a part-time nurse Source of population and two full-time health workers staff the registry. The Lampang registry was established in 1995 with Census 2000, Lampang Provincial Statistical Ofce. the backup data of a population-based cancer registry in Lampang dating from 1983 which was collected by Dr.Nimit Multiple primary rules used Martin, our expert consultant. The registration uses passive IACR rules (1990). methods by notication from 21 sources of data consisting of cancer centres, general hospitals, community hospitals, Notes on the data private hospitals, university hospital, the provincial public The Editors recommend that some care be taken in the interpretation of these data; see Chapter 5 (Categorisation). health service of Lampang and pathological laboratories.

265

Asia

Thailand, Songkhla
Registration area The Songkhla Registry covers the population of 16 districts in the south of Thailand. The population at the 2000 census was 1 255 662. About 80% of the population is Buddhist, and nearly 20% are Moslems. Christians and others account for less than 1% of the population. People with Chinese ancestry live in Songkhla town and Hat Yai city, which is the economic centre of the south of Thailand. registry. The registry staff visits Hat Yai, Songkhla, and private hospitals to consult medical records and pathology records. Assigned staff in community hospitals send the record forms of cancer cases to the registry once a year. Registry staff regularly visit them to reviews procedures. Some cases are sent to the registry by the network of cancer registries in Thailand, especially the registry of Bangkok.

Interpreting the results The number of undiagnosed and unregistered cancer cases is Cancer care facilities The government of Thailand predominantly provides general difcult to estimate. Some Moslems in a remote area in the south health care in the region. There are three hospitals with over of Songkhla visit large hospitals in the two nearby provinces, 500 beds, 13 community hospitals and an extensive network and some residents, especially the elderly, use traditional herbal medicines and never enter the of healthcare facilities at countrys healthcare system. the household level. Private Because of the linkage between practitioners, a few private THAILAND, SONGKHLA (1998-2002) the referral system and the hospitals, and a few small special THAILAND, SONGKHLA (1998-2002) new national health assurance hospitals, all in the urban area, system, it is expected that only a supplement this. The university small number of cancer patients hospital of Prince of Songkla in that remote area seek medical University is the larger of the two facilities outside the province. A places in the south of Thailand &'(#&&& '#% #&(&&& few other cases look for special providing radiotherapy services. &)&&& ' &$&&& !&'&&& $# $&#&&& medical care in Bangkok, the A few other large hospitals )&'&&& $ &'#&&& capital of Thailand. also have facilities for cancer &)'&&& ## &(!#&&& #&!)(&&& # '&!&&& There were no screening surgery and chemotherapy. !&!#'&&& !# $&#&&& programmes over the period Patients suspected to have !&##&&& ! !#&#&&& !(&!!#&&& # #&')&&& in question, and PSA testing is cancer in the health care system #&!#&&&  ##&'&&& not common. and community hospitals are #&((&&& # #(&'&&& #$&'!&&&  #)&)&&& referred to Songkhla, Hat Yai or A very recent study of ours $&!!!&&& # #)&'$&&& Songklanagarind hospitals. demonstrates a relationship #'&'!&&&  ##&$&&& #$&)#&&& # #&!$&&& between radium-contaminated #&'!&&&  !)&(&&& Registry structure and shallow well water and oral methods pharynx and oesophageal cancer.  #   #   & "  & " The registry is located within $!&!$&&& $#&$&&&  the Faculty of Medicine, Use of the data Prince of Songkla University. 
   The registry is preparing a fteenThree part-time medical   &&& &

& year report providing information 
& & ))"& doctors, a full-time nurse as a 



 registrar and four full-time on cancer incidence and trends in Songkhla. It provides data for workers staff the registry. causation studies, especially in the eld of oral and esophageal The Songkhla registry undertakes active casending from cancer, which is the main burden in this area. Extent of disease and 23 sources of data, consisting of Songklanagarind hospital, survival are reported in Cancer in Thailand vol. IV. Hat Yai hospital, Songkhla hospital, community hospitals, The Thai Network of Cancer Registries (TNCR) was private hospitals, special hospitals, provincial health ofce, recently founded. The Thai NCI and TNCR work together and the population registration ofce of the province. to supply policymakers, academic bodies and public The completeness of death registration is acceptable organisations recent accurate cancer statistics, projections, but the cause of death is not so accurate, being mostly and ideas for cancer control for Thailand. We plan to cardiopulmonary arrest and senility. After the national undertake this collaboration as a non-governmental academic heath care reform started in 2000, the validity of the death body to have more power and a louder voice. certicates has been improving. The registry staff also runs the hospital-based registry of Source of population the Songklanagarind hospital, and the data are shared with the Census 2000, National Statistical Ofce. registry of Songkhla. Hat Yai hospital has its own system of cancer case reporting but not a full-scale hospital-based cancer Multiple primary rules used registry, and provides the cases residing in Songkhla to the IACR rules (1990).

266

Asia

Turkey, Antalya
Registration area Antalya is a city located in the southern part of Turkeys Mediterranean region. The province of Antalya is located between the 3607N latitude and 2920E longitude. The population of Antalya according to health statistics is 1 392 172 (2000); 74% of the population lives in urban areas. The region of the most of people is Islam. Antalya has had the fastest population growth in Turkey in recent years because of internal immigration. Regional income comes from trade, agriculture (especially commercial growing of hothouse owers, vegetables, or fruits), tourism and construction. Cancer care facilities Genera l hea lt h ca re is predominantly provided by primary health centres and government hospitals, but in the last few years the number of private health centres has increased. Patients suspected to have cancer in the primary and secondary care facilities in the registry area are mostly referred to Mediterranean University hospital and government hospitals in the centre of Antalya. areas, and the cause of death is often not mentioned or given as cardio-respiratory arrest. The registry staffs work government and university hospitals, where they scrutinise the records kept in medical records departments, and the registers of individual departments concerned with diagnosis of cancers, to identify and abstract information on cases of cancer, diagnosed by all methods. Additionally, private hospitals and other sources are visited monthly by registry personnel who take note of medical records of cancer patients.

Interpreting the results It is not possible to estimate how many cancer cases remain undiagnosed, but underdiagnosis probably occurs for elderly subjects in rural areas. An opportunistic screening service for cervical cancer has TURKEY, ANTALYA (1998-2002) been operated by the cancer TURKEY, ANTALYA (1998-2002) society since 2006. Use of the data The registry prepares an annual report of cancer incidence, highlighting trends and changes. In 2006, the pathology laboratories of three hospitals in Antalya with access to county government hospital records were scrutinised and our data were examined for completeness and accuracy for 19982002. The statistical analysis of the information recorded is not yet complete.

%.1/&... &.%1)... ).+0%... %%.'&1... %,.1/,... &#.+//... &).+#%... '%.&0%... '1.#1&... )0.1/)... +1.'&%...

0+0#! /+! /#! ,+! ,#! ++! +#! )+! )#! '+!

&.+##... &.0,&... +.#/0... %%.0/+... %,.)&#... &#.+/+... &'.)#0... '#.'10... '/.#+1... )+.10%...

+,.%+/... Registry structure and ,'.'0+... '#! ,%.1##... methods ,,.%'0... &+! ,0.'+#... ,).+',... &#! ,0.00%... The registry centre is staffed ,'.0%0... %+! ,&.')+... by a full-time public health ,%./''... %#! +1.)&%... ,#.''0... +! +/.,0/... specialist (MD), and full-time ,%.0%+... #! +0./%)... health workers. Additionally there are 17 cancer registry %# + # # + %# staff in the hospital; the six Source of population 
.($* 

.($* ,01.,%%... /#&.+,%...  staff members who work in Annual registrations by the government and university  
 primary health center of the hospital in the centre of
.
. . .
.

..
. .
.

..
..&###. Provincial Health Directorate  
   Antalya are full-time, other registry staff are part-time. of Antalya in 2000. 
.
.(%11#*..    The Antalya Cancer Registry collects data on
.
..
.
 
..

.2.

. 
.+.(
*". all new cases 
..

..
.
. of cancer from all hospitals and some clinics that provide all Multiple primary rules used diagnostic and treatment services for cancer in the province. IACR rules (1990) In 19982002, Antalya registry used active case nding from 14 government hospitals, 2 university hospitals, 2 private Notes on the data radiotherapy clinics and 7 private pathology laboratories. The The Editors recommend that some care be taken in the death registration system is incomplete, particularly in the rural interpretation of these data; see Chapter 5 (Categorisation).

267

Asia

Turkey, Izmir
Registration area The Izmir Cancer Registry covers the population of the province of Izmir, which is divided into 28 administrative districts. zmir province is in the extreme west of the country, on the Aegean Sea coast. The population is 3.37 million (mid 2000), making it the third-largest province in Turkey; 81% of the population lives in urban areas, with the remaining 19% in rural areas. Most of the people are Islamic. Izmir is one of the most developed and westernised parts of the country. are continuously done for all cases and for whole database, in addition to this, re-coding of selected cases (10% by random selection) for each series are performed systematically. Similar to Turkey in general, mortality data in Izmir are incomplete, and notied only for urban areas, with a problem of accuracy in regard to underlying cause of death. Although ICR collects data of death certicates referred to cancer obtained from Provincial Health Directorate records, these certicates are poor in quality and lack information even for socio-demographic data and addresses. Matching these data with ICR database is quite difcult. Despite all these realities, ICR began in 2005 to routinely match the death certicates with the records of incident cases and process them.

Cancer care facilities The registry is a subdivision of the Provincial Health Directorate of Izmir and is mainly funded by the state. ICR is also nancially supported by the MECC (Middle East Interpreting the results Cancer Consortium). TURKEY, IZMIR (1998-2002) It is not possible to estimate General healthcare in the TURKEY, IZMIR (1998-2002) how many cancer cases region is provided predominantly remain undiagnosed, but by the Turkish state health services underdiagnosis probably department, through the two occurs for older adults in rural university hospitals, state hospitals (/0$,/// 1,. ,/1$1/// -/($1/// 1$" 1/,--/// areas. While awareness of the and a network of primary health &,/012/// 0," &2/$1*/// public has been increasing in centres. This is supplemented by (&/0&$/// 0$" (-/22$/// *,/(1'/// -," ,$/$11/// the last 510 years, cancer private physicians and private ,*/2&(/// -$" ,1/,$&/// diagnosis at health facilities hospitals. While major hospitals -0/($&/// ,," --/*(2/// 11/*20/// ,$" 10/$$0/// in the region has improved provide radiotherapy and &$-/'&0/// *," &$$/2',/// consistently. Opportunistic chemotherapy services, cancer &''/*2&/// *$" &&0/(1*/// &(,/*-(/// (," &('/*&$/// screenings for breast, prostate, diagnosis and cancer surgery &*'/',-/// ($" &(2/-(*/// cervical and colorectal cancers procedures are available in most &,,/$''/// '," &,*/0$*/// &-$/,&1/// '$" &-(/02'/// are quite widely performed. health facilities. Also, there are &,*/$*$/// &," &*2/'&2/// Systematic screening for five private oncology centres &*$/$22/// &$" &(,/$((/// &($/*&'/// ," &',/*$-/// breast cancer has been applied that provide radiotherapy and &'(/202/// $" &&1/(,*/// for a small population, which chemotherapy facilities. With its covers approximately 2000 developed health services, Izmir &$ , $ $ , &$ women aged 5069. ICR is a referral centre for patients /)%+  /)%+ collects data from all of these from other provinces, especially &/--2/(*(/// &/-1*/&$'///  screenings. the provinces of the Aegean  
 Region. It is possible that some
//!/
 /// ///// / #/  
   Izmir residents with cancer choose to be treated elsewhere, such Use of the data 
//)&22$+//    as Istanbul or Europe. However, this is unlikely to be more than The registry has published the results occasionally in // // //!////
/ //3// 
/,/) +#/ 1% of the cancer patients, bearing in mind the social composition scientic meetings and journals and at the website: http:// www.ism.gov.tr/kidem. of the population. Some special studies such as survival of registered cancer cases and some casecontrol (colorectal cancer) studies have Registry structure and methods The Izmir Cancer Registry (ICR) collects data on all new been carried out. cases of cancer from all of the facilities in the province, including university hospitals, state hospitals, teaching Source of population hospitals, municipality hospitals, other governmental Annual registrations by primary health center of the hospitals, private hospitals, private cancer centres (n=25) and Provincial Health Directorate of Izmir. pathology laboratories (n=23). Nine hospitals have hospitalbased cancer registries, from which the ICR receives the Multiple primary rules used data directly. The staffs of these hospital registries apply the IACR rules (1990). same rules with ICR while collecting, abstracting and coding the data and are supervised by ICR. For all other sources, Notes on the data data collection is active at the time of visits by full-time, The Editors recommend that some care be taken in the medically qualied registrars. Internal consistency checks interpretation of these data; see Chapter 5 (Categorisation).

268

Europe

Central and Western Europe

France

Italy

Portugal and Spain

Switzerland

United Kingdom and Ireland

Europe

Austria
Four Austrian provinces run their own regional cancer Registration area The Austrian National Cancer Registry covers the whole registries. Information on every cancer case is collected in population of Austria, approximately 8.3 million (2007) close cooperation with the main hospital of the respective inhabitants. About 90% of the Austrian population are Austrian area and is electronically processed. The information is citizens; other nationalities and/or ethnic groups include Turks, forwarded to Statistics Austria on a regular basis. Serbs, Germans and Croatians. Approximately 15% of the All invasive and in-situ tumours are registered, and topography, population are foreign-born. More than 80% of the population morphology and behaviour are coded to ICD-O-3. The coding is are Catholic, and about 5% are Protestant. Another 5% are part done centrally in Vienna apart from the codes assigned by the of Islamic, Israelite and other Non-Catholic denominations. Tyrolean Cancer Registry are accepted separately. Austria is divided into 9 provinces. The population is All incoming data are stored in a database that performs distributed as follows. Most of them reside in the provinces data checks at the point of data entry. These data checks of Vienna (19.5%) and Lower Austria (19.2%), followed by are based on the IARC CHECK program, broadened at the Upper Austria (17.1%), Styria (14.7%), and Tyrol (8.4%). The national level. IARC/IACR rules for classifying multiple lowest population can be found primaries are implemented as in Salzburg (6.4%), Carinthia well. Multiple notications for (6.9%), Vorarlberg (4.4%) and the same person are identied AUSTRIA (1998-2002) Burgenland (3.4%). using the full name, date of AUSTRIA (1998-2002) The Austrian territory birth, sex and address as well covers 83 871 km of which as social security number. 2/5 is permanently habitable. For the quality control and The country is characterised assessment of completeness, #'*''*** ,') !'*+(*** %#*+'!*** , !!*%,*** by a diversied geographical electronic data of pathology -%*+%*** +' !,+*'#*** situation. laboratories and of various !#(*'-'*** + !-"*%((*** !'(*#"*** (' !,%*#("*** study groups are used. !--*(-(*** ( "!(*#!"*** Cancer care facilities The causes of death statistics "#+*,(*** '' "%,*+--*** "%%*+!*** ' "%+*#'*** A nationwide social security are available electronically and "(*'*** %' "(*+#(*** system covers 98% of the are used for passive follow up #+*!"*** % #!*%+-*** #'"*-(!*** #' #%*,%*** Austrian population. For and generating DCN cases. All #%#*+'+*** # ##'*+(#*** inpatient treatment about 275 death certificates mentioning ",*#"*** "' ",!*#-'*** "%!*,",*** " "#(*#!+*** hospitals are available. More cancer are available for the "%(*#!%*** !' "#'*#-+*** than two thirds of Austrian registry as paper forms as well, "%"*#-(*** ! "#*%#!*** "%!*-(*** ' "#*#(%*** hospital beds are maintained and are traced back when the "!'*","***  "%*,'"*** by 133 public hospitals. Four of patient died in a hospital. these hospitals are university ! '   ' ! hospitals, located in Vienna, Interpreting the results 
*$ & 

*$ & Graz, Salzburg and Innsbruck. For the whole of Austria %*!%!*(,*** #*,,*%#(***  More than thirty hospitals run opportunistic screening is 
   departments specialising in 
**
*

***
*
**
**"!*** 
**
*
* *
* carried out for cervix, breast cancer treatment; many include 



 a radiotherapy department. and prostate. For some regions organised screening is carried 
*
*$"%&**** out for prostate and large bowel. A regional comparability Registry structure and methods study of the data is currently underway. The Austrian National Cancer Registry is located in Vienna and is operated by Statistics Austria, the former sterreichisches Use of the data Statistisches Zentralamt. According to the Federal Statistics The registry publishes data annually since 1970 in the Act 2000 (Bundesstatistikgesetz 2000) the Austrian government yearbook on health statistics. Tables printed in this annual appointed Statistics Austria as the national provider of various report show incidence rates broken down by primary site, statistics. The government nances all statistics prescribed stage, sex, age and region. In 2005 a publication contrasting by this law (including cancer statistics). Altogether 13 people incidence and mortality data was released. In 2006 the scope are directly involved in the cancer registry workow. Some of was further enlarged when it was published on the Internet. them work part-time or are involved in other projects as well, A special analysis of survival for colorectal cancer was which results in 9.4 FTE. published in 2006 as well. Preparatory work for the cancer statistics was done by the Highly aggregated data are available for all interests. Austrian Cancer Society, which led to a legal basis for cancer Medical Universities, the Gesundheit sterreich GmbH registration in 1957 (Krankenanstaltengesetz). Since 1969 a (GG), and cancer study groups are provided with data, more detailed law (Krebsstatistikgesetz) obliges hospitals to which are at a lower aggregation level but still anonymous. report every cancer case to Statistics Austria. Populationbased data collection started only one year later. Hospitals Source of population ll in a form providing personal data, topography, histology The data are estimated by Statistics Austria, based on census data and behaviour of the tumour as well as the incidence date. 2001 and data provided by the Central Population Registry. The stage of the tumour at diagnosis and the rst treatment are also reported. Files are increasingly now transmitted Multiple primary rules used electronically (via disk or secure FTP). IACR rules (2004) on historical data.

276

Europe

Austria, Tyrol
Registration area Tyrol is one of nine provinces in Austria, and is situated in the west. The area covers 12 648 km; only some 12.5% is habitable. The average altitude of the habitable regions is about 740m. Nearly 20% of the population lives in one town with more than 100 000 inhabitants (the capital Innsbruck), the rest in smaller towns (less than 15 000) and in some 260 villages. Nine percent of the people are from foreign countries, mainly from the former Yugoslavia and Turkey. About 90% are Roman Catholics. The main occupational groups are personal services (32%), commerce and trafc (22%), industry and trade (22%) and tourism (10%), with some 6% unemployed. Multiple cancers are recorded separately at the request of the physicians, but the IARC rules are used for reporting. Follow up information is based on probabilistic record linkage between the incidence data and all-cause mortality data for the province of Tyrol. Coding is done by one trained person in cooperation with a pathologist. Programs for checking personal data were developed within the registry. Lists generated are checked manually, and if there are queries the local communities are contacted. The cancer data are checked using IARC Tools. For formal evaluation of completeness, since 2003 we have applied the Bullard method using a program developed by the Thames Cancer Registry. Besides extensive plausibility checks, no formal evaluation of accuracy has been done to date.

Cancer care facilities Medical facilities are provided Interpreting the results The population in the province by Innsbruck Medical University AUSTRIA, TYROL (1998-2002) is stable, and there have not (offering both basic facilities for AUSTRIA, TYROL (1998-2002) been changes in the structure Innsbruck and special facilities of the medical services. The for the whole province), nine local organisation of the registry has hospitals in the rural districts not changed in the last ten years. and two semi-private hospitals '/2&-/// 1,. 0/*,1/// (/(&$/// 1$" 0/&12/// PSA tests were introduced in in Innsbruck. All diagnostic -/0$*/// 0," &'/,(-/// 1988/89 and since 1993 have and therapeutic services for &$/&,&/// 0$" &(/*,2/// &'/',*/// -," &(/002/// been offered to all men aged oncological patients are provided &,/-(*/// -$" &-/02*/// 4574 free of charge; more in the country. Most pathology &1/--(/// ,," &2/,*0/// &2/0,$/// ,$" &2/2*-/// than 3/4 of all men in this age diagnoses are done by one main '$/,&$/// *," '&/$1,/// group had at least one PSA test institute in Innsbruck and ve '*/1(,/// *$" '*/-$-/// '2/201/// (," '2/($-/// in the last decade. There is also smaller pathology laboratories. ($/,$(/// ($" ($/$(,/// a spontaneous mammography Radiotherapy is offered by one ',/'0'/// '," ',/,$&/// '&/-&$/// '$" '&/&*$/// programme which has had some Department of Radiotherapy at '&/11$/// &," '$/1&*/// inuence on breast cancer rates. Innsbruck Medical University '&/,,2/// &$" '$/,&2/// '&/1($/// ," '$/12$/// In addition, Pap smear tests and and by a radiotherapy unit within &2/0-'/// $" &1/10&/// haemoccult tests are offered free the Department of Gynaecology of charge, and dermatologists of Innsbruck Medical University. &$ , $ $ , &$ orga n ise e a rly d et e ct ion Chemotherapy is provided by all /)%+ /)%+ activities for melanomas every (*(/*0*/// ('0/&''///  hospitals. For some cancer sites spring. We have no knowledge (leukaemias and lymphomas, 
   //
#///'$$&!//

//// /// !////// of unusual environmental or head and neck cancer, ovarian  /

///

/ // ////#/ cancers, and advanced melanomas) most patients are treated at occupational exposures in Tyrol that could influence cancer  



 
//)'$$*+// ,//
/ Innsbruck Medical University. Treatment outside the country is incidence figures on the population level besides high radon rather rare. Tumour boards have been installed in the last years, exposure in a small village with a population of 2800. but until now did not cover all cancer patients. Use of the data Annual reports have been produced since 1988. Besides usual Registry structure and methods The Cancer Registry of Tyrol commenced operations at gures, the report also includes staging information, regional the end of 1986, and has been population-based since distribution and relative survival rates. Reports are distributed to 1988. Since 1969 there has been a law obliging hospitals key decision makers and are accessible online from our website. to report every cancer case to the Austrian Federal Bureau The data are widely used by physicians (especially from Innsbruck of Statistics. In addition, local registries are responsible for Medical University). Quality improvement programmes at the cancer registration in some provinces. department level make use of survival rates. Survival data have The Cancer Registry of Tyrol is a department within been published within the EUROCARE study group. and funded by the TILAK, an organisation managing Besides routine reports, the registry has been involved in a study of the university hospital of Innsbruck and some smaller radon exposure and lung cancer. Main scientic work is concentrating on hospitals in the Tyrol. The registry is staffed by a part- analysing time trends, mainly for prostate cancer and breast cancer. time epidemiologist, a full time registrar and one part-time registrar, and data entry clerks as needed. Source of population All hospitals are obliged to report cancer cases. Most Ofcial population data collected by Statistics Austria. In 2001, the departments ll in a form consisting of personal data, population data were extracted from the census le; in the other years incidence date, most valid basis of diagnosis, topography, the population gures have been estimated in usual way. histology, behaviour, staging and summary of rst treatment. All pathology diagnoses concerning cancer and all death Multiple primary rules used certicates are sent to the registry. IACR rules (2004) on CI5 IX period.

277

Europe

Austria, Vorarlberg
medicine. Per Vorarlberg government decree, hospitals are Registration area Vorarlberg is the westernmost of the nine federal states of required to send their records to the local cancer registry, Austria. It borders Switzerland, Germany, Liechtenstein and from where they are forwarded to the Federal Bureau of the Austrian federal state of Tyrol (19% of the border). Lake Statistics. The main source of the data is the Institute of Constance comprises 8% of the border between Austria and Pathology (histological, cytological and necropsy diagnoses). Germany and Austria and Switzerland. Vorarlberg covers The data are transferred to the cancer registry and compared 2601 km, of which only 21% are habitable. 90% of the area to data already registered. From there a registration sheet is mountainous. Vorarlberg lies between 9 and 10E and (including the pathology diagnosis) is sent to the hospital for further information. In cases with no pathology diagnosis 46 and 47N. The total population of 351 570 (177 971 females, the hospitals report the cases directly. The radiooncology 173 599 males per census 2001) lives in 96 communities, ve department, which tracks each patient, also sends data to of which are cities; 51% live in communities with more than the registry. In general, multiple notications are received 10 000 inhabitants, 43% in communities with 1000 to 10 000 for one cancer phase. Persons are identied by name, date of birth, sex, address and (since inhabitants and the others in 1995) social security number. smaller communities. The A sophisticated program Rheintal (Rhine River valley) AUSTRIA, VORARLBERG (1998-2002) developed by the Cancer and Walgau are home to AUSTRIA, VORARLBERG (1998-2002) Registry of Tyrol establishes 81% of the population. The links between various records. population density in the Multiple cancers for a person Rheintal (permanently settled are recorded separately. area) is 1125/km, whereas %.&'0... 0+'.+/0... %.'&/... 0#! '.%%'... Follow-up is conned to date the population density for '.#1/... /+! +.0+1... of death. the whole federal state ).0/'... /#! ,.+&0... ,.%+%... ,+! /.#'%... Topography and histology (permanently settled area) is 0.#,+... ,#! 0.+,,... are classied according to 620/km. Life expectancy at 1./,)... ++! 1.,%'... %#./)'... +#! %#.&,%... ICD-O-DA (German edition). birth is 75.8 for males and 82.6 %%.#/0... )+! %%.%',... Coding is done by a trained for females (2001). Inhabitants %&.1'/... )#! %&.+,,... %+.))+... '+! %).+/&... person in cooperation with from foreign countries make %+.+,0... '#! %).1#+... a pathologist and medical up 14.5% of the population: %'.%,&... &+! %'.%%/... %%./,+... &#! %%.+'&... doctor. The rst quality 5.2% from Turkey, 4.6% %&.%%/... %+! %%.+'%... inspection is performed by former Yugoslavia, 2.8% from %%.0,#... %#! %%.#1+... %&.&&,... +! %%.+&/... the medical manager before Germany, and 0.4% from %%.%&&... #! %#.,/#... data is entered. In addition, Switzerland. 87.2% are Roman IARC check programs and Catholics, 2.8% Protestants, %# + # # + %# .($* .($* plausibility checks established 4.7% Muslims, 3.3% other %//.&##... %/&.+'/...  by the Cancer Registry are denominations. The main applied periodically. occupational groups are: 
   The only pathology services (55.4%) and industry .. ......... ..    ..... .&##%".  



 
. .(&##)*.. +..
 . and trade (42.7%). The 2001 unemployment rate was 4.3%. institute in our region provides the rst information on cancer at primary histological diagnosis and on autopsy See http://www.vorarlberg.at for further information. reports. Clinicians from the clinical departments supplement the remaining data. Aks staff merge the data into the cancer Cancer care facilities 5 public hospitals and 2 private hospitals cover most medical registry. Completeness is examined by comparison with all needs. In special cases patients are sent to hospitals in other hospitals discharge diagnoses. We organise team sessions on areas, mostly the university hospital in Innsbruck, Tyrol. a regular basis with participation from responsible persons Cancer treatment is provided by every hospital. There is from the aks. only one Radio-Oncology department in the province, in Feldkirch. Hohenems hospital has recently opened a Interpreting the results The population in the province is stable and there have palliative care department. been no changes in the medical services structure or in availability of diagnostic or treatment services. Case Registry structure and methods The Cancer Registry of Vorarlberg was founded in 1978 by denitions and coding did not change in 19982002. Wellthe Pathology Department at Feldkirch hospital. Electronic organised preventive care and early detection programs have been available in Vorarlberg for many years. In 19982000, data processing was introduced in 1981. In 1968 a cancer registration law was passed in Austria, 37% of women and 32% of men took part in health checks obliging hospitals to report every cancer case to the Federal (including hemocult tests) and 45% in gynaecological exams Bureau of Statistics. In addition to this federal registry, local (including Pap smear). Mammography screening has been cancer registries exist in some federal states. In Vorarlberg active since 1989. the cancer registry is part of the Arbeitskreis fr Vorsorge und Sozialmedizin (aks), a non-prot organisation founded Use of the data in 1964, working on behalf of the local government in the Annual reports are made to the government health eld of health promotion, preventive medicine and social department. The data are used for evaluating local cancer

278

Europe

screening programs, such as early breast cancer detection, cervical cytology and colon adenoma. In Vorarlberg, health checks (Gesundenuntersuchungen) are very common, so the cancer registry also documents dysplasia and adenoma of the colon as cancer risks. Incidence data for the Cancer Registry of Vorarlberg between diagnosis years 19962000 have appeared in a publication entitled Cancer Mapping in Alpine Regions 1996-2000: Trentino, South Tyrol, Carinthia, Tyrol, Vorarlberg. Data are linked and used for publications and scientic reports known as the Vorarlberg

Health Monitoring and Promotion Programm (VHM&PP). For further information see: http://www.aks.or.at and search Health Monitoring & Promotion. Source of population The data are estimated by the Institute of Statistics in the Government of Vorarlberg, based on census data from 2001. Multiple primary rules used IACR rules (2004) on CI5 IX period.

279

Europe

Belarus
Registration area The Belarussian Cancer Registry covers the population of Belarus, which occupies 207 600 km2. The population in 1999 was 10 179 121 (males 46.6%, females 53.4%, urban 70.3%). from the Institute for Oncology and Medical Radiology, the Childrens Oncological and Haematological Centre, Centre for Thyroid Tumours Pathology, Institute for Neurology, haematological hospitals, hospitals with cancer beds, and out-patient clinics, where cancer is diagnosed and treated. Pathologists must also complete and send a notication if they incidentally diagnose cancer as a result of an autopsy. Cancer care facilities Death certicates are checked monthly by the personnel The main treatment facilities are the 12 oncological dispensaries, which combine outpatient and inpatient clinics, of the oncological dispensaries and the Institute for Oncology and Medical Radiology in regional state statistics departments and an Institute for Oncology and Medical Radiology. for any mention of cancer. Information found is checked against the database in the dispensary. For each cancer case Registry structure and methods Cancer registration is mandatory and has been carried out not found in the database additional information is requested from the institution, which according to the directive of issued the certicate. the Ministry of Public Health In-situ cancers are of the USSR since 1953. BELARUS (1998-2002) registered but are not included However, until the beginning BELARUS (1998-2002) in the cancer statistics. of the 1970s, it was performed Primary multiple tumours on the basis of obligatory are registered as separate ofcial statistical reports, cancer cases if they appear and there was no computer '20((2000 2-/ 1(02))000 (-0+'-000 2%# 2%0.3%000 (simultaneously or at a later database with individual .20+-2000 1-# '2'032'000 time) in different organs or information on cancer cases. '+-0312000 1%# (120.)1000 '2-0-2%000 .-# (3)0%%2000 different parts of the same The Belarussian Cancer ((20.)1000 .%# )(%0'.3000 organ (including skin); each Registry includes complete '3%0.+2000 --# ()10)3.000 (-303(1000 -%# (3-0'-2000 tumour is entered into the individual information on ))20)%2000 +-# ).30(.(000 database separately according cancer cases since 1978, but +%-0%32000 +%# +(-0.(2000 )310%1'000 )-# +%10)%+000 to the 4-digit ICD-9 code. The for the period 19781985 there )+)03%+000 )%# )-'02%)000 records have the same unique are no personal identiers )+10+((000 (-# )+10+-(000 )1)0()3000 (%# ).(0...000 key and may be analysed such as name and address. In +'+03-+000 '-# +%%0.%.000 together if desired. 19851988 a computer system +%.0(%+000 '%# )230.+(000 )'%0+)2000 -# (3-0)3'000 was gradually set up in the (+'0(-'000 %# ((102+)000 Interpreting the results oncological dispensaries, In 1986 the Chernobyl which allowed long-term '% % % '% accident resulted in radiation continuous data collection for 0*&,  0*&, -0))10+.3000 exposure to about 20% of +01%%01.%000  each patient and easier followthe Belarussian population. up. Since 1991 this system  
 "00!0000
 000!0 00'3330"0 00 0!00 After 1991, a high increase has functioned on personal
0

00 "00 0000 000$00000
0!000 00
0000 0
 $0 computers in all the Belarussian oncological dispensaries in the number of thyroid cancers in children, related to I131  
   
00*(%%+,00 -00
0 and the Institute for Oncology and Medical Radiology. Since irradiation of the thyroid gland, was observed. 00 00 00!0000
0 00400 
0-0* ,$0 1999 new computer system was   introduced based on ICD-10 and ICD-O-2 morphological classication. Use of the data The Belarussian cancer registry has been located in the The Belarussian Cancer Registry submits ofcial statistical Belarussian Centre for Medical Technologies, Computer reports to the Ministry of Health annually, including data on Systems, Administration, and Economics of Public Health cancer incidence, mortality and treatment in Belarus, as well in Minsk since 1992. as the statistical collection Malignant Neoplasms in Belarus In Belarus, the majority (about 8085%) of cancer patients for a Decade, highlighting trends and changes. are diagnosed and treated in the oncological dispensaries and the Institute for Oncology and Medical Radiology, which is Source of population responsible for the registration of cancer cases for Minsk oblast Annual populations are estimates, calculated by the State (region). This makes data collection signicantly easier. The Statistical Department on the basis of the 1999 census, 12 oncological dispensaries and the Institute for Oncology making allowance for births and deaths, and migration into and Medical Radiology are responsible for registration of and out of the registration area. Migration data are annually all cancer patients permanently residing in their service provided by the Ministry of Internal Affairs to the State area, and regional sub-registries of the Belarussian Cancer Statistical Department. Registry are maintained in the oncological dispensaries and the Institute for Oncology and Medical Radiology. Multiple primary rules used Most information is entered onto computers directly IACR rules (2004) on CI5 IX period. from patients medical records (outpatient medical card and history of disease) stored in the dispensaries and the Institute Notes on the data for Oncology and Medical Radiology. Extracts of medical The Editors recommend that some care be taken in the documents and special notication forms are also obtained interpretation of these data; see Chapter 5 (Categorisation).

280

Europe

Belgium, Antwerp
Registration area The Antwerp Cancer Registry covers the province of Antwerp in the north-west of Belgium. Almost half of its population of 1.6 million inhabitants is concentrated in and around the city of Antwerp. The western half of the province has a high urbanisation grade, whereas the eastern half of the province is mainly rural. Cancer care facilities The province of Antwerp has 36 hospitals, of which 6 have an oncology centre. Five hospitals in the registration area have radiotherapy departments Registry structure and methods The ACR is located at the Department of Epidemiology and Community Medicine of the University of Antwerp and is funded by the Flemish government. The staff of the registry consists of a head medical ofcer, an epidemiologist and 7 registration workers. The registration process is based upon the Dutch cancer registry, characterised by active case nding, data collection and coding by the registration workers in all hospitals and the major private pathology laboratories of the province. There is no access to death certicates; therefore these are not used for case nding. Interpreting the results Coverage of the entire province was not complete until the incidence year 2000, when all hospitals in the registration area participated in registration; under-registration in 1998 and 1999 may be estimated around 5%. Some organised screening programmes exist for cervical, breast and prostate cancer; however, these data are not being used directly for case nding.

$/-0$0--%(-$+"--&&-**&--("-*.%--(&-"$$--((-/%0--*(-("/--*/-*".--+(-&*$--+.-*0*--+%-0%+--*(-"*0--(0-%%$--(0-0.*--(/-0%&--(0-(+/--(+-""%---

Use of the data The ACR reports crude, age-specic and age-adjusted (ESR) incidences annually; moreover, each participating hospital obtains an annual report on all of its own diagnosed and/ or treated cancer patients. Registration data are provided for research purposes to internal BELGIUM, ANTWERP (1998-2002) as well as external institutions. BELGIUM, ANTWERP (1998-2002) Our data are used directly by local health authorities, for evaluation of screening programs and indirectly: hospitals report /", ($-%""--to the federal health department .* &(-$""--using cancer registration data. ." ("-.(/--+* +" ** *" (* (" &* &" %* %" $* $" * " ((-+($--((-&(&--((-$/"--*%-.("--*+-%.&--+%-$+"--+*-&%0--+"-.%&--*%-0/.--(.-//%--(.-/+/--(+-/"*--(.-*""--((-%$"---

Source of population Ofcial data from population register, provided by the administration. Multiple primary rules used IACR rules (1990). Notes on the data The Editors recommend that some care be taken in the interpretation of these data; see Chapter 5 (Categorisation).

$"

* 
-'#)

"

"

* 

-'#)

$"

/$"-(.0---



/&&-+0"---

 
 ---  -

- 
--
- 
   
-
-'$00")   
- -

--
-
-
-
--
-
 
--

-1-

- 
-*-'
)!-

281

Europe

Belgium, Flanders
Registration area Flanders is situated in the north of Belgium and comprises 5 provinces. The estimated mid-year population for 2000 was 5 946 402, of whom approximately 5% are foreigners. The mean population density is 439 inhabitants per km. In 2000 people over age 60 made up 22.2% of the total population, with 11.7% older than 70 years of age. The life expectancy at birth was 76.0 years for men and 81.9 years for women. consisted of 2 data managers, a part-time pathologist and a physician coordinator. Both active and passive data collection methods are used in this network, but all data are provided electronically to the Belgian Cancer Registry in a predened structure. Due to privacy regulations only encrypted data are allowed to be transmitted. The personal identiers are encrypted by the same procedure at the hospitals, the National Health Services and the pathology laboratories. All invasive and in situ tumours are registered. Topography, morphology, behaviour and differentiation Cancer care facilities In 2000 there were 3.1 physicians per 1000 inhabitants and are coded to ICD-O-2. In Flanders the majority of the 5.1 general hospital beds per 1000 inhabitants. The medical pathologists work with CODAP codes which are translated automatically to ICD-O-2 by care institutions are easily means of a computer program. accessible and medical care For staging of tumours the is provided by 116 general BELGIUM, FLANDERS (1998-2001) TNM classication is used. hospitals. BELGIUM, FLANDERS (1998-2001) The IARC rules for classifying There are no specic cancer multiple primaries were hospitals or regional cancer adapted slightly. centres. Oncological care and radiotherapy are provided All incoming data are checked 


 









within general and university at the Belgian Cancer Registry 







hospitals. For the whole country with a control programme based 














in 2000, 163 radiotherapists and on the rules of the IARC-check 







almost 287 pathologists were program and supplemented with 







 



 


registered at the Ministry of other controls developed at the 





 

Health and Social Affairs. In registry. Multiple notifications 












 

2000 there were 25 radiotherapy for the same tumour are linked 






services in Belgium, of which according to the encrypted  




 



 





14 were located in the Region personal identier at the Cancer 







of Flanders. Registry and summarised by 





 








More than 99% of the automated decision rules. A 







population living in Flanders signicant number of cases are are afliated with one of the resolved manually.       National Health Services for Death certicates are )%"' )%"' 



$)+$+)*#&)))  mandatory medical insurance. also transmitted to the All of these National Health 
   cancer registry, but they are Services are grouped in a #++*-$!!#)))

) ),) ))-)
) )))) ) anonymous and do not permit  



 National Health Insurance System. any trace-back procedure. They can only be used as an 
))%$!!&')) ())
) Although there were no regional or national organised additional check for date of death and the cause of death. The screening programs for cervical nor breast cancer until June independent data set method was used in 2005 to evaluate 2001, many women did have a Pap smear and mammography the completeness of the cancer registry (year of incidence taken regularly at that time. In June 2001 a national breast 20002001). The completeness was estimated to be 98.2%. cancer screening program was launched for women aged 5069 years. There are also local initiatives for screening Use of the data of cervical cancer and malignant melanoma. Opportunistic Annual incidence data by sex, age, site and geographical PSA testing has been used increasingly. units are routinely produced. Detailed data for the major cancer sites are analysed in separate chapters that are Registry structure and methods published and distributed. Survival data were published The Belgian Cancer Registry is subsidised by the National for the rst time in March 2006. Data are also displayed Ministry of Public Health and by the Ministries of Public on the website of The Belgian Cancer Registry and www. Health of both communities (French and Flemish). Since tegenkanker.be/kankerregistratie. Numerous requests for 1983 the National Health Services have been collecting data are provided to research workers, clinicians, health care data on newly diagnosed malignant tumours among their planners, paramedics and the general public. contributing members and families. In Flanders, from 1996 onwards, different cancer registration systems, essentially Source of population the provincial cancer registry in Antwerp (AKR), the 19972001: Mid-year population estimate. Source: FOD provincial pathology cancer registry in Limburg (LIKAR), Economie Algemene Directie Statistiek en Economische the bronchus carcinoma registry for Flanders (VRGT), Informatie. some hospital cancer registries and almost all pathology laboratories, have been integrated in a cancer registration Multiple primary rules used network. In 2003 the Flemish staff of the cancer registry IACR rules (2004) on CI5 IX period.

282

Europe

Bulgaria
Registration area The Bulgarian National Cancer Registry (BNCR) covers the whole population of Bulgaria. The population at the most recent census (1 March 2001) was 7 932 984. About 70% of the population (<6 000 000) lives in urban areas. The predominant religion is Eastern Orthodox Christians (85%); 13% are Moslems and nearly 1% Catholics. Dispensary clerks frequently visit all hospitals with wards diagnosing or treating cancer patients, pathological laboratories, etc. to add to the rapid notication data. In January 2006 the ICD-10 was introduced in Bulgaria; all cancer cases since 1993 have been recoded. To improve the registration system a check of the Central Population Register was made for all cases who died after 1998. For registration of malignant neoplasms a new software product has been developed. In each regional register trained Cancer care facilities Until 1989, medical care in Bulgaria was free. Private medical clerks, under the supervision of physicians, code the data. practice has been permitted since 1991. National Health Processing includes verification of completeness, checking Insurance was introduced in 2000. Health care is mostly public, for duplicates by name, identication number (PIN), address including regional hospitals, university clinics, specialised and diagnosis, consistency and compliance between clinical and morphological diagnosis, hospitals and primary health computerised checking and establishments, supplemented correction of coding and typing by private practitioners and BULGARIA (1998-2002) errors. Histology is coded hospitals. BULGARIA (1998-2002) according to ICD-0-2. Benign A sp e cia l ise d ca ncer lesions and those of uncertain network was founded in behaviour are not registered. The Bulgaria in 1952. It includes BNCR uses IARC Tools Version 13 Regional Oncological ).13()111 3.0 ,,1,22111 ,.1**/111 3&# 2&1.4*111 2.03 (2006) and DEPedits C e n t e r s (d i s p e n s a r i e s), ((.1()2111 2.# (/312)(111 Version 1.00 (2006). Legislation covering populations between (/41*42111 2&# )))1/)*111 )&21,2,111 /.# ).)1.((111 for data condentiality is not yet 370 000 and 1.2 million )&412&3111 /&# ),*134,111 available in Bulgaria; thus each inhabitants. Another part, ))41),2111 ..# ).*13/)111 )241&2.111 .&# )421233111 patient is assigned a unique ID National Oncological Hospital )3.1344111 ,.# )421&32111 number. (NOH) is located in Sofia. )241)2.111 ,&# )3*1/./111 )2&13/4111 *.# )/313.4111 The specialised cancer system In the registry we currently )2/1/&3111 *&# )/41*4.111 provides prevention, diagnostic, compare (for completeness and )4/1())111 ).# )33122*111 *&4134/111 )&# )4.1/22111 t reat ment (r ad iot her apy, accuracy) and evaluate the data )3.1///111 (.# )2&1*)(111 surgery, chemotherapy) and between: incidence and mortality )/*13&)111 (&# ).(1(/&111 )()1,((111 .# )&(1.32111 follow-up services for cancer data; incidence data between 28 (2*1,24111 &# (/,1(2(111 patients. In 2000 a total of 27 districts in Bulgaria and over 526 physicians were engaged time; incidence data between (& . & & . (&  1+'! 1+'in healthcare activities, 471 Balkan countries, etc. Every three ,1(,.1(.*111 *14*.1)&,111   of whom were physicians in months we receive information oncological centres. Natioanlly  
 for all deaths from the Central there were 60 552 hospital  1! $1511  1  11+5%%$$"-1 Population Register in Bulgaria.  
   

11+)&&,-11
.111 beds, of which 2005 were in oncological centres. This comparison is published in Lung Cancer: Current Status    September 2005; Balkan Union of Oncology, 11!!1 1!1 1"1 111 111 and  611
 Perspectives, 1.1+
 -$1 11 111 1 1 111! $1 Registry structure and methods Proceedings/ Educational Book, 5th Congress, etc. The Bulgarian National Cancer Registry, funded by the Ministry of Health, is part of the National Oncological Interpreting the results Hospital. One physician, one statistician, one specialist in Despite active and passive methods of cancer registration computing and six full-time clerks staff it. In each of the there is possible nonregistration of cancer cases mainly 13 dispensaries, there is a Regional Cancer Registry, usually among elderly people and among inhabitants of the rural staffed by one full-time physician and 2-3 clerks. areas. There are some omissions in coding cause of death The BNCR uses active and passive methods of data collection. (metastasis instead of primary site) as well, leading to a Compulsory registration of malignant diseases in Bulgaria was discrepancy between incidence and mortality data, especially introduced in 1952. Every physician is required to send a rapid in liver cancer, esophageal cancer, etc. notication to the Regional Oncological Centre for each newly Bulgaria now has opportunistic screening for breast cancer and diagnosed or suspected cancer case, death from a malignant cervix uteri cancer funds from the National Health Insurance Fund. neoplasm, and since 1975 for cancer in situ as well. The rapid A Strategy for Prophylactic Oncological Screening in Bulgaria was notication system was updated in 1992. From 1993 cancer patients created for 20012006. It includes breast cancer, cervical cancer have been followed up by type of treatment and date of death as and prostate cancer. The Strategy was accepted by the Council well. In 2000 new items and codes were introduced according to of Ministers on 23rd of April 2001 but it was not undertaken for European Network of Cancer Registries recommendations. various reasons (faults in program organisation, screening tests, Other sources of information on cancer patients are medical interpretation of the results, etc.). PSA testing is not common. records from oncological centres and other specialized hospitals, university clinics, primary health establishments (outpatient Use of the data and inpatient), pathology and haematology laboratories, The BNCR annually publishes cancer incidence data in death certicates, Central Population Register, hospices, etc. Bulgaria. The data available in the BNCR are used for

283

Europe

epidemiological studies, reports, communications and the like. Bulgarian policymakers use cancer registry data for planning or evaluation of health services. Source of population Ofcial estimate. Source: The National Statistical Institute (http://www.nsi.bg).

Multiple primary rules used IACR rules (2004) on CI5 IX period. Notes on the data The Editors recommend that some care be taken in the interpretation of these data; see Chapter 5 (Categorisation). This registry has the lowest histological verication rate in the monograph.

284

Europe

Croatia
Registration area The Croatian National Cancer Registry covers the whole country of Croatia. The Republic of Croatia is situated along the eastern coast of the Adriatic Sea and covers an area stretching up to the last slopes of the Alps and deep into the Pannonian Valley to the banks of the Drava and Danube Rivers. Croatia is divided into three geographical regions: the Mediterranean, the Mountainous, and the Pannonian. Roman Catholics account for 87.8% of the population. Administratively, the country is divided into 20 counties and the City of Zagreb. are used as a supplementary data source. Topography is coded in ICD-10, and morphology in ICD-0-2 classication. Interpreting the results There have been no organised population-based screening programmes in Croatia in the period 19982002. National population-based screening programmes were introduced in 2006 for breast cancer and in 2007 for colorectal cancer. However, opportunistic screening for cervical cancer has been going on since the 1960s, and the number of Pap smears taken yearly is increasing, as well as the number of mammographies. Opportunistic screening by faecal occult blood test has been going on in some regions, while PSA testing is becoming more common, but only in patients with urological symptoms.

Cancer care facilities In 2003, the health service entry points are 2372 primary care physicians, i.e. general practitioners, gynaecologists and paediatricians. There were 23 CROATIA (1998-2002) general hospitals. In addition, there CROATIA (1998-2002) were 12 clinical and two clinical teaching hospitals, and some specialised hospitals, of which one was dedicated to oncology. $$-*.+--/*, $.-"("--/" Most health institutions admitted ((-$(0--.* oncology cases, but the main /$-//(--." $$"-(*0--+* regional oncology centres with a $%"-++.--+" full range of services are located $"/-+.&--** $(/-%%(--*" in the clinical hospitals in Zagreb, $+/-%0"--(* Split, Osijek and Rijeka. $++-(00--("

Use of the data Cancer incidence data have appeared each year in an annual report (bulletin in Croatian and &"-0..--&0-0$(--English) and in the Institutes 0&-"*%--joint annual report since 1976. $%%-""$--$(%-(//--Analyses and observed trends $($-&(0--are published in medical $%$-$"%--$*$-*(0--journals, masters and doctoral $+*-%/+--theses, and presented in $++-0"(--$*/-*"+--&* $*/-.+.--congresses and other scientic $(.-0%"--&" $(.-*$$--gatherings. Survival analyses of Registry structure and $(/-+++--%* $(*-/&$--$**-.&0--%" $(0-/0%--registered cancer cases in the methods $*%-+.+--$* $(*-0&"--periods 19881993 and 1994 The registry is part of the $&.-$.*--$" $&$-("0--$%.-%.(--* $%$-%*(--1998 have been carried out. Chronic Disease Epidemiology $%$-.$/--" $$*-/"(--The registry was created Service at the Croatian in response to the growing National Institute of Public $" * " " * $" public health problem posed 
-'#) 

-'#) Health in Zagreb, the capital /-.+*--! $"-*("--%-&"$-*+"--%-$&*-0""-- by cancer. Data on cancer of Croatia, and is funded by incidence and mortality the Ministry of Health and 
   are used for planning and Social Welfare. A medical 
-%""$!-
--  -
--
 -&$--%""$-


-%-$.-


-%""&-
---1-

--! 



 doctor specialist of epidemiology, a senior statistician, a evaluation of preventive measures and healthcare services. 
-
-'%""()---technician and two data entry clerks staffs the registry fullSource of population time. Software support is provided by an external IT rm. The basic notications are from hospital discharge, Census 2001. Census of population, households and dwellings pathology reports and primary care. Additional information 31st March 2001, Release 2, 17th September 2003, Republic is derived from every ofcial death certicate that mentions of Croatia Central Bureau of Statistics. cancer. Notications include the name of the health providers (hospital or physician) so that they can be contacted for further Multiple primary rules used information. Hospital discharge records in electronic format IACR rules (2004) on historical data

285

Europe

Czech Republic
nurses) and about 80 physicians look after data entry and Registration area The National Cancer Registry of the Czech Republic is proper classication. In the Czech Republic reporting of malignant neoplasms, a territorial registry covering all residents of the Czech Republic, which lies in Central Europe. Mild climatic in situ neoplasms and neoplasms of uncertain or unspecied conditions do not vary markedly with geographical latitude behaviour is obligatory. The report is returned by the physician who diagnoses the neoplasm. Data collection is over the territory. The population of the Czech Republic is 10.2 million performed with the aid of Regional Units of the NCR, which (2002). According to the 2001 Census more than 70% of collect the mandatory reports, histopathological reports, the population is urban. A signicant ageing trend in the discharge reports, protocols on surgery, etc. These data are population is accompanied by low fertility rates (during collated by the workers of the NCR Regional Units. Collated data are transferred electronically to the 1998-2002 total fertility rate was below 1.2). Life expectancy at birth was 72.1 years for males and 78.5 years for females Registry. All data are collected, processed and transferred to the central database using unied software with built-in (2002). online controls. Data are kept The population of the condential in the recording Czech Republic is ethnically and data transfer process. homogenous. The majority CZECH REPUBLIC (1998-2002) The central unit updates the of population (90.2 %) CZECH REPUBLIC (1998-2002) Registry after checking and declared Czech nationality eliminating duplicates. This (Census 2001). The biggest process is supplemented by ethnic minorities are annual comparison with the Slovak (1.9 % of the whole 


 









database of deaths run by the population) and Polish (0.5 % 

 





Czech Statistical Ofce; NCR of the whole population). 







 






also has access to the death Regarding religion, many 







certicate database, which are nondenominational 














is used for additional case(59.0%); the majority of  




 


nding. believers (26.8% of the total 





 








Apart from this statistical population) were afliated 







activity, patients are followed with the Roman Catholic 














continuously (except nonChurch. 







melanoma skin cancer 







 






patients). Specialised followCancer care facilities 







up (dispensary) health There is an extended network establishments return a of health services in the       mandatory check-up report Czech Republic. Oncological  $ "  $ " 



for each case after 1, 2, 3, 4, !$&&$##$$$  diseases are treated in 5, 7 and 10 years, then every specialised establishments in 
   ve years and on the patients accordance with the kind of  $  $$ $$  $
$&&%'$ $ $$ $$$&&$$
$'$$ $$$$ $  



 cancer. There are 83 outpatient establishments for clinical death. The Regional Units employ physician cancer specialists 
$ $ !"$$$$ oncology, employing 112 physicians and 226 paramedical and nurses on part-time contracts, mostly in addition to their personnel. There are 39 outpatient radiotherapy departments practice in the eld. The centre in IHIS has three specialists with 117 physicians and 362 paramedical personnel. In the working directly in NCR activities. hospitals there are 11 departments of clinical oncology with 286 beds and 48 physicians, and 24 radiotherapy departments Interpreting the results with 1185 beds, staffed by 113 physicians (as of the end of The rst organised screening programme in the Czech Republic was introduced in August 2001 for colorectal 2002). cancer. Women and men older than 50 years are involved in the colorectal screening programme. Nationwide organised Registry structure and methods The National Cancer Registry of the Czech Republic (NCR) breast cancer screening of women aged 4569 was was founded in 1976 and connected with data collection introduced in September 2002. Opportunistic screening for on mortality from oncological diseases. However, cancer cervical cancer could inuence incidence rates. In the Czech incidence has been registered since 1956. The NCR receives Republic PSA testing was introduced in 1990 and has been nancial support from the Ministry of Health. Administrator done routinely since 1992. of the NCR is the Institute of Health Information and Use of the data Statistics (IHIS). The National Cancer Registry of the CR itself has no IHIS publishes a yearbook entitled Cancer Incidence in regular staff. Programming is outsourced; data managing the Czech Republic, containing detailed data on incidence and analysis are done by three full-time employees of IHIS of neoplasms and mortality from cancer. Additional details CR and two full-time employees of the Coordination Centre (stage of disease, therapy) are analysed for 10 selected for Departmental Medical Information Systems (CCDMIS diagnoses. The Central Unit in IHIS processes additional has an executive role in managing NCR). About 120 data responding to about 50 special requests a year, from professionals are responsible for data entry (mostly hospital specialists as well as the lay public (media), and compiles

286

Europe

additional special publications. Other publications using registry data are prepared by other specialists or organisations. Although IHIS of CR is not involved in epidemiological research, data of NCR of CR are submitted to scientists (e.g. researchers in Masaryk Memorial Cancer Institute). One of the tasks of the National Oncological Programme (NOP) is to support continuity, stabilisation, modernisation and practical utilisation of the database for controlled preventive and diagnosis-treatment care in oncology. NOP was ofcially supported by President Vaclav Klaus and

by Ministry of Health of CR. The politicians devote great interest in oncological data. Practical cancer incidence data are used to evaluate the quality of hospitals services. Source of population Postcensal estimates. The population estimates for 19982000 are based on the 3 March 1991 Census and for 20012002 on the 1 March 2001 Census. Multiple primary rules used IACR rules (2004) on historical data.

287

Europe

Denmark
Registration area The Kingdom of Denmark, excluding Greenland and the Faroe Islands, covers 43 080 km2 between latitudes 55 and 58 N, and longitudes 8 and 1230E. The mean population of Denmark was 5 340 000; it is of Caucasian stock and fairly homogeneous. Approximately one third of the population live in the greater Copenhagen area, 40% live in provincial towns of 10 000 to about 200 000 inhabitants, and the rest live in rural areas. Since 1968 all inhabitants have been given a unique personal identifying number, used in most registration systems, including the cancer registry. A central computerised population register keeps a continuously updated le of personal information on all inhabitants. copy of the Danish Cancer Registry operates under the law on private registries also supervised by the National Data Protection Agency. Data extraction and requests for data for research projects external to the Danish Cancer Society must be forwarded to the Cancer Registry at the National Board of Health. Upon receipt at the cancer registry, notications are checked and coded. Medical coding is carried out by physicians (1 fulltime equivalent) and trained medical coding staff (10 full-time persons), supported by an academic staff and IT coordinator (1 full-time equivalent). Duplicate registrations are readily picked up with the help of the personal ID number. The entire coding process is supported by computer checks of consistency between variables (sex, codes, Cancer care facilities procedures, etc.), warning The medical care system is programmes and manual check DENMARK (1998-2002) organised into a private sector procedures. New tumour cases DENMARK (1998-2002) of general practitioners and are then included in the registrys specialists under contract computerised database and with the National Health additions or corrections are made insurance, and a public sector to previously notified cases. 


 









operating hospitals under the If the information received is 







authority of the counties and incomplete or contradictory, an 





 


 





municipalities or the Danish inquiry is made to the notifying 







State. Health care is provided clinician. All data up to 1977 

 





 



 


free to all inhabitants. Cancer were classified according to 







surgery is carried out both a modified version of ICD-7  












 

at general hospitals and at expanded to include information 







oncological centres. The on histology and tumour  














hospital departments are behaviour. All cases diagnosed 







serviced by 23 institutes since 1978 have been classied 














of pathology. Non-surgical according to the ICD-O as well 







cancer treatment is partially as the modied ICD-7. centralised at ve university Reported cases of cancer       hospitals with radiotherapy are linked to the Central '"$ '"$ and oncology expertise and Population Registry using 



'&!(')%'''  one regional oncological centre the personal identication 
   (Vejle Hospital). Almost the
'''''

''''* '
'''' '' ' number, the identity is checked  



 entire population is capable of reaching a specialised cancer and information corresponding to the date of diagnosis is 
' '" #$'' %''
 ' centre within a few hours by ground transport. transferred to the registry le. The entire registry database is cross-checked annually by Registry structure and methods computerised record linkage with all deaths that occur in the The Danish Cancer Registry was founded in May 1942 as country. Medical certication of death by medical doctors a nationwide programme to register all cancer cases in the is compulsory. Follow-back on death certied cancer cases population. Incidence gures are available from 1 January unreported to the cancer registry is accomplished by mailed 1943. Registration is compulsory by administrative order as enquiries to the certifying physician or hospital. Less than of 1 March 1987, today incorporated in the National Health 2% remain as death-certicate-only cases. Law. This order also covers Greenland, and a similar order Computerised medical information systems on hospital was issued for the Faroe Islands by the Faroe authorities. discharges have been operating nationally since 1977. Data from Greenland are not included in the Danish Since 1987, cases are also captured from this registry but incidence gures, but published separately. Data from the only included if conrmed. In preparation for extensive Faroe Islands are not included in the Danish Cancer Registry. computerised data capture from 2004, the reporting of The registry was, until January 1997 administratively part cancer to the discharge registry was expanded and improved of the Danish Cancer Society, but has since then been the to full the requirements of the cancer registry. responsibility of the National Board of Health. A close collaboration between the Cancer Registry and the Danish Interpretation and use of data Cancer Society that holds the full and regularly updated Assessments by linkage to patient discharge registers, copy of the cancer registry for research purposes has been pathology registers, and patient series have shown that the established. The Cancer Registry operates under the law on completeness of the registry is 9597%. public authorities registries with instructions established The registry produces morbidity statistics in relation to by the Ministry of Health and supervised by the National variation over time, age and geographical location, and is Data Protection Agency, whereas the Danish Cancer Society used extensively for research. Since 1978, incidence data

288

Europe

have been published for each year separately. From 1999 onwards the annual incidence publication can be obtained electronically from http://www.sst.dk (search term: cancer) at the level of ICD-7, and tabulated electronically from 1977, or from the NORDCAN database http://www.ancr.nu where annual data are available from 1972.

Source of population A continuous count of the population is maintained. The midyear point has been taken for each year. Multiple primary rules used IACR rules (2004) on CI5 IX period.

289

Europe

Estonia
Registration area The Estonian Cancer Registry (ECR) covers the whole Republic of Estonia, population 1.4 million according to the 2000 census. Of the total population at the 2000 census, 68% were Estonians, 26% Russians, 2% Ukrainians, 1% Byelorussians and 3% other ethnic minorities; 69% of the population was living in urban areas. The life expectancy at birth was 65.1 years for men and 76.0 years for women. the Statistical Ofce of Estonia, and the Registry performed a trace-back procedure for cancer cases rst notied by a death certicate. But due to the lack of legislative basis, the Registry has no access to death certicates issued in Estonia since 2001; therefore the incidence data may also be incomplete. For updating the migration data and other personal data, in 2000 the Registry started regular linkage with the Population Registry (founded in 1992 when the national identication code was introduced in Estonia). In 1998, the Cancer care facilities After Estonia regained independence in 1991, the national data condentiality issue was drastically emphasised in the healthcare system was reorganised from a state-controlled public media. To solve the conict between the Ministries system to a decentralised health-insurance-based system. and specify the legal aspects of personal data protection, the forwarding of notications to Patients suspected of having the Registry was suspended cancer by the primary for a month by administrative and secondary healthcare ESTONIA (1998-2002) order. In February 2001, the facilities are mostly referred ESTONIA (1998-2002) Minister of Social Affairs to two specialised cancer issued a revised Decree (No. hospitals, which provide 21) on Cancer Registration radiotherapy, cancer surgery and Running the Estonian and chemotherapy. Some 


 
 








Cancer Registry, providing cancer treatment is performed 







access to the Registrys data in in general hospitals (surgery) 














accordance with the Personal or other specialised hospitals/ 







Data Protection Act. Recently, departments (neurosurgery, 








 





the Ministry of Social Affairs haematology, paediatric 







of Estonia has started to oncology). 





 








modify the existing laws 







in order to create the legal Registry structure and 














basis for all health registries, methods 







including the ECR. Cancer registration in Estonia 














dates to 1953 when compulsory The quality of the ECRs data 







registration of incident cancer has not been formally evaluated; cases started in the former the rst study that partially covered       USSR. The Estonian Cancer this subject was carried out within *%!' *%!' "+(***  "#$*** Registry was founded in 


the framework of a doctoral )$#*",+***  1978, while reliable incidence thesis by a young researcher and 
   **# -** data are available since 1968. ",,+.",,,-*
***",+,**** ******* *# published in 2005. # ".# #-****# **** ****** ** Until 1991, the Registry consisted of two subdivisions:  



 
**%# &'**** (a) The Department of Statistics of the Estonian Cancer Interpreting the results Centre (ECC), and (b) Department of Epidemiology and No nationwide organised mass screening programmes for the Biostatistics of the Institute of Experimental and Clinical early detection of cancer have been introduced in Estonia. Medicine. In 1991, the former of these subunits, responsible However, the wide use of PSA testing since 1993 may have for the data collection, was renamed the Estonian Cancer caused the rapid increase in detection of prostate cancer. Registry; the scientic analyses based on the Registrys data Opportunistic mammographic screening was introduced continued to be a responsibility of the latter subunit (since in some regions of the country in the 1990s and in the whole 2003, the Department of Epidemiology and Biostatistics country in 2002. Also, an early detection project for cervical of the National Institute for Health Development). The cancer in Estonia was introduced in 2003, and all regions year 1994 was a landmark of major reorganisations in the were included by 2004. Registry, particularly in the data collection procedures and the structure of the database. The Registry is funded from Use of the data the state budget and employs a staff of ve (Director, Data The Registry publishes annual reports of cancer incidence, analyst, Physician-Data Manager, two Coding Clerks). Since highlighting also time trends in incidence (the rst report the end of 2001, the ECR has operated as a subunit of the available for 1996, the last for 2000). Registry data have been North-Estonian Regional Hospital Foundations Cancer used for a number of descriptive and analytical epidemiological Centre. studies, including international comparisons. In 1996, a Reporting of cancer cases in Estonia is compulsory. statistical compendium, Cancer in Estonia 19681992: The Registry receives notications from treating physicians Incidence, Mortality, Prevalence, Survival, was published. and pathology and haematology laboratories. Coding and For the rst time, the National Cancer Strategy was input are carried out in the Registry. The cancer patients developed by the Working Group and presented to the are followed up to death or emigration. The data le for all Government in Spring 2000, but was not approved and death certicates issued in Estonia was provided annually by nanced. The present version of the Strategy covering the

290

Europe

years 20072015, was submitted to the Government in 2006, and state funding will start in 2007. Source of population 19981999: Estimate, based on 1989 census, making allowance for births, deaths and migration and revised after

2000 census. 2000: census. 20012002: estimate, based on 2000 census, making allowance for births and deaths but not for migration. Multiple primary rules used IACR rules (2004) on historical data.

291

Europe

Finland
The principal sources of information on cancer cases are Registration area The Registry covers the whole of Finland (area 338 145 km2), physicians and hospitals, pathological laboratories and death which is bordered to the north by Norway, to the east by Russia, certicates from Statistics Finland. Reporting of cancer cases has been compulsory since to the west by Sweden and the Gulf of Bothnia, and to the south by the Gulf of Finland. The average altitude is 150m. Finland 1961. If needed, requests are sent to notiers in order to has 33 615 km2 of inland water and belongs to the coniferous ensure accurate information of the identity of the individual forest zone. The population of Finland is 5 181 000 (2000). in question, and primary site and date of diagnosis of the Ethnically, the Finns are Caucasian, and of mixed origin, tumour. Coding of information at the Cancer Registry including Baltic, Scandinavian and probably eastern elements; has always been done or supervised by a physician. Case 85% are Lutherans. The ofcial languages of the country are identication is based on the personal identication number Finnish and Swedish; 5.6% of the population speak Swedish as used in Finland since 1967. This also enables accurate followtheir mother tongue. The main occupational groups are: industry up of cancer patients for death through ofcial sources. (26.8%), services (65.5%) and agriculture and forestry (6.1%). Besides continuous quality control procedures, formal evaluations also take place. Some 60% of the population Nationwide screening lives in urban municipalities. programmes for breast, The population of Helsinki with FINLAND (1998-2002) cervical and colorectal cancer its suburbs accounts for 18% of FINLAND (1998-2002) are coordinated, monitored the total. The life expectancy at and evaluated by the Mass birth is 73.7 years for males and Screening Registry that is a 81.0 years for females. part of the Cancer Registry. 


 









Opportunistic PSA testing is Cancer care facilities 







very common. In 1999 Finland had 15 














800 physicians (3 per 1000 





 

Use of the data inhabitants) and 39 700 














Apart from producing routine hospital beds (excluding 




 
 

statistics (annual incidence psychiatric hospitals). The  







 
 



 

rates by sex, age, primary country is divided into 22 







site and healthcare district) healthcare districts, of which 














and data for planning and ve (Helsinki, Turku, Oulu, 







health education purposes, Kuopio and Tampere) have a 














the Registry is actively university teaching hospital. 

 





engaged in research on cancer Diagnosis and treatment epidemiology, biometrics of cancer is only partly       and cancer patient survival, centralised; cancer surgery 
)%!' 

)%!' and provides material for is practiced in all major 



#)($ )"* )))  clinical and pathological hospitals and also in many  
 studies, and follow-up data smaller clinics. Nine hospitals
)
)))
)  ))
 
))))))
) )

)

)
)

))  ) ) ",,+-# #)) 
)) )))) have a radiotherapy unit. Specialised paediatric oncological on cancer patients. The Registry also acts as a consultant  
   
) 
))
))
)
)
 ) body in Finland on issues related to cancer epidemiology services are available in ve university hospitals.    &&)
))
))
) ) and research. Registry structure and methods The Finnish Cancer Registry (Institute for Statistical and Source of population Epidemiological Cancer Research) was established in 1952 A census count of the population is performed on a on the initiative of the Cancer Society of Finland. Data on continuous basis by the Population Register Centre. The newly diagnosed cancer cases have been collected since average annual population for 19982002 is published by 1953. Finland has been included in all the previous eight Population Statistics, Statistics Finland. volumes of Cancer Incidence in Five Continents. The total number of employees in the registry is 36, of Multiple primary rules used whom 22 are at the cancer registry and 14 at the Mass Screening IACR rules, modied by the cancer registry. Registry (part of the Finnish Cancer Registry). There are 7 senior ofcials; IT personnel, secretaries and clerks account Notes on the data C44 does not include basal cell carcinoma. for 20 more, and researchers an additional nine.

292

Europe

France, Bas-Rhin
Cancer registration is active, the doctors from the Registration area The dpartement (French administrative district) of Bas-Rhin registry visiting each of many sources regularly to establish constitutes the northern half of the Alsace region, occupying the lists of new cases and to complete an epidemiological west side of the plain drained by the Rhine, which represents a questionnaire. The lists from each of these sources are natural border with Germany. On the opposite side the Bas-Rhin compared to ensure complete registration and to eliminate reaches the massif of the Vosges on the west, with a total area of errors, particularly duplicate registrations. Cancers 4 58 km2. The town of Strasbourg is its regional centre. Forest discovered by autopsy are registered. Death certicates covers 30% of the land area. The maximum altitude (1100m) is are not used as a source, but serve only to verify the reached in the Vosges, and the minimum (32m) on the Rhine completeness of registration. For each case of cancer registered, the identity and plain. The climate is temperate to semi-continental. The population consisted of 1 026 120 inhabitants in 1999 address of the patient are noted as well as the date (density: 216 inhabitants/km2). Of these, 54.4% live in an urban of diagnosis, the method of diagnosis, the pathology environment in agglomerations with over 5000 inhabitants, and 27.6% department, the identication number of the pathological examination, the topography in villages with fewer than 2000; and morphology coded to 40.8% live in the urban district ICD-O, and the behaviour. of Strasbourg. The population is FRANCE, BAS-RHIN (1998-2002) The two sources where the slightly younger than the general FRANCE, BAS-RHIN (1998-2002) most complete information French population. was found are also noted, The economically active as well as the identication population amounts to 53.1% number of the medical le, of the total population: 67.0% '.0/#... 0+%&.%''... ).,/,... 0# %#.#&1... the date of death or the of these work in the services %#.''1... /+ %1.%0/... date of last infor mation sector, 30.8% in industry, and %+.0%%... /# &%.01&... &#.##1... ,+ &'.'#%... concerning vital status of the 2.2% in agriculture. &&.)/'... ,# &'.&+/... patient. The dpartement is without &).,10... ++ &'.1&'... '&.0#1... +# '%.+01... T h e id ent it y of t h e mineral resources and does '0.#++... )+ '/.)#0... patients is used only to avoid not produce any raw materials, '1.'1+... )# '1.+/'... )%.&'&... '+ )#.0'+... registering more than once but has a major energy)%.,//... '# )#.)1#... the same patient with the production industry (petrol '1.+%%... &+ '1.))%... ',.#1)... &# '/.&,,... same cancer. The data are reneries and hydroelectric ')./#0... %+ ').%0%... coded by the doctors who stations). The mechanical ''.1&'... %# '&.1%#... ''.+'0... + '%./%%... have visited the information and electrical construction ''.'#0... # '%.)0+... sources. industry and the food industry Lesions or cancers (including breweries and %# + # # + %# 
.($* 

.($* diagnosed or discovered in wine production) are the most +'#.,%&... +#,.%&,...  situ and with histological important. Agriculture plays verication are registered, but an important role in spite  
 are not included in calculations of the low percentage of the 3.
.

.
.  ..%
.
.2
.4.   .
.



.
.%11#.
.
.%111!. 3""!

! .  
   
. 

.(&##)*.. .. of incidence. population employed in this sector.    Bas-Rhin is a relatively wealthy dpartement: incomes are high, ))..
!. and the level of consumption is also high, notably for food. Life Interpreting the data Organised breast cancer screening of the population aged expectancy in 1999 was 75 years for males and 82 years for females. 5065 has been carried out since 1989 (20 000 examinations annually). Organised screening for cervical cancer was Cancer care facilities Bas-Rhin has a high level of medico-social equipment, with introduced in 1994 for women aged 2565. Screening for 8457 hospital beds in 1999 (1 bed per 121 inhabitants), 1636 cancer of other sites is opportunistic. general practitioners and 1802 specialists. Hospitals employ 37.2% of all doctors. Many scattered small rural hospitals Source of population allow for hospital care close to the place of residence. More INSEE: http://www.insee.fr than 70% of cancer patients die in hospitals. Multiple primary rules used IACR rules (2004) on historical data. Registry structure and methods The activity of the Cancer Registry of Bas-Rhin began in 1974. The registration of cases covers the resident population Notes on the data C44 not available. of the dpartement of the Bas-Rhin.

293

Europe

France, Calvados
Registration area The dpartement (French administrative district) of Calvados covers an area of 5548 km2. Situated in Normandy, it includes parts of the Armorican Massif (Bocage) and the Paris Basin (Pays dAuge, Plaine de Caen, Bessin). To the North is the coastline of the English Channel. The highest elevation is 365m above sea level. The dpartement of Calvados includes 621 rural communes (37.7% of the population) and 84 urban communes. There are 652 273 inhabitants, of whom 6.9% are aged 75 years and older. Among those employed (250 725 individuals), 5.2% are in agriculture, 19% in industry, 5.6% in building, 13.6% in commerce, and 56.6% in the service industries. In 1999, unemployment was 7.4%. doctors including 1137 specialists, and ve pathology laboratories. Registration is active, and information is directly taken from the medical and pathology records. Death certicates are also referred to; however, cases for which information only originates in death certicates are not registered. Completeness is ensured by linking the information collected from all sources. The index date is the date of rst pathological diagnosis or, if not available, the date of rst diagnosis (radiological or biological). TNM stage and treatment are routinely coded for digestive tumours. Follow-up information is collected at regular intervals from treating doctors as well as from public registry ofces for all cases. Data from the different registries are linked periodically in order to exclude cases registered twice. Paper documentation is kept for each FRANCE, CALVADOS (1998-2002) case. FRANCE, CALVADOS (1998-2002)

Registry structure and methods Two cancer registries, both located in Caen, the departmental Use of the data capital, cover the dpartement of In addition to analysis of Calvados. The general registry incidence and trends, many is located at the Comprehensive &.101... 0+0.000... './,0... 0# /.&0+... studies are conducted: change Cancer Centre Franois 0.,#&... /+ %'.&&+... of disease stage at diagnosis, Baclesse, and the specialised %%.&+0... /# %+.%##... %&.1&%... ,+ %,.#10... evaluation of mass screening, digestive tumour registry at the %'.%00... ,# %+.%&'... evaluation of treatment impact University Hospital. These two %).%+,... ++ %).1/+... &%.))&... +# &%.,1#... on survival, and survival registries are supported by the &'.0'1... )+ &).#'1... trends. Relationships between National Institute for Heath and &'.%++... )# &'.0&+... &&.,,0... '+ &'.#%'... environmental factors and Medical Research (INSERM) &&.&11... '# &&.&0#... oesophageal cancer, colorectal and by the Health Watch &&.1++... &+ &&.,&#... &'.//0... &# &).#'&... cancer, peritoneal and pleural Institute (InVS) of the Ministry &'.0,1... %+ &'./10... mesotheliomas are also studied, of Health. They also receive &&.&1+... %# &%.,%,... &#.//%... + %1.10&... as well as occupational exposure contributions from the Conseil &#./,+... # %1.1/#... to pesticides and cancer. Rgional de Basse-Normandie. They are affiliated with the %# + # # + %# Source of population French Association of Cancer 
.($* 

.($* INSEE: http://www.insee.fr. Registries (FRANCIM), and to ''/.++0... '%)./%,...  the EUROCARE network.  
 Multiple primary rules used Registration has been 3.
.

.
.  ..%
.
.2
.4.   .
.



.
.%11#.
.
.%111!. 3""!

! .  
   carried out without interruption since 1978, using data from IACR rules (2004) on historical data. 
. 
.(&##)*.. ..    private as well as public medical facilities. They include a ))..
!. University Hospital, one regional comprehensive cancer Notes on the data centre and one cancer hospital, 22 general hospitals, 2160 C44 not available.

294

Europe

France, Doubs
registration area are found using discharge recording systems Registration area The registration area is the Doubs departement (French of hospitals and clinics outside the registration area. Death administrative district), which covers 5234 km2. According registration is based on death notication in the patients to the 1999 census, the total population comprises 499 062 birthplace. The registry staff visits the sources and consults inhabitants, of whom 346 720 live in urban areas and 152 computerised medical records to collect data. Data collection follows rules and recommendations of the 342 in rural areas. The economically active sector includes 204 219 residents, and the unemployment rate is 10.4%. A ENCR. All types of invasive tumours are included (basal and notable proportion of residents living by the border cross it to squamous cell skin cancer are included) as well as uncertainwork in Switzerland. There are 26 262 foreigners who work behaviour tumours and in situ tumours of the urinary bladder, in the department, mostly from North Africa. The main and in situ tumours of the cervix and breast. Benign tumours of the brain and in situ tumours of colon and rectum and religion is Roman Catholic. There are two industrial areas: one in Sochaux- melanoma were not included for the study period but have Montbeliard, with a large automobile factory, and the been registered since 2003. French registries must maintain data security, condentiality other in Besanon, the main and information to patient city, which has several small following recommendations industries that produce little FRANCE, DOUBS (1998-2002) of the CNIL (Commission or no pollution. FRANCE, DOUBS (1998-2002) Nationale Informatique et Libert), and the Doubs Cancer care facilities registry has developed internal There was one physician per checking and rules to follow 523 inhabitants in 1999. The &.'0&... 0+,.&'0... &.0&'... 0# +.#,/... these recommendations. entire population is covered +.1'&... /+ 0.1')... Checking for duplicates is done by health insurance. Nearly 0.)%0... /# %#./#+... %#.&&0... ,+ %%.,/,... at data entry, and regularly all Doubs residents are treated %#.1&&... ,# %%.+0'... veried on the database using in the departement. There are %&.'/#... ++ %&.%1&... %/.'##... +# %,.0%'... computer programmes. two oncology-radiotherapy %/.',+... )+ %/.0#)... wards, one in the teaching %/.)'1... )# %0.#%)... %0.#0%... '+ %0.##1... Uses of the data hospital of Besanon and %0.)'#... '# %0.%%)... The registry prepares an one in the general hospital of %0.%1+... &+ %/.0/1... %0.')'... &# %0.&,0... annual report of cancer Montbliard. During the study %0./&,... %+ %0.%%%... incidence, highlighting trends period there was no cancer %/.%')... %# %,.'0/... %,.%%'... + %+.)&+... and changes. It collaborates screening programme (the %,.%%/... # %+.',%... with the French Cancer breast screening programme Network FRANCIM to began in 2003). %# + # # + %# publish studies on national 
.($* 

.($* &+,.+/1... &),.'%1...  and regional incidence Registry structure and estimates as well as survival methods  
 and evaluation of care studies. The Doubs Cancer registry 3.
.

.
.  ..%
.
.2
.4.   .
.



.
.%11#.
.
.%111!. 3""!

! .  
   began its activities in 1976. The registry is mainly supported The registry also conducts specic studies in collaboration 
. 
.(&##)*.. .. by the InVS (Institut de Veille   Sanitaire, a national agency with local clinicians and epidemiologists. ))..
!. funded by the Health Ministry, and by the teaching hospital Source of population of Besanon. The registry uses active and passive casending from 38 INSEE: http://www.insee.fr. sources of data consisting of public and private pathology laboratories, computerised hospital and clinic discharge Multiple primary rules used recording systems, and medical records. The law allows IACR rules (2004) on historical data. physicians to transmit data to registries. In the registration area, there are only a few physicians who do not collaborate Notes on the data with the registry. The few residents treated outside of C44 not available.

295

Europe

France, Haut-Rhin
The hospital infrastructure, public and private, comprises 1582 Registration area The dpartement (French administrative district) of Haut- beds in medical wards, 1141 in surgery, and 325 in gynaecology Rhin, an area of 3522 km, is situated in the northeast of and obstetrics. There are two radiotherapy wards, one in the France. It is adjacent to the dpartement of Bas-Rhin in south (Mulhouse), and the other in the north (Colmar). There is the north (with which it constitutes the Alsace region), the no specialised cancer centre in the dpartement. dpartement of the Vosges to the west, and the Franche-Comt region and Switzerland to the south. To the east, the Rhine Registry structure and methods separates Haut-Rhin from Germany. The altitude varies The Haut-Rhin Cancer Registry is a general populationfrom 195m on the Rhine to 1424 m in the Vosges mountains. based registry. Created in 1989, it is administered by an The climate is semi-continental, with fairly cold winters and association under a specially constituted law for the purpose. hot, dry summers. The conditions favour the vineyards of the It is entirely nanced by local funds (local and regional lower slopes of the Vosges. The area has four geographical groups, health insurance funds, the Anti-Cancer League). The registry collects information on all new cases of regions: the Vosges mountains (crystalline massif), the lower cancer occurring among the hills of the Vosges (wine and inhabitants of Haut-Rhin, fruit cultivation), the plain of including those diagnosed and the Rhine (land of loess and FRANCE, HAUT-RHIN (1998-2002) treated elsewhere. Registration former marshland), and the FRANCE, HAUT-RHIN (1998-2002) is active. The main sources Alsacian Jura (limestone). of information are pathology The population of Hautand cytology laboratories, Rhin is divided into 377 and radiotherapy, oncology, communes, of which 269 are &.,)%... 0+0.'/)... '.%'&... 0# ,.,0,... paediatrics and haematology rural with fewer than 1000 /.0##... /+ %'.)+#... services. The medical inhabitants. Haut-Rhin has %&.#'+... /# %,.&+1... %).00&... ,+ %/.&1)... information departments and a higher proportion (47%) of %,.%%%... ,# %,.)/+... medical records departments of economically active (aged %/.1/'... ++ %/.#,#... &).#11... +# &&.+#,... the hospitals are also excellent 1564) persons and a lower &/.#1)... )+ &,.,+&... sources of first notifications. proportion aged over 65 &/.+'&... )# &/.+1%... &0.,'0... '+ &0.%+1... Cases discovered at autopsy years than France as a whole. &0.%,0... '# &/.+'%... are registered, and identified Foreigners make up 8.1% of &).//#... &+ &).,'&... &#.1,'... &# &#.%++... as such. The data collected residents, of whom 69% were &'.001... %+ &&.+10... are systematically verified, born outside metropolitan &).,)+... %# &'.,,1... &'.+/+... + &&.+%,... c o m pl e t e d o r m o d i f i e d , France. The population is &'.%#%... # &&.#0&... usi ng se cond a r y sou rces 21% rural; 52% live in the 23 (hospitalisation ser vices, communes with more than %# + # # + %# t reating physicia ns). T he 5000 inhabitants. The urban 
.($* 

.($* average number of sources per area of Mulhouse has 228 115 ','.,1%... '+%.#)/...  registered case is over three. inhabitants. The average  
 Death certicates are not used. population density is 201 3.
.

.
.  ..%
.
.2
.4.   .
.



.
.%11#.
.
.%111!. 3""!

! .  
   Data are entered using the IARC CanReg software. inhabitants per km, varying from 81 in the rural communes 
. 
.(&##)*.. ..    to 4975 in the commune of Mulhouse. ))..
!. The unemployment rate is 9% among men and women. Use of the data The industrial sector employs 25% of the active population The registry was established in order to obtain data on the (automobile, arms, chemicals, textiles, wood and paper, nuclear burden of cancers in the area, so as to maintain an updated power); the agricultural sector 2% (market gardening, wine database for evaluation of public health measures in the production, forestry), the building sector 6%, and the tertiary prevention, screening and treatment of cancer. sector 67% (commerce, administration, education, health, transport). A special feature related to the geographical situation Source of population of Haut-Rhin is that 12% of the employed population resident INSEE: http://www.insee.fr. in the dpartement works in Switzerland or Germany. Multiple primary rules used IACR rules (2004) on historical data. Cancer care facilities With 98 general practitioners and 63 specialists per 100 000 inhabitants, the medical coverage of the Haut-Rhin population Notes on the data is below the national French average (respectively 113 and 88). C44 not available.

296

Europe

France, Hrault
3 radiotherapy units, 2 general hospitals, 10 private clinics, Registration area The registry is located in Montpellier, the capital of the general and specialist practitioners, and the medical les Hrault dpartement (French administrative district), which of 2 health insurance companies. For data collection, 20% is part of the Languedoc-Roussillon region and covers 6101 are collected via active search, 65% by passive notication, and 15% as pre-coded data from the hospital specialising in km2 in the south of France, near the Mediterranean. In 2000 the population of Hrault comprised 920 000 cancer. Registration is active: medical and pathology records inhabitants (48% males, 52% females) with a population are consulted directly by medical doctors and registry density of 151 inhabitants per km2. The departement is investigators. The administrative information is coded by the registrars highly urbanised (the urban population is 4.25 times the and all medical information is coded by the medical director rural population). Of the active population, 81.1% work in the services of the registry. Death certicates are not used as a source. All invasive and in situ cancers are registered, with the sector, 15% in industry and 3.9% in the agricultural sector. exception of basal cell carcinomas of the skin. Stages are The unemployment rate is 14.5%. registered for all localisations The population is slightly and coded according to the older than the general French TNM 5th edition. population (23.1% older than FRANCE, HERAULT (1998-2002) 60, vs. 19.8% in France). There is active follow-up FRANCE, HERAULT (1998-2002) Life expectancy is 76.3 years of the registered cancer cases for males and 83.2 years for since 1997. females (vs. 75.9 and 82.9 years in France, respectively). Interpreting the results +.11%... 0+%'.1/+... /.'%+... 0# %%.,,,... The birth rate is 12.0 per Since 1990, we have had %).,&&... /+ &#.,+0... 1000 and the mortality rate 9.5 two organised breast cancer %0.'#%... /# &&.1,)... &#.0++... ,+ &'.1)/... per 1000 (vs. 12.7 and 9.0 per screening programmes for &#.'',... ,# &&.&0)... 1000 respectively in France). women aged 4049 years &&.0&+... ++ &).'1)... &1.+01... +# '%.,#)... and 5069 years. Hrault is &1.0/,... )+ '&.&),... Cancer care facilities the only French area covered &1.,/1... )# '&.'1)... '#.,%1... '+ ''.&)'... Hrault has a high level of by a cancer registry in which '#.&0'... '# '&.%+/... medico-social equipment, there is an organised breast '%.%#+... &+ '&.)+%... '&.1)+... &# '+.,+,... with 2.5 beds per 1000 screening programme for '#.'1&... %+ '#.%'+... inhabitants in medicine and women aged 4049 years. &0./'#... %# &/.)#+... &/.'/+... + &+.001... 2.2 beds per 1000 inhabitants &,.+,)... # &+.%/)... in surgery (vs. 2.2 and 1.8 per Use of the data 1000 inhabitants in France A report of all data is %# + # # + %# respectively) distributed published biannually. The last 
.($* 

.($* among one hospital report was published in April )/0.&)%... )'/.)#)...  specialising in cancer, 10 2005 for cancers diagnosed  
 public hospitals (including one 3.
.

.
.  ..%
.
.2
.4.   .
.



.
.%11#.
.
.%111!. 3""!

! . in 20012002. All incidence  
   academic hospital in Montpellier and 6 small rural hospitals) data, chronological tendencies and relative survival by 
. 
.(&##)*.. ..    and 16 private clinics. The medical coverage of the Hrault sex, age and stages for each organ are detailed. Screening ))..
!. population is greater than the national average of 200 general programmes for breast cancer are evaluated. practitioners and 246 specialists per 100 000 inhabitants. The Hrault Cancer Registry performs many studies (casecontrol studies, medical economic studies, evaluation Registry structure and methods of therapeutic practices), alone and in collaboration with The majority of the registrys budget comes from the other French or European registries. National Health Department through InVS (Institut de Veille Sanitaire) but also from INSERM (Institut National de la Source of population Sant et de la Recherche Mdicale) and Hrault Committees INSEE: http://www.insee.fr. League against Cancer. The registry staff consists of ve persons: one medical Multiple primary rules used epidemiologist, one secretary, two registrars and one IACR rules (2004) on historical data. investigator. Our principal sources of information on cancer cases are 11 Notes on the data pathological laboratories, one hospital specialising in cancer, C44 not available.

297

Europe

France, Isre
Registration area The Isre Cancer Registry covers the population of the dpartement (administrative region) of Isre in southeastern France. Besides some recreational activities (e.g. ski resorts, lakes), industrial activities are important (chemical production), and research and teaching (universities). Less than 20% of the population resides in rural areas. In 2002 the population was estimated to be 1 126 000, with 301 000 people under age 20, 622 000 aged 2059 years and 203 000 over age 60. in the medical records departments. As death certicates are anonymous, they are of no use for case-nding. There is no active follow-up of the registered cases, except for specic survival studies.

Interpreting the results An active screening programme (breast, colon and cervix) and well-implemented habits of PSA testing for prostate cancer may explain rather high incidence rates for these tumours, as compared with French standards. In operation since 1985 (PSA) and 1990 (screening), these activities probably no longer have an effect on trends, but some Cancer care facilities In 2001, the density of specialised and general practitioners research has shown an increase in the proportion of localised compared to distant tumours, was 206 per 100 000 which supports a benecial inhabitants. In December 1999, effect of those programmes there were 3586 physicians FRANCE, ISERE (1998-2002) for the populations health. in charge of the populations FRANCE, ISERE (1998-2002) Systematic sending of health in Isre. There are two medical record abstracts specialist cancer hospitals, by hospitals may improve and diagnosis and treatment coverage in coming years. are also undertaken in general ).0%)... 0+%'.%0'... +.0/+... 0# %#.'0%... hospitals and private clinics. %'.%'0... /+ %1.%&,... Use of the data %/./&+... /# &&.,#+... &%.%'%... ,+ &'.0++... A report for researchers and Registry structure and &'.&//... ,# &'.10%... people in charge of cancer in methods &0.#,0... ++ &/./0/... '/.#1,... +# ',.0,+... Isre is published annually. Of the registrys budget, 70% '0.'0,... )+ '1.'&'... The prevalence of cancer has comes from the Isre General '1.)+1... )# )#.#/&... )%./++... '+ )%./,%... been estimated. Mapping Council (Conseil Gnral) )%.,+%... '# )%.&&)... of disease is carried out by and from InVS (Institut de la )#.),%... &+ '1.##&... )#.+1&... &# '0.,/#... the registry. The screening Veille Sanitaire) and INSERM '1./%,... %+ '/.0&'... programmes for breast, (Institut National de la Sant '0.//%... %# ',.0))... '/.'+&... + '+.''0... colon and cervix cancers are et de la Recherche Mdicale). '/.&+)... # '+.&&/... evaluated. The bulk of the research The registry also work is funded by the French %# + # # + %# undertakes surveillance League against Cancer and by 
.($* 

.($* of occupational cohorts. foundations or by contracts +,'.#,/... +),.+&#...  In co-operation with other with industrial companies.  
 French Cancer Registries The registry staff, both for 3.
.

.
.  ..%
.
.2
.4.   .
.



.
.%11#.
.
.%111!. 3""!

! . registration and research work, 
   consists of two clerks (part- (FRANCIM) and the Institut de la Veille Sanitaire, the 
. 
.(&##)*.. ..    time), two registrars (part-time), 1.6 medical epidemiologists, registry contributes to the detection of new cancer risks in ))..
!. one statistician and one secretary. For some studies, extra the French population. Analyses of different methods of diagnosis and medical interviewers are hired. Among the sources of information, in Isre and in treatment for some cancer sites, including breast, prostate, three contiguous areas, there are 34 laboratories providing bladder, kidney and colon cancer, have been carried out as pathological reports. The registry also obtains information well. from two hospitals specialising in cancer, 13 general hospitals, the network of hospitals in the city of Lyon, six Source of population private clinics and the medical les of two Health Insurance INSEE: http://www.insee.fr. Companies. Since 1997, abstracts of the medical les from the hospital patient-disease information systems are received Multiple primary rules used for most patients treated for cancer, at least for hospitals IACR rules (2004) on historical data. in the public domain. All of the information received is carefully checked and when judged insufcient, registry Notes on the data staff visit the sources where they scrutinise the records kept C44 not available.

298

Europe

France, Loire-Atlantique and Vende

Registration area The registration area is composed of the two dpartements (French administrative districts) of Loire-Atlantique and Vende, situated in western France, which cover 13 535 km and have a total population of 1 134 493 for Loire-Atlantique and 539 806 for Vende according to the 1999 census. The population density gures were 172 and 84 inhabitants per km in Loire-Altantique and in Vende respectively. About 54% of the Loire-Atlantique population and 25% of the Vende population live in urban areas (10 000 inhabitants). Cancer care facilities There are 23 public and 37 private hospitals in the two dpartements, including one university hospital and two anticancer centres. Most radiotherapy and chemotherapy structures are present in the 3 main towns (Nantes, Saint Nazaire, La Roche-sur-Yon). The two dpartements have 2613 general practitioners and 2520 specialists (respectively, 108 and 62 per 100 000 inhabitants). Registry structure and methods The Loire-Atlantique and Vende Cancer Registry is a general population-based registry. Created in 1998, it is one of the biggest French Registry, affiliated with the association of French Cancer Registries (FRANCIM) and recognized by the National Committee of Registries (CNR). It is administered by an association according to the French association law of 1901. It is entirely nanced by the General Council, the Regional Council, the Departmental League Against Cancer, the Loire-Atlantique private anticancer centre, the National Institute for Medical Research (INSERM) and the Health Watch Institute (InVS). The registry is located within the university hospital of Loire-Atlantique (CHU Nantes) and the departmental public hospital of Vende (CHD La Roche-sur-Yon). The registry is staffed by a medical epidemiologist, a part-time anatomopathologist and 10.5 full-time equivalent persons. Cancer cases are found by an active search in the medical records from several sources of data. The three main sources are pathologists, medical information systems in the hospitals and clinics, and health insurance notications. The registry staff visits these sources, where they scrutinise the records kept in medical records departments, to identify and abstract information on cases of cancer (diagnosis and treatment of cancers) among residents of the registry dpartements. Until now, death certicates have been forbidden by law to be used as data sources for registries in France. Although cancer is not a notiable disease, a few registration forms are received from private practitioners. Arrangements have been made with the hospitals outside the registration area to notify the registry of any resident cancer cases that they diagnose and treat. Quality in the registry is monitored every four years by the National Committee of Registries (CNR). The Registry is monitored by the National Commission of Data Processing and Freedom (CNIL) for condentiality. Interpreting the results Organised breast cancer screening of the population aged 50-74 has been carried out since 1996 in Loire-Atlantique and since 2002 in Vende. Uses of the data The Loire-Atlantique and Vende Cancer Registry has produced basic descriptive data and participated in collaborative studies at a national level. It prepares an annual report of cancer incidence, highlighting trends and changes. Some special studies have been carried out (including evaluation of clinical care for breast cancer or colon cancer, and survival).

FRANCE, LOIRE-ATLANTIQUE (1998-2002) FRANCE, LOIRE-ATLANTIQUE (1998-2002)

FRANCE, VENDEE (1998-2002) FRANCE, VENDEE (1998-2002)

+.&++... ,.')0... %).+'/... %0.010... &&.%0&... &'.'#1... &+.++&... '0.,1,... )%.%#+... )%.#+&... )%.,'&... )#.,##... )#.+&+... )%.,,,... )&.#'0... '1.&+,... '/.'##... '0.#&)...

0+0# /+ /# ,+ ,# ++ +# )+ )# '+ '# &+ &# %+ %# + #

%+.)+/... %&.%,/... &&.0&%... &,.&),... &/.&'#... &,.&%&... &/.%)1... '1.+/'... )&.#/0... )%./0/... )%.1'1... )#.,)#... )#.##+... )#.)#'... )#.&1#... '/./0,... '+.0+'... ',.&0+...

'.+0)... ).%0%... 1.+/+... %&.)&/... %).++'... %'.1'1... %&.//,... %0.)#%... %1.1'+... %1.1)1... %1.///... %0.+//... %/.','... %,.+/,... %0./%&... %0.##0... %,.)%)... %,.)##...

0+0# /+ /# ,+ ,# ++ +# )+ )# '+ '# &+ &# %+ %# + #

1.%/+... ,./1'... %'.&'1... %+.''0... %+.11#... %).1&%... %'.)+/... %0.%&#... %1.%1+... %1.)+&... %1.'1%... %/.0))... %,.')#... %).'%0... %/.),1... %/.%)/... %+./,%... %+.,)1...

%#

+ 
.($*

+ 

.($*

%#

%#

+ 
.($*

+ 

.($*

%#

++/.1/+...



+1'.1&%...

&/%.%)/...



&/1.+1/...

Source of population  
   
. 

.(&##)*.. .. INSEE:    http://www.insee.fr.
))..
!.

 
 3.
.

.
.  ..%
.
.2
.4.   .
.



.
.%11#.
.
.%111!. 3""!

! .

 
 3.
.

.
.  ..%
.
.2
.4.   .
.



.
.%11#.
.
.%111!. 3""!

! .

Multiple primary rules used IACR rules (2004) on historical data.

Notes on the data    ))..

!. C44 not available.

 
   
. 

.(&##)*.. ..

299

Europe

France, Manche
and was created by an association of practitioners of the Registration area Situates in the area of Basse Normandie, the dpartement department. It is supported by the Ministry of Health, the (French administrative region) of the Manche covers 5938 Regional Council of Basse Normandie, the General Council km and has 330km of coastline. It is a part of the Armorican of Manche, the local League against Cancer, communes, massif and consists of three different zones: in the north the local associations, and industries. It is afliated with the Cotentin peninsula; in the centre a formerly swampy zone, association of French Cancer Registries (FRANCIM). Data collection is active in Manche and the surrounding now meadows; in the south the hills of the Norman bocage, which reach 368m. The climate is of the oceanic type. The departments. The registration of cases covers the resident department contains 602 communes, 86% of which have population of the department of the Manche. The sources of fewer than 1000 inhabitants. The population is slightly older information are regional, including 12 pathology and cytology than the national average. It is mainly rural, with only 48% laboratories, services of oncology, radiotherapy, paediatrics living in the ve urban areas (of which half are in the only and haematology, and medical records departments of urban zone, Cherbourg, in the North) and density is low (81 hospitals. After rst notication of cases, every medical le is checked in regional, private habitants per km). and public, medical facilities, The working population and then coded to ICD-O by represents 43.2% of the total FRANCE, MANCHE (1998-2002) the physician. All invasive and population. Among those FRANCE, MANCHE (1998-2002) in situ cancers are registered employed, 47.5% are in the except basal cell skin cancers. service sector, 19.9% in industry Death certicates are not (predominantly farm produce), used as a source of data. The 14.4% in agriculture, 10.4% in &.,)/... 0+/.,/,... '.+,,... 0# ,.+''... registry carries out active commerce and 7.8% in building 0.&#'... /+ %&.#&'... follow-up of all cases from the and public works. In 1999 %#./1#... /# %'.1&+... %&.'%+... ,+ %).')0... municipal registry ofce. the unemployment rate was %%.,%+... ,# %&.1&+... The industrial characteristics 11.5%. The dpartement has %#./##... ++ %%.&#+... %+.,''... +# %+.',&... of the north of the department a low proportion of foreigners %/.&0#... )+ %,.&&#... led to the implementation of a (0.8%). The economy is %0.#/0... )# %,.0,)... %0.##&... '+ %/.%,&... specialised collection system mainly agricultural, breeding %,.)0)... '# %,.#0,... for haematopoietic cancers. representing 90% of this %).,0'... &+ %).&%&... %'.)/,... &# %&.#%+... It consists of collection of production. Fishing and tourism %,.+++... %+ %+.&&)... reports from the medical are developed in the coastal %,./)#... %# %+.1%0... %+.)0'... + %)./%+... biology laboratories of the zones. There is an industrial %).,1'... # %).&0+... department, validation by a area in the north, mainly the haematologist, and records nuclear industry (nuclear waste %# + # # + %# of immunophenotypic, reprocessing plant, surface 
.($* 

.($* conventional cytogenetic and storage facility for nuclear waste, &),./##... &',.1))...  molecular data, and the tumour power station) and shipyards.  
 3.
.

.
.  ..%
.
.2
.4.   .
.



.
.%11#.
.
.%111!. 3""!

! . cells are cryopreserved.  
   Cancer care facilities 
. 

.(&##)*.. .. With 611 general practitioners    and 511 specialists in 2002, Use of the data ))..
!. the department has a low medical coverage. There are seven The Manche Cancer Registry produces basic descriptive beds per 1000 inhabitants. The department possesses 11 data and participates in collaborative studies at a national public hospitals, general and local, and seven private care and international level. structures. There is no specialised cancer centre, but there are two radiotherapy units, one private in the south of the Source of population department, one public in the north which is a delocalised INSEE: http://www.insee.fr. structure associated with the regional cancer care centre of Multiple primary rules used the neighbouring department (Calvados). IACR rules (2004) on historical data. Registry structure and methods The Cancer Registry of Manche began its activities in 1994. Notes on the data The registry is based in Cherbourg, in the general hospital, C44 not available.

300

Europe

France, Somme
Cancer cases are collected by active search from listings and Registration area Situated 140km from Paris, the Somme registry covers in medical records of about 90 sources of data. The two main 6170 km2, includes 60km of coastline and is composed of sources are pathologists and medical information ofces of public three main types of landscapes: Bocage in the West, Picardy and private hospitals, but also registers of chemotherapy and plateau at the centre, and Santerre in the East, occupied by radiotherapy in two clinics, The Regional Factory Inspectorate, extensive cultures. The river Somme passes through and Parisian hospitals administration, and regional cancer centres is bordered by ponds and marshes attracting many anglers contribute to collection. Every year the registrars contact the and hunters. Tourism is developed. The Bay of Somme is a outside sources and consult their records. Cancer is not a notiable disease in France. Identifying natural reserve and a landing zone for migratory birds. The population is 41.5% rural. The West of the county data are known only by registry staff. The Registry refers its is traditionally both rural and industrial, with factories work to Commission Nationale Informatique et Liberts. producing taps and locks. There is also a large industrial Every four years the registry undergoes a quality audit by Registries National Committee. area around Amiens. The Somme Registry is the Interpreting the results only general registry north of Paris. The population census A written agreement was signed FRANCE, SOMME (1998-2002) in 2000 counted 557 121 with private pathologists and FRANCE, SOMME (1998-2002) inhabitants. Amiens is the a public one in 1998, so the principal town with 136 000 incidence has increased since inhabitants; the other towns count then. There have been no changes less than 30 000 inhabitants. in case denition and coding. &.1)#... 0+/.))+... '.)#,... 0# ,.#0'... The natural population A screening programme /./)&... /+ %%.&%/... increase by birthrate is +2.6% for breast cancer has existed 1.1,,... /# %'.%'+... %%.%++... ,+ %'.)0%... (INSEE 2003). since 1990. In 1996 PSA testing %%.)%%... ,# %&.+0+... was introduced, and we have %&.)&&... ++ %&.,++... %0.)'&... +# %0.&+/... Cancer care facilities likewise improved monitoring %1./)/... )+ %1.+/1... Theres no specialised cancer of prostate cancers. %1.',,... )# %1./+0... %1./1/... '+ %1.,#)... care centre in the dpartement. There are no known %1.11%... '# %1.+1+... Cancer care is shared by the unusual environmental, &#.%0+... &+ %1.1/'... %1.1%#... &# &#.#%'... University Regional Hospital occupational exposures that &#.&0)... %+ %1./1&... and the general hospitals and may inuence incidence. %1.&,)... %# %0.)0/... %/.,'&... + %/.##+... clinics located in six towns Melanomas and squamous cell %/./%/... # %,.011... of Somme. Ten percent of carcinomas of skin are not likely patients are treated outside the to be exhaustive, for many are %# + # # + %# 
.($* 

.($* registration area in cancer care diagnosed by non-corresponding &0+.+,'... &/%.',,...  centres in Paris or Lille (to the pathologists in Paris. north), or in a general hospital  
 or clinic in Saint-Quentin and 3.
.

.
.  ..%
.
.2
.4.   .
.



.
.%11#.
.
.%111!. 3""!

! . Use of the data  
   
. 

.(&##)*.. .. Chauny (Aisne dpartement). Chemotherapy and radiotherapy Tables of incidence are carried out every year, and trends are    are dispensed privately or publicly. Since about 1998 physicians produced for physicians on request. Area oncologists also ))..
!. groups have organised multidisciplinary examinations of patient receive the results of any specic studies. records to improve quality of treatment and more consistently Somme is a participating registry in the Eurocare project, apply national consensus standards of care. Europreval and European Rare Cancers studies, Epilymph, Since 1997 the regional health authority has recognised cancer and Eurodeucatam. The Somme registry has been part of the Regional as one of the priorities of the county. The registry is acknowledged Schedule of Care organization since 1994, and a member of to be the best tool to monitor cancer in the community. the Oncopic network. Registry structure and methods Somme cancer registry is managed by the 1901 law and Source of population funded by Institut de Veille Sanitaire, Inserm, County INSEE: http://www.insee.fr committee of National League against Cancer and General Multiple primary rules used Council. It forms part of FRANCIM network. The registry is presided over by a Public Health Professor IACR rules (2004) on historical data and counselled by another Public Health Professor; there are also an epidemiologist doctor (DM, PhD), a technical Notes on the data C44 not available. director (MSc), two inquirers/registrars and a secretary.

301

Europe

France, Tarn
load in the different sources. The staff also visit Toulouse Registration area The department of Tarn is part of the Midi-Pyrenean region, University Hospital and the Regional Cancer Control Centre. situated in the southwest of France. It covers an area of 5758 km2, In recent years, the search for cases in public hospitals has mostly situated south of latitude 44N and on longitude 2E. been simplied by the existence of Medical Information In 1999, the population was composed of 343 402 inhabitants, Departments, which provide computerised lists of the cancer with an urban/rural ratio of 1.65, and a ratio of French citizens cases treated in those establishments. Name-specic death to foreigners of 22.8. The population overall is slowly increasing certicates are not used as a source of information, according (344 620 at mid-year 2000), but certain areas are undergoing to French law. For each case, a notication form is completed with the quite a rapid increase while others are in recession. The Tarn Cancer Registry was created in 1981. The medical and administrative information from the medical arguments favouring the creation of a Registry in this le. The names of the doctors involved in the diagnosis and department included the insufcient development of population- the treatment of the patient, including primary physician, are based cancer registries in France at this time and their systematically noted in order to contact them if necessary. absence in the Southwest, and When the forms arrive in certain characteristics of the the registry, the secretaries rst department of Tarn such as the check the computing database FRANCE, TARN (1998-2002) age-structure of its population to avoid duplicate registrations. FRANCE, TARN (1998-2002) and its relative stability with The cases are then systematically little migration, the large size checked in a second source by of its rural population and some the investigators. If information longstanding industries such as is not sufcient, a questionnaire '.%0/... 0+/.'##... '.&,+... 0# +.##'... tanning, textiles and minerals. is sent to the regular doctor. /.'+)... /+ 1./&+... These procedures allow missing 1.#&0... /# %#.11)... 1./0/... ,+ %#.0%0... Cancer care facilities information to be completed and 0.0'+... ,# 1.+)1... The department of Tarn is fairly patients with metastasis from or 0.0+1... ++ 1.'#&... %%.10/... +# %&.%)0... autonomous in its provision of recurrence of a cancer diagnosed %&.))%... )+ %&.,/%... cancer care facilities. These prior to 1982, or not resident in %&.%%%... )# %&.+&%... %%.1))... '+ %&.%&#... are complemented by a cancer the area, to be excluded. %#.010... '# %%.#1&... care network. Medical coverage The medical information 1.+)1... &+ 1.)&/... 1.''#... &# 0.'/)... is high, with 118 general on the remaining cases is %#.1#0... %+ %#.#/#... practitioners and 118 specialists coded by the Medical Director %#.+0%... %# 1.1&'... 1./)&... + 1.&#%... per 100 000 inhabitants, of the registry, assisted by 1.&&1... # 0./,)... including four pathologists, two specially trained coders. The medical oncologists and two administrative data are coded %# + # # + %# radiotherapists. There are four by two secretaries. The data are 
.($* 

.($* public hospitals and four private then entered onto the computer %/1.##%... %,1.#'+...  of the registry, creating a clinics in the department of Tarn.  
 computing le which can be However, a few types of cancer 3.
.

.
.  ..%
.
.2
.4.   .
.



.
.%11#.
.
.%111!. 3""!

! .  
   (haematological, paediatric) are sent to the specialised services of updated when additional information from other sources 
. 
.(&##)*.. ..    reaches the registry. This le has been declared to the National the University Hospital or to the Regional ))..
!. Cancer Control Centre, Commission on Information and Liberty (CNIL). both situated in Toulouse, the capital of the region. Active follow-up by writing to the town halls where the In the department of Tarn, a programme of organised breast cancer screening has existed since 2003, and a patients were born and writing to the regular doctor is only colorectal cancer screening programme is underway. carried out for cases that are the object of special studies. However these elements do not affect the data published Use of the data here, given that the period of study is 1998-2002. In addition to basic descriptive epidemiology, the Tarn Cancer Registry carries out several studies, alone or in collaboration Registry structure and methods The Tarn Cancer Registry operates as a French Law 1901 with other registries (the Association of French Cancer Registries Association and is constituted by representatives of the medical FRANCIM and the European Network). These include estimates and university sectors, and of the elected ofcials of the department of the incidence and prevalence of cancer in France, the study of and the Midi-Pyrenean region. Funding for registration activities time trends, casecontrol studies and evaluation of diagnostic comes from the General Council of Tarn, the departmental and therapeutic regimes for selected sites. committee of the National League Against Cancer and the Source of population Ministry of Health. Research is funded through grants. The staff, composed of 11 people (8.8 full-time equivalents) INSEE: http://www.insee.fr. carries out both registration activities and research. The search for the cases is active, and four investigators Multiple primary rules used of the registry staff visit the data sources. The different IACR rules (2004) on historical data. laboratory, private and public hospital departments, administrative services and medical specialists in Tarn are Notes on the data regularly visited, with a frequency varying according to case- C44 not available.

302

Europe

Germany, Federal States of Berlin, Brandenburg, Mecklenburg-Western Pomerania, Saxony-Anhalt and the Free States of Saxony and Thuringia
Registration area The Common Cancer Registry (CCR) covers the population of the federal states Berlin, Brandenburg, Mecklenburg-Western Pomerania, Saxony-Anhalt and of the Free States of Saxony and Thuringia, all located in the east part of Germany and constituting the territory of the former German Democratic Republic (GDR), except for West Berlin. Thus, the CCR is the only cancer registry in Germany that covers several states. The population in the catchment area of the CCR is about 17.1 million inhabitants, 48.9% males and 51.1% females (2002), almost all of them being of Caucasian origin. About 59% live in urban areas (dened as population >5000 and population density >400 inhabitants per km). Cancer care facilities The territory covered by the CCR has 339 hospitals (Berlin 71, Brandenburg 47, Mecklenburg-Western Pomerania 34, Saxony-Anhalt 51, Saxony 86, Thuringia 50), most of them afliated with a regional tumour centre. Although there are some hospitals specialising in oncology services, most of the other hospitals are involved in cancer care as well (e.g. offering special diagnostic or treatment methods). The tumour centres, however, are the focal point in cancer care. Tumour centres are specic hospitals and university hospitals specialising in diagnostics, treatment, and aftercare of cancer patients and the documentation of pertinent information. Also, general practitioners, radiotherapy departments and other specialists are involved in cancer care on an outpatient basis. Registry structure and methods The CCR is located in Berlin and is associated with the Senate Department for Health, the Environment and Consumer Protection (Senatsverwaltung fr Gesundheit, Umwelt und Verbraucherschutz) in Berlin. The registry is funded by the contributing states according to their population size and is staffed with 1 physician, 3 mathematicians/statisticians/ computer experts, 2 epidemiologists, 15 documentation or coding employees and 2 administration secretaries. In Germany, cancer is a reportable disease. Cancer notication became mandatory in all states of the CCR (Saxony 1993, Mecklenburg-Western Pomerania 1998, Saxony-Anhalt 2000, Thuringia 2003, Berlin 2004, Brandenburg 2006). Patients are informed about the notication to the registry by the diagnosing physician. The major sources of notication in the CCR are the regionally organised tumour centres (Tumorzentren). Tumour centres cooperate with the population-based registry in that they abstract all pertinent information from medical records of cancer cases seen in a hospital or special clinic afliated with a tumour centre and report them to the CCR. There are about 30 tumour centres reporting to the CCR, providing >90% of all notications per year. The remaining 10% the registry receives directly from the physician via the traditional reporting by means of notication forms. Additionally, all death certicates have been made available to the registry by local health authorities. Data of German non-residents of the CCR are exchanged with neighbouring cancer registries. The cancer registration law from 1995 requires, for reasons of condentiality, that all population-based registries have two independent units (in terms of space, organisation and personnel): one unit handling incoming (person identifying) notication (Vertrauensstelle) and one unit holding the epidemiological data set and conducting the statistical analysis with the anonymised data (Registerstelle). Registration and quality control are performed according to the ENCR and IACR guidelines. Accuracy of the information is checked in an automated manner, in that implausible or questionable information will be identied and corrected if necessary. Annually, our data are formally evaluated on completeness by the Robert-Koch-Institute, the National Cancer Reporting Unit. Interpreting the results After 1989 the notication rate declined sharply due to political changes in the former GDR and the resulting lack of a legal framework for cancer registration. With the cancer registration law taking effect in 1995, the legal basis was re-established for the CCR and cancer cases were again reported to the registry. The availability of death certicates as a principal source of information on cancer cases was regulated by the cancer registration law. Since 1995, the number of reported cancer cases has steadily increased, while the percentage of DCO cases is decreasing. Note that although cancer is a reportable disease, it became mandatory only recently for some of the states of the CCR (see above). There are opportunistic screening programmes for colorectal, prostate, cervical and female breast cancer and for skin melanoma. Data on testing for PSA are not available, but it is increasing in this population. In the past there were some unusual occupational exposures of radon for employees in the Wismut mining area (West Saxony and East Thuringia), as well as unusual environmental exposures of radon in houses which might still be a problem in parts of this area today. Use of the data CCR data have been used for health services planning and for epidemiological research. Linkage with the CCR was performed for casecontrol and cohort studies. Annual reports on cancer incidence and mortality are published for the entire population of the CCR. In addition, state-specic reports are prepared on request. In cooperation with the association of population based cancer registries in Germany (GEKID) and the Robert-KochInstitute, the data are pooled for nation-wide analyses.

303

Europe

Germany, Brandenburg
Registration area The state of Brandenburg is one of the six states covered by the Common Cancer Registry (CCR) and is located in the North-East of Germany. The population of Brandenburg is about 2.6 million inhabitants, 49.4% males and 50.6% females (2002), almost all of them being of Caucasian origin. About 48% live in urban areas (dened as population >5000 and population density >400 inhabitants per km). available to the registry by local health authorities. Data on German non-residents of the CCR are exchanged with neighbouring cancer registries. Interpreting the results After 1989 the notication rate in Brandenburg declined sharply due to political changes in the former GDR and the resulting lack of a legal framework for cancer registration. With the cancer registration law taking effect in 1995, the legal basis for cancer registration was re-established and cancer Cancer care facilities In Brandenburg there are 47 hospitals, most of them afliated cases were again reported to the registry. The availability with one of the regional tumour centres (see below). The state of death certicates as a principal source of information on of Brandenburg has ve tumour centres, located in the cities cancer cases was regulated by the cancer registration law. Since 1995, reported cancer of Cottbus, Frankfurt/Oder, cases from Brandenburg have Neu r uppi n, Potsda m a nd been steadily increasing, Schwedt. Although there are GERMANY, BRANDENBURG (1998-2002) while the percentage of DCO some hospitals specialising in GERMANY, BRANDENBURG (1998-2002) cases is decreasing. Note that oncology services, most of the although cancer is a reportable other hospitals are involved disease, it became mandatory in cancer care as well (e.g. by only recently for the state of offering special diagnostic or 


 








Brandenburg (see above). treatment methods). The tumour 







There are opportunistic centres, however, are the focal 














screening programmes for point in cancer care. Tumour 







colorectal, prostate, cervical centres are specic hospitals and 














and female breast cancer university hospitals specialising 







and for skin melanoma. Data in diagnostics, treatment, and 














on testing for PSA are not aftercare of cancer patients







available, but it is increasing and the documentation 








 





in this population. of per tinent infor mation.







We are aware of no Also, general practitioners, 

 












unusual environmental and/ radiotherapy departments and 







or occupational exposures in other specialists are involved in Brandenburg. cancer care as they see cancer       patients in an outpatient setting. ,($* ,($* Use of the data 



%,&-.,').,,,  Brandenburg cancer data have Registry structure and 
   ,, ,,22,,  ,,,, ,,, 1,, ,,', ,%//#,,,, been used for health services methods   ,,,, ,,, , !, , ,",0,,, ,
3 ", For a description of the structure of the registry, please refer planning and for epidemiological research. Linkage with  



 
,,(&##)*,,
+,, , the CCR was performed for case-control and cohort studies. to the general narrative for the CCR. In Brandenburg, cancer is a reportable disease. However, Annual reports on cancer incidence and mortality are cancer notication became mandatory only recently (2006). prepared. In cooperation with the association of population Patients are informed about the notication to the registry by based cancer registries in Germany (GEKID) and the RobertKoch-Institute, the data are pooled for nation-wide analyses. the diagnosing physician. The major sources of notication in Brandenburg are the regionally organised tumour centres (Tumorzentren). The Source of population tumour centres abstract all pertinent information from The estimate of the population at risk is based on an extract medical records of cancer cases residing in the state of from the central residents registration ofce on 3 October Brandenburg seen in a hospital or special clinic afliated 1990, which is annually updated with the results of the with a tumour centre and report them to the CCR. The tumour statistics of births, deaths and migration. Source: Statistisches centres provide 99% of all notications per year. Thus, the Amt der Lnder. registry receives only 1% of the notications directly from the physician via traditional reporting by means of notication Multiple primary rules used forms. Additionally, all death certicates have been made IACR rules (2004) on CI5 IX period

304

Europe

Germany, Mecklenburg-Western Pomerania

Registration area The state of Mecklenburg-Western Pomerania is one of the six states covered by the Common Cancer Registry (CCR) and is located in the North-East of Germany. The population of Mecklenburg-Western Pomerania is about 1.8 million inhabitants, 49.5% males and 50.5% females (2002), almost all of them being of Caucasian origin. About 36% live in urban areas (dened as population >5000 and population density >400 inhabitants per km). of reporting by means of notication forms. Additionally, all death certicates have been made available to the registry by local health authorities. Data of non-residents of the CCR are exchanged with German neighbour cancer registries.

Interpreting the results After 1989 the notication rate in Mecklenburg-Western Pomerania declined sharply due to political changes in the former GDR and the resulting lack of a legal framework for cancer registration. With the cancer registration law taking effect in 1995, the legal basis for cancer registration was Cancer care facilities In Mecklenburg-Western Pomerania there are 34 hospitals, re-established and cancer cases were again reported to the most of them afliated with one of the regional tumour registry. The availability of death certicates as a principal source of information on centres (see below). The state cancer cases was regulated of Mecklenburg-Western by the cancer registration Pomerania has four tumour GERMANY, MECKLENBURG-WESTERN law. Since 1995, the number centres, located in the cities of GERMANY, MECKLENBURG-WESTERN POMERANIA (1998-2002) POMERANIA (1998-2002) of reported cancer cases Greifswald, Neubrandenburg, from Mecklenburg-Western Rostock and Schwerin. Pomerania has been steadily Although there are some increasing, while the hospitals specialising in 
 

 









percentage of DCO cases is oncology services, most of the 







decreasing. other hospitals are involved 














There are opportunistic in cancer care as well (e.g. by 

 





screening programmes for offering special diagnostic or 














colorectal, prostate, cervical treatment methods). The tumour 







and female breast cancer centres, however, provide a focal 














and skin melanoma. Data point in cancer care. Tumour 







on testing for PSA are not centres are specic hospitals and 













available but it is increasing in university hospitals specialising 







this population. in diagnostics, treatment, and 














We are not aware of any aftercare of cancer patients 







unusual environmental and/ and the documentation or occupational exposures of pertinent information.       in Mecklenburg-Western ,($* ,($* Also, general practitioners, 


.-/,)##,,,  Pomerania. radiotherapy departments and other specialists are involved in 
    ,,,, ,,, 1,, ,,', ,%//#,,,, Use of the data cancer care, as they see cancer ,, ,,22,,   ,,,, ,,, , !, , ,",0,,, ,
3 ", Mecklenburg-Western Pomerania cancer data have been  



 patients in an outpatient setting. 
,,(&##)*,,
+,, , used for health services planning and for epidemiological research. Linkage with the CCR was performed for caseRegistry structure and methods For a description of the structure of the registry, please refer control and cohort studies. Annual reports on cancer incidence and mortality are prepared. In cooperation with to the general narrative for the CCR. In Mecklenburg-Western Pomerania, cancer is a the association of population based cancer registries in reportable disease. In 1998, cancer notication became Germany (GEKID) and the Robert-Koch-Institute, the data mandatory in this state. Patients are informed about the are pooled for nation-wide analyses. notication to the registry by the diagnosing physician. The major sources of notication in Mecklenburg-Western Source of population Pomerania are the regionally organised tumour centres The estimate of the population at risk is based on an extract (Tumorzentren). The tumour centres abstract all pertinent from the central residents registration ofce on 3 October information from medical records of cancer cases residing 1990, which is annually updated with the results of the in the state of Mecklenburg-Western Pomerania seen in a statistics of births, deaths and migration. Source: Statistisches hospital or special clinic being afliated with a tumour centre, Amt der Lnder. and report them to the CCR. The tumour centres provide 95% of all notications per year. The remaining 5% the registry Multiple primary rules used receives directly from the physician via the traditional way IACR rules (2004) on CI5 IX period.

305

Europe

Germany, Free State of Saxony

Registration area The state of Saxony is one of the six states covered by the Common Cancer Registry (CCR) and is located in the East of Germany. The population of Saxony is about 4.4 million inhabitants, 48.5% males and 51.5% females (2002), almost all of them being of Caucasian origin. About 57% live in urban areas (dened as population >5000 and population density >400 inhabitants per km). to the registry by local health authorities. Data of German non-residents of the CCR are exchanged with neighbouring cancer registries. Interpreting the results After 1989 the notication rate in Saxony declined sharply due to political changes in the former GDR and the resulting lack of a legal framework for cancer registration. With the cancer registration law taking effect in 1995, the legal basis for cancer registration was re-established and cancer cases Cancer care facilities In Saxony there are 86 hospitals, most of them afliated were again reported to the registry. The availability of death with one of the regional tumour centres. The state of Saxony certicates as a principal source of information on cancer has ve tumour centres, located in the cities of Chemnitz, cases was regulated by the cancer registration law. Since 1995, the number of reported Dresden, Grlitz, Leipzig, and cancer cases from Saxony Zwickau. Although there are has been steadily increasing, some hospitals specialising in GERMANY, FREE STATE OF SAXONY while the percentage of DCO oncology services, most of the (1998-2002) GERMANY, FREE STATE OF SAXONY (1998-2002) cases is decreasing. other hospitals are involved There are opportunistic in cancer care as well (e.g. by screening programmes for offering special diagnostic or colorectal, prostate, cervical treatment methods). The tumour 


 









and female breast cancer centres, however, are the focal 







and for skin melanoma. Data point in cancer care. Tumour 














on testing for PSA are not centres are specic hospitals and 






available, but it is increasing university hospitals specialising 








 





in this population. in diagnostics, treatment and 







aftercare of cancer patients In the past there were some 














and the documentation unusual occupational exposures of 







of pertinent information. radon for employees in the Wismut 














Also, general practitioners, mining area (West Saxony), as 







radiotherapy departments and well as unusual environmental 














other specialists are involved exposures of radon in houses 







in cancer care, as they see which might be still a problem in cancer patients in an outpatient parts of this area today.       setting. -($* -($* 

 

&-%)/-.%,-- Use of the data Registry structure and 

   Saxony cancer data have -- --22--  ---- --- 1-- --'- -%//#---methods been used for health services   ---- --- - !- - -"-0--- -
3 "For a description of the structure of the registry, please refer planning and for epidemiological research. Linkage with the  



 
--(&##)*--
+-- to the general narrative for the CCR. CCR was performed for casecontrol and cohort studies. In Saxony, cancer is a reportable disease. In 1993, Annual reports on cancer incidence and mortality are cancer notication became mandatory in this state. Patients prepared. In cooperation with the association of population are informed about the notication to the registry by the based cancer registries in Germany (GEKID) and the Robertdiagnosing physician. Koch-Institute, the data are pooled for nation-wide analyses. The major sources of notication in Saxony are the regionally organised tumour centres (Tumorzentren). The Source of population tumour centres abstract all pertinent information from The estimate of the populationatrisk is based on an medical records of cancer cases residing in the state of Saxony extract from the central residents registration ofce on 3 seen in a hospital or special clinic afliated with a tumour october 1990 which is annually updated with the results centre and report them to the CCR. The tumour centres of the statistics of births, deaths and migration. Source: provide 93% of all notications per year. The remaining Statistisches Amt der Lnder. 7% the registry receives directly from the physician via the traditional reporting by means of notication forms. Multiple primary rules used Additionally, all death certicates have been made available IACR rules (2004) on CI5 IX period

306

Europe

Germany, Hamburg
Registration area With 1.7 million inhabitants, the Free and Hanseatic City of Hamburg is the second-largest city in Germany and one of the 16 federal states. The city area comprises 755 km2, 14% of which are covered by green spaces, water and recreational areas. Hamburg is one of the worlds major trade centres. Its port is the central hub for trade with Eastern and Northern Europe, supplemented by important rail and motorway connections. The predominantly urban area shows highly specialised industries, particularly medical devices, biotechnology and aircraft industry. With 11 universities, higher education is a main focus. Cancer care facilities Being a metropolitan area, the medical infrastructure in the city of Hamburg is above-average. Medical care is provided by a complex healthcare system including 3600 general practitioners and specialists, and 53 hospitals including a university hospital. The main institutions of specialised cancer care are about 10 hospital departments and 8 oncological practices, the latter including in- and outpatient settings. These are supplemented by numerous diagnostic, therapeutic and supporting facilities, such as laboratories, pathology units, radiology and radiotherapy institutions and psychosocial services. Up to 25% of oncological patients reside outside of Hamburg. In addition, all death-certicates are made available to the cancer registry staff for evaluation and trace back. The procedure of matching the HCR-data with information kept in residential registry ofces was started in 2004. The step was a one-time check of 75 000 cases without date of death. Since then the update has been done monthly. Many plausibility tests are done, and a Best-of tumour information is generated in case of multiple notications of a single malignancy.


 











 

























Interpreting the results Since 1995 the number of notications to the HCR has doubled while the DCO rate has declined signicantly. Completeness is independently reviewed by the Robert Koch Institute based on the M/I index, having been GERMANY, HAMBURG (1998-2002) estimated in 2005 as sufciently GERMANY, HAMBURG (1998-2002) complete. Nevertheless quality differs considerably concerning site and year of diagnosis. Although methods of  






early detection are used 




widely (e.g. Pap smear, PSA, 








mammography) it is impossible 




to quantify their numbers and 








to estimate their inuence on 




incidence rates. 





















Use of the data Comprehensive reports 







on cancer incidence and 














mortality in Hamburg are 







published every third year. In addition, in 2004 the HCR       started publishing data online 
,(%* 

,(%* (www.krebsregister.hamburg. 


.'$,-&/,,,  de). Routine reports cover data 

    
,(,
, ,  ,,
1
!, 0##"1 "
*, on incidence and mortality. In  



 2005 we began including survival analysis for clinical use. 
, 
,('$$)*,,+,,
, In cooperation with the Association of population-based Registry structure and methods Having started between 1926 and 1929, the Hamburg Cancer cancer registries in Germany (GEKID) and the Robert-KochRegistry (HCR) is one of the oldest population-based cancer Institute (RKI) the data are pooled and documented in Krebs registries of the world. During the Second World War the in Deutschland. The HCR both initiates and participates in various reporting process stopped, and again paused in the 1980s because of a general controversy on data protection in research projects, for instance risk factors for breast Germany. Since 1985 the HCR has been based on a specic carcinoma, regional analysis of incidence concerning law with two essential elements: the principle of informed leukaemia and lymphoma, feedback on long-term survival consent from the patient and voluntary cooperation on the to notifying institutions, acute and post-traumatic stress disorder in breast cancer patients. physicians side. Since 1991 notications are remunerated. One current project is the multi-centre MARIE- Study The state health authority, staffed with four scientists, two computer experts and six documentation and coding (Postmenopausal Hormone Replacement Therapy and breast employees, runs the HCR. Additional project equipment is cancer risk). The HCR also collaborates with the hospital planning unit of the Ministry of Health in Hamburg in the provided by the Hamburg cancer society. Traditionally the physicians in hospitals report by means assessment of numbers of cancer cases given from the hospitals, of notication forms. Pathologists provide a partly lled and is involved in the evaluation of mammography screening. notication form to be completed by the attending physician. Electronic data transmission is now realised by providing Source of population purpose-developed software to the cooperating practitioners. Projection (Statistical ofce for Hamburg and This software transfers data from the surgerys software into SchleswigHolstein, http://www.statistiknord.de). an electronic notication form completed on screen by the physician. A rising number of hospitals are supplied with Multiple primary rules used IACR rules (2004) on CI5 IX period. facilities to enable electronic notications as well.

307

Europe

Germany, Munich
send cancer-specic forms with pre-coded data on an Registration area Munich is the capital of the federal state of Bavaria, one of individual level, including identifying items for each primary sixteen states of the Federal Republic of Germany (Munich malignancy. Additionally, collaborating hospitals report on City: latitude 488 N, longitude 1134 E, 519m above sea local and regional progressions and on the occurrence of level, area 310km2). With its 1.3 million inhabitants, Munich metastases. These data are important outcome criteria for is Germanys third-largest city, located in the southeast of clinicians and are used for evaluating therapeutic strategies and for quality control. the country about 50km north of the Alps. Since 1994, the 12 pathological services have been The Munich Cancer Registry (MCR) covers the population of the City of Munich and 7 surrounding districts, in total sending copies of the reports for malignant diagnoses to 2.3m inhabitants, 56% living in Munich City. About 23% of the MCR. The histological verication rate for almost all the inhabitants are foreigners, 8.6% from the EU. Most of prognostic favourable types of cancer is 95%. The Bavarian Cancer Registration Law allows the them come from Turkey (3.4%), and from Croatia, Serbia, Greece, Austria and Italy each with about 1.7%. Most work MCR to process all death certicates in the catchment area. Information from in the service and trade sector death certicates has been and in growth industries such compared with registry data as media, information and GERMANY, MUNICH (1998-2002) on an individual level since communication technology, GERMANY, MUNICH (1998-2002) 1998. This has revealed a the nancial industry and noteworthy underreporting for biotechnology. Munich is prognostically unfavourable Germanys second-largest cancer sites like pancreas, university city. %"#'%%% '"$ % (%%% %& %%% ' (%'&%%% liver, gallbladder, CNS and In 1998, legislation was "%"%%% &" '%( %%% lung. Remarkably, the agepassed authorising population'%%%% & '%(&#%%% (%#%%% #" ""%%%% standardised mortality rate for based cancer registration in &(% "'%%% # '%# (%%% lung cancer in Munich is about Bavaria. The registration '%('&%%% "" '%'& %%% &#%'&%%% " '%#(%%% 30% lower than the overall rate system in Bavaria for a total &%& %%% " &&%& %%% for Germany, corresponding of 12.4m people, based at ''%(' %%%  '#% &%%% % %%% "  %'%%% to a high social status and low the Munich Cancer Centre #%%%%  &%#%%% rate of smoking. and ve other comprehensive '%#%%% " '% %%% #"% %%%  #&%'(%%% Haematological diseases cancer centres, has been "%"#%%% " "%''&%%% are underreported. For centralised to further improve ""%# #%%%  "% #%%% "&% #%%% " " % %%% the other cancer sites, a the collection and processing #% %%%  "'%&&%%% remarkable incidence rate of cancer data. Since 2007 the could be obtained without MCR has covered the entirety  "   "  involvement of DCO-cases 
%!

%! of Southern Bavaria, with %%"%%% %'%'&%%%  and without including follow4.4m inhabitants. back results. The impact on 
   %
%

% success of motivation to join Cancer care facilities  



 Hospitals and private practitioners provide health care in the MCR can be assessed by analysing the stable incidence 
%
% !%%"%%
% the region. There are two university hospitals in the city of rate from 342.5/266.4 in 1998 to 361.7/ 271.0 in 2002 (male/ Munich. All necessary diagnostic and treatment services female, world standard, without 174/C44). In 2002 we handled about 29 000 pathological reports, are available to deliver healthcare according to international standards. The population-based stage distributions and 36 000 death certicates and 50 000 other forms and reports. treatment results show international comparability. All Additionally, life status was veried by more than 100 000 hospitals cooperate in the comprehensive Munich Cancer requests at Residents Registration Ofces. This paperwork is done by 13 documentation ofcers. In addition three Centre. The MCR supports networking in oncology by compiling scientists are responsible for organisation, statistics and cancer data from all sources. Presentation of individual computer technology. In Germany, cancer screening is offered but the and aggregated data is offered to the closed community of participation rate varies widely between men and women, cooperating doctors. according to their age. Medical examination includes palpation of breast, cervical smear, haemoccult test and Registry structure and methods As part of the comprehensive Munich Cancer Centre, the palpation of prostate, with a high rate of self-initiated PSA MCR started registering patients in 1978. In the rst years tests at the patients own expense. a few departments of the Ludwig-Maximilians-University and the Technical University Munich collaborated. There Use of the data are now 39 hospitals in Munich, and 11 hospitals from the The MCR analyses cancer incidence and mortality surrounding districts taking part in the MCR. The number of concerning secular and regional aspects. Survival rates are cooperating institutions and the catchment rate has reached a calculated for the different cancer sites. Results are used to answer important questions, e.g. concerning quality steady state and guarantees a high coverage rate. Notication is on a voluntary basis, and no legal duty assurance in health care. Additionally, the MCR releases is imposed upon doctors to report cancer cases. Hospitals periodical reports via Internet for all cooperating hospitals

308

Europe

to keep them permanently informed about the medical data they have provided. Many of the most frequent cancer diagnoses are analysed in detail. Routine statistics show comparisons to the recommendations of guidelines with hints to those patients for whom the standards are not realised. The larger hospitals are informed about their own results, main outcome criteria are compared anonymously with the other hospitals. Some

of the data are available for the scientic community on the internet (www.tumorregister-muenchen.de). Source of population 2000. Postcensal estimate. Multiple primary rules used IACR rules (2004) on CI5 IX period.

309

Europe

Germany, North Rhine-Westphalia: Mnster

registry include hospitals, outpatient departments and private practitioners. Since 1998 the registry has included Registration area The Muenster District (Regierungsbezirk) is a region of reports from pathologists with anonymised personal the Federal State of North Rhine-Westphalia (NRW). It identiers. Follow-up of patients is largely passive. is located in the north-west of Germany bordering the Annually, the register database is linked with death Netherlands. The population of Regierungsbezirk Muenster certicates from the district. Follow-back is pursued if was 2 625 637 in 2002, with 48.8% males and 51.2% females patients were initially identied in the register by death and a population density of 379 inhabitants per km2. The certicate. District encompasses rural areas as well as large industrial areas and cities. The great majority of the population are Interpreting the results Caucasians. The Muenster Registry was the only cancer The catchment area has remained unchanged over the registry in NRW until 2005, when it was transferred into reporting period. Likewise, the diagnostic and therapeutic the Epidemiologisches Krebsregister Nordrhein-Westfalen, facilities developed in line with the general medical progress in Germany. Coding has been a new epidemiological cancer performed according to ICDregistry now covering the 10 and the ICD-O-3 guidelines entire state of North RhineGERMANY, NORTHRHINE-WESTPHALIA: throughout the period. No Westphalia. (1998-2002) GERMANY,MUNSTER NORTHRHINE-WESTPHALIA: MUNSTER (1998-2002) organised population-wide cancer screening programmes Cancer care facilities have been established, although Cancer diagnosis and opportunistic mammography, treatment in Regierungsbezirk %"$%""" $! "%""" "$""" $ "##""" colonoscopy, skin inspection Muenster are carried out by "%""" # #"""" and PSA testing are rather hospitals and specialists. "#""" # """" "$$"""  %" %""" common. There are 63 hospitals with #%"%"""  $"$%""" more than 20 000 beds #"##"""  #" """ #"$"""  #"$ """ Use of the data in the registration area. $%"%"""  $$"%""" The registry prepares regular Morphological examinations "#% """  "%""" """"  "#""" annual reports of cancer and diagnoses are performed in %" """  "%$""" incidence and mortality. More 14 pathological institutes, one $"#"""  $" #""" #""""  #"%""" detailed reports of trends specialising in neuropathology ##" """  #"%%$""" and survival are prepared and ve in dermatohistology. $"%"""  ##" #""" #%" """  #"%#""" infrequently for specic Radiology services are #""""  $"#""" entities (e.g. breast, leukaemia, provided by departments in malignant melanoma and numerous hospitals.       prostate cancer). Data are also  "   " provided by an interactive "%"$ """ "#"%%"""  Registry structure and database via Internet. The methods 
   registry contributes frequently The registry was established  "  



 in 1985 and was completely funded by the State Ministry of to the ofcial Health Report System in North Rhine
 "
 """""
" Health. Full-time personnel comprise two senior scientists Westphalia. for data management and analysis, one epidemiologist, and four medical records clerks. A consultant from the Institute Source of population of Epidemiology and Social Medicine of the University of Census. Muenster accompanies the registry. Cancer notication requires the signed consent of Multiple primary rules used patients. The sources of notication for the Muenster IACR rules (2004) on CI5 IX period.

310

Europe

Germany, Saarland
force in April 2002. Since April 2000 the registry has been an Registration area The Saarland Cancer Registry covers the population of the Federal integrated unit of the Ministry of Public Health. Until 1999, it was State of Saarland. Located in the south-west of Germany between nanced by the Government of Saarland and by regular subsidies latitudes 49038 and 49007 and longitudes 6021 and 7024, bordering from the Federal Ministry of Health. Since 2000, it has been France and Luxembourg, Saarland is the second-smallest state in completely funded by Saarland State. Two full-time ofcers of Germany. The area amounts to 2569 km2 of hilly country with health holding a university degree, two full-time registrars and altitudes ranging from 150 to 695m above sea level. Saarland lies three half-time clerks are afliated with the registry. in the cooler part of the temperate zone, occupying an intermediate The basic system of registration is centralised collecting of position between the oceanic climate in the west and the continental individual records including personal identiers, which do not climate of the east. The average annual temperature is about 100 require the written formal consent of the registered patients. Notication is compulsory since 2002. Hospitals, physicians C. Average annual rainfall is about 1050 L/m2. The administrative structure consists of ve counties and one and persons acting on their behalf are obliged to report all newly metropolitan area, comprising 52 communities altogether. diagnosed and treated cancer cases. In principle physicians must The population of the Saarland inform patients on the reporting is 1 070 102 (in 2000); 48.5% are to the registry, but there are some males and 51.5% females, at a derogations. Patients have a right GERMANY, SAARLAND (1998-2002) density of 417 inhabitants/km2. to withdraw from registration, GERMANY, SAARLAND (1998-2002) but in practice withdrawal Some 52.9% live in 13 conurbations is extremely rare. Sources of more than 20 000 inhabitants. of information are hospitals, Life expectancy for males is 75.0 outpatient depa r tments, years and 80.5 years for females. ',%*.,,, .)+ #),#-*,,, *,!!),,, .! #',''#,,, pathology and radiotherapy The overwhelming majority #',#-!,,, -) $-,'!.,,, departments and private (72.7%) are Roman Catholic, $$,#-),,, -! %!,#.',,, $.,'%*,,, *) %#,/%$,,, practitioners. Death certicates with 21.7% Protestants and 5.6% %*,-)-,,, *! %/,'**,,, are also used, and traced back with other/no religious afliation. %#,'/-,,, )) %$,$%#,,, %$,.%!,,, )! %#,-%.,,, Of the total population, 92.5% are when necessary. '!,)#),,, ') %.,/.*,,, German and 7.5% possess foreign Due to restrictive legal '','$!,,, '! '$,')$,,, '*,'%',,, %) '),!$#,,, regulations, follow-up of patients nationality. About 47.8% of Saarland '#,/*/,,, %! '!,$./,,, is largely passive. Though all residents are married, 36.8% %#,!$%,,, $) $/,/'*,,, $-,/-.,,, $! $-,%#-,,, physicians treating cancer unmarried and 15.4% widowed $.,.$.,,, #) $-,$!/,,, patients are generally requested or divorced. The economically $/,-./,,, #! $.,!$#,,, $-,/.-,,, ) $*,)$-,,, to report any serious change active population, 46.1% of the $%,.**,,, ! $$,//.,,, in a patients health status, total, is employed in production the registry is not allowed to industries (32.7%), distribution, #! ) ! ! ) #! conduct further enquiries. The transport and communications 
,&"( 

,&"( les of the registered cases are (23.6%), agriculture, forestry and ))#,%'#,,, )#/,!'*,,,  linked annually with all death sheries (1.0%) and other sectors/ 
   
,
,,
,#/.-,
,,
, , ,,
,,
,, , ,,,,,
,
 ,
 , certicates. services (42.7%). Cancer care facilities Cancer treatment is carried out by both hospitals and private physicians. Treatment at the hospital level in Germany has been coordinated under a governmental programme structured on several levels. The Tumorzentren (tumour centres involved in both research and treatment) cover large regions and are connected with big university hospitals. In the Saarland area there is one Tumorzentrum and one big university clinic. A series of regional hospitals dedicate considerable personnel and funds to cancer treatment. A small number of private oncological practices provide diagnostic and aftercare structures. There are 27 hospitals with 8060 beds in the registration area. Hospitals comprise 144 special medical departments including four radiotherapeutic units. Morphological examinations and diagnoses are performed in eight pathological institutes, one specialising in neuropathology. Registry structure and methods The registry was established in 1967 in the State Statistical Ofce and is based on the Saarland Law on Cancer Registration, whose rst edition came into force in 1979. A new, completely revised Saarland Law on Cancer Registration regulating and improving the use of personal data for epidemiological research, came into
 



 
, 
,&$!!'(,,),,
,

Interpreting the results Early detection and population screening activities in Germany started in 1971. Since programme restructuring in 1982, the population has been screened for cervix, breast, rectal and skin cancer. All tests are offered annually to eligible population groups, but there was no individually organised invitation by letter with location and time of testing. To date (September 2006) there is no regular PSA testing for men in Germany. Organised mammography screening for women from 50 to 69 years of age is currently to be established in all federal states of Germany. Use of the data The registry prepares annual reports of cancer incidence and mortality, and provides an interactive database (www. krebsregister.saarland.de) on the Internet. The registry carries out descriptive and analytical epidemiological studies, independently and in national and international collaborations. Source of population Estimate based on the 1987 census, making allowance for births and deaths, as well as for migration into and out of the registration area. Multiple primary rules used IACR rules (2004) on CI5 IX period.

311

Europe

Iceland
Registration area The Icelandic Cancer Registry is a population-based nationwide cancer registry covering the whole of the Icelandic population. Iceland is located in the middle of the North Atlantic Ocean between 6468N and 1424W. The geographical size of the country is 103 000 km2. The Icelandic population is around 300 000 inhabitants. Around 80% of the population is urban, and the urban population is mostly located in the southwest part of Iceland. The population ethnicity is northern European, and the religion is Christian Protestantism for the vast majority of the population. the registry from the Icelandic government. A new law was enacted in 2007 which makes cancer registration in Iceland compulsory. The core staff consists of a medical director, a managing director, two registrars, a computer technician, a data manager and a statistician. In addition there are part-time positions for 12 researchers. The sources of data for the cancer registration are the pathology and haematology laboratories, all hospital departments and healthcare facilities. Registrations are also received from private-practicing consultants. Incomplete information is followed up by contact with the aforementioned institutions and individuals. The majority of the data is received in electronic form. The rst information on cancer cases in most instances ICELAND (1998-2002) (>95%) comes from pathology ICELAND (1998-2002) laboratories. Further information is then requested from all those who are likely to give additional details if  
 





needed. 



The Icelandic Cancer 








Registry receives information 




from all death certicates from 






 

Statistics Iceland, where there 



is a mention of a malignant 






 

disease. The registry further 




checks this information and 








additional information called 




for if needed. 








Periodically, all 



registration for each site is checked and discrepancies      are further investigated. The )$!& )$!& IARC check program is used. 




Cancer care facilities Patients in Iceland have easy access to physicians, whether in primary health care or consulting in a specic eld of medicine. The healthcare system is a socialised system and the proportion of the cost 





of the healthcare burden laid 



on the individual or his private 






insurance is minimal. 


Imaging facilities 



 

are available with highly



sophisticated techniques both 






in the major hospitals and in 



private practice. There are 






four pathology laboratories in 



the country, one of which is 






purely for dermatopathology, 



and all of those provide the Cancer Registry with their  valuable information. There are also well-equipped "% )(%#))) haematology and biochemical  
 laboratories as well as a )

++ ) ) )))) ))
 ))"*'#))  )
) ) ))) ) Use of the data  
   cytogenetic laboratory available for %&)) )) various investigations Figures on incidence, prevalence and survival are published 
) )$# of patients. Cancer surgery in    Iceland is for the most part every year in the yearbook of the Icelandic Cancer Society %%)))))) ) limited to two hospitals, although minor surgical operations as well as on the home page of the Icelandic Cancer Registry are performed both in private ofces and in smaller hospitals. (www.cancerregistry.is). The registry staff is actively engaged Specialised work on cancer treatment like neurosurgery and in epidemiological research on cancer, and the registry radiation treatment of cancer is centralised at Landspitalinn is also the source of data for such research conducted by others. The Icelandic Cancer Registry in addition provides University Hospital in Reykjavik. A nationwide screening programme for cervical cancer information to assist public health ofcials in planning for has been operating since 1964 and for breast cancer both the prevention and treatment of cancer. since 1987. It has been decided that Iceland shall take up nationwide colorectal cancer screening in the near future. It Source of population is quite common for men above the age of 50 to have their The populationatrisk derives from the Icelandic National Roster, in operation since 1952 and regularly updated for PSA levels measured. births, deaths and migration. Registry structure and methods At the request of the Director General of Health the Multiple primary rules used Icelandic Cancer Society undertook in 1954 to establish IACR rules (2004) on historical data. and run a cancer registry. It has ever since been located at and run by the Icelandic Cancer Society. In recent years the Notes on the data Society has received a subsidy towards the cost of running C44 does not include basal cell carcinoma.

312

Europe

Ireland
The Registry is administered by the National Cancer Registration area The catchment area of the National Cancer Registry is the Registry Board, whose members are mainly medical Republic of Ireland. A separate registry covers Northern practitioners, and is fully funded by the Department of Health and Children. The Registry has a staff of 42, 22 of Ireland. The Republic of Ireland is situated between 5130 and whom are engaged in active data collection. Reporting of cancer cases is not obligatory, and the 5530 N and between 60 and 1040 W. The total land area is 70 282 km2, comprising 83% of the island of Ireland, Registry collects most of its information through active with a long indented coastline of 3169km. The highlands casending and data abstraction. Most notications come are mainly coastal, with a central limestone plain, and the from pathology departments, with a smaller number from country does not rise above 1040m at any point. The climate other hospital sources, death certicates and GPs. The Registry has full access to all death certicates is temperate and oceanic, with average winter temperatures between 4C and 7C, and summer temperatures between issued in Ireland since 1994, and uses these for case14C and 16C. Yearly rainfall is highest on the mountains of nding and follow-up. Death certicates are followed up with the hospital of death the west and lowest in the east or the certifying doctor if midlands. the cancer is not already The population at the IRELAND (1998-2002) registered. Unconrmed death 2002 census was 3 917 203 (1 IRELAND (1998-2002) certicates are registered as 946 164 males and 1 971 039 death certicate only (DCO). females). The population is At present the Registry does predominantly native-born and not carry out active follow-up. Caucasian, but information on 


 









All data is extracted directly ethnicity is not collected either 







onto laptop computers and no at census or by the Registry. 














paper forms are generated. Most of the population (88% 







The ICD-O-2 coding system is at the 2002 census) are Roman 












 

used for both topography and Catholic. In 2002, 40% of the 
 





morphology. All malignant, in population lived in rural areas 














situ and uncertain cancers are (centres with fewer than 1500 






registered, as well as benign inhabitants). 














intracranial and intraspinal 







cancers. CIN III of cervix is Cancer care facilities 








 





not registered on the basis of Cancer patients in Ireland 





 

cytology, but only if conrmed can avail of either private or by biopsy. public health care. All public       
)&"( 

)&"( We have recently carried and private hospitals allow the 



#)++*),*%)))  out a formal evaluation of Registry full access to case completeness, using statistical information. The majority of 
   methodology, in collaboration cancer patients (about 84% of )#,,*.$!!#-)  )))

)&)
)
)
))
)&() 
))

))
)  ))
)))
 ))))
))
))

)))

))
))))()))))))))))))))))))))$!!$-)
)$!!$)  



 incident cases) attend public hospitals. There are two main with Dr David Robinson of Thames Cancer Registry. 
)
)&$!!'()))) publicly-funded radiotherapy centres in Ireland, located in Periodic checks for completeness are carried out against Dublin and Cork, and two smaller private centres both in other cancer databases. We plan to carry out a reabstraction Dublin. Almost all cancer treatment is provided within the of a 2% sample of records next year. country. No co-ordinated screening programmes existed in Use of the data Ireland in the period 19942000, but breast screening began Annual reports, with information on incidence, mortality, in 2000 and by the end of 2002 covered approximately 50% treatment and survival are produced. The Registry has also of the population. It is hoped to have full population cover published a number of scientic papers and special reports by the end of 2007. Opportunistic but unorganised cervical on a number of different topics, a list of which is available on screening has existed for many years, but it is not possible the website (www.ncri.ie/pubs/pubs.shtml). The data are also to estimate the proportion of the population covered. In widely used in the Irish health services for service planning October 2000 the rst phase of a national cervical screening and needs assessment. program was established in one region of the country. PSA Source of population testing is common in the population. For 19972001: Population and migration estimates (Each year the Central Statistics Ofce (CSO) publishes an Registry structure and methods The National Cancer Registry was founded in 1991 and estimate of the population at April of that year. This is based began collecting population-based cancer incidence data for on the natural increase and on estimates of the gross annual the entire country in 1994. In 1991 it took over the functions migration ows). For 2002: Census 2002. of the Southern Tumour Registry, which had provided population-based registration for about one sixth of the Multiple primary rules used IACR rules (2004) on historical data. country since 1975.

313

Europe

Italy, Biella Province

staff looks up other specic les of hospital departments Registration Area The Cancer Registry covers an area with 82 municipalities: (radiology, radiotherapy, oncology), laboratories, the 22 have fewer than 500 inhabitants and 15 have a population palliative care unit (active since 2000) or the hospital cancer between 500 and 1000 inhabitants. Most of the population registry (active 19591997). Finally, the registry regularly (187 041 inhabitants in the 2001 census) resides in urban receives records from the local ofcial mortality registry areas (24.3%). The textile industry had always been the main and has access to original documents for further checks. activity in the area; however, during the last 20 years other Completeness and accuracy of the information are formally electronic and metal-mechanical industries have arisen. Due evaluated in several ways. After data verication with the to its industrial background dating back to the 19th century, IARC-Check tools, we analyse short-term trends in number this area has always been a place of immigration. In the of cases, percentage contributions of each information 1950s people arrived from the Northeast of Italy (about 20% sources, cases with poor site or histological specication, of population now aged 6080) while in the 1970s people microscopic verication, prevalence of multiple primary migrated from the south of Italy. Migrations from other cases, mortality incidence ratio, and proportion of DCI and DCO. countries are only recent and limited to young people (<5% Interpreting the results of population). The birth rate ITALY, BIELLA PROVINCE (1998-2002) Cancer incidence in the is rather low (7.36 in 2001) and ITALY, BIELLA PROVINCE (1998-2002) Province of Biella is the elderly index high (198.95 inuenced by its social and in 2004). Nowadays, there is industrial history, with a high relative demographic stability, incidence of larynx, lung, especially in the valleys where &/(*'/// 1,. */'*1/// &/,'-/// 1$" (/'(-/// oesophagus and stomach the communities are more (/'2,/// 0," ,/-((/// cancers in men. Recently, isolated. */-'&/// 0$" -/,,1/// ,/*0&/// -," -/-*&/// screening programmes have -/&10/// -$" -/1(,/// made an important impact, Cancer care facilities -/$$*/// ,," -/(',/// -/,2*/// ,$" -/-,'/// with increasing incidence The registry area is served by -/*,0/// *," -/*-$/// rates for breast, prostate, and one public hospital of about -/,-(/// *$" -/($(/// 0/(,(/// (," -/2'0/// rectum cancers. Clusters of 500 beds with the main surgical 0/*11/// ($" 0/&('/// cases in a particular area and medical specialities, -/02*/// '," -/(00/// ,/'-1/// '$" ,/$$*/// (mainly thyroid cancer) are radiotherapy, oncology and a */$($/// &," (/1(0/// presently under study. palliative care unit, and two (/0((/// &$" (/(1'/// (/0-(/// ," (/-$'/// private clinics. Population(/-*2/// $" (/,$'/// Use of the data based screening programmes The Registry reports on have been active since 1997 &$ , $ $ , &$ incidence, mortality, survival for cervical cancer, and since /)%+ /)%+ and their trends to the local 1995 for breast cancer, while 21/-,(/// 2$/&(1///  and regional authorities. In in the previous years screening 
   // / // addition, it reports on hospital practice was rather diffuse /'$$&///3////

//(&#&'/ //!//
/ //)+#///
//// /

/ although opportunistic. A multi-centre evaluation trial has cancer patient migration and quality of hospital records. The  



 
//)'$$*+//// been carried out for colorectal cancer screening using FOBT Registry collaborates to the evaluation of cancer care quality and endoscopy since 1997. Opportunistic screenings with and to the preparation of cancer treatment guidelines. It also PSA for prostate and with clinical skin examination for provides a follow-up service for clinical and epidemiological melanoma were carried out with the support of the local researches, and is actively involved in the following studies: the Colon-rectal screening evaluation trial (SCORE), cancer foundations for the past few years. the evaluation of prostate screening, the evaluation of implementation of colon-rectal cancer treatment (TRIPPs) Registry structure and methods The registry is part of the Centre for Cancer Prevention in collaboration with CPO, and the prevalence of anaemia (CPO) of the Piedmont Region, located in the Epidemiology in the elderly (ANGEM) in collaboration with the Mario Unit of the Local Health Authority (ASL 12), staffed by a Negri Institute. The Registry contributes its own data to director, a part-time public health doctor and a registrar the National Database of the Italian Association of Cancer nurse. The registry actively searches for cases in all clinical Registry (AIRTum). records of local hospitals and pathology laboratories. It also actively searches for patients who migrated towards other Source of population centres, mainly in Piedmont and Lombardy, as indicated by Census 2001 and Intercensual estimates: Intercensual the reports originating from the regional hospital discharge estimates with population as of 31.12 of every year are provided records. The registry also double-checks data with other by the statistical ofce of the Piedmont region (BBDE). The repositories of cancer data: the Piedmont Childhood Cancer registry provides the annual median population. Registry, the National Malignant Bone Tumour Registry and the Mesothelioma Piedmont Cancer Registry. If case Multiple primary rules used conrmation or prevalence checks are needed, the registrys IACR rules (2004) on historical data.

314

Europe

Italy, Brescia Province

Ofce collects all hospital discharge data from Lombardy Registration area Brescia is one of the most densely populated provinces in the and bordering regions, the proportion of cases missed is likely Lombardy region of northern Italy. The Brescia Health Unit to be very small. Most pathological records are uncoded, and Cancer Registry covers about 91% of the population of the Registry staff code about 80% of them to ICD-O-2. Computerised records containing all the collected data province. Registry data are available for 19931995 and for 19992001. The Brescia Health Unit Cancer Registry started (hospital discharge records, pathological records and death in 1994 using manual methods, and covered a smaller area with certicates) are automatically linked to the Social Security about 390 000 inhabitants, consisting of the town of Brescia System to assign a patient code to each record, and all records and 23 surrounding municipalities. The Registry currently uses with that code are linked with prevalence les. Concordant an automated population-based cancer registration system. It incident malignant cases are assigned to the Registry. For covers an area of 3460 km2 at 45N latitude. It covers Brescia discordant and incomplete cases, the Registry staff review (population 195 000) and 163 other smaller towns, 55 with the computerised information, and if any remain unresolved, more than 5000 inhabitants (33.7%) and 108 with fewer than they scrutinise hospital records and abstract information on cancer cases directly. For 5000 inhabitants (66.3%). The cases with death certicate population was 1 004 980 notication, they trace-back inhabitants, 51% females, at ITALY, BRESCIA PROVINCE (1999-2001) and ultimately reister those the October 2001 census. The ITALY, BRESCIA PROVINCE (1999-2001) that do not link with another population density is 290/ source as death certicate km2. only (DCO). In 2001 about 8% of the Completeness and population were foreigners: 


 









accuracy of ascertainment of 30% came from East Europe 







cases are provided through and 70% from non-European 














comprehensive computerised countries (25% from Asia, 

 





data sources and also through 20% from North Africa, 20% 













checking and comparison of from Sub-Saharan Africa, and 







incidence rates in previous 5% from South America). 














years and with other registries 







in northern Italy. Cancer care facilities 














In the Registry area there 







Interpreting the results are 12 public and 9 private 

 












Two ndings from the Brescia hospitals; the largest, located 







data are high frequencies of in Brescia, has medical and liver cancer among men and surgical specialists and a       breast cancer among women. Radiotherapy Department. ($!& ($!& A comparison with 1993 The Oncology Department 


%*'(#)*(((  1995 data conrms these covers the Brescia province. 
   "((((((((((( ndings. In the last decade, In 2001 there were 3822 beds ((((((((( (("**"((# (( (($( (((+(
&( in public hospitals and 2365 in private hospitals (6.1/1000 epidemiological studies have been carried out to investigate  



 

(($"** &( inhabitants), and is 846 general practitioners (84.2/100 000 the causes of liver cancer, mainly hepatocellular carcinoma, inhabitants). Brescia has had mammographic screening for in the area; the role of hepatitis B and C viruses and of heavy alcohol intake have been elucidated. The breast cancer women aged 5069 years since the late 1980s. rate among women may be partially due to populationbased mammographic screening in the area in recent years. Registry structure and methods The Brescia Cancer Registry is located in the Brescia Non-organized PSA testing concerns 12.56% of the male Local Health Unit (Azienda Sanitaria Locale, ASL), which population (38.7% aged 50 years). The Brescia province is a highly industrialised area, with provides nancial support. The Registry is also funded by the non-prot Lega Italiana per la Lotta Contro i Tumori, one of the highest concentrations of steel and metalworking Sezione di Brescia (Italian League Against Cancer, Brescia industries in Europe. Working in these factories has been Division), and ASM S.p.A. (Public Utility Company). The associated with possible exposure to IARC class 1 and 2A ASL provides all the equipment and some of the human carcinogens. Air pollution has been observed in the area, resources (4 nurses and a secretary); the two other founders especially on the plain: the mean annual PM10 concentration support the activity of 1 medical doctor and 1 computer ranged from 3042 /m3 and most daily values in the winter programmer. A medical doctor and university researcher of 2004-2005 exceeded 75 /m3. also provide scientic support. The Registry uses three computerised data sources: Use of the data hospital discharge records provided by the Lombardy Region, The aim of the Registry is to produce and analyse incidence, pathology reports from 9 public and private laboratories, and mortality, prevalence and survival data according to death certicates provided by the Local Health Unit death demographic, topographic, morphological and behavioural registration ofce. All Italian hospitals must report each characteristics. The Registry works alongside Regional and admission using a standardised form in order to receive other Italian Cancer Registries in research projects and on payment. As the Regional Hospital Discharge Diagnosis publications of incidence, prevalence and survival data. A

315

Europe

multi-centre national study coordinated by the Director of the Brescia Health Unit Cancer Registry and funded by the Italian Ministry of Research is being conducted on the prevention of liver cancer through improved control of hepatitis B and C. A programme for the prevention and control of liver disease by general practitioners is also underway. Registry data are used routinely for monitoring population-based cancer screening programmes in the Brescia Local Health Unit.

Source of population The resident population is estimated annually on the basis of the 1991 and 2001 censuses, taking into account births, deaths and migrations, by the National Institute of Statistics (Istituto Nazionale di Statistica ISTAT). Multiple primary rules used IACR rules (1990).

316

Europe

Italy, Ferrara Province

The main sources of information are discharge diagnoses Registration area The province of Ferrara is located in the northwest of Emilia- from all national hospitals and the database of the Pathology Romagna Region and is mainly agricultural. It lies close to Department (covering all pathological diagnostic activity in the sea level (maximum altitude 22m) and is bordered to the province). Additional information is provided by direct contact north by the Po River, to the east by the Adriatic Sea, to the with care services (medical records) and general practitioners. south by the provinces of Bologna and Ravenna and to the Mortality data for all causes are provided by public health services west by those of Modena and Mantova. to identify DCN and DCO cases and for follow-up purposes. The population (348 651 in 2000) is fairly stable, Data collection is performed both actively and passively. characterised by elevated aging (24% over 65 years) with a Personal identifying data are protected in compliance with crude annual birth rate at the lowest levels in Italy (6.1/1000 current Italian law. Regular maintenance is carried out on inhabitants in 2000). Among the 26 municipalities of the the computerised database. Checks for duplicates, errors and province, the only one with a population >100 000 is Ferrara consistency are performed using the IARCcrg and DEPedits (132 085 inhabitants in 2000). tools. Completeness and accuracy evaluations are performed The prevalence of nonusing death certicates, recordCaucasians is low, and the linkage with pathological most widespread religion archives and checking of siteITALY, FERRARA PROVINCE (1998-2002) is Christian Catholic. The specic changes in incidence ITALY, FERRARA PROVINCE (1998-2002) number of immigrants is over time. lower than in other regional provinces, but the proportion Interpreting the results increased in size from the late The high prevalence of old-aged 


 









1990s (from 0.52% in 1995 to population has a great effect on 







2.43% in 2004). A majority crude incidence rates of many

 












(54.5%) of them come from sites. In the area covered by 







ve countries (Morocco, the Registry, lung cancer is 














Ukraine, Albania, Romania traditionally the most common 







and Pakistan), and the female/ male malignant tumour. The 














male ratio is 1.23. rate of cigarette smoking in the 







The level of employment Province (32.6% over 14 years 













was 47.8% (35.6% industry, old in 1996) is the highest in the 

 





9.4% agriculture, 55.0% trade Region (average 26.3%) and one 





 








and services). Mechanical and of the highest in Italy. About 







chemical industries are present 42% of children have at least in the province, and they one smoker parent. Air pollution       represent the main sources from the aforementioned sources 
*&#( 

*&#( of water and air pollution, 


and fog also add further risk for $))*'')***  together with animal breeding, lung cancer. Dietary risks are 
   * *
*

*  *&
** 
.* 
 *
-** trafc, heating plants and $,,+*/*%""%-*
** 
.*

* 
 also remarkable, due to high 

*

*/*0** -!!
 


/ !

!  $ (* agriculture chemical treatments. In 2000 the average meat, cold cuts and saturated fats intake, compared with low  



 
*
*&%""'(**** temperature was 13.3C (monthly average from 0.5C in vegetable consumption. The province shows also high incidence January to 23.8C in August) and the overall rainfall was rates for colorectal, gallbladder, soft tissue and endometrial 443mm. In the period 19982002 the population showed a cancers, brain tumours and multiple myeloma. progressive decrease due to a fall in births and low migration The very high incidence of breast and cervix cancer is rates from other areas. explained by the population-based screenings started in 199697. Prostate and thyroid cancers also increased in the Cancer care facilities period, the former as a result of PSA diffusion, the latter of In 2000 the province had a network of three care districts diagnostic echography improvement. DCN and nal DCO with 5 general hospitals (1851 beds). These provided cancer were 1.1% and 1% respectively. The proportion of cancer surgery units, haematology, radiotherapy and chemotherapy deaths necropsied in 19982002 was low (<1%). services. Cervix uteri and breast cancer organised screening programmes started in 1996 and 1997 respectively as a part Use of the data of a regional project. Colorectal cancer screening started The Registry is involved in local and regional cancer in 2005. PSA testing is widespread among the adult male care networks and it publishes periodic reports on cancer population, especially in recent years. In 2003, 14.6% of incidence, prevalence and survival. Determining the impact patients were treated outside the Registry area. of screening on incidence, mortality and therapy and cancer care needs in the covered population are its main purposes. Registry structure and methods It is also involved in several studies on multiple tumours, the The Registry is supported by the Emilia-Romagna regional prognostic and predictive power of biological assessment in Health Care Service since 1994, and it has also been funded breast cancer, social inequalities and cancer care access. by the Health Care Units of Ferrara province. Its staff of three The Registry is part of the Italian Association of Tumor clerks and a director is located in the Pathology Department Registries (AIRTum). Several studies on cancer descriptive of Ferrara University. epidemiology and breast cancer screening in Italy are now

317

Europe

in progress. Further activities on registration and coding techniques are also being carried out. Source of population 1998 2002: Census and municipalities residents les. Ofcial regional resident population based on municipalities les.

Source: Statistics Department Regione EmiliaRomagna, Italy (http://rersas.regione.emiliaromagna.it/statexe/popol1. htm). Multiple primary rules used IACR rules (2004) on historical data.

318

Europe

Italy, Florence and Prato

concerning each tumour, including personal identication and Registration area The territory of the Tuscany Cancer Registry (RTT) corresponds full clinic details, is coded and registered into the computer. to two of the ten provinces of the Tuscany region, the provinces Specic procedures and key words protect the access to the RTT of Florence and Prato. It is situated at 44N and 11E. The les; names and other personal data and clinical information registry covers an area of 3879 km2, with a population of 1 are stored on different les and, when necessary, are linked 162 273 inhabitants according to the 2001 census (density 300 each other by an identication number. Death certicates with personal identiers are received from inhabitants/km2). The territory is divided into 52 municipalities (the municipality of Fucecchio, 21 105 inhabitants at the 2001 the Regional Mortality Registry, which collects and analyses census, is included since 1997) collected in 3 local health units. for all inhabitants in the region a copy of the National Institute The only two municipalities with a population larger of Statistics mortality form. Mortality data are periodically than 100 000 in 2001 were Prato (population 172 499) and checked against the cancer registry records to identify cases not otherwise notied. Florence (population 356 118). Catholicism is the prevalent religion in the area. About 4.1% The current staff of the registry comprises clinical of the residents (at 2001) in the e p id em iolog i st s, nu r s e s area are foreign, mainly coming s p e c i a l i si ng i n t u m o u r from Europe and Asia. registration, biologist, statisticians ITALY, FLORENCE AND PRATO (1998-2002) I n 20 01, 74.1% of t he and data managers. ITALY, FLORENCE AND PRATO (1998-2002) residents aged 1564 years were employed. Industry in Interpreting the results the provinces is concentrated The completeness in case mainly in the surroundings of collection was estimated at 97.4%
 

 









the cities of Florence and Prato. during a formal evaluation carried 







Since 2006 the RTT has been out in 2001. Data are periodically 













embedded within the regional veried according to IARC tools 







oncological network, and the and specific software developed 














coverage of all the resident by the Italian Network of Cancer 







population of Tuscany (about 3 Registries (AIRTum). 





 








500 000 inhabitants) is ongoing. Since the late 1990s screening 







for female breast, cervix and 














Cancer care facilities colorectal cancer has been active in 







The registry is part of the all areas covered by the RTT. From 













Tuscany Cancer Institute, a the regional report on screening 







network of all health services activity, the average compliance active in the Tuscany region was 67% for mammographic       aimed at cancer research, breast cancer, 45% for cervix uteri ! ! 
 

prevention and care.  ! "!!!  screening and 51% for colorectal In 2002, in the whole 
   cancer screening. Tuscany region there were ##"%$!!!! !
!!
! In the district of Florence a  



 14 956 beds in public hospitals and 2353 beds in private cohort of more than 6800 males aged 6074 years were included 
!
!!! 
!! hospitals. There were 4.9 beds for every 1,000 inhabitants. during 19911994 in the European Randomized Study of Screening for Prostate Cancer (ERSPC). Moreover, widespread Registry structure and methods spontaneous PSA testing is worth noting; the regional archive The Tuscany Cancer Registry is associated with the Unit of Clinical of diagnostic examinations in 2004 estimated that about 25% of and Descriptive Epidemiology of the Centre for the Study and resident men over 50 had undergone a PSA test. In the RTT area a pilot study of lung cancer screening with Prevention of Cancer (CSPO) in Florence. The registry, which is commissioned and funded by the Tuscany Region Department of low-dose computed tomography has been performed, and a Health, collects, registers and analyses information related to cases of randomised clinical trial named Italung-CT is ongoing. cancer in residents of the provinces of Florence and Prato. The Registry started its activity on 1 January 1985 after a one-year experimental Use of the data The registry routinely publishes incidence and survival data phase to evaluate feasibility and to collect prevalent cases. While instituted by regional law, notication is and participates in clinical and analytical epidemiological studies. RTT is improving the collection of relevant clinical compulsory by an administrative order. The registry receives from the Regional Health Authority data for the evaluation of the diagnostic and clinical pattern. It copies of the ofcial les of hospital admissions in Italian public is participating in national and international projects on cancer or private hospitals (provided the latter are funded by the Public incidence, prevalence and survival (e.g. the Eurocare project). Health system), which have been abstracted from pre-coded electronic media since 1995. Copies of the autopsies and cyto- Source of population histology referrals are received from the pathology departments 19982002: Census 2001 and ofcial intercensal estimates of the whole Tuscany region. Since 1998 pathological data have (ISTAT). been received on computerised les. The RTT used ICD-O-1 and ICD-O-2; all case series have Multiple primary rules used now been automatically recoded into ICD-O-3. The information IACR rules (2004) on historical data.

319

Europe

Italy, Genoa Province

Registration area The Liguria Region Cancer Registry (LRCR) covers the population of Genoa Province (1834.3 km2) within the Liguria Region in northwestern Italy. The population (67 municipalities) at 30 June 2000 was 900 736 inhabitants (Statistical Ofce of the Region of Liguria). About 70% of the population lives in the urban area of Genova (632 366 inhabitants). In 2002 the Liguria Region age-adjusted death rate per 100 000 inhabitants was 1370.1, among the highest in Italy, due to the ageing of the population, the oldest in Italy; the birth rate is among the lowest, 7.3. Cancer care facilities Healthcare services are provided by hospitals and centres located predominantly in the city of Genoa. They consist of 17 public and 4 private hospitals providing radiotherapy, cancer surgery and chemotherapy services, and microscopic verications supplied by ve pathology services. Among the public hospitals there is also a comprehensive cancer centre, the National Cancer Research Institute (NCRI) as the mortality data, in addition to the LRDCR source, the registry also uses ofcial mortality data obtained through the regional organs ofcially connected with the National Statistics Service (ISTAT).

Registry structure and methods The LRCR is property of the Health Councillorship of the Liguria Region and is located at the Descriptive Epidemiology Service of NCRI, which is also houses 
   the Liguria Region Registry of #%%'&
# ##
# Cause of Death (LRDCR). The  



 LRCR is staffed by eight full
# # !## ## time researchers and one clerk: two are coders; two manage the electronic records provided by the Ligurian Health Informative System (hospital discharge records, registers of population) and the pathological records, and perform the quality control and statistical analyses; four are registrars; the clerk is mostly engaged in following the cancer cases for vital status. They are also supported by a full-time researcher and two clerks from the LRDCR, who select the certicates of causes of death of each registered case. The LRCR registry uses active case nding from various sources of data consisting of cancer hospitals (NCRI), general hospitals (13), teaching hospitals (St. Martino and University Clinics) and pathology laboratories. The registry staff visit these sources, where they scrutinise the records kept in medical records departments, and registers of individual departments concerned with diagnosis and treatment of cancers, to identify and abstract information on cases of cancer, diagnosed by all methods, among residents of the registry region. Arrangements have been made with the hospitals outside the registration area to collect the resident cancer cases they diagnose and treat; they are consulted once a year to ask for the clinical records of these cases. As regards

Interpreting the results The LRCR collects and records data on all malignant tumours and on in situ carcinomas and other tumours of benign and uncertain nature of the urinary tract, brain and central nervous system; multiple primary cancers (multiple skin cancers excluded) are included as independent primary tumours. The Registry uses the IARC/IACR CHECK Program to test the validation of dataset. To conform to the Italian law regarding the care of personal data, the Registry follows an Ethical Code of ITALY, GENOA PROVINCE (1998-2000) Behaviour (published in ITALY, GENOA PROVINCE (1998-2000) their Web site and sent to all collaborating institutions and to the National Authority for Individual Data Protection), 


 






 

created to describe the data 







collection and managing 














procedures and the physical 







and electronic measures 














adopted to protect the Cancer 

 





Registry data bank. 














A screening programme 






for breast cancer has been 














operating since 1998, 







organised by the NCRI on 














the behalf of the Region 







Health Councillorship and collaborating with all hospitals,       pathology departments and  #!  #! territorial health services of 


$#"%"###  the region. Use of the data The LRCR is involved in the planning and evaluation of health programmes in the Ligurian Region. It also collaborates with the Italian Association of Cancer Registries on joint research efforts and publication programmes devoted to describe cancer incidence, mortality, and prevalence and survival data. With the same purposes, it actively contributes to many European projects (e.g. EUROCARE, EUROPREVAL, etc) aimed at analysing data on incidence, mortality, survival and prevalence (or their determinants) in Italy and in Europe. In these latter projects, the LRCR is interested in some specic research elds: the socio-economic determinants of cancer survival, cancer in the elderly, and the equity in care resources allocation. Recently, LRCR work has aimed at producing regional and national estimates of survival in the European population by using the demographic, socio-economic and clinical (Health System organisation) characteristics of each area. Source of population 19932000: ISTAT for the Province Multiple primary rules used IACR rules (2004) on historical data

320

Europe

Italy, Macerata Province

laboratories, radiotherapy centres, the Italian cancer registry Registration area The Macerata province registry covers the population of and the death certicates from Mortality Registry of the whole province (57 municipalities) ranging from a Macerata Province. This mortality registry receives copies mountainous zone in the west to the Adriatic Sea on the east of death certicates for all inhabitants from LHUs and a list of all deaths from the municipalities. The registry staff visit within the Marches Region, in central Italy. The population at the recent cancer registry census (2000) these sources and record diagnosis and treatments for every was 304 443. Around 32% of the municipalities are located resident patient in the province. Cancer is not a notiable in the mountainous areas and have a low population density disease; registration forms are not received from private with a high proportion of people engaged in services. The practitioners. The information concerning each tumour, 5% of municipalities situated in the coastal areas bordering including personal identication and full clinical details, is the Adriatic Sea have a high number of people engaged coded and entered using the CanReg 4 computer program. The accuracy of age, residential status and other in the industrial sector, and few in agriculture. Some 63% are located in the hill zone and can be characterised as demographic data are veried before records are included. The registry collects data not only intermediate between the on cancer incidence but also on other two zones. diagnostic procedures, cancer Practically 100% of the ITALY, MACERATA PROVINCE (1998-2000) characteristics (including population covered by the ITALY, MACERATA PROVINCE (1998-2000) stage and grade), treatment registry is white, with a small and survival. Follow-up is percentage of immigrants performed to obtain complete from China, India, Pakistan registration information and and Africa. The predominant "*+#(*** ,') '*,#"*** "*-(%*** , %*,-+*** documentation on all cases. religion is Catholic, but (*%"*** +' ,*'(%*** there are now also Muslim +*,++*** + -*(##*** ,*''+*** (' -*+'*** Interpreting the results minorities. -*'%#*** ( !*#!"*** Screening for breast and ,*#"-*** '' ,*,("*** -*%!"*** ' -*'(+*** cervical cancer has been Cancer care facilities !*!""*** %' -*,!(*** implemented in the province General health care in !*'-*** % !*"'+*** !!*(+!*** #' !!*+!*** by the Sanitary Service, the province is provided !!*-#(*** # !!*!(*** but the magnitude of these predominantly by the three !*-%*** "' !*'+(*** -*"+*** " ,*,'"*** practices is as yet unknown. Local Health Districts +*%'-*** !' +*#%"*** PSA is used frequently, but it (LHUs), through the district (*-"%*** ! (*+"(*** (*+"+*** ' (*#,!*** is not possible to determine hospitals, a network of (*"-+***  '*-##*** the proportion of the male primary health centres and adult population screened. two pathology laboratories. ! '   ' ! 
*$ & 

*$ & This is supplemented by !''*%,%*** !%+*#!(***  Use of the data private practitioners and Information on incidence, regional oncology hospitals. 
   prevalence, survival and Each province in the region !--!**"*

*
*
 *

*
*
*  **#!*


**

*
 * *
* 
*  



 
* 
*$"%&** ** provides one radiotherapy centre. Many patients suspected mortality are produced and used in the LHUs and in the to have cancer in the primary and secondary care facilities Regional Health Agency for service planning and needs in the registry area are referred to Ancona regional hospital assessment. The data are also sent to the Italian Cancer (4090km distant), to Perugia regional hospital (80130km, Registries databank. The registry collaborates with some Umbria Region) or, occasionally to one of the cancer hospitals other registries in research projects and publications. Registry data are used to monitor cancer incidence and mortality in northern Italy (e.g. Milano, Aviano). in the province, as well as for health service planning and epidemiological research. Registry structure and methods The registry (cancer and mortality) is located within the Department of Experimental Medicine and Public Health of Source of population Camerino University, and is funded partly by the Regional 1991 and 2000 censuses. Cancer registry personnel census Health Agency. The registry is staffed by two epidemiologists the population as of 31 December of every year through the and a registrar full-time; a doctor, a medical oncologist and Municipalities. a pathologist as consultants. The Macerata Cancer registry uses active case nding from different sources of data Multiple primary rules used consisting of public and private general hospitals, pathology IACR rules (2004) on historical data.

321

Europe

Italy, Milan
Registration area The Milano Cancer Registry refers to the resident population of Milano, the largest metropolitan town in northern Italy (Lat. 45 27 N; Long. 9 10 E), covering a total area of 182 km2. The population at the last 2001 census was 1 263 158 inhabitants with a population density of 6940/Km2. At the last census 87 590 subjects (6.7%; 42 146 males and 45 444 females) were immigrants originating from Asia (30 116), Africa (19 481), South America (17 873) and Europe (19 950). Overall the automated procedure identied 165 614 prevalent cancer cases, 66 485 in situ/benign neoplasm; accepted 24 841 invasive cancer cases and temporarily rejected 24 695 cases. After manually resolving rejected cases, 39 404 incident cases were identied. Manually resolved cases, as well as all automatically detected genitourinary, haematological and soft tissue neoplasms, were coded with ICD-10 for topography and with ICD-O-3 for morphology. For selected cancers (including breast cancer) stage was systematically recorded.

Cancer care facilities A single Local Health Authority serves the population Interpreting the results area. In the registration area there are 29 hospitals, which Population-based breast cancer screening was initiated in Milano in November 1999. allow full access to case Furthermore, opportunistic information. Among them, PSA screening for prostate two research hospitals ITALY, MILAN (1999-2002) cancer was extensively (National Cancer Institute of ITALY, MILAN (1999-2002) adopted in the same period: Milan and European Institute 26.9% of male population aged for Oncology) admit only 40 or older with no history of oncological cases. A very prostate cancer have received small proportion of cancer 


 









at least one PSA test in 2 years; cases are treated outside the 






the same rate rises to 34% for Lombardy region. 














subjects older than 50 (J Med 







Screen. 2002;9(4):179-80). Registry structure and 














methods 






Use of the data The cancer registry is located 














The Milano Cancer Registry in the Epidemiology Unit of 







will be used to evaluate breast the Local Health Authority 














and colorectal cancer screening of Milano; it was established 







programmes. Furthermore, in May 2002 in adherence to 














policymakers use registry data the Regional Health Plan and 







to evaluate healthcare and funded by the Lombardy Region cancer treatment policies and Department of Health. The       to plan prevention activities. registry employs three medical -($*  -($* Considering the high epidemiologists and four nurses  


,%&-'#,-- proportion of immigrants, as cancer registrars. 

   -!---&##%-"----!"--- ---!--- --registry data will be also The registry is based on
-
 ---(- --- ----.-
*the automated cancer registration procedure (ACR) rst used to study differential cancer risks within the resident  



 

--(&##)*--
+--adopted in Italy by the Venetian Tumour Registry and by the population and to plan differential preventive actions. The registry supports etiological research. Cases are North East Cancer Surveillance Network. Accordingly, the resident population roster, death certicates, hospital/day- followed annually to determine survival, taking advantage of hospital discharges and pathology records archives are fed a consolidated record linkage between the registry database and the Municipal Census Ofce. into the information system of the cancer registry. The underlying cause of death and hospital admission diagnoses are coded in ICD-9. Pathology records are coded Source of population in SNOMED, and ad hoc transcoding algorithms from Annual estimates based on the 2001 census, taking into SNOMED to ICD-9 were developed and implemented. A account births, deaths and migration, were produced by the total of 524 722 hospital/day-hospital discharges (1990 Ufcio Sistemi Statistici del Comune di Milano (Municipal 2003), 289 980 pathology records (19762003) and 18 295 Ofce of the National Institute of Statistics ISTAT). death certicates (19992002), corresponding to 281 635 subjects, were considered in estimating the population Multiple primary rules used IACR rules (2004) on CI5 IX period. incidence of cancer in the period 19992002.

322

Europe

Italy, Modena Province

Registration area The Modena Cancer Registry (MCR) covers the population of the province of Modena, which is one of the nine provinces of the Emilia-Romagna region in northern Italy. Modena borders the provinces of Bologna to the east, Lucca and Pistoia to the south, Reggio Emilia to the west and Mantua and Ferrara to the north. The population according to the 2001 census was about 634 000 (growing by about 1% every year). Approximately 7% of all residents had emigrated from other countries (34% from northern Africa, 19% from Asia, 18% from Eastern Europe, 14% from the European Union and 11% from West Africa). The province is divided into 47 municipalities. The only municipality with a population greater than 100 000 is Modena (about 175 000 inhabitants in 2001). Cancer care facilities With respect to health services, the province of Modena shows the features typical of most western countries. The area is served by 9 public general hospitals, including one university teaching hospital, and by 5 private clinics. The university hospital also includes a Comprehensive Cancer Centre (Centro Oncologico Modenese). The registry mostly carries out follow-up by matching registrations with notications of death and with public health databases. Only non-matched patients (less than 1%) are actively followed-up by obtaining information directly from the registry ofces. All data are evaluated for completeness using IARC software and a tool developed by Modena Cancer Registry and distributed among Italian Cancer Registries that consists of more than one thousand internal checks.

Registry structure and 












 

Use of the data methods 







The MCR produces annual The MCR, established in reports on cancer incidence, 1988, is located in the Cancer       mortality and survival, Centre of the University of  !   ! including trends and Modena and Reggio Emilia. 


"!#""!!!  predictions of cancer incidence It is recognised and supported 

   and survival for the coming by the Emilia-Romagna    !!!!  !
!##"$!!!
!  



 region, the Azienda USL of Modena and the Angela Serra years. The MCR is involved in many collaborative studies, 
! !!! !! ! such as EUROCARE studies. The registry also participates Association for Research on Cancer. Registry staff comprises a medical director and in the evaluation of breast, cervix and the recently organised coordinator, a research manager, a statistician, a system colorectal screening programmes. Other areas of interest are: the investigation of local clustering of disease, estimations of manager, two registrars and a secretary. The principal data sources are the reports from the three future cancer incidence and survival, high-resolution studies pathology laboratories located in Modena (including one on lymphoma and myeloma, and quality control techniques. haematological laboratory), hospital discharge les and death certicates. These les are periodically sent to the registry Source of population and processed by specic software. All cases are identied Census 2001 and population estimates for 19982000 and and pre-coded by the computer system, and then the trained 2002 (ISTAT). registry staff manually reviews them. Several validation checks are performed by the computer system at the time of Multiple primary rules used IACR rules (2004) on CI5 IX period. data entry, and periodically over the whole archive.

Interpreting the results Since 1994, two organised screening programmes have been offered to all women aged 2464 and 5069 respectively for early detection of cervical and breast cancer. The impact of cervical screening seems to ITALY, MODENA PROVINCE (1998-2002) be less marked because it was ITALY, MODENA PROVINCE (1998-2002) carried out many years earlier, but not on population basis. It should be underlined that the increasing use of 


 









PSA testing has resulted 







in an increase in prostate 













cancer incidence rates, while 







the advances in diagnostic 














medical practices and new 







histological criteria seems to 














be related to an increasing 






incidence of thyroid cancer in 





 








the province of Modena. 





 

323

Europe

Italy, Naples
Registration area Registry structure and methods The Population Cancer Registry of Campania Region c/o The Registry is a structure of Campania Region and A.S.L. Local Health Unit Napoli 4 (R.T.P.-A.S.L. NA4) covers an NA4; The Registry personnel is composed of a physician, area of 499 km2 in the northeast part of the province of specialising in oncology and epidemiology, one informatics Naples, in the Campania region of southern Italy (latitude technician and four social workers. Data collection method 40 47 N; longitude 14 23). According to the national is active, and the sources of information are: census of 31 October 2001, the population covered by the Case sheets, clinical records and pathology laboratories data, Registry is 537 860 inhabitants (264 472 males and 273 388 supplied by: a) National Cancer Institute of Naples, b) the two females) distributed in 35 towns. In the last ten years the area University General Hospitals, c) the Campania Region hospitals; covered by the Registry has been characterised by signicant d) the biggest private hospitals in the region; migration from Naples, which is the largest and most important Regional Centre of Hospital Discharging Forms (SDO), city in the region. In fact, between the national census years which also provides data referring to patients who are admitted of 1991 and 2001 the population of the area covered by the in other Italian regions; A.S.L . NA4 regist r ies Registry increased by 45 000 referring to patients who are inhabitants. In the area, which exempted from bearing health is economically depressed ITALY, NAPLES (1998-2002) participation expenses because and characterised by high ITALY, NAPLES (1998-2002) of oncological diseases; unemployment, there are a A.S.L. NA4 records referring vast rural zone, an industrial to admissions abroad; pole with large and middle General practitioners of the sized factories, and also small


 









area covered by the Registry sized disorderly distributed 







(about 480) consulted for DCN factories. 











cases; and 






Mortality data coded by the Cancer care facilities 














ASL NA4 epidemiology ofce. In the area covered by the 







Registry there are two public 














Registry personnel have general hospitals with two 







access to both the ofcial chemotherapy services, one 














mortality statistics and to pathology laboratory and one 







individual death certicates private radiotherapy service 














mentioning cancer. Incidence having an agreement with 







cases are coded by Registry the Public Health Service. personnel. Malignant tumours The majority of resident       included in incidence gures patients who are affected by  !   ! 


 ! !!!  are dened as those for which oncological diseases (about the ICD-O-3 behaviour code is 80%) seek care in Naples, 
   3, and according to the IARCabout 10km away, at the    !  !!
!##"$!
!!   !
!!!   !  !
!!
!  



 National Cancer Institute, at the two University Faculties of IACR rules. Mortality data are coded and provided by the 
! !! Medicine and at the oncology departments of other hospitals A.S.L. NA4 epidemiology service; they are dened as those in the city. Though it is decreasing, there is still migration coded in sections 140208 of ICD-9. The software used for from the area to health services located in Northern Italy for the registration of incidence data is CANREG-4, which is the treatment of oncological diseases. In the same area, and provided by IARC. The Registry prepares periodical reports of cancer over the whole Campania Region, there are also many private hospitals having an agreement with Public Health Service, in incidence, mortality and survival; moreover, it collaborates which patients affected by cancer are admitted. All patients with public health services in the planning and evaluation of affected by oncological diseases are exempted from bearing cancer services. health participation expenses, and all patients who are admitted to hospitals abroad are previously authorised and Source of population Intercensal estimate for 19972000 (ISTAT), national registered by the A.S.L. NA4 ofces. Since April 1996, screening for uterine cervix carcinoma census for 2001 and postcensal estimates for 2002 (ISTAT). has been active over the entire Registry area, while breast cancer screening has been active since November 1998 over Multiple primary rules used IACR rules (2000). a limited part of the area covered by the Registry.

324

Europe

Italy, North East Cancer Surveillance Network

registration (ACR) methodology, which implies availability of Registration area The area covered by the North East Cancer Surveillance Network computerised and coded (ICD and SNOMED) diagnoses of (NEICSAN) is located in northeast Italy, and is made up of three cancer from the pathology departments, hospital archives and parts: the provinces of Bolzano (4603N, 1314E; 7400 km2; population ofces (for population les and death certicates). 485 042 inhabitants; 65.5 inhabitants/km2) and Trento (4604N, The process is carried out through record linkage procedures 1108E; 6202 km2; 499 321 inhabitants; 80.5 inhabitants/km2), and that include analyses of computerised records, ascertainment the whole of the Friuli Venezia Giulia region (4603N, 1314E; of prevalent cases, case consolidation and quality control. Traditional cancer registration techniques based on collection 6845 km2; 1 184 000 inhabitants; 173.0 inhabitants/km2). The provinces of Trento and Bolzano are mostly mountainous of cancer forms prepared by pathologists, medical personnel areas, while the Friuli Venezia Giulia is a largely industrialised in the hospitals and general practitioners are still used in the region bordered by the Adriatic Sea and the Padanian Valley Province of Bolzano, where the ACR process has been carried (South), Slovenia (East) and Austria (East, North-East). out in parallel to the existing system. Approximately 50% of the population of Trento and Bolzano For the period 19982002, a total of 9 461 762 records were treated by the automated and 80% of population of Friuli Venezia Giulia lives in urban process. Approximately 20% of areas (largest cities are Trento these records concerned cancer ITALY, NORTH EAST CANCER with 112 142 inhabitants, Bolzano cases, and the automated process ITALY, NORTH EAST CANCER SURVEILLANCE NETWORK (1998-2002) SURVEILLANCE NETWORK (1998-2002) with 98 657 and Trieste with registered nearly two thirds of incident cases. Quality controls 242 235). In addition to industry are based on the IARC Check in the Friuli Venezia Giulia software: quality indicators region, agriculture and tourism #',#)-,,, .)+ '!,$$/,,, #',.)#,,, .! %!,#*$,,, such as the percentage of represent the main economical %%,!-.,,, -) )*,$-#,,, microscopically veried cases activities of the whole area, '%,-#',,, -! *!,$/-,,, )!,-'*,,, *) *!,'-',,, (histology and cytology), the with low unemployment rates *#,$*',,, *! *),.#.,,, by Italian standards (between percentage of cases known from *.,'%!,,, )) -!,$$',,, -#,/.#,,, )! -#,//),,, 2.7% and 6%). In the Bolzano the death certicate only (DCO) -!,!%-,,, ') */,$/.,,, province, 68% of the population and the mortality/incidence ratio -',*-*,,, '! -#,/'/,,, .*,**%,,, %) .$,))),,, is German-speaking. are also veried.
/!,#*#,,, .$,##.,,, *%,%)!,,, %! $) $! .*,!#*,,, -.,%.-,,, *!,$..,,, Cancer care facilities Interpreting the results )!,-!),,, #) '-,.).,,, The territory is divided into 11 Several analytical studies '*,*.!,,, #! '',*!#,,, '-,./',,, ) '),-/-,,, local health units of variable conducted in the Friuli Venezia '/,#-/,,, ! '*,*'!,,, size, being smaller in the Giulia region have shown cancer mountainous area. Hospital excesses associated with personal #! ) ! ! ) #! services are provided by 35 habits and occupational exposures ,&"( ,&"( public hospitals (including one (namely exposure to asbestos #,!..,.*!,,, #,!#/,*.%,,,  National Cancer Institute in in the shipbuilding industry). 
   Aviano, Friuli Venezia Giulia)
,,,,,,#//#,,$!!#,,,,, ,,, ,
,,,,, Incidence rates for the period ,&,,,,0,
(, and 16 private clinics. Cancer patients are generally treated 19982002 well reect these previous ndings. Changes in smoking  



 
, ,&$!!'(,, ,, at the National Cancer Institute, and in the oncology and habits in recent decades are a likely explanation for diverging trends radiotherapy departments uniformly distributed throughout in lung cancer rates seen in the two sexes, with a decline observed the territory. A small proportion of cancer patients are also in men (from 56.3 in 19951997 to 49.1 in the most recent period) treated outside the region, including Innsbruck (Austria) for and a slight increase in women (from 11.3 to 12.0). PSA testing has some patients from the province of Bolzano. been widely used in men for voluntary testing. Accordingly, prostate cancer turned out to be by far the most frequently diagnosed cancer Registry structure and methods in men (69.3/100.000; it was 51.6 in 19951997). The NEICSAN is a collaborative network of cancer registration in three administrative units: Azienda Sanitaria Use of the data di Bolzano, Registro tumori dellAlto Adige-Tumorregister The main task of the NEICSAN is to help plan careful Sud Tirol (1 director, 1 pathologist, 1 statistician/IT manager, surveillance and preventive programmes. In addition, 1 data collection ofcer and 5 collaborators); Agenzia the registry data are used to implement population-based Regionale della Sanit, Udine, Friuli Venezia Giulia (1 intervention studies (e.g. Pap smear and cervical cancer) director, 1 pathologist, 1 data manager, 2 statisticians, 2 data and investigations on the causes of cancer (e.g. alcohol collection ofcers and 5 collaborators); Azienda Provinciale consumption and risk of liver cancer). per i Servizi Sanitari, Osservatorio Epidemiologico, Trento (1 director, 1 pathologist, 2 statistician/it manager, 1 data Source of population collection ofcer). In the Friuli Venezia Giulia region, cancer Annual estimates based on the 1991 and 2001 censuses, taking registration began in 1984 in the province of Trieste, and it into account births, deaths and migration, produced by the Ufcio has been expanded to the whole region since 1995. Sistemi Statistici (National Institute of Statistics, ISTAT). The objective was to produce comparable cancer incidence estimates in a large population (about 2 150 000 inhabitants). Multiple primary rules used Incidence data have been collected using the automated cancer IACR rules (2004) on historical data.

325

Europe

Italy, Parma Province

director, or consulting the patients family doctor by written Registration area On 1 January 1998 the population of the registry area was request. Patient vital status is easily updatable, since PCR 393 963; ve years later it was 404 722. This increasing trend has access to the computerised registry database of the Local is mainly related to foreign immigration; overall foreigners, Health Service. Data are regularly submitted to IARC Check program. most from North Africa, currently represent 5% of Parma residents. About 80% of the population lives in urban Complementary evaluations have been made to compare areas, 43% in the principal town. Local migration from the our data (incidence trends and crude rates, percentage of mountainous municipalities towards the city has been steady MV/Dco, relative and observed survival rates) with those of since the 1970s. In 2001 the employment rate was 74% for men neighbouring registries, and to examine the main features and 55% for women, while unemployment was respectively of special sub-areas of Parma Province (urban/rural area, 2% and 4%. The main occupational group is tertiary (59.4% altimetric zone, health service districts, etc.). of the total employed population), followed by industry (37.4) and agriculture (3.2%). The industrial sector employs Interpreting the results Two screening services began workers primarily in the agroto operate in the area of alimentary branch (45%), registration: the population followed by manufacturing ITALY, PARMA PROVINCE (1998-2002) aged 5069 has been screened (15%) and building (15%). ITALY, PARMA PROVINCE (1998-2002) for breast cancer since 1997 and the population aged 24 Cancer care facilities 67 for cervical cancer since The area is served by one main 1998. Some recent, increasing general university hospital, two !(&%+((( *%' +(! #((( #(! ((( * )(%%#((( trends of incidencebreast small public hospitals and three )(+* ((( )%  (!%!((( and prostate cancerreect private ones; the hospital of Parma +(+#((( )  (**&((( (**((( &%  ())&((( the diffusion of early diagnosis houses a division of Medical  (&+&((( & !(&! ((( due to voluntary screening Oncology, including a section for  (# &((( %%  ()+((( !( ))((( % !(# *((( and asymptomatic forms cytopathological diagnosis, and a  ()+((( #%  (& *((( through PSA testing. Trends in radiotherapy Service. #(##!((( # !(&!((( &(+)+((( !% %(%&!((( melanoma can be interpreted )( +((( ! &(&+((( as being related to previous Registry structure and #(*+((( % #(!!!((( (%*+(((  (*((( underestimation. M/I ratio methods *(!((( % )(%!#((( offers an encouraging sign The PCR is located at the )(%+)(((  )(  ((( )(&)((( % )( &((( of the level of completeness Medical Oncology Division )(+))(((  )(#%((( obtained for each site. PCR of the local hospital; continues to integrate and the staff is made up of a  %   %  correct data previously medical doctor as Director, a  ("$   ("$ collected. statistician as data manager, &( !)((( +!(*+(((  and a full-time biologist
 ("
(, $( Use of the data for collecting and decoding 
    



 data. Information regarding new cases is obtained through Study data are aimed on one hand to promote the comparison 
( (" #$(( (( examination of discharge forms from public and private of data and collaborative studies with other Cancer Registries, hospitals (representing the rst level of information for each and on the other to support Health Services programming by case, independent from the hospital where each patient was estimating and quantifying the cancer burden. treated), oncological outpatient clinics, day hospitals, death certicates, and from the two archives of pathology services. Source of population The staff has direct access to the public pathology archive; the Estimates (ISTAT http://www.istat.it). private hospitals annually provide the registry with electronic data. For extra-provincial hospital discharges, diagnoses Multiple primary rules used are detected through an ofcial inquiry to the departments IACR rules (2004) on historical data.

326

Europe

Italy, Ragusa Province

Registration area The Ragusa Cancer Registry (RCR) covers the population of the province of Ragusa in southeast Sicily (Italy). At the 2001 census the population was 295 264 (5650 of whom were migrants, mainly from North Africa) living in small to medium-sized municipalities: the largest is Ragusa city, with 68 000 inhabitants; 9 cities consist of 8000 to 50 000 inhabitants, and in two villages the population accounts for 3000 people. Almost all people are white and Catholic; about 20% of the working population is involved in agricultural occupations (mainly farming and cattle). with the Sicilian computerised hospital discharge recording system; the latter is an independent source of data that includes all hospital discharges of all of the patients resident in Ragusa province who were admitted in any Italian hospital.

Interpreting the results Cancer occurrence in Ragusa province has been slightly increasing in the last ten years, but this area is still at a lower cancer risk in comparison to other registries from western countries. This is mainly attributable to Mediterranean dietary habits and to a lesser extent to the un-polluted environment. Despite this low risk, the 5-year relative survival ranks among Cancer care facilities the lowest in comparison The local health system is to North European cancer arranged in one Main Hospital registries; this low survival (Azienda Ospedaliera Civile ITALY, RAGUSA PROVINCE (1998-2002) seems to be related to an M.P.Arezzo, Ragusa), one ITALY, RAGUSA PROVINCE (1998-2002) advanced stage of the tumour Local Health Authority (AUSL at diagnosis. 7) that includes one private and The main change in 4 small public hospitals, and the period 19982002 that 350 general practitioners. There 


 









may have affected cancer are two histopathological units, 







registration was the settlement one oncological department and 





 








of the radiotherapy unit and one radiotherapy unit; all of the 







public CT facilities: this has public radiological departments 














made it possible to retrieve have CT facilities, and the main 







core cancer data like anatomic public hospital provides MRI














site, histological reports and exams. All of the 7 surgical 







stage at a more detailed level. units of the local hospitals 














PSA testing has become provide cancer surgery. A

 





more common since 2000, and district-based breast cancer











prostate needle-biopsies have screening programme was 







been increasing from year established in 1995, covering 2001 according to the data of half of the provinces female       the local surgical pathological population aged 5069 years.  # "   # " laboratories; these practices 


!!#$###  may have slightly affected Registry structure and 
       #  ###  #
#   # 
"#
#%%&#   #
##    #  ###  #
#   # the local prostate cancer methods
## RCR is part of the Oncological department of the main occurrence in the period 19982002.  



 
# # !"## ## hospital (Azienda Ospedaliera Civile M.P.Arezzo, Ragusa). It is funded by the hospital itself and the Sicilian Use of the data Government. The staff consists of a half-time medical doctor Data are sent to the Italian Association of Cancer Registry, pathologist (director), two full-time social workers, and 12 which publishes periodical national reports including specic part-time collaborators. Cancer registration is essentially an tables of RCR. RCR is a collaborating centre for the European active process by means of eld workers who abstract the Prospective Investigation into Cancer and Nutrition (the required information from hospital admission/discharge les EPIC study), and a partner and member of the EUROCARE and clinical notes; case nding is also performed at pathology and EUROCHIP studies and the EU-funded research EPIClaboratories, radiotherapy units, oncological outpatient ELDERLY, the EU integrated project INTERACT and EUclinics and the local private TC centre (CITC srl Ragusa); coordinated action HECTOR. RCR data have been used for a notable source of cases are the administrative ofces evaluation of the local breast cancer screening programme that deal with cancer patients needs (i.e. exemption from (the Italian IMPACT study). cancer care and diagnostic charges). The local vital statistics and death registration ofces provide RCR with all death Source of population certicates where cancer is mentioned. Municipal registers Intercensus estimate by Italian Institute of statistics (ISTAT) are involved for validation of the identity and residential data for 19922000, census for 2001, intercensus estimate by Italian Institute of Statistics for 2002. of each registered case, and checking vital status. Ragusa Cancer Registry is carrying on a linkage study in order to evaluate the completeness of registration by Multiple primary rules used comparing the records already detected from clinical notes IACR rules (2004) on historical data.

327

Europe

Italy, Reggio Emilia Province

The staff is composed of an oncologist as director, Registration area The Reggio Emilia Cancer Registry (RECR) covers the three biologists as data collectors, one statistician and one population of Reggio Emilia Province in the centre of the healthcare planning administrator. The purpose of the registry, since its founding in Emilia-Romagna Region, in north Italy. Reggio Emilia is characterised by an interesting and varied landscape that 2001, has been to collect cancer incidence and survival ranges from the vast plain in the North, where the main for the target population, to promote ad hoc studies and Italian river (Po) ows, to the Apennine Mountains in the to collaborate with studies organised by other institutions. These activities contribute both to producing scientic South, which reach a height of 2150 meters. The territory is divided into 45 municipalities, the reports and publication and to improving cancer prevention principal one being Reggio Emilia, which accounts for more and control in the province of Reggio Emilia. than 142 000 inhabitants. The main sources of information are: the files of the two The total population at the end of 2003 was 477 534; pathology services, hospital discharge records and death certicates. foreign residents represented 6.4%. The most common Site-specific cancer registry information (i.e. mesothelioma, foreign groups came from melanoma, breast and cervix) is North Africa, Eastern Europe also used to improve the accuracy and Central-South Asia. of RECR data. EMILIA PROVINCE (1998-2002) Reggio Emilia is a ITALY, REGGIO At the end of each incidence ITALY, REGGIO EMILIA PROVINCE (1998-2002) highly industrialised area: year, data are checked using the principal industries are IARCcrgTools. Other checks mechanical and ceramics are also performed to evaluate production, although data completeness and validity 


 
 








agriculture is also present. (mortality incidence ratio, the 





 

Until the late 1980s, some proportions of DCO, cases with 














of the most important Italian morphological conrmation, 







asbestos cement factories were and unknown cases). When data 














in this province, although the have been processed, incidence 







number of workers employed trends are analysed. 














there was limited. 







Interpreting the results 














Cancer care facilities Population-based breast and 







Public healthcare is provided cervical cancer screening














by the territorial-based programmes might inuence the 







Azienda USL and the incidence rates. It should also be Arcispedale Santa Maria underlined that increasing use of       #! #! Nuova (ASMN) hospital. The PSA testing most likely caused 


#$###  Azienda USL is divided into an articial rise in the incidence 6 healthcare districts, each 
   of prostate cancer. with its own hospital. The ###

## #%%$&#######'#
!#  



 
# # !## "##
 # oncology and ASMN includes several healthcare facilities: Use of the data radiotherapy departments (both since the 1970s), digestive The registry publishes data periodically on incidence, endoscopy, dermatology and pathology departments. In each mortality and survival. The RECR is involved in several inhealthcare district there is a medical oncology unit. house and collaborative studies. These cover many elds: At present, there are three working screening programmes from epidemiological studies to clinical research, public in the province of Reggio Emilia: for breast and cervix health surveillance and social inequality studies. cancers (since 1994) and for colorectal cancer (since 2005). Source of population Registry structure and methods Census 2001 and population estimates for 19982000 and The RECR is recognised and nanced by the Emilia- 2002 (National Institute of Statistics, ISTAT). Romagna Region. The registry is physically located at the Unit of Multiple primary rules used Epidemiology of the Department of Public Health. IACR rules (2004) on CI5 IX period.

328

Europe

Italy, Romagna Region

Registry structure and methods Registration area The area covered by the Romagna Cancer Registry is part of The Romagna Cancer Registry was funded by the Istituto the Emilia-Romagna region situated in the northeast of Italy. Oncologico Romagnolo until 1995, and has been supported The Romagna region extends from the Adriatic Sea in the by the Government of the Emilia-Romagna Region since east to the borders of the provinces of Bologna in the west, 1995. The major information sources for the Romagna Ferrara in the north, Florence and Pesaro in the south. The Cancer Registry are the archives of histology and cytology population is fairly stable. Among residents, the prevalence of reports, hospital discharge forms, outpatient records of non-Caucasians as well as of foreigners is low. The Romagna the medical oncology departments, the archives of private region amounts to 4769 km. The south of the region (48% clinics, and death certicates obtained from the departments of the total surface) is hilly and sparsely populated. The area of public health of local health care districts. The registry is is subdivided into three provinces (Ravenna, Forl-Cesena staffed by an epidemiologist, two statisticians, and 12 data and Rimini) with a total of 68 municipalities. The population managers. density is 158/km in the Province of Forl-Cesena, 199/ Interpreting the results km in the Province of Between 1996 and 1997, Ravenna and 544/km in population-based screening the Province of Rimini. The ITALY, ROMAGNA REGION (1998-2002) programmes for breast cancer area is socioeconomically ITALY, ROMAGNA REGION (1998-2002) and cervical cancer were homogeneous. The proportion progressively implemented in of adults employed is 59.9 each of the four health care 60.5% for men and 40.542.9% districts of Romagna. In 2005, for women. The industrial and $" """ $! %" """ %" %""" $ "% """ a screening programme for agricultural sectors employ %"$""" #  "%""" colorectal cancer was also 29.6% and 7.5% of the active "$""" # %"""" #" $ """  "#""" launched. population, respectively.
"$#""" %"%%"""  "##""" "  """ "%"""  " """ Use of the data Cancer care facilities "%$"""  "%""" Incidence data from the The Romagna region has "$%"""  "%#""" "%%"""  $"%""" Romagna Cancer Registry are 13 public (National Health "%"""  %"%""" published through the IARC, Service) hospitals and 15 #""""   """" #"$"""   """" the Health Department of certied private hospitals. "%%"""  %"%%""" the Emilia-Romagna Region, The total number of hospital %"$"""  $"#""" %""""  $"##""" and the Italian Association of beds is 5163 (or 5.2 per 1000 """"  $"$#""" Cancer Registry (AIRTum). residents) with 221 821 annual The registry participates discharges. The number of       in many research projects general practitioners is 836  "   "  "$""" #$" """  coordinated by the AIRTum. (0.84 per 1000 adult residents). The active contribution of the Cancer care facilities in the registry to local cancer control area include medical oncology 
  


 
 "
 """""
" departments and centres for early detection of cancer at the strategies includes situation analyses (studies of the patterns hospitals of Ravenna, Forl, Faenza, Lugo, Cesena, Rimini of stage, diagnosis and treatment of major malignancies) as and Riccione. The hospital-based oncology departments in well as cervical and breast cancer screening monitoring. the three provinces of Romagna (Forl-Cesena, Ravenna The registry database has been used for several cohort and and Rimini), offering a total of 168 beds (87 inpatient and casecontrol studies. Most of these have addressed the 81 outpatient), have long been working towards a greater relationship between diet and digestive tumours, diet and understanding of all aspects of the cancer problem, with the breast cancer, pesticides and haematopoietic malignancies. nal aim of improving the quality of health care and patient Others have evaluated the risk of breast cancer for women management. The Cancer Institute of Romagna (Istituto bearing breast cysts and the risk of colorectal cancer for Scientico Romagnolo per lo Studio e la Cura dei Tumori subjects undergoing polypectomy. The registry participates [IRST]) has recently been established to further enhance in the planning, conduct and analysis of numerous studies the already high-quality health care for cancer patients of aimed at validation of diagnostic techniques and evaluation the region and to become a cancer centre of excellence for of health services. central Italy. Part of the institutes mission is to take in hand the fundamental research programmes and activities that the Multiple primary rules used IACR rules (2004) on CI5 IX period. public health sector cannot cope with. 

329

Europe

Italy, Salerno Province

Registration area The Salerno Cancer Registry (SCR) covers the population of the whole Province of Salerno. It is the largest province in the Campania Region, consisting of 158 municipalities. The province of Salerno extends from the Tyrrhenian Sea in the west, to the borders of the provinces of Napoli and Avellino in the north and Potenza in the southeast. The vast area of Salerno has a varied territory, divided into inland hills (that cover 45% of its total area), mountains (29%) and coastal hills (15%), while only 11% is covered by plains. Salerno is characterised by a densely populated urban area with a number of industrial activities in the north and by a wide rural area in the south. Coastal settlements and mountain villages are found in the west and in the east respectively. completeness of the data, the staff of SCR actively collects hospital discharges and pathology les from these hospitals. A huge population data le allows us to prevent double registrations. Follow-up status is periodically updated, and this procedure consists of annual linkage with the mortality registry and by active research for vital status in the registry ofces.

Registry structure and methods The registry is supported Use of the data by the local administration 


 









Reports on incidence, (Provincia di Salerno) and is 







mortality and survival are staffed by a Director, a data 














periodically provided by the collection coordinator, an 







Salerno Cancer Registry to IT manager, two full-time 








 





general practitioners, public registrars and ve part-time 







health professionals and workers. 














epidemiologists. Specic Almost all sources of 







and collaborative studies on information (pathology 














survival, dietary and other reports, hospital discharge 







risk factors are in progress. forms and death certicates) 














come from electronic media, 







Source of population but they are processed by Census 2001 and population registry personnel without       estimates for 19982000 any automated coding. $ " $ " (Istituto Nazionale di Statistica Compared with the cancer 


#$#!%$$$  ISTAT). registries of northern Italy, a 

   higher proportion of patients $$$

$$ $&&%'$$ $$$$'$
"$ are likely to be diagnosed and 



 treated in hospitals located Multiple primary rules used 
$ $ !"$$ $$ outside the province of Salerno. In order to assure the IACR rules (2004) on historical data.

Interpreting the results Incidence rates are inuenced by a probable risk gradient between the urban north and the rural south. In the north some areas are also potentially affected by water pollution due to past industrial contaminations. A population-based screening programme for breast cancer was implemented only few years ago; we expect ITALY, SALERNO PROVINCE (1998-2001) that it will affect breast cancer ITALY, SALERNO PROVINCE (1998-2001) incidence and mortality rates only in the future.

330

Europe

Italy, Sassari Province

are considered just when evidence is clear or when a tumour Registration area The Sassari cancer registry covers the population of Sassari diagnosis is found on the death certicate. The variables collected are: health unit to which patients province in the Mediterranean island of Sardinia (Italy). The population at the most recent census (2001) was 453 628. belong, name, place and date of birth, sex, marital status, Between 1991 and 2001 there was a small population decrease of address, occupation or social class, attending physician, about 0.3% (1276 persons); nevertheless in the previous decade hospital and department of admission, site of tumour, presence of tumour in other family member, basis of there was an increase of about 4.5% (20 286 persons). The province covers 7520 km2 and has a population density diagnosis, grading, extension (or TNM) of neoplasm, leading of 60 persons/km2, nearly 1/3 of the national population density. treatment, causes of death, and place and date of death. The registry receives the list of all persons admitted to The population is not evenly distributed across the land; the provincial chief town has 128 000 inhabitants; three towns have Sassari Hospital and the list of biopsies. In addition, we use 30 00040 000 inhabitants, three towns have 10 000 inhabitants active casending in two regional hospitals (Sassari and Nuoro), in ve district hospitals, in all medical ofces for and all the other people live in 83 small villages. oncology and in the death With few exceptions, the registration ofces. population is of the same race and the same culture. The economic Registry staff visit these ITALY, SASSARI PROVINCE (1998-2002) sources per iodically, and activities are mostly agriculture ITALY, SASSARI PROVINCE (1998-2002) scrutinise the medical records and tourism. In the north of the of departments concerned with area there are also two harbours diagnosis and treatment of for trade and one cracking plant. cancer, to identify and abstract 


 









Cancer care facilities information on cases of cancer, 







The National Health Service diagnosed by all methods, 














provides general health care among residents of the registry 







through 1 regional and 4 area. Cancer is not a reportable 














district hospitals and primary disease, and the registry does not 
 





health centres. Private receive information about cancer 














practitioners supplement this. cases from private practitioners. 







The oncology department is Arrangements have been made 














located in the regional hospital with the hospitals outside the 







in Sassari, and provides facilities region to notify the cancer cases 














for diagnosis, PSA testing as a in Sassari residents that are 







routine procedure for elderly diagnosed or treated in their area. people, cancer surgery, and In order to verify the       chemotherapy services. completeness of the registry, the  '#%  '#% 
 

!" '(&)'''  Patients suspected to have mortality/incidence ratio and cancer in the primary and 
   DCO percentage are calculated ))!+!!*'  '  '# '' ' )) ''! ' ''' '
'' ''''''
' ' secondary care facilities are  %' annually, and the list is linked mostly referred to district or  



 regional hospitals. Usually with that of the hospitals inpatient records and biopsies. 
' '#!$%'''' patients are referred to district hospitals, but can also use hospitals in other provinces or outside of the island. Interpreting the results In the registry area, hospitals and diagnostic facilities are Registry structure and methods adequate in number and well distributed in the territory, so that it The registry is a result of the work in partnership between is unlikely that cases referred will be missed. Also, ASL operates the Epidemiology Service of Azienda Sanitaria of Sassari a screening service for breast cancer and cervical cancer. and the Anatomy and Histopathology Institute of Sassari University. It is funded by Azienda Sanitaria and is located Use of the data in the Epidemiology Service. Four epidemiologists and two The registry prepares an annual report of cancer incidence health workers staff the registry. highlighting changes and peculiar tumours (e.g. Kaposi The registry collaborates in research with the institute of sarcoma, chronic myeloid leukaemia, chronic lymphatic Anatomy and Histopathology Institute of Sassari University leukaemia), and points out the registered cancer cases and the genetics OU of the CNR in order to dene the survival after ve years from registration. prevalence of some genetic markers (BRCA, BRAF) and The data of the registry have been used from the regional their inuence on the prognosis of tumours. government to dene cancer-control plans. The Sassari Cancer Registry (SCR) has collected, starting from 1 January 1992, all cases of malignant tumours Source of population occurring in the Sassari province. Particularly, all tumours 19922002: Intercensal estimates (based on the 1991 and listed in sections 140-208 of the ICD-9 and in sections 2001 census data, making allowance for births, deaths and C00C97 of the ICD-10; intracranial and spinal neoplasms, migration into and out of the province). malignant and benign; in situ carcinomas are normally collected but not utilised to calculate incidence, except Multiple primary rules used urinary bladder carcinoma. The cases with insufcient detail IACR rules (2004) on historical data.

331

Europe

Italy, Sondrio
Registration area The Sondrio Registry covers the population of the district of Sondrio in Northern Italy. It is a predominantly mountainous district, but about 68% of the population lives under 600m above sea level, 18% from 6001000m and the remainder over 1000m. The main city is Sondrio, with 23 000 inhabitants. The greater part of the population lives in rural areas or small towns with <5000 inhabitants. The population is Caucasian (99.8%), and predominantly Christian. Women (51.1%) have longer life expectancy (median age of death for males is 74 years; for females, 84 years). In the district of Sondrio a small proportion of immigrants (1.4%) were registered in the national census of 2001. Cancer care facilities The public health services department, through 4 public hospitals and a network of primary health centres, provides general health care in the region. Hospitals provide cancer surgery, thoracic surgery, neurosurgery, haematology, radiotherapy and chemotherapy services and imaging services (4 CAT scan, 2 NMR). About 15% of patients with cancer are referred to secondary care in hospitals in Milano (120km distant). and recodes all cancer cases. The staff scrutinises registers of radiotherapy and chemotherapy services and of hospitals when cases are uncertain. If DCO (Death Certicate Only) cases are detected, the registry interviews the practitioner. Quality control, i.e. evaluation of DCO, of percentage of microscopically veried cases, of mortality/incidence ratio, of time trends, external comparison with Italian Registries, and capturerecapture analysis with independent databases (the Registry of Mesotheliomas, Italian Association of Paediatric Oncologists), are carried out with INT. The registry began the registration of incident cases in 1998 and has collected 6600 prevalent cases (with incidence date before 1998). Interpreting the results The population within the area is stable, and there have been no changes in the availability of diagnostic and treatment services or in denition and coding. Screening for breast cancer by mammography has been active since 2000; screening for melanoma has been offered since 1999. The number of PSA tests is increasing; in 2004 there were 16 000. In the past many workers have been exposed to siliceous powder, and in 2004, the prevalence of silicosis was 800 cases.

ITALY, SONDRIO (1998-2002)

ITALY, SONDRIO (1998-2002)






 











































 





































































 

Registry structure and Use of the data methods       # # The registry prepares an The registry is located within 


$"#!###  annual report of cancer the Public Health Department, incidence and survival. The which provides physical and 
   data are used for evaluation of nancial support. The registry ###

## #%%$&######'#
 #  



 
# # ## !##
 # is staffed by a full-time medical doctor (epidemiological health services (for example migration of patients, terminal specialist), a full-time nurse (registrar), and a part-time care). Some special studies on therapy for breast cancer have informatics specialist. The Istituto Nazionale per la cura been carried out. dei Tumori of Milano (INT) provides technical and Source of population epidemiological support. The registry receives all Italian Hospital Discharge Census 2001 and population estimates for 19982000 Data of inhabitants in the area of the registry, databases (National Institute of Statistics, ISTAT). of pathology laboratories in Sondrio and Milano area and mortality databases (pre-coded data). The registry Multiple primary rules used scrutinises the records with cancer diagnosis or treatment IACR rules (2004) on CI5 IX period.

332

Europe

Italy, Syracuse Province

the archives of private clinics, clinical and administrative Registration area The Syracuse Cancer Registry inhabits the Territorial records of local healthcare districts, and death certicates Registry of Pathology (RTP) of the Local Health Authority obtained from the department of public health. The registry of Syracuse. The Registry covers 21 municipalities within the checks municipality rosters for vital status. Since 1996 the Registry has received from the Regional province of Syracuse in southeast Sicily. The area consists of a western highland with altitudes ranging from 450865m, Department of Epidemiological Observatory the records and an eastern coastal plan facing the Mediterranean Sea. of all residents admitted to any regional or extra-regional The province borders the province of Catania in the north and hospital. Active casending is undertaken in hospitals, the province of Ragusa in the south. The population density pathology laboratories, and local healthcare districts. is 193 inhabitants/km2. The province has about 400 000 The department of public health provides copies of death inhabitants; the principal town, Syracuse, has about 123 000. certicates for all causes. Arrangements have been made People over age 65 comprise 15.5% of the population; those with hospitals outside the region to notify the Syracuse under age 14 comprise 17%. The area is socioeconomically residents diagnosed and treated in their area. A traceback is performed for undened heterogeneous, with an malignity, unknown primary industrial economy in the site, with outpatient record cities of Augusta, Priolo and ITALY, SYRACUSE PROVINCE (1999-2002) as the only source or other Melilli, and an agricultural ITALY, SYRACUSE PROVINCE (1999-2002) missing information as well as economy in the north (District death certicate notications. of Lentini) and south (District Traceback includes contacting of Noto). The great majority the general practitioner and of Syracuses population is %-%*"--/*, (-"$&--%-0."--/" (-+%%--rescreening the sources. employed in tertiary activities, *-/(/--.* .-0($--Data collection and especially tourism. With a few .-/$.--." 0-&&*--0-"/.--+* $"-$**--registration is done in three exceptions, the population is $"-&*"--+" $$-%&$--steps: a) checking data quality of the same race and the same $"-0+.--** $$-*$"--$%-/+&--*" $&-%./--and linkage with the other culture. $%-%""--(* $%-+0*--information; b) evaluating $&-*&.--(" $(-"$"--$*-"$$--&* $*-$"*--and coding all cases by Cancer care facilities $*-%0&--&" $*-&.$--two epidemiologists; c) In the area covered by RTP $*-++%--%* $*-&""--$(-"(+--%" $&-.*.--computer entry with IARC there is a main hospital (A.O. $%-00&--$* $%-&0(--CanReg software. Follow-up Umberto I) in Syracuse and $%-&+$--$" $$-*+/--$$-""(--* $"-*&"--procedures include periodic four other public municipal 0-.+%--" 0-&&0--record linkage with mortality hospitals (in Lentini, Augusta, data. Specic procedures and Avola and Noto), ve certied $" * " " * $" keywords restrict le access. private hospitals and 396 -'#) -'#) general practitioners. The %"%-$*(--$0(-"%$-- Interpreting the results Syracuse and Avola hospitals 
   have medical oncology units - ----%""$------------ -- --1-
!- The insufcient cancer care with chemotherapy services.  



 There are no radiotherapy facilities and the number of cancer patients hospitalised 

--'%""()--
*--services. The province has few cancer care facilities; many outside the province create many problems for casending. patients are admitted to hospitals and specialised institutes Differential distribution of environmental and occupational outside the RTP area at the University of Catania. Many exposure can lead to different incidence rates. In the cases are diagnosed and treated in extra-regional hospitals registry area some suspected etiological factors have been with comprehensive cancer services (esp. in northern Italy). investigated. Chemical industries in Augusta, for example, represent the main source of water and air pollution that inuence the high incidence rates of several tumours, Registry structure and methods The registry is sited within and supported by the Healthcare especially of lung cancer. Since 2001 there have been population-based screening District of Syracuse. RTP was established in 1997 by the Sicilian Government with the partnership of Department programmes for breast cancer and cervical cancer in Syracuse of Hygiene of the University of Catania and the Syracuse city (although breast cancer screening was interrupted Local Health Authority. In 2005 it joined the new Integrated in 2004). PSA testing is commonly used as a diagnostic Cancer Registry (RTI) of the Province of Catania, Messina technique, but not in organised screening programmes. and Syracuse. Two full-time epidemiologists, one part-time epidemiologist, two full-time health nurses and one full-time Use of the data registrar staff the registry, with MDs and undergraduates The Registry aims to identify cancer incidence in an area (epidemiologist and pathologist) of the University of Catania. (southern Italy) formerly covered only by the Ragusa Cancer RTP started on 1 January 1999, after a one-year experimental Registry, that has low incidence rates, probably related to phase to evaluate feasibility and to collect prevalent cases. Mediterranean dietary habits and lifestyle. The registry seeks to establish these incidence rates to evaluate future Registration is voluntary and based on active casending. The major information sources for the Syracuse Cancer needs and to target prevention activities appropriately. The Registry are histology and cytology reports, the regional registry contributes to local cancer control strategies via archive of hospital discharge forms, hospital clinical records, monitoring cervical cancer screening and evaluating health

333

Europe

services. The registry prepares an annual report of cancer mortality and, more recently, of incidence as well. The Registry is not currently involved in national or international epidemiological research, but data are provided to the Local Health Unit and the Regional Government for planning health services. Survival studies will be possible after ve years of recording.

Source of population Source of population is the 2001 census, taking into account birth, deaths and migration, produced by the National institute of Statistics (ISTAT). Multiple primary rules used IACR rules (2004) on CI5 IX period.

334

Europe

Italy, Torino
Registration area The area covered by the Piedmont Cancer Registry corresponds to the city of Torino, which is the main city of the Piedmont Region, in the northwest of Italy. At the year 2001 census the population was 902 235 inhabitants. The present population structure is still inuenced by signicant internal migration: 4.4% of the population was born in the northeast of Italy, 4.5% in the centre and 26.6 in the south. This composition may inuence incidence gures, as people born in southern Italy have lower risk proles than people born in northern regions. Cancer care facilities In Turin and its surroundings there are 14 public hospitals and 12 private clinics: all these hospitals and clinics offer cancer treatments in varying proportions. Recently the Piedmont Region has developed a regional network for cancer services with four sub-areas serving the city of Turin. Since 1992, two screening programmes have been set up in the Turin area: mammographic screening for women aged 5069 years and cytological screening for women 2564 years of age. In 1998 a screening program for colon cancer was implemented, based on sigmoidoscopy for men and women aged 58 years or faecal occult blood test for men and women between 59 and 69 who refused the sigmoidoscopy. input, after checks for data quality and linkage with other information. Follow-up procedures include periodical record linkage with the mortality Registry and the active follow-up in the municipality rosters.

Interpreting the results During recent years, the incidence trend slowed its increase. Tobacco- and alcohol-related cancers are clearly decreasing in both sexes, with the only exception being lung cancer in women. Breast, colorectal and prostate cancers are increasing, mainly due to the screening programs (for breast and colon) or the increasing use of opportunistic PSA testing. For more than a century, Torino has been the Italian capital of automotive industry ITALY, TORINO (1998-2002) (cars, trains, trucks, planes). ITALY, TORINO (1998-2002) In recent decades, automation of the production processes had importantly cut the proportion of manpower, as #&$)&&& (#% $&'&&& '&(&&& ( !&(&&& well as had improved the #&!!&&& '# !&$$&&& working conditions and put &)#&&& ' )&!(&&& $&$#&&& $# &!!!&&& occupational hazards under &)(&&& $ !&!(&&& strict control. However, due to )&$!&&& ## &($#&&& &($&&& # &$&&& the latency of cancer induction, )&$&&& !# &!)&&& a consistent occupational &#&&& ! &!!&&& $&'!(&&& # !&!(&&& etiological fraction is still )&#$&&&  $&!&&& present in the Turin cancer #&)&&& # &(&&& !&!&&&  &('&&& incidence of mesothelioma, '&($!&&& # $&(#(&&& lung and bladder cancers. $&$!&&&  #&##'&&& $&#!&&& # #&$#(&&& Furthermore, this heavy '&#'&&&  $&$&&& industrial environment, together with road trafc, has  #   #  also induced signicant air 
& "

& " pollution, responsible for a !$)&#$(&&& !&$'&&&  further fraction of respiratory 
    &
& 
&&

&  &

&&
& &
&&
&
&&
&
"& cancers.
 



 
&
& !"&&&&

Registry structure and methods The Registry is a part of Centre for Cancer Prevention (CPO). The registry is staffed by a director, two epidemiologists, two full time registrars and six part-time registrars. Sources of information and methods of registration remained unchanged in recent years. The principal sources of information for the Registry are: a) the hospital archive of clinical records; b) the regional archive of hospital discharge forms; c) pathology reports; d) the archives of Day Hospitals and Radiotherapy Services; e) health insurance les for those cases treated outside the region; and f) death certicates. The Registry has access to the municipality roster in order to check personal data for vital status. Registration is carried out in an almost completely active manner. The collection of data comes about in two steps: a) a provisional input into a portable computer, carried out at hospital archives after reading clinical records and histological reports; b) a denitive

Use of the data The registry provides periodical reports on cancer incidence, prevalence, mortality and survival, published and updated on the web (www.cpo.it). The data are used by local heath authorities for planning for the regional network of cancer services. The data are also sent to the Italian Cancer Registries Association database. The Torino branch of the EPIC cohort study is annually linked with the Piedmont Cancer Registry in order to check the occurrence of cancers. A follow-up facility is also provided on demand for clinical epidemiological studies. Source of population Municipality rosters (balance of resident population recorded by the municipality roster at the end of each year). Multiple primary rules used IACR rules (2004) on historical data.

335

Europe

Italy, Umbria Region

hospitals. Other sources of data are cytology centres for Registration area The Umbrian population-based Cancer Registry covers the cervical cancer screening, personal case histories and population of the Umbria Region. Umbria is a small Region independent studies, reimbursement requests for patient in central Italy, divided into two Provinces. The regional treated outside the region, and other cancer registries. A traceback is performed for cases of undened population was 825 826 inhabitants (426 664 females) at the last census (2001). The regions area is 8456 km2, and population malignity, of unknown primary site, with outpatient record density is about 96 inhabitants per km2. The population is older as the only source or with other missing information besides than the Italian average: the ratio of people >65 years old to death certicate incident cases. The traceback procedure all residents is over 23%. The population is stable, growing includes contacting the family doctor and re-abstracting or slowly due to migration while natural balance is negative. re-screening of acquired sources. Foreigners, most of them coming from Eastern Europe and North Africa, form about 2% of the resident population. Nearly Interpreting the results 70% of people live in centres of >5000 inhabitants. The great Opportunistic screening for cervical cancer was introduced long ago. More recently, the majority of Umbrias population opportunistic screening was is employed in services and supplanted by an organised industry (agriculture 6% both ITALY, UMBRIA REGION (1998-2002) programme, and an organised sexes). The unemployment rate ITALY, UMBRIA REGION (1998-2002) screening programme for beast is at 8.9%. cancer was also introduced (1999). Opportunistic Cancer care facilities screening activities for Health care is provided 


 









prostate cancer and melanoma mostly in public hospitals and 







do exist, but are perhaps less districts of the 4 Local Health 














widespread than in most Services. There are 2 main 







other northern Italian regions. teaching hospitals and 18 














Invitation letters for the rst public hospitals in the region 







round of the large bowel with 3949 beds overall, as 














screening program are now well as 5 private clinics. 







being distributed. Historically, The main specialised 














there has been an area of high oncology centres (including 







risk for gastric cancer in the clinical oncology, surgical 














north of the region. oncology, paediatric oncology, 







radiotherapy and haematology Use of the data specialties) are located in the       Annual incidence and survival two larger cities, Perugia and ! ! reports are produced and Terni (maximum distance 


#"!"!!!  distributed. A survival study within the region 55km). As an 
   by prognostic factor for breast overall technology investment !!!!!!##"$!!!
 !  



 indicator 18 TC, 7 RMN, and 2 PET are available in the regional and large bowel cancer is ongoing. The registry participates 
!!!!
$ $!! in various multicenter researches (e.g. the EUROCARE centres (data from Osservatorio Regionale Tecnologie). study on patient survival, the OCCAM study on occupational cancer monitoring, and the IMPACT study on breast cancer Registry structure and methods The Cancer Registry is managed at the Department of screening effectiveness). Policymakers also use registry data Hygiene of the University of Perugia. The registry is funded for planning and evaluation of health services. by the Regional Health Authority while staff and equipment are supplied by the University. All the staff is yet part-time. Source of population Sources used for casending include public and private Census 2001 and population estimates for 19982000 and clinics/hospitals outpatient records, pathology reports, 2002 (ISTAT). radiotherapy outpatient records, and death certicates. Relevant information for eligible cases (i.e. residents) is Multiple primary rules used abstracted from medical records of 20 public and 5 private IACR rules based on ICDO1.

336

Europe

Italy, Varese Province

Cancer Institute. The professional registry staff consists of Registration area The Province of Varese is in northern Italy. It is bordered three epidemiologists, two data managers/statisticians, three to the north by Switzerland, to the west by Lake Verbano case ascertainers and three clerks concerned with record and the river Ticino, which mark the border with the Region linkage and the checking of data. The Varese Cancer Registry uses an automated cancer of Piedmont, and to south and east by two other Provinces of the Region of Lombardy, to which Varese Province also registration system, called Open Registry (Methods of belongs. The northern part of the Province is mountainous; Information in Medicine 2005;44:66-71) developed inthe southern part encompasses part of the Lombardy plain house and based on the Linux operating system and Oracle database. The main electronic information sources are and is at. The Province has an area of 1198 km2. The population has increased considerably since the hospital discharges, routinely generated by all hospitals in 1960s (581 526 in 1961; 807 579 in 2000). In these years Italy; surgical pathology reports from pathology units in the considerable numbers of people have moved into the Province and, since 1998, from major pathology units outside Province from eastern and southern Italy. Those who settled the Province, which often examine specimens from persons resident in the Province; tended to retain the distinctive and mortality data from dietary and cultural habits Local Health Units. Using of their origins, which differ ITALY, VARESE PROVINCE (1998-2000) the Open Registry software considerably from those of the ITALY, VARESE PROVINCE (1998-2000) and translation tables to cope indigenous population. These with the different information differences have made it coding systems in use, 60% possible to conduct descriptive of cases are identied and studies on differences in #(!((( *%'  (&))((( #()+%((( * ( #((( accepted automatically. cancer risk by place of birth +(+%+((( )% &(+)((( For the remaining cases, and also to perform analytical %( +((( ) ( +#((( +()*%((( &% !(%((( the clinical records are studies on diet and cancer. !(*!*((( & &()#((( scrutinised manually. The The population density is &(!&((( %% )(& &((( )(!+((( % *(!! ((( accuracy of the automated 695.6 inhabitants per km2. The )(&+((( #% *(# ((( system has been tested by ratio of elderly to children (over )()#((( # *( !((( !(!&!((( !% !(+*)((( comparison with manual 64 years/less than 15 years) !%(!* ((( ! !#(#%((( registration and showed a site was 132.8 in 2000. Currently ! ()#!((( % !(! &((( )( &(((  &(&+((( code concordance between about 43% of the working (%%((( % +(& )((( the two systems (automated population are employed in *(#%&(((  )(#!!((( *(! %((( % )(%*!((( and manual) of 98.4%. In industrya considerable )(++%(((  )(&((( collaboration with Local decline compared to 1971 Health Units of the Lombardy and about 2% are employed in  %   %  Provinces of Brescia, Mantova agriculture; it is not possible  ("$   ("$ and Sondrio of the Lombardy #)(!*)((( to partition the Province into !**() (((  Region, Open Registry has urban and rural areas. 
  
 ("
(, $( been exported to the Cancer  



 Registries of these Provinces. The completeness of registration Cancer care facilities 
( (" #$((%(( ( The Province of Varese is served by 11 general hospitals, is monitored yearly using capture-recapture methods. Clinical including one university teaching hospital with modern consistency is also checked routinely by re-abstraction and facilities for the diagnosis and treatment of cancer. There are manual recoding of a random sample of cases. The Varese Cancer Registry participates in major also ve private clinics. There are 3950 hospital beds; the epidemiological studies, including those of EUROCARE, hospitalization rate is 161/1000 per year. ORDET, EPIC and ACCIS. Registry structure and methods The Lombardy Cancer Registry, which serves the Province Source of population of Varese, was established in 1974; is it now called the Varese Estimates (ISTAT http://www.istat.it). Cancer Registry. The Registry is supported by the Lombardy Regional Health Authority and is run by the Cancer Registry Multiple primary rules used and Environmental Epidemiology Unit of the Milan National IACR rules (2004) on CI5 IX period.

337

Europe

Italy, Veneto Region

2. Death certicates relating to all deaths among residents Registration area in the region, transmitted by the same Department; and The Veneto Region is the largest region in Northeast Italy, with 4 527 694 inhabitants at the 2001 Census, 44% of 3. Pathology records transmitted by the fteen pathology laboratories covering the registered areas. whom (2 002 705 inhabitants) reside in the area covered by the Veneto Tumour Registry, which includes six of the seven Furthermore, all the LHUs of the region transmit a copy of major urban centres and almost all the mountainous part of the population les, which are merged into a single archive, used as a reference for linking source records: the latter are the Region. Immigrants make up 6% of the population covered by the evaluated using a case resolution programme that accepts: Veneto Tumour Registry (source: Ministry of the Interior). cancer cases where data from two or more sources are Most of these come from Eastern Europe (47.8%) and from identical; histologically conrmed cases in the presence Africa (16.7% from Maghreb and 11% from other Countries); of other compatible hospital diagnoses (e.g. metastases or ill-dened sites); and histologically conrmed skin cancer 15% are from Asia (including China). Most Venetians are Christian Catholics, whereas half of unless combined with skin melanoma. The programme rejects immigrants embrace Christian diagnoses based on only religions (25% Orthodox one source (unless based on Church, 17% Catholic, and ITALY, VENETO REGION (1998-2001) histology), multiple primary 4% Protestant); a third of the ITALY, VENETO REGION (1998-2001) tumours and discordant or foreign population is Muslim. incompatible diagnoses: The Region encompasses in these situations manual many of the leading economic checking is carried out by the districts in Italy: the 


 









registry operators, who where unemployment rate in 2001 

 





necessary gather further was only 4.1%, compared to 














information from the local the national average of 11.6%. 







information systems of the At the 2001 Census, 














LHUs and clinical records employment was distributed 







from the hospitals. as follows: 4% in agriculture, 

 










 

A quality assessment of 42% in industry and 54% 







in other activities (national automatically accepted cases was 














averages are 5%, 34% and carried out by a re-abstraction 







61%, respectively): industrial study in the year 2002, with 














activities are distributed positive results, and a few 







throughout the territory rather corrections were consequently than being geographically made to the programme.       concentrated. 
($ & 

($ & 



+'+(%*(((  Interpreting the results Cancer care facilities The proportion of aged 
   Twenty-one Local Health !++)-",( (
 
(

((  ((#!(


($ 
,((
(((
&("!(
( population has markedly (
(((
("",( (
 
(

((  ((#!(


($ 
,((
(( Units (LHU) are responsible (
&( for all public health-related increased: ageing index for the whole region, which was 107  



 
( 
($"%&(( (( matters, including the management of all the hospitals in the in 1991, had become 136 in 2001; in the area covered by the Region (98 in the year 2000). Only the two major hospitals registry it rose from 119 to 145. are managed autonomously. Most of the LHUs provide A prevention programme for early detection of skin comprehensive services for cancer diagnosis, surgery and melanoma has existed since 1990. Organised screening for chemotherapy: radiotherapy and a few expensive diagnostic breast and cervix cancer detection started in 1998 in three tools are available at least at county level (the Region includes and ve LHUs, respectively, and progressively included seven counties), while patients with rare cancers or particular further LHUs. PSA testing became a routine practice in the sites involved (i.e. brain tumours) are mostly referred to a late 1990s. restricted number of departments. Paediatric patients are treated in the two major hospitals. Use of the data Incidence gures with LHU details are reported on the Registry structure and methods Registry website, as well as prevalence and survival gures The Registry is nancially supported by the Regional for the entire Registry area: a report has also been prepared administration. The staff is composed of a physician (director and some small area analyses of incidence and mortality of the registry), three registry operators, three statisticians, a have been carried out. data manager, two computer programmers and two clerks The Registry collaborates with all other Italian Registries with secretarial and data-entry duties. in research projects and publications of incidence, prevalence The registration system uses medical information, and survival data. received annually from the following computerised and The Veneto Tumour Registry is currently involved in codied sources: epidemiological researche (EUROCARE IV, Concord, 1. Hospital discharge records from all the hospitals in Haematocare, ACCIS, Eurocim, and others). the region, transmitted by the Regional Department of Veneto Tumour Registrys data are used for drafting the Social Security and Health; Oncological Regional Health Plan of the Veneto Region.

338

Europe

Source of population 19972000: Municipal registries estimates of population at 31st December (source: National Institute of Statistics, ISTAT). 2001: census, National Institute of Statistics, ISTAT. 2002: Municipal registries estimates of population

at 31st December (source: National Institute of Statistics, ISTAT). Multiple primary rules used IACR rules (2004) on historical data

339

Europe

Latvia
Cancer care facilities The Latvian Oncology Centre, 2 regional oncology hospitals and the oncology department at the Republics Clinical Hospital provide complete specialized diagnostic and treatment services for the population of Latvia. All of these hospitals have well-equipped radiology departments. Specialised aid for children is provided by the oncology department of the Central Childrens Hospital. 29 000 of the population were lost because of emigration; but mainlyabout 71 000because of the natural decrease in the population (about 14 000 persons per year). Interpreting the results The availability of medical services is nearly the same over time, with some difculties for the less-secure population, but cancer diagnosis and treatment possibilities have increased. From the beginning of the registry the ICD-7,8,9 revisions were used for coding of malignancies. Now all Registry structure and methods The staff of Latvian Cancer Registry (LCR) includes 5 data are transformed to ICD-10 (topography) and ICD-0 ofcials: an MD medical statistician, an epidemiologist (morphology) codes. No organised screening programmes have been organised (biologist), a programmer, a PC operator and the principal of in Latvia, but opportunistic CR (director). programmes for breast cancer All physicians and (mammography) and cervical practitioners (GP, outLATVIA (1998-2002) carcinoma (Pap smears) as patient department, hospital, LATVIA (1998-2002) well as PSA tests are ongoing. pathology and forensic medicine laboratory) have Use of the data to report new cancer cases The LCR publishes regular to LCR. At least quarterly 


 









statistical issues. During the the persons responsible for 







19982002 period: Cancer oncology at every district 








 





Incidence in Latvia 19971998 central hospital in the republic 

 





(the 4th issue) and 19992000 provide information on cancer 














(5th issue); Cancer Mortality in their districts (new cases, 







in Latvia, 19802000 (2002) deaths, changes of therapy, 














and Cancer Incidence and progress of the disease, etc.). 







Mortality in Latvia, 2001 Additionally, the LCR 














2002 in 2004. receives regular information 







The LCR is not currently from the Latvian Agency for 











involved in epidemiological Medical Statistics concerning 







research, but some projects have the cases identied from death been completed recently. The certicates.       CR data are widely requested .)%+ .)%+ The completeness of 

 

&.$00.$00...  and used by policy makers, the data is evaluated by insurance companies, etc. comparison of the CR data 
   # .. .".
.'$$$.).(&!'$$$++1. with the data of big hospitals. &00/2&000.
... .
.). .. .. ..'$$$..2.. !!'$$&!-'.".'$$&2'$$'1. . 2. ..
.. . .
". Source of population A specic evaluation study is not performed.  



 
..)'$$*+..
,.. . 19981999 Central Statistical Bureau of Latvia (estimation allowing for the birth/death levels and migration. Census Registration area Since 1965, the cancer registry has covered all the population 2000 (March 31, 2000): Provisional results of the 2000 of the republic, but a separate cancer registry unit (LCR) population census Statistical bulletin, Riga, 2001, 62p. was organised in 1993, after state independence was re- 20012002: Estimated data from the Central Statistical established. The area covered has not changed, but the bureau of Latvia. population has changed considerably: in 19661967 mainly because of the departure of Soviet Army troops and their Multiple primary rules used families; during the reporting period (19982002) about IACR rules (2004) on CI5 IX period.

340

Europe

Lithuania
Registration area Lithuania is the southernmost of the Baltic States, which were part of the USSR from 1940 through 1990. In 1990, Lithuania gained independence. Lithuania has total land area of 653000 km2 giving a population density of 53.68 persons per km2. The resident population in Lithuania in 2001 was 3 483 972 1 629 148 males and 1 854 824 females (census data) where 83.45% of inhabitants are Lithuanians, 6.74% Polish, 6.31% Russians, and 3.5% others. Birth rate in Lithuania has been decreasing for the last decade, and it continues to fall. In 2000, the crude birth rate was 8.52 per 1000 population. Average annual rate of natural increase was 1.3%. The infant mortality was 8.52 per 1000 live births. edition since 1993 and ICD-O-3 since 2003. Before 1993, a local one-digit morphology code was used. The cancer registry le is updated monthly with information on death certicates that are completed according to the international standards. The last update for the analyses presented here was done on 31 March 2005. On average, two notications from different sources per skin melanoma case were registered since 2000. There are obstacles to continuing the full-scale activity of the cancer registry due to legislative issues. The rst regulations of the registry were signed by the Ministry of Heath in 1984. Discussion continued on cancer registry regulations despite the law on the registries adopted by the Lithuanian Parliament in 1996. The importance of the registry data was recognised by researchers, health care organisers and policymakers. The cancer registry data was used as a basis for the National Cancer LITHUANIA (1998-2002) Control programme adopted LITHUANIA (1998-2002) by the government in 2003, establishing cervical and breast cancer screening programmes and numerous local investment      projects funded by EU and local   sources.  

Cancer care facilities There were 97.9 hospital beds and 40.3 medical doctors per 100 000 population in 2000. The availability of diagnostic and treatment services is increasing. Modern complex treatment   of oncology patients (surgery,  radiotherapy, chemotherapy) is       provided at Institute of Oncology    Vilnius University, Kaunas Interpreting the results         Medical University Clinics, During 19982002 there    Klaipeda City Hospital and were no nation-wide cancer        screening programmes. Some Siauliai City Hospital. Surgery and     small-scale opportunistic chemotherapy are also available       activities were established at other university hospitals and     for cervical, breast or colon major treatment centres.        cancer. PSA testing became The highly centralised     widely available around 2000. healthcare system has been The cervical cancer screening finally changed to a state       programme with a 3-year insurance-based system in 1997.   invitation interval started in The changes required the registry    
 June 2004. The mammography to establish new connections screening programme started in with primary healthcare centres 
  



   (360 in 2006) that became to play a major role in primary cancer May 2006 though it is still lacking coverage due to limited mammography services. Despite the opposition of the experts, assessment and referral of patients to diagnostic services. lobbying activities forced the introduction of nationwide free PSA testing in 2006. The registry is responsible for evaluating Registry structure and methods The cancer registry operates as a separate department of the effectiveness of these cancer screening programmes. Institute of Oncology, Vilnius University. The registry staff includes 10 employees: epidemiologist, medical doctor, medical Use of the data coders, programmer and registry clerks. Support to the registry Annual registry reports on cancer incidence, extent of is provided by the Institute of oncology. The principal sources disease, microscopic verication of cases, mortality, and of information on cancer cases are primary, secondary and prevalence by site and municipality have been published tertiary healthcare institutions that are required to complete since 1994. Registry publications covering incidence and mortality trends and survival data have been published on a notication when cancer is diagnosed. Lithuania has a compulsory nationwide cancer registration some individual sites. The registry is also involved in cancer since 1957. Administratively Lithuania was divided to 44 districts epidemiology research, and has participated in several (municipalities) up to the year 2000. The new administrative descriptive and occupational epidemiology projects including division is built upon 60 municipalities established within the Chernobyl clean-up workers, nuclear workers, radiologists, borders of previous territory units. Some of districts were split in and asbestos-, cement- and wood dust-exposed workers. two or three municipalities; some small territories were joined The occupational exposure pattern in Lithuania follows that across borders. The cancer registry successfully adopted the in industrial countries; study of environmental radiation new territorial division without loss of information on long-term exposure due to Chernobyl is needed in order to evaluate the consequences for the general population. A study of clean-up trends within major units. The compulsory case notication includes surname, name, workers from Lithuania shows no elevated cancer risk. sex, date of birth, place of residence, nationality, date of diagnosis, site according to ICD-9 from 1978 through 1997 and according Multiple primary rules used to ICD-10 since 1997, morphology according to ICD-O-2 IACR rules (1990).

341

Europe

Malta
active and passive). Passive methods include the receipt of Registration area The Malta National Cancer Registry covers the population notications of cancer from the clinicians, a monthly report of the Maltese Islands, a small archipelago in the middle of from the Oncology department on the new cases referred to the Mediterranean Sea. The total resident population at the their department and an annual report on the cases of cancer sent abroad for treatment by the state. most recent census (2005) was 404 039. The National Mortality Registry is also housed within There is no clear distinction on the islands between urban and rural areas. However the harbour area (centred around the Department of Health Information, and linkage between the capital Valletta) can be considered as the most urban, the cancer and mortality databases is routinely performed. with much of the rest of Malta being suburban, and most of The mortality registry is the recognised national source on death statistics. the northwest part and the whole of Gozo being rural. The majority of the local population are Roman Catholic. The number of foreigners resident on the Islands is increasing, Interpreting the results leading to growing changes in the ethnic compositions of It is estimated that only a small proportion of the cancers diagnosed in Maltese the resident population. The residents remain unregistered. Maltese people are descendents These mainly include cases of ancient Carthaginians and MALTA (1998-2002) diagnosed, treated and Phoenicians, with strong GrecoMALTA (1998-2002) followed-up abroad. The Roman and Arab influences. registry staff actively tries to European elements, namely reduce the proportion of cases Italian, Spanish and French with that remain registered on the traces of Anglo-Saxon origins, 
 

 









basis of a death certicate were assimilated later. 







only by reviewing all possible 














medical information on the Cancer care facilities 







cases. The staff is permitted In Malta, there is a comprehensive 














access to the hospital les of national health service that is 







cases diagnosed and treated at available to all Maltese residents 














all public and private hospitals and entirely free at the point 






and clinics. of delivery. All residents have 





 








To date, no organised access to preventive, diagnostic, 







cancer screening programme therapeutic and rehabilitative 














has been implemented in services in the Government Health 







Malta. However, facilities Centres and Hospitals. The public for opportunistic screening health services are funded from       $!# $!# for breast, cervical, prostate general taxation. There is one  


&$" $$$  and colorectal cancers are major general acute hospital in available locally. Malta, a smaller one in Gozo and 
   a number of public health centres &&%('$
($$$$$$ $$$$$$ $$$$  



 
$$!&&#$ scattered all over the islands. Since 1996, three private hospitals Use of the data have also been operating in Malta. Cancer surgery is carried out in The registry has published cancer incidence and mortality any of the above-mentioned hospitals, whilst radiotherapy and most information since 1992. On the registrys web site (http:// of the chemotherapy are given at the oncology department in Sir www.sahha.gov.mt/pages.aspx?page=91) there are les with cancer incidence and mortality data for Maltese residents Paul Boffa Hospital, which is the only cancer centre in Malta. from 19942005/6 as well as other cancer statistics including survival and temporal trends. The registry is the recognised Registry structure and methods The registry is located near to the major general acute (St. national source of information on cancer incidence. Its staff Lukes) hospital in Malta. It is part of the Department of annually answers several requests for information originating Health Information within the Health Division and is wholly from various sources, including both local and foreign funded by the Government of Malta. A full-time principal clinicians and other professionals, students, journalists and medical ofcer, one full-time and one part-time registrar interested organisations. staff the registry. The Malta National Cancer Registry uses both active Source of population and passive methods from multiple sources for data 19982002: Postcensal estimates. Census data with collection. Active data collection includes review of and addition of births and immigrants and deletion of deaths and extraction from the pathology laboratories reports databases emigrants. (histology, cytology and autopsy reports) of cases of cancer, review of the hospital les of known cases and collection Multiple primary rules used of information from the National Mortality Registry (both IACR rules (1990).

342

Europe

Norway
Registration area Norway covers 324 000 km2 between latitudes 57 and 71 N and longitudes 4 and 31 E. The total population is 4 640 219 (1 January 2006), most of whom are Caucasians, but 0.5% are Lapps and 8% are foreign-born (2% western and 6% non-western). At the 2005 census the main occupations for men were: industry 32%, agriculture 5%, community 22% and other services 41%; the corresponding gures for women were: industry 1.5%, agriculture 8%, community 57% and other services 33%. tonsils or the stomach are coded both to the lymphoma site and to the specic organ site. The registry is based on compulsory reporting of all new cases of cancer in the Norwegian population since 1953. Each year the registry receives more than 100 000 reports which include clinical forms, copies of cytology, biopsy and autopsy reports, and copies of death certicates from Statistics Norway. In recent years the Patient Administrative System has been linked to the Cancer Registry of Norway to ensure completeness and quality. The registry is organised as a multi-user online database. All reports are interpreted and, after coding, updated and processed. At regular intervals, the Cancer care facilities registry material is matched against all deaths in the country and In 2004 there were approximately 4 hospital beds and 3.5 physicians date and cause of death are recorded. Since the 1960 census, all per 1000 inhabitants. Surgical inhabitants in Norway have had treatment of cancer is carried out a unique personal identication both in general hospitals and at number, and this number is used NORWAY (1998-2002) oncological centres. There are to link records from the different NORWAY (1998-2002) about 90 hospitals (both private data sources. and public) and a number of private clinics offering diagnostics Interpreting the results The Norwegian Cancer and treatment of cancer in "$ """ $! "#""" " %""" $ #"""" Registry has both a cervical Norway. Most cancer diagnosis "%#""" # $%"# """ screening programme and a and treatment is, however, carried #"$#""" # $%"""" #%""""  $#"$""" breast screening programme. out at the public hospitals. These %""""  %"""" PSA testing has become hospitals are organised in regions  "% %"""  """" "%"""  $" """ increasingly more common covering different parts of Norway  " """  " """ since the rst commercial PSA (Eastern Norway Regional Health  "  """   "%""" #"$#"""   "$""" test became available in 1989, Authority, Southern Norway #$"% """  #"#$""" and is now very common in Regional Health Authority,  "$$"""  %"#""" "#"""   "%""" the Norwegian population. Western Norway Regional Health #"$ """  "$""" Authority, Central Norway %"%"""  "$ """ $""""  %"# """ Use of the data Regional Health Authority and "#"""  "#%""" The purpose of the Cancer Northern Norway Regional Registry is to: Health Authority). There are       collect and, within the 10 radiotherapy departments in "
" scope of the Regulations, Norway, situated at different parts "#"$""" "%"$"""  process data relating to cases of the country. 
  


 of cancer and cancer studies 
 " """ "" in Norway in order to document the distribution of cancer Registry structure and methods in the country and describe changes over time; The Cancer Registry of Norway was initiated by the conduct, promote and provide a basis for research to Norwegian Cancer Society and established in 1951. Since develop new knowledge of the causes, diagnosis, natural 1979 the Ministry of Health and Social Affairs has been course and effects of treatment of cancer in order to administratively and nancially responsible for the registry. improve and enhance the quality of preventive measures There are 130 employees in the Norwegian Cancer Registry. The and medical assistance that are offered or provided to Cancer Registry is organised in 4 departments: an administration combat cancer, including the follow-up of individual (29 employees, including 9 information and 13 IT-staff) and three patients and groups of patients; research departments (environmental and occupational research, provide advice and counselling on medical assistance to screening research and clinical research). The staff consists of, combat cancer; and among others, doctors, scientists, statisticians, research assistants, provide advice and information to other public IT staff, economy, personnel and PR. administrative bodies and the population at large on Site and morphology have been coded according to measures that may prevent the development of cancer. ICD-O-2 since 1993. Before 1993, site was coded according to ICD-7, while the morphology was coded according to a In addition to such purposes data in the Cancer Registry modied version of SNOMED. Primary tumours in different may be processed for the following purposes: management, organs in one individual are classied as independent planning and quality assurance of public health services tumours. If multiple tumours occur within paired organs or and the public health administration, for the preparation of other sites within the same ICD code (e.g. kidney, colon), the statistics and for research. case is classied in such a way that it can be counted either as Main research areas are etiological screening-based and one primary cancer only or as the number of primaries that clinical, based on population data and epidemiological methods. actually exists. For the female breast, two primary cancers may be registered in one individual. A double coding system Multiple primary rules used is also used for lymphomas. Lymphomas in, for instance, the IACR rules (2004) on historical data.

343

Europe

Poland, Cracow
Registration area The Cracow Cancer Registry covers the population of the Maopolska Province in southern Poland, an area of 15 144 km2, with 3 233 799 inhabitants. In 2000 the City of Cracow, the data for which are presented here, an area 327 km2, had 741 500 inhabitants (46.8% male, 53.2% female). The population is little differentiated ethnically, and the large majority is Roman Catholic. The city of Cracow is one of the biggest industrial (with metallurgical, electromechanical, chemical and food industries), cultural and educational centres of Poland. Cancer care facilities In Cracow, diagnostic and treatment services for cancer are provided by the Centre of Oncology Maria SkodowskaCurie Memorial Institute (220bed hospital and an out-patient department for 300 patients daily) as well as 22 clinics of Collegium Medicum Jagiellonian University. Types of treatment include chemotherapy, immunotherapy, surgery and radiotherapy. Patients are also treated at ten hospitals in Cracow. The registry also conducts active registration by checking hospital records, pathology records and death certicates. Patient follow-up is carried out by the registry every year through the checking of medical records and death certicates. If no data about cancer patients are available, information is collected via the Address Ofce in Cracow. Quality control of the data is done using the IARCCHECK programme and other programs developed in the registry.














 



















Registry structure and 






methods 


The registry is a part of the 






Epidemiology Unit of the Centre 



of Oncology Maria SkodowskaSource of population Curie Memorial Institute, and       19982001: population receives nancial support 
)%!' 

)%!' estimates. 2002: Census. from the Ministry of Health  


$&*)*$$)))  and Social Welfare. The staff  

 Multiple primary rules used consists of an epidemiologist, "++*.# ",)  )

)
)# #)  
   IACR rules (2004) on historical data. four registrars, a statistician and one computer 
) 
)%# &')) )) programmer.    Notication of cancer cases or suspected malignant 
) )

))
)
)
)
))
)

))

)-)

) 
)()%
 ') )
 ))
)
))
) 
))
)  )) neoplasms has been compulsory in Poland since 1952. All Notes on the data hospitals and outpatient clinics must report all cancer cases The Editors recommend that some care be taken in the on special cards, which are submitted to the registry. In the interpretation of these data; see Chapter 5 (Categorisation). registry, each new notication is compared and checked with This registry has the lowest histological verication rate in the monograph. the main database of cases already registered.

Use of the data The registry publishes an annual report of cancer incidence and mortality by sex, age, primary site and place of residence. In addition, the registry prepares survival analyses of cancer patients. POLAND, CRACOW (1998-2002) The Cracow Cancer POLAND, CRACOW (1998-2002) Registry is participating in the EUROCARE international, multicentre studies on survival and care of patients.  

The registry also participates 




in studies on childhood cancer 








incidence and survival. 


 

The registry data serve 








as a basis for planning of 




cancer control programmes 








and epidemiological research 




as well as for education of 


 





clinicians and postgraduate 




students in the eld of cancer 








prevention. 



344

Europe

Poland, Kielce
completed and checked by the registry staff against data Registration area The registry covers the Holycross Province (area 11 691 obtained from local civil departments and hospitals. The National Cancer Registry of Poland evaluates our km), one of 16 provinces in Poland. It is located in the south-eastern part of the country between latitudes 50 and incidence data every year. In 2002 the completeness was 100%. 51 N and longitudes 19 and 21 E. The Holycross Mountains (with mountains about 600m above sea level) are situated in the northern part of the Interpreting the results province. In the south there is a fertile agricultural region. In 1999, administration reform took place and the area of our The Vistula (Wisa) river forms the provinces southeastern registry was enlarged, and the population increased. In 1999 border. The annual average temperature is 6.9 C (max. we changed from ICD-9 to ICD-10, and in 2002 we changed 32.9 C and min.-33.9 C). Annual rainfall amounts to about morphology from MOTNAC to ICD-O-3. There are some organised and opportunistic screening 565mm. The population as of the ofcial statistical ofce estimate programs for breast cancer, prostate cancer, colon cancer and cervix uteri cancer, and (30 June 2000) was 1 325 PSA testing is common. 000 (about 3% of the Polish population), with 49% males POLAND, KIELCE (1998-2002) Use of the data and 51% females. Of these, POLAND, KIELCE (1998-2002) The registry maintains two 47% lived in towns and 53% basic les: a computerised in the country. The population le containing the patients of Holycross province is serial number, sex, name and predominantly white race '((''' )$& *'*''' %'(''' ) '%''' surname, date of birth, date belonging to the Slavonic  '''' ($  '(''' of the rst cancer diagnosis, group; 95% are Roman '%)''' ( ')))''' "'))''' %$ '%""''' ICD code and year of death Catholic. %'"''' % '**''' (if applicable), and a le $')%''' $$ )'*$''' "'" )''' $ "'"()''' containing cards of rst and Cancer care facilities $'%%''' "$ "*'()(''' follow-up registration arranged The Holycross Cancer Centre $')''' " "*'"%*''' " '%(''' $ "'*()''' according to information is located in Kielce, the capital "'%%*'''  ('))''' mentioned above. of the Holycross province, and "('$ ''' $ " ')"''' $"'%('''  $'"(%''' The registry prepares an provides various services in the $%'**''' $ $"')*''' annual report on cancer eld of treatment (oncological "*'$ ('''  "('"((''' "'  ''' $ "'$"''' incidence and mortality for surgery, chemotherapy, "'%%'''  '"$(''' local government as well as radiotherapy, brachytherapy, sending the incidence data to hematology, endocrynology,  $   $  the National Cancer Registry palliative care) and diagnostics 
'!# 

'!# of Poland. The Registry (e.g. radiology, nuclear %$)'")*''' % ' '''  cooperates with the European medicine, microbiology). 
   
''
'' ' Network, IARC and IACR,  



 and is a member of ENCR. Registry structure and methods 
'
'!"#''$''
' We report regularly on extent of diseases. The Registry is The Holycross Cancer Registry is a department of the Holycross Cancer Centre; its full name is Department not involved in epidemiology research. Policymakers use our of Epidemiology and Cancer Control, Regional Cancer cancer registry data but (in our opinion) not in a sufcient Registry. It is managed by a physician oncologist, one full- way. Every two years incidence data are sent to the National time biologist and four full-time registrars. The Registry closely cooperates with the IT department in data processing Cancer Registry of Poland, which publishes bulletins of cancer incidence in Poland. and statistical analysis. All medical centres are obliged to report all cases of cancer on a special notication form that includes basic demographic Source of population and diagnostic information. These notication forms are the Central Statistical Ofce in Poland. main sources of information on cancer incidence. Although cancer reporting is obligatory, it is often Multiple primary rules used neglected, and therefore all the received records are IACR rules (2004) on CI5 IX period.

345

Europe

Poland, Warsaw
cancers, and registration now embraces all sites. The registry Registration area In the years 19631988 the Warsaw Cancer Registry collected is located at the Maria Sklodowska-Curie Memorial Cancer data on the population living in Warsaw city and selected rural Center and Institute of Oncology in Warsaw, the institution populations in the provinces of Warsaw, Ciechanow, Plock responsible for organising nationwide epidemiological studies, and Siedlce. In 19891998 the Registry collected data on the scientic research, and therapeutic services related to cancer. population in Warsaw city and six voivodships (the Province It is supported by the Ministry of Health and Social Welfare. of Warsaw, Ciechanow, Ostroleka, Plock, Radom, and Siedlce). The total database now contains over 70 000 records from the After 1999 this area became one voivodship (Mazovian). The old database (Warsaw and Selected Rural Areas: 196388), Mazovian Province covers an area of 38 000 km2, 12.5% of and over 260 000 from the new database (19892005). The the total Polish territory. The area is inhabited by 5 112 000 Registry now contains over 50 000 records from the old database (19631986) and over 100 000 from the new (19872005). people (13.5% of the total Polish population). The recording and reporting on a special reporting card Warsaw, the capital of Poland and the largest centre of the Mazovian Province, is a major industrial centre in Poland of every case or suspected case of malignant neoplasm by all health service institutions lying on the river Vistula, in the and individual physicians has Mazovian Lowland in eastern been compulsory in Poland central Poland, at 52 16 N POLAND, WARSAW CITY (1998-2002) since 1952. Information and 20 59 E. The registration POLAND, WARSAW CITY (1998-2002) about cancer-related deaths area amounts to 495 km2, in Warsaw in 19982002 was populated by 1 673 000 pertaken from death certicates sons. The average altitude is issued by the Central 100m above sea level. '*%#%*** ,') !(*,-%*** (*---*** , !(*,#*** Statistical Ofce of Poland. The population structure !,*-'"*** +' #"*+!,*** Since 1989 the database by sex and age groups was #"*#'!*** + %(*,%!*** #,*##+*** (' '%*!"-*** has been maintained in a analysed on the basis of #+*!--*** ( '"*-(*** computerised le arranged data released by the Central #,*!-,*** '' %-*#%+*** '(*-,*** ' (,*+%*** by patients names, date of Statistical Ofce of Poland, +*+%%*** %' ,"*#'-*** birth and cancer site, and a valid by June 30 every year. ('*!#,*** % +#*'%+*** %-*!("*** #' '"*('*** card le containing the rst The population-at-risk is the %,*!%(*** # %-*#((*** registration and follow-up average of the population at ',*#%,*** "' (*(%#*** ('*!'#*** " ('*''(*** cards arranged by sex and 30 June of each the years 1998 '-*!+-*** !' '+*(!%*** registration number. through 2002, estimated on %'*+#%*** ! %#*+"%*** #'*'!'*** ' ##*,%!*** The epidemiological the basis of the 1988 Census #*-,%***  "-*(#,*** data on cancer incidence in population. The population is 19982002 in Warsaw were ethnically little differentiated, ! '   ' ! 
*$ & 

*$ & collected from the Cancer and mostly Roman Catholic. ,,'*+%%*** +("*''#***  Reporting Cards (MzN-1) routinely submitted to the Cancer care facilities 
   Warsaw Cancer Registry. The Poland is divided into 16 
*
**
*  ****
**
*!-,,*
* *
****
*  



 
*
*$"%&**'**
* regions with regional oncological centres localised in data collected are recorded on reporting cards and include each of them. Nationwide supervision is performed by personal identication data (name and surname, sex, date of the Maria Sklodowska-Curie Memorial Cancer Center birth, address, occupation); medical institution; date of rst and Institute of Oncology in Warsaw and two branches in diagnosis/rst hospital admission; primary site, pathology, Cracow and Gliwice. Provincial Oncological Clinics provide clinical stage, method of diagnosis, methods of treatment, oncological diagnostic and therapeutic health services, and (if applicable) date of death. The reporting cards are sent from hospitals and outpatient including radiotherapy, in each of Polands 16 provinces. The oncologists are usually concentrated where the oncological clinics from Warsaw city, the region and other areas of Poland; for all from oncological outpatient clinics, medical centres are located. In Warsaw, specialised cancer care is provided by the records departments, and other cancer registries. New Maria Sklodowska-Curie Memorial Cancer Center and notications are immediately checked for consistency of the Institute of Oncology, clinics of the Medical Academy, the identifying data. When more than one neoplasm is observed, Institute of Mother and Child and Center of Child Health. with other histopathology, in the same person, a new card Patients are also treated at other hospital wards in Warsaw, is prepared for each different site. All entries are checked district outpatient clinics and specialist private and public for duplicates. Site is coded to ICD-9 (to 1998), to ICD-10 centres, as well as cooperatives and foundations. Warsaw has (from 1999) and histology to MOTNAC. Active and passive follow-up continue until the patients death. If current data over 400 oncologists and 1000 oncological beds. about the patients vital status are unavailable, information is requested from the Address Register. Registry structure and methods The Warsaw Cancer Registry was one of the rst Registries in Poland, established in 1963 in collaboration with the USA Interpreting the results National Cancer Institute to conduct comparative studies The percentage of underregistration was estimated in on gastric cancer incidence in Poland and among Polish- Poland in 19982002 at about 12%; however, in Warsaw Americans. These studies were subsequently extended to other underregistration is lower. In Warsaw there are organised

346

Europe

screening programs for the cancers of the cervix uteri, breast in women and for the cancers of colon and prostate. Use of the data The data are analysed to describe the patterns and trends of incidence and mortality by sex, age groups and cancer site in Warsaw. Clinical stage is also analysed for selected cancers. Survival studies are conducted, as well as analysis of treatment regimes for some sites. The data are published in annual reports, monographs, and other publications and

papers. They are also used in many research projects and international collaborative projects. Policymakers use registry data for health services planning and evaluation. Source of population The estimation of the population at risk is based on the 1988 census, making allowance for births and deaths. Multiple primary rules used IACR rules (2004) on CI5 IX period.

347

Europe

Portugal, Porto
The main method of data collection is passive notication Registration area The Registo Oncolgico Regional do Norte (RORENO) of the cases. The majority of the information on classication registers all new cancer cases of the North Region of Portugal. of cancer arrives already coded (ICD-O-1). In 2000, 81.4% According with the last census, in 2001, the population was 3 of the registrations (32 sources of data) were coming from 236 089 inhabitants distributed in ve districts (Porto, Braga, public health institutions and 18.6% from eight private Viana do Castelo, Vila Real and Bragana). The population pathology laboratories and hospitals. Since mid-June 2005 every hospital has had the ability to reveals a relatively young age structure, and is fairly unevenly distributed, its density in Porto being 53 times greater than in send the data via a common website: www.roreno.ipoporto. min-saude.pt. the easternmost parts of the region. Although the registry was built on a legal framework, The Portuguese population is remarkably homogenous and has been so for all of its history. Legal immigrants access to a unique personal identication number is denied. represent around 1.5% of the north population, and the largest Our main problems concern the promotion of the follow-up communities are from Brazil, Cape Verde and Angola and of all the cancer cases, access to digital death certicates and the completeness of some lately from Eastern European items as address and age. countries. Around 96% of the population is Roman PORTUGAL, PORTO (1998-2002) Interpreting the results Catholic. PORTUGAL, PORTO (1998-2002) There has been an improvement Some specific areas such on completeness of data as Ave and Minho-Lima are and for most cancer sites; highly industrialised, mainly incidence rates must be close in textiles, clothing, footwear to reality. Some undiagnosed and furniture. The mountains 


 


cancers concern mainly those on Northwest and the eastern 

 












with clinical and radiological region are predominantly rural 







diagnosis only. areas with little socio-economic 














dynamism. The worlds first 







Uses of the data demarcated wine region is 














Every year since 1988 an located in the Douro Valley 

 





annual report of cancer where Porto wine grapes grow. 














incidence in the North Region 







has been published. Childhood Cancer care facilities 












 

cancer data were used for a Porto is home to the main cancer 






few masters theses and for treatment centre of the north epidemiological studies. The region, the Instituto Portugus       registry receives weekly data de Oncologia do Porto, which ,($* ,($* requests for epidemiological 



%,+'.,.-.,,,  provides radiotherapy, surgery studies on risk factors and and chemotherapy for all  
 , ,

,,,,!, ,, ,",,,,&###!,,,
, ,%#,,, survival. A study on quality patients. In Porto there are also %//.2&###0, ,
 ,, , ",,,, , ,,,,,,",&##%, ,", two general hospitals capable of providing cancer treatment. (accuracy) of the data was published in 1995. Registry data  
   
,,(&##)*,, +,,
, Some kinds of cancer may be treated in the other districts. The have been used to support some projects of the Regional    ,,,,,, ,,,,
, ,,1,, 
,+,( *", health system is based on a network of primary health centres Health Administration, namely in planning of screening services. and is supplemented by private clinics and laboratories. Screening programmes are mostly opportunistic and include cancers of the breast, cervix, prostate and colorectum. Source of population In 2001 population-based screening for breast cancer began 19982000: Ofcial numbers for population in the north region, for years between census. For the year 2000, only in Bragana, involving 22 541 women. age groups of 10 years were published and freely available. These estimates allow for births and deaths and to migration Registry structure and methods The registry is located in Porto at the Instituto Portugus movements. 2001: ofcial census. de Oncologia, which is responsible for the co-ordination and organisation of the program and for the quality of its data. Multiple primary rules used In 2000 a medical epidemiologist, two full-time registrars IACR rules (2004) on CI5 IX period. and a part-time statistician staffed the registry. Two medical pathologists were also included as consultants. The staff is Notes on the data responsible for treating the incoming information from the The Editors recommend that some care be taken in the interpretation of these data; see Chapter 5 (Categorisation). health institutions and also for quality evaluation.

348

Europe

Portugal, South Regional

pathology report from all hospital and private pathology Registration area The South Regional Cancer Registry (ROR-Sul) is the labs. Necessary information is abstracted from the medical population-based cancer registry responsible for cancer records in each hospital or health centre by trained tumour registration in the south of Portugal. Its area of activity registrars or local physicians and entered into the central includes the Lisbon area, Alentejo and Algarve regions, server via the network. In addition, hospital discharge les and Madeira Autonomous Region, covering approximately of cancer patients, and hospital pharmacy and radiotherapy half of the country (39 700 km2) both in terms of area and service records are compared with registry database, and all the cases not in the registry are reviewed. population. Site and morphology codes have been coded according According to the end-of-year 2001 estimates, RORSul has 4 490 491 inhabitants, 17.5% of them aged 65 or to ICD-O-3 since 2000. The rules used for coding multiple more. Of these, 45% live in the Lisbon region (capital of the tumours are those proposed by IARC/IACR. For the staging country and suburbs). Birth rate in 2001 was 10.9%, and life of tumours, the TNM classication is used. Completeness of records, data consistency and expectancy was 73.5 for men and 80.3 for women. duplicate records are The occupational distribution continuously and extensively by economic sector in the 2001 checked using the IARCcensus was distributed as PORTUGAL, SOUTH REGIONAL (1999-2001) Check program, other specic follows: 5% agricultural, 35.1% PORTUGAL, SOUTH REGIONAL (1999-2001) computer program developed industry and construction, and in the registry, and by 59.9% services. reviewing a sample of cases. Arrangements have Cancer care facilities been made with the other two General health care in the 


  


Regional Cancer Registries region is provided by 40 














in order to exchange public general hospitals, one 







information on those resident university hospital, a network 














cases diagnosed and treated of 147 primary health care 







in hospitals outside the centres and Lisbons Cancer 














registration area. Institute. There is one 







Patient follow up is general practitioner per 2000 














carried out every year by inhabitants. Almost all cancer 







checking death certicates. patients are diagnosed and 

 












treated by medical specialists 







Use of the data working at the hospitals. The main purpose of the       
'# % 

'# % registry is to estimate cancer Registry structure and 



"'!$$')"('''  incidence in the region, and methods annually the registry prepares South Regional Cancer 
   a report on incidence. In Registry began operation 
'

''  **'
'
''
'!))!''"!'
' '
''''
'''' 
''

' '''''
'
'
'  



 in 1989 as part of a programme for nationwide cancer addition some casecontrol studies have been carried out. 
'
'#"%''&''
' The registry also participates in several national and registration, and is nanced by public health funds. Since 2000 there has been a registry network; data are international research projects, including EUROCARE. The registry is the recognised regional source of collected by laptop computer from all hospitals and health centres, and by means of standardised paper forms for information on cancer incidence. There are often requests private hospitals and pathology labs and for annual follow for information from physicians, politicians, journalists and up. The laptop is under the control of one clinician at each interested organisations. site. The Registry network server is located in Lisbons Source of population Cancer Institute. The permanent staff of the Registry network includes The estimates of populationatrisk are based on the 1991 two physician specialising in epidemiology, one of them and 2001 Censuses, making allowance of births and deaths. as head of the registry, three statisticians and ten tumour It was not possible to estimate migration into and out of the registrars. In addition, two consultantsone pathologist and registration area. one oncologistare available. The Registry is based on compulsory reporting of all Multiple primary rules used new cases since 1988. The rst tumour identier is the IACR rules (2000) on CI5 IX period.

349

Europe

Russia, St. Petersburg

detects a cancer patient must send a notication card to the Registration area St. Petersburg is the second largest city in Russia and one oncological dispensary or the cancer registry for the region its biggest industrial, scientic and cultural centres. It was of residence of the patient. On the basis of this card and other founded in May 1703, and in 1914 its name was changed to supporting documents a control card is compiled and entered Petrograd and in 1924 to Leningrad. It was the capital of the into the computer. The data of the oncological dispensary are state from 1712 to 1728 and from 1732 to 1918. St. Petersburg checked regularly against those of the statistics department, is situated at the point where the Neva River ows into the which is responsible for registering cancer deaths. Gulf of Finland and includes 42 islands of the Neva delta. The climate is of a maritime type with mild winters, rather Interpreting the results cool summers, and very changeable weather. The average There are screening programs, but since 1991 they have been temperature in January is -7 -9 C, in July +17.7 C. The performed less actively. PSA testing is used but not widely annual precipitation is 585mm and the total area is 570 km. because of nancial difculties. The main occupations are heavy industry, especially Use of the data heavy engineering (energy Information about all cancer engineering industry, patients and about deaths is machine-tool construction, RUSSIA, ST PETERSBURG (1998-2002) included in special tables, shipbuilding). In 2000 the total RUSSIA, ST PETERSBURG (1998-2002) which are sent to the Russian population was 4 660 792. Ministry of Health annually. The mortality rate for all N. Toichkin made the rst causes in St. Petersburg in 2000 evaluation of cancer rates in was 16.3 per 1000 inhabitants, !*-+"*** ,') %!*("+*** !%*%,#*** , '"*'%*** St. Petersburg in 1912. His and the average life expectancy "-*'"*** +' --*'*** research was based on the in 2000 was 66.0 years. ('*'%(*** + !#,*(,,*** ,"*'++*** (' !%"*%((*** cancer mortality rate of 93 The national structure of !!#*+"%*** ( !+*!,%*** 99 per 100 000 inhabitants the population in St. Petersburg -"*('"*** '' !"#*('+*** !%*,#,*** ' !,"*!,"*** in St. Petersburg from 1901 according to the census of !(#*+"-*** %' "!*#'#*** to 1910, which he obtained 2002 was 3949.6 thousand !+-*-#(*** % ""*#"*** !+%*-"+*** #' !--*-+*** from the municipal statistics Russians (84.7%), 87.1 thousand !+"*%(#*** # !("*""(*** department. U k r a i n ia n s (1.9%), 5 4. 5 !+,*!%'*** "' !("*#!!*** !('*-'-*** " !(%*,(%*** In 1926 N. N. Petrov thousand Belorussians (1.2%), !+%*!++*** !' !(,*!,*** initiated an institute of 36.6 thousand Jews (0.8%) and !',*#'+*** ! !'!*!%(*** !'*,(%*** ' !*(#+*** oncology in St. Petersburg, 35.6 thousand Tatars (0.8%). ,*%"#***  +'*++-*** which was later named after him. Obligatory registration Cancer care facilities ! '   ' ! was attempted in St. There are three medical *$ & *$ & Petersburg in the 1930s and institutes and two advanced "*'(%*+%-*** "*!%*"-#***  was permanently adopted training institutes for doctors, 
   after the Second World as well as a large number

* *****""**$***

** &*  



 of clinics and hospitals. Some of the patients come from War. Epidemiological research is carried out in the Petrov 
**$"&**** other parts of the country. Treatment of cancer patients is Institute of Oncology, including a study of cancer incidence carried out mostly in the City oncological dispensary at the in different areas of the ex-USSR. Annually we publish 12 editions on morbidity and Professor N. N. Petrov Research Institute of Oncology, or in a number of oncology departments in large general hospitals. survival. Additionally we systematically take part in different The total number of oncological beds is 1252, including 428 conferences and have TV and radio presentations. Data of radiological and 75 paediatric. Ordinary hospitals and clinics the Cancer Registry are systematically presented to the local government, and they are taken into account in developing treat 40% of oncological patients. Since 1953 in Russia there has been an established the organisation of oncological services to the population. state system of oncological services (cancer control). Each Our suggestions to develop establishment of further cancer administrative territory has its own centre (an oncological registries are accepted in a draft of the Order of the Ministry dispensary) with 200 to 1000 beds depending on population. of Health concerning improvement of oncological services This oncological centre provides all three components of curative in Russia. treatment (surgery, radiotherapy and chemo-hormonotherapy). In general this therapy is free of charge using federal funds as Source of population well as funds of obligatory medical insurance. Ofcial governmental estimates based on the 2002 census. (Committee on Statistics of St. Petersburg). Registry structure and methods The General process of registration is the same as that used Multiple primary rules used across the whole territory of the ex-USSR. A doctor who IACR rules (2000) on historical data.

350

Europe

Serbia
Registration area The Population Register for Cancer was formed in Serbia in 1970, originating from the Plan of Statistical Research of Interest for the Republic of Serbia. In the 1990s the data quality and the functioning of the registry greatly improved. The Central Serbia Cancer Registry covers an area of 55 968 km2, and had a population of 5 484 920 (June 2000 estimate). About half live in urban areas (48.7% male, 51.3% female); 90% are Serbs and 60% are Orthodox Christians. Central Serbia includes 18 districts, in the central part, within the Republic of Serbia, divided into 115 municipalities. Cancer care facilities Notication of neoplasms is mandatory by law for every physician who diagnoses or treats a malignant tumour. Information sources concerning new cancer cases/ deceased cases are data from the oncology institutes, oncology dispensaries, oncology clinics, hospitals and outpatient health institutions, pat hoh ist olog y/cy t olog y, haematology and other laboratories, death reports, health insurance funds and targeted researches. The notication is sent to a regional Cancer Registry located in the Institute of Public Health of Serbia. The Central Serbia Cancer Registry includes the following data: personal characteristics of new cases/ deceased, possible appearance of multiple primary tumours, date of determination of current illness, diagnostic methods, tumour characteristics (primary and secondary anatomy localisation, histology type, stage), outcome of the disease, as well as data on the health institution reporting the tumour.

)%.%&&... /#.&+/... %&&.0/,... %,%.&+,... %,#.&,'... %)#.)),... %01.'++... &&/.#00... %1+.)')... %/,.,%#... %/%.&/,... %0%.)+'...

Interpreting the results Since 1994 the diagnosis, cause of death and morphology have been coded using ICD-10, and according to the ICD-10 and ICD-O-2 (1998) and ICD-O-3 (2001). The Register does not include in situ tumours (codes D00-D09), but includes clinical stage in situ. The Register is supported by the CanReg3 (1998) and SERBIA (1999-2002) CanReg4 (2001) programme SERBIA (1999-2002) packages. With the aim of providing quality in collection, entry, keeping, processing and 0#,).&,1... analysis of data in the /+! %#/.,+#... Registry, the methodology of /#! %,#.,&0... ,+! %01.',)... international associations was ,#! %/0.1%'... applied (IARC I ENCR) for ++! %+%.'%,... +#! %1,./',... cancer registers.
)+! )#! '+! '#! &+! &&1.&),... %11.0+/... %0%.'%&... %/).+#1... %0%.&#,...

Use of the data Following the aforementioned %01./,)... &#! %0).#&1... activities and the several %0,.%#)... %+! %/0.'00... years necessary for achieving %,0.+/+... %#! %,#.+'&... %+&./#+... +! %)+.#%&... stability of the data, conditions %',.#%%... #! %&1.&)/... were created for issuing the rst Report in December %# + # # + %# 2001. 
.($* 

.($* Registry structure and &.0%&.&%)... &.,/#.+1)...  Unpublished data of the methods Republic Statistics Institute In 1986, with the aim of 
   .&###..&##%.
.

. 
..
..
..
..
".
.

.  .

. were used for the analysis of applying a unied Registry 
.  . .%111 .
  . .
.&##&.
..
 . ..

.
..
.  ". methodology in all territorial units of the Former Yugoslavia, death due to malignant tumours in Central Serbia.  



 
. 
.(%11#..&###*.. Apart from crude rates, the Report includes standardised the Guidelines On Ways And Procedures Of Reporting Persons With Malign Neoplasms, the Regulation Book For incidence and mortality rates on World population. These rates The Register Form And The Method Of Updating, The were standardised by the method of direct standardisation, with Report Forms And Reporting And Cancelation Procedures the World, European or truncated population as the standard population. Registry data calculated and analysed at the Center For Certain Diseases were adopted. Imprecise guidelines, insufcient education of medical of Prevention and Control of Noncommunicable Diseases have personnel, and a lack of informatics support resulted in the been used for the purposes of descriptive epidemiology. The percentage of new malign tumour cases registered under-registration of newly found cases of cancer, as well as relatively poor data quality on the report forms themselves. on a death report only basis, as well as the percentage of Starting from legal obligations and role of the Registry, the histologically and cytologically-veried malignant tumours reorganisation of the Register began in 1996, in accordance of the total number of reported cancer cases, were the with the recommendations of the International Agency for foundation for the evaluation of Registry data quality. Research on Cancer (IARC), and European Network of Cancer Registries (ENCR). The reorganisation encompassed: Source of population decentralisation (registers are formed on a regional level, The populations for 1999, 2000 and 2001 are estimates while the main database for Central Serbia is located in the provided by The Statistical Ofce of Republic of Serbia. The Institute of Public Health of Serbia), active data collection, estimated populations were an extrapolation from the 2002 new sources of information, education of medical personnel, census assuming linear growth in every age and sex group. informatics support and a feedback system. In 1998, due to this successful reorganisation, the Central Serbia Cancer Multiple primary rules used IACR rules (1990 and 2000). Registry was admitted into the IACR.

351

Europe

Slovak Republic
Registration area clinics is provided about change of name, address, diagnosis The National Cancer Registry of the Slovak Republic covers the and about the death of any cancer patient. In the registry whole population of the Slovak Republic, with 5 400 679 inhabitants each newly notied patient is compared and checked with (2 625 691 males and 2 774 988 females) in 2000. The Slovak the main le of patients already registered to ensure proper Republic is divided into 8 regional units and 79 districts and covers registration of new primaries and elimination of duplicates. an area of 49 035 km2, with a perimeter of 1672 km and a population All death certicates (all causes of death) are regularly density of 110.1/km2. In 2000 nearly 13% of the inhabitants lived reviewed to ensure the inclusion of previously unregistered in the two bigger cities, Bratislava and Koice. Twelve percent lived cases and consequently to include DCO cases. The National Cancer Registry database is annually in another nine towns with 50 000100 000 inhabitants, 30.4% in communities and smaller towns of 500049 999 inhabitants, and reconciled with the database of hospitalised patients the remainder in villages with fewer than 5000 inhabitants. In 2000 (established by the Ministry of Health). If any cancer report the majority of the working population was employed in industry is missing, it is searched for and requested of the provider. and agriculture (37.8%), the remainder being employed in building The completion of dates of death is now also assessed using and service industries, research data from the Office for the and trade. In 2000, employees Evidence of Population of the in the Slovak Republic could be Slovak Republic. Since 1990, the SLOVAK REPUBLIC (1998-2002) divided by education into four registry has received considerable SLOVAK REPUBLIC (1998-2002) categories: basic (9.1%), trained information about cancer (29.2%), secondary (48.8%) patients from other documents and university (12.9%). The accompanying the notication majority of the population is of form (discharge summary, 


 









Slovak nationality, the second hospital record, operation report, 







most numerous group being results of histology or cytology 














Hungarian. Unemployment was and autopsy report). 







18.3% in 2000, but 9.6% at the 

 












end of 2006. Interpreting the results 







There was no national screening 







 



 


programme in 19982002, Cancer care facilities 







although screening for colorectal In 2000 there were 95 hospitals 














cancer was introduced in 2002 in the Slovak Republic. There 







and PSA testing is widely were 92 public (state) hospitals 




 









available. An increase of in situ and hospitals with polyclinics (7 







cervical cancer and a decrease university hospitals, 79 hospitals in breast cancer mortality and 6 psychiatric hospitals) and       despite increasing incidence 3 private hospitals. Cancer care 
(# % 

(# % would suggest the existence of at the highest level is provided 



"('"&('*!(((  some screening programmes by the St Elisabeth Cancer 

   or at least an improvement Institute and the National Cancer !**),"+(

("!(
(""(

(#(
((
(
%(  



 Institute, both in the capital of Slovakia. There are oncology in diagnosis and health education. The national screening 
( 
(#"$%((&((
( and radiology departments at the university and most of the programme for cervical cancer became available in 2007. county hospitals. The peripheral network of oncology outpatient clinics is oriented to registration and notication of diagnosis, Use of the data active lifelong follow-up and providing treatment for cancer Annual reports have been published regularly since 1983. The patients. The creation in 2000 of the Eastern Slovak Cancer annual report contains detailed data on cancer incidence in Institute has also contributed to improving high-level cancer Slovakia, including sub-regions, and is distributed to all the care and, in general, the quality of diagnostic and treatment health institutions of the country (Ministry of Health, central institutes, hospitals, centres of clinical oncology, public services for cancer patients is gradually improving. health institutes). The data are used for policy preparation for cancer care and prevention, as well as for planning Registry structure and methods The National Cancer Registry of the Slovak Republic is facilities for the diagnosis and treatment of cancer patients. a population-based cancer registry established in 1976. Recently these data have been increasingly used by the It covers the entire population of the country and collects National Centre of Health Promotion and by the Slovakian League Against Cancer, mainly for health education of the cancer data from the year 1968 onwards. Cancer reports and death notication forms are used for data population in the eld of cancer prevention. The data are also used for many other international collection. The registry has had its own computer centre since 1990. In 2005 it moved from the National Cancer Institute to the National collaborative projects. Centre for Health Information, Bratislava. The staff of the registry now consists of one epidemiologist, one full-time and four part-time Source of population physicians (oncologists and pathologists), seven registrars and one 19982000: estimates. 2001: Census. 2002: estimates computer specialist. Notication of cancer is compulsory, and all (Statistical Ofce of the Slovak Republic). physicians have three months to complete the notication forms. The registry notication form is completed in the district Multiple primary rules used oncology outpatient clinics. Further information from the IACR rules (2004) on CI5 IX period.

352

Europe

Slovenia
Registration area The Cancer Registry of Slovenia covers the entire population of the Republic. The population at the most recent census (2002) was 1 964 036. About 50.8% of the population lives in urban areas (>3000 inhabitants); 83.1% are Slovenians, 2.0% Serbs, 1.8% Croats, the remainder other nationalities, mainly from neighbouring countries and countries of former Yugoslavia. The prevailing religion is Roman Catholic, and 84.7% of population is aged 15 years or over. information as well as to the hospitals or doctors who signed the death certicates in case the patient had not yet been registered. Trained registrars, supervised by a physician, perform coding of the information. Case identication is based on a personal identication number that also enables accurate follow-up of patients for death by regular linkage of our data to the Central Population Register. Data protection regulations are strictly respected.

Interpreting the results The small and stable proportion of cases registered after Cancer care facilities Health care centres and private practitioners provide the publication of annual reports (about 4%) shows that the primary and outpatient secondary health care; most of them majority of cases are reported to the Registry by the time of publication. The registration are included in the public of patients treated in the health care network. There outpatient department only are 12 general hospitals and SLOVENIA (1998-2002) (e.g. non-melanoma skin Clinical Center in Ljubljana as SLOVENIA (1998-2002) cancer, multiple myeloma, a tertiary healthcare facility. chronic lymphatic leukaemia, The Institute of Oncology, as well as prostate cancer) is founded in Ljubljana in 1938, incomplete. is the only Slovenian national #$,.$',,, .!+ %',!!),,, There are no ofcial comprehensive cancer centre. #-,$-',,, -) %.,#)#,,, data on PSA testing, but it is Besides patient care, it is %!,'#*,,, -! '/,)#),,, '$,#)/,,, *) )',..),,, becoming very popular among involved in research and '/,%'!,,, *! )',/!.,,, urologists. It is not paid to education in the framework )',$-.,,, )) )*,%/',,, *),*!.,,, )! *%,-#$,,, general practitioners by health of the University of Ljubljana .#,%.*,,, ') --,!.#,,, insurance. Medical Faculty. Common -/,$'%,,, '! --,!-!,,, --,!'.,,, %) -*,)'#,,, cancers are treated in general -%,*//,,, %! -%,%-$,,, Use of the data hospitals, though the Institute -%,'/',,, $) -!,)*),,, -*,/-.,,, $! -$,-*),,, Annual reports on cancer of Oncology is the referral -!,..%,,, #) *-,**/,,, incidence have been published centre for rare cancers. Except *$,*/*,,, #! )/,-!%,,, )$,)#),,, ) '/,-*-,,, since 1951, since 1965 in for skin cancer, radiotherapy '-,!--,,, ! '',$.*,,, Slovenian and English. is administered only there. The data collected serve as About half of cancer patients #! ) ! ! ) #! the basis for assessing the are admitted to the Institute 
,&"( 

,&"( national cancer burden, for at some time during their #,!$!,%/!,,, /**,/#/,,,  programming and evaluation illness. 
   ,
,,
,  ,,,%!,
, 
,,
,,
,,
,
,,
,
,,
,
,  , of primary prevention, 

,,
,
,,
, diagnosis, treatment and rehabilitation, for programming Registry structure and methods  



 
,
,&$!!'(,,,, The registry was founded in 1950 and is located at the and evaluating primary prevention, diagnosis, treatment and Institute of Oncology Ljubljana. Notication of cancer has rehabilitation, planning facilities and funding needed for been compulsory since the beginning and is prescribed by cancer control (personnel, equipment and hospital capacities) law. In 2003, the Registry was merged with Epidemiology as well as for clinical and epidemiological research in Unit in a single service, Epidemiology and Cancer Slovenia and in international multicentric studies. The results Registries, which also comprises, the hospital-based Cancer of our studies are published in national and foreign medical Registry of the Institute of Oncology, Epidemiology Unit literature and as publications for lay readers. Our data have been published in all eight volumes for epidemiological studies and Cervical Cancer Screening Registry, which coordinates, monitors and evaluates the of the Cancer Incidence in Five Continents. The data on nationwide organised cervical cancer screening program, cancer incidence and mortality for the years 198399 were introduced in 2002. The Registry is staffed by two full- also included in the international databases EUROCIM, time medical doctors, specialising in epidemiology and GLOBOCAN, ACCIS. The survival of Slovenian cancer public health, a junior researcher in statistics, 4 registrars, a patients is included into and analysed by the international computer operator and part-time system analyst. Other staff studies EUROCARE II and EUROCARE III. are involved in screening and other work. The main sources of data are notications gathered Source of population from all hospitals and diagnostic centres in Slovenia, and Ofcial number of the population as at 30 June provided by exceptionally from primary health care centres in cases in the Statistical Ofce of the Republic of Slovenia based on the which the patient was not referred for further diagnostic Central Population Register of the Republic of Slovenia. investigations. Death certicates and autopsy protocols stating cancer diagnosis supplement this information. When Multiple primary rules used needed, requests are sent to notiers to ensure accurate IACR rules (2004) on historical data.

353

Europe

Spain, Albacete
the Comunidad Autonoma. Our Registry currently employs Registration area Albacete is situated in the Central Meseta in the southeast of 2 doctors and a nurse. Data collection is active, carried out by the personnel Spain. The province consists of 87 municipalities, 67.5% of which have fewer than 2000 inhabitants and only 5.9% have of the registry from lists provided by the sources, and by more than 10 000. The climate is Mediterranean temperate consulting the les and clinical records concerned. The with some continental features. The average total annual registry records cases voluntarily notied by physicians in the primary care services. rainfall is approximately 275mm. No active follow-up of cases is carried out. The registry The size of population covered by the registry at midyear 2000 was 363 263 inhabitants. The population density has access to death certicates mentioning cancer for local (24 inhabitants per km2) is very low compared to that of residents who die in the Autonomous Community. Death the country as a whole. Of this population, 15.5 % live in certicates are traced back to nd further information if the rural areas of fewer than 2000 inhabitants, 24.5% in semi- case is not already registered, and if no further information rural areas of 2000-10 000 inhabitants, and 60.0% in urban is found the case is registered as death certicate only. There is no personal contact with areas. patients or their families. The ethnic/racial All data are automatically composition that our Registry SPAIN, ALBACETE (1998-2001) processed using a system, covers is practically all white. SPAIN, ALBACETE (1998-2001) which includes checking Only in recent years have for duplicate registrations immigrants accounted for by name, social security 35% of the population, and number or clinical record. these are generally young (# ((( *%' !(++*((( (+%!((( * #(&)*((( Cases are coded by ICD-O people with low risk of %(&+%((( )% )(! *((( topography and morphology. cancer. *( +((( ) +(! ((( +(! #((( &% ( *((( Multiple tumours are coded *(&+&((( & +( +%((( following the IARC/IACR Cancer care facilities *( #)((( %% *(%%*((( *(+#*((( % +(&&((( recommendations. The Six hospital centres are +(* ((( #% +(% ((( CHECK program is used to located in the province, three (**((( # (#)((( #(% ((( !% !(* *((( detect errors and discrepancies of which are private surgical %(*((( ! #(&+%((( in the data. hospitals and three public #(+#((( % #( )#((( #(+)+(((  #(#%((( general hospitals. There is one !(&#((( %  ( &+((( Interpreting the results private pathology laboratory. (% (((  (+%)((( ()&&((( % ()((( It is not possible to estimate There are 34 public primary +(#*(((  *(*((( how many cancer cases remain care centres. Almost all of undiagnosed, but it probably the population is covered  %   %  does occur for elderly subjects by the public health system 
("$

("$ in rural areas. SESCAM has (SESCAM). * (#!)((( *(&(((  a full range of diagnostic Data for the registry 
   facilities, so it is unlikely that are obtained from the 
,(((
((" ,

$( General Hospital of Albacete  



 (pathology and haematology cases referred will be missed. A screening service for breast 
(
("++$(( laboratories, oncological and medical records departments); cancer is operated by the Asociacin Espaola contra el the Local Hospital of Hellin (pathology and haematology Cncer since 1991. Use of PSA tests is opportunistic and of laboratories and medical records); the hospitals N S de los an unknown extent, but in general it is not uncommon. Llanos; Santa Cristina, Virgen del Rosario and Clinica de Recoletas; the Dr liguez de Onzoo pathology laboratory, Use of the data the Provincial Ofce of SESCAM, the regional mortality The registry prepares an annual report of cancer incidence by site, sex and age. The registry also participates in analytical register and the National Institute of Statistics. In general our area has a good availability of diagnostic epidemiological investigations. Policymakers use our cancer and treatment services, but the radiotherapy department did registry data for planning or evaluation of health services, especially in breast cancer screening programme and the not begin operation until the year 2002. regional cancer programme. Registry structure and methods The Cancer Registry of Albacete was created in February Source of population 1990 by the Consejera de Salud de la Comunidad Autonoma Census: Instituto Nacional de Estadistica (http://www.ine.es). de Castilla-La Mancha, and it belongs to the Regional Service of epidemiology with the principal objective of Multiple primary rules used analysing cancer incidence in the province. It is nanced by IACR rules (1990).

354

Europe

Spain, Asturias
funded by a Public Health Directorate from Asturias Health Registration area The Asturias cancer registry covers the whole Principality of and Health Services Council, a government body in charge Asturias, a Spanish Autonomous Community of 10 565 km2 of planning and providing health care and public health located on the northern coast of the Iberian Peninsula. This services to the whole Asturian population. The registry staff well-dened region lies between latitudes 42 and 43 N and comprises one part-time epidemiologist and two full time registrars. longitudes 4 and 7 W. The registry uses active casending from different In 2000 the total population was 1 076 567 inhabitants. Of these, 21.4% were aged 65 or more, and 60.4% lived in sources including public and private hospitals, pathology and the central urban area of Asturias but only 43.4% in cities of haematology laboratories and death certicates to identify more than 100 000 inhabitants. The population density that cancer cases diagnosed among the residents of Asturias. There is also a hospital-based registry in Central Hospital, year was 101.53 inhabitants per km2. In 2000 the unemployment rate was 16.4% in Asturias, and which provides computer les to the registry. Cancer is not a the distribution of occupation by sector was 10.2% in agriculture notiable disease in Asturias. and shing, 16.9% in industry, Interpreting the results 11.8% in the building sector and From 1998 to 2000 an 61.1% in services. SPAIN, ASTURIAS (1996-2000) organised breast cancer The prevailing religion in SPAIN, ASTURIAS (1996-2000) screening programme was Asturias is Roman Catholic. implemented in Asturias covering women aged 5064, Cancer care facilities reaching a 60.5% participation General health care in "$"$$$ &!# "$!!$$$ '$%!$$$ & &$$$$ in the rst round. Asturias is provided mostly %$!$$$ %! "$$$$ Trends in prostate cancer by public services through a !$&$$$ % $!$$$ $""$$$ "! %$&$$$ incidence should be evaluated well-developed network that $$$$ " $!$$$ with caution because the comprises 8 district hospitals, $!&$$$ !! !$'%'$$$ $!""$$$ ! !$!!$$$ impact of opportunistic PSA 220 urban and local primary %$%$$$ ! %$"'$$$ screening. health care centres, and Central '$"$$$  $&$$$ $%!$$$ ! $%"$$$ Hospital in the capital (Oviedo), '$&$$$  '$!$$$ Use of the data home to a comprehensive $"$$$ ! '$$$$ $&$$$  $"$$$ The registry publishes regular oncology centre that offers "$&$$$ ! !$%$$$ reports on cancer incidence. cancer surgery, radiotherapy %$""$$$  !$"$$$ '$&%'$$$ ! '$%$$$ Data from the registry have and chemotherapy services. !$"!$$$  $&&$$$ been used for etiological Patients suspected to have research in the EPIC cohort, cancer are diagnosed and  !   !  evaluation of breast cancer given treatment in the 8 health  $   $ programmes, and to plan districts and referred to Central !"$$$$ !'$!$$$  radiotherapy facilities and Hospital when required. These 
   other cancer services. facilities are supplemented by    $$
$" $  



 one private hospital that offers some cancer treatments. Very few 
$ $ $$ $$ Source of population cancer cases require additional treatment outside Asturias. Census data (INE 2006). Registry structure and methods The registry was initiated in 1978 and become population- Multiple primary rules used based in 1982. It is located in Oviedo and since 1981 has been IACR rules (2004) on historical data.

355

Europe

Spain, Basque Country

an epidemiologist partially assigned to the registry, and Registration area The area covered by the Basque Country Cancer Registry several administrative registrars have the hospital registries (BCCR) is the Autonomous Community of the Basque Country, as the main sources of information. Notication is voluntary. an area of 7261 km2 situated in northern Spain between latitude An active system of data collection from other sources has 4027 and 4228N and longitudes 144 and 326W. It been established, and cases are abstracted from clinical consists of three provinces: Alava, Bizkaia and Gipuzkoa. records and entered in the computer. Data from incident At the 2001 census, the total population was 2 082 587, of cases are complemented by death certicates mentioning whom 17% were over 65 years old. The population density cancer (pre-1996) and all death certicates since then. A is 286.8 persons/km2. About 28% of the population live in case is registered as Death Certicate Only when no further rural municipalities. The employment of the active population information has been obtained after looking for information by sector is: services sector 62%, industry 27.5%, building in the sources. Checking for duplicates is routine, and the activity 8.7% and agriculture 1.8%. The prevalence of smoking IARC-Check program is used periodically. Arrangements in men and women is decreasing: 31% and 21% respectively. have been made with cancer registries outside the registration area to notify the BCCR of The proportion of immigrants any resident cancer cases they was low but increasing. Most diagnose or treat. of the population is Roman SPAIN, BASQUE COUNTRY (1998-2001) Catholic. SPAIN, BASQUE COUNTRY (1998-2001) Interpreting the results Rates from 1986 to 1994 were Cancer care facilities converted from ICD-O-1 to General health care in the ICD-O-2. Since November region is provided by the -*##*** ,') "'*-!'*** !%*(%#*** , ",*##'*** 1995 there has been an Osakidetza, the public Basque "+*,(+*** +' %!*-!"*** organised breast cancer Health Service, to 95% of %"*-,(*** + '#*!,%*** '#*'"#*** (' (*",,*** screening programme in the the population. There are 40 '"*'+*** ( ''*%"(*** Basque Country covering hospitals (public and private, (*''*** '' ("*!",*** (,*+#*** ' (-*"+*** women aged 5064 years. one of them devoted to +"*-,,*** %' +#*'%*** There is no populationcancer treatment) excluding +-*#'%*** % ,*#"(*** ,'*%%*** #' ,'*(*** based cervical screening the psychiatric ones, and ,(*-%'*** # ,#*-("*** programme, but there is approximately 4 beds per ,-*-#-*** "' ,'*###*** ,!*-!*** " +,*'%*** opportunistic screening 1000 inhabitants. Most cancer (#*!#*** !' '-*+%*** mainly in women at higher patients attending the network %+*''*** ! %'*#+(*** %!*"'#*** ' #-*'"*** risk. The large increase in of primary healthcare centres %"*#%!***  %*#*** prostate cancer in recent years are referred to medical can be related to the use of specialists at the general ! '   ' ! PSA by general practitioners hospitals with oncology  *$ &   *$ & !*((*+!'*** !*"*'!"***  and specialists since 1998. facilities. Over the last 10 years the number of radiology 
   Use of the data facilities for cancer diagnosis  *
* ***** ** *!--(**"!* ** *** *
* * ***  



 and treatment as well as the number of oncology specialists A report with descriptive results of the registry is published 
* *$"%&**** in an annual report by the Basque Health Department. has increased in both the private and the public system. Information provided by the registry is used for planning and evaluation of health services. Survival has been studied Registry structure and methods The Basque Country Cancer Registry was created in in the framework of the EUROCARE study. Data have been used for the evaluation of the breast 1986 by the Department of Health. The main aim was to determine cancer incidence and its characteristics in the screening programme and in several collaborative studies Basque Country, to provide information for the planning of such as EUROCARE, Europreval, ACCIS and EPIC among cancer services and preventive activities, and to facilitate others. In-house studies include several cancer sites and their relation to health services, and evaluation of coding to epidemiological research. A major reorganisation of the Cancer Registry has taken implement a semi-automated programme. place since 1995. In each province a team was dened and ve hospital cancer registries were established. The Source of population coordination of the BCCR remained in the Health Department Estimate of the population at risk is based on the 1996 and (Vitoria-Gasteiz), where a computer technician and one 2001 censuses without taking into account immigration into epidemiologist were assigned part-time to the registry. or out of the area. Previously registered cases were converted from ICD-O-1 to ICD-O-2 with IARCtools, and a new data management Multiple primary rules used application was developed. The head of the provincial team, IACR rules (2004) on historical data.

356

Europe

Spain, Canary Islands

method or tumour site. Since 2006 we have had internetRegistration area The archipelago of the Canary Islands is one of the based access to the records of the 4 major hospitals, which autonomous regions of Spain. It is located 100km east has been an excellent tool. Some patients go to hospitals in mainland Spain for from the African coast and 1500km from mainland Spain, treatment, but most diagnoses are made in the islands, and in between latitude 27 and 30 N. The Registry covers the population of the two major any case many of these are collected via death certicates, so islands (Gran Canaria and Tenerife), which are the we believe the registry completeness level is acceptable. administrative capitals of the two provinces. Those two islands had a population at mid-year 2000 of 1 474 802 Interpreting the results There is an organised screening programme for breast inhabitants (population covered by the registry). The population is almost 100% Catholic although there cancer in women aged 5064 years from, and opportunistic are some people from India who have lived in the islands for screening for cervix and prostate cancer. PSA testing is generations. In recent years, especially in 2001 and 2002, common in the population. the islands have undergone Use of the data a strong immigration The registry publicises an phenomenon, mostly from SPAIN, CANARY ISLANDS (1997-2001) annual report of incidence South America. SPAIN, CANARY ISLANDS (1997-2001) with the cases of one given The economic activities year, available online at: http:// are agriculture (7%), industry www.gobier nodecanarias. (3.4%) and services, mainly org/sanidad/scs/3/3_5/cancer/ tourism (77.9%). 
 

 









ppal.jsp. 






The data are used Cancer care facilities 














continuously by health There is a network of 







managers in health planning primary health care centres 














for the hospitals and and two reference hospitals 





 

government. The Registry has in each island with services 












 

also conducted some other of oncology, radiotherapy, 







studies in cancer mortality, haematology and cancer 














and collaborates with several surgery and chemotherapy. 







investigations of colorectal, 













breast, cervix and thyroid Registry structure and 







cancer and melanoma. methods The registry belongs to the       Source of population Public Health headquarters 
*&"(

*&"( 1998 Census. Geometrical and is part of the Epidemiology 


+#+*#%#***  interpolation between Service. Each island has a  

 *

*
 *


*#--).#--- *#---.$!!#*
 *

*
 *


*
*  **
** 19961999. 19992001 team of 2 medical doctors, 2 #--,*
 ****
*
**
*  **
******
*
*
* Census. Geometrical interpolation between the population nurses and 1 clerk.  
   
*
*&$!!'(**** The Registry actively collects data from public and private on the rst day of January of the year, and the population on    )+*
**
* * sources. Registrars search for cases at pathology, oncology, the rst day of January of the next year. radiotherapy, and haematology services, in inpatient records and hospital cancer registries, as well as in private pathology Multiple primary rules used laboratories and among death certicates with cancer as IACR rules (2004) on historical data. primary cause of death. If necessary, patient medical records are veried by the Notes on the data originating hospitals, either to conrm the incidence date, C67 includes only invasive tumours.

357

Europe

Spain, Cuenca
3. To know the temporal evolution of cancer incidence in our Registration area The population-based Cancer Registry of Cuenca was created in province. 1993, within the Epidemiology Service of the Health Department 4. To know survival rates in cancer patients and their temporal evolution. of the Autonomous Community of Castilla-La Mancha. The area covered by the Registry is the Cuenca province, 5. To contribute to improving and encouraging epidemiological located between 4033 and 3935 N latitude, corresponding investigation, preventive measures and sanitary care in oncology patients. to the Spanish Central Plateau. The population (according to the 2000 census) was 201 060 inhabitants (100 127 males and 100 933 females), Material and methods including 1289 immigrants; 44% live in rural areas (<2000 All malignant tumours diagnosed from 1 January 1993 inhabitants). Some 25% are older than 65 years, and 14% are in persons residing in Cuenca at the moment of diagnosis under the age of 15. The province covers 17 140 km2 (238 are eligible for the RCCU. Furthermore, following WHO municipalities), at a population density of 11.7 inhabitants/ recommendations, we register all bladder tumours, independent of their behaviour. km2. The economic activity Basal and squamous cell skin rate for the population aged cancers are not registered. 1665 is about 50%. Economic SPAIN, CUENCA (1998-2002) The data are automatically activity is developed in the SPAIN, CUENCA (1998-2002) processed using a system services sector (45.1%), in that includes checking to agriculture (25.2%) and in avoid duplication, such as industry and construction surnames, Social Security (29.7%). '/&*-/// 1,. (/-31/// '/,30/// 1$! (/111/// number and Clinical History */-0&/// 0,! ,/0(0/// code. We use the CHECK Cancer care facilities -/'03/// 0$! -/03'/// -/1'$/// -,! 0/$1*/// program to detect errors and In the registry area there are ,/,-&/// -$! -/&&0/// inconsistencies between the a public hospital (with 90% of */0-,/// ,,! ,/&0*/// ,/$$(/// ,$! */1&*/// different variables. the beds) and a private hospital. ,/(-0/// *,! */110/// Cases are codied according In the public hospital, there is -/0-'/// *$! ,/3&$/// 0/3-,/// (,! 0/&-$/// to the ICD-O-2, following the an oncology service where 0/00(/// ($! -/333/// recommendations of the IARC chemotherapy is provided, 0/'$&/// ',! -/,3,/// -/30-/// '$! -/'00/// to classify multiple primary and a surgery service that -/$&&/// &,! ,/-,-/// tumours as well as to register the serves cancer patients. Patients ,/(-,/// &$! ,/''1/// ,/$('/// ,! */11&/// different variables (incidence are sent to referral centres for (/3-,/// $! (/1,&/// date, diagnosis basis). Access radiotherapy. There are 37 public to patient data is restricted to Primary Health Care Centres &$ , $ $ , &$ Registry personnel. covering the province. /)%+ /)%+ Use of the data Registry structure and 
  
2//
2/
/////5/
/
///// /) +"/
4##"" / The registry publishes a report methods 
//
2///&/5//&331 //////////"/ The personnel devoted to the Cancer Registry of Cuenca are of cancer incidence from 1993 to 2002, highlighting trends,  



 
//)'$$$+/ evaluating survival and making geographical comparisons. two physicians, three nurses and a clerk (all part-time). Data collection is carried out actively by the personnel Our registry is also taking part in the Regional Plan Oncology of the Registry through the review of clinical histories in the in CastillaLa Mancha. The registry also participates in a hospital or in the Primary Health Care Centres. The registry national research project about rare tumours. The information obtained was used to produce three receives the automated discharge les and the computerised pathology reports from the public hospital. Furthermore, we incidence posters at the National and Regional Epidemiology receive individualised information from the cases treated by Annual Conference. The data will also be used to measure the effect of the general practitioners, and from the hospital physicians who attend patients with cancer, as well as information from death breast cancer screening programme. certicates. There is an organised screening programme for breast cancer that also informs us of newly diagnosed cases. Source of population The principal objectives of the Population Cancer Updated information from the municipal registers of inhabitants for each year published by the Instituto Registry of Cuenca are: Nacional de Estadistica (INE http://www.ine.es), except for 1. To know the real incidence of the Cancer in our province, the population aged less than 1 year in 1998, which was as well as its distribution by age, sex, morphology and calculated based on annual growth. topographic site of the different tumours. 2. To compare our incidence with that in other registries in Multiple primary rules used IACR rules (2000). Spain and other countries.
&$$/',1///  &$$/0,$///

358

Europe

Spain, Girona
year the registry analyses all death certicates. The registry Registration area The Girona Cancer Registry covers the population of Girona staff visit the sources, where they check medical records Health Region, located in the north of Catalonia in the and database of individual departments related to both the northeast of Spain. The population at the most recent census diagnosis and treatment of cancers. Their main objective is (2000) was 538 139. The area covered by the registry is to identify and abstract information on cases of cancer that divided into 209 municipalities, with Girona city the largest have been diagnosed by all methods. Arrangements have (approximately 86 672 inhabitants). Within this region, also been made with the hospitals located outside the Girona about 57% of the population live in urban areas (>5000 registration area in order to obtain information from patients whose cancers have been diagnosed and treated outside the inhabitants). The population in Girona province is ethnically very Girona area. Accordingly, these sources are visited once a homogeneous, with the majority of the population being year to review these procedures. All records are interpreted Caucasian. However in recent years there has been a huge increase and after coding, updated and processed. The registry is in immigration from Africa. According to the 2001 census in organised as a multi-user online database. Morphology has been coded the province of Girona, 7.7% of according to ICD-O-3 since the population are immigrants, 1998 and site has been coded originating from other European SPAIN, GIRONA (1998-2002) according to ICD-O-3 since countries (1.8%), Africa (4.0%), SPAIN, GIRONA (1998-2002) 2000. Before 2000, site was South America (0.85%) and Asia coded according to ICD-O-1 (0.26%). and morphology according to ICD-O-2 since 1993. The Cancer care facilities 


 









rules used for coding multiple He a lt h c a r e i s p r ov id e d 







tumours are those proposed by predominantly by the National 





 








IARC/IACR. Quality control Health Service through the 







of data is ensured through the district hospitals and a network 





 








DEPedit programme. of primary health care centres. 







Condentiality is ensured There are nine public hospitals 














by the application of the rules with 1087 beds and three private 






proposed by the European hospitals with 233 beds (2.45 

 












Network of Cancer Registries beds per 1000 inhabitants). 







(ENCR). Medical specialties concerning 














The estimated completeness ca ncer t reat ment i nclude 







for the period 19982002, taking radiotherapy, cancer surgery into account the proportion of and chemotherapy and are       
)$!& 

)$!& DCN cases, was around 95.7%. carried out at different general 


#*")''()))  hospitals but coordinated by the Interpreting the results reference cancer centre in the 
   )  )
)

)

)
))
)",,())# ")

)

)
)))
)) A screening program for city of Girona (Catalan Institute 
)",,+)",,,)#  )
)

)
)
)# "))# #)  )
) 
)

)

)
)
)
 )
))
)",,+-# )) 

) 
)) ))
)
)))
)
)) of Oncology-Hospital Universitari de Girona Dr. Josep Trueta) breast cancer was started in the area covered by the registry  



 
)
)$# %&)))) which has radiotherapy facilities at its disposal. Some cancer in 1999, and there are opportunistic screening services for patients may be diagnosed in hospitals located in Barcelona cervical cancer in the area. Use of the PSA test in the medical (100km from Girona), and the cancer registry also covers such practices has also increased during this period. sources of information. Use of the data The information obtained is used to produce annual incidence Registry structure and methods The Girona Cancer Registry began its activities in 1995. reports. Data on cancer incidence serve as a basis for health It is funded by the Department of Health of the Catalan planning. Our registry has carried out and participated in Government and is carried out by the Catalan Institute of epidemiological studies. Studies on both survival and care of patients with some specic tumours are also being carried out. Oncology. The staff is composed of a director, an oncologist as a coordinator, an epidemiologist, a technical registrar and Source of population a clerk. Several oncologists, hematologists, pathologists, The 1998, 1999, 2000 populations are intercensal estimates computer scientists and statisticians are external based on the 1996 and 2001 censuses, where allowance for births, deaths and migration have been made. The 2001 and collaborators. Notication of cancer is voluntary. Data collection is 2002 populations are postcensal estimates, where the same active, from 21 sources consisting of general hospitals and methodology used in 19982000 has been applied, without pathology laboratories. Data are obtained mainly from making any correction based on a later census. admission services and medical records, as well as from pathology, oncology and haematology departments. The Multiple primary rules used death registration system is adequate and complete; every IACR rules (2004) on historical data.

359

Europe

Spain, Granada
les for the hospitals and the computerised pathological Registration area The population covered is the province of Granada within reports from the public hospitals. Data collection is mixed: the Andalusian Region in the south of Spain. It lies between incorporation of the automated hospital systems and active latitudes 38 and 36 N, and has an area of 12 635.3 km2. The complementary search in hospital records by the registry province has 71km of coast along the Mediterranean; a large staff. Information based on primary health care is limited. part of its territory is mountainous, and one of the highest Due to condentiality requirements, access to death certicates at the National Statistics Institute is not possible, summits of Spain is found there (Mulhacn, 3481 m). The population in 2000 was 809 006 inhabitants (395 and registry personnel have to collect this information in 659 men and 413 347 women), 16% of them aged 65 years each of the municipalities. Coverage of this source was about or more. The province is divided into 168 municipalities: 90% until the year 2000. From this year the access to this there is only one urban centre (Granada) with approximately source is forbidden. Data processing is carried out on a personal computer, 240 000 inhabitants, and 6 other municipalities have more than 20 000 inhabitants, the rest of the population (56%) living and quality control of the data is ensured through the IARCCHECK programme and in smaller municipalities. The other specic programmes population is ethnically very developed in the registry. homogeneous. SPAIN, GRANADA (1998-2002) Granada has been one of SPAIN, GRANADA (1998-2002) Interpreting the results the Spanish provinces with the lowest income per inhabitant, Undiagnosed cancer cases are an important factor inuencing unlikely because diagnosis migratory movements from and treatment (radiotherapy &+ , +++ -(* -+"- +++ (+)"$+++ -  /+&$-+++ 1950 to 1970, which have since and chemotherapy) of cancer " +/ (+++ ,( "(+""-+++ stabilised. Of the economically are available in the province ")+"()+++ ,  "/+,($+++ # +","+++ )( ##+()#+++ active population, 10% are of Granada. From the year "-+#-(+++ )  # +&- +++ employed in agriculture, 22% 2000 it is not possible to use "-+$$&+++ (( "/+)/,+++ # +("#+++ (  #"+(/&+++ in industry and building, and death certificates as a source ##+&$)+++ &( ##+, "+++ 62% in services. Industrial for case-nding, and this could #,+(#(+++ &  #,+($(+++ $"+(#(+++ $( $"+,,$+++ activity is limited to light slightly decrease the degree $$+$"#+++ $  $$+"/"+++ industry, particularly food and of completeness, although $$+-(/+++ #( $$+ ((+++ $&+/, +++ #  $$+/#)+++ wood processing. The rate of the percentage of DCO in the $ +-("+++ "( #/+))&+++ unemployment is 7% of the previous period was quite low #)+/& +++ "  #(+," +++ #&+(,#+++ ( #$+&#-+++ active population. (4%). ",+ /,+++  ")+ #,+++ An organised populationCancer care facilities based breast cancer screening " ( ( " The entire population (100%) programme has been +%!' +%!' has free access to public established gradually in the &"$+-$&+++ $/,+"$&+++  hospitalisation. The area is province of Granada since the 
   served by four public (2137 .++
 .+
++++"++ +++0++
0+%
'+  0++0+++ year 1997. Opportunistic PSA  



 beds) and three private (356 beds) hospitals. Private hospitals screening for prostate cancer could be responsible for the 
+ +%# &'++ (++
 + serve a small part of the population. Diagnosis and treatment increase of prostate cancer incidence rates in the area. of cancer are available within the province, so few cancer cases are diagnosed or treated outside. Use of the data In addition to incidence gures and descriptive studies, some Registry structure and methods casecontrol studies on lip, skin and oral cavity cancer have The Cancer Registry of Granada was established in 1985. It is been carried out. The registry is also involved in studies on supported by the Regional Health Department of Andaluca care and survival of cancer patients within the framework and run by the Andalusian School of Public Health in of the EUROCARE study, and in a cohort study on diet and Granada. cancer (EPIC Project). The main registry staff consists of an oncologist as director, one physician, and three clerks for case-nding Source of population and data processing. In addition, one epidemiologist, one Updated using municipal registers of residents as of 1 January. statistician and one computer expert (part-time) collaborate Instituto de Estadstica de Andaluca (IEA). Consejera de with the activities of the registry and research projects. Economa y Salud. Cancer notication in Granada is voluntary. The basic information sources include all public and private hospitals of Multiple primary rules used the province. The registry receives the automated discharge IACR rules (2004) on CI5 IX period.

360

Europe

Spain, Murcia
pathology, hematology, oncology, radiotherapy, outpatient Registration area The Murcia Cancer Registry (Registro de Cncer de clinics and clinical departments of public hospitals. Registry Murcia) covers the whole region of Murcia, one of the 17 staff abstracts medical records to complete cancer data. autonomous communities of Spain. This region is situated In private hospitals the main sources of information are in the southeast, a Mediterranean area. The average pathology laboratories and medical record departments. In density is 118.1 inhabitants. The region is divided into 45 order to ascertain cancer patients who are treated out of the municipalities. Approximately 53% of the population lives region, the RCM receives notications from the National in three municipalities with more than 50 000 inhabitants, Registry for Childhood Cancer (RNTI) as well as from while 7% lives in rural areas (<10 000 inhabitants). The the social security reimbursement service, which refunds main cities are Murcia, the capital, with 409 818 inhabitants, expenses for being treated in hospitals out of the Region of Murcia. Cartagena with 203 945 and Lorca 87 153. In 1996, a new semi-automated program was developed. The population (2000) was 1 149 328, of whom 17.7% are children. Nearly 11% of the working population is employed All previously registered cases were converted from ICD-O-1 to ICD-O-2 with in agriculture, although the IARCtools and, in addition, a proportion has been decreasing considerable number of cases during the last decades; 62% SPAIN, MURCIA (1997-2001) were manually reviewed. work in services and 27% in SPAIN, MURCIA (1997-2001) When cancer is mentioned industry and construction. The on a death certicate (DC), region has an important foodand the Registry has no processing industry. Adequate information on that case, the food consumption frequencies %*%!+*** ,') .*.*** (*++,*** , !!*(!.*** main les of the principal are observed in most of the !#*%'+*** +' !,*('*** hospitals are searched. If the population for fruit, dairy "*%.*** + "%*...*** "%*..!*** (' ",*",%*** case is not found, the certifying products, olive oil and protein "'*((*** ( "+*%'.*** physician is questioned. If foods such as poultry, eggs "%*(#*** '' "(*!.+*** ",*.+(*** ' #*!"*** the information gathered is and sh. Consumption of #"*!"*** %' #"*!(.*** sufcient to register the case, red meat is higher than #,*!(*** % #+*(!.*** %'*!#*** #' %#*+!,*** that case is registered as a recommended. Two in three '*.'!*** # %,*'!*** Death Certicate Notication people are overweight. The '"*%%#*** "' %,*,(#*** '"*.!"*** " %.*.!*** (DCN). If no other information prevalence of smoking in %'*#+'*** !' %"*'.!*** is available apart from that on 2002 was 41% in males and #+*,(#*** ! #'*'(*** #'*#'%*** ' ##*"+%*** the DC, the case is accepted 34% in females, showing an #"*"'"***  #*%.*** as a Death Certicate Only increasing trend for women (DCO). Both DCO and DCN, and a decreasing one for men. ! '   ' ! among other indicators, are During the last decades the 
*$ & 

*$ & used for monitoring quality city of Cartagena had severe '+,*%%+*** '+!*!%,***  control. air pollution problems, mostly 
   due to industrial emissions.
*

/*
-*
* -*
*
**!*
**
*!..(*!..+*!..,*!...*"*"!* **  



 Interpreting the results 
* 
*$!..&* Opportunistic screening for cervical cancer is carried out Cancer care facilities Primary health care and hospital treatment are provided by public and private healthcare, increasing the number of free of charge to every member of the population through a Pap tests from the eighties to the nineties, but there is a National Health Service. The region is divided into 6 health low number of total cervical cytology compared with the districts, each with at least one public hospital. There are 25 rest of Spain. The PSA testing is an irregular practise in Hospitals, 12 public and 13 private hospitals for a total of the region of Murcia operating by the cancer society and 4317 beds, 73% of which belong to public hospitals, although clinicians. A population-based screening programme for practically all private beds may be used by the public health breast cancer started at the end of 1995 with a current participation rate near 70% of the total female population service by agreement. Patients suspected to have cancer in the primary and in the region. secondary care facilities in the registry area are referred rstly to local public hospitals, and secondarily to the reference Use of the data hospital located in Murcia, which has a comprehensive The main purpose of the Registry is to estimate cancer incidence in the region, trends and survival. In addition, cancer Radiotherapy Unit. the RCM is used for planning and evaluation of cancer control programmes as well as for epidemiological studies. Registry structure and methods The Murcia Cancer Registry (Registro de Cncer de Murcia, The RCM has participated in two multicentre casecontrol RCM) was established in 1981 as a project of the Consejera studies, one on HPV and cervical cancer carried out in de Sanidad of the Region of Murcia, developed by the Colombia and Spain, and another on non-melanoma skin Department of Epidemiology. The database is registered at cancer in four Mediterranean countries (initially Helios I Project and afterwards Helios II Project). Currently it the Spanish Data Protection Authority as stipulated by law. Information is principally collected by registry personnel. is involved in the European Prospective Investigation on The identication of new cases is done mainly through the Nutrition and Cancer (EPIC study), coordinated by IARC.

361

Europe

The registry participates in EUROCARE, following up cases diagnosed between 1990 and 1998 to provide data and contribute to calculating survival throughout Europe. The Registry is also involved in two multicentre Spanish studies, the first in rare tumours and the second in validating the cancer diagnoses in the minimum dataset from hospitals.

Source of population Annual estimates: Updated using municipal registers of residents as of 1 May of 1996, 1997, 1998, 1999, 2000, 2001. Madrid, INE. Multiple primary rules used IACR rules (1990).

362

Europe

Spain, Navarra
Association Against Cancer and the Public Health Institute Registration area The area covered is the Community of Navarra, one of the of Navarra. The main objective is to study the incidence and 17 Autonomous Communities of Spain. Situated in the north principal characteristics of cancers occurring in Navarra, to of the peninsula, Navarra borders on France to the north (the promote and facilitate epidemiological investigations, and to Pyrenees), the Autonomous Community of Aragn to the east, provide data for planning of health services and preventive the Autonomous Community of La Rioja to the south and the activities. The registry staff includes one part-time epidemiologist, Autonomous Community of the Basque Country to the west. The total area of Navarra is 10 491 km2. Navarra is and a full-time nurse and a social assistant who are scantily populated, with a density of 49.6 inhabitants per responsible for casending and coding. An administrator records and processes the data. The Advisory Committee of km2, and is the fth least inhabited Community in Spain. According to the 2001 census, Navarra had 555 829 the Navarra Cancer Registry collaborates with the staff. The inhabitants, of whom 33.5% lived in Pamplona, capital of data are processed in the Registry itself. Active casending involves systematic collection of the provincerising to 50% if the surrounding area is information on all cancer included with the city. Of this cases diagnosed in hospital population 49.8% are men, departments in Navarra. 13.7% are aged 014, and SPAIN, NAVARRA (1998-2002) Notication of cancer is 18.1% are 65 or over. SPAIN, NAVARRA (1998-2002) voluntary. The principal In the last decade Navarra sources of information are the has had a small positive pathology and haematology migratory balance, as well as laboratories, radiotherapy a signicant re-distribution (/0&$/// 1,. 1/'01/// */2'-/// 1$! 1/,&0/// and oncology departments, of the population toward 1/1'0/// 0,! &&/22'/// as well as the medical records Pamplona and its surrounding &&/-$&/// 0$! &(/1$,/// &(/($(/// -,! &*/*&(/// departments of all public and area. There are more &'/,0'/// -$! &'/20,/// private hospitals. Data on births than deaths, and the &,/&*2/// ,,! &*/0'2/// &0/-*$/// ,$! &0/',&/// incident cases are completed population has grown older &1/,21/// *,! &0/00*/// by data on deaths obtained over the last years due to the '$/1(0/// *$! &2/1$'/// '(/&&2/// (,! '&/,(*/// from the Mortality Registry large decrease in mortality. '*/(*'/// ($! ''/*'1/// through a systematic search, During the last 25 years, the '*/*'$/// ',! ''/*2'/// ''/'&(/// '$! '$/0&(/// mainly for completing the birth rate fell from 17.72 in &-/-&*/// &,! &,/,&0/// cause and date of death. 197576 to 10.04 in 2001. &(/*2*/// &$! &'/*02/// &'/-*$/// ,! &&/1&,/// Follow-up is carried The mortality rate adjusted &'/220/// $! &'/'&-/// out through examination for the European population of medical records and in the period 199599 was &$ , $ $ , &$ death certicates. There is 774.8/100 000 inhabitants for /)%+ /)%+ no personal contact with men, and 410.9 for women; '01/0((/// '00/$$'///  patients. Data are recorded on in 200004 it was 691.6 and 
   //"/ individual notication forms 368.1, respectively. During /"/// 5//"/ 
4##""###
 #3#332-$'"/ 200004, life expectancy for those born in Navarra was 77.9 and later entered onto computer with a system of individual  



 
//)'$$*+// ,//
/ access for each registry staff member. Duplicate and quality for men and 85.0 for women. control checks are run periodically. The IARC rules are used for multiple primaries. Cancer care facilities The Navarra Health Service covers 95% of the population. Health care in Navarra is composed of basic health districts, Interpreting the results which are grouped into three health areas. All inhabitants During this period, no changes occurred in the area covered, have access to the health system through the primary level although the number of inhabitants increased by 6.7% (Health and Consultation Centres), or through the emergency between 1996 and 2001. The aging of the population is to departments at the primary or secondary (specialised) level. be taken into consideration: at the time of the 1996 Census Cancer control activities in the region are based on there were 14.3% population under 15 years and 17.4% over promotion of healthy lifestyle, health checks for people 65 years. There have been no changes in the availability of occupationally exposed to carcinogenic substances, and diagnostic services and/or treatment. In 1993, topography and morphology were coded using hepatitis B vaccination in childhood. There is breast cancer screening in women aged 4569, cytology screening for CIE-0-2 for Oncology. During 19932002, the European cervical cancer among groups considered to be at risk, and Network of Cancer Registries recommendations on incidence ad hoc advice to the population. Any patient suspected of date and behavioural classication in bladder cancer were having cancer has access to any diagnostic and treatment applied. Since 1995, all tumours of the Central Nervous facilities considered necessary, and is followed by public System have been collected. Since 1990, there has been a breast cancer screening assistance services and/or by private services. programme for women aged 45-64, raised to age 69 for the years 19982002. The increase of prostate cancer incidence Registry structure and methods The population-based Cancer Registry of Navarra was created rates could be due to increased use of the PSA test during in 1970, as a result of the collaboration between the Spanish this period.

363

Europe

Use of the data The registry produces local reports on cancer incidence in Navarra for biennial and quinquennial periods. It has collaborated in evaluation of the breast cancer screening programme in Navarra. The registry has participated in two casecontrol studies on cancer of the cervix and of the larynx, and in a study on brain cancer. It is collaborating in the EPIC study as well as in studies of trends and of childhood cancer. The registry participates in EUROCARE and the EUROPREVAL group. It has been providing data

to Cancer Incidence in Five Continents since Volume III, as well as to the ACCIS and EUROCIM databases of IARC. Source of population Intercensal estimates. Instituto de Estadstica de Navarra. Gobierno de Navarra. http://www.cfnavarra.es/estadistica/ agregados/poblacion/estim_censo/estim_censo_9602.xls. Multiple primary rules used IACR rules (2004) on CI5 IX period.

364

Europe

Spain, Tarragona
by active search in the rest. The main sources of information Registration area The Tarragona Cancer Registry covers the province of are inpatient records, pathology laboratories, hospital-based Tarragona, located in the south of Catalonia in the northeast cancer registries and haematology laboratories. The Registry of Spain next to the Mediterranean Sea. In July 2000 the receives copies of all death certicates of people who were population was 595 652. The two largest towns have 114 000 living in the province. Cases notied from a death certicate and 89 000 inhabitants respectively. Five other towns have are systematically traced, and if no further information is more than 20 000 inhabitants, 26 other towns have 3000 obtained, are registered as death-certicate only cases. The Registry records malignant tumours whether in situ 20 000 inhabitants and 147 villages fewer than 3000. Approximately a third of the population was born in other or invasive, and includes tumours of the nervous system of parts of Spain and migrated between the 1950s and 1970s. undetermined nature. Bladder papillomas, if histologically About 20 000 foreigners are ofcially residents in the province veried, are not registered. Although the Registry employs a set (among them, more than 8000 from Morocco and 7000 from of rules for the inclusion of multiple primaries, which are more Europe). Since the establishment of the Registry in 1980, liberal than those of IARC/IACR, the results presented here strictly follow these rules. there have been no changes in The control of duplicates the area covered by it, although is based on name, birthdate, the population increased from SPAIN, TARRAGONA (1998-2001) sex, places of birth and 513 000 in 1980 to 607 000 in SPAIN, TARRAGONA (1998-2001) residence, personal identity 2001. Most of the people belong number and social security to the white Mediterranean race. number. Online checks are Roman Catholicism is the major made when entering the data religion. 


 









in the computer to detect The prevalence of smoking





 

errors and inconsistencies. in people aged 1564 was 55% 





 








The IARC-Check program in males and 20% in females 





 

is used periodically to detect in 1982, and 43% in males 











errors and unlikely situations. and 25% in females in 1998. 







From 1998, the Registry Of the working population, 














adopted the criteria and 7% belong to the agricultural 

 





the codes of ICD-O-3 for sector, 21% to the industrial 














recording morphology. sector, 14% to the building 





 

sector and 58% to the service 








 



 

Interpreting the results sector. In the province there 







Some assessments indicate is a petrochemical complex that the completeness of the active since the 1970s. Three       
*%!' 

*%!' Registry exceeds 9697%. nuclear power stations have  


#.(* #+***  Since the beginning of the been running from the 1980s; Registry in 1980, availability another has been stripped down 
   "..,0# "
*

*

*
*
**
*"..)**# "*

**
* * *
** **** of diagnostic and treatment after running since 1975. *
*
 *
*
*
* -*
*# "**$/*
**  



 services increased, although it is difcult to estimate the 
* 
*%# &'** ** inuence of these changes in the cancer incidence trends. Cancer care facilities There was no population-based cervical cancer screening Practically all the population is covered by the National Health Service. In 2000 the number of physicians was around 2000. programme in the area during the period, but an annual In the period 19982001 there were seven public hospitals average of approximately 36 000 cytological examinations and six private ones in the area, with a total of 1250 beds. for cervical cancer were carried out. A population-based breast cancer screening programme One of the public hospitals has a 32-bed oncology department that includes medical oncology, radiotherapy oncology and started in 1998 for women aged 5064, raised to age 66 in palliative care units. Some cancer patients are transferred the second round. The participation rate in the rst round to specic hospitals in Barcelona (100km from Tarragona), was 58%. About 36% of participants of this programme had a previous mammogram within the two years before the which are also sources of information for the Registry. mammogram of the programme. The use of the PSA test was quite high during this period, Registry structure and methods Since 2001, the Registry has belonged to the Foundation but the degree of inuence of this diagnostic procedure on the League for the Cancer Research and Prevention, which prostate cancer incidence rates in Tarragona is not known. receives nancial support from the Department of Health of the Catalan Government. The Registry also receives funds Use of the data The Registry produces cancer incidence and survival from the provincial administration. The staff includes a director, two epidemiologists, a statistics for the area, and describes their major computer scientist, a nurse, a medical ofcer and one clerk. epidemiological characteristics and their evolution. It Several specialists (in oncology, pathology, epidemiology also promotes epidemiological research and advises policymakers on current and future needs for cancer care and others) act as external collaborators. Notication of cancer is voluntary. Data collection is services. It collaborates directly in the evaluation of the through passive notication in the majority of sources and Breast Cancer Screening Programme of the province,

365

Europe

supports the evaluation of cervical cancer prevention and other cancer control activities and evaluates its effects. Source of population 19982001. The intercensal estimates are based on the 1996 and 2001 censuses, making allowance for births,

deaths and migrations into and out of the registration area. Population census of 2001. Institut dEstadstica de Catalunya. Multiple primary rules used IACR rules (2004) on historical data.

366

Europe

Spain, Zaragoza
Registration area The Zaragoza Cancer Registry covers the population of one province (Zaragoza) within the region of Aragn, in the northeast of Spain. The population at the most recent census (2000) was 848 006. About 81% of the population lives in urban areas; most are Christians. death certificates when cause of death is identified as cancer. For some cancers, such as haematological tumours and childhood tumours, complementary information sources (such as the Haematological Registry and the paediatric hospital cancer registry) are used to evaluate the completeness and accuracy of the information recorded.

Cancer care facilities General health care in the region is provided predominantly Interpreting the results by the Health Services Department of Aragn through a It is not possible to estimate how many cancer cases remain network of primary health centres and public hospitals. undiagnosed, but it probably occurs only for elderly subjects This is supplemented by private practitioners and hospitals. who have had a pathology diagnosis. PSA testing is common The Zaragoza Cancer Registry is located in Zaragoza, the in the population. In interpreting these results, capital of the province, and note that since year 2000 data provides radiotherapy, cancer have been received electronically, surgery and chemotherapy SPAIN, ZARAGOZA (1996-2000) as a new met hod of d at a services. Patients suspected SPAIN, ZARAGOZA (1996-2000) collection. Automatic registration to have cancer in the primary began in 2000 as well. and secondary care facilities in the registry area are mostly Use of the data diagnosed and treated in the #&)&&& (#% &###&&& '&#&&& ( &$)&&& The registry prepares an annual public hospitals of Zaragoza. &)&&& '# )&)&&& report of cancer incidence, We estimate that very few )&)&&& ' &)&&& &&&& $# $&!&&& highlighting trends and patients are followed outside &'&&& $ !&'$&&& changes. Some special studies the registry area. &!&&& ## &$)&&& $&'&&& # $&(&&& have been carried out. The '&)&&& !# '&#''&&& Registry is participating in Registry structure and )&!&&& ! )&(&&& &(&&& # &!##&&& several epidemiological studies methods &)'$&&&  &'(!&&& such as risk of second primary The registry was funded &$!&&& # &#)&&& &!'&&&  &('!&&& cancers, rare tumours in Spain, in 1960 by the state Health '&($&&& # #&)'&&& childhood cancer trends, Department. The registry &'(&&&  &&&& (&(&&& # '&#&&& incidence and mortality cancer is staffed by two part-time $&(&&&  $&!&&& inequalities, the HAEMACARE medical ofcers, one part-time project and validity of hospital administrative worker and one  #   #  discharge records for estimating full-time health worker. 
& " 

& " cancer incidence. Policymakers The Zaragoza Cancer !&!(&&& !&&&&  mainly use our cancer registry R e g i s t r y u s e s s e ve r a l 
& & &
& data for planning purposes. different sources of data: 
    



 primarily pathology and haematology laboratories, 
& 
& ))"&& radiotherapy and chemotherapy services and hospital Source of population discharge records. The registry staff visits these sources Obtained from municipal census. and records all cases with diagnosis and treatment of cancers diagnosed by all methods, among residents of Multiple primary rules used the registry region. We supplement this information with IACR rules (1990).

367

Europe

Sweden
Registration area The Swedish Cancer Registry covers the whole population of Sweden. The mean population in 2002 was 8 924 958. About 24% of the population lives in urban areas (>100 000 inhabitants). The main part of the population is Protestant; approximately 15% are not members of the Church in Sweden. The registration of newly detected tumour cases is based on compulsory reporting by all physicians responsible for in-patient and out-patient departments in all public and private establishments for medical treatment. The data in the Registry are supplemented with information on cause and date of death by computerised linking with the Cause of Death Registry. The Swedish Cancer Registry does not use information on cancers based on death certicates only.

Cancer care facilities Cancer care facilities in Sweden are incorporated with Interpreting the results the general healthcare system. There are oncological The overall reporting to the registry is estimated to be 96% centres in each one of the six medical regions of Sweden. of all diagnosed cases. There are two main screening programmes in Sweden: Nearly every cancer case will sooner or later be seen at a breast and cervix cancer. PSA hospital. Hospital and forensic testing for men is also quite pathologists make independent common in recent years. compulsory reports on every SWEDEN (1998-2002) cancer diagnosis made from SWEDEN (1998-2002) surgical biopsies, cytological Use of the data specimens and autopsies. The registry prepares an annual report of cancer Registry structure and %'" ''' )$& "' )''' *"'( ''' ) "*' "''' incidence, highlighting trends methods "$'$%''' ($ * ')$"''' and changes. The publication The Swedish Cancer Registry, %%'%%''' ( **' ")''' )'*$''' %$ ' )"''' is, since year 2000, only which was established in 1958, %'($(''' % ' ''' published on the Internet. is managed by the Centre for )*' ''' $$ )'%%''' "'%"''' $ (')"''' Many researchers in Epidemiology (EpC) at the **'))%''' "$ *'*(''' Sweden and in other parts of National Board of Health and *('*)$''' " )(' * ''' )'*$''' $  '%*''' the world use the registry. Welfare. The Government $' $'''  ')"''' nances the registry. Six **'% "''' $ )*'%''' %%')))'''  $%'*%"''' regional cancer registries %' ''' $ ")'"" ''' Source of population covering the whole country *$'*'''  (*' "''' '))''' $ )%'''' Ofcial population statistics perform the registration of new "'$)'''   '$)''' from Statistics Sweden. cancer reports and the major check-up and correction work.  $   $  These registries are associated  '!#  '!# Multiple primary rules used with the oncological centres "'")*'%''' "' *'% '''  IACR rules (2004) on in each medical region of 
  
'''''  ' historical data. Sweden.
 



 
' '!"#''''

368

Europe

Switzerland, Geneva
is located in an apartment opposite the Geneva University Registration Area The Canton of Geneva is situated at the extreme west of Hospital in the centre of the city. Diagnostic and treatment services are easily accessible: Switzerland. It has a total surface of 282 km2, of which Lake Geneva occupies 36 km2. The climate is temperate: mean Biopsies are mainly carried out at the central laboratory or temperature is 11.5C, with temperatures varying from -8.8C in other specialised services of the public hospital. Since two to 35.3C in 2002. The annual rainfall amounts to 1166mm years ago, a large part of the biopsies have been transmitted (2002). Air quality is fairly good: the annual average pollutant in electronic form, allowing a linkage with the registrys concentrations observed in the centre of Geneva are 6 g/m3 database each month. There are three private pathology for S02, 32 g/m3 for NO, 42 g/m3 for NO2, 34 g/m3 for 03 laboratories that provide records to the registry or permit systematic consultation of them. Autopsies are performed at and 0.6 mg/m3 for CO (2002, from ROPAG-SCPA). On 31 December 2002, the population of the canton was the university hospitals, and the necropsy rate is estimated at 427 705, of whom 14.5% were aged 65 and more and only 21.9% 7% of deceased residents (2002). Every case has a personal younger than 20. This structure is due not only to the joint number for condentiality. Data collection for the effects of a low fertility rate and registry is undertaken by an increase in life expectancy, examining the university but also reects fairly heavy SWITZERLAND, GENEVA (1998-2002) hospitals records of the immigration (often temporary) SWITZERLAND, GENEVA (1998-2002) various services concerned, as at the ages of economic well as by a questionnaire sent activity. This immigration out to private practitioners. comes traditionally from Latin The response rate of the latter countries. Due to a restrictive 


 









is more than 90%. policy in granting Swiss 







We have access to nationality, the proportion 














all reports from the only of the resident population







department of radiation considered as foreign remains 








 





oncology in the canton. This high, at 38.4%, of which 18% 







department provides us with were Portuguese, 14% were 














a control listing each year. Italian, 12% French and 10% 







The registry also has access Spanish. 





 








to all death certicates in The economically active 







the canton, which in addition population is concentrated in 














to clinical records, permit the administrative and service 







a continuous follow-up. sectors (82%), with production In addition to this passive workers comprising most       follow-up, the registry also of the remaining population  *%!'   *%!' undertakes active follow-up 


",)*(++***  (16%); agricultural workers of all cases each year. This are few (<2%), due to the small 
   follow-up is facilitated by amount of cultivated land and
  *- **  * ** * * ** *** **   *$"*
 * * * * the high degree of agricultural mechanisation (1995 gures). direct access to the Cantonal Ofce of Population. In  



 
* *%# &'**** the case of death, the primary cause is recorded and reThese gures remain unchanged to date. examined, as well as the possible presence of a tumour, clinical or conrmed, at the time of death. Cancer care facilities The hospital facilities for acute illnesses comprise one general public university hospital with 1267 beds (1997) Interpreting the results and some smaller private hospitals and clinics. Cancer As an indicator of reliability of the data, a very low patients are also treated at two other university hospitals, percentage of cases (<1% 19982002) are recorded from namely a geriatric institution (300 beds) and a hospital death certicates only. In addition, the low rate of cases for chronic affections (300 beds). No hospital, either found at autopsy (0.7% 19982002) compared with the total public or private, has beds reserved specifically for number of cases conrmed histologically suggests that most cancer patients. Between 1997 and 2002 there were no cases are identied during the lifetime of the patient. During this period 19982002, there was not yet a screening major changes. program in the canton for any localisation of cancer, but since 1 January 1999 there has been a screening programme Registry structure and methods The Geneva Cancer Registry was founded in 1969 and for breast cancer. Nonetheless, spontaneous screening is started recording cases in 1970. In 1991, the Registry was well accepted in the population, with mean annual screening attached directly to the Public Health Service of the Canton rates of about 40% for Pap tests (women aged 15) and about of Geneva. Since 1999, it has been attached to the University 20% for mammographic screening (19911995). PSA testing of Geneva, which provides most of the budget. Additional is generalised in the population of the canton. funds are obtained from the Federal Ministry of Health, Use of the data through the Swiss Association of Cancer Registries. The staff is composed of 12 persons, most of whom are Policymakers do not use our cancer data to evaluate health part-time, with 3 doctors and 2 statisticians. The registry services. For planning, the cancer registry has received an

369

Europe

ofcial mandate to evaluate the breast cancer screening program and the campaign against melanoma. In addition to the processing and publication of routine, incidence and survival data, the registry initiates or participates in analytical epidemiological investigations. Several casecontrol and cohort studies have been undertaken for etiological or evaluative purposes.

Source of population Average midyear annual estimates, based on ofcial numbers of births, deaths, immigrations and emigrations, on December 31st. Ofce cantonal de statistique. Multiple primary rules used IACR rules (2004) on historical data.

370

Europe

Switzerland, Graubnden and Glarus

Switzerland and the central ofce help to complete the data Registration area The cancer registry of Graubnden Glarus covers the les in the registry of Graubnden and Glarus, which in fact population of the two corresponding cantons in the needs more personnel. As an active member of the Swiss eastern part of Switzerland. The Canton of Glarus has 29 Association of Cancer Registries, the registry has permission communities and Graubnden 213. The population at the from the Central Data Commission for Data Protection in ofcial census 2000 was 36 600 for Glarus and 187 058 for Medical Research of the Swiss Government to receive nonGraubnden. About 15% of the population of Glarus live anonymised data on cancer patients. Periodically quality control and plausibility procedures in the capital of Glarus, while 20% of the population of Graubnden live in the capital Chur. In both cantons about are performed partly by the registry itself, partly by the 40% are Catholics and 50% Protestants. Glarus has about Swiss Association of Cancer Registries. During the reported period there have not been any 25% foreigners, while in Graubnden there are about 15%. Most are Christians, whereas only a very small minority are changes in the covered area or the population registered. Muslims. Only very few people immigrated from African Case denition and coding have been kept stable, except for adaptation to TNMor South American countries. Classication or the Among the population of recommendations of the Graubnden, 27 038 were rtoSWITZERLAND, GRAUBUNDEN AJCC. Reporting includes roman, who keep their native AND GLARUS SWITZERLAND, GRAUBUNDEN(1998-2002) AND GLARUS (1998-2002) incidence and follow-up for language, the Rumantsch. periods of 5 and 10 years. Cancer care facilities Interpreting the results General healthcare in Glarus 


 









Because neither of the two is provided by the district 







cantons has university service hospital in the capital Glarus 














and because a large population and a network of about 40 







live in rural areas, some cancers practitioners. In the main 











might go unrecognised. hospital, cancer surgery and 







However, the cooperation chemotherapy are available. 











of the neighbouring cantons In Graubnden cancer







ensures that cancers treated care is provided mostly in the 














outside the registration area main hospital in Chur, which 







are captured. includes all cancer services. 














Still, screening for some Radiotherapy is available only 







cancers (e.g. cervix) is not at the centre in Chur; some thoroughly established, and of the patients are treated in       needs further distribution Zurich or St. Gall. A network )'#( )'#( among the rural population of some 10 hospitals and about 


$$")*"&)))  at the cantons periphery. 300 practitioners supplement 

   ))))%""")))))) )))!) For other cancers, i.e. breast this care. Altogether 5% of the
)) )
))

)), +)) ) ) )!) patients are treated in the cantons of St. Gall, Zurich, Ticino cancer, a screening program is widely accepted. PSA  



 
))'%"""()) or even at hospitals over the Italian frontier (patients from screening for cancer of the prostate is widely accepted and performed. Discussion is ongoing on the possibility of lung the Posciavo). cancer associated with exposure to free radicals (i.e. radon) and also to dust-mediated pneumopathies. Registry structure and methods The registry is located within the Department of Pathology at the main hospital at Chur, and is funded partly by the cantons Use of the data of Graubnden and Glarus, and by the Federal Government The main objective of the registry is to make the data on of Switzerland. A part-time pathologist (less than 10%) and a cancer incidence available to the Swiss Association of Cancer part-time registrar (80%) are responsible for the registration Registries for publication and dissemination. In the future, of new cases. The method of registration is strongly related more active participation in analytical epidemiological to guidelines of the cancer registry network of Switzerland. investigations is planned. Providing data to policymakers About 85% of new cases are directly notied through the for planning and evaluation of health services has to be pathology network, the reminder being found by case study established in the future. (scrutinising medical documents) in about 30 departments of 12 hospitals of the two cantons. Notication is based on a Source of population voluntary agreement between the medical institutions and the Annual estimate of permanently resident population at registry. Death certicates are provided by the Federal Ofce midyear, based on the 2000 census and taking into account of Statistics by special contract. In fact, there are more and births, deaths and migration. Source: Federal Ofce of more pre-coded data available, facilitating the registry work. Statistics, Switzerland. Cancer registries of Zurich, St. Gall and the Ticino complete the datasets with information about patients hospitalised Multiple primary rules used outside the registration area. The network of the registries in IACR rules (2000).

371

Europe

Switzerland, Neuchtel
Registration area The Registry, which covers the whole of the French-speaking canton of Neuchtel (800 km2 with about 168 000 inhabitants), is located in the western part of Switzerland, sharing half of its frontier with France. The canton is a mainly rural region with only two cities of approximately 35 000 inhabitants. In the absence of heavy industry, watchmaking and the microtechnical industry are the main activities. Almost all the population is of Caucasian origin; 38% are Protestant, 31% are Catholic, and foreigners, predominantly of Mediterranean origin, currently account for about 23% of residents. In 2000, the main occupational sectors in the canton of Neuchtel were: industry 34%, agriculture 4% and services 62%. Cancer care facilities In 2000, the region covered by the Registry had around 900 hospital beds available for diagnosis and treatment (i.e. about ve beds per 1000 population). In the same year there were about 520 practicing physicians (one per 320 population). Radiotherapy and oncology services are integrated in a unique coordinated multi-site public organisation covering the whole area. an abstract of the medical record in the registry datale and periodic computer linkage between the latter and the centralised cantonal administrative population database (active follow-up). All death certicates are checked annually against the Registry les. This constitutes a process of passive follow-up, each subsequent item of information being used to complete the record of an already-registered case. All relevant information is manually scrutinised before being interactively introduced into the computer of the Computer Center of Neuchatel. Additional, more sophisticated automated verications and analyses are also performed on stored data in batch mode using ad hoc programs by the Vaud Cancer Registry on the computer of the University of Lausanne (UNIL). Interpreting the results There has been no organised screening during the incidence period for CI5-IX, but prescription of the PSA test is increasing, although not as dramatically as in most western European countries (preventive prostate examinationvia biological test or clinical examinationreported on average by 15% of men aged 4069 and resident in Frenchspeaking Swiss cantons).

SWITZERLAND, NEUCHATEL (1998-2002)

SWITZERLAND, NEUCHATEL (1998-2002)








































 



































































Registry structure and 







Use of the data methods The registry provides routine The bulk of information       statistical annual incidence is provided by the local ! 1,(.  #! 1,(. and mortality data by sex, age Institute of Pathology (INAP) 


2'1033111 ! and primary site, and data for through biopsy, cytology and 
   1 11!61  1 !1$1 "1! 1/8 !1! 111  #$ 1+)&1 51 1 local planning purposes. It is autopsy reports. Notication #! 51 #! 1#1 1!! 4 4! 1 1 !1! 1,.%1  61  1!! 1 1! &1
! 1! 1 1!1 1
7 %1
7 %1)3328*''*&1 is based on voluntary agreement between the recording also engaged in (mostly) descriptive epidemiological studies  



 
1 1,*''-.11/11  1 medical institutions of the canton and the Registry. Other in collaboration with the Vaud Cancer Registry and the six sources of information are the departments of oncology and other Swiss population-based registries belonging to the haematology, which also centralise diagnostic and therapeutic Swiss Institute for Applied Cancer Research (SIAK). Among the research opportunities offered by the procedures for malignant haematological disorders. The Registry is nancially supported by the local League operating structure within the collaboration agreement with against Cancer (60% of the budget) and by the cantonal public the Registry of the Canton of Vaud is the denition of risk health department for the remainder. Marginal support is of second neoplasms for patients registered with a dened also provided by the Swiss government through the Swiss primary. Association of Cancer Registries. Moreover, information on residents diagnosed or treated Source of population outside hospital, elsewhere in Switzerland, or in other Estimate: estimates from the Cantonal Ofce of Statistics; countries, is provided by the neighbouring cantonal tumour resident populations by sex and 5year age group on registries of Vaud and Geneva (mostly upper aero-digestive December 31st. Sources: Ofce rne; Service Cantonal de tract, skin and childhood cancer cases) and the general Statistiques. Annuaires statistiques du canton de Neuchtel, Neuchtel, 19982002. practitioners. Further information is also abstracted and systematically checked by the registry staff from hospital charts. A specicity Multiple primary rules used and strength of the registry is the routine integration of IACR rules (2004) on CI5 IX period.

372

Europe

Switzerland, St Gall-Appenzell
Registration area The registry covers the three cantons of St Gall, Appenzell AR and Appenzell IR in the northeastern part of Switzerland, a total area of 2430km2. It extends between latitudes 46 and 47 N; the lowest point is 396m and the highest 3247m above sea level. The registry covers the entire resident population, amounting to 521 971 in mid-2002. Of this total, 87% belong to the canton of St Gall. Major parts of the area are rural. There is one city with 73 000 inhabitants. Important industries are metal machines and vehicles, and construction, which are relatively broadly distributed over much of the region. In 2000 the per capita income was 86% of the Swiss average in St Gall, 81% in Appenzell AR and 87% in Appenzell IR. Five sixths of the population are Swiss, the others mainly of other European origin. follow-up for survival is carried out systematically at 5 and 10 years after diagnosis. Reports are usually checked within a few days after receipt. Names and dates of birth are checked in order to nd duplicates. In case of doubt, a physician is asked for advice. Six months after receipt of the rst report, additional information is sought if necessary by mailed questionnaire or in the case notes of hospitals. Addresses are checked with ofcial population control ofces. Cases are nally coded and closed by a physician only about two years after onset. Several logical checks are automatically made by the computer system. The coding is visually checked on the screen and, after completion of a case, on the case printout. Additional systematic checks on duplicate registrations are done after SWITZERLAND, ST GALL-APPENZELL completion of a registration year. Checks on consistency of (1998-2002) SWITZERLAND, ST GALL-APPENZELL (1998-2002) site, morphology and age are done through the Association of Swiss Cancer Registries. Completeness of registration 


 









has been traditionally evaluated 





 

by the incidence/mortality 












method (death cer tificate 







method) and more recently via 














the so-called flow method 







(Boullard et al.). By this method 














it was ascertained that over 







90% of the incident cases are 








 





registered within 12 months. 







Cancer care facilities In 2002 there were 882 active physicians (1 per 592 inhabitants). About 1720 hospital beds were available in acute hospitals. The central hospital in the city of St Gall has a special clinic for oncology as well as for radiooncology, and a public outpatient clinic for cancer patients that takes care of patients referred by general practitioners and other clinics. In addition, there are ten consultant oncologists. For inpatient care patients are usually 













Interpreting the results referred to a hospital within their 







region. Most cancer patients are There are no population-based treated at the central hospital or cancer screening programmes       in one of the peripheral acute in this region. Screening is *%#' *%#' 


$((*&)$***  hospitals within the region at performed as an individual least once during their disease. 
   initiative and seems to be ****$"""****** ***!* Some people in areas adjacent to
** *
**

**, popular and effective for cervical +** * * *!* the urbanised canton of Zurich seek care there. cancer. More than 85% of cervical cancers registered were in situ  



 
**%$""&'**** carcinomas. Early detection of breast cancer, on the other hand, Registry structure and methods could be much improved. Only 7% of breast cancers registered in The cancer registry was founded by the Regional Cancer women aged 5069 years during 20002004 were non-invasive. League in 1960 at the department of pathology in the central hospital of St Gall. It was hospital-based until 1980, when Use of the data it became population-based. The sponsoring bodies are the The registry prepares yearly routine reports on cancer incidence Regional Cancer League and the three cantons covered by the including ve-year periods. Analyses such as time trends of cancer registry, and it is also subsidised by the Federal Government. incidence and mortality, survival and stage distribution in selected At present the registry has 3.6 full-time positions. cancer sites are also carried out. Ad hoc analyses are done on request. Reporting of cancer cases is voluntary. The most The registrys data have been included in joint studies of important data source is active and passive collection of the Association of Swiss Cancer Registries, e.g. on time trends reports from the central pathology laboratory. In addition, of incidence of lung cancer, incidence of cancer in childhood, the registry staff actively collects data in the other pathology and the risk of cancer by occupation. The registry takes part laboratories in the region and in all regional acute hospitals. in international studies (ACCIS, EUROCARE, CONCORD, In the central hospital, the departments of oncology, EUROPREVAL, EUROCHIP) as well. haematology, radiotherapy, neurosurgery, paediatrics and the geriatric clinic are actively scrutinised. There is a routine Source of population exchange of information with the other cancer registries of Annual estimate of permanently resident population at midyear, Switzerland, especially with those covering two neighbouring based on the 2000 census and taking into account births, deaths cantons (Zurich and Grisons). Active case ascertainment and migration. Source: Federal Ofce of Statistics, Switzerland. has also been organised with consultant oncologists in the region. Finally, all death certicates with a cancer diagnosis Multiple primary rules used are scrutinised, and further information is sought out. Active IACR rules (2004) on historical data.

373

Europe

Switzerland, Ticino
radiotherapy and oncology centres, haematology laboratory, Registration area The Canton of Ticino is situated at the extreme south of oncologists, general practitioners and from cancer registries Switzerland. It has a total area of 2812 km2 and is bordered of Geneva, Vaud, Basel, Zrich and St Gallen (mostly skin on the north by the Canton of Uri, on the east by the Canton cancer). Autopsy is performed on 3% of all deaths. Finally, of Graubnden and Italy, and on the south and west by Italy. death certicates with cancer diagnosis are scrutinised and The highest point is 3402m and the lowest 194m above see additional information is found by mailing a questionnaire level. The climate is temperate, with average temperatures to the physician or by examining case notes in hospitals. varying from 4.0 in January to 21.8 in August, and the annual Online control of inhabitants of the canton is performed at rainfall amounts to 1564mm (1997). Air quality has been the Cantonal Ofce of Population Registry. The Registry collects all malignant invasive and in measured in Ticino from 1990: the annual average pollutant concentrations observed are 13 g/m3 for SO2, 44 g/m3 for situ tumours. The registration of basal-cell carcinoma is incomplete for the years 19962003. The following data are NO2 and 218 g/m3 for O3 (City of Lugano, 1996). The population of the canton at 31 December 2000 was coded: personal identication number, tumour occurring before the registry was 309 357. The structure also started personal data, date reects immigration in the of rst symptoms, date of age of economic activity: SWITZERLAND, TICINO (1998-2002) morphology conrmation, 73% of the population have SWITZERLAND, TICINO (1998-2002) topography, morphology, Swiss nationality and 27% is stage, diameter in mm and foreign, mainly from Italy and axillary node for breast cancer, the former Yugoslavia. The basis of diagnosis, method of majority of the population 


 









diagnosis, rst treatment and is Christian, with 84% 







date of death. Roman Catholics. The 














All information are ofcial language is Italian. 







manually checked and coded Employment distribution














(according to ICD-O-2) by the is: 1.7% in agriculture and 





 

registry staff before entry in forestry, 24.8% in industry 














the computer. The computers and 71.8% in the service sector 







themselves do preliminary (census 2000). 














plausibility tests at data 







entry, and a second check is Cancer care facilities 











performed by the staff daily. In 2000, there were ve public 

 





Several plausibility checks, regional hospitals and four like logical sequence of dates, zone hospitals, for a total of       validity of codes, morphology 1042 beds and 695 hospital +'#) +'#) by topography, by sex and age 


$(,+,*(+++  and private practitioners in (over 200 crosschecks) are the canton. There are no 
   ++++++ + +++ ++ +&$!++ performed monthly in addition population-based screening
+-++ ++!+ programmes in Canton Ticino. Spontaneous screening is to the IARC Check programme.  



 
++'%""()++ *++
+ Active follow-up of all patients with tumours is performed well accepted in the population, for either breast or cervical cancer. There is one radiotherapy department for the entire yearly. We have published a study of completeness: http:// region covered by the Cancer Registry. Opportunistic PSA www.ti.ch/DSS/DSP/IstCP/RCT/pdf_ppt/Relazioni_e_ Poster/2005/GRELL05_completeness.pdf. testing is common in the population. Registry structure and methods The Cancer Registry of Canton Ticino was founded in 1995 by the local government. Collection of population-based data began in 1996. The Cantone Ticino provides most of the budget and additional funds are obtained from the Federal Ministry of Health, through the Swiss Association of Cancer Registries. The Registry was founded on a cantonal law, based on a popular initiative. It is located at the Cantonal Institut of Pathology. One medical doctor and a data manager are responsible for active data collection and coding. A statistician is responsible for quality control and data elaboration. Reporting of cancer cases is done on a voluntary basis. A web page is updated regularly (www.ti.ch/cancer). About 80% of cases are notied by the Cantonal Institute of Pathology and Cytology. Additional cases come from main hospitals, Use of the data The Registry is currently involved in epidemiological research such as biomolecular epidemiology, survival analysis (EUROCARE), and others: http://www.ti.ch/DSS/DSP/IstCP/RCT/temi/studies.htm . Policymakers use our Cancer Registry data for planning and evaluation of health services. Please see the website for further information: www.ti.ch/tumori. Source of population Average midyear annual estimates, based on ofcial numbers of births, deaths, immigrations and emigrations, on December 31st. Ofce cantonal de statistique. Multiple primary rules used IACR rules (2004) on CI5 IX period.

374

Europe

Switzerland, Valais
(CIVH). The registry is largely nanced by the Canton of Registration area The canton of Valais covers an area of 5225 km2, with a Valais; the Swiss Confederation contributes 1015% of the population of 281 500 at the end of 2002. The population budget. The staff consists of a physician responsible for is 35% urban, the majority living in a rural area or in the mountainous region of the Alpine range. The Valais Alps, registration (80% of one post), an assistant physician (40% a non-productive area, account for 54% of the land surface. of one post) and two secretaries (one post full-time, one halfThe climate is relatively drier and sunnier than in the rest of time). The principal source is the pathology department of the northern Switzerland. The German-speaking High Valais, 28% of the canton, is distinguished from French-speaking CIVH, whose histological or cytological reports concerning Central Valais and Low Valais not only by language, but cancer are available to the registry via specic software. This source represents about 75% of the cases registered. also by culture. The population is largely of Caucasian origin; the Other sources comprise registries situated in the university majority are Roman Catholics (81%). The population is 17.6% centres of other cantons, the medical records of the hospitals (notications are made on the of foreign origin, principally basis of computerised lists of Italian Portuguese and people hospitalisation with diagnoses from the former Yugoslavia. SWITZERLAND, VALAIS (1998-2002) coded to the ICD), oncological The structure is that of an SWITZERLAND, VALAIS (1998-2002) specialists who send a copy ageing population, with 15.6% of their consultation reports, of people older than 65 years. and a computerised listing of One of the features of this deaths. population is its great stability, 


 









Notication is essentially the genetic structure being 







passive, but a questionnaire is more homogeneous than is 














sent to the treating physician general in the countrya fact 







for the majority of registered demonstrated by the studies 













cases, and demographic on genetic predisposition to







data are veried through colorectal cancer. 














the municipalities, again by The economically active 







questionnaire. population works 58.5% in













Access to death certicates the services and tourism 







is authorised for DCN cases sector, 22.5% in industry 











through a contract with the (construction, chemical, 







Federal Ofce of Statistics, metallurgical, wood) and Neuchtel, thus guaranteeing 3.5% in agriculture. Valais is       condentiality. an important producer of wine +'#) +'#) Notication of cancer (40% of the national total), 


$&*+,,$+++  is voluntary. Physicians are fruit and vegetables. From 
   ++++%"""++++++ +++!+ authorised to transmit data if the viewpoint of potential
++ +
++

++. -++ + + +!+ their patient has not specically refused such communication, occupational risk factors, there 



 are three industrial centres, 
++'%""()++++ each with more than 1000 employees, producing plastics, which had never happened by the end of 2002. In 1995 an colorants, agrochemical products, aluminium (exposure to expert commission on professional secrecy and medical uorine and asbestos), solvents and products derived from research authorised regulations for medical condentiality throughout the process of data collection, storage and cyanide. processing of data. The data are validated by different programs, including Cancer care facilities There are 19 physicians per 10 000 inhabitants. The health IARC Check. Quality control of data notied electronically system centres around six public hospitals, a specialist is carried out by the suppliers. respiratory centre and one private clinic, a total of 840 beds for acute care, excluding several geriatric, psychiatric and Interpreting the results chronic care institutions. The Department of Oncology of Most demographic factors have remained stable. The Valais is a network of cancer care facilities which gather increasing percentage of foreigners since 2000 is due partly specialists consulting in the public hospitals and in private, or to a renewal of immigration and a more constant birth rate in working in a centralised radiotherapy service in Sion. A few the native population. cases requiring additional facilities are treated in university Use of the data centres such as Lausanne, Geneva, Berne, Zurich or Basel. The incidence data are used to inform the public health planners and the medical profession about cancer in the Registry structure and methods Since 2002, the registry has been attached administratively population. The results of the most recent reports have to a newly created Health Observatory of Valais, supervised conrmed discrepancies between the incidence of some by the Public Health Service of the canton and situated in tumours in two different regions, i.e. High Valais and the capital Sion. The registry is located there and shares the Low Valais. In particular, lung cancer is more frequent computer network of the Central Institute of Valais Hospitals in the western (lower) part than in the eastern, German-

375

Europe

speaking (higher) part of canton Valais. The intensication of cancer screening (an ofcial breast cancer screening programme for women aged 5070 started in autumn 1999) has contributed to an increase in the incidence of breast cancer mainly and prostate cancer secondarily. The registry also participates in survival studies at the national (Association of Swiss Cancer Registries) and international levels (CONCORD study).

Source of population Annual estimate of permanently resident population at midyear, based on the 2000 census and taking into account births, deaths and migration. Source: Federal Ofce of Statistics, Switzerland. Multiple primary rules used IACR rules (2004) on historical data.

376

Europe

Switzerland, Vaud
private pathology laboratories, which perform the majority of Registration area The registry covers the French-speaking Canton of Vaud, the histological examinations for the population. Most cases the fourth-largest of the 26 cantons in the Swiss Confederation are registered repeatedly and from different institutions. (surface area 3212 km2) and third in number of inhabitants Cancer cases are listed alphabetically and according to a chronological registration numerical index. (about 640 000 in 2000). The 385 communes that compose the canton are grouped All relevant information is checked manually by the registry into 19 administrative and political districts. The density of staff and subsequently coded before being entered into the computer population (193/km2) slightly exceeds the mean for the whole of the University Hospital of Lausanne (CHUV). A rst series of country. In 2000, foreigners, predominantly of Mediterranean automatic checks on data is run whenever new information or origin, accounted for about 25% of residents. Since the early modications are added. Data are transferred to the computer of the 1970s the number of resident workers has remained stable. In University of Lausanne (UNIL), where more specialised checks and 2000, the main occupations were industry (19%), agriculture and analyses are performed. Passive and active follow-up information shing (5%) and services (76%). In December 2000, only 23% of is recorded. Identication data on all deaths in the Canton of Vaud the Vaud population were 019 as well as on cancer deaths are years old, while 15% were aged available. 65 years and older. Although SWITZERLAND, VAUD (1998-2002) Lausanne, the capital and its Interpreting the results SWITZERLAND, VAUD (1998-2002) suburbs represent only 4% (115 A mammography screening km2) of the cantons area, about programme for breast cancer was activated in 1999 45% of the total population targeting all resident (about reside there. 
 











70 000) women aged 5069 





 

(participation rate around 50% Cancer care facilities














in 2003). Spontaneous screening In 2000, about 3000 public and 





 

for cervical cancer is common private hospital beds (about 

 












(over two thirds of women aged five hospital beds per 1000 






20 or older report at least one population) were available for 














examination). According to the diagnosis and treatment. In the 







most recent National Health same year there were about 














Survey, on average 15% of men 2800 hospital medical doctors 







aged 4069 and residing in the and private practitioners (one 














French-speaking cantons (Suisse per 230 population). The health 







Romande) reported a biological care system is insurance-based, test or clinical examination of but practically the whole of the       -($* -($* the prostate within the year population enjoys access to 


&0,-.#.-- preceding the survey. medical care. A major public university multi-disciplinary 
   -Use of the data oncology and radiotherapy (1142
-2--%00/2&##&"-1- ----( *------2--
!- -- !-!---!--  -'%" 



 Annual incidence data by sex, age, site and morphology treatments in 2003) centre is available to the whole population, 
--(&##)*-- +--
as well as a few peripheralmostly hospital-basedmedical and are routinely provided. The registry is also engaged in both surgical oncological facilities. Two additional radiotherapy private descriptive and analytical research in the eld of epidemiology. Features of the registry include good registration of nonunits are in operation (overall, 948 treatments in 2003). melanoma skin, since traditionally the large majority of cutaneous lesions are surgically resected and examined by Registry structure and methods The Registre Vaudois des Tumeurs (RVT) began in January a pathologist, linkage of selected pre-neoplastic conditions 1972, and population-based data have been available since to the cancer registry datale in order to study subsequent 1974. The registry is a constituent part of the Cancer cancer risk, risk of second neoplasms for patients registered Epidemiology Unit at the Social and Preventive Medicine with a dened primary, and systematic analyses of trends in Institute (IUMSP), University of Lausanne. The majority survival. The registry cooperates with clinicians, and is used of the nancial support comes from the Public Health for population-based casecontrol studies on ENT, colorectal, Department of the Canton of Vaud. Additional ad hoc funds breast, endometrial and thyroid cancers. It also serves to are supplied by the Swiss Federal Government and the Swiss evaluate the three breast cancer screening programmes run League against Cancer, which support several studies in the in the Cantons of Vaud, Wallis and Jura. elds of descriptive and analytical epidemiology. In addition to the director, the staff comprises one part-time Source of population medical associate, one part-time computer programmer, and 3.5 Average midyear annual 19982002. Estimate: Cantonal clerks. The director is also in charge of the administrative and Ofce of Statistics (SCRIS) for each calendar year and veyear age group, based on ofcial numbers of births, scientic supervision of the cantonal Registry of Neuchatel. Notication is based on a voluntary agreement between deaths, immigrations and emigrations, on December 31st. the recording medical institutions of the canton and the registry. The main sources are the cantonal University Multiple primary rules used Pathology Department of Lausanne and three other major IACR rules (2004) on CI5 IX period.

377

Europe

The Netherlands
Registration area The Netherlands Cancer Registry (NCR) comprises nine regional cancer registries and covers the whole population of the Netherlands. The population in 2007 was 16.3 million. registration is funded according to the policy regulations of the National Health Tariffs Authority on the basis of the National Health Tariffs Act. The main source of data is the pathological automated archive (PALGA). Notication also comes from radiotherapy centres and haematology labs, and once a year the cancer registry is linked with the Hospital Discharge Register, which accounts for about 8% of the registered cases. Death certicates are not available because of privacy regulations. Specially trained registration clerks register direct from the medical records in the hospitals.

Comprehensive Cancer Centres General health care in the Netherlands is provided by general practitioners and specialists in academic (7), oncological (2) and general hospitals (520 hospitals per region). At least one radiotherapy institution is situated in every region. The nine Comprehensive Cancer Centres (CCC), which are partnerships between healthcare professionals and cancer and palliative care institutions, together form the Association of Comprehensive Interpreting the results The Netherlands Cancer Cancer Centres). The purpose is to Registry has been populationprovide access to comprehensive based since 1989 and is more and high-quality care as close THE NETHERLANDS (1998-2002) than 95% complete. Patients to home as possible. The CCCs THE NETHERLANDS (1998-2002) with cancer only on their support networks of specialists death certicate will be and tumour-specific working missed, as will cases that have groups with the development, no pathology, cytology or implementation and evaluation of 


 









hospital intake. national and regional guidelines. 







Consultants are supported for 














Use of the data several specialties. Patients in 





 

The registry prepares an need of specialist care can be 














annual report of cancer referred out of their CCC region. 







incidence, highlighting trends More than 300 employees work 














and changes on both national in these CCCs, and about 400 







and regional level. Data are consultants are actively involved. 





 








linked with the breast cancer CCC,s are independent, private 







screening programme for institutions and all hospitals,  














evaluation purposes. Several radiological cent res and 







projects (e.g. guideline pathology labs are afliated with evaluation and evaluation of one of the nine centres.       the National Cancer Control The CCCs receive a xed $! $! Plan) with hospitals and 



%$&%'$%'#$$$  annual sum for stafng, universities are supported by materials and location costs, and  
 cancer registry data. More a variable amount to cover the $$  
   costs of consultants funded according to the policy regulations than 25 data requests are answered every year, both at the 
$$ !$$ "$$
$    of the National Health Tariffs Authority on the basis of the national and regional levels. #%$$$$($$ National Health Tariffs Act. In addition, grants are obtained from various bodies including the Dutch Cancer Society (used Source of population for activities such as the support of clinical trials), the Ministry Statistics Netherlands. of Health, Welfare and Sport (for developing guidelines) and Multiple primary rules used from other organisations (for projects). IACR rules (2004) on CI5 IX period. Registry structure and methods The nine regional Cancer Registries, located within the Notes on the data CCCs, pool their data once a year in the NCR. Cancer C67 does not include noninvasive tumours.

378

Europe

The Netherlands, Eindhoven

the number of hospital beds decreased from 5 to 2.0 per 1000 Registration Area Since 1972 the registry has served an area of about 2500 km2, persons in the past 25 years, while the number of nursing home lying 2050m above sea level and including almost one beds has increased, as has, more recently, home care provision. million inhabitants (6% of the 1990 Dutch population). In the late 1990s, hospitals halved in number by mergers to only Since 1988 another million have been added bringing the middle- and large-sized hospitals from 400 to 800 beds. total 2000 population to 2.3m and being part of the national registry. This dataset only includes incidence and mortality Registry structure and methods data from the original population that grew from almost 300 This regional registry began operation in 1955 as part of 000 since 1958. The population density was about 400 per a programme for nationwide cancer registration. The 13 km2, roughly the national average; 47% of the population- participating hospitals of the 1970s have now been merged at-risk live in urban, 43% in suburban and 10% in rural into 6. The registry has always cooperated systematically municipalities. The traditionally Catholic population has with up to three regional pathology laboratories, which secularised rapidly since the mid-1960s, with concurrent have parafn-embedded blocks of biopsy specimens from all patients since the 1970s. large-scale introduction of These laboratories also serve oral contraceptives leading to GPs. Moreover, through a lower fertility rate (from 3 THE NETHERLANDS, EINDHOVEN (1998-2002) the various medical records to 1.5) and higher age at rst THE NETHERLANDS, EINDHOVEN (1998-2002) departments the registry birth (from 22 to 29 years). has access to the medical The proportion of immigrants records of most hospitals, in has been rapidly rising since particular in the department of the 1970s, to >10% at younger %-++.--/*, .-0"%--(-/""--/" 0-*&&--Radiotherapy in Eindhoven, and middle age. $"-$/*--.* $*-$(*--which has gradually extended With regard to the $*-&(*--." $0-%&*--%$-$*$--+* %&-"($--service to all of these hospitals. environment, an intensive %(-0&"--+" %*-$/%--Since 1988 the registry has pig and poultry breeding %0-+0*--** %/-"+0--&.-"&(--*" &(-/.$--functioned within the scope industry has developed since &/-%*"--(* &*-."/--of a national scheme for the 1970s, contributing ("-/0.--(" &/-%*%--(&-/*&--&* ($-&"$--cancer registration, developed considerably to acid rain (&-"*"--&" &0-.(+--since 1984. Assessment of and rising nitrate levels in &.-%"0--%* &(-%$%--&"-/0%--%" %/-"*$--completeness and accuracy groundwater, decreasing &"-"/"--$* %/-(*+--was carried out in the period again since the 90s. The main &$-**%--$" &"-$("--&%-./$--* &$-(".--198083 with continuing industries produce electronic &$-0"0--" &"-((/--support from the Department goods, trucks, photocopiers, of Epidemiology, now Public textiles and milk products, $" * " " * $" Health, of Erasmus University, -'#) -'#) but increasingly replaced *""-+0/--*"+-%/%-- Rotterdam. Extensive analyses by employment in services of incidence since 1958 thus and transport. The declining 
   became possible, e.g. for lung tobacco-processing and cigar 
------$-1---------
-

-! 



 and breast cancer, both of which exhibited major changes. 
--'%""()---- area until the industry, important in the south-of-Eindhoven 1980s, had a marked effect on the incidence of lung cancer Such data have now been submitted to Cancer Incidence in among males, whose prevalence of smoking was 95% in Five Continents since 1958 and EUROCIM since the early 80s. the 1950s. By contrast, smoking prevalence and incidence They includein a large part of the areanon-melanoma skin of smoking-related cancers among females have only risen cancer, based on early involvement of also dermatologists. Using the municipal population registers, active followrapidly since the mid-60s. Among those born after 1965 up with respect to vital status was performed in 1987, incidence appears to have begun decreasing again. 1991, 1994, 1999, 2002 and 2006. Patients lost to follow-up declined from 5% to less than 1%, with regular aid from the Cancer care facilities In 2004 we began a national obligatory insurance system. Central Bureau of Genealogy. Some 98% of the inhabitants are covered by Sickness Benet Funds, a compulsory social insurance policy for people Interpreting the results with low income; less than 1% of the population may be Screening for cervical cancer, started during the 1970s but declining in the 1980s, started again in 1988, being adapted uninsured. The growing interest in oncology during the 1970s in 1996 among women 3060 years of age at 5-year intervals. led in 1979 to a regional organisation, the Cooperating Biannual mass mammography screening for breast cancer Association of Hospitals in Oncology (SOOZ). In 1982 the gradually started among women between 50 and 70 years Comprehensive Cancer Centre South (IKZ) was founded during 199296, rising to age 75 in 1998. as a collaborative effort of the radiotherapy institutes in Eindhoven and Tilburg and 18 community hospitals, one of Use of the data Regular overviews of trends in incidence, stage and survival its main tasks being cancer registration. Access to clinical specialists was good but deteriorated of patients registered since 1958 are published every ve a bit until 2000, generally through general practitioners, one years, including detailed information on uncommon tumours for every 2200 persons. Despite a markedly ageing population and prevalence since 1970 and co-morbidity at diagnosis

379

Europe

since 1993. Cancer survival has also been studied since 1978 within the framework of the EUROCARE study. In recent years the data have been used increasingly for quality-of-care purposes and studies of cancer in the elderly; for that purpose, serious co-morbidity at diagnosis was also registered and a research department developed with a strong regional, national and European orientation.

Source of population Population data are calculated annually for 1 January; they are derived by Statistics Netherlands from the municipal population registries. Multiple primary rules used IACR rules (2004) on historical data.

380

Europe

The Netherlands, Maastricht

computer programmer and six tumour registrars. In addition, Registration area The Maastricht Cancer Registry is situated in the southeastern one consultant on cancer registration is available. Notication is voluntary. The cancer registry receives part of The Netherlands, and comprises the southern and middle parts of the province of Limburg, an area of some lists of newly diagnosed cases on a regular basis from the 1355 km2. A large area to the west, south and east is bordered four pathology departments in the region. In addition, the by Belgium and Germany. The Eindhoven Cancer Registry medical records departments of the ve hospitals provide lists of hospitalised cancer patients. Following notication, is on the northern boundary. In the southern part of Limburg, the population density the medical records of newly diagnosed patients are collected is very high, with about 30% of the population living in rural and trained tumour registrars for the cancer registry abstract municipalities, 57% in sparsely and moderately urbanised the necessary information from them. Death certicates cannot be used because of the privacy municipalities and 14% in densely urbanised municipalities. Current industrial activities in the region include chemical, regulations of the Dutch Central Bureau of Statistics. Tumour automobile, ceramic and cement industries. Until 1975, coal data are copied onto registration forms at the hospitals and entered into the computer at the mining was a very important registration ofce. Completeness source of employment. of records, data consistency The vast majority of MAASTRICHT (1998-2002) and the possibility of duplicate the Limburg population is THE NETHERLANDS, THE NETHERLANDS, MAASTRICHT (1998-2002) records are continuously and Catholic. extensively checked by the computer program. Cancer care facilities There is easy access to medical $%$$$ &!# &$'$$$ !$"$$$ & $"%$$$ Interpreting the results care in the Netherlands. In the $&"!$$$ %! "$"&$$$ Research into the completeness province of Limburg there is !$%!$$$ % '$'"$$$ '$&&!$$$ "! $'$$$ of ascertainment and into about one general practitioner $'$$$ " $"!$$$ the validity and accuracy of (GP) per 2300 inhabitants. %$'!$$$ !! "$"!"$$$ $'&$$$ ! $&!$$$ data show that the quality of Medical specialists usually $!$$$ ! $!$$$ the data is high (Int J Epid work at the hospitals: they !$'$$$  $&'&$$$ "$"&'$$$ ! !$!&$$$ 1993;22:369-76, Br J Cancer can be consulted after referral $$$$  $!$$$ 1993; 68:947-77, Int J Epid by the GP. Due to the ageing "$$$$ ! !$!%&$$$ $&%'$$$  $"&$$$ 1994 23;1111-6). population, cancer care $"'$$$ ! $%$$$ In 1990 a breast cancer facilities will be consulted !$""$$$  $!%$$$ !$%$$$ ! $%%$$$ screening programme started, more frequently in the future. $'$$$  $&$$$ resulting in a large increase in Almost all cancer patients the incidence of breast cancer. are diagnosed and treated by  !   !  A cervical cancer screening medical specialists. In the  $   $ &$$$$ &$&"$$$  program started in 1992 and area of the Maastricht Cancer expanded to the whole region Registry, there are four general 
   in 1996 for women aged 30 hospitals and one university $ 
$ 60. Trends in prostate cancer incidence also show a large hospital. The area also has one  



 radiotherapy institute. 
$
 $ $$ 
$$ increase, associated with opportunistic PSA screening. Registry structure and methods The Maastricht Cancer Registry was established in 1984 as Use of the data part of the Comprehensive Cancer Centre (CCC) Limburg. The registry regularly publishes a report on cancer incidence. Within CCC, there is collaboration between the hospitals, Data for the Maastricht Cancer Registry have been used for Maastricht University and the Maastro Clinic (radiotherapy etiological research, evaluation of guidelines, evaluation of institute). The aim of the CCC is to improve care for screening programmes and the treatment of cancer in the cancer patients through research, treatment, guidelines and elderly. The data are also used to plan healthcare facilities. coordination of regional activities (e.g. cancer screening). The Maastricht Cancer Registry (MCR) is part of the Source of population nine regional cancer registries in the Netherlands. Together Statistics Netherlands. these registries make up the Netherlands Cancer Registry. The staff of the registry includes one epidemiologist as Multiple primary rules used head of the registry, two epidemiological researchers, one IACR rules (2004) on historical data.

381

Europe

UK, England, East of England Region

Registration area ECRIC registers cancers occurring in the resident population of Norfolk, Suffolk, Cambridgeshire and, since 1996, Bedfordshire. It is situated in eastern England UK with a population (at the most recent census) of 2.75 million; 90% of the population describe themselves as white British. In 1995 the registry assumed responsibility for the resident population of Bedfordshire, and in 2006 responsibility for Hertfordshire and Essex was added. As a result of this, the population covered increased from approximately 2.2 million to 2.6 million in 1995, and from 2.8 million to 5.3 million in 2006. Cancer care facilities The registry is situated in Addenbrookes NHS Trust Hospital in Cambridge, with 2 satellite ofces in The Norfolk and Norwich University Hospital in Norwich and the Ipswich Hospital. Each of them has radiotherapy, oncology and surgical facilities. There are 6 other hospitals in the region providing oncology services. Some patients are sent out of the area to receive radiotherapy treatment at Mount Vernon Hospital, Northwood, Middlesex. Registry structure and methods The registry is funded by the government Department of Health under the Public Health budget. There are 24 staff as follows: Director, operations manager, consultant oncologist, two senior registration ofcers, 11 registration ofcers, two clerical ofcers and three workers each in analysis/quality assurance and IT. Registry staff extract data from patients notes and hospital PAS systems at all the hospitals in the region. Data are recorded on paper forms and later transferred to a computer database when complete. A monthly updated snapshot of the database is produced using Microsoft Access for the analysis team to interrogate to produce reports and answer specic queries from external sources. A detailed formal evaluation of Annual UK, ENGLAND, EAST OF Performance Indicators is already carried out according ENGLAND REGION (1998-2002) UK, ENGLAND, EAST OF ENGLAND REGION (1998-2002) to the guidelines established by the UKACR.
$! $ # #               %"#""" $"$""" " %#""" "$#""" "%#""" %"#$""" $"""" % "%""" $%"#""" %" """ """" "$$$""" $%"""" #"%#""" $"%""" $"""" $"# """ #%"$ """

 "#""" " """ "%%""" "##""" "##""" $"$""" #%"%# """ %" %""" $#"#""" %" %""" """" "%$""" %"""" #$" """ $"$""" $%"$%""" $%"$%""" $"#"""

Interpreting the results PSA testing is quite common, and parts of the registry population are included in a large-scale study evaluating screening for prostate cancer. Multiple primary rules used IACR rules (2004) on historical data.



 "


"



""% """



"$#""""


  


 
 " """ ""

382

Europe

UK, England, Merseyside and Cheshire

Registration area Since 1974, the registry has collected data on all cancers occurring in residents of Merseyside and Cheshire, wherever treated, and on residents of other areas treated in Merseyside and Cheshire hospitals. The registry also collects data on Isle of Man residents. Population centres in the area include the city of Liverpool; industrial towns such as Birkenhead (previously shipbuilding), Runcorn (chemicals), St Helens (glass); the retirement coastal town of Southport; and the rural towns of Cheshire. Validation checks within the system were extended in 1994 to improve the quality of data inputting. The registry has a rolling programme of quality assurance focussing on the ascertainment, completeness, timeliness and housekeeping, and several projects have explored different aspects of data quality. Data are coded in ICD-0-2, kept securely and released in a controlled manner, in accordance with ethical and data protection conventions. Regular backups are taken of the data and kept both locally and off-site.

Interpreting the results There have been no coding or registration practice changes that affect the interpretation of the data in this report compared Cancer care facilities with earlier volumes. Local Cancer Services Organised screening have been reorganised into networks with a specialist UK, ENGLAND, MERSEYSIDE AND CHESHIRE programmes are in place for breast and cervical tumours. cancer centre (containing full (1998-2002) UK, ENGLAND, MERSEYSIDE AND CHESHIRE (1998-2002) In 1988 a national breast radiotherapy and oncology screening programme was facilities) and cancer units in a introduced, through women hub and spoke arrangement aged 5064 years are routinely to achieve the most effective #!,.*-,,, .)+ %#,$-#,,, #-,'*/,,, .! %$,%.*,,, invited to be screened for concentration of expertise %$,!/%,,, -) '-,)#),,, breast cancer every three and also obtain the closer '',!./,,, -! )',-%$,,, )$,.*#,,, *) ).,)/#,,, years; women above 64 years involvement of primary care. )/,$/*,,, *! *%,!*!,,, are screened if they, or their **,$%',,, )) *.,#*.,,, -/,.%#,,, )! .#,')/,,, general practitioners, request Registry structure and -*,!*#,,, ') -.,-)#,,, a test. A similar screening methods .!,/!$,,, '! .),##!,,, .-,)$$,,, %) /%,)$),,, programme for cervical cancer The registry was founded .%,'--,,, %! ./,!)',,, was introduced in 1964, in 1944 as the Liverpool -#,*%$,,, $) -',./$,,, *','#/,,, $! **,/)),,, whereby all women aged 20Clinical Cancer Registry, -*,''-,,, #) -),$).,,, 64 are screened, currently with the primary objective .$,//.,,, #! -/,).#,,, -/,$*#,,, ) -),#)*,,, every three to ve years, of registering all cases of */,-**,,, ! **,'*',,, depending on their primary malignancy occurring in the care trust and their age. area served by the Liverpool #! ) ! ! ) #! The increasing use of Radium Institute. It extended  ,&"(   ,&"( opportunistic PSA testing its coverage to the surrounding #,$$#,/$.,,, #,#%),$$),,,  within Merseyside and area in 1974. The registry is  
 Cheshire coincides with an part of the National Health ,
,,,, ,,$!!#, , ,
,,, ,, ,,,,
, ,,  
   increase in the number of prostate cancer cases registered Service. 
, ,&$!!'(,,,, Registry staff comprise: a    medical director, a general locally. '',, , manager, two deputy managers, an epidemiologist, a secretary, a quality assurance ofcer, an IM&T ofcer, an Use of the data intelligence ofcer, 6 registration ofcers and a database Publications include specialist reports on breast cancer specialist. In addition, project work is undertaken by students (2003), colon cancer (2003) and oesophageal cancer (2003). Other output includes responding to over 80 ad hoc studying for higher degrees and professional examinations. The most important source of notication is pathology queries annually; presentations concerned with place of reports, copies of which are routinely sent to the registry. All death and also cervical screening age; audits with specialist cases are followed up by trained registration ofcers, who researchers; responding to genetic counselling service abstract relevant clinical information from hospital records. enquiries; contributions to the regional public health report; Notications are also received from the Ofce for National analyses to support the planning of local cancer services; Statistics about death certicates for people who have died and regular presentations to specialist groups. of cancer. Full registration for these cases is then sought by Merseyside and Cheshire Cancer Registry from the hospital Source of population or certifying doctor. The local specialist centres for oncology Estimation of population at risk based on 2001 census, also supply notications. Details of Merseyside and Cheshire allowing for births and deaths and migration into and out residents whose cancers are diagnosed elsewhere are supplied of the area. by the local registry. Cases registered during life are agged at the National Health Service Central Register so that the Multiple primary rules used IACR rules (2004) on historical data. cancer registry is informed when these cases die. Registry data are held on a dedicated relational personbased system. Each tumour is allocated a unique tumour Notes on the data number in addition to the patients unique identier. C44 not available.

383

Europe

UK, England, North Western

Registration area The North Western Cancer Registry (NWCR) collects data on all residents of Greater Manchester, Lancashire, South Cumbria and a small part of Derbyshire who develop cancer. The Registry covers an area of 4500km2 and has a population of four million. Sixty-ve percent of the population resides in the conurbation of Greater Manchester, which is almost entirely urban. The remainder of the region is of mixed urban-industrial and rural character. Eleven percent of the population lives in areas adjoining the coast, which are characterised by a high proportion of elderly retired residents. Ethnic minority groups comprise almost 8% of the North West population, concentrated mainly in large cities. Cancer care facilities Local cancer care services are being reorganised into networks with a specialist cancer centre (containing full radiotherapy and oncology facilities) and cancer units in a hub and spoke arrangement to achieve the most effective concentration of expertise and obtain closer involvement of primary care. Cases are followed up through the statutory registration of deaths. All patients are agged at the National Health Service Central Register and the Ofce for National Statistics informs the Registry of patients who have been previously agged as having developed cancer. All addresses are assigned post-codes, and all information is computerised and submitted to validation and consistency checks. Diagnostic details are entered on the computer, which then automatically codes them to ICD-O. Validation checks within the system were extended in 1994 to improve the quality of data input. Interpreting the results There have been no coding or registration practice changes that affect the interpretation of the data in this report compared with earlier volumes.

UK, ENGLAND, NORTH WESTERN (1998-2002)

UK, ENGLAND, NORTH WESTERN (1998-2002)

Use of the data A number of reports have '(*("#*** +' ,"*+'#*** been published examining +!*--'*** + ,-*(""*** ,(*!+%*** (' -'*!%*** variations in cancer incidence !*,"+*** ( !#*"'#*** and survival in the population !!'*,,*** '' !!(*,""*** !#-*%',*** ' !#,*+"#*** covered by the Registry. A joint !#*#,-*** %' !"-*++(*** report with the Merseyside Registry structure and !#,*##,*** % !#-*-+'*** !''*--'*** #' !'+*,((*** and Cheshire Cancer Registry methods !'(*-+%*** # !',*-"#*** (MCCR) covering the whole The NWCR was founded in !#,*%+-*** "' !#-*',*** !""*+"*** " !"#*(,+*** of the North West Region has 1962. It is situated at the Christie !#%*"%*** !' !#!*!('*** been published. Registry data Hospital, the principal cancer !%'*'(+*** ! !#-*!,'*** !%"*'#*** ' !#%*,+*** are used to plan and evaluate centre serving the Region. !"-****  !""*(!,*** cancer services, including the Registry staff comprise a breast and cervical screening medical director, ofce manager, ! '   ' ! programmes. A number of systems manager, epidemiologist,  *$ &  *$ & audits using Registry data information manager, systems "*!!(*!"%*** "*!%*!"-***  have been undertaken. Several analyst, deputy manager, quality  
 research studies, both national assurance ofcer, one secretary,  .*"!* *
 ****  
   and international have used Registry data. In addition, and eight cancer registration ofcers. 
* *$"%&****    The vast majority of patients receive their hospital care in Registry staff have collaborated on several studies on a %%** * the National Health Service hospitals. All NHS and private range of topics, including the genetics of breast cancer and hospitals use special form to notify the Registry of all cases the reasons why women with bladder cancer have a worse of cancer diagnosed in patients admitted to their hospital. The prognosis than men. registries of other regions notify the Registry of residents of the region who are treated in hospitals outside the region. The Source of population Registry also receives data from hospital information systems. Source: 2001 Census, Ofce for National Statistics. The Registry has links with all pathology laboratories in the region so that copies of pathology reports can be sent directly to Multiple primary rules used the Registry. The Registry receives copies of death certicates IACR rules (2004) on historical data. of all regional residents whose certicate mentions cancer. The Registry collects further information on patients identied Notes on the data C44 not available. only by a death certicate.
!-*"(,*** #*"%*** ,') , '(*#'+*** '(*%''***

384

Europe

UK, England, Northern & Yorkshire

regional cancer registries of Northern and Yorkshire. Due to the quality of pre-1998 Northern data, only Yorkshire cases Registration area The area covered by NYCRIS (Northern and Yorkshire have been included in earlier volumes of CI-5. NYCRIS is based in Leeds, adjacent to Cookridge Cancer Registry and Information Service) is a little under 30 000 km2, and includes much of the North of England: Hospital, which is part of Leeds Cancer Centre. It currently from North Cumbria to Northumberland (Scottish border), employs around 50 staff, of whom approximately 60% are down to West Yorkshire (east of the Pennines) and across to involved in data collection and validation (for the whole of the Northern and Yorkshire area), 15% in data management/ Humberside and the North Lincolnshire Coast. The region comprises the large rural expanses of the quality assurance and 15% in information and research. Northern Lake District, Northumberland, County Durham, Cancer registration in the UK is mandatory, and cases West, East and North Yorkshire. Within these are several diagnosed in hospitals (inpatient and outpatient) are notied densely populated urban clusters, including Tyne & Wear/ directly to NYCRIS. All pathology laboratories throughout the Teesside, Leeds/Bradford, Hudderseld/Calderdale and region routinely send copies of pathology reports, and these act as Humberside, along with a cross-reference to information some smaller (formerly received directly. Northern fortied) cities, such as York, UK, ENGLAND, NORTHERN AND YORKSHIRE & Yorkshire residents treated Durham and Carlisle. Health outside the region are notied (1998-2002) UK, ENGLAND, NORTHERN AND YORKSHIRE (1998-2002) geography, for 19982002, by other cancer registries. maps the area directly to Notication also comes from four Cancer Networks or 44 Breast Screening Units and Primary Care Trusts (PCTs). hospices. Cases are registered '$*''' )$& )(')"''' "*'* )''' ) *'$''' by registry staff who visit the Total population is around * ') "''' ($  '*(*''' 6.7 million (at 2001 census), hospitals and abstract treatment '")''' ( $'$)''' "$'%"''' %$ %'(()''' which constitutes 12.4% of the details from hospital case notes %'(%$''' % ('("''' following primary notication. population of England & Wales. )'(* ''' $$ )"'%*$''' "'"''' $ $'"(''' Copies of death certificates There is marked variation in  '** ''' "$ "'( ''' are routinely received from population density across the ('))''' "  '%%%''' "$'"''' $ $'"()''' National Statistics for all cases region, varying from 0 to over  %'"%'''  "$'$"''' 2500 people/km 2 in Hull & where cancer is a cause of death. "'%"%''' $ '"''' *%'$ '''  *$'$((''' When this information is the rst Stockton-on-Tees (www.statistics.  '*("''' $ (') "''' notication of cancer, the registry gov.uk/regionalsnapshot/). Ethnic "'%$'''  $'$%''' (' ''' $ ('%%''' traces the death to search for groups include Black 0.4%, Asian *$'")'''  )%'(*''' further information. When the 3.4%, and Other 0.4% (% of total population, 2001 census). cause of death is non-malignant,  $   $   '!#  '!# the registry is notied by the The age structure is not ' (')%''' '))'$('''  signicantly different from National Health Service Central that of England and Wales 
   Register, where all registered as a whole, although the 
''
 ' ' ' cancer patients are agged. 
' '!"#''$'' ' percentage aged 2535 years is 



 slightly higher. A new registration system (PRAXIS) was implemented Traditional industries include shipping, shing, textile in 2006 to enable NYCRIS to move from the current, largely & clothing manufacture, steel production, shipbuilding and manual, cancer registration process to one making greater coal mining. use of electronic data feeds. The cancer registry database is patient-based. Records of existing registrations are updated Cancer care facilities with new information, new cases being assigned an accession The vast majority of patients receive their hospital care in number by the computer. All data items are encoded by the National Health Service (NHS) hospitals. A major national computer. The system also automatically generates a general reorganisation of cancer services has taken place since 1995, practitioners enquiry letter, a cancer registration document following the report of an Expert Advisory Group on Cancer and a follow-up enquiry letter where necessary. At the point to the Chief Medical Ofcers of England and Wales. The of entry, data are validated using the National Statistics edit subsequent National Cancer Plan (2000) established a system procedures. Data are regularly exchanged with local specialist of Cancer Networks each serving populations of 13 million tumour registers to ensure complete ascertainment. and organising specialist cancer care through multidisciplinary teams. There are four such networks in the NYCRIS region, Use of the data based around hospitals in Newcastle, Middlesbrough, Leeds In addition to providing a responsive information service, and Hull, which, together with their associated local units in NYCRIS regularly produces data and reports in a variety of media smaller district hospitals, provide integrated cancer services and actively promotes the use of its data. Summary statistical for their populations. The hospitals within these 4 cities are the information (incidence, mortality and survival) is contained in cancer treatment centres; there are radiotherapy departments CIS (Cancer Information Service), a web-based analytical tool located proximate to the treatment centres. available over NHSnet (protected health service WAN). Details of CIS and all of its published reports are Registry structure and methods available on its web site (www.nycris.org.uk). In addition NYCRIS was set up in 1997 to integrate the two separate NYCRIS has conducted a series of regional audit reports,

385

Europe

on important issues related to cancer service delivery; for example, analysis of variation in the patterns of cancer care and the effect of such variation on survival, an examination of methods to improve the registration of skin cancer and analyses of patient waiting times before receiving treatment.

Source of population UKACR Populations Dataset Version 3. Multiple primary rules used IACR rules (2004) on CI5 IX periods.

386

Europe

UK, England, Oxford Region

for National Statistics (ONS). In addition, all registered Registration area The Oxford region consists of the counties of Berkshire, cancer patients are agged on the NHS Cancer Register to Buckinghamshire, Northamptonshire and Oxfordshire, and ensure that the local registry is informed of deaths among covers a population of about 2.7 million people. There are the registered population, including those from causes other slightly more females than males (51%/49%). During the last than cancer and those occurring outside the region. There is 20 years higher population growth has been experienced collaboration with specialist registers (e.g. Childhood Cancer Research Group, Oxford Regional Leukaemia Register) and within major urban areas. Berkshire has the highest population with 800 100 directly with clinicians to collect certain types of data. The registry collects data on all malignant tumours, in situ residents, Buckinghamshire has 686 100, Oxfordshire has 605 500 and Northamptonshire 629 700. Oxfordshire has neoplasms and certain benign tumours. An abstract of each the highest proportion of elderly residents, with 14.5% tumour record is passed to ONS for inclusion in the National being 65 or over. Northamptonshire has 14.2% of over-65s, Cancer Registration Scheme. Information on non-residents Buckinghamshire has 13.3% and Berkshire 12.7%. Around treated within the Oxford Region is passed to the appropriate regional registry and is part of 13% of the population are a reciprocal arrangement. aged under 10, about 13% are Until 1992, the process aged between 20 and 30 and UK, ENGLAND, OXFORD REGION (1998-2002) of registration was entirely 6% are aged 75 or over. UK, ENGLAND, OXFORD REGION (1998-2002) manual. In September 1992, Berkshire has more a Hewlett Packard 9000 residents from Black (African, RISC minicomputer system Caribbean or other), Indian, was installed running Unix, Pakistani, Bangladeshi, !)&))) +&( " )&'))) +)$+))) + ")+'))) Informix, SQL and the C-Cris Chinese, or other minority "!)$!))) *& $$)&$))) 1 Cancer Registration System. ethnic groups (including other $!)"+))) * $+)+$))) & )"$))) '& &")''))) Currently electronic versions of White ethnic groups) than the '),))) ' ') '))) pathology reports (abstracted by other counties, accounting *&)"))) && *$)*))) ,$)!$))) & ,$) !))) identifying all cancer SNOMED for 15% of its population. , )$))) $& , )$))) codes) with demographic Buckinghamshire has 11.4% ) +))) $ ,,) '))) !) +))) "& ) $))) details separately identied are Black and minority ethnic )&))) " )"))) received from all laboratories. citizens, Oxfordshire 8.8% ,+)'))) !& ,')+))) +") '))) ! + )!$))) Electronic downloads from and Northamptonshire 6.7%. +,)'$))) & +")&!))) Casemix/Patient Administration In general, the regional ,!),!)))  +')&!))) ,!)'+))) & +*) '))) Systems and from Oncology population is healthier and +*)+$)))  +")'))) systems are received from all less deprived than those provider sites. Ox-link record living in many other parts of  &   &  matching software is used to England. There are, however, )#% )#% distinguish new registrations pockets of deprivation in )"',),!))) )"$')*')))  from amendments or nonsome parts of the Region 
   registrable cases. Demographic and there are higher rates of ))))))) ,, ))! )# )) )%)  



 diseases (e.g. breast cancer) associated with a higher social details of new registrations are added automatically to the le. 

))#!$%))
&))) Clerks then add the diagnosis and treatment details. class distribution. Cancer care facilities Cancer services are organised by the Thames Valley Cancer Network for Berkshire, Buckinghamshire and Oxfordshire, and by the Leicestershire, Northamptonshire and Rutland Cancer Network for Northamptonshire. Within the area there are eight hospitals providing cancer care; three of these have radiotherapy facilities. PSA (prostate specic antigen) testing has been common within the area since the early 1990s, but there are currently no routine data on levels of testing. Registry structure and methods The registry is centrally funded by the Department of Health. There are 15 full-time-equivalent staff members, with 5.5 in the registration section, 4.5 information analysts, 4.0 IT and business support, and a part-time Medical Director. Cancer registration data have been collected on a regional basis since 1952. The registry is notied of cases by histopathology and cytopathology laboratories and medical records departments. Death certicates where cancer is mentioned are also passed to the registry from the Ofce Interpreting the results All borderline malignant tumours were included in downloads from anniversary year 1993. Prior to this, apart from one or two tumour types (i.e. polycythaemia vera) with a fth digit of 1 (borderline malignant), they were not collected. There were signicant changes to the UK practice of bladder coding from anniversary year 2000. This meant that bladder cases diagnosed as papillary non-invasive transitional cell carcinomagrades I and IIwhich had previously been coded as malignant (pathology reports also reported them as 81303 - malignant) were now to be coded to a borderline code. This had quite an impact in the number of malignant cases reported; the malignant cases reduced in number and the borderline cases rose signicantly. It was also agreed at the same time that papillary non-invasive transitional cell carcinoma grade III was to be coded to in situ. Use of the data The Oxford Cancer Registry is now part of the Oxford Cancer Intelligence Unit (OCIU). OCIU is responsible for cancer registration, for providing a cancer information

387

Europe

service, managing quality assurance and evaluation of the breast and cervical screening programmes in the Region and undertaking and contributing to programmes of clinical audit and research. The registry contributes to the annual UK Association of Cancer Registries review of the completeness and accuracy of registry data.

Source of population Mid-year estimates based on censuses in 1991 and 2001 (Ofce for National Statistics). Multiple primary rules used IACR rules (2004) on CI5 IX period.

388

Europe

UK, England, South and Western Regions

Interpreting the results The coverage provided by the above range of sources, and veried by checks made through audit, is over 99%. Death Certicate Only registrations are less than 3%. The UK runs screening services of more than ten years standing for cervical and breast cancer. The registry has only recently started registering skin cancers of basal cell carcinoma (BCC, C44) due to the large numbers and limited interest in this type of cancer in the past. C44 were not collected systematically until 1998. For BCC and Squamous Cell Carcinoma (SCC) only the rst primary diagnosis is registered. Cervix in situ D06 is incomplete for all Cancer care facilities The SWCIS area is served by 12 main hospitals, within which areas. Registration of D45 is incomplete until 2001/2002. Bladder C67/D41 coding was changed there are seven designated in 2000. Some 80% of cancer cancer centres. There are a registrations are supported by further eight regional hospitals UK, ENGLAND, SOUTH pathological conrmation. The with Accident and Emergency AND WESTERN REGIONS (1998-2002) UK, ENGLAND, SOUTH AND WESTERN REGIONS (1998-2002) incidence of prostate cancer (A&E) departments and has risen dramatically in parts signicant treatment facilities, of the registry area since 2001. as well as numerous small This has largely been attributed hospitals for minor injuries ##(+))((( *%'  (#!((( &!(+&&((( * *( )&((( to increased PSA testing. and recuperation. Registration area The South West Cancer Intelligence Service (SWCIS) collects data on all cancers and suspected cancers for the South West region of England, including Hampshire and the Isle of Wight. In all, it covers an area some 300km by 100km, with a coastline of over 1400km. The population of 6.8 million is nearly all white Caucasian and predominantly Christian, with an approximate 60/40% split between urban/ suburban and rural. A large proportion of the population (approximately 20%) are retired.
*(+!+((( !#(*#((( )% ) % (*)!((( &(+&((( % ()+#((( &% &&(!%((( Use of the data Registry structure and &*(&))((( & )#(&#+((( There are ve principal ways methods ++(&))((( %%  (&+((( !#(!((( % !+( )#((( in which our data are made The SWCIS is one of nine !()&%((( #% +(%*((( available: regional registries in England. &(##((( # +()&!((( #)(&#%((( !% %()*((( It is split between two sites, T h e S W PH O we b s i t e !*(+((( ! # (&((( one in Bristol (mainly data (www.swpho.nhs.uk). This &(#!)((( % !(++((( +(&!(((  )+(&) ((( users) and one in Winchester site is accessible to all for *(%+#((( % +#(%+ ((( (mainly registration and epidemiological statistics of the )(!%(((  %(%!((( +(+%&((( % ++(#%%((( IT). The SWCIS is funded important cancers and information + (**(((  * (!*!((( by government, through the on cancer epidemiology. Department of Health. An ad-hoc information request  %   %  In 2005 the SWCIS service. Each year the SWCIS 
("$ 

("$ merged with the South West deals with over 200 information !(# %(!*)((( !( %+(#!(((  Public Health Observatory requests by phone, email, fax or 
   (SWPHO). The aim of the (
 (

(
((

((++(( ("
( (($( letter from a wide range of health  



 SWPHO is to provide a seamless public health intelligence professionals and others. Regular users of the service are strategic 
( 
("++*$( service for the region. The SWCIS employs 17 registry staff, health authorities, consultants, medical students, clinical audit, 4 information analysts, 5 clinical audit team members, and research bodies and the media. 5 Network Liaison Ofcers who provide an important link To government via data exchange. A regular download between the registry and cancer networks. Their work is of new and updated registrations is sent to the National supported by Business Management, IT and Publications Registry (ONS) for Government publication. and Communications teams who work across the whole Publications. Cancers of special interest, patterns of treatment, organisation. and health service facility usage are regular topics of reports. The SWCIS collects its data from three principal Collaborative research. The SWCIS works with a variety sources: Hospital Patient Administration Systems (Clearnet); of partners including Cancer Networks on a range of topics pathology laboratory reporting systems, and the national to produce varied outputs including audit, new databases, deaths database. These are accessed via electronic capture and follow-up studies and treatment effectiveness have all been processing with manual intervention to resolve complexity or covered in recent years. data conict. Over 75% of records are initially electronically captured with more than two independent sources usually Source of population involved. Eight subsidiary data sources include: private Mid-year estimates based on censuses in 1991 and 2001 hospitals, military hospitals, cancer screening centres, (Ofce for National Statistics). follow-up with consultants, audit databases, other cancer registries, cancer/treatment centre databases and national Multiple primary rules used research centres. UKACR rules (1998).

389

Europe

UK, England, Thames

The Registry collects patient identifying information. Registration area The Registry was founded in 1958 as the South Metropolitan Special provision within the Health and Social Care Act 2001 Cancer Registry, became population-based in 1960, and enables the Registry to continue this practice without the direct was renamed the South Thames Cancer Registry in 1974. consent of patients. Cancer is not a notiable disease in the UK. A wide range of data validation checks are applied by the Until 1984 it covered the South East and South West Thames Regional Health Authority areas (the South Thames Health Registrys computerised registration system at the time of Regions), with a population of approximately 6.8 million. In data entry/import. Automated retrospective validation checks 1985 the Registry expanded to include the North Thames are made daily. Patient deduplication is done annually. The Health Regions, becoming the Thames Cancer Registry Registry regularly reports and monitors the stability of its (TCR) and covering, in 2000, a population of approximately case ascertainment and data and process quality indicators. 14 million across the counties of Hertfordshire, Essex, The Registry participates in the quality assurance activities London, Surrey, Sussex and Kent. Data in this volume cover of the United Kingdom Association of Cancer Registries, this population, and have been submitted for diagnosis years which formally evaluate the Registrys stability, data quality and completeness. 19852002. Previous volumes have covered the South Interpreting the results Thames Health Regions only. UK, ENGLAND, THAMES (1998-2002) Previous volumes have The Registry region UK, ENGLAND, THAMES (1998-2002) reported incidence in the includes some of the most South Thames Health afuent areas in England, Regions only. The data in the and also some of the most present submission cover the deprived. London has an 


  









residential population of South ethnically diverse population. 







East England (the counties of In the 2001 census, 17% of 











 


Hertfordshire, Essex, London, the TCR population were not 







Surrey, Sussex and Kent) in classed as white, compared 














the period 19852002. This with 9% in England. 







is the territory of the (now 














historic) North and South Cancer care facilities  







Thames Health Regions. The majority of cancer patients 














are treated within the National There are organised 




 


Health Service (NHS). The national screening programmes 














Registry region is covered by for breast and cervical cancer. 







13 NHS Cancer Networks and The Registry exchanges data more than 50 NHS secondary with the breast-screening       and tertiary care trusts. The programme. Prostate-specic ,'#) ,'#) Cancer Networks co-ordinate antigen testing is common in 



+,-%&,/.",,,  cancer care. the Registrys population, and 

   Most patients are ,

,,,,, ,,

, ,
,,, , ,,,')!,,,, this has led to increased rates

, ,,, ,,,,$/.*,1,%""%,,, ,,,,$/.*,1,%""%!,,,, ,,$/.$ ,$//$,,%""$!,,$//$,,%""$,

,,,,, ,,,,,!,,

, ,,, diagnosed and treated in a secondary care trust. Patients of prostate cancer, particularly in men under 70 years of age. ,,, ,,0,,,,,!,  



 with rare cancers and those requiring specialised care are 
,,'%""(),,,, referred to a tertiary care trust. There are 22 radiotherapy Use of the data centres in the area, 19 NHS and 3 private. A range of reports are provided for health organisations in the Registrys region. Research activity and output in the Registry Registry structure and methods have increased in recent years. The Registry contributes data to The Registry is located on the Guys Hospital campus at a regional Cancer Information Service available online to NHS London Bridge, and is a department in Kings College users. The Registry recently prepared national long-term cancer London School of Medicine. It is funded through a contract incidence predictions for the Department of Heath. For further with the Regional Director of Public Health in London. information, see http://www.tcr.org.uk/. The Registry has approximately 70 staff. Thirty mobile staff actively abstract registration information from hospital Source of population medical records. The other 40 staff, at the London Bridge The population table has been extracted from national ofce, perform data entry, computing, quality assurance, population les produced by the Ofce for National Statistics analysis, reporting, research and management functions. (ONS). It details the population of the Thames Cancer Principal sources of information on cancer cases are Registry diagnosis years 1985-2002 catchment area for the pathology reports and information systems, paper medical calendar years 1985-2002. National censuses were held in records, hospital patient information systems and death 1981, 1991 and 2001. The 1991 and 2001 populations in this certicates. table are from the censuses in those years. The populations for the other years in the le are midyear estimates based Death certicates are provided electronically to the Registry on census data. by the Ofce for National Statistics. Certicates are provided for registered patients, and for all people dying in the Multiple primary rules used Registrys catchment area from or with cancer. IACR rules (2004) on historical data.

390

Europe

UK, England, Trent

from a merger with the East Midlands Public Health Registration area The Trent region covers the counties of Derbyshire (except Observatory giving greater opportunities for joint working its north-west tip), Leicestershire, Rutland, Lincolnshire, and signicantly expanding the type of work/projects the Nottinghamshire and South Yorkshire, an area of 14 763 km2 registry is able to undertake. Trent Cancer Registry collects a common minimum with a resident population of 4.8 million. The area is served by 11 Acute Trusts, 12 Primary Care Trusts and three medical dataset on cancer. Cases diagnosed in hospitals (inpatient schools (Leicester, Nottingham and Shefeld). It spans two and outpatient) are notied to the registry electronically, Government Ofce Regions (Yorkshire and the Humber, and including details taken from pathology reports. Other East Midlands) and is the lead Cancer Registry for providing cancer registries notify the registry of Trent residents treated information to four Cancer Networks (North Trent, Mid outside the region. Copies of Death Certicates are routinely Trent, Derby/Burton, Leicestershire, Northamptonshire and received from the Ofce for National Statistics (ONS) for Rutland). Cancer Centres are located in Derby, Leicester, all cases where cancer is a cause of death. When the cause Nottingham and Shefeld, where radiotherapy and of death is not cancer related, the registry is notied by the National Health Service chemotherapy services are Central Register, where all available. United Lincolnshire registered cancer patients are Hospitals NHS Trust is a UK, ENGLAND, TRENT (1998-2002) agged. cancer unit with radiotherapy UK, ENGLAND, TRENT (1998-2002) On receipt, data are services. validated using extensive edit Despite variations within procedures (incorporating the region, the overall those of the ONS), and checked Trent population prole is $'"$$$ &!# "$&""$$$ '$"$$$ & ""$&$$$ for duplicate registrations and comparable with that of %$&''$$$ %! '%$!$$$ identication of patients with England. Forty percent of '$$$$ % %$&$$$ !$!$$$ "! $!$$$ multiple primaries. Formal Trent local authorities are &$%%$$$ " $%$$$ evaluation of the completeness in the two most deprived '$'$$$ !! '$%%"$$$ "!$&%$$$ ! "$&'$$$ and accuracy of information quintile groups for the whole !$&!$$$ ! !$%$$$ recorded by Trent Cancer of England, compared with "$'""$$$  "$&$$$ &$!$$$ ! &$'"$$$ Registry is ongoing as part of 35% in the two least deprived %'$&%$$$  &$!"'$$$ the UKACR National Cancer quintile groups. Just less than !$"$$$ ! !!$%$$$ "$$$$  $'!$$$ Peer Review Programme. 75% of the resident population !$"%!$$$ ! !$&!$$$ This aims to improve the live in urban areas. The ethnic !'$&$$$  !$$$$ !%$&"&$$$ ! '$$$$ processes, timeliness, quality prole of the population is $!&$$$  $'$$$ and provision of cancer predominantly White (93.7%), information. with sizeable numbers from  !   !  The current database holds Asian ethnic groups (3.9%), $ $ $%$'"$$$ $&$$$$  records from 1966 comprising most notably Indian (2.5%). more than 900 000 individual The area covers a variety 
   registrations from across the of industry. The decline of the 
 $ $$
$$  



 coal and steel industries over the last thirty years has led to Trent Region, with approximately 35 000 new registrations 
 $
$''& $ considerable economic re-development with heavy industry (malignant and non-malignant) each year. At intervals, new being replaced with light engineering and service industries. registrations are abstracted and sent to ONS to update the Textiles and the pharmaceutical industry also have a strong national system. hold in the region. Many of the rural areas support farming, Use of the data food production and tourism. Routine breast and cervical screening programmes Data are used for a variety of purposes, in particular, operate in the Trent Region. Roll-out of the regional bowel responding to local health requests for information to support cancer screening programme commenced in March 2007 at the effective provision of cancer services, use in studies both the Derbyshire Screening Centre, and completion is planned locally and nationally, providing information to support for 2009. The NHS Prostate Cancer Programme was launched genetic counselling service enquiries, and responding to ad in 2000 and testing for prostate cancer is now available on hoc requests as appropriate. Some statistics, further details and also information request to men aged over 50 years on an informed choice about reports and other publications, can be found on the basis. Trent Cancer Registry Website: www.trentcancer.nhs.uk Registry structure and methods Cancer registration in the Trent region began in 1955. Since Source of population then there have been a number of signicant changes and UKACR Populations Dataset Version 3. recongurations that have resulted in the organisation we see today: Most recently, in 2003, the Registry moved to the Multiple primary rules used current premises in Fulwood, Shefeld and in 2005 beneted UKACR rules (1998).

391

Europe

UK, England, West Midlands

5 staff. A further 6 staff provide business, administrative Registration area The West Midlands registration area covers a population and secretarial support. The WMCIU is funded, as are all of 5 300 000 people in 2002, just over 10% of the total English cancer registries, via top-sliced, earmarked funding population of England. There are marked differences in from the Department of Health. Cancer registration is not a legal requirement in the UK population density across the region, with very densely populated urban areas and more sparsely populated rural at present. However, regulations passed under section 60 of areas. Non-white residents make up 11% of the total West the Health and Social Care Act 2002 permit cancer registries Midlands population, with the largest ethnic groups being to collect identiable patient data assuming the implicit Indian (3.4%), Pakistani (2.9%) and Black Caribbean (1.6%) consent of the data subjects. Cases are mainly registered (2001 census). The percentage of non-white residents is following receipt of information from clerical staff at considerably higher in some areas of the West Midlands such individual hospitals in the form of relevant histopathology as Birmingham (30%), Wolverhampton (22%), Sandwell reports and clinical case notes, such as radiotherapy reports. Some hospitals send this information in electronic format (20%) and Coventry (16%). as a single patient record. In April 2002, the West The information collected Midlands region was divided includes demographic details, into three Strategic Health UK, ENGLAND, WEST MIDLANDS (1998-2002) tumour characteristics, details Authorities, but in October UK, ENGLAND, WEST MIDLANDS (1998-2002) of the involved clinicians and 2006 these were amalgamated hospitals, and the nature of into single Strategic Health treatment. Copies of death Authority covering the whole certicates are routinely region. There are ve cancer 


 
 








received from the Ofce for networks covering the West 







National Statistics (ONS) for Midlands population. Three 












 

all cases mentioning cancer. (Arden, Pan Birmingham 

 





If no further information is and the Greater Midlands 














received after six months, Cancer Networks) are entirely 







additional details are sought contained within the West 

 





 



 
 

from Primary Care Trust Midlands; the Derby/Burton 







medical records departments and 3 Counties Cancer 














(to whom all general Networks also include 







practitioner records are residents of other registration 














returned after a patients death) areas. 







and hospitals are contacted to obtain relevant details. NonCancer care facilities       cancer deaths are provided There are 18 acute hospital 
+'#) 

+'#) routinely by the National NHS Trusts within the 
 


%+*--+,,&+++  Health Service Central West Midlands, all of 

   !+++

+
+

+
++

+ Register where all registered which diagnose and treat  +

+
+
++
+%""$+
+++ ++
+

++ 
+  +++++
+
+
+$..-/%""%!+ cancer patients. Five of these  



 are cancer centres providing cancer patients are agged. Active follow-up of patients is 
+
+'%""()++++ radiotherapy. A relatively small number of cancers are carried out for specic research studies (particularly survival diagnosed in private hospitals, nursing homes and hospices. studies that include extra-regional cases) but not routinely. In 1994, the WMCIUs existing tumour-based records The WMCIU receives diagnostic and treatment information were converted to a patient-based system in which all patients from all of these organisations. Whilst there are no routine data available on the rates have a unique identier and individual patients can have of PSA testing in the West Midlands, there has been a large several tumours each with a unique tumour number. This increase in prostate cancer since the late 1980s, when the increased the ease and speed of registration and facilitated PSA test was made widely available. Furthermore, this more complex validation and data-quality checks in line with IARC and ONS recommendations. increase is much greater in the most afuent men. Registry structure and methods Cancer registration in Birmingham dates to 1936. Originally based on a single hospital, its scope was gradually extended until by 1957 it included the whole region. The WMCIU employs 23 staff in the cancer registration and data quality section. Four teams of tumour registrars and cancer registration clerks are responsible for processing the data received from NHS and private hospitals, nursing homes and hospices in a particular geographical area. Each team leader also has a specic area of responsibility; cancer registration, data quality, training and records management. The research and information team consists of 7 staff and the computing and automated cancer registration teams of Use of the data The WMCIUs database is used for routine data provision and for clinical audit and research purposes. Since 1995, data collected by the WMCIU have been used to assist in planning and monitoring the efcacy and cost-effectiveness of cancer services. The WMCIU is also involved in the EUROCARE study and contributes data to EUROCIM. The April 1996 incorporation of the NHS Breast and Cervical Screening Quality Assurance Services into the existing structure facilitated the synergistic combination of cancer registration and screening databases. The rst major outcome of this has been the establishment of routine systems for obtaining breast and cervical cancer screening histories for all women

392

Europe

in the screening age band, including the determination of interval cancer and non-attender rates. In 2001, the WMCIU launched the electronic Cancer Information Service (CIS), providing a powerful tool to enable health workers connected to the NHS Net to access cancer data from their own PC. Modules available include cancer incidence, mortality and survival data, analyses of cancer registration data quality and outcome measures relevant to the quality assurance of the NHS Breast and Cervical Screening Programmes. The WMCIU has a web site (www.wmpho.org.uk/wmciu/) from which general

information on cancer incidence, mortality and survival can be obtained. Source of population Population estimates are based on the 2001 Census and built up from Census Area Statistical Wards. ONS estimates have been used to estimate the populations forwards and backwards to cover the period 19982002. Multiple primary rules used IACR rules (2004) on historical data.

393

Europe

UK, Northern Ireland

Registration Area The registry collects information on all neoplasms Northern Ireland consists of the six counties in the north diagnosed in Northern Ireland. Some cancer-related of the island of Ireland and is part of the United Kingdom. conditions such as Barretts oesophagus, hydatiform moles The population of Northern Ireland was 1 689 319 at the and CIN-I and CIN-II of the cervix are also recorded. last census year of 2001. Whereas most of the population A major focus of the registrys operation work is on the is rural, there are two major urban areas situated around verication of information from a single death certicate the cities of Belfast and Londonderry. Most of the heavy (death initiated cases), a single hospital admission or a single industry is located in the two urban areas. The population histopathology report. Registry staff examine practitioners is relatively racially homogeneous with only a few small notes for patients who have died from cancer. The staff ethnic minorities, although there has been a recent inux of also examines hospital records for cases identied without immigrants mainly from Eastern Europe. conrmatory histopathology or cytology. Histopathology The Northern Ireland Cancer Registry is a population-based reports are also checked for conicting information or other registry that covers the entire population of Northern Ireland. possible errors. Historically we have had high The registry does not death rates from mesothelioma routinely receive tumour staging due to the shipbuilding industry information but extracts some UK, NORTHERN IRELAND (1998-2002) in Belfast. In April 2007, a staging information from the UK, NORTHERN IRELAND (1998-2002) smoking ban was introduced written histopathology reports. into all work and public places. Pathological staging is carried out by Registry staff on selected Cancer care facilities sites onlybreast, colon, rectum, 
 

 







 

Most cancer patients are treated cervix, melanoma, bladder, testis 





 

within the National Health and ovary. An electronic tool 














Service system and even most to facilitate clinicians staging 







private patients receive some cancer has been developed 














of their treatment in National by the registry. Pilot studies 





 

Health Service hospitals. indicate enhanced recording of 














Until 1 April 2007 there were stage. The Registry has piloted 






13 separate Hospital Trusts, the capture of staging and other 














which treat cancer patients information at Multidisciplinary 







amongst the four regional Team meetings, which discuss 








 





Health Boards. There is one individual patient treatment 





 

radiotherapy department in plans and care. the region, serving all cancer The Registry has rigorous       "!1,(. #"!1,(. patients in the area. The vast Quality Control and Quality 


2**1)20111 "! majority of patients receive all Assurance programmes to their care within the region. 
   ensure high levels of data A major re-organisation of *'')1&11!" 1 !"11  11*31
!1*'')&1)332%1)333%1*'''%1*''*&1 1
"1  !"1$" 111 completeness and accuracy. !111)33)1" 1*'')11"  11"1"11%1"1" 1"1$ 11"1" 11 4
"1 "11 +'11 cancer services in 1997 introduced the concept of a cancer The Registry contributes annually to the UAKACR Quality  



 centre and four cancer units for
1!1,*''-.11/11  1 the population. Assurance Group to help monitor data quality issues. Additionally we routinely use the Flow Method for case ascertainment and Registry structure and methods yearly data re-abstraction to monitor data quality. The current N. Ireland Cancer Registry was established in 1994 to provide information on cancers in the Northern Interpreting the results Ireland population for the purposes of research, education Population-based breast screening has been offered to all and the planning of services. The new registry, located in women aged 5064 since 1993. The programme operates Queens University Belfast, replaced an existing Department a three yearly recall system and was recently extended to of Health and Social Services (DHSS) Registry that began in include women up to the age of 70. Cervical screening has 1959. It is funded by an annual grant from the Department been available population-wide to all women over 20 since of Health with ve yearly reviews to ensure quality and to the late 1980s. PSA testing for prostate cancer has steadily advise on direction. risen since the early 1990s; however there are no formal The registry uses an automated computer system with guidelines at present to use this for population screening. multiple sources of notication of patients with cancer. The Registry uses three main sources for registration, the Patient Use of the data Administration System (PAS) used by all the Hospital Trusts, The registry not only registers all cancers in the region, but histopathology reports and death notifications. From PAS also provides a cancer information service and has a close the registry obtains demographic information on individual connection with the breast and cervical screening services patients along with data on their length of hospital stay and basic and the local cancer network. Registry data are routinely tumour site and behaviour information as an ICD-10 code. PAS used by policymakers to evaluate and plan cancer services information includes limited surgical treatment information. The throughout the region. Registry reports on cancer survival, tumour information is supplemented by electronic downloads trends, cluster investigation and disease-specic audits are available at www.qub.ac.uk/nicr. The registry data on from histopathology and cytopathology laboratories

394

Europe

Barretts oesophagus and prostate cancer screening have formed the basis of research projects. Source of population 2001 census. Northern Ireland Population census conducted on 29th April 2001. 1998, 1999, 2000, 2002: Mid Year

population based on the results of the 1991 and 2001 censuses adjusted to take account of births, deaths and migration between Census Day and the MidYear date of 30th June. Multiple primary rules used IACR rules (2004) on CI5 IX period.

395

Europe

UK, Scotland
Registration area The Scottish Cancer Registry covers the whole of Scotland, which has a population of just over ve million. The majority of the population live in an industrialised belt across the centre of the country. The majority (87.15%) of the population were born in Scotland but 9.07% were born elsewhere in the United Kingdom (England, Wales, or Northern Ireland). A relatively small percentage (1.53%) were born elsewhere in Europe, and 2.25% in the rest of the world. Interpreting the results The registry introduced ICD-10 and the second edition of ICD-O for diagnostic coding of patients diagnosed on or after 1 January 1997. Previously records were coded to ICD-9 and morphology to the rst edition of ICD-O. The registry dataset was also expanded in 1997 to include most valid basis of diagnosis, method of rst detection, grade of differentiation, stage of disease (for colorectal, female breast and cervix cancers), treatment details and entry to any clinical trial. Cancer care facilities Cervical screening began in parts of Scotland in the The National Health Service in Scotland is funded mainly early 1960s, but coverage was uneven until a computerised through taxation and is mostly free at the point of use. Access call-recall system was introduced in the late 1980s, offering to hospital care is controlled cervical smears to eligible by a well-developed system women in the age group of primary care. Radiotherapy 2060 every three years. A UK, SCOTLAND (1998-2002) facilities are provided at ve national breast screening UK, SCOTLAND (1998-2002) main centres (Inverness, programme was phased in to Aberdeen, Dundee, Scotland in the late 1980s for Edinburgh, and Glasgow), but all women aged 5064 years many patients with cancer are every three years, and older 


 









diagnosed and receive their women on demand. However, 







primary therapy at district beginning in 2003/04, the 














general hospitals. The private age range for invitation was 






healthcare sector in Scotland extended to include women up 














is relatively small. to the age of 70. In April 2000, 







in three (out of 15) Scottish 







 






Registry structure and health boards, a colorectal 







methods cancer screening pilot project 














The Scottish Cancer Registry was established to assess the 







forms part of the Information feasibility of introducing a 














Services Division (ISD) of national screening programme 

 





the National Health Service based on offering faecal occult National Services Scotland blood testing to individuals       
-)&+ 
!
-)&+ (NHS NSS). The core aged 5069 every two years. 

 

'-*(*-,/.-- registration function is funded The prostate specic by the Scottish Executive 
   antigen (PSA) test was -
!
0-1
 -)(%-
+-  -
!
#-

-

-
--)+0-)!1
 -'%%'+Health Department. introduced to Scotland in  0$$# 1##$$"  $  
$%'1!1
 1"
$
#! 



 Until 1997, ve regional cancer registries carried out 1989, and use of the test has increased strikingly since then. 
- 
-)'%%*+-- -registration, and the role of the national registry was limited Although screening for prostate cancer is not currently to coordination, data collation, analysis and publication. recommended in Scotland, there is some evidence of In 1997, the national registry assumed responsibility for differing thresholds for application of the PSA test since all aspects of registration and established a network of there is now considerable variation in incidence across the outposted, peripatetic cancer registration ofcers based in 15 Scottish health board areas despite much less variation the main hospitals. Currently the registry is staffed by a in mortality. medical director, a national coordinator, six central registry In adults, the prevalence of smoking is estimated to have staff (two of whom work part-time), and 24 outposted staff fallen from 46% in 1976 to 28% in 2002, although serious (three of whom work part-time). concerns remain about the prevalence of smoking among Cancer is not a notiable disease in Scotland. Until 1997, teenagers in Scotland. Alcohol consumption has increased the regional registries relied mainly on hospital inpatient greatly in Scotland since the 1950s. The diet in Scotland sources, pathology records and death records to identify is widely regarded as unhealthy, and there is no evidence registrations. Since reorganisation, potential registrations of any substantial change overall in fresh fruit or vegetable are identied from four main computerised sources: hospital consumption since the early 1950s. discharge records, oncology records, pathology records and death records. Information from these and other, Use of the data non-computerised sources is linked to create provisional The Scottish Cancer Registry publishes data regularly registrations that are made available to the outposted cancer on incidence, and periodically on survival. Increasingly, information ofcers. By referring to medical records, information is being made available on the internet (http://www. the outposted staff validate the provisional registration isdscotland.org/cancer). Ad hoc analyses of the data are carried and abstract additional information that cannot currently out in response to many requests for information from a wide be collected electronically. The registry has an active variety of data users. The Scottish Cancer Registry is involved programme of quality assurance. in several major studies, both in-house and collaborative. The

396

Europe

registry data are used for a wide range of purposes including public health surveillance, needs assessment, planning and commissioning of cancer services, evaluating the impact of interventions on incidence and survival, clinical audit and health services research, epidemiological studies aimed at determining the causes of cancer, and providing information to support a range of functions including genetic counselling and health education.

Source of population Ofcial estimates: Midyear (30 June) population estimates. General Register Ofce Scotland (GROS): (midyear 2002) ht t p://www.g ro scotla nd.gov.u k /st atistics/ l ibra r y/ poptest/02midyeartables/index.html. Multiple primary rules used IACR rules (2004) on historical data.

397

Oceania

Oceania

Australian Capital Territory

Registration area The Australian Capital Territory (ACT) covers an area of approximately 2400 km2 and is surrounded on all sides by the state of New South Wales (NSW). Almost all the ACT residents live in metropolitan Canberra, although 85% of the Territorys land mass is devoted to national park, nature reserves, pine plantations and properties. The population at the most recent census in 2001 was 311 947, which represents 1.6% of the Australians population. The estimated median age in 2001 was 32 years. paper notications, with the exception of the Department of Radiation Oncology at the Canberra Hospital and one private hospital in the ACT. The forms are collated and forwarded onto the NSW Cancer Registry, which processes all new cases of cancer for the ACT. Data on deaths from cancer is obtained from the ACT Registrar of Births, Deaths and Marriages.

Interpreting the results Under the current arrangements, it is unlikely that any referred Cancer care facilities cases will be missed. Before 1994, voluntary reporting led to a The ACT Health oversees general health care in the region dramatic under-reporting of cancer cases. Since 1994, the reporting in partnership with the service providers. The ACT has a of cancer cases has improved steadily to a level at or near 100%. For comprehensive range of cancer example, the age-standardised prevention, early detection, rate for malignant melanoma of treatment, community care and the skin for males was 30.6 in the CAPITAL TERRITORY (1998-2002) 1998-92 statistics, and 40.7 in the palliative services available to AUSTRALIAN AUSTRALIAN CAPITAL TERRITORY (1998-2002) the local community, in both 199496 statistics. the public and private sectors. The Canberra Hospital is the Use of the data principal cancer care provider in The registry monitors the 

 









the ACT and surrounding NSW incidence and trends in cancer 







region, and offers expertise in for ACT residents. With 














surgery, medical and radiation regard to the small numbers 







oncology and haematology involved in the ACT cancer 














services. The Canberra Hospital statistics, data on incidence 







is active in cancer research and and mortality are analysed in 





 








clinical trials. ve-year blocks and reported 







There is a strong network every two years. 














of consumer and carer support Record information is 







groups and the Cancer Council made available to approved 














ACT is well supported by medical researchers engaged 







service providers and the ACT in studies that are considered community. by the ACT Health Ethics        0+'" 0+'Committee to be of importance 


(./0((.000   Registry structure and to the community. methods 

    0)&&(0 00 $0  0 0 4" 0  0
  0 0" 0 %00 0 The cancer registry is (22($0(22/0 Source of population " 0 0#  0 "0000#0  0 0  0 0 0#$0  0  0"" %00 0  0000  0 0 0 %0 0#0 0  0!30
  0 0  000(22)000 the agency established under 00 0%0 30
 the Public Health (Cancer (221%0
0
 0%0*)&(%&+(221-0
# $0
  0 0 0 %0 1991, 1996 and 2001 are census populations, adjusted for  



 Reporting) Regulations gazetted in 1994, to receive underenumeration and Australian residents temporarily 

00+)&&,-00
.00 0 notication of cancer in the ACT. Previously, the NSW overseas. The intercensal estimates are obtained from the Cancer Registry had been collecting data for the ACT since previous census by advancing age and allowing for births, 1972, although notication was voluntary. deaths and immigration. They are adjusted in the light of The ACT Health funds the registry, which is located the succeeding census. Ref: Australian Bureau of Statistics. at the Canberra Hospital in Woden in ACT. Since the Population by age and sex: Australian States and Territories regulations came into effect in July 1994, notication of June 1992 to June 1997. ABS Catalogue no. 3201.0(1997) malignant neoplasms has been mandatory for all ACT Canberra, Australian Bureau of Statistics. hospitals (public, private and day), radiotherapy departments, pathology laboratories, hospice facilities and nursing homes. Multiple primary rules used Currently, data are received from 18 sources. These are all IACR rules (2004) on CI5 IX period.

399

Oceania

Australia, New South Wales

manager, biostatistician, analyst programmer, medical Registration area The NSW Central Cancer Registry covers the population of adviser, medical coders and data entry clerks. The Registry New South Wales. There were 6 686 644 residents in 2003; maintains a register of cases of cancer diagnoses since 1972. of these, two thirds live in the capital city, Sydney. NSW is The information collected includes name, address, date of the most populated of the six federated states, with 34% of birth, country of birth, clinical details about the cancer, the population of Australia. The area of NSW is 801 400 Km2 the notifying institution and doctor. All information sent (309 433 square miles), comprising 10.4% of the total area of to the Registry is kept condential, held under security and Australia. Geographically, the Western Slopes of the Tablelands protected by the Public Health Act. Presently there is an and the Western Plains occupy two thirds of the State, but initiative to develop clinical cancer registries to collect TNM most of the population lives in the east, with 74% living in the staging and treatment information. These are being piloted in 5 of the 9 Area Health Services. adjacent coastal cities of Sydney, Newcastle and Wollongong. Forty percent of all notications are received electronically; At 30 June 2003, 20% of the population was aged under 15 years of age, 67% between 15 and 65 and 13% 65 years and the remaining notications and pathology reports are paper based. Death registrations are older. By comparison, in 1972, provided by the Registrar of the rst year of registration of Births, Deaths and Marriages cancer in New South Wales, AUSTRALIA, NEW SOUTH WALES (1998-2002) and received regularly. Coded 9% of the population was aged AUSTRALIA, NEW SOUTH WALES (1998-2002) death registrations are also over 65 years. received from the Australia In the 2001 Census, 4 450 Bureau of Statistics. The 772 people (70.5%) stated that Registry routinely matches they were Australian-born. This 


 









cancer cases against deaths in compares with 4 394 326 people 

 



 

Australia from all causes. (73.3%) in the 1996 Census and 







 





4 284 568 (75.1%) in the 1991 







Interpreting the results Census.1 The number of people 














As notification is mandatory born overseas in the 2001 Census 







and provided through a number was 1 474 987 (23.4%) compared 




 








of different sources (on average, with 1 388 849 (23.2%) in the 
 





four notications per case), the 1996 Census and 1 286 847 













level of enumeration is likely to (22.5%) in the 1991 Census. Of 







those born overseas, the three be high. Indicators of data quality 












 

main countries of birth in the support this assertion, with only 






2001 Census were the United 1.4% of cases registered as death Kingdom 275 130 (4.4%), New certicate only and 88% of all        !   ! cases histologically veried. Zealand 105 708 (1.7%) and China 



!!#!!!  (excludes Special Administrative Use of the data Region and Taiwan Province) 85 
  
 !  !!!!$! !##"$! An annual statistical report 363 (1.4%).  



 
! !!! !! ! is published that provides information on the number of new cases and deaths by counts, rates and trends over time. The Cancer care facilities There are 9 metropolitan and rural Area Health Services Registry contributes to the prevention, planning, control and responsible for providing cancer services. These Area Health treatment of cancer in the population of NSW by providing Services provide hospital inpatient, outpatient and community timely accurate data and the evaluation of both breast and health care and specialist Cancer Care Centres for their residents. cervical screening programs. It contributes to national and Radiotherapy and chemotherapy services are predominantly international publications and a variety of specialist reports by outpatient and provided in specialist Cancer Care Facilities. cancer site. In addition, there are a number of other reports on specic cancer sites, risk factors and cancer survival in NSW Cancer services are also provided by private facilities. Notication of malignant neoplasms is a statutory in progress. Tabulated data is made available through a web requirement and currently operates under the authority of the based reporting module that can be accessed at www.statistics. Public Health Act of 1991. All public and private hospitals, cancerinstitute.org.au. Unit record information is made available to approved departments of radiation oncology, nursing homes and pathology laboratories, outpatient departments and day procedure centres medical researchers engaged in studies that are considered are required by law to notify the NSW Central Cancer Registry by the NSW Cancer Institute Ethics Committee and the Department of Health Ethics Committee to be of benet to when cancer is diagnosed or treated by them. the wider community. Registry structure and methods The NSW Central Cancer Registry is managed and funded Source of population by the NSW Cancer Institute on behalf of the NSW Estimated resident population data June 19982002. Health Department. There are 19 full-time-equivalent staff employed at the Registry. These include a manager, Multiple primary rules used operations coordinator, coding supervisor, data quality IACR rules (2004) on CI5 IX period.

400

Oceania

Australia, Northern Territory

Registration area The Registry was established in 1981 to cover the entire population of the Northern Territory, a sparsely settled area of 1.4 million square kilometres in central and northern Australia. The population of the Northern Territory increased from 122 000 in 1981 to 203 000 in 2005. Seventy-ve percent live in ve urban areas. The population has a very young age distribution, with only 5% of the population aged over 65 years, although the over-65 population is increasing at a faster rate than are younger age-groups. Twenty-nine percent of the population are Indigenous Australians, most of whom live in small, remote communities. cancer registries for cases notied in one state but resident in another at the time of diagnosis. There have been no substantial changes to case denitions or coding practices since 1991. Interpreting the results Prior to 1991, case ascertainment is estimated to have been only about 60% complete. A data quality audit of the register estimated that since 1991, case ascertainment has been less than 3% incomplete, in comparison with registration rates of other Australian registries. Incidence rates for Indigenous people under-estimate actual cancer incidence by approximately 18% because of mis-classication of indigenous status (Indigenous people incorrectly identied as non-Indigenous). Indigenous Australians Cancer care facilities (Aborigines and Torres Strait There are six hospitals, AUSTRALIA, NORTHERN TERRITORY Islanders) have a very different including two referral pattern of cancer incidence and (1998-2002) AUSTRALIA, NORTHERN TERRITORY (1998-2002) hospitals, and a well-developed survival at specic cancer sites private health care system in than other Australians, with the larger towns. much higher incidence of some There has been some cancers but lower incidence improvement in cancer of others, and lower cancer 


 


diagnostic and treatment survival. Cancer incidence and 

 











services since the establishment mortality statistics are published 







of the Registry. A breast separately for Indigenous and 












 

cancer screening service non-Indigenous people. Among 







commenced operation in Indigenous Australians, smoking 














1994 and a cervical screening prevalence is very high (over 50%







register in 1996. The extent of of adults are current smokers),














PSA testing is not known. A as is consumption of alcohol at 







specialist medical oncologist dangerous levels; the prevalence 

 









commenced practice in the NT of chronic infection with Hepatitis







in 1991 and a haematologist B virus is also high, but Pap test in 2006, but other specialist participation rates are relatively       oncology services are provided low. The prevalence of smoking "!2-)/ #"!2-)/ by visiting specialists from and consumption of alcohol at 


*(+2,0(222 "! interstate; there is no specialist dangerous levels is also higher 
   cancer treatment centre or #"22!"%2$"227"2&2
"!"2"22"&2,++4&(272 #"2#"2"262 among non-Indigenous people in
%22"2%2*550&2
""!2 2,++4&(&2-""!"$!2"2 6'' &"$&&"'

'"$8&' $
!!'
3. 
5.(,3

+01 (((+3.51./22 radiotherapy facility. the NT than for the total Australian population.  



 

2!2-*55(2"2+(((/22 Patients requiring treatment not available locally are transferred to specialist treatment centres in an interstate Use of the data capital city. There is an extensive network of primary health Because of the small number of cases registered each year, care centres in remote communities. the registry produces statistical reports only every few years. The Registry participates in a small epidemiological Registry structure and methods research program focussing predominantly on issues relating The Registry is located within and fully funded by the Health to cancer in Indigenous Australians and performance of Gains Planning Branch of the state health department and local cancer diagnosis and treatment services. In recent staffed by one full-time research assistant. Data processing, years Registry data have been increasingly used for health coding and database maintenance are performed under service planning purposes, particularly in consideration of contract by the South Australian Cancer Registry. Data the feasibility of establishing a radiation oncology service analysis and publication are performed by Health Gains within the Northern Territory. Planning Branch staff. Notication of cases from the three pathology laboratories Source of population in the NT and the Registry of Births, Deaths and Marriages Estimated Resident Population, based on veyears census. has been mandatory under the Cancer (Registration) Act Australian Bureau of Statistics. 3228.0 Demographic since 1991. The Registry also performs active case detection Estimates and Projections: Concepts, Sources and Methods, from hospital inpatient morbidity data and follow-up from 1995. Catalogue No 3228.0. (available at http://www. hospital medical records and medical practitioners for abs.gov.au/AUSSTATS/abs@.nsf/DSSbyCollectionid/ incomplete notications. FCEF74DBECB94037CA256BD000274964). Death registration in the NT is complete. The Hospital Morbidity Dataset is complete for the ve public hospitals. There Multiple primary rules used is a well-established system to exchange data with interstate IACR rules (1990 and 2000).

401

Oceania

Australia, Queensland
Registration area The Queensland Cancer Registry collects data relevant to the State of Queensland, which occupies the northeastern portion of the Australian continent. Queensland is the second-largest of the six Australian states and has the largest habitable area. Queensland boasts a subtropical to tropical climate. The Queensland population of 3 522 044 (2001) is 19% of the total population of Australia. Queenslands population is the least centralised of all the mainland states of Australia. Aboriginal and Torres Strait Islander people represent approximately 3.1% of the total population. Approximately 70% of the population are of Christian denomination. Cancer care facilities Specialist cancer treatment is primarily provided by the major Brisbane hospitals (Princess Alexandra Hospital, Mater Misericordiae Hospital, Royal Brisbane and Womens Hospitals and the Greenslopes and Wesley Private Hospitals) with large regional hospitals (e.g. Townsville and Rockhampton hospitals) also providing specialised treatment. In addition, some oncology specialists visit patients at regional centres. Radium treatment is available at Townsville and Brisbane. Arrangements for completion of forms vary according to the type of hospital. Resident medical staff and medical records staff are involved in the larger hospitals, medical superintendents and nursing staff at smaller hospitals.

Interpreting the results A number of new initiatives have been undertaken in recent years. Quality assurance reviews have been conducted on cause of death coding from the Australian Bureau of Statistics. A review comparing cancer notications against the hospital morbidity collection has been conducted and indicated underreporting. The registry is able to obtain access to electronic pathology reports for all public hospitals, and is currently working on accessing other pathology laboratory results electronically. Access to the AUSTRALIA, QUEENSLAND (1998-2002) electoral roll with date of AUSTRALIA, QUEENSLAND (1998-2002) birth has been gained, which assists in identifying patients still alive, and the registrar of births, death and marriages %'.0+)... 0+&0.1'#... &%.,)1... 0#! '&.++#... ahs introduced date of birth '0.)&0... /+! )/./)1... and indigenous identier to +%.0+1... /#! +,.'%#... +1.1'1... ,+! ,#.&,%... the death certicates. /'.)/,... ,#! /#.))'... There is population-based, 1'.+&1... ++! 01.%)%... %%1.#/&... +#! %%+.&#,... coordinated screening for %&+.+)1... )+! %&).1+%... breast and cervix, and about %''.'+1... )#! %'+.&&/... %'+.1'/... '+! %'1.)),... 30% of men older than 50 %'#.1,0... '#! %''.%0/... yrs have a PSA test in any %').'/+... &+! %').,%)... %&0.+%&... &#! %&+.+0+... specied year.
%''.00%... %+! %&/.%1%... %&+.%%0... %#! +! #! %&+.0/+... %%0.110...

Use of the data Registry structure and While the QCR doesnt undertake methods an epidemiological research %# + # # + %# The registry is located at the itself, it does provide data for .($* .($* Queensland Cancer Fund and researchers wishing to undertake %./1#./0'... %./0).,00...  is funded and managed by epidemiological research. Policy  
 ..... . ...
. the Queensland Department
.. ."..&##%. . .
.. makers also use our cancer &#%+"'"... of Health. The registry has a core of eight clinical coding registry data for planning and evaluation of health services.  
   
..(&##)*.. +..
. staff as well as a number of temporary staff to undertake    )).........". supplementary projects. Source of population Data collection for the Queensland cancer Registry Australian Bureau of Statistics. 2001 Census of Population commenced on 1 January 1982. The registry operates under and Housing, Selected Social and Housing Characteristics an Act of Parliament that requires compulsory notication for Statistical local Areas 2015.3. of all cancer patients in Queensland to the registry from all hospitals (public, private, psychiatric) and nursing homes. In Multiple primary rules used addition, it is compulsory for all pathology laboratories to IACR rules (2004) on CI5 IX period. provide pathology reports mentioning cancer to the registry. Death certicates are accessed where the cause of death is Notes on the data cancer and also for cancer patients dying of causes other C44 does not include basal cell or squamous cell than cancer. carcinoma.
%'&.%%'... %'&.//'... %&+.)%,...

402

Oceania

South Australia
Registration area South Australia is a state in the Australian federation of six states and two territories. It is situated between 26 and 38S and 129 and 141E, and covers a total area of 984 375 km2. Over one third of this area is desert, and over half of the state is devoted to extensive pastoral pursuits. Approximately 99% of the population lives south of the 32nd parallel, and a high proportion of the population lives in or around the coastal state capital city, Adelaide. South Australia has a multicultural population with increasing immigration from many overseas countries. The Cancer Registry records Country of Birth and Race (whether Caucasian, Indigenous, Asian or Other). searching the current le of death certicates obtained from the Registrar of Births, Deaths and Marriages. Hospitals or treating medical advisers are consulted when a cancer death certificate is received for someone not already known to the registry. All Australian registries communicate regularly with each other about cases who have moved interstate. Ascertainment checks to nd unreported cases are performed at least every six months by comparing hospitals inpatient separation data with the registrys les. An annual data validation check is performed in addition to the routine editing and validation procedures incorporated into the data entry software. Since 1987, a system of hospital-based (clinical) registries has been established SOUTH AUSTRALIA (1998-2002) in major teaching hospitals SOUTH AUSTRALIA (1998-2002) in South Australia. Special liaisons have been established with the hospitals departments to facilitate the follow-up of  


patients by clinicians and 




to enable them to evaluate 






 

clinical aspects such as 




treatment outcomes in relation 








to disease stage and important 




prognostic factors. The 








relevant clinical areas own 




these hospital-based registries, 








but signicant interaction 


 

with the population-based 








registry is required for case 




ascertainment and data provision.     

Registry structure and methods The South Australian Cancer Registry started in 1976, on a voluntary basis, but since 1977 notication of cancer has been a statutory obligation (without 


penalty) for all hospitals and 



pathology laboratories in 





South Australia. Hospitals are 



required to report all cases of 






cancer (expect non-melanotic 



skin cancers) within one 






calendar month of the patients 



commencing radiotherapy, 
 




the patients discharge from 



the hospital and/or death of 

 




the patient in the hospital. 



Pathology laboratories are required to send copies of  ,'#) ,'#) reports of all cases of cancer 


-(&,-*.,,,  Use of the data within one calendar month The primary objective of the of the nalisation of the 
   , 0,%""",,, ,,,
,, , , ,,,$//+, , , ,, ,, registry is to describe the pathology report. , ,, , !, Registry staff consists of  



 a Manager and ve cancer nature and extent of cancer in South Australia, to monitor 

,,'%""(),,
*,, , cancer incidence, mortality and survival, and to evaluate registry project ofcers. The system of notication varies among hospitals spatial and sub-population differences. Registry publications depending on hospital size, stafng and types of record on cancer in South Australia are current, timely and wellsystems. In general, the responsibility lies with medical received locally, interstate and overseas. The data are used extensively for monitoring the burden records ofcers in public hospitals and managers in private institutions. The multiple notications received are linked of cancer in the community and evaluating the effectiveness and a le is created for each patient. Checks are available to of cancer control and prevention programmes, for example the registry from death certications and pathology reports. breast and cervical cancer screening, and of clinical Cases from such sources that are not reported by hospitals services. PSA testing is also common within the population. Other international, national and local bodies also use the are followed up. Information collected includes country of birth, race, data extensively for their cancer prevention, cancer control, occupation, Breslow thickness and Clark level for melanoma clinical services and/or research activities. The Cancer Council South Australia is one local organisation that uses and tumour diameter and nodal status for breast cancer. The registry staff regularly telephone, visit or write registry data heavily in its activities. An analysis of survival has provided valuable information all hospitals to obtain information on inadequately reported cases and cases identified from pathology for the entire South Australian community, and has served as laboratory reports. Patients medical advisers may be a standard comparison for intra-hospital survival studies. The consulted by letter or telephone if case discrepancies are data are now sufcient for ten-year relative survival rates to not resolved by other means. An annual cross-linkage be calculated based on the proportion of survivors from 1977 checks cancer registry live cases with the Registrar in the patient group, as related to the proportion of survivors of Deaths main deaths le to see whether any cancer in a similar group of people without the disease. Cancer registry data also are used in investigating cases have died of a condition other than cancer. Cancer deaths are detected on a monthly basis by electronically perceived cancer clusters in various geographical areas.

403

Oceania

These perceptions usually arise from a citizen or group of citizens concerned about their local environment. Other cancer epidemiology and statistics endeavours are supported, such as the National Malignant Mesothelioma Project, National Paediatric Cancer Registry, the National Cancer Statistics Clearing House and various ad hoc international, national and local projects.

Source of population The midyear 2000 population was estimated by the Australian Bureau of Statistics, based on the 1996 census, and advancing age and allowing for migration, births and deaths. Multiple primary rules used IACR rules (2004) on CI5 IX period.

404

Oceania

Australia, Tasmania
Registration area transfer. Death certicates of Tasmanian people are reviewed for Tasmania, the smallest state of Australia, is a group of islands mention of cancer as a cause of death. Since 1994 breast and cervix of 68 114 km2, about 0.9% of the total area of Australia, lying cancer screening programs have been undertaken in Tasmania, and between 40 and 43S, and having a temperate climate. The listings from these sources are available to check against registry principal industries are aquaculture, viticulture, mining and records. In the 1990s, the increase in the incidence of prostate forestry. Secondary industries include textile, confectionery, cancer coincided with a greater use of PSA testing. Incidence beer and beverages, zinc and aluminium smelters, and peaked in 1995 before declining. Interstate registries supply data vegetable and milk processing. Tourism is also a major to the Tasmanian Cancer Registry on Tasmania residents who industry in Tasmania. Waterpower stations provide nearly seek treatment interstate or who move interstate at some time all the electricity generated in the state. Wood res used for after cancer diagnosis. home heating produce smoke in populated areas during the The Tasmanian Cancer Registry collects and registers winter. A degree of heavy metal pollution of river waters non-melanoma skin cancers (NMSC) on a register established occurs in some areas. in 2001 for this purpose. Currently NMSC registrations are complete from 1978 to 2004. Only 2.5% of Australias To help achieve high data population reside in Tasmania. quality and case ascertainment, Ta sm a n ia i s t h e mo st AUSTRALIA, TASMANIA (1998-2002) data are obtained from multiple decentralised state in Australia, AUSTRALIA, TASMANIA (1998-2002) sources including pathology with almost 60% of people living laboratories, hospitals and the outside the capital city statistical Registrar of Births, Deaths and division. Like the national Marriages. Most registered population, that of Tasmania 


 









cases include data from both is ageing with an increasing 







a pathology laboratory and proportion of the population 













a hospital service (inpatient aged 65 years and over. 

 





or radiation oncology clinic). Tasmania is the least diverse 





 








Where information received population in multicultural terms 







is insufcient to enable of all the states in Australia with 

 












complete registration, active 95.5% of the population born in 







follow-up is undertaken by Australia, the USA, the UK, 














contacting treating doctors, New Zealand and South Africa. 







pathology laboratories and Three percent of the population 














medical records departments. are of indigenous origin. 







In addition, the National Cancer Statistics Clearing Cancer care facilities       House (NCSCH) in the Tasmania is well served by ! /+' "! /+'national capital, Canberra, oncology services. The three 


)*)/1(0/// ! collates all State and Territory main population regions all  
 !$/! // 3 " !/!/
! !/  / "! /  !%/ /  ! / "! / data and checks for duplicate have a public hospital system as (11./!/)&&(/! / / ! /#! /"/ / / /#/!!/! /!/! //#$/ !/!/"!%/ /! /! // / // /  / %/ %2/
! !/ "!/!$/
! !/ !//!$/!%/
%/*(&(%&$/ %/(11.3)&&(%/
/
$/ well as a number of private hospitals. There are two radiation registrations across two or more States. !"!!/ !//(11.$/
! !/ !//!$/!%/
%/*(&(%.$/(11.%/  
   Prior to the year 2000 cases were not accepted by the oncology units in the state. 
/ /+)&&,-//! /!!/    registry on the basis of death certicate only. Each death ,,//!! !# %/ certicate is actively followed up to ascertain the time Registry structure and methods The Tasmanian Cancer Registry was established in 1977 as and place of diagnosis and to verify the diagnosis, and the a population-based registry covering the state. The registry percentage of death certicate only cases registered since was set up for the purpose of providing the state government 2000 is 1% per annum. with accurate cancer incidence and mortality statistics and to provide the capacity to monitor cancer trends. In July 1988 Use of the data the responsibility for the operation of the cancer registry The registry publishes a report each year showing the was transferred from the Department of Health and Human number of new cases of cancer in Tasmania, and each cancer Services to the Menzies Research Institute, University of registry in Australia sends information to the NCSCH which publishes a national report. More detailed information Tasmania, Hobart. Cancers were proclaimed as notiable diseases in is made available to the State Government healthcare December 1992, and since then cancer has had a legislative institutions, healthcare professionals and health researchers basis. The registry is assisted by an Advisory Committee. to plan cancer education, treatment and research. In ethically The registry staff currently comprises a director, manager, approved research projects, identied data from the cancer registry may be released to researchers. two medical coders and a clerical assistant. All the pathology laboratories in the State send the registry copies of histopathology, cytology and cell marker reports of cancer. Source of population Notication of cancer forms are supplied by the two radiation 1996 and 2001 are Census populations, adjusted for oncology clinics. Private and public hospitals notify diagnoses underenumeration and Australian residents temporarily of cancer to the registry upon discharge of patients or provide a overseas. The intercensal estimates are obtained from the computerised listing of cancer cases periodically by electronic previous census by advancing age and allowing for births,

405

Oceania

deaths and migration. They are adjusted in the light of the succeeding census. Ref.: Australian Demographic Statistics, Australian Bureau of Statistics, Cat. No. 3101.0, Dec. 19962001. Allen DN, Tasmanian Year Book 1996, Australian Bureau of Statistics, Cat. No. 3101.6, 1996.

Multiple primary rules used IACR rules (2004) on historical data. Notes on the data C44 not available.

406

Oceania

Australia, Victoria
Registry structure and methods Registration area The Victorian Cancer Registry covers the State of The Victorian Cancer Registry was established in 1940 by Victoria, the second most populous State in the Australian the Anti-Cancer Council of Victoria (as it was then known). Commonwealth, situated in the southeastern corner of the Since legislation was passed in December 1982, cancer continent and bounded to the north by New South Wales and notication has been compulsory for all hospitals and to the west by South Australia. The estimated population pathology laboratories in Victoria, and fully populationin 2004 comprised 4 962 970 persons, of whom 19% were based coverage was achieved in 1982. The registry is central under 15 years and 13% were aged 65 years or more. One in to Cancer Council Victorias cancer control programme, four Australians lives in Victoria, and almost three quarters and is housed in its Cancer Control Research Institute in of these live in the Melbourne Metropolitan Area with most Melbourne. The registry is also funded by the Department of the remainder in small provincial cities. The average of Human Services, Victoria. The Registry has a staff of 20: population density is 22 persons/km2, ranging from <2 in medical coders and clerical staff, a consultant pathologist, registrar and deputy registrar, director, information manager the Wimmera to over 400 in Melbourne. and administrative support Since the registrys inception from the Cancer Epidemiology in 1982, the population has Centre. both grown and aged, and AUSTRALIA, VICTORIA (1998-2002) The registry is largely a the mix of immigrants has AUSTRALIA, VICTORIA (1998-2002) passive notication system, altered from predominantly receiving reports from European to growing numbers around 250 hospitals and 50 from Asia, South America and pathology labs in Victoria Africa. The newest migrant 


 









and exchanging non-resident groups tend to be younger 







data with neighbouring states. and, therefore, contribute 














Hospital data are received on little to cancer incidence. At 







handwritten forms, computer the 2001 census, 24% of the 














printouts or increasingly population was described as 







in electronic format. being overseas born. Of these 














Notications from pathologists 1 080 344 persons, 15% were 







are usually full copies of from the United Kingdom, 4% 














pathology reports in computer from New Zealand, 7% from 







readable format. Over 70 000 Italy, 4% from Greece, and 4% 














notications are processed for from Vietnam. The remainder 







each year of incidence data. originated in China, India, Sri Other data sources include Lanka, Malaysia, Germany,       details of all death certicates former Yugoslavia and other  .*&,  ! .*&, supplied on magnetic tape by European countries, and small 



(.)-+./))...  the Registrar of Births, Deaths numbers from Asia, South 
   0.
#. . .  $.
. ...$.
$. and Marriages. Some active America, Africa and Oceania.  1 . ! .  ..*,.". .. . )(%'$%.*$"$$,. Almost 70% of Victorians were Christians (28% Catholic) with follow-up is pursued for cases in specialist sub-registers e.g.  



 
. .*(%%+,..-..  . less than 1% each of Muslim, Jewish, Buddhist, Hindu and other for in-situ and small invasive breast cancers, CNS neoplasms, childhood cancers, and prostate cancers. religious denominations; one third stated no religion. The Victorian Cancer Registry adheres to IACR Because of its low latitude and highly susceptible population Victoria has a high incidence of skin cancers. No denition and coding recommendations; all data from other cancer risk factors are particularly prominent; smoking 1982 have been recoded according to IACR rules. Data are rigorously computer-checked for validity and consistency, has long been in decline but obesity is increasing. and routine checks are regularly conducted on the entire le. Data quality is assured by matching pathology reports with Cancer care facilities Victorias medical care system is a mix of private and hospital registrations for cases where diagnosis was based public sectors. In 20034 it had a well-established system on histological conrmation. There are no plans for a formal of 144 public hospitals with several specialist oncology units review of completeness or accuracy. Periodic record linkage including Radiation Oncology centres, and one large hospital with other administrative databases has conrmed virtually dedicated to cancer treatment, for a total of 11 950 public complete casending. For death certicate only registrations, hospital beds. In addition there were 135 private hospitals correspondence is sent to the signatory doctor to conrm containing 6674 beds. A mix of public hospital departments diagnosis. The registry only contacts patients directly within and private laboratories provided pathology services. In the the context of research study recruitment. last two decades there has been some de-centralisation of Use of the data treatment services, especially radiotherapy. Victoria has organised screening programmes for breast The registry produces regular statistical reports and overviews and cervical cancer and bowel cancer screening is being of its accumulated data. It also produces a regular pamphlet, introduced. Since the early 1990s the use of the PSA test has CANSTAT, a topical epidemiological digest of cancer facts become widespread, though this is not supported by cancer and gures. Registry data are used to assess the extent of the cancer epidemic and to monitor trends, particularly in agencies or the government.

407

Oceania

cancers targeted by prevention programs (skin, lung, breast and cervix). The registry also facilitates cancer management surveys by identifying random samples of patients and sending their treating doctors questionnaires regarding care patterns. Cancers surveyed in this way have included breast, bowel, prostate, lung, and testis, rectum, ovary and bladder. One of the registrys most important functions is to facilitate epidemiological research. In addition to epidemiological analysis of registry data, the registry is used to follow up cancer events in cohort studies, to identify cases for case-

control studies, and to conrm cancer occurrence in population-based studies. Source of population Midyear estimated resident population (ERP) by age group and sex; Australia, States and Territories. Australian Bureau of Statistics Cat. No. 3201.0 (www.abs.gov.au). Multiple primary rules used IACR rules (2004) on CI5 IX period.

408

Oceania

Western Australia
additional data when necessary; enquiries are also made of Registration area The Western Australian population of is approximately 10% private pathology laboratories and medical practitioners in of the total population of Australia. Western Australia now case of need. Mortality information is routinely searched has a high proportion of migrant inhabitants; 69% of the for outcomes of known cases, and additional cases are population were born in Australia, 22% in New Zealand, recordedthen subjected to the routine enquiry process and 18% in Europe (including the UK). Approximately 3% when a death certicate indicates a cancer in an individual of the population are Aboriginals, for whom life expectancy previously unknown to the Registry. Search and matching is on average between 15 and 20 years less than for non- routines are now fully computerised. For selected cancers, additional data (such as level and Aboriginal persons. The Registry covers the entire State of Western Australia, depth for melanomas) are stored in linked data les. The an area of 2 525 500 km2, almost one third of the total area database is a relational structure consisting of individual of Australia. The State lies between latitude 13 and 35S and linked Dbase3+ les controlled by a locally-developed longitude 113 and 129E and extends approximately 2400 program using the Clipper5 compiler. There are 4 hospital-based km from north to south. The cancer registries in Western northern third of the State lies Australia that collect additional within the tropics where desert WESTERN AUSTRALIA (1998-2002) data concerning cancer stage or near-desert conditions prevail WESTERN AUSTRALIA (1998-2002) and treatment, and regularly over some 900 000 km 2 and exchange information with the population density is sparse. central Registry and hospital Population distribution overall registries. This enhances is extremely uneven; 73% of the 
 

 






the completeness of WACR population live in the capital city 







data, and provides hospital Perth, in the south of the State 














teams with outcome (survival) The States economy has 







information. diversied, and it is now a 








 





leading producer of several key 







Interpreting the results minerals. Heavy manufacturing 














In Western Australian is relatively insignicant, 







women, around 54% of the but light manufacturing is 














target population (5069 widespread. Air pollution has 







years) are screened for breast not been a major problem in 














cancer and 61% of the target Western Australia; however, 





 

population (2069) undergo there has been increasing routine Pap smears to detect public concern over the possible       cervical cancer. Screening for effects of industry, to which 
($!& 

($!& other specic diseases is at the Cancer Registry has had to 


)%"("')(((  present reserved for high-risk devote signicant time in recent 
   
(

((
(  **((
((
(

((
(
(((
*
(

( ( families. years. 
((((
(( (((((
(
(
( Within WACR, data quality is assessed in various ways.  



 
(
($# %&(((( For completeness of data, the mortality to incidence ratio is Cancer care facilities Cancer therapy is concentrated in the Perth metropolitan a reasonable indicator and for the 2004 data were 0.33 for area, the major (government-operated) teaching hospitals males and 0.30 for females. The IARC rules for agging of and several private clinics acting as referral centres for non-reportable multiple primary tumours are incorporated in the Registry software (recently updated to the current country areas. ICDO-3 rules). Processing of death information has a special statusat Registry structure and methods Reporting of cancer in Western Australia became a statutory the time of death data linkage, each case is reviewed for obligation in August 1981 with the establishment of the compatibility of incidence and mortality data, cause of death population-based Western Australian Cancer Registry. is coded by registry staff, and letters are sent to doctors or Notications are received from pathologists and radiation hospitals to resolve outstanding questions. The Registry oncologists. Scope includes all malignancies and in situ records cause and date of death when notied of events neoplasms other than primary cutaneous BCC and SCC, and outside our jurisdiction, so as to facilitate accurate survival analysis and prevalence studies. includes benign CNS tumours. The WACR has the equivalent of 6 full-time staff who handle preparation, linkage, coding and entry of data, as Use of the data well as administrative and statistical reporting functions. The WACR maintains a comprehensive statistical analysis A detailed statistical report is produced each year and tool for response to queries, based on a statistical extract includes incidence and mortality rates and most common which can be updated periodically. Population les are cancer types data, while other analyses such as survival and maintained to serve the Department of health administrative boundaries, and a choice of standard population weightings geographic-area analysis are periodically included. Registry staff have access to medical records is available to meet the needs of both local and International departments of major public hospitals to allow collection of communities.

409

Oceania

Data from the WA Cancer Registry are used in a wide variety of research projects, many of which include the contacting of individual persons on behalf of researchers. Use of named data for such purposes is strictly controlled, and the increasing use of Registry data for research purposes is encouraged. The staff support the view that the value of the Registry lies mainly in its being used.

Source of population The estimate of the populationatrisk is based on Australian censuses and Australian Bureau of Statistics intercensal estimates, making allowance for births and deaths, and migration into and out of the registration area. Multiple primary rules used IACR rules (2004) on historical data.

410

Oceania

French Polynesia
recommended the establishment of a cancer registry in each Registration area The registry covers all of the islands of French Polynesia, country of the region. To date, only two island countries i.e. 118 main islands distributed over 5 archipelagos, have such a registry: Papua New Guinea (since 1958) and corresponding to a total of 4000 km2 land area, but spread Fiji (since 1965). French Polynesia, as well as American Samoa and New Caledonia, immediately showed interest in over an area of ocean the size of Europe. Seventy-ve per cent of the 244 830 inhabitants (Nov. having a common notication system for cancer cases. Other 2002 population census) live on the island of Tahiti, where countries of the region have since adhered to this proposal. Data collection started in French Polynesia in 1981, with the Papeete is the only real town of the area. The population is young: 40% are aged less than 20 years. In 2002, the birth technical assistance of the South Pacic Commission, UCLA rate was 19.6%; during the same period, the crude mortality and the University of Hawaii Cancer Research Institute. rate was 4.6%, and 6.7% for child mortality. The cancer registry of French Polynesia is not an administrative Census data for 1988 show the following ethnic independent body: it is managed by the Health Directorate, under distribution (information on ethnic groups has no longer the administrative responsibility of the Director. been collected after that date): Sources of cancer data Polynesian and related groups include: Physicians voluntary 83%, European and related notications, pathology FRENCH POLYNESIA (1998-2002) groups 12%, and Asian and reports from the three existing FRENCH POLYNESIA (1998-2002) related groups 4%. laboratories, cytology reports The majority of the population from the biology laboratories, is of Christian denominations, the computerised medical mostly Protestant. In 2002, the systems (PMSI) of the French (&*--0", .(+--economically active rate was Polynesia University Hospital ."*--.* 000--58%. Centre and private clinics, $-&*"--." $-(%&--%-%$(--+* %-$"1--death certicates and the &-"(&--+" %-.(0--Cancer care facilities registry of repatriation towards (-"1*--** &-*.0--(-11+--*" (-($&--Health care in French Polynesia France or New Zealand and +-&1&--(* *-.(0--is characterised by the cothe long-diseases registry of .-1%+--(" .-".1--1-%0"--&* 0-*+1--existence of an important public the Social Security system. $"-%(.--&" 1-*$"--sector and a free enterprise Some physicians are often $"-"".--%* 1-&&+--$"-$+*--%" 1-*++--sector that has greatly increased reluctant to reveal the names of $$-0&"--$* $$-&+0--over the past 10 years. their cancer patients. However, $&-%&(--$" $%-*%0--$%-.*.--* $$-1""--Healthca re expenses follow-up of identied cases $%-"%.--" $$-$0&--have been evaluated to 420 has improved thanks to the million euros. Since 1995, all above PMSI. $" * " " * $" Polynesians have had social Data is coded according 
-'#) 

-'#) healthcare coverage. Moreover, $$%-+1%--to Version 3 of the WHO $%"-."*-- an interaction between International Classication of 
   preventive and medical care, the -
--  -

-

!--
--
-
- 2
-/
-'!! !!)!-%""%3-



-22-
-Diseases for Oncology. A patient  -
- 2
-/
-

-%""%!improvement of lifestyle and education, and the development of with two distinct tumours will be entered twice. The crude registry  



 
-
-'$11")-public structures such as drinking-water networks and wastewater data are analysed on a yearly basis (number of cases declared and treatment have improved the level of health indicators, despite the distribution). A 5-year synthesis is performed regularly. important rise of diseases linked to lifestyle (diabetes, obesity). The Polynesian health system on Tahiti Island has one Interpreting the data well-equipped university hospital centre with 436 beds, Cancer currently is the second-leading cause of death in 2 private clinics, one secondary hospital, administered by Polynesia (23% of certied deaths), following cardiovascular the Health Directorate, with 44 beds for medico-obstetrics, diseases. In the majority of cases, cancer treatment leads to public community clinics also administered by the Health medical repatriation towards France or New Zealand, once the Directorate and one growing free-enterprise sector with diagnosis has been conrmed by one of the of the countrys 193 physicians (as at 1 Jan 2007), corresponding to 114 per three pathology laboratories. Only basic chemotherapy protocols 100 000 inhabitants in Tahiti. and surgery of some tumours take place locally. The global healthcare distribution currently (2007) is of 282 physicians per 100 000 inhabitants in Tahiti, and of 234 Use of the data per 100 000 over the whole country, the actual distribution The registrys current task is limited to basic descriptive being very uneven (84% work on the island of Tahiti). analysis of the distribution by sex and age of the main cancer In addition to the above there are 7 specialised medical clinic incidence in French Polynesia. departments combining care and prevention: Hygiene and Public Health, Mothers Care, Child Care, School Health, Dental care, Sources: Child and Youth Psychiatry, and Alcohol and Drug Addiction. - French Polynesian Institute of Statistics - Department of Health Care Planning, Health Directorate, Registry structure and methods French Polynesia The 8th Regional Conference of South Pacic Commission - Cancer Registry of French Polynesia, Health Directorate, Health Directors organised in 1979 in Apia (Western Samoa) French Polynesia

411

Oceania

Source of population Estimated annual median population. Institut de la Statistique de Polynsie Franaise (I.S.P.F.). 2002: General census of the population in French Polynesia, November 2002.

Multiple primary rules used IACR rules (1990).

412

Oceania

New Zealand
Registration area New Zealand is situated in the South Pacic Ocean, 1600 km southeast of Australia. It is a long mountainous country surrounded by a large expanse of ocean, and consists of two main land masses: the North Island and the South Island. The total land area (including offshore islands) is 270 534 km. In 2001, 75% of the population lived in the North Island, and more than 30% of the population lived in the Auckland region. New Zealand is one of the most urbanised countries in the worldapproximately 85% of New Zealands 2001 Census usual population count lived in an urban area. In 2001, 80% of New Zealanders identied as European and 14.7% identied as Maori. The other main ethnic groups were Asian (6.6%) and Pacic Peoples (6.5%). Cancer care facilities Cancer care in New Zealand is predominantly statefunded, supplemented by private hospitals and private practitioners. Cancer surgery and chemotherapy services are provided in the main centres of population; there are six radiotherapy centres. cell skin cancers. Additional data sources include Medical Certicates of Causes of Death, Coroners Findings, and public and private hospital discharge data received in electronic form. All cancer registrations are coded by registry staff. Quality control procedures include computerised validation checks at data input, and rigorous edit checks on prepublication incidence data. The New Zealand Cancer Registry carries out internal and external audits from time to time. We last had a review by an external auditor in 2005. Use of the data Cancer registry data are used to monitor the burden of disease and to assess the impact of screening programmes, and as a resource for cancer research. The New Zealand Health Information Service produces an annual cancer publication containing information about cancer incidence and trends. The registry provides data for epidemiological research and identies cases for ethicsapproved case-control studies. Cancer registry data is also used by Genetics Services centres to assist in identifying familial cancers. Policymakers use our cancer registry data for planning and evaluation of health services.

NEW ZEALAND (1998-2002)

NEW ZEALAND (1998-2002)


































 





























 


 










Registry structure and 





 

methods 













The New Zealand Cancer 







Registry is located in the New 














Zealand Health Information 







Service (NZHIS), which is a unit of the New Zealand Ministry       of Health in Wellington. The -)%+  -)%+ Source of population registry has operated since 



&-./,-(&$-- Annual estimates of the 1948. The New Zealand Cancer 
   ---0--1--!-- - "-!---2-----usually resident population Registry is staffed by seven
- !"--- #clinical coders and two support staff. Honorary consultants supplied by Statistics New Zealand, based on a veyearly  



 

--)'$$*+--
,--census and taking into account births, deaths and include pathologists, epidemiologists and oncologists. Since 1994, laboratories have been the primary source migration. of cancer notications to the New Zealand Cancer Registry. Laboratories are required by law to report any new diagnosis Multiple primary rules used of cancer in New Zealand, excluding squamous and basal IACR rules (2004) on CI5 IX period.

413

Oceania

USA, Hawaii
Registration area The Hawaii Tumor Registry (HTR) is an active cancer surveillance monitoring system for the entire US state of Hawaii, consisting of 8 major and 124 minor islands, covering 1367 miles from tip to tip. The resident population in 2005 was approximately 1 275 000, with the majority of residents living on the island of Oahu. Cancer care facilities As the central statewide collection point for cancer data, the HTR receives data from collaborating hospitals maintaining their own hospital-based Tumor Registries. HTR staff also gathers data from other facilities, in addition to cases from oncology clinics, pathology labs, private physicians and radiation oncology facilities. The HTR database currently contains 137 591 reportable resident cases. Registry structure and methods The Hawaii Tumor Registry (HTR) maintains a database of information on all cases of cancer diagnosed in the State of Hawaii. It provides complete cancer reporting for the entire state and serves as a resource for nearly all epidemiologic cancer research and cancer control activities in Hawaii. HTR collects the required SEER demographic and diagnostic items for all malignancies diagnosed in the state. Patients are followed annually during their lifetime. To ensure accuracy, strict quality control and assurance procedures have been established. The HTR was established in 1960 by the Hawaii Medical Association (HMA), the Hawaii State Department of Health (DOH) and the Hawaii Pacic Division of the American Cancer Society (ACS). Presently, HTR is jointly operated by the Cancer Research Center of Hawaii and DOH, and became a member of the National Cancer Institute, Surveillance, Epidemiology and End Results (NCI/SEER) program in 1973. HTR has received its primary nancial support from the National Cancer Institute through its Surveillance, Epidemiology and End Results (NCI/SEER) Program, with additional funding from a DOH fee-forservice contract. Interpreting the results In its years of operation, HTR has been a major source of cancer data and information, locally, nationally and internationally. HTR data collected for diagnosis years 1973 2003 are complete. There is some difference in incidence rates between males and females and among several ethnic groups. Hawaii is unique in that its population is racially diverse, with no one ethnicity in the majority. Use of the data Hawaii statistics on a wide variety of malignancies are available to the research community world wide. The most recently available statistical publication, Hawaii Cancer Facts & Figures 2003-2004, is available for download at http://www.crch.org/Cancer0304.pdf. The publication provides an overview of cancer, a discussion of the impact of gender and age and racial/ethnic disparities in cancer, and an analysis of six major cancer sites by race/ethnicity.

USA, HAWAII USA, HAWAII (1998-2002) (1998-2002)

USA, HAWAII: CHINESE (1998-2002) USA, HAWAII: CHINESE (1998-2002)





























 




















 

 
























 














































4((333 6,,333 *3.54333 *3410333 *315+333 *315*333 +3(6,333 ,3((*333 ,3+4(333 ,3.(*333 ,3,(1333 +34.4333 +310*333 +31+,333 +364.333 ,3**+333 ,3(*5333 +304+333

502 5(% 40% 4(% 10% 1(% 00% 0(% .0% .(% ,0% ,(% +0% +(% *0% *(% 0% (%

*3*(*333 *3,(*333 *3465333 +3(46333 *3610333 *36,*333 +3+*5333 ,3,(1333 ,31.+333 ,315,333 ,3001333 ,3*0,333 +3404333 +3064333 +351,333 +3605333 +351.333 +31,+333



 /*',

 !/*',



*(

0  3-)/

0 ! 3-)/

*(

.((/0()///






.,3(*1333

 

.13.(.333

Source of population  




 July 1 county population estimates by age, sex, race, and 
/ /*)&&+,// -//
 / Hispanic origin; postcensal estimates based on 2000 United States Census. The population data include the bridged singlerace estimates derived from the original multiplerace categories in the 2000 United States Census. http://www.seer.cancer.gov/popdata. Multiple primary rules used IACR rules (2004) on CI5 IX period


   /(//

/!/"/#/ #/ #//
/ 2/
/!/"//)&&&/// $//

////" /3 /!/ / !// /!
3 / ///)&&&/// $/ 
1%%$ $ $%

$/

Source of population  




 

33-+((./33
033 3 State and County Intercensal Population Estimates : 1990 to 2000. Source: Population Division, U.S. Census Bureau, Washington, DC 20233 (http://www.hawaii.gov/dbedt/).


    3  3
3 3 3! 373*66(33+(((&3733 3 $3&&3
3 $3# $3
33+(+,,3 -7''&  &' " '/3

Multiple primary rules used IACR rules (2004) on CI5 IX period

414

Oceania

USA, HAWAII: FILIPINO (1998-2002)

USA, HAWAII: FILIPINO (1998-2002)

USA, HAWAII: JAPANESE (1998-2002)

USA, HAWAII: JAPANESE (1998-2002)

*346.333 *3*6,333 +3.50333 +36(*333 ,3(1+333 ,35*5333 .3,15333 03*06333 13+(4333 43,+0333 434+,333 430(4333 43,05333 43*45333 434(.333 4310.333 43606333 135*5333

502 5(% 40% 4(% 10% 1(% 00% 0(% .0% .(% ,0% ,(% +0% +(% *0% *(% 0% (%

*3((6333 *3++6333 +3,.6333 ,3.+5333 .3(.5333 .340(333 03+46333 13(5(333 135((333 435,0333 53.,6333 53(.,333 431(5333 135.*333 43,*+333 43.+1333 43,*0333 13,10333

+34(5333 .3(,+333 13*,+333 13405333 031.5333 03,+(333 13540333 63*+(333 63461333 63,04333 43554333 13+6+333 03*.*333 .31*,333 03++1333 03(55333 .3454333 ,3560333

502 5(% 40% 4(% 10% 1(% 00% 0(% .0% .(% ,0% ,(% +0% +(% *0% *(% 0% (%

.3.1*333 03104333 53+(0333 63.1+333 53(*,333 13*.(333 43+(,333 5360+333 63051333 63,5.333 53++(333 1350+333 030,*333 .3.4.333 .360,333 .356.333 .3,4*333 ,315,333

*(

0  3-)/

0 ! 3-)/

*(

*(

0  3-)/

0 ! 3-)/

*(

653+*,333

 

*(+3*01333

*(53140333

 

*+(3(.*333

-7''&  &' " '/3 Source of population  




 

33-+((./33
033 3 State and County Intercensal Population Estimates : 1990 to 2000. Source: Population Division, U.S. Census Bureau, Washington, DC 20233 (http://www.hawaii.gov/dbedt/).


    3  3
3 3 3! 373*66(33+(((&3733 3 $3&&3
3 $3# $3
33+(+,,3

-7''&  &' " '/3 Source of population  




 

33-+((./33
033 3 State and County Intercensal Population Estimates : 1990 to 2000. Source: Population Division, U.S. Census Bureau, Washington, DC 20233 (http://www.hawaii.gov/dbedt/).


    3  3
3 3 3! 373*66(33+(((&3733 3 $3&&3
3 $3# $3
33+(+,,3

Multiple primary rules used IACR rules (2004) on CI5 IX period.

Multiple primary rules used IACR rules (2004) on CI5 IX period.

USA, HAWAII: HAWAIIAN (1998-2002)

USA, HAWAII: HAWAIIAN (1998-2002)

USA, HAWAII: WHITE (1998-2002)

USA, HAWAII: WHITE (1998-2002)

,01333 1(0333 *3*0.333 *340,333 +3,6(333 ,3(.*333 .3,*(333 030,1333 135++333 43600333 5304.333 53*6*333 53.+,333 63*,5333 *+3+(6333 *,3+.0333 *,34++333 *+3160333

502 5(% 40% 4(% 10% 1(% 00% 0(% .0% .(% ,0% ,(% +0% +(% *0% *(% 0% (%

4.1333 644333 *3011333 +3,+0333 +3406333 ,3,++333 .30(.333 03.46333 1364,333 436**333 536*.333 53+,1333 53**1333 5354,333 **3.50333 *+3.*0333 *+360,333 **365+333


 
















 








 


 











 










 






































































*(

0  3-)/

0 ! 3-)/

*(



 /+'-

 !/+'-



*+(3**6333

 

**630,1333

(.0/,1*///






-7''&  &' " '/3 Source of population  




 

33-+((./33
033 3 State and County Intercensal Population Estimates : 1990 to 2000. Source: Population Division, U.S. Census Bureau, Washington, DC 20233 (http://www.hawaii.gov/dbedt/).


    3  3
3 3 3! 373*66(33+(((&3733 3 $3&&3
3 $3# $3
33+(+,,3


////" /4 /!/ / !// /!
4 / ///)&&&/// $/ Source of population 
2%%$ $ $%

$/  



 July 1 county population estimates by age, sex, race, and 
/ /+)&&,-// .//
 / Hispanic origin; postcensal estimates based on 2000 United States Census. The population data include the bridged singlerace estimates derived from the original multiplerace categories in the 2000 United States Census. http://www.seer.cancer.gov/popdata.


   /(//

/!/"/#/ #/ #//
/ 3/
/!/"//)&&&/// $//

Multiple primary rules used IACR rules (2004) on CI5 IX period.

Multiple primary rules used IACR rules (2004) on CI5 IX period.

415

The Tables Age-standardized and cumulative incidence rates (three-digit rubrics)

359

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Lip (C00)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 17 21 12 0 1 12 29 10 23 356 2 14 6 3 2 6 1423 167 122 195 60 137 1 80 521 9 131 263 3 259 12 128 1219 16 7 84 1073 196 0 1 0 0 10 174 221 4 2 1 0 0 36 171 133 43 0 41 2 1 1 504 2 497 171 5 165 19 0 19 140 309 2 294 241 263 231 171 4 166 1 17 Male ASR(W) CUM 0-74 0.9 0.4 1.2 0.1 1.5 1.5 1.4 1.5 1.7 0.2 0.4 0.1 0.1 0.2 0.8 1.7 1.8 0.8 4.4 2.2 7.0 1.8 2.3 1.3 1.6 2.9 1.8 0.1 2.2 0.8 0.7 1.2 0.1 0.1 0.5 1.6 0.9 0.0 0.4 1.3 0.8 0.2 0.2 0.1 0.6 1.3 1.0 0.3 0.4 0.2 0.1 0.2 0.8 0.0 0.9 0.8 0.1 0.9 0.2 0.3 3.2 0.7 0.0 0.8 1.2 2.2 1.7 1.3 0.1 1.7 0.1 0.9 0.23 0.10 0.36 0.13 0.45 0.29 0.46 0.32 0.09 0.17 0.11 0.03 0.08 0.15 0.32 0.05 0.14 0.07 0.34 0.29 0.62 1.77 0.27 0.06 0.57 0.28 0.11 0.07 0.14 0.23 0.06 0.03 0.04 0.05 0.06 0.05 0.07 0.03 0.14 0.10 0.06 0.08 0.16 0.08 0.10 0.11 0.09 0.06 0.06 0.11 0.13 0.24 0.04 0.02 0.04 0.06 0.04 0.07 0.06 0.08 0.28 0.04 0.03 0.05 0.08 0.15 0.12 0.10 0.07 0.13 0.13 0.22 0.15 0.16 0.17 0.15 0.18 0.02 0.04 0.01 0.01 0.02 0.15 0.19 0.20 0.10 0.49 0.27 0.81 0.44 0.24 0.14 0.19 0.34 0.22 0.02 0.26 0.09 0.07 0.14 0.02 0.01 0.05 0.19 0.10 0.06 0.14 0.09 0.02 0.03 0.07 0.15 0.11 0.04 0.04 0.02 0.02 0.04 0.08 0.00 0.09 0.08 0.01 0.10 0.02 0.03 0.37 0.08 0.01 0.09 0.15 0.25 0.19 0.17 0.02 0.21 0.02 0.11 0.05 0.04 0.07 0.04 0.01 0.02 0.01 0.00 0.01 0.02 0.07 0.01 0.02 0.01 0.05 0.04 0.09 0.44 0.03 0.01 0.08 0.04 0.02 0.01 0.02 0.04 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.04 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.04 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.02 0.02 0.03 Cases 1 6 2 2 1 1 13 1 12 117 0 5 4 0 2 3 410 42 39 50 7 27 0 26 187 4 28 56 3 51 3 33 385 2 6 27 329 73 0 1 0 0 4 64 76 6 0 0 0 0 12 56 38 17 0 15 1 0 1 200 1 196 45 5 40 6 2 4 25 85 3 75 52 54 51 32 3 29 1 5 Female ASR(W) CUM 0-74 0.0 0.1 0.2 0.2 0.1 0.1 0.5 0.2 0.7 0.4 0.1 0.1 0.1 0.3 0.4 0.4 0.2 0.9 0.2 1.0 0.6 0.3 0.7 0.5 0.3 0.1 0.3 0.1 0.1 0.3 0.0 0.1 0.1 0.4 0.3 0.1 0.1 0.4 0.2 0.2 0.1 0.3 0.2 0.1 0.1 0.0 0.1 0.2 0.0 0.3 0.1 0.1 0.2 0.1 0.1 0.0 0.5 0.2 0.1 0.2 0.2 0.3 0.3 0.2 0.1 0.2 0.0 0.1 0.05 0.04 0.14 0.16 0.15 0.11 0.15 0.19 0.20 0.04 0.06 0.03 0.10 0.16 0.02 0.07 0.03 0.15 0.08 0.21 0.12 0.03 0.40 0.11 0.04 0.05 0.05 0.08 0.02 0.02 0.01 0.04 0.03 0.02 0.03 0.06 0.07 0.05 0.02 0.08 0.04 0.04 0.04 0.03 0.03 0.02 0.09 0.02 0.01 0.02 0.02 0.03 0.03 0.03 0.07 0.03 0.11 0.02 0.03 0.02 0.03 0.06 0.04 0.03 0.04 0.04 0.04 0.04 0.01 0.05 0.03 0.07 0.05 0.02 0.01 0.01 0.05 0.04 0.06 0.02 0.10 0.02 0.10 0.08 0.03 0.10 0.05 0.04 0.01 0.04 0.01 0.01 0.03 0.00 0.01 0.01 0.04 0.03 0.01 0.01 0.04 0.02 0.02 0.02 0.03 0.02 0.01 0.01 0.02 0.03 0.02 0.01 0.02 0.01 0.01 0.01 0.05 0.02 0.01 0.02 0.02 0.04 0.03 0.02 0.00 0.02 0.01 * * * *

0.01 0.02 0.03 0.03 0.01 0.01 0.00 0.01 0.04 * 0.00 0.01 0.01 0.02 0.01 0.03 0.02 0.00 0.06 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.01 0.01

418

*Important. See note on population page.

360

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Lip (C00) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 77 149 292 5 270 95 4 88 271 0 268 74 7085 63 6786 140 2 135 177 5 23 149 284 9 274 166 2 155 296 206 258 2 251 28 945 5 909 2559 20 21 119 2325 135 2 131 724 7 705 76 22 200 105 61 172 3 4 27 2 2 22 3 7 21 49 8 82 16 39 12 260 245 14 3 4 1 8 7 13 7 Male ASR(W) CUM 0-74 1.5 0.7 0.9 0.1 0.9 0.7 0.1 0.8 1.4 1.5 2.1 0.9 0.1 1.0 0.5 0.1 0.5 3.0 1.6 1.1 4.2 0.4 0.1 0.5 0.4 0.1 0.4 2.4 1.6 0.5 0.1 0.6 0.6 1.1 0.1 1.2 1.1 0.1 0.1 0.5 1.3 1.0 0.1 1.3 1.2 0.2 1.3 1.4 1.0 1.0 0.8 0.8 0.9 0.6 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.2 0.2 0.9 0.4 0.5 0.6 0.4 1.6 1.6 0.9 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.18 0.06 0.05 0.06 0.06 0.08 0.07 0.09 0.09 0.09 0.25 0.01 0.01 0.01 0.04 0.05 0.05 0.23 0.75 0.24 0.37 0.03 0.04 0.03 0.03 0.04 0.04 0.15 0.12 0.03 0.05 0.04 0.13 0.04 0.03 0.04 0.02 0.03 0.02 0.05 0.03 0.09 0.05 0.11 0.05 0.06 0.05 0.17 0.22 0.07 0.08 0.11 0.07 0.34 0.03 0.03 0.10 0.07 0.02 0.05 0.11 0.05 0.04 0.32 0.04 0.12 0.10 0.13 0.10 0.11 0.25 0.04 0.05 0.03 0.02 0.03 0.01 0.05 0.20 0.08 0.11 0.01 0.11 0.08 0.01 0.10 0.16 0.18 0.22 0.11 0.01 0.12 0.04 0.01 0.05 0.36 0.24 0.11 0.52 0.04 0.01 0.05 0.05 0.01 0.05 0.29 0.18 0.06 0.01 0.07 0.05 0.12 0.01 0.14 0.12 0.01 0.01 0.06 0.16 0.12 0.00 0.15 0.14 0.02 0.16 0.18 0.12 0.12 0.09 0.09 0.11 0.05 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.04 0.02 0.08 0.04 0.06 0.07 0.04 0.18 0.19 0.12 0.01 0.02 0.00 0.01 0.01 0.00 0.01 0.03 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.00 0.00 0.00 0.01 0.01 0.01 0.03 0.12 0.03 0.05 0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.02 0.01 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.02 0.01 0.01 0.01 0.02 0.03 0.01 0.01 0.02 0.01 0.04 0.00 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.04 0.01 0.02 0.01 0.01 0.01 0.01 0.04 0.01 0.01 0.00 0.00 0.01 0.00 0.00 Cases 33 63 113 7 102 42 5 37 54 0 54 13 2112 40 1974 68 3 64 36 0 5 31 137 4 130 73 0 71 49 52 101 1 98 16 270 10 251 754 8 23 35 663 27 1 25 158 2 149 12 4 69 41 13 60 0 1 14 0 3 14 3 2 19 23 1 41 9 22 7 99 94 5 0 2 1 7 5 13 3 Female ASR(W) CUM 0-74 0.5 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.1 0.2 0.5 0.2 0.7 0.1 0.0 0.2 0.1 0.1 0.3 0.3 0.1 0.0 0.1 0.3 0.2 0.1 0.3 0.2 0.0 0.1 0.1 0.3 0.1 0.0 0.2 0.2 0.0 0.2 0.2 0.1 0.3 0.2 0.1 0.2 0.0 0.1 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.4 0.3 0.5 0.5 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.09 0.03 0.03 0.06 0.03 0.04 0.07 0.04 0.03 0.03 0.08 0.00 0.01 0.01 0.02 0.05 0.02 0.09 0.09 0.14 0.01 0.02 0.02 0.02 0.02 0.05 0.05 0.02 0.03 0.02 0.08 0.02 0.04 0.02 0.01 0.01 0.02 0.02 0.01 0.03 0.03 0.03 0.02 0.02 0.02 0.06 0.07 0.04 0.04 0.04 0.04 0.02 0.02 0.08 0.01 0.03 0.06 0.05 0.03 0.10 0.03 0.08 0.08 0.10 0.05 0.06 0.13 0.02 0.02 0.01 0.01 0.01 0.01 0.06 0.02 0.03 0.02 0.03 0.02 0.02 0.02 0.02 0.03 0.03 0.02 0.00 0.02 0.02 0.01 0.02 0.05 0.01 0.08 0.01 0.00 0.02 0.01 0.02 0.03 0.04 0.01 0.00 0.02 0.02 0.02 0.01 0.03 0.02 0.00 0.01 0.01 0.03 0.01 0.00 0.01 0.02 0.00 0.02 0.02 0.02 0.03 0.02 0.01 0.03 0.00 0.01 0.01 0.01 0.01 0.01 0.03 0.02 0.01 0.03 0.03 0.04 0.04 0.05 0.05 0.03 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.01 0.00 * 0.00 - * 0.01 0.00 * 0.01 * 0.01 * 0.01 0.00 * 0.01 0.00 0.01 * 0.01 * 0.01 * 0.01 0.01 0.02 0.00 0.00 0.00 0.00 -

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
361

419

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Lip (C00) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
362

Male ASR(W) CUM 0-74 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.0 0.2 0.1 0.5 0.9 0.2 0.3 0.2 2.9 1.3 0.7 1.0 1.1 4.0 0.4 0.8 3.0 2.3 0.8 1.4 1.3 2.0 0.3 1.0 1.4 0.6 1.3 2.7 0.5 1.0 1.3 0.8 0.3 0.2 0.9 0.5 0.0 0.7 1.1 1.0 0.7 0.4 2.7 1.2 0.8 0.2 0.4 0.1 1.0 1.6 0.6 2.6 0.4 0.1 0.7 1.9 0.8 0.6 0.9 1.2 1.7 0.01 0.03 0.05 0.05 0.11 0.02 0.14 0.02 0.10 0.04 0.19 0.19 0.08 0.11 0.08 0.32 0.13 0.05 0.20 0.31 0.12 0.08 0.06 0.10 0.12 0.05 0.08 0.17 0.10 0.09 0.21 0.20 0.12 0.18 0.40 0.16 0.24 0.23 0.09 0.04 0.05 0.13 0.07 0.02 0.12 0.36 0.09 0.29 0.12 0.39 0.14 0.23 0.10 0.09 0.05 0.26 0.13 0.16 0.50 0.13 0.05 0.15 0.31 0.27 0.12 0.14 0.25 0.15 0.01 0.01 0.00 0.02 0.01 0.02 0.04 0.00 0.01 0.00 0.09 0.11 0.03 0.03 0.02 0.37 0.16 0.09 0.11 0.12 0.51 0.04 0.08 0.37 0.27 0.09 0.16 0.18 0.23 0.05 0.12 0.17 0.07 0.16 0.30 0.07 0.10 0.15 0.10 0.03 0.03 0.12 0.05 0.01 0.08 0.13 0.12 0.05 0.04 0.38 0.15 0.08 0.04 0.00 0.14 0.19 0.07 0.27 0.06 0.02 0.09 0.21 0.09 0.08 0.11 0.14 0.21 0.00 0.01 0.00 0.01 0.01 0.00 0.03 0.00 0.01 0.00 0.04 0.03 0.01 0.01 0.01 0.05 0.02 0.01 0.03 0.04 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.03 0.02 0.02 0.03 0.03 0.02 0.03 0.05 0.03 0.03 0.03 0.01 0.01 0.01 0.02 0.01 0.00 0.02 0.05 0.01 0.03 0.02 0.06 0.02 0.02 0.01 0.00 0.04 0.02 0.03 0.06 0.02 0.01 0.02 0.05 0.03 0.02 0.02 0.03 0.02

Cases 49 3 1 0 1 3 0 10 0 2 0 1 3 1 7 3 1 0 0 1 17 13 15 16 12 85 8 2 374 6 49 282 156 131 105 36 228 10 11 0 0 14 5 24 16 4 5 7 9 22 5 19 19 6 6 4 13 0 5 12 8 4 0 7 1 1 53 6 3 1 1 4 5 0 1 6 15 3 40

Female ASR(W) CUM 0-74 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.1 0.1 0.4 0.0 0.0 0.1 0.4 0.6 0.4 0.6 0.2 0.2 0.2 0.1 0.6 0.0 0.2 0.5 0.6 0.2 0.4 0.4 0.6 0.2 0.3 0.2 0.1 0.3 0.4 0.1 0.2 0.2 0.1 0.1 0.0 0.2 0.1 0.0 0.1 0.2 0.1 0.1 0.3 0.1 0.1 0.1 0.0 0.1 0.3 0.3 0.1 0.1 0.0 0.1 0.2 0.0 0.1 0.1 0.1 0.3 0.01 0.02 0.02 0.02 0.03 0.01 0.16 0.05 0.05 0.08 0.16 0.02 0.01 0.15 0.10 0.16 0.11 0.14 0.04 0.02 0.07 0.07 0.03 0.02 0.03 0.03 0.05 0.02 0.04 0.07 0.05 0.06 0.10 0.06 0.03 0.07 0.11 0.06 0.13 0.07 0.03 0.01 0.02 0.04 0.03 0.02 0.03 0.12 0.03 0.04 0.12 0.03 0.04 0.04 0.02 0.07 0.07 0.13 0.05 0.07 0.01 0.05 0.08 0.03 0.04 0.04 0.04 0.05 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.01 0.04 0.00 0.04 0.05 0.03 0.05 0.01 0.02 0.03 0.02 0.07 0.00 0.02 0.07 0.06 0.02 0.05 0.05 0.06 0.03 0.03 0.02 0.01 0.03 0.03 0.01 0.02 0.01 0.01 0.00 0.00 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.01 0.01 0.01 0.03 0.03 0.01 0.02 0.03 0.00 0.01 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 * 0.02 * 0.00 * 0.01 * 0.02 * 0.01 0.02 * 0.01 * 0.00 0.01 0.02 0.00 * 0.00 * 0.00 0.01 * 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.02 0.00 0.01 0.02 0.00 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.00 0.01 0.01 0.01

91 3 4 0 0 5 1 25 0 3 3 3 2 8 25 0 0 0 0 0 10 6 5 84 97 224 23 12 1190 23 164 1013 386 297 318 60 418 9 24 0 0 57 28 58 56 12 21 35 79 54 13 61 43 6 33 11 118 6 12 56 77 17 3 24 3 16 171 14 30 11 8 24 40 10 0 27 52 26 132

420

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Lip (C00) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 111 277 38 255 24 202 48 204 196 112 455 335 97 109 68 194 219 102 92 307 291 133 74 99 508 12 25 0 28 2 2 17 743 64 22 110 24 29 210 88 127 79 53 65 74 238 884 29 862 475 158 878 325 16 1 144 16 1 0 1 0 12 Male ASR(W) CUM 0-74 1.4 2.5 2.8 1.4 1.0 4.6 0.7 1.9 1.7 0.8 2.4 2.1 1.4 8.8 1.2 2.6 4.7 9.0 3.8 9.8 7.4 5.2 3.3 2.6 1.1 0.8 2.4 1.5 0.2 0.2 0.6 1.3 1.7 0.6 0.9 0.2 0.2 0.7 0.9 0.4 0.2 0.3 0.3 1.3 1.1 4.0 5.5 7.4 8.8 9.5 5.4 5.4 1.6 0.3 1.1 0.4 0.1 0.3 0.9 0.14 0.15 0.47 0.09 0.20 0.34 0.10 0.14 0.13 0.07 0.12 0.12 0.14 0.92 0.15 0.19 0.33 1.04 0.42 0.59 0.45 0.48 0.42 0.28 0.06 0.24 0.52 0.30 0.12 0.14 0.15 0.05 0.21 0.13 0.09 0.05 0.03 0.05 0.09 0.04 0.02 0.04 0.04 0.15 0.08 0.14 1.08 0.26 0.42 0.79 0.19 0.31 0.42 0.26 0.10 0.10 0.13 0.26 0.28 0.16 0.29 0.36 0.15 0.14 0.55 0.09 0.22 0.19 0.10 0.31 0.26 0.16 1.05 0.12 0.32 0.56 1.11 0.44 1.28 0.90 0.65 0.41 0.33 0.12 0.10 0.21 0.19 0.01 0.04 0.07 0.16 0.21 0.07 0.11 0.03 0.02 0.08 0.10 0.05 0.02 0.03 0.03 0.14 0.13 0.41 0.58 0.78 0.94 1.02 0.59 0.58 0.19 0.03 0.12 0.04 0.03 0.08 0.02 0.02 0.07 0.01 0.03 0.05 0.02 0.02 0.02 0.01 0.02 0.02 0.02 0.12 0.02 0.03 0.05 0.14 0.06 0.08 0.06 0.07 0.06 0.04 0.01 0.03 0.06 0.04 0.01 0.03 0.02 0.01 0.03 0.02 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.02 0.01 0.02 0.15 0.03 0.05 0.10 0.02 0.04 0.06 0.03 0.01 0.01 0.03 0.03 Cases 48 76 5 82 7 42 23 109 50 36 147 106 32 9 23 29 39 18 18 44 27 19 10 8 265 4 4 0 5 0 0 5 237 18 7 34 11 23 114 37 65 59 16 23 16 90 351 9 322 155 55 371 127 6 0 74 9 1 0 0 3 5 Female ASR(W) CUM 0-74 0.3 0.3 0.2 0.4 0.2 0.6 0.2 0.7 0.3 0.1 0.6 0.4 0.3 0.5 0.2 0.2 0.6 0.8 0.5 1.0 0.4 0.4 0.2 0.1 0.5 0.2 0.4 0.1 0.1 0.3 0.4 0.2 0.2 0.1 0.1 0.3 0.3 0.1 0.1 0.1 0.1 0.1 0.3 1.2 2.6 2.3 2.0 2.4 1.7 1.8 0.5 0.4 0.2 0.3 0.1 0.4 0.05 0.04 0.12 0.05 0.06 0.11 0.05 0.07 0.05 0.03 0.05 0.04 0.06 0.20 0.06 0.04 0.11 0.24 0.13 0.17 0.09 0.10 0.09 0.05 0.04 0.12 0.22 0.06 0.06 0.02 0.10 0.10 0.04 0.03 0.03 0.03 0.05 0.02 0.01 0.02 0.02 0.04 0.04 0.07 0.96 0.14 0.19 0.37 0.10 0.17 0.20 0.06 0.06 0.33 0.05 0.21 0.03 0.04 0.02 0.05 0.02 0.07 0.02 0.08 0.03 0.01 0.07 0.05 0.03 0.04 0.02 0.02 0.07 0.06 0.05 0.13 0.05 0.04 0.01 0.01 0.05 0.03 0.05 0.02 0.02 0.03 0.04 0.01 0.02 0.01 0.01 0.03 0.04 0.01 0.01 0.01 0.01 0.02 0.03 0.13 0.39 0.27 0.20 0.26 0.19 0.18 0.03 0.05 0.02 0.03 0.01 0.06 0.01 0.01 0.02 0.01 0.01 * 0.01 0.01 0.01 * 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.03 0.02 0.02 0.01 0.02 0.01 0.01 0.00 0.02 0.03 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.18 0.02 0.02 0.05 0.01 0.02 0.02 0.01 0.01 0.03 0.01 0.03

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
363

421

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Tongue (C01-02)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 3 42 3 8 9 13 100 33 70 1338 3 33 55 10 33 9 1594 183 259 88 47 34 0 74 851 9 49 361 66 291 52 409 2674 146 174 237 2083 538 39 29 9 4 40 394 647 88 10 6 8 7 90 414 273 307 22 280 57 39 17 2010 134 1858 683 136 541 186 42 143 91 1019 166 827 523 235 363 390 82 305 19 81 Male ASR(W) CUM 0-74 0.2 0.9 0.4 0.7 0.6 1.5 4.2 4.7 4.9 6.4 0.4 1.0 0.8 0.3 3.1 1.1 2.1 2.0 1.9 2.3 1.8 1.9 2.4 2.2 1.9 1.5 2.6 2.6 2.7 3.2 2.6 2.8 1.2 3.1 1.5 3.4 2.7 2.9 1.8 0.9 1.3 1.9 3.2 2.6 3.6 0.7 0.8 1.4 1.2 1.4 3.4 2.1 2.7 3.2 2.7 3.7 4.1 3.2 3.5 2.6 3.6 3.1 3.0 3.1 2.6 2.1 2.9 2.3 2.8 4.0 2.7 2.9 2.5 2.9 3.0 2.6 3.2 2.0 4.3 0.10 0.15 0.21 0.30 0.23 0.44 0.45 0.86 0.61 0.18 0.21 0.17 0.11 0.10 0.55 0.37 0.05 0.15 0.12 0.25 0.27 0.32 0.28 0.08 0.63 0.22 0.14 0.33 0.16 0.46 0.13 0.06 0.10 0.24 0.10 0.08 0.12 0.48 0.35 0.31 0.67 0.31 0.17 0.10 0.38 0.25 0.32 0.56 0.47 0.16 0.17 0.13 0.16 0.69 0.17 0.49 0.67 0.79 0.08 0.23 0.09 0.12 0.26 0.14 0.20 0.35 0.25 0.25 0.09 0.31 0.09 0.13 0.17 0.16 0.16 0.29 0.18 0.46 0.50 0.18 0.48 0.52 0.49 0.77 0.04 0.13 0.10 0.03 0.44 0.16 0.25 0.24 0.23 0.27 0.22 0.23 0.29 0.26 0.19 0.19 0.32 0.34 0.32 0.34 0.31 0.34 0.12 0.37 0.19 0.42 0.33 0.34 0.19 0.09 0.13 0.22 0.41 0.31 0.44 0.06 0.07 0.15 0.13 0.18 0.42 0.24 0.34 0.42 0.33 0.47 0.51 0.41 0.42 0.32 0.44 0.36 0.36 0.37 0.31 0.24 0.35 0.27 0.34 0.50 0.32 0.36 0.30 0.36 0.36 0.28 0.38 0.21 0.55 0.06 0.06 0.11 0.07 0.02 0.03 0.03 0.02 0.01 0.08 0.06 0.01 0.02 0.02 0.03 0.04 0.05 0.04 0.01 0.08 0.03 0.02 0.05 0.02 0.06 0.02 0.01 0.01 0.03 0.01 0.01 0.02 0.06 0.04 0.04 0.08 0.04 0.02 0.01 0.05 0.03 0.04 0.07 0.07 0.02 0.02 0.02 0.02 0.10 0.02 0.07 0.09 0.12 0.01 0.03 0.01 0.02 0.04 0.02 0.03 0.04 0.03 0.03 0.01 0.04 0.01 0.02 0.02 0.02 0.02 0.04 0.02 0.06 0.07 Cases 2 24 4 2 5 7 35 5 10 370 1 41 34 21 8 12 894 111 179 46 20 6 0 28 453 8 43 172 28 143 14 188 1328 115 71 145 971 267 15 17 3 0 25 190 365 38 15 13 8 4 56 213 139 138 9 122 23 14 8 931 57 858 321 54 264 94 25 68 49 515 51 444 216 139 145 177 29 147 6 38 Female ASR(W) CUM 0-74 0.1 0.5 0.4 0.2 0.5 0.7 1.4 0.7 0.6 1.3 0.1 0.9 0.4 0.6 0.5 1.1 1.0 1.1 1.1 1.0 0.7 0.3 0.7 1.0 1.7 1.1 0.9 0.7 1.0 0.9 1.0 1.1 0.8 1.0 0.7 1.3 1.1 1.0 0.8 0.2 0.9 1.3 1.1 1.2 1.2 1.2 1.2 0.6 0.7 1.4 1.0 0.9 0.9 0.9 1.1 1.0 1.2 1.3 0.8 1.3 1.1 0.9 1.2 1.1 1.0 1.1 1.1 1.1 0.9 1.1 0.9 1.1 0.9 1.0 0.7 1.2 0.5 1.5 0.08 0.10 0.22 0.13 0.25 0.29 0.25 0.31 0.19 0.07 0.11 0.15 0.07 0.15 0.18 0.32 0.04 0.11 0.09 0.17 0.16 0.14 0.14 0.05 0.60 0.18 0.08 0.14 0.09 0.26 0.08 0.03 0.08 0.13 0.06 0.05 0.07 0.25 0.21 0.14 0.19 0.10 0.06 0.19 0.31 0.34 0.47 0.29 0.10 0.11 0.09 0.09 0.32 0.09 0.24 0.29 0.46 0.05 0.11 0.05 0.07 0.13 0.08 0.12 0.22 0.15 0.17 0.05 0.13 0.06 0.07 0.11 0.08 0.08 0.13 0.11 0.20 0.28 0.10 0.17 0.08 0.09 0.15 0.01 0.12 0.05 0.09 0.05 0.16 0.11 0.13 0.13 0.12 0.09 0.04 0.09 0.11 0.18 0.15 0.11 0.08 0.12 0.10 0.12 0.13 0.09 0.13 0.08 0.15 0.13 0.14 0.09 0.04 0.12 0.15 0.13 0.15 0.12 0.15 0.12 0.05 0.07 0.16 0.12 0.10 0.09 0.09 0.14 0.12 0.18 0.15 0.10 0.15 0.13 0.12 0.13 0.13 0.13 0.13 0.14 0.13 0.12 0.13 0.10 0.12 0.11 0.13 0.09 0.15 0.08 0.18 * * * *

0.04 0.04 0.04 0.03 0.01 0.01 0.02 0.01 0.03 0.02 0.06 * 0.00 0.02 0.01 0.02 0.02 0.02 0.02 0.01 0.07 0.03 0.01 0.02 0.01 0.04 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.04 0.03 0.02 0.03 0.01 0.01 0.03 0.04 0.05 0.05 0.03 0.01 0.01 0.01 0.01 0.04 0.01 0.03 0.04 0.08 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.03 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.03 0.04

422

*Important. See note on population page.

364

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Tongue (C01-02) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 122 622 914 133 768 410 112 293 484 46 434 81 19700 1871 17237 841 110 692 98 1 25 71 1589 202 1341 937 82 813 303 347 1221 89 1096 103 2208 216 1856 6133 260 573 351 4885 414 111 301 1521 127 1364 120 46 531 368 180 454 8 79 361 8 11 146 62 21 473 1250 52 1048 222 207 165 132 118 10 59 33 74 142 120 560 88 Male ASR(W) CUM 0-74 2.7 3.1 3.0 4.0 2.9 3.4 4.6 3.1 2.8 3.3 2.7 2.7 2.9 3.1 2.9 3.2 4.0 3.1 1.7 0.3 1.4 2.1 2.7 3.0 2.8 2.6 2.6 2.5 2.8 3.1 3.0 3.0 2.9 3.0 2.8 3.2 2.8 2.8 1.4 3.2 1.6 3.1 3.4 4.1 3.2 2.7 2.5 2.7 2.2 2.3 2.9 3.0 2.8 2.7 1.4 1.4 1.7 0.6 0.5 0.6 1.9 1.0 5.1 6.1 5.8 4.6 5.5 3.2 6.0 0.8 0.8 0.6 1.5 1.0 1.8 1.5 1.9 1.6 1.5 0.25 0.13 0.10 0.36 0.11 0.17 0.45 0.19 0.13 0.50 0.13 0.31 0.02 0.07 0.02 0.11 0.39 0.12 0.18 0.25 0.28 0.25 0.07 0.22 0.08 0.09 0.29 0.09 0.16 0.17 0.09 0.32 0.09 0.31 0.06 0.22 0.07 0.04 0.09 0.14 0.09 0.05 0.17 0.39 0.19 0.07 0.23 0.08 0.21 0.34 0.13 0.16 0.21 0.13 0.51 0.16 0.09 0.20 0.14 0.05 0.25 0.22 0.24 0.18 0.82 0.15 0.38 0.23 0.47 0.08 0.08 0.19 0.20 0.18 0.22 0.13 0.18 0.07 0.18 0.35 0.37 0.36 0.49 0.34 0.41 0.57 0.38 0.33 0.42 0.32 0.31 0.35 0.38 0.35 0.38 0.49 0.37 0.22 0.02 0.15 0.27 0.33 0.36 0.34 0.31 0.30 0.30 0.33 0.36 0.36 0.38 0.35 0.38 0.34 0.39 0.35 0.34 0.15 0.39 0.20 0.38 0.41 0.49 0.38 0.33 0.32 0.33 0.27 0.28 0.36 0.37 0.34 0.32 0.10 0.15 0.20 0.03 0.05 0.08 0.22 0.11 0.61 0.73 0.60 0.55 0.67 0.38 0.71 0.10 0.10 0.07 0.17 0.10 0.20 0.17 0.22 0.18 0.16 0.04 0.02 0.01 0.05 0.01 0.02 0.06 0.03 0.02 0.07 0.02 0.04 0.00 0.01 0.00 0.01 0.05 0.02 0.02 0.02 0.04 0.04 0.01 0.03 0.01 0.01 0.04 0.01 0.02 0.02 0.01 0.04 0.01 0.04 0.01 0.03 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.05 0.02 0.01 0.03 0.01 0.03 0.05 0.02 0.02 0.03 0.02 0.05 0.02 0.01 0.02 0.02 0.01 0.03 0.03 0.03 0.03 0.10 0.02 0.05 0.03 0.06 0.01 0.01 0.03 0.03 0.02 0.03 0.02 0.02 0.01 0.02 Cases 60 337 428 39 378 180 33 145 235 10 222 38 9410 699 8311 387 41 328 57 2 11 41 808 93 690 434 25 392 123 183 584 44 519 55 1125 88 927 2976 205 228 201 2301 185 34 150 693 48 629 63 30 259 185 90 239 7 67 221 4 4 141 23 17 144 317 22 399 68 126 81 109 100 4 28 33 42 96 76 288 51 Female ASR(W) CUM 0-74 1.0 1.3 1.1 0.9 1.1 1.2 1.0 1.2 1.0 0.6 1.1 1.0 1.1 0.9 1.1 1.1 1.1 1.1 0.9 0.5 0.5 1.0 1.0 1.0 1.0 0.9 0.6 1.0 0.9 1.3 1.1 1.1 1.0 1.3 1.1 1.0 1.1 1.1 0.9 1.0 0.8 1.2 1.2 0.9 1.3 1.0 0.7 1.0 1.0 1.3 1.2 1.2 1.2 1.2 1.1 1.1 1.0 0.2 0.2 0.5 0.6 0.7 1.6 1.8 2.4 1.9 1.7 2.0 2.6 0.5 0.5 0.2 0.7 0.7 1.0 0.8 0.9 0.7 0.7 0.15 0.08 0.06 0.14 0.06 0.09 0.18 0.11 0.07 0.18 0.08 0.19 0.01 0.03 0.01 0.06 0.17 0.07 0.12 0.38 0.16 0.17 0.04 0.10 0.04 0.05 0.12 0.05 0.09 0.11 0.05 0.17 0.05 0.20 0.04 0.11 0.04 0.02 0.07 0.07 0.06 0.03 0.09 0.16 0.11 0.04 0.11 0.04 0.14 0.25 0.08 0.10 0.14 0.08 0.43 0.14 0.07 0.12 0.08 0.05 0.13 0.17 0.14 0.11 0.51 0.10 0.21 0.18 0.30 0.05 0.05 0.11 0.13 0.15 0.16 0.09 0.13 0.04 0.12 0.12 0.16 0.13 0.10 0.13 0.13 0.11 0.13 0.12 0.06 0.12 0.13 0.13 0.10 0.13 0.12 0.12 0.12 0.10 0.07 0.04 0.12 0.12 0.12 0.12 0.11 0.07 0.11 0.10 0.16 0.12 0.13 0.12 0.16 0.13 0.11 0.13 0.13 0.10 0.12 0.08 0.14 0.13 0.10 0.14 0.12 0.08 0.12 0.12 0.19 0.13 0.14 0.14 0.14 0.10 0.14 0.12 0.03 0.01 0.06 0.07 0.08 0.19 0.22 0.29 0.24 0.20 0.22 0.32 0.05 0.05 0.02 0.08 0.09 0.10 0.09 0.09 0.07 0.08 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.03 0.00 0.00 0.00 0.01 0.02 0.01 0.02 0.05 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.01 0.03 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.04 0.01 0.01 0.02 0.01 0.04 0.02 * 0.01 0.02 * 0.01 0.01 * 0.02 * 0.02 * 0.02 0.02 * 0.07 0.01 0.03 * 0.02 * 0.04 * 0.01 0.01 0.01 0.02 0.02 0.02 0.01 0.01 0.01 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
365

423

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Tongue (C01-02) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
366

Male ASR(W) CUM 0-74 1.0 1.0 1.1 1.0 0.7 0.8 1.0 1.0 1.5 0.6 0.8 1.4 1.1 0.9 5.3 1.8 1.7 1.7 1.7 1.4 2.1 0.9 4.4 0.7 0.8 2.4 2.3 2.1 2.4 2.1 2.5 1.9 3.7 2.5 1.8 2.8 1.5 5.0 5.9 3.5 4.9 4.5 3.1 5.9 5.2 7.0 3.8 4.1 2.5 2.3 2.1 2.9 3.3 1.9 3.4 0.9 1.6 3.2 2.7 1.8 1.4 2.3 1.2 2.3 1.4 1.3 3.3 2.6 0.6 1.1 1.4 1.4 3.4 1.1 3.4 2.2 1.9 2.5 3.2 0.03 0.12 0.15 0.22 0.17 0.14 0.37 0.07 0.40 0.25 0.31 0.28 0.18 0.24 0.46 0.18 0.14 0.16 0.52 0.39 0.24 0.20 0.41 0.16 0.10 0.09 0.33 0.45 0.09 0.19 0.12 0.08 0.16 0.09 0.10 0.26 0.09 0.39 0.55 0.47 0.45 0.39 0.30 0.41 0.57 0.64 0.58 0.46 0.16 0.12 0.18 0.21 0.20 0.14 0.29 0.32 0.12 0.63 0.35 0.37 0.17 0.33 0.58 0.24 0.24 0.29 0.20 0.40 0.25 0.25 0.19 0.23 0.46 0.34 0.71 0.25 0.23 0.37 0.23 0.12 0.10 0.14 0.12 0.10 0.09 0.14 0.12 0.16 0.07 0.13 0.18 0.13 0.10 0.64 0.24 0.19 0.20 0.17 0.13 0.24 0.13 0.51 0.07 0.11 0.28 0.26 0.24 0.30 0.24 0.29 0.22 0.44 0.28 0.23 0.34 0.18 0.63 0.69 0.43 0.56 0.52 0.36 0.68 0.61 0.84 0.41 0.47 0.29 0.27 0.25 0.34 0.38 0.23 0.39 0.09 0.19 0.40 0.30 0.19 0.16 0.26 0.12 0.28 0.16 0.17 0.41 0.32 0.06 0.15 0.16 0.15 0.42 0.09 0.47 0.24 0.26 0.30 0.37 0.01 0.01 0.02 0.03 0.03 0.02 0.06 0.01 0.05 0.03 0.07 0.04 0.03 0.03 0.07 0.03 0.02 0.02 0.06 0.04 0.03 0.03 0.06 0.02 0.02 0.01 0.04 0.05 0.01 0.02 0.02 0.01 0.02 0.01 0.01 0.03 0.01 0.05 0.07 0.06 0.06 0.05 0.04 0.05 0.07 0.08 0.06 0.06 0.02 0.01 0.02 0.03 0.02 0.02 0.04 0.04 0.02 0.08 0.04 0.04 0.02 0.04 0.05 0.03 0.03 0.04 0.03 0.05 0.03 0.03 0.02 0.03 0.06 0.03 0.11 0.03 0.03 0.05 0.03

Cases 418 48 29 11 16 23 1 123 3 10 6 17 33 6 128 90 70 56 9 5 37 19 22 17 42 233 9 16 96 40 141 91 101 173 173 42 191 34 28 21 40 38 23 44 20 25 12 18 58 120 67 50 116 76 54 7 76 13 22 13 52 28 5 61 22 8 101 19 6 13 32 11 17 8 8 37 38 17 68

Female ASR(W) CUM 0-74 0.4 0.4 0.4 0.3 0.5 0.4 0.1 0.5 0.1 0.9 0.3 0.8 0.9 0.4 6.6 1.1 0.7 0.7 1.4 0.4 0.9 0.8 0.7 0.5 0.5 0.6 0.3 1.3 0.2 0.6 0.7 0.2 0.5 0.4 0.7 0.6 0.8 0.9 0.9 1.1 1.4 1.0 0.6 1.0 0.8 1.1 0.6 0.8 0.5 0.5 0.8 0.7 1.1 0.6 1.0 0.6 0.6 0.9 0.8 0.6 0.8 0.7 0.3 0.9 0.6 0.4 0.9 0.8 0.5 0.5 0.6 0.3 0.8 0.5 0.9 0.7 0.9 0.6 0.8 0.02 0.07 0.08 0.10 0.12 0.08 0.11 0.04 0.08 0.29 0.17 0.19 0.16 0.15 0.63 0.12 0.09 0.09 0.50 0.17 0.15 0.18 0.15 0.13 0.08 0.05 0.10 0.34 0.02 0.10 0.06 0.03 0.05 0.03 0.06 0.10 0.06 0.16 0.19 0.24 0.24 0.18 0.13 0.16 0.21 0.23 0.20 0.20 0.07 0.05 0.11 0.10 0.11 0.08 0.15 0.25 0.07 0.33 0.18 0.21 0.13 0.19 0.17 0.13 0.13 0.14 0.10 0.23 0.22 0.16 0.12 0.11 0.20 0.20 0.35 0.12 0.17 0.16 0.12 0.04 0.05 0.05 0.05 0.05 0.04 0.01 0.05 0.01 0.10 0.03 0.11 0.10 0.04 0.80 0.14 0.07 0.07 0.15 0.03 0.10 0.09 0.10 0.08 0.06 0.07 0.03 0.14 0.03 0.06 0.07 0.03 0.06 0.04 0.08 0.06 0.09 0.10 0.08 0.14 0.16 0.11 0.06 0.10 0.11 0.12 0.07 0.08 0.05 0.06 0.09 0.07 0.13 0.07 0.11 0.06 0.07 0.09 0.09 0.06 0.09 0.08 0.05 0.10 0.08 0.02 0.11 0.10 0.04 0.05 0.07 0.03 0.09 0.06 0.12 0.07 0.11 0.08 0.09 0.00 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.04 0.02 0.03 0.02 0.02 * 0.09 * 0.02 * 0.01 0.01 0.06 0.01 0.02 * 0.03 * 0.02 0.02 * 0.01 * 0.01 0.01 0.04 0.00 * 0.01 * 0.01 0.00 * 0.01 0.00 0.01 0.01 0.01 0.02 0.02 0.03 0.03 0.02 0.02 0.02 0.03 0.03 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.03 0.01 0.04 0.02 0.02 0.02 0.02 0.03 0.02 0.02 0.01 0.01 0.03 0.02 0.02 0.02 0.01 0.03 0.03 0.05 0.01 0.02 0.02 0.01

919 83 66 27 20 41 8 233 20 5 19 25 42 16 151 122 140 114 11 15 81 21 118 20 63 640 50 23 692 129 433 554 576 874 358 118 279 165 124 58 118 142 110 215 91 128 51 83 240 391 133 184 280 179 137 8 188 27 64 28 71 57 8 106 36 21 279 45 6 22 63 39 57 12 24 86 79 48 202

424

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Tongue (C01-02) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 162 255 15 240 46 41 83 263 334 395 288 745 216 30 159 243 189 13 55 77 106 44 57 84 398 40 17 19 46 25 29 71 878 42 61 162 146 300 461 140 455 781 277 282 90 467 525 28 321 97 45 325 137 17 10 172 120 8 5 12 38 53 Male ASR(W) CUM 0-74 2.2 2.6 1.2 1.5 2.0 1.0 1.5 2.7 3.4 2.8 1.8 4.9 3.2 2.9 3.8 3.9 4.3 1.5 2.7 2.8 2.9 2.2 3.3 2.7 1.1 2.8 2.2 3.4 2.6 2.0 3.1 3.4 1.6 1.2 1.8 1.6 1.7 2.0 2.0 1.5 1.8 1.7 1.5 1.5 1.7 2.6 2.4 6.1 2.7 1.9 2.9 2.1 2.3 1.8 2.2 1.4 2.9 2.2 0.7 2.4 3.0 4.7 0.17 0.17 0.32 0.10 0.29 0.16 0.16 0.17 0.19 0.14 0.11 0.18 0.22 0.56 0.31 0.25 0.32 0.47 0.38 0.33 0.29 0.35 0.45 0.31 0.06 0.45 0.53 0.78 0.39 0.42 0.59 0.42 0.05 0.18 0.24 0.13 0.14 0.12 0.09 0.13 0.09 0.06 0.10 0.09 0.18 0.12 0.11 1.21 0.16 0.20 0.44 0.12 0.20 0.45 0.71 0.11 0.27 0.87 0.32 0.70 0.56 0.66 0.27 0.30 0.15 0.18 0.25 0.12 0.16 0.31 0.40 0.34 0.21 0.55 0.39 0.37 0.46 0.48 0.53 0.19 0.32 0.33 0.37 0.27 0.39 0.33 0.13 0.35 0.27 0.43 0.31 0.25 0.39 0.41 0.19 0.12 0.20 0.17 0.18 0.24 0.23 0.17 0.21 0.19 0.17 0.18 0.20 0.31 0.29 0.70 0.33 0.24 0.37 0.25 0.25 0.22 0.27 0.16 0.34 0.24 0.05 0.25 0.39 0.56 0.02 0.02 0.04 0.01 0.04 0.02 0.02 0.02 0.02 0.02 0.01 0.02 0.03 0.07 0.04 0.03 0.04 0.06 0.05 0.04 0.04 0.04 0.06 0.04 0.01 0.06 0.07 0.10 0.05 0.06 0.08 0.05 0.01 0.02 0.03 0.02 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.15 0.02 0.03 0.06 0.02 0.02 0.06 0.09 0.01 0.04 0.11 0.03 0.08 0.08 0.09 Cases 40 52 8 142 14 12 39 76 97 118 94 82 43 7 38 75 44 0 18 30 45 15 15 19 295 25 7 15 16 6 7 31 660 39 30 100 88 150 229 102 301 492 181 183 42 253 277 5 150 59 14 179 52 8 4 100 73 5 7 11 24 23 Female ASR(W) CUM 0-74 0.3 0.3 0.5 0.7 0.4 0.2 0.5 0.6 0.7 0.5 0.5 0.4 0.5 0.5 0.7 1.0 0.8 0.8 0.9 1.0 0.7 0.6 0.5 0.7 1.4 0.8 2.2 0.8 0.4 0.6 1.2 1.0 1.1 0.9 0.8 0.8 0.9 0.8 0.9 0.9 0.8 0.9 0.8 0.6 1.1 1.1 1.6 1.2 0.9 0.8 1.0 0.7 0.7 0.8 0.7 1.4 1.2 1.0 2.2 1.2 2.0 0.05 0.05 0.18 0.07 0.10 0.07 0.08 0.07 0.08 0.05 0.06 0.05 0.08 0.22 0.13 0.13 0.13 0.20 0.17 0.16 0.18 0.17 0.11 0.05 0.31 0.31 0.60 0.20 0.18 0.25 0.23 0.04 0.18 0.17 0.09 0.09 0.08 0.06 0.10 0.06 0.04 0.07 0.07 0.11 0.08 0.07 0.79 0.10 0.12 0.22 0.08 0.11 0.27 0.40 0.08 0.18 0.56 0.37 0.67 0.32 0.44 0.04 0.04 0.05 0.08 0.04 0.03 0.06 0.06 0.07 0.06 0.06 0.05 0.06 0.07 0.08 0.12 0.09 0.10 0.09 0.12 0.08 0.05 0.06 0.08 0.19 0.10 0.23 0.08 0.03 0.06 0.13 0.12 0.12 0.11 0.09 0.09 0.09 0.08 0.11 0.10 0.10 0.10 0.09 0.08 0.13 0.13 0.23 0.13 0.10 0.09 0.11 0.09 0.07 0.02 0.08 0.17 0.11 0.09 0.27 0.13 0.28 0.01 0.01 0.02 0.01 0.01 * 0.01 0.01 0.01 * 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.02 0.02 0.03 0.02 0.02 0.02 0.02 0.02 0.01 0.04 0.04 0.07 0.03 0.02 0.03 0.03 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.14 0.01 0.02 0.03 0.01 0.02 0.03 0.01 0.01 0.02 0.07 0.04 0.09 0.04 0.07

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
367

425

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Mouth (C03-06)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 7 57 9 16 8 16 117 35 58 1414 2 29 78 11 39 12 1458 163 245 64 40 29 1 63 799 13 41 362 74 283 27 292 1758 99 153 184 1294 352 30 15 7 1 31 249 467 82 6 1 4 5 70 286 193 261 20 236 65 53 11 1553 141 1388 565 148 413 156 49 104 69 908 146 731 419 249 363 446 136 309 32 59 Male ASR(W) CUM 0-74 0.3 1.3 1.0 1.6 0.4 2.2 5.5 4.9 3.8 6.7 0.2 0.8 1.1 0.4 3.7 1.3 1.9 1.8 1.7 1.6 1.5 1.6 1.0 1.9 2.1 2.6 1.1 2.5 2.8 2.4 1.7 1.8 1.8 0.9 2.6 1.1 2.0 1.7 2.2 0.9 0.8 0.6 1.2 2.0 1.9 3.3 0.5 0.2 0.8 1.0 1.2 2.3 1.5 2.3 3.0 2.2 3.9 5.2 2.1 2.6 2.7 2.6 2.6 3.3 2.4 2.3 2.8 2.2 1.8 2.5 3.4 2.3 2.2 2.6 2.8 3.4 4.3 3.1 3.4 2.9 0.11 0.18 0.33 0.46 0.17 0.55 0.54 0.89 0.52 0.19 0.17 0.16 0.13 0.12 0.61 0.39 0.05 0.15 0.11 0.21 0.25 0.30 0.98 0.25 0.07 0.75 0.18 0.14 0.34 0.15 0.34 0.11 0.04 0.09 0.21 0.09 0.06 0.10 0.41 0.23 0.32 0.58 0.23 0.13 0.09 0.37 0.23 0.18 0.40 0.45 0.15 0.15 0.11 0.15 0.68 0.15 0.50 0.73 0.65 0.07 0.23 0.08 0.11 0.28 0.12 0.19 0.43 0.22 0.22 0.08 0.29 0.09 0.11 0.17 0.15 0.16 0.38 0.18 0.61 0.40 0.27 0.66 0.62 0.44 0.78 0.04 0.11 0.13 0.03 0.48 0.13 0.23 0.23 0.21 0.20 0.18 0.18 0.12 0.23 0.25 0.25 0.14 0.30 0.34 0.29 0.25 0.21 0.22 0.11 0.29 0.13 0.26 0.21 0.24 0.10 0.09 0.07 0.10 0.25 0.24 0.38 0.10 0.03 0.11 0.10 0.17 0.29 0.17 0.28 0.31 0.28 0.46 0.60 0.26 0.31 0.33 0.31 0.32 0.42 0.30 0.30 0.37 0.29 0.24 0.31 0.43 0.29 0.27 0.30 0.35 0.42 0.53 0.39 0.39 0.36 0.07 0.08 0.13 0.07 0.03 0.03 0.03 0.02 0.02 0.08 0.06 0.01 0.02 0.02 0.03 0.03 0.04 0.12 0.04 0.01 0.09 0.03 0.02 0.04 0.02 0.06 0.01 0.01 0.01 0.03 0.01 0.01 0.01 0.06 0.03 0.04 0.07 0.02 0.02 0.01 0.05 0.04 0.03 0.06 0.06 0.02 0.02 0.02 0.02 0.08 0.02 0.07 0.09 0.09 0.01 0.03 0.01 0.02 0.04 0.02 0.03 0.07 0.03 0.03 0.01 0.04 0.01 0.02 0.02 0.02 0.02 0.05 0.03 0.08 0.06 Cases 2 55 1 14 7 13 45 13 23 559 0 49 39 10 9 8 1000 113 198 65 25 11 2 48 486 8 44 248 34 211 14 178 1394 97 92 127 1036 273 29 10 8 5 10 187 332 37 9 11 4 1 54 206 151 205 14 188 29 22 7 1076 91 971 378 87 288 110 35 73 53 597 75 503 276 171 218 212 50 160 16 33 Female ASR(W) CUM 0-74 0.1 1.0 0.1 1.0 0.4 1.1 1.8 1.9 1.2 1.9 1.1 0.5 0.3 0.7 0.7 1.0 1.1 1.1 1.3 0.8 0.6 2.0 1.2 1.0 1.3 0.9 1.1 0.8 1.2 1.0 0.9 1.1 0.7 1.3 0.6 1.2 1.1 1.9 0.4 0.6 1.3 0.4 1.2 1.0 1.1 0.6 1.0 0.6 0.2 0.6 1.2 1.0 1.2 1.5 1.2 1.3 1.5 1.0 1.3 1.3 1.3 1.2 1.4 1.2 1.2 1.3 1.2 1.0 1.2 1.2 1.2 1.1 1.2 1.3 1.2 1.1 1.2 1.2 1.2 0.05 0.14 0.12 0.32 0.20 0.33 0.28 0.55 0.26 0.09 0.16 0.08 0.10 0.24 0.25 0.04 0.11 0.09 0.18 0.18 0.17 1.50 0.19 0.05 0.52 0.16 0.08 0.15 0.09 0.27 0.07 0.03 0.07 0.14 0.06 0.04 0.07 0.36 0.14 0.23 0.63 0.13 0.10 0.06 0.19 0.22 0.31 0.36 0.15 0.09 0.10 0.09 0.10 0.40 0.10 0.26 0.35 0.42 0.05 0.14 0.05 0.07 0.15 0.08 0.13 0.24 0.15 0.15 0.05 0.15 0.06 0.07 0.11 0.09 0.09 0.16 0.10 0.32 0.24 0.12 0.23 0.25 0.11 0.20 0.12 0.04 0.04 0.07 0.08 0.12 0.13 0.14 0.17 0.09 0.08 0.22 0.13 0.12 0.16 0.09 0.13 0.11 0.13 0.16 0.10 0.13 0.07 0.14 0.07 0.15 0.13 0.20 0.05 0.10 0.12 0.07 0.14 0.11 0.12 0.09 0.09 0.08 0.02 0.07 0.14 0.11 0.15 0.17 0.15 0.16 0.18 0.14 0.15 0.14 0.16 0.14 0.17 0.13 0.15 0.17 0.14 0.10 0.14 0.14 0.14 0.13 0.13 0.15 0.13 0.11 0.14 0.14 0.15 * * * *

0.04 0.05 0.09 0.03 0.01 0.02 0.01 0.02 0.03 0.04 * 0.01 0.02 0.01 0.03 0.02 0.03 0.17 0.02 0.01 0.07 0.02 0.01 0.02 0.01 0.05 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.04 0.02 0.04 0.07 0.02 0.01 0.01 0.02 0.04 0.04 0.05 0.02 0.01 0.01 0.01 0.01 0.06 0.02 0.04 0.05 0.07 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.04 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.04 0.03

426

*Important. See note on population page.

368

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Mouth (C03-06) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 136 523 773 133 614 370 119 247 375 46 324 51 15646 1967 13136 548 80 447 85 2 16 65 1288 218 1024 738 103 618 196 212 984 112 838 74 1762 233 1429 4669 180 606 265 3560 361 134 221 1226 136 1061 70 44 389 261 169 436 7 89 334 8 11 176 44 17 548 821 60 1460 224 449 247 161 140 18 33 39 81 137 131 510 72 Male ASR(W) CUM 0-74 3.0 2.6 2.5 4.1 2.2 3.1 5.0 2.6 2.1 3.2 2.0 1.6 2.2 3.2 2.1 2.1 2.9 2.0 1.5 0.6 1.0 1.9 2.2 3.2 2.1 2.0 3.4 1.8 1.7 1.9 2.3 3.8 2.1 2.1 2.2 3.5 2.1 2.1 1.0 3.3 1.2 2.2 2.9 4.9 2.2 2.1 2.6 2.1 1.3 2.1 2.1 2.1 2.6 2.5 1.3 1.7 1.6 0.6 0.4 0.8 1.3 0.8 6.0 3.9 7.1 6.1 5.5 6.7 9.2 1.0 1.0 1.2 0.8 0.9 1.9 1.3 1.9 1.4 1.2 0.27 0.12 0.09 0.36 0.09 0.16 0.47 0.17 0.11 0.49 0.11 0.23 0.02 0.07 0.02 0.09 0.33 0.10 0.17 0.43 0.24 0.25 0.06 0.22 0.07 0.08 0.34 0.08 0.13 0.14 0.08 0.37 0.08 0.26 0.05 0.24 0.06 0.03 0.08 0.14 0.08 0.04 0.15 0.44 0.15 0.06 0.23 0.07 0.16 0.33 0.11 0.13 0.21 0.12 0.49 0.18 0.09 0.21 0.13 0.06 0.21 0.20 0.26 0.15 0.92 0.17 0.38 0.33 0.59 0.08 0.09 0.29 0.15 0.15 0.22 0.11 0.18 0.06 0.16 0.37 0.31 0.30 0.48 0.28 0.37 0.58 0.32 0.26 0.36 0.25 0.18 0.27 0.39 0.26 0.25 0.33 0.24 0.18 0.05 0.13 0.22 0.25 0.36 0.25 0.25 0.43 0.23 0.22 0.26 0.28 0.45 0.26 0.28 0.26 0.41 0.26 0.26 0.12 0.40 0.15 0.27 0.33 0.61 0.25 0.27 0.33 0.26 0.16 0.27 0.26 0.24 0.32 0.29 0.18 0.17 0.19 0.07 0.06 0.09 0.16 0.09 0.73 0.46 0.86 0.72 0.63 0.82 1.15 0.12 0.12 0.15 0.10 0.12 0.24 0.17 0.25 0.17 0.13 0.04 0.02 0.01 0.05 0.01 0.02 0.06 0.02 0.02 0.06 0.02 0.03 0.00 0.01 0.00 0.01 0.04 0.01 0.02 0.05 0.04 0.03 0.01 0.03 0.01 0.01 0.05 0.01 0.02 0.02 0.01 0.05 0.01 0.04 0.01 0.03 0.01 0.00 0.01 0.02 0.01 0.01 0.02 0.06 0.02 0.01 0.03 0.01 0.02 0.05 0.02 0.02 0.03 0.02 0.08 0.02 0.01 0.03 0.02 0.01 0.03 0.03 0.04 0.02 0.13 0.02 0.05 0.05 0.09 0.01 0.01 0.04 0.02 0.02 0.03 0.02 0.02 0.01 0.02 Cases 77 335 558 46 484 240 38 198 272 16 254 33 10804 1005 9372 421 46 358 69 0 12 56 929 115 788 507 54 436 164 179 640 66 563 44 1309 118 1114 3368 144 304 178 2681 215 53 159 771 76 672 62 20 317 210 106 305 3 48 165 2 9 176 12 9 441 323 50 735 130 315 124 127 116 4 41 20 29 91 75 341 39 Female ASR(W) CUM 0-74 1.3 1.2 1.4 1.0 1.3 1.4 1.1 1.5 1.1 0.8 1.1 0.8 1.1 1.2 1.1 1.1 1.1 1.1 0.9 0.6 1.2 1.1 1.1 1.1 1.0 1.3 1.0 1.0 1.1 1.1 1.5 1.0 0.9 1.2 1.3 1.2 1.1 0.6 1.2 0.7 1.2 1.3 1.4 1.2 1.1 1.1 1.1 0.9 0.7 1.3 1.2 1.2 1.3 0.5 0.8 0.7 0.1 0.4 0.6 0.4 0.3 5.2 1.8 5.4 3.7 3.4 5.0 4.1 0.6 0.6 0.2 0.9 0.3 0.5 0.6 0.8 0.7 0.4 0.16 0.07 0.06 0.16 0.07 0.10 0.19 0.12 0.07 0.21 0.08 0.15 0.01 0.04 0.01 0.06 0.17 0.07 0.12 0.18 0.18 0.04 0.11 0.04 0.05 0.18 0.05 0.08 0.10 0.05 0.20 0.05 0.16 0.04 0.13 0.04 0.02 0.05 0.07 0.05 0.03 0.09 0.20 0.11 0.04 0.13 0.04 0.13 0.17 0.08 0.10 0.13 0.08 0.28 0.11 0.06 0.06 0.12 0.05 0.11 0.11 0.25 0.10 0.77 0.14 0.30 0.29 0.37 0.06 0.06 0.12 0.15 0.09 0.10 0.07 0.10 0.04 0.08 0.15 0.15 0.15 0.11 0.15 0.16 0.13 0.17 0.13 0.10 0.13 0.08 0.13 0.14 0.13 0.12 0.12 0.12 0.10 0.07 0.13 0.13 0.13 0.13 0.12 0.16 0.11 0.10 0.14 0.12 0.17 0.12 0.11 0.14 0.15 0.14 0.13 0.07 0.13 0.08 0.14 0.14 0.17 0.13 0.13 0.13 0.13 0.11 0.10 0.14 0.13 0.13 0.16 0.10 0.09 0.08 0.04 0.07 0.05 0.03 0.68 0.22 0.69 0.44 0.41 0.60 0.52 0.07 0.07 0.03 0.12 0.03 0.04 0.06 0.09 0.08 0.04 0.02 0.01 0.01 0.02 0.01 0.01 0.03 0.02 0.01 0.03 0.01 0.02 0.00 0.01 0.00 0.01 0.02 0.01 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.03 0.01 0.01 0.01 0.01 0.03 0.01 0.02 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.03 0.01 0.01 0.02 0.01 0.02 0.03 0.01 0.01 0.02 0.01 0.07 0.02 * 0.01 - * 0.02 0.01 * 0.01 * 0.01 * 0.04 0.02 * 0.11 0.02 0.04 * 0.04 * 0.06 * 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
369

427

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Mouth (C03-06) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
370

Male ASR(W) CUM 0-74 1.5 1.3 1.4 1.2 1.6 1.4 2.5 1.4 1.3 1.0 0.7 1.7 1.0 0.9 15.3 1.8 1.5 1.5 2.8 0.5 2.0 1.3 4.6 0.6 0.8 2.7 3.6 2.4 3.7 2.6 3.5 2.0 3.3 2.5 3.1 3.1 1.3 6.8 6.9 6.0 5.0 4.6 4.5 7.4 7.5 7.9 3.3 5.4 2.8 3.0 3.4 4.4 3.3 2.9 5.7 1.6 1.9 3.1 2.6 2.4 1.8 2.2 1.0 1.7 1.6 1.4 4.1 2.8 1.5 1.8 1.5 1.1 1.8 1.0 3.6 2.7 1.5 2.8 4.5 0.04 0.15 0.18 0.24 0.27 0.19 0.65 0.09 0.40 0.33 0.28 0.30 0.17 0.24 0.78 0.18 0.14 0.16 0.63 0.24 0.23 0.25 0.42 0.15 0.10 0.10 0.41 0.48 0.12 0.21 0.15 0.08 0.15 0.09 0.13 0.27 0.09 0.46 0.59 0.61 0.45 0.39 0.36 0.45 0.70 0.68 0.51 0.54 0.17 0.14 0.24 0.26 0.20 0.18 0.39 0.44 0.13 0.64 0.34 0.40 0.20 0.31 0.38 0.20 0.26 0.30 0.22 0.43 0.39 0.31 0.19 0.19 0.33 0.29 0.74 0.28 0.21 0.39 0.27 0.18 0.16 0.17 0.15 0.20 0.17 0.34 0.17 0.11 0.08 0.11 0.27 0.14 0.10 1.73 0.22 0.18 0.19 0.26 0.08 0.21 0.10 0.53 0.06 0.10 0.31 0.40 0.29 0.45 0.31 0.40 0.23 0.40 0.28 0.36 0.39 0.15 0.81 0.84 0.75 0.60 0.52 0.51 0.82 0.85 0.90 0.36 0.59 0.31 0.34 0.40 0.50 0.37 0.35 0.65 0.23 0.23 0.34 0.31 0.33 0.22 0.26 0.11 0.21 0.19 0.15 0.50 0.33 0.18 0.24 0.18 0.13 0.21 0.11 0.48 0.33 0.19 0.31 0.55 0.01 0.02 0.03 0.03 0.04 0.03 0.10 0.01 0.04 0.03 0.06 0.05 0.03 0.03 0.11 0.03 0.02 0.02 0.07 0.04 0.03 0.03 0.06 0.02 0.01 0.01 0.05 0.06 0.01 0.03 0.02 0.01 0.02 0.01 0.02 0.04 0.01 0.06 0.08 0.08 0.06 0.05 0.04 0.06 0.08 0.08 0.06 0.06 0.02 0.02 0.03 0.03 0.02 0.02 0.05 0.07 0.02 0.08 0.04 0.05 0.03 0.04 0.05 0.03 0.03 0.04 0.03 0.05 0.05 0.04 0.02 0.02 0.04 0.04 0.10 0.04 0.03 0.05 0.04

Cases 634 54 31 17 26 21 5 151 10 4 7 25 48 9 249 129 64 45 13 6 67 43 47 12 55 252 26 13 131 65 194 124 129 249 362 40 204 51 39 29 38 59 55 53 16 30 25 13 81 154 109 54 120 110 64 17 108 4 32 19 61 39 1 56 19 15 151 21 8 28 37 17 16 5 11 67 32 21 108

Female ASR(W) CUM 0-74 0.5 0.5 0.4 0.5 0.6 0.3 0.4 0.6 0.6 0.4 0.8 1.2 1.4 0.5 12.3 1.7 0.7 0.6 2.8 0.6 1.6 1.7 1.5 0.4 0.7 0.7 1.1 1.1 0.3 0.8 0.9 0.3 0.7 0.6 1.4 0.5 0.8 1.3 1.6 1.3 1.4 1.4 1.3 0.9 0.6 1.4 1.3 0.5 0.7 0.6 1.3 0.7 1.1 0.9 1.3 1.2 0.7 0.2 1.1 0.9 0.9 1.0 0.2 0.7 0.7 0.8 1.4 0.8 0.6 0.9 0.5 0.4 0.8 0.3 1.4 1.2 0.5 0.7 1.1 0.02 0.07 0.08 0.11 0.13 0.07 0.17 0.05 0.20 0.19 0.42 0.24 0.20 0.18 0.83 0.15 0.09 0.09 0.81 0.26 0.20 0.27 0.22 0.11 0.09 0.05 0.24 0.30 0.03 0.11 0.07 0.04 0.06 0.04 0.08 0.09 0.06 0.20 0.27 0.27 0.24 0.20 0.20 0.15 0.18 0.28 0.32 0.19 0.09 0.06 0.14 0.10 0.11 0.10 0.17 0.33 0.08 0.13 0.23 0.23 0.14 0.19 0.17 0.11 0.21 0.22 0.13 0.21 0.21 0.20 0.09 0.11 0.24 0.17 0.47 0.18 0.11 0.18 0.13 0.05 0.06 0.05 0.05 0.05 0.03 0.03 0.06 0.07 0.06 0.07 0.17 0.18 0.06 1.42 0.21 0.07 0.05 0.31 0.05 0.18 0.16 0.19 0.05 0.09 0.08 0.11 0.12 0.03 0.10 0.11 0.03 0.07 0.06 0.17 0.06 0.08 0.15 0.18 0.12 0.16 0.15 0.13 0.09 0.04 0.15 0.13 0.06 0.08 0.07 0.15 0.08 0.13 0.11 0.16 0.11 0.08 0.05 0.13 0.12 0.10 0.11 0.02 0.07 0.07 0.08 0.16 0.09 0.07 0.10 0.04 0.04 0.07 0.03 0.18 0.13 0.07 0.09 0.13 0.00 0.01 0.01 0.01 0.02 0.01 0.02 0.01 0.03 0.04 0.05 0.04 0.03 0.02 * 0.11 * 0.02 * 0.01 0.01 0.10 0.03 0.03 * 0.03 * 0.03 0.02 * 0.01 * 0.01 0.02 0.04 0.00 * 0.02 * 0.01 0.00 * 0.01 0.00 0.01 0.01 0.01 0.02 0.03 0.03 0.03 0.02 0.02 0.02 0.02 0.03 0.03 0.02 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.05 0.01 0.03 0.03 0.03 0.02 0.02 0.02 0.01 0.02 0.03 0.02 0.03 0.03 0.03 0.01 0.01 0.02 0.02 0.06 0.02 0.02 0.02 0.02

1264 98 74 29 38 66 17 274 14 10 21 35 34 16 440 125 119 93 21 5 79 29 124 17 64 727 78 26 1050 158 597 578 513 849 604 132 256 224 143 100 123 148 165 279 120 143 48 107 272 508 215 285 289 276 230 14 214 25 62 41 98 58 7 75 43 21 355 46 16 40 70 35 31 14 24 108 56 53 283

428

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Mouth (C03-06) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 188 297 18 241 42 76 110 256 297 506 281 761 300 27 109 335 216 16 60 76 152 53 71 78 486 70 17 22 33 30 39 113 1265 79 81 151 214 378 504 121 403 774 326 290 100 625 470 14 276 101 44 333 137 20 11 186 82 5 8 8 21 33 Male ASR(W) CUM 0-74 2.5 3.0 1.4 1.5 1.8 1.9 2.0 2.7 3.1 3.7 1.7 4.9 4.4 2.6 2.6 5.5 5.0 2.0 2.8 2.8 4.3 2.5 3.9 2.4 1.3 4.9 2.0 3.7 1.9 2.6 4.2 5.3 2.3 2.2 2.4 1.4 2.4 2.6 2.1 1.2 1.4 1.6 1.8 1.5 1.9 3.4 2.1 3.0 2.4 1.8 2.7 2.1 2.3 2.1 2.5 1.5 1.8 1.5 1.2 1.7 1.2 2.7 0.19 0.18 0.34 0.10 0.27 0.22 0.19 0.17 0.18 0.16 0.11 0.18 0.26 0.53 0.26 0.31 0.34 0.56 0.38 0.34 0.36 0.36 0.50 0.29 0.06 0.59 0.50 0.81 0.33 0.49 0.67 0.51 0.07 0.25 0.27 0.12 0.17 0.14 0.10 0.12 0.08 0.06 0.10 0.09 0.19 0.14 0.10 0.86 0.15 0.18 0.41 0.12 0.20 0.49 0.76 0.11 0.21 0.78 0.47 0.61 0.31 0.50 0.32 0.35 0.14 0.18 0.21 0.25 0.23 0.31 0.35 0.45 0.20 0.57 0.51 0.29 0.31 0.64 0.63 0.21 0.32 0.35 0.54 0.29 0.46 0.27 0.15 0.59 0.22 0.46 0.26 0.27 0.47 0.63 0.28 0.27 0.28 0.15 0.29 0.30 0.25 0.14 0.17 0.18 0.21 0.17 0.22 0.42 0.26 0.36 0.29 0.21 0.36 0.28 0.28 0.23 0.37 0.19 0.20 0.09 0.16 0.22 0.12 0.30 0.02 0.02 0.04 0.01 0.04 0.03 0.02 0.02 0.02 0.02 0.01 0.02 0.03 0.06 0.03 0.04 0.05 0.06 0.05 0.04 0.05 0.05 0.06 0.03 0.01 0.08 0.06 0.10 0.05 0.06 0.08 0.06 0.01 0.03 0.03 0.01 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.03 0.02 0.01 0.11 0.02 0.03 0.06 0.02 0.03 0.06 0.13 0.02 0.03 0.05 0.07 0.09 0.04 0.07 Cases 39 59 21 191 17 18 46 68 76 108 219 106 68 8 50 86 38 5 21 24 46 25 10 32 395 32 17 14 20 20 10 46 923 46 36 115 123 234 305 104 314 555 212 244 82 362 308 6 158 69 28 233 65 12 5 142 45 1 9 3 9 20 Female ASR(W) CUM 0-74 0.3 0.4 1.1 0.8 0.5 0.3 0.6 0.5 0.5 0.5 1.4 0.5 0.8 0.7 0.9 1.0 0.8 0.4 0.7 0.7 1.0 0.9 0.4 0.7 0.8 1.7 1.5 2.1 1.0 1.3 0.9 1.6 1.4 1.1 1.0 0.9 1.1 1.3 1.0 0.9 0.9 0.8 0.9 1.0 1.1 1.5 1.1 2.3 1.2 1.0 1.3 1.2 0.9 1.2 1.1 0.9 0.9 0.3 1.2 0.5 0.5 1.7 0.06 0.05 0.26 0.07 0.13 0.09 0.09 0.07 0.06 0.05 0.10 0.05 0.11 0.29 0.16 0.12 0.13 0.24 0.18 0.16 0.16 0.21 0.14 0.15 0.05 0.33 0.42 0.62 0.23 0.33 0.31 0.26 0.05 0.17 0.19 0.09 0.11 0.09 0.06 0.09 0.06 0.04 0.07 0.07 0.13 0.09 0.07 0.97 0.10 0.14 0.28 0.09 0.12 0.36 0.50 0.08 0.15 0.33 0.42 0.29 0.19 0.41 0.03 0.04 0.13 0.10 0.05 0.05 0.07 0.05 0.06 0.05 0.13 0.06 0.10 0.06 0.10 0.11 0.08 0.05 0.08 0.07 0.11 0.10 0.05 0.08 0.09 0.22 0.18 0.21 0.12 0.15 0.11 0.20 0.16 0.12 0.12 0.10 0.12 0.15 0.11 0.10 0.10 0.09 0.11 0.12 0.12 0.18 0.13 0.34 0.14 0.11 0.14 0.13 0.11 0.17 0.15 0.11 0.11 0.03 0.14 0.04 0.06 0.22 0.01 0.01 0.04 0.01 0.01 * 0.01 0.01 0.01 * 0.01 0.01 0.01 0.01 0.01 0.03 0.02 0.02 0.02 0.03 0.02 0.02 0.02 0.03 0.02 0.02 0.01 0.05 0.05 0.07 0.03 0.04 0.04 0.03 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.15 0.01 0.02 0.03 0.01 0.02 0.06 0.08 0.01 0.02 0.03 0.06 0.03 0.03 0.06

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
371

429

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Salivary glands (C07-08)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 5 33 8 12 16 8 28 6 14 231 5 31 39 8 10 2 722 48 96 35 28 17 0 22 436 3 37 142 19 120 13 160 998 64 41 89 789 216 15 13 8 2 13 159 244 11 3 7 3 4 38 171 116 126 6 118 19 9 9 806 42 755 209 37 169 72 24 46 38 407 35 358 185 113 132 157 28 128 8 21 Male ASR(W) CUM 0-74 0.3 0.7 0.9 0.6 0.4 0.9 1.1 0.8 0.9 1.1 0.5 0.9 0.5 0.3 1.0 0.2 0.9 0.5 0.6 0.8 1.0 0.9 0.6 1.1 0.6 0.9 0.9 0.7 1.0 0.7 0.9 1.0 0.6 0.7 0.5 1.2 1.0 1.1 0.8 0.9 0.6 0.5 1.2 0.9 0.4 0.4 1.0 0.5 0.7 0.5 1.3 0.9 1.0 0.8 1.0 1.1 0.9 1.4 1.1 0.7 1.2 0.9 0.8 1.0 1.0 1.3 0.9 0.9 1.0 0.8 1.0 0.9 1.0 1.0 1.1 0.8 1.2 0.8 1.0 0.12 0.14 0.32 0.21 0.16 0.34 0.24 0.37 0.26 0.07 0.24 0.16 0.08 0.11 0.31 0.13 0.03 0.07 0.07 0.14 0.19 0.21 0.14 0.05 0.35 0.15 0.08 0.17 0.09 0.20 0.07 0.03 0.07 0.11 0.06 0.05 0.07 0.28 0.23 0.32 0.45 0.16 0.10 0.06 0.14 0.20 0.38 0.33 0.33 0.09 0.11 0.08 0.09 0.35 0.10 0.26 0.30 0.50 0.04 0.11 0.05 0.06 0.13 0.08 0.12 0.28 0.14 0.14 0.05 0.13 0.06 0.07 0.10 0.09 0.09 0.16 0.12 0.29 0.22 0.10 0.09 0.09 0.07 0.11 0.04 0.09 0.05 0.03 0.14 0.09 0.05 0.08 0.09 0.07 0.06 0.08 0.11 0.12 0.10 0.10 0.09 0.11 0.08 0.09 0.11 0.07 0.07 0.05 0.13 0.11 0.09 0.10 0.13 0.07 0.04 0.13 0.10 0.05 0.05 0.10 0.07 0.07 0.06 0.15 0.09 0.11 0.07 0.11 0.11 0.10 0.14 0.12 0.07 0.13 0.10 0.09 0.11 0.11 0.16 0.09 0.10 0.11 0.09 0.11 0.10 0.09 0.11 0.12 0.09 0.13 0.12 0.12 0.04 0.02 0.05 0.02 0.01 0.03 0.02 0.01 0.01 0.05 0.00 0.01 0.01 0.02 0.02 0.02 0.02 0.01 0.07 0.02 0.01 0.02 0.01 0.03 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.03 0.03 0.05 0.07 0.01 0.01 0.01 0.02 0.03 0.05 0.05 0.04 0.01 0.01 0.01 0.01 0.05 0.01 0.03 0.04 0.06 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.04 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.05 0.03 Cases 4 27 4 6 20 9 34 5 12 257 7 33 56 8 10 2 552 49 82 21 15 11 1 16 322 8 27 107 21 80 13 110 690 76 44 91 459 169 12 12 9 0 16 101 168 17 6 4 4 3 37 89 98 95 4 89 13 8 4 491 45 437 196 44 148 67 15 48 33 300 29 257 147 86 89 94 28 64 7 11 Female ASR(W) CUM 0-74 0.2 0.6 0.4 0.4 0.7 1.0 1.1 0.7 0.6 0.9 0.7 0.7 0.6 0.2 0.7 0.1 0.6 0.5 0.6 0.5 0.5 0.5 1.3 0.4 0.8 1.3 0.7 0.6 0.6 0.6 0.8 0.6 0.6 0.6 0.6 0.4 0.7 0.7 0.8 0.6 0.8 0.6 0.8 0.5 0.5 0.6 0.4 0.7 0.4 0.4 0.6 0.6 0.7 0.4 0.7 0.5 0.6 0.4 0.7 0.7 0.7 0.7 0.6 0.7 0.8 0.5 0.9 0.7 0.7 0.5 0.7 0.6 0.7 0.6 0.6 0.6 0.5 0.5 0.4 0.09 0.11 0.21 0.23 0.22 0.36 0.20 0.31 0.19 0.06 0.27 0.13 0.09 0.09 0.24 0.10 0.03 0.07 0.07 0.13 0.14 0.15 1.31 0.11 0.05 0.51 0.14 0.06 0.13 0.07 0.24 0.06 0.02 0.07 0.10 0.05 0.04 0.06 0.23 0.19 0.26 0.16 0.09 0.04 0.13 0.27 0.19 0.37 0.26 0.07 0.08 0.07 0.08 0.21 0.09 0.17 0.21 0.22 0.04 0.10 0.04 0.05 0.10 0.07 0.10 0.13 0.14 0.14 0.04 0.10 0.05 0.06 0.09 0.07 0.06 0.12 0.07 0.21 0.12 0.09 0.13 0.07 0.10 0.09 0.08 0.08 0.07 0.03 0.06 0.01 0.06 0.04 0.05 0.05 0.05 0.05 0.16 0.03 0.08 0.12 0.08 0.06 0.06 0.06 0.09 0.07 0.06 0.07 0.07 0.04 0.07 0.08 0.10 0.07 0.09 0.07 0.09 0.05 0.06 0.08 0.04 0.06 0.07 0.03 0.06 0.07 0.08 0.05 0.08 0.06 0.07 0.02 0.07 0.08 0.07 0.07 0.06 0.07 0.08 0.05 0.10 0.07 0.07 0.05 0.07 0.06 0.07 0.06 0.06 0.06 0.06 0.06 0.04 * * * *

0.03 0.03 0.04 0.03 0.01 0.04 0.02 0.01 0.01 0.02 0.01 * 0.00 0.01 0.01 0.01 0.02 0.02 0.16 0.01 0.01 0.05 0.02 0.01 0.01 0.01 0.03 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.03 0.02 0.03 0.02 0.01 0.01 0.02 0.03 0.02 0.04 0.04 0.01 0.01 0.01 0.01 0.03 0.01 0.02 0.03 0.02 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.02

430

*Important. See note on population page.

372

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Salivary glands (C07-08) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 47 201 371 31 332 150 16 132 196 11 183 26 7507 506 6735 313 35 269 53 3 13 37 669 58 589 351 26 313 131 128 475 31 430 28 884 63 761 2345 106 158 130 1925 138 23 112 615 44 558 63 20 178 126 72 167 3 38 146 2 5 143 21 10 48 180 5 129 18 29 8 158 138 12 22 12 35 49 44 120 25 Male ASR(W) CUM 0-74 0.9 0.9 1.1 0.9 1.1 1.1 0.6 1.2 1.0 0.8 1.0 0.7 1.0 0.8 1.0 1.0 1.0 1.1 0.9 0.6 0.7 1.0 1.1 0.9 1.1 0.9 0.8 0.9 1.1 1.0 1.0 1.0 1.0 0.7 1.0 0.9 1.1 1.0 0.6 0.8 0.5 1.1 1.1 0.8 1.1 1.0 0.8 1.0 1.1 0.9 1.0 1.0 0.9 0.9 0.4 0.6 0.7 0.2 0.2 0.6 0.6 0.4 0.5 0.8 0.6 0.5 0.4 0.4 0.3 0.9 0.9 0.6 0.7 0.3 0.9 0.5 0.7 0.3 0.4 0.14 0.07 0.06 0.16 0.06 0.09 0.15 0.11 0.08 0.25 0.08 0.15 0.01 0.04 0.01 0.06 0.18 0.07 0.13 0.36 0.19 0.17 0.04 0.11 0.05 0.05 0.16 0.05 0.10 0.10 0.05 0.18 0.05 0.15 0.04 0.11 0.04 0.02 0.06 0.06 0.05 0.03 0.09 0.17 0.11 0.04 0.12 0.05 0.15 0.21 0.07 0.09 0.12 0.07 0.26 0.11 0.06 0.11 0.09 0.06 0.13 0.12 0.08 0.06 0.26 0.05 0.10 0.08 0.11 0.08 0.08 0.18 0.16 0.09 0.16 0.07 0.11 0.03 0.08 0.10 0.10 0.11 0.09 0.11 0.11 0.05 0.12 0.11 0.09 0.11 0.07 0.11 0.08 0.11 0.11 0.08 0.12 0.10 0.05 0.06 0.13 0.12 0.09 0.12 0.10 0.09 0.09 0.12 0.11 0.12 0.10 0.11 0.08 0.11 0.09 0.11 0.11 0.07 0.08 0.05 0.12 0.12 0.10 0.12 0.11 0.09 0.12 0.13 0.08 0.10 0.11 0.10 0.09 0.01 0.08 0.07 0.02 0.02 0.06 0.07 0.03 0.06 0.10 0.09 0.06 0.06 0.04 0.03 0.10 0.10 0.05 0.06 0.04 0.10 0.05 0.09 0.04 0.04 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.00 0.00 0.00 0.01 0.02 0.01 0.02 0.03 0.02 0.03 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.03 0.01 0.01 0.02 0.01 0.02 0.03 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.01 0.01 0.02 0.02 0.01 0.01 0.04 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.00 0.01 Cases 34 154 271 29 237 126 21 101 125 5 117 22 5454 512 4650 253 28 203 33 3 11 19 523 56 443 288 27 247 78 90 348 27 310 33 707 57 576 1724 136 149 127 1270 86 14 71 436 68 360 54 11 140 95 37 141 2 32 116 5 2 130 10 12 28 107 5 85 11 25 9 119 107 8 15 8 13 34 35 69 19 Female ASR(W) CUM 0-74 0.7 0.6 0.7 0.6 0.8 0.9 0.6 0.9 0.5 0.3 0.6 0.5 0.6 0.6 0.6 0.8 0.7 0.7 0.6 0.6 0.5 0.6 0.7 0.6 0.7 0.6 0.6 0.6 0.5 0.7 0.7 0.6 0.7 0.6 0.7 0.6 0.8 0.7 0.7 0.6 0.4 0.7 0.6 0.4 0.6 0.6 1.0 0.6 0.8 0.4 0.7 0.7 0.4 0.7 0.2 0.5 0.5 0.3 0.1 0.6 0.3 0.6 0.3 0.5 0.5 0.4 0.3 0.4 0.3 0.6 0.5 0.4 0.4 0.2 0.3 0.3 0.5 0.2 0.3 0.13 0.06 0.05 0.12 0.05 0.08 0.14 0.10 0.05 0.13 0.06 0.14 0.01 0.03 0.01 0.05 0.14 0.06 0.10 0.38 0.16 0.16 0.03 0.08 0.04 0.04 0.11 0.04 0.07 0.09 0.04 0.12 0.04 0.12 0.03 0.08 0.04 0.02 0.06 0.05 0.04 0.02 0.07 0.10 0.08 0.03 0.12 0.03 0.12 0.14 0.06 0.07 0.08 0.06 0.13 0.09 0.05 0.14 0.07 0.06 0.09 0.16 0.06 0.05 0.25 0.04 0.08 0.07 0.09 0.06 0.06 0.15 0.11 0.07 0.08 0.06 0.10 0.02 0.08 0.07 0.06 0.07 0.06 0.08 0.09 0.06 0.10 0.06 0.04 0.06 0.05 0.07 0.06 0.07 0.08 0.08 0.08 0.06 0.06 0.06 0.06 0.07 0.06 0.08 0.07 0.05 0.07 0.06 0.08 0.07 0.07 0.07 0.05 0.08 0.07 0.08 0.07 0.07 0.07 0.04 0.07 0.07 0.04 0.07 0.07 0.10 0.06 0.08 0.05 0.07 0.07 0.04 0.08 0.01 0.05 0.05 0.05 0.00 0.06 0.02 0.06 0.03 0.06 0.07 0.04 0.03 0.04 0.03 0.05 0.05 0.03 0.04 0.02 0.04 0.04 0.05 0.01 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.00 0.00 0.00 0.01 0.02 0.01 0.01 0.04 0.02 0.02 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.02 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 * 0.01 0.03 * 0.00 0.01 * 0.01 * 0.02 * 0.01 0.01 * 0.04 0.01 0.01 * 0.01 * 0.01 * 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
373

431

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Salivary glands (C07-08) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
374

Male ASR(W) CUM 0-74 0.6 0.5 0.6 0.3 0.7 0.6 0.7 0.7 0.7 0.5 0.5 1.0 0.3 0.4 1.0 0.8 0.7 0.8 0.6 0.4 0.7 0.4 0.2 0.7 0.5 0.7 0.8 0.5 0.8 0.5 0.9 0.6 1.6 0.8 0.7 0.8 0.7 0.8 0.4 0.7 0.7 0.8 0.6 0.8 0.6 0.7 0.7 0.5 0.6 0.6 0.8 0.7 0.7 0.4 0.7 0.9 0.7 0.3 0.6 0.8 0.8 1.0 0.4 0.9 0.5 0.9 0.8 0.5 0.9 0.6 1.0 0.9 0.6 0.5 1.0 0.9 1.0 0.8 1.0 0.03 0.08 0.10 0.11 0.18 0.12 0.32 0.06 0.22 0.22 0.27 0.23 0.09 0.16 0.18 0.11 0.09 0.11 0.31 0.18 0.13 0.14 0.08 0.16 0.08 0.05 0.19 0.20 0.05 0.09 0.07 0.05 0.10 0.05 0.06 0.14 0.06 0.16 0.14 0.20 0.17 0.16 0.12 0.15 0.19 0.20 0.21 0.14 0.08 0.06 0.12 0.11 0.09 0.07 0.13 0.32 0.08 0.16 0.16 0.23 0.14 0.22 0.22 0.15 0.14 0.25 0.10 0.16 0.26 0.20 0.18 0.18 0.19 0.21 0.34 0.16 0.19 0.25 0.12 0.07 0.06 0.05 0.04 0.07 0.06 0.08 0.08 0.08 0.05 0.09 0.12 0.03 0.04 0.09 0.10 0.08 0.09 0.05 0.04 0.08 0.04 0.01 0.07 0.05 0.08 0.09 0.05 0.09 0.05 0.10 0.08 0.19 0.09 0.08 0.09 0.07 0.08 0.02 0.09 0.08 0.11 0.05 0.07 0.06 0.07 0.07 0.06 0.06 0.06 0.08 0.09 0.07 0.04 0.07 0.09 0.07 0.02 0.06 0.09 0.09 0.10 0.08 0.09 0.04 0.10 0.07 0.06 0.07 0.06 0.10 0.11 0.07 0.07 0.13 0.10 0.12 0.07 0.09 0.00 0.01 0.01 0.01 0.02 0.02 0.05 0.01 0.03 0.03 0.06 0.03 0.01 0.02 0.02 0.02 0.01 0.02 0.03 0.02 0.02 0.02 0.01 0.02 0.01 0.01 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.01 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.04 0.01 0.02 0.02 0.03 0.02 0.02 0.04 0.02 0.01 0.03 0.01 0.02 0.03 0.02 0.02 0.02 0.03 0.03 0.06 0.02 0.02 0.02 0.01

Cases 427 31 27 17 18 26 3 136 11 9 9 19 21 7 25 64 48 44 2 2 22 10 10 15 27 163 13 10 184 24 92 127 115 266 126 44 127 25 10 6 18 24 15 28 6 7 4 8 49 87 43 34 53 47 17 8 63 6 14 10 33 29 3 32 19 10 53 6 6 10 33 16 13 4 6 32 25 20 41

Female ASR(W) CUM 0-74 0.4 0.3 0.4 0.5 0.5 0.4 0.4 0.5 0.6 0.6 0.7 0.7 0.6 0.3 1.1 0.7 0.5 0.6 0.2 0.2 0.5 0.4 0.3 0.5 0.3 0.4 0.4 0.6 0.4 0.3 0.4 0.4 0.6 0.6 0.5 0.7 0.5 0.6 0.4 0.4 0.6 0.7 0.4 0.5 0.2 0.2 0.3 0.3 0.4 0.3 0.5 0.4 0.4 0.4 0.3 1.0 0.4 0.6 0.4 0.5 0.5 0.8 0.2 0.5 0.6 0.6 0.5 0.3 0.3 0.3 0.6 0.5 0.5 0.4 1.1 0.7 0.6 0.9 0.5 0.02 0.05 0.08 0.12 0.11 0.08 0.23 0.04 0.19 0.20 0.37 0.17 0.12 0.13 0.24 0.10 0.08 0.09 0.17 0.16 0.11 0.13 0.10 0.13 0.06 0.04 0.14 0.21 0.04 0.07 0.05 0.03 0.06 0.04 0.06 0.11 0.05 0.13 0.13 0.17 0.17 0.15 0.10 0.12 0.11 0.10 0.15 0.15 0.06 0.05 0.09 0.08 0.07 0.07 0.08 0.37 0.06 0.30 0.13 0.18 0.10 0.26 0.19 0.11 0.17 0.20 0.10 0.13 0.15 0.12 0.13 0.14 0.15 0.19 0.57 0.17 0.15 0.25 0.09 0.04 0.03 0.03 0.04 0.05 0.03 0.03 0.05 0.09 0.07 0.04 0.07 0.07 0.03 0.12 0.08 0.06 0.07 0.02 0.03 0.04 0.05 0.03 0.05 0.04 0.04 0.04 0.09 0.04 0.03 0.05 0.04 0.06 0.06 0.05 0.07 0.05 0.06 0.04 0.03 0.07 0.06 0.03 0.05 0.03 0.02 0.04 0.03 0.04 0.03 0.05 0.04 0.04 0.04 0.03 0.13 0.04 0.07 0.05 0.05 0.05 0.07 0.01 0.06 0.07 0.05 0.05 0.03 0.05 0.05 0.07 0.05 0.05 0.04 0.10 0.08 0.06 0.10 0.05 0.00 0.01 0.01 0.01 0.02 0.01 0.02 0.01 0.03 0.04 0.03 0.02 0.02 0.01 * 0.03 * 0.01 * 0.01 0.01 0.01 0.02 0.01 * 0.02 * 0.01 0.02 * 0.01 * 0.00 0.01 0.04 0.00 * 0.01 * 0.01 0.00 * 0.01 0.00 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.05 0.01 0.03 0.02 0.02 0.01 0.02 0.01 0.01 0.02 0.02 0.01 0.02 0.03 0.02 0.01 0.01 0.02 0.02 0.05 0.02 0.02 0.03 0.01

553 51 36 10 18 29 5 156 10 6 12 21 15 8 35 70 60 52 4 4 26 10 5 21 39 216 17 5 224 34 157 201 253 301 141 35 125 27 8 12 20 30 23 30 10 13 11 12 58 112 49 47 62 42 32 9 87 5 15 14 38 29 4 46 17 14 72 10 13 11 44 31 12 7 8 36 39 14 67

432

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Salivary glands (C07-08) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 53 100 8 117 36 40 45 58 83 109 121 147 26 7 33 43 25 10 13 18 27 15 10 16 246 8 9 5 9 15 7 21 344 21 20 62 55 99 161 66 192 325 123 110 34 102 264 6 153 57 9 118 57 10 4 104 37 1 8 5 8 10 Male ASR(W) CUM 0-74 0.7 1.0 0.6 0.7 1.5 1.0 0.8 0.6 0.8 0.8 0.7 0.9 0.4 0.6 0.7 0.7 0.5 1.1 0.5 0.6 0.6 0.6 0.5 0.4 0.7 0.6 1.2 0.8 0.4 1.2 0.7 0.9 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.7 0.6 0.6 0.6 0.5 0.6 0.5 1.1 1.7 1.2 1.0 0.5 0.7 0.9 1.0 1.1 0.8 0.9 0.4 1.3 0.8 0.5 0.9 0.10 0.10 0.22 0.07 0.25 0.15 0.11 0.08 0.09 0.08 0.07 0.08 0.08 0.23 0.14 0.11 0.11 0.49 0.15 0.16 0.13 0.18 0.16 0.12 0.05 0.23 0.43 0.38 0.15 0.33 0.27 0.20 0.03 0.13 0.14 0.08 0.09 0.07 0.05 0.08 0.05 0.04 0.06 0.05 0.11 0.05 0.07 0.74 0.10 0.14 0.19 0.07 0.12 0.33 0.58 0.09 0.15 0.37 0.48 0.38 0.19 0.29 0.08 0.10 0.06 0.09 0.17 0.11 0.08 0.06 0.09 0.10 0.09 0.11 0.05 0.06 0.08 0.06 0.06 0.07 0.05 0.05 0.07 0.08 0.05 0.05 0.08 0.08 0.12 0.12 0.06 0.13 0.10 0.12 0.07 0.07 0.07 0.05 0.07 0.06 0.07 0.07 0.06 0.07 0.07 0.06 0.08 0.07 0.12 0.11 0.13 0.12 0.06 0.07 0.09 0.09 0.07 0.09 0.10 0.03 0.14 0.08 0.07 0.09 0.01 0.01 0.03 0.01 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.02 0.01 0.01 0.04 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.03 0.05 0.06 0.02 0.04 0.04 0.03 0.00 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.02 0.01 0.01 0.07 0.01 0.02 0.02 0.01 0.02 0.04 0.04 0.01 0.02 0.03 0.06 0.04 0.03 0.04 Cases 45 91 8 107 22 19 40 41 49 100 94 91 36 7 25 31 16 11 9 9 21 12 11 16 229 16 3 1 9 3 6 8 279 16 20 58 41 88 120 49 160 248 110 89 30 103 152 1 79 47 14 100 40 9 4 75 37 1 6 7 11 6 Female ASR(W) CUM 0-74 0.4 0.6 0.4 0.6 0.6 0.4 0.5 0.3 0.4 0.4 0.5 0.4 0.4 0.5 0.5 0.4 0.3 1.1 0.4 0.3 0.5 0.5 0.4 0.3 0.6 0.9 0.5 0.1 0.5 0.3 0.5 0.3 0.5 0.4 0.6 0.5 0.4 0.5 0.5 0.5 0.6 0.4 0.6 0.4 0.5 0.4 0.6 0.2 0.6 0.6 0.8 0.6 0.6 1.1 0.9 0.6 0.9 0.4 0.8 1.3 1.2 0.6 0.07 0.07 0.16 0.07 0.14 0.09 0.08 0.05 0.06 0.05 0.06 0.05 0.08 0.21 0.14 0.08 0.08 0.41 0.15 0.10 0.11 0.16 0.16 0.09 0.05 0.25 0.31 0.10 0.16 0.18 0.24 0.13 0.03 0.11 0.17 0.08 0.07 0.06 0.05 0.07 0.05 0.03 0.06 0.05 0.09 0.05 0.05 0.21 0.07 0.10 0.23 0.06 0.11 0.36 0.45 0.07 0.15 0.36 0.35 0.48 0.44 0.31 0.04 0.06 0.04 0.06 0.07 0.05 0.06 0.03 0.04 0.05 0.06 0.05 0.05 0.07 0.06 0.04 0.03 0.12 0.04 0.02 0.05 0.06 0.04 0.03 0.06 0.08 0.04 0.03 0.05 0.03 0.05 0.03 0.05 0.05 0.05 0.05 0.04 0.05 0.05 0.05 0.06 0.05 0.06 0.04 0.06 0.04 0.06 0.01 0.05 0.06 0.09 0.06 0.06 0.13 0.12 0.06 0.08 0.05 0.09 0.14 0.10 0.04 0.01 0.01 0.02 0.01 0.02 * 0.01 0.01 0.01 * 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.01 0.01 0.04 0.02 0.01 0.01 0.02 0.02 0.01 0.01 0.02 0.02 0.03 0.02 0.02 0.03 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.01 0.05 0.06 0.01 0.02 0.05 0.04 0.06 0.04 0.02

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
375

433

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Tonsil (C09)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 7 8 4 5 3 12 24 10 25 339 0 24 43 8 27 3 927 101 179 47 50 18 1 64 434 5 28 247 47 199 29 232 1663 72 118 170 1279 325 25 10 8 3 28 244 387 57 8 1 5 5 53 251 172 175 21 152 44 35 7 1305 118 1174 447 95 348 129 34 91 55 653 116 524 356 142 286 253 65 187 18 32 Male ASR(W) CUM 0-74 0.4 0.2 0.4 0.4 0.1 1.6 1.0 1.6 1.7 1.6 0.7 0.6 0.3 2.6 0.4 1.2 1.1 1.3 1.3 2.0 1.0 0.8 2.1 1.2 1.2 0.9 1.8 1.8 1.8 1.5 1.5 1.8 0.6 2.1 1.0 2.2 1.7 1.9 0.6 0.9 0.7 1.3 2.1 1.6 2.4 0.7 0.2 1.3 1.0 0.8 2.1 1.3 1.6 3.0 1.5 2.7 3.7 1.1 2.5 2.3 2.5 2.0 2.1 2.0 1.8 1.8 1.8 1.4 1.8 2.7 1.7 2.0 1.6 2.3 2.0 2.0 2.0 2.0 1.8 0.14 0.06 0.21 0.20 0.09 0.47 0.23 0.51 0.35 0.09 0.14 0.10 0.11 0.50 0.23 0.04 0.11 0.10 0.19 0.29 0.23 0.80 0.26 0.06 0.53 0.18 0.12 0.27 0.13 0.30 0.10 0.04 0.08 0.20 0.08 0.06 0.10 0.39 0.19 0.33 0.43 0.26 0.14 0.08 0.32 0.25 0.17 0.58 0.44 0.12 0.14 0.10 0.12 0.66 0.13 0.42 0.63 0.43 0.07 0.21 0.08 0.09 0.22 0.11 0.16 0.34 0.19 0.19 0.07 0.26 0.08 0.11 0.13 0.14 0.13 0.26 0.15 0.48 0.32 0.18 0.12 0.23 0.17 0.20 0.07 0.08 0.03 0.35 0.07 0.15 0.12 0.15 0.16 0.26 0.10 0.07 0.25 0.15 0.14 0.11 0.21 0.21 0.21 0.19 0.17 0.21 0.08 0.27 0.12 0.25 0.21 0.20 0.05 0.12 0.14 0.16 0.26 0.20 0.34 0.09 0.02 0.17 0.15 0.11 0.25 0.15 0.18 0.37 0.17 0.31 0.44 0.09 0.29 0.28 0.29 0.23 0.25 0.23 0.21 0.22 0.21 0.17 0.22 0.34 0.20 0.23 0.19 0.28 0.23 0.25 0.23 0.24 0.20 0.06 0.03 0.09 0.04 0.01 0.02 0.01 0.02 0.07 0.04 0.01 0.01 0.01 0.03 0.04 0.03 0.07 0.03 0.01 0.07 0.02 0.01 0.04 0.02 0.04 0.01 0.01 0.01 0.03 0.01 0.01 0.01 0.05 0.02 0.05 0.10 0.03 0.02 0.01 0.05 0.04 0.02 0.08 0.08 0.02 0.02 0.01 0.02 0.09 0.02 0.05 0.08 0.04 0.01 0.03 0.01 0.01 0.03 0.01 0.02 0.05 0.02 0.03 0.01 0.04 0.01 0.01 0.02 0.02 0.02 0.03 0.02 0.06 0.04 Cases 0 8 1 4 1 2 4 3 3 78 0 12 9 0 3 1 335 30 54 24 14 9 0 17 172 1 14 89 17 71 4 50 462 23 37 33 365 80 3 3 0 0 6 65 113 25 1 1 2 1 14 66 50 60 6 54 8 5 3 422 44 373 143 37 105 35 16 19 20 177 27 148 88 41 69 77 18 59 6 14 Female ASR(W) CUM 0-74 0.2 0.1 0.1 0.0 0.3 0.2 0.3 0.1 0.3 0.3 0.1 0.2 0.1 0.4 0.3 0.3 0.6 0.4 0.5 0.5 0.4 0.2 0.4 0.5 0.5 0.6 0.3 0.3 0.4 0.2 0.5 0.2 0.5 0.3 0.2 0.2 0.2 0.5 0.4 0.8 0.1 0.1 0.5 0.2 0.2 0.5 0.4 0.5 0.7 0.5 0.4 0.4 0.6 0.6 0.7 0.6 0.5 0.6 0.5 0.4 0.6 0.4 0.4 0.4 0.5 0.4 0.4 0.4 0.5 0.5 0.5 0.6 0.5 0.7 0.06 0.11 0.09 0.02 0.19 0.08 0.20 0.06 0.03 0.08 0.05 0.13 0.08 0.02 0.06 0.05 0.12 0.12 0.17 0.13 0.03 0.22 0.11 0.06 0.12 0.07 0.15 0.04 0.02 0.04 0.09 0.03 0.03 0.04 0.11 0.10 0.09 0.06 0.04 0.16 0.12 0.10 0.36 0.15 0.05 0.07 0.06 0.06 0.28 0.07 0.16 0.18 0.35 0.03 0.11 0.04 0.05 0.10 0.05 0.07 0.16 0.09 0.11 0.03 0.09 0.04 0.05 0.06 0.06 0.06 0.11 0.08 0.20 0.20 0.03 0.01 0.03 0.01 0.03 0.04 0.02 0.03 0.05 0.05 0.04 0.08 0.05 0.06 0.07 0.05 0.02 0.04 0.07 0.06 0.07 0.03 0.04 0.05 0.02 0.07 0.02 0.07 0.04 0.04 0.02 0.02 0.06 0.05 0.09 0.01 0.01 0.05 0.01 0.02 0.07 0.05 0.06 0.10 0.06 0.06 0.05 0.09 0.08 0.09 0.08 0.07 0.07 0.06 0.05 0.07 0.04 0.05 0.05 0.05 0.05 0.05 0.04 0.05 0.07 0.06 0.07 0.07 0.08 * * * *

0.02 0.01 0.02 0.00 0.00 0.01 0.01 0.02 - * 0.00 0.01 0.01 0.02 0.02 0.02 0.02 0.00 0.02 0.01 0.01 0.02 0.01 0.02 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.04 0.02 0.01 0.01 0.01 0.01 0.05 0.01 0.02 0.02 0.05 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.03 0.02

434

*Important. See note on population page.

376

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Tonsil (C09) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 104 284 518 90 421 243 79 163 334 29 301 64 11940 1348 10283 376 72 295 79 3 16 59 791 108 669 566 73 480 215 194 687 88 582 39 1337 169 1099 3719 120 430 236 2895 257 67 190 969 101 849 48 36 338 255 120 270 0 15 52 1 5 29 16 3 124 402 10 251 71 47 24 32 30 1 2 2 15 17 18 79 4 Male ASR(W) CUM 0-74 2.5 1.5 1.7 2.7 1.6 2.0 3.2 1.7 2.0 2.2 1.9 2.1 1.8 2.2 1.8 1.5 2.5 1.4 1.5 0.9 0.9 1.9 1.4 1.6 1.4 1.6 2.3 1.5 2.0 1.8 1.7 3.1 1.6 1.2 1.7 2.5 1.7 1.7 0.7 2.4 1.1 1.9 2.1 2.4 2.1 1.7 2.0 1.7 0.9 1.7 1.9 2.0 1.9 1.6 0.3 0.2 0.2 0.2 0.1 0.5 0.1 1.4 1.9 1.2 1.1 1.9 0.8 0.9 0.2 0.2 0.1 0.0 0.1 0.4 0.2 0.3 0.2 0.0 0.25 0.09 0.08 0.29 0.08 0.13 0.37 0.14 0.11 0.41 0.11 0.27 0.02 0.06 0.02 0.08 0.30 0.08 0.17 0.52 0.23 0.25 0.05 0.15 0.06 0.07 0.28 0.07 0.14 0.13 0.07 0.33 0.07 0.20 0.05 0.19 0.05 0.03 0.06 0.12 0.07 0.04 0.13 0.30 0.15 0.06 0.21 0.06 0.14 0.29 0.10 0.13 0.18 0.10 0.08 0.03 0.21 0.09 0.03 0.13 0.08 0.12 0.10 0.38 0.07 0.23 0.12 0.18 0.04 0.04 0.08 0.03 0.05 0.09 0.04 0.08 0.03 0.02 0.29 0.18 0.20 0.34 0.18 0.23 0.40 0.20 0.22 0.29 0.22 0.23 0.21 0.27 0.21 0.17 0.30 0.16 0.18 0.10 0.12 0.22 0.16 0.20 0.17 0.18 0.28 0.17 0.23 0.20 0.20 0.36 0.18 0.14 0.20 0.30 0.20 0.20 0.08 0.29 0.13 0.22 0.24 0.29 0.23 0.20 0.25 0.20 0.10 0.20 0.22 0.24 0.20 0.19 0.02 0.03 0.03 0.01 0.07 0.02 0.17 0.23 0.16 0.14 0.23 0.09 0.09 0.02 0.02 0.01 0.00 0.01 0.05 0.02 0.03 0.03 0.01 0.03 0.01 0.01 0.04 0.01 0.02 0.05 0.02 0.01 0.06 0.01 0.03 0.00 0.01 0.00 0.01 0.04 0.01 0.02 0.06 0.03 0.03 0.01 0.02 0.01 0.01 0.04 0.01 0.02 0.02 0.01 0.04 0.01 0.03 0.01 0.03 0.01 0.00 0.01 0.02 0.01 0.00 0.02 0.04 0.02 0.01 0.03 0.01 0.02 0.04 0.01 0.02 0.02 0.01 0.01 0.00 0.02 0.00 0.02 0.01 0.02 0.01 0.06 0.01 0.03 0.02 0.02 0.00 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.00 0.00 Cases 28 118 160 19 139 74 16 58 97 2 94 19 3515 377 3061 117 17 100 20 0 2 16 256 39 214 186 20 161 49 66 202 32 167 10 357 42 297 1043 34 114 49 838 65 15 50 245 19 225 8 13 91 55 38 85 1 3 13 1 1 20 2 1 21 69 0 54 10 23 2 10 10 0 2 1 5 1 3 20 1 Female ASR(W) CUM 0-74 0.6 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.1 0.5 0.6 0.4 0.5 0.4 0.4 0.5 0.4 0.3 0.1 0.5 0.4 0.4 0.4 0.4 0.5 0.4 0.4 0.5 0.4 0.8 0.4 0.3 0.4 0.5 0.4 0.4 0.2 0.5 0.2 0.5 0.5 0.4 0.5 0.4 0.3 0.4 0.1 0.5 0.4 0.4 0.5 0.5 0.2 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.2 0.4 0.3 0.2 0.4 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.11 0.05 0.04 0.11 0.04 0.06 0.13 0.08 0.05 0.08 0.05 0.13 0.01 0.03 0.01 0.03 0.11 0.04 0.08 0.08 0.13 0.02 0.07 0.03 0.03 0.11 0.04 0.06 0.07 0.03 0.15 0.03 0.09 0.02 0.07 0.02 0.01 0.03 0.05 0.03 0.02 0.06 0.11 0.07 0.02 0.06 0.03 0.05 0.15 0.05 0.05 0.08 0.05 0.18 0.03 0.02 0.09 0.04 0.02 0.04 0.04 0.05 0.05 0.04 0.08 0.08 0.04 0.02 0.02 0.03 0.01 0.05 0.01 0.01 0.01 0.00 0.07 0.07 0.06 0.05 0.06 0.06 0.06 0.07 0.06 0.01 0.06 0.06 0.05 0.06 0.06 0.04 0.05 0.04 0.03 0.01 0.05 0.05 0.05 0.05 0.05 0.06 0.05 0.04 0.06 0.05 0.09 0.05 0.03 0.05 0.06 0.05 0.05 0.02 0.06 0.02 0.06 0.06 0.05 0.06 0.04 0.03 0.05 0.02 0.05 0.05 0.04 0.06 0.06 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.03 0.05 0.03 0.03 0.04 0.00 0.01 0.01 0.00 0.02 0.00 0.00 0.00 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.02 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.00 * 0.00 0.01 * 0.00 * 0.00 * 0.01 * 0.01 0.01 * 0.01 0.01 * 0.01 * 0.00 * 0.00 0.00 0.00 0.01 0.00 0.00 0.00 -

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
377

435

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Tonsil (C09) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
378

Male ASR(W) CUM 0-74 0.6 0.6 0.5 0.7 0.4 0.5 0.3 0.8 0.2 0.1 0.2 0.4 0.1 1.0 0.6 0.7 0.7 0.9 0.6 1.3 0.5 1.3 0.2 0.3 1.7 1.5 1.4 1.2 1.6 1.7 1.4 2.0 2.2 2.0 0.6 0.8 2.8 4.1 3.7 2.6 3.1 3.4 5.3 3.0 4.9 1.9 2.8 2.0 1.5 1.4 1.8 2.3 0.7 2.2 0.4 0.7 1.2 1.9 2.0 0.7 1.7 0.3 0.9 0.5 0.8 1.8 1.6 0.3 0.8 1.3 0.5 1.5 0.4 1.1 1.4 0.7 1.6 1.8 0.03 0.09 0.10 0.19 0.13 0.10 0.23 0.07 0.14 0.11 0.12 0.11 0.08 0.21 0.09 0.09 0.11 0.36 0.27 0.19 0.16 0.22 0.08 0.06 0.08 0.27 0.36 0.06 0.16 0.10 0.07 0.11 0.08 0.10 0.12 0.06 0.29 0.45 0.48 0.33 0.33 0.31 0.39 0.43 0.54 0.39 0.37 0.15 0.10 0.15 0.17 0.17 0.09 0.24 0.23 0.08 0.40 0.30 0.38 0.13 0.28 0.23 0.15 0.15 0.24 0.15 0.33 0.16 0.21 0.19 0.13 0.30 0.19 0.42 0.19 0.15 0.30 0.17 0.07 0.08 0.08 0.09 0.05 0.05 0.06 0.10 0.03 0.01 0.02 0.05 0.01 0.15 0.06 0.09 0.09 0.13 0.05 0.15 0.05 0.12 0.01 0.04 0.20 0.18 0.13 0.14 0.19 0.19 0.17 0.24 0.25 0.23 0.06 0.09 0.36 0.50 0.44 0.35 0.35 0.39 0.66 0.31 0.60 0.17 0.33 0.24 0.17 0.16 0.22 0.26 0.09 0.26 0.05 0.08 0.16 0.23 0.24 0.09 0.20 0.04 0.10 0.07 0.09 0.22 0.18 0.04 0.10 0.15 0.06 0.18 0.05 0.14 0.18 0.09 0.20 0.22 0.00 0.01 0.02 0.03 0.02 0.01 0.05 0.01 0.02 0.01 0.01 0.02 0.01 0.04 0.01 0.01 0.02 0.05 0.03 0.02 0.02 0.03 0.01 0.01 0.01 0.03 0.04 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.04 0.06 0.06 0.05 0.04 0.04 0.05 0.05 0.07 0.04 0.05 0.02 0.01 0.02 0.02 0.02 0.01 0.03 0.03 0.01 0.05 0.04 0.05 0.02 0.03 0.02 0.02 0.02 0.03 0.02 0.04 0.02 0.03 0.02 0.02 0.04 0.02 0.05 0.03 0.02 0.04 0.02

Cases 90 7 4 1 3 8 1 35 0 0 1 5 10 0 9 30 16 14 1 1 15 4 6 1 5 151 16 10 43 33 80 53 36 160 142 7 46 19 14 10 17 26 21 23 11 19 8 10 46 79 36 21 53 23 18 2 28 4 9 8 15 11 1 22 4 0 28 5 2 7 12 5 1 4 3 14 6 1 20

Female ASR(W) CUM 0-74 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.2 0.3 0.5 0.4 0.2 0.2 0.2 0.1 0.3 0.2 0.2 0.0 0.1 0.5 0.7 0.7 0.1 0.5 0.4 0.1 0.2 0.4 0.7 0.1 0.2 0.5 0.5 0.6 0.6 0.9 0.5 0.5 0.6 1.0 0.7 0.5 0.4 0.4 0.5 0.3 0.5 0.2 0.4 0.2 0.3 0.5 0.4 0.4 0.2 0.4 0.0 0.4 0.1 0.3 0.2 0.2 0.4 0.2 0.2 0.1 0.3 0.4 0.3 0.2 0.1 0.2 0.01 0.02 0.03 0.03 0.05 0.04 0.11 0.02 0.03 0.08 0.08 0.18 0.07 0.04 0.05 0.20 0.08 0.09 0.08 0.06 0.04 0.03 0.04 0.18 0.25 0.02 0.09 0.05 0.02 0.03 0.03 0.06 0.03 0.03 0.13 0.15 0.19 0.16 0.17 0.12 0.11 0.20 0.23 0.24 0.17 0.06 0.04 0.08 0.07 0.07 0.05 0.11 0.17 0.05 0.28 0.13 0.17 0.07 0.14 0.03 0.09 0.07 0.06 0.10 0.15 0.15 0.07 0.07 0.07 0.16 0.24 0.09 0.07 0.06 0.06 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.00 0.02 0.03 0.06 0.04 0.02 0.02 0.03 0.01 0.03 0.03 0.02 0.00 0.01 0.05 0.09 0.06 0.01 0.05 0.05 0.02 0.02 0.04 0.08 0.01 0.02 0.06 0.06 0.07 0.06 0.09 0.06 0.05 0.08 0.09 0.07 0.05 0.04 0.05 0.06 0.04 0.06 0.02 0.05 0.02 0.03 0.05 0.04 0.06 0.03 0.05 0.05 0.02 0.03 0.02 0.02 0.05 0.03 0.01 0.01 0.03 0.04 0.04 0.02 0.01 0.03 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.01 0.01 - * 0.02 * 0.01 * 0.01 0.01 0.03 0.01 0.01 * 0.01 * 0.01 0.00 * 0.00 * 0.00 0.02 0.02 0.00 * 0.01 * 0.01 0.00 * 0.00 0.00 0.01 0.00 0.00 0.02 0.02 0.02 0.02 0.02 0.01 0.01 0.03 0.02 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.02 0.01 0.03 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.02 0.03 0.01 0.01 0.01 0.01

496 58 29 15 10 25 2 169 3 1 0 4 16 2 26 45 54 42 7 5 49 12 34 5 28 467 31 16 331 99 288 406 304 760 382 25 139 93 84 60 64 100 121 195 53 86 27 65 194 257 91 121 196 66 88 4 73 10 44 31 36 39 2 44 14 12 156 26 3 13 53 14 25 5 7 62 25 31 113

436

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Tonsil (C09) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 76 69 8 169 18 17 22 130 128 107 120 507 166 5 47 100 85 1 32 22 44 15 18 21 365 50 9 15 21 19 23 54 504 31 44 74 101 198 244 77 221 434 123 185 18 214 253 28 163 78 19 189 87 8 9 112 57 1 5 13 9 24 Male ASR(W) CUM 0-74 1.0 0.7 0.6 1.1 0.8 0.4 0.3 1.4 1.3 0.8 0.7 3.3 2.4 0.6 1.2 1.7 2.0 0.2 1.6 0.8 1.3 0.8 1.0 0.6 1.1 3.4 1.1 2.8 1.3 1.6 2.6 2.6 0.9 0.8 1.3 0.8 1.2 1.4 1.1 0.8 0.9 1.0 0.7 1.0 0.3 1.2 1.2 5.5 1.4 1.5 1.2 1.2 1.5 0.9 1.9 1.0 1.4 0.3 0.6 2.5 1.0 2.0 0.12 0.08 0.23 0.09 0.19 0.10 0.08 0.12 0.12 0.07 0.07 0.15 0.19 0.29 0.18 0.17 0.22 0.22 0.29 0.19 0.20 0.21 0.25 0.14 0.06 0.49 0.39 0.74 0.28 0.36 0.54 0.35 0.04 0.15 0.20 0.09 0.13 0.10 0.07 0.10 0.07 0.05 0.07 0.08 0.08 0.08 0.08 1.11 0.11 0.18 0.27 0.09 0.16 0.32 0.64 0.09 0.19 0.33 0.30 0.70 0.36 0.42 0.13 0.08 0.07 0.14 0.09 0.05 0.04 0.15 0.16 0.10 0.08 0.37 0.30 0.05 0.14 0.20 0.23 0.02 0.18 0.12 0.14 0.09 0.10 0.08 0.13 0.44 0.14 0.31 0.16 0.21 0.30 0.30 0.11 0.10 0.16 0.09 0.15 0.16 0.12 0.10 0.10 0.11 0.08 0.12 0.04 0.14 0.14 0.60 0.17 0.18 0.13 0.15 0.17 0.10 0.21 0.11 0.16 0.03 0.08 0.32 0.11 0.21 0.02 0.01 0.03 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.03 0.03 0.02 0.02 0.03 0.02 0.04 0.03 0.02 0.03 0.03 0.02 0.01 0.07 0.05 0.08 0.04 0.05 0.07 0.05 0.01 0.02 0.03 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.13 0.02 0.02 0.03 0.01 0.02 0.04 0.08 0.01 0.02 0.03 0.05 0.10 0.04 0.05 Cases 23 20 1 58 5 10 19 11 12 31 19 40 39 0 5 9 10 0 1 3 2 0 3 5 166 17 2 6 4 5 8 22 272 9 18 35 42 49 99 30 79 144 36 74 6 83 84 6 47 21 4 62 19 3 2 28 21 2 2 0 2 13 Female ASR(W) CUM 0-74 0.2 0.1 0.1 0.3 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.5 0.1 0.2 0.2 0.0 0.1 0.0 0.1 0.1 0.5 1.0 0.2 0.7 0.2 0.4 0.9 0.8 0.5 0.2 0.5 0.3 0.5 0.3 0.4 0.3 0.3 0.3 0.2 0.4 0.1 0.4 0.4 1.6 0.4 0.3 0.3 0.4 0.3 0.3 0.4 0.2 0.4 0.6 0.2 0.0 1.1 0.04 0.03 0.09 0.05 0.09 0.07 0.05 0.03 0.03 0.02 0.02 0.03 0.08 0.05 0.05 0.07 0.04 0.08 0.04 0.08 0.07 0.04 0.25 0.16 0.32 0.11 0.18 0.32 0.19 0.03 0.08 0.12 0.06 0.08 0.05 0.04 0.06 0.03 0.02 0.03 0.04 0.05 0.05 0.04 0.72 0.06 0.08 0.13 0.05 0.08 0.19 0.32 0.04 0.10 0.43 0.18 0.03 0.34 0.02 0.01 0.01 0.04 0.02 0.02 0.03 0.01 0.01 0.01 0.01 0.02 0.06 0.01 0.01 0.02 0.01 0.01 0.00 0.01 0.01 0.06 0.12 0.03 0.11 0.03 0.04 0.10 0.09 0.05 0.03 0.06 0.04 0.05 0.04 0.05 0.03 0.03 0.03 0.02 0.04 0.01 0.05 0.04 0.24 0.05 0.04 0.03 0.05 0.04 0.04 0.06 0.02 0.05 0.08 0.02 0.16 0.01 0.00 0.01 0.01 0.01 * 0.01 0.01 0.00 * 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.00 0.03 0.02 0.05 0.02 0.02 0.04 0.02 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.13 0.01 0.01 0.02 0.01 0.01 0.03 0.04 0.01 0.01 0.06 0.02 0.05

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
379

437

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other oropharynx (C10)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 0 3 1 7 6 7 24 14 22 464 2 6 8 0 23 0 288 24 53 19 5 5 0 21 149 0 12 103 29 74 7 53 271 8 31 37 194 50 6 1 0 0 8 35 84 17 1 0 0 2 16 47 33 55 6 49 23 21 2 356 57 296 144 52 92 45 25 20 12 231 50 179 76 20 60 84 33 51 5 8 Male ASR(W) CUM 0-74 0.1 0.1 0.6 0.4 0.9 1.1 1.8 1.5 2.2 0.2 0.2 0.1 2.2 0.4 0.3 0.4 0.5 0.2 0.3 0.6 0.4 0.3 0.8 1.1 0.7 0.3 0.3 0.3 0.1 0.6 0.3 0.3 0.3 0.5 0.1 0.4 0.3 0.4 0.7 0.1 0.4 0.3 0.4 0.3 0.5 1.0 0.5 1.4 2.1 0.4 0.6 1.1 0.6 0.7 1.2 0.6 0.7 1.5 0.5 0.3 0.6 1.2 0.6 0.4 0.2 0.5 0.6 0.9 0.5 0.4 0.5 0.04 0.11 0.28 0.20 0.35 0.23 0.49 0.32 0.11 0.15 0.09 0.04 0.47 0.02 0.06 0.05 0.12 0.09 0.14 0.14 0.03 0.10 0.08 0.21 0.08 0.13 0.05 0.02 0.03 0.10 0.04 0.02 0.04 0.20 0.06 0.13 0.05 0.04 0.17 0.10 0.27 0.08 0.06 0.05 0.07 0.42 0.07 0.31 0.48 0.25 0.03 0.15 0.03 0.06 0.17 0.06 0.11 0.31 0.11 0.09 0.04 0.17 0.04 0.05 0.04 0.06 0.07 0.17 0.08 0.20 0.17 0.10 0.16 0.20 0.17 0.27 0.02 0.04 0.01 0.26 0.05 0.04 0.04 0.06 0.02 0.05 0.07 0.05 0.05 0.09 0.13 0.09 0.03 0.04 0.04 0.01 0.08 0.03 0.04 0.04 0.07 0.01 0.05 0.04 0.05 0.10 0.01 0.07 0.05 0.05 0.03 0.06 0.14 0.06 0.19 0.27 0.06 0.08 0.14 0.07 0.09 0.15 0.07 0.09 0.20 0.06 0.04 0.08 0.14 0.07 0.05 0.02 0.06 0.07 0.09 0.07 0.02 0.06 0.04 0.04 0.06 0.04 0.01 0.02 0.02 0.01 0.06 0.00 0.01 0.01 0.02 0.01 0.02 0.02 0.00 0.02 0.01 0.03 0.01 0.01 0.01 0.00 0.00 0.02 0.01 0.00 0.01 0.03 0.01 0.02 0.01 0.01 0.03 0.01 0.06 0.01 0.01 0.01 0.01 0.06 0.01 0.04 0.06 0.05 0.00 0.02 0.00 0.01 0.02 0.01 0.02 0.05 0.02 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.02 Cases 0 2 1 1 1 1 7 4 2 88 0 3 1 1 5 2 88 11 19 3 0 0 0 5 46 1 3 29 5 24 2 29 123 4 13 10 94 27 4 1 0 0 1 21 35 6 0 1 0 0 4 24 17 24 1 23 5 5 0 134 14 118 47 16 31 18 8 10 9 65 12 51 43 11 17 20 5 15 3 1 Female ASR(W) CUM 0-74 0.0 0.1 0.0 0.0 0.1 0.2 0.7 0.1 0.3 0.1 0.0 0.0 0.3 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.0 0.2 0.0 0.1 0.1 0.3 0.1 0.0 0.1 0.1 0.2 0.1 0.0 0.2 0.1 0.2 0.1 0.2 0.2 0.3 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.3 0.2 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.03 0.12 0.02 0.02 0.13 0.10 0.35 0.06 0.04 0.04 0.01 0.04 0.16 0.15 0.01 0.04 0.03 0.03 0.05 0.02 0.06 0.06 0.03 0.06 0.04 0.10 0.03 0.01 0.01 0.05 0.01 0.01 0.02 0.13 0.06 0.04 0.03 0.02 0.07 0.06 0.02 0.04 0.03 0.04 0.13 0.04 0.09 0.14 0.02 0.06 0.02 0.03 0.06 0.03 0.05 0.11 0.06 0.07 0.02 0.06 0.02 0.03 0.03 0.02 0.03 0.06 0.03 0.15 0.06 0.02 0.03 0.09 0.01 0.04 0.01 0.00 0.00 0.04 0.03 0.01 0.01 0.01 0.00 0.02 0.01 0.01 0.02 0.02 0.02 0.03 0.02 0.01 0.00 0.02 0.00 0.02 0.01 0.03 0.00 0.01 0.02 0.01 0.02 0.01 0.02 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.02 0.01 0.03 0.01 * * * *

0.02 0.02 0.05 0.01 0.00 0.01 0.00 0.00 0.02 0.02 * 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.02 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.02 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.01 0.02 0.01 0.01 0.02 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.02 0.01

438

*Important. See note on population page.

380

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other oropharynx (C10) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 18 100 145 26 116 43 20 23 71 13 58 11 3321 628 2638 107 21 84 7 0 1 6 347 79 264 168 25 143 46 52 208 41 161 22 269 59 200 754 19 145 56 532 121 59 61 227 31 192 7 5 59 40 26 94 1 16 3 1 28 4 7 99 140 12 172 40 29 49 28 25 2 28 12 29 102 34 242 40 Male ASR(W) CUM 0-74 0.4 0.5 0.5 0.8 0.4 0.4 0.8 0.2 0.4 1.1 0.4 0.3 0.5 1.0 0.4 0.4 0.8 0.4 0.1 0.0 0.2 0.6 1.2 0.5 0.5 0.8 0.4 0.4 0.4 0.5 1.4 0.4 0.7 0.3 0.9 0.3 0.3 0.1 0.8 0.3 0.3 1.0 2.2 0.6 0.4 0.6 0.4 0.1 0.3 0.3 0.3 0.4 0.5 0.2 0.3 0.2 0.0 0.1 0.1 0.3 1.1 0.7 1.5 0.8 1.1 0.5 1.8 0.2 0.2 0.1 0.7 0.3 0.7 1.0 0.5 0.7 0.6 0.10 0.05 0.04 0.16 0.04 0.06 0.19 0.05 0.05 0.30 0.05 0.10 0.01 0.04 0.01 0.04 0.17 0.04 0.05 0.04 0.07 0.03 0.14 0.03 0.04 0.16 0.04 0.07 0.06 0.04 0.22 0.03 0.14 0.02 0.13 0.02 0.01 0.03 0.07 0.04 0.01 0.09 0.29 0.08 0.03 0.12 0.03 0.05 0.11 0.04 0.05 0.08 0.06 0.21 0.09 0.14 0.04 0.03 0.06 0.12 0.11 0.06 0.43 0.06 0.18 0.09 0.26 0.04 0.04 0.09 0.14 0.09 0.13 0.11 0.09 0.04 0.11 0.06 0.06 0.06 0.09 0.05 0.05 0.09 0.04 0.05 0.15 0.05 0.05 0.06 0.13 0.06 0.05 0.10 0.04 0.02 0.00 0.02 0.08 0.16 0.07 0.06 0.11 0.05 0.06 0.06 0.06 0.17 0.05 0.10 0.04 0.12 0.04 0.04 0.01 0.10 0.04 0.04 0.11 0.25 0.07 0.05 0.08 0.05 0.01 0.04 0.04 0.03 0.04 0.06 0.03 0.04 0.03 0.01 0.01 0.01 0.04 0.14 0.09 0.20 0.10 0.14 0.06 0.25 0.02 0.02 0.00 0.09 0.04 0.11 0.13 0.06 0.09 0.08 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.04 0.01 0.02 0.00 0.01 0.00 0.01 0.03 0.01 0.01 0.00 0.01 0.00 0.02 0.00 0.01 0.02 0.01 0.01 0.01 0.00 0.03 0.00 0.02 0.00 0.02 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.04 0.01 0.00 0.02 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.03 0.01 0.02 0.01 0.00 0.01 0.02 0.02 0.01 0.06 0.01 0.02 0.01 0.04 0.00 0.00 0.00 0.02 0.01 0.02 0.01 0.01 0.01 0.01 Cases 9 48 40 6 34 17 3 13 16 0 16 2 1247 182 1040 58 13 45 5 0 0 5 140 29 109 65 10 53 17 17 75 11 63 10 109 16 89 311 6 46 16 240 29 14 15 76 10 64 3 3 23 11 14 42 0 0 0 0 11 0 0 11 20 0 29 6 5 1 13 11 2 6 2 3 12 5 34 10 Female ASR(W) CUM 0-74 0.2 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.3 0.1 0.1 0.1 0.2 0.3 0.2 0.1 0.3 0.1 0.1 0.1 0.1 0.3 0.1 0.3 0.1 0.2 0.1 0.1 0.0 0.2 0.1 0.1 0.2 0.3 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.2 0.2 0.0 0.1 0.1 0.2 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.06 0.03 0.02 0.06 0.02 0.03 0.06 0.03 0.02 0.02 0.04 0.00 0.02 0.00 0.02 0.10 0.02 0.03 0.06 0.02 0.05 0.02 0.02 0.09 0.02 0.03 0.03 0.02 0.10 0.02 0.10 0.01 0.05 0.01 0.01 0.01 0.03 0.01 0.01 0.04 0.09 0.04 0.01 0.06 0.01 0.02 0.05 0.02 0.03 0.05 0.04 0.01 0.04 0.03 0.03 0.07 0.04 0.03 0.02 0.02 0.08 0.06 0.03 0.04 0.03 0.03 0.01 0.04 0.03 0.02 0.01 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.03 0.02 0.02 0.04 0.02 0.01 0.02 0.02 0.04 0.02 0.02 0.03 0.02 0.02 0.02 0.02 0.04 0.02 0.04 0.01 0.02 0.01 0.01 0.00 0.02 0.01 0.01 0.03 0.03 0.02 0.02 0.02 0.01 0.01 0.00 0.02 0.01 0.03 0.03 0.00 0.01 0.01 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.02 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.01 - * - * 0.00 * - * - * 0.00 0.00 * 0.00 0.01 * 0.01 * 0.01 * 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
381

439

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other oropharynx (C10) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
382

Male ASR(W) CUM 0-74 0.3 0.3 0.3 0.3 0.7 0.2 0.1 0.2 0.5 0.6 0.2 0.1 0.5 0.1 0.3 0.4 0.1 0.2 0.3 0.6 0.0 0.1 1.1 1.1 1.4 2.1 0.4 0.8 0.3 1.4 0.8 0.7 2.3 0.1 3.5 4.4 3.1 2.9 2.3 2.2 3.3 4.3 3.4 1.8 3.2 1.5 1.7 2.5 2.5 0.7 2.4 2.2 0.1 0.3 0.7 0.9 0.9 0.5 0.4 0.7 1.0 0.2 0.9 0.3 0.3 0.7 0.2 0.3 0.2 0.0 0.7 1.2 0.4 1.3 0.5 0.02 0.06 0.08 0.12 0.17 0.07 0.09 0.04 0.23 0.19 0.09 0.08 0.16 0.04 0.06 0.08 0.14 0.07 0.12 0.16 0.03 0.03 0.06 0.22 0.36 0.09 0.08 0.07 0.04 0.10 0.05 0.06 0.24 0.02 0.33 0.47 0.43 0.35 0.28 0.25 0.31 0.52 0.44 0.40 0.41 0.12 0.10 0.20 0.20 0.09 0.16 0.24 0.11 0.06 0.29 0.20 0.24 0.11 0.14 0.13 0.20 0.13 0.11 0.15 0.17 0.20 0.07 0.11 0.12 0.04 0.32 0.19 0.11 0.27 0.09 0.04 0.04 0.04 0.04 0.11 0.03 0.01 0.03 0.09 0.09 0.03 0.01 0.07 0.01 0.04 0.06 0.01 0.02 0.04 0.07 0.00 0.01 0.13 0.13 0.17 0.25 0.05 0.09 0.04 0.17 0.09 0.08 0.29 0.01 0.41 0.54 0.37 0.35 0.25 0.26 0.41 0.47 0.39 0.18 0.36 0.17 0.18 0.30 0.28 0.09 0.29 0.26 0.01 0.04 0.11 0.10 0.13 0.06 0.04 0.10 0.10 0.03 0.11 0.04 0.04 0.09 0.02 0.04 0.03 0.11 0.15 0.04 0.14 0.06 0.00 0.01 0.01 0.02 0.03 0.01 0.01 0.01 0.05 0.03 0.01 0.01 0.02 0.00 0.01 0.01 0.01 0.01 0.02 0.02 0.00 0.01 0.01 0.03 0.05 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.03 0.00 0.04 0.06 0.06 0.05 0.03 0.03 0.04 0.06 0.05 0.04 0.05 0.02 0.01 0.03 0.02 0.01 0.02 0.03 0.01 0.01 0.05 0.02 0.03 0.01 0.02 0.02 0.02 0.02 0.01 0.02 0.02 0.03 0.01 0.01 0.02 0.05 0.02 0.01 0.03 0.01

Cases 22 3 1 1 2 1 0 5 2 0 0 4 5 0 5 3 3 3 0 0 3 3 0 1 2 60 4 7 27 6 23 10 38 51 62 12 5 23 14 5 8 9 7 15 4 12 3 5 31 41 70 26 22 68 19 0 6 0 3 1 5 5 0 10 7 0 15 2 1 3 1 2 3 0 2 9 2 5 6

Female ASR(W) CUM 0-74 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.2 0.1 0.3 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.2 0.2 0.6 0.1 0.1 0.1 0.0 0.2 0.1 0.3 0.2 0.0 0.7 0.6 0.3 0.3 0.3 0.2 0.3 0.3 0.6 0.3 0.3 0.3 0.2 1.0 0.3 0.2 0.7 0.4 0.0 0.1 0.1 0.1 0.1 0.2 0.3 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.3 0.2 0.0 0.3 0.1 0.00 0.02 0.01 0.03 0.04 0.02 0.01 0.08 0.10 0.05 0.12 0.03 0.02 0.02 0.04 0.07 0.03 0.02 0.03 0.10 0.24 0.01 0.03 0.03 0.01 0.03 0.02 0.04 0.06 0.01 0.14 0.17 0.14 0.11 0.09 0.07 0.09 0.14 0.18 0.16 0.12 0.05 0.03 0.12 0.06 0.05 0.09 0.10 0.02 0.05 0.08 0.04 0.06 0.07 0.10 0.05 0.06 0.11 0.09 0.02 0.04 0.08 0.22 0.06 0.01 0.12 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.03 0.00 0.05 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.02 0.02 0.08 0.01 0.01 0.01 0.00 0.02 0.01 0.04 0.02 0.00 0.08 0.07 0.03 0.04 0.03 0.02 0.04 0.03 0.07 0.02 0.02 0.03 0.02 0.11 0.04 0.02 0.08 0.04 0.01 0.01 0.01 0.01 0.02 0.02 0.04 0.02 0.01 0.01 0.02 0.00 0.01 0.01 0.04 0.02 0.03 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 0.00 - * 0.02 * 0.01 * 0.00 0.00 0.01 * 0.00 * 0.00 * 0.00 * 0.00 0.01 0.03 0.00 * 0.00 * 0.00 0.00 * 0.00 0.00 0.01 0.01 0.00 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.03 0.01 0.01 0.00

229 24 13 7 20 10 1 44 4 0 0 12 8 2 14 6 26 25 1 0 7 5 17 1 9 287 23 15 596 27 131 88 220 277 129 97 17 119 93 52 71 67 82 122 73 59 23 62 142 271 157 159 63 223 91 1 37 7 21 16 23 8 0 33 26 3 75 6 4 13 8 9 4 1 5 47 14 22 30

440

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other oropharynx (C10) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 89 225 4 47 27 59 120 95 87 220 94 420 217 1 118 111 52 3 14 22 13 26 17 14 51 34 10 4 24 15 6 35 350 24 27 17 38 61 71 18 54 111 43 51 13 85 106 10 63 19 9 60 24 3 4 25 13 0 3 1 3 4 Male ASR(W) CUM 0-74 1.2 2.3 0.3 0.3 1.0 1.5 2.1 1.0 0.9 1.6 0.6 2.7 3.2 0.1 3.0 1.8 1.2 0.4 0.8 0.9 0.4 1.3 1.0 0.5 0.1 2.4 1.3 0.7 1.4 1.2 0.6 1.7 0.6 0.7 0.8 0.2 0.4 0.4 0.3 0.2 0.2 0.2 0.2 0.3 0.3 0.5 0.5 2.1 0.6 0.4 0.6 0.4 0.4 0.4 0.8 0.2 0.3 0.2 0.2 0.3 0.4 0.13 0.15 0.15 0.05 0.20 0.20 0.20 0.11 0.10 0.11 0.06 0.13 0.22 0.12 0.29 0.18 0.17 0.25 0.21 0.20 0.11 0.27 0.26 0.13 0.02 0.41 0.42 0.37 0.29 0.31 0.25 0.28 0.03 0.14 0.15 0.04 0.07 0.05 0.03 0.05 0.03 0.02 0.04 0.04 0.07 0.05 0.05 0.68 0.07 0.09 0.20 0.05 0.08 0.21 0.41 0.04 0.09 0.13 0.19 0.19 0.18 0.16 0.26 0.03 0.04 0.14 0.17 0.26 0.12 0.11 0.20 0.07 0.30 0.39 0.01 0.35 0.21 0.14 0.06 0.09 0.11 0.04 0.16 0.13 0.05 0.02 0.30 0.16 0.08 0.17 0.14 0.05 0.21 0.08 0.09 0.09 0.02 0.05 0.05 0.04 0.02 0.02 0.03 0.03 0.03 0.03 0.05 0.06 0.24 0.07 0.04 0.06 0.06 0.04 0.04 0.08 0.03 0.03 0.02 0.03 0.04 0.02 0.02 0.02 0.01 0.03 0.02 0.03 0.01 0.01 0.01 0.01 0.02 0.03 0.01 0.03 0.02 0.02 0.03 0.03 0.02 0.01 0.03 0.03 0.01 0.00 0.06 0.05 0.04 0.04 0.04 0.03 0.04 0.00 0.02 0.02 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.08 0.01 0.01 0.02 0.01 0.01 0.02 0.04 0.01 0.01 0.02 0.02 0.02 Cases 11 20 0 25 4 7 46 7 3 33 14 14 16 0 6 6 0 0 0 1 2 1 1 1 25 13 2 2 5 6 2 10 125 8 3 9 12 20 20 4 18 46 11 16 8 35 24 2 15 8 2 20 5 1 0 6 3 0 0 1 0 2 Female ASR(W) CUM 0-74 0.1 0.1 0.1 0.1 0.1 0.6 0.1 0.0 0.1 0.1 0.1 0.2 0.2 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.8 0.3 0.3 0.3 0.4 0.2 0.4 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.4 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.2 0.04 0.03 0.03 0.06 0.05 0.09 0.02 0.01 0.03 0.02 0.02 0.05 0.06 0.04 0.02 0.04 0.05 0.03 0.04 0.01 0.23 0.20 0.22 0.14 0.18 0.12 0.14 0.02 0.08 0.05 0.03 0.04 0.03 0.02 0.02 0.01 0.01 0.02 0.02 0.05 0.02 0.02 0.32 0.04 0.05 0.06 0.03 0.04 0.11 0.02 0.04 0.18 0.13 0.01 0.02 0.02 0.01 0.01 0.07 0.01 0.02 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.11 0.03 0.05 0.03 0.04 0.01 0.05 0.03 0.03 0.01 0.01 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.05 0.02 0.01 0.02 0.02 0.01 0.03 0.00 0.01 0.02 0.02 0.00 0.00 0.00 0.01 * 0.01 0.01 0.00 * 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.00 0.00 0.03 0.02 0.03 0.02 0.02 0.01 0.02 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.00 0.01 0.02 0.00 0.00 0.03 0.00 0.01 0.02 0.02

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
383

441

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Nasopharynx (C11)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 140 57 44 42 20 3 17 2 25 216 3 17 68 6 9 2 623 64 152 20 8 16 4 16 326 1 16 85 20 65 24 71 809 431 43 79 247 236 6 120 28 2 10 43 229 23 64 29 1 5 28 41 55 67 5 58 13 12 0 388 45 326 133 33 93 40 14 20 13 216 50 137 91 35 78 107 44 53 11 13 Male ASR(W) CUM 0-74 5.4 1.2 4.6 2.3 0.6 0.4 0.5 0.3 1.4 1.0 0.3 0.5 0.8 0.2 0.9 0.2 0.8 0.7 1.1 0.5 0.4 0.9 4.3 0.5 0.9 0.2 0.5 0.6 0.7 0.6 1.5 0.4 0.9 3.8 0.7 0.4 0.4 1.2 0.4 8.1 3.1 0.9 0.4 0.4 0.9 0.9 6.0 3.8 0.3 1.1 0.3 0.4 0.4 0.6 0.7 0.6 0.8 1.2 0.7 0.8 0.7 0.6 0.7 0.6 0.6 0.7 0.4 0.3 0.6 1.1 0.5 0.5 0.4 0.6 0.8 1.4 0.6 1.2 0.7 0.50 0.17 0.71 0.48 0.16 0.22 0.13 0.22 0.31 0.07 0.17 0.12 0.10 0.09 0.29 0.16 0.03 0.09 0.09 0.13 0.13 0.23 2.31 0.13 0.05 0.20 0.13 0.07 0.16 0.07 0.31 0.06 0.03 0.19 0.11 0.05 0.03 0.08 0.19 0.75 0.60 0.65 0.13 0.06 0.06 0.19 0.77 0.72 0.33 0.49 0.07 0.06 0.06 0.08 0.31 0.08 0.22 0.36 0.04 0.12 0.04 0.05 0.12 0.06 0.09 0.20 0.09 0.10 0.04 0.16 0.04 0.06 0.07 0.07 0.08 0.21 0.08 0.35 0.20 0.03 0.03 0.03 0.14 0.11 0.02 0.05 0.08 0.02 0.11 0.03 0.09 0.08 0.11 0.07 0.04 0.12 0.55 0.06 0.09 0.05 0.05 0.07 0.06 0.07 0.17 0.05 0.09 0.41 0.07 0.05 0.05 0.14 0.06 0.94 0.31 0.10 0.04 0.05 0.09 0.10 0.63 0.40 0.04 0.13 0.04 0.04 0.05 0.07 0.09 0.06 0.09 0.14 0.08 0.08 0.08 0.07 0.07 0.07 0.07 0.07 0.05 0.03 0.07 0.11 0.05 0.06 0.04 0.07 0.09 0.16 0.06 0.14 0.08 0.02 0.01 0.03 0.04 0.01 0.01 0.01 0.01 0.01 0.04 0.02 0.00 0.01 0.01 0.02 0.01 0.03 0.34 0.02 0.01 0.05 0.02 0.01 0.01 0.01 0.05 0.01 0.00 0.02 0.01 0.01 0.00 0.01 0.03 0.09 0.07 0.08 0.02 0.01 0.01 0.02 0.09 0.08 0.04 0.06 0.01 0.01 0.01 0.01 0.05 0.01 0.03 0.04 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.03 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.05 0.03 Cases 47 23 21 31 9 1 7 2 4 97 2 13 27 1 5 1 270 21 76 15 4 2 1 6 140 0 5 42 9 32 14 28 373 205 25 31 109 127 5 66 12 0 4 24 99 10 24 9 1 1 16 24 22 26 2 22 5 5 0 206 29 166 81 24 50 23 12 6 8 128 29 79 41 22 33 40 14 26 6 8 Female ASR(W) CUM 0-74 1.7 0.4 1.9 1.3 0.3 0.1 0.3 0.3 0.2 0.3 0.2 0.3 0.3 0.0 0.3 0.1 0.3 0.2 0.5 0.4 0.2 0.1 1.3 0.2 0.4 0.2 0.3 0.3 0.3 0.9 0.1 0.4 1.5 0.3 0.1 0.2 0.6 0.3 4.0 1.0 0.1 0.2 0.3 0.3 1.9 0.8 0.1 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.4 0.3 0.4 0.3 0.3 0.3 0.3 0.3 0.4 0.1 0.2 0.3 0.5 0.2 0.2 0.2 0.2 0.3 0.3 0.2 0.4 0.4 0.27 0.08 0.43 0.34 0.12 0.14 0.11 0.21 0.09 0.04 0.14 0.08 0.06 0.02 0.16 0.12 0.02 0.05 0.06 0.10 0.10 0.06 1.31 0.09 0.03 0.07 0.04 0.09 0.05 0.26 0.03 0.02 0.11 0.07 0.03 0.02 0.06 0.16 0.50 0.30 0.07 0.06 0.03 0.09 0.39 0.28 0.06 0.27 0.04 0.04 0.04 0.04 0.12 0.05 0.16 0.21 0.03 0.08 0.03 0.04 0.07 0.04 0.06 0.13 0.05 0.07 0.03 0.10 0.03 0.04 0.05 0.04 0.04 0.09 0.05 0.18 0.14 0.01 0.03 0.04 0.01 0.03 0.02 0.03 0.02 0.02 0.01 0.03 0.02 0.05 0.04 0.01 0.00 0.16 0.03 0.04 0.01 0.03 0.02 0.03 0.13 0.02 0.04 0.16 0.04 0.01 0.02 0.07 0.02 0.44 0.12 0.02 0.02 0.03 0.03 0.18 0.09 0.01 0.01 0.02 0.02 0.02 0.01 0.02 0.03 0.04 0.04 0.04 0.03 0.03 0.03 0.03 0.02 0.04 0.01 0.02 0.03 0.05 0.03 0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.05 * * * *

0.01 0.02 0.03 0.01 0.00 0.02 0.01 0.01 0.01 0.01 * 0.00 0.01 0.01 0.01 0.01 0.00 0.16 0.01 0.00 0.01 0.01 0.01 0.01 0.04 0.00 0.00 0.01 0.01 0.00 0.00 0.01 0.01 0.06 0.04 0.01 0.01 0.00 0.01 0.04 0.04 0.02 0.00 0.01 0.00 0.01 0.01 0.01 0.02 0.02 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.02 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.02

442

*Important. See note on population page.

384

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Nasopharynx (C11) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 22 131 146 28 111 73 21 48 78 9 62 11 4294 565 2791 189 26 126 14 3 3 5 499 59 255 155 18 127 57 43 192 31 137 18 577 50 276 1610 592 166 105 714 87 29 58 332 62 242 23 8 111 82 31 84 14 1343 3884 53 28 918 946 10 82 132 5 117 20 35 18 144 119 20 16 9 17 43 30 149 20 Male ASR(W) CUM 0-74 0.5 0.7 0.5 0.8 0.4 0.6 0.9 0.5 0.5 0.7 0.4 0.4 0.6 0.9 0.5 0.7 0.8 0.6 0.3 0.6 0.1 0.2 0.9 0.9 0.6 0.5 0.6 0.4 0.6 0.4 0.5 1.0 0.4 0.6 0.7 0.7 0.4 0.8 3.4 0.9 0.4 0.5 0.8 1.0 0.7 0.6 1.0 0.5 0.4 0.4 0.6 0.7 0.5 0.5 2.0 22.2 17.8 4.0 1.1 4.1 26.9 0.5 0.8 0.6 0.6 0.5 0.4 0.4 0.6 1.0 0.9 1.1 0.4 0.3 0.5 0.5 0.6 0.5 0.4 0.12 0.06 0.04 0.16 0.04 0.08 0.20 0.08 0.05 0.22 0.05 0.12 0.01 0.04 0.01 0.05 0.17 0.05 0.07 0.36 0.08 0.10 0.04 0.11 0.04 0.04 0.13 0.04 0.08 0.06 0.04 0.18 0.03 0.14 0.03 0.11 0.03 0.02 0.14 0.07 0.04 0.02 0.08 0.19 0.09 0.03 0.13 0.03 0.09 0.15 0.06 0.08 0.09 0.05 0.56 0.62 0.29 0.57 0.21 0.14 0.90 0.16 0.09 0.05 0.26 0.05 0.10 0.08 0.15 0.08 0.09 0.27 0.11 0.10 0.12 0.08 0.12 0.04 0.09 0.05 0.07 0.05 0.08 0.05 0.07 0.09 0.06 0.05 0.07 0.05 0.05 0.07 0.09 0.06 0.08 0.08 0.07 0.02 0.05 0.01 0.01 0.10 0.09 0.06 0.05 0.06 0.05 0.06 0.05 0.06 0.10 0.05 0.07 0.08 0.08 0.05 0.08 0.37 0.09 0.05 0.05 0.08 0.12 0.07 0.06 0.10 0.06 0.05 0.05 0.07 0.08 0.07 0.05 0.19 2.23 1.88 0.47 0.12 0.45 2.82 0.05 0.09 0.07 0.07 0.05 0.04 0.04 0.07 0.11 0.10 0.15 0.04 0.03 0.05 0.06 0.06 0.05 0.04 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.00 0.00 0.00 0.01 0.02 0.01 0.01 0.03 0.01 0.01 0.00 0.01 0.00 0.00 0.02 0.00 0.01 0.01 0.00 0.02 0.00 0.02 0.00 0.01 0.00 0.00 0.02 0.01 0.01 0.00 0.01 0.02 0.01 0.00 0.02 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.07 0.07 0.03 0.07 0.03 0.02 0.10 0.02 0.01 0.01 0.03 0.01 0.01 0.01 0.02 0.01 0.01 0.05 0.01 0.01 0.01 0.01 0.01 0.00 0.01 Cases 9 79 83 10 68 40 6 31 33 6 24 3 2116 295 1383 81 10 48 9 2 1 6 242 42 137 84 6 69 37 24 97 21 73 5 286 26 131 721 269 74 43 315 38 16 20 160 26 116 13 6 46 35 17 44 2 613 1503 17 14 351 367 7 27 44 0 47 12 15 9 69 63 6 2 3 12 13 11 53 9 Female ASR(W) CUM 0-74 0.2 0.4 0.2 0.2 0.2 0.3 0.2 0.3 0.2 0.3 0.1 0.1 0.3 0.4 0.2 0.3 0.3 0.2 0.2 0.4 0.1 0.2 0.3 0.4 0.2 0.2 0.2 0.2 0.3 0.2 0.2 0.5 0.2 0.1 0.3 0.3 0.2 0.3 1.3 0.3 0.2 0.2 0.3 0.4 0.2 0.3 0.4 0.2 0.2 0.3 0.2 0.3 0.2 0.2 0.3 9.8 6.7 1.3 0.5 1.5 10.1 0.3 0.3 0.2 0.2 0.3 0.2 0.3 0.4 0.4 0.4 0.1 0.0 0.3 0.1 0.2 0.1 0.1 0.10 0.04 0.03 0.08 0.03 0.05 0.07 0.06 0.03 0.13 0.03 0.04 0.01 0.02 0.01 0.03 0.09 0.03 0.06 0.30 0.06 0.12 0.02 0.07 0.02 0.02 0.07 0.02 0.05 0.04 0.02 0.12 0.02 0.05 0.02 0.05 0.02 0.01 0.08 0.04 0.02 0.01 0.05 0.11 0.05 0.02 0.08 0.02 0.07 0.14 0.04 0.05 0.05 0.04 0.23 0.40 0.18 0.32 0.14 0.08 0.54 0.12 0.05 0.04 0.03 0.08 0.06 0.09 0.05 0.05 0.15 0.05 0.03 0.08 0.04 0.05 0.02 0.05 0.02 0.04 0.03 0.03 0.02 0.04 0.02 0.04 0.02 0.03 0.02 0.01 0.03 0.03 0.02 0.03 0.03 0.02 0.02 0.02 0.01 0.02 0.04 0.04 0.03 0.02 0.02 0.02 0.04 0.02 0.02 0.05 0.02 0.01 0.03 0.02 0.02 0.03 0.14 0.03 0.01 0.02 0.03 0.04 0.02 0.03 0.04 0.02 0.03 0.04 0.02 0.02 0.03 0.03 0.04 0.99 0.69 0.12 0.06 0.16 1.03 0.04 0.03 0.03 0.02 0.03 0.02 0.03 0.04 0.04 0.05 0.01 0.00 0.03 0.01 0.02 0.02 0.02 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.02 0.00 0.00 0.01 0.00 0.03 0.04 * 0.02 0.03 * 0.02 0.01 * 0.06 * 0.01 * 0.01 0.01 * 0.00 0.01 * 0.01 * 0.01 * 0.01 0.01 0.03 0.00 0.00 0.01 0.00 0.01 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
385

443

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Nasopharynx (C11) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
386

Male ASR(W) CUM 0-74 0.9 0.8 0.8 1.0 1.0 0.9 2.0 1.1 0.9 1.7 0.6 9.3 15.0 1.0 1.4 5.8 11.0 12.8 1.8 5.5 3.9 2.5 2.7 1.3 1.3 0.4 0.7 0.5 0.5 0.4 0.4 0.9 0.7 0.6 0.4 0.2 0.3 0.5 0.4 0.6 1.0 0.7 0.5 0.6 0.3 0.5 0.9 0.5 0.5 0.4 0.7 0.6 0.4 0.3 0.3 0.5 0.5 1.7 0.5 0.8 0.9 0.7 0.3 1.0 0.5 1.1 0.8 0.5 0.9 0.9 0.8 0.8 0.2 0.8 1.1 0.7 0.4 1.2 0.5 0.03 0.09 0.12 0.20 0.18 0.13 0.51 0.07 0.26 0.42 0.25 0.64 0.62 0.24 0.21 0.29 0.34 0.41 0.50 0.74 0.32 0.34 0.31 0.21 0.12 0.04 0.19 0.22 0.04 0.08 0.06 0.06 0.07 0.04 0.05 0.08 0.04 0.12 0.15 0.20 0.21 0.15 0.12 0.13 0.14 0.16 0.29 0.16 0.07 0.05 0.13 0.10 0.07 0.06 0.09 0.27 0.07 0.51 0.15 0.24 0.15 0.18 0.20 0.19 0.14 0.26 0.10 0.19 0.33 0.25 0.15 0.17 0.10 0.26 0.43 0.15 0.11 0.28 0.10 0.11 0.09 0.10 0.09 0.10 0.09 0.28 0.12 0.07 0.21 0.09 1.01 1.63 0.11 0.13 0.66 1.17 1.37 0.15 0.57 0.42 0.26 0.28 0.15 0.13 0.04 0.08 0.06 0.06 0.05 0.04 0.09 0.07 0.07 0.04 0.04 0.03 0.06 0.06 0.06 0.10 0.07 0.05 0.06 0.02 0.05 0.10 0.05 0.05 0.04 0.07 0.06 0.05 0.04 0.03 0.06 0.05 0.18 0.07 0.10 0.09 0.08 0.06 0.10 0.05 0.11 0.08 0.05 0.08 0.11 0.09 0.09 0.01 0.10 0.14 0.08 0.05 0.14 0.06 0.00 0.01 0.02 0.02 0.02 0.01 0.09 0.01 0.02 0.06 0.06 0.08 0.08 0.03 0.02 0.04 0.04 0.05 0.05 0.09 0.04 0.04 0.04 0.02 0.01 0.00 0.02 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.02 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.05 0.02 0.03 0.02 0.02 0.03 0.02 0.02 0.03 0.01 0.02 0.03 0.03 0.02 0.02 0.01 0.04 0.06 0.02 0.01 0.03 0.01

Cases 346 39 15 13 10 22 3 84 6 10 9 81 280 7 15 238 373 348 1 24 63 33 31 16 46 61 2 2 58 9 18 109 35 61 33 8 26 6 5 6 4 7 9 8 1 1 5 0 13 29 20 13 9 17 7 6 13 3 9 3 16 4 0 16 5 1 20 2 4 7 10 6 6 2 5 3 12 8 13

Female ASR(W) CUM 0-74 0.3 0.3 0.2 0.3 0.3 0.3 0.3 0.3 0.3 0.8 0.8 3.3 6.5 0.3 0.6 2.4 3.6 4.1 0.1 2.0 1.5 1.5 0.9 0.5 0.5 0.2 0.1 0.2 0.2 0.2 0.1 0.4 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.4 0.1 0.1 0.2 0.2 0.0 0.1 0.3 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.7 0.1 0.4 0.4 0.1 0.3 0.1 0.3 0.2 0.1 0.2 0.1 0.4 0.3 0.3 0.2 0.3 0.2 0.7 0.1 0.3 0.4 0.3 0.02 0.05 0.05 0.10 0.10 0.07 0.20 0.03 0.15 0.26 0.43 0.37 0.41 0.11 0.19 0.17 0.19 0.22 0.11 0.43 0.20 0.27 0.17 0.12 0.08 0.02 0.04 0.13 0.02 0.07 0.03 0.04 0.04 0.02 0.03 0.09 0.03 0.08 0.10 0.16 0.07 0.06 0.08 0.08 0.04 0.06 0.17 0.03 0.03 0.06 0.06 0.03 0.05 0.08 0.33 0.03 0.25 0.13 0.07 0.08 0.06 0.10 0.11 0.06 0.05 0.08 0.18 0.14 0.09 0.09 0.13 0.17 0.33 0.06 0.10 0.16 0.11 0.03 0.04 0.03 0.04 0.04 0.03 0.02 0.04 0.04 0.10 0.06 0.34 0.72 0.03 0.06 0.26 0.36 0.41 0.01 0.18 0.17 0.19 0.10 0.05 0.06 0.02 0.01 0.02 0.02 0.01 0.01 0.04 0.02 0.02 0.02 0.01 0.01 0.02 0.03 0.03 0.02 0.02 0.03 0.01 0.01 0.01 0.03 0.01 0.02 0.03 0.02 0.01 0.02 0.02 0.08 0.00 0.03 0.05 0.01 0.03 0.01 0.04 0.02 0.01 0.02 0.01 0.05 0.04 0.03 0.02 0.03 0.02 0.10 0.01 0.03 0.04 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.02 0.04 0.03 0.04 0.05 0.01 * 0.02 * 0.02 * 0.02 0.03 0.01 0.04 0.02 * 0.04 * 0.02 0.01 * 0.01 * 0.00 0.01 0.02 0.00 * 0.01 * 0.00 0.00 * 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.00 0.00 0.01 0.01 0.00 0.00 0.01 0.04 0.00 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.04 0.00 0.01 0.02 0.01

902 80 52 30 34 55 16 262 14 17 23 225 633 20 48 518 1089 1012 14 63 154 58 78 44 112 108 13 6 140 23 60 229 101 213 60 11 53 16 9 8 23 22 18 20 5 8 11 9 41 65 40 36 37 31 14 4 51 13 11 12 36 19 3 35 11 17 62 9 7 15 35 22 3 9 7 25 16 21 33

444

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Nasopharynx (C11) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 31 46 27 54 9 18 32 84 100 55 132 94 29 12 53 77 34 8 20 27 31 11 17 23 128 5 1 1 15 6 10 8 240 15 10 36 23 45 65 26 96 202 62 69 20 52 178 5 49 19 6 128 31 2 14 73 76 26 20 10 7 9 Male ASR(W) CUM 0-74 0.4 0.5 2.2 0.4 0.4 0.5 0.6 0.9 1.2 0.4 0.8 0.6 0.4 1.3 1.5 1.3 0.8 0.7 1.2 1.0 0.9 0.5 1.0 0.8 0.4 0.4 0.1 0.2 0.9 0.5 1.2 0.3 0.5 0.4 0.3 0.4 0.3 0.3 0.3 0.3 0.4 0.5 0.4 0.4 0.4 0.3 0.9 1.6 0.5 0.4 0.4 0.9 0.6 0.3 2.6 0.6 2.0 9.9 3.3 2.0 0.6 0.8 0.08 0.07 0.42 0.05 0.13 0.11 0.11 0.10 0.12 0.05 0.08 0.07 0.08 0.39 0.22 0.15 0.13 0.30 0.27 0.20 0.16 0.16 0.25 0.18 0.04 0.16 0.12 0.18 0.24 0.21 0.38 0.12 0.03 0.12 0.11 0.07 0.06 0.05 0.04 0.07 0.05 0.03 0.05 0.05 0.09 0.05 0.07 0.75 0.07 0.09 0.17 0.08 0.10 0.21 0.72 0.07 0.24 1.98 0.77 0.65 0.26 0.28 0.05 0.05 0.25 0.04 0.05 0.06 0.07 0.09 0.13 0.05 0.09 0.07 0.05 0.12 0.15 0.15 0.08 0.07 0.12 0.11 0.09 0.05 0.12 0.08 0.04 0.04 0.01 0.03 0.07 0.07 0.10 0.03 0.05 0.04 0.03 0.04 0.03 0.03 0.03 0.04 0.04 0.05 0.04 0.04 0.04 0.03 0.09 0.12 0.05 0.04 0.05 0.10 0.06 0.02 0.29 0.07 0.23 1.08 0.42 0.21 0.06 0.08 0.01 0.01 0.05 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.04 0.02 0.02 0.02 0.04 0.03 0.02 0.02 0.02 0.03 0.02 0.00 0.02 0.01 0.03 0.02 0.03 0.03 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.08 0.01 0.01 0.02 0.01 0.01 0.01 0.09 0.01 0.03 0.22 0.11 0.08 0.03 0.03 Cases 21 25 14 17 4 9 12 28 40 34 53 43 20 1 12 22 12 1 3 6 8 4 6 4 48 1 1 0 2 3 2 6 104 2 1 13 20 31 30 18 58 84 23 30 7 33 75 1 16 7 4 47 8 1 4 32 18 4 8 1 3 0 Female ASR(W) CUM 0-74 0.2 0.2 1.1 0.1 0.1 0.2 0.2 0.2 0.4 0.1 0.3 0.2 0.3 0.1 0.3 0.3 0.3 0.2 0.1 0.3 0.2 0.1 0.3 0.1 0.2 0.1 0.2 0.1 0.3 0.3 0.3 0.2 0.1 0.0 0.1 0.3 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.2 0.4 0.2 0.1 0.1 0.2 0.3 0.1 0.1 0.9 0.3 0.4 1.1 1.3 0.2 0.2 0.05 0.04 0.30 0.03 0.05 0.07 0.06 0.05 0.07 0.03 0.04 0.04 0.07 0.14 0.10 0.07 0.08 0.25 0.08 0.16 0.08 0.07 0.15 0.05 0.03 0.07 0.16 0.08 0.16 0.25 0.12 0.02 0.04 0.03 0.03 0.06 0.04 0.03 0.05 0.03 0.02 0.03 0.03 0.04 0.03 0.04 0.25 0.03 0.04 0.09 0.05 0.05 0.10 0.48 0.05 0.11 0.60 0.45 0.24 0.15 0.02 0.02 0.13 0.01 0.01 0.02 0.02 0.02 0.04 0.02 0.03 0.03 0.03 0.01 0.03 0.03 0.03 0.02 0.02 0.02 0.02 0.01 0.04 0.01 0.01 0.01 0.01 0.01 0.03 0.02 0.03 0.02 0.01 0.00 0.01 0.02 0.02 0.01 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.04 0.03 0.02 0.02 0.01 0.03 0.01 0.01 0.12 0.02 0.05 0.09 0.12 0.03 0.02 0.00 0.00 0.03 0.00 0.01 * 0.01 0.01 0.01 * 0.01 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.02 0.02 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.03 0.00 0.01 0.01 0.01 0.01 0.01 0.06 0.00 0.01 0.05 0.05 0.03 0.02 -

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
387

445

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Hypopharynx (C12-13)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 82 56 1 2 2 6 36 8 45 420 2 10 42 1 30 0 643 76 104 32 33 11 0 30 328 6 23 185 47 138 11 141 827 52 74 116 578 162 17 8 3 0 12 115 213 34 5 2 3 5 48 111 77 142 15 126 52 43 9 738 103 631 287 101 184 66 27 37 27 421 97 315 193 90 138 156 47 108 15 24 Male ASR(W) CUM 0-74 4.4 1.3 0.1 0.3 0.1 0.6 1.5 1.4 3.1 2.1 0.3 0.3 0.5 0.0 2.7 0.8 0.9 0.7 0.8 1.2 0.7 0.9 0.9 1.3 0.6 1.3 1.9 1.2 0.8 0.8 0.8 0.5 1.3 0.8 0.9 0.8 1.3 0.4 0.4 0.7 0.9 0.8 1.4 0.5 0.2 0.6 0.9 0.8 0.8 0.6 1.2 2.2 1.2 3.3 4.3 1.7 1.2 2.1 1.1 1.3 2.3 1.1 1.0 1.5 0.8 0.7 1.1 2.3 1.0 1.0 0.9 1.1 1.2 1.6 1.1 1.7 1.1 0.49 0.18 0.10 0.21 0.13 0.27 0.27 0.52 0.47 0.11 0.18 0.09 0.09 0.02 0.51 0.03 0.10 0.07 0.15 0.22 0.20 0.17 0.05 0.55 0.13 0.10 0.28 0.10 0.25 0.07 0.03 0.07 0.16 0.07 0.04 0.07 0.33 0.16 0.23 0.19 0.09 0.06 0.24 0.24 0.16 0.38 0.41 0.12 0.08 0.07 0.11 0.58 0.11 0.46 0.67 0.59 0.05 0.20 0.05 0.08 0.24 0.08 0.12 0.30 0.14 0.14 0.06 0.24 0.06 0.07 0.10 0.09 0.10 0.23 0.11 0.44 0.24 0.09 0.19 0.25 0.38 0.27 0.03 0.03 0.06 0.33 0.11 0.12 0.08 0.13 0.15 0.09 0.12 0.12 0.18 0.10 0.17 0.25 0.15 0.13 0.11 0.11 0.06 0.16 0.09 0.12 0.11 0.16 0.06 0.07 0.09 0.13 0.11 0.16 0.08 0.02 0.11 0.09 0.10 0.11 0.08 0.16 0.33 0.16 0.47 0.58 0.31 0.16 0.29 0.15 0.17 0.31 0.14 0.13 0.16 0.11 0.09 0.15 0.29 0.13 0.12 0.12 0.13 0.15 0.21 0.14 0.22 0.14 0.05 0.04 0.10 0.07 0.02 0.02 0.01 0.01 0.07 0.01 0.02 0.01 0.03 0.03 0.03 0.03 0.01 0.08 0.02 0.01 0.04 0.01 0.04 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.05 0.03 0.04 0.03 0.01 0.01 0.03 0.04 0.02 0.06 0.05 0.02 0.01 0.01 0.02 0.10 0.02 0.07 0.10 0.11 0.01 0.03 0.01 0.01 0.04 0.01 0.02 0.05 0.02 0.02 0.01 0.03 0.01 0.01 0.01 0.01 0.01 0.04 0.02 0.07 0.04 Cases 9 56 1 0 1 0 1 0 5 54 0 1 6 1 4 0 126 11 25 8 3 0 0 7 67 1 4 30 8 22 1 35 274 12 19 14 229 64 6 0 1 2 5 48 64 9 1 0 4 0 2 48 13 41 3 38 14 9 4 212 17 193 69 14 55 17 2 15 13 100 19 79 49 27 35 43 13 30 6 7 Female ASR(W) CUM 0-74 0.5 1.0 0.1 0.1 0.0 0.3 0.2 0.0 0.1 0.0 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.1 0.3 0.1 0.3 0.3 0.4 0.1 0.4 0.2 0.3 0.2 0.3 0.1 0.8 0.0 0.3 0.1 0.3 0.3 0.3 0.6 0.6 0.5 0.3 0.3 0.3 0.3 0.2 0.3 0.2 0.1 0.3 0.3 0.2 0.3 0.2 0.2 0.2 0.2 0.3 0.3 0.3 0.5 0.3 0.16 0.14 0.11 0.15 0.03 0.13 0.03 0.03 0.03 0.03 0.12 0.01 0.04 0.03 0.08 0.08 0.07 0.02 0.22 0.07 0.03 0.09 0.04 0.06 0.03 0.02 0.03 0.07 0.02 0.02 0.04 0.18 0.10 0.30 0.10 0.05 0.03 0.10 0.05 0.43 0.01 0.05 0.03 0.05 0.16 0.05 0.18 0.22 0.25 0.02 0.06 0.02 0.03 0.06 0.04 0.05 0.05 0.08 0.09 0.02 0.08 0.03 0.03 0.05 0.04 0.04 0.10 0.05 0.22 0.12 0.00 0.03 0.02 0.00 0.01 0.00 0.02 0.02 0.02 0.02 0.02 0.01 0.02 0.02 0.04 0.02 0.02 0.03 0.02 0.01 0.02 0.03 0.01 0.03 0.01 0.04 0.04 0.06 0.02 0.02 0.02 0.05 0.02 0.03 0.08 0.04 0.01 0.04 0.02 0.04 0.09 0.09 0.06 0.04 0.03 0.04 0.03 0.03 0.03 0.03 0.01 0.04 0.03 0.03 0.04 0.03 0.02 0.03 0.03 0.03 0.04 0.03 0.07 0.04 * * * *

0.00 0.01 0.00 0.00 0.00 0.00 0.01 - * 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.04 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.03 0.02 0.02 0.01 0.01 0.00 0.01 0.05 0.01 0.00 0.01 0.02 0.01 0.03 0.03 0.05 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.03 0.02

446

*Important. See note on population page.

388

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Hypopharynx (C12-13) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 45 270 355 88 260 167 68 97 157 31 125 20 7101 1170 5763 270 58 202 31 1 14 15 532 91 429 339 46 284 94 84 433 80 345 46 788 130 583 2080 118 317 162 1467 179 81 97 553 73 474 29 22 136 96 64 210 3 77 310 6 6 42 28 2 460 430 23 840 119 151 52 33 27 4 36 23 67 142 127 560 71 Male ASR(W) CUM 0-74 1.0 1.3 1.1 2.8 0.9 1.4 3.0 1.0 0.9 2.3 0.8 0.6 1.0 2.0 0.9 1.0 2.1 0.9 0.5 0.4 0.7 0.4 0.9 1.4 0.9 0.9 1.5 0.9 0.8 0.8 1.0 2.8 0.8 1.3 1.0 1.9 0.9 0.9 0.7 1.8 0.8 0.9 1.4 3.1 1.0 1.0 1.5 1.0 0.6 1.0 0.7 0.8 0.9 1.3 0.6 1.3 1.4 0.5 0.2 0.2 0.8 0.1 5.1 2.3 2.6 4.1 3.1 2.4 2.0 0.2 0.2 0.3 0.9 0.6 1.6 1.4 1.9 1.5 1.1 0.15 0.08 0.06 0.31 0.06 0.11 0.37 0.10 0.07 0.42 0.07 0.15 0.01 0.06 0.01 0.06 0.27 0.06 0.09 0.38 0.19 0.11 0.04 0.15 0.04 0.05 0.23 0.05 0.09 0.09 0.05 0.32 0.05 0.21 0.04 0.18 0.04 0.02 0.06 0.10 0.06 0.02 0.11 0.35 0.10 0.04 0.18 0.04 0.12 0.22 0.07 0.08 0.12 0.09 0.33 0.15 0.08 0.19 0.10 0.03 0.16 0.07 0.24 0.12 0.55 0.14 0.29 0.20 0.28 0.04 0.04 0.16 0.15 0.12 0.20 0.12 0.18 0.06 0.14 0.13 0.17 0.15 0.34 0.12 0.18 0.37 0.13 0.11 0.29 0.09 0.08 0.13 0.26 0.12 0.14 0.27 0.13 0.06 0.06 0.07 0.05 0.11 0.17 0.11 0.12 0.19 0.11 0.11 0.11 0.12 0.37 0.10 0.18 0.13 0.25 0.12 0.12 0.08 0.23 0.10 0.12 0.19 0.41 0.12 0.13 0.18 0.12 0.07 0.12 0.10 0.11 0.12 0.17 0.04 0.16 0.17 0.05 0.04 0.02 0.11 0.01 0.63 0.30 0.28 0.54 0.38 0.30 0.27 0.03 0.03 0.04 0.12 0.07 0.23 0.18 0.24 0.19 0.14 0.02 0.01 0.01 0.04 0.01 0.02 0.05 0.02 0.01 0.06 0.01 0.02 0.00 0.01 0.00 0.01 0.04 0.01 0.01 0.06 0.03 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.01 0.01 0.01 0.05 0.01 0.03 0.01 0.03 0.01 0.00 0.01 0.02 0.01 0.00 0.02 0.05 0.01 0.01 0.03 0.01 0.02 0.03 0.01 0.01 0.02 0.01 0.04 0.02 0.01 0.03 0.02 0.00 0.02 0.01 0.03 0.02 0.07 0.02 0.04 0.03 0.04 0.01 0.01 0.02 0.02 0.02 0.03 0.02 0.02 0.01 0.02 Cases 14 86 75 19 55 33 15 18 45 5 40 8 2002 260 1702 74 9 63 9 1 3 5 171 33 137 92 9 82 14 34 124 12 111 11 232 28 195 618 16 68 23 506 47 16 31 161 25 134 9 3 55 43 13 62 2 6 30 4 1 7 0 2 166 95 3 183 41 65 6 20 15 4 4 5 14 25 11 51 23 Female ASR(W) CUM 0-74 0.3 0.3 0.2 0.5 0.2 0.2 0.5 0.1 0.2 0.3 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.2 0.3 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.3 0.2 0.3 0.2 0.3 0.2 0.2 0.1 0.3 0.1 0.3 0.3 0.5 0.3 0.2 0.4 0.2 0.1 0.1 0.3 0.3 0.1 0.3 0.4 0.1 0.1 0.2 0.0 0.0 0.1 1.8 0.5 0.3 0.9 1.0 1.0 0.2 0.1 0.1 0.2 0.1 0.1 0.3 0.2 0.2 0.1 0.3 0.08 0.04 0.02 0.11 0.02 0.04 0.13 0.04 0.03 0.13 0.03 0.09 0.01 0.02 0.01 0.03 0.08 0.03 0.05 0.23 0.08 0.06 0.02 0.06 0.02 0.02 0.07 0.03 0.03 0.05 0.02 0.09 0.02 0.09 0.02 0.06 0.02 0.01 0.02 0.04 0.02 0.01 0.05 0.12 0.05 0.02 0.08 0.02 0.05 0.08 0.04 0.05 0.04 0.05 0.27 0.04 0.03 0.13 0.03 0.01 0.07 0.14 0.06 0.20 0.07 0.16 0.12 0.08 0.03 0.03 0.11 0.06 0.03 0.08 0.04 0.05 0.02 0.08 0.04 0.05 0.02 0.05 0.02 0.03 0.06 0.02 0.02 0.03 0.02 0.03 0.03 0.04 0.03 0.02 0.03 0.02 0.02 0.02 0.02 0.01 0.03 0.04 0.03 0.03 0.02 0.03 0.02 0.04 0.03 0.03 0.03 0.04 0.03 0.04 0.03 0.03 0.01 0.04 0.01 0.03 0.04 0.06 0.03 0.03 0.05 0.03 0.02 0.02 0.03 0.04 0.02 0.05 0.04 0.01 0.01 0.02 0.00 0.00 0.01 0.21 0.06 0.04 0.10 0.12 0.12 0.02 0.01 0.01 0.01 0.01 0.00 0.04 0.03 0.02 0.01 0.04 0.01 0.01 0.00 0.01 0.00 0.01 0.02 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.01 * 0.00 0.01 * 0.00 0.00 * - * 0.01 * 0.02 0.01 * 0.03 0.01 0.02 * 0.02 * 0.01 * 0.00 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
389

447

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Hypopharynx (C12-13) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
390

Male ASR(W) CUM 0-74 1.3 1.0 1.2 1.0 1.5 1.2 1.1 1.2 0.7 0.3 1.0 1.3 0.6 0.2 4.6 0.4 1.0 1.0 1.4 0.7 1.4 0.5 2.7 0.0 0.6 2.3 2.0 1.6 2.8 1.5 1.7 1.1 4.8 1.6 1.3 1.9 0.5 8.0 9.6 7.3 4.5 4.3 4.7 6.1 9.8 10.2 3.9 5.0 3.1 2.3 2.4 3.3 3.2 2.6 3.2 0.6 0.8 2.5 3.1 0.9 0.7 1.3 0.1 1.2 0.7 0.7 3.5 1.4 0.5 0.4 0.5 2.0 0.3 2.0 1.6 0.7 2.2 1.8 0.04 0.12 0.16 0.20 0.26 0.17 0.42 0.09 0.26 0.19 0.55 0.28 0.14 0.11 0.46 0.09 0.12 0.13 0.47 0.30 0.19 0.16 0.32 0.04 0.09 0.09 0.31 0.38 0.10 0.16 0.10 0.06 0.18 0.07 0.08 0.21 0.05 0.50 0.70 0.66 0.43 0.38 0.36 0.41 0.77 0.77 0.57 0.51 0.18 0.12 0.20 0.23 0.20 0.17 0.28 0.29 0.09 0.59 0.37 0.25 0.12 0.23 0.12 0.18 0.17 0.21 0.21 0.30 0.16 0.10 0.14 0.35 0.16 0.56 0.22 0.14 0.35 0.17 0.16 0.13 0.15 0.12 0.19 0.15 0.17 0.15 0.07 0.06 0.03 0.14 0.07 0.02 0.58 0.05 0.12 0.13 0.17 0.10 0.15 0.07 0.35 0.07 0.27 0.24 0.20 0.34 0.19 0.21 0.12 0.59 0.19 0.15 0.22 0.06 1.01 1.19 0.87 0.56 0.49 0.56 0.75 1.20 1.24 0.43 0.55 0.36 0.26 0.29 0.39 0.38 0.30 0.37 0.10 0.11 0.30 0.41 0.12 0.08 0.17 0.02 0.15 0.11 0.09 0.44 0.19 0.06 0.05 0.06 0.23 0.04 0.26 0.18 0.08 0.30 0.21 0.01 0.02 0.02 0.03 0.04 0.03 0.08 0.01 0.03 0.04 0.02 0.04 0.02 0.01 0.07 0.01 0.02 0.02 0.06 0.04 0.03 0.02 0.05 0.01 0.01 0.04 0.05 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.07 0.09 0.09 0.06 0.05 0.05 0.05 0.10 0.10 0.07 0.06 0.02 0.01 0.02 0.03 0.02 0.02 0.03 0.05 0.01 0.07 0.05 0.03 0.02 0.03 0.02 0.02 0.03 0.03 0.03 0.04 0.02 0.01 0.02 0.04 0.02 0.08 0.03 0.02 0.05 0.02

Cases 77 9 2 0 3 1 0 17 0 2 2 8 10 6 34 11 12 7 3 2 16 4 14 2 22 83 4 2 9 17 41 39 68 60 68 1 21 14 10 8 5 15 16 10 6 7 2 5 29 44 19 17 31 33 24 1 37 3 12 2 7 7 0 11 9 1 22 1 0 2 3 2 3 0 1 6 1 3 18

Female ASR(W) CUM 0-74 0.1 0.1 0.0 0.1 0.0 0.1 0.2 0.3 0.4 0.3 0.3 1.8 0.1 0.1 0.1 0.6 0.2 0.4 0.2 0.5 0.1 0.3 0.3 0.2 0.1 0.0 0.3 0.2 0.1 0.3 0.1 0.3 0.0 0.1 0.4 0.4 0.4 0.2 0.4 0.4 0.3 0.3 0.3 0.1 0.3 0.3 0.2 0.3 0.2 0.3 0.3 0.6 0.2 0.3 0.2 0.4 0.1 0.1 0.3 0.2 0.4 0.1 0.2 0.1 0.1 0.0 0.1 0.2 0.2 0.1 0.0 0.1 0.2 0.01 0.03 0.02 0.04 0.02 0.02 0.18 0.30 0.13 0.09 0.14 0.33 0.04 0.04 0.04 0.35 0.14 0.10 0.09 0.12 0.04 0.05 0.03 0.08 0.10 0.01 0.07 0.04 0.02 0.04 0.02 0.04 0.01 0.02 0.12 0.14 0.14 0.09 0.12 0.10 0.09 0.15 0.13 0.10 0.12 0.05 0.03 0.06 0.06 0.06 0.06 0.13 0.15 0.05 0.10 0.13 0.10 0.04 0.11 0.07 0.13 0.07 0.05 0.06 0.07 0.01 0.05 0.10 0.15 0.06 0.04 0.08 0.06 0.01 0.01 0.00 0.00 0.01 0.03 0.08 0.05 0.03 0.04 0.20 0.01 0.02 0.01 0.12 0.04 0.04 0.02 0.05 0.01 0.03 0.03 0.02 0.03 0.00 0.04 0.03 0.01 0.04 0.01 0.04 0.00 0.01 0.06 0.05 0.04 0.03 0.05 0.04 0.03 0.03 0.03 0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.04 0.07 0.01 0.04 0.02 0.06 0.02 0.01 0.03 0.02 0.04 0.01 0.02 0.01 0.01 0.01 0.02 0.02 0.02 0.00 0.01 0.03 0.00 0.00 0.00 0.00 0.00 0.03 0.08 0.02 0.01 0.02 * 0.04 * 0.00 * 0.01 0.01 0.07 0.03 0.01 * 0.01 * 0.02 0.00 * 0.01 * 0.00 0.01 0.02 0.00 * 0.01 * 0.00 0.00 * 0.01 0.00 0.01 0.00 0.00 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.00 0.01 0.01

1061 81 61 24 36 52 7 238 9 3 13 22 23 5 108 27 78 62 10 6 55 12 73 1 48 603 42 17 798 88 296 307 752 567 244 78 96 263 198 125 111 132 174 229 177 182 52 101 298 385 156 217 279 235 129 5 95 20 73 16 35 33 1 48 20 10 303 24 0 9 15 15 34 5 13 60 28 42 108

448

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Hypopharynx (C12-13) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 183 304 7 116 16 22 72 139 197 429 295 746 233 16 195 269 190 8 57 51 62 55 52 45 247 50 13 23 29 28 31 92 662 38 62 62 78 134 223 47 133 333 117 166 41 247 216 16 149 40 10 161 62 8 6 80 59 8 6 11 19 13 Male ASR(W) CUM 0-74 2.5 3.1 0.6 0.7 0.7 0.6 1.2 1.5 2.1 3.1 1.8 4.8 3.4 1.6 4.7 4.4 4.4 1.1 3.0 2.0 1.8 2.7 3.1 1.4 0.6 3.6 1.8 4.0 1.7 2.5 3.1 4.2 1.2 1.1 1.8 0.5 0.8 0.9 0.9 0.5 0.5 0.7 0.6 0.8 0.7 1.3 0.9 3.7 1.2 0.7 0.5 1.0 1.0 0.9 1.5 0.6 1.4 2.1 0.9 2.2 1.7 1.3 0.19 0.18 0.22 0.07 0.18 0.12 0.15 0.13 0.15 0.15 0.11 0.18 0.23 0.43 0.35 0.28 0.33 0.43 0.41 0.29 0.23 0.37 0.45 0.22 0.04 0.52 0.49 0.85 0.31 0.47 0.58 0.45 0.05 0.17 0.23 0.07 0.10 0.08 0.06 0.07 0.04 0.04 0.06 0.06 0.11 0.08 0.07 1.00 0.10 0.12 0.18 0.08 0.13 0.32 0.62 0.07 0.20 0.80 0.39 0.68 0.43 0.36 0.30 0.37 0.08 0.09 0.08 0.07 0.15 0.17 0.25 0.39 0.21 0.54 0.43 0.19 0.57 0.51 0.53 0.13 0.38 0.24 0.22 0.34 0.38 0.16 0.09 0.47 0.22 0.44 0.21 0.32 0.37 0.57 0.15 0.11 0.24 0.07 0.10 0.12 0.11 0.06 0.05 0.09 0.08 0.10 0.08 0.17 0.12 0.57 0.17 0.08 0.08 0.13 0.13 0.13 0.26 0.09 0.19 0.22 0.11 0.28 0.25 0.19 0.02 0.02 0.03 0.01 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.02 0.03 0.05 0.04 0.03 0.04 0.05 0.05 0.04 0.03 0.05 0.05 0.03 0.01 0.07 0.06 0.10 0.04 0.06 0.07 0.07 0.01 0.02 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.19 0.02 0.02 0.03 0.01 0.02 0.05 0.11 0.01 0.03 0.10 0.06 0.10 0.06 0.06 Cases 9 13 3 30 3 1 15 4 11 22 65 22 17 0 2 8 5 0 0 1 6 2 1 0 54 7 4 6 2 5 7 20 188 10 12 29 37 54 77 17 52 128 43 78 12 98 50 1 25 5 3 37 7 1 0 15 9 0 0 1 1 7 Female ASR(W) CUM 0-74 0.1 0.1 0.2 0.2 0.1 0.0 0.2 0.0 0.1 0.1 0.4 0.1 0.2 0.0 0.1 0.1 0.0 0.2 0.1 0.0 0.1 0.5 0.4 0.9 0.1 0.4 0.8 0.9 0.3 0.3 0.3 0.2 0.3 0.3 0.2 0.1 0.1 0.2 0.2 0.3 0.2 0.4 0.2 0.2 0.2 0.1 0.2 0.2 0.1 0.1 0.1 0.2 0.2 0.0 0.5 0.03 0.03 0.12 0.04 0.05 0.03 0.05 0.02 0.03 0.02 0.05 0.03 0.06 0.03 0.05 0.05 0.02 0.07 0.08 0.02 0.02 0.18 0.22 0.37 0.06 0.17 0.29 0.20 0.02 0.09 0.10 0.04 0.06 0.04 0.03 0.04 0.02 0.02 0.03 0.04 0.05 0.05 0.03 0.20 0.04 0.04 0.09 0.03 0.05 0.10 0.03 0.06 0.18 0.04 0.20 0.01 0.01 0.03 0.02 0.02 0.00 0.02 0.00 0.01 0.01 0.04 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.05 0.03 0.10 0.01 0.05 0.09 0.10 0.03 0.03 0.03 0.03 0.04 0.04 0.03 0.02 0.02 0.03 0.02 0.04 0.02 0.05 0.03 0.02 0.03 0.01 0.01 0.03 0.02 0.01 0.01 0.02 0.02 0.01 0.04 0.00 0.00 0.02 0.00 0.01 * 0.00 0.01 0.00 * 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.02 0.02 0.04 0.01 0.02 0.04 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.02 0.01 0.03

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
391

449

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Pharynx unspecified (C14)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 2 8 1 1 1 6 23 21 4 228 2 16 16 2 15 0 282 27 29 12 6 9 0 16 171 0 12 63 16 46 5 59 253 8 23 20 196 27 4 0 1 0 2 20 59 7 1 1 1 0 7 39 72 31 2 29 13 10 2 468 44 419 98 34 64 28 14 14 8 169 43 120 72 17 50 78 29 49 10 10 Male ASR(W) CUM 0-74 0.1 0.2 0.1 0.0 0.1 0.7 0.9 3.5 0.3 1.1 0.2 0.5 0.2 0.1 1.3 0.4 0.3 0.2 0.3 0.2 0.5 0.4 0.4 0.4 0.4 0.7 0.4 0.3 0.4 0.3 0.1 0.4 0.1 0.3 0.1 0.3 0.1 0.1 0.2 0.2 0.3 0.1 0.1 0.1 0.1 0.3 0.6 0.2 0.3 0.2 0.8 0.9 0.4 0.8 0.8 0.8 0.4 0.7 0.4 0.4 0.8 0.3 0.2 0.5 1.0 0.4 0.4 0.1 0.4 0.6 1.0 0.5 1.1 0.5 0.08 0.06 0.10 0.03 0.07 0.30 0.20 0.79 0.15 0.08 0.15 0.13 0.06 0.06 0.35 0.02 0.06 0.04 0.09 0.09 0.17 0.12 0.03 0.11 0.06 0.17 0.06 0.13 0.05 0.02 0.03 0.09 0.03 0.02 0.03 0.17 0.10 0.08 0.04 0.03 0.12 0.07 0.13 0.14 0.05 0.05 0.07 0.05 0.21 0.05 0.23 0.31 0.27 0.04 0.13 0.04 0.05 0.13 0.05 0.08 0.22 0.09 0.07 0.04 0.16 0.04 0.05 0.04 0.05 0.07 0.19 0.07 0.36 0.16 0.10 0.11 0.39 0.05 0.13 0.01 0.06 0.02 0.01 0.18 0.04 0.04 0.03 0.04 0.03 0.08 0.05 0.05 0.05 0.06 0.10 0.05 0.03 0.05 0.03 0.01 0.05 0.02 0.04 0.02 0.04 0.01 0.02 0.02 0.03 0.04 0.03 0.04 0.02 0.04 0.07 0.02 0.04 0.02 0.09 0.11 0.05 0.10 0.11 0.10 0.05 0.08 0.05 0.05 0.07 0.05 0.02 0.06 0.13 0.05 0.05 0.02 0.04 0.08 0.14 0.06 0.14 0.05 0.05 0.03 0.10 0.03 0.01 0.01 0.02 0.01 0.01 0.05 0.00 0.01 0.01 0.01 0.01 0.03 0.02 0.00 0.02 0.01 0.03 0.01 0.02 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.02 0.01 0.02 0.01 0.01 0.02 0.03 0.04 0.01 0.01 0.01 0.01 0.03 0.01 0.03 0.04 0.03 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.05 0.02 Cases 1 8 0 1 0 2 7 8 0 62 0 6 5 1 1 0 128 10 13 2 1 1 0 5 92 0 4 22 5 17 2 27 142 2 11 7 119 23 1 0 0 0 1 20 28 6 2 0 0 0 1 19 21 13 4 9 2 1 1 199 16 182 35 8 26 9 2 7 4 62 11 50 29 6 17 23 8 15 2 6 Female ASR(W) CUM 0-74 0.1 0.1 0.1 0.2 0.2 1.1 0.2 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.0 0.1 0.0 0.2 0.1 0.1 0.0 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.5 0.1 0.1 0.1 0.2 0.2 0.2 0.3 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.2 0.06 0.05 0.09 0.12 0.08 0.38 0.03 0.05 0.02 0.02 0.14 0.01 0.03 0.02 0.03 0.01 0.05 0.07 0.02 0.06 0.03 0.06 0.03 0.13 0.03 0.01 0.01 0.04 0.01 0.02 0.02 0.06 0.03 0.03 0.02 0.07 0.11 0.01 0.03 0.03 0.03 0.25 0.03 0.08 0.08 0.20 0.02 0.06 0.02 0.02 0.06 0.02 0.05 0.08 0.05 0.05 0.02 0.06 0.02 0.02 0.02 0.02 0.03 0.06 0.03 0.08 0.09 0.01 0.02 0.09 0.02 0.01 0.00 0.01 0.02 0.01 0.01 0.00 0.00 0.02 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.00 0.01 0.00 0.02 0.01 0.01 0.00 0.02 0.01 0.02 0.02 0.00 0.01 0.02 0.02 0.09 0.01 0.01 0.01 0.02 0.03 0.03 0.03 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.00 0.01 0.02 0.02 0.01 0.02 0.02 * * * *

0.01 0.01 0.04 0.00 0.01 0.00 0.01 - * 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.02 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.02 0.00 0.00 0.01 0.00 0.05 0.00 0.01 0.01 0.02 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.02 0.01

450

*Important. See note on population page.

392

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Pharynx unspecified (C14) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 22 63 137 23 113 73 20 51 70 8 62 10 2892 448 2382 91 22 67 15 0 4 11 235 47 181 135 21 112 56 26 146 27 117 6 238 41 191 689 13 118 32 518 67 22 45 264 44 216 14 7 49 33 22 52 0 10 9 0 5 8 9 2 60 86 1 198 24 28 9 14 12 2 14 3 12 10 37 66 14 Male ASR(W) CUM 0-74 0.5 0.3 0.5 0.7 0.4 0.6 0.8 0.6 0.4 0.6 0.4 0.3 0.4 0.7 0.4 0.3 0.8 0.3 0.3 0.2 0.3 0.4 0.7 0.3 0.4 0.7 0.3 0.5 0.2 0.3 1.0 0.3 0.2 0.3 0.6 0.3 0.3 0.1 0.7 0.2 0.3 0.5 0.8 0.5 0.5 0.9 0.4 0.3 0.4 0.2 0.2 0.4 0.3 0.2 0.0 0.3 0.0 0.3 0.1 0.6 0.4 0.1 1.0 0.6 0.4 0.3 0.1 0.1 0.1 0.4 0.1 0.3 0.1 0.5 0.2 0.2 0.11 0.04 0.04 0.14 0.04 0.08 0.19 0.08 0.05 0.20 0.05 0.10 0.01 0.04 0.01 0.04 0.18 0.04 0.07 0.12 0.10 0.03 0.10 0.03 0.03 0.16 0.03 0.07 0.05 0.03 0.19 0.03 0.08 0.02 0.10 0.02 0.01 0.02 0.06 0.03 0.01 0.07 0.18 0.07 0.03 0.14 0.03 0.07 0.15 0.04 0.05 0.08 0.04 0.06 0.01 0.15 0.01 0.10 0.04 0.09 0.05 0.12 0.07 0.12 0.09 0.11 0.02 0.02 0.09 0.11 0.05 0.10 0.03 0.09 0.02 0.06 0.06 0.04 0.06 0.08 0.06 0.08 0.10 0.08 0.05 0.06 0.05 0.03 0.05 0.09 0.05 0.04 0.11 0.04 0.04 0.03 0.05 0.05 0.08 0.04 0.05 0.08 0.04 0.06 0.03 0.04 0.12 0.03 0.04 0.04 0.07 0.04 0.04 0.01 0.08 0.02 0.04 0.06 0.11 0.05 0.06 0.11 0.05 0.03 0.04 0.03 0.03 0.04 0.04 0.02 0.01 0.02 0.00 0.04 0.08 0.06 0.02 0.12 0.07 0.06 0.05 0.01 0.01 0.01 0.06 0.01 0.04 0.01 0.07 0.02 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.01 0.03 0.01 0.01 0.00 0.01 0.00 0.01 0.03 0.01 0.01 0.02 0.02 0.00 0.01 0.00 0.00 0.02 0.00 0.01 0.01 0.00 0.03 0.00 0.02 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.03 0.01 0.00 0.02 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.02 0.01 0.02 0.00 0.00 0.01 0.02 0.01 0.01 0.00 0.01 0.00 0.01 Cases 4 33 44 8 36 16 4 12 28 3 25 2 1168 156 990 52 9 42 5 0 1 4 89 23 65 61 11 48 17 10 53 12 39 4 98 11 87 318 3 41 13 258 27 10 17 87 7 77 7 3 30 23 9 24 0 1 1 0 3 3 1 3 29 15 1 55 9 11 2 10 9 1 0 1 2 2 5 15 1 Female ASR(W) CUM 0-74 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.0 0.1 0.2 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.3 0.1 0.1 0.3 0.2 0.2 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.05 0.02 0.02 0.06 0.02 0.03 0.06 0.03 0.02 0.09 0.02 0.04 0.00 0.02 0.00 0.02 0.07 0.02 0.05 0.07 0.05 0.01 0.05 0.01 0.02 0.08 0.02 0.03 0.03 0.01 0.07 0.01 0.05 0.01 0.04 0.01 0.01 0.01 0.03 0.01 0.01 0.03 0.08 0.03 0.01 0.04 0.02 0.04 0.07 0.03 0.04 0.04 0.03 0.02 0.00 0.08 0.01 0.03 0.10 0.06 0.02 0.12 0.04 0.07 0.05 0.05 0.01 0.01 0.06 0.01 0.04 0.01 0.03 0.01 0.01 0.01 0.02 0.02 0.03 0.01 0.02 0.02 0.02 0.01 0.02 0.01 0.01 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.00 0.01 0.01 0.02 0.01 0.02 0.03 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.02 0.01 0.00 0.02 0.00 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.02 0.02 0.02 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.03 0.01 0.01 0.03 0.02 0.02 0.01 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.00 0.02 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.01 0.00 0.00 * 0.00 - * 0.01 0.00 * 0.00 * 0.01 * 0.01 0.00 * 0.01 0.01 0.01 * 0.01 * 0.01 * 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
393

451

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Pharynx unspecified (C14) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
394

Male ASR(W) CUM 0-74 0.2 0.1 0.3 0.1 0.4 0.2 0.3 0.1 0.3 0.0 0.2 0.1 0.6 0.9 0.1 0.1 0.1 0.1 0.3 0.0 0.0 0.3 0.3 1.0 0.1 0.2 0.4 0.2 0.4 0.1 0.1 0.2 0.0 1.8 0.6 0.3 2.0 0.5 0.6 1.1 1.4 3.0 0.1 1.0 0.3 0.2 0.8 1.0 0.3 0.3 0.4 0.4 0.3 0.3 0.2 0.4 0.4 0.3 0.2 0.2 1.8 0.1 0.1 0.1 0.3 0.2 1.6 0.4 0.3 0.3 0.1 0.1 1.5 0.01 0.04 0.08 0.06 0.14 0.07 0.22 0.03 0.17 0.02 0.09 0.05 0.17 0.12 0.04 0.05 0.05 0.05 0.10 0.03 0.01 0.04 0.12 0.31 0.02 0.05 0.05 0.03 0.05 0.02 0.03 0.08 0.02 0.23 0.17 0.15 0.29 0.13 0.13 0.17 0.30 0.42 0.10 0.23 0.06 0.04 0.12 0.13 0.05 0.10 0.06 0.22 0.11 0.12 0.06 0.12 0.26 0.09 0.08 0.11 0.15 0.09 0.09 0.09 0.08 0.09 0.31 0.18 0.19 0.08 0.04 0.06 0.16 0.02 0.02 0.05 0.01 0.06 0.03 0.02 0.01 0.02 0.00 0.01 0.01 0.08 0.12 0.01 0.02 0.01 0.00 0.02 0.00 0.00 0.04 0.04 0.12 0.01 0.02 0.05 0.02 0.05 0.01 0.02 0.03 0.01 0.23 0.09 0.04 0.24 0.07 0.08 0.12 0.17 0.36 0.01 0.11 0.04 0.02 0.10 0.11 0.03 0.04 0.05 0.05 0.03 0.04 0.02 0.05 0.06 0.04 0.02 0.03 0.23 0.01 0.01 0.01 0.03 0.03 0.19 0.03 0.05 0.03 0.01 0.01 0.20 0.00 0.01 0.01 0.01 0.02 0.01 0.02 0.00 0.02 0.00 0.01 0.01 0.03 0.02 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.02 0.04 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.03 0.03 0.02 0.04 0.02 0.02 0.02 0.04 0.05 0.01 0.03 0.01 0.00 0.02 0.01 0.01 0.01 0.01 0.03 0.01 0.02 0.01 0.02 0.03 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.04 0.02 0.04 0.01 0.01 0.01 0.02

Cases 22 3 1 0 0 2 0 4 0 0 0 2 2 1 6 32 4 2 1 1 3 2 0 2 2 17 1 0 4 1 12 13 10 14 9 4 6 5 4 0 6 0 5 1 0 1 2 4 2 10 19 7 0 10 3 0 17 0 2 1 3 1 2 1 0 0 42 0 0 1 2 2 3 0 0 6 2 0 21

Female ASR(W) CUM 0-74 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.4 0.1 0.0 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.2 0.1 0.0 0.1 0.1 0.2 0.0 0.0 0.2 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.3 0.0 0.4 0.0 0.0 0.1 0.1 0.1 0.0 0.3 0.00 0.02 0.02 0.03 0.01 0.06 0.04 0.08 0.09 0.07 0.03 0.04 0.21 0.08 0.04 0.05 0.04 0.02 0.01 0.04 0.01 0.02 0.02 0.01 0.02 0.01 0.01 0.02 0.01 0.07 0.10 0.09 0.06 0.03 0.06 0.10 0.10 0.01 0.01 0.06 0.03 0.03 0.01 0.03 0.02 0.02 0.03 0.04 0.22 0.02 0.07 0.01 0.02 0.05 0.05 0.03 0.02 0.07 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.01 0.02 0.05 0.00 0.00 0.03 0.01 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.02 0.02 0.02 0.01 0.00 0.01 0.02 0.02 0.00 0.01 0.03 0.01 0.01 0.02 0.00 0.01 0.03 0.00 0.05 0.01 0.00 0.01 0.01 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 * 0.01 * 0.01 * 0.00 0.00 0.03 0.01 0.01 * 0.00 * 0.00 * 0.00 * 0.00 0.01 0.00 * 0.00 * 0.00 0.00 * 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.02 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.01

126 12 14 4 11 8 2 16 3 0 1 3 2 0 15 60 9 9 0 0 5 2 8 1 1 80 7 10 27 11 82 62 70 46 25 10 10 59 14 5 48 17 21 42 23 53 3 19 32 37 55 66 0 26 13 0 52 3 7 5 8 10 3 12 5 3 148 1 1 3 11 8 27 4 2 10 3 2 99

452

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Pharynx unspecified (C14) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 15 36 0 13 8 9 13 40 62 89 45 40 2 2 34 93 85 2 8 4 30 12 7 9 10 5 0 4 1 4 1 11 37 3 2 14 42 78 84 30 109 173 71 37 33 89 105 5 71 11 7 57 24 2 7 25 5 0 1 0 1 3 Male ASR(W) CUM 0-74 0.2 0.4 0.1 0.3 0.2 0.2 0.4 0.6 0.6 0.3 0.3 0.0 0.2 0.8 1.6 2.0 0.1 0.4 0.1 0.9 0.6 0.5 0.3 0.0 0.4 0.7 0.1 0.4 0.1 0.5 0.1 0.1 0.1 0.1 0.4 0.5 0.4 0.3 0.4 0.4 0.4 0.2 0.6 0.5 0.5 1.2 0.6 0.2 0.4 0.4 0.4 0.2 1.8 0.2 0.1 0.2 0.0 0.2 0.05 0.06 0.02 0.12 0.08 0.07 0.07 0.08 0.07 0.04 0.04 0.02 0.15 0.14 0.16 0.22 0.08 0.16 0.08 0.17 0.19 0.20 0.09 0.01 0.17 0.38 0.06 0.19 0.13 0.15 0.01 0.05 0.04 0.04 0.07 0.06 0.04 0.06 0.04 0.03 0.05 0.03 0.11 0.05 0.05 0.57 0.07 0.06 0.16 0.05 0.08 0.15 0.68 0.04 0.05 0.20 0.03 0.15 0.03 0.05 0.01 0.05 0.03 0.03 0.05 0.07 0.08 0.03 0.03 0.00 0.03 0.10 0.17 0.24 0.02 0.05 0.02 0.10 0.06 0.05 0.03 0.00 0.05 0.10 0.01 0.05 0.02 0.06 0.01 0.01 0.01 0.02 0.06 0.06 0.04 0.04 0.05 0.04 0.04 0.02 0.07 0.06 0.06 0.09 0.08 0.03 0.05 0.04 0.04 0.03 0.22 0.02 0.01 0.03 0.03 0.01 0.01 0.00 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.00 0.02 0.02 0.02 0.03 0.02 0.02 0.01 0.02 0.02 0.02 0.01 0.00 0.03 0.05 0.01 0.03 0.02 0.02 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.05 0.01 0.01 0.02 0.01 0.01 0.03 0.10 0.01 0.01 0.03 0.02 Cases 1 5 2 3 5 3 3 4 11 16 14 8 1 0 1 15 2 0 0 1 2 1 1 1 5 1 0 2 0 2 0 6 8 0 0 6 16 30 30 21 50 77 31 24 16 48 21 1 24 6 6 19 5 0 1 12 2 0 0 0 0 2 Female ASR(W) CUM 0-74 0.0 0.0 0.1 0.0 0.2 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.2 0.0 0.0 0.1 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.2 0.2 0.1 0.3 0.2 0.1 0.3 0.1 0.1 0.3 0.1 0.1 0.3 0.01 0.02 0.10 0.01 0.08 0.04 0.02 0.02 0.04 0.02 0.02 0.01 0.01 0.01 0.06 0.03 0.05 0.03 0.06 0.05 0.02 0.01 0.02 0.11 0.11 0.09 0.00 0.02 0.03 0.03 0.02 0.04 0.03 0.02 0.03 0.02 0.06 0.03 0.02 0.33 0.04 0.03 0.14 0.02 0.04 0.28 0.02 0.05 0.19 0.00 0.00 0.02 0.00 0.02 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.02 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.03 0.01 0.02 0.00 0.00 0.01 0.02 0.01 0.02 0.02 0.01 0.02 0.01 0.03 0.03 0.01 0.02 0.01 0.04 0.01 0.01 0.05 0.01 0.01 0.03 0.00 0.00 0.01 0.00 0.01 * 0.00 0.00 0.00 * 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.01 0.01 0.00 0.00 0.03 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.02 0.00 0.00 0.05 0.00 0.01 0.02

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
395

453

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Oesophagus (C15)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 4 70 5 125 219 58 262 72 115 2406 81 112 159 55 82 26 3568 349 673 171 112 62 5 174 1836 30 156 816 243 569 91 799 4569 282 325 492 3436 912 73 55 14 13 72 661 1036 133 28 13 23 17 189 605 625 714 53 655 179 149 26 3734 433 3276 1292 470 809 359 132 219 210 2562 421 2098 1179 600 763 823 259 557 57 105 Male ASR(W) CUM 0-74 0.2 1.7 0.5 14.1 15.1 6.7 13.1 11.7 8.1 12.0 9.2 3.3 2.1 2.0 7.1 3.1 4.3 3.9 4.3 4.2 4.2 3.3 6.5 5.1 4.5 6.1 4.0 5.7 9.6 4.8 6.3 4.4 4.5 2.5 5.9 3.3 5.0 4.5 5.9 3.4 1.8 3.5 3.6 5.1 4.0 5.4 2.4 1.7 4.5 3.0 3.3 4.4 5.0 6.0 7.9 5.9 10.8 14.8 4.1 5.6 8.4 5.4 5.9 11.1 4.6 5.4 8.2 4.6 5.1 6.6 10.1 6.2 6.0 5.5 5.8 6.1 8.2 5.4 5.9 5.1 0.10 0.22 0.22 1.39 1.15 0.92 0.85 1.43 0.78 0.25 1.04 0.32 0.17 0.28 0.81 0.62 0.08 0.21 0.17 0.34 0.41 0.43 3.05 0.40 0.11 1.14 0.35 0.20 0.63 0.21 0.69 0.16 0.07 0.16 0.33 0.15 0.09 0.16 0.71 0.48 0.48 1.09 0.43 0.21 0.13 0.47 0.48 0.48 0.98 0.74 0.25 0.19 0.20 0.24 1.11 0.25 0.83 1.24 0.84 0.10 0.41 0.10 0.17 0.53 0.17 0.29 0.75 0.32 0.37 0.14 0.50 0.14 0.18 0.24 0.21 0.22 0.52 0.24 0.81 0.53 0.79 1.43 1.51 1.01 1.48 1.06 0.36 0.25 0.26 0.95 0.33 0.54 0.49 0.55 0.53 0.55 0.35 0.93 0.61 0.55 0.78 0.48 0.71 1.22 0.61 0.86 0.55 0.56 0.32 0.77 0.42 0.63 0.58 0.85 0.46 0.27 0.32 0.42 0.66 0.50 0.67 0.30 0.21 0.62 0.28 0.43 0.55 0.63 0.74 1.03 0.73 1.36 1.81 0.56 0.71 1.04 0.68 0.74 1.44 0.57 0.68 1.04 0.58 0.64 0.83 1.27 0.78 0.77 0.67 0.74 0.74 1.00 0.66 0.67 0.62 0.13 0.11 0.22 0.11 0.04 0.15 0.05 0.03 0.05 0.12 0.09 0.01 0.03 0.03 0.05 0.06 0.06 0.55 0.06 0.02 0.17 0.05 0.03 0.09 0.03 0.11 0.02 0.01 0.02 0.05 0.02 0.01 0.02 0.12 0.07 0.08 0.14 0.06 0.03 0.02 0.07 0.07 0.07 0.15 0.10 0.04 0.03 0.03 0.03 0.17 0.04 0.12 0.17 0.15 0.01 0.06 0.01 0.02 0.08 0.02 0.05 0.11 0.05 0.05 0.02 0.07 0.02 0.03 0.03 0.03 0.03 0.07 0.03 0.11 0.08 Cases 4 41 2 78 67 36 95 19 43 621 51 78 55 24 17 5 1424 123 293 68 43 12 0 58 759 6 62 238 72 164 24 243 1677 112 141 140 1273 345 34 10 10 10 19 245 418 72 15 8 6 1 54 258 198 288 36 250 65 58 7 1288 171 1105 419 198 215 129 62 62 62 800 168 616 350 180 205 254 82 171 19 38 Female ASR(W) CUM 0-74 0.2 0.9 0.2 8.4 5.3 3.1 3.9 2.7 2.6 2.2 4.9 1.7 0.6 0.7 1.0 0.4 1.3 1.1 1.5 1.2 1.2 0.4 1.2 1.3 0.8 1.2 1.2 1.9 1.0 1.5 1.0 1.2 0.8 2.0 0.7 1.4 1.3 2.0 0.5 0.7 1.8 0.6 1.4 1.1 2.1 1.1 0.7 0.8 0.1 0.6 1.3 1.3 1.7 3.9 1.6 2.6 3.5 0.8 1.4 2.4 1.3 1.4 3.1 0.9 1.4 2.5 0.9 1.2 1.5 2.8 1.2 1.3 1.2 1.0 1.4 1.9 1.2 1.5 1.3 0.09 0.14 0.16 1.03 0.74 0.57 0.42 0.66 0.39 0.09 0.70 0.20 0.09 0.15 0.27 0.18 0.04 0.11 0.10 0.16 0.20 0.13 0.18 0.05 0.40 0.18 0.08 0.24 0.08 0.32 0.07 0.03 0.08 0.17 0.06 0.05 0.08 0.37 0.18 0.24 0.67 0.15 0.10 0.06 0.26 0.32 0.25 0.35 0.10 0.09 0.10 0.10 0.12 0.66 0.12 0.36 0.50 0.34 0.05 0.19 0.05 0.07 0.24 0.06 0.13 0.34 0.12 0.16 0.06 0.22 0.06 0.08 0.10 0.08 0.10 0.22 0.10 0.35 0.24 0.38 0.50 0.28 0.29 0.26 0.65 0.23 0.06 0.10 0.15 0.04 0.15 0.12 0.16 0.14 0.14 0.03 0.13 0.16 0.08 0.14 0.15 0.25 0.12 0.16 0.12 0.15 0.10 0.27 0.08 0.18 0.16 0.28 0.07 0.08 0.21 0.06 0.18 0.14 0.29 0.16 0.09 0.13 0.07 0.16 0.16 0.22 0.50 0.20 0.36 0.47 0.08 0.17 0.28 0.16 0.17 0.40 0.10 0.16 0.30 0.09 0.16 0.18 0.35 0.15 0.17 0.14 0.13 0.18 0.28 0.15 0.24 0.16 * * * *

0.08 0.07 0.08 0.05 0.01 0.11 0.03 0.01 0.03 0.04 0.03 * 0.01 0.02 0.01 0.03 0.03 0.02 0.02 0.01 0.05 0.03 0.01 0.04 0.01 0.05 0.01 0.01 0.01 0.03 0.01 0.01 0.01 0.06 0.03 0.04 0.09 0.02 0.02 0.01 0.04 0.05 0.04 0.06 0.01 0.01 0.02 0.02 0.10 0.02 0.06 0.08 0.06 0.01 0.03 0.01 0.01 0.04 0.01 0.02 0.05 0.02 0.03 0.01 0.03 0.01 0.01 0.01 0.01 0.01 0.04 0.02 0.06 0.03

454

*Important. See note on population page.

396

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Oesophagus (C15) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 312 1495 2086 280 1791 814 217 591 1088 130 955 173 41538 5264 35284 1646 259 1355 278 11 61 201 3517 556 2861 2412 252 2089 611 703 2875 287 2534 239 4513 503 3715 11756 496 1380 721 9070 898 377 516 2800 352 2410 202 124 1114 748 415 1278 23 514 2030 254 230 2291 532 25 808 1070 69 1369 333 380 91 358 332 15 252 246 503 1656 773 4084 892 Male ASR(W) CUM 0-74 6.5 7.1 6.4 8.8 6.2 6.5 9.3 5.9 5.7 9.5 5.4 5.1 5.7 8.9 5.5 5.8 9.6 5.5 4.6 3.4 3.4 5.5 5.7 8.4 5.4 6.2 8.2 5.9 5.2 5.8 6.2 9.6 5.9 6.7 5.4 8.0 5.3 5.1 2.9 7.9 3.6 5.3 7.1 14.4 5.2 4.9 7.2 4.7 3.7 6.1 5.8 5.8 5.8 6.9 4.2 9.3 9.4 20.2 10.3 9.2 16.5 1.1 9.1 5.5 8.3 6.7 8.7 6.1 3.5 2.1 2.1 1.1 6.4 6.0 12.1 15.4 10.7 10.8 13.0 0.38 0.19 0.15 0.54 0.15 0.24 0.65 0.25 0.18 0.85 0.18 0.40 0.03 0.12 0.03 0.15 0.60 0.16 0.29 1.06 0.44 0.41 0.10 0.36 0.11 0.13 0.53 0.13 0.22 0.23 0.12 0.58 0.13 0.46 0.08 0.36 0.09 0.05 0.14 0.22 0.14 0.06 0.24 0.75 0.23 0.09 0.39 0.10 0.27 0.56 0.18 0.22 0.30 0.20 0.88 0.42 0.21 1.31 0.71 0.20 0.73 0.23 0.32 0.18 1.01 0.19 0.49 0.33 0.37 0.11 0.12 0.29 0.41 0.40 0.54 0.39 0.40 0.17 0.46 0.77 0.90 0.82 1.17 0.79 0.84 1.24 0.75 0.73 1.21 0.70 0.67 0.72 1.14 0.69 0.73 1.34 0.68 0.57 0.44 0.39 0.69 0.72 1.06 0.69 0.78 1.05 0.74 0.64 0.73 0.79 1.24 0.75 0.84 0.68 1.06 0.66 0.64 0.37 1.04 0.44 0.66 0.90 1.91 0.64 0.62 0.94 0.60 0.48 0.77 0.74 0.73 0.69 0.87 0.44 1.03 1.19 2.60 1.08 1.01 2.04 0.12 1.14 0.68 1.12 0.83 1.02 0.75 0.47 0.24 0.24 0.17 0.80 0.78 1.59 1.96 1.39 1.37 1.70 0.05 0.03 0.02 0.08 0.02 0.04 0.10 0.04 0.03 0.13 0.03 0.06 0.00 0.02 0.00 0.02 0.10 0.02 0.04 0.16 0.06 0.06 0.01 0.05 0.02 0.02 0.08 0.02 0.03 0.03 0.02 0.09 0.02 0.07 0.01 0.06 0.01 0.01 0.02 0.03 0.02 0.01 0.03 0.11 0.03 0.01 0.06 0.01 0.04 0.08 0.03 0.03 0.04 0.03 0.12 0.06 0.03 0.19 0.09 0.03 0.10 0.03 0.05 0.03 0.16 0.03 0.07 0.05 0.06 0.02 0.02 0.05 0.06 0.06 0.08 0.06 0.06 0.02 0.07 Cases 93 501 600 110 487 264 90 174 312 54 255 46 13450 2101 10997 613 100 499 51 1 9 39 1382 309 1043 771 110 631 150 224 870 134 723 82 1470 229 1158 3998 169 544 202 3061 244 97 145 854 133 704 45 46 338 230 117 352 10 120 455 70 43 965 60 7 479 598 19 905 214 295 28 228 221 7 37 61 106 327 123 823 150 Female ASR(W) CUM 0-74 1.2 1.5 1.3 2.4 1.2 1.4 2.6 1.1 1.2 2.7 1.0 1.0 1.3 2.5 1.2 1.5 2.6 1.4 0.6 0.1 0.3 0.8 1.5 3.0 1.3 1.4 2.4 1.3 1.0 1.4 1.3 3.1 1.1 1.4 1.3 2.6 1.2 1.3 0.8 2.3 0.8 1.3 1.4 2.5 1.1 1.1 2.0 1.0 0.6 1.6 1.4 1.3 1.2 1.4 1.8 1.8 1.7 4.8 1.7 3.0 1.9 0.3 5.4 3.6 2.0 4.6 5.7 5.0 0.9 0.9 0.9 0.4 0.8 1.1 2.0 2.2 1.2 1.7 1.6 0.15 0.08 0.06 0.25 0.06 0.10 0.29 0.10 0.07 0.39 0.07 0.16 0.01 0.06 0.01 0.07 0.27 0.07 0.09 0.14 0.11 0.13 0.05 0.18 0.05 0.06 0.24 0.06 0.09 0.10 0.05 0.28 0.05 0.19 0.04 0.18 0.04 0.02 0.06 0.10 0.06 0.03 0.10 0.27 0.10 0.04 0.18 0.04 0.10 0.27 0.08 0.10 0.13 0.08 0.58 0.17 0.09 0.60 0.27 0.10 0.25 0.11 0.25 0.15 0.47 0.16 0.40 0.29 0.18 0.06 0.07 0.14 0.14 0.16 0.20 0.14 0.12 0.06 0.16 0.16 0.17 0.16 0.28 0.14 0.17 0.31 0.13 0.14 0.33 0.12 0.15 0.16 0.32 0.15 0.20 0.35 0.18 0.07 0.03 0.10 0.18 0.38 0.15 0.17 0.32 0.15 0.12 0.16 0.16 0.40 0.13 0.15 0.15 0.31 0.14 0.16 0.10 0.30 0.09 0.16 0.17 0.29 0.13 0.13 0.25 0.12 0.08 0.17 0.17 0.16 0.14 0.17 0.36 0.23 0.19 0.64 0.22 0.34 0.27 0.03 0.66 0.45 0.21 0.55 0.66 0.62 0.13 0.10 0.10 0.03 0.10 0.11 0.25 0.26 0.14 0.19 0.19 0.02 0.01 0.01 0.03 0.01 0.01 0.04 0.01 0.01 0.05 0.01 0.03 0.00 0.01 0.00 0.01 0.04 0.01 0.01 0.02 0.02 0.01 0.03 0.01 0.01 0.04 0.01 0.01 0.01 0.01 0.04 0.01 0.03 0.01 0.03 0.01 0.00 0.01 0.02 0.01 0.00 0.01 0.04 0.01 0.01 0.03 0.01 0.02 0.04 0.01 0.02 0.02 0.01 0.12 0.03 * 0.01 0.09 * 0.04 0.02 * 0.04 * 0.02 * 0.03 0.02 * 0.06 0.02 0.05 * 0.04 * 0.03 * 0.01 0.01 0.02 0.02 0.02 0.03 0.02 0.02 0.01 0.02

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
397

455

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Oesophagus (C15) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
398

Male ASR(W) CUM 0-74 8.3 8.1 8.1 6.0 10.6 6.3 7.2 7.1 7.9 2.2 1.4 2.5 2.2 2.6 6.7 3.1 5.0 5.8 3.3 1.7 2.2 1.6 7.8 1.6 2.3 4.5 4.1 5.1 6.1 5.2 6.7 2.2 5.8 5.0 6.1 5.1 3.4 10.9 14.6 9.0 10.1 5.9 6.7 12.7 13.1 14.1 5.4 10.3 6.7 5.7 6.6 7.7 6.0 6.8 6.8 5.2 7.6 4.8 7.1 4.1 2.2 3.0 1.3 3.7 2.1 2.4 8.0 4.2 0.9 2.5 1.8 1.8 4.3 1.3 6.7 3.0 2.1 4.8 6.6 0.10 0.35 0.42 0.52 0.68 0.39 1.04 0.21 0.95 0.50 0.63 0.37 0.26 0.40 0.54 0.23 0.26 0.31 0.69 0.46 0.24 0.27 0.55 0.24 0.17 0.13 0.43 0.68 0.15 0.28 0.19 0.09 0.19 0.12 0.17 0.34 0.13 0.58 0.84 0.73 0.64 0.43 0.43 0.59 0.85 0.89 0.61 0.70 0.26 0.18 0.31 0.35 0.26 0.27 0.40 0.77 0.25 0.78 0.55 0.51 0.20 0.34 0.40 0.29 0.28 0.40 0.30 0.48 0.28 0.36 0.20 0.24 0.50 0.33 0.97 0.27 0.23 0.49 0.32 1.09 1.02 1.08 0.79 1.26 0.83 0.84 0.91 1.07 0.23 0.13 0.32 0.29 0.28 0.85 0.38 0.61 0.69 0.44 0.24 0.26 0.17 1.05 0.21 0.29 0.56 0.47 0.67 0.76 0.64 0.82 0.27 0.71 0.60 0.75 0.66 0.41 1.43 1.83 1.10 1.25 0.75 0.81 1.54 1.58 1.70 0.64 1.29 0.81 0.70 0.84 0.92 0.73 0.85 0.85 0.59 0.91 0.60 0.98 0.54 0.24 0.39 0.19 0.44 0.27 0.28 1.02 0.54 0.10 0.32 0.22 0.23 0.53 0.13 0.85 0.39 0.27 0.65 0.85 0.02 0.05 0.07 0.08 0.10 0.06 0.14 0.03 0.15 0.07 0.08 0.06 0.04 0.06 0.08 0.04 0.04 0.05 0.10 0.07 0.03 0.04 0.08 0.03 0.02 0.02 0.06 0.10 0.02 0.04 0.03 0.01 0.03 0.02 0.03 0.05 0.02 0.08 0.12 0.10 0.09 0.06 0.06 0.08 0.11 0.12 0.08 0.10 0.03 0.02 0.04 0.04 0.04 0.04 0.05 0.11 0.04 0.10 0.08 0.07 0.03 0.05 0.06 0.04 0.04 0.05 0.04 0.07 0.04 0.05 0.03 0.03 0.07 0.04 0.14 0.04 0.03 0.07 0.05

Cases 662 75 49 16 29 41 7 154 12 16 3 39 55 41 166 61 110 94 11 5 31 16 49 18 95 340 27 11 209 108 373 205 213 319 518 48 399 38 78 18 53 58 51 93 43 42 20 33 144 271 172 117 147 206 85 16 597 19 40 20 54 37 5 81 27 13 198 37 4 19 35 16 12 6 14 54 29 27 144

Female ASR(W) CUM 0-74 0.6 0.7 0.7 0.5 0.8 0.7 0.5 0.6 0.7 1.6 0.5 1.7 1.7 2.7 8.6 0.8 1.1 1.2 2.5 0.6 0.7 0.6 1.7 0.6 1.1 0.8 1.0 0.6 0.4 1.1 1.5 0.5 0.9 0.6 1.8 0.5 1.1 0.9 2.1 0.7 1.4 1.2 1.0 1.6 1.6 1.5 0.7 1.0 1.0 0.9 1.8 1.1 1.2 1.6 1.5 1.3 3.5 1.3 1.2 0.6 0.5 0.8 0.2 0.9 0.6 0.7 1.3 1.3 0.2 0.6 0.4 0.3 0.5 0.5 1.4 0.8 0.5 0.7 1.3 0.02 0.08 0.10 0.12 0.15 0.10 0.19 0.05 0.20 0.41 0.43 0.28 0.23 0.44 0.73 0.10 0.11 0.12 0.78 0.26 0.13 0.16 0.24 0.14 0.12 0.05 0.20 0.21 0.03 0.13 0.08 0.04 0.06 0.04 0.09 0.08 0.06 0.16 0.27 0.19 0.21 0.18 0.15 0.19 0.30 0.26 0.21 0.19 0.10 0.06 0.15 0.12 0.10 0.12 0.17 0.35 0.16 0.33 0.21 0.16 0.09 0.15 0.10 0.12 0.13 0.20 0.11 0.26 0.09 0.16 0.09 0.08 0.16 0.20 0.41 0.13 0.10 0.16 0.13 0.06 0.08 0.07 0.06 0.08 0.08 0.03 0.08 0.08 0.20 0.08 0.20 0.22 0.35 1.04 0.08 0.12 0.13 0.12 0.02 0.09 0.09 0.28 0.05 0.14 0.10 0.12 0.07 0.04 0.14 0.17 0.05 0.10 0.06 0.23 0.07 0.12 0.11 0.26 0.09 0.17 0.13 0.10 0.18 0.18 0.20 0.07 0.11 0.12 0.10 0.21 0.13 0.14 0.19 0.19 0.18 0.38 0.15 0.16 0.06 0.06 0.08 0.02 0.09 0.05 0.09 0.15 0.18 0.01 0.06 0.05 0.03 0.06 0.06 0.21 0.10 0.04 0.09 0.15 0.00 0.01 0.01 0.02 0.02 0.02 0.02 0.01 0.03 0.06 0.07 0.04 0.03 0.07 * 0.10 * 0.01 * 0.02 0.02 0.06 0.02 0.02 * 0.03 * 0.04 0.01 * 0.02 * 0.01 0.03 0.03 0.00 * 0.02 * 0.01 0.00 * 0.01 0.00 0.01 0.01 0.01 0.02 0.04 0.03 0.03 0.02 0.02 0.03 0.04 0.04 0.03 0.03 0.01 0.01 0.02 0.02 0.01 0.02 0.02 0.06 0.02 0.05 0.03 0.02 0.01 0.02 0.02 0.02 0.02 0.03 0.02 0.04 0.01 0.02 0.01 0.01 0.02 0.03 0.07 0.02 0.01 0.02 0.02

6856 620 397 142 253 280 51 1334 83 20 14 45 72 41 174 195 390 352 25 13 84 34 204 47 182 1297 97 58 1742 362 1274 702 943 1780 1329 224 700 370 327 161 253 211 261 503 268 271 97 237 679 1036 456 513 553 680 302 49 941 42 170 71 134 92 12 181 62 36 748 87 13 53 94 63 79 19 49 133 95 100 452

456

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Oesophagus (C15) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 435 707 39 600 115 166 210 740 578 1077 549 1253 371 43 311 576 355 36 143 103 148 101 109 156 1345 125 57 44 96 87 76 221 4306 237 204 995 1046 1708 2367 861 2824 4622 2032 1918 455 2391 1123 29 682 308 135 856 326 45 39 694 190 18 12 33 68 45 Male ASR(W) CUM 0-74 5.8 6.8 2.8 3.3 4.7 4.0 3.6 7.4 5.5 7.7 3.1 8.2 5.4 3.8 7.0 8.6 8.1 3.4 6.7 3.6 4.0 4.9 5.6 4.6 3.4 8.3 6.6 6.9 5.3 6.5 7.1 9.3 7.3 6.5 5.7 7.8 10.3 10.0 8.5 8.2 8.8 8.4 9.7 8.4 7.9 11.7 4.7 7.7 5.4 5.2 7.6 4.8 5.1 5.2 9.3 5.2 4.6 5.4 1.7 7.1 6.0 3.8 0.28 0.26 0.46 0.14 0.44 0.32 0.26 0.29 0.24 0.24 0.13 0.23 0.28 0.62 0.42 0.37 0.43 0.67 0.58 0.37 0.34 0.50 0.57 0.38 0.10 0.76 0.91 1.07 0.56 0.71 0.84 0.65 0.11 0.43 0.41 0.26 0.33 0.25 0.18 0.29 0.18 0.13 0.23 0.20 0.38 0.25 0.14 1.54 0.22 0.31 0.68 0.17 0.29 0.79 1.53 0.20 0.35 1.37 0.51 1.26 0.81 0.60 0.73 0.83 0.35 0.41 0.58 0.50 0.46 0.86 0.64 0.96 0.40 1.01 0.68 0.44 0.84 1.04 1.02 0.40 0.81 0.43 0.47 0.58 0.67 0.53 0.43 1.08 0.80 0.85 0.67 0.82 0.81 1.18 0.90 0.78 0.67 0.90 1.20 1.19 1.03 0.99 1.03 0.99 1.13 1.00 0.91 1.43 0.56 0.78 0.68 0.60 0.97 0.56 0.62 0.51 1.10 0.61 0.58 0.70 0.23 0.84 0.79 0.48 0.04 0.03 0.07 0.02 0.06 0.04 0.03 0.04 0.03 0.03 0.02 0.03 0.04 0.08 0.05 0.05 0.06 0.08 0.08 0.05 0.04 0.06 0.08 0.05 0.01 0.11 0.12 0.15 0.08 0.11 0.11 0.10 0.02 0.06 0.06 0.04 0.05 0.04 0.03 0.04 0.03 0.02 0.03 0.03 0.05 0.04 0.02 0.19 0.03 0.04 0.10 0.02 0.04 0.11 0.21 0.03 0.05 0.19 0.09 0.17 0.11 0.09 Cases 76 103 11 252 30 42 63 203 106 446 165 128 93 5 40 75 55 4 25 20 24 20 12 20 596 55 13 15 17 27 20 69 1796 85 61 602 692 992 1525 483 1791 2878 1176 1347 304 1524 664 10 293 161 59 484 158 25 4 370 43 0 7 9 9 17 Female ASR(W) CUM 0-74 0.5 0.6 0.6 1.0 0.7 0.7 0.7 1.3 0.6 1.4 0.8 0.6 0.9 0.2 0.5 0.8 0.9 0.4 0.9 0.4 0.4 0.6 0.5 0.4 1.1 2.4 1.2 1.6 0.6 1.5 1.4 2.2 2.3 1.9 1.5 3.3 4.6 3.8 3.6 3.3 3.6 3.3 3.8 4.1 3.4 4.7 2.0 3.1 1.8 2.1 2.2 1.9 2.0 2.3 1.1 1.9 0.8 0.9 1.8 0.7 1.0 0.07 0.06 0.18 0.08 0.14 0.11 0.09 0.10 0.06 0.07 0.07 0.05 0.10 0.08 0.10 0.11 0.13 0.26 0.20 0.09 0.09 0.17 0.16 0.10 0.05 0.36 0.38 0.48 0.16 0.33 0.35 0.29 0.06 0.22 0.21 0.16 0.20 0.14 0.11 0.17 0.10 0.07 0.13 0.13 0.22 0.14 0.09 1.02 0.12 0.18 0.33 0.10 0.18 0.50 0.55 0.11 0.13 0.33 0.61 0.35 0.27 0.05 0.07 0.05 0.12 0.08 0.07 0.08 0.15 0.05 0.13 0.09 0.06 0.10 0.01 0.05 0.08 0.10 0.04 0.12 0.03 0.03 0.07 0.06 0.04 0.13 0.27 0.15 0.17 0.06 0.17 0.17 0.26 0.27 0.22 0.16 0.36 0.52 0.43 0.40 0.37 0.39 0.37 0.41 0.46 0.40 0.53 0.22 0.27 0.21 0.24 0.26 0.20 0.25 0.27 0.13 0.21 0.10 0.13 0.22 0.06 0.14 0.01 0.01 0.02 0.01 0.02 * 0.01 0.01 0.01 * 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.03 0.03 0.01 0.01 0.02 0.02 0.01 0.01 0.05 0.05 0.06 0.02 0.04 0.05 0.04 0.01 0.03 0.03 0.02 0.03 0.02 0.02 0.03 0.02 0.01 0.02 0.02 0.03 0.02 0.01 0.12 0.02 0.03 0.05 0.01 0.03 0.08 0.08 0.02 0.02 0.06 0.08 0.03 0.05

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
399

457

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Stomach (C16)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 147 147 51 59 129 120 575 119 259 5895 381 935 2444 599 236 222 6653 702 1144 363 247 257 8 296 3300 30 306 896 320 563 116 955 7725 1312 595 1638 4112 1610 153 204 38 57 222 785 2393 261 121 45 107 177 672 940 634 1033 96 916 154 116 30 4540 624 3851 1314 477 792 377 163 179 199 2842 498 2194 1052 573 792 1016 410 592 117 136 Male ASR(W) CUM 0-74 7.1 3.3 5.1 6.2 9.0 13.4 29.0 19.2 19.0 29.4 43.1 27.4 33.2 21.8 18.7 25.2 7.9 7.5 7.1 8.1 8.7 13.4 10.9 8.2 7.9 5.5 7.3 5.8 11.6 4.4 8.3 5.1 7.3 11.1 10.2 10.3 5.8 7.6 11.5 11.4 4.2 14.3 10.3 5.8 8.8 10.1 9.8 5.2 17.1 33.0 10.9 6.5 5.0 8.0 13.4 7.6 8.6 10.4 4.9 6.2 11.6 5.7 5.7 10.5 4.4 5.6 10.3 3.7 4.6 7.0 11.6 6.1 5.1 5.1 5.8 7.1 12.2 5.5 12.0 6.4 0.62 0.29 0.73 0.92 0.92 1.29 1.30 1.84 1.21 0.40 2.24 0.93 0.69 0.93 1.26 1.73 0.10 0.29 0.22 0.45 0.58 0.86 4.04 0.50 0.14 1.06 0.45 0.20 0.67 0.19 0.80 0.18 0.09 0.32 0.43 0.27 0.10 0.20 0.96 0.84 0.70 2.14 0.72 0.22 0.19 0.64 0.94 0.80 1.86 2.52 0.44 0.23 0.20 0.26 1.39 0.27 0.73 1.01 0.97 0.10 0.47 0.10 0.16 0.50 0.16 0.30 0.85 0.28 0.34 0.14 0.53 0.14 0.16 0.23 0.21 0.23 0.62 0.23 1.14 0.58 1.48 3.32 2.31 2.21 3.43 5.24 3.36 3.77 2.56 2.23 2.94 0.91 0.83 0.82 0.92 1.01 1.65 1.71 0.96 0.92 0.71 0.85 0.68 1.40 0.51 0.95 0.62 0.86 1.26 1.19 1.19 0.68 0.91 1.40 1.25 0.48 1.41 1.19 0.72 1.03 1.16 1.06 0.62 1.88 4.16 1.25 0.77 0.60 0.92 1.43 0.88 1.04 1.25 0.53 0.71 1.31 0.66 0.68 1.22 0.53 0.68 1.24 0.44 0.54 0.82 1.40 0.72 0.59 0.60 0.70 0.81 1.39 0.62 1.36 0.77 0.18 0.19 0.28 0.18 0.06 0.34 0.14 0.10 0.14 0.19 0.27 0.01 0.04 0.03 0.07 0.09 0.13 0.75 0.07 0.02 0.17 0.07 0.03 0.10 0.03 0.12 0.03 0.01 0.05 0.06 0.04 0.01 0.03 0.15 0.12 0.10 0.30 0.11 0.03 0.03 0.09 0.14 0.13 0.26 0.40 0.07 0.03 0.03 0.04 0.20 0.04 0.11 0.14 0.14 0.01 0.07 0.01 0.02 0.07 0.02 0.05 0.14 0.04 0.05 0.02 0.08 0.02 0.02 0.03 0.03 0.03 0.09 0.03 0.16 0.08 Cases 71 111 25 64 102 83 343 70 167 3600 182 736 1438 484 157 187 3736 431 650 200 131 110 5 172 1832 18 187 640 197 435 64 525 5064 970 439 1241 2379 1071 105 142 39 61 165 467 1748 217 105 27 70 137 557 591 427 647 49 592 149 117 23 2685 429 2205 954 386 541 297 136 144 131 1904 377 1430 631 329 460 719 331 378 84 92 Female ASR(W) CUM 0-74 3.1 2.0 2.5 6.9 9.2 7.0 13.2 9.4 9.0 12.4 16.0 15.9 17.3 13.8 8.7 16.5 3.5 3.7 3.2 3.3 3.3 4.8 7.3 3.5 3.4 2.1 3.4 2.8 4.1 2.4 4.4 2.3 3.7 6.3 5.3 6.0 2.5 3.8 5.7 6.4 3.0 10.8 5.7 2.4 4.9 5.5 7.2 2.3 9.4 18.3 6.6 3.1 2.5 3.3 4.8 3.2 5.1 5.8 2.6 2.7 5.4 2.5 2.9 5.2 2.2 3.1 5.1 2.1 2.4 3.1 5.3 2.7 2.1 2.0 2.4 3.5 6.4 2.5 5.3 2.8 0.37 0.20 0.50 0.94 1.02 0.85 0.76 1.16 0.72 0.22 1.22 0.62 0.47 0.67 0.76 1.25 0.06 0.20 0.14 0.27 0.33 0.52 3.49 0.31 0.09 0.57 0.29 0.13 0.32 0.13 0.58 0.11 0.06 0.21 0.27 0.18 0.06 0.13 0.60 0.58 0.50 1.56 0.47 0.13 0.13 0.40 0.75 0.46 1.27 1.63 0.29 0.15 0.13 0.15 0.72 0.16 0.48 0.61 0.62 0.06 0.27 0.06 0.10 0.29 0.10 0.19 0.47 0.19 0.24 0.08 0.29 0.08 0.10 0.13 0.12 0.15 0.38 0.15 0.61 0.34 0.76 1.53 0.86 0.90 1.37 1.62 1.81 1.84 1.48 1.00 2.03 0.39 0.43 0.35 0.35 0.35 0.53 0.99 0.42 0.39 0.19 0.40 0.31 0.43 0.27 0.56 0.26 0.42 0.68 0.59 0.66 0.28 0.43 0.67 0.65 0.34 1.38 0.59 0.27 0.56 0.61 0.71 0.20 1.10 1.92 0.73 0.37 0.28 0.37 0.56 0.35 0.55 0.59 0.29 0.30 0.57 0.26 0.33 0.57 0.25 0.35 0.57 0.24 0.27 0.33 0.55 0.28 0.23 0.22 0.27 0.40 0.71 0.29 0.58 0.32 * * * *

0.11 0.11 0.15 0.10 0.03 0.17 0.09 0.07 0.10 0.11 0.20 * 0.01 0.03 0.02 0.04 0.05 0.07 0.52 0.05 0.01 0.08 0.04 0.02 0.05 0.02 0.09 0.02 0.01 0.03 0.04 0.03 0.01 0.02 0.09 0.08 0.07 0.23 0.07 0.02 0.02 0.06 0.10 0.06 0.17 0.22 0.04 0.02 0.02 0.02 0.11 0.02 0.07 0.08 0.09 0.01 0.04 0.01 0.01 0.04 0.01 0.03 0.07 0.03 0.03 0.01 0.04 0.01 0.01 0.02 0.02 0.02 0.06 0.02 0.09 0.05

458

*Important. See note on population page.

400

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Stomach (C16) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 334 1654 2091 373 1681 1072 283 768 1056 148 881 203 50995 6864 40907 2581 343 2090 397 41 180 168 5747 796 4514 2267 326 1866 603 686 3454 365 2987 320 6215 738 4457 17304 2093 2025 2196 10779 895 365 517 3861 556 3189 265 119 1194 855 379 1213 47 917 3291 431 585 8367 302 164 1119 704 51 961 158 265 122 2025 1907 101 1967 2673 3377 7073 4446 19306 5290 Male ASR(W) CUM 0-74 6.6 7.2 6.1 11.0 5.5 7.9 11.2 7.1 5.3 10.4 4.8 5.7 6.6 10.9 6.0 8.7 12.3 8.0 6.4 11.8 9.5 4.4 8.7 11.7 8.0 5.5 9.8 4.9 4.9 5.3 7.0 11.2 6.6 7.6 7.0 11.0 6.0 7.2 11.5 11.0 10.3 5.9 6.7 12.8 4.9 6.4 10.6 5.9 4.5 5.3 6.0 6.4 5.1 6.3 8.5 17.0 14.7 32.1 24.8 34.1 9.4 7.0 12.2 3.4 6.1 4.6 4.1 4.3 4.6 11.6 12.0 6.7 50.2 64.8 80.3 65.8 59.5 51.3 79.4 0.38 0.19 0.14 0.59 0.14 0.26 0.70 0.27 0.17 0.87 0.17 0.42 0.03 0.13 0.03 0.18 0.67 0.19 0.33 1.90 0.72 0.36 0.12 0.42 0.13 0.12 0.56 0.12 0.21 0.22 0.13 0.60 0.13 0.46 0.09 0.42 0.10 0.06 0.26 0.25 0.23 0.06 0.23 0.69 0.22 0.11 0.46 0.11 0.29 0.51 0.18 0.23 0.27 0.19 1.26 0.58 0.26 1.56 1.05 0.39 0.55 0.56 0.37 0.14 0.86 0.15 0.33 0.27 0.42 0.27 0.29 0.70 1.14 1.33 1.40 0.81 0.95 0.38 1.17 0.82 0.83 0.71 1.26 0.64 0.93 1.29 0.84 0.63 1.27 0.57 0.66 0.77 1.27 0.70 1.03 1.49 0.95 0.74 1.42 1.08 0.51 1.00 1.36 0.92 0.63 1.15 0.56 0.59 0.61 0.83 1.26 0.78 0.84 0.82 1.28 0.70 0.85 1.32 1.28 1.20 0.70 0.79 1.51 0.59 0.74 1.17 0.70 0.49 0.63 0.69 0.74 0.56 0.75 0.97 1.92 1.66 4.26 3.08 3.96 1.24 0.87 1.53 0.41 0.77 0.56 0.49 0.49 0.59 1.36 1.41 0.77 6.05 7.83 9.94 7.90 7.21 6.04 9.72 0.06 0.03 0.02 0.09 0.02 0.04 0.10 0.04 0.02 0.13 0.02 0.06 0.00 0.02 0.00 0.03 0.10 0.03 0.05 0.29 0.11 0.05 0.02 0.06 0.02 0.02 0.08 0.02 0.03 0.03 0.02 0.09 0.02 0.07 0.01 0.06 0.01 0.01 0.04 0.04 0.03 0.01 0.03 0.10 0.03 0.02 0.07 0.02 0.04 0.08 0.03 0.03 0.04 0.03 0.18 0.08 0.04 0.24 0.15 0.06 0.08 0.09 0.05 0.02 0.13 0.02 0.05 0.04 0.06 0.04 0.04 0.10 0.16 0.18 0.21 0.11 0.13 0.05 0.16 Cases 181 1087 1359 313 1017 751 254 490 615 102 493 115 32695 5303 25097 1653 254 1295 248 36 130 74 4025 763 2988 1469 253 1164 364 353 2193 297 1845 242 4040 580 2718 11269 1532 1564 1623 6413 544 230 307 2519 423 2009 175 65 688 489 227 650 31 487 1926 156 295 4839 149 110 544 327 24 477 76 149 31 1371 1279 60 945 1492 1637 3249 2317 9372 2799 Female ASR(W) CUM 0-74 2.4 3.0 2.8 5.7 2.3 3.6 6.0 2.9 2.2 4.4 1.9 2.6 3.0 5.3 2.6 3.7 5.9 3.3 3.4 7.8 5.7 1.7 4.1 6.5 3.6 2.4 4.6 2.1 2.0 2.1 2.9 5.5 2.6 3.8 3.2 5.6 2.6 3.4 6.4 5.6 5.9 2.5 2.8 4.9 2.1 3.2 5.4 2.9 2.4 2.1 2.7 2.9 2.1 2.4 5.4 7.6 7.3 10.6 11.6 17.2 4.2 4.3 6.0 1.7 2.6 2.3 1.9 2.4 1.0 6.3 6.3 3.5 21.6 27.9 30.2 24.2 22.3 19.8 31.3 0.21 0.11 0.09 0.35 0.08 0.15 0.41 0.16 0.10 0.47 0.10 0.28 0.02 0.08 0.02 0.11 0.38 0.11 0.23 1.34 0.53 0.22 0.07 0.25 0.08 0.07 0.31 0.07 0.12 0.13 0.07 0.35 0.07 0.30 0.06 0.25 0.06 0.04 0.17 0.15 0.15 0.04 0.13 0.35 0.13 0.07 0.28 0.07 0.19 0.31 0.12 0.15 0.16 0.11 0.99 0.35 0.18 0.88 0.69 0.27 0.36 0.43 0.26 0.10 0.54 0.11 0.23 0.20 0.18 0.18 0.19 0.47 0.75 0.86 0.80 0.48 0.55 0.22 0.72 0.27 0.34 0.29 0.57 0.25 0.37 0.62 0.30 0.24 0.46 0.21 0.29 0.34 0.58 0.29 0.42 0.66 0.36 0.39 0.87 0.64 0.20 0.46 0.71 0.40 0.28 0.49 0.24 0.22 0.24 0.32 0.61 0.28 0.42 0.36 0.60 0.29 0.39 0.69 0.62 0.66 0.28 0.29 0.53 0.22 0.36 0.60 0.33 0.29 0.22 0.32 0.34 0.24 0.28 0.88 0.91 0.76 1.41 1.45 1.92 0.50 0.47 0.74 0.19 0.32 0.27 0.22 0.26 0.15 0.69 0.71 0.37 2.52 3.07 3.37 2.67 2.45 2.18 3.49 0.03 0.02 0.01 0.05 0.01 0.02 0.06 0.02 0.01 0.06 0.01 0.04 0.00 0.01 0.00 0.02 0.06 0.02 0.03 0.20 0.07 0.03 0.01 0.04 0.01 0.01 0.05 0.01 0.02 0.02 0.01 0.05 0.01 0.04 0.01 0.04 0.01 0.01 0.02 0.02 0.02 0.01 0.02 0.05 0.02 0.01 0.04 0.01 0.03 0.04 0.02 0.02 0.02 0.02 0.18 0.05 * 0.02 0.14 * 0.10 0.04 * 0.05 * 0.06 * 0.04 0.01 * 0.07 0.02 0.03 * 0.03 * 0.03 * 0.03 0.03 0.06 0.10 0.11 0.11 0.06 0.07 0.03 0.09

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
401

459

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Stomach (C16) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
402

Male ASR(W) CUM 0-74 65.9 59.9 69.2 73.8 66.6 62.4 54.3 63.7 67.4 3.4 2.8 12.5 12.3 13.4 6.0 7.9 18.3 21.5 7.8 6.5 5.9 5.3 2.7 10.6 11.0 13.1 17.1 12.4 35.7 7.5 9.0 17.2 21.8 14.1 7.1 27.6 10.2 10.5 9.4 9.3 11.5 7.0 9.6 8.5 13.3 8.3 7.3 9.8 16.2 16.4 11.4 19.9 13.0 15.0 13.6 11.4 11.4 14.5 26.3 15.3 21.7 13.6 29.8 13.7 18.7 13.9 20.0 24.1 10.8 20.7 27.0 10.8 9.0 10.3 25.7 13.1 23.5 22.3 15.7 0.28 0.92 1.21 1.78 1.69 1.20 2.75 0.60 2.48 0.63 0.77 0.85 0.61 0.91 0.51 0.38 0.49 0.60 1.06 0.85 0.40 0.49 0.32 0.61 0.38 0.21 0.86 1.05 0.35 0.33 0.21 0.23 0.37 0.20 0.19 0.79 0.23 0.55 0.64 0.71 0.66 0.44 0.49 0.46 0.80 0.65 0.66 0.64 0.40 0.29 0.40 0.55 0.37 0.38 0.54 1.12 0.31 1.24 1.04 0.92 0.61 0.69 1.85 0.52 0.78 0.95 0.46 1.10 0.94 0.96 0.74 0.58 0.69 0.91 1.89 0.55 0.77 1.03 0.48 8.20 7.38 8.42 9.15 8.28 7.86 6.77 7.71 7.93 0.38 0.25 1.50 1.57 1.68 0.73 0.93 2.05 2.44 0.88 0.71 0.70 0.65 0.30 1.28 1.34 1.44 1.93 1.38 4.52 0.84 0.98 2.13 2.65 1.58 0.84 3.46 1.11 1.24 0.99 1.04 1.34 0.78 1.06 0.96 1.43 0.86 0.78 1.12 1.80 1.87 1.29 2.31 1.38 1.66 1.56 1.29 1.35 1.69 3.06 1.75 2.47 1.61 3.41 1.52 2.17 1.63 2.33 2.73 1.30 2.31 3.10 1.20 1.12 1.24 2.89 1.53 2.74 2.49 1.85 0.04 0.13 0.18 0.27 0.25 0.18 0.42 0.09 0.37 0.09 0.08 0.13 0.09 0.14 0.07 0.06 0.07 0.09 0.13 0.12 0.05 0.07 0.04 0.09 0.05 0.03 0.12 0.15 0.05 0.05 0.03 0.03 0.05 0.03 0.03 0.11 0.03 0.08 0.09 0.10 0.10 0.06 0.07 0.07 0.11 0.09 0.09 0.09 0.05 0.04 0.06 0.08 0.05 0.05 0.08 0.17 0.05 0.18 0.15 0.13 0.09 0.10 0.26 0.07 0.11 0.13 0.07 0.16 0.14 0.14 0.11 0.08 0.10 0.13 0.26 0.08 0.11 0.15 0.07

Cases 29856 2617 2009 1019 989 1474 228 7165 490 30 42 181 220 99 83 427 958 884 33 41 195 81 36 162 443 3733 366 124 7638 369 1323 3682 2395 3873 933 999 1741 210 160 97 172 172 259 215 205 108 68 107 1346 2842 697 1011 1175 1241 521 70 910 112 497 223 1099 356 196 698 430 145 1529 400 86 338 1202 273 121 76 120 431 823 368 873

Female ASR(W) CUM 0-74 25.9 23.9 28.8 29.1 27.5 22.5 19.8 27.1 26.8 2.6 4.2 8.1 6.2 6.2 3.6 5.4 9.9 10.8 5.9 3.8 4.6 3.3 1.2 5.5 5.1 7.1 9.5 6.7 15.3 3.6 4.3 8.3 9.5 6.9 3.2 13.1 5.6 3.7 3.8 3.4 4.3 3.1 4.4 3.2 5.0 3.2 2.5 2.5 8.4 8.4 5.8 9.1 7.5 7.6 6.9 5.8 5.6 7.1 12.9 7.2 10.8 7.0 13.9 7.9 8.8 7.9 9.3 10.8 5.1 9.4 14.7 5.8 4.9 4.2 9.6 6.1 12.4 10.8 7.3 0.15 0.47 0.65 0.94 0.89 0.60 1.37 0.33 1.28 0.50 0.92 0.61 0.42 0.64 0.43 0.27 0.33 0.37 1.05 0.62 0.34 0.38 0.19 0.43 0.25 0.14 0.56 0.67 0.19 0.21 0.14 0.15 0.21 0.12 0.12 0.46 0.15 0.29 0.36 0.39 0.38 0.28 0.31 0.25 0.43 0.36 0.37 0.29 0.26 0.19 0.26 0.32 0.26 0.25 0.35 0.78 0.20 0.84 0.67 0.66 0.40 0.48 1.22 0.36 0.52 0.68 0.29 0.68 0.64 0.64 0.52 0.39 0.49 0.54 1.02 0.36 0.53 0.66 0.29 3.05 2.81 3.43 3.42 3.32 2.65 2.13 3.20 3.15 0.29 0.38 0.88 0.76 0.80 0.37 0.61 1.07 1.19 0.83 0.33 0.56 0.39 0.16 0.63 0.61 0.74 1.01 0.68 1.85 0.39 0.44 0.96 1.06 0.74 0.36 1.56 0.60 0.35 0.36 0.35 0.47 0.35 0.48 0.34 0.49 0.35 0.27 0.28 0.90 0.89 0.64 0.91 0.78 0.80 0.78 0.64 0.63 0.74 1.39 0.75 1.09 0.72 1.48 0.86 0.90 0.86 1.02 1.15 0.48 1.01 1.59 0.67 0.57 0.50 1.03 0.64 1.28 1.05 0.80 0.02 0.07 0.09 0.13 0.13 0.09 0.18 0.05 0.18 0.08 0.10 0.08 0.06 0.10 * 0.05 * 0.04 * 0.05 0.06 0.16 0.07 0.05 * 0.05 * 0.03 0.06 * 0.03 * 0.02 0.08 0.09 0.03 * 0.03 * 0.02 0.02 * 0.03 0.02 0.02 0.06 0.02 0.04 0.05 0.05 0.05 0.04 0.04 0.03 0.06 0.05 0.05 0.04 0.03 0.03 0.04 0.04 0.04 0.03 0.05 0.11 0.03 0.11 0.09 0.08 0.05 0.06 0.16 0.05 0.07 0.09 0.04 0.09 0.08 0.09 0.07 0.05 0.07 0.08 0.14 0.05 0.07 0.08 0.04

57198 5009 3645 1924 1701 3039 413 13090 944 31 44 225 420 219 156 497 1439 1316 60 63 227 120 73 310 881 4213 420 145 10596 574 1940 5898 3697 5209 1574 1233 2106 380 245 183 312 293 405 370 316 187 151 270 1662 3261 844 1339 1282 1600 657 116 1426 151 667 330 1488 457 311 750 654 218 2052 571 153 538 1550 383 180 141 196 624 1135 489 1176

460

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Stomach (C16) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 1842 3018 148 1825 447 793 646 3584 2352 4592 2581 3088 1460 159 850 1401 489 168 314 360 506 407 275 509 3182 118 115 58 186 193 140 188 6687 436 383 1341 1434 2412 4017 955 3386 5543 2833 3084 780 2740 2083 22 1078 567 155 1751 512 71 29 1212 546 21 63 59 285 77 Male ASR(W) CUM 0-74 24.0 27.7 10.9 9.1 17.7 18.1 10.2 33.3 19.9 32.7 13.9 19.2 20.9 12.7 15.8 19.0 10.3 12.3 12.4 10.9 11.9 15.8 12.6 12.3 7.2 7.9 11.8 7.9 9.0 13.9 12.4 7.6 11.0 11.5 10.6 10.1 13.8 13.7 13.6 8.7 10.0 9.5 12.6 13.1 12.9 12.8 8.5 6.4 8.3 9.2 7.9 9.9 8.0 8.1 6.8 9.1 11.1 4.6 8.7 12.8 17.2 5.7 0.56 0.51 0.91 0.23 0.85 0.66 0.41 0.60 0.43 0.48 0.28 0.35 0.55 1.10 0.58 0.53 0.48 1.12 0.75 0.61 0.55 0.84 0.82 0.58 0.14 0.75 1.16 1.09 0.69 1.04 1.09 0.58 0.14 0.56 0.55 0.29 0.38 0.29 0.23 0.29 0.18 0.13 0.25 0.25 0.48 0.25 0.19 1.42 0.26 0.41 0.66 0.25 0.36 0.99 1.30 0.27 0.51 1.15 1.18 1.69 1.22 0.70 2.98 3.40 1.42 1.04 2.18 2.24 1.23 3.88 2.30 3.99 1.71 2.26 2.46 1.52 1.82 2.23 1.21 1.35 1.53 1.29 1.43 1.80 1.44 1.46 0.82 1.02 1.31 0.86 0.99 1.56 1.38 0.88 1.30 1.40 1.29 1.16 1.60 1.59 1.60 0.96 1.15 1.07 1.48 1.55 1.58 1.53 0.97 0.76 0.93 1.12 0.93 1.17 0.92 1.01 0.79 1.01 1.34 0.39 1.14 1.74 2.12 0.56 0.08 0.07 0.14 0.03 0.12 0.10 0.06 0.08 0.06 0.07 0.04 0.05 0.08 0.15 0.08 0.07 0.07 0.15 0.11 0.08 0.08 0.12 0.11 0.08 0.02 0.11 0.17 0.16 0.10 0.15 0.16 0.08 0.02 0.08 0.08 0.04 0.06 0.04 0.03 0.04 0.03 0.02 0.04 0.04 0.07 0.04 0.03 0.21 0.04 0.06 0.10 0.04 0.05 0.15 0.18 0.04 0.08 0.14 0.18 0.27 0.18 0.10 Cases 1567 2245 85 1192 241 435 394 2428 1563 4582 1346 1913 936 88 524 722 298 79 214 225 338 244 161 333 2084 89 59 33 120 140 68 105 3935 272 270 658 829 1402 2405 505 1745 3168 1534 1554 507 1860 1171 13 530 305 87 1014 276 46 20 743 381 24 34 51 191 45 Female ASR(W) CUM 0-74 11.6 12.4 4.6 4.4 6.0 6.6 4.2 17.1 9.8 15.9 6.0 7.8 8.8 6.0 6.5 7.1 4.9 5.1 6.5 5.6 6.0 6.7 5.4 5.6 3.7 3.7 4.5 3.0 4.4 5.9 4.4 3.2 4.7 5.7 5.4 3.6 5.1 5.1 5.6 3.3 3.6 3.6 4.9 4.6 5.7 5.8 3.8 3.1 3.5 3.7 3.8 4.4 3.5 4.8 5.0 4.5 5.9 4.1 4.3 8.3 7.2 3.0 0.32 0.28 0.53 0.15 0.41 0.35 0.23 0.39 0.28 0.26 0.18 0.19 0.31 0.77 0.34 0.30 0.30 0.73 0.52 0.42 0.37 0.52 0.51 0.36 0.10 0.44 0.70 0.63 0.46 0.60 0.60 0.37 0.08 0.37 0.36 0.17 0.21 0.16 0.13 0.17 0.10 0.08 0.15 0.14 0.28 0.15 0.12 0.94 0.17 0.24 0.46 0.16 0.23 0.74 1.13 0.18 0.34 0.97 0.76 1.19 0.68 0.52 1.38 1.41 0.56 0.51 0.70 0.73 0.49 1.97 1.06 1.80 0.71 0.87 1.02 0.60 0.71 0.76 0.48 0.53 0.72 0.66 0.67 0.73 0.56 0.58 0.41 0.43 0.45 0.36 0.49 0.62 0.42 0.33 0.54 0.62 0.60 0.38 0.56 0.54 0.62 0.34 0.39 0.39 0.55 0.49 0.65 0.64 0.43 0.37 0.37 0.39 0.37 0.48 0.41 0.60 0.74 0.53 0.61 0.38 0.46 0.93 0.71 0.32 0.04 0.04 0.08 0.02 0.06 * 0.05 0.03 0.05 * 0.04 0.03 0.02 0.03 0.04 0.09 0.05 0.04 0.04 0.09 0.07 0.06 0.05 0.07 0.07 0.05 0.01 0.07 0.09 0.09 0.06 0.08 0.08 0.05 0.01 0.05 0.05 0.02 0.03 0.02 0.02 0.02 0.01 0.01 0.02 0.02 0.04 0.02 0.02 0.15 0.02 0.03 0.06 0.02 0.03 0.11 0.20 0.03 0.05 0.13 0.10 0.18 0.09 0.08

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
403

461

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Small intestine (C17)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 5 20 8 0 2 4 56 3 12 240 9 25 37 15 11 6 893 121 122 45 20 18 2 57 451 18 39 173 47 124 12 202 1179 84 131 139 815 223 28 9 4 2 16 146 317 64 5 5 5 2 51 178 173 166 13 150 35 28 7 836 83 745 282 81 199 90 35 54 44 591 105 463 303 176 218 231 75 154 24 39 Male ASR(W) CUM 0-74 0.3 0.6 0.9 0.1 0.4 2.3 0.4 0.9 1.2 1.1 0.7 0.5 0.6 0.9 0.8 1.1 1.3 0.8 1.1 0.7 1.0 1.6 1.6 1.1 3.7 0.9 1.2 1.7 1.0 0.8 1.1 1.2 0.7 2.3 0.8 1.2 1.1 2.2 0.6 0.5 0.7 0.8 1.1 1.2 2.5 0.4 0.6 0.9 0.4 0.8 1.3 1.4 1.4 1.9 1.4 1.8 2.3 1.1 1.2 1.5 1.2 1.2 1.7 1.1 1.3 2.1 1.1 1.1 1.5 2.5 1.4 1.5 1.6 1.7 1.7 2.3 1.5 2.4 1.9 0.13 0.13 0.33 0.07 0.21 0.35 0.21 0.27 0.08 0.36 0.15 0.08 0.15 0.28 0.31 0.04 0.12 0.07 0.18 0.17 0.24 1.15 0.22 0.06 0.91 0.15 0.09 0.25 0.10 0.25 0.08 0.04 0.08 0.20 0.08 0.05 0.08 0.42 0.20 0.27 0.50 0.20 0.10 0.07 0.32 0.17 0.28 0.45 0.29 0.12 0.11 0.11 0.11 0.55 0.12 0.33 0.46 0.43 0.05 0.17 0.05 0.07 0.20 0.08 0.14 0.37 0.15 0.17 0.07 0.25 0.07 0.09 0.13 0.12 0.11 0.27 0.12 0.51 0.31 0.05 0.26 0.04 0.14 0.14 0.13 0.09 0.06 0.06 0.10 0.10 0.13 0.16 0.08 0.14 0.08 0.13 0.15 0.17 0.14 0.41 0.11 0.14 0.23 0.12 0.09 0.13 0.14 0.08 0.26 0.11 0.15 0.13 0.22 0.08 0.06 0.07 0.09 0.14 0.14 0.30 0.03 0.04 0.11 0.01 0.11 0.15 0.17 0.17 0.26 0.17 0.19 0.25 0.08 0.14 0.16 0.14 0.15 0.20 0.13 0.17 0.26 0.14 0.13 0.18 0.29 0.16 0.18 0.19 0.20 0.20 0.28 0.17 0.24 0.25 0.03 0.05 0.02 0.05 0.01 0.05 0.02 0.01 0.02 0.04 0.05 0.01 0.02 0.01 0.02 0.02 0.04 0.11 0.03 0.01 0.12 0.02 0.01 0.04 0.01 0.03 0.01 0.01 0.01 0.03 0.01 0.01 0.01 0.05 0.03 0.03 0.07 0.03 0.01 0.01 0.05 0.01 0.03 0.06 0.01 0.02 0.01 0.02 0.02 0.09 0.02 0.05 0.06 0.05 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.06 0.02 0.02 0.01 0.03 0.01 0.01 0.02 0.02 0.02 0.04 0.02 0.07 0.05 Cases 3 27 2 0 4 3 46 7 10 220 12 32 32 32 12 4 746 95 91 50 26 22 0 39 378 6 39 178 58 119 13 182 1051 79 112 143 708 193 24 13 8 3 16 120 320 63 8 12 5 3 61 163 138 167 8 154 42 36 6 706 88 603 318 94 222 111 43 66 54 540 87 440 257 150 172 181 65 113 23 28 Female ASR(W) CUM 0-74 0.1 0.5 0.2 0.2 0.3 1.7 0.8 0.5 0.8 1.1 0.7 0.4 1.0 0.8 0.4 0.8 0.9 0.5 0.8 0.8 1.0 1.0 0.8 1.1 0.9 0.9 1.4 0.8 0.9 0.9 0.8 0.5 1.5 0.7 0.9 0.8 1.3 0.7 0.6 0.6 0.6 0.8 0.9 1.8 0.5 1.0 0.6 0.4 0.8 1.0 0.9 1.1 0.7 1.1 1.8 2.2 0.9 0.8 1.2 0.8 1.1 1.3 1.0 1.2 1.6 1.1 1.1 1.1 1.4 1.0 1.0 1.1 1.0 1.0 1.4 0.9 1.8 1.1 0.08 0.10 0.16 0.08 0.18 0.28 0.31 0.15 0.06 0.33 0.14 0.07 0.19 0.25 0.20 0.03 0.10 0.06 0.14 0.17 0.23 0.17 0.04 0.49 0.16 0.08 0.20 0.08 0.26 0.07 0.03 0.06 0.15 0.06 0.04 0.06 0.29 0.21 0.23 0.38 0.17 0.08 0.06 0.24 0.19 0.30 0.32 0.24 0.10 0.09 0.08 0.10 0.27 0.10 0.30 0.41 0.39 0.04 0.13 0.04 0.06 0.14 0.07 0.12 0.26 0.15 0.16 0.05 0.16 0.05 0.07 0.10 0.09 0.08 0.19 0.09 0.39 0.23 0.03 0.19 0.08 0.03 0.10 0.13 0.08 0.05 0.12 0.10 0.07 0.09 0.11 0.05 0.08 0.10 0.13 0.13 0.09 0.14 0.10 0.11 0.16 0.09 0.10 0.10 0.10 0.04 0.18 0.09 0.10 0.09 0.13 0.06 0.05 0.04 0.07 0.09 0.11 0.23 0.04 0.09 0.05 0.06 0.09 0.11 0.10 0.13 0.09 0.13 0.22 0.27 0.11 0.10 0.15 0.09 0.12 0.13 0.12 0.13 0.15 0.12 0.13 0.13 0.15 0.12 0.12 0.13 0.12 0.13 0.17 0.12 0.24 0.16 * * * *

0.02 0.04 0.04 0.01 0.01 0.05 0.02 0.01 0.03 0.03 0.04 * 0.00 0.01 0.01 0.02 0.03 0.03 0.03 0.01 0.06 0.02 0.01 0.03 0.01 0.04 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.04 0.02 0.02 0.04 0.02 0.01 0.01 0.04 0.02 0.04 0.03 0.05 0.01 0.01 0.01 0.01 0.05 0.01 0.04 0.05 0.06 0.00 0.02 0.00 0.01 0.02 0.01 0.02 0.03 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.06 0.04

462

*Important. See note on population page.

404

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Small intestine (C17) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 65 268 455 95 355 221 78 141 230 26 203 51 9691 1303 8097 422 63 341 72 3 24 42 855 126 710 514 54 447 130 153 654 79 561 53 1211 168 968 3122 138 438 212 2307 175 64 110 751 108 626 95 28 283 190 65 237 2 75 125 8 17 231 22 17 21 44 3 51 2 12 6 151 142 9 30 21 53 82 57 264 39 Male ASR(W) CUM 0-74 1.4 1.2 1.4 2.7 1.2 1.7 3.0 1.4 1.2 1.8 1.2 1.5 1.3 2.1 1.3 1.5 2.2 1.4 1.2 1.1 1.4 1.1 1.4 1.8 1.3 1.3 1.7 1.3 1.1 1.3 1.4 2.5 1.3 1.4 1.4 2.4 1.4 1.4 0.8 2.4 1.0 1.4 1.3 2.2 1.1 1.3 2.1 1.2 1.8 1.3 1.5 1.5 0.9 1.2 0.3 1.3 0.6 0.6 0.7 1.0 0.7 0.7 0.2 0.2 0.4 0.2 0.1 0.2 0.2 0.9 0.9 0.6 0.8 0.6 1.3 0.8 0.8 0.7 0.6 0.18 0.08 0.07 0.28 0.07 0.12 0.35 0.12 0.09 0.37 0.09 0.21 0.01 0.06 0.01 0.08 0.28 0.08 0.15 0.61 0.29 0.17 0.05 0.17 0.05 0.06 0.23 0.06 0.10 0.11 0.06 0.29 0.06 0.20 0.04 0.19 0.05 0.03 0.07 0.12 0.07 0.03 0.10 0.28 0.11 0.05 0.21 0.05 0.19 0.25 0.09 0.11 0.12 0.08 0.24 0.15 0.05 0.21 0.17 0.07 0.16 0.18 0.05 0.03 0.22 0.04 0.04 0.06 0.10 0.08 0.08 0.22 0.14 0.14 0.18 0.09 0.11 0.05 0.11 0.17 0.14 0.16 0.32 0.14 0.20 0.35 0.17 0.14 0.21 0.14 0.19 0.16 0.24 0.15 0.17 0.26 0.16 0.14 0.15 0.18 0.12 0.16 0.21 0.16 0.16 0.21 0.16 0.13 0.17 0.16 0.30 0.15 0.17 0.17 0.28 0.17 0.16 0.09 0.28 0.13 0.16 0.16 0.24 0.14 0.15 0.25 0.14 0.21 0.17 0.18 0.17 0.11 0.15 0.15 0.06 0.07 0.09 0.12 0.09 0.10 0.02 0.02 0.04 0.03 0.01 0.02 0.03 0.11 0.11 0.06 0.07 0.08 0.16 0.09 0.10 0.09 0.07 0.03 0.01 0.01 0.04 0.01 0.02 0.05 0.02 0.01 0.05 0.01 0.03 0.00 0.01 0.00 0.01 0.04 0.01 0.02 0.09 0.04 0.02 0.01 0.02 0.01 0.01 0.03 0.01 0.01 0.02 0.01 0.04 0.01 0.03 0.01 0.03 0.01 0.00 0.01 0.02 0.01 0.00 0.01 0.04 0.02 0.01 0.03 0.01 0.03 0.04 0.01 0.02 0.02 0.01 0.02 0.01 0.03 0.03 0.01 0.02 0.03 0.01 0.00 0.03 0.01 0.00 0.01 0.01 0.01 0.01 0.03 0.02 0.02 0.03 0.01 0.02 0.01 0.01 Cases 62 256 403 107 293 216 81 133 228 39 188 32 8829 1309 7267 370 61 296 66 2 15 46 822 148 661 506 68 428 111 119 604 78 515 60 1104 175 867 2744 117 400 207 1988 146 45 100 696 110 568 70 27 232 157 75 231 3 55 121 3 17 210 20 3 7 30 1 38 2 12 3 117 107 9 24 36 25 45 48 168 32 Female ASR(W) CUM 0-74 1.0 0.9 1.0 2.3 0.8 1.3 2.3 1.1 0.9 1.9 0.9 0.9 1.0 1.5 0.9 1.0 1.6 0.9 1.0 0.4 0.7 1.1 1.0 1.4 1.0 1.0 1.5 1.0 0.8 0.8 1.0 1.8 0.9 1.3 1.0 1.8 1.0 1.0 0.5 1.6 0.8 0.9 0.9 1.2 0.8 1.0 1.6 0.9 1.1 0.8 1.0 1.0 0.9 1.0 0.5 0.9 0.5 0.2 0.7 0.8 0.6 0.1 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.5 0.5 0.5 0.5 0.6 0.5 0.3 0.5 0.4 0.4 0.15 0.06 0.05 0.23 0.05 0.10 0.27 0.10 0.07 0.33 0.07 0.16 0.01 0.04 0.01 0.06 0.21 0.06 0.13 0.26 0.20 0.19 0.04 0.12 0.04 0.05 0.20 0.05 0.08 0.08 0.05 0.21 0.05 0.19 0.03 0.15 0.04 0.02 0.05 0.08 0.06 0.02 0.08 0.18 0.09 0.04 0.16 0.04 0.14 0.18 0.07 0.09 0.11 0.07 0.30 0.12 0.05 0.14 0.17 0.06 0.13 0.08 0.03 0.03 0.13 0.03 0.04 0.06 0.06 0.05 0.06 0.16 0.11 0.12 0.10 0.05 0.08 0.03 0.10 0.11 0.10 0.12 0.29 0.10 0.16 0.27 0.13 0.11 0.23 0.10 0.11 0.11 0.18 0.11 0.12 0.20 0.11 0.11 0.02 0.09 0.13 0.12 0.17 0.11 0.13 0.19 0.12 0.09 0.11 0.12 0.22 0.11 0.15 0.12 0.21 0.12 0.11 0.05 0.19 0.10 0.11 0.09 0.13 0.08 0.11 0.20 0.11 0.15 0.09 0.13 0.13 0.10 0.12 0.06 0.10 0.05 0.03 0.10 0.10 0.08 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.06 0.06 0.04 0.08 0.09 0.05 0.03 0.06 0.04 0.05 0.02 0.01 0.01 0.03 0.01 0.01 0.04 0.01 0.01 0.05 0.01 0.02 0.00 0.01 0.00 0.01 0.03 0.01 0.02 0.02 0.03 0.02 0.01 0.02 0.01 0.01 0.03 0.01 0.01 0.01 0.01 0.03 0.01 0.03 0.00 0.02 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.03 0.01 0.01 0.01 0.01 0.04 0.02 * 0.01 0.02 * 0.03 0.01 * 0.02 * 0.01 * 0.00 0.00 * 0.01 0.00 0.01 * 0.01 * 0.01 * 0.01 0.01 0.02 0.02 0.02 0.01 0.01 0.01 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
405

463

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Small intestine (C17) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
406

Male ASR(W) CUM 0-74 1.0 1.1 1.3 0.8 1.4 1.2 0.7 1.1 1.6 0.4 0.3 0.9 0.4 0.3 0.2 0.7 0.8 1.0 0.6 0.3 0.3 0.2 0.4 0.5 0.4 0.8 0.4 0.9 0.3 0.8 0.8 0.3 0.5 0.8 0.8 0.6 1.0 1.0 1.3 0.9 1.0 1.1 1.0 1.3 1.0 1.2 0.8 1.0 0.8 0.8 0.7 0.8 1.1 0.9 0.6 1.3 1.1 0.8 1.1 0.9 1.0 0.9 0.4 1.2 1.6 0.9 1.2 1.0 1.0 1.4 1.3 0.7 0.6 0.5 1.0 0.7 0.5 0.9 1.0 0.03 0.13 0.16 0.17 0.24 0.17 0.32 0.08 0.37 0.21 0.09 0.22 0.11 0.14 0.09 0.11 0.10 0.12 0.31 0.18 0.09 0.10 0.12 0.13 0.07 0.05 0.14 0.27 0.03 0.11 0.07 0.03 0.06 0.05 0.06 0.12 0.07 0.17 0.23 0.22 0.19 0.19 0.16 0.18 0.23 0.26 0.24 0.22 0.09 0.07 0.11 0.11 0.11 0.09 0.12 0.40 0.10 0.29 0.21 0.22 0.14 0.19 0.22 0.17 0.25 0.24 0.12 0.24 0.29 0.26 0.18 0.14 0.20 0.21 0.37 0.13 0.11 0.22 0.12 0.12 0.13 0.14 0.11 0.20 0.15 0.11 0.12 0.20 0.05 0.03 0.10 0.06 0.05 0.02 0.07 0.10 0.12 0.06 0.03 0.03 0.03 0.04 0.06 0.05 0.09 0.05 0.11 0.04 0.09 0.10 0.04 0.07 0.09 0.09 0.09 0.11 0.13 0.15 0.09 0.11 0.13 0.12 0.13 0.10 0.15 0.11 0.15 0.10 0.09 0.08 0.09 0.14 0.10 0.08 0.11 0.14 0.13 0.11 0.10 0.11 0.10 0.06 0.15 0.21 0.10 0.14 0.13 0.13 0.18 0.16 0.08 0.08 0.04 0.10 0.09 0.06 0.10 0.11 0.01 0.02 0.02 0.03 0.04 0.03 0.06 0.01 0.06 0.03 0.01 0.03 0.02 0.03 0.01 0.01 0.01 0.02 0.03 0.02 0.01 0.02 0.02 0.02 0.01 0.01 0.02 0.04 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.03 0.03 0.03 0.03 0.02 0.02 0.02 0.03 0.04 0.03 0.03 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.04 0.01 0.05 0.03 0.03 0.02 0.02 0.03 0.02 0.03 0.03 0.02 0.03 0.04 0.04 0.02 0.02 0.03 0.02 0.05 0.02 0.02 0.03 0.02

Cases 650 54 53 12 25 36 8 172 10 8 4 13 12 4 7 35 58 48 4 6 13 3 3 10 11 239 20 9 114 47 148 85 63 233 142 31 183 29 27 10 28 39 27 35 14 13 9 18 76 154 45 46 77 72 31 12 78 10 13 25 41 32 3 40 34 7 101 25 8 30 49 22 6 6 3 30 24 16 43

Female ASR(W) CUM 0-74 0.6 0.5 0.8 0.4 0.7 0.6 0.7 0.7 0.5 0.6 0.6 0.6 0.3 0.3 0.4 0.4 0.6 0.6 0.8 0.5 0.3 0.1 0.1 0.3 0.1 0.5 0.5 0.7 0.3 0.5 0.6 0.2 0.3 0.5 0.5 0.5 0.7 0.6 0.8 0.5 0.8 0.9 0.5 0.7 0.7 0.5 0.4 0.7 0.6 0.5 0.4 0.5 0.7 0.5 0.5 1.2 0.5 0.6 0.4 0.7 0.6 0.9 0.3 0.5 0.9 0.4 0.7 1.1 0.6 1.1 0.8 0.5 0.2 0.4 0.4 0.5 0.5 0.5 0.5 0.02 0.07 0.11 0.11 0.14 0.09 0.25 0.05 0.18 0.25 0.40 0.16 0.10 0.13 0.14 0.08 0.08 0.09 0.38 0.22 0.08 0.07 0.06 0.11 0.04 0.04 0.13 0.25 0.03 0.08 0.06 0.02 0.04 0.03 0.05 0.09 0.06 0.12 0.17 0.16 0.17 0.16 0.11 0.13 0.21 0.16 0.15 0.18 0.07 0.05 0.07 0.08 0.09 0.07 0.11 0.39 0.06 0.21 0.12 0.18 0.11 0.18 0.23 0.09 0.18 0.14 0.09 0.24 0.22 0.23 0.14 0.12 0.12 0.19 0.25 0.10 0.13 0.14 0.09 0.06 0.06 0.09 0.05 0.08 0.06 0.06 0.08 0.06 0.04 0.05 0.07 0.05 0.04 0.03 0.06 0.07 0.07 0.12 0.03 0.04 0.01 0.02 0.03 0.02 0.06 0.06 0.07 0.03 0.06 0.07 0.02 0.03 0.05 0.06 0.05 0.08 0.07 0.09 0.05 0.09 0.12 0.06 0.08 0.08 0.07 0.06 0.09 0.06 0.06 0.05 0.06 0.08 0.06 0.06 0.12 0.05 0.06 0.05 0.09 0.07 0.11 0.03 0.05 0.11 0.04 0.08 0.14 0.07 0.13 0.09 0.07 0.02 0.06 0.03 0.05 0.06 0.05 0.05 0.00 0.01 0.01 0.02 0.02 0.01 0.03 0.01 0.03 0.02 0.05 0.02 0.02 0.02 * 0.01 * 0.01 * 0.01 0.01 0.07 0.02 0.01 * 0.01 * 0.01 0.01 * 0.01 * 0.01 0.02 0.03 0.00 * 0.01 * 0.01 0.00 * 0.00 0.00 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.02 0.01 0.02 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.05 0.01 0.03 0.02 0.03 0.01 0.02 0.02 0.01 0.02 0.02 0.01 0.03 0.03 0.03 0.02 0.02 0.01 0.03 0.02 0.01 0.01 0.02 0.01

879 85 71 23 36 55 5 224 24 4 12 17 19 5 8 45 67 60 4 3 11 5 10 14 31 240 10 10 93 55 167 109 91 282 166 28 204 36 33 17 28 42 39 53 20 22 13 25 78 154 43 49 103 88 27 12 126 8 26 20 54 26 4 56 48 14 114 20 12 33 65 26 11 6 7 35 27 19 68

464

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Small intestine (C17) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 37 55 9 242 11 7 16 94 143 33 104 111 46 4 37 54 29 4 25 23 39 20 12 17 541 19 8 6 29 20 15 28 485 20 32 76 85 150 247 85 294 363 170 181 73 163 282 2 157 65 19 166 61 7 4 146 54 1 5 11 9 25 Male ASR(W) CUM 0-74 0.5 0.5 0.7 1.4 0.5 0.2 0.3 0.9 1.2 0.2 0.6 0.7 0.7 0.3 0.7 0.8 0.6 0.3 1.1 0.7 1.0 0.8 0.6 0.5 1.4 1.2 0.8 0.9 1.5 1.6 1.4 1.0 0.8 0.5 0.9 0.6 0.9 0.9 0.9 0.8 0.9 0.7 0.9 0.9 1.3 0.8 1.2 0.3 1.3 1.1 1.0 1.0 1.0 0.8 0.9 1.1 1.3 0.2 0.6 2.2 0.6 2.1 0.08 0.07 0.23 0.09 0.14 0.06 0.07 0.09 0.11 0.04 0.06 0.07 0.10 0.15 0.13 0.11 0.12 0.19 0.24 0.16 0.16 0.18 0.18 0.12 0.06 0.28 0.31 0.39 0.29 0.37 0.35 0.21 0.04 0.12 0.16 0.08 0.10 0.08 0.06 0.09 0.06 0.04 0.07 0.07 0.16 0.07 0.08 0.25 0.11 0.15 0.25 0.08 0.13 0.32 0.44 0.10 0.18 0.23 0.29 0.68 0.22 0.44 0.07 0.06 0.12 0.16 0.06 0.02 0.03 0.10 0.14 0.02 0.07 0.07 0.08 0.06 0.09 0.09 0.08 0.05 0.11 0.09 0.13 0.11 0.10 0.05 0.17 0.13 0.10 0.08 0.19 0.24 0.22 0.12 0.10 0.05 0.10 0.07 0.09 0.10 0.11 0.10 0.11 0.09 0.10 0.10 0.17 0.11 0.14 0.04 0.14 0.13 0.11 0.11 0.12 0.10 0.11 0.13 0.14 0.06 0.06 0.26 0.07 0.26 0.01 0.01 0.04 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.02 0.01 0.02 0.03 0.03 0.02 0.02 0.03 0.03 0.02 0.01 0.04 0.05 0.04 0.04 0.06 0.07 0.03 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.03 0.01 0.02 0.05 0.06 0.01 0.02 0.06 0.04 0.09 0.03 0.07 Cases 43 65 10 247 7 12 13 81 117 75 77 97 32 7 38 40 23 6 9 12 20 11 11 19 475 17 11 10 17 15 5 33 422 18 20 87 86 135 222 61 241 300 134 144 67 162 221 2 119 47 14 160 43 5 5 115 24 1 5 6 6 4 Female ASR(W) CUM 0-74 0.3 0.3 0.6 1.2 0.2 0.2 0.1 0.6 0.7 0.3 0.4 0.4 0.3 0.3 0.5 0.5 0.4 0.7 0.4 0.4 0.3 0.4 0.4 0.4 1.0 0.9 1.3 1.1 0.7 0.8 0.4 1.2 0.6 0.4 0.5 0.6 0.7 0.6 0.6 0.4 0.6 0.5 0.6 0.5 0.8 0.6 0.9 0.4 0.9 0.7 0.8 0.8 0.6 0.6 1.2 0.8 0.5 0.2 0.7 1.1 0.2 0.3 0.06 0.05 0.21 0.09 0.06 0.06 0.04 0.07 0.07 0.04 0.05 0.05 0.07 0.13 0.09 0.09 0.10 0.31 0.14 0.13 0.08 0.13 0.14 0.10 0.05 0.23 0.40 0.41 0.20 0.24 0.17 0.23 0.03 0.10 0.12 0.07 0.08 0.06 0.05 0.06 0.05 0.03 0.06 0.05 0.12 0.06 0.06 0.25 0.09 0.12 0.23 0.07 0.10 0.29 0.61 0.08 0.11 0.19 0.34 0.45 0.09 0.17 0.04 0.05 0.07 0.16 0.01 0.03 0.02 0.07 0.07 0.03 0.04 0.05 0.04 0.05 0.06 0.05 0.06 0.09 0.04 0.05 0.04 0.04 0.07 0.05 0.13 0.12 0.17 0.12 0.09 0.10 0.06 0.15 0.07 0.04 0.05 0.07 0.08 0.07 0.07 0.04 0.07 0.06 0.07 0.06 0.09 0.08 0.10 0.03 0.10 0.10 0.10 0.09 0.06 0.08 0.14 0.09 0.05 0.05 0.08 0.10 0.02 0.03 0.01 0.01 0.03 0.01 0.01 * 0.01 0.01 0.01 * 0.01 0.00 0.01 0.01 0.01 0.03 0.01 0.01 0.01 0.04 0.02 0.01 0.01 0.02 0.02 0.01 0.01 0.03 0.05 0.05 0.03 0.03 0.03 0.03 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.03 0.01 0.01 0.04 0.07 0.01 0.01 0.05 0.04 0.05 0.02 0.02

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
407

465

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Large bowel (C18-21)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 152 339 113 75 125 260 494 103 246 6570 119 472 975 234 189 84 35704 3709 5920 1999 1211 1017 54 1839 18074 241 1640 5782 1090 4634 554 6296 36828 3456 2344 4536 26000 7417 522 556 254 130 686 4889 9612 1109 390 259 293 192 1616 5523 4308 5373 280 5004 767 570 173 28655 2171 26101 8695 1991 6609 2479 760 1660 1402 17898 2146 15271 8658 5039 6168 6449 1620 4777 492 953 Male ASR(W) CUM 0-74 6.6 6.9 12.0 7.5 7.4 28.5 24.4 15.8 17.7 32.8 13.5 13.6 13.0 8.4 16.2 9.4 0.58 0.40 1.15 1.03 0.80 1.85 1.18 1.65 1.17 0.42 1.26 0.65 0.43 0.57 1.21 1.05 3.37 2.81 1.90 2.20 3.86 1.62 1.51 1.49 0.98 1.93 1.13 5.14 4.82 4.32 5.59 5.30 6.58 8.51 5.84 5.34 4.90 4.83 4.59 4.80 4.53 4.77 3.88 4.15 3.53 4.89 3.49 4.32 4.13 4.28 3.82 3.77 4.40 3.69 4.26 4.23 5.33 3.81 3.94 5.30 4.56 3.30 4.55 4.06 5.02 4.75 5.01 4.88 5.68 3.36 4.69 4.97 4.66 4.54 5.22 4.40 4.34 5.34 4.10 3.85 5.20 6.06 5.08 4.92 5.19 5.30 5.55 5.93 5.46 6.22 5.65 0.27 0.17 0.24 0.18 0.06 0.19 0.09 0.06 0.08 0.17 0.16 0.03 0.10 0.07 0.16 0.20 0.26 1.49 0.18 0.05 0.44 0.16 0.07 0.18 0.08 0.26 0.06 0.03 0.08 0.13 0.07 0.04 0.06 0.25 0.21 0.29 0.53 0.19 0.08 0.06 0.20 0.25 0.31 0.43 0.41 0.11 0.08 0.08 0.09 0.36 0.10 0.23 0.31 0.34 0.04 0.13 0.04 0.06 0.15 0.07 0.11 0.27 0.13 0.13 0.05 0.16 0.05 0.07 0.10 0.09 0.09 0.19 0.10 0.36 0.23 Cases 154 271 95 89 94 210 590 106 330 7518 144 648 1020 290 275 106 31165 2914 5048 1746 1137 774 33 1690 16167 253 1403 5630 1330 4231 506 5592 35620 3312 2506 3981 25444 7219 524 529 251 145 552 4878 9675 1268 333 217 276 180 1562 5592 4216 5659 382 5210 930 690 211 27711 2363 24982 8668 2299 6285 2623 861 1714 1342 18153 2456 15259 8780 5302 6335 6035 1737 4262 521 912 Female ASR(W) CUM 0-74 6.8 4.8 9.2 8.1 6.3 15.9 23.0 15.4 18.2 26.3 13.5 14.3 12.1 8.9 18.0 9.0 29.4 26.1 25.9 30.5 31.7 35.3 45.6 35.3 30.4 36.8 27.0 27.3 31.9 26.0 33.4 23.8 25.7 22.6 32.4 19.9 26.9 25.6 28.9 25.2 20.5 26.9 19.7 26.5 26.3 34.3 23.1 19.9 35.3 24.8 19.1 28.6 25.6 31.2 38.9 30.5 33.2 37.1 23.9 29.4 32.3 29.0 28.1 34.0 26.6 28.5 35.3 26.3 24.5 31.2 38.1 30.0 30.7 32.2 34.1 31.5 36.3 29.9 35.9 28.7 0.57 0.30 0.96 0.98 0.79 1.24 1.02 1.55 1.03 0.32 1.16 0.59 0.39 0.55 1.17 0.91 0.18 0.52 0.41 0.84 1.05 1.35 8.34 0.97 0.26 2.63 0.85 0.40 0.95 0.44 1.55 0.35 0.15 0.41 0.68 0.33 0.20 0.34 1.36 1.17 1.33 2.53 0.88 0.44 0.30 1.02 1.35 1.39 2.47 1.91 0.50 0.46 0.43 0.48 2.05 0.50 1.24 1.60 1.96 0.21 0.69 0.22 0.33 0.75 0.37 0.60 1.27 0.69 0.75 0.26 0.80 0.28 0.37 0.53 0.47 0.45 0.93 0.51 1.66 1.11 1.84 2.69 1.97 2.06 2.98 1.58 1.67 1.29 1.04 1.96 0.94 3.41 2.99 2.97 3.56 3.74 4.23 5.40 4.01 3.55 4.29 3.09 3.19 3.82 3.00 3.96 2.72 2.93 2.59 3.79 2.26 3.08 2.89 3.30 2.91 2.30 3.29 2.12 2.99 2.95 3.96 2.48 2.26 3.93 2.72 2.15 3.25 3.02 3.60 4.80 3.51 3.63 4.12 2.38 3.35 3.73 3.30 3.28 4.03 3.08 3.35 4.14 3.09 2.81 3.59 4.48 3.44 3.57 3.73 4.01 3.63 4.14 3.45 4.03 3.30 * * * *

0.17 0.15 0.25 0.15 0.04 0.17 0.09 0.06 0.08 0.15 0.13 * 0.03 0.08 0.06 0.12 0.15 0.20 1.31 0.14 0.04 0.39 0.12 0.06 0.14 0.06 0.24 0.05 0.02 0.06 0.10 0.05 0.03 0.05 0.20 0.17 0.18 0.35 0.12 0.07 0.04 0.15 0.19 0.19 0.32 0.26 0.07 0.07 0.07 0.07 0.31 0.07 0.17 0.22 0.28 0.03 0.10 0.03 0.05 0.11 0.05 0.09 0.19 0.10 0.11 0.04 0.12 0.04 0.05 0.08 0.07 0.06 0.13 0.07 0.24 0.16

42.6 0.23 40.1 0.68 37.2 0.51 46.7 1.11 42.9 1.28 53.5 1.72 71.7 10.25 51.0 1.24 43.6 0.34 43.5 2.94 40.4 1.08 38.2 0.52 39.8 1.25 37.7 0.57 38.3 1.69 33.1 0.44 35.1 0.19 30.0 0.52 40.9 0.86 29.1 0.45 36.6 0.24 35.3 0.43 38.7 1.74 32.7 1.46 29.2 1.89 38.5 3.74 32.4 1.28 36.2 0.55 35.6 0.38 43.9 1.34 33.0 1.76 32.7 2.10 47.5 3.13 35.9 2.63 27.1 0.70 38.4 0.56 33.7 0.53 42.0 0.61 40.1 2.45 41.9 0.64 42.6 1.60 50.7 2.22 27.6 2.20 39.5 0.26 41.2 0.90 39.2 0.27 38.4 0.42 44.4 1.03 37.1 0.47 36.9 0.77 46.3 1.77 34.5 0.87 32.1 0.90 43.6 0.34 49.9 1.10 42.7 0.37 41.7 0.47 43.7 0.66 44.7 0.59 46.3 0.59 49.8 1.27 45.4 0.68 51.6 2.38 45.1 1.54

466

*Important. See note on population page.

408

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Large bowel (C18-21) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 2171 9712 13112 1629 11279 5555 1254 4224 8625 715 7832 1340 307163 27683 268954 13569 1396 11779 2009 73 633 1260 28258 2766 24605 16548 1421 14702 4945 4489 22290 1524 20421 1789 33857 3020 27826 92106 5622 8328 6364 70792 5557 1321 4180 22324 2474 19326 1688 865 7301 4765 3249 7687 80 1374 8775 272 427 6533 575 510 543 1155 36 1334 249 335 151 7337 6966 272 1630 1812 2304 6166 3464 14062 3652 Male ASR(W) CUM 0-74 42.5 42.8 38.5 48.2 37.3 41.7 50.1 40.0 42.8 49.2 42.4 37.8 40.1 44.7 39.6 44.9 49.6 44.7 32.5 21.4 34.3 32.4 43.1 41.3 43.9 41.1 43.4 40.0 39.8 35.4 45.3 48.9 44.7 45.2 38.4 45.3 37.9 38.6 31.5 45.8 30.4 39.3 42.3 47.7 40.6 37.3 47.9 36.3 29.5 38.6 36.7 35.5 44.4 39.8 13.2 25.4 39.2 20.9 18.3 27.2 17.4 21.6 5.7 5.4 4.1 5.9 6.0 5.3 5.6 41.7 43.0 19.2 41.5 44.3 54.8 58.7 46.8 37.4 55.8 0.96 0.46 0.35 1.24 0.37 0.59 1.47 0.65 0.48 1.88 0.50 1.09 0.08 0.27 0.08 0.41 1.35 0.44 0.75 2.57 1.39 0.97 0.27 0.80 0.30 0.33 1.18 0.35 0.59 0.56 0.32 1.29 0.34 1.15 0.22 0.85 0.24 0.13 0.43 0.51 0.39 0.16 0.58 1.35 0.65 0.26 0.99 0.27 0.75 1.37 0.45 0.54 0.82 0.48 1.52 0.70 0.43 1.30 0.90 0.35 0.74 1.00 0.25 0.17 0.69 0.17 0.39 0.30 0.46 0.51 0.55 1.20 1.04 1.10 1.16 0.77 0.84 0.32 0.99 5.00 5.19 4.58 5.74 4.43 4.98 6.00 4.77 5.07 5.77 5.02 4.47 4.77 5.35 4.72 5.32 5.81 5.30 3.94 2.59 4.10 3.96 5.14 5.07 5.23 4.93 5.19 4.81 4.68 4.24 5.43 6.09 5.36 5.30 4.55 5.26 4.51 4.57 3.73 5.42 3.65 4.66 5.09 5.80 4.88 4.44 5.73 4.32 3.42 4.65 4.37 4.20 5.30 4.83 1.67 3.00 4.63 2.59 2.26 3.25 2.06 2.74 0.64 0.63 0.48 0.67 0.70 0.60 0.74 4.97 5.15 2.40 5.10 5.44 6.74 7.21 5.68 4.44 6.79 0.14 0.07 0.05 0.18 0.05 0.09 0.22 0.10 0.07 0.28 0.07 0.16 0.01 0.04 0.01 0.06 0.19 0.07 0.11 0.37 0.20 0.14 0.04 0.12 0.04 0.05 0.17 0.05 0.09 0.08 0.05 0.19 0.05 0.17 0.03 0.13 0.04 0.02 0.06 0.08 0.06 0.02 0.08 0.20 0.09 0.04 0.15 0.04 0.11 0.21 0.07 0.08 0.12 0.07 0.23 0.10 0.06 0.18 0.13 0.05 0.10 0.15 0.03 0.02 0.10 0.02 0.05 0.04 0.07 0.08 0.08 0.19 0.15 0.15 0.17 0.11 0.12 0.04 0.13 Cases 2240 10291 13331 1813 11320 5814 1412 4348 8496 840 7594 1186 305145 31173 263920 13925 1499 12088 1710 58 477 1138 29994 3664 25520 17131 1611 15061 4719 4518 22679 1724 20624 1864 33868 3361 27853 91132 5089 9161 5649 70342 5153 1389 3715 20818 2653 17644 1657 888 6881 4644 3310 7392 47 1135 7234 242 366 6339 448 457 395 675 34 914 160 302 115 7371 6982 257 1220 1454 1749 4331 2842 10353 2807 Female ASR(W) CUM 0-74 32.6 30.8 28.6 37.3 27.3 30.8 38.4 28.8 29.9 37.9 29.2 26.7 29.2 34.1 28.5 32.2 36.2 31.9 22.2 13.3 20.9 23.8 31.7 33.8 31.6 30.4 33.4 29.5 28.3 27.5 31.7 34.6 31.2 31.6 28.4 35.5 27.9 28.3 22.5 35.5 21.2 28.7 28.9 32.8 27.5 26.4 36.0 25.2 23.8 29.8 27.0 27.0 33.9 27.6 7.3 17.8 28.4 17.8 14.9 23.2 12.7 16.9 4.3 3.7 3.6 4.4 3.9 4.9 3.9 33.8 34.7 15.8 26.8 28.0 32.7 32.6 27.3 21.7 31.4 0.79 0.35 0.28 0.94 0.29 0.46 1.09 0.51 0.37 1.40 0.39 0.88 0.06 0.20 0.06 0.31 0.97 0.34 0.58 1.79 1.00 0.79 0.21 0.59 0.23 0.26 0.89 0.27 0.46 0.47 0.25 0.90 0.26 0.87 0.17 0.65 0.19 0.10 0.33 0.39 0.29 0.13 0.44 0.94 0.50 0.20 0.74 0.21 0.64 1.13 0.37 0.44 0.67 0.37 1.11 0.54 0.36 1.19 0.79 0.31 0.62 0.85 0.22 0.15 0.63 0.15 0.32 0.29 0.37 0.43 0.45 1.01 0.81 0.86 0.83 0.55 0.60 0.23 0.71 3.78 3.51 3.30 4.32 3.14 3.59 4.49 3.36 3.43 4.35 3.35 3.17 3.36 3.99 3.28 3.73 4.34 3.67 2.55 1.56 2.35 2.76 3.66 4.01 3.64 3.57 3.94 3.46 3.28 3.19 3.68 4.02 3.62 3.66 3.27 4.17 3.22 3.26 2.57 4.16 2.42 3.31 3.33 3.79 3.16 3.02 4.20 2.88 2.73 3.41 3.16 3.14 3.91 3.19 0.78 2.20 3.28 2.21 1.81 2.78 1.56 2.01 0.49 0.43 0.46 0.51 0.42 0.59 0.52 3.95 4.08 1.90 3.11 3.28 3.86 3.81 3.18 2.50 3.70 0.11 0.05 0.04 0.13 0.04 0.07 0.16 0.07 0.05 0.20 0.06 0.13 0.01 0.03 0.01 0.05 0.14 0.05 0.08 0.25 0.14 0.11 0.03 0.09 0.03 0.04 0.13 0.04 0.07 0.07 0.04 0.13 0.04 0.13 0.03 0.10 0.03 0.02 0.05 0.06 0.04 0.02 0.06 0.13 0.07 0.03 0.11 0.03 0.09 0.16 0.05 0.07 0.09 0.05 0.15 0.08 * 0.05 0.16 * 0.11 0.04 * 0.09 * 0.12 * 0.03 0.02 * 0.09 0.02 0.04 * 0.04 * 0.06 * 0.06 0.06 0.15 0.11 0.11 0.12 0.07 0.08 0.03 0.09

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
409

467

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Large bowel (C18-21) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
410

Male ASR(W) CUM 0-74 29.5 25.8 29.0 34.8 27.5 31.4 21.9 36.6 27.2 13.7 8.3 24.4 13.8 5.3 7.1 24.3 40.1 46.0 15.8 22.5 9.9 12.1 9.7 12.9 14.4 40.9 37.6 39.2 26.4 37.4 40.6 30.6 42.5 59.1 39.3 31.6 25.6 48.7 33.6 38.6 45.7 38.0 40.3 39.0 32.4 37.5 37.2 40.2 43.2 43.8 30.7 43.9 45.7 44.4 51.1 31.2 43.2 39.4 39.6 50.4 47.1 42.4 41.6 41.7 44.5 29.0 47.4 42.6 30.9 43.3 45.5 28.2 32.0 28.8 37.4 42.4 47.0 43.4 44.9 0.19 0.61 0.79 1.22 1.10 0.86 1.76 0.46 1.59 1.24 1.26 1.19 0.64 0.56 0.53 0.66 0.72 0.87 1.54 1.62 0.51 0.75 0.60 0.67 0.43 0.37 1.27 1.86 0.30 0.73 0.46 0.31 0.51 0.41 0.43 0.84 0.36 1.18 1.21 1.46 1.33 1.03 1.02 0.99 1.27 1.39 1.54 1.31 0.65 0.48 0.66 0.81 0.70 0.66 1.05 1.86 0.61 2.05 1.27 1.68 0.93 1.24 2.22 0.93 1.25 1.38 0.72 1.50 1.61 1.45 0.99 0.93 1.31 1.52 2.26 0.98 1.10 1.47 0.81 3.61 3.02 3.47 4.29 3.39 3.84 2.80 4.35 3.56 1.56 0.87 3.02 1.66 0.65 0.83 2.89 4.63 5.36 1.81 2.60 1.14 1.39 1.11 1.61 1.77 4.98 4.53 4.93 3.31 4.44 4.82 3.84 5.22 7.32 4.64 4.06 2.96 5.93 3.78 4.73 5.36 4.54 4.80 4.75 3.82 4.62 4.60 5.03 5.32 5.36 3.54 5.30 5.47 5.18 6.17 3.76 5.27 5.03 4.62 6.18 5.61 5.09 5.12 4.84 5.48 3.25 5.68 5.29 3.63 5.37 5.54 3.45 4.07 3.59 4.48 5.07 5.73 5.09 5.45 0.03 0.09 0.11 0.18 0.16 0.13 0.27 0.07 0.26 0.18 0.16 0.18 0.09 0.08 0.08 0.10 0.10 0.13 0.19 0.23 0.07 0.10 0.09 0.10 0.06 0.05 0.19 0.28 0.04 0.11 0.06 0.04 0.07 0.06 0.07 0.12 0.05 0.17 0.17 0.22 0.19 0.15 0.15 0.15 0.18 0.20 0.22 0.19 0.09 0.07 0.10 0.12 0.10 0.09 0.15 0.28 0.09 0.31 0.18 0.24 0.13 0.18 0.32 0.13 0.18 0.19 0.10 0.22 0.23 0.21 0.14 0.13 0.20 0.22 0.33 0.14 0.16 0.21 0.12

Cases 19979 1665 1245 642 623 1167 156 5539 327 152 83 373 438 62 112 1483 2782 2537 72 173 384 235 217 272 842 11780 858 435 8868 2287 7301 8271 5693 16111 8821 1803 5780 1367 747 576 1012 1348 1362 1372 641 703 571 718 4166 8443 2851 2773 4239 4923 2438 269 4075 367 983 861 2490 1344 371 2302 1104 431 3974 814 365 779 2112 840 469 396 265 1839 1798 811 2751

Female ASR(W) CUM 0-74 17.7 15.4 18.4 18.8 17.6 18.6 14.1 21.6 18.7 12.5 9.5 16.8 12.2 3.7 5.2 18.5 29.3 31.7 13.7 18.2 9.2 9.7 7.1 9.2 9.9 24.3 23.9 26.4 18.2 23.1 26.7 19.6 23.7 30.6 29.8 22.3 19.5 26.1 20.2 21.9 27.2 25.4 24.6 21.9 19.3 22.8 22.9 21.0 26.4 25.7 23.4 26.0 29.3 29.2 32.8 23.8 26.6 25.7 27.8 31.8 29.5 29.8 28.7 27.8 25.6 22.3 28.4 27.1 22.8 26.0 31.6 18.9 19.7 23.6 25.3 27.7 30.5 27.5 26.6 0.13 0.38 0.52 0.76 0.72 0.56 1.18 0.30 1.07 1.07 1.41 0.88 0.59 0.48 0.53 0.50 0.57 0.65 1.69 1.42 0.48 0.64 0.49 0.56 0.34 0.26 0.92 1.39 0.21 0.55 0.35 0.23 0.34 0.26 0.36 0.57 0.29 0.80 0.86 1.03 0.96 0.80 0.75 0.68 0.92 1.00 1.17 0.92 0.45 0.33 0.52 0.54 0.51 0.48 0.77 1.60 0.46 1.73 1.01 1.30 0.70 1.01 1.78 0.68 0.91 1.12 0.53 1.17 1.34 1.12 0.81 0.73 1.00 1.31 1.79 0.75 0.85 1.08 0.59 2.12 1.84 2.22 2.22 2.14 2.27 1.54 2.62 2.29 1.46 1.03 1.98 1.42 0.41 0.59 2.24 3.30 3.58 1.66 2.12 1.09 1.09 0.93 1.10 1.20 2.75 2.58 3.00 2.25 2.60 3.03 2.38 2.77 3.60 3.52 2.71 2.16 3.04 2.25 2.38 3.07 2.98 2.75 2.45 2.15 2.56 2.53 2.50 3.03 2.93 2.63 2.88 3.30 3.27 3.72 2.71 3.10 2.92 3.12 3.66 3.33 3.43 3.39 3.10 2.97 2.69 3.26 3.08 2.66 3.03 3.71 2.19 2.35 2.83 2.85 3.12 3.61 3.25 3.09 0.02 0.05 0.08 0.11 0.11 0.08 0.15 0.04 0.16 0.15 0.20 0.13 0.08 0.07 * 0.07 * 0.08 * 0.08 0.09 0.24 0.20 0.06 * 0.08 * 0.07 0.08 * 0.05 * 0.04 0.13 0.20 0.03 * 0.08 * 0.05 0.03 * 0.05 0.04 0.05 0.08 0.04 0.11 0.12 0.14 0.13 0.11 0.10 0.09 0.12 0.14 0.15 0.13 0.06 0.05 0.07 0.07 0.07 0.07 0.11 0.23 0.07 0.21 0.13 0.17 0.09 0.13 0.24 0.09 0.12 0.16 0.07 0.15 0.18 0.15 0.11 0.10 0.14 0.18 0.24 0.10 0.12 0.15 0.08

25365 2101 1490 899 695 1497 165 7332 369 131 152 443 490 94 210 1560 3228 2907 117 204 389 265 265 385 1139 12767 908 452 7875 2819 8578 10419 7224 21727 8994 1454 5234 1780 858 744 1224 1570 1675 1671 754 813 709 1076 4491 8616 2277 2975 4465 4778 2473 308 5362 401 1013 1036 3008 1364 416 2257 1433 452 4781 944 425 1019 2470 1009 638 398 286 2052 2175 920 3307

468

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Large bowel (C18-21) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 2116 3384 375 7808 801 1245 1860 4368 4871 5299 5616 8311 3093 358 2043 3328 1453 343 1126 995 1681 1022 934 1236 13048 527 335 272 648 503 372 935 23987 1627 1541 4507 4206 6644 11592 3604 11560 18022 7801 8807 2382 9035 11289 144 6249 2928 885 8543 2894 438 69 6436 1890 134 270 200 739 458 Male ASR(W) CUM 0-74 26.9 30.4 27.6 40.7 31.6 28.6 28.8 40.4 40.9 37.4 30.0 52.5 44.5 26.0 37.5 44.8 30.6 28.5 44.1 29.9 38.5 39.4 41.3 29.7 30.0 32.8 35.5 37.9 32.2 36.0 35.1 36.9 39.8 43.9 42.0 35.0 40.9 38.6 40.5 33.8 35.5 32.0 36.1 38.3 40.1 43.1 47.2 36.8 50.1 48.5 48.4 48.3 46.3 50.9 17.3 49.3 41.1 33.1 38.5 41.7 53.8 37.0 0.59 0.53 1.46 0.50 1.14 0.83 0.69 0.65 0.61 0.52 0.41 0.59 0.80 1.51 0.89 0.81 0.82 1.80 1.42 1.01 0.98 1.32 1.46 0.91 0.29 1.47 2.03 2.45 1.32 1.67 1.89 1.27 0.26 1.10 1.10 0.55 0.66 0.50 0.39 0.58 0.36 0.25 0.43 0.43 0.85 0.47 0.46 3.29 0.65 0.94 1.69 0.54 0.88 2.50 2.18 0.64 1.01 3.22 2.52 3.01 2.29 1.81 3.44 3.74 3.40 4.75 3.82 3.53 3.72 5.04 4.92 4.67 3.72 6.59 5.45 2.91 4.39 5.32 3.62 3.39 5.20 3.63 4.47 4.89 4.89 3.39 3.56 3.87 4.29 4.76 3.74 4.37 4.26 4.36 4.80 5.37 5.11 4.11 4.92 4.63 4.88 4.06 4.20 3.77 4.23 4.60 4.87 5.19 5.81 4.80 6.17 5.94 6.06 5.83 5.51 6.33 2.07 6.13 4.99 3.57 4.67 4.96 6.68 4.37 0.09 0.08 0.22 0.07 0.16 0.12 0.10 0.09 0.09 0.07 0.06 0.09 0.12 0.20 0.12 0.11 0.12 0.24 0.20 0.14 0.14 0.19 0.21 0.12 0.04 0.22 0.30 0.37 0.19 0.25 0.27 0.19 0.04 0.16 0.16 0.08 0.10 0.07 0.06 0.09 0.05 0.04 0.06 0.06 0.13 0.07 0.07 0.53 0.10 0.14 0.25 0.08 0.13 0.38 0.31 0.09 0.15 0.43 0.36 0.45 0.32 0.27 Cases 2598 3472 390 8066 779 1093 1752 3528 3749 7610 3859 6086 2450 268 1381 2129 1224 252 789 774 1299 717 687 962 12548 569 262 209 561 454 257 856 22425 1493 1382 3983 3309 5751 9400 3204 10896 17201 6420 7116 2181 8111 9461 82 5143 2605 830 7252 2282 340 40 6296 1470 116 143 162 613 334 Female ASR(W) CUM 0-74 18.5 19.1 22.6 32.7 20.3 17.9 18.5 25.2 24.2 27.3 17.7 26.7 23.9 16.6 18.9 22.0 21.2 19.2 26.4 19.6 24.3 22.1 25.8 18.8 23.4 24.9 21.1 21.3 20.9 23.3 19.4 24.7 28.7 32.3 29.4 24.5 23.0 24.5 24.2 23.7 24.8 22.3 22.9 23.9 27.7 27.5 33.2 24.9 35.3 34.1 36.3 33.1 30.7 32.7 9.8 39.5 26.4 22.5 18.6 28.8 32.0 24.8 0.39 0.35 1.21 0.43 0.77 0.59 0.47 0.47 0.44 0.34 0.30 0.36 0.52 1.19 0.60 0.54 0.64 1.55 1.09 0.79 0.75 0.97 1.14 0.71 0.25 1.18 1.49 1.71 1.00 1.28 1.33 0.97 0.21 0.89 0.87 0.45 0.46 0.37 0.29 0.47 0.28 0.20 0.33 0.32 0.66 0.35 0.38 2.94 0.54 0.76 1.40 0.43 0.70 1.88 1.57 0.55 0.76 2.44 1.61 2.33 1.62 1.50 2.30 2.25 2.64 3.80 2.31 2.12 2.26 3.00 2.71 3.28 2.14 3.15 2.80 1.79 2.23 2.47 2.38 2.22 3.02 2.27 2.85 2.59 2.89 2.15 2.82 2.77 2.52 2.41 2.47 2.67 2.30 2.96 3.40 3.89 3.58 2.87 2.62 2.86 2.80 2.78 2.83 2.57 2.65 2.76 3.23 3.21 3.96 2.67 4.15 3.91 4.25 3.89 3.50 3.68 1.01 4.77 3.01 2.38 2.14 3.24 3.74 2.80 0.06 0.05 0.17 0.06 0.11 * 0.08 0.07 0.06 * 0.06 0.05 0.04 0.05 0.07 0.15 0.08 0.07 0.09 0.19 0.15 0.10 0.10 0.13 0.15 0.09 0.04 0.16 0.22 0.23 0.14 0.17 0.18 0.14 0.03 0.13 0.13 0.06 0.07 0.05 0.04 0.07 0.04 0.03 0.05 0.05 0.09 0.05 0.05 0.40 0.08 0.11 0.20 0.06 0.10 0.27 0.21 0.08 0.11 0.33 0.22 0.31 0.21 0.22

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
411

469

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Colon (C18)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 66 212 62 29 67 186 311 53 146 3866 68 270 616 150 125 55 22226 2205 3437 1195 742 638 30 1163 11659 150 1007 4096 819 3239 366 4278 24224 2130 1663 2803 17350 4881 364 370 135 87 434 3269 6405 784 269 151 178 108 1016 3763 2821 3649 195 3394 549 418 117 20057 1574 18229 5951 1436 4457 1669 522 1111 902 12175 1594 10275 5820 3443 4144 4365 1183 3153 357 632 Male ASR(W) CUM 0-74 3.0 4.2 6.5 2.9 3.8 20.3 15.3 7.9 10.5 19.3 7.8 7.8 8.3 5.5 10.9 6.0 26.1 23.6 21.2 27.2 25.7 33.2 40.2 31.7 27.7 25.5 24.2 26.7 29.7 25.9 25.9 21.9 22.6 18.3 29.1 18.2 23.7 22.8 26.8 21.1 15.3 26.6 20.5 23.6 23.3 30.8 22.3 18.8 27.0 20.3 17.4 25.2 21.8 28.0 28.1 27.8 29.7 36.0 18.0 26.6 30.0 26.2 26.2 32.4 24.7 25.1 33.0 23.0 20.3 29.1 36.9 28.0 27.5 29.0 29.6 30.7 36.1 29.2 37.2 29.0 0.40 0.31 0.85 0.63 0.55 1.56 0.94 1.14 0.90 0.32 0.96 0.49 0.34 0.47 1.00 0.83 0.18 0.52 0.38 0.84 0.98 1.35 7.70 0.97 0.27 2.20 0.83 0.43 1.08 0.47 1.40 0.36 0.15 0.41 0.73 0.36 0.19 0.34 1.45 1.16 1.36 3.15 1.02 0.44 0.30 1.12 1.43 1.58 2.30 1.98 0.57 0.45 0.43 0.50 2.05 0.51 1.33 1.86 1.76 0.21 0.77 0.22 0.35 0.88 0.38 0.63 1.51 0.71 0.71 0.28 0.94 0.29 0.38 0.53 0.47 0.48 1.08 0.54 2.02 1.22 2.34 1.74 0.94 1.32 2.23 0.97 0.86 0.94 0.65 1.33 0.68 3.08 2.77 2.41 3.15 3.19 3.98 4.79 3.61 3.33 2.47 2.80 3.19 3.58 3.09 3.17 2.50 2.64 2.14 3.45 2.16 2.76 2.64 2.94 2.45 1.96 3.14 2.26 2.74 2.74 3.73 2.50 2.26 2.90 2.56 2.14 2.94 2.57 3.29 3.29 3.27 3.34 4.00 2.10 3.11 3.62 3.06 3.06 3.77 2.90 2.88 3.77 2.65 2.37 3.41 4.41 3.28 3.21 3.34 3.45 3.65 4.25 3.48 4.45 3.71 0.22 0.14 0.17 0.14 0.05 0.15 0.07 0.05 0.07 0.14 0.12 0.03 0.08 0.06 0.12 0.15 0.20 1.12 0.14 0.04 0.31 0.12 0.06 0.16 0.07 0.22 0.05 0.02 0.06 0.11 0.05 0.03 0.05 0.21 0.17 0.21 0.45 0.15 0.07 0.05 0.17 0.21 0.24 0.32 0.32 0.09 0.07 0.06 0.07 0.30 0.08 0.19 0.26 0.28 0.03 0.11 0.03 0.05 0.13 0.06 0.09 0.23 0.11 0.11 0.04 0.14 0.04 0.06 0.08 0.07 0.07 0.16 0.08 0.30 0.19 Cases 65 152 62 43 44 145 378 56 189 4593 101 409 673 181 177 51 22087 1979 3389 1218 804 553 16 1190 11744 185 1009 4170 1056 3064 341 4033 25391 2270 1928 2702 18248 5262 405 382 175 99 376 3588 6826 981 239 147 193 107 1041 3965 3041 4142 286 3812 717 541 153 20498 1768 18470 6326 1756 4515 1913 641 1239 968 13615 1933 11369 6573 4004 4596 4388 1308 3055 391 652 Female ASR(W) CUM 0-74 2.8 2.7 6.1 4.1 3.2 11.2 14.9 8.0 10.5 15.9 9.4 9.0 7.9 5.5 11.3 4.3 20.3 17.3 16.7 20.5 21.7 24.9 22.3 24.2 21.6 26.1 18.7 19.6 25.0 18.0 23.2 16.5 17.7 15.3 24.7 13.5 18.3 18.0 22.1 17.9 14.1 17.3 13.3 18.5 17.9 26.2 16.3 13.4 23.1 14.3 12.6 19.2 18.0 21.9 29.2 21.2 25.3 28.4 17.5 20.7 24.0 20.2 20.1 25.7 18.5 20.5 26.3 18.5 16.7 22.6 29.7 21.4 22.1 23.3 23.9 22.1 27.0 20.4 26.4 19.1 0.37 0.22 0.79 0.68 0.56 1.05 0.82 1.12 0.78 0.25 0.96 0.46 0.31 0.42 0.92 0.63 0.15 0.42 0.32 0.68 0.86 1.13 5.78 0.80 0.22 2.18 0.70 0.34 0.84 0.36 1.31 0.29 0.12 0.33 0.60 0.27 0.16 0.28 1.19 0.98 1.10 1.97 0.72 0.37 0.24 0.89 1.12 1.14 1.95 1.44 0.41 0.37 0.36 0.40 1.78 0.41 1.08 1.38 1.69 0.17 0.60 0.18 0.27 0.65 0.30 0.50 1.10 0.58 0.61 0.22 0.71 0.24 0.31 0.44 0.39 0.37 0.80 0.42 1.41 0.88 1.31 1.66 0.92 1.16 1.78 1.07 1.05 0.81 0.65 1.19 0.47 2.34 1.97 1.89 2.40 2.53 2.99 2.38 2.72 2.51 3.13 2.14 2.29 3.02 2.08 2.83 1.87 1.99 1.73 2.90 1.51 2.07 2.02 2.53 2.11 1.58 2.12 1.39 2.07 2.00 3.01 1.75 1.52 2.46 1.54 1.39 2.17 2.10 2.49 3.74 2.39 2.82 3.21 1.80 2.34 2.77 2.29 2.34 3.03 2.15 2.41 3.07 2.18 1.90 2.58 3.46 2.43 2.54 2.70 2.79 2.50 3.04 2.32 2.87 2.14 * * * *

0.15 0.12 0.17 0.11 0.04 0.14 0.07 0.04 0.06 0.12 0.10 * 0.02 0.06 0.05 0.10 0.13 0.17 0.96 0.12 0.03 0.34 0.10 0.05 0.12 0.05 0.21 0.04 0.02 0.05 0.09 0.04 0.02 0.04 0.17 0.14 0.15 0.28 0.10 0.05 0.04 0.13 0.16 0.16 0.26 0.19 0.06 0.05 0.05 0.06 0.28 0.06 0.15 0.19 0.24 0.02 0.09 0.02 0.04 0.10 0.04 0.08 0.17 0.09 0.09 0.03 0.10 0.03 0.05 0.07 0.06 0.05 0.11 0.06 0.20 0.13

470

*Important. See note on population page.

412

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Colon (C18) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 1409 6516 8957 1194 7635 3694 915 2732 6017 529 5439 882 208706 20141 181971 9177 985 7955 1313 40 391 853 19243 1971 16695 11405 1069 10071 3494 3009 15234 1124 13884 1207 22515 2129 18527 61287 3435 5945 3951 47351 3907 984 2891 15039 1794 12914 1100 598 4771 3105 2149 5270 48 756 5366 127 219 3788 280 335 181 548 18 672 113 147 62 5047 4823 149 983 1133 1368 3850 2063 8907 2263 Male ASR(W) CUM 0-74 27.1 28.1 25.9 35.2 24.8 27.3 36.3 25.3 29.4 36.6 28.9 24.2 26.7 32.5 26.2 29.8 35.1 29.4 20.8 12.1 21.0 21.5 28.7 29.5 29.0 27.8 32.7 26.8 27.5 23.0 30.2 36.0 29.6 29.8 25.1 32.2 24.7 25.2 19.1 32.8 19.1 25.6 29.3 35.3 27.6 24.8 34.8 23.8 18.8 26.0 23.6 22.8 29.0 26.7 7.9 14.0 23.8 9.8 9.4 15.8 8.5 14.1 1.9 2.6 2.0 3.0 2.7 2.3 2.2 28.2 29.2 10.6 24.9 27.2 32.1 36.0 27.2 23.6 33.9 0.76 0.37 0.29 1.06 0.30 0.47 1.25 0.51 0.40 1.63 0.41 0.86 0.06 0.23 0.06 0.33 1.14 0.35 0.60 1.96 1.09 0.78 0.22 0.67 0.24 0.27 1.03 0.28 0.49 0.45 0.26 1.11 0.27 0.93 0.18 0.72 0.19 0.11 0.34 0.44 0.31 0.13 0.48 1.16 0.53 0.21 0.84 0.22 0.59 1.11 0.36 0.43 0.66 0.39 1.17 0.53 0.33 0.89 0.65 0.27 0.52 0.81 0.14 0.12 0.47 0.12 0.27 0.20 0.29 0.42 0.45 0.89 0.80 0.85 0.88 0.60 0.64 0.25 0.76 3.17 3.39 3.04 4.17 2.90 3.23 4.34 2.98 3.45 4.34 3.39 2.80 3.14 3.88 3.07 3.48 4.08 3.44 2.55 1.68 2.61 2.60 3.38 3.63 3.40 3.29 3.85 3.18 3.19 2.70 3.59 4.48 3.50 3.49 2.93 3.72 2.89 2.95 2.24 3.85 2.28 2.99 3.51 4.31 3.29 2.90 4.13 2.79 2.18 3.03 2.79 2.68 3.44 3.21 0.96 1.66 2.78 1.24 1.14 1.88 1.00 1.78 0.21 0.30 0.23 0.34 0.32 0.25 0.30 3.32 3.46 1.35 2.99 3.30 3.89 4.42 3.30 2.78 4.05 0.11 0.06 0.04 0.16 0.04 0.07 0.19 0.08 0.06 0.24 0.06 0.13 0.01 0.03 0.01 0.05 0.16 0.05 0.09 0.32 0.17 0.12 0.03 0.10 0.04 0.04 0.15 0.04 0.07 0.07 0.04 0.17 0.04 0.14 0.03 0.11 0.03 0.02 0.05 0.06 0.05 0.02 0.07 0.17 0.08 0.03 0.12 0.03 0.09 0.17 0.06 0.07 0.10 0.06 0.17 0.08 0.05 0.13 0.09 0.04 0.07 0.12 0.02 0.02 0.07 0.02 0.04 0.03 0.04 0.06 0.07 0.14 0.11 0.12 0.13 0.09 0.09 0.04 0.10 Cases 1655 7521 9822 1380 8309 4194 1055 3108 6382 685 5653 883 223919 24011 193048 10170 1141 8811 1224 42 347 809 22028 2776 18687 12656 1248 11106 3533 3241 16792 1335 15260 1370 24700 2530 20284 65837 3504 6945 3845 50950 3917 1105 2780 15045 2040 12661 1140 647 5017 3370 2358 5610 32 698 4875 119 192 4051 225 325 148 339 19 479 73 141 46 5341 5060 175 835 1040 1198 2932 1869 7354 1954 Female ASR(W) CUM 0-74 22.7 21.4 20.3 27.6 19.2 21.3 27.7 19.7 21.6 31.0 20.7 19.1 20.6 26.0 20.0 22.8 27.4 22.4 15.5 9.7 15.0 16.5 22.5 25.3 22.2 21.7 25.5 20.8 20.5 18.7 22.5 26.5 22.1 22.7 19.9 26.4 19.4 19.7 15.2 26.6 14.4 19.8 21.4 25.9 19.8 18.5 27.3 17.4 15.6 20.7 18.9 18.8 23.3 20.2 5.1 10.9 18.9 8.7 7.8 14.6 6.5 12.1 1.6 1.9 2.1 2.4 1.8 2.3 1.6 24.0 24.6 10.8 18.1 19.6 21.9 21.5 17.1 15.0 21.1 0.65 0.29 0.23 0.80 0.24 0.38 0.92 0.41 0.31 1.27 0.32 0.73 0.05 0.18 0.05 0.26 0.84 0.28 0.48 1.53 0.85 0.65 0.17 0.50 0.19 0.22 0.77 0.23 0.39 0.38 0.21 0.79 0.21 0.74 0.14 0.56 0.16 0.09 0.27 0.34 0.24 0.10 0.37 0.83 0.42 0.16 0.64 0.17 0.51 0.93 0.30 0.37 0.55 0.31 0.94 0.42 0.29 0.83 0.57 0.25 0.45 0.72 0.13 0.11 0.48 0.11 0.22 0.20 0.24 0.36 0.38 0.84 0.66 0.71 0.68 0.44 0.46 0.19 0.57 2.58 2.42 2.32 3.14 2.20 2.47 3.20 2.29 2.45 3.56 2.35 2.29 2.36 3.03 2.28 2.61 3.24 2.55 1.79 1.20 1.67 1.92 2.58 2.99 2.54 2.53 2.98 2.43 2.35 2.15 2.60 3.08 2.55 2.62 2.28 3.09 2.23 2.25 1.71 3.11 1.62 2.27 2.46 3.03 2.28 2.09 3.15 1.97 1.77 2.34 2.21 2.18 2.72 2.33 0.59 1.37 2.16 1.10 0.94 1.78 0.81 1.45 0.18 0.24 0.26 0.27 0.18 0.28 0.21 2.80 2.89 1.35 2.11 2.30 2.59 2.54 2.00 1.72 2.51 0.10 0.04 0.03 0.12 0.04 0.06 0.13 0.06 0.05 0.18 0.05 0.11 0.01 0.03 0.01 0.04 0.12 0.04 0.07 0.23 0.12 0.09 0.03 0.07 0.03 0.03 0.11 0.03 0.06 0.06 0.03 0.11 0.03 0.11 0.02 0.08 0.02 0.01 0.04 0.05 0.04 0.02 0.05 0.12 0.06 0.02 0.09 0.02 0.07 0.14 0.05 0.06 0.08 0.05 0.13 0.06 * 0.04 0.11 * 0.08 0.03 * 0.06 * 0.10 * 0.02 0.02 * 0.07 0.02 0.02 * 0.03 * 0.03 * 0.05 0.05 0.13 0.09 0.09 0.10 0.06 0.06 0.03 0.08

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
413

471

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Colon (C18) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
414

Male ASR(W) CUM 0-74 14.2 12.7 13.5 16.7 14.6 15.5 11.2 18.7 14.8 8.4 5.5 13.9 7.3 2.5 3.6 14.5 22.6 26.5 7.4 10.5 5.0 7.9 5.3 7.6 7.8 24.1 21.3 23.4 12.1 20.1 22.8 15.8 21.4 31.6 22.1 18.3 14.4 28.9 19.0 22.4 28.2 23.2 22.8 22.9 18.7 21.8 17.0 24.8 24.7 24.2 18.8 25.1 27.6 26.6 29.6 23.4 24.3 26.2 26.4 36.0 30.3 27.0 29.9 29.2 33.5 19.7 32.1 28.5 18.5 30.3 30.5 19.4 20.6 18.1 24.6 29.0 28.8 30.2 30.1 0.13 0.44 0.55 0.86 0.82 0.61 1.25 0.33 1.21 0.97 1.06 0.89 0.47 0.38 0.38 0.52 0.54 0.66 1.04 1.11 0.36 0.61 0.44 0.51 0.32 0.28 0.95 1.43 0.20 0.53 0.34 0.22 0.36 0.30 0.32 0.63 0.27 0.90 0.90 1.11 1.04 0.80 0.76 0.76 0.96 1.05 1.01 1.03 0.49 0.35 0.51 0.62 0.54 0.50 0.80 1.62 0.45 1.67 1.03 1.42 0.74 0.98 1.87 0.76 1.09 1.13 0.59 1.22 1.24 1.20 0.80 0.77 1.05 1.18 1.83 0.81 0.86 1.22 0.66 1.72 1.43 1.64 2.07 1.76 1.85 1.52 2.23 1.91 0.91 0.58 1.64 0.85 0.29 0.42 1.70 2.57 3.03 0.90 1.18 0.58 0.87 0.59 0.93 0.93 2.85 2.48 3.03 1.49 2.32 2.66 1.96 2.59 3.88 2.56 2.32 1.62 3.45 2.16 2.67 3.25 2.76 2.67 2.76 2.13 2.73 2.13 3.07 3.06 2.94 2.09 2.98 3.24 3.02 3.52 2.91 2.94 3.24 3.08 4.47 3.61 3.20 3.63 3.34 4.11 2.18 3.84 3.56 2.18 3.77 3.69 2.40 2.62 2.31 2.78 3.42 3.50 3.49 3.67 0.02 0.06 0.08 0.13 0.12 0.09 0.21 0.05 0.19 0.14 0.13 0.13 0.07 0.05 0.05 0.08 0.08 0.10 0.14 0.15 0.05 0.08 0.06 0.07 0.04 0.04 0.14 0.22 0.03 0.08 0.05 0.03 0.05 0.04 0.05 0.09 0.04 0.13 0.13 0.16 0.15 0.12 0.11 0.11 0.13 0.16 0.15 0.15 0.07 0.05 0.07 0.09 0.08 0.07 0.11 0.25 0.07 0.25 0.15 0.21 0.11 0.14 0.27 0.11 0.16 0.15 0.09 0.18 0.18 0.18 0.12 0.11 0.16 0.18 0.26 0.12 0.12 0.17 0.10

Cases 10043 838 613 303 319 611 75 2938 169 94 55 231 254 37 73 906 1810 1673 41 96 208 172 117 167 452 7688 523 294 4608 1475 4783 4762 3021 9660 5730 1138 3739 885 473 367 665 882 883 880 415 433 330 494 2659 5401 1953 1797 2874 3419 1587 187 2772 264 676 639 1675 954 279 1698 851 298 2857 586 242 567 1504 597 326 288 188 1341 1219 575 2023

Female ASR(W) CUM 0-74 8.8 7.8 9.1 8.8 8.9 9.8 6.9 11.5 9.9 7.6 6.7 10.4 7.1 2.2 3.5 11.4 19.0 20.8 8.2 9.9 5.0 7.2 3.8 5.6 5.3 15.5 14.3 17.3 9.4 14.2 16.9 11.2 12.6 18.0 18.7 13.9 12.5 16.1 12.5 13.4 17.2 16.3 15.6 13.6 11.5 13.5 12.7 13.9 16.5 15.9 15.1 16.4 19.3 19.4 20.2 15.6 17.8 18.6 18.9 23.2 19.5 21.0 21.9 20.1 19.5 15.6 20.2 19.8 15.1 19.0 21.9 13.3 13.7 16.6 18.4 20.0 19.9 19.0 19.4 0.09 0.27 0.37 0.52 0.51 0.40 0.82 0.22 0.79 0.83 1.20 0.70 0.45 0.38 0.44 0.39 0.46 0.52 1.32 1.04 0.36 0.56 0.35 0.44 0.25 0.21 0.71 1.12 0.15 0.42 0.28 0.17 0.25 0.20 0.28 0.45 0.24 0.62 0.67 0.80 0.75 0.64 0.59 0.53 0.68 0.76 0.87 0.74 0.35 0.25 0.40 0.43 0.41 0.38 0.59 1.26 0.37 1.53 0.83 1.09 0.57 0.85 1.56 0.58 0.79 0.94 0.45 1.01 1.09 0.96 0.66 0.60 0.83 1.08 1.55 0.64 0.68 0.89 0.50 1.04 0.91 1.10 1.02 1.06 1.19 0.77 1.38 1.17 0.93 0.69 1.22 0.83 0.23 0.42 1.34 2.09 2.31 1.02 1.11 0.60 0.78 0.48 0.72 0.63 1.74 1.57 1.92 1.17 1.55 1.88 1.36 1.46 2.11 2.18 1.69 1.35 1.81 1.41 1.39 1.91 1.93 1.73 1.52 1.22 1.46 1.38 1.63 1.86 1.77 1.65 1.78 2.11 2.14 2.23 1.75 2.05 1.98 2.12 2.70 2.22 2.40 2.60 2.26 2.26 1.79 2.32 2.27 1.76 2.21 2.56 1.54 1.64 2.02 2.09 2.25 2.31 2.26 2.26 0.01 0.04 0.05 0.07 0.07 0.06 0.10 0.03 0.11 0.12 0.15 0.10 0.07 0.05 * 0.06 * 0.06 * 0.07 0.08 0.19 0.14 0.05 * 0.07 * 0.05 0.06 * 0.03 * 0.03 0.10 0.16 0.02 * 0.06 * 0.04 0.02 * 0.03 0.03 0.04 0.06 0.03 0.09 0.09 0.11 0.10 0.09 0.08 0.07 0.09 0.10 0.11 0.10 0.05 0.04 0.06 0.06 0.06 0.05 0.08 0.18 0.05 0.17 0.11 0.15 0.08 0.11 0.21 0.08 0.11 0.13 0.06 0.13 0.15 0.13 0.09 0.08 0.11 0.16 0.20 0.08 0.09 0.12 0.07

12181 1014 684 422 362 727 85 3682 194 80 83 253 261 46 101 909 1818 1663 58 97 197 174 143 230 619 7660 529 273 3598 1542 4908 5360 3660 11758 5161 844 2972 1072 496 437 765 973 957 992 440 473 347 676 2576 4836 1427 1700 2724 2911 1454 230 3060 269 681 746 1950 885 301 1615 1086 308 3270 643 260 729 1684 697 417 256 190 1421 1344 641 2250

472

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Colon (C18) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 1076 1582 206 4719 481 629 1105 2564 2947 2941 2702 4401 1648 203 1299 2026 913 205 747 608 1007 589 607 745 7768 339 228 168 348 336 233 551 14436 938 858 2547 2457 3738 6158 2032 7285 10533 4271 4988 1472 5425 6716 86 3900 1789 527 5136 1705 268 36 3941 1198 89 149 115 466 320 Male ASR(W) CUM 0-74 13.6 14.3 15.1 24.1 18.8 14.3 17.0 23.6 24.6 20.7 14.6 27.5 23.6 14.5 23.3 27.0 19.2 17.4 28.6 18.2 23.0 22.6 26.6 17.9 17.5 20.5 23.6 22.8 16.8 23.3 21.3 21.3 23.6 25.1 23.3 19.3 23.5 21.1 21.0 18.8 21.9 18.3 19.4 21.3 24.6 25.4 27.8 22.3 30.8 29.2 28.1 28.5 27.0 31.2 9.6 29.8 25.6 21.6 20.6 24.5 31.9 25.9 0.42 0.36 1.08 0.38 0.87 0.59 0.53 0.49 0.47 0.38 0.29 0.42 0.59 1.12 0.69 0.62 0.64 1.43 1.13 0.78 0.76 1.00 1.17 0.71 0.22 1.15 1.64 1.89 0.94 1.32 1.46 0.96 0.20 0.83 0.82 0.41 0.49 0.36 0.28 0.43 0.28 0.19 0.31 0.32 0.67 0.36 0.35 2.58 0.51 0.73 1.27 0.41 0.67 1.96 1.66 0.49 0.79 2.61 1.82 2.33 1.72 1.52 1.73 1.72 1.93 2.80 2.20 1.81 2.19 2.91 2.98 2.55 1.78 3.41 2.92 1.67 2.69 3.14 2.24 2.03 3.33 2.22 2.66 2.77 3.09 2.03 2.02 2.33 2.81 2.74 1.91 2.82 2.57 2.56 2.82 3.08 2.77 2.20 2.77 2.48 2.47 2.26 2.56 2.11 2.21 2.50 2.93 3.00 3.38 2.86 3.74 3.52 3.44 3.40 3.14 3.90 1.22 3.65 3.08 2.32 2.53 2.74 3.98 3.07 0.06 0.05 0.16 0.06 0.12 0.09 0.08 0.07 0.07 0.06 0.04 0.06 0.08 0.15 0.10 0.09 0.09 0.19 0.16 0.11 0.11 0.15 0.16 0.10 0.03 0.17 0.25 0.28 0.14 0.20 0.21 0.14 0.03 0.12 0.12 0.06 0.07 0.05 0.04 0.07 0.04 0.03 0.05 0.05 0.10 0.05 0.05 0.41 0.08 0.11 0.19 0.06 0.10 0.30 0.25 0.07 0.12 0.35 0.27 0.33 0.25 0.23 Cases 1488 1943 252 5538 477 622 1089 2202 2485 4872 1932 3628 1376 193 944 1386 828 170 558 521 886 469 478 590 8313 380 191 131 357 307 163 531 15383 1013 881 2588 2173 3704 5926 2044 7595 11270 4203 4727 1502 5550 6511 56 3697 1750 572 4992 1542 239 23 4505 1051 90 96 108 452 235 Female ASR(W) CUM 0-74 10.4 10.8 14.1 21.8 12.4 10.0 11.4 15.5 15.8 17.2 8.9 15.8 13.3 11.9 12.9 14.0 14.2 12.8 18.6 13.0 16.3 14.3 17.6 11.5 15.2 16.0 14.8 12.4 12.5 15.0 11.9 14.8 19.2 21.5 18.2 15.4 14.8 15.5 14.8 14.7 16.9 14.2 14.7 15.4 18.5 18.4 22.3 18.2 24.8 22.3 24.8 22.3 20.4 23.6 5.8 27.6 18.1 17.3 12.3 18.9 22.0 16.6 0.29 0.26 0.94 0.35 0.60 0.44 0.37 0.37 0.35 0.27 0.22 0.28 0.39 1.00 0.50 0.43 0.52 1.27 0.92 0.64 0.61 0.78 0.94 0.55 0.20 0.93 1.23 1.28 0.75 1.00 1.02 0.74 0.17 0.72 0.67 0.35 0.37 0.29 0.22 0.37 0.23 0.16 0.26 0.26 0.54 0.28 0.31 2.59 0.45 0.61 1.15 0.35 0.57 1.62 1.22 0.45 0.62 2.14 1.30 1.87 1.30 1.21 1.30 1.25 1.65 2.52 1.41 1.17 1.37 1.83 1.74 2.06 1.06 1.86 1.54 1.31 1.54 1.56 1.57 1.42 2.13 1.53 1.92 1.69 1.95 1.35 1.81 1.73 1.82 1.38 1.45 1.69 1.44 1.75 2.26 2.55 2.21 1.79 1.69 1.81 1.71 1.73 1.92 1.63 1.68 1.76 2.15 2.13 2.67 2.00 2.92 2.56 2.96 2.59 2.33 2.77 0.61 3.30 2.05 1.82 1.41 2.05 2.56 1.89 0.04 0.04 0.14 0.05 0.08 * 0.06 0.05 0.05 * 0.05 0.04 0.03 0.04 0.05 0.13 0.07 0.06 0.07 0.15 0.12 0.09 0.08 0.11 0.12 0.07 0.03 0.13 0.18 0.18 0.11 0.14 0.15 0.11 0.03 0.10 0.10 0.05 0.05 0.04 0.03 0.06 0.03 0.02 0.04 0.04 0.08 0.04 0.04 0.36 0.07 0.09 0.17 0.05 0.08 0.24 0.16 0.07 0.09 0.28 0.18 0.25 0.18 0.18

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
415

473

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Rectum (C19-20)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 84 104 48 44 54 72 164 46 98 2535 47 183 335 77 59 25 12700 1457 2380 779 441 374 24 649 5889 89 618 1595 249 1329 182 1891 11596 1297 601 1616 7891 2289 129 181 114 42 228 1448 2946 286 118 106 114 83 558 1591 1392 1645 74 1544 175 123 43 7981 524 7338 2534 506 1992 712 208 481 476 5420 497 4755 2685 1545 1930 1966 416 1529 125 283 Male ASR(W) CUM 0-74 3.6 2.1 5.1 4.4 3.4 8.1 8.1 7.3 7.1 12.7 5.3 5.2 4.4 2.6 4.9 2.9 15.6 16.0 15.4 18.8 16.2 20.1 31.6 18.5 14.6 17.6 15.8 10.9 9.3 11.2 12.0 10.5 11.5 11.4 10.6 10.3 11.8 11.3 9.8 11.3 13.4 11.7 10.9 11.2 11.3 11.5 10.4 13.8 20.2 15.4 9.1 11.8 11.2 13.4 10.6 13.5 10.3 11.8 7.3 11.8 9.9 12.0 11.3 11.1 11.4 10.5 12.0 10.1 11.2 13.7 11.8 13.9 13.4 14.3 14.4 14.6 13.1 15.1 13.4 14.0 0.42 0.22 0.75 0.80 0.57 0.99 0.68 1.15 0.74 0.26 0.78 0.41 0.25 0.32 0.66 0.59 0.14 0.43 0.33 0.71 0.80 1.06 6.77 0.75 0.20 1.93 0.69 0.28 0.61 0.32 0.93 0.26 0.11 0.32 0.44 0.27 0.14 0.25 0.89 0.88 1.29 2.01 0.75 0.31 0.22 0.69 1.00 1.38 2.10 1.71 0.40 0.32 0.31 0.35 1.26 0.37 0.80 1.10 1.15 0.14 0.44 0.15 0.23 0.51 0.26 0.41 0.89 0.48 0.54 0.19 0.54 0.21 0.27 0.39 0.34 0.34 0.66 0.40 1.23 0.87 1.01 0.95 0.88 0.86 1.54 0.59 0.57 0.51 0.32 0.55 0.39 1.94 1.99 1.84 2.35 1.99 2.58 3.72 2.14 1.86 2.40 1.98 1.34 1.13 1.38 1.56 1.29 1.39 1.36 1.29 1.26 1.43 1.36 1.11 1.33 1.75 1.26 1.33 1.36 1.38 1.43 1.25 1.67 2.38 1.95 1.11 1.46 1.41 1.65 1.30 1.67 1.27 1.42 0.97 1.46 1.20 1.48 1.39 1.34 1.40 1.32 1.43 1.29 1.40 1.69 1.51 1.72 1.62 1.79 1.76 1.81 1.63 1.87 1.67 1.71 0.15 0.10 0.17 0.11 0.04 0.11 0.06 0.04 0.05 0.09 0.09 0.02 0.06 0.05 0.11 0.12 0.16 0.99 0.11 0.03 0.31 0.10 0.04 0.09 0.04 0.14 0.04 0.02 0.05 0.06 0.04 0.02 0.04 0.12 0.12 0.19 0.27 0.11 0.05 0.03 0.10 0.14 0.20 0.28 0.25 0.06 0.05 0.05 0.05 0.18 0.05 0.12 0.15 0.18 0.02 0.06 0.02 0.03 0.08 0.04 0.06 0.14 0.07 0.08 0.03 0.08 0.03 0.04 0.06 0.05 0.05 0.10 0.06 0.18 0.12 Cases 88 97 31 43 48 55 175 45 128 2606 42 180 303 88 83 42 8067 858 1490 489 289 209 16 448 3837 63 368 1285 246 1021 144 1368 8860 983 511 1129 6114 1714 105 142 71 46 154 1101 2517 257 89 67 83 65 450 1418 1022 1390 84 1284 182 130 46 6214 525 5593 2024 482 1515 600 190 396 323 4069 456 3495 1931 1174 1545 1466 393 1062 115 225 Female ASR(W) CUM 0-74 3.8 1.7 2.9 4.0 3.0 3.9 6.7 6.5 7.1 9.2 4.0 3.9 3.6 2.8 5.8 3.5 8.1 8.0 8.2 9.2 8.5 9.9 21.3 9.8 7.6 10.1 7.8 6.7 6.2 6.8 8.9 6.3 6.9 6.9 6.8 5.7 7.2 6.5 5.9 7.1 5.9 9.6 5.6 6.6 7.4 7.3 6.5 6.2 12.2 9.4 5.7 8.1 6.6 8.5 8.4 8.5 6.6 7.3 5.0 7.3 7.3 7.3 6.9 7.5 6.8 6.8 8.0 6.5 6.6 7.6 7.4 7.6 7.3 7.9 9.0 8.3 8.6 8.3 8.5 8.1 0.43 0.17 0.54 0.70 0.56 0.60 0.55 1.01 0.64 0.19 0.64 0.31 0.22 0.31 0.68 0.56 0.10 0.29 0.23 0.47 0.55 0.72 5.68 0.52 0.13 1.43 0.47 0.20 0.42 0.23 0.77 0.19 0.08 0.23 0.31 0.18 0.10 0.17 0.62 0.63 0.72 1.59 0.47 0.23 0.16 0.48 0.73 0.78 1.51 1.19 0.28 0.25 0.22 0.26 0.95 0.27 0.55 0.72 0.87 0.11 0.33 0.11 0.16 0.36 0.19 0.30 0.61 0.35 0.40 0.13 0.36 0.15 0.19 0.27 0.25 0.23 0.46 0.28 0.83 0.61 0.46 0.85 0.95 0.86 1.07 0.50 0.46 0.41 0.31 0.69 0.32 0.95 0.94 0.97 1.08 1.02 1.21 2.69 1.15 0.90 1.06 0.88 0.78 0.73 0.79 0.96 0.73 0.81 0.81 0.79 0.66 0.85 0.75 0.65 0.79 0.65 1.17 0.64 0.77 0.84 0.85 0.70 0.70 1.47 1.04 0.67 0.93 0.80 1.01 0.92 1.01 0.69 0.79 0.44 0.85 0.85 0.85 0.81 0.91 0.79 0.81 0.97 0.76 0.78 0.90 0.90 0.90 0.90 0.92 1.07 0.99 1.02 0.98 1.07 0.98 * * * *

0.09 0.09 0.18 0.10 0.03 0.10 0.05 0.03 0.04 0.09 0.07 * 0.01 0.04 0.03 0.07 0.08 0.10 0.84 0.08 0.02 0.19 0.06 0.03 0.06 0.03 0.11 0.03 0.01 0.03 0.05 0.03 0.01 0.02 0.09 0.08 0.09 0.21 0.07 0.03 0.02 0.07 0.10 0.10 0.20 0.16 0.04 0.03 0.03 0.04 0.13 0.04 0.07 0.09 0.11 0.01 0.05 0.02 0.02 0.05 0.03 0.04 0.09 0.05 0.06 0.02 0.05 0.02 0.03 0.04 0.03 0.03 0.06 0.04 0.12 0.09

474

*Important. See note on population page.

416

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Rectum (C19-20) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 712 3003 3938 403 3462 1760 313 1418 2478 171 2279 436 92462 6836 81871 4194 368 3670 643 30 230 369 8436 703 7431 4887 322 4411 1373 1363 6756 369 6275 553 10604 788 8701 28865 2142 2156 2260 21944 1542 320 1198 6819 622 6014 561 253 2368 1551 1042 2313 26 605 1558 140 201 2688 287 170 311 447 18 581 109 157 85 2202 2060 118 623 669 919 2289 1391 5043 1374 Male ASR(W) CUM 0-74 14.3 13.8 11.9 12.2 11.9 13.6 12.8 13.9 12.7 11.7 12.8 13.0 12.6 11.1 12.6 14.4 13.1 14.6 10.8 8.5 12.6 9.8 13.4 10.5 13.9 12.6 9.8 12.5 11.6 11.3 14.4 12.0 14.5 14.6 12.5 11.8 12.4 12.5 12.2 11.9 10.7 12.8 12.1 11.8 12.1 11.7 12.1 11.7 10.2 12.0 12.3 11.9 14.6 12.5 4.4 11.1 7.0 10.7 8.6 11.2 8.7 7.3 3.3 2.0 2.1 2.6 2.6 2.4 3.2 13.0 13.3 8.3 16.0 16.9 22.3 22.4 19.5 13.5 21.7 0.56 0.27 0.20 0.63 0.21 0.34 0.75 0.39 0.27 0.91 0.28 0.65 0.04 0.14 0.05 0.23 0.69 0.26 0.44 1.58 0.85 0.54 0.15 0.40 0.17 0.19 0.56 0.20 0.33 0.32 0.19 0.64 0.20 0.66 0.13 0.43 0.14 0.08 0.27 0.26 0.23 0.09 0.32 0.67 0.36 0.15 0.50 0.16 0.45 0.78 0.26 0.32 0.47 0.27 0.90 0.46 0.18 0.93 0.62 0.23 0.52 0.59 0.19 0.10 0.51 0.11 0.26 0.20 0.35 0.29 0.31 0.79 0.65 0.69 0.74 0.48 0.55 0.19 0.63 1.69 1.69 1.46 1.49 1.45 1.66 1.58 1.70 1.54 1.37 1.56 1.58 1.54 1.36 1.55 1.76 1.60 1.78 1.29 0.84 1.43 1.23 1.65 1.29 1.73 1.56 1.23 1.55 1.41 1.41 1.76 1.50 1.78 1.73 1.52 1.40 1.51 1.53 1.46 1.45 1.30 1.56 1.47 1.43 1.47 1.45 1.49 1.45 1.18 1.54 1.48 1.44 1.77 1.56 0.56 1.31 0.85 1.29 1.08 1.35 1.03 0.93 0.37 0.23 0.25 0.29 0.31 0.28 0.42 1.59 1.61 1.02 2.04 2.12 2.79 2.76 2.36 1.63 2.70 0.08 0.04 0.03 0.09 0.03 0.05 0.11 0.06 0.04 0.13 0.04 0.09 0.01 0.02 0.01 0.03 0.10 0.04 0.06 0.19 0.12 0.08 0.02 0.06 0.02 0.03 0.08 0.03 0.05 0.05 0.03 0.09 0.03 0.10 0.02 0.06 0.02 0.01 0.04 0.04 0.03 0.01 0.04 0.10 0.05 0.02 0.07 0.02 0.06 0.12 0.04 0.05 0.07 0.04 0.13 0.07 0.03 0.13 0.09 0.03 0.07 0.09 0.03 0.01 0.07 0.02 0.04 0.03 0.06 0.04 0.05 0.12 0.09 0.10 0.11 0.07 0.07 0.03 0.08 Cases 523 2519 3164 383 2720 1463 315 1125 1888 142 1730 267 71954 6378 62612 3407 331 2969 419 16 121 271 7177 773 6171 4025 320 3559 1044 1076 5377 352 4903 444 8137 733 6667 22327 1502 1989 1591 16974 1089 268 806 5065 548 4349 448 223 1600 1087 830 1627 15 429 1055 122 168 2223 215 127 206 265 13 368 73 147 67 1930 1826 78 368 403 539 1374 955 2892 840 Female ASR(W) CUM 0-74 8.7 8.4 7.4 8.6 7.2 8.5 9.3 8.2 7.4 6.3 7.5 6.6 7.5 7.2 7.4 8.4 8.1 8.5 5.7 3.6 5.5 5.9 8.2 7.3 8.3 7.8 6.8 7.6 6.7 7.3 8.3 7.3 8.2 7.7 7.4 8.1 7.4 7.5 6.9 8.0 6.0 7.7 6.6 6.6 6.5 6.9 7.7 6.7 7.0 8.3 6.9 7.0 9.0 6.7 2.2 6.8 4.2 9.0 6.8 8.3 6.0 4.6 2.2 1.4 1.4 1.8 1.8 2.4 2.2 9.3 9.6 4.7 8.4 8.2 10.6 10.9 10.0 6.5 10.2 0.42 0.19 0.15 0.46 0.15 0.25 0.55 0.28 0.19 0.57 0.20 0.45 0.03 0.09 0.03 0.16 0.46 0.18 0.30 0.92 0.52 0.40 0.11 0.28 0.12 0.14 0.40 0.14 0.23 0.25 0.13 0.42 0.14 0.43 0.09 0.31 0.10 0.06 0.18 0.19 0.16 0.07 0.22 0.43 0.25 0.10 0.35 0.11 0.36 0.62 0.19 0.23 0.35 0.19 0.60 0.33 0.14 0.85 0.53 0.19 0.42 0.44 0.16 0.09 0.38 0.09 0.21 0.20 0.28 0.23 0.24 0.55 0.46 0.47 0.48 0.32 0.37 0.13 0.42 1.07 0.98 0.87 1.04 0.84 1.00 1.13 0.96 0.87 0.70 0.89 0.75 0.88 0.86 0.88 1.00 1.01 1.00 0.65 0.36 0.63 0.68 0.96 0.89 0.98 0.93 0.82 0.92 0.80 0.87 0.98 0.82 0.98 0.91 0.87 0.95 0.86 0.88 0.81 0.95 0.71 0.90 0.76 0.72 0.77 0.81 0.93 0.79 0.81 0.99 0.81 0.83 1.01 0.77 0.20 0.82 0.49 1.10 0.82 0.97 0.71 0.56 0.25 0.15 0.17 0.20 0.20 0.29 0.30 1.10 1.13 0.54 0.95 0.96 1.25 1.25 1.16 0.76 1.17 0.06 0.03 0.02 0.06 0.02 0.03 0.08 0.04 0.03 0.08 0.03 0.06 0.00 0.01 0.00 0.02 0.07 0.03 0.04 0.11 0.07 0.06 0.02 0.04 0.02 0.02 0.06 0.02 0.03 0.04 0.02 0.06 0.02 0.06 0.01 0.04 0.01 0.01 0.03 0.03 0.02 0.01 0.03 0.06 0.03 0.01 0.05 0.02 0.05 0.09 0.03 0.03 0.05 0.03 0.07 0.05 * 0.02 0.12 * 0.07 0.03 * 0.06 * 0.06 * 0.02 0.01 * 0.06 0.01 0.03 * 0.03 * 0.04 * 0.03 0.03 0.08 0.06 0.06 0.07 0.04 0.05 0.02 0.05

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
417

475

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Rectum (C19-20) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
418

Male ASR(W) CUM 0-74 14.9 12.6 15.2 17.7 12.6 15.4 10.7 17.4 12.1 5.2 2.8 9.9 6.3 2.1 2.9 9.5 17.1 19.1 7.9 11.6 4.6 3.9 4.4 5.1 6.3 16.3 15.8 15.7 13.8 17.0 17.3 14.2 20.9 27.0 16.6 13.0 11.0 19.2 13.9 15.8 17.0 14.2 17.0 15.4 13.6 15.5 19.7 14.6 18.0 19.0 10.9 18.3 17.7 17.2 20.9 7.6 18.3 12.6 12.7 13.3 16.2 14.7 11.6 12.1 10.6 8.9 14.4 13.4 12.0 12.2 14.4 8.1 11.1 10.2 12.5 12.5 17.6 12.8 14.1 0.13 0.42 0.57 0.86 0.73 0.59 1.24 0.32 1.03 0.76 0.68 0.76 0.43 0.36 0.33 0.41 0.47 0.56 1.11 1.17 0.35 0.43 0.40 0.42 0.29 0.24 0.84 1.18 0.22 0.50 0.30 0.21 0.36 0.28 0.28 0.54 0.24 0.74 0.79 0.94 0.82 0.63 0.67 0.63 0.83 0.89 1.15 0.80 0.42 0.32 0.40 0.52 0.44 0.41 0.68 0.92 0.40 1.17 0.72 0.87 0.54 0.74 1.18 0.51 0.62 0.76 0.40 0.86 1.01 0.79 0.56 0.50 0.78 0.92 1.31 0.54 0.67 0.79 0.46 1.85 1.55 1.82 2.17 1.62 1.95 1.28 2.08 1.62 0.63 0.28 1.33 0.79 0.28 0.30 1.16 2.01 2.27 0.86 1.36 0.52 0.49 0.51 0.63 0.81 2.06 1.97 1.89 1.76 2.09 2.12 1.80 2.60 3.39 2.02 1.72 1.32 2.41 1.54 2.01 2.05 1.72 2.06 1.92 1.66 1.85 2.39 1.88 2.21 2.35 1.35 2.26 2.18 2.11 2.58 0.84 2.27 1.74 1.49 1.59 1.93 1.80 1.49 1.45 1.33 1.04 1.77 1.66 1.41 1.51 1.79 0.96 1.43 1.20 1.66 1.53 2.15 1.55 1.70 0.02 0.06 0.08 0.13 0.11 0.09 0.17 0.05 0.17 0.11 0.08 0.12 0.06 0.06 0.04 0.06 0.07 0.08 0.13 0.16 0.05 0.06 0.06 0.06 0.04 0.03 0.12 0.17 0.03 0.07 0.04 0.03 0.05 0.04 0.04 0.08 0.03 0.11 0.11 0.14 0.12 0.09 0.10 0.09 0.12 0.13 0.16 0.12 0.06 0.05 0.06 0.07 0.06 0.06 0.10 0.13 0.06 0.18 0.10 0.12 0.08 0.10 0.17 0.07 0.09 0.11 0.06 0.12 0.14 0.11 0.08 0.07 0.12 0.12 0.20 0.08 0.09 0.12 0.06

Cases 9613 796 605 332 298 543 78 2505 154 51 25 133 180 24 31 563 927 825 29 73 158 60 96 104 363 3724 302 122 4093 775 2424 3356 2612 6213 2786 620 1919 436 235 182 318 385 420 453 200 244 224 195 1378 2836 769 907 1278 1420 782 71 1227 89 281 200 743 342 90 540 233 123 967 200 114 187 562 218 137 100 72 428 539 217 662

Female ASR(W) CUM 0-74 8.6 7.4 8.9 9.8 8.5 8.7 7.0 9.7 8.6 4.2 2.4 6.0 5.0 1.4 1.3 7.0 9.9 10.5 5.1 7.8 3.7 2.4 3.2 3.5 4.2 7.9 8.6 7.6 8.4 8.4 9.5 8.1 10.9 12.1 9.8 7.8 6.6 8.9 6.5 7.4 9.1 7.3 7.8 7.6 6.8 8.4 9.4 6.1 9.0 9.2 6.9 8.9 9.3 9.2 11.5 7.0 8.3 5.9 8.2 7.8 8.9 7.6 6.7 6.8 5.6 6.3 7.1 6.2 7.2 6.3 8.9 5.1 5.8 6.4 6.5 6.5 9.8 7.8 6.6 0.09 0.26 0.37 0.55 0.50 0.38 0.82 0.20 0.73 0.62 0.69 0.53 0.38 0.29 0.26 0.31 0.33 0.38 1.01 0.94 0.30 0.31 0.33 0.35 0.22 0.15 0.56 0.75 0.14 0.34 0.21 0.15 0.23 0.17 0.21 0.34 0.17 0.48 0.49 0.61 0.57 0.43 0.43 0.41 0.57 0.62 0.76 0.51 0.27 0.20 0.29 0.32 0.29 0.28 0.47 0.90 0.26 0.72 0.56 0.68 0.39 0.50 0.85 0.35 0.43 0.59 0.27 0.55 0.76 0.55 0.44 0.38 0.54 0.71 0.88 0.37 0.49 0.59 0.30 1.05 0.90 1.07 1.17 1.07 1.05 0.75 1.19 1.12 0.43 0.33 0.71 0.59 0.17 0.14 0.88 1.16 1.23 0.55 0.96 0.43 0.30 0.43 0.39 0.53 0.90 0.91 0.91 1.04 0.99 1.11 0.98 1.28 1.43 1.20 0.95 0.77 1.10 0.70 0.86 1.07 0.85 0.90 0.85 0.82 1.00 1.07 0.73 1.05 1.08 0.80 1.02 1.09 1.07 1.37 0.81 0.98 0.80 0.90 0.90 1.00 0.88 0.79 0.73 0.63 0.83 0.82 0.70 0.84 0.72 1.07 0.58 0.68 0.74 0.71 0.73 1.20 0.93 0.76 0.01 0.04 0.05 0.08 0.07 0.05 0.10 0.03 0.11 0.08 0.12 0.07 0.05 0.04 * 0.03 * 0.05 * 0.05 0.06 0.13 0.13 0.04 * 0.05 * 0.05 0.05 * 0.03 * 0.02 0.08 0.11 0.02 * 0.05 * 0.03 0.02 * 0.03 0.02 0.03 0.05 0.02 0.07 0.07 0.08 0.08 0.06 0.06 0.05 0.08 0.09 0.10 0.07 0.04 0.03 0.04 0.04 0.04 0.04 0.06 0.12 0.04 0.11 0.07 0.08 0.05 0.07 0.12 0.04 0.06 0.09 0.04 0.07 0.10 0.07 0.06 0.05 0.07 0.09 0.12 0.05 0.07 0.08 0.04

12875 1054 795 468 326 750 80 3555 173 50 65 179 223 37 90 631 1377 1218 55 104 182 85 119 149 496 4954 367 178 4135 1253 3587 4846 3529 9827 3696 594 2221 686 345 300 448 577 697 653 310 336 355 384 1866 3660 785 1240 1698 1815 991 75 2234 126 318 271 1025 457 114 622 332 138 1428 286 162 275 759 287 214 134 94 590 804 270 1010

476

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Rectum (C19-20) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 1011 1767 160 3012 310 611 734 1712 1866 2328 2856 3817 1423 152 695 1268 525 131 363 368 660 419 318 471 5100 177 101 96 289 164 131 365 9330 678 677 1897 1672 2808 5229 1504 4063 7132 3410 3722 876 3492 4341 55 2250 1119 337 3307 1148 164 30 2422 676 44 119 82 271 130 Male ASR(W) CUM 0-74 12.9 15.8 11.9 16.2 12.4 14.1 11.5 16.0 15.7 16.4 15.1 24.4 20.5 11.1 13.1 17.3 11.1 10.4 14.8 11.1 15.2 16.3 14.4 11.3 12.1 11.6 11.2 13.7 14.9 12.4 13.0 14.9 15.8 18.4 18.5 15.1 16.6 16.9 18.8 14.3 12.9 13.0 16.2 16.5 14.9 17.1 18.4 13.6 18.5 19.0 19.1 19.2 18.6 18.9 7.2 18.9 15.2 11.4 17.6 16.5 21.8 10.5 0.41 0.38 0.96 0.32 0.72 0.59 0.44 0.41 0.38 0.34 0.29 0.40 0.55 0.99 0.53 0.50 0.49 1.05 0.83 0.62 0.62 0.85 0.87 0.56 0.18 0.90 1.16 1.47 0.92 1.00 1.17 0.82 0.17 0.72 0.73 0.37 0.42 0.33 0.27 0.38 0.22 0.16 0.29 0.28 0.52 0.30 0.29 1.97 0.40 0.59 1.08 0.35 0.56 1.51 1.39 0.40 0.62 1.88 1.72 1.86 1.49 0.96 1.67 1.98 1.39 1.92 1.57 1.70 1.50 2.02 1.88 2.09 1.90 3.11 2.51 1.22 1.56 2.14 1.34 1.29 1.79 1.37 1.77 2.04 1.74 1.30 1.49 1.43 1.41 1.83 1.79 1.53 1.60 1.74 1.93 2.26 2.32 1.85 2.05 2.07 2.32 1.72 1.56 1.59 1.96 2.04 1.87 2.11 2.31 1.74 2.32 2.38 2.43 2.36 2.29 2.32 0.81 2.41 1.87 1.25 2.13 2.07 2.68 1.24 0.06 0.06 0.14 0.05 0.10 0.08 0.06 0.06 0.05 0.05 0.04 0.06 0.08 0.13 0.07 0.07 0.07 0.15 0.12 0.09 0.09 0.12 0.12 0.08 0.03 0.13 0.17 0.23 0.13 0.15 0.16 0.12 0.02 0.10 0.11 0.05 0.06 0.05 0.04 0.06 0.03 0.02 0.04 0.04 0.08 0.04 0.04 0.31 0.06 0.09 0.16 0.05 0.08 0.23 0.18 0.06 0.09 0.25 0.24 0.29 0.20 0.14 Cases 1049 1481 131 2356 285 466 605 1223 1153 2660 1872 2372 1030 73 414 704 378 73 221 240 398 233 196 352 3823 143 69 59 175 132 79 263 6736 464 481 1298 1043 1870 3203 1071 2943 5403 2054 2207 637 2373 2671 24 1330 799 239 2146 685 92 15 1664 393 24 47 52 158 80 Female ASR(W) CUM 0-74 7.7 8.1 8.2 10.1 7.5 7.7 6.6 8.9 7.7 9.7 8.5 10.5 10.1 4.6 5.7 7.5 6.8 5.7 7.3 6.4 7.6 7.3 7.8 7.0 7.3 6.7 6.0 6.8 7.1 7.2 6.3 7.9 9.0 10.4 10.8 8.4 7.4 8.1 8.6 8.3 6.9 7.2 7.6 7.8 8.5 8.4 9.8 6.2 9.7 10.9 10.6 10.3 9.5 8.3 3.5 11.0 7.7 4.8 6.3 9.5 9.8 6.6 0.26 0.23 0.75 0.24 0.47 0.39 0.28 0.28 0.25 0.20 0.21 0.23 0.34 0.63 0.33 0.32 0.37 0.84 0.57 0.46 0.42 0.56 0.64 0.44 0.14 0.62 0.81 1.00 0.60 0.72 0.77 0.55 0.12 0.51 0.54 0.27 0.26 0.22 0.17 0.28 0.15 0.11 0.19 0.19 0.37 0.19 0.21 1.36 0.28 0.43 0.76 0.24 0.39 0.93 0.92 0.29 0.42 1.13 0.95 1.35 0.95 0.80 0.95 0.96 0.93 1.18 0.86 0.95 0.82 1.09 0.88 1.19 1.04 1.25 1.21 0.47 0.65 0.86 0.78 0.71 0.84 0.71 0.90 0.84 0.90 0.77 0.90 0.75 0.68 0.80 0.84 0.88 0.74 0.97 1.09 1.29 1.32 1.00 0.84 0.94 1.00 0.96 0.79 0.84 0.91 0.92 1.02 0.99 1.17 0.63 1.14 1.25 1.19 1.23 1.09 0.86 0.33 1.36 0.91 0.51 0.73 1.13 1.15 0.76 0.04 0.03 0.10 0.03 0.06 * 0.05 0.04 0.04 * 0.03 0.03 0.03 0.03 0.05 0.08 0.04 0.04 0.05 0.11 0.08 0.06 0.06 0.08 0.09 0.06 0.02 0.08 0.11 0.13 0.08 0.10 0.10 0.08 0.02 0.07 0.08 0.04 0.04 0.03 0.02 0.04 0.02 0.02 0.03 0.03 0.05 0.03 0.03 0.17 0.04 0.06 0.11 0.04 0.06 0.13 0.11 0.04 0.06 0.15 0.13 0.18 0.12 0.11

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
419

477

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Anus (C21)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 2 23 3 2 4 2 19 4 2 169 4 19 24 7 5 4 778 47 103 25 28 5 0 27 526 2 15 91 22 66 6 127 1008 29 80 117 759 247 29 5 5 1 24 172 261 39 3 2 1 1 42 169 95 79 11 66 43 29 13 617 73 534 210 49 160 98 30 68 24 303 55 241 153 51 94 118 21 95 10 38 Male ASR(W) CUM 0-74 0.1 0.6 0.3 0.2 0.2 0.2 0.9 0.6 0.1 0.8 0.5 0.6 0.3 0.2 0.4 0.5 1.0 0.5 0.7 0.7 1.1 0.2 0.8 1.3 0.4 0.4 0.6 0.8 0.6 0.3 0.8 1.0 0.3 1.3 0.6 1.2 1.2 2.0 0.3 0.6 0.3 1.0 1.4 1.0 1.5 0.3 0.2 0.3 0.2 0.5 1.3 0.7 0.7 1.4 0.6 2.6 2.8 2.3 1.1 1.3 1.0 0.9 0.9 0.9 1.3 1.2 1.3 0.6 0.8 1.2 0.7 0.8 0.5 0.7 0.9 0.6 1.0 1.0 2.1 0.06 0.13 0.20 0.16 0.09 0.14 0.22 0.32 0.09 0.06 0.24 0.14 0.07 0.08 0.19 0.23 0.04 0.08 0.07 0.14 0.21 0.11 0.15 0.06 0.25 0.11 0.07 0.18 0.07 0.15 0.07 0.03 0.05 0.15 0.06 0.05 0.08 0.38 0.14 0.25 0.25 0.21 0.11 0.06 0.24 0.20 0.15 0.27 0.22 0.09 0.11 0.08 0.08 0.44 0.08 0.40 0.54 0.66 0.04 0.15 0.05 0.06 0.14 0.07 0.13 0.25 0.17 0.13 0.05 0.16 0.05 0.07 0.07 0.08 0.08 0.13 0.10 0.32 0.34 0.02 0.12 0.08 0.01 0.09 0.06 0.08 0.03 0.01 0.06 0.07 0.11 0.06 0.07 0.08 0.13 0.02 0.09 0.16 0.02 0.04 0.07 0.09 0.07 0.04 0.09 0.12 0.03 0.15 0.07 0.14 0.13 0.23 0.04 0.06 0.10 0.16 0.11 0.17 0.05 0.01 0.02 0.05 0.04 0.15 0.08 0.08 0.16 0.08 0.27 0.27 0.30 0.12 0.15 0.11 0.10 0.10 0.10 0.14 0.13 0.15 0.08 0.09 0.13 0.09 0.09 0.06 0.08 0.10 0.05 0.11 0.10 0.22 0.02 0.03 0.04 0.01 0.01 0.04 0.02 0.01 0.01 0.03 0.05 0.00 0.01 0.01 0.02 0.03 0.01 0.02 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.05 0.02 0.03 0.03 0.01 0.01 0.03 0.03 0.01 0.02 0.05 0.01 0.01 0.01 0.01 0.06 0.01 0.05 0.06 0.09 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.03 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.04 0.04 Cases 1 22 2 3 2 10 37 5 13 319 1 59 44 21 15 13 1011 77 169 39 44 12 1 52 586 5 26 175 28 146 21 191 1369 59 67 150 1082 243 14 5 5 0 22 189 332 30 5 3 0 8 71 209 153 127 12 114 31 19 12 999 70 919 318 61 255 110 30 79 51 469 67 395 276 124 194 181 36 145 15 35 Female ASR(W) CUM 0-74 0.1 0.4 0.2 0.0 0.0 0.8 1.4 0.8 0.6 1.1 0.1 1.4 0.6 0.7 0.9 1.2 1.1 0.7 1.0 0.8 1.5 0.5 2.0 1.3 1.2 0.7 0.6 1.0 0.7 1.1 1.3 1.0 1.1 0.4 0.9 0.8 1.4 1.0 0.9 0.2 0.4 0.8 1.3 1.0 0.9 0.3 0.3 1.1 0.9 1.3 1.1 0.9 1.2 0.8 1.3 1.4 1.4 1.4 1.0 1.4 1.2 0.9 1.3 1.2 1.0 1.3 1.1 1.0 1.1 1.0 1.2 1.1 1.2 1.1 0.8 1.2 1.0 1.5 0.07 0.10 0.11 0.03 0.03 0.29 0.24 0.37 0.18 0.07 0.12 0.18 0.09 0.15 0.25 0.34 0.04 0.09 0.08 0.14 0.24 0.15 1.96 0.19 0.05 0.34 0.13 0.08 0.14 0.10 0.29 0.08 0.03 0.06 0.12 0.06 0.05 0.07 0.25 0.10 0.20 0.18 0.10 0.06 0.16 0.15 0.19 0.40 0.11 0.10 0.09 0.08 0.36 0.09 0.26 0.33 0.46 0.05 0.12 0.05 0.07 0.12 0.08 0.12 0.20 0.16 0.17 0.05 0.14 0.05 0.08 0.11 0.09 0.09 0.14 0.11 0.28 0.27 0.07 0.18 0.10 0.05 0.13 0.01 0.17 0.08 0.08 0.08 0.15 0.12 0.08 0.12 0.08 0.19 0.04 0.33 0.14 0.14 0.10 0.07 0.12 0.07 0.13 0.17 0.12 0.13 0.05 0.10 0.08 0.16 0.11 0.12 0.01 0.07 0.09 0.15 0.11 0.09 0.03 0.04 0.14 0.09 0.15 0.12 0.11 0.14 0.11 0.12 0.13 0.13 0.15 0.11 0.16 0.13 0.09 0.14 0.13 0.09 0.15 0.12 0.11 0.11 0.11 0.13 0.11 0.14 0.13 0.08 0.16 0.09 0.18 * * * *

0.03 0.04 0.05 0.02 0.01 0.01 0.03 0.01 0.02 0.03 0.05 * 0.00 0.01 0.01 0.02 0.03 0.02 0.33 0.02 0.01 0.06 0.02 0.01 0.02 0.01 0.05 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.04 0.01 0.03 0.03 0.01 0.01 0.02 0.02 0.03 0.06 0.02 0.01 0.01 0.01 0.05 0.01 0.03 0.03 0.07 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.03 0.03

478

*Important. See note on population page.

420

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Anus (C21) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 50 193 217 32 182 101 26 74 130 15 114 22 5995 706 5112 198 43 154 53 3 12 38 579 92 479 256 30 220 78 117 300 31 262 29 738 103 598 1954 45 227 153 1497 108 17 91 466 58 398 27 14 162 109 58 104 6 13 5 7 57 8 5 51 160 0 81 27 31 4 88 83 5 24 10 17 27 10 112 15 Male ASR(W) CUM 0-74 1.1 0.9 0.7 0.8 0.6 0.8 0.9 0.7 0.7 0.9 0.7 0.7 0.8 1.0 0.8 0.7 1.3 0.7 0.9 0.9 0.6 1.1 1.0 1.3 1.0 0.7 0.9 0.7 0.7 1.0 0.7 1.0 0.7 0.8 0.9 1.3 0.9 0.9 0.3 1.1 0.6 0.9 0.9 0.6 1.0 0.8 1.0 0.8 0.5 0.7 0.8 0.8 0.8 0.5 1.0 0.3 0.4 0.3 0.2 0.2 0.2 0.5 0.8 0.3 0.6 0.5 0.1 0.5 0.5 0.3 0.6 0.2 0.4 0.3 0.1 0.3 0.2 0.16 0.07 0.05 0.15 0.05 0.08 0.19 0.09 0.06 0.23 0.07 0.15 0.01 0.04 0.01 0.05 0.21 0.06 0.13 0.52 0.19 0.19 0.04 0.13 0.05 0.05 0.17 0.05 0.08 0.10 0.04 0.18 0.04 0.16 0.03 0.13 0.04 0.02 0.04 0.08 0.05 0.02 0.08 0.14 0.10 0.04 0.13 0.04 0.10 0.18 0.07 0.08 0.11 0.06 0.39 0.08 0.17 0.12 0.03 0.09 0.09 0.08 0.06 0.04 0.12 0.09 0.07 0.06 0.06 0.13 0.13 0.06 0.09 0.05 0.04 0.03 0.07 0.14 0.10 0.08 0.08 0.07 0.09 0.08 0.09 0.08 0.07 0.08 0.09 0.10 0.12 0.09 0.08 0.12 0.08 0.10 0.07 0.06 0.13 0.11 0.15 0.11 0.08 0.11 0.07 0.08 0.13 0.08 0.11 0.07 0.08 0.10 0.14 0.10 0.10 0.03 0.12 0.07 0.11 0.10 0.06 0.12 0.09 0.11 0.09 0.07 0.08 0.10 0.09 0.09 0.07 0.15 0.04 0.06 0.04 0.02 0.03 0.02 0.06 0.10 0.04 0.07 0.07 0.02 0.06 0.07 0.03 0.07 0.02 0.06 0.03 0.02 0.04 0.03 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.00 0.01 0.00 0.01 0.02 0.01 0.02 0.05 0.02 0.02 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.00 0.02 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.01 0.00 0.02 0.01 0.02 0.03 0.01 0.01 0.02 0.01 0.07 0.01 0.03 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.02 0.01 0.01 0.00 0.01 Cases 62 251 345 50 291 157 42 115 226 13 211 36 9272 784 8260 348 27 308 67 0 9 58 789 115 662 450 43 396 142 201 510 37 461 50 1031 98 902 2968 83 227 213 2418 147 16 129 708 65 634 69 18 264 187 122 155 0 8 1 6 65 8 5 41 71 2 67 14 14 2 100 96 4 17 11 12 25 18 107 13 Female ASR(W) CUM 0-74 1.2 1.0 0.9 1.1 0.9 1.0 1.3 0.9 0.9 0.6 1.0 1.0 1.1 0.9 1.1 1.0 0.7 1.0 1.0 0.4 1.4 1.0 1.1 1.1 1.0 1.0 1.0 1.1 1.5 0.9 0.9 0.9 1.1 1.0 1.1 1.1 1.1 0.4 0.9 0.8 1.2 0.9 0.4 1.1 1.0 0.9 1.1 1.1 0.7 1.2 1.2 1.6 0.7 0.1 0.1 0.2 0.2 0.2 0.1 0.5 0.4 0.2 0.3 0.4 0.2 0.1 0.5 0.5 0.2 0.4 0.2 0.2 0.2 0.2 0.2 0.1 0.16 0.07 0.05 0.16 0.05 0.08 0.21 0.09 0.07 0.17 0.07 0.18 0.01 0.03 0.01 0.06 0.14 0.07 0.12 0.14 0.21 0.04 0.11 0.04 0.05 0.16 0.05 0.10 0.11 0.04 0.15 0.05 0.17 0.03 0.11 0.04 0.02 0.04 0.06 0.06 0.03 0.08 0.10 0.11 0.04 0.12 0.04 0.14 0.19 0.08 0.09 0.15 0.06 0.05 0.06 0.10 0.03 0.08 0.07 0.08 0.05 0.16 0.04 0.10 0.06 0.05 0.05 0.06 0.11 0.09 0.07 0.07 0.04 0.05 0.02 0.04 0.13 0.11 0.11 0.14 0.10 0.12 0.17 0.11 0.11 0.10 0.11 0.13 0.12 0.10 0.13 0.12 0.10 0.12 0.11 0.05 0.16 0.12 0.13 0.12 0.11 0.14 0.11 0.13 0.17 0.10 0.12 0.10 0.14 0.12 0.13 0.13 0.13 0.05 0.10 0.09 0.14 0.10 0.05 0.12 0.12 0.11 0.12 0.15 0.08 0.13 0.13 0.18 0.09 0.02 0.00 0.04 0.03 0.03 0.01 0.07 0.05 0.03 0.04 0.04 0.02 0.01 0.05 0.06 0.00 0.04 0.02 0.03 0.02 0.02 0.03 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.01 0.03 0.01 0.03 0.00 0.00 0.00 0.01 0.02 0.01 0.02 0.02 0.03 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.01 0.02 0.00 0.02 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.02 0.01 0.01 0.02 0.01 0.01 * 0.00 * 0.02 0.00 * 0.01 * 0.01 * 0.01 0.01 * 0.02 0.01 0.01 * 0.01 * 0.01 * 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
421

479

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Anus (C21) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
422

Male ASR(W) CUM 0-74 0.4 0.4 0.2 0.4 0.3 0.5 0.5 0.2 0.1 0.1 0.5 0.2 0.7 0.7 0.3 0.4 0.4 0.5 0.3 0.3 0.3 0.1 0.2 0.3 0.5 0.5 0.1 0.5 0.3 0.4 0.6 0.2 0.4 0.6 0.3 0.2 0.6 0.7 0.4 0.4 0.6 0.5 0.7 0.2 0.2 0.5 0.7 0.5 0.6 1.0 0.5 0.4 0.5 0.6 0.2 0.6 0.6 0.5 1.0 0.6 0.7 0.1 0.5 0.4 0.4 0.8 0.8 0.3 0.7 0.5 0.7 0.3 0.6 0.3 1.0 0.7 0.5 0.7 0.02 0.08 0.07 0.13 0.11 0.12 0.06 0.14 0.11 0.05 0.17 0.07 0.21 0.17 0.06 0.07 0.08 0.25 0.19 0.08 0.12 0.06 0.09 0.06 0.04 0.15 0.09 0.04 0.07 0.05 0.05 0.04 0.03 0.06 0.09 0.03 0.13 0.18 0.16 0.14 0.14 0.12 0.14 0.11 0.11 0.19 0.20 0.07 0.06 0.13 0.09 0.07 0.07 0.13 0.14 0.07 0.24 0.15 0.25 0.11 0.16 0.06 0.11 0.12 0.15 0.10 0.21 0.19 0.20 0.12 0.14 0.13 0.21 0.20 0.16 0.15 0.16 0.10 0.04 0.04 0.02 0.05 0.02 0.05 0.05 0.04 0.01 0.01 0.04 0.02 0.08 0.10 0.04 0.06 0.06 0.06 0.05 0.03 0.03 0.01 0.04 0.03 0.06 0.07 0.01 0.06 0.03 0.04 0.08 0.02 0.04 0.07 0.02 0.03 0.07 0.08 0.04 0.06 0.06 0.08 0.07 0.02 0.04 0.07 0.08 0.05 0.07 0.11 0.06 0.06 0.05 0.07 0.01 0.06 0.05 0.05 0.12 0.07 0.09 0.04 0.05 0.03 0.08 0.07 0.03 0.09 0.06 0.09 0.02 0.08 0.05 0.12 0.08 0.05 0.08 0.00 0.01 0.01 0.02 0.01 0.02 0.01 0.03 0.01 0.01 0.02 0.01 0.03 0.03 0.01 0.01 0.01 0.03 0.03 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.01 0.01 0.00 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.02 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.03 0.02 0.03 0.01 0.02 0.01 0.02 0.02 0.01 0.02 0.02 0.03 0.01 0.02 0.01 0.03 0.03 0.02 0.02 0.02 0.01

Cases 323 31 27 7 6 13 3 96 4 7 3 9 4 1 8 14 45 39 2 4 18 3 4 1 27 368 33 19 167 37 94 153 60 238 305 45 122 46 39 27 29 81 59 39 26 26 17 29 129 206 129 69 87 84 69 11 76 14 26 22 72 48 2 64 20 10 150 28 9 25 46 25 6 8 5 70 40 19 66

Female ASR(W) CUM 0-74 0.3 0.3 0.4 0.2 0.2 0.2 0.3 0.4 0.2 0.6 0.4 0.4 0.1 0.1 0.4 0.2 0.5 0.5 0.4 0.5 0.5 0.1 0.1 0.0 0.3 0.9 1.0 1.5 0.3 0.5 0.4 0.4 0.3 0.5 1.3 0.7 0.4 1.0 1.2 1.2 0.9 1.7 1.2 0.7 1.0 1.0 0.8 1.1 0.9 0.7 1.4 0.7 0.8 0.6 1.1 1.2 0.5 1.1 0.8 0.8 1.0 1.2 0.1 0.8 0.6 0.5 1.1 1.0 0.5 0.7 0.8 0.6 0.3 0.6 0.4 1.2 0.8 0.6 0.7 0.02 0.05 0.08 0.08 0.07 0.06 0.17 0.04 0.09 0.25 0.28 0.13 0.05 0.06 0.13 0.04 0.07 0.08 0.29 0.26 0.11 0.07 0.07 0.03 0.06 0.05 0.20 0.35 0.03 0.09 0.05 0.03 0.04 0.04 0.08 0.11 0.04 0.16 0.22 0.24 0.18 0.22 0.17 0.13 0.22 0.21 0.23 0.22 0.09 0.06 0.14 0.09 0.09 0.07 0.15 0.38 0.07 0.35 0.17 0.21 0.15 0.21 0.05 0.12 0.14 0.15 0.10 0.23 0.19 0.17 0.13 0.14 0.12 0.23 0.19 0.16 0.15 0.16 0.10 0.03 0.03 0.04 0.02 0.01 0.03 0.03 0.05 0.00 0.10 0.01 0.05 0.01 0.01 0.03 0.02 0.04 0.04 0.08 0.05 0.06 0.01 0.02 0.00 0.04 0.10 0.11 0.17 0.04 0.06 0.04 0.04 0.03 0.06 0.15 0.08 0.05 0.13 0.14 0.13 0.09 0.21 0.12 0.08 0.11 0.11 0.08 0.14 0.11 0.08 0.18 0.08 0.09 0.06 0.12 0.15 0.07 0.14 0.10 0.06 0.11 0.15 0.10 0.08 0.07 0.11 0.11 0.06 0.10 0.08 0.07 0.03 0.07 0.04 0.14 0.10 0.06 0.07 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.00 0.05 0.00 0.02 0.01 0.01 * 0.01 * 0.01 * 0.01 0.01 0.06 0.03 0.02 * 0.01 * 0.01 0.00 * 0.01 * 0.01 0.02 0.04 0.00 * 0.01 * 0.01 0.00 * 0.00 0.00 0.01 0.01 0.01 0.02 0.03 0.03 0.02 0.03 0.02 0.02 0.03 0.03 0.03 0.03 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.05 0.01 0.05 0.02 0.02 0.02 0.03 0.02 0.02 0.03 0.01 0.03 0.03 0.03 0.02 0.02 0.01 0.03 0.03 0.02 0.02 0.02 0.01

309 33 11 9 7 20 0 95 2 1 4 11 6 11 19 20 33 26 4 3 10 6 3 6 24 153 12 1 142 24 83 213 35 142 137 16 41 22 17 7 11 20 21 26 4 4 7 16 49 120 65 35 43 52 28 3 68 6 14 19 33 22 1 20 15 6 83 15 3 15 27 25 7 8 2 41 27 9 47

480

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Anus (C21) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 29 35 9 77 10 5 21 92 58 30 58 93 22 3 49 34 15 7 16 19 14 14 9 20 180 11 6 8 11 3 8 19 221 11 6 63 77 98 205 68 212 357 120 97 34 118 232 3 99 20 21 100 41 6 3 73 16 1 2 3 2 8 Male ASR(W) CUM 0-74 0.4 0.3 0.6 0.4 0.4 0.1 0.3 0.9 0.5 0.2 0.3 0.6 0.3 0.3 1.0 0.5 0.3 0.7 0.8 0.6 0.3 0.6 0.4 0.5 0.5 0.7 0.7 1.4 0.5 0.2 0.7 0.6 0.4 0.3 0.2 0.5 0.8 0.6 0.8 0.6 0.7 0.7 0.6 0.5 0.6 0.6 1.0 0.9 0.8 0.4 1.2 0.6 0.7 0.8 0.5 0.6 0.4 0.1 0.3 0.7 0.2 0.6 0.07 0.06 0.20 0.05 0.13 0.05 0.07 0.10 0.07 0.04 0.04 0.06 0.07 0.18 0.16 0.09 0.08 0.32 0.21 0.14 0.09 0.16 0.13 0.13 0.04 0.23 0.29 0.52 0.15 0.15 0.26 0.16 0.03 0.10 0.08 0.07 0.10 0.07 0.06 0.08 0.05 0.04 0.06 0.05 0.11 0.06 0.07 0.53 0.09 0.08 0.26 0.06 0.11 0.32 0.28 0.07 0.09 0.14 0.21 0.42 0.15 0.23 0.04 0.04 0.08 0.04 0.05 0.01 0.03 0.11 0.06 0.02 0.04 0.07 0.03 0.02 0.14 0.04 0.04 0.07 0.08 0.05 0.04 0.07 0.06 0.05 0.05 0.11 0.07 0.19 0.04 0.02 0.10 0.06 0.04 0.03 0.02 0.06 0.10 0.08 0.09 0.08 0.09 0.08 0.07 0.06 0.07 0.07 0.12 0.19 0.11 0.04 0.18 0.07 0.09 0.11 0.04 0.07 0.04 0.02 0.15 0.02 0.06 0.01 0.01 0.03 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.03 0.02 0.02 0.01 0.02 0.02 0.01 0.00 0.04 0.03 0.07 0.02 0.01 0.04 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.13 0.01 0.01 0.04 0.01 0.02 0.05 0.03 0.01 0.01 0.02 0.09 0.02 0.03 Cases 61 48 7 172 17 5 58 103 111 78 55 86 44 2 23 39 18 9 10 13 15 15 13 20 412 46 2 19 29 15 15 62 306 16 20 97 93 177 271 89 358 528 163 182 42 188 279 2 116 56 19 114 55 9 2 127 26 2 0 2 3 19 Female ASR(W) CUM 0-74 0.4 0.3 0.4 0.9 0.4 0.1 0.6 0.7 0.7 0.3 0.3 0.4 0.5 0.1 0.3 0.4 0.3 0.7 0.4 0.3 0.3 0.5 0.4 0.3 0.9 2.2 0.3 2.0 1.4 1.0 1.2 2.0 0.4 0.4 0.4 0.7 0.8 0.9 0.8 0.8 1.0 0.9 0.6 0.7 0.6 0.8 1.1 0.4 0.8 0.9 0.9 0.6 0.8 0.7 0.5 0.9 0.5 0.4 0.4 0.1 1.5 0.06 0.05 0.14 0.07 0.11 0.04 0.09 0.07 0.08 0.04 0.04 0.04 0.08 0.12 0.08 0.08 0.08 0.28 0.15 0.08 0.09 0.16 0.13 0.09 0.05 0.35 0.19 0.53 0.27 0.35 0.36 0.28 0.03 0.10 0.10 0.08 0.09 0.08 0.06 0.09 0.06 0.04 0.06 0.06 0.10 0.06 0.07 0.31 0.08 0.13 0.23 0.06 0.11 0.24 0.36 0.09 0.11 0.32 0.30 0.09 0.38 0.05 0.04 0.06 0.10 0.05 0.01 0.07 0.08 0.09 0.04 0.03 0.04 0.05 0.01 0.03 0.05 0.02 0.10 0.05 0.02 0.03 0.06 0.04 0.03 0.11 0.29 0.02 0.23 0.18 0.10 0.11 0.25 0.05 0.04 0.05 0.08 0.09 0.11 0.10 0.09 0.12 0.10 0.06 0.08 0.06 0.08 0.12 0.05 0.10 0.10 0.10 0.07 0.08 0.04 0.07 0.10 0.06 0.05 0.05 0.02 0.15 0.01 0.01 0.03 0.01 0.02 * 0.00 0.01 0.01 * 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.04 0.02 0.01 0.01 0.02 0.02 0.01 0.01 0.05 0.02 0.07 0.04 0.03 0.04 0.04 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.02 0.03 0.01 0.01 0.02 0.07 0.01 0.01 0.05 0.04 0.02 0.05

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
423

481

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Liver (C22)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 22 912 20 100 265 41 135 41 49 585 46 105 444 94 44 22 3301 417 736 168 59 32 1 87 1696 16 89 638 123 506 100 798 7052 1858 525 1594 2987 1651 139 294 93 21 240 616 2083 224 190 99 36 144 591 642 537 602 57 527 135 98 30 3370 358 2914 872 216 603 326 108 170 130 2031 343 1553 766 379 516 853 228 591 86 162 Male ASR(W) CUM 0-74 1.1 21.9 2.2 8.7 14.4 4.5 6.3 6.4 3.4 2.9 5.4 3.1 5.8 3.4 3.6 2.4 4.2 4.6 5.0 4.2 2.3 1.9 1.8 2.4 4.4 3.2 2.3 4.2 4.4 4.1 6.2 4.6 7.2 16.8 9.2 10.3 4.6 8.5 10.9 18.9 10.4 7.0 11.1 5.0 8.3 9.0 17.2 12.5 7.9 27.5 10.2 5.0 4.2 4.9 7.8 4.6 8.2 9.7 5.5 5.2 6.5 4.9 3.9 4.5 3.5 4.8 5.5 3.7 3.2 5.2 8.0 4.6 4.0 3.5 3.8 6.3 7.1 5.8 9.2 7.6 0.23 0.76 0.51 1.05 1.09 0.74 0.58 1.05 0.50 0.12 0.81 0.31 0.28 0.37 0.57 0.52 0.08 0.23 0.19 0.34 0.31 0.37 1.77 0.27 0.11 0.92 0.27 0.17 0.40 0.19 0.65 0.17 0.09 0.40 0.41 0.27 0.09 0.22 0.94 1.15 1.10 1.64 0.74 0.22 0.19 0.61 1.32 1.29 1.55 2.33 0.43 0.21 0.19 0.21 1.06 0.22 0.73 1.01 1.15 0.10 0.35 0.10 0.14 0.32 0.15 0.27 0.57 0.29 0.29 0.12 0.44 0.12 0.15 0.19 0.17 0.22 0.48 0.25 1.02 0.62 0.51 0.67 0.84 0.40 0.35 0.61 0.36 0.65 0.42 0.39 0.29 0.51 0.54 0.59 0.53 0.29 0.25 0.44 0.28 0.54 0.32 0.28 0.49 0.52 0.47 0.75 0.54 0.88 2.05 1.10 1.28 0.54 1.03 1.34 2.36 1.21 0.98 1.27 0.60 1.02 1.04 1.97 1.59 0.84 3.40 1.33 0.59 0.47 0.58 0.89 0.55 0.95 1.12 0.61 0.61 0.71 0.58 0.46 0.52 0.42 0.58 0.59 0.47 0.40 0.63 1.02 0.55 0.46 0.43 0.44 0.73 0.83 0.66 1.12 0.89 0.11 0.08 0.17 0.07 0.02 0.11 0.05 0.04 0.06 0.08 0.08 0.01 0.03 0.03 0.05 0.05 0.05 0.44 0.04 0.02 0.12 0.04 0.02 0.06 0.03 0.10 0.02 0.01 0.06 0.06 0.04 0.01 0.03 0.13 0.16 0.16 0.25 0.10 0.03 0.03 0.08 0.18 0.20 0.17 0.33 0.07 0.03 0.03 0.03 0.15 0.03 0.10 0.13 0.14 0.01 0.05 0.01 0.02 0.04 0.02 0.04 0.08 0.05 0.04 0.02 0.07 0.02 0.02 0.03 0.02 0.03 0.07 0.03 0.14 0.09 Cases 16 227 7 73 159 16 148 26 22 300 41 124 321 129 25 13 1393 164 309 79 25 18 0 45 708 5 40 359 81 271 47 345 3296 804 207 768 1475 713 56 92 47 22 114 276 1072 92 84 33 46 73 340 348 257 276 18 249 56 49 7 1550 153 1356 457 108 323 143 53 73 74 1074 185 834 392 203 291 349 89 255 36 67 Female ASR(W) CUM 0-74 0.8 4.4 0.7 5.8 12.7 1.3 5.8 3.9 1.2 1.1 3.8 2.7 3.8 3.9 1.5 1.2 1.4 1.5 1.7 1.4 0.7 1.1 0.9 1.5 0.7 0.8 1.7 1.9 1.7 3.3 1.6 2.6 5.7 2.8 4.0 1.7 2.9 3.3 4.8 3.7 3.7 4.5 1.7 3.2 2.7 6.1 2.6 7.3 10.2 4.3 2.1 1.7 1.7 1.9 1.6 2.1 2.6 1.0 1.8 2.1 1.7 1.5 1.6 1.4 1.6 2.2 1.1 1.4 1.9 2.9 1.7 1.5 1.3 1.6 1.9 2.0 1.8 2.6 2.1 0.20 0.30 0.25 0.79 1.17 0.37 0.50 0.80 0.25 0.07 0.61 0.25 0.22 0.37 0.33 0.33 0.04 0.13 0.11 0.20 0.15 0.30 0.17 0.06 0.37 0.16 0.10 0.23 0.11 0.50 0.10 0.05 0.21 0.20 0.15 0.05 0.12 0.48 0.54 0.55 0.88 0.44 0.13 0.11 0.29 0.74 0.47 1.39 1.24 0.24 0.14 0.11 0.12 0.47 0.13 0.31 0.42 0.44 0.05 0.18 0.06 0.08 0.17 0.08 0.15 0.32 0.14 0.18 0.07 0.22 0.07 0.09 0.11 0.11 0.11 0.22 0.13 0.45 0.30 0.18 0.67 0.55 0.07 0.13 0.42 0.31 0.41 0.49 0.17 0.12 0.17 0.16 0.19 0.15 0.08 0.10 0.08 0.19 0.09 0.09 0.21 0.21 0.20 0.39 0.18 0.32 0.70 0.34 0.48 0.20 0.36 0.37 0.60 0.46 0.58 0.59 0.19 0.39 0.33 0.64 0.28 0.87 1.15 0.51 0.24 0.19 0.19 0.20 0.18 0.24 0.29 0.13 0.20 0.26 0.19 0.17 0.19 0.15 0.20 0.30 0.13 0.16 0.23 0.33 0.20 0.18 0.16 0.18 0.22 0.23 0.21 0.29 0.26 * * * *

0.05 0.07 0.12 0.02 0.01 0.09 0.04 0.03 0.06 0.05 0.04 * 0.01 0.02 0.01 0.02 0.02 0.03 0.02 0.01 0.05 0.02 0.01 0.03 0.02 0.07 0.01 0.01 0.03 0.03 0.02 0.01 0.02 0.06 0.08 0.09 0.15 0.07 0.02 0.02 0.04 0.10 0.07 0.16 0.17 0.04 0.02 0.02 0.02 0.06 0.02 0.04 0.06 0.07 0.01 0.03 0.01 0.01 0.02 0.01 0.02 0.05 0.02 0.03 0.01 0.03 0.01 0.01 0.02 0.01 0.02 0.03 0.02 0.06 0.04

482

*Important. See note on population page.

424

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Liver (C22) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 196 1162 1613 295 1257 791 233 529 813 146 646 99 39416 4843 30392 1621 229 1247 368 37 175 145 4206 616 3072 1576 265 1247 495 462 2366 354 1865 201 4885 584 3210 13843 2592 1483 2082 7485 583 141 427 4014 463 3301 163 73 991 748 259 893 30 2425 6289 440 713 6001 857 74 269 491 34 895 65 209 78 556 463 42 862 815 1632 1709 1923 13494 969 Male ASR(W) CUM 0-74 4.1 5.6 5.0 8.9 4.3 6.2 9.8 5.2 4.4 10.6 3.8 3.0 5.5 7.8 4.8 5.8 8.1 5.1 6.3 10.6 9.8 4.0 6.9 9.2 5.9 4.1 8.4 3.5 4.1 3.9 5.3 11.6 4.4 5.4 5.9 8.7 4.6 6.2 15.1 8.1 9.9 4.4 4.5 4.9 4.2 6.9 8.8 6.4 2.9 3.4 5.2 5.8 3.7 4.8 5.3 42.5 29.5 33.8 30.3 25.9 25.7 3.2 3.0 2.4 3.9 4.5 1.6 3.4 2.8 3.3 3.1 2.7 22.0 20.4 39.8 16.4 26.8 35.6 14.3 0.31 0.17 0.13 0.53 0.13 0.23 0.65 0.24 0.16 0.89 0.16 0.31 0.03 0.11 0.03 0.15 0.54 0.15 0.34 1.77 0.75 0.35 0.11 0.37 0.11 0.11 0.52 0.10 0.19 0.19 0.11 0.63 0.11 0.40 0.09 0.37 0.09 0.05 0.30 0.21 0.22 0.05 0.19 0.42 0.21 0.11 0.42 0.11 0.24 0.41 0.17 0.22 0.24 0.17 0.98 0.88 0.38 1.66 1.16 0.35 0.90 0.39 0.18 0.12 0.67 0.15 0.21 0.24 0.32 0.15 0.15 0.43 0.75 0.76 1.00 0.42 0.65 0.31 0.50 0.48 0.67 0.59 1.09 0.52 0.76 1.23 0.62 0.52 1.36 0.44 0.35 0.65 0.92 0.56 0.67 0.94 0.60 0.73 1.26 1.14 0.46 0.83 1.10 0.71 0.46 0.96 0.39 0.48 0.43 0.62 1.35 0.53 0.65 0.69 1.04 0.55 0.73 1.82 0.96 1.21 0.52 0.51 0.55 0.48 0.80 1.04 0.74 0.35 0.45 0.59 0.67 0.42 0.60 0.58 4.79 3.51 4.10 3.59 2.94 3.00 0.36 0.37 0.28 0.43 0.56 0.19 0.41 0.32 0.41 0.38 0.29 2.89 2.59 5.27 2.05 3.52 4.75 1.76 0.04 0.02 0.02 0.07 0.02 0.03 0.09 0.03 0.02 0.13 0.02 0.04 0.00 0.02 0.00 0.02 0.07 0.02 0.05 0.27 0.10 0.05 0.02 0.05 0.02 0.01 0.07 0.01 0.03 0.03 0.02 0.08 0.02 0.06 0.01 0.05 0.01 0.01 0.04 0.03 0.03 0.01 0.03 0.06 0.03 0.02 0.06 0.02 0.03 0.06 0.02 0.03 0.03 0.02 0.13 0.12 0.05 0.23 0.15 0.05 0.12 0.05 0.03 0.02 0.09 0.02 0.03 0.04 0.04 0.02 0.02 0.06 0.11 0.11 0.15 0.06 0.09 0.05 0.07 Cases 72 488 799 113 664 373 90 271 375 59 309 66 18834 2074 15047 752 83 619 178 15 68 88 1981 291 1520 854 102 729 291 238 1074 140 895 97 2297 232 1574 6525 1129 582 970 3746 250 71 164 1854 179 1588 96 27 506 382 143 430 17 729 1771 174 252 2300 177 29 83 232 8 433 35 88 30 333 293 15 388 446 659 880 906 5654 607 Female ASR(W) CUM 0-74 1.1 1.6 1.9 2.6 1.8 2.2 2.7 2.0 1.5 2.8 1.4 1.5 1.9 2.3 1.7 1.8 1.9 1.7 2.4 3.2 2.8 2.2 2.2 2.7 2.0 1.6 2.1 1.5 1.8 1.6 1.6 2.9 1.4 1.9 2.1 2.6 1.7 2.2 5.3 2.4 3.8 1.6 1.5 1.7 1.2 2.4 2.4 2.3 1.4 1.1 2.1 2.4 1.4 1.7 3.1 11.3 7.3 12.6 10.3 8.3 5.0 1.1 0.9 1.3 0.8 2.2 0.9 1.4 1.0 1.5 1.4 0.7 8.0 7.5 11.9 5.6 8.2 11.2 5.9 0.15 0.09 0.08 0.25 0.08 0.13 0.30 0.14 0.09 0.38 0.10 0.22 0.02 0.05 0.02 0.08 0.22 0.08 0.20 0.87 0.35 0.28 0.06 0.17 0.06 0.06 0.22 0.07 0.12 0.12 0.06 0.27 0.06 0.24 0.05 0.18 0.05 0.03 0.17 0.10 0.12 0.03 0.10 0.22 0.10 0.06 0.19 0.06 0.16 0.26 0.11 0.14 0.14 0.10 0.76 0.43 0.19 1.00 0.66 0.20 0.39 0.22 0.10 0.09 0.30 0.11 0.15 0.15 0.18 0.09 0.09 0.19 0.43 0.41 0.50 0.21 0.32 0.16 0.31 0.12 0.18 0.23 0.32 0.21 0.25 0.35 0.22 0.17 0.34 0.16 0.14 0.22 0.27 0.20 0.21 0.21 0.20 0.29 0.38 0.30 0.27 0.26 0.33 0.23 0.17 0.23 0.15 0.20 0.20 0.18 0.33 0.16 0.19 0.25 0.32 0.19 0.26 0.65 0.28 0.44 0.19 0.17 0.21 0.14 0.27 0.26 0.26 0.16 0.09 0.22 0.25 0.15 0.21 0.41 1.26 0.87 1.59 1.15 0.95 0.60 0.13 0.10 0.16 0.10 0.25 0.10 0.15 0.12 0.17 0.16 0.05 0.99 0.95 1.62 0.66 1.04 1.43 0.74 0.02 0.01 0.01 0.04 0.01 0.02 0.04 0.02 0.01 0.06 0.01 0.03 0.00 0.01 0.00 0.01 0.03 0.01 0.03 0.14 0.05 0.04 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.02 0.01 0.04 0.01 0.03 0.01 0.03 0.01 0.00 0.02 0.01 0.02 0.00 0.01 0.03 0.01 0.01 0.03 0.01 0.02 0.03 0.01 0.02 0.02 0.01 0.12 0.06 * 0.03 0.14 * 0.09 0.03 * 0.05 * 0.03 * 0.01 0.01 * 0.05 0.02 0.02 * 0.02 * 0.03 * 0.01 0.01 0.02 0.07 0.06 0.08 0.03 0.05 0.03 0.04

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
425

483

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Liver (C22) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
426

Male ASR(W) CUM 0-74 44.9 49.8 46.1 35.4 50.2 36.7 44.4 44.1 42.7 8.1 6.0 10.6 9.1 7.4 5.4 21.7 18.8 21.3 8.1 12.3 18.4 32.3 8.6 3.8 3.2 8.6 7.3 6.9 3.4 1.2 2.5 5.9 6.9 7.1 4.0 4.2 4.8 13.6 15.2 7.9 11.6 9.0 11.7 14.6 6.4 7.8 4.9 7.9 6.0 6.5 5.0 6.7 4.3 5.8 6.9 1.8 2.4 14.4 29.5 11.6 9.0 11.5 7.3 15.2 10.4 34.8 17.4 20.0 14.5 10.1 6.9 14.6 16.0 11.3 26.0 13.0 9.3 14.9 18.2 0.23 0.81 0.95 1.18 1.42 0.88 2.42 0.47 1.84 0.97 1.16 0.76 0.52 0.68 0.48 0.60 0.49 0.59 1.10 1.20 0.69 1.21 0.57 0.37 0.20 0.17 0.56 0.79 0.11 0.13 0.12 0.14 0.21 0.14 0.14 0.33 0.16 0.63 0.83 0.67 0.68 0.52 0.55 0.63 0.61 0.64 0.55 0.60 0.25 0.19 0.27 0.32 0.22 0.24 0.40 0.42 0.15 1.24 1.12 0.80 0.41 0.70 0.90 0.57 0.61 1.51 0.44 1.02 1.13 0.71 0.41 0.67 0.93 1.00 1.91 0.55 0.47 0.86 0.52 5.40 6.06 5.32 4.25 6.13 4.37 5.29 5.23 5.19 0.86 0.66 1.34 1.16 0.99 0.69 2.55 2.21 2.56 0.78 1.33 2.18 3.97 1.05 0.43 0.41 1.10 0.92 0.88 0.43 0.16 0.30 0.72 0.85 0.86 0.49 0.47 0.55 1.89 1.96 1.06 1.55 1.13 1.50 1.98 0.85 1.13 0.65 1.14 0.73 0.82 0.57 0.84 0.57 0.71 0.85 0.19 0.28 1.82 3.88 1.41 1.11 1.34 1.05 1.90 1.37 4.67 2.23 2.58 1.84 1.34 0.87 1.93 2.08 1.39 3.53 1.63 1.15 1.98 2.40 0.03 0.12 0.13 0.17 0.21 0.13 0.34 0.07 0.27 0.13 0.16 0.12 0.08 0.10 0.07 0.09 0.07 0.09 0.13 0.15 0.09 0.17 0.08 0.05 0.03 0.03 0.08 0.12 0.02 0.02 0.02 0.02 0.03 0.02 0.02 0.04 0.02 0.10 0.12 0.10 0.10 0.07 0.08 0.09 0.08 0.10 0.08 0.09 0.03 0.03 0.04 0.04 0.03 0.03 0.06 0.06 0.02 0.19 0.17 0.12 0.06 0.09 0.14 0.08 0.09 0.23 0.07 0.15 0.16 0.11 0.06 0.10 0.14 0.14 0.29 0.08 0.07 0.13 0.08

Cases 13339 1582 869 339 374 712 131 3269 185 37 27 82 114 53 70 568 459 409 14 36 278 347 60 36 111 1319 78 31 705 50 366 1100 784 1449 540 150 744 104 77 48 96 110 123 75 21 52 31 39 386 666 280 231 129 324 156 7 164 59 284 129 294 185 29 383 192 199 635 296 86 104 193 295 184 90 52 249 277 122 525

Female ASR(W) CUM 0-74 12.0 14.9 12.9 10.3 10.8 11.7 12.0 13.0 11.0 3.6 6.6 3.8 3.1 3.2 3.7 7.0 4.8 5.0 3.2 3.6 6.7 14.8 1.9 1.2 1.3 2.7 2.3 1.9 1.4 0.6 1.3 2.5 3.0 2.6 1.9 2.0 2.1 2.2 2.4 1.6 2.6 2.3 2.1 1.4 1.2 1.9 1.1 1.4 2.5 2.1 2.2 2.1 1.0 2.1 2.1 0.6 1.1 3.7 7.4 3.9 3.0 3.5 2.3 4.0 4.0 10.2 3.8 9.0 5.0 3.5 2.4 6.2 6.4 4.8 4.1 3.3 3.6 3.4 4.2 0.11 0.38 0.44 0.57 0.57 0.45 1.10 0.23 0.84 0.62 1.40 0.42 0.30 0.46 0.46 0.30 0.23 0.26 0.90 0.61 0.41 0.81 0.25 0.20 0.12 0.09 0.29 0.37 0.06 0.10 0.09 0.09 0.12 0.08 0.09 0.20 0.09 0.23 0.32 0.26 0.32 0.25 0.22 0.18 0.30 0.30 0.27 0.25 0.15 0.10 0.16 0.15 0.10 0.13 0.20 0.26 0.09 0.56 0.49 0.44 0.20 0.32 0.62 0.26 0.37 0.75 0.18 0.69 0.61 0.44 0.21 0.41 0.51 0.55 0.65 0.24 0.25 0.35 0.21 1.46 1.85 1.53 1.26 1.34 1.41 1.30 1.59 1.33 0.41 0.79 0.47 0.36 0.39 0.45 0.80 0.50 0.53 0.22 0.39 0.81 1.79 0.20 0.14 0.14 0.32 0.30 0.23 0.16 0.07 0.15 0.30 0.34 0.30 0.22 0.22 0.20 0.28 0.28 0.17 0.28 0.29 0.23 0.18 0.13 0.20 0.11 0.18 0.28 0.26 0.27 0.24 0.11 0.25 0.22 0.10 0.13 0.45 0.95 0.44 0.37 0.41 0.25 0.47 0.46 1.44 0.45 1.07 0.57 0.44 0.28 0.71 0.84 0.60 0.48 0.37 0.42 0.41 0.49 0.01 0.06 0.06 0.08 0.08 0.06 0.14 0.03 0.12 0.09 0.22 0.06 0.04 0.07 * 0.06 * 0.05 * 0.03 0.04 0.09 0.08 0.06 * 0.11 * 0.03 0.03 * 0.02 * 0.01 0.05 0.06 0.01 * 0.01 * 0.01 0.01 * 0.02 0.01 0.01 0.02 0.01 0.03 0.04 0.04 0.04 0.03 0.03 0.03 0.03 0.04 0.03 0.03 0.02 0.01 0.02 0.02 0.01 0.02 0.03 0.04 0.01 0.08 0.07 0.06 0.03 0.05 0.07 0.04 0.05 0.12 0.03 0.09 0.08 0.06 0.03 0.06 0.09 0.09 0.10 0.03 0.04 0.05 0.03

40709 4438 2582 990 1349 1961 352 9909 659 74 77 209 325 124 138 1570 1522 1352 59 111 730 723 233 109 253 2604 174 79 998 88 496 1949 1162 2569 878 182 972 485 372 150 301 339 475 588 128 162 93 197 619 1255 355 459 407 615 323 20 291 149 732 243 558 351 75 794 333 535 1709 450 188 224 354 510 316 145 192 608 456 308 1325

484

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Liver (C22) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 313 420 35 388 92 122 182 330 623 651 1070 1041 415 66 491 778 395 61 219 264 285 202 177 194 1250 176 57 58 88 216 125 214 1029 40 58 223 506 634 825 239 907 1736 595 616 136 794 997 28 439 196 55 836 229 34 59 506 395 46 68 54 107 69 Male ASR(W) CUM 0-74 4.0 3.9 2.5 2.1 3.5 2.9 2.9 3.2 5.4 4.8 5.6 6.7 6.0 4.9 9.8 10.7 8.4 4.5 9.2 7.8 6.9 7.7 8.3 5.3 3.0 11.7 6.3 8.5 4.3 16.3 12.0 9.3 1.8 1.1 1.7 1.8 5.1 3.7 3.0 2.3 3.0 3.4 2.8 2.8 2.4 3.9 4.3 7.8 3.6 3.2 3.5 4.9 3.7 4.1 13.4 4.2 9.1 13.9 10.2 11.0 8.5 5.5 0.23 0.19 0.44 0.12 0.37 0.28 0.22 0.18 0.23 0.19 0.18 0.21 0.30 0.66 0.50 0.40 0.43 0.67 0.68 0.51 0.43 0.59 0.66 0.41 0.09 0.91 0.87 1.17 0.48 1.14 1.11 0.67 0.06 0.17 0.24 0.13 0.24 0.16 0.11 0.16 0.11 0.09 0.12 0.12 0.21 0.15 0.14 1.56 0.18 0.24 0.49 0.18 0.25 0.73 1.83 0.19 0.49 2.20 1.31 1.52 1.09 0.69 0.48 0.45 0.33 0.22 0.40 0.37 0.36 0.41 0.66 0.56 0.72 0.82 0.79 0.56 1.27 1.37 1.03 0.57 1.10 0.98 0.86 0.91 1.13 0.70 0.34 1.43 0.79 1.11 0.53 2.00 1.57 1.20 0.22 0.13 0.21 0.22 0.61 0.43 0.35 0.26 0.35 0.40 0.32 0.33 0.25 0.46 0.52 0.89 0.44 0.39 0.41 0.58 0.45 0.51 1.54 0.49 1.02 1.57 1.27 1.13 0.87 0.61 0.03 0.03 0.07 0.02 0.05 0.04 0.03 0.03 0.03 0.03 0.02 0.03 0.04 0.09 0.07 0.06 0.06 0.10 0.09 0.07 0.06 0.08 0.10 0.06 0.01 0.13 0.13 0.18 0.07 0.17 0.17 0.10 0.01 0.02 0.03 0.02 0.03 0.02 0.02 0.02 0.01 0.01 0.02 0.02 0.03 0.02 0.02 0.23 0.03 0.04 0.06 0.03 0.04 0.11 0.25 0.03 0.07 0.28 0.19 0.20 0.12 0.10 Cases 251 299 17 250 61 117 152 159 269 565 793 667 168 37 146 332 187 31 99 112 135 76 78 98 705 50 22 20 37 64 31 72 484 28 23 163 673 425 540 155 607 912 401 366 114 512 378 6 189 72 19 292 85 18 18 247 171 17 21 27 65 18 Female ASR(W) CUM 0-74 1.9 1.7 1.1 1.1 1.4 1.7 1.7 1.2 1.7 2.1 3.5 2.8 1.6 1.9 1.8 3.1 3.2 2.0 2.8 2.5 2.1 1.9 2.7 1.7 1.4 2.1 1.8 2.1 1.4 3.2 2.3 2.3 0.7 0.6 0.6 1.0 4.4 1.7 1.4 1.1 1.5 1.2 1.4 1.2 1.5 1.7 1.4 2.0 1.4 0.9 1.1 1.3 1.2 1.8 4.4 1.6 3.3 3.9 2.7 4.4 3.5 1.5 0.13 0.11 0.28 0.08 0.19 0.17 0.15 0.11 0.13 0.10 0.14 0.12 0.14 0.37 0.17 0.20 0.25 0.50 0.34 0.26 0.20 0.27 0.36 0.20 0.07 0.33 0.42 0.54 0.27 0.53 0.44 0.32 0.04 0.14 0.16 0.09 0.20 0.10 0.07 0.11 0.08 0.05 0.08 0.08 0.15 0.09 0.08 0.87 0.11 0.12 0.28 0.09 0.15 0.44 1.06 0.11 0.28 1.06 0.61 0.87 0.54 0.38 0.22 0.19 0.15 0.12 0.16 0.15 0.21 0.14 0.18 0.23 0.42 0.32 0.20 0.15 0.20 0.35 0.39 0.19 0.29 0.29 0.25 0.22 0.31 0.20 0.17 0.27 0.25 0.24 0.16 0.38 0.35 0.28 0.08 0.07 0.05 0.10 0.51 0.19 0.15 0.12 0.17 0.14 0.16 0.14 0.19 0.20 0.16 0.28 0.16 0.12 0.12 0.14 0.14 0.23 0.66 0.19 0.41 0.52 0.29 0.48 0.45 0.17 0.02 0.01 0.04 0.01 0.03 * 0.02 0.02 0.01 * 0.02 0.01 0.02 0.02 0.02 0.05 0.02 0.03 0.04 0.06 0.05 0.04 0.03 0.04 0.05 0.03 0.01 0.05 0.07 0.07 0.04 0.07 0.07 0.04 0.00 0.02 0.01 0.01 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.13 0.02 0.02 0.03 0.01 0.02 0.07 0.18 0.02 0.04 0.16 0.08 0.12 0.08 0.05

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
427

485

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Gallbladder etc. (C23-24)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 38 49 16 3 9 24 53 7 41 488 110 87 152 126 13 26 1402 152 258 82 31 23 1 42 740 4 69 183 28 152 23 284 1663 236 81 351 985 292 19 34 7 5 45 156 506 36 19 19 17 32 148 218 168 226 16 207 15 10 5 1197 91 1090 268 41 216 80 11 59 66 669 60 586 318 186 220 194 39 152 5 33 Male ASR(W) CUM 0-74 2.1 1.2 1.8 0.5 0.7 2.9 3.0 1.1 3.1 2.4 12.3 2.5 2.0 4.5 1.1 3.0 1.6 1.6 1.6 1.9 1.0 1.2 1.4 1.0 1.7 0.6 1.6 1.1 1.0 1.2 1.5 1.4 1.5 2.0 1.4 2.2 1.3 1.4 1.4 1.8 0.8 1.4 2.2 1.1 1.9 1.4 1.6 2.3 2.6 5.9 2.4 1.5 1.3 1.6 2.5 1.6 0.9 1.1 0.8 1.5 1.7 1.5 1.2 0.9 1.2 1.1 0.7 1.2 1.4 1.5 1.5 1.5 1.5 1.6 1.5 1.3 1.1 1.4 0.5 1.5 0.35 0.19 0.45 0.28 0.25 0.60 0.43 0.43 0.49 0.11 1.20 0.28 0.17 0.42 0.32 0.60 0.05 0.13 0.11 0.22 0.19 0.26 1.41 0.17 0.07 0.30 0.21 0.09 0.19 0.10 0.34 0.09 0.04 0.13 0.16 0.12 0.05 0.08 0.33 0.33 0.30 0.65 0.33 0.10 0.09 0.24 0.38 0.55 0.71 1.06 0.20 0.11 0.11 0.12 0.64 0.12 0.24 0.34 0.37 0.05 0.18 0.05 0.07 0.15 0.08 0.13 0.21 0.16 0.18 0.06 0.19 0.07 0.09 0.12 0.11 0.10 0.18 0.12 0.22 0.27 0.38 0.33 0.12 0.44 0.28 1.45 0.27 0.21 0.51 0.14 0.37 0.19 0.17 0.19 0.24 0.11 0.16 0.10 0.20 0.05 0.19 0.13 0.11 0.13 0.18 0.16 0.18 0.23 0.15 0.25 0.15 0.15 0.14 0.20 0.09 0.18 0.20 0.14 0.22 0.15 0.23 0.26 0.25 0.74 0.28 0.17 0.16 0.18 0.42 0.17 0.13 0.16 0.09 0.18 0.19 0.18 0.13 0.10 0.13 0.11 0.05 0.11 0.15 0.18 0.19 0.18 0.17 0.17 0.18 0.14 0.10 0.15 0.04 0.15 0.09 0.06 0.07 0.08 0.02 0.18 0.04 0.02 0.06 0.05 0.09 0.01 0.02 0.02 0.03 0.03 0.04 0.02 0.01 0.05 0.03 0.01 0.03 0.01 0.05 0.01 0.01 0.02 0.02 0.02 0.01 0.01 0.04 0.05 0.04 0.11 0.04 0.02 0.01 0.03 0.07 0.08 0.09 0.17 0.03 0.02 0.02 0.02 0.12 0.02 0.04 0.05 0.06 0.01 0.03 0.01 0.01 0.02 0.01 0.02 0.03 0.02 0.03 0.01 0.03 0.01 0.01 0.02 0.02 0.01 0.02 0.02 0.03 0.04 Cases 199 47 31 4 9 33 107 13 60 839 274 234 258 245 33 78 1872 219 294 111 52 30 4 87 957 15 103 250 63 185 33 338 2347 318 115 672 1230 438 24 36 15 7 87 236 780 62 30 24 17 30 300 295 228 291 18 269 33 25 7 1386 140 1224 403 81 307 118 25 79 73 1053 107 907 427 279 304 313 96 209 32 33 Female ASR(W) CUM 0-74 10.0 1.0 3.1 0.4 0.7 2.7 4.6 2.0 3.5 2.9 27.3 5.3 3.2 7.4 2.2 7.5 1.7 1.9 1.4 1.9 1.1 1.4 5.0 1.8 1.7 2.3 1.6 1.1 1.4 1.0 2.3 1.5 1.7 2.1 1.4 3.5 1.3 1.6 1.3 1.6 1.2 1.3 3.3 1.3 2.2 1.6 2.2 2.0 1.4 3.6 3.9 1.5 1.3 1.6 1.8 1.5 1.2 1.4 0.9 1.4 1.9 1.4 1.2 1.1 1.2 1.2 0.9 1.1 1.4 1.8 1.7 1.8 1.5 1.6 1.5 1.5 1.9 1.4 2.2 1.1 0.72 0.14 0.56 0.24 0.26 0.52 0.47 0.59 0.46 0.10 1.69 0.36 0.20 0.50 0.41 0.87 0.04 0.14 0.09 0.21 0.17 0.26 2.64 0.22 0.06 0.66 0.19 0.08 0.19 0.08 0.42 0.09 0.04 0.12 0.14 0.14 0.04 0.09 0.28 0.30 0.32 0.55 0.36 0.10 0.09 0.21 0.43 0.42 0.39 0.68 0.23 0.10 0.09 0.11 0.43 0.11 0.24 0.31 0.36 0.05 0.17 0.05 0.06 0.13 0.07 0.12 0.20 0.14 0.18 0.06 0.17 0.07 0.08 0.12 0.09 0.10 0.20 0.11 0.40 0.23 0.32 0.60 0.24 0.40 0.32 3.23 0.67 0.37 0.85 0.25 0.96 0.20 0.21 0.16 0.22 0.12 0.20 0.61 0.23 0.20 0.31 0.16 0.13 0.16 0.11 0.30 0.17 0.21 0.23 0.16 0.43 0.15 0.19 0.14 0.17 0.10 0.18 0.41 0.16 0.27 0.18 0.24 0.20 0.07 0.43 0.47 0.19 0.14 0.19 0.16 0.19 0.14 0.14 0.14 0.17 0.21 0.16 0.13 0.11 0.13 0.14 0.11 0.13 0.19 0.21 0.20 0.21 0.18 0.19 0.16 0.17 0.19 0.16 0.23 0.14 * * * *

0.07 0.08 0.09 0.07 0.01 0.24 0.06 0.03 0.07 0.05 0.14 * 0.01 0.02 0.01 0.03 0.03 0.04 0.48 0.03 0.01 0.11 0.03 0.01 0.03 0.01 0.07 0.01 0.01 0.02 0.02 0.02 0.01 0.01 0.04 0.04 0.04 0.08 0.06 0.02 0.01 0.03 0.06 0.06 0.04 0.11 0.03 0.02 0.01 0.02 0.05 0.02 0.03 0.04 0.07 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.04 0.02 0.03 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.03 0.02 0.06 0.03

486

*Important. See note on population page.

428

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Gallbladder etc. (C23-24) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 72 351 537 62 463 251 46 199 278 16 261 56 11835 863 10369 514 44 441 110 13 41 54 1163 100 993 576 39 525 156 158 876 49 804 63 1417 101 1122 3811 389 267 467 2649 185 40 144 855 81 740 76 33 266 173 93 300 4 147 681 28 51 858 140 46 88 764 3 333 31 56 16 255 215 27 236 381 263 817 570 2172 638 Male ASR(W) CUM 0-74 1.4 1.4 1.5 1.8 1.4 1.8 1.8 1.8 1.3 1.0 1.3 1.5 1.5 1.4 1.5 1.6 1.6 1.5 1.7 3.8 2.1 1.4 1.7 1.5 1.7 1.4 1.1 1.4 1.2 1.2 1.7 1.5 1.6 1.4 1.5 1.5 1.5 1.5 2.1 1.5 2.2 1.4 1.3 1.3 1.3 1.4 1.6 1.4 1.3 1.4 1.3 1.2 1.3 1.5 0.8 2.8 2.9 2.2 2.1 3.5 4.4 1.7 1.0 3.9 0.3 1.6 0.8 0.9 0.6 1.5 1.3 2.0 5.9 8.0 6.1 6.9 7.0 5.7 8.4 0.17 0.08 0.07 0.24 0.07 0.12 0.27 0.13 0.08 0.25 0.09 0.21 0.01 0.05 0.02 0.07 0.25 0.08 0.17 1.09 0.34 0.20 0.05 0.15 0.06 0.06 0.18 0.06 0.10 0.10 0.06 0.22 0.06 0.20 0.04 0.16 0.05 0.03 0.11 0.09 0.11 0.03 0.10 0.22 0.12 0.05 0.18 0.05 0.15 0.26 0.08 0.10 0.14 0.09 0.40 0.24 0.12 0.45 0.30 0.13 0.39 0.27 0.10 0.15 0.20 0.09 0.14 0.13 0.14 0.10 0.10 0.39 0.39 0.44 0.38 0.25 0.31 0.12 0.36 0.16 0.16 0.17 0.22 0.17 0.21 0.23 0.21 0.14 0.09 0.15 0.17 0.17 0.16 0.17 0.18 0.18 0.18 0.21 0.37 0.24 0.19 0.19 0.17 0.19 0.17 0.12 0.17 0.15 0.13 0.19 0.19 0.19 0.16 0.17 0.20 0.16 0.17 0.24 0.17 0.25 0.16 0.15 0.14 0.15 0.16 0.19 0.15 0.15 0.17 0.15 0.14 0.15 0.17 0.09 0.30 0.32 0.29 0.26 0.37 0.54 0.20 0.12 0.49 0.03 0.19 0.10 0.11 0.07 0.17 0.16 0.29 0.66 0.80 0.69 0.71 0.76 0.59 0.90 0.03 0.01 0.01 0.04 0.01 0.02 0.04 0.02 0.01 0.03 0.01 0.03 0.00 0.01 0.00 0.01 0.03 0.01 0.03 0.14 0.05 0.03 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.01 0.01 0.03 0.01 0.03 0.01 0.03 0.01 0.00 0.02 0.01 0.02 0.00 0.01 0.03 0.02 0.01 0.03 0.01 0.02 0.04 0.01 0.02 0.02 0.01 0.05 0.03 0.02 0.06 0.04 0.02 0.06 0.04 0.01 0.02 0.02 0.01 0.02 0.02 0.02 0.01 0.01 0.07 0.06 0.06 0.06 0.04 0.04 0.02 0.05 Cases 107 513 733 96 627 338 75 259 484 49 430 70 16980 1597 14558 774 83 659 157 34 64 58 1879 228 1568 833 81 739 229 231 1236 92 1120 117 1909 149 1540 5370 465 452 864 3513 233 63 166 1286 132 1117 88 37 374 250 121 496 5 165 783 50 50 1538 90 69 72 1476 8 457 29 71 12 455 401 40 259 484 296 911 834 2632 749 Female ASR(W) CUM 0-74 1.6 1.4 1.6 2.0 1.5 1.8 2.0 1.7 1.7 2.2 1.7 1.4 1.6 1.7 1.5 1.7 2.0 1.6 2.0 7.1 3.0 1.1 1.9 2.0 1.9 1.4 1.5 1.3 1.4 1.3 1.7 1.9 1.6 2.1 1.6 1.5 1.5 1.6 2.0 1.7 3.4 1.4 1.2 1.5 1.1 1.6 1.7 1.6 1.2 1.1 1.4 1.4 1.1 1.8 0.9 2.6 2.8 3.4 2.0 5.1 2.4 2.3 0.8 8.6 0.9 2.3 0.8 1.2 0.4 2.0 1.8 2.8 5.0 6.5 4.5 5.2 6.4 4.7 6.0 0.17 0.07 0.07 0.22 0.07 0.11 0.25 0.12 0.09 0.34 0.09 0.20 0.01 0.05 0.01 0.07 0.23 0.07 0.18 1.28 0.39 0.16 0.05 0.14 0.06 0.05 0.19 0.06 0.10 0.10 0.06 0.21 0.06 0.23 0.04 0.13 0.04 0.03 0.10 0.08 0.12 0.03 0.09 0.20 0.10 0.05 0.16 0.05 0.14 0.20 0.08 0.10 0.11 0.09 0.40 0.20 0.11 0.50 0.29 0.14 0.26 0.30 0.10 0.23 0.31 0.11 0.14 0.14 0.12 0.10 0.10 0.44 0.33 0.35 0.29 0.19 0.26 0.10 0.26 0.20 0.15 0.18 0.25 0.17 0.20 0.26 0.18 0.20 0.29 0.19 0.18 0.18 0.20 0.18 0.21 0.25 0.19 0.25 0.85 0.40 0.12 0.22 0.24 0.22 0.15 0.16 0.15 0.16 0.15 0.19 0.21 0.19 0.24 0.18 0.18 0.18 0.19 0.22 0.20 0.41 0.16 0.14 0.20 0.12 0.19 0.18 0.19 0.14 0.11 0.17 0.17 0.12 0.20 0.10 0.30 0.29 0.46 0.22 0.60 0.24 0.29 0.10 1.05 0.13 0.27 0.08 0.14 0.06 0.24 0.22 0.38 0.51 0.67 0.43 0.53 0.67 0.47 0.60 0.03 0.01 0.01 0.03 0.01 0.02 0.04 0.02 0.01 0.05 0.01 0.03 0.00 0.01 0.00 0.01 0.04 0.01 0.03 0.21 0.06 0.02 0.01 0.02 0.01 0.01 0.03 0.01 0.01 0.01 0.01 0.03 0.01 0.03 0.01 0.02 0.01 0.00 0.01 0.01 0.02 0.00 0.01 0.03 0.01 0.01 0.02 0.01 0.02 0.03 0.01 0.02 0.02 0.01 0.05 0.03 * 0.02 0.08 * 0.04 0.02 * 0.03 * 0.05 * 0.01 0.03 * 0.05 0.02 0.02 * 0.02 * 0.02 * 0.02 0.02 0.07 0.05 0.05 0.04 0.03 0.04 0.01 0.04

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
429

487

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Gallbladder etc. (C23-24) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
430

Male ASR(W) CUM 0-74 8.1 9.3 10.4 7.0 10.0 7.1 8.5 8.0 10.1 1.8 1.2 1.0 0.6 0.8 1.3 1.2 2.0 2.1 2.3 1.4 1.7 2.9 0.8 1.4 1.5 2.1 2.0 1.9 1.2 0.6 1.0 1.3 2.8 4.4 1.4 1.6 2.1 1.8 2.0 1.5 1.9 1.5 2.2 1.2 0.7 0.8 1.7 0.6 2.6 3.2 1.4 3.7 2.3 2.4 2.5 1.6 2.0 2.2 2.9 4.1 2.8 3.2 2.2 3.1 1.8 3.5 3.2 2.5 3.7 1.4 2.6 3.8 3.9 3.3 3.0 3.9 2.7 4.1 3.0 0.10 0.40 0.50 0.58 0.69 0.43 1.16 0.23 1.03 0.46 0.51 0.24 0.14 0.22 0.24 0.15 0.16 0.19 0.59 0.36 0.22 0.37 0.17 0.23 0.14 0.08 0.28 0.41 0.06 0.09 0.07 0.06 0.13 0.11 0.08 0.19 0.10 0.23 0.28 0.28 0.27 0.20 0.24 0.17 0.18 0.18 0.31 0.15 0.16 0.13 0.14 0.24 0.15 0.15 0.23 0.45 0.13 0.47 0.34 0.47 0.22 0.33 0.49 0.25 0.23 0.48 0.18 0.33 0.52 0.24 0.22 0.34 0.45 0.51 0.64 0.29 0.25 0.44 0.20 0.98 1.14 1.23 0.80 1.17 0.89 0.86 0.89 1.38 0.17 0.17 0.05 0.09 0.10 0.16 0.14 0.24 0.24 0.29 0.15 0.23 0.35 0.08 0.16 0.21 0.23 0.18 0.27 0.14 0.06 0.11 0.15 0.31 0.51 0.16 0.20 0.21 0.21 0.20 0.17 0.24 0.13 0.27 0.13 0.10 0.07 0.20 0.06 0.30 0.37 0.16 0.40 0.24 0.27 0.30 0.21 0.22 0.20 0.35 0.44 0.32 0.34 0.23 0.36 0.16 0.49 0.36 0.24 0.44 0.19 0.27 0.42 0.46 0.42 0.38 0.44 0.34 0.49 0.34 0.02 0.06 0.07 0.08 0.10 0.07 0.15 0.03 0.17 0.06 0.08 0.02 0.02 0.03 0.04 0.02 0.02 0.03 0.08 0.05 0.03 0.05 0.02 0.03 0.02 0.01 0.04 0.07 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.03 0.01 0.03 0.04 0.04 0.04 0.02 0.04 0.02 0.03 0.02 0.05 0.02 0.02 0.02 0.02 0.03 0.02 0.02 0.03 0.07 0.02 0.06 0.05 0.06 0.03 0.05 0.07 0.04 0.03 0.08 0.03 0.05 0.08 0.04 0.03 0.05 0.07 0.08 0.10 0.04 0.04 0.07 0.03

Cases 6518 782 504 159 210 312 101 1609 120 19 10 29 32 17 94 101 225 191 10 24 101 92 38 50 167 1433 88 50 623 81 314 837 933 3436 486 150 887 87 75 43 85 81 109 69 51 41 39 29 726 1699 187 559 338 554 258 18 360 66 131 111 256 175 37 268 97 107 578 107 60 91 212 236 109 71 28 291 214 110 361

Female ASR(W) CUM 0-74 5.6 7.4 7.5 4.8 5.8 5.0 8.0 6.3 7.0 1.7 2.5 1.3 0.9 1.1 4.9 1.3 2.4 2.4 2.3 2.5 2.4 3.7 1.2 1.8 2.0 2.6 2.3 2.7 1.2 0.8 1.1 1.9 3.5 6.0 1.5 1.8 2.5 1.4 1.6 1.5 2.3 1.2 1.8 1.0 1.6 1.1 1.4 0.7 4.4 4.8 1.4 4.9 2.1 3.0 3.1 1.4 2.2 3.5 3.3 3.4 2.7 3.3 2.7 2.8 1.9 5.3 3.3 2.9 3.3 2.8 2.4 5.0 3.7 4.0 2.3 3.6 3.0 3.1 3.0 0.07 0.27 0.34 0.39 0.41 0.29 0.84 0.16 0.67 0.42 0.81 0.25 0.15 0.28 0.53 0.13 0.16 0.18 0.75 0.53 0.25 0.39 0.20 0.25 0.16 0.08 0.28 0.43 0.05 0.10 0.07 0.07 0.12 0.11 0.08 0.16 0.10 0.17 0.22 0.26 0.27 0.16 0.19 0.13 0.27 0.20 0.28 0.15 0.18 0.13 0.12 0.22 0.13 0.15 0.22 0.38 0.13 0.49 0.32 0.40 0.20 0.31 0.55 0.20 0.24 0.53 0.16 0.35 0.48 0.35 0.20 0.36 0.39 0.51 0.50 0.25 0.25 0.34 0.18 0.67 0.94 0.93 0.63 0.64 0.58 0.76 0.73 0.84 0.24 0.25 0.16 0.08 0.15 0.57 0.15 0.26 0.25 0.30 0.33 0.30 0.50 0.14 0.20 0.23 0.30 0.25 0.28 0.16 0.10 0.13 0.23 0.39 0.67 0.18 0.22 0.27 0.17 0.14 0.17 0.28 0.15 0.19 0.10 0.16 0.12 0.16 0.08 0.49 0.55 0.16 0.54 0.22 0.34 0.34 0.16 0.25 0.41 0.39 0.35 0.30 0.42 0.31 0.31 0.23 0.64 0.36 0.28 0.35 0.34 0.25 0.61 0.41 0.49 0.24 0.38 0.33 0.34 0.36 0.01 0.04 0.05 0.06 0.06 0.04 0.11 0.02 0.10 0.07 0.12 0.04 0.02 0.04 * 0.07 * 0.02 * 0.02 0.03 0.11 0.08 0.04 * 0.06 * 0.03 0.04 * 0.02 * 0.01 0.04 0.06 0.01 * 0.01 * 0.01 0.01 * 0.02 0.02 0.01 0.02 0.01 0.03 0.03 0.04 0.04 0.03 0.03 0.02 0.03 0.03 0.04 0.02 0.03 0.02 0.02 0.03 0.02 0.02 0.03 0.06 0.02 0.08 0.05 0.05 0.03 0.05 0.07 0.03 0.03 0.08 0.02 0.05 0.07 0.05 0.03 0.05 0.06 0.08 0.07 0.03 0.04 0.05 0.03

6557 682 477 163 233 308 58 1468 111 16 16 18 21 12 32 74 162 129 17 16 68 62 20 39 120 698 52 22 340 43 216 459 471 1652 338 72 435 65 55 31 49 66 96 51 16 20 35 16 271 644 104 239 229 265 127 15 256 25 73 90 191 111 23 172 74 56 341 67 58 39 163 134 83 47 23 200 140 91 243

488

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Gallbladder etc. (C23-24) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 109 183 19 285 83 109 182 154 300 252 247 587 245 18 57 180 95 28 73 83 83 89 45 54 771 32 10 15 33 33 16 42 1152 70 62 112 105 163 285 83 327 596 224 244 108 321 403 11 236 120 40 318 128 11 6 175 103 7 16 15 43 14 Male ASR(W) CUM 0-74 1.4 1.6 1.3 1.5 3.4 2.3 2.8 1.4 2.4 1.8 1.3 3.6 3.5 1.2 1.1 2.3 2.0 1.7 2.8 2.3 1.9 3.1 1.9 1.2 1.8 2.0 1.1 2.4 1.6 2.4 1.5 1.6 1.9 1.9 1.6 0.8 1.1 0.9 1.0 0.8 1.0 1.0 1.0 1.0 1.9 1.5 1.6 2.7 1.8 1.9 2.0 1.8 2.0 1.1 1.5 1.3 2.0 1.2 2.1 3.2 2.4 1.0 0.13 0.12 0.31 0.09 0.37 0.23 0.22 0.12 0.14 0.11 0.08 0.15 0.22 0.30 0.15 0.18 0.21 0.37 0.38 0.26 0.22 0.36 0.31 0.18 0.07 0.36 0.35 0.64 0.30 0.44 0.37 0.26 0.06 0.23 0.22 0.08 0.11 0.08 0.06 0.09 0.06 0.05 0.07 0.07 0.19 0.09 0.08 0.90 0.12 0.18 0.33 0.10 0.18 0.35 0.60 0.10 0.22 0.51 0.56 0.84 0.45 0.29 0.18 0.19 0.14 0.17 0.36 0.25 0.35 0.17 0.26 0.22 0.16 0.42 0.40 0.16 0.13 0.26 0.22 0.18 0.32 0.25 0.21 0.35 0.25 0.14 0.22 0.21 0.14 0.27 0.20 0.31 0.20 0.18 0.22 0.21 0.19 0.08 0.13 0.11 0.11 0.09 0.11 0.12 0.11 0.12 0.23 0.18 0.20 0.28 0.22 0.21 0.21 0.21 0.24 0.08 0.15 0.16 0.22 0.12 0.23 0.40 0.25 0.08 0.02 0.02 0.04 0.01 0.05 0.03 0.03 0.02 0.02 0.02 0.01 0.02 0.03 0.05 0.02 0.03 0.03 0.05 0.05 0.04 0.03 0.05 0.05 0.03 0.01 0.05 0.06 0.08 0.04 0.07 0.06 0.04 0.01 0.03 0.03 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.01 0.12 0.02 0.03 0.05 0.02 0.03 0.04 0.07 0.02 0.03 0.08 0.08 0.12 0.06 0.04 Cases 182 460 30 385 190 345 388 176 330 651 444 1455 414 49 101 317 179 37 91 201 151 131 83 115 1337 41 31 18 76 40 29 82 1617 109 99 169 158 216 393 102 484 834 350 386 158 420 636 7 275 185 61 429 138 18 9 235 85 8 11 7 35 17 Female ASR(W) CUM 0-74 1.2 2.3 1.7 1.5 4.5 5.2 3.7 1.1 1.8 2.1 1.9 5.9 3.5 3.0 1.2 2.8 2.9 1.8 2.3 4.3 2.5 3.0 2.7 1.8 2.5 1.8 2.6 1.7 2.3 2.1 1.8 2.2 1.9 2.2 1.9 0.9 1.1 0.9 1.0 0.7 1.1 1.1 1.3 1.3 1.9 1.3 2.0 2.6 1.6 2.2 2.4 1.9 1.7 1.8 2.2 1.4 1.4 1.3 1.4 1.2 1.5 1.0 0.10 0.12 0.33 0.09 0.35 0.31 0.20 0.09 0.11 0.09 0.10 0.17 0.19 0.51 0.14 0.18 0.23 0.39 0.28 0.34 0.22 0.32 0.34 0.20 0.08 0.31 0.54 0.50 0.30 0.38 0.38 0.28 0.05 0.22 0.21 0.09 0.10 0.07 0.06 0.08 0.06 0.04 0.08 0.07 0.17 0.08 0.09 1.01 0.11 0.18 0.35 0.10 0.15 0.43 0.75 0.10 0.17 0.55 0.43 0.47 0.33 0.28 0.14 0.29 0.20 0.17 0.51 0.61 0.42 0.13 0.21 0.23 0.24 0.70 0.38 0.32 0.12 0.29 0.34 0.21 0.25 0.52 0.26 0.29 0.29 0.21 0.31 0.23 0.29 0.16 0.26 0.24 0.18 0.29 0.23 0.23 0.21 0.10 0.11 0.11 0.12 0.06 0.12 0.12 0.15 0.15 0.22 0.15 0.24 0.31 0.18 0.26 0.27 0.22 0.18 0.21 0.32 0.16 0.15 0.14 0.22 0.13 0.17 0.10 0.01 0.02 0.05 0.01 0.05 * 0.04 0.03 0.01 * 0.02 0.01 0.01 0.02 0.03 0.07 0.02 0.03 0.03 0.06 0.04 0.05 0.03 0.05 0.05 0.03 0.01 0.05 0.07 0.06 0.05 0.05 0.05 0.04 0.01 0.03 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.16 0.02 0.03 0.05 0.02 0.02 0.06 0.12 0.01 0.02 0.08 0.08 0.06 0.05 0.04

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
431

489

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Pancreas (C25)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 9 164 22 12 66 90 112 28 47 1315 39 141 341 81 56 18 5651 667 1058 302 223 50 5 285 2750 38 273 1178 283 892 115 1237 7730 627 552 1015 5484 1470 119 94 45 21 129 1006 1966 252 55 30 36 38 341 1182 940 1079 76 995 188 139 40 5626 464 5100 1741 467 1256 520 164 343 294 3509 482 2955 1549 893 1023 1360 402 949 116 196 Male ASR(W) CUM 0-74 0.5 4.0 2.5 1.2 4.6 9.9 5.7 4.2 3.6 6.6 4.2 4.2 4.6 3.0 4.7 2.0 6.7 7.1 6.7 7.1 7.7 2.8 5.8 7.9 6.6 6.7 6.5 7.7 10.0 7.2 8.0 6.7 7.4 5.4 9.9 6.6 7.7 7.0 9.1 5.7 5.0 5.2 6.3 7.5 7.3 10.3 4.5 3.6 5.5 6.9 5.8 8.1 7.3 8.4 10.9 8.2 10.5 12.5 6.4 7.8 8.8 7.7 7.7 10.6 7.0 7.8 10.1 7.1 6.6 8.6 11.2 8.3 7.6 8.0 7.5 9.7 12.5 8.9 12.6 8.8 0.17 0.33 0.54 0.40 0.63 1.09 0.57 0.83 0.54 0.18 0.68 0.36 0.25 0.35 0.66 0.48 0.09 0.28 0.22 0.43 0.54 0.40 2.75 0.49 0.13 1.15 0.43 0.23 0.62 0.25 0.78 0.20 0.09 0.22 0.43 0.21 0.11 0.19 0.86 0.61 0.77 1.27 0.57 0.25 0.17 0.66 0.64 0.68 1.03 1.14 0.32 0.25 0.25 0.27 1.27 0.28 0.80 1.10 1.06 0.11 0.42 0.12 0.19 0.51 0.20 0.35 0.83 0.40 0.41 0.15 0.52 0.16 0.20 0.29 0.24 0.27 0.64 0.30 1.19 0.67 1.23 0.66 0.50 0.42 0.79 0.49 0.54 0.48 0.38 0.51 0.19 0.79 0.82 0.78 0.90 0.90 0.39 0.57 0.96 0.79 0.67 0.73 0.94 1.19 0.88 1.03 0.80 0.89 0.63 1.27 0.81 0.92 0.84 1.15 0.67 0.62 0.57 0.85 0.88 0.88 1.36 0.48 0.43 0.71 0.75 0.72 0.96 0.84 0.99 1.32 0.98 1.22 1.46 0.67 0.93 1.05 0.92 0.90 1.28 0.82 0.90 1.25 0.81 0.74 1.04 1.40 1.00 0.93 0.97 0.88 1.17 1.66 1.04 1.80 0.98 0.16 0.08 0.12 0.08 0.03 0.11 0.06 0.04 0.06 0.08 0.06 0.01 0.04 0.03 0.07 0.08 0.06 0.34 0.07 0.02 0.16 0.06 0.03 0.09 0.04 0.12 0.03 0.01 0.03 0.07 0.03 0.02 0.03 0.14 0.09 0.12 0.20 0.09 0.04 0.03 0.10 0.09 0.10 0.16 0.16 0.05 0.04 0.04 0.04 0.19 0.04 0.12 0.16 0.15 0.02 0.06 0.02 0.03 0.08 0.03 0.05 0.13 0.06 0.06 0.02 0.08 0.02 0.03 0.04 0.03 0.04 0.10 0.04 0.20 0.09 Cases 8 109 18 6 56 89 113 14 65 1449 41 182 337 102 49 28 5909 657 1156 332 230 38 5 287 2897 40 267 1265 325 930 105 1190 8080 650 646 1139 5594 1647 156 84 51 33 150 1100 2102 295 56 53 56 25 449 1132 908 1128 78 1033 210 159 42 5598 524 5010 1710 495 1198 504 183 314 320 3752 571 3103 1593 906 1062 1317 420 891 119 188 Female ASR(W) CUM 0-74 0.3 2.3 1.9 0.4 4.8 6.4 4.8 2.1 3.8 5.0 3.8 4.0 4.0 2.9 3.3 2.6 5.3 5.6 5.5 5.4 6.2 1.8 7.2 5.7 5.2 5.0 4.8 5.5 6.9 5.2 7.2 4.9 5.7 4.3 8.1 5.8 5.7 5.6 8.3 3.6 4.0 6.0 5.5 5.7 5.6 7.7 3.7 4.5 6.4 3.2 5.5 5.8 5.4 6.2 7.7 6.0 7.2 8.2 4.6 5.7 7.0 5.6 5.3 7.0 4.8 5.4 7.2 4.8 5.6 6.3 8.7 6.0 5.5 5.4 5.4 6.4 8.4 5.8 8.1 6.0 0.12 0.23 0.46 0.17 0.71 0.76 0.47 0.57 0.48 0.13 0.61 0.30 0.22 0.30 0.52 0.51 0.08 0.24 0.18 0.35 0.47 0.30 3.36 0.38 0.11 0.91 0.35 0.17 0.42 0.19 0.73 0.16 0.07 0.18 0.34 0.18 0.09 0.16 0.73 0.42 0.58 1.21 0.47 0.20 0.14 0.48 0.52 0.65 0.98 0.67 0.27 0.20 0.20 0.22 0.90 0.22 0.57 0.74 0.84 0.09 0.32 0.09 0.14 0.34 0.15 0.26 0.56 0.29 0.35 0.12 0.38 0.13 0.16 0.21 0.18 0.20 0.44 0.22 0.79 0.50 0.75 0.59 0.25 0.41 0.57 0.49 0.45 0.41 0.33 0.39 0.32 0.60 0.64 0.59 0.63 0.74 0.23 0.97 0.65 0.59 0.48 0.55 0.63 0.84 0.58 0.90 0.57 0.66 0.51 0.97 0.66 0.67 0.64 0.98 0.39 0.39 0.61 0.64 0.66 0.66 0.95 0.40 0.55 0.80 0.30 0.63 0.68 0.64 0.75 0.84 0.73 0.85 0.96 0.50 0.67 0.80 0.66 0.63 0.84 0.57 0.64 0.80 0.59 0.65 0.76 1.05 0.72 0.67 0.64 0.62 0.77 0.97 0.70 0.90 0.71 * * * *

0.11 0.07 0.09 0.07 0.02 0.10 0.05 0.03 0.05 0.07 0.08 * 0.01 0.04 0.03 0.05 0.07 0.05 0.59 0.06 0.02 0.13 0.05 0.03 0.07 0.03 0.11 0.02 0.01 0.03 0.05 0.03 0.01 0.02 0.11 0.06 0.07 0.15 0.07 0.03 0.02 0.08 0.08 0.10 0.15 0.09 0.04 0.03 0.03 0.03 0.13 0.03 0.09 0.11 0.13 0.01 0.05 0.01 0.02 0.05 0.02 0.04 0.09 0.05 0.05 0.02 0.06 0.02 0.02 0.03 0.03 0.03 0.07 0.03 0.11 0.07

490

*Important. See note on population page.

432

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Pancreas (C25) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 419 1813 2760 395 2334 1241 305 921 1614 150 1455 244 60120 6260 52183 2532 273 2188 458 20 149 278 5743 634 4925 2992 322 2633 952 906 3988 346 3587 304 7026 717 5767 18724 1048 1937 1390 14219 1047 277 765 4459 539 3845 381 182 1607 1080 517 1543 28 180 1006 91 172 1812 84 94 134 412 21 436 50 116 47 1446 1300 71 349 381 369 1119 733 3524 718 Male ASR(W) CUM 0-74 8.3 8.1 8.2 11.8 7.8 9.5 12.4 8.8 8.1 10.5 8.0 6.6 7.9 10.2 7.7 8.5 9.9 8.4 7.4 6.3 7.9 7.2 8.8 9.5 8.8 7.5 9.8 7.3 7.7 7.1 8.2 11.4 7.9 8.0 8.0 10.9 7.9 7.9 5.8 10.9 6.7 7.9 7.8 9.9 7.2 7.4 10.4 7.2 6.8 8.4 8.2 8.2 7.2 8.0 4.9 3.4 4.5 7.1 7.5 7.5 2.6 4.0 1.4 2.1 2.5 2.2 1.3 1.9 1.7 8.4 8.3 5.0 8.8 8.8 8.6 10.1 9.3 9.3 9.9 0.43 0.20 0.16 0.61 0.17 0.28 0.74 0.31 0.21 0.88 0.22 0.45 0.03 0.13 0.04 0.18 0.61 0.19 0.36 1.42 0.66 0.46 0.12 0.38 0.13 0.14 0.56 0.15 0.26 0.25 0.14 0.63 0.14 0.49 0.10 0.42 0.11 0.06 0.19 0.25 0.19 0.07 0.25 0.61 0.27 0.11 0.46 0.12 0.36 0.65 0.21 0.26 0.33 0.22 0.94 0.26 0.15 0.76 0.58 0.19 0.29 0.43 0.13 0.11 0.54 0.11 0.19 0.18 0.25 0.23 0.24 0.61 0.48 0.48 0.46 0.31 0.36 0.16 0.40 1.01 0.97 0.97 1.44 0.92 1.13 1.57 1.04 1.00 1.24 0.98 0.75 0.94 1.25 0.92 1.02 1.24 1.01 0.93 0.91 0.96 0.90 1.05 1.18 1.05 0.90 1.19 0.87 0.92 0.85 0.99 1.46 0.95 1.00 0.97 1.37 0.95 0.95 0.67 1.39 0.82 0.94 0.89 1.15 0.82 0.90 1.29 0.87 0.81 1.05 1.00 1.01 0.84 0.96 0.63 0.41 0.53 0.88 0.96 0.90 0.36 0.48 0.16 0.26 0.32 0.27 0.15 0.23 0.22 1.00 0.99 0.64 1.04 1.03 0.99 1.17 1.10 1.07 1.15 0.06 0.03 0.02 0.09 0.02 0.04 0.11 0.04 0.03 0.13 0.03 0.07 0.00 0.02 0.01 0.03 0.09 0.03 0.05 0.23 0.10 0.07 0.02 0.06 0.02 0.02 0.08 0.02 0.04 0.04 0.02 0.09 0.02 0.07 0.02 0.06 0.02 0.01 0.03 0.04 0.03 0.01 0.04 0.09 0.04 0.02 0.07 0.02 0.05 0.10 0.03 0.04 0.05 0.03 0.15 0.04 0.02 0.11 0.08 0.03 0.04 0.06 0.02 0.02 0.08 0.02 0.02 0.03 0.04 0.03 0.04 0.09 0.07 0.07 0.07 0.04 0.05 0.02 0.06 Cases 417 2124 2860 467 2358 1360 357 993 1620 210 1399 233 63114 7539 53793 2885 363 2456 422 22 150 240 6762 972 5643 3192 404 2748 923 980 4149 434 3646 386 7256 832 5787 19530 1119 2209 1542 14516 1138 378 757 4479 564 3832 325 156 1617 1111 463 1660 17 134 797 82 122 1587 48 58 60 234 11 299 21 72 31 1373 1260 37 242 353 285 987 661 2874 546 Female ASR(W) CUM 0-74 6.1 6.3 6.1 9.6 5.6 7.2 9.6 6.6 5.5 8.9 5.2 5.3 5.9 8.0 5.6 6.5 8.2 6.4 5.2 4.7 6.3 4.7 6.9 8.5 6.8 5.5 8.1 5.2 5.3 5.9 5.9 8.6 5.5 6.3 6.0 8.6 5.7 5.9 4.8 8.3 5.8 5.7 6.0 8.5 5.3 5.5 7.5 5.3 4.5 5.5 6.2 6.3 4.4 6.1 2.8 2.1 3.1 5.4 5.1 5.3 1.4 1.8 0.7 1.4 1.2 1.6 0.5 1.2 1.0 5.9 5.8 2.4 5.0 5.3 4.9 6.3 5.2 5.4 5.1 0.34 0.16 0.13 0.47 0.13 0.22 0.55 0.24 0.16 0.67 0.16 0.40 0.03 0.10 0.03 0.14 0.45 0.15 0.28 1.04 0.54 0.34 0.09 0.29 0.10 0.11 0.43 0.11 0.20 0.22 0.11 0.45 0.11 0.39 0.08 0.32 0.09 0.05 0.15 0.19 0.15 0.06 0.20 0.47 0.21 0.09 0.34 0.09 0.27 0.49 0.17 0.22 0.23 0.17 0.70 0.18 0.12 0.63 0.46 0.14 0.22 0.25 0.09 0.10 0.36 0.09 0.12 0.14 0.19 0.17 0.18 0.40 0.34 0.34 0.31 0.22 0.24 0.11 0.26 0.75 0.75 0.73 1.16 0.67 0.87 1.19 0.79 0.65 1.06 0.61 0.65 0.69 0.95 0.67 0.75 0.92 0.74 0.64 0.48 0.75 0.58 0.80 1.01 0.79 0.65 0.98 0.61 0.60 0.71 0.69 1.03 0.66 0.74 0.71 1.03 0.68 0.69 0.55 0.97 0.67 0.67 0.71 1.03 0.61 0.65 0.90 0.62 0.51 0.68 0.72 0.75 0.55 0.72 0.33 0.25 0.37 0.62 0.60 0.63 0.19 0.20 0.08 0.18 0.15 0.19 0.06 0.15 0.13 0.67 0.67 0.29 0.58 0.57 0.54 0.66 0.56 0.60 0.55 0.05 0.02 0.02 0.07 0.02 0.03 0.08 0.04 0.02 0.10 0.02 0.06 0.00 0.01 0.00 0.02 0.07 0.02 0.04 0.13 0.08 0.05 0.01 0.04 0.02 0.02 0.07 0.02 0.03 0.03 0.02 0.07 0.02 0.06 0.01 0.05 0.01 0.01 0.02 0.03 0.02 0.01 0.03 0.07 0.03 0.01 0.05 0.01 0.04 0.07 0.03 0.03 0.04 0.03 0.10 0.03 * 0.02 0.09 * 0.07 0.02 * 0.03 * 0.04 * 0.01 0.01 * 0.05 0.01 0.01 * 0.02 * 0.03 * 0.03 0.03 0.06 0.05 0.05 0.04 0.03 0.03 0.02 0.04

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
433

491

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Pancreas (C25) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
434

Male ASR(W) CUM 0-74 7.8 7.7 7.3 7.9 8.3 7.8 5.0 8.7 8.7 3.7 3.2 3.4 2.3 2.1 0.9 4.3 5.0 5.4 3.1 3.9 1.4 2.0 1.8 4.2 4.1 8.8 8.9 8.6 7.6 4.0 5.0 8.6 9.4 11.0 7.8 10.6 8.8 7.4 7.6 5.8 7.5 6.6 6.2 4.4 4.5 5.1 6.2 4.0 9.6 8.7 8.8 9.7 8.3 9.9 8.2 8.0 7.4 8.6 11.9 9.3 7.8 8.0 7.2 8.9 8.0 6.0 10.1 9.6 9.1 6.5 9.4 5.1 9.7 7.3 12.2 7.0 7.2 8.7 9.9 0.10 0.35 0.41 0.60 0.63 0.43 0.86 0.23 0.89 0.64 0.91 0.44 0.26 0.36 0.19 0.28 0.25 0.30 0.70 0.68 0.19 0.30 0.26 0.39 0.23 0.17 0.62 0.87 0.16 0.25 0.16 0.17 0.24 0.18 0.20 0.49 0.21 0.46 0.57 0.58 0.55 0.45 0.41 0.34 0.49 0.51 0.65 0.43 0.31 0.22 0.36 0.38 0.30 0.31 0.43 0.95 0.25 0.98 0.70 0.73 0.37 0.54 0.92 0.44 0.52 0.63 0.34 0.71 0.87 0.56 0.44 0.40 0.72 0.78 1.31 0.39 0.43 0.65 0.38 0.95 0.91 0.89 0.97 1.01 0.97 0.83 1.02 1.10 0.44 0.30 0.42 0.25 0.21 0.10 0.50 0.56 0.62 0.26 0.47 0.17 0.21 0.24 0.59 0.49 1.06 1.10 1.09 0.94 0.52 0.63 1.03 1.10 1.34 0.92 1.32 1.04 0.96 0.87 0.70 0.91 0.81 0.80 0.62 0.59 0.61 0.76 0.59 1.11 1.03 1.08 1.21 0.96 1.13 0.98 0.97 0.84 1.02 1.47 1.15 0.91 0.93 0.90 1.06 0.99 0.71 1.22 1.19 1.09 0.81 1.13 0.60 1.07 0.79 1.61 0.81 0.85 1.07 1.14 0.01 0.05 0.06 0.09 0.09 0.06 0.16 0.03 0.14 0.09 0.11 0.06 0.04 0.04 0.02 0.04 0.04 0.04 0.07 0.10 0.03 0.04 0.04 0.06 0.03 0.03 0.09 0.13 0.02 0.04 0.02 0.02 0.03 0.03 0.03 0.07 0.03 0.07 0.08 0.08 0.08 0.06 0.06 0.05 0.07 0.07 0.09 0.07 0.04 0.03 0.05 0.05 0.04 0.04 0.06 0.14 0.04 0.14 0.10 0.10 0.05 0.08 0.13 0.06 0.08 0.09 0.05 0.10 0.13 0.08 0.06 0.05 0.10 0.10 0.20 0.06 0.06 0.10 0.05

Cases 4709 411 294 149 154 244 43 1253 80 31 16 53 64 25 9 305 336 294 11 31 51 44 21 78 225 3397 232 90 1872 272 1050 1895 1368 3958 1958 438 2098 263 196 100 172 219 279 118 62 116 103 69 1028 1957 751 687 893 1021 476 66 916 103 275 171 510 303 86 609 255 77 1115 274 103 204 485 165 175 94 96 408 291 173 857

Female ASR(W) CUM 0-74 4.1 3.8 4.4 4.5 4.4 3.8 3.6 5.0 4.6 3.0 2.6 2.5 1.8 1.6 0.5 4.0 3.5 3.6 2.3 3.1 1.2 1.9 0.7 2.6 2.7 6.5 6.0 5.0 3.6 3.0 3.9 4.3 5.2 7.2 6.6 5.3 6.4 5.0 5.2 3.5 4.3 4.2 4.8 2.1 2.4 3.8 3.5 2.5 6.6 6.0 6.1 6.4 5.7 6.1 6.3 5.3 5.5 6.5 6.9 5.8 5.2 5.9 5.7 6.3 5.4 3.7 7.1 7.6 5.6 5.5 5.8 3.6 6.0 5.0 7.0 5.5 4.3 4.9 7.0 0.06 0.19 0.26 0.37 0.36 0.25 0.58 0.14 0.54 0.55 0.78 0.34 0.23 0.34 0.18 0.23 0.20 0.22 0.72 0.58 0.17 0.29 0.16 0.30 0.18 0.13 0.45 0.58 0.09 0.20 0.13 0.11 0.15 0.12 0.17 0.28 0.16 0.34 0.43 0.39 0.37 0.33 0.32 0.21 0.35 0.40 0.43 0.34 0.23 0.16 0.26 0.27 0.22 0.22 0.34 0.72 0.20 0.76 0.47 0.53 0.28 0.42 0.76 0.30 0.40 0.44 0.25 0.60 0.62 0.47 0.32 0.32 0.51 0.57 0.82 0.33 0.31 0.43 0.28 0.49 0.47 0.53 0.56 0.56 0.45 0.43 0.60 0.61 0.33 0.35 0.32 0.22 0.22 0.06 0.48 0.39 0.41 0.28 0.34 0.17 0.22 0.09 0.36 0.34 0.72 0.63 0.58 0.45 0.36 0.45 0.52 0.61 0.83 0.80 0.63 0.70 0.64 0.60 0.37 0.48 0.52 0.53 0.25 0.30 0.46 0.39 0.31 0.78 0.69 0.72 0.72 0.62 0.69 0.70 0.61 0.63 0.77 0.83 0.67 0.54 0.67 0.60 0.70 0.62 0.44 0.82 0.85 0.58 0.60 0.63 0.39 0.65 0.58 0.75 0.60 0.45 0.58 0.82 0.01 0.03 0.04 0.06 0.06 0.04 0.08 0.02 0.09 0.07 0.12 0.05 0.03 0.05 * 0.02 * 0.04 * 0.03 0.03 0.10 0.08 0.03 * 0.04 * 0.02 0.05 * 0.03 * 0.02 0.06 0.09 0.01 * 0.03 * 0.02 0.01 * 0.02 0.02 0.03 0.04 0.02 0.05 0.06 0.06 0.05 0.05 0.05 0.03 0.05 0.06 0.06 0.04 0.03 0.02 0.04 0.04 0.03 0.03 0.05 0.11 0.03 0.11 0.07 0.07 0.04 0.06 0.10 0.04 0.06 0.06 0.04 0.08 0.08 0.07 0.04 0.04 0.07 0.08 0.12 0.04 0.04 0.06 0.04

6464 592 359 194 193 361 36 1664 113 34 32 61 82 34 25 261 399 342 21 36 54 45 48 122 320 2732 214 99 2229 280 1026 2816 1555 4030 1746 466 1811 267 192 109 194 244 248 170 92 110 112 94 985 1686 638 655 818 1051 386 78 939 84 300 184 501 253 71 468 262 92 985 213 125 153 527 181 195 99 90 345 335 185 747

492

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Pancreas (C25) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 853 1175 97 1403 243 383 386 265 702 1338 1143 1650 561 66 281 530 378 64 160 149 244 208 129 170 2162 148 79 59 183 134 92 175 3716 240 193 799 737 1114 1886 702 2200 4002 1537 1525 380 1418 1586 28 862 403 118 1253 397 43 17 815 365 35 45 48 123 92 Male ASR(W) CUM 0-74 11.2 10.9 7.3 7.3 9.6 8.9 6.3 2.6 6.0 9.6 6.2 10.4 8.1 5.3 5.5 7.4 8.0 5.5 6.6 4.8 6.0 8.3 5.9 4.3 5.3 9.0 8.4 8.3 8.9 9.6 8.4 7.0 6.2 6.4 5.3 6.3 7.2 6.4 6.7 6.4 6.7 7.1 7.2 6.6 6.3 6.8 6.3 7.0 6.7 6.4 6.1 7.1 6.3 5.0 4.0 6.1 7.6 8.2 5.9 10.1 7.8 7.1 0.39 0.32 0.76 0.21 0.62 0.47 0.33 0.16 0.24 0.26 0.19 0.26 0.34 0.71 0.35 0.33 0.42 0.82 0.56 0.42 0.40 0.62 0.56 0.36 0.12 0.76 0.99 1.15 0.68 0.86 0.91 0.56 0.10 0.42 0.39 0.24 0.28 0.20 0.16 0.25 0.15 0.12 0.19 0.18 0.34 0.19 0.17 1.41 0.23 0.34 0.59 0.21 0.33 0.79 1.00 0.22 0.43 1.62 0.95 1.49 0.84 0.79 1.37 1.32 0.96 0.84 1.15 1.04 0.78 0.32 0.72 1.14 0.77 1.30 0.96 0.68 0.62 0.87 0.93 0.60 0.76 0.58 0.72 1.05 0.68 0.48 0.67 1.07 0.99 0.99 1.08 1.08 0.99 0.87 0.76 0.76 0.64 0.74 0.84 0.78 0.79 0.71 0.77 0.81 0.86 0.77 0.72 0.80 0.72 0.91 0.77 0.75 0.73 0.83 0.76 0.58 0.46 0.73 0.89 0.87 0.72 1.24 0.93 0.79 0.05 0.04 0.12 0.03 0.09 0.06 0.04 0.02 0.03 0.04 0.03 0.04 0.05 0.10 0.05 0.05 0.06 0.10 0.08 0.06 0.05 0.09 0.08 0.05 0.02 0.12 0.15 0.17 0.11 0.12 0.13 0.08 0.02 0.06 0.06 0.03 0.04 0.03 0.02 0.04 0.02 0.02 0.03 0.03 0.05 0.03 0.02 0.22 0.03 0.05 0.09 0.03 0.05 0.12 0.14 0.03 0.06 0.22 0.15 0.22 0.12 0.12 Cases 807 1033 125 1633 247 363 365 213 620 1668 840 1317 594 52 269 484 281 50 136 141 176 166 138 165 2336 144 84 50 163 141 81 191 3781 202 186 803 761 1188 2093 718 2258 4283 1587 1572 369 1630 1594 17 788 389 138 1200 417 45 19 780 384 27 37 68 159 73 Female ASR(W) CUM 0-74 5.6 5.3 6.9 5.8 6.0 5.3 3.7 1.5 3.7 5.7 3.7 5.5 5.5 2.6 3.1 4.6 4.5 2.7 4.2 3.3 3.2 4.3 4.6 2.7 4.6 5.9 5.8 5.5 5.2 6.0 5.2 5.1 4.7 4.1 4.0 4.6 4.9 4.7 5.2 4.9 4.7 5.2 5.5 5.0 4.2 5.3 5.0 5.7 4.9 4.6 5.3 4.8 5.2 4.5 4.5 4.5 6.7 5.0 4.5 11.5 8.3 5.6 0.22 0.18 0.65 0.17 0.41 0.30 0.21 0.11 0.17 0.15 0.14 0.16 0.24 0.42 0.23 0.24 0.28 0.49 0.42 0.31 0.27 0.40 0.46 0.25 0.11 0.56 0.74 0.88 0.47 0.60 0.66 0.42 0.09 0.31 0.32 0.19 0.21 0.16 0.13 0.21 0.12 0.09 0.16 0.14 0.25 0.15 0.14 1.43 0.19 0.27 0.52 0.16 0.28 0.70 1.06 0.18 0.38 1.11 0.76 1.44 0.83 0.73 0.66 0.62 0.85 0.65 0.70 0.59 0.44 0.18 0.38 0.65 0.46 0.66 0.64 0.25 0.33 0.49 0.46 0.31 0.49 0.38 0.39 0.50 0.50 0.30 0.58 0.63 0.70 0.68 0.56 0.64 0.54 0.58 0.56 0.47 0.49 0.55 0.55 0.52 0.59 0.56 0.54 0.58 0.65 0.58 0.48 0.62 0.59 0.61 0.53 0.51 0.58 0.52 0.56 0.61 0.59 0.51 0.77 0.49 0.51 1.20 0.97 0.69 0.03 0.02 0.10 0.03 0.06 * 0.04 0.03 0.01 * 0.02 0.02 0.02 0.02 0.03 0.06 0.03 0.03 0.04 0.07 0.06 0.04 0.04 0.06 0.06 0.03 0.02 0.08 0.12 0.12 0.07 0.09 0.09 0.06 0.01 0.05 0.05 0.03 0.03 0.02 0.02 0.03 0.02 0.01 0.02 0.02 0.04 0.02 0.02 0.22 0.03 0.04 0.08 0.02 0.04 0.12 0.18 0.03 0.05 0.15 0.11 0.19 0.11 0.11

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
435

493

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Nose, sinuses etc. (C30-31)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 8 22 2 2 16 3 22 3 9 157 10 19 18 15 7 8 394 57 62 24 11 10 0 17 197 2 14 100 21 75 11 89 554 55 35 105 349 102 5 10 2 5 15 57 157 21 4 2 0 4 45 74 74 63 6 57 8 6 2 411 33 370 163 36 124 55 11 42 23 258 32 216 120 42 107 100 25 75 10 14 Male ASR(W) CUM 0-74 0.4 0.5 0.2 0.2 0.8 0.3 1.2 0.5 0.6 0.7 1.2 0.5 0.2 0.5 0.6 1.0 0.5 0.6 0.4 0.6 0.4 0.5 0.4 0.5 0.5 0.4 0.7 0.7 0.7 0.8 0.6 0.6 0.5 0.6 0.6 0.6 0.5 0.4 0.7 0.3 1.5 0.6 0.5 0.6 0.8 0.4 0.2 0.7 0.6 0.6 0.6 0.5 0.8 0.5 0.5 0.7 0.3 0.7 0.6 0.7 0.7 0.8 0.7 0.8 0.6 0.9 0.6 0.7 0.8 0.7 0.6 0.4 0.8 0.8 0.8 0.7 1.0 0.7 0.13 0.11 0.12 0.11 0.25 0.17 0.26 0.31 0.20 0.06 0.39 0.12 0.05 0.14 0.21 0.34 0.03 0.08 0.06 0.12 0.12 0.17 0.11 0.04 0.34 0.13 0.07 0.17 0.08 0.23 0.06 0.02 0.07 0.10 0.06 0.03 0.06 0.20 0.23 0.19 0.78 0.17 0.06 0.05 0.18 0.19 0.15 0.36 0.10 0.08 0.07 0.07 0.34 0.07 0.18 0.27 0.19 0.04 0.11 0.04 0.06 0.13 0.07 0.11 0.19 0.14 0.13 0.04 0.14 0.05 0.06 0.07 0.08 0.08 0.16 0.09 0.33 0.19 0.01 0.17 0.04 0.05 0.07 0.15 0.06 0.02 0.06 0.07 0.10 0.05 0.06 0.04 0.06 0.05 0.07 0.04 0.05 0.08 0.04 0.09 0.10 0.09 0.07 0.07 0.07 0.07 0.07 0.06 0.06 0.07 0.04 0.10 0.05 0.19 0.07 0.06 0.07 0.08 0.05 0.02 0.11 0.06 0.07 0.08 0.05 0.11 0.05 0.05 0.08 0.01 0.07 0.07 0.07 0.09 0.08 0.09 0.10 0.07 0.11 0.06 0.08 0.09 0.08 0.07 0.05 0.09 0.09 0.09 0.09 0.10 0.09 0.01 0.04 0.03 0.03 0.01 0.05 0.02 0.01 0.02 0.03 0.05 0.00 0.01 0.01 0.02 0.02 0.03 0.01 0.00 0.06 0.01 0.01 0.02 0.01 0.03 0.01 0.00 0.01 0.02 0.01 0.00 0.01 0.03 0.03 0.04 0.11 0.03 0.01 0.01 0.02 0.03 0.02 0.06 0.01 0.01 0.01 0.01 0.06 0.01 0.02 0.03 0.01 0.00 0.01 0.00 0.01 0.02 0.01 0.02 0.03 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.04 0.03 Cases 3 17 4 2 13 1 18 0 9 124 2 31 26 24 2 6 287 21 70 10 14 3 0 12 138 2 17 68 10 58 8 69 420 42 21 66 286 79 6 4 3 2 6 53 121 11 3 5 3 4 35 56 53 51 1 49 7 4 3 315 27 284 88 23 65 37 16 21 15 166 19 139 77 51 62 56 13 43 5 9 Female ASR(W) CUM 0-74 0.1 0.3 0.4 0.1 0.6 0.1 0.6 0.5 0.4 0.2 0.7 0.3 0.8 0.2 0.6 0.3 0.2 0.4 0.2 0.5 0.2 0.4 0.3 0.3 0.4 0.4 0.2 0.4 0.6 0.3 0.3 0.3 0.3 0.3 0.4 0.3 0.4 0.3 0.3 0.2 0.2 0.3 0.4 0.3 0.1 0.5 0.2 0.6 0.4 0.4 0.4 0.3 0.1 0.4 0.3 0.3 0.5 0.4 0.4 0.4 0.3 0.3 0.3 0.4 0.6 0.4 0.4 0.3 0.3 0.3 0.3 0.4 0.4 0.3 0.3 0.4 0.4 0.4 0.08 0.09 0.19 0.10 0.20 0.13 0.15 0.16 0.04 0.13 0.13 0.06 0.17 0.11 0.25 0.02 0.05 0.06 0.07 0.14 0.11 0.12 0.03 0.24 0.11 0.05 0.08 0.06 0.21 0.04 0.02 0.05 0.07 0.04 0.03 0.04 0.16 0.17 0.16 0.17 0.09 0.05 0.04 0.10 0.09 0.24 0.10 0.29 0.07 0.07 0.06 0.05 0.08 0.06 0.14 0.15 0.34 0.03 0.07 0.03 0.04 0.07 0.04 0.07 0.14 0.08 0.10 0.03 0.07 0.03 0.04 0.06 0.06 0.05 0.08 0.06 0.19 0.14 0.02 0.07 0.05 0.04 0.02 0.09 0.03 0.09 0.03 0.11 0.03 0.02 0.05 0.03 0.07 0.02 0.04 0.03 0.02 0.04 0.05 0.02 0.05 0.06 0.04 0.04 0.03 0.04 0.04 0.04 0.04 0.06 0.03 0.03 0.03 0.02 0.04 0.04 0.03 0.01 0.07 0.08 0.04 0.04 0.04 0.04 0.01 0.04 0.04 0.03 0.07 0.04 0.03 0.05 0.03 0.03 0.03 0.04 0.04 0.04 0.04 0.04 0.02 0.04 0.04 0.04 0.04 0.04 0.02 0.04 0.03 0.04 * * * *

0.02 0.02 0.02 0.00 0.02 0.02 0.01 0.02 0.02 0.05 * 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.00 0.02 0.01 0.01 0.01 0.01 0.03 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.03 0.02 0.02 0.03 0.01 0.01 0.00 0.01 0.01 0.04 0.05 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.05 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02

494

*Important. See note on population page.

436

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Nose, sinuses etc. (C30-31) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 43 112 183 16 163 80 11 66 115 7 108 23 4421 447 3787 183 22 157 28 1 9 17 359 55 287 231 26 198 62 56 271 20 240 19 464 39 383 1346 79 126 136 987 81 16 63 383 41 335 35 14 100 73 35 98 3 44 140 4 10 128 23 6 67 58 1 142 44 66 24 81 72 5 21 24 35 98 58 254 79 Male ASR(W) CUM 0-74 1.0 0.6 0.6 0.5 0.6 0.6 0.5 0.7 0.6 0.5 0.6 0.6 0.6 0.7 0.6 0.7 0.8 0.7 0.5 0.3 0.5 0.5 0.6 0.8 0.6 0.6 0.9 0.6 0.6 0.5 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.5 0.7 0.6 0.6 0.7 0.6 0.7 0.7 0.8 0.7 0.6 0.7 0.5 0.5 0.5 0.6 0.4 0.7 0.7 0.3 0.4 0.6 0.7 0.3 0.7 0.2 0.1 0.6 1.1 1.0 0.9 0.5 0.5 0.3 0.5 0.7 0.9 1.0 0.8 0.7 1.3 0.16 0.05 0.04 0.13 0.05 0.08 0.16 0.09 0.06 0.20 0.06 0.14 0.01 0.03 0.01 0.05 0.17 0.06 0.09 0.25 0.15 0.12 0.03 0.11 0.04 0.04 0.17 0.04 0.08 0.07 0.04 0.14 0.04 0.14 0.03 0.10 0.03 0.02 0.05 0.06 0.05 0.02 0.08 0.15 0.09 0.03 0.12 0.04 0.11 0.22 0.05 0.06 0.09 0.06 0.24 0.11 0.06 0.14 0.13 0.06 0.15 0.11 0.09 0.03 0.12 0.05 0.17 0.13 0.18 0.06 0.06 0.15 0.12 0.15 0.15 0.11 0.11 0.05 0.16 0.11 0.06 0.07 0.06 0.07 0.07 0.07 0.07 0.08 0.06 0.08 0.06 0.07 0.08 0.07 0.08 0.10 0.08 0.05 0.02 0.05 0.06 0.07 0.09 0.07 0.07 0.10 0.06 0.07 0.05 0.07 0.06 0.07 0.06 0.06 0.07 0.06 0.07 0.06 0.08 0.06 0.07 0.07 0.06 0.07 0.08 0.08 0.08 0.07 0.07 0.05 0.05 0.06 0.06 0.04 0.08 0.08 0.03 0.03 0.06 0.10 0.02 0.09 0.03 0.02 0.07 0.12 0.12 0.10 0.06 0.06 0.03 0.06 0.07 0.10 0.12 0.10 0.08 0.16 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.00 0.00 0.00 0.01 0.02 0.01 0.01 0.02 0.02 0.02 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.01 0.00 0.02 0.00 0.01 0.03 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.00 0.02 0.01 0.02 0.02 0.03 0.01 0.01 0.02 0.01 0.02 0.02 0.01 0.02 0.01 0.02 Cases 22 96 137 16 117 58 12 45 75 5 69 13 3161 251 2766 126 10 112 28 1 12 13 305 38 250 165 9 150 39 49 203 11 188 11 365 35 300 975 62 77 90 732 52 12 40 249 21 220 14 7 83 51 38 75 1 42 90 4 6 100 11 6 39 37 3 93 21 38 12 49 45 1 14 18 21 60 40 153 38 Female ASR(W) CUM 0-74 0.4 0.4 0.4 0.3 0.4 0.4 0.3 0.4 0.3 0.3 0.4 0.3 0.4 0.3 0.4 0.4 0.2 0.4 0.4 0.1 0.6 0.4 0.4 0.4 0.4 0.3 0.2 0.3 0.2 0.3 0.4 0.2 0.4 0.2 0.4 0.3 0.4 0.4 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.4 0.4 0.5 0.3 0.2 0.7 0.4 0.2 0.2 0.4 0.3 0.2 0.4 0.2 0.3 0.5 0.5 0.6 0.4 0.2 0.2 0.1 0.4 0.4 0.5 0.4 0.4 0.3 0.4 0.10 0.04 0.04 0.09 0.04 0.05 0.09 0.07 0.04 0.14 0.05 0.09 0.01 0.02 0.01 0.04 0.08 0.04 0.09 0.13 0.17 0.11 0.02 0.06 0.03 0.03 0.07 0.03 0.04 0.05 0.03 0.07 0.03 0.08 0.02 0.06 0.02 0.01 0.04 0.04 0.04 0.02 0.05 0.09 0.06 0.02 0.07 0.02 0.06 0.10 0.05 0.06 0.08 0.05 0.20 0.12 0.04 0.12 0.10 0.05 0.10 0.11 0.07 0.03 0.18 0.05 0.11 0.10 0.11 0.03 0.04 0.06 0.10 0.10 0.11 0.07 0.08 0.03 0.09 0.04 0.04 0.04 0.03 0.04 0.04 0.02 0.05 0.04 0.04 0.04 0.03 0.04 0.03 0.04 0.04 0.03 0.05 0.04 0.06 0.03 0.04 0.05 0.04 0.03 0.02 0.03 0.02 0.03 0.04 0.02 0.04 0.03 0.04 0.03 0.04 0.04 0.03 0.03 0.04 0.04 0.04 0.03 0.04 0.04 0.04 0.03 0.02 0.03 0.04 0.04 0.05 0.04 0.03 0.07 0.04 0.03 0.04 0.05 0.04 0.03 0.05 0.03 0.05 0.06 0.05 0.07 0.04 0.02 0.02 0.01 0.05 0.05 0.06 0.05 0.05 0.03 0.05 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.02 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.03 0.01 * 0.01 0.02 * 0.02 0.01 * 0.01 * 0.02 * 0.01 0.01 * 0.04 0.01 0.01 * 0.01 * 0.01 * 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
437

495

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Nose, sinuses etc. (C30-31) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
438

Male ASR(W) CUM 0-74 0.7 0.7 0.7 0.7 0.8 0.7 0.5 0.6 0.4 0.3 0.6 0.4 0.4 0.4 0.7 1.0 0.9 0.9 0.3 0.7 0.7 0.4 0.9 0.6 0.5 0.5 0.9 0.9 0.7 0.7 1.1 0.5 0.9 0.5 0.9 0.9 0.5 1.2 0.9 0.9 1.0 0.8 1.1 1.6 1.2 1.1 0.9 1.6 0.5 0.5 0.6 0.5 0.5 0.5 0.6 1.0 0.5 1.4 0.6 0.5 0.8 0.6 0.8 0.5 0.5 0.4 0.9 1.1 0.6 0.2 0.6 0.5 0.4 0.3 1.0 0.7 0.9 1.0 0.9 0.03 0.09 0.13 0.18 0.18 0.12 0.24 0.06 0.15 0.17 0.39 0.15 0.10 0.14 0.17 0.12 0.11 0.12 0.19 0.29 0.14 0.13 0.18 0.14 0.08 0.04 0.20 0.29 0.05 0.11 0.08 0.04 0.08 0.04 0.07 0.15 0.05 0.20 0.21 0.24 0.19 0.15 0.17 0.21 0.26 0.25 0.30 0.27 0.07 0.05 0.09 0.08 0.08 0.07 0.11 0.35 0.07 0.39 0.16 0.17 0.13 0.15 0.34 0.10 0.14 0.16 0.11 0.27 0.22 0.11 0.12 0.12 0.20 0.17 0.39 0.16 0.20 0.23 0.14 0.08 0.10 0.10 0.07 0.10 0.08 0.06 0.07 0.04 0.03 0.02 0.04 0.04 0.04 0.07 0.12 0.09 0.11 0.02 0.06 0.08 0.04 0.10 0.08 0.06 0.06 0.09 0.10 0.08 0.07 0.14 0.05 0.10 0.06 0.11 0.10 0.05 0.14 0.13 0.11 0.16 0.08 0.14 0.21 0.14 0.13 0.12 0.22 0.07 0.06 0.07 0.05 0.06 0.06 0.07 0.08 0.05 0.20 0.07 0.05 0.09 0.07 0.12 0.06 0.05 0.05 0.10 0.12 0.07 0.02 0.06 0.05 0.05 0.05 0.13 0.07 0.11 0.13 0.10 0.00 0.02 0.02 0.02 0.03 0.02 0.03 0.01 0.02 0.02 0.01 0.02 0.01 0.02 0.02 0.02 0.01 0.02 0.02 0.03 0.02 0.02 0.02 0.02 0.01 0.01 0.02 0.04 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.03 0.03 0.03 0.03 0.02 0.03 0.03 0.03 0.03 0.04 0.04 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.04 0.01 0.06 0.02 0.02 0.02 0.02 0.05 0.01 0.02 0.02 0.01 0.03 0.03 0.01 0.01 0.02 0.02 0.03 0.05 0.02 0.02 0.03 0.02

Cases 363 29 32 14 22 15 2 103 3 3 2 11 13 3 7 70 21 21 0 0 17 10 7 4 20 80 11 6 124 13 59 84 96 115 134 28 81 14 10 3 5 14 18 12 8 5 5 5 37 61 21 28 32 40 13 5 55 1 6 6 6 12 3 11 4 8 31 7 4 5 16 8 4 2 1 11 15 8 32

Female ASR(W) CUM 0-74 0.3 0.3 0.5 0.4 0.6 0.2 0.2 0.4 0.2 0.2 0.0 0.5 0.3 0.1 0.4 0.8 0.2 0.3 0.4 0.4 0.2 0.1 0.2 0.2 0.4 0.4 0.3 0.1 0.3 0.2 0.4 0.2 0.5 0.4 0.3 0.3 0.3 0.1 0.2 0.4 0.3 0.2 0.4 0.2 0.4 0.1 0.2 0.2 0.2 0.3 0.2 0.3 0.3 0.6 0.4 0.2 0.2 0.3 0.1 0.2 0.2 0.1 0.1 0.5 0.2 0.1 0.4 0.2 0.3 0.2 0.1 0.2 0.1 0.2 0.3 0.3 0.3 0.02 0.05 0.09 0.10 0.14 0.06 0.15 0.04 0.11 0.13 0.02 0.15 0.09 0.08 0.15 0.10 0.05 0.06 0.10 0.13 0.08 0.07 0.05 0.03 0.13 0.19 0.03 0.04 0.04 0.03 0.05 0.03 0.05 0.07 0.04 0.09 0.11 0.07 0.08 0.11 0.09 0.07 0.14 0.09 0.18 0.06 0.04 0.03 0.05 0.06 0.05 0.06 0.09 0.28 0.05 0.19 0.08 0.14 0.03 0.09 0.15 0.04 0.06 0.17 0.05 0.06 0.20 0.11 0.08 0.09 0.08 0.12 0.12 0.07 0.09 0.13 0.07 0.04 0.03 0.06 0.04 0.07 0.03 0.02 0.04 0.02 0.02 0.00 0.07 0.02 0.01 0.05 0.10 0.02 0.03 0.05 0.04 0.02 0.02 0.03 0.03 0.04 0.07 0.03 0.01 0.03 0.02 0.05 0.02 0.06 0.04 0.03 0.03 0.04 0.03 0.02 0.05 0.04 0.02 0.04 0.02 0.05 0.02 0.03 0.02 0.03 0.03 0.03 0.04 0.03 0.05 0.04 0.02 0.02 0.03 0.01 0.03 0.03 0.01 0.02 0.06 0.02 0.02 0.05 0.03 0.03 0.02 0.02 0.02 0.02 0.02 0.03 0.03 0.04 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.02 0.01 0.01 * 0.02 * 0.02 * 0.01 0.01 0.01 * 0.02 * 0.01 0.01 * 0.01 * 0.00 0.01 0.03 0.00 * 0.00 * 0.00 0.00 * 0.01 0.00 0.01 0.01 0.00 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.02 0.01 0.02 0.00 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01

612 59 36 22 20 39 4 146 8 3 11 9 15 6 17 87 69 60 2 7 28 9 25 19 41 140 21 10 201 48 205 137 141 192 184 38 91 42 20 16 25 29 42 61 23 24 13 36 51 90 42 30 48 50 27 10 55 13 16 11 44 20 7 23 17 6 71 18 8 5 30 17 6 4 7 27 32 20 54

496

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Nose, sinuses etc. (C30-31) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 74 90 6 128 12 22 35 63 60 70 115 98 60 2 70 58 35 4 10 15 13 17 11 31 162 14 8 2 13 12 9 26 463 27 25 59 31 87 141 60 155 255 89 81 42 102 159 2 59 35 21 106 41 7 2 47 22 1 5 2 5 8 Male ASR(W) CUM 0-74 1.0 0.9 0.4 0.8 0.5 0.6 0.6 0.6 0.6 0.5 0.6 0.6 0.9 0.2 1.7 0.9 0.8 0.3 0.4 0.6 0.3 0.7 0.5 1.0 0.4 0.8 1.5 0.2 0.7 0.9 0.9 1.2 0.8 0.7 0.8 0.5 0.3 0.6 0.6 0.6 0.5 0.5 0.4 0.4 0.7 0.5 0.7 0.6 0.5 0.7 1.2 0.7 0.7 0.9 0.3 0.4 0.5 0.1 0.8 0.4 0.4 0.7 0.12 0.09 0.18 0.07 0.15 0.13 0.11 0.08 0.07 0.06 0.06 0.06 0.12 0.13 0.22 0.12 0.14 0.18 0.14 0.15 0.09 0.19 0.17 0.22 0.04 0.23 0.58 0.12 0.21 0.26 0.31 0.24 0.04 0.13 0.16 0.08 0.07 0.07 0.05 0.08 0.05 0.03 0.05 0.05 0.11 0.06 0.06 0.41 0.07 0.12 0.28 0.07 0.10 0.33 0.19 0.06 0.11 0.13 0.39 0.31 0.22 0.26 0.12 0.10 0.02 0.09 0.06 0.07 0.08 0.07 0.06 0.06 0.07 0.07 0.11 0.02 0.21 0.11 0.08 0.05 0.03 0.07 0.04 0.09 0.08 0.10 0.05 0.08 0.14 0.07 0.10 0.10 0.18 0.10 0.07 0.09 0.05 0.04 0.07 0.06 0.05 0.06 0.06 0.05 0.04 0.07 0.06 0.09 0.11 0.06 0.07 0.15 0.08 0.06 0.13 0.02 0.04 0.05 0.08 0.06 0.04 0.07 0.02 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.03 0.02 0.02 0.03 0.01 0.02 0.01 0.03 0.03 0.02 0.00 0.03 0.05 0.02 0.04 0.04 0.04 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.09 0.01 0.01 0.04 0.01 0.01 0.06 0.02 0.01 0.01 0.04 0.05 0.03 0.03 Cases 40 65 0 73 8 14 20 28 38 68 80 56 32 2 21 21 15 3 4 5 6 5 6 10 128 9 3 3 3 3 4 15 223 13 13 42 42 64 102 39 123 191 55 67 27 88 81 0 32 12 5 67 17 2 0 48 18 1 1 2 5 7 Female ASR(W) CUM 0-74 0.3 0.4 0.4 0.2 0.3 0.2 0.2 0.3 0.3 0.4 0.3 0.3 0.1 0.4 0.3 0.3 0.3 0.1 0.2 0.1 0.3 0.3 0.2 0.3 0.5 0.1 0.4 0.1 0.1 0.4 0.5 0.3 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.4 0.3 0.2 0.3 0.3 0.3 0.3 0.2 0.2 0.3 0.3 0.2 0.2 0.4 0.4 0.3 0.1 0.4 0.5 0.5 0.06 0.06 0.05 0.08 0.08 0.05 0.04 0.05 0.05 0.04 0.04 0.06 0.11 0.13 0.09 0.07 0.25 0.08 0.09 0.06 0.19 0.13 0.09 0.03 0.17 0.06 0.24 0.08 0.11 0.18 0.15 0.02 0.09 0.10 0.06 0.07 0.05 0.04 0.06 0.04 0.02 0.03 0.04 0.07 0.04 0.04 0.05 0.06 0.15 0.05 0.06 0.16 0.05 0.10 0.31 0.15 0.25 0.37 0.19 0.04 0.05 0.04 0.03 0.04 0.03 0.02 0.03 0.03 0.04 0.03 0.04 0.01 0.05 0.03 0.03 0.02 0.01 0.02 0.01 0.02 0.03 0.02 0.03 0.06 0.04 0.03 0.01 0.06 0.07 0.03 0.03 0.03 0.04 0.03 0.03 0.04 0.03 0.04 0.03 0.02 0.03 0.04 0.04 0.04 0.02 0.02 0.03 0.03 0.02 0.02 0.04 0.04 0.05 0.01 0.06 0.03 0.05 0.01 0.01 0.01 0.01 * 0.01 0.01 0.01 * 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.00 0.02 0.03 0.02 0.01 0.03 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.05 0.01 0.05 0.02 0.03

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
439

497

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Larynx (C32)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 53 162 51 14 55 70 184 57 108 2542 10 181 233 40 59 17 3092 291 497 140 134 106 4 164 1577 38 141 947 240 696 51 719 3868 192 392 513 2724 722 88 36 11 5 75 476 1041 196 19 15 6 13 200 575 470 631 70 550 151 128 20 4264 417 3786 1483 396 1076 336 120 212 172 2323 421 1861 1107 530 995 1022 339 680 113 147 Male ASR(W) CUM 0-74 2.8 4.2 5.7 1.4 4.2 8.8 9.2 8.9 7.8 12.8 1.2 5.4 3.3 1.5 5.0 2.0 3.9 3.3 3.4 3.6 5.1 5.8 5.5 4.7 4.0 7.9 3.8 6.7 9.3 6.0 3.3 4.3 4.0 1.7 7.1 3.5 4.2 3.7 6.9 2.1 1.5 1.6 3.8 3.8 4.2 8.0 1.4 1.9 1.0 2.3 3.6 4.5 3.9 5.4 10.1 5.1 9.3 12.7 3.7 6.8 8.2 6.6 6.8 9.1 6.3 5.1 6.9 4.6 4.1 6.2 10.0 5.7 5.9 5.4 7.9 7.8 11.0 6.9 12.2 7.6 0.40 0.34 0.81 0.43 0.63 1.10 0.72 1.22 0.76 0.26 0.38 0.41 0.22 0.25 0.67 0.48 0.07 0.20 0.16 0.32 0.45 0.57 2.83 0.38 0.10 1.32 0.34 0.22 0.62 0.23 0.49 0.17 0.07 0.12 0.37 0.16 0.09 0.14 0.76 0.36 0.46 0.78 0.45 0.18 0.13 0.58 0.33 0.51 0.48 0.66 0.26 0.20 0.18 0.23 1.23 0.23 0.78 1.15 0.84 0.11 0.41 0.12 0.18 0.47 0.20 0.29 0.67 0.33 0.32 0.13 0.50 0.14 0.18 0.24 0.25 0.25 0.61 0.27 1.18 0.65 1.14 1.19 1.01 0.91 1.64 0.16 0.64 0.41 0.18 0.62 0.21 0.50 0.42 0.43 0.47 0.63 0.76 0.55 0.57 0.52 1.03 0.50 0.86 1.18 0.78 0.46 0.57 0.51 0.21 0.93 0.44 0.54 0.48 0.90 0.27 0.25 0.24 0.50 0.49 0.54 1.05 0.14 0.27 0.13 0.27 0.50 0.58 0.53 0.69 1.28 0.64 1.19 1.54 0.59 0.85 1.06 0.83 0.88 1.09 0.83 0.65 0.81 0.61 0.53 0.79 1.26 0.73 0.76 0.69 1.01 1.00 1.40 0.88 1.58 0.98 0.15 0.11 0.17 0.11 0.04 0.06 0.06 0.03 0.04 0.10 0.07 0.01 0.03 0.02 0.05 0.07 0.09 0.32 0.06 0.02 0.20 0.05 0.03 0.09 0.03 0.08 0.02 0.01 0.02 0.06 0.02 0.01 0.02 0.12 0.06 0.08 0.12 0.07 0.03 0.02 0.09 0.05 0.09 0.06 0.09 0.04 0.03 0.03 0.03 0.18 0.03 0.11 0.15 0.15 0.02 0.06 0.02 0.03 0.07 0.03 0.04 0.09 0.05 0.05 0.02 0.07 0.02 0.03 0.03 0.04 0.04 0.09 0.04 0.18 0.09 Cases 3 14 2 6 8 5 56 9 16 486 1 47 14 7 11 6 615 76 88 27 36 17 1 31 300 6 33 225 46 176 18 170 967 27 101 78 750 167 23 7 4 0 14 118 245 44 1 1 2 1 29 164 136 180 16 162 32 23 9 1052 96 943 346 91 253 86 37 49 37 538 118 406 328 137 288 267 74 191 25 41 Female ASR(W) CUM 0-74 0.1 0.3 0.2 0.3 0.9 0.6 2.1 1.4 0.9 1.8 0.1 1.1 0.2 0.2 0.9 0.6 0.7 0.8 0.5 0.7 1.3 0.9 1.9 1.0 0.7 1.1 0.8 1.4 1.4 1.4 1.2 0.9 0.9 0.2 1.5 0.4 1.1 0.7 1.5 0.4 0.4 0.5 0.8 0.8 1.4 0.1 0.1 0.2 0.1 0.4 1.1 1.0 1.3 1.7 1.3 1.5 1.7 1.3 1.5 1.5 1.5 1.4 1.6 1.3 1.1 1.8 0.9 0.9 1.2 2.1 1.1 1.5 1.2 2.0 1.7 1.8 1.7 1.9 1.7 0.09 0.07 0.16 0.18 0.33 0.26 0.29 0.48 0.23 0.09 0.06 0.17 0.05 0.08 0.28 0.23 0.03 0.09 0.06 0.14 0.23 0.22 1.88 0.18 0.04 0.52 0.15 0.10 0.21 0.11 0.29 0.07 0.03 0.04 0.15 0.05 0.04 0.06 0.33 0.16 0.18 0.15 0.08 0.06 0.22 0.07 0.09 0.17 0.10 0.07 0.10 0.09 0.11 0.45 0.11 0.28 0.37 0.48 0.05 0.15 0.05 0.08 0.17 0.09 0.13 0.30 0.14 0.16 0.06 0.20 0.06 0.09 0.11 0.12 0.11 0.21 0.13 0.39 0.29 0.07 0.25 0.22 0.09 0.22 0.15 0.02 0.02 0.11 0.07 0.09 0.11 0.07 0.09 0.18 0.11 0.47 0.13 0.09 0.12 0.10 0.17 0.18 0.17 0.15 0.11 0.12 0.03 0.20 0.06 0.14 0.10 0.20 0.07 0.05 0.08 0.11 0.11 0.19 0.01 0.02 0.03 0.05 0.16 0.14 0.17 0.20 0.17 0.19 0.22 0.18 0.19 0.19 0.19 0.18 0.22 0.18 0.15 0.24 0.12 0.11 0.16 0.26 0.15 0.20 0.16 0.26 0.21 0.23 0.21 0.24 0.22 * * * *

0.03 0.04 0.08 0.03 0.01 0.03 0.01 0.01 0.04 0.03 * 0.00 0.01 0.01 0.02 0.03 0.03 0.47 0.02 0.01 0.06 0.02 0.01 0.03 0.01 0.04 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.05 0.03 0.03 0.03 0.01 0.01 0.03 0.01 0.02 0.03 0.01 0.01 0.01 0.02 0.06 0.02 0.04 0.05 0.08 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.05 0.02 0.02 0.01 0.03 0.01 0.01 0.02 0.02 0.01 0.03 0.02 0.05 0.04

498

*Important. See note on population page.

440

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Larynx (C32) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 244 1122 1744 312 1411 787 243 535 1163 130 1027 145 39169 5208 33037 1522 242 1246 228 4 70 148 3308 459 2778 2089 260 1778 664 451 2577 283 2254 202 3811 544 3062 10735 328 1512 742 8052 911 281 624 3200 486 2669 126 103 729 472 488 874 25 273 958 14 90 679 156 71 419 1546 44 1341 313 370 133 766 656 89 113 96 194 354 258 926 191 Male ASR(W) CUM 0-74 5.3 5.4 5.6 9.7 5.1 6.5 10.2 5.6 6.3 9.5 6.1 4.5 5.6 8.7 5.4 5.5 8.9 5.3 3.9 1.3 3.8 4.2 5.5 7.0 5.5 5.7 8.3 5.4 5.8 3.9 5.8 9.4 5.6 5.8 4.7 8.4 4.6 4.9 1.9 8.6 3.7 4.9 7.2 10.4 6.3 5.7 9.9 5.3 2.4 5.1 4.0 3.8 7.3 5.0 4.7 4.9 4.4 1.1 3.8 2.8 5.1 3.2 4.7 8.0 5.3 6.5 8.5 6.2 5.1 4.9 4.6 6.1 2.8 2.2 4.6 3.3 3.6 2.4 2.9 0.35 0.17 0.14 0.56 0.14 0.24 0.67 0.25 0.19 0.85 0.20 0.39 0.03 0.12 0.03 0.15 0.58 0.16 0.27 0.67 0.47 0.36 0.10 0.33 0.11 0.13 0.52 0.13 0.23 0.19 0.12 0.57 0.12 0.43 0.08 0.37 0.09 0.05 0.11 0.23 0.14 0.06 0.24 0.63 0.26 0.10 0.46 0.11 0.22 0.52 0.15 0.18 0.34 0.18 0.94 0.30 0.15 0.29 0.41 0.11 0.41 0.39 0.23 0.21 0.82 0.18 0.49 0.33 0.44 0.18 0.19 0.66 0.27 0.23 0.33 0.18 0.23 0.08 0.22 0.67 0.69 0.71 1.23 0.65 0.83 1.31 0.72 0.79 1.25 0.76 0.58 0.72 1.11 0.69 0.71 1.13 0.67 0.53 0.21 0.54 0.56 0.70 0.90 0.70 0.74 1.04 0.70 0.75 0.51 0.76 1.24 0.73 0.71 0.61 1.07 0.60 0.63 0.24 1.11 0.48 0.64 0.90 1.33 0.78 0.72 1.25 0.68 0.31 0.63 0.54 0.51 0.93 0.66 0.77 0.63 0.56 0.17 0.47 0.36 0.70 0.44 0.56 1.01 0.76 0.81 1.08 0.82 0.65 0.63 0.59 0.73 0.35 0.26 0.57 0.43 0.48 0.29 0.37 0.05 0.02 0.02 0.08 0.02 0.03 0.10 0.04 0.03 0.13 0.03 0.06 0.00 0.02 0.00 0.02 0.08 0.02 0.04 0.12 0.08 0.05 0.01 0.05 0.02 0.02 0.08 0.02 0.03 0.03 0.02 0.09 0.02 0.06 0.01 0.06 0.01 0.01 0.02 0.03 0.02 0.01 0.03 0.09 0.04 0.02 0.07 0.02 0.03 0.07 0.02 0.03 0.05 0.03 0.18 0.05 0.02 0.05 0.06 0.02 0.06 0.06 0.03 0.03 0.13 0.03 0.07 0.05 0.07 0.03 0.03 0.10 0.04 0.03 0.05 0.03 0.03 0.01 0.03 Cases 76 315 508 95 408 247 75 171 272 41 228 37 10149 1407 8548 414 65 345 68 1 9 56 996 172 817 559 85 462 184 117 665 107 549 57 1013 165 813 2848 53 403 129 2243 204 50 152 739 107 623 37 36 191 121 129 235 4 22 78 2 17 80 9 8 47 185 1 170 54 65 7 127 115 9 14 10 14 25 14 75 10 Female ASR(W) CUM 0-74 1.5 1.3 1.4 2.2 1.3 1.7 2.3 1.6 1.3 2.2 1.2 1.1 1.3 1.8 1.2 1.3 1.7 1.3 1.0 0.2 0.4 1.4 1.4 1.8 1.3 1.3 2.1 1.2 1.4 1.0 1.3 2.7 1.2 1.1 1.1 2.0 1.1 1.1 0.3 1.8 0.5 1.2 1.4 1.4 1.4 1.1 1.7 1.1 0.7 1.5 0.9 0.8 1.7 1.2 0.7 0.3 0.3 0.2 0.7 0.2 0.3 0.3 0.5 1.1 0.1 0.8 1.4 1.1 0.2 0.7 0.7 0.6 0.3 0.2 0.3 0.2 0.1 0.2 0.1 0.19 0.08 0.07 0.23 0.07 0.12 0.28 0.13 0.08 0.35 0.09 0.18 0.01 0.05 0.01 0.07 0.22 0.07 0.13 0.22 0.15 0.20 0.05 0.14 0.05 0.06 0.23 0.06 0.11 0.09 0.05 0.27 0.05 0.17 0.04 0.16 0.04 0.02 0.04 0.09 0.05 0.03 0.10 0.20 0.12 0.04 0.17 0.05 0.11 0.28 0.07 0.08 0.16 0.08 0.36 0.07 0.04 0.11 0.17 0.03 0.10 0.11 0.08 0.08 0.12 0.06 0.19 0.13 0.09 0.06 0.07 0.21 0.08 0.07 0.08 0.04 0.03 0.02 0.04 0.21 0.17 0.18 0.28 0.17 0.21 0.30 0.20 0.17 0.27 0.16 0.17 0.16 0.23 0.16 0.17 0.21 0.17 0.14 0.02 0.05 0.19 0.17 0.21 0.17 0.17 0.27 0.15 0.18 0.13 0.16 0.37 0.15 0.14 0.14 0.25 0.14 0.15 0.04 0.23 0.07 0.16 0.18 0.17 0.18 0.14 0.22 0.14 0.09 0.18 0.13 0.11 0.22 0.16 0.11 0.04 0.03 0.03 0.11 0.03 0.04 0.03 0.06 0.14 0.01 0.10 0.17 0.12 0.03 0.08 0.08 0.09 0.04 0.03 0.04 0.03 0.01 0.02 0.01 0.03 0.01 0.01 0.03 0.01 0.02 0.04 0.02 0.01 0.05 0.01 0.03 0.00 0.01 0.00 0.01 0.03 0.01 0.02 0.02 0.02 0.03 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.01 0.01 0.04 0.01 0.02 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.03 0.02 0.01 0.02 0.01 0.02 0.04 0.01 0.01 0.02 0.01 0.06 0.01 * 0.00 0.02 * 0.03 0.00 * 0.01 * 0.01 * 0.01 0.01 * 0.01 0.01 0.03 * 0.02 * 0.02 * 0.01 0.01 0.03 0.01 0.01 0.01 0.01 0.00 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
441

499

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Larynx (C32) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
442

Male ASR(W) CUM 0-74 4.8 4.8 5.1 4.6 5.0 4.4 6.3 4.7 5.4 2.7 2.5 4.7 2.1 1.4 10.7 5.5 4.4 4.9 2.4 3.0 3.0 1.9 3.8 7.2 10.9 4.9 5.8 5.9 10.1 5.5 7.0 9.0 12.5 6.5 4.7 8.4 2.6 6.4 9.1 7.2 7.4 8.3 7.3 11.5 9.1 9.2 5.5 8.8 5.2 4.1 5.3 5.7 4.4 4.8 5.9 3.2 4.3 10.1 13.7 9.3 8.4 11.5 8.4 9.2 8.3 11.7 10.3 8.9 4.7 9.8 8.3 8.3 8.5 5.8 13.3 7.8 7.7 8.2 11.2 0.08 0.27 0.33 0.45 0.46 0.32 0.93 0.16 0.71 0.55 0.62 0.52 0.25 0.29 0.69 0.31 0.24 0.29 0.57 0.59 0.28 0.30 0.38 0.50 0.37 0.13 0.52 0.73 0.19 0.30 0.20 0.18 0.28 0.14 0.16 0.44 0.12 0.44 0.66 0.66 0.55 0.52 0.45 0.56 0.74 0.72 0.64 0.68 0.23 0.15 0.29 0.29 0.22 0.23 0.37 0.62 0.19 1.10 0.77 0.76 0.41 0.69 1.06 0.46 0.56 0.89 0.35 0.72 0.66 0.72 0.44 0.52 0.70 0.70 1.41 0.44 0.46 0.65 0.42 0.64 0.64 0.74 0.55 0.73 0.57 0.81 0.59 0.57 0.27 0.35 0.62 0.23 0.15 1.38 0.70 0.56 0.64 0.26 0.36 0.37 0.21 0.43 0.89 1.40 0.60 0.74 0.73 1.27 0.68 0.89 1.06 1.55 0.79 0.60 1.04 0.31 0.85 1.20 0.91 0.93 0.99 0.88 1.38 1.09 1.13 0.62 1.07 0.66 0.51 0.64 0.72 0.56 0.59 0.73 0.38 0.53 1.30 1.78 1.25 1.08 1.49 1.11 1.11 1.05 1.56 1.32 1.11 0.67 1.23 1.08 1.02 1.11 0.76 1.60 0.97 1.01 1.10 1.45 0.01 0.04 0.06 0.06 0.08 0.05 0.14 0.02 0.09 0.07 0.11 0.08 0.04 0.04 0.10 0.05 0.04 0.04 0.07 0.08 0.04 0.04 0.05 0.07 0.05 0.02 0.07 0.10 0.03 0.04 0.03 0.02 0.04 0.02 0.02 0.06 0.02 0.06 0.09 0.09 0.08 0.07 0.06 0.07 0.09 0.10 0.08 0.09 0.03 0.02 0.04 0.04 0.03 0.03 0.05 0.09 0.03 0.15 0.11 0.11 0.06 0.09 0.15 0.06 0.08 0.13 0.05 0.10 0.10 0.10 0.06 0.07 0.10 0.10 0.19 0.06 0.06 0.10 0.06

Cases 408 58 27 12 12 31 7 85 5 4 3 11 16 6 38 65 27 23 2 2 23 20 10 18 41 167 12 3 80 47 133 151 166 259 228 27 67 24 18 15 16 44 32 32 11 10 11 13 48 53 81 36 66 78 31 10 103 8 20 20 49 28 3 59 29 18 114 12 3 12 48 21 13 4 11 37 23 7 88

Female ASR(W) CUM 0-74 0.3 0.6 0.4 0.4 0.3 0.5 0.8 0.4 0.3 0.5 0.4 0.5 0.5 0.3 1.8 0.8 0.3 0.3 0.4 0.2 0.6 0.8 0.3 0.6 0.5 0.5 0.4 0.2 0.2 0.7 0.7 0.4 0.8 0.6 1.0 0.5 0.2 0.6 0.8 0.8 0.4 1.2 0.8 0.7 0.6 0.5 0.6 0.7 0.4 0.2 1.1 0.4 0.6 0.7 0.6 1.4 0.7 0.8 0.7 0.9 0.7 0.8 0.5 0.8 0.8 1.1 1.0 0.5 0.2 0.5 1.0 0.7 0.7 0.3 1.5 0.6 0.5 0.2 1.0 0.02 0.07 0.08 0.11 0.10 0.09 0.31 0.04 0.13 0.23 0.31 0.15 0.12 0.14 0.31 0.11 0.06 0.06 0.29 0.14 0.12 0.18 0.11 0.14 0.07 0.04 0.14 0.13 0.02 0.11 0.06 0.04 0.07 0.04 0.07 0.09 0.03 0.13 0.20 0.22 0.12 0.19 0.14 0.13 0.21 0.16 0.21 0.19 0.06 0.04 0.13 0.08 0.08 0.08 0.13 0.44 0.08 0.32 0.16 0.21 0.12 0.18 0.31 0.12 0.16 0.26 0.11 0.17 0.12 0.17 0.16 0.15 0.20 0.14 0.48 0.11 0.11 0.10 0.12 0.04 0.08 0.05 0.07 0.03 0.07 0.07 0.04 0.04 0.04 0.09 0.03 0.06 0.04 0.21 0.10 0.03 0.03 0.08 0.02 0.08 0.11 0.05 0.07 0.06 0.06 0.05 0.03 0.02 0.08 0.08 0.04 0.10 0.07 0.13 0.06 0.03 0.06 0.09 0.11 0.05 0.13 0.09 0.08 0.06 0.07 0.08 0.08 0.05 0.03 0.13 0.05 0.08 0.08 0.08 0.18 0.09 0.09 0.07 0.12 0.09 0.11 0.05 0.12 0.10 0.10 0.12 0.08 0.01 0.06 0.12 0.07 0.07 0.04 0.16 0.07 0.05 0.03 0.13 0.00 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.03 0.08 0.01 0.02 0.02 * 0.04 * 0.02 * 0.01 0.01 0.06 0.02 0.02 * 0.03 * 0.02 0.02 * 0.01 * 0.01 0.02 0.02 0.00 * 0.01 * 0.01 0.00 * 0.01 0.00 0.01 0.01 0.00 0.02 0.02 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.02 0.01 0.00 0.02 0.01 0.01 0.01 0.02 0.06 0.01 0.04 0.02 0.03 0.01 0.02 0.03 0.02 0.02 0.03 0.01 0.02 0.01 0.02 0.02 0.02 0.02 0.02 0.05 0.02 0.01 0.01 0.02

3999 382 256 111 122 203 48 916 67 24 45 84 70 22 267 334 340 294 19 27 116 41 100 211 875 1376 128 65 2908 369 1322 2647 2001 2289 975 359 515 220 202 124 183 285 276 434 169 169 85 182 523 745 351 381 402 474 262 29 502 92 325 168 473 317 71 448 241 178 924 179 55 206 404 271 151 74 94 343 312 166 761

500

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Larynx (C32) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 589 940 70 534 223 544 450 702 813 818 2122 1391 516 107 648 1042 475 92 208 323 535 282 228 508 775 78 33 48 74 94 71 108 2868 204 180 328 429 783 1271 295 970 1745 720 864 270 1237 931 34 492 172 69 596 226 23 19 330 183 10 15 22 39 88 Male ASR(W) CUM 0-74 7.8 9.2 5.2 3.0 9.2 13.2 7.6 7.2 7.9 5.9 12.3 9.2 7.6 10.1 14.6 16.1 10.8 10.5 9.7 11.2 14.3 13.2 12.0 15.4 2.0 5.6 4.2 8.0 4.1 7.6 7.3 4.9 5.0 5.6 5.1 2.7 4.6 5.0 4.9 2.9 3.4 3.4 3.7 4.1 4.9 6.4 4.1 8.6 4.1 2.8 3.8 3.6 3.8 2.2 4.7 2.6 4.5 3.1 1.9 4.2 3.2 8.0 0.32 0.30 0.64 0.14 0.62 0.58 0.37 0.28 0.29 0.21 0.27 0.25 0.34 1.05 0.61 0.51 0.50 1.24 0.71 0.65 0.64 0.82 0.84 0.72 0.08 0.64 0.75 1.20 0.49 0.80 0.89 0.49 0.10 0.40 0.39 0.16 0.23 0.19 0.14 0.18 0.11 0.09 0.14 0.14 0.31 0.19 0.14 1.56 0.19 0.22 0.47 0.15 0.26 0.48 1.09 0.15 0.35 1.04 0.54 0.91 0.58 0.89 1.03 1.16 0.61 0.37 1.10 1.64 0.97 0.88 0.96 0.76 1.53 1.13 0.95 1.21 1.78 1.96 1.35 1.26 1.18 1.44 1.78 1.63 1.54 1.89 0.26 0.68 0.53 0.91 0.55 1.03 0.87 0.60 0.64 0.69 0.64 0.33 0.57 0.62 0.62 0.37 0.43 0.43 0.46 0.51 0.61 0.81 0.53 1.21 0.53 0.35 0.49 0.47 0.48 0.18 0.65 0.34 0.60 0.43 0.18 0.57 0.47 1.07 0.05 0.04 0.09 0.02 0.08 0.08 0.05 0.04 0.04 0.03 0.03 0.03 0.05 0.13 0.08 0.07 0.07 0.15 0.09 0.09 0.08 0.11 0.11 0.09 0.01 0.08 0.10 0.15 0.07 0.12 0.11 0.07 0.01 0.06 0.06 0.02 0.03 0.03 0.02 0.03 0.02 0.01 0.02 0.02 0.04 0.03 0.02 0.26 0.03 0.03 0.07 0.02 0.04 0.06 0.18 0.02 0.05 0.15 0.07 0.15 0.09 0.13 Cases 40 54 9 96 43 57 88 31 44 64 212 87 56 4 21 57 22 0 3 5 20 8 5 15 162 13 5 7 16 13 8 23 526 31 29 72 107 184 315 59 188 357 153 158 66 301 114 5 42 27 12 89 35 3 1 48 27 1 0 8 7 10 Female ASR(W) CUM 0-74 0.3 0.4 0.6 0.5 1.4 1.2 1.2 0.2 0.3 0.3 1.1 0.5 0.7 0.2 0.5 0.8 0.5 0.2 0.2 0.5 0.4 0.3 0.4 0.4 0.7 0.5 1.1 0.7 1.0 0.7 0.9 0.9 0.8 0.8 0.5 0.9 1.0 1.0 0.5 0.5 0.6 0.6 0.6 1.1 1.3 0.4 1.7 0.3 0.4 0.7 0.5 0.5 0.3 0.3 0.4 0.5 0.1 1.4 0.4 0.6 0.06 0.05 0.22 0.05 0.22 0.16 0.13 0.05 0.05 0.04 0.08 0.05 0.09 0.09 0.12 0.12 0.11 0.10 0.08 0.11 0.16 0.16 0.11 0.03 0.21 0.25 0.42 0.20 0.30 0.26 0.20 0.04 0.15 0.15 0.07 0.09 0.08 0.06 0.07 0.04 0.03 0.06 0.06 0.14 0.08 0.04 0.79 0.05 0.09 0.22 0.05 0.09 0.15 0.28 0.06 0.10 0.11 0.52 0.18 0.22 0.04 0.04 0.07 0.07 0.17 0.13 0.14 0.03 0.03 0.03 0.13 0.05 0.08 0.03 0.05 0.10 0.06 0.02 0.02 0.06 0.04 0.04 0.04 0.05 0.07 0.07 0.13 0.09 0.11 0.09 0.11 0.11 0.10 0.10 0.07 0.12 0.13 0.13 0.06 0.06 0.07 0.09 0.08 0.14 0.18 0.05 0.26 0.04 0.06 0.11 0.07 0.06 0.04 0.05 0.05 0.06 0.18 0.05 0.07 0.01 0.01 0.03 0.01 0.03 * 0.02 0.02 0.01 * 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.01 0.00 0.02 0.04 0.05 0.03 0.03 0.04 0.03 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.02 0.01 0.01 0.14 0.01 0.01 0.03 0.01 0.01 0.03 0.05 0.01 0.01 0.07 0.02 0.04

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
443

501

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Trachea, bronchus and lung (C33-34)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 374 541 335 46 146 379 500 154 266 6525 100 711 810 214 156 52 40042 3948 6580 2196 1850 837 34 2329 20105 307 1856 10879 1969 8849 744 8606 46192 3838 3728 3847 34497 8531 890 565 394 97 565 5650 10878 1697 357 367 184 195 1327 6474 5102 6670 443 6176 1141 886 221 43150 3357 39440 15518 3314 12103 3682 1105 2519 1913 24478 3560 20524 13811 6363 12143 10320 2882 7389 895 1478 Male ASR(W) CUM 0-74 19.9 14.0 37.1 4.8 9.5 45.5 26.8 26.3 21.0 33.5 11.2 21.5 11.1 7.9 13.7 5.9 47.9 42.8 41.5 51.2 66.6 45.6 49.2 65.8 48.6 60.2 44.8 72.1 73.5 71.7 53.2 45.6 44.7 33.1 66.6 25.7 49.4 41.2 69.3 31.1 44.7 26.2 27.8 42.6 41.2 68.0 29.3 45.5 29.3 36.0 23.2 46.4 40.6 53.9 66.1 53.4 66.2 82.6 36.2 61.2 64.9 61.0 70.2 77.8 68.8 57.2 70.7 54.0 43.8 61.1 83.8 58.8 68.7 56.7 90.1 75.0 91.7 70.3 96.6 69.6 1.05 0.63 2.05 0.84 0.90 2.42 1.25 2.18 1.30 0.42 1.14 0.82 0.40 0.56 1.12 0.83 0.25 0.70 0.53 1.16 1.61 1.62 8.78 1.42 0.35 3.55 1.13 0.71 1.71 0.79 2.01 0.52 0.22 0.55 1.11 0.43 0.28 0.47 2.39 1.38 2.33 2.95 1.20 0.60 0.41 1.68 1.64 2.47 2.41 2.62 0.66 0.62 0.59 0.70 3.19 0.73 2.03 2.87 2.58 0.32 1.14 0.34 0.58 1.39 0.64 0.97 2.23 1.11 1.05 0.41 1.43 0.43 0.61 0.76 0.84 0.76 1.75 0.85 3.30 1.92 5.72 3.31 3.17 2.71 4.23 1.37 2.62 1.29 0.99 1.87 0.70 6.09 5.40 5.16 6.42 8.70 6.23 7.08 8.33 6.21 7.92 5.60 9.33 9.28 9.32 6.92 5.80 5.67 4.04 8.49 3.07 6.34 5.16 8.94 3.47 5.69 3.40 3.22 5.44 5.20 8.67 3.48 5.80 3.88 4.28 2.85 5.92 5.22 6.89 8.31 6.84 8.21 10.25 4.38 7.78 8.11 7.78 9.10 9.92 8.99 7.25 8.73 6.96 5.72 7.84 10.54 7.57 8.97 7.32 11.69 9.59 11.61 9.04 12.16 8.97 0.34 0.19 0.34 0.21 0.06 0.18 0.13 0.06 0.09 0.17 0.13 0.04 0.11 0.08 0.18 0.26 0.25 1.49 0.22 0.05 0.56 0.17 0.11 0.26 0.12 0.32 0.08 0.03 0.09 0.17 0.07 0.04 0.07 0.37 0.20 0.36 0.48 0.18 0.10 0.06 0.26 0.25 0.40 0.37 0.41 0.10 0.10 0.09 0.11 0.48 0.11 0.30 0.41 0.40 0.05 0.17 0.05 0.09 0.22 0.10 0.15 0.35 0.18 0.17 0.06 0.21 0.07 0.09 0.12 0.13 0.12 0.26 0.13 0.49 0.29 Cases 37 174 17 40 59 106 307 71 173 3247 51 412 364 136 74 52 30202 3097 5444 1777 1133 404 23 1597 15202 219 1306 6475 997 5430 586 6977 40142 2420 2582 2941 31947 7758 684 377 170 89 479 5687 9142 1174 263 187 112 116 982 6156 4288 5844 324 5489 831 611 203 33649 1840 31524 9874 1722 8086 2847 723 2089 1408 18851 2509 16117 9897 4518 8305 6723 1501 5186 487 1180 Female ASR(W) CUM 0-74 1.7 3.6 1.7 3.8 4.8 11.0 12.5 10.4 10.0 11.7 4.6 9.4 4.5 4.1 4.9 4.8 31.6 30.4 30.8 36.6 36.2 21.6 36.9 38.3 31.4 38.5 30.3 34.1 25.6 36.2 40.9 32.1 31.4 16.5 36.0 15.3 37.9 29.8 41.7 16.9 13.7 15.5 18.3 34.8 26.7 34.1 18.9 16.5 14.2 15.2 12.3 35.8 28.4 37.4 33.4 38.2 34.1 36.8 28.5 39.3 26.9 40.8 34.9 27.5 37.4 33.7 30.9 35.5 29.1 37.1 41.2 37.2 40.1 33.5 50.3 37.8 33.5 39.7 34.9 41.7 0.29 0.28 0.43 0.69 0.69 1.13 0.75 1.27 0.78 0.21 0.67 0.48 0.24 0.37 0.61 0.68 0.20 0.58 0.46 0.97 1.16 1.11 7.88 1.05 0.27 2.81 0.94 0.45 0.86 0.53 1.76 0.42 0.17 0.35 0.74 0.29 0.24 0.37 1.69 0.94 1.09 1.82 0.87 0.52 0.30 1.04 1.24 1.25 1.51 1.47 0.41 0.52 0.47 0.55 1.91 0.58 1.30 1.63 2.25 0.24 0.65 0.26 0.37 0.70 0.44 0.67 1.21 0.83 0.84 0.30 0.85 0.33 0.44 0.56 0.59 0.50 0.91 0.60 1.65 1.37 1.32 1.52 1.28 1.18 1.41 0.51 1.19 0.53 0.49 0.61 0.58 4.07 3.90 3.86 4.74 4.80 2.96 5.46 4.97 4.02 4.98 4.02 4.49 3.29 4.79 5.43 4.19 4.04 1.95 4.64 1.88 4.96 3.79 5.26 1.88 1.67 2.19 2.34 4.53 3.39 4.38 2.17 1.96 1.89 1.76 1.53 4.66 3.71 4.87 4.18 4.98 4.30 4.54 3.87 5.01 3.43 5.20 4.63 3.54 4.98 4.42 4.01 4.70 3.90 4.84 5.20 4.87 5.30 4.40 6.68 4.86 4.19 5.14 4.35 5.33 * * * *

0.14 0.11 0.20 0.12 0.03 0.10 0.07 0.04 0.06 0.09 0.10 * 0.03 0.09 0.07 0.14 0.17 0.16 1.38 0.16 0.04 0.41 0.14 0.07 0.13 0.08 0.28 0.06 0.03 0.05 0.11 0.04 0.04 0.06 0.25 0.14 0.16 0.28 0.14 0.08 0.05 0.16 0.18 0.19 0.23 0.22 0.06 0.08 0.07 0.08 0.29 0.09 0.19 0.23 0.37 0.03 0.10 0.04 0.06 0.11 0.07 0.11 0.19 0.13 0.13 0.04 0.13 0.05 0.07 0.08 0.09 0.07 0.13 0.09 0.25 0.20

502

*Important. See note on population page.

444

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Trachea, bronchus and lung (C33-34) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 3155 12065 19922 2761 16959 8615 2062 6473 13338 1232 12012 1818 437751 45345 382072 16153 1982 13847 2377 43 545 1723 34267 4036 29314 25578 2624 22547 8706 6547 28694 2648 25678 2444 44153 4900 36166 123409 5996 13468 5597 97660 9181 2074 7059 34371 4249 29652 1483 1190 10394 6966 5602 10021 186 3847 12941 600 1282 12766 1088 569 962 2525 175 1933 284 363 264 5201 4506 553 1511 1627 1806 4635 3806 16759 2877 Male ASR(W) CUM 0-74 64.0 54.4 60.0 83.7 57.5 66.6 85.0 62.8 68.1 88.4 66.5 51.2 58.3 75.0 57.4 54.7 72.3 53.8 37.8 12.2 28.7 44.2 53.3 60.8 53.4 64.8 81.1 62.7 71.5 52.5 59.7 85.9 57.6 64.6 51.2 76.5 50.3 52.8 33.6 76.5 27.8 55.4 70.0 75.7 68.2 58.1 85.3 56.1 26.3 54.5 53.4 53.1 77.9 53.0 34.2 71.9 57.9 46.7 55.5 51.5 34.0 24.8 10.8 13.5 21.3 9.7 7.5 6.1 9.9 32.2 30.5 40.4 37.5 34.9 42.0 40.6 46.2 43.3 38.2 1.19 0.52 0.44 1.65 0.46 0.75 1.94 0.83 0.62 2.58 0.64 1.26 0.09 0.36 0.10 0.45 1.64 0.49 0.81 1.91 1.26 1.12 0.30 0.97 0.33 0.42 1.63 0.44 0.80 0.69 0.38 1.72 0.39 1.40 0.26 1.12 0.28 0.16 0.45 0.67 0.38 0.19 0.75 1.70 0.84 0.32 1.34 0.34 0.71 1.64 0.55 0.67 1.08 0.56 2.53 1.19 0.52 1.95 1.59 0.48 1.05 1.07 0.35 0.28 1.62 0.23 0.45 0.33 0.62 0.46 0.47 1.76 0.97 0.91 1.00 0.62 0.79 0.34 0.76 8.32 7.04 7.81 10.75 7.50 8.65 11.06 8.16 8.83 10.92 8.67 6.55 7.50 9.54 7.40 6.97 9.39 6.84 4.76 1.16 3.42 5.69 6.74 7.71 6.76 8.38 10.51 8.11 9.06 6.83 7.72 10.93 7.46 8.51 6.56 9.79 6.47 6.75 4.13 9.77 3.34 7.14 9.05 9.68 8.87 7.44 11.03 7.19 3.37 7.03 6.84 6.74 9.95 6.83 4.05 8.61 7.00 6.11 6.49 6.29 4.41 3.19 1.37 1.76 3.03 1.21 0.96 0.78 1.28 4.20 3.99 5.28 4.20 3.95 5.14 4.78 5.50 4.85 4.55 0.18 0.08 0.07 0.25 0.07 0.12 0.30 0.13 0.09 0.38 0.10 0.20 0.01 0.05 0.02 0.07 0.25 0.07 0.13 0.27 0.19 0.17 0.05 0.15 0.05 0.07 0.25 0.07 0.12 0.11 0.06 0.26 0.06 0.22 0.04 0.17 0.04 0.02 0.07 0.10 0.06 0.03 0.11 0.26 0.13 0.05 0.21 0.05 0.11 0.26 0.09 0.11 0.16 0.09 0.38 0.17 0.08 0.29 0.21 0.07 0.16 0.16 0.05 0.04 0.26 0.03 0.07 0.05 0.09 0.07 0.07 0.28 0.14 0.13 0.15 0.09 0.12 0.05 0.11 Cases 2458 11381 15710 1980 13569 7167 1527 5592 9559 858 8626 1485 339134 29126 302680 13910 1389 12332 1747 18 327 1378 29887 3048 26285 19374 1850 17242 6075 5846 21873 2074 19547 2008 35923 3445 30559 99833 3766 8824 4128 82579 5538 963 4531 24136 2400 21393 920 853 9039 6168 4148 7694 64 1765 6136 182 845 5720 521 128 228 540 20 600 96 182 51 2496 2334 82 589 618 720 1801 1608 7144 1042 Female ASR(W) CUM 0-74 41.5 40.3 39.1 44.1 38.6 43.3 44.4 43.6 39.9 42.7 39.8 38.1 36.4 34.3 37.2 36.5 35.0 37.9 23.7 3.9 14.6 30.7 35.5 29.5 37.5 38.9 41.2 38.4 41.1 40.5 35.8 46.8 34.7 42.0 33.8 38.7 35.1 34.3 16.8 36.5 16.0 38.5 33.6 24.2 36.5 32.9 35.6 33.0 14.3 33.3 39.8 40.0 46.3 34.7 11.8 26.7 23.4 13.0 34.6 19.9 14.8 5.0 2.6 3.2 2.3 3.1 2.4 3.0 1.7 12.1 12.4 5.1 12.1 10.4 12.9 12.5 14.6 13.9 11.7 0.92 0.42 0.34 1.04 0.36 0.56 1.20 0.65 0.45 1.53 0.47 1.08 0.07 0.21 0.07 0.34 0.97 0.38 0.61 0.96 0.85 0.90 0.23 0.55 0.26 0.31 1.01 0.32 0.57 0.58 0.27 1.09 0.28 1.06 0.20 0.69 0.22 0.12 0.29 0.41 0.26 0.15 0.48 0.82 0.58 0.23 0.76 0.24 0.51 1.23 0.46 0.56 0.79 0.44 1.49 0.65 0.32 0.99 1.20 0.28 0.68 0.46 0.17 0.14 0.51 0.13 0.26 0.22 0.24 0.26 0.28 0.58 0.53 0.49 0.52 0.33 0.42 0.18 0.43 5.38 5.24 5.15 5.74 5.09 5.70 5.77 5.77 5.25 5.40 5.25 5.12 4.73 4.40 4.86 4.65 4.44 4.84 3.12 0.50 1.79 4.13 4.55 3.70 4.83 5.14 5.45 5.08 5.41 5.39 4.63 5.98 4.50 5.37 4.40 5.00 4.61 4.45 2.04 4.68 1.97 5.04 4.39 3.05 4.80 4.27 4.62 4.29 1.87 4.42 5.22 5.21 6.08 4.58 1.41 3.13 2.62 1.69 4.28 2.37 1.90 0.65 0.32 0.40 0.28 0.37 0.29 0.37 0.19 1.49 1.53 0.63 1.36 1.21 1.52 1.43 1.70 1.53 1.33 0.14 0.06 0.05 0.16 0.05 0.08 0.18 0.10 0.07 0.22 0.07 0.17 0.01 0.03 0.01 0.05 0.15 0.06 0.09 0.16 0.13 0.14 0.03 0.08 0.04 0.05 0.15 0.05 0.09 0.09 0.04 0.16 0.04 0.15 0.03 0.11 0.03 0.02 0.04 0.06 0.04 0.02 0.07 0.12 0.09 0.03 0.12 0.04 0.08 0.19 0.07 0.09 0.12 0.07 0.22 0.10 * 0.05 0.14 * 0.18 0.04 * 0.10 * 0.07 * 0.02 0.02 * 0.07 0.02 0.03 * 0.03 * 0.03 * 0.04 0.04 0.09 0.08 0.07 0.07 0.05 0.06 0.03 0.06

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
445

503

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Trachea, bronchus and lung (C33-34) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
446

Male ASR(W) CUM 0-74 51.1 46.2 52.8 46.3 51.4 50.2 45.0 49.7 57.6 15.6 15.3 39.0 21.0 9.8 25.2 51.7 45.3 51.8 12.1 34.8 32.6 51.7 15.4 37.5 74.5 42.4 45.5 47.3 64.4 54.6 58.0 49.6 72.1 64.4 46.2 65.8 37.3 59.2 55.6 53.3 51.6 47.5 49.5 40.8 48.6 61.4 41.1 34.5 55.6 46.4 53.9 60.9 36.8 56.7 59.6 32.3 41.4 63.2 62.7 64.4 52.9 63.3 44.0 57.8 55.6 66.2 49.1 53.9 45.1 50.7 58.5 50.0 49.4 45.0 67.1 57.8 44.6 61.2 64.0 0.26 0.85 1.10 1.46 1.54 1.12 2.64 0.56 2.45 1.33 1.92 1.51 0.81 0.79 1.08 0.97 0.77 0.93 1.35 2.02 0.94 1.56 0.77 1.15 0.98 0.38 1.42 2.04 0.47 0.90 0.55 0.41 0.67 0.43 0.48 1.21 0.43 1.31 1.62 1.75 1.45 1.21 1.15 1.06 1.68 1.84 1.67 1.31 0.74 0.49 0.89 0.95 0.63 0.75 1.14 1.96 0.59 2.63 1.60 1.89 0.99 1.52 2.27 1.09 1.39 2.07 0.73 1.67 2.01 1.54 1.11 1.23 1.65 1.90 3.06 1.14 1.06 1.73 0.96 6.59 5.90 6.86 6.03 6.92 6.41 5.55 5.89 7.46 1.91 1.62 5.04 2.70 1.27 3.31 6.69 5.37 6.26 1.27 4.03 4.18 6.71 2.06 4.79 9.89 5.34 5.73 6.06 8.53 6.85 7.44 6.28 9.34 8.33 6.05 8.91 4.64 7.55 7.09 6.70 6.63 6.06 6.28 5.18 5.93 7.79 5.02 4.16 7.21 6.04 6.83 7.87 4.58 7.17 7.56 4.23 5.17 8.26 8.14 8.38 6.75 8.03 5.77 7.23 7.39 8.93 6.30 6.89 5.92 6.38 7.48 6.54 6.30 6.07 8.65 7.39 5.78 7.79 8.24 0.04 0.13 0.17 0.23 0.25 0.18 0.41 0.08 0.39 0.20 0.25 0.24 0.12 0.12 0.17 0.15 0.11 0.14 0.16 0.29 0.13 0.23 0.12 0.16 0.15 0.06 0.21 0.31 0.07 0.13 0.08 0.05 0.09 0.06 0.07 0.18 0.07 0.19 0.23 0.25 0.21 0.17 0.17 0.15 0.22 0.26 0.23 0.17 0.11 0.07 0.13 0.14 0.09 0.11 0.17 0.30 0.09 0.39 0.24 0.28 0.14 0.22 0.34 0.16 0.21 0.32 0.11 0.25 0.29 0.23 0.17 0.18 0.24 0.29 0.46 0.17 0.16 0.26 0.15

Cases 14691 1303 933 399 479 822 120 3667 227 46 22 220 395 36 62 1139 1584 1436 33 115 934 634 168 142 505 5532 447 186 2337 1021 2330 2789 2830 6851 7803 678 2745 479 218 202 306 403 400 362 128 196 139 167 1597 2188 1901 1104 1648 1875 990 303 3066 166 391 327 900 496 101 1295 470 189 1625 398 92 343 856 260 187 88 112 815 510 309 1459

Female ASR(W) CUM 0-74 12.5 12.2 13.6 11.7 13.3 13.0 10.7 14.4 13.9 4.6 3.1 9.9 11.2 2.3 3.6 14.8 16.4 17.5 6.8 11.8 23.6 27.0 5.4 4.8 5.9 13.9 15.2 13.2 4.6 13.4 10.7 7.0 12.5 14.0 31.6 8.7 9.6 11.1 7.7 9.8 9.9 10.5 8.7 7.7 6.0 8.4 6.7 6.9 11.5 7.7 20.8 11.6 13.6 14.2 17.3 31.3 20.3 10.8 11.3 12.7 12.1 11.5 9.0 16.7 12.9 10.2 12.0 13.5 5.4 13.4 14.1 6.1 8.2 6.4 11.4 12.6 9.8 10.9 14.3 0.11 0.34 0.45 0.60 0.62 0.46 1.01 0.24 0.95 0.72 0.81 0.68 0.57 0.39 0.47 0.45 0.42 0.48 1.25 1.13 0.78 1.09 0.43 0.40 0.26 0.21 0.79 1.03 0.10 0.46 0.24 0.14 0.25 0.18 0.39 0.36 0.20 0.55 0.57 0.74 0.61 0.57 0.47 0.43 0.59 0.66 0.68 0.58 0.31 0.19 0.54 0.38 0.37 0.37 0.61 1.92 0.40 1.00 0.64 0.82 0.47 0.62 1.05 0.54 0.67 0.77 0.35 0.82 0.62 0.84 0.57 0.42 0.65 0.74 1.20 0.51 0.51 0.70 0.43 1.47 1.40 1.56 1.34 1.58 1.52 1.35 1.65 1.73 0.54 0.24 1.25 1.44 0.25 0.47 1.85 1.72 1.86 0.48 1.33 3.07 3.47 0.66 0.60 0.74 1.67 1.82 1.72 0.56 1.70 1.29 0.84 1.51 1.73 4.23 1.07 1.16 1.34 0.90 1.16 1.21 1.23 1.02 0.93 0.69 0.93 0.69 0.83 1.43 0.95 2.57 1.48 1.68 1.71 2.12 4.09 2.60 1.32 1.35 1.61 1.45 1.41 1.09 2.00 1.56 1.20 1.48 1.63 0.69 1.64 1.69 0.70 1.00 0.77 1.39 1.51 1.21 1.31 1.74 0.02 0.05 0.07 0.09 0.09 0.07 0.15 0.04 0.15 0.11 0.08 0.10 0.09 0.05 * 0.07 * 0.07 * 0.06 0.07 0.13 0.15 0.11 * 0.16 * 0.06 0.06 * 0.04 * 0.03 0.11 0.15 0.01 * 0.06 * 0.03 0.02 * 0.03 0.03 0.06 0.05 0.03 0.07 0.07 0.10 0.08 0.07 0.06 0.06 0.07 0.08 0.08 0.07 0.04 0.03 0.07 0.05 0.05 0.05 0.08 0.28 0.06 0.14 0.09 0.11 0.06 0.08 0.14 0.07 0.09 0.10 0.05 0.11 0.09 0.11 0.07 0.05 0.09 0.09 0.17 0.07 0.07 0.09 0.06

41176 3368 2480 1083 1201 2170 309 9057 628 143 156 698 711 160 596 3165 3547 3145 89 313 1236 1117 409 1090 5886 12849 1071 547 19017 3997 11993 15536 12086 23276 10243 2971 7809 2091 1257 978 1316 1740 1958 1579 941 1212 727 776 5810 9140 3833 4175 3525 6019 2873 296 5184 632 1607 1346 3306 1994 432 3125 1812 1035 4931 1212 565 1236 3179 1795 961 609 501 2790 2091 1308 4797

504

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Trachea, bronchus and lung (C33-34) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 4793 6950 533 6516 1506 3229 2955 3133 3718 7745 10672 9481 4033 491 2833 3857 2287 443 1300 1402 2074 1254 1037 1839 8437 705 403 343 779 648 514 1126 32797 2272 2138 4688 5873 9094 15639 3630 11995 23713 10193 10435 2693 12969 9278 175 5270 2323 816 6619 2524 223 250 4733 1983 121 332 324 504 566 Male ASR(W) CUM 0-74 61.8 64.5 38.8 35.5 60.2 76.9 48.2 30.5 32.5 55.0 59.3 61.2 57.8 38.1 56.4 54.3 49.4 38.2 54.7 43.0 50.4 51.6 49.3 49.1 20.9 45.4 44.7 49.3 39.9 48.8 48.7 46.8 54.6 60.4 57.4 35.4 55.9 51.9 53.4 33.0 35.8 41.2 46.0 44.3 44.8 60.9 37.7 51.4 41.2 36.3 42.9 36.6 39.8 25.6 62.3 35.3 43.8 28.6 48.7 68.4 31.0 48.1 0.90 0.78 1.72 0.47 1.57 1.39 0.91 0.56 0.55 0.63 0.59 0.64 0.91 1.87 1.13 0.91 1.05 2.12 1.62 1.22 1.16 1.55 1.64 1.21 0.24 1.76 2.33 2.80 1.48 1.97 2.22 1.46 0.31 1.28 1.27 0.55 0.76 0.57 0.45 0.57 0.35 0.28 0.48 0.45 0.89 0.55 0.41 4.07 0.59 0.79 1.56 0.47 0.81 1.77 4.06 0.53 1.05 2.92 2.86 3.86 1.64 2.11 8.23 8.48 5.01 4.53 7.90 10.24 6.46 3.89 4.05 7.27 7.58 8.06 7.54 4.78 6.89 6.51 6.05 4.67 6.80 5.63 6.27 6.59 6.04 6.28 2.79 5.72 5.57 6.61 5.14 6.47 6.28 5.94 7.10 7.74 7.43 4.32 6.73 6.46 6.62 3.90 4.31 4.92 5.60 5.50 5.79 7.64 4.77 6.44 5.14 4.51 5.51 4.49 5.02 3.07 7.86 4.42 5.63 3.60 6.17 8.88 3.80 6.45 0.13 0.11 0.27 0.07 0.23 0.20 0.13 0.08 0.08 0.09 0.08 0.10 0.14 0.26 0.15 0.12 0.15 0.28 0.23 0.18 0.16 0.22 0.23 0.17 0.04 0.27 0.35 0.44 0.23 0.31 0.33 0.22 0.05 0.20 0.19 0.08 0.11 0.09 0.07 0.09 0.05 0.04 0.07 0.07 0.14 0.08 0.06 0.62 0.09 0.12 0.24 0.07 0.13 0.27 0.60 0.08 0.16 0.45 0.42 0.61 0.25 0.34 Cases 929 1230 98 3761 613 611 1520 685 867 1894 3076 1777 1188 49 354 558 398 39 134 122 231 166 99 172 6073 391 106 140 274 250 197 528 12386 740 729 2606 4320 6169 10864 2130 7253 15168 6107 5650 1735 9764 4685 70 2487 1202 447 3685 1339 138 95 3159 1275 85 143 257 278 423 Female ASR(W) CUM 0-74 7.0 6.6 6.1 19.2 17.0 10.4 17.4 5.3 6.2 6.6 15.3 8.1 13.0 3.3 5.8 7.0 7.5 3.4 5.4 3.3 4.8 6.9 4.1 4.2 14.5 18.9 10.9 17.3 12.9 15.5 16.8 19.0 19.7 18.7 19.1 17.3 31.9 28.3 30.0 16.4 17.8 21.1 23.1 19.9 22.9 34.9 17.1 22.7 18.1 16.7 21.4 17.5 18.5 13.7 23.6 21.3 24.2 16.7 19.1 45.9 13.7 33.3 0.25 0.21 0.65 0.35 0.73 0.45 0.47 0.22 0.23 0.17 0.29 0.20 0.40 0.53 0.36 0.33 0.40 0.71 0.52 0.33 0.34 0.59 0.47 0.38 0.20 1.04 1.15 1.61 0.84 1.09 1.27 0.90 0.19 0.71 0.74 0.38 0.54 0.40 0.32 0.39 0.24 0.19 0.33 0.30 0.60 0.39 0.27 2.87 0.39 0.54 1.10 0.32 0.54 1.24 2.45 0.41 0.74 2.06 1.64 2.93 1.03 1.77 0.85 0.76 0.77 2.54 2.00 1.25 2.22 0.64 0.70 0.77 1.83 0.95 1.63 0.43 0.64 0.76 0.85 0.31 0.66 0.38 0.54 0.79 0.42 0.45 1.90 2.38 1.33 2.11 1.58 1.88 2.13 2.35 2.54 2.37 2.40 2.15 4.07 3.67 3.89 2.08 2.21 2.65 2.97 2.56 2.98 4.52 2.18 2.92 2.34 2.11 2.61 2.19 2.36 1.68 2.93 2.74 3.10 2.20 2.42 5.88 1.68 4.34 0.03 0.03 0.09 0.05 0.10 * 0.06 0.06 0.03 * 0.03 0.02 0.04 0.03 0.05 0.08 0.04 0.04 0.05 0.07 0.07 0.04 0.04 0.07 0.06 0.04 0.03 0.15 0.15 0.22 0.11 0.14 0.18 0.12 0.03 0.10 0.10 0.06 0.08 0.06 0.05 0.06 0.04 0.03 0.05 0.04 0.09 0.06 0.04 0.49 0.06 0.08 0.16 0.05 0.08 0.19 0.36 0.06 0.11 0.32 0.24 0.44 0.15 0.28

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
447

505

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other thoracic organs (C37-38)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 38 21 5 1 12 15 58 12 11 148 2 36 46 11 3 1 355 43 40 12 7 3 0 12 219 3 16 49 14 35 5 53 431 57 27 99 241 92 6 6 6 4 15 47 116 10 5 3 4 1 34 54 44 36 4 32 8 4 3 225 28 194 85 25 56 40 15 24 16 141 23 111 58 29 35 63 15 45 6 10 Male ASR(W) CUM 0-74 1.8 0.4 0.5 0.0 0.7 1.6 2.9 2.1 0.7 0.7 0.2 1.0 0.6 0.3 0.3 0.1 0.5 0.5 0.4 0.3 0.3 0.2 0.5 0.6 0.6 0.5 0.4 0.6 0.4 0.3 0.3 0.5 0.5 0.5 0.4 0.4 0.5 0.5 0.3 0.7 1.5 0.5 0.5 0.5 0.4 0.6 0.3 0.9 0.2 0.4 0.5 0.4 0.4 0.5 0.4 0.5 0.4 0.4 0.4 0.5 0.4 0.4 0.5 0.3 0.6 0.7 0.5 0.5 0.4 0.5 0.4 0.3 0.3 0.3 0.5 0.5 0.6 0.6 0.5 0.30 0.08 0.24 0.02 0.24 0.45 0.40 0.61 0.21 0.06 0.14 0.17 0.09 0.10 0.17 0.06 0.03 0.07 0.07 0.09 0.12 0.11 0.17 0.04 0.36 0.14 0.06 0.15 0.07 0.16 0.05 0.02 0.07 0.09 0.04 0.03 0.06 0.21 0.14 0.29 0.81 0.13 0.08 0.04 0.13 0.28 0.20 0.46 0.19 0.07 0.07 0.06 0.07 0.25 0.07 0.17 0.22 0.25 0.03 0.10 0.04 0.04 0.10 0.05 0.09 0.20 0.10 0.12 0.03 0.11 0.04 0.05 0.07 0.06 0.07 0.12 0.09 0.24 0.18 0.16 0.32 0.28 0.05 0.08 0.04 0.12 0.06 0.03 0.03 0.00 0.05 0.04 0.04 0.03 0.03 0.02 0.04 0.06 0.08 0.06 0.04 0.06 0.04 0.03 0.03 0.05 0.05 0.05 0.03 0.05 0.05 0.07 0.05 0.06 0.14 0.04 0.05 0.05 0.05 0.07 0.04 0.09 0.02 0.03 0.05 0.03 0.03 0.05 0.03 0.04 0.04 0.04 0.04 0.06 0.04 0.04 0.06 0.03 0.06 0.08 0.06 0.05 0.04 0.05 0.04 0.03 0.03 0.03 0.05 0.05 0.06 0.05 0.06 0.06 0.06 0.10 0.02 0.01 0.03 0.03 0.01 0.02 0.02 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.06 0.02 0.01 0.02 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.03 0.02 0.03 0.09 0.01 0.01 0.01 0.02 0.03 0.03 0.05 0.02 0.01 0.01 0.01 0.01 0.03 0.01 0.02 0.02 0.02 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.03 0.02 0.01 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.03 0.02 Cases 17 6 2 3 11 4 69 3 9 154 1 19 28 1 12 1 255 28 34 6 5 0 0 6 166 1 9 42 11 30 3 32 199 39 20 34 105 56 4 5 3 2 7 26 51 8 1 2 1 1 11 24 28 40 4 36 7 5 1 151 21 126 65 21 42 24 10 13 5 108 13 93 40 13 25 39 12 26 4 11 Female ASR(W) CUM 0-74 0.8 0.1 0.1 0.2 0.6 0.4 2.7 0.4 0.5 0.6 0.1 0.4 0.4 0.0 0.9 0.1 0.3 0.3 0.3 0.1 0.2 0.2 0.4 0.3 0.4 0.3 0.3 0.2 0.2 0.2 0.2 0.3 0.3 0.2 0.2 0.3 0.2 0.3 0.2 0.4 0.2 0.2 0.2 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.2 0.4 0.4 0.4 0.4 0.3 0.2 0.2 0.3 0.2 0.3 0.3 0.2 0.3 0.4 0.2 0.2 0.3 0.2 0.3 0.2 0.1 0.2 0.3 0.3 0.3 0.3 0.7 0.20 0.05 0.10 0.18 0.27 0.22 0.35 0.22 0.16 0.05 0.09 0.10 0.07 0.04 0.26 0.12 0.02 0.06 0.06 0.06 0.08 0.08 0.03 0.27 0.13 0.04 0.09 0.05 0.09 0.03 0.01 0.05 0.06 0.03 0.02 0.04 0.15 0.14 0.15 0.33 0.10 0.04 0.03 0.08 0.10 0.13 0.08 0.16 0.04 0.05 0.04 0.07 0.22 0.08 0.18 0.15 0.17 0.02 0.07 0.03 0.03 0.08 0.04 0.06 0.14 0.06 0.07 0.03 0.06 0.03 0.03 0.03 0.04 0.05 0.08 0.07 0.14 0.26 0.04 0.31 0.04 0.04 0.06 0.01 0.05 0.04 0.00 0.08 0.02 0.03 0.03 0.03 0.02 0.02 0.03 0.04 0.03 0.03 0.03 0.03 0.03 0.01 0.02 0.02 0.03 0.03 0.02 0.02 0.03 0.01 0.02 0.02 0.03 0.02 0.02 0.02 0.03 0.01 0.02 0.01 0.02 0.02 0.02 0.04 0.04 0.04 0.04 0.03 0.04 0.02 0.03 0.02 0.03 0.03 0.02 0.03 0.05 0.02 0.02 0.03 0.03 0.03 0.02 0.01 0.02 0.03 0.03 0.03 0.04 0.07 * * * *

0.02 0.05 0.03 0.02 0.01 0.01 0.02 0.01 0.00 0.03 0.02 * 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.03 0.01 0.00 0.01 0.01 0.01 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.01 0.01 0.02 0.03 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.03 0.01 0.02 0.02 0.04 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.02 0.02

506

*Important. See note on population page.

448

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other thoracic organs (C37-38) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 20 95 149 22 125 68 15 53 77 11 66 11 2800 328 2298 146 15 120 17 0 9 8 269 38 209 123 16 103 34 39 178 18 154 11 366 46 275 978 99 101 140 628 44 11 31 220 29 176 22 5 84 66 24 51 5 50 134 7 42 288 22 8 29 111 3 80 11 27 8 116 100 9 27 26 40 62 51 162 24 Male ASR(W) CUM 0-74 0.5 0.5 0.5 0.6 0.5 0.6 0.6 0.7 0.4 0.8 0.4 0.4 0.4 0.5 0.4 0.6 0.5 0.6 0.3 0.5 0.3 0.5 0.5 0.5 0.4 0.5 0.4 0.3 0.4 0.5 0.6 0.5 0.4 0.5 0.6 0.5 0.5 0.6 0.5 0.4 0.5 0.4 0.4 0.4 0.4 0.5 0.4 0.4 0.2 0.5 0.6 0.4 0.3 0.8 0.9 0.6 0.6 1.8 1.2 0.7 0.5 0.3 0.5 0.3 0.3 0.3 0.4 0.3 0.7 0.7 0.4 0.9 0.8 1.1 0.7 0.8 0.5 0.4 0.12 0.06 0.05 0.13 0.05 0.08 0.15 0.10 0.05 0.25 0.06 0.12 0.01 0.03 0.01 0.05 0.14 0.06 0.09 0.17 0.17 0.03 0.09 0.04 0.04 0.12 0.04 0.06 0.07 0.04 0.14 0.04 0.13 0.03 0.10 0.03 0.02 0.06 0.05 0.04 0.02 0.07 0.11 0.09 0.03 0.10 0.03 0.09 0.10 0.06 0.07 0.09 0.05 0.36 0.13 0.06 0.24 0.28 0.08 0.15 0.18 0.06 0.05 0.19 0.04 0.08 0.09 0.10 0.07 0.08 0.17 0.18 0.17 0.20 0.09 0.13 0.05 0.09 0.04 0.05 0.05 0.05 0.05 0.06 0.05 0.07 0.04 0.10 0.04 0.04 0.04 0.05 0.04 0.06 0.05 0.06 0.02 0.05 0.02 0.05 0.05 0.05 0.03 0.04 0.03 0.03 0.04 0.05 0.06 0.05 0.04 0.05 0.07 0.05 0.05 0.05 0.05 0.04 0.05 0.03 0.04 0.03 0.04 0.05 0.03 0.04 0.02 0.05 0.06 0.05 0.03 0.11 0.10 0.07 0.05 0.21 0.13 0.07 0.05 0.03 0.07 0.03 0.03 0.03 0.05 0.02 0.08 0.08 0.06 0.09 0.10 0.11 0.07 0.09 0.05 0.05 0.01 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.04 0.01 0.01 0.00 0.00 0.00 0.01 0.02 0.01 0.01 0.02 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.06 0.02 0.01 0.03 0.04 0.01 0.02 0.02 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.02 0.02 0.02 0.01 0.01 0.00 0.01 Cases 10 67 83 10 73 38 6 31 52 6 46 10 1812 255 1455 100 13 83 16 0 4 12 194 26 158 83 15 67 31 25 132 15 110 8 218 25 160 548 65 67 50 364 30 12 15 145 27 116 8 5 41 28 7 52 1 25 102 5 28 178 13 10 14 93 0 61 8 9 6 104 93 7 12 6 13 38 38 87 21 Female ASR(W) CUM 0-74 0.2 0.3 0.3 0.2 0.3 0.3 0.2 0.4 0.3 0.2 0.3 0.3 0.2 0.3 0.2 0.4 0.4 0.3 0.3 0.2 0.5 0.3 0.3 0.3 0.2 0.4 0.2 0.3 0.2 0.3 0.4 0.3 0.4 0.3 0.3 0.3 0.2 0.3 0.3 0.2 0.2 0.2 0.3 0.2 0.2 0.3 0.2 0.1 0.2 0.2 0.2 0.1 0.3 0.2 0.4 0.5 0.4 1.1 0.8 0.4 0.4 0.2 0.5 0.3 0.2 0.2 0.2 0.6 0.6 0.2 0.3 0.1 0.4 0.4 0.6 0.2 0.2 0.06 0.05 0.03 0.07 0.04 0.06 0.09 0.07 0.04 0.11 0.05 0.13 0.01 0.02 0.01 0.04 0.12 0.04 0.08 0.09 0.18 0.02 0.05 0.03 0.03 0.10 0.03 0.06 0.05 0.03 0.11 0.03 0.14 0.02 0.06 0.02 0.01 0.04 0.04 0.03 0.01 0.05 0.10 0.06 0.02 0.07 0.02 0.04 0.08 0.04 0.05 0.04 0.05 0.20 0.08 0.05 0.17 0.22 0.08 0.11 0.13 0.04 0.06 0.04 0.07 0.05 0.08 0.06 0.07 0.09 0.09 0.06 0.14 0.09 0.13 0.03 0.05 0.02 0.03 0.03 0.01 0.03 0.03 0.01 0.03 0.03 0.02 0.03 0.03 0.02 0.03 0.02 0.03 0.03 0.03 0.02 0.01 0.04 0.03 0.02 0.03 0.02 0.02 0.02 0.02 0.02 0.03 0.04 0.03 0.03 0.03 0.03 0.02 0.02 0.03 0.03 0.02 0.02 0.02 0.04 0.01 0.02 0.04 0.02 0.01 0.03 0.02 0.02 0.01 0.02 0.03 0.04 0.05 0.05 0.12 0.08 0.04 0.06 0.01 0.06 0.03 0.02 0.02 0.02 0.05 0.05 0.02 0.05 0.01 0.03 0.04 0.07 0.02 0.03 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.03 0.01 * 0.01 0.02 * 0.03 0.01 * 0.01 * 0.02 * 0.00 0.01 * 0.00 0.01 * 0.01 * 0.01 * 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
449

507

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other thoracic organs (C37-38) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
450

Male ASR(W) CUM 0-74 0.8 1.1 0.9 0.9 0.9 0.6 0.8 0.8 1.5 0.4 0.8 0.4 0.4 0.4 0.3 0.8 0.5 0.6 0.2 0.5 0.4 0.3 0.5 0.6 0.6 0.4 0.8 0.6 0.4 0.7 0.8 0.7 0.8 0.5 0.3 0.3 1.0 0.7 0.3 0.5 0.5 0.7 0.9 0.9 0.4 0.8 0.8 0.6 0.7 0.3 0.8 0.6 0.6 0.8 0.4 0.5 0.5 0.7 0.9 0.9 1.3 1.5 0.6 0.7 2.1 0.6 0.8 1.3 0.8 0.8 0.7 0.9 0.7 0.9 0.9 0.5 0.8 1.1 0.03 0.13 0.14 0.19 0.19 0.12 0.32 0.07 0.41 0.19 0.45 0.13 0.11 0.15 0.13 0.12 0.08 0.09 0.21 0.23 0.10 0.09 0.13 0.09 0.05 0.14 0.27 0.05 0.09 0.06 0.06 0.07 0.05 0.06 0.09 0.04 0.18 0.19 0.15 0.15 0.12 0.14 0.16 0.25 0.14 0.25 0.20 0.07 0.07 0.09 0.13 0.09 0.08 0.17 0.24 0.07 0.20 0.17 0.23 0.17 0.23 0.54 0.14 0.18 0.38 0.09 0.25 0.36 0.22 0.15 0.16 0.23 0.27 0.33 0.16 0.12 0.22 0.16 0.08 0.12 0.10 0.13 0.09 0.06 0.10 0.09 0.12 0.03 0.09 0.04 0.05 0.03 0.05 0.10 0.05 0.05 0.01 0.04 0.03 0.02 0.04 0.08 0.07 0.04 0.08 0.07 0.05 0.08 0.09 0.07 0.09 0.05 0.03 0.03 0.12 0.09 0.03 0.05 0.05 0.06 0.08 0.10 0.04 0.12 0.09 0.07 0.08 0.02 0.08 0.06 0.06 0.09 0.03 0.05 0.04 0.08 0.08 0.07 0.14 0.18 0.04 0.08 0.22 0.06 0.08 0.17 0.09 0.09 0.06 0.11 0.08 0.07 0.08 0.06 0.08 0.11 0.00 0.02 0.02 0.03 0.02 0.01 0.06 0.01 0.04 0.02 0.06 0.01 0.02 0.01 0.02 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.02 0.03 0.02 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.03 0.02 0.03 0.01 0.03 0.06 0.01 0.02 0.05 0.01 0.03 0.05 0.03 0.02 0.02 0.03 0.03 0.04 0.02 0.02 0.02 0.02

Cases 424 50 31 13 17 37 2 121 5 3 3 2 20 1 5 56 32 27 2 3 4 2 4 8 12 122 7 3 107 21 111 112 84 191 74 11 54 13 8 6 5 11 9 8 9 8 2 16 52 56 22 27 34 33 12 1 39 3 14 15 29 31 4 33 13 21 28 17 10 16 20 14 5 5 7 18 16 8 29

Female ASR(W) CUM 0-74 0.4 0.5 0.5 0.3 0.5 0.6 0.2 0.5 0.3 0.2 0.8 0.1 0.5 0.0 0.2 0.7 0.3 0.3 0.4 0.2 0.1 0.1 0.1 0.3 0.1 0.4 0.3 0.3 0.3 0.3 0.5 0.4 0.4 0.4 0.3 0.3 0.2 0.3 0.4 0.3 0.2 0.3 0.2 0.1 0.6 0.4 0.1 0.6 0.4 0.2 0.2 0.3 0.3 0.3 0.2 0.1 0.3 0.2 0.6 0.7 0.3 0.6 0.3 0.4 0.5 1.2 0.3 0.6 0.8 0.8 0.4 0.3 0.3 0.4 1.1 0.4 0.3 0.6 0.5 0.02 0.07 0.09 0.09 0.12 0.10 0.12 0.05 0.14 0.13 0.51 0.06 0.12 0.02 0.11 0.09 0.06 0.07 0.29 0.15 0.06 0.05 0.07 0.09 0.04 0.04 0.11 0.15 0.04 0.08 0.06 0.04 0.05 0.04 0.04 0.10 0.04 0.09 0.16 0.12 0.13 0.09 0.08 0.06 0.24 0.14 0.10 0.17 0.06 0.05 0.06 0.07 0.06 0.05 0.06 0.12 0.05 0.11 0.21 0.22 0.07 0.15 0.22 0.09 0.15 0.27 0.07 0.19 0.28 0.29 0.09 0.09 0.13 0.19 0.42 0.10 0.10 0.28 0.12 0.04 0.05 0.06 0.02 0.06 0.06 0.01 0.05 0.03 0.02 0.11 0.01 0.06 0.00 0.02 0.06 0.04 0.04 0.05 0.03 0.01 0.01 0.02 0.04 0.02 0.04 0.04 0.03 0.03 0.04 0.05 0.04 0.05 0.04 0.03 0.02 0.02 0.03 0.03 0.03 0.03 0.03 0.02 0.02 0.06 0.05 0.02 0.07 0.05 0.02 0.02 0.03 0.03 0.03 0.02 0.01 0.03 0.03 0.05 0.06 0.03 0.08 0.03 0.05 0.05 0.13 0.02 0.07 0.11 0.07 0.05 0.03 0.04 0.06 0.13 0.04 0.05 0.05 0.04 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.02 0.08 0.01 0.02 0.00 * 0.02 * 0.01 * 0.01 0.01 0.04 0.02 0.00 * 0.00 * 0.01 0.01 * 0.00 * 0.00 0.02 0.02 0.00 * 0.01 * 0.01 0.00 * 0.01 0.00 0.01 0.01 0.00 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.01 0.02 0.02 0.01 0.02 0.03 0.01 0.02 0.04 0.02 0.01 0.01 0.02 0.03 0.05 0.01 0.01 0.02 0.01

707 96 53 23 26 35 6 176 18 6 10 11 17 8 8 54 41 36 1 4 14 0 8 14 51 159 8 9 169 23 141 237 99 284 97 13 53 31 15 5 12 17 27 33 16 8 12 18 60 119 11 43 52 56 36 3 61 6 18 19 41 44 12 35 18 30 48 14 14 15 37 21 16 8 8 37 17 14 67

508

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other thoracic organs (C37-38) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 55 87 4 93 28 57 38 63 74 53 156 136 22 6 18 51 24 3 13 10 26 14 16 16 71 7 6 6 14 2 2 11 225 13 16 41 77 92 79 25 282 175 107 82 12 90 90 7 54 15 4 53 15 4 3 69 25 1 5 4 7 6 Male ASR(W) CUM 0-74 0.8 0.8 0.3 0.6 1.2 1.4 0.6 0.7 0.7 0.4 1.0 0.9 0.4 0.6 0.4 0.8 0.6 0.3 0.7 0.5 0.7 0.8 0.9 0.5 0.2 0.5 0.6 0.9 0.8 0.2 0.3 0.5 0.4 0.4 0.5 0.4 0.7 0.6 0.3 0.3 1.0 0.4 0.6 0.4 0.3 0.5 0.5 2.0 0.5 0.3 0.2 0.4 0.3 0.4 0.7 0.6 0.7 0.1 0.9 0.7 0.6 0.5 0.12 0.09 0.14 0.06 0.24 0.19 0.11 0.09 0.09 0.06 0.09 0.08 0.08 0.24 0.10 0.14 0.13 0.16 0.23 0.19 0.15 0.21 0.24 0.13 0.03 0.20 0.27 0.37 0.22 0.12 0.24 0.15 0.03 0.12 0.14 0.07 0.09 0.07 0.04 0.05 0.06 0.03 0.06 0.05 0.07 0.05 0.05 0.78 0.07 0.09 0.10 0.06 0.07 0.19 0.38 0.08 0.14 0.11 0.41 0.33 0.28 0.22 0.09 0.10 0.02 0.06 0.12 0.17 0.08 0.07 0.09 0.05 0.11 0.10 0.04 0.08 0.05 0.09 0.06 0.03 0.08 0.04 0.09 0.08 0.10 0.06 0.02 0.06 0.05 0.10 0.09 0.03 0.03 0.05 0.04 0.04 0.05 0.03 0.07 0.07 0.04 0.02 0.12 0.04 0.07 0.05 0.03 0.05 0.04 0.25 0.05 0.03 0.02 0.03 0.03 0.03 0.08 0.07 0.06 0.09 0.05 0.05 0.05 0.01 0.01 0.02 0.01 0.03 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.01 0.01 0.02 0.02 0.01 0.02 0.02 0.03 0.02 0.00 0.03 0.03 0.05 0.03 0.02 0.02 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.12 0.01 0.01 0.01 0.01 0.01 0.02 0.05 0.01 0.01 0.04 0.02 0.03 0.02 Cases 43 45 4 41 18 26 42 43 54 57 85 84 19 4 15 23 8 5 7 3 11 6 8 8 51 8 2 2 1 3 2 10 120 7 4 24 73 61 49 18 187 125 73 34 7 64 46 2 24 7 2 40 14 1 0 38 17 1 4 4 5 1 Female ASR(W) CUM 0-74 0.5 0.3 0.3 0.2 0.6 0.5 0.5 0.4 0.5 0.3 0.5 0.4 0.2 0.7 0.4 0.4 0.2 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.1 0.5 0.3 0.2 0.1 0.1 0.2 0.5 0.2 0.3 0.1 0.3 0.5 0.3 0.2 0.2 0.5 0.2 0.3 0.2 0.2 0.2 0.2 0.7 0.2 0.1 0.1 0.3 0.2 0.1 0.3 0.4 0.3 0.5 0.7 0.6 0.1 0.09 0.06 0.14 0.03 0.15 0.11 0.11 0.08 0.09 0.05 0.05 0.05 0.06 0.41 0.18 0.11 0.09 0.20 0.21 0.16 0.09 0.18 0.15 0.15 0.02 0.19 0.19 0.11 0.06 0.09 0.15 0.18 0.02 0.11 0.05 0.06 0.06 0.04 0.03 0.04 0.04 0.02 0.05 0.03 0.08 0.04 0.03 0.54 0.04 0.04 0.05 0.05 0.06 0.09 0.06 0.11 0.31 0.27 0.38 0.28 0.09 0.05 0.03 0.04 0.02 0.07 0.05 0.05 0.05 0.05 0.03 0.05 0.04 0.03 0.05 0.04 0.03 0.02 0.04 0.03 0.01 0.03 0.03 0.04 0.03 0.02 0.07 0.03 0.03 0.01 0.02 0.03 0.04 0.02 0.02 0.01 0.02 0.06 0.04 0.02 0.02 0.06 0.02 0.04 0.02 0.01 0.03 0.02 0.11 0.03 0.01 0.01 0.03 0.02 0.01 0.03 0.04 0.05 0.06 0.06 0.05 0.01 0.01 0.01 0.02 0.00 0.02 * 0.01 0.01 0.01 * 0.01 0.00 0.01 0.01 0.01 0.03 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.00 0.02 0.02 0.03 0.01 0.02 0.02 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.09 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.05 0.04 0.04 0.02 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
451

509

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Bone (C40-41)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 45 106 5 29 44 12 97 25 24 558 13 67 78 48 13 11 688 72 116 24 22 18 0 28 381 1 26 137 21 112 19 138 942 67 51 264 547 157 7 7 6 0 36 92 250 27 8 5 3 2 84 113 142 93 7 81 12 7 3 513 49 459 195 41 148 67 16 48 31 303 37 253 182 86 115 114 41 72 14 24 Male ASR(W) CUM 0-74 1.4 1.5 0.4 1.2 1.4 1.6 3.3 3.2 1.1 2.2 1.3 1.6 0.8 1.4 1.4 0.9 1.1 0.9 1.1 0.8 1.0 1.5 1.2 1.3 0.1 1.0 1.1 0.7 1.2 1.1 1.0 1.1 0.7 0.8 1.0 1.3 1.0 0.6 0.5 0.9 1.2 1.1 1.0 1.1 0.9 0.8 1.6 0.5 0.8 1.4 1.3 1.0 0.8 1.1 0.9 0.8 0.5 1.2 0.8 1.2 1.0 0.8 1.0 0.9 0.7 1.1 0.9 0.9 0.8 1.0 1.2 1.1 1.0 1.0 1.2 1.0 1.4 1.9 0.23 0.16 0.16 0.34 0.27 0.48 0.37 0.71 0.23 0.10 0.38 0.20 0.10 0.21 0.41 0.29 0.05 0.11 0.11 0.18 0.23 0.38 0.25 0.07 0.14 0.19 0.10 0.16 0.12 0.26 0.09 0.04 0.08 0.12 0.07 0.06 0.08 0.23 0.22 0.38 0.21 0.13 0.07 0.22 0.33 0.35 0.99 0.38 0.10 0.15 0.11 0.11 0.30 0.13 0.28 0.33 0.30 0.06 0.12 0.07 0.07 0.13 0.09 0.12 0.18 0.17 0.17 0.06 0.13 0.06 0.09 0.13 0.10 0.10 0.19 0.12 0.39 0.42 0.14 0.31 0.37 0.07 0.18 0.12 0.14 0.07 0.11 0.12 0.07 0.09 0.08 0.08 0.05 0.09 0.10 0.09 0.10 0.09 0.09 0.05 0.10 0.07 0.09 0.08 0.05 0.06 0.08 0.10 0.08 0.04 0.04 0.05 0.10 0.09 0.08 0.08 0.07 0.05 0.11 0.03 0.07 0.10 0.11 0.09 0.06 0.09 0.07 0.07 0.05 0.10 0.08 0.10 0.09 0.08 0.09 0.08 0.06 0.09 0.07 0.08 0.06 0.08 0.08 0.09 0.08 0.08 0.11 0.08 0.14 0.13 0.04 0.05 0.11 0.02 0.01 0.04 0.02 0.01 0.02 0.04 0.03 0.00 0.01 0.01 0.01 0.02 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.02 0.03 0.01 0.01 0.02 0.03 0.02 0.07 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.03 0.03 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.04 0.03 Cases 35 71 6 29 49 11 67 27 21 482 9 41 63 37 5 7 516 52 76 18 16 7 1 11 314 1 20 98 21 76 12 129 680 57 49 197 366 114 10 7 7 2 18 61 194 20 5 7 3 3 72 80 106 74 5 69 13 6 5 386 50 333 145 36 106 43 15 26 27 278 33 235 133 73 100 116 25 88 10 16 Female ASR(W) CUM 0-74 1.2 1.0 0.5 0.7 1.5 1.4 1.9 3.1 0.9 1.7 0.8 0.8 0.7 1.0 0.3 0.4 0.8 0.7 0.7 0.6 0.7 0.6 1.8 0.4 0.9 0.2 0.7 0.7 0.6 0.7 0.8 0.9 0.8 0.5 0.8 0.8 0.8 0.7 0.7 0.6 0.7 0.3 0.6 0.8 0.8 0.7 0.4 0.8 1.1 1.0 0.7 0.9 1.0 0.7 0.4 0.8 0.7 0.4 0.8 0.8 0.7 0.8 0.7 0.6 0.7 0.6 0.5 0.6 0.8 0.8 0.6 0.8 0.8 0.8 0.8 0.9 0.6 1.0 0.8 0.8 0.23 0.13 0.22 0.17 0.25 0.43 0.25 0.65 0.22 0.08 0.29 0.13 0.09 0.16 0.17 0.17 0.04 0.10 0.08 0.15 0.20 0.24 1.77 0.12 0.06 0.21 0.17 0.07 0.13 0.09 0.24 0.08 0.03 0.07 0.11 0.06 0.05 0.07 0.24 0.27 0.28 0.25 0.15 0.12 0.06 0.17 0.22 0.30 0.77 0.63 0.09 0.12 0.10 0.09 0.17 0.11 0.20 0.23 0.38 0.05 0.10 0.05 0.06 0.10 0.08 0.09 0.15 0.13 0.15 0.05 0.11 0.06 0.07 0.10 0.09 0.08 0.12 0.11 0.26 0.21 0.11 0.18 0.33 0.09 0.14 0.07 0.06 0.06 0.07 0.02 0.04 0.06 0.05 0.05 0.04 0.06 0.04 0.22 0.02 0.08 0.02 0.05 0.06 0.04 0.06 0.05 0.07 0.06 0.04 0.07 0.07 0.06 0.05 0.06 0.04 0.05 0.04 0.06 0.06 0.06 0.07 0.03 0.08 0.09 0.05 0.05 0.07 0.07 0.06 0.02 0.07 0.06 0.03 0.10 0.06 0.06 0.07 0.05 0.04 0.06 0.04 0.04 0.05 0.07 0.07 0.04 0.07 0.06 0.07 0.07 0.07 0.05 0.08 0.06 0.08 * * * *

0.03 0.03 0.10 0.03 0.01 0.03 0.01 0.01 0.02 0.01 0.03 * 0.00 0.01 0.01 0.01 0.02 0.02 0.22 0.01 0.00 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.02 0.02 0.04 0.02 0.01 0.00 0.02 0.01 0.03 0.05 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.05 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02

510

*Important. See note on population page.

452

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Bone (C40-41) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 38 173 294 31 257 108 22 85 146 10 134 29 6323 581 5433 268 22 225 45 4 13 26 567 76 454 289 27 256 95 101 365 28 321 23 707 61 586 2047 113 179 336 1382 95 21 72 583 48 512 82 20 144 89 46 155 12 63 146 21 73 283 36 29 118 502 9 295 67 75 17 225 194 24 12 15 13 56 27 118 33 Male ASR(W) CUM 0-74 1.1 1.1 1.1 0.9 1.2 1.0 0.9 1.1 1.0 0.7 1.0 1.2 1.1 0.9 1.1 1.2 0.7 1.3 1.0 0.8 0.7 1.2 1.1 1.1 1.1 1.0 0.8 1.0 1.0 1.1 1.1 0.9 1.1 0.8 1.0 0.8 1.1 1.1 0.7 0.9 1.0 1.2 0.9 0.7 1.0 1.1 0.8 1.1 1.4 1.2 0.9 0.8 0.9 1.1 1.5 1.1 0.9 1.5 3.1 1.3 1.0 1.6 1.1 1.7 0.9 1.0 1.3 0.9 0.6 1.5 1.5 0.9 0.4 0.4 0.5 0.9 0.8 0.5 0.8 0.19 0.09 0.07 0.16 0.08 0.10 0.19 0.13 0.08 0.21 0.09 0.22 0.01 0.04 0.02 0.08 0.16 0.09 0.14 0.42 0.19 0.25 0.05 0.13 0.06 0.06 0.16 0.07 0.11 0.12 0.06 0.17 0.07 0.18 0.04 0.10 0.05 0.02 0.07 0.07 0.06 0.03 0.09 0.16 0.12 0.05 0.12 0.05 0.16 0.27 0.08 0.09 0.14 0.09 0.47 0.14 0.08 0.34 0.38 0.08 0.18 0.30 0.10 0.08 0.30 0.06 0.16 0.11 0.16 0.10 0.11 0.21 0.13 0.12 0.14 0.13 0.17 0.05 0.17 0.07 0.08 0.09 0.07 0.09 0.09 0.07 0.09 0.09 0.07 0.09 0.09 0.09 0.07 0.09 0.10 0.07 0.11 0.07 0.06 0.05 0.10 0.09 0.07 0.10 0.08 0.08 0.08 0.09 0.09 0.09 0.08 0.09 0.07 0.09 0.06 0.09 0.09 0.06 0.07 0.08 0.09 0.07 0.05 0.08 0.09 0.08 0.09 0.13 0.11 0.07 0.07 0.08 0.08 0.22 0.09 0.07 0.22 0.34 0.12 0.10 0.13 0.10 0.16 0.08 0.09 0.09 0.09 0.05 0.12 0.13 0.08 0.04 0.04 0.04 0.07 0.06 0.04 0.07 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.00 0.00 0.00 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.02 0.03 0.01 0.01 0.01 0.01 0.09 0.01 0.01 0.06 0.05 0.01 0.02 0.03 0.01 0.01 0.03 0.01 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.01 0.01 0.01 0.01 0.00 0.01 Cases 28 136 241 27 207 86 19 65 141 11 121 22 5246 519 4457 232 18 193 45 3 19 23 594 90 479 247 26 211 95 77 274 16 244 19 587 54 484 1638 91 145 269 1099 87 21 66 509 50 438 61 13 145 104 39 118 5 34 107 9 48 251 23 22 92 283 2 178 27 54 13 183 158 18 13 13 10 30 17 93 21 Female ASR(W) CUM 0-74 0.8 0.7 0.8 0.7 0.9 0.7 0.6 0.8 0.8 0.6 0.8 1.0 0.8 0.7 0.9 0.9 0.5 0.9 0.9 0.6 1.0 0.9 1.1 1.1 1.1 0.8 0.7 0.8 0.9 0.8 0.8 0.4 0.8 0.6 0.8 0.6 0.8 0.8 0.5 0.6 0.8 0.8 0.8 0.6 0.9 0.9 0.7 0.9 1.1 0.7 0.8 0.9 0.9 0.7 0.6 0.6 0.6 0.6 1.9 1.1 0.6 1.2 0.9 1.2 0.2 0.7 0.6 0.7 0.4 1.1 1.2 0.6 0.5 0.3 0.4 0.5 0.3 0.4 0.5 0.17 0.07 0.06 0.13 0.07 0.09 0.15 0.11 0.07 0.18 0.08 0.22 0.01 0.03 0.01 0.07 0.12 0.08 0.14 0.35 0.23 0.22 0.05 0.12 0.06 0.05 0.14 0.06 0.11 0.10 0.05 0.10 0.06 0.15 0.03 0.08 0.04 0.02 0.06 0.05 0.05 0.03 0.09 0.14 0.12 0.04 0.10 0.05 0.14 0.22 0.07 0.09 0.15 0.08 0.30 0.10 0.06 0.22 0.28 0.08 0.12 0.26 0.09 0.08 0.12 0.05 0.11 0.10 0.13 0.09 0.10 0.16 0.14 0.10 0.16 0.09 0.08 0.05 0.15 0.06 0.06 0.07 0.05 0.07 0.06 0.04 0.07 0.07 0.05 0.07 0.07 0.07 0.05 0.07 0.08 0.04 0.08 0.07 0.04 0.07 0.07 0.09 0.09 0.10 0.06 0.05 0.06 0.07 0.07 0.06 0.03 0.06 0.05 0.06 0.04 0.07 0.06 0.04 0.05 0.07 0.07 0.06 0.05 0.07 0.07 0.06 0.08 0.09 0.05 0.07 0.08 0.06 0.07 0.08 0.05 0.05 0.09 0.22 0.11 0.05 0.10 0.07 0.12 0.01 0.06 0.05 0.06 0.04 0.09 0.09 0.05 0.04 0.03 0.03 0.04 0.02 0.03 0.04 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.03 0.02 0.02 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.05 0.01 * 0.01 0.03 * 0.04 0.01 * 0.02 * 0.02 * 0.01 0.01 * 0.01 0.01 0.01 * 0.01 * 0.01 * 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
453

511

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Bone (C40-41) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
454

Male ASR(W) CUM 0-74 1.0 1.1 1.0 0.9 1.5 1.0 1.1 1.1 1.0 0.6 1.9 1.0 0.9 0.7 1.3 2.7 0.6 0.6 0.3 0.4 0.8 0.6 0.6 1.0 1.1 1.0 0.9 1.0 1.3 0.8 1.3 1.1 3.2 1.1 1.0 1.4 0.9 0.7 1.0 1.2 0.9 1.1 1.3 0.5 1.3 1.2 1.2 1.0 1.3 0.9 0.7 0.8 0.7 0.8 1.3 1.8 1.1 1.3 1.4 1.1 1.5 1.2 1.3 1.2 0.9 1.9 1.0 1.4 0.8 1.4 0.9 1.3 0.5 0.9 2.0 1.2 1.3 1.0 0.9 0.03 0.12 0.14 0.18 0.22 0.13 0.39 0.08 0.27 0.18 0.68 0.23 0.14 0.18 0.17 0.20 0.08 0.10 0.21 0.22 0.16 0.18 0.14 0.17 0.11 0.08 0.22 0.35 0.07 0.14 0.11 0.07 0.18 0.06 0.09 0.20 0.08 0.17 0.26 0.32 0.23 0.24 0.23 0.13 0.33 0.30 0.38 0.27 0.14 0.09 0.15 0.14 0.12 0.11 0.26 0.50 0.11 0.65 0.34 0.38 0.28 0.38 0.59 0.26 0.24 0.39 0.16 0.46 0.34 0.37 0.22 0.25 0.19 0.36 0.71 0.23 0.30 0.27 0.16 0.08 0.08 0.08 0.10 0.13 0.07 0.14 0.09 0.08 0.03 0.09 0.11 0.08 0.07 0.10 0.28 0.05 0.06 0.04 0.05 0.06 0.05 0.04 0.09 0.09 0.08 0.10 0.07 0.12 0.07 0.11 0.10 0.28 0.09 0.07 0.12 0.07 0.06 0.08 0.09 0.07 0.08 0.11 0.05 0.11 0.09 0.09 0.08 0.11 0.08 0.06 0.08 0.06 0.06 0.09 0.17 0.08 0.09 0.11 0.10 0.10 0.08 0.11 0.10 0.11 0.12 0.08 0.12 0.06 0.12 0.07 0.09 0.04 0.07 0.14 0.12 0.11 0.11 0.07 0.00 0.01 0.01 0.03 0.02 0.01 0.06 0.01 0.03 0.01 0.03 0.03 0.02 0.03 0.02 0.03 0.01 0.01 0.02 0.03 0.01 0.02 0.01 0.02 0.01 0.01 0.03 0.03 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.02 0.02 0.02 0.02 0.01 0.03 0.02 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.05 0.01 0.04 0.03 0.03 0.02 0.02 0.05 0.02 0.02 0.03 0.01 0.04 0.03 0.03 0.02 0.02 0.02 0.03 0.05 0.02 0.02 0.03 0.01

Cases 722 81 52 30 22 57 7 187 21 15 11 20 36 16 57 203 49 41 4 4 19 17 14 24 57 159 18 1 282 28 135 205 311 234 102 33 103 14 22 15 19 17 38 24 9 13 8 16 85 132 34 46 60 62 21 1 78 5 13 5 37 14 4 29 13 19 50 18 9 13 28 28 5 3 6 23 34 9 32

Female ASR(W) CUM 0-74 0.7 0.8 0.9 0.9 0.7 0.9 0.8 0.8 1.2 0.9 1.0 0.8 0.7 0.4 1.5 2.0 0.6 0.6 0.9 0.4 0.6 0.8 0.4 0.7 0.7 0.7 1.1 0.2 0.9 0.6 1.0 0.8 2.3 0.7 0.7 0.8 0.6 0.6 1.3 1.1 0.8 0.7 1.2 0.6 0.5 0.8 0.6 0.9 1.0 1.0 0.8 0.9 1.0 1.0 0.8 0.2 0.7 0.6 0.7 1.3 1.0 0.9 0.4 0.7 0.7 1.3 0.9 1.1 1.0 1.1 1.1 1.0 0.3 0.5 1.8 0.9 1.3 0.3 0.6 0.03 0.10 0.13 0.16 0.14 0.13 0.33 0.06 0.26 0.26 0.40 0.18 0.12 0.11 0.22 0.15 0.08 0.10 0.49 0.22 0.14 0.20 0.12 0.15 0.09 0.07 0.29 0.16 0.06 0.12 0.09 0.07 0.15 0.05 0.08 0.16 0.07 0.17 0.30 0.29 0.21 0.18 0.21 0.13 0.19 0.26 0.28 0.25 0.14 0.12 0.16 0.14 0.15 0.14 0.20 0.15 0.09 0.31 0.23 0.63 0.22 0.37 0.22 0.19 0.24 0.32 0.15 0.30 0.36 0.39 0.29 0.24 0.15 0.32 0.79 0.26 0.29 0.13 0.15 0.06 0.07 0.07 0.07 0.05 0.08 0.08 0.06 0.10 0.09 0.11 0.07 0.05 0.03 0.12 0.21 0.04 0.04 0.04 0.02 0.03 0.08 0.04 0.07 0.05 0.06 0.09 0.01 0.07 0.05 0.08 0.07 0.18 0.06 0.06 0.06 0.05 0.04 0.09 0.08 0.07 0.05 0.10 0.04 0.06 0.08 0.04 0.07 0.09 0.08 0.06 0.07 0.07 0.07 0.06 0.01 0.06 0.04 0.07 0.08 0.09 0.07 0.05 0.06 0.06 0.10 0.07 0.11 0.07 0.07 0.07 0.07 0.03 0.04 0.12 0.07 0.11 0.03 0.05 0.00 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.03 0.03 0.06 0.02 0.01 0.01 * 0.02 * 0.02 * 0.01 0.01 0.03 0.01 0.01 * 0.02 * 0.01 0.02 * 0.01 * 0.00 0.02 0.01 0.00 * 0.01 * 0.01 0.01 * 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.01 0.02 0.01 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.02 0.03 0.02 0.02 0.03 0.01 0.02 0.02 0.01 0.03 0.03 0.02 0.02 0.02 0.01 0.02 0.05 0.02 0.02 0.01 0.01

900 92 57 29 49 60 8 250 18 15 25 23 47 18 61 244 46 39 3 4 30 12 20 34 95 199 17 9 345 37 178 270 388 309 132 48 131 18 17 15 16 25 38 18 16 16 14 15 95 128 32 45 45 53 29 13 107 6 21 15 41 14 6 30 20 26 52 17 7 17 23 35 7 8 10 36 28 15 39

512

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Bone (C40-41) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 85 126 9 127 21 42 39 92 108 106 370 207 50 8 41 59 36 3 25 22 30 16 10 31 234 10 6 2 18 10 7 14 423 34 19 65 128 91 138 58 226 366 107 132 26 129 178 2 100 49 8 128 43 8 17 133 33 0 5 6 6 11 Male ASR(W) CUM 0-74 1.3 1.3 1.0 1.1 1.0 1.1 0.9 1.1 1.3 1.0 2.7 1.5 0.9 1.2 1.4 1.4 0.9 0.4 2.0 1.0 1.0 1.1 0.9 1.4 1.0 0.9 0.8 0.8 1.2 1.3 1.0 1.1 1.0 1.1 0.7 0.8 1.7 0.9 0.8 0.7 1.2 1.1 0.9 1.0 0.6 1.1 1.0 0.4 1.1 1.3 0.7 1.0 0.8 0.9 3.0 1.3 1.0 0.9 1.1 1.3 1.0 0.14 0.12 0.37 0.10 0.22 0.17 0.15 0.12 0.14 0.11 0.16 0.11 0.13 0.46 0.24 0.21 0.16 0.34 0.45 0.24 0.20 0.30 0.30 0.30 0.07 0.31 0.35 0.54 0.29 0.44 0.38 0.32 0.05 0.21 0.17 0.11 0.16 0.10 0.08 0.10 0.09 0.06 0.10 0.09 0.12 0.10 0.08 0.29 0.11 0.19 0.25 0.09 0.13 0.34 0.77 0.12 0.19 0.40 0.44 0.62 0.31 0.13 0.13 0.07 0.08 0.09 0.11 0.07 0.10 0.11 0.08 0.26 0.14 0.08 0.11 0.11 0.11 0.07 0.03 0.14 0.09 0.08 0.09 0.06 0.11 0.08 0.06 0.10 0.04 0.10 0.10 0.09 0.08 0.08 0.10 0.07 0.07 0.15 0.07 0.06 0.06 0.10 0.08 0.06 0.07 0.05 0.08 0.08 0.02 0.09 0.10 0.06 0.08 0.08 0.08 0.35 0.10 0.09 0.10 0.10 0.10 0.09 0.02 0.01 0.02 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.04 0.02 0.02 0.01 0.02 0.03 0.02 0.01 0.02 0.02 0.02 0.01 0.02 0.05 0.03 0.03 0.03 0.04 0.02 0.00 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.02 0.01 0.01 0.03 0.12 0.01 0.02 0.05 0.06 0.04 0.03 Cases 64 104 7 111 15 38 28 85 88 85 260 146 47 7 26 33 22 4 17 11 29 8 15 32 164 13 1 3 17 10 5 14 389 27 14 45 138 59 114 56 225 286 98 114 23 93 144 4 87 34 7 99 47 5 12 87 19 2 2 3 4 5 Female ASR(W) CUM 0-74 0.8 0.8 0.8 0.9 0.7 1.0 0.4 1.0 0.9 0.5 1.7 0.9 0.7 0.7 0.7 0.6 0.6 0.5 1.0 0.4 1.0 0.5 1.4 1.3 0.7 1.3 0.1 0.9 1.1 1.1 0.7 1.0 0.9 1.1 0.5 0.5 1.4 0.5 0.6 0.8 1.0 0.8 0.7 0.8 0.4 0.6 0.8 0.8 0.9 0.7 0.5 0.8 0.9 0.6 1.9 0.9 0.6 0.8 0.4 0.5 1.0 0.8 0.12 0.09 0.31 0.10 0.19 0.17 0.09 0.12 0.12 0.07 0.12 0.08 0.12 0.29 0.17 0.12 0.13 0.30 0.27 0.14 0.21 0.20 0.40 0.27 0.06 0.39 0.14 0.55 0.31 0.43 0.31 0.29 0.05 0.24 0.16 0.09 0.14 0.08 0.06 0.12 0.08 0.05 0.09 0.08 0.10 0.08 0.07 0.40 0.11 0.14 0.21 0.08 0.14 0.28 0.57 0.10 0.16 0.53 0.28 0.27 0.54 0.41 0.07 0.07 0.05 0.07 0.05 0.08 0.04 0.08 0.07 0.05 0.16 0.08 0.06 0.07 0.06 0.05 0.04 0.03 0.08 0.03 0.07 0.03 0.10 0.10 0.05 0.10 0.01 0.06 0.07 0.09 0.06 0.07 0.07 0.09 0.05 0.04 0.13 0.04 0.05 0.06 0.08 0.06 0.05 0.06 0.03 0.05 0.06 0.07 0.07 0.06 0.04 0.06 0.08 0.05 0.14 0.07 0.04 0.08 0.03 0.03 0.07 0.05 0.01 0.01 0.02 0.01 0.01 * 0.01 0.01 0.01 * 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.03 0.02 0.00 0.03 0.01 0.03 0.02 0.03 0.03 0.02 0.00 0.02 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.04 0.01 0.01 0.02 0.01 0.01 0.02 0.04 0.01 0.01 0.06 0.02 0.02 0.04 0.02

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
455

513

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Melanoma of skin (C43)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 5 15 5 9 15 27 102 16 69 1392 16 124 188 73 18 16 8496 945 1550 352 283 116 6 458 4438 62 286 1557 17 1420 149 2636 15400 100 57 536 13688 2657 9 15 4 1 67 2391 3197 24 12 6 6 2 185 2737 2176 2053 7 1971 123 8 108 8811 41 8590 3205 46 3080 1229 15 1181 671 4084 28 3832 2336 1357 2145 1179 30 1129 9 183 Male ASR(W) CUM 0-74 0.2 0.3 0.6 0.9 0.9 3.3 4.2 2.7 4.4 6.5 1.8 3.5 2.4 2.5 1.4 1.8 10.9 10.3 10.8 9.1 11.3 6.4 5.9 14.0 11.4 12.6 8.0 10.8 0.6 12.4 8.8 15.4 15.2 0.9 1.0 2.9 22.0 12.9 0.6 0.9 0.4 0.1 2.6 19.3 11.9 1.0 1.2 0.8 1.1 0.3 2.8 21.7 16.9 18.0 0.9 19.0 7.1 0.8 17.3 13.7 0.8 15.1 14.1 1.0 17.7 17.3 0.9 23.8 16.8 10.6 0.6 11.7 12.2 13.7 16.7 8.6 0.9 11.3 1.0 9.0 0.11 0.10 0.25 0.37 0.28 0.66 0.46 0.70 0.55 0.20 0.46 0.33 0.18 0.30 0.35 0.47 0.12 0.34 0.28 0.51 0.69 0.61 2.59 0.68 0.18 1.65 0.50 0.28 0.15 0.34 0.76 0.31 0.13 0.09 0.13 0.13 0.20 0.26 0.21 0.24 0.19 0.15 0.34 0.41 0.22 0.21 0.37 0.34 0.51 0.25 0.22 0.44 0.37 0.42 0.37 0.45 0.66 0.28 1.72 0.16 0.12 0.18 0.25 0.15 0.32 0.51 0.25 0.71 0.67 0.17 0.12 0.20 0.26 0.39 0.37 0.26 0.16 0.35 0.33 0.70 0.34 0.57 0.35 0.46 0.70 0.19 0.35 0.25 0.24 0.15 0.25 1.21 1.11 1.17 1.00 1.24 0.66 0.68 1.62 1.28 1.29 0.89 1.22 0.07 1.39 0.94 1.72 1.70 0.10 0.10 0.32 2.44 1.46 0.05 0.12 0.03 0.31 2.18 1.35 0.12 0.15 0.10 0.12 0.01 0.30 2.43 1.85 2.06 0.11 2.17 0.80 0.11 1.98 1.53 0.09 1.69 1.63 0.11 2.02 1.99 0.08 2.72 1.83 1.21 0.08 1.34 1.37 1.49 1.83 0.94 0.09 1.22 0.13 1.02 0.08 0.08 0.10 0.07 0.03 0.06 0.04 0.02 0.04 0.05 0.08 0.02 0.04 0.04 0.06 0.09 0.07 0.35 0.09 0.02 0.21 0.06 0.04 0.02 0.04 0.10 0.04 0.02 0.01 0.02 0.02 0.03 0.04 0.03 0.04 0.02 0.05 0.06 0.03 0.03 0.05 0.05 0.06 0.01 0.03 0.06 0.05 0.06 0.05 0.06 0.09 0.04 0.24 0.02 0.02 0.02 0.04 0.02 0.04 0.07 0.03 0.10 0.08 0.02 0.02 0.03 0.03 0.05 0.05 0.03 0.02 0.04 0.05 0.09 Cases 11 14 5 16 28 29 122 15 93 1687 32 135 173 96 19 23 7658 948 1329 285 298 129 4 441 3834 78 312 1180 17 1045 115 1697 11330 111 44 689 9605 1995 6 13 4 4 114 1711 2389 20 7 7 5 6 236 1947 1727 1665 5 1595 92 4 79 5923 68 5726 2478 44 2351 946 17 907 488 3133 34 2916 1862 1262 1796 890 35 834 10 135 Female ASR(W) CUM 0-74 0.4 0.3 0.5 1.4 2.3 2.9 4.2 2.0 4.5 5.7 3.5 2.9 2.1 2.8 1.1 2.1 9.3 10.0 8.9 7.0 11.1 6.7 5.3 12.5 9.2 15.7 8.5 7.4 0.5 8.8 6.7 9.7 10.3 0.8 0.6 3.1 15.7 8.9 0.3 0.6 0.3 0.8 4.0 13.8 7.9 0.6 0.4 0.7 0.9 1.2 2.6 16.2 12.6 13.3 0.5 14.3 4.3 0.1 11.6 8.9 0.9 10.2 9.3 0.6 12.6 10.7 0.6 16.6 11.6 7.3 0.5 8.4 9.0 12.6 13.0 5.7 0.7 7.9 0.6 6.6 0.14 0.07 0.22 0.40 0.50 0.60 0.43 0.53 0.49 0.16 0.62 0.27 0.17 0.31 0.27 0.45 0.11 0.34 0.26 0.44 0.68 0.62 2.88 0.63 0.16 1.89 0.52 0.23 0.12 0.29 0.66 0.25 0.10 0.08 0.10 0.12 0.18 0.21 0.14 0.17 0.16 0.41 0.39 0.37 0.17 0.14 0.17 0.28 0.44 0.61 0.18 0.41 0.32 0.35 0.25 0.39 0.47 0.08 1.40 0.13 0.12 0.15 0.19 0.10 0.27 0.36 0.15 0.57 0.56 0.14 0.09 0.17 0.22 0.39 0.32 0.20 0.12 0.30 0.19 0.62 0.32 0.46 0.23 0.47 0.61 0.39 0.34 0.23 0.31 0.14 0.27 0.96 1.00 0.92 0.74 1.20 0.76 0.68 1.33 0.95 1.69 0.86 0.74 0.06 0.87 0.69 0.98 1.06 0.07 0.07 0.33 1.58 0.92 0.02 0.05 0.03 0.08 0.41 1.42 0.82 0.08 0.03 0.08 0.10 0.10 0.27 1.64 1.23 1.40 0.05 1.50 0.43 0.03 1.24 0.93 0.11 1.05 0.97 0.06 1.28 1.13 0.08 1.70 1.18 0.75 0.04 0.86 0.89 1.23 1.29 0.57 0.07 0.78 0.06 0.64 * * * *

0.07 0.06 0.08 0.06 0.02 0.08 0.04 0.02 0.04 0.04 0.07 * 0.01 0.04 0.03 0.05 0.08 0.08 0.41 0.07 0.02 0.22 0.06 0.02 0.02 0.03 0.08 0.03 0.01 0.01 0.01 0.02 0.02 0.02 0.01 0.02 0.02 0.05 0.05 0.04 0.02 0.02 0.01 0.03 0.05 0.05 0.02 0.04 0.03 0.04 0.03 0.04 0.05 0.02 0.18 0.01 0.02 0.02 0.02 0.01 0.03 0.04 0.03 0.07 0.06 0.02 0.01 0.02 0.02 0.04 0.03 0.02 0.02 0.03 0.03 0.06

514

*Important. See note on population page.

456

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Melanoma of skin (C43) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 706 3140 4579 36 4343 1721 21 1679 1781 8 1751 395 93718 462 89053 3941 16 3863 824 8 44 771 5706 53 5589 4566 25 4153 1192 2108 5533 20 5175 640 12579 58 12120 33579 174 162 734 31093 1823 17 1763 6036 25 5664 968 428 3235 2168 855 2002 2 45 150 2 2 107 7 59 24 58 4 61 13 0 5 1774 1701 23 18 17 17 48 36 129 23 Male ASR(W) CUM 0-74 15.7 15.0 14.5 1.0 15.8 13.7 0.8 17.4 9.8 0.5 10.6 12.7 13.1 0.7 14.4 14.2 0.5 16.6 14.2 2.1 2.4 23.7 9.3 0.8 10.9 12.4 0.8 12.6 10.3 18.5 12.7 0.6 13.1 18.2 15.1 0.8 17.9 14.8 1.0 0.9 3.0 19.4 14.4 0.6 18.4 10.2 0.5 10.9 16.7 20.6 17.2 16.9 13.2 11.3 0.4 0.8 0.7 0.1 0.1 0.4 0.2 2.9 0.3 0.3 0.5 0.3 0.4 0.2 11.2 12.2 1.4 0.5 0.4 0.5 0.5 0.7 0.4 0.4 0.62 0.28 0.22 0.18 0.25 0.34 0.19 0.44 0.24 0.19 0.27 0.67 0.04 0.03 0.05 0.24 0.14 0.28 0.51 0.77 0.36 0.91 0.13 0.11 0.15 0.19 0.16 0.20 0.31 0.42 0.18 0.15 0.19 0.76 0.14 0.11 0.17 0.08 0.08 0.07 0.12 0.12 0.35 0.15 0.45 0.13 0.09 0.15 0.56 1.03 0.31 0.38 0.47 0.26 0.25 0.12 0.06 0.10 0.05 0.05 0.08 0.39 0.05 0.04 0.23 0.04 0.10 0.09 0.27 0.30 0.32 0.12 0.11 0.13 0.09 0.13 0.04 0.09 1.69 1.69 1.61 0.10 1.75 1.52 0.09 1.91 1.08 0.04 1.18 1.40 1.46 0.08 1.61 1.63 0.05 1.90 1.59 0.20 0.28 2.58 1.05 0.09 1.24 1.37 0.08 1.39 1.15 2.08 1.42 0.07 1.45 2.11 1.69 0.09 2.00 1.65 0.11 0.09 0.33 2.15 1.62 0.07 2.03 1.13 0.04 1.20 1.79 2.20 1.93 1.89 1.45 1.26 0.05 0.10 0.07 0.01 0.01 0.05 0.03 0.36 0.03 0.03 0.06 0.03 0.04 0.02 1.24 1.33 0.17 0.05 0.03 0.05 0.05 0.06 0.04 0.04 0.08 0.04 0.03 0.02 0.03 0.04 0.03 0.06 0.03 0.02 0.03 0.08 0.01 0.00 0.01 0.03 0.01 0.04 0.07 0.09 0.05 0.11 0.02 0.02 0.02 0.02 0.02 0.03 0.04 0.05 0.02 0.02 0.02 0.10 0.02 0.02 0.02 0.01 0.01 0.01 0.02 0.01 0.04 0.02 0.06 0.02 0.01 0.02 0.07 0.13 0.04 0.05 0.06 0.03 0.05 0.02 0.01 0.01 0.01 0.01 0.01 0.05 0.01 0.01 0.03 0.00 0.01 0.01 0.04 0.04 0.04 0.01 0.01 0.01 0.01 0.01 0.00 0.01 Cases 576 2716 3804 29 3590 1428 18 1392 1271 10 1232 307 71525 545 67236 3099 24 3023 583 3 72 504 4554 73 4434 3779 23 3426 831 1764 4297 17 3997 453 10207 55 9791 26085 190 160 942 23543 1392 35 1306 4277 49 3921 781 361 2810 1922 668 1591 1 28 129 4 5 91 7 82 28 44 1 48 3 0 9 1726 1681 16 22 14 28 45 41 87 32 Female ASR(W) CUM 0-74 11.8 11.5 11.4 0.7 12.9 10.5 0.6 14.2 6.2 0.4 6.8 9.7 9.2 0.6 10.3 9.7 0.6 11.8 9.7 0.8 3.5 16.5 6.4 0.7 7.8 9.6 0.5 9.9 6.5 15.5 9.4 0.4 9.9 11.1 11.4 0.6 14.1 10.5 0.9 0.6 3.2 14.4 10.0 0.8 13.4 6.4 0.6 6.8 13.0 17.4 14.5 14.3 9.9 8.7 0.2 0.5 0.6 0.3 0.2 0.3 0.2 3.3 0.3 0.2 0.1 0.2 0.1 0.3 9.5 10.5 0.8 0.6 0.3 0.7 0.5 0.5 0.2 0.5 0.54 0.24 0.20 0.13 0.23 0.29 0.14 0.41 0.19 0.15 0.21 0.60 0.04 0.03 0.04 0.19 0.12 0.24 0.42 0.45 0.42 0.81 0.10 0.08 0.13 0.17 0.11 0.18 0.24 0.39 0.16 0.10 0.17 0.57 0.12 0.08 0.15 0.07 0.06 0.05 0.11 0.10 0.28 0.15 0.39 0.10 0.09 0.12 0.48 0.96 0.29 0.34 0.42 0.23 0.18 0.09 0.05 0.14 0.09 0.04 0.06 0.39 0.06 0.04 0.09 0.04 0.05 0.09 0.24 0.27 0.22 0.12 0.11 0.13 0.08 0.09 0.03 0.12 1.16 1.20 1.13 0.08 1.26 1.03 0.06 1.38 0.61 0.04 0.67 0.97 0.94 0.07 1.05 1.03 0.07 1.23 0.98 0.10 0.37 1.60 0.67 0.07 0.82 0.96 0.06 0.99 0.68 1.53 0.96 0.07 1.00 1.17 1.16 0.06 1.42 1.08 0.08 0.07 0.34 1.45 1.03 0.11 1.35 0.64 0.07 0.69 1.34 1.75 1.45 1.43 0.98 0.89 0.05 0.05 0.06 0.05 0.03 0.04 0.02 0.36 0.04 0.03 0.03 0.01 0.03 0.99 1.09 0.08 0.05 0.03 0.06 0.04 0.04 0.02 0.05 0.06 0.03 0.02 0.02 0.02 0.03 0.02 0.04 0.02 0.02 0.02 0.06 0.00 0.00 0.00 0.02 0.02 0.03 0.05 0.06 0.05 0.08 0.01 0.01 0.01 0.02 0.02 0.02 0.03 0.04 0.02 0.02 0.02 0.07 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.03 0.02 0.04 0.01 0.01 0.01 0.06 0.10 0.03 0.04 0.04 0.03 0.05 0.01 * 0.01 0.03 * 0.02 0.00 * 0.01 * 0.05 * 0.01 0.01 * 0.01 0.00 * - * 0.01 * 0.03 0.03 0.03 0.01 0.01 0.01 0.01 0.01 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
457

515

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Melanoma of skin (C43) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
458

Male ASR(W) CUM 0-74 0.5 0.5 0.7 0.3 0.7 0.5 0.4 0.6 0.5 0.2 0.6 0.5 1.2 0.4 0.5 0.8 0.4 0.4 0.4 0.7 0.6 0.8 0.5 1.0 1.3 8.6 13.0 12.4 2.7 4.6 5.5 2.7 6.9 9.9 11.9 5.3 8.8 11.3 4.7 7.4 10.7 7.1 7.2 9.8 6.7 6.2 6.2 7.3 7.4 8.6 9.7 6.4 12.7 8.0 8.1 9.3 7.4 9.8 8.4 6.4 9.8 7.9 9.6 10.4 7.0 3.9 9.5 7.8 3.8 6.1 10.0 5.0 3.4 4.6 5.4 10.7 5.6 7.8 9.4 0.02 0.09 0.11 0.11 0.16 0.10 0.21 0.06 0.14 0.17 0.27 0.17 0.19 0.16 0.13 0.12 0.07 0.08 0.25 0.29 0.13 0.20 0.13 0.18 0.12 0.18 0.80 1.08 0.10 0.28 0.18 0.10 0.22 0.17 0.26 0.36 0.22 0.59 0.48 0.70 0.69 0.49 0.45 0.52 0.65 0.62 0.74 0.62 0.28 0.23 0.40 0.32 0.40 0.31 0.46 1.08 0.26 1.21 0.64 0.70 0.51 0.66 1.32 0.53 0.57 0.51 0.36 0.75 0.64 0.67 0.55 0.42 0.47 0.64 0.92 0.57 0.44 0.67 0.41 0.06 0.06 0.08 0.04 0.10 0.07 0.05 0.06 0.04 0.02 0.10 0.02 0.16 0.05 0.05 0.10 0.04 0.04 0.04 0.05 0.06 0.10 0.04 0.12 0.14 0.93 1.38 1.35 0.30 0.49 0.58 0.30 0.74 1.13 1.30 0.59 0.97 1.24 0.50 0.79 1.15 0.75 0.78 1.03 0.69 0.65 0.67 0.78 0.85 0.95 1.08 0.73 1.40 0.83 0.89 0.97 0.77 0.96 0.92 0.66 1.02 0.84 0.97 1.08 0.76 0.43 1.02 0.84 0.37 0.60 1.05 0.52 0.36 0.53 0.61 1.19 0.60 0.85 1.05 0.00 0.01 0.02 0.02 0.03 0.02 0.03 0.01 0.01 0.02 0.06 0.01 0.03 0.02 0.02 0.02 0.01 0.01 0.03 0.03 0.01 0.03 0.02 0.03 0.02 0.02 0.09 0.13 0.01 0.03 0.02 0.01 0.03 0.02 0.03 0.04 0.03 0.07 0.06 0.08 0.08 0.06 0.06 0.06 0.07 0.07 0.08 0.07 0.04 0.03 0.05 0.04 0.05 0.03 0.05 0.13 0.03 0.13 0.08 0.08 0.05 0.07 0.13 0.06 0.06 0.06 0.04 0.08 0.07 0.07 0.06 0.05 0.05 0.08 0.12 0.07 0.05 0.08 0.05

Cases 490 38 22 26 19 27 3 124 13 4 3 9 16 6 6 47 35 32 0 3 16 7 13 47 86 2570 284 159 1422 371 1543 790 1034 3586 2811 400 1626 432 165 180 304 252 323 505 205 124 114 227 759 1564 739 506 1078 930 334 153 1397 83 183 129 500 189 79 441 166 57 947 126 53 127 353 154 56 56 72 425 209 158 638

Female ASR(W) CUM 0-74 0.4 0.3 0.3 0.8 0.5 0.4 0.2 0.5 0.5 0.3 0.3 0.4 0.5 0.3 0.3 0.6 0.4 0.4 0.2 0.4 0.3 0.4 1.5 1.0 7.8 11.4 12.9 3.5 5.9 8.8 2.4 5.8 8.8 14.1 6.6 7.5 12.1 6.3 9.5 11.5 7.3 8.4 11.8 9.8 5.7 7.5 10.4 7.0 8.0 10.5 7.0 11.5 10.1 7.8 19.0 11.0 10.1 8.2 7.9 10.6 7.4 11.4 9.7 6.3 3.4 10.6 7.1 4.4 6.7 9.3 5.1 3.3 4.7 9.5 11.4 6.2 7.6 10.0 0.02 0.06 0.07 0.16 0.12 0.08 0.15 0.04 0.16 0.18 0.23 0.14 0.12 0.15 0.12 0.08 0.06 0.07 0.13 0.10 0.10 0.12 0.22 0.11 0.17 0.74 1.09 0.10 0.34 0.25 0.09 0.19 0.16 0.29 0.36 0.20 0.61 0.55 0.77 0.72 0.50 0.49 0.57 0.79 0.56 0.81 0.80 0.28 0.23 0.43 0.34 0.38 0.37 0.49 1.57 0.31 1.28 0.69 0.82 0.54 0.68 1.41 0.52 0.54 0.46 0.39 0.73 0.67 0.69 0.57 0.44 0.46 0.69 1.22 0.63 0.51 0.66 0.44 0.05 0.04 0.03 0.08 0.05 0.04 0.03 0.06 0.05 0.03 0.03 0.05 0.06 0.03 0.03 0.06 0.04 0.04 0.04 0.06 0.02 0.06 0.17 0.11 0.79 1.09 1.28 0.38 0.60 0.87 0.24 0.58 0.93 1.43 0.71 0.80 1.21 0.68 0.96 1.16 0.77 0.83 1.19 0.98 0.59 0.77 1.01 0.75 0.83 1.08 0.73 1.17 0.94 0.78 1.71 1.14 1.03 0.79 0.80 1.01 0.71 1.10 0.97 0.64 0.34 1.07 0.71 0.45 0.69 0.87 0.48 0.33 0.45 1.03 1.11 0.60 0.79 1.00 0.00 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.02 0.03 0.02 0.02 0.02 * 0.01 * 0.01 * 0.01 0.01 0.03 0.02 * 0.01 * 0.02 0.03 * 0.01 * 0.02 0.08 0.12 0.01 * 0.03 * 0.02 0.01 * 0.02 0.02 0.03 0.04 0.02 0.06 0.06 0.08 0.08 0.05 0.05 0.06 0.08 0.06 0.08 0.08 0.03 0.02 0.04 0.04 0.04 0.03 0.05 0.15 0.04 0.13 0.07 0.08 0.05 0.06 0.14 0.05 0.06 0.05 0.04 0.07 0.07 0.07 0.05 0.04 0.05 0.07 0.14 0.06 0.05 0.07 0.04

465 42 37 9 18 23 3 123 11 2 10 9 39 6 16 55 34 26 2 6 27 18 13 32 107 2407 278 135 782 289 958 822 1044 3457 2303 222 1664 375 104 120 258 236 261 373 124 110 89 159 721 1497 629 406 1113 726 336 78 860 76 186 99 441 177 63 449 178 59 772 136 39 104 395 148 56 56 36 399 196 141 568

516

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Melanoma of skin (C43) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 238 385 72 2305 137 151 259 259 367 523 642 1006 595 55 152 308 181 31 114 112 239 143 113 129 4232 269 97 104 230 148 110 371 5348 327 285 882 580 988 1570 892 2772 2977 1064 1303 395 1471 8624 127 6504 1658 498 4434 2658 294 15 4284 564 1 7 13 22 483 Male ASR(W) CUM 0-74 3.2 3.7 5.5 14.2 5.7 3.7 4.4 2.6 3.7 3.8 4.0 6.4 9.0 5.0 3.4 4.9 3.9 3.3 5.2 4.3 6.5 6.6 6.4 4.0 11.9 18.5 11.5 18.6 12.8 12.4 11.8 16.6 10.0 9.4 8.9 8.8 6.9 6.8 6.9 9.8 10.7 6.2 6.1 6.9 7.5 8.4 38.5 25.4 55.8 31.0 30.8 27.3 44.5 32.4 3.1 34.8 13.6 0.3 1.0 2.4 2.2 41.1 0.21 0.19 0.67 0.31 0.50 0.31 0.28 0.17 0.20 0.17 0.16 0.20 0.37 0.73 0.30 0.29 0.30 0.72 0.53 0.43 0.43 0.58 0.66 0.39 0.20 1.17 1.22 1.93 0.88 1.07 1.17 0.90 0.14 0.53 0.55 0.31 0.30 0.23 0.18 0.34 0.22 0.12 0.20 0.20 0.39 0.23 0.43 2.44 0.71 0.79 1.44 0.42 0.88 1.93 0.83 0.55 0.60 0.33 0.41 0.68 0.55 1.95 0.35 0.43 0.64 1.58 0.71 0.41 0.51 0.27 0.41 0.42 0.43 0.74 0.98 0.52 0.37 0.52 0.39 0.35 0.51 0.42 0.69 0.72 0.68 0.40 1.34 1.95 1.10 1.95 1.41 1.39 1.13 1.77 1.06 0.98 0.93 0.94 0.72 0.71 0.74 1.08 1.16 0.66 0.64 0.73 0.78 0.88 4.31 2.88 6.14 3.31 3.42 2.98 4.88 3.69 0.36 3.86 1.53 0.03 0.16 0.29 0.24 4.66 0.03 0.02 0.09 0.04 0.07 0.04 0.04 0.02 0.02 0.02 0.02 0.03 0.05 0.08 0.04 0.03 0.03 0.08 0.06 0.04 0.05 0.07 0.07 0.04 0.02 0.14 0.13 0.21 0.11 0.13 0.13 0.11 0.02 0.06 0.06 0.04 0.03 0.03 0.02 0.04 0.03 0.01 0.02 0.02 0.05 0.03 0.06 0.35 0.09 0.10 0.18 0.05 0.11 0.26 0.11 0.07 0.08 0.03 0.07 0.10 0.06 0.26 Cases 464 728 70 2472 166 190 341 412 550 1055 663 1191 686 57 272 447 242 28 142 147 276 149 146 148 4267 293 109 97 247 176 157 448 7164 430 386 1020 831 1364 2153 1212 3267 3802 1345 1608 607 1954 6068 100 4821 1427 518 3977 1927 254 20 4140 356 4 6 10 19 278 Female ASR(W) CUM 0-74 4.2 5.2 5.1 14.6 5.6 4.0 4.6 3.5 4.8 4.8 3.8 6.3 8.7 4.8 5.8 6.6 4.8 2.0 6.6 4.8 7.0 7.5 8.7 4.2 12.1 19.0 13.2 15.4 12.7 14.3 16.5 19.6 12.9 12.9 12.6 9.8 9.4 9.1 8.9 12.6 11.9 7.1 7.5 8.2 10.2 10.1 26.5 21.7 41.1 25.7 32.4 23.4 31.5 26.0 4.7 31.4 8.3 0.9 1.0 1.6 1.4 26.3 0.21 0.21 0.64 0.32 0.46 0.30 0.27 0.19 0.22 0.16 0.16 0.19 0.36 0.72 0.39 0.34 0.32 0.47 0.61 0.43 0.45 0.68 0.83 0.40 0.21 1.20 1.38 1.71 0.88 1.20 1.41 1.01 0.16 0.66 0.69 0.33 0.36 0.27 0.21 0.39 0.24 0.13 0.22 0.22 0.45 0.25 0.36 2.34 0.62 0.74 1.51 0.39 0.75 1.69 1.08 0.51 0.47 0.49 0.41 0.50 0.45 1.68 0.45 0.57 0.53 1.53 0.55 0.44 0.50 0.35 0.51 0.52 0.39 0.66 0.92 0.52 0.61 0.65 0.52 0.25 0.72 0.49 0.69 0.70 0.77 0.41 1.26 1.83 1.29 1.52 1.33 1.33 1.66 1.99 1.27 1.26 1.21 1.03 0.91 0.89 0.87 1.26 1.23 0.73 0.74 0.82 1.02 0.99 2.79 2.16 4.18 2.58 3.33 2.42 3.21 2.76 0.67 3.30 0.87 0.11 0.11 0.15 0.15 2.86 0.02 0.02 0.07 0.04 0.05 * 0.04 0.03 0.02 * 0.02 0.02 0.02 0.02 0.04 0.08 0.04 0.03 0.04 0.06 0.07 0.05 0.05 0.06 0.07 0.04 0.02 0.12 0.14 0.17 0.10 0.11 0.15 0.11 0.02 0.07 0.07 0.04 0.04 0.03 0.02 0.04 0.03 0.01 0.02 0.02 0.05 0.03 0.04 0.30 0.07 0.08 0.16 0.05 0.09 0.21 0.18 0.06 0.05 0.06 0.05 0.06 0.04 0.20

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
459

517

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other skin (C44)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White *Important. See note on population page.
460

Male ASR(W) CUM 0-74 7.7 6.8 13.4 3.9 2.9 18.9 120.1 69.9 198.1 94.8 15.6 0.7 42.5 29.1 16.8 21.9 6.5 1.0 0.6 119.2 1.0 1.5 1.2 0.2 0.9 1.1 0.9 0.7 0.9 0.9 0.8 1.4 0.6 1.2 0.7 1.6 1.2 0.6 0.6 1.0 0.4 0.6 1.5 1.6 1.5 0.4 0.7 1.3 0.6 2.1 1.4 1.0 0.5 1.0 1.1 1.3 0.9 0.9 0.5 0.9 1.0 1.1 0.9 1.2 1.2 1.2 0.7 0.9 0.8 0.8 0.9 1.1 1.0 1.1 0.7 1.2 0.7 0.9 0.64 0.44 1.19 0.72 0.48 1.54 2.72 3.55 3.91 0.82 1.32 0.15 0.78 1.08 1.26 1.61 0.09 0.10 0.06 1.75 0.21 0.28 0.20 0.02 0.42 0.19 0.08 0.16 0.09 0.24 0.07 0.04 0.07 0.14 0.06 0.05 0.08 0.21 0.21 0.33 0.44 0.16 0.11 0.08 0.24 0.19 0.30 0.58 0.09 0.14 0.11 0.10 0.28 0.10 0.26 0.36 0.41 0.04 0.09 0.04 0.07 0.14 0.07 0.13 0.24 0.16 0.13 0.05 0.13 0.05 0.07 0.11 0.09 0.09 0.15 0.11 0.27 0.20 2.30 13.71 8.73 22.24 10.75 1.65 0.07 4.73 3.32 1.79 2.41 0.71 0.09 0.06 13.65 0.10 0.13 0.11 0.02 0.07 0.13 0.09 0.06 0.10 0.11 0.07 0.14 0.07 0.13 0.06 0.16 0.14 0.05 0.08 0.12 0.07 0.07 0.17 0.15 0.16 0.06 0.06 0.10 0.05 0.21 0.15 0.09 0.04 0.09 0.12 0.14 0.09 0.09 0.04 0.09 0.10 0.09 0.09 0.10 0.11 0.10 0.06 0.09 0.07 0.08 0.09 0.12 0.11 0.11 0.06 0.13 0.05 0.10 0.22 0.40 0.55 0.57 0.12 0.19 0.02 0.11 0.16 0.16 0.24 0.01 0.01 0.01 0.25 0.03 0.03 0.02 0.00 0.05 0.03 0.01 0.01 0.01 0.04 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.03 0.05 0.07 0.03 0.02 0.01 0.03 0.03 0.03 0.06 0.01 0.02 0.01 0.01 0.03 0.01 0.03 0.05 0.05 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.03 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.03

Cases 97 128 107 33 86 141 2531 372 3177 21205 169 27 3079 934 253 226 5026 105 117 4594 35 24 34 73 3 41 104 27 76 12 124 1212 67 68 143 849 237 14 13 2 2 20 165 358 32 9 3 4 1 57 221 119 109 8 98 17 10 4 485 59 417 182 53 127 66 28 37 31 359 43 302 155 114 102 127 25 100 6 18

Female ASR(W) CUM 0-74 4.5 2.5 10.5 2.1 4.5 12.4 97.0 51.7 177.1 72.9 15.8 0.6 37.5 27.6 18.4 19.2 4.9 1.0 0.7 88.7 0.9 1.1 0.8 0.2 0.8 0.9 0.6 0.8 0.6 0.7 0.6 1.0 0.5 0.9 0.6 1.1 0.9 1.0 0.6 0.2 0.5 0.6 1.1 1.1 1.0 0.7 0.3 0.4 0.2 0.6 1.4 0.8 0.7 0.9 0.7 0.8 0.7 0.8 0.7 0.8 0.6 0.6 0.8 0.6 0.7 0.9 0.6 0.6 0.7 0.7 0.7 0.6 0.9 0.6 0.7 0.6 0.8 0.5 0.6 0.46 0.23 1.03 0.49 0.68 1.17 2.13 2.86 3.21 0.60 1.26 0.12 0.70 0.96 1.22 1.33 0.08 0.10 0.07 1.48 0.17 0.24 0.16 0.02 0.46 0.16 0.07 0.16 0.07 0.21 0.06 0.03 0.06 0.12 0.06 0.05 0.07 0.27 0.17 0.16 0.37 0.15 0.10 0.06 0.18 0.25 0.17 0.27 0.19 0.09 0.12 0.08 0.08 0.33 0.08 0.20 0.26 0.38 0.04 0.11 0.04 0.05 0.11 0.06 0.09 0.18 0.11 0.13 0.04 0.11 0.05 0.06 0.10 0.07 0.07 0.12 0.09 0.19 0.16 1.36 11.09 6.07 19.41 8.08 1.64 0.06 4.05 3.19 2.02 2.05 0.53 0.09 0.06 9.96 0.07 0.11 0.08 0.02 0.10 0.09 0.06 0.06 0.06 0.07 0.06 0.10 0.04 0.09 0.06 0.11 0.09 0.09 0.04 0.02 0.04 0.05 0.11 0.11 0.10 0.06 0.03 0.02 0.02 0.07 0.14 0.08 0.07 0.08 0.07 0.08 0.06 0.10 0.06 0.08 0.06 0.06 0.07 0.05 0.08 0.09 0.07 0.06 0.07 0.06 0.07 0.06 0.09 0.06 0.08 0.05 0.09 0.04 0.07 * * * *

154 262 133 50 64 164 2474 431 2703 19192 145 26 3175 796 192 196 5590 98 96 5168 24 29 44 82 5 44 146 20 120 15 140 1461 69 78 134 1090 261 8 10 9 1 16 199 438 39 4 5 7 0 50 294 177 125 4 117 20 15 5 643 28 603 235 66 163 92 30 58 31 348 36 291 172 129 142 155 23 129 7 22

0.15 0.32 0.43 0.47 0.09 0.17 0.02 0.10 0.14 0.15 0.20 * 0.01 0.01 0.01 0.20 0.02 0.03 0.02 0.00 0.06 0.02 0.01 0.01 0.01 0.03 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.03 0.02 0.01 0.03 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.03 0.01 0.02 0.02 0.05 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02

Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data 518

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other skin (C44) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 33 252 349 45 289 168 30 132 179 17 158 25 7591 600 6578 343 37 292 67 0 17 49 676 65 597 303 28 254 95 113 497 24 454 57 1072 84 909 3014 121 220 178 2382 123 18 101 506 48 435 93 15 219 168 57 146 23 122 1267 25 15 420 74 543 117 267 20 317 45 100 45 599 551 35 99 93 264 315 473 416 143 Male ASR(W) CUM 0-74 0.8 1.1 1.1 1.3 1.0 1.3 1.2 1.3 0.9 1.2 0.8 0.7 1.0 0.9 1.0 1.2 1.2 1.2 1.1 0.9 1.3 1.1 0.9 1.1 0.8 0.8 0.7 0.8 0.9 1.1 0.8 1.1 1.6 1.2 1.1 1.3 1.3 0.7 1.1 0.6 1.4 0.9 0.6 1.0 0.8 0.8 0.8 1.6 0.7 1.1 1.2 0.9 0.8 4.1 2.2 5.7 1.9 0.7 1.8 2.3 21.9 1.3 1.3 2.3 1.4 1.1 1.6 1.7 3.4 3.5 2.1 2.6 2.2 6.2 3.0 5.9 1.1 2.1 0.14 0.08 0.06 0.20 0.06 0.11 0.23 0.12 0.07 0.30 0.07 0.15 0.01 0.04 0.01 0.07 0.20 0.08 0.14 0.23 0.21 0.04 0.11 0.05 0.05 0.15 0.05 0.08 0.09 0.05 0.16 0.06 0.23 0.04 0.12 0.04 0.02 0.06 0.08 0.05 0.03 0.09 0.14 0.10 0.04 0.12 0.04 0.18 0.20 0.08 0.10 0.12 0.07 0.88 0.21 0.17 0.38 0.19 0.09 0.28 1.02 0.12 0.08 0.53 0.08 0.17 0.16 0.25 0.15 0.16 0.38 0.27 0.25 0.39 0.17 0.29 0.06 0.20 0.08 0.11 0.11 0.14 0.10 0.13 0.15 0.13 0.09 0.14 0.08 0.06 0.10 0.08 0.10 0.13 0.12 0.13 0.10 0.10 0.11 0.11 0.08 0.11 0.08 0.08 0.07 0.08 0.10 0.11 0.08 0.11 0.16 0.12 0.12 0.13 0.13 0.07 0.11 0.06 0.14 0.08 0.05 0.09 0.09 0.08 0.08 0.18 0.10 0.12 0.13 0.09 0.09 0.55 0.22 0.61 0.28 0.06 0.20 0.24 2.42 0.17 0.14 0.31 0.15 0.13 0.16 0.17 0.35 0.35 0.25 0.25 0.23 0.69 0.29 0.60 0.11 0.20 0.02 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.01 0.04 0.01 0.02 0.00 0.00 0.00 0.01 0.02 0.01 0.02 0.03 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.03 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.03 0.01 0.01 0.01 0.01 0.14 0.03 0.02 0.06 0.02 0.01 0.04 0.15 0.02 0.01 0.08 0.01 0.02 0.02 0.03 0.02 0.02 0.06 0.03 0.03 0.06 0.02 0.04 0.01 0.02 Cases 36 249 345 42 284 168 32 126 142 11 128 22 6513 647 5465 272 24 238 61 4 13 44 699 85 600 281 35 234 67 102 402 40 348 55 968 93 791 2537 110 204 179 1926 107 26 80 351 46 291 75 26 235 186 51 142 13 104 1499 13 8 372 62 502 96 162 7 172 31 67 28 634 604 25 123 61 247 327 573 408 140 Female ASR(W) CUM 0-74 0.6 1.0 0.9 0.9 0.9 1.1 0.9 1.1 0.6 0.5 0.6 0.6 0.7 0.8 0.7 0.8 0.6 0.8 1.0 1.0 0.6 1.2 0.9 0.9 0.9 0.6 0.8 0.6 0.5 0.7 0.8 1.0 0.7 1.3 1.0 1.0 1.0 0.9 0.5 0.8 0.6 1.0 0.7 0.7 0.7 0.5 0.6 0.4 1.2 1.1 1.1 1.2 0.7 0.7 2.2 1.6 5.4 0.8 0.3 1.3 1.7 17.1 1.0 1.0 0.8 0.8 0.8 1.1 0.9 3.0 3.2 1.3 2.2 1.1 3.9 2.2 4.3 0.8 1.3 0.11 0.07 0.05 0.14 0.06 0.09 0.17 0.11 0.06 0.16 0.06 0.14 0.01 0.03 0.01 0.05 0.12 0.06 0.13 0.49 0.18 0.21 0.04 0.10 0.04 0.04 0.15 0.04 0.07 0.08 0.04 0.16 0.04 0.21 0.03 0.11 0.04 0.02 0.05 0.06 0.05 0.03 0.07 0.14 0.09 0.03 0.10 0.03 0.15 0.23 0.08 0.10 0.11 0.06 0.64 0.16 0.15 0.24 0.11 0.07 0.22 0.85 0.11 0.08 0.29 0.07 0.14 0.13 0.17 0.13 0.14 0.28 0.22 0.20 0.28 0.14 0.23 0.04 0.15 0.08 0.10 0.09 0.08 0.08 0.11 0.09 0.11 0.06 0.04 0.06 0.06 0.07 0.07 0.07 0.08 0.05 0.08 0.10 0.10 0.06 0.13 0.09 0.08 0.09 0.06 0.07 0.06 0.05 0.08 0.08 0.09 0.07 0.13 0.10 0.10 0.10 0.09 0.04 0.08 0.06 0.10 0.06 0.06 0.06 0.05 0.06 0.04 0.13 0.10 0.10 0.12 0.07 0.06 0.32 0.16 0.53 0.11 0.04 0.13 0.20 1.88 0.11 0.11 0.10 0.09 0.08 0.13 0.11 0.31 0.33 0.13 0.18 0.13 0.36 0.19 0.37 0.08 0.13 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.00 0.00 0.00 0.01 0.01 0.01 0.02 0.06 0.02 0.02 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.02 0.00 0.02 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.02 0.03 0.01 0.01 0.01 0.01 0.10 0.02 * 0.02 0.04 * 0.02 0.01 * 0.03 * 0.12 * 0.01 0.01 * 0.04 0.01 0.02 * 0.02 * 0.03 * 0.02 0.02 0.04 0.03 0.02 0.04 0.02 0.03 0.01 0.02

*Important. See note on population page. Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data Cancer Incidence in Five Continents Vol. IX, IARC 2007

461

519

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other skin (C44) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
462

Male ASR(W) CUM 0-74 2.6 2.4 3.8 2.3 3.1 2.7 2.1 2.4 2.2 1.4 2.8 5.6 4.6 4.2 4.3 3.5 8.8 10.3 1.8 4.4 3.7 3.7 4.9 19.8 12.7 24.2 17.1 13.4 23.3 10.5 33.1 21.0 62.4 64.2 29.0 8.6 0.06 0.20 0.29 0.32 0.38 0.26 0.53 0.13 0.45 0.39 0.66 0.56 0.37 0.51 0.42 0.26 0.33 0.41 0.49 0.73 0.31 0.42 0.43 0.85 0.42 0.28 0.85 1.07 0.29 0.37 0.41 0.25 0.42 0.56 0.81 0.20 0.30 0.28 0.44 0.30 0.35 0.26 0.26 0.24 0.28 0.15 0.40 0.56 0.56 0.56 0.50 0.35 0.92 1.09 0.15 0.53 0.39 0.41 0.58 2.41 1.45 2.62 1.90 1.32 2.62 1.02 3.63 2.47 7.16 7.14 3.25 0.79 0.01 0.03 0.04 0.05 0.05 0.03 0.08 0.02 0.07 0.05 0.11 0.07 0.06 0.08 0.06 0.03 0.05 0.06 0.05 0.10 0.04 0.06 0.06 0.12 0.06 0.04 0.12 0.15 0.04 0.05 0.06 0.04 0.06 0.08 0.11 0.03

Cases 2282 189 230 68 112 155 17 459 47 14 14 92 137 70 84 234 754 706 14 34 145 84 114 450 831 8005 425 165 10604 538 6600 6478 23883 14960 2074 2144

Female ASR(W) CUM 0-74 1.9 1.8 3.4 2.0 3.0 2.5 1.5 1.8 2.6 1.3 1.6 4.1 3.8 4.2 4.1 2.9 7.6 8.3 2.7 3.7 3.4 3.6 3.5 15.4 9.8 16.3 11.7 7.8 20.7 4.6 25.9 14.5 46.3 57.6 27.1 5.3 0.04 0.13 0.22 0.24 0.29 0.20 0.38 0.09 0.40 0.37 0.58 0.43 0.33 0.52 0.48 0.20 0.28 0.32 0.78 0.65 0.29 0.40 0.33 0.74 0.34 0.21 0.65 0.68 0.22 0.23 0.36 0.20 0.33 0.53 0.65 0.13 0.21 0.19 0.34 0.21 0.35 0.26 0.18 0.19 0.31 0.12 0.18 0.43 0.43 0.52 0.49 0.33 0.73 0.81 0.18 0.47 0.36 0.38 0.36 1.83 1.16 1.73 1.20 0.74 2.43 0.44 2.78 1.70 5.19 6.36 3.23 0.44 0.01 0.02 0.03 0.03 0.05 0.03 0.06 0.01 0.06 0.05 0.08 0.06 0.05 0.08 * 0.06 * 0.03 * 0.04 0.05 0.07 0.09 0.04 * 0.05 * 0.04 0.11 * 0.05 * 0.03 0.09 0.10 0.03 * 0.03 * 0.05 0.03 * 0.04 0.07 0.09 0.02

2191 187 193 59 76 137 16 456 28 15 49 102 161 69 116 224 714 658 16 40 146 79 133 563 955 7813 420 161 6844 855 7012 7323 23175 14331 1299 1883

O 766 1807 3721 491 688 4696 2536 101 13904 631 1838 1725 3882 1908 686 2524 1996 344 6187 986 924 1550 3499 1214 1255 915 469 2073 2235 1240 5264 7.5 8.6 49.8 7.4 6.7 43.7 52.2 9.4 111.8 63.5 72.5 82.7 61.6 60.5 69.0 47.4 62.0 22.0 62.7 43.1 69.9 66.7 65.0 34.3 62.9 64.8 61.2 44.7 44.9 58.7 71.7 0.28 0.21 0.84 0.34 0.26 0.65 1.07 0.99 0.98 2.68 1.73 2.16 1.08 1.52 2.94 1.00 1.49 1.20 0.84 1.51 2.46 1.83 1.20 1.03 1.84 2.25 2.90 1.04 1.04 1.71 1.03 0.75 0.80 5.58 0.71 0.64 4.87 5.89 0.86 12.99 7.45 8.32 9.47 7.06 6.82 7.71 5.48 7.13 2.36 7.12 4.76 8.16 7.75 7.38 4.05 7.48 7.84 7.26 5.13 5.11 6.65 8.18 0.04 0.03 0.12 0.04 0.04 0.09 0.15 0.13 0.14 0.37 0.24 0.30 0.15 0.20 0.39 0.14 0.20 0.16 0.12 0.20 0.34 0.25 0.16 0.14 0.26 0.33 0.42 0.14 0.15 0.24 0.14 705 1365 3574 437 462 4202 2310 104 12196 598 1538 1249 2990 1524 567 2217 1540 252 5979 697 465 1142 2559 895 869 408 499 1902 1549 991 4524 3.6 3.1 35.0 3.3 3.0 29.1 34.2 9.1 80.9 45.1 45.2 45.1 40.6 39.0 44.1 31.6 39.4 12.7 45.3 26.2 30.8 41.0 41.0 19.6 37.8 26.3 46.0 32.1 24.6 35.0 46.3 0.16 0.10 0.68 0.18 0.16 0.51 0.82 0.99 0.80 2.30 1.33 1.56 0.89 1.24 2.28 0.80 1.19 0.84 0.70 1.26 1.60 1.48 0.97 0.74 1.41 1.44 2.41 0.87 0.78 1.26 0.81 0.30 0.28 3.98 0.29 0.29 3.27 3.74 1.07 9.22 4.96 4.84 5.02 4.42 4.36 4.72 3.61 4.40 1.38 4.99 2.83 3.53 4.47 4.59 2.15 4.11 3.04 5.04 3.61 2.60 3.91 5.13 0.02 0.01 0.09 0.02 0.02 0.07 0.11 0.14 0.11 0.28 0.16 0.20 0.11 0.15 0.28 0.10 0.15 0.11 0.09 0.15 0.21 0.18 0.12 0.10 0.18 0.19 0.32 0.11 0.10 0.16 0.10

Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data 520

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other skin (C44) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 1417 3226 1009 2602 535 778 840 42 1257 1715 4520 7495 2852 21 59 33 3 1687 2594 2159 2253 1790 1997 6517 2123 264 738 1611 970 3180 10368 645 531 9624 20783 2 33917 6412 14644 9 5886 16153 22 199 309 41 34 1263 71 0 167 67 4 8 7 10 32 Male ASR(W) CUM 0-74 18.1 29.4 72.2 12.5 21.2 17.7 13.0 0.4 9.9 12.1 24.1 46.3 41.0 1.8 1.0 0.7 0.6 64.5 79.7 51.0 88.1 79.4 48.6 12.8 133.3 24.1 102.2 78.3 90.9 126.3 16.3 17.0 14.0 75.9 73.4 0.0 105.3 10.1 68.3 0.1 97.3 77.0 0.1 1.5 5.6 2.1 0.2 19.7 7.5 1.2 1.4 1.0 1.3 1.3 0.6 2.5 0.49 0.52 2.34 0.27 0.93 0.65 0.46 0.07 0.30 0.29 0.37 0.55 0.77 0.43 0.14 0.12 0.41 1.71 1.66 1.15 1.99 2.12 1.17 0.17 2.98 1.58 3.99 2.04 3.02 2.36 0.17 0.69 0.63 0.83 0.54 0.01 0.62 0.13 0.60 0.02 1.32 0.63 0.02 0.11 0.33 0.34 0.03 0.57 0.91 0.10 0.19 0.55 0.47 0.50 0.22 0.47 2.09 3.37 8.12 1.25 2.37 2.07 1.45 0.05 1.05 1.42 2.88 5.40 4.75 0.17 0.08 0.07 0.04 7.23 9.56 5.80 9.95 8.79 5.44 1.20 15.17 2.42 11.98 8.87 10.87 14.58 1.66 1.63 1.43 8.49 8.22 0.00 11.87 0.98 7.66 0.00 11.01 8.65 0.01 0.13 0.58 0.25 0.02 2.09 0.74 0.12 0.15 0.08 0.16 0.10 0.06 0.26 0.07 0.07 0.33 0.04 0.13 0.09 0.06 0.01 0.04 0.04 0.05 0.08 0.11 0.05 0.01 0.02 0.03 0.24 0.23 0.15 0.27 0.29 0.16 0.03 0.43 0.24 0.58 0.29 0.43 0.34 0.02 0.09 0.09 0.11 0.07 0.00 0.09 0.02 0.08 0.00 0.19 0.09 0.00 0.01 0.04 0.05 0.00 0.08 0.12 0.01 0.02 0.06 0.06 0.06 0.03 0.07 Cases 2193 5494 653 2128 653 837 918 74 1177 3397 3951 8083 3144 14 62 45 7 1376 2008 1705 1930 1529 1441 4870 2292 260 767 1471 978 3329 7079 394 357 7911 19689 1 28668 4323 12311 5 5297 15547 13 140 207 45 19 672 38 1 148 43 4 3 4 9 15 Female ASR(W) CUM 0-74 15.5 31.3 39.4 7.1 16.8 12.7 9.5 0.6 6.0 12.2 17.6 35.2 29.8 1.6 0.9 0.8 0.7 45.2 52.1 31.5 67.5 61.8 30.2 7.0 113.0 14.6 80.3 56.2 73.8 105.2 7.8 7.7 7.1 52.1 53.7 0.0 72.9 4.4 46.6 0.0 64.7 54.2 0.0 1.0 2.8 1.9 0.1 8.9 3.8 0.2 0.8 1.0 0.9 0.5 0.6 0.4 1.5 0.36 0.46 1.63 0.19 0.70 0.48 0.34 0.07 0.20 0.23 0.30 0.42 0.58 0.46 0.13 0.13 0.36 1.43 1.31 0.85 1.79 1.90 0.93 0.13 2.60 1.10 3.39 1.67 2.61 2.07 0.11 0.42 0.42 0.68 0.44 0.01 0.51 0.08 0.48 0.02 1.00 0.50 0.01 0.09 0.23 0.31 0.02 0.37 0.65 0.23 0.08 0.16 0.50 0.30 0.32 0.18 0.42 1.86 3.67 4.51 0.69 1.93 1.37 1.10 0.06 0.53 1.43 2.04 4.07 3.31 0.17 0.08 0.09 0.05 4.87 5.84 3.47 7.34 7.08 3.26 0.69 12.89 1.24 8.80 6.38 8.31 11.70 0.78 0.75 0.75 5.80 5.94 0.00 8.08 0.41 5.16 0.00 7.16 5.91 0.01 0.10 0.29 0.19 0.01 0.91 0.47 0.08 0.09 0.11 0.06 0.06 0.04 0.14 0.05 0.06 0.22 0.03 0.10 * 0.06 0.05 0.01 * 0.03 0.03 0.04 0.06 0.08 0.05 0.01 0.02 0.03 0.18 0.17 0.11 0.22 0.25 0.11 0.02 0.35 0.15 0.44 0.23 0.35 0.27 0.01 0.06 0.06 0.09 0.06 0.00 0.07 0.01 0.06 0.00 0.14 0.07 0.00 0.01 0.03 0.04 0.00 0.05 0.10 0.01 0.02 0.06 0.03 0.03 0.02 0.05

*Important. See note on population page. Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data Cancer Incidence in Five Continents Vol. IX, IARC 2007

463

521

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Mesothelioma (C45)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 2 18 1 0 4 10 5 0 0 38 2 10 3 4 2 6 1045 149 263 53 31 9 0 51 438 4 47 158 17 141 22 194 1228 32 50 181 960 253 16 3 8 2 25 195 275 21 2 2 1 2 70 176 129 173 2 170 15 8 7 880 22 853 148 8 140 34 2 32 50 584 21 561 242 86 134 210 30 179 12 60 Male ASR(W) CUM 0-74 0.1 0.4 0.1 0.2 1.2 0.2 0.2 0.2 0.3 0.0 0.1 0.2 0.6 1.3 1.6 1.6 1.3 1.1 0.5 1.5 1.1 0.8 1.2 1.0 0.6 1.1 1.7 1.0 1.1 0.3 0.8 1.2 1.2 1.1 1.1 0.2 0.9 0.5 1.1 1.3 1.0 0.8 0.1 0.2 0.1 0.4 1.2 1.1 1.0 1.3 0.3 1.3 0.9 0.9 1.0 1.1 0.4 1.1 0.6 0.2 0.8 0.5 0.1 0.7 1.0 1.4 0.5 1.5 1.1 0.8 0.9 1.4 0.9 1.6 1.3 2.7 0.07 0.09 0.11 0.11 0.40 0.09 0.03 0.12 0.09 0.03 0.08 0.13 0.25 0.04 0.14 0.11 0.19 0.21 0.17 0.21 0.05 0.43 0.19 0.08 0.14 0.10 0.37 0.07 0.03 0.05 0.12 0.09 0.04 0.07 0.28 0.10 0.34 0.38 0.23 0.10 0.06 0.17 0.06 0.15 0.08 0.27 0.14 0.09 0.09 0.10 0.22 0.11 0.24 0.31 0.40 0.04 0.09 0.04 0.05 0.07 0.07 0.09 0.10 0.12 0.15 0.06 0.11 0.07 0.08 0.09 0.08 0.10 0.17 0.12 0.38 0.37 0.12 0.02 0.02 0.01 0.03 0.01 0.02 0.03 0.03 0.17 0.22 0.20 0.16 0.16 0.06 0.22 0.15 0.12 0.16 0.12 0.05 0.14 0.21 0.11 0.13 0.03 0.07 0.14 0.15 0.13 0.10 0.01 0.12 0.04 0.10 0.16 0.11 0.08 0.03 0.05 0.14 0.13 0.11 0.15 0.03 0.16 0.11 0.11 0.12 0.13 0.06 0.14 0.08 0.02 0.09 0.07 0.01 0.09 0.09 0.17 0.05 0.19 0.13 0.10 0.12 0.17 0.14 0.18 0.23 0.30 0.05 0.01 0.00 0.01 0.01 0.00 0.01 0.02 0.02 0.01 0.02 0.02 0.03 0.03 0.03 0.04 0.01 0.07 0.03 0.01 0.02 0.01 0.06 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.04 0.01 0.05 0.04 0.03 0.02 0.01 0.02 0.03 0.03 0.02 0.01 0.01 0.02 0.03 0.02 0.03 0.04 0.06 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.03 0.02 0.08 0.05 Cases 0 13 0 0 0 7 3 0 2 39 2 6 5 1 1 9 235 31 47 18 6 4 2 8 105 1 13 31 1 30 3 46 348 15 14 53 260 80 5 1 4 0 10 57 86 7 1 0 3 1 21 53 34 47 2 45 2 2 0 242 12 228 57 10 47 16 2 14 15 181 10 170 57 33 49 58 12 46 8 26 Female ASR(W) CUM 0-74 0.3 0.7 0.1 0.1 0.1 0.2 0.1 0.1 0.0 0.1 0.8 0.3 0.3 0.3 0.4 0.2 0.2 2.9 0.2 0.2 0.2 0.3 0.1 0.0 0.2 0.1 0.2 0.3 0.1 0.2 0.3 0.3 0.3 0.3 0.1 0.4 0.3 0.3 0.3 0.2 0.1 0.4 0.2 0.3 0.3 0.2 0.3 0.3 0.3 0.2 0.2 0.3 0.2 0.3 0.2 0.1 0.2 0.2 0.1 0.2 0.3 0.3 0.1 0.4 0.2 0.2 0.3 0.3 0.3 0.4 0.6 1.0 0.07 0.28 0.08 0.08 0.02 0.13 0.06 0.03 0.02 0.06 0.28 0.02 0.06 0.04 0.11 0.09 0.10 2.12 0.08 0.02 0.22 0.10 0.03 0.01 0.04 0.08 0.03 0.02 0.03 0.05 0.04 0.02 0.04 0.14 0.08 0.20 0.11 0.05 0.03 0.09 0.07 0.27 0.18 0.06 0.05 0.04 0.05 0.19 0.05 0.13 0.18 0.02 0.05 0.02 0.03 0.05 0.03 0.04 0.07 0.06 0.09 0.03 0.05 0.03 0.03 0.05 0.04 0.05 0.08 0.06 0.20 0.22 0.07 0.02 0.01 0.02 0.02 0.02 0.01 0.02 0.11 0.03 0.03 0.03 0.05 0.02 0.02 0.57 0.02 0.03 0.02 0.03 0.02 0.02 0.01 0.03 0.03 0.01 0.02 0.03 0.04 0.04 0.02 0.01 0.04 0.05 0.05 0.03 0.04 0.01 0.03 0.03 0.03 0.03 0.03 0.04 0.04 0.04 0.01 0.02 0.03 0.03 0.03 0.02 0.02 0.02 0.02 0.01 0.02 0.05 0.04 0.02 0.04 0.02 0.02 0.03 0.04 0.03 0.05 0.05 0.13 * * * *

0.03 0.02 0.01 0.00 0.02 0.01 0.00 0.02 0.05 * 0.00 0.01 0.01 0.01 0.01 0.02 0.48 0.01 0.00 0.02 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.02 0.01 0.02 0.02 0.01 0.00 0.01 0.01 0.03 0.03 0.01 0.01 0.01 0.01 0.03 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.03

522

*Important. See note on population page.

464

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Mesothelioma (C45) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 96 392 429 18 406 155 15 138 186 6 180 51 9676 385 9164 558 25 527 73 3 26 43 805 44 754 502 19 476 109 194 783 38 734 62 1068 37 979 3001 65 129 242 2547 129 15 114 607 27 577 66 21 350 245 119 292 2 10 38 1 0 13 11 11 10 3 0 11 0 0 3 128 116 9 5 12 35 40 39 340 15 Male ASR(W) CUM 0-74 1.8 1.6 1.2 0.5 1.3 1.1 0.6 1.3 0.9 0.4 0.9 1.4 1.2 0.6 1.3 1.7 0.9 1.8 1.1 0.9 1.4 1.0 1.2 0.6 1.3 1.2 0.5 1.2 0.9 1.5 1.5 1.1 1.5 1.5 1.1 0.6 1.3 1.2 0.4 0.7 1.2 1.3 0.9 0.5 1.0 1.0 0.5 1.0 1.1 0.9 1.6 1.7 1.6 1.5 0.4 0.2 0.2 0.1 0.1 0.4 0.4 0.1 0.0 0.0 0.1 0.8 0.8 0.6 0.1 0.3 0.8 0.4 0.6 0.9 0.2 0.20 0.09 0.06 0.13 0.07 0.10 0.16 0.12 0.07 0.18 0.07 0.21 0.01 0.03 0.01 0.08 0.18 0.09 0.14 0.51 0.28 0.16 0.04 0.10 0.05 0.06 0.13 0.06 0.09 0.11 0.06 0.19 0.06 0.21 0.04 0.09 0.04 0.02 0.05 0.06 0.08 0.03 0.08 0.15 0.10 0.04 0.10 0.04 0.14 0.21 0.09 0.12 0.15 0.09 0.28 0.07 0.03 0.08 0.02 0.11 0.14 0.04 0.01 0.01 0.06 0.07 0.08 0.22 0.05 0.09 0.14 0.06 0.09 0.05 0.06 0.21 0.19 0.15 0.08 0.16 0.14 0.10 0.15 0.11 0.05 0.12 0.17 0.14 0.07 0.15 0.20 0.13 0.21 0.13 0.06 0.18 0.11 0.13 0.07 0.15 0.14 0.06 0.15 0.10 0.17 0.17 0.12 0.17 0.19 0.13 0.07 0.15 0.14 0.04 0.09 0.14 0.15 0.13 0.07 0.14 0.12 0.06 0.13 0.14 0.08 0.19 0.19 0.20 0.19 0.07 0.02 0.02 0.01 0.01 0.04 0.05 0.01 0.00 0.01 0.01 0.10 0.11 0.08 0.02 0.02 0.10 0.05 0.08 0.11 0.03 0.03 0.01 0.01 0.02 0.01 0.02 0.03 0.02 0.01 0.03 0.01 0.03 0.00 0.00 0.00 0.01 0.03 0.01 0.02 0.06 0.05 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.03 0.01 0.03 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.02 0.01 0.01 0.01 0.02 0.02 0.01 0.02 0.02 0.01 0.05 0.01 0.00 0.01 0.00 0.01 0.02 0.01 0.00 0.00 0.01 0.01 0.01 0.04 0.01 0.01 0.02 0.01 0.01 0.01 0.01 Cases 30 81 134 8 123 52 4 47 58 1 56 17 2618 138 2425 148 4 139 13 0 5 8 218 14 201 130 4 123 31 38 191 12 175 18 272 12 250 826 23 40 74 679 35 6 29 157 14 142 14 11 70 42 30 87 0 24 20 0 0 5 7 7 1 2 0 5 0 0 3 49 43 4 1 6 5 14 16 102 2 Female ASR(W) CUM 0-74 0.4 0.3 0.3 0.2 0.3 0.3 0.1 0.3 0.2 0.0 0.2 0.3 0.3 0.2 0.3 0.3 0.1 0.4 0.2 0.2 0.2 0.3 0.1 0.3 0.2 0.1 0.2 0.2 0.3 0.3 0.2 0.3 0.3 0.2 0.1 0.3 0.3 0.1 0.2 0.3 0.3 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.5 0.2 0.2 0.2 0.3 0.4 0.1 0.0 0.2 0.3 0.0 0.0 0.0 0.1 0.3 0.3 0.2 0.0 0.1 0.1 0.1 0.2 0.2 0.0 0.09 0.03 0.03 0.06 0.03 0.04 0.05 0.05 0.03 0.02 0.03 0.09 0.01 0.01 0.01 0.03 0.05 0.04 0.06 0.10 0.08 0.02 0.04 0.02 0.02 0.04 0.02 0.04 0.05 0.02 0.07 0.02 0.08 0.02 0.04 0.02 0.01 0.02 0.03 0.03 0.01 0.04 0.05 0.04 0.02 0.05 0.02 0.07 0.16 0.03 0.04 0.05 0.04 0.09 0.02 0.01 0.08 0.10 0.01 0.01 0.01 0.06 0.04 0.04 0.12 0.02 0.04 0.06 0.03 0.04 0.02 0.03 0.04 0.03 0.04 0.02 0.04 0.03 0.01 0.03 0.02 0.03 0.03 0.03 0.02 0.03 0.04 0.02 0.04 0.02 0.02 0.03 0.03 0.02 0.04 0.03 0.01 0.03 0.02 0.03 0.03 0.03 0.03 0.04 0.03 0.01 0.03 0.03 0.01 0.02 0.03 0.03 0.03 0.01 0.03 0.03 0.02 0.03 0.03 0.05 0.02 0.02 0.02 0.04 0.05 0.01 0.00 0.03 0.03 0.00 0.00 0.00 0.01 0.03 0.03 0.03 0.01 0.01 0.01 0.02 0.02 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.02 0.00 0.01 0.01 0.01 0.01 * 0.00 - * 0.00 * 0.01 * 0.02 * 0.00 0.00 * 0.00 - * - * 0.01 * 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.00 0.00

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
465

523

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Mesothelioma (C45) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
466

Male ASR(W) CUM 0-74 0.1 0.2 0.1 0.4 0.1 0.2 0.1 0.2 0.3 0.4 0.7 0.1 0.3 0.1 0.1 0.3 0.4 0.1 0.4 1.1 0.7 0.8 0.6 1.5 0.6 2.3 2.0 0.2 1.4 0.5 1.7 0.4 1.3 1.0 1.3 0.5 0.6 1.0 2.0 2.5 2.1 1.3 0.8 0.8 0.7 0.7 3.6 0.6 1.3 2.3 1.6 1.0 0.6 1.0 1.8 2.3 1.1 5.8 0.6 1.6 0.9 1.9 3.0 1.3 0.7 2.1 1.3 0.7 0.8 2.7 2.8 1.7 0.8 2.2 1.8 0.01 0.05 0.05 0.15 0.07 0.07 0.13 0.03 0.17 0.23 0.41 0.06 0.13 0.07 0.04 0.07 0.08 0.08 0.22 0.19 0.10 0.05 0.17 0.37 0.04 0.18 0.10 0.03 0.09 0.04 0.09 0.10 0.08 0.17 0.23 0.17 0.16 0.17 0.23 0.25 0.35 0.26 0.23 0.19 0.09 0.06 0.23 0.10 0.12 0.15 0.18 0.34 0.08 0.37 0.28 0.38 0.15 0.47 0.25 0.18 0.19 0.36 0.18 0.27 0.27 0.34 0.19 0.15 0.21 0.48 0.64 0.20 0.15 0.33 0.16 0.02 0.03 0.02 0.04 0.01 0.02 0.02 0.02 0.02 0.02 0.05 0.01 0.04 0.01 0.01 0.05 0.05 0.06 0.15 0.09 0.09 0.08 0.23 0.07 0.29 0.25 0.02 0.17 0.06 0.22 0.05 0.16 0.12 0.18 0.07 0.07 0.12 0.27 0.33 0.24 0.19 0.09 0.10 0.08 0.07 0.44 0.08 0.16 0.31 0.20 0.15 0.08 0.14 0.22 0.26 0.13 0.74 0.08 0.20 0.10 0.19 0.38 0.18 0.06 0.26 0.15 0.08 0.10 0.36 0.41 0.21 0.10 0.27 0.23 0.00 0.01 0.01 0.02 0.01 0.01 0.02 0.00 0.02 0.02 0.03 0.01 0.02 0.01 0.01 0.01 0.01 0.03 0.03 0.01 0.01 0.02 0.06 0.01 0.03 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.04 0.03 0.02 0.02 0.04 0.04 0.04 0.04 0.03 0.03 0.01 0.01 0.03 0.01 0.02 0.02 0.03 0.06 0.01 0.05 0.04 0.05 0.02 0.07 0.04 0.03 0.02 0.04 0.03 0.04 0.03 0.05 0.02 0.02 0.03 0.07 0.10 0.03 0.02 0.05 0.02

Cases 71 12 3 2 0 3 0 16 0 2 4 0 0 1 0 3 9 9 0 0 0 0 0 26 29 128 6 7 97 23 88 56 56 136 76 11 79 5 19 6 1 8 22 15 4 12 7 6 59 100 83 29 47 51 7 2 17 7 38 13 21 44 1 69 13 20 71 13 4 11 25 4 5 5 12 62 14 15 44

Female ASR(W) CUM 0-74 0.1 0.1 0.0 0.1 0.0 0.1 0.2 0.4 0.1 0.0 0.1 0.1 0.8 0.3 0.3 0.2 0.6 0.2 0.3 0.4 0.2 0.3 0.3 0.3 0.2 0.3 0.1 0.6 0.2 0.0 0.2 0.4 0.3 0.2 0.6 0.4 0.1 0.4 0.4 0.7 0.3 0.4 0.3 0.1 0.2 0.2 0.6 1.2 0.6 0.3 1.0 0.0 0.9 0.3 1.0 0.5 0.7 0.4 0.5 0.5 0.1 0.3 0.4 1.0 1.0 0.4 0.6 0.4 0.01 0.03 0.02 0.04 0.03 0.02 0.15 0.31 0.06 0.02 0.03 0.03 0.17 0.06 0.03 0.08 0.23 0.02 0.07 0.05 0.03 0.04 0.03 0.04 0.06 0.03 0.06 0.16 0.10 0.02 0.07 0.09 0.07 0.12 0.17 0.16 0.06 0.08 0.05 0.08 0.06 0.06 0.05 0.06 0.15 0.04 0.25 0.22 0.20 0.07 0.18 0.03 0.13 0.10 0.23 0.07 0.19 0.21 0.16 0.11 0.05 0.13 0.18 0.31 0.15 0.11 0.17 0.07 0.01 0.01 0.00 0.01 0.01 0.01 0.04 0.09 0.00 0.00 0.01 0.01 0.11 0.04 0.04 0.03 0.05 0.03 0.03 0.05 0.02 0.03 0.04 0.04 0.02 0.04 0.02 0.08 0.03 0.01 0.02 0.05 0.04 0.03 0.08 0.04 0.02 0.04 0.04 0.08 0.03 0.05 0.04 0.01 0.04 0.02 0.07 0.12 0.05 0.04 0.15 0.10 0.04 0.11 0.07 0.09 0.05 0.06 0.06 0.01 0.04 0.04 0.12 0.13 0.04 0.07 0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.08 0.01 * - * 0.00 * 0.00 0.00 - * - * 0.02 * 0.01 * 0.00 0.01 0.02 0.00 * 0.01 * 0.01 0.00 * 0.00 0.00 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.03 0.03 0.02 0.01 0.03 0.02 0.01 0.03 0.01 0.03 0.02 0.02 0.01 0.01 0.02 0.02 0.05 0.02 0.01 0.02 0.01

129 15 6 9 2 11 1 34 3 4 10 1 0 5 4 5 28 23 1 4 0 0 0 35 57 225 14 17 165 164 403 54 225 176 368 18 257 37 33 10 16 39 84 107 41 25 15 24 74 132 263 42 128 241 77 9 72 8 44 41 58 169 7 87 27 29 291 25 8 44 63 26 15 33 19 78 36 44 125

524

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Mesothelioma (C45) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 57 34 24 286 11 21 22 24 37 69 44 77 81 4 41 57 8 2 13 21 26 27 10 22 530 23 16 13 47 16 20 26 1654 78 139 382 396 530 1188 292 1185 1813 585 528 239 766 712 0 414 212 34 450 295 21 3 285 37 5 1 4 11 15 Male ASR(W) CUM 0-74 0.8 0.3 1.7 1.5 0.5 0.5 0.4 0.2 0.3 0.5 0.3 0.5 1.2 0.3 0.9 0.8 0.2 0.2 0.5 0.7 0.7 1.1 0.5 0.7 1.3 1.7 1.7 2.0 2.6 1.2 1.8 1.3 2.8 2.1 3.8 3.1 3.8 3.1 4.2 2.8 3.8 3.4 2.8 2.4 4.0 3.6 2.9 3.3 3.6 1.9 2.5 4.7 2.5 0.6 2.1 0.7 0.7 0.1 0.9 0.6 1.2 0.10 0.06 0.36 0.10 0.14 0.11 0.08 0.05 0.06 0.06 0.04 0.06 0.13 0.19 0.16 0.11 0.06 0.18 0.15 0.17 0.14 0.22 0.17 0.15 0.06 0.37 0.46 0.58 0.39 0.31 0.42 0.25 0.07 0.24 0.33 0.17 0.20 0.14 0.13 0.17 0.12 0.08 0.12 0.11 0.27 0.14 0.11 0.17 0.26 0.33 0.12 0.28 0.56 0.39 0.13 0.13 0.32 0.08 0.44 0.21 0.32 0.10 0.04 0.21 0.19 0.05 0.06 0.05 0.03 0.04 0.06 0.03 0.06 0.14 0.03 0.09 0.09 0.02 0.04 0.07 0.10 0.10 0.14 0.07 0.07 0.16 0.18 0.20 0.22 0.38 0.14 0.22 0.17 0.36 0.26 0.53 0.40 0.47 0.41 0.54 0.35 0.47 0.43 0.36 0.31 0.52 0.44 0.36 0.38 0.46 0.28 0.30 0.57 0.39 0.11 0.27 0.08 0.06 0.16 0.08 0.11 0.01 0.01 0.05 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.01 0.01 0.03 0.02 0.02 0.02 0.03 0.02 0.02 0.01 0.04 0.07 0.07 0.06 0.04 0.06 0.03 0.01 0.04 0.05 0.03 0.03 0.02 0.02 0.03 0.02 0.01 0.02 0.02 0.04 0.02 0.02 0.02 0.04 0.05 0.02 0.04 0.10 0.08 0.02 0.02 0.06 0.09 0.04 0.04 Cases 42 39 4 52 13 8 22 14 18 60 20 42 46 1 18 15 7 0 7 5 6 23 6 11 127 2 5 2 6 6 4 5 259 16 10 81 68 120 229 64 192 402 104 99 27 116 157 0 84 40 7 97 45 1 1 52 5 0 1 0 3 0 Female ASR(W) CUM 0-74 0.4 0.3 0.3 0.3 0.4 0.1 0.2 0.1 0.2 0.2 0.1 0.2 0.5 0.1 0.4 0.2 0.2 0.3 0.1 0.1 1.0 0.2 0.2 0.3 0.1 0.4 0.3 0.2 0.3 0.3 0.1 0.4 0.4 0.3 0.6 0.5 0.5 0.6 0.6 0.5 0.6 0.4 0.4 0.4 0.4 0.5 0.6 0.6 0.4 0.5 0.6 0.1 0.3 0.3 0.1 0.1 0.1 0.07 0.04 0.14 0.04 0.13 0.05 0.05 0.03 0.04 0.03 0.03 0.03 0.08 0.13 0.10 0.06 0.06 0.12 0.06 0.06 0.22 0.07 0.07 0.03 0.09 0.21 0.23 0.10 0.15 0.17 0.05 0.02 0.10 0.09 0.07 0.07 0.05 0.05 0.08 0.04 0.03 0.05 0.04 0.08 0.04 0.05 0.07 0.11 0.15 0.05 0.10 0.11 0.28 0.05 0.04 0.12 0.08 0.04 0.03 0.02 0.04 0.04 0.01 0.04 0.02 0.02 0.03 0.01 0.02 0.06 0.01 0.04 0.03 0.02 0.02 0.01 0.01 0.11 0.02 0.03 0.03 0.02 0.08 0.04 0.02 0.06 0.06 0.01 0.05 0.05 0.03 0.06 0.07 0.06 0.08 0.08 0.06 0.07 0.06 0.05 0.05 0.05 0.06 0.07 0.07 0.05 0.06 0.08 0.01 0.07 0.03 0.01 0.03 0.01 0.01 0.01 0.01 0.01 0.01 * 0.01 0.01 0.00 * 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.01 0.00 0.01 0.04 0.03 0.01 0.03 0.03 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.01 0.07 0.01 0.01 0.03 0.01 -

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
467

525

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Kaposi sarcoma (C46)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 3 9 5 802 1822 4 24 4 19 452 2 113 60 7 13 7 214 24 76 10 8 4 0 6 80 1 5 36 8 27 5 72 1477 48 209 412 717 382 64 3 8 0 54 229 610 102 5 8 2 0 225 228 93 67 14 50 85 60 16 587 135 447 288 154 125 237 137 91 4 212 93 108 61 18 36 118 46 70 21 24 Male ASR(W) CUM 0-74 0.1 0.2 0.5 33.0 52.2 0.5 0.8 0.3 1.0 1.6 0.2 2.5 0.6 0.2 1.2 0.7 0.3 0.2 0.5 0.3 0.3 0.2 0.1 0.2 0.2 0.1 0.2 0.3 0.2 0.2 0.5 1.4 0.4 2.9 1.5 1.2 1.7 4.1 0.2 0.8 1.4 1.9 2.1 3.7 0.5 1.0 0.5 2.0 2.0 0.6 0.6 1.5 0.5 4.6 6.2 2.3 1.2 2.0 1.0 1.1 2.3 0.7 2.4 4.3 1.5 0.1 0.5 1.9 0.3 0.3 0.2 0.3 0.9 1.3 0.7 2.0 1.5 0.08 0.08 0.24 1.56 1.46 0.27 0.18 0.16 0.25 0.09 0.12 0.24 0.08 0.07 0.33 0.28 0.02 0.05 0.06 0.10 0.09 0.11 0.06 0.02 0.22 0.06 0.04 0.10 0.05 0.10 0.06 0.04 0.05 0.20 0.08 0.05 0.09 0.52 0.12 0.27 0.21 0.13 0.09 0.37 0.23 0.36 0.37 0.14 0.14 0.07 0.07 0.39 0.07 0.51 0.80 0.58 0.05 0.18 0.05 0.07 0.19 0.06 0.16 0.39 0.16 0.05 0.04 0.19 0.03 0.04 0.05 0.05 0.08 0.19 0.09 0.44 0.30 0.07 0.09 0.03 0.09 0.14 0.21 0.04 0.01 0.12 0.10 0.03 0.03 0.05 0.03 0.02 0.04 0.01 0.02 0.02 0.01 0.02 0.02 0.02 0.02 0.04 0.12 0.03 0.25 0.15 0.11 0.16 0.36 0.02 0.06 0.16 0.17 0.19 0.32 0.07 0.08 0.04 0.18 0.18 0.06 0.05 0.13 0.05 0.40 0.51 0.22 0.10 0.18 0.09 0.09 0.19 0.06 0.20 0.36 0.13 0.01 0.05 0.16 0.03 0.03 0.02 0.02 0.07 0.09 0.06 0.17 0.12 0.04 0.03 0.01 0.03 0.01 0.02 0.01 0.00 0.04 0.05 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.00 0.02 0.01 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.02 0.01 0.00 0.01 0.05 0.01 0.02 0.03 0.01 0.01 0.03 0.03 0.03 0.03 0.02 0.01 0.01 0.01 0.03 0.01 0.05 0.07 0.07 0.00 0.02 0.00 0.01 0.02 0.01 0.02 0.04 0.02 0.01 0.00 0.02 0.00 0.00 0.00 0.00 0.01 0.02 0.01 0.04 0.03 Cases 1 1 5 641 909 1 7 2 3 74 1 9 10 4 2 4 32 6 12 2 1 3 0 2 6 0 0 8 3 3 2 7 111 4 10 25 62 27 4 0 0 0 5 14 38 4 0 1 0 0 11 17 4 24 2 22 6 6 0 103 43 60 14 9 4 8 6 2 1 33 9 23 13 2 9 32 8 24 1 8 Female ASR(W) CUM 0-74 0.1 0.0 0.5 21.5 25.2 0.0 0.2 0.3 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.3 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.3 0.5 0.1 0.6 0.1 0.0 0.1 0.0 0.1 0.2 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.2 0.06 0.02 0.22 1.14 1.04 0.03 0.08 0.20 0.09 0.03 0.12 0.05 0.04 0.05 0.04 0.12 0.01 0.03 0.03 0.02 0.01 0.04 0.01 0.00 0.01 0.04 0.01 0.06 0.01 0.01 0.01 0.04 0.02 0.01 0.02 0.14 0.08 0.02 0.02 0.07 0.10 0.03 0.02 0.01 0.03 0.13 0.03 0.12 0.19 0.02 0.09 0.01 0.01 0.04 0.01 0.03 0.07 0.03 0.03 0.01 0.06 0.01 0.02 0.01 0.02 0.02 0.05 0.03 0.04 0.07 0.02 0.04 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.02 0.01 0.03 0.04 0.01 0.06 0.01 0.00 0.01 0.00 0.01 0.02 0.00 0.00 0.01 0.02 0.01 0.00 0.00 0.01 0.01 0.00 0.00 * * * *

0.01 0.03 0.01 0.00 0.01 0.00 0.00 0.01 0.01 * 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.02 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00

526

*Important. See note on population page.

468

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Kaposi sarcoma (C46) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 5 146 145 56 83 105 47 56 63 13 48 7 5568 1446 3787 258 86 161 37 3 19 13 831 300 515 99 20 71 30 44 215 85 122 27 946 275 597 2509 68 561 505 1243 31 24 6 435 68 361 10 4 137 114 18 34 1 0 7 0 0 0 0 11 0 1 0 3 0 0 0 517 487 17 2 0 0 1 0 0 0 Male ASR(W) CUM 0-74 0.1 0.7 0.5 1.5 0.3 0.8 1.8 0.5 0.3 0.7 0.3 0.3 0.8 1.9 0.6 0.9 2.4 0.6 0.7 0.7 0.9 0.5 1.4 3.8 1.0 0.3 0.6 0.2 0.3 0.4 0.5 2.5 0.3 0.7 1.1 3.0 0.9 1.1 0.3 2.4 1.4 0.8 0.3 0.8 0.1 0.7 0.9 0.7 0.2 0.2 0.7 0.8 0.3 0.2 0.2 0.0 0.5 0.0 0.0 2.8 2.9 1.2 0.1 0.0 0.06 0.06 0.04 0.20 0.03 0.08 0.26 0.07 0.04 0.21 0.04 0.11 0.01 0.05 0.01 0.06 0.27 0.05 0.11 0.43 0.22 0.14 0.05 0.22 0.05 0.03 0.13 0.03 0.05 0.06 0.04 0.27 0.03 0.15 0.04 0.18 0.04 0.02 0.04 0.10 0.07 0.02 0.05 0.16 0.03 0.03 0.11 0.04 0.05 0.09 0.06 0.08 0.06 0.03 0.22 0.01 0.14 0.00 0.00 0.13 0.14 0.30 0.04 0.01 0.01 0.06 0.04 0.12 0.02 0.07 0.14 0.04 0.03 0.06 0.02 0.02 0.07 0.16 0.05 0.08 0.22 0.06 0.06 0.05 0.10 0.04 0.12 0.33 0.09 0.02 0.05 0.02 0.03 0.04 0.04 0.20 0.03 0.06 0.10 0.25 0.08 0.09 0.03 0.20 0.14 0.07 0.02 0.06 0.00 0.06 0.07 0.06 0.01 0.01 0.06 0.07 0.02 0.02 0.04 0.00 0.04 0.00 0.00 0.31 0.32 0.17 0.01 0.00 0.01 0.01 0.00 0.02 0.00 0.01 0.02 0.01 0.00 0.02 0.00 0.01 0.00 0.00 0.00 0.01 0.03 0.01 0.01 0.04 0.03 0.01 0.00 0.02 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.02 0.00 0.01 0.00 0.02 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.02 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.04 0.00 0.02 0.00 0.00 0.02 0.02 0.05 0.01 0.00 Cases 1 24 27 4 20 17 4 12 11 1 10 1 767 187 537 49 9 39 7 0 5 2 164 57 105 14 0 13 7 4 30 4 25 7 94 19 69 270 6 43 42 168 1 0 1 71 9 60 3 1 7 5 3 8 1 0 1 0 0 0 0 7 0 2 0 0 0 0 0 229 212 6 2 0 0 0 2 0 0 Female ASR(W) CUM 0-74 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.2 0.0 0.2 0.6 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.0 0.2 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.0 0.9 0.9 0.4 0.1 0.0 0.01 0.02 0.01 0.04 0.01 0.02 0.04 0.02 0.01 0.02 0.01 0.04 0.00 0.02 0.00 0.02 0.08 0.02 0.03 0.09 0.01 0.02 0.08 0.01 0.01 0.01 0.01 0.02 0.01 0.06 0.01 0.05 0.01 0.04 0.01 0.01 0.01 0.02 0.02 0.01 0.00 0.00 0.01 0.04 0.01 0.02 0.01 0.01 0.02 0.02 0.01 0.18 0.00 0.09 0.02 0.06 0.07 0.16 0.04 0.01 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.02 0.00 0.01 0.02 0.01 0.01 0.02 0.01 0.05 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.02 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.02 0.00 0.08 0.09 0.04 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 - * 0.00 - * - * - * 0.01 * 0.00 * - * - * - * 0.01 0.01 0.02 0.01 0.00 -

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
469

527

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Kaposi sarcoma (C46) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
470

Male ASR(W) CUM 0-74 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.0 0.5 0.0 0.1 0.1 0.1 0.1 0.1 0.5 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.1 0.1 0.0 0.4 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.7 0.2 1.0 2.2 1.3 1.0 1.7 0.9 1.9 1.4 0.8 0.6 1.1 0.8 1.7 1.0 0.5 2.1 0.5 0.8 2.1 0.2 1.5 1.1 0.01 0.01 0.02 0.02 0.07 0.06 0.14 0.03 0.03 0.15 0.04 0.02 0.19 0.02 0.03 0.04 0.06 0.04 0.06 0.14 0.04 0.02 0.04 0.08 0.02 0.05 0.03 0.02 0.02 0.01 0.04 0.06 0.03 0.05 0.07 0.04 0.11 0.05 0.05 0.10 0.06 0.03 0.06 0.02 0.01 0.04 0.02 0.04 0.02 0.04 0.25 0.04 0.38 0.30 0.30 0.16 0.28 0.37 0.23 0.24 0.24 0.08 0.27 0.24 0.31 0.17 0.12 0.33 0.21 0.31 0.24 0.07 0.30 0.14 0.00 0.00 0.00 0.02 0.02 0.02 0.01 0.00 0.03 0.01 0.00 0.09 0.00 0.01 0.01 0.00 0.00 0.00 0.05 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.00 0.01 0.00 0.03 0.01 0.01 0.02 0.00 0.01 0.01 0.00 0.02 0.00 0.01 0.00 0.01 0.05 0.01 0.10 0.25 0.13 0.10 0.18 0.09 0.17 0.16 0.07 0.06 0.10 0.09 0.18 0.07 0.06 0.21 0.05 0.09 0.23 0.02 0.17 0.11 0.00 0.00 0.00 0.01 0.01 0.02 0.00 0.00 0.02 0.00 0.00 0.04 0.00 0.00 0.01 0.01 0.00 0.00 0.02 0.01 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.03 0.00 0.04 0.04 0.03 0.02 0.03 0.04 0.02 0.03 0.03 0.01 0.03 0.04 0.04 0.01 0.02 0.05 0.02 0.05 0.03 0.01 0.04 0.02

Cases 24 0 1 1 2 2 0 10 1 0 0 1 0 7 1 1 0 0 0 0 0 0 0 7 3 5 0 0 18 2 12 11 9 23 7 2 48 0 0 0 0 4 1 0 1 0 0 0 1 1 2 2 3 0 0 8 3 9 20 12 16 13 1 26 19 7 23 4 6 17 6 15 24 5 1 28 6 9 15

Female ASR(W) CUM 0-74 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.7 0.4 0.4 0.2 0.4 0.0 0.3 0.4 0.3 0.1 0.2 0.3 0.5 0.1 0.2 1.1 0.2 0.2 0.5 0.1 0.2 0.1 0.00 0.01 0.02 0.04 0.02 0.01 0.03 0.06 0.15 0.02 0.01 0.09 0.02 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.08 0.03 0.01 0.01 0.00 0.02 0.01 0.01 0.17 0.02 0.27 0.12 0.12 0.05 0.12 0.04 0.07 0.12 0.13 0.04 0.11 0.11 0.16 0.06 0.07 0.25 0.09 0.20 0.12 0.04 0.08 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.04 0.00 0.03 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.06 0.03 0.04 0.02 0.05 0.03 0.04 0.03 0.02 0.01 0.03 0.05 0.01 0.03 0.10 0.03 0.02 0.05 0.01 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02 * 0.00 * - * - * - * 0.01 * 0.00 * 0.00 0.00 * 0.00 * 0.00 0.00 * 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.03 0.01 0.02 0.01 0.02 0.01 0.02 0.02 0.00 0.01 0.02 0.02 0.01 0.01 0.03 0.02 0.02 0.01 0.01 0.01 0.01

34 2 1 1 2 6 1 26 1 2 2 0 1 8 0 2 10 9 0 1 3 1 0 14 11 13 1 1 27 6 20 32 17 29 45 7 44 0 1 2 1 11 3 3 2 1 1 1 6 1 9 2 13 4 3 8 19 8 55 22 52 43 8 75 34 13 53 20 13 35 41 17 44 7 6 85 6 27 67

528

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Kaposi sarcoma (C46) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 6 13 9 25 3 2 1 66 169 16 1 14 4 10 25 43 58 0 16 9 24 9 17 10 92 19 1 3 4 10 5 18 171 6 9 8 6 28 12 9 17 210 11 20 3 22 138 0 31 26 0 74 19 3 0 13 28 1 2 3 1 14 Male ASR(W) CUM 0-74 0.1 0.1 0.6 0.1 0.1 0.1 0.0 0.7 2.1 0.1 0.0 0.1 0.1 0.9 0.7 0.7 1.3 0.9 0.3 0.7 0.3 1.0 0.3 0.2 1.4 0.1 0.5 0.2 0.7 0.5 0.9 0.3 0.2 0.3 0.1 0.1 0.2 0.1 0.1 0.1 0.5 0.1 0.1 0.1 0.2 0.6 0.3 0.4 0.4 0.3 0.4 0.1 0.7 0.4 0.4 0.6 0.1 1.2 0.03 0.03 0.22 0.03 0.06 0.04 0.01 0.08 0.17 0.03 0.01 0.02 0.03 0.31 0.15 0.11 0.17 0.22 0.10 0.15 0.10 0.27 0.10 0.03 0.31 0.07 0.29 0.12 0.24 0.23 0.21 0.03 0.08 0.09 0.03 0.04 0.04 0.02 0.03 0.02 0.03 0.02 0.03 0.03 0.03 0.06 0.05 0.09 0.05 0.07 0.21 0.03 0.14 0.37 0.29 0.34 0.12 0.33 0.01 0.01 0.06 0.01 0.02 0.00 0.06 0.18 0.01 0.00 0.01 0.00 0.13 0.06 0.06 0.13 0.08 0.03 0.06 0.03 0.09 0.02 0.03 0.14 0.03 0.02 0.06 0.06 0.09 0.03 0.02 0.03 0.01 0.01 0.02 0.00 0.01 0.01 0.04 0.01 0.01 0.01 0.01 0.06 0.03 0.05 0.05 0.03 0.04 0.01 0.07 0.03 0.03 0.09 0.01 0.13 0.00 0.00 0.03 0.00 0.01 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.04 0.01 0.01 0.02 0.02 0.01 0.01 0.02 0.02 0.01 0.00 0.04 0.02 0.01 0.03 0.03 0.02 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.00 0.01 0.03 0.02 0.06 0.01 0.04 Cases 3 5 4 16 0 2 1 19 35 6 2 7 2 6 11 13 3 0 4 5 5 1 2 4 43 3 0 1 0 3 1 1 28 0 0 3 2 7 5 2 6 49 5 3 1 4 20 0 2 6 0 23 4 2 0 4 3 0 0 0 1 2 Female ASR(W) CUM 0-74 0.0 0.0 0.2 0.1 0.0 0.0 0.2 0.4 0.0 0.0 0.0 0.0 0.4 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0.1 0.02 0.01 0.13 0.02 0.02 0.01 0.04 0.07 0.01 0.01 0.01 0.02 0.20 0.05 0.04 0.03 0.07 0.05 0.05 0.05 0.09 0.07 0.01 0.12 0.10 0.12 0.03 0.04 0.01 0.01 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.03 0.02 0.14 0.02 0.01 0.02 0.05 0.00 0.00 0.03 0.00 0.01 0.00 0.01 0.03 0.00 0.00 0.00 0.00 0.05 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.02 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.02 0.00 0.00 0.00 0.02 0.00 - * 0.00 0.00 0.00 * 0.01 0.00 0.00 0.00 0.00 0.02 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.03 0.02 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 -

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
471

529

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Connective and soft tissue (C47+C49)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 22 169 15 42 46 19 102 13 46 767 20 87 150 81 25 35 1808 193 272 95 61 39 1 81 963 10 93 356 69 276 36 428 2749 189 158 505 1801 537 37 26 16 9 83 332 694 64 13 18 4 6 194 365 353 304 26 268 31 19 10 1691 163 1513 570 132 434 198 61 135 99 957 121 797 492 265 346 357 88 261 21 48 Male ASR(W) CUM 0-74 0.8 3.3 1.4 1.5 1.5 2.5 3.8 1.6 2.6 3.4 2.2 2.2 1.8 2.7 2.4 3.6 2.4 2.2 2.0 2.3 2.6 2.2 1.8 2.5 2.7 2.0 2.7 2.5 2.4 2.4 2.3 2.6 2.8 1.7 2.6 2.4 3.0 2.8 2.7 1.8 2.0 2.6 2.9 2.9 2.6 2.6 1.2 2.2 1.4 1.3 2.2 3.0 2.8 2.8 3.2 2.6 1.9 1.9 1.6 2.8 2.8 2.8 2.6 2.5 2.7 2.9 2.7 3.0 2.7 2.6 2.7 2.6 2.8 2.7 2.9 2.7 2.6 2.7 2.0 2.4 0.18 0.28 0.37 0.32 0.28 0.59 0.42 0.48 0.40 0.13 0.50 0.24 0.15 0.32 0.50 0.63 0.06 0.16 0.13 0.25 0.36 0.35 1.81 0.30 0.09 0.66 0.31 0.14 0.30 0.16 0.40 0.13 0.06 0.13 0.21 0.11 0.08 0.13 0.46 0.36 0.51 0.89 0.35 0.18 0.10 0.33 0.35 0.53 0.93 0.54 0.17 0.18 0.15 0.17 0.64 0.18 0.36 0.45 0.54 0.08 0.22 0.08 0.11 0.22 0.14 0.21 0.37 0.27 0.28 0.09 0.25 0.10 0.13 0.18 0.16 0.15 0.28 0.18 0.43 0.37 0.22 0.32 0.14 0.26 0.33 0.26 0.23 0.17 0.28 0.27 0.44 0.23 0.20 0.19 0.22 0.24 0.20 0.30 0.24 0.26 0.11 0.24 0.24 0.21 0.24 0.21 0.24 0.27 0.18 0.25 0.23 0.29 0.28 0.27 0.20 0.20 0.27 0.32 0.29 0.25 0.25 0.14 0.20 0.09 0.10 0.20 0.28 0.28 0.27 0.32 0.26 0.14 0.16 0.09 0.28 0.28 0.28 0.24 0.23 0.25 0.26 0.26 0.27 0.24 0.26 0.26 0.25 0.27 0.28 0.28 0.26 0.24 0.26 0.13 0.24 0.06 0.05 0.05 0.06 0.02 0.07 0.03 0.02 0.04 0.06 0.10 0.01 0.02 0.01 0.03 0.04 0.04 0.30 0.03 0.01 0.05 0.03 0.02 0.03 0.02 0.05 0.01 0.01 0.02 0.03 0.02 0.01 0.02 0.06 0.04 0.06 0.11 0.05 0.02 0.01 0.04 0.05 0.06 0.05 0.05 0.02 0.02 0.02 0.02 0.08 0.02 0.03 0.04 0.03 0.01 0.03 0.01 0.01 0.03 0.01 0.02 0.05 0.03 0.03 0.01 0.03 0.01 0.02 0.02 0.02 0.02 0.03 0.02 0.03 0.04 Cases 14 173 15 46 43 21 72 22 47 892 11 106 143 87 15 24 1481 147 205 70 44 37 2 56 837 15 68 311 86 216 34 338 2074 151 126 465 1288 357 29 15 10 1 59 219 559 59 12 16 7 5 180 262 290 244 20 220 44 31 12 1284 160 1103 490 153 330 168 66 98 82 807 121 660 438 203 288 330 112 216 36 48 Female ASR(W) CUM 0-74 0.5 2.7 1.3 2.7 1.8 2.2 2.3 2.7 2.3 3.2 1.0 2.3 1.6 2.6 1.1 2.2 1.9 1.7 1.5 1.6 1.8 2.0 2.6 1.5 2.2 2.8 2.2 2.0 2.5 1.8 2.3 1.9 2.0 1.2 1.8 2.0 2.1 1.7 1.9 0.8 1.3 0.4 2.0 1.8 1.9 1.8 0.9 1.8 1.5 0.6 2.0 2.2 2.2 1.9 2.1 1.9 2.0 2.3 1.8 2.1 2.3 2.0 2.0 2.3 1.8 2.2 2.6 2.1 2.0 1.9 2.0 1.9 2.2 1.9 2.1 2.2 2.5 2.0 2.8 2.2 0.14 0.21 0.35 0.51 0.38 0.56 0.30 0.62 0.35 0.11 0.32 0.23 0.14 0.29 0.32 0.46 0.06 0.15 0.12 0.22 0.30 0.35 2.05 0.23 0.08 0.85 0.29 0.13 0.28 0.14 0.41 0.11 0.05 0.11 0.16 0.10 0.07 0.10 0.37 0.25 0.43 0.43 0.27 0.15 0.09 0.24 0.26 0.50 0.76 0.27 0.15 0.17 0.14 0.14 0.48 0.15 0.34 0.44 0.75 0.07 0.19 0.08 0.09 0.20 0.11 0.18 0.34 0.23 0.24 0.08 0.19 0.09 0.12 0.16 0.14 0.13 0.25 0.15 0.47 0.38 0.22 0.24 0.28 0.22 0.31 0.12 0.24 0.16 0.26 0.10 0.24 0.18 0.15 0.15 0.16 0.16 0.20 0.38 0.14 0.20 0.26 0.22 0.19 0.25 0.16 0.19 0.19 0.19 0.12 0.17 0.19 0.20 0.16 0.19 0.07 0.10 0.03 0.20 0.18 0.18 0.18 0.12 0.18 0.11 0.05 0.18 0.20 0.21 0.19 0.25 0.18 0.20 0.23 0.13 0.20 0.23 0.20 0.19 0.23 0.18 0.23 0.30 0.21 0.19 0.18 0.19 0.18 0.20 0.18 0.19 0.21 0.22 0.20 0.22 0.23 * * * *

0.06 0.04 0.08 0.04 0.01 0.05 0.03 0.02 0.04 0.03 0.06 * 0.01 0.01 0.01 0.02 0.03 0.04 0.33 0.02 0.01 0.09 0.03 0.01 0.03 0.01 0.04 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.04 0.02 0.03 0.03 0.03 0.02 0.01 0.03 0.04 0.05 0.06 0.04 0.02 0.02 0.02 0.02 0.07 0.02 0.04 0.05 0.05 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.05 0.02 0.03 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.03 0.02 0.04 0.04

530

*Important. See note on population page.

472

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Connective and soft tissue (C47+C49) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 109 523 816 78 706 359 55 294 442 48 389 65 18132 1599 15738 749 61 663 186 11 45 128 1496 171 1268 889 74 772 218 294 1033 74 932 105 2293 188 1909 6152 317 479 664 4546 271 61 207 1406 137 1216 175 65 531 337 163 402 10 85 352 5 13 343 37 38 113 468 12 337 56 123 35 521 457 43 31 21 45 97 69 264 45 Male ASR(W) CUM 0-74 2.4 2.6 2.7 2.2 2.7 3.0 2.2 3.2 2.5 3.3 2.5 2.4 2.7 2.4 2.7 2.9 2.1 3.0 3.4 2.9 2.5 4.0 2.6 2.5 2.7 2.6 2.3 2.5 2.0 2.5 2.5 2.4 2.5 2.9 2.9 2.5 3.0 2.8 1.9 2.4 2.4 2.9 2.3 2.1 2.3 2.5 2.3 2.4 3.0 3.5 3.0 2.8 2.7 2.4 1.4 1.5 1.9 0.4 0.5 1.6 1.1 1.9 1.1 1.8 1.3 1.3 1.3 1.6 1.3 3.3 3.3 2.0 1.0 0.7 1.3 1.1 1.3 1.0 1.2 0.25 0.12 0.10 0.26 0.11 0.17 0.30 0.20 0.13 0.48 0.13 0.34 0.02 0.06 0.02 0.11 0.28 0.13 0.26 0.89 0.37 0.39 0.07 0.19 0.08 0.09 0.27 0.10 0.15 0.16 0.09 0.29 0.09 0.32 0.06 0.18 0.07 0.04 0.11 0.11 0.10 0.05 0.14 0.27 0.17 0.07 0.21 0.07 0.23 0.47 0.14 0.16 0.23 0.13 0.46 0.17 0.11 0.20 0.14 0.11 0.19 0.32 0.11 0.09 0.38 0.07 0.17 0.16 0.22 0.15 0.16 0.35 0.19 0.21 0.22 0.12 0.19 0.07 0.25 0.22 0.27 0.25 0.19 0.26 0.28 0.20 0.30 0.25 0.31 0.24 0.21 0.26 0.24 0.26 0.28 0.22 0.30 0.36 0.36 0.25 0.43 0.26 0.25 0.26 0.25 0.23 0.24 0.21 0.26 0.25 0.25 0.25 0.29 0.28 0.24 0.29 0.27 0.18 0.24 0.24 0.28 0.21 0.17 0.22 0.24 0.24 0.23 0.30 0.33 0.28 0.26 0.28 0.24 0.11 0.14 0.18 0.04 0.05 0.16 0.11 0.22 0.11 0.18 0.13 0.13 0.12 0.18 0.13 0.35 0.35 0.25 0.09 0.06 0.10 0.12 0.12 0.08 0.10 0.03 0.01 0.01 0.03 0.01 0.02 0.03 0.02 0.01 0.05 0.01 0.03 0.00 0.01 0.00 0.01 0.04 0.01 0.03 0.14 0.05 0.05 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.02 0.01 0.04 0.01 0.04 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.03 0.02 0.01 0.03 0.01 0.03 0.05 0.02 0.02 0.03 0.01 0.05 0.02 0.01 0.02 0.02 0.01 0.02 0.04 0.01 0.01 0.05 0.01 0.02 0.02 0.03 0.02 0.02 0.06 0.02 0.02 0.02 0.01 0.02 0.01 0.02 Cases 95 483 672 82 571 270 52 213 342 29 305 64 15124 1756 12703 662 95 548 105 7 35 61 1403 199 1149 730 85 617 225 245 919 88 801 76 1703 182 1402 4827 231 505 604 3408 274 84 186 1100 136 924 127 41 411 272 135 342 4 91 340 8 5 302 23 36 86 373 13 241 54 79 26 400 350 31 24 19 30 94 66 206 35 Female ASR(W) CUM 0-74 2.1 2.0 2.0 2.1 2.0 2.0 1.8 2.0 1.7 1.5 1.7 1.9 2.0 2.1 2.0 2.2 2.6 2.2 1.7 1.6 1.6 1.7 2.1 2.2 2.1 1.8 2.1 1.7 1.9 2.1 1.9 2.2 1.8 1.9 1.9 2.1 2.0 2.0 1.2 2.1 2.0 2.1 2.0 2.2 2.0 1.7 1.9 1.7 2.2 2.0 2.2 2.1 1.9 1.8 0.5 1.5 1.8 0.7 0.2 1.3 0.7 1.9 0.9 1.7 1.1 1.0 1.2 1.1 0.8 2.3 2.3 1.2 0.8 0.4 0.9 1.1 1.1 0.7 0.7 0.26 0.11 0.09 0.24 0.10 0.13 0.26 0.16 0.11 0.29 0.11 0.29 0.02 0.05 0.02 0.10 0.28 0.11 0.18 0.60 0.28 0.28 0.06 0.16 0.07 0.08 0.24 0.08 0.14 0.16 0.08 0.25 0.08 0.26 0.05 0.16 0.06 0.03 0.08 0.10 0.09 0.04 0.13 0.25 0.17 0.05 0.17 0.06 0.20 0.35 0.12 0.15 0.19 0.11 0.24 0.16 0.11 0.27 0.09 0.09 0.14 0.34 0.10 0.10 0.31 0.07 0.17 0.13 0.16 0.12 0.13 0.24 0.18 0.10 0.21 0.13 0.17 0.06 0.17 0.19 0.20 0.19 0.19 0.19 0.18 0.16 0.19 0.16 0.16 0.15 0.21 0.19 0.21 0.19 0.20 0.26 0.20 0.16 0.14 0.14 0.17 0.20 0.22 0.20 0.17 0.24 0.16 0.18 0.18 0.18 0.22 0.17 0.20 0.18 0.21 0.19 0.19 0.11 0.21 0.19 0.20 0.19 0.21 0.18 0.16 0.19 0.16 0.20 0.18 0.20 0.19 0.18 0.16 0.04 0.15 0.16 0.08 0.03 0.14 0.05 0.16 0.08 0.18 0.08 0.11 0.11 0.10 0.09 0.23 0.23 0.12 0.07 0.04 0.08 0.10 0.11 0.06 0.05 0.02 0.01 0.01 0.03 0.01 0.01 0.03 0.02 0.01 0.04 0.01 0.03 0.00 0.01 0.00 0.01 0.03 0.01 0.02 0.06 0.03 0.03 0.01 0.02 0.01 0.01 0.03 0.01 0.01 0.01 0.01 0.03 0.01 0.03 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.03 0.02 0.01 0.02 0.01 0.02 0.03 0.01 0.01 0.02 0.01 0.02 0.02 * 0.01 0.03 * 0.01 0.01 * 0.01 * 0.03 * 0.01 0.01 * 0.02 0.01 0.02 * 0.01 * 0.02 * 0.01 0.01 0.03 0.02 0.01 0.02 0.01 0.01 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
473

531

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Connective and soft tissue (C47+C49) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
474

Male ASR(W) CUM 0-74 1.3 1.3 1.3 1.1 1.2 1.6 0.9 1.4 1.4 1.3 1.0 1.3 1.4 1.4 2.4 2.3 1.4 1.5 1.1 1.7 1.1 1.2 1.3 2.3 1.7 2.2 2.7 2.2 2.1 1.9 2.5 1.9 2.1 2.3 2.4 2.1 2.9 2.1 2.3 3.1 2.1 3.1 1.5 1.9 2.0 1.5 1.8 1.3 2.1 2.3 2.4 2.1 2.7 2.7 1.9 2.0 2.4 1.7 1.9 2.4 2.4 1.9 2.1 3.4 1.8 1.8 2.5 2.0 1.7 2.2 1.8 1.8 1.9 1.4 0.7 2.8 1.7 2.5 2.5 0.04 0.13 0.15 0.22 0.21 0.18 0.34 0.09 0.31 0.33 0.42 0.26 0.18 0.25 0.29 0.19 0.14 0.16 0.41 0.42 0.18 0.25 0.21 0.28 0.15 0.10 0.39 0.45 0.09 0.19 0.14 0.10 0.13 0.09 0.13 0.24 0.15 0.28 0.36 0.56 0.33 0.37 0.22 0.25 0.41 0.30 0.45 0.29 0.18 0.14 0.25 0.21 0.22 0.20 0.23 0.50 0.15 0.47 0.37 0.56 0.25 0.31 0.67 0.35 0.37 0.36 0.21 0.42 0.41 0.44 0.33 0.28 0.42 0.38 0.32 0.37 0.27 0.42 0.24 0.14 0.13 0.14 0.08 0.13 0.17 0.11 0.15 0.11 0.14 0.07 0.14 0.12 0.12 0.23 0.26 0.15 0.15 0.11 0.17 0.11 0.10 0.13 0.23 0.17 0.22 0.24 0.23 0.20 0.18 0.24 0.18 0.20 0.22 0.22 0.22 0.26 0.20 0.23 0.21 0.21 0.27 0.15 0.18 0.18 0.15 0.20 0.13 0.21 0.24 0.24 0.21 0.24 0.26 0.20 0.20 0.24 0.19 0.16 0.26 0.23 0.17 0.22 0.34 0.17 0.18 0.23 0.16 0.19 0.21 0.15 0.19 0.18 0.13 0.06 0.26 0.17 0.22 0.23 0.01 0.01 0.02 0.02 0.03 0.02 0.04 0.01 0.04 0.04 0.03 0.03 0.02 0.03 0.04 0.03 0.02 0.02 0.04 0.05 0.02 0.02 0.03 0.03 0.02 0.01 0.04 0.06 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.03 0.04 0.04 0.03 0.03 0.02 0.03 0.04 0.04 0.05 0.03 0.02 0.01 0.02 0.02 0.02 0.02 0.03 0.06 0.02 0.06 0.03 0.05 0.03 0.03 0.07 0.03 0.03 0.04 0.02 0.04 0.05 0.04 0.02 0.03 0.04 0.04 0.04 0.03 0.03 0.04 0.02

Cases 1071 96 83 24 36 67 8 299 26 19 15 31 51 22 59 203 96 79 5 12 28 19 28 52 134 533 47 24 642 88 347 363 272 601 360 98 437 65 42 25 36 70 58 63 35 26 27 16 176 310 156 105 174 207 66 8 165 11 40 36 87 61 11 98 46 18 163 27 12 23 69 54 26 15 5 70 49 29 108

Female ASR(W) CUM 0-74 1.0 0.9 1.2 0.7 1.1 1.1 1.0 1.2 1.3 1.3 0.7 1.2 1.1 0.8 2.3 2.0 1.0 1.0 0.8 1.1 0.7 1.0 0.9 1.6 1.7 1.7 2.1 1.9 1.8 1.4 2.0 1.3 1.5 1.6 1.8 1.8 2.3 1.6 1.9 1.3 1.7 2.1 1.5 1.5 1.6 1.6 1.7 0.8 1.7 1.5 2.2 1.4 1.9 2.0 1.4 0.9 1.4 1.1 2.0 1.8 2.0 2.3 1.7 2.2 2.1 1.1 1.8 1.3 1.1 1.8 1.5 1.9 2.0 1.3 0.6 2.2 1.3 1.2 1.5 0.03 0.10 0.14 0.15 0.19 0.14 0.35 0.07 0.26 0.34 0.24 0.23 0.16 0.19 0.34 0.15 0.11 0.13 0.38 0.34 0.14 0.24 0.17 0.23 0.15 0.09 0.36 0.44 0.08 0.17 0.13 0.08 0.11 0.08 0.11 0.23 0.14 0.23 0.34 0.33 0.31 0.31 0.23 0.23 0.32 0.37 0.41 0.26 0.16 0.12 0.23 0.17 0.18 0.18 0.23 0.36 0.12 0.38 0.36 0.36 0.29 0.42 0.63 0.32 0.42 0.28 0.18 0.35 0.33 0.50 0.22 0.30 0.50 0.40 0.33 0.39 0.27 0.27 0.17 0.10 0.10 0.13 0.06 0.11 0.09 0.09 0.12 0.11 0.13 0.07 0.12 0.10 0.07 0.24 0.20 0.09 0.09 0.05 0.11 0.06 0.08 0.06 0.14 0.14 0.16 0.20 0.13 0.17 0.13 0.19 0.12 0.15 0.16 0.17 0.17 0.21 0.16 0.17 0.08 0.15 0.16 0.15 0.15 0.15 0.12 0.16 0.07 0.17 0.15 0.22 0.14 0.18 0.19 0.14 0.07 0.14 0.14 0.18 0.18 0.16 0.21 0.14 0.22 0.18 0.10 0.17 0.13 0.11 0.13 0.17 0.16 0.16 0.11 0.06 0.19 0.13 0.12 0.14 0.00 0.01 0.02 0.01 0.02 0.01 0.03 0.01 0.03 0.05 0.03 0.03 0.02 0.03 * 0.04 * 0.02 * 0.01 0.01 0.02 0.04 0.01 * 0.02 * 0.01 0.02 * 0.01 * 0.01 0.03 0.03 0.01 * 0.02 * 0.01 0.01 * 0.01 0.01 0.01 0.02 0.01 0.02 0.03 0.02 0.03 0.02 0.02 0.02 0.03 0.03 0.04 0.02 0.01 0.01 0.02 0.02 0.02 0.02 0.02 0.03 0.01 0.05 0.03 0.04 0.02 0.03 0.05 0.03 0.03 0.03 0.02 0.03 0.04 0.03 0.02 0.03 0.04 0.03 0.03 0.03 0.02 0.03 0.02

1224 119 75 30 39 95 8 320 24 19 30 27 64 38 84 200 122 96 8 18 43 25 40 69 140 585 56 25 556 121 399 461 285 703 426 81 468 62 45 38 46 87 53 65 33 28 26 29 184 358 130 120 198 220 80 17 265 15 35 39 114 53 13 132 39 26 191 35 20 37 59 51 28 16 5 90 58 45 140

532

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Connective and soft tissue (C47+C49) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 113 158 31 329 27 62 65 178 208 196 291 267 113 13 72 139 91 11 56 67 75 40 34 53 846 35 19 15 42 20 26 67 1245 94 79 187 181 281 512 195 672 834 369 331 109 324 429 15 357 138 48 407 162 12 11 378 119 5 22 19 30 32 Male ASR(W) CUM 0-74 1.6 1.6 2.5 2.1 1.3 1.6 1.2 1.8 2.3 1.5 2.0 1.8 2.2 1.4 1.6 2.3 2.2 2.5 2.9 2.6 2.1 1.6 2.5 2.1 2.5 2.4 2.1 2.5 2.4 2.0 2.9 3.5 2.5 2.9 2.8 1.7 2.1 2.0 2.3 2.2 2.6 1.8 2.1 1.9 2.1 1.9 2.1 3.5 3.1 2.8 3.1 2.6 2.9 1.3 2.3 3.0 2.9 1.5 3.9 3.5 2.6 2.9 0.16 0.14 0.46 0.13 0.28 0.20 0.15 0.14 0.19 0.12 0.13 0.12 0.24 0.47 0.21 0.22 0.24 1.00 0.45 0.34 0.27 0.28 0.53 0.36 0.10 0.43 0.50 0.75 0.41 0.48 0.60 0.47 0.08 0.32 0.36 0.14 0.17 0.13 0.11 0.17 0.11 0.07 0.12 0.12 0.21 0.11 0.11 0.98 0.17 0.26 0.47 0.14 0.24 0.37 0.75 0.16 0.29 0.79 0.91 0.83 0.54 0.60 0.16 0.15 0.27 0.21 0.13 0.17 0.12 0.17 0.22 0.17 0.20 0.18 0.17 0.11 0.18 0.22 0.22 0.14 0.24 0.25 0.21 0.22 0.22 0.15 0.24 0.28 0.19 0.26 0.23 0.20 0.23 0.33 0.24 0.31 0.28 0.18 0.23 0.19 0.23 0.21 0.25 0.18 0.20 0.17 0.20 0.19 0.20 0.30 0.33 0.27 0.36 0.26 0.27 0.11 0.19 0.31 0.27 0.10 0.38 0.20 0.28 0.29 0.02 0.01 0.06 0.01 0.03 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.02 0.04 0.02 0.02 0.03 0.06 0.04 0.03 0.03 0.04 0.04 0.03 0.01 0.06 0.06 0.09 0.05 0.05 0.06 0.05 0.01 0.04 0.04 0.02 0.02 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.11 0.02 0.03 0.06 0.02 0.03 0.04 0.07 0.02 0.03 0.06 0.10 0.06 0.06 0.07 Cases 136 210 21 285 29 61 77 188 177 292 196 255 109 9 75 103 62 19 32 58 55 38 37 49 668 18 9 9 26 17 23 51 1038 79 70 155 129 199 366 154 604 669 292 269 91 260 362 8 228 102 37 329 83 13 9 269 70 6 8 14 13 25 Female ASR(W) CUM 0-74 1.7 1.6 1.4 1.5 1.1 1.4 1.2 1.8 1.5 1.4 1.2 1.5 1.4 1.0 1.4 1.6 1.3 3.1 1.4 2.2 1.4 2.0 2.2 1.5 2.0 1.2 1.2 1.0 1.1 1.2 1.4 2.0 1.8 2.1 2.2 1.5 1.3 1.3 1.4 1.6 2.2 1.3 1.6 1.4 1.4 1.3 1.7 2.5 1.8 2.0 2.0 1.9 1.4 1.1 2.3 2.1 1.5 1.9 1.2 2.2 0.7 2.2 0.20 0.13 0.36 0.11 0.21 0.21 0.16 0.15 0.14 0.11 0.10 0.10 0.14 0.35 0.18 0.20 0.19 0.92 0.31 0.35 0.22 0.42 0.50 0.26 0.10 0.33 0.52 0.39 0.26 0.41 0.33 0.33 0.07 0.27 0.31 0.15 0.13 0.11 0.09 0.15 0.11 0.06 0.11 0.10 0.16 0.09 0.10 0.94 0.13 0.22 0.39 0.12 0.16 0.33 0.77 0.14 0.21 0.89 0.46 0.60 0.26 0.53 0.15 0.16 0.13 0.14 0.10 0.13 0.12 0.16 0.13 0.15 0.12 0.13 0.14 0.10 0.15 0.15 0.11 0.26 0.13 0.20 0.13 0.19 0.18 0.17 0.18 0.10 0.10 0.11 0.08 0.11 0.16 0.20 0.17 0.21 0.20 0.14 0.13 0.12 0.13 0.16 0.22 0.13 0.16 0.14 0.13 0.13 0.16 0.39 0.19 0.17 0.18 0.20 0.14 0.13 0.30 0.20 0.12 0.14 0.11 0.20 0.06 0.17 0.01 0.01 0.04 0.01 0.02 * 0.02 0.01 0.01 * 0.01 0.01 0.01 0.01 0.02 0.04 0.02 0.02 0.02 0.07 0.03 0.03 0.02 0.04 0.04 0.03 0.01 0.03 0.04 0.05 0.02 0.03 0.05 0.03 0.01 0.03 0.03 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.19 0.02 0.02 0.04 0.01 0.02 0.05 0.12 0.02 0.02 0.07 0.04 0.07 0.03 0.05

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
475

533

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Breast (C50)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 12 31 8 15 9 16 13 1 10 211 1 11 28 9 10 1 541 50 93 31 16 15 0 27 279 5 25 206 41 161 9 237 710 42 67 64 526 150 16 4 5 2 8 107 196 31 2 4 0 3 21 132 75 134 8 124 41 18 22 598 56 534 166 50 115 60 27 32 49 367 58 298 157 65 92 158 56 100 23 23 Male ASR(W) CUM 0-74 0.6 0.8 0.9 1.4 0.6 1.9 0.6 0.1 0.8 1.0 0.1 0.3 0.4 0.3 0.8 0.1 0.7 0.5 0.6 0.7 0.6 0.8 0.8 0.7 1.1 0.6 1.4 1.4 1.4 0.6 1.3 0.7 0.4 1.1 0.4 0.8 0.7 1.3 0.3 0.5 0.9 0.4 0.8 0.7 1.2 0.3 0.5 0.6 0.3 1.0 0.6 1.1 1.1 1.2 2.5 1.8 3.7 0.9 1.0 0.9 0.7 1.1 0.6 0.9 1.7 0.7 1.2 0.9 1.3 0.9 0.8 0.6 0.7 1.1 1.7 1.0 2.2 1.2 0.19 0.14 0.32 0.42 0.22 0.48 0.18 0.12 0.26 0.07 0.08 0.11 0.08 0.12 0.25 0.11 0.03 0.08 0.06 0.13 0.15 0.21 0.16 0.04 0.50 0.12 0.10 0.23 0.11 0.21 0.09 0.03 0.06 0.14 0.05 0.04 0.06 0.32 0.14 0.25 0.66 0.15 0.08 0.06 0.23 0.19 0.28 0.33 0.08 0.09 0.07 0.10 0.40 0.11 0.39 0.43 0.80 0.04 0.14 0.04 0.06 0.17 0.06 0.12 0.34 0.13 0.17 0.05 0.18 0.05 0.07 0.08 0.08 0.09 0.23 0.10 0.48 0.26 0.19 0.10 0.01 0.10 0.11 0.04 0.05 0.04 0.09 0.01 0.08 0.06 0.08 0.09 0.05 0.09 0.09 0.08 0.14 0.06 0.17 0.16 0.17 0.09 0.15 0.08 0.04 0.14 0.04 0.09 0.09 0.13 0.03 0.06 0.10 0.04 0.10 0.09 0.16 0.03 0.06 0.07 0.03 0.12 0.06 0.14 0.08 0.14 0.35 0.28 0.51 0.10 0.12 0.10 0.09 0.15 0.08 0.13 0.22 0.11 0.14 0.11 0.14 0.11 0.09 0.08 0.09 0.13 0.17 0.11 0.22 0.15 0.06 0.03 0.01 0.04 0.01 0.01 0.01 0.02 0.04 0.01 0.00 0.01 0.01 0.02 0.02 0.03 0.02 0.01 0.07 0.02 0.01 0.03 0.02 0.04 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.04 0.01 0.04 0.08 0.02 0.01 0.01 0.03 0.02 0.04 0.04 0.01 0.01 0.01 0.01 0.04 0.02 0.06 0.07 0.14 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.06 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.06 0.04 Cases 414 2426 308 332 330 844 2023 423 1046 22598 300 2139 2971 966 730 332 69765 7942 12036 3532 2309 1418 69 3165 35883 438 2973 14411 2772 11396 1578 15932 103024 8465 5850 12858 74632 21604 1265 1061 727 317 1869 15257 26058 2796 654 958 509 289 4837 15293 13519 13411 791 12386 2156 1299 754 62279 4975 56396 24156 5235 18594 8107 2159 5757 4044 42991 5240 36402 20631 10645 13794 14040 3757 10202 1199 2240 Female ASR(W) CUM 0-74 18.8 42.5 29.8 23.4 19.0 85.7 68.7 51.7 53.8 80.8 30.9 47.5 37.4 30.7 55.2 29.4 80.7 81.9 77.1 80.8 78.3 72.2 75.6 83.1 82.3 81.9 76.2 83.8 74.5 85.3 96.7 84.7 91.0 62.6 81.4 63.9 105.2 94.5 77.7 59.0 63.8 79.3 70.7 110.9 86.1 84.4 52.1 92.1 87.7 43.7 58.6 110.0 95.6 97.1 80.8 98.6 98.5 88.4 115.2 88.0 71.5 90.2 89.0 78.4 92.5 94.1 80.0 102.0 91.0 93.5 87.5 94.4 90.2 89.3 89.4 86.4 85.4 87.0 87.9 93.0 0.96 0.88 1.74 1.53 1.24 3.16 1.67 2.65 1.71 0.56 1.82 1.06 0.71 1.02 2.12 1.65 0.32 0.96 0.74 1.47 1.73 1.99 9.77 1.58 0.46 4.17 1.54 0.74 1.48 0.85 2.55 0.71 0.30 0.69 1.10 0.58 0.42 0.68 2.27 1.88 2.40 4.81 1.69 0.97 0.56 1.64 2.10 3.02 4.24 2.60 0.87 0.97 0.86 0.91 2.94 0.96 2.26 2.63 4.53 0.39 1.04 0.43 0.60 1.13 0.71 1.09 1.83 1.41 1.52 0.48 1.24 0.53 0.67 0.95 0.80 0.77 1.44 0.92 2.61 2.15 9.73 7.69 5.47 5.80 9.15 3.30 5.40 4.25 3.41 5.92 3.15 9.32 9.47 8.89 9.29 9.08 8.30 8.71 9.66 9.52 9.61 8.81 9.70 8.33 9.96 11.16 9.95 10.64 7.05 9.28 7.37 12.43 10.94 8.82 6.52 7.33 9.11 8.20 13.05 10.02 9.74 5.67 10.29 10.00 4.73 6.73 12.96 11.16 11.29 9.22 11.48 11.10 9.87 13.37 10.17 8.07 10.43 10.34 8.81 10.85 10.97 9.08 12.00 10.74 10.86 9.99 11.00 10.54 10.37 10.33 9.99 9.58 10.20 9.84 10.96 * * * *

0.38 0.23 0.35 0.22 0.07 0.22 0.14 0.09 0.13 0.25 0.20 * 0.04 0.13 0.10 0.19 0.23 0.26 1.42 0.21 0.06 0.55 0.20 0.09 0.19 0.11 0.36 0.09 0.04 0.09 0.15 0.08 0.05 0.09 0.30 0.23 0.30 0.58 0.23 0.13 0.07 0.22 0.26 0.37 0.51 0.30 0.12 0.13 0.12 0.12 0.39 0.13 0.29 0.32 0.61 0.05 0.14 0.05 0.08 0.15 0.09 0.15 0.25 0.19 0.20 0.06 0.16 0.07 0.09 0.12 0.10 0.10 0.19 0.12 0.34 0.28

534

*Important. See note on population page.

476

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Breast (C50) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 63 184 310 42 262 120 29 90 134 21 111 20 6798 760 5823 266 30 228 33 0 5 28 728 79 622 317 35 269 76 82 477 45 421 26 653 83 539 1787 67 229 85 1390 147 42 103 692 65 617 34 25 125 88 46 197 1 9 69 1 3 106 13 16 43 133 2 93 64 62 8 191 181 6 13 8 5 22 18 72 15 Male ASR(W) CUM 0-74 1.3 0.8 0.9 1.3 0.9 0.9 1.2 0.9 0.7 1.6 0.6 0.6 0.9 1.2 0.9 0.9 1.0 0.9 0.5 0.3 0.6 1.1 1.2 1.1 0.8 1.1 0.8 0.6 0.7 1.0 1.4 1.0 0.7 0.8 1.2 0.8 0.8 0.4 1.2 0.4 0.8 1.1 1.5 1.0 1.2 1.2 1.2 0.6 1.1 0.6 0.7 0.6 1.1 0.2 0.2 0.3 0.1 0.2 0.4 0.4 0.7 0.5 0.7 0.2 0.4 1.5 1.0 0.3 1.1 1.2 0.4 0.3 0.2 0.1 0.2 0.2 0.2 0.2 0.17 0.07 0.05 0.20 0.06 0.09 0.22 0.10 0.06 0.34 0.06 0.14 0.01 0.05 0.01 0.06 0.19 0.06 0.09 0.12 0.13 0.04 0.14 0.05 0.05 0.19 0.05 0.08 0.08 0.05 0.21 0.05 0.14 0.03 0.14 0.03 0.02 0.05 0.08 0.04 0.02 0.10 0.24 0.10 0.05 0.16 0.05 0.10 0.22 0.06 0.08 0.09 0.08 0.16 0.05 0.04 0.07 0.11 0.04 0.10 0.18 0.07 0.06 0.17 0.05 0.19 0.13 0.11 0.09 0.09 0.16 0.09 0.06 0.06 0.05 0.06 0.02 0.06 0.15 0.10 0.11 0.13 0.11 0.11 0.12 0.10 0.08 0.21 0.07 0.07 0.11 0.14 0.11 0.11 0.12 0.11 0.05 0.02 0.07 0.14 0.16 0.14 0.10 0.13 0.09 0.09 0.08 0.12 0.16 0.11 0.08 0.09 0.14 0.09 0.09 0.04 0.14 0.04 0.10 0.13 0.18 0.12 0.14 0.14 0.14 0.06 0.12 0.07 0.08 0.07 0.12 0.02 0.02 0.03 0.01 0.01 0.05 0.05 0.09 0.06 0.08 0.03 0.05 0.16 0.12 0.04 0.14 0.14 0.03 0.05 0.01 0.02 0.03 0.02 0.02 0.03 0.02 0.01 0.01 0.03 0.01 0.01 0.03 0.01 0.01 0.05 0.01 0.02 0.00 0.01 0.00 0.01 0.03 0.01 0.01 0.01 0.02 0.01 0.02 0.01 0.01 0.03 0.01 0.01 0.01 0.01 0.03 0.01 0.02 0.00 0.02 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.03 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.01 0.03 0.01 0.02 0.02 0.02 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.00 0.01 Cases 5015 25386 34337 3770 29961 13845 2801 10870 19564 1685 17697 3222 764169 66900 668489 31011 3104 26794 5242 160 1327 3650 67708 7618 58020 40806 3548 36041 12184 13397 49083 3566 44441 4034 89413 7442 75089 237378 13427 19968 17512 184010 13371 2974 10251 56843 5499 49755 4884 2325 22098 14728 6593 19401 340 1903 9411 199 703 8508 561 1444 2487 5839 149 5792 1133 1598 746 16409 15456 686 1309 1102 1774 3966 2481 11103 1882 Female ASR(W) CUM 0-74 93.3 101.5 92.4 84.9 93.2 91.2 83.7 94.5 89.7 86.1 90.3 91.0 91.6 79.3 93.4 93.3 78.9 96.8 81.0 36.3 65.5 95.8 91.4 76.1 96.0 90.9 83.0 89.7 91.3 102.2 92.8 83.8 92.6 92.7 93.2 81.2 97.1 90.9 64.7 81.7 65.4 98.5 88.4 77.5 91.6 84.5 78.9 85.2 81.4 97.6 105.1 103.1 83.8 94.5 46.8 31.4 41.3 14.7 25.7 35.3 15.4 62.2 26.5 30.7 16.0 26.9 27.4 24.4 24.2 92.2 96.8 38.5 35.8 32.2 41.7 42.5 38.1 32.0 35.3 1.41 0.69 0.53 1.44 0.58 0.83 1.65 0.98 0.69 2.17 0.73 1.71 0.11 0.32 0.12 0.57 1.45 0.64 1.17 2.92 1.84 1.70 0.37 0.89 0.43 0.48 1.45 0.51 0.88 0.95 0.46 1.47 0.49 1.61 0.33 0.98 0.38 0.20 0.57 0.60 0.51 0.25 0.80 1.47 0.96 0.37 1.10 0.40 1.22 2.15 0.75 0.90 1.11 0.73 2.68 0.73 0.45 1.07 0.98 0.40 0.67 1.69 0.54 0.42 1.33 0.36 0.84 0.63 0.89 0.75 0.82 1.52 1.03 1.06 1.03 0.71 0.83 0.32 0.90 10.90 11.76 10.76 9.69 10.90 10.56 9.56 10.98 10.50 9.77 10.60 10.73 10.67 9.00 10.91 10.75 9.00 11.16 9.41 4.15 7.52 11.19 10.58 8.67 11.15 10.64 9.62 10.51 10.75 12.13 10.79 9.64 10.78 10.69 10.86 9.25 11.37 10.58 7.36 9.29 7.52 11.55 10.29 8.73 10.74 9.85 9.00 9.96 9.49 11.37 12.44 12.20 9.72 11.01 5.03 3.21 4.31 1.51 2.80 3.81 1.54 6.89 2.96 3.44 1.76 3.03 2.95 2.73 2.63 10.59 11.12 4.29 3.85 3.39 4.50 4.54 4.05 3.40 3.73 0.18 0.09 0.07 0.19 0.08 0.11 0.22 0.13 0.09 0.28 0.09 0.23 0.01 0.04 0.02 0.07 0.19 0.08 0.15 0.38 0.24 0.22 0.05 0.12 0.06 0.06 0.19 0.07 0.12 0.13 0.06 0.19 0.06 0.21 0.04 0.13 0.05 0.03 0.07 0.08 0.07 0.03 0.10 0.19 0.12 0.05 0.15 0.05 0.16 0.28 0.10 0.12 0.14 0.10 0.33 0.08 * 0.05 0.12 * 0.12 0.05 * 0.07 * 0.20 * 0.07 0.06 * 0.16 0.05 0.10 * 0.08 * 0.11 * 0.09 0.10 0.20 0.12 0.11 0.12 0.08 0.09 0.04 0.09

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
477

535

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Breast (C50) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
478

Male ASR(W) CUM 0-74 0.2 0.2 0.2 0.2 0.2 0.3 0.4 0.2 0.7 0.7 0.4 0.2 0.9 1.0 1.2 0.3 0.3 0.3 0.2 0.3 0.1 0.2 0.5 0.8 0.7 0.6 0.8 0.4 0.9 1.0 0.5 1.0 0.6 0.6 0.5 0.4 0.5 1.2 0.7 0.5 0.9 0.9 0.7 0.5 0.9 0.6 1.1 0.5 0.6 0.8 0.5 0.6 0.8 0.6 0.8 0.5 0.7 1.1 0.7 0.9 0.9 0.8 1.3 0.9 0.2 0.7 0.8 0.4 0.7 0.6 0.7 0.6 0.6 0.6 0.8 0.6 1.4 0.7 0.02 0.07 0.06 0.08 0.08 0.09 0.05 0.12 0.27 0.40 0.14 0.06 0.23 0.20 0.15 0.06 0.07 0.22 0.17 0.09 0.08 0.09 0.13 0.10 0.05 0.15 0.28 0.04 0.12 0.07 0.04 0.08 0.04 0.05 0.11 0.04 0.12 0.24 0.20 0.15 0.17 0.15 0.13 0.16 0.22 0.23 0.22 0.07 0.06 0.11 0.08 0.08 0.09 0.12 0.31 0.07 0.27 0.22 0.20 0.14 0.18 0.34 0.17 0.18 0.12 0.09 0.23 0.20 0.18 0.11 0.14 0.19 0.20 0.30 0.14 0.13 0.27 0.11 0.02 0.02 0.02 0.02 0.03 0.04 0.05 0.03 0.08 0.04 0.03 0.02 0.09 0.12 0.14 0.03 0.02 0.05 0.02 0.03 0.01 0.03 0.07 0.10 0.08 0.06 0.13 0.04 0.10 0.13 0.06 0.11 0.07 0.07 0.05 0.04 0.06 0.12 0.08 0.06 0.09 0.10 0.08 0.07 0.12 0.06 0.15 0.05 0.07 0.09 0.07 0.06 0.09 0.07 0.11 0.06 0.03 0.13 0.07 0.09 0.11 0.07 0.15 0.11 0.03 0.07 0.10 0.06 0.09 0.07 0.08 0.06 0.10 0.06 0.09 0.07 0.17 0.07 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.03 0.02 0.01 0.01 0.03 0.03 0.02 0.01 0.01 0.03 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.04 0.00 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.03 0.03 0.02 0.02 0.02 0.02 0.02 0.03 0.03 0.03 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.05 0.01 0.02 0.03 0.03 0.02 0.03 0.04 0.02 0.02 0.02 0.01 0.03 0.03 0.03 0.02 0.02 0.02 0.04 0.04 0.02 0.02 0.04 0.01

Cases 26441 2540 1857 968 803 1756 163 8501 491 551 519 1055 845 265 1497 5148 5335 4553 270 512 959 538 593 940 3071 23551 1905 998 14046 6288 19351 16212 10984 24587 18687 2828 17864 3610 2268 1513 2547 3514 3675 4278 1599 1825 1212 1929 7317 13711 6113 5075 8997 8671 3965 756 9637 800 2622 1833 4932 2598 575 5368 2808 1058 8570 1840 748 1995 4313 1971 1415 831 667 4074 3155 2088 6894

Female ASR(W) CUM 0-74 23.3 21.2 24.9 25.2 21.2 25.0 16.6 28.8 21.3 41.3 39.2 43.9 20.5 14.6 69.0 55.2 54.1 56.4 45.0 43.5 21.6 22.0 18.2 29.1 34.8 67.2 72.3 75.1 35.6 93.2 101.3 47.9 57.4 55.9 83.7 47.2 80.6 93.9 91.0 79.1 91.8 95.1 90.2 98.1 78.8 86.1 74.5 85.7 62.4 60.9 77.7 64.5 84.9 76.1 76.6 84.6 78.1 81.6 97.4 100.7 87.0 84.1 65.4 94.4 98.2 62.9 84.4 96.3 61.6 95.7 91.0 59.1 73.9 63.7 89.3 86.7 79.3 91.9 91.6 0.15 0.43 0.58 0.83 0.77 0.62 1.32 0.32 1.02 1.85 2.46 1.38 0.73 0.93 1.92 0.81 0.76 0.85 2.86 2.02 0.72 0.97 0.76 0.97 0.63 0.48 1.77 2.52 0.32 1.26 0.78 0.40 0.58 0.38 0.66 0.94 0.64 1.65 2.03 2.15 1.93 1.73 1.57 1.59 2.17 2.16 2.40 2.11 0.79 0.58 1.09 0.97 0.96 0.89 1.34 3.23 0.83 3.28 2.06 2.64 1.38 1.93 3.11 1.45 2.02 1.98 1.02 2.51 2.43 2.39 1.54 1.42 2.07 2.37 3.72 1.52 1.58 2.19 1.22 2.33 2.19 2.49 2.53 2.16 2.55 1.58 2.97 2.08 4.41 4.66 4.74 2.13 1.56 7.65 6.22 5.84 6.12 5.15 4.27 2.23 2.28 1.87 3.14 3.83 7.59 8.22 8.39 3.95 10.54 11.32 5.38 6.41 6.38 9.64 5.31 9.06 10.80 10.50 9.15 10.49 10.68 10.29 11.28 8.89 9.77 8.40 9.80 7.01 6.88 9.00 7.18 9.72 8.59 8.70 9.60 8.79 9.03 11.03 11.45 9.53 9.41 7.15 10.82 11.03 6.99 9.48 10.94 6.94 10.72 10.28 6.54 8.45 7.04 10.22 9.87 9.05 10.20 10.25 0.02 0.05 0.06 0.09 0.09 0.07 0.13 0.04 0.11 0.23 0.38 0.17 0.09 0.12 * 0.25 * 0.11 * 0.09 0.11 0.38 0.22 0.08 * 0.11 * 0.09 0.12 * 0.08 * 0.06 0.22 0.31 0.04 * 0.15 * 0.09 0.05 * 0.07 0.05 0.08 0.11 0.08 0.20 0.25 0.27 0.24 0.20 0.19 0.19 0.25 0.26 0.28 0.25 0.09 0.07 0.13 0.11 0.12 0.11 0.16 0.40 0.10 0.37 0.24 0.30 0.16 0.22 0.35 0.17 0.23 0.24 0.12 0.29 0.29 0.28 0.18 0.16 0.25 0.28 0.44 0.18 0.18 0.26 0.14

201 15 11 4 4 13 0 76 4 6 12 8 6 15 24 83 22 18 2 2 13 3 6 16 68 218 16 9 108 63 207 163 163 213 131 23 73 20 25 12 13 30 35 31 13 20 9 27 48 120 59 33 54 77 29 7 63 8 26 13 49 28 7 65 25 4 71 15 6 18 36 23 10 8 5 37 25 28 48

536

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Breast (C50) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 32 60 11 79 16 17 24 78 67 72 230 88 42 4 29 49 27 4 9 16 24 15 11 18 163 11 5 6 10 9 6 19 358 19 21 58 61 81 156 60 245 320 107 154 37 77 160 3 75 37 6 15 33 7 3 74 25 3 0 5 4 12 Male ASR(W) CUM 0-74 0.4 0.5 0.8 0.4 0.6 0.4 0.4 0.7 0.6 0.5 1.3 0.5 0.6 0.3 0.5 0.7 0.6 0.5 0.3 0.5 0.6 0.7 0.6 0.5 0.4 0.7 0.4 0.9 0.5 0.7 0.6 0.8 0.6 0.5 0.6 0.4 0.6 0.5 0.5 0.6 0.8 0.6 0.5 0.7 0.6 0.4 0.7 0.9 0.6 0.6 0.3 0.1 0.5 0.9 0.8 0.5 0.6 1.0 1.1 0.2 1.0 0.08 0.07 0.25 0.05 0.15 0.10 0.08 0.09 0.08 0.06 0.09 0.06 0.10 0.15 0.11 0.10 0.11 0.28 0.12 0.14 0.13 0.19 0.19 0.13 0.03 0.23 0.20 0.39 0.16 0.23 0.24 0.18 0.03 0.12 0.13 0.06 0.08 0.05 0.05 0.07 0.05 0.03 0.05 0.06 0.10 0.04 0.06 0.55 0.07 0.10 0.13 0.02 0.09 0.33 0.48 0.07 0.13 0.62 0.48 0.13 0.32 0.06 0.07 0.09 0.04 0.06 0.04 0.05 0.09 0.08 0.05 0.16 0.06 0.07 0.03 0.07 0.08 0.06 0.05 0.04 0.05 0.07 0.06 0.08 0.07 0.04 0.09 0.02 0.09 0.05 0.08 0.05 0.09 0.07 0.05 0.07 0.04 0.06 0.06 0.06 0.06 0.09 0.07 0.05 0.08 0.07 0.04 0.08 0.20 0.08 0.08 0.03 0.01 0.07 0.10 0.09 0.06 0.07 0.09 0.11 0.01 0.15 0.01 0.01 0.03 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.03 0.02 0.02 0.02 0.02 0.03 0.02 0.00 0.03 0.02 0.05 0.02 0.03 0.03 0.03 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.13 0.01 0.02 0.02 0.00 0.01 0.04 0.06 0.01 0.02 0.07 0.06 0.01 0.05 Cases 4645 6192 1027 12521 1840 2083 4068 5924 7428 10556 10774 9223 4910 517 2675 4454 2998 389 1460 1651 2282 1447 1232 1998 29643 1759 675 653 1395 1130 975 2547 56440 3486 3193 9817 8126 13745 21597 8802 27384 44467 16611 17740 4688 17137 19216 277 10449 4952 1405 14383 5228 906 339 11339 4078 241 433 667 1311 1184 Female ASR(W) CUM 0-74 44.1 43.7 67.7 71.0 57.0 43.0 53.5 52.0 63.5 47.7 59.1 46.9 58.8 47.7 54.1 64.3 60.2 45.2 66.5 55.9 57.3 66.2 64.1 54.6 78.9 103.0 71.4 90.3 68.0 78.0 90.7 99.1 90.3 90.4 85.9 84.4 79.9 81.3 79.1 85.2 89.1 80.4 82.0 80.9 76.5 79.2 83.1 70.0 86.6 87.5 80.4 83.9 84.4 93.1 75.1 86.5 92.1 59.5 64.3 118.9 107.5 105.6 0.69 0.59 2.20 0.69 1.39 0.99 0.88 0.72 0.79 0.49 0.60 0.51 0.88 2.32 1.17 1.03 1.14 2.70 1.90 1.48 1.28 1.89 2.00 1.34 0.50 2.59 3.00 3.84 1.96 2.53 3.06 2.10 0.40 1.59 1.61 0.93 0.96 0.75 0.58 0.96 0.60 0.41 0.69 0.66 1.19 0.65 0.63 4.55 0.88 1.31 2.25 0.74 1.21 3.19 4.19 0.85 1.52 4.19 3.14 4.69 3.38 3.24 5.00 4.88 7.62 8.05 6.57 4.86 6.09 5.65 7.05 5.33 6.58 5.34 6.66 5.09 5.96 6.98 6.73 4.93 7.34 6.20 6.27 7.09 7.10 6.04 9.07 11.81 7.85 10.44 7.66 8.88 10.35 11.49 10.23 10.37 9.57 9.46 8.90 9.01 8.73 9.46 9.90 8.99 9.08 8.97 8.48 8.79 9.52 7.98 10.06 9.86 9.35 9.63 9.55 10.69 8.36 9.67 10.77 6.84 7.18 14.05 12.66 12.34 0.08 0.07 0.27 0.09 0.17 * 0.12 0.10 0.08 * 0.09 0.06 0.07 0.06 0.11 0.25 0.13 0.12 0.14 0.29 0.22 0.17 0.15 0.21 0.23 0.15 0.06 0.32 0.36 0.47 0.24 0.31 0.37 0.26 0.05 0.20 0.19 0.11 0.12 0.09 0.07 0.12 0.07 0.05 0.08 0.08 0.14 0.08 0.08 0.66 0.11 0.16 0.28 0.09 0.15 0.42 0.54 0.11 0.19 0.54 0.38 0.62 0.40 0.43

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
479

537

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Vulva (C51)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White Male ASR(W) CUM 0-74 Cases 1 31 4 7 16 6 35 5 29 474 5 43 59 11 10 21 1402 153 228 60 69 34 2 65 724 10 57 327 45 274 28 251 1594 59 85 211 1203 337 20 9 8 2 27 260 402 42 2 3 4 1 91 250 197 272 16 253 39 26 11 1182 64 1102 458 69 383 145 27 117 49 837 79 728 403 266 305 321 73 246 26 51 Female ASR(W) CUM 0-74 0.0 0.7 0.3 0.3 0.7 0.5 1.4 0.8 1.5 1.6 0.5 0.9 0.7 0.3 0.6 2.0 1.4 1.3 1.2 1.1 2.3 1.5 1.9 1.5 1.5 1.9 1.2 1.7 1.2 1.9 1.8 1.2 1.2 0.4 1.1 1.0 1.4 1.3 1.2 0.5 0.7 0.2 0.9 1.7 1.1 1.2 0.1 0.3 0.3 0.1 1.0 1.5 1.3 1.5 1.5 1.5 1.6 1.8 0.9 1.5 0.9 1.6 1.5 1.0 1.7 1.5 0.9 1.8 0.9 1.5 1.3 1.6 1.6 1.9 1.8 1.9 1.6 2.0 2.0 2.1 0.04 0.13 0.17 0.13 0.21 0.22 0.24 0.39 0.29 0.08 0.23 0.15 0.09 0.11 0.20 0.44 0.04 0.11 0.09 0.16 0.30 0.28 1.32 0.21 0.06 0.67 0.19 0.11 0.18 0.13 0.35 0.08 0.03 0.05 0.13 0.07 0.05 0.08 0.28 0.16 0.26 0.14 0.19 0.12 0.06 0.19 0.10 0.18 0.15 0.10 0.11 0.11 0.10 0.11 0.38 0.11 0.29 0.38 0.34 0.05 0.11 0.06 0.08 0.12 0.09 0.13 0.19 0.18 0.14 0.06 0.15 0.07 0.09 0.14 0.11 0.11 0.20 0.14 0.40 0.33 0.06 0.14 0.16 0.18 0.17 0.05 0.08 0.07 0.04 0.05 0.23 0.15 0.14 0.12 0.11 0.25 0.17 0.14 0.17 0.15 0.19 0.13 0.18 0.12 0.19 0.19 0.12 0.13 0.04 0.12 0.10 0.16 0.14 0.11 0.07 0.09 0.10 0.18 0.13 0.13 0.02 0.04 0.03 0.12 0.17 0.15 0.16 0.14 0.16 0.16 0.19 0.06 0.15 0.09 0.16 0.16 0.11 0.18 0.16 0.10 0.20 0.09 0.17 0.14 0.17 0.17 0.21 0.20 0.20 0.18 0.22 0.25 0.22 * * * *

0.03 0.04 0.08 0.04 0.01 0.03 0.02 0.01 0.02 0.03 0.07 * 0.01 0.02 0.01 0.02 0.04 0.04 0.10 0.03 0.01 0.08 0.02 0.01 0.02 0.01 0.05 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.03 0.02 0.04 0.03 0.02 0.01 0.03 0.02 0.02 0.03 0.02 0.01 0.01 0.01 0.05 0.02 0.03 0.04 0.04 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.03 0.03 0.02 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.03 0.02 0.06 0.04

538

*Important. See note on population page.

480

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Vulva (C51) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Male ASR(W) CUM 0-74 Cases 134 470 736 55 669 318 37 277 396 24 372 50 14291 985 12897 633 62 560 91 4 20 67 1307 107 1182 820 42 753 221 238 1081 62 999 114 1684 114 1497 4323 106 326 300 3530 264 51 210 941 65 848 81 46 344 235 157 335 1 18 2 0 99 7 37 53 82 1 65 28 8 10 240 233 3 8 15 33 39 35 111 21 Female ASR(W) CUM 0-74 2.1 1.4 1.7 1.2 1.8 1.8 1.1 2.0 1.6 1.2 1.7 1.3 1.5 1.1 1.5 1.5 1.5 1.6 1.2 0.8 0.8 1.6 1.4 1.0 1.6 1.5 0.9 1.6 1.5 1.6 1.7 1.5 1.7 2.2 1.5 1.2 1.6 1.4 0.5 1.3 1.1 1.6 1.5 1.3 1.6 1.3 0.9 1.3 1.2 1.6 1.5 1.5 1.7 1.3 0.2 0.3 0.1 0.3 0.2 1.3 0.6 0.5 0.1 0.3 0.7 0.1 0.3 1.0 1.1 0.2 0.2 0.2 0.5 0.2 0.3 0.2 0.2 0.20 0.08 0.07 0.17 0.08 0.11 0.18 0.14 0.09 0.26 0.10 0.20 0.01 0.04 0.02 0.07 0.19 0.08 0.14 0.41 0.19 0.23 0.05 0.10 0.05 0.06 0.14 0.07 0.11 0.12 0.06 0.20 0.06 0.24 0.04 0.11 0.05 0.02 0.05 0.07 0.06 0.03 0.10 0.19 0.12 0.04 0.11 0.05 0.14 0.26 0.09 0.10 0.15 0.08 0.19 0.06 0.10 0.04 0.08 0.22 0.09 0.06 0.09 0.04 0.14 0.05 0.11 0.07 0.08 0.11 0.07 0.07 0.10 0.04 0.05 0.02 0.05 0.24 0.15 0.18 0.11 0.19 0.18 0.10 0.21 0.17 0.14 0.18 0.13 0.16 0.12 0.16 0.17 0.17 0.18 0.12 0.07 0.07 0.16 0.16 0.12 0.17 0.16 0.09 0.17 0.16 0.18 0.18 0.16 0.17 0.25 0.16 0.11 0.17 0.15 0.05 0.14 0.11 0.18 0.16 0.14 0.17 0.14 0.10 0.14 0.12 0.18 0.16 0.15 0.18 0.14 0.02 0.03 0.01 0.04 0.02 0.15 0.09 0.06 0.04 0.09 0.02 0.05 0.11 0.12 0.03 0.02 0.02 0.05 0.03 0.03 0.02 0.02 0.03 0.01 0.01 0.02 0.01 0.01 0.02 0.02 0.01 0.03 0.01 0.02 0.00 0.00 0.00 0.01 0.03 0.01 0.02 0.04 0.02 0.03 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.01 0.03 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.02 0.01 0.02 0.01 0.02 0.04 0.01 0.01 0.02 0.01 0.02 0.01 * 0.01 * 0.01 * 0.01 * 0.03 * 0.01 0.01 * 0.01 0.02 * 0.01 * 0.02 * 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
481

539

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Vulva (C51) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
482

Male ASR(W) CUM 0-74

Cases 261 25 21 4 9 18 1 69 1 3 2 12 7 3 3 30 53 50 0 3 50 18 14 17 42 674 60 20 691 109 303 502 313 961 429 163 365 63 28 34 41 42 60 45 23 31 12 19 254 487 108 163 194 215 101 12 185 19 47 49 122 61 26 94 49 32 208 39 17 58 105 78 16 29 9 79 106 40 165

Female ASR(W) CUM 0-74 0.2 0.2 0.3 0.1 0.3 0.3 0.1 0.3 0.0 0.3 0.1 0.5 0.2 0.2 0.1 0.4 0.6 0.7 0.3 1.2 0.7 0.5 0.6 0.5 1.4 1.6 1.0 1.2 1.1 1.2 1.2 1.2 1.8 1.5 1.9 1.2 1.2 0.8 1.3 1.0 0.8 1.2 0.6 0.5 0.9 0.3 0.6 1.7 1.6 0.8 1.6 1.4 1.4 1.4 1.0 1.2 1.0 1.2 1.4 1.3 1.2 2.0 1.0 0.9 1.7 1.4 1.2 0.9 1.8 1.4 1.5 0.5 1.4 0.7 1.1 1.6 1.2 1.3 0.01 0.05 0.07 0.06 0.09 0.07 0.06 0.03 0.04 0.19 0.13 0.16 0.07 0.14 0.07 0.08 0.08 0.10 0.20 0.17 0.18 0.12 0.14 0.08 0.06 0.24 0.26 0.05 0.12 0.08 0.06 0.08 0.06 0.08 0.16 0.07 0.17 0.17 0.25 0.18 0.14 0.17 0.11 0.13 0.20 0.12 0.17 0.12 0.09 0.10 0.14 0.11 0.11 0.16 0.32 0.10 0.29 0.20 0.25 0.14 0.19 0.47 0.14 0.15 0.31 0.12 0.25 0.24 0.29 0.16 0.19 0.13 0.29 0.29 0.15 0.19 0.21 0.12 0.03 0.03 0.04 0.01 0.04 0.03 0.04 0.04 0.02 0.07 0.02 0.06 0.01 0.05 0.07 0.08 0.03 0.12 0.08 0.05 0.07 0.06 0.15 0.19 0.08 0.15 0.10 0.12 0.14 0.14 0.19 0.15 0.22 0.13 0.13 0.08 0.14 0.14 0.08 0.12 0.06 0.05 0.10 0.01 0.06 0.19 0.17 0.09 0.20 0.14 0.14 0.15 0.09 0.12 0.09 0.13 0.14 0.16 0.14 0.22 0.09 0.09 0.22 0.16 0.12 0.11 0.21 0.16 0.18 0.04 0.18 0.06 0.13 0.17 0.15 0.14 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.02 0.02 0.01 0.03 * 0.01 * 0.01 * 0.01 0.01 0.03 0.02 * 0.02 * 0.02 0.02 * 0.01 * 0.01 0.04 0.03 0.01 * 0.01 * 0.01 0.01 * 0.01 0.01 0.01 0.02 0.01 0.02 0.02 0.03 0.03 0.02 0.02 0.01 0.02 0.03 0.01 0.02 0.02 0.01 0.01 0.02 0.02 0.01 0.02 0.04 0.01 0.04 0.03 0.03 0.02 0.03 0.06 0.02 0.02 0.05 0.02 0.03 0.04 0.04 0.02 0.03 0.02 0.05 0.03 0.02 0.03 0.03 0.02

540

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Vulva (C51) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White Male ASR(W) CUM 0-74 Cases 206 259 57 373 40 98 82 222 162 436 335 343 172 15 83 115 57 19 36 51 75 56 29 65 766 25 20 10 27 32 9 44 1220 87 60 254 212 372 637 179 690 906 462 531 124 445 394 16 175 96 45 253 90 10 2 231 51 4 5 5 13 20 Female ASR(W) CUM 0-74 1.4 1.3 3.5 1.5 1.0 1.4 0.9 1.4 1.0 1.4 1.5 1.4 1.7 0.7 1.1 1.0 0.9 1.2 1.1 1.1 1.3 1.7 1.1 1.0 1.5 0.9 1.6 0.9 1.1 1.4 0.5 1.2 1.4 1.6 1.2 1.5 1.5 1.7 1.8 1.3 1.6 1.2 1.6 1.8 1.6 1.6 1.3 3.3 1.3 1.1 1.9 1.1 1.2 0.9 0.4 1.4 0.9 0.8 0.6 0.9 0.5 1.6 0.11 0.09 0.49 0.09 0.17 0.16 0.11 0.10 0.08 0.07 0.09 0.08 0.14 0.21 0.14 0.11 0.12 0.33 0.21 0.17 0.16 0.27 0.23 0.15 0.06 0.21 0.42 0.35 0.23 0.28 0.18 0.21 0.05 0.19 0.18 0.11 0.12 0.10 0.08 0.11 0.07 0.05 0.09 0.09 0.16 0.09 0.07 0.87 0.10 0.13 0.31 0.08 0.13 0.28 0.31 0.10 0.15 0.43 0.30 0.43 0.18 0.41 0.16 0.16 0.40 0.14 0.11 0.15 0.10 0.16 0.10 0.15 0.19 0.15 0.18 0.05 0.11 0.11 0.11 0.17 0.12 0.12 0.13 0.21 0.12 0.11 0.16 0.08 0.15 0.12 0.11 0.16 0.07 0.13 0.16 0.17 0.15 0.16 0.14 0.19 0.18 0.14 0.18 0.12 0.17 0.20 0.17 0.16 0.14 0.23 0.14 0.11 0.21 0.12 0.13 0.09 0.08 0.14 0.10 0.12 0.05 0.13 0.05 0.17 0.01 0.01 0.07 0.01 0.02 * 0.02 0.01 0.01 * 0.01 0.01 0.01 0.01 0.02 0.03 0.02 0.02 0.02 0.05 0.03 0.02 0.02 0.04 0.03 0.02 0.01 0.03 0.05 0.05 0.03 0.04 0.03 0.03 0.01 0.03 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.07 0.01 0.02 0.04 0.01 0.02 0.04 0.07 0.01 0.02 0.07 0.03 0.07 0.03 0.05

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
483

541

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Vagina (C52)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White Male ASR(W) CUM 0-74 Cases 4 12 4 6 6 9 37 6 12 255 4 38 25 11 13 2 440 60 70 19 12 11 0 24 226 4 14 102 22 78 8 70 580 58 48 109 356 112 9 2 7 2 15 67 164 24 6 0 1 4 59 62 73 61 7 51 23 15 7 375 49 320 188 58 128 46 18 28 17 239 61 170 127 60 100 118 44 74 13 13 Female ASR(W) CUM 0-74 0.2 0.2 0.4 0.6 0.3 1.0 1.5 0.8 0.6 0.9 0.4 0.7 0.3 0.3 0.9 0.2 0.4 0.6 0.4 0.3 0.4 0.4 0.5 0.5 0.9 0.3 0.5 0.5 0.5 0.6 0.3 0.5 0.4 0.7 0.6 0.4 0.4 0.6 0.1 0.5 0.4 0.6 0.4 0.5 0.8 0.4 0.3 0.5 0.8 0.4 0.5 0.4 0.7 0.3 0.9 0.8 1.0 0.5 0.7 0.5 0.6 0.8 0.6 0.5 0.7 0.4 0.3 0.5 0.9 0.4 0.5 0.4 0.6 0.7 1.0 0.6 1.1 0.7 0.11 0.07 0.20 0.29 0.11 0.33 0.26 0.35 0.17 0.06 0.19 0.13 0.06 0.11 0.26 0.11 0.02 0.08 0.05 0.09 0.12 0.13 0.12 0.03 0.44 0.10 0.06 0.11 0.06 0.21 0.04 0.02 0.06 0.11 0.06 0.03 0.05 0.21 0.10 0.21 0.33 0.16 0.05 0.04 0.16 0.18 0.25 0.25 0.10 0.06 0.06 0.05 0.29 0.05 0.20 0.23 0.40 0.03 0.10 0.03 0.05 0.11 0.06 0.08 0.17 0.09 0.09 0.03 0.12 0.03 0.05 0.06 0.06 0.07 0.16 0.08 0.32 0.25 0.10 0.18 0.13 0.01 0.11 0.02 0.06 0.03 0.03 0.11 0.01 0.05 0.06 0.04 0.04 0.04 0.03 0.06 0.05 0.09 0.03 0.05 0.05 0.06 0.07 0.04 0.05 0.04 0.10 0.07 0.05 0.05 0.08 0.02 0.05 0.03 0.08 0.04 0.06 0.12 0.04 0.03 0.03 0.08 0.05 0.05 0.04 0.07 0.04 0.10 0.08 0.14 0.06 0.08 0.05 0.06 0.09 0.06 0.04 0.08 0.03 0.04 0.05 0.08 0.04 0.06 0.04 0.07 0.07 0.10 0.06 0.15 0.07 * * * *

0.04 0.04 0.07 0.01 0.01 0.01 0.02 0.01 0.01 0.04 0.01 * 0.00 0.01 0.01 0.01 0.02 0.01 0.02 0.00 0.04 0.01 0.01 0.01 0.01 0.03 0.01 0.00 0.01 0.02 0.01 0.00 0.01 0.03 0.01 0.02 0.03 0.03 0.01 0.01 0.03 0.02 0.03 0.02 0.01 0.01 0.01 0.01 0.03 0.01 0.03 0.03 0.07 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.04 0.02

542

*Important. See note on population page.

484

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Vagina (C52) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Male ASR(W) CUM 0-74 Cases 34 127 242 43 194 102 30 70 96 20 75 16 4543 672 3689 163 28 127 35 4 12 18 371 68 294 232 35 189 67 64 276 29 240 23 486 71 379 1376 81 196 150 929 87 22 59 422 59 351 18 15 102 71 49 97 2 13 1 3 48 6 5 71 85 6 127 0 45 7 62 59 3 0 9 10 23 20 69 14 Female ASR(W) CUM 0-74 0.5 0.4 0.6 1.0 0.6 0.6 0.8 0.6 0.4 0.9 0.4 0.6 0.5 0.7 0.5 0.5 0.7 0.4 0.5 1.0 0.6 0.4 0.5 0.7 0.4 0.5 0.8 0.4 0.5 0.4 0.4 0.5 0.4 0.5 0.5 0.8 0.4 0.5 0.4 0.8 0.6 0.4 0.5 0.5 0.5 0.6 0.7 0.5 0.3 0.5 0.4 0.5 0.6 0.4 0.4 0.2 0.1 0.1 0.2 0.2 0.2 0.8 0.5 0.7 0.6 0.7 0.2 0.3 0.3 0.2 0.1 0.3 0.2 0.2 0.1 0.3 0.10 0.04 0.04 0.16 0.04 0.07 0.16 0.08 0.05 0.21 0.05 0.17 0.01 0.03 0.01 0.04 0.14 0.04 0.09 0.49 0.18 0.10 0.03 0.09 0.03 0.03 0.14 0.03 0.06 0.06 0.03 0.11 0.03 0.13 0.02 0.10 0.02 0.01 0.04 0.06 0.05 0.02 0.06 0.11 0.07 0.03 0.10 0.03 0.07 0.14 0.05 0.06 0.10 0.05 0.26 0.06 0.06 0.06 0.03 0.08 0.10 0.10 0.06 0.28 0.06 0.11 0.09 0.04 0.04 0.10 0.06 0.11 0.04 0.06 0.02 0.08 0.05 0.04 0.07 0.11 0.06 0.07 0.09 0.07 0.05 0.08 0.04 0.06 0.05 0.08 0.05 0.05 0.08 0.05 0.06 0.17 0.09 0.04 0.05 0.08 0.05 0.05 0.08 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.09 0.05 0.05 0.04 0.09 0.07 0.05 0.06 0.06 0.05 0.06 0.07 0.06 0.03 0.06 0.05 0.05 0.06 0.04 0.09 0.02 0.02 0.01 0.02 0.02 0.03 0.10 0.06 0.09 0.08 0.08 0.03 0.03 0.03 0.02 0.01 0.03 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.00 0.00 0.00 0.01 0.02 0.01 0.01 0.10 0.03 0.01 0.00 0.01 0.00 0.00 0.02 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.01 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.07 0.01 * 0.02 * 0.01 0.00 * 0.01 * 0.01 * 0.01 0.01 * 0.04 0.01 - * 0.01 * 0.01 * 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
485

543

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Vagina (C52) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
486

Male ASR(W) CUM 0-74

Cases 207 12 32 6 9 15 1 63 4 3 2 9 3 6 6 27 40 37 0 3 15 3 12 3 16 171 6 8 131 31 102 150 73 239 125 45 91 23 9 8 22 15 9 21 4 11 3 6 72 155 50 53 43 72 19 3 43 2 19 14 25 10 3 27 9 9 61 9 4 16 23 15 8 4 3 20 9 5 43

Female ASR(W) CUM 0-74 0.2 0.1 0.5 0.2 0.3 0.2 0.1 0.2 0.2 0.3 0.0 0.4 0.1 0.3 0.3 0.3 0.4 0.5 0.3 0.4 0.1 0.4 0.1 0.2 0.4 0.2 0.7 0.3 0.4 0.5 0.4 0.4 0.5 0.4 0.6 0.3 0.4 0.3 0.3 0.5 0.4 0.2 0.5 0.1 0.4 0.2 0.1 0.5 0.5 0.5 0.5 0.4 0.5 0.2 0.2 0.3 0.1 0.6 0.6 0.2 0.3 0.3 0.3 0.2 0.4 0.4 0.1 0.3 0.3 0.3 0.4 0.3 0.2 0.1 0.2 0.2 0.1 0.4 0.01 0.04 0.08 0.08 0.09 0.06 0.06 0.03 0.12 0.18 0.03 0.14 0.04 0.15 0.14 0.07 0.07 0.08 0.17 0.09 0.07 0.11 0.06 0.05 0.03 0.10 0.25 0.03 0.08 0.05 0.04 0.05 0.03 0.04 0.10 0.04 0.10 0.11 0.12 0.12 0.13 0.07 0.12 0.03 0.14 0.11 0.07 0.06 0.05 0.08 0.08 0.07 0.08 0.06 0.15 0.05 0.04 0.15 0.19 0.06 0.09 0.21 0.08 0.08 0.14 0.07 0.04 0.16 0.10 0.08 0.10 0.12 0.12 0.06 0.05 0.08 0.04 0.07 0.02 0.01 0.06 0.02 0.04 0.04 0.03 0.02 0.05 0.00 0.06 0.01 0.04 0.03 0.04 0.05 0.06 0.05 0.04 0.03 0.02 0.02 0.04 0.02 0.08 0.03 0.06 0.05 0.05 0.04 0.06 0.05 0.07 0.03 0.04 0.03 0.02 0.05 0.03 0.02 0.05 0.04 0.03 0.02 0.05 0.06 0.06 0.05 0.04 0.05 0.02 0.01 0.03 0.08 0.07 0.03 0.03 0.03 0.03 0.02 0.06 0.04 0.05 0.02 0.03 0.04 0.04 0.02 0.02 0.01 0.01 0.04 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.01 0.03 0.00 0.02 0.00 0.02 * 0.02 * 0.01 * 0.01 0.01 0.03 0.01 * - * 0.01 0.01 * 0.01 * 0.00 0.01 0.03 0.00 * 0.01 * 0.01 0.00 * 0.01 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01

544

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Vagina (C52) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White Male ASR(W) CUM 0-74 Cases 39 48 3 78 14 13 20 54 37 95 114 83 59 2 16 18 16 2 10 8 10 5 8 16 194 2 10 5 8 7 3 18 224 11 8 42 41 108 137 33 116 222 106 100 32 104 126 0 62 28 8 52 33 4 0 54 16 3 0 2 3 6 Female ASR(W) CUM 0-74 0.3 0.3 0.2 0.4 0.3 0.2 0.2 0.4 0.3 0.3 0.5 0.4 0.6 0.1 0.2 0.2 0.3 0.1 0.3 0.2 0.2 0.1 0.4 0.3 0.4 0.1 0.8 0.4 0.3 0.3 0.2 0.6 0.3 0.3 0.2 0.3 0.3 0.5 0.5 0.3 0.3 0.3 0.5 0.4 0.5 0.5 0.5 0.4 0.4 0.4 0.2 0.5 0.3 0.4 0.3 0.9 0.3 0.3 0.5 0.07 0.04 0.11 0.05 0.09 0.06 0.06 0.06 0.05 0.04 0.06 0.04 0.08 0.09 0.06 0.06 0.07 0.04 0.10 0.09 0.09 0.06 0.15 0.10 0.03 0.09 0.27 0.22 0.14 0.15 0.14 0.17 0.02 0.08 0.08 0.05 0.06 0.06 0.04 0.05 0.03 0.03 0.05 0.05 0.09 0.06 0.05 0.06 0.08 0.14 0.04 0.09 0.18 0.06 0.08 0.53 0.20 0.19 0.21 0.03 0.03 0.02 0.04 0.02 0.02 0.03 0.04 0.03 0.04 0.07 0.04 0.06 0.03 0.02 0.02 0.03 0.04 0.03 0.01 0.00 0.03 0.03 0.04 0.01 0.09 0.05 0.04 0.03 0.03 0.07 0.03 0.03 0.02 0.03 0.03 0.06 0.05 0.03 0.04 0.04 0.05 0.04 0.06 0.05 0.05 0.05 0.04 0.05 0.02 0.05 0.02 0.04 0.05 0.12 0.04 0.04 0.10 0.01 0.01 0.01 0.01 0.01 * 0.01 0.01 0.01 * 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.00 0.02 0.01 0.00 0.01 0.04 0.03 0.02 0.02 0.02 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.00 0.01 0.02 0.01 0.01 0.07 0.04 0.02 0.05

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
487

545

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Cervix uteri (C53)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White Male ASR(W) CUM 0-74 Cases 229 109 72 649 818 139 1154 302 711 6028 216 1314 1655 637 220 498 5389 797 828 267 191 138 6 295 2623 30 214 1157 391 723 119 965 8109 909 532 2990 3524 1263 112 59 61 13 295 581 2769 262 64 91 23 69 1404 740 799 700 82 600 194 151 23 4771 854 3794 2098 662 1371 647 247 353 216 3401 775 2492 1410 651 1245 1244 513 711 151 126 Female ASR(W) CUM 0-74 11.6 2.1 7.1 45.8 47.3 16.0 37.7 37.7 33.9 21.1 22.2 27.9 18.9 20.0 16.5 43.9 6.9 8.6 5.8 7.0 7.4 7.7 7.0 9.1 6.6 6.3 7.0 7.5 10.3 6.6 6.5 6.0 7.7 6.6 7.1 13.0 6.2 5.8 6.5 3.1 5.2 3.6 10.0 5.0 9.5 7.8 4.9 8.8 4.6 9.8 15.1 6.6 5.9 5.7 8.2 5.5 9.8 12.0 3.8 8.6 12.1 8.3 7.9 9.5 7.4 7.0 8.7 6.1 5.5 8.4 13.1 7.5 7.2 7.0 9.3 8.8 12.0 7.6 11.4 6.7 0.78 0.21 0.86 2.11 1.99 1.42 1.20 2.30 1.32 0.28 1.54 0.82 0.48 0.83 1.16 2.03 0.10 0.31 0.21 0.45 0.57 0.68 3.15 0.55 0.13 1.19 0.50 0.23 0.54 0.26 0.62 0.20 0.09 0.22 0.32 0.25 0.11 0.17 0.64 0.42 0.68 1.04 0.61 0.22 0.19 0.50 0.63 0.94 1.01 1.20 0.42 0.26 0.22 0.23 0.93 0.24 0.73 1.01 0.83 0.13 0.42 0.14 0.18 0.39 0.21 0.29 0.59 0.34 0.39 0.15 0.48 0.16 0.20 0.29 0.27 0.26 0.54 0.30 0.94 0.62 1.54 4.16 4.35 3.80 2.29 2.17 3.02 1.96 2.27 1.86 5.05 0.67 0.82 0.56 0.68 0.71 0.78 1.02 0.86 0.64 0.65 0.67 0.74 1.09 0.63 0.63 0.59 0.77 0.72 0.70 1.37 0.59 0.59 0.58 0.33 0.53 0.33 1.06 0.49 0.98 0.80 0.54 0.98 0.41 1.19 1.62 0.66 0.57 0.58 0.89 0.55 1.05 1.26 0.44 0.85 1.31 0.80 0.79 1.01 0.72 0.74 0.96 0.61 0.55 0.84 1.34 0.75 0.70 0.65 0.91 0.88 1.24 0.73 1.14 0.64 * * * *

0.14 0.16 0.32 0.18 0.04 0.17 0.10 0.06 0.11 0.14 0.27 * 0.01 0.03 0.02 0.05 0.06 0.07 0.58 0.06 0.01 0.13 0.05 0.02 0.07 0.03 0.07 0.02 0.01 0.03 0.04 0.03 0.01 0.02 0.07 0.05 0.08 0.10 0.07 0.02 0.02 0.06 0.08 0.12 0.10 0.17 0.05 0.03 0.02 0.02 0.12 0.03 0.08 0.11 0.11 0.01 0.05 0.01 0.02 0.05 0.02 0.04 0.08 0.04 0.04 0.02 0.05 0.02 0.02 0.03 0.03 0.03 0.06 0.03 0.11 0.06

546

*Important. See note on population page.

488

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Cervix uteri (C53) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Male ASR(W) CUM 0-74 Cases 278 1224 2193 425 1690 1013 337 645 1390 216 1146 206 55469 8693 43436 2339 466 1759 394 27 150 201 4976 1199 3533 2569 302 2191 919 719 3020 415 2487 215 5553 826 4075 17731 1395 2360 3732 9923 1113 399 688 5333 712 4439 311 153 1102 734 591 1247 38 298 2251 33 86 722 133 101 2550 3653 93 3121 741 1138 284 911 853 44 229 204 500 512 651 1963 313 Female ASR(W) CUM 0-74 6.1 5.4 6.7 9.5 6.3 7.4 10.0 6.7 7.4 10.6 7.0 6.9 7.6 10.2 7.2 7.9 11.9 7.5 6.9 5.5 7.5 6.8 7.5 12.2 6.8 6.8 7.0 6.7 8.3 6.5 7.1 10.3 6.6 6.2 6.3 8.5 6.0 7.4 6.6 9.4 12.3 6.4 8.3 10.5 7.6 8.3 9.8 8.2 5.3 7.3 5.8 5.5 9.1 7.6 6.0 4.6 9.8 2.4 3.0 2.8 3.5 4.3 28.0 19.5 10.6 14.5 18.4 17.3 9.4 5.4 5.8 2.4 6.2 6.3 12.2 6.0 10.9 5.6 6.8 0.39 0.16 0.15 0.48 0.16 0.24 0.56 0.28 0.21 0.75 0.22 0.51 0.03 0.11 0.04 0.17 0.56 0.19 0.36 1.08 0.62 0.52 0.11 0.36 0.12 0.14 0.42 0.15 0.29 0.25 0.14 0.52 0.14 0.44 0.09 0.31 0.10 0.06 0.18 0.20 0.21 0.07 0.26 0.55 0.30 0.12 0.38 0.13 0.31 0.62 0.18 0.21 0.40 0.23 1.01 0.27 0.22 0.43 0.33 0.11 0.31 0.45 0.56 0.34 1.11 0.27 0.69 0.53 0.56 0.18 0.20 0.37 0.42 0.49 0.57 0.28 0.48 0.14 0.43 0.62 0.55 0.65 0.96 0.60 0.72 1.00 0.64 0.73 1.04 0.69 0.66 0.75 1.06 0.70 0.80 1.22 0.74 0.69 0.52 0.74 0.67 0.77 1.31 0.68 0.67 0.71 0.65 0.81 0.62 0.70 1.07 0.65 0.59 0.62 0.88 0.58 0.74 0.71 0.97 1.29 0.62 0.81 1.10 0.71 0.81 1.02 0.79 0.49 0.76 0.56 0.53 0.89 0.70 0.67 0.43 1.07 0.28 0.34 0.29 0.36 0.48 3.22 2.25 1.42 1.66 2.10 1.99 1.15 0.55 0.58 0.23 0.66 0.60 1.22 0.56 1.04 0.56 0.64 0.04 0.02 0.02 0.06 0.02 0.03 0.07 0.03 0.02 0.08 0.02 0.05 0.00 0.01 0.00 0.02 0.07 0.02 0.04 0.12 0.07 0.05 0.01 0.04 0.01 0.01 0.05 0.02 0.03 0.03 0.01 0.06 0.01 0.04 0.01 0.04 0.01 0.01 0.02 0.02 0.03 0.01 0.03 0.06 0.03 0.01 0.05 0.01 0.03 0.07 0.02 0.02 0.04 0.02 0.13 0.03 * 0.03 0.06 * 0.04 0.01 * 0.03 * 0.05 * 0.07 0.05 * 0.17 0.04 0.09 * 0.07 * 0.08 * 0.02 0.02 0.04 0.05 0.05 0.06 0.03 0.05 0.01 0.04

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
489

547

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Cervix uteri (C53) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
490

Male ASR(W) CUM 0-74

Cases 17576 1812 1169 696 540 1375 141 5033 283 58 90 416 671 108 159 1966 1023 910 35 78 1297 546 573 136 467 2644 285 82 4015 419 1503 5148 1920 5414 2019 771 788 312 165 135 200 328 237 240 149 161 100 110 1102 1937 539 761 714 747 426 74 930 64 171 105 276 195 33 283 172 83 585 106 65 113 312 183 79 63 46 247 179 112 355

Female ASR(W) CUM 0-74 15.4 15.3 16.0 18.6 14.5 19.8 13.8 17.8 14.2 4.5 5.3 17.9 15.9 6.5 7.5 19.8 10.6 11.5 6.3 7.3 28.9 22.4 17.8 4.4 5.4 8.7 12.0 6.8 10.9 6.6 8.7 18.0 11.5 14.9 10.7 14.7 4.0 8.3 6.9 7.9 7.8 9.8 6.2 5.6 7.6 8.0 7.6 5.8 11.2 11.1 7.7 11.4 7.8 7.0 9.8 9.2 8.1 7.9 7.0 7.2 5.4 7.5 4.4 5.8 6.4 5.0 6.9 6.5 5.7 6.1 7.3 5.7 4.6 5.1 6.5 5.5 4.9 5.6 5.4 0.12 0.36 0.47 0.73 0.64 0.55 1.18 0.26 0.90 0.63 0.83 0.89 0.63 0.64 0.63 0.47 0.34 0.39 1.11 0.86 0.83 0.98 0.76 0.38 0.25 0.18 0.74 0.79 0.18 0.35 0.24 0.26 0.28 0.21 0.25 0.56 0.16 0.49 0.57 0.70 0.57 0.57 0.43 0.39 0.71 0.67 0.83 0.60 0.36 0.28 0.36 0.44 0.31 0.28 0.51 1.09 0.27 1.10 0.58 0.75 0.37 0.62 0.84 0.38 0.53 0.56 0.31 0.69 0.76 0.63 0.46 0.45 0.54 0.67 1.04 0.40 0.41 0.58 0.31 1.67 1.61 1.78 2.02 1.57 2.19 1.51 1.99 1.65 0.50 0.63 2.08 1.67 0.86 0.83 2.14 1.18 1.27 0.69 0.80 3.08 2.35 1.95 0.51 0.61 0.86 1.12 0.69 1.11 0.66 0.86 1.78 1.16 1.48 1.03 1.50 0.40 0.84 0.71 0.77 0.78 0.99 0.60 0.54 0.72 0.82 0.73 0.53 1.07 1.08 0.77 1.09 0.75 0.72 0.96 0.89 0.78 0.81 0.71 0.72 0.57 0.80 0.48 0.61 0.65 0.56 0.68 0.68 0.64 0.61 0.72 0.59 0.46 0.57 0.60 0.57 0.49 0.56 0.54 0.01 0.04 0.06 0.09 0.08 0.07 0.14 0.03 0.12 0.08 0.14 0.12 0.08 0.10 * 0.08 * 0.06 * 0.04 0.05 0.14 0.11 0.10 * 0.11 * 0.09 0.05 * 0.03 * 0.02 0.07 0.08 0.02 * 0.04 * 0.02 0.03 * 0.03 0.02 0.03 0.06 0.02 0.05 0.06 0.07 0.06 0.06 0.04 0.04 0.07 0.07 0.08 0.06 0.04 0.03 0.04 0.04 0.03 0.03 0.05 0.11 0.03 0.11 0.06 0.08 0.04 0.06 0.09 0.04 0.06 0.07 0.03 0.07 0.09 0.06 0.05 0.05 0.06 0.08 0.10 0.04 0.04 0.06 0.03

548

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Cervix uteri (C53) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White Male ASR(W) CUM 0-74 Cases 980 2400 54 1524 502 702 871 1356 1033 1874 4149 2664 1007 52 323 324 415 36 132 167 244 86 129 141 2235 66 58 22 119 86 46 109 3380 177 191 536 728 1289 2081 407 1809 2842 1257 1448 405 1591 1338 48 805 261 108 837 412 49 73 993 298 16 56 56 47 75 Female ASR(W) CUM 0-74 10.4 18.9 3.9 10.0 17.5 15.5 12.5 12.5 10.1 9.3 25.7 15.0 14.5 5.3 7.1 5.0 8.8 5.3 6.6 6.0 6.7 4.3 7.4 4.1 7.0 4.0 6.5 3.5 6.6 6.5 4.4 4.5 5.9 4.9 5.7 5.4 8.3 8.8 9.2 4.2 7.5 5.6 7.5 8.1 7.6 8.9 6.1 10.0 7.0 5.1 7.1 5.1 6.7 5.0 15.6 8.0 7.4 4.7 8.4 9.3 5.2 7.5 0.35 0.40 0.56 0.27 0.80 0.61 0.44 0.35 0.33 0.23 0.42 0.30 0.47 0.79 0.43 0.29 0.44 0.97 0.61 0.49 0.44 0.50 0.70 0.37 0.16 0.54 0.91 0.78 0.63 0.77 0.70 0.47 0.11 0.38 0.43 0.26 0.33 0.26 0.22 0.22 0.19 0.11 0.23 0.23 0.39 0.24 0.17 1.57 0.25 0.33 0.71 0.18 0.34 0.73 1.89 0.26 0.44 1.33 1.15 1.26 0.85 0.91 1.08 1.89 0.39 0.97 1.77 1.62 1.33 1.25 1.01 0.92 2.59 1.47 1.38 0.49 0.75 0.51 0.89 0.54 0.67 0.61 0.69 0.42 0.78 0.44 0.67 0.38 0.66 0.37 0.67 0.65 0.43 0.44 0.58 0.50 0.58 0.48 0.80 0.85 0.85 0.40 0.69 0.54 0.71 0.76 0.72 0.83 0.61 0.97 0.68 0.48 0.70 0.51 0.67 0.51 1.70 0.78 0.70 0.41 0.84 0.86 0.48 0.70 0.04 0.04 0.06 0.03 0.09 * 0.07 0.05 0.04 * 0.03 0.02 0.04 0.03 0.05 0.08 0.05 0.03 0.05 0.10 0.06 0.05 0.05 0.05 0.08 0.04 0.02 0.06 0.10 0.09 0.07 0.08 0.07 0.05 0.01 0.04 0.05 0.02 0.03 0.03 0.02 0.02 0.02 0.01 0.02 0.02 0.04 0.02 0.02 0.19 0.03 0.03 0.07 0.02 0.04 0.09 0.24 0.03 0.04 0.12 0.12 0.13 0.08 0.09

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
491

549

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Corpus uteri (C54)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White Male ASR(W) CUM 0-74 Cases 22 127 32 38 53 87 185 14 110 2025 48 247 548 125 91 47 13240 1569 2129 808 410 260 2 561 6857 84 560 2047 429 1574 235 2436 17933 1495 879 2403 12921 3857 215 171 141 60 330 2719 4814 440 106 165 84 50 995 2827 1992 2793 124 2628 345 215 110 10691 951 9590 3500 739 2715 1159 276 855 686 8021 756 6999 4140 2326 2441 2012 521 1471 145 286 Female ASR(W) CUM 0-74 1.1 2.6 3.4 3.7 4.1 8.2 7.5 2.0 6.1 7.4 4.9 5.9 7.2 4.0 6.2 4.7 15.4 16.8 13.7 18.9 13.9 13.1 2.0 14.8 15.7 14.8 14.9 11.4 11.3 11.4 15.4 12.8 15.8 11.1 12.7 12.3 17.7 16.7 13.6 9.4 12.1 13.2 12.8 19.2 16.1 13.6 8.8 16.0 14.7 7.4 12.3 20.0 14.3 20.4 13.7 21.0 15.1 13.4 16.8 14.6 14.1 14.9 13.0 12.1 13.5 14.1 11.8 15.4 15.5 17.8 12.7 18.6 18.6 20.1 16.1 12.3 11.9 12.8 11.0 12.4 0.24 0.23 0.60 0.64 0.64 0.96 0.59 0.56 0.60 0.17 0.73 0.39 0.32 0.37 0.69 0.70 0.14 0.44 0.32 0.72 0.73 0.85 1.40 0.67 0.20 1.74 0.69 0.27 0.58 0.31 1.05 0.28 0.13 0.29 0.44 0.26 0.17 0.29 0.98 0.74 1.04 1.89 0.73 0.40 0.24 0.67 0.88 1.26 1.74 1.06 0.41 0.41 0.34 0.42 1.26 0.45 0.87 0.99 1.74 0.16 0.47 0.17 0.23 0.47 0.27 0.43 0.75 0.55 0.63 0.21 0.48 0.24 0.31 0.46 0.34 0.29 0.55 0.36 0.94 0.80 0.99 0.94 0.31 0.72 0.93 0.57 0.71 0.85 0.51 0.81 0.65 1.91 2.10 1.70 2.35 1.80 1.57 0.20 1.83 1.94 1.78 1.81 1.39 1.47 1.36 1.90 1.54 1.92 1.28 1.58 1.46 2.19 2.05 1.73 1.11 1.36 1.50 1.58 2.40 1.96 1.69 1.03 1.85 1.66 0.75 1.48 2.49 1.75 2.51 1.81 2.58 1.88 1.68 2.13 1.79 1.86 1.80 1.61 1.58 1.65 1.77 1.58 1.91 1.89 2.19 1.56 2.29 2.27 2.49 1.95 1.48 1.55 1.49 1.38 1.36 * * * *

0.13 0.09 0.11 0.09 0.03 0.10 0.05 0.04 0.06 0.10 0.11 * 0.02 0.06 0.04 0.10 0.10 0.11 0.14 0.09 0.03 0.24 0.09 0.04 0.08 0.04 0.15 0.04 0.02 0.04 0.06 0.04 0.02 0.04 0.14 0.10 0.13 0.23 0.10 0.06 0.03 0.09 0.11 0.16 0.20 0.12 0.06 0.06 0.05 0.06 0.19 0.06 0.12 0.14 0.26 0.02 0.07 0.02 0.03 0.07 0.04 0.06 0.12 0.08 0.09 0.03 0.07 0.03 0.04 0.06 0.05 0.04 0.08 0.05 0.14 0.10

550

*Important. See note on population page.

492

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Corpus uteri (C54) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Male ASR(W) CUM 0-74 Cases 1115 4929 6898 611 6164 2846 485 2330 3828 268 3521 560 139510 10674 123708 6790 575 6039 864 50 215 582 14221 1549 12287 8369 523 7592 1706 2233 11360 578 10565 823 17062 1156 14502 43641 2417 3047 3196 34472 2045 519 1484 8506 775 7526 990 511 3778 2608 1516 3771 33 370 1848 14 70 1358 359 282 171 623 10 547 90 117 82 2363 2187 139 202 145 312 588 463 1263 316 Female ASR(W) CUM 0-74 21.9 20.4 18.9 14.4 19.6 19.0 14.9 20.5 17.5 13.9 18.0 15.7 16.9 13.0 17.4 20.7 14.8 22.1 13.5 10.6 10.6 15.3 19.5 15.8 20.6 19.1 12.3 19.5 12.4 17.0 22.3 13.7 23.1 19.4 17.9 13.5 18.8 16.8 11.8 13.0 12.3 18.4 13.2 13.7 13.0 12.7 11.7 12.9 16.6 21.5 18.0 18.3 19.8 18.9 5.2 6.2 8.8 1.0 2.8 6.0 10.8 11.8 2.0 3.7 1.1 2.8 2.3 1.9 2.8 13.0 13.2 9.0 5.2 3.9 7.2 5.9 6.9 3.3 5.5 0.70 0.31 0.24 0.61 0.27 0.38 0.71 0.46 0.30 0.89 0.33 0.71 0.05 0.13 0.05 0.27 0.63 0.31 0.48 1.52 0.74 0.68 0.17 0.41 0.20 0.22 0.56 0.24 0.32 0.39 0.23 0.60 0.24 0.74 0.15 0.41 0.17 0.09 0.24 0.24 0.23 0.11 0.31 0.63 0.36 0.14 0.44 0.16 0.56 1.01 0.31 0.38 0.54 0.33 0.94 0.32 0.21 0.28 0.34 0.17 0.58 0.72 0.15 0.15 0.35 0.12 0.25 0.18 0.31 0.28 0.30 0.78 0.38 0.35 0.42 0.26 0.34 0.10 0.35 2.67 2.54 2.33 1.84 2.40 2.34 1.87 2.52 2.15 1.85 2.19 1.93 2.07 1.67 2.13 2.59 1.89 2.76 1.62 1.10 1.27 1.87 2.42 2.05 2.55 2.36 1.55 2.39 1.55 2.07 2.72 1.75 2.80 2.40 2.21 1.72 2.33 2.06 1.36 1.65 1.48 2.27 1.61 1.76 1.55 1.55 1.51 1.57 2.06 2.54 2.20 2.27 2.38 2.33 0.55 0.70 0.98 0.12 0.31 0.69 1.16 1.49 0.24 0.47 0.10 0.36 0.26 0.25 0.32 1.63 1.65 1.12 0.61 0.46 0.81 0.69 0.77 0.38 0.64 0.09 0.04 0.03 0.09 0.04 0.05 0.10 0.06 0.04 0.13 0.04 0.10 0.01 0.02 0.01 0.04 0.09 0.04 0.06 0.19 0.10 0.09 0.02 0.06 0.03 0.03 0.08 0.03 0.04 0.05 0.03 0.08 0.03 0.10 0.02 0.06 0.02 0.01 0.03 0.04 0.03 0.01 0.04 0.09 0.05 0.02 0.07 0.02 0.08 0.14 0.04 0.05 0.07 0.04 0.11 0.04 * 0.03 0.04 * 0.04 0.02 * 0.07 * 0.10 * 0.02 0.02 * 0.03 0.02 0.03 * 0.03 * 0.04 * 0.04 0.04 0.11 0.05 0.04 0.05 0.03 0.04 0.01 0.04

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
493

551

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Corpus uteri (C54) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
494

Male ASR(W) CUM 0-74

Cases 3157 274 190 116 77 188 24 972 49 42 29 129 118 14 130 876 867 734 46 87 140 73 90 215 548 4778 371 202 5719 917 2892 5420 2582 8224 3079 939 3535 563 276 232 393 442 446 401 205 295 200 235 1611 3754 620 1159 1544 1407 809 122 1219 144 361 276 820 349 105 701 492 155 1182 350 164 307 650 353 256 187 115 614 571 315 919

Female ASR(W) CUM 0-74 2.9 2.4 2.7 3.3 2.1 2.9 2.5 3.5 2.4 3.6 4.3 5.7 3.1 0.9 6.7 9.9 9.2 9.4 7.8 8.6 3.5 3.1 3.0 7.2 6.5 12.5 12.6 14.5 14.2 11.6 12.9 15.3 12.2 18.1 12.5 14.5 14.4 13.2 9.2 10.8 13.2 10.2 10.0 8.0 8.7 11.5 10.4 8.7 12.1 14.5 6.6 12.9 12.7 11.0 13.3 12.6 9.6 13.1 12.1 13.3 13.7 10.0 11.1 11.0 15.9 8.8 10.9 15.0 12.3 13.4 12.3 9.9 12.3 13.9 14.5 11.4 13.0 12.4 11.6 0.05 0.15 0.20 0.32 0.25 0.22 0.53 0.11 0.36 0.59 0.95 0.51 0.29 0.24 0.62 0.35 0.32 0.36 1.18 0.96 0.30 0.37 0.32 0.50 0.28 0.20 0.71 1.09 0.20 0.42 0.26 0.22 0.26 0.21 0.24 0.50 0.26 0.60 0.61 0.77 0.71 0.54 0.51 0.44 0.68 0.74 0.84 0.63 0.32 0.26 0.30 0.41 0.35 0.32 0.51 1.22 0.29 1.21 0.69 0.90 0.53 0.62 1.24 0.46 0.78 0.73 0.35 0.92 1.04 0.85 0.53 0.56 0.82 1.08 1.46 0.51 0.61 0.76 0.42 0.31 0.27 0.29 0.38 0.22 0.34 0.25 0.39 0.24 0.48 0.49 0.72 0.36 0.13 0.76 1.19 1.07 1.10 1.09 0.93 0.42 0.37 0.33 0.88 0.79 1.59 1.60 1.86 1.73 1.51 1.67 1.90 1.52 2.28 1.60 1.77 1.86 1.70 1.25 1.31 1.67 1.24 1.29 1.01 1.10 1.53 1.31 1.14 1.57 1.82 0.85 1.63 1.64 1.38 1.69 1.49 1.20 1.75 1.46 1.67 1.58 1.20 1.32 1.38 1.99 1.09 1.35 1.84 1.55 1.68 1.49 1.23 1.55 1.72 1.74 1.41 1.56 1.55 1.42 0.01 0.02 0.02 0.04 0.03 0.03 0.06 0.01 0.04 0.09 0.12 0.07 0.04 0.04 * 0.08 * 0.05 * 0.04 0.05 0.19 0.11 0.04 * 0.05 * 0.04 0.07 * 0.04 * 0.03 0.10 0.15 0.02 * 0.06 * 0.04 0.03 * 0.03 0.03 0.04 0.06 0.04 0.08 0.09 0.10 0.10 0.07 0.07 0.06 0.09 0.11 0.11 0.09 0.05 0.04 0.04 0.06 0.05 0.04 0.07 0.16 0.04 0.16 0.09 0.12 0.06 0.08 0.15 0.06 0.10 0.10 0.05 0.12 0.14 0.11 0.07 0.07 0.11 0.14 0.18 0.07 0.08 0.10 0.05

552

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Corpus uteri (C54) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White Male ASR(W) CUM 0-74 Cases 1856 2424 252 2760 485 662 1012 874 1246 3184 2349 3409 1402 141 575 901 597 115 314 448 522 347 269 442 6404 228 108 142 262 160 150 346 7601 487 507 1522 1087 1843 2785 1114 3646 5776 2381 2635 618 2291 2237 36 1418 751 164 2052 593 81 58 1473 806 46 111 158 216 208 Female ASR(W) CUM 0-74 16.4 16.4 16.5 14.2 14.9 13.5 12.4 7.0 9.4 14.0 12.2 17.0 16.2 10.5 10.4 11.4 11.5 11.9 13.0 13.6 12.3 14.6 12.7 10.8 14.6 11.2 10.8 16.9 11.8 9.6 13.0 12.6 11.3 11.9 12.6 12.2 10.1 10.1 9.4 10.3 11.1 9.7 10.8 11.2 9.8 10.0 9.2 10.3 11.3 12.3 8.6 11.5 9.0 8.7 12.9 11.0 19.0 13.1 16.9 28.0 19.6 19.5 0.40 0.35 1.08 0.30 0.70 0.55 0.41 0.25 0.29 0.26 0.26 0.30 0.46 0.99 0.48 0.41 0.49 1.30 0.81 0.70 0.57 0.86 0.86 0.57 0.20 0.81 1.14 1.57 0.79 0.83 1.13 0.74 0.14 0.56 0.59 0.34 0.33 0.26 0.19 0.33 0.20 0.14 0.24 0.24 0.42 0.22 0.21 1.84 0.32 0.48 0.72 0.27 0.39 1.01 1.74 0.30 0.70 2.04 1.63 2.27 1.49 1.43 2.06 1.99 2.08 1.76 1.87 1.71 1.59 0.88 1.18 1.73 1.46 2.16 2.05 1.34 1.33 1.41 1.48 1.45 1.64 1.71 1.51 1.73 1.52 1.35 1.89 1.36 1.38 2.30 1.54 1.23 1.58 1.65 1.40 1.47 1.59 1.57 1.26 1.27 1.19 1.32 1.39 1.24 1.36 1.43 1.21 1.24 1.12 1.26 1.40 1.53 1.00 1.42 1.09 1.17 1.57 1.38 2.20 1.58 1.85 3.29 2.14 2.39 0.05 0.04 0.15 0.04 0.09 * 0.07 0.05 0.03 * 0.04 0.03 0.03 0.04 0.06 0.13 0.06 0.05 0.07 0.16 0.11 0.09 0.07 0.11 0.11 0.07 0.03 0.11 0.16 0.23 0.11 0.12 0.15 0.10 0.02 0.08 0.08 0.05 0.04 0.03 0.03 0.05 0.03 0.02 0.03 0.03 0.06 0.03 0.03 0.28 0.04 0.07 0.10 0.04 0.05 0.15 0.24 0.04 0.09 0.26 0.19 0.30 0.16 0.20

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
495

553

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Uterus unspecified (C55)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White Male ASR(W) CUM 0-74 Cases 6 17 5 19 24 8 176 54 19 915 6 41 57 50 16 0 290 24 33 14 5 5 0 16 174 2 17 65 25 39 5 98 375 28 41 67 232 61 10 2 0 0 5 36 80 17 3 5 1 0 25 26 15 74 5 68 30 20 10 435 68 365 127 46 80 32 9 22 34 343 80 254 79 49 66 71 29 42 6 11 Female ASR(W) CUM 0-74 0.3 0.3 0.5 1.7 1.9 0.8 5.6 7.3 1.0 3.3 0.7 0.9 0.7 1.2 1.3 0.3 0.2 0.1 0.2 0.1 0.2 0.3 0.3 0.3 0.4 0.4 0.7 0.3 0.2 0.5 0.3 0.2 0.5 0.3 0.3 0.2 0.6 0.1 0.2 0.2 0.2 0.4 0.2 0.4 0.2 0.3 0.1 0.1 0.5 0.4 0.5 1.3 1.3 1.5 0.5 1.0 0.5 0.4 0.6 0.4 0.3 0.3 0.3 0.7 0.7 1.3 0.6 0.3 0.4 0.4 0.4 0.6 0.4 0.4 0.4 0.14 0.09 0.22 0.47 0.43 0.30 0.46 1.04 0.24 0.11 0.27 0.14 0.09 0.19 0.34 0.02 0.04 0.03 0.07 0.05 0.10 0.09 0.03 0.28 0.12 0.05 0.15 0.05 0.11 0.06 0.02 0.04 0.09 0.04 0.02 0.04 0.21 0.08 0.08 0.04 0.03 0.12 0.10 0.20 0.22 0.06 0.03 0.03 0.06 0.17 0.07 0.26 0.32 0.52 0.03 0.12 0.03 0.04 0.10 0.04 0.06 0.12 0.08 0.13 0.04 0.15 0.04 0.04 0.06 0.05 0.05 0.11 0.06 0.16 0.14 0.09 0.61 0.84 0.09 0.36 0.07 0.08 0.07 0.11 0.14 0.02 0.02 0.01 0.01 0.00 0.02 0.03 0.03 0.03 0.04 0.04 0.10 0.03 0.01 0.05 0.03 0.03 0.05 0.03 0.03 0.03 0.04 0.01 0.01 0.03 0.02 0.05 0.02 0.07 0.02 0.03 0.01 0.01 0.05 0.02 0.05 0.15 0.15 0.14 0.06 0.12 0.05 0.04 0.07 0.04 0.03 0.04 0.03 0.08 0.08 0.15 0.06 0.03 0.05 0.04 0.05 0.07 0.04 0.03 0.04 * * * *

0.04 0.06 0.15 0.03 0.02 0.03 0.02 0.01 0.03 0.04 - * 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.00 0.03 0.01 0.01 0.02 0.01 0.01 0.01 0.00 0.01 0.01 0.00 0.00 0.00 0.02 0.01 0.01 0.01 0.00 0.02 0.02 0.04 0.02 0.01 0.00 0.00 0.01 0.01 0.01 0.03 0.04 0.06 0.00 0.02 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.02

554

*Important. See note on population page.

496

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Uterus unspecified (C55) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Male ASR(W) CUM 0-74 Cases 26 147 233 40 191 70 24 45 147 13 133 0 4929 866 3906 267 59 206 36 5 9 20 579 147 414 285 45 238 190 27 143 17 123 15 351 53 265 1092 43 177 100 753 87 34 53 642 130 488 9 8 74 26 36 212 9 13 30 3 0 190 27 11 47 125 1 189 14 31 14 292 262 18 26 38 10 99 75 532 42 Female ASR(W) CUM 0-74 0.5 0.5 0.5 0.9 0.5 0.4 0.7 0.3 0.5 0.6 0.5 0.5 1.0 0.5 0.7 1.4 0.7 0.4 0.8 0.4 0.3 0.7 1.4 0.6 0.6 1.0 0.5 1.3 0.2 0.2 0.3 0.2 0.3 0.3 0.6 0.3 0.4 0.2 0.7 0.4 0.3 0.5 0.9 0.4 0.9 1.8 0.8 0.1 0.3 0.3 0.1 0.4 0.9 1.5 0.2 0.2 0.2 0.7 0.8 0.4 0.5 0.7 0.1 1.0 0.3 0.5 0.4 1.6 1.5 1.1 0.6 0.6 0.2 0.7 0.8 1.1 0.4 0.11 0.05 0.04 0.15 0.04 0.06 0.16 0.05 0.05 0.17 0.05 0.01 0.03 0.01 0.05 0.19 0.05 0.08 0.35 0.14 0.08 0.03 0.12 0.03 0.04 0.15 0.04 0.10 0.04 0.02 0.09 0.02 0.08 0.02 0.08 0.02 0.01 0.03 0.05 0.04 0.01 0.06 0.16 0.07 0.04 0.16 0.04 0.04 0.11 0.04 0.03 0.08 0.07 0.53 0.06 0.03 0.13 0.06 0.16 0.15 0.08 0.07 0.12 0.07 0.09 0.09 0.12 0.10 0.10 0.25 0.13 0.13 0.06 0.08 0.11 0.05 0.08 0.05 0.05 0.06 0.10 0.05 0.04 0.08 0.03 0.06 0.07 0.06 0.06 0.12 0.05 0.09 0.17 0.08 0.03 0.04 0.04 0.02 0.08 0.16 0.07 0.06 0.13 0.05 0.14 0.02 0.02 0.03 0.02 0.03 0.03 0.06 0.03 0.04 0.02 0.08 0.03 0.04 0.06 0.12 0.04 0.10 0.19 0.09 0.01 0.03 0.03 0.01 0.04 0.10 0.18 0.02 0.02 0.04 0.07 0.09 0.04 0.06 0.09 0.01 0.11 0.03 0.06 0.05 0.18 0.19 0.11 0.06 0.05 0.02 0.07 0.07 0.10 0.03 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.00 0.00 0.00 0.01 0.03 0.01 0.01 0.02 0.02 0.01 0.00 0.02 0.00 0.00 0.02 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.02 0.01 0.00 0.02 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.06 0.01 * 0.00 0.02 * 0.01 * 0.02 * 0.01 * 0.01 0.01 * 0.01 0.01 0.01 * 0.01 * 0.02 * 0.01 0.01 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
497

555

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Uterus unspecified (C55) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
498

Male ASR(W) CUM 0-74

Cases 626 61 35 16 20 39 2 157 19 9 15 20 31 22 5 196 0 0 0 0 2 0 3 22 21 245 1 6 194 5 181 238 129 265 136 9 74 36 6 5 2 3 14 47 6 33 9 19 83 148 183 65 72 154 38 0 89 0 8 10 47 20 11 18 1 42 174 5 14 16 30 58 14 22 6 18 22 6 142

Female ASR(W) CUM 0-74 0.5 0.5 0.5 0.4 0.5 0.6 0.2 0.6 0.7 0.7 1.4 0.8 0.7 1.2 0.2 2.1 0.1 0.1 0.7 0.2 0.4 0.0 0.3 0.5 0.1 0.8 0.7 0.5 0.5 0.5 0.1 0.2 0.8 0.2 0.3 0.1 0.1 0.3 1.0 0.2 1.2 0.2 0.6 0.5 0.4 1.6 0.5 0.5 0.9 0.5 0.7 0.2 0.4 0.4 0.3 1.0 0.2 0.0 2.1 1.5 0.1 0.6 0.4 0.4 1.4 0.4 1.1 0.6 0.1 0.4 0.2 1.8 0.02 0.07 0.08 0.10 0.12 0.09 0.11 0.05 0.16 0.25 0.51 0.19 0.13 0.28 0.12 0.16 0.04 0.06 0.14 0.05 0.03 0.01 0.12 0.04 0.04 0.07 0.05 0.05 0.03 0.05 0.04 0.03 0.14 0.07 0.13 0.05 0.06 0.08 0.16 0.11 0.25 0.11 0.16 0.06 0.04 0.14 0.07 0.07 0.09 0.09 0.07 0.09 0.13 0.08 0.10 0.37 0.06 0.05 0.35 0.13 0.05 0.19 0.14 0.09 0.21 0.12 0.27 0.30 0.03 0.11 0.08 0.17 0.05 0.07 0.04 0.02 0.06 0.07 0.02 0.05 0.05 0.07 0.20 0.09 0.07 0.16 0.03 0.23 0.00 0.01 0.06 0.02 0.04 0.03 0.06 0.01 0.09 0.07 0.04 0.05 0.06 0.01 0.02 0.08 0.02 0.03 0.00 0.01 0.02 0.11 0.02 0.11 0.02 0.07 0.05 0.03 0.16 0.04 0.05 0.08 0.05 0.08 0.02 0.04 0.03 0.03 0.11 0.02 0.00 0.20 0.17 0.01 0.05 0.04 0.04 0.17 0.03 0.12 0.06 0.00 0.05 0.01 0.19 0.00 0.01 0.01 0.01 0.02 0.01 0.02 0.01 0.01 0.03 0.09 0.02 0.01 0.05 * 0.01 * 0.02 * 0.00 * - * 0.01 0.02 * 0.01 * 0.00 0.02 0.00 * 0.00 * 0.01 0.01 * 0.01 0.00 0.01 0.00 0.00 0.02 0.01 0.02 0.00 0.01 0.01 0.02 0.01 0.03 0.01 0.02 0.01 0.00 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.04 0.01 0.00 0.04 0.02 0.01 0.03 0.02 0.01 0.03 0.02 0.04 0.03 0.00 0.01 0.01 0.02

556

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Uterus unspecified (C55) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White Male ASR(W) CUM 0-74 Cases 22 131 6 53 16 49 22 132 127 61 313 83 53 11 48 52 19 9 14 4 8 10 17 13 664 6 3 1 4 26 6 3 36 0 0 44 92 122 246 72 224 335 187 207 25 214 138 0 43 0 4 109 10 7 15 30 15 0 3 3 5 3 Female ASR(W) CUM 0-74 0.1 0.8 0.3 0.2 0.5 1.0 0.2 1.1 0.7 0.2 1.6 0.3 0.5 0.9 0.8 0.6 0.3 1.1 0.5 0.1 0.1 0.3 0.7 0.2 1.7 0.2 0.3 0.0 0.1 1.5 0.3 0.0 0.1 0.3 0.8 0.6 0.7 0.7 0.5 0.4 0.8 0.8 0.3 0.9 0.5 0.3 0.2 0.5 0.1 0.6 3.3 0.2 0.3 0.3 0.6 0.3 0.3 0.03 0.08 0.14 0.03 0.12 0.15 0.06 0.10 0.07 0.03 0.10 0.04 0.08 0.33 0.14 0.10 0.07 0.43 0.16 0.03 0.05 0.12 0.19 0.08 0.07 0.09 0.19 0.04 0.03 0.32 0.15 0.02 0.01 0.05 0.09 0.06 0.05 0.08 0.04 0.03 0.06 0.06 0.06 0.06 0.05 0.05 0.09 0.06 0.05 0.25 0.86 0.03 0.08 0.20 0.37 0.16 0.18 0.01 0.09 0.03 0.02 0.05 0.10 0.03 0.12 0.07 0.03 0.18 0.03 0.06 0.07 0.09 0.06 0.03 0.10 0.06 0.01 0.01 0.04 0.08 0.03 0.19 0.04 0.03 0.20 0.03 0.01 0.03 0.09 0.07 0.08 0.07 0.06 0.05 0.08 0.08 0.02 0.11 0.06 0.03 0.02 0.05 0.01 0.07 0.34 0.02 0.04 0.02 0.08 0.03 0.04 0.00 0.01 0.02 0.00 0.01 * 0.02 0.01 0.01 * 0.01 0.00 0.01 0.00 0.01 0.03 0.02 0.01 0.01 0.04 0.02 0.01 0.01 0.02 0.02 0.01 0.01 0.02 0.02 0.05 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.04 0.10 0.00 0.01 0.02 0.05 0.02 0.03

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
499

557

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Ovary (C56)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data 558
500

Male ASR(W) CUM 0-74

Cases 53 290 34 114 122 97 331 52 126 3197 81 426 483 207 70 68 8326 815 1365 428 283 137 4 342 4580 46 326 1721 270 1431 129 1702 11298 996 478 1758 7981 2275 121 130 83 31 226 1562 2961 216 104 86 52 40 739 1633 1467 1412 45 1340 193 123 59 7411 510 6817 2573 477 2061 843 206 612 440 4556 417 3987 2204 1275 1516 1438 322 1111 106 234

Female ASR(W) CUM 0-74 2.1 5.1 3.3 8.1 6.8 9.1 11.0 6.2 6.6 11.6 8.6 9.5 5.9 6.4 5.2 6.0 9.4 8.3 8.3 9.5 9.4 7.3 3.9 8.8 10.3 8.1 8.0 9.5 6.9 10.2 8.3 8.8 9.9 7.5 6.6 8.7 11.0 9.9 7.2 7.7 7.2 7.7 8.5 11.1 9.7 6.4 8.2 8.6 9.8 6.0 8.9 11.7 10.2 10.0 4.8 10.4 9.0 8.4 9.4 10.1 7.1 10.6 9.3 7.2 10.0 9.9 8.2 10.7 9.4 9.8 7.0 10.2 9.5 10.3 9.7 8.7 7.2 9.5 7.9 10.0 0.31 0.31 0.57 0.92 0.79 1.00 0.66 0.90 0.61 0.21 0.98 0.47 0.28 0.46 0.66 0.75 0.11 0.31 0.24 0.51 0.61 0.65 2.07 0.52 0.16 1.33 0.50 0.25 0.45 0.29 0.76 0.23 0.10 0.24 0.31 0.22 0.14 0.22 0.68 0.73 0.81 1.47 0.58 0.31 0.19 0.46 0.84 0.94 1.44 0.98 0.34 0.33 0.28 0.29 0.73 0.32 0.71 0.82 1.42 0.13 0.33 0.15 0.19 0.35 0.23 0.36 0.61 0.46 0.49 0.16 0.35 0.18 0.22 0.33 0.27 0.25 0.42 0.31 0.80 0.73 1.05 1.25 0.66 0.72 1.34 0.87 1.10 0.67 0.72 0.52 0.64 1.07 0.95 0.93 1.08 1.09 0.85 0.11 1.02 1.17 0.79 0.90 1.12 0.82 1.20 0.94 0.99 1.13 0.81 0.76 0.99 1.28 1.12 0.81 0.79 0.78 0.82 0.98 1.29 1.11 0.74 0.86 0.96 1.12 0.68 0.99 1.36 1.17 1.16 0.58 1.21 1.02 0.96 0.99 1.16 0.80 1.21 1.09 0.82 1.18 1.18 0.94 1.29 1.04 1.12 0.78 1.17 1.10 1.16 1.09 1.01 0.84 1.10 0.91 1.14 * * * *

0.13 0.09 0.12 0.08 0.03 0.11 0.06 0.04 0.06 0.07 0.09 * 0.01 0.04 0.03 0.06 0.08 0.08 0.07 0.07 0.02 0.15 0.06 0.03 0.06 0.04 0.10 0.03 0.01 0.03 0.04 0.03 0.02 0.03 0.09 0.08 0.10 0.16 0.08 0.04 0.02 0.06 0.10 0.11 0.17 0.13 0.05 0.04 0.04 0.04 0.10 0.04 0.09 0.10 0.17 0.02 0.05 0.02 0.03 0.05 0.03 0.05 0.09 0.06 0.06 0.02 0.05 0.02 0.03 0.04 0.03 0.03 0.06 0.04 0.11 0.09

*Important. See note on population page.

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Ovary (C56) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Male ASR(W) CUM 0-74 Cases 538 2656 3771 336 3385 1586 258 1313 2101 131 1950 394 84293 5946 75272 3942 320 3473 602 47 166 382 8177 818 7068 4229 255 3886 1302 1325 5647 301 5213 426 9907 657 8477 26634 1518 1762 2344 20761 1361 273 1069 5991 478 5358 601 223 2414 1670 831 2179 49 322 47 133 1634 139 190 559 1802 45 1541 282 443 148 1741 1617 64 232 239 313 668 448 1994 352 Female ASR(W) CUM 0-74 9.6 10.4 9.9 7.4 10.4 10.0 7.4 11.0 9.2 6.4 9.6 10.9 9.9 6.9 10.3 11.7 8.1 12.3 9.2 10.9 7.9 10.1 11.0 8.1 11.6 9.3 5.9 9.6 9.5 9.8 10.6 6.7 10.8 10.1 10.1 7.2 10.6 10.0 7.4 7.2 8.7 10.9 8.6 6.8 9.1 8.7 6.8 9.0 9.6 9.4 11.3 11.4 10.3 10.6 7.4 5.5 3.7 5.2 7.1 4.1 8.1 6.0 9.4 4.8 7.1 6.4 6.8 4.8 9.5 9.9 3.7 6.3 6.7 7.8 7.0 6.6 5.3 6.2 0.46 0.22 0.18 0.43 0.19 0.27 0.49 0.34 0.22 0.59 0.24 0.60 0.04 0.09 0.04 0.20 0.47 0.23 0.40 1.62 0.64 0.57 0.13 0.29 0.15 0.16 0.39 0.17 0.29 0.29 0.16 0.41 0.17 0.55 0.11 0.29 0.13 0.07 0.19 0.18 0.19 0.08 0.25 0.44 0.30 0.12 0.32 0.13 0.41 0.67 0.25 0.30 0.39 0.25 1.10 0.31 0.56 0.46 0.19 0.35 0.61 0.26 0.23 0.73 0.19 0.39 0.33 0.40 0.24 0.26 0.48 0.44 0.49 0.46 0.29 0.36 0.13 0.38 1.10 1.18 1.14 0.85 1.18 1.14 0.85 1.25 1.05 0.72 1.08 1.25 1.14 0.79 1.19 1.32 0.90 1.40 1.07 1.27 0.90 1.17 1.25 0.92 1.33 1.07 0.68 1.11 1.08 1.13 1.21 0.76 1.23 1.13 1.15 0.83 1.23 1.15 0.79 0.82 0.98 1.26 1.00 0.75 1.07 0.98 0.78 1.01 1.06 1.09 1.33 1.34 1.18 1.23 0.67 0.60 0.38 0.58 0.75 0.41 0.98 0.67 1.03 0.53 0.80 0.65 0.81 0.52 1.10 1.14 0.47 0.65 0.72 0.81 0.72 0.68 0.56 0.64 0.06 0.03 0.02 0.06 0.02 0.04 0.07 0.04 0.03 0.08 0.03 0.08 0.00 0.01 0.01 0.03 0.06 0.03 0.05 0.22 0.08 0.07 0.02 0.04 0.02 0.02 0.05 0.02 0.04 0.04 0.02 0.05 0.02 0.07 0.01 0.04 0.02 0.01 0.02 0.02 0.03 0.01 0.03 0.06 0.04 0.02 0.05 0.02 0.05 0.09 0.03 0.04 0.05 0.03 0.14 0.04 * 0.06 * 0.06 0.02 * 0.04 * 0.08 * 0.03 0.03 * 0.09 0.03 0.04 * 0.05 * 0.05 * 0.03 0.03 0.07 0.05 0.05 0.05 0.03 0.04 0.01 0.04

*Important. See note on population page. Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data Cancer Incidence in Five Continents Vol. IX, IARC 2007

501

559

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Ovary (C56) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
502

Male ASR(W) CUM 0-74

Cases 5334 565 340 167 186 354 43 1618 116 64 60 230 289 111 201 1133 771 619 44 108 235 124 178 195 425 4153 338 128 4081 622 2208 3729 2529 5834 2984 784 2217 398 246 191 336 371 378 311 232 199 129 165 1175 2561 861 842 1267 1402 560 105 1531 96 243 163 593 308 82 574 310 127 881 268 107 209 482 297 161 110 95 483 420 252 680

Female ASR(W) CUM 0-74 4.9 5.1 4.9 4.7 5.2 5.4 4.5 5.9 5.8 5.4 5.8 9.7 6.7 6.2 8.8 11.8 8.2 8.0 7.1 10.1 5.6 5.4 5.6 6.1 4.9 11.3 12.1 9.3 10.4 8.2 10.5 11.3 13.3 13.6 13.2 12.3 9.6 9.8 8.7 9.2 11.8 9.2 8.6 6.9 10.1 8.9 7.0 6.5 9.3 10.4 9.7 10.0 10.9 11.3 10.1 10.6 11.8 9.1 9.3 7.7 10.0 10.2 8.4 9.1 9.4 7.6 8.8 11.9 9.5 9.1 9.3 8.3 7.8 8.3 11.0 9.6 9.9 10.5 8.0 0.07 0.22 0.27 0.38 0.39 0.30 0.70 0.15 0.57 0.72 1.03 0.65 0.41 0.62 0.67 0.37 0.30 0.33 1.12 1.01 0.38 0.50 0.43 0.45 0.24 0.20 0.72 0.88 0.17 0.36 0.24 0.20 0.28 0.19 0.26 0.48 0.22 0.53 0.61 0.73 0.70 0.52 0.48 0.42 0.75 0.68 0.72 0.57 0.30 0.24 0.38 0.38 0.34 0.34 0.49 1.11 0.32 1.07 0.69 0.70 0.46 0.72 1.07 0.45 0.63 0.69 0.34 0.86 1.02 0.72 0.51 0.53 0.67 0.85 1.25 0.50 0.58 0.73 0.35 0.50 0.53 0.52 0.47 0.55 0.56 0.45 0.63 0.59 0.61 0.75 1.07 0.69 0.71 0.97 1.32 0.88 0.86 0.72 1.07 0.60 0.54 0.58 0.74 0.56 1.25 1.31 1.03 1.17 0.99 1.20 1.26 1.51 1.54 1.60 1.41 1.11 1.12 1.04 1.03 1.34 1.13 0.97 0.80 1.21 1.10 0.82 0.83 1.06 1.22 1.13 1.14 1.25 1.29 1.10 1.19 1.37 1.07 1.05 0.86 1.16 1.11 0.93 0.98 1.05 0.88 0.97 1.35 1.02 1.04 1.00 0.88 0.87 0.98 1.24 1.09 1.07 1.19 0.90 0.01 0.03 0.03 0.04 0.05 0.04 0.08 0.02 0.07 0.10 0.18 0.08 0.05 0.09 * 0.09 * 0.05 * 0.04 0.04 0.13 0.12 0.04 * 0.05 * 0.05 0.06 * 0.03 * 0.02 0.09 0.11 0.02 * 0.05 * 0.03 0.02 * 0.03 0.02 0.03 0.06 0.03 0.07 0.08 0.09 0.08 0.07 0.06 0.05 0.09 0.09 0.09 0.07 0.04 0.03 0.05 0.05 0.04 0.04 0.06 0.14 0.04 0.13 0.08 0.08 0.05 0.08 0.13 0.05 0.07 0.09 0.04 0.10 0.11 0.09 0.06 0.06 0.08 0.10 0.16 0.06 0.06 0.09 0.04

Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data 560

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Ovary (C56) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White Male ASR(W) CUM 0-74 Cases 1405 2120 159 2343 473 563 797 477 902 2547 1720 2140 818 77 600 581 388 81 195 256 338 214 167 264 3989 185 111 82 224 128 128 256 5946 392 345 1543 1294 1963 3399 1246 4131 6896 2494 2789 905 2656 1967 24 1035 494 148 1515 500 84 36 1262 381 24 59 50 111 110 Female ASR(W) CUM 0-74 13.2 14.5 10.8 12.8 14.9 11.7 10.4 4.3 7.3 11.6 9.6 11.0 9.7 6.4 11.4 8.1 7.8 8.4 7.9 8.3 8.2 9.1 8.3 7.1 10.5 9.2 11.9 10.5 9.7 9.1 10.7 9.2 9.2 10.0 9.4 12.2 11.9 11.0 11.4 11.6 12.7 11.8 11.6 12.1 14.8 11.1 7.9 6.1 8.2 7.9 7.8 8.1 7.6 8.4 8.2 9.3 8.6 5.6 8.5 8.8 10.3 9.3 0.38 0.34 0.89 0.29 0.72 0.52 0.39 0.21 0.27 0.25 0.25 0.25 0.36 0.84 0.56 0.37 0.42 1.18 0.65 0.56 0.48 0.69 0.71 0.49 0.18 0.74 1.23 1.37 0.72 0.89 1.02 0.64 0.13 0.54 0.55 0.35 0.37 0.27 0.22 0.36 0.22 0.16 0.26 0.25 0.53 0.24 0.19 1.38 0.27 0.40 0.69 0.23 0.36 0.96 1.40 0.28 0.48 1.27 1.14 1.28 1.20 0.96 1.48 1.64 1.25 1.48 1.66 1.30 1.21 0.47 0.81 1.28 1.06 1.24 1.12 0.70 1.25 0.91 0.89 0.86 0.86 0.90 0.93 1.04 0.92 0.80 1.23 1.05 1.35 1.17 1.16 1.09 1.23 1.13 1.08 1.20 1.09 1.44 1.39 1.30 1.34 1.39 1.51 1.39 1.38 1.42 1.65 1.30 0.89 0.72 0.93 0.86 0.94 0.91 0.85 0.95 1.07 1.04 0.92 0.63 0.77 0.92 1.12 0.99 0.04 0.04 0.11 0.04 0.09 * 0.06 0.05 0.02 * 0.03 0.03 0.03 0.03 0.04 0.10 0.06 0.04 0.05 0.12 0.08 0.06 0.06 0.08 0.08 0.06 0.02 0.10 0.15 0.16 0.10 0.11 0.13 0.08 0.02 0.07 0.07 0.04 0.05 0.03 0.03 0.05 0.03 0.02 0.03 0.03 0.06 0.03 0.02 0.20 0.04 0.05 0.09 0.03 0.05 0.13 0.21 0.04 0.06 0.16 0.12 0.16 0.12 0.12

*Important. See note on population page. Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data Cancer Incidence in Five Continents Vol. IX, IARC 2007

503

561

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other female genital organs (C57)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White Male ASR(W) CUM 0-74 Cases 1 7 4 1 1 54 101 3 0 144 2 20 17 4 6 1 577 44 41 15 4 9 0 11 434 4 15 37 5 32 9 69 500 36 28 59 373 104 10 5 3 0 7 72 141 13 2 3 0 0 24 95 63 62 2 59 10 4 5 313 25 285 105 23 80 40 14 26 23 178 18 153 80 70 51 31 10 21 3 7 Female ASR(W) CUM 0-74 0.0 0.1 0.4 0.1 0.1 7.3 2.2 0.4 0.5 0.2 0.4 0.2 0.1 0.4 0.1 0.7 0.5 0.3 0.3 0.1 0.4 0.3 1.0 0.8 0.4 0.2 0.1 0.2 0.7 0.4 0.4 0.3 0.4 0.3 0.5 0.5 0.6 0.2 0.3 0.3 0.5 0.5 0.4 0.2 0.3 0.3 0.6 0.4 0.4 0.2 0.5 0.3 0.2 0.6 0.4 0.3 0.4 0.4 0.4 0.4 0.5 0.6 0.5 0.5 0.4 0.3 0.4 0.4 0.5 0.3 0.1 0.2 0.1 0.2 0.2 0.04 0.05 0.18 0.05 0.05 0.99 0.24 0.26 0.04 0.15 0.10 0.05 0.05 0.16 0.10 0.03 0.07 0.05 0.09 0.07 0.14 0.10 0.05 0.42 0.11 0.03 0.06 0.04 0.24 0.05 0.02 0.04 0.07 0.04 0.03 0.05 0.19 0.10 0.17 0.12 0.07 0.04 0.12 0.12 0.16 0.06 0.07 0.06 0.06 0.15 0.07 0.12 0.13 0.30 0.03 0.07 0.03 0.04 0.08 0.04 0.09 0.17 0.10 0.11 0.03 0.07 0.04 0.04 0.07 0.05 0.03 0.06 0.03 0.11 0.09 0.59 0.21 0.05 0.05 0.02 0.05 0.02 0.01 0.05 0.01 0.08 0.05 0.03 0.04 0.02 0.04 0.04 0.12 0.13 0.05 0.02 0.01 0.02 0.08 0.05 0.05 0.03 0.04 0.03 0.06 0.06 0.05 0.03 0.04 0.04 0.07 0.06 0.05 0.02 0.04 0.04 0.08 0.05 0.05 0.02 0.05 0.03 0.02 0.04 0.05 0.03 0.05 0.05 0.05 0.05 0.07 0.08 0.06 0.05 0.05 0.04 0.05 0.04 0.06 0.05 0.02 0.02 0.01 0.03 0.03 * * * *

0.08 0.03 0.03 0.01 0.02 0.01 0.01 0.00 0.02 0.01 * 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.07 0.02 0.00 0.01 0.01 0.03 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.02 0.02 0.02 0.01 0.01 0.02 0.02 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.04 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.03 0.02 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.02 0.02

562

*Important. See note on population page.

504

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other female genital organs (C57) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Male ASR(W) CUM 0-74 Cases 38 121 127 14 108 52 9 40 94 7 87 11 3315 274 2913 137 13 115 27 1 10 15 319 36 273 134 13 119 44 76 189 13 172 21 452 37 379 1097 60 84 83 857 61 7 54 218 31 179 25 13 124 85 23 73 2 14 5 1 81 5 1 8 36 0 35 1 6 4 111 105 2 3 6 5 14 17 39 5 Female ASR(W) CUM 0-74 0.7 0.5 0.3 0.3 0.3 0.3 0.2 0.3 0.4 0.3 0.4 0.3 0.4 0.3 0.4 0.4 0.4 0.4 0.4 0.2 0.5 0.4 0.4 0.3 0.5 0.3 0.3 0.3 0.3 0.6 0.3 0.2 0.3 0.5 0.5 0.4 0.5 0.4 0.3 0.3 0.3 0.4 0.4 0.1 0.5 0.3 0.4 0.3 0.4 0.5 0.6 0.6 0.2 0.3 0.4 0.2 0.4 0.0 0.3 0.1 0.0 0.1 0.2 0.2 0.0 0.1 0.1 0.6 0.6 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.13 0.05 0.03 0.08 0.03 0.05 0.08 0.06 0.05 0.11 0.05 0.09 0.01 0.02 0.01 0.04 0.10 0.04 0.08 0.23 0.15 0.11 0.03 0.06 0.03 0.03 0.09 0.03 0.05 0.07 0.03 0.07 0.03 0.12 0.02 0.07 0.03 0.01 0.04 0.04 0.04 0.02 0.05 0.06 0.07 0.02 0.09 0.02 0.09 0.16 0.06 0.07 0.06 0.04 0.26 0.06 0.17 0.04 0.04 0.07 0.04 0.03 0.03 0.03 0.03 0.04 0.07 0.06 0.06 0.09 0.05 0.08 0.06 0.03 0.06 0.02 0.04 0.09 0.06 0.04 0.03 0.04 0.04 0.03 0.04 0.05 0.02 0.05 0.03 0.05 0.04 0.05 0.06 0.05 0.06 0.06 0.02 0.05 0.06 0.05 0.04 0.05 0.04 0.04 0.04 0.04 0.07 0.04 0.03 0.04 0.06 0.06 0.05 0.06 0.05 0.04 0.04 0.04 0.06 0.04 0.02 0.05 0.04 0.05 0.04 0.05 0.05 0.08 0.07 0.02 0.04 0.09 0.03 0.04 0.04 0.02 0.01 0.01 0.02 0.02 0.00 0.01 0.01 0.07 0.07 0.03 0.01 0.02 0.01 0.01 0.03 0.01 0.01 0.02 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.02 0.01 0.01 0.02 0.02 0.02 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.02 0.00 0.01 0.00 0.00 0.01 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.07 0.01 * 0.02 * 0.01 * 0.01 * 0.01 * 0.00 0.00 * 0.00 0.00 * 0.00 * 0.01 * 0.01 0.01 0.02 0.01 0.01 0.01 0.00 0.01 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
505

563

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other female genital organs (C57) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
506

Male ASR(W) CUM 0-74

Cases 152 14 13 3 6 14 2 34 3 1 0 3 2 0 0 13 26 20 5 1 15 1 3 2 15 275 23 9 211 26 54 105 101 355 163 30 293 23 13 7 8 7 20 17 14 21 1 6 122 180 56 61 54 66 26 6 33 7 36 14 27 26 2 18 15 2 231 8 8 11 26 17 4 5 0 32 10 12 118

Female ASR(W) CUM 0-74 0.1 0.1 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.3 0.3 0.6 0.1 0.4 0.0 0.1 0.1 0.2 0.8 0.9 0.6 0.4 0.3 0.3 0.3 0.5 0.7 0.7 0.4 1.1 0.6 0.4 0.4 0.3 0.2 0.5 0.3 0.4 0.9 0.0 0.3 0.8 0.6 0.5 0.7 0.5 0.5 0.5 0.8 0.3 0.9 1.2 0.5 0.4 0.8 0.3 0.2 0.5 0.1 1.8 0.4 0.5 0.5 0.5 0.4 0.2 0.3 0.6 0.2 0.5 1.5 0.01 0.03 0.05 0.05 0.07 0.06 0.14 0.02 0.11 0.08 0.08 0.04 0.04 0.06 0.06 0.27 0.13 0.10 0.03 0.05 0.05 0.05 0.05 0.20 0.22 0.03 0.08 0.04 0.03 0.05 0.04 0.06 0.08 0.07 0.14 0.12 0.16 0.10 0.08 0.12 0.09 0.14 0.21 0.02 0.11 0.08 0.05 0.08 0.10 0.07 0.07 0.10 0.33 0.05 0.37 0.22 0.17 0.09 0.19 0.18 0.06 0.14 0.09 0.15 0.15 0.19 0.18 0.10 0.10 0.11 0.16 0.11 0.08 0.15 0.15 0.02 0.01 0.02 0.01 0.01 0.03 0.02 0.02 0.02 0.01 0.01 0.01 0.02 0.03 0.03 0.05 0.02 0.04 0.00 0.01 0.01 0.02 0.09 0.10 0.07 0.05 0.04 0.03 0.03 0.06 0.07 0.08 0.05 0.13 0.07 0.04 0.06 0.04 0.02 0.07 0.04 0.05 0.12 0.03 0.10 0.07 0.06 0.09 0.06 0.06 0.05 0.10 0.03 0.08 0.12 0.06 0.05 0.08 0.04 0.03 0.04 0.01 0.19 0.05 0.04 0.05 0.05 0.04 0.02 0.05 0.07 0.03 0.07 0.17 0.00 0.00 0.01 0.01 0.01 0.01 0.02 0.00 0.01 0.01 0.01 0.01 - * - * 0.01 * 0.01 0.01 0.02 0.02 0.01 * 0.00 * 0.00 0.01 * 0.01 * 0.01 0.02 0.03 0.00 * 0.01 * 0.00 0.00 * 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.01 0.02 0.01 0.02 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.04 0.01 0.03 0.03 0.02 0.01 0.02 0.03 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.02

564

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other female genital organs (C57) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White Male ASR(W) CUM 0-74 Cases 39 41 6 160 10 22 30 128 56 67 101 75 52 13 31 34 27 4 9 3 17 9 11 10 296 11 2 8 19 17 3 19 206 13 22 23 20 48 45 26 189 123 46 86 20 79 92 1 41 29 10 80 28 4 2 62 15 1 2 1 1 5 Female ASR(W) CUM 0-74 0.4 0.3 0.4 0.8 0.3 0.4 0.4 1.0 0.3 0.3 0.6 0.3 0.6 0.9 0.6 0.4 0.4 0.4 0.3 0.1 0.4 0.2 0.3 0.2 0.7 0.6 0.1 0.9 0.7 0.7 0.2 0.5 0.3 0.3 0.5 0.2 0.2 0.3 0.2 0.3 0.6 0.2 0.2 0.3 0.3 0.3 0.4 0.2 0.3 0.5 0.6 0.4 0.4 0.4 0.5 0.4 0.3 0.2 0.3 0.2 0.1 0.4 0.08 0.05 0.19 0.07 0.09 0.09 0.07 0.10 0.05 0.04 0.06 0.04 0.08 0.29 0.11 0.07 0.09 0.22 0.12 0.06 0.10 0.07 0.12 0.07 0.05 0.19 0.09 0.35 0.17 0.20 0.12 0.14 0.02 0.08 0.12 0.05 0.05 0.05 0.03 0.06 0.05 0.02 0.03 0.04 0.07 0.04 0.04 0.17 0.05 0.10 0.20 0.05 0.09 0.19 0.36 0.06 0.09 0.19 0.24 0.17 0.13 0.17 0.05 0.03 0.04 0.10 0.03 0.04 0.04 0.12 0.03 0.03 0.06 0.04 0.07 0.11 0.06 0.04 0.05 0.03 0.05 0.01 0.05 0.01 0.03 0.01 0.09 0.07 0.02 0.11 0.09 0.10 0.01 0.07 0.04 0.03 0.07 0.03 0.02 0.03 0.02 0.03 0.07 0.03 0.02 0.04 0.04 0.03 0.05 0.01 0.04 0.07 0.09 0.05 0.06 0.06 0.07 0.06 0.03 0.05 0.03 0.04 0.01 0.02 0.01 0.01 0.02 0.01 0.01 * 0.01 0.01 0.01 * 0.01 0.00 0.01 0.01 0.01 0.04 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.03 0.02 0.05 0.03 0.03 0.01 0.02 0.00 0.01 0.02 0.01 0.01 0.01 0.00 0.01 0.01 0.00 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.03 0.01 0.01 0.04 0.05 0.01 0.01 0.05 0.02 0.04 0.01 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
507

565

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Placenta (C58)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White Male ASR(W) CUM 0-74 Cases 0 15 3 39 23 1 10 1 3 42 0 7 2 17 1 1 25 2 1 2 4 0 0 1 14 0 1 11 8 3 2 11 83 16 7 38 21 15 2 3 0 0 3 5 31 2 1 2 0 0 17 7 9 6 2 4 1 1 0 53 16 35 26 16 8 7 5 1 2 28 9 15 13 7 4 10 4 6 0 3 Female ASR(W) CUM 0-74 0.2 0.3 0.9 0.5 0.2 0.2 0.1 0.1 0.1 0.1 0.0 0.4 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.1 0.3 0.0 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.2 0.05 0.15 0.20 0.12 0.15 0.07 0.07 0.07 0.02 0.04 0.01 0.10 0.09 0.05 0.01 0.02 0.01 0.06 0.10 0.06 0.01 0.05 0.03 0.09 0.03 0.12 0.03 0.01 0.03 0.04 0.02 0.01 0.02 0.11 0.13 0.05 0.02 0.02 0.05 0.07 0.18 0.04 0.03 0.03 0.03 0.17 0.03 0.06 0.11 0.02 0.06 0.02 0.03 0.06 0.02 0.03 0.06 0.02 0.04 0.02 0.06 0.02 0.03 0.04 0.02 0.03 0.05 0.03 0.14 0.01 0.02 0.00 0.01 0.01 0.01 0.00 0.03 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.01 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.01 0.01 0.02 0.01 0.01 0.02 0.00 0.01 0.01 0.00 0.00 0.01 0.01 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.02 * * * *

0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.00 * 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01

566

*Important. See note on population page.

508

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Placenta (C58) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Male ASR(W) CUM 0-74 Cases 0 14 33 17 15 15 11 4 7 2 5 0 506 139 311 36 14 19 5 1 4 0 54 19 30 21 5 14 4 0 24 3 21 1 72 20 36 195 28 43 53 65 12 4 7 27 6 19 6 0 7 6 3 13 2 18 9 0 0 14 7 0 4 46 0 26 5 3 0 10 7 3 2 1 1 3 2 7 3 Female ASR(W) CUM 0-74 0.1 0.1 0.5 0.1 0.2 0.5 0.1 0.0 0.1 0.0 0.1 0.2 0.1 0.2 0.4 0.1 0.1 0.2 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.2 0.3 0.0 0.1 0.2 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.02 0.03 0.12 0.02 0.05 0.14 0.03 0.02 0.09 0.02 0.00 0.02 0.00 0.03 0.12 0.03 0.05 0.17 0.12 0.02 0.05 0.02 0.02 0.06 0.02 0.03 0.02 0.06 0.02 0.04 0.01 0.05 0.01 0.01 0.03 0.03 0.02 0.01 0.03 0.06 0.04 0.01 0.04 0.01 0.04 0.02 0.02 0.04 0.03 0.12 0.06 0.01 0.04 0.06 0.02 0.02 0.02 0.04 0.02 0.02 0.02 0.06 0.05 0.03 0.02 0.02 0.04 0.01 0.06 0.01 0.01 0.03 0.01 0.01 0.03 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.03 0.01 0.01 0.01 0.02 0.01 0.02 0.01 0.01 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.00 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.02 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 * 0.00 - * 0.00 * 0.00 * - * 0.00 0.00 * 0.00 0.01 * 0.00 * - * 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
509

567

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Placenta (C58) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
510

Male ASR(W) CUM 0-74

Cases 287 34 8 9 7 22 5 68 4 3 4 4 9 4 11 64 4 3 0 1 23 1 15 0 4 4 1 0 20 3 4 17 6 17 7 5 10 2 0 0 1 1 5 3 1 0 0 2 2 9 0 11 2 1 0 0 4 0 0 1 5 1 0 1 0 0 1 0 0 0 2 1 0 0 0 0 4 1 0

Female ASR(W) CUM 0-74 0.2 0.3 0.1 0.2 0.2 0.3 0.5 0.2 0.2 0.2 0.1 0.1 0.2 0.2 0.3 0.5 0.0 0.0 0.1 0.5 0.1 0.4 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.0 0.0 0.2 0.1 0.1 0.2 0.0 0.1 0.3 0.0 0.0 0.0 0.2 0.2 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.01 0.05 0.04 0.07 0.06 0.06 0.23 0.02 0.09 0.09 0.05 0.06 0.06 0.11 0.09 0.06 0.02 0.02 0.12 0.11 0.07 0.11 0.02 0.01 0.04 0.02 0.05 0.02 0.02 0.02 0.02 0.02 0.07 0.03 0.06 0.05 0.04 0.08 0.06 0.07 0.14 0.03 0.03 0.09 0.02 0.01 0.02 0.18 0.09 0.09 0.03 0.02 0.07 0.01 0.07 0.06 0.02 0.02 0.01 0.02 0.01 0.02 0.04 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.04 0.00 0.00 0.01 0.04 0.00 0.03 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.00 0.01 0.02 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.02 0.00 0.01 0.01 0.00 0.01 0.01 0.01 * 0.01 * 0.01 * 0.00 0.00 0.01 0.01 * 0.00 * 0.01 - * 0.00 * 0.00 0.00 0.00 * 0.00 * 0.00 0.00 * 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.00 -

568

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Placenta (C58) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White Male ASR(W) CUM 0-74 Cases 19 9 1 13 1 0 3 9 6 7 5 7 3 0 0 2 0 0 1 1 0 1 3 0 12 1 0 0 1 1 0 1 25 2 2 4 1 5 9 4 9 12 6 5 0 8 11 1 3 5 0 6 2 3 0 16 8 1 2 0 0 1 Female ASR(W) CUM 0-74 0.3 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.3 0.0 0.1 0.0 0.0 0.3 0.2 0.2 0.4 0.4 0.2 0.07 0.03 0.11 0.03 0.04 0.04 0.03 0.03 0.02 0.02 0.02 0.03 0.03 0.07 0.05 0.05 0.14 0.02 0.07 0.09 0.09 0.09 0.01 0.06 0.05 0.03 0.02 0.02 0.02 0.03 0.02 0.01 0.02 0.02 0.02 0.02 0.25 0.02 0.07 0.02 0.03 0.18 0.04 0.08 0.38 0.25 0.19 0.02 0.01 0.01 0.01 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.02 0.01 0.02 0.03 0.03 0.01 0.01 0.00 0.01 0.00 0.00 * 0.00 0.00 * 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.03 0.02 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
511

569

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Penis (C60)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 0 1 0 25 19 10 80 15 38 330 6 64 100 21 9 15 507 58 88 34 25 11 0 32 233 1 25 72 16 55 9 79 461 30 25 106 292 80 5 3 4 2 17 43 109 7 5 0 0 0 45 49 58 83 5 77 12 9 2 376 41 329 138 29 107 28 8 19 26 231 25 193 116 66 127 88 26 61 3 11 Male ASR(W) CUM 0-74 0.0 2.8 0.9 1.1 3.7 2.3 2.6 1.5 0.7 1.8 1.3 0.8 0.7 1.8 0.6 0.7 0.6 0.9 0.9 0.6 0.9 0.6 0.2 0.6 0.5 0.5 0.5 0.7 0.5 0.4 0.3 0.4 0.6 0.4 0.4 0.3 0.2 0.4 0.6 0.7 0.3 0.4 0.3 0.4 0.6 0.3 0.4 0.6 0.6 0.6 0.7 0.9 0.4 0.6 0.7 0.5 0.6 0.6 0.6 0.4 0.5 0.4 0.6 0.6 0.6 0.5 0.6 0.6 1.0 0.6 0.8 0.6 0.3 0.5 0.03 0.65 0.26 0.37 0.44 0.66 0.45 0.09 0.27 0.24 0.13 0.18 0.24 0.49 0.03 0.09 0.06 0.16 0.19 0.18 0.17 0.04 0.24 0.13 0.06 0.14 0.07 0.24 0.05 0.02 0.05 0.09 0.06 0.03 0.04 0.16 0.09 0.23 0.45 0.18 0.05 0.04 0.11 0.18 0.11 0.05 0.06 0.07 0.29 0.08 0.22 0.31 0.25 0.03 0.12 0.03 0.05 0.12 0.06 0.08 0.20 0.09 0.13 0.04 0.11 0.04 0.06 0.08 0.09 0.07 0.16 0.08 0.20 0.16 0.15 0.43 0.19 0.34 0.17 0.08 0.19 0.15 0.10 0.07 0.23 0.07 0.08 0.07 0.09 0.10 0.08 0.09 0.07 0.04 0.08 0.06 0.05 0.06 0.05 0.05 0.05 0.03 0.04 0.06 0.05 0.04 0.01 0.03 0.06 0.07 0.07 0.03 0.04 0.02 0.07 0.08 0.03 0.05 0.07 0.04 0.07 0.10 0.13 0.06 0.06 0.07 0.06 0.07 0.09 0.07 0.04 0.08 0.03 0.08 0.06 0.07 0.06 0.06 0.07 0.11 0.07 0.08 0.07 0.05 0.04 0.06 0.06 0.08 0.07 0.01 0.04 0.03 0.02 0.03 0.03 0.07 0.00 0.01 0.01 0.02 0.02 0.03 0.02 0.01 0.04 0.02 0.01 0.02 0.01 0.03 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.02 0.04 0.07 0.02 0.01 0.01 0.01 0.04 0.01 0.01 0.01 0.01 0.03 0.01 0.03 0.05 0.05 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.04 0.01 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.03 0.02 Cases Female ASR(W) CUM 0-74 * * * *

570

*Important. See note on population page.

512

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Penis (C60) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 37 139 190 18 170 81 16 65 106 2 103 24 4146 356 3636 172 16 146 33 7 14 10 363 33 318 193 8 178 72 48 243 18 218 24 448 37 381 1237 47 108 171 887 84 21 62 412 32 373 23 16 83 59 58 89 1 17 11 5 71 20 17 162 211 9 196 68 87 22 19 15 4 5 8 10 28 20 55 12 Male ASR(W) CUM 0-74 0.7 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.5 0.1 0.6 0.7 0.6 0.6 0.6 0.6 0.5 0.6 0.5 1.8 0.7 0.2 0.6 0.5 0.6 0.5 0.2 0.5 0.6 0.4 0.5 0.6 0.5 0.6 0.5 0.5 0.5 0.5 0.3 0.6 0.7 0.5 0.6 0.7 0.6 0.7 0.6 0.7 0.4 0.8 0.4 0.4 0.8 0.5 0.2 0.3 0.9 0.3 0.3 0.6 0.7 1.7 0.9 1.0 0.8 1.6 1.3 0.8 0.1 0.1 0.2 0.1 0.2 0.2 0.3 0.3 0.2 0.2 0.12 0.06 0.04 0.14 0.05 0.07 0.17 0.08 0.06 0.10 0.06 0.14 0.01 0.03 0.01 0.05 0.13 0.05 0.09 0.70 0.19 0.08 0.03 0.08 0.03 0.04 0.09 0.04 0.07 0.06 0.03 0.14 0.04 0.13 0.02 0.09 0.03 0.02 0.04 0.06 0.06 0.02 0.07 0.17 0.08 0.04 0.11 0.04 0.09 0.20 0.05 0.06 0.11 0.05 0.17 0.07 0.27 0.13 0.04 0.14 0.17 0.14 0.07 0.34 0.06 0.21 0.14 0.18 0.02 0.02 0.13 0.06 0.06 0.07 0.05 0.07 0.02 0.05 0.09 0.07 0.07 0.06 0.07 0.07 0.06 0.07 0.06 0.01 0.07 0.08 0.06 0.06 0.06 0.07 0.05 0.07 0.05 0.20 0.07 0.03 0.06 0.05 0.07 0.06 0.03 0.06 0.06 0.05 0.06 0.06 0.06 0.08 0.05 0.05 0.06 0.06 0.03 0.06 0.08 0.06 0.07 0.08 0.07 0.08 0.08 0.08 0.05 0.09 0.05 0.05 0.10 0.06 0.03 0.08 0.03 0.03 0.08 0.07 0.20 0.10 0.12 0.09 0.21 0.13 0.09 0.01 0.01 0.01 0.02 0.02 0.02 0.03 0.04 0.01 0.02 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.00 0.00 0.00 0.01 0.02 0.01 0.01 0.10 0.03 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.01 0.00 0.02 0.01 0.01 0.03 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.00 0.02 0.02 0.02 0.01 0.05 0.01 0.03 0.02 0.02 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 * * * * * * * * * Cases Female ASR(W) CUM 0-74

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
513

571

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Penis (C60) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
514

Male ASR(W) CUM 0-74 0.3 0.2 0.4 0.2 0.2 0.2 0.1 0.2 0.0 0.4 0.9 0.0 0.6 0.5 0.5 0.4 1.7 1.6 2.2 0.0 0.0 0.8 0.6 0.4 0.7 0.6 0.6 0.7 0.6 0.9 1.1 0.9 0.5 0.6 0.7 0.6 0.7 0.6 0.6 0.5 0.8 0.8 0.7 0.3 0.9 0.8 0.8 1.0 0.6 0.6 0.6 1.1 0.9 0.6 0.2 0.5 0.7 0.7 0.7 0.8 0.5 0.4 0.6 0.8 0.7 0.4 0.8 1.2 0.6 1.1 0.9 0.7 0.9 0.4 0.7 0.02 0.06 0.10 0.11 0.13 0.07 0.09 0.04 0.03 0.16 0.15 0.05 0.10 0.07 0.09 0.23 0.21 0.27 0.29 0.03 0.02 0.05 0.16 0.20 0.05 0.09 0.06 0.05 0.06 0.05 0.07 0.15 0.05 0.13 0.17 0.19 0.17 0.13 0.13 0.11 0.20 0.20 0.19 0.11 0.10 0.07 0.11 0.12 0.08 0.08 0.12 0.36 0.09 0.24 0.09 0.16 0.12 0.16 0.29 0.13 0.14 0.15 0.08 0.21 0.24 0.16 0.14 0.20 0.18 0.32 0.36 0.12 0.16 0.14 0.10 0.03 0.03 0.03 0.05 0.03 0.02 0.01 0.02 0.00 0.04 0.10 0.05 0.04 0.05 0.05 0.21 0.17 0.29 0.00 0.00 0.09 0.08 0.04 0.07 0.06 0.07 0.08 0.07 0.10 0.12 0.10 0.06 0.05 0.08 0.07 0.07 0.06 0.06 0.04 0.09 0.09 0.07 0.04 0.11 0.09 0.10 0.11 0.06 0.06 0.06 0.13 0.10 0.05 0.03 0.05 0.09 0.06 0.07 0.09 0.05 0.02 0.06 0.09 0.07 0.05 0.08 0.12 0.06 0.12 0.08 0.08 0.09 0.06 0.07 0.00 0.01 0.01 0.02 0.02 0.01 0.01 0.00 0.00 0.02 0.02 0.01 0.01 0.01 0.03 0.03 0.03 0.04 0.00 0.00 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.02 0.02 0.02 0.02 0.01 0.03 0.03 0.03 0.02 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.05 0.01 0.03 0.01 0.02 0.02 0.02 0.04 0.02 0.02 0.02 0.01 0.03 0.03 0.02 0.02 0.02 0.02 0.04 0.04 0.02 0.02 0.02 0.01

Cases

Female ASR(W) CUM 0-74

215 21 16 6 3 12 1 43 0 0 3 8 42 0 1 47 40 37 3 0 69 36 58 1 2 225 13 4 197 41 132 226 96 338 240 39 99 23 21 10 19 25 26 22 16 18 16 7 95 151 58 67 60 59 30 10 106 6 4 9 39 20 6 39 15 6 60 15 11 8 40 41 12 13 7 32 35 9 50

* * *

* * * *

* * *

572

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Penis (C60) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 67 104 11 127 12 28 56 113 123 80 132 111 40 14 42 50 48 14 21 26 57 20 27 29 379 13 8 8 18 6 7 22 466 26 19 94 90 154 256 101 264 354 190 170 67 176 115 4 75 28 7 84 27 7 3 62 13 0 3 0 3 7 Male ASR(W) CUM 0-74 0.9 1.0 0.8 0.7 0.5 0.7 0.9 1.1 1.1 0.6 0.7 0.7 0.6 1.2 0.9 0.7 1.0 1.0 0.9 0.9 1.4 0.7 1.3 0.7 1.0 0.9 0.9 1.2 1.0 0.5 0.6 0.9 0.8 0.7 0.5 0.8 1.0 0.9 1.0 1.0 0.9 0.7 1.0 0.8 1.2 0.9 0.5 1.1 0.6 0.4 0.4 0.5 0.4 0.8 0.7 0.5 0.3 0.3 0.2 0.6 0.11 0.10 0.24 0.06 0.14 0.13 0.13 0.10 0.11 0.07 0.07 0.07 0.09 0.35 0.15 0.10 0.15 0.30 0.22 0.19 0.19 0.16 0.27 0.14 0.05 0.24 0.32 0.44 0.23 0.20 0.25 0.19 0.04 0.14 0.12 0.09 0.11 0.08 0.06 0.10 0.06 0.04 0.08 0.07 0.15 0.07 0.05 0.58 0.07 0.09 0.14 0.05 0.08 0.32 0.38 0.06 0.08 0.18 0.12 0.23 0.10 0.11 0.08 0.08 0.03 0.06 0.11 0.12 0.13 0.07 0.08 0.09 0.06 0.11 0.10 0.08 0.11 0.13 0.11 0.10 0.16 0.09 0.17 0.06 0.11 0.08 0.09 0.09 0.12 0.05 0.06 0.11 0.09 0.07 0.07 0.09 0.11 0.11 0.10 0.11 0.10 0.07 0.11 0.09 0.13 0.10 0.06 0.12 0.07 0.05 0.04 0.05 0.04 0.09 0.07 0.05 0.03 0.03 0.02 0.07 0.01 0.01 0.04 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.04 0.02 0.01 0.02 0.04 0.03 0.02 0.03 0.03 0.04 0.02 0.01 0.03 0.04 0.05 0.04 0.02 0.03 0.03 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.09 0.01 0.01 0.02 0.01 0.01 0.04 0.04 0.01 0.01 0.03 0.02 0.03 Cases Female ASR(W) CUM 0-74

* *

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
515

573

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Prostate (C61)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 142 273 134 262 418 341 1727 415 1029 16155 529 2070 3406 1075 1932 229 76342 9362 14085 3649 2562 1515 29 3315 37402 542 3881 13398 3460 9447 1496 14987 103927 6246 9190 12278 70762 21432 1903 920 605 229 1740 14539 27673 4491 587 670 466 160 4991 14329 12995 14162 1156 12665 2665 1934 603 72917 7976 63829 23930 7023 16649 7971 2714 5119 4628 41322 6238 33285 17485 11050 13571 15914 4777 11003 1343 2008 Male ASR(W) CUM 0-74 7.5 8.5 14.1 37.6 38.1 36.4 101.5 79.3 83.4 84.8 57.6 63.2 47.0 39.7 153.0 27.3 93.3 105.1 92.1 87.0 94.3 81.3 43.7 95.1 91.8 112.1 93.6 90.5 133.2 78.1 109.1 84.5 106.4 55.7 170.9 87.4 108.2 110.4 155.8 52.0 68.5 66.6 91.6 118.0 110.2 186.4 48.7 88.5 74.7 30.9 92.8 109.3 109.4 121.5 177.5 116.3 158.6 178.6 109.4 105.8 160.6 100.4 111.2 172.9 97.2 129.4 185.7 114.9 110.3 107.2 149.3 99.8 89.3 100.9 100.9 116.7 153.6 106.1 148.2 97.7 0.64 0.53 1.22 2.45 2.02 2.08 2.62 3.94 2.62 0.69 2.55 1.47 0.83 1.27 3.61 1.84 0.35 1.12 0.81 1.52 1.94 2.15 8.35 1.71 0.49 4.97 1.63 0.80 2.34 0.83 2.91 0.72 0.34 0.73 1.81 0.80 0.43 0.79 3.65 1.80 2.88 4.87 2.23 1.03 0.69 2.82 2.12 3.56 3.89 2.48 1.34 0.97 0.99 1.08 5.28 1.10 3.18 4.22 4.61 0.42 1.82 0.43 0.73 2.11 0.77 1.49 3.69 1.65 1.69 0.55 1.92 0.57 0.70 1.02 0.89 0.96 2.28 1.05 4.13 2.30 4.68 12.14 10.27 10.21 10.57 6.83 7.80 5.47 4.74 20.08 3.56 12.39 14.07 12.12 11.67 12.55 11.05 5.95 12.38 12.25 14.96 12.08 12.21 17.85 10.65 14.40 11.58 14.41 7.54 22.95 11.87 14.74 15.02 21.24 7.16 9.39 9.59 12.58 16.13 14.83 25.00 6.26 12.20 10.24 4.31 12.40 14.84 14.96 16.57 24.28 15.88 21.48 23.85 15.33 14.56 21.78 13.85 15.06 22.90 13.33 17.78 24.62 16.08 14.87 14.56 19.69 13.61 12.14 13.60 13.34 15.45 20.10 14.15 19.67 13.29 0.33 0.40 0.65 0.42 0.11 0.41 0.23 0.13 0.20 0.58 0.31 0.05 0.18 0.13 0.24 0.31 0.34 1.38 0.27 0.08 0.76 0.26 0.12 0.36 0.13 0.46 0.11 0.05 0.12 0.28 0.13 0.07 0.13 0.57 0.30 0.47 0.81 0.36 0.16 0.11 0.44 0.34 0.58 0.61 0.43 0.21 0.15 0.16 0.17 0.83 0.17 0.50 0.65 0.75 0.06 0.29 0.07 0.12 0.33 0.12 0.24 0.59 0.27 0.27 0.09 0.30 0.09 0.11 0.16 0.14 0.15 0.36 0.16 0.65 0.36 Cases Female ASR(W) CUM 0-74 * * * *

574

*Important. See note on population page.

516

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Prostate (C61) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 5417 25644 42512 6463 34438 19137 5154 13626 17661 1980 15519 3980 784436 95223 653240 38030 5225 31523 5891 143 1533 4074 70437 12099 56746 38748 4595 31442 11245 13098 53915 5325 46933 4342 97659 11739 79315 255181 10110 30470 17271 189664 15161 4735 10135 55354 6685 47288 6477 2302 21790 14760 7073 20032 78 335 3553 16 47 1838 73 1030 326 1346 36 1219 108 346 143 8689 7779 253 573 690 981 2688 1787 4452 1106 Male ASR(W) CUM 0-74 111.1 125.3 131.2 200.9 120.0 151.2 216.0 135.6 94.6 147.3 90.5 118.8 108.5 163.0 102.2 134.7 195.0 128.7 98.8 43.8 85.2 110.3 114.8 187.9 108.3 100.4 146.5 89.4 93.3 111.5 117.3 180.6 110.0 118.8 118.4 190.1 116.0 113.7 58.0 178.8 90.8 112.3 117.6 178.5 99.8 97.4 139.1 93.2 120.1 110.5 117.7 118.7 96.5 110.6 14.3 6.7 15.0 1.4 2.1 6.9 2.3 40.8 3.9 8.4 4.4 6.9 3.0 6.4 5.6 50.2 49.2 20.0 14.2 13.6 21.5 22.0 20.0 11.3 13.4 1.58 0.82 0.66 2.58 0.68 1.15 3.13 1.23 0.74 3.38 0.75 1.96 0.13 0.54 0.13 0.72 2.73 0.77 1.33 3.75 2.22 1.81 0.45 1.73 0.48 0.53 2.21 0.53 0.92 1.03 0.54 2.54 0.54 1.93 0.40 1.80 0.43 0.23 0.60 1.04 0.70 0.27 0.98 2.66 1.02 0.43 1.74 0.44 1.56 2.38 0.83 1.02 1.20 0.82 1.63 0.39 0.26 0.37 0.31 0.17 0.27 1.35 0.22 0.23 0.73 0.20 0.30 0.35 0.47 0.57 0.59 1.27 0.60 0.54 0.70 0.44 0.49 0.17 0.43 15.04 17.26 17.64 26.62 16.24 20.18 28.79 18.11 13.04 19.76 12.52 16.23 14.74 21.79 13.93 18.29 26.34 17.48 13.34 5.24 11.46 14.96 15.55 24.98 14.72 13.53 19.88 12.06 12.47 15.31 16.04 24.53 15.07 15.93 16.00 25.45 15.73 15.34 7.74 23.85 12.28 15.23 15.79 23.87 13.54 13.23 18.39 12.70 16.40 14.99 15.98 16.05 12.85 15.04 1.38 0.65 1.67 0.12 0.22 0.71 0.32 5.08 0.48 1.04 0.62 0.76 0.38 0.67 0.66 6.55 6.45 2.76 1.69 1.51 2.43 2.46 2.34 1.20 1.53 0.25 0.13 0.10 0.40 0.11 0.18 0.49 0.19 0.11 0.52 0.12 0.31 0.02 0.08 0.02 0.11 0.43 0.12 0.21 0.56 0.36 0.28 0.07 0.27 0.07 0.08 0.34 0.08 0.14 0.16 0.08 0.39 0.08 0.30 0.06 0.28 0.07 0.04 0.10 0.16 0.11 0.04 0.15 0.42 0.16 0.07 0.27 0.07 0.25 0.37 0.13 0.16 0.19 0.13 0.23 0.05 0.04 0.04 0.04 0.02 0.04 0.22 0.03 0.04 0.13 0.03 0.04 0.05 0.07 0.09 0.09 0.22 0.09 0.08 0.11 0.07 0.08 0.02 0.07 * * * * * * * * * Cases Female ASR(W) CUM 0-74

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
517

575

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Prostate (C61) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
518

Male ASR(W) CUM 0-74 8.5 7.3 7.7 5.8 9.0 7.8 11.8 12.7 8.6 10.5 9.4 11.3 5.8 10.5 10.1 25.3 17.3 18.6 11.1 16.1 5.3 4.9 4.6 19.1 13.7 79.5 117.3 103.7 19.9 70.0 84.8 17.1 27.7 39.5 40.4 39.4 82.7 87.7 70.0 76.7 78.4 82.7 75.1 99.2 59.6 73.2 79.0 80.8 55.6 47.8 56.6 55.6 78.9 56.3 65.3 82.7 66.6 57.7 65.4 41.5 46.1 51.5 52.4 56.2 58.9 18.6 69.3 49.1 28.1 42.7 57.1 23.8 34.5 28.3 67.6 56.1 41.7 63.0 57.9 0.11 0.37 0.45 0.54 0.69 0.46 1.41 0.31 1.07 1.12 1.63 0.84 0.43 0.82 0.72 0.74 0.48 0.56 1.29 1.40 0.36 0.49 0.41 0.86 0.44 0.52 2.30 3.02 0.26 0.99 0.65 0.22 0.41 0.33 0.43 0.92 0.64 1.56 1.74 2.02 1.71 1.48 1.38 1.58 1.63 1.87 2.18 1.82 0.73 0.49 0.88 0.91 0.90 0.72 1.15 3.04 0.75 2.40 1.59 1.43 0.86 1.28 2.27 1.03 1.39 1.09 0.84 1.50 1.41 1.37 1.03 0.80 1.29 1.40 2.98 1.07 0.94 1.70 0.89 0.95 0.81 0.85 0.72 0.91 0.93 1.27 1.30 0.97 1.31 0.88 1.16 0.69 1.37 1.34 2.75 1.96 2.14 1.07 1.90 0.51 0.51 0.48 2.42 1.78 10.39 15.59 13.72 2.49 8.85 10.86 2.11 2.99 4.74 4.71 4.77 10.11 11.62 9.56 10.01 9.82 10.91 9.68 13.22 7.85 9.20 10.31 10.75 6.80 5.88 7.13 6.84 10.19 7.00 8.38 10.64 8.17 7.44 8.32 5.04 5.76 6.36 6.71 7.05 8.07 2.23 8.94 6.14 3.29 5.57 7.08 2.90 4.19 3.37 9.20 7.14 5.31 7.69 7.38 0.02 0.05 0.07 0.09 0.09 0.07 0.20 0.04 0.16 0.18 0.20 0.12 0.07 0.13 0.12 0.11 0.07 0.09 0.15 0.21 0.05 0.07 0.06 0.13 0.07 0.08 0.35 0.47 0.04 0.15 0.10 0.03 0.06 0.05 0.07 0.14 0.10 0.25 0.28 0.32 0.27 0.23 0.22 0.25 0.26 0.29 0.33 0.28 0.11 0.07 0.14 0.13 0.14 0.11 0.18 0.48 0.12 0.38 0.25 0.22 0.14 0.20 0.37 0.16 0.22 0.16 0.13 0.24 0.22 0.22 0.16 0.12 0.21 0.22 0.49 0.17 0.15 0.26 0.14

Cases

Female ASR(W) CUM 0-74

6354 455 309 123 187 308 74 1947 75 88 58 186 187 166 206 1239 1314 1093 84 137 211 106 127 508 1014 24603 2691 1204 6114 5407 18254 6551 4879 15172 9906 1857 17314 3267 1789 1535 2185 3574 3157 4325 1512 1710 1576 2244 5902 9864 4245 3814 7814 6291 3313 823 8490 626 1752 957 3268 1827 611 3207 2004 298 7321 1225 446 1100 3480 948 776 448 534 2935 2251 1423 4572

* * *

* * * *

* * *

576

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Prostate (C61) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 2548 5009 509 14669 633 1468 2002 5755 7139 2654 3385 4821 2875 622 2768 4282 2692 457 1578 1062 1822 1558 1111 1787 37300 1327 686 558 1640 724 826 2234 34831 2108 2029 7547 5424 9897 15705 7073 20113 31674 10334 13588 2759 10668 19271 199 9436 5171 1439 13958 4668 753 233 13827 3762 283 604 328 1184 1140 Male ASR(W) CUM 0-74 31.4 43.0 35.1 76.0 24.7 31.2 30.0 50.9 55.4 18.5 16.0 28.8 40.6 39.2 45.6 54.1 55.3 29.9 57.5 29.0 38.5 56.4 43.6 42.2 84.6 85.4 67.6 77.7 76.9 49.6 75.1 88.7 56.5 55.9 54.3 54.8 49.1 53.1 51.4 64.2 56.9 54.1 44.4 54.6 43.6 47.6 78.4 61.7 73.1 82.0 74.0 77.3 75.3 89.0 67.9 104.4 79.8 69.1 78.0 71.3 74.2 95.3 0.63 0.61 1.61 0.68 1.00 0.84 0.69 0.73 0.68 0.36 0.28 0.42 0.76 1.68 0.92 0.85 1.08 1.58 1.55 0.94 0.94 1.52 1.41 1.06 0.47 2.40 2.74 3.48 1.99 1.91 2.70 1.97 0.31 1.24 1.23 0.67 0.69 0.56 0.43 0.80 0.43 0.32 0.46 0.49 0.86 0.48 0.59 4.55 0.78 1.20 2.03 0.68 1.13 3.33 4.57 0.92 1.40 4.61 3.46 4.00 2.54 2.96 3.86 5.13 4.13 9.49 2.84 3.63 4.07 6.72 6.82 2.34 1.89 3.32 4.97 4.61 5.47 6.75 7.01 3.47 7.60 3.79 4.48 7.40 5.24 5.80 10.85 11.43 8.20 10.02 9.95 6.15 9.70 11.90 7.31 7.23 6.97 6.62 5.64 6.32 6.16 7.86 6.78 6.66 5.11 6.51 5.18 5.74 10.01 7.55 8.96 10.30 8.96 9.33 9.47 10.87 7.48 13.29 10.30 8.96 9.82 9.50 9.55 12.40 0.09 0.09 0.25 0.11 0.14 0.13 0.11 0.11 0.10 0.05 0.04 0.06 0.11 0.26 0.14 0.13 0.17 0.24 0.25 0.15 0.14 0.24 0.22 0.17 0.08 0.38 0.44 0.54 0.33 0.31 0.42 0.32 0.05 0.19 0.19 0.10 0.11 0.09 0.07 0.13 0.07 0.05 0.07 0.08 0.13 0.07 0.09 0.68 0.12 0.19 0.31 0.10 0.17 0.50 0.64 0.14 0.22 0.71 0.55 0.65 0.39 0.47 Cases Female ASR(W) CUM 0-74

* *

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
519

577

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Testis (C62)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 6 33 5 7 16 40 49 10 34 740 86 115 276 147 13 38 3034 451 520 153 76 39 4 115 1508 19 149 443 34 401 98 665 4585 180 96 1171 3063 926 31 25 8 13 164 640 1126 29 14 11 10 3 444 597 698 493 14 467 50 7 40 1840 70 1735 858 66 779 340 37 294 185 1554 60 1426 817 467 511 454 45 405 14 75 Male ASR(W) CUM 0-74 0.2 0.5 0.4 0.6 0.6 5.5 1.6 1.0 1.4 2.7 8.8 2.3 2.6 3.9 1.3 2.7 4.7 5.2 4.5 5.0 3.6 2.5 2.9 4.6 4.6 5.1 5.5 3.8 1.2 4.7 5.3 4.7 4.7 1.5 1.4 3.7 6.8 4.7 2.3 1.8 1.0 4.2 3.7 6.7 4.2 1.1 1.6 1.7 2.8 0.6 3.7 6.8 5.5 5.4 1.5 6.0 3.0 0.9 5.2 4.4 1.1 5.2 3.7 1.0 4.8 3.7 1.2 5.2 5.2 4.6 1.3 5.2 5.0 6.1 4.6 3.9 1.3 5.2 1.3 4.9 0.09 0.10 0.19 0.26 0.18 0.89 0.26 0.37 0.24 0.10 0.96 0.23 0.16 0.33 0.36 0.45 0.09 0.25 0.20 0.42 0.42 0.41 1.49 0.44 0.12 1.21 0.46 0.18 0.21 0.24 0.56 0.19 0.07 0.12 0.14 0.11 0.13 0.16 0.43 0.36 0.39 1.19 0.30 0.29 0.13 0.21 0.42 0.53 0.92 0.36 0.18 0.30 0.21 0.25 0.39 0.29 0.43 0.35 0.85 0.11 0.13 0.13 0.13 0.13 0.17 0.21 0.20 0.31 0.39 0.12 0.17 0.14 0.18 0.29 0.21 0.18 0.19 0.26 0.36 0.58 0.41 0.15 0.12 0.10 0.20 0.68 0.19 0.20 0.30 0.10 0.21 0.36 0.39 0.35 0.39 0.28 0.20 0.23 0.34 0.35 0.37 0.43 0.29 0.09 0.36 0.44 0.37 0.37 0.12 0.11 0.27 0.52 0.37 0.18 0.14 0.07 0.34 0.28 0.52 0.31 0.08 0.12 0.11 0.22 0.04 0.26 0.52 0.42 0.41 0.11 0.46 0.22 0.06 0.40 0.34 0.08 0.40 0.28 0.08 0.36 0.28 0.09 0.40 0.40 0.35 0.09 0.39 0.38 0.47 0.36 0.30 0.11 0.40 0.10 0.40 0.07 0.03 0.06 0.02 0.01 0.08 0.02 0.01 0.03 0.03 0.04 0.01 0.02 0.02 0.03 0.03 0.03 0.11 0.03 0.01 0.09 0.04 0.01 0.02 0.02 0.05 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.03 0.02 0.09 0.02 0.02 0.01 0.02 0.03 0.03 0.07 0.02 0.01 0.02 0.02 0.02 0.03 0.02 0.03 0.02 0.07 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.03 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.02 0.02 0.03 0.05 Cases Female ASR(W) CUM 0-74 * * * *

578

*Important. See note on population page.

520

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Testis (C62) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 204 1019 1292 41 1220 515 28 478 640 17 618 137 29216 887 27275 1183 47 1101 237 16 89 131 2360 108 2190 1507 43 1413 385 612 1739 52 1663 148 3800 121 3465 9956 315 298 1489 7701 385 29 351 2520 77 2373 333 110 983 685 202 914 11 43 292 8 5 142 24 72 75 242 2 256 50 66 13 587 520 41 55 41 81 152 53 264 42 Male ASR(W) CUM 0-74 5.7 5.8 4.8 1.1 5.5 4.7 1.1 6.0 4.4 1.1 4.9 6.0 4.8 1.2 5.4 5.2 1.4 6.3 5.2 3.6 4.7 6.5 4.5 1.4 5.4 5.0 1.3 5.4 4.2 6.5 5.5 1.7 6.0 5.2 5.1 1.4 6.0 4.8 1.7 1.3 3.6 6.3 3.6 0.9 4.7 4.3 1.2 4.9 5.4 6.8 5.9 5.8 4.4 6.2 1.0 0.8 1.6 0.7 0.2 0.7 0.7 4.0 0.6 0.7 0.2 0.7 1.0 0.8 0.4 3.8 4.1 1.3 1.8 1.8 2.7 2.5 1.6 1.1 1.5 0.42 0.19 0.14 0.18 0.16 0.21 0.22 0.29 0.18 0.26 0.20 0.53 0.03 0.04 0.03 0.16 0.20 0.20 0.35 0.93 0.50 0.60 0.10 0.14 0.12 0.13 0.20 0.15 0.22 0.27 0.13 0.24 0.15 0.44 0.08 0.13 0.10 0.05 0.10 0.08 0.10 0.07 0.19 0.18 0.26 0.09 0.13 0.10 0.30 0.68 0.19 0.23 0.32 0.21 0.33 0.13 0.10 0.25 0.09 0.08 0.15 0.48 0.08 0.05 0.11 0.05 0.14 0.10 0.11 0.16 0.18 0.22 0.24 0.31 0.31 0.21 0.24 0.07 0.24 0.45 0.45 0.37 0.09 0.42 0.36 0.09 0.46 0.33 0.08 0.37 0.45 0.37 0.10 0.42 0.40 0.11 0.47 0.39 0.26 0.34 0.50 0.35 0.12 0.42 0.39 0.10 0.42 0.32 0.50 0.42 0.14 0.46 0.40 0.39 0.11 0.46 0.37 0.13 0.10 0.26 0.48 0.28 0.07 0.36 0.33 0.09 0.37 0.41 0.52 0.45 0.45 0.34 0.48 0.06 0.06 0.11 0.07 0.02 0.06 0.05 0.30 0.06 0.06 0.01 0.06 0.10 0.08 0.03 0.29 0.32 0.10 0.13 0.14 0.21 0.19 0.12 0.08 0.11 0.03 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.01 0.02 0.02 0.04 0.00 0.00 0.00 0.01 0.02 0.01 0.03 0.07 0.04 0.04 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.02 0.01 0.02 0.01 0.03 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.05 0.01 0.02 0.02 0.02 0.02 0.01 0.01 0.03 0.01 0.01 0.01 0.04 0.01 0.01 0.01 0.00 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.02 * * * * * * * * * Cases Female ASR(W) CUM 0-74

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
521

579

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Testis (C62) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
522

Male ASR(W) CUM 0-74 0.6 0.6 0.7 0.4 0.5 0.5 0.4 0.6 0.7 1.2 1.3 0.9 0.8 0.4 1.2 1.1 1.0 0.9 1.0 1.3 0.7 0.5 0.3 2.2 2.3 7.5 7.4 7.9 1.7 3.6 3.7 3.7 5.4 6.5 9.2 2.5 3.7 6.6 4.7 5.5 7.4 4.6 5.0 5.8 4.1 4.7 5.7 5.7 7.7 8.1 5.9 8.9 8.8 8.0 8.1 5.1 5.6 6.1 5.6 4.6 4.1 4.2 5.2 4.7 5.4 3.7 5.0 4.5 3.6 4.8 5.0 4.7 4.6 4.2 8.5 5.4 5.7 7.3 5.2 0.03 0.09 0.11 0.13 0.13 0.09 0.27 0.05 0.19 0.25 0.54 0.20 0.13 0.14 0.18 0.10 0.11 0.12 0.44 0.34 0.13 0.15 0.11 0.25 0.16 0.19 0.63 0.91 0.08 0.30 0.18 0.13 0.22 0.15 0.26 0.28 0.18 0.48 0.53 0.64 0.63 0.46 0.42 0.44 0.58 0.58 0.88 0.66 0.34 0.27 0.35 0.42 0.38 0.35 0.54 0.81 0.24 1.11 0.61 0.83 0.41 0.61 1.11 0.44 0.62 0.50 0.31 0.73 0.69 0.63 0.45 0.46 0.63 0.74 1.42 0.51 0.55 0.80 0.37 0.04 0.04 0.04 0.03 0.04 0.03 0.02 0.05 0.06 0.09 0.07 0.09 0.05 0.04 0.10 0.10 0.07 0.07 0.06 0.08 0.07 0.05 0.03 0.18 0.18 0.58 0.58 0.59 0.14 0.27 0.28 0.29 0.40 0.50 0.71 0.18 0.27 0.52 0.36 0.42 0.57 0.34 0.39 0.46 0.32 0.34 0.42 0.44 0.60 0.65 0.47 0.71 0.68 0.62 0.64 0.41 0.42 0.48 0.41 0.35 0.31 0.31 0.42 0.36 0.42 0.26 0.37 0.35 0.25 0.38 0.37 0.35 0.32 0.31 0.61 0.42 0.43 0.54 0.38 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.02 0.02 0.02 0.03 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.05 0.07 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.02 0.01 0.04 0.04 0.05 0.05 0.03 0.03 0.04 0.05 0.04 0.06 0.05 0.03 0.02 0.03 0.03 0.03 0.03 0.04 0.07 0.02 0.08 0.04 0.06 0.03 0.04 0.08 0.03 0.05 0.04 0.02 0.05 0.05 0.05 0.03 0.03 0.04 0.05 0.10 0.04 0.04 0.06 0.03

Cases

Female ASR(W) CUM 0-74

554 47 38 13 20 31 2 181 15 24 37 21 42 12 53 147 85 64 6 15 32 14 11 87 228 1717 146 80 445 158 461 816 610 1859 1361 85 469 198 81 76 145 104 151 178 51 69 46 81 589 1042 308 482 613 587 247 40 583 32 94 43 118 58 25 139 90 55 292 47 27 64 139 108 58 35 40 132 120 95 227

* * *

* * * *

* * *

580

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Testis (C62) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 128 185 41 1171 85 102 179 155 137 215 563 980 411 28 66 151 99 15 59 54 92 41 48 57 1214 82 65 26 147 75 62 151 2611 158 126 446 401 702 1104 565 1316 2156 699 809 277 1038 1044 18 537 220 84 734 288 61 18 696 133 7 11 28 24 53 Male ASR(W) CUM 0-74 2.1 1.9 4.0 9.6 4.1 2.9 4.2 1.8 1.9 1.7 5.1 6.6 7.5 3.5 2.2 3.1 2.3 3.4 3.9 2.4 2.8 2.6 3.7 2.5 5.3 6.9 10.3 6.0 10.6 8.6 7.8 9.1 6.0 5.6 5.7 6.1 6.5 6.3 6.5 7.4 7.6 5.6 5.6 5.7 6.2 7.6 5.8 2.9 5.5 5.3 6.3 5.5 5.3 6.4 2.7 6.8 3.9 3.5 2.2 4.7 4.4 5.3 0.19 0.14 0.63 0.29 0.45 0.29 0.33 0.15 0.17 0.12 0.22 0.21 0.38 0.66 0.29 0.26 0.24 0.89 0.52 0.33 0.31 0.41 0.56 0.35 0.16 0.79 1.34 1.25 0.91 1.03 1.02 0.77 0.12 0.47 0.54 0.30 0.34 0.25 0.20 0.32 0.22 0.12 0.22 0.20 0.38 0.24 0.18 0.70 0.24 0.37 0.71 0.21 0.32 0.83 0.65 0.26 0.34 1.37 0.70 0.90 0.97 0.74 0.17 0.17 0.31 0.74 0.31 0.22 0.32 0.13 0.14 0.14 0.38 0.48 0.56 0.23 0.16 0.23 0.16 0.23 0.30 0.17 0.20 0.18 0.27 0.18 0.41 0.54 0.78 0.44 0.81 0.67 0.61 0.71 0.45 0.43 0.42 0.48 0.52 0.50 0.50 0.57 0.59 0.44 0.43 0.45 0.49 0.60 0.45 0.21 0.42 0.42 0.51 0.43 0.42 0.52 0.20 0.53 0.30 0.24 0.16 0.37 0.34 0.42 0.02 0.01 0.05 0.02 0.04 0.02 0.02 0.01 0.01 0.01 0.02 0.02 0.03 0.05 0.02 0.02 0.02 0.06 0.04 0.02 0.02 0.03 0.04 0.02 0.01 0.06 0.10 0.09 0.07 0.08 0.08 0.06 0.01 0.04 0.04 0.02 0.03 0.02 0.02 0.02 0.02 0.01 0.02 0.02 0.03 0.02 0.01 0.05 0.02 0.03 0.06 0.02 0.03 0.07 0.05 0.02 0.03 0.09 0.05 0.07 0.07 0.06 Cases Female ASR(W) CUM 0-74

* *

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
523

581

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other male genital organs (C63)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 0 2 0 1 0 2 6 1 2 32 1 5 3 1 1 0 174 14 17 7 4 1 0 4 116 2 9 14 3 11 4 36 194 22 8 31 127 45 3 5 2 0 2 28 61 4 1 3 1 2 15 32 21 17 0 16 3 3 0 98 12 86 34 6 26 13 6 5 4 50 6 43 32 23 14 21 7 14 2 2 Male ASR(W) CUM 0-74 0.1 0.0 0.3 0.3 0.2 0.1 0.1 0.2 0.2 0.0 0.0 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.1 0.3 0.3 0.3 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.3 0.1 0.2 0.2 0.2 0.0 0.3 0.1 0.3 0.2 0.2 0.2 0.1 0.2 0.2 0.3 0.2 0.2 0.1 0.2 0.1 0.2 0.2 0.3 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.1 0.04 0.02 0.20 0.14 0.16 0.10 0.03 0.15 0.09 0.02 0.03 0.10 0.02 0.05 0.03 0.07 0.09 0.05 0.06 0.03 0.26 0.09 0.03 0.05 0.03 0.11 0.03 0.01 0.04 0.05 0.03 0.02 0.04 0.14 0.11 0.22 0.05 0.05 0.03 0.08 0.04 0.18 0.08 0.24 0.06 0.05 0.04 0.04 0.04 0.09 0.15 0.02 0.06 0.02 0.03 0.05 0.03 0.05 0.12 0.05 0.05 0.02 0.05 0.02 0.03 0.05 0.03 0.03 0.07 0.04 0.12 0.05 0.02 0.05 0.02 0.02 0.01 0.02 0.00 0.00 0.01 0.02 0.02 0.01 0.02 0.03 0.00 0.01 0.03 0.04 0.03 0.01 0.00 0.01 0.03 0.02 0.02 0.03 0.02 0.02 0.02 0.03 0.03 0.04 0.05 0.00 0.02 0.03 0.02 0.03 0.04 0.02 0.03 0.02 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.02 0.04 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.02 0.02 0.01 0.01 0.01 0.02 0.02 0.02 0.00 0.01 0.01 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.04 0.01 0.00 0.00 0.00 0.02 0.00 0.00 0.01 0.01 0.00 0.00 0.01 0.02 0.02 0.04 0.00 0.01 0.00 0.01 0.03 0.03 0.01 0.01 0.00 0.00 0.01 0.01 0.02 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 Cases Female ASR(W) CUM 0-74 * * * *

582

*Important. See note on population page.

524

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other male genital organs (C63) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 7 22 59 3 55 35 3 32 23 3 18 6 1109 98 951 44 3 40 7 1 4 2 89 11 74 46 5 41 10 17 82 10 69 6 183 13 136 425 42 30 41 300 22 2 20 84 8 74 11 3 36 28 8 19 1 8 4 3 70 6 2 14 8 0 15 0 5 1 17 17 0 10 6 15 15 28 65 13 Male ASR(W) CUM 0-74 0.1 0.1 0.2 0.1 0.2 0.3 0.1 0.4 0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.2 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.3 0.1 0.3 0.2 0.1 0.2 0.0 0.1 0.1 0.0 0.1 0.1 0.3 0.1 0.4 0.1 0.3 0.2 0.2 0.05 0.02 0.03 0.06 0.03 0.05 0.08 0.07 0.03 0.12 0.03 0.08 0.00 0.02 0.01 0.02 0.06 0.03 0.04 0.23 0.09 0.03 0.02 0.05 0.02 0.02 0.07 0.02 0.03 0.04 0.02 0.09 0.02 0.07 0.02 0.05 0.02 0.01 0.04 0.03 0.03 0.01 0.04 0.05 0.04 0.02 0.05 0.02 0.06 0.07 0.03 0.04 0.04 0.02 0.11 0.05 0.15 0.06 0.04 0.07 0.05 0.04 0.02 0.02 0.03 0.04 0.03 0.03 0.09 0.05 0.11 0.04 0.07 0.02 0.07 0.02 0.01 0.02 0.01 0.03 0.04 0.01 0.04 0.02 0.02 0.01 0.03 0.02 0.01 0.02 0.02 0.01 0.02 0.01 0.02 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.03 0.02 0.02 0.03 0.02 0.02 0.02 0.03 0.02 0.02 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.03 0.01 0.02 0.02 0.01 0.01 0.01 0.02 0.02 0.01 0.03 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.04 0.02 0.03 0.02 0.03 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.00 0.01 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.01 * * * * * * * * * Cases Female ASR(W) CUM 0-74

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
525

583

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other male genital organs (C63) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
526

Male ASR(W) CUM 0-74 0.1 0.1 0.3 0.1 0.2 0.3 0.2 0.0 0.0 0.1 0.1 0.1 0.3 0.3 0.1 0.2 0.2 0.0 0.0 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.1 0.1 0.2 0.4 0.2 0.1 0.1 0.2 0.0 0.3 0.2 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.2 0.1 0.3 0.2 0.1 0.2 0.1 0.5 0.1 0.2 0.0 0.4 0.1 0.0 0.2 0.1 0.2 0.1 0.2 0.1 1.3 0.1 0.01 0.04 0.08 0.06 0.08 0.23 0.04 0.05 0.03 0.05 0.07 0.05 0.06 0.07 0.08 0.17 0.06 0.05 0.03 0.02 0.02 0.08 0.12 0.01 0.04 0.03 0.02 0.03 0.02 0.02 0.09 0.02 0.04 0.09 0.16 0.11 0.05 0.07 0.08 0.04 0.13 0.11 0.04 0.03 0.04 0.05 0.02 0.03 0.05 0.13 0.04 0.09 0.10 0.13 0.08 0.08 0.04 0.15 0.08 0.05 0.03 0.23 0.08 0.02 0.07 0.09 0.10 0.14 0.11 0.07 0.35 0.03 0.02 0.01 0.04 0.01 0.04 0.06 0.03 0.00 0.00 0.01 0.01 0.01 0.03 0.03 0.01 0.02 0.01 0.00 0.01 0.01 0.02 0.04 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.00 0.02 0.05 0.02 0.01 0.01 0.03 0.01 0.02 0.02 0.02 0.02 0.01 0.01 0.00 0.00 0.01 0.01 0.02 0.02 0.03 0.02 0.01 0.02 0.01 0.06 0.00 0.03 0.03 0.02 0.00 0.02 0.01 0.03 0.02 0.01 0.02 0.12 0.01 0.00 0.01 0.01 0.01 0.01 0.05 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.00 0.01 0.02 0.01 0.00 0.01 0.01 0.02 0.02 0.01 0.01 0.03 0.00

Cases

Female ASR(W) CUM 0-74

115 9 15 3 0 11 2 48 1 0 0 1 3 0 1 5 20 17 1 2 6 1 0 1 3 25 3 2 16 6 20 41 25 66 20 5 12 2 4 8 3 5 5 9 1 5 0 3 14 34 12 7 3 4 6 1 19 1 7 3 4 5 0 5 13 1 21 1 4 4 3 6 2 3 1 6 6 19 5

* * *

* * * *

* * *

584

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other male genital organs (C63) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 5 12 2 30 9 18 5 29 6 9 18 21 11 0 10 16 8 0 2 2 6 4 2 3 36 3 1 3 2 2 4 6 67 5 5 19 12 21 37 10 69 37 30 48 10 38 40 2 13 12 3 21 5 3 3 20 16 0 2 1 10 2 Male ASR(W) CUM 0-74 0.1 0.1 0.2 0.2 0.3 0.4 0.1 0.3 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.5 0.1 0.2 0.4 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.2 0.2 0.5 0.1 0.2 0.2 0.1 0.1 0.3 0.9 0.2 0.3 0.4 0.2 0.4 0.2 0.06 0.04 0.16 0.03 0.12 0.10 0.04 0.05 0.02 0.02 0.03 0.03 0.06 0.08 0.07 0.07 0.08 0.08 0.07 0.08 0.09 0.04 0.02 0.12 0.14 0.31 0.07 0.11 0.20 0.10 0.02 0.06 0.07 0.04 0.04 0.03 0.02 0.03 0.03 0.01 0.03 0.03 0.06 0.04 0.03 0.40 0.03 0.06 0.11 0.03 0.04 0.20 0.58 0.04 0.09 0.30 0.17 0.16 0.15 0.01 0.01 0.01 0.02 0.03 0.04 0.01 0.03 0.00 0.01 0.01 0.02 0.02 0.02 0.02 0.03 0.01 0.01 0.02 0.01 0.01 0.00 0.01 0.02 0.01 0.05 0.02 0.03 0.05 0.02 0.01 0.01 0.02 0.02 0.02 0.01 0.02 0.01 0.03 0.01 0.01 0.03 0.01 0.02 0.02 0.10 0.01 0.02 0.02 0.01 0.01 0.07 0.09 0.02 0.03 0.03 0.05 0.03 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.01 0.01 0.04 0.01 0.02 0.03 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.09 0.00 0.01 0.01 0.00 0.00 0.04 0.08 0.00 0.01 0.02 0.03 0.02 Cases Female ASR(W) CUM 0-74

* *

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
527

585

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Kidney (C64)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 18 121 25 21 45 76 114 20 66 1368 58 131 291 79 26 29 7444 892 1066 460 309 169 7 433 3675 55 378 1438 284 1140 190 1833 9195 517 645 1673 6274 1725 125 63 47 17 222 1171 2355 298 40 49 32 23 606 1275 1185 1358 88 1249 188 126 52 6808 483 6239 2372 586 1771 729 225 494 393 4479 568 3797 2277 1186 1623 1806 453 1349 117 281 Male ASR(W) CUM 0-74 0.7 2.5 2.6 0.5 1.8 9.3 5.0 2.8 4.7 6.7 6.8 3.9 3.9 3.0 2.3 3.3 9.6 9.9 7.4 11.4 11.6 9.5 8.5 13.1 9.5 11.0 10.7 10.1 10.9 9.9 12.4 10.7 9.4 4.6 11.2 10.4 9.9 8.7 9.9 4.1 5.5 5.5 10.4 9.5 9.3 12.0 3.4 6.6 6.1 4.5 9.8 10.1 9.5 11.8 12.2 11.8 11.3 12.1 9.4 10.6 9.2 10.8 10.7 12.8 10.3 10.9 13.0 10.6 9.8 11.8 13.4 11.6 12.0 11.7 12.6 13.7 14.3 13.8 12.6 14.4 0.18 0.24 0.53 0.13 0.31 1.11 0.52 0.67 0.59 0.19 0.90 0.35 0.23 0.35 0.46 0.63 0.12 0.34 0.24 0.56 0.68 0.78 3.37 0.66 0.16 1.52 0.59 0.27 0.66 0.30 0.94 0.26 0.10 0.21 0.45 0.26 0.13 0.22 0.91 0.55 0.81 1.42 0.73 0.30 0.20 0.70 0.57 0.96 1.19 1.00 0.41 0.30 0.29 0.34 1.33 0.35 0.85 1.12 1.41 0.14 0.43 0.15 0.22 0.55 0.25 0.42 0.92 0.50 0.51 0.18 0.57 0.20 0.26 0.36 0.32 0.33 0.69 0.39 1.19 0.91 1.05 0.53 0.30 0.55 0.82 0.85 0.51 0.45 0.35 0.32 0.40 1.13 1.16 0.89 1.34 1.38 1.15 1.08 1.55 1.12 1.35 1.25 1.25 1.38 1.21 1.55 1.27 1.13 0.57 1.31 1.26 1.18 1.05 1.20 0.48 0.62 0.78 1.30 1.13 1.11 1.41 0.32 0.74 0.86 0.43 1.19 1.21 1.15 1.46 1.52 1.46 1.42 1.45 1.35 1.28 1.16 1.30 1.27 1.55 1.22 1.33 1.58 1.29 1.21 1.42 1.57 1.40 1.46 1.42 1.49 1.68 1.72 1.70 1.54 1.73 0.14 0.07 0.08 0.09 0.03 0.13 0.05 0.03 0.05 0.07 0.09 0.02 0.05 0.03 0.08 0.09 0.10 0.54 0.09 0.02 0.23 0.08 0.04 0.10 0.04 0.15 0.04 0.01 0.03 0.06 0.04 0.02 0.03 0.13 0.07 0.11 0.22 0.11 0.04 0.03 0.10 0.07 0.12 0.17 0.12 0.06 0.04 0.04 0.05 0.20 0.05 0.12 0.15 0.22 0.02 0.06 0.02 0.03 0.08 0.03 0.06 0.14 0.07 0.07 0.03 0.08 0.03 0.04 0.05 0.04 0.05 0.10 0.05 0.17 0.12 Cases 34 84 16 15 37 37 79 13 45 863 39 113 186 60 25 17 4780 569 642 290 221 114 2 284 2381 29 248 931 233 686 81 1096 5346 312 409 1120 3448 1001 99 41 35 14 158 625 1443 186 23 32 17 13 409 738 748 868 55 797 121 95 21 4005 359 3607 1490 382 1091 394 133 253 290 3025 420 2545 1548 766 1033 1202 314 885 95 183 Female ASR(W) CUM 0-74 1.2 1.5 1.6 0.3 1.7 3.9 2.9 1.9 2.5 3.2 4.1 2.7 2.4 2.0 1.9 1.5 5.4 5.8 3.8 6.0 7.2 6.0 2.6 6.9 5.4 5.5 5.9 5.3 6.5 4.9 5.2 5.7 4.6 2.3 5.8 5.8 4.6 4.3 6.3 2.0 3.0 2.6 6.1 4.3 4.7 5.6 1.8 3.1 3.4 2.4 5.1 4.9 5.2 6.2 5.7 6.2 5.6 6.7 2.8 5.3 5.4 5.3 5.5 5.9 5.4 4.7 5.5 4.5 6.8 6.4 7.0 6.4 6.8 6.2 6.6 7.4 7.2 7.5 7.0 7.3 0.23 0.17 0.41 0.08 0.35 0.68 0.35 0.54 0.39 0.12 0.67 0.26 0.18 0.26 0.39 0.38 0.09 0.26 0.17 0.40 0.53 0.62 2.07 0.46 0.12 1.17 0.43 0.19 0.45 0.21 0.60 0.19 0.07 0.14 0.30 0.18 0.09 0.15 0.68 0.34 0.52 0.79 0.50 0.20 0.13 0.44 0.42 0.57 1.11 0.75 0.26 0.21 0.20 0.24 0.80 0.25 0.58 0.77 0.84 0.10 0.29 0.11 0.15 0.32 0.18 0.25 0.50 0.31 0.43 0.13 0.35 0.14 0.19 0.26 0.22 0.23 0.42 0.28 0.75 0.61 0.47 0.32 0.22 0.25 0.35 0.45 0.30 0.27 0.23 0.19 0.21 0.62 0.65 0.44 0.71 0.81 0.76 0.38 0.84 0.62 0.71 0.71 0.61 0.77 0.56 0.61 0.68 0.54 0.27 0.65 0.70 0.54 0.49 0.67 0.20 0.37 0.31 0.75 0.51 0.54 0.61 0.19 0.36 0.38 0.35 0.61 0.57 0.61 0.73 0.61 0.74 0.65 0.80 0.25 0.61 0.65 0.61 0.63 0.71 0.62 0.56 0.65 0.52 0.82 0.74 0.81 0.74 0.80 0.72 0.77 0.86 0.82 0.89 0.79 0.89 * * * *

0.08 0.05 0.08 0.05 0.01 0.09 0.04 0.02 0.03 0.04 0.07 * 0.01 0.03 0.02 0.05 0.07 0.08 0.33 0.06 0.02 0.16 0.06 0.02 0.06 0.03 0.09 0.02 0.01 0.02 0.04 0.03 0.01 0.02 0.08 0.04 0.07 0.10 0.07 0.03 0.02 0.06 0.05 0.07 0.10 0.10 0.04 0.03 0.03 0.03 0.10 0.03 0.07 0.10 0.09 0.01 0.04 0.01 0.02 0.05 0.02 0.04 0.07 0.04 0.06 0.02 0.05 0.02 0.02 0.03 0.03 0.03 0.06 0.04 0.10 0.08

586

*Important. See note on population page.

528

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Kidney (C64) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 559 2329 3460 480 2924 1568 353 1188 2192 209 1971 318 78891 7436 69100 3419 346 2968 621 45 224 345 7053 653 6214 4018 384 3555 1268 1121 5201 474 4632 465 8810 864 7372 23773 897 2320 2290 17980 1519 334 1165 7196 675 6378 447 215 2009 1374 762 2008 27 123 21 75 1090 56 110 115 558 6 435 43 105 40 1747 1628 69 167 201 252 641 356 1360 216 Male ASR(W) CUM 0-74 12.5 11.3 11.0 14.4 10.5 12.5 14.3 12.1 12.1 15.3 11.9 10.0 11.2 12.1 11.2 12.6 12.5 12.8 10.7 14.0 12.5 9.9 11.8 9.8 12.3 10.8 12.1 10.6 11.2 9.7 11.9 15.6 11.4 13.1 10.8 12.9 11.0 10.7 5.2 12.8 10.6 11.1 12.0 12.1 11.9 12.5 13.1 12.6 8.3 10.3 10.7 10.8 11.3 11.4 4.7 2.3 1.6 3.2 4.8 1.8 5.1 1.3 2.6 0.7 2.0 1.0 1.7 1.5 11.0 11.4 4.4 4.5 5.6 6.3 6.6 5.3 3.9 3.4 0.55 0.25 0.19 0.67 0.20 0.33 0.78 0.37 0.27 1.08 0.28 0.59 0.04 0.14 0.04 0.23 0.68 0.25 0.44 2.13 0.85 0.58 0.15 0.39 0.17 0.18 0.63 0.19 0.32 0.31 0.18 0.74 0.18 0.64 0.12 0.45 0.13 0.07 0.18 0.27 0.23 0.09 0.32 0.68 0.36 0.15 0.52 0.16 0.41 0.73 0.25 0.30 0.43 0.27 0.93 0.22 0.38 0.37 0.16 0.25 0.51 0.12 0.12 0.30 0.10 0.16 0.17 0.24 0.27 0.29 0.56 0.36 0.44 0.41 0.27 0.30 0.11 0.25 1.55 1.37 1.33 1.75 1.28 1.51 1.73 1.46 1.45 1.82 1.43 1.18 1.35 1.47 1.35 1.54 1.57 1.56 1.33 2.18 1.54 1.19 1.43 1.20 1.50 1.31 1.47 1.27 1.33 1.15 1.41 1.81 1.36 1.59 1.30 1.57 1.32 1.30 0.63 1.55 1.29 1.33 1.46 1.48 1.45 1.51 1.61 1.52 1.00 1.24 1.26 1.26 1.37 1.37 0.60 0.26 0.15 0.44 0.56 0.16 0.59 0.15 0.30 0.08 0.24 0.13 0.19 0.17 1.37 1.42 0.57 0.51 0.63 0.73 0.80 0.61 0.44 0.38 0.08 0.03 0.03 0.10 0.03 0.05 0.11 0.05 0.04 0.15 0.04 0.08 0.01 0.02 0.01 0.03 0.10 0.03 0.06 0.37 0.12 0.08 0.02 0.06 0.02 0.02 0.09 0.03 0.04 0.04 0.02 0.10 0.02 0.09 0.02 0.07 0.02 0.01 0.03 0.04 0.03 0.01 0.04 0.10 0.05 0.02 0.08 0.02 0.06 0.10 0.04 0.04 0.06 0.04 0.14 0.03 0.04 0.06 0.02 0.03 0.07 0.02 0.02 0.04 0.01 0.02 0.02 0.03 0.04 0.04 0.09 0.05 0.05 0.05 0.04 0.04 0.01 0.03 Cases 325 1600 2339 349 1950 1049 278 762 1452 138 1297 193 50061 5308 43312 2126 236 1838 353 31 144 170 4542 505 3931 2828 297 2473 796 652 3416 310 3044 307 5337 616 4386 14423 530 1567 1519 10643 871 248 613 4617 549 3987 295 137 1141 760 494 1313 25 65 9 46 574 18 57 70 222 3 193 21 59 9 1057 992 33 61 97 92 291 184 631 148 Female ASR(W) CUM 0-74 5.9 6.2 6.2 7.9 5.9 6.9 8.4 6.5 6.5 6.7 6.5 5.1 5.9 6.4 5.9 6.1 6.3 6.2 5.5 7.5 6.9 4.6 5.9 5.1 6.2 6.2 6.9 6.1 5.9 5.1 6.2 7.1 6.1 6.8 5.5 7.0 5.6 5.4 2.6 6.6 5.8 5.5 5.7 6.6 5.3 6.8 8.0 6.7 4.8 5.8 5.4 5.3 5.9 6.2 3.5 1.2 0.6 1.9 2.4 0.6 2.8 0.8 1.2 0.4 0.9 0.5 0.9 0.3 5.6 5.8 1.6 1.5 1.9 1.9 2.5 2.1 1.5 1.9 0.37 0.17 0.14 0.44 0.15 0.24 0.53 0.27 0.19 0.60 0.20 0.42 0.03 0.09 0.03 0.15 0.42 0.16 0.31 1.36 0.59 0.39 0.10 0.24 0.11 0.13 0.42 0.14 0.23 0.22 0.12 0.43 0.13 0.45 0.08 0.29 0.09 0.05 0.12 0.17 0.16 0.06 0.21 0.44 0.24 0.11 0.36 0.11 0.30 0.54 0.18 0.21 0.30 0.19 0.75 0.16 0.21 0.28 0.12 0.14 0.40 0.10 0.08 0.23 0.07 0.12 0.12 0.11 0.18 0.20 0.31 0.21 0.22 0.21 0.17 0.19 0.07 0.18 0.70 0.74 0.72 0.95 0.69 0.79 1.00 0.74 0.75 0.78 0.75 0.57 0.68 0.75 0.69 0.72 0.73 0.74 0.67 1.01 0.83 0.55 0.69 0.58 0.72 0.73 0.80 0.71 0.70 0.59 0.72 0.88 0.71 0.80 0.64 0.81 0.65 0.63 0.30 0.76 0.70 0.64 0.66 0.74 0.62 0.80 0.94 0.80 0.56 0.68 0.62 0.61 0.71 0.72 0.35 0.10 0.10 0.23 0.27 0.07 0.29 0.08 0.12 0.03 0.10 0.05 0.09 0.02 0.69 0.72 0.14 0.18 0.24 0.21 0.28 0.24 0.15 0.22 0.05 0.02 0.02 0.06 0.02 0.03 0.07 0.03 0.02 0.08 0.03 0.05 0.00 0.01 0.00 0.02 0.06 0.02 0.04 0.21 0.08 0.05 0.01 0.03 0.01 0.02 0.06 0.02 0.03 0.03 0.02 0.06 0.02 0.06 0.01 0.04 0.01 0.01 0.02 0.02 0.02 0.01 0.03 0.06 0.03 0.01 0.05 0.02 0.04 0.07 0.02 0.03 0.04 0.03 0.09 0.02 * 0.04 * 0.04 0.01 * 0.02 * 0.04 * 0.01 0.01 * 0.02 0.01 0.01 * 0.01 * 0.01 * 0.03 0.03 0.03 0.03 0.03 0.03 0.02 0.02 0.01 0.02

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
529

587

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Kidney (C64) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
530

Male ASR(W) CUM 0-74 4.7 4.9 5.2 4.6 3.9 4.3 4.7 5.6 5.9 5.8 3.4 3.6 2.0 1.7 1.7 4.6 4.6 5.3 1.7 3.0 1.7 0.8 0.7 2.9 3.3 12.2 11.0 10.6 13.0 7.3 8.6 5.4 9.8 20.2 7.4 15.6 10.2 15.0 9.1 9.8 11.6 9.5 8.4 11.4 7.2 10.8 8.3 8.4 16.3 16.0 8.4 17.1 11.9 9.5 11.3 15.0 8.7 10.2 15.2 12.2 13.1 10.5 10.9 12.6 13.6 7.3 12.3 10.6 4.6 11.5 13.3 6.5 8.1 3.7 14.1 8.5 11.6 13.0 14.2 0.07 0.25 0.32 0.43 0.39 0.31 0.82 0.17 0.70 0.80 0.86 0.44 0.25 0.31 0.26 0.28 0.24 0.29 0.52 0.58 0.22 0.18 0.17 0.31 0.21 0.21 0.72 0.99 0.22 0.34 0.23 0.15 0.26 0.24 0.20 0.62 0.24 0.69 0.67 0.78 0.69 0.55 0.49 0.56 0.62 0.77 0.78 0.67 0.42 0.31 0.37 0.52 0.37 0.31 0.51 1.36 0.28 1.12 0.84 1.02 0.53 0.66 1.22 0.57 0.72 0.70 0.40 0.83 0.68 0.83 0.59 0.48 0.71 0.56 1.46 0.49 0.57 0.85 0.49 0.56 0.60 0.63 0.58 0.49 0.51 0.51 0.65 0.78 0.75 0.33 0.46 0.25 0.17 0.21 0.59 0.54 0.63 0.16 0.32 0.20 0.08 0.08 0.35 0.41 1.48 1.23 1.33 1.55 0.93 1.06 0.63 1.18 2.50 0.88 1.94 1.22 1.79 1.05 1.24 1.42 1.10 1.00 1.36 0.78 1.38 0.97 0.99 2.05 1.98 0.98 2.16 1.42 1.16 1.41 1.73 0.99 1.27 1.84 1.38 1.57 1.29 1.33 1.55 1.77 0.89 1.49 1.29 0.56 1.37 1.64 0.79 1.00 0.46 1.68 1.00 1.46 1.60 1.71 0.01 0.04 0.05 0.07 0.06 0.04 0.11 0.02 0.12 0.12 0.08 0.07 0.04 0.04 0.04 0.05 0.03 0.04 0.06 0.08 0.03 0.02 0.02 0.04 0.03 0.03 0.09 0.14 0.03 0.05 0.03 0.02 0.03 0.03 0.03 0.08 0.03 0.09 0.09 0.11 0.10 0.07 0.07 0.08 0.08 0.11 0.10 0.08 0.06 0.04 0.05 0.07 0.05 0.04 0.07 0.18 0.04 0.15 0.11 0.11 0.07 0.09 0.16 0.07 0.10 0.10 0.05 0.11 0.09 0.11 0.08 0.06 0.09 0.08 0.19 0.06 0.08 0.12 0.06

Cases 1967 214 154 63 48 120 20 546 31 27 17 38 26 34 21 224 226 194 7 25 34 9 16 47 138 2720 182 74 2533 307 1084 804 988 4572 1059 469 1577 293 102 76 205 151 196 238 95 108 73 108 1120 2010 375 757 681 672 349 77 537 48 201 122 384 162 51 336 212 86 635 124 38 129 372 118 76 35 50 243 232 135 568

Female ASR(W) CUM 0-74 1.9 2.1 2.3 2.0 1.4 2.1 1.9 2.2 1.6 2.0 4.0 1.7 0.7 1.6 0.8 2.5 2.4 2.5 1.4 2.3 0.9 0.4 0.6 1.6 1.6 6.8 6.5 5.2 6.1 3.8 5.0 2.4 4.8 9.5 4.2 6.6 5.8 6.5 3.9 3.5 6.4 3.8 4.2 5.1 3.8 4.7 3.2 4.2 8.7 7.9 4.1 8.8 5.5 4.9 6.1 7.6 4.2 3.6 6.6 4.9 5.4 4.4 4.5 5.0 6.3 4.9 5.5 6.0 3.3 5.2 6.6 3.3 3.7 2.6 6.7 4.3 5.4 5.5 6.4 0.04 0.15 0.19 0.25 0.21 0.19 0.46 0.10 0.30 0.42 1.13 0.28 0.14 0.30 0.19 0.18 0.17 0.19 0.56 0.48 0.16 0.14 0.15 0.24 0.14 0.15 0.54 0.65 0.13 0.25 0.18 0.10 0.17 0.15 0.15 0.34 0.17 0.44 0.44 0.43 0.49 0.36 0.34 0.37 0.44 0.50 0.45 0.49 0.30 0.21 0.26 0.39 0.24 0.22 0.40 0.94 0.20 0.59 0.55 0.53 0.34 0.41 0.74 0.36 0.54 0.57 0.26 0.78 0.65 0.53 0.45 0.35 0.52 0.56 1.15 0.37 0.51 0.55 0.32 0.21 0.24 0.25 0.22 0.17 0.24 0.19 0.26 0.17 0.25 0.22 0.17 0.09 0.16 0.07 0.28 0.28 0.29 0.12 0.27 0.09 0.05 0.05 0.17 0.18 0.81 0.73 0.58 0.72 0.48 0.57 0.27 0.56 1.18 0.51 0.83 0.68 0.73 0.43 0.42 0.77 0.43 0.46 0.60 0.49 0.58 0.38 0.47 1.09 0.99 0.48 1.06 0.66 0.54 0.70 0.90 0.48 0.50 0.79 0.55 0.61 0.52 0.57 0.57 0.77 0.58 0.67 0.59 0.31 0.60 0.71 0.36 0.38 0.28 0.72 0.49 0.55 0.67 0.77 0.01 0.02 0.02 0.03 0.03 0.03 0.05 0.01 0.04 0.07 0.09 0.03 0.02 0.04 * 0.02 * 0.03 * 0.02 0.03 0.05 0.07 0.02 * 0.02 * 0.01 0.03 * 0.02 * 0.02 0.07 0.08 0.02 * 0.03 * 0.02 0.01 * 0.02 0.02 0.02 0.04 0.02 0.05 0.05 0.06 0.07 0.04 0.04 0.05 0.06 0.06 0.06 0.05 0.04 0.03 0.03 0.05 0.03 0.03 0.05 0.13 0.03 0.09 0.07 0.07 0.04 0.05 0.10 0.04 0.06 0.07 0.03 0.07 0.06 0.07 0.05 0.04 0.05 0.06 0.12 0.04 0.05 0.07 0.04

4253 439 282 130 108 227 35 1229 89 58 42 70 75 32 51 314 385 344 12 29 63 18 19 87 264 3569 246 119 3743 511 1622 1559 1557 7193 1550 670 1993 501 209 172 298 344 318 445 155 215 137 181 1651 2971 571 1140 1091 976 516 132 1021 91 358 207 734 297 92 579 399 112 1105 206 51 239 640 203 146 45 98 369 478 261 954

588

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Kidney (C64) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 1033 1619 82 1503 239 492 589 484 546 1665 934 1831 645 57 436 769 202 48 165 127 196 212 126 200 2563 127 71 69 149 131 77 170 4518 284 276 721 690 1126 2067 663 2233 3514 1527 1484 425 1667 2165 29 1142 616 185 1610 561 85 26 1044 358 23 42 51 100 125 Male ASR(W) CUM 0-74 13.7 15.6 6.5 8.7 9.7 12.1 9.8 4.9 5.4 12.1 5.4 12.0 9.8 4.8 9.6 11.3 4.5 5.4 7.6 4.6 5.2 9.4 6.2 5.9 6.8 8.3 8.3 11.0 7.7 11.3 7.6 7.3 7.9 7.8 8.0 6.5 7.4 7.1 8.1 6.8 7.8 6.9 7.8 7.4 7.6 8.7 9.7 6.9 9.5 10.9 10.6 9.7 9.2 9.3 5.7 8.3 8.8 6.2 6.7 10.7 8.4 11.8 0.43 0.40 0.76 0.24 0.64 0.57 0.42 0.23 0.25 0.31 0.19 0.29 0.40 0.69 0.54 0.43 0.33 1.02 0.65 0.44 0.39 0.69 0.61 0.49 0.15 0.76 1.06 1.42 0.65 1.08 0.89 0.60 0.12 0.47 0.50 0.26 0.30 0.22 0.19 0.28 0.18 0.12 0.21 0.20 0.39 0.23 0.22 1.36 0.29 0.46 0.81 0.25 0.40 1.03 1.15 0.27 0.49 1.47 1.09 1.53 1.00 1.11 1.68 1.95 0.73 1.02 1.20 1.49 1.23 0.59 0.64 1.46 0.63 1.48 1.14 0.54 1.11 1.35 0.54 0.55 0.91 0.55 0.64 1.16 0.71 0.66 0.84 0.99 1.03 1.28 0.97 1.35 0.90 0.87 0.97 0.94 0.99 0.75 0.87 0.83 0.97 0.80 0.91 0.81 0.94 0.87 0.91 1.03 1.15 1.02 1.12 1.30 1.27 1.13 1.07 1.02 0.78 0.98 1.06 0.59 0.76 1.41 0.96 1.49 0.06 0.05 0.10 0.03 0.09 0.08 0.06 0.03 0.03 0.04 0.02 0.04 0.05 0.09 0.06 0.06 0.04 0.10 0.08 0.05 0.05 0.09 0.08 0.05 0.02 0.11 0.15 0.18 0.10 0.13 0.12 0.08 0.02 0.07 0.07 0.03 0.04 0.03 0.03 0.04 0.02 0.02 0.03 0.03 0.05 0.03 0.03 0.25 0.04 0.06 0.11 0.03 0.06 0.14 0.18 0.04 0.07 0.18 0.14 0.23 0.12 0.15 Cases 845 1218 55 946 166 326 376 273 291 1602 590 1213 354 32 200 320 116 28 84 90 109 93 65 106 1843 56 42 27 87 62 38 116 2929 187 170 446 421 724 1374 384 1326 2052 939 854 292 1156 1247 12 669 300 124 996 309 66 9 614 180 13 27 21 54 49 Female ASR(W) CUM 0-74 7.1 7.9 3.6 4.3 4.7 6.2 4.6 2.4 2.4 6.5 3.0 6.0 4.2 2.6 3.5 4.1 2.3 3.3 3.2 2.8 2.6 3.2 2.7 2.9 4.2 2.9 4.1 3.3 3.7 3.6 3.7 4.0 4.4 4.5 4.6 3.4 3.7 3.7 4.4 3.4 3.9 3.3 4.1 3.6 4.3 4.5 4.9 3.0 5.0 4.7 6.5 5.5 4.9 6.4 2.1 4.5 3.8 2.3 3.6 3.9 3.5 4.4 0.28 0.25 0.51 0.17 0.38 0.39 0.28 0.17 0.17 0.19 0.14 0.19 0.27 0.51 0.35 0.30 0.25 0.90 0.39 0.33 0.28 0.43 0.42 0.38 0.12 0.46 0.76 0.69 0.44 0.54 0.70 0.42 0.09 0.37 0.43 0.19 0.21 0.16 0.14 0.19 0.13 0.09 0.16 0.14 0.28 0.15 0.15 0.90 0.21 0.30 0.64 0.19 0.30 0.85 0.72 0.20 0.30 0.77 0.72 0.87 0.56 0.71 0.88 0.95 0.42 0.49 0.57 0.73 0.56 0.26 0.26 0.78 0.34 0.72 0.47 0.34 0.38 0.44 0.23 0.33 0.36 0.32 0.30 0.33 0.31 0.31 0.51 0.30 0.48 0.40 0.47 0.41 0.46 0.49 0.53 0.51 0.53 0.39 0.42 0.42 0.50 0.39 0.45 0.37 0.48 0.41 0.49 0.52 0.56 0.30 0.55 0.54 0.78 0.60 0.55 0.72 0.29 0.51 0.46 0.21 0.51 0.47 0.44 0.51 0.03 0.03 0.07 0.02 0.05 * 0.05 0.03 0.02 * 0.02 0.02 0.02 0.02 0.03 0.07 0.03 0.03 0.03 0.08 0.05 0.04 0.03 0.05 0.05 0.04 0.02 0.05 0.09 0.10 0.06 0.07 0.08 0.06 0.01 0.05 0.05 0.02 0.03 0.02 0.02 0.03 0.02 0.01 0.02 0.02 0.04 0.02 0.02 0.13 0.03 0.04 0.08 0.02 0.04 0.12 0.12 0.03 0.04 0.10 0.11 0.12 0.07 0.09

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
531

589

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Renal pelvis (C65)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 0 17 4 0 0 1 1 0 3 30 1 4 10 4 2 6 392 54 79 47 28 2 0 16 146 3 17 86 10 75 8 74 605 30 23 91 458 92 7 4 0 1 9 65 174 13 3 1 3 1 35 115 90 70 2 66 4 2 2 526 18 503 115 15 98 34 6 28 16 260 11 246 181 63 84 100 17 83 3 17 Male ASR(W) CUM 0-74 0.5 0.4 0.1 0.0 0.2 0.2 0.1 0.1 0.1 0.2 0.2 0.7 0.5 0.6 0.5 1.1 1.0 0.1 0.4 0.3 0.7 0.4 0.5 0.4 0.6 0.5 0.4 0.6 0.3 0.4 0.6 0.6 0.4 0.6 0.2 0.4 0.4 0.5 0.6 0.5 0.2 0.1 0.6 0.2 0.6 0.8 0.7 0.5 0.3 0.5 0.2 0.2 0.3 0.7 0.3 0.7 0.5 0.4 0.5 0.5 0.4 0.6 0.3 0.6 0.3 0.7 0.9 0.5 0.6 0.7 0.5 0.8 0.3 0.9 0.12 0.20 0.13 0.03 0.14 0.03 0.08 0.06 0.04 0.08 0.13 0.30 0.02 0.08 0.06 0.17 0.20 0.06 0.12 0.03 0.41 0.11 0.06 0.12 0.07 0.17 0.05 0.02 0.05 0.09 0.06 0.03 0.05 0.23 0.12 0.40 0.14 0.06 0.05 0.15 0.12 0.13 0.37 0.19 0.11 0.08 0.08 0.07 0.22 0.07 0.10 0.12 0.23 0.03 0.08 0.04 0.05 0.09 0.06 0.09 0.18 0.11 0.09 0.04 0.09 0.05 0.07 0.07 0.07 0.07 0.12 0.09 0.16 0.22 0.02 0.00 0.04 0.02 0.02 0.02 0.02 0.03 0.07 0.05 0.06 0.05 0.15 0.12 0.00 0.05 0.04 0.11 0.06 0.06 0.04 0.06 0.07 0.04 0.07 0.03 0.06 0.06 0.08 0.05 0.11 0.02 0.05 0.04 0.05 0.08 0.06 0.01 0.03 0.08 0.02 0.08 0.10 0.09 0.07 0.04 0.07 0.03 0.02 0.05 0.08 0.04 0.09 0.06 0.03 0.07 0.07 0.05 0.08 0.04 0.08 0.03 0.09 0.12 0.06 0.07 0.08 0.04 0.09 0.02 0.11 0.02 0.00 0.02 0.00 0.01 0.01 0.01 0.02 0.04 0.00 0.01 0.01 0.03 0.03 0.00 0.02 0.00 0.06 0.02 0.01 0.02 0.01 0.03 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.05 0.02 0.05 0.02 0.01 0.01 0.02 0.01 0.03 0.05 0.02 0.02 0.01 0.01 0.01 0.03 0.01 0.02 0.02 0.05 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.03 Cases 0 5 1 2 0 0 2 0 1 24 0 1 2 1 1 2 285 43 55 18 12 3 0 17 122 0 15 68 6 61 4 76 461 28 18 58 355 86 5 7 2 0 10 60 155 10 7 2 2 2 33 98 42 57 2 55 10 7 3 359 13 343 95 12 82 26 3 22 19 212 8 198 177 60 76 61 9 52 3 11 Female ASR(W) CUM 0-74 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.2 0.2 0.3 0.2 0.3 0.3 0.1 0.4 0.2 0.3 0.3 0.1 0.3 0.3 0.3 0.3 0.2 0.2 0.3 0.4 0.3 0.2 0.3 0.1 0.3 0.3 0.4 0.3 0.6 0.2 0.3 0.7 0.4 0.4 0.3 0.4 0.2 0.4 0.3 0.3 0.2 0.3 0.2 0.4 0.3 0.2 0.3 0.3 0.1 0.4 0.4 0.4 0.1 0.4 0.6 0.3 0.4 0.3 0.2 0.3 0.2 0.3 0.05 0.09 0.04 0.03 0.05 0.02 0.02 0.02 0.04 0.08 0.12 0.02 0.06 0.04 0.08 0.09 0.07 0.11 0.02 0.09 0.04 0.05 0.04 0.17 0.04 0.02 0.04 0.05 0.04 0.02 0.03 0.09 0.12 0.09 0.11 0.05 0.03 0.09 0.23 0.11 0.26 0.53 0.07 0.05 0.05 0.05 0.14 0.06 0.10 0.14 0.11 0.02 0.05 0.02 0.03 0.05 0.04 0.06 0.08 0.08 0.10 0.03 0.05 0.03 0.05 0.05 0.05 0.04 0.07 0.04 0.13 0.11 0.00 0.01 0.00 0.00 0.01 0.01 0.02 0.03 0.04 0.02 0.03 0.04 0.02 0.05 0.03 0.04 0.02 0.01 0.03 0.05 0.04 0.04 0.02 0.02 0.03 0.04 0.03 0.01 0.03 0.02 0.03 0.04 0.04 0.03 0.08 0.01 0.03 0.06 0.04 0.05 0.04 0.05 0.03 0.05 0.04 0.05 0.04 0.02 0.04 0.04 0.02 0.04 0.04 0.01 0.05 0.06 0.04 0.01 0.05 0.08 0.05 0.04 0.02 0.03 0.02 0.03 0.05 * * * *

0.00 0.00 0.00 0.00 0.01 0.01 0.01 * 0.00 0.01 0.00 0.01 0.02 0.01 0.02 0.00 0.01 0.00 0.00 0.01 0.03 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.02 0.02 0.02 0.01 0.01 0.01 0.04 0.01 0.03 0.04 0.01 0.01 0.01 0.01 0.03 0.01 0.02 0.02 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02

590

*Important. See note on population page.

532

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Renal pelvis (C65) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 43 136 223 15 205 81 9 71 109 5 103 31 4799 203 4487 172 7 163 24 0 8 15 395 19 362 177 9 162 57 81 383 11 367 29 478 27 407 1372 65 69 114 1119 69 7 60 296 15 279 24 11 157 85 51 116 0 24 3 0 103 6 6 2 8 0 0 0 1 1 110 94 13 46 32 66 124 99 323 50 Male ASR(W) CUM 0-74 0.9 0.6 0.7 0.4 0.7 0.6 0.3 0.6 0.6 0.4 0.6 0.8 0.6 0.3 0.6 0.6 0.2 0.6 0.4 0.4 0.4 0.6 0.3 0.6 0.4 0.3 0.4 0.5 0.6 0.8 0.4 0.8 0.7 0.5 0.4 0.5 0.6 0.4 0.4 0.5 0.6 0.5 0.3 0.6 0.5 0.3 0.5 0.4 0.5 0.8 0.6 0.7 0.6 0.5 0.2 0.4 0.2 0.3 0.0 0.0 0.0 0.0 0.7 0.6 0.9 1.1 0.8 1.5 1.1 1.2 0.8 0.8 0.14 0.05 0.05 0.11 0.05 0.07 0.12 0.08 0.06 0.18 0.06 0.15 0.01 0.02 0.01 0.05 0.09 0.05 0.08 0.14 0.10 0.03 0.07 0.03 0.03 0.09 0.04 0.06 0.07 0.04 0.11 0.04 0.13 0.03 0.09 0.03 0.02 0.05 0.05 0.05 0.02 0.06 0.10 0.07 0.03 0.08 0.03 0.09 0.15 0.06 0.07 0.10 0.06 0.10 0.12 0.04 0.08 0.12 0.01 0.01 0.01 0.04 0.07 0.07 0.26 0.17 0.16 0.18 0.10 0.13 0.05 0.12 0.12 0.07 0.08 0.04 0.08 0.07 0.04 0.07 0.07 0.06 0.07 0.10 0.07 0.04 0.08 0.07 0.04 0.07 0.05 0.05 0.05 0.07 0.04 0.08 0.05 0.03 0.06 0.06 0.07 0.09 0.05 0.09 0.09 0.06 0.06 0.06 0.07 0.05 0.05 0.06 0.07 0.06 0.03 0.07 0.06 0.04 0.06 0.05 0.05 0.09 0.08 0.08 0.07 0.06 0.02 0.05 0.02 0.04 0.00 0.01 0.00 0.01 0.08 0.07 0.10 0.13 0.09 0.16 0.14 0.15 0.10 0.09 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.00 0.00 0.00 0.01 0.02 0.01 0.01 0.03 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.01 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.00 0.00 0.00 0.01 0.01 0.01 0.03 0.02 0.02 0.03 0.02 0.02 0.01 0.02 Cases 29 150 166 14 149 84 13 70 83 2 81 11 3724 173 3463 171 9 161 9 0 4 4 307 23 278 171 7 161 45 67 280 9 267 25 383 25 336 1101 43 60 70 925 58 7 51 226 11 207 11 9 111 73 42 90 0 12 1 0 67 3 1 1 3 0 2 0 1 1 52 50 1 19 18 30 49 43 125 25 Female ASR(W) CUM 0-74 0.5 0.5 0.4 0.3 0.4 0.4 0.4 0.5 0.3 0.1 0.3 0.2 0.3 0.2 0.4 0.4 0.2 0.4 0.1 0.2 0.1 0.3 0.2 0.4 0.3 0.1 0.3 0.3 0.4 0.4 0.2 0.4 0.6 0.3 0.3 0.3 0.3 0.2 0.2 0.3 0.4 0.3 0.2 0.4 0.3 0.1 0.3 0.2 0.2 0.4 0.4 0.4 0.3 0.2 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.1 0.4 0.2 0.5 0.3 0.3 0.2 0.3 0.09 0.04 0.03 0.09 0.03 0.05 0.10 0.06 0.03 0.05 0.04 0.07 0.01 0.01 0.01 0.03 0.07 0.04 0.05 0.11 0.05 0.02 0.04 0.02 0.03 0.06 0.03 0.04 0.06 0.03 0.06 0.03 0.13 0.02 0.05 0.02 0.01 0.03 0.03 0.03 0.01 0.04 0.06 0.06 0.02 0.04 0.02 0.06 0.09 0.04 0.05 0.07 0.04 0.05 0.10 0.03 0.05 0.03 0.01 0.01 0.01 0.01 0.04 0.03 0.04 0.07 0.10 0.06 0.10 0.05 0.05 0.02 0.07 0.06 0.06 0.04 0.04 0.04 0.05 0.04 0.06 0.03 0.01 0.03 0.02 0.04 0.02 0.04 0.04 0.02 0.05 0.01 0.02 0.01 0.04 0.02 0.04 0.04 0.02 0.04 0.04 0.05 0.05 0.01 0.05 0.07 0.04 0.03 0.04 0.04 0.02 0.03 0.03 0.04 0.04 0.02 0.04 0.03 0.02 0.03 0.03 0.02 0.05 0.03 0.06 0.04 0.01 0.01 0.03 0.01 0.01 0.00 0.00 0.00 0.00 0.03 0.03 0.02 0.05 0.02 0.06 0.04 0.03 0.03 0.03 0.01 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.02 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 * 0.01 * 0.00 * 0.01 * 0.01 * 0.00 * 0.00 - * 0.00 * 0.00 * 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
533

591

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Renal pelvis (C65) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
534

Male ASR(W) CUM 0-74 0.6 0.6 0.3 0.8 1.2 0.5 0.8 0.8 0.4 0.4 0.0 0.4 0.1 0.0 0.0 0.4 0.5 0.3 0.1 0.2 0.8 0.2 0.3 0.3 0.5 0.5 0.4 0.1 1.0 0.9 0.3 0.2 0.9 1.2 0.5 0.6 0.7 0.7 0.5 0.7 0.9 0.7 0.1 0.7 1.2 0.6 0.1 0.7 0.6 0.9 0.8 0.8 1.0 0.8 0.9 0.2 0.6 0.7 1.5 0.4 1.0 0.2 1.1 0.6 0.5 1.5 0.6 0.3 1.0 0.2 0.8 1.0 0.8 1.0 0.6 0.8 0.7 0.03 0.10 0.07 0.19 0.24 0.11 0.34 0.07 0.18 0.21 0.01 0.16 0.06 0.05 0.01 0.08 0.09 0.22 0.10 0.06 0.19 0.08 0.10 0.06 0.04 0.15 0.19 0.02 0.13 0.07 0.03 0.04 0.05 0.08 0.11 0.06 0.14 0.19 0.16 0.17 0.16 0.13 0.06 0.20 0.25 0.19 0.06 0.08 0.06 0.11 0.11 0.09 0.10 0.13 0.29 0.04 0.23 0.17 0.29 0.09 0.18 0.16 0.15 0.15 0.07 0.28 0.25 0.12 0.14 0.08 0.21 0.31 0.29 0.14 0.11 0.19 0.10 0.08 0.08 0.03 0.11 0.17 0.08 0.09 0.11 0.03 0.04 0.00 0.07 0.01 0.01 0.00 0.05 0.06 0.03 0.03 0.02 0.09 0.02 0.04 0.04 0.07 0.06 0.06 0.02 0.11 0.12 0.03 0.03 0.11 0.15 0.06 0.08 0.08 0.10 0.05 0.10 0.12 0.08 0.02 0.08 0.15 0.08 0.01 0.08 0.08 0.12 0.08 0.09 0.12 0.11 0.04 0.03 0.08 0.10 0.20 0.05 0.13 0.04 0.15 0.08 0.06 0.21 0.07 0.04 0.13 0.02 0.12 0.12 0.08 0.12 0.07 0.09 0.10 0.00 0.01 0.01 0.03 0.04 0.02 0.04 0.01 0.02 0.03 0.00 0.03 0.01 0.01 0.00 0.01 0.01 0.03 0.03 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.03 0.00 0.02 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.02 0.03 0.02 0.03 0.02 0.02 0.01 0.03 0.04 0.03 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.03 0.01 0.04 0.03 0.04 0.01 0.03 0.03 0.02 0.02 0.01 0.04 0.03 0.02 0.02 0.01 0.03 0.04 0.05 0.02 0.02 0.03 0.02

Cases 156 14 4 3 8 7 2 51 4 0 0 4 2 0 0 1 20 19 1 0 1 5 1 5 10 134 9 4 16 36 96 40 28 286 215 9 84 19 5 6 10 18 9 7 4 9 8 0 74 104 59 63 60 72 26 10 10 7 8 16 19 22 0 26 5 0 25 7 3 8 26 5 6 3 3 30 14 5 33

Female ASR(W) CUM 0-74 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.2 0.1 0.0 0.2 0.2 0.2 0.0 0.2 0.0 0.2 0.1 0.3 0.2 0.2 0.0 0.3 0.3 0.1 0.1 0.6 0.8 0.1 0.3 0.4 0.1 0.2 0.3 0.2 0.1 0.1 0.2 0.2 0.5 0.5 0.3 0.5 0.7 0.5 0.5 0.4 0.7 0.1 0.2 0.2 0.6 0.2 0.3 0.3 0.1 0.2 0.2 0.2 0.3 0.3 0.1 0.2 0.1 0.4 0.4 0.4 0.2 0.4 0.01 0.04 0.03 0.06 0.09 0.04 0.11 0.03 0.12 0.11 0.04 0.01 0.04 0.05 0.21 0.03 0.09 0.03 0.08 0.04 0.03 0.08 0.10 0.01 0.06 0.04 0.02 0.03 0.04 0.06 0.04 0.04 0.09 0.07 0.08 0.10 0.06 0.05 0.05 0.10 0.08 0.19 0.06 0.04 0.08 0.09 0.07 0.06 0.09 0.25 0.02 0.10 0.09 0.16 0.06 0.09 0.07 0.07 0.04 0.11 0.12 0.11 0.07 0.06 0.10 0.07 0.24 0.08 0.12 0.09 0.07 0.02 0.02 0.01 0.01 0.03 0.01 0.02 0.03 0.04 0.04 0.01 0.00 0.01 0.02 0.00 0.02 0.01 0.02 0.02 0.03 0.02 0.01 0.00 0.05 0.05 0.01 0.02 0.07 0.10 0.02 0.03 0.04 0.02 0.01 0.04 0.03 0.02 0.01 0.02 0.01 0.07 0.06 0.05 0.07 0.09 0.06 0.05 0.04 0.12 0.01 0.02 0.04 0.07 0.03 0.03 0.04 0.02 0.02 0.03 0.03 0.04 0.04 0.01 0.03 0.01 0.04 0.06 0.04 0.03 0.05 0.00 0.01 0.00 0.01 0.01 0.00 0.02 0.00 0.02 0.02 0.01 - * - * 0.00 * 0.01 0.01 0.00 * 0.01 * 0.01 0.01 * 0.01 * 0.00 0.01 0.01 0.00 * 0.01 * 0.01 0.00 * 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.05 0.00 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.01 0.01 0.02 0.01 0.03 0.01 0.01 0.01 0.01

522 49 13 19 29 25 6 164 6 4 1 8 0 1 1 1 34 31 2 1 6 17 4 7 26 172 14 5 44 73 202 84 31 312 254 22 126 23 17 10 20 37 29 6 14 24 10 5 74 130 65 54 79 102 41 11 25 7 16 29 27 31 2 59 19 0 51 31 7 8 53 7 15 12 7 47 31 19 53

592

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Renal pelvis (C65) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 19 31 3 84 33 20 25 23 35 42 80 100 35 5 39 73 45 3 23 41 40 33 22 18 275 14 12 2 14 8 10 18 492 31 30 74 37 100 216 61 116 124 89 128 26 82 214 3 100 40 16 110 28 5 1 57 29 2 1 2 16 7 Male ASR(W) CUM 0-74 0.2 0.3 0.2 0.4 1.4 0.5 0.4 0.2 0.3 0.3 0.4 0.6 0.5 0.4 0.7 1.0 0.9 0.3 1.1 1.3 1.0 1.2 1.0 0.5 0.7 0.7 1.4 0.4 0.7 0.5 0.9 0.7 0.8 0.8 0.8 0.6 0.4 0.6 0.8 0.6 0.4 0.2 0.5 0.6 0.5 0.4 0.9 0.8 0.8 0.6 0.9 0.6 0.4 0.5 0.2 0.4 0.6 0.5 0.1 0.5 1.2 0.4 0.06 0.05 0.12 0.05 0.25 0.11 0.08 0.04 0.05 0.05 0.05 0.06 0.09 0.22 0.12 0.12 0.14 0.17 0.24 0.22 0.16 0.22 0.24 0.12 0.04 0.20 0.43 0.28 0.19 0.20 0.29 0.17 0.04 0.15 0.15 0.07 0.06 0.06 0.06 0.08 0.04 0.02 0.05 0.05 0.09 0.05 0.06 0.50 0.08 0.10 0.23 0.06 0.09 0.25 0.20 0.06 0.12 0.38 0.14 0.36 0.35 0.18 0.03 0.04 0.03 0.05 0.18 0.06 0.06 0.03 0.04 0.04 0.05 0.08 0.06 0.06 0.08 0.13 0.13 0.03 0.13 0.17 0.13 0.18 0.12 0.07 0.09 0.07 0.20 0.06 0.08 0.05 0.09 0.07 0.10 0.12 0.09 0.07 0.04 0.07 0.10 0.08 0.05 0.03 0.06 0.08 0.05 0.05 0.10 0.05 0.11 0.07 0.11 0.08 0.05 0.07 0.02 0.05 0.08 0.06 0.03 0.06 0.18 0.04 0.01 0.01 0.02 0.01 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.02 0.02 0.02 0.02 0.03 0.03 0.02 0.04 0.03 0.02 0.01 0.03 0.07 0.04 0.03 0.03 0.04 0.02 0.01 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.04 0.01 0.01 0.03 0.01 0.01 0.04 0.02 0.01 0.02 0.06 0.03 0.06 0.05 0.03 Cases 6 25 1 67 28 8 24 8 20 22 73 113 35 3 19 24 15 5 9 12 13 7 6 8 214 2 5 5 13 2 3 16 322 20 27 41 31 81 135 46 84 95 61 74 7 68 296 4 144 36 6 89 39 6 1 41 12 0 1 0 7 3 Female ASR(W) CUM 0-74 0.1 0.1 0.1 0.3 0.8 0.2 0.3 0.1 0.1 0.1 0.3 0.5 0.3 0.2 0.3 0.2 0.2 0.3 0.3 0.2 0.2 0.2 0.2 0.1 0.4 0.1 0.3 0.6 0.5 0.1 0.1 0.4 0.4 0.5 0.5 0.2 0.2 0.4 0.4 0.3 0.2 0.1 0.2 0.3 0.1 0.2 0.9 1.2 0.9 0.5 0.2 0.4 0.6 0.6 0.3 0.2 0.2 0.1 0.3 0.2 0.02 0.03 0.05 0.04 0.16 0.06 0.06 0.02 0.03 0.02 0.05 0.05 0.06 0.12 0.07 0.06 0.06 0.15 0.12 0.07 0.07 0.08 0.10 0.05 0.03 0.05 0.15 0.30 0.15 0.07 0.08 0.13 0.03 0.11 0.11 0.04 0.05 0.05 0.04 0.06 0.03 0.02 0.03 0.03 0.04 0.03 0.06 0.64 0.08 0.08 0.09 0.05 0.10 0.24 0.27 0.04 0.06 0.08 0.12 0.14 0.01 0.02 0.01 0.03 0.10 0.02 0.03 0.01 0.01 0.01 0.03 0.06 0.04 0.01 0.03 0.03 0.04 0.03 0.03 0.03 0.03 0.02 0.03 0.01 0.05 0.01 0.02 0.10 0.06 0.01 0.02 0.06 0.05 0.06 0.05 0.03 0.03 0.04 0.05 0.04 0.03 0.02 0.03 0.03 0.01 0.03 0.12 0.11 0.12 0.06 0.01 0.05 0.08 0.07 0.03 0.02 0.04 0.02 0.00 0.00 0.01 0.01 0.02 * 0.01 0.01 0.00 * 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.02 0.01 0.00 0.01 0.02 0.05 0.02 0.01 0.02 0.02 0.00 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.08 0.01 0.01 0.01 0.01 0.02 0.04 0.01 0.01 0.02 0.02

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
535

593

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Ureter (C66)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 0 11 3 2 0 1 2 0 1 30 2 1 1 0 4 0 331 27 80 26 7 10 0 30 134 1 16 74 4 69 4 92 327 32 6 29 257 65 2 4 0 0 2 51 70 2 5 1 2 0 11 49 69 48 2 46 4 4 0 382 5 375 92 9 82 15 4 11 19 198 9 186 87 38 65 84 8 76 3 14 Male ASR(W) CUM 0-74 0.3 0.3 0.3 0.1 0.1 0.1 0.1 0.2 0.0 0.0 0.3 0.4 0.3 0.5 0.6 0.2 0.5 0.8 0.3 0.2 0.4 0.5 0.1 0.6 0.3 0.5 0.3 0.3 0.1 0.2 0.3 0.3 0.2 0.2 0.1 0.4 0.2 0.1 0.3 0.1 0.2 0.2 0.3 0.5 0.4 0.4 0.4 0.2 0.4 0.5 0.1 0.5 0.4 0.2 0.4 0.2 0.3 0.2 0.4 0.5 0.2 0.5 0.4 0.3 0.4 0.6 0.3 0.7 0.3 0.5 0.08 0.19 0.24 0.10 0.09 0.09 0.03 0.15 0.04 0.01 0.15 0.02 0.05 0.06 0.13 0.08 0.18 0.16 0.03 0.24 0.12 0.06 0.07 0.07 0.17 0.05 0.02 0.05 0.05 0.04 0.02 0.04 0.12 0.12 0.08 0.05 0.03 0.07 0.15 0.10 0.16 0.06 0.05 0.06 0.06 0.25 0.06 0.13 0.20 0.03 0.04 0.03 0.04 0.07 0.05 0.06 0.14 0.07 0.10 0.03 0.07 0.04 0.05 0.06 0.06 0.07 0.10 0.08 0.21 0.14 0.03 0.03 0.02 0.02 0.03 0.00 0.00 0.02 0.04 0.02 0.05 0.08 0.01 0.06 0.11 0.04 0.04 0.04 0.06 0.02 0.07 0.08 0.06 0.03 0.03 0.01 0.02 0.04 0.03 0.01 0.02 0.02 0.04 0.03 0.01 0.04 0.04 0.01 0.04 0.06 0.05 0.05 0.05 0.03 0.04 0.05 0.01 0.06 0.04 0.02 0.05 0.02 0.03 0.02 0.06 0.06 0.02 0.06 0.05 0.05 0.05 0.08 0.04 0.09 0.04 0.05 0.03 0.02 0.02 0.00 0.03 0.00 0.00 0.02 0.00 0.01 0.01 0.02 0.01 0.03 0.03 0.00 0.04 0.01 0.01 0.01 0.01 0.04 0.01 0.00 0.01 0.01 0.00 0.00 0.01 0.01 0.02 0.01 0.01 0.00 0.01 0.03 0.04 0.01 0.01 0.01 0.01 0.04 0.01 0.02 0.03 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.03 0.02 Cases 0 3 1 0 0 0 5 0 1 10 0 1 3 0 0 1 199 22 39 8 8 3 0 15 91 2 11 39 2 36 2 62 240 20 12 21 185 44 3 3 0 3 2 32 52 4 4 1 2 2 7 32 40 46 2 43 2 1 1 237 7 229 68 7 60 19 3 16 8 134 5 127 69 30 60 41 5 36 0 9 Female ASR(W) CUM 0-74 0.1 0.1 0.2 0.1 0.0 0.0 0.0 0.1 0.2 0.2 0.2 0.2 0.2 0.1 0.3 0.2 0.2 0.2 0.2 0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.7 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.3 0.1 0.1 0.3 0.3 0.2 0.3 0.0 0.0 0.0 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.2 0.2 0.3 0.2 0.1 0.2 0.3 0.04 0.12 0.10 0.07 0.01 0.02 0.02 0.10 0.01 0.04 0.03 0.07 0.09 0.06 0.09 0.02 0.11 0.07 0.03 0.05 0.04 0.10 0.03 0.01 0.03 0.05 0.02 0.01 0.02 0.11 0.07 0.43 0.04 0.03 0.02 0.05 0.12 0.09 0.17 0.20 0.03 0.03 0.04 0.04 0.15 0.05 0.03 0.03 0.04 0.02 0.03 0.02 0.02 0.04 0.03 0.05 0.08 0.06 0.04 0.02 0.04 0.02 0.03 0.04 0.04 0.03 0.05 0.04 0.11 0.03 0.01 0.00 0.01 0.01 0.02 0.02 0.02 0.02 0.03 0.01 0.06 0.02 0.03 0.03 0.01 0.03 0.03 0.03 0.02 0.01 0.02 0.01 0.02 0.01 0.03 0.01 0.05 0.01 0.01 0.01 0.04 0.02 0.03 0.03 0.01 0.02 0.03 0.03 0.02 0.03 0.03 0.01 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.00 0.02 0.01 0.03 0.03 0.02 0.04 0.02 0.02 0.03 0.03 * * * *

0.02 0.01 0.00 0.00 0.01 * 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.02 0.01 0.05 0.00 0.00 0.01 0.03 0.02 0.03 0.03 0.00 0.00 0.01 0.01 0.02 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.02 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.02

594

*Important. See note on population page.

536

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Ureter (C66) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 23 94 174 8 164 44 7 37 95 0 92 18 3617 98 3425 142 3 136 19 1 4 12 306 6 292 180 3 176 61 54 290 7 279 18 285 17 246 856 49 33 39 730 61 4 55 268 12 250 14 6 96 41 47 91 0 6 0 1 63 3 1 2 5 0 8 1 1 1 72 67 3 26 45 55 102 75 281 55 Male ASR(W) CUM 0-74 0.4 0.4 0.5 0.2 0.5 0.3 0.3 0.4 0.5 0.5 0.5 0.5 0.2 0.5 0.5 0.1 0.5 0.3 0.3 0.2 0.3 0.4 0.1 0.5 0.4 0.1 0.5 0.5 0.4 0.6 0.2 0.6 0.5 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.4 0.4 0.1 0.5 0.4 0.2 0.4 0.2 0.3 0.5 0.3 0.7 0.4 0.1 0.0 0.3 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.4 0.3 0.7 1.0 1.3 0.9 0.8 0.7 0.8 0.10 0.04 0.04 0.08 0.04 0.05 0.11 0.06 0.05 0.05 0.12 0.01 0.02 0.01 0.04 0.07 0.05 0.07 0.26 0.11 0.09 0.03 0.04 0.03 0.04 0.06 0.04 0.07 0.05 0.04 0.09 0.04 0.12 0.02 0.07 0.02 0.01 0.04 0.03 0.03 0.02 0.06 0.06 0.07 0.03 0.07 0.03 0.05 0.11 0.05 0.06 0.10 0.05 0.04 0.04 0.04 0.07 0.05 0.02 0.01 0.01 0.03 0.01 0.04 0.05 0.06 0.15 0.13 0.15 0.17 0.09 0.10 0.04 0.11 0.06 0.05 0.06 0.02 0.06 0.04 0.02 0.05 0.05 0.06 0.06 0.05 0.02 0.06 0.06 0.02 0.06 0.04 0.03 0.05 0.04 0.05 0.01 0.06 0.05 0.01 0.06 0.06 0.04 0.07 0.03 0.07 0.06 0.04 0.03 0.04 0.04 0.03 0.02 0.02 0.05 0.05 0.01 0.06 0.05 0.03 0.06 0.02 0.02 0.06 0.05 0.08 0.05 0.01 0.01 0.04 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.06 0.06 0.04 0.09 0.12 0.17 0.12 0.09 0.08 0.09 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.03 0.03 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.03 0.02 0.02 0.03 0.01 0.02 0.01 0.02 Cases 18 91 111 4 106 36 2 34 73 2 71 12 2410 83 2267 89 2 84 19 0 4 15 201 7 188 127 5 122 38 43 213 6 205 15 228 10 193 630 41 27 33 525 34 3 31 157 5 146 6 3 48 28 25 55 0 11 1 0 76 0 1 4 3 0 4 0 1 0 33 33 0 15 21 34 58 51 161 42 Female ASR(W) CUM 0-74 0.3 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.3 0.1 0.3 0.2 0.2 0.1 0.2 0.2 0.0 0.2 0.2 0.1 0.3 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.3 0.3 0.1 0.3 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.2 0.2 0.2 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.3 0.3 0.5 0.4 0.4 0.3 0.4 0.07 0.03 0.02 0.05 0.03 0.03 0.05 0.04 0.03 0.08 0.04 0.06 0.00 0.01 0.01 0.03 0.04 0.03 0.06 0.07 0.10 0.02 0.02 0.02 0.02 0.05 0.02 0.04 0.05 0.02 0.05 0.02 0.06 0.01 0.04 0.01 0.01 0.03 0.02 0.02 0.01 0.03 0.03 0.04 0.02 0.03 0.02 0.04 0.06 0.03 0.03 0.05 0.03 0.05 0.07 0.03 0.03 0.02 0.01 0.01 0.02 0.03 0.03 0.08 0.07 0.10 0.05 0.06 0.02 0.07 0.05 0.03 0.03 0.01 0.03 0.03 0.01 0.03 0.04 0.02 0.04 0.01 0.03 0.01 0.03 0.02 0.00 0.03 0.03 0.01 0.05 0.03 0.01 0.03 0.03 0.01 0.03 0.03 0.03 0.03 0.02 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.02 0.03 0.00 0.04 0.02 0.01 0.02 0.01 0.01 0.02 0.02 0.03 0.02 0.02 0.01 0.03 0.01 0.00 0.00 0.00 0.00 0.02 0.02 0.03 0.04 0.05 0.04 0.04 0.03 0.04 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.01 * 0.01 * 0.00 * - * 0.01 * 0.00 0.00 * 0.00 - * 0.00 * - * 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
537

595

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Ureter (C66) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
538

Male ASR(W) CUM 0-74 0.5 0.5 0.6 1.0 0.6 0.5 0.1 0.6 0.4 0.1 0.1 0.1 0.0 0.1 0.3 0.4 0.1 0.1 0.1 0.1 0.4 0.2 0.3 0.1 0.6 0.6 0.1 0.2 0.2 0.6 0.3 0.2 0.4 0.4 0.3 0.3 0.8 0.4 0.3 0.3 0.5 0.6 0.4 0.4 0.3 0.4 0.5 0.4 0.5 0.4 0.2 0.3 1.3 1.0 0.9 0.6 0.7 0.3 0.8 0.6 0.4 0.7 0.3 0.2 0.4 0.6 0.4 0.6 0.6 0.3 0.6 0.8 0.8 0.7 0.03 0.09 0.11 0.20 0.16 0.11 0.14 0.06 0.19 0.07 0.06 0.07 0.04 0.03 0.06 0.08 0.06 0.04 0.06 0.05 0.04 0.09 0.16 0.02 0.10 0.05 0.02 0.03 0.03 0.05 0.08 0.03 0.11 0.14 0.13 0.10 0.14 0.10 0.09 0.10 0.14 0.17 0.14 0.07 0.04 0.07 0.09 0.07 0.07 0.09 0.14 0.05 0.36 0.20 0.21 0.10 0.15 0.18 0.12 0.14 0.15 0.09 0.13 0.09 0.14 0.12 0.12 0.17 0.21 0.20 0.11 0.15 0.20 0.10 0.07 0.07 0.10 0.12 0.07 0.07 0.02 0.08 0.06 0.00 0.01 0.01 0.01 0.01 0.03 0.04 0.00 0.01 0.01 0.02 0.05 0.02 0.02 0.01 0.06 0.07 0.01 0.03 0.03 0.08 0.04 0.03 0.05 0.06 0.04 0.02 0.09 0.05 0.04 0.03 0.06 0.09 0.05 0.05 0.04 0.05 0.06 0.05 0.05 0.04 0.02 0.04 0.17 0.13 0.13 0.08 0.08 0.02 0.08 0.08 0.02 0.09 0.04 0.02 0.04 0.07 0.04 0.07 0.08 0.02 0.08 0.10 0.08 0.09 0.00 0.01 0.02 0.03 0.03 0.02 0.02 0.01 0.03 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.02 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.06 0.03 0.04 0.02 0.02 0.02 0.02 0.02 0.01 0.01 0.02 0.02 0.02 0.02 0.01 0.03 0.03 0.02 0.02 0.02 0.03 0.02

Cases 235 26 9 3 5 10 3 58 4 0 0 0 4 1 0 4 20 17 0 3 0 0 1 3 5 90 6 5 24 27 65 17 47 89 67 10 42 14 11 2 2 14 7 7 2 7 6 4 23 52 19 22 33 27 17 5 15 1 15 6 15 10 0 16 2 2 22 2 0 4 20 8 3 0 3 14 7 4 18

Female ASR(W) CUM 0-74 0.2 0.2 0.1 0.1 0.1 0.2 0.3 0.2 0.3 0.1 0.0 0.0 0.2 0.2 0.4 0.0 0.1 0.1 0.2 0.2 0.2 0.0 0.3 0.2 0.0 0.2 0.2 0.2 0.1 0.1 0.2 0.3 0.1 0.1 0.3 0.1 0.1 0.0 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.6 0.1 0.2 0.4 0.3 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.1 0.2 0.01 0.05 0.04 0.06 0.07 0.05 0.16 0.03 0.14 0.06 0.05 0.02 0.05 0.05 0.22 0.03 0.07 0.03 0.02 0.09 0.10 0.01 0.06 0.03 0.01 0.03 0.02 0.03 0.04 0.02 0.07 0.09 0.07 0.05 0.08 0.05 0.06 0.03 0.09 0.12 0.06 0.03 0.02 0.04 0.04 0.04 0.03 0.06 0.28 0.03 0.15 0.12 0.13 0.04 0.08 0.05 0.05 0.09 0.03 0.10 0.07 0.06 0.07 0.07 0.12 0.05 0.06 0.07 0.04 0.03 0.03 0.01 0.01 0.02 0.03 0.03 0.03 0.06 0.02 0.00 0.00 0.01 0.01 0.02 0.02 0.01 0.02 0.03 0.03 0.01 0.04 0.03 0.01 0.02 0.02 0.03 0.02 0.01 0.02 0.03 0.01 0.00 0.03 0.02 0.02 0.01 0.02 0.02 0.01 0.02 0.02 0.02 0.02 0.04 0.02 0.02 0.10 0.01 0.01 0.04 0.03 0.02 0.03 0.01 0.00 0.01 0.02 0.01 0.02 0.03 0.02 0.01 0.02 0.02 0.01 0.01 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.03 0.01 0.00 * - * 0.00 * 0.00 0.01 0.02 - * - * 0.01 * 0.00 * 0.00 0.01 0.02 0.00 * 0.01 * 0.00 0.00 * 0.00 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.04 0.00 0.02 0.01 0.02 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01

438 44 30 24 13 24 1 112 6 0 0 2 4 1 1 3 24 23 0 1 3 0 2 0 9 128 5 3 27 47 121 26 36 89 130 12 44 16 10 6 7 34 15 12 9 11 13 8 43 71 33 35 43 53 24 2 35 15 26 20 44 22 3 45 17 6 63 8 3 9 34 15 11 9 3 31 30 16 51

596

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Ureter (C66) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 16 21 1 38 0 3 10 14 21 8 64 35 14 8 34 25 8 6 11 23 25 17 11 15 102 6 7 3 8 6 4 4 313 13 17 46 37 67 140 28 100 127 78 77 30 80 106 0 75 25 7 66 20 1 0 40 19 2 0 0 11 6 Male ASR(W) CUM 0-74 0.2 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.3 0.2 0.2 0.5 0.6 0.3 0.2 0.6 0.4 0.6 0.6 0.7 0.5 0.4 0.2 0.3 0.8 0.4 0.4 0.4 0.3 0.2 0.5 0.3 0.4 0.3 0.3 0.4 0.5 0.3 0.3 0.2 0.4 0.3 0.5 0.4 0.4 0.6 0.4 0.4 0.3 0.3 0.2 0.3 0.4 0.3 1.0 0.4 0.05 0.04 0.09 0.03 0.04 0.05 0.04 0.04 0.02 0.04 0.04 0.05 0.19 0.11 0.07 0.06 0.26 0.13 0.14 0.12 0.18 0.16 0.11 0.03 0.13 0.31 0.26 0.16 0.16 0.17 0.09 0.03 0.10 0.11 0.05 0.06 0.05 0.04 0.06 0.03 0.02 0.04 0.04 0.10 0.04 0.04 0.07 0.07 0.15 0.04 0.07 0.15 0.05 0.10 0.25 0.35 0.19 0.02 0.03 0.01 0.02 0.01 0.02 0.02 0.03 0.01 0.05 0.03 0.02 0.06 0.09 0.04 0.02 0.08 0.06 0.09 0.07 0.10 0.07 0.05 0.03 0.02 0.12 0.06 0.09 0.04 0.04 0.03 0.06 0.05 0.06 0.04 0.04 0.05 0.06 0.04 0.04 0.03 0.05 0.04 0.08 0.05 0.05 0.08 0.04 0.05 0.04 0.04 0.03 0.04 0.05 0.06 0.12 0.06 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.03 0.02 0.01 0.01 0.04 0.02 0.02 0.02 0.03 0.03 0.01 0.00 0.02 0.05 0.04 0.03 0.03 0.03 0.02 0.00 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.06 0.05 0.04 Cases 6 11 0 47 1 1 8 4 16 13 49 28 12 0 7 8 4 1 9 1 6 10 2 3 99 3 3 0 5 6 2 8 160 8 11 25 27 37 79 11 74 80 42 32 20 49 100 0 59 15 4 27 12 3 0 28 14 2 3 1 7 0 Female ASR(W) CUM 0-74 0.0 0.1 0.2 0.0 0.0 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.0 0.2 0.0 0.1 0.2 0.0 0.1 0.2 0.1 0.2 0.2 0.3 0.1 0.2 0.2 0.2 0.3 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.2 0.3 0.4 0.2 0.1 0.1 0.2 0.2 0.2 0.2 0.3 0.3 0.2 0.3 0.02 0.02 0.03 0.03 0.02 0.03 0.02 0.02 0.02 0.03 0.02 0.03 0.05 0.03 0.02 0.03 0.09 0.02 0.05 0.09 0.02 0.04 0.02 0.07 0.16 0.09 0.16 0.06 0.07 0.02 0.06 0.09 0.03 0.04 0.02 0.03 0.03 0.02 0.01 0.03 0.02 0.06 0.03 0.04 0.05 0.06 0.07 0.02 0.05 0.10 0.04 0.06 0.21 0.19 0.17 0.11 0.01 0.01 0.02 0.00 0.00 0.01 0.00 0.01 0.01 0.03 0.02 0.01 0.01 0.01 0.00 0.04 0.01 0.01 0.02 0.00 0.02 0.02 0.02 0.03 0.03 0.02 0.02 0.02 0.03 0.01 0.02 0.02 0.03 0.01 0.03 0.01 0.02 0.01 0.03 0.02 0.04 0.05 0.02 0.02 0.01 0.03 0.02 0.04 0.05 0.06 0.04 0.04 0.00 0.00 0.00 0.00 * 0.00 0.00 0.00 * 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.02 0.01 0.01 0.01 0.00 0.00 0.02 0.02 0.02 0.02 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.02 0.00 0.01 0.01 0.01 0.05 0.04 0.04 0.02 -

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
539

597

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Bladder (C67)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White *Important. See note on population page.
540

Male ASR(W) CUM 0-74 4.5 27.9 19.0 3.0 6.6 15.1 12.8 7.0 12.8 16.8 3.8 8.8 5.8 5.2 7.1 3.8 17.5 19.4 20.2 16.5 22.8 18.7 10.3 25.2 14.8 17.8 19.6 17.2 7.5 19.2 21.6 20.7 19.0 8.0 11.4 10.1 23.3 17.4 10.8 6.8 6.9 9.3 10.8 21.9 17.1 11.5 9.3 6.3 11.3 8.4 9.3 23.9 20.7 26.4 10.3 27.3 14.6 12.4 17.4 23.6 9.3 24.9 18.8 10.9 20.9 17.6 10.2 20.3 22.3 22.8 10.9 24.3 21.5 22.0 22.7 19.6 10.9 22.3 13.8 23.7 0.51 0.89 1.45 0.66 0.78 1.37 0.87 1.13 1.01 0.30 0.66 0.54 0.29 0.46 0.79 0.68 0.15 0.47 0.37 0.65 0.93 1.00 3.60 0.87 0.19 1.91 0.74 0.34 0.52 0.40 1.28 0.35 0.14 0.27 0.45 0.26 0.19 0.30 0.92 0.63 0.88 1.74 0.74 0.43 0.26 0.67 0.89 0.87 1.35 1.28 0.41 0.44 0.42 0.48 1.24 0.51 0.92 1.07 1.75 0.19 0.42 0.21 0.29 0.52 0.35 0.53 0.85 0.67 0.74 0.24 0.51 0.27 0.33 0.46 0.42 0.38 0.59 0.47 1.23 1.09 1.89 1.48 0.91 1.44 1.97 0.44 1.04 0.68 0.63 0.79 0.51 2.04 2.31 2.35 1.97 2.75 2.20 1.09 2.94 1.73 1.95 2.24 2.07 0.83 2.31 2.43 2.40 2.20 0.87 1.33 1.12 2.75 2.02 1.24 0.75 0.65 1.15 1.16 2.61 1.98 1.33 0.92 0.59 1.25 0.98 1.04 2.85 2.44 3.10 1.09 3.22 1.72 1.48 1.97 2.80 1.04 2.96 2.24 1.31 2.48 2.06 1.19 2.37 2.60 2.70 1.24 2.89 2.56 2.64 2.74 2.26 1.24 2.59 1.68 2.78 0.20 0.13 0.19 0.15 0.05 0.10 0.08 0.04 0.07 0.11 0.12 0.02 0.07 0.06 0.10 0.14 0.15 0.53 0.13 0.03 0.27 0.11 0.05 0.08 0.06 0.19 0.05 0.02 0.04 0.07 0.04 0.03 0.05 0.14 0.09 0.12 0.28 0.11 0.07 0.04 0.10 0.13 0.13 0.21 0.19 0.06 0.07 0.06 0.07 0.17 0.08 0.14 0.16 0.27 0.03 0.06 0.03 0.04 0.08 0.05 0.08 0.13 0.10 0.11 0.04 0.07 0.04 0.05 0.07 0.06 0.06 0.09 0.07 0.19 0.16

Cases 11 262 22 17 63 31 104 16 59 1299 17 109 138 53 33 16 5241 599 1169 238 209 114 2 300 2279 30 301 933 134 789 72 1269 6751 292 312 562 5496 1390 72 48 17 17 100 1099 1601 154 30 10 29 20 206 1119 874 1293 38 1240 162 111 47 6100 258 5773 1515 267 1241 457 113 340 266 3514 325 3100 1584 880 1080 975 219 749 66 188

Female ASR(W) CUM 0-74 0.5 5.4 2.2 1.8 4.1 2.6 4.2 2.5 3.3 4.5 1.7 2.4 1.7 1.7 1.6 1.3 4.9 5.5 6.1 4.1 5.8 5.4 2.0 6.5 4.2 4.0 6.5 4.3 3.0 4.7 4.7 5.4 4.8 1.8 3.9 2.8 5.9 4.9 3.9 1.9 1.4 3.2 3.5 6.2 4.2 4.2 1.9 0.9 3.6 2.7 2.5 5.6 5.5 7.5 3.4 7.9 5.7 5.6 6.0 6.2 3.3 6.6 4.6 3.6 4.9 4.8 4.5 5.2 4.9 6.1 4.6 6.3 5.5 5.6 5.7 4.9 4.3 5.2 4.3 6.5 0.16 0.34 0.48 0.48 0.61 0.53 0.44 0.63 0.44 0.13 0.41 0.24 0.15 0.24 0.31 0.35 0.08 0.24 0.20 0.31 0.46 0.54 1.50 0.42 0.10 0.82 0.43 0.16 0.28 0.19 0.58 0.17 0.07 0.11 0.23 0.12 0.09 0.15 0.49 0.29 0.34 0.91 0.36 0.22 0.12 0.36 0.37 0.30 0.77 0.63 0.18 0.20 0.20 0.24 0.58 0.26 0.51 0.60 1.01 0.09 0.22 0.10 0.13 0.24 0.15 0.25 0.45 0.31 0.33 0.12 0.27 0.13 0.16 0.23 0.19 0.17 0.31 0.21 0.56 0.54 0.27 0.49 0.25 0.35 0.49 0.24 0.26 0.20 0.22 0.12 0.12 0.57 0.63 0.70 0.48 0.64 0.66 0.22 0.78 0.47 0.44 0.79 0.52 0.36 0.55 0.53 0.64 0.57 0.21 0.47 0.33 0.72 0.58 0.44 0.29 0.15 0.33 0.38 0.75 0.49 0.54 0.19 0.16 0.42 0.34 0.30 0.66 0.68 0.93 0.38 0.97 0.69 0.67 0.77 0.73 0.37 0.77 0.53 0.41 0.58 0.57 0.52 0.62 0.58 0.71 0.50 0.75 0.67 0.64 0.68 0.57 0.48 0.61 0.46 0.81 * * * *

81 1080 175 29 95 136 238 41 168 3309 35 293 423 141 88 33 15145 1812 3282 734 647 378 9 911 6445 96 831 2720 221 2462 307 4103 20643 969 659 1534 17188 3784 145 129 68 37 227 3022 4768 301 122 57 88 44 538 3524 2662 3457 73 3329 273 147 110 18528 495 17800 4275 466 3773 1147 153 971 1008 9640 477 8908 4492 2611 3158 2849 365 2463 131 536

0.06 0.07 0.09 0.06 0.02 0.07 0.04 0.02 0.04 0.04 0.05 * 0.01 0.03 0.03 0.05 0.06 0.08 0.17 0.06 0.01 0.13 0.06 0.02 0.04 0.03 0.09 0.02 0.01 0.02 0.04 0.02 0.01 0.02 0.07 0.06 0.05 0.12 0.06 0.03 0.02 0.06 0.05 0.06 0.10 0.10 0.03 0.03 0.03 0.04 0.09 0.04 0.08 0.09 0.16 0.01 0.03 0.01 0.02 0.04 0.02 0.04 0.07 0.05 0.05 0.02 0.04 0.02 0.02 0.03 0.03 0.03 0.05 0.03 0.08 0.08

Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data 598

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Bladder (C67) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 1393 6244 8537 417 8007 3423 308 3093 4338 166 4145 827 175440 6605 164400 8084 325 7603 1064 12 208 832 16299 697 15312 9715 387 8991 2404 3190 13141 418 12544 1254 19184 734 17511 51459 1585 2080 2241 45005 2691 257 2407 10569 504 9864 1001 522 4877 3292 1817 4435 81 351 2499 73 138 1996 169 500 238 1128 35 767 109 167 51 4767 4422 255 415 473 718 1174 951 3011 549 Male ASR(W) CUM 0-74 27.7 27.0 24.5 11.9 26.0 25.1 11.7 28.8 20.8 11.4 21.6 22.3 22.1 10.5 23.5 26.2 11.7 28.5 16.5 3.7 10.9 20.8 24.1 10.2 26.6 23.5 11.5 23.9 18.7 24.5 26.1 13.0 27.0 31.2 21.1 11.0 23.3 20.9 8.5 11.4 10.9 24.2 19.7 8.8 22.5 17.2 9.7 18.0 16.7 23.0 23.8 23.9 24.0 22.2 14.7 6.7 10.9 5.9 6.2 8.1 5.0 20.7 2.8 6.2 4.2 3.8 2.8 2.8 1.9 27.7 28.1 18.1 10.6 10.8 16.6 10.6 11.8 7.9 7.4 0.78 0.36 0.28 0.60 0.31 0.45 0.70 0.55 0.33 0.91 0.36 0.82 0.06 0.13 0.06 0.31 0.66 0.35 0.53 1.10 0.78 0.76 0.20 0.39 0.23 0.25 0.60 0.27 0.40 0.46 0.24 0.66 0.26 0.95 0.16 0.42 0.19 0.10 0.22 0.26 0.24 0.12 0.39 0.57 0.47 0.17 0.44 0.19 0.55 1.05 0.36 0.44 0.59 0.35 1.66 0.37 0.22 0.73 0.56 0.19 0.40 0.97 0.18 0.19 0.71 0.14 0.28 0.22 0.27 0.42 0.45 1.16 0.53 0.53 0.63 0.32 0.41 0.15 0.34 3.34 3.26 2.92 1.32 3.10 2.99 1.33 3.46 2.46 1.40 2.55 2.61 2.62 1.22 2.79 3.16 1.36 3.45 1.98 0.57 1.27 2.51 2.84 1.13 3.16 2.79 1.31 2.85 2.16 2.94 3.15 1.58 3.26 3.79 2.50 1.27 2.76 2.46 0.95 1.32 1.24 2.88 2.35 0.97 2.70 2.05 1.15 2.15 1.96 2.65 2.79 2.80 2.91 2.67 1.77 0.75 1.23 0.62 0.60 0.87 0.59 2.50 0.34 0.79 0.58 0.46 0.33 0.34 0.24 3.41 3.45 2.09 1.24 1.26 1.95 1.17 1.38 0.83 0.81 0.12 0.06 0.04 0.09 0.05 0.07 0.10 0.08 0.05 0.14 0.05 0.12 0.01 0.02 0.01 0.05 0.10 0.05 0.08 0.20 0.12 0.11 0.03 0.06 0.03 0.04 0.09 0.04 0.06 0.07 0.04 0.10 0.04 0.14 0.02 0.06 0.03 0.01 0.03 0.04 0.04 0.02 0.06 0.08 0.07 0.03 0.07 0.03 0.09 0.16 0.06 0.07 0.09 0.05 0.25 0.05 0.03 0.09 0.07 0.03 0.06 0.15 0.03 0.03 0.11 0.02 0.04 0.03 0.04 0.06 0.07 0.18 0.08 0.07 0.09 0.04 0.06 0.02 0.05 Cases 541 2466 2899 242 2617 1214 191 1013 1470 96 1361 281 61379 3832 56118 3036 204 2777 348 3 61 280 6382 448 5848 3526 220 3194 805 1022 4820 236 4527 482 6653 445 5923 17555 478 1156 824 14924 854 175 674 3460 277 3111 306 225 1512 1013 766 1611 21 95 803 15 45 609 37 100 86 225 2 182 37 61 13 1153 1101 26 112 143 207 423 291 937 216 Female ASR(W) CUM 0-74 8.2 7.9 6.4 4.6 6.6 6.4 4.6 7.1 5.3 4.0 5.4 6.5 5.8 3.9 6.2 7.2 4.6 7.8 4.5 0.8 2.4 5.9 6.8 3.8 7.5 6.2 4.3 6.2 4.7 6.3 7.0 4.5 7.2 9.2 5.6 4.4 6.1 5.4 1.9 4.2 3.1 6.3 4.6 3.8 5.0 4.2 3.5 4.3 4.4 7.7 5.9 5.9 7.9 6.3 3.8 1.4 2.8 1.0 1.8 2.0 0.9 3.5 1.0 1.4 0.2 1.0 1.0 1.0 0.4 5.1 5.3 1.7 2.1 2.2 3.5 2.6 2.2 1.7 2.0 0.40 0.18 0.13 0.32 0.15 0.21 0.36 0.25 0.16 0.45 0.17 0.43 0.03 0.07 0.03 0.15 0.34 0.17 0.26 0.45 0.33 0.39 0.10 0.19 0.11 0.12 0.31 0.13 0.19 0.23 0.12 0.32 0.13 0.49 0.08 0.22 0.09 0.05 0.09 0.13 0.11 0.06 0.17 0.31 0.21 0.08 0.23 0.09 0.27 0.58 0.17 0.21 0.32 0.18 0.83 0.15 0.11 0.27 0.27 0.09 0.16 0.38 0.11 0.10 0.15 0.07 0.17 0.13 0.12 0.16 0.17 0.33 0.22 0.22 0.27 0.14 0.16 0.06 0.16 0.96 0.97 0.77 0.49 0.80 0.77 0.46 0.86 0.65 0.45 0.67 0.84 0.70 0.45 0.74 0.86 0.55 0.93 0.52 0.11 0.25 0.72 0.81 0.45 0.90 0.73 0.47 0.74 0.53 0.76 0.83 0.54 0.86 1.15 0.67 0.48 0.74 0.64 0.21 0.48 0.35 0.75 0.57 0.45 0.61 0.50 0.41 0.52 0.52 0.95 0.70 0.71 0.95 0.76 0.29 0.17 0.29 0.13 0.21 0.22 0.10 0.41 0.14 0.18 0.01 0.10 0.15 0.12 0.05 0.59 0.62 0.19 0.21 0.25 0.40 0.27 0.23 0.17 0.22 0.06 0.03 0.02 0.05 0.02 0.03 0.05 0.04 0.02 0.07 0.03 0.07 0.00 0.01 0.00 0.02 0.05 0.02 0.04 0.07 0.05 0.06 0.01 0.03 0.02 0.02 0.04 0.02 0.03 0.03 0.02 0.05 0.02 0.07 0.01 0.03 0.01 0.01 0.01 0.02 0.02 0.01 0.03 0.05 0.03 0.01 0.04 0.01 0.04 0.09 0.03 0.03 0.05 0.03 0.09 0.02 * 0.02 0.04 * 0.04 0.01 * 0.02 * 0.05 * 0.02 0.01 * 0.01 0.01 0.03 * 0.02 * 0.02 * 0.02 0.03 0.05 0.03 0.03 0.04 0.02 0.02 0.01 0.02

*Important. See note on population page. Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data Cancer Incidence in Five Continents Vol. IX, IARC 2007

541

599

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Bladder (C67) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
542

Male ASR(W) CUM 0-74 9.1 10.2 9.2 10.1 10.2 8.9 6.8 11.0 8.5 6.3 7.0 7.3 3.1 5.1 9.3 4.7 7.6 8.0 4.6 7.9 5.1 5.6 4.4 15.8 17.6 20.9 25.9 24.3 14.4 21.5 25.8 12.9 18.0 20.1 26.6 16.3 13.6 16.0 15.0 15.8 18.8 15.7 15.1 12.5 11.5 15.8 15.3 11.2 22.4 21.5 21.2 25.5 19.8 22.7 12.8 20.3 14.5 33.0 32.9 35.2 37.2 40.4 34.1 30.6 31.7 47.2 21.8 30.9 33.1 31.3 35.8 37.8 28.7 34.0 38.8 38.5 34.4 31.6 31.3 0.11 0.40 0.46 0.69 0.69 0.47 1.01 0.27 0.96 0.85 1.18 0.66 0.31 0.56 0.66 0.30 0.31 0.36 0.80 0.96 0.36 0.51 0.40 0.76 0.49 0.26 1.05 1.46 0.22 0.54 0.36 0.20 0.33 0.24 0.35 0.60 0.26 0.68 0.81 0.93 0.85 0.64 0.61 0.56 0.74 0.88 0.96 0.70 0.47 0.33 0.54 0.62 0.46 0.46 0.52 1.53 0.35 1.92 1.17 1.40 0.83 1.24 1.95 0.79 1.06 1.75 0.48 1.27 1.70 1.22 0.87 1.07 1.23 1.62 2.30 0.94 0.93 1.24 0.68 1.08 1.25 1.10 1.17 1.21 1.09 0.86 1.25 1.06 0.75 0.63 0.94 0.35 0.53 1.20 0.56 0.79 0.84 0.51 0.79 0.65 0.68 0.49 2.05 2.23 2.46 3.12 3.06 1.79 2.49 3.09 1.62 2.12 2.48 3.18 1.98 1.49 1.77 1.82 1.93 2.29 1.81 1.77 1.52 1.30 1.85 1.85 1.33 2.74 2.57 2.43 3.07 2.21 2.59 1.43 2.25 1.66 4.06 4.09 4.32 4.62 4.89 4.36 3.58 3.80 6.01 2.62 3.81 3.93 4.05 4.41 4.75 3.52 4.25 4.95 4.81 4.26 3.78 3.82 0.02 0.06 0.07 0.10 0.10 0.07 0.16 0.04 0.15 0.13 0.12 0.11 0.04 0.07 0.10 0.05 0.04 0.05 0.10 0.13 0.05 0.08 0.06 0.11 0.07 0.04 0.16 0.22 0.03 0.08 0.05 0.03 0.05 0.04 0.05 0.09 0.04 0.09 0.12 0.14 0.13 0.09 0.09 0.08 0.11 0.13 0.14 0.10 0.07 0.05 0.08 0.09 0.07 0.07 0.07 0.22 0.05 0.27 0.17 0.20 0.12 0.17 0.29 0.11 0.15 0.26 0.07 0.18 0.24 0.19 0.13 0.15 0.18 0.24 0.35 0.14 0.13 0.18 0.10

Cases 1935 176 139 67 77 104 16 548 24 27 14 39 30 36 47 102 181 159 3 19 96 39 23 72 175 2560 249 81 865 393 1467 992 983 2731 2156 268 951 135 67 64 108 148 127 147 70 76 78 56 881 1565 646 607 769 909 262 72 721 93 212 195 551 339 75 536 253 122 687 196 85 188 455 223 115 65 97 469 364 155 672

Female ASR(W) CUM 0-74 1.6 1.7 2.1 2.0 2.1 1.6 1.1 2.1 1.4 2.9 2.7 1.8 0.8 2.2 2.6 1.3 1.8 1.9 0.8 2.0 2.3 1.6 0.7 2.5 2.1 5.4 7.5 5.0 1.7 3.8 5.1 2.3 3.9 5.2 7.7 2.9 3.0 2.2 1.6 2.1 2.6 2.5 1.9 2.1 1.9 2.6 2.3 1.6 5.3 4.6 5.4 5.6 5.1 5.5 3.4 6.5 4.7 6.4 5.6 6.8 7.0 7.0 5.8 6.1 6.0 6.4 4.3 6.4 5.4 6.1 6.5 5.0 4.3 3.9 10.1 6.7 6.2 5.0 6.5 0.04 0.13 0.18 0.25 0.25 0.16 0.31 0.09 0.30 0.57 0.83 0.29 0.15 0.38 0.41 0.13 0.14 0.15 0.46 0.48 0.24 0.25 0.15 0.30 0.16 0.12 0.53 0.61 0.06 0.22 0.15 0.08 0.13 0.11 0.18 0.20 0.11 0.21 0.24 0.30 0.29 0.24 0.20 0.20 0.28 0.34 0.32 0.25 0.20 0.14 0.25 0.25 0.21 0.21 0.24 0.84 0.19 0.80 0.44 0.61 0.37 0.48 0.80 0.32 0.44 0.60 0.20 0.57 0.69 0.53 0.37 0.37 0.44 0.53 1.16 0.37 0.39 0.45 0.29 0.19 0.18 0.25 0.26 0.27 0.19 0.08 0.24 0.15 0.40 0.36 0.20 0.07 0.28 0.37 0.17 0.18 0.18 0.06 0.20 0.28 0.18 0.06 0.33 0.25 0.63 0.87 0.63 0.20 0.41 0.58 0.27 0.45 0.63 0.96 0.32 0.32 0.24 0.17 0.22 0.30 0.30 0.19 0.22 0.19 0.31 0.22 0.20 0.61 0.55 0.66 0.67 0.57 0.59 0.37 0.78 0.55 0.77 0.62 0.76 0.79 0.77 0.68 0.67 0.70 0.71 0.49 0.78 0.59 0.75 0.77 0.54 0.46 0.45 1.26 0.77 0.73 0.58 0.78 0.01 0.02 0.03 0.04 0.04 0.02 0.04 0.01 0.04 0.09 0.12 0.04 0.02 0.06 * 0.06 * 0.02 * 0.02 0.02 0.04 0.06 0.03 * 0.04 * 0.02 0.05 * 0.02 * 0.02 0.07 0.09 0.01 * 0.03 * 0.02 0.01 * 0.02 0.02 0.03 0.03 0.02 0.03 0.03 0.04 0.04 0.04 0.03 0.03 0.04 0.05 0.05 0.04 0.03 0.02 0.04 0.04 0.03 0.03 0.03 0.12 0.03 0.11 0.06 0.08 0.05 0.06 0.11 0.04 0.06 0.08 0.03 0.08 0.09 0.07 0.05 0.05 0.06 0.07 0.16 0.05 0.05 0.06 0.04

7405 766 447 236 242 395 47 2022 95 57 103 128 107 85 219 279 600 493 35 72 199 121 119 445 1353 6654 630 284 4323 1691 5587 4313 3079 7424 6154 743 2856 588 378 311 504 695 652 538 279 363 310 295 2329 4370 1603 1734 1968 2526 645 196 1844 330 836 737 2310 1276 356 1674 1024 739 2273 699 436 755 1960 1356 583 479 295 1820 1602 675 2331

Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data 600

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Bladder (C67) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 1153 1844 368 3889 444 1005 1016 1985 1931 1597 2931 2303 1061 370 1553 2329 1044 286 898 1002 1592 905 853 1214 7588 468 140 98 247 266 250 433 9000 975 908 2858 2432 4480 7475 1875 8350 11249 5203 4994 721 5012 2964 25 2516 1443 397 1413 592 111 45 2115 637 33 49 55 211 261 Male ASR(W) CUM 0-74 14.8 16.6 26.8 19.6 17.9 22.9 16.0 18.1 15.9 11.3 15.5 14.4 15.1 27.1 29.3 31.9 21.5 22.2 35.8 30.2 37.6 37.0 37.5 30.7 17.4 29.6 14.6 13.4 11.7 18.3 22.7 16.9 14.5 25.9 24.4 21.9 23.1 25.4 25.5 17.0 25.2 19.3 23.5 21.5 11.8 23.4 11.5 7.7 19.1 22.4 20.9 7.5 8.9 12.0 11.3 15.4 12.9 7.5 6.5 12.2 13.0 20.5 0.44 0.39 1.43 0.34 0.86 0.74 0.52 0.43 0.38 0.29 0.30 0.31 0.47 1.54 0.80 0.69 0.68 1.53 1.29 1.01 0.98 1.31 1.39 0.94 0.22 1.41 1.29 1.44 0.79 1.17 1.49 0.86 0.16 0.84 0.83 0.44 0.49 0.40 0.31 0.41 0.30 0.19 0.34 0.32 0.46 0.34 0.22 1.61 0.40 0.62 1.10 0.21 0.38 1.18 1.70 0.35 0.55 1.54 1.01 1.67 1.09 1.33 1.75 2.00 3.36 2.27 2.10 2.89 1.93 2.20 1.88 1.39 1.91 1.74 1.78 3.04 3.38 3.78 2.49 2.67 4.43 3.68 4.43 4.54 4.45 3.76 2.09 3.74 1.80 1.59 1.38 2.19 2.77 2.07 1.70 3.06 2.88 2.51 2.68 3.01 2.99 1.96 2.92 2.19 2.74 2.54 1.37 2.79 1.30 0.90 2.18 2.66 2.22 0.81 0.95 1.27 1.48 1.76 1.54 0.63 0.84 1.24 1.55 2.51 0.06 0.06 0.22 0.05 0.12 0.11 0.07 0.06 0.05 0.04 0.04 0.04 0.07 0.21 0.11 0.10 0.10 0.21 0.18 0.14 0.14 0.18 0.20 0.13 0.03 0.22 0.20 0.21 0.12 0.18 0.22 0.13 0.02 0.12 0.12 0.06 0.07 0.06 0.05 0.06 0.04 0.03 0.05 0.05 0.07 0.05 0.03 0.24 0.06 0.09 0.15 0.03 0.06 0.18 0.27 0.05 0.08 0.19 0.16 0.22 0.16 0.21 Cases 381 545 85 1341 146 196 384 583 556 666 947 765 350 58 289 451 173 54 165 133 246 158 161 202 2691 140 38 33 99 74 71 132 2682 272 263 1039 962 1883 3041 624 3062 4242 2015 1881 293 2203 1089 2 791 474 141 547 213 34 13 778 182 12 14 22 54 62 Female ASR(W) CUM 0-74 2.6 2.7 4.6 5.4 3.8 3.3 4.1 3.7 3.2 2.2 4.1 3.3 3.2 3.1 3.8 4.7 2.6 3.4 4.6 3.0 4.2 5.2 5.5 3.8 5.0 6.2 2.8 2.9 3.4 3.4 5.2 3.6 3.2 5.9 5.8 6.3 6.4 7.9 7.7 4.4 7.0 5.2 7.1 6.0 3.2 7.5 3.3 0.7 5.0 6.0 6.0 2.2 2.4 3.3 3.3 4.4 3.0 1.7 1.7 3.7 2.3 4.6 0.14 0.13 0.54 0.18 0.33 0.26 0.24 0.17 0.15 0.09 0.14 0.13 0.19 0.47 0.26 0.25 0.21 0.59 0.43 0.30 0.30 0.49 0.51 0.32 0.11 0.58 0.54 0.58 0.39 0.46 0.68 0.37 0.07 0.38 0.39 0.23 0.24 0.21 0.16 0.20 0.15 0.09 0.18 0.16 0.21 0.18 0.11 0.52 0.20 0.31 0.57 0.11 0.18 0.60 0.97 0.18 0.25 0.58 0.48 0.80 0.41 0.65 0.32 0.30 0.54 0.64 0.44 0.38 0.49 0.42 0.34 0.24 0.48 0.40 0.39 0.28 0.40 0.49 0.29 0.38 0.47 0.31 0.47 0.59 0.57 0.41 0.59 0.77 0.33 0.34 0.44 0.39 0.61 0.43 0.38 0.69 0.70 0.75 0.73 0.96 0.93 0.48 0.80 0.60 0.83 0.71 0.38 0.93 0.39 0.10 0.58 0.72 0.62 0.25 0.24 0.40 0.52 0.49 0.32 0.12 0.19 0.40 0.21 0.53 0.02 0.02 0.08 0.03 0.05 * 0.03 0.03 0.02 * 0.02 0.01 0.02 0.02 0.03 0.06 0.03 0.03 0.03 0.08 0.06 0.04 0.04 0.06 0.07 0.04 0.02 0.09 0.08 0.09 0.06 0.07 0.10 0.05 0.01 0.05 0.05 0.03 0.03 0.03 0.02 0.03 0.02 0.01 0.03 0.02 0.03 0.03 0.02 0.08 0.03 0.05 0.08 0.02 0.03 0.09 0.18 0.03 0.03 0.07 0.07 0.11 0.05 0.10

*Important. See note on population page. Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data Cancer Incidence in Five Continents Vol. IX, IARC 2007

543

601

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other urinary organs (C68)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 0 8 2 0 1 3 6 1 2 41 1 3 7 1 0 0 946 15 21 20 4 3 0 5 872 1 5 29 6 22 2 43 228 12 13 29 156 26 5 1 0 0 3 16 68 2 3 2 0 2 9 47 23 21 2 18 2 1 1 106 8 97 59 18 40 16 6 9 4 79 8 71 38 15 36 24 8 16 2 4 Male ASR(W) CUM 0-74 0.2 0.2 0.0 0.3 0.3 0.2 0.1 0.2 0.1 0.1 0.1 0.1 1.1 0.2 0.1 0.4 0.2 0.1 0.1 2.1 0.1 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.3 0.1 0.2 0.1 0.2 0.1 0.2 0.3 0.4 0.1 0.3 0.2 0.2 0.2 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.3 0.4 0.2 0.3 0.4 0.2 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.08 0.17 0.02 0.21 0.14 0.16 0.09 0.03 0.12 0.05 0.04 0.05 0.04 0.04 0.03 0.09 0.08 0.07 0.06 0.07 0.14 0.03 0.03 0.10 0.04 0.09 0.03 0.01 0.03 0.06 0.04 0.02 0.03 0.16 0.05 0.09 0.03 0.03 0.05 0.14 0.23 0.28 0.05 0.05 0.04 0.04 0.18 0.04 0.08 0.10 0.19 0.01 0.05 0.01 0.03 0.10 0.03 0.07 0.18 0.07 0.03 0.02 0.06 0.02 0.03 0.04 0.04 0.03 0.08 0.04 0.12 0.10 0.03 0.04 0.00 0.02 0.03 0.01 0.01 0.01 0.13 0.02 0.01 0.04 0.02 0.01 0.01 0.24 0.02 0.04 0.02 0.02 0.02 0.01 0.02 0.02 0.02 0.01 0.02 0.03 0.01 0.03 0.01 0.04 0.05 0.07 0.01 0.04 0.02 0.02 0.01 0.02 0.02 0.01 0.05 0.01 0.01 0.01 0.02 0.05 0.02 0.02 0.08 0.01 0.00 0.02 0.01 0.03 0.02 0.02 0.02 0.02 0.02 0.01 0.01 0.02 0.02 0.02 0.00 0.00 0.03 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.02 0.02 0.00 0.00 0.01 0.03 0.03 0.06 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.05 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.04 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.01 Cases 1 0 0 0 1 2 8 0 3 28 0 2 7 2 0 0 317 8 11 7 5 3 0 2 279 1 1 18 3 15 2 13 134 12 22 14 80 20 8 0 1 0 1 9 41 11 1 2 0 1 5 18 14 16 2 14 3 3 0 71 14 56 34 15 19 11 5 6 2 50 16 32 26 11 16 14 8 6 0 1 Female ASR(W) CUM 0-74 0.1 0.1 0.2 0.3 0.2 0.1 0.0 0.1 0.0 0.3 0.1 0.0 0.1 0.1 0.2 0.0 0.6 0.3 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.5 0.1 0.1 0.0 0.1 0.3 0.0 0.2 0.2 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.0 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.0 0.06 0.05 0.13 0.13 0.11 0.02 0.04 0.03 0.02 0.02 0.02 0.02 0.03 0.07 0.09 0.02 0.04 0.27 0.01 0.02 0.04 0.02 0.07 0.02 0.01 0.02 0.06 0.02 0.01 0.02 0.18 0.05 0.05 0.01 0.02 0.09 0.04 0.15 0.18 0.02 0.03 0.03 0.02 0.12 0.03 0.07 0.10 0.01 0.06 0.01 0.02 0.06 0.02 0.04 0.09 0.05 0.01 0.01 0.07 0.01 0.02 0.02 0.03 0.02 0.06 0.01 0.02 0.03 0.04 0.02 0.01 0.01 0.04 0.01 0.00 0.01 0.02 0.03 0.06 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.04 0.01 0.01 0.01 0.06 0.01 0.00 0.01 0.04 0.03 0.03 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.03 0.01 0.03 0.01 0.01 0.03 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.00 * * * *

0.02 0.02 0.01 0.00 0.01 - * 0.00 0.00 0.00 0.01 0.01 0.02 0.00 0.03 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.03 0.01 0.00 0.00 0.02 0.02 0.03 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.02 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 -

602

*Important. See note on population page.

544

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other urinary organs (C68) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 10 71 164 23 128 76 17 54 33 4 29 8 1715 154 1486 83 9 70 15 1 4 10 190 18 171 57 4 50 18 26 97 6 89 14 206 31 162 561 21 61 39 414 21 5 15 86 7 78 8 2 72 32 18 33 0 9 0 8 15 0 2 3 7 0 3 1 5 0 41 39 1 17 7 12 18 13 25 3 Male ASR(W) CUM 0-74 0.2 0.3 0.5 0.6 0.4 0.6 0.6 0.5 0.2 0.3 0.1 0.2 0.2 0.2 0.2 0.2 0.3 0.2 0.2 0.3 0.2 0.2 0.3 0.3 0.3 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.2 0.3 0.2 0.4 0.2 0.2 0.1 0.3 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.3 0.2 0.2 0.2 0.2 0.3 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.2 0.1 0.4 0.3 0.3 0.2 0.2 0.1 0.0 0.06 0.04 0.04 0.14 0.04 0.07 0.16 0.07 0.03 0.14 0.03 0.09 0.01 0.02 0.01 0.03 0.09 0.03 0.06 0.25 0.11 0.08 0.02 0.07 0.02 0.02 0.06 0.02 0.04 0.04 0.02 0.09 0.02 0.09 0.02 0.08 0.02 0.01 0.03 0.04 0.03 0.01 0.03 0.07 0.04 0.02 0.06 0.02 0.05 0.04 0.04 0.04 0.06 0.03 0.05 0.12 0.02 0.06 0.02 0.01 0.01 0.02 0.04 0.04 0.04 0.06 0.11 0.13 0.08 0.04 0.05 0.01 0.02 0.02 0.03 0.06 0.06 0.05 0.07 0.06 0.07 0.02 0.05 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.03 0.02 0.04 0.01 0.03 0.03 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.02 0.04 0.03 0.05 0.03 0.02 0.01 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.04 0.02 0.02 0.02 0.02 0.06 0.01 0.01 0.00 0.00 0.00 0.00 0.02 0.03 0.03 0.00 0.06 0.01 0.03 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.00 0.03 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.02 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.00 0.01 0.02 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.02 0.01 0.01 0.01 0.01 0.00 0.00 Cases 5 24 65 13 49 28 8 19 27 8 18 2 938 204 690 38 15 22 1 0 0 1 92 18 71 39 11 28 14 14 58 17 39 4 94 23 64 286 16 66 15 181 21 9 11 76 17 57 2 2 21 13 8 28 0 8 0 2 16 0 1 2 3 0 4 2 1 0 24 23 1 9 3 4 12 13 22 10 Female ASR(W) CUM 0-74 0.1 0.1 0.2 0.3 0.1 0.2 0.2 0.2 0.1 0.4 0.1 0.0 0.1 0.2 0.1 0.1 0.4 0.0 0.0 0.0 0.1 0.2 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.4 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.3 0.1 0.1 0.3 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.0 0.1 0.05 0.02 0.02 0.08 0.02 0.03 0.08 0.04 0.02 0.15 0.02 0.03 0.00 0.02 0.00 0.02 0.10 0.01 0.01 0.01 0.01 0.04 0.01 0.02 0.09 0.01 0.03 0.02 0.01 0.10 0.01 0.03 0.01 0.05 0.01 0.01 0.02 0.03 0.02 0.01 0.03 0.09 0.03 0.01 0.07 0.01 0.02 0.03 0.02 0.03 0.03 0.02 0.04 0.06 0.02 0.05 0.02 0.01 0.01 0.04 0.02 0.02 0.02 0.08 0.06 0.02 0.04 0.03 0.05 0.01 0.03 0.01 0.01 0.02 0.04 0.02 0.02 0.02 0.02 0.01 0.06 0.01 0.00 0.01 0.03 0.01 0.01 0.05 0.00 0.01 0.02 0.01 0.01 0.04 0.01 0.01 0.00 0.01 0.04 0.01 0.01 0.01 0.03 0.01 0.01 0.01 0.03 0.01 0.01 0.02 0.03 0.01 0.01 0.03 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 * - * 0.01 0.00 * - * 0.00 * 0.00 0.00 * 0.00 0.01 * 0.00 * - * 0.00 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.00

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
545

603

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other urinary organs (C68) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
546

Male ASR(W) CUM 0-74 0.1 0.1 0.0 0.1 0.1 0.1 0.3 0.1 0.2 0.1 0.0 0.3 0.2 0.1 0.0 0.2 0.2 0.2 0.0 0.1 0.1 0.4 0.2 0.3 0.0 0.3 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.0 0.1 0.0 0.2 0.3 0.1 0.3 0.5 0.3 0.3 0.3 0.6 0.2 0.1 0.7 0.5 0.2 0.1 0.3 1.4 0.7 0.3 0.3 0.2 0.4 0.0 0.2 2.4 0.1 0.2 0.0 0.3 0.2 0.2 0.2 0.3 0.3 1.0 0.8 2.1 0.01 0.03 0.02 0.10 0.07 0.05 0.19 0.03 0.14 0.07 0.02 0.13 0.10 0.06 0.01 0.05 0.06 0.07 0.05 0.06 0.04 0.03 0.08 0.17 0.01 0.06 0.03 0.03 0.02 0.02 0.03 0.05 0.03 0.07 0.02 0.04 0.07 0.02 0.09 0.08 0.06 0.12 0.18 0.12 0.06 0.04 0.09 0.06 0.03 0.08 0.10 0.15 0.03 0.18 0.23 0.20 0.07 0.11 0.18 0.08 0.03 0.11 0.16 0.07 0.13 0.04 0.07 0.08 0.10 0.13 0.22 0.08 0.16 0.19 0.17 0.01 0.01 0.00 0.00 0.02 0.02 0.02 0.01 0.03 0.01 0.00 0.03 0.02 0.02 0.00 0.02 0.02 0.03 0.01 0.01 0.02 0.04 0.03 0.02 0.00 0.03 0.03 0.03 0.01 0.01 0.02 0.01 0.01 0.02 0.02 0.01 0.05 0.02 0.03 0.06 0.04 0.05 0.03 0.07 0.02 0.01 0.07 0.04 0.03 0.01 0.03 0.16 0.05 0.02 0.03 0.04 0.02 0.01 0.01 0.24 0.01 0.03 0.01 0.03 0.02 0.03 0.04 0.04 0.04 0.11 0.10 0.20 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.02 0.01 0.00 0.02 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.02 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.02 0.03 0.02 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.03 0.00 0.02 0.03 0.02 0.01 0.01 0.03 0.01 0.01 0.01 0.02 0.01 0.02 0.01 0.01 0.01 0.02 0.03 0.03 0.01 0.02 0.03 0.02

Cases 78 10 2 3 2 4 0 19 4 0 0 1 0 0 0 2 8 8 0 0 5 1 0 0 1 77 2 2 16 6 16 45 15 33 25 5 28 2 1 3 2 2 1 4 2 0 3 2 24 62 25 7 17 49 13 1 9 4 15 8 7 6 0 9 2 1 130 1 0 7 8 5 2 0 0 5 15 6 63

Female ASR(W) CUM 0-74 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.2 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.2 0.2 0.0 0.1 0.3 0.1 0.2 0.1 0.3 0.4 0.2 0.1 0.3 0.1 0.0 0.0 0.8 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.5 0.01 0.03 0.02 0.05 0.04 0.03 0.02 0.12 0.05 0.02 0.03 0.04 0.05 0.05 0.01 0.02 0.05 0.09 0.01 0.03 0.02 0.02 0.02 0.02 0.02 0.04 0.02 0.03 0.02 0.10 0.02 0.04 0.03 0.09 0.03 0.03 0.06 0.03 0.04 0.05 0.02 0.03 0.04 0.05 0.16 0.02 0.15 0.13 0.08 0.05 0.27 0.05 0.01 0.04 0.09 0.07 0.03 0.06 0.06 0.06 0.04 0.07 0.10 0.07 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.00 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.02 0.01 0.00 0.01 0.01 0.01 0.02 0.02 0.03 0.00 0.01 0.03 0.02 0.02 0.01 0.05 0.04 0.02 0.01 0.02 0.01 0.01 0.08 0.01 0.02 0.02 0.01 0.01 0.03 0.03 0.05 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.02 0.01 - * - * 0.00 * 0.00 0.00 0.01 * 0.01 * - * 0.00 * 0.00 0.01 0.01 0.00 * 0.00 * 0.00 0.00 * 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.01 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.02 0.00 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01

67 6 1 2 3 4 2 19 3 1 1 5 0 3 3 1 13 13 0 0 6 1 0 3 8 117 5 3 11 21 50 71 12 37 26 5 26 6 1 1 4 2 8 12 3 9 9 8 36 66 47 16 9 81 24 2 12 3 36 14 21 11 2 22 2 2 244 3 2 1 18 6 4 3 2 17 46 18 165

604

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other urinary organs (C68) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 10 6 0 27 1 5 3 61 106 3 41 15 5 6 182 15 17 5 3 4 19 10 8 0 97 3 1 4 6 3 5 6 121 8 10 21 19 33 19 9 112 82 49 23 26 29 59 0 34 1 0 36 18 2 1 31 5 0 1 0 2 2 Male ASR(W) CUM 0-74 0.1 0.1 0.2 0.0 0.1 0.1 0.6 0.8 0.0 0.2 0.1 0.1 0.4 3.2 0.2 0.3 0.6 0.1 0.1 0.4 0.3 0.3 0.2 0.2 0.1 0.5 0.3 0.2 0.4 0.2 0.2 0.2 0.3 0.1 0.2 0.2 0.1 0.1 0.3 0.2 0.2 0.1 0.4 0.1 0.2 0.3 0.0 0.2 0.2 0.2 0.3 0.2 0.1 0.1 0.1 0.1 0.04 0.02 0.03 0.03 0.06 0.03 0.08 0.08 0.01 0.04 0.03 0.03 0.18 0.27 0.06 0.08 0.31 0.04 0.06 0.09 0.12 0.10 0.02 0.10 0.14 0.29 0.11 0.13 0.19 0.11 0.02 0.07 0.10 0.03 0.04 0.03 0.01 0.03 0.03 0.02 0.03 0.02 0.09 0.02 0.03 0.04 0.01 0.03 0.06 0.12 0.26 0.04 0.04 0.08 0.07 0.10 0.01 0.01 0.02 0.01 0.01 0.01 0.07 0.09 0.00 0.03 0.01 0.01 0.06 0.38 0.03 0.04 0.07 0.01 0.03 0.05 0.03 0.03 0.03 0.02 0.05 0.03 0.03 0.05 0.03 0.02 0.01 0.03 0.01 0.01 0.02 0.01 0.01 0.04 0.02 0.02 0.01 0.05 0.01 0.02 0.03 0.00 0.02 0.01 0.03 0.03 0.01 0.01 0.01 0.01 0.00 0.00 0.01 0.01 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.03 0.04 0.01 0.01 0.04 0.01 0.01 0.02 0.02 0.00 0.02 0.02 0.03 0.02 0.02 0.03 0.02 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.03 0.01 0.01 0.01 0.01 Cases 7 14 0 18 1 4 6 23 78 11 24 9 3 3 43 1 4 1 3 1 5 2 3 0 70 0 1 0 2 4 0 2 44 1 7 4 11 11 14 5 46 40 13 18 10 22 16 0 12 6 1 4 5 0 0 10 0 0 0 0 0 0 Female ASR(W) CUM 0-74 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.4 0.0 0.1 0.0 0.0 0.2 0.5 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.02 0.03 0.02 0.02 0.04 0.03 0.04 0.05 0.02 0.02 0.01 0.02 0.14 0.10 0.02 0.03 0.03 0.03 0.04 0.04 0.07 0.08 0.02 0.05 0.09 0.05 0.02 0.01 0.01 0.04 0.02 0.02 0.02 0.01 0.02 0.02 0.01 0.02 0.01 0.05 0.02 0.01 0.03 0.04 0.07 0.01 0.04 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.01 0.00 0.01 0.03 0.06 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.00 0.00 0.00 - * 0.00 0.00 0.00 * 0.01 0.00 0.00 0.00 0.00 0.02 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.00 -

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
547

605

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Eye (C69)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 4 24 3 56 141 3 38 8 19 310 3 33 60 21 1 7 555 61 91 23 10 9 0 18 312 3 28 64 4 59 9 100 718 20 13 117 544 143 2 1 2 0 15 114 165 3 2 0 1 0 49 104 82 62 2 60 3 2 1 482 23 441 121 16 103 32 2 27 17 235 12 208 126 85 109 88 9 78 2 17 Male ASR(W) CUM 0-74 0.2 0.4 0.3 2.2 3.8 0.4 1.5 1.2 1.2 1.5 0.4 0.9 0.7 0.7 0.1 0.6 0.8 0.8 0.7 0.6 0.4 0.6 0.6 0.9 0.7 0.9 0.5 0.2 0.6 0.8 0.6 0.8 0.3 0.2 0.6 1.0 0.8 0.1 0.2 0.3 0.5 1.0 0.7 0.2 0.3 0.9 0.6 1.0 0.7 0.6 0.2 0.7 0.4 0.4 0.5 0.9 0.4 1.0 0.6 0.3 0.7 0.5 0.1 0.6 0.3 0.7 0.3 0.7 0.7 0.9 0.9 0.7 0.3 0.9 0.1 0.9 0.09 0.09 0.18 0.40 0.37 0.23 0.26 0.44 0.29 0.09 0.21 0.18 0.10 0.16 0.06 0.22 0.04 0.11 0.09 0.14 0.13 0.24 0.17 0.06 0.38 0.18 0.07 0.08 0.09 0.27 0.07 0.03 0.06 0.07 0.06 0.05 0.07 0.08 0.17 0.25 0.13 0.11 0.06 0.11 0.26 0.86 0.09 0.12 0.08 0.09 0.13 0.10 0.25 0.29 0.55 0.05 0.09 0.06 0.06 0.09 0.08 0.09 0.06 0.13 0.08 0.05 0.09 0.05 0.07 0.11 0.09 0.08 0.10 0.11 0.10 0.23 0.04 0.16 0.12 0.15 0.14 0.04 0.08 0.07 0.07 0.04 0.08 0.07 0.08 0.08 0.05 0.07 0.05 0.09 0.10 0.10 0.05 0.01 0.06 0.07 0.07 0.08 0.02 0.01 0.05 0.10 0.08 0.00 0.01 0.04 0.04 0.11 0.06 0.01 0.03 0.04 0.06 0.09 0.08 0.06 0.01 0.06 0.02 0.02 0.02 0.09 0.03 0.09 0.06 0.02 0.07 0.05 0.00 0.06 0.02 0.07 0.02 0.07 0.08 0.09 0.09 0.07 0.02 0.09 0.12 0.03 0.04 0.07 0.05 0.01 0.03 0.02 0.01 0.02 0.02 0.00 0.01 0.01 0.02 0.02 0.03 0.02 0.01 0.06 0.02 0.01 0.01 0.01 0.03 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.03 0.01 0.01 0.01 0.00 0.02 0.04 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.03 Cases 0 14 2 60 117 4 32 3 18 300 3 32 35 21 0 6 454 46 73 17 14 7 1 14 259 2 21 45 5 40 3 80 547 13 6 86 420 112 1 0 2 0 12 92 120 3 1 1 0 0 29 83 107 81 3 77 4 2 1 412 11 387 91 10 79 28 5 22 20 185 11 164 97 73 90 75 7 68 3 15 Female ASR(W) CUM 0-74 0.2 0.2 2.0 3.8 0.4 1.0 0.3 0.9 1.1 0.3 0.8 0.4 0.6 0.5 0.6 0.5 0.5 0.4 0.6 0.3 1.5 0.3 0.7 0.2 0.6 0.3 0.2 0.3 0.2 0.5 0.5 0.1 0.1 0.4 0.7 0.6 0.1 0.1 0.5 0.8 0.4 0.1 0.1 0.1 0.4 0.7 0.9 0.7 0.5 0.7 0.3 0.3 0.1 0.7 0.2 0.7 0.4 0.2 0.5 0.4 0.3 0.5 0.6 0.5 0.3 0.5 0.5 0.8 0.7 0.6 0.2 0.7 0.3 0.8 0.06 0.14 0.32 0.47 0.26 0.19 0.20 0.22 0.07 0.16 0.14 0.07 0.14 0.20 0.03 0.08 0.07 0.11 0.20 0.12 1.45 0.10 0.05 0.11 0.15 0.06 0.08 0.07 0.09 0.06 0.03 0.03 0.04 0.05 0.04 0.06 0.07 0.11 0.14 0.11 0.04 0.07 0.07 0.09 0.07 0.09 0.09 0.09 0.26 0.10 0.16 0.22 0.05 0.04 0.06 0.05 0.05 0.07 0.06 0.09 0.12 0.11 0.14 0.04 0.08 0.05 0.06 0.11 0.08 0.07 0.09 0.10 0.18 0.24 0.02 0.09 0.03 0.07 0.10 0.02 0.07 0.04 0.03 0.04 0.06 0.05 0.05 0.05 0.04 0.04 0.06 0.04 0.06 0.05 0.03 0.01 0.03 0.02 0.04 0.05 0.01 0.01 0.04 0.07 0.06 0.01 0.01 0.05 0.08 0.04 0.01 0.01 0.01 0.04 0.07 0.09 0.06 0.03 0.06 0.02 0.02 0.06 0.02 0.07 0.04 0.01 0.05 0.04 0.01 0.05 0.05 0.05 0.02 0.05 0.05 0.07 0.06 0.05 0.02 0.07 0.03 0.08 * * * *

0.02 0.03 0.02 0.02 0.01 0.02 0.02 0.01 0.01 0.02 * 0.00 0.01 0.01 0.01 0.02 0.02 0.06 0.01 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02

606

*Important. See note on population page.

548

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Eye (C69) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 33 159 188 9 170 66 7 57 138 4 130 25 4871 180 4491 190 9 174 34 3 8 23 438 25 403 221 8 206 85 94 324 10 304 20 530 14 486 1546 37 46 151 1271 66 8 57 387 13 366 51 9 143 95 53 157 0 13 32 1 2 28 5 6 23 95 1 37 13 7 4 76 59 7 3 0 4 21 6 21 4 Male ASR(W) CUM 0-74 0.9 0.9 0.7 0.3 0.7 0.7 0.3 0.8 0.8 0.3 0.8 0.9 0.8 0.3 0.8 0.8 0.4 0.8 0.7 0.8 0.5 0.7 0.9 0.4 1.0 0.7 0.3 0.7 0.8 0.9 0.9 0.3 0.9 0.6 0.7 0.2 0.8 0.8 0.3 0.3 0.6 0.9 0.6 0.3 0.6 0.7 0.3 0.8 1.0 0.6 0.8 0.8 0.9 1.0 0.3 0.3 0.1 0.1 0.3 0.2 0.3 0.3 0.3 0.1 0.2 0.3 0.1 0.2 0.5 0.5 0.3 0.2 0.2 0.3 0.3 0.2 0.1 0.17 0.07 0.06 0.10 0.06 0.09 0.13 0.11 0.07 0.15 0.08 0.21 0.01 0.02 0.01 0.06 0.12 0.07 0.12 0.45 0.17 0.17 0.05 0.09 0.05 0.05 0.10 0.05 0.09 0.10 0.06 0.11 0.06 0.13 0.03 0.05 0.04 0.02 0.05 0.04 0.05 0.03 0.08 0.11 0.10 0.04 0.07 0.04 0.14 0.21 0.07 0.09 0.14 0.09 0.09 0.06 0.06 0.06 0.07 0.08 0.11 0.06 0.03 0.13 0.03 0.09 0.04 0.09 0.06 0.06 0.12 0.11 0.12 0.10 0.15 0.04 0.09 0.09 0.09 0.06 0.02 0.07 0.06 0.03 0.07 0.09 0.02 0.09 0.10 0.08 0.02 0.08 0.08 0.03 0.09 0.06 0.02 0.05 0.07 0.08 0.03 0.09 0.07 0.02 0.07 0.10 0.11 0.08 0.04 0.09 0.08 0.07 0.01 0.08 0.07 0.02 0.02 0.04 0.09 0.05 0.01 0.06 0.07 0.01 0.08 0.12 0.05 0.08 0.08 0.10 0.08 0.02 0.02 0.00 0.01 0.02 0.01 0.04 0.02 0.02 0.01 0.01 0.02 0.01 0.02 0.05 0.05 0.04 0.01 0.01 0.02 0.02 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.00 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.01 0.00 0.01 0.02 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.00 0.01 0.01 0.00 0.01 Cases 40 145 153 5 141 58 5 51 99 1 98 23 4121 128 3816 172 3 162 35 1 10 24 416 17 389 213 7 201 67 84 274 13 258 22 483 14 448 1291 27 32 113 1087 45 1 39 301 14 274 38 12 131 82 37 128 1 11 26 1 2 18 6 5 19 39 1 33 14 3 4 65 57 4 3 2 3 6 8 24 1 Female ASR(W) CUM 0-74 0.9 0.6 0.5 0.1 0.5 0.4 0.2 0.5 0.6 0.1 0.7 0.9 0.6 0.2 0.6 0.6 0.1 0.6 0.5 0.1 0.5 0.6 0.7 0.3 0.8 0.6 0.3 0.6 0.6 0.7 0.6 0.5 0.6 0.6 0.6 0.2 0.7 0.6 0.2 0.2 0.4 0.7 0.3 0.0 0.4 0.5 0.3 0.5 0.6 0.6 0.8 0.7 0.6 0.8 0.1 0.3 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.3 0.0 0.2 0.4 0.4 0.2 0.1 0.0 0.3 0.1 0.3 0.2 0.0 0.16 0.06 0.05 0.07 0.05 0.06 0.10 0.08 0.07 0.09 0.08 0.23 0.01 0.02 0.01 0.05 0.08 0.06 0.11 0.14 0.16 0.15 0.04 0.07 0.05 0.05 0.10 0.05 0.09 0.08 0.05 0.13 0.05 0.15 0.03 0.06 0.04 0.02 0.04 0.03 0.04 0.03 0.06 0.04 0.08 0.03 0.07 0.04 0.11 0.22 0.08 0.09 0.12 0.08 0.09 0.09 0.05 0.08 0.20 0.07 0.10 0.09 0.06 0.03 0.12 0.03 0.09 0.03 0.10 0.05 0.05 0.09 0.03 0.02 0.15 0.07 0.14 0.05 0.02 0.10 0.07 0.04 0.01 0.05 0.04 0.02 0.04 0.05 0.00 0.06 0.07 0.06 0.01 0.06 0.05 0.01 0.06 0.05 0.02 0.07 0.06 0.02 0.07 0.05 0.02 0.05 0.06 0.08 0.06 0.04 0.06 0.07 0.05 0.01 0.06 0.05 0.01 0.01 0.04 0.07 0.03 0.00 0.04 0.05 0.02 0.05 0.07 0.06 0.08 0.07 0.06 0.08 0.00 0.02 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.02 0.00 0.01 0.03 0.03 0.02 0.00 0.00 0.01 0.01 0.02 0.01 0.00 0.02 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.00 0.01 0.02 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.02 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.00 0.01 * 0.00 - * 0.01 0.00 * 0.01 * 0.01 * 0.00 0.00 * 0.01 0.00 0.00 * 0.00 * 0.01 * 0.01 0.01 0.01 0.00 0.00 0.01 0.00 0.01 0.00 0.00

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
549

607

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Eye (C69) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
550

Male ASR(W) CUM 0-74 0.3 0.2 0.3 0.5 0.3 0.3 0.3 0.3 0.5 0.2 0.4 0.2 0.3 0.5 0.6 0.3 0.2 0.2 0.5 0.1 0.5 0.3 0.5 0.4 0.3 0.4 0.6 0.6 0.8 0.4 0.6 0.4 0.7 0.7 1.3 1.0 1.0 0.8 0.6 1.0 0.7 0.6 0.8 1.0 0.8 1.0 0.6 0.5 0.6 0.6 0.4 0.6 0.5 0.6 0.6 0.6 0.9 0.3 0.8 0.2 0.6 0.4 0.3 0.5 0.5 0.4 0.8 0.4 0.4 0.9 0.7 0.5 0.3 0.7 0.5 0.7 1.1 0.7 0.7 0.02 0.06 0.08 0.13 0.12 0.08 0.19 0.05 0.18 0.13 0.25 0.09 0.09 0.16 0.13 0.05 0.07 0.08 0.33 0.14 0.15 0.15 0.14 0.13 0.07 0.04 0.18 0.21 0.06 0.12 0.07 0.05 0.08 0.05 0.10 0.18 0.08 0.16 0.22 0.28 0.17 0.17 0.16 0.20 0.26 0.28 0.21 0.13 0.11 0.08 0.08 0.14 0.08 0.10 0.12 0.30 0.09 0.24 0.23 0.14 0.15 0.12 0.19 0.15 0.20 0.18 0.13 0.17 0.20 0.29 0.17 0.12 0.13 0.24 0.31 0.22 0.34 0.20 0.14 0.02 0.03 0.03 0.03 0.02 0.02 0.03 0.03 0.02 0.00 0.07 0.01 0.03 0.05 0.05 0.02 0.01 0.01 0.02 0.04 0.02 0.02 0.03 0.03 0.04 0.05 0.06 0.08 0.04 0.06 0.04 0.08 0.08 0.13 0.11 0.10 0.10 0.05 0.08 0.08 0.07 0.07 0.08 0.06 0.08 0.09 0.06 0.06 0.06 0.05 0.06 0.06 0.06 0.07 0.04 0.09 0.03 0.08 0.03 0.07 0.04 0.04 0.05 0.04 0.04 0.08 0.04 0.05 0.11 0.07 0.04 0.03 0.09 0.05 0.04 0.07 0.07 0.07 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.00 0.01 0.00 0.06 0.01 0.01 0.02 0.02 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.02 0.03 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.03 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.02 0.02 0.01 0.01 0.02 0.03 0.01 0.02 0.02 0.01 0.02 0.03 0.03 0.02 0.01 0.02 0.03 0.03 0.01 0.02 0.02 0.01

Cases 177 13 9 5 8 10 0 51 2 0 4 4 12 12 10 36 7 5 0 2 4 4 7 8 37 111 13 5 259 12 118 118 146 222 180 42 135 23 8 17 19 13 45 18 7 16 3 10 53 115 28 44 41 39 21 3 109 4 10 18 23 6 4 23 18 4 52 5 4 7 20 11 2 6 1 14 21 6 42

Female ASR(W) CUM 0-74 0.2 0.2 0.2 0.2 0.3 0.2 0.3 0.1 1.0 0.2 0.2 0.5 0.3 0.3 0.1 0.1 0.2 0.1 0.2 0.3 0.3 0.5 0.3 0.5 0.6 0.7 0.2 0.6 0.4 0.8 0.6 0.9 0.9 0.7 0.7 0.5 1.0 0.7 0.3 1.1 0.4 0.4 0.7 0.1 0.2 0.5 0.5 0.4 0.5 0.4 0.5 0.4 0.3 0.9 0.3 0.5 1.2 0.5 0.2 0.6 0.4 0.9 0.3 0.7 0.1 0.4 0.5 0.4 0.4 0.1 0.6 0.1 0.3 0.6 0.2 0.5 0.02 0.06 0.06 0.09 0.11 0.07 0.05 0.10 0.56 0.10 0.07 0.16 0.11 0.05 0.05 0.06 0.15 0.08 0.10 0.10 0.10 0.09 0.04 0.14 0.28 0.05 0.06 0.06 0.05 0.08 0.05 0.07 0.18 0.07 0.14 0.22 0.27 0.20 0.13 0.19 0.12 0.17 0.19 0.09 0.10 0.10 0.07 0.09 0.09 0.07 0.11 0.10 0.19 0.10 0.21 0.21 0.52 0.17 0.10 0.31 0.14 0.28 0.17 0.15 0.08 0.19 0.27 0.10 0.14 0.06 0.35 0.09 0.09 0.19 0.11 0.11 0.02 0.01 0.02 0.02 0.01 0.02 0.02 0.00 0.09 0.01 0.02 0.04 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.04 0.03 0.05 0.05 0.07 0.02 0.06 0.04 0.08 0.06 0.10 0.09 0.07 0.08 0.04 0.10 0.07 0.03 0.13 0.05 0.05 0.09 0.02 0.02 0.05 0.06 0.04 0.05 0.04 0.04 0.04 0.03 0.09 0.03 0.05 0.11 0.04 0.02 0.05 0.04 0.07 0.02 0.06 0.01 0.05 0.04 0.05 0.04 0.01 0.06 0.02 0.03 0.06 0.02 0.06 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.00 0.08 0.00 0.01 0.02 * 0.02 * 0.00 * 0.00 0.00 0.01 0.00 * 0.01 * 0.01 0.01 * 0.01 * 0.00 0.02 0.02 0.00 * 0.01 * 0.01 0.00 * 0.01 0.00 0.01 0.01 0.01 0.02 0.02 0.03 0.02 0.01 0.02 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.02 0.03 0.01 0.01 0.03 0.01 0.02 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.03 0.02 0.01 0.02 0.01 0.01

206 13 14 14 9 14 3 53 9 4 7 4 15 12 23 40 15 12 2 1 17 4 13 10 20 104 12 7 201 20 102 115 101 236 217 41 168 27 10 15 19 19 26 32 12 16 10 14 54 100 29 34 41 49 27 5 96 2 15 3 28 10 2 18 10 5 58 7 5 15 29 16 5 8 3 18 22 13 40

608

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Eye (C69) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 54 64 3 141 16 15 16 50 45 56 86 115 35 9 16 30 23 2 9 15 12 10 7 15 291 7 9 5 6 4 6 11 357 35 11 51 47 107 147 63 204 265 110 82 32 129 225 2 170 76 17 149 65 9 6 137 12 0 1 4 3 4 Male ASR(W) CUM 0-74 0.8 0.7 0.5 0.9 0.7 0.5 0.4 0.6 0.6 0.5 0.6 0.8 0.6 0.9 0.5 0.6 0.5 0.3 0.5 0.6 0.3 0.7 0.4 0.5 0.9 0.7 1.2 1.0 0.3 0.8 0.5 0.4 0.8 1.0 0.3 0.5 0.6 0.8 0.7 0.8 0.9 0.6 0.7 0.5 0.6 0.8 1.1 0.3 1.5 1.6 1.0 1.0 1.2 1.2 1.0 1.2 0.3 0.1 0.8 0.6 0.3 0.11 0.09 0.30 0.09 0.17 0.14 0.11 0.10 0.10 0.09 0.07 0.08 0.11 0.32 0.18 0.15 0.10 0.20 0.16 0.19 0.09 0.28 0.15 0.17 0.06 0.32 0.42 0.44 0.13 0.45 0.23 0.14 0.04 0.18 0.10 0.08 0.11 0.08 0.07 0.11 0.08 0.04 0.08 0.07 0.12 0.08 0.08 0.25 0.12 0.20 0.25 0.09 0.15 0.41 0.41 0.11 0.11 0.08 0.42 0.43 0.18 0.09 0.07 0.02 0.09 0.09 0.04 0.04 0.05 0.06 0.05 0.06 0.09 0.06 0.11 0.04 0.06 0.05 0.04 0.05 0.07 0.02 0.05 0.05 0.04 0.09 0.04 0.15 0.13 0.04 0.04 0.05 0.06 0.08 0.11 0.05 0.05 0.06 0.08 0.07 0.08 0.09 0.06 0.07 0.05 0.06 0.08 0.11 0.04 0.17 0.16 0.11 0.10 0.11 0.13 0.06 0.13 0.02 0.02 0.04 0.05 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.04 0.01 0.01 0.01 0.03 0.02 0.02 0.01 0.02 0.02 0.01 0.01 0.02 0.06 0.06 0.02 0.02 0.03 0.02 0.00 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.03 0.02 0.02 0.03 0.01 0.02 0.05 0.03 0.01 0.01 0.01 0.03 0.03 Cases 57 91 9 147 10 21 27 41 48 101 87 118 33 4 15 25 8 1 6 4 12 8 10 10 254 5 5 6 12 2 1 8 309 10 17 53 40 59 138 46 198 276 80 59 17 152 161 0 98 64 9 86 35 11 1 124 11 0 2 0 1 7 Female ASR(W) CUM 0-74 0.7 0.6 1.0 0.8 0.4 0.5 0.4 0.4 0.7 0.7 0.6 0.7 0.4 0.4 0.4 0.5 0.2 0.6 0.4 0.1 0.3 0.3 0.6 0.4 0.7 0.3 0.8 1.3 0.7 0.1 0.1 0.5 0.6 0.3 0.6 0.5 0.5 0.4 0.6 0.5 0.8 0.5 0.5 0.3 0.3 0.8 0.7 1.0 1.1 0.5 0.5 0.6 1.2 0.3 1.0 0.3 0.5 0.0 0.9 0.14 0.08 0.39 0.08 0.12 0.13 0.10 0.08 0.14 0.10 0.08 0.07 0.08 0.28 0.18 0.13 0.06 0.62 0.20 0.07 0.10 0.13 0.27 0.17 0.06 0.13 0.46 0.64 0.24 0.10 0.12 0.21 0.04 0.11 0.18 0.09 0.09 0.06 0.06 0.09 0.07 0.04 0.07 0.05 0.08 0.08 0.07 0.11 0.16 0.22 0.06 0.11 0.39 0.27 0.10 0.11 0.39 0.02 0.41 0.06 0.07 0.05 0.08 0.04 0.04 0.04 0.03 0.05 0.06 0.05 0.06 0.03 0.04 0.04 0.04 0.02 0.03 0.03 0.02 0.02 0.03 0.04 0.03 0.07 0.03 0.05 0.10 0.08 0.02 0.01 0.05 0.06 0.03 0.05 0.05 0.04 0.04 0.06 0.05 0.08 0.05 0.05 0.03 0.03 0.08 0.07 0.09 0.12 0.03 0.05 0.06 0.11 0.10 0.02 0.04 0.06 0.01 0.01 0.02 0.01 0.01 * 0.01 0.01 0.01 * 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.03 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.03 0.05 0.03 0.02 0.01 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.04 0.01 0.01 0.03 0.03

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
551

609

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Brain, nervous system (C70-72)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White *Important. See note on population page.
552

Male ASR(W) CUM 0-74 0.7 4.0 3.7 0.6 1.6 4.2 7.8 7.0 5.4 8.0 3.8 5.5 3.7 4.3 2.8 4.3 6.6 6.0 6.0 6.4 7.6 6.8 2.6 7.0 6.9 5.3 5.9 6.0 3.6 6.7 5.9 5.9 5.9 3.1 3.6 4.7 7.4 5.8 4.3 3.4 2.1 3.9 4.6 7.3 5.3 3.2 3.4 3.1 3.6 1.8 4.5 7.4 6.4 7.0 3.8 7.3 5.9 5.5 5.9 6.4 4.2 6.7 6.1 3.8 6.8 6.1 4.0 7.3 8.6 5.9 3.8 6.2 6.1 6.6 6.2 5.7 3.7 6.4 4.0 5.6 0.15 0.28 0.63 0.28 0.28 0.79 0.58 1.05 0.59 0.20 0.65 0.38 0.22 0.40 0.53 0.66 0.10 0.28 0.23 0.45 0.63 0.68 1.94 0.53 0.15 1.24 0.45 0.23 0.37 0.28 0.63 0.21 0.08 0.18 0.25 0.16 0.13 0.19 0.60 0.52 0.52 1.58 0.45 0.30 0.15 0.38 0.70 0.73 1.36 0.61 0.25 0.31 0.24 0.28 0.73 0.31 0.66 0.81 1.26 0.12 0.28 0.14 0.17 0.28 0.22 0.31 0.45 0.43 0.51 0.14 0.30 0.15 0.20 0.29 0.25 0.22 0.34 0.29 0.64 0.65 0.36 0.77 0.79 0.56 0.83 0.36 0.54 0.37 0.44 0.33 0.44 0.66 0.59 0.61 0.64 0.75 0.72 0.51 0.71 0.69 0.52 0.57 0.60 0.35 0.66 0.66 0.58 0.58 0.28 0.35 0.45 0.72 0.58 0.45 0.33 0.16 0.30 0.50 0.73 0.51 0.31 0.29 0.28 0.22 0.18 0.42 0.71 0.64 0.69 0.30 0.73 0.59 0.53 0.64 0.61 0.39 0.64 0.60 0.37 0.67 0.58 0.35 0.68 0.87 0.59 0.35 0.63 0.60 0.66 0.60 0.56 0.35 0.63 0.36 0.55 0.07 0.08 0.16 0.07 0.02 0.08 0.05 0.03 0.05 0.07 0.09 0.01 0.03 0.03 0.05 0.07 0.08 0.45 0.06 0.02 0.12 0.05 0.02 0.04 0.03 0.09 0.02 0.01 0.02 0.03 0.02 0.01 0.02 0.08 0.06 0.05 0.13 0.06 0.03 0.02 0.04 0.06 0.07 0.09 0.07 0.03 0.03 0.03 0.03 0.07 0.03 0.07 0.08 0.14 0.01 0.03 0.01 0.02 0.03 0.02 0.04 0.05 0.05 0.06 0.02 0.03 0.02 0.02 0.03 0.03 0.03 0.04 0.03 0.07 0.07

Cases 35 200 20 14 63 36 190 46 95 1716 26 188 295 105 23 38 3700 364 587 163 112 62 1 170 2064 22 155 683 85 591 71 725 4423 270 207 934 2976 834 35 38 22 4 132 552 1135 104 24 14 5 12 362 596 584 564 31 524 71 40 26 2740 203 2488 1042 165 870 323 67 254 197 1767 135 1579 936 509 636 588 137 446 41 76

Female ASR(W) CUM 0-74 1.6 3.1 1.8 0.7 2.8 4.3 5.9 5.9 4.8 6.3 2.8 4.1 3.4 3.0 1.8 2.7 4.8 4.2 4.3 4.0 4.8 3.9 1.8 5.5 5.2 5.1 4.8 4.4 2.3 5.1 4.8 4.3 4.3 2.3 3.1 4.2 5.1 4.3 2.5 2.4 2.2 1.0 4.6 5.2 4.0 3.4 2.5 1.7 0.9 2.5 4.0 4.9 4.6 5.0 3.5 5.2 4.6 3.7 5.1 4.7 3.1 5.0 4.3 2.6 4.9 4.1 2.6 5.1 5.2 4.5 2.4 4.9 4.9 5.3 5.2 4.2 3.3 4.8 3.4 4.2 0.29 0.23 0.42 0.23 0.47 0.77 0.47 0.90 0.51 0.16 0.56 0.31 0.21 0.31 0.39 0.46 0.09 0.24 0.20 0.36 0.53 0.55 1.77 0.50 0.13 1.19 0.43 0.18 0.26 0.24 0.60 0.18 0.07 0.15 0.22 0.14 0.11 0.16 0.44 0.42 0.51 0.50 0.41 0.27 0.13 0.36 0.56 0.49 0.49 0.82 0.22 0.25 0.21 0.24 0.64 0.27 0.62 0.67 1.23 0.11 0.23 0.12 0.14 0.22 0.18 0.24 0.34 0.35 0.40 0.12 0.21 0.14 0.18 0.28 0.23 0.19 0.29 0.26 0.55 0.59 0.47 0.60 0.64 0.50 0.63 0.22 0.42 0.32 0.29 0.19 0.21 0.47 0.40 0.42 0.40 0.44 0.43 0.22 0.51 0.52 0.51 0.47 0.44 0.24 0.50 0.53 0.41 0.41 0.20 0.27 0.41 0.48 0.40 0.25 0.20 0.21 0.10 0.48 0.47 0.39 0.30 0.21 0.15 0.07 0.26 0.39 0.49 0.44 0.48 0.32 0.49 0.39 0.35 0.40 0.45 0.29 0.47 0.41 0.23 0.48 0.39 0.27 0.48 0.46 0.43 0.22 0.47 0.47 0.47 0.48 0.40 0.34 0.44 0.39 0.35 * * * *

26 231 36 10 57 30 221 51 94 1796 35 217 312 126 30 48 4603 506 769 226 172 111 2 201 2401 21 194 778 95 673 97 896 5486 334 219 998 3884 1080 55 50 19 8 125 766 1314 77 30 19 12 9 379 756 777 703 28 665 91 49 31 3326 238 3044 1275 197 1053 420 89 318 305 2041 168 1812 1054 591 707 695 125 562 40 93

0.08 0.06 0.13 0.07 0.02 0.05 0.04 0.02 0.04 0.04 0.05 * 0.01 0.03 0.02 0.04 0.05 0.06 0.22 0.05 0.01 0.12 0.04 0.02 0.03 0.02 0.08 0.02 0.01 0.01 0.02 0.02 0.01 0.02 0.05 0.04 0.05 0.05 0.05 0.02 0.01 0.04 0.05 0.04 0.04 0.08 0.03 0.02 0.02 0.02 0.07 0.03 0.05 0.06 0.10 0.01 0.03 0.01 0.02 0.02 0.02 0.03 0.04 0.04 0.04 0.01 0.02 0.01 0.02 0.03 0.02 0.02 0.04 0.02 0.07 0.05

Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data 610

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Brain, nervous system (C70-72) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 301 1264 1915 143 1741 744 106 621 1081 62 1015 181 40649 2489 36753 1625 119 1419 282 10 92 175 3656 278 3237 2118 137 1918 657 723 2388 103 2211 208 4792 300 4221 12623 551 738 1347 9855 663 103 552 3510 246 3169 372 125 1233 819 354 1082 24 179 618 46 130 1212 64 98 314 1093 36 1006 142 274 85 945 802 107 95 86 72 187 104 675 99 Male ASR(W) CUM 0-74 7.6 6.9 6.7 4.1 7.1 6.6 4.2 7.3 6.8 4.2 7.1 6.8 6.4 3.9 6.8 6.7 4.1 7.0 5.3 2.5 5.0 6.3 6.8 4.2 7.4 6.5 4.5 6.7 6.5 7.2 6.4 3.4 6.6 6.6 6.4 4.1 7.1 6.1 3.3 3.8 4.9 7.1 5.8 3.8 6.4 6.4 4.4 6.6 6.8 7.1 7.4 7.3 6.4 6.7 3.0 3.4 3.4 4.0 5.6 5.7 1.9 5.2 3.0 4.1 3.7 3.7 3.0 3.6 2.9 6.1 6.1 4.9 2.8 2.6 2.3 2.7 2.1 2.5 2.4 0.48 0.21 0.16 0.35 0.18 0.25 0.42 0.31 0.22 0.55 0.24 0.54 0.03 0.08 0.04 0.18 0.38 0.20 0.33 0.81 0.53 0.55 0.12 0.26 0.14 0.15 0.39 0.16 0.27 0.28 0.14 0.34 0.16 0.49 0.10 0.24 0.12 0.06 0.15 0.14 0.14 0.08 0.24 0.38 0.29 0.11 0.29 0.12 0.36 0.67 0.22 0.27 0.37 0.22 0.67 0.27 0.15 0.69 0.52 0.19 0.24 0.55 0.18 0.14 0.64 0.12 0.26 0.23 0.32 0.20 0.22 0.53 0.30 0.32 0.30 0.22 0.24 0.11 0.31 0.76 0.69 0.67 0.38 0.71 0.65 0.42 0.72 0.66 0.42 0.69 0.65 0.63 0.37 0.67 0.68 0.40 0.71 0.53 0.21 0.54 0.60 0.67 0.39 0.72 0.64 0.45 0.65 0.63 0.71 0.62 0.32 0.64 0.62 0.63 0.40 0.70 0.61 0.31 0.36 0.48 0.70 0.61 0.41 0.67 0.62 0.41 0.65 0.69 0.70 0.74 0.72 0.65 0.69 0.36 0.29 0.32 0.41 0.59 0.60 0.17 0.52 0.31 0.43 0.38 0.38 0.28 0.36 0.29 0.64 0.63 0.53 0.24 0.26 0.22 0.23 0.20 0.23 0.21 0.05 0.02 0.02 0.04 0.02 0.03 0.05 0.03 0.02 0.07 0.02 0.06 0.00 0.01 0.00 0.02 0.05 0.02 0.04 0.09 0.07 0.05 0.01 0.03 0.01 0.02 0.04 0.02 0.03 0.03 0.01 0.04 0.02 0.05 0.01 0.03 0.01 0.01 0.02 0.02 0.02 0.01 0.03 0.05 0.03 0.01 0.03 0.01 0.04 0.07 0.03 0.03 0.04 0.02 0.10 0.03 0.01 0.07 0.06 0.02 0.03 0.06 0.02 0.02 0.08 0.02 0.03 0.03 0.04 0.02 0.03 0.08 0.03 0.03 0.03 0.02 0.02 0.01 0.02 Cases 238 1114 1509 120 1372 618 89 517 920 50 858 159 33939 2282 30558 1407 111 1236 219 12 75 127 3258 320 2826 1799 122 1646 563 514 2097 107 1948 194 3832 241 3355 10362 430 702 1228 7893 560 99 454 2915 208 2634 287 85 967 646 302 889 8 141 397 45 116 1404 51 91 200 542 19 649 123 129 64 740 632 69 64 90 58 132 94 623 112 Female ASR(W) CUM 0-74 5.4 5.1 4.6 2.8 4.9 4.6 2.8 5.2 4.8 2.5 5.2 5.1 4.7 2.9 5.0 4.9 2.9 5.3 4.1 2.7 3.9 4.4 5.1 3.6 5.5 4.7 3.1 4.9 5.0 4.6 4.9 2.7 5.1 5.5 4.6 2.8 5.2 4.5 2.4 3.0 4.2 5.2 4.2 2.6 4.9 4.7 3.1 5.0 5.0 4.0 5.4 5.3 4.9 4.9 0.9 2.7 2.2 3.6 4.7 6.2 1.5 4.7 2.1 2.3 1.9 2.8 2.6 1.9 2.2 4.3 4.3 3.3 1.9 2.4 1.6 1.8 1.9 2.0 1.8 0.41 0.18 0.13 0.27 0.15 0.21 0.32 0.27 0.18 0.38 0.20 0.45 0.03 0.06 0.03 0.15 0.29 0.18 0.30 0.77 0.46 0.48 0.10 0.22 0.12 0.12 0.29 0.14 0.23 0.23 0.13 0.28 0.14 0.46 0.08 0.19 0.10 0.05 0.12 0.12 0.12 0.07 0.20 0.28 0.27 0.09 0.22 0.10 0.31 0.50 0.19 0.23 0.33 0.19 0.35 0.25 0.12 0.57 0.47 0.20 0.22 0.54 0.15 0.11 0.45 0.11 0.24 0.17 0.28 0.16 0.18 0.43 0.27 0.33 0.25 0.18 0.26 0.10 0.22 0.49 0.48 0.44 0.24 0.47 0.42 0.23 0.49 0.47 0.28 0.49 0.54 0.45 0.27 0.48 0.47 0.27 0.51 0.36 0.21 0.35 0.39 0.48 0.33 0.52 0.45 0.28 0.47 0.48 0.42 0.47 0.25 0.49 0.54 0.43 0.25 0.48 0.43 0.21 0.28 0.41 0.49 0.40 0.24 0.45 0.45 0.30 0.47 0.49 0.39 0.51 0.49 0.46 0.47 0.11 0.24 0.19 0.44 0.48 0.67 0.13 0.43 0.20 0.23 0.20 0.29 0.24 0.21 0.18 0.44 0.43 0.33 0.16 0.23 0.15 0.16 0.17 0.17 0.18 0.04 0.02 0.01 0.03 0.02 0.02 0.03 0.03 0.02 0.05 0.02 0.05 0.00 0.01 0.00 0.02 0.03 0.02 0.03 0.09 0.05 0.04 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.02 0.01 0.03 0.01 0.05 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.03 0.02 0.01 0.03 0.01 0.03 0.05 0.02 0.02 0.03 0.02 0.05 0.02 * 0.01 0.07 * 0.05 0.02 * 0.02 * 0.05 * 0.02 0.01 * 0.06 0.01 0.03 * 0.02 * 0.03 * 0.02 0.02 0.06 0.02 0.03 0.02 0.01 0.02 0.01 0.02

*Important. See note on population page. Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data Cancer Incidence in Five Continents Vol. IX, IARC 2007

553

611

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Brain, nervous system (C70-72) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
554

Male ASR(W) CUM 0-74 3.0 3.0 2.5 3.5 3.2 3.0 2.7 3.5 2.7 5.1 3.1 3.5 1.6 3.5 3.3 2.8 2.1 2.3 2.7 1.4 1.6 1.1 1.5 6.0 5.3 6.5 4.6 6.6 4.5 4.8 5.9 6.1 10.2 6.1 6.3 5.9 6.5 5.8 5.4 5.4 5.9 5.8 6.4 5.8 4.3 5.4 5.4 4.2 6.3 6.0 6.1 6.1 5.9 5.6 6.3 5.7 7.5 3.8 7.6 7.5 6.5 7.2 7.6 6.7 6.2 8.0 6.8 9.4 7.2 7.2 7.3 6.4 7.5 7.5 4.9 6.8 7.0 8.3 6.9 0.06 0.19 0.22 0.35 0.35 0.24 0.57 0.14 0.41 0.69 0.84 0.40 0.19 0.41 0.32 0.19 0.17 0.21 0.66 0.36 0.21 0.22 0.23 0.44 0.26 0.18 0.47 0.86 0.14 0.31 0.21 0.17 0.30 0.15 0.20 0.41 0.22 0.45 0.58 0.61 0.55 0.50 0.44 0.44 0.55 0.63 0.68 0.52 0.32 0.23 0.38 0.36 0.29 0.28 0.49 0.85 0.27 0.91 0.74 0.95 0.47 0.83 1.29 0.52 0.60 0.76 0.38 0.97 0.96 0.80 0.54 0.51 0.72 0.90 0.92 0.56 0.58 0.80 0.41 0.29 0.30 0.23 0.35 0.29 0.27 0.32 0.33 0.25 0.51 0.24 0.34 0.15 0.36 0.33 0.29 0.18 0.20 0.24 0.10 0.14 0.10 0.13 0.63 0.52 0.66 0.52 0.62 0.43 0.51 0.58 0.64 1.02 0.65 0.64 0.60 0.64 0.64 0.53 0.56 0.67 0.57 0.63 0.61 0.48 0.54 0.62 0.47 0.68 0.63 0.64 0.64 0.62 0.57 0.65 0.64 0.78 0.43 0.75 0.78 0.68 0.70 0.72 0.67 0.66 0.78 0.66 0.96 0.75 0.73 0.76 0.65 0.80 0.84 0.54 0.70 0.70 0.86 0.71 0.01 0.03 0.02 0.05 0.04 0.03 0.08 0.02 0.05 0.08 0.07 0.05 0.02 0.06 0.04 0.03 0.02 0.02 0.06 0.03 0.02 0.02 0.02 0.05 0.03 0.02 0.06 0.09 0.01 0.03 0.02 0.02 0.03 0.02 0.02 0.04 0.02 0.05 0.06 0.07 0.06 0.05 0.05 0.05 0.06 0.06 0.08 0.06 0.03 0.02 0.04 0.04 0.03 0.03 0.05 0.11 0.03 0.09 0.07 0.09 0.05 0.07 0.11 0.05 0.06 0.08 0.03 0.09 0.10 0.08 0.05 0.05 0.08 0.10 0.11 0.05 0.05 0.08 0.04

Cases 2469 218 125 75 92 171 24 731 44 44 33 72 71 67 86 252 140 108 13 19 53 44 38 143 264 1460 86 55 1012 210 760 1253 1322 1734 975 205 927 145 83 77 97 151 169 141 56 72 50 68 473 839 308 317 460 453 175 52 622 31 120 111 288 119 50 206 141 94 401 109 56 93 227 188 109 52 24 201 210 90 363

Female ASR(W) CUM 0-74 2.4 2.1 2.0 2.3 2.7 2.8 2.6 3.0 2.3 3.1 3.0 2.9 1.5 2.6 2.7 2.4 1.7 1.6 2.1 1.7 1.4 2.2 1.2 4.4 3.1 4.8 3.4 5.0 3.3 3.2 4.7 4.3 7.9 4.6 4.9 4.1 5.2 4.2 3.7 4.4 3.9 4.5 4.3 3.8 3.0 3.9 2.9 3.6 4.7 4.4 4.5 4.6 4.7 4.5 4.0 6.0 5.0 4.1 5.7 6.2 5.6 4.5 6.0 3.8 5.2 6.0 4.0 5.8 5.3 5.1 4.5 6.0 5.5 4.4 3.7 4.5 5.5 3.8 5.5 0.05 0.15 0.19 0.27 0.29 0.22 0.55 0.12 0.37 0.51 0.80 0.35 0.18 0.37 0.33 0.16 0.15 0.16 0.63 0.40 0.19 0.36 0.20 0.38 0.20 0.15 0.41 0.76 0.11 0.24 0.20 0.13 0.25 0.13 0.18 0.32 0.20 0.39 0.45 0.55 0.45 0.41 0.36 0.35 0.46 0.52 0.47 0.50 0.27 0.21 0.33 0.34 0.27 0.25 0.36 0.89 0.22 1.04 0.68 0.91 0.45 0.60 0.96 0.37 0.61 0.66 0.27 0.81 0.79 0.69 0.40 0.51 0.64 0.73 0.94 0.45 0.53 0.45 0.38 0.23 0.20 0.16 0.20 0.27 0.28 0.24 0.30 0.23 0.29 0.27 0.28 0.14 0.25 0.25 0.23 0.15 0.14 0.18 0.16 0.11 0.17 0.09 0.42 0.31 0.48 0.35 0.50 0.31 0.36 0.45 0.44 0.81 0.49 0.51 0.42 0.47 0.40 0.38 0.44 0.42 0.49 0.47 0.40 0.34 0.37 0.34 0.38 0.47 0.45 0.47 0.47 0.48 0.46 0.42 0.63 0.52 0.38 0.52 0.63 0.59 0.46 0.74 0.38 0.49 0.61 0.40 0.56 0.56 0.46 0.48 0.64 0.51 0.45 0.37 0.48 0.57 0.44 0.55 0.01 0.02 0.02 0.03 0.03 0.03 0.05 0.01 0.05 0.07 0.10 0.04 0.02 0.04 * 0.04 * 0.02 * 0.02 0.02 0.06 0.04 0.02 * 0.03 * 0.02 0.04 * 0.02 * 0.01 0.04 0.08 0.01 * 0.03 * 0.02 0.01 * 0.02 0.01 0.02 0.03 0.02 0.04 0.05 0.06 0.05 0.04 0.04 0.04 0.05 0.05 0.06 0.05 0.02 0.02 0.03 0.03 0.03 0.02 0.04 0.11 0.03 0.08 0.06 0.08 0.04 0.05 0.11 0.03 0.05 0.07 0.03 0.07 0.08 0.06 0.04 0.05 0.06 0.07 0.09 0.04 0.05 0.05 0.03

2797 264 152 110 103 177 23 774 50 67 61 80 76 87 124 282 170 137 17 16 56 23 43 195 431 1618 100 64 1165 273 916 1606 1386 1923 1135 225 1056 180 96 87 129 167 228 188 68 89 75 80 541 931 340 363 488 478 223 50 810 28 142 107 303 144 48 263 152 116 472 147 68 113 277 184 126 79 31 231 221 136 385

Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data 612

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Brain, nervous system (C70-72) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 439 630 65 955 146 355 347 445 735 573 1345 876 332 64 221 402 240 50 128 128 187 142 109 146 1586 94 56 33 95 72 45 116 2871 172 182 570 599 727 1464 562 1676 2833 1064 1019 338 1071 1328 24 686 334 106 1070 349 55 25 783 158 6 19 29 27 68 Male ASR(W) CUM 0-74 7.0 6.5 5.7 6.7 7.0 9.7 6.6 5.1 7.8 4.7 9.4 6.1 5.6 6.1 5.6 6.6 5.5 5.8 6.9 4.8 5.7 7.6 6.1 5.0 5.7 7.2 8.1 6.5 5.8 7.4 5.2 5.7 5.8 5.5 6.2 5.9 7.5 5.4 6.8 6.5 7.3 6.5 6.6 5.9 6.9 6.5 6.6 4.7 6.3 6.8 7.1 7.2 6.3 6.5 4.8 7.0 4.4 1.7 2.7 5.1 3.2 8.2 0.37 0.27 0.74 0.23 0.65 0.54 0.39 0.26 0.32 0.22 0.28 0.22 0.33 0.86 0.45 0.36 0.37 0.96 0.74 0.45 0.45 0.78 0.65 0.46 0.16 0.78 1.21 1.27 0.64 1.00 0.82 0.57 0.11 0.44 0.50 0.27 0.33 0.22 0.19 0.29 0.20 0.13 0.22 0.20 0.39 0.21 0.19 1.02 0.25 0.40 0.73 0.23 0.35 0.91 1.00 0.26 0.38 0.81 0.67 0.97 0.80 1.19 0.67 0.69 0.60 0.70 0.72 1.00 0.73 0.53 0.81 0.49 0.98 0.65 0.58 0.65 0.58 0.72 0.61 0.61 0.66 0.53 0.54 0.75 0.66 0.52 0.59 0.84 0.77 0.63 0.64 0.78 0.52 0.59 0.61 0.57 0.64 0.64 0.78 0.56 0.71 0.70 0.75 0.70 0.66 0.62 0.69 0.69 0.69 0.45 0.66 0.72 0.70 0.71 0.64 0.55 0.50 0.72 0.40 0.12 0.28 0.48 0.26 0.74 0.03 0.03 0.08 0.03 0.07 0.06 0.04 0.03 0.03 0.02 0.03 0.02 0.03 0.09 0.04 0.04 0.04 0.10 0.07 0.05 0.04 0.07 0.07 0.05 0.02 0.10 0.12 0.12 0.07 0.10 0.09 0.06 0.01 0.05 0.05 0.03 0.04 0.02 0.02 0.03 0.02 0.02 0.02 0.02 0.04 0.02 0.02 0.12 0.03 0.05 0.08 0.03 0.04 0.09 0.13 0.03 0.04 0.07 0.09 0.12 0.06 0.11 Cases 383 590 45 736 126 369 316 362 605 571 1121 699 261 39 211 362 202 37 108 110 148 123 111 132 1164 64 49 24 77 60 39 89 2131 138 127 418 487 615 1056 375 1208 2171 866 740 254 823 983 14 528 234 70 815 247 43 20 508 124 4 10 25 23 49 Female ASR(W) CUM 0-74 4.3 4.8 3.2 4.8 4.5 8.3 4.5 3.6 5.7 3.4 7.5 4.0 3.7 2.8 4.9 5.2 4.3 4.6 5.4 3.5 3.7 5.5 6.2 3.8 4.0 3.8 6.4 5.3 4.0 4.5 3.7 4.2 4.1 4.3 4.3 4.0 5.1 4.3 4.4 4.1 4.8 4.3 4.9 3.9 4.6 4.1 4.6 4.3 4.7 4.2 4.5 5.0 3.9 4.5 4.0 4.0 3.4 1.9 1.5 4.5 3.2 5.1 0.25 0.22 0.51 0.20 0.48 0.48 0.30 0.21 0.29 0.18 0.26 0.16 0.27 0.55 0.46 0.35 0.33 0.97 0.64 0.38 0.35 0.63 0.69 0.43 0.13 0.58 1.08 1.26 0.50 0.72 0.68 0.50 0.10 0.41 0.44 0.23 0.26 0.20 0.15 0.23 0.16 0.11 0.20 0.16 0.32 0.17 0.16 1.23 0.22 0.31 0.60 0.20 0.27 0.72 0.93 0.19 0.34 0.96 0.51 0.92 0.97 0.88 0.45 0.48 0.36 0.48 0.45 0.88 0.47 0.37 0.55 0.33 0.74 0.41 0.38 0.28 0.50 0.51 0.43 0.42 0.55 0.38 0.38 0.57 0.64 0.39 0.41 0.38 0.61 0.48 0.41 0.40 0.41 0.40 0.42 0.45 0.45 0.43 0.55 0.44 0.45 0.42 0.48 0.45 0.48 0.40 0.45 0.43 0.47 0.52 0.46 0.43 0.45 0.50 0.40 0.41 0.43 0.41 0.31 0.17 0.14 0.43 0.26 0.46 0.02 0.02 0.06 0.02 0.05 * 0.05 0.03 0.02 * 0.03 0.01 0.02 0.02 0.03 0.06 0.04 0.03 0.04 0.09 0.06 0.04 0.04 0.06 0.07 0.04 0.01 0.06 0.10 0.10 0.06 0.07 0.08 0.05 0.01 0.04 0.04 0.02 0.03 0.02 0.02 0.03 0.02 0.01 0.02 0.02 0.03 0.02 0.02 0.22 0.02 0.03 0.06 0.02 0.03 0.08 0.12 0.02 0.03 0.08 0.06 0.10 0.06 0.08

*Important. See note on population page. Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data Cancer Incidence in Five Continents Vol. IX, IARC 2007

555

613

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Thyroid (C73)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 32 53 14 11 14 6 88 8 39 861 16 85 141 57 11 17 2095 295 271 68 54 26 2 54 1243 3 79 300 38 257 63 475 2720 329 103 470 1789 545 22 37 33 5 66 339 779 47 26 37 17 18 169 438 432 386 7 368 82 36 40 1434 69 1334 568 66 484 213 26 173 117 1100 62 972 476 290 332 318 47 266 15 54 Male ASR(W) CUM 0-74 1.4 1.1 1.3 0.5 1.0 0.7 3.5 1.1 2.1 3.6 1.7 2.2 1.7 2.0 1.0 1.7 2.9 3.2 2.1 2.0 2.2 1.5 1.5 1.7 3.4 0.6 2.6 2.2 1.4 2.4 3.6 3.0 2.8 2.9 1.6 2.3 3.2 2.8 1.5 2.5 3.7 2.2 2.3 3.0 3.0 1.8 2.3 4.8 4.0 3.2 2.2 3.9 3.4 3.8 0.9 4.1 5.1 3.8 6.3 2.6 1.3 2.8 2.5 1.3 2.8 2.8 1.1 3.5 3.1 3.0 1.4 3.2 2.6 3.2 2.7 2.5 1.5 2.9 1.7 3.1 0.26 0.17 0.37 0.23 0.30 0.31 0.41 0.42 0.36 0.13 0.44 0.25 0.15 0.28 0.30 0.42 0.06 0.19 0.13 0.25 0.31 0.30 1.07 0.24 0.10 0.38 0.30 0.13 0.23 0.15 0.48 0.14 0.06 0.16 0.17 0.11 0.08 0.12 0.34 0.42 0.66 1.01 0.31 0.17 0.11 0.27 0.47 0.81 1.00 0.77 0.18 0.20 0.17 0.20 0.34 0.22 0.57 0.64 1.02 0.07 0.15 0.08 0.11 0.16 0.13 0.20 0.24 0.27 0.29 0.09 0.18 0.10 0.12 0.19 0.15 0.14 0.23 0.18 0.43 0.43 0.04 0.42 0.14 0.22 0.38 0.22 0.24 0.18 0.21 0.09 0.20 0.30 0.34 0.22 0.23 0.19 0.14 0.10 0.22 0.35 0.09 0.28 0.23 0.16 0.25 0.40 0.31 0.30 0.30 0.19 0.25 0.34 0.29 0.18 0.24 0.37 0.23 0.28 0.32 0.32 0.20 0.23 0.51 0.47 0.35 0.24 0.40 0.36 0.38 0.08 0.40 0.53 0.42 0.63 0.28 0.16 0.30 0.28 0.14 0.32 0.31 0.13 0.37 0.34 0.32 0.17 0.33 0.29 0.35 0.28 0.27 0.19 0.31 0.23 0.33 0.03 0.06 0.07 0.05 0.02 0.07 0.03 0.02 0.04 0.03 0.07 0.01 0.02 0.01 0.03 0.03 0.03 0.07 0.03 0.01 0.06 0.03 0.02 0.03 0.02 0.06 0.02 0.01 0.02 0.02 0.02 0.01 0.01 0.05 0.04 0.07 0.11 0.05 0.02 0.01 0.03 0.05 0.10 0.12 0.10 0.02 0.02 0.02 0.02 0.03 0.02 0.07 0.08 0.12 0.01 0.02 0.01 0.01 0.02 0.02 0.03 0.03 0.03 0.04 0.01 0.02 0.01 0.01 0.02 0.02 0.02 0.03 0.02 0.07 0.05 Cases 88 151 34 26 45 17 338 43 208 4399 42 450 739 356 80 68 6839 802 733 265 178 102 7 180 4349 19 204 898 171 704 173 1368 8487 1264 308 2002 4783 1572 57 135 94 22 236 826 2516 129 81 155 33 59 802 1160 1256 1113 51 1007 191 107 62 4052 345 3582 1774 334 1377 720 157 525 367 3380 277 2908 1451 861 1057 1052 209 831 59 163 Female ASR(W) CUM 0-74 3.6 2.6 3.1 1.5 3.1 1.9 9.8 4.8 9.3 14.9 4.4 9.4 8.2 10.2 6.5 5.7 9.3 8.8 5.6 7.5 7.3 5.9 6.0 5.8 11.8 4.1 6.7 6.4 4.8 6.9 10.0 9.0 8.4 9.5 4.3 8.3 9.0 7.8 3.7 8.5 8.8 5.8 7.4 7.9 8.9 4.0 6.8 15.7 6.9 9.3 8.3 11.1 9.6 10.2 4.9 10.6 10.3 8.9 10.1 7.8 4.9 8.3 7.1 4.8 8.0 8.1 5.1 9.9 10.0 8.8 4.8 9.5 7.8 9.8 8.4 7.7 4.9 9.2 4.6 9.0 0.41 0.22 0.54 0.38 0.54 0.47 0.60 0.79 0.67 0.24 0.69 0.46 0.31 0.56 0.75 0.72 0.12 0.32 0.22 0.49 0.57 0.60 2.33 0.46 0.18 0.99 0.49 0.22 0.38 0.27 0.79 0.25 0.09 0.27 0.25 0.20 0.14 0.20 0.50 0.77 0.92 1.45 0.50 0.30 0.18 0.36 0.79 1.29 1.27 1.25 0.31 0.35 0.28 0.32 0.70 0.36 0.76 0.89 1.32 0.13 0.27 0.15 0.17 0.27 0.22 0.31 0.43 0.45 0.54 0.16 0.29 0.18 0.21 0.35 0.27 0.24 0.35 0.33 0.61 0.75 0.22 1.04 0.53 0.90 1.46 0.49 0.96 0.78 1.03 0.65 0.68 0.87 0.83 0.53 0.68 0.67 0.54 0.57 0.53 1.10 0.39 0.62 0.59 0.48 0.63 0.92 0.85 0.80 0.94 0.43 0.82 0.83 0.73 0.37 0.78 0.89 0.58 0.69 0.72 0.86 0.40 0.57 1.54 0.69 0.97 0.82 1.05 0.90 0.95 0.51 0.98 1.03 0.92 0.99 0.73 0.47 0.77 0.68 0.49 0.76 0.78 0.51 0.93 0.90 0.83 0.47 0.88 0.72 0.89 0.77 0.73 0.50 0.85 0.48 0.89 * * * *

0.06 0.08 0.10 0.08 0.03 0.09 0.06 0.03 0.07 0.08 0.10 * 0.01 0.03 0.02 0.05 0.05 0.06 0.24 0.04 0.02 0.10 0.05 0.02 0.04 0.03 0.08 0.02 0.01 0.03 0.03 0.02 0.01 0.02 0.06 0.07 0.10 0.14 0.06 0.03 0.02 0.04 0.07 0.14 0.13 0.14 0.04 0.03 0.03 0.03 0.08 0.03 0.08 0.10 0.14 0.01 0.03 0.01 0.02 0.03 0.02 0.03 0.05 0.05 0.05 0.02 0.03 0.02 0.02 0.03 0.03 0.02 0.04 0.03 0.07 0.07

614

*Important. See note on population page.

556

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Thyroid (C73) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 99 644 842 65 756 384 53 323 480 22 452 108 19839 1052 17616 969 64 845 222 7 81 131 2019 112 1790 856 42 766 230 305 1513 76 1381 116 2588 121 2216 6586 518 330 680 4971 265 37 223 1699 96 1518 202 52 580 411 179 463 8 84 447 11 18 314 35 54 82 262 17 184 17 53 58 526 474 43 50 81 93 175 122 432 77 Male ASR(W) CUM 0-74 2.4 3.4 2.8 2.0 2.9 3.2 2.2 3.5 2.8 1.5 3.0 3.6 3.0 1.6 3.1 3.8 2.2 4.0 4.1 1.7 4.3 4.5 3.6 1.6 3.9 2.5 1.3 2.5 2.2 2.9 3.9 2.4 3.9 3.6 3.3 1.6 3.5 3.0 2.9 1.7 2.5 3.4 2.2 1.2 2.5 2.9 1.7 3.0 3.7 2.8 3.3 3.4 3.1 2.8 1.1 1.4 2.2 1.0 0.7 1.4 0.9 2.7 0.8 1.0 1.7 0.7 0.4 0.7 2.0 3.4 3.5 2.0 1.3 2.7 2.3 2.0 2.0 1.3 1.5 0.25 0.14 0.10 0.26 0.11 0.17 0.31 0.20 0.13 0.33 0.15 0.36 0.02 0.05 0.02 0.13 0.28 0.14 0.28 0.66 0.48 0.41 0.08 0.15 0.10 0.09 0.21 0.09 0.15 0.17 0.10 0.29 0.11 0.35 0.07 0.15 0.08 0.04 0.13 0.10 0.10 0.05 0.14 0.20 0.17 0.07 0.18 0.08 0.26 0.41 0.14 0.17 0.24 0.14 0.42 0.15 0.11 0.33 0.17 0.08 0.16 0.38 0.09 0.07 0.45 0.06 0.10 0.11 0.27 0.15 0.17 0.34 0.19 0.32 0.25 0.16 0.20 0.06 0.19 0.26 0.36 0.29 0.25 0.30 0.35 0.26 0.37 0.30 0.20 0.32 0.37 0.31 0.18 0.33 0.41 0.24 0.43 0.41 0.22 0.42 0.45 0.39 0.17 0.42 0.26 0.15 0.26 0.23 0.29 0.41 0.27 0.42 0.36 0.34 0.19 0.36 0.32 0.31 0.20 0.27 0.36 0.23 0.12 0.26 0.31 0.17 0.32 0.40 0.29 0.33 0.34 0.30 0.28 0.14 0.14 0.23 0.08 0.09 0.15 0.10 0.29 0.09 0.12 0.22 0.08 0.05 0.09 0.23 0.35 0.37 0.19 0.14 0.28 0.29 0.21 0.22 0.14 0.17 0.03 0.02 0.01 0.04 0.01 0.02 0.04 0.02 0.02 0.05 0.02 0.04 0.00 0.01 0.00 0.01 0.03 0.02 0.03 0.10 0.05 0.04 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.02 0.01 0.04 0.01 0.04 0.01 0.02 0.01 0.00 0.02 0.01 0.01 0.01 0.02 0.03 0.02 0.01 0.02 0.01 0.03 0.04 0.02 0.02 0.02 0.01 0.06 0.02 0.01 0.03 0.02 0.01 0.02 0.04 0.01 0.01 0.08 0.01 0.01 0.02 0.04 0.02 0.02 0.04 0.02 0.03 0.03 0.02 0.02 0.01 0.02 Cases 338 2132 2696 242 2348 1171 180 946 1496 93 1370 321 60456 4256 51843 2966 213 2522 636 40 214 371 6201 564 5205 2605 170 2314 596 848 4903 365 4355 377 7819 494 6306 20454 2014 1224 2779 14047 839 162 659 4887 332 4285 691 170 1760 1215 542 1288 57 295 1557 20 33 1044 105 190 202 579 44 355 42 93 196 1948 1747 161 196 221 472 819 473 1194 393 Female ASR(W) CUM 0-74 8.4 10.4 8.7 5.6 9.2 9.0 5.5 10.3 8.5 4.9 9.0 11.9 8.7 5.2 9.1 11.0 5.6 11.9 11.6 8.4 10.9 13.6 10.1 5.9 11.0 7.3 4.2 7.4 5.7 8.1 12.5 9.6 12.6 11.4 9.5 5.2 10.0 9.1 9.8 5.0 8.8 9.8 6.6 4.5 7.6 8.0 4.8 8.3 11.8 8.5 9.9 9.7 9.1 7.9 7.7 4.7 7.2 1.5 1.2 4.7 3.0 9.3 1.9 2.6 3.9 1.5 1.0 1.4 5.8 11.7 12.1 7.0 5.6 6.2 11.6 9.2 7.4 3.2 8.0 0.49 0.23 0.17 0.37 0.20 0.28 0.43 0.36 0.23 0.52 0.26 0.70 0.04 0.08 0.04 0.21 0.39 0.25 0.47 1.35 0.76 0.76 0.13 0.25 0.16 0.15 0.33 0.16 0.24 0.29 0.19 0.51 0.20 0.61 0.11 0.24 0.13 0.07 0.22 0.15 0.17 0.09 0.24 0.36 0.31 0.12 0.27 0.13 0.46 0.69 0.24 0.29 0.41 0.23 1.09 0.28 0.19 0.34 0.21 0.15 0.30 0.69 0.14 0.12 0.60 0.08 0.15 0.15 0.42 0.27 0.30 0.58 0.41 0.47 0.55 0.34 0.38 0.10 0.46 0.75 0.96 0.80 0.58 0.83 0.84 0.57 0.93 0.80 0.47 0.84 1.08 0.82 0.52 0.85 1.03 0.56 1.10 1.12 0.81 1.08 1.26 0.96 0.59 1.02 0.68 0.41 0.69 0.53 0.74 1.18 0.96 1.18 1.03 0.89 0.53 0.92 0.86 0.97 0.51 0.86 0.91 0.62 0.45 0.69 0.76 0.47 0.78 1.09 0.77 0.91 0.90 0.86 0.71 0.80 0.45 0.69 0.15 0.14 0.46 0.28 0.83 0.21 0.28 0.32 0.14 0.12 0.15 0.49 1.17 1.21 0.68 0.57 0.68 1.23 0.99 0.76 0.33 0.82 0.04 0.02 0.02 0.04 0.02 0.03 0.05 0.03 0.02 0.06 0.02 0.06 0.00 0.01 0.00 0.02 0.04 0.02 0.05 0.15 0.08 0.07 0.01 0.03 0.02 0.01 0.04 0.02 0.02 0.03 0.02 0.05 0.02 0.06 0.01 0.03 0.01 0.01 0.02 0.02 0.02 0.01 0.02 0.04 0.03 0.01 0.03 0.01 0.05 0.07 0.02 0.03 0.04 0.02 0.13 0.03 * 0.02 0.04 * 0.03 0.02 * 0.03 * 0.06 * 0.02 0.02 * 0.06 0.01 0.02 * 0.02 * 0.04 * 0.03 0.03 0.07 0.04 0.05 0.06 0.04 0.04 0.01 0.04

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
557

615

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Thyroid (C73) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
558

Male ASR(W) CUM 0-74 2.3 2.2 1.7 2.2 3.6 1.9 3.1 2.5 2.4 3.5 1.0 1.1 1.1 1.7 0.7 2.9 2.0 2.0 1.3 2.3 1.1 0.8 1.7 1.1 1.1 2.8 3.4 2.3 3.3 1.1 1.2 0.9 2.1 1.7 1.2 1.2 2.2 2.3 3.1 3.8 2.4 2.2 4.3 3.0 2.0 2.2 3.8 5.1 2.2 2.1 1.2 2.1 2.5 1.4 1.9 4.6 0.8 3.2 4.9 6.3 3.3 3.5 2.4 3.2 5.9 3.6 2.8 4.9 3.3 5.2 4.2 3.5 3.1 3.6 2.5 2.5 3.7 2.9 2.8 0.05 0.18 0.17 0.27 0.35 0.20 0.64 0.10 0.40 0.56 0.20 0.23 0.17 0.32 0.15 0.21 0.15 0.17 0.43 0.51 0.17 0.20 0.24 0.19 0.12 0.11 0.40 0.46 0.11 0.15 0.09 0.06 0.13 0.07 0.08 0.17 0.11 0.27 0.42 0.50 0.32 0.29 0.36 0.30 0.36 0.37 0.59 0.54 0.16 0.12 0.15 0.19 0.18 0.13 0.24 0.74 0.09 0.69 0.50 0.74 0.30 0.48 0.64 0.32 0.55 0.49 0.20 0.63 0.61 0.59 0.37 0.37 0.45 0.63 0.65 0.32 0.41 0.46 0.24 0.24 0.22 0.16 0.21 0.42 0.16 0.37 0.27 0.25 0.37 0.10 0.10 0.12 0.20 0.07 0.32 0.21 0.21 0.16 0.29 0.13 0.13 0.18 0.12 0.12 0.30 0.38 0.25 0.29 0.12 0.13 0.09 0.22 0.18 0.11 0.16 0.23 0.23 0.27 0.38 0.27 0.23 0.44 0.31 0.20 0.22 0.40 0.53 0.24 0.22 0.12 0.23 0.26 0.15 0.20 0.52 0.10 0.38 0.51 0.69 0.36 0.36 0.23 0.33 0.54 0.36 0.27 0.52 0.35 0.55 0.42 0.33 0.35 0.34 0.22 0.26 0.36 0.30 0.29 0.01 0.02 0.02 0.03 0.05 0.02 0.10 0.01 0.06 0.07 0.03 0.02 0.02 0.04 0.02 0.03 0.02 0.02 0.05 0.07 0.02 0.03 0.03 0.02 0.01 0.01 0.05 0.06 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.03 0.04 0.05 0.04 0.03 0.04 0.03 0.04 0.04 0.06 0.06 0.02 0.01 0.02 0.02 0.02 0.01 0.03 0.10 0.01 0.08 0.05 0.08 0.03 0.05 0.06 0.03 0.05 0.05 0.02 0.07 0.07 0.06 0.04 0.04 0.05 0.06 0.06 0.03 0.04 0.05 0.03

Cases 13725 989 753 339 809 715 128 4122 265 120 86 103 138 137 71 1206 636 512 46 78 191 87 209 157 329 1880 198 70 3860 128 512 785 1254 2012 524 293 1281 198 203 182 119 220 461 405 122 165 214 306 526 930 152 405 637 308 216 91 263 51 334 266 451 203 49 341 349 150 700 198 97 259 520 341 200 146 58 306 295 123 482

Female ASR(W) CUM 0-74 12.2 8.5 10.1 8.8 21.4 10.3 13.1 14.1 12.3 7.3 5.0 4.0 3.2 5.9 2.9 11.1 6.6 6.5 7.0 6.8 4.5 3.7 6.2 4.5 3.6 6.5 8.7 5.5 12.2 2.0 3.0 2.8 8.2 5.4 2.9 5.5 7.0 5.8 9.9 11.2 5.2 7.3 13.2 10.9 8.0 9.3 18.1 17.0 5.4 5.1 2.2 6.3 7.5 3.2 5.3 10.9 2.3 8.2 17.0 20.4 10.7 10.0 7.6 8.3 15.4 9.5 8.9 14.1 10.0 16.5 14.8 12.4 12.0 14.2 8.7 8.7 10.3 7.1 8.0 0.11 0.28 0.38 0.49 0.77 0.40 1.18 0.22 0.81 0.72 0.91 0.40 0.28 0.54 0.38 0.35 0.27 0.30 1.08 0.81 0.33 0.41 0.43 0.37 0.20 0.16 0.65 0.70 0.20 0.19 0.14 0.11 0.24 0.13 0.14 0.34 0.21 0.43 0.73 0.86 0.49 0.51 0.63 0.56 0.77 0.75 1.31 1.04 0.26 0.19 0.21 0.34 0.32 0.20 0.39 1.19 0.14 1.30 1.03 1.39 0.55 0.81 1.19 0.51 0.88 0.79 0.37 1.09 1.06 1.11 0.71 0.70 0.88 1.21 1.21 0.55 0.67 0.69 0.39 1.19 0.87 0.98 0.83 2.14 1.02 1.34 1.42 1.23 0.75 0.55 0.44 0.33 0.53 0.31 1.22 0.64 0.64 0.69 0.70 0.44 0.38 0.60 0.47 0.36 0.65 0.81 0.60 1.12 0.21 0.30 0.27 0.80 0.55 0.27 0.57 0.67 0.57 0.93 1.09 0.50 0.71 1.30 1.07 0.76 0.95 1.80 1.67 0.55 0.52 0.21 0.61 0.76 0.31 0.54 1.06 0.22 0.75 1.61 2.03 1.03 0.94 0.79 0.81 1.51 0.85 0.89 1.33 0.93 1.64 1.41 1.11 1.24 1.32 0.93 0.86 0.96 0.65 0.79 0.01 0.03 0.04 0.05 0.09 0.04 0.13 0.03 0.09 0.09 0.13 0.05 0.03 0.06 * 0.05 * 0.05 * 0.03 0.03 0.12 0.10 0.04 * 0.05 * 0.05 0.04 * 0.02 * 0.02 0.06 0.08 0.02 * 0.02 * 0.01 0.01 * 0.02 0.01 0.01 0.04 0.02 0.04 0.07 0.09 0.05 0.05 0.06 0.06 0.07 0.08 0.13 0.10 0.03 0.02 0.02 0.03 0.03 0.02 0.04 0.12 0.02 0.11 0.09 0.13 0.05 0.07 0.12 0.05 0.08 0.07 0.04 0.10 0.10 0.11 0.07 0.06 0.09 0.11 0.13 0.05 0.06 0.06 0.04

2314 215 118 73 121 109 25 644 49 46 62 25 46 32 25 260 180 147 11 22 43 18 52 38 90 737 73 25 892 64 206 244 306 571 210 52 384 75 59 60 58 62 143 106 32 36 46 96 205 337 75 136 209 122 71 41 94 23 105 87 143 71 17 119 127 53 210 71 31 84 151 93 50 35 15 80 104 45 156

616

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Thyroid (C73) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 70 167 19 247 43 59 66 194 151 152 125 219 116 10 55 94 81 9 40 27 68 51 23 37 407 27 7 15 38 25 17 41 524 34 24 95 78 105 230 84 232 433 153 189 72 177 506 14 304 112 35 257 130 20 26 181 132 5 37 23 18 40 Male ASR(W) CUM 0-74 1.0 1.7 1.7 1.6 1.8 1.5 1.2 2.1 1.7 1.1 0.8 1.4 1.8 1.3 1.5 1.6 1.8 1.0 2.4 1.0 2.2 2.4 1.7 1.4 1.3 2.0 1.0 2.3 2.0 2.5 1.8 2.0 1.0 0.9 0.8 0.9 1.0 0.8 1.0 0.9 1.0 0.9 0.9 1.1 1.4 1.1 2.5 2.7 2.7 2.3 2.3 1.7 2.2 2.2 5.4 1.6 3.4 1.6 5.7 4.3 1.8 3.8 0.12 0.13 0.39 0.11 0.28 0.20 0.15 0.16 0.14 0.09 0.08 0.10 0.17 0.44 0.21 0.18 0.20 0.39 0.39 0.21 0.28 0.35 0.42 0.24 0.07 0.40 0.39 0.65 0.34 0.52 0.44 0.34 0.04 0.16 0.16 0.10 0.12 0.08 0.07 0.10 0.07 0.05 0.08 0.08 0.17 0.08 0.11 0.76 0.16 0.22 0.41 0.11 0.20 0.51 1.13 0.12 0.31 0.75 0.98 0.91 0.47 0.62 0.11 0.18 0.17 0.18 0.19 0.17 0.14 0.21 0.17 0.13 0.09 0.16 0.18 0.09 0.15 0.16 0.20 0.14 0.22 0.10 0.20 0.25 0.14 0.13 0.13 0.23 0.10 0.17 0.18 0.23 0.22 0.22 0.10 0.11 0.07 0.09 0.09 0.08 0.11 0.09 0.10 0.10 0.09 0.11 0.15 0.11 0.26 0.31 0.27 0.24 0.25 0.17 0.22 0.23 0.66 0.17 0.33 0.17 0.56 0.45 0.17 0.34 0.01 0.02 0.04 0.01 0.03 0.02 0.02 0.02 0.02 0.01 0.01 0.01 0.02 0.03 0.02 0.02 0.03 0.05 0.04 0.02 0.03 0.04 0.03 0.02 0.01 0.05 0.04 0.06 0.04 0.05 0.06 0.04 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.12 0.02 0.02 0.05 0.01 0.02 0.06 0.17 0.01 0.03 0.09 0.11 0.11 0.05 0.06 Cases 412 838 112 649 214 340 320 1233 564 714 405 802 342 42 197 239 294 20 112 185 254 185 72 123 1031 98 21 26 90 55 66 106 1293 85 76 209 213 322 588 252 640 1133 363 475 160 485 1639 21 857 310 107 750 334 52 180 598 430 38 138 61 60 81 Female ASR(W) CUM 0-74 4.2 6.7 9.4 4.2 7.7 8.1 5.2 12.4 6.0 3.5 2.5 4.5 4.9 4.7 4.7 4.1 6.3 3.4 6.5 7.4 7.4 10.1 4.4 4.0 3.3 6.5 2.4 4.6 4.8 4.9 6.6 4.9 2.4 2.6 2.3 2.3 2.6 2.3 2.6 3.0 2.8 2.3 2.2 2.7 3.0 2.7 8.1 3.9 7.8 6.5 6.9 5.0 5.9 5.3 37.4 5.1 11.5 11.7 22.5 10.4 6.8 8.5 0.22 0.24 0.91 0.18 0.55 0.46 0.31 0.37 0.27 0.14 0.13 0.16 0.28 0.76 0.37 0.28 0.38 0.83 0.65 0.56 0.48 0.80 0.56 0.39 0.11 0.69 0.57 0.95 0.55 0.75 0.87 0.51 0.07 0.30 0.29 0.17 0.19 0.14 0.12 0.20 0.12 0.07 0.12 0.13 0.25 0.13 0.21 0.94 0.27 0.39 0.69 0.19 0.33 0.75 2.87 0.22 0.57 2.01 1.94 1.35 1.02 0.99 0.44 0.69 0.85 0.41 0.78 0.81 0.51 1.18 0.57 0.37 0.26 0.45 0.48 0.44 0.46 0.38 0.60 0.31 0.61 0.72 0.67 0.94 0.41 0.40 0.31 0.64 0.26 0.45 0.46 0.48 0.65 0.47 0.22 0.25 0.22 0.21 0.25 0.22 0.24 0.28 0.26 0.22 0.20 0.24 0.29 0.25 0.77 0.41 0.74 0.59 0.65 0.46 0.53 0.45 4.18 0.48 1.11 1.20 2.18 1.02 0.68 0.81 0.02 0.03 0.08 0.02 0.06 * 0.05 0.03 0.04 * 0.03 0.02 0.01 0.02 0.03 0.07 0.04 0.03 0.04 0.07 0.06 0.05 0.05 0.07 0.05 0.04 0.01 0.07 0.07 0.09 0.06 0.07 0.09 0.05 0.01 0.03 0.03 0.02 0.02 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.14 0.03 0.04 0.07 0.02 0.03 0.07 0.37 0.02 0.06 0.22 0.20 0.15 0.10 0.10

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
559

617

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Adrenal gland (C74)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 2 30 2 0 8 3 15 4 5 118 0 3 17 2 0 1 199 19 19 3 3 0 0 4 144 2 5 30 5 25 4 53 249 17 12 62 153 53 2 1 1 0 12 33 63 6 2 0 2 1 20 32 32 25 2 23 5 1 4 148 15 132 53 9 42 28 6 20 5 89 11 76 49 25 23 16 3 13 0 2 Male ASR(W) CUM 0-74 0.1 0.6 0.2 0.2 0.4 0.5 0.4 0.3 0.6 0.1 0.2 0.1 0.1 0.4 0.3 0.2 0.1 0.3 0.2 0.5 0.8 0.1 0.4 0.2 0.4 0.3 0.4 0.3 0.2 0.2 0.3 0.4 0.4 0.2 0.1 0.2 0.5 0.5 0.3 0.3 0.2 1.0 0.5 0.2 0.5 0.3 0.4 0.3 0.4 0.5 0.2 1.3 0.4 0.3 0.4 0.3 0.2 0.4 0.5 0.3 0.6 0.2 0.3 0.3 0.3 0.4 0.4 0.2 0.2 0.1 0.2 0.3 0.04 0.11 0.12 0.09 0.24 0.14 0.23 0.15 0.06 0.05 0.06 0.04 0.15 0.03 0.08 0.06 0.07 0.17 0.12 0.05 0.64 0.07 0.07 0.10 0.09 0.16 0.06 0.02 0.05 0.07 0.04 0.04 0.06 0.15 0.05 0.23 0.14 0.10 0.04 0.12 0.16 0.87 0.48 0.05 0.10 0.06 0.08 0.18 0.09 0.26 0.20 0.79 0.04 0.08 0.05 0.05 0.07 0.06 0.10 0.14 0.14 0.09 0.04 0.09 0.04 0.06 0.09 0.05 0.05 0.06 0.07 0.21 0.05 0.04 0.01 0.03 0.04 0.01 0.02 0.00 0.02 0.03 0.02 0.02 0.01 0.01 0.02 0.04 0.06 0.02 0.02 0.01 0.03 0.01 0.03 0.03 0.01 0.02 0.02 0.03 0.03 0.03 0.00 0.01 0.03 0.04 0.02 0.02 0.03 0.07 0.02 0.01 0.03 0.02 0.03 0.02 0.03 0.03 0.01 0.06 0.03 0.02 0.03 0.02 0.02 0.02 0.03 0.03 0.03 0.01 0.02 0.03 0.02 0.03 0.02 0.02 0.01 0.01 0.02 0.01 0.03 0.02 0.01 0.02 0.00 0.01 0.01 0.00 0.02 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.05 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.02 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.05 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.03 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.02 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.01 Cases 1 16 0 0 4 1 12 2 8 149 1 11 13 3 2 4 222 26 30 9 8 7 0 4 132 1 5 31 7 24 7 47 207 14 10 53 126 36 0 2 1 0 8 23 50 7 3 2 0 0 19 19 29 24 1 23 4 2 2 143 13 124 38 5 33 14 2 12 9 85 12 67 53 22 22 46 13 32 6 6 Female ASR(W) CUM 0-74 0.0 0.2 0.3 0.1 0.4 0.2 0.4 0.7 0.1 0.3 0.2 0.1 0.2 0.3 0.4 0.4 0.3 0.3 0.5 0.7 0.2 0.4 0.2 0.2 0.3 0.2 0.3 0.4 0.4 0.3 0.2 0.2 0.2 0.3 0.3 0.2 0.2 0.3 0.3 0.2 0.3 0.4 0.2 0.2 0.3 0.3 0.3 0.1 0.3 0.4 0.3 0.7 0.4 0.3 0.4 0.2 0.1 0.3 0.2 0.1 0.4 0.2 0.3 0.2 0.3 0.4 0.3 0.2 0.4 0.3 0.5 0.5 0.4 0.03 0.06 0.17 0.13 0.11 0.16 0.15 0.06 0.11 0.08 0.04 0.05 0.12 0.16 0.03 0.09 0.07 0.12 0.20 0.31 0.13 0.04 0.23 0.12 0.06 0.10 0.07 0.16 0.06 0.02 0.05 0.05 0.03 0.03 0.05 0.18 0.19 0.11 0.08 0.03 0.11 0.28 0.18 0.05 0.07 0.06 0.06 0.08 0.08 0.22 0.22 0.60 0.04 0.07 0.05 0.04 0.03 0.06 0.07 0.04 0.12 0.07 0.03 0.07 0.04 0.06 0.07 0.05 0.07 0.10 0.10 0.22 0.22 0.02 0.02 0.01 0.02 0.04 0.01 0.02 0.02 0.01 0.02 0.03 0.03 0.03 0.02 0.02 0.04 0.04 0.01 0.03 0.02 0.02 0.02 0.02 0.02 0.04 0.03 0.02 0.01 0.01 0.02 0.02 0.02 0.02 0.01 0.02 0.02 0.02 0.02 0.03 0.02 0.02 0.02 0.02 0.02 0.01 0.02 0.03 0.02 0.04 0.03 0.02 0.03 0.01 0.00 0.02 0.01 0.00 0.02 0.03 0.02 0.02 0.02 0.03 0.02 0.02 0.04 0.04 0.04 0.06 0.03 * * * *

0.02 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.02 * 0.00 0.01 0.00 0.01 0.01 0.02 0.01 0.00 0.02 0.01 0.00 0.01 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.01 0.02 0.01 0.01 0.00 0.00 0.00 0.01 0.00 0.01 0.02 0.03 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.03 0.01

618

*Important. See note on population page.

560

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Adrenal gland (C74) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 9 55 86 9 75 36 5 31 38 8 29 4 1680 163 1448 72 7 65 11 0 5 6 180 33 142 66 6 57 23 18 83 9 71 3 205 15 173 532 31 35 76 384 29 6 23 157 13 134 16 4 33 21 19 36 4 27 4 1 71 10 7 14 64 1 41 8 1 4 73 59 12 12 9 9 25 13 70 8 Male ASR(W) CUM 0-74 0.3 0.5 0.4 0.3 0.4 0.4 0.2 0.4 0.3 0.6 0.3 0.2 0.3 0.3 0.4 0.4 0.2 0.4 0.3 0.3 0.2 0.5 0.6 0.5 0.3 0.2 0.3 0.3 0.2 0.3 0.3 0.3 0.2 0.4 0.2 0.4 0.3 0.2 0.2 0.3 0.4 0.3 0.2 0.4 0.3 0.2 0.3 0.3 0.2 0.3 0.2 0.4 0.3 0.4 0.6 0.3 0.2 0.3 0.3 0.6 0.2 0.2 0.1 0.2 0.2 0.0 0.2 0.5 0.5 0.5 0.6 0.6 0.5 0.6 0.6 0.5 0.2 0.12 0.07 0.04 0.10 0.05 0.07 0.11 0.09 0.06 0.21 0.06 0.10 0.01 0.02 0.01 0.05 0.09 0.06 0.09 0.15 0.08 0.04 0.10 0.04 0.04 0.09 0.04 0.07 0.06 0.04 0.12 0.04 0.12 0.03 0.06 0.03 0.02 0.04 0.03 0.03 0.02 0.06 0.10 0.08 0.03 0.06 0.03 0.08 0.11 0.05 0.06 0.10 0.05 0.21 0.12 0.13 0.19 0.05 0.11 0.22 0.05 0.03 0.11 0.03 0.07 0.01 0.09 0.06 0.06 0.16 0.19 0.23 0.19 0.15 0.18 0.07 0.10 0.02 0.03 0.03 0.02 0.03 0.03 0.02 0.03 0.02 0.04 0.02 0.01 0.02 0.02 0.03 0.03 0.02 0.03 0.02 0.01 0.03 0.03 0.05 0.03 0.02 0.01 0.02 0.02 0.02 0.02 0.02 0.02 0.01 0.02 0.02 0.03 0.02 0.02 0.02 0.02 0.03 0.03 0.01 0.03 0.03 0.02 0.03 0.03 0.02 0.02 0.01 0.03 0.02 0.02 0.05 0.02 0.01 0.04 0.02 0.03 0.01 0.01 0.01 0.01 0.02 0.00 0.01 0.04 0.04 0.04 0.04 0.04 0.03 0.04 0.03 0.03 0.02 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.01 Cases 7 58 76 13 61 42 15 25 45 4 41 10 1758 154 1519 70 4 63 8 0 2 6 200 19 172 82 5 75 25 24 101 13 83 11 196 18 161 515 28 46 72 362 29 5 24 178 12 162 12 4 50 35 12 50 0 12 2 0 48 2 3 17 34 2 28 1 2 4 50 38 9 6 7 6 15 9 50 7 Female ASR(W) CUM 0-74 0.3 0.4 0.3 0.4 0.3 0.5 0.6 0.4 0.4 0.2 0.4 0.6 0.3 0.2 0.3 0.4 0.1 0.4 0.2 0.1 0.3 0.4 0.3 0.5 0.3 0.2 0.3 0.3 0.2 0.4 0.4 0.3 0.4 0.3 0.2 0.3 0.3 0.2 0.2 0.2 0.3 0.3 0.2 0.3 0.3 0.2 0.4 0.2 0.3 0.4 0.4 0.2 0.3 0.3 0.1 0.2 0.0 0.2 0.2 0.1 0.2 0.1 0.0 0.0 0.1 0.3 0.3 0.3 0.4 0.6 0.4 0.3 0.3 0.4 0.1 0.13 0.06 0.04 0.11 0.04 0.08 0.17 0.09 0.06 0.12 0.07 0.22 0.01 0.02 0.01 0.05 0.06 0.06 0.07 0.09 0.18 0.03 0.06 0.04 0.04 0.08 0.04 0.07 0.05 0.04 0.12 0.04 0.15 0.03 0.06 0.03 0.01 0.04 0.03 0.03 0.02 0.06 0.08 0.08 0.03 0.06 0.03 0.07 0.18 0.06 0.07 0.07 0.05 0.10 0.10 0.04 0.03 0.12 0.05 0.02 0.16 0.02 0.02 0.03 0.08 0.05 0.05 0.11 0.18 0.24 0.19 0.10 0.14 0.06 0.09 0.02 0.03 0.02 0.03 0.02 0.04 0.06 0.03 0.03 0.02 0.03 0.04 0.02 0.02 0.03 0.03 0.01 0.03 0.01 0.01 0.02 0.03 0.02 0.03 0.02 0.01 0.02 0.02 0.02 0.03 0.03 0.02 0.03 0.02 0.02 0.02 0.02 0.01 0.02 0.02 0.02 0.03 0.01 0.03 0.03 0.02 0.03 0.01 0.02 0.03 0.03 0.02 0.03 0.02 0.03 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.02 0.02 0.02 0.02 0.03 0.02 0.02 0.02 0.02 0.01 0.01 0.00 0.00 0.01 0.00 0.01 0.02 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.01 * 0.02 * 0.00 * 0.00 * 0.01 * 0.00 0.00 * 0.01 0.00 0.00 * 0.01 * 0.01 * 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
561

619

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Adrenal gland (C74) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
562

Male ASR(W) CUM 0-74 0.4 0.3 0.3 0.4 0.4 0.3 0.1 0.5 0.3 0.2 0.4 0.1 0.1 0.1 0.1 0.2 0.3 0.3 0.5 0.1 0.1 0.2 0.3 0.3 0.5 0.0 0.7 0.5 0.3 0.5 0.2 0.6 0.3 0.4 0.3 0.2 0.4 0.4 0.8 0.6 0.4 0.5 0.4 0.5 0.8 0.1 0.3 0.4 0.3 0.1 0.3 0.4 0.7 0.9 0.4 0.2 0.8 0.6 0.5 0.1 0.6 0.5 0.5 1.1 0.4 0.1 0.2 0.8 0.3 0.2 0.1 0.9 0.4 0.5 0.4 0.02 0.07 0.09 0.13 0.14 0.09 0.08 0.05 0.12 0.09 0.38 0.06 0.05 0.08 0.06 0.06 0.07 0.08 0.23 0.05 0.07 0.09 0.10 0.06 0.06 0.04 0.36 0.05 0.10 0.08 0.03 0.08 0.04 0.06 0.09 0.04 0.16 0.15 0.28 0.22 0.15 0.17 0.14 0.28 0.26 0.15 0.10 0.09 0.12 0.08 0.10 0.09 0.27 0.40 0.07 0.16 0.26 0.45 0.20 0.08 0.64 0.20 0.28 0.35 0.12 0.04 0.09 0.27 0.11 0.10 0.08 0.33 0.17 0.32 0.11 0.03 0.03 0.02 0.03 0.04 0.02 0.01 0.03 0.02 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.02 0.02 0.02 0.01 0.00 0.01 0.02 0.03 0.03 0.00 0.03 0.05 0.02 0.04 0.02 0.05 0.03 0.03 0.04 0.02 0.03 0.04 0.06 0.04 0.04 0.02 0.02 0.02 0.06 0.01 0.02 0.02 0.03 0.01 0.02 0.03 0.03 0.07 0.02 0.04 0.06 0.04 0.04 0.02 0.03 0.03 0.03 0.06 0.03 0.04 0.06 0.04 0.02 0.01 0.05 0.03 0.04 0.03 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.00 0.01 0.01 0.02 0.00 0.00 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.02 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.03 0.00 0.03 0.02 0.02 0.01 0.01 0.03 0.01 0.01 0.02 0.01 0.02 0.02 0.01 0.01 0.01 0.02 0.01 0.02 0.01

Cases 233 9 16 12 7 16 3 51 3 2 7 12 3 9 2 8 19 15 1 3 4 2 9 8 14 72 4 3 116 9 60 48 66 99 44 19 68 8 6 3 3 8 12 6 3 7 0 6 31 32 13 15 22 27 4 3 35 1 6 2 8 8 0 13 3 5 19 2 5 5 10 13 5 3 4 17 8 6 18

Female ASR(W) CUM 0-74 0.3 0.1 0.3 0.4 0.3 0.3 0.4 0.3 0.2 0.1 1.4 0.6 0.1 0.3 0.0 0.1 0.3 0.3 0.2 0.3 0.1 0.1 0.4 0.3 0.2 0.4 0.3 0.6 0.4 0.2 0.5 0.2 0.5 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.2 0.4 0.6 0.2 0.3 0.3 0.4 0.7 0.3 0.2 0.4 0.4 0.4 0.2 0.4 0.4 0.0 0.3 0.6 0.4 0.5 0.5 0.2 0.4 0.4 0.4 0.7 0.3 0.4 0.8 0.2 0.3 0.4 0.5 0.3 0.8 0.4 0.02 0.05 0.09 0.14 0.10 0.08 0.26 0.04 0.13 0.05 0.68 0.18 0.04 0.12 0.03 0.03 0.08 0.08 0.25 0.20 0.06 0.06 0.12 0.09 0.05 0.05 0.15 0.35 0.04 0.07 0.08 0.03 0.08 0.03 0.06 0.08 0.05 0.11 0.15 0.17 0.12 0.17 0.18 0.11 0.20 0.14 0.19 0.17 0.08 0.07 0.16 0.10 0.10 0.11 0.25 0.07 0.04 0.13 0.49 0.19 0.29 0.20 0.11 0.19 0.13 0.33 0.38 0.18 0.19 0.26 0.08 0.18 0.24 0.22 0.17 0.39 0.12 0.02 0.01 0.02 0.02 0.02 0.02 0.03 0.02 0.02 0.00 0.06 0.03 0.01 0.03 0.00 0.01 0.02 0.02 0.01 0.03 0.01 0.01 0.02 0.03 0.02 0.03 0.02 0.03 0.03 0.02 0.04 0.02 0.04 0.03 0.02 0.04 0.04 0.03 0.03 0.02 0.01 0.03 0.04 0.02 0.02 0.04 0.04 0.04 0.02 0.02 0.03 0.03 0.03 0.01 0.04 0.03 0.03 0.03 0.02 0.03 0.03 0.02 0.03 0.03 0.02 0.04 0.03 0.03 0.05 0.02 0.03 0.04 0.05 0.02 0.03 0.03 0.00 0.00 0.00 0.01 0.01 0.01 0.02 0.00 0.01 0.00 0.03 0.01 0.01 0.01 * 0.00 * 0.00 * 0.00 0.01 0.01 0.02 0.00 * 0.00 * 0.01 0.01 * 0.00 * 0.00 0.01 0.02 0.00 * 0.01 * 0.01 0.00 * 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.02 0.03 0.01 0.01 0.02 0.01

267 24 17 9 11 16 1 83 5 5 3 2 5 3 5 20 20 15 0 5 4 1 5 8 19 72 1 4 127 9 51 50 71 95 43 13 39 8 7 9 10 10 8 8 3 10 0 1 16 31 11 4 14 22 9 6 32 2 14 3 12 3 1 11 4 11 18 2 0 5 17 10 3 1 0 10 11 4 16

620

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Adrenal gland (C74) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 35 46 1 27 14 22 27 16 25 51 44 36 15 1 13 17 15 2 5 9 16 5 4 4 55 0 2 0 3 3 2 8 98 9 1 14 15 27 52 22 80 117 32 44 16 42 67 1 25 7 1 31 20 3 5 34 9 4 0 1 2 2 Male ASR(W) CUM 0-74 0.5 0.5 0.1 0.2 0.6 0.5 0.6 0.3 0.5 0.4 0.4 0.3 0.3 0.0 0.7 0.4 0.5 0.3 0.5 0.5 0.7 0.3 0.2 0.1 0.2 0.3 0.2 0.5 0.2 0.7 0.3 0.4 0.0 0.2 0.3 0.3 0.4 0.3 0.5 0.4 0.3 0.3 0.4 0.4 0.4 0.3 0.3 0.2 0.0 0.3 0.5 0.5 0.9 0.4 0.4 2.6 0.2 0.7 0.2 0.09 0.07 0.08 0.05 0.15 0.11 0.16 0.08 0.11 0.06 0.06 0.05 0.08 0.04 0.28 0.12 0.15 0.23 0.26 0.19 0.20 0.20 0.11 0.06 0.04 0.18 0.10 0.35 0.16 0.28 0.03 0.14 0.03 0.06 0.09 0.07 0.06 0.08 0.06 0.04 0.06 0.06 0.10 0.07 0.06 0.29 0.07 0.07 0.03 0.05 0.12 0.31 0.43 0.07 0.13 1.34 0.19 0.63 0.14 0.06 0.05 0.01 0.02 0.08 0.06 0.06 0.02 0.03 0.05 0.03 0.03 0.03 0.05 0.03 0.04 0.03 0.03 0.04 0.05 0.02 0.02 0.01 0.02 0.04 0.02 0.04 0.03 0.04 0.02 0.03 0.00 0.01 0.02 0.02 0.02 0.02 0.03 0.03 0.02 0.03 0.03 0.03 0.03 0.04 0.02 0.02 0.02 0.03 0.05 0.13 0.03 0.02 0.15 0.01 0.04 0.03 0.01 0.01 0.01 0.00 0.02 0.01 0.01 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.03 0.01 0.02 0.02 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.04 0.01 0.01 0.00 0.01 0.03 0.08 0.01 0.01 0.08 0.01 0.03 0.02 Cases 44 44 5 40 16 18 22 18 9 50 37 24 8 3 13 18 10 1 1 5 7 7 7 6 60 4 0 4 2 2 0 4 112 2 2 12 29 31 61 23 67 125 41 33 14 43 56 0 29 11 4 36 14 2 1 31 12 0 2 3 2 5 Female ASR(W) CUM 0-74 0.5 0.4 0.5 0.3 0.5 0.5 0.4 0.3 0.1 0.4 0.3 0.1 0.2 0.6 0.5 0.5 0.5 0.1 0.0 0.3 0.2 0.8 0.5 0.5 0.3 0.3 1.1 0.1 0.3 0.5 0.3 0.1 0.1 0.2 0.4 0.3 0.4 0.3 0.4 0.4 0.3 0.3 0.4 0.4 0.3 0.4 0.3 0.5 0.3 0.4 0.4 0.2 0.4 0.5 0.4 0.6 0.1 1.3 0.10 0.06 0.25 0.06 0.12 0.14 0.13 0.07 0.05 0.08 0.05 0.03 0.07 0.38 0.24 0.16 0.16 0.13 0.01 0.19 0.10 0.37 0.26 0.27 0.04 0.23 0.62 0.08 0.27 0.24 0.03 0.08 0.11 0.07 0.10 0.06 0.06 0.07 0.06 0.04 0.06 0.05 0.12 0.07 0.05 0.08 0.11 0.28 0.05 0.12 0.26 0.21 0.08 0.16 0.32 0.33 0.11 0.65 0.04 0.03 0.04 0.03 0.06 0.04 0.04 0.02 0.01 0.03 0.02 0.01 0.01 0.04 0.04 0.03 0.03 0.02 0.02 0.02 0.04 0.04 0.03 0.02 0.03 0.08 0.01 0.03 0.02 0.02 0.01 0.01 0.01 0.03 0.02 0.03 0.03 0.03 0.03 0.02 0.02 0.03 0.03 0.02 0.02 0.02 0.03 0.02 0.02 0.02 0.01 0.03 0.03 0.03 0.06 0.01 0.06 0.01 0.01 0.02 0.00 0.02 * 0.01 0.01 0.00 * 0.00 0.00 0.00 0.00 0.01 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.02 0.02 0.01 0.00 0.02 0.04 0.01 0.02 0.01 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.03 0.04 0.01 0.03

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
563

621

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other endocrine (C75)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 0 3 1 0 3 3 16 2 4 75 5 2 5 0 2 1 86 5 11 2 3 2 0 3 57 0 3 19 5 14 3 23 147 20 6 36 81 37 2 4 1 1 5 21 36 3 0 2 0 1 13 15 19 12 2 10 5 1 2 69 13 56 20 6 13 6 3 3 4 39 5 29 23 9 13 27 8 18 3 1 Male ASR(W) CUM 0-74 0.0 0.1 0.3 0.4 0.5 0.2 0.2 0.3 0.6 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.1 0.2 0.2 0.2 0.3 0.2 0.9 0.2 0.3 0.2 0.2 0.3 0.3 0.2 0.2 0.2 0.1 0.3 0.1 0.4 0.1 0.3 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.3 0.1 0.03 0.10 0.18 0.21 0.14 0.14 0.13 0.04 0.27 0.03 0.03 0.11 0.05 0.02 0.03 0.04 0.06 0.09 0.08 0.09 0.02 0.06 0.04 0.08 0.05 0.10 0.04 0.02 0.05 0.05 0.03 0.03 0.04 0.14 0.18 0.15 0.91 0.07 0.07 0.03 0.09 0.23 0.26 0.05 0.06 0.04 0.04 0.18 0.05 0.17 0.10 0.20 0.02 0.06 0.03 0.02 0.05 0.03 0.04 0.06 0.05 0.06 0.02 0.04 0.02 0.04 0.05 0.03 0.05 0.08 0.06 0.18 0.11 0.07 0.04 0.01 0.02 0.04 0.07 0.00 0.01 0.02 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.01 0.05 0.01 0.02 0.02 0.01 0.02 0.01 0.02 0.02 0.02 0.01 0.05 0.01 0.03 0.01 0.03 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.01 0.04 0.01 0.01 0.02 0.01 0.04 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.05 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.04 0.00 0.01 0.01 0.02 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 Cases 0 0 0 1 8 1 17 2 4 76 1 0 3 2 2 0 104 6 7 0 1 0 0 4 84 0 2 17 7 9 0 12 81 12 7 22 39 16 1 1 1 0 4 8 24 5 1 1 1 1 6 6 12 10 0 9 1 1 0 47 11 36 14 4 8 5 2 2 3 35 7 25 18 7 10 12 6 6 2 2 Female ASR(W) CUM 0-74 0.0 0.3 0.1 0.6 0.3 0.2 0.3 0.1 0.0 0.0 0.2 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.02 0.14 0.13 0.16 0.25 0.09 0.03 0.12 0.02 0.03 0.13 0.02 0.03 0.03 0.01 0.08 0.03 0.07 0.03 0.08 0.04 0.02 0.01 0.03 0.04 0.02 0.02 0.02 0.05 0.13 0.11 0.07 0.03 0.02 0.08 0.05 0.10 0.25 0.07 0.03 0.04 0.03 0.04 0.05 0.05 0.08 0.02 0.05 0.02 0.02 0.03 0.02 0.03 0.06 0.03 0.05 0.02 0.05 0.02 0.03 0.03 0.03 0.03 0.07 0.04 0.11 0.07 0.02 0.08 0.03 0.01 0.03 0.01 0.00 0.00 0.02 0.01 0.01 0.00 0.01 0.02 0.01 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 * * * *

0.02 0.02 0.03 0.01 0.00 0.01 0.00 0.00 0.01 - * 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01

622

*Important. See note on population page.

564

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other endocrine (C75) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 10 21 34 8 24 22 7 15 26 1 24 2 895 103 725 39 5 34 5 0 2 3 95 17 74 30 2 25 9 13 51 4 46 6 113 15 83 317 30 34 52 196 10 3 7 85 6 77 12 3 18 15 8 19 0 2 5 4 239 2 1 13 13 0 19 4 11 1 21 19 2 5 7 10 13 8 44 4 Male ASR(W) CUM 0-74 0.3 0.2 0.1 0.2 0.1 0.2 0.3 0.2 0.2 0.1 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.1 0.2 0.2 0.3 0.2 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.1 0.0 0.5 0.2 1.2 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.1 0.2 0.1 0.2 0.2 0.4 0.3 0.3 0.2 0.1 0.10 0.03 0.02 0.08 0.02 0.05 0.11 0.05 0.04 0.07 0.04 0.05 0.01 0.02 0.01 0.03 0.08 0.04 0.05 0.07 0.12 0.02 0.06 0.02 0.02 0.04 0.02 0.03 0.05 0.03 0.07 0.03 0.13 0.02 0.05 0.02 0.01 0.04 0.03 0.02 0.01 0.03 0.08 0.05 0.02 0.05 0.02 0.07 0.10 0.03 0.04 0.07 0.03 0.02 0.26 0.13 0.08 0.03 0.07 0.03 0.02 0.02 0.05 0.05 0.03 0.03 0.04 0.04 0.09 0.10 0.14 0.08 0.10 0.04 0.08 0.02 0.01 0.01 0.02 0.01 0.02 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.01 0.01 0.01 0.02 0.02 0.02 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.04 0.02 0.12 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.00 0.01 0.03 0.03 0.02 0.02 0.02 0.01 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.00 0.02 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.00 0.01 0.00 0.00 0.02 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 Cases 4 16 27 6 19 10 3 6 13 1 12 5 613 96 481 32 4 26 10 1 3 6 63 10 52 24 4 20 9 4 31 4 26 4 71 6 53 193 19 22 35 112 8 4 4 90 11 74 6 1 8 6 2 17 2 2 4 0 304 0 2 7 13 0 21 1 13 0 14 11 1 3 10 5 3 8 16 4 Female ASR(W) CUM 0-74 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.2 0.2 0.1 0.0 0.1 0.0 0.1 0.1 0.2 0.0 0.4 1.4 0.2 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.1 0.4 0.2 0.1 0.2 0.1 0.1 0.07 0.03 0.02 0.05 0.02 0.03 0.04 0.04 0.02 0.05 0.03 0.09 0.00 0.01 0.00 0.02 0.06 0.03 0.06 0.18 0.09 0.11 0.02 0.04 0.02 0.02 0.06 0.02 0.02 0.03 0.02 0.06 0.02 0.05 0.01 0.03 0.01 0.01 0.03 0.02 0.02 0.01 0.03 0.06 0.02 0.02 0.06 0.02 0.04 0.01 0.02 0.02 0.04 0.03 0.13 0.03 0.20 0.09 0.12 0.02 0.02 0.02 0.01 0.05 0.02 0.02 0.06 0.07 0.15 0.08 0.04 0.08 0.03 0.06 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.03 0.14 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.04 0.01 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 * 0.02 * 0.01 * - * 0.01 * 0.00 0.00 * 0.00 0.00 * 0.00 * - * 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.00

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
565

623

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other endocrine (C75) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
566

Male ASR(W) CUM 0-74 0.2 0.2 0.2 0.2 0.2 0.3 0.3 0.2 0.1 0.0 0.2 0.2 0.1 0.0 0.0 0.3 0.3 0.3 0.1 0.0 0.1 0.1 0.2 0.1 0.2 0.1 0.0 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.0 0.2 0.2 0.1 0.1 0.1 0.2 0.2 0.1 0.0 0.2 0.2 0.3 0.3 0.2 0.1 0.1 0.3 0.0 0.1 0.1 0.6 0.1 0.0 0.1 0.0 0.6 0.4 0.2 0.3 0.1 0.1 0.02 0.05 0.05 0.08 0.08 0.07 0.04 0.09 0.05 0.02 0.11 0.07 0.07 0.03 0.02 0.07 0.08 0.15 0.06 0.03 0.06 0.04 0.03 0.08 0.15 0.01 0.01 0.04 0.03 0.04 0.02 0.03 0.06 0.04 0.07 0.11 0.07 0.10 0.07 0.05 0.12 0.18 0.09 0.02 0.02 0.07 0.06 0.04 0.02 0.09 0.22 0.05 0.23 0.11 0.07 0.10 0.13 0.02 0.09 0.03 0.33 0.07 0.03 0.04 0.03 0.20 0.23 0.12 0.15 0.08 0.06 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.00 0.00 0.02 0.02 0.02 0.00 0.00 0.02 0.02 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.03 0.03 0.01 0.01 0.04 0.00 0.01 0.04 0.02 0.01 0.06 0.03 0.01 0.02 0.01 0.01 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.01 0.02 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.00 0.01 0.01 0.00 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.00 0.01 0.01 0.00 0.02 0.02 0.00 0.02 0.02 0.01 0.01 0.01 0.00

Cases 94 12 3 3 3 9 2 31 5 0 1 10 3 1 10 3 6 2 2 2 2 1 1 2 8 35 1 1 15 0 14 20 39 24 16 0 24 2 5 3 0 4 5 3 2 0 1 3 13 27 4 4 7 5 1 1 18 3 4 1 7 1 0 1 4 2 13 3 1 1 2 3 13 0 1 0 6 2 7

Female ASR(W) CUM 0-74 0.1 0.1 0.0 0.1 0.1 0.1 0.3 0.1 0.3 0.1 0.4 0.1 0.0 0.3 0.0 0.1 0.0 0.3 0.2 0.0 0.0 0.0 0.1 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.2 0.0 0.3 0.2 0.1 0.2 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.0 0.1 0.0 0.0 0.2 0.1 0.2 0.4 0.1 0.1 0.1 0.1 0.8 0.0 0.2 0.1 0.2 0.01 0.04 0.03 0.05 0.04 0.05 0.21 0.02 0.13 0.05 0.12 0.03 0.02 0.11 0.02 0.04 0.03 0.23 0.14 0.03 0.03 0.04 0.05 0.03 0.03 0.05 0.08 0.01 0.03 0.02 0.04 0.02 0.03 0.04 0.04 0.12 0.15 0.08 0.08 0.04 0.13 0.02 0.07 0.03 0.03 0.05 0.09 0.05 0.04 0.07 0.05 0.04 0.08 0.06 0.03 0.04 0.02 0.01 0.18 0.08 0.08 0.30 0.11 0.06 0.06 0.07 0.23 0.05 0.11 0.09 0.07 0.01 0.01 0.01 0.01 0.00 0.01 0.02 0.01 0.03 0.00 0.03 0.00 0.00 0.03 0.00 0.01 0.00 0.04 0.01 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.02 0.01 0.01 0.01 0.00 0.03 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.02 0.02 0.01 0.01 0.00 0.00 0.01 0.02 0.02 0.03 0.01 0.01 0.01 0.01 0.07 0.02 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.02 0.00 0.01 0.00 0.00 * 0.01 * 0.00 * 0.00 0.00 0.04 0.01 0.00 * 0.00 * 0.00 0.01 * 0.00 * 0.00 0.01 0.01 0.00 * - * 0.00 0.00 * 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.00 0.01 0.02 0.01 0.01 0.01

201 17 9 7 7 16 0 61 3 2 1 5 10 2 3 6 20 17 0 3 4 1 0 3 9 39 2 2 17 1 22 31 26 39 15 3 20 4 2 0 2 5 3 1 0 2 2 1 5 15 7 8 6 4 4 1 32 2 5 1 3 6 0 0 1 1 11 5 1 2 2 2 10 3 0 3 7 2 6

624

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other endocrine (C75) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 5 7 1 17 3 9 11 21 21 13 39 15 3 3 6 3 1 0 2 5 7 1 3 2 28 3 0 1 1 0 0 3 36 1 3 16 16 18 33 13 51 49 10 22 5 14 25 0 12 3 1 21 6 1 4 17 9 0 3 3 1 2 Male ASR(W) CUM 0-74 0.1 0.1 0.1 0.1 0.1 0.3 0.2 0.3 0.3 0.1 0.3 0.1 0.1 0.6 0.3 0.1 0.0 0.2 0.4 0.3 0.0 0.2 0.1 0.1 0.2 0.2 0.1 0.3 0.1 0.0 0.1 0.2 0.3 0.2 0.2 0.2 0.3 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.6 0.2 0.3 0.6 0.5 0.1 0.5 0.04 0.03 0.15 0.04 0.07 0.10 0.07 0.06 0.07 0.03 0.05 0.03 0.03 0.33 0.12 0.03 0.02 0.13 0.18 0.10 0.05 0.10 0.12 0.03 0.12 0.20 0.10 0.15 0.02 0.03 0.05 0.06 0.07 0.04 0.04 0.06 0.04 0.02 0.03 0.04 0.05 0.03 0.03 0.04 0.04 0.10 0.04 0.05 0.10 0.35 0.04 0.11 0.37 0.27 0.11 0.35 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.01 0.03 0.01 0.00 0.03 0.02 0.00 0.01 0.02 0.02 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.00 0.01 0.02 0.02 0.01 0.01 0.02 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.08 0.01 0.02 0.04 0.03 0.01 0.03 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.02 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.02 0.01 0.01 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.05 0.00 0.01 0.03 0.02 0.01 0.02 Cases 4 9 1 11 2 12 10 10 15 12 37 7 0 1 5 4 2 0 0 2 2 1 2 3 34 4 0 0 0 0 0 4 19 2 1 8 4 6 23 8 51 42 11 15 6 8 6 0 6 2 1 15 2 1 2 8 4 0 0 0 1 0 Female ASR(W) CUM 0-74 0.1 0.1 0.1 0.1 0.1 0.4 0.2 0.1 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.2 0.3 0.1 0.2 0.3 0.04 0.02 0.09 0.02 0.05 0.13 0.06 0.04 0.04 0.02 0.04 0.02 0.14 0.04 0.04 0.04 0.08 0.05 0.07 0.08 0.10 0.02 0.12 0.11 0.01 0.06 0.03 0.03 0.03 0.02 0.03 0.03 0.04 0.02 0.03 0.03 0.05 0.02 0.01 0.02 0.05 0.06 0.03 0.02 0.15 0.24 0.03 0.08 0.29 0.01 0.01 0.01 0.01 0.01 0.03 0.01 0.01 0.01 0.01 0.02 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.02 0.03 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.02 0.00 0.01 0.02 0.00 0.00 0.01 0.00 0.00 * 0.01 0.01 0.00 * 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.00 0.00 0.02 -

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
567

625

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Hodgkin lymphoma (C81)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 50 180 31 37 27 16 75 24 41 627 19 79 183 43 9 10 1751 233 285 76 50 27 1 68 932 8 71 273 61 209 33 305 2281 112 146 524 1453 491 26 21 12 1 82 317 627 70 8 6 2 3 213 308 318 300 27 265 50 26 22 1216 118 1066 562 148 402 223 71 143 93 973 114 815 477 216 342 290 65 223 21 48 Male ASR(W) CUM 0-74 1.5 2.5 2.8 1.4 0.9 2.1 2.3 2.7 2.0 2.5 2.2 1.9 1.9 1.4 0.8 0.8 2.7 2.8 2.5 2.4 2.5 1.8 0.9 2.7 2.9 2.3 2.6 2.3 2.2 2.2 2.0 2.1 2.4 1.0 2.2 2.2 3.1 2.7 1.9 1.6 1.2 0.7 2.5 3.6 2.5 2.7 0.8 0.8 1.1 0.6 2.4 3.4 2.7 3.3 3.0 3.4 3.1 2.8 3.2 2.7 1.9 2.8 2.5 2.5 2.5 2.8 2.6 2.9 2.7 2.9 2.5 2.9 2.9 2.6 3.2 2.4 1.9 2.8 2.0 3.3 0.23 0.20 0.53 0.32 0.21 0.53 0.30 0.61 0.33 0.11 0.50 0.22 0.15 0.23 0.29 0.26 0.07 0.19 0.15 0.28 0.38 0.37 0.89 0.35 0.10 0.84 0.31 0.14 0.28 0.16 0.36 0.13 0.05 0.10 0.19 0.10 0.09 0.13 0.38 0.37 0.36 0.72 0.30 0.22 0.10 0.33 0.30 0.33 0.77 0.35 0.18 0.21 0.15 0.20 0.59 0.23 0.45 0.56 0.75 0.08 0.18 0.09 0.11 0.22 0.13 0.19 0.32 0.26 0.29 0.09 0.23 0.11 0.14 0.19 0.18 0.15 0.23 0.19 0.43 0.51 0.19 0.21 0.26 0.17 0.20 0.24 0.15 0.16 0.13 0.07 0.06 0.23 0.23 0.21 0.21 0.22 0.14 0.06 0.22 0.24 0.18 0.22 0.19 0.17 0.20 0.18 0.18 0.21 0.09 0.20 0.21 0.26 0.24 0.19 0.15 0.10 0.05 0.25 0.30 0.22 0.23 0.07 0.08 0.06 0.03 0.23 0.29 0.23 0.27 0.20 0.28 0.29 0.30 0.24 0.23 0.16 0.24 0.22 0.23 0.22 0.22 0.21 0.23 0.21 0.25 0.20 0.25 0.24 0.23 0.26 0.21 0.16 0.24 0.19 0.31 0.05 0.04 0.09 0.03 0.01 0.07 0.02 0.02 0.03 0.03 0.02 0.01 0.02 0.01 0.03 0.03 0.03 0.06 0.03 0.01 0.07 0.03 0.01 0.02 0.02 0.04 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.05 0.04 0.03 0.05 0.04 0.02 0.01 0.03 0.03 0.04 0.04 0.02 0.02 0.02 0.01 0.02 0.04 0.02 0.05 0.06 0.06 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.03 0.02 0.02 0.01 0.02 0.01 0.01 0.02 0.02 0.01 0.02 0.02 0.05 0.05 Cases 46 83 18 24 16 20 58 14 37 544 8 69 154 29 8 8 1410 181 194 54 46 18 0 59 780 10 68 223 46 173 27 235 1789 110 102 389 1164 361 19 13 15 2 55 233 505 51 2 17 2 2 153 273 240 285 26 252 35 19 13 985 103 864 454 121 329 184 57 123 89 766 94 640 402 203 274 284 66 216 23 41 Female ASR(W) CUM 0-74 1.2 1.2 1.4 1.6 0.4 2.2 1.5 1.5 1.6 1.8 0.8 1.4 1.6 0.8 0.8 0.6 2.2 2.3 1.8 1.8 2.3 1.3 2.4 2.4 2.7 2.5 1.8 1.4 1.9 1.8 1.6 1.9 0.9 1.5 1.6 2.6 2.0 1.4 0.7 1.7 0.9 1.8 2.7 1.9 1.7 0.1 1.9 0.6 0.3 1.6 3.2 2.1 3.1 2.4 3.3 2.0 1.8 1.8 2.1 1.5 2.3 2.0 1.8 2.1 2.2 1.8 2.6 2.5 2.2 1.7 2.3 2.4 2.6 2.4 2.2 1.6 2.6 1.8 2.9 0.19 0.14 0.33 0.42 0.13 0.52 0.22 0.44 0.28 0.08 0.30 0.19 0.13 0.16 0.28 0.22 0.06 0.18 0.14 0.25 0.36 0.33 0.33 0.09 0.89 0.31 0.12 0.21 0.16 0.35 0.11 0.05 0.09 0.15 0.08 0.08 0.11 0.34 0.22 0.45 0.68 0.25 0.19 0.09 0.24 0.08 0.48 0.41 0.20 0.13 0.22 0.14 0.20 0.48 0.22 0.35 0.44 0.52 0.07 0.15 0.09 0.10 0.17 0.12 0.17 0.24 0.25 0.27 0.08 0.18 0.10 0.13 0.19 0.15 0.14 0.20 0.19 0.39 0.49 0.21 0.13 0.17 0.16 0.15 0.10 0.16 0.13 0.08 0.06 0.04 0.17 0.18 0.14 0.15 0.18 0.09 0.18 0.19 0.21 0.19 0.14 0.11 0.15 0.13 0.13 0.16 0.07 0.14 0.14 0.21 0.17 0.09 0.07 0.12 0.06 0.17 0.22 0.16 0.15 0.01 0.13 0.04 0.02 0.14 0.25 0.18 0.25 0.20 0.26 0.16 0.16 0.15 0.17 0.13 0.18 0.16 0.14 0.17 0.18 0.14 0.20 0.21 0.18 0.15 0.19 0.19 0.20 0.19 0.17 0.13 0.20 0.14 0.22 * * * *

0.05 0.02 0.07 0.04 0.01 0.04 0.03 0.01 0.02 0.02 0.02 * 0.01 0.01 0.01 0.02 0.03 0.02 0.03 0.01 0.07 0.03 0.01 0.02 0.01 0.03 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.02 0.02 0.03 0.05 0.03 0.02 0.01 0.02 0.01 0.03 0.03 0.02 0.01 0.02 0.01 0.02 0.04 0.02 0.03 0.04 0.05 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.02 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.02 0.03 0.04

626

*Important. See note on population page.

568

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Hodgkin lymphoma (C81) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 135 576 797 99 682 349 68 276 419 39 376 65 17078 1677 14764 729 85 612 118 1 41 73 1737 226 1468 893 80 784 267 255 1136 100 1007 89 2023 210 1686 5363 196 515 741 3832 233 59 169 1370 139 1192 127 54 477 315 138 454 18 34 157 3 2 90 14 50 129 474 3 261 42 67 19 565 470 86 13 13 16 41 19 109 12 Male ASR(W) CUM 0-74 3.9 3.4 3.0 2.8 3.1 3.3 2.7 3.7 2.8 2.5 2.9 2.5 2.8 2.4 2.9 3.3 2.7 3.5 2.3 0.2 2.2 3.0 3.4 3.1 3.7 3.0 2.5 3.0 2.8 2.7 3.4 3.1 3.5 3.1 2.8 2.5 3.0 2.6 1.2 2.4 2.4 3.1 2.1 2.0 2.1 2.4 2.2 2.5 2.1 3.2 2.9 2.8 2.9 3.1 1.8 0.6 0.9 0.2 0.1 0.5 0.4 2.8 1.2 1.5 0.3 0.9 0.9 0.8 0.7 3.7 3.7 3.2 0.4 0.5 0.5 0.5 0.4 0.4 0.2 0.35 0.15 0.11 0.29 0.12 0.18 0.34 0.23 0.14 0.41 0.16 0.33 0.02 0.06 0.02 0.13 0.30 0.15 0.22 0.20 0.34 0.38 0.08 0.21 0.10 0.10 0.28 0.11 0.17 0.18 0.11 0.31 0.11 0.34 0.06 0.18 0.07 0.04 0.08 0.11 0.09 0.05 0.14 0.27 0.17 0.07 0.19 0.07 0.19 0.45 0.14 0.16 0.26 0.15 0.43 0.10 0.08 0.14 0.05 0.05 0.12 0.40 0.11 0.08 0.19 0.06 0.14 0.10 0.16 0.15 0.17 0.38 0.13 0.17 0.13 0.09 0.09 0.04 0.07 0.32 0.29 0.25 0.25 0.25 0.28 0.24 0.30 0.24 0.22 0.24 0.22 0.24 0.21 0.25 0.28 0.22 0.29 0.21 0.21 0.26 0.28 0.25 0.30 0.24 0.20 0.24 0.23 0.23 0.29 0.27 0.29 0.28 0.24 0.22 0.25 0.23 0.10 0.21 0.22 0.26 0.19 0.18 0.19 0.21 0.19 0.22 0.18 0.26 0.25 0.24 0.22 0.26 0.11 0.05 0.07 0.04 0.01 0.04 0.03 0.21 0.10 0.13 0.03 0.08 0.09 0.08 0.05 0.31 0.31 0.28 0.03 0.05 0.05 0.04 0.03 0.04 0.02 0.03 0.01 0.01 0.03 0.01 0.02 0.03 0.02 0.01 0.04 0.01 0.03 0.00 0.01 0.00 0.01 0.03 0.01 0.02 0.04 0.03 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.02 0.01 0.03 0.01 0.03 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.03 0.02 0.01 0.02 0.01 0.02 0.04 0.01 0.02 0.02 0.01 0.03 0.01 0.01 0.02 0.01 0.01 0.01 0.03 0.01 0.01 0.02 0.01 0.02 0.01 0.01 0.01 0.02 0.04 0.01 0.01 0.01 0.01 0.01 0.00 0.01 Cases 80 505 672 84 575 310 67 239 324 26 296 66 14009 1349 12155 689 77 600 76 2 23 51 1490 155 1297 748 68 658 192 200 952 72 865 78 1696 181 1420 4515 160 424 533 3346 219 56 159 1032 126 879 112 55 388 268 116 379 15 23 101 4 2 44 8 63 59 176 1 118 15 37 15 540 461 69 8 6 10 27 12 54 7 Female ASR(W) CUM 0-74 2.3 2.7 2.5 2.1 2.5 2.8 2.2 3.1 2.1 1.4 2.2 2.7 2.2 1.7 2.4 3.0 2.2 3.3 1.5 0.3 1.2 2.4 2.8 1.8 3.1 2.3 1.9 2.4 2.0 2.2 2.7 2.1 2.8 2.6 2.3 1.9 2.6 2.2 0.9 1.8 1.7 2.7 2.0 1.7 2.1 1.8 1.9 1.8 1.8 3.4 2.5 2.5 2.1 2.6 1.8 0.4 0.5 0.8 0.1 0.2 0.2 3.5 0.5 0.8 0.1 0.5 0.3 0.5 0.5 3.4 3.5 2.8 0.3 0.2 0.3 0.4 0.2 0.2 0.1 0.27 0.13 0.10 0.23 0.11 0.17 0.28 0.22 0.12 0.28 0.14 0.35 0.02 0.05 0.02 0.12 0.25 0.15 0.18 0.24 0.25 0.37 0.08 0.15 0.09 0.09 0.23 0.10 0.15 0.16 0.10 0.25 0.11 0.32 0.06 0.15 0.07 0.03 0.07 0.09 0.07 0.05 0.14 0.23 0.18 0.06 0.17 0.06 0.18 0.49 0.13 0.16 0.21 0.14 0.51 0.08 0.06 0.44 0.06 0.04 0.07 0.46 0.07 0.06 0.08 0.05 0.08 0.08 0.12 0.15 0.17 0.36 0.12 0.09 0.09 0.08 0.08 0.03 0.06 0.18 0.22 0.19 0.16 0.20 0.22 0.16 0.24 0.16 0.11 0.17 0.21 0.18 0.14 0.19 0.24 0.19 0.26 0.13 0.03 0.11 0.19 0.22 0.15 0.25 0.19 0.15 0.19 0.16 0.16 0.22 0.16 0.23 0.20 0.18 0.14 0.20 0.18 0.07 0.15 0.14 0.22 0.16 0.14 0.17 0.14 0.16 0.15 0.16 0.28 0.19 0.19 0.18 0.21 0.18 0.04 0.04 0.05 0.01 0.02 0.02 0.26 0.04 0.07 0.00 0.05 0.02 0.04 0.04 0.27 0.27 0.26 0.03 0.02 0.03 0.03 0.02 0.02 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.02 0.01 0.02 0.01 0.03 0.00 0.00 0.00 0.01 0.02 0.01 0.02 0.02 0.03 0.03 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.03 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.04 0.01 0.01 0.02 0.01 0.06 0.01 * 0.00 0.02 * 0.00 0.00 * 0.01 * 0.03 * 0.01 0.01 * 0.00 0.01 0.01 * 0.01 * 0.01 * 0.01 0.01 0.05 0.01 0.01 0.01 0.01 0.01 0.00 0.00

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
569

627

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Hodgkin lymphoma (C81) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
570

Male ASR(W) CUM 0-74 0.4 0.3 0.3 0.4 0.4 0.4 0.3 0.4 0.3 3.2 2.2 0.5 0.6 2.8 2.0 0.6 0.9 0.9 0.9 1.2 0.9 0.1 0.5 1.5 1.5 2.1 1.7 2.1 2.6 2.2 2.5 2.5 2.5 2.4 2.4 2.0 2.7 2.2 2.4 2.4 2.0 2.4 2.6 2.8 2.6 2.2 2.8 2.3 2.4 2.4 2.1 2.2 2.3 2.3 2.0 3.2 2.3 6.9 3.3 2.7 3.5 3.0 2.7 4.2 3.6 3.3 3.1 2.5 3.1 3.7 2.9 3.1 4.2 3.0 1.6 3.5 3.6 3.1 4.4 0.02 0.06 0.08 0.11 0.12 0.09 0.19 0.05 0.15 0.49 0.59 0.15 0.12 0.36 0.24 0.09 0.11 0.13 0.43 0.36 0.16 0.08 0.12 0.21 0.14 0.10 0.33 0.49 0.10 0.24 0.15 0.11 0.15 0.10 0.14 0.25 0.15 0.29 0.38 0.44 0.34 0.32 0.30 0.30 0.47 0.39 0.62 0.42 0.19 0.15 0.23 0.22 0.21 0.19 0.27 0.66 0.15 1.37 0.49 0.58 0.39 0.59 0.90 0.46 0.57 0.48 0.26 0.54 0.69 0.61 0.39 0.37 0.64 0.61 0.55 0.47 0.46 0.49 0.37 0.03 0.03 0.04 0.04 0.04 0.03 0.02 0.04 0.03 0.29 0.13 0.05 0.05 0.25 0.16 0.07 0.07 0.07 0.07 0.10 0.09 0.02 0.04 0.13 0.14 0.17 0.14 0.16 0.21 0.18 0.20 0.22 0.22 0.20 0.20 0.15 0.21 0.19 0.18 0.19 0.16 0.20 0.22 0.22 0.23 0.16 0.21 0.19 0.21 0.19 0.17 0.18 0.19 0.20 0.19 0.28 0.19 0.59 0.28 0.22 0.27 0.22 0.21 0.34 0.28 0.29 0.25 0.20 0.22 0.29 0.23 0.27 0.31 0.26 0.17 0.26 0.28 0.28 0.33 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.06 0.03 0.02 0.01 0.04 0.02 0.01 0.01 0.01 0.03 0.03 0.02 0.01 0.01 0.02 0.01 0.01 0.03 0.04 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.03 0.03 0.04 0.03 0.03 0.03 0.03 0.04 0.03 0.04 0.03 0.02 0.01 0.02 0.02 0.02 0.02 0.02 0.07 0.01 0.10 0.04 0.05 0.03 0.04 0.06 0.03 0.04 0.05 0.02 0.04 0.05 0.05 0.03 0.03 0.05 0.05 0.06 0.03 0.03 0.04 0.03

Cases 191 22 13 6 7 8 3 56 6 33 25 10 23 33 32 63 48 27 7 14 18 0 11 35 77 334 21 18 712 72 280 369 312 646 260 93 304 52 30 31 44 73 60 68 15 27 18 36 161 248 107 101 138 110 45 14 213 15 54 34 102 40 14 77 47 35 154 42 17 37 73 61 40 21 13 68 59 40 112

Female ASR(W) CUM 0-74 0.2 0.2 0.2 0.2 0.2 0.1 0.3 0.2 0.3 1.8 1.2 0.4 0.5 1.3 1.0 0.5 0.6 0.4 0.9 1.2 0.4 0.3 1.0 0.9 1.5 1.1 1.9 2.6 1.6 2.2 1.6 2.5 2.1 1.7 2.5 2.3 1.6 1.7 2.4 2.3 2.7 2.1 2.3 1.3 1.8 1.6 2.7 2.1 1.9 2.2 1.9 2.2 1.5 1.5 1.8 2.0 2.8 3.1 3.4 3.7 3.6 2.7 2.7 2.9 2.5 2.5 4.2 2.1 2.4 3.0 2.6 3.3 2.8 2.9 2.4 2.6 3.2 2.6 0.01 0.05 0.06 0.08 0.07 0.05 0.18 0.03 0.14 0.36 0.35 0.13 0.11 0.26 0.20 0.07 0.09 0.08 0.38 0.35 0.10 0.09 0.18 0.10 0.09 0.25 0.47 0.10 0.21 0.14 0.09 0.15 0.09 0.12 0.27 0.14 0.24 0.34 0.45 0.37 0.34 0.28 0.29 0.38 0.35 0.44 0.48 0.19 0.14 0.24 0.21 0.21 0.16 0.27 0.50 0.14 0.86 0.49 0.68 0.43 0.68 0.87 0.39 0.50 0.43 0.23 0.79 0.55 0.52 0.42 0.36 0.58 0.65 0.84 0.34 0.41 0.58 0.29 0.02 0.02 0.01 0.02 0.02 0.01 0.01 0.02 0.04 0.17 0.11 0.03 0.05 0.14 0.09 0.04 0.05 0.03 0.09 0.14 0.05 0.02 0.09 0.07 0.11 0.09 0.15 0.19 0.12 0.17 0.13 0.20 0.17 0.14 0.19 0.17 0.15 0.11 0.19 0.18 0.21 0.15 0.16 0.09 0.14 0.13 0.20 0.16 0.15 0.17 0.15 0.17 0.11 0.12 0.13 0.17 0.23 0.26 0.27 0.27 0.25 0.18 0.20 0.22 0.20 0.19 0.32 0.17 0.20 0.22 0.19 0.24 0.19 0.21 0.20 0.20 0.25 0.20 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.02 0.05 0.05 0.01 0.01 0.04 * 0.03 * 0.01 * 0.01 0.01 0.04 0.05 0.01 * - * 0.01 0.02 * 0.01 * 0.01 0.02 0.04 0.01 * 0.02 * 0.01 0.01 * 0.01 0.01 0.01 0.02 0.01 0.02 0.02 0.03 0.03 0.03 0.02 0.02 0.02 0.03 0.03 0.03 0.01 0.01 0.02 0.02 0.02 0.01 0.02 0.04 0.01 0.06 0.04 0.05 0.03 0.04 0.06 0.03 0.03 0.04 0.02 0.05 0.04 0.04 0.03 0.03 0.04 0.04 0.06 0.03 0.03 0.04 0.02

346 31 20 15 13 22 2 111 5 54 58 13 29 78 81 62 69 51 5 13 35 3 16 54 130 440 29 19 665 100 323 564 308 682 355 66 370 63 43 34 38 60 84 90 36 33 26 34 184 293 102 110 153 168 68 26 239 34 56 27 106 40 14 115 54 48 181 29 24 46 77 74 49 27 9 78 81 46 175

628

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Hodgkin lymphoma (C81) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 122 194 35 285 49 92 100 179 205 276 403 285 96 17 76 177 79 9 45 46 84 40 39 64 471 33 19 14 38 34 21 44 1076 74 55 235 135 319 505 207 472 1049 318 351 97 333 422 14 183 94 29 321 102 15 8 203 63 3 10 10 9 21 Male ASR(W) CUM 0-74 2.0 2.3 3.4 2.4 2.3 2.7 2.4 2.1 2.8 2.4 3.3 2.0 1.8 1.9 2.4 3.9 1.9 1.4 2.8 2.1 2.6 2.7 2.7 2.6 2.0 3.1 3.3 3.6 2.3 3.9 2.5 2.5 2.5 2.6 2.2 3.3 2.1 2.9 2.9 2.8 2.6 2.8 2.4 2.5 2.1 2.4 2.3 2.6 1.9 2.4 2.3 2.5 2.0 1.7 1.4 2.0 1.8 1.3 1.6 1.7 1.7 1.9 0.19 0.17 0.60 0.15 0.34 0.28 0.26 0.16 0.21 0.15 0.18 0.12 0.19 0.50 0.30 0.31 0.22 0.53 0.44 0.31 0.29 0.46 0.47 0.35 0.10 0.58 0.80 1.01 0.41 0.75 0.59 0.41 0.08 0.32 0.32 0.23 0.19 0.17 0.14 0.20 0.13 0.09 0.14 0.14 0.22 0.14 0.12 0.74 0.14 0.26 0.44 0.14 0.21 0.44 0.53 0.14 0.23 0.80 0.54 0.54 0.71 0.44 0.16 0.18 0.28 0.20 0.20 0.22 0.19 0.16 0.23 0.18 0.28 0.17 0.14 0.17 0.20 0.30 0.15 0.12 0.23 0.17 0.22 0.21 0.22 0.22 0.16 0.24 0.29 0.26 0.21 0.32 0.20 0.21 0.20 0.21 0.20 0.27 0.17 0.25 0.24 0.24 0.21 0.23 0.21 0.21 0.18 0.20 0.20 0.25 0.17 0.20 0.19 0.20 0.16 0.12 0.18 0.17 0.15 0.10 0.17 0.14 0.14 0.16 0.02 0.01 0.05 0.01 0.03 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.02 0.04 0.03 0.02 0.02 0.04 0.04 0.03 0.03 0.03 0.04 0.03 0.01 0.04 0.07 0.07 0.04 0.06 0.05 0.04 0.01 0.03 0.03 0.02 0.02 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.08 0.01 0.02 0.04 0.01 0.02 0.03 0.09 0.01 0.02 0.06 0.06 0.05 0.05 0.04 Cases 126 255 15 222 42 84 93 164 165 327 285 320 113 13 69 108 72 8 25 31 55 39 25 42 400 35 6 11 36 37 18 41 773 54 51 167 133 191 327 130 381 742 221 246 81 301 351 6 151 62 21 269 74 13 6 185 36 1 6 9 5 12 Female ASR(W) CUM 0-74 2.0 2.6 1.3 1.8 1.8 2.3 2.1 1.9 2.3 2.5 2.3 2.1 2.1 1.4 2.3 2.4 1.7 1.4 1.8 1.5 1.8 2.5 2.2 1.6 1.7 3.1 1.1 2.4 2.8 4.5 2.1 2.1 1.9 2.0 2.3 2.2 2.1 1.7 1.8 1.9 2.0 1.8 1.6 1.8 1.7 2.1 2.0 1.2 1.6 1.6 1.4 2.0 1.4 1.6 0.9 1.7 1.0 0.1 1.0 1.6 0.5 1.6 0.19 0.17 0.34 0.13 0.32 0.26 0.23 0.16 0.20 0.15 0.15 0.12 0.21 0.41 0.31 0.25 0.21 0.60 0.40 0.28 0.25 0.43 0.46 0.28 0.09 0.60 0.48 0.84 0.49 0.84 0.55 0.38 0.07 0.29 0.35 0.19 0.20 0.13 0.11 0.17 0.11 0.07 0.12 0.12 0.19 0.13 0.11 0.50 0.13 0.21 0.33 0.13 0.17 0.44 0.37 0.13 0.19 0.09 0.42 0.53 0.32 0.51 0.14 0.19 0.11 0.13 0.16 0.19 0.15 0.14 0.17 0.18 0.19 0.16 0.15 0.10 0.17 0.18 0.13 0.10 0.12 0.11 0.13 0.19 0.15 0.13 0.13 0.23 0.10 0.18 0.19 0.34 0.18 0.18 0.14 0.17 0.16 0.18 0.16 0.14 0.14 0.15 0.16 0.15 0.14 0.14 0.15 0.16 0.15 0.07 0.12 0.12 0.13 0.16 0.11 0.16 0.06 0.15 0.08 0.08 0.18 0.03 0.12 0.01 0.01 0.03 0.01 0.03 * 0.02 0.02 0.01 * 0.01 0.01 0.01 0.01 0.02 0.03 0.02 0.02 0.02 0.04 0.03 0.02 0.02 0.03 0.03 0.02 0.01 0.04 0.04 0.06 0.03 0.06 0.05 0.03 0.01 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.03 0.01 0.01 0.05 0.03 0.01 0.02 0.04 0.07 0.02 0.04

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
571

629

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Non-Hodgkin lymphoma (C82-85,C96)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 130 869 71 150 248 52 293 34 125 2472 47 363 469 270 100 93 11312 1179 2054 622 390 186 9 514 5791 63 504 1852 247 1580 256 2238 15345 1210 785 2413 10622 3423 197 144 109 36 349 2363 4037 331 90 116 76 42 954 2271 1803 1969 90 1852 264 172 80 9688 738 8799 2930 562 2323 1054 266 764 585 6054 526 5346 2853 1595 2015 1996 369 1609 124 343 Male ASR(W) CUM 0-74 5.3 16.9 6.7 6.0 7.7 6.4 11.9 4.3 8.0 11.4 5.3 9.8 5.9 9.2 8.8 10.1 14.4 13.0 14.0 15.1 14.8 10.7 12.7 16.0 14.9 13.9 13.7 12.9 9.0 13.7 16.6 12.7 15.0 10.5 12.8 13.2 16.4 16.6 14.3 9.5 11.8 10.8 13.9 18.9 15.0 12.8 8.0 14.7 13.5 7.5 13.5 17.5 14.1 16.7 11.6 17.1 15.7 16.9 13.7 15.0 12.6 15.1 12.9 10.9 13.3 14.4 11.9 15.5 14.3 15.5 11.8 15.9 14.7 15.0 15.5 14.7 11.0 16.0 12.2 17.7 0.50 0.62 0.83 0.71 0.60 0.93 0.77 0.80 0.75 0.24 0.78 0.53 0.28 0.58 0.91 1.09 0.14 0.39 0.32 0.64 0.78 0.81 4.45 0.73 0.20 1.82 0.65 0.31 0.59 0.36 1.09 0.28 0.13 0.31 0.47 0.29 0.17 0.30 1.05 0.85 1.16 1.97 0.79 0.42 0.25 0.71 0.88 1.40 1.82 1.17 0.47 0.40 0.34 0.40 1.26 0.43 1.01 1.32 1.70 0.17 0.47 0.18 0.24 0.48 0.29 0.46 0.80 0.58 0.62 0.21 0.52 0.23 0.29 0.40 0.36 0.34 0.59 0.42 1.12 1.02 0.60 1.34 0.48 0.75 1.24 0.52 1.11 0.63 0.96 1.02 1.21 1.61 1.46 1.54 1.65 1.61 1.26 1.51 1.83 1.67 1.44 1.55 1.48 1.00 1.57 1.81 1.40 1.65 1.10 1.42 1.48 1.81 1.81 1.63 1.03 1.20 1.22 1.54 2.06 1.64 1.37 0.80 1.59 1.49 0.63 1.51 1.91 1.55 1.88 1.23 1.94 1.64 1.70 1.59 1.60 1.31 1.62 1.41 1.17 1.46 1.53 1.27 1.65 1.59 1.72 1.28 1.78 1.69 1.71 1.77 1.61 1.20 1.74 1.31 1.92 0.10 0.11 0.12 0.09 0.03 0.10 0.08 0.04 0.08 0.12 0.16 0.02 0.05 0.04 0.09 0.10 0.11 0.61 0.10 0.03 0.21 0.09 0.04 0.08 0.05 0.15 0.04 0.02 0.04 0.06 0.04 0.02 0.04 0.15 0.10 0.15 0.27 0.12 0.05 0.03 0.09 0.11 0.19 0.23 0.14 0.07 0.05 0.05 0.05 0.16 0.06 0.12 0.15 0.23 0.02 0.06 0.02 0.03 0.06 0.04 0.06 0.11 0.08 0.08 0.03 0.07 0.03 0.04 0.05 0.05 0.04 0.08 0.05 0.15 0.13 Cases 96 548 38 128 190 74 185 23 121 2313 42 372 392 255 100 88 9680 992 1622 549 360 152 3 400 5113 39 450 1724 240 1458 180 1914 12707 1009 613 1991 8842 2740 145 132 91 38 319 1838 3274 291 85 94 66 27 747 1853 1663 1779 89 1664 196 108 78 8470 609 7752 2629 489 2089 872 217 626 552 5491 447 4892 2649 1574 1915 1867 345 1509 108 307 Female ASR(W) CUM 0-74 3.8 9.9 3.7 4.4 6.0 6.8 6.8 2.9 6.3 8.2 4.3 8.2 4.8 7.8 7.2 7.3 10.4 9.5 9.5 11.2 11.3 7.7 3.9 10.2 11.1 6.7 10.6 8.8 6.3 9.4 11.5 9.4 10.2 7.0 8.2 9.7 11.2 10.9 8.5 6.9 7.1 8.0 11.5 12.0 9.8 8.4 6.1 8.6 8.5 3.8 8.8 11.5 11.1 11.5 9.3 11.7 8.3 7.1 10.6 10.5 8.7 10.6 9.0 7.2 9.4 9.7 7.9 10.3 11.5 10.7 7.5 11.2 10.6 11.1 11.1 10.6 7.7 11.6 8.1 11.4 0.41 0.44 0.61 0.53 0.54 0.87 0.54 0.62 0.59 0.18 0.68 0.44 0.25 0.51 0.77 0.81 0.12 0.32 0.26 0.54 0.66 0.66 2.38 0.56 0.17 1.19 0.57 0.23 0.43 0.28 0.90 0.24 0.10 0.23 0.34 0.23 0.14 0.23 0.74 0.67 0.78 1.58 0.67 0.33 0.18 0.51 0.72 0.93 1.21 0.75 0.34 0.32 0.29 0.31 1.01 0.33 0.65 0.77 1.33 0.13 0.36 0.15 0.19 0.34 0.22 0.35 0.57 0.45 0.53 0.16 0.36 0.18 0.23 0.33 0.28 0.27 0.44 0.33 0.81 0.76 0.69 0.82 0.29 0.71 0.90 0.53 0.88 0.52 0.88 0.72 0.83 1.18 1.10 1.07 1.31 1.28 0.95 0.49 1.18 1.24 0.69 1.24 1.02 0.72 1.09 1.27 1.06 1.16 0.77 0.92 1.09 1.27 1.21 0.99 0.73 0.73 0.85 1.29 1.34 1.09 0.93 0.54 1.03 1.05 0.50 0.98 1.30 1.27 1.30 1.02 1.32 0.92 0.76 1.33 1.17 0.91 1.19 1.01 0.75 1.07 1.04 0.83 1.12 1.39 1.22 0.84 1.28 1.21 1.30 1.24 1.20 0.84 1.34 0.93 1.29 * * * *

0.10 0.08 0.08 0.09 0.02 0.10 0.06 0.03 0.07 0.09 0.12 * 0.02 0.05 0.03 0.07 0.09 0.09 0.35 0.07 0.02 0.15 0.08 0.03 0.06 0.04 0.12 0.03 0.01 0.03 0.05 0.03 0.02 0.03 0.10 0.08 0.10 0.18 0.10 0.04 0.03 0.07 0.08 0.13 0.17 0.12 0.05 0.04 0.04 0.04 0.13 0.04 0.08 0.09 0.21 0.02 0.05 0.02 0.03 0.04 0.03 0.05 0.07 0.06 0.08 0.02 0.05 0.02 0.03 0.04 0.04 0.04 0.06 0.04 0.11 0.10

630

*Important. See note on population page.

572

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Non-Hodgkin lymphoma (C82-85,C96) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 715 3238 4891 419 4369 2039 315 1689 2859 167 2671 488 109372 8060 96987 4916 481 4230 711 34 186 478 9967 1084 8574 5837 384 5291 1642 1834 7425 447 6761 563 13409 933 11473 35380 1885 2516 3246 27178 1701 269 1407 8169 654 7307 878 304 3215 2244 979 2745 47 376 1685 37 71 1199 137 207 431 1241 30 1072 175 250 95 2778 2526 188 183 279 331 727 495 2128 343 Male ASR(W) CUM 0-74 15.0 15.3 15.1 12.1 15.3 16.0 12.6 17.0 15.0 11.2 15.4 14.5 15.0 12.2 15.3 17.5 16.0 17.6 12.0 9.7 10.0 13.5 16.3 15.2 16.7 15.3 11.8 15.4 14.1 15.3 16.4 13.9 16.2 15.5 15.8 12.6 16.5 15.4 10.6 12.8 13.3 16.3 13.3 9.3 14.4 13.8 11.4 14.0 15.5 14.5 16.7 17.1 14.6 14.9 7.1 6.7 8.1 3.4 3.1 5.5 4.3 9.7 4.4 5.3 3.3 4.4 4.0 3.7 3.5 17.1 17.5 10.0 4.8 7.3 8.8 7.4 7.5 6.2 5.7 0.59 0.28 0.23 0.61 0.24 0.37 0.73 0.44 0.29 0.89 0.31 0.69 0.05 0.14 0.05 0.26 0.74 0.29 0.47 1.71 0.75 0.67 0.17 0.47 0.19 0.21 0.62 0.22 0.36 0.38 0.20 0.67 0.21 0.70 0.14 0.43 0.16 0.09 0.25 0.26 0.25 0.11 0.33 0.58 0.40 0.16 0.46 0.17 0.54 0.87 0.31 0.38 0.49 0.30 1.08 0.36 0.21 0.60 0.41 0.18 0.37 0.70 0.22 0.16 0.60 0.14 0.31 0.25 0.37 0.34 0.36 0.79 0.37 0.47 0.51 0.29 0.39 0.14 0.35 1.68 1.69 1.69 1.33 1.72 1.79 1.40 1.90 1.68 1.21 1.72 1.56 1.67 1.31 1.70 1.91 1.67 1.93 1.38 1.13 1.21 1.52 1.78 1.61 1.83 1.76 1.32 1.77 1.58 1.66 1.82 1.40 1.81 1.69 1.77 1.38 1.85 1.70 1.12 1.39 1.51 1.81 1.49 0.98 1.61 1.53 1.22 1.56 1.80 1.63 1.88 1.94 1.66 1.67 0.78 0.72 0.86 0.38 0.33 0.61 0.44 1.11 0.46 0.61 0.32 0.47 0.41 0.40 0.44 1.90 1.96 1.03 0.56 0.82 0.94 0.79 0.81 0.67 0.60 0.08 0.04 0.03 0.08 0.03 0.05 0.10 0.06 0.04 0.12 0.04 0.09 0.01 0.02 0.01 0.03 0.09 0.04 0.06 0.25 0.11 0.09 0.02 0.06 0.02 0.03 0.08 0.03 0.05 0.05 0.03 0.08 0.03 0.09 0.02 0.06 0.02 0.01 0.03 0.03 0.04 0.01 0.04 0.07 0.05 0.02 0.06 0.02 0.08 0.12 0.04 0.05 0.06 0.04 0.15 0.05 0.03 0.07 0.05 0.02 0.04 0.09 0.03 0.02 0.07 0.02 0.04 0.03 0.05 0.04 0.05 0.11 0.05 0.06 0.06 0.04 0.04 0.02 0.04 Cases 679 3122 4586 390 4097 1881 283 1571 2632 170 2437 416 98397 6768 87949 4547 380 4019 636 31 148 446 9221 901 8073 5333 336 4833 1455 1637 6863 348 6338 571 11471 776 9845 30766 1562 2062 2615 24065 1557 257 1280 7336 570 6580 654 305 2684 1833 978 2491 35 247 1246 19 47 841 82 159 220 639 20 604 84 155 71 2651 2433 172 149 226 290 605 406 1614 305 Female ASR(W) CUM 0-74 11.5 11.1 11.2 8.6 11.4 11.3 8.2 12.3 10.6 8.1 10.8 10.9 10.6 7.9 10.9 12.3 9.6 12.7 8.9 6.7 6.9 10.4 11.4 9.1 11.9 10.6 7.5 10.6 9.4 11.3 11.4 8.0 11.4 11.4 10.8 8.3 11.3 10.7 7.0 8.3 9.6 11.4 9.4 6.7 10.2 10.1 8.1 10.3 9.9 11.8 11.7 11.8 11.3 10.8 5.6 4.2 5.3 1.6 1.9 3.5 2.5 6.5 2.3 3.4 2.1 2.9 1.9 2.4 2.3 13.7 14.0 9.1 3.6 4.4 6.1 5.2 4.9 3.8 3.7 0.50 0.23 0.18 0.45 0.20 0.29 0.51 0.35 0.23 0.65 0.25 0.60 0.04 0.10 0.04 0.21 0.51 0.23 0.38 1.24 0.59 0.56 0.13 0.31 0.15 0.16 0.43 0.17 0.28 0.31 0.16 0.45 0.17 0.56 0.11 0.31 0.13 0.07 0.19 0.19 0.20 0.08 0.26 0.44 0.31 0.13 0.35 0.14 0.41 0.76 0.25 0.30 0.41 0.25 0.98 0.28 0.16 0.40 0.28 0.14 0.28 0.54 0.16 0.14 0.47 0.12 0.22 0.20 0.28 0.28 0.30 0.73 0.31 0.35 0.40 0.24 0.31 0.11 0.27 1.33 1.26 1.27 0.92 1.30 1.32 0.88 1.45 1.21 0.88 1.25 1.23 1.21 0.86 1.25 1.38 1.00 1.44 1.02 0.71 0.82 1.18 1.27 0.99 1.35 1.22 0.83 1.23 1.07 1.28 1.30 0.85 1.32 1.28 1.22 0.90 1.30 1.21 0.77 0.90 1.08 1.31 1.06 0.71 1.16 1.16 0.94 1.18 1.12 1.32 1.32 1.35 1.32 1.21 0.66 0.44 0.58 0.19 0.21 0.38 0.24 0.74 0.22 0.37 0.22 0.31 0.18 0.27 0.24 1.56 1.59 0.99 0.41 0.48 0.63 0.57 0.50 0.40 0.41 0.07 0.03 0.02 0.06 0.03 0.04 0.07 0.05 0.03 0.09 0.03 0.08 0.01 0.01 0.01 0.03 0.06 0.03 0.05 0.17 0.08 0.07 0.02 0.04 0.02 0.02 0.06 0.02 0.04 0.04 0.02 0.06 0.02 0.07 0.02 0.04 0.02 0.01 0.03 0.02 0.03 0.01 0.03 0.05 0.04 0.02 0.05 0.02 0.06 0.10 0.03 0.04 0.05 0.03 0.14 0.03 * 0.02 0.05 * 0.04 0.02 * 0.03 * 0.07 * 0.02 0.02 * 0.06 0.02 0.02 * 0.03 * 0.03 * 0.04 0.04 0.10 0.04 0.04 0.05 0.03 0.03 0.01 0.03

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
573

631

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Non-Hodgkin lymphoma (C82-85,C96) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
574

Male ASR(W) CUM 0-74 5.6 4.5 5.7 5.6 6.9 6.1 4.7 6.8 4.9 10.4 5.1 7.0 6.6 8.2 7.6 6.8 8.1 8.1 3.3 11.9 7.1 6.0 5.5 5.3 5.0 8.7 11.1 10.1 4.2 9.0 11.0 4.0 7.0 8.0 9.6 7.4 11.9 10.1 9.3 11.8 11.4 10.7 10.7 13.0 9.3 10.9 8.1 12.3 9.5 8.0 10.7 9.3 8.6 9.3 10.7 10.8 11.2 11.0 15.7 14.7 14.2 12.9 12.3 14.6 15.9 11.7 14.1 14.3 7.9 15.8 14.4 11.1 12.1 8.9 12.0 14.2 11.1 18.1 14.0 0.08 0.23 0.34 0.46 0.53 0.35 0.79 0.19 0.61 0.99 0.71 0.61 0.43 0.68 0.53 0.33 0.32 0.36 0.71 1.13 0.43 0.53 0.44 0.42 0.25 0.18 0.75 0.98 0.13 0.40 0.27 0.13 0.23 0.16 0.23 0.44 0.26 0.56 0.67 0.85 0.72 0.61 0.56 0.60 0.74 0.81 0.81 0.77 0.34 0.23 0.44 0.39 0.33 0.33 0.53 1.14 0.32 1.26 0.86 1.09 0.62 0.88 1.28 0.66 0.87 0.90 0.45 1.03 0.95 1.03 0.63 0.65 0.89 0.91 1.32 0.66 0.64 1.10 0.52 0.62 0.51 0.64 0.59 0.81 0.66 0.51 0.75 0.58 1.16 0.50 0.79 0.71 0.99 0.78 0.73 0.88 0.89 0.35 1.34 0.74 0.65 0.62 0.60 0.54 0.92 1.23 1.16 0.45 0.93 1.18 0.43 0.75 0.88 1.07 0.80 1.28 1.10 0.97 1.32 1.22 1.15 1.14 1.41 1.01 1.20 0.87 1.41 1.06 0.89 1.09 1.05 0.92 0.98 1.15 1.11 1.24 1.15 1.67 1.66 1.51 1.38 1.44 1.56 1.72 1.26 1.51 1.61 0.79 1.80 1.65 1.16 1.31 1.08 1.40 1.53 1.18 1.81 1.55 0.01 0.03 0.05 0.06 0.08 0.05 0.10 0.03 0.09 0.14 0.07 0.08 0.06 0.10 0.07 0.05 0.04 0.05 0.08 0.16 0.05 0.06 0.06 0.06 0.03 0.02 0.09 0.13 0.01 0.05 0.03 0.01 0.03 0.02 0.03 0.05 0.03 0.07 0.08 0.11 0.09 0.07 0.07 0.08 0.09 0.10 0.10 0.10 0.04 0.03 0.05 0.05 0.04 0.04 0.06 0.14 0.04 0.14 0.10 0.12 0.07 0.09 0.17 0.07 0.10 0.11 0.05 0.12 0.10 0.12 0.08 0.07 0.11 0.12 0.18 0.08 0.07 0.12 0.06

Cases 3537 334 224 133 134 211 33 1085 48 91 64 97 165 93 121 460 464 377 21 66 188 105 127 124 351 2439 200 110 1130 495 1734 876 964 2579 1818 335 2296 331 187 161 241 325 347 454 150 173 112 220 840 1507 727 626 720 836 466 64 1068 107 329 203 578 333 76 608 347 174 1190 285 92 277 537 314 165 86 92 487 408 293 854

Female ASR(W) CUM 0-74 3.3 3.2 3.3 3.8 3.9 3.2 3.2 4.2 2.5 6.5 6.5 4.2 4.2 4.4 5.1 5.1 5.0 5.0 4.0 6.6 4.6 4.6 4.0 3.9 4.1 6.1 6.9 7.9 2.7 6.0 7.8 2.7 5.1 5.5 7.4 5.1 8.9 7.1 6.3 6.8 7.6 7.8 7.5 8.7 5.5 6.8 6.3 7.6 6.6 5.8 8.0 7.0 5.8 6.5 7.9 6.5 8.1 8.7 10.6 8.9 9.0 9.5 7.4 9.2 10.6 10.0 10.8 12.9 7.0 11.5 9.2 8.9 8.0 7.2 10.3 9.5 8.7 11.8 9.7 0.06 0.18 0.22 0.34 0.34 0.23 0.59 0.13 0.38 0.74 1.15 0.44 0.34 0.51 0.51 0.25 0.24 0.27 0.91 0.84 0.35 0.46 0.36 0.36 0.22 0.14 0.54 0.82 0.09 0.31 0.22 0.10 0.18 0.12 0.19 0.33 0.21 0.44 0.52 0.60 0.55 0.50 0.45 0.46 0.54 0.59 0.73 0.60 0.27 0.18 0.35 0.31 0.25 0.26 0.43 0.87 0.26 0.98 0.68 0.76 0.47 0.69 1.06 0.44 0.71 0.79 0.38 0.99 0.81 0.86 0.49 0.57 0.68 0.90 1.20 0.55 0.55 0.85 0.40 0.36 0.36 0.36 0.44 0.43 0.34 0.37 0.46 0.31 0.72 0.80 0.46 0.48 0.48 0.52 0.61 0.55 0.53 0.46 0.76 0.49 0.50 0.44 0.45 0.47 0.66 0.77 0.97 0.31 0.66 0.87 0.29 0.54 0.62 0.85 0.53 0.98 0.78 0.75 0.78 0.87 0.81 0.86 0.99 0.62 0.80 0.68 0.92 0.73 0.65 0.87 0.81 0.61 0.75 0.88 0.73 0.95 1.06 1.21 1.02 0.98 1.05 0.78 1.07 1.14 1.11 1.19 1.40 0.79 1.30 1.05 0.95 0.92 0.77 1.26 1.06 0.94 1.27 1.08 0.01 0.02 0.03 0.05 0.05 0.03 0.08 0.02 0.06 0.10 0.18 0.06 0.05 0.07 * 0.06 * 0.04 * 0.03 0.03 0.12 0.11 0.04 * 0.06 * 0.05 0.05 * 0.03 * 0.02 0.07 0.11 0.01 * 0.04 * 0.03 0.01 * 0.02 0.01 0.03 0.03 0.03 0.06 0.07 0.08 0.07 0.06 0.06 0.06 0.07 0.08 0.08 0.08 0.03 0.02 0.04 0.04 0.03 0.03 0.05 0.11 0.04 0.13 0.08 0.09 0.05 0.07 0.12 0.05 0.08 0.10 0.04 0.10 0.10 0.10 0.06 0.06 0.08 0.09 0.16 0.06 0.06 0.09 0.05

5102 417 320 164 197 331 37 1506 82 135 182 142 255 161 247 550 684 539 25 120 283 131 159 164 410 2469 244 111 1136 577 1983 1106 1041 2723 1961 305 2257 348 219 207 273 355 397 519 189 206 138 303 894 1422 679 600 757 908 468 98 1289 94 366 242 701 314 110 648 432 173 1194 265 84 300 661 333 209 109 88 570 409 323 882

632

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Non-Hodgkin lymphoma (C82-85,C96) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 380 570 133 1777 154 266 353 848 1031 624 769 989 539 62 467 661 583 53 259 243 363 230 220 295 3659 195 74 82 192 176 112 287 5935 356 287 1168 1005 1633 2551 1053 3625 5683 1946 2087 617 2056 3166 42 1598 912 252 2533 832 131 42 1550 545 56 79 69 135 159 Male ASR(W) CUM 0-74 5.4 5.6 10.5 10.8 6.6 6.6 6.2 8.7 10.8 4.8 5.0 6.4 8.3 6.4 10.2 10.7 13.1 5.7 12.1 8.9 9.8 10.8 12.5 9.3 9.7 13.6 8.4 12.8 10.2 14.6 11.1 12.6 10.6 10.0 8.7 10.5 11.2 10.7 10.2 10.9 13.3 11.6 10.3 10.5 11.4 11.0 14.0 8.6 13.1 16.6 14.7 15.3 13.6 14.9 8.6 12.3 12.4 13.9 10.9 13.4 11.1 13.6 0.28 0.24 0.95 0.27 0.57 0.42 0.36 0.32 0.37 0.20 0.20 0.21 0.38 0.87 0.54 0.46 0.56 0.97 0.82 0.61 0.55 0.80 0.95 0.62 0.18 1.03 1.04 1.54 0.79 1.22 1.12 0.80 0.14 0.55 0.55 0.33 0.38 0.28 0.22 0.35 0.24 0.16 0.25 0.24 0.48 0.26 0.26 1.39 0.34 0.58 0.98 0.32 0.49 1.34 1.37 0.32 0.57 2.12 1.32 1.65 1.29 1.18 0.57 0.58 1.00 1.19 0.77 0.77 0.67 0.93 1.13 0.51 0.54 0.71 0.86 0.69 1.05 1.11 1.41 0.60 1.34 0.98 1.03 1.13 1.33 0.93 1.10 1.48 0.89 1.48 1.09 1.60 1.20 1.43 1.16 1.12 0.90 1.17 1.21 1.20 1.15 1.23 1.49 1.26 1.15 1.17 1.31 1.22 1.55 0.89 1.39 1.84 1.61 1.69 1.45 1.66 0.94 1.37 1.32 1.51 1.26 1.55 1.17 1.36 0.03 0.03 0.11 0.04 0.07 0.05 0.04 0.04 0.04 0.02 0.02 0.03 0.04 0.10 0.06 0.05 0.07 0.10 0.10 0.07 0.06 0.09 0.10 0.06 0.02 0.13 0.13 0.20 0.10 0.15 0.14 0.10 0.02 0.07 0.06 0.04 0.05 0.04 0.03 0.05 0.03 0.02 0.03 0.03 0.06 0.03 0.03 0.16 0.04 0.07 0.12 0.04 0.06 0.19 0.18 0.04 0.07 0.28 0.18 0.24 0.14 0.14 Cases 386 571 111 1645 150 202 337 701 970 646 669 951 555 75 457 597 527 31 216 202 317 203 180 262 3183 148 83 54 156 176 83 272 5014 289 264 1055 877 1438 2389 901 3190 4990 1799 1818 681 2127 2640 28 1305 798 208 2206 627 118 31 1434 441 32 59 47 140 127 Female ASR(W) CUM 0-74 3.6 3.8 7.6 8.0 4.5 3.7 4.1 5.7 7.8 2.9 3.8 4.7 6.0 6.2 7.8 7.3 10.1 4.1 9.3 6.0 7.3 7.5 8.4 6.4 6.8 7.8 7.8 6.4 7.0 11.1 6.8 8.9 7.3 7.2 6.6 7.9 7.7 7.4 7.6 7.8 9.4 7.9 7.8 7.6 9.9 8.6 9.8 6.9 9.8 12.1 10.2 11.0 9.0 11.7 6.4 9.6 8.7 7.5 7.4 8.0 7.6 11.2 0.21 0.18 0.78 0.23 0.40 0.29 0.25 0.24 0.29 0.13 0.17 0.17 0.28 0.81 0.43 0.34 0.47 1.03 0.71 0.48 0.45 0.60 0.73 0.49 0.14 0.72 0.98 1.01 0.62 1.02 0.81 0.62 0.11 0.46 0.45 0.28 0.30 0.22 0.18 0.29 0.19 0.13 0.21 0.20 0.42 0.21 0.21 1.40 0.29 0.48 0.78 0.26 0.39 1.14 1.20 0.28 0.46 1.46 1.01 1.19 0.81 1.10 0.41 0.44 0.84 0.92 0.57 0.41 0.50 0.63 0.86 0.33 0.40 0.53 0.66 0.77 0.89 0.78 1.13 0.41 1.09 0.66 0.79 0.88 0.91 0.66 0.79 0.88 0.88 0.77 0.80 1.26 0.87 0.92 0.83 0.79 0.77 0.90 0.87 0.83 0.85 0.87 1.07 0.89 0.88 0.85 1.13 0.98 1.11 0.69 1.08 1.36 1.16 1.21 1.06 1.34 0.71 1.13 0.95 0.96 0.80 0.82 0.83 1.24 0.02 0.02 0.09 0.03 0.05 * 0.03 0.03 0.03 * 0.03 0.01 0.02 0.02 0.03 0.10 0.05 0.04 0.06 0.08 0.09 0.05 0.05 0.08 0.08 0.05 0.02 0.09 0.13 0.13 0.08 0.12 0.11 0.07 0.01 0.06 0.06 0.04 0.04 0.03 0.02 0.04 0.02 0.02 0.03 0.02 0.05 0.03 0.03 0.18 0.04 0.06 0.10 0.03 0.05 0.16 0.17 0.04 0.06 0.21 0.14 0.15 0.10 0.14

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
575

633

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Immunoproliferative diseases (C88)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 0 1 1 0 0 0 0 0 0 10 0 0 2 0 2 0 207 31 11 29 10 7 0 19 76 2 22 12 1 11 4 27 374 17 9 29 305 93 4 1 3 0 5 75 82 3 2 1 1 0 9 65 36 40 0 40 7 3 4 178 8 168 25 1 24 10 1 9 16 110 4 103 38 42 23 26 1 25 0 5 Male ASR(W) CUM 0-74 0.0 0.1 0.0 0.0 0.2 0.2 0.3 0.1 0.6 0.3 0.4 0.5 0.2 0.4 0.5 0.1 0.0 0.1 0.3 0.1 0.3 0.1 0.1 0.2 0.4 0.4 0.2 0.1 0.3 0.3 0.5 0.3 0.1 0.2 0.1 0.1 0.2 0.5 0.3 0.3 0.3 0.4 0.3 0.7 0.2 0.1 0.2 0.1 0.0 0.1 0.2 0.0 0.2 0.3 0.3 0.1 0.3 0.2 0.3 0.2 0.2 0.0 0.2 0.2 0.01 0.13 0.02 0.02 0.12 0.02 0.06 0.02 0.12 0.10 0.14 0.12 0.02 0.29 0.12 0.02 0.04 0.03 0.16 0.03 0.02 0.03 0.05 0.04 0.03 0.05 0.12 0.06 0.18 0.13 0.06 0.04 0.07 0.15 0.08 0.14 0.06 0.06 0.05 0.05 0.06 0.16 0.15 0.37 0.02 0.05 0.02 0.02 0.02 0.03 0.05 0.04 0.07 0.09 0.03 0.05 0.03 0.03 0.05 0.03 0.04 0.02 0.05 0.07 0.00 0.00 0.04 0.03 0.05 0.01 0.08 0.02 0.04 0.07 0.02 0.07 0.05 0.01 0.01 0.01 0.06 0.02 0.04 0.01 0.01 0.02 0.05 0.05 0.01 0.01 0.02 0.05 0.06 0.04 0.01 0.02 0.02 0.06 0.03 0.03 0.03 0.07 0.04 0.12 0.03 0.02 0.03 0.01 0.00 0.01 0.01 0.00 0.01 0.04 0.03 0.01 0.03 0.02 0.03 0.02 0.02 0.03 0.01 0.00 0.00 0.03 0.00 0.01 0.00 0.02 0.01 0.02 0.02 0.00 0.05 0.02 0.00 0.01 0.00 0.03 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.03 0.03 0.07 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.01 Cases 0 3 0 0 0 0 1 0 0 14 0 0 0 0 0 0 132 19 2 21 9 2 0 8 58 2 11 15 3 12 1 16 206 7 8 13 174 55 2 2 1 0 3 45 47 3 1 0 1 0 4 37 24 22 0 21 2 2 0 131 2 128 20 2 18 6 2 4 11 76 3 71 26 19 15 12 3 9 0 5 Female ASR(W) CUM 0-74 0.0 0.0 0.0 0.1 0.2 0.0 0.3 0.2 0.1 0.2 0.1 0.4 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.02 0.02 0.01 0.01 0.04 0.00 0.08 0.06 0.05 0.07 0.02 0.32 0.05 0.02 0.06 0.02 0.10 0.02 0.01 0.02 0.03 0.02 0.02 0.03 0.07 0.09 0.10 0.07 0.04 0.02 0.02 0.04 0.05 0.03 0.04 0.03 0.03 0.03 0.07 0.12 0.01 0.02 0.01 0.02 0.02 0.02 0.03 0.05 0.04 0.08 0.02 0.03 0.02 0.02 0.03 0.02 0.02 0.02 0.02 0.08 0.00 0.01 0.01 0.02 0.03 0.01 0.01 0.01 0.01 0.08 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.00 0.01 0.01 0.02 0.02 0.01 0.02 0.02 0.02 0.02 0.02 0.01 0.03 0.02 0.02 0.02 0.01 0.02 0.01 0.00 0.02 0.01 0.00 0.01 0.01 0.00 0.01 0.04 0.01 0.00 0.02 0.01 0.01 0.01 0.01 0.01 0.02 * * * *

0.00 0.00 - * 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.05 0.01 0.00 0.01 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.02 0.01 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01

634

*Important. See note on population page.

576

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Immunoproliferative diseases (C88) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 33 86 89 7 76 40 4 35 36 0 36 10 1952 73 1798 110 5 102 18 0 1 17 174 7 162 76 2 71 16 33 141 6 132 6 280 8 258 759 27 22 37 658 18 3 15 119 6 107 13 8 75 50 13 64 0 0 0 0 1 0 0 0 0 0 0 0 0 0 20 19 1 0 3 4 5 2 19 4 Male ASR(W) CUM 0-74 0.7 0.4 0.2 0.2 0.2 0.3 0.2 0.3 0.2 0.2 0.3 0.2 0.1 0.3 0.4 0.2 0.4 0.3 0.1 0.5 0.3 0.1 0.3 0.2 0.1 0.2 0.1 0.2 0.3 0.2 0.3 0.1 0.3 0.1 0.3 0.3 0.1 0.1 0.2 0.4 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.4 0.4 0.4 0.2 0.3 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.13 0.04 0.03 0.08 0.03 0.05 0.09 0.05 0.03 0.03 0.09 0.01 0.01 0.01 0.04 0.08 0.04 0.07 0.05 0.12 0.02 0.04 0.02 0.02 0.04 0.02 0.03 0.04 0.03 0.07 0.03 0.07 0.02 0.04 0.02 0.01 0.03 0.03 0.03 0.01 0.03 0.06 0.04 0.02 0.05 0.02 0.07 0.13 0.04 0.06 0.05 0.04 0.00 0.03 0.03 0.08 0.03 0.05 0.02 0.01 0.01 0.03 0.09 0.04 0.02 0.03 0.02 0.03 0.02 0.04 0.01 0.01 0.03 0.03 0.01 0.03 0.05 0.02 0.05 0.03 0.00 0.05 0.03 0.01 0.03 0.02 0.01 0.02 0.01 0.02 0.04 0.01 0.04 0.02 0.03 0.01 0.04 0.04 0.02 0.01 0.02 0.04 0.02 0.01 0.02 0.02 0.01 0.02 0.02 0.04 0.05 0.05 0.02 0.03 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.01 0.02 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.00 0.02 0.00 0.01 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 Cases 19 68 82 9 66 36 3 32 32 5 27 7 1331 66 1216 58 3 54 11 0 2 9 150 7 142 46 0 45 9 17 106 4 94 6 180 7 164 433 13 20 19 375 19 4 13 77 8 68 13 6 46 29 9 41 0 0 0 0 0 0 0 0 0 0 0 0 0 0 10 10 0 2 1 1 2 2 12 1 Female ASR(W) CUM 0-74 0.3 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.07 0.02 0.02 0.06 0.03 0.04 0.05 0.05 0.02 0.10 0.02 0.04 0.00 0.01 0.00 0.02 0.04 0.02 0.05 0.07 0.07 0.02 0.03 0.02 0.01 0.01 0.02 0.03 0.02 0.05 0.02 0.03 0.01 0.03 0.01 0.01 0.02 0.02 0.02 0.01 0.02 0.05 0.02 0.01 0.05 0.01 0.05 0.10 0.03 0.04 0.04 0.03 0.01 0.01 0.03 0.02 0.01 0.01 0.01 0.01 0.02 0.03 0.02 0.03 0.02 0.03 0.03 0.02 0.03 0.01 0.01 0.01 0.00 0.01 0.01 0.02 0.02 0.01 0.02 0.02 0.01 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.01 0.02 0.01 0.02 0.02 0.00 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.03 0.03 0.02 0.02 0.02 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.02 0.00 0.01 0.01 0.00 - * - * - * - * - * - * - * - * - * 0.00 0.00 0.01 0.00 0.00 0.00 0.00

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
577

635

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Immunoproliferative diseases (C88) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
578

Male ASR(W) CUM 0-74 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.3 0.2 0.0 0.1 0.2 0.6 0.2 0.2 0.7 0.9 0.6 1.2 0.9 0.7 2.0 1.2 0.2 0.6 1.6 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.8 0.2 1.4 0.0 0.3 0.3 0.1 0.1 0.2 0.9 0.2 0.1 0.2 0.2 0.1 0.1 0.0 0.3 0.0 0.1 0.01 0.01 0.03 0.04 0.02 0.05 0.07 0.01 0.03 0.01 0.06 0.03 0.00 0.03 0.02 0.05 0.06 0.03 0.14 0.20 0.18 0.22 0.15 0.13 0.22 0.23 0.11 0.19 0.26 0.02 0.02 0.04 0.04 0.02 0.02 0.04 0.32 0.04 0.40 0.04 0.13 0.06 0.06 0.06 0.06 0.17 0.10 0.03 0.06 0.10 0.10 0.14 0.03 0.09 0.04 0.03 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.03 0.02 0.00 0.02 0.02 0.07 0.02 0.02 0.07 0.09 0.05 0.16 0.08 0.08 0.25 0.18 0.03 0.09 0.20 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.09 0.02 0.16 0.01 0.05 0.04 0.01 0.02 0.09 0.02 0.01 0.02 0.03 0.01 0.02 0.00 0.04 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.02 0.03 0.02 0.03 0.02 0.02 0.03 0.04 0.01 0.03 0.04 0.00 0.00 0.01 0.01 0.00 0.00 0.01 0.04 0.01 0.05 0.01 0.02 0.01 0.01 0.01 0.02 0.02 0.00 0.01 0.02 0.01 0.02 0.00 0.01 0.00

Cases 6 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 1 1 0 0 0 1 0 0 0 12 4 0 7 10 28 0 12 57 73 12 35 13 11 7 22 15 21 44 19 4 7 22 13 28 3 6 0 4 1 6 24 7 1 5 16 4 1 4 16 0 3 0 1 0 4 1 6 0 1 1 4 2 4

Female ASR(W) CUM 0-74 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.2 0.3 0.2 0.5 0.2 0.4 0.7 0.6 0.2 0.4 0.8 0.1 0.1 0.0 0.0 0.0 0.0 0.7 0.1 0.3 0.0 0.2 0.2 0.1 0.1 0.1 0.4 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.1 0.0 0.0 0.00 0.01 0.03 0.08 0.04 0.01 0.01 0.04 0.01 0.06 0.01 0.03 0.02 0.01 0.02 0.03 0.04 0.02 0.07 0.10 0.08 0.12 0.06 0.09 0.12 0.17 0.10 0.15 0.19 0.02 0.01 0.02 0.02 0.01 0.02 0.30 0.03 0.13 0.01 0.13 0.07 0.04 0.10 0.04 0.11 0.01 0.03 0.01 0.03 0.13 0.19 0.02 0.05 0.03 0.02 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.02 0.04 0.01 0.05 0.02 0.04 0.08 0.08 0.02 0.06 0.12 0.01 0.01 0.01 0.01 0.00 0.00 0.08 0.01 0.03 0.02 0.02 0.01 0.02 0.01 0.06 0.00 0.00 0.05 0.02 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.00 - * - * - * - * 0.01 * - * - * 0.00 0.01 0.00 * 0.01 * 0.00 - * 0.00 0.00 0.00 0.01 0.00 0.01 0.02 0.01 0.02 0.01 0.01 0.02 0.03 0.01 0.02 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.04 0.00 0.02 0.01 0.01 0.01 0.02 0.00 0.02 0.00 0.00 0.02 0.02 0.00 0.01 0.01 0.00

24 1 1 0 0 2 0 9 0 0 0 0 0 1 0 0 0 0 0 0 0 2 0 0 0 8 1 0 7 18 41 1 22 75 145 7 37 25 22 12 32 44 29 92 31 4 11 41 6 24 11 7 4 3 4 7 32 14 1 6 19 6 1 8 32 3 8 0 0 0 11 0 4 2 1 2 14 1 5

636

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Immunoproliferative diseases (C88) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 10 20 5 92 1 31 3 3 17 5 8 10 4 3 28 11 19 2 5 3 5 3 1 9 118 1 1 0 7 4 3 0 291 10 12 31 22 50 87 59 136 206 66 81 8 63 80 0 40 23 3 73 26 7 1 94 13 1 1 2 3 6 Male ASR(W) CUM 0-74 0.1 0.2 0.4 0.5 0.0 0.8 0.0 0.0 0.2 0.0 0.0 0.1 0.1 0.2 0.5 0.1 0.4 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.3 0.0 0.1 0.4 0.3 0.2 0.5 0.3 0.3 0.2 0.2 0.3 0.3 0.5 0.4 0.3 0.3 0.3 0.1 0.3 0.3 0.3 0.4 0.2 0.4 0.4 0.9 0.5 0.7 0.3 0.1 0.1 0.4 0.2 0.5 0.04 0.04 0.18 0.05 0.04 0.14 0.03 0.02 0.04 0.02 0.01 0.02 0.03 0.10 0.10 0.04 0.09 0.10 0.06 0.05 0.05 0.05 0.03 0.09 0.03 0.04 0.14 0.14 0.16 0.09 0.03 0.09 0.09 0.04 0.04 0.04 0.03 0.07 0.04 0.02 0.04 0.04 0.04 0.04 0.04 0.05 0.09 0.11 0.05 0.09 0.35 0.46 0.07 0.08 0.13 0.06 0.28 0.14 0.23 0.02 0.02 0.04 0.05 0.01 0.11 0.01 0.00 0.02 0.00 0.01 0.01 0.01 0.01 0.05 0.02 0.06 0.01 0.02 0.01 0.01 0.01 0.02 0.03 0.02 0.07 0.04 0.06 0.04 0.04 0.03 0.02 0.03 0.03 0.05 0.04 0.04 0.03 0.04 0.00 0.03 0.03 0.04 0.06 0.03 0.04 0.05 0.05 0.08 0.04 0.06 0.04 0.06 0.01 0.01 0.02 0.01 0.01 0.02 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.02 0.03 0.02 0.00 0.01 0.02 0.01 0.01 0.01 0.00 0.01 0.01 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.03 0.01 0.01 0.06 0.03 0.03 Cases 8 17 3 55 1 46 2 1 11 2 14 16 2 2 13 3 4 1 0 4 4 0 3 4 63 0 4 0 6 3 7 0 193 10 5 27 5 29 53 26 89 146 44 57 9 62 58 0 25 18 3 47 21 2 1 60 6 1 2 0 1 2 Female ASR(W) CUM 0-74 0.1 0.1 0.1 0.2 0.0 0.7 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.3 0.1 0.4 0.3 0.2 0.1 0.2 0.0 0.1 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.3 0.2 0.3 0.3 0.1 0.1 0.3 0.0 0.1 0.02 0.03 0.08 0.03 0.02 0.11 0.02 0.01 0.02 0.00 0.02 0.02 0.01 0.11 0.05 0.01 0.02 0.08 0.06 0.03 0.05 0.05 0.02 0.07 0.12 0.03 0.17 0.02 0.07 0.06 0.04 0.01 0.03 0.02 0.04 0.02 0.02 0.02 0.03 0.03 0.03 0.03 0.03 0.07 0.10 0.03 0.07 0.15 0.28 0.04 0.04 0.09 0.19 0.02 0.09 0.01 0.01 0.01 0.02 0.08 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.07 0.03 0.03 0.02 0.02 0.00 0.01 0.01 0.02 0.02 0.02 0.01 0.03 0.01 0.02 0.02 0.01 0.02 0.02 0.02 0.04 0.05 0.05 0.03 0.01 0.02 0.02 0.00 0.00 0.01 0.00 - * 0.02 0.00 0.00 * 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.02 0.03 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.04 0.05 0.01 0.00 0.02 0.02

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
579

637

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Multiple myeloma (C90)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 7 68 16 11 43 20 38 12 42 778 28 105 94 56 87 28 3480 350 558 178 120 52 1 137 1915 18 151 650 195 450 63 570 4060 265 465 615 2642 801 111 31 32 8 94 482 1094 212 15 25 16 5 210 572 549 545 46 491 112 94 16 2798 381 2394 1056 353 691 349 136 206 190 1823 360 1412 807 498 631 745 315 427 83 68 Male ASR(W) CUM 0-74 0.4 1.5 1.7 1.0 3.0 2.3 2.0 1.8 3.1 3.9 3.1 3.1 1.3 2.2 6.9 3.6 4.1 3.8 3.6 4.1 4.1 2.7 0.7 3.7 4.5 3.4 3.7 4.3 7.0 3.7 4.2 3.0 3.9 2.4 8.3 3.9 3.8 4.0 8.6 1.9 3.6 2.2 4.4 3.7 4.1 8.6 1.2 3.1 2.6 1.0 3.4 4.0 4.3 4.3 6.6 4.1 6.0 7.8 2.7 3.9 7.2 3.6 4.6 8.1 3.8 5.3 8.5 4.3 4.3 4.5 8.3 4.0 4.0 4.3 4.6 5.2 9.4 4.0 8.6 3.1 0.15 0.20 0.43 0.35 0.52 0.54 0.35 0.55 0.49 0.14 0.61 0.31 0.14 0.31 0.77 0.69 0.07 0.21 0.16 0.32 0.40 0.39 0.66 0.33 0.11 0.85 0.33 0.18 0.52 0.18 0.55 0.13 0.06 0.15 0.39 0.16 0.08 0.15 0.84 0.36 0.66 0.86 0.47 0.18 0.13 0.60 0.32 0.64 0.76 0.45 0.24 0.18 0.19 0.20 0.99 0.20 0.59 0.85 0.69 0.08 0.38 0.08 0.15 0.44 0.15 0.29 0.77 0.31 0.32 0.11 0.45 0.11 0.15 0.21 0.19 0.20 0.55 0.20 0.97 0.40 0.30 0.27 0.23 0.42 0.49 0.39 0.37 0.16 0.30 0.81 0.50 0.48 0.47 0.41 0.48 0.47 0.38 0.06 0.41 0.52 0.40 0.42 0.54 0.86 0.47 0.58 0.35 0.48 0.31 1.03 0.47 0.45 0.49 1.05 0.28 0.42 0.32 0.52 0.46 0.50 1.07 0.17 0.39 0.32 0.10 0.41 0.49 0.51 0.51 0.83 0.49 0.72 0.94 0.29 0.46 0.86 0.42 0.56 1.04 0.45 0.69 1.20 0.55 0.49 0.55 0.98 0.48 0.51 0.54 0.55 0.64 1.07 0.51 0.97 0.37 0.08 0.06 0.08 0.08 0.02 0.09 0.04 0.02 0.05 0.11 0.10 0.01 0.03 0.02 0.05 0.06 0.06 0.06 0.05 0.02 0.12 0.05 0.03 0.08 0.03 0.09 0.02 0.01 0.02 0.06 0.02 0.01 0.02 0.12 0.06 0.10 0.15 0.07 0.03 0.02 0.09 0.06 0.10 0.11 0.05 0.04 0.03 0.03 0.03 0.15 0.03 0.09 0.13 0.09 0.01 0.05 0.01 0.02 0.07 0.02 0.05 0.13 0.05 0.05 0.02 0.06 0.02 0.02 0.03 0.03 0.03 0.08 0.03 0.14 0.06 Cases 7 33 15 4 44 22 40 13 39 785 22 84 80 41 78 14 3034 269 463 164 94 28 0 122 1749 23 122 562 199 361 42 417 3542 268 453 586 2159 723 106 34 25 10 93 425 987 219 20 26 10 10 225 440 423 467 57 406 122 101 18 2326 388 1908 911 362 536 293 136 151 137 1760 464 1254 714 422 540 604 255 346 62 64 Female ASR(W) CUM 0-74 0.3 0.6 1.5 0.4 4.0 1.8 1.7 1.9 2.3 2.9 2.4 2.0 1.0 1.3 4.6 1.2 2.9 2.4 2.5 2.8 2.7 1.2 2.5 3.3 3.3 2.4 2.8 4.9 2.2 2.8 1.9 2.7 1.8 6.0 3.1 2.4 2.7 5.9 1.4 1.9 2.1 3.5 2.5 2.8 6.0 1.2 2.3 1.5 1.2 2.8 2.4 2.7 2.8 5.9 2.6 4.9 5.9 2.9 2.6 5.4 2.3 3.1 5.7 2.3 3.4 5.7 2.5 2.6 3.2 7.5 2.5 2.7 2.6 2.9 3.2 5.4 2.4 4.2 2.1 0.11 0.12 0.40 0.23 0.66 0.46 0.27 0.56 0.37 0.11 0.51 0.22 0.12 0.21 0.58 0.34 0.06 0.16 0.13 0.26 0.30 0.24 0.26 0.09 0.78 0.25 0.13 0.37 0.13 0.46 0.10 0.05 0.11 0.29 0.13 0.06 0.11 0.61 0.26 0.39 0.78 0.38 0.14 0.10 0.42 0.28 0.46 0.51 0.38 0.20 0.13 0.14 0.15 0.80 0.15 0.49 0.64 0.73 0.06 0.28 0.06 0.11 0.31 0.11 0.21 0.51 0.22 0.25 0.09 0.36 0.08 0.11 0.15 0.14 0.14 0.36 0.14 0.57 0.31 0.18 0.23 0.22 0.30 0.36 0.32 0.25 0.12 0.15 0.48 0.10 0.34 0.29 0.30 0.35 0.35 0.17 0.29 0.38 0.37 0.31 0.34 0.62 0.27 0.33 0.22 0.33 0.21 0.70 0.38 0.30 0.32 0.66 0.14 0.20 0.29 0.43 0.30 0.34 0.71 0.14 0.30 0.16 0.13 0.34 0.29 0.33 0.34 0.68 0.31 0.60 0.69 0.42 0.32 0.65 0.28 0.38 0.72 0.28 0.42 0.67 0.32 0.31 0.40 0.92 0.31 0.33 0.30 0.36 0.39 0.66 0.29 0.49 0.24 * * * *

0.06 0.04 0.08 0.06 0.02 0.07 0.03 0.02 0.03 0.08 0.04 * 0.01 0.02 0.02 0.04 0.05 0.04 0.04 0.01 0.11 0.04 0.02 0.06 0.02 0.07 0.01 0.01 0.02 0.04 0.02 0.01 0.02 0.09 0.04 0.06 0.11 0.06 0.02 0.01 0.06 0.05 0.07 0.06 0.06 0.03 0.02 0.02 0.02 0.11 0.02 0.07 0.09 0.12 0.01 0.04 0.01 0.02 0.05 0.02 0.03 0.08 0.03 0.04 0.01 0.05 0.01 0.02 0.02 0.02 0.02 0.05 0.02 0.08 0.04

638

*Important. See note on population page.

580

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Multiple myeloma (C90) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 212 885 1516 303 1198 711 230 477 741 118 615 140 31760 4949 25840 1387 252 1096 236 15 73 144 3068 535 2461 1580 263 1287 441 524 2003 250 1712 155 3921 559 3119 10233 424 1566 860 7262 587 214 358 2509 416 2045 261 80 935 633 276 784 12 78 8 20 291 21 46 71 445 11 280 38 57 46 708 620 45 49 65 60 187 134 531 123 Male ASR(W) CUM 0-74 4.1 4.0 4.5 8.9 4.0 5.4 9.1 4.5 3.7 8.2 3.3 3.7 4.2 8.0 3.8 4.7 9.1 4.2 4.0 4.2 4.0 4.0 4.7 7.9 4.3 4.0 8.0 3.5 3.5 4.2 4.0 8.1 3.7 3.8 4.5 8.4 4.3 4.3 2.5 8.7 4.1 4.0 4.4 7.7 3.5 4.2 8.1 3.8 4.5 3.7 4.7 4.7 3.7 4.1 2.2 1.5 0.6 1.1 1.2 0.6 2.1 0.8 2.4 1.3 1.4 1.0 0.9 1.7 4.2 4.0 3.2 1.2 1.4 1.4 1.6 1.6 1.4 1.7 0.30 0.14 0.12 0.53 0.12 0.21 0.62 0.22 0.14 0.78 0.14 0.34 0.02 0.12 0.03 0.13 0.58 0.14 0.27 1.11 0.47 0.35 0.09 0.35 0.09 0.10 0.51 0.10 0.18 0.20 0.10 0.53 0.10 0.33 0.08 0.37 0.08 0.04 0.12 0.22 0.14 0.05 0.19 0.54 0.19 0.09 0.41 0.09 0.29 0.43 0.16 0.20 0.23 0.15 0.65 0.17 0.22 0.28 0.08 0.14 0.33 0.10 0.12 0.41 0.09 0.17 0.13 0.26 0.17 0.17 0.49 0.18 0.19 0.18 0.12 0.15 0.06 0.16 0.48 0.47 0.53 1.04 0.48 0.65 1.04 0.56 0.45 1.03 0.40 0.41 0.50 0.97 0.46 0.57 1.13 0.51 0.48 0.43 0.48 0.49 0.55 0.94 0.51 0.49 0.97 0.44 0.41 0.51 0.48 0.98 0.43 0.39 0.55 1.05 0.52 0.53 0.31 1.06 0.49 0.49 0.53 0.96 0.41 0.50 0.97 0.46 0.57 0.47 0.55 0.56 0.46 0.51 0.33 0.16 0.08 0.10 0.15 0.07 0.24 0.09 0.30 0.21 0.18 0.15 0.11 0.23 0.50 0.48 0.41 0.15 0.16 0.16 0.19 0.19 0.15 0.17 0.04 0.02 0.02 0.08 0.02 0.03 0.09 0.03 0.02 0.12 0.02 0.05 0.00 0.02 0.00 0.02 0.09 0.02 0.04 0.15 0.07 0.05 0.01 0.05 0.01 0.02 0.07 0.02 0.03 0.03 0.01 0.08 0.01 0.05 0.01 0.06 0.01 0.01 0.02 0.03 0.02 0.01 0.03 0.08 0.03 0.01 0.06 0.01 0.05 0.07 0.02 0.03 0.04 0.02 0.11 0.02 0.03 0.02 0.01 0.02 0.04 0.01 0.02 0.07 0.01 0.03 0.02 0.04 0.02 0.02 0.08 0.03 0.03 0.03 0.02 0.02 0.01 0.02 Cases 183 786 1374 328 1021 704 258 438 687 114 567 115 28286 5324 22012 1348 298 1018 190 18 69 100 3016 733 2223 1490 262 1207 382 388 1957 299 1621 166 3318 592 2499 8886 413 1559 779 5998 587 260 318 2266 450 1760 174 57 676 462 257 628 8 50 0 17 212 18 41 53 289 15 167 16 43 36 660 581 43 36 66 83 192 149 515 123 Female ASR(W) CUM 0-74 2.8 2.5 3.1 6.9 2.5 3.8 7.2 2.9 2.5 5.3 2.2 2.6 2.8 6.0 2.5 3.3 7.3 2.8 2.6 4.5 3.2 2.2 3.3 6.7 2.9 2.7 5.6 2.4 2.4 2.5 2.9 6.1 2.5 3.0 2.9 6.4 2.6 2.9 1.8 6.2 3.1 2.5 3.3 6.2 2.4 3.0 6.3 2.6 2.5 1.8 2.8 2.8 2.6 2.6 1.5 0.8 0.7 0.8 0.5 1.6 0.6 1.8 1.6 0.9 0.4 0.7 1.2 3.2 3.0 2.8 0.8 1.0 1.4 1.2 1.3 1.0 1.1 0.23 0.10 0.09 0.40 0.09 0.16 0.48 0.16 0.11 0.53 0.11 0.27 0.02 0.09 0.02 0.10 0.44 0.10 0.20 1.07 0.40 0.24 0.07 0.26 0.07 0.08 0.37 0.08 0.13 0.14 0.07 0.38 0.07 0.27 0.06 0.28 0.06 0.03 0.09 0.16 0.11 0.04 0.15 0.41 0.15 0.07 0.31 0.07 0.20 0.26 0.12 0.15 0.18 0.12 0.54 0.12 0.16 0.06 0.12 0.26 0.08 0.11 0.42 0.07 0.11 0.11 0.20 0.13 0.14 0.44 0.14 0.14 0.16 0.10 0.13 0.05 0.12 0.33 0.32 0.38 0.82 0.32 0.47 0.88 0.35 0.30 0.68 0.27 0.31 0.35 0.72 0.30 0.39 0.90 0.33 0.31 0.71 0.39 0.25 0.40 0.80 0.34 0.33 0.68 0.29 0.29 0.31 0.35 0.74 0.31 0.35 0.35 0.76 0.32 0.35 0.22 0.74 0.38 0.31 0.41 0.77 0.29 0.36 0.74 0.32 0.30 0.22 0.34 0.34 0.32 0.31 0.18 0.10 0.06 0.10 0.08 0.22 0.08 0.22 0.12 0.11 0.05 0.09 0.16 0.40 0.38 0.39 0.11 0.12 0.18 0.14 0.16 0.11 0.14 0.03 0.02 0.01 0.06 0.01 0.02 0.07 0.02 0.02 0.08 0.02 0.04 0.00 0.01 0.00 0.01 0.07 0.01 0.03 0.19 0.06 0.03 0.01 0.04 0.01 0.01 0.05 0.01 0.02 0.02 0.01 0.06 0.01 0.04 0.01 0.04 0.01 0.01 0.01 0.02 0.02 0.01 0.02 0.06 0.02 0.01 0.05 0.01 0.03 0.04 0.02 0.02 0.03 0.02 0.08 0.02 * - * 0.02 0.01 * 0.02 * 0.04 * 0.01 0.02 * 0.04 0.01 0.01 * 0.02 * 0.03 * 0.02 0.02 0.07 0.02 0.02 0.03 0.01 0.02 0.01 0.02

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
581

639

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Multiple myeloma (C90) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
582

Male ASR(W) CUM 0-74 1.3 1.1 1.3 1.8 1.2 1.4 1.6 1.7 1.0 1.3 1.8 0.8 1.4 2.0 1.8 0.7 1.4 1.3 1.3 2.6 0.7 0.6 0.8 1.8 1.7 2.6 3.1 2.8 1.3 2.6 3.8 1.1 2.9 3.0 3.3 2.4 3.2 3.7 3.8 3.8 4.2 3.2 3.5 2.9 4.0 2.9 2.5 2.0 3.6 3.3 3.7 3.7 2.3 3.8 3.0 3.4 4.6 2.8 3.7 4.9 3.8 4.9 4.3 3.8 4.4 4.1 4.1 5.1 3.6 3.7 6.0 3.2 3.5 4.4 4.1 4.8 3.3 4.4 4.2 0.04 0.12 0.16 0.27 0.22 0.17 0.48 0.10 0.30 0.38 0.63 0.21 0.21 0.35 0.28 0.11 0.13 0.14 0.46 0.57 0.13 0.18 0.17 0.25 0.15 0.09 0.36 0.50 0.07 0.19 0.14 0.06 0.13 0.09 0.13 0.23 0.13 0.32 0.41 0.45 0.41 0.31 0.30 0.27 0.43 0.38 0.40 0.29 0.19 0.13 0.23 0.23 0.16 0.19 0.25 0.63 0.20 0.53 0.40 0.51 0.27 0.42 0.74 0.29 0.40 0.51 0.21 0.52 0.53 0.43 0.36 0.32 0.44 0.59 0.73 0.33 0.29 0.48 0.25 0.17 0.15 0.14 0.24 0.16 0.17 0.23 0.20 0.13 0.16 0.16 0.13 0.19 0.25 0.22 0.09 0.17 0.14 0.16 0.36 0.08 0.07 0.11 0.20 0.22 0.32 0.39 0.32 0.17 0.27 0.44 0.15 0.34 0.37 0.41 0.33 0.35 0.42 0.48 0.38 0.52 0.38 0.37 0.33 0.47 0.38 0.26 0.28 0.45 0.39 0.47 0.47 0.26 0.47 0.36 0.44 0.53 0.36 0.44 0.58 0.44 0.55 0.56 0.45 0.50 0.55 0.50 0.59 0.40 0.43 0.70 0.37 0.43 0.49 0.49 0.63 0.40 0.49 0.52 0.01 0.02 0.02 0.05 0.04 0.02 0.08 0.01 0.05 0.06 0.07 0.04 0.03 0.05 0.04 0.02 0.02 0.02 0.06 0.09 0.02 0.03 0.03 0.03 0.02 0.01 0.06 0.07 0.01 0.03 0.02 0.01 0.02 0.01 0.02 0.03 0.02 0.05 0.06 0.06 0.06 0.04 0.04 0.04 0.06 0.06 0.05 0.04 0.03 0.02 0.03 0.03 0.02 0.03 0.04 0.09 0.03 0.08 0.06 0.07 0.04 0.06 0.10 0.04 0.05 0.08 0.03 0.07 0.08 0.06 0.05 0.04 0.06 0.08 0.11 0.05 0.04 0.06 0.04

Cases 900 68 59 39 22 43 10 280 10 14 5 25 22 28 24 81 95 73 7 15 23 13 30 42 102 943 60 35 517 180 734 368 498 1092 629 134 741 139 82 72 103 128 144 140 87 61 55 56 365 733 239 237 168 440 137 29 411 46 127 84 242 133 30 204 137 45 424 120 48 93 291 112 77 43 34 197 147 81 339

Female ASR(W) CUM 0-74 0.8 0.6 0.9 1.2 0.6 0.7 0.7 1.1 0.7 1.3 0.7 1.1 0.6 1.9 1.3 1.1 1.0 0.9 1.5 1.6 0.5 0.5 1.0 1.5 1.2 2.0 1.9 2.2 1.1 1.8 2.8 1.0 2.2 2.1 2.3 1.8 2.4 2.5 2.3 2.7 2.8 2.5 2.5 2.6 2.8 2.0 2.3 1.8 2.5 2.3 2.1 2.4 1.2 2.8 1.9 2.3 2.6 3.3 3.6 3.0 2.8 2.4 1.8 2.6 3.5 2.4 2.9 4.1 3.0 3.1 3.9 2.5 2.9 2.6 3.1 3.0 2.3 3.1 3.2 0.03 0.08 0.12 0.20 0.13 0.11 0.23 0.07 0.22 0.36 0.42 0.22 0.12 0.36 0.29 0.12 0.11 0.11 0.59 0.41 0.11 0.14 0.19 0.23 0.12 0.07 0.27 0.40 0.05 0.16 0.12 0.05 0.11 0.07 0.10 0.17 0.10 0.24 0.29 0.36 0.31 0.25 0.24 0.24 0.35 0.29 0.37 0.28 0.14 0.10 0.16 0.17 0.10 0.15 0.19 0.47 0.14 0.61 0.36 0.39 0.21 0.25 0.39 0.21 0.35 0.37 0.16 0.46 0.48 0.38 0.27 0.27 0.36 0.43 0.62 0.25 0.22 0.38 0.20 0.11 0.09 0.12 0.16 0.08 0.11 0.10 0.15 0.10 0.17 0.13 0.13 0.06 0.26 0.17 0.15 0.12 0.11 0.14 0.20 0.07 0.07 0.16 0.20 0.16 0.24 0.23 0.23 0.15 0.21 0.34 0.13 0.27 0.26 0.28 0.23 0.27 0.29 0.28 0.31 0.34 0.30 0.28 0.34 0.35 0.25 0.27 0.22 0.30 0.28 0.26 0.31 0.15 0.33 0.23 0.26 0.30 0.36 0.44 0.36 0.34 0.26 0.20 0.31 0.45 0.32 0.35 0.48 0.37 0.36 0.44 0.29 0.36 0.38 0.31 0.36 0.28 0.34 0.39 0.00 0.01 0.02 0.03 0.02 0.02 0.04 0.01 0.03 0.05 0.09 0.03 0.01 0.06 * 0.04 * 0.02 * 0.02 0.02 0.06 0.06 0.02 * 0.02 * 0.03 0.03 * 0.02 * 0.01 0.04 0.05 0.01 * 0.02 * 0.02 0.01 * 0.01 0.01 0.01 0.02 0.01 0.03 0.04 0.05 0.04 0.04 0.03 0.03 0.05 0.04 0.05 0.04 0.02 0.01 0.02 0.02 0.02 0.02 0.03 0.07 0.02 0.07 0.05 0.05 0.03 0.04 0.06 0.03 0.05 0.06 0.02 0.06 0.07 0.05 0.04 0.04 0.05 0.07 0.08 0.03 0.03 0.05 0.03

1137 96 70 45 30 70 11 346 14 11 26 13 47 34 44 46 111 80 10 21 26 12 22 52 141 802 73 33 380 202 792 365 480 1084 740 106 663 137 96 75 110 118 146 120 98 65 50 53 363 652 270 254 217 411 152 31 583 31 91 108 237 159 39 194 137 64 422 114 52 87 332 111 66 61 33 222 155 90 312

640

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Multiple myeloma (C90) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 128 239 28 810 61 101 166 209 293 248 238 493 173 44 171 225 164 53 82 94 144 54 74 117 1492 50 28 18 59 44 37 64 2205 110 106 461 341 627 1065 408 1427 2175 850 831 276 814 1099 13 583 307 78 785 260 37 11 706 146 4 30 26 18 56 Male ASR(W) CUM 0-74 1.6 2.2 2.0 4.2 2.4 2.3 2.7 2.0 2.6 1.8 1.3 3.1 2.5 3.2 3.1 3.0 3.5 4.3 3.2 2.8 3.5 1.9 3.0 2.9 3.6 3.2 3.0 2.9 2.8 3.1 3.3 2.5 3.7 3.0 2.9 3.6 3.3 3.6 3.8 3.9 4.4 3.9 3.9 3.6 4.5 3.8 4.5 3.8 4.5 5.0 4.2 4.4 4.1 4.3 2.8 5.2 3.1 1.5 3.3 5.3 1.2 4.4 0.15 0.14 0.38 0.16 0.31 0.24 0.22 0.14 0.16 0.11 0.09 0.14 0.19 0.52 0.25 0.21 0.28 0.69 0.38 0.30 0.30 0.29 0.38 0.29 0.10 0.46 0.59 0.70 0.38 0.49 0.57 0.33 0.08 0.29 0.29 0.18 0.19 0.15 0.12 0.20 0.12 0.09 0.14 0.13 0.28 0.14 0.14 1.12 0.19 0.30 0.49 0.16 0.26 0.72 0.85 0.20 0.28 0.78 0.66 1.06 0.32 0.61 0.21 0.28 0.25 0.49 0.34 0.28 0.32 0.26 0.32 0.24 0.17 0.38 0.31 0.38 0.34 0.35 0.42 0.49 0.39 0.37 0.41 0.20 0.34 0.34 0.43 0.37 0.36 0.40 0.39 0.33 0.40 0.28 0.44 0.39 0.34 0.43 0.39 0.42 0.44 0.47 0.50 0.45 0.45 0.45 0.54 0.45 0.51 0.37 0.53 0.59 0.48 0.49 0.47 0.52 0.40 0.58 0.33 0.15 0.28 0.63 0.14 0.46 0.02 0.02 0.06 0.02 0.05 0.03 0.03 0.02 0.02 0.02 0.01 0.02 0.03 0.07 0.03 0.03 0.04 0.09 0.06 0.05 0.04 0.04 0.05 0.04 0.01 0.07 0.09 0.10 0.07 0.07 0.08 0.05 0.01 0.04 0.04 0.03 0.03 0.02 0.02 0.03 0.02 0.01 0.02 0.02 0.04 0.02 0.02 0.14 0.03 0.04 0.07 0.02 0.04 0.11 0.15 0.03 0.04 0.09 0.09 0.16 0.05 0.08 Cases 168 335 32 748 66 110 192 151 295 378 232 569 222 41 192 206 147 27 79 116 144 52 65 114 1280 44 36 23 70 63 36 68 1809 117 102 404 272 606 971 354 1257 1957 806 766 220 790 858 1 442 228 64 629 200 20 16 506 111 5 20 24 24 27 Female ASR(W) CUM 0-74 1.3 1.9 1.8 3.0 1.7 2.0 2.0 1.2 2.0 1.5 1.1 2.5 2.2 2.6 2.5 2.0 2.5 1.9 2.7 2.9 2.7 1.7 2.0 2.2 2.5 1.8 3.1 1.7 2.7 2.8 2.6 1.9 2.3 2.5 2.2 2.5 1.9 2.6 2.6 2.7 2.8 2.6 2.9 2.5 2.6 2.5 2.9 0.5 3.0 2.9 2.5 2.7 2.6 1.8 4.1 3.0 2.0 0.7 2.6 4.5 1.5 1.7 0.10 0.11 0.34 0.13 0.22 0.20 0.16 0.10 0.12 0.08 0.08 0.11 0.16 0.49 0.21 0.16 0.22 0.44 0.34 0.29 0.25 0.26 0.28 0.23 0.08 0.31 0.59 0.40 0.37 0.39 0.48 0.27 0.06 0.25 0.24 0.14 0.13 0.12 0.10 0.16 0.10 0.07 0.12 0.11 0.20 0.10 0.11 0.48 0.16 0.22 0.35 0.12 0.20 0.44 1.04 0.15 0.21 0.32 0.61 0.94 0.36 0.36 0.17 0.24 0.21 0.36 0.19 0.25 0.28 0.15 0.26 0.19 0.14 0.32 0.27 0.29 0.27 0.24 0.28 0.25 0.36 0.39 0.33 0.22 0.21 0.27 0.30 0.25 0.32 0.19 0.30 0.38 0.32 0.24 0.28 0.31 0.30 0.31 0.22 0.32 0.32 0.32 0.32 0.31 0.35 0.28 0.29 0.29 0.33 0.08 0.36 0.36 0.23 0.30 0.31 0.19 0.58 0.35 0.26 0.10 0.27 0.59 0.19 0.19 0.01 0.02 0.05 0.02 0.03 * 0.03 0.02 0.01 * 0.02 0.01 0.01 0.02 0.02 0.06 0.03 0.02 0.03 0.06 0.05 0.04 0.03 0.04 0.04 0.03 0.01 0.05 0.07 0.07 0.05 0.07 0.07 0.04 0.01 0.04 0.04 0.02 0.02 0.02 0.01 0.02 0.01 0.01 0.02 0.01 0.03 0.01 0.02 0.08 0.02 0.03 0.05 0.02 0.03 0.06 0.16 0.02 0.03 0.07 0.08 0.15 0.05 0.06

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
583

641

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Leukaemia (C91-95)
Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 85 375 53 33 84 104 174 65 117 2029 58 304 551 253 68 69 8363 1101 1315 444 248 95 1 307 4318 58 476 1138 177 940 146 1469 10422 722 528 1926 7022 1912 105 98 60 16 244 1262 2755 219 58 53 34 21 721 1541 1373 1253 52 1163 119 69 39 6990 424 6479 1960 371 1556 667 157 491 467 4269 399 3720 1933 1420 1435 1465 301 1154 84 211 Male ASR(W) CUM 0-74 3.2 6.5 5.1 1.3 2.6 13.7 5.9 7.4 7.0 9.1 6.9 7.8 6.2 8.2 6.2 6.2 11.3 12.7 9.7 11.7 10.6 6.4 1.8 9.9 11.7 13.6 13.3 8.1 6.3 8.5 10.0 8.9 10.8 6.8 9.0 9.1 11.5 10.0 7.8 7.2 7.3 5.1 8.7 10.8 10.8 9.0 6.1 7.4 8.5 4.7 9.0 12.6 11.2 11.1 7.2 11.4 7.8 7.3 7.3 10.9 7.6 11.4 9.1 7.8 9.6 10.2 8.8 11.3 11.4 11.2 9.1 11.5 10.3 13.5 11.3 11.0 9.0 12.0 8.4 11.7 0.38 0.37 0.71 0.35 0.38 1.60 0.50 0.98 0.68 0.21 0.93 0.46 0.27 0.53 0.80 0.79 0.13 0.40 0.30 0.60 0.75 0.73 1.81 0.63 0.19 1.90 0.67 0.26 0.49 0.31 0.87 0.25 0.11 0.27 0.40 0.22 0.16 0.25 0.79 0.81 1.00 1.72 0.59 0.36 0.22 0.62 0.89 1.07 1.89 1.07 0.36 0.39 0.32 0.35 1.03 0.38 0.78 0.95 1.36 0.15 0.38 0.17 0.21 0.42 0.26 0.41 0.76 0.54 0.56 0.18 0.46 0.21 0.25 0.40 0.32 0.30 0.53 0.38 0.94 0.92 1.29 0.51 0.56 0.62 0.84 0.54 0.65 0.50 0.71 0.58 0.60 1.13 1.36 0.95 1.25 1.03 0.61 0.30 0.91 1.15 1.31 1.50 0.80 0.62 0.83 1.06 0.84 1.06 0.63 0.96 0.81 1.16 0.98 0.81 0.62 0.66 0.36 0.71 1.11 1.07 1.02 0.51 0.67 0.74 0.56 0.84 1.26 1.06 1.13 0.73 1.15 0.76 0.70 0.76 1.08 0.78 1.12 0.92 0.82 0.95 1.04 0.90 1.13 1.11 1.12 1.00 1.13 1.03 1.43 1.14 1.11 0.92 1.19 0.72 1.16 0.17 0.07 0.11 0.09 0.03 0.09 0.05 0.03 0.06 0.09 0.10 0.02 0.05 0.03 0.07 0.08 0.07 0.30 0.07 0.02 0.20 0.09 0.03 0.06 0.03 0.12 0.03 0.01 0.03 0.05 0.03 0.02 0.03 0.11 0.08 0.11 0.14 0.07 0.04 0.03 0.08 0.09 0.12 0.15 0.15 0.05 0.04 0.04 0.04 0.13 0.04 0.09 0.10 0.16 0.02 0.05 0.02 0.03 0.06 0.03 0.05 0.11 0.07 0.07 0.02 0.06 0.02 0.03 0.05 0.04 0.04 0.07 0.05 0.11 0.10 Cases 75 300 39 29 51 79 114 49 117 1739 42 290 434 226 63 72 5993 757 920 355 155 56 2 249 3150 34 315 973 183 773 113 1059 7617 562 405 1510 4990 1438 89 64 36 13 198 965 2049 187 48 46 25 22 610 1025 987 979 53 914 94 61 27 5232 447 4707 1533 320 1192 479 109 358 333 3443 356 2989 1570 1001 1103 1140 281 844 79 171 Female ASR(W) CUM 0-74 2.7 4.8 3.6 1.4 2.0 8.3 3.4 5.7 5.7 6.4 4.3 6.2 4.8 6.5 5.1 5.8 6.9 8.0 6.1 7.8 6.1 4.0 3.3 6.9 7.1 6.5 7.5 5.4 4.5 5.7 7.5 5.8 6.8 4.7 5.5 6.6 7.0 6.4 5.1 4.0 3.5 2.6 6.7 7.0 6.9 5.5 4.3 5.2 3.3 4.4 6.7 7.4 7.0 7.3 5.4 7.5 4.3 3.8 4.8 7.1 6.3 7.2 5.7 4.7 6.1 5.7 4.1 6.7 7.3 7.2 5.9 7.4 6.9 7.7 7.0 6.9 6.3 7.1 6.1 6.9 0.34 0.29 0.58 0.40 0.37 1.20 0.33 0.86 0.54 0.16 0.68 0.38 0.23 0.45 0.70 0.71 0.11 0.32 0.25 0.49 0.59 0.64 2.36 0.54 0.15 1.41 0.50 0.20 0.37 0.25 0.74 0.20 0.09 0.22 0.29 0.18 0.13 0.20 0.59 0.57 0.65 0.82 0.49 0.30 0.17 0.43 0.73 0.85 0.75 1.05 0.28 0.32 0.25 0.28 0.78 0.31 0.55 0.60 1.25 0.13 0.31 0.14 0.16 0.28 0.21 0.28 0.41 0.41 0.46 0.15 0.33 0.17 0.20 0.31 0.25 0.23 0.40 0.29 0.72 0.67 0.68 0.27 0.54 0.52 0.58 0.38 0.51 0.39 0.57 0.45 0.57 0.66 0.80 0.55 0.78 0.61 0.31 0.49 0.59 0.67 0.53 0.81 0.52 0.44 0.54 0.63 0.51 0.61 0.41 0.54 0.55 0.65 0.54 0.44 0.32 0.26 0.24 0.53 0.62 0.62 0.57 0.36 0.47 0.39 0.30 0.57 0.69 0.67 0.68 0.50 0.71 0.38 0.36 0.39 0.66 0.58 0.67 0.53 0.45 0.56 0.53 0.37 0.63 0.68 0.70 0.59 0.71 0.66 0.73 0.66 0.71 0.63 0.74 0.64 0.73 * * * *

0.11 0.04 0.12 0.07 0.02 0.08 0.04 0.03 0.05 0.07 0.09 * 0.01 0.04 0.02 0.06 0.06 0.05 0.37 0.05 0.02 0.13 0.06 0.02 0.04 0.03 0.08 0.02 0.01 0.02 0.04 0.02 0.01 0.02 0.07 0.05 0.05 0.09 0.05 0.03 0.02 0.05 0.07 0.08 0.10 0.07 0.03 0.03 0.03 0.03 0.09 0.03 0.05 0.06 0.11 0.01 0.04 0.01 0.02 0.03 0.02 0.03 0.05 0.05 0.05 0.02 0.04 0.02 0.02 0.03 0.03 0.03 0.05 0.03 0.09 0.07

642

*Important. See note on population page.

584

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Leukaemia (C91-95) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 553 1978 3415 292 3044 1477 217 1226 1903 150 1738 363 74692 5241 66537 3090 250 2689 643 26 157 441 6804 526 6069 3491 259 3137 1130 1144 4892 249 4511 411 9246 597 7939 24462 1175 1669 2517 18641 1168 233 913 6207 510 5502 612 224 2223 1543 683 2154 62 353 1032 52 100 939 163 167 432 1715 30 1169 265 245 119 1800 1531 160 129 157 211 433 546 1712 200 Male ASR(W) CUM 0-74 12.2 9.8 11.2 8.5 11.6 12.1 8.8 13.2 10.4 10.2 10.5 11.2 10.7 8.2 11.0 11.5 8.8 11.7 11.8 6.6 8.7 13.9 11.4 7.8 12.1 9.7 8.0 9.7 10.3 10.5 11.4 7.8 11.5 12.0 11.4 8.5 12.0 11.1 7.1 8.9 9.2 11.8 9.5 8.0 9.9 11.0 9.6 11.1 10.7 11.7 11.9 12.1 10.4 12.1 8.5 6.8 5.8 5.8 4.6 4.9 5.2 8.4 4.3 5.8 2.9 4.4 5.3 3.0 4.5 10.8 10.5 7.5 4.2 4.8 6.5 5.4 9.0 6.0 4.2 0.58 0.24 0.21 0.51 0.23 0.34 0.62 0.41 0.26 0.85 0.28 0.65 0.04 0.12 0.05 0.23 0.57 0.25 0.49 1.33 0.71 0.77 0.15 0.35 0.17 0.18 0.51 0.19 0.33 0.34 0.18 0.50 0.20 0.66 0.13 0.36 0.15 0.08 0.22 0.22 0.20 0.10 0.29 0.54 0.36 0.14 0.44 0.16 0.45 0.86 0.27 0.33 0.44 0.29 1.15 0.38 0.20 0.93 0.55 0.21 0.42 0.69 0.21 0.15 0.53 0.14 0.34 0.21 0.42 0.26 0.28 0.67 0.41 0.46 0.50 0.31 0.45 0.17 0.37 1.21 1.00 1.14 0.95 1.17 1.27 0.98 1.35 1.04 1.01 1.05 1.10 1.07 0.85 1.10 1.15 0.91 1.17 1.22 0.70 0.87 1.45 1.15 0.77 1.23 0.97 0.83 0.96 1.03 1.08 1.16 0.79 1.17 1.15 1.16 0.91 1.22 1.11 0.64 0.93 0.84 1.19 0.95 0.81 0.98 1.08 1.02 1.08 1.08 1.21 1.21 1.19 1.07 1.28 0.79 0.55 0.52 0.45 0.45 0.45 0.47 0.80 0.37 0.52 0.20 0.40 0.45 0.28 0.39 1.10 1.06 0.76 0.40 0.50 0.57 0.50 0.93 0.56 0.41 0.07 0.03 0.03 0.07 0.03 0.04 0.08 0.05 0.03 0.11 0.03 0.08 0.01 0.02 0.01 0.03 0.07 0.03 0.06 0.18 0.09 0.09 0.02 0.04 0.02 0.02 0.07 0.02 0.04 0.04 0.02 0.07 0.02 0.08 0.02 0.05 0.02 0.01 0.02 0.03 0.03 0.01 0.04 0.07 0.04 0.02 0.06 0.02 0.06 0.10 0.03 0.04 0.05 0.04 0.15 0.04 0.02 0.07 0.05 0.02 0.04 0.07 0.02 0.02 0.04 0.02 0.04 0.03 0.04 0.03 0.03 0.10 0.04 0.05 0.05 0.03 0.05 0.02 0.03 Cases 378 1746 2760 296 2389 1329 226 1075 1440 123 1300 251 57712 4675 50808 2407 218 2092 428 19 116 288 5553 543 4847 2775 216 2490 856 888 3850 249 3489 308 6957 509 5983 18307 891 1393 1963 13749 921 208 688 4597 410 4059 437 162 1605 1080 563 1711 37 242 828 41 63 748 113 116 256 942 30 738 139 175 78 1393 1182 102 89 96 156 341 438 1158 159 Female ASR(W) CUM 0-74 7.2 7.1 7.3 6.4 7.4 8.3 6.6 8.8 6.4 6.1 6.4 6.7 6.8 5.4 7.0 7.2 5.6 7.4 6.7 4.2 5.5 8.3 7.1 5.5 7.4 6.1 4.8 6.2 6.4 7.1 7.2 5.7 7.2 7.1 7.1 5.5 7.5 7.0 4.8 5.6 6.6 7.2 5.9 5.3 6.0 6.7 5.7 6.9 6.7 7.0 7.6 7.4 7.0 8.0 4.2 5.1 4.4 4.5 3.3 3.7 3.6 5.7 2.7 3.8 3.0 3.2 3.0 2.4 2.8 7.0 6.7 4.5 2.9 2.7 3.8 3.7 5.9 3.7 3.1 0.46 0.21 0.16 0.40 0.18 0.27 0.47 0.33 0.20 0.58 0.22 0.52 0.03 0.08 0.04 0.18 0.40 0.20 0.37 0.99 0.53 0.66 0.11 0.25 0.13 0.14 0.35 0.15 0.26 0.29 0.15 0.39 0.16 0.51 0.10 0.26 0.12 0.06 0.18 0.16 0.15 0.08 0.23 0.40 0.28 0.11 0.30 0.12 0.34 0.67 0.22 0.26 0.37 0.23 0.73 0.36 0.18 0.82 0.53 0.18 0.35 0.59 0.18 0.13 0.56 0.12 0.27 0.19 0.32 0.20 0.21 0.48 0.34 0.37 0.36 0.25 0.38 0.14 0.35 0.71 0.67 0.72 0.69 0.71 0.81 0.72 0.84 0.61 0.58 0.61 0.67 0.64 0.53 0.66 0.68 0.51 0.70 0.59 0.35 0.44 0.73 0.66 0.52 0.70 0.57 0.45 0.58 0.59 0.67 0.70 0.54 0.71 0.68 0.66 0.55 0.70 0.65 0.42 0.56 0.55 0.68 0.57 0.53 0.58 0.63 0.53 0.64 0.63 0.65 0.74 0.72 0.65 0.80 0.43 0.37 0.36 0.39 0.28 0.34 0.29 0.54 0.22 0.35 0.30 0.27 0.24 0.22 0.25 0.69 0.67 0.42 0.27 0.25 0.36 0.34 0.59 0.33 0.26 0.05 0.02 0.02 0.05 0.02 0.03 0.06 0.04 0.02 0.07 0.02 0.06 0.00 0.01 0.00 0.02 0.05 0.02 0.04 0.10 0.05 0.06 0.01 0.03 0.01 0.01 0.04 0.02 0.03 0.03 0.02 0.04 0.02 0.05 0.01 0.03 0.01 0.01 0.02 0.02 0.02 0.01 0.03 0.05 0.03 0.01 0.04 0.01 0.04 0.07 0.03 0.03 0.04 0.03 0.11 0.03 * 0.02 0.07 * 0.04 0.01 * 0.03 * 0.06 * 0.02 0.02 * 0.07 0.01 0.03 * 0.02 * 0.03 * 0.02 0.03 0.06 0.03 0.03 0.04 0.02 0.03 0.01 0.03

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
585

643

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Leukaemia (C91-95) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
586

Male ASR(W) CUM 0-74 5.0 4.9 4.9 4.8 5.2 4.4 5.4 5.7 3.9 5.3 7.6 6.9 4.8 5.6 4.8 6.6 6.1 6.2 5.1 6.6 4.6 4.9 3.9 5.9 5.3 8.2 9.8 9.7 8.4 6.4 9.5 6.0 10.3 9.8 10.8 8.6 8.3 10.1 9.6 10.6 11.5 9.1 11.1 13.4 11.4 6.8 9.1 6.8 10.8 9.1 8.7 11.6 8.4 9.5 9.0 9.0 10.6 15.2 11.7 9.2 9.1 9.8 9.2 11.3 11.6 10.0 9.2 11.7 9.5 11.8 12.8 10.3 11.2 10.6 14.1 9.5 10.8 10.5 9.9 0.08 0.27 0.30 0.42 0.43 0.29 0.92 0.18 0.50 0.65 1.28 0.57 0.33 0.52 0.36 0.29 0.30 0.35 0.96 0.83 0.38 0.54 0.38 0.45 0.27 0.20 0.74 1.07 0.19 0.35 0.26 0.17 0.30 0.19 0.26 0.50 0.25 0.59 0.71 0.81 0.70 0.61 0.59 0.64 0.95 0.65 0.98 0.67 0.42 0.28 0.44 0.52 0.37 0.37 0.59 1.08 0.32 1.97 0.89 0.97 0.61 0.87 1.56 0.71 0.86 0.88 0.42 1.04 1.08 1.06 0.73 0.66 0.83 1.21 1.88 0.63 0.76 0.89 0.50 0.45 0.43 0.44 0.47 0.46 0.36 0.44 0.49 0.36 0.47 0.51 0.60 0.39 0.55 0.39 0.60 0.49 0.49 0.39 0.62 0.38 0.38 0.39 0.53 0.49 0.78 0.94 0.97 0.92 0.70 0.99 0.62 1.01 1.00 1.11 0.88 0.74 1.02 1.00 1.18 1.27 0.94 1.11 1.40 1.10 0.72 0.86 0.67 1.02 0.95 0.84 1.12 0.79 0.91 0.80 1.01 1.08 1.42 1.13 1.00 0.80 0.94 0.87 1.02 1.21 0.96 0.88 1.16 0.93 1.10 1.16 0.96 1.26 0.91 1.18 0.88 1.02 1.02 0.95 0.01 0.03 0.03 0.06 0.05 0.03 0.10 0.02 0.06 0.09 0.08 0.06 0.04 0.07 0.04 0.04 0.03 0.03 0.08 0.10 0.03 0.05 0.05 0.05 0.03 0.02 0.08 0.12 0.02 0.04 0.03 0.02 0.03 0.02 0.03 0.06 0.02 0.07 0.08 0.10 0.09 0.07 0.07 0.08 0.09 0.08 0.09 0.07 0.04 0.03 0.05 0.05 0.04 0.04 0.05 0.14 0.04 0.16 0.09 0.10 0.05 0.08 0.13 0.06 0.08 0.09 0.04 0.10 0.11 0.09 0.07 0.07 0.11 0.10 0.16 0.06 0.07 0.09 0.05

Cases 3477 290 242 113 125 218 32 973 64 71 61 120 181 109 126 624 348 276 20 52 146 85 118 128 321 1947 177 68 2158 285 1206 1297 1289 2488 1625 371 1218 260 178 136 231 219 316 347 147 117 106 74 776 1456 462 549 563 770 270 62 848 72 184 124 399 212 48 368 215 122 685 161 91 140 424 243 118 60 49 318 263 162 522

Female ASR(W) CUM 0-74 3.7 3.1 3.8 3.5 3.9 3.7 4.0 4.1 3.5 3.8 7.4 5.2 3.9 4.1 4.1 5.5 4.3 4.1 3.8 5.0 4.0 4.3 4.0 4.1 4.1 5.3 6.4 6.1 5.6 3.6 6.2 4.4 7.2 5.7 7.2 5.9 5.7 6.9 6.3 6.7 8.0 6.0 6.8 7.3 7.2 5.4 5.5 3.6 6.5 6.0 5.3 6.7 5.2 6.6 4.8 6.6 6.7 5.2 6.6 6.0 6.2 7.8 5.6 6.9 6.7 7.8 6.5 8.8 7.4 5.7 7.5 6.8 6.4 4.9 6.3 7.3 6.6 9.3 6.5 0.07 0.20 0.26 0.35 0.36 0.26 0.76 0.14 0.46 0.51 1.45 0.48 0.30 0.45 0.42 0.24 0.24 0.27 0.87 0.72 0.36 0.49 0.38 0.37 0.23 0.16 0.60 0.90 0.14 0.25 0.22 0.15 0.25 0.14 0.22 0.38 0.21 0.50 0.60 0.69 0.63 0.52 0.44 0.48 0.77 0.59 0.78 0.49 0.33 0.24 0.33 0.38 0.29 0.33 0.38 0.96 0.26 0.85 0.64 0.98 0.49 0.90 1.24 0.55 0.65 0.76 0.37 1.12 1.01 0.66 0.57 0.54 0.74 0.77 1.17 0.65 0.59 1.04 0.42 0.31 0.26 0.34 0.30 0.33 0.30 0.33 0.37 0.29 0.33 0.40 0.42 0.34 0.40 0.36 0.50 0.36 0.35 0.29 0.49 0.34 0.39 0.32 0.29 0.37 0.50 0.60 0.50 0.60 0.38 0.60 0.42 0.67 0.57 0.69 0.63 0.50 0.72 0.63 0.66 0.80 0.55 0.68 0.71 0.69 0.52 0.48 0.35 0.59 0.57 0.52 0.67 0.50 0.55 0.49 0.54 0.62 0.58 0.64 0.53 0.58 0.67 0.53 0.66 0.65 0.71 0.56 0.74 0.70 0.57 0.69 0.62 0.65 0.46 0.61 0.61 0.60 0.82 0.62 0.01 0.02 0.03 0.03 0.03 0.02 0.06 0.01 0.05 0.06 0.08 0.05 0.04 0.06 * 0.05 * 0.03 * 0.02 0.03 0.07 0.08 0.03 * 0.05 * 0.04 0.03 * 0.02 * 0.02 0.06 0.08 0.01 * 0.03 * 0.02 0.01 * 0.02 0.01 0.02 0.04 0.02 0.05 0.06 0.07 0.07 0.05 0.05 0.05 0.07 0.06 0.07 0.05 0.03 0.02 0.03 0.04 0.03 0.03 0.04 0.09 0.03 0.10 0.06 0.07 0.04 0.06 0.10 0.04 0.06 0.08 0.03 0.08 0.09 0.07 0.05 0.05 0.07 0.07 0.11 0.05 0.05 0.08 0.04

4462 409 289 140 157 263 36 1218 75 89 149 157 233 151 204 670 458 359 31 68 160 93 108 182 413 2195 201 94 2275 421 1682 1640 1449 3150 2091 346 1360 326 212 185 294 293 410 509 190 130 128 135 930 1532 524 675 688 841 333 77 1207 107 237 162 411 248 67 425 275 139 736 221 107 203 563 303 216 106 79 364 381 187 598

644

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Leukaemia (C91-95) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 629 1020 115 1440 133 300 304 417 663 984 982 1334 509 80 366 483 365 62 162 211 338 145 171 229 3035 155 68 44 178 98 85 175 4314 246 250 895 654 1231 2349 900 2547 4448 1596 1776 473 1746 2640 26 1483 770 162 1615 588 94 45 1776 384 20 46 57 91 124 Male ASR(W) CUM 0-74 9.3 10.2 10.3 9.1 6.1 7.4 6.3 4.8 7.3 8.3 7.0 9.1 8.4 8.1 8.1 7.8 8.8 5.1 7.7 8.4 9.0 7.2 9.1 7.7 9.0 10.7 8.8 8.0 10.3 9.5 8.4 8.4 8.6 7.8 8.0 8.6 7.7 8.4 9.8 9.9 9.6 9.4 8.8 9.1 9.0 9.9 12.3 6.7 12.9 14.2 10.0 10.3 10.1 11.8 9.7 14.8 9.5 5.9 7.2 10.8 9.2 11.2 0.40 0.34 1.03 0.27 0.59 0.46 0.42 0.25 0.33 0.30 0.26 0.26 0.41 1.07 0.52 0.43 0.51 0.78 0.73 0.71 0.53 0.75 0.82 0.67 0.19 0.95 1.24 1.37 0.86 1.17 1.00 0.72 0.14 0.54 0.57 0.33 0.34 0.27 0.23 0.36 0.22 0.16 0.25 0.24 0.45 0.27 0.26 1.38 0.36 0.56 0.85 0.28 0.44 1.26 1.50 0.37 0.53 1.59 1.18 1.46 1.41 1.16 0.95 1.08 0.99 0.89 0.58 0.85 0.62 0.43 0.70 0.83 0.68 0.95 0.83 0.74 0.82 0.74 0.81 0.54 0.74 0.80 0.92 0.72 0.87 0.69 0.90 1.08 0.92 0.82 0.98 0.81 0.76 0.80 0.85 0.74 0.81 0.85 0.69 0.81 0.96 1.00 0.90 0.91 0.84 0.92 0.88 0.99 1.23 0.60 1.28 1.48 1.03 0.96 1.00 1.02 1.00 1.51 0.95 0.66 0.62 1.10 0.79 1.21 0.04 0.04 0.11 0.03 0.06 0.06 0.04 0.02 0.03 0.03 0.02 0.03 0.04 0.10 0.05 0.04 0.05 0.10 0.07 0.06 0.06 0.07 0.08 0.06 0.02 0.12 0.14 0.15 0.09 0.10 0.11 0.08 0.02 0.06 0.06 0.04 0.03 0.03 0.02 0.04 0.02 0.02 0.03 0.03 0.05 0.03 0.03 0.18 0.04 0.07 0.10 0.03 0.05 0.14 0.20 0.05 0.06 0.19 0.12 0.20 0.12 0.14 Cases 616 942 76 1098 153 355 279 333 495 1250 712 1047 422 71 277 355 257 49 113 163 274 96 108 183 2274 130 48 43 126 73 65 137 3163 198 141 643 515 964 1954 656 2076 3417 1140 1357 325 1331 1827 20 1048 577 118 1212 389 66 38 1253 269 15 27 45 69 77 Female ASR(W) CUM 0-74 5.9 6.5 5.8 5.9 6.4 6.9 4.3 3.6 5.0 5.9 4.4 5.7 5.8 5.9 5.7 5.0 5.7 5.8 5.4 5.4 7.1 4.6 5.2 5.6 6.4 6.3 4.8 6.0 6.3 4.7 5.8 5.1 5.4 5.4 4.2 5.4 5.1 5.5 6.7 6.1 6.2 5.8 5.3 6.0 4.9 6.1 7.5 4.6 8.3 9.1 6.4 6.6 6.3 6.8 8.4 8.7 6.6 4.1 4.2 8.1 6.5 7.5 0.32 0.26 0.76 0.22 0.68 0.44 0.37 0.23 0.28 0.23 0.20 0.20 0.37 0.89 0.54 0.35 0.41 1.24 0.70 0.52 0.53 0.66 0.70 0.62 0.17 0.71 0.88 1.27 0.68 0.73 0.89 0.58 0.11 0.44 0.44 0.27 0.30 0.22 0.19 0.29 0.18 0.13 0.20 0.20 0.32 0.22 0.21 1.07 0.29 0.46 0.72 0.23 0.36 0.92 1.40 0.28 0.47 1.37 0.89 1.23 1.19 1.10 0.60 0.64 0.57 0.53 0.55 0.68 0.39 0.30 0.45 0.59 0.42 0.55 0.52 0.48 0.51 0.46 0.57 0.51 0.46 0.52 0.67 0.37 0.50 0.46 0.60 0.63 0.44 0.51 0.65 0.46 0.60 0.44 0.52 0.54 0.40 0.51 0.42 0.49 0.62 0.58 0.57 0.54 0.47 0.58 0.46 0.56 0.71 0.26 0.82 0.92 0.52 0.58 0.58 0.64 0.93 0.89 0.57 0.29 0.40 0.82 0.56 0.58 0.03 0.02 0.08 0.02 0.05 * 0.05 0.03 0.02 * 0.02 0.02 0.02 0.02 0.03 0.08 0.04 0.03 0.04 0.09 0.06 0.05 0.05 0.05 0.06 0.04 0.02 0.08 0.09 0.11 0.07 0.07 0.09 0.05 0.01 0.05 0.04 0.03 0.03 0.02 0.02 0.03 0.02 0.01 0.02 0.02 0.03 0.02 0.02 0.07 0.03 0.05 0.07 0.02 0.04 0.11 0.19 0.03 0.04 0.11 0.09 0.15 0.09 0.09

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
587

645

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Lymphoid leukaemia (C91)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 37 174 23 16 30 45 84 26 44 788 28 138 293 113 28 29 4577 669 685 297 119 40 1 156 2267 29 314 524 75 436 70 695 5009 247 232 1079 3298 869 48 34 19 2 136 568 1367 100 23 14 10 6 403 746 704 601 18 560 41 27 10 3265 186 3040 895 168 705 308 67 228 236 1927 188 1665 905 760 748 688 140 546 36 97 Male ASR(W) CUM 0-74 1.2 3.1 2.2 0.6 1.1 6.1 2.7 3.1 2.8 3.6 3.6 3.5 3.1 3.7 2.6 2.2 6.5 8.0 5.5 7.9 5.5 3.1 1.8 5.5 6.4 6.8 8.9 3.9 2.8 4.2 4.9 4.7 5.5 2.7 4.1 4.8 5.9 5.0 3.8 3.3 2.8 0.3 4.9 5.3 5.7 4.2 2.8 2.6 3.6 1.7 4.8 6.7 6.0 5.7 2.4 5.9 3.1 3.4 1.8 5.5 3.5 5.9 4.4 3.6 4.8 4.9 3.8 5.7 5.9 5.4 4.3 5.5 5.0 7.6 6.2 5.5 4.3 6.1 3.6 6.2 0.22 0.26 0.46 0.20 0.25 1.13 0.33 0.65 0.43 0.14 0.68 0.30 0.19 0.36 0.53 0.43 0.10 0.32 0.24 0.50 0.58 0.55 1.81 0.49 0.15 1.38 0.56 0.18 0.33 0.23 0.61 0.19 0.08 0.18 0.27 0.16 0.12 0.18 0.56 0.62 0.68 0.21 0.44 0.27 0.16 0.43 0.62 0.74 1.47 0.74 0.26 0.30 0.24 0.26 0.59 0.29 0.53 0.69 0.69 0.11 0.26 0.13 0.15 0.28 0.19 0.29 0.50 0.40 0.41 0.13 0.32 0.15 0.18 0.31 0.24 0.22 0.37 0.29 0.61 0.74 0.53 0.21 0.27 0.26 0.30 0.22 0.25 0.22 0.28 0.18 0.15 0.63 0.85 0.53 0.84 0.53 0.25 0.30 0.50 0.61 0.64 0.99 0.39 0.28 0.41 0.47 0.40 0.52 0.22 0.42 0.39 0.57 0.46 0.42 0.25 0.20 0.40 0.52 0.52 0.47 0.21 0.22 0.26 0.13 0.42 0.63 0.56 0.56 0.29 0.58 0.28 0.34 0.12 0.53 0.37 0.55 0.41 0.37 0.42 0.47 0.41 0.51 0.54 0.52 0.48 0.52 0.47 0.78 0.62 0.53 0.44 0.57 0.27 0.57 0.11 0.04 0.09 0.06 0.01 0.05 0.03 0.02 0.04 0.05 0.04 0.01 0.04 0.03 0.06 0.06 0.04 0.30 0.05 0.02 0.14 0.07 0.02 0.04 0.02 0.08 0.02 0.01 0.02 0.04 0.02 0.01 0.02 0.08 0.05 0.05 0.05 0.03 0.02 0.06 0.05 0.06 0.09 0.06 0.03 0.03 0.03 0.03 0.09 0.03 0.05 0.07 0.06 0.01 0.04 0.01 0.02 0.04 0.02 0.03 0.07 0.04 0.05 0.02 0.04 0.02 0.02 0.04 0.03 0.03 0.05 0.03 0.07 0.07 Cases 27 114 22 14 12 35 53 23 37 592 24 141 233 107 19 25 2979 439 444 198 80 22 2 103 1481 14 196 413 75 327 51 443 3308 188 150 736 2123 602 25 18 9 3 95 419 923 78 20 11 6 8 306 451 449 422 15 399 36 23 9 2338 157 2149 609 124 474 202 40 157 151 1408 135 1221 685 465 536 464 105 355 24 60 Female ASR(W) CUM 0-74 0.9 1.9 2.0 0.5 0.5 4.5 1.6 2.5 1.9 2.3 2.6 3.2 2.5 3.2 1.8 2.0 3.6 4.8 3.2 4.4 3.3 2.2 3.3 3.1 3.5 3.3 4.5 2.5 2.0 2.6 3.8 2.7 3.3 1.9 2.1 3.2 3.4 3.0 1.4 1.3 1.1 0.6 3.2 3.5 3.4 2.5 2.3 1.8 0.9 1.8 3.3 3.6 3.4 3.5 1.6 3.7 1.8 1.3 2.4 3.3 2.4 3.5 2.5 1.9 2.8 2.7 1.6 3.4 3.5 3.1 2.3 3.3 3.2 3.9 3.6 2.9 2.4 3.1 2.1 2.5 0.18 0.19 0.43 0.23 0.20 1.00 0.23 0.54 0.32 0.10 0.54 0.27 0.17 0.32 0.46 0.42 0.08 0.26 0.19 0.38 0.44 0.53 2.36 0.39 0.11 1.14 0.39 0.14 0.25 0.18 0.55 0.15 0.06 0.15 0.18 0.12 0.10 0.15 0.32 0.36 0.42 0.39 0.34 0.24 0.12 0.30 0.60 0.60 0.42 0.75 0.19 0.24 0.18 0.21 0.43 0.24 0.36 0.35 1.00 0.09 0.20 0.11 0.11 0.18 0.15 0.21 0.26 0.31 0.33 0.10 0.21 0.12 0.15 0.24 0.19 0.16 0.25 0.20 0.45 0.44 0.29 0.12 0.18 0.18 0.18 0.21 0.21 0.17 0.24 0.14 0.18 0.34 0.48 0.27 0.43 0.32 0.13 0.49 0.25 0.33 0.25 0.49 0.23 0.17 0.24 0.35 0.22 0.27 0.13 0.20 0.23 0.29 0.23 0.08 0.10 0.08 0.07 0.22 0.28 0.29 0.27 0.16 0.15 0.08 0.10 0.25 0.32 0.30 0.31 0.13 0.33 0.17 0.13 0.21 0.30 0.21 0.31 0.22 0.19 0.24 0.23 0.15 0.28 0.30 0.29 0.23 0.29 0.28 0.35 0.32 0.28 0.22 0.31 0.20 0.27 * * * *

0.07 0.03 0.06 0.04 0.01 0.06 0.02 0.02 0.03 0.04 0.05 * 0.01 0.03 0.02 0.04 0.04 0.03 0.37 0.03 0.01 0.09 0.05 0.01 0.03 0.02 0.07 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.03 0.03 0.05 0.03 0.02 0.01 0.04 0.04 0.05 0.05 0.04 0.02 0.02 0.02 0.02 0.04 0.02 0.04 0.04 0.08 0.01 0.02 0.01 0.01 0.02 0.01 0.02 0.03 0.03 0.03 0.01 0.03 0.01 0.01 0.02 0.02 0.02 0.03 0.02 0.05 0.04

646

*Important. See note on population page.

588

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Lymphoid leukaemia (C91) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 309 932 1657 114 1495 699 86 593 831 68 752 168 35444 2308 31706 1515 111 1334 376 15 83 268 3319 238 3009 1584 106 1428 475 615 2292 107 2119 200 4552 249 4022 11971 390 727 1360 9184 565 106 448 2969 227 2625 308 121 1150 800 338 1029 26 139 304 6 29 252 40 99 174 761 14 480 98 104 55 1028 879 81 34 31 55 113 295 525 44 Male ASR(W) CUM 0-74 7.2 5.0 5.7 3.4 6.1 6.0 3.5 6.7 5.0 4.9 5.0 5.2 5.4 3.7 5.7 5.9 4.1 6.2 7.2 3.7 4.7 8.8 5.8 3.6 6.3 4.7 3.3 4.8 4.8 5.9 5.8 3.3 5.9 6.5 5.9 3.7 6.5 5.8 2.7 4.0 4.8 6.2 4.9 3.8 5.3 5.5 4.4 5.6 5.7 6.8 6.4 6.6 5.4 6.2 3.3 3.0 2.2 0.9 1.5 1.6 1.4 5.2 1.9 2.6 1.4 1.8 2.0 1.2 2.2 6.2 6.1 3.7 1.5 1.4 2.3 1.8 4.7 2.2 1.3 0.46 0.18 0.15 0.33 0.17 0.24 0.39 0.31 0.19 0.60 0.20 0.45 0.03 0.08 0.04 0.17 0.39 0.19 0.40 0.98 0.53 0.63 0.11 0.24 0.13 0.13 0.32 0.14 0.24 0.26 0.14 0.33 0.15 0.51 0.09 0.24 0.11 0.06 0.14 0.15 0.14 0.07 0.22 0.38 0.28 0.11 0.30 0.12 0.33 0.69 0.21 0.25 0.33 0.21 0.71 0.27 0.14 0.41 0.32 0.14 0.22 0.55 0.15 0.10 0.37 0.09 0.21 0.13 0.30 0.20 0.22 0.46 0.29 0.30 0.35 0.20 0.32 0.11 0.24 0.68 0.48 0.56 0.37 0.58 0.60 0.38 0.66 0.48 0.52 0.48 0.48 0.52 0.38 0.54 0.58 0.41 0.60 0.72 0.30 0.43 0.90 0.57 0.37 0.61 0.45 0.30 0.45 0.43 0.60 0.55 0.30 0.56 0.60 0.59 0.40 0.63 0.56 0.22 0.41 0.39 0.61 0.47 0.39 0.50 0.53 0.47 0.53 0.57 0.64 0.65 0.63 0.56 0.63 0.27 0.23 0.15 0.05 0.16 0.12 0.12 0.52 0.13 0.21 0.09 0.15 0.14 0.09 0.17 0.64 0.63 0.34 0.11 0.12 0.17 0.14 0.52 0.18 0.11 0.05 0.02 0.02 0.04 0.02 0.03 0.05 0.03 0.02 0.08 0.02 0.05 0.00 0.01 0.00 0.02 0.05 0.02 0.05 0.10 0.06 0.07 0.01 0.03 0.01 0.01 0.04 0.02 0.02 0.03 0.01 0.04 0.02 0.05 0.01 0.03 0.01 0.01 0.01 0.02 0.02 0.01 0.02 0.05 0.03 0.01 0.04 0.01 0.04 0.07 0.03 0.03 0.04 0.02 0.09 0.02 0.01 0.02 0.03 0.01 0.02 0.06 0.01 0.01 0.02 0.01 0.02 0.01 0.03 0.03 0.03 0.06 0.02 0.02 0.02 0.01 0.04 0.01 0.02 Cases 179 772 1174 130 1005 556 105 444 534 43 487 109 25064 1827 22147 1112 93 967 216 9 58 146 2577 242 2272 1080 81 963 322 415 1653 102 1490 128 3028 199 2664 8086 292 559 949 6078 395 76 309 2123 147 1895 195 72 748 483 230 773 13 98 223 5 20 151 37 61 90 336 15 271 41 64 25 731 628 38 27 20 42 110 279 401 35 Female ASR(W) CUM 0-74 3.6 3.5 3.4 2.8 3.4 3.7 3.1 4.0 2.7 2.4 2.7 3.4 3.2 2.2 3.4 3.6 2.5 3.7 3.7 2.0 2.8 4.8 3.5 2.5 3.8 2.6 1.8 2.7 2.6 3.7 3.4 2.3 3.4 3.4 3.4 2.2 3.7 3.4 1.9 2.4 3.2 3.5 2.8 2.0 3.0 3.4 2.0 3.5 3.1 3.5 3.8 3.5 3.1 4.0 1.1 2.5 1.6 0.9 1.1 1.0 1.4 3.1 1.0 1.3 1.5 1.2 0.9 0.9 1.0 3.5 3.5 1.5 1.1 1.0 1.3 1.4 3.4 1.5 0.8 0.34 0.16 0.12 0.27 0.13 0.19 0.33 0.24 0.14 0.39 0.15 0.40 0.02 0.05 0.03 0.13 0.28 0.15 0.29 0.69 0.39 0.54 0.09 0.18 0.10 0.10 0.22 0.11 0.18 0.22 0.11 0.25 0.12 0.38 0.07 0.17 0.09 0.04 0.12 0.11 0.11 0.06 0.17 0.26 0.22 0.08 0.18 0.09 0.24 0.51 0.17 0.19 0.27 0.18 0.32 0.27 0.13 0.40 0.34 0.11 0.24 0.46 0.11 0.08 0.41 0.07 0.15 0.11 0.20 0.14 0.15 0.27 0.25 0.27 0.25 0.18 0.28 0.10 0.20 0.33 0.31 0.32 0.31 0.31 0.36 0.35 0.37 0.24 0.20 0.25 0.31 0.28 0.21 0.29 0.32 0.24 0.33 0.31 0.13 0.21 0.40 0.31 0.23 0.34 0.22 0.17 0.22 0.22 0.30 0.30 0.21 0.31 0.31 0.30 0.22 0.32 0.29 0.13 0.23 0.23 0.31 0.25 0.20 0.26 0.29 0.17 0.30 0.27 0.30 0.35 0.33 0.27 0.38 0.06 0.16 0.11 0.05 0.09 0.08 0.09 0.27 0.06 0.11 0.14 0.09 0.07 0.07 0.07 0.34 0.34 0.15 0.08 0.07 0.10 0.12 0.37 0.12 0.06 0.03 0.01 0.01 0.04 0.01 0.02 0.04 0.02 0.01 0.04 0.01 0.04 0.00 0.01 0.00 0.01 0.03 0.01 0.03 0.05 0.04 0.04 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.02 0.01 0.03 0.01 0.04 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.03 0.02 0.01 0.02 0.01 0.03 0.05 0.02 0.02 0.02 0.02 0.02 0.02 * 0.01 0.02 * 0.02 0.01 * 0.02 * 0.04 * 0.01 0.01 * 0.05 0.01 0.01 * 0.01 * 0.02 * 0.02 0.02 0.04 0.02 0.02 0.02 0.01 0.03 0.01 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
589

647

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Lymphoid leukaemia (C91) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
590

Male ASR(W) CUM 0-74 1.6 1.7 1.4 1.5 1.4 1.4 1.4 1.9 1.0 2.3 5.2 2.2 1.9 2.4 2.0 1.9 2.6 2.5 3.1 2.5 1.7 2.0 1.1 3.0 2.7 4.4 7.0 5.9 5.0 3.5 5.3 3.0 5.9 6.0 6.5 4.9 4.9 5.6 5.7 6.0 6.1 5.3 6.2 8.6 7.1 3.9 5.4 3.6 6.0 5.0 4.6 6.4 4.6 4.8 4.6 5.7 6.1 8.2 7.1 4.9 4.9 5.7 5.6 6.8 7.3 3.4 4.9 6.1 5.3 6.0 7.0 5.5 5.7 5.3 8.9 4.6 5.8 6.0 4.9 0.05 0.16 0.17 0.24 0.23 0.17 0.48 0.11 0.24 0.39 1.12 0.32 0.20 0.33 0.22 0.14 0.21 0.24 0.77 0.48 0.25 0.38 0.21 0.32 0.20 0.15 0.65 0.86 0.15 0.26 0.20 0.13 0.24 0.16 0.21 0.37 0.20 0.46 0.54 0.61 0.52 0.47 0.46 0.52 0.77 0.52 0.80 0.47 0.34 0.22 0.34 0.41 0.29 0.29 0.45 0.88 0.25 1.55 0.75 0.68 0.51 0.74 1.33 0.58 0.72 0.53 0.34 0.84 0.88 0.85 0.58 0.51 0.63 0.94 1.60 0.47 0.62 0.71 0.38 0.11 0.11 0.10 0.14 0.09 0.09 0.07 0.13 0.06 0.17 0.32 0.12 0.12 0.24 0.13 0.13 0.17 0.17 0.21 0.15 0.10 0.10 0.09 0.22 0.21 0.39 0.66 0.59 0.55 0.38 0.55 0.29 0.55 0.62 0.65 0.52 0.41 0.56 0.62 0.68 0.71 0.54 0.58 0.91 0.64 0.39 0.52 0.37 0.55 0.53 0.43 0.61 0.43 0.44 0.36 0.59 0.61 0.75 0.64 0.58 0.40 0.52 0.54 0.61 0.76 0.27 0.43 0.57 0.49 0.52 0.66 0.51 0.62 0.38 0.77 0.42 0.50 0.58 0.47 0.00 0.01 0.01 0.03 0.02 0.01 0.02 0.01 0.02 0.05 0.06 0.02 0.02 0.05 0.02 0.01 0.02 0.02 0.05 0.04 0.02 0.02 0.02 0.03 0.02 0.01 0.07 0.10 0.02 0.03 0.02 0.01 0.02 0.02 0.02 0.04 0.02 0.05 0.07 0.08 0.07 0.05 0.05 0.06 0.07 0.06 0.07 0.05 0.03 0.02 0.03 0.04 0.03 0.03 0.04 0.11 0.03 0.12 0.07 0.08 0.04 0.06 0.11 0.05 0.07 0.05 0.03 0.07 0.08 0.07 0.05 0.05 0.07 0.07 0.13 0.04 0.05 0.07 0.03

Cases 885 66 64 29 44 64 4 263 18 33 26 39 67 47 44 185 92 69 6 17 45 25 36 57 145 862 101 30 1151 137 563 545 662 1275 875 211 579 121 103 80 118 118 139 212 74 64 57 34 338 615 191 261 251 308 105 36 447 41 78 48 179 90 16 194 107 35 295 92 41 51 213 120 63 20 24 143 115 75 209

Female ASR(W) CUM 0-74 1.1 1.0 1.2 1.1 1.5 1.2 0.6 1.3 1.1 1.5 4.8 1.9 1.3 1.5 1.3 1.5 1.4 1.4 1.4 1.6 1.6 1.5 1.3 1.9 2.0 2.6 3.8 2.9 3.1 1.8 3.1 2.0 3.9 2.9 3.9 3.4 3.1 3.3 3.5 4.2 3.9 3.4 3.1 4.4 3.9 3.1 3.3 1.7 3.1 2.9 2.3 3.3 2.7 3.2 2.1 4.0 3.7 2.8 3.1 3.0 3.1 3.8 2.6 4.0 3.7 2.8 3.0 5.7 3.6 2.3 4.2 3.3 3.6 1.6 3.5 3.8 3.4 5.2 3.1 0.04 0.13 0.16 0.21 0.23 0.16 0.31 0.09 0.26 0.30 1.24 0.31 0.16 0.26 0.23 0.12 0.16 0.18 0.57 0.40 0.25 0.32 0.23 0.26 0.17 0.12 0.49 0.64 0.11 0.19 0.17 0.12 0.20 0.10 0.17 0.30 0.17 0.36 0.45 0.56 0.44 0.42 0.30 0.37 0.58 0.46 0.66 0.35 0.25 0.18 0.24 0.30 0.23 0.25 0.27 0.78 0.20 0.65 0.49 0.83 0.39 0.73 1.04 0.46 0.51 0.51 0.28 0.95 0.74 0.47 0.48 0.41 0.57 0.47 0.97 0.55 0.49 0.83 0.34 0.07 0.06 0.08 0.07 0.11 0.08 0.04 0.09 0.08 0.10 0.23 0.11 0.08 0.15 0.10 0.11 0.09 0.09 0.06 0.12 0.10 0.11 0.09 0.11 0.16 0.22 0.31 0.25 0.32 0.18 0.29 0.18 0.34 0.28 0.37 0.35 0.24 0.34 0.33 0.42 0.39 0.30 0.33 0.45 0.40 0.30 0.25 0.16 0.27 0.27 0.22 0.32 0.24 0.26 0.20 0.31 0.35 0.27 0.28 0.26 0.27 0.31 0.21 0.37 0.36 0.22 0.24 0.45 0.33 0.22 0.35 0.27 0.36 0.14 0.32 0.28 0.29 0.41 0.26 0.00 0.01 0.01 0.01 0.02 0.01 0.02 0.01 0.02 0.03 0.06 0.02 0.01 0.04 * 0.03 * 0.01 * 0.01 0.01 0.03 0.04 0.02 * 0.02 * 0.02 0.02 * 0.02 * 0.01 0.04 0.05 0.01 * 0.02 * 0.01 0.01 * 0.02 0.01 0.02 0.03 0.01 0.04 0.05 0.06 0.05 0.04 0.04 0.04 0.05 0.05 0.05 0.03 0.02 0.01 0.02 0.03 0.02 0.02 0.03 0.07 0.02 0.07 0.04 0.05 0.03 0.05 0.07 0.03 0.04 0.04 0.02 0.07 0.06 0.04 0.04 0.03 0.05 0.04 0.08 0.03 0.04 0.06 0.02

1234 128 72 44 38 76 10 365 19 50 71 48 101 77 95 230 166 120 18 28 51 32 31 86 202 1103 135 54 1319 223 908 778 784 1906 1194 198 749 171 129 103 154 169 210 321 115 71 69 74 473 791 261 357 346 375 151 47 670 56 130 85 186 130 35 241 160 45 351 107 52 88 286 156 102 44 45 164 167 103 273

648

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Lymphoid leukaemia (C91) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 334 597 52 739 58 189 161 179 308 523 587 827 311 46 187 223 173 27 61 99 152 62 63 119 1832 86 43 25 103 44 45 79 2236 129 118 484 286 588 1427 492 1397 2321 878 1004 223 990 1238 11 801 397 78 710 298 45 18 1107 140 7 9 22 17 58 Male ASR(W) CUM 0-74 5.2 6.1 5.3 5.0 3.0 4.8 3.6 2.2 3.7 4.7 4.4 5.8 5.3 5.3 4.0 4.1 4.5 2.6 3.4 4.4 4.2 3.8 3.5 4.9 5.6 6.4 6.0 4.9 6.1 4.9 4.6 4.3 4.8 4.4 4.2 5.0 3.7 4.2 6.2 5.8 5.5 5.2 5.1 5.3 4.5 5.8 6.2 3.2 7.3 7.8 4.9 5.0 5.5 6.0 4.1 9.5 3.9 2.0 1.6 4.2 3.2 5.5 0.32 0.27 0.79 0.21 0.47 0.38 0.34 0.18 0.25 0.24 0.22 0.22 0.34 0.94 0.36 0.35 0.39 0.59 0.55 0.56 0.38 0.63 0.54 0.61 0.16 0.77 1.06 1.16 0.67 0.92 0.76 0.56 0.11 0.43 0.45 0.26 0.26 0.20 0.19 0.29 0.18 0.12 0.20 0.19 0.33 0.21 0.19 0.98 0.28 0.44 0.61 0.21 0.34 0.94 0.99 0.30 0.36 1.04 0.55 0.93 1.03 0.84 0.52 0.61 0.45 0.47 0.27 0.56 0.33 0.19 0.33 0.45 0.41 0.62 0.53 0.42 0.42 0.36 0.39 0.30 0.29 0.41 0.45 0.32 0.34 0.38 0.55 0.70 0.67 0.40 0.56 0.45 0.42 0.40 0.46 0.42 0.40 0.48 0.29 0.38 0.61 0.57 0.50 0.50 0.47 0.52 0.40 0.59 0.61 0.34 0.74 0.80 0.49 0.45 0.51 0.50 0.49 0.97 0.40 0.21 0.14 0.48 0.22 0.58 0.03 0.03 0.07 0.02 0.04 0.05 0.03 0.02 0.02 0.02 0.02 0.03 0.04 0.08 0.04 0.03 0.04 0.07 0.05 0.05 0.04 0.05 0.05 0.04 0.02 0.09 0.12 0.10 0.07 0.08 0.08 0.05 0.01 0.04 0.04 0.03 0.02 0.02 0.02 0.03 0.02 0.01 0.02 0.02 0.03 0.02 0.02 0.15 0.03 0.05 0.07 0.02 0.04 0.09 0.15 0.04 0.04 0.11 0.06 0.13 0.07 0.10 Cases 290 455 32 518 64 211 126 134 223 611 385 555 245 41 135 149 125 22 50 62 125 35 48 95 1181 63 24 15 69 32 31 53 1457 86 65 320 200 401 1015 328 987 1667 527 697 135 703 818 4 577 284 43 501 193 28 6 696 107 5 7 18 19 42 Female ASR(W) CUM 0-74 2.9 3.4 2.8 3.1 3.6 4.2 2.4 1.7 2.3 3.1 2.6 3.1 3.7 3.6 3.1 2.1 3.1 2.8 2.8 2.2 3.7 2.2 2.9 3.4 3.5 3.6 2.2 2.8 3.5 2.3 2.6 2.4 2.7 2.5 1.9 2.8 2.3 2.5 3.6 3.3 2.9 3.1 2.7 3.3 2.1 3.4 3.6 0.8 4.8 5.0 2.9 3.1 3.5 3.1 1.2 4.9 3.3 1.7 1.5 3.5 3.3 5.1 0.24 0.20 0.57 0.17 0.60 0.37 0.32 0.18 0.21 0.19 0.17 0.16 0.32 0.75 0.47 0.24 0.33 1.03 0.55 0.37 0.40 0.52 0.60 0.54 0.13 0.58 0.57 1.00 0.51 0.55 0.62 0.46 0.09 0.32 0.29 0.21 0.22 0.17 0.15 0.23 0.13 0.10 0.16 0.16 0.22 0.17 0.15 0.45 0.23 0.36 0.54 0.17 0.29 0.65 0.52 0.21 0.37 1.02 0.66 0.83 1.04 1.00 0.28 0.30 0.27 0.27 0.27 0.40 0.19 0.13 0.19 0.29 0.23 0.29 0.31 0.29 0.26 0.20 0.30 0.22 0.20 0.21 0.35 0.15 0.24 0.25 0.32 0.35 0.20 0.22 0.36 0.20 0.23 0.15 0.25 0.25 0.18 0.25 0.15 0.19 0.33 0.28 0.26 0.27 0.22 0.30 0.19 0.30 0.34 0.04 0.47 0.49 0.21 0.23 0.31 0.28 0.11 0.51 0.26 0.10 0.12 0.32 0.25 0.39 0.02 0.02 0.05 0.02 0.04 * 0.03 0.02 0.01 * 0.02 0.01 0.01 0.01 0.02 0.06 0.03 0.02 0.03 0.06 0.04 0.03 0.04 0.03 0.04 0.03 0.01 0.06 0.06 0.07 0.05 0.05 0.06 0.03 0.01 0.03 0.03 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.02 0.03 0.04 0.04 0.01 0.03 0.07 0.07 0.03 0.03 0.06 0.05 0.09 0.07 0.08

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
591

649

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Myeloid leukaemia (C92-94)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 39 139 30 3 44 39 72 23 64 1007 24 124 226 127 25 36 3137 373 525 134 112 47 0 100 1670 29 147 516 89 419 71 680 4919 444 275 801 3334 957 53 58 37 14 106 626 1295 116 32 37 22 13 302 735 597 557 31 513 62 33 22 3155 205 2911 967 186 770 338 83 249 213 2007 177 1761 947 591 594 665 140 518 41 100 Male ASR(W) CUM 0-74 1.6 2.3 2.9 0.3 1.2 5.1 2.5 2.8 3.8 4.5 2.7 3.1 2.7 4.1 2.3 3.6 4.0 4.2 3.6 3.5 4.4 2.9 3.0 4.3 6.8 4.1 3.7 3.1 3.7 4.8 3.8 4.8 3.9 4.6 4.0 5.2 4.7 3.8 3.6 4.1 4.9 3.7 5.1 4.8 4.7 3.2 4.5 4.7 2.6 3.9 5.6 4.7 4.8 4.3 4.7 3.7 2.9 4.6 4.7 3.6 4.8 4.3 3.8 4.4 4.9 4.5 5.2 5.1 5.0 4.0 5.1 4.9 5.4 4.5 4.8 4.1 5.0 4.1 4.9 0.29 0.22 0.54 0.22 0.25 0.97 0.33 0.62 0.50 0.15 0.55 0.29 0.18 0.38 0.47 0.62 0.08 0.22 0.17 0.32 0.46 0.45 0.33 0.11 1.31 0.36 0.17 0.34 0.19 0.59 0.16 0.07 0.19 0.28 0.15 0.10 0.16 0.53 0.51 0.70 1.71 0.38 0.23 0.14 0.44 0.63 0.77 1.18 0.73 0.25 0.24 0.20 0.22 0.79 0.23 0.50 0.54 1.10 0.10 0.26 0.10 0.14 0.29 0.17 0.28 0.53 0.35 0.36 0.12 0.30 0.13 0.17 0.24 0.19 0.19 0.36 0.23 0.65 0.53 0.50 0.24 0.21 0.33 0.45 0.26 0.27 0.25 0.41 0.27 0.40 0.43 0.44 0.37 0.40 0.44 0.31 0.28 0.46 0.66 0.47 0.36 0.30 0.37 0.52 0.40 0.50 0.40 0.51 0.39 0.54 0.48 0.37 0.35 0.41 0.36 0.30 0.54 0.52 0.54 0.29 0.45 0.49 0.37 0.40 0.60 0.45 0.52 0.37 0.52 0.40 0.28 0.55 0.49 0.37 0.50 0.47 0.40 0.49 0.55 0.44 0.60 0.53 0.53 0.44 0.54 0.52 0.59 0.46 0.52 0.43 0.55 0.39 0.54 0.11 0.05 0.07 0.06 0.02 0.07 0.03 0.02 0.05 0.06 0.09 0.01 0.03 0.02 0.04 0.05 0.05 0.04 0.01 0.14 0.05 0.02 0.04 0.02 0.09 0.02 0.01 0.02 0.04 0.02 0.01 0.02 0.07 0.06 0.08 0.14 0.04 0.03 0.02 0.06 0.07 0.10 0.12 0.12 0.03 0.03 0.02 0.03 0.09 0.03 0.06 0.07 0.14 0.01 0.03 0.01 0.02 0.04 0.02 0.04 0.08 0.05 0.05 0.02 0.04 0.02 0.02 0.03 0.02 0.03 0.05 0.03 0.08 0.07 Cases 38 142 17 6 34 27 47 20 66 961 17 108 173 93 29 36 2445 291 389 142 65 27 0 95 1311 18 107 470 88 377 53 520 3834 351 230 711 2508 756 63 44 20 8 96 486 1018 100 26 33 19 13 282 504 480 463 33 426 46 30 14 2435 250 2143 798 163 625 249 60 182 162 1711 185 1484 798 476 495 569 145 414 45 103 Female ASR(W) CUM 0-74 1.5 2.2 1.6 0.5 1.3 2.6 1.3 2.5 3.1 3.4 1.6 2.2 1.9 2.6 2.1 2.9 2.8 2.9 2.6 3.2 2.5 1.5 2.6 2.9 3.0 2.8 2.5 2.2 2.7 3.1 2.6 3.2 2.7 3.0 3.2 3.3 3.2 3.6 2.6 1.9 1.5 3.2 3.3 3.2 2.8 1.9 3.3 2.4 2.2 3.1 3.6 3.3 3.3 3.4 3.3 2.3 2.2 2.1 3.3 3.4 3.2 2.8 2.3 3.0 2.8 2.2 3.1 3.5 3.5 3.1 3.6 3.4 3.5 3.1 3.5 3.3 3.5 3.4 4.2 0.26 0.19 0.40 0.26 0.29 0.63 0.21 0.60 0.40 0.11 0.41 0.22 0.15 0.29 0.41 0.50 0.06 0.19 0.15 0.30 0.36 0.33 0.32 0.09 0.82 0.31 0.13 0.25 0.16 0.44 0.13 0.06 0.15 0.21 0.12 0.08 0.13 0.49 0.44 0.44 0.63 0.35 0.18 0.11 0.30 0.40 0.60 0.63 0.68 0.19 0.21 0.17 0.18 0.62 0.19 0.40 0.46 0.75 0.08 0.22 0.09 0.11 0.20 0.13 0.19 0.31 0.25 0.30 0.10 0.24 0.11 0.14 0.19 0.16 0.16 0.29 0.19 0.53 0.49 0.27 0.10 0.29 0.27 0.34 0.17 0.21 0.19 0.25 0.20 0.28 0.28 0.29 0.24 0.34 0.27 0.15 0.24 0.29 0.28 0.30 0.26 0.23 0.27 0.25 0.26 0.32 0.27 0.31 0.30 0.34 0.31 0.35 0.23 0.13 0.14 0.30 0.33 0.32 0.28 0.20 0.31 0.31 0.18 0.30 0.36 0.34 0.34 0.34 0.34 0.20 0.21 0.18 0.32 0.33 0.32 0.28 0.23 0.30 0.29 0.21 0.33 0.36 0.37 0.32 0.38 0.36 0.36 0.30 0.37 0.34 0.38 0.38 0.44 * * * *

0.07 0.02 0.09 0.05 0.01 0.05 0.03 0.02 0.04 0.04 0.07 * 0.01 0.02 0.02 0.04 0.04 0.03 0.03 0.01 0.09 0.04 0.02 0.03 0.02 0.05 0.01 0.01 0.02 0.03 0.02 0.01 0.01 0.06 0.04 0.04 0.07 0.04 0.02 0.01 0.04 0.05 0.06 0.09 0.06 0.02 0.02 0.02 0.02 0.08 0.02 0.04 0.05 0.07 0.01 0.03 0.01 0.01 0.02 0.02 0.03 0.04 0.03 0.04 0.01 0.03 0.01 0.02 0.02 0.02 0.02 0.04 0.02 0.07 0.06

650

*Important. See note on population page.

592

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Myeloid leukaemia (C92-94) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 227 937 1547 147 1373 670 110 547 887 68 815 169 34462 2587 30520 1385 127 1186 235 11 64 151 3099 256 2715 1608 130 1436 531 483 2326 128 2137 185 4177 311 3478 11146 723 851 1079 8360 548 114 424 2805 250 2487 279 96 961 670 311 963 30 155 658 20 23 418 109 65 195 749 14 539 126 107 57 669 571 71 78 116 152 276 232 1014 141 Male ASR(W) CUM 0-74 4.7 4.5 4.9 4.3 4.9 5.4 4.4 5.7 4.6 4.4 4.7 5.2 4.7 4.0 4.8 5.0 4.4 4.9 4.1 2.9 3.5 4.5 5.0 3.7 5.2 4.3 4.1 4.2 4.6 4.3 5.2 4.0 5.1 5.1 4.9 4.3 5.0 4.8 4.1 4.4 4.1 5.0 4.3 3.8 4.3 4.8 4.7 4.8 4.6 4.7 4.9 5.1 4.6 5.2 4.4 2.7 3.3 2.2 1.2 2.0 3.4 3.0 1.8 2.5 1.3 2.0 2.5 1.4 2.0 4.0 3.9 3.6 2.3 3.2 4.1 3.1 4.0 3.3 2.7 0.35 0.16 0.13 0.36 0.14 0.22 0.44 0.26 0.17 0.55 0.18 0.44 0.03 0.08 0.03 0.14 0.39 0.16 0.28 0.90 0.45 0.42 0.10 0.23 0.11 0.11 0.37 0.12 0.21 0.21 0.12 0.36 0.12 0.41 0.08 0.25 0.09 0.05 0.16 0.16 0.13 0.06 0.19 0.36 0.22 0.09 0.30 0.10 0.29 0.50 0.17 0.21 0.29 0.18 0.85 0.23 0.14 0.54 0.30 0.12 0.33 0.40 0.13 0.10 0.36 0.09 0.23 0.14 0.27 0.16 0.17 0.47 0.27 0.34 0.36 0.21 0.31 0.12 0.26 0.51 0.48 0.52 0.47 0.53 0.59 0.50 0.62 0.48 0.43 0.49 0.54 0.50 0.42 0.51 0.52 0.45 0.52 0.45 0.40 0.40 0.48 0.53 0.35 0.56 0.45 0.47 0.45 0.52 0.45 0.55 0.44 0.55 0.53 0.52 0.44 0.54 0.51 0.40 0.47 0.42 0.53 0.45 0.39 0.46 0.49 0.50 0.50 0.46 0.54 0.52 0.52 0.48 0.58 0.42 0.22 0.33 0.19 0.09 0.21 0.31 0.27 0.17 0.24 0.10 0.20 0.25 0.15 0.20 0.41 0.39 0.38 0.25 0.35 0.40 0.33 0.39 0.33 0.29 0.04 0.02 0.02 0.05 0.02 0.03 0.06 0.03 0.02 0.07 0.02 0.05 0.00 0.01 0.00 0.02 0.05 0.02 0.04 0.15 0.06 0.05 0.01 0.03 0.01 0.01 0.05 0.02 0.03 0.03 0.01 0.05 0.02 0.05 0.01 0.03 0.01 0.01 0.02 0.02 0.02 0.01 0.02 0.05 0.03 0.01 0.04 0.01 0.04 0.07 0.02 0.03 0.03 0.02 0.11 0.02 0.01 0.04 0.02 0.01 0.03 0.04 0.02 0.01 0.03 0.01 0.03 0.02 0.03 0.02 0.02 0.07 0.03 0.04 0.04 0.02 0.03 0.01 0.03 Cases 175 828 1383 149 1204 673 110 543 786 66 710 124 28270 2463 24773 1123 108 975 183 10 50 121 2601 265 2244 1381 117 1233 441 422 1953 131 1778 156 3468 284 2917 8992 557 732 925 6690 460 116 335 2124 224 1861 214 82 789 551 286 798 19 112 533 16 11 333 66 52 128 505 11 344 78 81 47 567 480 52 50 68 103 198 150 638 114 Female ASR(W) CUM 0-74 3.3 3.2 3.5 3.2 3.6 4.0 3.2 4.2 3.4 3.1 3.4 3.1 3.2 2.8 3.3 3.2 2.7 3.3 2.7 2.2 2.3 3.1 3.2 2.7 3.3 3.0 2.7 3.0 3.2 3.2 3.6 3.1 3.6 3.3 3.4 3.0 3.5 3.3 2.7 2.9 3.1 3.4 2.8 2.9 2.7 3.0 3.2 3.0 3.3 3.3 3.6 3.6 3.5 3.6 2.2 1.9 2.5 1.5 0.4 1.5 1.9 2.4 1.3 2.1 1.1 1.5 1.7 1.1 1.6 3.0 2.9 2.4 1.4 1.6 2.3 2.0 2.4 1.8 2.1 0.30 0.13 0.11 0.28 0.12 0.18 0.32 0.22 0.14 0.40 0.15 0.32 0.02 0.06 0.02 0.11 0.27 0.13 0.22 0.70 0.34 0.33 0.07 0.17 0.08 0.09 0.26 0.10 0.18 0.18 0.10 0.29 0.10 0.32 0.06 0.19 0.07 0.04 0.12 0.11 0.11 0.05 0.15 0.29 0.17 0.07 0.23 0.08 0.24 0.42 0.14 0.18 0.24 0.15 0.55 0.19 0.12 0.41 0.13 0.10 0.24 0.36 0.12 0.10 0.33 0.08 0.19 0.13 0.24 0.13 0.14 0.36 0.21 0.25 0.25 0.17 0.26 0.09 0.28 0.35 0.34 0.37 0.35 0.37 0.41 0.34 0.42 0.34 0.34 0.34 0.34 0.33 0.29 0.34 0.33 0.26 0.34 0.26 0.22 0.21 0.30 0.32 0.28 0.33 0.30 0.25 0.31 0.31 0.34 0.37 0.28 0.38 0.34 0.34 0.31 0.35 0.33 0.27 0.29 0.30 0.34 0.30 0.30 0.29 0.31 0.32 0.31 0.33 0.32 0.36 0.37 0.34 0.38 0.23 0.16 0.24 0.13 0.05 0.15 0.17 0.26 0.12 0.20 0.11 0.14 0.14 0.12 0.16 0.31 0.30 0.22 0.14 0.16 0.23 0.21 0.21 0.18 0.19 0.03 0.02 0.01 0.04 0.01 0.02 0.04 0.03 0.02 0.05 0.02 0.04 0.00 0.01 0.00 0.01 0.03 0.01 0.03 0.09 0.04 0.04 0.01 0.02 0.01 0.01 0.03 0.01 0.02 0.02 0.01 0.03 0.01 0.04 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.04 0.02 0.01 0.03 0.01 0.03 0.05 0.02 0.02 0.03 0.02 0.08 0.02 * 0.01 0.04 * 0.02 0.01 * 0.03 * 0.04 * 0.01 0.01 * 0.04 0.01 0.02 * 0.02 * 0.03 * 0.02 0.02 0.04 0.02 0.02 0.03 0.02 0.02 0.01 0.02

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
593

651

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Myeloid leukaemia (C92-94) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
594

Male ASR(W) CUM 0-74 2.9 2.6 2.9 2.2 3.3 2.5 3.5 3.3 2.4 2.6 2.2 3.8 2.5 2.4 2.3 3.0 3.2 3.3 1.4 3.7 2.5 2.1 2.1 2.7 2.4 3.5 2.7 3.3 3.1 2.8 3.8 2.2 4.1 3.3 4.2 3.5 3.2 4.2 3.5 4.5 5.0 3.7 4.7 4.8 3.8 2.7 3.7 2.4 4.2 3.7 3.8 4.6 3.0 4.1 4.2 3.3 3.7 6.9 4.3 3.7 3.3 3.8 2.5 4.5 4.2 3.8 4.0 4.7 3.8 5.1 5.3 3.9 5.3 5.1 5.0 4.4 4.9 4.0 4.3 0.06 0.18 0.22 0.28 0.34 0.21 0.74 0.13 0.41 0.48 0.60 0.42 0.24 0.36 0.26 0.21 0.21 0.24 0.46 0.64 0.27 0.33 0.28 0.29 0.17 0.12 0.36 0.57 0.11 0.22 0.16 0.10 0.18 0.11 0.16 0.32 0.14 0.37 0.43 0.53 0.45 0.38 0.36 0.37 0.50 0.38 0.58 0.40 0.23 0.16 0.27 0.28 0.21 0.22 0.37 0.62 0.18 1.21 0.46 0.53 0.30 0.44 0.75 0.41 0.46 0.53 0.25 0.51 0.60 0.57 0.43 0.39 0.53 0.75 0.98 0.40 0.43 0.49 0.29 0.29 0.26 0.29 0.22 0.32 0.23 0.32 0.32 0.25 0.30 0.16 0.37 0.23 0.25 0.21 0.31 0.30 0.30 0.15 0.42 0.22 0.21 0.26 0.28 0.26 0.36 0.28 0.35 0.33 0.30 0.41 0.24 0.42 0.35 0.44 0.33 0.31 0.44 0.34 0.49 0.53 0.41 0.51 0.49 0.41 0.32 0.34 0.21 0.44 0.39 0.39 0.47 0.30 0.42 0.42 0.42 0.39 0.65 0.47 0.38 0.33 0.38 0.19 0.41 0.44 0.41 0.41 0.53 0.40 0.51 0.47 0.38 0.62 0.51 0.39 0.41 0.51 0.41 0.42 0.01 0.02 0.03 0.04 0.04 0.02 0.08 0.02 0.06 0.07 0.04 0.05 0.03 0.05 0.03 0.03 0.02 0.02 0.05 0.09 0.03 0.04 0.04 0.04 0.02 0.01 0.05 0.07 0.01 0.03 0.02 0.01 0.02 0.01 0.02 0.03 0.02 0.05 0.05 0.07 0.06 0.04 0.05 0.04 0.06 0.05 0.06 0.04 0.03 0.02 0.03 0.03 0.02 0.03 0.04 0.09 0.02 0.11 0.06 0.06 0.03 0.05 0.06 0.04 0.05 0.06 0.03 0.07 0.08 0.06 0.04 0.04 0.08 0.08 0.09 0.04 0.05 0.06 0.03

Cases 2210 193 153 77 69 140 24 633 39 38 33 66 99 42 67 269 225 182 12 31 87 43 57 62 171 979 71 36 892 134 578 554 580 1102 714 152 583 133 72 53 100 101 161 132 64 47 44 38 374 734 239 265 219 394 146 26 293 30 97 69 185 109 24 171 106 49 366 55 42 84 184 105 52 32 25 160 131 81 266

Female ASR(W) CUM 0-74 2.1 1.8 2.2 2.2 2.0 2.2 3.0 2.5 2.0 2.3 2.1 2.6 2.3 1.8 2.4 2.4 2.5 2.4 1.9 2.9 2.1 2.0 1.8 1.9 2.0 2.5 2.5 2.9 2.3 1.7 2.8 1.7 3.1 2.6 3.1 2.4 2.4 3.5 2.7 2.4 3.6 2.6 3.6 2.9 2.9 2.1 2.2 1.9 3.0 2.9 2.8 3.1 2.1 3.1 2.5 2.6 2.4 2.4 3.4 2.8 2.8 3.7 2.3 2.9 3.0 2.9 3.3 2.4 3.2 3.3 3.0 2.9 2.7 2.9 2.8 3.2 3.0 3.9 3.1 0.05 0.14 0.18 0.26 0.25 0.20 0.64 0.10 0.35 0.41 0.64 0.33 0.24 0.31 0.33 0.16 0.17 0.19 0.59 0.54 0.23 0.32 0.24 0.24 0.16 0.10 0.34 0.59 0.09 0.17 0.14 0.08 0.15 0.09 0.14 0.23 0.12 0.34 0.38 0.39 0.42 0.31 0.32 0.30 0.48 0.36 0.41 0.35 0.20 0.15 0.23 0.24 0.17 0.20 0.26 0.57 0.15 0.54 0.41 0.51 0.28 0.52 0.63 0.30 0.41 0.44 0.23 0.46 0.64 0.46 0.29 0.31 0.47 0.60 0.65 0.34 0.33 0.61 0.25 0.20 0.17 0.22 0.21 0.19 0.19 0.25 0.25 0.19 0.23 0.15 0.24 0.24 0.17 0.23 0.24 0.24 0.23 0.19 0.30 0.21 0.19 0.18 0.15 0.20 0.26 0.28 0.24 0.25 0.18 0.29 0.18 0.32 0.26 0.32 0.26 0.24 0.37 0.28 0.23 0.37 0.25 0.35 0.26 0.26 0.20 0.23 0.19 0.29 0.28 0.29 0.33 0.22 0.27 0.28 0.22 0.23 0.31 0.35 0.25 0.27 0.35 0.23 0.29 0.29 0.31 0.30 0.22 0.31 0.34 0.30 0.30 0.28 0.28 0.28 0.31 0.30 0.39 0.33 0.00 0.01 0.02 0.03 0.03 0.02 0.05 0.01 0.04 0.05 0.04 0.04 0.03 0.04 * 0.04 * 0.02 * 0.02 0.02 0.06 0.07 0.03 * 0.03 * 0.03 0.02 * 0.02 * 0.01 0.04 0.05 0.01 * 0.02 * 0.01 0.01 * 0.02 0.01 0.02 0.02 0.01 0.04 0.04 0.04 0.04 0.03 0.04 0.03 0.04 0.04 0.05 0.03 0.02 0.01 0.02 0.03 0.02 0.02 0.03 0.06 0.02 0.07 0.04 0.05 0.03 0.04 0.06 0.03 0.04 0.05 0.02 0.04 0.06 0.05 0.03 0.03 0.05 0.06 0.07 0.03 0.03 0.05 0.03

2782 239 182 69 105 164 24 769 46 35 74 88 117 54 91 287 261 215 10 36 95 45 60 87 197 988 64 35 846 187 706 632 610 1109 868 139 566 146 77 79 129 122 189 188 68 55 58 45 403 658 245 292 257 400 171 30 427 50 102 71 175 107 19 184 114 53 351 99 49 104 252 120 109 57 33 179 204 77 280

652

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Myeloid leukaemia (C92-94) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 264 375 63 605 53 99 136 205 339 377 327 461 179 33 145 166 176 19 82 102 172 69 77 84 1105 64 25 14 69 49 39 85 1994 110 127 382 321 593 874 390 1034 2004 687 713 228 728 1283 15 658 365 77 834 261 49 23 628 214 13 32 32 62 58 Male ASR(W) CUM 0-74 3.6 3.6 5.0 3.6 2.2 2.4 2.6 2.3 3.5 3.0 2.1 3.0 2.8 2.7 3.3 2.4 3.9 1.5 3.6 3.6 4.4 3.0 4.2 2.2 3.2 4.0 2.7 2.3 3.9 4.2 3.8 3.7 3.6 3.2 3.6 3.5 3.4 3.9 3.5 4.0 3.7 4.0 3.6 3.5 4.2 4.0 5.6 3.5 5.4 6.3 4.7 4.9 4.2 5.7 4.7 5.0 5.0 3.9 5.1 5.9 5.5 5.1 0.23 0.19 0.66 0.16 0.31 0.25 0.24 0.17 0.21 0.16 0.13 0.14 0.22 0.52 0.33 0.21 0.31 0.40 0.44 0.40 0.36 0.38 0.54 0.26 0.11 0.53 0.64 0.65 0.52 0.69 0.64 0.44 0.09 0.31 0.33 0.20 0.20 0.17 0.13 0.21 0.13 0.10 0.15 0.14 0.29 0.16 0.17 0.97 0.22 0.35 0.58 0.18 0.27 0.84 1.03 0.21 0.38 1.20 1.00 1.07 0.94 0.75 0.39 0.42 0.54 0.37 0.23 0.26 0.27 0.21 0.36 0.31 0.22 0.31 0.28 0.32 0.33 0.26 0.39 0.16 0.38 0.35 0.44 0.35 0.42 0.24 0.32 0.36 0.25 0.30 0.41 0.32 0.33 0.38 0.38 0.30 0.40 0.35 0.36 0.40 0.33 0.41 0.37 0.39 0.36 0.37 0.45 0.39 0.57 0.26 0.52 0.67 0.51 0.48 0.44 0.52 0.45 0.53 0.49 0.45 0.41 0.56 0.54 0.52 0.03 0.03 0.08 0.02 0.04 0.03 0.03 0.02 0.02 0.02 0.01 0.02 0.02 0.07 0.03 0.02 0.04 0.05 0.05 0.04 0.04 0.05 0.06 0.03 0.01 0.06 0.07 0.09 0.06 0.06 0.07 0.05 0.01 0.04 0.04 0.02 0.03 0.02 0.01 0.03 0.01 0.01 0.02 0.02 0.04 0.02 0.02 0.11 0.03 0.04 0.07 0.02 0.04 0.11 0.13 0.03 0.04 0.15 0.10 0.14 0.09 0.09 Cases 280 408 42 501 71 125 146 169 261 518 263 452 164 28 106 137 124 21 56 95 124 50 42 70 999 60 23 26 54 33 31 71 1643 108 76 299 284 498 900 306 984 1627 565 600 168 602 916 16 451 282 66 652 186 36 27 529 144 10 17 25 45 33 Female ASR(W) CUM 0-74 2.6 2.7 2.8 2.5 2.3 2.4 1.8 1.7 2.6 2.3 1.5 2.4 2.0 2.2 2.1 2.0 2.5 2.2 2.5 3.0 2.9 1.9 1.9 1.9 2.6 2.5 2.4 3.0 2.7 2.0 3.1 2.5 2.6 2.8 2.4 2.5 2.6 2.7 3.0 2.7 3.0 2.6 2.4 2.5 2.5 2.6 3.6 3.7 3.4 4.0 3.2 3.3 2.7 3.5 6.0 3.7 3.0 2.3 2.2 4.2 3.0 2.3 0.18 0.15 0.49 0.13 0.31 0.23 0.19 0.14 0.19 0.12 0.10 0.12 0.18 0.48 0.25 0.21 0.25 0.60 0.43 0.36 0.30 0.35 0.33 0.28 0.10 0.39 0.66 0.78 0.44 0.40 0.62 0.34 0.07 0.30 0.32 0.17 0.18 0.14 0.12 0.18 0.12 0.08 0.13 0.12 0.22 0.13 0.13 0.97 0.18 0.28 0.47 0.15 0.22 0.63 1.19 0.18 0.28 0.92 0.56 0.86 0.56 0.45 0.27 0.29 0.30 0.24 0.24 0.25 0.20 0.15 0.25 0.25 0.16 0.25 0.21 0.18 0.20 0.18 0.26 0.22 0.23 0.29 0.28 0.19 0.22 0.19 0.26 0.24 0.22 0.27 0.27 0.23 0.33 0.26 0.26 0.29 0.22 0.25 0.26 0.27 0.29 0.29 0.30 0.26 0.24 0.26 0.25 0.25 0.34 0.23 0.34 0.42 0.30 0.32 0.26 0.35 0.69 0.37 0.27 0.19 0.23 0.45 0.28 0.19 0.02 0.02 0.06 0.01 0.03 * 0.03 0.02 0.01 * 0.02 0.01 0.01 0.01 0.02 0.05 0.02 0.02 0.03 0.06 0.04 0.04 0.03 0.04 0.04 0.03 0.01 0.05 0.06 0.08 0.05 0.05 0.07 0.04 0.01 0.03 0.03 0.02 0.02 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.07 0.02 0.03 0.05 0.02 0.03 0.08 0.17 0.02 0.03 0.09 0.07 0.11 0.06 0.05

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
595

653

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Leukaemia unspecified (C95)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 9 62 0 14 10 20 18 16 9 234 6 42 32 13 15 4 649 59 105 13 17 8 0 51 381 0 15 98 13 85 5 94 494 31 21 46 390 86 4 6 4 0 2 68 93 3 3 2 2 2 16 60 72 95 3 90 16 9 7 570 33 528 98 17 81 21 7 14 18 335 34 294 81 69 93 112 21 90 7 14 Male ASR(W) CUM 0-74 0.3 1.0 0.5 0.4 2.5 0.7 1.5 0.5 1.0 0.7 1.2 0.4 0.4 1.4 0.4 0.8 0.6 0.6 0.3 0.6 0.5 1.5 0.9 0.3 0.6 0.4 0.6 0.4 0.5 0.4 0.2 0.3 0.3 0.5 0.4 0.3 0.3 0.4 0.1 0.4 0.3 0.1 0.2 0.2 0.2 0.4 0.2 0.3 0.5 0.7 0.5 0.7 1.0 1.0 0.9 0.7 0.6 0.8 0.4 0.4 0.4 0.3 0.5 0.3 0.4 0.9 0.8 0.9 0.4 0.5 0.7 0.8 0.6 0.9 0.7 0.6 0.13 0.15 0.18 0.15 0.62 0.18 0.38 0.17 0.07 0.30 0.19 0.07 0.11 0.38 0.23 0.03 0.08 0.06 0.08 0.15 0.18 0.22 0.05 0.09 0.06 0.12 0.07 0.17 0.05 0.02 0.04 0.08 0.04 0.03 0.04 0.16 0.14 0.22 0.08 0.06 0.03 0.07 0.11 0.13 0.11 0.26 0.06 0.05 0.07 0.08 0.29 0.08 0.28 0.38 0.40 0.04 0.10 0.04 0.04 0.09 0.05 0.07 0.18 0.07 0.11 0.05 0.14 0.06 0.05 0.07 0.08 0.08 0.14 0.10 0.28 0.18 0.25 0.06 0.08 0.03 0.09 0.06 0.13 0.03 0.03 0.13 0.06 0.07 0.06 0.05 0.01 0.06 0.05 0.14 0.08 0.04 0.05 0.04 0.05 0.06 0.04 0.04 0.02 0.03 0.02 0.04 0.04 0.03 0.02 0.05 0.01 0.05 0.03 0.00 0.01 0.05 0.02 0.03 0.04 0.05 0.08 0.05 0.08 0.09 0.09 0.07 0.05 0.07 0.04 0.05 0.04 0.02 0.04 0.01 0.04 0.07 0.08 0.07 0.04 0.06 0.06 0.07 0.05 0.08 0.06 0.05 0.07 0.02 0.02 0.01 0.01 0.03 0.03 0.01 0.01 0.04 0.04 0.00 0.01 0.01 0.01 0.02 0.02 0.03 0.01 0.01 0.01 0.02 0.01 0.03 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.02 0.04 0.01 0.01 0.00 0.00 0.01 0.05 0.01 0.01 0.01 0.01 0.05 0.01 0.03 0.04 0.06 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.03 0.02 Cases 10 44 0 9 5 17 14 6 14 186 1 41 28 26 15 11 569 27 87 15 10 7 0 51 358 2 12 90 20 69 9 96 475 23 25 63 359 80 1 2 7 2 7 60 108 9 2 2 0 1 22 70 58 94 5 89 12 8 4 459 40 415 126 33 93 28 9 19 20 324 36 284 87 60 72 107 31 75 10 8 Female ASR(W) CUM 0-74 0.4 0.7 0.3 0.2 1.4 0.4 0.7 0.7 0.7 0.1 0.9 0.3 0.7 1.2 0.9 0.5 0.2 0.4 0.2 0.3 0.3 1.2 0.6 0.1 0.2 0.4 0.4 0.4 0.7 0.4 0.3 0.1 0.3 0.3 0.3 0.2 0.1 0.1 0.5 0.5 0.2 0.2 0.2 0.2 0.1 0.1 0.3 0.2 0.2 0.3 0.5 0.4 0.5 0.3 0.3 0.2 0.5 0.5 0.5 0.3 0.4 0.3 0.3 0.3 0.3 0.3 0.6 0.5 0.6 0.2 0.3 0.3 0.5 0.6 0.5 0.6 0.2 0.12 0.11 0.19 0.10 0.39 0.13 0.30 0.19 0.05 0.06 0.14 0.06 0.15 0.32 0.29 0.03 0.04 0.05 0.06 0.14 0.13 0.20 0.04 0.08 0.08 0.05 0.10 0.06 0.23 0.05 0.01 0.03 0.06 0.03 0.02 0.03 0.06 0.04 0.21 0.35 0.07 0.03 0.02 0.07 0.07 0.11 0.30 0.05 0.03 0.04 0.07 0.20 0.07 0.09 0.14 0.10 0.03 0.08 0.03 0.04 0.08 0.04 0.05 0.09 0.07 0.09 0.04 0.09 0.05 0.03 0.05 0.05 0.06 0.12 0.08 0.20 0.08 0.12 0.04 0.06 0.07 0.06 0.09 0.03 0.08 0.11 0.11 0.04 0.02 0.03 0.01 0.01 0.04 0.10 0.05 0.01 0.03 0.03 0.03 0.03 0.03 0.02 0.01 0.03 0.02 0.02 0.01 0.01 0.05 0.04 0.01 0.01 0.01 0.02 0.01 0.02 0.02 0.01 0.03 0.04 0.04 0.04 0.01 0.02 0.04 0.03 0.04 0.03 0.04 0.03 0.02 0.01 0.02 0.02 0.04 0.04 0.04 0.02 0.03 0.04 0.05 0.07 0.05 0.06 0.03 * * * *

0.04 0.02 0.03 0.02 0.01 0.02 0.01 0.02 0.03 0.04 * 0.00 0.01 0.01 0.01 0.01 0.02 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.01 0.02 0.04 0.01 0.00 0.00 0.01 0.01 0.02 0.01 0.00 0.01 0.01 0.03 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.02 0.01 0.03 0.01

654

*Important. See note on population page.

596

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Leukaemia unspecified (C95) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 17 109 211 31 176 108 21 86 185 14 171 26 4786 346 4311 190 12 169 32 0 10 22 386 32 345 299 23 273 124 46 274 14 255 26 517 37 439 1345 62 91 78 1097 55 13 41 433 33 390 25 7 112 73 34 162 6 59 70 26 48 269 14 3 63 205 2 150 41 34 7 103 81 8 17 10 4 44 19 173 15 Male ASR(W) CUM 0-74 0.3 0.4 0.6 0.9 0.5 0.8 0.8 0.8 0.8 0.9 0.8 0.7 0.6 0.5 0.6 0.6 0.4 0.6 0.5 0.5 0.6 0.5 0.4 0.6 0.7 0.7 0.7 0.9 0.3 0.5 0.5 0.5 0.5 0.5 0.6 0.5 0.5 0.3 0.5 0.3 0.5 0.4 0.4 0.4 0.7 0.6 0.7 0.4 0.3 0.5 0.4 0.4 0.7 0.8 1.1 0.3 2.8 2.0 1.3 0.4 0.2 0.6 0.7 0.2 0.6 0.8 0.5 0.3 0.6 0.5 0.3 0.4 0.2 0.1 0.5 0.3 0.6 0.3 0.07 0.04 0.04 0.16 0.04 0.08 0.19 0.09 0.06 0.25 0.06 0.14 0.01 0.03 0.01 0.05 0.12 0.05 0.09 0.16 0.14 0.03 0.08 0.03 0.04 0.15 0.04 0.09 0.05 0.03 0.13 0.03 0.11 0.02 0.10 0.03 0.01 0.04 0.05 0.04 0.02 0.05 0.12 0.06 0.03 0.10 0.04 0.08 0.10 0.05 0.06 0.08 0.06 0.33 0.15 0.04 0.63 0.33 0.10 0.12 0.09 0.08 0.05 0.13 0.05 0.13 0.08 0.10 0.06 0.06 0.13 0.11 0.08 0.04 0.09 0.07 0.05 0.08 0.03 0.03 0.06 0.11 0.05 0.07 0.10 0.07 0.08 0.05 0.08 0.08 0.05 0.05 0.05 0.05 0.04 0.05 0.06 0.04 0.07 0.05 0.05 0.05 0.06 0.06 0.06 0.09 0.03 0.05 0.05 0.05 0.02 0.05 0.07 0.05 0.05 0.03 0.05 0.03 0.05 0.03 0.04 0.03 0.06 0.05 0.06 0.04 0.02 0.04 0.03 0.03 0.08 0.10 0.10 0.04 0.22 0.20 0.12 0.04 0.02 0.06 0.06 0.00 0.06 0.06 0.03 0.02 0.06 0.05 0.04 0.04 0.04 0.01 0.04 0.02 0.05 0.02 0.01 0.01 0.01 0.03 0.01 0.01 0.03 0.01 0.01 0.02 0.01 0.02 0.00 0.00 0.00 0.01 0.02 0.01 0.01 0.02 0.02 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.00 0.02 0.00 0.01 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.02 0.01 0.00 0.02 0.00 0.01 0.02 0.01 0.01 0.01 0.01 0.05 0.02 0.01 0.05 0.03 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.01 Cases 24 146 203 17 180 100 11 88 120 14 103 18 4378 385 3888 172 17 150 29 0 8 21 375 36 331 314 18 294 93 51 244 16 221 24 461 26 402 1229 42 102 89 981 66 16 44 350 39 303 28 8 68 46 47 140 5 32 72 20 32 264 10 3 38 101 4 123 20 30 6 95 74 12 12 8 11 33 9 119 10 Female ASR(W) CUM 0-74 0.3 0.3 0.4 0.4 0.4 0.5 0.3 0.6 0.3 0.6 0.3 0.3 0.4 0.4 0.4 0.4 0.3 0.4 0.3 0.3 0.5 0.3 0.3 0.4 0.5 0.3 0.5 0.6 0.2 0.3 0.3 0.3 0.4 0.3 0.2 0.3 0.3 0.2 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.4 0.4 0.3 0.2 0.2 0.2 0.4 0.4 0.8 0.7 0.3 2.1 1.7 1.2 0.3 0.2 0.4 0.4 0.4 0.5 0.4 0.4 0.2 0.4 0.4 0.5 0.3 0.1 0.2 0.3 0.1 0.3 0.2 0.07 0.04 0.03 0.09 0.04 0.06 0.10 0.08 0.04 0.16 0.03 0.09 0.01 0.02 0.01 0.03 0.08 0.04 0.08 0.12 0.18 0.02 0.05 0.03 0.03 0.08 0.03 0.07 0.04 0.02 0.08 0.03 0.09 0.02 0.05 0.02 0.01 0.03 0.04 0.03 0.01 0.04 0.09 0.04 0.02 0.08 0.02 0.06 0.08 0.03 0.04 0.08 0.05 0.37 0.14 0.04 0.59 0.39 0.10 0.10 0.10 0.07 0.04 0.20 0.05 0.10 0.08 0.08 0.05 0.05 0.17 0.09 0.06 0.07 0.07 0.03 0.04 0.09 0.03 0.02 0.04 0.03 0.03 0.05 0.03 0.05 0.02 0.05 0.02 0.02 0.03 0.03 0.03 0.03 0.02 0.03 0.02 0.02 0.03 0.03 0.02 0.03 0.04 0.02 0.05 0.06 0.02 0.02 0.04 0.02 0.03 0.03 0.02 0.03 0.03 0.02 0.03 0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.02 0.02 0.02 0.04 0.04 0.13 0.05 0.02 0.21 0.13 0.11 0.03 0.01 0.04 0.04 0.04 0.04 0.03 0.03 0.02 0.04 0.03 0.05 0.05 0.02 0.03 0.01 0.01 0.03 0.01 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.02 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.07 0.01 * 0.00 0.05 * 0.03 0.01 * 0.01 * 0.01 * 0.01 0.01 * 0.02 0.01 0.01 * 0.01 * 0.01 * 0.01 0.01 0.02 0.02 0.01 0.01 0.00 0.00 0.00 0.01

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
597

655

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Leukaemia unspecified (C95) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
598

Male ASR(W) CUM 0-74 0.5 0.6 0.7 1.0 0.5 0.5 0.4 0.5 0.5 0.4 0.2 0.9 0.4 0.7 0.5 1.6 0.4 0.4 0.5 0.5 0.4 0.8 0.6 0.3 0.2 0.3 0.1 0.6 0.4 0.2 0.4 0.8 0.3 0.4 0.1 0.2 0.3 0.2 0.4 0.1 0.4 0.0 0.3 0.5 0.1 0.0 0.8 0.6 0.4 0.3 0.5 0.8 0.6 0.2 0.9 0.1 0.3 0.6 0.8 0.3 1.1 0.0 2.8 0.4 0.9 0.3 0.7 0.4 0.8 0.2 0.3 0.2 0.5 0.1 0.4 0.7 0.03 0.10 0.12 0.21 0.14 0.11 0.27 0.06 0.16 0.21 0.13 0.21 0.10 0.19 0.13 0.15 0.07 0.08 0.34 0.23 0.10 0.21 0.15 0.10 0.05 0.03 0.05 0.28 0.04 0.05 0.05 0.06 0.05 0.03 0.03 0.06 0.05 0.08 0.16 0.09 0.12 0.02 0.08 0.25 0.08 0.03 0.24 0.09 0.05 0.08 0.14 0.09 0.07 0.07 0.09 0.13 0.15 0.45 0.14 0.11 0.33 0.03 0.46 0.06 0.35 0.15 0.27 0.09 0.18 0.09 0.14 0.17 0.14 0.04 0.19 0.13 0.05 0.07 0.05 0.12 0.05 0.04 0.06 0.04 0.04 0.00 0.03 0.10 0.04 0.06 0.05 0.16 0.02 0.02 0.03 0.06 0.05 0.07 0.05 0.03 0.02 0.03 0.04 0.04 0.02 0.04 0.09 0.03 0.03 0.01 0.04 0.02 0.03 0.04 0.01 0.03 0.03 0.05 0.02 0.09 0.03 0.03 0.02 0.05 0.06 0.05 0.02 0.08 0.02 0.02 0.04 0.07 0.04 0.14 0.01 0.28 0.04 0.07 0.03 0.06 0.03 0.07 0.02 0.03 0.02 0.04 0.00 0.03 0.06 0.00 0.01 0.01 0.03 0.02 0.01 0.05 0.01 0.02 0.00 0.02 0.03 0.01 0.02 0.02 0.02 0.01 0.01 0.02 0.03 0.01 0.02 0.02 0.01 0.01 0.00 0.02 0.00 0.01 0.01 0.01 0.01 0.00 0.00 0.01 0.00 0.01 0.02 0.01 0.01 0.01 0.02 0.01 0.03 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.01 0.02 0.05 0.01 0.05 0.01 0.03 0.02 0.02 0.01 0.02 0.02 0.02 0.02 0.01 0.00 0.01 0.01

Cases 382 31 25 7 12 14 4 77 7 0 2 15 15 20 15 170 31 25 2 4 14 17 25 9 5 106 5 2 115 14 65 198 47 111 36 8 56 6 3 3 13 0 16 3 9 6 5 2 64 107 32 23 93 68 19 0 108 1 9 7 35 13 8 3 2 38 24 14 8 5 27 18 3 8 0 15 17 6 47

Female ASR(W) CUM 0-74 0.4 0.3 0.4 0.2 0.4 0.2 0.5 0.3 0.3 0.4 0.6 0.3 0.7 0.5 1.5 0.3 0.3 0.4 0.5 0.4 0.8 0.8 0.3 0.1 0.2 0.2 0.3 0.3 0.1 0.3 0.6 0.2 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.5 0.2 0.0 0.4 0.2 0.1 0.0 0.4 0.3 0.2 0.2 0.5 0.3 0.2 0.6 0.0 0.1 0.2 0.4 0.2 0.7 0.0 0.0 2.1 0.1 0.7 0.6 0.1 0.4 0.6 0.1 0.3 0.3 0.2 0.2 0.3 0.02 0.05 0.09 0.09 0.12 0.06 0.26 0.04 0.13 0.39 0.16 0.08 0.19 0.13 0.13 0.06 0.07 0.30 0.25 0.10 0.19 0.17 0.10 0.03 0.03 0.08 0.23 0.03 0.05 0.04 0.06 0.04 0.02 0.03 0.05 0.03 0.06 0.09 0.07 0.18 0.04 0.02 0.17 0.09 0.04 0.02 0.08 0.03 0.04 0.05 0.06 0.04 0.05 0.06 0.02 0.05 0.09 0.08 0.07 0.29 0.01 0.01 0.37 0.03 0.35 0.25 0.07 0.08 0.16 0.05 0.13 0.08 0.06 0.10 0.05 0.03 0.03 0.03 0.02 0.03 0.03 0.04 0.03 0.02 0.02 0.06 0.02 0.08 0.03 0.15 0.03 0.03 0.04 0.07 0.03 0.08 0.06 0.02 0.00 0.02 0.02 0.01 0.03 0.01 0.02 0.06 0.02 0.02 0.01 0.01 0.02 0.01 0.01 0.01 0.04 0.00 0.00 0.04 0.02 0.02 0.02 0.01 0.02 0.05 0.03 0.01 0.04 0.01 0.02 0.03 0.01 0.09 0.18 0.01 0.06 0.06 0.01 0.03 0.05 0.01 0.04 0.02 0.01 0.02 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.02 0.00 0.01 0.02 0.02 0.01 0.03 * 0.01 * 0.02 * 0.01 0.01 0.03 0.04 0.01 * 0.02 * 0.02 0.01 * 0.00 * 0.00 0.01 0.01 0.00 * 0.01 * 0.00 0.01 * 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.00 0.00 0.02 0.01 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.04 0.04 0.00 0.02 0.03 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01

446 42 35 27 14 23 2 84 10 4 4 21 15 20 18 153 31 24 3 4 14 16 17 9 14 104 2 5 110 11 68 230 55 135 29 9 45 9 6 3 11 2 11 0 7 4 1 16 54 83 18 26 85 66 11 0 110 1 5 6 50 11 13 0 1 41 34 15 6 11 25 27 5 5 1 21 10 7 45

656

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Leukaemia unspecified (C95) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 31 48 0 96 22 12 7 33 16 84 68 46 19 1 34 94 16 16 19 10 14 14 31 26 98 5 0 5 6 5 1 11 84 7 5 29 47 50 48 18 116 123 31 59 22 28 119 0 24 8 7 71 29 0 4 41 30 0 5 3 12 8 Male ASR(W) CUM 0-74 0.4 0.4 0.5 0.9 0.3 0.1 0.3 0.2 0.6 0.4 0.3 0.3 0.0 0.8 1.3 0.4 1.1 0.7 0.4 0.3 0.4 1.4 0.6 0.3 0.3 0.7 0.3 0.4 0.1 0.3 0.2 0.2 0.2 0.2 0.5 0.3 0.2 0.2 0.4 0.2 0.1 0.3 0.3 0.1 0.5 0.2 0.1 0.4 0.4 0.5 0.9 0.3 0.6 0.5 0.6 0.5 0.7 0.08 0.06 0.06 0.19 0.08 0.05 0.06 0.05 0.07 0.06 0.04 0.06 0.04 0.19 0.14 0.11 0.32 0.18 0.13 0.08 0.12 0.31 0.13 0.03 0.16 0.33 0.14 0.17 0.05 0.10 0.02 0.07 0.12 0.04 0.09 0.06 0.03 0.04 0.04 0.02 0.03 0.04 0.07 0.03 0.05 0.04 0.04 0.15 0.05 0.09 0.47 0.05 0.12 0.26 0.36 0.19 0.24 0.04 0.05 0.05 0.08 0.03 0.02 0.03 0.01 0.07 0.05 0.03 0.03 0.07 0.12 0.02 0.08 0.07 0.04 0.02 0.06 0.11 0.08 0.02 0.02 0.11 0.01 0.04 0.02 0.01 0.02 0.01 0.02 0.05 0.02 0.02 0.01 0.04 0.02 0.01 0.03 0.03 0.01 0.05 0.02 0.01 0.03 0.04 0.05 0.06 0.02 0.06 0.07 0.06 0.03 0.11 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.04 0.02 0.01 0.01 0.02 0.03 0.02 0.00 0.01 0.06 0.01 0.02 0.01 0.00 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.02 0.01 0.01 0.05 0.01 0.02 0.05 0.04 0.02 0.05 Cases 46 79 2 79 18 19 7 30 11 121 64 40 13 2 36 69 8 6 7 6 25 11 18 18 94 7 1 2 3 8 3 13 63 4 0 24 31 65 39 22 105 123 48 60 22 26 93 0 20 11 9 59 10 2 5 28 18 0 3 2 5 2 Female ASR(W) CUM 0-74 0.5 0.4 0.1 0.3 0.4 0.3 0.1 0.2 0.1 0.5 0.3 0.2 0.1 0.1 0.6 0.9 0.1 0.7 0.2 0.2 0.5 0.4 0.4 0.4 0.3 0.2 0.1 0.2 0.1 0.5 0.2 0.2 0.1 0.0 0.1 0.2 0.3 0.1 0.1 0.3 0.1 0.2 0.2 0.3 0.1 0.3 0.1 0.1 0.2 0.3 0.1 0.2 1.2 0.1 0.3 0.4 0.4 0.2 0.1 0.10 0.06 0.10 0.04 0.11 0.08 0.03 0.04 0.02 0.06 0.05 0.03 0.03 0.04 0.13 0.15 0.04 0.34 0.07 0.10 0.15 0.22 0.12 0.12 0.04 0.11 0.12 0.15 0.05 0.27 0.14 0.08 0.01 0.02 0.02 0.05 0.05 0.02 0.02 0.04 0.02 0.03 0.03 0.07 0.02 0.04 0.02 0.04 0.07 0.04 0.04 0.14 0.53 0.03 0.09 0.23 0.30 0.14 0.06 0.04 0.04 0.01 0.03 0.04 0.03 0.01 0.03 0.01 0.05 0.04 0.01 0.01 0.06 0.08 0.01 0.07 0.02 0.01 0.03 0.03 0.04 0.03 0.02 0.03 0.02 0.02 0.01 0.02 0.03 0.03 0.01 0.00 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.02 0.03 0.01 0.03 0.01 0.01 0.01 0.02 0.01 0.01 0.12 0.01 0.04 0.04 0.05 0.03 0.01 0.01 0.01 0.01 0.01 * 0.01 0.00 0.01 * 0.00 0.01 0.01 0.00 0.00 0.01 0.01 0.01 0.04 0.01 0.01 0.01 0.01 0.02 0.01 0.00 0.02 0.02 0.02 0.01 0.02 0.02 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.07 0.00 0.01 0.03 0.04 0.02 -

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
599

657

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Myeloproliferative disorders (MPD)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White *Important. See note on population page.
600

Male ASR(W) CUM 0-74 0.0 0.3 0.0 0.3 1.0 1.2 2.0 2.3 1.6 0.2 1.1 0.5 0.4 1.6 0.0 0.0 0.0 0.5 0.3 0.5 0.4 0.5 0.4 0.2 0.3 0.4 0.2 0.4 0.5 0.7 0.6 0.2 0.1 0.2 0.5 0.6 0.0 0.4 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.6 0.4 0.0 0.0 0.0 0.0 0.8 0.7 0.8 0.6 0.8 0.7 1.0 0.03 0.18 0.03 0.16 0.04 0.11 0.12 0.25 0.25 0.10 0.18 0.04 0.30 0.22 0.02 0.02 0.01 0.02 0.06 0.09 0.05 0.03 0.05 0.12 0.14 0.22 0.10 0.06 0.05 0.18 0.24 0.17 0.08 0.22 0.09 0.07 0.01 0.06 0.18 0.07 0.03 0.05 0.00 0.01 0.00 0.01 0.02 0.01 0.08 0.20 0.09 0.03 0.01 0.01 0.01 0.09 0.08 0.08 0.14 0.09 0.25 0.24 0.05 0.01 0.04 0.12 0.14 0.21 0.28 0.21 0.02 0.11 0.05 0.03 0.17 0.00 0.00 0.00 0.06 0.03 0.05 0.04 0.06 0.04 0.01 0.03 0.03 0.02 0.05 0.06 0.08 0.06 0.03 0.05 0.04 0.06 0.00 0.05 0.02 0.05 0.00 0.00 0.00 0.00 0.00 0.05 0.06 0.05 0.00 0.00 0.00 0.00 0.09 0.09 0.09 0.06 0.09 0.08 0.11 0.03 0.01 0.02 0.01 0.02 0.02 0.04 0.04 0.01 0.02 0.00 0.03 0.03 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.02 0.02 0.01 0.01 0.01 0.02 0.03 0.02 0.05 0.01 0.01 0.00 0.01 0.02 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.03 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.02 0.01 0.04 0.03

Cases 0 1 0 0 0 4 0 0 0 0 0 1 1 0 2 0 929 137 365 112 29 3 0 35 155 4 89 7 1 6 0 5 476 41 38 72 303 58 6 5 4 0 8 29 165 19 2 5 2 0 42 90 2 46 2 43 0 0 0 1 0 1 3 0 3 33 7 25 0 3 0 3 1 84 87 98 21 77 7 27

Female ASR(W) CUM 0-74 0.0 0.4 0.0 0.0 0.2 0.9 1.3 1.9 2.4 0.7 0.1 0.9 0.3 0.6 1.7 0.0 0.0 0.0 0.0 0.4 0.3 0.5 0.4 0.3 0.2 0.4 0.3 0.4 0.3 0.1 0.5 0.6 0.1 0.5 0.1 0.5 0.5 0.0 0.3 0.3 0.3 0.0 0.0 0.0 0.0 0.3 0.2 0.4 0.0 0.0 0.0 0.6 0.5 0.6 0.5 0.7 0.6 1.2 0.02 0.22 0.03 0.01 0.11 0.03 0.12 0.11 0.25 0.15 0.08 0.18 0.03 0.34 0.21 0.01 0.01 0.02 0.01 0.02 0.05 0.09 0.04 0.02 0.03 0.18 0.14 0.19 0.10 0.03 0.04 0.13 0.09 0.22 0.08 0.08 0.07 0.00 0.05 0.18 0.05 0.00 0.00 0.01 0.01 0.06 0.08 0.09 0.00 0.00 0.01 0.08 0.06 0.07 0.11 0.08 0.21 0.26 0.04 0.00 0.00 0.01 0.10 0.17 0.20 0.27 0.05 0.01 0.10 0.04 0.07 0.23 0.00 0.00 0.00 0.04 0.03 0.06 0.04 0.04 0.02 0.06 0.03 0.06 0.03 0.01 0.05 0.06 0.01 0.05 0.06 0.06 0.03 0.02 0.03 0.00 0.00 0.03 0.01 0.04 0.00 0.00 0.00 0.06 0.06 0.07 0.05 0.08 0.09 0.17 * * * *

0 3 0 0 0 3 0 0 0 0 0 1 0 0 4 0 865 109 332 93 43 3 0 37 182 2 64 4 0 4 0 3 551 41 28 74 379 82 4 5 4 0 5 54 149 17 7 2 1 1 33 81 2 47 1 45 1 1 0 2 1 1 3 1 2 31 9 22 1 4 0 3 3 95 98 101 22 78 7 21

0.03 0.00 0.00 0.01 - * 0.00 0.02 0.02 0.03 0.02 0.01 0.02 0.00 0.05 0.03 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.03 0.02 0.03 0.02 0.00 0.01 0.02 0.01 0.03 0.01 0.01 0.01 0.02 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.01 0.01 0.02 0.01 0.04 0.04

Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data 658

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Myeloproliferative disorders (MPD) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 1 5 7 0 7 136 23 109 2 0 2 0 116 18 89 209 27 169 58 3 18 35 588 45 528 3 1 2 3 3 10 0 8 2 602 42 503 1502 74 121 116 1140 0 0 0 15 2 11 29 1 6 109 0 1 6 37 0 0 0 2 0 0 1 0 0 0 0 0 1 282 250 11 0 0 5 5 4 0 0 Male ASR(W) CUM 0-74 0.0 0.0 0.0 0.0 1.0 0.8 1.0 0.0 0.0 0.0 0.0 0.0 0.8 0.9 0.7 1.0 0.7 1.0 1.0 0.9 0.7 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.6 0.7 0.6 0.4 0.6 0.5 0.7 0.0 0.0 0.0 0.5 0.0 0.0 0.8 0.0 1.0 0.8 0.0 0.0 0.0 1.7 1.7 0.5 0.1 0.0 0.1 0.02 0.01 0.01 0.01 0.09 0.18 0.11 0.01 0.01 0.00 0.01 0.00 0.05 0.18 0.06 0.14 0.40 0.24 0.20 0.04 0.10 0.04 0.01 0.04 0.01 0.02 0.01 0.01 0.01 0.03 0.03 0.09 0.03 0.02 0.05 0.06 0.05 0.02 0.01 0.02 0.01 0.10 0.05 0.01 0.08 0.01 0.43 0.14 0.01 0.01 0.04 0.11 0.11 0.16 0.05 0.02 0.03 0.00 0.00 0.00 0.00 0.12 0.10 0.12 0.00 0.00 0.00 0.00 0.00 0.09 0.13 0.08 0.12 0.03 0.12 0.12 0.10 0.08 0.11 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.07 0.08 0.07 0.04 0.08 0.06 0.08 0.00 0.00 0.00 0.06 0.00 0.00 0.10 0.00 0.18 0.09 0.00 0.00 0.00 0.21 0.20 0.05 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.03 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.03 0.01 0.02 0.02 0.03 0.02 0.01 0.01 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.00 0.09 0.02 0.00 0.00 0.00 0.02 0.02 0.02 0.01 0.00 0.01 Cases 0 2 13 1 12 145 33 104 1 0 1 0 101 8 88 210 25 170 54 0 18 36 572 58 503 4 0 4 0 1 3 0 3 0 550 52 448 1383 73 137 109 1019 3 0 3 18 0 17 25 2 10 97 1 0 4 26 0 0 0 2 0 0 0 0 0 0 0 0 0 250 217 18 0 0 2 2 1 0 0 Female ASR(W) CUM 0-74 0.0 0.0 0.0 0.0 0.7 0.9 0.7 0.0 0.0 0.0 0.0 0.0 0.5 0.6 0.5 0.8 0.9 0.9 0.6 0.6 0.7 0.0 0.0 0.0 0.0 0.0 0.5 0.5 0.5 0.5 0.3 0.5 0.4 0.5 0.0 0.0 0.0 0.0 0.4 0.1 0.0 0.6 0.0 0.6 0.4 0.0 1.2 1.2 0.9 0.0 0.0 0.0 0.01 0.01 0.01 0.01 0.07 0.16 0.08 0.00 0.00 0.00 0.00 0.00 0.04 0.13 0.05 0.11 0.21 0.16 0.03 0.08 0.04 0.01 0.01 0.00 0.01 0.01 0.02 0.08 0.03 0.01 0.04 0.05 0.04 0.02 0.00 0.01 0.01 0.01 0.08 0.08 0.01 0.06 0.00 0.29 0.08 0.00 0.08 0.09 0.24 0.02 0.01 0.02 0.00 0.00 0.00 0.08 0.11 0.07 0.00 0.00 0.00 0.06 0.07 0.06 0.10 0.12 0.11 0.07 0.06 0.07 0.00 0.00 0.00 0.00 0.05 0.06 0.05 0.05 0.03 0.06 0.05 0.05 0.00 0.00 0.03 0.02 0.00 0.06 0.04 0.05 0.00 0.13 0.13 0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.01 0.00 0.00 0.00 0.01 0.02 0.01 0.02 0.03 0.02 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.03 0.01 * - * 0.00 * - * - * - * - * - * - * 0.01 0.01 0.03 0.00 0.00 0.00 -

*Important. See note on population page. Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data Cancer Incidence in Five Continents Vol. IX, IARC 2007

601

659

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Myeloproliferative disorders (MPD) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
602

Male ASR(W) CUM 0-74 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.7 0.6 0.8 1.8 0.1 0.1 1.9 0.2 0.2 0.8 0.2 0.0 1.0 2.7 2.0 2.7 1.5 2.1 0.9 2.8 1.9 2.1 0.8 0.7 0.8 0.6 0.9 0.6 0.1 2.0 4.2 1.9 5.5 5.2 0.7 0.2 0.1 2.8 0.1 2.4 4.3 1.2 0.9 0.1 0.01 0.03 0.05 0.03 0.11 0.13 0.09 0.09 0.10 0.35 0.46 0.04 0.03 0.29 0.03 0.05 0.07 0.03 0.01 0.05 0.28 0.30 0.39 0.21 0.23 0.16 0.40 0.33 0.38 0.19 0.09 0.06 0.12 0.10 0.08 0.05 0.13 0.82 0.36 0.38 0.48 0.29 0.05 0.05 0.43 0.03 0.36 0.62 0.34 0.18 0.05 0.00 0.01 0.01 0.00 0.01 0.03 0.01 0.08 0.06 0.07 0.21 0.00 0.01 0.24 0.03 0.03 0.09 0.02 0.00 0.11 0.31 0.24 0.31 0.21 0.23 0.10 0.29 0.23 0.22 0.09 0.07 0.10 0.06 0.09 0.07 0.02 0.24 0.45 0.23 0.60 0.60 0.07 0.02 0.00 0.36 0.01 0.23 0.58 0.12 0.11 0.01 0.00 0.00 0.01 0.00 0.01 0.03 0.01 0.01 0.01 0.03 0.06 0.00 0.00 0.04 0.00 0.01 0.01 0.00 0.00 0.01 0.04 0.04 0.05 0.03 0.03 0.02 0.05 0.04 0.05 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.09 0.05 0.04 0.06 0.03 0.01 0.00 0.06 0.00 0.05 0.09 0.04 0.02 0.01 -

Cases 34 13 0 0 0 0 1 0 0 1 2 2 0 1 1 0 43 33 4 6 0 0 0 2 7 0 52 0 77 16 128 60 2 349 0 1 0 70 79 50 0 63 79 39 55 35 35 20 66 215 0 65 80 85 7 0 220 39 0 15 197 68 4 4 0 17 5 50 36 0 0 0 0 14 0 28 0 0 0

Female ASR(W) CUM 0-74 0.0 0.1 0.1 0.0 0.2 0.1 0.1 0.0 0.5 0.4 0.7 0.6 0.1 0.1 1.9 0.2 0.2 0.5 0.1 0.0 0.8 0.0 1.6 2.5 2.4 1.5 1.7 0.8 2.0 1.5 1.7 0.7 0.5 0.7 0.6 0.6 0.6 0.1 1.4 3.4 0.6 3.0 1.7 0.2 0.0 1.1 0.0 1.6 2.7 1.2 0.5 0.01 0.04 0.06 0.05 0.13 0.05 0.06 0.03 0.07 0.08 0.37 0.27 0.05 0.03 0.29 0.02 0.05 0.05 0.02 0.00 0.05 0.01 0.21 0.31 0.36 0.21 0.20 0.13 0.33 0.27 0.34 0.17 0.07 0.06 0.08 0.08 0.08 0.04 0.10 0.78 0.18 0.25 0.25 0.12 0.02 0.26 0.02 0.28 0.51 0.34 0.11 0.00 0.02 0.00 0.02 0.01 0.00 0.00 0.05 0.05 0.09 0.07 0.00 0.01 0.20 0.02 0.03 0.06 0.02 0.09 0.00 0.17 0.31 0.30 0.17 0.19 0.09 0.20 0.19 0.21 0.08 0.06 0.09 0.08 0.06 0.07 0.01 0.14 0.35 0.07 0.33 0.22 0.05 0.01 0.13 0.00 0.18 0.29 0.12 0.07 0.00 0.00 0.00 0.02 0.00 0.01 * 0.00 * - * 0.01 0.01 0.05 0.03 - * - * 0.00 * 0.00 * 0.03 0.00 * 0.01 * 0.01 0.00 * 0.01 0.00 0.03 0.04 0.05 0.03 0.03 0.02 0.04 0.04 0.04 0.02 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.08 0.02 0.03 0.03 0.03 0.00 0.03 0.00 0.04 0.06 0.03 0.01 -

31 4 0 2 0 2 1 0 0 1 4 0 0 0 0 0 58 36 6 16 0 0 0 2 6 0 41 0 62 14 157 59 3 342 0 0 0 92 51 52 0 63 85 38 57 37 41 19 67 146 0 34 76 63 7 0 231 35 0 32 265 138 6 10 2 43 8 56 55 0 0 0 0 13 0 35 2 0 0

Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data 660

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Myeloproliferative disorders (MPD) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 72 43 11 179 2 1 24 120 63 3 3 236 75 14 0 0 0 0 36 0 0 0 20 0 796 35 1 0 20 2 0 1 247 13 8 237 103 253 554 24 1148 983 435 383 0 743 272 0 398 0 7 365 95 10 0 0 34 2 3 5 9 13 Male ASR(W) CUM 0-74 0.9 0.4 0.8 1.0 0.1 0.0 0.4 1.2 0.6 0.0 0.0 1.4 1.1 1.0 1.5 0.8 2.0 2.0 0.1 1.1 0.1 0.1 0.4 0.3 0.2 1.9 1.0 1.5 1.9 0.2 4.1 1.8 2.1 1.7 3.8 1.1 3.2 0.3 2.0 1.4 1.1 0.8 0.5 0.5 1.0 0.6 1.1 0.11 0.06 0.25 0.08 0.04 0.03 0.08 0.11 0.08 0.01 0.01 0.10 0.13 0.29 0.26 0.19 0.08 0.35 0.05 0.25 0.09 0.05 0.03 0.10 0.09 0.13 0.10 0.10 0.08 0.04 0.13 0.06 0.11 0.09 0.15 0.07 0.17 0.12 0.11 0.15 0.37 0.14 0.36 0.31 0.46 0.23 0.33 0.12 0.05 0.09 0.11 0.01 0.00 0.04 0.13 0.07 0.00 0.00 0.18 0.14 0.12 0.17 0.09 0.24 0.17 0.14 0.01 0.00 0.05 0.05 0.03 0.22 0.10 0.16 0.20 0.02 0.45 0.20 0.23 0.19 0.45 0.12 0.35 0.01 0.20 0.16 0.14 0.10 0.03 0.09 0.11 0.07 0.14 0.02 0.01 0.03 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.00 0.01 0.02 0.04 0.04 0.03 0.01 0.05 0.04 0.01 0.00 0.00 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.01 0.02 0.01 0.01 0.02 0.05 0.02 0.03 0.05 0.06 0.03 0.05 Cases 90 43 15 143 9 1 29 93 62 9 4 207 92 9 0 0 0 0 38 0 0 0 11 0 860 33 0 0 11 0 0 0 216 14 4 266 101 270 647 10 962 1209 411 419 0 822 232 0 299 0 6 353 98 8 0 0 26 0 4 3 6 7 Female ASR(W) CUM 0-74 0.8 0.3 0.9 0.7 0.2 0.0 0.3 0.7 0.5 0.0 0.0 1.0 1.0 0.5 1.4 0.4 1.8 0.8 0.5 0.3 0.4 0.1 1.8 0.7 1.2 1.7 0.1 2.5 1.7 1.5 1.4 3.1 0.8 2.2 0.3 1.5 1.3 0.8 0.6 0.6 0.5 0.4 0.8 0.09 0.04 0.25 0.06 0.07 0.01 0.07 0.08 0.07 0.01 0.01 0.07 0.11 0.19 0.26 0.12 0.07 0.16 0.17 0.02 0.11 0.04 0.13 0.08 0.09 0.08 0.03 0.10 0.06 0.09 0.08 0.12 0.06 0.14 0.14 0.09 0.14 0.28 0.12 0.28 0.30 0.18 0.30 0.10 0.03 0.11 0.07 0.02 0.04 0.08 0.06 0.01 0.00 0.11 0.12 0.08 0.15 0.03 0.21 0.05 0.06 0.03 0.04 0.01 0.21 0.07 0.13 0.19 0.01 0.27 0.18 0.17 0.16 0.35 0.08 0.23 0.03 0.13 0.13 0.14 0.08 0.07 0.10 0.05 0.10 0.01 0.01 0.03 0.01 0.01 * 0.01 0.01 * 0.01 0.00 0.00 0.01 0.01 0.03 0.03 0.02 0.01 0.02 0.02 0.00 0.01 0.01 0.02 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.02 0.01 0.02 0.02 0.01 0.02 0.06 0.02 0.04 0.06 0.02 0.04

*Important. See note on population page. Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data Cancer Incidence in Five Continents Vol. IX, IARC 2007

603

661

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Myelodysplastic syndromes (MDS)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White *Important. See note on population page.
604

Male ASR(W) CUM 0-74 0.1 0.6 0.3 0.0 3.3 0.2 0.9 1.3 1.8 2.9 2.1 1.9 1.1 0.2 1.4 0.9 0.0 0.0 0.9 0.7 0.9 0.7 0.9 0.6 0.9 0.5 0.8 0.6 0.7 0.9 0.8 0.3 0.8 0.8 0.8 1.0 0.6 0.6 0.0 0.0 0.8 0.3 1.0 1.0 0.9 1.0 0.5 1.1 0.8 1.2 0.04 0.27 0.15 0.02 0.58 0.13 0.03 0.12 0.11 0.26 0.27 0.33 0.20 0.03 0.51 0.16 0.02 0.02 0.03 0.07 0.13 0.07 0.04 0.06 0.26 0.16 0.34 0.16 0.07 0.06 0.18 0.15 0.30 0.26 0.12 0.08 0.07 0.08 0.00 0.01 0.12 0.14 0.15 0.09 0.08 0.08 0.13 0.10 0.30 0.24 0.09 0.03 0.00 0.44 0.09 0.11 0.16 0.28 0.22 0.20 0.13 0.03 0.15 0.09 0.00 0.01 0.08 0.05 0.09 0.08 0.09 0.06 0.08 0.06 0.05 0.06 0.07 0.09 0.09 0.03 0.05 0.09 0.10 0.06 0.07 0.00 0.00 0.08 0.01 0.11 0.09 0.11 0.10 0.03 0.11 0.05 0.13 0.05 0.02 0.00 0.08 0.00 0.02 0.01 0.04 0.04 0.05 0.03 0.00 0.08 0.02 0.00 0.00 0.00 0.01 0.02 0.01 0.01 0.01 0.03 0.03 0.03 0.02 0.01 0.01 0.03 0.02 0.04 0.02 0.01 0.01 0.01 0.00 0.00 0.02 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.02 0.04

Cases 0 6 0 0 0 7 0 0 9 0 0 0 1 0 34 1 559 72 206 85 55 20 0 27 75 4 15 2 1 1 0 0 798 67 41 124 541 121 8 6 7 2 14 75 218 22 8 7 6 0 41 126 0 75 2 71 1 1 0 0 0 0 0 0 0 43 13 29 0 0 0 0 0 136 153 123 25 97 7 22

Female ASR(W) CUM 0-74 0.1 0.5 0.5 0.0 2.5 0.1 0.5 0.6 0.9 1.2 1.6 0.9 0.6 0.2 0.3 0.2 0.0 0.0 0.0 0.5 0.4 0.5 0.6 0.5 0.4 0.5 0.2 0.8 0.5 0.5 0.4 0.5 0.5 0.5 0.5 0.5 0.5 0.6 0.4 0.1 0.4 0.1 0.1 0.4 0.5 0.4 0.7 0.8 0.6 0.5 0.6 0.5 0.7 0.04 0.19 0.17 0.01 0.46 0.11 0.02 0.07 0.07 0.16 0.25 0.22 0.12 0.02 0.20 0.08 0.01 0.04 0.00 0.02 0.05 0.08 0.06 0.03 0.04 0.19 0.10 0.32 0.40 0.14 0.05 0.04 0.11 0.18 0.20 0.20 0.08 0.06 0.05 0.10 0.05 0.05 0.08 0.07 0.16 0.09 0.07 0.07 0.06 0.11 0.08 0.20 0.22 0.07 0.04 0.32 0.03 0.05 0.06 0.08 0.12 0.19 0.11 0.06 0.02 0.04 0.03 0.00 0.00 0.05 0.04 0.04 0.06 0.05 0.04 0.06 0.03 0.10 0.05 0.05 0.04 0.05 0.04 0.04 0.04 0.05 0.05 0.07 0.04 0.04 0.01 0.01 0.05 0.06 0.04 0.07 0.09 0.06 0.05 0.06 0.06 0.05 * * * *

0 5 0 0 0 5 0 0 3 0 0 0 3 0 35 2 856 130 305 145 65 36 0 39 92 8 36 5 0 5 0 0 1034 83 52 111 765 148 12 10 6 0 13 103 286 22 5 8 9 0 45 183 0 85 0 85 0 0 0 0 0 0 1 0 1 55 6 47 0 0 0 0 0 138 136 140 18 121 7 29

0.04 0.02 0.06 0.03 * 0.00 0.01 0.01 0.02 0.04 0.03 0.02 0.00 0.04 0.01 0.00 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.03 0.02 0.04 0.05 0.02 0.01 0.01 0.01 0.03 0.03 0.04 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.03 0.02

Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data 662

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Myelodysplastic syndromes (MDS) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 0 0 9 0 9 214 38 170 0 0 0 0 22 0 22 318 25 281 54 1 21 32 900 34 846 2 0 2 2 0 0 0 0 0 928 56 806 2476 133 147 154 2005 0 0 0 0 0 0 55 0 0 206 0 0 4 0 0 0 0 0 0 8 0 0 0 0 0 0 1 281 248 10 9 0 32 51 103 0 4 Male ASR(W) CUM 0-74 0.0 0.0 1.5 1.4 1.4 0.0 0.0 1.0 0.9 0.9 0.8 0.3 1.1 0.7 1.2 0.5 1.3 0.0 0.0 0.0 0.9 0.8 1.0 0.9 0.7 0.8 0.7 1.0 0.8 1.4 0.7 0.4 0.0 1.4 1.4 0.7 0.2 0.8 0.4 1.3 0.1 0.01 0.01 0.11 0.24 0.12 0.00 0.00 0.06 0.18 0.06 0.12 0.34 0.24 0.14 0.04 0.08 0.05 0.01 0.01 0.01 0.03 0.11 0.04 0.02 0.06 0.07 0.06 0.02 0.11 0.10 0.35 0.14 0.04 0.09 0.09 0.23 0.08 0.14 0.06 0.15 0.03 0.00 0.00 0.15 0.12 0.14 0.00 0.00 0.11 0.12 0.11 0.10 0.08 0.15 0.08 0.11 0.04 0.12 0.00 0.00 0.09 0.06 0.10 0.10 0.06 0.08 0.09 0.10 0.08 0.14 0.11 0.05 0.00 0.14 0.13 0.09 0.04 0.10 0.04 0.11 0.01 0.00 0.00 0.02 0.03 0.02 0.00 0.00 0.01 0.03 0.01 0.02 0.08 0.04 0.02 0.01 0.01 0.01 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.02 0.02 0.07 0.02 0.00 0.01 0.01 0.04 0.01 0.02 0.01 0.02 0.00 Cases 0 0 6 0 6 219 38 179 1 0 1 0 14 3 11 263 38 214 34 0 11 22 795 53 724 0 0 0 2 0 0 0 0 1 829 67 714 2105 103 174 162 1630 0 0 0 0 0 0 42 1 0 186 0 0 3 0 0 0 0 0 0 2 0 0 0 0 0 0 1 224 189 9 4 0 16 35 75 0 1 Female ASR(W) CUM 0-74 0.0 0.0 1.1 1.0 1.1 0.0 0.0 0.0 0.0 0.0 0.5 0.8 0.5 0.4 0.5 0.4 0.7 0.4 0.7 0.0 0.0 0.6 0.7 0.7 0.6 0.4 0.6 0.6 0.6 0.6 0.0 1.0 0.5 0.1 0.0 0.9 0.8 0.4 0.1 0.3 0.2 0.6 0.0 0.01 0.01 0.09 0.17 0.10 0.01 0.01 0.00 0.00 0.00 0.04 0.14 0.04 0.08 0.16 0.09 0.03 0.06 0.03 0.01 0.03 0.03 0.09 0.03 0.01 0.04 0.05 0.05 0.02 0.10 0.02 0.09 0.28 0.04 0.03 0.06 0.06 0.15 0.05 0.08 0.03 0.09 0.00 0.00 0.00 0.11 0.13 0.11 0.00 0.00 0.00 0.00 0.00 0.06 0.09 0.05 0.04 0.07 0.03 0.06 0.04 0.07 0.00 0.00 0.07 0.08 0.07 0.06 0.04 0.07 0.06 0.06 0.08 0.11 0.05 0.01 0.08 0.08 0.02 0.01 0.03 0.01 0.06 0.00 0.00 0.01 0.03 0.01 0.00 0.00 0.00 0.00 0.00 0.01 0.02 0.01 0.01 0.02 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.00 0.02 0.01 0.05 - * - * - * - * 0.01 * - * - * - * - * 0.01 0.01 0.01 0.01 0.01 0.00 0.01 -

*Important. See note on population page. Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data Cancer Incidence in Five Continents Vol. IX, IARC 2007

605

663

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Myelodysplastic syndromes (MDS) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
606

Male ASR(W) CUM 0-74 0.1 0.1 0.1 0.0 0.2 0.0 0.1 0.1 0.0 0.5 0.5 0.3 0.2 0.3 0.8 0.3 0.8 0.0 0.8 1.2 1.2 2.6 1.4 2.4 0.4 1.6 1.2 2.9 0.8 0.7 1.3 1.2 1.3 1.9 2.1 0.9 2.6 1.4 1.2 0.0 0.8 0.1 3.0 1.0 1.5 0.01 0.03 0.14 0.01 0.16 0.01 0.07 0.05 0.02 0.08 0.09 0.15 0.08 0.06 0.18 0.06 0.06 0.00 0.05 0.18 0.22 0.36 0.18 0.25 0.10 0.26 0.23 0.38 0.10 0.07 0.14 0.12 0.11 0.12 0.44 0.39 0.22 0.21 0.18 0.04 0.22 0.06 0.49 0.28 0.19 0.01 0.01 0.02 0.00 0.03 0.00 0.01 0.02 0.01 0.04 0.05 0.01 0.03 0.04 0.08 0.02 0.08 0.00 0.09 0.10 0.13 0.27 0.13 0.23 0.03 0.17 0.14 0.26 0.09 0.07 0.15 0.10 0.12 0.17 0.19 0.07 0.27 0.14 0.11 0.01 0.08 0.01 0.37 0.10 0.19 0.00 0.00 0.02 0.00 0.02 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.00 0.01 0.02 0.03 0.05 0.02 0.03 0.01 0.04 0.04 0.05 0.01 0.01 0.02 0.01 0.01 0.02 0.06 0.03 0.03 0.03 0.02 0.01 0.03 0.01 0.07 0.04 0.03 -

Cases 43 13 0 0 0 1 1 0 0 3 1 1 0 0 0 1 30 27 1 2 0 0 0 8 29 0 23 0 0 26 149 0 0 344 0 0 0 38 22 47 0 38 62 9 38 19 45 0 69 163 0 67 129 128 0 0 184 16 0 13 144 40 4 42 0 10 0 2 36 0 0 0 0 10 0 57 0 0 0

Female ASR(W) CUM 0-74 0.0 0.1 0.0 0.1 0.3 0.1 0.1 0.0 0.3 0.3 0.2 0.2 0.3 0.4 0.6 0.2 0.4 0.6 0.6 0.5 1.3 0.5 0.9 0.2 0.7 0.6 1.4 0.5 0.5 0.6 0.6 0.7 1.0 0.9 0.2 1.8 0.6 0.2 0.4 0.4 0.0 2.1 0.6 0.8 0.01 0.03 0.01 0.09 0.16 0.13 0.05 0.01 0.06 0.06 0.21 0.16 0.10 0.07 0.14 0.04 0.03 0.04 0.12 0.14 0.21 0.10 0.12 0.06 0.14 0.15 0.26 0.09 0.05 0.09 0.06 0.08 0.09 0.26 0.06 0.23 0.12 0.11 0.08 0.14 0.02 0.39 0.22 0.12 0.00 0.01 0.00 0.02 0.04 0.02 0.01 0.03 0.03 0.02 0.02 0.03 0.06 0.02 0.03 0.07 0.06 0.05 0.12 0.05 0.09 0.02 0.06 0.07 0.13 0.05 0.05 0.06 0.06 0.07 0.11 0.10 0.17 0.04 0.03 0.04 0.05 0.23 0.07 0.09 0.00 0.00 0.00 0.02 0.03 0.02 0.01 - * - * - * 0.01 0.01 0.02 - * - * 0.01 * 0.01 * 0.02 - * 0.01 * 0.01 - * 0.01 0.02 0.02 0.03 0.01 0.02 0.01 0.02 0.02 0.04 0.01 0.01 0.01 0.01 0.01 0.01 0.04 0.02 0.01 0.02 0.01 0.02 0.05 0.03 0.02 -

59 9 0 0 0 0 1 1 0 2 1 1 4 0 0 2 38 35 0 3 0 0 0 5 25 0 22 0 0 23 183 1 0 308 0 0 0 50 35 57 0 69 101 19 42 32 69 0 80 149 0 89 117 138 0 0 250 25 0 15 174 53 0 66 1 13 0 1 44 0 0 0 0 16 0 71 0 0 0

Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data 664

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Myelodysplastic syndromes (MDS) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 0 20 20 198 12 0 34 47 149 0 0 95 43 27 0 1 0 0 69 0 0 0 13 0 433 29 0 0 43 0 0 0 387 21 21 288 183 357 540 24 1272 1298 716 479 0 627 464 0 454 0 15 623 211 10 0 0 38 4 11 4 15 3 Male ASR(W) CUM 0-74 0.2 1.2 0.9 0.5 0.5 0.4 1.3 0.6 0.6 1.8 0.0 2.2 0.5 0.9 1.6 2.0 0.6 0.5 0.6 1.9 1.5 1.8 1.7 0.2 3.2 2.0 2.9 1.8 2.6 1.7 3.2 0.8 3.0 3.0 1.3 0.7 0.6 1.3 1.0 1.0 0.2 0.04 0.28 0.07 0.15 0.09 0.07 0.11 0.06 0.09 0.37 0.01 0.29 0.15 0.05 0.31 0.33 0.03 0.12 0.13 0.12 0.11 0.10 0.08 0.05 0.10 0.06 0.11 0.09 0.11 0.08 0.16 0.21 0.12 0.21 0.43 0.13 0.33 0.45 0.51 0.31 0.13 0.03 0.09 0.08 0.05 0.06 0.04 0.16 0.06 0.07 0.24 0.25 0.05 0.09 0.13 0.25 0.06 0.05 0.08 0.18 0.10 0.14 0.16 0.02 0.26 0.19 0.25 0.15 0.23 0.16 0.28 0.08 0.24 0.28 0.04 0.08 0.06 0.09 0.13 0.12 0.03 0.01 0.03 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.06 0.05 0.02 0.01 0.04 0.05 0.00 0.02 0.02 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.02 0.03 0.02 0.03 0.03 0.02 0.06 0.05 0.08 0.04 0.02 Cases 0 12 15 37 10 0 30 29 131 0 0 119 46 22 0 0 0 0 52 0 0 0 10 0 379 16 0 0 43 0 0 0 299 19 14 214 161 336 402 15 1131 987 676 360 0 606 347 0 327 0 8 432 118 5 0 0 26 3 0 3 7 11 Female ASR(W) CUM 0-74 0.1 0.8 0.2 0.2 0.2 0.2 0.8 0.5 0.4 1.3 1.3 0.2 0.6 0.7 1.4 0.4 0.4 0.4 1.0 0.8 1.1 0.8 0.1 1.9 1.0 2.0 1.0 1.6 0.9 1.8 0.2 1.4 1.2 0.5 0.4 0.4 0.6 0.3 0.6 0.02 0.24 0.03 0.07 0.05 0.04 0.09 0.05 0.06 0.35 0.21 0.09 0.04 0.26 0.25 0.03 0.10 0.11 0.08 0.07 0.07 0.05 0.03 0.08 0.04 0.09 0.06 0.08 0.05 0.11 0.08 0.08 0.13 0.25 0.08 0.23 0.35 0.14 0.21 0.01 0.08 0.01 0.03 0.03 0.03 0.09 0.05 0.04 0.10 0.13 0.01 0.06 0.05 0.18 0.05 0.04 0.04 0.10 0.06 0.10 0.08 0.01 0.17 0.10 0.18 0.09 0.15 0.07 0.17 0.02 0.12 0.08 0.06 0.05 0.05 0.07 0.03 0.10 0.00 0.03 0.00 0.01 * 0.01 0.01 * 0.01 0.01 0.01 0.03 0.03 0.01 0.01 0.02 0.04 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01 0.01 0.02 0.02 0.01 0.02 0.03 0.01 0.05 0.04 0.02 0.05

*Important. See note on population page. Care should be taken when comparing populations. See Chapter 5 Comparability and quality of data Cancer Incidence in Five Continents Vol. IX, IARC 2007

607

665

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other and unspecified (O&U)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 59 440 53 91 102 111 359 97 143 3823 128 472 781 142 61 38 9061 825 1385 421 181 181 3 473 5167 42 383 1428 295 1121 95 1783 8785 641 602 1155 6299 1688 157 93 47 15 143 1149 2216 282 48 57 52 24 442 1265 1054 953 70 874 191 134 47 6799 604 6118 2026 484 1526 531 154 367 397 3642 562 2995 1672 751 1479 1298 401 890 133 205 Male ASR(W) CUM 0-74 2.7 10.3 5.7 7.0 6.3 12.6 16.7 15.3 10.4 18.7 13.9 13.9 10.1 5.0 5.2 4.2 10.4 8.8 8.6 9.4 6.0 10.2 3.9 13.0 11.9 7.6 8.3 9.2 10.6 8.8 6.2 9.4 8.2 5.4 10.6 7.3 8.6 7.8 12.0 5.3 5.1 3.3 7.0 8.3 8.0 11.1 3.8 6.8 8.8 4.6 7.1 8.7 7.9 7.4 10.0 7.2 10.8 12.1 7.4 9.4 11.4 9.2 8.9 10.9 8.5 8.0 9.3 7.6 8.6 8.8 13.2 8.3 8.0 6.4 10.7 9.3 12.1 8.4 13.8 9.7 0.37 0.52 0.80 0.97 0.75 1.27 0.97 1.63 0.90 0.32 1.26 0.66 0.37 0.43 0.68 0.70 0.11 0.31 0.24 0.49 0.48 0.77 2.35 0.63 0.17 1.22 0.47 0.25 0.64 0.28 0.66 0.24 0.09 0.22 0.44 0.22 0.12 0.20 0.98 0.58 0.77 0.94 0.60 0.27 0.18 0.67 0.57 0.94 1.35 0.96 0.35 0.27 0.25 0.26 1.22 0.27 0.82 1.10 1.13 0.13 0.47 0.13 0.20 0.51 0.22 0.36 0.80 0.41 0.46 0.15 0.57 0.16 0.20 0.25 0.29 0.27 0.62 0.30 1.23 0.73 1.35 1.84 1.74 1.20 2.18 1.56 1.72 1.05 0.53 0.62 0.54 1.14 0.95 0.94 1.05 0.61 1.38 0.42 1.45 1.29 0.94 0.82 1.04 1.22 1.00 0.67 1.05 0.92 0.59 1.26 0.82 0.97 0.86 1.46 0.54 0.55 0.39 0.80 0.90 0.91 1.27 0.44 0.76 0.95 0.62 0.76 0.99 0.86 0.80 1.03 0.79 1.31 1.47 0.86 1.05 1.33 1.02 1.03 1.23 1.00 0.91 1.04 0.88 0.91 1.01 1.63 0.93 0.94 0.69 1.21 1.04 1.35 0.96 1.52 1.07 0.17 0.14 0.25 0.13 0.05 0.18 0.10 0.05 0.06 0.10 0.11 0.02 0.04 0.03 0.07 0.07 0.12 0.33 0.09 0.02 0.20 0.07 0.04 0.09 0.04 0.10 0.03 0.01 0.03 0.07 0.03 0.02 0.03 0.15 0.08 0.10 0.16 0.09 0.04 0.03 0.10 0.09 0.14 0.18 0.16 0.05 0.04 0.04 0.04 0.16 0.04 0.12 0.16 0.17 0.02 0.07 0.02 0.03 0.07 0.03 0.05 0.12 0.06 0.07 0.02 0.08 0.02 0.03 0.04 0.04 0.04 0.09 0.04 0.17 0.10 Cases 49 369 43 94 92 81 451 116 143 4007 133 608 684 211 74 60 9366 1071 1669 509 194 172 0 487 4719 48 497 1438 328 1086 85 1830 10405 728 689 1409 7459 2135 183 115 63 23 195 1464 2556 287 59 59 36 28 527 1504 1213 1237 70 1156 239 173 62 6816 603 6125 2253 573 1654 613 208 390 408 4446 634 3723 1967 993 1512 1321 400 908 134 216 Female ASR(W) CUM 0-74 2.1 7.3 4.3 8.0 6.3 6.2 16.5 14.8 8.0 13.9 12.3 13.4 8.2 6.3 4.4 5.4 8.1 9.0 8.1 8.0 4.6 8.2 9.8 8.0 6.6 9.1 6.6 7.4 6.3 5.7 7.6 7.3 4.9 8.9 7.0 7.7 7.3 10.0 5.2 5.0 3.8 6.9 7.6 6.8 7.8 4.0 4.8 4.6 4.1 6.3 7.5 7.0 6.6 6.7 6.6 8.3 8.7 7.5 7.0 8.0 6.8 6.9 7.9 6.6 6.5 8.0 5.9 7.3 7.4 9.5 7.1 6.9 6.1 7.7 6.6 8.0 6.1 9.3 6.7 0.31 0.39 0.66 0.98 0.78 0.82 0.83 1.45 0.68 0.23 1.10 0.56 0.32 0.45 0.55 0.73 0.10 0.30 0.23 0.42 0.38 0.66 0.52 0.13 1.08 0.49 0.20 0.45 0.22 0.64 0.20 0.08 0.19 0.36 0.19 0.11 0.18 0.80 0.52 0.66 0.86 0.52 0.24 0.15 0.49 0.58 0.65 0.87 0.79 0.29 0.24 0.22 0.22 0.82 0.23 0.61 0.75 1.11 0.10 0.34 0.11 0.16 0.36 0.18 0.28 0.59 0.33 0.41 0.13 0.40 0.14 0.17 0.23 0.22 0.20 0.43 0.23 0.85 0.53 0.63 1.74 1.47 0.87 1.48 1.34 1.53 0.85 0.68 0.46 0.65 0.86 0.96 0.86 0.86 0.52 1.07 1.09 0.82 0.83 1.02 0.75 0.82 0.72 0.66 0.85 0.83 0.56 1.02 0.79 0.87 0.81 1.10 0.61 0.64 0.50 0.80 0.83 0.75 0.92 0.34 0.53 0.47 0.53 0.69 0.84 0.77 0.73 0.72 0.72 0.92 0.96 0.80 0.76 0.88 0.75 0.75 0.91 0.70 0.73 0.93 0.66 0.83 0.81 1.06 0.78 0.79 0.68 0.87 0.72 0.87 0.67 1.04 0.77 * * * *

0.10 0.12 0.19 0.10 0.03 0.16 0.08 0.05 0.06 0.08 0.11 * 0.01 0.04 0.03 0.06 0.06 0.10 0.07 0.02 0.18 0.07 0.03 0.06 0.03 0.10 0.03 0.01 0.03 0.05 0.03 0.02 0.03 0.11 0.08 0.10 0.13 0.08 0.03 0.02 0.07 0.07 0.10 0.11 0.12 0.04 0.03 0.03 0.03 0.12 0.03 0.09 0.11 0.16 0.01 0.05 0.01 0.02 0.05 0.03 0.04 0.09 0.05 0.06 0.02 0.06 0.02 0.03 0.03 0.03 0.03 0.06 0.03 0.12 0.08

666

*Important. See note on population page.

608

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other and unspecified (O&U) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 490 2039 2938 390 2495 992 251 718 1866 199 1655 285 67689 6912 58753 2483 310 2113 519 21 157 331 4701 576 3984 3928 378 3462 972 1049 4342 394 3864 349 6253 668 5102 19199 957 1930 1550 14585 1276 328 935 5675 640 4918 310 184 1260 762 656 2376 45 459 2433 21 58 1436 38 100 622 1808 115 1207 456 334 251 1672 1516 109 221 86 127 361 236 1205 175 Male ASR(W) CUM 0-74 9.4 8.7 8.7 11.6 8.3 7.5 10.1 6.8 9.0 13.6 8.6 7.6 8.7 11.2 8.5 8.3 11.0 8.1 8.3 5.6 8.1 8.8 7.1 8.6 7.0 9.6 11.5 9.3 8.0 8.0 8.7 12.8 8.3 8.8 7.0 10.1 6.8 7.9 5.3 10.6 7.2 8.0 9.6 11.8 8.9 9.4 12.5 9.1 5.3 8.2 6.1 5.5 8.9 11.3 7.4 8.4 10.9 1.6 2.5 6.0 1.2 4.2 6.8 8.7 13.8 5.7 11.6 5.4 9.4 9.6 9.5 7.1 5.8 2.0 3.1 3.4 3.2 3.2 2.7 0.45 0.21 0.17 0.61 0.18 0.25 0.66 0.27 0.22 0.99 0.23 0.48 0.04 0.14 0.04 0.18 0.63 0.19 0.38 1.26 0.66 0.51 0.11 0.36 0.12 0.16 0.61 0.17 0.27 0.27 0.14 0.66 0.15 0.52 0.09 0.40 0.10 0.06 0.18 0.25 0.19 0.07 0.28 0.67 0.30 0.13 0.51 0.13 0.32 0.65 0.18 0.21 0.37 0.25 1.15 0.40 0.23 0.36 0.34 0.17 0.20 0.44 0.28 0.22 1.30 0.17 0.57 0.30 0.60 0.25 0.26 0.71 0.40 0.25 0.29 0.19 0.24 0.10 0.24 1.07 0.93 0.98 1.39 0.92 0.84 1.18 0.75 0.98 1.62 0.93 0.85 0.98 1.32 0.95 0.93 1.28 0.90 0.95 0.45 0.88 1.03 0.79 1.01 0.77 1.08 1.31 1.04 0.93 0.90 0.98 1.62 0.92 0.91 0.79 1.16 0.76 0.89 0.59 1.23 0.81 0.90 1.08 1.39 0.98 1.06 1.53 1.02 0.60 0.82 0.69 0.60 1.00 1.18 0.94 0.94 1.20 0.19 0.29 0.63 0.17 0.50 0.84 1.03 1.74 0.69 1.36 0.62 1.23 1.10 1.10 0.87 0.63 0.20 0.32 0.33 0.32 0.32 0.25 0.07 0.03 0.02 0.09 0.02 0.04 0.09 0.04 0.03 0.15 0.03 0.07 0.01 0.02 0.01 0.02 0.09 0.03 0.05 0.16 0.10 0.07 0.02 0.05 0.02 0.02 0.08 0.02 0.04 0.04 0.02 0.10 0.02 0.07 0.01 0.06 0.01 0.01 0.03 0.04 0.03 0.01 0.04 0.10 0.04 0.02 0.08 0.02 0.05 0.08 0.03 0.03 0.05 0.04 0.18 0.05 0.03 0.05 0.04 0.02 0.03 0.06 0.04 0.03 0.19 0.03 0.08 0.04 0.09 0.04 0.04 0.12 0.05 0.03 0.04 0.02 0.03 0.01 0.03 Cases 541 2615 3425 421 2952 1204 283 901 2197 226 1954 320 76745 7787 66703 3062 380 2620 550 38 160 342 6121 770 5209 4545 460 4002 1017 1284 5550 496 4958 421 7716 790 6376 22584 1056 2209 1881 17206 1228 315 902 5785 677 4981 392 212 1510 995 725 2076 24 372 1989 17 35 1476 37 86 330 1100 73 802 280 268 171 1982 1814 101 210 101 114 345 216 1242 184 Female ASR(W) CUM 0-74 7.4 7.5 7.4 8.7 7.2 6.3 7.6 5.9 7.3 9.9 7.0 6.4 7.1 8.2 7.0 6.8 8.9 6.7 6.8 7.8 6.4 7.2 6.2 6.8 6.2 7.9 9.4 7.6 6.1 7.4 7.6 10.1 7.3 6.8 6.3 8.0 6.2 6.8 4.6 8.3 6.9 6.8 6.4 6.8 6.2 7.0 8.7 6.8 5.2 6.8 5.8 5.6 6.7 7.5 4.2 6.0 7.3 1.3 1.4 5.1 1.1 2.9 3.6 6.1 8.0 3.9 7.1 4.3 5.7 8.4 8.4 6.1 4.3 1.7 2.3 2.3 1.9 2.3 2.1 0.37 0.18 0.14 0.45 0.15 0.21 0.49 0.23 0.18 0.71 0.19 0.42 0.03 0.10 0.03 0.14 0.48 0.16 0.32 1.32 0.54 0.50 0.09 0.26 0.10 0.13 0.47 0.14 0.22 0.24 0.12 0.49 0.13 0.41 0.08 0.30 0.09 0.05 0.15 0.19 0.17 0.06 0.20 0.42 0.23 0.10 0.36 0.11 0.29 0.53 0.17 0.20 0.29 0.19 0.87 0.32 0.18 0.32 0.24 0.15 0.19 0.34 0.20 0.19 0.95 0.14 0.44 0.27 0.44 0.21 0.22 0.63 0.33 0.23 0.26 0.16 0.18 0.07 0.23 0.79 0.82 0.86 1.02 0.83 0.71 0.92 0.65 0.79 1.13 0.76 0.69 0.79 0.92 0.77 0.74 0.99 0.71 0.71 0.76 0.67 0.74 0.67 0.76 0.67 0.89 1.05 0.86 0.67 0.82 0.84 1.10 0.81 0.75 0.70 0.93 0.69 0.76 0.52 0.95 0.78 0.76 0.69 0.71 0.68 0.76 0.95 0.73 0.55 0.72 0.66 0.65 0.71 0.85 0.41 0.70 0.76 0.13 0.17 0.54 0.13 0.32 0.43 0.71 0.96 0.46 0.75 0.50 0.70 0.88 0.88 0.72 0.42 0.15 0.24 0.21 0.17 0.22 0.19 0.05 0.02 0.02 0.07 0.02 0.03 0.07 0.03 0.03 0.10 0.03 0.06 0.00 0.01 0.00 0.02 0.07 0.02 0.04 0.19 0.08 0.06 0.01 0.04 0.01 0.02 0.07 0.02 0.03 0.04 0.02 0.07 0.02 0.06 0.01 0.05 0.01 0.01 0.02 0.03 0.02 0.01 0.03 0.06 0.03 0.01 0.05 0.02 0.04 0.07 0.03 0.03 0.04 0.03 0.11 0.04 * 0.02 0.04 * 0.03 0.02 * 0.03 * 0.05 * 0.03 0.03 * 0.14 0.02 0.05 * 0.04 * 0.06 * 0.03 0.03 0.09 0.04 0.02 0.03 0.02 0.02 0.01 0.02

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
609

667

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other and unspecified (O&U) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
610

Male ASR(W) CUM 0-74 6.2 6.2 7.3 5.8 7.5 4.9 5.8 6.7 5.4 5.8 6.9 15.4 8.0 6.1 18.5 10.7 5.5 5.9 4.0 4.6 21.4 13.8 5.6 5.3 7.5 4.4 4.1 4.8 7.2 6.3 12.2 11.2 10.9 9.6 12.2 8.5 6.0 10.9 8.9 6.7 6.1 8.4 8.4 15.8 8.7 13.1 9.1 12.0 8.0 8.3 6.3 9.2 10.7 7.9 9.4 5.2 14.2 8.3 2.3 7.0 5.9 8.3 6.9 7.1 6.8 10.6 10.3 5.7 7.6 4.6 5.8 6.6 8.2 5.3 8.7 5.9 4.0 7.1 8.3 0.09 0.32 0.40 0.50 0.59 0.34 0.95 0.20 0.82 0.79 1.33 0.92 0.49 0.61 0.90 0.43 0.27 0.31 0.79 0.73 0.75 0.81 0.46 0.43 0.32 0.13 0.41 0.65 0.16 0.31 0.26 0.20 0.26 0.17 0.24 0.45 0.17 0.57 0.64 0.61 0.49 0.50 0.46 0.65 0.69 0.84 0.77 0.77 0.29 0.22 0.31 0.38 0.34 0.28 0.46 0.75 0.34 0.94 0.34 0.77 0.32 0.63 0.92 0.39 0.46 0.83 0.33 0.55 0.81 0.44 0.35 0.46 0.69 0.65 1.19 0.35 0.34 0.58 0.36 0.72 0.74 0.84 0.67 0.85 0.56 0.69 0.74 0.56 0.54 0.49 1.80 0.96 0.78 2.35 1.22 0.60 0.66 0.42 0.50 2.47 1.62 0.68 0.66 0.96 0.46 0.40 0.55 0.91 0.76 1.43 1.36 1.23 1.08 1.36 0.95 0.60 1.19 1.00 0.81 0.71 0.94 0.90 1.95 1.01 1.48 1.06 1.47 0.89 0.89 0.70 1.03 1.18 0.85 1.02 0.67 1.58 0.87 0.28 0.65 0.59 0.82 0.73 0.68 0.70 1.22 1.13 0.57 0.94 0.54 0.63 0.74 0.85 0.62 0.89 0.54 0.39 0.81 0.86 0.01 0.05 0.06 0.07 0.08 0.05 0.14 0.03 0.10 0.11 0.12 0.13 0.07 0.09 0.14 0.06 0.04 0.05 0.10 0.10 0.10 0.11 0.07 0.06 0.05 0.02 0.06 0.09 0.02 0.04 0.04 0.03 0.03 0.02 0.04 0.06 0.02 0.08 0.08 0.09 0.07 0.07 0.06 0.09 0.09 0.11 0.11 0.10 0.04 0.03 0.04 0.05 0.05 0.04 0.06 0.12 0.05 0.13 0.04 0.08 0.04 0.07 0.12 0.05 0.06 0.12 0.05 0.07 0.12 0.07 0.05 0.06 0.09 0.09 0.14 0.05 0.04 0.08 0.05

Cases 4260 440 302 132 149 222 35 1211 55 54 45 242 238 97 268 751 402 345 17 40 716 214 105 83 413 1754 164 63 1396 424 2369 2480 1578 3820 3164 322 1915 324 119 105 127 208 282 424 147 194 181 187 850 1988 544 692 1092 1070 476 84 1990 92 76 191 463 307 75 505 264 141 1047 161 83 133 375 230 165 50 68 367 157 167 656

Female ASR(W) CUM 0-74 3.7 4.1 4.6 3.8 4.1 3.5 2.9 4.7 3.0 4.7 8.4 10.6 6.1 5.8 13.2 8.9 4.2 4.2 3.6 4.4 17.3 9.0 3.3 2.8 4.9 3.2 3.7 3.9 3.0 4.5 10.0 6.0 6.3 6.8 10.1 4.3 5.5 5.8 3.5 3.8 3.5 4.0 4.6 7.6 4.9 6.7 6.5 6.6 4.9 5.6 4.3 6.3 7.3 5.9 6.0 7.3 11.6 4.4 2.1 6.3 4.3 5.8 5.2 4.5 4.8 6.8 6.2 3.7 4.8 3.0 4.1 5.0 5.6 3.0 4.6 4.5 2.0 4.8 4.7 0.06 0.20 0.27 0.34 0.35 0.24 0.51 0.14 0.42 0.68 1.56 0.69 0.41 0.61 0.87 0.34 0.21 0.23 0.90 0.70 0.66 0.63 0.33 0.32 0.24 0.10 0.35 0.58 0.09 0.25 0.24 0.13 0.18 0.12 0.21 0.29 0.15 0.38 0.37 0.43 0.36 0.33 0.32 0.41 0.48 0.57 0.61 0.56 0.20 0.15 0.23 0.28 0.27 0.22 0.32 0.89 0.29 0.56 0.31 0.65 0.28 0.43 0.76 0.24 0.40 0.60 0.24 0.39 0.60 0.34 0.29 0.38 0.50 0.54 0.68 0.29 0.20 0.50 0.23 0.40 0.46 0.51 0.42 0.49 0.37 0.27 0.51 0.35 0.44 0.82 1.11 0.65 0.77 1.50 1.07 0.42 0.40 0.42 0.56 2.08 1.05 0.37 0.34 0.57 0.28 0.27 0.35 0.36 0.53 1.06 0.71 0.62 0.71 1.14 0.49 0.56 0.58 0.38 0.43 0.38 0.39 0.46 0.91 0.55 0.76 0.66 0.76 0.49 0.56 0.44 0.63 0.73 0.55 0.62 0.82 1.24 0.44 0.17 0.65 0.39 0.55 0.53 0.37 0.43 0.65 0.61 0.32 0.48 0.26 0.40 0.54 0.56 0.28 0.36 0.43 0.19 0.50 0.42 0.01 0.03 0.04 0.05 0.05 0.03 0.06 0.02 0.07 0.09 0.20 0.09 0.05 0.10 * 0.12 * 0.05 * 0.03 0.03 0.13 0.10 0.09 * 0.08 * 0.04 0.04 * 0.03 * 0.01 0.04 0.07 0.01 * 0.03 * 0.03 0.02 * 0.02 0.02 0.03 0.03 0.02 0.05 0.05 0.06 0.05 0.04 0.04 0.06 0.06 0.07 0.08 0.07 0.03 0.02 0.03 0.03 0.03 0.03 0.04 0.13 0.04 0.08 0.03 0.07 0.03 0.05 0.09 0.03 0.05 0.08 0.03 0.05 0.08 0.04 0.04 0.05 0.07 0.06 0.08 0.04 0.03 0.06 0.03

5170 456 357 147 180 234 41 1298 60 67 76 300 284 106 480 741 431 360 28 43 856 301 152 156 588 1342 104 56 2094 448 2478 3567 1786 3481 2843 372 1259 390 208 124 161 327 354 641 182 264 171 283 800 1601 451 608 1037 835 453 53 1824 88 53 142 417 274 70 386 247 165 1075 143 100 123 348 229 167 75 61 315 181 156 630

668

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

Other and unspecified (O&U) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 566 893 169 1568 450 586 513 452 1200 664 1178 1313 294 118 898 952 598 72 305 349 410 233 226 188 4238 110 58 60 160 128 83 188 7606 462 609 1603 1087 3183 4349 1354 4029 7991 3014 3213 811 3125 3230 72 1430 674 215 1774 610 122 53 1579 273 9 42 66 60 77 Male ASR(W) CUM 0-74 7.5 8.3 12.3 7.7 18.2 13.5 8.2 4.5 10.3 4.9 6.9 8.4 4.4 8.5 17.0 13.1 12.5 5.0 11.7 10.5 9.4 8.6 10.2 4.8 10.0 7.0 5.8 7.5 7.6 9.1 7.7 7.2 12.5 12.5 16.7 11.9 10.1 17.8 14.6 12.1 11.9 13.5 13.4 13.5 13.3 14.1 12.9 20.2 11.0 10.4 10.8 9.5 9.3 14.0 13.3 11.7 5.9 1.9 6.3 13.1 3.8 6.0 0.32 0.28 0.97 0.21 0.88 0.58 0.37 0.22 0.32 0.20 0.22 0.24 0.27 0.86 0.62 0.44 0.53 0.69 0.73 0.60 0.49 0.61 0.73 0.39 0.17 0.70 0.81 1.05 0.64 0.84 0.88 0.57 0.15 0.59 0.70 0.32 0.32 0.33 0.23 0.34 0.21 0.16 0.26 0.25 0.49 0.26 0.24 2.52 0.30 0.43 0.77 0.24 0.39 1.31 1.94 0.31 0.38 0.72 1.03 1.65 0.62 0.72 0.91 0.99 1.59 0.81 2.06 1.61 0.90 0.52 1.15 0.59 0.77 1.00 0.47 0.92 1.87 1.47 1.38 0.48 1.24 1.21 1.02 0.92 1.12 0.57 1.19 0.74 0.69 0.69 0.80 1.01 0.93 0.70 1.46 1.49 1.93 1.25 1.06 1.99 1.58 1.27 1.26 1.44 1.43 1.46 1.47 1.52 1.45 2.49 1.22 1.14 1.01 1.01 0.98 1.49 1.37 1.28 0.72 0.18 0.86 1.47 0.42 0.76 0.04 0.04 0.15 0.03 0.12 0.08 0.05 0.03 0.04 0.03 0.03 0.03 0.03 0.11 0.08 0.06 0.07 0.09 0.10 0.08 0.07 0.08 0.10 0.05 0.02 0.09 0.13 0.14 0.09 0.12 0.13 0.07 0.02 0.09 0.10 0.04 0.05 0.05 0.03 0.05 0.03 0.02 0.04 0.04 0.07 0.04 0.03 0.38 0.04 0.06 0.10 0.03 0.06 0.19 0.25 0.04 0.06 0.10 0.16 0.23 0.08 0.11 Cases 462 767 169 2025 495 506 544 363 1031 852 1137 1266 350 106 648 716 430 74 247 275 347 214 186 141 5339 135 69 68 142 149 78 215 7267 420 534 1795 1048 3650 5017 1555 4836 9407 3469 3511 975 3777 3121 52 1375 766 233 1904 549 108 47 1724 251 25 23 39 65 75 Female ASR(W) CUM 0-74 3.6 4.3 9.5 6.9 12.2 8.1 5.6 2.7 6.5 3.4 5.7 5.2 3.2 5.8 7.6 6.5 6.4 4.2 6.9 5.8 5.6 5.4 6.2 2.2 9.9 4.9 4.6 6.1 4.5 5.9 4.6 5.7 9.1 8.7 11.0 9.9 6.9 14.6 11.8 10.1 10.2 11.0 11.2 10.7 11.1 11.2 9.7 17.9 8.5 9.0 9.4 7.8 6.4 9.4 10.7 10.0 4.2 3.3 3.1 6.7 2.5 5.3 0.20 0.18 0.81 0.19 0.59 0.40 0.27 0.16 0.23 0.15 0.19 0.16 0.20 0.72 0.37 0.28 0.33 0.68 0.56 0.43 0.34 0.49 0.64 0.23 0.16 0.49 0.66 0.89 0.47 0.61 0.60 0.47 0.12 0.45 0.53 0.28 0.25 0.28 0.20 0.30 0.18 0.14 0.22 0.21 0.41 0.21 0.20 2.63 0.25 0.38 0.70 0.20 0.30 0.97 1.60 0.27 0.30 0.74 0.66 1.11 0.39 0.69 0.40 0.49 0.97 0.72 1.31 0.90 0.62 0.32 0.66 0.37 0.62 0.53 0.31 0.51 0.78 0.61 0.61 0.38 0.63 0.57 0.58 0.51 0.49 0.20 1.17 0.45 0.49 0.62 0.46 0.51 0.43 0.60 1.04 0.95 1.23 1.01 0.72 1.67 1.29 1.05 1.07 1.19 1.21 1.18 1.22 1.19 1.04 2.54 0.87 0.93 0.96 0.81 0.62 0.96 1.17 1.09 0.49 0.30 0.40 0.83 0.29 0.63 0.02 0.02 0.10 0.03 0.08 * 0.05 0.03 0.02 * 0.03 0.02 0.02 0.02 0.02 0.08 0.05 0.04 0.05 0.08 0.07 0.05 0.05 0.06 0.06 0.03 0.02 0.07 0.09 0.12 0.06 0.08 0.08 0.06 0.02 0.06 0.07 0.04 0.03 0.04 0.03 0.04 0.02 0.02 0.03 0.03 0.06 0.03 0.03 0.46 0.04 0.05 0.10 0.03 0.04 0.14 0.23 0.04 0.04 0.12 0.10 0.17 0.06 0.11

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
611

669

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

All sites (C00-96)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 1998 7170 1512 2223 4435 2365 9206 2036 6295 89421 2185 7792 16831 4990 3802 1452 275145 30369 47439 19207 9638 5784 196 13118 134782 1811 12801 50875 10053 39857 5148 55282 344567 25289 23702 42913 243207 68192 5266 3778 2051 776 6067 46120 88323 11073 2412 2073 1584 1223 16380 49689 41622 46838 2948 43013 7527 5313 1882 252570 20979 228235 81730 19084 61662 24914 7226 17092 14337 146682 18815 123103 69755 39254 54223 55109 14466 40191 4284 7967 Male ASR(W) CUM 0-74 94.0 162.9 159.6 157.5 205.5 275.1 450.8 329.1 458.4 441.4 242.4 224.7 222.3 178.0 314.3 159.8 2.22 2.06 4.17 4.39 3.94 5.95 5.15 7.65 5.94 1.58 5.28 2.66 1.77 2.63 5.29 4.33 32.18 51.93 40.00 52.69 51.71 27.64 26.19 24.67 20.15 39.20 18.81 40.76 40.59 37.13 54.53 43.45 39.33 33.42 45.34 40.49 43.99 38.39 42.50 46.94 41.02 43.64 37.35 41.57 26.55 53.02 32.35 44.68 41.28 51.49 26.62 28.48 27.78 33.68 44.77 41.21 56.31 23.65 32.62 32.01 28.07 32.37 45.40 40.95 48.08 54.07 47.53 54.46 60.98 39.79 45.38 50.53 44.95 45.69 54.79 43.85 46.76 55.00 45.18 41.46 45.93 54.82 44.49 43.57 44.09 49.71 49.24 55.78 47.60 56.48 47.64 0.82 0.76 1.18 0.88 0.23 0.77 0.40 0.26 0.39 0.78 0.67 0.10 0.29 0.22 0.51 0.56 0.63 3.09 0.50 0.14 1.29 0.45 0.23 0.57 0.25 0.78 0.20 0.09 0.21 0.42 0.21 0.11 0.20 0.88 0.55 0.79 1.34 0.57 0.27 0.18 0.65 0.64 0.92 1.06 1.02 0.34 0.26 0.25 0.28 1.21 0.29 0.77 1.00 1.18 0.11 0.42 0.12 0.20 0.50 0.22 0.38 0.86 0.44 0.44 0.15 0.48 0.16 0.20 0.28 0.26 0.26 0.58 0.29 1.06 0.66 Cases 1912 6765 1093 2810 3866 2493 10535 2017 7282 98563 2072 9636 16531 6069 2691 2173 249053 26901 41466 17636 8318 4577 185 11591 125992 1588 10799 46382 9096 36501 4628 50440 327502 26805 19127 44719 232115 65969 4386 3546 2108 963 6232 45112 84936 9106 2333 2429 1550 1249 17571 48254 40098 45106 2577 41807 6885 4593 1987 218022 17456 197537 75178 16505 57610 24091 6600 16887 12601 142725 17765 120853 68746 37312 49728 47324 12401 34579 3823 7451 Female ASR(W) CUM 0-74 84.7 121.8 106.0 173.5 199.4 240.3 376.8 263.3 389.3 347.1 203.7 211.8 199.1 183.0 189.9 190.3 2.03 1.53 3.27 4.14 4.09 5.29 4.00 6.20 4.69 1.19 4.60 2.25 1.60 2.47 3.89 4.22 26.41 42.64 29.76 42.25 38.34 22.20 23.76 21.37 20.32 20.61 21.60 30.83 30.37 27.89 41.43 31.11 27.02 28.91 32.87 31.03 31.63 29.44 29.32 26.88 29.70 34.41 29.08 31.36 21.39 30.16 24.44 35.32 30.99 29.86 20.10 20.07 24.05 25.87 35.20 30.16 30.86 18.58 25.60 26.67 19.76 23.29 36.80 31.48 35.32 30.45 35.79 33.29 32.70 32.72 32.21 28.20 32.77 30.89 28.50 31.82 31.99 29.64 33.70 31.30 33.65 33.25 33.76 33.35 33.19 35.60 31.89 31.14 32.43 31.45 33.54 * * * *

0.63 0.58 0.89 0.66 0.16 0.61 0.31 0.22 0.34 0.48 0.60 * 0.08 0.23 0.18 0.41 0.43 0.48 2.87 0.39 0.11 1.02 0.36 0.17 0.35 0.19 0.66 0.16 0.07 0.16 0.27 0.15 0.09 0.15 0.57 0.42 0.52 0.94 0.42 0.22 0.13 0.40 0.50 0.61 0.83 0.69 0.23 0.21 0.20 0.21 0.74 0.23 0.51 0.60 0.99 0.09 0.27 0.09 0.14 0.28 0.16 0.27 0.49 0.33 0.35 0.11 0.31 0.12 0.16 0.22 0.20 0.18 0.35 0.22 0.64 0.49

338.3 0.67 335.1 1.98 311.5 1.50 456.1 3.48 355.6 3.79 313.8 4.27 259.5 19.52 380.2 3.47 334.4 0.95 363.7 8.93 321.5 3.09 344.1 1.58 376.1 3.87 332.9 1.73 353.7 5.13 308.0 1.39 341.6 0.61 222.2 1.44 423.1 2.80 267.2 1.35 367.8 0.80 338.6 1.36 411.4 5.82 224.3 3.86 232.4 5.31 225.8 9.08 280.1 3.75 366.3 1.83 338.5 1.19 448.5 4.32 205.7 4.44 265.2 6.05 268.9 7.88 230.9 6.72 266.3 2.18 375.0 1.83 335.2 1.70 391.7 1.93 431.8 8.09 388.0 2.01 442.0 5.29 497.4 7.09 320.3 7.83 370.7 0.81 404.5 2.83 368.1 0.86 369.7 1.32 440.1 3.29 355.2 1.47 378.6 2.48 445.8 5.54 365.4 2.89 340.7 2.97 373.5 1.02 442.1 3.28 362.6 1.09 354.1 1.40 361.3 1.96 407.4 1.81 403.6 1.78 453.9 3.87 391.2 2.03 457.8 7.16 388.4 4.63

271.2 0.59 267.3 1.73 247.0 1.33 362.2 3.06 269.1 3.24 231.3 3.63 232.4 18.26 287.0 2.95 273.4 0.83 275.9 7.64 255.8 2.80 254.1 1.28 232.6 2.60 257.5 1.48 296.6 4.56 253.4 1.23 273.5 0.52 192.6 1.22 260.3 1.96 217.6 1.07 305.8 0.72 272.1 1.15 261.4 4.18 184.4 3.31 180.3 4.04 206.6 7.46 228.1 3.00 305.6 1.63 264.6 0.97 265.0 2.90 176.0 3.87 230.3 4.81 236.2 6.85 180.7 5.35 208.3 1.64 319.6 1.68 274.5 1.46 306.3 1.62 263.5 5.34 310.5 1.73 294.5 3.90 289.2 4.71 285.8 7.22 282.4 0.69 247.2 1.94 287.7 0.76 267.3 1.03 247.5 2.03 275.5 1.23 276.0 1.88 256.3 3.35 291.2 2.40 271.6 2.62 292.3 0.85 289.6 2.25 292.9 0.94 287.5 1.20 290.9 1.72 308.8 1.50 277.8 1.38 273.9 2.58 281.9 1.67 277.1 4.66 290.6 3.83

670

*Important. See note on population page.

612

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

All sites (C00-96) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 18958 83650 128563 16315 109126 56025 12644 42507 68150 6183 61375 12123 2686175 260784 2324530 117613 13191 100666 18988 640 5110 12840 236554 28983 200510 139168 13229 120447 41564 43120 181129 14757 162003 15177 312187 30233 258954 839579 40402 80696 59469 643810 49964 12350 36947 200621 21177 174615 17690 7759 71096 48290 26569 67434 952 14409 58043 2611 4487 53948 5958 4854 9868 24525 995 22464 4079 5655 2593 49005 44374 2853 9474 10694 14450 32173 22523 95427 19083 Male ASR(W) CUM 0-74 393.9 393.5 394.9 494.6 379.8 438.8 519.9 422.4 357.6 443.3 351.5 358.7 366.7 430.1 360.5 411.8 478.2 408.7 318.0 184.5 277.3 355.9 378.8 437.8 378.5 360.5 413.1 343.8 348.7 360.4 392.0 484.9 379.4 409.2 370.4 465.4 372.1 366.2 229.2 454.4 276.8 379.4 387.4 452.8 367.7 343.9 419.3 337.2 316.8 368.0 374.0 375.9 376.4 365.8 160.1 262.2 265.3 204.6 193.8 225.6 181.2 210.1 106.6 116.5 115.9 102.2 100.6 88.2 96.6 291.4 291.8 183.4 243.3 255.4 346.8 301.5 300.1 256.1 281.4 3.02 1.44 1.15 4.00 1.21 1.95 4.80 2.17 1.43 5.76 1.49 3.44 0.23 0.86 0.25 1.27 4.22 1.38 2.40 7.50 3.97 3.37 0.82 2.61 0.90 1.01 3.68 1.04 1.79 1.84 0.99 4.10 1.02 3.57 0.70 2.76 0.77 0.42 1.18 1.63 1.18 0.50 1.78 4.18 1.98 0.79 2.96 0.83 2.48 4.36 1.47 1.79 2.43 1.49 5.35 2.25 1.14 4.16 3.00 1.04 2.40 3.18 1.09 0.79 3.72 0.71 1.63 1.22 1.91 1.37 1.46 3.63 2.55 2.66 2.96 1.77 2.17 0.86 2.23 48.34 48.79 48.61 61.81 46.69 54.13 65.50 51.73 44.04 55.05 43.24 43.81 44.96 53.69 44.12 50.63 60.32 50.09 38.92 21.59 33.59 43.56 46.15 54.43 46.03 44.23 51.96 42.03 42.41 44.39 48.32 61.14 46.69 50.07 45.33 58.27 45.49 44.75 27.31 56.76 33.59 46.29 47.74 56.90 45.09 42.10 52.22 41.21 38.89 44.90 45.77 45.79 45.85 45.01 18.58 29.35 30.29 25.20 22.63 25.90 21.39 24.72 12.60 13.79 14.53 11.96 11.65 10.17 11.70 34.72 34.74 22.34 28.62 29.91 41.83 35.21 35.58 29.73 33.28 0.44 0.21 0.17 0.60 0.18 0.29 0.72 0.32 0.21 0.85 0.21 0.50 0.03 0.13 0.04 0.18 0.63 0.20 0.35 1.11 0.59 0.47 0.12 0.39 0.13 0.15 0.54 0.15 0.26 0.27 0.14 0.60 0.14 0.52 0.10 0.42 0.11 0.06 0.18 0.25 0.18 0.07 0.26 0.63 0.28 0.12 0.45 0.12 0.37 0.63 0.22 0.27 0.35 0.22 0.79 0.30 0.15 0.58 0.40 0.14 0.32 0.45 0.15 0.11 0.55 0.10 0.22 0.17 0.27 0.20 0.21 0.57 0.36 0.36 0.43 0.24 0.29 0.12 0.30 Cases 17375 83775 115047 13343 99568 49400 10216 38551 65573 5798 59111 10517 2519943 227098 2201064 109504 11131 94985 16661 708 4437 11200 235446 27323 201213 135728 11881 120100 38428 41351 170312 13041 153676 14412 290580 25281 243156 782044 42010 67270 60468 602779 42401 9751 32096 183968 18766 160260 15155 7435 67409 45844 24719 62680 957 10312 46991 1520 3548 45867 3810 4583 10633 23406 749 22062 4196 6520 2604 52806 49053 2439 7024 8033 10507 22714 17037 66574 13873 Female ASR(W) CUM 0-74 306.6 311.6 295.0 292.7 294.8 307.5 295.2 315.3 280.8 281.9 281.6 283.3 285.0 262.3 288.7 307.0 278.2 316.0 247.3 155.8 208.7 286.2 296.5 266.3 307.4 286.1 265.6 282.7 271.7 301.4 300.7 293.1 298.3 309.2 286.7 274.0 296.7 283.2 196.4 270.9 221.5 303.3 267.9 244.8 274.7 260.8 265.2 260.5 241.1 299.9 308.7 308.1 296.3 289.0 143.7 165.8 196.1 111.7 141.1 175.4 108.2 188.7 115.7 124.3 80.0 104.5 102.3 101.2 85.2 273.7 282.2 134.5 166.2 166.2 214.1 189.4 189.9 152.1 179.0 2.59 1.21 0.95 2.66 1.03 1.52 3.09 1.80 1.21 3.90 1.29 3.05 0.20 0.57 0.22 1.03 2.72 1.16 2.04 6.01 3.25 3.04 0.67 1.67 0.77 0.86 2.56 0.91 1.52 1.63 0.83 2.72 0.88 2.95 0.58 1.81 0.67 0.35 0.99 1.09 0.93 0.44 1.39 2.62 1.67 0.65 2.03 0.70 2.08 3.80 1.29 1.56 2.10 1.29 4.86 1.68 0.97 3.02 2.43 0.90 1.82 2.96 1.14 0.86 2.97 0.72 1.62 1.29 1.69 1.26 1.37 2.85 2.12 2.21 2.26 1.42 1.75 0.66 1.87 35.37 35.88 34.02 33.90 33.96 35.42 34.29 36.22 32.48 32.56 32.56 32.85 32.77 30.26 33.22 35.09 32.06 36.11 28.16 17.29 23.28 32.60 33.96 30.61 35.24 33.20 31.08 32.79 31.50 35.02 34.50 33.93 34.21 35.41 32.89 31.73 34.09 32.50 21.90 31.29 24.86 34.91 30.73 27.93 31.51 29.92 30.66 29.89 27.22 34.24 35.75 35.64 34.21 33.32 16.15 18.05 21.04 13.37 16.39 19.62 12.02 20.93 13.18 14.22 9.12 11.83 11.16 11.58 9.57 30.84 31.87 15.03 18.37 18.25 23.69 20.57 20.51 16.51 19.54 0.34 0.16 0.13 0.37 0.14 0.20 0.42 0.23 0.16 0.53 0.17 0.41 0.03 0.08 0.03 0.13 0.38 0.15 0.27 0.83 0.43 0.38 0.09 0.23 0.10 0.11 0.35 0.12 0.20 0.22 0.11 0.36 0.11 0.38 0.08 0.25 0.09 0.05 0.13 0.15 0.13 0.06 0.18 0.35 0.21 0.09 0.28 0.09 0.28 0.50 0.18 0.21 0.27 0.17 0.67 0.21 * 0.12 0.40 * 0.33 0.11 * 0.23 * 0.37 * 0.15 0.12 * 0.39 0.10 0.20 * 0.17 * 0.22 * 0.16 0.17 0.39 0.27 0.26 0.28 0.17 0.20 0.08 0.21

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
613

671

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

All sites (C00-96) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
614

Male ASR(W) CUM 0-74 284.5 273.7 293.2 277.3 301.3 267.6 256.8 298.3 288.2 121.4 103.3 184.6 129.3 105.1 166.6 213.3 230.3 257.0 108.4 166.6 148.1 165.9 109.2 182.0 213.6 335.6 382.5 361.2 287.4 287.4 365.2 238.5 320.5 394.4 347.3 322.1 280.8 385.3 342.5 334.8 352.5 323.4 328.7 375.3 312.2 352.4 297.7 309.7 330.5 308.4 341.0 353.3 327.3 359.7 385.1 298.6 407.5 422.4 472.0 433.8 399.4 416.5 383.9 392.8 401.8 345.6 431.0 391.1 329.3 380.2 419.4 295.3 349.4 315.8 461.1 388.4 351.4 433.9 445.4 0.59 2.00 2.51 3.45 3.62 2.49 6.09 1.32 5.21 3.59 4.70 3.21 1.93 2.50 2.65 1.94 1.72 2.06 4.06 4.37 1.99 2.80 2.02 2.54 1.67 1.10 4.17 5.73 1.01 2.09 1.41 0.91 1.45 1.07 1.33 2.74 1.23 3.38 4.00 4.42 3.78 3.14 2.98 3.17 4.17 4.37 4.59 3.84 1.87 1.33 2.29 2.37 1.93 1.92 3.00 5.89 1.87 7.22 4.55 5.25 2.87 4.18 7.08 3.03 3.93 4.79 2.25 4.77 5.44 4.52 3.15 3.09 4.44 5.16 8.19 3.17 3.16 4.79 2.65 34.60 33.09 35.29 33.84 36.96 32.45 31.22 34.68 35.03 13.44 9.85 21.86 15.24 12.58 20.03 25.14 25.91 29.35 11.16 18.54 17.10 19.73 12.79 21.99 26.50 39.85 46.19 44.01 35.25 34.12 43.53 28.54 37.70 46.86 40.08 39.42 32.04 47.10 41.50 40.30 42.39 38.75 38.97 45.81 36.73 42.37 35.38 37.87 39.12 36.29 39.81 41.87 38.22 41.69 45.38 35.22 47.50 50.58 56.56 51.44 46.66 48.68 45.76 45.54 48.62 41.65 51.25 46.31 38.74 45.46 49.29 34.96 41.76 37.92 56.38 45.98 41.58 50.77 53.04 0.09 0.29 0.37 0.52 0.54 0.37 0.90 0.19 0.79 0.51 0.54 0.47 0.28 0.37 0.39 0.29 0.24 0.30 0.47 0.60 0.26 0.39 0.29 0.36 0.24 0.15 0.59 0.82 0.14 0.29 0.19 0.12 0.19 0.15 0.19 0.38 0.17 0.48 0.56 0.62 0.53 0.43 0.42 0.44 0.55 0.60 0.61 0.52 0.25 0.18 0.32 0.32 0.27 0.26 0.40 0.85 0.27 0.97 0.63 0.70 0.38 0.54 0.94 0.40 0.54 0.67 0.31 0.64 0.74 0.61 0.42 0.42 0.62 0.71 1.16 0.42 0.42 0.66 0.37

Cases 185902 17437 12268 5967 6357 10959 1548 51125 3143 1662 1382 3988 4924 1697 4169 18872 18939 16474 795 1670 6699 3656 3104 3883 10715 93710 7450 3413 80489 16623 60301 69055 45175 135496 81492 15337 56933 10427 6207 4596 7329 9563 10454 11068 4781 5241 3881 5218 29805 57464 24225 20759 29529 34948 16391 2750 45548 3429 9797 7300 20320 10553 2831 19278 10409 4142 35731 7427 3220 7452 17706 8214 5392 3198 2780 15262 12700 7356 26927

Female ASR(W) CUM 0-74 164.7 158.2 175.9 168.4 175.6 167.6 144.9 190.7 165.4 128.6 135.4 171.8 124.3 90.7 192.0 207.9 197.3 206.0 141.7 157.9 159.1 154.3 97.7 125.8 124.5 235.1 253.4 238.8 188.0 216.3 278.7 190.4 220.4 285.9 331.9 226.8 226.6 246.3 222.0 218.9 243.0 236.7 234.0 232.9 204.4 222.3 208.1 213.0 227.2 220.2 262.3 233.9 250.3 264.9 274.9 284.5 324.8 287.4 325.8 329.9 303.1 292.1 263.6 289.8 308.4 232.6 301.2 314.2 235.2 305.8 314.1 218.4 251.9 227.5 308.5 281.7 263.8 288.6 305.8 0.39 1.22 1.61 2.24 2.25 1.65 3.84 0.87 3.11 3.38 5.28 2.77 1.82 2.35 3.23 1.60 1.47 1.66 5.28 4.02 2.00 2.61 1.78 2.05 1.22 0.88 3.27 4.48 0.72 1.87 1.27 0.79 1.15 0.85 1.29 2.03 1.07 2.64 3.14 3.55 3.12 2.72 2.50 2.44 3.45 3.42 3.97 3.34 1.50 1.10 1.96 1.83 1.65 1.63 2.48 5.83 1.64 6.02 3.79 4.81 2.58 3.67 6.03 2.53 3.57 3.76 1.90 4.58 4.68 4.24 2.84 2.69 3.79 4.46 6.72 2.76 2.87 3.90 2.19 18.20 17.75 19.56 18.71 19.62 18.60 15.11 21.29 18.70 14.12 14.69 19.12 13.72 10.43 21.51 23.69 21.06 22.10 15.38 16.70 17.94 17.33 10.62 14.18 14.12 26.02 27.58 26.37 21.24 24.56 30.78 21.48 24.31 32.37 38.26 25.88 24.81 27.80 24.93 24.16 27.34 26.27 25.84 26.09 22.50 25.14 22.62 23.97 25.27 24.54 29.82 25.85 27.87 29.20 30.71 31.81 36.68 32.07 35.92 36.54 32.78 32.05 28.84 32.30 34.18 25.93 33.28 34.54 26.00 33.84 34.66 23.66 28.11 25.42 34.32 31.18 29.00 31.87 33.98 0.05 0.16 0.22 0.30 0.30 0.22 0.46 0.12 0.43 0.47 0.74 0.37 0.24 0.34 * 0.42 * 0.23 * 0.19 0.22 0.68 0.50 0.25 * 0.33 * 0.23 0.27 * 0.16 * 0.11 0.41 0.56 0.08 * 0.23 * 0.15 0.09 * 0.13 0.11 0.17 0.24 0.13 0.33 0.38 0.43 0.38 0.32 0.31 0.30 0.40 0.42 0.46 0.39 0.18 0.13 0.24 0.22 0.21 0.20 0.30 0.75 0.22 0.70 0.45 0.54 0.29 0.41 0.70 0.30 0.42 0.47 0.23 0.52 0.56 0.50 0.33 0.31 0.46 0.54 0.82 0.31 0.33 0.46 0.26

243346 22186 15093 7143 7639 12877 1894 59887 3832 1309 1674 3511 4799 1928 4570 14343 18524 16174 792 1558 5764 3617 2979 5325 16862 100923 8845 4102 83984 20910 74128 76508 52071 142735 75917 14278 56395 13603 8068 6181 9136 12391 13093 15210 6560 7230 5332 7567 33357 58801 24147 23444 30859 37498 18015 2837 50202 4067 11675 8645 24241 12704 3727 20126 12505 5323 41765 8486 4271 8629 22131 10166 6796 4242 3400 17841 15898 8957 31928

672

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

All sites (C00-96) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 21561 35364 4247 56101 7077 13212 14604 27124 32573 36569 45672 56329 23176 3206 16262 24800 13875 2611 9769 10643 14450 10197 8399 11808 112960 7495 2934 2928 7382 4110 4380 11173 180671 11857 11233 42553 30029 51419 105676 27818 125296 153763 72892 63447 21535 82051 80987 1258 46659 21326 6318 56537 22211 2950 1168 46370 13882 928 1932 1654 4071 4386 Male ASR(W) CUM 0-74 282.6 327.9 314.6 306.2 286.8 310.4 239.0 259.2 286.0 263.8 258.0 358.2 339.6 249.9 320.7 351.6 299.4 221.7 400.4 334.7 350.3 413.2 389.9 310.8 274.2 487.3 318.5 430.6 372.3 315.3 417.1 462.4 306.8 323.2 314.1 339.6 299.0 303.6 378.1 267.3 396.6 279.2 344.7 282.0 365.0 399.1 343.8 323.5 377.9 359.6 349.7 326.8 359.7 338.7 284.3 359.5 308.8 238.8 270.8 341.9 285.9 371.1 1.96 1.77 4.99 1.40 3.49 2.78 2.07 1.67 1.69 1.41 1.27 1.54 2.27 4.87 2.77 2.36 2.60 5.24 4.42 3.48 3.06 4.44 4.69 3.13 0.90 5.83 6.29 8.51 4.56 5.25 6.55 4.64 0.75 3.04 3.08 1.77 1.83 1.41 1.23 1.68 1.22 0.76 1.37 1.19 2.59 1.46 1.26 9.75 1.81 2.61 4.61 1.44 2.48 6.41 8.67 1.73 2.81 8.87 6.65 8.57 5.55 5.95 34.63 39.58 36.78 35.47 34.12 37.89 29.38 31.17 33.29 32.25 30.74 42.87 40.24 28.57 37.22 41.14 35.26 25.37 47.07 40.40 40.51 49.26 45.01 36.82 32.59 57.88 36.57 51.32 44.01 37.18 49.80 55.22 36.58 38.45 37.54 38.64 34.06 35.23 43.62 30.65 44.93 31.78 39.04 32.72 42.36 46.35 40.51 38.62 43.74 42.13 40.84 37.49 41.47 38.66 33.19 42.52 36.97 27.05 32.61 41.34 34.07 44.47 0.27 0.25 0.71 0.20 0.48 0.39 0.28 0.23 0.22 0.19 0.16 0.22 0.31 0.64 0.36 0.31 0.36 0.65 0.60 0.47 0.41 0.61 0.63 0.41 0.13 0.83 0.88 1.19 0.66 0.72 0.92 0.66 0.11 0.43 0.43 0.25 0.25 0.20 0.17 0.24 0.17 0.11 0.19 0.17 0.37 0.20 0.18 1.45 0.26 0.36 0.65 0.20 0.35 0.92 1.23 0.25 0.41 1.20 0.97 1.28 0.73 0.86 Cases 22927 35963 3914 51515 8211 11163 16331 22281 26510 49126 43071 50203 21964 2043 10480 15630 10019 1592 6597 7896 10085 7151 5973 7976 103557 7323 2419 2679 6151 3767 3739 10547 170281 10593 9924 39434 29546 49763 100693 26649 118708 151471 69355 59509 21981 82865 67703 921 38316 17722 5438 50028 18092 2701 1165 40625 12411 798 1467 1901 3708 3558 Female ASR(W) CUM 0-74 195.9 230.3 249.9 253.4 241.0 209.0 200.1 182.9 202.8 201.6 226.7 239.0 243.4 157.1 181.2 196.8 190.5 151.6 252.4 227.5 218.9 272.3 264.6 188.3 242.1 378.8 226.1 324.8 264.8 233.7 311.7 365.8 254.5 259.8 251.0 289.2 251.1 254.7 308.0 232.9 330.3 235.2 291.6 239.9 307.7 323.5 267.1 245.6 295.9 276.3 280.8 262.6 270.1 271.2 260.6 286.1 262.3 181.8 210.2 335.2 255.6 308.2 1.45 1.32 4.24 1.28 2.86 2.16 1.71 1.34 1.41 1.02 1.18 1.13 1.79 4.05 2.16 1.79 2.02 4.95 3.61 2.88 2.41 3.77 4.04 2.50 0.87 4.89 5.28 7.24 3.80 4.43 5.58 4.01 0.67 2.69 2.76 1.67 1.66 1.30 1.11 1.57 1.13 0.69 1.27 1.11 2.30 1.27 1.12 8.79 1.62 2.30 4.17 1.28 2.14 5.46 7.85 1.53 2.55 7.30 5.65 7.86 5.25 5.66 22.47 25.85 28.14 28.60 27.05 23.27 23.08 20.02 21.71 22.65 25.25 26.99 27.27 16.57 19.80 21.03 20.88 16.03 27.59 25.24 23.93 29.31 28.59 20.43 27.78 42.57 24.69 36.53 29.96 25.90 35.37 41.40 28.86 29.51 28.41 32.49 28.11 28.76 34.52 26.00 36.58 26.31 32.70 26.89 34.53 36.41 30.05 28.01 33.09 30.65 31.23 29.23 29.78 30.66 30.38 32.25 29.59 20.31 23.10 38.68 28.79 34.99 0.17 0.16 0.54 0.16 0.35 * 0.26 0.21 0.16 * 0.16 0.12 0.13 0.14 0.22 0.46 0.24 0.21 0.25 0.52 0.43 0.34 0.29 0.44 0.48 0.28 0.11 0.62 0.65 0.89 0.49 0.53 0.71 0.50 0.09 0.34 0.34 0.21 0.21 0.16 0.14 0.20 0.14 0.09 0.16 0.14 0.30 0.16 0.14 1.32 0.21 0.29 0.53 0.17 0.28 0.75 1.10 0.20 0.32 0.94 0.70 1.06 0.60 0.74

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
615

673

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

All sites but non-melanoma skin (C00-96/C44)

Cases Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 1844 6908 1379 2173 4371 2201 6732 1605 3592 70229 2040 7766 13656 4194 3610 1256 269555 30271 47343 14039 9614 5755 196 13074 134700 1806 12757 50729 10033 39737 5133 55142 343106 25220 23624 42779 242117 67931 5258 3768 2042 775 6051 45921 87885 11034 2408 2068 1577 1223 16330 49395 41445 46713 2944 42896 7507 5298 1877 251927 20951 227632 81495 19018 61499 24822 7196 17034 14306 146334 18779 122812 69583 39125 54081 54954 14443 40062 4277 7945 Male ASR(W) CUM 0-74 86.3 156.1 146.1 153.6 202.6 256.2 330.6 259.2 260.3 346.6 226.8 224.0 179.8 148.9 297.5 137.8 2.12 2.01 4.00 4.33 3.91 5.75 4.37 6.77 4.47 1.37 5.11 2.65 1.59 2.40 5.14 4.02 29.88 38.20 31.27 30.45 40.88 25.98 26.12 19.94 16.83 37.42 16.40 40.05 40.50 37.07 40.88 43.35 39.21 33.42 45.22 40.47 43.91 38.26 42.41 46.88 40.92 43.52 37.28 41.43 26.48 52.89 32.29 44.52 41.14 51.44 26.54 28.36 27.71 33.61 44.60 41.06 56.14 23.59 32.56 31.90 28.07 32.31 45.19 40.80 47.99 54.03 47.44 54.34 60.84 39.70 45.29 50.49 44.86 45.59 54.70 43.75 46.66 54.89 45.08 41.39 45.84 54.75 44.41 43.47 43.97 49.60 49.12 55.72 47.47 56.43 47.54 0.79 0.65 1.05 0.67 0.20 0.75 0.40 0.23 0.36 0.77 0.62 0.10 0.29 0.22 0.44 0.56 0.63 3.09 0.50 0.14 1.29 0.44 0.23 0.57 0.25 0.78 0.20 0.09 0.21 0.42 0.21 0.11 0.20 0.88 0.55 0.79 1.34 0.57 0.27 0.18 0.65 0.64 0.92 1.06 1.02 0.33 0.26 0.25 0.28 1.21 0.29 0.77 1.00 1.18 0.11 0.42 0.12 0.20 0.50 0.22 0.38 0.86 0.44 0.44 0.15 0.48 0.16 0.20 0.28 0.26 0.26 0.58 0.29 1.06 0.66 Cases 1815 6637 986 2777 3780 2352 8004 1645 4105 77358 1903 9609 13452 5135 2438 1947 244027 26796 41349 13042 8283 4553 185 11557 125919 1585 10758 46278 9069 36425 4616 50316 326290 26738 19059 44576 231266 65732 4372 3533 2106 961 6212 44947 84578 9074 2324 2426 1546 1248 17514 48033 39979 44997 2569 41709 6868 4583 1983 217537 17397 197120 74996 16452 57483 24025 6572 16850 12570 142366 17722 120551 68591 37198 49626 47197 12376 34479 3817 7433 Female ASR(W) CUM 0-74 80.3 119.3 95.5 171.4 194.9 227.9 280.2 211.7 212.1 273.8 187.9 211.2 161.6 155.4 171.5 171.0 1.97 1.51 3.10 4.11 4.03 5.16 3.39 5.51 3.42 1.03 4.42 2.24 1.44 2.27 3.70 4.01 25.04 31.61 23.72 22.84 30.22 20.56 23.69 17.32 17.13 18.59 19.55 30.30 30.28 27.83 31.48 31.04 26.91 28.91 32.79 31.02 31.53 29.35 29.26 26.81 29.64 34.34 29.02 31.26 21.35 30.07 24.38 35.21 30.90 29.77 20.06 20.06 24.01 25.82 35.09 30.05 30.75 18.52 25.57 26.65 19.74 23.21 36.66 31.39 35.25 30.37 35.73 33.21 32.64 32.62 32.15 28.13 32.72 30.84 28.43 31.77 31.91 29.55 33.63 31.24 33.58 33.19 33.69 33.28 33.10 35.54 31.81 31.08 32.34 31.41 33.47 * * * *

0.62 0.48 0.78 0.46 0.14 0.59 0.31 0.20 0.31 0.46 0.56 * 0.08 0.23 0.18 0.35 0.43 0.48 2.87 0.39 0.11 1.01 0.36 0.17 0.35 0.19 0.66 0.16 0.07 0.16 0.27 0.15 0.09 0.15 0.57 0.42 0.52 0.94 0.42 0.22 0.13 0.40 0.49 0.61 0.83 0.69 0.23 0.21 0.20 0.21 0.74 0.23 0.51 0.60 0.99 0.09 0.27 0.09 0.14 0.28 0.16 0.27 0.49 0.33 0.35 0.11 0.31 0.12 0.16 0.22 0.20 0.18 0.35 0.22 0.64 0.49

331.8 0.67 334.1 1.98 310.9 1.50 336.9 3.01 354.6 3.79 312.3 4.26 259.5 19.52 378.9 3.47 334.2 0.95 362.8 8.92 320.4 3.08 343.2 1.57 375.5 3.87 331.9 1.73 352.8 5.12 307.2 1.38 340.2 0.61 221.6 1.44 421.9 2.79 266.6 1.35 366.2 0.80 337.4 1.35 410.8 5.81 223.7 3.85 231.4 5.30 225.4 9.07 279.5 3.75 364.8 1.82 337.0 1.18 447.0 4.32 205.4 4.44 264.5 6.04 267.6 7.86 230.9 6.72 265.7 2.18 372.9 1.83 333.8 1.69 390.7 1.92 431.2 8.09 387.0 2.01 440.8 5.28 496.1 7.08 319.4 7.82 369.8 0.81 404.0 2.83 367.2 0.86 368.7 1.32 439.0 3.28 354.3 1.47 377.4 2.48 444.6 5.54 364.2 2.88 340.0 2.97 372.6 1.02 441.3 3.27 361.7 1.09 353.2 1.39 360.1 1.95 406.4 1.80 402.5 1.77 453.2 3.87 390.0 2.03 457.1 7.15 387.5 4.63

266.3 0.59 266.3 1.73 246.3 1.33 273.5 2.68 268.2 3.23 230.2 3.62 232.4 18.26 286.2 2.94 273.3 0.83 275.2 7.63 255.0 2.79 253.5 1.28 231.8 2.59 256.9 1.48 295.8 4.55 252.8 1.22 272.5 0.52 192.1 1.22 259.4 1.96 217.0 1.07 304.6 0.72 271.2 1.15 260.4 4.17 183.9 3.30 180.1 4.04 206.1 7.45 227.5 3.00 304.5 1.63 263.5 0.97 264.0 2.90 175.3 3.86 230.0 4.81 235.8 6.84 180.5 5.35 207.6 1.63 318.2 1.67 273.7 1.46 305.6 1.62 262.6 5.33 309.8 1.73 293.7 3.90 288.4 4.71 285.1 7.21 281.7 0.69 246.4 1.93 287.1 0.76 266.7 1.03 246.7 2.03 274.9 1.23 275.3 1.88 255.4 3.35 290.6 2.39 271.0 2.62 291.5 0.85 288.9 2.25 292.2 0.94 286.8 1.20 289.9 1.72 308.2 1.50 277.1 1.38 273.3 2.58 281.1 1.66 276.6 4.66 290.0 3.82

674

*Important. See note on population page.

616

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

All sites but non-melanoma skin (C00-96/C44) (contd)

Cases America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 18925 83398 128214 16270 108837 55857 12614 42375 67971 6166 61217 12098 2678584 260184 2317952 117270 13154 100374 18921 640 5093 12791 235878 28918 199913 138865 13201 120193 41469 43007 180632 14733 161549 15120 311115 30149 258045 836565 40281 80476 59291 641428 49841 12332 36846 200115 21129 174180 17597 7744 70877 48122 26512 67288 929 14287 56776 2586 4472 53528 5884 4311 9751 24258 975 22147 4034 5555 2548 48406 43823 2818 9375 10601 14186 31858 22050 95011 18940 Male ASR(W) CUM 0-74 393.2 392.4 393.8 493.3 378.8 437.5 518.6 421.2 356.8 442.1 350.7 358.0 365.7 429.3 359.5 410.6 477.0 407.5 316.9 184.5 276.4 354.6 377.7 436.9 377.4 359.7 412.3 343.0 347.9 359.5 390.9 484.1 378.3 407.6 369.2 464.3 370.8 364.9 228.5 453.3 276.2 378.1 386.5 452.3 366.7 343.1 418.5 336.4 315.2 367.2 372.9 374.6 375.6 365.0 156.0 260.0 259.6 202.7 193.1 223.9 178.9 188.0 105.3 115.2 113.6 100.9 99.5 86.7 95.0 288.0 288.4 181.3 240.7 253.2 340.6 298.5 294.2 255.0 279.3 3.01 1.44 1.15 4.00 1.21 1.95 4.79 2.17 1.43 5.76 1.49 3.44 0.23 0.86 0.25 1.26 4.21 1.37 2.39 7.50 3.96 3.36 0.81 2.60 0.89 1.01 3.68 1.04 1.78 1.84 0.98 4.10 1.02 3.56 0.69 2.75 0.77 0.42 1.18 1.63 1.18 0.50 1.78 4.17 1.98 0.79 2.95 0.83 2.47 4.36 1.47 1.79 2.43 1.48 5.28 2.24 1.13 4.15 2.99 1.04 2.39 3.00 1.09 0.79 3.68 0.71 1.62 1.21 1.90 1.37 1.45 3.61 2.53 2.65 2.93 1.76 2.15 0.85 2.22 48.26 48.68 48.51 61.67 46.59 53.99 65.35 51.60 43.95 54.91 43.16 43.75 44.86 53.61 44.02 50.50 60.21 49.96 38.82 21.59 33.49 43.45 46.05 54.34 45.91 44.15 51.88 41.96 42.34 44.30 48.21 61.06 46.58 49.90 45.21 58.15 45.36 44.62 27.25 56.65 33.53 46.15 47.66 56.85 44.99 42.02 52.14 41.13 38.71 44.79 45.65 45.66 45.77 44.92 18.03 29.14 29.68 24.92 22.56 25.71 21.15 22.28 12.43 13.65 14.21 11.80 11.52 10.01 11.52 34.37 34.38 22.08 28.37 29.68 41.14 34.92 34.98 29.62 33.07 0.44 0.21 0.17 0.59 0.18 0.29 0.72 0.32 0.21 0.85 0.21 0.50 0.03 0.13 0.04 0.18 0.63 0.20 0.35 1.11 0.59 0.47 0.12 0.39 0.13 0.15 0.54 0.15 0.26 0.27 0.14 0.60 0.14 0.52 0.10 0.42 0.11 0.06 0.18 0.25 0.18 0.07 0.26 0.63 0.28 0.12 0.45 0.12 0.37 0.63 0.22 0.27 0.35 0.22 0.78 0.30 0.15 0.57 0.39 0.14 0.32 0.43 0.15 0.11 0.55 0.10 0.22 0.17 0.27 0.20 0.21 0.56 0.36 0.36 0.42 0.24 0.29 0.12 0.30 Cases 17339 83526 114702 13301 99284 49232 10184 38425 65431 5787 58983 10495 2513430 226451 2195599 109232 11107 94747 16600 704 4424 11156 234747 27238 200613 135447 11846 119866 38361 41249 169910 13001 153328 14357 289612 25188 242365 779507 41900 67066 60289 600853 42294 9725 32016 183617 18720 159969 15080 7409 67174 45658 24668 62538 944 10208 45492 1507 3540 45495 3748 4081 10537 23244 742 21890 4165 6453 2576 52172 48449 2414 6901 7972 10260 22387 16464 66166 13733 Female ASR(W) CUM 0-74 306.0 310.6 294.1 291.8 294.0 306.4 294.3 314.3 280.1 281.4 281.0 282.7 284.3 261.6 288.0 306.2 277.6 315.2 246.3 154.9 208.1 285.0 295.6 265.4 306.5 285.4 264.8 282.1 271.1 300.7 299.9 292.1 297.6 307.8 285.8 273.0 295.7 282.3 195.9 270.1 220.9 302.3 267.2 244.1 274.0 260.3 264.5 260.1 239.9 298.8 307.7 306.9 295.6 288.3 141.4 164.2 190.7 110.9 140.8 174.1 106.5 171.4 114.6 123.4 79.2 103.7 101.5 100.1 84.3 270.7 279.0 133.2 164.0 165.1 210.1 187.2 185.6 151.3 177.7 2.59 1.20 0.95 2.66 1.03 1.52 3.08 1.79 1.21 3.89 1.29 3.05 0.20 0.57 0.22 1.03 2.72 1.16 2.04 5.99 3.24 3.04 0.67 1.67 0.77 0.86 2.56 0.91 1.52 1.63 0.83 2.72 0.88 2.94 0.58 1.80 0.66 0.35 0.99 1.09 0.93 0.44 1.39 2.61 1.66 0.65 2.03 0.70 2.07 3.80 1.29 1.56 2.09 1.28 4.82 1.67 0.96 3.01 2.43 0.90 1.80 2.83 1.14 0.85 2.95 0.72 1.62 1.28 1.68 1.26 1.36 2.83 2.11 2.20 2.24 1.41 1.74 0.66 1.87 35.30 35.78 33.93 33.82 33.88 35.32 34.20 36.12 32.41 32.51 32.50 32.79 32.70 30.19 33.15 35.01 32.01 36.03 28.06 17.19 23.22 32.47 33.87 30.53 35.15 33.14 31.01 32.73 31.46 34.94 34.42 33.84 34.14 35.28 32.80 31.63 33.99 32.41 21.86 31.21 24.80 34.81 30.67 27.88 31.45 29.87 30.60 29.85 27.10 34.14 35.65 35.53 34.14 33.27 15.83 17.89 20.51 13.26 16.35 19.49 11.82 19.03 13.06 14.12 9.02 11.73 11.08 11.46 9.46 30.52 31.54 14.90 18.19 18.12 23.32 20.38 20.14 16.43 19.41 0.34 0.16 0.13 0.37 0.13 0.20 0.42 0.23 0.16 0.53 0.17 0.41 0.03 0.08 0.03 0.13 0.38 0.15 0.27 0.82 0.43 0.38 0.09 0.23 0.10 0.11 0.35 0.12 0.20 0.22 0.11 0.36 0.11 0.38 0.08 0.25 0.09 0.05 0.13 0.15 0.13 0.06 0.18 0.35 0.21 0.09 0.28 0.09 0.28 0.50 0.18 0.21 0.27 0.17 0.66 0.21 * 0.12 0.40 * 0.33 0.11 * 0.23 * 0.35 * 0.15 0.12 * 0.39 0.10 0.20 * 0.17 * 0.22 * 0.16 0.17 0.39 0.27 0.26 0.28 0.17 0.20 0.08 0.21

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
617

675

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

All sites but non-melanoma skin (C00-96/C44) (contd)

Cases Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
618

Male ASR(W) CUM 0-74 281.9 271.3 289.4 275.0 298.2 264.9 254.7 295.8 286.1 119.9 100.5 179.1 124.7 100.9 162.3 209.8 221.5 246.7 106.5 162.2 144.4 162.2 104.3 162.2 200.9 311.4 365.4 347.8 264.1 276.9 332.2 217.5 320.5 332.0 283.0 293.1 272.2 385.3 342.5 334.8 352.5 323.4 328.7 375.3 312.2 352.4 297.7 309.7 323.0 299.8 291.2 345.8 320.6 315.9 332.9 289.2 295.6 358.9 399.5 351.1 337.8 356.0 314.8 345.4 339.8 323.6 368.3 348.0 259.5 313.5 354.4 261.1 286.6 251.0 399.8 343.7 306.5 375.2 373.6 0.59 1.99 2.49 3.44 3.60 2.48 6.06 1.31 5.19 3.56 4.66 3.16 1.90 2.45 2.62 1.93 1.69 2.02 4.03 4.31 1.96 2.77 1.97 2.39 1.62 1.06 4.08 5.63 0.97 2.05 1.35 0.87 1.45 0.99 1.21 2.62 1.21 3.38 4.00 4.42 3.78 3.14 2.98 3.17 4.17 4.37 4.59 3.84 1.85 1.31 2.13 2.34 1.91 1.81 2.81 5.81 1.60 6.70 4.20 4.79 2.66 3.89 6.44 2.86 3.64 4.64 2.09 4.53 4.86 4.13 2.91 2.91 4.04 4.64 7.66 3.00 2.98 4.47 2.44 34.30 32.82 34.85 33.54 36.62 32.19 30.96 34.44 34.75 13.28 9.46 21.30 14.68 12.02 19.53 24.79 24.99 28.26 11.01 18.00 16.71 19.32 12.21 19.59 25.06 37.23 44.29 42.70 32.63 33.10 39.90 26.07 37.70 39.70 32.94 36.17 31.25 47.10 41.50 40.30 42.39 38.75 38.97 45.81 36.73 42.37 35.38 37.87 38.38 35.49 34.23 41.16 37.58 36.82 39.49 34.37 34.51 43.13 48.23 41.98 39.60 41.86 38.05 40.05 41.48 39.28 44.13 41.56 30.58 37.71 41.91 30.92 34.28 30.08 49.12 40.85 36.47 44.12 44.86 0.09 0.29 0.36 0.52 0.54 0.37 0.90 0.19 0.79 0.51 0.53 0.47 0.27 0.36 0.38 0.29 0.24 0.29 0.47 0.59 0.26 0.39 0.28 0.33 0.23 0.15 0.58 0.81 0.13 0.29 0.19 0.11 0.19 0.14 0.17 0.36 0.17 0.48 0.56 0.62 0.53 0.43 0.42 0.44 0.55 0.60 0.61 0.52 0.25 0.18 0.29 0.32 0.27 0.24 0.37 0.84 0.23 0.89 0.58 0.63 0.35 0.51 0.86 0.37 0.50 0.65 0.29 0.61 0.66 0.56 0.39 0.39 0.56 0.63 1.08 0.40 0.39 0.61 0.34

Cases 183620 17248 12038 5899 6245 10804 1531 50666 3096 1648 1368 3896 4787 1627 4085 18638 18185 15768 781 1636 6554 3572 2990 3433 9884 85705 7025 3248 69885 16085 53701 62577 45175 111613 66532 13263 54789 10427 6207 4596 7329 9563 10454 11068 4781 5241 3881 5218 29100 56099 20651 20322 29067 30746 14081 2646 33352 2831 8259 6051 17330 9029 2264 17061 8869 3890 29752 6730 2755 6310 15147 7319 4523 2790 2281 13360 11151 6365 22403

Female ASR(W) CUM 0-74 162.7 156.4 172.5 166.5 172.6 165.1 143.4 188.9 162.8 127.2 133.8 167.7 120.5 86.5 187.9 205.0 189.7 197.7 139.0 154.2 155.7 150.8 94.2 110.4 114.7 218.8 241.7 231.0 167.3 211.7 252.7 175.9 220.4 239.7 274.3 199.7 221.3 246.3 222.0 218.9 243.0 236.7 234.0 232.9 204.4 222.3 208.1 213.0 223.6 217.1 227.3 230.6 247.3 235.8 240.7 275.4 243.9 242.3 280.6 284.7 262.4 253.1 219.4 258.2 269.0 219.9 255.9 288.0 204.5 264.8 273.0 198.9 214.1 201.2 262.6 249.6 239.1 253.6 259.4 0.39 1.21 1.60 2.23 2.24 1.64 3.82 0.86 3.09 3.36 5.25 2.73 1.79 2.29 3.19 1.59 1.45 1.62 5.22 3.97 1.98 2.58 1.75 1.92 1.17 0.86 3.20 4.42 0.69 1.85 1.22 0.77 1.15 0.78 1.18 1.92 1.06 2.64 3.14 3.55 3.12 2.72 2.50 2.44 3.45 3.42 3.97 3.34 1.49 1.09 1.84 1.82 1.64 1.55 2.34 5.74 1.44 5.56 3.55 4.55 2.42 3.45 5.58 2.41 3.37 3.66 1.77 4.40 4.39 3.97 2.67 2.59 3.52 4.23 6.27 2.62 2.76 3.69 2.03 17.99 17.56 19.23 18.50 19.26 18.33 14.93 21.09 18.39 13.99 14.51 18.69 13.28 9.91 21.02 23.36 20.33 21.29 15.20 16.23 17.57 16.95 10.26 12.35 12.96 24.28 26.37 25.64 18.81 24.11 28.00 19.78 24.31 27.18 31.90 22.65 24.36 27.80 24.93 24.16 27.34 26.27 25.84 26.09 22.50 25.14 22.62 23.97 24.97 24.26 25.84 25.57 27.58 25.93 26.97 30.74 27.46 27.11 31.08 31.51 28.35 27.70 24.12 28.68 29.78 24.55 28.29 31.71 22.47 29.37 30.07 21.51 24.00 22.37 29.28 27.56 26.40 27.96 28.85 0.05 0.16 0.21 0.30 0.30 0.22 0.46 0.12 0.43 0.47 0.73 0.36 0.24 0.33 * 0.42 * 0.23 * 0.19 0.21 0.67 0.49 0.25 * 0.33 * 0.22 0.25 * 0.15 * 0.11 0.40 0.55 0.08 * 0.23 * 0.14 0.09 * 0.13 0.10 0.15 0.23 0.13 0.33 0.38 0.43 0.38 0.32 0.31 0.30 0.40 0.42 0.46 0.39 0.18 0.13 0.23 0.22 0.21 0.19 0.28 0.73 0.19 0.64 0.42 0.50 0.27 0.38 0.64 0.28 0.39 0.46 0.21 0.49 0.52 0.46 0.31 0.30 0.43 0.50 0.75 0.30 0.31 0.43 0.24

241155 21999 14900 7084 7563 12740 1878 59431 3804 1294 1625 3409 4638 1859 4454 14119 17810 15516 776 1518 5618 3538 2846 4762 15907 93110 8425 3941 77140 20055 67116 69185 52071 119560 61586 12979 54512 13603 8068 6181 9136 12391 13093 15210 6560 7230 5332 7567 32591 56994 20426 22953 30171 32802 15479 2736 36298 3436 9837 6920 20359 10796 3041 17602 10509 4979 35578 7500 3347 7079 18632 8952 5541 3327 2931 15768 13663 7717 26664

676

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Age-standardized (world) incidence (per 100,000) and cumulative (0-74) incidence (percent) rates and standard errors

All sites but non-melanoma skin (C00-96/C44) (contd)

Cases Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 20144 32138 3238 53499 6542 12434 13764 27082 31316 34854 41152 48834 20324 3185 16262 24741 13842 2608 8082 8049 12291 7944 6609 9811 106443 5372 2670 2190 5771 4110 3410 7993 170303 11212 10702 32929 30029 51419 84893 27816 91379 147351 58248 63438 15649 65898 80965 1258 46460 21017 6277 56503 20948 2879 1168 46203 13815 924 1924 1647 4061 4354 Male ASR(W) CUM 0-74 264.5 298.5 242.4 293.8 265.6 292.7 226.0 258.8 276.1 251.7 233.8 311.9 298.6 248.0 320.7 350.6 298.7 221.1 335.9 255.0 299.3 325.2 310.2 262.2 261.4 354.0 294.4 328.4 294.0 315.3 326.2 336.1 290.6 306.1 300.1 263.7 299.0 303.6 304.8 267.3 291.4 269.1 276.4 281.9 267.8 322.1 343.7 323.5 376.5 354.0 347.6 326.6 339.9 331.3 284.3 358.2 307.4 237.8 269.5 340.7 285.3 368.6 1.90 1.69 4.41 1.37 3.36 2.71 2.01 1.67 1.66 1.38 1.22 1.44 2.13 4.85 2.77 2.35 2.60 5.22 4.08 3.06 2.84 3.96 4.18 2.91 0.88 5.01 6.09 7.52 4.08 5.25 5.81 3.99 0.73 2.96 3.02 1.57 1.83 1.41 1.11 1.68 1.06 0.75 1.23 1.19 2.23 1.32 1.26 9.75 1.81 2.59 4.60 1.44 2.42 6.35 8.67 1.73 2.81 8.86 6.63 8.56 5.54 5.93 32.53 36.20 28.66 34.22 31.75 35.82 27.93 31.13 32.25 30.83 27.85 37.47 35.48 28.40 37.22 41.06 35.19 25.34 39.83 30.84 34.72 39.31 36.15 31.38 31.40 42.71 34.16 39.34 35.14 37.18 38.92 40.64 34.92 36.83 36.11 30.15 34.06 35.23 35.40 30.65 33.06 30.80 31.39 32.71 31.35 37.70 40.50 38.62 43.61 41.55 40.59 37.47 39.38 37.92 33.19 42.39 36.83 26.97 32.45 41.23 34.01 44.20 0.26 0.24 0.63 0.20 0.46 0.38 0.27 0.23 0.22 0.19 0.15 0.20 0.29 0.63 0.36 0.31 0.36 0.65 0.55 0.41 0.38 0.54 0.56 0.38 0.13 0.72 0.85 1.04 0.59 0.72 0.81 0.56 0.10 0.42 0.42 0.22 0.25 0.20 0.15 0.24 0.14 0.11 0.17 0.17 0.32 0.18 0.18 1.45 0.26 0.36 0.65 0.20 0.34 0.91 1.23 0.25 0.41 1.20 0.97 1.28 0.73 0.86 Cases 20734 30469 3261 49387 7558 10326 15413 22207 25333 45729 39120 42120 18820 2029 10480 15568 9974 1585 5221 5888 8380 5221 4444 6535 98687 5031 2159 1912 4680 3767 2761 7218 163202 10199 9567 31523 29546 49763 81004 26648 90040 147148 57044 59504 16684 67318 67690 921 38176 17515 5393 50009 17420 2663 1164 40477 12368 794 1464 1897 3699 3543 Female ASR(W) CUM 0-74 180.4 199.0 210.5 246.4 224.2 196.3 190.6 182.4 196.7 189.5 209.1 203.8 213.6 155.5 181.2 195.9 189.7 150.9 207.2 175.4 187.4 204.8 202.2 158.1 235.2 265.9 211.5 244.5 208.6 233.7 237.9 260.6 246.7 252.1 243.9 237.2 251.1 254.7 254.4 232.9 257.5 230.8 245.1 239.9 242.9 269.4 267.1 245.6 294.9 273.5 278.9 262.5 261.2 267.4 260.4 285.2 261.3 180.9 209.7 334.5 255.2 306.8 1.40 1.24 3.91 1.27 2.78 2.10 1.68 1.34 1.40 0.99 1.15 1.05 1.70 4.03 2.16 1.79 2.02 4.93 3.31 2.56 2.26 3.31 3.55 2.32 0.86 4.15 5.16 6.39 3.41 4.43 4.93 3.43 0.66 2.66 2.73 1.53 1.66 1.30 1.02 1.57 1.01 0.68 1.17 1.11 2.07 1.17 1.12 8.79 1.61 2.29 4.16 1.28 2.11 5.42 7.85 1.52 2.55 7.28 5.65 7.85 5.25 5.65 20.61 22.18 23.63 27.91 25.13 21.90 21.98 19.97 21.18 21.22 23.22 22.92 23.97 16.40 19.80 20.94 20.79 15.98 22.71 19.40 20.46 21.97 21.49 17.18 27.10 29.68 23.45 27.73 23.58 25.90 27.06 29.70 28.07 28.76 27.66 26.69 28.11 28.76 28.58 26.00 28.50 25.89 27.54 26.89 27.37 30.50 30.04 28.01 32.99 30.36 31.04 29.22 28.87 30.19 30.38 32.17 29.50 20.20 23.04 38.62 28.75 34.85 0.16 0.15 0.49 0.16 0.34 * 0.25 0.20 0.16 * 0.16 0.12 0.13 0.13 0.20 0.46 0.24 0.21 0.25 0.52 0.39 0.30 0.27 0.38 0.41 0.26 0.11 0.52 0.64 0.78 0.43 0.53 0.62 0.43 0.08 0.34 0.34 0.19 0.21 0.16 0.13 0.20 0.12 0.09 0.15 0.14 0.26 0.15 0.14 1.32 0.21 0.29 0.53 0.17 0.27 0.74 1.10 0.20 0.32 0.93 0.70 1.06 0.60 0.74

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
619

677

Age-standardized incidence rates by histological type

621

Age-standardized (world) incidence rates (per 100,000) by histological type

Oesophagus (C15) - Male

Squamous Adeno 0.4 0.7 0.4 1.2 1.9 0.9 0.8 1.0 1.3 0.8 0.3 0.6 0.7 0.6 2.3 2.1 2.5 2.1 2.3 1.5 4.6 2.8 2.4 2.7 2.4 2.4 0.6 2.8 4.2 2.8 2.6 2.4 0.5 0.4 0.4 1.6 0.5 3.3 1.9 0.9 0.3 0.5 1.5 0.5 2.7 0.5 0.8 1.6 3.3 3.5 3.6 1.1 3.8 1.9 1.5 2.3 2.9 0.5 3.2 2.4 2.3 0.4 3.0 0.8 2.8 3.5 3.7 1.0 4.2 4.0 3.9 3.4 2.7 0.9 3.3 1.0 3.2 4.4 4.6 Carcinoma Other 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.3 0.1 0.1 0.1 0.1 0.2 0.0 0.2 0.0 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.4 0.2 0.1 0.1 0.2

Unspec. 0.1 0.1 0.5 9.5 2.3 0.4 0.7 0.4 0.7 1.0 0.1 0.1 0.1 0.4 0.4 0.2 0.2 0.2 0.3 0.3 0.2 0.2 0.2 0.2 0.2 0.3 0.7 0.3 0.2 0.3 0.3 0.4 0.4 0.1 0.3 0.4 0.3 0.4 0.2 0.2 0.2 0.3 0.2 0.2 0.4 0.2 0.1 0.3 0.2 0.3 0.1 0.2 0.2 0.2 0.2 0.4 0.4 0.4 0.4 0.2 0.2 0.4 0.2 0.4 0.2 0.4 0.3 0.7 0.3 0.3 0.2 0.3 0.4 0.4 0.1 0.4 0.4 0.4 0.3

Sarcoma

Other

Unspec.

Number of cases MV Total

Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.0 0.9 0.5 5.9 4.5 3.2 7.7 7.0 6.1 7.8 5.7 1.4 1.1 1.1 5.8 1.9 1.5 1.4 1.5 1.5 1.7 1.5 1.9 1.6 1.5 2.6 1.3 2.6 7.8 1.5 1.8 1.1 1.5 1.6 4.9 2.8 1.0 1.3 2.7 1.2 1.6 3.9 1.9 0.7 1.4 3.7 2.6 1.2 1.8 4.4 1.3 1.2 0.9 2.0 6.4 1.8 7.7 11.2 1.7 1.8 6.6 1.4 2.9 2.6 7.2 1.1 9.3 1.3 1.1 2.3 7.8 1.5 1.5 1.2 1.7 2.8 3.7 1.6 6.3 1.6 1.4 1.8

0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0

0.0 0.2 7.0 0.7 3.0 3.1 0.6 2.5 1.1 0.8 0.7 0.3 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.3 0.3 0.6 0.1 0.2 0.3 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.3 0.0 0.0 0.7 1.1 0.4 0.8 0.4 0.2 0.1 0.2 0.1 0.5 0.2 0.1 0.1 0.4 0.1 0.1 0.2 0.2 0.2 0.4 0.2 0.3 0.1 0.2 0.2

3 64 5 70 92 48 227 56 103 1878 72 89 113 48 81 24 3307 332 640 160 110 62 5 162 1663 27 146 766 227 535 90 752 4397 872 68 55 13 67 12 634 1011 129 27 13 186 22 17 589 275 311 477 3301 582 705 53 646 166 136 26 3452 391 3038 1226 349 128 213 440 773 199 2463 397 2023 1129 577 716 794 52 102 251 536 303 1437

4 70 5 125 219

* * * *

58 262 72 115 2406 81 112 159 55 82 26 * 3568 349 673 171 112 62 5 174 1836 30 156 816 243 569 91 799 4569 912 73 55 14 72 13 661 1036 133 28 13 189 23 17 605 282 325 492 3436 625 714 53 655 179 149 26 3734 433 3276 1292 359 132 219 470 809 210 2562 421 2098 1179 600 763 823 57 105 259 557 312 1495

680

*I N

622

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Oesophagus (C15) - Male (Contd)

Squamous Adeno 3.8 3.1 0.7 3.8 0.7 4.2 3.6 1.5 3.8 3.5 3.0 1.1 3.3 2.9 1.5 3.9 2.7 0.7 3.1 3.2 0.9 3.5 3.9 1.0 4.0 3.1 3.9 4.0 1.2 4.2 4.5 3.0 0.6 3.5 2.8 0.5 0.9 1.6 3.5 2.8 0.7 3.4 2.6 0.8 2.8 3.1 4.4 3.8 3.6 3.9 4.3 1.4 0.2 0.4 0.9 0.1 0.4 0.5 0.4 1.1 0.4 0.1 0.5 0.6 1.0 1.0 0.3 0.4 0.1 0.2 0.4 0.2 0.3 0.6 0.3 0.2 0.4 0.2 0.3 0.3 Carcinoma Other 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.3 0.3 0.2 0.1 0.1 0.1 0.2 0.0 0.0 0.2 Unspec. 0.4 0.5 1.0 0.4 0.8 0.4 0.2 0.6 0.2 0.3 0.3 0.5 0.3 0.4 0.3 0.2 0.5 0.3 0.4 0.3 0.3 0.5 0.3 0.4 0.8 0.4 0.2 0.3 0.2 0.4 0.2 0.4 0.3 0.7 0.3 0.3 0.1 0.5 0.2 0.3 0.3 0.8 0.2 0.3 0.3 0.2 0.1 0.4 0.3 0.4 0.3 0.3 0.3 3.0 0.3 4.8 0.0 4.3 0.3 0.7 0.1 0.1 1.6 0.1 0.1 0.2 0.0 0.1 0.5 0.1 1.1 0.1 0.1 0.1 0.0 0.1 0.0 0.3 0.1

Sarcoma

Other

Unspec.

Number of cases MV Total

America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

1.9 2.7 7.3 1.5 6.7 1.4 1.5 6.8 1.0 1.1 2.2 7.5 1.6 1.1 2.6 1.5 0.8 2.3 6.9 1.7 1.8 6.9 1.3 1.6 5.8 1.1 1.3 1.3 1.8 7.7 1.4 1.6 1.9 6.4 1.3 1.8 2.2 6.1 1.6 1.3 3.7 12.2 1.4 1.7 5.4 1.3 0.4 0.9 1.4 1.6 1.3 1.8 2.1 5.7 8.1 14.6 1.1 11.6 0.6 6.0 5.0 3.7 7.8 2.1 2.1 0.8 0.8 0.6 4.6 5.0 11.1 12.5 9.1 7.3 10.4 6.5 6.1 6.6 4.7 8.3 4.7

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 -

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1

0.2 0.1 0.3 0.1 0.5 0.2 0.3 0.5 0.3 0.0 0.2 0.3 0.2 0.2 0.6 0.1 0.1 0.2 0.4 0.2 0.2 0.4 0.2 0.2 0.5 0.2 0.5 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.0 0.2 0.1 0.1 0.2 0.4 0.1 0.3 0.6 0.3 0.3 0.1 0.1 0.1 0.4 0.4 0.4 0.4 10.3 8.0 0.0 2.4 1.5 2.4 0.8 1.4 6.1 0.6 0.1 0.1 0.1 1.3 0.8 2.0 2.8 1.8 1.3 1.6 0.8 1.1 1.6 1.1

2002 792 206 580 265 1722 1019 119 897 162 1574 249 1295 257 8 57 188 3281 518 2668 39349 4922 33481 2266 227 1970 550 670 2809 278 2481 228 4367 482 3599 11316 483 1328 697 8724 855 355 495 2582 317 2236 198 114 1069 722 398 1173 19 365 1937 196 181 1453 508 24 605 56 901 312 804 290 76 319 304 14 207 220 480 1411 698 3118 777 5843 511 361 124 216 236

2086 814 217 591 280 1791 1088 130 955 173 1646 259 1355 278 11 61 201 3517 556 2861 41538 5264 35284 2412 252 2089 611 703 2875 287 2534 239 4513 503 3715 11756 496 1380 721 9070 898 377 516 2800 352 2410 202 124 1114 748 415 1278 23 514 2030 254 230 2291 532 25 808 69 1369 333 1070 380 91 358 332 15 252 246 503 1656 773 4084 892 6856 620 397 142 253 280 * * * * *

* * * *

Cancer Incidence in Five Continents Vol. IX, IARC 2008

623

681

Age-standardized (world) incidence rates (per 100,000) by histological type

Oesophagus (C15) - Male (Contd)

Squamous Adeno 0.1 0.2 0.4 0.5 0.0 0.7 0.4 0.7 1.0 0.6 0.6 0.5 0.6 0.9 0.1 0.1 0.1 0.3 0.4 1.1 0.7 1.5 0.5 2.7 2.8 0.3 0.3 1.2 2.9 0.2 1.5 1.4 1.7 1.5 1.6 1.4 2.9 1.3 2.8 1.2 2.6 1.3 1.6 1.3 1.6 3.0 4.0 1.0 0.9 1.4 0.5 0.9 0.3 0.7 0.5 0.9 1.3 0.9 0.1 0.7 0.4 0.6 1.1 1.4 0.6 0.6 0.2 0.7 0.9 0.5 0.6 1.2 1.4 0.6 0.3 1.1 0.7 0.6 Carcinoma Other 0.3 0.1 0.1 0.1 0.0 0.1 0.2 0.0 0.0 0.1 0.1 0.2 0.1 0.0 0.2 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.2 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.1 Unspec. 0.1 0.1 0.2 0.3 0.2 0.1 0.3 0.3 0.2 0.2 0.1 0.4 0.1 0.1 0.5 0.2 0.7 0.1 0.2 0.5 0.0 0.5 0.3 0.3 0.2 0.4 0.4 0.2 0.6 0.2 0.3 0.2 0.2 0.7 0.3 0.3 1.9 0.1 1.7 0.2 0.4 0.2 0.2 0.0 0.3 0.4 0.1 0.2 0.6 0.3 0.1 0.1 0.1 0.1 0.1 0.3 0.3 0.2 0.2 0.3 0.2 0.4 0.1 0.1 0.2 0.3 0.4 0.2 1.0

Sarcoma

Other

Unspec.

Number of cases MV Total

Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

5.0 5.5 5.8 0.6 0.5 1.2 1.3 1.6 5.3 1.4 3.9 4.6 2.5 0.2 1.8 0.9 6.6 1.0 1.5 2.3 2.9 2.5 3.9 2.1 3.1 0.5 3.1 2.7 2.5 4.0 8.8 11.8 7.1 7.9 4.0 4.9 9.3 11.3 10.3 3.6 7.1 3.3 3.7 3.7 4.5 2.0 2.4 3.4 4.9 2.1 1.2 1.4 0.8 2.2 1.4 0.9 5.5 2.9 0.5 1.3 1.1 0.7 2.5 3.7 0.6 1.6 1.2 3.7 4.6 3.5 4.2 0.8 1.6 2.7 2.4 5.7 3.7 4.0

0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 -

1.7 1.2 1.6 0.8 0.6 0.2 0.4 0.1 0.0 0.7 0.2 0.2 0.1 0.3 0.4 1.1 0.3 0.2 0.5 0.1 0.3 1.5 0.1 0.2 1.4 1.8 0.8 0.3 0.5 0.1 0.8 0.0 0.0 0.0 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.5 0.0 0.2 0.6 0.1 1.0 0.5 0.4 0.4 0.2 0.4 0.1 0.4 0.6 0.1 0.2 0.4 0.2 0.5 0.6 1.0 0.1 0.4 0.4 0.1 0.7 1.6 1.6 0.7 0.1 1.1 0.6 0.2 0.9 2.0

40 1133 68 13 10 42 62 38 166 135 377 340 24 13 76 25 181 40 166 1149 92 50 1476 355 1212 244 639 1494 1223 203 365 307 160 252 210 255 501 267 261 93 234 316 500 561 293 49 856 40 147 62 103 76 11 158 58 30 711 83 9 47 83 45 66 42 16 114 76 97 407 340 575 31 578 65 177 717 479 807

51 1334 83 20 14 45 72 41 174 195 390 352 25 13 84 34 204 47 182 1297 97 58 1742 362 1274 702 943 1780 1329 224 370 327 161 253 211 261 503 268 271 97 237 456 553 680 302 49 941 42 170 71 134 92 12 181 62 36 748 87 13 53 94 63 79 49 19 133 95 100 452 435 707 39 600 115 210 740 578 1077

Eu

* * *

* * * *

* * *

* *

682

*I N

624

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Oesophagus (C15) - Male (Contd)

Squamous Adeno 0.5 0.8 0.6 0.5 1.0 1.1 1.5 1.2 1.6 1.2 1.0 0.6 0.8 0.8 1.6 2.6 2.8 1.9 2.1 2.7 1.8 2.7 4.2 3.6 2.5 5.0 5.8 5.6 5.0 5.5 5.2 4.8 6.0 5.1 4.2 6.6 2.3 2.8 3.2 3.8 2.6 2.9 3.2 1.0 2.8 1.1 0.3 1.0 0.5 2.7 Carcinoma Other 0.0 0.0 0.1 0.3 0.0 0.2 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.3 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.8 0.2 0.1 0.1 0.3 0.1 0.0 0.2 Unspec. 0.2 0.3 0.3 0.5 0.3 0.2 0.5 0.0 0.0 0.1 0.2 0.1 0.3 0.2 0.2 0.2 0.4 0.1 0.2 0.5 0.3 0.3 0.5 0.8 1.9 1.5 0.7 0.8 0.6 1.3 1.4 0.9 0.9 0.5 0.4 0.3 0.2 0.2 0.2 0.3 0.4 0.6 0.3 0.1 0.2 0.2 0.1 0.1

Sarcoma

Other

Unspec.

Number of cases MV Total

Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White

1.7 5.6 3.9 1.9 5.3 6.8 5.4 1.8 4.7 1.9 2.6 4.0 4.2 3.2 1.5 5.1 3.3 4.9 2.9 3.1 5.1 5.6 2.5 2.4 2.4 1.8 2.4 2.7 2.4 1.8 1.7 2.0 2.1 2.2 1.8 3.9 1.8 2.2 0.9 3.0 1.6 1.6 1.1 7.5 1.6 3.2 5.4 1.2 5.5 5.1 1.0

0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 -

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 -

0.6 1.5 0.5 0.5 0.4 0.4 0.5 0.4 0.3 0.3 0.2 0.0 0.4 0.4 0.0 0.3 0.1 0.1 0.2 0.3 0.2 0.2 0.1 0.1 0.1 0.0 0.0 0.2 0.0 1.2 0.3 0.1 0.1 0.8 0.4 0.1 0.0 0.1 0.3 0.4 0.1 0.2 0.2 0.4 0.1 0.3 0.1 0.1

419 1023 355 36 286 543 332 30 137 93 140 98 101 141 1336 120 56 43 93 85 74 215 4235 233 199 902 877 1519 2148 807 2322 3861 1803 1767 408 2240 1051 639 297 127 782 312 35 38 634 187 18 12 32 67 44

549 1253 371 43 311 576 355 36 143 103 148 101 109 156 1345 125 57 44 96 87 76 221 4306 237 204 995 1046 1708 2367 861 2824 4622 2032 1918 455 2391 1123 682 308 135 856 326 45 39 694 190 18 12 33 68 45

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

625

683

Age-standardized (world) incidence rates (per 100,000) by histological type

Oesophagus (C15) - Female

Squamous Adeno 0.0 0.1 0.1 0.3 0.0 0.6 0.5 0.5 0.2 0.2 0.2 0.1 0.0 0.2 0.2 0.2 0.3 0.2 0.3 0.3 0.5 0.1 0.3 0.3 0.5 0.2 0.3 0.2 0.3 0.7 0.4 0.4 0.3 0.2 0.2 0.2 0.5 0.3 0.3 0.3 0.0 0.2 0.3 0.4 0.1 0.2 0.3 0.4 0.4 0.6 0.2 0.6 0.1 0.1 0.1 0.4 0.3 0.4 0.2 0.2 0.1 0.2 0.2 0.2 0.5 0.5 0.2 0.5 0.5 0.4 0.4 0.3 0.0 0.3 0.1 0.4 0.4 0.6 Carcinoma Other 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 Unspec. 0.0 0.0 0.2 3.2 1.2 0.2 0.3 0.2 0.9 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.3 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.0

Sarcoma

Other

Unspec.

Number of cases MV Total

Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.0 0.6 0.1 3.4 1.8 1.2 2.4 1.6 1.7 1.4 3.6 1.1 0.3 0.2 0.7 0.2 0.8 0.7 1.0 0.7 0.5 0.2 0.7 0.8 0.1 0.8 0.8 1.5 0.6 0.8 0.5 0.7 0.8 1.7 0.5 0.2 0.4 1.3 0.9 0.7 1.6 0.9 0.3 0.2 0.8 0.1 0.7 0.6 1.6 0.4 0.8 0.7 1.0 3.3 0.8 2.3 3.0 0.6 0.8 1.9 0.6 1.0 1.1 2.3 0.6 2.7 0.5 0.7 0.9 2.3 0.6 0.7 0.6 0.5 1.0 1.4 0.8 1.7 0.7 0.7 0.8

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.1 4.5 0.1 0.1 0.8 0.6 0.4 0.5 0.1 0.3 0.2 0.3 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1

3 36 2 37 30 29 86 15 34 466 49 62 33 15 16 5 1256 115 275 60 39 12 0 50 643 6 56 215 65 149 24 223 1582 325 33 10 9 19 10 227 391 68 14 7 50 6 1 241 107 136 132 1196 183 279 34 243 61 54 7 1182 163 1009 399 124 59 61 186 208 59 765 163 586 335 162 192 241 18 32 81 159 85 470

4 41 2 78 67

* * * *

36 95 19 43 621 51 78 55 24 17 5* 1424 123 293 68 43 12 0 58 759 6 62 238 72 164 24 243 1677 345 34 10 10 19 10 245 418 72 15 8 54 6 1 258 112 141 140 1273 198 288 36 250 65 58 7 1288 171 1105 419 129 62 62 198 215 62 800 168 616 350 180 205 254 19 38 82 171 93 501

684

*I N

626

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Oesophagus (C15) - Female (Contd)

Squamous Adeno 0.5 0.3 0.2 0.4 0.2 0.5 0.4 0.3 0.5 0.5 0.5 0.3 0.5 0.2 0.1 0.0 0.3 0.4 0.2 0.5 0.4 0.2 0.5 0.6 0.2 0.6 0.4 0.6 0.5 0.3 0.5 0.6 0.4 0.2 0.4 0.4 0.1 0.2 0.3 0.4 0.3 0.1 0.4 0.3 0.2 0.3 0.3 0.9 0.5 0.5 0.5 0.5 0.0 0.1 0.3 0.0 0.1 0.1 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.1 Carcinoma Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 Unspec. 0.1 0.2 0.3 0.1 0.3 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.4 0.6 0.1 0.6 0.0 0.4 0.1 0.1 0.1 1.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 -

Sarcoma

Other

Unspec.

Number of cases MV Total

America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.7 0.9 2.1 0.6 1.9 0.5 0.6 2.2 0.4 0.4 0.9 2.1 0.7 0.3 0.2 0.4 0.9 2.5 0.7 0.7 2.0 0.6 0.6 1.8 0.5 0.4 0.6 0.7 2.6 0.5 0.7 0.8 2.1 0.6 0.8 0.6 1.9 0.4 0.7 1.0 2.0 0.6 0.6 1.6 0.5 0.3 0.4 0.7 0.7 0.5 0.7 1.4 1.1 1.3 4.0 0.3 1.3 0.2 4.0 1.6 2.8 5.0 1.6 0.6 0.5 0.6 0.2 0.5 0.8 1.8 1.8 1.0 1.1 1.2 0.3 0.3 0.5 0.3 0.4 0.4

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1 1.7 2.6 1.1 0.2 1.5 0.6 0.8 5.0 0.1 0.1 0.1 0.1 0.2 0.2 0.3 0.5 0.3 0.2 0.3 0.2 0.1 0.2 0.2

551 248 87 161 106 442 279 49 228 41 591 96 482 46 1 9 34 1267 291 947 12480 1989 10162 709 99 580 127 205 827 131 686 79 1376 221 1075 3774 161 526 192 2873 228 87 139 747 122 610 43 41 306 207 111 322 10 85 428 59 31 538 57 7 378 17 620 199 461 211 26 195 189 6 24 50 98 260 105 585 114 437 48 39 12 23 27

600 264 90 174 110 487 312 54 255 46 613 100 499 51 1 9 39 1382 309 1043 13450 2101 10997 771 110 631 150 224 870 134 723 82 1470 229 1158 3998 169 544 202 3061 244 97 145 854 133 704 45 46 338 230 117 352 10 120 455 70 43 965 60 7 479 19 905 214 598 295 28 228 221 7 37 61 106 327 123 823 150 662 75 49 16 29 41 * * * * *

* * * *

Cancer Incidence in Five Continents Vol. IX, IARC 2008

627

685

Age-standardized (world) incidence rates (per 100,000) by histological type

Oesophagus (C15) - Female (Contd)

Squamous Adeno 0.1 0.0 0.2 0.3 0.5 0.3 0.1 0.2 0.1 0.2 0.2 0.0 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.4 0.4 0.1 0.1 0.1 0.5 0.0 0.1 0.3 0.1 0.1 0.1 0.1 0.3 0.1 0.2 0.3 0.2 0.2 0.2 0.2 0.3 0.6 0.8 0.2 0.1 0.2 0.0 0.1 0.0 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.0 0.1 0.3 0.1 0.1 0.0 0.0 0.2 0.1 0.1 0.2 0.3 0.1 0.1 0.2 0.1 0.1 Carcinoma Other 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Unspec. 0.0 0.1 0.0 0.0 0.2 0.5 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.3 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.3 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2

Sarcoma

Other

Unspec.

Number of cases MV Total

Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.2 0.4 0.3 1.3 0.1 1.2 1.1 1.6 7.5 0.3 0.8 0.8 2.3 0.3 0.4 0.3 1.2 0.3 0.9 0.4 0.6 0.5 0.2 0.7 0.8 0.1 0.4 0.3 1.1 0.4 0.7 1.3 0.7 1.2 1.0 0.9 1.3 1.5 1.1 0.4 0.7 1.0 0.9 1.0 1.0 0.3 2.1 0.9 0.9 0.4 0.3 0.4 0.1 0.5 0.3 0.1 1.0 1.0 0.1 0.3 0.3 0.1 0.2 0.7 0.3 0.5 0.3 0.5 0.9 0.2 0.3 0.2 0.6 0.4 0.4 0.9 0.3 0.6

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0

0.2 0.2 0.2 0.2 0.3 0.3 0.3 0.3 0.3 0.2 0.1 0.1 0.3 0.3 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.3 0.3 0.1 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.4 0.0 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.1 0.0 0.2 0.0 0.1 0.0 0.0 0.1 0.1 0.2 0.2 0.2 0.1 0.0 0.3 0.1 0.0 0.2 0.5

4 111 8 14 1 36 49 35 141 36 103 87 11 5 20 7 42 17 89 276 22 11 155 108 343 55 126 241 468 41 36 71 18 52 56 48 93 43 39 18 32 113 124 172 81 16 507 17 29 17 38 25 3 67 22 10 178 30 3 16 30 7 11 11 5 49 20 20 117 41 73 9 241 13 46 197 74 272

7 154 12 16 3 39 55 41 166 61 110 94 11 5 31 16 49 18 95 340 27 11 209 108 373 205 213 319 518 48 38 78 18 53 58 51 93 43 42 20 33 172 147 206 85 16 597 19 40 20 54 37 5 81 27 13 198 37 4 19 35 16 12 14 6 54 29 27 144 76 103 11 252 30 63 203 106 446

Eu

* * *

* * * *

* * *

* *

686

*I N

628

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Oesophagus (C15) - Female (Contd)

Squamous Adeno 0.1 0.1 0.2 0.0 0.2 0.1 0.2 0.2 0.2 0.1 0.1 0.0 0.1 0.1 0.3 0.3 0.2 0.1 0.2 0.5 0.1 0.3 0.8 0.8 0.5 1.0 1.3 1.0 1.1 1.0 1.0 1.0 1.0 1.0 1.2 1.6 0.4 0.3 0.5 0.3 0.4 0.5 1.2 0.3 0.4 0.2 0.2 0.2 0.3 Carcinoma Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.0 0.5 0.0 0.1 0.0 0.1 Unspec. 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.2 0.1 0.1 0.1 0.4 0.8 0.7 0.3 0.4 0.3 0.6 0.6 0.5 0.3 0.3 0.2 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.0 0.1

Sarcoma

Other

Unspec.

Number of cases MV Total

Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White

0.4 0.3 0.5 0.1 0.3 0.6 0.5 0.1 0.5 0.2 0.2 0.4 0.3 0.2 0.8 1.9 0.8 1.5 0.4 0.9 1.1 1.5 1.3 1.0 0.8 1.8 2.3 2.0 2.0 1.8 1.7 1.6 2.0 2.4 1.6 2.6 1.4 1.4 1.0 1.6 1.2 1.3 0.9 0.8 1.1 0.6 0.7 1.8 0.5 0.6

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.0 0.2 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.5 0.2 0.0 0.1 0.3 0.1 0.0 0.0 0.1 0.2 0.2 0.0 0.1 0.2 0.0 0.1

135 95 85 5 32 66 43 3 21 14 22 14 7 15 591 53 12 15 17 21 18 68 1761 84 60 524 568 829 1338 421 1373 2238 1005 1190 266 1392 604 266 152 53 419 148 20 4 321 40 0 7 9 8 15

165 128 93 5 40 75 55 4 25 20 24 20 12 20 596 55 13 15 17 27 20 69 1796 85 61 602 692 992 1525 483 1791 2878 1176 1347 304 1524 664 293 161 59 484 158 25 4 370 43 0 7 9 9 17

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

629

687

Age-standardized (world) incidence rates (per 100,000) by histological type

Anus (C21) - Male

Squamous Adeno 0.3 0.1 0.4 0.0 0.2 0.5 0.2 0.2 0.1 0.2 0.5 0.1 0.2 0.3 0.5 0.1 0.3 0.8 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.3 0.3 0.2 0.2 0.3 0.2 0.1 0.2 0.2 0.2 0.1 0.3 0.2 0.2 0.1 0.1 0.1 0.1 0.5 0.6 0.4 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.1 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.5 0.3 0.2 0.2 0.2 0.2 Carcinoma Other 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0

Unspec. 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0

Sarcoma

Other

Unspec.

Number of cases MV Total

Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.0 0.1 0.3 0.1 0.2 0.5 0.1 0.3 0.3 0.1 0.1 0.2 0.4 0.4 0.3 0.5 0.4 0.6 0.2 0.4 0.4 0.1 0.2 0.4 0.6 0.4 0.3 0.5 0.8 1.0 1.8 0.3 0.6 1.2 0.7 1.1 0.1 0.3 1.1 0.1 1.0 0.4 1.0 0.5 0.5 1.2 0.5 2.0 2.1 2.0 0.8 0.9 0.8 0.7 1.1 1.1 1.1 0.6 0.7 0.4 0.6 0.9 0.5 0.6 0.4 0.5 0.7 0.5 1.6 0.4 0.7 0.8 0.7

0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.2 0.3 0.1 0.2 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

2 22 3 0 4 2 17 4 2 124 4 17 23 7 5 4 736 46 102 24 28 5 0 27 487 2 15 90 22 65 6 127 1001 245 29 5 5 24 1 170 260 39 3 2 41 1 1 169 29 80 116 753 94 78 11 65 43 29 13 609 73 526 208 98 30 68 48 159 24 301 54 240 153 51 92 118 10 38 21 95 49 191

2 23 3 2 4

* * * *

2 19 4 2 169 4 19 24 7 5 4* 778 47 103 25 28 5 0 27 526 2 15 91 22 66 6 127 1008 247 29 5 5 24 1 172 261 39 3 2 42 1 1 169 29 80 117 759 95 79 11 66 43 29 13 617 73 534 210 98 30 68 49 160 24 303 55 241 153 51 94 118 10 38 21 95 50 193

688

*I N

630

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Anus (C21) - Male (Contd)

Squamous Adeno 0.2 0.3 0.2 0.3 0.2 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.4 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.3 0.1 0.1 0.3 0.2 0.1 0.2 0.2 0.1 7.6 0.4 0.0 0.2 0.0 0.2 0.1 0.3 0.1 0.0 0.3 0.3 0.1 0.4 0.2 0.2 0.2 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.2 Carcinoma Other 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 -

Unspec. 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 -

Sarcoma

Other

Unspec.

Number of cases MV Total

America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.4 0.5 0.6 0.5 0.5 0.4 0.6 0.7 0.6 0.4 0.6 1.0 0.5 0.7 0.3 0.4 0.9 0.7 1.0 0.7 0.6 0.7 0.6 0.5 0.5 0.5 0.5 0.7 0.5 0.8 0.5 0.7 0.7 1.1 0.7 0.7 0.1 0.8 0.4 0.7 0.6 0.4 0.7 0.6 0.6 0.6 0.3 0.4 0.6 0.6 0.5 0.4 1.0 0.0 0.1 0.0 0.2 0.2 0.2 0.2 0.3 0.1 0.2 0.2 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.1 0.3 0.2 0.2

0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.3 0.2 0.1 0.0 0.1 0.1 0.5 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1

215 101 26 74 31 181 127 15 111 21 197 42 154 52 3 12 37 569 92 470 5932 701 5055 252 29 217 77 113 296 31 258 29 735 103 595 1942 45 226 152 1487 107 17 90 458 57 392 27 14 160 109 58 104 6 9 1739 5 7 49 8 5 44 0 71 23 136 27 4 85 80 5 21 8 16 26 10 91 14 264 29 10 9 7 18

217 101 26 74 32 182 130 15 114 22 198 43 154 53 3 12 38 579 92 479 5995 706 5112 256 30 220 78 117 300 31 262 29 738 103 598 1954 45 227 153 1497 108 17 91 466 58 398 27 14 162 109 58 104 6 13 1851 5 7 57 8 5 51 0 81 27 160 31 4 88 83 5 24 10 17 27 10 112 15 309 33 11 9 7 20 * * * * *

* * * *

Cancer Incidence in Five Continents Vol. IX, IARC 2008

631

689

Age-standardized (world) incidence rates (per 100,000) by histological type

Anus (C21) - Male (Contd)

Squamous Adeno 0.2 0.2 0.3 0.1 0.1 0.4 0.2 0.2 0.3 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.3 0.2 0.1 0.4 0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.0 0.2 0.0 0.1 0.1 0.0 0.1 0.1 0.2 0.0 0.1 0.2 0.4 0.3 0.6 0.2 0.3 0.0 0.2 0.2 0.4 0.2 0.2 0.2 0.4 0.2 0.1 0.1 0.4 0.4 0.1 0.3 0.2 0.2 0.1 0.1 0.3 0.6 0.2 0.0 Carcinoma Other 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0

Unspec. 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0

Sarcoma

Other

Unspec.

Number of cases MV Total

Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.2 0.1 0.1 0.1 0.0 0.4 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.3 0.5 0.1 0.2 0.2 0.1 0.0 0.1 0.5 0.1 0.4 0.6 0.4 0.3 0.4 0.3 0.5 0.1 0.0 0.4 0.5 0.7 0.2 0.4 0.5 0.1 0.3 0.2 0.1 0.3 0.4 0.2 0.4 0.2 0.2 0.4 0.3 0.4 0.2 0.1 0.1 0.1 0.4 0.5 0.2 0.3 0.3 0.1 0.1 0.4 0.3 0.1 0.2 0.1 0.2 0.1

0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 -

0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.2 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0

0 84 2 1 4 11 6 9 18 18 33 26 4 3 10 4 2 5 23 151 12 0 124 24 79 178 22 125 131 16 22 17 7 11 20 21 26 4 4 7 15 61 43 44 28 3 64 6 12 18 32 19 1 20 15 5 62 14 3 15 26 23 6 2 7 39 26 8 44 25 32 8 77 6 16 89 57 26

0 95 2 1 4 11 6 11 19 20 33 26 4 3 10 6 3 6 24 153 12 1 142 24 83 213 35 142 137 16 22 17 7 11 20 21 26 4 4 7 16 65 43 52 28 3 68 6 14 19 33 22 1 20 15 6 83 15 3 15 27 25 7 2 8 41 27 9 47 29 35 9 77 10 21 92 58 30

Eu

* * *

* * * *

* * *

* *

690

*I N

632

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Anus (C21) - Male (Contd)

Squamous Adeno 0.2 0.4 0.2 0.8 0.2 0.1 0.3 0.2 0.3 0.1 0.2 0.3 0.0 0.0 0.8 0.2 0.0 0.2 0.2 0.1 0.1 0.0 0.1 0.3 0.1 0.2 0.2 0.1 0.1 0.2 0.1 0.2 0.1 0.3 0.3 0.2 0.4 0.3 0.3 0.7 0.2 0.2 0.1 0.2 0.2 0.2 Carcinoma Other 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.3 0.0 -

Unspec. 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 -

Sarcoma

Other

Unspec.

Number of cases MV Total

Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White

0.1 0.1 0.1 0.2 0.2 0.2 0.1 0.4 0.6 0.2 0.2 0.2 0.1 0.4 0.4 0.7 0.6 0.5 0.2 0.2 0.5 0.4 0.3 0.3 0.1 0.4 0.4 0.5 0.5 0.4 0.5 0.5 0.3 0.3 0.4 0.4 0.7 0.5 0.1 0.7 0.3 0.4 0.1 0.3 0.2 0.1 0.7 0.4

0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 -

0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 -

51 82 22 2 47 33 13 7 16 19 14 14 8 19 179 11 6 7 10 3 8 19 216 11 6 59 67 96 196 64 163 320 109 94 34 116 225 92 20 21 96 41 6 3 69 16 1 2 3 2 8

58 93 22 3 49 34 15 7 16 19 14 14 9 20 180 11 6 8 11 3 8 19 221 11 6 63 77 98 205 68 212 357 120 97 34 118 232 99 20 21 100 41 6 3 73 16 1 2 3 2 8

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

633

691

Age-standardized (world) incidence rates (per 100,000) by histological type

Anus (C21) - Female

Squamous Adeno 0.1 0.4 0.0 0.0 0.1 0.4 0.2 0.1 0.1 0.1 0.2 0.1 0.3 0.3 0.1 0.1 0.1 0.3 0.2 2.0 0.1 0.4 0.2 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.3 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.4 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.3 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Carcinoma Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.0

Unspec. 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0

Sarcoma

Other

Unspec.

Number of cases MV Total

Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.0 0.0 0.5 0.8 0.8 0.5 0.7 1.0 0.4 0.4 0.5 1.1 0.7 0.6 0.9 0.6 1.1 0.3 1.1 0.7 0.6 0.4 0.8 0.5 0.9 1.2 0.9 1.0 0.8 0.6 0.1 0.3 0.6 1.2 0.8 0.7 0.1 0.2 0.6 0.7 1.2 0.2 0.7 0.6 1.3 1.0 0.7 0.9 0.7 1.2 1.3 1.2 1.1 0.7 1.2 1.0 1.0 0.8 1.2 0.7 1.1 1.0 0.9 0.9 0.9 1.0 0.9 1.1 0.9 0.7 1.4 0.6 1.1 1.1 0.9

0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0

0.2 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

1 22 2 3 2 10 36 5 13 256 1 57 41 20 15 13 973 77 168 38 44 12 1 52 550 5 26 170 28 141 21 189 1359 240 14 5 5 22 0 186 332 30 5 3 71 0 8 209 58 67 150 1073 153 126 12 113 30 19 11 991 68 913 314 110 30 79 59 253 51 466 67 392 275 122 193 178 15 35 36 142 62 248

1 22 2 3 2

* * * *

10 37 5 13 319 1 59 44 21 15 13 * 1011 77 169 39 44 12 1 52 586 5 26 175 28 146 21 191 1369 243 14 5 5 22 0 189 332 30 5 3 71 0 8 209 59 67 150 1082 153 127 12 114 31 19 12 999 70 919 318 110 30 79 61 255 51 469 67 395 276 124 194 181 15 35 36 145 62 251

692

*I N

634

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Anus (C21) - Female (Contd)

Squamous Adeno 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 4.7 0.1 0.0 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 Carcinoma Other 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

Unspec. 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 -

Sarcoma

Other

Unspec.

Number of cases MV Total

America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.7 0.8 1.0 0.7 0.9 0.7 0.8 0.5 0.8 0.9 0.8 0.7 0.8 0.8 0.3 1.3 0.9 0.9 0.9 0.9 0.7 1.0 0.9 0.9 0.8 1.0 1.2 0.8 0.7 0.8 1.0 0.9 0.8 0.9 0.9 0.2 0.7 0.6 1.1 0.8 0.3 1.0 0.9 0.7 0.9 0.9 0.5 1.0 1.1 1.4 0.6 0.0 0.2 0.1 0.1 0.3 0.1 0.2 0.1 0.1 0.3 0.3 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.2 0.1 0.2 0.1 0.1

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.2 0.1 0.1 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0

342 156 41 115 48 290 224 13 209 35 342 27 302 65 0 9 56 779 113 654 9174 772 8176 449 43 395 139 201 504 37 455 50 1021 97 893 2939 82 226 213 2391 146 16 128 693 63 621 68 17 260 185 121 152 0 8 1208 1 4 49 8 5 35 2 55 14 56 12 2 97 93 4 16 11 12 22 18 87 11 267 25 25 5 5 12

345 157 42 115 50 291 226 13 211 36 348 27 308 67 0 9 58 789 115 662 9272 784 8260 450 43 396 142 201 510 37 461 50 1031 98 902 2968 83 227 213 2418 147 16 129 708 65 634 69 18 264 187 122 155 0 8 1304 1 6 65 8 5 41 2 67 14 71 14 2 100 96 4 17 11 12 25 18 107 13 323 31 27 7 6 13 * * * * *

* * * *

Cancer Incidence in Five Continents Vol. IX, IARC 2008

635

693

Age-standardized (world) incidence rates (per 100,000) by histological type

Anus (C21) - Female (Contd)

Squamous Adeno 0.2 0.1 0.0 0.3 0.3 0.0 0.1 0.2 0.1 0.2 0.2 0.4 0.2 0.1 0.0 0.1 0.1 0.2 0.2 0.2 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.2 0.4 0.1 0.1 0.1 0.2 0.1 0.0 0.2 0.2 0.2 0.1 0.3 0.2 0.1 0.3 0.3 0.0 0.3 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.4 0.1 0.0 Carcinoma Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 -

Unspec. 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

Sarcoma

Other

Unspec.

Number of cases MV Total

Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.3 0.0 0.2 0.1 0.0 0.0 0.2 0.0 0.2 0.2 0.4 0.1 0.2 0.1 0.1 0.7 0.8 1.1 0.1 0.4 0.3 0.1 0.1 0.4 1.1 0.5 0.9 1.1 1.1 0.7 1.6 1.1 0.6 0.9 0.8 0.7 0.8 1.1 0.6 0.5 0.9 1.2 0.3 0.7 0.7 0.6 0.7 1.0 0.6 0.3 0.2 0.5 0.8 0.2 0.5 0.6 0.2 0.2 0.3 0.9 0.3 0.5 0.4 0.2 0.1 0.1 0.8 0.1 0.5 0.3 0.6 0.2

0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.1 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.0 0.0 0.0 0.0 0.2 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0

3 91 3 5 2 8 4 1 8 12 43 37 2 4 17 3 4 1 26 354 33 19 147 37 90 121 40 216 294 42 46 39 27 28 81 57 39 26 26 17 28 118 86 76 69 11 74 14 25 19 68 48 2 58 20 10 117 27 9 23 43 17 6 4 8 70 28 19 55 51 45 7 170 9 52 101 109 72

3 96 4 7 3 9 4 1 8 14 45 39 2 4 18 3 4 1 27 368 33 19 167 37 94 153 60 238 305 45 46 39 27 29 81 59 39 26 26 17 29 129 87 84 69 11 76 14 26 22 72 48 2 64 20 10 150 28 9 25 46 25 6 5 8 70 40 19 66 61 48 7 172 17 58 103 111 78

Eu

* * *

* * * *

* * *

* *

694

*I N

636

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Anus (C21) - Female (Contd)

Squamous Adeno 0.1 0.2 0.2 0.1 0.2 0.2 0.0 0.4 0.1 0.2 0.1 0.1 0.1 0.0 0.0 0.2 0.7 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.2 0.0 0.2 0.2 0.2 0.5 0.1 0.0 0.1 Carcinoma Other 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.1 0.0 -

Unspec. 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1

Sarcoma

Other

Unspec.

Number of cases MV Total

Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White

0.1 0.1 0.2 0.1 0.2 0.2 0.3 0.0 0.2 0.3 0.3 0.3 0.9 2.0 0.3 1.2 1.2 0.7 1.0 1.7 0.3 0.3 0.3 0.5 0.6 0.7 0.7 0.6 0.7 0.7 0.5 0.6 0.5 0.7 0.8 0.6 0.5 0.7 0.3 0.5 0.5 0.7 0.5 0.4 0.1 1.4

0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 -

0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 -

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

44 79 43 2 23 37 17 8 10 13 14 15 13 20 412 45 2 19 29 14 13 61 303 16 20 95 84 173 266 86 310 489 155 176 41 183 272 104 54 18 110 53 9 2 125 26 2 0 2 3 19

55 86 44 2 23 39 18 9 10 13 15 15 13 20 412 46 2 19 29 15 15 62 306 16 20 97 93 177 271 89 358 528 163 182 42 188 279 116 56 19 114 55 9 2 127 26 2 0 2 3 19

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

637

695

Age-standardized (world) incidence rates (per 100,000) by histological type

Liver (C22) - Male

Carcinoma

Hepato Cholangio Other Unspec. blastoma Haemangio Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 0.2 19.8 1.1 1.8 13.9 1.9 1.7 0.8 2.0 2.4 0.7 1.3 1.1 1.3 2.0 2.1 2.7 3.3 3.6 2.7 1.4 1.2 1.8 1.6 2.7 1.6 1.2 2.6 3.0 2.5 4.5 3.3 5.8 7.0 9.5 16.5 8.8 9.1 6.4 3.8 6.6 7.5 14.1 10.2 8.4 5.3 22.7 3.6 14.4 7.7 8.3 3.4 3.0 3.6 6.1 3.3 5.7 6.5 4.3 3.4 4.2 3.1 2.8 3.7 4.7 2.6 3.5 2.4 1.9 3.7 5.7 3.2 2.9 2.4 2.7 4.3 6.3 6.0 4.8 3.9 2.6 4.0 0.2 0.5 0.4 0.5 0.4 0.7 1.2 1.9 0.5 0.3 0.1 0.6 0.3 0.7 0.3 0.2 0.4 0.6 0.5 0.6 0.6 0.2 0.4 0.3 0.4 0.2 0.7 0.5 0.7 0.8 0.6 0.6 0.8 0.6 1.1 0.4 1.0 0.4 0.7 0.6 0.5 0.9 0.8 0.6 0.6 1.3 0.6 1.0 0.5 0.8 0.6 0.4 0.8 1.2 0.8 0.7 0.8 0.3 0.5 0.6 0.5 0.5 0.7 0.5 0.8 0.5 0.5 0.8 0.7 0.8 0.7 0.4 0.6 0.5 0.7 1.0 0.6 0.9 0.7 0.7 0.6 0.1 0.1 0.1 0.4 0.1 0.1 0.3 0.1 0.0 0.1 0.6 0.1 0.1 0.2 0.1 0.3 0.0 0.1 0.0 0.1 0.2 0.1 0.2 0.1 0.1 0.2 0.3 0.2 0.2 0.2 0.1 0.3 0.3 0.1 0.5 0.3 0.8 0.8 0.5 0.7 1.5 0.4 0.5 0.4 0.4 0.2 0.1 0.2 0.1 0.2 0.4 0.4 0.3 0.2 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.5 0.2 0.2 1.5 0.3 0.5 0.0 0.2 0.0 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.0 0.1 0.1 0.0 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.3 0.5 0.5 0.3 0.1 0.2 0.2 0.4 0.5 0.3 0.1 0.7 0.1 0.4 0.3 0.4 0.1 0.1 0.3 0.4 0.2 0.2 0.1 0.3 0.2 0.3 0.2 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.3 0.6 0.3 0.2 0.1 0.2 0.4 0.2 0.1 0.6 0.3 0.2 0.1 0.0 0.0 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.6 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.5 0.1 0.9 0.5 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.2 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

Hepato-

Sarcoma Other 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 -

Other Unspec.

Number of cases MV 13 377 17 40 38 22 113 24 38 554 11 70 123 37 36 22 1882 265 383 78 42 29 1 46 972 12 54 409 79 324 77 576 4915 1091 90 190 63 157 14 426 1479 161 142 80 392 21 95 472 1304 374 1045 2134 383 499 50 434 101 69 26 2457 263 2111 691 263 83 143 170 480 86 1547 241 1189 572 288 395 640 62 127 169 441 121 867 Total 22 912 20 100 265 * * * *

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 -

0.5 1.0 0.4 6.2 0.1 0.4 2.6 3.0 0.8 0.1 4.1 1.1 4.3 1.1 0.8 0.7 0.2 0.3 0.5 0.3 1.1 0.6 0.6 0.4 0.3 0.4 0.4 0.2 0.2 0.2 0.3 0.5 0.1 0.2 0.1 0.2 0.2 0.5 0.1 0.3 0.3 0.8 0.1 0.4 0.2 0.4 0.2 0.4 0.1 0.1 1.1 1.6 0.2 0.8 1.1 0.8 0.2 0.1 0.1 0.1 0.2 0.2 0.2 0.3 0.6 0.2 0.2 0.2 0.1 0.5 1.5 0.6 0.7 0.5 0.3 0.6

41 135 41 49 585 46 105 444 94 44 22 * 3301 417 736 168 59 32 1 87 1696 16 89 638 123 506 100 798 7052 1651 139 294 93 240 21 616 2083 224 190 99 591 36 144 642 1858 525 1594 2987 537 602 57 527 135 98 30 3370 358 2914 872 326 108 170 216 603 130 2031 343 1553 766 379 516 853 86 162 228 591 196 1162

696

*I N

638

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Liver (C22) - Male (Contd)

Carcinoma Hepato-

Sarcoma Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0

Hepato Cholangio Other Unspec. blastoma Haemangio America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008 3.3 4.6 7.9 3.6 7.1 2.7 2.9 7.4 2.4 2.1 4.1 5.9 3.5 4.5 7.0 7.7 2.5 5.1 6.7 4.2 3.9 5.8 3.3 2.5 5.8 2.0 2.2 2.9 3.9 9.8 3.2 4.1 4.5 7.2 3.3 4.7 12.7 6.4 7.9 3.1 2.9 3.1 2.7 5.1 6.5 4.7 2.3 2.2 3.8 4.4 2.2 2.8 3.4 21.0 19.1 5.1 0.8 5.0 1.5 1.7 0.9 2.6 1.2 0.9 3.3 1.3 2.4 2.3 1.8 11.8 19.1 35.6 11.4 22.3 30.4 5.7 34.6 37.8 33.8 26.9 38.1 28.7 0.8 0.8 0.9 0.7 0.7 0.8 0.6 0.8 0.5 0.4 0.7 0.9 0.7 0.7 1.8 0.7 0.6 0.8 0.9 0.8 0.7 0.7 0.6 0.6 0.8 0.6 0.4 0.5 0.7 0.6 0.6 0.6 0.7 0.8 0.7 0.7 1.0 0.7 0.7 0.6 0.6 0.6 0.6 0.7 0.8 0.6 0.5 0.6 0.8 0.8 0.8 0.9 1.4 0.3 1.6 1.3 0.2 0.3 0.9 0.3 0.6 0.6 0.3 0.5 0.1 0.1 0.2 0.2 0.1 1.0 1.0 1.7 1.2 0.9 1.6 0.6 2.9 2.5 2.7 2.6 2.4 2.7 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.2 0.3 0.4 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.1 0.1 0.2 0.1 0.3 0.3 0.2 0.3 0.2 0.2 0.1 0.2 0.4 0.2 0.4 0.2 0.1 0.0 0.1 0.2 0.2 0.2 0.1 0.3 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.2 0.1 0.0 0.2 0.1 0.2 0.2 0.1 0.3 0.2 0.1 0.9 0.9 1.2 1.1 0.8 1.2 0.2 0.4 0.5 0.4 0.4 0.2 0.2 0.2 0.2 0.3 0.2 0.4 0.1 0.3 0.7 0.3 0.3 0.3 0.6 0.2 0.2 0.4 0.2 0.4 0.9 0.3 0.2 0.1 0.2 0.4 0.1 0.1 0.2 0.3 0.2 0.2 0.3 0.4 0.3 0.2 0.3 0.3 0.2 0.2 0.1 0.2 0.0 0.1 0.2 0.2 0.2 0.2 0.4 20.7 0.3 0.1 0.0 20.3 0.3 0.0 0.3 0.1 0.4 0.2 0.0 0.0 0.1 2.1 0.1 2.2 0.0 0.0 0.2 0.2 0.1 0.2 0.1 0.2 0.1 0.0 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0

Other Unspec.

Number of cases MV 1230 618 189 404 224 956 621 111 491 62 1242 170 965 249 23 120 97 3028 449 2226 28846 3534 22272 1226 196 974 313 285 1868 275 1473 159 3585 446 2365 10058 1858 1115 1397 5553 434 97 325 2854 313 2355 127 64 681 505 210 688 20 706 3669 88 487 1070 353 67 185 18 685 60 389 165 50 310 273 32 509 144 583 536 640 12227 262 9822 881 796 277 235 467 Total 1613 791 233 529 295 1257 813 146 646 99 1621 229 1247 368 37 175 145 4206 616 3072 39416 4843 30392 1576 265 1247 495 462 2366 354 1865 201 4885 584 3210 13843 2592 1483 2082 7485 583 141 427 4014 463 3301 163 73 991 748 259 893 30 2425 6289 440 713 6001 857 74 269 34 895 65 491 209 78 556 463 42 862 815 1632 1709 1923 13494 969 40709 4438 2582 990 1349 1961 * * * * *

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.4 0.2 0.2 0.2 0.5 0.4 0.5 1.7 0.4 0.5 0.8 0.5 0.4 0.5 0.5 0.3 0.4 0.8 0.3 0.4 0.7 0.4 0.3 0.6 0.3 1.1 0.2 0.2 0.4 0.1 0.2 0.2 0.2 0.1 0.3 0.5 0.4 0.4 0.2 0.4 0.6 0.3 0.6 1.0 0.6 0.0 0.1 0.2 0.2 0.2 0.6 0.3 8.2 27.3 30.3 24.8 0.2 0.8 1.8 1.1 0.1 0.5 1.2 0.4 0.3 0.4 9.2 0.1 0.1 3.4 0.8 3.3 7.8 6.2 8.3 8.2 4.5 8.7 3.9

* * * *

639

697

Age-standardized (world) incidence rates (per 100,000) by histological type

Liver (C22) - Male (Contd)

Carcinoma Hepato-

Sarcoma Other 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 -

Hepato Cholangio Other Unspec. blastoma Haemangio Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 37.6 34.2 28.1 3.4 1.8 6.4 6.6 5.3 4.2 12.7 5.0 5.8 1.3 2.3 4.7 3.7 2.3 2.6 2.3 5.4 5.8 3.2 0.5 0.9 1.4 0.7 1.9 3.7 2.0 1.6 5.9 10.9 6.6 7.7 7.7 8.8 10.9 4.5 6.6 3.4 5.9 3.7 3.7 4.5 3.9 1.5 1.1 4.7 15.7 5.3 2.8 6.9 2.2 8.5 4.6 25.0 7.5 14.3 3.8 7.5 3.9 4.3 7.9 10.1 6.2 3.8 7.9 14.2 9.4 1.1 1.1 1.1 1.4 1.0 1.3 2.1 2.4 0.6 2.2 2.6 3.8 0.2 1.0 0.2 1.1 0.7 0.6 0.3 0.4 0.1 0.1 3.8 3.3 0.5 0.5 0.2 1.0 0.5 0.3 0.4 0.1 0.5 0.1 0.5 0.8 0.9 0.6 1.2 0.5 1.1 1.3 1.1 0.7 0.9 0.5 0.7 0.5 0.9 0.8 0.3 0.4 0.8 0.3 0.3 0.3 1.2 0.6 0.5 0.6 0.1 0.5 0.4 0.6 1.2 0.7 0.3 1.2 0.3 1.1 0.8 1.1 0.1 0.4 0.3 0.6 0.8 0.0 0.5 0.4 0.3 0.3 0.2 0.5 0.4 0.3 0.9 0.8 1.6 0.0 0.3 0.2 0.2 0.1 0.1 0.1 0.1 0.0 0.0 0.2 0.2 0.4 0.4 0.8 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.2 0.1 0.0 0.2 0.1 0.1 0.2 0.1 0.1 0.2 0.4 0.1 0.5 0.3 0.0 0.8 0.1 0.2 0.2 0.2 1.6 0.2 0.7 0.3 0.0 0.1 0.1 0.1 0.4 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.2 0.0 0.2 0.2 1.0 0.2 0.5 0.3 0.2 2.5 0.1 0.1 0.3 0.1 0.0 0.1 0.0 0.0 0.0 0.3 0.1 0.2 0.3 0.1 0.0 0.5 0.1 0.2 0.3 0.2 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.4 0.0 0.0 0.2 0.1 0.0 0.1 0.4 0.6 0.2 0.2 0.3 0.2 0.9 0.9 0.4 0.2 0.1 0.7 0.3 0.5 0.1 0.1 0.0 0.3 0.1 0.2 0.1 0.4 0.1 0.1 0.1 0.2 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.3 0.1 0.1 0.0 0.2 0.1 0.0 0.0 0.1 0.1 0.2 0.1 0.2 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0

Other Unspec.

Number of cases MV 82 2277 220 26 33 115 175 107 78 403 458 419 13 26 338 164 82 96 143 1897 101 49 428 71 369 299 517 1591 735 140 268 109 83 201 296 273 424 65 121 62 154 166 395 477 226 19 156 45 423 113 252 138 29 388 151 173 943 206 47 109 208 210 176 94 40 213 289 212 687 53 245 21 324 49 121 294 340 312 Total 352 9909 659 74 77 209 325 124 138 1570 1522 1352 59 111 730 723 233 109 253 2604 174 79 998 88 496 1949 1162 2569 878 182 485 372 150 301 339 475 588 128 162 93 197 355 407 615 323 20 291 149 732 243 558 351 75 794 333 535 1709 450 188 224 354 510 316 192 145 608 456 308 1325 313 420 35 388 92 182 330 623 651

0.0 0.1 0.0 -

3.5 6.2 8.9 3.3 3.9 2.2 2.1 0.4 0.2 5.6 13.2 14.8 6.4 9.6 9.8 25.1 5.7 0.4 0.3 1.3 0.5 2.5 2.1 0.0 0.2 4.9 3.7 2.2 0.6 1.1 6.0 3.8 0.1 2.1 0.1 2.0 2.7 1.0 0.3 0.9 0.5 0.1 0.1 1.6 1.0 9.3 11.2 4.9 5.2 3.6 4.5 6.0 5.1 6.6 7.6 3.8 10.2 1.2 2.4 8.5 6.8 14.2 4.6 8.5 1.0 7.6 2.9 2.1 0.7 0.2 1.8 1.3 0.3 2.2 3.5

Eu

* * *

* * * *

* * *

* *

698

*I N

640

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Liver (C22) - Male (Contd)

Carcinoma Hepato-

Sarcoma Other 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 -

Hepato Cholangio Other Unspec. blastoma Haemangio Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 1.3 2.2 3.1 3.1 7.4 5.8 5.6 2.3 3.8 2.2 4.0 5.5 5.1 3.5 2.2 5.5 2.7 4.1 3.1 11.9 5.3 5.3 1.1 0.6 1.2 1.0 1.7 1.9 1.8 1.4 1.5 1.9 1.4 1.7 0.7 2.2 3.4 2.5 2.7 1.6 2.4 2.8 2.8 9.5 3.1 6.7 10.4 8.0 7.6 5.8 4.1 1.1 0.7 0.6 0.5 0.8 0.6 0.7 0.4 0.6 0.1 0.4 1.0 0.2 0.5 0.6 0.5 0.5 0.6 0.2 1.3 0.5 0.8 0.2 0.1 0.1 0.7 2.3 1.4 1.0 0.8 0.8 0.7 1.1 0.5 0.3 1.0 0.6 0.8 0.4 0.5 0.3 0.5 1.0 0.3 0.6 1.0 2.3 1.0 1.3 1.2 0.3 0.3 0.3 0.1 0.2 0.3 0.3 0.1 0.2 0.1 0.3 0.5 0.5 0.1 0.1 0.1 0.2 0.4 0.2 0.1 0.2 0.1 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.0 0.0 0.0 0.1 0.4 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.4 0.3 0.2 0.2 0.2 0.0 0.6 0.2 0.1 0.0 0.5 0.3 0.0 0.0 0.3 0.2 0.0 0.1 0.2 0.0 0.1 0.0 0.1 0.0 0.2 0.5 0.0 0.1 0.2 0.2 0.1 0.0 0.1 0.1 0.3 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.2 0.0 0.2 0.4 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 -

Other Unspec.

Number of cases MV 599 530 381 28 280 313 218 25 113 86 190 120 105 158 1241 95 26 34 67 110 61 150 810 30 50 112 269 278 364 136 377 805 289 296 65 408 658 227 77 40 465 150 24 43 335 296 35 54 44 84 43 Total 1070 1041 415 66 491 778 395 61 219 264 285 202 177 194 1250 176 57 58 88 216 125 214 1029 40 58 223 506 634 825 239 907 1736 595 616 136 794 997 439 196 55 836 229 34 59 506 395 46 68 54 107 69

0.0 0.0 0.0 0.0 -

2.2 3.0 1.9 1.0 1.0 3.9 1.9 1.6 4.3 5.0 1.9 0.7 2.7 0.9 0.0 5.5 2.7 3.5 0.9 2.3 5.6 2.7 0.4 0.3 0.2 0.1 0.0 0.1 0.0 0.6 0.4 0.1 0.4 1.0 0.3 0.1 0.0 0.1 1.0 2.0 0.1 2.9 0.4 1.1 1.2 1.0 1.5 0.7 0.9

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

641

699

Age-standardized (world) incidence rates (per 100,000) by histological type

Liver (C22) - Female

Carcinoma

Hepato Cholangio Other Unspec. blastoma Haemangio Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 4.1 0.3 1.3 12.0 0.6 0.6 0.2 0.3 0.6 0.6 0.6 0.5 1.2 0.8 0.8 0.7 0.8 0.8 0.8 0.1 0.6 0.3 0.7 0.2 0.4 0.8 0.9 0.7 2.3 1.0 1.7 2.0 2.2 3.8 2.5 3.2 2.9 1.0 2.1 1.8 4.8 1.6 2.8 4.6 9.1 1.2 4.5 1.9 2.7 1.0 1.0 1.0 1.6 0.9 1.7 2.2 0.6 0.8 1.1 0.8 0.7 1.0 1.5 0.6 0.8 0.6 0.7 1.0 1.8 0.9 0.9 0.6 0.7 1.0 1.4 1.3 1.0 1.0 0.6 0.7 0.3 0.1 0.1 0.3 0.3 0.1 2.4 1.3 0.3 0.3 0.4 1.0 0.2 0.8 0.1 0.2 0.3 0.4 0.4 0.3 0.4 0.1 0.2 0.3 0.2 0.1 0.5 0.5 0.5 0.5 0.3 0.5 0.5 0.6 0.4 0.9 0.9 0.2 0.3 0.6 0.4 0.5 0.7 0.8 0.9 0.7 0.4 0.6 0.4 0.7 0.4 0.4 0.4 0.1 0.4 0.3 0.2 0.5 0.4 0.5 0.4 0.4 0.3 0.4 0.3 0.4 0.4 0.5 0.5 0.5 0.5 0.3 0.4 0.5 0.4 0.3 0.4 0.4 0.4 0.4 0.5 0.1 0.1 0.1 0.2 0.1 0.1 0.4 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.3 0.1 0.2 0.4 0.1 0.2 0.3 0.2 0.1 0.3 0.4 0.3 0.2 0.2 0.2 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.4 0.5 0.6 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.0 0.2 0.0 0.1 0.1 0.1 0.1 0.4 0.2 0.3 0.1 0.0 0.2 0.1 0.1 0.1 0.0 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.0 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.2 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.9 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0

Hepato-

Sarcoma Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0

Other Unspec.

Number of cases MV 10 88 5 21 23 9 122 16 11 274 15 85 66 35 21 13 726 91 157 27 17 15 0 22 375 3 19 228 54 170 33 238 2246 433 37 57 32 78 12 165 752 64 60 27 238 32 48 242 535 141 536 1003 187 222 14 199 44 37 7 1093 110 948 329 109 38 55 78 228 54 751 125 589 302 141 226 261 27 51 63 196 50 311 Total 16 227 7 73 159 * * * *

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.4 0.0 0.2 4.2 0.1 0.2 2.0 1.8 0.5 0.1 2.1 0.9 2.9 1.6 0.2 0.2 0.1 0.1 0.2 0.0 0.1 0.4 0.2 0.2 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.2 0.3 0.2 0.2 0.0 0.1 0.0 0.1 0.2 0.0 0.1 0.2 0.1 0.0 0.1 0.1 0.2 0.3 0.2 0.2 0.1 0.1 0.2

16 148 26 22 300 41 124 321 129 25 13 * 1393 164 309 79 25 18 0 45 708 5 40 359 81 271 47 345 3296 713 56 92 47 114 22 276 1072 92 84 33 340 46 73 348 804 207 768 1475 257 276 18 249 56 49 7 1550 153 1356 457 143 53 73 108 323 74 1074 185 834 392 203 291 349 36 67 89 255 72 488

700

*I N

642

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Liver (C22) - Female (Contd)

Carcinoma Hepato-

Sarcoma Other 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

Hepato Cholangio Other Unspec. blastoma Haemangio America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008 0.9 1.2 1.9 1.0 1.7 0.7 0.7 1.6 0.6 0.6 0.9 1.2 0.7 1.3 1.2 1.6 1.0 1.2 1.7 1.0 1.0 1.4 0.9 0.7 1.1 0.6 0.6 0.9 0.9 2.0 0.7 1.0 1.2 1.8 0.9 1.3 4.0 1.5 2.4 0.8 0.7 0.7 0.6 1.4 1.6 1.3 0.7 0.3 1.1 1.3 0.5 0.7 1.0 3.8 3.8 2.0 0.2 0.8 0.5 0.3 0.1 1.0 0.6 0.3 1.3 0.4 0.9 0.9 0.3 4.1 7.0 10.0 3.5 6.0 9.1 1.9 8.0 9.6 8.1 7.0 7.3 7.8 0.5 0.5 0.3 0.5 0.3 0.5 0.4 0.6 0.4 0.5 0.5 0.3 0.5 0.6 1.1 0.5 0.6 0.5 0.4 0.5 0.5 0.4 0.5 0.5 0.5 0.4 0.5 0.4 0.4 0.5 0.4 0.6 0.5 0.4 0.4 0.5 0.6 0.4 0.7 0.4 0.4 0.4 0.3 0.5 0.4 0.5 0.4 0.4 0.6 0.6 0.6 0.5 0.8 0.1 1.1 0.2 0.1 0.2 0.4 0.2 0.1 0.4 0.2 0.4 0.1 0.1 0.2 0.2 0.1 0.7 0.4 0.8 0.6 0.6 0.8 0.3 1.3 1.4 1.0 1.1 0.6 1.4 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.2 0.3 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.4 0.4 0.6 0.5 0.3 0.4 0.2 0.2 0.2 0.2 0.2 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.3 0.5 0.3 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.6 7.3 0.1 0.0 3.9 0.1 0.0 0.1 0.0 0.3 0.1 0.0 0.0 0.0 0.9 0.0 0.9 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.1 0.1 0.3 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0

Other Unspec.

Number of cases MV 565 281 72 197 86 461 282 45 231 38 522 63 419 122 11 44 61 1348 202 1037 13170 1472 10518 639 75 544 201 149 788 105 653 77 1611 172 1102 4591 781 420 679 2643 180 54 112 1217 111 1053 70 21 340 252 106 311 11 146 968 29 180 343 67 24 53 3 319 34 167 53 20 184 168 14 225 49 182 201 263 5036 128 3177 312 234 89 71 185 Total 799 373 90 271 113 664 375 59 309 66 752 83 619 178 15 68 88 1981 291 1520 18834 2074 15047 854 102 729 291 238 1074 140 895 97 2297 232 1574 6525 1129 582 970 3746 250 71 164 1854 179 1588 96 27 506 382 143 430 17 729 1771 174 252 2300 177 29 83 8 433 35 232 88 30 333 293 15 388 446 659 880 906 5654 607 13339 1582 869 339 374 712 * * * * *

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0

0.2 0.1 0.1 0.0 0.2 0.2 0.1 0.2 0.1 0.0 0.2 0.2 0.2 0.2 0.3 0.2 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.3 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.3 0.2 0.2 0.1 0.1 0.2 0.1 0.3 0.3 0.2 0.1 0.0 0.1 0.1 0.1 0.3 0.8 0.1 2.1 10.4 10.3 8.0 0.1 0.3 0.5 0.6 0.0 0.4 0.4 0.2 0.1 0.1 3.2 0.0 1.4 0.4 1.0 3.3 2.1 3.4 3.0 1.4 2.4 1.9

* * * *

643

701

Age-standardized (world) incidence rates (per 100,000) by histological type

Liver (C22) - Female (Contd)

Carcinoma Hepato-

Sarcoma Other 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

Hepato Cholangio Other Unspec. blastoma Haemangio Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 6.8 9.0 7.0 0.9 1.0 1.7 1.8 2.0 2.2 3.7 1.1 1.2 0.4 0.5 1.3 0.8 0.4 0.9 0.7 1.1 1.4 0.5 0.2 0.3 0.5 0.3 0.6 1.0 0.5 0.6 0.5 1.3 0.8 1.0 1.6 1.3 0.8 0.6 1.0 0.5 0.5 1.3 0.7 1.2 1.0 0.1 0.3 0.6 3.4 1.4 0.5 1.6 0.3 1.9 1.3 6.9 1.1 6.6 1.1 2.0 1.3 1.3 2.1 0.7 2.6 0.7 2.6 3.1 1.6 0.6 0.2 0.4 0.5 0.1 0.5 0.6 0.4 0.2 1.3 1.3 1.1 0.1 1.1 0.8 0.4 0.8 0.8 0.5 0.3 0.3 0.1 1.8 2.3 0.2 0.2 0.1 0.7 0.3 0.3 0.2 0.2 0.4 0.1 0.3 0.4 0.6 0.4 0.6 0.3 0.7 0.9 0.6 0.4 0.2 0.3 0.6 0.2 0.4 0.7 0.2 0.3 0.5 0.3 0.2 0.5 0.4 0.8 0.3 0.4 0.2 0.1 0.4 0.6 0.4 0.2 0.4 0.6 0.2 0.6 0.4 0.3 0.3 0.3 0.2 0.2 0.4 0.1 0.5 0.2 0.3 0.3 0.2 0.3 0.2 0.2 1.0 0.3 0.4 0.3 0.1 0.2 0.1 0.0 0.0 0.0 0.1 0.3 0.3 0.3 0.3 0.1 0.0 0.1 0.0 0.1 0.1 0.2 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.2 0.2 0.0 0.4 0.2 0.2 0.0 0.1 0.3 0.0 0.0 0.1 0.1 0.0 0.4 0.0 0.5 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.3 0.9 0.1 0.3 0.9 0.1 0.1 0.2 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.3 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.2 0.0 0.0 0.2 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.8 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.2 0.1 0.2 0.0 0.0 0.1 0.2 0.3 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 -

Other Unspec.

Number of cases MV 31 791 52 9 11 40 71 45 39 157 133 121 4 8 128 73 19 35 55 891 36 19 316 44 240 153 299 793 403 115 56 29 23 60 98 61 54 14 33 19 32 85 125 225 90 7 76 13 144 43 80 55 9 136 71 67 274 110 13 51 104 99 70 13 18 68 131 76 197 51 171 10 193 20 89 142 110 261 Total 131 3269 185 37 27 82 114 53 70 568 459 409 14 36 278 347 60 36 111 1319 78 31 705 50 366 1100 784 1449 540 150 104 77 48 96 110 123 75 21 52 31 39 280 129 324 156 7 164 59 284 129 294 185 29 383 192 199 635 296 86 104 193 295 184 52 90 249 277 122 525 251 299 17 250 61 152 159 269 565

0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 -

2.7 2.2 2.3 2.3 2.4 0.9 0.6 0.4 0.3 1.8 3.3 3.4 2.5 2.9 3.6 11.7 1.3 0.0 0.1 0.5 0.2 0.7 0.7 0.0 0.1 2.1 1.8 1.0 0.3 0.5 0.9 0.5 0.0 0.3 0.0 0.3 0.3 0.0 0.1 0.2 0.2 0.0 0.0 0.5 0.5 2.4 3.2 1.5 2.1 1.4 1.5 1.9 2.0 2.2 2.1 1.4 3.5 0.5 0.8 3.9 3.8 3.0 1.9 2.2 0.7 0.0 2.0 1.2 0.8 0.4 0.1 0.9 0.9 0.1 0.8 1.4

Eu

* * *

* * * *

* * *

* *

702

*I N

644

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Liver (C22) - Female (Contd)

Carcinoma Hepato-

Sarcoma Other 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

Hepato Cholangio Other Unspec. blastoma Haemangio Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 0.7 0.6 0.6 0.6 1.1 1.3 1.7 0.6 1.2 0.4 0.8 1.0 1.5 0.7 0.7 0.6 0.6 0.9 0.8 1.8 0.9 0.8 0.3 0.2 0.2 0.3 0.4 0.5 0.4 0.3 0.5 0.4 0.4 0.4 0.4 0.5 0.8 0.6 0.5 0.4 0.4 0.7 1.0 2.6 0.8 2.1 2.3 1.6 2.3 2.7 0.8 0.7 0.6 0.4 0.2 0.3 0.4 0.5 0.2 0.3 0.2 0.4 0.5 0.1 0.5 0.5 0.3 0.5 0.3 0.3 0.3 0.5 0.7 0.1 0.2 0.2 0.6 1.8 1.0 0.8 0.8 0.6 0.5 0.8 0.5 0.6 0.9 0.4 0.5 0.3 0.2 0.2 0.4 0.7 0.5 0.5 0.6 1.2 0.6 1.1 0.4 0.4 0.2 0.2 0.1 0.3 0.1 0.1 0.3 0.3 0.1 0.0 0.1 0.2 0.0 0.0 0.1 0.1 0.2 0.1 0.1 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.2 0.1 0.0 0.2 0.1 0.0 0.0 1.8 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.5 0.0 0.2 0.0 0.0 0.1 0.0 0.1 0.3 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1

Other Unspec.

Number of cases MV 429 323 143 9 65 116 98 6 49 29 70 33 35 64 687 19 13 16 30 30 22 50 361 18 17 61 232 146 193 77 234 352 152 137 54 230 230 80 31 11 145 49 16 14 148 127 11 15 20 53 12 Total 793 667 168 37 146 332 187 31 99 112 135 76 78 98 705 50 22 20 37 64 31 72 484 28 23 163 673 425 540 155 607 912 401 366 114 512 378 189 72 19 292 85 18 18 247 171 17 21 27 65 18

0.0 0.0 0.0 0.0 -

1.5 1.2 0.5 0.6 0.2 1.1 0.7 1.0 1.2 1.7 0.7 0.3 0.9 0.4 0.0 1.1 0.5 0.6 0.2 0.5 0.5 0.5 0.2 0.2 0.1 0.0 0.0 0.1 0.0 0.3 0.1 0.0 0.2 0.3 0.1 0.0 0.0 0.0 0.3 0.6 0.0 0.8 0.3 0.4 0.4 0.5 0.7 0.2 0.2

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

645

703

Age-standardized (world) incidence rates (per 100,000) by histological type

Lung (C34) - Male

Carcinoma

Squamous Adeno Small cell Large cell Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 12.0 2.6 16.9 1.0 1.6 8.0 7.8 6.9 6.5 7.6 2.3 3.9 2.2 1.1 3.4 0.7 11.5 10.8 9.9 11.5 18.1 12.9 21.4 15.5 11.3 17.7 12.0 19.6 19.5 19.7 12.7 9.9 9.3 8.0 15.5 4.7 8.7 5.4 5.4 8.4 8.8 18.1 5.2 10.1 4.6 4.8 9.2 9.5 6.2 16.0 5.1 10.2 9.3 12.0 16.4 11.7 17.9 23.2 8.4 13.0 14.9 12.9 18.1 13.9 18.6 12.9 21.6 17.5 10.1 15.2 23.0 14.5 18.4 14.0 25.7 20.4 28.1 16.0 27.5 18.4 16.0 12.3 1.1 2.6 6.7 0.5 1.2 7.1 4.6 3.6 5.6 6.9 0.9 2.8 1.7 2.9 3.9 2.8 12.5 12.0 9.6 15.0 19.5 8.8 11.2 15.0 13.0 15.5 11.6 17.9 19.8 17.4 15.1 13.1 14.2 13.2 20.7 11.6 15.9 8.7 8.3 13.4 13.3 20.4 10.9 13.8 8.0 10.9 10.4 14.9 11.9 20.2 8.5 15.4 11.9 18.1 21.0 18.0 21.3 26.2 13.4 17.1 16.9 17.1 17.2 15.1 17.5 14.3 18.9 16.7 11.6 17.7 23.5 17.0 16.5 16.6 20.7 20.7 22.5 23.7 22.3 20.2 15.5 16.9 0.1 1.6 5.4 0.2 0.4 2.3 1.7 0.4 1.4 2.5 1.1 1.5 0.7 0.4 2.0 0.2 6.1 6.5 5.2 5.8 8.6 6.8 10.4 8.2 5.9 9.8 6.0 10.1 7.3 10.7 9.1 6.3 5.8 5.0 6.6 3.2 4.8 3.4 2.5 5.6 5.3 6.7 2.7 5.5 2.8 3.4 7.4 6.5 3.6 6.6 3.3 6.8 6.4 7.3 6.6 7.4 6.2 8.4 2.1 8.2 6.4 8.4 9.9 7.5 7.4 7.8 7.6 10.5 6.7 9.0 8.5 9.3 11.3 9.4 15.2 10.4 11.6 10.2 10.3 10.5 9.3 7.7 4.6 4.3 5.7 0.8 5.5 25.5 3.7 3.5 3.3 5.3 1.2 3.0 1.3 0.9 2.8 0.7 8.7 8.1 11.6 11.8 14.5 12.6 5.3 12.5 6.7 7.2 7.0 13.8 16.5 13.2 6.4 9.2 9.1 9.1 14.3 8.1 9.2 6.0 5.8 9.4 8.4 12.9 7.1 10.2 4.5 6.1 6.4 9.5 7.2 12.9 5.1 10.1 5.2 10.2 13.8 10.1 8.1 10.0 4.3 12.1 14.2 11.9 15.3 13.4 17.6 12.3 17.8 14.8 8.4 10.8 17.7 10.0 13.7 8.5 15.7 14.4 19.2 11.0 19.5 12.9 13.4 9.0

O&U 0.2 0.1 0.3 0.0 0.2 0.3 0.3 0.2 0.2 0.1 0.1 2.3 2.9 2.7 3.0 2.4 2.6 0.8 4.1 1.8 2.4 2.4 5.5 5.1 5.6 5.1 4.0 4.3 4.3 8.5 2.9 5.1 3.6 3.6 4.2 3.9 7.2 2.7 3.8 2.0 2.6 1.8 4.4 3.1 7.8 2.3 4.7 3.3 4.7 6.4 4.7 6.0 6.6 4.0 4.4 4.3 4.4 4.9 4.8 6.4 4.3 5.9 4.6 4.3 4.9 6.5 4.7 5.6 5.0 7.1 4.8 6.3 2.9 6.1 4.5 5.7 4.6

Sarcoma Other Unspec.

Number of cases MV 357 447 324 29 65 261 437 91 211 4331 49 393 443 149 143 39 31475 3302 5387 1742 1518 766 33 1790 15244 264 1429 9394 1678 7659 673 7658 41702 7670 802 521 369 524 91 5026 10034 1563 336 335 1228 168 187 5953 3569 3412 3531 30936 4375 6141 408 5683 1000 783 193 37576 2876 34387 13622 3355 1002 2297 2880 10649 1620 21907 3176 18363 12457 5620 10585 9159 782 1323 2500 6614 2740 10743 Total 373 541 335 45 146 * * * *

0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.3 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.2 0.2 0.2 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1

0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.3 0.0 0.4 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0

1.9 2.6 2.4 2.3 0.6 2.1 8.7 11.5 3.8 10.6 5.4 10.1 5.0 2.4 1.4 1.4 6.7 2.4 2.3 3.9 3.4 1.8 . 10.4 9.7 7.3 5.5 4.9 5.0 4.9 4.7 2.9 1.9 1.5 3.6 0.7 1.0 0.6 0.6 1.5 1.3 2.4 0.7 1.6 1.1 1.0 0.4 1.3 1.0 2.8 1.2 2.0 4.5 1.3 2.0 1.3 6.5 8.0 3.8 6.2 8.0 6.1 4.7 2.5 3.1 2.4 5.7 4.5 2.6 3.3 4.5 3.1 2.9 3.1 5.4 4.2 8.7 5.7 6.0 3.7 4.0 3.7

377 496 153 265 6486 98 711 808 214 155 52 * 39973 3942 6567 2193 1850 837 34 2327 20062 306 1855 10858 1963 8834 744 8603 46149 8526 888 565 394 564 97 5648 10869 1696 357 367 1326 184 193 6469 3834 3720 3842 34471 5096 6667 443 6173 1141 886 221 43100 3355 39393 15499 3679 1104 2517 3310 12088 1910 24456 3559 20503 13797 6358 12132 10313 894 1477 2880 7384 3151 12045

704

*I N

646

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Lung (C34) - Male (Contd)

Carcinoma

Squamous Adeno Small cell Large cell America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008 15.3 16.9 22.7 15.7 22.2 14.5 17.2 23.5 16.7 12.4 12.3 19.9 11.8 8.5 2.4 5.8 10.2 12.0 15.3 11.8 13.9 19.9 13.6 16.6 21.8 16.0 16.8 11.8 14.9 23.5 14.2 16.3 11.7 19.4 11.4 12.2 6.7 20.6 5.7 12.7 19.0 21.1 18.4 14.1 21.8 13.6 6.0 11.0 11.2 10.8 21.2 12.3 9.5 15.1 11.9 7.9 1.8 4.8 6.0 2.5 3.2 1.9 2.9 2.6 1.1 8.0 7.6 10.4 7.1 9.3 11.9 10.7 10.9 10.0 10.7 17.2 14.2 20.3 16.3 18.4 17.1 16.7 19.8 24.0 19.0 23.0 16.0 17.8 23.4 17.3 14.4 17.7 20.4 17.7 10.5 3.6 7.6 12.4 17.1 18.6 17.2 16.4 20.4 16.1 17.1 21.9 16.5 16.2 15.2 17.4 25.1 16.8 21.4 15.5 21.2 15.2 15.8 12.0 21.0 8.8 16.5 16.9 17.5 16.6 14.9 22.2 14.2 7.8 15.8 15.7 15.6 18.4 15.5 6.2 17.7 17.1 6.1 2.0 4.4 11.0 1.6 3.0 2.5 1.8 1.0 2.0 8.1 7.8 10.1 13.2 12.2 18.2 13.2 16.9 13.0 11.5 9.5 8.3 10.3 9.2 8.9 10.1 8.5 9.3 9.6 9.5 8.8 8.6 10.3 9.1 10.4 8.7 7.5 7.3 7.7 5.6 2.4 4.0 6.8 6.6 5.5 7.0 8.2 7.5 8.5 9.4 7.8 9.6 9.8 7.5 9.3 8.6 9.4 9.6 7.1 8.1 7.4 7.4 3.6 8.1 3.6 8.2 10.1 7.5 10.8 8.0 8.6 8.0 3.8 8.2 7.3 7.3 12.4 7.5 4.5 2.2 5.2 0.7 0.3 1.3 3.1 0.5 2.9 0.9 0.4 2.5 0.4 4.1 3.9 6.1 3.9 3.4 4.9 4.5 5.2 4.6 4.6 6.4 5.1 7.7 6.4 5.9 6.3 11.4 13.9 18.7 12.8 18.1 10.6 11.3 16.6 10.8 10.0 8.6 13.3 8.3 6.5 2.3 6.0 7.2 8.7 11.1 8.6 10.9 15.5 10.5 13.4 18.9 12.8 13.9 9.6 10.2 16.4 9.7 8.8 10.2 17.3 9.8 10.1 6.8 15.7 5.5 10.4 14.6 18.9 13.3 10.0 16.2 9.6 4.1 11.4 11.4 11.9 14.0 7.5 10.3 33.0 4.1 31.7 0.2 23.1 1.2 1.6 2.2 0.7 0.5 4.8 0.9 3.2 3.1 3.6 0.8 1.4 5.8 3.4 11.6 1.7 1.3 2.7 1.8 2.5 2.5 3.2 2.4

O&U 4.2 4.8 6.9 4.3 6.4 3.9 4.8 7.1 4.6 4.2 5.0 6.5 4.9 3.5 0.6 2.5 4.1 4.8 4.9 4.8 4.6 6.0 4.5 4.1 5.2 4.0 4.5 4.1 5.3 8.3 5.1 5.2 4.6 7.4 4.4 4.7 3.1 7.1 2.5 4.8 5.4 6.2 5.2 5.0 7.0 4.9 2.4 4.5 5.1 5.6 4.8 4.0 0.2 0.4 7.6 0.2 0.2 0.2 1.0 0.0 1.8 0.1 0.0 0.0 0.3 5.4 5.2 7.1 0.3 0.4 1.0 0.3 1.4 0.3 0.3 0.8 0.6 0.3 0.7 0.2 1.0

Sarcoma Other Unspec.

Number of cases MV 17713 7877 1871 5935 2467 15075 11412 1078 10247 1568 14601 1789 12523 2003 34 442 1469 29281 3476 24994 384973 39822 335775 22804 2277 20150 7101 5595 25861 2389 23134 2241 39650 4445 32365 110720 5554 12119 5066 87367 8131 1807 6278 29383 3612 25360 1298 1048 9060 6141 4718 8404 148 2238 10409 195 976 5831 590 511 496 114 1268 235 2037 269 190 4368 3841 504 1074 1226 1476 3558 2991 12242 2110 30712 2375 2015 863 889 1656 Total 19900 8606 2060 6466 2758 16940 13325 1230 12001 1817 16143 1981 13838 2371 43 545 1718 34233 4032 29285 437311 45289 381699 25553 2622 22525 8702 6544 28666 2643 25655 2441 44116 4895 36135 123305 5991 13454 5592 97580 9164 2070 7047 34338 4244 29624 1482 1190 10388 6962 5598 10010 186 3831 12932 600 1280 12764 1086 569 956 175 1923 284 2515 362 264 5190 4498 551 1510 1625 1805 4633 3803 16745 2876 41126 3365 2476 1082 1199 2168 * * * * *

0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1

0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1

3.8 1.6 2.7 1.3 4.8 3.7 6.5 8.4 6.4 1.3 3.4 4.7 3.3 3.0 0.9 2.8 3.2 3.9 5.2 3.8 4.1 5.5 4.0 4.0 5.4 3.8 10.2 4.0 2.4 3.6 2.3 3.2 2.0 2.9 2.0 2.5 1.3 3.8 1.5 2.6 3.8 4.3 3.6 5.9 9.4 5.7 1.9 3.5 2.5 1.8 6.9 5.9 3.5 3.0 11.8 . 55.4 47.0 . 2.5 4.4 8.1 3.5 1.8 2.6 6.1 5.2 3.2 2.7 2.9 12.0 8.1 0.1 8.5 0.1 13.6 9.8 14.3 16.1 11.6 10.9 14.8 13.2

* * * *

647

705

Age-standardized (world) incidence rates (per 100,000) by histological type

Lung (C34) - Male (Contd)

Carcinoma

Squamous Adeno Small cell Large cell Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 14.1 16.1 16.5 2.2 3.9 10.0 5.6 2.2 9.5 7.0 10.6 12.8 2.2 4.4 8.3 9.4 4.8 13.8 19.8 10.1 12.1 12.2 22.4 18.5 19.2 15.7 25.9 24.3 12.7 25.3 26.2 20.7 21.0 22.3 16.1 15.9 14.4 17.7 25.8 15.8 12.2 10.7 9.5 15.6 18.2 7.7 12.4 13.7 15.1 18.3 15.6 14.9 11.7 10.0 13.4 17.4 12.1 12.1 7.1 11.0 17.3 14.2 12.2 25.0 13.4 11.7 13.8 15.8 18.3 16.6 24.4 12.3 8.8 23.4 13.3 10.1 8.8 16.2 8.2 11.0 9.3 2.5 1.6 7.5 3.1 2.0 2.0 8.0 14.7 16.7 3.8 11.5 9.8 9.6 4.8 5.0 10.2 11.6 14.8 11.2 4.6 13.6 12.2 2.1 9.6 7.9 12.2 5.4 14.0 12.3 13.7 13.3 14.3 13.7 11.8 12.5 14.9 9.5 9.3 11.3 8.2 10.5 14.5 10.6 6.4 18.7 16.4 20.3 8.3 16.5 9.1 15.9 13.6 10.6 11.5 12.1 7.3 10.0 15.4 7.1 14.3 15.6 8.2 12.6 10.5 12.1 14.3 4.7 5.7 6.5 9.2 5.9 5.7 9.5 7.1 4.1 4.9 6.6 8.1 2.0 1.2 3.4 1.0 0.5 4.0 3.4 5.0 5.6 1.0 5.0 2.4 5.6 1.3 7.0 10.9 6.9 7.3 6.2 3.6 9.5 8.9 4.1 7.7 8.1 8.1 10.9 7.6 8.4 8.8 7.3 8.2 7.3 6.4 8.3 8.7 7.7 5.2 9.8 5.5 10.5 11.0 5.3 5.5 7.4 5.2 7.5 5.2 5.0 4.7 5.2 6.1 5.2 5.2 7.6 2.7 6.6 7.6 4.8 5.6 6.5 3.4 6.2 4.9 6.9 5.0 4.9 6.5 5.1 6.6 7.0 6.5 4.7 3.7 4.2 2.5 3.0 2.8 2.2 3.0 6.4 3.4 2.3 6.7 10.2 7.9 8.7 3.1 7.6 2.6 9.4 0.8 2.0 4.2 7.1 4.4 8.6 3.0 8.7 11.9 1.4 9.2 4.9 4.0 4.2 6.1 7.6 6.6 6.0 6.3 7.3 5.3 6.4 5.5 3.5 5.5 18.9 2.7 16.4 6.1 6.5 6.1 5.2 5.0 10.9 6.2 6.2 4.3 5.1 5.1 8.7 9.2 11.5 4.6 6.8 7.0 4.7 4.0 6.0 2.4 13.7 6.4 9.9 7.1 1.6 4.3 5.3 4.4 3.5 1.8 3.5 4.6 8.8

O&U 0.8 0.5 1.3 3.9 2.6 0.7 0.1 0.2 1.0 5.3 0.6 0.7 0.3 0.3 0.1 0.5 3.7 19.8 0.7 3.8 1.7 0.8 1.4 1.0 0.6 0.2 0.8 3.2 0.6 2.2 3.5 0.8 0.6 1.4 2.1 1.4 1.4 3.1 2.7 0.6 2.3 3.3 2.6 1.0 0.8 0.4 3.7 1.5 1.0 2.5 0.9 2.8 4.7 1.3 6.0 0.9 0.5 2.2 0.4 0.9 0.3 0.6 0.7 2.4 0.6 0.5 0.6 1.5 0.3 0.3 0.0 2.9 1.4 0.4 1.1 1.0 0.4

Sarcoma Other Unspec.

Number of cases MV 233 7134 459 111 134 561 509 123 445 1763 3092 2751 77 264 897 730 314 932 5075 11013 964 438 12938 3757 10367 7437 8837 17998 8554 2265 1984 1210 923 1252 1689 1797 1532 913 1116 690 756 2673 2776 4661 2428 283 3805 472 1157 1056 2296 1334 337 2129 1242 709 3993 945 382 944 2544 1132 724 418 398 2168 1587 964 3613 2835 5052 405 5682 931 2471 2968 2915 4832 Total 309 9048 625 143 156 697 711 160 595 3164 3541 3140 88 313 1229 1117 408 1089 5860 12825 1069 545 18962 3987 11974 15483 12028 23221 10221 2965 2082 1251 961 1312 1727 1950 1564 931 1203 723 766 3830 3503 6011 2870 296 5178 628 1588 1340 3297 1989 432 3124 1811 1031 4909 1208 564 1213 3170 1791 955 501 607 2788 2078 1305 4789 4781 6927 532 6505 1501 2947 3115 3710 7722

0.2 0.1 0.4 0.1 0.2 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.2 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.2 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0

0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.2 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0

14.2 12.4 18.9 2.8 3.0 10.8 7.8 2.5 1.9 17.9 6.4 7.1 1.5 5.9 9.2 17.7 3.1 5.8 9.1 5.9 2.9 7.2 29.7 2.8 4.5 25.5 19.0 18.2 5.8 19.0 2.5 2.6 1.4 1.9 0.8 2.8 1.0 1.6 2.7 1.7 1.0 0.8 7.2 0.8 8.5 1.3 10.4 14.1 18.7 6.1 14.9 19.6 11.3 16.8 16.1 17.9 9.9 9.8 21.1 14.9 10.1 18.7 12.3 12.9 15.0 12.9 8.1 15.7 17.6 33.6 23.0 9.3 3.3 18.8 20.3 1.3 7.1 21.1

Eu

* * *

* * * *

* * *

* *

706

*I N

648

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Lung (C34) - Male (Contd)

Carcinoma

Squamous Adeno Small cell Large cell Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 23.4 25.3 22.1 16.0 24.2 18.4 16.4 13.5 17.4 16.2 16.6 19.6 17.7 19.7 5.8 13.4 13.3 15.6 13.1 11.4 15.8 13.0 17.8 21.7 17.2 12.3 15.4 15.8 17.1 10.2 9.1 10.9 12.3 13.0 11.1 18.3 9.2 10.8 5.0 14.1 8.7 8.1 5.5 17.1 9.8 10.6 5.5 11.5 18.9 7.5 11.0 9.6 6.2 12.8 5.0 11.2 12.6 10.8 3.7 10.9 5.8 9.2 8.7 7.9 10.2 6.4 13.0 16.4 11.6 10.2 13.3 16.0 11.8 11.7 10.5 9.5 5.6 9.4 5.5 7.6 5.9 4.9 6.1 5.7 5.7 4.0 9.7 8.7 12.3 10.2 8.9 9.1 11.3 8.9 8.8 8.1 14.8 13.8 18.1 17.7 10.0 17.0 7.0 7.5 10.5 7.0 10.3 8.2 5.8 7.8 8.4 6.3 9.5 7.5 8.0 7.3 3.1 6.7 7.1 8.2 6.4 7.4 9.1 6.6 8.9 9.8 9.2 4.7 7.8 6.7 8.0 4.9 4.4 4.9 6.5 6.1 4.6 9.7 4.8 5.1 4.8 5.2 4.6 5.5 2.8 8.0 4.4 5.2 1.5 7.5 7.2 3.8 5.7 2.3 5.1 5.3 4.1 4.9 7.9 7.8 5.4 10.3 5.1 7.0 10.5 7.8 5.8 4.3 8.1 4.1 7.8 6.1 11.6 3.6 10.7 10.3 12.4 15.5 12.0 22.2 22.8 14.6 11.5 9.5 16.0 17.4 15.7 4.0 12.7 12.1 10.2 8.2 5.6 7.2 10.8 7.0 17.6 5.4 6.9 4.5 6.7 11.4 5.4 7.5

O&U 2.1 1.2 2.3 0.3 0.5 0.7 0.7 0.2 1.2 0.9 0.3 1.0 0.4 0.5 0.4 1.1 0.4 1.3 0.6 0.6 0.4 0.9 1.9 1.1 2.8 0.4 0.5 0.5 0.5 0.3 0.4 0.3 2.8 0.5 2.1 3.6 1.2 2.4 3.7 1.2 0.6 1.7 1.1 1.2 0.5 3.5 2.0 3.1 7.2 2.8 3.1

Sarcoma Other Unspec.

Number of cases MV 8298 7012 3920 408 2510 3314 1947 324 1113 1060 1727 1120 854 1584 8225 651 356 306 702 577 467 1025 30297 2084 2010 3439 3770 5988 8950 2607 7604 15734 6703 7476 1795 9697 7871 4200 1926 657 5304 2156 194 215 3689 1829 115 310 299 466 515 Total 10626 9443 4013 489 2825 3851 2280 441 1292 1399 2072 1253 1034 1836 8419 704 402 342 779 647 513 1121 32734 2267 2134 4680 5866 9062 15621 3625 11985 23674 10178 10415 2686 12957 9268 5264 2321 816 6609 2523 222 250 4728 1981 121 332 324 504 564

0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.2 0.3 0.1

0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.2 0.1

13.3 15.5 4.5 5.6 4.9 6.3 7.6 7.3 6.0 8.5 7.8 4.2 7.4 5.6 0.8 3.1 3.2 4.5 3.2 4.3 3.6 3.5 3.8 4.6 2.9 0.3 0.5 0.3 5.5 0.1 7.4 2.7 1.2 3.2 18.6 6.7 1.5 0.3 4.2 7.9 6.1 2.1 0.3 9.6 7.0 2.6 1.3 1.8 5.5 1.2 3.4

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

649

707

Age-standardized (world) incidence rates (per 100,000) by histological type

Lung (C34) - Female

Carcinoma

Squamous Adeno Small cell Large cell Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 0.7 0.2 0.4 0.2 0.9 0.5 1.9 1.1 1.8 1.6 0.6 1.3 0.6 0.5 0.6 0.3 4.5 4.7 4.2 4.6 6.8 4.0 7.5 5.2 4.3 5.7 5.7 6.1 4.7 6.5 6.9 4.9 4.3 3.7 5.8 0.9 1.1 2.8 1.9 4.4 3.6 5.9 1.1 0.7 1.6 1.3 2.0 4.7 1.5 6.1 2.1 5.2 4.4 5.2 5.8 5.2 5.8 6.7 3.9 5.5 5.0 5.6 5.9 5.2 5.9 5.0 5.1 6.1 4.5 6.1 7.9 5.9 7.1 5.2 9.9 6.9 6.6 6.4 7.0 6.8 6.3 5.9 0.5 1.4 0.5 1.0 0.9 2.5 3.6 1.8 3.8 3.3 0.5 2.1 1.0 1.8 2.2 2.1 11.2 11.3 10.3 15.3 13.5 5.2 9.2 12.5 11.2 12.4 11.0 10.2 9.1 10.5 13.9 10.7 11.9 11.7 15.1 9.2 7.8 7.0 6.6 13.1 10.4 11.0 10.4 10.8 5.2 6.6 8.5 13.6 8.8 12.3 6.0 14.1 10.3 15.8 13.1 16.1 13.7 14.1 12.8 14.0 8.9 14.6 10.7 10.5 9.1 11.2 8.8 11.4 9.7 13.0 13.5 13.0 11.9 11.6 14.3 11.9 11.5 15.3 9.9 12.8 12.6 15.6 0.2 0.2 0.0 0.2 0.6 0.6 0.3 0.7 1.0 0.3 0.5 0.2 0.2 0.2 0.2 4.7 4.8 4.7 5.3 6.4 4.6 13.5 5.8 4.4 7.7 4.5 6.9 3.3 7.8 7.5 5.4 4.8 3.9 5.5 0.5 0.5 2.6 1.5 5.0 4.0 5.1 0.6 0.7 1.7 0.8 1.5 6.0 1.0 5.1 2.1 6.2 5.3 5.9 4.0 6.1 4.0 4.6 2.6 6.4 3.0 6.9 6.3 5.5 3.9 6.4 3.4 7.2 5.0 7.0 5.4 7.4 8.2 6.9 11.1 7.1 4.9 8.2 5.0 8.0 8.5 6.3 0.3 0.9 0.6 0.7 2.3 6.6 1.4 1.9 1.4 1.8 0.5 1.1 0.4 0.3 1.2 0.9 5.4 5.7 7.7 7.0 6.4 5.9 6.0 7.0 4.3 6.0 4.1 5.9 4.7 6.1 5.9 6.2 5.9 6.0 9.0 2.9 2.2 3.7 2.9 7.1 5.1 7.4 4.3 1.9 2.2 3.9 1.9 6.8 2.7 7.6 2.8 7.0 3.5 6.1 5.7 6.2 5.0 5.5 4.5 7.0 5.4 7.2 7.1 7.7 6.6 8.3 5.8 7.5 4.6 5.9 8.2 5.7 7.6 4.6 8.2 6.9 6.3 6.2 6.9 7.0 8.1 6.2

O&U 0.0 0.0 0.0 0.1 0.1 0.2 0.2 0.1 0.1 0.0 0.1 1.9 2.3 2.6 2.7 1.5 1.5 0.7 2.7 1.4 2.9 2.1 2.7 2.4 2.8 2.8 3.0 3.1 3.4 4.7 2.7 1.5 1.9 1.8 3.8 2.6 3.5 1.7 1.5 1.1 1.0 1.0 3.6 1.8 3.6 1.6 3.7 2.3 3.6 3.6 3.7 2.7 2.6 3.1 3.1 2.3 3.2 2.7 3.1 3.7 3.0 2.6 2.8 3.4 3.3 3.7 3.3 3.6 3.3 4.2 2.8 2.3 2.6 2.6 2.9 3.5 3.9

Sarcoma Other Unspec.

Number of cases MV 32 132 17 28 33 74 259 39 134 2151 21 231 186 90 66 41 23632 2571 4479 1442 936 380 22 1234 11342 184 1042 5559 856 4660 514 6221 35421 6780 603 345 158 432 80 4918 8276 1076 247 174 900 102 110 5521 2233 2343 2659 27963 3647 5291 298 4965 718 528 178 29402 1634 27513 8547 2570 655 1882 1493 6994 1174 16664 2197 14257 8789 3885 7178 5844 426 1026 1294 4517 2079 9969 Total 37 174 17 40 56 * * * *

0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.1 0.2 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0

0.3 0.8 . 1.8 0.2 0.6 4.5 5.0 2.0 3.6 2.6 4.2 2.1 1.3 0.7 1.2 3.8 1.6 1.3 1.6 1.6 0.2 . 5.0 5.7 3.8 2.9 2.2 1.4 2.3 3.8 1.9 1.3 1.1 1.5 0.7 0.6 0.3 0.5 1.4 0.8 0.9 0.6 0.6 0.5 0.5 0.3 1.0 0.6 1.1 0.7 1.5 2.5 0.8 1.1 0.8 2.6 2.9 1.5 3.0 2.2 3.1 2.2 1.5 1.6 1.5 1.7 2.3 1.7 1.7 2.3 1.7 1.6 1.7 2.5 2.1 3.2 3.0 2.1 2.1 2.2 2.4

105 300 71 173 3229 51 408 359 136 74 52 * 30148 3093 5440 1773 1133 402 23 1594 15166 219 1305 6470 997 5425 586 6967 40104 7753 684 377 170 479 88 5683 9129 1171 263 185 980 112 116 6150 2414 2579 2937 31924 4288 5840 324 5485 831 611 203 33616 1835 31497 9866 2842 721 2086 1720 8080 1406 18830 2508 16097 9892 4513 8299 6716 487 1178 1501 5179 2454 11373

708

*I N

650

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Lung (C34) - Female (Contd)

Carcinoma Squamous Adeno Small cell Large cell

O&U 3.0 3.4 4.0 3.3 3.7 2.9 3.3 4.0 3.2 3.1 3.6 3.7 3.7 2.3 0.4 1.3 3.1 3.4 2.6 3.7 3.1 3.0 3.2 2.8 3.0 2.8 2.7 3.3 3.6 4.3 3.5 3.3 3.2 4.0 3.3 3.2 1.6 3.5 1.5 3.6 2.6 2.2 2.8 3.1 3.7 3.0 1.4 3.2 3.6 4.1 3.0 3.2 0.2 0.3 2.7 0.1 0.1 0.2 0.4 0.1 0.1 0.1 0.0 0.2 2.3 2.4 0.5 0.2 0.3 0.2 0.1 0.4 0.1 0.2 0.3 0.2 0.1 0.4 0.0 0.2

Sarcoma Other Unspec.

Number of cases MV 13779 6414 1376 4996 1769 11864 8154 748 7340 1251 12223 1265 10796 1407 15 262 1112 25381 2728 22156 294649 25734 262301 17097 1642 15197 4995 4937 19180 1865 17095 1787 31654 3103 26803 87820 3465 7929 3695 72275 4793 826 3929 20246 2010 17936 807 719 7798 5393 3426 6375 52 987 4620 59 629 2455 285 119 115 15 404 83 427 122 42 2035 1951 68 427 426 577 1258 1216 4842 721 9096 770 640 278 294 532 Total 15696 7159 1527 5584 1980 13555 9549 857 8617 1485 13898 1386 12323 1744 18 325 1377 29864 3044 26268 338828 29095 302420 19352 1847 17223 6072 5843 21859 2073 19534 2007 35887 3443 30528 99738 3758 8816 4120 82510 5536 963 4529 24106 2397 21367 919 853 9027 6164 4146 7691 64 1759 6134 182 840 5718 521 128 226 20 599 96 537 182 51 2493 2331 82 588 617 720 1798 1605 7141 1041 14666 1302 930 399 479 822 * * * * *

America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

6.6 7.1 8.7 6.8 8.4 6.3 6.8 7.6 6.7 5.9 5.2 6.8 5.2 3.5 0.4 2.0 4.5 5.1 4.9 5.3 5.7 6.4 5.7 6.4 7.8 6.3 6.3 6.2 5.7 9.6 5.3 6.0 5.0 7.1 5.1 5.2 1.8 7.0 2.3 5.7 6.4 5.0 6.8 5.3 6.5 5.3 2.0 3.8 5.7 5.9 8.2 5.3 2.6 2.4 1.7 1.0 0.3 1.1 0.6 0.4 0.4 0.3 0.8 0.4 0.2 1.4 1.5 0.3 0.7 0.5 1.1 0.8 0.9 1.3 0.7 1.3 1.3 1.9 1.5 1.4 1.3

13.1 15.3 15.3 15.4 15.1 12.8 13.0 12.9 13.0 14.7 14.1 12.3 14.8 8.3 1.5 5.1 10.8 14.2 12.1 14.9 12.6 11.6 12.8 12.4 14.0 12.1 11.7 13.9 12.8 17.0 12.4 16.9 12.4 13.1 12.8 12.5 8.6 12.1 6.1 13.9 10.3 8.1 11.0 10.2 10.1 10.2 5.1 11.3 14.1 14.2 12.7 11.9 3.1 10.1 11.5 3.3 1.4 4.0 3.5 0.6 0.8 1.2 0.9 0.6 0.5 5.0 5.3 2.2 7.8 6.6 9.3 7.8 9.3 6.8 7.2 4.8 4.1 5.5 4.8 4.8 5.4

7.4 8.1 6.0 8.8 5.9 7.7 7.6 7.3 7.6 7.0 5.8 4.7 6.2 4.1 0.6 2.5 5.5 5.3 3.5 5.8 6.4 4.6 6.8 7.7 5.9 7.8 7.7 7.3 6.5 6.1 6.6 8.1 5.7 5.1 6.3 5.8 1.4 5.1 2.3 6.9 6.3 2.4 7.6 5.9 5.4 6.1 2.4 6.9 7.0 7.0 10.5 6.1 1.7 0.4 0.9 0.1 0.0 0.2 0.3 0.1 0.1 0.3 0.2 0.6 0.1 1.0 1.1 0.9 0.4 0.4 0.8 0.7 0.7 1.1 0.6 1.0 0.8 1.2 0.8 1.5 1.0

6.8 8.3 9.0 8.2 8.6 6.6 6.3 8.1 6.1 6.8 5.2 5.3 5.4 3.5 0.8 2.1 4.5 5.3 5.0 5.5 6.2 6.5 6.3 7.3 7.9 7.1 7.3 6.7 5.7 8.0 5.4 5.2 6.2 7.9 6.3 6.0 2.7 7.1 2.8 6.7 5.7 4.6 6.1 5.2 6.1 5.2 2.4 5.8 7.6 7.6 8.1 4.5 2.8 12.2 1.3 8.5 0.1 9.3 0.0 0.4 0.1 0.2 0.1 1.0 0.2 1.1 1.1 0.4 0.1 0.2 1.5 0.5 3.0 0.3 0.2 0.6 0.5 0.6 0.5 0.7 0.5

0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 -

2.2 1.0 1.4 0.9 2.4 2.1 3.0 2.6 3.0 0.7 2.3 2.1 2.4 1.9 0.3 1.5 2.2 2.1 1.5 2.2 2.2 2.0 2.3 2.2 2.5 2.1 5.2 2.9 1.4 1.7 1.4 2.3 1.2 1.4 1.2 1.5 0.7 1.6 0.8 1.7 1.9 1.5 2.1 3.0 3.6 3.0 0.9 2.3 1.6 1.0 3.7 3.6 1.4 1.2 5.2 . 34.4 18.0 . 0.2 1.0 0.7 1.0 0.4 0.7 3.0 0.6 1.2 1.0 0.6 2.8 2.3 0.0 2.6 0.0 4.2 2.6 4.5 5.2 4.3 3.5 4.7 4.6

* * * *

Cancer Incidence in Five Continents Vol. IX, IARC 2008

651

709

Age-standardized (world) incidence rates (per 100,000) by histological type

Lung (C34) - Female (Contd)

Carcinoma Squamous Adeno Small cell Large cell

O&U 0.4 0.2 0.3 0.6 0.5 0.4 0.0 0.2 1.5 0.2 0.2 0.4 0.3 0.1 0.1 0.2 0.7 1.3 0.5 1.9 0.6 0.2 0.5 0.5 0.2 0.1 0.3 2.3 0.3 0.7 0.6 0.2 0.0 0.5 0.7 0.5 0.8 0.5 0.8 0.2 1.1 1.6 0.7 0.4 2.4 0.5 0.5 0.6 0.6 0.6 0.4 0.4 1.1 0.9 1.4 0.4 0.4 0.2 0.3 0.7 0.3 0.5 1.0 0.4 0.5 0.4 0.7 0.1 0.1 0.2 1.8 0.4 0.1 0.3 0.5 0.1

Sarcoma Other Unspec.

Number of cases MV 83 2520 146 32 19 169 292 32 47 652 1306 1176 28 102 692 429 123 116 416 4564 396 137 1282 966 2029 1137 1864 4966 6507 454 446 207 192 280 398 367 342 123 183 125 161 1250 1253 1404 807 286 2111 104 274 234 576 293 73 811 315 119 1250 272 59 273 670 145 142 90 60 582 376 200 986 470 731 76 3264 365 1223 641 652 1047 Total 120 3659 227 45 22 220 395 36 61 1138 1582 1434 33 115 933 633 167 141 500 5519 446 185 2330 1021 2324 2782 2804 6825 7790 677 478 217 200 304 402 399 357 127 195 137 165 1897 1638 1873 987 302 3052 165 386 321 897 495 101 1294 470 189 1620 394 91 336 853 259 186 112 88 813 509 309 1454 922 1224 98 3751 609 1519 681 863 1891

Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

1.4 1.5 2.1 0.7 0.3 1.5 1.6 0.5 1.0 1.1 1.7 1.9 0.6 0.8 4.4 4.7 0.9 0.8 0.7 1.5 2.1 1.5 0.7 2.5 1.6 1.4 2.2 3.2 5.0 1.8 2.0 1.1 1.1 2.9 1.8 1.4 1.2 1.0 1.7 1.0 0.9 2.6 1.5 2.2 3.3 5.3 4.0 1.1 1.2 2.0 2.0 1.4 0.7 1.4 1.4 0.9 1.6 1.3 0.2 1.2 2.2 1.0 1.2 1.0 0.5 1.2 1.3 1.7 1.9 0.9 1.2 1.3 2.7 3.8 2.7 0.6 0.6 1.0

4.7 6.1 4.6 1.0 1.1 3.6 3.1 0.7 0.6 4.1 8.1 8.8 3.1 5.6 8.6 7.4 2.6 1.7 1.7 5.4 6.9 3.6 0.9 5.4 4.1 0.9 3.3 2.8 11.9 1.6 4.7 3.0 4.4 4.0 4.4 3.7 3.8 1.9 3.3 2.9 3.9 5.1 4.6 3.7 5.7 12.6 4.3 3.8 4.4 4.5 3.2 4.2 3.0 6.2 4.0 2.9 4.3 4.5 1.7 4.2 5.6 1.9 3.3 5.1 2.4 3.6 3.2 3.6 5.0 1.4 1.4 2.0 6.2 2.7 2.8 3.0 2.6 1.2

0.7 1.1 1.2 0.5 0.4 0.1 0.6 0.3 0.4 0.4 1.4 1.6 0.6 2.2 2.0 0.2 0.5 0.8 2.4 2.8 2.2 0.1 2.5 1.7 0.5 1.4 2.1 6.3 1.7 1.9 1.5 1.9 1.2 1.9 1.4 1.0 1.3 1.9 1.2 0.6 4.7 2.3 3.9 3.9 4.5 3.4 1.6 1.0 1.3 1.1 0.7 1.0 1.6 2.0 0.9 1.4 1.4 0.1 2.0 1.6 0.4 0.5 1.2 0.4 1.7 1.1 1.2 1.1 0.5 0.5 0.6 4.2 2.9 3.6 0.5 0.4 0.3

0.7 0.8 0.8 0.3 0.3 1.3 1.8 0.5 1.0 2.5 2.2 2.2 0.9 2.8 2.0 4.2 0.2 0.2 0.3 2.1 1.0 3.2 0.2 2.0 2.0 0.2 1.6 1.2 2.6 0.6 1.3 1.1 1.8 1.3 1.7 1.1 0.8 0.7 0.6 0.3 1.0 7.0 1.2 3.4 1.9 5.1 2.9 1.3 1.1 2.9 1.7 1.1 1.0 1.8 1.3 0.7 2.1 3.0 0.3 1.8 1.7 0.5 1.0 1.7 0.5 2.8 1.9 0.7 1.7 0.2 0.5 0.6 2.8 1.6 0.8 0.6 0.7 1.2

0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.2 0.1 0.1 0.0 0.1 0.2 0.1 0.0 0.0 0.0 0.0

0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

2.8 4.5 4.7 1.5 0.6 3.0 4.0 0.3 0.2 5.1 2.7 2.8 1.8 1.7 6.2 8.6 1.3 0.8 1.0 1.9 0.6 2.1 2.4 0.5 0.7 3.8 3.8 4.3 3.3 2.7 0.4 0.4 0.2 0.3 0.1 0.3 0.3 0.1 0.3 0.4 0.1 0.2 2.4 0.3 2.0 1.4 5.1 2.4 2.8 1.3 3.3 3.7 2.9 4.5 3.3 3.3 2.2 2.7 2.8 3.4 2.1 2.3 1.7 1.7 1.5 2.8 1.7 3.2 3.7 3.9 2.8 1.2 1.4 5.5 7.3 0.2 1.3 2.7

Eu

* * *

* * * *

* * *

* *

710

*I N

652

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Lung (C34) - Female (Contd)

Carcinoma Squamous Adeno Small cell Large cell

O&U 0.6 0.4 0.7 0.3 0.3 0.3 0.4 0.3 0.1 0.2 0.1 0.4 0.2 0.2 0.6 0.6 0.8 0.4 0.8 0.3 0.6 0.9 0.5 1.1 0.5 0.4 0.4 0.4 0.2 0.3 0.3 1.6 0.5 1.2 2.1 0.9 1.4 1.7 0.7 0.5 0.9 0.5 1.0 0.6 1.8 1.1 1.2 3.8 0.6 2.7

Sarcoma Other Unspec.

Number of cases MV 2346 1266 1149 42 288 464 320 22 111 85 184 143 74 138 5881 347 87 123 252 223 172 480 11486 692 682 1792 2620 3795 5722 1434 4311 9568 3762 3859 1084 6883 3877 1978 974 371 2878 1111 117 78 2331 1165 79 136 238 250 378 Total 3064 1765 1180 49 351 557 396 39 134 121 229 166 96 172 6054 391 106 140 274 247 196 525 12354 739 726 2602 4310 6150 10848 2130 7229 15134 6089 5635 1728 9746 4677 2480 1202 446 3676 1339 138 95 3151 1273 85 142 256 278 423

Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White

4.8 2.0 2.0 0.5 0.6 0.9 0.9 0.4 0.5 0.6 0.4 1.0 0.5 0.8 2.3 3.4 1.4 2.8 2.0 1.3 2.2 1.7 3.3 3.4 3.2 4.1 5.8 5.5 6.6 3.4 3.2 3.9 4.2 3.8 3.9 7.1 2.3 3.0 1.3 4.3 2.4 2.6 1.4 4.7 3.8 3.5 2.8 1.7 7.9 1.7 5.4

3.4 1.8 5.3 0.9 2.6 3.3 3.2 1.2 2.5 1.4 2.5 3.2 1.4 1.7 5.8 7.2 6.2 5.6 5.3 6.0 8.3 7.4 6.1 4.8 4.8 3.7 7.0 4.1 5.3 4.1 3.1 4.4 3.9 3.5 2.7 7.0 5.4 6.7 6.0 5.9 5.9 6.3 5.5 4.5 5.8 10.4 9.5 10.6 14.5 7.2 13.1

2.0 1.0 2.8 0.2 0.8 0.7 0.6 0.2 0.6 0.1 0.3 0.4 0.5 0.2 2.5 3.7 1.7 3.4 2.6 1.7 3.3 3.4 4.3 4.1 4.4 2.9 5.9 5.1 5.9 3.0 2.6 3.1 4.3 3.6 3.6 7.5 2.7 2.8 2.2 4.0 2.6 2.9 1.6 4.4 3.3 3.6 1.0 2.0 9.1 1.0 5.5

0.6 0.9 1.1 1.0 0.9 1.0 1.1 0.4 0.9 0.3 0.7 1.4 0.5 0.6 2.8 2.8 0.8 2.9 1.9 4.7 1.3 4.8 3.8 5.0 4.6 5.9 12.4 12.9 8.5 5.7 5.0 8.1 8.3 7.0 2.2 7.4 5.1 3.9 3.6 3.6 3.4 4.9 4.3 4.7 3.4 3.7 1.8 3.0 8.0 2.6 3.9

0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.1 0.2

0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 -

3.4 2.0 0.9 0.3 0.6 0.6 1.2 0.9 0.7 0.6 0.7 0.5 0.7 0.5 0.5 1.2 0.7 1.8 0.7 0.8 1.3 1.1 1.1 1.0 0.9 0.2 0.3 0.2 3.2 0.0 3.5 1.2 0.7 1.3 9.3 3.7 0.6 0.1 1.8 2.8 2.6 1.0 0.3 4.0 4.4 1.2 0.5 0.4 2.4 0.5 2.4

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

653

711

Age-standardized (world) incidence rates (per 100,000) by histological type

Bone (C40-41) - Male

Sarcoma Osteo Chondro 0.2 0.3 0.2 0.0 0.3 0.1 0.3 0.2 0.3 0.3 0.2 0.2 0.5 0.1 0.3 0.3 0.3 0.2 0.4 0.1 0.1 0.3 0.1 0.3 0.3 0.1 0.3 0.4 0.2 0.3 0.2 0.1 0.1 0.1 0.2 0.3 0.2 0.3 0.2 0.2 0.2 0.3 0.1 0.2 0.3 0.3 0.3 0.4 0.2 0.4 0.2 0.2 0.3 0.3 0.1 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.1 0.2 0.3 0.3 0.2 0.3 0.3 0.2 0.4 0.2 0.2 0.2 Ewing 0.2 0.2 0.1 0.0 0.1 0.1 0.1 0.4 0.3 0.1 0.2 0.1 0.1 0.2 0.2 0.2 0.2 0.3 0.2 0.1 0.8 0.3 0.2 0.1 0.2 0.0 0.2 0.2 0.2 0.2 0.1 0.1 0.4 0.2 0.1 0.2 0.0 0.2 0.1 0.4 0.1 0.0 0.2 0.2 0.2 0.2 0.3 0.2 0.2 0.1 0.3 0.2 0.2 0.0 0.3 0.0 0.3 0.2 0.2 0.2 0.2 0.3 0.3 0.2 0.2 0.1 0.4 0.1 0.3 0.3 0.3

Other 0.1 0.2 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.0 0.3 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1

Unspec. 0.3 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0

Other

Unspec.

Number of cases MV 43 91 5 14 32 11 69 18 21 384 11 58 63 47 9 10 587 66 106 24 22 18 0 25 300 1 25 123 20 99 18 130 914 153 7 7 6 35 0 90 246 27 8 5 83 3 2 110 66 50 258 529 137 91 7 79 12 7 3 485 48 432 189 66 15 48 39 146 29 295 37 246 175 83 108 108 14 24 40 67 36 170 Total 45 106 5 29 44 * * * *

Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.2 0.4 0.3 0.4 0.5 0.8 0.3 0.2 0.2 0.8 0.5 0.7 0.3 0.6 0.2 0.3 0.3 0.2 0.4 0.4 0.3 0.4 0.5 0.4 0.3 0.4 0.4 0.3 0.3 0.3 0.4 0.4 0.4 0.2 0.4 0.4 0.4 0.4 0.6 0.4 0.5 0.3 1.3 0.5 0.4 0.3 0.5 0.4 0.4 0.5 0.3 0.6 0.3 0.3 0.5 0.4 0.5 0.4 0.4 0.3 0.4 0.3 0.5 0.3 0.3 0.3 0.3 0.3 0.4 0.4 0.4 0.4 0.7 1.0 0.4 0.3 0.3 0.4

0.3 0.1 0.0 0.2 0.9 1.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.3 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.3 0.3 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1

0.2 0.4 0.6 0.5 0.1 1.8 1.6 0.2 0.8 0.2 0.3 0.2 0.0 0.5 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0

12 97 25 24 558 13 67 78 48 13 11 * 688 72 116 24 22 18 0 28 381 1 26 137 21 112 19 138 942 157 7 7 6 36 0 92 250 27 8 5 84 3 2 113 67 51 264 547 142 93 7 81 12 7 3 513 49 459 195 67 16 48 41 148 31 303 37 253 182 86 115 114 14 24 41 72 38 173

712

*I N

654

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Bone (C40-41) - Male (Contd)

Sarcoma Osteo Chondro 0.3 0.3 0.1 0.4 0.2 0.3 0.3 0.2 0.3 0.4 0.3 0.1 0.3 0.2 0.3 0.1 0.3 0.2 0.3 0.3 0.2 0.3 0.3 0.2 0.3 0.2 0.3 0.3 0.1 0.3 0.2 0.3 0.2 0.3 0.3 0.1 0.2 0.3 0.3 0.2 0.2 0.2 0.2 0.2 0.3 0.4 0.4 0.3 0.3 0.2 0.2 0.1 0.1 0.0 0.0 0.2 0.1 0.3 0.2 0.2 0.1 0.0 0.3 0.4 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 Ewing 0.2 0.2 0.3 0.3 0.2 0.2 0.3 0.3 0.1 0.3 0.2 0.2 0.1 0.4 0.2 0.1 0.3 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.3 0.2 0.1 0.3 0.0 0.2 0.0 0.2 0.2 0.1 0.0 0.2 0.3 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.3 0.5 0.0 0.1 0.0 0.1 0.4 0.1 0.1 0.1 0.2 0.2 0.0 0.4 0.4 0.2 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Other 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.4 0.0 0.0 0.0 0.1 0.2 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.2 0.1

Unspec. 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0

Other

Unspec.

Number of cases MV 269 105 20 84 27 236 137 9 126 28 261 21 219 45 4 13 26 529 70 424 5985 554 5140 281 27 248 86 100 353 28 310 23 694 58 576 1988 112 173 328 1340 89 18 69 519 42 458 81 19 138 88 45 131 11 47 126 10 58 141 35 27 92 8 259 61 421 68 14 208 182 22 9 7 12 50 26 98 29 725 71 50 23 41 56 Total 294 108 22 85 31 257 146 10 134 29 268 22 225 45 4 13 26 567 76 454 6323 581 5433 289 27 256 95 101 365 28 321 23 707 61 586 2047 113 179 336 1382 95 21 72 583 48 512 82 20 144 89 46 155 12 63 146 21 73 283 36 29 118 9 295 67 502 75 17 225 194 24 12 15 13 56 27 118 33 900 92 57 29 49 60 * * * * *

America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.4 0.3 0.3 0.3 0.3 0.4 0.3 0.3 0.4 0.4 0.4 0.3 0.4 0.4 0.4 0.3 0.5 0.4 0.6 0.3 0.4 0.4 0.4 0.3 0.3 0.3 0.4 0.4 0.4 0.5 0.3 0.3 0.4 0.4 0.3 0.4 0.3 0.4 0.4 0.4 0.3 0.3 0.3 0.4 0.2 0.4 0.5 0.4 0.3 0.3 0.3 0.3 0.2 0.4 0.4 0.7 0.1 0.3 0.7 0.3 0.3 0.3 0.4 0.8 0.3 0.4 0.4 0.3 0.2 0.1 0.1 0.3 0.4 0.2 0.4 0.4 0.4 0.5 0.3 0.7 0.4

0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.0 0.0 0.1 0.1 0.2 0.0 0.1 0.9 0.0 0.1 0.2 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1

0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.3 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.5 0.1 3.1 1.1 0.4 0.4 0.2 0.2 0.1 0.3 0.9 0.1 0.1 0.1 0.1 0.1 0.3 0.0 0.0 0.1 0.1 0.2 0.3 0.1 0.3 0.3 0.1

* * * *

Cancer Incidence in Five Continents Vol. IX, IARC 2008

655

713

Age-standardized (world) incidence rates (per 100,000) by histological type

Bone (C40-41) - Male (Contd)

Sarcoma Osteo Chondro 0.2 0.2 0.0 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.0 0.0 0.1 0.3 0.2 0.3 0.3 0.2 0.2 0.4 0.2 0.1 0.2 0.1 0.3 0.2 0.2 0.2 0.2 0.3 0.3 0.1 0.1 0.3 0.4 0.1 0.2 0.2 0.2 0.3 0.6 0.2 0.3 0.4 0.4 0.4 0.2 0.1 0.2 0.3 0.2 0.2 0.1 0.1 0.4 0.1 0.1 0.1 0.3 0.2 0.3 0.0 0.3 0.2 0.1 0.2 0.3 0.2 0.2 0.2 0.3 0.2 0.1 Ewing 0.3 0.1 0.0 0.2 1.5 0.1 0.0 0.1 0.3 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.3 0.2 0.1 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.4 0.1 0.3 0.6 0.1 0.4 0.3 0.1 0.2 0.2 0.0 0.2 0.3 0.5 0.4 0.3 0.4 0.4 0.4 0.3 0.1 0.4 0.3 0.1 0.1 0.2 0.2 0.1 0.4 0.2 0.3 0.2 0.1 0.2 0.0 0.1 0.5 0.2 0.1 0.1 0.2 0.3 0.3 Other 0.1 0.1 0.1 0.1 0.3 0.0 0.0 0.0 0.0 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.2 0.0 0.1 0.1 0.0 0.1 0.5 0.0 0.1 0.1 0.2 0.1 0.1 0.0 0.1 0.0 0.1 0.0

Unspec. 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 1.8 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.2 0.1 0.0 0.1 0.6 0.1 0.1 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0

Other

Unspec.

Number of cases MV 6 204 16 12 23 15 43 17 58 116 45 38 3 4 27 5 18 32 93 184 15 8 277 37 173 170 325 260 119 44 18 16 15 14 25 35 16 16 16 13 15 25 45 44 29 13 97 5 18 12 37 14 5 29 18 18 44 11 5 14 20 21 7 9 7 34 14 14 36 57 97 8 122 18 28 88 72 79 Total 8 250 18 15 25 23 47 18 61 244 46 39 3 4 30 12 20 34 95 199 17 9 345 37 178 270 388 309 132 48 18 17 15 16 25 38 18 16 16 14 15 32 45 53 29 13 107 6 21 15 41 14 6 30 20 26 52 17 7 17 23 35 7 10 8 36 28 15 39 85 126 9 127 21 39 92 108 106

Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.4 0.5 0.4 0.2 0.2 0.2 0.5 0.1 0.3 0.9 0.3 0.3 0.3 0.2 0.5 0.2 0.4 0.5 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.3 0.3 0.2 0.3 0.5 0.5 0.2 0.2 0.4 0.4 0.3 0.2 0.6 0.5 0.5 0.7 0.2 0.3 0.2 0.4 0.6 0.2 0.8 0.1 0.1 0.5 0.3 0.2 0.4 0.3 0.4 0.1 0.7 0.4 0.3 0.3 0.1 0.3 0.1 0.1 0.4 0.3 0.2 0.3 0.4 0.3 0.2 0.4 0.3 0.2 0.4 0.3 0.2

0.0 0.2 0.0 0.1 0.0 0.1 0.2 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.2 0.2 0.0 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.2 0.0 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.2 0.4 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1

0.4 0.3 0.2 0.2 0.0 0.5 0.2 0.2 0.1 1.4 0.0 0.0 0.1 0.3 0.1 0.0 0.1 0.1 0.2 0.4 0.0 0.3 0.4 0.3 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.3 0.4 0.1 0.2 0.1 0.1 0.7 0.3 0.2 0.2 0.4 0.1 0.4 0.1 0.1 0.0 0.0 0.6 0.0 0.1 0.4 0.5 0.0 0.1 0.2 0.1 0.3 0.3

Eu

* * *

* * * *

* * *

* *

714

*I N

656

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Bone (C40-41) - Male (Contd)

Sarcoma Osteo Chondro 0.1 0.3 0.4 0.3 0.2 0.3 0.2 0.1 0.4 0.2 0.1 0.3 0.2 0.4 0.3 0.5 0.5 0.5 0.2 0.3 0.1 0.3 0.5 0.2 0.2 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.3 0.2 0.1 0.4 0.3 0.1 0.6 0.2 0.3 0.6 0.2 0.3 Ewing 0.3 0.3 0.1 0.5 0.3 0.4 0.3 0.3 0.4 0.0 0.3 0.1 0.1 0.3 0.2 0.1 0.4 0.1 0.6 0.5 0.5 0.2 0.2 0.1 0.3 0.3 0.2 0.2 0.1 0.2 0.3 0.3 0.2 0.1 0.3 0.3 0.3 0.3 0.4 0.1 0.1 0.4 0.7 0.3 0.1 0.2 0.1 Other 0.3 0.0 0.2 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.2 -

Unspec. 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.4 0.0 -

Other

Unspec.

Number of cases MV 269 156 50 6 36 54 32 2 23 21 29 16 9 29 234 9 6 2 18 10 7 13 420 34 19 61 79 78 131 51 151 304 97 129 23 121 167 97 46 8 123 40 8 15 127 33 0 5 6 6 11 Total 370 207 50 8 41 59 36 3 25 22 30 16 10 31 234 10 6 2 18 10 7 14 423 34 19 65 128 91 138 58 226 366 107 132 26 129 178 100 49 8 128 43 8 17 133 33 0 5 6 6 11

Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White

0.9 0.3 0.3 0.6 0.3 0.2 0.8 0.4 0.4 0.6 0.4 0.4 0.4 0.2 0.4 0.5 0.4 0.3 0.2 0.2 0.2 0.3 0.4 0.3 0.2 0.2 0.3 0.3 0.3 0.2 0.3 0.3 0.3 0.5 0.3 0.2 0.2 0.3 0.5 0.5 0.2 0.4 1.1 0.5

0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.1 0.0 0.1 0.2 0.4 0.1 0.1 0.1 0.1 0.0 0.0 0.7 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.9 0.2 0.1 0.2 0.1

0.9 0.3 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 -

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

657

715

Age-standardized (world) incidence rates (per 100,000) by histological type

Bone (C40-41) - Female

Sarcoma Osteo Chondro 0.2 0.1 0.2 0.0 0.2 0.1 0.0 0.1 0.3 0.3 0.1 0.2 0.0 0.2 0.1 0.1 0.0 0.3 0.1 1.8 0.1 0.2 0.2 0.1 0.1 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.2 0.2 0.1 0.1 0.2 0.3 0.1 0.2 0.1 0.1 0.2 0.2 0.3 0.2 0.2 0.2 0.2 0.5 0.2 0.2 0.2 0.2 0.1 0.1 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.3 0.2 0.3 0.2 0.3 0.1 0.1 Ewing 0.2 0.1 0.2 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.0 0.2 0.2 0.2 0.2 0.0 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.0 0.0 0.1 0.2 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.2 0.0 0.2 0.2 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.2

Other 0.2 0.1 0.1 0.3 0.0 0.4 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1

Unspec. 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0

Other

Unspec.

Number of cases MV 33 57 6 17 33 7 51 20 21 298 5 37 52 34 4 7 418 51 71 16 16 7 1 11 225 1 19 80 15 64 10 117 650 110 10 6 6 17 1 61 193 20 5 7 72 3 3 79 54 48 190 347 105 70 4 66 13 6 5 361 45 313 140 42 15 25 35 102 25 270 33 227 128 70 95 99 9 12 21 75 28 130 Total 35 71 6 29 49 * * * *

Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.2 0.4 0.2 0.3 0.4 0.5 0.2 0.8 0.3 0.5 0.3 0.4 0.2 0.6 0.2 0.3 0.3 0.3 0.3 0.2 0.4 0.1 0.2 0.3 0.2 0.3 0.2 0.3 0.2 0.3 0.3 0.3 0.3 0.4 0.4 0.3 0.2 0.3 0.4 0.4 0.2 0.1 0.3 0.4 0.4 0.4 0.3 0.4 0.3 0.3 0.3 0.2 0.1 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.3 0.1 0.4 0.2 0.2 0.3 0.3 0.3 0.3 0.2 0.3 0.3 0.5 0.1 0.3 0.3 0.4 0.2

0.0 0.0 0.1 0.0 0.3 0.4 0.6 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.7 0.5 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1

0.3 0.2 0.3 0.5 0.3 1.2 1.0 0.0 0.7 0.4 0.1 0.2 0.2 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.1 0.1 0.0

11 67 27 21 482 9 41 63 37 5 7* 516 52 76 18 16 7 1 11 314 1 20 98 21 76 12 129 680 114 10 7 7 18 2 61 194 20 5 7 72 3 3 80 57 49 197 366 106 74 5 69 13 6 5 386 50 333 145 43 15 26 36 106 27 278 33 235 133 73 100 116 10 16 25 88 28 136

716

*I N

658

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Bone (C40-41) - Female (Contd)

Sarcoma Osteo Chondro 0.2 0.2 0.0 0.2 0.0 0.2 0.3 0.2 0.3 0.1 0.3 0.2 0.3 0.2 0.2 0.1 0.3 0.3 0.3 0.3 0.2 0.1 0.2 0.2 0.0 0.2 0.2 0.3 0.2 0.1 0.2 0.2 0.2 0.1 0.3 0.2 0.1 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.5 0.1 0.3 0.4 0.2 0.2 0.1 0.1 0.0 0.3 0.1 0.1 0.1 0.1 0.1 0.3 0.3 0.2 0.2 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.2 0.2 0.0 0.2 Ewing 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.3 0.4 0.3 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.3 0.1 0.0 0.2 0.1 0.1 0.0 0.1 0.2 0.2 0.3 0.2 0.0 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.0 0.1 0.3 0.1 0.1 0.1 0.2 0.1 0.3 0.3 0.2 0.0 0.2 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.0 Other 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0

Unspec. 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 -

Other

Unspec.

Number of cases MV 225 83 16 65 24 194 132 9 114 20 218 17 181 41 3 17 21 553 86 446 4909 483 4171 234 25 199 83 75 263 16 234 18 564 50 466 1550 88 135 257 1040 78 20 58 459 43 398 59 12 135 99 37 96 5 27 90 2 41 110 20 21 70 2 144 26 235 47 13 164 148 16 10 6 10 25 15 76 13 585 54 48 25 17 45 Total 241 86 19 65 27 207 141 11 121 22 232 18 193 45 3 19 23 594 90 479 5246 519 4457 247 26 211 95 77 274 16 244 19 587 54 484 1638 91 145 269 1099 87 21 66 509 50 438 61 13 145 104 39 118 5 34 107 9 48 251 23 22 92 2 178 27 283 54 13 183 158 18 13 13 10 30 17 93 21 722 81 52 30 22 57 * * * * *

America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.3 0.4 0.4 0.4 0.5 0.3 0.2 0.2 0.2 0.5 0.3 0.1 0.3 0.3 0.4 0.2 0.4 0.6 0.4 0.3 0.3 0.3 0.3 0.2 0.2 0.3 0.2 0.2 0.1 0.2 0.1 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.4 0.3 0.3 0.4 0.3 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.1 0.1 0.3 0.1 0.2 0.2 0.2 0.2 0.5 0.2 0.4 0.4 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.3 0.2 0.5 0.3 0.3 0.4

0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.4 0.0 0.0 0.5 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.2 0.1 1.9 1.0 0.2 0.1 0.3 0.2 0.1 0.2 0.7 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.2 0.1 0.3 0.1 0.2 0.2 0.2

* * * *

Cancer Incidence in Five Continents Vol. IX, IARC 2008

659

717

Age-standardized (world) incidence rates (per 100,000) by histological type

Bone (C40-41) - Female (Contd)

Sarcoma Osteo Chondro 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.3 0.2 0.1 0.2 0.1 0.3 0.4 0.2 0.1 0.1 0.1 0.1 0.1 0.3 0.3 0.2 0.2 0.5 0.1 0.3 0.1 0.0 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.3 0.2 0.1 0.2 0.1 0.3 0.1 0.6 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.1 0.1 0.1 Ewing 0.1 0.1 0.1 0.2 0.2 0.0 0.1 0.2 0.4 0.1 0.1 0.0 0.2 0.1 0.1 0.2 0.1 0.2 0.2 0.4 0.2 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.3 0.1 0.1 0.3 0.1 0.4 0.1 0.3 0.1 0.3 0.2 0.2 0.2 0.8 0.2 0.5 0.1 0.3 0.2 0.2 0.3 0.8 0.5 0.1 0.2 0.2 0.3 0.1 0.2 0.0 0.1 0.4 0.2 0.1 0.0 0.2 0.2 0.1 Other 0.0 0.1 0.0 0.0 0.1 0.0 0.3 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.0 0.0 0.1 0.3 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.2 0.0 0.2 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.0

Unspec. 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.2 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0

Other

Unspec.

Number of cases MV 6 157 20 11 11 15 32 15 54 106 44 37 3 4 17 5 12 23 56 145 16 1 236 28 133 141 266 179 87 30 14 22 14 19 17 36 23 9 13 8 14 25 58 55 21 1 73 2 11 5 30 11 4 27 12 12 41 16 6 12 25 15 4 6 3 21 22 6 28 48 81 7 108 10 20 75 58 59 Total 7 187 21 15 11 20 36 16 57 203 49 41 4 4 19 17 14 24 57 159 18 1 282 28 135 205 311 234 102 33 14 22 15 19 17 38 24 9 13 8 16 34 60 62 21 1 78 5 13 5 37 14 4 29 13 19 50 18 9 13 28 28 5 6 3 23 34 9 32 64 104 7 111 15 28 85 88 85

Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.4 0.3 0.8 0.1 0.4 0.2 0.3 0.1 0.3 0.8 0.3 0.4 0.6 0.1 0.3 0.1 0.1 0.2 0.2 0.3 0.3 0.2 0.1 0.2 0.3 0.3 0.1 0.2 0.3 0.2 0.5 0.3 0.3 0.2 0.5 0.1 0.1 0.2 0.2 0.3 0.2 0.5 0.4 0.4 0.2 0.2 0.0 0.4 0.3 0.1 0.2 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.3 0.3 0.2 1.4 0.2 0.3 0.2 0.1 0.3 0.2 0.3 0.3 0.2 0.1 0.3 0.3 0.2

0.0 0.1 0.3 0.0 0.0 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0

0.1 0.1 0.2 0.3 0.4 0.1 0.0 0.2 0.9 0.0 0.0 0.4 0.1 0.5 0.1 0.1 0.0 0.0 0.2 0.0 0.2 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.1 0.1 0.0 0.0 0.4 0.1 0.1 0.4 0.2 0.1 0.4 0.0 0.1 0.4 0.1 0.0 0.2 0.2 0.0 0.2 0.1 0.1 0.2 0.1

Eu

* * *

* * * *

* * *

* *

718

*I N

660

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Bone (C40-41) - Female (Contd)

Sarcoma Osteo Chondro 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.5 0.1 0.1 0.1 0.2 0.2 0.2 0.5 0.5 0.2 0.0 0.2 0.2 0.3 0.4 0.3 0.1 0.1 0.1 0.1 0.3 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.3 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.3 0.1 0.1 0.0 Ewing 0.1 0.2 0.0 0.1 0.1 0.1 0.2 0.1 0.5 0.1 0.8 0.4 0.1 0.3 0.1 0.4 0.2 0.2 0.1 0.3 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.8 0.2 0.1 0.3 0.3 Other 0.2 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2

Unspec. 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 -

Other

Unspec.

Number of cases MV 168 105 47 6 25 28 20 2 16 11 26 7 15 29 162 13 1 3 16 9 5 14 385 27 14 40 88 47 102 52 128 240 82 108 18 84 136 81 32 7 94 43 5 9 84 19 2 2 3 4 5 Total 260 146 47 7 26 33 22 4 17 11 29 8 15 32 164 13 1 3 17 10 5 14 389 27 14 45 138 59 114 56 225 286 98 114 23 93 144 87 34 7 99 47 5 12 87 19 2 2 3 4 5

Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White

0.6 0.3 0.3 0.1 0.3 0.2 0.2 0.2 0.2 0.0 0.2 0.2 0.3 0.4 0.2 0.1 0.1 0.4 0.6 0.9 0.2 0.4 0.3 0.3 0.2 0.2 0.3 0.2 0.2 0.3 0.3 0.2 0.2 0.4 0.1 0.2 0.3 0.4 0.2 0.3 0.2 0.3 0.3 0.3 0.3 0.3 0.4 0.2 0.2 0.4 0.3

0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.0 0.6 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.3 0.1 0.0 0.4 -

0.6 0.2 0.0 0.2 0.0 0.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 -

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

661

719

Age-standardized (world) incidence rates (per 100,000) by histological type

Skin (C43-44) - Male

Carcinoma Squamous Basal cell 4.4 3.5 9.5 0.8 0.4 12.9 101.0 55.5 149.0 71.3 10.8 29.6 23.4 11.7 14.9 4.8 0.0 94.2 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 Other 0.2 0.3 0.1 0.1 0.3 0.5 0.3 0.2 0.8 0.8 0.3 0.1 0.4 0.0 0.5 0.3 0.3 0.7 0.3 0.7 0.7 0.7 0.6 0.1 0.8 0.7 0.6 0.1 0.6 0.6 0.5 0.9 0.9 0.1 0.4 0.7 0.4 0.4 1.1 1.1 0.6 0.2 0.5 0.3 1.3 1.5 0.4 0.4 0.4 1.1 0.8 0.6 0.2 0.6 0.5 0.5 0.5 0.6 0.1 0.6 0.5 0.7 0.4 0.7 0.3 0.6 0.4 0.5 0.2 0.5 0.5 0.7 0.7 0.7 0.8 0.2 0.9 0.4 0.7

Unspec. 0.2 0.0 0.2 0.0 1.7 0.9 1.5 1.3 1.2 0.1 0.1 0.2 0.4 0.0 0.0 0.1 0.2 0.1 -

Melanoma

Other

Unspec.

Number of cases MV 158 263 138 44 71 182 2547 438 2734 20558 160 146 3228 863 210 212 13837 1043 1633 5498 307 141 6 501 4312 67 329 1673 35 1512 160 2743 16790 2907 17 25 13 82 2 2580 3625 63 16 11 234 13 2 3022 168 134 667 14717 2338 2163 11 2073 139 22 110 9319 67 9062 3396 1316 45 1234 112 3199 689 4394 64 4087 2491 1479 2274 1319 16 200 53 1243 693 3357 Total 159 277 138 59 79 * * * *

Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

2.5 2.8 3.0 1.7 1.8 3.4 14.2 11.5 46.8 21.2 4.4 0.1 10.4 5.2 3.7 6.5 1.2 23.8 -

0.2 0.3 0.6 0.9 0.9 3.3 4.2 2.7 4.4 6.5 1.8 3.5 2.4 2.5 1.4 1.8 10.9 10.3 10.8 9.1 11.3 6.4 5.9 14.0 11.4 12.6 8.0 10.8 0.6 12.4 8.8 15.4 15.2 12.9 0.6 0.9 0.4 2.6 0.1 19.3 11.9 1.0 1.2 0.8 2.8 1.1 0.3 21.7 0.9 1.0 2.9 22.0 16.9 18.0 0.9 19.0 7.1 0.8 17.3 13.7 0.8 15.1 14.1 17.3 0.9 23.8 1.0 17.7 16.8 10.6 0.6 11.7 12.2 13.7 16.7 8.6 1.0 9.0 0.9 11.3 15.7 15.0

0.1 0.1 0.8 0.3 0.3 0.3 0.2 0.2 0.4 0.1 0.1 0.5 0.3 0.2 0.3 0.2 0.3 0.3 0.4 0.3 0.0 0.1 0.3 0.3 0.5 0.2 0.3 0.3 0.4 0.3 0.4 0.2 0.2 0.2 0.3 0.5 0.9 0.1 0.2 0.3 0.6 0.2 0.8 0.3 0.4 0.5 0.4 0.3 0.4 0.5 0.6 0.4 0.3 0.3 0.2 0.4 0.6 0.8 0.4 0.8 0.3 0.2 0.4 0.6 0.3 0.3 0.4 0.3 0.4 0.7 0.1 0.5 0.3 0.3 0.4

0.3 0.1 1.0 0.1 0.5 3.2 1.0 0.4 0.1 0.2 0.0 1.8 0.1 0.1 0.0 0.0 0.1 0.1 0.2 -

191 2576 447 2772 20584 161 150 3363 869 210 212 * 14086 1043 1646 5520 307 145 6 502 4520 67 330 1703 37 1540 164 2776 16861 2918 17 25 13 83 2 2590 3635 63 16 11 235 13 2 3031 169 135 670 14778 2353 2178 11 2088 143 23 113 9454 69 9193 3440 1321 45 1239 112 3243 702 4432 64 4123 2508 1486 2287 1334 16 205 53 1258 739 3392

720

*I N

662

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Skin (C43-44) - Male (Contd)

Carcinoma Squamous Basal cell 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 2.5 0.7 3.6 0.7 0.2 1.0 16.6 0.2 0.3 0.3 0.2 0.3 0.6 1.3 1.3 0.8 1.0 1.0 3.2 1.5 3.5 0.5 0.8 1.2 1.2 2.0 1.0 2.0 1.4 Other 0.6 0.7 0.4 0.7 0.4 0.6 0.5 0.2 0.5 0.4 0.7 0.3 0.8 0.7 0.5 0.9 0.5 0.2 0.6 0.6 0.2 0.7 0.4 0.1 0.4 0.5 0.5 0.7 0.2 0.7 1.1 0.7 0.4 0.8 0.8 0.4 0.3 0.4 0.9 0.6 0.1 0.7 0.6 0.3 0.6 0.9 0.4 0.7 0.8 0.5 0.5 0.2 0.2 0.2 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.5 0.5 0.2 0.2 0.3 0.4 0.1 0.5 0.2 0.2 0.2 0.2 0.2 0.1 0.1 0.1

Unspec. 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 -

Melanoma

Other

Unspec.

Number of cases MV 4857 1883 50 1806 76 4566 1897 22 1849 413 4239 53 4111 875 8 59 806 6128 112 5941 99891 1040 94280 4803 52 4345 1218 2204 5980 44 5586 696 13579 141 12958 36383 294 380 906 33280 1915 34 1836 6315 70 5878 1056 438 3431 2326 901 2100 25 151 1403 27 14 490 81 532 131 24 371 53 288 93 50 2199 2110 57 111 100 274 342 505 515 158 2510 218 224 66 92 152 Total 4928 1889 51 1811 81 4632 1960 25 1909 420 4284 53 4155 891 8 61 820 6382 118 6186 101309 1062 95631 4869 53 4407 1287 2221 6030 44 5629 697 13651 142 13029 36593 295 382 912 33475 1946 35 1864 6542 73 6099 1061 443 3454 2336 912 2148 25 167 1417 27 17 527 81 602 141 24 378 58 325 100 50 2373 2252 58 117 110 281 363 509 545 166 2656 229 230 68 94 160 * * * * *

America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.0 0.0 1.5 0.7 1.3 0.9 0.1 0.8 5.2 0.8 1.8 0.8 0.7 0.5 0.8 1.0 1.0 0.5 1.0 0.6 2.3 1.1 1.8 0.4 0.9 0.9 0.8 1.4 0.8 0.8 0.9

14.5 13.7 0.8 17.4 1.0 15.8 9.8 0.5 10.6 12.7 14.2 0.5 16.6 14.2 2.1 2.4 23.7 9.3 0.8 10.9 13.1 0.7 14.4 12.4 0.8 12.6 10.3 18.5 12.7 0.6 13.1 18.2 15.1 0.8 17.9 14.8 1.0 0.9 3.0 19.4 14.4 0.6 18.4 10.2 0.5 10.9 16.7 20.6 17.2 16.9 13.2 11.3 0.4 0.8 0.7 0.1 0.1 0.4 0.2 2.9 0.3 0.5 0.3 0.4 0.3 0.2 11.2 12.2 1.4 0.5 0.4 0.5 0.5 0.7 0.4 0.4 0.5 0.5 0.7 0.3 0.7 0.5

0.5 0.6 0.9 0.5 0.9 0.4 0.4 0.8 0.3 0.2 0.5 0.9 0.4 0.4 0.5 0.4 0.4 0.6 0.4 0.4 0.6 0.3 0.4 0.7 0.3 0.2 0.3 0.4 0.6 0.4 0.4 0.5 0.7 0.4 0.4 0.3 0.7 0.3 0.4 0.3 0.5 0.3 0.3 0.4 0.2 0.6 0.3 0.4 0.4 0.4 0.3 0.2 0.2 0.4 0.1 0.0 0.3 0.0 0.1 0.1 0.0 0.1 0.1 0.5 0.5 0.4 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.2

0.1 0.1 0.1 0.1 0.1 0.7 1.4 0.1 0.1 0.0 0.1 0.2 1.6 0.2 0.2 0.1 0.3 0.2 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.2

* * * *

Cancer Incidence in Five Continents Vol. IX, IARC 2008

663

721

Age-standardized (world) incidence rates (per 100,000) by histological type

Skin (C43-44) - Male (Contd)

Carcinoma Squamous Basal cell 0.9 0.9 0.8 0.8 1.5 2.4 2.4 2.6 1.5 1.6 5.4 6.6 0.3 1.9 2.0 1.7 2.0 13.7 8.9 16.1 10.6 0.6 17.6 1.0 22.3 14.6 50.9 53.9 24.9 39.4 1.2 35.5 42.2 0.5 72.4 52.0 57.7 61.6 48.8 50.0 56.8 39.7 50.7 13.6 45.8 33.3 51.9 52.2 51.2 22.6 47.2 44.3 52.4 39.1 32.4 48.3 55.3 12.1 21.6 53.4 0.9 18.5 9.8 0.1 0.0 9.5 Other 0.2 0.2 0.1 0.4 0.3 0.1 0.3 0.3 0.5 0.5 0.4 0.3 0.1 0.1 0.1 0.2 0.3 0.5 0.2 0.2 0.3 0.8 0.2 0.4 0.3 0.1 0.3 0.3 0.8 0.4 0.2 0.7 0.3 0.5 0.9 0.4 0.6 0.6 0.4 0.2 1.3 0.6 0.5 1.2 0.5 0.5 0.2 0.8 0.4 0.3 0.3 0.2 0.5 0.6 0.2 0.2 0.4 0.3 0.1 0.2 0.1 0.2 0.2

Unspec. 0.0 0.0 0.2 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.2 0.4 0.1 0.1 0.1 0.1 0.3 0.8 0.1 0.5 0.5 2.3 0.2 0.3 1.8 0.5 0.9 0.2 0.4 0.4 0.1 0.3 0.3 0.2 0.1 0.1 0.3 0.2 0.0

Melanoma

Other

Unspec.

Number of cases MV 19 554 35 17 58 108 199 75 129 271 748 684 18 46 171 92 144 591 1036 10083 695 294 7544 1140 7946 8015 1013 26236 16162 1476 375 104 120 258 236 258 373 124 110 89 159 4096 1738 5144 2865 179 13952 706 1976 1816 3999 1996 746 2954 2172 373 6955 1122 959 1651 3884 1317 1309 503 969 2467 2294 1367 5821 1638 3551 1058 4895 666 1057 301 1598 2143 Total 19 579 39 17 59 111 200 75 132 279 748 684 18 46 173 97 146 595 1062 10220 698 296 7626 1144 7970 8145 1044 26632 16634 1521 375 104 120 258 236 261 373 124 110 89 159 4350 1801 5422 2872 179 14764 707 2024 1824 4323 2085 749 2973 2174 403 6959 1122 963 1654 3894 1362 1311 505 971 2472 2431 1381 5832 1655 3611 1081 4907 672 1099 301 1624 2238

Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

1.0 1.0 0.8 0.4 0.7 2.4 1.9 1.4 2.1 1.3 2.5 2.8 0.8 2.1 1.5 1.8 2.7 5.5 3.4 7.5 6.0 12.2 4.1 8.8 9.3 5.7 10.0 8.9 3.0 9.9 4.5 7.1 9.4 7.9 37.8 10.4 12.5 19.7 7.1 7.0 11.3 5.7 10.4 4.7 11.8 9.0 14.0 13.0 12.3 8.3 13.8 14.1 11.3 4.5 10.5 9.0 14.8 1.7 5.3 16.1 10.8 2.0 1.9 9.0 1.5

0.4 0.6 0.5 0.2 0.6 0.5 1.2 0.4 0.5 0.8 0.4 0.4 0.4 0.7 0.6 0.8 0.5 1.0 1.3 8.6 13.0 12.4 2.7 4.6 5.5 2.7 6.9 9.9 11.9 5.3 11.3 4.7 7.4 10.7 7.1 7.2 9.8 6.7 6.2 6.2 7.3 9.7 12.7 8.0 8.1 9.3 7.4 9.8 8.4 6.4 9.8 7.9 9.6 10.4 7.0 3.9 9.5 7.8 3.8 6.1 10.0 5.0 3.4 5.4 4.6 10.7 5.6 7.8 9.4 3.2 3.7 5.5 14.2 5.7 4.4 2.6 3.7 3.8

0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.3 0.1 0.2 0.2 0.2 0.1 0.0 0.3 0.1 0.1 0.3 0.1 0.2 0.3 0.1 0.2 0.2 0.1 0.1 0.0 0.2 0.2 0.7 0.3 0.6 0.5 0.1 0.4 0.3 0.4 0.5 0.5 0.3 0.5 0.4 0.2 0.1 0.6 0.3 0.4 1.3 0.4 0.4 0.4 0.2 0.5 0.2 0.4 0.3 0.3 0.2 0.2 0.3 0.0

0.2 0.5 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.1 1.2 0.1 0.2 0.4 0.8 0.7 0.8 0.2 0.7 0.1 0.1 0.3 0.1 1.3 0.3 4.8 2.3 0.1 0.3 0.0 1.6 3.5 0.2 0.7 0.2 1.1 0.1 0.3 0.1 0.1 1.0 0.5 0.2 4.1 1.7 1.6 0.1 0.2 0.6 0.3 0.9

Eu

* * *

* * * *

* * *

* *

722

*I N

664

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Skin (C43-44) - Male (Contd)

Carcinoma Squamous Basal cell 15.0 38.9 32.6 0.3 0.0 0.1 48.8 61.1 36.3 68.1 62.5 36.7 0.8 100.0 1.0 79.3 59.4 68.8 91.2 0.0 0.0 0.0 59.5 58.7 0.0 79.7 0.3 54.6 0.0 65.8 59.1 0.0 0.0 0.1 0.3 0.0 4.8 0.2 0.0 Other 0.5 0.2 0.3 0.3 0.3 0.2 0.4 0.7 0.8 0.9 0.1 0.1 0.5 1.6 0.3 0.8 0.3 0.8 1.0 0.5 0.4 0.4 0.4 0.4 0.0 0.5 0.3 0.4 0.0 0.4 0.4 0.1 1.1 0.8 0.6 2.4 2.0 0.8 0.9 0.6 0.7 0.4 0.5 2.0

Unspec. 1.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.2 0.4 0.3 0.1 0.1 0.0 0.1 0.1 0.1 0.2 0.2 0.1 0.3 0.1 0.1 0.3 0.1 0.0 0.0 0.0 0.5 0.1 -

Melanoma

Other

Unspec.

Number of cases MV 4875 8368 3440 70 145 365 213 32 1798 2705 2387 2391 1896 2125 10744 2390 361 842 1833 146 1079 3548 15706 970 816 10348 564 967 22022 891 34824 8958 15432 1300 6143 17514 8554 6638 1954 537 4434 3897 362 14 4437 630 5 15 20 32 514 Total 5162 8501 3447 76 152 367 214 34 1801 2706 2398 2396 1903 2126 10749 2392 361 842 1841 148 1080 3551 15716 972 816 10506 580 988 22353 894 36689 9389 15708 1312 6281 17624 8646 6703 1967 539 4468 3921 365 15 4451 631 5 15 20 32 515

Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White

4.9 6.5 7.4 0.4 0.0 14.6 17.4 13.2 17.9 15.7 11.3 11.0 31.1 22.7 21.4 18.0 20.4 33.3 15.3 15.8 13.2 15.7 14.0 19.6 9.2 12.9 27.7 17.1 4.1 0.9 11.7 5.2 0.0 -

3.8 6.4 9.0 5.0 3.4 4.9 3.9 3.3 5.2 4.3 6.5 6.6 6.4 4.0 11.9 18.5 11.5 18.6 12.8 12.4 11.8 16.6 10.0 9.4 8.9 8.8 6.9 6.8 6.9 9.8 10.7 6.2 6.1 6.9 7.5 8.4 38.5 55.8 31.0 30.8 27.3 44.5 32.4 3.1 34.8 13.6 0.3 1.0 2.4 2.2 41.1

0.1 0.2 0.2 0.6 0.6 0.4 0.6 0.5 0.3 0.3 0.8 0.6 0.2 0.3 0.2 0.1 0.4 0.3 0.6 0.4 0.4 0.6 0.2 0.1 0.2 0.1 0.2 0.2 0.0 0.3 0.2 0.3 0.5 0.1 0.0 0.2 0.1 0.2 0.5 0.4 0.5 0.8 0.1 0.5

0.8 0.4 0.4 0.0 0.0 0.0 0.2 0.0 0.2 0.1 0.3 0.0 0.2 0.3 0.3 0.2 0.0 0.1 0.0 0.0 5.1 0.1 0.1 2.8 0.1 0.1 0.2 0.1 0.1 -

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

665

723

Age-standardized (world) incidence rates (per 100,000) by histological type

Skin (C43-44) - Female

Carcinoma Squamous Basal cell 2.6 1.5 8.6 0.0 1.1 9.5 83.1 43.6 137.0 57.4 11.7 28.5 22.7 14.4 13.5 3.8 0.0 0.0 75.4 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Other 0.1 0.1 0.2 0.2 0.4 0.3 0.8 0.2 0.9 0.6 0.3 0.2 0.3 0.1 1.6 0.2 0.2 0.5 0.3 0.6 0.5 0.4 0.3 0.1 0.5 0.2 0.1 0.3 0.3 0.3 0.5 0.5 0.1 0.4 0.3 0.6 0.6 0.2 0.1 0.1 0.4 0.2 0.2 0.9 0.2 0.2 0.3 0.6 0.5 0.3 0.1 0.3 0.3 0.1 0.4 0.3 0.2 0.3 0.2 0.3 0.2 0.3 0.1 0.2 0.3 0.3 0.1 0.3 0.3 0.4 0.3 0.4 0.3 0.2 0.5 0.4 0.5

Unspec. 0.1 0.0 0.2 0.0 1.1 0.8 0.1 1.6 1.1 0.4 0.1 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.3 0.1 -

Melanoma

Other

Unspec.

Number of cases MV 107 134 111 33 109 166 2625 382 3233 22859 194 161 3101 1012 271 249 12460 1052 1432 4861 333 153 4 472 3719 81 353 1262 44 1099 124 1803 12486 2220 20 26 6 133 6 1865 2746 52 16 10 293 9 7 2167 178 112 829 10407 1828 1770 13 1689 109 14 83 6346 126 6082 2627 1009 45 941 93 2449 518 3457 73 3187 2004 1368 1886 1009 16 151 60 926 582 2934 Total 108 142 112 49 114 * * * *

Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

1.2 0.7 1.3 0.9 2.6 1.1 9.3 6.7 36.7 13.5 2.5 6.6 4.5 2.0 5.3 0.6 12.2 -

0.4 0.3 0.5 1.4 2.3 2.9 4.2 2.0 4.5 5.7 3.5 2.9 2.1 2.8 1.1 2.1 9.3 10.0 8.9 7.0 11.1 6.7 5.3 12.5 9.2 15.7 8.5 7.4 0.5 8.8 6.7 9.7 10.3 8.9 0.3 0.6 0.3 4.0 0.7 13.8 7.9 0.6 0.4 0.7 2.6 0.9 1.2 16.2 0.8 0.6 3.1 15.7 12.6 13.3 0.5 14.3 4.3 0.1 11.6 8.9 0.9 10.2 9.3 10.7 0.6 16.6 0.6 12.6 11.6 7.3 0.5 8.4 9.0 12.6 13.0 5.7 0.6 6.6 0.7 7.9 11.8 11.5

0.3 0.1 0.4 0.0 0.4 0.2 0.4 0.2 0.4 0.3 0.2 0.3 0.2 0.0 0.1 0.0 0.2 0.4 0.3 0.5 0.3 0.3 0.3 0.1 0.8 0.3 0.4 0.7 0.3 0.4 0.3 0.4 0.4 0.9 0.2 0.2 0.3 0.5 0.5 0.4 0.8 0.6 0.2 0.2 0.3 0.6 0.3 0.7 0.3 0.5 0.4 0.4 0.8 0.3 0.5 0.7 0.4 0.4 0.7 0.3 0.4 0.5 0.8 0.3 0.6 0.3 0.3 0.4 0.6 0.4 0.3 0.5 0.3 0.3 0.5 0.2 0.4 0.3 0.2 0.4

0.1 0.0 0.1 0.8 0.0 0.1 2.5 0.8 0.2 0.1 0.8 0.0 1.8 0.3 0.2 0.0 0.0 0.0 0.0 0.0 -

170 2653 387 3270 22892 201 162 3252 1030 272 249 * 12684 1053 1446 4879 333 153 4 475 3907 81 353 1284 44 1121 127 1821 12542 2232 20 26 6 134 6 1876 2747 52 16 10 293 9 7 2168 178 112 832 10454 1846 1774 13 1693 109 14 83 6408 127 6143 2660 1012 45 944 97 2478 519 3492 77 3218 2017 1376 1898 1017 16 153 60 934 612 2965

724

*I N

666

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Skin (C43-44) - Female (Contd)

Carcinoma Squamous Basal cell 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.8 3.5 0.3 0.1 0.7 13.4 0.3 0.7 0.3 0.1 0.4 0.2 1.8 2.0 0.5 0.9 0.3 2.2 1.1 2.4 0.4 0.5 1.0 1.0 1.9 1.0 1.8 1.2 Other 0.4 0.5 0.2 0.5 0.2 0.4 0.3 0.1 0.3 0.2 0.4 0.1 0.4 0.5 0.8 0.4 0.5 0.4 0.2 0.4 0.4 0.2 0.4 0.3 0.2 0.3 0.2 0.4 0.4 0.2 0.4 0.6 0.4 0.2 0.5 0.5 0.2 0.2 0.3 0.5 0.3 0.1 0.3 0.2 0.2 0.2 0.5 0.4 0.5 0.6 0.3 0.3 0.1 0.2 0.1 0.2 0.3 0.1 0.1 0.1 0.1 0.3 0.3 0.1 0.1 0.3 0.3 0.1 0.4 0.1 0.1 0.1 0.2 0.2 0.1 0.1 0.1 Unspec. 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0

Melanoma

Other

Unspec.

Number of cases MV 4099 1588 48 1512 68 3829 1378 21 1325 324 3313 44 3209 637 7 84 542 5058 155 4844 77044 1168 71774 3999 56 3601 859 1858 4666 57 4318 506 11122 146 10533 28441 298 356 1116 25311 1470 59 1362 4498 94 4087 855 381 3025 2096 709 1704 14 121 1609 16 13 420 69 520 118 8 215 33 184 63 37 2213 2155 40 143 67 269 346 606 457 162 2606 214 250 87 127 175 Total 4149 1596 50 1518 71 3874 1413 21 1360 329 3371 48 3261 644 7 85 548 5253 158 5034 78038 1192 72701 4060 58 3660 898 1866 4699 57 4345 508 11175 148 10582 28622 300 364 1121 25469 1499 61 1386 4628 95 4212 856 387 3045 2108 719 1733 14 132 1628 17 13 463 69 584 124 8 220 34 206 67 37 2360 2285 41 145 75 275 372 614 495 172 2772 227 252 94 131 182 * * * * *

America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.0 0.0 0.0 0.4 0.3 1.1 0.4 0.0 0.5 3.1 0.5 0.1 0.4 0.6 0.2 0.4 0.4 0.4 0.3 1.1 0.3 1.2 0.6 1.2 0.2 0.5 0.6 0.3 1.1 0.4 0.9 0.8

11.4 10.5 0.6 14.2 0.7 12.9 6.2 0.4 6.8 9.7 9.7 0.6 11.8 9.7 0.8 3.5 16.5 6.4 0.7 7.8 9.2 0.6 10.3 9.6 0.5 9.9 6.5 15.5 9.4 0.4 9.9 11.1 11.4 0.6 14.1 10.5 0.9 0.6 3.2 14.4 10.0 0.8 13.4 6.4 0.6 6.8 13.0 17.4 14.5 14.3 9.9 8.7 0.2 0.5 0.6 0.3 0.2 0.3 0.2 3.3 0.3 0.1 0.2 0.1 0.2 0.3 9.5 10.5 0.8 0.6 0.3 0.7 0.5 0.5 0.2 0.5 0.4 0.3 0.3 0.8 0.5 0.4

0.5 0.6 0.7 0.5 0.7 0.4 0.3 0.4 0.3 0.3 0.4 0.5 0.4 0.4 0.2 0.2 0.7 0.4 0.7 0.3 0.4 0.6 0.3 0.3 0.7 0.3 0.3 0.3 0.4 0.8 0.3 0.7 0.5 0.8 0.5 0.4 0.3 0.6 0.3 0.4 0.4 0.5 0.3 0.2 0.5 0.2 0.7 0.7 0.5 0.6 0.4 0.4 0.3 0.1 0.5 0.0 0.1 0.2 0.0 0.0 0.1 0.0 0.4 0.4 0.4 0.0 0.1 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2

0.0 0.0 0.0 0.1 0.1 0.3 1.0 0.2 0.1 0.0 0.0 0.1 1.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.1

* * * *

Cancer Incidence in Five Continents Vol. IX, IARC 2008

667

725

Age-standardized (world) incidence rates (per 100,000) by histological type

Skin (C43-44) - Female (Contd)

Carcinoma Squamous Basal cell 0.8 0.8 1.2 0.8 1.5 2.6 2.6 3.0 2.1 1.5 5.3 5.8 1.0 2.5 2.0 2.1 2.1 11.9 7.4 11.9 8.2 0.6 16.6 0.6 20.7 10.7 40.1 52.5 24.2 30.4 0.8 25.6 29.7 0.6 62.4 40.7 38.1 36.6 33.6 34.6 38.9 27.5 35.3 8.3 35.7 22.9 26.1 34.2 36.1 13.7 32.2 38.4 23.4 29.2 18.6 30.9 38.6 10.6 24.4 32.8 0.4 15.0 7.5 0.3 0.0 10.1 Other 0.2 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.2 0.4 0.4 0.4 0.0 0.0 0.1 0.2 0.2 0.3 0.0 0.2 0.2 0.6 0.1 0.3 0.3 0.1 0.2 0.2 0.4 0.3 0.5 0.4 0.2 0.7 0.3 0.4 0.3 0.5 0.2 0.2 0.5 0.6 0.3 0.4 0.3 0.3 0.2 0.4 0.0 0.3 0.2 0.2 0.4 0.5 0.1 0.3 0.3 0.3 0.0 0.3 0.1 0.3 0.2 Unspec. 0.0 0.0 0.0 0.2 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.3 0.0 0.1 0.1 0.1 0.1 0.1 0.6 0.1 0.4 0.6 0.9 0.3 0.3 0.9 0.4 0.2 0.1 0.3 0.4 0.1 0.4 0.4 0.1 0.3 0.1 0.1 0.0

Melanoma

Other

Unspec.

Number of cases MV 19 547 58 18 17 99 151 75 89 263 784 733 14 37 161 88 126 493 903 10413 702 318 11872 905 8102 7108 991 26983 17279 2397 431 165 180 302 252 319 505 204 120 114 226 4090 1482 4850 2637 257 12876 677 1683 1375 3200 1622 644 2634 1706 274 6916 822 513 1261 2892 998 922 564 458 2323 1627 1131 5147 2612 6122 705 4584 806 1217 486 1704 4230 Total 20 583 60 18 17 101 153 76 90 281 789 738 14 37 161 91 127 497 917 10575 709 324 12026 909 8143 7268 1034 27469 17771 2474 432 165 180 304 252 323 505 205 124 114 227 4313 1540 5132 2644 257 13593 681 1721 1378 3490 1713 646 2658 1706 309 6926 823 518 1269 2912 1049 925 571 464 2327 1758 1149 5162 2657 6222 723 4600 819 1259 486 1727 4452

Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.4 0.6 1.2 0.1 0.0 1.1 1.1 0.9 1.4 1.0 1.6 1.6 1.4 0.8 1.2 1.1 1.2 3.2 1.9 3.9 2.9 6.9 2.6 3.5 3.9 3.2 5.0 3.8 1.9 4.2 1.4 2.8 3.9 7.6 17.3 3.2 5.0 7.9 2.5 1.9 4.2 2.3 3.3 1.9 5.6 2.7 2.9 4.8 3.7 3.5 4.4 6.7 2.3 1.9 4.4 2.9 6.1 0.8 4.1 5.3 6.0 0.9 1.0 5.3 0.9

0.2 0.5 0.5 0.3 0.3 0.4 0.5 0.3 0.3 0.6 0.4 0.4 0.2 0.4 0.3 0.4 1.5 1.0 7.8 11.4 12.9 3.5 5.9 8.8 2.4 5.8 8.8 14.1 6.6 12.1 6.3 9.5 11.5 7.3 8.4 11.8 9.8 5.7 7.5 10.4 10.5 11.5 10.1 7.8 19.0 11.0 10.1 8.2 7.9 10.6 7.4 11.4 9.7 6.3 3.4 10.6 7.1 4.4 6.7 9.3 5.1 3.3 9.5 4.7 11.4 6.2 7.6 10.0 4.2 5.2 5.1 14.6 5.6 4.6 3.5 4.8 4.8

0.1 0.1 0.2 0.1 0.0 0.0 0.1 0.2 0.1 0.3 0.3 0.3 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.3 0.1 0.2 0.2 0.3 0.1 0.2 0.3 0.1 0.1 0.2 0.2 0.3 0.3 0.2 0.8 0.5 0.2 0.3 0.5 0.3 0.5 0.4 0.1 0.2 0.3 0.4 0.9 0.4 0.1 0.3 0.2 0.2 0.5 0.4 0.4 0.6 0.0 0.2 0.3 0.3 0.3 0.2 0.2 0.1 0.1

0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 1.1 0.0 0.2 0.3 0.6 0.6 0.7 0.1 0.5 0.0 0.0 0.2 0.2 0.9 0.0 3.7 1.6 0.1 0.3 1.4 2.6 0.0 0.2 0.6 0.1 1.2 0.1 0.4 0.1 0.0 0.7 0.4 0.1 4.0 1.9 0.7 0.0 0.3 0.4 0.2 0.7

Eu

* * *

* * * *

* * *

* *

726

*I N

668

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Skin (C43-44) - Female (Contd)

Carcinoma Squamous Basal cell 11.7 31.0 24.9 0.1 0.0 0.0 38.2 43.1 24.9 59.7 53.0 25.8 0.5 93.0 0.5 64.3 46.0 61.5 83.8 0.0 45.3 47.0 59.8 0.3 40.8 0.0 48.1 45.8 0.0 0.0 0.0 0.6 0.0 3.2 0.3 0.0 Other 0.3 0.2 0.3 0.4 0.2 0.4 0.1 0.3 0.6 0.5 0.7 0.4 0.0 0.4 0.9 0.5 0.2 0.4 0.7 0.6 0.4 0.4 0.4 0.3 0.2 0.4 0.2 0.3 0.3 0.3 0.0 0.5 0.5 0.4 1.4 1.2 0.2 0.6 0.4 0.3 0.3 0.3 0.3 0.5 Unspec. 1.0 0.1 0.2 0.2 0.0 0.1 0.0 0.4 0.1 0.0 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.6 0.1 0.0 0.0 0.0 0.2 0.1 0.0 -

Melanoma

Other

Unspec.

Number of cases MV 4344 9089 3819 71 269 507 282 34 1510 2153 1965 2074 1667 1585 9137 2572 368 863 1713 175 1132 3774 14233 821 743 8751 811 1344 21488 1202 30173 7660 13407 1598 5712 17393 6019 4905 1629 560 3979 2586 286 21 4272 398 8 9 14 28 292 Total 4614 9274 3830 71 272 509 287 35 1518 2155 1981 2079 1675 1589 9137 2585 369 864 1718 176 1135 3777 14243 824 743 8931 831 1364 21842 1213 31935 8125 13656 1613 5904 17501 6081 4961 1634 563 3996 2599 292 21 4288 399 8 9 14 28 293

Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White

2.8 3.4 3.9 0.1 6.2 8.0 5.4 6.4 7.2 4.1 5.8 18.6 13.1 15.5 9.4 11.3 19.9 7.0 6.7 6.4 6.3 6.2 8.8 3.7 5.1 12.9 7.7 1.9 0.3 3.7 2.0 0.0 -

3.6 6.3 8.7 4.8 5.8 6.6 4.8 2.0 6.6 4.8 7.0 7.5 8.7 4.2 12.1 19.0 13.2 15.4 12.7 14.3 16.5 19.6 12.9 12.9 12.6 9.8 9.4 9.1 8.9 12.6 11.9 7.1 7.5 8.2 10.2 10.1 26.5 41.1 25.7 32.4 23.4 31.5 26.0 4.7 31.4 8.3 0.9 1.0 1.6 1.4 26.3

0.1 0.1 0.1 1.0 0.7 0.4 0.7 0.2 0.4 0.4 0.7 0.6 0.2 0.3 0.2 0.3 0.2 0.2 0.2 0.8 0.3 0.5 0.2 0.1 0.2 0.0 0.2 0.1 0.3 0.0 0.2 0.2 0.4 0.5 0.4 0.0 0.3 0.2 0.2 0.6 0.6 0.2 0.3 0.1 1.0

0.6 0.5 0.4 0.1 0.0 0.2 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 2.6 0.0 0.2 0.0 0.0 0.0 -

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

669

727

Age-standardized (world) incidence rates (per 100,000) by histological type

Cervix uteri (C53)

Carcinoma Squamous Adeno 0.2 0.3 0.2 1.3 2.3 1.3 4.5 3.8 4.2 2.5 1.8 2.5 2.2 1.8 3.1 3.2 1.4 1.6 1.4 1.3 1.6 1.4 0.9 1.8 1.3 0.9 1.1 1.0 1.1 1.0 1.2 1.0 1.5 1.3 1.1 1.0 1.2 1.8 0.7 1.3 1.6 0.8 0.7 2.2 2.3 0.7 1.7 1.4 1.4 0.9 2.2 1.4 1.2 1.1 0.9 1.1 1.3 1.3 1.4 1.5 1.3 1.6 1.3 1.3 1.2 1.5 1.2 1.4 1.0 1.5 1.2 1.5 1.3 1.6 1.4 1.2 0.8 1.7 1.1 1.3 1.0 1.2

Other 0.1 0.8 0.6 0.6 0.2 0.3 0.7 0.4 0.2 0.1 0.6 0.4 0.7 0.2 0.4 0.4 0.5 0.2 0.4 0.4 0.2 0.3 0.2 0.4 0.2 0.3 0.5 0.4 0.4 0.6 0.7 0.3 0.4 0.7 0.4 0.1 1.0 1.1 0.7 0.4 0.6 0.5 0.4 0.8 0.4 0.3 0.4 0.7 0.4 0.2 0.3 0.4 0.5 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.2 0.3 0.4 0.3 0.4 0.4 0.4 0.3 0.3 0.4 0.3 0.4 0.3 0.4

Unspec. 0.7 0.1 1.3 13.2 3.1 1.7 1.2 4.3 1.6 1.3 2.2 0.4 0.6 1.8 0.9 0.2 0.2 0.1 0.3 0.2 0.1 0.2 0.1 0.3 0.3 0.4 0.3 0.3 0.3 0.2 0.2 0.1 0.3 0.2 0.2 0.2 0.2 0.2 0.1 0.1 0.3 0.3 0.3 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.5 0.2 0.8 0.9 0.6 0.5 0.6 0.4 0.3 0.4 0.7 0.2 0.4 0.3 0.2 0.3 0.6 0.3 0.3 0.3 0.3 0.4 0.6 0.2 0.5 0.3 0.1 0.1

Sarcoma

Other

Unspec.

Number of cases MV 218 107 72 384 593 132 1053 269 700 5161 200 1233 1477 595 203 479 5187 789 816 265 190 136 6 292 2451 30 212 1112 371 703 116 934 8009 1254 112 58 60 294 13 576 2749 259 64 91 1397 22 68 734 900 529 2967 3462 778 690 80 592 183 149 21 4672 831 3719 2046 639 244 350 648 1335 209 3308 753 2422 1379 641 1199 1226 147 125 506 700 273 1207 Total 229 109 72 649 818 * * * *

Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

10.0 1.5 6.6 24.1 29.8 11.4 24.4 27.2 24.1 13.7 16.7 19.8 13.7 16.1 9.9 37.3 4.7 6.0 4.1 5.0 5.0 5.7 6.1 6.7 4.4 5.0 5.4 5.7 8.1 4.9 4.6 4.3 5.3 3.9 4.9 1.7 3.1 7.3 2.6 3.1 6.8 6.3 4.0 5.5 11.2 2.9 7.3 4.3 4.4 5.5 9.6 4.0 4.1 3.9 6.2 3.7 7.3 9.3 1.7 6.0 9.2 5.7 5.7 4.9 6.3 4.0 7.2 5.2 3.9 6.1 10.5 5.3 5.2 4.5 6.9 6.8 9.3 4.3 9.9 5.5 4.7 3.6

0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1

0.0 0.1 0.1 0.2 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.1

0.6 0.1 0.2 19.1 1.2 0.1 6.4 5.2 0.5 3.0 1.9 2.7 2.2 1.4 1.4 1.9 0.2 0.0 0.0 0.0 0.1 0.3 0.0 0.1 0.3 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.2 0.1 0.1 0.2 0.4 0.2 0.1 0.0 0.1 0.0 0.2 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.2 0.1 0.4 0.1 0.2 0.1 0.0 0.0

139 1154 302 711 6028 216 1314 1655 637 220 498 * 5389 797 828 267 191 138 6 295 2623 30 214 1157 391 723 119 965 8109 1263 112 59 61 295 13 581 2769 262 64 91 1404 23 69 740 909 532 2990 3524 799 700 82 600 194 151 23 4771 854 3794 2098 647 247 353 662 1371 216 3401 775 2492 1410 651 1245 1244 151 126 513 711 278 1224

728

*I N

670

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Cervix uteri (C53) (Contd)

Carcinoma Squamous Adeno 1.3 1.3 0.9 1.4 0.9 1.4 1.3 0.8 1.4 1.2 1.4 1.4 1.4 1.3 1.6 0.9 1.7 1.3 1.3 1.3 1.3 1.1 1.4 1.1 0.8 1.2 1.4 1.1 1.3 0.9 1.3 1.1 1.3 0.9 1.3 1.4 1.4 1.0 2.0 1.3 1.4 1.0 1.6 1.3 1.1 1.3 1.1 1.1 1.2 1.1 1.5 1.4 0.6 0.5 1.6 0.2 0.2 0.8 0.6 0.7 0.6 1.1 0.8 0.9 0.5 0.8 0.9 0.3 1.0 0.9 1.5 1.0 1.5 0.8 1.2 1.4 1.3 1.7 1.2 2.2 1.7 Other 0.3 0.4 0.6 0.4 0.5 0.3 0.3 0.7 0.3 0.4 0.4 0.6 0.4 0.3 0.2 0.3 0.4 0.5 0.4 0.4 0.4 0.4 0.3 0.4 0.3 0.4 0.4 0.4 0.4 0.4 0.5 0.4 0.4 0.3 0.4 0.5 0.4 0.7 0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.3 0.6 0.3 0.3 0.3 0.2 0.1 0.1 0.4 0.0 0.1 0.1 0.3 0.1 0.1 0.2 0.2 0.2 0.1 0.2 0.6 0.7 0.2 0.7 0.2 0.3 0.4 0.5 0.4 0.6 0.2 0.6

Unspec. 0.3 0.4 0.7 0.3 0.5 0.3 0.2 0.3 0.2 0.4 0.5 0.7 0.4 0.3 0.3 0.3 0.3 0.5 1.0 0.4 0.3 0.5 0.3 0.3 0.2 0.3 0.3 0.1 0.3 0.5 0.3 0.2 0.3 0.6 0.2 0.3 0.2 0.5 0.4 0.3 0.3 0.3 0.2 0.3 0.3 0.3 0.3 0.0 0.2 0.3 0.6 0.7 0.6 0.6 0.2 0.1 0.0 0.4 0.1 0.7 0.1 0.2 0.1 4.6 0.2 0.2 0.2 0.1 0.0 0.2 0.1 0.1 0.4 0.0 0.2 0.1 0.2 0.1 0.9 0.1

Sarcoma

Other

Unspec.

Number of cases MV 2133 992 330 631 415 1640 1359 211 1120 196 2278 451 1715 374 24 143 191 4807 1157 3414 54030 8445 42321 2488 284 2128 860 709 2964 402 2448 214 5461 813 4004 17422 1383 2317 3685 9723 1088 390 673 5083 680 4232 308 149 1083 722 578 1211 38 265 2193 33 77 629 133 98 2253 80 2731 722 2965 1010 261 855 809 41 208 191 489 449 627 1713 298 16649 1693 1149 678 532 1305 Total 2193 1013 337 645 425 1690 1390 216 1146 206 2339 466 1759 394 27 150 201 4976 1199 3533 55469 8693 43436 2569 302 2191 919 719 3020 415 2487 215 5553 826 4075 17731 1395 2360 3732 9923 1113 399 688 5333 712 4439 311 153 1102 734 591 1247 38 298 2251 33 86 722 133 101 2550 93 3121 741 3653 1138 284 911 853 44 229 204 500 512 651 1963 313 17576 1812 1169 696 540 1375 * * * * *

America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

4.6 5.1 7.6 4.4 7.3 4.1 5.4 8.6 5.0 4.7 5.4 8.8 5.0 4.9 3.5 5.9 4.4 5.1 8.8 4.5 5.3 7.9 5.0 4.9 5.3 4.8 5.8 4.7 4.9 8.0 4.5 4.3 4.3 6.4 4.0 5.2 4.4 7.3 9.0 4.3 6.2 8.7 5.3 5.9 7.5 5.8 3.6 5.3 4.0 3.8 6.6 5.1 4.8 3.1 7.2 2.1 0.5 2.2 3.5 22.9 8.3 11.1 16.8 10.4 7.6 3.9 4.2 1.9 4.2 4.2 9.8 4.1 8.2 3.8 5.0 12.3 12.1 13.4 14.9 10.9 16.1

0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.3 0.2 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.2 0.1 0.1 0.3 0.1 0.4 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.3 0.3 0.0 0.1 0.1 0.1 0.1 0.2 0.1 0.2 3.0 2.1 0.0 3.4 1.5 1.9 0.8 3.6 17.3 0.8 0.1 0.1 0.7 0.5 0.0 0.5 0.7 0.3 1.0 1.2 0.3 1.8 0.2 1.2

* * * *

Cancer Incidence in Five Continents Vol. IX, IARC 2008

671

729

Age-standardized (world) incidence rates (per 100,000) by histological type

Cervix uteri (C53) (Contd)

Carcinoma Squamous Adeno 1.3 1.6 1.2 0.5 0.4 2.2 2.9 0.5 0.8 2.2 2.0 2.3 0.6 0.8 3.7 3.9 2.4 0.7 0.6 0.9 1.3 1.3 0.9 0.9 1.1 1.3 0.9 1.3 1.7 0.8 1.2 0.9 1.1 0.8 1.0 1.2 1.3 0.6 0.7 1.2 0.5 0.9 1.3 0.9 1.1 1.6 1.1 1.4 1.3 1.1 1.1 1.5 1.0 1.1 1.1 0.8 1.1 1.0 1.5 1.1 1.1 0.3 0.4 0.9 1.0 0.9 0.7 0.9 0.9 0.8 1.4 0.4 1.6 1.1 0.9 1.7 1.0 0.8 Other 0.6 0.5 0.5 0.3 0.2 0.5 0.1 0.1 0.7 0.6 0.6 0.2 1.1 0.5 0.5 0.4 0.5 0.2 0.2 0.3 0.2 0.1 0.2 0.3 0.5 0.2 0.2 0.4 0.3 0.3 0.2 0.1 0.1 0.2 0.1 0.1 0.8 0.1 0.2 0.1 0.2 0.2 0.3 0.4 0.4 0.2 0.3 0.3 0.1 0.2 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.4 0.0 0.3 0.2 0.4 0.1

Unspec. 0.2 0.0 0.1 0.7 0.7 0.3 0.3 4.5 0.4 0.4 0.2 0.3 0.2 0.1 0.1 0.1 0.9 0.3 0.5 0.1 0.2 1.2 0.2 1.8 0.3 0.2 0.3 0.2 0.1 0.2 0.2 0.3 0.0 0.1 0.3 0.1 0.2 1.1 0.1 0.8 0.6 0.1 0.5 0.1 0.2 0.5 0.3 0.3 0.2 0.3 0.3 0.0 0.2 0.1 0.7 0.2 0.2 0.2 0.6 0.5 0.3 0.2 0.3 0.9 0.2 0.2 1.1 0.4 0.5 0.5 0.6

Sarcoma

Other

Unspec.

Number of cases MV 137 4644 260 56 89 398 632 104 157 1770 1011 899 35 77 1265 511 543 126 451 2555 279 77 3974 415 1404 4851 1682 5272 1962 757 309 165 135 200 327 236 240 149 158 100 110 475 653 672 421 74 909 64 154 102 266 182 32 272 172 76 576 105 64 111 306 163 76 45 59 240 162 110 349 944 2235 53 1518 481 860 1260 998 1829 Total 141 5033 283 58 90 416 671 108 159 1966 1023 910 35 78 1297 546 573 136 467 2644 285 82 4015 419 1503 5148 1920 5414 2019 771 312 165 135 200 328 237 240 149 161 100 110 539 714 747 426 74 930 64 171 105 276 195 33 283 172 83 585 106 65 113 312 183 79 46 63 247 179 112 355 980 2400 54 1524 502 871 1356 1033 1874

Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

11.0 13.9 11.2 3.5 4.2 13.1 10.3 5.2 6.3 10.9 7.5 8.1 5.1 4.9 23.7 16.4 14.0 2.8 4.1 6.3 9.9 4.6 9.3 5.2 5.5 15.1 7.2 12.6 8.1 13.1 6.4 5.4 6.4 6.8 8.3 4.5 4.1 5.9 6.9 6.0 4.8 5.3 5.6 5.0 7.7 7.3 6.4 6.2 4.3 5.5 3.9 5.3 3.1 4.0 5.0 3.4 5.1 5.4 3.7 4.8 5.8 3.9 3.8 4.9 3.7 3.7 3.4 3.7 4.0 8.5 14.3 3.0 7.8 14.7 10.6 9.0 7.7 7.6

0.0 0.1 0.3 0.0 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.2 0.0 0.1 0.2 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0

0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.9 1.6 1.3 0.2 1.6 1.4 0.4 0.1 1.5 0.1 0.2 0.1 0.8 1.5 1.0 0.2 0.2 0.3 0.1 0.2 0.4 0.0 0.7 0.8 1.4 0.4 0.1 0.3 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.2 0.0 0.6 0.0 0.0 0.2 0.6 0.3 0.2 0.2 0.0 0.3 0.0 0.4 0.1 0.0 0.0 0.2 0.0 0.7 0.1 0.4 0.2 0.1 0.3 0.3 0.1 0.7 2.2 0.1 0.0 0.6 0.3 1.0 0.4 0.2

Eu

* * *

* * * *

* * *

* *

730

*I N

672

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Cervix uteri (C53) (Contd)

Carcinoma Squamous Adeno 1.7 1.4 1.7 1.4 1.0 1.0 1.4 1.6 1.7 1.1 0.9 1.2 0.7 0.5 1.6 1.2 1.4 0.7 0.9 1.1 1.0 0.5 1.1 0.7 1.5 1.3 1.5 1.4 1.4 1.0 1.5 1.2 1.4 1.6 1.3 1.4 1.1 1.3 1.1 1.0 1.2 1.3 1.0 1.2 1.2 1.5 1.5 2.1 1.6 1.2 1.7 Other 0.3 0.4 1.2 0.1 0.2 0.2 0.1 0.2 0.4 0.1 0.1 0.0 0.2 0.2 0.2 0.2 0.2 0.3 0.1 0.3 0.3 0.1 0.2 0.5 0.5 0.6 0.2 0.3 0.3 0.5 0.6 0.5 0.4 0.3 0.4 1.1 0.4 0.3 0.3 0.2 0.3 0.5 0.4 0.2 0.7 0.2 0.5

Unspec. 0.7 0.2 0.1 0.2 0.2 0.1 0.5 0.4 0.2 0.3 0.7 0.3 0.3 0.1 0.1 0.2 0.1 0.2 0.2 0.2 0.3 0.1 0.6 0.5 0.5 0.1 0.2 0.5 0.7 0.3 0.2 0.2 0.2 0.4 0.1 0.1 0.1 0.2 0.1 1.4 0.1 0.1 0.1 0.2 0.2 0.1 0.0

Sarcoma

Other

Unspec.

Number of cases MV 3782 2575 1004 50 316 322 407 36 127 165 234 86 128 137 2231 66 58 22 117 86 45 108 3368 175 191 522 678 1224 2018 398 1655 2603 1173 1403 389 1561 1304 744 259 107 815 401 49 72 979 298 16 56 56 47 75 Total 4149 2664 1007 52 323 324 415 36 132 167 244 86 129 141 2235 66 58 22 119 86 46 109 3380 177 191 536 728 1289 2081 407 1809 2842 1257 1448 405 1591 1338 805 261 108 837 412 49 73 993 298 16 56 56 47 75

Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White

20.6 12.6 11.3 3.4 5.6 3.6 6.7 3.2 4.3 4.1 4.6 2.7 6.3 3.2 5.1 2.6 4.9 2.8 5.5 5.0 3.0 3.7 4.3 3.6 3.8 3.7 5.7 6.3 6.7 2.8 5.1 3.6 4.9 5.6 5.3 6.7 4.3 4.9 2.8 5.5 3.4 4.8 3.7 12.1 6.1 5.3 2.8 6.1 6.8 3.7 5.3

0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 -

0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.3 0.1

2.1 0.4 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.3 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.1 0.0 0.0 0.3 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.4 0.1 -

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

673

731

Age-standardized (world) incidence rates (per 100,000) by histological type

Corpus uteri (C54)

Carcinoma Adeno Other 0.5 0.0 0.3 0.1 0.2 0.3 0.1 0.1 0.1 0.6 0.2 0.2 0.3 0.1 0.1 0.0 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.4 0.2 0.4 0.2 0.1 0.3 0.2 0.7 0.6 0.5 0.5 0.5 0.9 0.3 0.5 0.3 0.4 0.2 0.5 0.7 0.5 0.2 0.2 0.2 0.5 0.2 0.2 0.3 0.3 0.3 0.3 0.2 0.1 0.2 0.4 0.2 0.1 0.2 0.3 0.2 0.1 0.1 0.3 0.1 0.3 0.3

Unspec. 0.1 0.1 0.1 0.4 1.9 2.1 0.1 0.1 0.2 0.1 0.2 0.2 0.2 0.4 0.1 0.1 0.1 0.2 0.0 0.1 0.2 0.1 0.2 0.2 0.2 0.3 0.1 0.0 0.3 0.2 0.2 0.1 0.0 0.2 0.2 0.4 0.2 0.1 0.3 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.2 0.3 0.2 0.4 0.2 0.2 0.2 0.2 0.4 0.4 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.3 0.3 0.2 0.3 0.1 0.2 0.1 0.1 0.2 0.3 0.1 0.2 0.1

Sarcoma

Other

Unspec.

Number of cases MV 22 127 32 26 31 76 172 14 106 1703 44 231 486 111 87 47 12749 1560 2113 802 409 259 2 553 6409 84 558 2021 421 1557 235 2416 17842 3843 215 171 140 329 60 2707 4798 439 106 164 993 83 50 2816 1492 877 2394 12844 1955 2780 123 2616 335 208 108 10591 939 9503 3466 1147 271 848 729 2691 675 7966 745 6956 4120 2302 2420 1990 144 284 512 1458 1096 4897 Total 22 127 32 38 53 * * * *

Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.5 1.9 2.3 1.6 1.3 5.3 5.5 1.8 5.5 5.4 2.5 4.4 5.6 2.9 4.8 4.2 13.6 15.4 12.4 17.1 13.0 12.1 2.0 13.2 13.4 12.8 13.8 9.9 8.8 10.2 13.7 11.5 13.8 14.9 11.0 8.3 10.7 11.1 12.4 17.2 13.5 9.7 7.8 13.9 10.1 13.0 6.0 17.3 9.7 9.5 10.3 15.8 12.7 18.3 10.1 19.1 11.9 10.1 13.7 12.7 10.2 13.2 11.2 11.9 8.8 13.6 9.4 12.0 14.1 15.9 9.5 16.9 16.8 18.4 14.4 10.7 8.9 10.9 9.1 11.5 19.8 18.7

0.1 0.2 0.5 0.3 0.1 0.3 0.1 0.1 0.0 0.2 0.6 0.2 0.1 0.3 0.5 0.2 0.3 0.3 0.3 0.2 0.1 0.3 0.2 0.4 0.3 0.2 0.2 0.2 0.2 0.1 0.1 0.4 0.4 0.4 0.3 0.5 0.2 0.3 0.5 0.5 0.8 0.3 0.6 0.5 1.0 0.6 0.5 0.4 0.5 0.5 0.4 0.3 0.3 0.5 0.3 0.6 0.5 0.7 0.3 0.8 0.3 0.3 0.4 0.6 0.3 0.5 0.3 0.3 0.3 0.6 0.3 0.4 0.3 0.2 0.3 0.5 0.3 0.5 0.3 0.3 0.3

0.5 0.4 0.5 0.1 0.4 0.3 0.4 0.8 0.6 0.3 0.2 0.3 0.9 0.8 0.7 1.1 0.7 0.6 1.1 0.9 1.5 0.6 1.0 1.9 0.7 1.2 0.7 1.0 0.9 1.7 0.5 0.8 0.8 0.1 1.0 1.2 2.2 0.3 0.9 1.1 0.6 0.5 1.1 0.7 1.9 0.9 0.9 0.8 1.0 1.9 1.0 2.1 2.1 2.2 0.9 2.0 0.8 1.0 1.2 1.8 0.9 1.6 0.8 0.7 1.0 1.7 0.9 0.9 1.1 0.9 1.0 1.2 0.9 1.7 0.7 1.2 1.0

0.0 0.1 1.1 0.2 0.1 1.1 0.1 1.1 0.3 0.3 0.8 0.4 0.2 0.4 0.0 0.0 0.1 0.0 0.1 0.8 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.1 0.1 0.2 0.3 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.1

87 185 14 110 2025 48 247 548 125 91 47 * 13240 1569 2129 808 410 260 2 561 6857 84 560 2047 429 1574 235 2436 17933 3857 215 171 141 330 60 2719 4814 440 106 165 995 84 50 2827 1495 879 2403 12921 1992 2793 124 2628 345 215 110 10691 951 9590 3500 1159 276 855 739 2715 686 8021 756 6999 4140 2326 2441 2012 145 286 521 1471 1115 4929

732

674

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Corpus uteri (C54) (Contd)

Carcinoma Adeno Other 0.3 0.4 0.5 0.4 0.5 0.3 0.2 0.2 0.2 0.1 0.3 0.3 0.3 0.3 0.3 0.3 0.5 0.6 0.5 0.3 0.4 0.3 0.2 0.2 0.2 0.2 0.1 0.3 0.5 0.3 0.4 0.3 0.4 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.4 0.2 0.4 0.6 0.4 0.1 0.2 0.2 0.2 0.2 0.2 0.1 0.0 0.0 0.1 0.6 0.1 0.1 0.3 0.2 0.2 0.2 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 Unspec. 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.3 0.2 0.5 0.2 0.3 0.2 0.3 0.2 0.4 0.4 0.6 0.3 0.3 0.3 0.2 0.3 0.4 0.3 0.3 0.1 0.3 0.3 0.2 0.2 0.3 0.3 0.2 0.2 0.2 0.3 0.2 0.2 0.1 0.2 0.1 0.2 0.3 0.2 0.1 0.1 0.3 0.4 0.3 0.2 0.6 0.8 0.2 0.1 0.0 1.2 0.1 0.2 0.1 0.1 1.2 0.1 0.4 0.4 0.2 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.0

Sarcoma

Other

Unspec.

Number of cases MV 6854 2831 481 2319 606 6125 3800 264 3497 545 6738 561 6001 848 50 210 572 14037 1524 12130 138265 10512 122663 8299 510 7537 1662 2219 11282 569 10496 820 16946 1145 14401 43352 2410 3009 3178 34247 2024 513 1470 8380 756 7424 986 505 3753 2592 1504 3723 33 324 1816 12 62 1271 358 281 147 10 526 84 545 107 81 2292 2141 138 192 144 305 531 451 1121 302 3069 270 190 111 73 183 Total 6898 2846 485 2330 611 6164 3828 268 3521 560 6790 575 6039 864 50 215 582 14221 1549 12287 139510 10674 123708 8369 523 7592 1706 2233 11360 578 10565 823 17062 1156 14502 43641 2417 3047 3196 34472 2045 519 1484 8506 775 7526 990 511 3778 2608 1516 3771 33 370 1848 14 70 1358 359 282 171 10 547 90 623 117 82 2363 2187 139 202 145 312 588 463 1263 316 3157 274 190 116 77 188 * * * * *

America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

16.9 16.6 11.5 18.3 11.3 17.6 15.7 10.8 16.3 13.7 18.4 11.5 19.9 11.7 9.2 9.2 13.4 16.8 11.7 18.1 14.9 9.8 15.6 17.4 9.7 17.9 10.9 15.6 20.0 10.0 20.9 17.7 15.9 10.3 16.9 14.8 10.2 9.8 10.5 16.5 11.5 10.5 11.9 11.0 8.6 11.3 14.9 19.8 16.2 16.4 18.0 17.2 4.0 4.7 7.5 0.8 1.0 9.0 10.1 1.4 0.5 2.3 1.7 1.7 2.3 11.0 11.2 8.1 4.3 3.3 6.5 5.0 6.1 2.6 4.8 2.2 1.9 2.0 2.4 1.7 2.5

0.3 0.4 0.5 0.3 0.4 0.3 0.3 0.2 0.3 0.6 0.4 0.7 0.4 0.3 0.5 0.4 0.3 0.4 0.6 0.4 0.3 0.5 0.3 0.3 0.7 0.3 0.2 0.3 0.5 0.7 0.4 0.4 0.4 0.5 0.4 0.4 0.4 0.6 0.4 0.3 0.3 0.5 0.2 0.2 0.4 0.2 0.5 0.2 0.4 0.5 0.5 0.2 0.2 0.2 0.2 0.1 0.0 0.1 0.4 0.0 0.1 0.0 0.0 0.0 0.4 0.4 0.3 0.2 0.0 0.3 0.0 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1

1.0 1.2 2.0 1.1 1.8 0.9 1.1 2.3 1.0 0.9 1.2 1.7 1.1 0.7 0.9 0.5 0.8 1.2 2.2 1.1 1.0 1.8 0.9 0.8 1.2 0.8 0.6 0.8 1.2 2.0 1.1 0.7 1.1 1.9 1.0 1.0 0.7 1.8 0.9 1.0 1.0 2.1 0.6 0.8 1.6 0.7 0.9 1.0 0.9 0.9 0.8 0.9 0.5 0.2 0.6 0.1 0.4 0.5 0.0 0.5 0.2 0.0 0.1 0.3 0.9 0.9 0.4 0.2 0.3 0.2 0.2 0.4 0.1 0.3 0.3 0.2 0.4 0.5 0.1 0.2

0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.3 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.3 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.3 0.2 2.8 4.9 0.0 0.3 0.1 0.2 0.5 1.9 0.0 0.2 0.1 0.5 0.2 0.0 0.4 0.4 0.2 0.1 0.1 0.0 0.3 0.1 0.1

* * * *

Cancer Incidence in Five Continents Vol. IX, IARC 2008

675

733

Age-standardized (world) incidence rates (per 100,000) by histological type

Corpus uteri (C54) (Contd)

Carcinoma Adeno Other 0.1 0.1 0.2 0.3 0.2 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.2 0.0 0.1 1.6 0.2 0.1 0.2 0.1 0.3 0.1 0.1 0.0 0.2 0.4 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.3 0.1 0.2 0.1 0.1 0.6 0.1 0.0 0.9 0.2 0.4 0.1 0.1 0.2 0.4 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.3 0.6 0.1 0.0 0.2 0.1 0.1 0.1 Unspec. 0.1 0.1 0.1 0.2 0.1 0.1 0.8 0.1 0.1 0.1 0.0 0.1 0.1 0.6 0.1 0.5 0.1 0.1 0.9 0.3 0.9 0.2 0.1 0.3 0.1 0.1 0.1 0.2 0.2 0.0 0.1 0.1 0.3 0.1 0.7 0.1 0.6 0.5 0.1 0.3 0.2 0.1 0.2 0.0 0.4 0.0 0.1 0.5 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.3 0.2 0.2 0.1 0.3 0.4 0.1 0.2 0.5 0.0 0.1 0.1 0.2

Sarcoma

Other

Unspec.

Number of cases MV 23 950 45 42 29 127 115 13 129 794 859 728 45 86 138 54 89 206 546 4698 369 196 5649 915 2762 5198 2329 8058 2975 923 559 274 228 390 436 438 401 205 289 197 230 559 1489 1347 804 120 1177 143 344 273 790 334 98 683 486 142 1154 335 159 296 622 323 253 114 184 600 521 304 899 1806 2322 250 2731 462 996 859 1218 2998 Total 24 972 49 42 29 129 118 14 130 876 867 734 46 87 140 73 90 215 548 4778 371 202 5719 917 2892 5420 2582 8224 3079 939 563 276 232 393 442 446 401 205 295 200 235 620 1544 1407 809 122 1219 144 361 276 820 349 105 701 492 155 1182 350 164 307 650 353 256 115 187 614 571 315 919 1856 2424 252 2760 485 1012 874 1246 3184

Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

2.3 2.7 1.7 2.8 3.4 5.0 2.3 0.4 5.6 7.7 7.8 8.0 6.5 6.8 3.0 2.1 2.4 5.7 5.5 10.6 10.6 11.4 11.0 10.4 11.0 13.5 9.2 16.2 11.2 12.3 12.2 8.1 9.3 12.1 8.6 9.0 7.2 7.6 9.9 9.8 7.1 5.5 11.5 9.8 11.9 11.3 8.1 11.9 9.1 12.4 11.3 8.5 9.5 9.8 14.2 6.5 9.5 13.6 10.9 11.6 10.5 7.9 10.5 12.9 11.4 9.8 11.1 10.7 10.0 14.0 13.5 15.3 12.6 12.8 11.2 5.9 7.9 12.0

0.1 0.1 0.1 0.1 0.1 0.1 0.4 0.1 0.4 0.4 0.6 0.5 0.3 0.0 0.1 0.3 0.2 0.4 0.9 0.9 0.7 0.2 0.2 0.3 0.4 0.4 0.6 0.9 0.2 0.1 0.5 0.3 0.6 0.4 0.2 0.4 0.2 0.2 0.4 0.1 0.2 0.1 0.3 0.3 0.1 0.6 0.3 0.4 0.4 0.4 0.5 0.8 0.0 0.2 0.4 0.1 0.5 0.4 0.4 0.9 0.7 0.6 0.4 0.6 0.5 0.3 1.0 0.4 0.2 0.5 0.5 0.4 0.4 0.4 0.6

0.1 0.3 0.1 0.5 0.6 0.1 0.1 0.2 0.4 0.5 0.8 0.8 0.5 1.1 0.2 0.2 0.3 0.5 0.5 0.5 1.0 1.3 0.4 0.8 0.6 0.5 0.3 0.6 0.4 0.7 0.6 0.6 0.3 0.4 0.5 0.5 0.4 0.5 0.8 0.3 0.7 0.2 0.4 0.4 0.4 0.8 0.5 0.2 1.3 0.4 1.4 0.7 0.3 0.5 0.7 0.3 0.5 0.4 0.8 0.7 0.6 0.2 0.7 0.4 1.2 0.7 0.1 0.8 0.8 0.3 0.3 0.7 0.8 0.4 0.4 0.4 0.6 0.4

0.1 0.1 0.2 0.3 0.2 0.7 0.1 0.1 0.2 0.1 0.1 0.7 0.1 0.3 0.0 0.2 0.0 0.4 0.4 0.0 0.2 0.5 1.2 0.3 0.1 0.3 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.3 0.0 0.3 0.1 0.1 0.2 0.0 0.9 0.1 0.3 0.3 0.4 0.2 0.2 0.6 0.3 0.3 0.3 0.4 0.5 0.8 0.1 0.0 0.3 0.2 0.9 0.2 0.2 0.5 1.2 0.1 0.1 0.5 0.4 0.1 0.2 0.6

* * *

* * * *

* * *

734

676

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Corpus uteri (C54) (Contd)

Carcinoma Adeno Other 0.9 0.1 0.1 0.1 0.1 0.1 0.4 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.2 0.1 0.1 0.0 0.2 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.4 0.1 0.3 0.1 0.3 0.3 0.2 0.5 0.4 0.1 Unspec. 0.2 0.2 0.1 0.1 0.1 0.0 0.0 0.5 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.3 0.1 0.2 0.0 0.0 0.0 0.0 0.3 0.4 0.4 0.2 0.3 0.3 0.6 0.6 0.4 0.3 0.2 0.2 0.1 0.1 0.1 0.2 0.2 0.5 0.3 0.1 0.5 0.4 0.4 1.3 0.2 0.5

Sarcoma

Other

Unspec.

Number of cases MV 2184 3310 1399 127 566 876 574 111 307 440 511 340 257 436 6402 228 108 140 258 160 148 344 7576 487 504 1469 1021 1768 2705 1082 3307 5406 2279 2569 604 2212 2210 1394 731 160 2017 574 80 57 1446 803 46 111 158 214 207 Total 2349 3409 1402 141 575 901 597 115 314 448 522 347 269 442 6404 228 108 142 262 160 150 346 7601 487 507 1522 1087 1843 2785 1114 3646 5776 2381 2635 618 2291 2237 1418 751 164 2052 593 81 58 1473 806 46 111 158 216 208

Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White

9.5 15.3 15.4 8.9 9.3 10.2 10.2 10.6 11.8 12.3 10.6 12.5 10.9 9.7 14.4 10.2 9.9 15.4 10.8 8.9 11.9 11.2 10.2 10.8 11.5 11.0 8.7 8.8 8.6 9.2 9.1 8.1 9.4 10.0 8.2 8.8 8.2 9.9 11.2 7.4 9.9 7.9 7.2 10.5 9.4 16.7 10.5 14.2 24.1 17.4 17.6

0.6 0.4 0.1 0.1 0.3 0.2 0.2 0.2 0.6 0.9 0.5 0.4 0.5 0.0 0.4 0.0 0.5 0.3 0.1 0.5 0.3 0.3 0.5 0.2 0.2 0.2 0.0 0.1 0.2 0.3 0.1 0.2 0.4 0.1 0.2 0.4 0.4 0.5 0.3 0.2 0.2 0.6 0.4 0.4 0.9 0.5 0.5 0.5 0.2

0.3 0.7 0.5 0.9 0.5 0.7 0.7 0.2 0.6 0.4 0.4 1.2 0.8 0.3 0.1 0.4 0.5 0.7 0.7 0.5 0.7 0.7 0.6 0.7 0.5 0.6 0.6 0.6 0.4 0.6 0.6 0.6 0.6 0.6 0.7 0.6 0.6 0.8 0.5 0.6 0.6 0.6 0.9 1.0 0.8 1.1 1.0 1.5 1.6 1.1 1.0

0.6 0.3 0.1 0.5 0.1 0.1 0.3 0.2 0.2 0.1 0.1 0.1 0.4 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.3 0.1 0.0 0.1 0.0 0.0

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

677

735

Age-standardized (world) incidence rates (per 100,000) by histological type

Ovary (C56)

Carcinoma Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

Serous Mucin. Endom. Clear Adeno. Oth. Unsp. stromal 0.6 1.2 1.5 0.6 2.2 1.6 1.0 0.8 1.8 1.7 2.4 1.4 1.1 0.7 1.3 3.5 3.5 3.8 3.1 4.3 3.3 1.4 2.9 3.5 3.2 3.1 3.3 2.1 3.7 2.8 3.2 3.8 4.0 2.2 1.6 1.9 3.5 2.0 4.9 3.6 1.9 2.3 3.2 2.9 3.3 2.4 4.7 2.2 2.0 3.0 4.5 4.2 4.0 0.9 4.3 3.0 3.0 3.1 3.7 1.9 4.0 3.5 3.9 2.5 4.5 1.9 4.0 3.4 3.7 1.8 4.1 3.6 4.2 3.2 2.7 1.6 2.9 1.9 3.1 4.4 4.4 0.5 0.7 0.3 0.6 0.5 0.9 0.2 0.6 0.8 0.4 0.9 0.7 0.4 0.5 0.6 0.7 0.5 0.4 1.0 0.6 1.0 1.1 0.7 0.5 0.6 0.6 0.3 0.6 0.6 0.7 0.8 0.8 0.9 0.5 1.0 0.6 1.1 0.8 0.8 0.6 1.1 1.2 0.7 0.2 1.1 0.8 0.8 0.7 0.7 0.8 0.8 0.6 0.1 0.7 0.6 0.3 1.0 0.8 0.5 0.8 0.6 0.6 0.5 0.6 0.5 0.6 0.6 0.8 0.4 0.9 0.8 0.9 0.8 0.7 0.3 0.7 0.6 0.8 0.5 0.8 0.3 0.3 0.2 0.3 1.2 0.1 0.3 2.1 2.2 0.8 0.4 0.4 0.3 0.4 1.0 1.3 0.9 1.2 1.1 0.8 1.3 1.2 1.0 1.4 0.9 1.6 0.7 1.9 1.3 1.1 1.2 1.1 0.2 1.5 1.0 1.0 1.4 1.2 1.3 0.5 1.1 1.6 1.1 2.2 0.6 1.6 1.1 0.4 1.1 1.4 1.3 1.4 0.4 1.5 1.0 0.4 1.4 0.9 0.4 0.9 1.0 1.2 0.7 1.4 0.5 1.1 1.2 1.2 0.6 1.3 1.2 1.3 1.2 0.8 0.8 1.1 0.5 1.0 1.1 1.5 0.0 0.1 0.3 0.1 0.5 0.2 0.2 0.1 0.3 0.4 0.6 0.6 0.7 0.7 0.3 0.4 0.5 0.6 0.5 0.6 0.2 0.0 0.3 0.2 0.4 0.5 0.6 0.2 0.9 0.9 0.4 0.6 0.6 0.5 0.2 0.9 0.7 0.5 2.0 0.6 0.7 0.2 0.3 0.5 0.5 0.6 0.1 0.7 0.5 0.3 0.7 0.3 0.1 0.4 0.3 0.4 0.1 0.5 0.1 0.4 0.5 0.5 0.1 0.5 0.5 0.4 0.4 0.2 0.1 0.2 0.1 0.2 0.5 0.7 0.6 0.6 0.6 2.6 0.6 1.0 2.1 1.9 3.0 1.9 0.6 0.8 0.6 1.6 1.4 1.5 1.4 1.0 1.1 1.4 1.2 0.6 1.2 1.5 1.7 0.5 1.3 1.8 1.4 1.9 1.5 1.6 1.5 1.4 1.4 1.1 0.7 0.9 1.1 1.6 1.3 1.1 0.8 0.5 1.5 1.0 0.9 1.4 0.9 1.3 1.5 1.6 1.4 1.4 1.5 1.4 1.3 1.8 0.3 2.0 1.6 2.0 1.9 2.1 2.3 2.0 1.8 1.9 1.5 1.7 2.0 1.6 1.8 1.3 1.8 2.1 2.5 3.0 1.9 2.2 1.3 1.2 0.3 0.1 0.1 0.6 0.1 0.8 0.6 0.8 0.4 0.6 0.4 0.3 0.1 0.6 0.3 1.1 0.2 0.1 0.2 0.3 0.2 0.0 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.3 0.4 0.3 0.0 0.5 0.2 0.3 0.7 0.4 0.6 0.4 0.7 0.5 0.4 0.6 0.3 0.8 0.4 0.2 0.4 0.5 0.3 0.3 0.2 0.3 0.7 0.5 1.4 0.3 0.4 0.3 0.3 0.3 0.2 0.3 0.2 0.3 0.5 0.3 0.2 0.3 0.2 0.3 0.4 0.5 0.3 0.5 0.4 0.5 0.1 0.4 0.5 0.4 1.8 3.0 0.7 0.4 0.3 0.7 0.5 0.6 0.3 0.3 0.7 0.2 0.3 0.3 0.5 0.6 0.4 0.2 0.2 0.3 0.1 0.3 0.5 0.5 0.5 0.7 0.5 0.6 0.6 0.5 0.2 0.6 0.6 0.1 0.7 0.5 0.7 0.5 0.4 0.5 0.2 0.5 0.4 0.6 0.5 0.6 0.5 0.6 0.5 0.6 0.4 0.3 0.3 0.8 0.7 0.9 0.7 0.7 0.7 0.7 0.8 0.7 0.7 0.5 0.5 0.5 0.5 0.5 0.6 0.6 0.7 0.4 0.7 0.5 0.4 0.3 0.1 0.3 0.3 0.6 0.0 0.1 0.1 0.1 0.6 0.2 0.1 0.3 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.4 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.3 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.3 0.2 0.2 0.3 0.1 0.2 0.1 0.2 0.1 0.2 0.0 0.3 0.1 0.1 0.2 0.3 0.2 0.2 0.1 0.2 0.2 0.4 0.4 0.2 0.2 0.1 0.1

sex cord Germ Other Unsp. cell 0.3 0.1 0.3 0.4 0.3 0.4 0.2 0.1 0.4 0.5 0.4 0.5 0.3 0.2 0.4 0.4 0.4 0.3 0.5 0.6 0.3 0.4 0.3 1.1 0.3 0.3 0.4 0.3 0.3 0.2 0.4 0.6 0.7 1.0 0.4 0.8 0.4 0.5 0.4 0.6 0.1 0.5 0.2 0.4 0.5 0.5 0.4 0.5 0.4 0.3 0.3 0.5 0.2 0.2 0.3 0.1 0.4 0.4 0.4 0.2 0.2 0.3 0.1 0.3 0.2 0.3 0.4 0.5 0.4 0.3 0.5 0.3 0.4 0.3 0.2 0.4 0.4 0.5 0.3

Number of cases MV 49 256 33 56 66 73 282 40 120 2379 69 310 357 171 65 67 7084 754 1258 382 255 128 4 308 3654 43 298 1528 227 1283 122 1566 10617 2158 111 128 80 218 31 1472 2812 194 99 81 710 52 40 1550 960 433 1693 7450 1349 1312 42 1245 170 104 55 6765 441 6245 2313 797 185 587 407 1871 401 4195 362 3688 2063 1158 1354 1311 95 221 285 1021 489 2445 Total 53 290 34 114 122 * * * *

0.2 0.1 0.2 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.3 0.2 0.2 0.3 0.3 0.2 0.3 0.3 0.4 0.3 0.2 0.2 0.2 0.1 0.2 0.3 0.3 0.5 0.5 0.2 0.3 0.8 0.3 0.3 0.1 0.1 0.1 0.3 0.2 0.4 0.2 0.2 0.3 0.3 0.3 0.3 0.3 0.3 0.5 0.6 0.2 0.3 0.3 0.3 0.2 0.3 0.3 0.2 0.2 0.2 0.2 0.3 0.2 0.3 0.2 0.3 0.3 0.2 0.5 0.3 0.2 0.2 0.3 0.4

0.1 0.8 4.0 1.7 0.9 3.3 1.6 0.6 2.9 1.2 2.8 1.7 1.2 0.7 0.1 0.9 0.2 0.2 0.3 0.3 0.3 0.5 1.5 0.2 0.3 0.5 0.6 0.5 0.6 0.4 0.2 0.1 0.2 0.0 0.1 0.0 0.1 0.2 0.3 0.1 0.2 0.2 0.2 0.1 0.3 0.2 0.2 0.5 0.2 0.2 0.7 0.7 0.8 0.5 0.7 0.5 0.5 0.3 0.5 0.2 0.6 0.5 0.4 0.3 0.4 0.3 0.2 0.4 0.5 0.4 0.4 0.3 0.5 0.3 0.3 0.4

97 331 52 126 3197 81 426 483 207 70 68 * 8326 815 1365 428 283 137 4 342 4580 46 326 1721 270 1431 129 1702 11298 2275 121 130 83 226 31 1562 2961 216 104 86 739 52 40 1633 996 478 1758 7981 1467 1412 45 1340 193 123 59 7411 510 6817 2573 843 206 612 477 2061 440 4556 417 3987 2204 1275 1516 1438 106 234 322 1111 538 2656

736

*I N

678

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Ovary (C56) (Contd)

Carcinoma

Serous Mucin. Endom. Clear Adeno. Oth. Unsp. stromal America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008 4.0 3.8 2.1 4.3 2.2 4.3 3.5 2.5 3.6 5.4 4.1 2.1 4.5 3.6 2.9 2.9 4.2 4.3 2.5 4.7 3.8 2.1 4.1 3.5 2.1 3.6 3.5 4.3 4.1 2.1 4.3 4.6 4.1 2.2 4.5 3.8 2.3 2.0 3.0 4.3 3.6 2.3 4.0 3.2 2.1 3.4 3.9 3.6 5.0 5.2 3.7 4.2 1.1 1.2 0.7 0.6 0.2 0.6 3.0 0.5 1.1 1.0 0.2 0.6 1.5 4.0 4.3 1.2 1.8 2.6 2.2 1.2 1.6 1.2 1.5 1.4 1.5 1.4 1.6 1.4 1.5 0.7 0.7 0.6 0.8 0.5 0.8 0.7 0.5 0.7 0.8 1.0 0.8 1.0 0.7 1.0 0.7 0.6 0.8 0.6 0.8 0.7 0.5 0.8 0.7 0.5 0.7 0.6 0.5 0.9 0.6 0.9 0.6 0.7 0.6 0.7 0.8 0.7 0.6 0.7 0.8 0.7 0.5 0.7 0.6 0.5 0.6 0.7 0.7 0.6 0.7 0.7 0.8 0.5 0.4 1.0 0.1 0.8 0.7 0.2 0.9 0.5 0.2 0.4 0.8 0.5 0.5 0.1 0.9 0.9 1.5 0.8 0.9 0.6 0.6 0.7 0.8 0.8 0.3 0.9 0.9 1.2 1.3 0.5 1.6 0.6 1.3 1.4 0.4 1.5 1.2 1.4 0.6 1.6 0.9 0.7 1.1 0.8 1.2 0.7 1.3 1.2 0.5 1.3 1.1 0.4 1.2 1.1 1.3 1.4 0.5 1.5 1.3 1.2 0.5 1.3 1.2 1.1 0.5 1.0 1.4 0.9 0.4 1.1 0.9 0.6 0.9 1.5 1.4 1.3 1.3 1.4 1.4 0.9 0.3 0.4 0.1 0.2 0.1 0.8 0.1 0.1 0.3 0.0 0.1 0.7 1.2 1.3 0.3 0.7 0.8 0.7 0.7 0.9 0.4 0.6 0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.4 0.1 0.6 0.2 0.5 0.4 0.2 0.5 0.4 0.5 0.2 0.5 0.4 0.3 0.3 0.4 0.5 0.2 0.6 0.4 0.1 0.5 0.4 0.0 0.5 0.3 0.5 0.6 0.2 0.6 0.6 0.5 0.1 0.6 0.5 0.6 0.2 0.3 0.5 0.3 0.1 0.4 0.3 0.1 0.3 0.6 0.8 0.5 0.5 0.3 0.6 0.1 0.0 0.3 0.1 0.1 0.3 0.1 0.0 0.0 0.0 0.2 0.2 0.2 0.0 0.7 0.4 1.2 1.2 0.8 0.5 0.7 0.2 0.2 0.3 0.2 0.1 0.3 1.4 1.4 1.4 1.5 1.4 1.4 1.5 1.0 1.5 1.4 2.1 1.6 2.2 1.4 2.9 1.1 1.4 1.6 1.3 1.6 1.6 1.4 1.6 1.6 1.2 1.7 1.6 1.4 1.5 0.8 1.6 1.1 1.4 1.6 1.5 1.6 0.9 1.6 1.5 1.7 1.3 1.2 1.3 1.4 1.2 1.4 1.0 1.3 1.6 1.5 1.6 1.5 2.8 1.1 0.2 1.5 0.4 0.6 1.6 1.8 1.6 2.3 4.2 2.0 0.8 1.4 1.4 0.8 0.7 0.3 0.8 0.9 0.7 0.6 0.9 0.4 0.5 0.4 0.7 0.6 0.4 0.3 0.4 0.2 0.5 0.3 0.4 0.3 0.1 0.3 0.3 0.4 0.4 0.4 0.4 0.5 0.5 0.4 0.4 0.3 0.4 0.3 0.3 0.4 0.2 0.1 0.2 0.3 0.2 0.4 0.3 0.4 0.2 0.3 0.2 0.4 0.4 0.4 0.3 0.4 0.4 0.2 0.1 0.3 0.4 0.4 0.4 0.3 0.1 0.3 0.3 0.6 0.3 0.1 0.1 0.1 0.1 0.1 0.2 0.5 0.2 0.1 0.6 0.4 0.4 0.1 0.2 0.2 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.5 0.8 0.8 0.8 0.7 0.5 0.3 0.2 0.3 0.8 0.6 0.6 0.6 0.6 1.1 0.5 0.7 0.8 0.9 0.8 0.6 0.6 0.6 0.6 0.3 0.6 0.5 0.6 0.6 0.7 0.6 0.5 0.7 0.7 0.7 0.6 0.4 0.7 0.5 0.6 0.4 0.6 0.4 0.5 0.3 0.5 0.5 0.2 0.8 0.8 0.8 0.5 0.9 1.4 0.0 0.0 0.2 0.8 0.1 0.2 0.1 3.7 0.1 0.7 0.7 0.1 0.4 0.2 0.8 0.0 0.1 0.1 0.2 0.2 0.1 0.4 0.1 0.3 0.3 0.6 0.3 0.5 0.2 0.2 0.3 0.2 0.1 0.2 0.5 0.2 0.1 0.3 0.1 0.0 0.2 0.4 0.2 0.2 0.3 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.3 0.2 0.1 0.2 0.4 0.1 0.2 0.1 0.3 0.2 0.1 0.2 0.5 0.1 0.2 0.3 0.2 0.1 0.2 0.1 0.1 0.2 0.2 0.6 0.0 0.1 0.1 0.0 0.1 0.5 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.1 0.1

sex cord Germ Other Unsp. cell 0.3 0.3 0.4 0.2 0.4 0.3 0.3 0.3 0.3 0.3 0.5 0.3 0.5 0.3 0.2 0.6 0.5 0.5 0.4 0.4 0.4 0.4 0.3 0.4 0.3 0.2 0.3 0.4 0.5 0.4 0.4 0.4 0.4 0.4 0.4 0.5 0.4 0.5 0.4 0.3 0.4 0.2 0.4 0.4 0.4 0.3 0.3 0.4 0.5 0.3 0.3 0.5 0.3 0.3 0.2 0.1 0.2 0.3 0.2 0.4 0.3 0.1 0.2 0.2 0.4 0.4 0.3 0.5 0.3 0.7 0.4 0.7 0.3 0.2 0.5 0.5 0.6 0.4 0.4 0.4

Number of cases MV 3441 1454 231 1210 302 3094 1914 116 1778 353 3643 282 3221 554 40 153 354 7413 740 6402 77255 5209 69131 3856 228 3543 1133 1222 5211 270 4812 405 9194 597 7866 24727 1451 1574 2237 19235 1232 222 993 5409 414 4860 562 210 2244 1554 731 1939 42 240 569 47 110 1338 125 185 351 41 1177 259 1467 323 144 1498 1434 53 199 192 293 506 370 1435 263 4596 495 313 148 163 283 Total 3771 1586 258 1313 336 3385 2101 131 1950 394 3942 320 3473 602 47 166 382 8177 818 7068 84293 5946 75272 4229 255 3886 1302 1325 5647 301 5213 426 9907 657 8477 26634 1518 1762 2344 20761 1361 273 1069 5991 478 5358 601 223 2414 1670 831 2179 49 322 616 47 133 1634 139 190 559 45 1541 282 1802 443 148 1741 1617 64 232 239 313 668 448 1994 352 5334 565 340 167 186 354 * * * * *

0.3 0.4 0.3 0.4 0.3 0.3 0.3 0.4 0.3 0.1 0.4 0.3 0.4 0.4 0.3 0.3 0.5 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.2 0.3 0.4 0.3 0.5 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.2 0.3 0.3 0.3 0.1 0.3 0.3 0.3 0.3 0.4 0.4 0.4 0.4 0.2 0.2 0.1 0.1 0.1 0.0 0.1 0.2 0.0 0.1 0.0 0.2 0.2 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.1 0.1

0.4 0.2 0.3 0.2 0.4 0.4 0.4 0.4 0.4 0.1 0.5 0.9 0.5 0.4 0.9 0.2 0.5 0.4 0.3 0.4 0.4 0.5 0.4 0.4 0.5 0.4 1.0 0.3 0.3 0.3 0.3 0.2 0.2 0.3 0.2 0.3 0.2 0.4 0.2 0.3 0.4 0.6 0.3 0.5 0.6 0.5 0.3 0.3 0.2 0.2 0.5 0.7 0.3 0.4 0.2 5.2 5.8 1.3 0.1 2.0 0.5 1.8 1.1 1.9 6.8 0.4 0.8 0.6 0.6 0.8 1.2 1.2 0.0 1.4 1.2 0.7 0.7 0.5 0.7 0.8 1.1

* * * *

679

737

Age-standardized (world) incidence rates (per 100,000) by histological type

Ovary (C56) (Contd)

Carcinoma

Serous Mucin. Endom. Clear Adeno. Oth. Unsp. stromal Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 1.0 1.7 1.6 1.2 1.8 1.7 0.9 1.0 2.0 1.7 2.4 2.4 3.1 2.2 1.0 0.9 1.7 2.0 2.0 3.2 6.4 3.4 1.7 3.5 3.4 1.3 2.2 4.4 5.6 5.6 5.7 3.4 3.7 3.5 3.6 3.9 2.6 5.6 3.6 2.9 1.7 2.6 5.3 3.0 3.8 6.1 3.7 2.7 2.8 2.5 3.9 3.3 1.9 3.3 3.0 1.5 2.4 3.5 3.1 3.2 2.9 1.7 2.0 3.8 3.1 3.1 3.0 4.4 2.7 1.8 0.8 2.7 6.0 0.3 3.3 1.4 1.8 4.4 0.6 0.7 0.7 0.4 0.4 1.2 1.6 0.9 1.3 1.6 0.8 0.8 0.4 0.7 1.3 0.9 1.7 0.6 0.4 0.8 1.5 0.9 0.5 1.0 0.9 1.1 1.0 1.5 1.5 1.3 1.1 1.0 1.0 1.4 0.9 0.9 0.6 0.9 0.9 0.6 0.6 0.6 0.8 1.0 1.1 0.7 1.3 0.6 0.6 0.4 0.9 1.0 0.4 0.5 0.6 0.7 0.9 0.7 1.0 0.8 0.8 0.9 1.5 1.3 0.5 0.8 0.6 0.7 0.7 0.7 0.5 1.7 1.1 0.1 1.1 0.6 0.7 0.7 0.3 0.6 0.3 0.6 0.9 1.0 0.2 0.5 0.5 1.8 1.4 1.4 1.6 2.0 1.0 0.5 0.3 1.3 0.6 0.9 1.5 1.2 0.2 0.9 0.8 0.4 1.1 1.6 1.4 0.4 0.3 1.4 0.6 0.7 0.4 0.8 0.5 1.4 1.1 0.5 0.6 0.6 1.1 0.7 0.8 0.4 0.9 0.5 1.6 0.8 1.1 1.9 0.9 1.1 1.1 0.6 0.7 0.6 0.8 0.2 1.4 0.5 0.6 0.9 0.6 1.0 0.5 0.7 0.7 0.2 0.3 1.1 1.5 0.4 1.4 0.2 0.5 0.8 0.1 0.3 0.1 0.1 0.1 0.9 0.2 0.1 0.5 1.3 1.4 0.3 1.3 0.8 0.4 0.4 0.2 0.3 0.1 0.2 0.2 0.1 0.5 0.4 0.3 0.0 0.3 0.7 0.3 0.2 0.4 0.3 0.1 0.2 0.4 0.2 0.2 0.0 0.4 0.3 0.1 0.3 0.1 0.2 0.7 0.4 0.2 0.4 0.2 0.4 0.2 0.3 0.3 0.1 0.4 0.5 0.2 0.2 0.4 0.0 0.1 0.2 0.2 0.3 0.2 0.3 0.2 0.1 0.1 0.9 0.6 0.3 0.2 0.2 0.2 0.5 0.5 0.5 1.1 1.2 1.8 1.7 1.4 2.7 1.0 0.7 0.7 0.4 1.4 0.4 0.5 0.5 0.6 0.3 2.8 1.1 1.1 3.6 1.4 2.1 2.8 2.9 2.0 2.2 1.1 1.1 1.5 2.1 4.1 2.7 1.4 2.1 1.2 1.7 1.4 1.6 2.1 0.8 2.6 1.8 0.8 2.7 3.4 0.4 1.8 0.9 1.7 2.2 1.5 1.5 1.5 2.5 3.3 0.5 2.3 1.6 1.6 1.5 2.4 1.5 1.7 2.2 2.1 1.7 5.8 7.3 2.2 1.8 8.6 1.6 0.8 1.3 1.2 0.1 0.2 0.2 0.3 0.2 0.4 0.4 0.3 0.5 0.2 0.1 0.1 0.2 0.2 0.0 0.1 0.1 0.1 0.1 0.4 0.2 0.1 1.1 0.2 0.3 2.0 0.3 0.9 0.2 0.4 0.2 0.2 0.5 0.6 0.4 0.1 0.2 0.6 0.5 0.5 0.2 0.5 0.3 0.4 0.1 0.4 0.4 0.3 0.7 0.7 0.1 0.1 0.5 0.2 0.8 0.6 0.4 0.7 0.7 0.0 0.3 0.2 0.5 0.8 0.2 0.3 0.1 0.2 1.6 1.4 0.2 0.2 0.5 0.3 0.1 0.3 0.1 0.2 0.1 0.2 0.7 0.4 0.2 0.2 0.6 0.5 1.3 0.1 0.1 0.0 0.1 0.2 0.2 1.4 0.3 1.5 0.2 0.3 1.3 0.4 2.3 0.7 0.3 0.7 0.4 0.2 0.4 0.6 0.3 0.3 0.1 0.1 0.1 0.1 0.5 2.7 0.3 2.7 0.7 0.9 0.6 0.2 0.8 0.3 0.8 0.4 0.6 0.5 0.8 0.5 0.5 1.0 0.5 0.5 0.5 0.3 0.4 0.5 0.9 0.8 0.6 0.6 0.4 0.6 0.4 0.3 2.1 0.7 0.3 0.5 0.9 0.1 0.2 0.3 0.0 0.1 0.2 0.1 0.3 0.0 0.0 0.0 0.2 0.1 0.1 0.2 0.1 0.2 0.1 0.6 0.2 0.2 0.5 0.1 0.4 0.3 0.6 0.2 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.2 0.1 0.0 0.1 0.0 0.4 0.4 0.1 0.2 0.0 0.3 0.0 0.1 0.5

sex cord Germ Other Unsp. cell 0.8 0.5 0.8 0.2 0.1 0.7 0.5 0.4 0.4 0.6 0.7 0.6 0.4 1.0 0.5 0.4 0.3 0.4 0.3 0.4 0.2 0.5 0.0 0.3 0.3 0.3 0.3 0.3 0.4 0.3 0.2 0.2 0.2 0.2 0.4 0.2 0.1 0.3 0.4 0.1 0.4 0.3 0.5 0.2 0.2 0.3 0.7 0.1 0.2 0.5 0.3 0.1 0.5 0.2 0.7 0.1 0.4 0.3 0.1 0.3 0.3 0.5 0.2 0.2 0.3 0.3 0.4 0.5 0.3 0.2 0.4 0.3 0.3

Number of cases MV 37 1398 104 51 58 208 262 98 195 826 736 594 41 101 223 90 167 180 406 3710 310 112 3816 610 1918 2900 1929 5182 2835 735 379 237 178 311 360 359 304 230 180 120 155 638 1046 1145 503 102 1319 88 214 134 481 269 66 468 264 106 830 227 90 172 394 221 130 80 97 413 330 217 582 1241 1825 144 2202 390 707 452 736 1938 Total 43 1618 116 64 60 230 289 111 201 1133 771 619 44 108 235 124 178 195 425 4153 338 128 4081 622 2208 3729 2529 5834 2984 784 398 246 191 336 371 378 311 232 199 129 165 861 1267 1402 560 105 1531 96 243 163 593 308 82 574 310 127 881 268 107 209 482 297 161 95 110 483 420 252 680 1405 2120 159 2343 473 797 477 902 2547

0.1 0.1 0.3 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.7 0.1 0.1 0.0 0.1 0.2 0.2 0.2 0.1 0.1 0.2 0.2 0.1 0.1 0.2 0.4 0.1 0.1 0.3 0.2 0.1 0.2 0.1 0.3 0.1 0.2 0.0 0.1 0.1 0.3 0.1 0.1 0.2 0.3 0.3 0.2 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.2 0.3 0.1 0.2 0.2 0.1 0.3 0.3 0.3 0.1 0.1 0.2 0.1 0.1 0.3 0.3 0.1 0.2 0.1 0.2 0.1

0.7 0.9 0.7 0.7 0.3 1.4 0.9 0.7 0.1 2.9 0.3 0.3 0.6 0.7 0.4 1.4 0.4 0.4 0.4 0.9 0.5 0.9 1.8 0.1 0.5 2.1 2.9 1.3 0.3 1.4 0.3 0.3 0.2 0.5 0.2 0.3 0.1 0.0 0.6 0.2 0.6 0.2 1.3 0.1 0.7 0.3 1.2 0.7 1.0 0.8 1.6 0.7 1.8 1.1 0.9 1.3 0.4 1.2 2.5 1.5 1.2 2.1 1.2 1.0 0.7 1.0 1.5 1.2 0.8 1.8 2.7 0.8 0.3 2.5 1.0 0.2 1.3 2.5

Eu

* * *

* * * *

* * *

* *

738

*I N

680

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Ovary (C56) (Contd)

Carcinoma

Serous Mucin. Endom. Clear Adeno. Oth. Unsp. stromal Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 1.6 3.8 4.9 1.9 3.6 2.4 2.4 2.2 2.8 2.0 2.5 4.0 3.3 2.0 4.3 4.7 6.7 3.4 4.4 3.6 5.0 5.0 3.2 3.4 3.3 4.5 2.6 2.9 3.5 4.1 3.7 3.0 3.5 3.3 4.0 3.5 3.6 3.6 3.2 4.2 3.2 3.8 3.7 2.4 3.4 3.2 1.5 3.3 3.0 2.8 4.7 0.9 1.3 0.6 1.2 0.8 1.0 1.3 0.5 0.3 1.0 1.1 0.9 0.7 0.9 1.1 1.0 1.5 0.9 0.8 0.6 0.7 0.4 1.1 1.3 1.4 1.1 1.3 1.0 1.3 0.8 1.2 1.0 1.0 1.1 2.5 1.1 0.7 1.0 0.6 0.4 0.6 0.3 0.7 0.9 0.9 0.6 0.2 0.5 1.0 0.7 0.5 0.6 1.1 1.4 0.3 3.0 1.3 0.6 1.5 1.0 1.5 0.9 1.3 0.8 1.3 1.4 0.5 0.8 1.0 0.3 1.7 0.8 0.7 1.0 1.1 1.0 1.0 1.1 1.8 1.5 1.7 1.0 0.8 1.3 1.2 1.5 1.4 0.7 0.9 0.8 0.8 0.8 0.5 0.6 1.2 0.9 1.0 1.8 0.5 1.9 0.8 0.0 0.4 0.3 0.4 0.7 0.3 0.3 0.4 1.0 0.3 0.3 0.5 0.8 0.5 0.6 0.2 0.1 0.5 0.1 1.0 0.1 0.7 0.4 0.2 0.4 0.6 0.4 0.7 0.7 0.7 0.5 0.4 0.6 0.7 0.8 0.6 0.5 0.5 0.3 0.4 0.5 0.4 0.2 0.2 0.5 0.6 1.6 0.5 1.1 0.1 3.3 1.4 1.1 0.9 1.4 1.4 1.0 0.9 1.2 1.3 1.5 1.1 1.1 0.9 1.6 1.3 1.2 2.1 2.9 0.8 2.2 1.0 2.2 2.5 1.8 2.5 3.2 2.1 2.2 2.3 2.7 2.8 2.1 2.8 1.7 2.0 1.0 0.9 1.4 0.7 1.2 1.0 1.1 2.1 1.3 1.1 1.1 0.8 0.8 1.0 1.5 0.7 0.8 0.1 0.0 0.3 0.4 0.2 0.3 0.4 0.3 0.2 0.2 0.3 0.2 0.1 0.1 0.2 0.4 0.3 0.8 0.1 0.2 0.2 0.2 0.2 0.4 0.2 0.2 0.1 0.2 0.3 0.2 0.2 1.1 0.3 0.1 0.1 0.2 0.1 0.3 0.2 0.2 0.2 0.2 0.1 0.4 0.2 0.3 0.2 0.5 0.3 0.5 0.5 0.3 0.6 0.6 0.4 0.3 0.5 0.1 0.2 0.5 0.4 0.4 0.2 1.0 0.0 0.5 0.3 0.5 0.1 0.1 0.1 1.5 2.1 1.6 0.8 1.2 1.4 2.1 1.9 1.2 0.7 0.8 0.4 0.5 0.3 0.2 0.2 0.4 1.0 0.5 0.4 0.4 0.5 0.4 0.4 0.4 0.4 0.4 0.3 0.1 0.0 0.1 0.1 0.4 0.1 0.1 0.2 0.4 0.2 0.3 0.2 0.3 0.1 0.2 0.3 0.4 0.2 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.0 0.1 0.2 0.1 0.1 0.2 0.2 0.1 0.2 0.4 0.2 -

sex cord Germ Other Unsp. cell 0.4 0.3 0.4 0.4 0.5 0.2 0.6 0.8 0.3 0.4 0.2 0.5 0.2 0.2 0.4 0.2 0.9 0.1 0.3 0.4 0.3 0.3 0.5 0.4 0.2 0.4 0.4 0.3 0.4 0.3 0.3 0.3 0.3 0.4 0.3 0.4 0.4 0.4 0.3 0.4 0.4 0.5 0.2 0.6 0.7 0.7 1.0 1.3 0.2

Number of cases MV 1458 1896 804 68 553 516 343 64 165 224 298 197 145 236 3984 171 100 73 212 122 119 238 5760 382 342 1317 1027 1602 2707 1104 3227 5335 1960 2370 787 2308 1794 925 436 135 1343 459 74 36 1146 353 21 56 48 104 100 Total 1720 2140 818 77 600 581 388 81 195 256 338 214 167 264 3989 185 111 82 224 128 128 256 5946 392 345 1543 1294 1963 3399 1246 4131 6896 2494 2789 905 2656 1967 1035 494 148 1515 500 84 36 1262 381 24 59 50 111 110

0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.0 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.1 0.3 0.3 0.1 0.1 0.3 0.2 0.3 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.3 0.4 0.2 0.4 0.3 0.3 0.3 0.3 0.3 0.2 0.4 0.2 0.3 0.3 0.3 0.2 1.0 0.1 0.3

1.2 1.0 0.3 0.5 0.5 0.5 0.7 0.8 0.8 0.6 0.7 0.3 0.7 0.5 0.0 0.4 0.5 0.5 0.2 0.1 0.3 0.3 0.2 0.2 0.1 0.0 0.1 0.1 0.5 0.1 1.3 0.6 0.3 0.5 1.5 0.6 0.2 0.1 0.3 0.5 0.5 0.2 0.2 0.6 0.6 0.4 0.2 0.2 0.3 0.5 0.6

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

681

739

Age-standardized (world) incidence rates (per 100,000) by histological type

Testis (C62)

Germ cell Seminoma Spermatocytic seminoma Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 0.1 0.2 0.3 0.3 0.0 2.2 0.2 0.5 0.7 1.1 3.8 1.3 1.0 1.8 0.6 1.6 2.4 2.7 2.4 2.6 1.8 1.6 1.5 2.7 2.4 2.7 2.7 2.2 0.8 2.7 2.4 2.6 2.5 2.6 1.1 1.3 0.5 2.1 3.4 3.6 2.1 0.7 1.0 0.7 1.7 1.5 0.2 3.4 0.9 0.8 1.9 3.6 3.2 3.1 1.0 3.4 1.7 0.4 3.1 2.4 0.5 2.8 2.0 2.1 0.7 2.9 0.6 2.6 3.2 2.6 0.7 2.9 2.8 3.4 2.6 2.3 0.7 2.8 0.7 3.1 3.2 3.1 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 Non-seminomatous 0.1 0.1 0.0 1.7 0.2 0.3 0.5 0.8 4.2 0.8 1.2 1.5 0.2 1.1 2.0 2.4 2.0 2.3 1.6 0.9 1.5 1.9 1.9 1.9 2.7 1.4 0.2 1.8 2.6 2.0 2.1 2.0 1.1 0.3 0.5 1.5 0.8 2.9 1.9 0.2 0.5 1.0 1.8 1.3 0.5 3.2 0.6 0.5 1.7 3.0 2.1 2.2 0.4 2.5 1.1 0.3 2.0 1.8 0.3 2.1 1.5 1.5 0.3 2.2 0.2 2.0 1.8 1.9 0.5 2.1 2.1 2.6 1.9 1.4 0.6 2.0 0.5 1.9 2.3 2.5

Other

Unspec.

Number of cases MV 6 32 5 5 8 38 40 10 33 566 84 107 248 136 11 38 2948 448 515 152 76 39 4 115 1432 18 149 439 33 398 98 660 4562 922 31 24 8 164 13 637 1122 27 14 11 443 10 3 596 179 94 1166 3048 691 491 14 465 48 7 39 1826 68 1723 853 337 36 292 65 775 183 1543 59 1416 812 466 505 450 14 75 44 402 202 1014 Total 6 33 5 7 16 * * * *

0.1 0.0 0.2 0.3 1.0 0.2 0.3 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.2 0.1 0.4 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.1

0.0 0.1 0.1 0.6 1.0 0.0 0.6 0.4 0.2 0.3 0.4 0.2 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0

40 49 10 34 740 86 115 276 147 13 38 * 3034 451 520 153 76 39 4 115 1508 19 149 443 34 401 98 665 4585 926 31 25 8 164 13 640 1126 29 14 11 444 10 3 597 180 96 1171 3063 698 493 14 467 50 7 40 1840 70 1735 858 340 37 294 66 779 185 1554 60 1426 817 467 511 454 14 75 45 405 204 1019

740

*I N

682

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Testis (C62) (Contd)

Germ cell Seminoma Spermatocytic seminoma

Non-seminomatous 1.9 1.8 0.5 2.2 0.4 2.2 1.8 0.3 2.1 2.7 2.2 0.4 2.7 2.3 1.7 1.9 3.0 1.7 0.3 2.1 2.0 0.4 2.3 2.1 0.4 2.3 1.6 2.9 2.2 0.8 2.4 2.4 2.1 0.5 2.5 2.0 0.7 0.4 1.7 2.7 1.6 0.3 2.2 1.9 0.4 2.1 2.6 2.1 2.3 2.3 1.8 2.3 0.4 0.2 0.5 0.0 0.2 1.6 0.1 0.2 0.1 0.2 0.2 1.5 1.7 0.6 0.9 0.3 1.0 0.9 0.8 0.3 0.2 0.3 0.4 0.4 0.3 0.3 0.3

Other

Unspec.

Number of cases MV 1280 513 28 476 40 1209 637 16 616 136 1178 47 1096 233 16 86 130 2330 106 2162 28977 871 27062 1495 42 1402 383 607 1732 52 1656 147 3787 120 3453 9905 314 294 1481 7663 381 29 347 2475 75 2333 333 109 976 684 201 899 9 37 282 8 5 126 22 71 62 2 225 42 215 61 13 535 487 38 54 38 79 145 52 238 37 525 44 36 12 20 29 Total 1292 515 28 478 41 1220 640 17 618 137 1183 47 1101 237 16 89 131 2360 108 2190 29216 887 27275 1507 43 1413 385 612 1739 52 1663 148 3800 121 3465 9956 315 298 1489 7701 385 29 351 2520 77 2373 333 110 983 685 202 914 11 43 292 8 5 142 24 72 75 2 256 50 242 66 13 587 520 41 55 41 81 152 53 264 42 554 47 38 13 20 31 * * * * *

America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

2.8 2.7 0.5 3.5 0.6 3.2 2.4 0.8 2.7 3.1 2.8 0.9 3.3 2.7 1.8 2.4 3.2 2.6 0.8 3.1 2.6 0.7 3.0 2.7 0.6 2.9 2.3 3.5 3.0 0.6 3.4 2.7 2.8 0.8 3.3 2.6 1.0 0.8 1.8 3.5 1.8 0.6 2.3 2.2 0.6 2.5 2.7 4.6 3.4 3.4 2.4 3.6 0.4 0.5 0.8 0.7 0.1 0.2 2.0 0.3 0.2 0.4 0.5 0.3 0.1 2.0 2.2 0.6 0.8 1.1 1.6 1.4 0.8 0.6 1.0 0.2 0.1 0.2 0.1 0.2 0.1

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.0 -

0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.3 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.2 0.1 0.0 0.2 0.0 0.3 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 -

0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.2 0.1 0.2 0.2 0.6 0.1 0.1 0.2 0.1 0.8 0.0 0.1 0.1 0.0 0.1 0.3 0.0 0.1 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0

* * * *

Cancer Incidence in Five Continents Vol. IX, IARC 2008

683

741

Age-standardized (world) incidence rates (per 100,000) by histological type

Testis (C62) (Contd)

Germ cell Seminoma Spermatocytic seminoma

Non-seminomatous 0.3 0.1 0.5 1.0 0.2 0.4 0.1 0.4 0.2 0.4 0.3 0.6 0.6 0.2 0.1 0.1 0.9 1.1 2.1 2.8 3.4 0.6 1.6 1.6 1.6 1.6 2.9 3.9 1.3 3.2 2.5 2.5 2.6 2.1 2.5 2.4 2.3 2.4 3.1 2.6 1.5 2.6 3.0 3.3 1.9 2.3 2.5 2.1 2.3 1.5 1.4 2.6 1.7 1.9 1.4 1.9 2.5 1.6 1.5 1.7 1.6 2.6 2.6 2.6 2.2 1.9 3.0 2.2 0.7 0.8 1.1 4.6 1.1 2.1 1.0 0.9 0.6

Other

Unspec.

Number of cases MV 1 171 15 24 37 21 38 11 52 118 83 62 6 15 28 12 11 84 220 1707 146 79 433 157 447 764 402 1818 1341 84 197 80 76 145 104 149 178 51 69 46 79 290 601 557 246 40 568 32 86 43 113 55 23 134 89 55 289 47 27 59 129 94 57 38 34 132 97 94 224 120 175 41 1166 82 170 154 131 202 Total 2 181 15 24 37 21 42 12 53 147 85 64 6 15 32 14 11 87 228 1717 146 80 445 158 461 816 610 1859 1361 85 198 81 76 145 104 151 178 51 69 46 81 308 613 587 247 40 583 32 94 43 118 58 25 139 90 55 292 47 27 64 139 108 58 40 35 132 120 95 227 128 185 41 1171 85 179 155 137 215

Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.2 0.4 0.7 0.2 0.4 0.3 0.3 0.6 0.5 0.6 0.5 0.4 0.6 0.4 0.4 0.2 1.2 1.0 4.5 3.9 4.2 0.8 1.9 1.6 1.7 1.6 3.3 5.0 1.0 3.3 2.0 3.1 4.6 2.4 2.3 3.2 1.7 2.1 2.3 2.8 4.1 5.8 4.6 4.5 3.2 3.1 3.3 3.0 2.3 2.2 2.6 1.6 2.7 3.0 2.2 2.6 1.6 1.6 2.9 2.7 2.1 2.0 4.5 1.4 3.0 2.7 3.9 2.8 0.9 0.8 2.8 4.9 2.0 1.9 0.6 0.8 0.7

0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.2 0.0 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.4 0.1 0.1 0.0 0.1 0.2 0.0 0.1 0.0 0.0 0.0 0.0

0.2 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.0 0.1 0.1 0.5 0.3 0.2 0.1 0.1 0.3 0.1 0.3 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.1 0.3 0.1 0.2 0.1 0.2 0.2 0.1 0.2 0.0 0.1 0.1 0.1 0.2 0.2 0.1 0.3 0.2 0.2 0.2 0.4 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.5 0.1 0.2 0.1 0.2

0.2 0.0 0.0 0.3 0.1 0.0 0.2 0.0 0.0 0.1 0.1 0.0 0.1 0.2 0.4 0.1 0.1 0.0 0.1 0.2 1.8 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.3 0.1 0.1 0.2 0.1 0.1 0.5 0.3 0.1 0.7 0.2 0.1 0.1 0.3 0.4 0.3 0.6 0.1 0.7 0.1 0.9 0.3 0.1 0.2 0.1 0.1 0.5 0.2 0.0 0.1 0.1

Eu

* * *

* * * *

* * *

* *

742

*I N

684

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Testis (C62) (Contd)

Germ cell Seminoma Spermatocytic seminoma

Non-seminomatous 1.2 3.5 4.2 2.0 0.8 1.5 1.2 2.2 1.8 1.6 1.4 1.3 1.5 1.2 2.5 2.8 4.7 2.6 4.4 2.8 2.9 3.3 3.1 2.9 3.2 2.6 2.4 2.7 2.6 3.0 2.8 2.0 2.2 2.4 2.6 3.1 2.5 2.5 2.1 1.5 2.2 2.0 1.9 0.7 2.3 1.5 1.2 1.1 1.4 1.5 2.0

Other

Unspec.

Number of cases MV 484 960 411 28 63 149 97 14 59 54 89 41 48 54 1213 81 65 26 145 75 62 151 2604 157 126 439 368 693 1096 546 1171 2032 684 784 270 1016 1021 524 214 84 714 288 59 18 685 133 7 11 28 24 53 Total 563 980 411 28 66 151 99 15 59 54 92 41 48 57 1214 82 65 26 147 75 62 151 2611 158 126 446 401 702 1104 565 1316 2156 699 809 277 1038 1044 537 220 84 734 288 61 18 696 133 7 11 28 24 53

Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White

2.4 2.7 3.2 1.4 1.1 1.5 0.9 0.8 1.7 0.8 1.0 1.3 1.9 0.9 2.8 3.9 5.6 3.5 5.9 5.7 4.8 5.6 2.8 2.6 2.5 3.4 3.8 3.5 3.6 4.0 3.8 3.3 3.2 3.1 3.3 4.3 3.1 2.8 3.1 4.7 3.1 3.3 4.4 1.4 4.3 2.4 2.3 1.2 3.2 2.9 3.3

0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 -

0.6 0.2 0.1 0.2 0.0 0.1 0.3 0.4 0.1 0.3 0.2 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.1 0.2 0.4 0.1 0.0 0.1 -

0.8 0.2 0.1 0.0 0.0 0.3 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.1 0.1 -

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

685

743

Age-standardized (world) incidence rates (per 100,000) by histological type

Kidney and renal pelvis (C64-65) - Male

Carcinoma Squamous Adeno 0.2 1.8 2.0 0.1 1.1 6.8 2.3 1.0 2.5 4.2 4.8 2.4 2.5 2.0 1.5 2.9 8.0 9.1 6.5 10.3 10.3 8.3 8.5 11.6 7.4 9.2 8.9 9.2 10.1 9.0 11.1 9.6 8.5 7.9 8.6 3.2 5.3 9.8 5.5 8.5 8.6 11.0 3.1 6.1 9.1 5.6 4.0 9.3 4.2 10.1 9.6 8.9 8.4 10.7 11.5 10.7 9.8 10.4 8.1 9.3 8.0 9.5 9.3 9.7 11.8 9.2 11.3 8.9 9.1 10.7 12.1 10.5 11.2 10.6 11.5 12.3 11.4 12.7 12.6 12.4 11.5 10.3 Other 0.0 0.0 0.1 0.4 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.2 0.5 0.1 0.2 0.1 0.2 0.3 0.6 0.2 0.3 0.3 0.1 0.5 0.2 0.2 0.1 0.2 0.2 0.2 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.0 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.0 0.0 Unspec. 0.0 0.1 0.0 2.1 0.8 0.3 0.2 0.5 0.4 0.1 0.0 0.1 0.2 0.1 0.2 0.2 0.3 0.3 0.8 0.2 0.2 0.1 0.2 0.2 0.3 0.2 0.2 0.2 0.1 0.1 0.0 0.2 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.3 0.1 0.3 0.3 0.4 0.3 0.2 0.3 0.2 0.1 0.2 0.1 0.3 0.2 0.1 0.3 0.4 0.3 0.2 0.1 0.2 0.3 0.1 0.1 0.5 0.3 0.2 0.1

Other

Unspec.

Number of cases MV 17 118 29 17 31 69 105 12 58 1053 51 108 220 68 26 35 6366 789 973 377 287 162 7 367 3018 48 338 1399 251 1135 183 1702 8946 1659 111 61 42 214 15 1133 2327 287 41 48 581 31 23 1283 497 601 1618 6142 1100 1348 88 1237 155 97 51 6642 444 6115 2278 731 219 502 542 1719 358 4334 521 3699 2244 1116 1539 1742 101 277 402 1338 540 2283 Total 18 138 29 21 45 * * * *

Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.1 0.5 0.7 0.1 0.5 0.1 0.2 0.1 0.1 0.4 0.2 0.2 0.3 0.7 0.6 0.6 0.6 1.2 1.1 0.4 0.5 0.5 0.7 0.8 0.8 0.4 0.9 0.6 0.7 0.7 0.6 0.6 0.5 0.7 0.4 0.6 0.6 0.4 0.2 0.3 0.6 0.6 0.2 0.8 0.4 0.4 0.7 0.7 0.9 0.8 0.4 0.8 0.5 0.4 0.7 0.9 0.4 1.0 0.9 0.9 0.7 1.0 0.6 1.0 0.6 0.8 0.4 0.9 0.9 0.8 0.8 0.9 0.3 1.0 0.6 1.0 1.0 0.8

0.3 0.1 0.3 0.3 0.4 0.5 0.5 0.7 0.2 0.4 0.2 0.2 0.3 0.2 0.3 0.3 0.3 0.2 0.6 0.4 0.3 0.4 0.2 0.2 0.3 0.2 0.2 0.3 0.3 0.4 0.3 0.2 0.5 0.3 0.2 0.2 0.1 0.3 0.5 0.3 0.1 0.4 0.2 0.4 0.2 0.3 0.1 0.3 0.3 0.3 0.6 0.3 0.2 0.4 0.4 0.4 0.3 0.6 0.4 0.4 0.2 0.3 0.4 0.3 0.4 0.4 0.4 0.4 0.1 0.7 0.2 0.5 0.3 0.3

0.1 0.4 0.2 0.2 1.3 0.9 0.9 1.6 0.9 0.9 1.1 0.5 0.5 0.1 0.9 0.2 0.2 0.6 0.5 0.2 0.8 1.4 1.7 0.7 0.2 0.3 0.1 0.5 0.2 0.1 0.1 0.3 0.1 0.1 0.1 0.2 0.0 0.3 0.1 0.0 0.2 0.1 0.1 0.5 0.0 0.1 0.0 0.6 0.7 0.4 0.5 0.7 0.4 0.3 0.1 0.3 0.1 0.4 0.3 0.1 0.3 0.2 0.3 0.1 0.2 0.2 0.3 0.8 0.5 0.7 0.2 0.2 0.4

77 115 20 69 1398 59 135 301 83 28 35 * 7836 946 1145 507 337 171 7 449 3821 58 395 1524 294 1215 198 1907 9800 1817 132 67 47 231 18 1236 2529 311 43 50 641 35 24 1390 547 668 1764 6732 1275 1428 90 1315 192 128 54 7334 501 6742 2487 763 231 522 601 1869 409 4739 579 4043 2458 1249 1707 1906 120 298 470 1432 602 2465

744

*I N

686

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Kidney and renal pelvis (C64-65) - Male (Contd)

Carcinoma Squamous America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008 0.8 0.7 0.5 0.7 0.6 0.9 0.8 0.7 0.8 1.0 0.9 0.5 1.0 0.6 0.8 0.5 0.9 0.5 0.9 0.8 0.5 0.9 0.8 0.4 0.8 0.9 0.7 1.0 0.5 1.0 0.8 0.7 0.6 0.7 0.7 0.5 0.5 0.6 0.8 0.9 0.5 1.0 0.8 0.5 0.8 0.5 0.9 0.8 0.6 0.9 0.8 0.4 0.6 0.3 0.4 0.1 0.2 0.6 0.1 0.1 0.0 0.1 0.1 0.8 0.8 1.3 0.8 0.7 1.3 1.0 1.0 0.6 0.6 0.7 0.6 0.6 0.8 1.1 0.7 Adeno 9.8 11.4 12.6 11.2 12.5 9.5 10.7 13.5 10.5 9.0 11.1 11.1 11.3 10.0 13.3 11.8 8.9 10.3 8.4 10.9 10.0 10.8 10.0 9.6 11.0 9.4 9.5 8.9 10.8 14.1 10.4 12.4 9.8 11.6 10.0 9.7 4.7 11.5 9.7 10.0 10.7 11.2 10.5 11.1 11.5 11.2 7.7 9.3 9.9 9.9 10.1 10.0 3.5 0.9 2.9 0.6 0.7 0.6 4.1 0.8 0.5 1.6 0.9 2.0 0.8 9.7 10.2 3.4 3.0 4.0 5.8 5.6 4.5 2.7 2.1 3.4 3.4 3.5 3.4 2.6 2.8 Other 0.1 0.2 0.2 0.1 0.3 0.1 0.0 0.0 0.1 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.3 0.0 0.0 0.1 0.1 0.3 0.1 0.0 0.1 0.2 0.1 0.2 0.1 0.3 0.2 0.2 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.2 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Unspec. 0.2 0.4 0.7 0.3 0.5 0.2 0.2 0.2 0.2 0.3 0.3 0.3 0.1 0.4 0.0 0.2 0.3 0.2 0.3 0.2 0.3 0.2 0.3 0.5 0.3 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.4 0.2 0.2 0.1 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.2 0.1 0.1 0.2 0.2 0.3 0.1 0.8 0.0 0.8 0.0 0.9 0.0 0.0 0.0 0.2 0.2 0.2 0.1 0.0 0.5 0.0 0.5 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 Other Unspec. Number of cases MV 3367 1528 329 1172 446 2866 2086 189 1884 319 3318 317 2896 566 38 204 318 6768 606 5976 76034 6776 66991 3869 359 3429 1158 1077 5034 413 4525 455 8516 813 7128 23015 886 2145 2211 17502 1432 303 1110 6711 605 5968 426 212 1932 1309 737 1955 20 110 706 15 69 826 42 111 104 5 404 43 512 101 34 1616 1527 72 161 177 279 640 380 1282 178 3977 392 247 126 110 207 Total 3683 1649 362 1259 495 3129 2301 214 2074 349 3591 353 3131 645 45 232 360 7448 672 6576 83690 7639 73587 4195 393 3717 1325 1202 5584 485 4999 494 9288 891 7779 25145 962 2389 2404 19099 1588 341 1225 7492 690 6657 471 226 2166 1459 813 2124 27 147 730 24 75 1193 62 116 117 6 435 43 566 106 41 1857 1722 82 213 233 318 765 455 1683 266 4775 488 295 149 137 252 * * * * *

Age-standardized (world) incidence rates (per 100,000) by histological type

0.4 0.3 0.4 0.3 0.5 0.4 0.4 0.8 0.4 0.5 0.4 0.3 0.5 0.3 0.2 0.5 0.4 0.5 0.4 0.3 0.3 0.3 0.3 0.1 0.3 0.2 0.3 0.4 0.6 0.3 0.2 0.3 0.4 0.4 0.3 0.2 0.3 0.3 0.4 0.3 0.2 0.4 0.3 0.3 0.3 0.3 0.2 0.3 0.3 0.3 0.4 0.3 0.2 0.1 0.1 0.0 0.3 0.4 0.2 0.1 0.1 0.1 0.2 0.2 0.3 0.3 0.2 0.2 0.2 0.1 0.1 0.0 0.2 0.0 0.2 0.2 0.2 0.1 0.2 0.2

0.3 0.1 0.2 0.1 0.4 0.3 0.5 0.7 0.5 0.1 0.4 0.6 0.4 0.1 0.3 0.1 0.1 0.3 0.4 0.3 0.3 0.4 0.3 0.2 0.1 0.2 0.8 0.1 0.2 0.4 0.2 0.3 0.1 0.2 0.1 0.2 0.1 0.3 0.1 0.2 0.3 0.2 0.4 0.6 0.8 0.5 0.0 0.1 0.1 0.1 0.2 0.6 0.6 0.2 0.1 3.2 4.3 0.2 0.1 0.1 0.2 0.3 1.7 0.4 0.6 0.5 0.5 1.6 1.4 0.2 0.9 0.4 1.2 1.3 1.0 1.2 1.1 1.0 1.1 1.1

* * * *

687

745

Kidney and renal pelvis (C64-65) - Male (Contd)

Carcinoma Squamous Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 1.0 0.9 0.6 0.5 0.1 0.5 0.1 0.2 0.1 0.1 0.4 0.5 0.3 0.1 0.8 0.8 0.3 0.3 0.6 0.9 0.4 0.4 0.5 1.1 0.9 0.3 0.3 1.0 1.2 0.5 0.6 0.7 0.5 0.7 1.0 0.7 0.8 0.7 1.1 0.6 0.4 0.8 0.7 0.9 0.8 0.9 0.5 0.5 1.1 1.3 0.4 0.8 0.5 1.1 1.3 0.5 0.7 1.7 0.5 0.2 0.9 0.8 0.5 0.8 0.7 0.8 0.7 0.9 0.9 0.2 0.4 0.3 0.4 0.2 0.4 0.6 0.3 0.4 Adeno 3.3 4.2 4.2 4.8 1.6 2.8 1.3 1.2 1.5 2.9 3.3 3.8 1.1 2.0 0.7 0.2 0.3 2.3 2.5 10.2 9.8 8.6 7.2 6.5 7.4 3.1 3.9 15.3 5.9 11.6 13.4 7.9 9.0 10.7 8.4 7.2 9.6 6.6 9.5 6.5 6.6 7.7 9.7 8.8 10.1 13.6 5.8 7.7 10.1 9.4 10.6 8.0 7.9 10.5 11.3 4.9 9.0 8.0 3.0 8.3 11.0 3.6 6.2 11.1 3.0 7.2 7.9 10.5 11.4 8.0 9.1 3.8 7.3 6.7 6.3 3.9 4.1 5.7 Other 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.3 0.1 0.3 0.3 0.2 0.1 0.1 0.7 0.3 0.4 0.1 0.2 0.0 0.5 0.1 0.1 0.4 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 Unspec. 0.0 0.3 0.1 0.0 0.1 0.0 0.6 0.1 0.1 0.0 0.0 0.0 0.0 0.5 0.3 0.6 0.1 0.2 0.4 0.1 2.4 0.3 0.2 0.6 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.5 0.1 0.3 0.4 0.2 0.2 1.5 0.3 0.4 0.4 1.0 0.1 0.5 0.2 1.8 0.5 0.4 0.3 0.2 0.5 0.2 0.2 1.4 0.5 0.5 0.1 0.4 0.1 0.3 0.7 0.4 0.2 0.3 1.3 Other Unspec. Number of cases MV 35 1201 83 53 38 69 58 29 50 206 340 309 11 20 60 24 18 84 266 3504 241 112 2499 539 1697 1062 1099 5910 1521 578 503 217 168 303 365 320 437 162 213 126 178 508 1023 947 524 136 777 70 319 196 641 257 82 552 376 87 1073 206 44 193 583 152 137 86 48 366 401 244 856 650 1190 63 1361 184 424 484 541 1061 Total 41 1393 95 62 43 78 75 33 52 315 419 375 14 30 69 35 23 94 290 3741 260 124 3787 584 1824 1643 1588 7505 1804 692 524 226 182 318 381 347 451 169 239 147 186 636 1170 1078 557 143 1046 98 374 236 761 328 94 638 418 112 1156 237 58 247 693 210 161 105 57 416 509 280 1007 1052 1650 85 1587 272 614 507 581 1707

Age-standardized (world) incidence rates (per 100,000) by histological type

0.3 0.1 0.1 0.2 1.1 0.2 0.2 0.1 0.2 0.1 0.2 0.2 0.2 0.0 0.0 0.0 0.3 0.3 0.3 0.4 0.2 0.3 0.1 0.4 0.3 0.3 0.2 0.2 0.5 0.9 0.4 0.4 0.4 0.3 0.2 0.4 0.2 0.2 0.0 0.6 0.3 0.4 0.2 0.0 0.6 0.3 0.3 0.8 0.4 0.1 0.3 0.1 0.4 0.7 0.4 0.4 0.2 0.5 0.3 0.3 0.2 0.3 0.3 0.5 0.9 0.3 0.0 0.2 0.5 0.4

0.9 1.1 1.1 0.7 0.4 0.6 0.5 0.1 0.9 1.0 1.1 0.4 1.0 0.2 0.5 0.2 0.2 0.2 0.9 0.6 1.2 4.9 0.5 0.5 1.8 3.1 4.2 0.9 2.8 0.5 0.5 0.3 0.3 0.3 0.6 0.3 0.3 1.0 0.9 0.4 0.1 1.4 0.1 0.6 0.6 2.1 2.5 2.3 1.8 1.7 2.0 1.3 1.7 1.1 1.6 0.8 1.1 1.7 2.4 1.7 1.9 1.1 2.7 0.8 1.0 2.1 1.6 1.8 5.4 5.3 1.6 0.9 3.6 3.1 0.2 0.4 4.7

Eu

* * *

* * * *

* * *

* *

746

*I N

688

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Kidney and renal pelvis (C64-65) - Male (Contd)

Carcinoma Squamous Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 0.8 0.7 0.5 0.9 1.0 1.1 1.1 0.3 1.0 1.3 1.3 1.1 1.0 0.7 0.7 0.8 1.4 0.4 0.6 0.6 0.9 1.0 0.8 0.7 0.8 0.6 0.6 0.6 0.8 0.6 0.6 0.5 0.7 0.6 0.5 0.7 0.8 1.0 0.6 1.1 0.6 0.9 0.5 0.5 0.5 0.8 0.5 0.3 0.7 1.4 0.8 Adeno 2.9 9.1 7.9 3.1 8.1 9.2 3.2 3.3 6.3 3.7 3.8 8.4 5.0 4.7 6.0 7.4 7.7 9.2 6.6 9.2 6.8 5.6 6.5 6.0 7.0 5.1 5.7 5.5 6.6 5.7 5.6 5.0 5.8 5.9 5.1 6.3 9.0 8.7 10.3 8.9 8.2 7.9 8.9 4.4 6.5 7.9 6.0 5.6 9.6 7.4 10.3 Other 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.2 Unspec. 0.2 0.1 0.1 0.8 0.2 0.3 0.2 0.5 0.1 0.0 0.3 0.4 0.1 0.0 0.1 0.2 0.2 0.4 0.1 0.3 0.3 0.4 0.1 0.1 0.1 1.0 1.1 1.3 0.6 0.8 0.5 1.0 1.4 0.8 0.3 1.0 0.3 0.3 0.1 0.1 0.2 0.1 0.2 0.2 0.2 0.2 0.4 0.1 0.3 Other Unspec. Number of cases MV 779 1527 663 52 405 717 206 39 166 153 210 216 122 205 2680 132 79 64 140 130 82 174 4322 261 274 566 491 832 1643 572 1714 2437 1071 1210 323 1309 2163 1066 543 180 1477 523 85 25 909 363 22 40 51 111 122 Total 1014 1931 680 62 475 842 247 51 188 168 236 245 148 218 2838 141 83 71 163 139 87 188 5010 315 306 795 727 1226 2283 724 2349 3638 1616 1612 451 1749 2379 1242 656 201 1720 589 90 27 1101 387 25 43 53 116 132

Age-standardized (world) incidence rates (per 100,000) by histological type

0.3 0.2 0.6 0.5 0.2 0.3 0.8 0.3 0.2 0.3 0.2 0.2 0.5 0.3 0.2 0.4 0.5 0.1 1.2 0.1 0.5 0.3 0.3 0.2 0.3 0.4 0.3 0.3 0.3 0.3 0.3 0.2 0.4 0.2 0.3 0.3 0.2 0.3 0.5 0.2 0.3 0.2 0.3 0.4 0.2 0.4 0.6 0.4

1.4 2.4 1.3 0.5 0.6 1.5 0.7 0.7 0.8 0.5 0.6 0.6 0.8 0.3 0.4 0.5 0.1 0.8 0.9 0.5 0.4 0.5 1.1 1.5 0.8 0.0 0.0 0.1 0.5 1.2 0.4 0.2 0.3 2.0 0.8 0.1 0.0 0.2 0.9 1.1 0.2 0.6 1.1 0.3 0.3 0.3 0.3 0.2 0.4

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

689

747

Age-standardized (world) incidence rates (per 100,000) by histological type

Kidney and renal pelvis (C64-65) - Female

Carcinoma Squamous Adeno 0.5 1.0 0.9 0.8 2.6 1.4 1.3 1.6 1.9 2.5 1.4 1.4 1.1 1.0 1.4 4.3 5.1 3.2 5.6 6.5 5.0 2.6 6.0 4.0 4.3 4.7 4.5 5.6 4.1 4.9 5.1 4.1 3.7 5.3 1.8 2.9 5.4 2.4 3.7 4.2 5.0 1.4 3.0 4.6 2.5 1.9 4.5 2.0 5.1 5.2 4.1 4.4 5.2 4.8 5.2 4.4 5.3 2.0 4.4 4.5 4.4 4.6 3.9 4.8 3.6 5.4 4.4 5.9 5.5 6.0 5.5 6.2 5.6 5.8 6.4 6.2 6.7 6.1 6.6 5.3 5.4 Other 0.1 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 Unspec. 0.1 0.1 0.0 0.0 1.0 0.3 0.3 0.1 0.2 0.3 0.1 0.0 0.0 0.3 0.1 0.1 0.1 0.1 0.2 0.0 0.2 0.0 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.3 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.0 0.1 0.2 0.0 0.2 0.2 0.1 0.1

Other

Unspec.

Number of cases MV 33 75 15 12 30 31 74 12 41 674 32 90 136 44 21 19 3947 507 554 215 198 108 2 250 1877 25 211 897 214 670 77 1044 5193 971 89 45 36 153 13 606 1422 172 27 32 409 19 15 727 316 371 1085 3367 672 844 53 775 117 89 23 3869 330 3500 1393 376 122 245 345 1031 275 2878 368 2446 1560 725 961 1099 84 169 280 817 312 1568 Total 34 89 17 17 37 * * * *

Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.0 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.3 0.4 0.3 0.3 0.3 0.3 0.5 0.3 0.5 0.4 0.2 0.5 0.4 0.5 0.4 0.4 0.2 0.3 0.1 0.5 0.5 0.4 0.3 0.6 0.2 0.4 0.3 0.1 0.4 0.2 0.2 0.3 0.4 0.4 0.5 0.2 0.6 0.4 0.4 0.3 0.5 0.3 0.5 0.5 0.5 0.3 0.6 0.2 0.5 0.6 0.5 0.3 0.5 0.6 0.4 0.6 0.4 0.2 0.4 0.3 0.4 0.6 0.6

0.6 0.2 0.6 0.2 0.3 0.2 0.5 0.3 0.4 0.4 0.5 0.2 0.3 0.1 0.4 0.5 0.3 0.2 0.3 0.5 0.3 0.4 0.6 0.4 0.5 0.6 0.4 0.2 0.3 0.3 0.3 0.6 0.1 0.4 0.3 0.3 0.4 0.3 0.3 0.9 1.0 0.2 0.2 0.4 0.3 0.3 0.3 0.5 0.6 0.5 0.7 0.8 0.6 0.4 0.5 0.3 0.4 0.4 0.3 0.4 0.2 0.4 0.6 0.4 0.2 0.4 0.4 0.4 0.3 0.4 0.4 0.2 0.5 0.3 0.2 0.3

0.0 0.3 0.1 0.1 0.6 0.1 0.4 0.7 0.8 0.6 0.7 0.5 0.3 0.5 0.0 0.1 0.2 0.1 0.3 0.4 0.8 0.5 0.4 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.2 0.1 0.1 0.1 0.2 0.3 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.2

37 81 13 46 887 39 114 188 61 26 19 * 5065 612 697 308 233 117 2 301 2503 29 263 999 239 747 85 1172 5807 1087 104 48 37 168 14 685 1598 196 30 34 442 19 15 836 340 427 1178 3803 790 925 57 852 131 102 24 4364 372 3950 1585 420 136 275 394 1173 309 3237 428 2743 1725 826 1109 1263 98 194 323 937 354 1750

748

*I N

690

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Kidney and renal pelvis (C64-65) - Female (Contd)

Carcinoma Squamous America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008 0.4 0.4 0.3 0.5 0.3 0.5 0.5 0.3 0.5 0.3 0.5 0.2 0.5 0.2 0.3 0.2 0.5 0.3 0.5 0.5 0.3 0.5 0.5 0.1 0.5 0.4 0.5 0.5 0.3 0.5 0.8 0.4 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.5 0.5 0.3 0.5 0.3 0.4 0.4 0.3 0.5 0.5 0.4 0.2 0.1 0.1 0.0 0.1 0.3 0.0 0.1 0.1 0.0 0.0 0.4 0.4 0.2 0.3 0.1 0.5 0.3 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.2 Adeno 5.4 5.9 7.3 5.6 6.8 5.1 5.5 6.0 5.5 4.3 5.3 5.3 5.4 4.8 7.1 6.0 4.0 4.9 4.2 5.2 5.1 5.5 5.1 5.4 6.2 5.2 4.8 4.5 5.5 6.3 5.4 6.0 4.8 6.1 4.8 4.7 2.2 5.7 5.2 4.8 5.0 5.8 4.7 5.9 6.9 5.8 4.4 5.2 4.8 4.8 5.3 5.3 2.6 0.4 1.5 0.4 0.3 0.3 1.7 0.4 0.6 0.3 0.9 0.1 4.8 5.1 0.9 1.1 1.3 1.7 2.0 1.7 0.9 1.4 1.2 1.3 1.5 1.2 1.0 1.2 Other 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Unspec. 0.1 0.2 0.3 0.2 0.3 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.1 0.1 0.2 0.2 0.2 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.4 0.0 0.2 0.0 0.2 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 Other Unspec. Number of cases MV 2227 1006 264 733 325 1864 1367 123 1229 172 2058 222 1787 305 28 125 144 4239 467 3670 47752 4824 41531 2712 274 2385 736 645 3268 267 2944 290 5077 575 4176 13785 525 1438 1453 10218 837 230 597 4280 480 3720 283 135 1083 723 479 1261 21 49 387 7 40 450 19 55 59 2 177 21 201 55 7 958 921 28 63 74 102 265 186 537 117 1674 172 125 51 44 100 Total 2505 1133 291 832 363 2099 1535 140 1378 204 2297 245 1999 362 31 148 174 4849 528 4209 53785 5481 46775 2999 304 2634 841 719 3696 319 3311 332 5720 641 4722 15524 573 1627 1589 11568 929 255 664 4843 560 4194 306 146 1252 833 536 1403 25 77 404 10 46 641 21 58 71 3 195 21 225 60 10 1109 1042 34 80 115 122 340 227 756 173 2123 228 158 66 56 127 * * * * *

Age-standardized (world) incidence rates (per 100,000) by histological type

0.4 0.6 0.7 0.6 0.6 0.4 0.4 0.1 0.4 0.5 0.4 0.5 0.4 0.3 0.2 0.4 0.3 0.4 0.5 0.5 0.4 0.4 0.4 0.4 0.3 0.4 0.5 0.3 0.4 0.3 0.3 0.4 0.4 0.5 0.4 0.3 0.2 0.4 0.3 0.3 0.4 0.6 0.3 0.3 0.4 0.3 0.3 0.3 0.3 0.3 0.2 0.4 0.3 0.2 0.0 0.0 0.0 0.7 0.3 0.1 0.1 0.2 0.1 0.1 0.3 0.3 0.4 0.1 0.2 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.3

0.2 0.0 0.0 0.0 0.2 0.2 0.2 0.3 0.2 0.1 0.2 0.3 0.2 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.1 0.1 0.4 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.3 0.4 0.3 0.0 0.0 0.1 0.1 0.1 0.2 0.3 0.1 0.1 1.9 2.2 0.1 0.1 0.1 0.1 0.1 0.9 0.1 0.3 0.2 0.2 0.5 0.7 0.0 0.3 0.2 0.4 0.5 0.4 0.5 0.5 0.5 0.4 0.5

* * * *

691

749

Kidney and renal pelvis (C64-65) - Female (Contd)

Carcinoma Squamous Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 0.1 0.2 0.2 0.2 0.1 0.1 0.2 0.2 0.2 0.2 0.5 0.2 0.2 0.2 0.2 0.4 0.2 0.1 0.1 0.3 0.3 0.1 0.2 0.6 0.8 0.1 0.4 0.2 0.3 0.3 0.2 0.2 0.4 0.2 0.2 0.5 0.3 0.5 0.5 0.4 0.4 0.7 0.2 0.2 0.3 0.5 0.2 0.3 0.0 0.3 0.4 0.2 0.3 0.3 0.2 0.3 0.3 0.2 0.2 0.3 0.1 0.4 0.4 0.3 0.5 0.1 0.2 0.1 0.2 0.2 0.3 0.2 0.1 0.2 Adeno 1.4 1.5 1.3 1.1 0.9 0.9 0.6 1.1 0.7 1.4 1.7 1.8 0.9 1.4 0.2 0.1 0.2 1.2 1.4 5.5 5.6 4.8 3.9 3.4 4.1 1.3 1.7 7.2 3.2 5.2 5.6 3.4 3.2 5.8 3.1 3.4 4.1 3.5 4.0 2.6 2.9 3.6 4.4 4.3 5.0 6.2 2.9 3.1 4.2 4.3 4.4 3.2 3.5 3.9 4.8 2.8 3.9 4.0 1.3 4.2 5.2 1.6 2.2 4.9 1.5 3.2 2.8 4.4 5.0 4.6 4.9 3.1 3.4 2.8 2.7 1.8 1.8 3.6 Other 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.3 0.0 0.1 0.0 0.0 0.1 0.0 0.5 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 Unspec. 0.0 0.1 0.3 0.1 0.4 0.0 0.0 0.0 0.0 0.2 0.2 0.1 0.0 0.0 0.1 0.1 1.1 0.1 0.1 0.2 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.3 0.2 0.1 0.1 0.3 0.2 0.1 0.4 0.1 0.1 0.2 0.3 0.1 0.1 0.1 0.8 0.3 0.4 0.1 0.0 0.3 0.2 0.5 0.1 0.3 0.0 0.2 0.1 0.4 0.2 0.0 0.1 0.6 Other Unspec. Number of cases MV 17 480 29 20 14 33 28 31 20 138 185 159 6 20 26 8 13 48 139 2572 171 70 1786 316 1069 549 640 3686 1038 390 287 100 75 194 162 179 237 91 103 68 102 335 614 627 343 74 422 40 170 113 328 129 41 280 183 64 595 104 27 107 310 75 61 42 27 214 179 117 484 537 910 49 795 117 270 272 291 1073 Total 22 597 35 27 17 42 28 34 21 225 246 213 8 25 35 14 17 52 148 2854 191 78 2549 343 1180 844 1016 4858 1274 478 312 107 82 215 169 205 245 99 117 81 108 434 741 744 375 87 547 55 209 138 403 184 51 362 217 86 660 131 41 137 398 123 82 53 38 273 246 140 601 851 1243 56 1013 194 400 281 311 1624

Age-standardized (world) incidence rates (per 100,000) by histological type

0.2 0.2 0.1 0.3 2.4 0.3 0.1 0.2 0.1 0.2 0.1 0.1 0.4 0.0 0.1 0.3 0.1 0.3 0.2 0.4 0.2 0.4 0.2 0.2 0.2 0.3 0.2 0.6 0.2 0.1 0.2 0.5 0.4 0.4 0.1 0.5 0.3 0.3 0.3 0.4 0.2 0.4 0.4 0.0 0.2 0.0 0.1 0.3 0.6 0.7 0.2 1.0 0.6 0.3 0.3 0.6 1.0 0.6 0.4 0.8 0.4 0.3 0.3 0.5 0.4 0.0 0.3 0.3 0.3 0.3

0.4 0.5 0.3 0.5 0.4 0.4 0.2 0.0 0.4 0.6 0.6 0.4 0.5 0.3 0.3 0.2 0.0 0.1 0.5 0.4 0.4 1.6 0.2 0.3 0.7 1.8 1.9 0.6 0.9 0.3 0.2 0.1 0.3 0.1 0.3 0.1 0.2 0.4 0.3 0.2 0.0 0.6 0.1 0.4 0.9 0.7 0.6 1.1 0.4 0.6 0.9 0.6 0.8 0.5 1.1 0.5 0.6 1.3 0.6 1.2 1.2 0.6 0.9 0.5 0.5 1.2 0.5 0.8 2.2 2.2 0.3 0.5 2.0 1.5 0.1 0.2 1.8

Eu

* * *

* * * *

* * *

* *

750

*I N

692

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Kidney and renal pelvis (C64-65) - Female (Contd)

Carcinoma Squamous Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 0.6 0.5 0.3 0.2 0.2 0.3 0.3 0.5 0.3 0.2 0.3 0.2 0.2 0.1 0.4 0.1 0.3 0.6 0.5 0.1 0.1 0.5 0.4 0.4 0.5 0.2 0.4 0.4 0.4 0.3 0.3 0.3 0.4 0.3 0.2 0.4 0.9 1.2 0.5 0.2 0.4 0.7 0.6 0.5 0.3 0.2 0.2 0.3 0.1 Adeno 1.5 4.4 3.1 2.0 2.9 2.9 1.4 1.6 2.7 2.1 1.9 2.5 1.9 2.3 3.6 2.4 3.4 3.0 3.3 2.9 2.9 3.0 3.4 3.3 3.4 2.6 2.8 2.8 3.4 2.8 2.7 2.2 2.8 2.7 2.7 3.1 4.3 4.2 4.2 5.7 4.4 4.1 5.6 0.6 3.4 3.3 2.0 3.2 3.9 2.8 3.8 Other 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.1 Unspec. 0.1 0.1 0.0 0.3 0.0 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.3 0.0 0.1 0.0 0.4 0.4 0.6 0.3 0.4 0.3 0.4 0.6 0.4 0.2 0.5 0.2 0.2 0.1 0.0 0.0 0.1 0.2 0.3 0.1 0.1 0.1 0.1 0.1 Other Unspec. Number of cases MV 517 1024 377 31 164 271 99 23 76 82 107 78 55 108 1926 48 40 29 92 55 38 113 2726 171 177 339 285 515 1035 319 967 1337 610 658 208 840 1355 663 273 113 931 297 67 6 522 170 10 28 20 51 49 Total 663 1326 389 35 219 344 131 33 93 102 122 100 71 114 2057 58 47 32 100 64 41 132 3251 207 197 487 452 805 1509 430 1410 2147 1000 928 299 1224 1543 813 336 130 1085 348 72 10 655 192 13 28 21 61 52

Age-standardized (world) incidence rates (per 100,000) by histological type

0.3 0.4 0.6 0.3 0.5 0.4 0.6 0.1 0.2 0.3 0.3 0.3 0.5 0.4 0.2 0.4 0.1 0.2 0.6 0.2 0.3 0.5 0.8 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.2 0.3 0.4 0.3 0.3 0.2 0.5 0.4 0.5 0.4 0.4 0.1 0.3

0.7 1.1 0.5 0.2 0.3 0.5 0.3 0.7 0.3 0.4 0.2 0.2 0.4 0.1 0.2 0.2 0.3 0.2 0.1 0.3 0.1 0.4 0.6 0.6 0.3 0.0 0.0 0.0 0.3 0.0 0.5 0.2 0.1 0.1 0.9 0.5 0.0 0.0 0.1 0.5 0.5 0.1 0.6 0.6 0.3 0.3 0.1 0.5 0.2

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

693

751

Age-standardized (world) incidence rates (per 100,000) by histological type

Bladder (C67) - Male

Carcinoma

Squamous Transitional Adeno Other Unspec. Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 0.5 4.7 0.2 0.1 1.0 0.4 0.5 0.2 0.1 0.2 0.0 0.2 0.2 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.3 0.1 0.2 0.1 0.1 0.3 0.1 0.1 0.2 0.2 0.2 0.2 0.2 0.3 0.2 0.2 0.5 0.1 0.1 0.2 0.0 0.3 0.1 0.2 0.2 0.2 0.4 0.2 0.3 0.4 0.2 0.2 0.3 0.2 0.2 0.2 0.3 0.2 0.3 0.2 0.2 0.1 0.2 0.1 0.2 0.2 0.3 0.2 0.3 0.3 0.3 0.2 0.1 0.2 2.2 17.8 17.9 0.9 1.3 11.0 9.3 5.0 11.1 12.9 3.2 6.8 4.4 4.0 5.0 2.7 15.5 18.5 19.2 14.5 21.6 18.3 10.3 23.6 12.1 17.1 18.6 16.2 6.7 18.2 20.5 19.7 18.0 16.5 9.7 6.2 6.5 10.1 8.9 20.9 16.3 10.1 8.8 6.1 8.7 11.0 7.8 22.9 7.5 10.2 9.3 22.2 19.5 25.3 9.3 26.2 13.3 11.0 16.3 22.1 8.0 23.4 17.6 16.4 8.7 19.1 9.6 19.8 21.6 21.7 10.0 23.1 20.4 21.1 21.6 18.4 12.0 22.5 9.4 21.4 26.4 26.0 0.5 1.2 0.3 0.0 0.1 0.8 0.5 0.9 0.4 0.5 0.3 0.2 0.1 0.5 0.4 0.2 0.2 0.1 0.3 0.1 0.2 0.3 0.3 0.4 0.1 0.2 0.1 0.3 0.3 0.2 0.2 0.4 0.0 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.1 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.3 0.2 0.1 0.3 0.4 0.3 0.2 0.3 0.3 0.3 0.4 0.2 0.1 0.2 0.1 0.3 0.3 0.2 0.2 0.3 0.2 0.3 0.5 0.3 0.3 0.2 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.2 0.2 0.0 0.1 0.1 0.1 0.0 0.1 0.3 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.0 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.5 1.2 0.4 0.3 2.9 3.1 0.2 0.2 0.4 0.9 0.1 0.4 0.1 0.2 0.4 0.5 0.2 0.3 0.2 0.4 0.4 0.1 0.2 0.1 0.1 0.4 0.3 0.2 0.3 0.4 0.3 0.3 0.3 0.2 0.4 0.2 0.2 0.3 0.3 0.4 0.3 0.1 0.2 0.3 0.3 0.2 0.2 0.2 0.3 0.3 0.4 0.2 0.5 0.4 0.4 0.4 0.5 0.3 0.5 0.3 0.3 0.5 0.3 0.4 0.3 0.2 0.4 0.3 0.4 0.3 0.2 0.3 0.3 0.7 0.1 0.4 0.3 0.4 0.2

Sarcoma Other Unspec.

Number of cases MV Total

0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.1 0.0

0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0

0.8 2.9 1.5 1.1 0.2 2.2 0.4 0.6 2.4 0.5 1.0 1.0 0.8 1.0 0.1 1.2 0.1 0.3 0.9 0.2 0.7 2.1 0.3 0.1 0.1 0.2 0.5 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.3 0.1 0.2 0.1 0.2 0.2 0.3 0.4 0.2 0.4 0.3 0.1 0.1 0.2 0.2 0.3 0.1 0.2 0.2 0.2 0.2 0.2 0.3 0.2 0.2 0.3 0.1 0.2 0.3 0.2

70 991 174 15 45 121 226 40 156 2839 32 260 343 120 77 33 13852 1776 3230 668 635 378 9 879 5371 96 810 2670 214 2419 302 4051 20410 3742 143 125 65 225 37 2992 4735 294 121 57 534 88 43 3504 954 647 1512 17006 2617 3419 71 3293 267 145 107 18260 480 17550 4199 1132 150 959 456 3708 996 9502 468 8779 4432 2570 3102 2814 130 530 358 2436 1363 6161

81 1080 175 29 95

* * * *

136 238 41 168 3309 35 293 423 141 88 33 * 15145 1812 3282 734 647 378 9 911 6445 96 831 2720 221 2462 307 4103 20643 3784 145 129 68 227 37 3022 4768 301 122 57 538 88 44 3524 969 659 1534 17188 2662 3457 73 3329 273 147 110 18528 495 17800 4275 1147 153 971 466 3773 1008 9640 477 8908 4492 2611 3158 2849 131 536 365 2463 1393 6244

752

*I N

694

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Bladder (C67) - Male (Contd)

Carcinoma

Squamous Transitional Adeno Other Unspec. America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008 0.2 0.2 0.3 0.2 0.3 0.2 0.2 0.6 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.2 0.2 0.2 0.2 0.3 0.2 0.1 0.2 0.1 0.1 0.2 0.2 0.4 0.2 0.1 0.2 0.3 0.2 0.2 0.1 0.3 0.1 0.2 0.2 0.3 0.2 0.1 0.2 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.6 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.5 0.1 0.2 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.3 0.1 0.0 0.0 0.0 0.0 0.0 23.3 23.9 10.7 27.5 10.7 24.8 19.7 10.0 20.5 21.3 24.9 10.7 27.1 15.7 3.7 10.2 19.9 22.7 9.0 25.1 20.9 9.4 22.3 22.0 10.5 22.4 17.3 23.5 25.0 11.8 26.0 29.9 20.2 9.8 22.3 19.8 8.1 10.2 10.2 23.1 18.7 7.9 21.5 16.2 8.6 17.0 16.0 21.2 22.8 22.9 23.0 20.9 10.7 4.3 9.9 5.3 1.1 3.6 19.8 1.6 2.9 2.7 2.5 3.0 1.8 25.8 26.2 17.2 9.3 9.7 15.8 9.2 10.9 5.8 5.9 7.6 8.4 8.0 8.5 8.4 7.6 0.2 0.3 0.4 0.3 0.4 0.2 0.2 0.5 0.2 0.2 0.3 0.3 0.3 0.2 0.2 0.2 0.3 0.3 0.3 0.2 0.3 0.2 0.3 0.5 0.3 0.3 0.2 0.2 0.3 0.2 0.3 0.2 0.4 0.2 0.2 0.1 0.3 0.2 0.2 0.2 0.2 0.3 0.2 0.3 0.2 0.1 0.2 0.2 0.2 0.2 0.3 1.3 0.2 0.2 0.2 0.1 0.0 0.3 0.1 0.2 0.1 0.1 0.1 0.0 0.3 0.3 0.2 0.2 0.2 0.3 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.4 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.3 0.1 0.2 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.4 0.3 0.5 0.2 0.3 0.2 0.1 0.2 0.5 0.4 0.2 0.4 0.2 0.1 0.3 0.5 0.3 0.6 0.4 0.3 0.4 0.6 0.2 0.6 0.3 0.2 0.3 0.3 0.3 0.2 0.3 0.3 0.3 0.3 0.2 0.3 0.2 0.3 0.2 0.1 0.3 0.3 0.3 0.3 0.2 0.8 0.2 0.3 0.3 0.4 1.4 1.8 0.1 0.1 0.0 1.3 0.3 0.1 0.0 1.4 0.0 0.5 0.6 0.0 0.3 0.1 0.7 0.1 0.1 0.1 0.0 0.1 0.2 0.1

Sarcoma Other Unspec.

Number of cases MV Total

0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 -

0.3 0.1 0.1 0.1 0.2 0.3 0.3 0.2 0.3 0.0 0.3 0.2 0.3 0.2 0.1 0.2 0.3 0.2 0.3 0.2 0.2 0.3 0.3 0.1 0.3 0.5 0.2 0.2 0.1 0.2 0.5 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.2 0.2 0.2 0.3 0.3 0.3 0.1 0.2 0.1 0.1 0.3 0.3 0.7 0.1 0.6 6.2 6.8 0.0 0.8 0.6 0.9 0.1 1.6 2.8 0.1 0.9 0.8 0.6 0.8 0.8 0.1 1.0 0.0 1.7 1.0 1.1 1.5 0.8 1.2 1.3 1.1

8399 3395 306 3067 410 7878 4258 163 4069 810 8003 322 7525 1043 12 202 817 15887 675 14926 172592 6453 161763 9512 373 8810 2324 3137 13004 416 12411 1234 18962 724 17311 50862 1566 2048 2206 44497 2641 249 2366 10289 482 9610 996 509 4809 3254 1795 4347 73 274 2376 71 116 1595 149 495 170 30 596 105 845 138 49 4558 4245 250 388 445 707 1026 896 2428 477 6688 676 421 217 220 355

8537 3423 308 3093 417 8007 4338 166 4145 827 8084 325 7603 1064 12 208 832 16299 697 15312 175440 6605 164400 9715 387 8991 2404 3190 13141 418 12544 1254 19184 734 17511 51459 1585 2080 2241 45005 2691 257 2407 10569 504 9864 1001 522 4877 3292 1817 4435 81 351 2499 73 138 1996 169 500 238 35 767 109 1128 167 51 4767 4422 255 415 473 718 1174 951 3011 549 7405 766 447 236 242 395 * * * * *

* * * *

695

753

Age-standardized (world) incidence rates (per 100,000) by histological type

Bladder (C67) - Male (Contd)

Carcinoma

Squamous Transitional Adeno Other Unspec. Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 0.1 0.0 0.2 0.3 0.1 0.1 0.6 0.2 0.1 0.1 0.0 0.2 0.2 0.2 0.1 0.2 0.4 0.1 0.1 0.4 0.4 0.2 0.2 0.3 0.2 0.2 0.2 0.2 0.3 0.1 0.2 0.4 0.2 0.2 0.1 0.2 0.3 0.5 0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.1 0.2 0.0 0.1 0.1 0.4 0.0 0.2 0.3 0.2 0.2 0.5 0.0 0.1 0.2 0.2 0.2 0.1 0.1 0.2 0.2 0.1 0.6 1.1 0.1 0.1 0.1 0.0 0.2 0.1 0.5 5.3 9.7 6.5 4.6 5.9 5.3 2.3 4.0 8.5 3.4 6.9 7.3 4.3 7.1 4.3 4.5 3.7 13.7 15.3 18.4 24.5 22.5 10.9 20.1 22.6 9.7 11.5 18.1 24.8 14.5 14.9 13.2 14.8 17.9 14.9 14.4 11.7 10.4 14.2 14.1 10.3 18.9 18.1 19.4 11.5 19.5 12.8 31.0 27.8 33.1 34.0 35.3 30.1 25.6 30.8 37.7 19.6 28.6 28.4 29.6 32.6 30.5 23.6 35.5 31.6 36.1 29.7 29.5 28.9 8.2 9.8 25.1 18.6 13.0 12.2 16.9 13.0 6.1 0.1 0.2 0.5 0.1 0.5 0.3 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.1 0.3 0.4 0.2 0.1 0.1 0.5 0.3 0.4 0.2 0.3 0.3 0.3 0.3 0.3 0.2 0.5 0.2 0.1 0.2 0.5 0.3 0.3 0.3 0.2 0.2 0.2 0.3 0.1 0.2 0.4 0.5 0.6 0.1 0.1 0.5 0.4 0.2 1.0 0.3 0.2 0.4 0.2 0.1 0.4 0.8 0.2 0.4 0.4 0.4 0.1 0.3 0.9 0.8 0.6 0.2 0.4 0.1 0.3 0.4 0.3 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.2 0.1 0.1 0.0 0.1 0.2 0.2 0.2 0.0 0.1 0.0 0.2 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.3 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.2 0.5 0.2 0.1 0.1 0.3 0.2 0.1 0.1 0.1 0.0 0.2 0.4 1.3 0.5 0.9 0.2 0.7 1.7 0.2 1.5 0.3 0.2 0.6 0.3 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.4 0.1 0.1 1.6 0.1 2.5 0.4 0.3 0.3 0.4 0.3 0.2 0.3 0.2 0.9 2.2 0.3 0.3 0.7 0.6 0.2 0.2 0.3 0.5 0.4 0.3 0.9 1.5 0.4 0.4 0.3 1.1 0.3 0.2 0.8 0.3 0.3 0.6 1.2

Sarcoma Other Unspec.

Number of cases MV Total

0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0

1.2 1.0 1.4 1.1 0.3 1.2 0.3 0.2 0.7 0.2 0.2 0.1 0.3 0.4 0.9 0.5 1.4 1.0 0.7 0.6 0.5 2.3 0.1 0.7 2.5 4.6 1.0 0.8 0.6 0.2 1.0 0.1 0.1 0.1 0.1 0.1 0.5 0.3 0.3 0.2 0.3 1.3 0.3 0.4 0.3 0.9 1.2 3.7 1.3 2.6 4.6 2.1 2.2 0.1 7.9 1.0 1.2 3.6 1.2 2.5 6.2 3.3 2.9 1.6 0.8 2.5 1.4 1.5 4.4 3.8 0.7 0.3 3.4 3.4 0.3 1.6 3.2

43 1892 83 46 101 122 99 83 218 237 586 482 34 70 188 101 106 416 1294 6476 622 275 3945 1686 5354 3418 2322 6995 5793 719 582 376 308 498 691 645 535 275 356 303 293 1418 1837 2313 625 192 1715 317 758 672 2132 1132 332 1558 1019 596 2172 661 401 721 1832 1142 507 276 453 1778 1456 649 2242 996 1566 359 3809 247 803 1947 1740 1149

47 2022 95 57 103 128 107 85 219 279 600 493 35 72 199 121 119 445 1353 6654 630 284 4323 1691 5587 4313 3079 7424 6154 743 588 378 311 504 695 652 538 279 363 310 295 1603 1968 2526 645 196 1844 330 836 737 2310 1276 356 1674 1024 739 2273 699 436 755 1960 1356 583 295 479 1820 1602 675 2331 1153 1844 368 3889 444 1016 1985 1931 1597

Eu

* * *

* * * *

* * *

* *

754

*I N

696

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Bladder (C67) - Male (Contd)

Carcinoma

Squamous Transitional Adeno Other Unspec. Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 0.2 0.3 0.2 0.3 0.1 0.2 0.4 0.3 0.2 0.2 0.3 0.2 0.1 0.2 0.1 0.3 0.8 0.2 0.2 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.3 0.3 0.2 0.4 0.2 0.2 0.2 0.1 0.4 0.1 0.1 0.2 0.3 0.1 0.2 0.3 0.1 0.0 0.2 0.1 11.8 12.4 13.7 24.0 27.4 29.8 19.4 18.6 34.3 27.9 34.5 34.6 34.6 28.4 16.8 27.9 12.0 12.3 10.8 16.6 21.5 15.4 13.6 25.2 23.5 20.6 21.3 23.0 23.9 15.6 20.7 17.0 21.1 19.9 9.4 21.2 10.7 18.2 21.6 20.1 6.4 8.1 11.3 10.2 14.4 12.4 7.5 6.1 11.5 12.5 19.8 0.7 0.2 0.2 0.4 0.3 0.2 0.2 0.4 0.1 0.2 0.1 0.5 0.1 0.3 0.2 0.5 0.3 0.1 0.2 0.2 0.5 0.2 0.2 0.2 0.2 0.2 0.3 0.2 0.1 0.4 0.2 0.3 0.3 0.1 0.2 0.2 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.3 0.1 0.0 0.1 0.1 0.1 0.4 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.2 0.2 0.3 0.3 0.4 0.3 0.5 0.5 0.2 0.7 0.5 0.6 0.6 0.9 0.1 0.2 0.9 0.6 0.2 0.6 0.3 0.1 0.1 0.2 0.6 1.1 1.4 0.6 0.9 0.8 1.3 1.4 0.8 0.2 0.7 0.3 0.4 0.1 0.2 0.1 0.2 0.2 0.3 0.1 0.2 0.2 0.2 0.1

Sarcoma Other Unspec.

Number of cases MV Total

0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.2 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 -

0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 -

1.6 1.2 0.6 1.9 1.1 1.3 1.0 2.4 1.0 1.1 2.1 0.6 2.0 0.8 0.1 0.4 0.5 0.3 0.3 0.7 0.4 0.3 0.2 0.0 0.2 0.0 0.1 0.4 0.3 0.0 2.8 0.4 0.3 0.2 1.8 0.5 0.1 0.0 0.2 0.3 0.6 0.1 0.2 0.6 0.5 0.1 0.0 0.2

2622 2085 1043 350 1488 2213 996 247 872 959 1505 884 796 1169 7571 461 133 95 238 254 245 425 8895 973 901 2759 2312 4249 7207 1795 7233 10247 4757 4800 618 4775 2779 2329 1384 393 1286 572 102 43 2039 631 33 49 55 210 257

2931 2303 1061 370 1553 2329 1044 286 898 1002 1592 905 853 1214 7588 468 140 98 247 266 250 433 9000 975 908 2858 2432 4480 7475 1875 8350 11249 5203 4994 721 5012 2964 2516 1443 397 1413 592 111 45 2115 637 33 49 55 211 261

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

697

755

Age-standardized (world) incidence rates (per 100,000) by histological type

Bladder (C67) - Female

Carcinoma

Squamous Transitional Adeno Other Unspec. Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 1.9 0.1 0.7 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.3 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.0 0.2 0.1 0.2 0.1 0.1 0.3 0.1 0.2 0.3 0.1 0.3 0.1 0.2 0.2 0.3 0.2 0.3 0.1 0.1 0.2 0.3 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.0 0.1 0.3 2.3 2.0 0.9 1.0 1.8 3.0 1.2 2.5 3.0 1.2 1.4 1.0 0.8 1.2 1.2 4.2 5.1 5.6 3.6 5.5 5.4 2.0 6.0 3.2 3.5 5.9 4.0 2.5 4.4 4.1 5.0 4.4 4.6 3.4 1.9 1.3 3.2 3.0 5.9 3.8 3.7 1.8 0.8 2.2 3.1 2.7 5.2 1.7 3.4 2.4 5.5 5.1 7.2 3.0 7.5 4.9 4.8 5.3 5.7 2.7 6.0 4.1 4.3 3.7 4.7 2.9 4.5 4.6 5.6 3.8 5.9 5.1 5.2 5.2 4.5 3.5 6.2 3.6 4.9 7.7 7.4 0.1 0.4 0.1 0.2 0.2 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.3 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.1 0.0 0.1 0.1 0.5 1.7 0.6 0.1 0.1 0.2 0.3 0.1 0.3 0.1 0.1 0.0 0.1 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.3 0.1 0.2 0.1 0.1 0.1

Sarcoma Other Unspec.

Number of cases MV Total

0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.1 0.8 0.5 0.4 0.2 0.6 0.7 0.3 0.9 0.3 0.4 0.5 0.3 0.1 0.4 0.1 0.1 0.2 0.0 0.3 0.6 0.2 0.2 0.0 0.1 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.1

10 232 22 11 31 26 96 11 51 1028 14 91 95 40 29 16 4663 568 1129 208 205 114 2 279 1843 27 288 903 125 768 67 1242 6592 1360 71 48 17 98 17 1073 1580 151 30 10 202 28 20 1106 286 307 549 5362 840 1269 38 1216 159 110 46 5990 249 5675 1472 451 109 338 254 1211 258 3427 308 3030 1545 846 1038 953 63 186 209 737 516 2403

11 262 22 17 63

* * * *

31 104 16 59 1299 17 109 138 53 33 16 * 5241 599 1169 238 209 114 2 300 2279 30 301 933 134 789 72 1269 6751 1390 72 48 17 100 17 1099 1601 154 30 10 206 29 20 1119 292 312 562 5496 874 1293 38 1240 162 111 47 6100 258 5773 1515 457 113 340 267 1241 266 3514 325 3100 1584 880 1080 975 66 188 219 749 541 2466

756

*I N

698

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Bladder (C67) - Female (Contd)

Carcinoma

Squamous Transitional Adeno Other Unspec. America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.3 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.0 0.2 0.1 0.1 0.2 0.3 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.1 0.2 0.1 0.4 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.0 0.0 0.0 5.9 6.0 3.7 6.8 3.7 6.2 4.8 3.4 4.9 6.2 6.6 3.8 7.2 4.1 0.5 2.1 5.5 6.2 3.0 6.9 5.4 3.2 5.7 5.7 3.6 5.7 4.1 6.0 6.6 4.0 6.8 8.8 5.2 3.6 5.8 5.0 1.8 3.5 2.7 5.8 4.2 3.1 4.5 3.7 2.8 3.9 4.0 7.1 5.6 5.5 7.2 5.8 2.7 1.0 2.4 0.8 0.3 0.5 3.5 0.5 0.1 0.6 0.9 0.6 0.3 4.6 4.8 1.6 1.6 1.7 3.0 2.0 1.9 1.1 1.6 1.3 1.2 1.6 1.6 1.7 1.2 0.1 0.1 0.3 0.1 0.3 0.1 0.1 0.3 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.4 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.2 0.2 0.2 0.1 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.3 0.1 0.2 0.0 0.4 0.0 0.0 0.3 0.1 0.1 0.1 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0

Sarcoma Other Unspec.

Number of cases MV Total

0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 -

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 -

0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.2 0.0 0.1 1.8 1.7 0.3 0.2 0.0 0.4 1.0 0.0 0.2 0.1 0.5 0.4 0.5 0.0 0.5 0.3 0.3 0.4 0.4 0.2 0.3 0.3

2853 1206 186 1010 235 2578 1424 94 1317 271 2971 196 2720 337 3 60 270 6148 430 5636 59765 3671 54695 3431 212 3109 766 1001 4735 227 4453 474 6508 433 5794 17144 469 1121 809 14573 823 162 656 3301 258 2974 300 222 1474 982 748 1563 20 74 768 13 41 465 29 100 64 2 140 36 156 48 12 1091 1051 26 89 120 193 327 256 676 175 1620 131 115 59 67 85

2899 1214 191 1013 242 2617 1470 96 1361 281 3036 204 2777 348 3 61 280 6382 448 5848 61379 3832 56118 3526 220 3194 805 1022 4820 236 4527 482 6653 445 5923 17555 478 1156 824 14924 854 175 674 3460 277 3111 306 225 1512 1013 766 1611 21 95 803 15 45 609 37 100 86 2 182 37 225 61 13 1153 1101 26 112 143 207 423 291 937 216 1935 176 139 67 77 104 * * * * *

* * * *

699

757

Age-standardized (world) incidence rates (per 100,000) by histological type

Bladder (C67) - Female (Contd)

Carcinoma

Squamous Transitional Adeno Other Unspec. Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 0.0 0.1 0.1 0.3 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.3 0.4 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.2 0.2 0.1 0.0 0.1 0.1 0.0 0.1 0.8 1.7 1.2 2.0 2.2 1.0 0.4 1.5 2.3 0.7 1.6 1.6 0.8 1.8 1.8 1.0 0.6 2.0 1.8 4.5 6.6 4.2 1.3 3.5 4.2 1.7 2.3 4.6 6.6 2.4 1.8 1.3 1.8 2.3 2.2 1.6 1.7 1.8 2.1 2.1 1.4 4.6 4.5 4.3 2.7 5.7 4.1 6.1 4.6 6.2 6.5 5.6 5.3 4.8 5.5 4.9 3.7 6.0 4.2 5.8 5.8 3.9 3.4 8.9 3.5 6.2 5.3 4.3 5.8 1.4 1.4 4.4 4.9 2.6 2.8 3.3 2.5 1.1 0.1 0.1 0.2 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.2 0.0 0.1 0.1 0.0 0.1 0.1 0.3 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.4 0.1 0.0 0.2 0.1 0.1 0.0 0.0 0.1 0.0 0.3 0.2 0.2 0.0 0.1 0.4 0.0 0.4 0.1 0.1 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.5 0.0 0.8 0.2 0.3 0.1 0.1 0.0 0.1 0.2 0.5 0.2 0.2 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.3 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.3

Sarcoma Other Unspec.

Number of cases MV Total

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0

0.3 0.3 0.2 0.4 0.3 0.2 0.1 0.2 0.0 0.3 0.1 0.1 0.1 0.3 0.4 0.1 0.3 0.1 0.3 0.6 0.2 0.3 0.0 0.2 0.5 1.0 0.3 0.4 0.2 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.3 0.1 0.1 0.0 0.3 0.2 0.8 0.4 0.5 1.2 0.3 0.6 0.2 1.4 0.2 0.2 0.8 0.3 0.6 0.9 0.5 0.8 0.2 0.3 0.4 0.3 0.3 0.7 0.7 0.0 0.1 0.9 1.0 0.1 0.4 0.7

11 472 20 21 12 37 26 35 46 81 172 151 3 18 82 28 21 63 165 2415 245 75 779 392 1342 757 719 2502 1960 243 129 63 63 103 148 120 144 70 70 76 56 518 693 760 245 71 667 88 178 170 493 261 69 467 246 86 630 181 72 179 410 184 98 88 60 439 339 143 634 313 430 84 1282 73 289 572 480 430

16 548 24 27 14 39 30 36 47 102 181 159 3 19 96 39 23 72 175 2560 249 81 865 393 1467 992 983 2731 2156 268 135 67 64 108 148 127 147 70 76 78 56 646 769 909 262 72 721 93 212 195 551 339 75 536 253 122 687 196 85 188 455 223 115 97 65 469 364 155 672 381 545 85 1341 146 384 583 556 666

Eu

* * *

* * * *

* * *

* *

758

*I N

700

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Bladder (C67) - Female (Contd)

Carcinoma

Squamous Transitional Adeno Other Unspec. Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.3 0.0 0.4 0.0 0.2 0.1 0.2 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.2 0.3 0.2 0.3 0.1 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.4 0.2 2.9 2.9 2.8 2.5 3.3 4.2 2.3 2.9 4.3 2.8 3.7 4.7 4.9 3.5 4.7 5.8 2.1 2.4 2.6 3.1 4.4 3.0 2.8 5.5 5.4 5.5 5.6 6.8 6.9 3.8 5.3 4.3 6.1 5.3 2.2 6.5 3.0 4.7 5.6 5.6 1.7 2.1 3.1 2.8 3.9 2.8 1.1 1.7 3.4 2.2 4.3 0.2 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.0 0.0 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.1 0.0 0.1 0.1 0.0 0.2 0.2 0.1 0.1 0.1 0.4 0.1 0.2 0.1 0.0 0.0 0.1 0.1 0.1 0.3 0.4 0.6 0.3 0.3 0.2 0.4 0.5 0.3 0.1 0.2 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 -

Sarcoma Other Unspec.

Number of cases MV Total

0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.6 0.3 0.1 0.2 0.2 0.3 0.2 0.3 0.2 0.0 0.3 0.2 0.3 0.1 0.0 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 1.0 0.1 0.1 0.1 0.5 0.3 0.0 0.0 0.1 0.2 0.2 0.0 0.5 0.2 0.0 0.1 0.0

803 677 339 53 262 402 156 46 152 129 231 142 146 191 2683 135 34 31 91 72 69 123 2620 269 262 957 872 1685 2814 569 2514 3671 1750 1731 244 2036 1014 726 456 135 492 194 31 11 732 179 12 14 21 54 61

947 765 350 58 289 451 173 54 165 133 246 158 161 202 2691 140 38 33 99 74 71 132 2682 272 263 1039 962 1883 3041 624 3062 4242 2015 1881 293 2203 1089 791 474 141 547 213 34 13 778 182 12 14 22 54 62

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

701

759

Age-standardized (world) incidence rates (per 100,000) by histological type

Eye (C69) - Male

Retinoblastoma Melanoma

Squamous Other Unspec. 0.1 0.3 0.2 1.6 3.4 0.8 0.7 0.4 0.4 0.2 0.3 0.4 0.4 0.1 0.4 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.2 0.2 0.0 0.2 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.2 0.2 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

Carcinoma

Sarcoma Other Unspec.

Number of cases MV Total

Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.1 0.1 0.1 0.2 0.0 0.2 0.4 0.3 0.1 0.2 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.0 0.1 0.4 0.1 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.3 0.9 0.2 0.2 0.1 0.2 0.2 0.1 0.1 0.1 0.4 0.4 0.5 0.2 0.2 0.2 0.2 0.1 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.1

0.0 0.2 0.0 0.3 0.3 0.2 0.1 0.1 0.5 0.5 0.5 0.5 0.4 0.4 0.3 0.5 0.2 0.6 0.3 0.0 0.3 0.2 0.4 0.4 0.5 0.1 0.2 0.7 0.3 0.1 0.1 0.5 0.1 0.0 0.1 0.6 0.5 0.4 0.4 0.5 0.0 0.6 0.3 0.3 0.4 0.4 0.3 0.4 0.0 0.5 0.5 0.6 0.6 0.5 0.6 0.1 0.6 0.5 0.7

0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.0 0.4 0.6 0.1 0.0 0.2 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0

4 21 3 48 140 3 34 8 19 257 3 32 54 20 1 7 360 47 39 14 9 9 0 15 205 3 19 43 2 40 6 79 542 108 2 1 2 0 10 86 136 3 1 0 44 0 82 17 12 100 394 55 46 2 44 3 2 1 269 16 241 92 25 2 20 14 76 13 172 11 148 73 63 83 65 2 12 5 59 18 53

4 24 3 56 141

* * * *

3 38 8 19 310 3 33 60 21 1 7* 555 61 91 23 10 9 0 18 312 3 28 64 4 59 9 100 718 143 2 1 2 0 15 114 165 3 2 0 49 1 0 104 20 13 117 544 82 62 2 60 3 2 1 482 23 441 121 32 2 27 16 103 17 235 12 208 126 85 109 88 2 17 9 78 33 159

760

*I N

702

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Eye (C69) - Male (Contd)

Retinoblastoma Melanoma

Squamous Other Unspec. 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.2 0.1 0.2 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

Carcinoma

Sarcoma Other Unspec.

Number of cases MV Total

America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.2 0.3 0.2 0.3 0.2 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.5 0.1 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.3 0.2 0.0 0.1 0.1 0.0 0.2 0.2 0.2 0.3 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1

0.4 0.3 0.1 0.4 0.1 0.4 0.6 0.6 0.6 0.5 0.1 0.6 0.3 0.1 0.4 0.5 0.0 0.6 0.5 0.0 0.5 0.4 0.0 0.5 0.5 0.7 0.6 0.1 0.6 0.5 0.5 0.0 0.5 0.5 0.1 0.1 0.1 0.6 0.3 0.4 0.4 0.0 0.5 0.7 0.3 0.6 0.6 0.6 0.7 0.0 0.0 0.1 0.0 0.1 0.0 0.2 0.2 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1

0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0

150 60 7 51 8 136 88 3 82 16 124 7 110 25 3 7 15 283 22 254 3312 143 3002 168 8 153 54 56 210 7 194 9 394 14 352 1141 34 38 125 909 46 7 38 302 10 284 30 3 89 62 42 125 0 12 31 1 1 22 5 4 21 1 31 12 82 6 4 60 50 6 3 0 4 21 6 16 3 153 10 14 10 6 11

188 66 7 57 9 170 138 4 130 25 190 9 174 34 3 8 23 438 25 403 4871 180 4491 221 8 206 85 94 324 10 304 20 530 14 486 1546 37 46 151 1271 66 8 57 387 13 366 51 9 143 95 53 157 0 13 32 1 2 28 5 6 23 1 37 13 95 7 4 76 59 7 3 0 4 21 6 21 4 206 13 14 14 9 14 * * * * *

* * * *

Cancer Incidence in Five Continents Vol. IX, IARC 2008

703

761

Age-standardized (world) incidence rates (per 100,000) by histological type

Eye (C69) - Male (Contd)

Retinoblastoma Melanoma

Squamous Other Unspec. 0.1 0.0 0.1 0.1 0.3 0.2 0.0 0.0 0.0 0.2 0.1 0.2 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0

Carcinoma

Sarcoma Other Unspec.

Number of cases MV Total

Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.2 0.1 0.2 0.3 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.2 0.1 0.2 0.1 0.3 0.2 0.3 0.0 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.6 0.1 0.1 0.1 0.4 0.1 0.1 0.2 0.2 0.1

0.1 0.1 0.0 0.3 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.2 0.1 0.3 0.5 0.5 0.5 0.3 0.4 0.2 0.3 0.5 0.8 0.8 0.6 0.2 0.6 0.5 0.3 0.5 0.6 0.4 0.7 0.5 0.2 0.4 0.1 0.4 0.5 0.3 0.6 0.3 0.3 0.1 0.4 0.3 0.3 0.3 0.3 0.2 0.3 0.3 0.2 0.5 0.4 0.3 0.2 0.4 0.7 0.3 0.3 0.5 0.5 0.4 0.4 0.1 0.7 0.5 0.2 0.2 0.3 0.3

0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 -

0.0 0.0 0.1 0.1 0.0 0.1 0.0 -

0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.2 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.3 0.1 0.2 0.0 0.1 0.2 0.0 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.1 0.3 0.1 0.1 0.1 0.0 0.1 0.3 0.0 0.3 0.1 0.1 0.2 0.2 0.1 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.0 0.1

2 46 7 2 6 4 11 12 22 33 13 11 1 1 14 3 13 10 19 83 12 6 192 19 80 107 56 194 161 34 12 8 9 5 19 13 14 9 8 7 12 19 18 39 27 5 64 1 10 1 13 5 1 10 6 5 41 6 4 13 24 11 5 3 4 10 16 10 24 47 58 3 95 14 15 48 41 51

3 53 9 4 7 4 15 12 23 40 15 12 2 1 17 4 13 10 20 104 12 7 201 20 102 115 101 236 217 41 27 10 15 19 19 26 32 12 16 10 14 29 41 49 27 5 96 2 15 3 28 10 2 18 10 5 58 7 5 15 29 16 5 3 8 18 22 13 40 54 64 3 141 16 16 50 45 56

Eu

* * *

* * * *

* * *

* *

762

*I N

704

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Eye (C69) - Male (Contd)

Retinoblastoma Melanoma

Squamous Other Unspec. 0.1 0.1 0.0 0.2 0.0 0.1 0.3 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.5 0.1 0.5 0.2 0.3 0.1 0.2 0.1 0.1 0.5 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 -

Carcinoma

Sarcoma Other Unspec.

Number of cases MV Total

Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White

0.0 0.1 0.1 0.2 0.1 0.1 0.4 0.1 0.1 0.4 0.6 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.3 0.2 0.1 0.2 0.6 0.2 0.1 0.4 -

0.1 0.6 0.5 0.6 0.3 0.3 0.2 0.1 0.2 0.4 0.2 0.2 0.2 0.3 0.5 0.2 0.9 0.6 0.3 0.1 0.4 0.3 0.5 0.9 0.3 0.4 0.4 0.6 0.5 0.5 0.4 0.5 0.5 0.3 0.3 0.5 0.6 0.8 1.1 0.4 0.6 0.6 1.0 0.2 0.7 0.0 0.1

0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.4 -

0.0 0.0 0.0 0.0 0.0 -

0.3 0.0 0.1 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.1 0.0 0.1 0.0 0.1 -

42 105 35 8 14 26 23 2 7 13 10 8 7 14 192 5 9 5 5 3 4 10 303 32 11 37 37 88 98 43 119 158 74 69 24 108 166 132 53 15 136 62 5 6 130 12 0 1 4 3 4

86 115 35 9 16 30 23 2 9 15 12 10 7 15 291 7 9 5 6 4 6 11 357 35 11 51 47 107 147 63 204 265 110 82 32 129 225 170 76 17 149 65 9 6 137 12 0 1 4 3 4

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

705

763

Age-standardized (world) incidence rates (per 100,000) by histological type

Eye (C69) - Female

Retinoblastoma Melanoma

Squamous Other Unspec. 0.0 0.1 1.6 3.0 0.0 0.2 0.1 0.5 0.2 0.3 0.1 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

Carcinoma

Sarcoma Other Unspec.

Number of cases MV Total

Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.1 0.1 0.2 0.1 0.3 0.3 0.3 0.2 0.3 0.1 0.1 0.1 0.1 0.0 0.2 1.5 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.0 0.0 0.2 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.2 0.3 0.1 0.1 0.2 0.2 0.1 0.2 0.1 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.0

0.1 0.1 0.1 0.0 0.2 0.1 0.3 0.2 0.1 0.1 0.0 0.1 0.4 0.4 0.4 0.3 0.3 0.3 0.3 0.4 0.2 0.3 0.2 0.0 0.2 0.1 0.3 0.4 0.4 0.1 0.1 0.4 0.5 0.3 0.0 0.1 0.5 0.0 0.0 0.2 0.5 0.7 0.4 0.1 0.4 0.1 0.1 0.4 0.1 0.5 0.2 0.2 0.3 0.0 0.3 0.4 0.3 0.0 0.3 0.4 0.5 0.5 0.3 0.2 0.5 0.1 0.5 0.7 0.5

0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.2 0.3 0.6 0.0 0.3 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0 13 2 51 111 3 16 3 17 229 3 31 30 19 0 6 270 38 27 12 12 7 1 11 149 2 11 28 5 23 2 54 375 85 1 0 1 0 10 71 81 2 1 1 23 0 52 9 5 66 281 45 51 3 48 4 2 1 214 6 200 67 20 5 14 10 55 13 132 11 113 52 55 69 45 3 8 6 39 8 45

0 14 2 60 117

* * * *

4 32 3 18 300 3 32 35 21 0 6* 454 46 73 17 14 7 1 14 259 2 21 45 5 40 3 80 547 112 1 0 2 0 12 92 120 3 1 1 29 0 0 83 13 6 86 420 107 81 3 77 4 2 1 412 11 387 91 28 5 22 10 79 20 185 11 164 97 73 90 75 3 15 7 68 40 145

764

*I N

706

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Eye (C69) - Female (Contd)

Retinoblastoma Melanoma

Squamous Other Unspec. 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

Carcinoma

Sarcoma Other Unspec.

Number of cases MV Total

America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.4 0.1 0.1 0.1 0.1 0.3 0.2 0.2 0.2 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.0 0.1 0.2 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.2 0.2 0.1 0.1 0.3 0.2 0.0 0.2 0.1 0.2 0.2 0.0 0.1 0.2 0.1 0.3 0.1 0.2 0.1 0.1 0.0 0.3 0.1 0.3 0.2 0.1 0.1 0.1 0.1 0.1 0.1

0.3 0.3 0.0 0.4 0.0 0.4 0.3 0.4 0.5 0.4 0.4 0.3 0.1 0.5 0.4 0.0 0.5 0.4 0.0 0.4 0.4 0.0 0.4 0.4 0.6 0.5 0.1 0.5 0.5 0.4 0.0 0.4 0.4 0.0 0.0 0.2 0.5 0.2 0.0 0.2 0.3 0.0 0.3 0.5 0.3 0.5 0.4 0.4 0.5 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0

116 47 4 42 4 107 70 1 69 17 98 3 90 24 1 8 15 246 15 221 2552 114 2319 146 7 136 40 34 153 12 138 9 343 13 314 872 22 29 89 711 21 1 19 222 14 199 19 5 92 59 23 106 1 9 24 1 2 14 6 5 19 1 32 14 31 3 4 49 45 4 1 2 2 6 6 23 1 133 11 8 3 8 9

153 58 5 51 5 141 99 1 98 23 172 3 162 35 1 10 24 416 17 389 4121 128 3816 213 7 201 67 84 274 13 258 22 483 14 448 1291 27 32 113 1087 45 1 39 301 14 274 38 12 131 82 37 128 1 11 26 1 2 18 6 5 19 1 33 14 39 3 4 65 57 4 3 2 3 6 8 24 1 177 13 9 5 8 10 * * * * *

* * * *

Cancer Incidence in Five Continents Vol. IX, IARC 2008

707

765

Age-standardized (world) incidence rates (per 100,000) by histological type

Eye (C69) - Female (Contd)

Retinoblastoma Melanoma

Squamous Other Unspec. 0.0 0.3 0.2 0.2 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0

Carcinoma

Sarcoma Other Unspec.

Number of cases MV Total

Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.4 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.5 0.2 0.1 0.2 0.1 0.1 0.3 0.2 0.1 0.2 0.1 0.6 0.1 0.1 0.1 0.4 0.1

0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.2 0.2 0.5 0.3 0.5 0.1 0.4 0.2 0.2 0.4 0.6 0.6 0.6 0.1 0.7 0.5 0.2 1.0 0.3 0.4 0.6 0.1 0.2 0.2 0.1 0.2 0.3 0.3 0.7 0.3 0.2 0.5 0.3 0.2 0.6 0.2 0.4 0.2 0.2 0.1 0.4 0.2 0.2 0.1 0.1 0.3 0.2 0.4 0.1 0.4 0.4 0.4 0.1 0.6 0.3 0.2 0.2 0.2 0.3

0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.1 -

0.0 0.0 0.0 0.0 0.1 0.0 0.0 -

0.0 0.1 0.7 0.0 0.0 0.1 0.1 0.0 0.0 0.3 0.1 0.0 0.0 0.4 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.2 0.1 0.1 0.2 0.1 0.0 0.0 0.1 0.5 0.0 0.3 0.2 0.3 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.2

0 44 1 0 2 3 10 12 10 27 7 5 0 2 3 4 7 6 31 86 8 3 237 12 95 107 54 179 133 35 13 7 8 8 13 13 12 7 8 0 7 20 20 26 20 3 67 1 4 14 10 4 3 10 14 3 29 3 1 4 9 2 2 0 5 6 9 5 18 52 75 8 108 8 20 40 42 86

0 51 2 0 4 4 12 12 10 36 7 5 0 2 4 4 7 8 37 111 13 5 259 12 118 118 146 222 180 42 23 8 17 19 13 45 18 7 16 3 10 28 41 39 21 3 109 4 10 18 23 6 4 23 18 4 52 5 4 7 20 11 2 1 6 14 21 6 42 57 91 9 147 10 27 41 48 101

Eu

* * *

* * * *

* * *

* *

766

*I N

708

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Eye (C69) - Female (Contd)

Retinoblastoma Melanoma

Squamous Other Unspec. 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.3 0.1 0.1 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 -

Carcinoma

Sarcoma Other Unspec.

Number of cases MV Total

Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White

0.1 0.1 0.1 0.2 0.1 0.6 0.2 0.1 0.2 0.1 0.1 0.4 0.5 0.2 0.3 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.0 0.1 0.2 0.2 0.2 0.2 0.0 0.0 0.2 0.2 0.1 0.4 0.3

0.1 0.5 0.3 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.2 0.3 0.2 0.4 0.2 0.3 0.4 0.4 0.1 0.1 0.2 0.4 0.2 0.3 0.4 0.3 0.2 0.5 0.3 0.3 0.4 0.3 0.2 0.1 0.6 0.5 0.7 0.9 0.3 0.4 0.5 0.9 0.7 0.1 0.0 0.2

0.0 0.2 0.1 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 -

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.2 0.1 0.0 0.0 0.1 0.1 0.2 0.1 0.0 0.2 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 -

57 99 33 1 13 21 7 1 4 2 6 7 8 10 165 2 4 6 8 2 1 8 259 7 16 41 36 41 100 26 98 150 62 47 14 130 124 63 37 7 75 29 9 1 118 10 0 2 0 1 6

87 118 33 4 15 25 8 1 6 4 12 8 10 10 254 5 5 6 12 2 1 8 309 10 17 53 40 59 138 46 198 276 80 59 17 152 161 98 64 9 86 35 11 1 124 11 0 2 0 1 7

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

709

767

Brain and central nervous system (C71-72) - Male

Astro. Oligo. Epend. Other Medullobl. Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 0.5 1.9 2.3 0.2 0.5 2.2 2.7 1.8 2.9 3.3 0.9 3.0 1.8 2.4 1.7 3.0 3.8 3.9 3.9 3.9 4.7 5.1 2.6 5.2 3.4 3.1 3.8 4.0 2.2 4.5 3.7 3.9 4.0 3.8 2.6 1.7 1.5 3.0 2.5 4.8 3.6 1.9 2.4 1.0 2.9 2.7 0.6 5.2 1.8 2.2 3.1 5.1 4.1 4.7 2.1 4.9 4.0 3.8 3.5 4.1 2.7 4.4 4.3 4.3 2.4 5.2 2.6 4.8 5.7 3.9 2.3 4.2 4.3 4.5 4.4 3.7 2.3 3.7 2.4 4.1 5.4 4.7 0.1 0.1 0.3 0.1 0.1 0.5 0.2 0.3 0.2 0.4 0.3 0.8 0.9 0.7 1.2 0.7 0.5 0.7 0.8 0.5 0.8 0.3 0.1 0.4 1.3 0.6 0.6 0.7 0.4 0.6 0.3 0.4 0.6 0.9 0.5 0.3 0.9 0.4 0.2 0.9 0.8 0.4 0.3 0.4 0.8 0.8 0.7 0.4 0.7 0.4 0.5 0.2 0.6 0.2 0.6 0.4 0.5 0.4 0.5 0.3 0.5 0.9 0.6 0.2 0.7 0.5 0.7 0.3 0.5 0.5 0.8 0.2 0.6 0.5 0.8 0.1 0.1 0.0 0.4 0.1 0.1 0.2 0.2 0.4 0.2 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.2 1.0 0.2 0.2 0.2 0.0 0.3 0.2 0.2 0.1 0.1 0.2 0.3 0.2 0.1 0.4 0.3 0.2 0.2 0.2 0.1 0.2 0.2 0.3 0.3 0.4 0.3 0.4 0.1 0.1 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.4 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.3 0.2 0.2 0.4 0.3 0.1 0.2 0.1 0.2 0.0 0.1 0.1 0.1 0.4 0.1 0.2 0.1 0.4 0.5 0.3 0.6 0.7 0.4 0.3 0.4 0.1 0.3 0.5 0.4 0.6 0.2 0.4 0.3 0.3 0.4 0.2 0.1 0.4 0.2 0.1 0.3 0.2 0.1 0.2 0.2 0.2 0.3 0.4 0.3 0.6 0.5 0.6 0.3 0.3 0.2 0.4 0.4 0.4 0.4 0.5 0.5 0.6 0.3 0.4 0.4 0.3 0.2 0.3 0.4 0.4 0.5 0.5 0.4 0.4 0.4 0.6 0.4 0.4 0.0 0.2 0.3 0.2 0.4 0.1 0.1 0.3 0.2 0.2 0.3 0.3 0.1 0.2 0.2 0.1 0.0 0.1 0.2 0.3 0.2 0.3 0.2 0.2 0.1 0.3 0.1 0.3 0.2 0.2 0.1 0.1 0.2 0.3 0.2 0.0 0.2 0.2 0.3 0.1 0.1 0.2 0.3 0.3 0.3 0.4 0.3 0.1 0.1 0.3 0.2 0.3 0.3 0.3 0.2 0.5 0.1 0.4 0.5 0.2 0.2 0.2 0.3 0.3 0.1 0.2 0.1 0.1 0.1 0.3 0.1 0.3 Gliomas Embryonal Other 0.0 0.3 0.0 0.1 0.1 0.1 0.2 0.2 0.1 0.0 0.0 0.1 0.2 0.1 0.3 0.1 0.7 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.2 0.2 0.2 0.3 0.2 0.8 0.2 0.2 0.3 0.3 0.2 0.4 0.1 0.2 0.2 0.2 0.1 0.1 0.1 0.5 0.4 1.2 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.2 0.2 0.1 0.1 0.4 0.1 0.2 0.1 0.1 Other neuro Other Unspec. Number of cases MV Total

Age-standardized (world) incidence rates (per 100,000) by histological type

0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0

0.0 0.4 0.7 0.8 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.3 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.2 0.3 0.2 0.1 0.1 0.3 0.1 0.6 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.3 0.1

0.1 1.3 0.4 0.2 0.4 0.4 3.7 3.3 1.4 3.3 2.4 1.3 1.3 0.7 0.2 0.9 0.6 0.1 0.2 0.1 0.3 0.2 0.3 1.1 0.2 0.2 0.3 0.2 0.3 0.3 0.2 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.3 0.1 0.2 0.2 0.1 0.1 0.2 0.2 0.2 0.4 0.1 0.1 0.2 0.2 0.2 0.5 0.4 0.5 0.2 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.3 0.2 0.1 0.2 0.2 0.3 0.1 0.2 0.2 0.3 0.2 0.2

22 149 31 4 21 22 176 26 65 1031 15 168 207 103 24 35 3574 427 670 171 137 98 2 164 1721 20 164 643 79 556 86 760 4802 956 44 45 15 115 8 677 1158 64 27 16 338 11 9 667 285 182 888 3404 658 633 26 598 72 39 26 2726 189 2502 1112 377 74 293 166 928 262 1754 133 1565 917 514 599 574 32 81 98 470 261 1129

26 227 35 9 45

* * * *

28 220 49 92 1747 34 213 309 123 27 47 * 4488 503 760 222 168 110 2 200 2316 21 186 758 94 654 96 883 5396 1058 52 48 18 122 8 753 1291 74 30 17 374 12 9 743 326 210 985 3824 768 691 28 653 87 48 29 3275 235 2999 1253 417 88 316 193 1037 300 1997 158 1779 1039 582 697 684 39 92 121 555 298 1248

768

*I N

710

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Brain and central nervous system (C71-72) - Male (Contd)

Astro. Oligo. Epend. Other Medullobl. America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008 4.2 4.1 2.1 4.7 2.2 4.5 4.3 2.5 4.5 4.3 4.3 2.6 4.5 3.5 0.6 3.5 4.1 4.2 2.5 4.6 4.2 2.4 4.5 4.4 2.8 4.5 4.1 4.4 4.6 2.3 4.7 4.7 4.2 2.4 4.7 4.1 2.0 2.3 3.2 4.8 4.2 2.4 4.8 3.9 2.6 4.0 4.6 4.6 4.7 4.5 4.4 4.3 1.4 1.1 1.7 0.2 0.2 0.6 3.7 1.9 1.4 2.4 2.0 2.1 1.3 4.1 4.0 3.5 1.2 0.7 1.5 1.4 1.4 0.9 0.9 1.0 0.8 1.0 1.1 1.3 0.8 0.9 1.0 0.6 1.1 0.5 1.0 0.7 0.6 0.7 0.9 0.6 0.1 0.6 0.7 0.9 0.4 0.9 0.7 0.3 0.8 0.6 0.3 0.7 0.6 0.1 0.6 0.5 1.1 0.5 0.2 0.5 0.8 0.8 0.4 0.8 0.6 0.4 0.3 0.4 0.8 0.5 0.2 0.5 0.6 0.3 0.6 0.9 0.9 0.9 0.9 0.8 0.8 0.0 0.3 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.6 0.7 0.5 0.2 0.1 0.2 0.2 0.0 0.2 0.1 0.2 0.3 0.5 0.2 0.3 0.2 0.1 0.3 0.1 0.3 0.2 0.1 0.2 0.3 0.3 0.3 0.3 0.3 0.2 0.1 0.3 0.3 0.2 0.3 0.2 0.1 0.3 0.3 0.2 0.3 0.2 0.3 0.2 0.2 0.2 0.3 0.2 0.2 0.3 0.2 0.1 0.2 0.2 0.3 0.2 0.1 0.2 0.3 0.1 0.3 0.2 0.2 0.2 0.2 0.2 0.3 0.1 0.0 0.2 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.2 0.2 0.2 0.1 0.3 0.2 0.1 0.2 0.1 0.1 0.2 0.2 0.1 0.1 0.4 0.4 0.4 0.4 0.3 0.5 0.3 0.1 0.3 0.5 0.4 0.3 0.5 0.2 0.2 0.3 0.5 0.4 0.5 0.4 0.3 0.4 0.4 0.4 0.4 0.3 0.5 0.4 0.1 0.4 0.1 0.5 0.4 0.5 0.4 0.2 0.3 0.3 0.5 0.3 0.4 0.3 0.4 0.4 0.4 0.4 0.5 0.6 0.8 0.5 0.2 0.7 0.6 0.3 1.2 0.3 0.5 0.1 0.2 0.4 0.5 0.8 0.4 0.3 0.3 0.0 0.0 0.3 0.4 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.0 0.1 0.2 0.3 0.2 0.3 0.3 0.3 0.4 0.2 0.4 0.5 0.2 0.1 0.2 0.2 0.2 0.4 0.3 0.2 0.3 0.3 0.2 0.3 0.3 0.2 0.3 0.3 0.2 0.2 0.1 0.2 0.2 0.3 0.2 0.3 0.2 0.2 0.1 0.2 0.3 0.3 0.1 0.3 0.3 0.2 0.3 0.3 0.3 0.3 0.4 0.2 0.2 0.2 0.1 0.3 0.0 0.1 0.2 0.1 0.2 0.2 0.1 0.2 0.1 0.3 0.3 0.3 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.1 0.2 0.3 Gliomas Embryonal Other 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.3 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.2 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 Other neuro Other Unspec. Number of cases MV Total

Age-standardized (world) incidence rates (per 100,000) by histological type

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0

0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.2 2.3 0.1 0.0 0.2 0.0 0.3 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.3 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1

0.4 0.2 0.3 0.2 0.3 0.4 0.5 0.5 0.5 0.1 0.3 0.4 0.3 0.2 0.2 0.2 0.2 0.3 0.2 0.3 0.3 0.3 0.3 0.2 0.5 0.2 0.8 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.2 0.2 0.2 0.3 0.2 0.2 0.5 0.3 0.5 0.1 0.2 0.2 0.1 0.1 0.6 0.2 1.3 0.4 5.6 4.2 0.5 0.3 0.5 1.3 0.4 0.2 0.6 3.5 1.0 0.3 0.2 0.1 1.0 1.3 0.2 0.0 0.8 0.5 1.1 1.3 0.6 1.2 0.7 1.2

1666 668 88 563 118 1520 911 51 856 156 1378 96 1209 233 7 73 148 3066 222 2727 34783 2019 31584 1820 100 1661 545 617 2115 90 1956 192 4204 251 3719 10961 470 608 1187 8589 571 81 484 2882 191 2625 337 112 1048 692 303 937 18 126 534 23 102 530 47 71 262 23 917 128 929 246 56 777 672 97 59 48 57 146 96 415 65 1787 143 113 73 78 106

1875 727 101 609 136 1709 1059 60 995 178 1580 116 1383 274 8 89 172 3499 260 3105 39855 2396 36100 2072 129 1882 651 715 2347 97 2177 208 4714 290 4161 12403 535 715 1330 9696 658 101 550 3426 236 3101 369 124 1222 813 352 1066 23 168 613 44 130 1011 59 93 309 34 998 140 1069 271 85 927 786 107 88 80 69 184 104 649 95 2698 248 144 105 98 168 * * * * *

* * * *

711

769

Brain and central nervous system (C71-72) - Male (Contd)

Astro. Oligo. Epend. Other Medullobl. Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 1.6 1.1 0.9 2.4 1.6 1.2 0.7 1.5 1.7 1.0 0.9 0.9 1.5 0.8 0.6 0.4 0.6 3.1 2.8 3.7 3.4 3.9 2.2 3.4 3.9 2.3 2.7 3.3 3.8 3.9 2.1 2.6 2.1 2.5 2.3 3.4 3.0 1.6 3.1 2.5 2.5 3.9 3.5 4.2 3.8 4.3 4.6 1.3 3.1 3.5 3.0 3.1 2.8 2.6 2.1 2.9 2.6 4.1 2.7 2.1 3.4 2.5 2.4 2.0 2.9 2.5 3.3 3.5 3.5 2.7 3.9 3.5 4.2 3.1 2.4 3.1 2.8 2.0 0.4 0.3 0.3 0.1 0.1 0.1 0.3 0.1 0.2 0.3 0.1 0.2 0.1 0.3 0.6 0.2 0.1 0.7 0.3 0.4 0.6 0.2 0.3 0.4 0.5 0.3 1.4 1.5 2.2 1.0 1.5 1.4 1.1 1.2 0.8 1.0 0.4 0.5 0.3 0.2 0.5 0.3 0.4 0.1 0.4 0.7 0.1 0.3 0.4 0.3 0.3 0.3 0.4 0.5 0.4 0.2 0.5 0.1 0.1 0.3 0.6 0.2 0.2 0.3 0.6 0.2 0.3 0.1 0.9 0.4 0.4 0.6 1.1 0.1 0.1 0.1 0.2 0.1 0.0 0.0 0.4 0.2 0.0 0.2 0.3 0.1 0.1 0.1 0.0 0.2 0.4 0.3 0.1 0.2 0.1 0.2 0.3 0.1 0.1 0.2 0.3 0.3 0.0 0.2 0.1 0.4 0.3 0.3 0.3 0.1 0.0 0.2 0.3 0.2 0.1 0.3 0.8 0.1 0.2 0.1 0.6 0.5 0.4 0.1 0.2 0.3 0.7 0.1 0.1 0.0 0.1 0.2 0.1 0.6 0.3 0.3 0.1 0.2 0.1 0.2 0.1 0.2 0.4 0.1 0.1 0.1 0.3 0.1 0.4 0.0 0.3 0.3 0.5 0.0 0.0 0.0 0.5 0.4 0.3 0.2 0.3 0.1 0.1 0.3 0.1 0.5 0.2 0.2 0.0 0.5 0.5 0.2 1.3 0.5 0.6 0.7 0.6 0.6 0.3 0.2 0.2 0.1 0.1 0.7 0.4 0.4 0.4 0.2 0.4 1.1 0.3 1.1 0.3 0.5 0.3 1.1 0.3 0.7 0.8 0.4 0.1 0.7 0.5 0.3 0.4 0.4 0.5 0.2 0.6 0.4 0.2 0.7 0.3 0.2 0.1 0.2 0.3 0.3 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.1 0.1 0.4 0.3 0.3 0.2 0.2 0.3 0.2 0.3 0.2 0.2 0.2 0.3 0.3 0.4 0.3 0.3 0.2 0.6 0.1 0.3 0.3 0.2 0.8 0.4 0.2 0.3 0.5 0.1 0.3 0.1 0.1 0.8 0.2 0.4 0.2 0.2 0.4 0.4 0.8 0.3 0.3 0.1 0.4 0.2 0.4 0.2 1.0 0.5 0.0 0.3 0.1 0.3 0.2 0.2 0.3 0.2 0.2 Gliomas Embryonal Other 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.2 0.1 0.5 0.1 0.1 0.1 0.3 0.2 0.2 0.0 0.0 0.1 0.0 0.2 0.1 0.2 0.1 0.1 0.0 0.3 0.1 0.2 0.0 0.2 0.0 0.2 0.2 0.4 0.0 0.0 0.3 0.2 0.1 0.0 0.1 0.1 0.2 0.2 0.0 0.2 0.0 0.1 0.6 0.0 0.2 0.1 0.0 Other neuro Other Unspec. Number of cases MV Total

Age-standardized (world) incidence rates (per 100,000) by histological type

0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0

0.1 0.2 0.1 0.4 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.0 0.3 0.1 0.2 0.1 0.1 0.2 0.1 0.0 0.1 0.2 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1

0.3 1.4 0.8 1.7 0.8 1.3 0.4 0.5 0.1 0.8 0.3 0.3 0.1 0.1 0.6 0.5 0.6 0.9 0.3 1.0 0.4 1.2 1.0 0.1 0.2 2.8 5.6 1.5 0.9 0.8 0.9 0.3 0.2 0.1 0.4 0.4 0.2 0.4 0.4 1.1 0.2 0.4 1.3 0.2 0.4 0.7 1.3 1.2 2.9 2.3 2.6 1.0 3.1 1.5 2.8 3.1 2.6 2.4 2.7 3.5 1.9 3.2 3.4 2.1 2.7 2.9 2.0 2.4 1.3 2.9 1.4 0.9 0.4 2.4 2.4 0.3 2.6 2.0

20 491 37 41 47 45 48 72 109 139 145 114 16 15 35 10 25 160 365 1270 86 51 856 254 832 731 607 1404 876 188 124 84 80 120 141 184 176 58 58 52 69 238 362 396 202 40 583 12 84 70 157 86 24 149 71 61 251 94 38 55 170 95 44 18 41 118 123 84 271 229 517 43 799 89 198 408 436 372

22 759 48 66 58 74 67 82 114 280 164 131 17 16 56 21 43 191 415 1524 100 62 1103 265 898 1529 1303 1853 1120 221 172 94 86 127 160 224 187 67 89 72 76 330 481 472 221 48 798 28 137 104 297 141 44 257 152 111 465 146 67 112 272 183 104 29 78 228 218 130 378 415 610 61 938 142 330 437 718 562

Eu

* * *

* * * *

* * *

* *

770

*I N

712

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Brain and central nervous system (C71-72) - Male (Contd)

Astro. Oligo. Epend. Other Medullobl. Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 5.0 2.9 3.3 3.6 3.7 3.8 3.8 4.0 3.2 3.1 2.6 3.5 2.6 3.1 3.5 4.7 5.7 3.1 3.6 4.9 3.5 4.0 3.5 3.2 4.1 3.6 3.9 3.8 4.3 4.1 3.4 3.9 3.9 4.1 3.4 4.1 4.5 4.4 5.1 4.9 4.8 4.4 4.4 1.2 4.4 2.7 0.6 1.3 3.5 2.1 4.7 0.2 0.3 0.4 0.1 0.2 0.4 0.6 0.4 0.1 0.3 0.2 0.3 0.3 0.3 0.5 0.9 0.3 0.3 0.6 0.2 0.4 0.6 0.6 0.7 0.4 0.5 0.6 0.3 0.4 0.3 0.5 0.4 0.3 0.4 0.4 0.6 0.5 0.5 0.2 0.5 0.5 0.5 0.1 0.2 0.7 0.3 0.5 0.3 0.3 0.4 0.1 0.3 0.2 0.1 0.3 0.1 0.0 0.2 0.2 0.2 0.6 0.1 0.4 0.5 0.5 0.1 0.2 0.2 0.3 0.4 0.6 0.3 0.2 0.2 0.3 0.1 0.2 0.3 0.2 0.2 0.4 0.1 0.2 0.3 0.2 0.5 0.4 0.2 0.6 0.2 0.2 0.1 0.2 0.1 0.5 0.6 0.1 0.2 1.7 0.6 0.3 0.5 0.6 0.5 0.3 0.9 1.0 1.1 0.4 0.3 0.1 0.3 0.3 0.1 0.3 0.2 0.2 0.4 0.7 0.9 0.6 0.9 1.1 0.9 1.1 1.0 0.6 0.3 0.6 0.6 0.5 0.6 0.2 0.2 0.3 0.7 0.5 0.4 0.3 0.4 0.1 0.3 0.1 0.4 0.3 0.3 0.5 0.2 0.2 0.1 0.4 0.1 0.5 0.6 0.1 0.3 0.3 0.3 0.4 0.6 0.5 0.5 0.2 0.2 0.2 0.1 0.3 0.4 0.1 0.3 0.2 0.2 0.2 0.3 0.2 0.2 0.3 0.3 0.2 0.4 0.1 0.2 0.2 0.6 0.8 0.4 0.5 0.6 0.4 1.6 Gliomas Embryonal Other 0.3 0.1 0.1 0.1 0.0 0.5 0.2 0.1 0.4 0.2 0.9 0.1 0.5 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.3 Other neuro Other Unspec. Number of cases MV Total 1279 856 326 62 218 392 237 50 127 121 186 139 106 144 1558 93 56 33 95 69 44 116 2836 171 182 564 585 723 1453 555 1648 2775 1050 1012 334 1063 1299 673 329 105 1061 344 54 25 775 153 5 18 29 25 67

Age-standardized (world) incidence rates (per 100,000) by histological type

0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3

0.2 0.4 0.1 0.1 0.0 0.0 0.1 0.0 0.3 0.2 0.1 0.2 0.1 0.3 0.1 0.1 0.0 0.0 1.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.9 0.1 0.1 0.6 0.5 0.1

2.2 1.6 0.6 0.5 0.4 1.3 0.4 0.8 1.7 0.6 1.2 0.8 1.7 0.7 0.2 0.9 1.2 1.2 0.7 0.5 0.7 0.4 0.7 0.5 0.5 0.4 0.2 0.2 0.3 0.4 1.8 0.4 0.4 0.2 2.0 0.6 0.1 0.1 0.1 0.7 0.9 0.2 1.1 0.6 0.1 0.1 0.0 0.1

976 593 319 24 151 281 192 18 79 99 116 74 65 118 1477 83 42 25 82 60 37 106 2394 148 160 425 370 521 1082 425 1041 1950 672 794 207 766 1132 565 256 88 903 302 42 13 631 137 4 14 27 24 61

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

713

771

Brain and central nervous system (C71-72) - Female

Astro. Oligo. Epend. Other Medullobl. Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 0.5 1.3 0.5 0.3 0.3 1.6 2.1 1.9 2.5 2.4 0.9 2.3 1.2 2.0 1.3 1.2 2.5 2.5 2.6 2.2 3.0 2.8 1.8 3.1 2.3 3.1 2.8 2.9 1.4 3.4 2.7 2.7 2.7 2.7 1.1 1.3 1.4 2.6 1.0 3.4 2.4 2.0 1.5 1.0 2.3 0.5 0.8 3.3 1.2 1.6 2.4 3.4 2.9 3.1 1.8 3.3 2.4 2.0 2.5 2.9 1.6 3.1 2.8 2.6 1.5 3.3 1.6 3.3 3.5 2.8 1.3 3.1 3.2 3.4 3.2 2.6 1.9 2.8 1.8 3.0 3.4 3.1 0.0 0.1 0.1 0.1 0.2 0.2 0.2 0.3 0.3 0.3 0.2 0.1 0.1 0.6 0.5 0.6 0.5 0.5 0.2 0.7 0.6 1.2 0.5 0.4 0.1 0.5 0.8 0.6 0.4 0.5 0.1 0.5 0.2 0.5 0.6 0.3 0.3 0.4 0.3 0.4 0.4 0.5 0.3 0.2 0.3 0.5 0.6 0.7 0.1 0.7 0.4 0.1 0.5 0.4 0.1 0.5 0.3 0.4 0.1 0.5 0.1 0.5 0.6 0.5 0.2 0.6 0.4 0.6 0.4 0.3 0.3 0.4 0.2 0.4 0.6 0.7 0.2 0.2 0.0 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.3 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.3 0.3 0.2 0.2 0.3 0.1 0.1 0.4 0.2 0.2 0.1 0.1 0.2 0.3 0.3 0.1 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.1 0.2 0.2 0.2 0.2 0.3 0.2 0.4 0.1 0.3 0.2 0.2 0.1 0.2 0.3 0.2 0.3 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.0 0.2 0.0 0.0 0.2 0.1 0.2 0.1 0.1 0.1 0.3 0.4 0.3 0.6 0.2 0.3 0.4 0.3 0.4 0.3 0.3 0.2 0.4 0.5 0.2 0.3 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.3 0.1 0.2 0.3 0.2 0.3 0.3 0.3 0.4 0.3 0.3 0.5 0.3 0.5 0.4 0.4 0.4 0.3 0.4 0.2 0.3 0.2 0.4 0.2 0.3 0.4 0.3 0.2 0.3 0.4 0.5 0.6 0.3 0.3 0.4 0.4 0.3 0.5 0.3 0.0 0.2 0.3 0.0 0.6 0.1 0.3 0.2 0.2 0.3 0.1 0.1 0.3 0.4 0.1 0.3 0.1 0.1 0.1 0.3 0.3 0.1 0.4 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.2 0.2 0.2 0.1 0.1 0.2 0.5 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.4 0.1 0.6 0.5 1.3 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.3 0.1 0.3 0.1 0.2 Gliomas Embryonal Other 0.0 0.1 0.1 0.3 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.6 0.1 0.3 0.1 0.1 0.0 0.1 0.0 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.2 0.2 0.3 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.3 0.4 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.1 Other neuro Other Unspec. Number of cases MV Total

Age-standardized (world) incidence rates (per 100,000) by histological type

0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0

0.2 0.0 0.0 0.0 0.1 0.2 0.4 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1

0.6 1.0 0.6 0.3 1.0 0.9 3.3 2.7 1.6 2.7 0.8 0.9 1.4 0.2 0.2 0.7 0.6 0.1 0.1 0.2 0.1 0.0 0.2 1.0 0.4 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.3 0.1 0.1 0.1 0.2 0.3 0.4 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.3 0.2 0.1 0.1 0.2 0.3 0.3 0.1 0.4 0.2 0.2 0.2

22 121 14 5 13 26 136 22 62 866 17 140 180 93 18 27 2541 286 456 107 90 54 1 111 1286 20 130 538 64 471 62 591 3592 695 24 29 16 110 4 472 898 74 20 6 294 4 10 474 209 149 776 2427 459 475 22 445 56 33 20 2174 150 1982 858 274 52 220 124 729 159 1456 104 1306 766 413 484 453 31 62 96 354 175 930

31 195 20 14 38

* * * *

31 186 43 94 1617 23 183 289 104 21 37 * 3511 357 569 159 111 62 1 161 1924 22 145 653 80 566 70 704 4284 808 32 36 21 126 4 540 1086 93 24 12 348 5 12 575 259 188 908 2894 578 543 28 507 67 38 24 2692 194 2449 998 314 64 248 154 838 193 1720 123 1545 917 498 615 574 39 76 132 437 229 1072

772

*I N

714

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Brain and central nervous system (C71-72) - Female (Contd)

Astro. Oligo. Epend. Other Medullobl. America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008 2.8 2.7 1.5 3.2 1.5 3.0 3.2 1.5 3.4 3.6 3.0 1.5 3.2 2.0 0.6 2.1 2.2 3.0 2.0 3.2 2.9 1.6 3.1 3.0 1.5 3.1 3.3 3.0 3.2 1.9 3.3 3.4 2.8 1.5 3.1 2.8 1.3 1.6 2.5 3.2 2.9 1.5 3.5 2.6 1.6 2.8 3.0 2.8 3.2 2.9 3.2 3.0 0.5 0.6 1.0 0.3 0.2 0.3 2.8 1.0 0.6 1.6 1.6 1.1 0.7 2.8 2.8 2.2 0.5 0.6 1.1 1.1 0.9 0.8 0.8 0.8 0.6 0.7 0.6 0.8 0.8 0.6 0.7 0.3 0.9 0.3 0.7 0.6 0.2 0.7 0.9 0.4 0.2 0.4 0.7 0.9 0.6 0.8 0.5 0.3 0.5 0.5 0.2 0.5 0.5 0.3 0.5 0.3 0.5 0.5 0.2 0.5 0.5 0.6 0.2 0.7 0.5 0.3 0.2 0.4 0.6 0.3 0.1 0.3 0.5 0.2 0.5 0.6 0.3 0.8 0.9 0.5 0.6 0.1 0.0 0.2 0.0 0.1 0.1 0.1 0.1 0.0 0.2 0.2 0.4 0.4 0.3 0.1 0.0 0.1 0.2 0.0 0.0 0.2 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.3 0.2 0.3 0.3 0.2 0.4 0.3 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.3 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.1 0.3 0.2 0.3 0.2 0.2 0.2 0.2 0.1 0.2 0.1 0.0 0.1 0.3 0.0 0.1 0.1 0.0 0.1 0.1 0.3 0.1 0.3 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.3 0.3 0.3 0.3 0.3 0.2 0.1 0.2 0.2 0.5 0.2 0.5 0.4 0.5 0.2 0.4 0.4 0.3 0.4 0.4 0.3 0.4 0.4 0.4 0.4 0.3 0.5 0.4 0.3 0.5 0.4 0.4 0.3 0.4 0.4 0.3 0.3 0.3 0.4 0.2 0.1 0.3 0.4 0.3 0.4 0.6 0.0 0.6 0.6 0.2 0.3 0.1 0.5 0.2 0.9 0.1 0.5 0.4 0.2 0.2 0.4 0.5 0.5 0.2 0.3 0.3 0.1 0.2 0.2 0.1 0.2 0.3 0.1 0.3 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.2 0.0 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.2 0.1 0.2 0.2 0.0 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.1 0.2 0.2 0.2 0.2 0.2 0.1 0.1 0.1 0.3 0.1 0.2 0.3 0.3 0.1 0.1 0.2 0.1 0.2 0.1 0.5 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.2 0.2 0.1 0.0 Gliomas Embryonal Other 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.4 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.3 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 Other neuro Other Unspec. Number of cases MV Total

Age-standardized (world) incidence rates (per 100,000) by histological type

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0

0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 1.5 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.2

0.2 0.2 0.1 0.2 0.1 0.3 0.4 0.3 0.4 0.1 0.3 0.4 0.3 0.1 0.0 0.2 0.3 0.3 0.3 0.2 0.2 0.2 0.2 0.3 0.2 0.6 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.1 0.3 0.2 0.4 0.0 0.3 0.1 0.1 0.2 0.4 1.0 0.2 0.1 4.7 3.9 0.2 0.4 0.5 0.5 0.3 0.2 0.4 1.8 0.7 0.3 0.2 0.2 0.7 0.9 0.2 0.1 0.7 0.5 0.9 1.0 0.5 1.0 1.1 1.0

1220 523 70 443 95 1112 721 35 675 130 1091 79 965 159 10 56 89 2446 221 2149 27120 1679 24573 1479 84 1367 447 406 1703 87 1580 157 3170 185 2795 8361 338 512 1017 6403 466 66 394 2188 150 1985 247 70 794 531 236 734 5 88 331 16 90 556 46 75 158 14 581 110 444 110 41 569 503 59 35 41 50 91 79 358 58 1405 109 98 40 49 96

1469 599 84 505 111 1344 903 47 844 159 1338 104 1178 203 11 67 120 3009 292 2623 32720 2119 29562 1748 114 1603 552 509 2031 103 1888 187 3717 228 3268 10022 410 656 1183 7672 549 90 452 2724 185 2472 285 81 945 633 293 857 8 126 380 37 116 934 48 89 195 19 639 121 527 127 64 722 617 69 56 74 58 126 89 580 106 2332 211 123 73 86 159 * * * * *

* * * *

715

773

Brain and central nervous system (C71-72) - Female (Contd)

Astro. Oligo. Epend. Other Medullobl. Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 0.6 0.9 0.6 0.8 1.0 0.7 0.4 0.9 1.2 0.8 0.7 0.7 0.8 0.8 0.6 0.6 0.6 2.2 1.6 2.5 2.6 2.7 1.6 2.5 2.8 1.5 2.0 2.4 2.8 3.0 1.4 1.5 1.2 1.8 2.2 2.1 1.7 1.5 2.3 1.7 2.0 2.7 2.5 3.2 2.2 3.6 2.8 2.5 2.6 2.2 2.3 1.8 3.5 1.8 2.1 2.1 1.4 3.1 1.8 1.2 2.2 2.1 1.6 2.0 1.1 1.6 1.8 1.5 2.5 1.6 2.7 1.9 2.7 1.6 1.5 2.1 2.0 1.3 0.8 0.2 0.1 0.0 0.0 0.0 0.3 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.2 0.3 0.1 0.2 0.3 0.3 0.2 0.5 0.2 0.2 0.3 0.5 0.2 1.1 1.2 2.2 0.8 1.1 0.8 1.0 0.5 0.3 0.8 0.9 0.3 0.3 0.2 0.5 0.3 0.4 0.2 0.5 0.3 0.0 0.7 0.1 0.1 0.4 0.3 0.5 0.4 0.7 0.4 0.1 0.1 0.2 0.3 0.3 0.3 0.4 0.1 0.3 0.1 0.7 0.1 0.2 0.4 0.7 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.1 0.0 0.2 0.2 0.2 0.3 0.0 0.1 0.2 0.3 0.1 0.1 0.2 0.2 0.3 0.1 0.1 0.5 0.2 0.3 0.3 0.2 0.1 0.4 0.1 0.3 0.1 0.3 0.3 0.1 0.8 0.3 0.0 0.3 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.7 0.6 0.2 0.6 0.1 0.4 0.0 0.1 0.1 0.2 0.0 0.2 0.3 0.2 0.1 0.1 0.2 0.6 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.2 0.1 0.3 0.4 0.2 0.0 0.2 0.1 0.1 0.3 0.1 0.4 0.1 0.2 0.0 0.3 0.3 0.2 0.6 0.2 0.4 0.4 0.3 0.4 0.2 0.4 0.1 0.2 0.3 0.2 0.2 0.1 0.3 0.2 1.1 0.1 0.4 0.4 0.4 0.3 0.4 0.8 0.2 0.3 0.2 0.2 0.2 0.2 0.7 0.3 0.3 0.3 0.2 0.4 0.4 0.1 0.3 0.2 0.3 0.1 0.2 0.1 0.1 0.1 1.0 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.4 0.2 0.0 0.1 0.1 0.3 0.1 0.2 0.1 0.4 0.2 0.2 0.1 0.1 0.2 0.1 0.0 0.5 0.2 0.1 0.2 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.3 0.2 0.0 0.0 0.7 0.3 0.4 0.2 0.3 0.5 0.2 0.1 0.1 0.2 0.2 0.4 0.7 0.0 0.1 0.2 0.3 0.0 0.2 0.1 0.3 0.2 0.2 0.4 0.1 Gliomas Embryonal Other 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.0 0.3 0.2 0.2 0.1 0.2 0.1 0.2 0.0 0.1 0.0 0.1 0.1 0.0 0.2 0.0 0.0 0.1 0.1 0.2 0.1 0.4 0.0 0.3 0.2 0.1 0.5 0.2 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.2 0.4 0.1 0.2 0.1 Other neuro Other Unspec. Number of cases MV Total

Age-standardized (world) incidence rates (per 100,000) by histological type

0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0

0.1 0.3 0.1 0.0 0.2 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.2 0.0 0.0 0.1 0.3 0.2 0.1 0.0 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1

0.8 1.1 1.0 1.8 0.3 0.9 0.2 0.6 0.2 1.0 0.3 0.3 0.3 0.1 0.7 1.0 0.3 0.8 0.2 0.8 0.2 1.1 0.7 0.1 0.2 1.9 4.0 1.1 0.7 0.4 0.7 0.2 0.1 0.4 0.4 0.1 0.2 0.2 0.3 0.1 0.4 1.0 0.3 0.3 1.0 1.1 0.4 1.6 2.1 1.9 0.9 1.2 0.9 1.8 2.0 1.4 1.2 1.5 2.6 1.3 2.7 1.9 0.2 1.7 2.0 1.7 1.2 1.3 1.7 1.1 0.7 0.3 1.8 1.8 0.2 1.8 1.4

15 426 24 17 24 36 40 51 73 115 109 80 11 18 25 21 27 108 208 997 72 38 707 185 648 545 522 1117 703 176 96 70 71 88 124 132 126 47 44 35 57 172 301 334 151 35 378 18 66 56 139 63 29 107 62 43 167 63 28 36 116 84 28 18 23 82 104 48 217 173 476 29 556 64 155 320 332 333

24 684 42 41 33 58 49 60 78 250 135 103 13 19 52 40 38 135 247 1279 86 54 925 203 732 1179 1150 1602 942 200 140 81 77 95 146 168 137 53 70 50 62 293 433 437 171 47 596 29 113 102 268 117 48 202 140 84 391 107 49 89 224 177 64 21 51 200 204 87 359 337 574 45 718 121 294 346 593 545

Eu

* * *

* * * *

* * *

* *

774

*I N

716

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Brain and central nervous system (C71-72) - Female (Contd)

Astro. Oligo. Epend. Other Medullobl. Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 3.7 2.0 2.0 1.7 2.7 2.9 2.7 1.7 2.8 2.0 1.5 3.6 2.7 2.2 2.3 2.3 4.4 2.2 2.6 2.8 2.2 2.8 2.4 2.5 2.5 2.1 2.4 2.4 2.8 2.3 2.0 2.4 2.7 2.6 2.3 2.5 2.8 3.0 3.0 2.9 3.0 2.8 2.7 1.1 2.3 2.3 1.2 1.2 2.9 2.1 3.7 0.3 0.3 0.4 0.4 0.3 0.4 0.5 0.2 0.3 0.0 0.2 0.3 0.3 0.4 0.1 0.6 0.5 0.1 0.2 0.5 0.3 0.6 0.4 0.6 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.3 0.3 0.5 0.5 0.3 0.5 0.4 0.4 0.1 0.4 0.3 0.6 0.0 0.6 0.1 0.1 0.2 0.1 0.2 0.1 0.0 0.1 0.2 0.2 0.1 0.4 0.2 0.3 0.1 0.4 0.5 0.5 0.3 0.2 0.4 0.1 0.2 0.1 0.3 0.2 0.2 0.1 0.2 0.1 0.1 0.3 0.1 0.2 0.2 0.1 0.5 0.2 0.1 0.1 0.2 0.2 0.2 0.7 0.6 0.0 0.2 0.5 0.6 0.2 0.4 1.5 0.3 0.2 0.8 0.7 1.1 0.3 0.2 0.4 0.1 0.8 0.1 0.5 0.0 0.2 0.2 0.3 0.6 0.7 0.8 0.5 0.6 0.7 0.7 0.9 0.4 0.3 0.4 0.5 0.4 0.3 0.2 0.2 0.2 0.7 0.5 0.4 0.2 0.6 0.1 0.3 0.1 0.1 0.1 0.2 0.2 0.3 0.0 0.3 0.1 0.2 0.1 0.3 0.2 0.4 1.3 0.2 0.2 0.1 0.2 0.1 0.4 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.5 0.1 0.1 0.3 Gliomas Embryonal Other 0.4 0.1 0.0 0.0 0.1 0.2 0.0 0.1 0.2 0.4 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.2 0.2 0.5 Other neuro Other Unspec. Number of cases MV Total 1017 676 248 37 201 353 201 37 106 105 145 117 105 126 1125 63 48 24 74 59 38 89 2077 134 126 411 474 608 1045 362 1169 2073 849 732 250 810 932 517 226 70 802 242 39 18 493 118 4 8 23 22 49

Age-standardized (world) incidence rates (per 100,000) by histological type

0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.3 0.0 0.1 0.2 0.1 0.1 0.0 0.1 0.9 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.2 0.9 0.0 -

1.6 1.0 0.5 0.1 0.7 1.0 0.5 1.0 1.3 0.6 0.9 0.5 1.1 0.4 0.3 0.8 0.3 0.6 0.5 0.6 0.6 0.5 0.4 0.5 0.2 0.4 0.1 0.2 0.3 0.4 1.2 0.3 0.3 0.1 1.3 0.4 0.1 0.1 0.1 0.2 0.8 0.1 0.6 0.4 0.1 0.2 0.1

786 464 238 12 125 224 139 10 69 80 75 55 69 101 1027 46 42 19 57 37 29 74 1684 103 112 270 258 389 693 248 654 1355 475 523 142 515 771 400 164 61 633 202 35 12 359 103 3 7 20 19 43

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

717

775

Age-standardized (world) incidence rates (per 100,000) by histological type

Thyroid (C73) - Male

Carcinoma

Follicular Papillary Medular Anaplastic Other Unspec. Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 0.5 0.2 0.1 0.1 0.3 0.0 0.5 0.3 0.3 0.5 0.3 0.1 0.2 0.1 0.3 0.2 0.2 0.4 0.1 0.4 0.1 0.3 0.3 0.3 0.4 0.3 0.5 0.4 0.3 0.3 0.2 0.3 0.3 0.1 1.1 0.4 0.3 0.4 0.4 0.2 0.2 0.3 0.4 0.3 0.4 0.2 0.3 0.4 0.3 0.4 0.3 0.9 0.8 0.7 0.4 0.2 0.4 0.3 0.3 0.2 0.4 0.2 0.4 0.4 0.4 0.2 0.4 0.3 0.3 0.4 0.6 1.0 0.6 0.5 0.6 0.3 0.4 0.6 0.5 0.9 0.3 0.4 1.9 0.6 1.2 1.9 1.3 1.4 1.3 1.1 0.7 1.2 2.3 2.7 1.7 1.5 1.6 1.0 1.5 1.4 2.6 0.4 2.0 1.6 0.7 1.8 2.8 2.4 2.2 2.2 1.1 2.1 3.2 1.9 1.1 2.4 2.4 1.1 1.7 4.6 1.7 3.7 3.0 3.2 2.4 1.1 1.8 2.6 2.7 3.1 0.5 3.4 4.0 2.8 5.3 1.9 0.7 2.1 1.8 2.2 0.7 2.8 0.8 2.1 2.5 2.3 1.0 2.5 2.0 2.6 2.1 1.7 0.4 2.2 0.8 2.1 1.8 2.7 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.4 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.0 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.2 0.1 0.0 0.1 0.2 0.2 0.1 0.2 0.0 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.3 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.1 0.2 0.1 0.4 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0

Sarcoma Other Unspec.

Number of cases MV Total

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.0 0.0 0.0 0.0 0.0 -

0.1 0.2 0.0 0.4 0.1 0.5 0.2 0.2 0.1 0.3 0.1 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

32 48 14 6 10 5 81 8 37 740 15 76 134 50 11 17 1961 293 269 68 54 26 2 52 1115 3 79 297 37 255 62 471 2706 542 22 36 33 66 5 337 776 47 26 37 168 17 18 436 328 102 469 1779 424 386 7 368 79 36 39 1408 65 1312 561 212 26 172 64 479 117 1088 60 962 475 288 328 316 15 54 45 266 99 638

32 53 14 11 14

* * * *

6 88 8 39 861 16 85 141 57 11 17 * 2095 295 271 68 54 26 2 54 1243 3 79 300 38 257 63 475 2720 545 22 37 33 66 5 339 779 47 26 37 169 17 18 438 329 103 470 1789 432 386 7 368 82 36 40 1434 69 1334 568 213 26 173 66 484 117 1100 62 972 476 290 332 318 15 54 47 266 99 644

776

*I N

718

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Thyroid (C73) - Male (Contd)

Carcinoma

Follicular Papillary Medular Anaplastic Other Unspec. America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008 0.3 0.3 0.2 0.4 0.2 0.3 0.4 0.4 0.4 0.4 0.6 0.4 0.7 0.5 0.3 0.7 0.4 0.3 0.5 0.4 0.3 0.4 0.4 0.2 0.3 0.3 0.3 0.5 0.5 0.5 0.5 0.4 0.3 0.4 0.4 0.3 0.4 0.3 0.4 0.3 0.2 0.3 0.4 0.5 0.4 0.3 0.3 0.4 0.4 0.4 0.4 0.2 0.3 0.3 0.1 0.0 0.2 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.3 0.3 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.3 2.2 2.6 1.6 2.9 1.5 2.4 2.1 0.7 2.2 2.9 2.8 1.5 3.0 3.3 1.7 3.6 3.6 2.8 1.0 3.1 2.3 1.0 2.4 1.9 0.9 1.9 1.5 2.3 3.1 1.7 3.2 2.8 2.6 1.1 2.9 2.4 2.4 1.1 2.0 2.7 1.6 0.8 1.9 2.2 1.0 2.3 3.1 2.2 2.6 2.7 2.3 2.2 0.9 0.6 1.6 0.2 0.2 0.4 2.3 0.3 1.3 0.3 0.0 0.3 1.4 2.6 2.8 1.7 0.9 2.1 1.9 1.6 1.5 0.9 1.0 1.7 1.6 1.3 1.5 3.1 1.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.0 0.1 0.2 0.0 0.1 0.1 0.0 0.1 0.0 0.2 0.2 0.2 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.2 0.0 0.1 0.0 0.0 0.1 0.2 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.2 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.2 0.0 0.3 0.1 0.0 0.2 0.0 0.0 0.0 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0

Sarcoma Other Unspec.

Number of cases MV Total

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 -

0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.7 1.2 0.2 0.0 0.2 0.1 0.1 0.2 0.7 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.3 0.1 0.2 0.1 0.2

832 381 52 321 63 748 473 21 446 105 958 62 836 219 7 79 130 1997 111 1769 19625 1025 17441 840 39 753 225 304 1507 76 1375 116 2574 120 2206 6542 516 324 676 4942 263 37 221 1669 94 1494 201 50 577 409 178 452 8 74 437 8 13 277 35 52 54 17 163 16 197 43 58 505 460 41 47 77 88 168 113 373 71 2212 200 114 69 118 99

842 384 53 323 65 756 480 22 452 108 969 64 845 222 7 81 131 2019 112 1790 19839 1052 17616 856 42 766 230 305 1513 76 1381 116 2588 121 2216 6586 518 330 680 4971 265 37 223 1699 96 1518 202 52 580 411 179 463 8 84 447 11 18 314 35 54 82 17 184 17 262 53 58 526 474 43 50 81 93 175 122 432 77 2314 215 118 73 121 109 * * * * *

* * * *

719

777

Age-standardized (world) incidence rates (per 100,000) by histological type

Thyroid (C73) - Male (Contd)

Carcinoma

Follicular Papillary Medular Anaplastic Other Unspec. Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 0.1 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.4 0.4 0.4 0.1 0.5 0.3 0.3 0.3 0.3 0.2 0.5 0.8 1.0 0.2 0.3 0.3 0.1 0.3 0.4 0.3 0.2 0.3 0.3 0.6 0.4 0.3 0.4 0.4 0.5 0.5 0.5 0.4 0.2 0.5 0.3 0.5 0.6 0.2 0.4 0.3 0.5 0.2 0.7 0.3 0.2 0.4 0.6 0.4 0.5 0.1 0.6 0.8 0.4 0.5 0.2 0.5 0.4 0.5 0.4 0.3 0.3 0.3 0.2 0.2 0.3 0.1 0.3 0.1 0.2 2.0 2.0 1.8 2.8 0.7 0.5 0.6 1.2 0.5 1.9 1.4 1.5 1.1 1.7 0.5 0.2 1.2 0.5 0.6 1.6 2.1 0.5 2.8 0.7 0.6 0.5 1.4 1.0 0.6 0.6 1.6 2.2 2.4 1.2 1.7 3.5 2.2 1.2 1.5 2.6 4.0 0.8 1.7 0.7 1.0 3.6 0.4 2.5 3.5 5.0 1.8 2.3 1.3 2.3 4.9 2.2 1.7 3.7 2.0 4.0 2.6 1.9 2.3 1.8 2.7 1.7 2.4 1.9 2.1 0.3 0.8 1.3 1.1 1.1 0.8 1.6 1.1 0.4 0.2 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.3 0.4 0.3 0.1 0.3 0.4 0.1 0.1 0.5 0.4 0.1 0.2 0.1 0.1 0.2 0.1 0.4 0.4 0.2 0.2 0.3 0.2 0.5 0.3 0.1 0.2 0.1 0.2 0.3 0.1 0.1 0.2 0.2 0.2 0.4 0.1 0.2 0.1 0.1 0.0 0.2 0.2 0.2 0.1 0.1 0.0 0.2 0.2 0.2 0.1 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.2 0.2 0.3 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.2 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.3 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.2 0.1 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.2 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.5 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1

Sarcoma Other Unspec.

Number of cases MV Total

0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.0 0.0 -

0.7 0.1 0.2 0.1 0.2 0.1 0.2 0.3 0.0 0.0 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.3 0.1 0.0 0.1 0.2 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.3 0.2 0.7 0.2 0.3 0.1 0.2 0.3 0.1 1.1 0.2 0.3 0.7 0.0 0.2 0.0 0.3 0.4 0.1 0.2 0.1 0.1 0.0 0.3 0.2 0.0 0.1 0.2

22 623 47 45 62 23 45 30 24 235 179 146 11 22 41 14 50 35 86 718 71 20 881 64 195 199 282 547 205 51 74 59 60 58 61 143 106 32 36 45 95 64 207 110 69 41 87 23 100 85 118 65 17 114 127 50 204 69 28 82 141 75 49 14 35 79 92 39 153 58 159 18 243 35 65 193 139 121

25 644 49 46 62 25 46 32 25 260 180 147 11 22 43 18 52 38 90 737 73 25 892 64 206 244 306 571 210 52 75 59 60 58 62 143 106 32 36 46 96 75 209 122 71 41 94 23 105 87 143 71 17 119 127 53 210 71 31 84 151 93 50 15 35 80 104 45 156 70 167 19 247 43 66 194 151 152

Eu

* * *

* * * *

* * *

* *

778

*I N

720

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Thyroid (C73) - Male (Contd)

Carcinoma

Follicular Papillary Medular Anaplastic Other Unspec. Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 0.1 0.2 0.4 0.1 0.2 0.3 0.4 0.2 0.3 0.2 0.8 0.2 0.3 0.2 0.4 0.4 0.4 0.7 0.5 0.3 0.1 0.2 0.3 0.2 0.3 0.3 0.1 0.3 0.3 0.2 0.2 0.2 0.3 0.4 0.3 0.4 0.6 0.3 0.5 0.3 0.3 0.6 0.9 0.3 0.5 0.5 0.7 0.4 0.9 0.3 0.9 1.0 0.8 1.1 1.0 1.2 0.6 1.6 0.5 1.0 1.1 1.2 0.5 0.8 1.5 0.1 1.7 1.0 1.7 1.1 1.3 0.6 0.4 0.5 0.4 0.5 0.4 0.6 0.4 0.5 0.5 0.5 0.6 0.6 0.6 1.8 1.8 1.8 1.4 1.1 1.8 1.6 3.7 1.1 2.6 1.6 5.1 3.2 1.2 2.5 0.1 0.1 0.2 0.4 0.1 0.2 0.1 0.2 0.3 0.1 0.8 0.0 0.1 0.2 0.1 0.4 0.2 0.1 0.2 0.3 0.4 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.5 0.1 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.3 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.7 0.0 0.0 0.0

Sarcoma Other Unspec.

Number of cases MV Total

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.0 0.0 -

0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 -

93 204 115 9 55 91 81 9 40 26 68 49 22 36 406 27 7 15 37 25 16 41 521 33 24 87 71 94 212 78 207 387 145 181 66 177 493 291 112 34 251 129 20 26 177 131 5 36 23 18 40

125 219 116 10 55 94 81 9 40 27 68 51 23 37 407 27 7 15 38 25 17 41 524 34 24 95 78 105 230 84 232 433 153 189 72 177 506 304 112 35 257 130 20 26 181 132 5 37 23 18 40

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

721

779

Age-standardized (world) incidence rates (per 100,000) by histological type

Thyroid (C73) - Female

Carcinoma

Follicular Papillary Medular Anaplastic Other Unspec. Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 1.3 0.4 0.6 0.5 0.7 0.3 0.9 0.7 1.6 1.9 0.2 0.5 0.5 1.0 0.8 0.9 0.7 0.8 0.4 0.6 0.4 0.6 0.4 0.8 0.5 0.7 0.7 0.9 0.6 0.7 0.9 0.8 0.7 0.4 0.5 0.9 0.7 1.3 0.6 0.7 0.6 0.4 1.0 0.6 0.3 0.9 0.8 0.7 0.7 0.8 0.9 1.0 0.9 1.0 1.3 1.3 0.9 0.9 0.8 0.9 0.9 1.0 0.7 1.2 0.7 1.0 1.1 0.8 0.8 0.8 0.9 1.0 0.9 1.2 1.6 1.5 1.2 1.2 0.8 0.9 1.8 1.5 2.2 0.1 0.6 1.0 7.1 1.8 6.2 8.5 3.6 8.0 6.9 7.2 3.7 4.2 7.8 7.7 4.8 6.5 6.6 5.0 5.2 5.1 9.7 3.6 5.8 5.3 3.5 5.9 8.7 7.8 7.3 6.7 3.1 7.6 7.4 6.4 4.4 6.9 7.9 3.1 6.1 14.0 7.3 6.3 8.8 9.8 8.2 3.4 7.2 7.9 8.4 8.7 3.7 9.2 8.6 7.0 9.0 6.4 3.6 6.9 5.9 6.7 3.7 8.4 3.7 6.7 8.7 7.7 3.6 8.3 6.5 8.4 7.0 6.0 2.6 6.7 3.4 7.4 7.0 9.1 0.1 0.0 0.3 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.2 0.3 0.1 0.2 0.2 0.1 0.1 0.2 0.1 0.1 0.2 0.0 0.2 0.3 0.1 0.1 0.1 0.2 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.1 0.2 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.0 0.2 0.2 0.2 0.2 0.1 0.2 0.1 0.3 0.1 0.2 0.1 0.1 0.0 0.1 0.2 0.1 0.2 0.2 0.1 0.3 0.1 0.2 0.6 0.2 0.1 0.4 0.0 0.4 0.1 0.3 0.2 0.3 0.1 0.3 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.4 0.0 0.3 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.2 0.1 0.2 0.2 0.2 0.1 0.0 0.0 0.5 0.1 0.0 0.0 0.1 0.1 0.7 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.2 0.2 0.1 0.0 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.2 0.0 0.1 0.0 0.0 0.1 0.5 1.1 0.2 0.3 0.1 0.3 1.9 0.1 0.2 0.1 0.3 0.1 0.4 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.3 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.3 0.1 0.1 0.0 0.1

Sarcoma Other Unspec.

Number of cases MV Total

0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 -

0.1 0.3 0.3 0.3 0.1 1.1 2.0 0.5 2.0 0.3 0.3 0.4 1.1 1.2 0.5 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.1 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.0

87 145 34 24 31 16 329 31 197 3798 39 440 706 320 65 68 6278 801 729 264 177 101 7 179 3798 19 203 891 169 699 172 1362 8447 1568 57 134 94 236 22 823 2507 127 81 155 801 33 58 1156 1256 304 1999 4761 1248 1107 50 1002 189 106 62 4028 342 3562 1765 720 157 525 331 1371 366 3362 273 2894 1446 858 1047 1036 59 158 206 818 335 2123

88 151 34 26 45

* * * *

17 338 43 208 4399 42 450 739 356 80 68 * 6839 802 733 265 178 102 7 180 4349 19 204 898 171 704 173 1368 8487 1572 57 135 94 236 22 826 2516 129 81 155 802 33 59 1160 1264 308 2002 4783 1256 1113 51 1007 191 107 62 4052 345 3582 1774 720 157 525 334 1377 367 3380 277 2908 1451 861 1057 1052 59 163 209 831 338 2132

780

*I N

722

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Thyroid (C73) - Female (Contd)

Carcinoma

Follicular Papillary Medular Anaplastic Other Unspec. America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008 0.8 0.9 1.0 0.9 0.9 0.8 0.8 0.9 0.8 0.9 1.3 0.9 1.4 0.9 1.2 0.8 0.9 1.1 0.9 1.1 0.9 0.9 0.9 0.8 0.9 0.8 0.4 0.6 1.4 1.6 1.3 0.8 0.9 0.8 0.9 0.9 0.8 0.9 0.8 1.0 0.9 0.9 0.9 0.9 1.1 0.9 0.9 0.7 0.8 0.9 1.1 0.9 0.9 0.5 0.9 0.0 0.6 0.5 0.3 0.4 0.4 0.6 0.4 0.7 0.8 0.8 1.0 0.2 0.3 0.4 0.2 1.0 0.3 0.4 0.8 0.4 0.7 0.3 0.6 1.0 7.5 7.7 4.2 9.0 4.2 8.0 7.4 3.5 7.9 10.7 9.1 4.3 9.9 10.3 7.0 9.5 12.5 8.6 4.5 9.4 7.4 3.9 7.8 6.1 2.9 6.3 5.0 7.1 10.7 7.5 10.9 10.3 8.2 4.0 8.7 7.7 8.5 3.8 7.6 8.5 5.4 3.4 6.2 6.7 3.4 7.0 10.6 7.5 8.7 8.5 7.6 6.7 5.9 3.3 5.9 1.3 0.8 1.8 8.3 1.1 2.9 0.6 0.2 0.8 4.7 10.2 10.6 5.5 4.8 5.5 10.9 8.6 6.1 2.2 6.9 10.6 7.3 8.8 7.6 19.7 8.1 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.2 0.2 0.1 0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.2 0.2 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.2 0.1 0.0 0.2 0.1 0.3 0.3 0.2 0.0 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.2 0.2 0.2 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.2 0.0 0.1 0.1 0.0 0.1 0.1 0.3 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.4 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.2 0.2 0.0 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.3 0.6 0.1 0.0 0.1 0.2 0.0 0.5 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.3 0.1

Sarcoma Other Unspec.

Number of cases MV Total

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 -

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.2 0.1 1.2 3.8 0.4 0.1 0.4 0.2 0.2 0.1 0.7 1.4 0.1 0.2 0.2 0.1 0.4 0.2 0.0 0.2 0.4 0.4 0.4 0.5 0.2 0.5 0.5 0.8

2665 1164 177 942 237 2322 1492 93 1366 318 2941 211 2500 630 40 211 368 6142 556 5157 60008 4202 51480 2590 168 2301 584 845 4873 363 4328 376 7789 490 6281 20337 2004 1211 2768 13969 830 161 651 4805 324 4216 690 170 1754 1212 536 1270 57 265 1525 19 29 950 104 189 159 42 310 40 439 71 195 1831 1659 154 189 211 456 802 457 1029 373 13311 940 743 328 794 668

2696 1171 180 946 242 2348 1496 93 1370 321 2966 213 2522 636 40 214 371 6201 564 5205 60456 4256 51843 2605 170 2314 596 848 4903 365 4355 377 7819 494 6306 20454 2014 1224 2779 14047 839 162 659 4887 332 4285 691 170 1760 1215 542 1288 57 295 1557 20 33 1044 105 190 202 44 355 42 579 93 196 1948 1747 161 196 221 472 819 473 1194 393 13725 989 753 339 809 715 * * * * *

* * * *

723

781

Age-standardized (world) incidence rates (per 100,000) by histological type

Thyroid (C73) - Female (Contd)

Carcinoma

Follicular Papillary Medular Anaplastic Other Unspec. Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 1.1 1.0 0.8 0.3 0.2 0.9 0.8 0.9 0.8 1.8 1.2 1.1 2.6 0.9 1.4 0.8 1.5 1.3 0.7 1.1 2.1 2.2 0.8 0.6 0.7 0.4 0.8 0.9 0.5 1.3 0.9 0.7 0.7 0.7 1.0 1.3 0.8 0.9 1.3 1.1 0.9 0.3 0.9 0.6 0.8 1.2 0.5 0.5 1.5 0.8 1.1 1.1 1.7 0.4 0.9 1.2 0.9 1.2 0.6 1.2 3.2 1.4 1.5 1.3 0.8 1.2 1.1 0.7 0.7 1.9 0.9 0.7 0.5 1.9 0.5 0.9 0.7 0.8 10.1 12.1 10.4 6.9 3.9 1.9 1.4 4.6 2.0 7.5 5.0 5.0 3.5 5.5 2.2 1.8 4.2 2.3 2.5 4.5 6.3 2.6 10.7 1.1 1.5 1.9 6.4 3.8 2.0 3.6 4.3 8.8 9.8 3.9 5.7 11.2 9.2 6.6 7.1 16.4 15.2 1.6 6.1 2.1 4.0 9.2 1.4 6.9 13.3 18.5 6.4 7.6 5.0 6.0 13.6 6.9 6.6 11.8 6.0 13.9 9.9 8.4 10.1 6.9 12.6 6.5 7.2 5.3 6.5 1.5 4.8 8.0 3.3 4.4 3.8 10.9 4.7 1.9 0.1 0.1 0.3 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.3 0.1 0.1 0.0 0.2 0.2 0.4 0.1 0.3 0.2 0.1 0.1 0.1 0.3 0.2 0.2 0.2 0.4 0.2 0.3 0.1 0.3 0.3 0.5 0.4 0.5 0.5 0.6 0.1 0.4 0.1 0.2 0.2 0.1 0.1 0.4 0.5 0.3 0.3 0.4 0.3 0.6 0.4 0.1 0.8 0.2 1.0 0.4 0.2 0.1 0.4 0.4 0.3 0.2 0.2 0.2 0.1 0.2 0.2 0.0 0.2 0.2 0.1 0.2 0.2 0.2 0.4 0.1 0.5 0.1 0.1 0.1 0.3 0.3 0.2 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.2 0.2 0.1 0.1 0.1 0.0 0.2 0.0 0.0 0.1 0.1 0.1 0.1 0.4 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.2 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.0 0.1 0.1 0.0 0.2 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.2 0.0 0.2 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.2 0.2 0.2 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.3 0.1 0.2 0.0 0.1 0.0 0.1 0.1 0.2 0.3 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.1 0.1 0.2 0.1 0.1 0.5 0.1 0.1 0.0 0.1 0.5 0.1 0.1 0.2 0.2 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.1 0.1 0.6 0.2 0.2 1.0 0.1 0.5 0.0 0.3 0.4 0.2 0.1 0.2 0.1 0.2 0.1 0.1 0.2 0.3 0.1 0.1 0.1 0.1 0.0 0.0 0.6 0.1 0.1 0.1 0.2

Sarcoma Other Unspec.

Number of cases MV Total

0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0

0.0 0.1 0.0 0.0 -

1.3 0.5 0.6 0.1 0.3 0.8 0.3 0.1 0.7 0.1 0.1 0.1 0.1 0.3 0.6 0.2 0.5 0.1 0.1 0.0 0.3 0.3 0.2 0.2 0.5 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 1.2 0.3 1.7 0.9 0.5 0.8 0.1 0.5 0.6 0.1 3.1 0.2 1.0 2.0 0.1 0.1 0.5 0.0 1.2 0.4 0.3 0.5 0.3 0.0 0.0 0.6 0.7 0.1 0.2 0.3

120 4024 256 119 84 98 129 135 70 1125 628 506 45 77 183 71 203 149 324 1824 196 66 3822 128 474 683 1167 1937 512 291 197 203 182 118 219 456 404 122 162 214 305 132 636 261 211 91 253 50 311 263 385 183 44 309 347 140 680 194 94 256 495 281 197 56 139 304 247 116 464 366 806 111 639 196 308 1223 542 647

128 4122 265 120 86 103 138 137 71 1206 636 512 46 78 191 87 209 157 329 1880 198 70 3860 128 512 785 1254 2012 524 293 198 203 182 119 220 461 405 122 165 214 306 152 637 308 216 91 263 51 334 266 451 203 49 341 349 150 700 198 97 259 520 341 200 58 146 306 295 123 482 412 838 112 649 214 320 1233 564 714

Eu

* * *

* * * *

* * *

* *

782

*I N

724

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Thyroid (C73) - Female (Contd)

Carcinoma

Follicular Papillary Medular Anaplastic Other Unspec. Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 0.3 0.6 0.6 0.5 1.0 0.7 0.8 1.1 1.0 1.1 1.7 0.9 0.3 0.5 0.9 0.2 0.4 1.6 0.6 1.1 0.7 0.5 0.7 0.5 0.4 0.5 0.5 0.6 0.9 0.6 0.4 0.5 0.8 0.7 0.7 1.1 1.5 1.1 0.8 1.0 0.5 0.8 3.9 1.1 1.2 0.8 1.5 1.6 1.2 1.3 0.9 3.4 3.8 3.7 3.2 3.1 4.8 3.4 5.0 6.1 4.9 7.9 3.2 3.1 2.4 4.9 1.7 4.2 2.9 4.0 5.2 3.7 1.6 1.9 1.3 1.5 1.8 1.5 1.7 1.8 1.6 1.5 1.3 1.5 1.7 1.7 6.4 6.0 5.2 5.6 3.5 5.1 4.4 31.5 3.6 10.1 10.9 20.5 8.6 5.5 7.1 0.1 0.2 0.2 0.3 0.1 0.1 0.3 0.2 0.1 1.2 0.3 0.2 0.3 0.2 0.1 0.3 0.1 0.1 0.3 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.2 0.2 0.0 0.0 0.1 0.2 0.1 0.1 0.0 0.2 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.3 0.1 0.1 0.3 0.2 0.0 0.5 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.3 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.2 0.1 0.0 0.1 0.1 0.1 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.6 0.0 0.0 -

Sarcoma Other Unspec.

Number of cases MV Total

0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

0.0 0.0 0.1 0.0 0.0 0.0 0.0 -

0.5 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.2 0.1 -

321 768 341 42 193 235 284 20 110 185 247 184 72 118 1029 98 20 26 90 54 65 105 1285 85 76 202 204 302 545 243 582 1036 339 456 139 472 1590 832 308 105 730 332 50 179 592 430 38 138 61 60 81

405 802 342 42 197 239 294 20 112 185 254 185 72 123 1031 98 21 26 90 55 66 106 1293 85 76 209 213 322 588 252 640 1133 363 475 160 485 1639 857 310 107 750 334 52 180 598 430 38 138 61 60 81

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

725

783

Age-standardized (world) incidence rates (per 100,000) by histological type

Hodgkin lymphoma - Male

Nodular Classical Nodular

lymphocytic lymphocyte-rich sclerosis cellularity Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.9 0.2 0.7 0.2 0.0 0.1 0.0 0.2 0.0 0.1 0.1 0.3 0.1 0.2 0.1 0.4 0.1 0.1 0.1 0.0 0.3 0.1 0.1 0.1 0.1 0.3 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.0 0.2 0.2 0.3 0.1 0.0 0.0 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.3 0.2 0.1 0.6 0.1 0.1 0.2 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.4 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.0 0.1 0.6 1.7 0.1 0.2 0.5 0.4 0.3 0.5 0.3 0.6 1.1 0.2 0.2 0.1 1.7 1.8 1.5 1.9 1.7 0.8 1.4 1.8 1.5 1.3 1.1 1.4 1.1 1.2 1.4 1.6 0.7 0.8 0.9 1.2 2.3 1.3 1.2 0.3 0.4 1.0 0.7 0.4 2.1 0.6 0.9 1.0 2.0 1.7 2.1 2.1 2.2 1.7 1.1 2.4 1.4 0.8 1.5 1.3 1.5 1.3 1.6 1.2 1.4 1.5 1.6 1.0 1.7 1.6 1.6 1.9 1.2 0.2 1.8 0.5 1.6 2.5 2.0 0.0 1.3 0.7 0.0 0.4 0.4 0.1 0.3 0.2 0.2 0.6 0.6 0.2 0.3 0.1 0.4 0.4 0.2 0.3 0.2 0.6 0.7 0.3 0.7 0.7 0.4 0.4 0.4 0.4 0.3 0.4 0.3 0.4 0.4 0.2 0.5 0.3 0.6 0.6 0.1 0.7 0.2 0.6 0.2 0.5 0.6 0.5 0.4 0.4 0.1 0.4 0.3 0.3 0.4 0.5 0.5 0.5 0.4 0.4 0.4 0.5 0.4 0.4 0.6 0.5 0.4 0.5 0.5 0.6 0.6 0.6 0.4 0.9 0.6 0.6 0.7 0.5

Mixed

Lymphocytic depletion 0.0 0.1 0.4 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0

Unspec.

Number of cases MV Total

1.4 0.2 0.5 0.6 0.2 1.2 1.6 2.3 1.4 1.6 1 0.4 0.3 0.7 0.6 0.4 0.5 0.3 0.4 0.1 0.4 0.1 . 0.2 0.6 . 0.1 0.3 0.3 0.4 0.3 0.5 0.4 0.6 0.4 0.5 0.1 0.7 0.7 0.7 0.4 0.5 0.4 0.1 0.3 . . 0.5 0.2 0.4 0.4 0.5 0.4 0.6 0.2 0.6 0.8 1.1 0.3 0.6 0.5 0.6 0.6 0.6 0.6 0.6 0.7 0.5 0.4 0.5 0.7 0.5 0.5 0.3 0.5 0.4 1.1 0.4 0.5 0.4 0.5 0.6

50 180 31 37 27 11 71 22 39 626 19 77 182 43 9 10 1694 233 284 76 50 27 1 67 877 8 71 272 61 208 33 300 2259 488 26 21 12 82 1 314 622 69 8 6 211 2 3 306 112 145 519 1438 310 298 27 263 46 25 21 1209 117 1060 554 219 71 140 146 397 91 956 113 799 473 215 333 288 20 47 64 222 133 564

50 180 31 37 27

* * * *

16 75 24 41 627 19 79 183 43 9 10 * 1751 233 285 76 50 27 1 68 932 8 71 273 61 209 33 305 2281 491 26 21 12 82 1 317 627 70 8 6 213 2 3 308 112 146 524 1453 318 300 27 265 50 26 22 1216 118 1066 562 223 71 143 148 402 93 973 114 815 477 216 342 290 21 48 65 223 135 576

784

*I N

726

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Hodgkin lymphoma - Male (Contd)

Nodular Classical Nodular

lymphocytic lymphocyte-rich sclerosis cellularity America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.4 0.1 0.3 0.1 0.2 0.1 0.0 0.0 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.2 0.1 0.1 0.0 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.2 0.2 0.1 0.1 0.3 0.2 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.2 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 1.9 2.2 1.5 2.5 1.4 2.0 1.6 1.2 1.7 1.3 1.9 1.4 2.1 1.3 1.0 1.9 2.0 1.4 2.2 1.6 1.1 1.7 1.7 1.2 1.8 1.3 1.7 2.1 1.5 2.2 1.6 1.7 1.4 1.8 1.5 0.7 1.1 1.1 1.9 1.0 0.8 1.1 1.3 1.1 1.4 1.4 2.0 1.6 1.6 1.5 1.8 0.4 0.0 0.4 0.0 0.0 1.5 0.0 0.1 0.0 0.2 1.9 2.0 1.4 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.4 0.5 0.5 0.4 0.6 0.4 0.4 0.2 0.5 0.6 0.5 0.5 0.5 0.3 0.6 0.3 0.6 0.6 0.6 0.5 0.5 0.5 0.5 0.6 0.5 0.6 0.2 0.6 0.7 0.6 0.7 0.4 0.4 0.4 0.5 0.3 0.5 0.6 0.5 0.5 0.5 0.5 0.4 0.2 0.5 0.2 0.2 0.6 0.5 0.5 0.5 0.3 0.2 0.2 0.0 0.0 0.8 0.2 0.1 0.2 0.0 0.1 0.3 0.7 0.7 0.8 0.1 0.0 0.3 0.1 0.0 0.1 0.1 0.1 0.1 0.2 0.1 0.2

Mixed

Lymphocytic depletion 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0

Unspec.

Number of cases MV Total

0.5 0.4 0.6 0.4 0.7 0.5 0.5 0.5 0.5 0.3 0.5 0.4 0.6 0.4 0.2 0.5 0.5 0.6 0.8 0.5 0.5 0.6 0.5 0.5 0.4 0.5 0.6 0.5 0.5 0.5 0.5 0.5 0.4 0.5 0.4 0.4 0.2 0.5 0.4 0.4 0.4 0.4 0.4 0.6 0.7 0.6 0.2 0.7 0.4 0.4 0.5 0.5 0.9 0.3 0.3 0.2 0.1 0.3 0.4 0.3 0.9 0.1 0.7 0.9 1.5 0.8 0.1 0.9 0.8 0.8 0.1 0.5 0.1 0.2 0.3 0.2 0.2 0.1 0.1 0.2 0.1 0.3 0.1

778 344 68 271 99 663 413 38 371 64 716 84 602 115 1 40 71 1687 217 1428 16774 1646 14505 874 80 766 261 254 1128 100 1000 88 2006 210 1670 5302 196 512 734 3786 224 57 162 1312 130 1145 127 53 473 315 135 451 16 34 155 3 2 89 14 47 128 3 261 42 474 66 19 547 457 85 13 13 14 37 19 109 12 346 31 20 15 13 22

797 349 68 276 99 682 419 39 376 65 729 85 612 118 1 41 73 1737 226 1468 17078 1677 14764 893 80 784 267 255 1136 100 1007 89 2023 210 1686 5363 196 515 741 3832 233 59 169 1370 139 1192 127 54 477 315 138 454 18 34 157 3 2 90 14 50 129 3 261 42 474 67 19 565 470 86 13 13 16 41 19 109 12 346 31 20 15 13 22 * * * * *

* * * *

727

785

Age-standardized (world) incidence rates (per 100,000) by histological type

Hodgkin lymphoma - Male (Contd)

Nodular Classical Nodular

lymphocytic lymphocyte-rich sclerosis cellularity Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 0.2 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.2 0.1 0.1 0.1 0.1 0.3 0.3 0.2 0.1 0.5 0.1 0.1 0.0 0.1 0.1 0.4 0.1 0.1 0.2 0.1 0.2 0.0 0.1 0.3 0.1 0.4 0.2 0.2 0.1 0.0 0.0 0.3 0.1 0.0 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.1 0.0 0.3 0.3 0.1 0.0 0.2 0.2 0.2 0.2 0.1 0.1 0.2 0.4 0.1 0.0 0.1 0.3 0.1 0.1 0.2 0.2 0.3 0.1 0.1 0.8 0.2 0.1 0.1 0.1 0.1 0.3 0.1 0.2 0.1 0.4 0.1 0.2 0.4 0.2 0.1 0.5 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.1 0.1 1.3 0.7 0.1 0.0 1.1 0.5 0.3 0.6 0.5 0.9 0.9 0.2 0.2 0.4 0.6 0.7 1.0 0.6 1.0 1.6 1.3 0.7 0.1 0.9 1.4 1.2 1.3 1.5 1.4 0.9 1.2 1.6 1.4 1.6 1.4 1.7 0.8 0.4 1.2 0.8 0.5 2.4 1.1 4.2 1.3 1.7 2.0 1.9 1.9 1.9 2.0 1.1 1.1 1.4 2.0 1.3 1.7 1.1 1.9 1.6 1.5 1.0 1.1 1.8 0.8 0.7 2.0 1.3 0.3 1.5 1.0 1.4 1.1 0.1 0.1 0.2 1.0 0.4 0.0 0.0 0.5 0.4 0.0 0.1 0.1 0.3 0.0 0.4 0.5 0.3 0.4 0.7 0.7 0.2 0.4 0.8 0.1 0.7 0.4 0.4 0.6 0.3 0.1 0.4 0.5 0.3 0.3 0.3 0.5 0.3 0.6 0.6 0.6 0.9 0.3 0.4 0.9 0.5 0.5 0.3 0.4 0.1 1.4 1.0 1.2 0.5 0.3 0.3 0.5 0.4 0.7 1.3 0.9 0.6 0.8 1.3 0.8 0.4 0.3 0.4 0.9 0.3 0.1 0.3 0.2 0.4 0.5

Mixed

Lymphocytic depletion 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.2 0.0 0.0 0.1 0.0 0.0 0.1 0.2 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.2 0.0 0.1 0.1 0.2 0.2 0.3 0.1 0.0 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0

Unspec.

Number of cases MV Total

0.1 0.2 0.1 0.3 0.8 0.3 0.6 1 1 0.3 0.1 0.1 . 0.3 0.3 0.1 0.1 0.4 0.2 0.9 0.3 0.5 0.3 0.2 0.6 0.7 2.1 0.5 0.4 0.1 0.2 0.1 0.5 0.6 0.4 0.6 0.8 0.3 0.5 0.1 0.5 0.9 0.3 0.6 0.1 0.4 0.5 1 1.1 0.2 1.1 0.4 0.6 0.5 0.2 0.6 1.3 0.5 0.3 1.8 0.4 0.9 0.1 0.6 0.1 0.8 0.8 0.8 1.7 0.7 0.9 0.2 0.3 1.8 0.3 0.8 0.9 0.7

2 111 5 53 57 13 29 78 81 60 69 51 5 13 35 3 16 51 124 428 29 19 655 100 323 564 306 662 344 66 63 43 34 37 60 81 90 36 33 26 34 86 147 164 67 26 237 34 55 27 100 39 14 115 54 48 180 29 24 46 76 73 49 9 27 78 71 45 172 118 194 35 285 46 100 179 205 270

2 111 5 54 58 13 29 78 81 62 69 51 5 13 35 3 16 54 130 440 29 19 665 100 323 564 308 682 355 66 63 43 34 38 60 84 90 36 33 26 34 102 153 168 68 26 239 34 56 27 106 40 14 115 54 48 181 29 24 46 77 74 49 9 27 78 81 46 175 122 194 35 285 49 100 179 205 276

Eu

* * *

* * * *

* * *

* *

786

*I N

728

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Hodgkin lymphoma - Male (Contd)

Nodular Classical Nodular

lymphocytic lymphocyte-rich sclerosis cellularity Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 0.0 0.1 0.1 0.1 0.2 0.3 0.3 0.1 0.2 0.5 0.1 0.1 0.4 0.0 0.1 0.1 0.1 0.1 0.0 0.2 0.2 0.2 0.1 0.0 0.0 0.1 0.1 0.1 0.2 0.2 0.2 0.1 0.2 0.0 0.1 0.1 0.1 0.0 0.2 0.1 0.3 0.2 0.2 0.2 0.1 0.1 0.2 0.2 0.2 0.6 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.2 0.2 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1 0.2 0.7 0.9 0.8 1.0 0.9 1.8 0.9 0.7 1.6 1.2 0.9 0.8 0.8 1.3 1.0 1.6 1.2 2.9 1.5 1.4 1.7 1.6 1.7 1.7 1.5 2.0 0.9 1.7 1.8 1.6 1.3 1.3 1.3 1.4 0.8 1.3 1.2 1.1 1.2 1.2 1.5 0.9 1.2 0.2 0.9 0.9 0.4 0.7 0.8 1.3 1.0 0.3 0.5 0.7 0.3 0.2 1.1 0.4 0.1 0.5 0.4 0.8 1.2 0.1 0.5 0.4 1.0 0.8 0.2 0.2 1.0 0.6 0.4 0.3 0.3 0.2 0.6 0.2 0.4 0.5 0.5 0.5 0.4 0.5 0.5 0.3 0.5 0.4 0.2 0.7 0.8 0.4 0.5 0.4 0.4 0.6 0.6 0.8 0.7 0.1 0.6

Mixed

Lymphocytic depletion 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.0 0.1 0.1 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 -

Unspec.

Number of cases MV Total

1.9 0.3 0.2 0.4 1 0.3 0.3 . 0.2 0.3 0.5 0.1 1.6 0.5 0.4 0.5 0.2 0.4 0.5 1.3 0.2 0.3 0.3 0.3 0.4 0.4 0.8 0.4 0.2 0.3 0.6 0.9 0.5 0.3 1 0.4 0.5 0.3 0.2 0.1 0.3 0.3 0.4 0.8 0.4 0.2 0.4 0.1 0.2 0.4 0.1

383 272 96 17 76 177 79 9 44 46 84 40 39 64 471 33 19 14 38 34 21 44 1076 74 55 235 127 312 497 207 396 959 310 344 83 330 412 175 92 29 319 101 14 8 201 63 3 10 10 9 21

403 285 96 17 76 177 79 9 45 46 84 40 39 64 471 33 19 14 38 34 21 44 1076 74 55 235 135 319 505 207 472 1049 318 351 97 333 422 183 94 29 321 102 15 8 203 63 3 10 10 9 21

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

729

787

Age-standardized (world) incidence rates (per 100,000) by histological type

Hodgkin lymphoma - Female

Nodular Classical Nodular

lymphocytic lymphocyte-rich sclerosis cellularity Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.2 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.4 0.9 0.1 0.2 0.1 0.3 0.2 0.2 0.4 0.2 0.6 1.1 0.2 0.3 1.6 1.8 1.3 1.4 1.8 1.0 1.8 1.7 2.4 2.0 1.2 0.9 1.4 1.5 1.1 1.4 1.5 1.0 0.5 1.4 1.3 0.9 2.1 1.3 1.1 1.5 1.0 0.6 0.3 2.4 0.7 0.9 1.1 2.0 1.6 2.3 1.6 2.4 1.0 0.7 1.5 1.5 0.9 1.6 1.3 1.5 1.3 1.8 1.1 1.5 2.0 1.7 1.2 1.8 1.7 2.0 1.5 1.5 0.9 2.0 0.9 1.8 1.9 2.1 0.5 0.3 0.1 0.1 0.4 0.2 0.2 0.1 0.2 0.3 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.1 0.1 0.3 0.2 0.3 0.3 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.1 0.1 0.2 0.2 0.3 0.2 0.0 0.1 0.3 0.4 0.1 0.2 0.2 0.2 0.1 0.2 0.3 0.2 0.2 0.3 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.2 0.2 0.1 0.2 0.2 0.3 0.4 0.4 0.5 0.4 0.3 0.4 0.1 0.2

Mixed

Lymphocytic depletion 0.0 0.3 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0

Unspec.

Number of cases MV Total

1.2 0.1 0.1 0.8 0 1.5 1 1.3 1.1 1.2 0.3 0.3 0.2 0.4 0.5 0.2 0.3 0.2 0.2 0.1 0.2 0.1 . 0.2 0.4 . 0 0.3 0.2 0.3 0.1 0.3 0.2 0.2 0.2 0 0.2 0.2 . 0.3 0.2 0.1 0.1 0.3 0.2 . . 0.3 0.1 0.2 0.2 0.3 0.3 0.5 0.3 0.5 0.8 0.8 0.3 0.4 0.3 0.4 0.3 0.4 0.2 0.5 0.3 0.4 0.2 0.3 0.4 0.3 0.4 0.1 0.4 0.2 0.3 0.4 0.2 0.3 0.2 0.3

45 83 18 23 15 15 55 13 35 544 8 66 153 29 8 8 1352 180 193 54 46 18 0 59 724 10 68 216 46 166 27 228 1773 358 19 13 15 54 2 231 505 51 2 17 153 2 2 273 110 102 387 1150 235 285 26 252 34 18 13 977 103 856 450 183 57 122 121 325 88 757 92 633 395 202 271 282 23 41 66 214 76 500

46 83 18 24 16

* * * *

20 58 14 37 544 8 69 154 29 8 8* 1410 181 194 54 46 18 0 59 780 10 68 223 46 173 27 235 1789 361 19 13 15 55 2 233 505 51 2 17 153 2 2 273 110 102 389 1164 240 285 26 252 35 19 13 985 103 864 454 184 57 123 121 329 89 766 94 640 402 203 274 284 23 41 66 216 80 505

788

*I N

730

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Hodgkin lymphoma - Female (Contd)

Nodular Classical Nodular Mixed

lymphocytic lymphocyte-rich sclerosis cellularity America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.2 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.2 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.8 2.2 1.6 2.4 1.4 1.9 1.7 0.8 1.8 2.0 2.1 1.2 2.5 1.2 0.3 0.9 1.9 1.9 1.1 2.2 1.6 1.0 1.7 1.7 1.1 1.8 1.2 1.6 2.0 1.5 2.1 1.6 1.7 1.4 2.0 1.6 0.6 1.1 1.1 2.1 1.2 0.7 1.4 1.2 1.0 1.2 1.5 2.8 1.9 1.9 1.3 2.0 0.8 0.1 0.3 0.0 2.5 0.1 0.1 0.0 0.2 2.1 2.2 1.7 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.2 0.2 0.1 0.2 0.1 0.2 0.2 0.2 0.2 0.3 0.3 0.3 0.3 0.1 0.1 0.2 0.3 0.2 0.3 0.2 0.2 0.2 0.2 0.4 0.2 0.3 0.2 0.3 0.2 0.3 0.5 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.3 0.2 0.3 0.2 0.1 0.1 0.1 0.1 0.0 0.2 0.2 0.2 0.2 0.4 0.0 0.1 0.0 0.5 0.1 0.1 0.0 0.1 0.5 0.4 0.6 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0

Lymphocytic depletion 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 -

Unspec.

Number of cases MV Total

0.4 0.3 0.2 0.3 0.3 0.4 0.2 0.3 0.2 0.3 0.3 0.3 0.4 0.2 . 0.2 0.3 0.4 0.3 0.4 0.3 0.3 0.3 0.3 0.2 0.3 0.4 0.2 0.3 0.1 0.3 0.4 0.3 0.2 0.3 0.3 0.1 0.2 0.2 0.3 0.4 0.4 0.4 0.4 0.5 0.3 0.2 0.5 0.2 0.3 0.4 0.3 0.6 0.2 0.1 0.8 0.1 0.2 0.2 0.5 0.4 . 0.4 0.3 0.8 0.5 0.1 0.8 0.8 0.4 0.2 0.2 0 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1

656 306 67 235 82 561 322 26 294 63 685 77 596 75 2 22 51 1451 151 1263 13794 1338 11955 741 68 651 188 197 949 72 862 78 1685 181 1409 4481 160 424 529 3316 213 56 153 987 123 838 112 55 385 266 116 374 15 21 98 4 2 44 8 62 58 1 118 15 176 37 15 511 439 68 8 6 10 24 12 54 7 187 21 13 6 7 7

672 310 67 239 84 575 324 26 296 66 689 77 600 76 2 23 51 1490 155 1297 14009 1349 12155 748 68 658 192 200 952 72 865 78 1696 181 1420 4515 160 424 533 3346 219 56 159 1032 126 879 112 55 388 268 116 379 15 23 101 4 2 44 8 63 59 1 118 15 176 37 15 540 461 69 8 6 10 27 12 54 7 191 22 13 6 7 8 * * * * *

* * * *

731

789

Age-standardized (world) incidence rates (per 100,000) by histological type

Hodgkin lymphoma - Female (Contd)

Nodular Classical Nodular Mixed

lymphocytic lymphocyte-rich sclerosis cellularity Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.3 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.2 0.0 0.0 0.1 0.1 0.2 0.0 0.2 0.1 0.3 0.2 0.0 0.1 0.0 0.2 0.0 0.3 0.2 0.1 0.2 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.2 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1 1.0 0.7 0.0 0.0 0.6 0.4 0.2 0.4 0.3 0.5 0.7 0.0 0.0 0.3 0.4 0.7 0.6 1.1 1.4 1.2 1.5 0.7 0.2 1.0 1.3 1.6 1.2 1.5 1.7 1.3 2.1 1.5 1.4 1.2 1.4 0.5 1.7 0.9 1.6 0.6 0.8 1.4 1.3 2.7 1.7 2.8 2.6 2.7 1.4 1.7 1.9 1.5 1.2 3.5 1.8 0.9 2.2 1.3 2.7 0.4 1.9 1.3 1.2 2.2 1.3 1.0 1.1 0.9 1.3 0.1 1.6 1.2 1.3 1.4 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.3 0.1 0.0 0.0 0.2 0.1 0.2 0.0 0.4 0.3 0.1 0.0 0.5 0.6 0.2 0.2 0.4 0.0 0.4 0.2 0.5 0.1 0.1 0.4 0.3 0.1 0.1 0.1 0.6 0.3 0.2 0.3 0.3 0.4 0.2 0.3 0.3 0.2 0.1 0.6 0.3 0.5 0.4 0.3 0.2 0.3 0.1 0.1 0.1 0.3 0.3 0.6 0.4 0.4 0.8 0.4 0.2 0.1 0.2 0.2 0.2 0.1 0.1 0.1 0.1 0.4

Lymphocytic depletion 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.2 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.0

Unspec.

Number of cases MV Total

0.1 0.1 0.1 0.2 0.3 0.2 0.5 0.4 0.3 0.2 0.2 0.1 0.2 0.5 0.2 . 0.1 0.3 0.1 0.6 0.4 0.1 0.3 0.2 0.4 0.4 2.1 0.4 0.2 0.2 0.1 0.1 0.3 0.3 0.2 0.3 0.7 . 0.4 0.4 0.6 1 0.1 0.5 0 . 0.3 0.1 1 0.1 1 0.2 1 0.3 0.2 0.5 0.9 0.2 0.2 1.3 0.6 0.9 0.2 1.9 0.3 0.4 0.4 0.4 1 0.6 1 0 0.1 1.6 0.2 0.6 0.8 0.6

3 55 6 33 24 10 23 32 31 60 48 27 7 14 18 0 10 32 76 319 21 18 703 72 280 369 306 620 250 91 52 30 31 42 73 58 68 15 27 18 36 99 128 108 45 14 211 15 53 34 95 37 14 77 47 35 152 42 17 37 73 61 40 13 21 68 50 40 107 120 255 15 219 40 93 164 165 324

3 56 6 33 25 10 23 33 32 63 48 27 7 14 18 0 11 35 77 334 21 18 712 72 280 369 312 646 260 93 52 30 31 44 73 60 68 15 27 18 36 107 138 110 45 14 213 15 54 34 102 40 14 77 47 35 154 42 17 37 73 61 40 13 21 68 59 40 112 126 255 15 222 42 93 164 165 327

Eu

* * *

* * * *

* * *

* *

790

*I N

732

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Age-standardized (world) incidence rates (per 100,000) by histological type

Hodgkin lymphoma - Female (Contd)

Nodular Classical Nodular Mixed

lymphocytic lymphocyte-rich sclerosis cellularity Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 0.0 0.0 0.0 0.0 0.2 0.0 0.2 0.1 0.0 0.0 0.1 0.1 0.4 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.2 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.4 0.4 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.2 0.4 1.4 1.4 1.0 1.3 1.8 1.1 0.7 1.1 1.0 1.3 1.9 1.1 0.7 1.2 2.2 1.1 1.8 2.2 2.2 1.5 1.6 1.5 1.6 1.7 1.5 1.4 1.4 1.3 1.3 1.4 1.0 1.1 1.2 0.8 1.5 1.3 1.2 1.2 0.6 1.5 1.1 0.6 0.5 1.1 0.8 0.7 1.0 0.4 1.3 0.2 0.3 0.4 0.1 0.2 0.4 0.3 0.6 0.3 0.3 0.2 0.4 0.2 0.2 0.3 0.1 0.3 0.5 0.1 0.1 0.1 0.2 0.2 0.3 0.2 0.1 0.2 0.2 0.1 0.2 0.2 0.2 0.1 0.2 0.2 0.1 0.2 0.6 0.2 0.1 0.5 0.2 0.0 0.1 0.1

Lymphocytic depletion 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 -

Unspec.

Number of cases MV Total

1.4 0.3 0.2 0.1 0.7 0.2 0.1 0 0.2 0.1 0.2 0 0.9 0.6 0.3 0.3 . 0.2 0.2 1.7 . 0.2 0.2 0.1 0.3 0.3 0.5 0.2 0.2 0.2 0.4 0.6 0.3 0.2 0.7 0.2 0.4 0.2 0 0.1 0.2 0.2 0.3 0.4 0.3 0.1 . 0.1 0.3 . 0.1

272 305 113 12 68 107 71 8 25 31 55 38 25 41 400 35 6 11 36 37 18 41 773 54 51 163 122 188 321 127 309 680 219 244 76 297 342 148 61 21 268 74 13 6 185 36 1 6 9 5 12

285 320 113 13 69 108 72 8 25 31 55 39 25 42 400 35 6 11 36 37 18 41 773 54 51 167 133 191 327 130 381 742 221 246 81 301 351 151 62 21 269 74 13 6 185 36 1 6 9 5 12

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

733

791

Age-standardized (world) incidence rates (per 100,000) by histological type

Haematopoietic and lymphoid tissues - Male

B-cell T-cell and NK-cell 0.5 0.6 0.1 0.1 0.3 0.2 0.7 0.5 0.4 0.6 0.4 0.8 1.1 1.2 1.3 1.2 1.3 1.8 0.9 1.1 1.2 0.8 1.1 1.1 1.3 1.0 1.2 0.9 1.5 2.1 1.9 1.0 1.2 1.7 0.4 2.2 1.5 1.7 0.6 1.6 1.4 1.1 1.0 1.6 1.3 1.9 1.3 1.5 1.3 1.6 1.8 1.6 1.4 1.2 1.4 1.2 1.6 1.2 1.1 1.5 1.6 1.5 1.4 1.0 1.1 1.1 1.2 1.0 1.1 1.1 1.3 1.5 2.6 1.9 1.6 1.4 0.9 1.4 Myeloid 1.6 2.5 2.9 0.3 1.2 6.0 2.5 2.8 4.0 4.5 2.7 3.1 2.7 4.1 5.9 3.7 5.9 6.6 7.4 8.7 8.1 4.9 5.1 4.8 8.5 6.6 3.7 3.1 3.7 4.8 3.8 6.2 5.7 4.9 4.4 5.3 4.5 4.9 6.2 6.3 6.2 4.1 5.6 5.2 5.6 2.8 7.2 4.9 6.0 5.1 6.6 4.7 5.7 4.5 5.8 3.7 2.9 4.6 4.7 3.6 4.8 4.3 6.2 5.4 6.7 3.9 4.5 5.1 5.0 4.0 5.1 4.9 7.2 6.1 6.5 5.5 7.2 5.3 6.8 4.7 4.5 lymphoma, NOS 5.0 1.2 0.8 3.9 2.9 7.6 4.2 2.9 6.1 1.2 1.1 0.6 2.6 6.6 2.5 2.7 0.4 1.0 0.7 0.5 1.4 0.7 4.7 1.2 0.6 1.2 0.6 1.3 1.1 1.3 0.9 0.9 0.9 0.5 0.5 0.8 0.8 1.0 0.7 0.7 0.3 0.5 0.6 0.5 0.3 0.9 0.6 0.8 0.8 1.0 1.0 1.2 0.6 1.2 2.1 2.7 1.1 1.8 1.4 1.8 1.3 1.0 0.7 1.1 0.8 1.4 0.6 1.3 1.1 1.3 1.0 0.6 1.2 1.2 1.2 1.3 1.0 1.2 1.4 1.2 Non-Hodgkin

Other

Unspec.

Number of cases MV Total 222 1321 141 194 375

Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4.

0.7 16.7 8.8 2.8 6.9 8.2 5.8 2.7 6.7 7.8 5.7 9.5 6.1 6.9 9.7 10.8 17.0 21.2 17.7 22.8 19.7 12.3 14.2 20.8 14.4 20.0 22.9 15.9 14.7 16.0 20.9 14.3 19.1 19.8 20.9 10.1 14.0 17.5 10.1 22.0 19.7 21.3 9.6 15.6 16.0 14.2 6.7 22.9 11.7 20.3 16.2 20.6 19.6 20.5 15.7 20.9 17.9 19.8 14.1 17.2 16.8 17.2 16.4 18.7 18.6 19.5 17.5 16.3 20.1 19.7 19.2 19.7 18.8 22.6 20.6 19.6 18.6 19.2 19.1 20.0 21.6 19.1

0.0 0.0 0.1 0.1 0.3 0.0 0.0 0.2 0.1 0.1 0.0 0.2 0.3 0.1 0.1 0.0 0.1 0.2 0.1 0.1 0.1 0.1 0.3 0.2 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.0 0.1 0.0 0.1

1.6 4.1 1.4 4.5 1.2 6.0 3.5 3.8 4.5 5.2 5.1 6.5 3.4 5.5 2.7 2.0 4.9 2.8 3.7 3.2 3.4 2.8 1.0 4.4 6.5 2.5 2.4 3.6 2.6 3.9 2.9 4.4 3.7 3.5 3.4 3.2 3.0 3.4 1.9 3.5 3.5 2.1 1.7 3.0 4.0 4.2 2.5 3.5 2.4 2.6 4.0 3.7 3.2 4.3 3.1 4.4 4.9 5.8 3.3 5.1 4.1 5.2 3.5 3.8 3.9 3.9 3.2 3.7 3.4 4.3 3.9 4.5 3.4 3.4 3.9 4.0 2.8 5.1 3.5 4.4 3.4 3.2

222 1217 138 158 322 129 459 72 240 5249 133 696 976 564 295 192 20569 2829 3855 1408 850 375 11 936 9117 149 1039 3297 550 2700 442 3817 30140 6195 409 281 202 684 57 4157 8169 778 172 199 1921 133 67 4575 2259 1768 4984 20474 3260 3711 180 3461 452 305 124 18821 1481 17087 5426 2010 516 1448 1142 4201 1172 11106 1163 9578 5213 3526 3765 4121 282 647 922 3167 1327 5614

* * * *

184 505 111 287 5289 133 773 1119 579 296 192 * 25083 2900 4575 1511 876 379 11 1053 12374 151 1253 3661 620 2990 469 4307 31786 6459 433 289 214 710 60 4339 8403 804 177 205 1972 137 69 4713 2338 1867 5168 21735 3763 3939 189 3676 503 339 139 19656 1552 17841 5975 2166 575 1539 1288 4597 1259 12260 1289 10584 5634 3788 4338 4473 305 677 1026 3414 1514 6192

792

*I N

734

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Haematopoietic and lymphoid tissues - Male (Contd)

B-cell America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008 19.6 21.4 19.7 22.0 19.0 19.6 18.3 18.8 18.3 19.5 21.5 22.6 21.5 17.6 10.1 13.8 20.8 20.4 20.3 20.9 18.7 18.4 18.8 17.6 17.3 17.4 15.6 19.8 20.7 19.4 20.5 19.5 20.7 19.1 21.6 19.9 11.4 20.0 16.4 21.0 16.9 16.4 17.0 17.1 18.4 17.0 21.1 18.4 22.4 23.1 18.1 19.5 4.6 2.2 6.7 0.7 1.5 1.9 0.8 9.9 1.9 3.6 2.2 1.4 3.2 1.2 3.8 20.4 20.6 12.0 3.8 2.8 6.1 5.4 3.5 3.6 3.3 4.5 3.6 4.5 4.5 5.0 4.8 T-cell and NK-cell 1.4 1.7 2.1 1.7 2.0 1.3 1.3 1.5 1.3 1.2 1.7 1.7 1.6 1.4 2.4 1.0 1.5 1.4 1.7 1.4 1.3 1.6 1.3 1.4 1.6 1.3 1.1 1.9 1.5 1.8 1.3 2.3 1.6 1.9 1.6 1.5 1.2 1.8 1.3 1.5 1.2 1.5 1.2 1.2 1.3 1.2 1.4 1.4 1.6 1.6 1.1 1.2 0.1 0.7 0.3 0.0 0.1 0.4 0.1 0.8 0.1 0.0 0.7 2.9 3.1 1.2 0.5 0.1 0.8 0.6 4.2 1.0 0.7 0.7 0.5 0.5 0.9 0.5 1.0 Myeloid 4.9 7.8 6.7 8.2 4.3 5.0 4.6 4.4 4.7 5.2 6.7 6.2 6.6 5.9 3.9 5.5 6.3 7.1 4.9 7.5 4.7 4.0 4.8 4.3 4.1 4.3 4.7 4.3 5.2 4.0 5.1 5.1 6.5 5.7 6.7 6.4 5.2 5.8 5.3 6.6 4.3 3.8 4.3 4.8 4.7 4.8 5.9 4.7 4.9 7.3 4.6 5.2 6.2 3.5 3.3 2.2 1.2 2.0 3.4 3.4 1.8 1.3 2.0 2.5 2.5 1.4 2.1 7.1 6.9 4.8 2.5 3.2 5.0 3.6 5.3 3.3 2.7 3.0 2.7 2.9 2.3 3.3 2.5 lymphoma, NOS 1.4 1.1 0.9 1.2 1.0 1.4 1.2 1.0 1.2 0.9 1.3 1.3 1.2 1.1 0.9 0.7 1.4 1.3 1.3 1.3 1.3 1.1 1.3 1.7 1.5 1.7 1.5 0.7 1.1 1.6 1.1 0.6 1.0 0.9 1.1 1.0 0.7 0.9 0.8 1.1 1.3 0.8 1.4 1.2 0.8 1.2 0.8 2.0 1.3 1.3 1.5 1.0 4.1 5.5 0.7 0.4 2.9 4.4 3.0 3.0 2.6 0.3 2.7 2.0 4.7 0.0 0.5 0.9 0.9 0.5 0.6 3.6 2.2 0.5 2.3 0.9 0.8 0.3 0.2 0.5 0.4 1.3 0.1 Non-Hodgkin Other Unspec. Number of cases MV Total

Age-standardized (world) incidence rates (per 100,000) by histological type

0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.1 0.2 0.0 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.4 0.1 0.2 0.1 0.2 0.2 0.0 0.2 0.1

3.8 4.1 3.5 4.4 3.5 3.9 3.8 3.9 3.8 2.8 4.6 4.1 4.5 3.9 4.2 3.8 3.7 4.3 4.0 4.5 4.1 3.4 4.2 4.1 3.4 4.1 5.1 3.5 3.6 3.0 3.7 3.8 3.7 3.5 3.8 3.8 2.7 3.3 4.1 3.8 3.7 2.7 4.0 4.8 3.9 4.9 3.0 3.8 3.3 3.3 3.6 4.4 4.7 4.3 4.3 6.3 3.2 3.2 2.6 3.8 3.1 1.4 3.2 4.4 3.0 5.0 2.6 3.8 3.7 3.3 3.1 3.8 3.2 4.8 3.9 4.8 4.1 3.3 3.4 3.6 3.9 3.2 3.5

9242 4408 774 3552 935 8112 4985 391 4553 862 9310 945 7968 1552 75 417 1023 18227 1959 15704 199998 16596 175615 10382 845 9252 2999 3288 12912 835 11717 1077 26924 2047 22862 70234 3588 5572 6632 53257 3032 608 2386 14880 1353 13146 1797 557 6111 4619 1822 5517 123 802 2900 97 151 2200 319 420 912 69 2521 476 3401 547 257 5263 4704 383 370 441 481 1065 1154 4390 574 10140 870 658 324 374 634

9927 4617 827 3706 1021 8703 5541 435 5062 1001 10030 1040 8567 1720 79 456 1147 21501 2231 18640 217914 18341 191273 10989 909 9790 3234 3538 14471 952 13124 1137 28386 2195 24098 74812 3718 6041 6930 56884 3474 719 2693 17019 1588 14972 1848 617 6454 4785 1951 5748 131 844 3127 97 191 2432 321 428 935 71 2521 478 3401 552 262 5869 5194 415 370 504 643 1408 1284 4390 674 10815 936 680 351 384 668 * * * * *

* * * *

735

793

Haematopoietic and lymphoid tissues - Male (Contd)

B-cell Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 4.1 6.0 3.7 8.5 6.1 1.6 2.5 5.3 8.0 3.6 6.8 6.6 3.6 11.5 5.1 3.7 3.1 5.5 5.8 7.2 15.0 9.2 5.1 12.0 13.1 3.6 7.1 11.3 15.0 10.7 16.6 16.7 19.2 19.2 16.9 17.5 20.7 19.3 14.2 13.3 13.3 11.2 10.3 11.1 13.3 17.2 13.9 17.3 14.9 19.2 13.6 18.0 13.6 18.0 20.5 12.5 12.1 16.3 12.4 6.8 20.4 11.2 18.0 16.8 13.0 16.5 7.7 16.4 11.6 5.7 7.9 8.7 14.3 5.0 7.6 4.9 8.3 6.0 T-cell and NK-cell 0.5 0.9 0.5 2.5 1.4 0.2 0.1 0.2 0.4 0.4 1.5 1.6 1.0 1.0 0.2 0.1 1.0 0.4 0.6 0.8 3.5 0.2 0.1 0.6 0.9 0.1 0.1 0.8 1.1 0.8 0.9 1.2 1.1 0.3 0.7 0.6 0.7 1.3 0.9 0.9 0.4 0.9 0.7 0.7 1.0 1.5 0.8 1.9 2.2 2.8 1.0 0.8 1.8 2.0 3.9 1.4 1.2 1.1 1.1 1.1 1.8 1.5 1.1 1.3 0.7 1.0 0.3 1.1 1.2 0.6 0.7 2.1 1.3 0.2 0.4 0.6 0.5 0.3 Myeloid 3.8 3.3 2.4 2.9 2.4 3.9 2.6 2.4 2.3 3.1 4.4 4.4 2.2 5.7 2.5 2.1 2.1 2.9 2.8 3.5 5.4 3.3 3.3 3.2 5.4 2.4 4.1 5.1 4.2 3.5 8.1 6.8 9.8 5.0 6.7 9.2 6.2 8.1 5.8 8.7 3.2 3.8 5.1 6.0 4.4 3.3 7.5 13.0 4.3 6.5 11.3 10.4 3.2 5.8 4.3 7.4 4.1 7.1 11.1 5.1 5.3 3.9 5.3 5.0 7.3 6.7 5.0 4.0 4.3 4.6 4.2 7.0 5.5 2.7 3.4 3.8 5.3 3.0 lymphoma, NOS 0.2 0.5 1.1 0.6 5.3 5.0 4.4 1.1 1.6 0.5 0.5 0.1 0.3 1.8 1.4 1.3 1.0 1.0 2.3 0.6 2.3 3.0 1.4 3.5 2.1 5.4 1.4 1.0 0.3 0.7 0.4 0.4 1.8 0.4 1.0 1.7 0.7 0.7 0.3 2.9 4.6 2.6 3.4 1.4 2.8 1.0 5.0 1.1 3.3 1.4 3.1 2.8 0.8 2.0 4.4 3.9 1.2 14.5 2.5 3.6 1.0 1.9 1.3 3.8 3.2 7.9 4.2 1.5 1.9 3.2 3.5 0.7 1.3 4.8 5.3 0.7 Non-Hodgkin Other Unspec. Number of cases MV Total

Age-standardized (world) incidence rates (per 100,000) by histological type

0.1 0.0 0.2 0.4 0.1 0.0 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.1 0.3 0.1 0.1 0.1 0.4 0.1 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.2 0.3 0.2 0.1 0.1 0.2 0.2 0.1 0.3 0.0 0.1 0.0 0.1 0.1 0.3 0.2 0.1 0.2 0.1 0.0 0.0 0.2 0.2 0.0

3.3 3.8 2.4 2.3 3.9 3.7 2.6 3.5 2.4 5.3 3.6 3.5 3.7 4.5 2.8 4.3 2.5 3.2 2.1 5.6 1.9 7.6 2.6 1.5 2.9 2.9 3.6 3.9 3.1 3.1 2.1 1.8 1.6 2.0 2.1 2.2 3.2 0.9 2.1 2.1 3.7 2.6 2.8 3.3 2.9 2.0 5.4 3.5 4.7 2.4 5.9 3.8 4.8 2.3 3.1 6.3 5.7 4.9 2.4 3.7 3.2 4.3 1.5 5.4 3.9 2.8 9.3 3.6 6.5 4.6 3.9 3.8 1.8 6.9 3.3 2.9 3.2 4.8

85 2907 159 231 356 295 524 318 485 1040 1349 1049 72 228 469 238 259 267 892 4934 572 219 3754 1255 4774 3172 2557 6554 4710 743 887 625 588 688 940 1129 1278 603 454 434 540 1159 1498 2017 887 212 3421 294 666 547 1353 745 209 1350 877 318 2347 655 326 578 1535 708 485 189 276 1228 722 567 1650 1156 1912 304 4301 302 840 1642 2200 1848

86 3080 171 238 362 313 539 347 495 1268 1349 1049 72 228 469 238 289 405 995 5474 582 238 3860 1255 4838 3172 2995 7682 4937 764 978 635 588 709 942 1168 1297 607 474 437 551 1484 1859 2364 964 213 3592 306 695 565 1807 918 223 1351 879 435 2368 657 342 590 1567 747 495 201 307 1264 961 601 1797 1219 1912 312 4496 363 884 1644 2216 1864

Eu

* * *

* * * *

* * *

* *

794

*I N

736

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Haematopoietic and lymphoid tissues - Male (Contd)

B-cell Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 5.2 11.2 11.8 9.1 11.5 12.7 14.7 10.3 15.1 11.7 11.5 10.0 10.4 9.4 11.6 14.2 11.8 10.8 15.5 15.5 14.9 13.4 15.2 13.2 12.2 12.0 8.7 11.4 14.2 14.9 14.4 11.4 12.4 12.6 10.1 14.5 18.0 19.1 21.9 18.7 18.9 16.1 18.0 8.7 21.0 14.1 11.3 11.8 16.8 10.7 17.3 T-cell and NK-cell 0.3 0.4 1.1 0.5 0.9 1.3 1.0 0.0 2.2 1.8 1.5 1.8 1.2 0.4 0.7 1.6 1.4 0.2 1.2 1.6 1.5 0.0 1.1 0.8 0.7 1.2 0.9 0.9 0.6 0.6 0.7 0.6 1.0 1.3 1.0 1.3 0.9 1.4 0.7 0.9 1.0 1.6 1.3 0.8 1.8 1.4 1.5 3.1 0.7 2.5 Myeloid 2.1 5.0 4.5 5.5 3.3 2.4 3.9 1.5 7.3 3.6 4.4 3.0 5.4 2.2 6.1 7.6 2.8 2.3 7.1 4.4 3.8 3.8 4.7 4.0 4.4 7.3 5.9 7.1 7.0 4.4 10.9 7.8 8.5 7.0 4.2 10.4 8.5 11.8 6.3 5.8 9.9 8.7 8.2 4.7 5.0 6.5 5.0 6.9 8.0 7.1 6.5 lymphoma, NOS 1.8 1.0 1.6 2.7 1.9 1.3 2.6 1.3 0.4 0.1 1.7 0.4 4.7 1.6 1.6 4.6 6.8 0.7 1.0 1.4 3.7 1.3 1.8 1.8 1.5 5.0 3.4 2.6 1.7 2.2 4.7 1.5 2.9 1.9 1.2 2.6 1.4 1.2 1.8 1.4 3.1 2.9 3.1 1.7 1.1 1.1 1.1 0.2 1.3 1.2 Non-Hodgkin Other Unspec. Number of cases MV Total

Age-standardized (world) incidence rates (per 100,000) by histological type

0.1 0.1 0.0 0.1 0.0 0.1 0.1 0.2 0.2 0.1 0.1 0.3 0.6 0.0 0.5 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.2 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.0 0.1 0.2 0.6 -

3.6 3.0 1.9 2.7 4.2 3.9 3.7 2.1 1.6 2.8 3.1 4.7 3.9 6.0 5.5 3.0 4.3 3.6 2.3 4.6 1.4 2.4 2.1 2.1 1.5 4.7 4.3 3.5 3.1 4.1 6.5 4.3 4.7 3.0 7.8 4.1 3.9 3.6 6.1 2.7 4.1 3.3 3.8 5.0 4.5 3.2 3.7 1.9 3.7 3.0 3.6

1826 2909 1343 224 966 1303 1058 144 582 526 768 409 471 612 9521 457 165 143 499 303 230 505 13212 746 671 2707 1694 3304 4934 2393 6089 11382 4815 4660 1095 5765 6650 3751 1897 485 5662 1793 237 96 4024 1130 83 164 160 264 352

2000 3157 1343 230 1032 1381 1131 170 613 551 850 432 499 650 9533 465 172 144 499 324 237 527 13379 756 684 3080 2308 4151 7146 2468 10155 14793 5609 5637 1374 6049 7721 4556 2012 517 5994 2012 289 99 4126 1160 87 170 163 271 361

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

737

795

Haematopoietic and lymphoid tissues - Female

B-cell Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Non-Hispanic White USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Georgia: Black USA, Georgia: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White USA, Louisiana: Black USA, Louisiana: White USA, Maine USA, Massachusetts *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 0.4 9.5 5.3 1.8 6.7 5.6 4.0 2.9 5.1 5.5 4.8 7.2 5.0 5.5 6.1 6.9 11.0 14.0 11.5 15.3 13.6 7.5 3.3 12.3 9.4 11.0 14.6 10.8 10.3 10.9 14.3 10.2 12.6 12.7 12.6 6.9 7.4 13.5 8.0 13.9 12.7 13.7 7.1 10.1 11.4 8.4 4.7 14.5 8.1 13.2 12.0 13.4 13.7 13.1 12.7 13.2 11.3 10.8 11.9 11.6 11.7 11.6 11.1 12.0 11.8 12.2 11.5 10.9 14.1 13.0 13.4 13.0 12.6 14.6 14.1 12.9 10.4 12.0 12.0 13.2 14.0 13.3 T-cell and NK-cell 0.3 0.2 0.2 0.8 0.3 0.2 0.3 0.4 0.2 0.6 0.2 0.4 1.4 0.6 0.9 0.8 0.9 0.9 0.8 0.5 1.9 1.1 0.9 0.3 1.0 0.6 0.9 0.5 1.3 0.5 0.9 1.3 1.2 1.0 1.3 1.1 1.2 1.3 0.9 1.4 0.6 0.6 0.5 0.9 0.5 0.9 0.8 1.3 0.7 0.9 0.8 1.0 1.3 1.0 0.7 0.7 0.8 0.8 1.3 0.7 0.8 1.2 1.4 1.0 1.0 0.7 0.7 0.7 1.1 0.6 0.6 0.6 0.8 0.9 0.9 0.7 1.1 0.8 0.6 0.9 Myeloid 1.5 2.3 1.6 0.5 1.3 3.4 1.3 2.5 3.6 3.4 1.6 2.3 2.0 2.6 4.8 3.0 4.1 4.8 5.3 6.9 4.8 2.6 4.1 3.3 4.0 4.8 2.6 2.2 2.7 3.1 2.7 4.1 3.8 4.5 3.1 3.0 4.0 2.0 3.8 4.2 3.8 2.5 4.3 4.1 3.0 2.2 4.7 3.4 4.0 4.1 4.2 3.3 4.0 3.8 4.0 2.4 2.3 2.1 3.3 3.4 3.2 2.8 3.5 3.0 3.9 2.3 3.0 3.5 3.5 3.1 3.6 3.5 4.8 4.3 4.7 4.5 6.1 4.3 4.8 3.3 3.2 lymphoma, NOS 3.7 0.7 0.6 3.3 2.7 4.2 1.6 2.0 4.5 1.2 0.7 0.5 2.3 4.7 1.5 2.0 0.3 0.6 0.6 0.2 0.7 0.6 3.5 0.3 0.4 0.7 0.5 0.7 0.5 0.9 0.6 0.4 0.4 0.3 0.1 0.6 0.3 0.5 0.4 0.3 0.1 0.4 0.3 0.1 0.5 0.2 0.3 0.5 0.6 0.7 0.9 0.6 0.9 0.8 0.7 1.1 1.2 0.8 1.2 0.7 0.5 0.2 0.6 0.6 0.8 0.7 0.9 0.9 0.9 0.9 0.4 0.7 0.9 0.6 1.5 0.5 1.1 1.2 0.8 Non-Hodgkin Other Unspec. Number of cases MV Total

Age-standardized (world) incidence rates (per 100,000) by histological type

0.1 0.0 0.0 0.1 0.2 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.2 0.0 0.1 0.0 0.0

1.3 2.7 1.7 3.3 0.6 5.1 2.0 3.2 3.7 3.6 2.8 5.6 2.9 4.7 2.5 2.4 3.6 2.0 2.5 2.1 3.0 2.8 2.0 3.3 4.8 2.3 1.7 2.4 2.0 2.5 2.6 2.9 2.5 2.6 1.7 1.7 2.0 3.2 1.7 2.7 2.4 1.6 2.0 1.7 2.9 1.6 1.7 2.1 1.8 1.8 3.0 2.4 2.3 3.3 2.5 3.5 2.6 2.6 2.4 3.4 3.2 3.5 2.4 2.4 2.1 2.6 2.2 2.5 2.6 3.0 2.5 3.2 2.7 2.4 2.4 2.5 3.1 2.1 2.4 2.6 2.5 2.6

178 811 91 129 236 134 287 51 239 4825 106 684 759 513 276 175 16141 2183 2895 1170 665 260 5 732 7334 103 794 2922 553 2330 317 2994 23719 4849 339 233 158 601 61 3166 6483 694 157 175 1624 108 58 3427 1885 1453 4112 15764 2673 3155 196 2913 367 242 108 15454 1378 13863 4507 1549 432 1069 1019 3408 944 9557 1108 8169 4550 2969 3269 3497 237 566 819 2647 1103 5051

178 891 92 161 285

* * * *

186 340 85 286 4851 106 747 908 522 277 175 * 20327 2246 3578 1286 702 261 5 841 10300 106 1002 3283 627 2611 336 3411 25346 5135 356 243 164 635 63 3377 6740 741 164 178 1669 110 59 3571 1954 1558 4296 17009 3099 3368 203 3119 415 273 123 16160 1446 14496 5096 1726 484 1193 1173 3838 1033 10773 1270 9209 4960 3236 3813 3844 263 596 930 2882 1259 5724

796

*I N

738

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Haematopoietic and lymphoid tissues - Female (Contd)

B-cell America, North (Contd) USA, Michigan USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Michigan: Black USA, Michigan: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York state USA, New York state: Black USA, New York state: White USA, NPCR USA, NPCR: Black USA, NPCR: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 registries) USA, SEER (9 registries): Black USA, SEER (9 registries): White USA, SEER (14 registries) USA, SEER (14 registries): Asian and Pacific Islander USA, SEER (14 registries): Black USA, SEER (14 registries): Hispanic White USA, SEER (14 registries): Non-hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, New Delhi India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008 13.6 14.7 14.0 15.1 14.1 13.4 12.1 11.5 12.2 13.7 14.4 15.1 14.5 11.4 10.3 9.4 13.0 13.8 14.0 14.1 12.6 12.4 12.7 11.6 11.6 11.4 10.2 13.6 13.9 13.1 13.8 14.3 13.2 13.1 13.7 13.1 8.0 13.2 11.7 13.7 11.4 11.8 11.1 11.8 12.9 11.7 12.1 12.4 14.5 14.6 12.7 13.2 2.2 1.2 4.5 0.1 0.8 1.0 0.7 6.0 1.1 2.8 1.3 0.6 2.2 1.0 2.8 15.5 15.6 9.9 2.9 1.7 4.4 4.2 2.8 2.5 2.3 2.7 2.5 2.6 3.3 2.5 2.9 T-cell and NK-cell 1.0 1.1 1.7 0.9 1.7 0.8 0.7 1.1 0.6 0.5 1.0 1.5 0.9 0.7 0.5 0.3 0.9 0.9 1.4 0.8 0.8 1.1 0.7 0.8 1.0 0.7 0.5 0.9 0.9 1.0 0.8 1.2 1.0 1.5 0.9 0.9 0.7 1.3 0.7 0.9 0.8 0.8 0.7 0.8 1.0 0.8 0.6 0.4 1.0 0.9 0.6 0.8 0.0 0.4 0.0 0.1 0.1 0.0 0.4 0.0 0.2 1.5 1.5 1.3 0.3 0.1 0.4 0.4 2.8 0.6 0.3 0.4 0.4 0.3 0.5 0.3 0.3 Myeloid 3.6 5.8 5.0 6.0 3.2 3.6 3.4 3.1 3.4 3.1 4.3 4.2 4.3 3.9 2.2 3.7 4.3 4.5 3.7 4.7 3.2 2.9 3.3 3.0 2.7 3.0 3.2 3.2 3.6 3.1 3.6 3.4 4.5 4.2 4.6 4.3 3.4 4.1 4.1 4.4 2.9 2.9 2.8 3.0 3.2 3.0 4.2 3.4 3.6 5.2 3.5 3.6 3.3 2.3 2.5 1.5 0.4 1.5 1.9 2.5 1.3 1.1 1.5 1.7 2.1 1.1 1.6 5.1 4.8 3.8 1.5 1.6 2.6 2.2 3.0 1.8 2.1 2.2 2.1 2.2 2.2 2.0 2.2 lymphoma, NOS 0.8 0.8 0.7 0.8 0.6 0.8 1.0 1.4 0.9 0.5 0.9 0.5 0.9 0.4 0.5 0.5 0.9 0.7 0.9 0.8 0.6 0.9 1.1 0.7 1.1 1.1 0.5 0.8 0.7 0.8 0.4 0.6 0.5 0.7 0.7 0.4 0.4 0.6 0.7 1.0 0.5 1.1 0.9 0.5 0.9 0.7 2.1 0.8 0.9 1.2 0.6 3.9 3.3 0.4 0.1 1.7 2.8 1.7 2.2 1.2 0.3 1.9 0.9 3.0 0.1 0.3 1.0 0.9 0.6 0.4 1.9 2.1 0.4 1.7 0.6 0.9 0.2 0.2 0.3 0.4 0.8 0.1 Non-Hodgkin Other Unspec. Number of cases MV Total

Age-standardized (world) incidence rates (per 100,000) by histological type

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.1 0.1 0.3 0.2 0.1 0.1 0.1 0.1 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.0 0.2 0.0 0.1 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.1 0.4 0.0 0.1 0.1 0.0 0.1 0.1 0.0 0.1 0.2 0.1

2.8 3.0 2.4 3.2 2.4 2.8 2.3 2.5 2.3 2.4 3.3 2.7 3.4 3.0 2.1 2.9 3.6 3.1 2.6 3.2 2.9 2.3 2.9 2.9 1.9 3.0 3.1 2.8 2.4 2.0 2.4 2.3 2.7 2.2 2.8 2.7 2.0 2.2 3.1 2.6 2.7 2.1 2.9 3.3 2.5 3.5 2.4 2.6 2.3 2.0 3.1 3.4 3.0 3.5 3.1 4.4 2.8 2.5 2.1 3.0 2.0 2.0 2.3 2.2 1.7 3.4 1.5 2.9 2.9 2.2 2.2 2.7 1.8 3.1 2.3 2.9 2.4 2.2 2.0 2.6 2.2 2.7 2.1

8119 4038 788 3179 941 6982 4302 379 3876 673 8067 866 6925 1176 61 321 778 16013 1978 13591 168138 15006 146647 8981 754 7981 2483 2699 11259 783 10171 986 21750 1865 18297 57226 2934 4875 5359 43115 2683 612 2037 12180 1195 10671 1286 472 4712 3538 1656 4609 79 540 2178 60 106 1631 210 314 515 62 1509 238 1870 370 184 4626 4173 312 280 328 410 899 935 3299 469 7497 679 507 271 273 458

8821 4314 841 3399 1024 7591 4793 412 4333 789 8833 962 7567 1353 68 364 901 19307 2295 16512 185841 16844 162084 9648 814 8579 2704 2931 12779 900 11545 1052 23305 2003 19653 61880 3055 5345 5647 46836 3087 729 2302 14294 1438 12484 1345 533 5021 3687 1808 4871 87 565 2408 60 127 1803 213 318 529 65 1509 239 1870 373 186 5188 4612 344 280 389 548 1177 1071 3299 589 7997 718 526 286 281 473 * * * * *

* * * *

739

797

Haematopoietic and lymphoid tissues - Female (Contd)

B-cell Asia (Contd) Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland (data not available) France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg (data not available) Germany, Free State of Saxony (data not available) Germany, Hamburg Germany, Mecklenburg-Western Pomerania (data not available) Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Sondrio Italy, Syracuse Province Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce (data not available) Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg *Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. 2.5 3.6 2.3 6.4 7.4 1.6 1.2 3.1 6.0 3.5 4.5 4.3 4.2 7.0 3.3 3.0 3.0 4.1 4.5 4.6 10.2 6.3 3.1 7.3 8.4 2.4 4.7 6.9 9.9 7.2 10.8 10.4 11.8 11.9 11.6 11.5 12.4 11.5 9.4 9.9 8.4 7.1 6.6 7.6 9.3 10.9 8.1 13.5 10.3 11.2 9.1 11.7 6.9 11.8 14.3 9.1 8.0 13.7 9.9 4.6 13.0 7.9 11.7 11.3 8.0 10.4 4.9 9.6 7.7 3.5 5.0 6.5 9.7 3.4 4.8 3.0 5.5 4.2 T-cell and NK-cell 0.5 0.4 0.3 1.1 0.6 0.0 0.0 0.1 0.2 0.7 0.7 0.9 0.3 0.1 0.1 0.8 0.2 0.4 0.4 0.9 0.1 0.1 0.4 0.6 0.1 0.0 0.4 0.7 0.4 0.4 0.5 0.2 0.3 0.3 0.1 0.4 0.9 0.5 0.1 0.3 0.5 0.2 0.3 0.4 0.5 0.6 0.2 0.7 1.5 0.6 0.8 0.1 0.6 1.7 0.6 0.6 0.4 0.6 0.4 0.4 1.1 0.4 0.6 1.1 0.7 0.3 0.8 0.9 0.4 0.5 1.5 0.6 0.1 0.2 0.1 0.4 0.1 Myeloid 3.1 2.5 2.0 2.6 2.4 2.7 2.3 1.8 2.4 2.4 3.3 3.2 2.9 3.8 2.1 2.0 1.8 2.2 2.5 2.5 5.0 2.9 2.5 2.1 3.7 1.9 3.1 4.0 3.1 2.4 5.7 5.7 6.1 3.6 4.5 6.1 3.8 5.6 4.1 5.3 2.6 2.8 3.3 4.5 2.6 2.6 4.8 6.7 3.4 3.6 7.6 6.0 2.8 3.3 3.0 4.4 3.4 4.0 8.1 3.3 3.0 2.9 2.7 2.8 4.8 4.5 3.0 3.9 3.1 3.3 3.0 4.6 3.3 2.6 2.3 2.6 3.9 2.4 lymphoma, NOS 0.1 0.2 0.3 0.8 0.6 3.3 3.4 2.9 0.5 1.1 0.4 0.4 0.1 1.1 1.2 0.7 0.8 0.6 1.8 0.3 1.3 2.1 1.2 2.7 1.4 3.9 1.2 0.8 0.2 0.5 0.2 0.2 0.9 0.5 0.9 1.4 0.3 0.6 0.2 1.4 3.3 1.4 2.4 1.0 2.3 0.6 3.9 0.7 2.5 0.5 2.4 1.6 0.4 1.5 3.8 4.3 1.0 10.8 1.8 2.7 0.7 2.4 0.9 2.6 2.0 5.7 3.2 0.9 1.1 2.3 2.6 0.4 1.0 3.2 4.0 0.3 Non-Hodgkin Other Unspec. Number of cases MV Total

Age-standardized (world) incidence rates (per 100,000) by histological type

0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.3 0.0 0.1 0.1 0.0 0.3 0.1 0.1 0.0 0.1 0.2 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.2 0.0 0.2 0.1 0.2 0.4 0.3 0.1 0.0 0.0 0.4 0.1 0.1 0.2 0.0 0.2 0.0 0.1 0.1 0.1 0.1 0.0

1.9 2.8 1.7 1.1 3.7 2.9 1.7 2.4 1.7 4.4 2.3 2.2 2.2 2.8 2.6 3.1 2.7 2.5 1.7 4.0 1.3 5.6 1.9 0.9 2.1 2.3 2.6 2.3 2.5 2.6 1.5 1.4 1.7 2.3 1.5 0.9 2.1 0.6 1.8 2.2 1.8 1.6 1.9 2.6 1.4 2.1 4.0 0.7 2.5 1.8 3.1 2.7 3.3 1.8 1.8 6.0 4.2 4.5 2.7 0.9 2.3 3.6 2.1 2.8 1.8 2.8 7.0 4.2 4.4 3.2 3.1 2.0 1.5 6.4 2.7 2.5 2.2 3.4

72 2205 118 180 128 225 354 219 269 925 981 787 53 141 357 204 226 211 717 4692 507 191 3804 1007 3913 2601 2365 5794 3937 833 774 552 473 575 787 935 1013 490 389 355 381 1056 1295 1877 803 161 2588 273 602 426 1108 662 145 1230 711 289 2278 618 282 505 1221 619 349 165 190 1044 630 497 1561 1198 1920 244 3568 314 819 1306 1948 2257

77 2338 122 181 133 246 368 231 272 1166 981 787 53 141 357 204 275 304 810 5341 516 213 3889 1012 3979 2601 2765 6909 4145 853 851 559 473 597 788 969 1033 496 409 360 392 1431 1660 2263 881 161 2755 287 641 444 1576 790 163 1230 715 368 2307 618 304 510 1256 670 366 176 213 1088 822 538 1719 1268 1920 252 3726 389 869 1308 1964 2285

Eu

* * *

* * * *

* * *

* *

798

*I N

740

Cancer Incidence in Five Continents Vol. IX, IARC 2008

Haematopoietic and lymphoid tissues - Female (Contd)

B-cell Europe (Contd) Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, England, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern And Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory (data not available) Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 3.8 7.5 7.9 7.3 8.1 8.0 10.7 4.7 12.8 8.7 8.8 7.2 7.7 6.7 7.4 8.1 8.5 6.4 10.8 11.9 9.4 8.3 9.9 9.1 8.6 8.2 5.2 7.7 9.2 9.5 9.2 7.3 8.3 8.4 6.6 10.1 11.5 13.3 14.6 11.4 12.6 10.9 12.2 6.8 13.1 9.6 7.4 7.8 12.0 7.8 12.8 T-cell and NK-cell 0.2 0.2 0.7 0.8 0.6 0.6 0.7 0.1 1.2 1.0 1.1 1.1 0.6 0.3 0.5 0.6 1.1 0.0 0.5 1.2 0.7 0.1 0.7 0.7 0.5 0.5 0.5 0.5 0.4 0.4 0.5 0.3 0.7 0.7 0.6 0.7 0.6 0.6 0.6 0.3 0.6 0.6 0.8 0.7 1.0 0.3 0.9 0.8 0.8 1.2 Myeloid 1.5 3.8 3.4 4.0 2.1 2.0 2.5 2.2 5.2 3.0 2.9 1.9 2.5 1.9 5.0 4.0 2.4 3.0 4.7 2.0 3.1 2.5 3.3 3.6 2.8 5.3 4.1 5.0 5.6 2.9 7.3 5.3 5.9 4.9 2.5 7.3 5.2 7.4 4.0 3.7 6.2 5.3 4.8 6.0 3.7 3.9 2.7 2.8 5.3 3.6 3.7 lymphoma, NOS 1.4 0.6 1.2 1.8 1.6 1.0 2.1 0.4 0.2 0.1 0.9 0.4 2.3 1.2 1.1 2.8 2.4 0.8 1.0 0.9 2.9 0.8 1.1 1.0 1.1 3.7 2.0 1.8 1.6 1.6 3.4 1.0 2.3 1.6 0.9 1.7 1.1 0.4 1.5 1.0 1.6 1.7 2.6 1.4 0.7 1.2 0.7 0.8 0.4 0.7 Non-Hodgkin Other Unspec. Number of cases MV Total

Age-standardized (world) incidence rates (per 100,000) by histological type

0.0 0.1 0.0 0.1 0.2 0.0 1.0 0.0 0.1 0.1 0.1 0.5 0.2 0.0 0.3 0.1 0.3 0.1 0.0 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 -

2.3 2.1 2.2 2.8 3.6 2.4 2.3 3.4 0.7 1.6 3.4 3.1 2.7 4.0 4.2 2.0 3.4 2.3 1.4 2.3 1.5 2.0 1.4 1.4 0.6 3.7 2.8 2.7 2.5 2.6 4.4 2.9 3.7 2.3 6.3 3.2 2.9 2.7 4.7 2.8 2.9 2.4 2.3 3.8 2.9 3.2 1.2 2.9 2.8 3.7 3.4

1476 2673 1339 210 862 1082 867 95 478 462 656 326 359 531 8026 362 159 120 412 291 179 439 10522 622 516 2241 1359 2768 4282 1882 4912 9474 4129 3912 975 5427 5077 2803 1518 392 4580 1299 181 82 3146 845 55 109 117 234 243

1631 2909 1339 220 939 1161 935 108 498 485 739 351 377 563 8039 371 171 120 412 315 191 477 10694 647 530 2609 1931 3643 6416 1962 8705 12706 4876 4777 1235 5738 5962 3446 1621 407 4879 1453 219 86 3253 879 56 112 122 247 251

*Important. See note on population page. Note: The rates are based on the histological groups described in Chapter 4. Cancer Incidence in Five Continents Vol. IX, IARC 2008

741

799

Indices of data quality

743

Indices of data quality

Oral cavity pharynx (C00-14)

Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 263 94.3 285 97.5 83 100.0 93 65.6 66 71.2 83 92.8 398 91.7 139 87.1 286 99.0 5006 85.5 21 81.0 180 86.7 355 93.5 49 89.8 188 96.3 34 100.0 7960 853 1239 512 277 276 7 386 4015 46 349 1811 321 1475 180 1545 10472 896 664 1016 7733 2102 142 197 64 12 154 1433 2551 323 100 48 25 33 386 1531 1124 1207 97 1089 288 223 58 8128 686 7344 2737 641 2069 741 229 494 453 4333 705 3485 2156 1164 1701 1842 468 1356 119 265 96.2 98.9 98.1 98.6 97.1 99.6 100.0 98.2 94.1 100.0 97.4 98.1 96.9 98.4 97.8 97.2 98.6 99.1 98.9 98.6 98.5 99.0 98.6 99.0 100.0 100.0 99.4 98.8 99.1 99.7 98.0 100.0 100.0 100.0 99.2 99.0 97.5 99.4 99.0 99.5 95.5 96.0 98.3 96.0 94.2 96.2 97.7 96.7 98.0 98.4 98.3 98.4 97.8 98.1 97.7 98.1 98.7 98.6 96.4 97.6 97.2 97.9 98.3 98.1 0.0 0.0 0.0 0.0 0.0 3.6 5.8 2.2 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 2.5 0.0 0.1 0.0 0.0 0.0 0.0 0.0 4.9 0.0 0.0 0.6 0.6 0.6 0.6 1.5 0.5 0.4 0.3 0.4 0.5 0.1 0.0 0.5 0.0 0.0 0.0 0.1 0.4 0.3 1.0 0.0 0.0 0.0 0.5 0.3 0.5 0.1 0.0 0.1 0.7 0.0 0.0 0.5 0.4 0.5 0.5 0.3 0.5 0.5 0.0 0.8 0.0 0.4 0.6 0.3 0.2 0.2 1.9 0.2 0.0 0.2 0.0 0.0 Female Cases MV(%) DCO(%) UB(%) MI(%) 66 100.0 209 97.1 35 100.0 61 68.9 45 73.3 36 97.2 153 88.2 41 75.6 71 97.2 1682 79.5 10 80.0 163 92.0 181 92.3 43 90.7 47 95.7 29 100.0 3803 398 685 234 89 67 4 158 1965 31 172 795 130 651 67 678 5171 536 318 485 3711 1103 75 110 33 7 72 720 1280 154 58 39 23 10 196 745 549 619 43 560 100 69 28 3871 314 3494 1315 289 1007 379 117 250 214 2029 256 1686 941 557 674 718 168 545 53 123 94.8 98.5 98.2 98.3 98.9 100.0 100.0 96.2 91.5 100.0 99.4 97.7 98.5 97.5 97.0 97.2 98.1 98.9 98.4 98.1 98.0 97.6 100.0 97.3 97.0 100.0 100.0 97.2 98.4 98.1 100.0 97.4 100.0 100.0 98.0 98.4 98.2 98.4 100.0 98.4 99.0 98.6 100.0 97.0 98.4 96.9 96.0 95.5 96.3 97.1 98.3 97.2 96.7 98.2 96.5 98.4 97.6 98.4 97.0 97.1 96.4 97.2 100.0 97.6 0.0 0.0 0.0 0.0 0.0 0.0 11.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 4.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 7.6 0.0 0.0 1.9 0.8 2.2 0.0 1.5 0.5 0.2 0.0 1.0 0.6 0.6 0.0 0.0 0.0 0.0 0.0 0.7 0.2 0.0 0.0 0.0 0.0 0.0 0.5 0.3 0.9 0.3 0.0 0.4 0.0 0.0 0.0 0.2 0.3 0.2 0.7 1.4 0.3 0.8 0.9 0.0 0.0 0.1 0.4 0.1 1.0 0.2 1.3 0.7 1.2 0.6 0.0 0.8 * * * *

2.1 4.5 2.4 2.3 7.2 0.7 4.9 9.5 3.9 3.9 8.2 0.0 0.6 0.0 0.5 0.6 0.0 0.0 0.5 0.7 0.0 0.9 0.9 1.2 0.7 0.6 0.5 0.4 0.1 0.3 0.2 0.4 0.3 0.7 0.0 0.0 0.0 0.6 0.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.8 0.2 1.0 0.2 1.7 2.2 0.0 2.7 3.2 2.6 0.8 1.4 0.6 0.1 0.4 0.0 2.2 1.2 1.4 1.1 0.6 0.5 0.8 0.7 1.1 0.6 0.0 0.4

15.4

0.0 4.4 2.8 0.7 17.1 1.4 5.5 0.0 0.6 3.9 4.7 0.0 0.5 0.0 0.4 0.4 0.0 0.0 0.0 0.8 0.0 0.6 0.3 0.0 0.3 1.5 0.4 0.7 0.6 0.9 0.0 0.8 1.2 0.0 0.9 3.0 0.0 0.0 1.5 0.5 1.3 0.0 2.6 0.0 0.0 0.0 0.5 0.2 0.5 0.0 0.4 1.0 1.4 0.0 2.1 1.0 2.2 2.3 2.1 2.4 1.3 0.9 1.6 2.3 1.2 2.3 1.1 1.0 0.7 0.9 1.0 0.6 1.1 0.0 0.0

15.8

49.4 31.7 36.0 48.6 35.3 47.6 50.6 51.5 49.0 47.9 31.4 27.4 33.7 23.2 30.7 22.8 42.9 36.5 33.1 41.3 24.6 25.6 41.7 22.3 26.1 26.8 25.4 34.7 34.5 26.0 23.9 26.1 38.7 18.8 23.0 25.4 32.8 46.0 37.5 40.0 24.2 26.9 22.4 20.7 24.7 38.1 23.7 35.4 41.3 17.2 26.5 34.0 25.9 24.9 36.3 21.5 19.8 27.1 16.8 21.4 25.2 33.2 24.0 21.4 21.1 26.3 28.9 39.5 25.4 42.9 36.2

38.9 17.0 26.8 36.6 22.1 80.0 34.4 42.5 46.5 34.6 31.5 32.4 30.9 27.8 36.0 17.9 50.0 25.3 32.9 12.9 33.1 27.4 26.9 28.1 26.9 26.5 29.8 27.8 36.5 21.0 31.5 31.0 38.7 15.3 35.1 29.4 35.1 41.4 23.1 21.7 50.0 20.9 30.9 21.1 23.7 20.9 24.5 31.0 33.3 28.6 26.4 30.3 26.3 28.2 31.8 27.1 23.5 27.4 21.6 28.5 24.2 33.2 23.4 25.9 23.5 28.6 32.7 36.3 31.9 39.6 38.2

802

*Important. See note on population page.

744

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Oral cavity pharynx (C00-14) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 593 97.0 2343 97.7 3651 98.0 557 98.2 3005 98.0 1624 98.8 459 99.3 1142 98.5 2036 97.9 193 97.9 1817 97.9 348 97.4 79486 97.5 8566 96.9 67751 97.5 2875 98.4 426 97.9 2317 98.4 559 97.9 18 100.0 115 98.3 418 97.6 6234 96.5 871 96.2 5026 96.5 3555 97.1 396 94.9 3045 97.4 1394 96.4 1292 97.8 4604 98.7 501 98.4 3957 98.7 364 99.5 9008 98.8 966 99.0 7304 98.7 24558 98.4 1428 99.1 2534 98.3 1456 98.5 18821 98.4 1759 97.2 528 97.7 1216 96.9 6431 95.8 625 93.9 5661 96.1 450 98.9 210 97.6 1991 98.4 1366 98.8 745 97.6 1939 96.3 39 89.7 1671 86.2 5254 95.9 83 96.4 74 90.5 1512 87.2 1133 98.3 79 100.0 1915 83.3 3490 87.6 176 92.0 4297 85.5 754 96.0 1014 86.9 584 93.8 962 93.2 854 95.0 83 95.2 213 93.0 137 87.6 331 93.4 650 90.0 548 92.7 2299 81.3 341 88.3 0.3 0.9 0.4 0.0 0.5 0.5 0.0 0.7 1.0 1.0 1.0 2.3 1.1 1.5 1.1 0.4 0.7 0.3 0.7 0.0 0.9 0.7 1.2 1.5 1.1 1.5 3.0 1.3 1.4 1.1 0.2 0.2 0.2 0.5 0.4 0.3 0.4 0.4 0.1 0.5 0.3 0.4 0.8 0.8 0.8 2.3 4.0 2.1 0.2 1.9 0.5 0.2 0.5 1.4 10.3 0.0 0.2 0.0 5.4 0.5 0.0 1.0 1.0 0.0 5.5 0.0 4.2 2.2 0.8 0.9 0.0 7.0 5.1 1.8 3.2 2.9 8.5 7.0 1.7 0.7 0.9 0.9 1.0 0.2 0.2 0.3 0.8 1.0 0.8 0.0 0.7 0.7 0.7 0.7 0.7 0.8 0.2 0.0 0.0 0.2 1.1 1.4 1.0 0.9 1.3 0.9 0.5 0.3 0.4 0.2 0.5 0.0 0.2 0.1 0.2 0.5 0.4 0.3 0.4 0.5 1.5 0.8 1.8 1.5 1.8 1.4 0.0 0.0 0.4 0.1 0.5 1.8 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.2 2.5 1.4 2.4 0.0 0.0 0.0 0.0 0.7 0.0 1.2 23.6 25.9 22.5 26.8 21.9 21.9 24.8 20.7 23.1 32.6 22.0 19.5 25.6 36.0 24.5 25.9 39.0 24.0 21.6 22.2 32.2 17.7 25.9 35.1 24.2 30.0 40.4 29.6 21.5 23.8 25.1 29.9 25.2 24.5 23.8 28.5 22.3 25.3 32.4 33.8 24.8 23.8 30.0 44.7 23.8 27.7 44.8 25.9 21.8 25.2 25.4 26.3 26.6 25.0 38.5 42.4 41.1 55.4 47.4 28.5 39.4 1.7 29.9 27.5 46.0 62.0 36.6 47.2 45.8 56.1 63.0 Female Cases MV(%) DCO(%) UB(%) MI(%) 268 95.9 1253 97.4 1772 97.9 183 98.9 1533 97.7 768 98.7 141 100.0 613 98.4 905 97.0 47 97.9 846 96.9 140 92.1 37828 97.1 3526 97.1 32483 97.1 1511 97.3 176 96.0 1251 97.3 243 96.7 8 100.0 46 97.8 183 96.7 3295 95.1 434 96.5 2713 94.8 1790 97.7 162 97.5 1559 97.6 548 94.2 655 99.1 2224 98.2 226 98.2 1943 98.2 188 98.9 4493 98.2 396 99.5 3667 98.2 11833 97.9 821 98.5 1047 98.0 685 98.1 9072 97.8 719 96.8 173 96.5 538 96.8 2787 94.8 281 93.6 2426 95.1 231 98.7 93 94.6 1030 98.5 698 98.4 337 97.9 1002 93.9 17 94.1 771 88.8 2093 94.8 33 93.9 37 83.8 853 88.4 418 98.6 53 96.2 886 80.9 1013 86.2 82 80.5 1628 84.9 296 95.9 607 90.3 241 90.5 576 92.5 525 93.3 34 100.0 98 87.8 75 81.3 121 92.6 281 86.8 226 94.7 884 83.4 156 87.2 1.5 1.0 0.8 0.0 0.9 0.3 0.0 0.3 1.5 0.0 1.7 4.3 1.3 1.2 1.4 1.3 0.6 1.4 0.4 0.0 0.0 0.5 1.6 1.2 1.8 1.3 1.9 1.3 3.1 0.5 0.7 0.4 0.8 1.1 0.6 0.3 0.6 0.7 0.6 0.6 0.1 0.8 1.0 1.7 0.7 2.8 2.8 2.9 0.0 3.2 0.2 0.3 1.2 2.0 5.9 0.1 0.3 0.0 0.0 0.7 0.0 1.1 0.5 0.0 5.3 0.0 2.6 3.3 1.6 1.7 0.0 10.2 6.7 0.8 7.1 0.9 8.9 8.3 1.9 1.0 0.5 0.5 0.5 0.1 0.0 0.2 1.0 2.1 0.9 2.9 0.8 0.8 0.8 0.8 3.4 0.5 0.8 0.0 0.0 0.5 1.4 1.2 1.5 0.8 0.0 0.9 0.5 0.0 0.5 0.4 0.6 0.0 0.4 0.3 0.2 0.6 0.6 1.0 0.7 0.5 1.3 1.2 1.3 1.5 1.8 1.2 0.0 0.0 0.5 0.3 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.2 0.0 0.0 0.0 0.0 0.0 0.0 2.8 1.9 0.0 2.0 2.7 0.0 0.0 0.0 0.0 0.6 26.1 27.1 25.5 30.1 25.4 24.1 31.2 22.0 30.1 51.1 29.1 33.6 27.2 31.8 27.3 25.7 32.4 25.7 23.5 25.0 21.7 24.6 25.6 31.6 24.9 27.5 32.1 28.3 27.6 31.1 25.9 26.1 26.2 32.4 25.5 30.1 25.4 27.8 25.5 33.2 20.3 28.4 28.5 37.6 26.0 28.4 29.2 28.9 20.3 31.2 26.7 27.4 25.5 27.6 47.1 33.3 * 29.3 * 40.5 35.4 * * 4.7 * 30.4 * 28.0 29.9 35.7 69.3 38.8 50.2 38.9 56.0 64.1 * * *

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
745

803

Indices of data quality

Oral cavity pharynx (C00-14) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
746

Female Cases MV(%) DCO(%) UB(%) MI(%) 2085 77.8 197 84.8 111 89.2 60 80.0 79 78.5 107 85.0 13 76.9 565 82.7 32 71.9 37 97.3 34 100.0 162 95.1 412 92.2 37 81.1 478 96.9 600 80.2 591 99.3 519 99.2 30 100.0 42 100.0 243 95.9 131 86.3 145 95.2 82 91.5 213 97.7 1105 83 62 926 201 650 848 688 1165 1080 194 854 187 135 85 136 192 156 206 80 106 66 70 318 586 388 241 423 390 212 45 361 33 108 69 200 128 12 216 86 36 485 62 30 72 131 65 67 23 37 180 133 78 335 93.4 98.8 96.8 97.0 100.0 97.7 87.0 71.5 93.5 97.4 93.8 97.5 98.9 100.0 100.0 97.8 100.0 99.4 99.5 100.0 97.2 100.0 98.6 87.4 93.0 80.2 88.4 92.4 86.9 95.8 100.0 93.1 97.0 90.7 91.3 89.5 85.9 83.3 97.2 97.7 83.3 95.5 98.4 76.7 80.6 91.6 73.8 92.5 95.7 91.9 96.1 88.0 97.4 95.2 15.1 6.6 5.4 10.0 17.7 3.7 23.1 12.0 18.8 2.7 0.0 1.2 4.6 2.7 0.4 7.7 0.2 0.2 0.0 0.0 0.4 0.8 4.1 0.0 0.0 5.7 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.2 0.0 1.6 0.0 0.0 2.3 0.0 24.0 2.1 1.7 0.0 1.2 0.5 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.9 0.0 0.0 3.1 0.0 0.0 0.4 0.0 0.8 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.0 0.0 0.0 40.5 36.5 35.1 36.7 48.1 33.6 80.8 30.8 34.4 12.3 19.4

5641 490 349 146 187 291 59 1417 77 45 92 350 775 77 862 973 1575 1409 68 98 466 155 462 194 461

87.1 90.4 96.6 91.1 89.8 85.6 91.5 88.1 80.5 95.6 95.7 96.9 92.9 97.4 99.2 77.7 99.2 99.3 97.1 99.0 96.8 86.5 97.0 95.9 97.0

5.7 2.4 1.1 6.2 4.3 3.8 1.7 5.4 9.1 4.4 2.2 1.1 4.3 0.0 0.0 8.7 0.0 0.0 0.0 0.0 0.0 0.6 2.4 2.6 0.0 4.0 0.4 2.3

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.9 0.1 0.0 0.8 0.0 0.0 1.3 0.0 13.6 1.1 1.5 0.0 0.3 0.0 0.0 0.0 0.5 0.0 0.5 0.0 0.0 0.7 0.0 1.2 2.1 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.5 0.0 0.0 8.7 0.0 0.0

41.5 41.2 34.1 43.8 35.3 44.0 53.4 31.5 41.6 17.1 18.1

50.8 1.9 79.4 58.0 14.9 15.0 53.2 46.5 36.2 51.3 37.3 41.0 51.0 57.2 41.4 71.6 31.1 35.2 33.1 35.0 36.5 30.1 37.7 37.9 35.4 40.1 34.0 51.5 107.4 36.9 46.0 30.9 43.8 48.4 45.1 30.4 49.7 65.5 53.4 38.8 37.2 49.6 51.6 52.2 50.9 37.0 48.3 43.1 47.5 47.4 41.4 47.2 46.8 40.3 55.6 46.6 49.4 41.3 41.0

40.9

* * *

1.6 * 67.9 * 151.0 7.3 * 18.3 * 49.2 48.2 43.5 42.1 * * 38.0 35.7 * 32.0 48.8 43.2 55.2 32.4 27.3 23.7 32.9 30.9 22.9 37.2 31.6 21.3 30.2 31.8 32.9 97.8 30.5 40.7 27.4 39.2 46.4 38.2 33.3 51.0 51.5 45.4 34.8 42.5 46.1 50.0 41.2 44.2 41.7 41.0 46.8 43.3 40.3 52.7 53.8 49.3 47.8 43.9 37.2 45.1 29.5 40.6

3352 95.5 284 99.6 130 94.6 5048 98.3 592 99.5 2208 98.1 3438 89.8 3175 82.9 4184 95.5 2261 97.9 566 95.6 1393 99.4 975 99.5 697 98.9 420 99.5 578 99.3 715 99.9 742 99.2 1190 99.7 608 99.5 684 98.4 247 100.0 493 97.8 1356 88.9 2080 96.2 909 88.0 1176 93.7 1249 94.6 1084 88.2 767 99.0 56 100.0 915 97.5 116 96.6 309 92.2 219 94.1 422 92.2 270 95.2 31 96.8 423 98.1 175 96.6 117 84.6 1621 97.5 181 98.3 80 93.8 137 94.2 307 96.4 197 83.8 233 97.4 67 88.1 90 96.7 461 98.5 312 90.4 259 96.1 1067 97.8

5.0 3.5 2.2 0.2 0.4 0.1

7.5 4.2 2.7 0.2 0.0 0.4

0.1 8.4 3.3 2.6 6.1 2.3 5.7 0.4 0.0 1.2 0.9 1.0 0.5 0.2 0.7 0.0 0.2 0.6 0.9 0.3 0.6 2.5 0.0 0.7 2.0 1.3 6.0 0.0 0.4 0.0 0.0 0.8

0.0 9.4 6.3 4.1 10.8 3.3 7.4 0.9 0.0 1.7 0.0 2.8 4.3 1.0 0.8 8.3 0.5 0.0 0.0 0.6 0.0 10.0 0.0 3.1 1.5 3.0 4.3 0.0 1.7 1.5 0.0 1.5

804

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Oral cavity pharynx (C00-14) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 908 88.8 1609 96.5 125 95.2 1252 99.1 226 88.5 484 92.8 545 96.3 1269 98.1 1484 95.4 2022 89.7 1831 88.9 3795 94.5 1286 99.2 209 98.6 816 97.9 1465 98.4 1095 98.2 163 97.5 351 97.7 604 98.8 756 97.4 364 98.4 323 97.2 389 97.7 2439 99.9 274 98.2 101 96.0 93 100.0 206 97.6 144 99.3 148 100.0 422 98.6 5023 99.6 317 100.0 329 99.7 688 97.8 721 93.5 1322 96.8 2023 96.4 613 97.9 1790 85.4 3212 90.0 1195 93.3 1255 96.3 423 94.6 2119 98.3 3001 96.2 141 99.3 2107 97.2 897 99.2 307 99.3 2249 97.4 884 98.8 86 98.8 66 95.5 921 98.2 465 99.1 50 100.0 56 96.4 61 100.0 106 99.1 161 99.4 3.1 0.4 0.8 0.0 3.5 2.7 0.0 3.9 4.5 4.6 0.4 0.5 1.2 0.2 0.6 0.6 1.7 0.0 1.1 0.3 2.2 2.1 0.0 1.0 0.0 0.0 0.7 0.0 0.9 0.2 0.0 0.0 0.0 0.0 1.9 0.2 0.0 0.0 3.7 0.1 0.3 0.4 0.5 0.2 0.5 0.1 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.1 0.5 0.0 1.5 2.6 3.0 0.5 0.0 0.0 0.2 0.0 0.0 0.1 0.1 0.3 0.8 0.1 0.0 0.0 0.0 0.2 0.0 1.8 0.0 0.0 0.0 63.2 66.6 40.8 40.7 55.3 36.4 54.3 45.0 49.7 82.7 46.8 68.9 51.9 23.0 48.4 33.6 42.4 17.2 32.5 17.5 31.2 30.2 35.6 40.9 36.3 40.9 41.6 36.6 35.4 45.8 43.2 41.0 33.6 43.2 33.3 35.9 44.3 39.1 34.6 38.0 41.3 38.1 41.3 39.0 38.2 26.6 32.6 21.5 21.0 12.2 24.4 26.9 34.9 50.0 41.9 28.6 Female Cases MV(%) DCO(%) UB(%) MI(%) 237 361 62 655 81 121 243 348 349 498 719 512 272 32 162 281 166 35 70 119 159 79 58 86 1482 116 40 46 63 50 42 154 2796 148 127 399 390 679 1024 382 1097 1833 663 761 219 1105 1342 32 836 377 130 1068 328 41 20 484 217 14 32 24 53 78 89.9 90.3 96.8 98.9 79.0 83.5 91.4 98.3 92.6 88.6 85.8 91.0 99.6 96.9 97.5 98.6 95.8 97.1 97.1 98.3 96.9 96.2 91.4 96.5 99.8 98.3 95.0 100.0 96.8 100.0 100.0 98.7 99.5 99.3 100.0 96.5 92.8 94.7 96.6 97.6 81.8 88.1 92.5 95.9 93.2 97.2 95.8 100.0 95.1 96.8 99.2 96.3 99.1 97.6 95.0 95.7 99.1 100.0 100.0 100.0 96.2 100.0 3.4 0.8 0.0 0.0 7.4 5.8 0.4 6.9 3.5 6.1 0.4 0.0 0.6 0.7 3.0 2.9 2.9 0.0 0.6 1.3 6.9 3.5 1.7 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 8.3 0.4 0.0 0.0 3.4 0.3 0.6 0.0 3.1 0.0 0.4 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.3 1.0 0.0 1.8 3.7 2.5 0.8 0.0 0.0 0.3 0.0 0.0 0.2 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 1.9 0.0 46.4 52.1 27.4 41.1 67.9 * 42.4 48.1 28.4 * 38.7 77.9 30.7 56.8 32.4 25.0 26.7 34.2 31.6 40.0 21.4 21.8 28.3 30.4 34.5 36.0 30.8 29.3 45.0 30.4 30.2 62.0 47.6 23.4 32.1 29.1 36.6 45.4 43.3 37.4 34.6 38.8 40.9 37.3 39.6 50.2 35.0 24.8 37.5 23.1 21.5 16.7 21.3 26.2 17.1 55.0 38.4 28.1

0.0 0.8 0.2 0.6 0.3 0.4 4.2 2.9 1.0 0.0 0.3 0.3 0.0 0.2 0.0 0.0 0.4 0.2 0.0 3.0 0.9 0.4 0.0 0.0 0.0 0.9 0.6

0.0 0.3 0.9 0.6 0.3 0.9 5.7 2.7 1.4 0.5 0.4 0.7 0.0 0.7 0.0 0.0 1.0 0.6 0.0 5.0 1.4 0.5 0.0 0.0 0.0 1.9 0.0

25.5

32.1

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
747

805

Indices of data quality

Oesophagus (C15)
Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 4 75.0 70 91.4 5 100.0 125 56.0 219 42.0 58 262 72 115 2406 81 112 159 55 82 26 3568 349 673 171 112 62 5 174 1836 30 156 816 243 569 91 799 4569 282 325 492 3436 912 73 55 14 13 72 661 1036 133 28 13 23 17 189 605 625 714 53 655 179 149 26 3734 433 3276 1292 470 809 359 132 219 210 2562 421 2098 1179 600 763 823 259 557 57 105 82.8 86.6 77.8 89.6 78.1 88.9 79.5 71.1 87.3 98.8 92.3 92.7 95.1 95.1 93.6 98.2 100.0 100.0 93.1 90.6 90.0 93.6 93.9 93.4 94.0 98.9 94.1 96.2 97.5 95.7 97.0 96.1 95.6 93.2 100.0 92.9 92.3 93.1 95.9 97.6 97.0 96.4 100.0 95.7 100.0 98.4 97.4 93.1 98.7 100.0 98.6 92.7 91.3 100.0 92.4 90.3 92.7 94.9 93.6 95.6 97.2 97.0 97.3 94.8 96.1 94.3 96.4 95.8 96.2 93.8 96.5 96.9 96.2 91.2 97.1 0.0 0.0 0.0 0.0 0.0 0.0 5.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.2 0.0 0.0 1.3 1.2 1.4 0.0 2.5 1.2 0.4 1.2 0.8 1.3 0.9 2.7 0.0 0.0 0.0 0.0 0.9 1.0 0.8 3.6 0.0 0.0 0.0 1.1 1.0 1.1 0.0 0.0 0.0 2.2 2.7 0.0 0.8 0.5 0.9 0.7 0.9 0.6 0.6 0.8 0.5 0.0 0.6 1.0 0.6 0.8 1.0 2.2 0.2 0.0 0.4 0.0 1.0 Female Cases MV(%) DCO(%) UB(%) MI(%) 4 75.0 41 87.8 2 100.0 78 47.4 67 44.8 36 80.6 95 90.5 19 78.9 43 79.1 621 75.0 51 96.1 78 79.5 55 60.0 24 62.5 17 94.1 5 100.0 1424 123 293 68 43 12 0 58 759 6 62 238 72 164 24 243 1677 112 141 140 1273 345 34 10 10 10 19 245 418 72 15 8 6 1 54 258 198 288 36 250 65 58 7 1288 171 1105 419 198 215 129 62 62 62 800 168 616 350 180 205 254 82 171 19 38 88.2 93.5 93.9 88.2 90.7 100.0 0.0 86.2 84.7 100.0 90.3 90.3 90.3 90.9 100.0 91.8 94.3 95.5 96.5 94.3 94.0 94.2 97.1 100.0 90.0 100.0 100.0 92.7 93.5 94.4 93.3 87.5 100.0 100.0 92.6 93.4 92.4 96.9 94.4 97.2 93.8 93.1 100.0 91.8 95.3 91.3 95.2 93.9 96.7 96.1 95.2 98.4 95.2 95.6 97.0 95.1 95.7 90.0 93.7 94.9 98.8 93.0 94.7 84.2 0.0 0.0 0.0 0.0 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.9 0.0 5.8 0.0 0.0 0.0 0.0 0.0 0.0 1.7 10.7 0.0 0.0 3.8 1.4 4.3 0.0 4.5 1.3 0.9 0.7 0.7 1.4 0.9 0.0 0.0 0.0 0.0 0.0 1.2 1.4 1.4 0.0 0.0 0.0 0.0 1.9 1.6 1.0 0.3 2.8 0.0 1.5 1.7 0.0 0.8 0.6 0.8 0.7 1.5 0.0 0.8 1.6 0.0 1.6 0.3 0.0 0.3 1.1 0.6 1.0 0.4 0.0 0.6 0.0 2.6 * * * *

7.1 14.2 17.2 8.0 18.1 9.6 9.3 6.2 9.8 13.2 7.3 0.0 1.3 0.3 1.0 2.3 0.0 0.0 2.9 1.5 0.0 1.3 2.8 2.5 3.0 0.0 0.8 1.0 1.8 0.6 0.8 1.0 1.5 1.4 0.0 7.1 7.7 2.8 1.2 0.6 0.8 0.0 0.0 4.3 0.0 0.5 0.5 1.4 0.3 0.0 0.3 3.4 4.0 0.0 5.2 7.6 4.9 2.5 3.2 2.1 1.4 0.8 1.8 5.2 2.0 3.6 1.8 1.5 1.7 1.3 0.9 1.2 0.7 3.5 0.0

25.7

9.8 13.4 16.7 6.3 15.8 16.3 10.6 3.9 10.3 16.4 16.7 0.0 2.6 0.0 2.0 2.9 0.0 0.0 1.7 3.4 0.0 3.2 5.0 6.9 4.3 0.0 0.4 1.7 1.8 1.4 0.7 1.9 2.9 2.9 0.0 10.0 0.0 0.0 3.3 1.7 1.4 6.7 0.0 0.0 0.0 0.0 1.9 2.0 1.0 2.8 0.8 3.1 3.4 0.0 5.6 1.8 6.2 2.6 2.5 2.3 2.3 3.2 0.0 0.0 2.5 3.0 2.4 2.0 5.0 1.5 0.4 0.0 0.6 0.0 0.0

39.0

103.4 55.3 59.7 86.1 65.1 91.4 83.9 106.9 74.5 88.4 112.9 110.0 111.9 136.3 106.3 127.4 80.0 119.5 111.2 100.0 112.8 84.8 87.7 84.0 80.2 99.2 94.4 83.0 86.8 82.7 98.1 87.2 83.6 73.6 90.8 93.9 92.5 89.3 76.9 121.7 94.1 77.8 100.5 86.4 87.5 101.9 86.6 89.9 96.0 69.2 86.8 90.1 86.8 91.6 91.9 92.0 91.1 95.5 88.6 93.8 84.2 86.5 84.8 93.8 91.3 92.9 86.6 89.6 85.6 87.7 98.1

100.0 48.4 52.6 69.8 54.8 74.5 76.9 100.0 62.5 80.9 101.3 118.7 94.2 105.9 116.3 150.0 1.0 96.6 99.9 133.3 91.9 90.8 101.4 87.2 95.8 92.6 89.0 73.2 97.2 70.0 92.1 91.6 117.6 73.7 92.7 88.8 88.9 100.0 75.0 33.3 100.0 59.3 96.9 85.9 74.0 75.0 73.6 96.9 94.8 100.0 80.6 72.5 82.2 92.6 92.4 94.4 92.2 88.7 100.0 90.3 85.0 88.1 85.4 90.0 91.1 85.9 95.3 103.7 91.2 105.3 92.1

806

*Important. See note on population page.

748

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Oesophagus (C15) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 312 1495 2086 280 1791 814 217 591 1088 130 955 173 41538 5264 35284 1646 259 1355 278 11 61 201 3517 556 2861 2412 252 2089 611 703 2875 287 2534 239 4513 503 3715 11756 496 1380 721 9070 898 377 516 2800 352 2410 202 124 1114 748 415 1278 23 514 2030 254 230 2291 532 25 808 1070 69 1369 333 380 91 358 332 15 252 246 503 1656 773 4084 892 97.1 96.1 96.0 94.6 96.1 97.3 94.9 98.1 93.7 91.5 93.9 93.6 94.7 93.5 94.9 95.6 96.1 95.6 92.4 72.7 93.4 93.5 93.3 93.2 93.3 93.9 90.1 94.3 90.0 95.3 97.7 96.9 97.9 95.4 96.8 95.8 96.9 96.3 97.4 96.2 96.7 96.2 95.2 94.2 95.9 92.2 90.1 92.8 98.0 91.9 96.0 96.5 95.9 91.8 82.6 71.0 95.4 77.2 78.7 63.4 95.5 96.0 74.9 75.1 81.2 65.8 93.7 76.3 83.5 89.1 91.6 93.3 82.1 89.4 95.4 85.2 90.3 76.3 87.1 1.3 1.5 1.1 0.4 1.2 1.2 2.3 0.8 1.8 2.3 1.8 4.6 2.3 3.1 2.2 1.4 0.8 1.5 2.9 9.1 1.6 3.0 2.8 3.4 2.8 3.3 6.0 3.1 2.5 2.4 0.6 0.7 0.6 0.8 1.0 1.4 1.0 1.1 1.4 1.1 1.0 1.0 1.2 1.1 1.4 4.3 6.0 4.0 0.0 3.2 0.9 0.3 1.2 3.4 8.7 0.2 0.8 1.2 3.0 0.6 0.0 2.1 2.4 2.9 13.3 0.0 7.1 2.2 2.8 1.8 0.0 15.5 3.7 1.4 8.4 4.8 12.0 8.4 0.6 1.1 1.5 3.2 1.3 0.4 0.5 0.3 4.0 3.8 4.0 0.6 1.4 1.3 1.4 1.0 0.8 1.0 1.1 9.1 1.6 0.5 1.5 0.9 1.6 2.0 1.2 2.1 1.3 0.6 0.6 1.0 0.4 0.8 0.7 0.8 0.7 1.0 0.4 0.7 0.7 1.1 1.9 2.4 1.6 2.3 2.6 2.0 0.0 0.0 1.4 1.6 1.7 3.6 0.0 0.0 0.0 0.0 1.7 0.0 0.0 4.0 1.6 0.0 0.0 0.2 0.0 0.0 0.0 1.7 1.2 0.0 2.4 1.2 0.0 0.0 0.1 0.0 0.6 95.5 89.8 89.5 78.9 91.5 90.9 72.8 98.1 84.5 76.9 85.5 107.5 89.8 87.3 91.1 89.2 79.9 91.7 87.4 109.1 95.1 84.6 87.7 84.2 89.4 93.3 88.5 96.8 92.8 96.0 92.5 93.0 93.9 82.0 90.6 85.7 91.7 92.3 83.7 84.6 78.9 95.2 87.4 90.5 85.7 90.5 90.6 91.1 92.6 87.1 91.9 94.3 85.8 84.8 73.9 86.0 74.6 76.1 70.4 30.0 46.7 14.5 51.7 76.8 69.0 56.9 56.9 57.7 66.0 76.7 68.5 Female Cases MV(%) DCO(%) UB(%) MI(%) 93 91.4 501 93.8 600 91.8 110 96.4 487 90.8 264 93.9 90 96.7 174 92.5 312 89.4 54 90.7 255 89.4 46 89.1 13450 92.8 2101 94.7 10997 92.4 613 96.4 100 96.0 499 96.6 51 90.2 1 100.0 9 100.0 39 87.2 1382 91.7 309 94.2 1043 90.8 771 92.0 110 90.0 631 91.9 150 84.7 224 91.5 870 95.1 134 97.8 723 94.9 82 96.3 1470 93.6 229 96.5 1158 92.8 3998 94.4 169 95.3 544 96.7 202 95.0 3061 93.9 244 93.4 97 89.7 145 95.9 854 87.5 133 91.7 704 86.6 45 95.6 46 89.1 338 90.5 230 90.0 117 94.9 352 91.5 10 100.0 120 70.8 455 94.1 70 84.3 43 72.1 965 55.8 60 95.0 7 100.0 479 78.9 598 77.1 19 89.5 905 68.5 214 93.0 295 71.5 28 92.9 228 85.5 221 85.5 7 85.7 37 64.9 61 82.0 106 92.5 327 79.5 123 85.4 823 71.1 150 76.0 2.2 2.6 1.3 0.0 1.6 2.7 1.1 3.4 4.2 3.7 4.3 8.7 2.9 2.2 3.1 1.5 2.0 1.4 0.0 0.0 0.0 0.0 2.2 1.6 2.4 4.0 4.5 4.1 4.0 4.5 1.0 0.0 1.2 2.4 2.3 1.7 2.3 1.7 2.4 1.5 0.5 1.8 2.5 3.1 2.1 7.3 3.8 8.1 4.4 8.7 1.5 0.9 1.7 3.1 0.0 0.0 1.1 2.9 4.7 0.8 0.0 2.1 1.2 0.0 15.4 0.0 13.6 0.0 4.8 5.0 0.0 27.0 9.8 1.9 12.8 7.3 16.8 14.0 1.1 1.8 2.7 2.7 2.7 1.1 1.1 1.1 3.5 5.6 3.1 0.0 1.7 1.5 1.7 0.7 1.0 0.6 3.9 0.0 0.0 5.1 2.4 1.0 2.9 3.0 4.5 2.9 2.0 1.3 1.4 0.7 1.1 0.0 0.8 1.3 0.8 1.0 0.6 0.9 1.0 1.0 2.0 3.1 1.4 2.8 1.5 2.8 0.0 0.0 1.5 1.3 0.0 2.3 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 2.7 0.0 8.1 0.0 0.0 0.0 1.6 0.0 2.7 100.0 81.4 83.8 79.1 85.0 83.0 67.8 89.7 83.7 75.9 86.3 102.2 87.0 86.2 88.2 81.4 83.0 81.2 107.8 200.0 144.4 97.4 82.9 75.4 86.0 88.7 94.5 91.8 90.0 92.0 94.8 85.8 97.8 96.3 85.9 82.1 87.0 87.2 74.0 87.9 67.3 89.1 88.1 91.8 84.8 90.3 100.0 88.8 62.2 93.5 92.6 91.3 80.3 84.7 100.0 75.8 * 71.4 * 65.1 72.0 * * 71.4 * 42.0 * 15.8 48.4 * * * 85.0 70.3 55.7 53.8 56.6 68.3 72.9 62.7

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
749

807

Indices of data quality

Oesophagus (C15) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
750

Female Cases MV(%) DCO(%) UB(%) MI(%) 662 66.0 75 64.0 49 79.6 16 75.0 29 79.3 41 65.9 7 57.1 154 72.1 12 66.7 16 87.5 3 33.3 39 92.3 55 89.1 41 85.4 166 84.9 61 59.0 110 93.6 94 92.6 11 100.0 5 100.0 31 64.5 16 43.8 49 85.7 18 94.4 95 93.7 340 27 11 209 108 373 205 213 319 518 48 399 38 78 18 53 58 51 93 43 42 20 33 144 271 172 117 147 206 85 16 597 19 40 20 54 37 5 81 27 13 198 37 4 19 35 16 12 6 14 54 29 27 144 81.2 81.5 100.0 74.2 100.0 92.0 26.8 59.2 75.5 90.3 85.4 92.5 94.7 91.0 100.0 98.1 96.6 94.1 100.0 100.0 92.9 90.0 97.0 69.4 67.2 65.7 76.1 84.4 83.5 95.3 100.0 84.9 89.5 72.5 85.0 70.4 67.6 60.0 82.7 81.5 76.9 89.9 81.1 75.0 84.2 85.7 43.8 91.7 83.3 78.6 90.7 69.0 74.1 81.3 16.2 16.0 8.2 12.5 6.9 14.6 0.0 14.9 16.7 12.5 66.7 2.6 5.5 4.9 0.0 13.1 0.0 0.0 0.0 0.0 0.0 18.8 4.1 0.0 0.0 16.5 14.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.0 1.5 30.0 0.9 2.9 0.0 1.5 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 2.4 0.0 0.0 2.8 0.0 0.0 0.9 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.2 0.0 0.0 85.6 81.3 65.3 100.0 65.5 92.7 42.9 61.7 83.3 64.1 18.2

6856 85.2 620 82.4 397 90.9 142 87.3 253 85.4 280 84.3 51 78.4 1334 84.9 83 81.9 20 65.0 14 71.4 45 93.3 72 86.1 41 92.7 174 95.4 195 69.2 390 96.7 352 96.6 25 96.0 13 100.0 84 90.5 34 73.5 204 88.7 47 85.1 182 91.2 1297 88.6 97 94.8 58 86.2 1742 84.7 362 98.1 1274 95.1 702 34.8 943 67.8 1780 83.9 1329 92.0 224 90.6 700 94.6 370 98.6 327 93.9 161 99.4 253 99.6 211 99.5 261 97.7 503 99.6 268 99.6 271 96.3 97 95.9 237 98.7 679 75.8 1036 82.2 456 69.3 513 84.4 553 90.4 680 82.5 302 97.0 49 100.0 941 91.0 42 95.2 170 86.5 71 87.3 134 76.9 92 82.6 12 91.7 181 87.3 62 93.5 36 83.3 748 95.1 87 95.4 13 69.2 53 88.7 94 88.3 63 71.4 79 83.5 19 84.2 49 85.7 133 85.7 95 80.0 100 97.0 452 90.0

5.7 4.8 4.0 4.9 3.6 3.9 2.0 6.7 2.4 35.0 21.4 4.4 8.3 0.0 0.0 6.7 0.0 0.0 0.0 0.0 0.0 5.9 2.0 2.1 0.0 10.2 3.1 6.9

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 1.1 0.1 0.0 1.7 0.0 0.0 3.8 0.0 22.6 0.7 3.5 0.0 1.3 0.0 0.3 0.0 0.0 0.0 0.4 0.2 0.0 1.1 1.0 0.4 1.9 0.3 0.0 0.8 0.0 1.9 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.3 0.0 0.0

78.0 82.4 66.8 85.2 60.1 77.5 73.5 61.5 88.0 88.9 62.5

90.8 1.2 94.1 62.3 61.7 48.9 90.6 83.5 63.8 92.4 77.5 107.1 93.0 93.9 109.6 92.4 84.3 79.7 78.0 82.0 84.6 97.6 79.7 78.9 77.6 85.6 86.6 95.8 170.4 61.1 75.4 55.8 75.8 84.9 78.8 85.7 102.3 92.9 84.7 83.1 106.0 90.2 108.3 97.2 80.6 67.1 89.0 93.1 107.7 98.1 108.5 71.4 69.6 100.0 79.1 88.7 118.9 88.0 93.6

90.9

* * *

* 81.3 * 224.5 38.9 * 46.3 * 91.2 92.6 81.8 100.5 * * 76.1 115.1 * 85.0 101.3 106.0 70.8 90.0 84.2 75.6 72.2 81.1 105.2 74.5 88.2 72.1 85.7 80.0 103.0 204.9 73.1 82.0 61.5 87.8 86.9 94.1 106.3 95.1 100.0 100.0 65.0 118.5 116.2 120.0 92.6 88.9 57.7 88.4 51.4 100.0 94.7 91.4 137.5 108.3 66.7 80.4 88.9 110.3 77.8 78.5

29.9 9.7 5.4 0.5 0.0 1.4

36.1 10.8 8.2 1.7 0.0 1.3

0.0 21.8 15.5 10.1 14.2 4.5 12.1 2.3 0.0 2.3 0.0 0.6 0.0 3.0 0.0 0.0 2.2 0.0 11.1 0.4 0.0 0.0 0.0 3.2 4.8 2.5 0.0 0.0 0.8 3.2 0.0 0.9

0.0 27.1 28.8 9.9 22.2 8.8 12.1 4.7 0.0 2.2 0.0 10.0 5.0 1.9 8.1 20.0 3.7 0.0 15.4 2.0 0.0 0.0 0.0 8.6 18.8 0.0 0.0 0.0 0.0 3.4 3.7 2.8

808

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Oesophagus (C15) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 435 707 39 600 115 166 210 740 578 1077 549 1253 371 43 311 576 355 36 143 103 148 101 109 156 1345 125 57 44 96 87 76 221 4306 237 204 995 1046 1708 2367 861 2824 4622 2032 1918 455 2391 78.2 81.3 79.5 96.3 56.5 77.1 84.3 96.9 82.9 74.9 76.3 81.6 95.7 83.7 92.0 94.3 93.5 83.3 95.8 90.3 94.6 97.0 92.7 90.4 99.3 96.0 98.2 97.7 96.9 97.7 97.4 97.3 98.4 98.3 97.5 90.7 83.8 88.9 90.7 93.7 82.2 83.5 88.7 92.1 89.7 93.7 5.1 2.0 7.7 0.7 10.4 5.4 1.0 12.1 10.0 12.5 1.6 2.3 3.9 1.9 2.3 8.3 2.8 1.9 0.7 1.0 1.8 6.4 0.0 0.0 2.3 1.0 1.1 0.0 2.3 0.2 0.0 0.0 0.0 0.0 3.0 0.0 0.1 0.0 7.2 0.0 0.8 2.7 0.0 0.6 0.2 0.3 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.1 1.2 0.0 3.3 2.9 3.6 0.9 0.0 0.0 1.0 0.0 0.0 0.0 0.6 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 94.3 92.5 107.7 88.7 100.0 100.2 110.5 90.9 90.8 106.0 89.6 98.9 100.5 104.7 99.1 87.5 93.0 72.2 81.8 100.0 90.5 93.1 71.6 96.8 91.7 63.2 80.7 75.0 72.9 82.8 85.5 79.6 94.4 94.1 106.1 101.1 105.3 102.0 99.4 107.0 91.0 88.1 105.5 106.6 95.1 95.7 75.9 98.5 91.2 90.7 104.1 74.8 108.9 66.7 86.2 88.9 Female Cases MV(%) DCO(%) UB(%) MI(%) 76 53.9 103 70.9 11 81.8 252 95.6 30 43.3 42 73.8 63 73.0 203 97.0 106 69.8 446 61.0 165 81.8 128 74.2 93 91.4 5 100.0 40 80.0 75 88.0 55 78.2 4 75.0 25 84.0 20 70.0 24 91.7 20 70.0 12 58.3 20 75.0 596 99.2 55 96.4 13 92.3 15 100.0 17 100.0 27 77.8 20 90.0 69 98.6 1796 98.1 85 98.8 61 98.4 602 87.0 692 82.1 992 83.6 1525 87.7 483 87.2 1791 76.7 2878 77.8 1176 85.5 1347 88.3 304 87.5 1524 91.3 664 10 293 161 59 484 158 25 4 370 43 0 7 9 9 17 91.0 100.0 90.8 94.4 89.8 86.6 93.7 80.0 100.0 86.8 93.0 0.0 100.0 100.0 88.9 88.2 7.9 2.9 0.0 0.4 6.7 2.4 0.0 21.7 10.3 17.2 4.3 0.0 10.0 8.0 14.5 0.0 8.0 20.0 0.0 25.0 33.3 5.0 1.8 0.0 0.0 0.0 3.7 0.0 1.4 0.0 0.0 0.0 0.0 0.0 7.1 0.0 0.0 0.0 9.0 0.0 1.6 4.3 0.0 2.5 0.0 0.0 0.0 0.0 0.0 4.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.4 1.5 0.1 8.5 5.1 4.1 1.0 0.0 0.0 0.8 0.0 0.0 0.0 0.6 0.0 2.5 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 103.9 93.2 100.0 84.1 116.7 * 77.4 123.8 114.8 * 95.3 114.3 86.7 110.9 97.8 120.0 66.7 84.0 88.6 75.0 88.0 135.0 116.7 90.0 100.0 80.0 93.5 85.5 92.3 93.3 105.9 66.7 110.0 73.9 95.8 80.3 95.0 101.3 96.2 95.2 101.0 98.2 86.3 91.6 90.3 98.0 95.4 81.6 60.0 81.6 82.6 66.4 96.7 81.0 60.0 50.0 86.5 72.1

0.4 4.0 1.7 1.5 0.9 1.1 6.4 3.9 1.7 0.9 0.5 1.2 3.4 0.4 0.0 0.7 1.6 1.5 0.0 2.6 3.3 0.5 0.0 0.0 3.0 0.0 0.0

0.3 3.9 2.1 1.4 1.0 2.5 9.5 4.1 3.6 1.3 0.4 0.6 0.0 2.0 0.0 0.0 2.3 2.5 0.0 0.0 5.4 2.3 0.0 0.0 0.0 11.1 0.0

1123 93.6 29 93.1 682 93.7 308 96.4 135 94.1 856 91.4 326 95.7 45 77.8 39 97.4 694 91.4 190 98.4 18 100.0 12 100.0 33 97.0 68 98.5 45 97.8

91.1

76.5

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
751

809

Indices of data quality

Stomach (C16)
Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 147 147 51 59 129 120 575 119 259 5895 381 935 2444 599 236 222 87.1 85.0 98.0 42.4 58.9 75.0 90.6 75.6 93.1 79.5 77.2 76.7 74.2 76.1 99.2 91.9 0.0 0.0 0.0 0.0 0.0 0.0 4.5 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 4.7 0.0 0.5 0.0 0.0 0.0 0.0 0.3 9.2 0.0 0.0 2.5 1.6 3.0 0.9 1.6 0.5 0.2 0.7 0.6 0.5 0.2 0.7 0.0 0.0 0.0 0.0 0.0 0.3 0.4 0.0 0.0 0.0 0.0 0.7 0.2 1.9 0.7 0.0 0.8 2.6 0.9 6.7 0.4 0.5 0.3 0.3 0.8 0.0 0.3 0.6 0.0 0.0 0.4 0.8 0.3 0.5 0.7 1.4 0.7 0.5 0.8 0.0 0.0 Female Cases MV(%) DCO(%) UB(%) MI(%) 71 95.8 111 75.7 25 100.0 64 45.3 102 58.8 83 343 70 167 3600 182 736 1438 484 157 187 3736 431 650 200 131 110 5 172 1832 18 187 640 197 435 64 525 5064 970 439 1241 2379 1071 105 142 39 61 165 467 1748 217 105 27 70 137 557 591 427 647 49 592 149 117 23 2685 429 2205 954 386 541 297 136 144 131 1904 377 1430 631 329 460 719 331 378 84 92 73.5 91.5 68.6 94.6 77.9 63.7 71.5 69.7 70.9 99.4 88.2 87.1 95.1 88.5 90.5 93.1 100.0 100.0 87.8 82.6 83.3 91.4 90.9 88.8 91.7 98.4 93.7 96.1 98.7 95.4 97.3 94.5 95.5 95.2 97.9 100.0 96.7 95.8 93.6 97.3 95.9 100.0 100.0 97.1 98.5 97.8 96.3 93.4 94.4 95.9 94.3 91.3 93.2 87.0 93.3 93.9 93.1 92.9 93.5 92.1 94.9 95.6 93.8 91.6 94.1 92.0 94.4 96.4 92.4 94.3 94.4 93.1 95.5 95.2 96.7 0.0 0.0 0.0 0.0 0.0 2.4 3.8 2.9 0.0 0.0 0.0 0.1 0.0 0.0 0.6 0.0 7.2 0.0 0.0 0.0 0.0 0.0 0.0 1.7 14.5 0.0 0.0 3.0 4.1 2.5 0.0 2.5 0.8 0.4 1.6 0.7 0.9 0.7 1.9 0.7 0.0 0.0 1.2 0.4 0.7 1.4 0.0 0.0 1.4 0.7 0.5 0.8 0.9 0.8 0.0 0.8 0.7 0.0 0.0 0.3 0.2 0.3 0.4 0.5 0.4 0.7 0.7 0.7 0.0 0.4 0.5 0.3 0.8 1.2 1.3 0.6 0.9 0.3 0.0 0.0 * * * *

13.6 10.1 23.3 4.0 19.3 5.0 8.4 16.0 10.1 11.7 17.0 4.1 1.3 0.4 1.4 2.5 0.0 0.0 1.4 1.3 0.0 3.6 2.1 1.6 2.3 0.9 1.8 0.5 0.6 1.0 0.4 0.4 0.7 2.0 0.0 0.0 0.0 0.5 0.8 0.5 0.8 0.8 0.0 0.9 1.7 0.6 0.1 1.3 1.1 1.0 1.1 5.2 5.2 6.7 3.7 4.2 3.6 2.8 3.4 2.7 1.3 1.8 1.1 4.0 1.5 3.6 1.0 1.5 0.7 1.1 1.0 1.7 0.5 0.0 0.0

39.5

21.6 12.7 22.9 4.1 24.3 3.0 9.6 28.0 15.4 15.9 21.1 5.3 2.5 0.5 3.8 4.0 0.0 0.0 4.7 2.4 5.6 3.2 4.5 4.6 4.6 0.0 2.7 0.9 0.3 0.2 0.5 1.6 1.5 1.0 0.0 0.0 0.0 1.8 2.4 0.6 0.0 0.0 0.0 0.0 0.7 0.4 1.4 2.1 2.6 2.0 2.7 6.0 5.1 8.7 5.0 4.7 5.1 4.1 4.1 4.3 3.4 2.2 4.9 3.1 3.7 6.6 3.1 1.4 1.8 1.7 0.7 0.9 0.5 2.4 0.0

45.9

112.5 41.6 63.9 61.8 55.1 92.1 75.8 75.4 65.9 75.7 63.1 59.5 63.0 59.8 63.6 84.4 62.5 59.1 62.6 66.7 65.4 61.2 63.1 60.9 62.1 62.8 59.8 60.0 70.9 61.7 58.0 57.2 74.5 58.1 55.9 63.0 74.3 79.3 60.0 61.7 66.7 61.5 60.1 57.6 56.1 61.5 56.3 78.6 85.3 70.0 58.4 70.4 56.8 63.4 70.9 59.6 63.1 67.5 61.5 49.2 59.7 68.9 59.2 55.9 55.7 57.8 66.2 77.3 57.6 76.1 49.3

97.6 38.8 54.3 48.5 50.3 90.1 73.6 75.9 78.1 66.9 71.0 70.5 66.8 66.5 75.6 112.7 80.0 73.3 69.7 50.0 75.9 70.2 87.8 63.0 64.1 68.8 63.4 61.8 65.1 60.0 66.1 64.1 70.5 64.8 64.0 61.0 66.8 56.2 37.0 70.0 49.6 59.6 64.5 63.2 65.2 71.4 64.4 71.8 78.6 60.9 62.7 67.6 62.3 64.5 67.1 63.0 61.6 66.2 57.6 55.0 65.3 70.6 64.8 68.9 62.6 68.9 63.7 72.5 56.1 86.9 56.5

6653 92.3 702 97.0 1144 94.4 363 92.8 247 96.4 257 99.2 8 100.0 296 92.9 3300 89.3 30 93.3 306 94.4 896 94.3 320 94.7 563 94.1 116 95.7 955 95.5 7725 97.9 1312 97.7 595 96.6 1638 98.2 4112 98.0 1610 98.0 153 96.1 204 97.1 38 100.0 57 96.5 222 99.1 785 98.5 2393 98.2 261 96.6 121 95.9 45 100.0 107 99.1 177 97.2 672 98.1 940 98.8 634 95.6 1033 97.5 96 97.9 916 97.4 154 91.6 116 93.1 30 86.7 4540 94.8 624 93.8 3851 94.9 1314 95.8 477 94.5 792 96.5 377 96.8 163 96.3 179 97.2 199 94.5 2842 97.1 498 94.4 2194 97.8 1052 97.3 573 97.6 792 96.7 1016 96.7 410 95.4 592 97.5 117 99.1 136 99.3

810

*Important. See note on population page.

752

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Stomach (C16) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 334 1654 2091 373 1681 1072 283 768 1056 148 881 203 50995 6864 40907 2581 343 2090 397 41 180 168 5747 796 4514 2267 326 1866 603 686 3454 365 2987 320 6215 738 4457 17304 2093 2025 2196 10779 895 365 517 3861 556 3189 265 119 1194 855 379 1213 47 917 3291 431 585 8367 302 164 1119 704 51 961 158 265 122 2025 1907 101 1967 2673 3377 7073 4446 19306 5290 96.7 97.1 96.7 97.1 96.6 97.9 97.9 97.9 94.7 94.6 94.6 94.1 96.1 94.8 96.3 97.3 98.3 97.2 94.5 90.2 96.7 92.9 95.0 92.7 95.5 94.9 93.3 95.2 93.2 96.1 97.9 97.0 98.0 95.9 97.4 97.2 97.5 97.5 97.7 96.9 98.0 97.5 95.2 95.1 95.4 93.0 90.8 93.5 97.7 95.8 97.2 97.8 96.8 94.4 91.5 82.0 95.7 90.7 81.7 72.6 92.1 98.8 64.5 77.0 52.9 69.9 91.8 80.0 73.8 93.2 93.7 97.0 84.6 93.5 98.1 84.8 94.4 77.4 90.0 0.3 1.0 0.8 0.3 0.9 1.3 1.1 1.3 2.6 3.4 2.5 3.0 1.8 2.5 1.7 1.0 0.3 1.1 3.5 7.3 1.7 4.8 1.9 3.0 1.7 1.8 2.5 1.7 1.8 1.2 0.5 0.0 0.6 2.5 1.0 1.4 1.1 0.8 0.5 1.0 0.5 0.8 1.2 1.1 1.2 4.2 5.9 3.9 0.0 3.4 0.8 0.4 1.3 2.1 2.1 0.0 0.6 0.5 1.5 0.4 0.0 3.9 3.4 5.9 9.8 0.6 6.8 7.4 1.9 1.6 1.0 13.3 3.1 0.7 11.0 2.6 10.5 6.3 0.9 1.0 1.3 1.9 1.2 0.1 0.0 0.1 2.1 0.0 2.5 0.0 1.0 1.1 0.9 0.9 0.6 0.9 0.8 0.0 1.1 0.6 1.6 1.6 1.5 2.4 3.1 2.3 0.5 0.4 0.4 1.1 0.4 0.6 0.3 0.3 0.4 0.6 0.2 0.5 0.8 0.6 2.6 2.5 2.7 1.2 0.9 1.3 0.0 0.0 0.4 0.4 0.8 2.3 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.6 9.5 0.0 0.0 0.1 0.0 0.0 0.0 0.9 0.8 0.0 2.1 0.6 0.0 0.0 0.2 0.0 0.6 57.8 61.0 56.0 57.9 55.8 51.0 54.4 50.0 61.0 75.0 59.6 52.2 58.2 68.9 57.1 54.9 64.7 54.7 62.2 70.7 66.7 56.0 52.2 64.3 50.7 62.5 69.9 62.8 60.4 55.8 55.2 64.7 55.0 61.9 55.6 63.6 54.7 58.3 57.5 67.9 59.1 56.7 64.6 72.6 60.3 62.5 75.2 60.8 56.6 49.6 53.3 51.7 64.4 50.9 78.7 71.4 62.2 72.3 62.0 24.4 53.6 13.7 42.9 69.0 51.4 39.7 34.0 40.7 41.9 58.7 44.1 Female Cases MV(%) DCO(%) UB(%) MI(%) 181 1087 1359 313 1017 751 254 490 615 102 493 115 32695 5303 25097 1653 254 1295 248 36 130 74 4025 763 2988 1469 253 1164 364 353 2193 297 1845 242 4040 580 2718 11269 1532 1564 1623 6413 544 230 307 2519 423 2009 175 65 688 489 227 650 31 487 1926 156 295 4839 149 110 544 327 24 477 76 149 31 1371 1279 60 945 1492 1637 3249 2317 9372 2799 90.1 92.7 94.3 92.7 94.7 95.1 93.3 95.9 94.1 93.1 94.1 88.7 93.8 93.2 93.7 95.7 95.7 95.8 90.7 94.4 90.0 90.5 92.7 92.7 92.5 92.5 90.9 92.6 87.6 94.9 96.0 94.6 96.3 92.6 94.7 94.5 93.9 95.4 98.3 94.5 96.5 94.6 93.4 93.5 93.2 90.7 88.9 91.0 93.1 95.4 95.2 94.5 93.0 88.3 87.1 80.3 94.1 81.4 83.1 68.8 89.3 99.1 61.8 70.6 62.5 68.6 84.2 65.8 64.5 90.7 92.3 91.7 78.0 90.3 96.2 81.1 89.8 73.1 86.1 3.9 2.6 1.0 1.3 1.0 1.9 2.8 1.4 1.6 2.9 1.4 7.8 2.7 3.0 2.8 1.8 0.4 2.2 4.0 2.8 4.6 2.7 2.5 1.4 2.8 3.9 5.5 3.8 1.9 1.7 0.8 0.7 0.9 2.1 1.8 2.2 2.1 1.4 0.3 1.2 1.2 1.7 2.6 2.6 2.6 6.2 7.6 6.1 1.1 1.5 1.2 0.6 1.8 4.5 3.2 0.0 1.0 0.6 0.3 0.5 0.0 5.5 2.1 8.3 12.8 0.0 14.1 12.9 3.4 2.5 3.3 19.0 3.7 2.3 14.7 5.4 14.0 9.4 2.8 2.4 2.6 3.2 2.6 0.7 0.4 0.8 3.3 2.9 3.4 0.9 1.3 1.7 1.3 0.7 1.6 0.5 1.6 2.8 1.5 1.4 1.7 2.4 1.5 2.3 2.0 2.5 1.1 0.8 1.0 2.4 0.7 0.0 0.9 0.7 1.1 0.8 0.4 1.0 0.7 0.9 2.4 2.6 2.3 1.5 2.1 1.3 0.6 0.0 1.2 1.6 0.9 4.8 0.0 0.2 0.0 0.0 1.4 0.0 0.0 0.9 10.7 0.0 0.0 0.4 0.0 0.0 0.0 0.9 0.9 1.7 3.0 0.9 0.0 0.0 0.3 0.0 0.7 69.6 70.1 63.2 60.7 64.4 61.8 57.5 63.5 64.2 77.5 62.1 60.0 64.4 67.8 64.8 63.0 60.6 64.9 70.2 72.2 72.3 68.9 58.4 56.1 60.2 66.2 69.6 67.8 65.4 68.8 62.1 64.0 62.8 67.4 63.8 62.1 64.7 63.6 60.9 64.5 58.9 65.6 71.3 79.1 66.4 70.5 77.5 69.8 70.9 70.8 64.4 60.3 70.5 64.2 48.4 89.1 * 65.6 * 58.6 62.4 * * 22.7 * 53.1 * 25.0 44.9 * * * 69.4 57.6 47.4 39.0 46.7 49.2 62.0 49.6

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
753

811

Indices of data quality

Stomach (C16) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
754

Female Cases MV(%) DCO(%) UB(%) MI(%) 29856 2617 2009 1019 989 1474 228 7165 490 30 42 181 220 99 83 427 958 884 33 41 195 81 36 162 443 84.4 85.5 89.1 88.5 84.9 86.7 82.9 87.1 87.3 63.3 61.9 82.9 87.3 88.9 97.6 63.7 93.4 93.7 90.9 90.2 90.8 75.3 94.4 85.8 90.3 8.0 5.5 6.0 4.8 5.7 3.4 1.3 7.4 4.1 26.7 33.3 10.5 7.7 1.0 0.0 13.3 0.0 0.0 0.0 0.0 0.0 12.3 0.0 1.2 0.0 12.1 3.3 13.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 2.0 0.1 0.0 0.8 0.0 0.0 7.4 0.3 18.9 0.5 3.3 0.0 0.6 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.3 0.0 1.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 9.4 0.0 0.0 55.3 58.7 49.2 48.4 47.8 55.3 61.2 45.0 50.4 22.1 18.2

57198 5009 3645 1924 1701 3039 413 13090 944 31 44 225 420 219 156 497 1439 1316 60 63 227 120 73 310 881

88.8 88.8 92.6 90.0 90.2 90.8 91.0 89.1 90.1 74.2 84.1 90.7 86.4 91.8 96.2 64.4 96.5 96.8 96.7 88.9 89.4 68.3 97.3 88.7 90.8

5.0 3.3 3.5 3.0 2.4 2.4 2.4 5.7 2.5 25.8 13.6 5.3 7.1 0.5 0.0 9.3 0.0 0.0 0.0 0.0 0.0 15.0 1.4 0.6 0.0 10.6 1.7 4.1

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.2 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 1.5 0.0 0.0 0.7 0.0 0.0 5.5 0.2 16.1 0.4 2.9 0.0 0.4 0.0 0.4 0.0 0.3 0.0 0.2 0.0 0.0 0.5 0.7 0.4 1.6 0.1 0.0 0.6 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 2.1 0.0 0.0 6.2 0.0 0.0

52.2 53.5 44.0 47.6 45.3 52.0 43.6 43.7 44.2 42.2 40.5

68.9 1.3 93.3 75.3 42.9 64.0 76.3 61.7 68.3 83.7 76.1 85.7 81.3 83.0 72.9 83.5 73.2 66.1 81.2 72.7 67.3 77.1 71.9 73.2 72.2 76.5 61.6 78.1 160.8 59.8 75.4 58.1 61.8 66.3 63.6 73.3 71.5 73.5 64.8 77.9 74.7 70.2 71.1 70.7 66.7 73.0 67.0 72.3 83.0 67.5 69.4 74.2 79.4 68.1 54.8 63.6 67.3 65.2 61.1

73.4

* * *

1.0 * 93.8 * 125.0 42.6 * 72.0 * 79.7 72.1 65.3 76.9 * * 81.3 89.1 * 77.9 86.1 85.9 83.6 75.1 70.5 85.6 79.4 85.5 71.5 62.9 70.7 77.1 74.1 73.5 106.5 171.8 62.9 81.9 58.2 68.3 79.5 72.4 61.4 78.2 67.0 60.8 74.9 76.9 73.0 71.9 74.1 75.1 67.8 68.1 73.5 93.0 74.0 65.5 72.5 71.9 73.7 67.7 73.8 70.5 65.2 65.1

4213 88.9 420 97.4 145 91.7 10596 87.1 574 98.8 1940 93.8 5898 46.7 3697 74.1 5209 86.1 1574 92.6 1233 92.8 2106 96.5 380 98.7 245 96.7 183 98.9 312 99.7 293 99.3 405 97.5 370 99.5 316 100.0 187 97.3 151 97.4 270 99.3 1662 70.1 3261 79.1 844 68.8 1339 74.6 1282 86.3 1600 84.8 657 93.9 116 99.1 1426 91.4 151 94.0 667 92.4 330 90.0 1488 87.4 457 88.2 311 90.4 750 85.7 654 94.5 218 87.6 2052 95.3 571 89.1 153 90.2 538 93.7 1550 93.9 383 81.2 180 92.2 141 83.7 196 94.9 624 94.7 1135 89.7 489 96.5 1176 93.9

26.0 9.8 5.1 0.4 0.6 1.0

0.0 27.7 19.3 12.8 24.3 8.3 10.6 4.3 0.0 2.7 2.6 1.9 0.6 0.9 1.5 1.9 2.0 0.6 1.4 0.8 1.4 2.0 0.6 1.8 3.9 3.9 4.3 0.0 1.3 0.4 0.0 0.4

3733 87.1 366 92.6 124 81.5 7638 84.3 369 99.2 1323 90.8 3682 41.3 2395 69.7 3873 82.4 933 90.6 999 90.2 1741 95.0 210 98.1 160 92.5 97 100.0 172 94.8 172 99.4 259 97.7 215 98.6 205 99.5 108 98.1 68 98.5 107 98.1 1346 63.0 2842 73.0 697 62.6 1011 69.0 1175 83.5 1241 81.5 521 91.6 70 100.0 910 85.6 112 90.2 497 90.1 223 87.9 1099 80.6 356 82.6 196 84.2 698 77.8 430 89.5 145 82.1 1529 92.3 400 85.3 86 81.4 338 85.5 1202 88.0 273 79.9 121 90.9 76 77.6 120 85.8 431 91.4 823 83.7 368 88.6 873 89.1

31.6 11.4 6.6 0.8 0.7 1.3

0.0 35.9 25.1 17.9 29.7 10.4 11.1 6.1 0.0 6.3 5.4 3.0 1.8 2.2 2.5 5.6 4.6 0.7 3.4 1.3 2.0 8.1 0.9 4.5 2.2 3.3 9.2 1.7 2.6 1.7 1.4 2.7

812

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Stomach (C16) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 1842 77.4 3018 81.7 148 95.9 1825 96.5 447 42.1 793 79.2 646 85.1 3584 97.4 2352 83.8 4592 79.2 2581 77.8 3088 82.7 1460 95.1 159 91.2 850 92.0 1401 93.1 489 93.5 168 83.3 314 92.4 360 92.2 506 91.7 407 94.1 275 90.5 509 91.9 3182 99.5 118 98.3 115 97.4 58 100.0 186 97.3 193 93.8 140 96.4 188 97.3 6687 98.0 436 98.4 383 99.0 1341 91.7 1434 85.6 2412 89.8 4017 92.2 955 91.5 3386 83.0 5543 81.6 2833 87.0 3084 91.0 780 92.3 2740 92.6 2083 95.3 22 100.0 1078 93.8 567 95.4 155 96.8 1751 94.6 512 96.5 71 98.6 29 96.6 1212 93.9 546 97.4 21 100.0 63 98.4 59 96.6 285 97.2 77 96.1 5.8 1.7 2.0 0.3 13.9 5.7 0.8 12.7 10.6 11.9 3.2 5.0 3.1 2.7 3.3 11.3 2.2 1.7 2.8 2.0 5.8 3.5 0.0 0.0 0.0 0.5 3.6 1.4 2.1 0.3 0.0 0.0 0.0 0.0 3.2 0.2 0.0 0.0 6.3 0.0 0.7 1.8 0.6 0.6 0.5 0.8 0.0 0.0 0.3 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.1 0.9 0.0 5.9 4.7 3.2 0.5 0.0 0.0 1.2 0.0 0.0 0.1 0.2 0.6 0.7 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 89.5 80.1 83.1 81.4 88.6 85.3 108.5 76.1 81.2 97.2 87.9 84.0 82.1 77.4 77.3 70.4 68.0 84.5 68.8 85.3 78.7 68.8 63.6 86.4 82.3 64.4 60.9 63.8 67.7 67.4 67.1 56.4 75.3 74.4 64.9 67.1 64.8 66.0 69.2 70.6 71.9 71.8 66.5 68.1 68.3 58.1 63.6 57.2 66.5 68.8 59.2 76.0 64.8 82.8 79.1 54.9 Female Cases MV(%) DCO(%) UB(%) MI(%) 1567 2245 85 1192 241 435 394 2428 1563 4582 1346 1913 936 88 524 722 298 79 214 225 338 244 161 333 2084 89 59 33 120 140 68 105 3935 272 270 658 829 1402 2405 505 1745 3168 1534 1554 507 1860 75.5 78.6 88.2 94.1 36.9 74.3 76.1 97.2 79.4 72.9 73.7 80.9 94.1 79.5 87.6 87.4 87.6 86.1 83.2 86.7 91.4 89.8 85.1 86.8 98.8 98.9 88.1 93.9 87.5 92.1 94.1 93.3 97.3 97.8 97.0 84.0 81.3 83.2 86.4 81.4 73.7 72.7 81.8 82.9 84.0 89.3 5.7 2.2 3.5 0.7 11.2 6.4 1.5 16.9 13.5 13.3 4.2 10.2 5.7 5.3 7.4 6.3 8.9 1.3 3.3 3.7 6.8 5.7 0.0 0.0 3.0 1.7 5.0 0.0 6.7 0.4 0.0 0.0 0.0 0.0 6.4 0.3 0.0 0.0 7.9 0.1 0.5 1.7 1.1 1.3 0.8 1.3 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.1 1.6 0.0 9.9 8.5 4.3 0.8 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.1 0.3 0.0 0.0 0.0 0.5 0.0 88.4 77.5 92.9 85.2 89.7 * 84.5 111.9 79.9 * 75.9 99.5 90.2 78.4 83.2 83.0 79.8 74.4 79.7 87.3 68.7 89.3 82.0 71.7 68.3 97.6 86.9 61.8 78.0 87.9 72.5 69.3 60.3 73.3 82.6 74.8 71.9 74.3 76.1 71.7 80.4 79.2 77.9 74.5 79.3 76.7 75.6 60.9 53.8 62.6 71.8 81.4 63.0 73.6 82.6 55.0 79.5 59.1

0.1 3.5 1.5 1.3 0.7 1.7 9.1 3.9 2.5 1.3 0.4 0.8 0.0 1.9 0.0 0.0 1.2 1.4 0.0 3.4 2.1 0.5 0.0 0.0 1.7 0.0 2.6

0.6 5.9 2.4 2.6 2.2 1.9 13.7 5.5 6.1 3.2 0.8 1.3 0.0 2.1 0.0 0.0 2.8 3.3 0.0 0.0 4.8 0.5 0.0 0.0 2.0 0.0 2.2

57.1

1171 93.3 13 100.0 530 89.6 305 93.4 87 95.4 1014 91.1 276 92.4 46 93.5 20 100.0 743 89.6 381 97.9 24 95.8 34 94.1 51 98.0 191 99.5 45 95.6

71.1

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
755

813

Indices of data quality

Large bowel (C18-21)

Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 152 339 113 75 125 260 494 103 246 6570 119 472 975 234 189 84 35704 3709 5920 1999 1211 1017 54 1839 18074 241 1640 5782 1090 4634 554 6296 36828 3456 2344 4536 26000 7417 522 556 254 130 686 4889 9612 1109 390 259 293 192 1616 5523 4308 5373 280 5004 767 570 173 28655 2171 26101 8695 1991 6609 2479 760 1660 1402 17898 2146 15271 8658 5039 6168 6449 1620 4777 492 953 94.1 90.0 98.2 58.7 71.2 76.2 92.3 86.4 90.2 81.8 83.2 84.1 79.1 85.5 97.9 97.6 93.4 96.0 96.2 94.6 96.9 99.2 98.1 93.6 91.0 96.3 95.5 97.0 96.0 97.2 97.5 97.3 97.7 98.5 97.4 97.8 97.7 97.9 97.1 98.4 98.4 96.9 97.5 97.9 98.2 97.4 99.0 98.5 99.3 99.0 98.2 98.3 96.4 98.4 97.5 98.4 96.5 96.1 97.1 96.6 95.3 96.7 96.5 95.1 96.9 97.7 96.8 98.1 96.6 97.0 95.3 97.1 97.3 97.4 96.9 97.4 95.6 98.1 95.3 98.2 0.0 0.3 0.0 0.0 0.0 0.0 5.1 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 4.1 0.1 0.1 0.1 0.0 0.1 0.0 0.3 7.9 0.0 0.0 1.3 1.7 1.2 1.3 0.7 0.4 0.3 0.6 0.6 0.4 0.2 0.8 0.0 0.0 0.0 0.4 0.1 0.4 0.6 0.5 0.0 0.0 0.5 0.2 0.3 0.6 0.1 0.0 0.2 0.8 0.7 1.2 0.2 0.3 0.2 0.3 0.4 0.3 0.3 0.5 0.2 0.1 0.3 0.6 0.2 0.4 0.1 1.1 0.3 0.5 0.2 0.8 0.2 Female Cases MV(%) DCO(%) UB(%) MI(%) 154 94.2 271 91.1 95 100.0 89 64.0 94 70.2 210 590 106 330 7518 144 648 1020 290 275 106 31165 2914 5048 1746 1137 774 33 1690 16167 253 1403 5630 1330 4231 506 5592 35620 3312 2506 3981 25444 7219 524 529 251 145 552 4878 9675 1268 333 217 276 180 1562 5592 4216 5659 382 5210 930 690 211 27711 2363 24982 8668 2299 6285 2623 861 1714 1342 18153 2456 15259 8780 5302 6335 6035 1737 4262 521 912 76.2 91.2 84.9 93.0 81.0 72.9 83.0 74.6 83.4 96.4 93.4 91.0 94.5 93.9 93.1 95.7 99.5 97.0 92.7 88.0 92.9 94.1 96.7 96.5 96.8 96.8 96.1 96.6 98.3 96.4 97.2 96.2 96.3 94.5 98.5 96.4 97.9 97.1 95.9 97.5 97.4 98.5 98.6 98.9 98.9 97.5 97.2 96.2 97.5 98.2 97.5 95.8 95.8 95.7 96.5 96.4 96.4 95.6 95.0 95.8 97.2 96.9 97.4 95.5 95.7 94.2 95.9 97.0 95.4 96.4 96.5 95.7 96.8 95.6 95.8 0.0 0.0 0.0 0.0 0.0 0.0 4.4 0.0 0.3 0.0 0.0 0.0 0.0 0.0 2.5 0.0 5.5 0.1 0.1 0.1 0.0 0.1 0.0 0.8 10.4 0.0 0.0 1.4 1.3 1.4 1.0 0.9 0.5 0.2 0.4 0.4 0.6 0.2 0.2 0.0 0.0 0.0 0.2 0.3 0.4 0.4 0.3 0.0 0.4 0.0 0.2 0.5 0.9 0.3 0.0 0.3 0.9 0.6 1.9 0.1 0.2 0.1 0.3 0.4 0.3 0.3 0.3 0.2 0.2 0.2 0.2 0.2 0.3 0.3 1.0 0.5 0.5 0.6 1.3 1.2 * * * *

4.1 9.6 22.7 2.2 7.8 6.9 6.2 9.2 6.6 7.7 7.7 0.0 0.7 0.1 0.6 1.2 0.1 0.0 0.8 0.8 0.0 2.3 0.7 0.5 0.7 0.2 1.0 0.6 0.3 0.6 0.5 0.6 0.7 1.3 0.7 0.4 0.8 0.4 0.7 0.4 0.5 0.3 0.8 0.0 0.0 0.6 0.3 1.3 0.8 1.8 0.7 2.1 2.3 1.7 2.3 3.2 2.2 1.7 2.1 1.5 0.8 0.9 0.7 2.2 1.5 3.0 1.4 0.9 0.9 0.8 0.8 1.9 0.5 2.6 0.6

21.2

6.6 19.1 21.4 4.2 7.5 4.5 7.0 11.8 7.1 11.9 9.7 4.7 1.3 0.3 1.8 1.6 0.2 0.0 1.1 1.3 0.0 2.7 0.8 0.5 0.9 0.0 1.2 0.9 0.4 0.8 0.6 1.0 1.4 1.0 0.0 1.2 1.4 0.9 1.8 0.5 0.4 0.9 0.5 0.0 0.6 0.4 0.6 1.4 0.8 0.8 0.8 2.0 2.3 0.9 2.2 2.0 2.2 2.1 2.2 2.1 1.2 1.0 1.3 1.8 2.0 3.9 1.7 1.0 1.5 0.6 0.9 1.1 0.8 1.0 0.8

21.4

87.7 29.8 30.1 45.9 37.9 57.1 57.0 56.6 49.1 54.9 34.4 32.0 31.9 39.5 31.8 36.6 29.6 27.5 35.7 34.9 37.7 38.3 52.3 35.4 31.9 37.2 35.3 32.3 45.1 30.4 36.2 34.7 50.2 31.5 35.1 35.4 44.3 35.9 28.6 33.4 27.6 32.5 35.7 36.5 33.9 38.9 34.1 44.3 44.4 49.1 35.1 41.6 34.9 35.5 42.5 33.6 32.9 40.3 29.5 37.4 37.6 45.7 37.0 38.2 35.5 37.2 39.6 49.1 36.6 53.7 39.8

93.3 28.6 32.1 42.1 36.8 62.5 58.3 60.7 52.8 40.0 34.4 33.2 33.2 39.6 30.3 35.3 21.2 29.9 35.0 28.1 37.4 39.1 46.6 37.3 29.2 37.1 36.4 29.0 44.2 29.2 38.1 35.6 46.9 29.0 37.5 35.0 42.6 30.3 27.6 27.2 32.2 31.9 35.9 36.2 35.2 33.8 35.5 43.3 46.2 37.4 34.4 41.0 34.1 37.4 44.6 34.9 36.0 41.7 33.4 35.4 38.5 43.5 38.3 39.3 35.9 36.5 38.3 43.8 36.1 45.1 38.3

814

*Important. See note on population page.

756

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Large bowel (C18-21) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 2171 9712 13112 1629 11279 5555 1254 4224 8625 715 7832 1340 307163 27683 268954 13569 1396 11779 2009 73 633 1260 28258 2766 24605 16548 1421 14702 4945 4489 22290 1524 20421 1789 33857 3020 27826 92106 5622 8328 6364 70792 5557 1321 4180 22324 2474 19326 1688 865 7301 4765 3249 7687 80 1374 8775 272 427 6533 575 510 543 1155 36 1334 249 335 151 7337 6966 272 1630 1812 2304 6166 3464 14062 3652 96.0 97.2 97.0 97.4 96.9 98.3 97.8 98.5 96.1 95.5 96.2 95.8 96.8 95.8 96.9 97.7 97.3 97.7 95.7 94.5 95.9 95.9 95.9 95.0 96.0 96.7 95.4 96.7 92.8 96.3 97.9 96.9 97.9 98.0 97.8 97.3 97.9 97.7 98.4 96.9 97.7 97.7 96.5 95.2 97.0 95.9 94.8 96.0 98.6 96.6 97.2 97.5 97.3 95.5 86.3 78.2 94.3 96.7 85.2 79.9 95.8 99.4 77.0 79.0 91.7 79.5 89.6 85.4 92.1 92.7 93.7 94.1 89.1 92.4 97.1 87.6 92.4 79.0 90.2 1.4 1.1 0.8 0.4 0.9 0.5 0.3 0.5 1.7 2.0 1.7 2.3 1.3 1.8 1.3 0.7 0.8 0.7 1.9 2.7 1.7 1.7 1.4 2.2 1.3 1.6 2.1 1.6 2.1 1.4 0.5 0.7 0.5 1.2 0.7 0.8 0.7 0.7 0.4 0.9 0.6 0.7 1.3 1.2 1.3 2.3 3.2 2.2 0.2 1.6 0.7 0.5 0.8 1.7 7.5 0.0 0.9 0.4 0.9 0.4 0.0 1.7 1.6 0.0 5.4 0.0 7.5 0.7 1.6 1.3 0.0 8.2 2.3 1.2 7.4 2.1 5.6 5.1 1.1 0.8 0.9 0.9 0.9 0.3 0.6 0.2 1.3 1.7 1.3 0.6 0.6 0.9 0.6 0.6 0.7 0.6 0.5 0.0 0.6 0.5 1.0 1.2 1.0 1.1 1.5 1.0 0.7 0.5 0.4 0.5 0.4 0.1 0.2 0.6 0.2 0.4 0.3 0.7 0.5 0.4 1.4 2.0 1.1 0.9 0.9 0.9 0.0 0.1 0.5 0.4 0.6 1.3 0.0 0.1 0.0 0.0 0.5 0.0 0.0 0.0 7.2 0.0 0.0 0.3 0.0 0.0 0.7 1.0 0.7 2.2 2.7 0.4 0.0 0.0 0.1 0.0 0.5 35.7 37.6 37.4 40.0 37.4 36.0 38.4 35.7 36.5 45.0 35.9 37.4 36.6 44.7 36.3 35.4 39.4 35.6 38.7 41.1 39.3 37.5 35.8 43.2 35.3 39.5 49.6 39.5 37.9 38.4 36.6 42.9 36.6 33.5 35.0 41.0 35.0 35.8 31.2 43.2 31.0 36.0 37.2 45.1 35.1 37.6 47.9 36.9 36.9 37.9 34.4 34.7 37.5 37.1 56.3 52.4 43.5 51.1 45.7 24.0 31.9 8.3 32.5 41.9 35.5 35.6 29.9 30.7 37.8 47.2 33.7 Female Cases MV(%) DCO(%) UB(%) MI(%) 2240 93.9 10291 94.9 13331 95.9 1813 95.1 11320 96.0 5814 97.0 1412 96.6 4348 97.1 8496 95.4 840 95.7 7594 95.3 1186 94.3 305145 95.8 31173 95.5 263920 95.8 13925 96.7 1499 96.7 12088 96.7 1710 94.3 58 100.0 477 93.7 1138 94.6 29994 94.9 3664 95.9 25520 94.6 17131 95.7 1611 94.4 15061 95.8 4719 92.3 4518 95.0 22679 96.6 1724 96.1 20624 96.7 1864 96.1 33868 96.6 3361 96.5 27853 96.4 91132 96.6 5089 98.0 9161 96.2 5649 97.0 70342 96.5 5153 95.5 1389 95.8 3715 95.5 20818 94.3 2653 93.9 17644 94.4 1657 97.3 888 94.9 6881 95.9 4644 96.2 3310 96.7 7392 93.9 47 1135 7234 242 366 6339 448 457 395 675 34 914 160 302 115 7371 6982 257 1220 1454 1749 4331 2842 10353 2807 91.5 80.8 93.4 97.1 84.7 79.2 94.4 98.2 78.5 72.0 85.3 76.0 98.8 82.5 93.0 91.7 92.9 94.2 84.7 89.3 94.5 83.9 89.1 74.7 86.6 2.3 1.6 1.0 0.8 1.1 1.2 1.1 1.3 1.7 1.8 1.7 3.8 1.6 1.9 1.6 1.1 1.0 1.1 3.2 0.0 2.7 3.4 1.5 1.0 1.6 2.5 3.9 2.4 2.1 1.8 0.8 1.4 0.8 1.6 1.2 1.1 1.3 1.0 0.4 1.0 0.8 1.1 1.7 1.4 1.9 3.4 3.7 3.4 0.5 1.9 1.1 0.8 1.1 2.4 4.3 0.0 1.1 0.0 1.4 0.6 0.2 2.8 1.6 0.0 7.8 0.0 8.6 1.7 2.3 1.9 0.8 12.3 3.8 2.2 11.5 4.2 8.7 6.3 0.8 1.6 1.4 1.9 1.4 0.2 0.3 0.2 1.6 0.8 1.8 0.6 0.8 0.8 0.8 0.6 0.7 0.6 0.4 0.0 0.6 0.4 1.1 1.0 1.1 1.1 0.9 1.1 0.7 0.8 0.6 0.6 0.5 0.5 0.3 0.3 0.3 0.5 0.3 0.5 0.5 0.5 1.7 1.7 1.6 1.0 1.2 1.0 0.1 0.1 0.8 0.8 0.4 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 5.3 0.0 0.0 0.2 0.0 0.0 0.0 1.0 0.8 1.9 3.0 0.5 0.0 0.0 0.1 0.0 0.7 36.3 38.3 36.8 40.7 36.5 36.2 40.6 34.9 39.1 42.5 38.8 35.2 37.3 43.4 37.2 37.2 38.0 37.8 41.1 41.4 47.8 38.3 36.4 41.3 36.1 40.0 47.7 40.3 39.2 35.7 38.4 45.2 38.2 38.3 35.9 40.9 36.1 36.6 28.6 41.8 29.8 37.3 38.4 40.6 37.9 38.8 45.7 38.4 37.3 40.1 35.5 35.3 37.9 38.1 53.2 52.6 * 43.3 * 34.2 43.4 * * 20.2 * 38.0 * 8.8 34.0 * * * 42.8 42.6 40.2 32.3 35.7 40.6 51.8 40.7

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
757

815

Indices of data quality

Large bowel (C18-21) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
758

Female Cases MV(%) DCO(%) UB(%) MI(%) 19979 1665 1245 642 623 1167 156 5539 327 152 83 373 438 62 112 1483 2782 2537 72 173 384 235 217 272 842 11780 858 435 8868 2287 7301 8271 5693 16111 8821 1803 5780 1367 747 576 1012 1348 1362 1372 641 703 571 718 4166 8443 2851 2773 4239 4923 2438 269 4075 367 983 861 2490 1344 371 2302 1104 431 3974 814 365 779 2112 840 469 396 265 1839 1798 811 2751 87.3 84.4 89.2 87.7 87.0 88.5 87.8 88.8 86.9 90.1 90.4 92.0 89.5 98.4 99.1 81.1 96.0 96.0 98.6 94.2 92.4 59.6 87.1 95.2 93.9 91.6 94.3 88.5 86.2 98.5 90.9 65.7 80.1 87.5 92.0 90.4 95.4 97.7 92.8 96.9 98.7 99.4 97.1 99.1 99.4 93.0 94.2 97.6 78.4 83.7 72.3 79.4 89.5 82.2 95.3 99.6 87.5 92.6 89.1 90.2 88.0 85.0 88.9 87.9 95.1 86.3 94.0 90.2 87.7 90.9 91.7 80.7 93.4 88.9 90.6 92.6 87.2 92.4 91.9 4.1 3.9 2.7 2.8 3.2 2.3 0.6 5.0 4.6 8.6 8.4 1.6 4.8 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 20.4 4.1 0.7 0.0 7.5 1.6 8.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.4 0.8 0.1 0.0 0.2 0.0 0.0 7.2 0.2 13.7 0.7 2.6 0.0 0.7 0.0 0.0 0.0 0.3 0.0 0.2 0.0 0.0 1.0 0.0 1.4 0.8 0.1 0.0 0.2 0.0 0.9 0.0 0.0 0.8 0.8 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.2 0.0 0.0 0.0 7.5 0.0 0.0 40.5 43.1 39.0 37.4 36.9 40.5 34.6 32.6 41.3 34.9 17.1

25365 2101 1490 899 695 1497 165 7332 369 131 152 443 490 94 210 1560 3228 2907 117 204 389 265 265 385 1139 12767 908 452 7875 2819 8578 10419 7224 21727 8994 1454 5234 1780 858 744 1224 1570 1675 1671 754 813 709 1076 4491 8616 2277 2975 4465 4778 2473 308 5362 401 1013 1036 3008 1364 416 2257 1433 452 4781 944 425 1019 2470 1009 638 398 286 2052 2175 920 3307

90.0 88.0 93.4 92.5 90.9 90.2 90.3 91.0 90.0 84.7 94.1 93.5 90.2 88.3 97.1 79.2 97.0 97.2 95.7 94.6 88.7 63.0 90.2 91.7 92.0 94.2 97.6 94.0 88.3 98.9 93.3 68.4 82.4 90.0 93.9 93.3 97.2 99.4 96.3 98.3 98.8 99.4 98.1 99.6 99.6 96.6 97.3 99.1 85.2 89.9 78.0 86.6 94.2 85.3 96.6 99.0 91.9 95.5 90.9 94.8 92.1 91.1 91.6 92.3 97.6 87.2 96.3 93.6 90.1 94.1 95.1 83.6 94.4 89.4 94.1 95.0 90.5 95.5 94.8

3.2 2.7 2.3 2.1 1.4 2.4 0.6 3.8 3.5 14.5 4.6 2.0 5.1 0.0 0.0 5.0 0.0 0.0 0.0 0.0 0.0 16.6 6.4 2.1 0.1 5.3 1.3 2.9

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 1.7 0.1 0.0 1.1 0.0 0.0 5.7 0.1 12.8 0.5 2.1 0.0 0.3 0.0 0.0 0.1 0.3 0.0 0.3 0.0 0.0 0.4 0.0 0.4 1.0 0.1 0.0 0.1 0.0 0.9 0.1 0.0 0.5 1.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.9 0.0 0.0 0.0 0.2 0.0 0.0 0.1 5.8 0.0 0.0

37.9 37.4 37.2 33.5 40.0 39.3 37.3 30.1 36.6 28.2 28.6

47.0 0.3 72.8 59.6 34.3 41.4 49.7 36.7 39.2 69.9 45.1 57.9 56.1 57.5 55.8 57.7 45.2 42.6 45.1 41.9 40.2 41.2 39.8 48.2 53.2 49.3 46.4 52.1 106.1 36.9 54.9 35.7 39.3 47.6 41.4 47.1 49.2 45.9 44.7 43.8 38.6 43.9 48.1 45.6 41.7 42.4 42.7 38.3 44.2 36.5 40.1 39.4 45.3 41.2 34.1 41.6 41.3 38.6 39.2

49.7

* * *

0.5 * 71.1 * 64.1 27.2 * 37.3 * 53.5 45.7 43.9 63.5 * * 46.9 58.2 * 56.6 58.7 59.5 57.4 45.3 44.5 51.9 46.2 49.9 39.1 43.5 49.5 57.6 50.1 47.1 60.4 124.3 44.0 61.0 39.8 42.8 52.4 44.7 47.6 47.5 52.0 40.1 44.3 42.0 44.8 41.0 44.7 41.6 36.0 46.8 45.1 45.2 37.5 38.8 45.0 48.0 41.4 46.2 45.8 43.9 39.5 40.9

14.0 4.7 2.9 0.3 0.3 0.6

16.2 6.2 3.9 0.3 0.5 0.9

0.1 12.7 8.5 8.5 12.1 2.9 7.5 2.5 0.0 1.8 1.2 1.0 0.4 0.5 0.8 1.0 1.0 0.1 1.8 0.4 0.2 1.2 0.1 0.5 1.1 1.6 3.0 0.7 1.0 0.4 0.1 0.7

0.3 18.5 13.4 11.2 18.0 5.8 9.8 3.2 0.0 3.4 1.1 2.2 0.9 0.6 1.6 1.6 2.3 0.1 1.2 0.7 0.7 2.5 0.3 1.1 0.8 2.3 4.0 1.1 1.5 0.9 0.1 1.2

816

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Large bowel (C18-21) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 2116 3384 375 7808 801 1245 1860 4368 4871 5299 5616 8311 3093 358 2043 3328 1453 343 1126 995 1681 1022 934 1236 13048 527 335 272 648 503 372 935 23987 1627 1541 4507 4206 6644 11592 3604 11560 18022 7801 8807 2382 9035 11289 144 6249 2928 885 8543 2894 438 69 6436 1890 134 270 200 739 458 80.9 84.6 93.1 96.1 55.8 84.9 87.5 98.0 89.1 84.8 81.4 88.2 98.0 93.3 93.2 94.5 96.6 89.5 94.9 95.2 93.9 95.8 92.2 93.3 99.1 97.9 94.3 96.3 97.2 98.4 97.0 97.5 98.1 98.8 98.6 91.1 87.5 90.7 92.3 93.1 86.2 85.0 87.2 91.0 90.4 93.1 96.2 95.8 93.7 93.9 95.8 94.4 96.7 95.4 97.1 95.1 98.4 97.0 97.8 99.0 99.1 97.8 3.6 1.3 0.8 0.4 6.5 2.5 0.3 8.8 7.1 6.9 1.2 2.2 2.3 1.9 1.9 5.2 2.4 0.5 2.1 1.5 4.6 3.3 0.0 0.0 0.4 0.2 0.4 0.8 1.8 0.4 0.0 0.0 0.0 0.0 2.0 0.2 0.1 0.0 5.3 0.1 0.5 0.8 0.3 0.6 0.5 0.3 0.0 0.1 0.0 0.4 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.2 1.0 0.0 4.6 4.0 2.7 0.8 0.0 0.0 0.6 0.0 0.0 0.1 0.5 0.0 1.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.4 66.6 61.1 59.7 50.1 65.2 58.9 63.0 45.8 52.9 78.7 58.0 62.3 54.8 53.9 58.6 45.9 46.5 43.7 43.2 48.3 43.7 42.5 45.7 61.0 48.3 35.5 43.3 41.9 40.3 37.6 44.9 40.6 45.2 42.1 42.8 46.4 45.8 44.6 46.7 48.8 47.6 45.6 46.4 44.9 47.4 36.8 27.8 36.0 38.4 39.9 38.4 40.6 33.3 37.7 45.3 31.2 Female Cases MV(%) DCO(%) UB(%) MI(%) 2598 3472 390 8066 779 1093 1752 3528 3749 7610 3859 6086 2450 268 1381 2129 1224 252 789 774 1299 717 687 962 12548 569 262 209 561 454 257 856 22425 1493 1382 3983 3309 5751 9400 3204 10896 17201 6420 7116 2181 8111 9461 82 5143 2605 830 7252 2282 340 40 6296 1470 116 143 162 613 334 77.9 82.9 92.1 94.5 56.6 81.3 86.3 97.0 85.9 82.2 80.5 86.1 96.4 89.2 90.8 89.9 92.8 84.1 88.6 93.9 93.5 90.9 88.1 91.4 98.7 94.2 92.7 96.2 94.7 95.6 96.9 95.1 97.4 98.1 97.3 87.2 83.0 85.4 87.2 87.8 81.0 79.7 82.5 86.2 88.9 89.5 94.4 96.3 91.9 92.1 92.0 92.5 93.6 92.4 92.5 93.0 97.1 95.7 96.5 98.8 97.4 96.7 4.6 1.7 1.5 0.5 8.3 3.3 0.6 11.8 9.1 8.4 2.2 6.0 4.3 4.1 3.6 7.9 5.8 0.9 2.1 2.2 6.8 4.6 1.1 0.4 1.4 0.0 1.5 0.4 3.6 0.5 0.0 0.0 0.0 0.0 2.9 0.1 0.1 0.0 6.1 0.1 0.4 1.3 0.4 0.6 0.1 0.5 1.2 0.4 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.3 1.3 0.0 7.4 6.2 3.1 0.7 0.0 0.0 0.6 0.0 0.0 0.1 0.2 0.0 0.8 0.1 0.0 0.0 0.0 0.3 1.7 0.7 0.0 0.0 0.0 66.9 61.7 50.0 49.7 65.1 * 61.5 66.0 43.9 * 54.1 81.1 60.4 59.9 56.9 50.4 55.8 46.5 49.6 49.6 45.2 54.3 46.0 51.6 44.7 61.6 49.5 37.3 45.4 49.3 45.3 39.4 44.0 40.0 49.1 47.5 46.1 47.0 48.7 46.2 47.8 51.0 50.0 48.5 47.8 45.0 48.2 36.7 35.4 36.0 37.6 43.9 40.2 41.5 43.5 45.0 44.3 29.3

0.2 3.1 1.0 1.1 0.5 1.3 6.2 3.5 2.5 1.0 0.4 0.4 1.4 0.8 0.0 0.1 0.8 1.2 0.0 2.9 1.4 0.4 0.7 0.4 0.0 0.5 0.2

0.4 3.8 2.0 1.8 1.5 2.0 8.9 5.3 4.3 1.5 0.7 1.0 1.2 1.5 0.0 0.6 1.5 1.8 0.6 5.0 2.6 0.7 0.9 0.0 0.0 0.3 1.5

31.2

33.2

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
759

817

Indices of data quality

Liver (C22)
Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 22 912 20 100 265 59.1 41.3 85.0 40.0 14.3 0.0 0.0 0.0 0.0 0.0 4.9 5.2 7.3 0.0 0.0 0.0 0.0 0.0 0.0 4.5 0.0 17.0 1.0 0.1 0.0 0.0 3.1 0.0 3.4 32.6 0.0 0.0 6.9 5.7 7.3 6.0 7.8 3.4 2.7 3.2 4.0 3.4 1.8 2.2 1.7 2.2 4.8 2.1 1.3 3.8 4.9 4.2 2.0 2.8 5.6 4.9 2.6 3.7 1.7 1.8 1.7 4.4 5.1 3.3 2.2 2.0 2.2 1.3 1.4 1.3 0.6 0.9 0.6 1.5 1.9 2.6 1.7 2.3 1.8 5.8 1.3 1.8 1.2 0.0 0.0 Female Cases MV(%) DCO(%) UB(%) MI(%) 16 227 7 73 159 62.5 38.8 71.4 28.8 14.5 6.3 0.0 0.0 0.0 0.0 12.5 4.1 3.8 0.0 0.0 0.0 0.0 0.0 0.0 8.0 0.0 18.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 36.6 0.0 0.0 8.9 11.1 8.1 8.5 9.0 4.2 3.4 3.9 4.0 4.7 1.8 1.8 3.3 0.0 4.5 0.0 1.8 4.9 4.3 7.1 3.0 2.2 9.6 5.3 4.0 3.9 2.5 0.0 2.8 1.8 2.0 0.0 2.0 2.6 2.0 2.2 2.8 2.2 0.7 1.9 0.0 2.7 2.2 2.2 2.3 0.8 3.4 4.5 0.3 0.0 0.4 0.0 1.5 * * * *

15.9 34.3 41.5 10.4 26.8 18.4 1.2 41.3 8.6 41.2 33.0 0.0 3.5 0.5 4.5 8.9 0.0 0.0 1.1 2.6 0.0 22.5 10.5 8.9 11.1 1.0 5.0 2.5 1.7 4.0 2.8 2.5 3.8 2.2 3.7 0.0 9.5 6.3 4.4 2.3 5.4 1.6 0.0 5.6 0.7 2.4 2.2 4.3 3.3 1.8 3.6 8.1 11.2 0.0 12.9 11.7 13.2 3.7 1.9 4.6 2.8 0.9 4.7 10.8 7.0 12.8 6.1 6.1 2.6 2.5 5.2 7.0 4.7 10.5 5.6

41.8

29.1 37.1 31.3 11.5 34.6 45.5 4.0 51.2 8.9 42.1 47.3 0.0 5.0 1.2 7.8 10.1 4.0 0.0 6.7 2.8 0.0 30.0 13.1 11.1 14.0 0.0 7.0 3.2 2.2 3.4 3.5 3.6 5.6 3.6 1.1 4.3 9.1 4.4 8.0 3.1 4.3 0.0 0.0 2.2 4.1 3.5 3.7 4.7 4.7 5.6 4.8 3.6 4.1 0.0 13.4 11.8 13.9 8.5 0.9 11.5 2.8 0.0 5.5 10.8 11.2 17.8 10.0 5.4 7.4 3.1 6.9 7.9 6.3 5.6 9.0

56.4

41 53.7 135 83.7 41 58.5 49 77.6 585 94.7 46 23.9 105 66.7 444 27.7 94 39.4 44 81.8 22 100.0 3301 57.0 417 63.5 736 52.0 168 46.4 59 71.2 32 90.6 1 100.0 87 52.9 1696 57.3 16 75.0 89 60.7 638 64.1 123 64.2 506 64.0 100 77.0 798 72.2 7052 69.7 1858 70.2 525 71.2 1594 65.6 2987 71.4 1651 66.1 139 64.7 294 64.6 93 67.7 21 66.7 240 65.4 616 69.2 2083 71.0 224 71.9 190 74.7 99 80.8 36 58.3 144 66.0 591 66.3 642 73.5 537 71.3 602 82.9 57 87.7 527 82.4 135 74.8 98 70.4 30 86.7 3370 72.9 358 73.5 2914 72.4 872 79.2 216 78.7 603 79.6 326 80.7 108 76.9 170 84.1 130 66.2 2031 76.2 343 70.3 1553 76.6 766 74.7 379 76.0 516 76.6 853 75.0 228 74.1 591 74.6 86 72.1 162 78.4

158.5 80.0 61.0 171.4 209.9 102.2 196.2 104.5 151.1 110.8 93.3 76.7 82.1 100.6 125.4 181.3 300.0 111.5 96.3 56.3 125.8 115.0 130.9 112.6 71.0 90.7 77.2 70.2 81.0 66.1 88.1 74.0 79.1 61.7 86.4 77.1 85.3 80.0 70.7 83.3 81.3 71.6 84.7 78.0 79.7 75.4 81.4 91.9 98.0 80.0 87.9 83.0 89.7 97.7 93.1 101.3 87.1 80.6 97.1 97.7 84.9 91.0 86.0 103.1 87.1 105.8 95.1 105.3 92.9 105.8 83.3

16 56.3 148 82.4 26 61.5 22 50.0 300 91.3 41 36.6 124 68.5 321 20.6 129 27.1 25 84.0 13 100.0 1393 52.1 164 55.5 309 50.8 79 34.2 25 68.0 18 83.3 0 0.0 45 48.9 708 53.0 5 60.0 40 47.5 359 63.5 81 66.7 271 62.7 47 70.2 345 69.0 3296 68.1 804 66.5 207 68.1 768 69.8 1475 68.0 713 60.7 56 66.1 92 62.0 47 68.1 22 54.5 114 68.4 276 59.8 1072 70.1 92 69.6 84 71.4 33 81.8 46 69.6 73 65.8 340 70.0 348 69.5 257 72.8 276 80.4 18 77.8 249 79.9 56 78.6 49 75.5 7 100.0 1550 70.5 153 71.9 1356 69.9 457 72.0 108 72.2 323 70.6 143 76.2 53 71.7 73 75.3 74 73.0 1074 69.9 185 67.6 834 70.6 392 77.0 203 69.5 291 77.7 349 74.8 89 70.8 255 76.9 36 75.0 67 76.1

231.3 63.5 76.9 200.0 280.0 117.1 183.9 110.6 139.5 155.0 126.0 112.8 104.2 132.9 168.0 194.4 2.0 144.4 128.8 180.0 195.0 125.9 135.8 125.1 78.7 112.5 92.1 79.0 96.6 83.1 104.7 91.3 87.5 73.7 110.1 88.3 108.7 92.9 78.8 78.3 69.9 80.9 101.1 103.1 97.8 100.0 97.2 108.9 95.9 185.7 103.8 113.1 104.5 118.6 120.4 121.7 109.1 96.2 127.4 108.1 107.3 114.1 108.3 122.7 104.9 125.4 137.0 127.0 138.8 119.4 111.9

818

*Important. See note on population page.

760

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Liver (C22) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 196 1162 1613 295 1257 791 233 529 813 146 646 99 39416 4843 30392 1621 229 1247 368 37 175 145 4206 616 3072 1576 265 1247 495 462 2366 354 1865 201 4885 584 3210 13843 2592 1483 2082 7485 583 141 427 4014 463 3301 163 73 991 748 259 893 30 2425 6289 440 713 6001 857 74 269 491 34 895 65 209 78 556 463 42 862 815 1632 1709 1923 13494 969 61.7 74.6 76.3 75.9 76.1 78.1 81.1 76.4 76.4 76.0 76.0 62.6 73.2 73.0 73.3 76.6 74.2 77.4 67.7 62.2 68.6 66.9 72.0 72.9 72.5 77.8 74.0 78.1 63.2 61.7 79.0 77.7 79.0 79.1 73.4 76.4 73.7 72.7 71.7 75.2 67.1 74.2 74.4 68.8 76.1 71.1 67.6 71.3 77.9 87.7 68.7 67.5 81.1 77.0 66.7 29.1 58.3 20.0 68.3 17.8 41.2 90.5 68.8 79.2 52.9 76.5 92.3 78.9 64.1 55.8 59.0 76.2 59.0 17.7 35.7 31.4 33.3 90.6 27.0 6.1 6.0 3.5 2.0 3.7 3.9 2.6 4.5 5.5 8.9 5.0 20.2 6.3 7.4 6.6 4.4 5.2 4.6 7.3 8.1 6.3 9.0 4.8 4.7 5.1 9.1 10.6 9.2 8.7 5.6 3.0 2.5 3.2 4.0 3.3 2.1 3.9 3.0 1.6 3.9 3.5 3.2 6.9 7.8 6.6 12.4 16.8 12.1 1.8 0.0 2.0 1.3 6.6 9.2 0.0 0.0 3.0 0.5 2.1 0.5 0.4 4.5 2.2 5.9 10.6 0.0 13.4 10.3 19.1 15.3 9.5 30.6 5.4 8.3 22.7 21.9 8.8 18.6 5.6 5.2 5.3 4.7 5.4 1.9 1.7 1.9 5.8 2.7 6.7 3.0 3.6 3.1 3.7 2.2 1.3 2.2 3.0 8.1 2.3 2.8 3.7 2.6 3.6 5.5 5.7 5.6 2.8 3.9 1.8 1.7 1.8 1.5 2.1 1.9 2.2 2.9 2.5 2.2 3.7 2.9 7.9 10.6 7.0 3.3 3.0 3.1 0.0 1.4 5.3 4.9 2.7 7.4 0.0 0.1 0.0 0.0 1.7 0.0 0.0 2.7 23.0 0.0 0.0 0.6 0.0 0.0 0.0 7.2 7.8 2.4 10.3 1.5 0.0 0.0 2.0 0.0 1.1 87.8 86.7 87.7 82.7 90.1 86.6 78.5 91.3 95.8 87.7 98.3 120.2 84.8 86.6 87.5 80.0 81.7 82.4 83.4 83.8 78.9 89.7 70.1 70.8 72.4 97.6 85.3 103.1 88.5 85.9 80.1 76.6 84.0 79.6 81.0 77.4 85.8 81.6 70.7 84.4 67.7 89.6 97.6 103.5 97.7 84.9 92.4 85.9 96.3 97.3 85.5 77.4 100.0 86.0 96.7 96.9 84.9 89.6 73.0 84.5 60.2 20.6 53.0 108.1 80.6 86.1 80.9 85.3 93.6 89.2 90.5 Female Cases MV(%) DCO(%) UB(%) MI(%) 72 488 799 113 664 373 90 271 375 59 309 66 18834 2074 15047 752 83 619 178 15 68 88 1981 291 1520 854 102 729 291 238 1074 140 895 97 2297 232 1574 6525 1129 582 970 3746 250 71 164 1854 179 1588 96 27 506 382 143 430 17 729 1771 174 252 2300 177 29 83 232 8 433 35 88 30 333 293 15 388 446 659 880 906 5654 607 69.4 63.7 70.7 76.1 69.4 75.3 80.0 72.7 75.2 76.3 74.8 57.6 69.9 71.0 69.9 69.4 75.9 67.7 68.5 73.3 64.7 69.3 68.0 69.4 68.2 74.8 73.5 74.6 69.1 62.6 73.4 75.0 73.0 79.4 70.1 74.1 70.0 70.4 69.2 72.2 70.0 70.6 72.0 76.1 68.3 65.6 62.0 66.3 72.9 77.8 67.2 66.0 74.1 72.3 64.7 20.0 54.7 16.7 71.4 14.9 37.9 82.8 63.9 72.0 37.5 73.7 97.1 60.2 66.7 55.3 57.3 93.3 58.0 11.0 27.6 22.8 29.0 89.1 21.1 1.4 10.5 4.1 1.8 4.4 5.4 3.3 6.3 4.0 3.4 4.2 24.2 8.0 8.1 8.4 7.6 4.8 8.4 14.6 20.0 17.6 12.5 7.1 8.2 7.4 11.5 13.7 11.5 5.5 6.7 3.5 3.6 3.6 5.2 5.1 2.6 6.2 4.4 2.2 4.0 5.3 4.9 7.6 5.6 9.1 15.7 15.6 15.8 4.2 7.4 3.6 1.3 1.4 12.8 17.6 0.0 5.0 0.6 2.4 1.1 0.0 10.8 1.7 25.0 15.7 0.0 21.6 13.3 16.2 13.0 0.0 30.7 7.8 14.1 28.8 29.1 10.3 20.6 8.3 9.2 6.9 6.2 7.1 2.1 1.1 2.6 8.0 5.1 8.7 0.0 4.2 3.9 4.3 2.9 1.2 3.2 0.6 0.0 0.0 1.1 4.0 3.1 4.1 4.8 5.9 4.8 2.7 6.3 2.8 1.4 3.1 1.0 2.1 1.3 2.3 3.3 2.8 2.2 3.7 3.4 7.6 9.9 6.7 3.7 3.9 3.3 2.1 3.7 3.4 2.6 6.3 10.2 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 24.1 0.0 0.0 0.0 0.0 0.0 3.3 9.9 9.9 6.7 11.3 0.9 0.0 0.0 2.1 0.0 1.2 145.8 102.0 105.5 99.1 106.5 100.0 100.0 100.4 127.7 111.9 131.4 101.5 102.8 106.3 105.7 99.1 101.2 101.5 91.6 93.3 104.4 83.0 85.3 89.7 87.1 102.2 108.8 103.2 94.5 104.2 105.8 97.9 109.7 105.2 97.3 95.7 102.1 98.9 80.5 104.0 82.5 108.7 121.6 118.3 128.7 102.9 110.6 103.2 109.4 118.5 97.8 91.1 128.0 104.2 105.9 96.3 * 92.9 * 71.4 76.3 * * 137.9 * 61.4 * 25.0 56.6 * * * 151.3 79.4 87.0 88.0 84.9 93.5 86.9 87.5

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
761

819

Indices of data quality

Liver (C22) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
762

Female Cases MV(%) DCO(%) UB(%) MI(%) 13339 1582 869 339 374 712 131 3269 185 37 27 82 114 53 70 568 459 409 14 36 278 347 60 36 111 23.8 19.7 26.9 26.3 19.0 26.0 23.7 24.2 28.1 24.3 40.7 48.8 62.3 84.9 55.7 27.6 29.0 29.6 28.6 22.2 46.0 21.0 31.7 97.2 49.5 10.1 7.6 9.9 7.4 9.6 4.8 1.5 11.3 10.3 67.6 48.1 13.4 18.4 1.9 1.4 26.4 0.0 0.0 0.0 0.0 0.4 25.1 3.3 0.0 0.0 23.4 6.4 29.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.8 0.2 0.0 3.2 0.0 0.0 11.5 0.7 39.7 2.1 5.4 0.0 3.6 0.0 1.3 0.0 5.2 0.0 3.3 1.3 0.0 7.7 0.0 12.8 7.3 1.2 0.0 1.3 0.0 0.9 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 3.8 3.3 0.0 0.4 23.5 0.0 0.0 73.9 74.2 73.6 71.1 77.0 73.7 64.1 58.1 83.2 85.4 61.4

40709 4438 2582 990 1349 1961 352 9909 659 74 77 209 325 124 138 1570 1522 1352 59 111 730 723 233 109 253 2604 174 79 998 88 496 1949 1162 2569 878 182 972 485 372 150 301 339 475 588 128 162 93 197 619 1255 355 459 407 615 323 20 291 149 732 243 558 351 75 794 333 535 1709 450 188 224 354 510 316 145 192 608 456 308 1325

24.1 19.9 30.8 28.0 17.4 23.8 23.3 23.0 33.4 35.1 42.9 55.0 53.8 86.3 56.5 25.7 30.1 31.0 22.0 23.4 46.3 22.7 35.2 88.1 56.5 72.8 58.0 62.0 42.9 80.7 74.4 15.3 44.5 61.9 83.7 76.9 82.4 55.3 29.3 55.3 66.8 87.3 57.5 72.1 50.8 74.7 66.7 78.2 45.4 52.4 46.8 47.9 97.1 77.6 70.0 95.0 53.6 30.2 57.8 46.5 45.2 39.3 38.7 48.9 45.3 32.3 55.2 45.8 25.0 48.7 58.8 41.2 55.7 27.6 49.0 35.0 63.4 68.8 51.8

8.6 5.5 6.7 6.5 5.2 3.1 2.6 8.5 5.8 44.6 36.4 13.9 16.9 5.6 0.7 28.2 0.0 0.0 0.0 0.0 0.4 22.1 4.7 1.8 0.0 18.1 2.9 17.7

0.0 0.0 0.1 0.0 0.0 0.0 0.9 0.0 0.0 2.7 0.0 0.5 0.3 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 1.8 2.4 0.2 0.0 5.1 0.0 0.0 10.5 0.3 35.5 1.1 5.0 0.0 1.9 0.0 0.5 0.7 8.3 0.0 2.3 0.5 0.0 0.6 1.1 9.6 7.1 1.7 0.0 2.8 0.0 1.0 0.3 0.0 3.4 2.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 7.4 0.0 0.0 0.0 2.2 10.3 0.0 0.5 20.6 0.0 0.0

77.6 78.8 76.6 79.0 70.8 77.3 82.7 63.6 79.5 76.6 50.8

95.7 0.4 84.6 54.5 66.1 86.2 73.0 78.5 106.7 143.3 129.3 102.5 109.8 87.4 123.6 96.4 101.4 89.8 102.0 118.6 112.1 105.1 146.8 191.4 117.9 143.0 235.5 209.5 68.4 69.6 71.9 145.2 73.3 84.5 125.0 146.7 83.9 78.0 87.2 95.0 78.9 90.7 89.8 85.0 62.8 78.1 67.3 81.9 80.4 83.3 94.3 93.0 91.0 83.3 76.3 76.8 83.4 78.4

105.2

* * *

1.1 * 90.8 * 233.3 108.3 * * 87.5 96.2 87.1 105.7 * * 156.0 143.7 * 99.0 129.3 96.3 121.3 113.7 140.4 123.4 106.3 137.5 129.1 109.8 217.3 261.9 146.2 177.4 220.5 206.5 80.5 62.9 80.5 214.7 81.2 92.9 257.1 187.2 98.3 92.3 114.0 101.0 89.7 144.8 113.8 83.3 98.4 92.4 66.9 105.8 94.2 94.8 99.7 97.3 97.8 103.4 96.8 86.6 100.8 83.8

45.6 20.0 11.3 1.0 1.1 4.0

0.6 45.2 36.7 16.3 45.1 0.0 14.6 15.5 0.0 3.4 0.7 1.1 0.8 1.4 2.6 5.3 1.6 0.9 1.7 1.0 0.9 6.4 0.4 3.7 7.6 6.3 6.9 1.6 2.1 0.9 0.0 3.0

1319 67.6 78 46.2 31 61.3 705 44.8 50 88.0 366 65.6 1100 13.9 784 38.1 1449 54.7 540 74.6 150 76.7 744 72.4 104 53.8 77 37.7 48 47.9 96 62.5 110 89.1 123 49.6 75 72.0 21 66.7 52 63.5 31 61.3 39 82.1 386 29.8 666 43.7 280 30.4 231 33.8 129 96.9 324 69.4 156 57.7 7 100.0 164 46.3 59 22.0 284 50.7 129 33.3 294 27.2 185 29.7 29 31.0 383 35.5 192 37.0 199 33.7 635 43.1 296 37.2 86 15.1 104 49.0 193 53.9 295 33.6 184 38.0 90 20.0 52 25.0 249 27.3 277 47.3 122 62.3 525 37.5

48.0 22.2 14.1 0.7 0.0 5.5

0.0 59.3 46.5 18.9 57.6 0.0 18.5 24.4 0.0 6.1 10.2 3.5 5.4 2.4 7.0 10.3 7.6 1.6 4.0 3.0 2.7 11.6 0.0 8.3 11.9 8.2 13.3 0.0 4.0 5.8 0.0 6.3

820

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Liver (C22) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 313 420 35 388 92 122 182 330 623 651 1070 1041 415 66 491 778 395 61 219 264 285 202 177 194 1250 176 57 58 88 216 125 214 1029 40 58 223 506 634 825 239 907 1736 595 616 136 794 997 28 439 196 55 836 229 34 59 506 395 46 68 54 107 69 16.9 58.3 60.0 83.5 53.3 48.4 66.5 89.1 54.6 47.9 56.0 50.9 91.8 42.4 57.0 40.2 55.2 41.0 51.6 32.6 66.7 59.4 59.3 81.4 99.3 54.0 45.6 58.6 76.1 50.9 48.8 70.1 78.7 75.0 86.2 50.2 53.2 43.8 44.1 56.9 41.6 46.4 48.6 48.1 47.8 51.4 66.0 64.3 51.7 39.3 72.7 55.6 65.5 70.6 72.9 66.2 74.9 76.1 79.4 81.5 78.5 62.3 18.2 5.5 5.7 2.1 19.6 9.8 0.0 35.2 20.5 12.4 5.3 12.1 9.8 6.4 10.6 13.1 10.0 2.3 6.7 7.9 14.7 11.9 1.1 0.0 6.9 0.0 8.3 0.0 11.7 1.9 0.0 0.0 0.0 0.0 13.1 0.0 0.0 0.0 17.1 0.3 15.7 2.9 1.5 4.1 2.4 2.0 0.0 1.8 0.0 2.1 0.5 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 3.6 0.4 5.5 0.2 25.1 11.8 7.8 2.0 0.0 0.0 2.4 0.0 0.0 0.5 1.0 0.0 3.3 0.4 0.0 1.7 0.2 0.5 2.2 0.0 0.0 0.0 1.4 111.5 96.7 108.6 78.1 107.3 138.3 139.6 109.7 93.1 109.7 121.9 104.0 103.1 113.6 93.7 73.9 87.3 98.4 84.9 117.4 93.3 94.1 76.8 123.2 132.2 75.0 66.7 91.4 93.2 75.0 88.0 93.5 142.2 136.2 115.2 57.1 80.0 95.0 91.6 88.6 94.8 80.3 93.3 158.8 90.8 89.3 92.9 89.1 90.3 109.1 85.0 81.2 76.5 101.7 88.3 72.7 Female Cases MV(%) DCO(%) UB(%) MI(%) 251 299 17 250 61 117 152 159 269 565 793 667 168 37 146 332 187 31 99 112 135 76 78 98 705 50 22 20 37 64 31 72 484 28 23 163 673 425 540 155 607 912 401 366 114 512 378 6 189 72 19 292 85 18 18 247 171 17 21 27 65 18 20.3 57.2 58.8 77.2 32.8 29.1 58.6 89.3 40.9 46.2 54.1 48.4 85.1 24.3 44.5 34.9 52.4 19.4 49.5 25.9 51.9 43.4 44.9 65.3 97.4 38.0 59.1 80.0 81.1 46.9 71.0 69.4 74.6 64.3 73.9 37.4 34.5 34.4 35.7 49.7 38.6 38.6 37.9 37.4 47.4 44.9 60.8 83.3 42.3 43.1 57.9 49.7 57.6 88.9 77.8 59.9 74.3 64.7 71.4 74.1 81.5 66.7 17.5 3.3 5.9 2.4 21.3 17.1 1.3 48.3 21.9 14.8 10.7 16.2 8.9 15.1 10.7 25.8 16.2 8.9 16.3 9.2 28.2 25.5 2.0 0.0 5.0 0.0 17.2 0.0 13.9 0.0 0.0 0.0 0.0 0.0 12.8 0.7 0.6 0.0 16.3 0.1 13.3 4.2 0.0 2.7 1.8 2.1 0.0 3.0 0.9 0.0 0.0 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.9 0.4 4.9 0.0 23.2 14.5 7.3 2.2 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 3.4 1.2 0.0 0.0 0.4 2.3 0.0 4.8 3.7 0.0 5.6 104.8 100.7 135.3 89.2 131.1 * 167.7 181.6 108.2 * 96.3 110.1 115.1 109.0 145.8 100.0 132.4 93.7 106.3 116.1 81.8 173.2 106.7 128.9 91.0 162.2 182.7 80.0 72.7 85.0 113.5 92.2 96.8 101.4 206.4 187.0 125.8 32.7 93.2 110.2 104.5 96.2 116.8 92.3 120.2 152.6 106.3 114.6 183.3 102.6 141.7 179.8 117.8 92.9 144.4 83.3 89.1 90.6

0.4 9.1 5.7 4.6 1.7 4.2 19.5 8.9 15.1 3.7 0.9 2.0 3.6 3.2 0.0 1.8 4.5 14.0 2.9 20.3 10.7 2.3 6.5 1.5 1.9 0.0 4.3

0.6 8.5 5.2 4.3 4.5 3.8 23.0 8.2 21.9 7.0 0.6 4.0 0.0 3.7 0.0 5.3 6.5 21.2 0.0 22.2 13.4 2.9 5.9 0.0 3.7 1.5 11.1

78.3

116.7

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
763

821

Indices of data quality

Pancreas (C25)
Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 9 164 22 12 66 90 112 28 47 1315 39 141 341 81 56 18 5651 667 1058 302 223 50 5 285 2750 38 273 1178 283 892 115 1237 7730 627 552 1015 5484 1470 119 94 45 21 129 1006 1966 252 55 30 36 38 341 1182 940 1079 76 995 188 139 40 5626 464 5100 1741 467 1256 520 164 343 294 3509 482 2955 1549 893 1023 1360 402 949 116 196 44.4 33.5 59.1 16.7 19.7 43.3 73.2 32.1 66.0 36.0 17.9 36.9 24.9 39.5 91.1 88.9 55.4 60.3 56.1 53.3 52.5 70.0 80.0 56.1 52.9 57.9 66.3 74.0 67.5 76.0 81.7 75.1 78.0 79.3 76.3 80.8 77.6 79.0 78.2 83.0 80.0 71.4 81.4 78.7 79.2 75.0 80.0 80.0 80.6 89.5 79.8 79.4 78.1 84.4 96.1 83.5 75.5 74.1 85.0 75.4 75.0 75.4 76.4 76.9 76.3 85.4 86.0 85.4 73.1 80.3 79.0 80.5 80.1 79.1 71.8 74.4 70.4 76.1 65.5 77.6 0.0 0.0 0.0 0.0 0.0 3.3 9.8 7.1 0.0 0.0 0.0 0.7 0.0 0.0 1.8 0.0 17.7 0.4 0.1 0.0 0.0 2.0 0.0 1.4 36.1 0.0 0.0 3.5 3.5 3.5 4.3 4.5 3.4 2.7 4.5 2.6 3.5 1.8 2.5 2.1 0.0 4.8 1.6 1.5 3.4 6.3 1.8 3.3 2.8 2.6 3.8 2.7 3.0 0.7 0.0 0.8 2.7 1.4 2.5 1.3 1.7 1.2 1.6 1.7 1.5 1.2 0.6 1.5 0.7 1.5 1.5 1.6 2.3 1.5 6.6 2.1 1.2 2.4 3.4 3.6 Female Cases MV(%) DCO(%) UB(%) MI(%) 8 109 18 6 56 89 113 14 65 1449 41 182 337 102 49 28 5909 657 1156 332 230 38 5 287 2897 40 267 1265 325 930 105 1190 8080 650 646 1139 5594 1647 156 84 51 33 150 1100 2102 295 56 53 56 25 449 1132 908 1128 78 1033 210 159 42 5598 524 5010 1710 495 1198 504 183 314 320 3752 571 3103 1593 906 1062 1317 420 891 119 188 62.5 29.4 66.7 16.7 19.6 32.6 77.9 35.7 56.9 38.2 43.9 35.7 26.1 31.4 67.3 75.0 48.7 54.6 52.9 39.5 51.7 71.1 80.0 49.5 45.5 47.5 55.1 65.1 65.2 65.2 81.9 68.9 71.4 78.5 70.4 77.3 69.4 68.9 72.4 67.9 74.5 84.8 72.0 66.6 73.5 70.2 78.6 75.5 80.4 68.0 80.2 70.9 66.3 77.6 79.5 77.4 75.7 76.7 78.6 70.5 72.3 70.2 68.4 70.1 67.6 78.2 78.7 78.3 67.2 72.9 73.7 72.6 76.8 71.7 65.9 65.8 69.0 64.3 68.1 72.3 0.0 0.0 0.0 0.0 0.0 1.1 13.3 7.1 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 20.8 0.5 0.0 0.0 0.0 0.0 0.0 3.8 42.0 0.0 0.0 6.5 4.9 7.0 2.9 7.3 3.8 2.8 3.3 2.7 4.1 1.6 1.9 3.6 0.0 0.0 0.0 1.7 3.9 4.4 5.4 5.7 1.8 4.0 2.4 4.2 3.6 1.1 0.0 1.2 2.4 1.3 4.8 1.3 1.5 1.3 1.6 2.2 1.4 1.6 1.1 1.9 2.8 1.4 2.1 1.3 1.9 2.1 6.7 1.7 1.4 1.8 0.8 2.1 * * * *

5.5 13.6 51.1 13.4 50.0 27.7 27.0 20.5 14.9 27.9 22.2 0.0 4.6 0.7 5.6 5.6 0.0 0.0 4.9 5.2 0.0 7.0 8.1 8.5 8.1 0.9 4.5 1.5 1.1 1.1 1.3 1.6 2.9 2.5 1.1 0.0 4.8 1.6 3.5 1.2 0.4 0.0 0.0 0.0 0.0 1.8 1.4 3.9 3.1 0.0 3.2 8.5 10.1 2.5 9.3 11.2 9.1 5.3 4.9 5.3 3.3 3.7 2.6 7.5 4.7 7.1 4.2 3.5 3.8 3.3 1.8 3.2 1.2 2.6 1.5

24.4

15.6 23.2 56.2 8.0 57.1 33.8 28.9 19.5 21.4 29.4 36.3 0.0 5.9 0.8 5.9 7.5 0.0 0.0 5.6 7.2 0.0 9.4 9.0 6.5 9.9 1.0 5.7 3.1 2.2 3.6 2.5 3.3 7.8 6.4 3.6 5.9 3.0 6.0 9.2 2.3 3.7 0.0 1.9 5.4 4.0 2.7 1.8 5.3 3.5 2.6 3.5 4.8 5.0 4.8 10.2 10.5 10.3 7.2 5.3 8.0 4.2 3.8 4.1 7.8 6.0 10.2 5.3 3.0 3.6 3.6 3.2 2.6 3.5 1.7 3.2

35.8

118.9 92.9 75.0 157.4 92.7 110.3 112.1 102.3 90.1 125.0 99.0 91.5 97.6 98.0 93.3 270.0 60.0 95.4 99.6 89.5 96.7 103.7 103.9 103.9 86.1 98.4 92.0 85.3 90.6 80.0 95.7 90.5 100.0 73.6 93.3 92.4 87.7 90.9 70.0 111.1 94.7 88.9 94.8 93.3 91.6 94.7 91.8 84.6 82.0 110.0 91.6 91.6 92.3 98.4 93.8 100.3 93.5 99.4 91.5 93.5 91.5 89.0 92.8 100.3 94.0 98.2 92.6 90.8 93.6 86.2 91.8

110.1 104.4 107.1 116.9 92.7 95.1 106.6 104.2 84.3 119.9 98.5 88.3 95.7 99.7 90.9 289.5 140.0 103.1 98.0 107.5 111.6 99.9 100.9 100.3 87.6 98.3 92.9 87.7 93.7 80.9 96.3 93.3 98.1 87.3 97.1 93.3 94.9 107.1 75.5 94.6 96.0 88.0 95.9 94.5 95.2 96.2 96.0 89.0 91.2 97.6 92.5 84.9 93.9 102.6 100.0 103.8 92.7 87.4 94.9 92.5 94.8 96.3 95.5 103.8 100.1 97.0 96.4 95.2 96.7 91.6 96.8

822

*Important. See note on population page.

764

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Pancreas (C25) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 419 1813 2760 395 2334 1241 305 921 1614 150 1455 244 60120 6260 52183 2532 273 2188 458 20 149 278 5743 634 4925 2992 322 2633 952 906 3988 346 3587 304 7026 717 5767 18724 1048 1937 1390 14219 1047 277 765 4459 539 3845 381 182 1607 1080 517 1543 28 180 1006 91 172 1812 84 94 134 412 21 436 50 116 47 1446 1300 71 349 381 369 1119 733 3524 718 74.2 78.5 79.0 79.5 78.8 84.4 84.3 84.6 75.3 74.0 75.6 68.4 77.4 75.9 77.5 81.0 78.4 81.4 68.8 60.0 71.1 68.3 75.5 73.2 75.6 78.3 78.9 78.1 72.5 70.9 80.9 79.5 81.0 78.6 80.0 83.5 80.1 78.5 76.5 77.7 80.1 78.6 77.8 72.9 79.7 76.5 72.9 76.6 78.7 83.0 77.4 77.0 70.6 73.4 60.7 40.0 40.5 30.8 73.3 22.2 47.6 74.5 42.5 72.6 23.8 52.8 82.0 71.6 27.7 52.3 54.2 67.6 35.0 30.2 48.8 42.4 34.7 42.4 25.9 1.2 5.2 2.6 1.5 2.8 2.9 2.3 3.1 5.6 8.0 5.4 10.7 4.9 5.9 4.8 3.3 4.4 3.2 8.1 20.0 6.7 8.3 5.4 4.9 5.5 5.9 7.8 5.8 5.5 3.5 1.6 2.0 1.5 6.6 3.0 2.5 2.9 2.4 2.2 2.5 2.0 2.4 5.6 5.4 5.6 9.4 12.8 9.1 0.5 3.8 2.2 1.3 5.0 7.0 14.3 0.0 5.7 0.0 1.7 1.0 0.0 2.2 3.2 0.0 17.4 0.0 10.3 4.3 11.8 10.8 7.0 27.2 6.3 10.6 26.2 20.5 22.8 20.2 4.8 4.1 3.7 3.8 3.7 1.1 0.7 1.3 7.7 6.7 7.9 1.2 3.2 2.9 3.2 1.7 1.5 1.7 2.8 0.0 0.7 4.0 3.1 2.1 3.2 6.3 6.5 6.3 2.2 3.6 2.0 0.9 2.1 0.7 1.7 1.0 1.8 2.7 2.3 2.4 2.2 2.8 5.8 6.1 5.8 3.2 2.6 3.3 0.0 0.5 4.5 3.8 3.3 5.8 3.6 0.0 0.0 0.0 1.7 0.0 0.0 2.1 47.8 0.0 0.0 0.5 0.0 0.0 0.0 3.7 3.7 2.8 37.8 0.5 0.0 0.0 1.9 0.0 2.6 95.0 96.6 92.9 83.8 94.8 87.3 81.6 89.7 95.2 109.3 93.7 100.4 94.1 94.1 94.9 90.6 96.3 90.4 91.0 110.0 90.6 91.0 87.1 87.9 88.0 96.5 100.0 97.2 95.2 100.3 94.9 96.2 95.7 103.0 91.1 91.1 91.7 92.4 85.2 91.1 80.8 94.5 105.2 102.5 106.0 97.8 99.1 98.4 99.0 96.7 92.0 91.7 97.5 94.3 92.9 93.3 87.7 97.1 75.2 77.1 53.7 4.8 52.8 98.5 98.9 99.5 97.3 93.5 92.8 91.8 96.4 Female Cases MV(%) DCO(%) UB(%) MI(%) 417 2124 2860 467 2358 1360 357 993 1620 210 1399 233 63114 7539 53793 2885 363 2456 422 22 150 240 6762 972 5643 3192 404 2748 923 980 4149 434 3646 386 7256 832 5787 19530 1119 2209 1542 14516 1138 378 757 4479 564 3832 325 156 1617 1111 463 1660 17 134 797 82 122 1587 48 58 60 234 11 299 21 72 31 1373 1260 37 242 353 285 987 661 2874 546 66.9 68.9 72.0 76.4 71.0 79.7 81.2 79.1 66.7 73.8 65.8 58.4 70.7 71.7 70.3 74.5 73.6 74.3 62.1 68.2 64.0 60.4 68.6 69.5 68.3 73.2 69.1 73.6 65.9 61.0 73.7 72.1 73.8 69.7 73.5 77.2 72.7 72.0 77.9 72.8 75.7 71.0 72.3 70.9 73.1 70.1 69.3 70.1 72.0 83.3 67.7 68.9 63.3 66.0 76.5 50.0 35.8 25.6 82.8 21.6 41.7 63.8 38.3 53.4 18.2 48.5 90.5 73.6 38.7 47.0 49.0 67.6 27.3 26.9 44.9 35.5 29.7 36.1 25.8 4.1 9.1 3.1 1.5 3.4 3.0 2.2 3.3 6.5 5.7 6.7 12.4 6.1 5.9 6.2 5.0 4.7 5.1 14.9 13.6 8.7 18.8 6.1 4.2 6.5 9.0 10.6 8.7 4.7 5.7 2.5 2.3 2.6 6.0 4.4 3.7 4.6 3.6 2.3 3.5 3.2 3.8 5.4 3.4 6.3 12.0 12.6 12.1 1.8 1.3 3.0 1.8 4.3 8.1 11.8 0.0 5.9 0.0 1.6 1.3 0.0 8.3 4.7 0.0 23.7 0.0 12.5 3.2 13.3 11.6 2.7 35.5 9.9 14.4 30.1 25.1 27.0 22.7 5.3 5.9 4.6 3.2 5.0 1.1 0.6 1.3 9.6 5.7 10.3 2.1 3.8 3.4 3.8 2.9 3.6 2.8 3.8 0.0 4.7 3.8 3.7 4.1 3.6 6.5 7.7 6.4 2.1 4.7 2.6 2.5 2.5 1.3 2.2 1.3 2.4 3.2 2.1 2.4 2.7 3.5 6.9 7.9 6.5 2.9 2.8 2.9 1.5 0.6 6.1 5.9 3.0 8.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.2 45.0 0.0 0.0 0.7 0.0 0.0 0.0 3.7 3.7 5.4 37.2 2.0 0.0 0.0 1.1 0.0 2.2 95.4 98.7 94.7 88.4 96.4 87.4 84.3 88.5 98.6 96.2 99.3 97.0 94.8 92.9 96.0 92.5 85.7 94.7 97.9 81.8 93.3 103.3 85.9 83.0 86.7 99.3 96.3 100.7 94.0 99.5 97.5 92.2 99.4 97.7 93.0 87.7 95.2 93.7 84.7 90.5 78.3 96.9 100.3 95.2 102.4 94.4 100.2 94.3 91.1 99.4 93.5 93.2 104.8 94.2 117.6 107.5 * 92.1 * 68.0 76.6 * * 43.1 * 46.7 * 52.2 94.1 97.5 101.7 100.4 91.5 92.4 91.9 94.7 * * *

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
765

823

Indices of data quality

Pancreas (C25) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
766

Female Cases MV(%) DCO(%) UB(%) MI(%) 4709 411 294 149 154 244 43 1253 80 31 16 53 64 25 9 305 336 294 11 31 51 44 21 78 225 3397 232 90 1872 272 1050 1895 1368 3958 1958 438 2098 263 196 100 172 219 279 118 62 116 103 69 1028 1957 751 687 893 1021 476 66 916 103 275 171 510 303 86 609 255 77 1115 274 103 204 485 165 175 94 96 408 291 173 857 34.0 29.4 24.8 38.9 33.1 37.3 30.2 39.8 31.3 45.2 62.5 67.9 75.0 36.0 55.6 37.4 51.8 51.7 45.5 54.8 56.9 40.9 57.1 66.7 62.7 69.7 50.9 47.8 45.8 75.7 54.9 19.7 52.8 44.6 60.0 52.3 59.5 69.6 44.9 56.0 64.5 68.0 67.7 70.3 59.7 62.9 36.9 82.6 40.8 44.5 38.2 35.7 45.0 47.7 53.8 66.7 38.3 41.7 41.8 40.4 33.3 39.9 44.2 40.6 34.1 36.4 42.9 38.0 32.0 33.3 30.9 30.9 40.6 29.8 35.4 37.3 33.0 38.2 43.6 10.2 7.8 9.5 9.4 8.4 7.0 2.3 13.4 11.3 38.7 25.0 0.0 14.1 4.0 0.0 15.7 0.3 0.0 0.0 3.2 0.0 0.0 0.0 1.3 0.0 23.6 8.6 20.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.1 1.8 0.4 0.0 5.6 0.0 0.0 21.6 0.3 32.7 1.2 4.0 0.0 3.8 0.0 1.5 0.0 1.7 0.0 1.1 0.0 0.0 0.0 1.9 10.1 4.5 1.2 0.0 1.7 0.0 2.2 0.4 0.0 2.0 1.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 3.4 1.1 0.0 0.0 17.2 0.0 0.0 99.0 98.1 87.8 102.0 86.4 101.2 80.2 78.8 100.0 37.7 23.4

6464 592 359 194 193 361 36 1664 113 34 32 61 82 34 25 261 399 342 21 36 54 45 48 122 320 2732 214 99 2229 280 1026 2816 1555 4030 1746 466 1811 267 192 109 194 244 248 170 92 110 112 94 985 1686 638 655 818 1051 386 78 939 84 300 184 501 253 71 468 262 92 985 213 125 153 527 181 195 99 90 345 335 185 747

38.5 34.1 32.9 40.7 32.1 41.8 44.4 47.6 44.2 52.9 59.4 77.0 58.5 55.9 80.0 32.2 54.9 56.4 61.9 36.1 51.9 33.3 50.0 66.4 60.0 74.4 65.9 50.5 49.1 81.1 64.3 18.2 59.0 49.1 69.1 59.4 69.4 71.2 49.5 65.1 71.1 71.7 70.6 85.3 79.3 70.9 58.9 73.4 44.4 54.4 43.7 42.9 55.5 58.4 67.1 79.5 43.0 48.8 47.0 45.1 41.1 41.9 39.4 54.5 35.9 44.6 50.6 47.4 28.0 43.8 42.3 40.9 48.7 36.4 44.4 47.2 42.7 52.4 48.9

8.5 9.1 8.1 8.2 5.2 4.4 2.8 11.0 5.3 44.1 25.0 1.6 14.6 0.0 0.0 11.1 0.0 0.0 0.0 0.0 0.0 6.7 4.2 0.8 0.0 20.1 4.2 12.1

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.1 1.9 0.4 0.0 2.0 0.0 0.0 18.6 0.2 30.7 0.9 3.1 0.0 2.7 0.0 0.5 0.0 4.6 0.0 3.2 0.0 0.0 0.0 0.9 9.6 8.2 0.9 0.0 2.1 0.0 1.4 0.3 0.0 1.8 1.2 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.6 2.0 0.0 0.3 19.1 0.0 0.0

98.7 101.9 94.4 96.9 86.0 97.2 116.7 76.2 97.3 8.2 54.9

103.3 9.3 86.7 72.9 63.9 101.3 92.5 70.7 96.5 140.1 83.7 89.8 96.7 102.4 100.2 94.8 116.5 104.7 118.3 112.9 123.8 115.3 170.0 170.7 151.8 104.5 224.5 211.3 73.9 93.3 73.0 99.5 88.6 97.9 97.4 101.7 91.7 92.0 91.8 101.4 88.1 88.7 91.7 103.1 87.9 91.3 89.7 89.6 109.2 92.6 101.7 87.7 102.0 87.5 96.8 93.4 90.8 90.4

101.2

* * *

3.9 * 106.8 * 128.6 44.9 * * 99.6 102.6 103.3 96.7 * * 144.8 84.5 * 90.8 97.7 102.7 95.0 93.2 116.0 98.5 142.0 111.6 139.3 110.0 210.2 219.4 138.8 116.5 276.8 219.1 79.2 96.9 78.7 98.7 93.5 100.4 125.8 98.5 100.0 93.5 84.2 95.3 94.4 105.8 92.8 99.6 99.6 97.0 84.3 87.4 94.6 92.2 101.8 96.0 93.6 91.1 95.8 92.1 85.0 89.0

25.8 10.2 9.2 0.8 0.9 3.9

26.6 14.5 11.6 1.0 0.9 5.7

0.0 41.6 30.0 17.1 38.9 21.9 16.1 19.2 0.0 5.9 0.0 3.3 2.2 0.6 2.4 5.6 2.8 1.5 2.2 1.2 0.9 4.0 0.7 3.6 3.9 4.1 5.1 1.1 2.6 0.6 0.0 2.1

0.0 44.7 37.9 22.8 48.2 28.6 19.3 22.3 0.0 6.9 3.9 6.5 0.6 2.2 3.3 2.3 4.8 1.2 5.2 1.9 1.8 5.8 1.0 6.0 10.9 3.4 5.3 4.2 4.4 2.4 0.6 2.9

824

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Pancreas (C25) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 853 1175 97 1403 243 383 386 265 702 1338 1143 1650 561 66 281 530 378 64 160 149 244 208 129 170 2162 148 79 59 183 134 92 175 3716 240 193 799 737 1114 1886 702 2200 4002 1537 1525 380 1418 1586 28 862 403 118 1253 397 43 17 815 365 35 45 48 123 92 21.2 50.3 30.9 60.9 39.5 54.3 59.6 78.5 46.7 52.1 59.6 49.2 91.8 39.4 43.4 53.0 51.9 50.0 40.0 51.7 55.3 68.8 55.0 44.1 87.5 64.9 64.6 74.6 78.7 60.4 72.8 76.6 64.8 50.4 74.6 42.3 37.6 31.1 38.0 43.7 33.0 40.4 38.3 43.1 38.4 48.2 63.0 57.1 49.3 59.6 62.7 54.8 65.0 72.1 70.6 49.6 73.2 71.4 77.8 70.8 71.5 76.1 9.1 2.8 7.2 1.7 16.0 6.5 0.3 30.8 18.0 21.2 3.2 13.6 6.4 7.0 8.2 9.4 12.5 0.7 6.6 2.9 7.8 20.0 2.7 0.0 1.7 1.6 9.7 2.2 6.3 1.1 0.0 0.0 0.1 0.0 6.8 0.0 0.4 0.0 12.9 0.3 1.0 5.0 3.0 1.1 1.1 1.9 1.6 1.9 0.0 0.4 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.3 5.3 0.0 34.0 13.2 6.8 2.1 0.0 0.0 1.6 0.0 0.0 0.5 0.2 0.0 5.4 1.0 0.0 0.0 0.5 0.8 0.0 0.0 0.0 0.8 1.1 102.7 89.9 121.6 96.3 91.0 94.6 115.5 204.5 106.4 95.7 114.2 95.5 101.2 92.4 131.1 90.6 89.0 89.1 94.4 106.0 101.6 93.3 81.4 147.1 149.2 77.7 87.3 98.3 90.7 96.3 100.0 106.3 115.3 125.9 95.5 92.1 96.8 94.4 98.7 105.5 91.2 89.8 94.5 113.4 98.8 96.9 92.9 91.9 90.6 99.6 93.5 94.7 125.6 147.1 94.4 87.1 Female Cases MV(%) DCO(%) UB(%) MI(%) 807 1033 125 1633 247 363 365 213 620 1668 840 1317 594 52 269 484 281 50 136 141 176 166 138 165 2336 144 84 50 163 141 81 191 3781 202 186 803 761 1188 2093 718 2258 4283 1587 1572 369 1630 1594 17 788 389 138 1200 417 45 19 780 384 27 37 68 159 73 20.0 48.4 30.4 50.0 40.1 44.1 54.5 73.7 42.3 45.6 59.8 47.6 87.4 36.5 32.3 45.9 52.0 32.0 30.9 40.4 52.8 57.2 37.7 41.2 86.2 63.9 52.4 62.0 71.2 52.5 49.4 62.3 55.7 48.5 65.6 34.0 28.3 25.5 31.3 33.3 26.9 34.3 30.6 34.3 33.1 41.7 58.2 52.9 42.1 51.4 50.0 46.0 51.3 62.2 63.2 40.3 76.0 85.2 78.4 75.0 78.0 68.5 8.9 3.4 9.6 2.7 14.6 5.8 1.1 30.2 17.3 24.4 4.9 7.7 10.8 12.0 10.3 18.0 9.6 1.4 11.4 5.4 14.5 20.0 4.9 2.4 2.0 3.1 14.9 0.0 20.4 1.0 0.0 0.0 0.0 0.0 8.8 0.0 0.0 0.0 13.6 0.1 0.8 7.7 1.9 1.9 1.7 1.1 0.0 0.0 0.0 1.7 0.6 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.6 0.0 5.9 0.1 38.9 17.2 6.4 1.9 0.0 0.0 1.4 0.0 0.0 0.5 0.5 0.0 6.8 1.9 0.0 0.0 0.4 0.3 0.0 0.0 0.0 0.6 0.0 98.3 87.6 93.6 97.6 99.2 * 96.1 136.4 235.7 * 96.5 99.5 119.5 94.8 99.3 105.8 133.8 92.1 102.3 88.0 95.6 117.7 99.4 103.0 84.1 145.5 162.8 82.6 86.9 106.0 96.3 112.1 86.4 103.1 124.1 130.6 94.1 94.2 98.0 93.6 99.3 109.0 93.9 91.9 96.1 106.8 96.3 93.3 94.1 89.6 94.1 90.6 95.2 88.2 115.6 89.5 99.0 85.7

0.8 9.8 5.1 4.0 5.3 4.7 16.5 8.7 15.3 3.7 0.8 2.6 3.6 3.2 0.0 0.8 3.3 13.9 0.0 23.5 10.1 2.7 2.9 6.7 0.0 3.3 0.0

0.7 13.7 6.0 3.9 3.6 4.9 18.2 12.4 18.1 3.3 1.0 4.0 0.0 4.7 0.0 2.9 4.9 19.7 8.9 31.6 13.2 2.3 0.0 2.7 4.4 0.6 5.5

93.5

87.7

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
767

825

Indices of data quality

Larynx (C32)
Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 53 98.1 162 95.1 51 100.0 14 57.1 55 69.1 70 95.7 184 88.6 57 87.7 108 96.3 2542 81.5 10 90.0 181 85.1 233 90.1 40 90.0 59 98.3 17 100.0 3092 291 497 140 134 106 4 164 1577 38 141 947 240 696 51 719 3868 192 392 513 2724 722 88 36 11 5 75 476 1041 196 19 15 6 13 200 575 470 631 70 550 151 128 20 4264 417 3786 1483 396 1076 336 120 212 172 2323 421 1861 1107 530 995 1022 339 680 113 147 96.6 97.6 97.4 96.4 97.8 99.1 100.0 98.8 95.4 97.4 99.3 97.4 97.5 97.3 100.0 97.2 98.2 99.0 97.7 98.6 98.2 97.8 98.9 100.0 100.0 100.0 97.3 97.9 98.8 98.0 94.7 100.0 100.0 100.0 98.0 99.5 96.6 98.7 97.1 98.9 96.7 98.4 85.0 95.9 94.7 96.1 98.2 98.0 98.3 99.7 100.0 99.5 95.9 97.4 97.6 97.3 98.4 98.3 97.0 98.0 97.6 98.2 97.3 98.6 0.0 0.0 0.0 0.0 0.0 0.0 5.4 5.3 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.2 0.0 0.0 0.0 0.0 0.6 3.9 0.0 0.0 1.4 2.5 1.0 0.0 1.0 0.4 0.5 0.5 0.0 0.4 0.3 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 5.3 0.0 0.0 0.0 0.0 0.2 0.4 0.0 0.0 0.0 2.0 0.8 10.0 0.2 0.2 0.2 0.2 0.3 0.2 0.0 0.0 0.0 0.6 0.3 0.0 0.4 0.0 0.2 0.8 0.4 0.6 0.3 0.9 0.7 Female Cases MV(%) DCO(%) UB(%) MI(%) 3 100.0 14 85.7 2 100.0 6 66.7 8 75.0 5 56 9 16 486 1 47 14 7 11 6 615 76 88 27 36 17 1 31 300 6 33 225 46 176 18 170 967 27 101 78 750 167 23 7 4 0 14 118 245 44 1 1 2 1 29 164 136 180 16 162 32 23 9 1052 96 943 346 91 253 86 37 49 37 538 118 406 328 137 288 267 74 191 25 41 100.0 78.6 88.9 100.0 74.5 100.0 68.1 92.9 85.7 100.0 100.0 95.0 94.7 97.7 100.0 97.2 100.0 100.0 93.5 93.0 100.0 97.0 97.3 93.5 98.9 100.0 96.5 96.9 100.0 100.0 100.0 96.0 98.8 100.0 100.0 100.0 0.0 100.0 98.3 96.7 100.0 100.0 100.0 100.0 100.0 100.0 95.1 95.6 97.8 100.0 98.1 93.8 95.7 88.9 97.0 96.9 96.9 97.1 97.8 96.8 98.8 100.0 98.0 97.3 96.7 96.6 96.6 97.6 99.3 96.9 97.4 95.9 97.9 92.0 97.6 0.0 0.0 0.0 0.0 0.0 0.0 19.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.0 0.0 0.0 1.8 2.2 1.1 0.0 1.8 0.6 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 1.0 0.7 1.4 0.5 0.0 0.0 * * * *

3.1 14.5 4.3 5.4 5.3 0.0 6.8 0.0 3.3 3.4 5.0 0.0 0.4 0.0 0.6 0.0 0.0 0.0 0.6 0.5 0.0 0.0 0.7 0.0 1.0 0.0 0.7 0.7 0.0 0.5 1.0 0.7 1.0 0.0 0.0 0.0 0.0 2.7 1.1 0.5 1.0 0.0 0.0 0.0 0.0 1.0 0.2 1.9 0.2 0.0 0.2 0.7 0.8 0.0 3.0 4.3 2.8 1.0 1.3 0.9 0.0 0.0 0.0 2.3 1.9 2.4 1.8 0.8 1.1 0.5 0.6 0.6 0.6 0.0 0.0

9.9

7.1 12.5 0.0 1.8 11.1 0.0 4.9 0.0 8.5 7.1 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.4 2.2 0.0 0.0 0.6 0.9 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 2.4 2.2 0.6 0.0 0.6 6.3 4.3 11.1 2.0 1.0 2.1 1.7 1.1 2.0 1.2 0.0 2.0 2.7 2.4 2.5 2.5 1.5 0.0 1.0 1.1 1.4 1.0 4.0 2.4

28.6

72.9 40.8 36.8 39.8 47.3 80.0 48.6 61.4 45.0 53.0 42.7 35.4 39.4 40.7 41.8 44.3 25.0 44.5 45.7 13.2 43.3 28.6 33.3 27.3 25.5 29.6 31.7 30.2 38.3 28.5 31.7 30.6 40.9 30.7 29.6 36.6 36.7 42.1 6.7 16.7 46.2 34.5 38.1 24.9 30.7 37.1 30.5 53.0 57.0 35.0 28.8 43.2 27.5 29.0 43.4 24.0 36.0 52.5 27.4 29.1 30.0 40.1 28.2 27.0 30.9 29.4 32.5 38.6 29.3 27.4 31.3

220.0 12.5 43.8 28.6 300.0 63.8 114.3 28.6 34.1 42.4 35.5 39.8 37.0 30.6 23.5 48.4 48.0 16.7 42.4 27.6 32.6 26.7 16.7 30.6 35.9 25.9 47.5 23.1 36.3 35.9 60.9 7.1 36.4 36.7 45.5 50.0 100.0 37.9 34.1 30.1 32.8 50.0 30.9 56.3 65.2 33.3 29.4 30.2 29.5 25.7 25.3 26.1 27.9 27.0 28.6 32.4 34.4 42.4 32.8 26.8 29.2 25.0 26.2 32.4 23.6 48.0 24.4

826

*Important. See note on population page.

768

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Larynx (C32) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 244 96.7 1122 97.1 1744 96.5 312 97.1 1411 96.3 787 98.7 243 98.8 535 98.7 1163 96.2 130 94.6 1027 96.4 145 97.2 39169 97.2 5208 96.7 33037 97.2 1522 98.1 242 98.8 1246 98.0 228 96.1 4 100.0 70 95.7 148 95.9 3308 96.7 459 94.8 2778 97.0 2089 96.8 260 95.8 1778 96.9 664 94.6 451 98.0 2577 98.1 283 97.9 2254 98.1 202 97.0 3811 98.6 544 98.9 3062 98.5 10735 98.2 328 99.1 1512 98.1 742 98.0 8052 98.2 911 97.6 281 96.8 624 98.1 3200 96.0 486 95.7 2669 96.1 126 100.0 103 99.0 729 97.8 472 98.3 488 98.2 874 97.0 25 92.0 273 86.8 958 94.7 14 100.0 90 80.0 679 86.7 156 96.8 71 97.2 419 86.2 1546 79.1 44 84.1 1341 73.0 313 95.2 370 84.1 133 96.2 766 92.2 656 93.8 89 95.5 113 92.0 96 84.4 194 94.3 354 94.1 258 96.5 926 83.7 191 94.8 1.2 1.1 1.4 1.6 1.3 0.6 0.4 0.7 2.3 3.1 2.2 1.4 1.4 1.8 1.4 0.6 0.4 0.6 1.8 0.0 1.4 2.0 1.3 3.3 1.0 2.2 3.5 2.1 1.5 1.1 0.8 0.4 0.8 3.0 0.6 0.2 0.7 0.6 0.0 0.4 0.9 0.7 0.8 0.7 0.6 2.0 3.1 1.9 0.0 1.0 1.1 0.6 1.0 1.0 4.0 0.0 0.3 0.0 3.3 0.7 0.0 1.4 1.2 0.0 10.4 0.0 4.3 1.5 1.2 0.8 1.1 5.3 3.1 1.5 1.1 0.8 6.8 3.1 0.4 1.0 1.4 1.0 1.5 0.1 0.4 0.0 0.9 1.5 0.8 1.4 0.7 0.8 0.6 0.5 0.4 0.5 0.0 0.0 0.0 0.0 1.0 0.9 1.0 0.8 0.8 0.8 0.8 0.2 0.3 0.0 0.3 0.0 0.1 0.2 0.1 0.4 0.3 0.5 0.3 0.3 1.3 2.1 1.0 1.3 1.0 1.2 0.0 0.0 0.1 0.0 0.2 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 1.4 0.0 0.0 0.0 0.0 0.0 0.8 3.1 2.6 1.1 2.7 5.2 0.0 0.0 0.4 0.0 0.5 28.3 35.4 31.1 42.0 28.8 31.0 40.3 26.5 29.1 36.2 28.3 24.8 30.6 41.5 29.3 30.6 40.5 28.7 30.7 125.0 31.4 29.1 34.6 53.2 31.9 31.2 40.4 30.7 28.5 31.9 31.2 41.0 30.3 38.1 31.1 43.0 29.1 31.3 31.7 40.3 29.2 29.9 27.2 36.3 23.4 30.8 38.5 29.7 28.6 28.2 32.1 32.2 28.9 27.9 76.0 63.0 40.1 38.9 39.6 10.6 41.3 4.5 38.9 34.1 24.8 38.5 16.0 22.0 25.6 36.3 27.2 Female Cases MV(%) DCO(%) UB(%) MI(%) 76 315 508 95 408 247 75 171 272 41 228 37 10149 1407 8548 414 65 345 68 1 9 56 996 172 817 559 85 462 184 117 665 107 549 57 1013 165 813 2848 53 403 129 2243 204 50 152 739 107 623 37 36 191 121 129 235 4 22 78 2 17 80 9 8 47 185 1 170 54 65 7 127 115 9 14 10 14 25 14 75 10 98.7 96.8 97.4 98.9 97.1 98.8 100.0 98.2 97.1 92.7 97.8 100.0 96.8 96.8 96.8 97.1 100.0 96.5 97.1 100.0 88.9 98.2 96.6 94.2 97.1 95.9 95.3 95.9 91.8 98.3 98.2 99.1 98.0 98.2 98.4 100.0 98.3 97.4 98.1 99.3 99.2 97.0 98.0 98.0 98.7 94.6 95.3 94.4 100.0 97.2 96.3 97.5 98.4 97.9 100.0 86.4 92.3 100.0 94.1 77.5 100.0 87.5 80.9 74.6 100.0 71.8 94.4 69.2 85.7 89.0 90.4 88.9 85.7 70.0 85.7 88.0 71.4 78.7 70.0 0.0 1.0 0.6 0.0 0.7 0.8 0.0 1.2 1.1 2.4 0.9 0.0 1.4 1.6 1.4 1.9 0.0 2.3 1.5 0.0 11.1 0.0 0.9 2.9 0.5 1.4 1.2 1.5 3.3 0.0 0.9 0.9 0.9 1.8 0.6 0.0 0.7 1.0 0.0 0.2 0.8 1.2 1.0 2.0 0.0 3.0 3.7 2.9 0.0 0.0 2.1 0.8 0.8 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.4 0.5 0.0 15.3 0.0 9.2 0.0 3.1 2.6 11.1 14.3 0.0 7.1 4.0 7.1 13.3 20.0 1.3 1.6 1.0 1.1 1.0 0.0 0.0 0.0 1.1 4.9 0.4 0.0 0.8 0.9 0.8 0.2 0.0 0.3 1.5 0.0 0.0 1.8 1.4 2.3 1.2 1.6 2.4 1.5 1.1 0.0 0.5 0.0 0.5 0.0 0.2 0.0 0.1 0.5 0.0 0.2 0.0 0.5 0.5 0.0 0.7 1.9 0.0 2.2 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.1 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 36.8 33.7 31.5 25.3 32.6 30.8 24.0 33.3 28.3 36.6 27.2 24.3 32.0 37.0 31.5 35.7 33.8 36.5 38.2 100.0 30.4 31.1 40.7 29.3 37.9 43.5 37.9 28.3 33.3 34.0 44.9 32.1 45.6 34.0 30.9 34.9 32.9 26.4 33.5 27.1 33.5 28.9 46.0 23.0 31.1 36.4 30.7 32.4 27.8 41.4 47.9 38.8 31.1 150.0 104.5 * 35.9 * 58.8 62.5 * * * 31.9 * 46.5 33.5 21.4 21.4 28.0 100.0 42.7 50.0 * * *

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
769

827

Indices of data quality

Larynx (C32) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
770

Female Cases MV(%) DCO(%) UB(%) MI(%) 408 58 27 12 12 31 7 85 5 4 3 11 16 6 38 65 27 23 2 2 23 20 10 18 41 167 12 3 80 47 133 151 166 259 228 27 67 24 18 15 16 44 32 32 11 10 11 13 48 53 81 36 66 78 31 10 103 8 20 20 49 28 3 59 29 18 114 12 3 12 48 21 13 4 11 37 23 7 88 64.0 72.4 85.2 100.0 66.7 71.0 100.0 62.4 80.0 25.0 100.0 72.7 87.5 83.3 100.0 76.9 96.3 95.7 100.0 100.0 87.0 80.0 80.0 88.9 92.7 94.0 100.0 100.0 98.8 100.0 97.7 65.6 77.7 93.4 98.2 92.6 100.0 100.0 94.4 100.0 100.0 100.0 96.9 100.0 100.0 100.0 100.0 92.3 83.3 92.5 84.0 77.8 92.4 83.3 100.0 100.0 92.2 100.0 90.0 90.0 79.6 96.4 100.0 91.5 100.0 94.4 93.9 100.0 66.7 91.7 93.8 71.4 84.6 100.0 90.9 100.0 82.6 85.7 96.6 21.8 17.2 0.0 0.0 25.0 19.4 0.0 28.2 20.0 75.0 0.0 0.0 12.5 0.0 0.0 15.4 0.0 0.0 0.0 0.0 0.0 5.0 10.0 5.6 0.0 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.6 0.0 0.0 0.0 0.0 2.3 0.7 15.7 1.2 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.2 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 13.0 0.0 0.0 101.0 86.2 74.1 58.3 116.7 61.3 21.4 82.4 80.0

3999 84.6 382 83.8 256 89.1 111 88.3 122 97.5 203 87.2 48 70.8 916 85.0 67 85.1 24 91.7 45 93.3 84 97.6 70 94.3 22 100.0 267 97.4 334 83.8 340 98.8 294 99.0 19 94.7 27 100.0 116 88.8 41 82.9 100 94.0 211 93.4 875 95.5 1376 128 65 2908 369 1322 2647 2001 2289 975 359 515 220 202 124 183 285 276 434 169 169 85 182 523 745 351 381 402 474 262 29 502 92 325 168 473 317 71 448 241 178 924 179 55 206 404 271 151 74 94 343 312 166 761 95.2 96.9 92.3 96.4 99.5 98.3 82.8 85.9 96.5 98.8 93.9 98.8 99.1 99.5 100.0 99.5 100.0 98.9 100.0 100.0 95.9 98.8 100.0 91.0 95.4 82.1 94.0 91.0 83.3 98.1 100.0 95.4 97.8 89.8 95.2 92.0 94.3 90.1 96.9 99.2 87.1 97.4 96.1 94.5 94.2 94.3 67.2 95.4 89.2 93.6 96.8 86.5 95.8 98.2

6.3 4.7 3.1 2.7 0.0 2.0 2.1 8.1 4.5 8.3 2.2 1.2 1.4 0.0 0.0 5.4 0.0 0.0 0.0 0.0 0.0 7.3 5.0 0.9 0.0 4.4 2.3 4.6

0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 1.5 0.0 0.0 1.5 0.0 0.0 1.5 0.2 8.5 0.5 0.9 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 1.2 0.0 0.0 1.9 0.0 0.0 0.3 0.0 0.8 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 11.5 0.0 0.0

64.1 67.5 57.4 50.5 55.7 62.1 65.6 38.2 65.7 17.9 7.1

31.3

56.8

63.0

* * *

78.0 56.0 23.7 26.7 56.7 41.4 33.8 87.5 40.4 59.4 61.5 55.7 48.3 61.3 32.2

* 65.0 * 320.0 22.2 * 68.3 * 58.7 50.0 33.3 93.8 * * 41.4 74.8 * 53.6 46.3 55.7 37.0 46.3

11.0 5.5 1.9 0.0 0.0 0.2

26.5 6.6 3.9 0.0 0.0 0.0

0.0 6.5 4.2 3.7 5.5 3.0 10.5 1.1 0.0 1.2 0.0 2.2 2.4 0.2 0.3 1.4 0.7 0.0 3.9 0.3 0.0 1.8 1.0 1.2 2.6 2.0 4.1 0.0 2.0 0.0 0.0 0.5

0.0 12.5 7.5 3.7 22.2 3.0 9.0 0.0 0.0 1.0 0.0 5.0 5.0 0.0 0.0 0.0 1.7 0.0 0.0 1.8 0.0 0.0 0.0 2.1 0.0 7.7 0.0 0.0 0.0 4.3 0.0 1.1

O 77.1 34.0 32.1 25.0 40.9 44.9 45.2 10.0 46.6 37.5 40.0 50.0 34.7 35.7 66.7 35.6 13.8 9.3 34.2 66.7 66.7 75.0 27.1 23.8 30.8 50.0 34.1 43.2 39.1 57.1 31.8

73.8 30.7 29.1 15.7 46.0 53.2 46.9 34.5 47.8 45.7 31.1 36.9 38.5 43.2 19.7 29.2 32.0 33.7 42.9 42.5 49.1 27.7 32.7 48.7 47.7 39.2 35.9 35.9 41.7 37.3 34.6

828

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Larynx (C32) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 589 88.5 940 93.4 70 98.6 534 99.4 223 79.4 544 90.4 450 97.3 702 97.3 813 88.6 818 83.7 2122 87.2 1391 93.7 516 99.0 107 93.5 648 97.2 1042 97.7 475 95.4 92 92.4 208 95.7 323 98.1 535 96.1 282 98.9 228 93.9 508 97.0 775 99.9 78 100.0 33 90.9 48 97.9 74 98.6 94 97.9 71 100.0 108 100.0 2868 99.4 204 98.5 180 98.3 328 96.3 429 93.7 783 95.3 1271 96.6 295 95.3 970 87.2 1745 90.1 720 95.0 864 96.9 270 95.2 1237 97.4 931 34 492 172 69 596 226 23 19 330 183 10 15 22 39 88 97.0 97.1 94.1 94.2 98.6 95.6 98.7 91.3 84.2 95.5 99.5 100.0 100.0 100.0 100.0 98.9 2.9 0.4 0.0 0.0 5.4 2.6 0.4 9.8 5.9 5.5 0.6 1.9 1.4 0.4 2.1 2.2 1.9 0.3 1.7 1.1 3.9 2.4 0.0 3.0 2.1 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 3.1 0.0 0.1 0.0 5.4 0.1 0.4 0.4 0.9 0.6 0.5 0.8 0.0 0.5 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.2 1.0 0.0 1.4 3.3 2.5 0.1 0.0 0.0 0.2 0.0 0.0 0.2 0.0 0.0 1.2 0.0 0.0 5.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 67.6 63.9 42.9 32.4 60.5 47.8 57.6 68.5 66.1 96.5 55.6 70.5 53.3 38.3 54.5 41.7 52.1 38.0 58.7 62.5 44.5 52.5 37.3 43.5 29.5 26.9 33.3 33.3 44.6 35.1 26.8 29.6 34.2 34.4 36.6 39.6 37.5 37.0 33.6 35.8 38.6 35.6 38.5 35.9 38.2 43.4 44.1 36.0 50.6 31.4 39.1 36.3 34.8 78.9 37.3 21.3 Female Cases MV(%) DCO(%) UB(%) MI(%) 40 54 9 96 43 57 88 31 44 64 212 87 56 4 21 57 22 0 3 5 20 8 5 15 162 13 5 7 16 13 8 23 526 31 29 72 107 184 315 59 188 357 153 158 66 301 114 5 42 27 12 89 35 3 1 48 27 1 0 8 7 10 80.0 92.6 100.0 95.8 83.7 93.0 96.6 100.0 72.7 76.6 87.7 94.3 98.2 75.0 95.2 96.5 100.0 0.0 100.0 100.0 90.0 100.0 100.0 93.3 100.0 84.6 100.0 100.0 100.0 100.0 100.0 95.7 99.6 100.0 100.0 97.2 92.5 94.0 96.2 98.3 81.4 84.9 91.5 94.3 92.4 97.3 91.2 100.0 97.6 96.3 100.0 91.0 97.1 100.0 100.0 95.8 96.3 100.0 0.0 100.0 85.7 100.0 10.0 1.9 0.0 0.0 0.0 0.0 0.0 22.7 5.7 5.7 1.8 25.0 4.8 1.8 0.0 0.0 0.0 0.0 5.0 0.0 0.0 6.7 0.0 0.0 0.0 0.0 0.0 0.0 4.3 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 10.9 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 1.1 0.0 0.0 7.4 3.9 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 62.5 68.5 22.2 41.7 26.2 * 41.7 64.8 100.0 * 75.0 95.3 53.8 56.3 51.8 50.0 63.5 29.8 22.7 33.3 200.0 15.0 50.0 40.0 53.3 27.8 61.5 40.0 28.6 43.8 23.1 25.0 21.7 39.2 37.9 48.6 36.4 41.3 32.4 44.1 46.8 49.0 49.7 50.6 42.4 38.5 46.5 60.0 64.3 14.8 34.7 44.9 31.4 66.7 43.8 11.1

0.3 0.7 0.4 0.6 1.0 1.0 4.8 2.4 1.4 0.4 0.4 0.0 0.0 0.2 0.0 0.0 1.2 0.0 8.7 10.5 0.9 0.0 0.0 0.0 0.0 0.0 0.0

0.0 0.9 0.0 0.6 1.7 0.0 7.3 4.6 1.9 0.0 0.0 1.8 0.0 2.4 0.0 0.0 1.1 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0

18.2

10.0

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
771

829

Indices of data quality

Lung (C33-34)
Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 374 541 335 46 146 379 500 154 266 6525 100 711 810 214 156 52 40042 3948 6580 2196 1850 837 34 2329 20105 307 1856 10879 1969 8849 744 8606 46192 3838 3728 3847 34497 8531 890 565 394 97 565 5650 10878 1697 357 367 184 195 1327 6474 5102 6670 443 6176 1141 886 221 43150 3357 39440 15518 3314 12103 3682 1105 2519 1913 24478 3560 20524 13811 6363 12143 10320 2882 7389 895 1478 95.7 82.6 96.7 65.2 44.5 69.4 88.0 59.1 79.7 66.9 51.0 55.3 54.9 69.6 92.3 75.0 78.8 83.8 82.1 79.5 82.1 91.5 97.1 76.9 76.0 86.3 77.0 86.5 85.5 86.7 90.5 89.0 90.4 93.1 91.7 91.9 89.7 90.0 90.3 92.2 93.7 93.8 92.9 89.0 92.3 92.2 94.1 91.3 91.3 96.9 92.6 92.0 85.9 92.1 92.1 92.1 87.6 88.4 87.3 87.2 85.7 87.3 87.9 87.0 88.1 91.2 90.8 91.3 84.8 89.6 89.2 89.6 90.3 88.4 87.3 88.8 86.8 89.6 87.5 89.6 0.0 0.0 0.0 0.0 0.0 3.7 5.8 1.3 0.0 0.0 0.0 0.0 0.0 0.0 2.6 0.0 9.8 0.1 0.1 0.0 0.0 0.2 0.0 0.9 19.3 0.0 0.1 3.6 4.0 3.5 2.7 3.1 1.7 1.1 1.1 1.8 1.7 0.8 1.3 1.2 1.0 0.0 0.9 0.6 1.4 0.8 1.7 0.8 2.2 1.0 2.0 1.5 2.1 0.6 0.7 0.6 2.5 1.9 2.3 0.8 0.9 0.8 0.6 0.4 0.7 0.5 0.0 0.6 0.4 0.8 1.0 0.8 0.7 0.8 3.2 0.6 0.5 0.6 0.6 0.4 Female Cases MV(%) DCO(%) UB(%) MI(%) 37 86.5 174 75.9 17 100.0 40 70.0 59 61.0 106 307 71 173 3247 51 412 364 136 74 52 30202 3097 5444 1777 1133 404 23 1597 15202 219 1306 6475 997 5430 586 6977 40142 2420 2582 2941 31947 7758 684 377 170 89 479 5687 9142 1174 263 187 112 116 982 6156 4288 5844 324 5489 831 611 203 33649 1840 31524 9874 1722 8086 2847 723 2089 1408 18851 2509 16117 9897 4518 8305 6723 1501 5186 487 1180 70.8 85.7 54.9 77.5 66.6 41.2 56.8 52.2 66.2 89.2 78.8 78.4 83.1 82.3 81.4 82.6 94.6 95.7 77.5 74.8 84.0 79.9 85.9 85.9 85.9 87.7 89.3 88.3 92.5 90.9 90.5 87.6 87.5 88.2 91.5 92.9 91.0 90.2 86.5 90.7 91.9 93.9 94.1 91.1 94.8 91.9 89.8 85.1 90.6 92.0 90.5 86.4 86.4 87.7 87.5 89.1 87.4 86.6 86.8 86.6 90.4 90.9 90.2 83.5 88.5 87.6 88.6 88.9 86.1 86.5 87.0 86.2 87.2 87.5 87.1 0.0 0.0 0.0 0.0 0.0 3.8 5.9 2.8 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 10.1 0.2 0.1 0.0 0.0 0.0 0.0 1.1 19.9 0.0 0.1 3.8 4.4 3.7 3.2 2.8 1.9 1.5 1.0 1.8 2.0 0.6 0.4 1.1 1.8 1.1 0.8 0.5 1.7 1.2 3.0 1.1 2.7 0.0 1.6 1.9 1.9 0.5 0.3 0.5 2.0 1.8 1.5 0.7 0.7 0.7 0.8 0.8 0.8 0.6 0.7 0.6 1.1 0.6 0.9 0.6 0.9 1.0 3.0 0.8 1.2 0.6 2.1 0.3 * * * *

8.7 16.4 19.8 5.2 34.4 13.2 13.8 16.0 12.7 21.9 23.8 0.0 2.6 0.4 2.6 4.0 0.1 0.0 3.2 2.8 0.3 7.3 4.9 4.6 5.1 0.7 2.4 1.2 0.8 1.0 1.1 1.3 1.9 1.7 1.1 1.0 2.1 1.2 2.1 0.9 0.8 0.6 0.8 0.5 0.0 1.3 0.9 3.8 1.9 1.8 1.9 5.9 5.3 8.6 6.5 7.4 6.5 4.3 4.1 4.3 2.9 2.4 3.1 5.0 3.1 5.3 2.7 2.4 2.3 1.9 2.2 2.8 2.0 4.2 2.4

32.5

12.1 11.9 17.9 7.8 35.2 13.9 14.2 27.5 13.6 23.9 25.0 0.0 2.9 0.5 2.5 3.0 0.1 0.0 2.8 3.5 0.0 6.7 5.1 4.1 5.3 1.0 2.6 1.6 1.0 1.2 1.7 1.7 3.0 2.0 1.3 1.2 4.5 1.9 3.4 1.2 0.8 0.8 0.5 0.0 1.7 1.8 1.3 3.5 2.3 0.9 2.4 5.9 5.1 8.4 5.5 4.2 5.6 4.3 3.5 4.4 3.1 2.8 3.3 5.0 3.3 5.5 3.0 2.7 2.3 1.9 2.2 2.5 2.1 3.5 2.0

37.9

123.0 73.6 66.2 90.6 72.8 110.0 88.2 99.3 91.6 82.5 84.7 82.3 84.8 83.3 84.1 116.7 94.1 83.2 83.8 92.5 88.0 86.5 95.5 84.9 74.6 81.9 81.4 74.5 83.6 72.4 83.1 80.5 88.0 62.7 83.5 81.0 82.3 89.6 68.4 74.5 86.7 80.1 82.4 78.1 74.5 76.3 74.6 80.0 83.4 76.0 78.6 83.7 78.6 82.6 83.6 82.6 80.4 78.3 81.9 81.8 80.5 85.6 80.1 84.4 81.5 80.7 84.3 89.6 82.2 95.6 80.7

153.8 63.2 62.0 93.1 65.5 115.7 88.1 102.7 97.1 77.7 78.7 77.4 81.1 73.7 74.1 102.7 65.2 79.5 78.1 77.2 81.9 80.6 86.8 79.9 71.7 77.7 77.8 71.9 81.4 57.1 80.1 77.6 78.4 54.1 80.7 77.4 83.7 81.4 50.3 83.9 81.0 65.7 79.5 76.0 72.6 67.9 73.0 82.3 84.3 80.8 72.6 71.9 73.1 77.5 76.7 77.8 75.3 72.6 76.8 76.6 75.7 81.6 75.2 80.7 74.8 74.6 79.8 84.9 78.5 87.3 77.5

830

*Important. See note on population page.

772

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Lung (C33-34) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 3155 12065 19922 2761 16959 8615 2062 6473 13338 1232 12012 1818 437751 45345 382072 16153 1982 13847 2377 43 545 1723 34267 4036 29314 25578 2624 22547 8706 6547 28694 2648 25678 2444 44153 4900 36166 123409 5996 13468 5597 97660 9181 2074 7059 34371 4249 29652 1483 1190 10394 6966 5602 10021 186 3847 12941 600 1282 12766 1088 569 962 2525 175 1933 284 363 264 5201 4506 553 1511 1627 1806 4635 3806 16759 2877 87.0 89.2 89.0 89.5 89.0 91.5 90.8 91.8 85.6 87.6 85.4 86.3 88.0 87.9 88.0 90.4 90.3 90.5 84.5 79.1 81.1 85.5 85.5 86.2 85.4 89.2 86.9 89.5 81.6 85.5 90.2 90.4 90.2 91.8 89.9 90.8 89.6 89.8 92.7 90.1 90.6 89.5 88.7 87.3 89.1 85.6 85.1 85.6 87.6 88.1 87.2 88.2 84.3 83.9 79.6 58.5 80.5 32.5 76.3 45.7 54.4 89.8 52.1 81.0 65.1 66.0 82.7 74.1 72.0 84.2 85.4 91.5 71.1 75.5 81.8 76.8 78.7 73.1 73.4 2.9 3.1 1.9 1.4 2.0 1.9 1.6 2.0 4.7 5.7 4.6 7.2 3.6 4.2 3.6 2.2 1.8 2.2 5.8 9.3 5.5 6.0 4.0 4.7 4.0 4.7 6.4 4.6 4.6 2.8 1.3 1.4 1.3 2.1 2.1 1.8 2.2 1.8 1.1 1.8 1.7 1.8 3.0 3.1 3.0 7.0 7.5 7.0 0.7 3.3 1.6 1.3 2.7 4.8 9.7 0.0 1.9 0.5 1.6 0.7 0.1 3.0 1.7 1.1 12.8 0.0 8.3 4.5 5.2 4.3 2.5 25.7 7.1 6.4 14.0 13.2 19.3 15.7 2.3 2.0 2.4 2.3 2.4 0.7 0.8 0.6 4.5 2.8 4.7 0.9 1.9 1.7 1.9 1.2 1.5 1.1 1.6 0.0 2.9 1.3 2.3 2.2 2.3 2.8 3.5 2.7 1.7 2.2 1.1 1.3 1.1 0.9 0.9 0.7 1.0 1.4 1.0 0.9 1.8 1.5 3.4 3.4 3.4 2.2 2.3 2.1 0.4 0.5 2.3 2.1 1.6 4.5 0.5 0.1 0.0 0.0 0.6 0.0 0.0 1.1 12.1 0.0 0.0 0.0 0.0 0.0 0.0 3.1 2.8 2.4 3.1 1.5 0.0 0.0 0.6 0.0 1.0 78.1 82.8 80.1 77.7 80.6 75.1 74.9 75.3 83.4 87.5 83.2 82.8 81.1 84.7 81.3 80.3 82.4 80.7 80.6 69.8 79.6 81.1 76.9 79.3 76.9 83.5 87.8 84.3 80.5 82.2 81.2 81.8 82.0 78.9 78.4 78.2 79.1 80.7 73.5 82.7 70.1 81.7 83.2 88.4 81.9 82.8 87.1 82.7 83.1 82.7 80.2 79.4 82.2 78.9 94.6 88.1 85.0 92.1 73.2 43.9 55.6 16.0 49.5 85.0 81.2 88.9 76.2 79.9 78.1 83.7 83.9 Female Cases MV(%) DCO(%) UB(%) MI(%) 2458 11381 15710 1980 13569 7167 1527 5592 9559 858 8626 1485 339134 29126 302680 13910 1389 12332 1747 18 327 1378 29887 3048 26285 19374 1850 17242 6075 5846 21873 2074 19547 2008 35923 3445 30559 99833 3766 8824 4128 82579 5538 963 4531 24136 2400 21393 920 853 9039 6168 4148 7694 64 1765 6136 182 845 5720 521 128 228 540 20 600 96 182 51 2496 2334 82 589 618 720 1801 1608 7144 1042 84.7 87.7 87.8 89.3 87.5 89.6 90.1 89.5 85.4 87.3 85.2 84.2 87.0 88.5 86.7 88.0 91.3 87.6 80.7 83.3 80.7 80.8 85.0 89.6 84.4 88.4 88.9 88.2 82.2 84.5 87.8 90.0 87.5 89.0 88.2 90.1 87.8 88.1 92.2 89.9 89.7 87.6 86.6 85.8 86.8 84.0 83.8 84.0 87.8 84.3 86.4 87.5 82.6 82.9 81.3 56.1 75.3 32.4 74.8 43.0 54.7 93.0 50.9 79.3 75.0 67.5 86.5 67.0 82.4 81.7 83.7 82.9 72.7 69.1 80.1 70.0 75.8 67.8 69.3 2.6 3.3 1.8 0.7 1.9 2.5 1.6 2.7 3.9 4.0 4.0 7.9 3.6 3.4 3.6 3.1 1.6 3.3 8.0 5.6 9.2 7.8 3.6 2.5 3.8 4.5 5.1 4.5 3.9 2.9 1.6 1.9 1.6 3.2 2.5 1.9 2.7 2.1 1.2 1.8 2.3 2.2 3.5 3.2 3.6 7.7 7.9 7.7 0.8 3.5 1.9 1.3 3.2 5.2 10.9 0.0 2.6 0.5 3.2 0.9 0.0 4.4 2.4 0.0 13.7 0.0 20.9 5.9 6.2 5.0 3.7 25.0 10.0 10.0 18.1 14.1 22.2 16.4 2.9 2.4 2.5 2.5 2.5 0.7 0.8 0.7 4.5 2.1 4.8 0.7 1.9 1.6 2.0 1.3 0.9 1.3 1.4 0.0 0.3 1.7 2.3 1.4 2.4 2.9 2.4 3.0 1.2 2.4 1.4 1.3 1.4 0.9 1.0 0.7 1.0 1.6 1.3 1.0 1.7 1.6 3.9 4.4 3.8 2.2 2.3 2.1 0.2 0.7 2.4 2.4 1.5 4.6 0.0 0.2 0.0 0.0 0.8 0.0 0.0 1.6 14.9 0.0 0.0 0.0 0.0 0.0 2.0 2.8 2.7 2.4 2.4 1.3 0.0 0.0 0.7 0.0 1.4 78.2 75.0 76.0 73.2 76.3 73.1 73.9 72.7 80.0 81.1 80.1 75.8 76.4 79.3 76.7 74.8 77.2 74.9 78.3 88.9 74.9 79.0 72.1 76.4 71.8 78.3 81.6 78.9 75.9 79.1 78.1 79.6 78.7 74.1 75.0 74.3 75.5 76.6 69.8 78.7 55.5 77.9 79.5 79.8 79.8 78.5 81.8 78.6 80.5 80.8 77.3 76.3 77.0 74.9 76.6 86.6 * 85.3 * 77.4 70.5 * * 46.9 * 53.1 * 20.0 52.7 * * * 75.2 74.2 85.6 68.8 69.5 69.6 81.5 78.3

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
773

831

Indices of data quality

Lung (C33-34) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
774

Female Cases MV(%) DCO(%) UB(%) MI(%) 14691 1303 933 399 479 822 120 3667 227 46 22 220 395 36 62 1139 1584 1436 33 115 934 634 168 142 505 5532 447 186 2337 1021 2330 2789 2830 6851 7803 678 2745 479 218 202 306 403 400 362 128 196 139 167 1597 2188 1901 1104 1648 1875 990 303 3066 166 391 327 900 496 101 1295 470 189 1625 398 92 343 856 260 187 88 112 815 510 309 1459 62.1 59.2 68.9 69.7 61.4 64.7 69.2 68.9 64.3 71.7 86.4 76.8 73.9 88.9 77.4 57.3 82.6 82.0 84.8 88.7 74.1 67.8 73.2 82.4 83.2 82.7 88.8 73.7 55.1 94.6 87.3 40.9 66.5 72.8 83.6 67.1 84.6 93.3 95.4 96.0 92.2 99.0 92.0 95.6 96.9 93.9 91.4 97.6 68.8 68.6 65.9 71.1 76.6 75.0 81.8 94.7 69.3 63.3 71.1 73.1 64.0 59.3 72.3 62.7 67.0 63.0 77.2 69.1 65.2 81.3 78.6 56.2 76.5 68.2 80.4 71.7 73.9 64.7 67.9 12.6 9.0 9.5 9.3 5.6 5.4 4.2 15.5 10.6 28.3 13.6 7.3 13.4 0.0 0.0 14.5 0.0 0.0 0.0 0.0 0.0 11.7 6.0 2.1 0.0 13.9 2.0 10.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 2.2 0.3 0.0 1.1 0.0 0.0 8.5 0.2 24.6 0.6 3.1 0.0 2.3 0.0 0.0 0.0 2.6 0.0 2.8 0.3 0.0 0.5 0.0 1.2 1.1 0.3 0.0 0.4 0.0 1.8 0.0 0.0 1.3 0.6 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 3.4 0.0 0.0 13.7 0.0 0.0 82.6 88.1 79.4 76.9 76.2 84.1 93.8 65.4 80.6 61.4 40.5

41176 3368 2480 1083 1201 2170 309 9057 628 143 156 698 711 160 596 3165 3547 3145 89 313 1236 1117 409 1090 5886 12849 1071 547 19017 3997 11993 15536 12086 23276 10243 2971 7809 2091 1257 978 1316 1740 1958 1579 941 1212 727 776 5810 9140 3833 4175 3525 6019 2873 296 5184 632 1607 1346 3306 1994 432 3125 1812 1035 4931 1212 565 1236 3179 1795 961 609 501 2790 2091 1308 4797

74.7 70.6 81.4 79.7 74.2 76.4 75.4 78.9 73.6 77.6 85.9 80.5 71.6 76.9 74.8 55.7 87.3 87.6 87.6 84.3 73.1 65.4 77.0 85.6 86.6 85.9 90.2 80.4 68.3 94.2 86.6 48.1 73.5 77.5 83.7 76.4 87.0 95.3 96.7 96.1 95.4 97.8 92.2 98.0 98.1 92.8 95.5 98.7 73.0 76.7 69.8 77.6 79.3 77.6 84.6 95.6 73.5 75.3 73.0 78.8 69.6 67.1 78.0 68.2 68.6 68.7 81.4 78.3 67.8 77.5 80.3 63.2 76.0 65.7 83.4 77.8 76.5 73.9 75.5

7.9 6.1 5.0 5.5 4.3 3.8 2.3 9.3 5.6 18.9 10.9 4.7 14.3 5.0 0.2 15.5 0.0 0.0 0.0 0.0 0.0 12.8 5.4 1.9 0.0 11.3 1.9 7.7

0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 1.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 2.0 0.2 0.0 1.8 0.0 0.0 9.0 0.1 19.3 0.4 2.9 0.0 1.8 0.1 0.2 0.0 1.7 0.0 2.2 0.1 0.0 0.8 0.0 0.4 1.0 0.2 0.0 0.3 0.0 1.1 0.0 0.0 1.3 0.3 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.8 2.8 0.0 0.3 10.9 0.0 0.0

84.2 87.4 75.1 81.7 77.4 81.0 85.0 69.5 85.0 59.5 48.5

91.8 0.3 87.9 68.2 64.6 72.4 90.8 86.0 81.7 86.2 102.5 78.8 86.3 93.5 94.4 94.3 90.2 84.7 97.2 91.4 99.1 108.4 87.4 112.3 100.4 100.0 97.7 130.7 184.1 69.9 84.7 70.9 81.4 85.7 89.0 93.2 91.1 86.4 86.7 86.1 88.0 85.2 91.2 90.0 90.2 86.1 94.5 82.0 85.1 93.0 85.0 90.4 88.0 85.6 93.1 86.6 87.0 87.7 85.9

90.4

* * *

0.1 * 84.5 * 141.1 56.3 * 128.1 * 87.4 80.3 71.0 82.6 * * 92.7 93.5 * 82.3 90.9 91.5 89.1 83.4 88.9 88.1 78.7 99.0 99.5 80.3 101.7 107.0 93.9 96.4 106.6 196.7 66.6 84.6 68.8 83.8 90.6 82.0 83.2 89.8 86.1 81.6 90.2 80.1 81.0 75.2 86.1 88.7 72.3 89.7 81.4 82.6 82.8 77.9 92.3 79.7 83.0 82.6 82.5 78.6 78.6 78.8

17.0 7.2 5.6 0.6 0.7 2.4

25.6 8.8 8.3 0.5 1.3 2.8

0.2 21.3 15.6 12.0 18.6 12.3 11.6 9.3 0.0 3.6 1.7 3.4 0.5 0.7 2.2 2.3 2.4 0.6 4.2 1.1 1.2 3.2 0.2 2.3 4.8 4.2 4.1 0.4 2.2 0.6 0.4 1.8

0.0 24.7 22.1 13.2 23.9 13.2 11.8 9.4 0.0 4.5 3.6 4.6 1.2 0.9 3.2 3.0 5.2 0.9 7.9 1.8 2.0 1.1 0.6 0.9 5.8 7.0 2.3 0.0 3.1 1.6 1.3 3.5

832

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Lung (C33-34) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 4793 6950 533 6516 1506 3229 2955 3133 3718 7745 10672 9481 4033 491 2833 3857 2287 443 1300 1402 2074 1254 1037 1839 8437 705 403 343 779 648 514 1126 32797 2272 2138 4688 5873 9094 15639 3630 11995 23713 10193 10435 2693 12969 9278 175 5270 2323 816 6619 2524 223 250 4733 1983 121 332 324 504 566 59.3 73.0 76.2 87.4 62.1 85.1 83.8 95.2 78.6 62.6 78.1 74.2 97.7 83.5 88.9 86.1 85.4 73.6 86.2 75.8 83.4 89.4 82.6 86.3 97.7 92.5 88.6 89.5 90.1 89.2 91.1 91.5 92.6 91.9 94.2 73.5 64.3 66.2 57.3 72.0 63.5 66.5 65.9 71.8 66.9 74.9 84.9 92.6 79.8 83.0 80.5 80.3 85.5 87.4 86.0 78.0 92.3 95.0 93.4 92.3 92.5 91.3 6.7 2.0 3.0 1.0 8.4 2.0 0.4 16.2 11.3 13.1 1.5 4.1 3.9 3.3 4.4 10.4 4.2 1.5 5.3 2.0 8.2 6.0 0.1 0.2 0.9 0.9 2.5 0.4 4.8 0.1 0.0 0.0 0.0 0.0 2.8 0.1 0.0 0.0 7.7 0.1 1.3 0.8 0.8 1.0 0.9 1.0 0.7 0.9 0.2 1.2 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.3 2.0 0.0 16.3 10.1 4.8 1.2 0.0 0.0 1.5 0.0 0.0 0.3 0.3 0.2 3.1 0.0 0.0 1.6 0.0 0.3 0.0 0.3 0.3 0.2 0.4 94.8 88.8 97.0 88.6 90.0 89.8 108.1 114.9 88.8 104.3 79.4 95.7 91.3 90.0 99.2 83.0 86.4 84.2 83.2 101.4 90.7 82.5 82.9 103.6 106.2 69.9 77.2 83.1 79.5 79.8 82.3 77.5 98.6 94.4 89.5 85.6 90.3 89.8 95.0 98.8 88.3 86.2 90.1 89.7 88.3 85.3 86.9 84.0 86.9 84.5 86.2 85.4 101.8 87.2 90.8 74.9 Female Cases MV(%) DCO(%) UB(%) MI(%) 929 1230 98 3761 613 611 1520 685 867 1894 3076 1777 1188 49 354 558 398 39 134 122 231 166 99 172 6073 391 106 140 274 250 197 528 12386 740 729 2606 4320 6169 10864 2130 7253 15168 6107 5650 1735 9764 4685 70 2487 1202 447 3685 1339 138 95 3159 1275 85 143 257 278 423 51.3 59.8 77.6 87.1 60.0 75.1 80.5 94.2 75.7 55.4 76.6 71.8 97.4 85.7 82.2 83.3 80.9 56.4 82.8 70.5 80.1 86.1 77.8 80.2 97.2 88.7 82.1 87.9 92.0 90.4 87.8 91.5 93.0 93.6 94.0 68.9 60.8 61.8 52.8 67.3 59.7 63.3 61.8 68.5 62.9 70.7 82.9 85.7 79.8 81.0 83.2 78.3 83.0 84.8 82.1 74.0 91.5 92.9 95.8 93.0 89.9 89.4 9.6 2.5 3.1 0.9 11.1 3.8 0.5 20.5 13.2 15.6 1.9 8.2 6.5 6.3 7.3 23.1 7.5 3.3 7.4 2.4 10.1 9.3 1.3 0.0 1.4 0.7 3.2 2.0 4.7 0.1 0.0 0.0 0.0 0.0 4.4 0.1 0.1 0.0 10.1 0.1 1.9 0.8 0.0 1.1 0.4 1.8 2.6 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.3 2.6 0.0 20.4 12.0 4.8 1.5 0.0 0.0 1.5 0.0 0.0 0.2 0.7 0.0 3.7 0.1 0.0 3.2 0.1 0.2 0.0 0.0 0.0 0.4 0.2 92.8 80.1 94.9 83.0 89.3 * 82.2 109.2 116.1 * 80.2 109.1 76.8 95.7 86.4 87.8 89.9 83.9 84.5 84.6 91.0 123.8 91.3 83.1 87.9 108.7 102.3 69.6 68.9 78.6 78.8 76.0 73.6 75.6 90.9 90.4 86.1 83.1 88.6 87.4 98.5 93.9 86.3 84.1 89.4 87.4 85.9 83.2 80.0 77.8 78.3 84.8 80.6 78.5 108.7 88.4 89.9 67.5

0.3 7.1 3.1 2.5 1.7 3.6 10.8 7.8 8.2 2.1 0.9 1.8 1.7 2.7 0.0 0.2 3.0 4.8 1.8 8.8 5.0 1.3 0.0 0.6 1.2 1.8 1.4

0.5 8.2 3.2 2.6 2.2 3.9 11.5 8.2 9.0 2.4 0.7 2.2 2.9 3.0 0.0 0.2 3.1 5.7 1.4 10.5 5.4 0.9 0.0 0.0 1.6 0.7 1.2

74.7

65.2

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
775

833

Indices of data quality

Melanoma of skin (C43)

Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 5 15 5 9 15 27 102 16 69 1392 16 124 188 73 18 16 8496 945 1550 352 283 116 6 458 4438 62 286 1557 17 1420 149 2636 15400 100 57 536 13688 2657 9 15 4 1 67 2391 3197 24 12 6 6 2 185 2737 2176 2053 7 1971 123 8 108 8811 41 8590 3205 46 3080 1229 15 1181 671 4084 28 3832 2336 1357 2145 1179 30 1129 9 183 100.0 100.0 100.0 100.0 66.7 74.1 96.1 100.0 98.6 99.6 100.0 96.8 98.4 97.3 100.0 100.0 97.7 100.0 99.7 99.1 100.0 98.3 100.0 100.0 95.8 100.0 99.7 98.1 88.2 98.1 97.3 98.8 99.6 99.0 98.2 99.4 99.6 99.7 100.0 100.0 100.0 100.0 98.5 99.7 99.7 100.0 100.0 100.0 100.0 100.0 99.5 99.7 99.4 99.3 100.0 99.2 96.7 87.5 97.2 98.5 95.1 98.5 98.6 100.0 98.6 99.6 100.0 99.6 98.2 99.1 100.0 99.1 99.3 99.6 99.4 98.9 100.0 98.8 100.0 97.8 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.1 0.0 0.0 1.7 0.0 0.0 4.0 0.0 0.0 1.4 5.9 1.5 2.7 0.5 0.2 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.2 1.6 0.0 1.9 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.3 0.1 0.1 0.4 0.2 0.0 0.2 0.0 0.0 70.4 20.6 37.5 10.1 20.0 37.5 31.5 39.4 57.5 34.7 20.8 17.2 20.1 22.4 13.4 18.1 16.7 16.8 22.6 16.1 22.4 22.6 29.4 24.4 17.4 18.6 16.0 31.0 21.1 22.4 16.8 16.4 11.1 11.9 17.3 14.9 29.2 58.3 16.7 50.0 20.0 15.5 16.3 13.8 14.4 22.0 62.5 20.4 21.3 29.3 21.7 18.3 19.6 18.7 13.8 20.0 14.1 19.4 21.3 39.3 22.3 23.0 18.3 19.1 24.1 70.0 23.2 55.6 27.3 Female Cases MV(%) DCO(%) UB(%) MI(%) 11 100.0 14 100.0 5 100.0 16 93.8 28 89.3 29 122 15 93 1687 32 135 173 96 19 23 7658 948 1329 285 298 129 4 441 3834 78 312 1180 17 1045 115 1697 11330 111 44 689 9605 1995 6 13 4 4 114 1711 2389 20 7 7 5 6 236 1947 1727 1665 5 1595 92 4 79 5923 68 5726 2478 44 2351 946 17 907 488 3133 34 2916 1862 1262 1796 890 35 834 10 135 89.7 95.1 100.0 98.9 100.0 100.0 99.3 100.0 92.7 100.0 100.0 97.5 99.9 99.4 99.6 100.0 100.0 100.0 99.8 95.3 100.0 100.0 98.1 100.0 97.9 97.4 98.9 99.5 100.0 100.0 99.6 99.6 99.5 100.0 100.0 100.0 100.0 99.1 99.5 100.0 100.0 100.0 100.0 100.0 100.0 100.0 99.9 99.0 99.8 100.0 99.7 100.0 100.0 100.0 99.0 98.5 98.9 98.7 90.9 98.9 99.8 100.0 99.8 99.8 99.0 91.2 99.0 99.4 99.4 99.3 99.2 100.0 99.2 100.0 98.5 0.0 0.0 0.0 0.0 0.0 0.0 4.1 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 4.3 0.0 0.0 1.4 0.0 1.6 2.6 0.4 0.2 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.1 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.1 0.3 0.4 0.2 0.0 0.2 0.0 0.0 * * * *

0.0 0.0 25.9 2.9 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.3 0.3 5.9 0.3 0.0 0.5 0.2 0.0 0.0 0.4 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.5 0.1 0.5 0.4 0.0 0.5 1.6 12.5 0.9 1.3 4.9 1.3 1.2 0.0 1.3 0.4 0.0 0.4 1.2 0.5 0.0 0.5 0.5 0.2 0.2 0.4 0.0 0.4 0.0 0.5

0.0 3.6 6.9 0.8 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.2 0.1 0.2 0.4 0.0 0.0 0.0 0.3 0.0 0.0 0.4 0.0 0.5 0.0 0.5 0.2 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.6 0.1 0.0 0.1 0.0 0.0 0.0 0.8 0.0 0.9 1.0 9.1 0.9 0.2 0.0 0.2 0.2 0.7 5.9 0.7 0.5 0.2 0.2 0.6 0.0 0.6 0.0 1.5

7.1

44.8 18.9 20.0 17.2 25.0 24.4 26.6 45.8 13.2 14.7 11.9 13.8 21.4 10.4 15.5 10.7 16.1 9.0 13.8 18.6 100.0 19.3 13.9 13.7 12.4 22.5 29.5 12.6 13.3 13.7 66.7 12.3 14.6 11.7 25.0 28.6 33.3 15.3 12.0 11.8 11.4 60.0 11.7 15.2 125.0 10.1 15.1 22.1 15.3 14.9 50.0 14.8 9.6 35.3 9.3 11.3 17.5 38.2 18.2 18.1 11.5 12.8 20.9 37.1 20.7 50.0 20.7

834

*Important. See note on population page.

776

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Melanoma of skin (C43) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 706 93.5 3140 98.9 4579 98.4 36 86.1 4343 98.5 1721 99.7 21 95.2 1679 99.7 1781 96.5 8 62.5 1751 96.6 395 98.2 93718 98.6 462 95.2 89053 98.5 3941 98.9 16 100.0 3863 98.9 824 98.2 8 100.0 44 95.5 771 98.3 5706 96.8 53 96.2 5589 96.8 4566 98.6 25 96.0 4153 98.5 1192 94.2 2108 99.3 5533 99.2 20 100.0 5175 99.2 640 99.8 12579 99.5 58 98.3 12120 99.5 33579 99.4 174 99.4 162 98.8 734 99.2 31093 99.4 1823 98.4 17 94.1 1763 98.5 6036 96.8 25 88.0 5664 96.7 968 99.5 428 98.8 3235 99.3 2168 99.6 855 98.7 2002 97.6 2 45 150 2 2 107 7 59 24 58 4 61 13 0 5 1774 1701 23 18 17 17 48 36 129 23 100.0 86.7 95.3 100.0 100.0 90.7 100.0 100.0 95.8 100.0 100.0 100.0 100.0 0.0 100.0 94.0 95.2 100.0 100.0 64.7 100.0 89.6 88.9 100.0 100.0 0.4 0.7 0.6 11.1 0.6 0.1 0.0 0.1 1.6 12.5 1.5 1.5 0.6 2.6 0.7 0.6 0.0 0.6 0.4 0.0 0.0 0.4 0.6 0.0 0.6 0.7 0.0 0.7 1.6 0.3 0.2 0.0 0.3 0.2 0.2 0.0 0.2 0.3 0.0 0.0 0.4 0.3 0.4 0.0 0.5 1.5 8.0 1.5 0.1 0.5 0.2 0.1 0.7 0.9 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.5 0.0 0.0 5.9 0.0 10.4 2.8 0.0 0.0 5.7 0.4 0.8 0.0 0.9 0.1 0.0 0.1 1.9 12.5 1.9 0.3 0.6 1.1 0.6 0.4 0.0 0.4 0.8 0.0 0.0 0.9 1.5 0.0 1.5 0.6 4.0 0.6 0.7 0.3 0.4 0.0 0.3 0.0 0.2 0.0 0.2 0.2 0.0 0.0 0.0 0.2 1.2 5.9 1.0 1.4 0.0 1.4 0.0 0.7 0.4 0.3 0.2 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 2.4 0.0 0.0 17.6 0.0 0.0 0.0 0.0 0.0 17.8 19.5 15.9 30.6 16.5 13.7 33.3 13.6 30.5 62.5 30.8 24.6 19.8 40.7 20.5 19.4 43.8 19.6 15.9 37.5 29.5 14.8 22.7 41.5 22.7 21.1 28.0 23.0 34.1 17.5 21.0 45.0 22.3 13.9 15.4 20.7 15.5 16.7 32.2 32.7 20.4 17.1 17.3 41.2 17.5 24.0 76.0 25.2 17.0 16.8 15.5 16.0 21.1 22.9 50.0 8.9 48.0 50.0 42.1 29.7 25.0 11.5 21.7 44.4 58.8 23.5 54.2 25.0 69.0 60.9 Female Cases MV(%) DCO(%) UB(%) MI(%) 576 94.8 2716 98.9 3804 98.8 29 89.7 3590 98.8 1428 99.4 18 88.9 1392 99.6 1271 97.2 10 100.0 1232 97.2 307 98.4 71525 98.7 545 96.0 67236 98.7 3099 98.1 24 83.3 3023 98.3 583 98.8 3 100.0 72 98.6 504 98.8 4554 96.9 73 97.3 4434 96.9 3779 98.5 23 95.7 3426 98.4 831 95.3 1764 99.6 4297 99.3 17 100.0 3997 99.3 453 99.6 10207 99.5 55 96.4 9791 99.5 26085 99.3 190 98.9 160 95.0 942 99.5 23543 99.4 1392 98.1 35 94.3 1306 98.4 4277 97.4 49 98.0 3921 97.3 781 99.9 361 98.3 2810 99.3 1922 99.4 668 98.5 1591 98.2 1 28 129 4 5 91 7 82 28 44 1 48 3 0 9 1726 1681 16 22 14 28 45 41 87 32 100.0 96.4 96.1 100.0 100.0 85.7 100.0 96.3 96.4 100.0 100.0 100.0 100.0 0.0 100.0 95.0 95.5 100.0 100.0 71.4 92.9 93.3 87.8 100.0 100.0 0.5 0.6 0.7 6.9 0.7 0.1 0.0 0.1 1.2 0.0 1.2 1.0 0.6 2.4 0.6 0.9 8.3 0.9 0.5 0.0 1.4 0.4 0.5 0.0 0.5 0.7 0.0 0.8 1.3 0.2 0.1 0.0 0.1 0.4 0.2 0.0 0.2 0.3 0.5 2.5 0.1 0.3 0.6 2.9 0.5 1.4 2.0 1.5 0.0 0.3 0.3 0.2 0.7 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 6.7 7.3 0.0 0.0 4.5 0.5 0.3 0.0 0.3 0.1 0.0 0.1 1.5 0.0 1.5 0.7 0.5 0.7 0.5 0.8 8.3 0.7 0.2 0.0 0.0 0.2 1.5 0.0 1.5 0.6 0.0 0.7 0.4 0.2 0.5 0.0 0.4 0.0 0.2 0.0 0.2 0.3 0.0 1.3 0.0 0.3 1.2 2.9 1.1 1.0 0.0 1.0 0.0 0.8 0.4 0.4 0.4 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.1 2.7 0.0 0.0 7.1 0.0 0.0 0.0 0.0 0.0 14.2 14.2 10.9 41.4 11.2 9.9 38.9 9.7 25.2 60.0 25.5 16.3 15.2 43.9 15.7 14.3 41.7 14.2 13.2 66.7 12.5 12.9 19.4 32.9 19.3 15.8 52.2 17.0 27.4 11.2 17.7 64.7 18.8 17.9 11.4 45.5 11.4 12.5 22.1 41.9 12.1 12.9 12.9 51.4 12.3 19.0 44.9 20.1 12.4 8.3 10.9 10.7 16.9 15.7 7.1 * 43.4 * 60.0 56.0 * * 9.1 * 25.0 * 6.3 18.1 9.1 64.3 35.7 44.4 39.0 67.8 50.0 * * *

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
777

835

Indices of data quality

Melanoma of skin (C43) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
778

Female Cases MV(%) DCO(%) UB(%) MI(%) 490 38 22 26 19 27 3 124 13 4 3 9 16 6 6 47 35 32 0 3 16 7 13 47 86 2570 284 159 1422 371 1543 790 1034 3586 2811 400 1626 432 165 180 304 252 323 505 205 124 114 227 759 1564 739 506 1078 930 334 153 1397 83 183 129 500 189 79 441 166 57 947 126 53 127 353 154 56 56 72 425 209 158 638 96.3 100.0 100.0 92.3 94.7 100.0 100.0 95.2 92.3 100.0 100.0 88.9 93.8 100.0 100.0 93.6 100.0 100.0 0.0 100.0 100.0 100.0 100.0 100.0 97.7 95.1 98.9 96.9 99.5 100.0 99.9 99.9 95.8 97.6 98.0 99.0 99.8 99.8 100.0 100.0 99.3 100.0 98.8 100.0 99.5 96.8 100.0 99.6 91.2 97.0 93.5 97.2 100.0 94.8 98.8 100.0 99.8 100.0 91.3 100.0 94.2 93.7 100.0 100.0 100.0 96.5 99.6 100.0 98.1 100.0 98.6 98.7 100.0 96.4 97.2 100.0 85.2 95.6 98.4 2.9 0.0 0.0 3.8 0.0 0.0 0.0 4.8 7.7 0.0 0.0 0.0 0.0 0.0 0.0 4.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.9 0.7 3.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.8 1.9 0.0 0.1 0.2 0.0 0.0 0.7 0.0 1.2 0.0 0.5 1.6 0.0 0.0 4.9 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.4 0.0 0.0 36.1 42.1 22.7 26.9 26.3 29.6 100.0 34.3 23.1

465 42 37 9 18 23 3 123 11 2 10 9 39 6 16 55 34 26 2 6 27 18 13 32 107 2407 278 135 782 289 958 822 1044 3457 2303 222 1664 375 104 120 258 236 261 373 124 110 89 159 721 1497 629 406 1113 726 336 78 860 76 186 99 441 177 63 449 178 59 772 136 39 104 395 148 56 56 36 399 196 141 568

97.2 97.6 94.6 100.0 100.0 100.0 100.0 96.7 90.9 100.0 100.0 88.9 100.0 100.0 93.8 89.1 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 97.2 95.3 100.0 99.3 99.2 100.0 99.9 100.0 97.0 97.6 98.0 98.2 99.7 100.0 100.0 100.0 100.0 100.0 98.9 100.0 100.0 100.0 100.0 100.0 91.3 97.0 90.1 95.1 100.0 97.2 98.2 100.0 99.8 100.0 90.3 100.0 92.5 96.0 98.4 99.6 100.0 100.0 100.0 100.0 97.4 99.0 100.0 95.9 100.0 100.0 100.0 99.0 83.7 97.2 98.4

1.7 2.4 2.7 0.0 0.0 0.0 0.0 3.3 9.1 0.0 0.0 0.0 0.0 0.0 6.3 5.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.7

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 1.0 1.9 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 4.6 0.1 0.0 1.2 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.8 0.0 0.0

42.6 59.5 21.6 44.4 50.0 30.4 60.0 54.5

12.8

52.9

62.9

* * *

92.3 25.0 39.3 29.4 18.7 23.0 60.1 31.8 41.2 42.0 26.5 24.7 39.6 24.9 16.8 40.4 20.0 13.6 29.2 21.5 18.8 31.5 11.8 25.8 27.7 52.8 18.9 18.1 17.5 18.8 14.6 22.0 20.5 19.7 21.1 23.1 19.2 24.3 26.0 17.5 27.5 35.3 25.5 27.2 38.5 25.0 21.0 27.7 37.5 28.6 27.8 19.8 36.2 29.8 20.8

30.8 17.0 * 40.7 *

* *

0.0 2.8 0.8 0.1 0.9 0.0

0.1 3.9 0.9 0.1 0.3 0.2

0.0 3.3 2.8 2.4 3.7 0.0 1.9 0.9 0.0 0.0 0.0 0.0 0.0 0.2 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2

0.0 3.8 2.7 2.2 2.8 0.0 2.2 1.2 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 1.8 0.0 0.0 1.9 0.0 0.8 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.3

26.0 15.8 10.7 31.6 * * 20.2 35.9 * 32.2 20.7 17.5 30.0 19.4 11.6 25.5 16.1 15.1 19.8 16.1 14.1 17.1 19.4 22.8 13.2 48.0 13.6 17.1 14.6 16.0 10.1 18.9 11.1 14.4 13.3 15.3 16.3 16.8 23.8 8.9 22.9 21.9 18.8 26.2 35.8 23.6 15.6 19.5 30.4 16.1 12.2 17.6 24.4 29.1 16.5

836

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Melanoma of skin (C43) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 238 385 72 2305 137 151 259 259 367 523 642 1006 595 55 152 308 181 31 114 112 239 143 113 129 4232 269 97 104 230 148 110 371 5348 327 285 882 580 988 1570 892 2772 2977 1064 1303 395 1471 8624 127 6504 1658 498 4434 2658 294 15 4284 564 1 7 13 22 483 95.4 100.0 100.0 99.7 97.1 96.7 95.4 100.0 98.9 95.4 91.3 96.9 100.0 90.9 95.4 99.7 99.4 93.5 100.0 100.0 99.2 97.9 98.2 99.2 100.0 100.0 100.0 100.0 100.0 98.6 100.0 99.5 100.0 100.0 100.0 99.3 97.2 97.9 99.2 99.7 93.7 94.6 95.8 99.1 98.7 99.3 99.0 99.2 99.2 99.2 100.0 99.9 99.5 100.0 93.3 99.7 99.8 100.0 100.0 100.0 100.0 99.8 2.1 0.0 0.0 0.0 2.2 2.6 0.4 0.0 6.4 1.7 0.0 3.6 2.0 0.0 0.0 3.2 0.0 0.0 0.0 0.7 0.9 0.8 0.0 0.0 0.0 0.0 1.4 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 1.1 0.0 1.3 0.0 5.5 2.0 0.3 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.7 0.4 0.1 0.2 1.5 1.2 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 59.2 39.5 20.8 28.1 35.6 38.9 37.8 36.7 36.2 49.9 46.1 40.3 32.8 18.2 45.0 22.4 25.6 48.4 22.8 28.6 24.7 28.0 25.7 36.4 25.9 15.6 20.6 14.4 19.1 23.6 12.7 15.9 26.5 22.5 25.5 25.2 25.5 25.9 21.5 26.5 34.5 27.5 27.9 20.3 23.6 14.7 12.6 11.0 13.9 15.9 14.6 10.7 12.9 33.3 17.4 10.1 Female Cases MV(%) DCO(%) UB(%) MI(%) 464 728 70 2472 166 190 341 412 550 1055 663 1191 686 57 272 447 242 28 142 147 276 149 146 148 4267 293 109 97 247 176 157 448 7164 430 386 1020 831 1364 2153 1212 3267 3802 1345 1608 607 1954 6068 100 4821 1427 518 3977 1927 254 20 4140 356 4 6 10 19 278 97.0 100.0 98.6 99.8 99.4 98.9 97.7 100.0 99.3 95.5 91.6 97.8 100.0 100.0 98.9 99.8 97.9 96.4 99.3 99.3 99.3 98.7 97.9 97.3 100.0 100.0 100.0 100.0 100.0 99.4 99.4 99.6 100.0 99.8 100.0 98.4 97.6 98.5 99.5 99.1 91.8 94.8 97.8 99.1 98.7 99.6 99.0 100.0 99.0 99.8 100.0 99.9 99.8 98.8 100.0 99.6 99.7 100.0 100.0 100.0 100.0 99.6 1.3 0.0 0.0 0.0 0.6 0.5 0.6 0.0 6.6 0.8 0.0 0.0 0.4 0.2 1.2 3.6 0.7 0.0 0.7 1.3 2.1 2.7 0.0 0.0 0.0 0.0 0.6 0.0 0.4 0.2 0.0 0.0 0.0 0.0 0.5 0.6 0.0 0.0 1.1 0.0 1.3 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.2 0.1 0.0 0.5 1.2 1.2 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 44.2 34.5 20.0 16.3 42.9 * 40.1 34.3 20.9 * 19.5 34.2 36.3 32.5 24.1 14.0 23.3 18.1 14.5 32.1 21.8 17.0 13.4 20.1 16.4 23.6 17.6 6.8 17.4 9.3 11.7 10.8 14.0 9.8 15.2 13.2 20.6 17.7 18.7 18.3 15.1 19.9 26.2 21.1 21.1 14.3 16.4 10.6 7.0 7.6 8.8 7.7 10.6 8.7 6.7 11.1 8.7

0.0 0.5 0.5 0.1 0.0 0.2 3.1 2.4 0.2 0.3 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.4 0.0 6.7 0.2 0.2 0.0 0.0 0.0 0.0 0.2

0.0 0.4 0.1 0.2 0.2 0.4 2.8 1.2 0.5 0.0 0.1 0.2 0.0 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.3 0.0 0.0 0.0 0.0 0.4

8.5

7.2

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
779

837

Indices of data quality

Breast (C50)
Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 12 100.0 31 93.5 8 100.0 15 53.3 9 100.0 16 13 1 10 211 1 11 28 9 10 1 541 50 93 31 16 15 0 27 279 5 25 206 41 161 9 237 710 42 67 64 526 150 16 4 5 2 8 107 196 31 2 4 0 3 21 132 75 134 8 124 41 18 22 598 56 534 166 50 115 60 27 32 49 367 58 298 157 65 92 158 56 100 23 23 93.8 84.6 100.0 100.0 83.4 100.0 90.9 89.3 100.0 90.0 100.0 97.0 96.0 100.0 100.0 100.0 100.0 0.0 100.0 95.0 100.0 100.0 96.1 97.6 95.7 100.0 96.6 99.0 100.0 98.5 98.4 99.0 98.7 100.0 100.0 100.0 100.0 87.5 99.1 100.0 100.0 100.0 100.0 0.0 100.0 100.0 100.0 97.3 100.0 100.0 100.0 100.0 100.0 100.0 98.0 96.4 98.1 98.2 100.0 97.4 100.0 100.0 100.0 95.9 98.1 98.3 98.0 96.2 98.5 95.7 97.5 98.2 97.0 95.7 91.3 0.0 0.0 0.0 0.0 0.0 0.0 15.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 1.5 2.4 1.2 0.0 0.8 0.3 0.0 0.0 1.6 0.2 0.7 0.0 0.0 0.0 0.0 12.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.4 0.6 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 1.1 0.6 1.8 0.0 4.3 0.0 Female Cases MV(%) DCO(%) UB(%) MI(%) 414 2426 308 332 330 844 2023 423 1046 22598 300 2139 2971 966 730 332 92.5 94.7 98.4 68.4 73.6 91.0 88.7 87.5 97.2 82.2 95.3 92.9 93.0 91.4 98.9 99.1 0.0 0.0 0.0 0.3 0.0 3.1 8.2 1.4 0.2 0.0 0.0 0.0 0.0 0.0 0.7 0.0 2.1 0.1 0.0 0.0 0.0 0.1 0.0 0.3 4.1 0.0 0.0 1.3 1.6 1.2 1.1 0.5 0.2 0.2 0.2 0.1 0.3 0.2 0.2 0.2 0.1 0.3 0.2 0.1 0.2 0.3 0.2 0.1 0.0 0.0 0.0 0.2 0.4 0.1 0.0 0.1 1.1 0.9 0.9 0.1 0.2 0.1 0.2 0.3 0.2 0.2 0.4 0.1 0.1 0.2 0.3 0.2 0.3 0.1 0.7 0.3 0.3 0.4 0.4 0.3 * * * *

6.5 0.0 0.0 0.0 0.0 0.0 3.8 0.0 9.1 3.6 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 1.5 0.0 1.9 0.0 1.3 0.4 0.0 1.5 0.0 0.4 0.7 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 1.5 3.6 1.3 0.6 0.0 0.9 0.0 0.0 0.0 4.1 1.6 1.7 1.7 1.3 1.5 1.1 1.3 0.0 2.0 0.0 8.7

19.4

4.5 12.1 5.0 3.1 6.6 2.0 4.6 2.7 2.2 2.5 3.9 0.6 0.6 0.1 0.6 1.2 0.0 0.0 0.8 0.7 0.0 1.0 0.6 0.6 0.6 0.0 0.7 0.6 0.2 0.4 0.4 0.7 0.7 0.6 0.2 0.3 0.3 0.5 0.9 0.4 0.3 0.2 0.1 0.4 0.0 0.3 0.6 0.7 0.7 0.6 0.7 1.2 1.3 1.1 1.2 1.6 1.2 1.7 2.0 1.6 0.7 0.8 0.7 1.2 1.4 2.1 1.3 1.0 0.7 0.7 0.7 0.9 0.6 1.3 0.9

13.6

162.5 7.7 20.0 12.3 100.0 54.5 64.3 22.2 12.5 27.2 40.0 20.4 19.4 50.0 13.3 25.9 28.3 24.0 17.0 24.4 15.5 11.1 17.3 24.1 21.4 23.9 28.1 24.3 16.7 31.3 50.0 11.2 28.1 22.6 75.0 33.3 28.8 16.0 20.9 37.5 20.2 4.9 11.1 20.7 28.6 20.2 24.1 16.0 27.8 11.7 11.1 12.5 10.2 28.6 50.0 25.2 43.9 21.5 32.6 24.1 28.6 22.0 26.1 8.7

41.7 20.0 19.4 22.3 22.8 32.0 33.7 31.8 32.3 25.3 25.7 23.9 24.3 27.5 27.2 31.7 17.4 28.3 25.8 29.0 26.1 23.8 32.6 22.1 15.5 21.2 20.1 16.1 29.4 17.6 20.6 19.1 31.1 15.1 19.7 20.8 29.1 19.4 16.0 16.7 15.9 19.4 20.7 17.6 21.1 26.9 21.0 27.2 33.8 18.4 21.0 30.5 20.4 21.1 28.7 19.2 20.2 27.0 18.1 20.3 22.7 31.1 22.1 22.4 22.6 22.5 25.1 32.3 22.4 33.4 23.1

69765 96.6 7942 98.6 12036 98.3 3532 98.0 2309 98.4 1418 99.6 69 100.0 3165 97.3 35883 95.0 438 97.9 2973 97.7 14411 97.6 2772 97.2 11396 97.7 1578 98.4 15932 98.2 103024 98.7 8465 99.4 5850 98.9 12858 99.3 74632 98.5 21604 98.8 1265 98.7 1061 99.5 727 99.6 317 99.4 1869 99.2 15257 98.6 26058 99.0 2796 98.9 654 99.4 958 99.6 509 99.0 289 99.7 4837 99.4 15293 98.8 13519 98.2 13411 98.6 791 99.0 12386 98.6 2156 97.0 1299 96.7 754 97.9 62279 98.2 4975 97.5 56396 98.3 24156 97.6 5235 96.9 18594 97.8 8107 98.8 2159 98.3 5757 99.0 4044 98.0 42991 97.7 5240 96.9 36402 97.7 20631 98.1 10645 98.1 13794 97.6 14040 98.0 3757 97.3 10202 98.3 1199 97.0 2240 97.9

838

*Important. See note on population page.

780

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Breast (C50) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 63 184 310 42 262 120 29 90 134 21 111 20 6798 760 5823 266 30 228 33 0 5 28 728 79 622 317 35 269 76 82 477 45 421 26 653 83 539 1787 67 229 85 1390 147 42 103 692 65 617 34 25 125 88 46 197 1 9 69 1 3 106 13 16 43 133 2 93 64 62 8 191 181 6 13 8 5 22 18 72 15 95.2 98.9 97.1 100.0 96.9 100.0 100.0 100.0 98.5 100.0 98.2 90.0 97.4 97.4 97.3 98.1 100.0 97.8 90.9 0.0 100.0 89.3 96.2 94.9 96.5 98.7 97.1 98.9 93.4 95.1 97.9 93.3 98.3 92.3 99.4 100.0 99.3 98.7 100.0 99.1 98.8 98.5 97.3 95.2 98.1 96.5 93.8 96.9 100.0 100.0 99.2 100.0 95.7 93.9 100.0 77.8 100.0 100.0 100.0 87.7 100.0 100.0 79.1 75.2 100.0 89.2 93.8 80.6 100.0 85.9 87.8 83.3 100.0 87.5 100.0 95.5 88.9 88.9 80.0 0.0 0.5 1.3 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 10.0 1.2 1.3 1.2 0.8 0.0 0.9 9.1 0.0 0.0 10.7 1.0 1.3 1.0 0.9 2.9 0.7 0.0 3.7 0.6 2.2 0.5 3.8 0.6 0.0 0.7 0.7 0.0 0.4 0.0 0.8 0.7 0.0 1.0 1.7 4.6 1.5 0.0 0.0 0.8 0.0 4.3 3.0 0.0 0.0 0.0 0.0 0.0 1.9 0.0 7.0 4.5 0.0 2.2 0.0 1.6 0.0 4.7 4.4 16.7 0.0 12.5 0.0 4.5 5.6 2.8 13.3 4.8 0.5 1.6 0.0 1.5 0.0 0.0 0.0 0.7 0.0 0.9 0.0 0.9 0.7 0.9 0.8 0.0 0.9 0.0 0.0 0.0 0.0 1.8 0.0 1.9 0.3 0.0 0.4 1.3 1.2 1.3 2.2 1.2 0.0 0.0 0.0 0.0 0.3 0.0 0.4 1.2 0.3 0.7 0.0 1.0 1.0 1.5 0.8 0.0 0.0 0.0 0.0 0.0 1.5 14.3 18.5 23.5 33.3 22.5 32.5 48.3 27.8 25.4 28.6 23.4 45.0 22.9 29.6 22.6 30.1 33.3 30.3 30.3 1.0 40.0 21.4 25.8 31.6 26.2 28.4 37.1 28.6 27.6 24.4 22.2 26.7 22.3 19.2 21.4 31.3 20.4 25.2 17.9 29.3 31.8 24.7 19.7 28.6 16.5 13.3 27.7 12.0 23.5 24.0 29.6 21.6 28.3 19.8 Female Cases MV(%) DCO(%) UB(%) MI(%) 5015 25386 34337 3770 29961 13845 2801 10870 19564 1685 17697 3222 764169 66900 668489 31011 3104 26794 5242 160 1327 3650 67708 7618 58020 40806 3548 36041 12184 13397 49083 3566 44441 4034 89413 7442 75089 237378 13427 19968 17512 184010 13371 2974 10251 56843 5499 49755 4884 2325 22098 14728 6593 19401 340 1903 9411 199 703 8508 561 1444 2487 5839 149 5792 1133 1598 746 16409 15456 686 1309 1102 1774 3966 2481 11103 1882 97.4 97.8 97.6 97.7 97.6 98.5 98.3 98.5 97.8 97.7 97.8 96.9 97.9 97.3 97.9 98.1 97.4 98.1 97.9 98.1 98.6 97.7 97.3 97.3 97.2 97.2 96.3 97.3 93.4 98.4 98.4 98.0 98.5 97.7 98.7 98.3 98.6 98.5 99.4 98.1 99.1 98.4 97.8 97.7 97.8 96.9 95.8 97.1 99.1 98.2 98.8 99.0 97.8 96.7 95.9 85.4 97.3 99.5 89.2 91.4 99.5 98.7 80.1 83.7 95.3 85.9 98.1 87.4 98.5 92.9 94.0 95.2 93.1 94.6 97.1 93.0 96.6 90.1 94.6 1.5 1.0 0.9 0.7 0.9 0.7 0.5 0.7 1.1 1.4 1.0 2.1 1.0 1.3 1.0 0.8 0.9 0.8 1.1 0.6 0.8 1.2 0.8 0.8 0.8 1.9 2.7 1.9 1.5 0.8 0.6 0.7 0.6 1.5 0.6 0.7 0.6 0.6 0.2 0.7 0.4 0.7 0.9 0.9 1.0 1.5 2.2 1.5 0.1 0.9 0.5 0.3 0.8 1.4 2.9 0.0 0.2 0.0 0.7 0.2 0.0 1.6 1.1 0.0 4.8 0.0 4.3 0.4 0.9 0.8 0.4 5.3 1.6 1.0 2.7 1.2 2.5 2.1 0.5 0.7 0.8 0.8 0.8 0.2 0.3 0.2 0.7 0.5 0.7 0.2 0.5 0.6 0.5 0.4 0.5 0.4 0.3 1.3 0.2 0.3 0.8 0.9 0.9 0.5 0.7 0.5 0.4 0.3 0.3 0.4 0.3 0.1 0.2 0.3 0.2 0.3 0.1 0.3 0.2 0.3 0.9 0.9 0.9 1.0 1.2 0.9 0.0 0.2 0.2 0.2 0.3 1.0 0.9 0.1 0.0 0.0 1.0 0.0 0.0 0.6 0.4 0.0 0.0 0.0 0.0 0.0 0.3 1.7 1.3 1.2 1.6 0.6 0.0 0.0 0.2 0.0 0.3 19.9 20.9 21.8 30.1 20.9 23.9 31.2 22.1 22.9 30.6 22.3 20.0 21.6 30.9 21.2 24.1 30.1 23.9 20.6 23.1 22.7 19.4 22.9 31.3 22.2 23.7 32.6 23.6 21.5 18.9 23.5 33.0 23.2 22.2 20.5 29.5 20.2 21.3 15.6 30.0 17.3 21.4 22.8 33.0 20.0 21.7 32.3 21.0 20.9 20.4 17.0 17.4 23.5 21.0 32.9 26.1 * 21.1 * 21.5 21.5 * * 11.3 * 26.8 * 5.4 24.1 * * * 27.9 22.4 23.4 19.6 21.4 22.7 30.5 23.5

0.0 100.0 0.0 11.1 0.0 13.0 0.0 0.0 1033.3 0.0 13.2 0.0 0.0 31.3 0.0 32.6 0.0 0.0 50.0 0.0 31.2 0.0 0.0 0.0 3.7 41.9 2.8 0.0 0.0 23.1 0.0 37.5 0.0 20.0 0.0 18.2 0.0 22.2 0.0 25.0 0.0 40.0

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
781

839

Indices of data quality

Breast (C50) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
782

Female Cases MV(%) DCO(%) UB(%) MI(%) 26441 2540 1857 968 803 1756 163 8501 491 551 519 1055 845 265 1497 5148 5335 4553 270 512 959 538 593 940 3071 23551 1905 998 14046 6288 19351 16212 10984 24587 18687 2828 17864 3610 2268 1513 2547 3514 3675 4278 1599 1825 1212 1929 7317 13711 6113 5075 8997 8671 3965 756 9637 800 2622 1833 4932 2598 575 5368 2808 1058 8570 1840 748 1995 4313 1971 1415 831 667 4074 3155 2088 6894 95.8 95.6 97.5 97.1 93.8 96.1 92.6 95.4 97.6 97.1 97.3 94.3 93.3 97.0 97.3 86.4 99.1 99.1 99.6 99.0 96.5 89.6 94.6 92.0 96.8 95.3 97.5 93.8 95.3 99.0 94.6 84.4 78.1 90.6 96.6 95.0 99.1 98.9 98.7 99.3 98.7 98.9 98.9 99.7 98.7 98.0 98.6 98.7 91.5 94.2 87.6 92.7 93.0 90.6 97.0 99.7 96.2 93.8 92.1 96.9 95.2 91.8 95.8 95.0 99.3 91.9 97.0 98.4 94.4 96.7 96.4 82.3 96.7 95.3 96.9 96.4 93.0 95.0 96.7 1.3 1.3 0.8 1.0 1.0 1.1 1.2 1.8 0.4 2.2 2.5 1.1 3.4 0.0 0.0 5.5 0.0 0.0 0.0 0.0 0.1 1.9 3.0 1.1 0.0 3.9 1.3 4.7 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 3.3 1.2 0.1 0.0 0.6 0.0 0.0 4.6 0.1 17.8 2.6 1.6 0.0 0.1 0.0 0.0 0.1 0.4 0.0 0.2 0.0 0.0 0.3 0.0 0.9 1.3 0.1 0.0 0.0 0.0 0.5 0.0 0.0 0.4 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.3 1.2 0.0 0.1 5.3 0.0 0.0 18.4 21.0 15.5 16.1 19.9 18.9 23.0 16.2 14.9 20.4 13.6

201 15 11 4 4 13 0 76 4 6 12 8 6 15 24 83 22 18 2 2 13 3 6 16 68 218 16 9 108 63 207 163 163 213 131 23 73 20 25 12 13 30 35 31 13 20 9 27 48 120 59 33 54 77 29 7 63 8 26 13 49 28 7 65 25 4 71 15 6 18 36 23 10 8 5 37 25 28 48

84.6 80.0 90.9 100.0 75.0 100.0 0.0 48.7 75.0 100.0 100.0 100.0 100.0 93.3 100.0 65.1 95.5 94.4 100.0 100.0 100.0 100.0 100.0 93.8 97.1 95.0 100.0 100.0 95.4 100.0 89.9 78.5 63.8 88.7 97.7 87.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 96.8 100.0 100.0 100.0 100.0 89.6 93.3 72.9 84.8 88.9 84.4 96.6 100.0 92.1 100.0 92.3 100.0 98.0 92.9 100.0 90.8 100.0 100.0 97.2 100.0 100.0 100.0 94.4 73.9 100.0 100.0 100.0 97.3 92.0 100.0 95.8

12.4 13.3 9.1 0.0 25.0 0.0 0.0 48.7 25.0 0.0 0.0 0.0 0.0 0.0 0.0 12.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.6 0.0 0.0

0.0 30.8 0.0 20.0 0.0 18.2 0.0 25.0 0.0 50.0 0.0 30.8 0.0 1.5 0.0 29.6 0.0 25.0 0.0 0.0 0.0 62.5 0.0 0.0 0.0 0.0 0.0 50.0 0.0 0.0 0.0 0.0 15.4 0.0 233.3 0.0 2333.3 0.0 1.5 35.3 0.0 0.0 0.0 0.0 0.0 9.2 0.0 30.7 2.8 2.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.0 0.0 0.0 34.9 18.8 64.8 27.1 35.6 50.9 44.6 36.6 47.8 21.9 55.0 28.0 41.7 69.2 53.3 34.3 41.9 76.9 40.0 55.6 40.7 70.8 19.2 52.5 21.2 57.4 77.9 37.9 57.1 33.3 25.0 15.4 7.7 10.2 17.9 20.0 28.0 36.6 6.7 50.0 22.2 16.7 26.1 30.0 50.0 25.0 18.9 44.0 14.3 39.6

25.5

* * *

4.5 * 34.2 * 17.0 14.8 * 17.3 * 34.2 30.1 26.9 42.7 * * 28.9 34.1 * 37.6 39.1 36.1 45.0 22.9 21.7 27.2 28.7 23.4 24.3 22.5 25.6 31.7 30.9 27.3 29.5 72.4 24.8 34.9 22.9 29.3 33.5 35.3 23.0 33.1 30.9 22.0 26.7 25.7 29.2 33.4 29.6 24.0 27.8 30.0 26.8 32.5 26.2 24.6 30.1 29.3 26.0 24.6 29.0 28.1 23.3 26.0

4.9 5.5 5.6 0.0 0.0 0.0

4.2 4.1 2.6 0.2 0.2 0.2

0.0 10.4 5.8 10.2 15.2 7.4 9.1 3.4 0.0 3.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.1 5.8 4.3 5.0 6.3 4.2 4.0 1.8 0.1 1.5 1.4 1.6 0.5 0.6 1.3 1.0 1.2 0.0 1.0 0.3 0.3 2.1 0.1 0.6 0.7 1.1 0.8 0.1 0.8 0.3 0.3 0.8

840

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Breast (C50) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 32 60 11 79 16 17 24 78 67 72 230 88 42 4 29 49 27 4 9 16 24 15 11 18 163 11 5 6 10 9 6 19 358 19 21 58 61 81 156 60 245 320 107 154 37 77 160 3 75 37 6 15 33 7 3 74 25 3 0 5 4 12 87.5 96.7 100.0 100.0 75.0 76.5 91.7 97.4 100.0 86.1 88.7 89.8 97.6 75.0 100.0 98.0 96.3 100.0 100.0 100.0 100.0 100.0 90.9 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 100.0 90.2 90.1 94.9 95.0 75.1 90.9 84.1 95.5 89.2 98.7 97.5 100.0 94.7 100.0 100.0 100.0 100.0 100.0 66.7 95.9 100.0 100.0 0.0 100.0 100.0 100.0 3.1 0.0 0.0 0.0 12.5 0.0 0.0 0.0 3.9 8.0 2.4 25.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 9.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.9 0.0 0.0 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 5.0 5.3 1.9 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 50.0 46.7 27.3 25.3 39.1 44.1 66.7 55.2 59.7 31.3 64.8 52.4 75.0 17.2 32.7 50.9 33.3 37.5 29.2 26.7 72.7 38.9 34.4 27.3 16.7 22.2 66.7 42.1 38.8 28.6 31.0 27.9 34.6 28.2 30.0 20.0 29.1 45.8 33.8 13.5 39.0 23.8 16.0 24.3 55.6 226.7 15.2 28.6 66.7 20.3 16.0 Female Cases MV(%) DCO(%) UB(%) MI(%) 4645 6192 1027 12521 1840 2083 4068 5924 7428 10556 10774 9223 4910 517 2675 4454 2998 389 1460 1651 2282 1447 1232 1998 29643 1759 675 653 1395 1130 975 2547 56440 3486 3193 9817 8126 13745 21597 8802 27384 44467 16611 17740 4688 17137 91.4 92.3 96.1 98.4 92.7 90.1 95.4 98.7 90.6 82.0 88.5 92.0 98.0 97.9 95.7 97.0 97.2 92.8 97.0 98.4 95.4 98.5 95.8 96.3 99.8 97.8 97.3 98.3 97.9 98.3 99.3 98.8 99.4 99.6 99.1 95.8 92.8 93.1 89.8 95.1 87.2 89.2 91.6 96.1 96.4 96.4 2.6 0.7 1.0 0.3 1.8 2.0 0.2 8.0 4.7 5.1 1.4 1.0 1.9 1.7 1.5 4.4 1.9 0.4 2.1 0.8 2.6 1.5 0.2 0.0 0.3 0.9 1.0 0.0 0.8 0.1 0.0 0.0 0.0 0.0 2.4 0.3 0.1 0.0 2.1 0.2 0.2 0.6 0.2 0.9 0.4 0.5 0.5 0.3 0.0 0.4 0.0 0.1 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.3 0.9 0.0 3.0 4.0 2.5 0.8 0.0 0.0 0.3 0.0 0.0 0.1 0.2 0.0 0.8 0.0 0.0 0.6 0.1 0.1 0.0 0.0 0.1 0.0 0.3 44.8 43.6 38.8 29.4 34.0 * 38.0 33.7 29.9 * 33.0 53.5 37.1 42.4 39.5 35.2 35.0 29.3 30.6 28.3 29.7 25.5 31.7 24.7 29.2 34.8 25.4 19.2 33.2 28.6 32.3 30.0 23.0 18.8 31.1 28.8 31.7 32.9 32.8 31.6 31.7 33.0 33.5 31.9 32.8 31.2 32.9 22.1 23.8 20.7 24.2 25.1 24.0 21.2 22.3 28.3 27.7 15.7

0.0 3.3 1.2 0.6 0.0 0.8 3.8 9.3 1.9 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 33.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.1 2.0 0.9 0.8 0.6 0.9 4.4 4.0 1.0 0.7 0.3 0.5 0.4 0.6 0.0 0.1 1.2 0.7 0.1 4.1 1.0 0.1 0.0 0.0 0.3 0.0 0.3

16.7

19216 97.9 277 98.9 10449 97.9 4952 98.3 1405 98.9 14383 96.9 5228 98.6 906 97.9 339 92.6 11339 97.3 4078 99.5 241 100.0 433 100.0 667 99.3 1311 99.9 1184 98.9

17.5

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
783

841

Indices of data quality

Cervix uteri (C53)

Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White Female Cases MV(%) DCO(%) UB(%) MI(%) 229 95.2 109 98.2 72 100.0 649 59.2 818 72.5 139 1154 302 711 6028 216 1314 1655 637 220 498 5389 797 828 267 191 138 6 295 2623 30 214 1157 391 723 119 965 8109 909 532 2990 3524 1263 112 59 61 13 295 581 2769 262 64 91 23 69 1404 740 799 700 82 600 194 151 23 4771 854 3794 2098 662 1371 647 247 353 216 3401 775 2492 1410 651 1245 1244 513 711 151 126 95.0 91.2 89.1 98.5 85.6 92.6 93.8 89.2 93.4 92.3 96.2 96.3 99.0 98.6 99.3 99.5 98.6 100.0 99.0 93.4 100.0 99.1 96.1 94.9 97.2 97.5 96.8 98.8 99.0 99.4 99.2 98.2 99.3 100.0 98.3 98.4 100.0 99.7 99.1 99.3 98.9 100.0 100.0 95.7 98.6 99.5 99.2 97.4 98.6 97.6 98.7 94.3 98.7 91.3 97.9 97.3 98.0 97.5 97.9 97.4 98.8 98.8 99.2 96.8 97.3 97.2 97.2 97.8 98.5 96.3 98.6 98.6 98.5 97.4 99.2 0.0 0.0 0.0 0.0 0.0 2.2 6.3 2.6 0.1 0.0 0.0 0.0 0.0 0.0 1.8 0.0 2.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.7 0.0 0.0 2.1 2.6 1.2 1.7 1.9 0.5 0.4 0.0 0.2 0.7 0.3 0.0 1.7 1.6 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.6 0.6 1.2 0.5 4.1 0.0 4.3 0.2 0.5 0.2 0.4 0.3 0.5 0.3 0.4 0.3 0.0 0.7 0.9 0.6 0.8 0.2 1.3 0.5 0.2 0.7 0.7 0.0 * * * *

0.9 7.0 2.9 2.2 5.6 1.1 4.1 2.3 2.1 3.3 3.9 2.6 0.3 0.0 0.4 0.4 0.0 0.0 0.7 0.4 0.0 0.5 0.7 1.3 0.4 0.0 0.7 0.3 0.3 0.2 0.2 0.5 0.2 0.0 0.0 0.0 0.0 0.3 0.2 0.3 0.4 0.0 0.0 4.3 1.4 0.1 0.5 1.1 0.7 1.2 0.7 1.5 1.3 4.3 1.6 2.1 1.5 1.7 1.5 1.8 0.6 0.8 0.3 3.2 1.5 1.5 1.6 1.0 1.1 1.2 0.4 0.4 0.4 0.7 0.8

22.9

26.6 15.5 17.5 20.1 24.9 44.0 34.1 39.5 31.2 26.7 29.4 24.1 27.1 31.5 28.3 44.2 34.9 29.7 30.0 35.5 34.7 43.0 32.0 21.0 33.6 28.0 29.4 44.0 20.5 32.5 24.6 40.2 14.6 26.5 28.5 51.1 43.8 27.5 34.8 15.9 21.4 35.5 25.2 26.7 30.5 26.7 33.5 35.8 39.1 30.4 39.5 29.0 28.7 33.8 27.0 24.3 26.3 23.8 33.8 30.6 35.7 29.8 31.4 30.4 28.2 29.7 35.7 25.7 37.1 18.3

842

*Important. See note on population page.

784

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Cervix uteri (C53) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Female Cases MV(%) DCO(%) UB(%) MI(%) 278 1224 2193 425 1690 1013 337 645 1390 216 1146 206 55469 8693 43436 2339 466 1759 394 27 150 201 4976 1199 3533 2569 302 2191 919 719 3020 415 2487 215 5553 826 4075 17731 1395 2360 3732 9923 1113 399 688 5333 712 4439 311 153 1102 734 591 1247 98.2 98.6 97.3 97.6 97.0 97.9 97.9 97.8 97.8 97.7 97.7 95.1 97.4 97.1 97.4 97.4 96.8 97.5 94.9 88.9 95.3 95.0 96.6 96.5 96.6 96.8 94.0 97.1 93.6 98.6 98.1 96.9 98.4 99.5 98.3 98.4 98.3 98.3 99.1 98.2 98.7 98.0 97.8 97.7 97.8 95.3 95.5 95.3 99.0 97.4 98.3 98.4 97.8 97.1 0.0 0.6 0.5 0.5 0.5 0.5 0.6 0.5 1.1 0.9 1.1 3.4 1.1 1.2 1.1 0.7 0.2 0.9 1.5 0.0 1.3 2.0 0.7 1.1 0.6 2.0 4.6 1.7 1.3 0.3 0.5 0.2 0.6 0.0 0.6 0.7 0.7 0.5 0.3 0.6 0.3 0.7 1.2 1.0 1.2 2.2 2.1 2.2 0.3 2.6 0.7 0.7 1.4 1.8 0.0 0.0 0.1 0.0 0.0 0.4 0.0 1.1 0.8 5.4 4.1 0.0 3.3 0.0 1.3 1.3 0.0 6.6 2.0 0.6 4.5 2.0 6.4 3.8 1.1 0.7 1.6 1.2 1.7 0.8 0.6 0.9 0.7 0.9 0.7 1.0 0.9 1.0 0.9 1.5 3.0 1.1 1.3 11.1 0.7 0.5 1.3 1.3 1.4 0.8 0.7 0.8 1.3 0.3 0.6 1.4 0.4 0.0 0.5 0.5 0.4 0.7 0.4 0.9 0.5 0.7 0.8 0.5 1.0 2.3 2.2 2.2 0.0 0.0 0.5 0.4 0.2 0.8 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.4 1.8 1.3 4.5 2.6 1.0 0.0 0.0 0.8 0.0 0.3 29.1 28.2 29.3 30.1 29.6 28.3 28.8 28.5 30.8 42.6 29.1 27.2 30.0 37.7 29.4 29.2 33.9 28.5 28.2 51.9 28.0 25.9 30.2 33.2 29.5 34.0 50.0 32.7 31.7 28.1 32.7 40.0 32.4 31.6 27.0 29.9 26.7 28.2 28.6 34.7 20.1 30.3 32.6 41.9 27.6 31.3 44.5 29.9 22.5 28.1 27.0 28.6 34.5 22.9 36.8 28.9 * 30.3 * 36.0 41.7 * * 19.8 * 27.9 * 4.3 23.1 * * * 29.8 33.2 42.2 19.6 31.4 26.9 42.3 26.8

38 100.0 298 88.9 2251 97.4 33 100.0 86 89.5 722 87.1 133 100.0 101 97.0 2550 88.4 3653 81.2 93 86.0 3121 87.5 741 97.4 1138 88.8 284 91.9 911 93.9 853 94.8 44 93.2 229 90.8 204 93.6 500 97.8 512 87.7 651 96.3 1963 87.3 313 95.2

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
785

843

Indices of data quality

Cervix uteri (C53) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
786

Female Cases MV(%) DCO(%) UB(%) MI(%) 17576 94.7 1812 93.4 1169 98.3 696 97.4 540 98.5 1375 94.9 141 97.2 5033 92.3 283 91.9 58 96.6 90 98.9 416 95.7 671 94.2 108 96.3 159 98.7 1966 90.0 1023 98.8 910 98.8 35 100.0 78 98.7 1297 97.5 546 93.6 573 94.8 136 92.6 467 96.6 2644 285 82 4015 419 1503 5148 1920 5414 2019 771 788 312 165 135 200 328 237 240 149 161 100 110 1102 1937 539 761 714 747 426 74 930 64 171 105 276 195 33 283 172 83 585 106 65 113 312 183 79 63 46 247 179 112 355 96.6 97.9 93.9 99.0 99.0 93.4 94.2 87.6 97.4 97.2 98.2 99.0 99.0 100.0 100.0 100.0 99.7 99.6 100.0 100.0 98.1 100.0 100.0 88.9 94.8 88.1 94.0 91.5 90.0 98.8 100.0 97.7 100.0 90.1 97.1 96.4 93.3 97.0 96.1 100.0 91.6 98.5 99.1 98.5 98.2 98.1 89.1 96.2 93.7 97.8 97.2 90.5 98.2 98.3 0.9 1.3 0.4 0.3 0.2 0.7 0.0 2.0 0.0 3.4 1.1 0.5 2.8 0.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.7 1.9 0.7 0.0 3.0 1.4 3.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.9 1.1 0.1 0.0 1.2 0.0 0.0 6.1 0.0 10.9 0.8 1.9 0.0 0.3 1.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.6 0.0 0.0 2.9 0.2 0.0 0.1 0.0 0.5 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 8.4 0.0 0.0 18.5 22.5 16.2 13.2 12.6 16.9 12.8 15.3 19.4 18.0 20.1

41.4

* * *

* 52.7 * 23.2 11.0 * 12.6 * 29.7 26.3 22.0 50.6 * * 30.2 35.0 * 25.8 36.0 38.1 42.4 39.6 24.0 26.1 24.4 25.0 17.4 20.7 19.2 21.5 21.1 15.0 20.9 83.3 31.9 36.9 31.4 30.0 36.9 33.6 29.7 39.4 15.6 17.5 10.5 14.9 15.9 12.1 20.1 14.5 20.0 6.6 10.8 15.0 12.8 12.6 11.4 6.3 21.7 24.7 29.1 16.1 12.4

3.0 1.4 1.1 0.2 0.0 0.3

0.0 7.8 4.4 3.5 5.8 3.6 5.4 0.5 0.0 0.4 0.0 1.8 0.0 0.4 0.5 0.0 0.4 0.0 0.0 0.3 0.0 0.0 0.0 0.3 0.5 0.0 0.0 0.0 1.6 0.0 0.0 0.0

844

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Cervix uteri (C53) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White Female Cases MV(%) DCO(%) UB(%) MI(%) 980 2400 54 1524 502 702 871 1356 1033 1874 4149 2664 1007 52 323 324 415 36 132 167 244 86 129 141 2235 66 58 22 119 86 46 109 3380 177 191 536 728 1289 2081 407 1809 2842 1257 1448 405 1591 1338 48 805 261 108 837 412 49 73 993 298 16 56 56 47 75 96.3 93.1 98.1 99.6 95.8 92.7 98.7 92.9 96.6 97.6 91.2 96.7 99.7 96.2 97.8 99.4 98.1 100.0 96.2 98.8 95.9 100.0 99.2 97.2 99.8 100.0 100.0 100.0 98.3 100.0 97.8 99.1 99.6 98.9 100.0 97.4 93.1 95.0 97.0 97.8 91.5 91.6 93.3 96.9 96.0 98.1 97.5 100.0 92.4 99.2 99.1 97.4 97.3 100.0 98.6 98.6 100.0 100.0 100.0 100.0 100.0 100.0 1.4 0.5 0.0 0.0 2.0 0.7 0.0 3.0 1.9 2.8 0.3 0.0 1.2 0.3 1.0 0.0 1.5 0.0 0.8 0.0 0.8 0.7 0.0 0.0 0.0 0.8 0.0 0.0 0.9 0.3 0.0 0.0 0.0 0.0 3.7 0.2 0.0 0.0 0.0 0.3 0.2 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.1 0.4 0.0 1.5 2.2 2.5 0.6 0.0 0.0 0.4 0.0 0.0 0.1 0.0 0.0 0.4 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 53.6 50.3 50.0 35.6 44.1 * 42.4 50.7 21.5 * 33.5 60.2 33.4 39.3 26.2 32.7 37.2 28.4 33.7 25.0 27.3 34.1 28.7 25.6 21.7 31.9 35.6 28.8 31.0 31.8 42.0 19.8 23.9 31.2 36.0 38.7 41.4 47.3 39.5 39.5 45.2 42.0 43.4 37.4 36.9 36.5 37.5 31.1 35.4 31.2 34.5 40.1 31.4 35.0 34.7 45.2 34.4 26.2

0.0 2.2 0.6 0.5 0.0 1.1 4.2 2.9 0.8 0.2 0.1 0.3 0.0 0.5 0.0 0.9 0.7 1.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0

26.7

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
787

845

Indices of data quality

Other uterus (C54-55)

Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White Female Cases MV(%) DCO(%) UB(%) MI(%) 28 100.0 144 91.0 37 100.0 57 71.9 77 63.6 95 85.3 361 78.7 68 72.1 129 93.8 2940 76.2 54 92.6 288 87.8 605 85.6 175 68.6 107 96.3 47 100.0 13530 1593 2162 822 415 265 2 577 7031 86 577 2112 454 1613 240 2534 18308 1523 920 2470 13153 3918 225 173 141 60 335 2755 4894 457 109 170 85 50 1020 2853 2007 2867 129 2696 375 235 120 11126 1019 9955 3627 785 2795 1191 285 877 720 8364 836 7253 4219 2375 2507 2083 550 1513 151 297 95.2 98.9 98.2 98.4 99.0 99.6 100.0 97.1 92.1 100.0 98.6 98.2 96.9 98.6 100.0 98.5 98.9 99.6 98.5 99.0 98.9 99.3 99.1 99.4 99.3 100.0 99.1 99.3 99.2 98.5 100.0 98.2 98.8 100.0 99.1 99.3 97.9 99.1 97.7 99.1 96.0 94.9 98.3 98.1 97.1 98.2 98.2 96.9 98.6 98.7 98.2 98.9 97.8 98.4 96.2 98.6 99.0 98.7 98.4 97.9 96.0 98.6 97.4 99.0 0.0 0.0 0.0 0.0 0.0 0.0 16.1 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.1 0.1 0.0 0.0 0.4 0.0 0.3 6.9 0.0 0.2 0.8 1.5 0.5 0.0 0.5 0.3 0.1 0.4 0.3 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.2 0.0 1.2 0.0 0.0 0.2 0.1 0.5 0.1 0.0 0.1 1.3 0.9 1.7 0.1 0.0 0.1 0.3 1.0 0.1 0.3 1.4 0.0 0.1 0.2 0.5 0.2 0.2 0.3 0.6 0.3 1.1 0.1 2.0 0.0 * * * *

8.3 9.1 10.5 4.7 20.6 3.9 8.3 3.7 6.3 5.3 21.7 0.0 0.7 0.1 0.8 0.9 0.0 0.0 1.7 0.8 0.0 0.9 0.5 0.7 0.5 0.0 0.6 0.4 0.1 0.4 0.4 0.4 0.4 0.4 0.0 0.0 0.0 0.9 0.3 0.3 0.7 0.0 0.6 0.0 0.0 0.4 0.2 0.8 0.3 0.8 0.3 1.3 2.1 0.0 1.2 1.8 1.1 1.0 1.5 0.8 0.4 0.0 0.6 1.0 0.9 2.4 0.7 0.4 0.5 0.4 0.6 0.9 0.5 0.7 0.7

20.8

68.4 37.1 52.9 39.5 40.1 44.4 50.7 42.1 90.9 73.6 17.5 15.8 16.2 16.8 21.7 17.0 20.8 17.9 15.1 16.8 23.6 44.1 18.4 11.7 15.7 17.7 13.1 33.3 16.4 17.6 17.3 31.6 17.0 17.4 19.0 34.1 13.8 11.8 9.4 16.0 17.5 18.6 16.4 15.1 26.4 14.8 37.1 48.1 20.8 18.7 32.7 17.4 20.0 33.5 16.5 17.8 28.1 14.7 18.2 19.3 34.2 18.0 19.0 17.2 16.9 21.0 38.0 15.0 35.8 17.8

846

*Important. See note on population page.

788

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Other uterus (C54-55) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Female Cases MV(%) DCO(%) UB(%) MI(%) 1141 5076 7131 651 6355 2916 509 2375 3975 281 3654 560 144439 11540 127614 7057 634 6245 900 55 224 602 14800 1696 12701 8654 568 7830 1896 2260 11503 595 10688 838 17413 1209 14767 44733 2460 3224 3296 35225 2132 553 1537 9148 905 8014 999 519 3852 2634 1552 3983 42 383 1878 17 70 1548 386 293 218 748 11 736 104 148 96 2655 2449 157 228 183 322 687 538 1795 358 97.6 98.6 98.4 97.1 98.5 98.5 97.6 98.6 98.1 97.2 98.1 97.3 98.3 96.8 98.4 98.7 96.1 99.0 96.4 96.4 96.0 96.8 97.9 96.9 98.0 98.6 96.5 98.7 95.6 99.1 98.8 97.1 98.8 99.0 98.8 98.1 98.8 98.8 99.5 97.4 98.7 98.8 98.2 97.6 98.4 97.0 95.0 97.3 99.4 98.3 98.7 98.9 98.6 97.6 97.6 87.2 97.7 88.2 88.6 89.6 99.0 99.3 81.2 86.0 90.9 85.5 93.3 81.8 96.9 94.7 95.9 96.2 88.6 84.2 96.0 82.5 91.3 75.5 89.1 0.9 0.5 0.5 0.8 0.5 0.7 0.8 0.6 0.8 1.1 0.8 1.8 0.7 1.4 0.7 0.3 0.6 0.3 1.8 0.0 1.3 1.8 0.7 1.1 0.6 0.8 2.1 0.7 1.0 0.4 0.4 1.3 0.3 0.5 0.4 0.6 0.4 0.4 0.2 0.6 0.4 0.4 0.6 0.5 0.7 1.6 2.7 1.4 0.0 0.4 0.3 0.3 0.4 1.2 2.4 0.0 0.2 0.0 0.0 0.3 0.5 3.2 1.1 0.0 10.1 0.0 12.8 2.1 0.8 0.8 0.6 10.5 4.4 1.9 10.3 4.5 12.9 7.0 0.7 0.7 0.7 1.2 0.6 0.3 0.6 0.3 0.7 1.1 0.6 0.4 0.4 0.7 0.4 0.4 0.8 0.3 0.7 1.8 0.9 0.5 0.6 0.6 0.6 0.3 0.5 0.3 0.3 0.1 0.3 0.5 0.3 0.2 0.2 0.6 0.2 0.3 0.1 0.7 0.4 0.3 0.7 0.5 0.7 0.9 1.4 0.7 0.0 0.4 0.4 0.3 0.0 0.8 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.0 6.9 0.0 0.0 0.1 0.0 0.0 0.0 1.6 1.1 1.9 0.9 2.7 0.0 0.0 0.7 0.0 0.6 16.2 16.6 17.2 32.1 15.9 18.4 32.4 15.6 18.5 33.8 17.4 22.3 18.3 34.8 17.3 18.8 29.3 18.0 20.3 20.0 21.9 19.4 18.1 33.8 16.2 17.8 33.1 17.3 20.4 18.4 17.5 32.8 17.0 13.8 17.0 30.3 16.3 17.8 14.3 32.7 15.6 17.1 21.0 38.0 15.4 20.5 37.9 19.0 17.1 17.5 16.4 15.9 17.0 18.0 28.6 36.0 * 15.7 * 34.3 22.2 * * 3.4 * 34.4 * 31.3 20.0 32.9 46.4 36.0 33.0 37.5 56.4 38.5 * * *

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
789

847

Indices of data quality

Other uterus (C54-55) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
790

Female Cases MV(%) DCO(%) UB(%) MI(%) 3783 335 225 132 97 227 26 1129 68 51 44 149 149 36 135 1072 867 734 46 87 142 73 93 237 569 86.0 85.4 92.4 87.9 83.5 85.9 88.5 87.8 92.6 98.0 97.7 96.0 96.0 91.7 99.3 81.6 99.1 99.2 97.8 98.9 98.6 74.0 98.9 94.9 98.8 10.3 11.6 6.2 7.6 11.3 7.0 7.7 9.3 1.5 2.0 2.3 0.0 1.3 0.0 0.0 10.4 0.0 0.0 0.0 0.0 0.0 15.1 1.1 0.4 0.0 4.5 0.5 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.4 0.1 0.0 1.0 0.0 0.0 4.9 0.0 9.0 0.3 2.9 0.0 0.2 0.0 0.7 0.4 0.5 0.0 0.2 0.0 0.0 1.2 0.0 2.0 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 1.5 1.0 0.0 0.0 7.8 0.0 0.0 57.2 65.7 59.1 47.7 78.4 60.4 69.2 48.7 48.5 16.8 3.4

19.5

* * *

8.5 * 43.8 * 24.7 9.7 * 26.2 * 35.1 25.0 26.9 33.0 * * 24.9 32.1 * 39.0 31.6 29.2 32.3 20.5 31.9 41.5 36.3 35.7 37.5 36.7 35.5 46.0 43.9 27.3 46.1 51.0 18.6 32.8 14.6 22.5 26.8 23.3 25.4 23.2 26.4 23.8 28.3 33.9 38.5 40.5 32.1 23.9 54.1 31.1 35.5 45.5 27.6 37.2 44.3 33.3 39.2 19.6 37.8 25.5 22.4 29.4

5023 95.0 372 99.2 208 94.7 5913 98.6 922 99.8 3073 94.6 5658 93.7 2711 86.1 8489 96.9 3215 96.4 948 97.7 3609 98.8 599 98.8 282 98.6 237 97.5 395 99.2 445 98.7 460 97.8 448 100.0 211 100.0 328 96.6 209 95.2 254 97.2 1694 92.6 3902 94.7 803 82.9 1224 92.2 1616 94.4 1561 91.0 847 97.5 122 98.4 1308 95.7 144 99.3 369 94.9 286 97.6 867 92.0 369 92.7 116 89.7 719 95.4 493 98.8 197 84.3 1356 96.3 355 94.6 178 92.1 323 92.9 680 92.6 411 87.1 270 94.8 209 95.2 121 97.5 632 95.1 593 89.5 321 96.3 1061 95.6

4.2 4.9 1.5 0.2 0.3 0.4

0.0 6.8 4.6 7.0 7.8 2.6 5.0 1.5 0.0 1.9 0.0 1.1 0.0 0.7 0.5 2.6 1.7 0.0 4.6 0.8 0.6 2.2 0.0 1.5 1.7 1.5 1.0 0.8 1.1 0.0 0.3 0.7

848

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Other uterus (C54-55) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White Female Cases MV(%) DCO(%) UB(%) MI(%) 1878 96.4 2555 95.2 258 98.8 2813 98.5 501 94.2 711 94.2 1034 97.5 1006 97.7 1373 90.5 3245 92.9 2662 90.2 3492 95.4 1455 99.0 152 88.2 623 96.5 953 96.3 616 95.0 124 93.5 328 96.6 452 97.3 530 97.0 357 96.9 286 93.4 455 95.8 7068 99.9 234 99.1 111 99.1 143 97.9 266 97.7 186 98.9 156 96.8 349 99.1 7637 99.6 487 100.0 507 99.4 1566 95.8 1179 92.2 1965 94.5 3031 95.7 1186 96.1 3870 88.5 6111 91.2 2568 94.0 2842 95.9 643 95.8 2505 95.8 2375 98.0 36 94.4 1461 97.1 751 97.3 168 97.0 2161 97.4 603 96.4 88 95.5 73 93.2 1503 97.2 821 99.3 46 100.0 114 99.1 161 100.0 221 98.6 211 99.1 1.5 0.7 0.4 0.2 0.6 1.0 0.1 8.2 4.7 3.8 0.8 5.3 2.1 1.6 2.3 4.8 1.8 0.9 1.7 1.1 3.5 2.9 0.4 0.0 0.0 0.4 0.0 0.6 0.9 0.2 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 4.2 0.3 0.1 0.3 0.7 0.3 0.4 0.8 1.6 0.0 0.0 0.2 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.3 0.3 0.0 1.9 3.0 1.9 0.4 0.0 0.0 0.2 0.0 0.0 0.1 0.4 0.0 0.4 0.7 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 37.4 29.4 20.2 23.1 24.7 * 29.9 26.2 13.4 * 41.4 46.3 35.4 32.4 28.9 28.3 32.6 29.7 30.8 28.2 28.4 30.8 27.7 23.2 28.3 33.6 22.7 18.8 25.2 21.7 24.1 24.2 23.7 24.4 26.3 25.2 22.9 24.7 25.1 24.2 25.5 28.5 26.9 25.3 24.5 27.2 27.1 18.7 19.4 17.3 19.0 20.8 17.8 21.4 27.3 49.3 28.4 15.1

0.0 1.3 0.8 1.0 0.7 1.3 4.9 3.0 1.9 0.6 0.7 0.6 0.0 0.6 0.0 0.0 1.2 1.5 1.1 4.1 1.6 0.1 0.0 0.9 0.0 0.0 0.0

10.9

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
791

849

Indices of data quality

Ovary (C56)
Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White Female Cases MV(%) DCO(%) UB(%) MI(%) 53 290 34 114 122 97 331 52 126 3197 81 426 483 207 70 68 8326 815 1365 428 283 137 4 342 4580 46 326 1721 270 1431 129 1702 11298 996 478 1758 7981 2275 121 130 83 31 226 1562 2961 216 104 86 52 40 739 1633 1467 1412 45 1340 193 123 59 7411 510 6817 2573 477 2061 843 206 612 440 4556 417 3987 2204 1275 1516 1438 322 1111 106 234 92.5 88.3 97.1 49.1 54.1 75.3 85.2 76.9 95.2 74.4 85.2 72.8 73.9 82.6 92.9 98.5 85.1 92.5 92.2 89.3 90.1 93.4 100.0 90.1 79.8 93.5 91.4 88.8 84.1 89.7 94.6 92.0 94.0 96.4 90.6 96.3 93.3 94.9 91.7 98.5 96.4 100.0 96.5 94.2 95.0 89.8 95.2 94.2 100.0 100.0 96.1 94.9 92.0 92.9 93.3 92.9 88.1 84.6 93.2 91.3 86.5 91.6 89.9 85.3 90.8 94.5 89.8 95.9 91.1 92.1 86.8 92.5 93.6 90.8 89.3 91.2 88.5 91.9 89.6 94.4 1.9 0.0 0.0 0.0 0.0 7.2 10.6 1.9 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.8 0.0 0.2 0.0 0.0 0.0 0.0 0.9 17.7 0.0 0.0 2.8 3.3 2.6 2.3 2.1 1.1 0.8 1.7 0.5 1.2 0.4 0.8 0.8 0.0 0.0 0.0 0.4 0.8 2.3 1.0 1.2 0.0 0.0 0.5 0.8 1.4 0.6 2.2 0.6 2.1 3.3 0.0 0.4 0.4 0.4 0.7 0.8 0.6 0.5 1.5 0.2 0.2 0.3 0.7 0.3 0.8 0.5 3.1 1.1 1.2 1.1 0.9 1.3 * * * *

3.1 14.8 13.4 3.3 9.6 4.0 9.1 3.7 7.7 7.2 5.8 0.0 1.4 0.6 1.2 2.6 0.0 0.0 1.2 1.5 0.0 3.7 4.5 5.9 4.3 3.1 1.6 0.9 0.3 1.7 0.5 1.1 1.2 0.8 0.0 0.0 0.0 0.0 1.6 0.8 1.9 0.0 0.0 0.0 0.0 0.9 0.7 2.9 2.1 2.2 1.9 4.1 4.1 5.1 3.5 4.3 3.5 3.9 4.8 3.7 2.5 3.4 2.3 4.1 2.8 5.3 2.5 1.6 2.6 1.5 1.4 2.5 1.1 2.8 0.4

20.3

59.8 31.7 38.5 43.7 38.3 46.9 59.9 53.0 50.7 28.6 67.4 67.0 75.7 66.4 68.6 92.0 75.0 73.7 62.8 63.0 82.8 72.3 83.0 71.1 56.6 68.8 65.5 49.5 73.0 49.8 70.9 62.2 64.5 50.0 68.6 65.3 79.2 53.8 55.8 53.8 60.0 49.3 74.3 63.1 66.4 62.2 67.7 78.2 92.7 62.7 65.7 65.1 66.2 67.4 66.0 68.0 59.5 64.1 58.7 76.4 67.9 77.5 68.6 75.2 72.2 66.1 67.0 72.0 65.6 67.9 73.1

850

*Important. See note on population page.

792

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Ovary (C56) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture Female Cases MV(%) DCO(%) UB(%) MI(%) 538 2656 3771 336 3385 1586 258 1313 2101 131 1950 394 84293 5946 75272 3942 320 3473 602 47 166 382 8177 818 7068 4229 255 3886 1302 1325 5647 301 5213 426 9907 657 8477 26634 1518 1762 2344 20761 1361 273 1069 5991 478 5358 601 223 2414 1670 831 2179 90.9 92.1 91.2 89.9 91.4 91.7 89.5 92.2 91.1 88.5 91.2 89.6 91.7 87.6 91.8 92.4 88.1 92.7 92.0 85.1 92.2 92.7 90.7 90.5 90.6 91.2 89.4 91.2 87.0 92.2 92.3 89.7 92.3 95.1 92.8 90.9 92.8 92.8 95.6 89.3 95.4 92.6 90.5 81.3 92.9 90.3 86.6 90.7 93.5 94.2 93.0 93.1 88.0 89.0 2.0 2.4 1.5 0.6 1.5 2.0 1.9 2.0 2.4 1.5 2.5 5.8 2.4 3.1 2.4 2.1 1.6 2.2 3.3 6.4 3.0 3.1 1.9 1.0 2.1 4.1 3.9 4.2 1.5 1.8 1.1 1.0 1.1 0.5 1.7 2.1 1.7 1.4 0.4 2.0 0.9 1.5 2.4 4.0 2.1 4.1 5.2 4.1 0.2 1.8 0.9 0.8 2.4 3.8 4.1 0.0 0.8 0.0 0.8 0.5 0.0 2.9 1.2 0.0 5.6 0.0 9.3 0.0 3.2 2.6 3.1 11.2 5.0 2.2 12.0 8.5 9.6 14.2 2.0 2.2 2.0 2.4 1.9 0.9 0.8 1.0 2.9 3.8 2.8 0.5 1.4 2.0 1.4 1.3 3.1 1.0 0.7 0.0 0.6 0.8 1.7 1.7 1.7 2.1 3.1 2.0 1.1 1.5 0.7 1.0 0.7 0.9 0.8 1.1 0.8 1.2 1.1 1.8 0.5 1.2 3.3 5.1 2.7 2.2 2.5 2.0 0.0 1.3 1.8 1.7 1.6 2.6 0.0 0.0 0.0 0.0 2.3 0.0 0.0 0.0 18.4 0.0 0.0 0.4 0.0 0.0 0.0 2.4 1.9 4.7 3.0 1.7 0.0 0.0 0.9 0.0 0.6 80.7 65.8 69.1 65.2 69.7 65.4 64.7 65.6 71.7 79.4 71.6 65.2 67.0 71.5 68.0 62.6 66.6 63.7 61.6 42.6 56.0 66.0 60.9 63.9 61.4 71.4 77.6 72.4 63.0 76.2 70.2 75.1 71.5 68.5 64.4 65.4 66.2 65.2 48.0 68.8 47.6 68.6 67.2 68.5 67.5 65.8 73.4 66.4 61.2 70.4 65.6 65.1 74.1 65.2 67.3 51.2 * 101.8 * 52.6 41.9 * * 25.0 * 35.1 * 33.0 63.3 47.4 52.3 38.0 55.8 56.9 69.7 53.1 * * *

49 85.7 322 74.5 616 92.4 47 100.0 133 82.7 1634 81.9 139 89.9 190 97.4 559 62.8 1802 81.4 45 91.1 1541 76.4 282 91.8 443 72.9 148 97.3 1741 86.0 1617 88.7 64 82.8 232 85.8 239 80.3 313 93.6 668 75.7 448 82.6 1994 72.0 352 74.7

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
793

851

Indices of data quality

Ovary (C56) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
794

Female Cases MV(%) DCO(%) UB(%) MI(%) 5334 565 340 167 186 354 43 1618 116 64 60 230 289 111 201 1133 771 619 44 108 235 124 178 195 425 4153 338 128 4081 622 2208 3729 2529 5834 2984 784 2217 398 246 191 336 371 378 311 232 199 129 165 1175 2561 861 842 1267 1402 560 105 1531 96 243 163 593 308 82 574 310 127 881 268 107 209 482 297 161 110 95 483 420 252 680 86.2 87.6 92.1 88.6 87.6 79.9 86.0 86.4 89.7 79.7 96.7 90.4 90.7 88.3 97.0 72.9 95.5 96.0 93.2 93.5 94.9 72.6 93.8 92.3 95.5 89.3 91.7 87.5 93.5 98.1 86.9 77.8 76.3 88.8 95.0 93.8 95.2 95.2 96.3 93.2 92.6 97.0 95.0 97.7 99.1 90.5 93.0 93.9 72.5 83.3 74.1 75.9 82.6 81.7 89.8 97.1 86.2 91.7 88.1 82.2 81.1 87.3 80.5 81.5 85.2 83.5 94.2 84.7 84.1 82.3 81.7 74.4 80.7 88.2 84.2 85.5 78.6 86.1 85.6 2.8 1.6 2.1 1.2 1.1 2.3 2.3 4.6 1.7 10.9 1.7 3.5 4.8 0.0 0.5 8.5 0.0 0.0 0.0 0.0 0.0 0.0 2.2 1.0 0.0 8.9 2.7 4.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 1.2 0.2 0.0 0.0 0.0 0.0 10.6 0.0 19.8 0.8 2.2 0.0 0.8 0.0 0.0 0.5 1.5 0.0 0.5 0.0 0.0 1.5 0.0 6.1 1.8 0.4 0.0 0.7 0.0 0.8 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 1.9 1.8 0.0 0.2 10.7 0.0 0.0 42.6 46.0 32.9 31.1 37.6 44.6 55.8 36.4 36.2 28.3 10.4

49.8

* * *

* 50.8 * 25.8 30.8 * * 65.4 58.9 64.1 67.1 * * 74.0 45.2 * 55.4 63.7 73.8 69.3 65.4 76.1 74.4 73.8 62.2 72.5 68.5 83.0 88.4 91.5 89.9 115.2 168.4 56.6 71.9 53.6 63.0 64.1 68.2 80.0 75.5 60.4 57.6 61.3 65.4 56.5 76.8 58.9 59.4 47.9 79.0 52.2 57.0 51.7 64.9 57.2 57.8 51.8 50.0 72.7 59.0 53.2 61.5

6.1 3.8 3.1 0.4 0.6 0.8

1.0 23.9 13.2 9.3 21.6 9.4 9.6 5.2 0.0 2.7 2.1 1.6 1.8 0.7 1.6 1.2 2.3 0.6 0.8 0.3 1.1 0.9 0.5 1.7 1.7 4.3 1.8 0.0 1.7 1.0 0.0 1.3

852

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Ovary (C56) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White Female Cases MV(%) DCO(%) UB(%) MI(%) 1405 2120 159 2343 473 563 797 477 902 2547 1720 2140 818 77 600 581 388 81 195 256 338 214 167 264 3989 185 111 82 224 128 128 256 5946 392 345 1543 1294 1963 3399 1246 4131 6896 2494 2789 905 2656 88.3 86.1 90.6 94.0 82.5 87.2 88.7 94.8 81.6 76.1 84.8 88.6 98.3 88.3 92.2 88.8 88.4 79.0 84.6 87.5 88.2 92.1 86.8 89.4 99.9 92.4 90.1 89.0 94.6 95.3 93.0 93.0 96.9 97.4 99.1 85.4 79.4 81.6 79.6 88.6 78.1 77.4 78.6 85.0 87.0 86.9 2.2 0.7 0.6 0.7 3.8 1.6 0.0 13.0 5.9 7.4 1.1 2.6 2.2 2.6 3.9 8.6 4.6 0.4 1.8 0.5 6.0 4.9 0.5 0.9 3.7 0.0 0.8 0.0 4.7 0.2 0.0 0.0 0.0 0.0 2.0 0.5 0.2 0.0 8.8 0.1 0.6 0.6 3.9 1.2 0.3 1.0 1.2 0.5 0.0 0.3 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 1.4 0.4 1.8 0.1 6.3 9.2 3.9 1.2 0.0 0.0 1.4 0.0 0.0 0.0 0.2 0.0 2.4 0.0 0.0 0.0 0.0 0.8 4.2 1.7 2.0 0.0 0.0 66.5 64.7 69.8 67.8 56.8 * 56.0 64.7 75.9 * 64.0 76.1 53.9 62.3 71.5 63.6 49.2 57.5 59.9 61.7 69.2 47.3 59.8 53.3 56.3 81.8 77.5 58.4 60.4 54.9 64.7 71.9 75.0 70.7 79.2 82.0 74.3 73.8 74.0 73.2 75.4 76.0 72.8 72.1 73.1 59.4 75.7 68.8 62.5 59.5 70.4 67.6 73.9 63.4 71.4 61.1 69.3 55.4

0.1 4.3 1.5 2.8 1.3 2.4 9.3 6.3 5.3 0.8 0.6 1.3 4.2 1.7 0.0 0.0 1.5 3.2 2.4 0.0 2.4 0.8 0.0 1.7 0.0 1.8 0.0

1967 91.2 24 83.3 1035 89.4 494 88.3 148 91.2 1515 88.6 500 91.8 84 88.1 36 100.0 1262 90.8 381 92.7 24 87.5 59 94.9 50 96.0 111 93.7 110 90.9

73.6

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
795

853

Indices of data quality

Prostate (C61)
Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 142 273 134 262 418 341 1727 415 1029 16155 529 2070 3406 1075 1932 229 76342 9362 14085 3649 2562 1515 29 3315 37402 542 3881 13398 3460 9447 1496 14987 103927 6246 9190 12278 70762 21432 1903 920 605 229 1740 14539 27673 4491 587 670 466 160 4991 14329 12995 14162 1156 12665 2665 1934 603 72917 7976 63829 23930 7023 16649 7971 2714 5119 4628 41322 6238 33285 17485 11050 13571 15914 4777 11003 1343 2008 90.8 71.4 96.3 57.6 63.4 88.9 95.0 81.2 93.8 83.8 92.4 85.1 78.0 82.9 99.8 94.3 94.3 91.8 96.1 96.1 97.3 99.7 96.6 96.9 93.4 95.6 93.1 94.5 92.4 95.2 96.3 96.2 97.0 97.9 96.6 97.4 96.7 97.1 95.6 98.3 96.7 96.1 97.5 97.0 97.9 97.5 99.7 98.4 98.1 97.5 98.0 97.6 95.8 97.9 97.9 97.8 96.5 96.5 98.0 97.2 95.1 97.4 95.8 93.9 96.6 98.0 97.3 98.3 96.1 96.3 94.8 96.4 96.5 96.1 95.9 96.1 94.0 96.9 94.9 96.0 0.0 0.0 0.0 0.0 0.0 0.3 2.3 1.7 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 2.9 0.1 0.1 0.0 0.0 0.2 0.0 0.4 5.7 0.0 0.0 2.5 3.1 2.3 2.0 1.3 0.6 0.4 0.6 0.5 0.7 0.4 0.6 0.4 1.0 0.4 0.5 0.3 0.4 0.4 0.2 0.3 0.2 0.0 0.3 0.5 0.8 0.3 0.3 0.3 1.7 1.3 1.3 0.3 0.3 0.3 0.7 0.7 0.7 0.7 0.7 0.7 0.2 0.5 0.4 0.5 0.5 0.4 1.6 0.3 0.2 0.3 0.4 0.7 Female Cases MV(%) DCO(%) UB(%) MI(%) * * * *

7.3 15.1 8.5 2.5 12.3 4.8 5.3 3.4 5.1 10.2 11.0 3.1 0.7 0.2 0.9 1.5 0.2 0.0 1.1 0.5 0.4 1.7 1.1 1.4 1.0 0.3 1.2 1.0 0.5 0.9 0.8 1.1 1.0 0.8 0.4 1.0 0.9 0.8 1.1 0.7 0.8 0.0 0.4 0.6 0.0 0.7 0.8 1.3 0.6 0.3 0.6 0.8 0.9 0.3 1.7 3.0 1.5 2.2 2.9 1.9 0.8 1.0 0.6 2.0 2.0 3.5 1.9 1.4 1.0 0.7 0.9 1.4 0.7 2.2 1.0

19.4

58.1 17.4 23.1 22.7 20.4 31.0 31.9 40.1 38.5 25.8 19.0 17.5 17.4 22.2 21.9 23.8 37.9 20.8 18.1 18.5 28.6 22.6 34.9 19.2 10.0 17.8 14.5 9.8 18.0 11.9 15.9 13.3 20.9 11.8 14.2 13.3 16.7 9.0 10.0 10.1 9.4 11.1 15.0 13.8 14.3 14.6 14.6 18.7 21.5 12.8 15.6 20.7 15.2 16.3 22.1 14.0 12.7 15.8 11.3 16.3 17.1 23.1 16.8 19.6 18.4 15.8 16.5 22.7 13.9 21.1 17.1

854

*Important. See note on population page.

796

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Prostate (C61) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 5417 25644 42512 6463 34438 19137 5154 13626 17661 1980 15519 3980 784436 95223 653240 38030 5225 31523 5891 143 1533 4074 70437 12099 56746 38748 4595 31442 11245 13098 53915 5325 46933 4342 97659 11739 79315 255181 10110 30470 17271 189664 15161 4735 10135 55354 6685 47288 6477 2302 21790 14760 7073 20032 78 335 3553 16 47 1838 73 1030 326 1346 36 1219 108 346 143 8689 7779 253 573 690 981 2688 1787 4452 1106 95.4 97.1 97.7 97.0 97.7 98.4 98.0 98.6 96.6 95.5 96.7 94.2 96.4 95.2 96.4 97.7 97.4 97.7 94.4 84.6 93.3 95.1 94.4 95.3 94.2 96.9 95.9 96.9 93.2 96.8 97.2 96.3 97.3 96.6 97.2 97.3 97.2 97.0 97.7 96.5 97.1 97.0 95.3 93.9 96.0 93.1 90.9 93.4 98.3 97.2 96.2 96.3 97.3 96.3 85.9 65.1 91.3 56.3 70.2 68.6 80.8 96.0 68.7 83.5 91.7 75.6 94.4 74.6 87.4 73.0 77.4 75.5 89.7 88.8 94.2 82.5 90.7 72.1 80.0 1.3 1.1 0.7 0.7 0.8 0.6 0.6 0.6 1.4 2.3 1.3 2.7 1.3 1.8 1.2 0.4 0.3 0.4 1.4 2.8 1.8 1.3 0.9 1.2 0.9 1.7 2.4 1.8 2.0 1.5 0.7 1.0 0.7 1.7 0.7 0.7 0.7 0.8 0.5 0.8 0.8 0.8 1.5 1.6 1.4 1.9 3.3 1.8 0.2 1.4 0.8 0.5 1.1 0.9 2.6 0.0 0.5 0.0 4.3 0.4 0.0 2.1 1.3 0.0 9.1 0.0 10.7 0.7 3.0 2.6 2.8 8.9 3.0 1.1 8.0 5.2 17.5 11.8 1.8 1.0 0.8 1.2 0.8 0.3 0.4 0.2 1.1 0.8 1.2 1.3 1.1 1.2 1.0 1.1 1.1 1.0 0.9 0.7 1.2 0.8 2.6 2.0 2.7 0.7 0.6 0.7 0.6 0.4 0.7 0.7 0.6 0.3 0.4 0.5 0.4 0.7 0.5 0.6 0.6 0.7 1.9 2.2 1.7 3.7 4.1 3.7 0.1 0.2 0.7 0.7 0.5 0.9 0.0 0.0 0.0 0.0 4.3 0.0 0.0 1.0 22.4 0.0 0.0 0.2 0.0 0.0 0.7 10.3 8.1 8.3 1.4 2.5 0.0 0.0 1.3 0.0 1.5 14.4 14.9 13.0 15.8 13.0 12.2 15.0 11.4 17.3 22.8 16.7 15.0 15.6 20.9 15.5 12.7 16.5 12.5 16.0 22.4 17.5 15.0 14.7 17.1 14.3 17.2 24.2 17.6 16.5 16.7 15.7 20.2 15.7 15.4 14.2 16.3 14.3 14.4 10.8 17.8 11.7 14.8 16.5 23.2 13.8 16.0 23.3 15.3 14.3 14.1 13.6 13.3 16.2 16.9 51.3 43.9 27.2 68.1 32.3 17.0 47.9 8.3 36.3 25.0 36.3 37.7 29.2 27.1 30.7 42.8 41.2 * * * * * * * * * Female Cases MV(%) DCO(%) UB(%) MI(%)

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
797

855

Indices of data quality

Prostate (C61) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
798

Female Cases MV(%) DCO(%) UB(%) MI(%)

6354 87.2 455 79.6 309 85.8 123 80.5 187 92.0 308 89.6 74 82.4 1947 91.6 75 90.7 88 86.4 58 91.4 186 94.6 187 92.0 166 84.3 206 100.0 1239 69.9 1314 96.6 1093 96.5 84 97.6 137 96.4 211 93.4 106 82.1 127 89.8 508 89.2 1014 91.5 24603 2691 1204 6114 5407 18254 6551 4879 15172 9906 1857 17314 3267 1789 1535 2185 3574 3157 4325 1512 1710 1576 2244 5902 9864 4245 3814 7814 6291 3313 823 8490 626 1752 957 3268 1827 611 3207 2004 298 7321 1225 446 1100 3480 948 776 448 534 2935 2251 1423 4572 95.4 98.6 96.6 92.3 99.4 91.9 62.5 76.9 91.2 87.1 86.8 98.2 98.8 98.4 99.4 98.2 98.9 97.3 99.4 98.6 96.0 96.6 99.2 87.0 85.6 78.1 84.9 88.8 84.8 97.1 98.9 85.9 96.3 88.8 83.1 83.1 85.9 89.5 84.0 98.1 71.5 95.5 92.4 81.4 92.9 89.2 81.3 82.2 82.8 95.3 93.0 86.9 93.5 89.7

3.2 2.4 3.2 1.6 2.1 1.9 0.0 3.1 2.7 13.6 3.4 0.0 4.3 1.2 0.0 10.3 0.0 0.0 0.0 0.0 0.0 4.7 3.9 2.2 0.0 4.1 0.7 2.1

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.8 3.5 0.1 0.0 0.6 0.0 0.0 7.4 0.1 12.9 0.9 4.2 0.0 0.5 0.0 0.2 0.1 0.6 0.0 0.6 0.0 0.0 0.7 0.2 0.3 1.7 0.2 0.0 0.6 0.0 1.0 0.1 0.0 1.0 0.3 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 1.9 2.9 0.0 0.1 9.0 0.0 0.0

37.3 42.4 40.5 56.1 38.0 36.0 26.4 25.4 36.0 5.4 2.7

34.2

* * *

45.3 43.3 18.1 52.8 24.1 14.2 17.9 57.7 20.3 53.4 48.6 43.9 54.4 44.9 22.5 19.3 29.5 20.2 20.9 22.4 22.7 19.3 33.0 27.9 24.5 27.2 59.6 21.5 30.1 18.5 18.6 29.9 22.3 29.2 31.1 22.5 16.2 26.3 28.4 27.1 25.5 22.1 18.5 45.0 22.8 26.0 38.1 27.3 22.5 46.0 39.7 37.5 19.9 21.1 34.6 17.5 19.8

* * * *

* * *

13.0 10.2 3.4 0.4 0.5 0.4

0.1 10.3 12.3 9.6 13.3 6.3 8.4 1.9 0.0 2.3 1.3 1.7 0.8 0.8 2.1 2.6 0.9 0.0 1.7 0.4 0.6 5.6 0.1 1.6 1.6 4.5 2.5 0.2 1.5 0.4 0.1 0.9

856

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Prostate (C61) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 2548 5009 509 14669 633 1468 2002 5755 7139 2654 3385 4821 2875 622 2768 4282 2692 457 1578 1062 1822 1558 1111 1787 37300 1327 686 558 1640 724 826 2234 34831 2108 2029 7547 5424 9897 15705 7073 20113 31674 10334 13588 2759 10668 19271 199 9436 5171 1439 13958 4668 753 233 13827 3762 283 604 328 1184 1140 81.9 88.6 91.0 92.1 67.1 74.9 90.5 98.3 84.0 75.1 84.0 86.2 94.4 85.9 90.0 89.5 86.4 70.2 90.7 89.2 86.5 89.5 88.2 97.3 99.3 93.9 89.7 93.5 96.0 90.5 89.7 95.3 97.9 98.3 97.9 86.1 86.7 88.5 90.1 89.0 82.2 80.9 79.9 89.4 78.3 84.3 94.3 97.0 88.5 95.5 88.0 91.9 94.9 94.7 97.0 89.6 97.1 98.6 96.9 96.6 97.3 96.7 2.9 1.3 1.0 1.0 9.8 4.1 0.6 12.2 8.5 9.3 2.6 4.8 4.7 3.7 6.6 5.7 3.8 0.7 5.3 2.1 4.3 0.6 0.4 0.3 1.4 0.4 2.3 0.6 2.5 0.7 0.0 0.0 0.0 0.0 5.4 0.0 0.0 0.0 5.3 0.1 0.7 3.0 1.8 1.8 1.1 2.4 2.6 1.6 0.3 0.9 0.1 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 2.3 0.5 1.4 0.0 6.7 7.3 3.4 1.5 0.0 0.0 0.9 0.0 0.0 0.3 0.2 0.4 1.3 0.1 0.0 0.4 0.0 0.5 0.0 0.3 0.3 0.6 0.6 46.9 40.4 37.1 36.8 48.8 46.0 40.8 32.4 34.0 60.7 54.2 53.1 43.8 26.8 36.8 26.3 29.8 44.2 29.2 47.5 36.6 29.3 30.5 43.4 32.9 21.0 33.1 28.0 25.8 30.7 24.1 24.0 33.8 31.3 33.4 34.4 32.6 32.3 28.6 36.9 34.4 38.0 32.8 37.5 35.3 23.2 13.6 25.9 23.2 30.0 25.6 20.4 19.0 29.6 20.6 14.7 Female Cases MV(%) DCO(%) UB(%) MI(%)

* *

0.3 2.9 1.5 5.2 0.9 1.7 5.9 5.4 2.7 0.5 0.3 0.8 0.5 1.1 0.0 0.7 1.9 2.2 0.5 2.6 1.9 0.6 0.4 0.5 0.9 0.5 0.6

17.6

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
799

857

Indices of data quality

Testis (C62)
Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 6 100.0 33 97.0 5 100.0 7 71.4 16 50.0 40 95.0 49 81.6 10 100.0 34 97.1 740 76.5 86 97.7 115 93.0 276 89.9 147 92.5 13 84.6 38 100.0 3034 451 520 153 76 39 4 115 1508 19 149 443 34 401 98 665 4585 180 96 1171 3063 926 31 25 8 13 164 640 1126 29 14 11 10 3 444 597 698 493 14 467 50 7 40 1840 70 1735 858 66 779 340 37 294 185 1554 60 1426 817 467 511 454 45 405 14 75 97.2 99.3 99.0 99.3 100.0 100.0 100.0 100.0 95.0 94.7 100.0 99.1 97.1 99.3 100.0 99.2 99.5 99.4 97.9 99.6 99.5 99.6 100.0 96.0 100.0 100.0 100.0 99.5 99.6 93.1 100.0 100.0 100.0 100.0 99.8 99.8 99.0 99.6 100.0 99.6 96.0 100.0 97.5 99.2 97.1 99.3 99.4 98.5 99.5 99.1 97.3 99.3 98.9 99.3 98.3 99.3 99.4 99.8 98.8 99.1 97.8 99.3 100.0 100.0 0.0 0.0 0.0 0.0 0.0 5.0 16.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.8 0.0 0.0 0.2 2.9 0.0 0.0 0.5 0.1 0.0 1.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 3.4 0.0 0.0 0.0 0.0 0.0 0.2 0.3 0.0 0.0 0.0 4.0 0.0 2.5 0.0 0.0 0.0 0.3 0.0 0.4 0.3 0.0 0.3 0.0 0.1 0.0 0.1 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 Female Cases MV(%) DCO(%) UB(%) MI(%) * * * *

3.0 18.8 0.0 2.0 0.0 0.0 2.0 1.2 0.9 1.1 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.2 0.0 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.0 0.2 0.0 0.0 0.0 0.3 1.4 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0

12.1

2.5 16.3 10.0 20.6 13.4 16.3 20.0 13.4 15.0 9.6 4.4 4.2 4.6 5.9 7.9 10.3 25.0 2.6 4.0 10.5 2.7 3.6 2.9 3.7 3.1 6.0 5.7 4.4 12.5 6.5 5.3 4.5 6.5 4.9 4.2 6.6 27.6 9.1 7.0 5.7 3.3 3.0 3.2 6.0 42.9 6.7 17.1 6.3 3.6 10.6 3.1 3.8 10.8 3.1 5.4 4.4 13.3 4.3 3.4 5.8 3.3 5.7 15.6 4.7 14.3 4.0

858

*Important. See note on population page.

800

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Testis (C62) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 204 1019 1292 41 1220 515 28 478 640 17 618 137 29216 887 27275 1183 47 1101 237 16 89 131 2360 108 2190 1507 43 1413 385 612 1739 52 1663 148 3800 121 3465 9956 315 298 1489 7701 385 29 351 2520 77 2373 333 110 983 685 202 914 11 43 292 8 5 142 24 72 75 242 2 256 50 66 13 587 520 41 55 41 81 152 53 264 42 99.0 99.5 99.1 97.6 99.1 99.6 100.0 99.6 99.5 94.1 99.7 99.3 99.2 98.2 99.2 99.6 100.0 99.5 98.3 100.0 96.6 99.2 98.7 98.1 98.7 99.2 97.7 99.2 99.5 99.2 99.6 100.0 99.6 99.3 99.7 99.2 99.7 99.5 99.7 98.7 99.5 99.5 99.0 100.0 98.9 98.2 97.4 98.3 100.0 99.1 99.3 99.9 99.5 98.4 81.8 86.0 96.6 100.0 100.0 88.7 91.7 98.6 82.7 88.8 100.0 87.9 84.0 92.4 100.0 91.1 93.7 92.7 98.2 92.7 97.5 95.4 98.1 90.2 88.1 0.0 0.2 0.1 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.2 0.2 0.2 0.0 0.0 0.0 0.4 0.0 0.0 0.8 0.1 0.0 0.1 0.3 2.3 0.2 0.0 0.2 0.2 0.0 0.2 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.3 0.0 0.9 0.2 0.0 0.0 0.4 0.0 0.0 0.3 0.0 0.0 0.7 0.0 1.3 0.4 0.0 2.0 0.0 1.5 0.0 0.3 0.4 0.0 1.8 4.9 0.0 0.0 1.9 1.5 4.8 0.5 0.0 0.5 0.0 0.5 0.2 0.0 0.2 0.2 5.9 0.0 0.0 0.3 0.7 0.3 0.1 0.0 0.1 0.4 0.0 1.1 0.0 0.5 1.9 0.4 0.3 0.0 0.3 0.0 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.1 0.0 0.3 0.1 0.1 0.8 0.0 0.9 1.0 1.3 0.8 0.0 0.0 0.2 0.0 0.0 0.9 9.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.0 0.0 0.0 0.4 0.0 0.0 0.0 5.3 3.1 7.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 4.3 4.5 17.1 4.1 3.5 14.3 2.7 3.6 5.9 3.6 6.6 5.0 10.8 4.9 3.6 6.4 3.5 6.3 6.3 9.0 4.6 4.8 7.4 4.7 6.4 11.6 6.4 6.2 5.6 4.2 5.8 4.2 4.1 4.3 8.3 4.0 4.9 5.4 10.1 6.0 4.4 7.5 17.2 6.8 5.9 11.7 5.9 3.6 2.7 4.8 3.9 4.0 4.3 9.1 9.3 7.2 40.0 20.4 25.3 14.8 3.4 5.5 7.3 8.6 6.6 15.1 17.8 9.5 * * * * * * * * * Female Cases MV(%) DCO(%) UB(%) MI(%)

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
801

859

Indices of data quality

Testis (C62) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
802

Female Cases MV(%) DCO(%) UB(%) MI(%)

554 47 38 13 20 31 2 181 15 24 37 21 42 12 53 147 85 64 6 15 32 14 11 87 228 1717 146 80 445 158 461 816 610 1859 1361 85 469 198 81 76 145 104 151 178 51 69 46 81 589 1042 308 482 613 587 247 40 583 32 94 43 118 58 25 139 90 55 292 47 27 64 139 108 58 35 40 132 120 95 227

94.8 93.6 94.7 92.3 100.0 93.5 50.0 94.5 100.0 100.0 100.0 100.0 90.5 91.7 98.1 80.3 97.6 96.9 100.0 100.0 87.5 85.7 100.0 96.6 96.5 99.4 100.0 98.8 97.3 99.4 97.0 93.6 65.9 97.8 98.5 98.8 99.4 99.5 98.8 100.0 100.0 100.0 98.7 100.0 100.0 100.0 100.0 97.5 95.2 95.8 94.2 96.9 98.0 94.9 99.6 100.0 97.4 100.0 91.5 100.0 95.8 94.8 92.0 96.4 98.9 100.0 99.0 100.0 100.0 92.2 92.8 87.0 98.3 97.1 95.0 100.0 80.8 98.9 98.7

0.9 0.0 2.6 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 7.1 0.0 0.0 4.8 1.2 1.6 0.0 0.0 0.0 0.0 0.0 2.3 0.0 0.5 0.0 0.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.1 0.0 1.3 0.0 0.0 3.0 0.0 32.8 0.7 0.9 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 1.2 2.9 1.0 0.0 0.4 0.0 0.2 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.0 0.0 0.0

13.9 21.3 15.8 15.4 5.0 9.7 9.0 6.7

11.9

9.4

* * *

21.4 18.2 9.2 4.6 3.4 3.8 4.6 22.1 12.0 12.0 5.8 20.0 6.2

* * * *

* * *

2.6 1.3 0.4 0.2 0.0 0.0

0.0 1.5 2.1 0.3 2.3 0.5 1.5 0.4 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4

O 16.3 6.5 9.7 4.8 3.8 4.3 2.0 5.0 6.5 6.3 5.3 7.0 11.9 1.7 4.0 7.2 3.3 4.1 10.6 3.7 9.4 6.5 11.1 1.7 11.4 3.8 7.5 5.3 4.4

860

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Testis (C62) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 128 185 41 1171 85 102 179 155 137 215 563 980 411 28 66 151 99 15 59 54 92 41 48 57 1214 82 65 26 147 75 62 151 2611 158 126 446 401 702 1104 565 1316 2156 699 809 277 1038 1044 18 537 220 84 734 288 61 18 696 133 7 11 28 24 53 93.8 94.6 100.0 99.6 96.5 94.1 95.0 99.4 95.6 94.0 86.0 98.0 100.0 100.0 95.5 98.7 98.0 93.3 100.0 100.0 96.7 100.0 100.0 94.7 99.9 98.8 100.0 100.0 98.6 100.0 100.0 100.0 99.7 99.4 100.0 98.4 91.8 98.7 99.3 96.6 89.0 94.2 97.9 96.9 97.5 97.9 97.8 100.0 97.6 97.3 100.0 97.3 100.0 96.7 100.0 98.4 100.0 100.0 100.0 100.0 100.0 100.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 3.6 1.2 0.9 0.0 0.0 0.0 1.3 1.0 6.7 0.0 0.0 0.0 0.0 0.0 3.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 1.9 0.2 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.5 0.0 0.0 2.5 1.0 2.7 0.6 0.0 0.0 0.3 0.0 0.0 0.0 0.5 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 33.6 30.8 7.3 4.3 13.2 22.1 14.5 13.5 22.6 13.3 9.4 5.1 3.6 5.1 4.6 5.1 13.3 7.4 6.5 9.8 6.3 15.8 3.7 3.7 1.5 11.5 8.2 4.0 4.8 4.0 5.0 8.7 3.8 4.7 5.1 3.6 2.7 4.0 3.0 4.7 5.3 4.0 4.5 4.5 5.6 2.8 3.6 1.0 3.5 2.8 3.3 11.1 6.0 8.3 Female Cases MV(%) DCO(%) UB(%) MI(%)

* *

0.0 0.5 0.1 0.3 0.0 0.3 0.6 0.3 0.6 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0

7.5

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
803

861

Indices of data quality

Kidney etc. (C64-66, C68)

Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 18 94.4 157 86.6 34 100.0 23 78.3 46 69.6 81 90.1 123 88.6 21 61.9 72 83.3 1469 74.1 62 87.1 139 80.6 309 73.5 84 82.1 32 90.6 35 100.0 9113 81.9 988 83.8 1246 85.5 553 75.4 348 85.6 184 95.1 7 100.0 484 82.4 4827 80.1 60 83.3 416 86.3 1627 92.2 304 85.2 1306 93.9 204 92.6 2042 89.9 10355 91.6 591 91.4 687 90.0 1822 92.0 7145 91.6 1908 91.5 139 84.2 72 91.7 47 89.4 18 83.3 236 92.8 1303 91.9 2667 92.4 315 92.4 51 96.1 53 96.2 37 89.2 26 96.2 661 90.9 1486 92.7 1367 87.0 1497 94.7 94 97.9 1379 94.3 198 81.3 133 76.7 55 94.5 7822 91.0 514 88.9 7214 91.2 2638 91.9 628 90.4 1991 92.3 794 96.0 241 95.0 542 96.3 432 88.0 5016 91.8 596 89.9 4300 91.9 2583 91.6 1302 89.7 1808 90.7 2014 91.7 486 86.0 1524 93.6 125 84.8 316 93.0 0.0 0.0 0.0 0.0 0.0 0.0 8.9 14.3 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.0 8.9 0.1 0.0 0.0 0.0 0.0 0.0 0.6 16.7 0.0 0.0 1.5 2.6 1.2 2.0 1.5 0.8 0.7 1.2 0.8 0.8 0.5 2.2 0.0 2.1 0.0 0.8 0.2 0.4 0.0 0.0 0.0 0.0 0.0 0.5 0.6 1.2 0.3 0.0 0.4 3.0 3.0 0.0 0.4 0.2 0.4 0.4 0.5 0.4 0.0 0.0 0.0 0.2 0.4 0.8 0.3 0.6 0.2 1.8 0.3 0.0 0.4 0.0 0.9 Female Cases MV(%) DCO(%) UB(%) MI(%) 35 92 18 17 38 97.1 84.8 88.9 70.6 81.6 0.0 0.0 0.0 0.0 0.0 2.6 6.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.5 0.2 0.0 0.0 0.0 0.0 0.0 0.6 20.4 0.0 0.0 1.8 1.2 2.0 0.0 1.4 1.0 0.5 1.1 0.6 1.1 0.6 0.9 0.0 0.0 0.0 0.6 0.6 1.1 0.9 0.0 0.0 0.0 0.0 0.2 1.5 1.7 0.8 0.0 0.9 1.5 1.9 0.0 0.4 0.5 0.4 0.4 0.5 0.3 0.2 0.0 0.3 0.9 0.4 0.4 0.4 0.6 0.2 2.2 0.5 0.6 0.4 0.0 0.0 * * * *

5.7 13.0 9.9 2.4 14.3 12.5 9.1 0.0 2.2 7.4 8.3 0.0 1.1 0.4 1.4 3.8 0.0 0.0 1.9 0.8 0.0 2.4 0.9 1.3 0.8 0.0 1.9 0.7 0.5 0.7 0.5 0.7 0.8 2.2 1.4 0.0 0.0 0.4 0.8 0.5 0.6 0.0 0.0 0.0 0.0 0.8 0.4 2.0 0.6 0.0 0.7 4.0 3.8 5.5 2.3 4.1 2.2 2.2 1.4 2.5 0.9 0.8 0.9 1.2 1.7 2.3 1.7 1.2 1.4 0.8 0.8 1.4 0.7 0.8 0.3

20.4

7.6 7.9 10.3 3.2 7.7 6.0 8.6 2.6 6.0 10.6 19.0 0.0 1.5 0.5 3.7 3.1 0.0 0.0 1.3 1.0 0.0 2.9 0.8 0.4 0.9 0.0 1.5 0.9 0.0 1.5 0.4 1.1 1.0 1.7 0.0 0.0 0.0 0.6 1.2 1.2 1.9 0.0 0.0 0.0 0.0 0.7 1.6 2.4 0.9 0.0 1.0 2.9 2.8 4.0 3.0 1.5 3.2 2.8 1.4 3.3 1.8 1.4 2.0 2.5 2.1 3.8 1.9 1.0 1.6 1.0 0.7 0.0 0.9 0.0 1.5

17.4

70.4 33.3 28.6 50.0 33.7 51.6 46.0 43.0 38.1 46.9 33.3 35.1 41.5 38.9 34.2 46.2 42.9 35.7 28.9 45.0 36.3 32.0 32.2 32.3 28.9 31.8 35.1 34.9 33.9 31.7 36.4 33.3 35.3 30.9 34.1 33.9 34.3 45.1 35.8 37.8 15.4 32.5 34.6 31.7 31.1 22.3 32.2 30.8 39.1 16.4 30.3 31.1 30.5 31.0 27.9 32.1 29.5 23.7 32.1 35.4 32.7 33.1 33.2 36.3 42.4 34.5 31.8 29.2 32.5 29.6 32.0

39 84.6 94 90.4 13 92.3 50 90.0 925 74.3 39 82.1 117 79.5 198 73.2 63 73.0 26 80.8 20 100.0 5581 79.0 642 83.2 747 80.6 323 71.2 246 85.4 123 91.9 2 100.0 318 83.6 2873 76.5 32 87.5 275 81.1 1056 90.2 244 89.8 798 90.2 89 89.9 1247 89.3 6181 89.7 372 92.7 461 87.9 1213 92.3 4068 88.8 1151 89.2 115 87.0 51 92.2 38 97.4 17 88.2 171 91.2 726 88.3 1691 89.5 211 88.6 35 91.4 37 94.6 21 100.0 18 100.0 454 92.7 886 87.5 844 85.7 987 91.8 61 93.4 909 91.5 136 89.0 106 86.8 25 96.0 4672 89.2 393 89.3 4235 89.2 1687 88.3 416 88.2 1252 88.3 450 90.0 144 90.3 297 89.6 319 89.3 3421 89.3 449 86.6 2902 89.5 1820 90.7 867 88.1 1185 87.4 1318 87.5 336 87.2 979 87.6 98 85.7 204 87.3

94.9 20.2 15.4 40.0 33.0 61.5 39.3 39.9 47.6 38.5 32.5 34.0 41.8 39.3 35.0 48.0 150.0 31.1 27.7 34.4 37.5 31.4 32.8 31.3 16.9 30.2 34.6 30.6 31.0 27.0 37.8 34.1 35.7 22.8 38.6 34.5 30.8 54.3 29.7 28.6 27.8 28.9 38.4 28.9 29.0 23.0 29.9 24.3 20.8 40.0 27.9 24.4 28.5 28.9 26.0 29.9 32.4 27.1 35.4 31.0 31.7 28.7 32.4 34.1 38.1 34.7 33.2 30.4 34.1 32.7 32.4

862

*Important. See note on population page.

804

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Kidney etc. (C64-66, C68) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 635 2630 4021 526 3421 1769 386 1350 2429 218 2195 375 89022 7891 78498 3816 365 3337 679 47 240 382 7944 696 7039 4432 400 3943 1404 1282 5971 498 5367 526 9779 939 8187 26562 1032 2483 2482 20243 1670 350 1295 7846 709 6985 493 234 2334 1532 878 2248 90.1 93.0 91.9 90.7 92.0 93.2 91.5 93.6 90.9 88.5 91.1 92.0 91.2 88.9 91.4 92.6 90.1 92.7 88.4 85.1 88.3 89.0 91.3 90.4 91.3 92.5 91.5 92.5 88.0 90.2 90.6 85.5 90.9 92.4 92.0 91.6 92.0 91.9 92.5 90.1 92.2 92.0 90.4 88.9 90.9 89.8 87.9 89.9 90.7 93.6 89.8 90.1 91.1 92.3 1.1 1.7 1.0 1.0 1.0 0.8 0.5 1.0 2.3 1.8 2.4 2.7 1.6 2.2 1.6 1.1 2.2 1.0 2.5 4.3 1.7 2.9 1.2 1.6 1.2 2.7 2.8 2.7 2.1 1.0 0.9 2.0 0.8 1.0 0.9 0.7 1.0 0.8 0.4 1.0 0.6 0.8 2.9 2.9 2.9 3.3 4.1 3.2 0.4 1.3 1.0 0.7 1.8 2.1 11.1 0.0 1.5 0.0 0.0 0.4 0.0 1.6 0.3 0.0 2.2 0.0 2.7 0.0 2.2 1.9 2.3 16.4 3.9 2.3 5.3 6.3 7.8 13.0 1.6 1.3 1.4 1.5 1.4 0.5 1.0 0.4 2.1 1.4 2.2 0.3 0.9 1.1 0.9 0.7 0.0 0.8 0.1 0.0 0.0 0.3 1.0 0.9 1.0 1.2 1.5 1.1 0.4 0.9 0.6 0.4 0.7 0.4 0.3 0.7 0.3 0.7 0.7 0.6 0.7 0.7 2.0 2.0 1.8 1.5 2.3 1.3 0.2 0.9 0.8 0.5 0.6 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 8.2 0.0 0.0 0.4 0.0 0.0 0.0 2.7 2.4 2.3 6.6 2.1 0.0 0.0 0.0 0.0 2.2 34.8 30.6 33.2 25.9 34.6 31.2 25.4 33.2 34.0 27.1 34.7 37.6 32.1 30.1 32.7 30.4 31.2 30.8 38.3 40.4 30.8 42.9 27.1 23.9 27.7 36.9 36.0 37.8 40.7 37.5 30.4 25.1 31.4 30.0 34.6 26.7 35.9 34.2 33.7 29.6 29.2 35.6 32.6 32.0 33.4 33.4 33.9 33.9 34.3 37.2 33.6 36.6 31.4 35.2 59.3 39.5 38.3 60.7 29.4 27.0 16.7 26.2 27.9 46.5 43.2 29.9 32.5 37.2 52.6 58.6 Female Cases MV(%) DCO(%) UB(%) MI(%) 377 1865 2681 380 2254 1197 301 885 1635 150 1467 218 57133 5768 49732 2424 262 2105 382 31 152 190 5142 553 4468 3165 320 2784 893 776 3967 342 3555 351 6042 674 4979 16440 630 1720 1637 12274 984 267 706 5076 582 4397 314 151 1321 874 569 1486 88.6 89.8 89.5 90.0 89.4 89.2 91.0 88.6 89.2 88.0 89.3 85.3 89.2 88.5 89.2 90.0 91.2 89.8 85.1 90.3 84.9 84.2 88.0 88.8 87.8 90.8 90.3 90.9 87.8 90.1 89.1 84.5 89.5 87.5 89.1 90.2 88.8 89.2 91.7 89.0 91.6 88.8 90.4 90.6 90.2 88.7 85.9 89.0 92.4 92.7 87.0 87.3 89.8 90.2 1.3 2.2 1.1 0.5 1.2 1.8 0.7 2.1 2.3 3.3 2.2 5.0 1.9 1.9 2.0 1.3 0.4 1.4 3.1 0.0 3.3 3.7 1.8 1.1 1.9 2.9 2.8 2.9 2.9 0.9 0.7 1.2 0.6 3.7 1.4 1.0 1.5 1.1 0.0 1.0 0.6 1.3 2.0 1.1 2.4 3.7 4.6 3.6 0.0 0.0 1.1 1.0 1.1 2.6 4.0 0.0 1.8 0.0 0.0 0.7 0.0 5.2 0.0 0.0 3.9 0.0 4.8 10.0 2.8 1.9 2.9 13.5 3.6 5.0 11.0 7.9 11.9 12.0 1.3 1.9 1.8 1.3 1.8 0.8 0.7 0.7 2.5 2.0 2.5 0.5 1.2 1.1 1.2 1.0 1.5 1.0 2.1 0.0 2.0 2.6 1.7 1.8 1.7 1.3 1.6 1.3 0.3 0.9 0.8 0.6 0.8 0.9 0.9 0.6 0.9 1.0 0.8 0.9 0.7 1.1 1.5 0.0 2.1 1.8 1.7 1.7 0.3 0.0 2.0 2.1 1.2 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 9.1 0.0 0.0 0.5 0.0 0.0 0.0 3.2 3.0 5.7 10.6 1.4 0.0 0.0 0.3 0.0 4.0 36.1 28.0 32.2 25.8 33.6 32.2 27.6 34.1 33.5 24.7 34.4 34.4 30.9 27.5 31.7 30.9 27.1 31.9 34.3 32.3 30.9 37.9 27.5 23.7 28.4 34.5 28.4 35.9 40.1 33.8 31.2 30.7 31.8 35.6 33.1 28.0 34.2 33.5 29.7 28.8 25.3 35.6 30.1 25.8 32.0 30.3 33.0 30.4 26.4 25.2 33.1 35.4 33.7 30.1 44.0 50.0 * 43.4 * 50.0 31.2 * * * 35.1 * 33.3 29.6 * * * 25.9 43.3 51.1 35.6 40.5 40.2 56.3 45.8

27 74.1 162 75.9 1033 89.3 24 62.5 84 91.7 1271 69.9 65 69.2 119 95.8 122 89.3 578 90.3 6 83.3 446 92.8 45 100.0 112 93.8 42 83.3 1970 87.6 1828 89.2 86 88.4 256 77.0 285 75.8 385 89.1 885 84.4 543 85.5 1989 76.1 324 68.5

25 84.0 96 66.7 601 86.7 11 72.7 48 87.5 733 72.2 21 90.5 60 95.0 77 83.1 231 89.2 3 66.7 203 90.6 23 100.0 62 90.3 10 70.0 1166 86.8 1098 88.7 35 82.9 104 76.0 139 67.6 160 85.6 410 77.3 291 81.1 939 70.8 225 67.6

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
805

863

Indices of data quality

Kidney etc. (C64-66, C68) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
806

Female Cases MV(%) DCO(%) UB(%) MI(%) 2436 79.7 264 75.4 169 79.3 72 79.2 63 81.0 141 79.4 25 76.0 674 81.5 43 83.7 27 74.1 17 82.4 43 79.1 32 100.0 35 91.4 21 95.2 231 62.3 274 77.7 238 77.3 8 75.0 28 82.1 40 75.0 15 53.3 18 77.8 55 89.1 154 94.2 3021 199 85 2589 376 1261 906 1078 4980 1366 493 1731 328 119 87 219 185 213 256 103 124 90 114 1241 2228 478 849 791 820 405 93 571 60 239 152 425 200 51 387 221 89 812 134 41 148 426 136 87 38 56 292 268 150 682 89.9 89.9 88.2 70.3 92.8 90.6 63.2 62.9 76.3 82.1 82.2 87.3 92.4 94.1 92.0 90.0 96.2 87.8 96.9 92.2 88.7 84.4 93.9 78.8 79.5 77.4 80.8 82.7 83.4 91.4 86.0 76.9 75.0 79.9 82.2 81.6 70.5 80.4 78.3 83.7 74.2 83.3 79.9 65.9 76.4 78.4 61.8 74.7 71.1 80.4 79.8 73.1 84.7 80.2 3.4 2.7 2.4 2.8 0.0 1.4 4.0 4.0 2.3 14.8 17.6 4.7 0.0 0.0 0.0 20.3 0.0 0.0 0.0 0.0 0.0 6.7 11.1 5.5 0.0 7.7 2.5 4.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.1 0.0 1.2 0.0 0.0 3.4 0.0 30.1 0.4 4.0 0.0 1.2 0.3 0.0 0.0 1.4 0.0 0.9 0.0 0.0 0.0 0.0 2.6 0.9 0.1 0.0 0.2 0.0 0.4 0.0 0.0 1.1 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.3 5.3 0.0 0.0 15.7 0.0 0.0 33.5 39.4 32.0 25.0 31.7 35.5 42.0 28.4 41.9

5280 538 326 175 153 280 44 1524 104 63 44 85 79 37 56 319 456 411 14 31 78 36 25 97 307 3986 270 130 3825 652 1995 1740 1636 7631 1960 709 2189 546 237 189 329 417 370 475 181 259 169 202 1804 3238 716 1245 1222 1212 605 147 1093 116 436 270 826 361 99 705 437 120 1463 248 63 257 745 231 176 69 110 464 585 314 1223

83.9 81.2 85.3 85.1 81.0 82.9 86.4 86.7 86.5 85.7 88.6 88.2 78.5 89.2 96.4 65.8 82.5 83.7 78.6 67.7 87.2 66.7 80.0 89.7 91.9 93.4 93.0 90.8 66.2 92.6 93.2 63.5 69.1 78.9 85.3 83.6 90.3 96.0 96.2 92.6 95.4 95.9 92.2 97.1 96.1 90.0 86.4 96.0 82.4 84.1 80.2 84.9 87.4 87.3 93.7 95.2 75.1 75.9 84.6 83.0 84.0 79.2 87.9 87.2 90.2 78.3 87.6 87.5 77.8 78.2 83.9 71.0 84.7 84.1 82.7 88.4 79.7 87.9 86.5

2.9 1.3 1.8 2.9 0.7 2.1 0.0 3.1 4.8 7.9 2.3 1.2 8.9 0.0 0.0 17.9 0.0 0.0 0.0 0.0 0.0 13.9 4.0 5.2 0.0 4.9 1.1 6.2

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 1.0 0.1 0.0 0.8 0.0 0.0 2.5 0.1 26.5 0.3 4.5 0.0 1.1 0.0 0.0 0.5 1.2 0.0 0.5 0.4 0.0 0.8 0.6 2.5 0.9 0.0 0.0 0.2 0.0 0.6 0.0 0.0 0.7 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 4.3 0.0 0.2 10.8 0.0 0.0

32.3 35.5 31.0 25.1 28.8 35.7 27.3 27.1 26.9

19.0

44.3

47.8

* * *

77.8 72.0 24.7 39.5 33.7 36.9 51.2 45.6 48.5 46.6 50.1 52.6 51.2 44.7 35.2 36.7 34.4 31.0 40.3 40.3 41.9 44.2 45.9 38.5 52.5 86.4 29.8 58.0 26.9 41.9 48.8 42.3 46.3 46.3 40.5 36.0 42.6 35.5 36.3 47.5 32.9 36.8 35.4 32.3 35.9 54.0 36.2 38.1 48.9 43.2 46.4 30.7 30.4 34.7 29.0 28.7

2.5 * 73.3 * 55.6 9.1 * * 41.1 38.2 37.6 42.5 * * 53.1 46.2 * 40.4 49.6 60.5 47.1 45.8 36.3 52.1 35.6 41.6 47.0 32.9 39.1 53.4 52.4 32.2 71.9 89.9 34.1 65.7 29.0 39.7 46.8 41.5 47.3 46.2 41.7 31.8 32.2 42.1 36.5 47.1 37.5 26.7 27.2 38.5 35.8 22.0 31.8 36.6 25.0 40.2 36.8 33.5 30.1 39.6 39.3 25.8

9.5 4.3 3.7 0.5 0.6 1.3

12.0 6.6 4.8 0.7 0.0 1.8

0.0 12.7 10.7 5.9 10.6 5.9 7.5 3.5 0.0 2.0 0.9 0.9 2.2 0.1 0.0 3.0 1.0 0.0 0.8 0.2 0.0 1.6 0.0 1.2 2.6 1.7 2.9 0.0 0.6 0.5 0.3 0.4

0.0 16.0 13.0 10.0 14.7 8.5 11.2 4.9 0.0 4.0 1.7 2.1 2.0 0.7 0.5 0.0 2.6 0.0 0.0 0.5 0.0 0.0 1.4 1.9 1.5 2.3 10.5 0.0 0.3 0.7 0.0 1.5

864

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Kidney etc. (C64-66, C68) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 1078 1677 86 1652 273 520 627 582 708 1718 1119 1981 699 76 691 882 272 62 202 195 280 272 167 233 3037 150 91 78 177 148 96 198 5444 336 333 862 783 1326 2442 761 2561 3847 1743 1712 507 1858 2544 32 1351 682 208 1822 627 93 28 1172 411 27 44 53 129 140 62.5 72.4 74.4 86.1 67.4 75.0 69.2 95.0 82.1 62.3 77.1 79.2 97.6 85.5 89.0 85.4 83.5 80.6 88.6 91.8 88.9 89.3 81.4 94.4 94.8 94.0 95.6 91.0 87.0 93.2 94.8 92.9 87.2 83.3 90.1 73.0 69.3 70.0 73.1 79.6 73.1 68.3 67.9 76.0 74.0 75.9 91.2 90.6 86.2 83.4 89.9 86.4 89.2 94.6 92.9 83.4 94.2 88.9 93.2 96.2 96.1 92.9 5.6 1.6 3.5 1.0 7.0 2.3 0.6 12.1 10.9 7.7 0.7 2.6 2.3 2.3 4.0 4.8 2.5 1.0 3.9 0.7 4.8 3.9 0.0 0.0 1.3 0.6 2.7 1.0 1.0 0.1 0.0 0.0 0.0 0.0 3.8 0.5 0.0 0.0 6.2 0.0 1.1 1.7 1.3 1.0 0.6 0.4 0.0 0.0 0.0 1.1 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 1.9 0.5 2.4 0.1 11.0 10.6 4.0 1.1 0.0 0.0 0.9 0.0 0.0 0.1 0.4 0.5 1.5 0.0 0.0 0.0 0.2 0.5 0.0 0.0 0.0 0.8 0.7 55.3 50.0 55.8 51.3 67.3 48.3 53.3 37.3 43.5 51.3 50.4 53.6 49.5 43.4 34.2 34.4 46.0 30.6 43.1 47.7 42.1 34.2 36.5 54.1 69.0 30.0 53.8 42.3 52.0 34.5 44.8 51.5 57.3 66.1 58.1 49.6 52.9 47.4 48.5 51.9 51.3 48.9 51.8 44.8 52.1 34.7 21.9 33.8 33.4 36.1 38.1 35.7 40.9 21.4 43.0 34.1 Female Cases MV(%) DCO(%) UB(%) MI(%) 864 1268 56 1078 196 339 414 308 405 1648 736 1363 404 38 269 353 139 35 105 104 133 112 76 117 2226 61 51 32 107 74 43 142 3455 216 215 516 490 853 1602 446 1530 2267 1055 978 329 1295 63.7 73.6 87.5 79.0 60.2 72.9 67.9 95.1 78.0 66.3 78.4 77.2 97.0 86.8 78.4 79.0 77.0 65.7 81.9 80.8 88.0 79.5 77.6 94.9 94.0 83.6 84.3 90.6 92.5 87.8 93.0 85.2 84.6 83.3 90.7 70.5 65.1 65.3 69.8 74.9 69.5 63.5 62.4 71.6 70.5 69.9 5.1 1.1 7.1 1.2 5.1 2.4 0.7 17.0 9.5 9.0 1.5 5.3 4.1 1.7 5.8 11.4 1.9 0.0 5.3 2.7 6.6 2.6 4.9 0.0 0.0 0.9 4.1 0.0 8.5 0.1 0.0 0.0 0.2 0.0 3.2 0.0 0.0 0.0 4.9 0.1 1.5 1.5 0.0 1.5 1.4 5.8 0.0 1.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.4 0.2 2.6 0.1 17.3 11.4 4.5 1.4 0.0 0.0 1.8 0.0 0.0 0.1 0.3 0.7 1.5 0.3 0.0 0.0 0.1 1.5 0.0 0.0 0.0 2.9 1.9 47.1 45.0 44.6 56.4 48.5 * 41.7 54.8 36.4 * 37.8 46.1 52.9 51.1 51.5 39.5 37.8 41.1 51.3 40.0 34.3 52.9 39.1 40.2 42.1 54.7 70.3 31.1 49.0 75.0 54.2 37.8 65.1 40.8 59.3 60.9 49.4 50.4 55.8 49.1 55.2 52.9 53.6 51.4 50.7 47.7 50.5 41.1 25.0 38.8 37.8 30.2 35.8 36.2 40.0 40.0 45.5 33.5

0.2 6.0 2.7 2.7 1.4 3.1 9.7 6.0 5.5 0.8 0.5 0.9 0.0 1.2 0.0 0.5 1.6 4.0 0.0 3.6 3.6 0.0 0.0 0.0 0.0 0.0 0.0

0.2 5.1 3.3 2.7 0.9 3.6 12.1 7.5 8.0 2.1 0.5 1.0 0.0 1.2 0.0 1.5 1.4 4.1 0.0 20.0 3.9 0.0 0.0 0.0 0.0 0.0 0.0

31.4

1659 88.1 16 100.0 884 82.4 357 81.8 135 86.7 1116 86.0 365 86.0 75 92.0 10 60.0 693 80.4 206 89.3 15 80.0 31 100.0 22 95.5 68 85.3 52 94.2

26.9

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
807

865

Indices of data quality

Bladder (C67)
Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 81 1080 175 29 95 86.4 91.8 99.4 51.7 47.4 0.0 0.0 0.0 0.0 0.0 1.5 3.4 0.0 0.0 0.0 0.0 0.3 0.0 0.0 1.1 0.0 6.8 0.1 0.0 0.1 0.0 0.0 0.0 0.1 16.0 0.0 0.0 0.8 1.4 0.8 1.3 0.4 0.2 0.0 0.5 0.3 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.7 0.0 0.0 0.0 0.0 0.2 0.1 0.2 0.1 0.0 0.1 0.7 0.7 0.0 0.1 0.4 0.1 0.3 0.0 0.3 0.3 0.0 0.3 0.0 0.2 0.4 0.2 0.4 0.1 0.9 0.1 0.0 0.1 0.0 0.0 Female Cases MV(%) DCO(%) UB(%) MI(%) 11 90.9 262 88.5 22 100.0 17 64.7 63 49.2 31 83.9 104 92.3 16 68.8 59 86.4 1299 79.1 17 82.4 109 83.5 138 68.8 53 75.5 33 87.9 16 100.0 5241 599 1169 238 209 114 2 300 2279 30 301 933 134 789 72 1269 6751 292 312 562 5496 1390 72 48 17 17 100 1099 1601 154 30 10 29 20 206 1119 874 1293 38 1240 162 111 47 6100 258 5773 1515 267 1241 457 113 340 266 3514 325 3100 1584 880 1080 975 219 749 66 188 89.0 94.8 96.6 87.4 98.1 100.0 100.0 93.0 80.9 90.0 95.7 96.8 93.3 97.3 93.1 97.9 97.6 97.9 98.4 97.7 97.6 97.8 98.6 100.0 100.0 100.0 98.0 97.6 98.7 98.1 100.0 100.0 96.6 100.0 98.1 98.8 96.1 98.1 100.0 98.1 98.1 99.1 97.9 98.2 96.5 98.3 97.2 95.1 97.6 98.7 96.5 99.4 97.0 97.5 94.8 97.7 97.5 96.1 96.1 97.7 95.4 98.4 95.5 98.9 0.0 0.0 0.0 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.4 0.2 0.1 0.0 0.0 0.0 0.0 0.3 16.9 0.0 0.0 1.7 3.0 1.5 4.2 0.8 0.5 1.0 0.3 0.9 0.4 0.3 0.0 0.0 0.0 0.0 2.0 0.2 0.2 0.6 0.0 0.0 3.4 0.0 0.0 0.1 0.9 0.1 0.0 0.1 0.6 0.0 2.1 0.2 0.4 0.2 0.3 0.4 0.3 0.2 0.0 0.3 0.0 0.2 0.3 0.2 0.3 0.2 1.5 0.3 0.5 0.3 0.0 0.5 * * * *

4.2 15.8 9.6 1.7 2.4 3.0 4.7 0.0 2.0 3.8 2.8 0.0 0.5 0.1 0.7 1.1 0.2 0.0 0.2 0.6 0.0 0.4 0.4 0.0 0.4 0.0 0.4 0.4 0.4 0.5 0.3 0.4 0.4 0.7 0.8 1.5 0.0 0.0 0.4 0.3 0.3 0.8 0.0 0.0 0.0 0.2 0.3 0.5 0.4 1.4 0.4 1.5 0.7 2.7 1.0 2.2 1.0 1.1 1.3 1.1 0.8 0.7 0.8 0.7 0.7 1.0 0.7 0.4 0.5 0.3 0.1 0.3 0.1 0.0 0.0

17.2

6.5 6.3 12.9 4.8 31.3 10.2 6.2 5.9 3.7 6.5 11.3 0.0 1.4 0.5 1.5 0.8 0.5 0.0 0.7 1.9 0.0 2.3 0.3 0.7 0.3 0.0 0.6 0.6 0.3 1.3 0.4 0.6 0.6 1.4 0.0 0.0 0.0 0.0 0.7 0.4 1.3 0.0 0.0 0.0 0.0 1.0 0.2 1.6 1.0 0.0 1.0 1.2 0.9 0.0 1.2 2.3 1.1 1.8 2.2 1.7 0.4 1.8 0.0 0.4 1.5 4.0 1.3 1.0 1.8 0.8 0.3 0.9 0.1 1.5 0.0

23.7

136 89.0 238 95.0 41 97.6 168 92.9 3309 85.8 35 91.4 293 88.7 423 81.1 141 85.1 88 87.5 33 100.0 15145 1812 3282 734 647 378 9 911 6445 96 831 2720 221 2462 307 4103 20643 969 659 1534 17188 3784 145 129 68 37 227 3022 4768 301 122 57 88 44 538 3524 2662 3457 73 3329 273 147 110 18528 495 17800 4275 466 3773 1147 153 971 1008 9640 477 8908 4492 2611 3158 2849 365 2463 131 536 91.5 98.0 98.4 91.0 98.1 100.0 100.0 96.5 83.3 100.0 97.5 98.2 96.8 98.3 98.4 98.7 98.9 98.5 98.2 98.6 98.9 98.9 98.6 96.9 95.6 100.0 99.1 99.0 99.3 97.7 99.2 100.0 100.0 97.7 99.3 99.4 98.3 98.9 97.3 98.9 97.8 98.6 97.3 98.6 97.0 98.6 98.2 97.9 98.3 98.7 98.0 98.8 98.8 98.6 98.1 98.6 98.7 98.4 98.2 98.8 98.1 98.9 99.2 98.9

48.5 22.7 22.0 35.1 26.6 42.9 33.1 35.0 32.6 39.8 26.4 21.2 19.8 30.2 20.7 31.7 33.3 21.7 32.0 18.8 24.3 19.7 32.1 18.8 14.7 18.5 19.6 19.0 25.6 17.7 19.8 18.9 29.7 17.2 18.6 19.8 24.9 17.2 14.0 17.0 18.2 20.6 19.9 15.6 17.4 28.8 17.5 24.9 31.3 19.1 17.9 29.9 17.8 19.1 31.8 17.6 19.9 31.4 18.4 19.4 18.0 24.5 18.1 20.3 17.6 19.8 17.1 26.0 15.8 26.0 18.5

96.8 26.0 50.0 44.1 27.3 41.2 34.9 47.1 49.1 64.4 29.8 25.0 23.3 30.7 27.8 33.3 50.0 21.3 36.8 20.0 21.3 26.3 38.1 24.5 26.4 24.1 27.4 27.1 41.3 24.7 27.3 26.3 51.4 20.0 26.1 28.5 40.3 33.3 20.0 34.5 15.0 25.7 28.1 24.8 21.6 21.1 21.8 40.1 44.1 29.8 22.8 53.1 21.7 30.8 46.1 27.6 31.5 43.4 27.6 30.1 26.1 43.4 24.9 28.0 26.0 28.4 28.0 40.2 24.3 33.3 27.7

866

*Important. See note on population page.

808

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Bladder (C67) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 1393 97.8 6244 98.7 8537 98.4 417 98.3 8007 98.4 3423 99.2 308 99.4 3093 99.2 4338 98.2 166 98.2 4145 98.2 827 97.9 175440 98.4 6605 97.7 164400 98.4 8084 99.0 325 99.1 7603 99.0 1064 98.0 12 100.0 208 97.1 832 98.2 16299 97.5 697 96.8 15312 97.5 9715 97.9 387 96.4 8991 98.0 2404 96.7 3190 98.3 13141 99.0 418 99.5 12544 98.9 1254 98.4 19184 98.8 734 98.6 17511 98.9 51459 98.8 1585 98.8 2080 98.5 2241 98.4 45005 98.9 2691 98.1 257 96.9 2407 98.3 10569 97.4 504 95.6 9864 97.4 1001 99.5 522 97.5 4877 98.6 3292 98.8 1817 98.8 4435 98.0 81 351 2499 73 138 1996 169 500 238 1128 35 767 109 167 51 4767 4422 255 415 473 718 1174 951 3011 549 90.1 78.1 95.1 97.3 84.1 79.9 88.2 99.0 71.4 74.9 85.7 77.7 96.3 82.6 96.1 95.6 96.0 98.0 93.5 94.1 98.5 87.4 94.2 80.6 86.9 0.6 0.6 0.6 1.2 0.5 0.4 0.0 0.4 0.7 1.8 0.7 1.5 0.6 1.0 0.6 0.3 0.0 0.3 0.7 0.0 1.4 0.5 0.5 1.3 0.5 1.1 1.6 1.1 0.7 0.7 0.3 0.0 0.3 0.8 0.4 0.4 0.4 0.3 0.3 0.3 0.4 0.3 0.6 1.6 0.5 1.0 1.4 1.0 0.0 0.8 0.4 0.1 0.7 0.8 1.2 0.0 0.3 0.0 2.9 0.5 0.0 0.8 1.2 0.0 6.3 0.0 3.6 2.0 0.9 0.8 0.0 6.0 0.8 0.6 5.8 3.0 9.4 5.8 0.8 0.5 0.6 0.0 0.6 0.2 0.0 0.2 0.6 0.0 0.7 0.1 0.4 0.6 0.4 0.4 0.6 0.4 0.4 0.0 0.0 0.5 0.7 0.6 0.7 0.6 1.3 0.5 0.2 0.2 0.2 0.2 0.2 0.2 0.1 0.0 0.1 0.3 0.1 0.3 0.2 0.3 0.9 1.2 0.8 1.1 1.4 1.1 0.0 0.4 0.2 0.2 0.2 0.8 2.5 0.3 0.0 0.0 2.2 0.0 0.0 0.8 22.7 0.0 0.0 0.1 0.0 0.0 0.0 1.2 1.2 0.0 0.5 0.6 0.0 0.0 0.3 0.0 1.6 20.7 18.2 18.7 23.0 18.6 16.9 25.3 16.0 18.6 28.3 18.3 20.6 18.8 27.0 18.8 18.3 26.5 18.2 20.3 41.7 21.2 19.6 19.0 25.3 18.7 20.1 28.4 20.5 21.5 19.0 18.3 25.6 18.3 17.1 18.0 27.1 17.7 18.8 18.5 25.8 17.0 18.7 19.1 26.1 18.4 19.8 28.4 19.6 18.9 21.5 17.7 17.2 17.8 19.7 43.2 43.9 28.6 46.4 35.9 4.5 42.4 8.6 27.9 20.0 17.8 27.9 16.4 24.2 27.7 36.5 35.9 Female Cases MV(%) DCO(%) UB(%) MI(%) 541 95.4 2466 97.4 2899 98.4 242 97.1 2617 98.5 1214 99.3 191 97.4 1013 99.7 1470 96.9 96 97.9 1361 96.8 281 96.4 61379 97.4 3832 95.8 56118 97.5 3036 97.9 204 96.1 2777 97.9 348 96.8 3 100.0 61 98.4 280 96.4 6382 96.3 448 96.0 5848 96.4 3526 97.3 220 96.4 3194 97.3 805 95.2 1022 97.9 4820 98.2 236 96.2 4527 98.4 482 98.3 6653 97.8 445 97.3 5923 97.8 17555 97.7 478 98.1 1156 97.0 824 98.2 14924 97.6 854 96.4 175 92.6 674 97.3 3460 95.4 277 93.1 3111 95.6 306 98.0 225 98.7 1512 97.5 1013 96.9 766 97.7 1611 97.0 21 95.2 95 77.9 803 95.6 15 86.7 45 91.1 609 76.4 37 78.4 100 100.0 86 74.4 225 69.3 2 100.0 182 76.9 37 97.3 61 78.7 13 92.3 1153 94.6 1101 95.5 26 100.0 112 79.5 143 83.9 207 93.2 423 77.3 291 88.0 937 72.1 216 81.0 1.5 1.1 0.5 0.8 0.5 0.2 0.5 0.1 1.6 2.1 1.5 1.4 1.0 2.1 1.0 0.8 1.5 0.8 2.3 0.0 1.6 2.5 1.0 1.3 1.0 1.5 2.7 1.4 0.4 1.0 0.4 1.7 0.4 1.2 0.8 1.1 0.8 0.7 0.4 1.1 0.5 0.7 1.5 2.3 1.3 2.3 4.3 2.1 0.0 0.4 0.5 0.3 0.5 0.9 4.8 0.0 0.4 0.0 0.0 0.7 0.0 3.5 0.4 0.0 8.8 0.0 11.5 0.0 1.3 1.1 0.0 17.0 4.2 3.4 14.4 5.2 14.5 13.0 1.8 0.9 0.5 0.8 0.5 0.1 0.5 0.0 0.9 0.0 1.0 0.4 0.6 0.8 0.6 0.5 0.5 0.5 0.6 0.0 0.0 0.7 0.9 0.7 0.9 0.9 0.5 0.9 0.4 0.2 0.4 0.4 0.4 0.0 0.3 0.2 0.3 0.5 0.8 0.4 0.6 0.4 1.4 4.0 0.7 1.4 1.8 1.4 0.0 0.0 0.5 0.6 0.7 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 20.9 0.0 0.0 0.0 0.0 0.0 0.0 1.3 1.3 0.0 3.6 2.1 0.0 0.0 0.3 0.0 0.9 23.1 24.4 23.2 39.3 22.0 21.3 35.6 18.6 24.8 27.1 24.6 24.9 25.4 42.4 24.6 24.4 37.3 23.7 28.7 66.7 39.3 26.1 23.9 44.6 22.3 26.6 39.1 26.7 26.6 25.2 24.1 43.2 23.3 23.9 24.6 39.1 23.5 25.9 26.6 39.1 24.0 25.2 29.5 42.9 26.1 28.4 45.8 27.4 23.2 26.2 21.8 21.6 28.1 25.6 42.9 70.5 * 33.5 * 33.3 40.7 * * 15.0 * 27.9 * 41.8 25.4 34.8 36.4 31.4 42.6 35.1 47.7 47.2 * * *

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
809

867

Indices of data quality

Bladder (C67) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
810

Female Cases MV(%) DCO(%) UB(%) MI(%) 1935 83.7 176 74.4 139 82.7 67 88.1 77 87.0 104 81.7 16 68.8 548 86.1 24 83.3 27 77.8 14 85.7 39 94.9 30 86.7 36 97.2 47 97.9 102 79.4 181 95.0 159 95.0 3 100.0 19 94.7 96 85.4 39 71.8 23 91.3 72 87.5 175 94.3 2560 94.3 249 98.4 81 92.6 865 90.1 393 99.7 1467 91.5 992 76.3 983 73.1 2731 91.6 2156 90.9 268 90.7 951 95.7 135 95.6 67 94.0 64 98.4 108 95.4 148 100.0 127 94.5 147 98.0 70 100.0 76 92.1 78 97.4 56 100.0 881 81.6 1565 82.8 646 80.2 607 85.2 769 90.1 909 83.6 262 93.5 72 98.6 721 92.5 93 94.6 212 84.0 195 87.2 551 89.5 339 77.0 75 92.0 536 87.1 253 97.2 122 70.5 687 91.7 196 92.3 85 84.7 188 95.2 455 90.1 223 82.5 115 85.2 65 92.3 97 90.7 469 93.6 364 93.1 155 92.3 672 94.3 5.9 6.3 5.0 3.0 3.9 4.8 0.0 8.6 8.3 14.8 14.3 5.1 0.0 0.0 0.0 2.9 0.0 0.0 0.0 0.0 0.0 5.1 0.0 5.6 0.0 5.1 1.2 6.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 7.0 0.1 22.2 0.3 3.6 0.0 0.4 0.0 0.0 0.0 0.9 0.0 1.6 0.7 0.0 1.3 0.0 0.0 0.8 0.1 0.0 0.0 0.0 0.4 0.0 0.0 0.3 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.4 0.0 0.0 39.7 44.9 36.0 34.3 40.3 46.2 28.1 34.2 75.0 12.8 16.7

7405 766 447 236 242 395 47 2022 95 57 103 128 107 85 219 279 600 493 35 72 199 121 119 445 1353 6654 630 284 4323 1691 5587 4313 3079 7424 6154 743 2856 588 378 311 504 695 652 538 279 363 310 295 2329 4370 1603 1734 1968 2526 645 196 1844 330 836 737 2310 1276 356 1674 1024 739 2273 699 436 755 1960 1356 583 479 295 1820 1602 675 2331

90.3 88.3 94.2 91.9 90.9 89.9 91.5 93.6 87.4 80.7 98.1 95.3 92.5 97.6 99.5 84.9 97.7 97.8 97.1 97.2 94.5 83.5 89.1 93.5 95.6 97.3 98.7 96.8 91.3 99.7 95.8 79.2 75.4 94.2 94.1 96.8 98.4 99.0 99.5 99.0 98.8 99.4 98.9 99.4 98.6 98.1 97.7 99.3 88.1 87.3 88.5 91.8 93.3 91.6 96.9 98.0 93.0 96.1 90.7 91.2 92.3 88.7 93.3 93.1 99.5 80.6 95.6 94.6 92.0 95.5 93.5 84.2 87.0 94.6 93.6 97.7 90.9 96.1 96.2

2.6 3.0 1.1 2.1 1.2 2.3 0.0 2.7 2.1 17.5 1.9 1.6 3.7 0.0 0.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 1.7 1.1 0.0 2.3 0.6 1.1

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 1.1 0.1 0.0 1.1 0.0 0.0 3.9 0.1 20.9 0.2 3.1 0.0 0.3 0.0 0.3 0.3 0.4 0.0 0.8 0.4 0.0 0.3 0.0 0.7 0.8 0.1 0.0 0.1 0.0 0.6 0.0 0.0 0.5 0.6 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.7 0.8 0.0 0.0 6.6 0.0 0.0

31.8 31.6 28.6 31.4 28.1 35.4 44.7 22.9 25.3 23.4 23.4

35.3

41.4

* * *

53.7 52.9 11.7 25.9 23.2 16.2 51.8 23.9 38.0 35.2 35.0 32.7 37.1 25.9 38.9 43.4 41.5 31.7 48.1 42.8 35.3 49.8 48.8 36.5 54.2 64.2 24.3 26.5 19.4 18.4 24.3 35.3 26.0 29.1 20.0 17.8 22.5 25.3 20.8 21.1 25.0 20.5 19.7 32.3 22.6 25.7 19.3 25.8 25.7 30.0 25.3 18.6 21.3 26.1 20.7 19.3

* 61.5 * 208.7 11.1 * * 33.9 24.9 32.1 52.0 * * 33.3 47.6 * 39.6 37.3 41.4 41.0 35.8 64.4 73.1 64.1 53.7 60.8 70.9 49.7 67.1 48.7 42.3 85.7 92.2 35.2 43.7 28.0 27.7 43.3 49.2 27.8 33.6 22.6 29.2 22.1 27.6 24.8 25.3 31.0 23.7 21.9 45.1 28.1 23.5 26.1 22.2 25.6 21.7 36.9 12.9 27.9 29.7 24.5 24.6

7.1 3.7 1.8 0.2 0.1 0.2

11.0 4.6 2.8 0.4 1.1 0.8

0.0 10.0 10.4 5.1 7.8 2.5 4.6 2.2 0.0 1.8 0.6 0.2 0.1 0.3 0.2 1.1 0.5 0.0 0.7 0.2 0.1 0.9 0.0 0.3 0.6 1.4 2.1 0.0 0.1 0.2 0.0 0.3

0.0 16.2 14.9 10.8 13.3 4.9 10.1 4.2 0.0 1.8 1.1 2.4 0.5 0.5 1.8 1.3 0.7 0.0 0.0 0.6 1.0 2.4 0.0 1.1 0.9 2.6 1.5 0.0 1.7 1.1 0.6 0.6

868

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Bladder (C67) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 1153 1844 368 3889 444 1005 1016 1985 1931 1597 2931 2303 1061 370 1553 2329 1044 286 898 1002 1592 905 853 1214 7588 468 140 98 247 266 250 433 9000 975 908 2858 2432 4480 7475 1875 8350 11249 5203 4994 721 5012 2964 25 2516 1443 397 1413 592 111 45 2115 637 33 49 55 211 261 86.4 84.9 97.6 97.9 55.6 85.8 79.0 98.1 90.1 71.9 89.5 90.5 98.3 94.6 95.8 95.0 95.4 86.4 97.1 95.7 94.5 97.7 93.3 96.3 99.8 98.5 95.0 96.9 96.4 95.5 98.0 98.2 98.8 99.8 99.2 96.5 95.1 94.8 96.4 95.7 86.6 91.1 91.4 96.1 85.7 95.3 93.8 100.0 92.6 95.9 99.0 91.0 96.6 91.9 95.6 96.4 99.1 100.0 100.0 100.0 99.5 98.5 2.4 0.6 0.8 0.2 6.3 0.7 0.2 6.5 4.2 6.4 1.0 2.2 2.1 1.0 1.7 7.7 1.1 0.0 1.8 0.3 2.1 2.1 0.0 0.0 0.0 0.4 0.8 0.0 1.6 0.3 0.0 0.0 0.0 0.0 3.7 0.0 0.1 0.0 4.9 0.2 0.5 0.7 0.8 1.2 0.5 0.6 1.0 0.1 0.1 0.4 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.2 0.5 0.0 2.7 1.6 1.9 0.5 0.0 0.0 0.3 0.0 0.0 0.2 0.3 0.3 1.6 0.2 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.4 55.0 45.1 32.1 32.0 50.1 39.3 42.5 29.4 36.5 52.7 38.0 43.9 39.7 32.4 32.0 28.0 38.6 35.7 23.8 28.0 28.4 27.7 23.7 35.0 28.2 19.2 39.3 38.8 36.0 34.6 14.8 30.3 44.1 23.3 28.6 26.9 26.5 26.0 37.8 26.0 32.6 27.4 27.6 36.5 27.6 34.5 52.0 22.3 20.6 20.2 51.4 40.2 46.8 15.6 27.1 18.4 Female Cases MV(%) DCO(%) UB(%) MI(%) 381 545 85 1341 146 196 384 583 556 666 947 765 350 58 289 451 173 54 165 133 246 158 161 202 2691 140 38 33 99 74 71 132 2682 272 263 1039 962 1883 3041 624 3062 4242 2015 1881 293 2203 1089 2 791 474 141 547 213 34 13 778 182 12 14 22 54 62 82.2 78.9 98.8 95.6 50.0 83.2 75.3 98.1 86.3 64.6 84.8 88.5 96.9 91.4 90.7 89.1 90.2 85.2 92.1 97.0 93.9 89.9 90.7 94.6 99.7 96.4 89.5 93.9 91.9 97.3 97.2 93.2 97.7 98.9 99.6 92.1 90.6 89.5 92.5 91.2 82.1 86.5 86.8 92.0 83.3 92.4 93.1 100.0 91.8 96.2 95.7 89.9 91.1 91.2 84.6 94.1 98.4 100.0 100.0 95.5 100.0 98.4 5.0 2.4 1.2 0.6 9.6 2.6 0.3 9.4 8.4 7.6 2.6 3.4 3.1 4.7 4.6 3.7 1.8 0.0 1.6 1.9 3.1 1.5 0.7 0.0 0.0 0.0 2.7 0.0 4.5 0.0 0.0 0.0 0.0 0.0 3.6 0.3 0.0 0.0 7.8 0.1 0.1 0.6 0.0 1.7 0.4 0.6 3.7 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.3 1.4 0.0 4.8 3.0 2.8 0.4 0.0 0.0 0.4 0.0 0.0 0.0 0.2 0.0 1.8 0.0 0.0 7.7 0.1 0.5 0.0 0.0 4.5 0.0 0.0 56.2 49.4 15.3 41.7 47.1 * 37.6 45.3 37.7 * 43.9 53.0 38.8 42.6 42.0 27.6 47.3 31.5 51.3 53.7 30.3 37.6 38.6 35.4 29.8 41.1 36.6 37.9 65.8 51.5 55.6 43.2 32.4 47.0 60.8 33.5 38.3 39.9 37.4 36.2 45.8 33.8 41.8 35.9 38.1 57.0 38.1 41.6 150.0 27.3 24.5 22.5 64.5 49.3 64.7 38.5 36.4 31.3

0.0 1.5 0.7 0.3 0.6 0.4 4.0 1.8 1.6 0.3 0.2 0.8 0.0 0.5 0.0 0.0 1.6 2.2 1.8 4.4 1.7 0.3 0.0 0.0 0.0 0.5 0.4

0.2 2.6 1.3 0.7 1.3 0.9 5.7 3.3 3.1 0.7 0.3 1.0 0.0 1.3 0.0 0.0 2.7 4.7 0.0 7.7 2.8 1.1 0.0 0.0 0.0 0.0 1.6

18.0

35.5

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
811

869

Indices of data quality

Brain and central nervous sytem (C70-72)

Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 26 231 36 10 57 30 221 51 94 1796 35 217 312 126 30 48 84.6 65.8 88.9 50.0 52.6 76.7 80.1 51.0 70.2 58.4 45.7 78.8 67.3 84.1 80.0 75.0 0.0 0.0 0.0 0.0 0.0 6.7 12.2 3.9 0.0 0.0 0.0 0.0 0.0 0.0 10.0 0.0 11.6 0.0 0.0 0.0 0.0 0.9 0.0 2.0 22.1 0.0 0.0 3.1 3.2 3.0 5.2 1.6 1.0 0.9 0.9 0.8 1.1 0.4 0.0 0.0 0.0 0.0 0.8 0.4 0.9 1.3 3.3 0.0 0.0 0.0 1.1 0.8 0.4 0.9 0.0 0.9 3.3 2.0 0.0 0.5 0.0 0.5 0.8 0.5 0.9 0.5 0.0 0.6 0.0 0.8 1.8 0.8 0.9 0.7 2.5 1.2 0.8 1.1 0.0 0.0 Female Cases MV(%) DCO(%) UB(%) MI(%) 35 200 20 14 63 36 190 46 95 1716 26 188 295 105 23 38 74.3 63.0 70.0 35.7 42.9 75.0 72.6 50.0 66.3 53.6 73.1 76.1 63.1 89.5 78.3 73.7 0.0 0.0 0.0 0.0 0.0 8.3 14.2 8.7 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 16.2 0.0 0.0 0.0 0.0 0.0 0.0 2.4 28.8 0.0 0.0 4.1 0.0 4.2 1.4 3.9 1.8 0.4 1.9 1.4 2.0 0.6 0.0 0.0 0.0 0.0 0.0 0.9 2.2 3.8 0.0 0.0 0.0 0.0 1.7 2.5 2.4 0.5 0.0 0.6 7.0 5.0 7.7 0.4 0.0 0.5 1.0 0.6 1.0 0.6 0.0 0.8 0.0 0.7 0.7 0.8 1.1 0.4 3.9 1.5 2.9 1.1 7.3 0.0 * * * *

24.2 14.0 3.3 7.7 41.2 21.3 14.9 14.3 2.8 13.1 7.1 0.0 1.2 0.2 0.8 0.4 0.0 0.0 1.0 1.5 0.0 4.1 4.4 5.3 4.2 0.0 1.2 0.9 1.2 2.3 0.4 1.0 1.7 3.6 0.0 5.3 0.0 0.0 2.0 1.1 2.6 0.0 5.3 0.0 0.0 0.8 0.9 2.4 1.0 0.0 1.1 3.3 2.0 6.5 5.5 3.8 5.7 2.0 2.0 1.9 1.7 2.2 1.3 3.9 2.7 3.6 2.8 1.1 2.2 1.1 1.3 2.4 1.1 2.5 0.0

36.4

26.0 15.9 2.8 8.9 34.8 28.4 16.1 7.7 4.8 19.3 3.8 0.0 1.6 0.5 1.9 2.5 0.0 0.0 1.2 1.9 0.0 1.3 5.6 7.1 5.4 1.4 1.9 2.1 4.1 2.4 1.7 2.1 3.5 8.6 5.3 0.0 0.0 3.0 3.3 2.7 1.0 8.3 14.3 0.0 8.3 1.7 3.2 2.4 2.5 6.5 2.3 1.4 2.5 0.0 6.1 7.4 6.1 2.7 2.4 2.8 1.5 1.5 1.6 3.0 3.2 7.4 2.8 1.3 3.7 2.5 2.9 4.4 2.5 0.0 1.3

36.5

93.3 51.6 60.8 93.6 61.5 37.1 67.3 76.0 75.4 54.2 66.9 68.0 68.8 69.9 54.1 82.9 100.0 74.6 64.9 38.1 75.8 73.1 64.2 75.5 52.6 67.1 71.6 65.3 68.5 51.0 78.2 69.7 70.9 44.8 74.8 70.4 79.2 63.3 63.2 100.0 88.9 52.2 79.1 58.7 61.3 42.9 62.9 63.7 75.5 61.3 73.2 59.7 74.9 63.8 57.4 65.3 58.3 49.4 59.7 65.2 68.1 57.1 70.5 74.0 76.8 77.1 74.2 73.6 75.4 80.0 67.7

58.3 67.9 67.4 80.0 59.3 26.9 73.9 74.6 76.2 81.5 63.1 69.2 67.0 72.4 72.3 87.1 200.0 64.7 58.2 68.2 70.3 73.8 77.6 74.1 56.3 66.3 69.9 53.7 69.6 49.5 78.4 64.1 51.4 40.2 75.0 70.7 76.9 75.0 78.6 60.0 41.7 52.5 82.2 64.7 59.8 58.1 60.3 56.3 55.0 61.5 68.7 63.1 70.2 60.0 49.7 62.0 56.7 50.7 57.1 66.5 64.2 67.4 65.2 71.5 72.3 68.7 73.3 66.4 75.6 53.7 76.3

4603 79.0 506 84.8 769 88.0 226 77.0 172 82.0 111 88.3 2 100.0 201 82.1 2401 73.3 21 95.2 194 88.1 778 85.0 95 84.2 673 85.1 97 89.7 896 85.9 5486 88.9 334 87.7 219 85.8 998 90.2 3884 89.0 1080 90.1 55 81.8 50 94.0 19 84.2 8 100.0 125 93.6 766 89.8 1314 89.8 77 87.0 30 90.0 19 94.7 12 91.7 9 100.0 379 90.5 756 89.8 777 85.6 703 91.3 28 92.9 665 91.3 91 81.3 49 79.6 31 87.1 3326 83.4 238 80.3 3044 83.6 1275 88.7 197 85.8 1053 89.5 420 90.2 89 84.3 318 92.5 305 86.9 2041 87.9 168 85.1 1812 88.0 1054 88.1 591 88.3 707 86.1 695 83.7 125 80.0 562 84.7 40 80.0 93 88.2

3700 71.6 364 79.9 587 80.4 163 68.1 112 80.4 62 87.1 1 100.0 170 67.6 2064 65.6 22 90.9 155 89.7 683 81.3 85 80.0 591 81.9 71 88.7 725 83.4 4423 83.9 270 81.5 207 81.2 934 85.5 2976 83.7 834 86.0 35 77.1 38 81.6 22 77.3 4 100.0 132 87.1 552 87.1 1135 82.7 104 81.7 24 83.3 14 57.1 5 80.0 12 83.3 362 84.8 596 81.9 584 79.5 564 86.7 31 77.4 524 87.0 71 84.5 40 87.5 26 84.6 2740 80.7 203 77.3 2488 80.9 1042 85.7 165 80.6 870 86.7 323 87.0 67 80.6 254 88.6 197 82.2 1767 84.4 135 83.0 1579 84.4 936 83.3 509 83.1 636 78.9 588 79.1 137 73.0 446 81.2 41 78.0 76 81.6

870

*Important. See note on population page.

812

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Brain and central nervous sytem (C70-72) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 301 1264 1915 143 1741 744 106 621 1081 62 1015 181 40649 2489 36753 1625 119 1419 282 10 92 175 3656 278 3237 2118 137 1918 657 723 2388 103 2211 208 4792 300 4221 12623 551 738 1347 9855 663 103 552 3510 246 3169 372 125 1233 819 354 1082 24 179 618 46 130 1212 64 98 314 1093 36 1006 142 274 85 945 802 107 95 86 72 187 104 675 99 87.7 90.4 88.6 86.0 88.8 91.5 86.8 92.1 85.8 83.9 85.8 87.3 87.2 84.0 87.4 87.0 82.4 87.3 85.5 90.0 82.6 86.3 87.1 84.9 87.4 87.8 77.4 88.2 83.3 86.4 89.8 92.2 89.5 92.3 89.0 86.0 89.3 88.3 87.8 84.6 89.3 88.5 86.9 80.6 88.0 84.2 80.9 84.7 91.4 90.4 85.8 85.1 85.9 87.6 79.2 75.4 87.2 54.3 78.5 54.9 79.7 76.5 85.0 86.6 66.7 91.8 91.5 90.9 65.9 83.9 85.8 90.7 68.4 62.8 83.3 78.6 92.3 63.1 68.7 1.3 1.5 1.7 0.0 1.8 1.9 1.9 1.9 4.7 8.1 4.5 3.9 2.6 3.2 2.6 1.8 4.2 1.7 5.0 10.0 5.4 4.6 1.6 1.1 1.6 3.6 10.2 3.2 4.3 2.9 0.8 1.0 0.9 1.0 1.7 2.3 1.7 1.3 1.3 2.4 0.7 1.3 3.3 3.9 3.3 5.3 3.3 5.3 0.3 1.6 1.3 1.6 1.4 3.5 4.2 0.0 2.4 0.0 2.3 0.9 0.0 1.9 1.2 5.6 2.6 0.7 3.3 16.5 4.1 3.4 3.7 23.2 20.9 1.4 4.3 1.0 6.8 20.2 2.3 1.3 1.9 3.5 1.8 0.4 1.9 0.2 3.1 1.6 3.3 0.0 1.5 1.7 1.4 1.0 2.5 1.0 0.7 0.0 1.1 0.6 1.9 1.8 1.9 2.3 4.4 2.2 1.7 0.7 0.7 0.0 0.8 0.0 0.5 0.7 0.5 1.0 0.7 1.2 0.8 1.0 4.1 4.9 3.8 1.6 2.0 1.5 0.3 0.8 0.8 0.6 1.4 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.1 12.4 0.0 0.0 0.0 0.0 0.0 2.4 3.7 2.9 0.0 8.4 1.2 0.0 0.0 0.0 0.0 2.0 66.1 65.6 68.8 60.8 69.8 66.3 61.3 68.0 68.1 50.0 69.2 66.3 67.8 60.7 69.5 56.2 45.4 59.1 63.8 10.0 62.0 68.0 54.2 46.8 55.9 70.8 70.1 72.8 71.2 73.9 66.5 61.2 68.6 76.4 68.4 58.7 69.3 69.2 61.9 61.2 48.3 73.7 79.3 75.7 81.0 67.7 61.0 69.5 63.4 65.6 74.8 77.7 68.1 68.1 66.7 108.4 57.6 69.2 51.7 74.0 35.7 55.6 30.1 75.9 66.3 41.9 41.7 41.7 49.0 44.6 41.4 Female Cases MV(%) DCO(%) UB(%) MI(%) 238 1114 1509 120 1372 618 89 517 920 50 858 159 33939 2282 30558 1407 111 1236 219 12 75 127 3258 320 2826 1799 122 1646 563 514 2097 107 1948 194 3832 241 3355 10362 430 702 1228 7893 560 99 454 2915 208 2634 287 85 967 646 302 889 8 141 397 45 116 1404 51 91 200 542 19 649 123 129 64 740 632 69 64 90 58 132 94 623 112 76.9 86.4 82.8 84.2 82.7 87.4 83.1 87.8 79.8 74.0 80.0 81.8 82.5 78.8 82.8 81.0 73.0 81.6 79.0 91.7 85.3 74.0 80.3 75.9 80.9 84.4 73.0 85.1 81.0 79.8 83.7 84.1 83.6 83.0 85.2 80.9 85.5 83.4 83.0 78.1 85.9 83.4 84.6 73.7 87.0 79.0 77.4 79.3 86.8 84.7 84.2 84.2 80.1 85.3 62.5 70.9 87.4 51.1 77.6 62.5 94.1 83.5 81.5 84.3 73.7 90.9 91.1 86.8 64.1 78.8 81.8 85.5 67.2 61.1 86.2 72.7 89.4 59.4 54.5 2.9 2.6 2.9 0.0 3.2 2.6 2.2 2.7 5.9 8.0 5.8 6.3 3.5 4.1 3.5 3.6 5.4 3.6 4.1 0.0 1.3 6.3 3.0 2.8 3.0 5.0 11.5 4.6 3.6 4.1 1.1 0.0 1.2 5.2 2.5 3.3 2.4 2.4 3.0 3.3 1.5 2.5 3.6 5.1 3.3 5.7 2.9 6.0 0.0 5.9 2.4 1.2 5.6 4.2 0.0 0.0 3.5 2.2 7.8 0.8 0.0 3.0 1.8 10.5 3.9 0.0 3.9 18.8 6.8 5.7 7.2 26.6 15.6 0.0 6.1 1.1 10.8 31.3 3.4 2.2 3.2 3.3 3.2 1.1 3.4 0.8 6.2 10.0 6.1 1.3 2.1 2.8 2.1 2.0 7.2 1.5 2.7 0.0 0.0 4.7 1.8 2.8 1.7 3.1 3.3 3.0 1.2 1.4 1.5 1.9 1.4 0.0 1.1 1.2 1.1 1.7 0.5 3.0 1.3 1.7 4.1 9.1 2.9 2.5 2.4 2.3 0.7 0.0 1.6 2.2 1.3 5.3 0.0 0.7 0.0 0.0 0.9 0.0 0.0 0.0 15.0 0.0 0.0 0.0 0.0 0.0 1.6 4.7 3.2 2.9 6.3 3.3 0.0 0.0 0.0 0.0 1.8 72.3 58.6 67.7 56.7 69.0 68.3 59.6 70.6 71.0 68.0 71.8 71.7 65.9 59.4 67.6 55.2 40.5 58.2 63.5 41.7 50.7 74.0 52.7 40.9 54.8 66.1 55.7 68.0 66.6 79.4 66.5 64.5 67.9 72.2 64.9 56.0 66.8 66.8 52.3 60.5 45.5 72.1 78.9 79.8 79.7 65.2 59.6 67.2 58.2 65.9 72.3 70.4 67.5 67.6 62.5 122.0 * 51.9 * 49.1 40.2 * * 87.9 * 31.5 * 63.2 32.8 * * * 75.2 76.6 22.2 34.5 31.8 45.7 40.0 38.4

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
813

871

Indices of data quality

Brain and central nervous sytem (C70-72) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
814

Female Cases MV(%) DCO(%) UB(%) MI(%) 2469 218 125 75 92 171 24 731 44 44 33 72 71 67 86 252 140 108 13 19 53 44 38 143 264 1460 86 55 1012 210 760 1253 1322 1734 975 205 927 145 83 77 97 151 169 141 56 72 50 68 473 839 308 317 460 453 175 52 622 31 120 111 288 119 50 206 141 94 401 109 56 93 227 188 109 52 24 201 210 90 363 60.8 52.3 79.2 54.7 58.7 61.4 62.5 62.5 56.8 45.5 72.7 59.7 85.9 86.6 94.2 46.4 81.4 78.7 84.6 94.7 49.1 56.8 71.1 81.1 85.2 79.1 83.7 70.9 78.5 91.0 88.7 49.0 50.6 70.1 74.1 88.3 79.5 69.7 85.5 92.2 92.8 85.4 78.7 90.1 89.3 62.5 70.0 89.7 60.7 71.0 56.8 62.1 70.4 76.2 88.6 69.2 61.9 64.5 55.8 53.2 52.8 53.8 58.0 53.4 44.7 50.0 43.4 57.8 57.1 39.8 51.5 48.4 26.6 46.2 79.2 41.3 50.0 54.4 60.6 14.8 15.1 4.0 6.7 14.1 6.4 0.0 20.1 29.5 45.5 18.2 11.1 2.8 0.0 0.0 20.6 0.0 0.0 0.0 0.0 0.0 13.6 2.6 2.8 0.0 14.0 5.8 14.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 1.1 0.7 0.0 1.8 0.0 0.0 0.7 0.3 42.9 1.0 2.9 0.0 2.6 0.0 0.0 0.0 2.1 0.0 0.6 0.0 0.0 4.2 0.0 1.5 3.6 1.2 0.0 1.3 0.0 0.7 0.0 0.0 1.6 3.2 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.9 5.8 0.0 0.0 20.5 0.0 0.0 75.1 83.0 94.4 68.0 70.7 66.1 37.5 56.8 88.6 48.6 35.2

2797 264 152 110 103 177 23 774 50 67 61 80 76 87 124 282 170 137 17 16 56 23 43 195 431 1618 100 64 1165 273 916 1606 1386 1923 1135 225 1056 180 96 87 129 167 228 188 68 89 75 80 541 931 340 363 488 478 223 50 810 28 142 107 303 144 48 263 152 116 472 147 68 113 277 184 126 79 31 231 221 136 385

66.6 59.8 78.3 69.1 80.6 65.0 91.3 65.1 78.0 62.7 82.0 61.3 73.7 88.5 96.0 50.0 88.2 86.9 94.1 93.8 62.5 47.8 58.1 84.1 88.2 83.7 86.0 82.8 78.8 96.0 92.6 49.8 48.8 75.7 78.3 85.3 86.0 73.3 89.6 93.1 94.6 88.6 82.0 94.1 86.8 65.2 73.3 87.5 68.4 74.4 70.9 71.9 75.6 83.7 91.0 80.0 72.6 42.9 60.6 68.2 53.5 61.8 54.2 58.6 46.7 54.3 54.4 64.6 57.4 48.7 62.1 51.6 36.5 53.2 61.3 51.9 56.1 64.0 72.2

11.1 12.9 7.2 10.0 5.8 4.5 0.0 15.8 12.0 28.4 14.8 18.8 13.2 1.1 0.0 16.3 0.0 0.0 0.0 0.0 1.8 34.8 7.0 3.1 0.0 12.7 3.0 3.1

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 4.7 0.0 0.0 0.9 0.2 45.1 0.6 2.7 0.0 1.4 0.6 0.0 0.0 3.1 0.0 1.8 0.0 0.0 2.2 0.0 2.5 4.6 0.3 0.0 0.0 0.0 2.1 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 5.1 0.0 0.4 18.6 0.0 0.0

76.8 88.3 74.3 73.6 71.8 61.0 65.2 58.9 70.0 50.0 46.1

74.7 10.7 95.7 88.4 46.2 76.1 101.0 62.5 90.6 93.7 86.0 72.5 100.6 85.6 108.9 74.8

86.4

* * *

15.1 * 47.7 * 81.6 34.3 * * 69.7 100.0 63.6 97.3 * * 93.3 82.6 * 63.5 101.6 82.4 107.3 71.1

32.6 6.0 8.4 0.2 1.8 1.5

34.6 6.4 10.1 0.2 1.5 2.2

0.0 23.5 20.4 13.2 24.5 15.2 9.8 4.0 2.0 3.0 0.0 3.5 1.9 0.7 0.0 4.2 1.1 1.3 2.6 0.8 0.0 0.0 0.0 3.2 4.3 4.8 8.9 0.0 1.7 0.9 0.7 2.1

0.0 31.5 23.4 19.8 33.8 19.1 14.6 5.7 0.0 4.3 0.0 5.0 1.8 2.1 1.7 2.0 4.9 2.1 6.4 1.7 0.0 3.6 0.0 3.5 6.9 4.6 9.6 4.2 1.0 1.9 0.0 1.9

O 154.3 73.3 89.3 23.7 63.3 100.9 77.7 80.8 71.1 54.8 54.2 47.7 70.5 52.9 56.0 70.9 60.3 51.4 97.5 40.4 55.4 62.4 74.0 56.4 41.3 98.1 78.1 63.2 93.8 62.2 52.3

147.1 70.2 92.9 32.5 70.1 97.9 72.2 112.0 75.1 78.6 52.8 63.6 71.6 54.2 77.1 60.5 52.0 55.3 91.3 48.3 61.8 61.9 72.9 53.3 43.7 86.1 72.6 68.8 89.1 61.0 52.2

872

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Brain and central nervous sytem (C70-72) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 439 630 65 955 146 355 347 445 735 573 1345 876 332 64 221 402 240 50 128 128 187 142 109 146 1586 94 56 33 95 72 45 116 2871 172 182 570 599 727 1464 562 1676 2833 1064 1019 338 1071 1328 24 686 334 106 1070 349 55 25 783 158 6 19 29 27 68 57.6 84.9 72.3 85.0 62.3 59.2 61.4 93.5 61.5 66.7 76.6 69.5 97.9 39.1 69.2 72.1 81.3 36.0 62.5 78.9 62.6 53.5 61.5 81.5 94.8 88.3 75.0 75.8 86.3 87.5 84.4 91.4 84.5 86.6 87.9 75.3 62.8 72.1 74.5 76.9 63.1 70.1 63.7 78.4 61.5 72.2 86.8 83.3 84.0 78.1 84.0 85.1 88.0 78.2 52.0 81.4 89.2 83.3 73.7 93.1 96.3 91.2 19.4 1.6 3.1 0.4 9.6 2.3 0.9 34.3 10.6 10.4 0.9 12.5 3.6 2.7 5.4 10.0 7.0 0.0 6.4 3.5 11.0 14.4 0.0 1.8 6.1 0.0 4.2 0.0 2.6 0.2 0.0 0.0 0.0 0.0 7.0 0.0 0.0 0.0 13.3 0.4 3.2 1.2 4.7 1.4 0.5 0.0 0.0 2.3 0.0 1.1 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.0 0.3 1.5 0.0 13.7 5.1 4.5 1.9 0.0 0.0 0.9 0.0 0.0 0.1 0.3 0.9 2.1 0.3 0.0 8.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 89.3 79.5 106.2 77.7 84.8 61.3 81.3 103.1 62.3 89.4 74.3 99.4 102.7 62.5 79.9 67.7 84.4 80.0 77.3 78.1 82.9 81.7 65.1 101.4 97.5 77.7 58.9 66.7 75.8 79.2 71.1 83.6 79.7 76.9 78.9 60.9 83.2 74.0 79.9 80.3 74.7 74.0 78.0 67.8 84.5 77.7 54.2 80.3 82.3 73.9 75.3 87.7 83.6 68.0 82.8 63.3 Female Cases MV(%) DCO(%) UB(%) MI(%) 383 590 45 736 126 369 316 362 605 571 1121 699 261 39 211 362 202 37 108 110 148 123 111 132 1164 64 49 24 77 60 39 89 2131 138 127 418 487 615 1056 375 1208 2171 866 740 254 823 983 14 528 234 70 815 247 43 20 508 124 4 10 25 23 49 55.4 82.0 64.4 77.3 52.4 48.0 53.8 92.8 56.7 62.2 76.8 69.4 96.2 33.3 61.6 63.8 69.3 27.0 65.7 74.5 50.7 48.8 65.8 78.8 91.3 73.4 87.8 79.2 77.9 63.3 76.9 83.1 81.4 77.5 89.0 65.3 54.4 63.9 66.2 68.8 55.5 64.5 55.8 71.5 55.9 64.0 82.4 64.3 76.9 72.6 87.1 79.1 83.4 88.4 70.0 72.8 87.1 75.0 90.0 84.0 87.0 87.8 20.6 2.7 6.7 1.0 14.3 2.7 1.3 37.7 10.9 9.7 2.7 12.8 2.8 5.5 4.5 10.8 1.9 0.9 8.8 3.3 9.0 12.9 1.6 0.0 0.0 1.3 13.3 0.0 5.6 0.3 0.0 0.0 0.0 0.0 6.0 0.3 0.0 0.0 14.4 0.1 1.6 1.1 2.6 2.8 1.9 1.0 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.1 0.0 2.4 0.0 18.7 6.7 4.0 2.3 0.0 0.0 1.2 0.0 0.0 0.0 0.4 0.0 3.2 0.0 0.0 5.0 0.0 0.8 0.0 0.0 0.0 0.0 2.0 90.1 76.9 75.6 76.1 82.3 * 44.4 92.1 103.0 * 53.6 105.3 72.1 102.4 103.1 110.3 78.2 69.3 79.2 62.2 68.5 81.8 70.3 79.7 64.0 93.2 101.5 89.1 67.3 79.2 79.2 75.0 102.6 74.2 80.6 78.0 80.1 56.1 74.8 75.2 80.5 76.7 74.5 66.6 79.3 67.7 87.2 73.1 78.6 80.7 80.8 81.0 76.6 88.3 79.1 55.0 88.8 56.5

0.0 4.7 1.0 0.6 0.9 1.5 6.5 5.8 4.6 0.9 0.2 0.6 4.2 0.7 0.0 0.0 1.8 2.3 0.0 16.0 4.0 1.3 0.0 0.0 0.0 3.7 1.5

0.5 6.0 3.1 1.6 1.6 1.8 8.4 7.3 6.1 1.2 0.5 1.3 0.0 1.7 0.0 0.0 3.2 4.5 0.0 10.0 4.9 2.4 0.0 0.0 4.0 4.3 2.0

64.7

59.2

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
815

873

Indices of data quality

Thyroid (C73)
Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 32 100.0 53 90.6 14 100.0 11 54.5 14 71.4 6 83.3 88 92.0 8 100.0 39 94.9 861 85.9 16 93.8 85 89.4 141 95.0 57 87.7 11 100.0 17 100.0 2095 295 271 68 54 26 2 54 1243 3 79 300 38 257 63 475 2720 329 103 470 1789 545 22 37 33 5 66 339 779 47 26 37 17 18 169 438 432 386 7 368 82 36 40 1434 69 1334 568 66 484 213 26 173 117 1100 62 972 476 290 332 318 47 266 15 54 93.6 99.3 99.3 100.0 100.0 100.0 100.0 96.3 89.7 100.0 100.0 99.0 97.4 99.2 98.4 99.2 99.5 99.7 99.0 99.8 99.4 99.4 100.0 97.3 100.0 100.0 100.0 99.4 99.6 100.0 100.0 100.0 100.0 100.0 99.4 99.5 98.1 100.0 100.0 100.0 96.3 100.0 97.5 98.2 94.2 98.4 98.8 97.0 99.0 99.5 100.0 99.4 100.0 98.9 96.8 99.0 99.8 99.3 98.8 99.4 95.7 100.0 100.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0 4.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 6.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.3 0.0 0.0 0.7 0.0 0.8 1.6 0.4 0.1 0.0 1.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.5 0.0 0.0 0.0 3.7 0.0 2.5 0.1 0.0 0.1 0.2 1.5 0.0 0.0 0.0 0.0 0.0 0.4 3.2 0.2 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 Female Cases MV(%) DCO(%) UB(%) MI(%) 88 98.9 151 96.0 34 100.0 26 92.3 45 68.9 17 94.1 338 97.3 43 72.1 208 94.7 4399 86.3 42 92.9 450 97.8 739 95.5 356 89.9 80 81.3 68 100.0 6839 802 733 265 178 102 7 180 4349 19 204 898 171 704 173 1368 8487 1264 308 2002 4783 1572 57 135 94 22 236 826 2516 129 81 155 33 59 802 1160 1256 1113 51 1007 191 107 62 4052 345 3582 1774 334 1377 720 157 525 367 3380 277 2908 1451 861 1057 1052 209 831 59 163 91.8 99.9 99.5 99.6 99.4 99.0 100.0 99.4 87.3 100.0 99.5 99.2 98.8 99.3 99.4 99.6 99.5 99.4 98.7 99.9 99.5 99.7 100.0 99.3 100.0 100.0 100.0 99.6 99.6 98.4 100.0 100.0 100.0 98.3 99.9 99.7 99.4 99.5 98.0 99.5 99.0 99.1 100.0 99.4 99.1 99.4 99.5 99.1 99.6 100.0 100.0 100.0 99.7 99.5 98.6 99.5 99.7 99.7 99.1 98.5 98.6 98.4 100.0 96.9 0.0 0.0 0.0 0.0 0.0 0.0 2.1 2.3 0.5 0.0 0.0 0.0 0.0 0.0 2.5 0.0 7.9 0.0 0.0 0.0 0.0 1.0 0.0 0.0 12.5 0.0 0.0 0.4 0.6 0.4 0.6 0.1 0.1 0.1 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 2.0 0.0 0.5 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.1 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.4 0.2 0.0 0.2 0.0 0.6 * * * *

5.7 0.0 16.7 3.4 0.0 2.6 1.2 0.0 2.4 0.7 3.5 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 1.4 4.3 1.3 0.4 0.0 0.4 0.0 0.0 0.0 0.0 0.5 0.0 0.6 0.2 0.3 0.3 0.0 0.0 0.0 0.0 0.0

11.3

2.0 4.4 5.9 0.6 4.7 2.9 0.7 0.0 0.0 0.8 2.8 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.1 0.0 0.5 0.1 0.0 0.1 0.0 0.1 0.1 0.2 0.3 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.2 0.8 0.0 0.0 0.0 1.7 0.0 0.1 0.1 0.2 0.0 0.2 0.5 0.9 0.0 0.2 0.6 0.2 0.3 0.9 0.2 0.0 0.0 0.0 0.0 0.3 0.7 0.2 0.1 0.1 0.2 0.4 0.0 0.5 0.0 0.6

4.6

50.0 12.5 12.5 10.3 7.8 25.0 27.1 9.9 24.6 34.1 10.2 8.8 16.6 10.3 11.1 26.9 14.8 8.4 12.7 16.0 28.9 14.0 6.3 11.6 11.2 9.7 14.6 11.9 11.2 11.4 18.2 6.1 13.0 11.0 12.8 15.4 10.8 17.6 5.6 16.0 9.4 8.8 11.4 14.3 11.4 7.3 13.9 2.5 12.3 15.9 12.4 9.3 12.1 9.3 4.7 7.7 4.6 6.8 9.7 4.8 10.6 13.2 10.3 12.0 13.5 25.5 11.7 33.3 13.0

47.1 7.7 4.7 10.6 3.3 14.3 8.9 7.3 13.5 4.7 4.4 4.0 9.0 7.5 6.2 7.8 4.4 3.2 15.8 6.9 5.7 9.9 4.8 1.2 3.5 5.2 6.3 7.8 4.9 5.0 5.0 7.0 5.9 3.9 6.2 11.6 6.2 8.4 9.1 8.5 4.7 6.3 4.2 4.1 2.0 4.2 4.7 7.5 1.6 6.8 7.8 6.8 4.2 5.1 3.8 3.3 3.2 3.0 4.1 4.7 8.3 4.5 6.5 5.2 6.5 7.1 12.0 6.0 15.3 6.7

874

*Important. See note on population page.

816

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Thyroid (C73) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 99 644 842 65 756 384 53 323 480 22 452 108 19839 1052 17616 969 64 845 222 7 81 131 2019 112 1790 856 42 766 230 305 1513 76 1381 116 2588 121 2216 6586 518 330 680 4971 265 37 223 1699 96 1518 202 52 580 411 179 463 8 84 447 11 18 314 35 54 82 262 17 184 17 53 58 526 474 43 50 81 93 175 122 432 77 100.0 99.1 98.8 96.9 98.9 99.2 98.1 99.4 98.5 95.5 98.7 97.2 98.9 97.4 99.0 98.9 96.9 98.9 98.6 100.0 97.5 99.2 98.9 99.1 98.8 98.1 92.9 98.3 97.8 99.7 99.6 100.0 99.6 100.0 99.5 99.2 99.5 99.3 99.6 98.2 99.4 99.4 99.2 100.0 99.1 98.2 97.9 98.4 99.5 96.2 99.5 99.5 99.4 97.6 100.0 88.1 97.8 72.7 72.2 88.2 100.0 96.3 65.9 75.2 100.0 88.6 94.1 81.1 100.0 96.0 97.0 95.3 94.0 95.1 94.6 96.0 92.6 86.3 92.2 0.0 0.8 0.5 0.0 0.5 0.5 1.9 0.3 0.8 0.0 0.9 1.9 0.5 0.9 0.5 0.1 0.0 0.1 0.5 0.0 0.0 0.8 0.2 0.0 0.3 1.2 7.1 0.9 0.4 0.3 0.1 0.0 0.1 0.0 0.2 0.8 0.1 0.2 0.0 0.3 0.0 0.2 0.4 0.0 0.4 0.6 1.0 0.6 0.0 1.9 0.3 0.2 0.6 0.9 0.0 0.0 0.2 0.0 0.0 0.3 0.0 1.2 0.0 0.0 3.8 0.0 0.0 0.0 1.0 0.6 0.0 6.0 1.2 2.2 1.1 4.1 5.3 6.5 0.0 0.2 0.6 3.1 0.4 0.0 0.0 0.0 0.4 0.0 0.4 0.9 0.4 0.9 0.3 0.6 1.6 0.6 0.5 0.0 1.2 0.0 0.2 0.0 0.3 0.5 0.0 0.5 0.4 0.0 0.2 0.0 0.2 0.0 0.1 0.0 0.1 0.2 0.0 0.6 0.3 0.2 0.4 0.0 0.4 0.9 1.0 0.7 0.5 0.0 0.2 0.2 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.7 18.3 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.4 2.3 0.0 1.2 0.0 0.0 0.0 0.0 0.0 18.2 9.3 11.8 15.4 11.8 11.2 15.1 10.8 12.7 9.1 13.1 9.3 10.6 14.4 10.8 9.8 14.1 9.9 9.9 28.6 8.6 9.2 7.9 10.7 8.0 14.7 19.0 15.4 15.7 8.9 7.5 9.2 7.7 13.8 9.6 14.0 9.3 10.6 9.5 16.1 10.4 10.5 14.7 21.6 13.9 10.1 11.5 10.5 8.4 13.5 7.4 7.1 13.4 12.5 12.5 19.0 15.0 44.4 16.2 32.9 22.3 16.4 42.0 14.8 15.1 22.9 18.9 31.9 40.3 Female Cases MV(%) DCO(%) UB(%) MI(%) 338 99.1 2132 99.6 2696 98.9 242 97.9 2348 98.9 1171 99.4 180 98.3 946 99.6 1496 99.7 93 100.0 1370 99.7 321 99.1 60456 99.3 4256 98.7 51843 99.3 2966 99.2 213 99.1 2522 99.1 636 99.1 40 100.0 214 98.6 371 99.2 6201 99.0 564 98.6 5205 99.1 2605 99.4 170 98.8 2314 99.4 596 98.0 848 99.6 4903 99.4 365 99.5 4355 99.4 377 99.7 7819 99.6 494 99.2 6306 99.6 20454 99.4 2014 99.5 1224 98.9 2779 99.6 14047 99.4 839 98.9 162 99.4 659 98.8 4887 98.3 332 97.6 4285 98.4 691 99.9 170 100.0 1760 99.7 1215 99.8 542 98.9 1288 98.6 57 100.0 295 89.8 1557 97.9 20 95.0 33 87.9 1044 91.0 105 99.0 190 99.5 202 78.7 579 75.8 44 95.5 355 87.3 42 95.2 93 76.3 196 99.5 1948 94.0 1747 95.0 161 95.7 196 96.4 221 95.5 472 96.6 819 97.9 473 96.6 1194 86.2 393 94.9 0.0 0.3 0.4 0.4 0.4 0.1 0.0 0.1 0.1 0.0 0.1 0.3 0.2 0.4 0.2 0.1 0.5 0.0 0.3 0.0 0.9 0.0 0.1 0.0 0.1 0.3 0.0 0.3 0.0 0.1 0.2 0.0 0.3 0.0 0.1 0.0 0.1 0.1 0.1 0.2 0.1 0.1 0.2 0.0 0.3 0.4 0.9 0.4 0.0 0.0 0.1 0.0 0.4 0.9 0.0 0.0 0.2 0.0 0.0 0.2 0.0 1.5 0.5 0.0 3.1 0.0 3.2 0.0 0.5 0.4 0.0 3.1 0.5 0.4 1.0 1.5 5.9 1.0 0.9 0.1 0.5 0.8 0.5 0.3 0.6 0.2 0.2 0.0 0.2 0.3 0.3 0.3 0.3 0.4 0.5 0.4 0.0 0.0 0.0 0.0 0.4 0.4 0.3 0.1 0.0 0.1 0.5 0.1 0.2 0.3 0.2 0.0 0.1 0.4 0.1 0.2 0.1 0.2 0.1 0.1 0.7 0.6 0.8 1.0 1.5 1.0 0.0 0.0 0.1 0.1 0.4 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 11.9 0.0 0.0 0.3 0.0 0.0 0.0 3.1 2.5 3.1 0.5 0.5 0.0 0.0 0.2 0.0 0.5 5.0 4.2 6.0 6.2 6.2 5.0 3.9 5.3 5.3 10.8 5.0 4.0 5.1 7.3 5.1 4.3 4.2 4.6 4.6 2.5 7.0 3.2 5.0 8.9 4.9 5.1 5.3 5.3 6.0 6.6 4.5 5.5 4.6 2.4 4.4 3.6 4.4 5.0 5.6 6.3 4.6 4.9 5.6 8.0 5.2 4.8 6.3 4.9 3.5 4.1 4.1 4.0 6.5 6.6 1.8 5.8 * 7.6 * 33.3 8.9 * * * 18.3 * 14.4 7.3 11.7 13.6 6.6 8.2 15.9 26.2 14.0 * * *

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
817

875

Indices of data quality

Thyroid (C73) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
818

Female Cases MV(%) DCO(%) UB(%) MI(%) 13725 989 753 339 809 715 128 4122 265 120 86 103 138 137 71 1206 636 512 46 78 191 87 209 157 329 1880 198 70 3860 128 512 785 1254 2012 524 293 1281 198 203 182 119 220 461 405 122 165 214 306 526 930 152 405 637 308 216 91 263 51 334 266 451 203 49 341 349 150 700 198 97 259 520 341 200 146 58 306 295 123 482 97.0 95.0 98.7 96.8 98.1 93.4 93.8 97.6 96.6 99.2 97.7 95.1 93.5 98.5 98.6 93.3 98.7 98.8 97.8 98.7 95.8 81.6 97.1 94.9 98.5 97.0 99.0 94.3 99.0 100.0 92.6 87.0 93.1 96.3 97.7 99.3 99.1 99.5 100.0 100.0 99.2 99.5 98.9 99.8 100.0 98.2 100.0 99.7 91.4 94.8 86.8 95.8 99.8 84.7 97.7 100.0 96.2 98.0 93.1 98.9 85.4 90.1 89.8 90.6 99.4 93.3 97.1 98.0 96.9 98.8 95.2 82.4 98.5 95.2 96.6 99.3 83.7 94.3 96.3 0.6 0.8 0.1 0.3 0.0 0.8 0.0 0.5 0.8 0.8 2.3 1.0 2.9 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 4.6 1.4 0.0 0.0 2.7 0.5 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.3 0.3 0.0 0.0 1.4 0.0 0.0 6.4 0.0 6.1 0.2 0.8 0.0 0.1 0.0 0.0 0.0 0.8 0.0 0.9 0.0 0.0 0.0 0.0 0.0 3.2 0.1 0.0 0.0 0.0 0.3 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 14.2 0.0 0.0 5.5 7.4 5.4 6.5 3.5 6.7 8.2 3.6 2.6

2314 95.6 215 93.0 118 96.6 73 94.5 121 97.5 109 90.8 25 88.0 644 96.7 49 95.9 46 97.8 62 100.0 25 92.0 46 97.8 32 93.8 25 96.0 260 90.4 180 99.4 147 99.3 11 100.0 22 100.0 43 95.3 18 77.8 52 96.2 38 92.1 90 95.6 737 73 25 892 64 206 244 306 571 210 52 384 75 59 60 58 62 143 106 32 36 46 96 205 337 75 136 209 122 71 41 94 23 105 87 143 71 17 119 127 53 210 71 31 84 151 93 50 35 15 80 104 45 156 97.4 97.3 80.0 98.8 100.0 94.7 81.6 92.2 95.8 97.6 98.1 98.7 98.7 100.0 100.0 100.0 98.4 100.0 100.0 100.0 100.0 97.8 99.0 92.7 94.7 85.3 96.3 99.0 90.2 97.2 100.0 92.6 100.0 95.2 97.7 82.5 91.5 100.0 95.8 100.0 94.3 97.1 97.2 90.3 97.6 93.4 80.6 98.0 100.0 93.3 98.8 88.5 86.7 98.1

1.0 0.5 2.5 1.4 0.0 2.8 0.0 1.7 2.0 2.2 0.0 0.0 2.2 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 5.6 3.8 5.3 0.0 2.4 2.7 8.0

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 4.0 0.0 0.0 4.9 0.0 7.2 0.7 1.4 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.4 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.5 0.0 0.0

12.9 16.7 11.0 15.1 4.1 13.8 12.0 9.3 6.1

3.6

15.6

11.0

* * *

55.6 78.8 10.5 22.7 28.8 36.0 12.3 31.6 47.5 19.6 27.7 33.8 36.5 21.6

* 33.3 * 15.3 3.8 * * 18.0 20.2 14.3 5.4 * * 26.6 24.5 * 9.2 17.8 22.3 18.1 11.9

10.2 0.7 1.8 0.0 0.0 0.0

6.4 0.8 1.7 0.2 0.0 0.2

0.0 2.9 5.0 6.7 3.7 0.0 4.1 2.8 0.0 3.2 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 1.3 0.0 2.2 0.0

0.0 4.2 4.3 2.6 4.0 0.0 5.5 1.9 0.0 0.8 0.0 0.3 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 1.0 0.0 0.2 0.3 0.5 0.0 0.0 0.3 0.3 0.0 0.2

O 23.6 17.2 26.3 5.2 13.3 25.0 19.0 11.0 24.3 9.8 4.2 5.3 11.1 9.9 10.2 11.1 6.6 7.2 12.6 5.6 8.2 5.0 6.7 8.5 6.0 6.8 8.6 10.5 11.5 12.2 11.0

32.7 22.0 30.7 8.1 26.8 24.6 21.1 17.1 38.3 17.4 15.2 8.0 15.4 12.7 35.3 19.3 7.1 14.2 20.0 18.3 9.7 19.0 11.3 19.4 22.0 11.4 8.3 11.3 17.3 17.8 15.4

876

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Thyroid (C73) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 70 167 19 247 43 59 66 194 151 152 125 219 116 10 55 94 81 9 40 27 68 51 23 37 407 27 7 15 38 25 17 41 524 34 24 95 78 105 230 84 232 433 153 189 72 177 506 14 304 112 35 257 130 20 26 181 132 5 37 23 18 40 82.9 95.2 94.7 98.4 81.4 91.5 98.5 99.5 92.1 79.6 74.4 93.2 99.1 90.0 100.0 96.8 100.0 100.0 100.0 96.3 100.0 96.1 95.7 97.3 99.8 100.0 100.0 100.0 97.4 100.0 94.1 100.0 99.4 97.1 100.0 91.6 91.0 89.5 92.2 92.9 89.2 89.4 94.8 95.8 91.7 100.0 97.4 100.0 95.7 100.0 97.1 97.7 99.2 100.0 100.0 97.8 99.2 100.0 97.3 100.0 100.0 100.0 5.7 0.0 0.0 0.4 2.3 1.7 0.0 7.3 10.4 5.5 0.9 0.0 0.0 3.2 0.0 0.0 0.0 0.0 0.0 3.9 4.3 0.0 0.0 0.0 0.0 2.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 7.9 0.0 0.5 0.0 10.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.1 0.0 1.0 0.0 4.8 3.4 2.3 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 45.7 35.3 26.3 26.3 32.0 31.8 30.3 16.5 23.2 52.8 28.3 28.4 40.0 33.3 23.4 18.5 22.2 22.5 25.9 16.2 25.5 26.1 43.2 32.2 11.1 28.6 6.7 28.9 32.0 23.5 39.0 33.0 33.3 31.6 21.8 54.3 28.3 15.5 29.3 28.4 29.4 23.3 19.4 24.3 11.7 21.4 11.2 17.0 23.8 17.9 12.3 7.7 18.2 11.4 Female Cases MV(%) DCO(%) UB(%) MI(%) 412 838 112 649 214 340 320 1233 564 714 405 802 342 42 197 239 294 20 112 185 254 185 72 123 1031 98 21 26 90 55 66 106 1293 85 76 209 213 322 588 252 640 1133 363 475 160 485 1639 21 857 310 107 750 334 52 180 598 430 38 138 61 60 81 88.8 96.2 99.1 98.5 91.6 96.8 96.3 99.2 96.1 90.6 79.3 95.8 99.7 100.0 98.0 98.3 96.6 100.0 98.2 100.0 97.2 99.5 100.0 95.9 99.8 100.0 95.2 100.0 100.0 98.2 98.5 99.1 99.4 100.0 100.0 96.7 95.8 93.8 92.7 96.4 90.9 91.4 93.4 96.0 86.9 97.3 97.0 100.0 97.1 99.4 98.1 97.3 99.4 96.2 99.4 99.0 100.0 100.0 100.0 100.0 100.0 100.0 2.9 0.6 0.9 0.2 1.4 0.6 0.6 3.2 6.4 3.0 0.3 0.0 0.0 0.8 1.7 0.0 0.9 0.0 0.8 0.0 0.0 3.3 0.0 0.0 0.0 0.0 1.8 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.3 0.3 0.0 0.0 3.4 0.0 0.5 0.0 0.0 0.0 0.4 1.4 0.0 0.9 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.5 0.9 0.0 2.8 3.0 1.9 0.3 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.9 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 31.6 15.3 12.5 19.3 11.7 * 13.6 14.1 4.1 * 13.1 33.6 16.5 16.1 2.4 23.7 15.9 13.2 15.0 11.6 7.0 8.3 5.4 12.5 18.7 23.8 11.2 47.6 15.4 15.6 20.0 22.7 16.0 24.3 26.3 18.7 21.1 26.1 17.5 12.7 20.8 21.4 25.1 19.8 16.3 23.1 5.4 4.8 3.4 6.5 12.5 7.9 9.6 3.8 7.2 9.5 4.9

0.0 0.0 1.0 0.9 0.0 1.7 4.4 2.6 1.1 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0

0.0 0.9 0.9 0.9 0.0 0.8 3.1 3.0 1.3 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.5 0.3 0.0 0.6 0.2 0.0 0.0 0.0 0.0 0.0 0.0

7.5

4.9

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
819

877

Indices of data quality

Lymphoma (C81-90,C96)
Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 187 100.0 1118 94.6 119 97.5 198 81.8 318 87.1 88 76.1 406 93.3 70 80.0 208 89.9 3887 99.4 94 100.0 547 90.5 748 96.3 369 95.9 198 99.5 131 100.0 16750 88.9 1793 96.9 2908 95.4 905 94.7 570 99.1 272 99.3 11 100.0 738 93.2 8714 82.5 91 97.8 748 94.7 2787 94.3 504 91.5 2250 94.8 356 95.5 3140 93.4 22060 96.3 1604 97.9 1405 95.2 3581 96.7 15022 96.1 4808 96.8 338 94.1 197 99.0 156 96.2 45 95.6 530 96.4 3237 96.9 5840 97.8 616 96.6 115 98.3 148 98.6 95 98.9 50 98.0 1386 97.3 3216 97.9 2706 91.7 2854 97.5 163 95.7 2648 97.6 433 92.1 295 92.9 122 92.6 13880 96.7 1245 95.9 12427 96.8 4573 93.5 1064 90.6 3440 94.5 1636 94.7 474 90.9 1122 96.6 884 95.1 8960 94.8 1004 92.6 7676 95.1 4175 95.3 2351 96.4 3011 93.2 3057 95.0 750 92.0 2284 96.0 228 93.4 464 96.8 0.0 0.0 0.0 0.0 0.0 11.4 1.0 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 8.3 0.0 0.2 0.1 0.0 0.0 0.0 0.9 15.8 0.0 0.1 2.7 2.4 2.8 2.0 2.4 1.0 0.6 0.9 0.9 1.1 0.7 0.9 0.5 1.3 0.0 1.1 0.6 0.5 0.5 0.0 0.0 0.0 0.0 0.6 0.6 2.1 0.4 0.0 0.4 3.5 3.1 2.5 0.1 0.1 0.1 1.2 1.6 1.0 1.7 2.3 1.2 0.5 0.8 1.2 0.8 0.8 0.9 2.7 0.7 0.5 0.7 0.0 0.9 Female Cases MV(%) DCO(%) UB(%) MI(%) 149 667 71 156 250 99.3 92.8 98.6 78.8 82.8 0.0 0.0 0.0 0.0 0.0 7.8 4.2 2.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 9.3 0.2 0.1 0.0 0.0 0.0 0.0 2.0 17.0 0.0 0.0 3.0 2.7 3.0 1.2 2.6 1.3 0.6 1.6 1.1 1.3 0.8 0.7 0.0 0.0 0.0 1.1 0.7 0.7 1.6 0.9 0.0 0.0 0.0 0.8 0.6 1.2 0.4 0.0 0.4 2.3 3.0 0.9 0.1 0.2 0.1 1.4 1.3 1.4 1.3 1.0 1.4 0.5 0.8 1.2 0.8 1.1 0.8 2.8 0.9 0.6 1.1 0.5 1.0 * * * *

1.3 7.2 9.1 5.2 11.4 8.7 0.0 0.0 0.4 0.7 0.8 0.0 0.6 0.1 0.9 1.0 0.0 0.0 1.4 0.6 0.0 0.9 0.7 1.0 0.7 0.3 1.6 0.7 0.5 0.6 0.5 0.7 0.8 0.3 0.0 1.3 2.2 0.6 1.0 0.5 1.0 0.0 0.7 0.0 0.0 0.4 0.5 1.6 0.4 0.6 0.3 1.8 2.0 1.6 2.5 2.6 2.5 2.6 2.7 2.6 0.8 0.6 0.8 1.7 1.8 2.3 1.8 1.5 0.9 1.0 0.7 0.9 0.6 1.8 0.2

16.4

3.3 10.0 15.5 8.1 10.0 7.1 0.0 0.0 0.6 1.4 0.6 0.0 0.9 0.1 0.9 0.6 0.0 0.0 1.2 1.1 0.0 0.9 0.8 0.6 0.8 0.8 1.4 0.9 0.5 1.0 0.4 1.0 1.1 1.1 0.0 0.8 0.0 1.1 1.4 0.4 0.9 0.9 0.0 1.3 0.0 0.2 0.3 1.9 0.4 0.6 0.4 3.1 2.2 4.6 2.7 2.4 2.7 3.0 2.7 3.2 1.6 1.0 2.0 2.0 2.5 5.0 2.2 1.8 1.4 1.5 1.1 1.0 1.1 1.0 0.7

16.6

94.3 39.2 37.1 13.0 35.8 60.6 41.0 60.4 45.3 34.7 45.7 42.4 46.5 52.0 49.3 48.9 27.3 48.1 44.8 50.5 47.9 52.5 56.9 52.2 36.5 51.5 42.0 38.0 41.4 35.0 45.2 38.0 41.4 31.1 40.4 39.8 40.1 45.2 45.3 37.9 30.0 34.6 43.5 40.5 39.6 40.5 39.9 42.5 43.7 43.4 46.3 40.2 47.6 44.5 45.0 44.8 38.1 36.9 38.9 42.1 45.3 46.2 46.1 51.4 46.7 46.1 47.0 47.5 47.1 52.6 43.8

116 74.1 284 87.3 50 78.0 197 91.9 3656 99.6 72 100.0 525 93.0 626 94.4 325 97.2 186 99.5 110 100.0 14256 87.1 1461 96.5 2281 93.7 788 93.9 509 95.5 200 99.5 3 100.0 589 91.0 7700 80.9 74 97.3 651 92.6 2524 93.3 488 90.2 2004 94.1 250 96.8 2582 93.1 18244 95.4 1394 97.2 1176 93.9 2979 96.2 12339 95.1 3879 96.1 272 94.9 181 96.1 132 97.7 50 100.0 470 95.5 2541 96.0 4813 97.0 564 94.3 108 97.2 137 99.3 79 98.7 39 97.4 1129 97.2 2603 97.3 2350 91.5 2553 97.7 172 97.7 2343 97.7 355 92.7 230 91.7 109 94.5 11912 96.5 1102 95.6 10652 96.6 4014 91.9 974 90.2 2972 92.4 1355 92.9 412 92.2 904 93.0 789 95.1 8093 93.9 1008 90.5 6857 94.2 3791 94.7 2218 95.0 2744 91.3 2767 94.1 669 90.3 2080 95.2 193 92.2 417 97.4

69.8 50.0 38.0 5.6 36.6 66.7 42.9 50.0 51.1 32.9 45.4 42.5 45.7 51.0 47.2 61.0 66.7 48.7 44.0 43.2 51.3 55.1 55.9 55.6 35.6 51.8 43.2 37.7 49.3 34.6 46.3 41.5 55.5 32.1 44.4 42.0 50.9 48.1 32.8 39.2 43.6 35.2 44.6 43.1 46.1 45.3 46.6 55.2 60.0 49.5 45.1 45.2 45.6 49.4 48.5 50.4 43.8 45.4 44.1 43.0 46.6 49.0 47.4 52.3 50.9 46.4 49.3 48.1 49.7 49.2 50.8

878

*Important. See note on population page.

820

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Lymphoma (C81-90,C96) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 1095 4785 7293 828 6325 3139 617 2477 4055 324 3698 703 160162 14759 139389 7142 823 6040 1083 50 301 712 14946 1852 12665 8386 729 7433 2366 2646 10705 803 9612 813 19633 1710 16536 51735 2532 4619 4884 38930 2539 545 1949 12167 1215 10651 1279 446 4702 3242 1406 4047 77 488 2252 48 93 1581 172 303 631 2160 44 1613 255 374 160 4071 3635 320 245 360 411 960 650 2787 482 93.3 94.9 95.6 93.8 95.8 96.7 95.0 97.1 93.9 91.0 94.1 92.7 94.7 92.3 94.9 95.4 92.6 95.8 93.0 94.0 95.0 91.9 91.5 90.6 91.6 95.5 94.2 95.6 94.6 95.3 95.0 91.9 95.3 95.9 96.4 94.2 96.6 95.9 97.7 93.6 96.4 96.1 91.3 88.4 92.6 91.5 87.7 92.0 97.4 94.8 95.3 96.5 95.7 96.8 94.8 96.9 94.8 100.0 81.7 88.7 98.8 97.7 98.7 100.0 97.7 100.0 100.0 98.4 100.0 93.0 94.0 94.7 100.0 86.4 84.9 79.1 83.5 100.0 79.9 2.0 1.8 0.7 0.2 0.7 0.9 1.0 0.8 2.4 4.3 2.2 3.7 1.5 1.9 1.5 0.8 1.2 0.8 2.3 0.0 1.3 2.9 1.4 1.8 1.4 2.3 4.0 2.2 0.6 1.6 0.6 0.7 0.6 2.5 0.7 0.7 0.7 0.7 0.7 0.9 0.6 0.8 1.8 1.1 1.6 2.4 4.1 2.3 0.1 1.8 0.8 0.5 1.4 3.2 1.3 0.0 1.0 0.0 2.2 0.6 0.0 1.1 0.0 0.0 0.0 0.0 1.3 0.0 2.1 1.8 0.6 0.0 5.6 1.9 11.0 7.4 0.0 12.9 2.6 1.3 1.8 2.1 1.8 0.7 0.8 0.7 2.2 2.5 2.2 1.1 1.6 1.8 1.6 1.6 2.4 1.5 1.5 2.0 1.0 1.7 3.2 2.8 3.3 1.1 0.5 1.1 2.1 0.5 1.4 1.7 1.3 0.2 0.8 1.1 0.8 1.1 0.6 1.2 0.9 1.1 4.2 5.7 3.6 4.1 4.0 3.9 0.4 0.9 1.3 0.8 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.3 2.8 3.4 0.0 1.7 0.0 0.0 2.0 0.0 1.5 45.8 43.9 48.5 46.1 49.5 44.7 45.7 44.7 48.3 46.0 48.7 45.5 45.1 44.3 46.2 41.2 39.5 42.5 44.7 56.0 43.9 44.4 38.7 36.3 39.6 49.6 53.4 50.5 48.3 47.9 45.6 43.5 46.9 46.6 42.2 42.0 42.8 42.9 39.0 42.5 33.4 45.1 47.8 51.0 47.9 44.9 48.0 45.3 44.8 44.4 43.7 42.5 48.2 47.8 58.4 39.5 50.5 84.9 48.6 10.7 34.2 2.3 35.1 38.0 73.1 69.7 55.5 60.9 67.7 71.9 78.4 Female Cases MV(%) DCO(%) UB(%) MI(%) 961 4481 6714 811 5759 2931 611 2280 3675 315 3327 604 142023 13507 123332 6642 758 5691 913 51 242 606 13877 1796 11735 7617 666 6743 2038 2242 9878 723 8918 821 16665 1556 13928 44600 2148 4065 3946 33784 2382 577 1770 10711 1154 9287 953 423 3794 2592 1360 3539 58 320 1681 23 66 1097 108 263 332 1104 36 889 115 235 122 3861 3485 284 195 299 384 826 569 2195 436 91.8 93.5 95.1 94.0 95.2 95.8 95.3 96.0 93.7 94.0 93.6 89.6 93.8 91.3 94.0 94.9 92.3 95.3 90.8 88.2 90.9 91.3 90.4 89.1 90.5 94.6 93.5 94.6 93.8 95.0 93.9 91.3 94.1 95.7 95.5 94.5 95.5 95.0 97.0 93.1 95.9 95.0 90.8 87.7 92.1 89.3 86.7 89.7 94.9 93.9 95.0 96.1 94.8 96.4 94.8 96.9 93.6 100.0 86.4 89.6 98.1 98.5 98.2 100.0 91.7 100.0 100.0 99.1 99.2 92.7 93.7 95.1 100.0 83.9 84.4 80.1 83.0 100.0 72.7 2.7 1.7 0.8 0.5 0.9 1.3 1.3 1.4 2.1 0.6 2.3 5.6 1.8 2.0 1.9 1.3 1.2 1.3 3.0 3.9 2.9 2.8 1.5 1.3 1.5 2.9 3.6 3.0 0.9 2.0 1.0 1.5 1.0 2.1 1.1 1.1 1.1 1.1 0.6 1.1 0.6 1.2 1.8 1.7 1.5 3.4 3.5 3.4 0.4 1.9 0.8 0.6 1.5 3.5 3.4 0.0 1.7 0.0 4.5 0.4 0.0 1.5 0.0 0.0 0.0 0.0 0.9 0.8 2.1 1.9 0.7 0.0 8.0 3.6 11.1 10.0 0.0 17.4 2.4 2.3 1.9 2.1 1.8 0.5 0.5 0.5 2.4 2.9 2.3 1.8 1.8 2.4 1.8 1.5 2.2 1.4 1.5 2.0 1.2 1.5 3.8 4.0 3.8 1.2 1.4 1.1 2.4 0.5 1.5 1.7 1.5 0.4 0.7 0.7 0.8 1.2 0.6 1.3 1.1 1.2 4.2 4.7 3.9 5.1 6.8 4.8 0.2 1.2 1.6 1.0 1.0 0.1 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.2 2.7 2.1 0.0 1.3 0.0 0.0 2.3 0.0 1.4 46.9 49.2 48.1 47.1 49.0 43.9 46.0 43.5 53.4 59.7 53.0 45.9 47.0 48.6 47.9 43.4 40.0 44.6 47.6 43.1 52.9 45.5 40.7 40.9 41.1 51.9 54.7 53.0 53.4 51.1 49.0 46.1 50.2 47.0 45.2 47.1 45.7 44.8 39.2 46.3 34.1 46.8 51.7 54.1 51.7 47.8 51.3 48.2 43.8 50.4 44.9 43.8 49.3 47.7 55.2 40.6 * 49.6 * 69.7 48.5 * * 18.1 * 35.5 * 2.8 37.3 * * * 39.1 82.1 65.9 48.2 51.8 59.2 69.2 72.7

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
821

879

Indices of data quality

Lymphoma (C81-90,C96) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
822

Female Cases MV(%) DCO(%) UB(%) MI(%) 4634 424 297 179 163 262 46 1421 64 139 94 133 210 154 177 604 608 478 35 95 229 119 168 201 530 3728 285 163 2366 757 2776 1613 1786 4374 2780 574 3376 535 310 271 410 541 572 706 271 265 192 334 1379 2516 1076 970 1026 1390 649 113 1716 175 511 326 938 510 121 893 547 254 1771 447 158 407 905 488 288 150 140 753 618 416 1309 94.3 94.3 96.3 95.0 98.2 95.0 93.5 94.9 96.9 100.0 96.8 94.0 97.1 98.1 97.7 77.5 100.0 100.0 100.0 100.0 100.0 100.0 97.6 86.6 91.3 90.3 97.9 91.4 97.4 99.6 97.7 100.0 97.1 89.1 96.2 97.2 92.5 96.6 97.7 100.0 97.1 99.8 97.7 97.2 98.2 95.8 97.4 97.9 79.1 81.3 77.9 87.0 87.9 87.6 94.3 100.0 94.9 92.6 93.3 95.7 81.3 89.6 93.4 100.0 99.5 85.4 98.2 100.0 89.9 99.3 98.5 93.4 94.4 88.0 92.1 95.1 80.4 93.5 93.0 4.2 3.3 3.4 2.8 1.2 3.8 0.0 4.2 1.6 0.0 0.0 0.8 0.5 0.6 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 8.7 1.4 8.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.5 1.1 0.0 0.0 0.0 0.0 0.0 1.8 0.0 0.2 0.5 3.4 0.0 0.8 0.9 0.0 0.0 2.0 0.0 1.7 0.1 0.0 1.5 0.5 1.2 1.7 0.3 0.0 0.4 0.0 1.6 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 2.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 2.7 0.0 0.5 16.3 0.0 0.0 47.9 46.5 42.4 46.4 42.3 48.5 55.4 35.9 28.1 33.8 40.5

6609 545 411 224 240 425 50 1972 101 200 266 168 331 274 372 658 864 670 40 154 344 148 197 270 681 3719 347 163 2188 897 3139 2036 1851 4564 3201 484 3327 573 380 328 453 577 656 821 354 308 225 431 1447 2391 1062 971 1131 1490 692 162 2143 173 514 383 1063 519 164 965 655 288 1805 408 160 433 1081 518 328 199 131 872 659 460 1374

94.8 93.6 97.8 96.0 98.8 95.8 98.0 95.6 96.0 98.5 98.5 97.0 98.5 98.5 97.6 80.2 100.0 100.0 100.0 100.0 100.0 100.0 98.5 87.4 91.5 92.6 97.7 96.3 96.2 100.0 98.0 100.0 97.0 90.7 96.3 96.9 95.0 97.2 97.4 100.0 98.2 99.7 97.0 97.7 98.9 95.8 98.7 98.6 78.9 86.1 79.8 88.1 88.5 89.1 95.1 100.0 95.2 94.2 95.5 97.1 84.9 88.1 95.7 99.9 99.7 83.7 98.8 99.8 91.9 98.4 98.3 96.1 97.0 86.9 90.8 96.7 79.8 95.9 94.3

3.8 3.5 1.2 2.7 0.0 2.1 0.0 3.5 3.0 0.0 0.4 1.2 0.9 0.0 0.3 4.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.0 6.6 1.4 3.7

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 1.8 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.4 0.4 3.4 0.0 0.5 0.5 0.0 0.0 0.7 0.0 2.4 0.0 0.0 1.0 0.0 1.2 2.4 0.2 0.0 0.4 0.0 1.1 0.1 0.0 0.7 0.6 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.2 1.3 0.0 0.0 0.0 0.3 3.5 0.0 0.1 18.4 0.0 0.0

50.6 54.5 41.8 49.1 42.1 52.2 57.0 41.8 55.4 26.8 18.1

48.8 1.2 103.4 70.6 22.6 88.8 54.7 39.5 45.4 55.1 44.2 44.4 50.2 54.6 53.6 58.3 50.8

43.3

* * *

0.4 * 108.4 * 64.9 20.9 * 66.6 * 58.5 46.0 46.0 45.6 * * 43.6 41.4 * 47.7 56.3 54.3 53.1 56.7

0.0 2.5 3.5 0.3 0.0 1.5

0.0 2.7 5.2 0.4 0.0 2.1

0.3 18.6 13.4 4.6 11.5 11.5 8.5 2.9 0.0 2.0 0.0 1.0 0.8 0.3 0.6 1.2 0.0 0.0 0.7 0.1 0.0 0.6 0.0 1.4 0.8 0.3 2.0 0.0 0.6 0.2 0.0 0.8

0.0 18.8 18.1 5.4 12.4 12.1 9.9 4.3 0.0 2.1 1.1 1.0 2.1 1.1 0.2 3.3 0.0 0.5 0.4 0.2 0.0 0.6 0.0 1.0 2.0 0.3 2.7 0.0 0.5 0.8 0.0 1.0

O 95.1 42.1 55.9 17.8 61.3 54.4 45.5 54.9 56.5 43.4 40.1 51.5 48.3 48.2 54.5 56.1 42.8 41.3 45.8 41.6 39.9 41.5 43.4 43.4 49.0 38.7 53.6 48.2 50.5 42.1 47.1

90.7 40.9 49.8 19.7 52.3 48.8 44.8 43.8 52.3 42.2 38.7 44.1 39.3 45.3 43.9 45.4 36.5 34.4 43.0 44.9 62.5 35.8 41.5 51.4 40.2 49.2 50.6 40.1 46.9 33.0 40.9

880

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Lymphoma (C81-90,C96) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 640 1023 201 2964 265 490 622 1239 1546 1153 1418 1777 812 126 742 1074 845 117 391 386 596 327 334 485 5740 279 122 114 296 258 173 395 9507 550 460 1895 1503 2629 4208 1727 5660 9113 3180 3350 998 3266 94.4 100.0 96.0 97.5 88.7 92.0 92.9 100.0 99.0 98.1 93.3 92.2 100.0 96.8 95.4 96.4 93.6 88.0 95.1 95.1 93.1 96.9 94.6 97.1 100.0 97.5 96.7 100.0 100.0 94.2 96.5 97.7 98.2 98.2 97.2 91.5 81.8 89.4 86.0 97.3 73.7 81.9 90.1 87.9 82.7 95.9 5.6 0.0 0.5 0.5 4.9 0.6 0.2 0.0 5.2 3.3 0.0 1.6 2.0 0.8 2.1 6.8 3.3 0.0 0.7 0.6 3.9 2.9 0.0 0.0 0.0 0.0 0.8 1.2 2.3 0.0 0.0 0.0 0.1 0.0 1.6 0.8 0.0 0.0 0.0 0.1 4.2 0.0 0.0 0.5 0.4 0.9 1.7 0.8 0.3 1.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.5 1.0 2.0 0.1 1.4 2.7 9.9 1.9 0.0 0.0 0.7 0.0 0.0 0.2 0.3 0.8 0.4 0.2 0.0 0.0 0.0 0.4 0.0 0.8 0.0 1.2 0.0 66.1 59.0 52.2 54.9 58.5 49.0 61.3 50.1 48.3 59.1 47.8 60.6 53.1 52.4 50.5 41.2 50.4 53.0 43.5 53.4 46.8 40.7 36.8 51.3 58.8 40.1 50.8 49.1 52.0 48.4 44.5 43.3 53.4 58.5 52.2 48.5 48.1 50.3 46.8 48.3 49.1 49.8 52.1 49.8 48.4 42.9 13.0 43.4 42.9 50.6 43.9 40.2 46.8 46.8 48.8 44.6 Female Cases MV(%) DCO(%) UB(%) MI(%) 688 1178 161 2670 259 442 624 1017 1441 1353 1200 1856 892 131 731 914 750 67 320 353 520 294 273 422 4926 227 129 88 268 279 144 381 7789 470 422 1653 1287 2264 3740 1411 4917 7835 2870 2887 991 3280 3907 35 1923 1106 296 3151 922 153 54 2185 594 39 87 80 170 168 95.1 100.0 95.0 96.1 86.9 88.7 92.0 99.9 99.0 97.7 93.6 92.2 100.0 94.7 94.5 93.9 93.7 86.6 96.9 94.1 91.7 96.3 94.9 96.9 100.0 96.5 96.1 100.0 100.0 93.9 91.7 96.3 97.8 95.1 96.7 88.6 80.4 86.7 83.6 95.8 71.1 79.7 89.7 87.5 82.7 95.8 91.4 97.1 89.0 94.7 97.0 97.7 94.7 90.2 96.3 97.6 96.8 97.4 98.9 95.0 96.5 97.0 4.8 0.0 0.6 0.7 6.2 0.9 0.2 0.0 4.8 3.9 0.0 3.8 2.6 2.7 2.0 10.4 2.2 0.0 1.7 1.7 4.0 3.1 0.0 0.8 0.0 0.0 2.2 0.0 3.7 0.0 0.0 0.0 0.1 0.0 3.4 1.1 0.0 0.0 0.0 0.1 3.8 0.0 0.8 1.0 0.2 1.2 0.0 0.0 0.0 0.8 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.7 0.5 2.4 0.0 2.0 4.0 10.7 1.6 0.0 0.0 0.8 0.0 0.0 0.3 0.1 0.0 0.2 0.2 0.0 1.9 0.0 0.3 0.0 0.0 0.0 0.6 0.6 59.4 52.8 49.1 54.7 72.9 * 50.3 62.0 51.1 * 52.4 56.8 42.2 53.1 52.9 61.1 50.2 46.6 55.3 61.2 41.6 56.9 46.9 45.9 43.2 53.8 63.1 41.9 51.2 55.7 46.3 40.5 46.5 47.0 58.2 53.3 51.7 53.8 51.8 51.7 50.8 51.9 51.9 50.2 54.0 49.2 53.0 47.3 45.7 42.3 48.3 52.4 45.1 47.3 58.2 31.5 48.3 44.3

0.2 4.5 1.6 1.4 0.6 1.2 5.9 5.3 4.8 1.2 0.4 0.6 0.0 0.8 0.0 0.6 1.5 3.4 0.5 3.2 1.8 0.7 3.1 1.7 0.0 0.0 0.4

0.2 5.5 1.9 1.6 1.3 1.9 6.8 4.9 4.8 1.0 0.2 0.6 2.9 1.0 0.0 0.0 1.6 2.8 1.3 0.0 2.2 0.7 0.0 0.0 0.0 1.2 0.6

4767 91.9 69 100.0 2404 88.6 1336 95.5 362 97.2 3712 97.7 1220 94.8 190 91.1 62 96.8 2553 98.1 767 98.0 64 95.3 120 96.7 107 100.0 165 98.8 242 97.5

44.2

42.9

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
823

881

Indices of data quality

Leukaemia (C91-95)
Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 85 100.0 375 88.3 53 100.0 33 100.0 84 85.7 104 174 65 117 2029 58 304 551 253 68 69 64.4 86.8 58.5 76.1 99.1 100.0 91.1 79.1 100.0 100.0 100.0 0.0 0.3 0.0 0.0 0.0 6.7 1.7 9.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.1 0.0 0.8 0.0 0.0 1.1 0.0 2.6 32.8 0.0 0.0 5.4 5.6 5.3 3.4 5.2 1.8 1.0 0.8 0.7 2.3 0.6 0.0 0.0 0.0 0.0 0.0 0.8 0.7 0.0 0.0 3.8 0.0 0.0 0.3 1.0 4.2 0.6 1.9 0.6 4.2 5.8 2.6 0.0 0.0 0.0 1.4 1.3 1.4 1.2 0.6 1.4 0.2 1.8 1.3 1.8 1.5 2.5 7.0 1.3 1.7 1.2 0.0 0.5 Female Cases MV(%) DCO(%) UB(%) MI(%) 75 100.0 300 89.3 39 100.0 29 100.0 51 86.3 79 114 49 117 1739 42 290 434 226 63 72 5993 757 920 355 155 56 2 249 3150 34 315 973 183 773 113 1059 7617 562 405 1510 4990 1438 89 64 36 13 198 965 2049 187 48 46 25 22 610 1025 987 979 53 914 94 61 27 5232 447 4707 1533 320 1192 479 109 358 333 3443 356 2989 1570 1001 1103 1140 281 844 79 171 68.4 82.5 51.0 75.2 99.4 100.0 90.0 73.5 100.0 100.0 100.0 66.8 99.3 69.8 88.5 94.8 100.0 100.0 81.5 52.1 100.0 67.3 80.1 85.8 78.7 90.3 77.1 92.0 96.4 93.3 96.7 89.9 91.8 96.6 96.9 97.2 84.6 94.4 89.8 95.5 93.6 91.7 95.7 100.0 100.0 98.2 94.0 76.7 86.0 96.2 85.2 75.5 78.7 66.7 94.2 95.7 94.1 82.5 81.6 82.6 86.2 85.3 86.0 84.7 78.8 80.9 78.3 86.3 88.4 79.2 86.8 85.8 87.1 88.6 91.8 0.0 0.0 0.0 0.0 0.0 5.1 2.6 6.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 20.4 0.1 0.2 0.0 0.0 0.0 0.0 4.0 38.4 0.0 0.0 6.8 4.4 7.2 6.2 7.3 2.3 0.5 1.5 0.9 3.0 0.8 0.0 0.0 0.0 0.0 0.0 1.0 0.9 1.1 2.1 2.2 0.0 0.0 0.5 1.2 4.3 1.0 1.9 1.0 2.1 1.6 3.7 0.0 0.0 0.0 2.3 1.9 2.4 1.9 0.9 2.2 0.9 2.1 2.2 2.1 1.3 2.1 8.0 0.6 1.1 0.5 0.0 0.6 * * * *

11.5 13.1 18.3 11.5 16.9 23.1 0.0 0.0 0.3 3.3 0.0 0.0 2.1 0.4 3.6 2.0 0.0 0.0 5.9 2.0 0.0 2.9 2.3 1.7 2.4 2.1 2.2 1.7 1.5 0.8 0.6 2.1 2.6 1.0 4.1 6.7 0.0 1.2 3.0 0.9 0.9 0.0 0.0 2.9 0.0 0.7 1.0 3.8 3.3 0.0 3.4 10.1 8.7 15.4 5.5 5.0 5.5 4.9 4.0 5.2 2.5 1.9 2.9 5.1 5.4 6.8 5.4 3.4 2.7 3.7 2.1 2.0 2.2 4.8 3.8

41.3

10.7 13.7 13.9 14.0 30.6 23.9 0.0 0.0 1.7 6.0 0.0 0.0 3.2 0.3 3.7 5.1 0.0 0.0 5.6 3.5 0.0 5.1 2.2 2.7 2.1 1.8 3.4 2.9 1.1 2.7 1.0 3.8 4.7 2.2 3.1 0.0 0.0 3.0 5.9 2.0 2.7 6.3 0.0 0.0 0.0 0.2 3.0 3.2 4.2 1.9 4.4 13.8 9.8 22.2 5.8 4.3 5.9 6.7 5.9 7.0 5.2 4.6 5.6 7.2 7.3 7.6 7.4 4.7 2.6 2.8 2.7 4.6 2.1 5.1 4.1

47.3

71.2 62.6 46.2 16.2 51.0 79.3 71.7 77.1 66.8 77.2 55.0 46.7 58.3 54.5 56.9 88.4 300.0 65.1 55.1 41.4 51.3 82.5 102.3 80.5 45.9 69.6 57.5 56.5 61.9 45.4 62.0 58.8 70.5 45.1 62.3 55.1 63.0 65.5 45.3 61.8 76.2 47.6 58.8 54.6 57.5 65.4 58.5 78.2 71.0 110.3 62.2 65.6 62.6 67.6 70.1 68.1 57.6 61.8 57.8 57.0 60.9 59.1 62.3 67.7 56.8 60.5 62.8 70.4 61.0 88.1 65.9

68.4 73.7 49.0 12.8 52.9 76.2 69.7 78.6 71.2 73.4 54.8 46.4 58.8 53.2 58.7 89.3 50.0 55.8 54.8 70.6 53.7 83.6 86.9 84.0 42.5 72.6 59.9 54.4 65.9 44.3 66.3 60.5 66.3 46.0 64.5 59.6 73.8 62.5 54.3 68.0 68.2 47.9 66.9 58.5 62.0 56.6 62.7 85.1 85.2 96.3 60.5 56.4 61.5 70.2 70.6 70.6 67.6 80.7 64.2 60.7 66.5 71.1 67.5 72.9 61.5 58.6 64.9 66.5 64.9 74.7 67.8

8363 72.0 1101 99.5 1315 73.1 444 94.8 248 93.1 95 98.9 1 100.0 307 82.7 4318 59.4 58 100.0 476 71.6 1138 82.2 177 84.7 940 81.7 146 92.5 1469 80.6 10422 93.8 722 95.8 528 96.0 1926 97.3 7022 92.3 1912 95.2 105 98.1 98 95.9 60 91.7 16 93.8 244 98.0 1262 94.3 2755 97.0 219 98.6 58 96.6 53 94.3 34 94.1 21 100.0 721 98.3 1541 96.1 1373 79.2 1253 88.7 52 96.2 1163 88.2 119 83.2 69 81.2 39 82.1 6990 94.4 424 95.0 6479 94.5 1960 86.8 371 87.3 1556 86.5 667 91.9 157 91.7 491 91.9 467 90.1 4269 83.4 399 86.7 3720 82.7 1933 88.3 1420 90.0 1435 79.8 1465 88.3 301 87.7 1154 88.4 84 90.5 211 94.3

882

*Important. See note on population page.

824

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Leukaemia (C91-95) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 553 79.0 1978 82.8 3415 89.0 292 88.0 3044 89.0 1477 95.0 217 92.2 1226 95.4 1903 83.4 150 89.3 1738 82.9 363 75.5 74692 87.1 5241 87.8 66537 86.8 3090 89.6 250 90.4 2689 89.4 643 89.1 26 100.0 157 87.3 441 88.7 6804 78.2 526 85.4 6069 77.2 3491 93.0 259 91.5 3137 92.9 1130 90.0 1144 89.0 4892 79.1 249 79.1 4511 78.9 411 93.4 9246 93.6 597 94.0 7939 93.3 24462 91.9 1175 96.0 1669 92.0 2517 95.9 18641 91.0 1168 80.3 233 78.5 913 81.4 6207 81.4 510 81.4 5502 81.5 612 97.9 224 83.0 2223 94.2 1543 98.0 683 89.6 2154 95.1 62 353 1032 52 100 939 163 167 432 1715 30 1169 265 245 119 1800 1531 160 129 157 211 433 546 1712 200 93.5 92.6 89.1 100.0 77.0 94.2 100.0 98.2 96.3 100.0 96.7 100.0 99.2 100.0 95.8 85.2 85.6 90.6 100.0 91.1 60.7 79.2 95.8 100.0 98.5 2.9 3.8 1.4 0.7 1.5 1.3 0.9 1.4 7.7 4.7 8.1 10.5 3.5 3.5 3.6 1.8 2.0 1.8 4.2 0.0 5.7 4.1 2.9 2.5 3.0 3.0 4.2 3.0 0.0 3.1 2.1 3.2 2.1 3.6 2.2 1.2 2.3 2.0 1.6 1.4 1.0 2.2 3.4 3.9 2.8 5.7 5.9 5.8 0.8 3.6 2.2 1.4 3.4 4.9 6.5 0.0 1.9 0.0 11.0 0.1 0.0 3.0 0.0 0.0 0.0 0.4 0.0 4.2 6.2 5.2 5.0 0.0 6.4 3.3 19.6 2.7 0.0 1.0 5.4 4.2 2.6 4.1 2.6 0.9 1.4 0.9 4.6 3.3 4.8 3.0 3.0 2.5 3.1 2.3 1.2 2.5 2.0 0.0 1.9 2.3 7.5 4.2 7.9 0.7 0.8 0.7 1.1 0.8 4.0 3.2 4.1 1.0 1.0 0.8 1.0 1.9 0.7 1.4 1.1 2.1 6.0 5.6 5.9 7.1 5.3 7.2 0.2 1.8 1.4 0.1 0.6 0.0 0.0 0.0 0.0 0.0 2.0 0.0 0.0 1.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.6 6.0 1.3 0.0 0.6 0.0 0.0 1.1 0.0 0.5 52.3 64.8 62.5 66.1 63.1 58.2 66.4 57.6 70.2 77.3 70.0 63.9 61.7 67.5 62.6 58.7 66.0 59.9 50.7 42.3 52.9 50.1 54.3 56.1 54.5 72.0 81.1 73.3 70.6 64.8 61.9 71.9 62.8 56.4 56.7 65.0 56.9 57.9 55.1 65.2 45.0 60.2 66.2 72.1 66.2 58.7 63.1 59.6 57.0 61.6 54.4 53.1 66.2 57.4 74.2 74.5 65.2 103.0 67.5 46.4 47.9 16.7 49.9 64.0 80.6 82.2 67.8 82.2 90.7 81.5 92.5 Female Cases MV(%) DCO(%) UB(%) MI(%) 378 1746 2760 296 2389 1329 226 1075 1440 123 1300 251 57712 4675 50808 2407 218 2092 428 19 116 288 5553 543 4847 2775 216 2490 856 888 3850 249 3489 308 6957 509 5983 18307 891 1393 1963 13749 921 208 688 4597 410 4059 437 162 1605 1080 563 1711 37 242 828 41 63 748 113 116 256 942 30 738 139 175 78 1393 1182 102 89 96 156 341 438 1158 159 78.6 78.0 86.2 88.2 85.7 90.6 92.9 90.0 81.9 88.6 81.0 77.7 84.4 85.6 84.0 85.5 86.2 85.3 83.4 94.7 89.7 80.2 74.4 83.6 73.0 90.7 92.1 90.4 88.6 86.0 76.1 78.3 75.7 89.9 90.8 92.3 90.2 89.6 95.7 89.2 95.5 88.3 79.3 77.9 80.8 78.2 77.6 78.2 98.9 79.0 92.4 97.4 85.8 91.8 91.9 93.4 84.8 100.0 81.0 92.2 99.1 99.1 96.5 100.0 100.0 100.0 99.3 99.4 98.7 80.8 82.5 84.3 100.0 86.5 55.1 76.5 91.1 100.0 99.4 4.0 6.1 1.7 2.0 1.7 2.6 0.9 3.0 6.3 3.3 6.7 11.6 4.5 3.9 4.6 3.0 1.4 3.3 6.3 0.0 4.3 7.6 3.5 1.1 3.9 4.5 4.6 4.6 0.0 3.0 2.4 2.0 2.5 6.5 3.2 2.0 3.5 2.9 1.0 2.7 1.2 3.4 4.7 1.9 4.5 7.4 8.5 7.4 0.0 5.6 3.1 1.9 3.9 8.2 8.1 0.0 3.5 0.0 0.0 0.4 0.9 3.1 0.0 0.0 0.0 0.7 0.0 1.3 10.1 7.8 10.8 0.0 8.3 4.5 23.2 4.8 0.0 0.6 6.1 4.4 4.2 3.4 4.4 1.1 0.4 1.2 6.2 3.3 6.5 1.6 3.7 3.2 3.8 3.2 3.2 3.2 2.8 0.0 0.9 3.8 9.4 5.9 9.9 0.5 0.0 0.5 2.0 1.1 4.5 2.8 4.5 1.3 1.1 0.8 1.2 2.3 0.9 2.1 1.0 2.6 8.3 8.2 8.0 8.0 7.1 8.1 0.2 1.9 1.9 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.9 6.1 3.9 0.0 1.0 0.0 0.0 1.8 0.0 0.0 57.1 65.1 64.5 67.6 65.5 57.6 65.5 56.4 75.7 67.5 77.3 67.3 64.7 68.1 65.9 63.6 58.7 66.1 52.6 31.6 50.9 54.2 57.3 61.1 57.4 76.7 81.0 78.4 72.4 65.2 66.1 61.8 68.0 58.1 60.3 67.8 60.3 60.9 54.7 65.5 44.1 64.3 72.4 77.4 72.8 62.2 72.4 62.2 60.2 64.8 59.0 59.2 70.2 63.9 64.9 71.5 * 67.6 * 54.0 65.0 * * 58.2 * 54.3 * 30.0 46.9 * * * 68.6 80.9 86.5 80.1 69.8 91.1 78.7 81.8

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
825

883

Indices of data quality

Leukaemia (C91-95) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
826

Female Cases MV(%) DCO(%) UB(%) MI(%) 3477 290 242 113 125 218 32 973 64 71 61 120 181 109 126 624 348 276 20 52 146 85 118 128 321 1947 177 68 2158 285 1206 1297 1289 2488 1625 371 1218 260 178 136 231 219 316 347 147 117 106 74 776 1456 462 549 563 770 270 62 848 72 184 124 399 212 48 368 215 122 685 161 91 140 424 243 118 60 49 318 263 162 522 93.1 94.5 96.7 94.7 96.0 98.6 93.8 93.6 96.9 98.6 95.1 89.2 95.6 90.8 100.0 82.7 100.0 100.0 100.0 100.0 100.0 100.0 61.0 47.7 87.5 84.4 98.3 88.2 98.6 99.3 99.8 100.0 72.6 78.1 93.2 98.4 91.4 86.2 100.0 100.0 94.8 100.0 93.7 100.0 99.3 94.0 100.0 95.9 55.3 64.4 68.6 67.6 69.3 77.5 84.8 100.0 91.9 98.6 96.7 96.8 56.9 75.0 79.2 100.0 99.5 71.3 100.0 100.0 94.5 98.6 95.0 92.2 99.2 91.7 100.0 97.8 69.6 91.4 86.4 6.3 4.1 2.9 4.4 4.0 1.4 0.0 6.2 3.1 0.0 1.6 9.2 4.4 0.9 0.0 17.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 15.4 1.7 11.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.1 0.0 22.1 0.8 5.4 0.0 0.8 1.5 0.0 0.0 2.2 0.0 2.8 0.0 0.0 1.7 0.0 0.0 1.5 0.1 0.0 0.4 0.0 1.0 0.0 0.0 1.9 0.0 0.0 0.0 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 27.8 0.0 0.0 69.8 70.3 63.6 69.0 65.6 56.9 51.6 59.4 53.1 58.3 58.0

4462 409 289 140 157 263 36 1218 75 89 149 157 233 151 204 670 458 359 31 68 160 93 108 182 413 2195 201 94 2275 421 1682 1640 1449 3150 2091 346 1360 326 212 185 294 293 410 509 190 130 128 135 930 1532 524 675 688 841 333 77 1207 107 237 162 411 248 67 425 275 139 736 221 107 203 563 303 216 106 79 364 381 187 598

92.6 92.4 95.5 87.1 95.5 93.9 100.0 92.9 89.3 94.4 98.0 91.7 95.7 83.4 99.5 85.1 100.0 100.0 100.0 100.0 100.0 100.0 75.0 42.3 89.8 87.5 99.0 86.2 98.6 100.0 99.9 100.0 73.6 80.3 94.4 98.3 92.5 84.7 100.0 100.0 95.2 100.0 96.3 100.0 100.0 96.9 100.0 96.3 64.1 71.7 76.0 73.8 74.0 82.5 86.8 98.7 95.2 99.1 97.0 95.7 66.9 81.5 89.6 100.0 100.0 71.9 100.0 99.5 97.2 97.5 97.3 93.4 100.0 95.3 100.0 98.1 70.1 91.4 88.0

6.8 6.6 3.5 10.0 4.5 5.3 0.0 6.8 8.0 1.1 1.3 6.4 3.9 0.7 0.5 14.0 0.0 0.0 0.0 0.0 0.0 0.0 0.9 1.1 0.0 12.3 1.0 13.8

0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 21.0 0.8 4.5 0.0 1.0 3.1 0.0 0.0 2.0 0.0 1.7 0.0 0.0 2.3 0.0 0.0 2.4 0.1 0.0 0.1 0.0 1.5 0.9 0.0 0.1 0.0 0.0 0.0 0.0 0.0 3.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 27.6 0.0 0.0

72.8 73.1 63.0 77.9 61.8 76.4 75.0 63.9 70.7 60.5 21.5

61.8

62.4

* * *

93.5 44.0 65.9 76.4 53.2 55.3 74.1 56.2 63.8 58.7 76.3 60.2 66.2 61.9

0.7 * * 57.6 48.4 * 62.6 * 78.2 55.4 66.2 71.8 * * 71.4 67.9 * 58.5 79.9 66.0 74.1 67.7

0.0 5.4 8.9 1.1 1.4 4.3

0.0 5.3 10.5 1.5 1.6 5.7

0.8 33.3 28.2 6.7 25.9 26.0 15.2 11.4 1.3 3.4 0.0 1.7 1.2 0.7 1.6 1.5 0.0 0.0 1.4 0.0 0.0 2.8 1.0 2.7 3.3 0.0 1.9 0.0 1.9 1.3 0.0 4.3

1.7 43.0 35.4 10.2 32.1 30.7 20.6 10.7 0.0 4.4 1.4 1.6 1.6 2.0 3.3 2.1 0.0 0.0 5.7 0.0 0.0 4.4 0.0 5.0 5.3 0.8 3.3 0.0 2.2 1.9 1.2 5.6

O 197.9 48.6 79.7 81.2 82.4 63.6 81.9 62.9 64.2 68.1 58.2 65.3 73.7 53.3 89.6 77.2 67.9 68.3 61.8 58.4 64.8 64.3 61.8 62.6 72.9 70.0 76.5 67.9 92.0 51.2 66.5

167.7 50.1 70.8 66.5 74.3 54.8 80.2 58.4 60.0 51.4 54.0 75.3 83.5 68.5 79.1 72.2 55.6 51.0 66.8 59.7 63.6 66.5 54.4 58.1 68.5 77.4 49.1 62.4 80.8 56.1 60.9

884

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

Leukaemia (C91-95) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 629 1020 115 1440 133 300 304 417 663 984 982 1334 509 80 366 483 365 62 162 211 338 145 171 229 3035 155 68 44 178 98 85 175 4314 246 250 895 654 1231 2349 900 2547 4448 1596 1776 473 1746 95.1 100.0 100.0 95.6 77.4 87.7 100.0 99.5 100.0 100.0 89.9 94.0 100.0 97.5 91.3 91.9 94.8 80.6 92.6 97.2 87.9 91.0 94.2 89.5 99.7 99.4 95.6 97.7 100.0 93.9 98.8 92.6 100.0 100.0 100.0 84.2 64.7 71.0 49.4 97.0 48.3 73.8 87.6 79.6 74.6 96.5 4.9 0.0 0.0 2.6 19.5 1.0 0.0 0.0 8.5 5.8 0.0 2.5 5.2 4.3 3.6 14.5 5.6 0.0 2.1 1.4 5.8 10.5 0.6 0.0 2.3 0.0 6.1 1.2 7.4 0.0 0.0 0.0 0.0 0.0 3.7 0.0 0.0 0.0 0.0 0.4 0.2 0.0 0.0 1.4 0.0 1.4 3.2 0.0 0.0 2.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 12.8 1.4 6.3 0.1 1.7 7.2 15.6 4.1 0.0 0.0 0.9 0.0 0.0 0.2 0.4 4.9 0.4 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 1.1 0.0 66.9 68.4 60.0 54.3 88.3 72.9 109.9 102.6 77.8 65.2 72.2 70.7 63.7 68.8 73.8 67.7 60.6 66.1 75.3 74.9 58.3 74.5 63.7 73.4 61.7 49.7 61.8 70.5 44.4 56.1 54.1 57.7 67.6 71.2 57.5 74.9 62.4 52.5 54.3 61.6 56.5 58.0 57.6 60.0 51.8 51.7 61.5 45.8 47.7 60.2 61.9 59.0 59.6 51.1 40.5 56.0 Female Cases MV(%) DCO(%) UB(%) MI(%) 616 942 76 1098 153 355 279 333 495 1250 712 1047 422 71 277 355 257 49 113 163 274 96 108 183 2274 130 48 43 126 73 65 137 3163 198 141 643 515 964 1954 656 2076 3417 1140 1357 325 1331 93.2 100.0 100.0 96.5 76.5 81.7 100.0 99.7 99.8 100.0 87.2 94.1 100.0 97.2 86.3 93.2 91.4 91.8 92.0 98.8 85.4 84.4 96.3 89.1 99.6 99.2 85.4 100.0 100.0 90.4 100.0 82.5 100.0 99.5 100.0 81.5 58.1 67.3 45.2 96.3 44.5 71.8 85.4 76.0 71.1 95.2 6.7 0.0 0.0 1.4 15.7 1.7 0.0 0.0 11.2 5.5 0.0 2.8 7.6 3.7 6.6 4.1 3.5 0.0 2.9 1.0 3.7 10.9 0.8 0.0 0.0 0.0 8.2 0.0 17.5 0.2 0.0 0.0 0.1 0.0 5.4 0.0 0.0 0.0 0.0 0.3 0.3 0.0 0.0 3.2 0.6 1.2 2.0 3.5 0.0 1.1 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 15.1 1.4 6.5 0.1 1.5 10.5 16.0 3.3 0.0 0.0 1.7 0.0 0.0 0.8 0.7 1.7 0.3 0.3 0.0 0.0 0.0 0.4 0.0 3.7 0.0 0.0 0.0 71.4 70.9 57.9 60.5 79.2 * 55.6 105.0 120.1 * 87.9 58.5 81.9 73.3 70.9 54.9 68.0 69.3 66.6 49.0 69.0 76.1 48.9 92.7 67.6 80.3 71.2 46.9 66.7 100.0 57.1 67.1 50.8 70.1 78.2 80.9 64.7 78.8 65.4 57.1 61.0 64.6 62.2 67.2 62.2 56.6 55.8 53.6 45.0 44.8 51.0 69.2 61.3 57.6 69.7 57.9 43.9 59.9

0.4 11.5 3.5 1.7 1.0 1.9 8.3 8.2 7.8 0.6 0.3 1.7 0.0 1.5 0.0 0.6 6.0 9.2 0.0 2.2 3.2 1.3 0.0 4.3 1.8 1.1 0.8

0.3 16.9 4.3 2.4 1.4 2.1 10.6 10.8 10.0 0.9 0.5 1.9 0.0 2.3 0.0 0.0 6.4 9.5 3.0 5.3 4.3 1.1 0.0 0.0 0.0 1.4 1.3

2640 83.6 26 92.3 1483 83.5 770 92.6 162 90.1 1615 93.1 588 90.6 94 72.3 45 97.8 1776 96.8 384 97.4 20 100.0 46 95.7 57 98.2 91 96.7 124 97.6

58.1

1827 82.3 20 100.0 1048 82.2 577 92.2 118 96.6 1212 92.6 389 90.2 66 77.3 38 94.7 1253 95.7 269 96.7 15 100.0 27 92.6 45 97.8 69 97.1 77 97.4

71.4

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
827

885

Indices of data quality

All sites but skin (C00-96/C44)

Male Cases MV(%) DCO(%) UB(%) MI(%) Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White 1844 6908 1379 2173 4371 2201 6732 1605 3592 70229 2040 7766 13656 4194 3610 1256 269555 30271 47343 14039 9614 5755 196 13074 134700 1806 12757 50729 10033 39737 5133 55142 343106 25220 23624 42779 242117 67931 5258 3768 2042 775 6051 45921 87885 11034 2408 2068 1577 1223 16330 49395 41445 46713 2944 42896 7507 5298 1877 251927 20951 227632 81495 19018 61499 24822 7196 17034 14306 146334 18779 122812 69583 39125 54081 54954 14443 40062 4277 7945 93.5 79.5 96.3 67.1 59.7 76.8 89.8 75.3 89.4 79.0 77.8 79.2 73.3 81.8 97.8 94.7 87.1 91.1 90.3 88.9 91.6 97.4 98.0 89.0 83.8 92.3 88.7 91.6 89.6 92.0 94.3 93.1 94.5 93.8 94.0 94.4 94.5 94.4 92.4 93.3 93.8 94.1 94.4 94.7 95.6 95.0 95.1 95.6 95.4 93.5 95.1 95.8 92.3 96.0 96.5 95.9 92.4 92.3 94.1 93.3 91.6 93.4 93.0 91.4 93.4 95.4 94.3 95.9 92.8 93.7 92.1 93.8 94.0 93.8 92.0 93.2 90.9 94.0 91.2 94.0 0.1 0.0 0.0 0.0 0.0 2.2 5.3 2.9 0.1 0.0 0.0 0.0 0.0 0.0 0.6 0.0 6.9 0.1 0.2 0.0 0.0 0.3 0.0 0.7 13.7 0.0 0.0 2.6 3.1 2.5 2.1 1.9 0.9 0.8 0.9 0.9 1.0 0.5 0.9 0.6 0.8 0.5 0.6 0.4 0.7 0.8 1.0 0.6 0.6 1.1 0.8 0.7 1.2 0.4 0.3 0.4 2.1 1.7 1.8 0.4 0.4 0.4 0.7 0.7 0.6 0.6 0.7 0.6 0.2 0.6 0.8 0.6 0.6 0.6 2.3 0.5 0.5 0.5 0.6 0.6 Female Cases MV(%) DCO(%) UB(%) MI(%) 1815 6637 986 2777 3780 2352 8004 1645 4105 77358 1903 9609 13452 5135 2438 1947 244027 26796 41349 13042 8283 4553 185 11557 125919 1585 10758 46278 9069 36425 4616 50316 326290 26738 19059 44576 231266 65732 4372 3533 2106 961 6212 44947 84578 9074 2324 2426 1546 1248 17514 48033 39979 44997 2569 41709 6868 4583 1983 217537 17397 197120 74996 16452 57483 24025 6572 16850 12570 142366 17722 120551 68591 37198 49626 47197 12376 34479 3817 7433 93.7 86.1 97.1 65.9 63.1 80.5 86.9 77.0 91.6 78.5 75.9 82.9 78.1 82.2 95.0 95.5 86.8 92.6 89.8 88.9 91.8 97.9 98.4 88.5 83.1 92.0 89.4 92.2 91.6 92.4 94.9 93.4 94.4 95.8 94.1 95.7 94.0 94.2 92.9 95.0 95.9 95.3 95.3 93.9 95.5 94.7 95.9 97.1 96.2 95.7 96.2 95.1 92.7 95.2 95.9 95.1 92.6 92.1 94.4 93.4 93.4 93.4 93.0 92.1 93.1 95.2 94.4 95.5 92.9 93.3 91.7 93.4 94.3 93.3 92.3 92.9 92.1 93.1 92.6 93.2 0.2 0.0 0.0 0.0 0.0 2.9 8.2 2.4 0.2 0.0 0.0 0.0 0.0 0.0 1.1 0.0 7.3 0.1 0.1 0.0 0.0 0.1 0.0 0.9 14.0 0.0 0.0 2.5 2.5 2.4 1.8 1.7 0.9 0.6 0.8 0.7 1.0 0.4 0.5 0.5 0.3 0.4 0.4 0.4 0.7 0.9 1.0 0.5 0.6 0.7 0.6 0.8 1.1 0.4 0.3 0.4 1.5 1.2 1.3 0.3 0.3 0.3 0.6 0.7 0.5 0.5 0.7 0.4 0.4 0.5 0.7 0.5 0.6 0.5 1.9 0.6 0.7 0.6 0.9 0.6 * * * *

7.8 12.9 17.5 4.2 16.9 7.9 7.6 9.5 6.3 11.5 10.2 1.3 1.4 0.2 1.5 2.4 0.1 0.0 1.7 1.4 0.2 3.4 2.3 2.4 2.4 0.4 1.5 0.9 0.6 0.9 0.8 1.0 1.2 1.2 0.9 1.0 1.3 1.1 1.3 0.7 0.8 0.3 0.5 0.6 0.4 0.7 0.7 2.0 1.1 0.8 1.1 2.8 2.9 2.8 3.5 4.5 3.4 2.7 3.1 2.6 1.3 1.3 1.3 2.8 2.3 4.0 2.1 1.6 1.3 1.2 1.2 1.9 1.0 2.7 1.2

25.3

8.2 12.0 12.5 4.3 14.4 6.4 7.1 11.7 6.0 9.5 10.0 1.5 1.7 0.3 1.9 2.5 0.1 0.0 1.8 1.9 0.1 3.6 2.2 2.0 2.3 0.5 1.5 1.0 0.6 1.0 0.7 1.1 1.6 1.5 0.5 0.9 1.1 1.1 1.9 0.7 0.8 0.7 0.4 0.5 1.0 0.6 0.8 1.8 1.3 1.1 1.3 2.9 2.9 3.0 3.1 2.9 3.1 2.7 2.7 2.7 1.5 1.5 1.5 2.5 2.4 4.1 2.1 1.5 1.5 1.2 1.3 1.4 1.2 1.8 1.4

22.7

88.6 36.9 44.4 50.9 41.6 62.3 55.0 60.7 53.9 45.8 44.9 40.8 42.7 47.5 48.0 57.6 54.6 46.7 45.0 44.5 48.5 51.7 61.5 50.3 35.7 43.2 39.2 41.7 43.5 34.7 40.6 37.7 48.0 32.3 38.0 38.0 41.9 47.3 35.4 38.7 52.8 34.9 39.2 36.7 37.6 39.9 38.0 44.7 49.7 37.1 41.1 45.2 41.2 44.0 48.1 43.1 37.4 40.9 36.1 38.9 43.2 50.3 43.1 47.6 42.3 45.3 46.0 53.0 43.6 55.6 45.6

69.6 30.6 35.0 38.1 34.5 62.5 50.8 52.1 52.8 45.4 44.0 41.3 43.9 45.8 45.4 54.8 46.5 46.6 43.4 44.4 46.6 47.7 55.8 46.6 33.6 41.8 39.9 34.7 49.9 31.8 41.8 39.1 52.4 30.4 40.8 39.4 50.5 41.5 27.1 37.0 38.5 33.8 41.0 37.0 39.5 42.5 39.7 47.7 54.2 37.9 41.1 45.9 41.1 42.3 48.0 41.0 38.4 44.5 36.5 39.6 42.8 51.2 42.5 44.7 41.4 42.5 46.0 51.9 44.0 52.8 45.0

886

*Important. See note on population page.

828

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

All sites but skin (C00-96/C44) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 18925 83398 128214 16270 108837 55857 12614 42375 67971 6166 61217 12098 2678584 260184 2317952 117270 13154 100374 18921 640 5093 12791 235878 28918 199913 138865 13201 120193 41469 43007 180632 14733 161549 15120 311115 30149 258045 836565 40281 80476 59291 641428 49841 12332 36846 200115 21129 174180 17597 7744 70877 48122 26512 67288 929 14287 56776 2586 4472 53528 5884 4311 9751 24258 975 22147 4034 5555 2548 48406 43823 2818 9375 10601 14186 31858 22050 95011 18940 91.8 94.1 94.4 93.6 94.4 95.9 95.1 96.2 91.6 90.9 91.7 91.5 93.2 91.9 93.3 94.9 94.2 95.0 91.2 85.2 90.0 91.9 91.2 91.5 91.1 93.9 92.0 93.9 89.2 93.0 94.3 93.2 94.4 94.9 94.8 94.5 94.9 94.4 94.1 93.6 94.2 94.5 92.7 91.1 93.2 90.4 88.1 90.7 96.0 93.9 93.7 94.2 92.6 91.2 84.4 65.5 84.4 61.3 77.9 58.4 78.0 95.3 73.3 82.9 76.4 80.5 88.0 82.5 83.0 85.4 87.3 90.1 77.9 78.6 84.5 78.6 81.5 77.6 78.5 1.7 1.8 1.1 0.9 1.2 1.0 0.9 1.0 3.2 4.3 3.1 4.1 2.0 2.7 2.0 1.1 1.0 1.1 2.8 4.5 2.8 2.8 1.9 2.3 1.9 2.7 4.0 2.7 2.7 1.8 0.9 1.2 0.8 1.8 1.1 1.0 1.1 1.0 0.7 1.1 1.0 1.1 2.0 2.0 1.9 3.8 5.3 3.7 0.3 2.0 1.0 0.7 1.7 2.6 6.5 0.0 1.5 0.5 2.2 0.6 0.1 2.7 2.4 4.3 6.9 3.4 6.1 5.8 3.3 2.8 2.1 17.0 4.3 3.1 11.3 7.7 11.6 9.9 2.2 1.4 1.5 1.8 1.4 0.5 0.6 0.4 2.5 2.0 2.6 1.0 1.3 1.4 1.3 1.0 1.2 1.0 1.1 1.1 1.3 1.0 2.3 2.0 2.3 1.6 1.9 1.5 1.1 0.9 0.9 0.9 0.8 0.4 0.6 0.7 0.6 0.9 0.7 0.9 0.9 0.9 2.5 2.8 2.3 2.7 2.8 2.6 0.1 0.4 1.1 0.9 0.9 3.2 0.5 0.1 0.0 0.0 1.0 0.0 0.0 1.2 9.3 0.0 0.0 0.1 0.0 0.0 0.4 4.0 3.2 2.6 5.1 1.1 0.0 0.0 0.7 0.0 1.0 41.5 41.2 39.6 41.4 40.0 37.3 39.6 36.9 46.5 51.8 46.1 41.3 42.0 47.6 42.2 37.8 41.9 38.0 40.3 49.5 42.6 38.7 38.0 39.5 38.0 46.1 53.4 47.2 46.8 41.8 41.9 46.5 42.4 40.1 38.5 41.6 38.3 39.8 41.2 44.3 34.0 40.4 44.2 50.4 42.7 43.7 52.5 43.3 35.6 40.9 38.6 38.0 46.1 41.5 67.8 71.7 60.7 80.3 56.7 24.9 44.1 54.9 37.8 46.0 57.1 55.8 47.6 50.4 56.5 67.9 57.2 Female Cases MV(%) DCO(%) UB(%) MI(%) 17339 83526 114702 13301 99284 49232 10184 38425 65431 5787 58983 10495 2513430 226451 2195599 109232 11107 94747 16600 704 4424 11156 234747 27238 200613 135447 11846 119866 38361 41249 169910 13001 153328 14357 289612 25188 242365 779507 41900 67066 60289 600853 42294 9725 32016 183617 18720 159969 15080 7409 67174 45658 24668 62538 944 10208 45492 1507 3540 45495 3748 4081 10537 23244 742 21890 4165 6453 2576 52172 48449 2414 6901 7972 10260 22387 16464 66166 13733 91.3 92.9 93.4 93.2 93.4 94.7 94.3 94.7 92.0 92.2 92.0 90.7 93.1 92.4 93.1 93.7 93.1 93.7 91.3 90.8 91.3 91.5 91.3 92.1 91.1 93.5 92.0 93.6 89.3 92.9 93.7 92.8 93.7 93.9 94.4 94.2 94.3 94.1 95.8 93.5 95.3 93.9 92.9 91.8 93.2 91.0 89.6 91.1 95.7 93.7 94.0 94.4 92.0 91.1 91.4 73.7 87.7 71.1 81.8 67.9 86.4 96.8 78.7 80.6 82.3 82.6 92.3 82.8 91.0 88.7 90.2 91.7 78.1 76.3 86.0 77.1 80.9 75.8 76.9 2.1 2.1 1.2 0.8 1.3 1.4 1.1 1.5 2.7 2.8 2.7 4.8 2.1 2.3 2.1 1.6 1.4 1.7 3.5 3.6 3.2 3.5 1.9 1.6 2.0 3.0 4.3 2.9 2.3 1.7 1.0 1.3 1.0 2.1 1.4 1.3 1.4 1.2 0.6 1.3 0.9 1.3 2.0 1.9 2.0 4.0 4.7 4.0 0.3 1.9 1.1 0.7 1.8 3.2 4.9 0.0 1.4 0.5 1.9 0.6 0.1 2.7 2.1 5.0 6.5 2.0 6.5 3.6 3.0 2.5 2.0 16.2 5.4 4.1 13.0 8.6 11.8 10.3 1.8 1.7 1.7 1.9 1.7 0.5 0.5 0.5 2.4 1.8 2.5 0.7 1.2 1.3 1.2 1.0 1.3 0.9 1.0 1.3 0.8 1.0 1.8 1.6 1.9 1.5 1.6 1.5 1.0 1.0 0.9 1.0 0.9 0.4 0.6 0.6 0.6 0.9 0.6 0.9 0.7 0.9 2.3 2.6 2.2 2.0 2.2 1.9 0.2 0.5 1.1 1.0 0.9 2.7 0.4 0.1 0.0 0.0 0.8 0.0 0.0 0.7 5.2 0.0 0.0 0.1 0.0 0.0 0.3 2.3 1.8 2.3 5.7 1.1 0.0 0.0 0.6 0.0 0.9 42.5 41.5 41.5 46.8 41.2 41.4 46.7 40.3 45.1 51.7 44.7 41.8 41.9 49.6 41.9 41.7 46.1 42.0 40.8 44.0 42.6 39.8 39.3 45.3 38.9 44.8 53.9 45.1 44.6 41.3 43.4 51.7 43.5 42.2 39.5 46.6 39.5 40.7 34.1 48.3 31.1 41.7 43.6 50.8 41.9 42.3 51.1 42.1 36.3 40.4 38.2 38.0 45.7 41.2 47.8 56.0 * 47.1 * 52.6 43.5 * * 18.9 * 33.5 * 46.0 32.1 * * * 42.0 50.2 53.4 42.1 46.1 51.6 61.6 52.2

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
829

887

Indices of data quality

All sites but skin (C00-96/C44) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region *Important. See note on population page.
830

Female Cases MV(%) DCO(%) UB(%) MI(%) 183620 17248 12038 5899 6245 10804 1531 50666 3096 1648 1368 3896 4787 1627 4085 18638 18185 15768 781 1636 6554 3572 2990 3433 9884 85705 7025 3248 69885 16085 53701 62577 45175 111613 66532 13263 54789 10427 6207 4596 7329 9563 10454 11068 4781 5241 3881 5218 29100 56099 20651 20322 29067 30746 14081 2646 33352 2831 8259 6051 17330 9029 2264 17061 8869 3890 29752 6730 2755 6310 15147 7319 4523 2790 2281 13360 11151 6365 22403 78.8 75.7 82.2 83.0 80.1 80.9 75.8 81.4 81.5 86.9 90.7 87.8 88.8 92.3 93.2 77.6 92.4 92.2 94.4 93.0 81.6 71.3 88.9 88.7 92.0 89.5 92.3 87.6 88.0 97.7 91.4 72.0 74.1 83.8 90.3 90.1 92.4 94.9 93.8 96.1 95.4 97.6 94.5 98.3 97.6 93.5 93.2 97.4 77.1 81.4 75.1 79.6 85.5 82.4 90.8 96.4 85.2 85.4 85.4 86.8 81.5 80.6 84.8 83.7 88.9 77.8 88.5 85.3 82.0 87.9 87.2 75.6 84.4 84.2 86.8 87.0 82.2 87.3 86.2 5.8 4.7 4.1 3.8 4.0 2.9 1.7 6.5 4.6 10.8 7.8 4.1 5.8 0.5 0.5 8.1 0.0 0.0 0.0 0.1 7.5 8.8 2.7 1.2 0.0 8.6 2.5 7.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 2.1 1.1 0.2 0.0 1.0 0.0 0.0 6.3 0.1 19.2 1.2 2.7 0.0 0.9 0.2 0.1 0.1 1.0 0.0 0.9 0.0 0.0 0.9 0.1 1.4 1.8 0.2 0.0 0.4 0.0 0.9 0.0 0.0 1.0 0.7 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.9 1.2 0.0 0.1 10.6 0.0 0.0 46.1 49.9 42.8 40.0 40.3 44.0 48.3 35.9 43.1 39.9 22.6

241155 21999 14900 7084 7563 12740 1878 59431 3804 1294 1625 3409 4638 1859 4454 14119 17810 15516 776 1518 5618 3538 2846 4762 15907 93110 8425 3941 77140 20055 67116 69185 52071 119560 61586 12979 54512 13603 8068 6181 9136 12391 13093 15210 6560 7230 5332 7567 32591 56994 20426 22953 30171 32802 15479 2736 36298 3436 9837 6920 20359 10796 3041 17602 10509 4979 35578 7500 3347 7079 18632 8952 5541 3327 2931 15768 13663 7717 26664

72.2 67.5 76.5 76.8 71.6 74.6 72.0 74.2 73.9 79.5 88.2 84.6 84.3 89.3 89.5 63.9 87.5 87.6 87.8 86.0 71.1 59.9 82.8 86.7 88.2 91.2 94.7 90.2 81.1 97.5 91.4 59.4 74.1 83.5 88.8 86.2 93.3 94.7 92.6 96.4 95.8 97.6 93.6 97.6 97.2 94.1 94.3 97.5 78.4 81.9 75.1 81.1 86.0 83.0 92.0 97.1 83.7 85.4 83.0 84.1 80.1 79.5 85.6 82.4 87.0 71.0 88.9 85.3 76.9 86.5 87.0 73.9 81.7 78.3 86.4 86.5 82.1 87.5 85.3

6.1 4.6 4.2 4.3 3.2 2.9 2.0 6.8 4.4 16.5 8.7 6.2 7.7 1.1 1.1 12.7 0.0 0.0 0.0 0.0 10.9 12.7 4.4 1.8 0.0 7.2 1.4 4.4

0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.5 0.2 0.0 0.3 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.0 1.7 0.1 0.0 1.3 0.0 0.0 6.4 0.1 18.9 0.7 3.2 0.0 0.9 0.2 0.1 0.1 1.2 0.0 1.3 0.1 0.0 0.8 0.2 1.1 2.0 0.2 0.0 0.5 0.0 1.0 0.1 0.0 0.9 0.5 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0 0.0 0.9 2.3 0.0 0.1 10.8 0.0 0.0

62.2 64.8 57.2 58.5 55.7 61.1 61.7 49.6 60.0 50.0 29.3

64.9 10.5 79.8 79.4 36.5 54.8 51.7 39.9 40.2 73.6 52.6 65.5 66.0 65.3 62.2 69.7 48.6 50.6 59.6 52.1 53.0 55.5 51.9 54.5 62.9 61.3 53.4 66.3 117.9 42.5 57.7 41.2 45.2 53.9 53.3 48.2 52.9 52.6 50.5 51.8 49.2 47.5 52.1 53.2 48.0 52.6 52.5 49.6 53.1 50.7 50.2 56.9 52.5 56.3 52.8 48.6 55.0 45.3 49.2

47.7

* * *

8.8 * 65.8 * 59.2 22.7 * 38.1 * 52.8 45.5 41.6 55.3 * * 47.2 51.9 * 52.8 56.3 57.0 57.4 44.8 43.8 50.5 45.4 47.5 47.1 42.8 46.5 54.2 51.4 47.3 56.3 117.0 41.1 59.0 38.5 46.2 51.8 51.1 45.1 49.5 49.2 42.2 41.5 42.4 41.9 52.2 50.8 41.6 44.0 49.0 44.2 44.8 43.0 44.8 46.6 40.3 43.4 48.4 47.8 48.4 38.2 43.9

15.5 7.0 4.5 0.5 0.6 1.2

11.7 6.6 4.8 0.4 0.5 1.4

0.1 17.5 14.1 9.2 16.0 8.2 9.3 4.9 0.1 2.6 1.1 1.7 0.8 0.7 1.4 2.0 1.4 0.3 2.4 0.6 0.7 2.7 0.2 1.6 2.8 3.1 3.2 0.3 1.4 0.5 0.2 1.3

0.2 18.9 14.8 9.7 17.5 8.6 9.2 5.2 0.1 3.0 2.0 2.5 1.2 1.0 2.0 2.3 2.6 0.5 2.8 0.9 1.0 3.2 0.3 2.0 2.6 3.0 2.9 0.6 1.7 1.0 0.5 1.8

888

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Indices of data quality

All sites but skin (C00-96/C44) (contd)

Male Cases MV(%) DCO(%) UB(%) MI(%) Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 20144 32138 3238 53499 6542 12434 13764 27082 31316 34854 41152 48834 20324 3185 16262 24741 13842 2608 8082 8049 12291 7944 6609 9811 106443 5372 2670 2190 5771 4110 3410 7993 170303 11212 10702 32929 30029 51419 84893 27816 91379 147351 58248 63438 15649 65898 80965 1258 46460 21017 6277 56503 20948 2879 1168 46203 13815 924 1924 1647 4061 4354 71.2 81.0 86.4 91.7 61.6 80.0 83.0 96.9 83.0 74.6 79.5 82.0 97.0 85.7 89.2 88.2 87.9 77.8 88.5 86.0 87.8 90.1 86.9 91.4 98.4 93.0 89.7 92.6 94.1 89.7 91.3 94.2 94.8 94.7 95.9 83.9 77.4 80.1 78.8 85.8 74.3 76.4 77.8 83.2 78.1 84.4 91.3 93.7 88.3 91.4 90.1 89.8 92.5 91.6 89.4 89.5 95.3 95.0 94.8 94.5 95.8 95.5 5.6 1.5 2.0 0.9 8.9 2.8 0.5 13.0 9.5 9.7 1.6 4.2 3.6 2.7 4.0 7.9 3.7 0.7 3.4 1.8 5.7 4.3 0.3 0.2 1.2 0.5 2.7 0.7 3.1 0.3 0.0 0.0 0.0 0.0 3.7 0.2 0.0 0.0 6.3 0.1 1.3 1.3 1.1 1.2 0.7 1.1 1.0 0.7 0.1 0.8 0.1 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 2.4 0.4 1.8 0.0 8.5 6.6 4.8 1.3 0.0 0.0 0.9 0.0 0.0 0.2 0.3 0.5 1.5 0.1 0.0 1.5 0.0 0.3 0.1 0.3 0.2 0.3 0.4 75.9 67.3 61.0 52.3 72.3 67.5 81.5 59.4 57.2 83.6 69.6 71.8 66.3 53.1 62.8 52.3 56.4 57.1 50.8 62.1 52.5 51.8 49.2 69.2 52.1 40.0 51.2 50.6 47.3 53.2 48.9 46.3 60.7 58.0 54.8 58.5 57.1 56.6 54.4 56.6 56.7 56.9 56.6 59.3 57.3 41.9 40.5 39.5 42.1 46.0 45.0 41.9 42.0 58.3 43.5 39.7 Female Cases MV(%) DCO(%) UB(%) MI(%) 20734 30469 3261 49387 7558 10326 15413 22207 25333 45729 39120 42120 18820 2029 10480 15568 9974 1585 5221 5888 8380 5221 4444 6535 98687 5031 2159 1912 4680 3767 2761 7218 163202 10199 9567 31523 29546 49763 81004 26648 90040 147148 57044 59504 16684 67318 67690 921 38176 17515 5393 50009 17420 2663 1164 40477 12368 794 1464 1897 3699 3543 80.1 84.6 89.3 92.0 73.7 80.2 85.5 96.7 83.9 78.8 82.5 84.9 97.0 86.1 88.0 87.5 89.2 79.4 87.7 88.0 89.0 89.1 86.2 90.0 98.2 93.2 90.9 94.4 93.8 91.3 93.4 94.0 95.6 95.8 96.1 85.0 77.8 79.5 77.1 86.0 74.5 77.2 79.5 83.9 82.8 85.1 91.6 93.8 90.0 91.6 92.0 90.6 92.4 92.4 91.2 90.7 96.0 95.3 97.2 96.1 95.9 95.7 4.6 1.3 2.0 0.8 6.6 2.8 0.6 12.8 7.9 8.5 1.9 4.7 3.8 3.9 3.9 8.1 4.4 1.0 3.3 2.2 6.4 5.0 0.9 0.4 0.8 0.8 3.3 0.5 3.8 0.2 0.0 0.0 0.0 0.0 4.1 0.3 0.1 0.0 5.4 0.2 1.0 1.0 0.8 1.1 0.5 0.9 0.9 0.5 0.0 0.5 0.0 0.2 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.9 0.3 2.0 0.0 8.2 7.1 4.5 1.1 0.0 0.0 0.8 0.0 0.0 0.2 0.3 0.1 1.3 0.2 0.0 1.5 0.1 0.3 0.4 0.3 0.2 0.3 0.3 62.0 55.5 47.9 49.1 58.2 * 55.2 70.6 46.9 * 49.8 69.8 55.5 56.9 55.7 50.7 53.9 48.0 49.6 51.0 45.1 52.2 43.9 47.1 44.7 62.2 51.3 35.8 47.6 46.9 47.0 46.9 43.5 40.2 52.2 49.7 51.3 56.4 54.6 54.1 53.2 53.2 54.2 52.7 53.5 52.4 54.5 38.7 37.4 34.5 40.1 43.0 41.1 38.4 41.9 43.4 44.3 34.6

0.3 5.0 2.0 2.4 1.1 1.9 7.8 5.6 5.1 1.2 0.5 0.9 1.0 1.3 0.0 0.5 2.0 3.3 0.6 7.0 2.7 0.7 1.0 0.8 0.7 0.7 0.6

0.3 5.3 2.2 1.8 1.4 2.0 8.3 6.0 5.4 1.6 0.6 1.1 0.8 1.4 0.0 0.5 2.2 2.9 0.9 4.8 2.9 0.6 0.6 0.3 0.8 0.5 0.8

36.4

34.4

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
831

889

Percentage of other and unspecified site (O&U) and unknown age (Unk), all sites
Male O&U Africa Algeria, Setif Egypt, Gharbiah Tunisia, Centre, Sousse Uganda, Kyadondo County Zimbabwe, Harare: African America, Central and South Argentina, Bahia Blanca Brazil, Brasilia Brazil, Cuiaba Brazil, Goiania Brazil, Sao Paulo Chile, Valdivia Colombia, Cali Costa Rica Ecuador, Quito France, La Martinique Peru, Trujillo America, North Canada (Excluding Quebec, Yukon and Nunavut) Canada, Alberta Canada, British Columbia Canada, Manitoba Canada, New Brunswick Canada, Newfoundland and Labrador Canada, Northwest Territories Canada, Nova Scotia Canada, Ontario Canada, Prince Edward Island Canada, Saskatchewan USA, Alabama USA, Alabama: Black USA, Alabama: White USA, Alaska USA, Arizona USA, California USA, California: Asian and Pacific Islander USA, California: Black USA, California: Hispanic White USA, California: Non-Hispanic White USA, California, Greater San Francisco Bay Area USA, California, Greater San Francisco Bay Area: Black USA, California, Greater San Francisco Bay Area: Chinese USA, California, Greater San Francisco Bay Area: Filipino USA, California, Greater San Francisco Bay Area: Japanese USA, California, Greater San Francisco Bay Area: Hispanic White USA, California, Greater San Francisco Bay Area: Non-Hispanic White USA, California, Los Angeles County USA, California, Los Angeles County: Black USA, California, Los Angeles County: Chinese USA, California, Los Angeles County: Filipino USA, California, Los Angeles County: Japanese USA, California, Los Angeles County: Korean USA, California, Los Angeles County: Hispanic White USA, California, Los Angeles County: Non-Hispanic White USA, Colorado USA, Connecticut USA, Connecticut: Black USA, Connecticut: White USA, District of Columbia USA, District of Columbia: Black USA, District of Columbia: White USA, Florida USA, Florida: Black USA, Florida: White USA, Georgia USA, Georgia: Black USA, Georgia: White USA, Georgia, Atlanta USA, Georgia, Atlanta: Black USA, Georgia, Atlanta: White USA, Idaho USA, Illinois USA, Illinois: Black USA, Illinois: White USA, Indiana USA, Iowa USA, Kentucky USA, Louisiana USA, Louisiana: Black USA, Louisiana: White USA, Louisiana, New Orleans: Black USA, Louisiana, New Orleans: White *Important. See note on population page.
832

Unk 2.8 2.5 2.7 6.1 1.1 0.3 10.5 0.0 4.6 0.9 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 -

Female O&U Unk 2.6 5.5 3.9 3.3 2.4 3.2 4.3 5.8 2.0 4.1 6.4 6.3 4.1 3.5 2.7 2.8 3.8 4.0 4.0 2.9 2.3 3.8 4.2 3.7 3.0 4.6 3.1 3.6 3.0 1.8 3.6 3.2 2.7 3.6 3.2 3.2 3.2 4.2 3.2 3.0 2.4 3.1 3.2 3.0 3.2 2.5 2.4 2.3 2.2 3.0 3.1 3.0 2.7 2.7 2.8 3.5 3.8 3.1 3.1 3.5 3.1 3.0 3.5 2.9 2.5 3.2 2.3 3.2 3.1 3.6 3.1 2.9 2.7 3.0 2.8 3.2 2.6 3.5 2.9 2.3 1.9 2.4 5.3 1.3 0.3 10.7 0.1 3.7 0.4 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 * * * *

3.0 6.1 3.5 4.1 2.3 4.7 3.9 4.8 2.3 4.3 5.9 6.1 4.6 2.8 1.6 2.6 3.3 2.7 2.9 2.2 1.9 3.1 1.5 3.6 3.8 2.3 3.0 2.8 2.9 2.8 1.8 3.2 2.5 2.5 2.5 2.7 2.6 2.5 3.0 2.5 2.3 1.9 2.4 2.5 2.5 2.5 2.0 2.7 3.3 2.0 2.7 2.5 2.5 2.0 2.4 2.0 2.5 2.5 2.5 2.7 2.9 2.7 2.5 2.5 2.5 2.1 2.1 2.1 2.8 2.5 3.0 2.4 2.4 1.9 2.7 2.4 2.8 2.2 3.1 2.6

890

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Percentage of other and unspecified site (O&U) and unknown age (Unk), all sites (Contd)
Male O&U America, North (contd) USA, Maine USA, Massachusetts USA, Michigan USA, Michigan: Black USA, Michigan: White USA, Michigan, Detroit USA, Michigan, Detroit: Black USA, Michigan, Detroit: White USA, Missouri USA, Missouri: Black USA, Missouri: White USA, Montana USA, NPCR USA, NPCR: Black USA, NPCR: White USA, New Jersey USA, New Jersey: Black USA, New Jersey: White USA, New Mexico USA, New Mexico: American Indian USA, New Mexico: Hispanic White USA, New Mexico: Non-Hispanic White USA, New York State USA, New York State: Black USA, New York State: White USA, Ohio USA, Ohio: Black USA, Ohio: White USA, Oklahoma USA, Oregon USA, Pennsylvania USA, Pennsylvania: Black USA, Pennsylvania: White USA, Rhode Island USA, SEER (9 Registries) USA, SEER (9 Registries): Black USA, SEER (9 Registries): White USA, SEER (14 Registries) USA, SEER (14 Registries): Asian and Pacific Islander USA, SEER (14 Registries): Black USA, SEER (14 Registries): Hispanic White USA, SEER (14 Registries): Non-Hispanic White USA, South Carolina USA, South Carolina: Black USA, South Carolina: White USA, Texas USA, Texas: Black USA, Texas: White USA, Utah USA, Vermont USA, Washington State USA, Washington, Seattle USA, West Virginia USA, Wisconsin Asia Bahrain: Bahraini China, Guangzhou City China, Hong Kong China, Jiashan China, Nangang District, Harbin City China, Shanghai China, Zhongshan Cyprus India, Chennai (Madras) India, New Delhi India, Karunagappally India, Mumbai (Bombay) India, Nagpur India, Poona India, Trivandrum Israel Israel: Jews Israel: Non-Jews Japan, Aichi Prefecture Japan, Fukui Prefecture Japan, Hiroshima Japan, Miyagi Prefecture Japan, Nagasaki Prefecture Japan, Osaka Prefecture Japan, Yamagata Prefecture 2.6 2.4 2.3 2.4 2.3 1.8 2.0 1.7 2.7 3.2 2.7 2.4 2.5 2.7 2.5 2.1 2.4 2.1 2.7 3.3 3.1 2.6 2.0 2.0 2.0 2.8 2.9 2.9 2.3 2.4 2.4 2.7 2.4 2.3 2.0 2.2 2.0 2.3 2.4 2.4 2.6 2.3 2.6 2.7 2.5 2.8 3.0 2.8 1.8 2.4 1.8 1.6 2.5 3.5 4.7 3.2 4.2 0.8 1.3 2.7 0.6 2.1 6.3 7.4 11.6 5.4 11.2 5.9 9.7 3.4 3.4 3.8 2.3 0.8 0.9 1.1 1.0 1.3 0.9 Unk 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.9 0.8 0.6 0.2 1.2 0.9 0.1 0.0 0.0 0.0 Female O&U Unk 3.1 3.1 3.0 3.2 3.0 2.4 2.8 2.3 3.4 3.9 3.3 3.0 3.0 3.4 3.0 2.8 3.4 2.8 3.3 5.4 3.6 3.1 2.6 2.8 2.6 3.3 3.9 3.3 2.6 3.1 3.3 3.8 3.2 2.9 2.7 3.1 2.6 2.9 2.5 3.3 3.1 2.9 2.9 3.2 2.8 3.1 3.6 3.1 2.6 2.9 2.2 2.2 2.9 3.3 2.5 3.6 4.2 1.1 1.0 3.2 1.0 1.9 3.1 4.7 9.7 3.6 6.7 4.1 6.6 3.8 3.7 4.1 3.0 1.3 1.1 1.5 1.3 1.9 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.1 1.9 0.8 0.1 0.2 1.3 0.8 0.1 0.0 * * * * * * * * *

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
833

891

Percentage of other and unspecified site (O&U) and unknown age (Unk), all sites (Contd)
Male O&U Asia (contd) Korea Korea, Busan Korea, Daegu Korea, Daejeon Korea, Gwangju Korea, Incheon Korea, Jejudo Korea, Seoul Korea, Ulsan Kuwait: Kuwaitis Kuwait: Non-Kuwaitis Malaysia, Penang Malaysia, Sarawak Oman: Omani Pakistan, South Karachi Philippines, Manila Singapore Singapore: Chinese Singapore: Indian Singapore: Malay Thailand, Chiang Mai Thailand, Lampang Thailand, Songkhla Turkey, Antalya Turkey, Izmir Europe Austria Austria, Tyrol Austria, Vorarlberg Belarus Belgium, Antwerp Belgium, Flanders Bulgaria Croatia Czech Republic Denmark Estonia Finland France, Bas-Rhin France, Calvados France, Doubs France, Haut-Rhin France, Herault France, Isere France, Loire-Atlantique France, Manche France, Somme France, Tarn France, Vendee Germany, Brandenburg Germany, Free State of Saxony Germany, Hamburg Germany, Mecklenburg-Western Pomerania Germany, Munich Germany, Northrhine-Westphalia: Munster Germany, Saarland Iceland Ireland Italy, Biella Province Italy, Brescia Province Italy, Ferrara Province Italy, Florence and Prato Italy, Genoa Province Italy, Macerata Province Italy, Milan Italy, Modena Province Italy, Naples Italy, North East Cancer Surveillance Network Italy, Parma Province Italy, Ragusa Province Italy, Reggio Emilia Province Italy, Romagna Region Italy, Salerno Province Italy, Sassari Province Italy, Syracuse Province Italy, Sondrio Italy, Torino Italy, Umbria Region Italy, Varese Province Italy, Veneto Region 2.1 2.1 2.4 2.1 2.4 1.8 2.2 2.2 1.6 5.1 4.5 8.5 5.9 5.5 10.5 5.2 2.3 2.2 3.5 2.8 14.9 8.3 5.1 2.9 3.5 1.3 1.2 1.4 2.5 2.1 3.3 4.7 3.4 2.4 3.7 2.6 2.2 2.9 2.6 2.0 1.8 2.6 2.7 4.2 2.8 3.7 3.2 3.7 2.4 2.7 1.9 2.6 3.4 2.2 2.5 1.9 3.6 2.2 0.5 1.6 1.7 2.2 1.9 1.9 2.0 3.1 2.6 1.7 2.3 1.4 1.6 2.3 2.5 1.8 1.8 1.8 1.1 1.7 2.0 Unk 0.0 0.5 0.1 0.1 0.1 1.3 0.0 0.0 0.1 0.2 0.1 0.1 Female O&U Unk 2.3 2.5 2.5 2.2 2.3 2.0 2.3 2.4 1.7 3.2 3.3 6.1 4.8 5.7 6.4 4.0 2.1 2.1 2.1 2.4 10.7 5.9 3.4 2.1 3.9 1.9 2.2 1.8 1.7 2.6 3.9 3.6 3.5 2.8 3.9 2.1 3.4 3.1 1.9 2.3 1.7 2.2 2.7 3.8 3.1 3.7 4.7 3.6 2.9 3.5 2.2 3.3 3.7 3.1 2.9 3.1 4.4 2.7 0.8 2.6 2.3 2.9 2.6 2.6 2.5 3.4 2.9 2.2 2.6 1.8 2.1 2.8 3.1 1.6 2.4 2.4 1.2 2.3 2.4 0.0 0.2 0.4 0.1 0.1 1.3 0.1 0.1 0.4 0.1 0.2 0.0 -

* * *

* * * *

* * *

892

*Important. See note on population page.

834

Cancer Incidence in Five Continents Vol. IX, IARC 2007

Percentage of other and unspecified site (O&U) and unknown age (Unk), all sites (Contd)
Male O&U Europe (contd) Latvia Lithuania Malta Norway Poland, Cracow Poland, Kielce Poland, Warsaw City Portugal, Porto Portugal, South Regional Russia, St Petersburg Serbia Slovak Republic Slovenia Spain, Albacete Spain, Asturias Spain, Basque Country Spain, Canary Islands Spain, Cuenca Spain, Girona Spain, Granada Spain, Murcia Spain, Navarra Spain, Tarragona Spain, Zaragoza Sweden Switzerland, Geneva Switzerland, Graubunden and Glarus Switzerland, Neuchatel Switzerland, St Gall-Appenzell Switzerland, Ticino Switzerland, Valais Switzerland, Vaud The Netherlands The Netherlands, Eindhoven The Netherlands, Maastricht UK, East of England Region UK, England, Merseyside and Cheshire UK, England, North Western UK, England, Northern and Yorkshire UK, England, Oxford Region UK, England, South and Western Regions UK, England, Thames UK, England, Trent UK, England, West Midlands UK, Northern Ireland UK, Scotland Oceania Australia, New South Wales Australia, Northern Territory Australia, Queensland Australia, South Australia, Tasmania Australia, Victoria Australia, Western Australian Capital Territory French Polynesia New Zealand USA, Hawaii USA, Hawaii: Chinese USA, Hawaii: Filipino USA, Hawaii: Hawaiian USA, Hawaii: Japanese USA, Hawaii: White 2.6 2.5 4.0 2.8 6.4 4.4 3.5 1.7 3.7 1.8 2.6 2.3 1.3 3.7 5.5 3.8 4.3 2.8 3.1 3.3 2.8 2.3 2.7 1.6 3.8 1.5 2.0 2.0 2.2 3.1 1.9 1.7 4.2 3.9 5.4 3.8 3.6 6.2 4.1 4.9 3.2 5.2 4.1 5.1 3.8 3.8 4.0 5.7 3.1 3.2 3.4 3.1 2.7 4.1 4.5 3.4 2.0 1.0 2.2 4.0 1.5 1.8 Unk 6.1 0.0 0.1 0.4 0.1 0.1 0.2 2.7 0.1 0.1 0.0 Female O&U Unk 2.0 2.1 4.3 3.9 6.0 4.5 3.3 1.6 3.9 1.7 2.6 2.5 1.6 5.2 6.2 4.6 4.3 4.6 3.7 3.5 3.4 3.0 3.1 1.8 5.2 1.8 2.9 2.5 2.3 4.0 2.1 2.0 4.3 4.0 5.4 4.6 3.5 7.3 5.0 5.8 4.1 6.2 5.0 5.9 4.4 4.6 4.6 5.6 3.6 4.3 4.3 3.8 3.0 4.0 4.0 4.2 2.0 3.1 1.6 2.1 1.8 2.1 4.8 0.0 0.1 0.9 0.1 0.0 0.2 3.3 0.1 0.1 0.2 -

* *

*Important. See note on population page. Cancer Incidence in Five Continents Vol. IX, IARC 2007
835

893

Cancer Incidence in Five Continents Volume VIII: Errata

1. The data for Spain, Girona, are for the period 19951997 (three years) and not 19941997 (four years). As a consequence, the annual population numbers indicated in the population pyramid on page 430 are wrong. The correct numbers are: Age 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80- 85+ Total Male 13281 13169 14864 19445 20131 19848 21060 20289 18636 16971 14746 11664 13909 13095 11250 7026 4300 2840 256524 Female 12225 12739 14496 18675 19905 19596 20496 19896 17653 16193 13876 11725 14664 14427 12963 9716 6827 5322 261394 x = (R1 R2) / (S12 + S22) There are typographical errors on page 72, in the right column: Line 23: in the population and / is the should be replaced by in the population and is the. Line 26: The estimate of f is given by should be replaced by The estimate of is given by.

6. There is a typographical error on page 73, in the left column, line 8, in the formulae: Var (yI) = (1-p)di The should be replaced by a p, thus: Var (yI) = p (1-p)di 7. There is a typographical error in Table 8.1 on page 87: In the last column, under row 85+, the figure should be 0.50, not 0.30. 8. It has come to our attention that there is a mistake in the population data for Switzerland, Geneva (19931997). The correct numbers are: Age 0- 5- 10- 15- 20- 25- 30- 35- 40- 45- 50- 55- 60- 65- 70- 75- 80- 85+ Total Male 11757 10721 10110 10766 12735 15542 17241 15888 14127 14535 13750 11340 9323 7109 5578 3587 2551 1949 188609 Female 11170 10340 9588 10650 13594 16533 17901 16023 15067 15875 14870 11748 10153 8975 7921 5978 5301 5745 207432

The corrected population pyramid can be downloaded at: http://www.iacr.com.fr/girona_pop_1995-1997.pdf. Please note that this does not affect the incidence rates published in the volume. 2. There were two typing errors at the top of page 88 in the formula giving the crude rate per 100 000: The sum of the person-years yi and the sum of cases di should be reversed. 5 x 1755/12925220 should be replaced by 105 x 1755/12925220. 3. Page 38, table 3.1: The O&U (Other and Unspecified) category does not include C75. C80 was omitted from this table and should be included in the O&U category. 4. There is a typographical error in Table 4.5 on page 47: The ICD-O codes for the melanoma category should be 8720-8790, not 8270-8790. 5. There were typographical errors in the Miettinen formula page 72:

(R1/R2)

1 Z/X

As a consequence, the crude, age-standardized and cumulative rates presented in the book for Switzerland, Geneva (1993 1997) are wrong.

895

Please download the http://www.iacr.com.fr/geneva.zip file which contains: 1. The corrected pages 448 and 449 as PDF files. 2. The age-specific tables (male and female) as a PDF file. 3. The corrected CI5VIII.POP file to be used with the CI5VIII Windows-based software included on the CD-ROM. Please replace the current file installed on your hard disk with this new one.

4. The corrected person-years at risk as text files (in CSV and PRN formats) to be incorporated into statistical packages. We apologize for any inconvenience this may have caused. The Editors

896

Achev dimprimer sur rotative par lImprimerie Darantiere Dijon-Quetigny en aot 2009

Dpt lgal : aot 2009 N dimpression : 29-0557 Imprim en France